﻿FN Clarivate Analytics Web of Science
VR 1.0
PT J
AU Matsubara, JA
   Tian, Y
   Cui, JZ
   Zeglinski, MR
   Hiroyasu, S
   Turner, CT
   Granville, DJ
AF Matsubara, Joanne A.
   Tian, Yuan
   Cui, Jing Z.
   Zeglinski, Matthew R.
   Hiroyasu, Sho
   Turner, Christopher T.
   Granville, David J.
TI Retinal Distribution and Extracellular Activity of Granzyme B: A Serine
   Protease That Degrades Retinal Pigment Epithelial Tight Junctions and
   Extracellular Matrix Proteins
SO FRONTIERS IN IMMUNOLOGY
LA English
DT Article
DE ZO-1; blood-eye barrier; Bruch's membrane; geographic atrophy; soft
   drusen; choroidal neovascularization; FITC-dextran permeability; ARPE-19
ID ENDOTHELIAL GROWTH-FACTOR; CHOROIDAL MAST-CELLS; MACULAR DEGENERATION;
   GENE-EXPRESSION; FACTOR BINDING; FIBRONECTIN; INFLAMMATION; CLEAVAGE;
   DISRUPTION; INJURY
AB Granzymes are a family of serine proteases first shown to be intracellular initiators of immune-mediated cell death in target pathogenic cells. In addition to its intracellular role, Granzyme B (GzmB) has important extracellular functions in immune regulation and extracellular matrix (ECM) degradation. Verified substrates of extracellular GzmB activity include tight junctional and ECM proteins. Interestingly, little is known about the activity of GzmB in the outer human retina, a tissue in which the degradation of the tight junctional contacts of retinal pigment epithelial (RPE) cells and within the external limiting membrane, as well as remodeling of the ECM in Bruch's membrane, cause the breakdown of the blood-retinal barrier and slowing of metabolite transport between neuroretina and choroidal blood supply. Such pathological changes in outer retina signal early events in the development of age-related macular degeneration (AMD), a multifactorial, chronic inflammatory eye disease. This study is the first to focus on the distribution of GzmB in the outer retina of the healthy and diseased post-mortem human eye. Our results revealed that GzmB is present in RPE and choroidal mast cells. More immunoreactive cells are present in older (>65 years) compared to younger (<55 years) donor eyes, and choroidal immunoreactive cells are more numerous in eyes with choroidal neovascularization (CNV), while RPE immunoreactive cells are more numerous in eyes with soft drusen, an early AMD event. In vitro studies demonstrated that RPE-derived tight junctional and ECM proteins are cleaved by exogenous GzmB stimulation. These results suggest that the increased presence of GzmB immunoreactive cells in outer retina of older (healthy) eyes as well as in diseased eyes with CNV (from AMD) and eyes with soft drusen exacerbate ECM remodeling in the Bruch's membrane and degradation of the blood-retinal barrier. Currently there are no treatments that prevent remodeling of the Bruch's membrane and/or the loss of function of the outer blood-retinal barrier, known to promote early AMD changes, such as drusen deposition, RPE dysfunction and pro-inflammation. Specific inhibitors of GzmB, already in preclinical studies for non-ocular diseases, may provide new strategies to stop these early events associated with the development of AMD.
C1 [Matsubara, Joanne A.; Tian, Yuan; Cui, Jing Z.] Univ British Columbia, Dept Ophthalmol & Visual Sci, Vancouver, BC, Canada.
   [Zeglinski, Matthew R.; Hiroyasu, Sho; Turner, Christopher T.; Granville, David J.] Univ British Columbia, Int Collaborat Repair Discoveries ICORD, Vancouver, BC, Canada.
   [Zeglinski, Matthew R.; Hiroyasu, Sho; Turner, Christopher T.; Granville, David J.] Univ British Columbia, Dept Pathol & Lab Med, Vancouver, BC, Canada.
C3 University of British Columbia; University of British Columbia;
   University of British Columbia
RP Matsubara, JA (通讯作者)，Univ British Columbia, Dept Ophthalmol & Visual Sci, Vancouver, BC, Canada.
EM jms@mail.ubc.ca
RI Turner, Chris/AAC-9775-2021
OI Turner, Chris/0000-0001-7409-4386; Hiroyasu, Sho/0000-0002-8290-2272
FU Canadian Institutes of Health Research (CIHR); Natural Sciences and
   Engineering Research Council of Canada (NSERC); Michael Smith Foundation
   for Health Research; CIHR Fellowships; Michael Smith Foundation for
   Health Research Studentship; Guangzhou Elite Project Overseas
   Scholarship
FX This study was funded by Canadian Institutes of Health Research (CIHR)
   (to JM and DG), Natural Sciences and Engineering Research Council of
   Canada (NSERC) (JM), and Michael Smith Foundation for Health Research
   (DG). MZ and CT were funded through CIHR Fellowships. MZ was
   additionally funded through a Michael Smith Foundation for Health
   Research Studentship. YT was funded through a Guangzhou Elite Project
   Overseas Scholarship.
CR Aisenbrey S, 2006, INVEST OPHTH VIS SCI, V47, P5537, DOI 10.1167/iovs.05-1590
   Akhtar-Schafer I, 2018, EMBO MOL MED, V10, DOI 10.15252/emmm.201708259
   Ambati J, 2013, NAT REV IMMUNOL, V13, P438, DOI 10.1038/nri3459
   Ambesi A, 2014, J CELL SCI, V127, P3805, DOI 10.1242/jcs.150458
   Arai R, 2017, MEDIAT INFLAMM, V2017, DOI 10.1155/2017/3124753
   Arias M, 2017, TRENDS CANCER, V3, P407, DOI 10.1016/j.trecan.2017.04.001
   Bailey TA, 2004, INVEST OPHTH VIS SCI, V45, P675, DOI 10.1167/iovs.03-0351
   Beasley S, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/417986
   Bhutto I, 2012, MOL ASPECTS MED, V33, P295, DOI 10.1016/j.mam.2012.04.005
   Bhutto IA, 2016, BRIT J OPHTHALMOL, V100, P720, DOI 10.1136/bjophthalmol-2015-308290
   Boivin WA, 2009, LAB INVEST, V89, P1195, DOI 10.1038/labinvest.2009.91
   Bousquet E, 2015, AM J PATHOL, V185, P2083, DOI 10.1016/j.ajpath.2015.04.002
   Buczek-Thomas JA, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20205065
   Buzza MS, 2005, J BIOL CHEM, V280, P23549, DOI 10.1074/jbc.M412001200
   Cao SJ, 2016, BRIT J OPHTHALMOL, V100, P713, DOI 10.1136/bjophthalmol-2015-307213
   Chen M, 2019, PROG RETIN EYE RES, V69, P159, DOI 10.1016/j.preteyeres.2018.10.003
   Chirco KR, 2017, EYE, V31, P10, DOI 10.1038/eye.2016.216
   Chung HY, 2009, AGEING RES REV, V8, P18, DOI 10.1016/j.arr.2008.07.002
   Clark SJ, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01778
   Copland DA, 2018, INVEST OPHTH VIS SCI, V59, pAMD83, DOI 10.1167/iovs.18-23893
   Curcio C.A., 2013, RETINA-J RET VIT DIS, VVolume 1, P465
   Curcio CA, 2017, INVEST OPHTH VIS SCI, V58, P211, DOI 10.1167/iovs.17-21872
   Dai Hongyan, 2011, Drug Discov Today Dis Models, V8, P47
   Fernandez-Godino R, 2016, ADV EXP MED BIOL, V854, P53, DOI 10.1007/978-3-319-17121-0_8
   Forsten-Williams K, 2011, BMC SYST BIOL, V5, DOI 10.1186/1752-0509-5-170
   Georgiadis A, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015730
   Goerges AL, 2004, J BIOL CHEM, V279, P2307, DOI 10.1074/jbc.M308482200
   Hendel A, 2010, CELL DEATH DIFFER, V17, P596, DOI 10.1038/cdd.2010.5
   Hendel A, 2014, LAB INVEST, V94, P716, DOI 10.1038/labinvest.2014.62
   Hendel A, 2013, MATRIX BIOL, V32, P14, DOI 10.1016/j.matbio.2012.11.013
   Hiebert PR, 2013, CELL DEATH DIFFER, V20, P1404, DOI 10.1038/cdd.2013.96
   Hiebert PR, 2012, TRENDS MOL MED, V18, P732, DOI 10.1016/j.molmed.2012.09.009
   Hiebert PR, 2011, EXP GERONTOL, V46, P489, DOI 10.1016/j.exger.2011.02.004
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Kurji KH, 2010, INVEST OPHTH VIS SCI, V51, P1151, DOI 10.1167/iovs.09-3622
   Matsubara JA, 2019, ARVO ANN M VANC BC
   McLeod DS, 2017, INVEST OPHTH VIS SCI, V58, P5879, DOI 10.1167/iovs.17-22989
   Mettu PS, 2012, MOL ASPECTS MED, V33, P376, DOI 10.1016/j.mam.2012.04.006
   Miura Y, 2009, GRAEF ARCH CLIN EXP, V247, P641, DOI 10.1007/s00417-009-1041-6
   Mullins RE, 2011, INVEST OPHTH VIS SCI, V52, P1606, DOI 10.1167/iovs.10-6476
   Narimatsu T, 2013, INVEST OPHTH VIS SCI, V54, P4555, DOI 10.1167/iovs.12-11572
   Nita M, 2014, MED SCI MONITOR, V20, P1003, DOI 10.12659/MSM.889887
   Nussenblatt RB, 2014, AM J OPHTHALMOL, V158, P5, DOI 10.1016/j.ajo.2014.03.014
   Pardo J, 2007, CELL DEATH DIFFER, V14, P1768, DOI 10.1038/sj.cdd.4402183
   Parkinson LG, 2015, AGING CELL, V14, P67, DOI 10.1111/acel.12298
   Russo V, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-28070-0
   Sack KD, 2016, J CELL PHYSIOL, V231, P2026, DOI 10.1002/jcp.25312
   Samuel W, 2017, MOL VIS, V23, P60
   Santacruz MS, 2018, GRANZYME B DISRUPTS
   Schultz R, 2018, INVEST OPHTH VIS SCI, V59
   Shi LF, 2000, METHOD ENZYMOL, V322, P125
   Turner CT, 2019, MATRIX BIOL, V75-76, P126, DOI 10.1016/j.matbio.2017.12.005
   Whitmore SS, 2015, PROG RETIN EYE RES, V45, P1, DOI 10.1016/j.preteyeres.2014.11.005
   Wijelath ES, 2002, CIRC RES, V91, P25, DOI 10.1161/01.RES.0000026420.22406.79
   Wroblewski M, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00327-8
   Xu HP, 2009, PROG RETIN EYE RES, V28, P348, DOI 10.1016/j.preteyeres.2009.06.001
NR 56
TC 12
Z9 12
U1 2
U2 5
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 1664-3224
J9 FRONT IMMUNOL
JI Front. Immunol.
PD APR 7
PY 2020
VL 11
AR 574
DI 10.3389/fimmu.2020.00574
PG 13
WC Immunology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Immunology
GA LH8LN
UT WOS:000529034300001
PM 32318066
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Waizel, M
   Todorova, MG
   Masyk, M
   Wolf, K
   Rickmann, A
   Helaiwa, K
   Blanke, BR
   Szurman, P
AF Waizel, Maria
   Todorova, Margarita G.
   Masyk, Michael
   Wolf, Katharina
   Rickmann, Annekatrin
   Helaiwa, Khaled
   Blanke, Bjoern R.
   Szurman, Peter
TI Switch to aflibercept or ranibizumab after initial treatment with
   bevacizumab in eyes with neovascular AMD
SO BMC OPHTHALMOLOGY
LA English
DT Article
DE Vascular endothelial growth factor a; Ranibizumab; Aflibercept;
   Bevacizumab; VEGF switch; Vascular endothelial growth factor
ID ANTI-VEGF THERAPY; MACULAR DEGENERATION; TACHYPHYLAXIS; BINDING; TRAP
AB Background: To evaluate changes in central macular thickness (CMT) and visual outcome in patients with neovascular age-related macular degeneration (AMD) treated initially with bevacizumab and subsequently switched to either aflibercept or ranibizumab. Methods: Observational clinical study was performed. We measured the structural outcome (CMT on SD-OCT; mu m) and the visual outcome (best corrected visual acuity (BCVA); logMAR), as follows: before treatment (at baseline), following bevacizumab treatment (switch follow-up) and after switching from bevacizumab to aflibercept- or ranibizumab treatment (final follow-up, AG/, RG).
   Results: From a total of 96 eyes treated with intravitreal injections of bevacizumab (10.5 +/- 7.6 (mean +/- SD)), 58 eyes switched to aflibercept (6.5 +/- 3.9; AG) and 38 eyes switched to ranibizumab (7.1 +/- 5.3; RG) (>= 3 injections, each). In addition, these eyes were compared to 37 eyes under bevacizumab monotherapy. Primary outcome: In the AG, the CMT decreased slightly from 430 +/- 220 mu m at baseline to 419 +/- 212 mu m at switch follow-up (p = 0.86), but decreased significantly to 318 +/- 159 mu m at final follow-up, AG (p < 0.0001). In the ranibizumab group (RG), the CMT increased from 396 +/- 174 mu m at baseline to 499 +/- 333 mu m at switch follow-up (p = 0.012), but decreased significantly to 394 +/- 202 mu m at final follow-up, RG (p = 0.007). Secondary outcome: In the AG, the mean BCVA worsened from logMAR 0.57 +/- 0.33 at baseline to 0.63 +/- 0.30 at switch follow-up and improved slightly to 0.53 +/- 0.71 at final follow-up, AG (p = 0.46). In the RG, mean BCVA worsened from 0.57 +/- 0.28 at baseline to 0.64 +/- 0.31 at switch follow-up and improved slightly to 0.60 +/- 0.36 at final follow-up, RG (p = 0.64).
   Conclusion: Switching from bevacizumab to either aflibercept, or ranibizumab, has a strong anatomical effect in eyes with neovascular AMD. Nevertheless, even if the switch to aflibercept shows a minimal functional benefit over that to ranibizumab, visual prognosis remains limited.
C1 [Waizel, Maria; Todorova, Margarita G.] Univ Basel, Dept Ophthalmol, Mittlere Str 91, CH-4031 Basel, Switzerland.
   [Waizel, Maria; Masyk, Michael; Wolf, Katharina; Rickmann, Annekatrin; Helaiwa, Khaled; Szurman, Peter] Knappschaft Hosp Saar, Knappschaft Eye Clin Sulzbach, Sulzbach, Germany.
   [Helaiwa, Khaled; Blanke, Bjoern R.; Szurman, Peter] Univ Eye Clin Tuebingen, Ctr Ophthalmol, Tubingen, Germany.
C3 University of Basel; Eberhard Karls University of Tubingen; Eberhard
   Karls University Hospital
RP Waizel, M (通讯作者)，Univ Basel, Dept Ophthalmol, Mittlere Str 91, CH-4031 Basel, Switzerland.; Waizel, M (通讯作者)，Knappschaft Hosp Saar, Knappschaft Eye Clin Sulzbach, Sulzbach, Germany.
EM maria.waizel@usb.ch
OI Waizel, Maria/0000-0002-6588-4842; Todorova, Margarita
   G./0000-0001-8326-1449
CR Bakall B, 2013, AM J OPHTHALMOL, V156, P15, DOI 10.1016/j.ajo.2013.02.017
   Binder S, 2012, BRIT J OPHTHALMOL, V96, P1, DOI 10.1136/bjophthalmol-2011-301236
   Cho H, 2013, BRIT J OPHTHALMOL, V97, P1032, DOI 10.1136/bjophthalmol-2013-303344
   Ehlken C, 2014, EYE, V28, P538, DOI 10.1038/eye.2014.64
   Fassnacht-Riederle H, 2014, GRAEF ARCH CLIN EXP, V252, P1705, DOI 10.1007/s00417-014-2589-3
   Forooghian F, 2011, ACTA OPHTHALMOL, V89, pE206, DOI 10.1111/j.1755-3768.2009.01773.x
   Gasperini JL, 2012, BRIT J OPHTHALMOL, V96, P14, DOI 10.1136/bjo.2011.204685
   Hall LB, 2014, J OCUL PHARMACOL TH, V30, P346, DOI 10.1089/jop.2013.0188
   Hariri A, 2015, OSLI RETINA, V46, P195, DOI 10.3928/23258160-20150213-18
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Homer N, 2015, EYE, V29, P1152, DOI 10.1038/eye.2015.87
   Kucukerdonmez C, 2015, EUR J OPHTHALMOL, V25, P51, DOI 10.5301/ejo.5000480
   Moisseiev E, 2015, RETINA-J RET VIT DIS, V35, P1323, DOI 10.1097/IAE.0000000000000500
   Papadopoulos N, 2012, ANGIOGENESIS, V15, P171, DOI 10.1007/s10456-011-9249-6
   Pinheiro-Costa J, 2015, OPHTHALMOLOGICA, V233, P155, DOI 10.1159/000381221
   Seguin-Greenstein S, 2016, J OPHTHALMOL, V2016, DOI 10.1155/2016/4095852
   Singh RP, 2014, BRIT J OPHTHALMOL, V98, P22, DOI 10.1136/bjophthalmol-2013-304798
   Yang JH, 2014, MOL PHARMACEUT, V11, P3421, DOI 10.1021/mp500160v
NR 18
TC 7
Z9 8
U1 0
U2 0
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1471-2415
J9 BMC OPHTHALMOL
JI BMC Ophthalmol.
PD MAY 23
PY 2017
VL 17
AR 79
DI 10.1186/s12886-017-0471-x
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA EV9KE
UT WOS:000402104100001
PM 28535756
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Schaal, KB
   Legarreta, AD
   Feuer, WJ
   Gregori, G
   Cheng, QQ
   Legarreta, JE
   Durbin, MK
   Stetson, PF
   Kubach, S
   Rosenfeld, PJ
AF Schaal, Karen B.
   Legarreta, Andrew D.
   Feuer, William J.
   Gregori, Giovanni
   Cheng, Qianqian
   Legarreta, John E.
   Durbin, Mary K.
   Stetson, Paul F.
   Kubach, Sophie
   Rosenfeld, Philip J.
TI Comparison between Widefield En Face Swept-Source OCT and Conventional
   Multimodal Imaging for the Detection of Reticular Pseudodrusen
SO OPHTHALMOLOGY
LA English
DT Article
ID SUBRETINAL DRUSENOID DEPOSITS; MACULAR DEGENERATION; GEOGRAPHIC ATROPHY;
   CHOROIDAL THICKNESS; ASSOCIATION; PROGRESSION; EYES; MICROPERIMETRY;
   SENSITIVITY; IMPACT
AB Purpose: The ability to detect reticular pseudodrusen (RPD)/subretinal drusenoid deposits (SDDs) using 12 Chi 12-mm widefield en face swept-source optical coherence tomography (SS-OCT) imaging was compared with conventional multimodal imaging (color, fundus autofluorescence (FAF), and infrared reflectance [IR] imaging) in eyes with nonexudative age-related macular degeneration (AMD).
   Design: Cross-sectional study.
   Participants: Patients with nonexudative AMD were prospectively enrolled in an SS-OCT imaging study at the Bascom Palmer Eye Institute.
   Methods: On the same day, all participants underwent color, FAF, and IR fundus imaging, as well as imaging with a prototype Zeiss 100 kHz SS-OCT instrument (Carl Zeiss Meditec Inc, Dublin, CA). Two masked graders assessed the presence, absence, or uncertainty of RPD/SDDs on conventional multimodal images and separately on 4 different SS-OCT en face images derived from the same volumetric dataset. The results from grading the conventional images and the SS-OCT en face images were compared.
   Main Outcome Measures: Agreement in the detection of RPD/SDDs using different imaging modalities.
   Results: A total of 307 eyes (209 patients) were graded for the presence or absence of RPD/SDDs. The agreement between SS-OCT and multimodal imaging was 83%. The difference in RPD/SDD detection with either image modality was not statistically significant (P = 0.21). The sensitivity of SS-OCT in RPD/SDD detection was 83%, and when using conventional imaging, the sensitivity was 75%. When using SS-OCT imaging alone, 10% of RPD/SDD cases would be missed, and when using conventional imaging alone, 14% of RPD/SDD cases would be missed. The presence of RPD/SDD was confirmed retrospectively in 48 of 52 cases once the overall grading was unmasked and the graders reevaluated the conventional multimodal images and the widefield SS-OCT en face images.
   Conclusions: All 4 imaging modalities used together provided the best strategy for the detection of RPD/SDDs. However, when using widefield en face SS-OCT slab imaging alone, the detection of RPD/SDDs was at least as good as conventional imaging. Ophthalmology 2017; 124: 205-214 (C) 2016 by the American Academy of Ophthalmology
C1 [Schaal, Karen B.; Legarreta, Andrew D.; Feuer, William J.; Gregori, Giovanni; Cheng, Qianqian; Legarreta, John E.; Rosenfeld, Philip J.] Univ Miami, Miller Sch Med, Bascom Palmer Eye Inst, Miami, FL USA.
   [Durbin, Mary K.; Stetson, Paul F.; Kubach, Sophie] Carl Zeiss Meditec Inc, Res & Dev, Dublin, CA USA.
C3 Bascom Palmer Eye Institute; University of Miami; Carl Zeiss AG
RP Rosenfeld, PJ (通讯作者)，Bascom Palmer Eye Inst, 900 NW 17th St, Miami, FL 33136 USA.
EM prosenfeld@miami.edu
RI Legarreta, Andrew/GRY-0710-2022
OI Cheng, Qianqian/0000-0003-0671-025X
FU Carl Zeiss Meditec, Inc (Dublin, CA); Macula Vision Research Foundation;
   National Eye Institute Center Core Grant [P30EY014801]; Research to
   Prevent Blindness; Feig Family Foundation; Emma Clyde Hodge Memorial
   Foundation; NATIONAL EYE INSTITUTE [P30EY014801] Funding Source: NIH
   RePORTER
FX Supported by a grant from Carl Zeiss Meditec, Inc (Dublin, CA), the
   Macula Vision Research Foundation, the National Eye Institute Center
   Core Grant (P30EY014801), an unrestricted grant from Research to Prevent
   Blindness, the Feig Family Foundation, and the Emma Clyde Hodge Memorial
   Foundation.
CR A Martillo Miguel, 2012, Med Hypothesis Discov Innov Ophthalmol, V1, P37
   Alten F, 2015, BRIT J OPHTHALMOL, V99, P717, DOI 10.1136/bjophthalmol-2014-305339
   Alten F, 2014, INVEST OPHTH VIS SCI, V55, P6073, DOI 10.1167/iovs.13-13804
   Alten F, 2013, INVEST OPHTH VIS SCI, V54, P3250, DOI 10.1167/iovs.13-11923
   Boddu S, 2014, AM J OPHTHALMOL, V157, P985, DOI 10.1016/j.ajo.2014.01.023
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Finger RP, 2016, OPHTHALMOLOGY, V123, P599, DOI 10.1016/j.ophtha.2015.10.029
   Fleiss JL, 1981, STAT METHODS RATES P, P218
   Forte R, 2014, OPHTHALMIC RES, V51, P32, DOI 10.1159/000354117
   Garg A, 2013, INVEST OPHTH VIS SCI, V54, P7075, DOI 10.1167/iovs.13-12474
   Haas P, 2014, INVEST OPHTH VIS SCI, V55, P2674, DOI 10.1167/iovs.13-13338
   Hogg RE, 2014, OPHTHALMOLOGY, V121, P1748, DOI 10.1016/j.ophtha.2014.03.015
   Hogg RE, 2014, OPTOMETRY VISION SCI, V91, P854, DOI 10.1097/OPX.0000000000000287
   Joachim N, 2014, OPHTHALMOLOGY, V121, P917, DOI 10.1016/j.ophtha.2013.10.043
   Marsiglia M, 2013, INVEST OPHTH VIS SCI, V54, P7362, DOI 10.1167/iovs.12-11073
   MIMOUN G, 1990, J FR OPHTALMOL, V13, P511
   Oak ASW, 2014, RETINA-J RET VIT DIS, V34, P825, DOI 10.1097/IAE.0000000000000121
   Ooto S, 2013, AM J OPHTHALMOL, V156, P1184, DOI 10.1016/j.ajo.2013.06.036
   Pumariega NM, 2011, OPHTHALMOLOGY, V118, P1619, DOI 10.1016/j.ophtha.2011.01.029
   Querques G, 2011, RETINA-J RET VIT DIS, V31, P518, DOI 10.1097/IAE.0b013e3181f04974
   Querques G, 2014, RETINA-J RET VIT DIS, V34, P321, DOI 10.1097/IAE.0b013e3182993df1
   Querques G, 2012, INVEST OPHTH VIS SCI, V53, P1264, DOI 10.1167/iovs.11-9063
   Rastogi N, 2016, SURV OPHTHALMOL, V61, P422, DOI 10.1016/j.survophthal.2015.10.003
   Rudolf M, 2008, EXP EYE RES, V87, P402, DOI 10.1016/j.exer.2008.07.010
   Saade C, 2014, CLIN EXP OPHTHALMOL, V42, P865, DOI 10.1111/ceo.12353
   Sarks J, 2011, BRIT J OPHTHALMOL, V95, P979, DOI 10.1136/bjo.2010.194977
   Schaal KB, 2015, OSLI RETINA, V46, P550, DOI 10.3928/23258160-20150521-06
   Schmitz-Valckenberg S, 2011, INVEST OPHTH VIS SCI, V52, P5009, DOI 10.1167/iovs.11-7235
   Smith RT, 2014, INVEST OPHTH VIS SCI, V55, P6262, DOI 10.1167/iovs.14-15387
   Smith RT, 2011, ARCH OPHTHALMOL-CHIC, V129, P1061, DOI 10.1001/archophthalmol.2011.212
   Smith RT, 2009, AM J OPHTHALMOL, V148, P733, DOI 10.1016/j.ajo.2009.06.028
   Spaide RF, 2014, RETINA-J RET VIT DIS, V34, P2336, DOI 10.1097/IAE.0000000000000377
   Spaide RF, 2013, RETINA-J RET VIT DIS, V33, P1800, DOI 10.1097/IAE.0b013e31829c3765
   Steinberg JS, 2015, BRIT J OPHTHALMOL, V99, P1289, DOI 10.1136/bjophthalmol-2014-306535
   Steinberg JS, 2015, OPHTHALMOLOGICA, V233, P35, DOI 10.1159/000368168
   Suzuki M, 2014, AM J OPHTHALMOL, V157, P1005, DOI 10.1016/j.ajo.2014.01.025
   Thorell MR, 2015, OSLI RETINA, V46, P513, DOI 10.3928/23258160-20150521-02
   Ueda-Arakawa N, 2014, AM J OPHTHALMOL, V157, P994, DOI 10.1016/j.ajo.2014.01.018
   Ueda-Arakawa N, 2013, RETINA-J RET VIT DIS, V33, P490, DOI 10.1097/IAE.0b013e318276e0ae
   Ueda-Arakawa N, 2013, AM J OPHTHALMOL, V155, P260, DOI 10.1016/j.ajo.2012.08.011
   Wu ZC, 2015, INVEST OPHTH VIS SCI, V56, P2100, DOI 10.1167/iovs.14-16210
   Yoneyama S, 2014, HUM MOL GENET, V23, P2498, DOI 10.1093/hmg/ddt626
   Zweifel SA, 2010, OPHTHALMOLOGY, V117, P303, DOI 10.1016/j.ophtha.2009.07.014
NR 43
TC 13
Z9 13
U1 0
U2 7
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD FEB
PY 2017
VL 124
IS 2
BP 205
EP 214
DI 10.1016/j.ophtha.2016.10.009
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA EP2PT
UT WOS:000397226300022
PM 27856030
DA 2022-11-30
ER

PT J
AU Sanders, DS
   Lattin, DJ
   Read-Brown, S
   Tu, DC
   Wilson, DJ
   Hwang, TS
   Morrison, JC
   Yackel, TR
   Chiang, MF
AF Sanders, David S.
   Lattin, Daniel J.
   Read-Brown, Sarah
   Tu, Daniel C.
   Wilson, David J.
   Hwang, Thomas S.
   Morrison, John C.
   Yackel, Thomas R.
   Chiang, Michael F.
TI Electronic Health Record Systems in Ophthalmology Impact on Clinical
   Documentation
SO OPHTHALMOLOGY
LA English
DT Article
ID INTENSIVE-CARE-UNIT; INFORMATION-TECHNOLOGY; VENOUS THROMBOEMBOLISM;
   DIABETIC-RETINOPATHY; MEDICAL INFORMATICS; TIME UTILIZATION;
   DATA-COLLECTION; PHYSICIANS; ERRORS; REPRESENTATION
AB Objective: To evaluate quantitative and qualitative differences in documentation of the ophthalmic examination between paper and electronic health record (EHR) systems.
   Design: Comparative case series.
   Participants: One hundred fifty consecutive pairs of matched paper and EHR notes, documented by 3 attending ophthalmologist providers.
   Methods: An academic ophthalmology department implemented an EHR system in 2006. Database queries were performed to identify cases in which the same problems were documented by the same provider on different dates, using paper versus EHR methods. This was done for 50 consecutive pairs of examinations in 3 different diseases: age-related macular degeneration (AMD), glaucoma, and pigmented choroidal lesions (PCLs). Quantitative measures were used to compare completeness of documenting the complete ophthalmologic examination, as well as disease-specific critical findings using paper versus an EHR system. Qualitative differences in paper versus EHR documentation were illustrated by selecting representative paired examples.
   Main Outcome Measures: (1) Documentation score, defined as the number of examination elements recorded for the slit-lamp examination, fundus examination, and complete ophthalmologic examination and for critical clinical findings for each disease. (2) Paired comparison of qualitative differences in paper versus EHR documentation.
   Results: For all 3 diseases (AMD, glaucoma, PCL), the number of complete examination findings recorded was significantly lower with paper than the EHR system (P < 0.004). Among the 3 individual examination sections (general, slit lamp, fundus) for the 3 diseases, 5 of the 9 possible combinations had significantly lower mean documentation scores with paper than EHR notes. For 2 of the 3 diseases, the number of critical clinical findings recorded was significantly lower using paper versus EHR notes (P <= 0.022). All (150/150) paper notes relied on graphical representations using annotated hand-drawn sketches, whereas no (0/150) EHR notes contained drawings. Instead, the EHR systems documented clinical findings using textual descriptions and interpretations.
   Conclusions: There were quantitative and qualitative differences in the nature of paper versus EHR documentation of ophthalmic findings in this study. The EHR notes included more complete documentation of examination elements using structured textual descriptions and interpretations, whereas paper notes used graphical representations of findings.
C1 [Sanders, David S.; Lattin, Daniel J.; Read-Brown, Sarah; Tu, Daniel C.; Wilson, David J.; Hwang, Thomas S.; Morrison, John C.; Chiang, Michael F.] Oregon Hlth & Sci Univ, Casey Eye Inst, Dept Ophthalmol, Portland, OR 97239 USA.
   [Tu, Daniel C.] Portland VA Med Ctr, Ophthalmol Operat Care Div, Portland, OR USA.
   [Yackel, Thomas R.; Chiang, Michael F.] Oregon Hlth & Sci Univ, Dept Med Informat & Clin Epidemiol, Portland, OR 97239 USA.
C3 Oregon Health & Science University; US Department of Veterans Affairs;
   Veterans Health Administration (VHA); Portland VA Medical Center; Oregon
   Health & Science University
RP Chiang, MF (通讯作者)，Oregon Hlth & Sci Univ, 3375 SW Terwilliger Blvd, Portland, OR 97239 USA.
EM chiangm@ohsu.edu
RI Hwang, Thomas/AAV-5146-2020; Hwang, Thomas S./AAW-6618-2020
OI Hwang, Thomas S./0000-0002-0535-4823; Read-Brown,
   Sarah/0000-0002-6526-2939
FU Research to Prevent Blindness, Inc, New York, New York
FX Supported by unrestricted departmental funding from Research to Prevent
   Blindness, Inc, New York, New York (D.S.S., S.R.B., D.C.T., D.J.W.,
   T.S.H., J.C.M., and M.F.C.). The funding organization had no role in the
   design or conduct of this research.
CR Abelson Reed, 2012, NY TIMES, p[A1, A3]
   Adams DL, 2002, J NATL MED ASSOC, V94, P430
   Ahmed A, 2011, CRIT CARE MED, V39, P1626, DOI 10.1097/CCM.0b013e31821858a0
   Apkon M, 2001, INTENS CARE MED, V27, P122, DOI 10.1007/s001340000777
   Berenholtz SM, 2004, CRIT CARE MED, V32, P2014, DOI 10.1097/01.CCM.0000142399.70913.2F
   Blumenthal D, 2007, NEW ENGL J MED, V356, P2527, DOI 10.1056/NEJMhpr066212
   Blumenthal D, 2010, NEW ENGL J MED, V363, P501, DOI 10.1056/NEJMp1006114
   Buntin MB, 2010, HEALTH AFFAIR, V29, P1214, DOI 10.1377/hlthaff.2010.0503
   Chiang MF, 2005, OPHTHALMOLOGY, V112, P175, DOI 10.1016/j.ophtha.2004.09.032
   Chiang MF, 2008, OPHTHALMOLOGY, V115, P1591, DOI 10.1016/j.ophtha.2008.03.024
   Chiang MF, 2011, OPHTHALMOLOGY, V118, P1681, DOI 10.1016/j.ophtha.2011.04.015
   Dick RS, 1997, COMPUTER BASED PATIE, P50
   [Committee on Patient Safety and Health Information Technology Institute of Medicine], 2012, HLTH IT PAT SAF BUIL, P31
   DesRoches CM, 2008, NEW ENGL J MED, V359, P50, DOI 10.1056/NEJMsa0802005
   Diaz-Montes TP, 2012, J PATIENT SAF, V8, P189, DOI 10.1097/PTS.0b013e318269896f
   GREENES R A, 1990, Journal of the American Medical Association, V263, P1114, DOI 10.1001/jama.263.8.1114
   Greenhalgh T, 2009, MILBANK Q, V87, P729, DOI 10.1111/j.1468-0009.2009.00578.x
   Hahn KA, 2011, AM J MED QUAL, V26, P272, DOI 10.1177/1062860610392365
   Hales BM, 2006, J CRIT CARE, V21, P231, DOI 10.1016/j.jcrc.2006.06.002
   Haut ER, 2012, ARCH SURG-CHICAGO, V147, P901, DOI 10.1001/archsurg.2012.2024
   Horsky J, 2003, J BIOMED INFORM, V36, P4, DOI 10.1016/S1532-0464(03)00062-5
   Hwang JC, 2006, OPHTHALMOLOGY, V113, P511, DOI 10.1016/j.ophtha.2006.01.017
   Integrating the Healthcare Enterprise, IHE EYE CAR TECHN FR
   Kaushal R, 2010, QUAL SAF HEALTH CARE, V19, DOI 10.1136/qshc.2008.031179
   KLEIN R, 1985, OPHTHALMOLOGY, V92, P485
   Mangalmurti SS, 2010, NEW ENGL J MED, V363, P2060, DOI 10.1056/NEJMhle1005210
   MOSS SE, 1985, OPHTHALMOLOGY, V92, P62
   O'Donnell HC, 2009, J GEN INTERN MED, V24, P63, DOI 10.1007/s11606-008-0843-2
   Overhage JM, 2001, J AM MED INFORM ASSN, V8, P361, DOI 10.1136/jamia.2001.0080361
   Patel VL, 2001, J AM MED INFORM ASSN, V8, P324, DOI 10.1136/jamia.2001.0080324
   Patel VL, 2000, J AM MED INFORM ASSN, V7, P569, DOI 10.1136/jamia.2000.0070569
   Pizziferri L, 2005, J BIOMED INFORM, V38, P176, DOI 10.1016/j.jbi.2004.11.009
   Poissant L, 2005, J AM MED INFORM ASSN, V12, P505, DOI 10.1197/jamia.M1700
   Siegler EL, 2009, AM J MED, V122, P495, DOI 10.1016/j.amjmed.2009.02.010
   Streiff MB, 2012, BMJ-BRIT MED J, V344, DOI 10.1136/bmj.e3935
   TIERNEY WM, 1993, JAMA-J AM MED ASSOC, V269, P379, DOI 10.1001/jama.269.3.379
   Turchin A, 2011, ARCH INTERN MED, V171, P1393, DOI 10.1001/archinternmed.2011.219
   Wilson FM, 2005, PRACTICAL OPHTHALMOL, P307
   Wong DH, 2003, CRIT CARE MED, V31, P2488, DOI 10.1097/01.CCM.0000089637.53301.EF
NR 39
TC 21
Z9 21
U1 0
U2 7
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD SEP
PY 2013
VL 120
IS 9
BP 1745
EP 1755
DI 10.1016/j.ophtha.2013.02.017
PG 11
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Ophthalmology
GA 213HG
UT WOS:000324045800025
PM 23683945
DA 2022-11-30
ER

PT J
AU McKay, GJ
   Loane, E
   Nolan, JM
   Patterson, CC
   Meyers, KJ
   Mares, JA
   Yonova-Doing, E
   Hammond, CJ
   Beatty, S
   Silvestri, G
AF McKay, Gareth J.
   Loane, Edward
   Nolan, John M.
   Patterson, Christopher C.
   Meyers, Kristin J.
   Mares, Julie A.
   Yonova-Doing, Ekaterina
   Hammond, Christopher J.
   Beatty, Stephen
   Silvestri, Giuliana
TI Investigation of Genetic Variation in Scavenger Receptor Class B, Member
   1 (SCARB1) and Association with Serum Carotenoids
SO OPHTHALMOLOGY
LA English
DT Article
ID AGE-RELATED MACULOPATHY; GENOME-WIDE ASSOCIATION; PIGMENT
   OPTICAL-DENSITY; BEAVER DAM EYE; MACULAR DEGENERATION; SR-BI;
   RISK-FACTORS; CARDIOVASCULAR-DISEASE; LIPID-LEVELS; POPULATION
AB Objective: To investigate association of scavenger receptor class B, member 1 (SCARB1) genetic variants with serum carotenoid levels of lutein (L) and zeaxanthin (Z) and macular pigment optical density (MPOD).
   Design: A cross-sectional study of healthy adults aged 20 to 70.
   Participants: We recruited 302 participants after local advertisement.
   Methods: We measured MPOD by customized heterochromatic flicker photometry. Fasting blood samples were taken for serum L and Z measurement by high-performance liquid chromatography and lipoprotein analysis by spectrophotometric assay. Forty-seven single nucleotide polymorphisms (SNPs) across SCARB1 were genotyped using Sequenom technology. Association analyses were performed using PLINK to compare allele and haplotype means, with adjustment for potential confounding and correction for multiple comparisons by permutation testing. Replication analysis was performed in the TwinsUK and Carotenoids in Age-Related Eye Disease Study (CAREDS) cohorts.
   Main Outcome Measures: Odds ratios for MPOD area, serum L and Z concentrations associated with genetic variations in SCARB1 and interactions between SCARB1 and gender.
   Results: After multiple regression analysis with adjustment for age, body mass index, gender, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, triglycerides, smoking, and dietary L and Z levels, 5 SNPs were significantly associated with serum L concentration and 1 SNP with MPOD (P < 0.01). Only the association between rs11057841 and serum L withstood correction for multiple comparisons by permutation testing (P < 0.01) and replicated in the TwinsUK cohort (P < 0.014). Independent replication was also observed in the CAREDS cohort with rs10846744 (P = 2 x 10(-4)), an SNP in high linkage disequilibrium with rs11057841 (r(2) = 0.93). No interactions by gender were found. Haplotype analysis revealed no stronger association than obtained with single SNP analyses.
   Conclusions: Our study has identified association between rs11057841 and serum L concentration (24% increase per T allele) in healthy subjects, independent of potential confounding factors. Our data supports further evaluation of the role for SCARB1 in the transport of macular pigment and the possible modulation of age-related macular degeneration risk through combating the effects of oxidative stress within the retina. (C) 2013 by the American Academy of Ophthalmology.
C1 [McKay, Gareth J.; Patterson, Christopher C.] Queens Univ Belfast, Ctr Publ Hlth, Royal Victoria Hosp, Belfast BT12 6BJ, Antrim, North Ireland.
   [Loane, Edward] Royal Victoria Eye & Ear Hosp, Dept Ophthalmol, Dublin, Ireland.
   [Nolan, John M.; Beatty, Stephen] Waterford Inst Technol, Dept Chem & Life Sci, Macular Pigment Res Grp, Waterford, Ireland.
   [Meyers, Kristin J.; Mares, Julie A.] Univ Wisconsin, Dept Ophthalmol & Visual Sci, Madison, WI USA.
   [Yonova-Doing, Ekaterina; Hammond, Christopher J.] Kings Coll London, Dept Twin Res & Genet Epidemiol, London, England.
   [Silvestri, Giuliana] Queens Univ Belfast, Ctr Vis & Vasc Sci, Royal Victoria Hosp, Belfast BT12 6BJ, Antrim, North Ireland.
C3 Queens University Belfast; South East Technological University (SETU);
   University of Wisconsin System; University of Wisconsin Madison;
   University of London; King's College London; Queens University Belfast
RP McKay, GJ (通讯作者)，Queens Univ Belfast, Inst Clin Sci, Royal Victoria Hosp, Ctr Publ Hlth, Grosvenor Rd, Belfast BT12 6BJ, Antrim, North Ireland.
EM g.j.mckay@qub.ac.uk
RI McKay, Gareth/AAZ-2601-2020; Nolan, John/N-4921-2014
OI McKay, Gareth/0000-0001-8197-6280; Hammond,
   Christopher/0000-0002-3227-2620; Nolan, John/0000-0002-5503-7084;
   Silvestri, Giuliana/0000-0001-5662-5374
FU Bausch and Lomb, Ireland; EU; Wellcome Trust; US National Institutes of
   Health (NIH)/National Eye Institute (NEI) [1RO1EY018246, EY013018,
   EY016886]; NIH Center for Inherited Disease Research; National Institute
   for Health Research comprehensive Biomedical Research Centre; St.
   Thomas' National Health Service Foundation Trust partnering with King's
   College London; Women's Health Initiative (WHI); National Heart, Lung
   and Blood Institute, NIH; ESRC [ES/G007438/1] Funding Source: UKRI;
   Economic and Social Research Council [ES/G007438/1] Funding Source:
   researchfish; Medical Research Council [MC_CF023241] Funding Source:
   researchfish; National Institute for Health Research [SRF/01/010]
   Funding Source: researchfish; NATIONAL EYE INSTITUTE [U10EY013018,
   R01EY016886, R01EY018246] Funding Source: NIH RePORTER
FX Supported in part by Bausch and Lomb, Ireland, and EU Strand 1 research
   funding. The TwinsUK authors received funding from the Wellcome Trust
   with genotyping supported in part by US National Institutes of Health
   (NIH)/National Eye Institute (NEI) grant 1RO1EY018246 and performed by
   the NIH Center for Inherited Disease Research. The TwinsUK study also
   received support from the National Institute for Health Research
   comprehensive Biomedical Research Centre award to Guy's and St. Thomas'
   National Health Service Foundation Trust partnering with King's College
   London. The CAREDS authors received funding from the NIH, NEI [grants
   EY013018, EY016886], Research to Prevent Blindness, and the Women's
   Health Initiative (WHI), of which CAREDS is ancillary to, and is
   supported by contracts from the National Heart, Lung and Blood
   Institute, NIH.
CR Acton S, 1996, SCIENCE, V271, P518, DOI 10.1126/science.271.5248.518
   Acton S, 1999, ARTERIOSCL THROM VAS, V19, P1734, DOI 10.1161/01.ATV.19.7.1734
   Anderson G, 1998, CONTROL CLIN TRIALS, V19, P61
   Beatty S, 2001, INVEST OPHTH VIS SCI, V42, P439
   BONE RA, 1992, VISION RES, V32, P105, DOI 10.1016/0042-6989(92)90118-3
   BONE RA, 1993, INVEST OPHTH VIS SCI, V34, P2033
   Bunce C, 2010, EYE, V24, P1692, DOI 10.1038/eye.2010.122
   Chen W, 2010, P NATL ACAD SCI USA, V107, P7401, DOI 10.1073/pnas.0912702107
   Chiba-Falek O, 2010, BMC MED GENET, V11, DOI 10.1186/1471-2350-11-9
   Curcio CA, 2011, BRIT J OPHTHALMOL, V95, P1638, DOI 10.1136/bjophthalmol-2011-300344
   Duncan KG, 2002, BIOCHEM BIOPH RES CO, V292, P1017, DOI 10.1006/bbrc.2002.6756
   During A, 2008, J LIPID RES, V49, P1715, DOI 10.1194/jlr.M700580-JLR200
   Hammond CJ, 2012, INVEST OPHTH VIS SCI, V53, P4963, DOI 10.1167/iovs.12-9618
   Hysi PG, 2010, NAT GENET, V42, P902, DOI 10.1038/ng.664
   Ji Y, 1997, J BIOL CHEM, V272, P20982, DOI 10.1074/jbc.272.34.20982
   Kathiresan S, 2009, NAT GENET, V41, P56, DOI 10.1038/ng.291
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Klein R, 2007, AM J OPHTHALMOL, V143, P473, DOI 10.1016/j.ajo.2006.11.058
   Klein R, 2010, ARCH OPHTHALMOL-CHIC, V128, P750, DOI 10.1001/archophthalmol.2010.92
   Liew SHM, 2005, INVEST OPHTH VIS SCI, V46, P4430, DOI 10.1167/iovs.05-0519
   Loane E, 2008, BRIT J OPHTHALMOL, V92, P1163, DOI 10.1136/bjo.2007.135566
   Loane E, 2010, INVEST OPHTH VIS SCI, V51, P2636, DOI 10.1167/iovs.09-4397
   Manichaikul A, 2012, ARTERIOSCL THROM VAS, V32, P1991, DOI 10.1161/ATVBAHA.112.249714
   Mares JA, 2006, AM J CLIN NUTR, V84, P1107
   McCarthy JJ, 2009, J CLIN ENDOCR METAB, V94, P1789, DOI 10.1210/jc.2008-2800
   Morabia A, 2004, ATHEROSCLEROSIS, V175, P159, DOI 10.1016/j.atherosclerosis.2004.03.014
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   Neale BM, 2010, P NATL ACAD SCI USA, V107, P7395, DOI 10.1073/pnas.0912019107
   Nolan JM, 2008, INVEST OPHTH VIS SCI, V49, P2134, DOI 10.1167/iovs.07-0933
   Nolan JM, 2007, EXP EYE RES, V84, P61, DOI 10.1016/j.exer.2006.08.016
   Parker RS, 1996, FASEB J, V10, P542, DOI 10.1096/fasebj.10.5.8621054
   Purcell S, 2007, AM J HUM GENET, V81, P559, DOI 10.1086/519795
   Reboul E, 2005, BIOCHEM J, V387, P455, DOI 10.1042/BJ20040554
   Rodriguez-Esparragon F, 2005, ARTERIOSCL THROM VAS, V25, P854, DOI 10.1161/01.ATV.0000157581.88838.03
   Schick JH, 2003, AM J HUM GENET, V72, P1412, DOI 10.1086/375500
   SEDDON JM, 1994, JAMA-J AM MED ASSOC, V272, P1413, DOI 10.1001/jama.272.18.1413
   SNODDERLY DM, 1995, AM J CLIN NUTR, V62, P1448
   Snow K K, 1999, Ophthalmic Epidemiol, V6, P125, DOI 10.1076/opep.6.2.125.1558
   Tabas I, 2007, CIRCULATION, V116, P1832, DOI 10.1161/CIRCULATIONAHA.106.676890
   Thurnham DI, 2008, BRIT J NUTR, V100, P1307, DOI 10.1017/S0007114508971336
   U.S. Centers for Disease Control and Prevention (CDC), 2004, MMWR MORN MORTAL WKL, V53, P1069
   Wang W, 2007, AM J CLIN NUTR, V85, P762, DOI 10.1093/ajcn/85.3.762
   Weeks DE, 2000, HUM MOL GENET, V9, P1329, DOI 10.1093/hmg/9.9.1329
   Willer CJ, 2008, NAT GENET, V40, P161, DOI 10.1038/ng.76
   Wooten BR, 1999, INVEST OPHTH VIS SCI, V40, P2481
   Yeum KJ, 1996, AM J CLIN NUTR, V64, P594, DOI 10.1093/ajcn/64.4.594
   Zerbib J, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007341
NR 47
TC 18
Z9 18
U1 2
U2 15
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0161-6420
J9 OPHTHALMOLOGY
JI Ophthalmology
PD AUG
PY 2013
VL 120
IS 8
BP 1632
EP 1640
DI 10.1016/j.ophtha.2013.01.030
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 196LW
UT WOS:000322778000025
PM 23562302
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Pumariega, NM
   Smith, RT
   Sohrab, MA
   LeTien, V
   Souied, EH
AF Pumariega, Nicole M.
   Smith, R. Theodore
   Sohrab, Mahsa A.
   LeTien, Valerie
   Souied, Eric H.
TI A Prospective Study of Reticular Macular Disease
SO OPHTHALMOLOGY
LA English
DT Article
ID AGE-RELATED MACULOPATHY; PSEUDODRUSEN; DEGENERATION; PREVALENCE; ATROPHY
AB Purpose: To determine the risk of progression to advanced age-related macular degeneration (AMD) conferred by reticular pseudodrusen (RPD), an imaging presentation of reticular macular disease (RMD), in high-risk fellow eyes of subjects with AMD and unilateral choroidal neovascularization (CNV) in a large, prospective study.
   Design: Cohort study.
   Participants: Two hundred seventy-one subjects with AMD; 94 with RPD and 177 without RPD.
   Methods: Images from a cohort of 271 subjects with AMD in the Nutritional AMD treatment phase II (NAT 2) Study, a 3-year prospective study of subjects with unilateral CNV and large soft drusen in the fellow eye, were studied. The fellow eye, at high risk for advanced AMD developing, was the study eye. There were 5 visits per subject. Imaging at each visit consisted of color, red-free, and blue-light photography and fluorescein angiography. The images were analyzed for the presence of RPD, following disease progression throughout the 3-year study.
   Main Outcome Measures: The development of advanced AMD (CNV or geographic atrophy).
   Results: For the 271 subjects who completed the full 3-year study, there was a significantly higher rate of advanced AMD (56% or 53/94) in fellow eyes with RPD at any visit compared with eyes without RPD (32% or 56/177; P < 0.0001, chi-square test; relative risk [RR], 1.8; 95% confidence interval [CI], 1.4-2.4). The chance of developing advanced AMD in the fellow eye in women with RPD (66%) was more than double that of women without RPD (30%; P < 0.00001; RR, 2.2; 95% CI, 1.6-3.1).
   Conclusions: To the authors' knowledge, this is the first comprehensive prospective study of RMD, a distinct clinical phenotype of AMD that includes RPD. It provides strong confirmation that RMD, a disease entity with stereotypical presentations across imaging methods, is associated with a high risk of progression to advanced AMD, perhaps on an inflammatory or vascular basis. Reticular macular disease deserves wider recognition and consideration by clinicians caring for patients with AMD.
   Financial Disclosure(s): Proprietary or commercial disclosure may be found after the references. Ophthalmology 2011; 118: 1619-1625 (C) 2011 by the American Academy of Ophthalmology.
C1 [Pumariega, Nicole M.; Smith, R. Theodore; Sohrab, Mahsa A.] Columbia Univ, Harkness Eye Inst, Dept Ophthalmol, New York, NY 10032 USA.
   [LeTien, Valerie; Souied, Eric H.] Univ Paris 12, Hop Intercommunal Creteil, Dept Ophthalmol, Creteil, France.
C3 Columbia University; Universite Paris-Est-Creteil-Val-de-Marne (UPEC);
   CHI Creteil
RP Smith, RT (通讯作者)，Columbia Univ, Harkness Eye Inst, Dept Ophthalmol, 160 Ft Washington Ave,Room 509C, New York, NY 10032 USA.
EM rts1@columbia.edu
OI smith, theodore/0000-0002-1693-943X
FU New York Community Trust, New York, New York; National Eye Institute,
   Bethesda, Maryland [R01 EY015520]; Research to Prevent Blindness, Inc.,
   New York, New York; NATIONAL EYE INSTITUTE [R01EY015520] Funding Source:
   NIH RePORTER
FX Supported by grants from The New York Community Trust, New York, New
   York; the National Eye Institute, Bethesda, Maryland (grant no.: R01
   EY015520 [RTS]); and unrestricted funds from Research to Prevent
   Blindness, Inc., New York, New York. The funding organizations had no
   role in the design or conduct of this research. Images from the NAT 2
   Study were obtained from L'Hopital Intercommunal de Creteil, Creteil,
   France, and Eric H. Souied, MD, PhD. ISRCTN (numeric system for the
   unique identification of randomized controlled trials) number for the
   NAT 2 Study: 98246501.
CR Arnold JJ, 1997, AM J OPHTHALMOL, V124, P344, DOI 10.1016/S0002-9394(14)70826-8
   ARNOLD JJ, 1995, RETINA-J RET VIT DIS, V15, P183, DOI 10.1097/00006982-199515030-00001
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Chen J, 2008, IEEE ENG MED BIO, P2242, DOI 10.1109/IEMBS.2008.4649642
   Cohen SY, 2007, BRIT J OPHTHALMOL, V91, P354, DOI 10.1136/bjo.2006.101022
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Klein R, 2008, AM J OPHTHALMOL, V145, P317, DOI 10.1016/j.ajo.2007.09.008
   MIMOUN G, 1990, J FR OPHTALMOL, V13, P511
   Querques G, 2009, EUR J OPHTHALMOL, V19, P100, DOI 10.1177/112067210901900115
   SanGiovanni JP, 2008, ARCH OPHTHALMOL-CHIC, V126, P1274, DOI 10.1001/archopht.126.9.1274
   Sarks J, 2006, BRIT J OPHTHALMOL, V90, P442, DOI 10.1136/bjo.2005.083022
   SARKS J, 2010, BR J OPHTHALMOL 1125
   Schmitz-Valckenberg S, 2010, OPHTHALMOLOGY, V117, P1169, DOI 10.1016/j.ophtha.2009.10.044
   Smith RT, 2006, INVEST OPHTH VIS SCI, V47, P5495, DOI 10.1167/iovs.05-1318
   Smith RT, 2009, AM J OPHTHALMOL, V148, P733, DOI 10.1016/j.ajo.2009.06.028
   Smith RT, 2005, ARCH OPHTHALMOL-CHIC, V123, P200, DOI 10.1001/archopht.123.2.200
   Spaide RF, 2010, RETINA-J RET VIT DIS, V30, P1441, DOI 10.1097/IAE.0b013e3181ee5ce8
   Walsh SJ, 2000, AM J PUBLIC HEALTH, V90, P1463, DOI 10.2105/AJPH.90.9.1463
   Zarbin MA, 2006, BRIT J OPHTHALMOL, V90, P396, DOI 10.1136/bjo.2005.086041
   Zweifel SA, 2010, OPHTHALMOLOGY, V117, P1775, DOI 10.1016/j.ophtha.2010.01.027
   Zweifel SA, 2010, OPHTHALMOLOGY, V117, P303, DOI 10.1016/j.ophtha.2009.07.014
NR 21
TC 114
Z9 118
U1 0
U2 7
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD AUG
PY 2011
VL 118
IS 8
BP 1619
EP 1625
DI 10.1016/j.ophtha.2011.01.029
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 800TT
UT WOS:000293390900020
PM 21550118
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Mora, AD
   Vieira, PM
   Manivannan, A
   Fonseca, JM
AF Mora, Andre D.
   Vieira, Pedro M.
   Manivannan, Ayyakkannu
   Fonseca, Jose M.
TI Automated drusen detection in retinal images using analytical modelling
   algorithms
SO BIOMEDICAL ENGINEERING ONLINE
LA English
DT Article
ID MACULAR DRUSEN; FUNDUS PHOTOGRAPHS; QUANTIFICATION; MACULOPATHY
AB Background: Drusen are common features in the ageing macula associated with exudative Age-Related Macular Degeneration (ARMD). They are visible in retinal images and their quantitative analysis is important in the follow up of the ARMD. However, their evaluation is fastidious and difficult to reproduce when performed manually.
   Methods: This article proposes a methodology for Automatic Drusen Deposits Detection and quantification in Retinal Images (AD3RI) by using digital image processing techniques. It includes an image pre-processing method to correct the uneven illumination and to normalize the intensity contrast with smoothing splines. The drusen detection uses a gradient based segmentation algorithm that isolates drusen and provides basic drusen characterization to the modelling stage. The detected drusen are then fitted by Modified Gaussian functions, producing a model of the image that is used to evaluate the affected area.
   Twenty two images were graded by eight experts, with the aid of a custom made software and compared with AD3RI. This comparison was based both on the total area and on the pixel-to-pixel analysis. The coefficient of variation, the intraclass correlation coefficient, the sensitivity, the specificity and the kappa coefficient were calculated.
   Results: The ground truth used in this study was the experts' average grading. In order to evaluate the proposed methodology three indicators were defined: AD3RI compared to the ground truth (A2G); each expert compared to the other experts (E2E) and a standard Global Threshold method compared to the ground truth (T2G). The results obtained for the three indicators, A2G, E2E and T2G, were: coefficient of variation 28.8 %, 22.5 % and 41.1 %, intraclass correlation coefficient 0.92, 0.88 and 0.67, sensitivity 0.68, 0.67 and 0.74, specificity 0.96, 0.97 and 0.94, and kappa coefficient 0.58, 0.60 and 0.49, respectively.
   Conclusions: The gradings produced by AD3RI obtained an agreement with the ground truth similar to the experts (with a higher reproducibility) and significantly better than the Threshold Method. Despite the higher sensitivity of the Threshold method, explained by its over segmentation bias, it has lower specificity and lower kappa coefficient. Therefore, it can be concluded that AD3RI accurately quantifies drusen, using a reproducible method with benefits for ARMD evaluation and follow-up.
C1 [Mora, Andre D.; Fonseca, Jose M.] Univ Nova Lisboa, Ctr Technol & Syst, P-2829516 Caparica, Portugal.
   [Mora, Andre D.; Fonseca, Jose M.] Univ Nova Lisboa, Dept Electrotech Engn, Fac Sci & Technol, P-2829516 Caparica, Portugal.
   [Vieira, Pedro M.] Univ Nova Lisboa, Dept Phys, Fac Sci & Technol, P-2829516 Caparica, Portugal.
   [Manivannan, Ayyakkannu] NHS Grampian, NHS Grampian Dept Biomed Phys & Bioengn, Aberdeen AB25 2ZD, Scotland.
   [Manivannan, Ayyakkannu] Univ Aberdeen, Aberdeen AB25 2ZD, Scotland.
C3 Universidade Nova de Lisboa; Universidade Nova de Lisboa; Universidade
   Nova de Lisboa; University of Aberdeen
RP Mora, AD (通讯作者)，Univ Nova Lisboa, Ctr Technol & Syst, Campus FCT UNL, P-2829516 Caparica, Portugal.
EM atbdm@fct.unl.pt
RI Manivannan, Ayyakkannu/AAD-1464-2019; Vieira, Pedro/H-9830-2016;
   Fonseca, Jose MMR/C-9497-2013; Mora, André/A-7912-2012; Manivannan,
   Ayyakkannu/A-2227-2012
OI Vieira, Pedro/0000-0002-3823-1184; Fonseca, Jose
   MMR/0000-0001-7173-7374; Mora, André/0000-0003-1354-4739; Manivannan,
   Ayyakkannu/0000-0003-0676-7918
FU Fundacao para a Ciencia e Tecnologia [POCI/SAU-ESP/57592/2004]
FX This work was partially financed by the Fundacao para a Ciencia e
   Tecnologia, through the POCTI and POSI Research Programs (project
   n<SUP>o</SUP> POCI/SAU-ESP/57592/2004).
CR CULPIN D, 1986, NUMER MATH, V48, P627, DOI 10.1007/BF01399686
   GOATMAN KA, 2003, P MED IM UND AN SHEF, P49
   Gonzalez RC, 2007, DIGITAL IMAGE PROCES
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   KIRKPATRICK JNP, 1995, EYE, V9, P48, DOI 10.1038/eye.1995.7
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   LANDIS JR, 1977, BIOMETRICS, V33, P159, DOI 10.2307/2529310
   MARQUARDT DW, 1963, J SOC IND APPL MATH, V11, P431, DOI 10.1137/0111030
   MORA A, 2005, P BIOMED2005 IASTED
   MORA A, 2006, P 4 IASTED INT C BIO
   MORA A, 2005, P 2 INT C COMP INT M
   MORGAN WH, 1994, AUST NZ J OPHTHALMOL, V22, P7, DOI 10.1111/j.1442-9071.1994.tb01688.x
   PELI E, 1990, J OPT SOC AM A, V7, P2032, DOI 10.1364/JOSAA.7.002032
   PELI E, 1986, OPHTHALMOLOGY, V93, P1575
   PHILLIPS RP, 1991, EYE, V5, P130, DOI 10.1038/eye.1991.24
   Rapantzikos K, 2003, MED IMAGE ANAL, V7, P95, DOI 10.1016/S1361-8415(02)00093-2
   SALEM NM, 2005, P BIOMED2005 IASTED
   Shin DS, 1999, OPHTHALMOLOGY, V106, P1119, DOI 10.1016/S0161-6420(99)90257-9
   Smith RT, 2003, BIOMED ENG ONLINE, V2, DOI 10.1186/1475-925X-2-10
   Smith RT, 2005, BRIT J OPHTHALMOL, V89, P87, DOI 10.1136/bjo.2004.042937
   Smith RT, 2005, ARCH OPHTHALMOL-CHIC, V123, P200, DOI 10.1001/archopht.123.2.200
   Soliz P, 2002, P SOC PHOTO-OPT INS, V4681, P159, DOI 10.1117/12.466917
   Thaibaoui A, 2000, INT C PATT RECOG, P748, DOI 10.1109/ICPR.2000.903025
   MD3RI MANUAL DRUSEN
NR 24
TC 40
Z9 42
U1 0
U2 10
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1475-925X
J9 BIOMED ENG ONLINE
JI Biomed. Eng. Online
PD JUL 12
PY 2011
VL 10
AR 59
DI 10.1186/1475-925X-10-59
PG 15
WC Engineering, Biomedical
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Engineering
GA 801CA
UT WOS:000293412800001
PM 21749717
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Helb, HM
   Issa, PC
   Fleckenstein, M
   Schmitz-Valckenberg, S
   Scholl, HPN
   Meyer, CH
   Eter, N
   Holz, FG
AF Helb, Hans-Martin
   Issa, Peter Charbel
   Fleckenstein, Monika
   Schmitz-Valckenberg, Steffen
   Scholl, Hendrik P. N.
   Meyer, Carsten H.
   Eter, Nicole
   Holz, Frank G.
TI Clinical evaluation of simultaneous confocal scanning laser
   ophthalmoscopy imaging combined with high-resolution, spectral-domain
   optical coherence tomography
SO ACTA OPHTHALMOLOGICA
LA English
DT Article
DE blue reflectance imaging; confocal scanning laser ophthalmoscopy;
   fluorescein angiography; fundus autofluorescence; indocyanine green
   angiography; infrared reflectance imaging; spectral-domain optical
   coherence tomography
ID FUNDUS AUTOFLUORESCENCE PATTERNS; INDOCYANINE-GREEN ANGIOGRAPHY; MACULAR
   HOLE FORMATION; GEOGRAPHIC ATROPHY; NEOVASCULAR MEMBRANES; JUNCTIONAL
   ZONE; VISUALIZATION; FLUORESCEIN; VIDEOANGIOGRAPHY; CLASSIFICATION
AB Purpose:
   To evaluate the clinical relevance of a new diagnostic modality, simultaneous confocal scanning laser ophthalmoscopy (cSLO) and high-speed, high-resolution, spectral-domain optical coherence tomography (OCT), for the visualization of macular pathologies.
   Methods:
   OCT images and simultaneous recording of fluorescein angiography, indocyanine green (ICG) angiography, infrared, and blue reflectance ('red-free') or fundus autofluorecence (FAF) images were obtained with a novel imaging device (Spectralis HRA + OCT; Heidelberg Engineering, Heidelberg, Germany). An optically pumped solid-state laser generated the excitation wavelength (488 nm) required for blue reflectance, FAF and fluorescein angiography images. For ICG angiography and infrared imaging, diode laser sources at 790 and 815 nm were used. For OCT, 40 000 A-scans per second were acquired with 7 mu m axial and 14 mu m lateral optical resolution. The B-scans covering a transversal range of 30 degrees had a scan width up to 1.536 A-scans with a digital lateral resolution of 5 mu m/pixel, a scan depth of 1.8 mm with 3.5 mu m/pixel digital axial resolution and a scan rate of up to 48 B-scans/second. In addition, volume scans could be obtained at 15, 20 and 30 degrees fields of view. An integrated eye tracking allowed for live averaging of cSLO images as well as OCT B-scans.
   Results:
   Early, neovascular and atrophic age-related macular degeneration, macular telangiectasia, retinal arterial, branch vein occlusion and other pathologies were imaged, and cSLO and OCT frames correlated. Fluorescein and ICG angiographic phenomena recorded in cSLO images could be analysed accurately in corresponding OCT cross-sections. Abnormal FAF signals were correlated to alterations at the outer retinal/retinal pigment epithelial cell layer in high-resolution OCT scans. Three-dimensional OCT enabled comprehensive retinal coverage. The imaging software tracked eye movements accurately. Averaging of live B-scans enhanced image quality considerably.
   Conclusion:
   The combined cSLO/OCT system allowed for simultaneous recordings of topographic and tomographic images with accurate correlation between the confocal angiograms, FAF images as well as other imaging modes with the OCT scans. The instrument thus provides simultaneous multi-modal imaging of retinal pathologies and disease.
C1 [Helb, Hans-Martin; Issa, Peter Charbel; Fleckenstein, Monika; Schmitz-Valckenberg, Steffen; Scholl, Hendrik P. N.; Meyer, Carsten H.; Eter, Nicole; Holz, Frank G.] Univ Bonn, Dept Ophthalmol, D-53127 Bonn, Germany.
C3 University of Bonn
RP Holz, FG (通讯作者)，Univ Bonn, Dept Ophthalmol, Ernst Abbe Str 2, D-53127 Bonn, Germany.
EM frank.holz@ukb.uni-bonn.de
RI Issa, Peter Charbel/O-2580-2019; Issa, Peter Charbel/E-8935-2018; Issa,
   Peter Charbel/F-9603-2011; Meyer, Carsten/A-3981-2017
OI Issa, Peter Charbel/0000-0002-0351-6673; Issa, Peter
   Charbel/0000-0002-0351-6673; Meyer, Carsten/0000-0002-0530-5298;
   Fleckenstein, Monika/0000-0001-8321-8037
FU DFG (German Research Council, Bonn, Germany) [SPP 1088, Ho 1926/1-3]; EU
   [LSHG-CT-2005-512036]
FX This study was presented in part at the Association for Research in
   Vision and Ophthalmology (ARVO) meeting, Fort Lauderdale, Florida, USA,
   May 2007. The study was supported by the DFG (German Research Council,
   Bonn, Germany), Research Priority Program Age-related Macular
   Degeneration SPP 1088, Ho 1926/1-3; EU FP6, Integrated Project
   'EVI-GENORET' (LSHG-CT-2005-512036). F.G.H. has served as a consultant
   for Heidelberg Engineering.
CR Arnold JJ, 1997, AM J OPHTHALMOL, V124, P344, DOI 10.1016/S0002-9394(14)70826-8
   Bellmann C, 2002, ARCH OPHTHALMOL-CHIC, V120, P579, DOI 10.1001/archopht.120.5.579
   Bellmann C, 1997, OPHTHALMOLOGE, V94, P385, DOI 10.1007/s003470050130
   Bindewald A, 2005, INVEST OPHTH VIS SCI, V46, P3309, DOI 10.1167/iovs.04-0430
   Bindewald A, 2005, BRIT J OPHTHALMOL, V89, P874, DOI 10.1136/bjo.2004.057794
   Cense B, 2004, OPT EXPRESS, V12, P2435, DOI 10.1364/OPEX.12.002435
   Chauhan DS, 2000, ARCH OPHTHALMOL-CHIC, V118, P32
   Delori FC, 2001, INVEST OPHTH VIS SCI, V42, P1855
   DELORI FC, 1995, INVEST OPHTH VIS SCI, V36, P718
   DITHMAR S, 1995, KLIN MONATSBL AUGENH, V207, P11, DOI 10.1055/s-2008-1035342
   Drexler W, 1999, OPT LETT, V24, P1221, DOI 10.1364/OL.24.001221
   Drexler W, 2003, ARCH OPHTHALMOL-CHIC, V121, P695, DOI 10.1001/archopht.121.5.695
   Drexler W, 2001, NAT MED, V7, P502, DOI 10.1038/86589
   Drexler W, 2004, J BIOMED OPT, V9, P47, DOI 10.1117/1.1629679
   Drexler W., 2005, SHAPE GLAUCOMA, P75
   Elsner AE, 1996, VISION RES, V36, P191, DOI 10.1016/0042-6989(95)00100-E
   FERCHER AF, 1995, OPT COMMUN, V117, P43, DOI 10.1016/0030-4018(95)00119-S
   Gaudric A, 1999, ARCH OPHTHALMOL-CHIC, V117, P744
   GUYER DR, 1992, OPHTHALMOLOGY, V99, P287
   GUYER DR, 1994, OPHTHALMOLOGY, V101, P1727
   Hausler G, 1998, J BIOMED OPT, V3, P21, DOI 10.1117/1.429899
   Hee MR, 1996, OPHTHALMOLOGY, V103, P1260, DOI 10.1016/S0161-6420(96)30512-5
   HEE MR, 1995, ARCH OPHTHALMOL-CHIC, V113, P325, DOI 10.1001/archopht.1995.01100030081025
   Holz FG, 2001, INVEST OPHTH VIS SCI, V42, P1051
   Holz FG, 1998, AM J OPHTHALMOL, V125, P227, DOI 10.1016/S0002-9394(99)80095-6
   Holz FG, 2001, OPHTHALMOLOGE, V98, P10, DOI 10.1007/s003470170194
   Holz FG, 1999, GRAEF ARCH CLIN EXP, V237, P145, DOI 10.1007/s004170050209
   Holz FG, 2007, AM J OPHTHALMOL, V143, P463, DOI 10.1016/j.ajo.2006.11.041
   HOPEROSS M, 1994, OPHTHALMOLOGY, V101, P529
   HUANG D, 1991, SCIENCE, V254, P1178, DOI 10.1126/science.1957169
   Issa PC, 2008, ACTA OPHTHALMOL, V86, P464, DOI 10.1111/j.1600-0420.2007.01041.x
   Issa PC, 2008, INVEST OPHTH VIS SCI, V49, P1172, DOI 10.1167/iovs.07-0636
   Jorzik JJ, 2005, RETINA-J RET VIT DIS, V25, P405, DOI 10.1097/00006982-200506000-00003
   *LAS I AM, 1993, Z13611993 ANSI LAS I
   Leitgeb RA, 2004, OPT EXPRESS, V12, P2156, DOI 10.1364/OPEX.12.002156
   Massin P, 2001, AM J OPHTHALMOL, V132, P599, DOI 10.1016/S0002-9394(01)01015-7
   Massin P, 2000, AM J OPHTHALMOL, V130, P732, DOI 10.1016/S0002-9394(00)00574-2
   Massin P, 2006, ACTA OPHTHALMOL SCAN, V84, P466, DOI 10.1111/j.1600-0420.2006.00694.x
   NOVOTNY HR, 1961, CIRCULATION, V24, P82, DOI 10.1161/01.CIR.24.1.82
   PULIAFITO CA, 1995, OPHTHALMOLOGY, V102, P217
   RABB MF, 1978, SURV OPHTHALMOL, V22, P387, DOI 10.1016/0039-6257(78)90134-0
   RUCKMANN VA, 1995, BR J OPHTHALMOL, V79, P407
   Sanchez-Tocino H, 2002, INVEST OPHTH VIS SCI, V43, P1588
   SCHEIDER A, 1992, AM J OPHTHALMOL, V113, P45, DOI 10.1016/S0002-9394(14)75752-6
   Schmitz-Valckenberg S, 2002, GRAEF ARCH CLIN EXP, V240, P73, DOI 10.1007/s00417-001-0413-3
   Schuman J S, 1995, Curr Opin Ophthalmol, V6, P89
   SCHUMAN JS, 1995, ARCH OPHTHALMOL-CHIC, V113, P586, DOI 10.1001/archopht.1995.01100050054031
   Soliman W, 2007, ACTA OPHTHALMOL SCAN, V85, P613, DOI 10.1111/j.1600-0420.2007.00917.x
   Spaide RF, 2003, OPHTHALMOLOGY, V110, P392, DOI 10.1016/S0161-6420(02)01756-6
   Spaide RF, 2002, AM J OPHTHALMOL, V133, P226, DOI 10.1016/S0002-9394(01)01377-0
   SPAIDE RF, 1999, DIS RETINA VITREOUS, P29
   Staurenghi G, 1996, ARCH OPHTHALMOL-CHIC, V114, P365, DOI 10.1001/archopht.1996.01100130361042
   STEIN MR, 1971, AM J OPHTHALMOL, V72, P861, DOI 10.1016/0002-9394(71)91681-3
   SWANSON EA, 1993, OPT LETT, V18, P1864, DOI 10.1364/OL.18.001864
   TITTL MK, 1999, DIS RETINA VITREOUS, P39
   WEBB RH, 1980, APPL OPTICS, V19, P2991, DOI 10.1364/AO.19.002991
   WEBB RH, 1987, APPL OPTICS, V26, P1492, DOI 10.1364/AO.26.001492
   WEINBERGER AW, 2007, INVEST OPHTH VIS SCI, V47, P3098
   Wojtkowski M, 2005, OPHTHALMOLOGY, V112, P1734, DOI 10.1016/j.ophtha.2005.05.023
   Wojtkowski M, 2004, AM J OPHTHALMOL, V138, P412, DOI 10.1016/j.ajo.2004.04.049
   Wolf S, 1994, Ger J Ophthalmol, V3, P224
   WORLD MED ASS, 2000, B MED ETHICS, V158, P9
   YANNUZZI LA, 1992, RETINA-J RET VIT DIS, V12, P191, DOI 10.1097/00006982-199212030-00003
   YONEYA S, 1993, ARCH OPHTHALMOL-CHIC, V111, P1165, DOI 10.1001/archopht.1993.01090090015002
NR 64
TC 84
Z9 86
U1 0
U2 11
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1755-375X
EI 1755-3768
J9 ACTA OPHTHALMOL
JI Acta Ophthalmol.
PD DEC
PY 2010
VL 88
IS 8
BP 842
EP 849
DI 10.1111/j.1755-3768.2009.01602.x
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 686LZ
UT WOS:000284699100018
PM 19706019
OA Bronze
DA 2022-11-30
ER

PT J
AU Wu, WC
   Hu, DN
   Gao, HX
   Chen, M
   Wang, DW
   Rosen, R
   McCormick, SA
AF Wu, Wen-Chuan
   Hu, Dan-Ning
   Gao, Hua-Xin
   Chen, Min
   Wang, Dawei
   Rosen, Richard
   McCormick, Steven A.
TI Subtoxic levels hydrogen peroxide-induced production of interleukin-6 by
   retinal pigment epithelial cells
SO MOLECULAR VISION
LA English
DT Article
ID COMPLEMENT FACTOR-H; NF-KAPPA-B; PROTEIN-KINASE INHIBITOR; OXIDATIVE
   STRESS; MACULAR DEGENERATION; UVEAL MELANOCYTES; GENE-EXPRESSION;
   AQUEOUS-HUMOR; P38 MAPK; IN-VITRO
AB Purpose: To study the effect of subtoxic levels of hydrogen peroxide (H2O2) on the expression and release of interleukin-6 (IL-6) by cultured retinal pigment epithelial (RPE) cells and to explore the relevant signal pathways.
   Methods: Cultured human RPE cells were stimulated with various subtoxic concentrations of H2O2 for different periods. Conditioned medium and cells were collected. IL-6 in the medium and IL-6 mRNA in the collected cells were measured using an IL-6 enzyme-linked immunosorbent assay kit and reverse transcriptase polymerase chain reaction, respectively. Nuclear factor-kappaB (NF-kappa B) in nuclear extracts and phosphorylated p38 mitogen-activated protein kinase (MAPK), extracellular signal-regulated kinase (ERK), and c-Jun N-terminal kinases (JNK) in cells cultured with and without H2O2 were measured by NF-kappa B and MAPK enzyme-linked immunosorbent assay kits. Inhibitors of p38 (SB203580), ERK (UO1026), JNK (SP600125), and NF-kappa B (BAY11-7082) were added to the cultures before the addition of H2O2 to test their effects.
   Results: Subtoxic levels of H2O2 (100 mu M and less) increased the IL-6 mRNA level and the release of IL-6 protein by the cultured human RPE cells in a dose-and time-dependent manner. This was accompanied by an increase of NF-kappa B in nuclear extracts and phosphorylated p38 MAPK, ERK, and JNK in cell lysates, particularly in the p38 and NF-kappa B. The NF-kappa B inhibitor decreased the H2O2-induced expression of IL-6. The p38 inhibitor, but not the ERK or JNK inhibitor, completely abolished H2O2-induced expression of IL-6 by RPE cells. The p38 inhibitor also abolished the increase of NF-kappa B in nuclear extracts in cells treated with H2O2.
   Conclusions: H2O2 stimulated the production of IL-6, a key factor in the modulation of immune responses, inflammatory processes, and the occurrence of autoimmune diseases, which recently has been documented to be increased in age-related macular degeneration (AMD). This may be a molecular linkage for the oxidative stress and inflammatory/autoimmune reactions in AMD and may provide a novel target for the treatment of AMD.
C1 [Hu, Dan-Ning; Chen, Min; Rosen, Richard; McCormick, Steven A.] New York Med Coll, Dept Pathol, Tissue Culture Ctr, New York Eye & Ear Infirm, New York, NY 10003 USA.
   [Hu, Dan-Ning; Chen, Min; Rosen, Richard; McCormick, Steven A.] New York Med Coll, Dept Ophthalmol, Tissue Culture Ctr, New York Eye & Ear Infirm, New York, NY 10003 USA.
   [Wu, Wen-Chuan] Kaoshiung Med Univ Hosp, Dept Ophthalmol, Kaohsiung, Taiwan.
   [Wu, Wen-Chuan] Kaohsiung Med Univ, Coll Med, Dept Ophthalmol, Kaohsiung, Taiwan.
   [Gao, Hua-Xin] Albert Einstein Coll Med, Bronx, NY 10467 USA.
   [Wang, Dawei] Off Chief Med Examiner New York City, New York, NY USA.
C3 New York Eye & Ear Infirmary of Mount Sinai; New York Medical College;
   New York Eye & Ear Infirmary of Mount Sinai; New York Medical College;
   Kaohsiung Medical University; Yeshiva University; Albert Einstein
   College of Medicine
RP Hu, DN (通讯作者)，New York Med Coll, Dept Pathol, Tissue Culture Ctr, New York Eye & Ear Infirm, New York, NY 10003 USA.
EM hu2095@yahoo.com
FU National Science Council, Taiwan [NSC96-2314-B-037-025];
   Bendheim-Lowenstein Family Foundation, New York; New York Eye and Ear
   Infirmary
FX This study was supported by the grant from National Science Council,
   Taiwan, (NSC96-2314-B-037-025), the Bendheim-Lowenstein Family
   Foundation, New York, and Pathology Research Fund of New York Eye and
   Ear Infirmary.
CR Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   Badolato R, 1996, SEMIN ARTHRITIS RHEU, V26, P526, DOI 10.1016/S0049-0172(96)80041-2
   Ballinger SW, 1999, EXP EYE RES, V68, P765, DOI 10.1006/exer.1998.0661
   Bok D, 2005, P NATL ACAD SCI USA, V102, P7053, DOI 10.1073/pnas.0502819102
   Cai JY, 2000, PROG RETIN EYE RES, V19, P205, DOI 10.1016/S1350-9462(99)00009-9
   Campbell S, 2006, J IMMUNOL, V176, P1889, DOI 10.4049/jimmunol.176.3.1889
   Chang JY, 2007, NEUROSCI LETT, V416, P217, DOI 10.1016/j.neulet.2007.01.076
   Chen M, 2007, EXP EYE RES, V84, P635, DOI 10.1016/j.exer.2006.11.015
   Chen M, 2010, EXP EYE RES, V90, P437, DOI 10.1016/j.exer.2009.12.004
   Colston JT, 2002, J BIOL CHEM, V277, P23477, DOI 10.1074/jbc.M108676200
   Craig R, 2000, J BIOL CHEM, V275, P23814, DOI 10.1074/jbc.M909695199
   DEBOER JH, 1992, CURR EYE RES, V11, P181, DOI 10.3109/02713689208999530
   Donoso LA, 2006, SURV OPHTHALMOL, V51, P137, DOI 10.1016/j.survophthal.2005.12.001
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Fijen JW, 2001, CLIN EXP IMMUNOL, V124, P16, DOI 10.1046/j.1365-2249.2001.01485.x
   FRANKS WA, 1992, CURR EYE RES, V11, P187, DOI 10.3109/02713689208999531
   Frossi B, 2003, EUR J IMMUNOL, V33, P2168, DOI 10.1002/eji.200323995
   Gao HX, 2009, CYTOKINE, V46, P24, DOI 10.1016/j.cyto.2008.12.001
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hogg R, 2004, CURR EYE RES, V29, P387, DOI 10.1080/02713680490517890
   Hollborn M, 2000, CURR EYE RES, V20, P488, DOI 10.1076/0271-3683(200006)20:6;1-Y;FT488
   Hollyfield JG, 2008, NAT MED, V14, P194, DOI 10.1038/nm1709
   HU DN, 1993, INVEST OPHTH VIS SCI, V34, P2210
   Hu DN, 2002, INT J TOXICOL, V21, P465, DOI 10.1080/10915810290169891
   Ishihara K, 2002, CYTOKINE GROWTH F R, V13, P357, DOI 10.1016/S1359-6101(02)00027-8
   JAFFE GJ, 1995, EXP EYE RES, V60, P533, DOI 10.1016/S0014-4835(05)80068-5
   Jarrett SG, 2005, FREE RADICAL BIO MED, V38, P1382, DOI 10.1016/j.freeradbiomed.2005.02.003
   Jarrett SG, 2006, FREE RADICAL RES, V40, P1155, DOI 10.1080/10715760600876613
   Jin GF, 2001, CURR EYE RES, V22, P165, DOI 10.1076/ceyr.22.3.165.5517
   Kavanaugh A, 2007, BULL HOSP JT DIS, V65, pS16
   Kijlstra A, 2005, OCUL IMMUNOL INFLAMM, V13, P3, DOI 10.1080/09273940590909185
   Kim Min-Ho, 2003, Korean J Ophthalmol, V17, P19
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Klein R, 2008, OPHTHALMOLOGY, V115, P1742, DOI 10.1016/j.ophtha.2008.03.021
   Kosmidou I, 2002, AM J RESP CELL MOL, V26, P587, DOI 10.1165/ajrcmb.26.5.4598
   Leung KW, 2009, MOL IMMUNOL, V46, P1374, DOI 10.1016/j.molimm.2008.12.001
   Li GR, 2007, MOL VIS, V13, P2282
   LOPEZ PF, 1991, AM J OPHTHALMOL, V112, P647, DOI 10.1016/S0002-9394(14)77270-8
   Marin-Castano ME, 2005, INVEST OPHTH VIS SCI, V46, P3331, DOI 10.1167/iovs.04-1224
   Martin KR, 2002, HUM EXP TOXICOL, V21, P71, DOI 10.1191/0960327102ht213oa
   Maulik N, 1998, FEBS LETT, V429, P365, DOI 10.1016/S0014-5793(98)00632-2
   McCubrey JA, 2006, ANTIOXID REDOX SIGN, V8, P1775, DOI 10.1089/ars.2006.8.1775
   Meri S, 2007, ANN NY ACAD SCI, V1109, P93, DOI 10.1196/annals.1398.011
   Moshfeghi DM, 2007, RETINA-J RET VIT DIS, V27, P269, DOI 10.1097/IAE.0b013e31802e3e9b
   MURRAY PI, 1990, INVEST OPHTH VIS SCI, V31, P917
   NAGINENI CN, 1994, CLIN DIAGN LAB IMMUN, V1, P569, DOI 10.1128/CDLI.1.5.569-577.1994
   Nakahara H, 2003, ARTHRITIS RHEUM-US, V48, P1521, DOI 10.1002/art.11143
   Nishimoto N, 2006, CURR OPIN RHEUMATOL, V18, P277, DOI 10.1097/01.bor.0000218949.19860.d1
   Nonn L, 2007, CARCINOGENESIS, V28, P1188, DOI 10.1093/carcin/bgl241
   Parasrampuria DA, 2003, J CLIN PHARMACOL, V43, P406, DOI 10.1177/0091270002250615
   Park JY, 2007, BULL HOSP JT DIS, V65, pS4
   Patel M, 2008, SEMIN IMMUNOPATHOL, V30, P97, DOI 10.1007/s00281-008-0112-9
   Poli G, 2004, CURR MED CHEM, V11, P1163, DOI 10.2174/0929867043365323
   Rein DB, 2009, ARCH OPHTHALMOL-CHIC, V127, P533, DOI 10.1001/archophthalmol.2009.58
   Roh MI, 2009, RETINA-J RET VIT DIS, V29, P523, DOI 10.1097/IAE.0b013e318195cb15
   Sano M, 2001, CIRC RES, V89, P661, DOI 10.1161/hh2001.098873
   Schreiber S, 2006, CLIN GASTROENTEROL H, V4, P325, DOI 10.1016/j.cgh.2005.11.013
   Sebba A, 2008, AM J HEALTH-SYST PH, V65, P1413, DOI 10.2146/ajhp070449
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P774, DOI 10.1001/archopht.123.6.774
   Thakkinstian A, 2006, HUM MOL GENET, V15, P2784, DOI 10.1093/hmg/ddl220
   Thalhamer T, 2008, RHEUMATOLOGY, V47, P409, DOI 10.1093/rheumatology/kem297
   Valko M, 2007, INT J BIOCHEM CELL B, V39, P44, DOI 10.1016/j.biocel.2006.07.001
   Wada M, 2001, CURR EYE RES, V23, P226, DOI 10.1076/ceyr.23.3.226.5467
   Willermain F, 2000, INVEST OPHTH VIS SCI, V41, P3485
   Winkler BS, 1999, MOL VIS, V5
   Woo MS, 2005, BIOCHEM BIOPH RES CO, V335, P1017, DOI 10.1016/j.bbrc.2005.07.174
   Yoshida Y, 1999, AM J PHYSIOL-LUNG C, V276, pL900, DOI 10.1152/ajplung.1999.276.6.L900
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
   Zechner D, 1998, J BIOL CHEM, V273, P8232, DOI 10.1074/jbc.273.14.8232
NR 70
TC 49
Z9 51
U1 0
U2 4
PU MOLECULAR VISION
PI ATLANTA
PA C/O JEFF BOATRIGHT, LAB B, 5500 EMORY EYE CENTER, 1327 CLIFTON RD, N E,
   ATLANTA, GA 30322 USA
SN 1090-0535
J9 MOL VIS
JI Mol. Vis.
PD SEP 12
PY 2010
VL 16
IS 200-02
BP 1864
EP 1873
PG 10
WC Biochemistry & Molecular Biology; Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Ophthalmology
GA 651BH
UT WOS:000281899100003
PM 21031020
DA 2022-11-30
ER

PT J
AU Yang, F
   Sun, YY
   Bai, YJ
   Li, SS
   Huang, L
   Li, XX
AF Yang, Fei
   Sun, Yaoyao
   Bai, Yujing
   Li, Shanshan
   Huang, Lvzhen
   Li, Xiaoxin
TI Asthma Promotes Choroidal Neovascularization via the Transforming Growth
   Factor Beta1/Smad Signalling Pathway in a Mouse Model
SO OPHTHALMIC RESEARCH
LA English
DT Article
DE Asthma; Choroidal neovascularization; Transforming growth factor beta;
   Animal model
ID AGE-RELATED MACULOPATHY; SMOOTH-MUSCLE-CELLS; MACULAR DEGENERATION;
   AIRWAY INFLAMMATION; PROLIFERATION; ANGIOGENESIS; PROGRESSION;
   INHIBITION; EXPRESSION; DISEASE
AB Introduction: The association between age-related macular degeneration and asthma is controversial. Transforming growth factor beta (TGF-beta), which plays a critical role in asthma, has been extensively studied with regard to its function in choroidal neovascularization (CNV). In the present study, we aimed to investigate the role of TGF-beta and the possible mechanism of CNV formation complicated with asthma and to explore the effect of a TGF-beta inhibitor on CNV development in asthma mouse models. Methods: Laser-induced CNV and ovalbumin-induced asthma mouse models were divided into 5 groups: control group, acute asthma group, chronic asthma group, inhibitor-treated acute asthma group, and inhibitor-treated chronic asthma group. The gene expression patterns of angiogenic cytokines, vascular endothelial growth factor (VEGF) receptors and inflammasomes in the control group, acute asthma group, and chronic asthma group were detected using a QuantiGene Plex 6.0 Reagent System. Fundus fluorescein angiography and histology of CNV lesions stained with haematoxylin-eosin were performed to evaluate CNV formation. Quantitative real-time PCR and western blotting were used to assess TGF-beta 1, TGF-beta 2, and VEGF expression and Smad2/3, AKT, p38 MAPK, and ERK1/2 signal transduction and phosphorylation in retinal and choroidal tissues from each group. Results: In this study, we verified that laser treatment led to more CNV and vascular leakage in asthmatic mice than that in control mice. The changes were particularly notable in the chronic asthma group. The respective TGF-beta 1, VEGF, and phosphorylated Smad2/3 (p-Smad2/3) mRNA and protein levels in retinal and choroidal tissues were significantly upregulated in both the acute and chronic asthma groups. After injection of a TGF-beta inhibitor, a distinct decline in VEGF, TGF-beta 1, and p-Smad2/3 protein and mRNA levels was observed, and the mean CNV area also decreased. Conclusion: We provide new evidence that asthma could be a risk factor for CNV development via the TGF-beta 1/Smad signalling pathway. A TGF-beta inhibitor can be applied as a useful, adjunctive therapeutic strategy for preventing CNV formation in asthmatic patients.
C1 [Yang, Fei; Sun, Yaoyao; Bai, Yujing; Huang, Lvzhen; Li, Xiaoxin] Peking Univ Peoples Hosp, Dept Ophthalmol, Beijing, Peoples R China.
   [Yang, Fei] Peking Univ Int Hosp, Dept Ophthalmol, Beijing, Peoples R China.
   [Yang, Fei; Sun, Yaoyao; Bai, Yujing; Huang, Lvzhen; Li, Xiaoxin] Peking Univ Peoples Hosp, Beijing Key Lab Diag & Therapy Retinal & Choroid, Beijing, Peoples R China.
   [Li, Shanshan] Shandong Univ, Qilu Hosp, Dept Ophthalmol, Jinan, Peoples R China.
   [Li, Xiaoxin] Xiamen Univ, Eye Inst, Xiamen, Peoples R China.
   [Li, Xiaoxin] Xiamen Univ, Xiamen Eye Ctr, Xiamen, Peoples R China.
C3 Peking University; Peking University; Shandong University; Xiamen
   University; Xiamen University
RP Huang, L (通讯作者)，Peking Univ Peoples Hosp, Dept Ophthalmol, Beijing, Peoples R China.; Huang, L (通讯作者)，Peking Univ Peoples Hosp, Beijing Key Lab Diag & Therapy Retinal & Choroid, Beijing, Peoples R China.
EM huanglvzhen@126.com
FU National Natural Science Foundation of China [81470649]; National Basic
   Research Program of China [973, 2011CB510200]; Beijing Nova Program;
   Science and Technology Innovation Project of Chinese Academy of Medical
   Sciences
FX This work was supported by the National Natural Science Foundation of
   China (Grant Nos. 81470649 and 81670870), the National Basic Research
   Program of China (973 Program, Grant Nos. 2011CB510200 and
   2012CB945101), the Beijing Nova Program (Z161100004916058), and Science
   and Technology Innovation Project of Chinese Academy of Medical Sciences
   (2019-RC-HL-019). The funders had no role in the study design, data
   collection and analysis, decision to publish, or preparation of the
   manuscript.
CR Apte RS, 2006, PLOS MED, V3, P1371, DOI 10.1371/journal.pmed.0030310
   Ba M, 2018, PULM PHARMACOL THER, V53, P12, DOI 10.1016/j.pupt.2018.09.004
   Bai YJ, 2014, MOL VIS, V20, P1258
   Bressler SB, 2009, OPHTHALMOLOGY, V116, pS1, DOI 10.1016/j.ophtha.2009.06.045
   Carmeliet P, 2011, NATURE, V473, P298, DOI 10.1038/nature10144
   D'Amato G, 2016, MULTIDISCIP RESP MED, V11, DOI 10.1186/s40248-016-0073-0
   Ding XY, 2009, PROG RETIN EYE RES, V28, P1, DOI 10.1016/j.preteyeres.2008.10.001
   Dobaczewski M, 2011, J MOL CELL CARDIOL, V51, P600, DOI 10.1016/j.yjmcc.2010.10.033
   Fisichella V, 2016, EUR J PHARMACOL, V787, P72, DOI 10.1016/j.ejphar.2016.02.002
   Gordon KJ, 2008, BBA-MOL BASIS DIS, V1782, P197, DOI 10.1016/j.bbadis.2008.01.006
   Ikushima H, 2010, NAT REV CANCER, V10, P415, DOI 10.1038/nrc2853
   Iwanishi H, 2016, LAB INVEST, V96, P641, DOI 10.1038/labinvest.2016.30
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Klein R, 1997, OPHTHALMOLOGY, V104, P7, DOI 10.1016/S0161-6420(97)30368-6
   Klein R, 2008, ARCH OPHTHALMOL-CHIC, V126, P840, DOI 10.1001/archopht.126.6.840
   Layland LE, 2013, PLOS NEGLECT TROP D, V7, DOI 10.1371/journal.pntd.0002379
   Liao K, 2018, ONCOL LETT, V15, P9681, DOI 10.3892/ol.2018.8556
   Liu ZY, 2018, GENET TEST MOL BIOMA, V22, P433, DOI 10.1089/gtmb.2017.0238
   Locke NR, 2007, AM J RESP CELL MOL, V36, P625, DOI 10.1165/rcmb.2006-0083OC
   Lozano R, 2013, LANCET, V381, P991, DOI 10.1016/S0140-6736(13)60704-7
   Ly LV, 2010, J IMMUNOL, V185, P3481, DOI 10.4049/jimmunol.0903479
   Melgert BN, 2011, J ALLERGY CLIN IMMUN, V127, P831, DOI 10.1016/j.jaci.2010.10.045
   Mikami F, 2006, J BIOL CHEM, V281, P22397, DOI 10.1074/jbc.M602124200
   Mitchell P, 2018, LANCET, V392, P1147, DOI 10.1016/S0140-6736(18)31550-2
   Moorthy S, 2011, AM J OPHTHALMOL, V151, P375, DOI 10.1016/j.ajo.2010.09.001
   Nagineni CN, 2003, J CELL PHYSIOL, V197, P453, DOI 10.1002/jcp.10378
   Ohlmann A, 2016, HISTOCHEM CELL BIOL, V146, P769, DOI 10.1007/s00418-016-1461-4
   Ojiaku CA, 2018, AM J RESP CELL MOL, V58, P575, DOI 10.1165/rcmb.2017-0247OC
   Saito A, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19082460
   Schlecht A, 2017, AM J PATHOL, V187, P2570, DOI 10.1016/j.ajpath.2017.06.018
   Shalev V, 2011, OPHTHAL EPIDEMIOL, V18, P83, DOI 10.3109/09286586.2011.560746
   Shan LS, 2018, MOL MED REP, V18, P2088, DOI 10.3892/mmr.2018.9183
   Shi S, 2018, ARCH MED SCI, V14, P1093, DOI 10.5114/aoms.2018.74538
   Stone EM, 2007, ANNU REV MED, V58, P477, DOI 10.1146/annurev.med.58.111405.133335
   Sun YY, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035415
   Tanaka H, 2010, ONCOL REP, V24, P1637, DOI 10.3892/or_00001028
   Tosi GM, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19113363
   Tsai MK, 2018, J ASTHMA, V55, P345, DOI 10.1080/02770903.2017.1339798
   van Meeteren LA, 2011, CURR PHARM BIOTECHNO, V12, P2108
   Vignola AM, 1997, AM J RESP CRIT CARE, V156, P591, DOI 10.1164/ajrccm.156.2.9609066
   Wang CY, 2019, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.01338
   Wang JJ, 2007, OPHTHALMOLOGY, V114, P92, DOI 10.1016/j.ophtha.2006.07.017
   Wang K, 2019, ACTA BIOCH BIOPH SIN, V51, P1, DOI 10.1093/abbs/gmy145
   Wang SQ, 2019, INT J CLIN EXP PATHO, V12, P1835
   Wang XL, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-10124-4
   Wenzel SE, 2012, IMMUNOL ALLERGY CLIN, V32, P401, DOI 10.1016/j.iac.2012.06.011
   Yang SQ, 2016, DRUG DES DEV THER, V10, P1857, DOI 10.2147/DDDT.S97653
   Yang ZC, 2020, INT ARCH ALLERGY IMM, V181, P239, DOI 10.1159/000505064
   Zarranz-Ventura J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0065434
   Zheng Y, 2020, RESP PHYSIOL NEUROBI, V276, DOI 10.1016/j.resp.2020.103412
   Zhong H, 2019, MOL IMMUNOL, V109, P51, DOI 10.1016/j.molimm.2019.02.017
NR 51
TC 2
Z9 2
U1 1
U2 5
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0030-3747
EI 1423-0259
J9 OPHTHALMIC RES
JI Ophthalmic Res.
PD FEB
PY 2022
VL 65
IS 1
BP 14
EP 29
DI 10.1159/000510778
PG 16
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA YW0WL
UT WOS:000753142500003
PM 32781454
OA Bronze
DA 2022-11-30
ER

PT J
AU Jiao, HH
   Rutar, M
   Fernando, N
   Yednock, T
   Sankaranarayanan, S
   Aggio-Bruce, R
   Provis, J
   Natoli, R
AF Jiao, Haihan
   Rutar, Matt
   Fernando, Nilisha
   Yednock, Ted
   Sankaranarayanan, Sethu
   Aggio-Bruce, Riemke
   Provis, Jan
   Natoli, Riccardo
TI Subretinal macrophages produce classical complement activator C1q
   leading to the progression of focal retinal degeneration
SO MOLECULAR NEURODEGENERATION
LA English
DT Article
DE Macrophages; Microglia; Complement system; Classical pathway; C1q;
   Inflammasome; Retinal degeneration; Photo-oxidative damage;
   Inflammation; Age-related macular degeneration
ID NLRP3 INFLAMMASOME ACTIVATION; PIGMENT EPITHELIAL-CELLS; MACULAR
   DEGENERATION; SYSTEM; MOUSE; EXPRESSION; MICROGLIA; PROTEIN; GENE;
   AUTOANTIBODIES
AB Background: The role of the alternative complement pathway and its mediation by retinal microglia and macrophages, is well-established in the pathogenesis of Age-Related Macular Degeneration (AMD). However, the contribution of the classical complement pathway towards the progression of retinal degenerations is not fully understood, including the role of complement component 1q (C1q) as a critical activator molecule of the classical pathway. Here, we investigated the contribution of C1q to progressive photoreceptor loss and neuroinflammation in retinal degenerations.
   Methods: Wild-type (WO, Clqa knockout (Clqa(-/-)) and mice treated with a C1q inhibitor (ANX-M1; Annexon Biosciences), were exposed to photo-oxidative damage (PD) and were observed for progressive lesion development Retinal function was assessed by electroretinography, followed by histological analyses to assess photoreceptor degeneration. Retinal inflammation was investigated through complement activation, macrophage recruitment and inflammasome expression using western blotting, qPCR and immunofluorescence. C1q was localised in human AMD donor retinas using immunohistochemistry.
   Results: PD mice had increased levels of Clqa which correlated with increasing photoreceptor cell death and macrophage recruitment. C1qa(-/-) mice did not show any differences in photoreceptor loss or inflammation at 7 days compared to WT, however at 14 days after the onset of damage, Clqa(-/-) retinas displayed less photoreceptor cell death, reduced microglia/macrophage recruitment to the photoreceptor lesion, and higher visual function. Clqa -/- mice displayed reduced inflammasome and IL-1 beta expression in microglia and macrophages in the degenerating retina. Retinal neutralisation of C1q, using an intravitreally-delivered anti-C1q antibody, reduced the progression of retinal degeneration following PD, while systemic delivery had no effect. Finally, retinal C1q was found to be expressed by subretinal microglia/macrophages located in the outer retina of early AMD donor eyes, and in mouse PD retinas.
   Conclusions: Our data implicate subretinal macrophages, C1q and the classical pathway in progressive retinal degeneration. We demonstrate a role of local C1q produced by microglia/macrophages as an instigator of inflammasome activation and inflammation. Crucially, we have shown that retinal C1q neutralisation during disease progression may slow retinal atrophy, providing a novel strategy for the treatment of complement-mediated retinal degenerations including AMD.
C1 [Jiao, Haihan; Rutar, Matt; Fernando, Nilisha; Aggio-Bruce, Riemke; Provis, Jan; Natoli, Riccardo] Australian Natl Univ, John Curtin Sch Med Res, Bldg 131,Garran Rd, Canberra, ACT 2601, Australia.
   [Rutar, Matt] Univ Melbourne, Dept Anat & Neurosci, Parkville, Vic, Australia.
   [Yednock, Ted; Sankaranarayanan, Sethu] Annexon Biosci, San Francisco, CA USA.
   [Provis, Jan; Natoli, Riccardo] Australian Natl Univ, ANU Med Sch, Canberra, ACT, Australia.
C3 Australian National University; John Curtin School of Medical Research;
   University of Melbourne; Australian National University
RP Natoli, R (通讯作者)，Australian Natl Univ, John Curtin Sch Med Res, Bldg 131,Garran Rd, Canberra, ACT 2601, Australia.; Natoli, R (通讯作者)，Australian Natl Univ, ANU Med Sch, Canberra, ACT, Australia.
EM riccardo.natoli@anu.edu.au
RI Aggio-Bruce, Riemke/AAX-4522-2020
OI Jiao, Haihan/0000-0002-5404-9307; Aggio-Bruce,
   Riemke/0000-0003-3086-2739; Natoli, Riccardo/0000-0002-9350-0439;
   Fernando, Nilisha/0000-0002-8488-1348; Rutar,
   Matthew/0000-0002-8893-5120
FU Australian Government Research Training Program (RTP) Scholarship
FX This research was supported by an Australian Government Research
   Training Program (RTP) Scholarship.
CR Ambati J, 2003, SURV OPHTHALMOL, V48, P257, DOI 10.1016/S0039-6257(03)00030-4
   Ambati J, 2013, NAT REV IMMUNOL, V13, P438, DOI 10.1038/nri3459
   Anderson DH, 2010, PROG RETIN EYE RES, V29, P95, DOI 10.1016/j.preteyeres.2009.11.003
   Begum R, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057828
   Bennett ML, 2016, P NATL ACAD SCI USA, V113, pE1738, DOI 10.1073/pnas.1525528113
   Biesemeier A, 2014, NEUROBIOL AGING, V35, P2562, DOI 10.1016/j.neurobiolaging.2014.05.003
   Bohlson SS, 2007, MOL IMMUNOL, V44, P33, DOI 10.1016/j.molimm.2006.06.021
   Brandstetter C, 2015, J MOL MED, V93, P905, DOI 10.1007/s00109-015-1275-1
   Chikazawa M, 2016, BIOCHEMISTRY-US, V55, P435, DOI 10.1021/acs.biochem.5b00777
   Doyle SL, 2012, NAT MED, V18, P791, DOI 10.1038/nm.2717
   Dunkelberger JR, 2010, CELL RES, V20, P34, DOI 10.1038/cr.2009.139
   Falavarjani KG, 2013, EYE, V27, P787, DOI 10.1038/eye.2013.107
   Fernando N, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0193740
   Fernando N, 2016, J NEUROINFLAMM, V13, DOI 10.1186/s12974-016-0514-x
   Fonseca MI, 2017, J NEUROINFLAMM, V14, DOI 10.1186/s12974-017-0814-9
   Fonseca MI, 2004, J NEUROSCI, V24, P6457, DOI 10.1523/JNEUROSCI.0901-04.2004
   Fraser DA, 2010, J NEUROCHEM, V112, P733, DOI 10.1111/j.1471-4159.2009.06494.x
   Gasque P, 2004, MOL IMMUNOL, V41, P1089, DOI 10.1016/j.molimm.2004.06.011
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Gu XR, 2003, J BIOL CHEM, V278, P42027, DOI 10.1074/jbc.M305460200
   Hageman GS, 1999, MOL VIS, V5
   Harvey H, 2014, EXP BRAIN RES, V232, P3363, DOI 10.1007/s00221-014-4078-7
   Hong S, 2016, SCIENCE, V352, P712, DOI 10.1126/science.aad8373
   Humphries MM, 2012, EUR J HUM GENET, V20, P64, DOI 10.1038/ejhg.2011.151
   Khandhadia S, 2012, IMMUNOBIOLOGY, V217, P127, DOI 10.1016/j.imbio.2011.07.019
   Liddelow SA, 2017, NATURE, V541, P481, DOI 10.1038/nature21029
   Ma WX, 2013, NEUROBIOL AGING, V34, P2310, DOI 10.1016/j.neurobiolaging.2013.03.022
   MA WX, 2017, SCI REP UK, V7
   Maslim J, 1997, INVEST OPHTH VIS SCI, V38, P1667
   Mukai R, 2018, FRONT AGING NEUROSCI, V10, DOI 10.3389/fnagi.2018.00015
   Mullins RF, 2017, HUM MOL GENET, V26, pR51, DOI 10.1093/hmg/ddx181
   Natoli R, 2017, INVEST OPHTH VIS SCI, V58, P2977, DOI 10.1167/iovs.17-21672
   Natoli R, 2017, MOL NEURODEGENER, V12, DOI 10.1186/s13024-017-0175-y
   Natoli R, 2010, MOL VIS, V16, P1801
   Natoli R, 2008, MOL VIS, V14, P1983
   Nauta AJ, 2002, EUR J IMMUNOL, V32, P1726, DOI 10.1002/1521-4141(200206)32:6<1726::AID-IMMU1726>3.0.CO;2-R
   Newman AM, 2012, GENOME MED, V4, DOI [10.1186/PREACCEPT-1418491035586234, 10.1186/gm315]
   Patel N, 2005, IMMUNOLOGY, V115, P422, DOI 10.1111/j.1365-2567.2005.02173.x
   PENFOLD PL, 1990, GRAEF ARCH CLIN EXP, V228, P270, DOI 10.1007/BF00920033
   Penfold PL, 2001, PROG RETIN EYE RES, V20, P385, DOI 10.1016/S1350-9462(00)00025-2
   Rohrer Barbel, 2011, Mol Immunol, V48, pe1, DOI 10.1016/j.molimm.2010.12.016
   Roumenina LT, 2011, J IMMUNOL, V187, P4369, DOI 10.4049/jimmunol.1101749
   Rutar M, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-014-0224-1
   Rutar M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0093343
   Rutar M, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-221
   Rutar M, 2011, INVEST OPHTH VIS SCI, V52, P5347, DOI 10.1167/iovs.10-7119
   Rutar M, 2011, INVEST OPHTH VIS SCI, V52, P2379, DOI 10.1167/iovs.10-6010
   Schafer MKH, 2000, J IMMUNOL, V164, P5446, DOI 10.4049/jimmunol.164.10.5446
   Silverman SM, 2016, MOL NEURODEGENER, V11
   Stasi K, 2006, INVEST OPHTH VIS SCI, V47, P1024, DOI 10.1167/iovs.05-0830
   Stephan AH, 2013, J NEUROSCI, V33, P13460, DOI 10.1523/JNEUROSCI.1333-13.2013
   Stevens B, 2007, CELL, V131, P1164, DOI 10.1016/j.cell.2007.10.036
   Tan PL, 2016, HUM GENOMICS, V10, DOI 10.1186/s40246-016-0079-x
   Tarallo V, 2012, CELL, V149, P847, DOI 10.1016/j.cell.2012.03.036
   Toapanta FR, 2006, IMMUNOL RES, V36, P197, DOI 10.1385/IR:36:1:197
   Tseng WA, 2013, INVEST OPHTH VIS SCI, V54, P110, DOI 10.1167/iovs.12-10655
   Walker RJ, 2007, INVEST OPHTH VIS SCI, V48, P5276, DOI 10.1167/iovs.07-0129
   Walport MJ, 2001, NEW ENGL J MED, V344, P1058, DOI 10.1056/NEJM200104053441406
   Xu HP, 2016, EUR J PHARMACOL, V787, P94, DOI 10.1016/j.ejphar.2016.03.001
NR 59
TC 23
Z9 24
U1 0
U2 7
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1750-1326
J9 MOL NEURODEGENER
JI Mol. Neurodegener.
PD AUG 20
PY 2018
VL 13
AR 45
DI 10.1186/s13024-018-0278-0
PG 18
WC Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology
GA GR0CJ
UT WOS:000442176600002
PM 30126455
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Yan, Y
   Wang, T
   Cao, J
   Wang, M
   Li, FH
AF Yan, Ying
   Wang, Tao
   Cao, Jing
   Wang, Meng
   Li, Fenghua
TI Clinical research on intravitreal injection of bevacizumab in the
   treatment of macula lutea and retinal edema of ocular fundus disease
SO PAKISTAN JOURNAL OF PHARMACEUTICAL SCIENCES
LA English
DT Article
DE Vitreous body; Bevacizumab; Ocular fundus disease
AB This paper aimed to explore clinically curative effect of intravitreal injection of bevacizumab in the treatment of macula lutea and retinal edema of ocular fundus disease. The number of 300 patients (390 eyes) with ocular fundus diseases including retinal vein occlusion (RVO), diabetic retinopathy (DR), age-related macular degeneration (ARMD), central serous chorioretinopathy (CSC), choridal new vessel (CNV) received and cured in the hospital from February 2010 to February 2014 were given intravitreal injection of bevacizumab (1.5mg) with once per month and a total of 2-3 times. Results of patients' vision and fluorescence fundus angiography (FFA), optical coherence tomography (OCT) before and after treatment were compared and curative effects were evaluated. Vision of 349 eyes (89.49%) improved obviously with the average of more than 2 lines, patient's intraocular pressure (IOP) was normal and all indexes were clearly better; vision of 26 eyes (6.67%) was stable before the treatment and without any changes after the treatment, the situation of fundus got better without increased IOP; vision of 15 eyes (3.85%) decreased to some extent, and the symptoms eased slightly after symptomatic treatment. In the 1st day after intravitreal injection, best-corrected visual acuity increased to 0.23 +/- 0.175, best-corrected visual acuity in 1 m was 0.315 +/- 0.182, in 3m continuously climbed to 0.350 +/- 0.270, and in 6 m was 0.362 +/- 0.282. Compared with vision before injection, t value was t=3.184, t=7.213, t=9.274 and t=9.970 (P=0.002, P=0.000, P=0.000 and P=0.000) respectively, and all P were less than 0.01. Furthermore, the difference was significant if a=0.01, whcih could confirm that 1m best corrected visual acuity of patients after intravitreal injection improved clearly in combination with before injection and 3m and 6 m visions enhanced constantly after injection. To sum up, intravitreal injection of bevacizumab in treating ocular fundus disease improves patient's vision effectively, also relieves macula lutea, retinal edema and other symptoms obviously, and promotes the hemorrhage absorption of vitreous body and retina.
C1 [Yan, Ying; Wang, Tao; Wang, Meng; Li, Fenghua] Linyi Peoples Hosp, Ophthalmol, Linyi, Shandong, Peoples R China.
   [Cao, Jing] Linyi Peoples Hosp, Dept Pharm, Linyi, Shandong, Peoples R China.
RP Li, FH (通讯作者)，Linyi Peoples Hosp, Ophthalmol, Linyi, Shandong, Peoples R China.
EM lfh@ibhsedu.com
CR Changwa M, 2009, OPHTHALMOL IN CHIN, V18, P243
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   de Jong PTVM, 2006, NEW ENGL J MED, V355, P1474, DOI 10.1056/NEJMra062326
   Duan YK, 2007, OPHTHALMOLOGY, V114, P732, DOI 10.1016/j.ophtha.2006.07.045
   Hao H, 2010, INT J OPHTHALMOL, V10, P2176
   Jiejin W, 2003, OPHTHALMOLOGY, V110, P1960
   Li L, 2012, CHIN J PRACTIC NURSI, V28, P32
   Li Zhiqiang, 2014, Nan Fang Yi Ke Da Xue Xue Bao, V34, P1207
   Mathias A, 2009, CRAEFES ARCH CLIN EX, V247, P27
   Mitchell P, 2002, OPHTHALMOLOGY, V109, P1092, DOI 10.1016/S0161-6420(02)01055-2
   Na M, 2014, GUIDE CHIN MED, V36, P117
   Nan M, 2012, RECENT ADV OPHTHALMO, V32, P552
   Tong Q, 2009, CHIN OPHTHALM RES, V27, P118
   van Leeuwen R, 2003, ARCH OPHTHALMOL-CHIC, V121, P519, DOI 10.1001/archopht.121.4.519
   Wanling C, 2010, B CHIN CANC, V19, P534
   Wong TY, 2007, OPHTHALMOLOGY, V114, P86, DOI 10.1016/j.ophtha.2006.06.039
   Xi X, 2010, EVERYONE IS WELL, V19, P14
   Xiao L, 2010, EPIDEMIOLOGICAL INVE
   Xiaorui Y, 2010, INT J OPHTHALMOLOGY, V10, P1913
NR 19
TC 2
Z9 2
U1 0
U2 1
PU UNIV KARACHI
PI KARACHI
PA UNIV CAMPUS, FAC PHARMACY, KARACHI, 75270, PAKISTAN
SN 1011-601X
J9 PAK J PHARM SCI
JI Pak. J. Pharm. Sci.
PD JUL
PY 2015
VL 28
IS 4
SU S
BP 1481
EP 1484
PG 4
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA CQ2HN
UT WOS:000360420800008
PM 26431660
DA 2022-11-30
ER

PT J
AU Li, YJ
   Xirasagar, S
   Pumkam, C
   Krishnaswamy, M
   Bennett, CL
AF Li, Yi-Jhen
   Xirasagar, Sudha
   Pumkam, Chaiporn
   Krishnaswamy, Malavika
   Bennett, Charles L.
TI Vision Insurance, Eye Care Visits, and Vision Impairment Among
   Working-Age Adults in the United States
SO JAMA OPHTHALMOLOGY
LA English
DT Article
ID OPEN-ANGLE GLAUCOMA; VISUAL IMPAIRMENT; INTRAOCULAR-PRESSURE;
   HEALTH-INSURANCE; PREVALENCE; SERVICES; MANAGEMENT; REDUCTION;
   DIAGNOSIS; UPDATE
AB Objectives: To compare rates of eye care visits and vision impairment among working-age adults with vision insurance vs without, among the total sample of Behavioral Risk Factor Surveillance Survey respondents and among a subsample of respondents who had diagnoses of glaucoma, age-related macular degeneration (ARMD), and/or cataract.
   Design: Using the Behavioral Risk Factor Surveillance Survey 2008 vision module data, we examined the likelihood of an eye care visit within the past year and of self-reported visual impairment among 27 152 adults aged 40 to 65 years and among a subset of 3158 persons (11.6%) with glaucoma, ARMD, and/or cataract. Multivariate logistic regression models were used.
   Results: About 40% of both the study population and the subsample with glaucoma, ARMD, and/or cataract had no vision insurance. Respondents with vision insurance were more likely than those without to have had eye care visits (general population adjusted odds ratio [AOR], 1.90 [95% CI, 1.89-1.90]; glaucoma-ARMD-cataract subsample AOR, 2.15 [95% CI, 2.13-2.17]), to have no dif-ficulty recognizing friends across the street (general population AOR, 1.24 [95% CI, 1.22-1.26]; eye-disease subsample AOR, 1.45 [95% CI, 1.42-1.49]), and to have no difficulty reading printed matter (general population AOR, 1.34 [95% CI, 1.33-1.35]; eye-disease subsample AOR, 1.37 [95% CI, 1.34-1.39]). Respondents from the total sample who had an eye care visit were better able to recognize friends across the street (AOR, 1.07) and had no difficulty reading printed matter (AOR, 1.70), and respondents from the eye-disease subsample who had an eye care visit also were better able to recognize friends across the street (AOR, 1.71) and had no difficulty reading printed matter (AOR, 1.45).
   Conclusions: Lack of vision insurance impedes eye care utilization, which, in turn, may irrevocably affect vision. Vision insurance for preventive eye care should cease to be a separate insurance benefit and should be mandatory in all health plans.
C1 [Li, Yi-Jhen; Xirasagar, Sudha; Pumkam, Chaiporn] Univ S Carolina, Arnold Sch Publ Hlth, Dept Hlth Serv Management & Policy, Columbia, SC 29208 USA.
   [Bennett, Charles L.] Univ S Carolina, Carolina Coll Pharm, South Carolina Coll Pharm, Columbia, SC 29208 USA.
   [Krishnaswamy, Malavika] MS Ramaiah Med Coll, Dept Ophthalmol, Bangalore, Karnataka, India.
C3 University of South Carolina; University of South Carolina System;
   University of South Carolina Columbia; Medical University of South
   Carolina; University of South Carolina; University of South Carolina
   System; University of South Carolina Columbia
RP Xirasagar, S (通讯作者)，Univ S Carolina, Arnold Sch Publ Hlth, Dept Hlth Serv Management & Policy, 800 Sumter St,Room 116, Columbia, SC 29208 USA.
EM sxirasagar@sc.edu
RI Xirasagar, Sudha/AAA-2350-2022
CR Adatia FA, 2005, CAN FAM PHYSICIAN, V51, P1229
   Alward WL, 1998, AM J OPHTHALMOL, V126, P498
   Babizhayev MA, 2009, APPL ERGON, V40, P545, DOI 10.1016/j.apergo.2007.09.003
   Clinical statements, 2009, CLIN STAT FREQ OC EX
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Elliott A. F., 2010, Morbidity and Mortality Weekly Report, V59, P588
   Fleming C, 2005, ANN FAM MED, V3, P167, DOI 10.1370/afm.293
   Fong A, 2009, AUST FAM PHYSICIAN, V38, P774
   Frick KD, 2007, ARCH OPHTHALMOL-CHIC, V125, P544, DOI 10.1001/archopht.125.4.544
   Gariano RF, 2004, AM FAM PHYSICIAN, V69, P1691
   Haymes SA, 2007, INVEST OPHTH VIS SCI, V48, P1149, DOI 10.1167/iovs.06-0886
   Heijl A, 2002, ARCH OPHTHALMOL-CHIC, V120, P1268, DOI 10.1001/archopht.120.10.1268
   Insurance Institute for Highway Safety (IIHS) Highway Loss Data Institute, FAT FACTS 2010 OLD P
   Kaufman SR, 2009, GERIATRICS, V64, P16
   LAATIKAINEN L, 1995, ACTA OPHTHALMOL SCAN, V73, P105
   Lee YC, 2010, BMC HEALTH SERV RES, V10, DOI 10.1186/1472-6963-10-225
   Livermore G, 2011, HEALTH AFFAIR, V30, P1664, DOI 10.1377/hlthaff.2011.0247
   Michelson G, 2008, DTSCH ARZTEBL INT, V105, P583, DOI 10.3238/arztebl.2008.0583
   National Eye Institute, VIS LOSS EYE DIS WIL
   Pollard TL, 2003, OPHTHAL PHYSL OPT, V23, P321, DOI 10.1046/j.1475-1313.2003.00123.x
   Prevent blindness America, 2007, EC IMP VIS PROBL TOL
   Rehabilitation Research and Training Center on Disability Statistics and Demographics, 2010, ANN DIS STAT COMP
   Rein DB, 2006, ARCH OPHTHALMOL-CHIC, V124, P1754, DOI 10.1001/archopht.124.12.1754
   Sharma P, 2008, SURV OPHTHALMOL, V53, pS17, DOI 10.1016/j.survophthal.2008.08.003
   Silverman Morton W, 2006, Optometry, V77, P180, DOI 10.1016/j.optm.2006.01.012
   Vitale S, 2006, JAMA-J AM MED ASSOC, V295, P2158, DOI 10.1001/jama.295.18.2158
   Wood Joanne M, 2002, Clin Exp Optom, V85, P214
   Yumori JW, 2011, J GERONTOL NURS, V37, P10, DOI 10.3928/00989134-20110210-01
   Zhang XZ, 2008, ARCH OPHTHALMOL-CHIC, V126, P1121, DOI 10.1001/archopht.126.8.1121
NR 29
TC 25
Z9 25
U1 0
U2 4
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA
SN 2168-6165
J9 JAMA OPHTHALMOL
JI JAMA Ophthalmol.
PD APR
PY 2013
VL 131
IS 4
BP 499
EP 506
DI 10.1001/jamaophthalmol.2013.1165
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 163JH
UT WOS:000320331600012
PM 23710504
OA Bronze
DA 2022-11-30
ER

PT J
AU Xi, L
   Tikhonovich, M
   Biesemeier, A
   Julien-Schraermeyer, S
   Schraermeyer, U
   Tschulakow, AV
AF Xi, Lei
   Tikhonovich, Marina
   Biesemeier, Antje
   Julien-Schraermeyer, Sylvie
   Schraermeyer, Ulrich
   Tschulakow, Alexander V. V.
TI Pigment Epithelium-Derived Factor Protects Retinal Neural Cells and
   Prevents Pathological Angiogenesis in an Ex Vivo Ischemia Model
SO OXIDATIVE MEDICINE AND CELLULAR LONGEVITY
LA English
DT Article
ID ENDOTHELIAL GROWTH-FACTOR; MACULAR DEGENERATION PATIENTS; CAROTID-ARTERY
   OCCLUSION; ATROPHY; BEVACIZUMAB; CONSUMPTION; PROGRESSION; EXPRESSION;
   INJECTION; HYPOXIA
AB Ocular ischemia/hypoxia is a severe problem in ophthalmology that can cause vision impairment and blindness. However, little is known about the changes occurring in the existing fully formed choroidal blood vessels. We developed a new whole organ culture model for ischemia/hypoxia in rat eyes and investigate the effects of pigment epithelium derived factor (PEDF) protein on the eye tissues. The concentration of oxygen within the vitreous was measured in the enucleated rat eyes and living rats. Then, ischemia was mimicked by incubating the freshly enucleated eyes in medium at 4 degrees C for 14 h. Eyes were fixed immediately after enucleation or were intravitreally injected with PEDF protein or with vehicle before incubation. After incubation, light and electron microscopy (EM) as well as Tunel staining was performed. In the living rats, the intravitreal oxygen concentration was on average at 16.4% of the oxygen concentration in the air and did not change throughout the experiment whereas it was ca. 28% at the beginning of the experiment and gradually decreased over time in the enucleated eyes. EM analysis revealed that the shape of the choriocapillaris changed dramatically after 14 h incubation in the enucleated eyes. The endothelial cells made filopodia-like projections into the vessel lumen. They appeared identical to the labyrinth capillaries found in surgically extracted choroidal neovascular membranes from patients with wet age-related macular degeneration (AMD). These filopodia-like projections nearly closed the vessel lumen and showed open gaps between neighboring endothelial cells. PEDF significantly inhibited labyrinth capillary formation and kept the capillary lumen open. The number of TUNEL-positive ganglion cells and inner nuclear layer cells was significantly reduced in the PEDF-treated eyes compared to the vehicle-treated eyes. The structural changes in the chroidal vessels observed under ischemia/hypoxia conditions can mimic early changes in the process of pathological angiogenesis as observed in wet AMD patients. This new model can be used to investigate short-term drug effects on the choriocapillaris after ischemia/hypoxia and it highlighted the potential of PEDF as a promising candidate for treating wet AMD.
C1 [Xi, Lei; Tikhonovich, Marina; Biesemeier, Antje; Julien-Schraermeyer, Sylvie; Schraermeyer, Ulrich; Tschulakow, Alexander V. V.] Univ Tubingen, Inst Ophthalm Res, Ctr Ophthalmol, Div Expt Vitreoretinal Surg, Tubingen, Germany.
   [Julien-Schraermeyer, Sylvie; Schraermeyer, Ulrich; Tschulakow, Alexander V. V.] STZ Ocutox, Preclin Drug Assessment, Hechingen, Germany.
C3 Eberhard Karls University of Tubingen; Eberhard Karls University
   Hospital
RP Tschulakow, AV (通讯作者)，Univ Tubingen, Inst Ophthalm Res, Ctr Ophthalmol, Div Expt Vitreoretinal Surg, Tubingen, Germany.; Tschulakow, AV (通讯作者)，STZ Ocutox, Preclin Drug Assessment, Hechingen, Germany.
EM eyexilei@163.com; marina.tikhonovich@gmail.com; antje.biesemeier@gmx.de;
   sylvie.julien@med.uni-tuebingen.de; u.schraermeyer@gmail.com;
   alexander.tschulakow@gmx.de
OI Biesemeier, Antje/0000-0002-3462-8803; Schraermeyer,
   Ulrich/0000-0002-7969-8426
FU Dr. Werner Jackstaedt Foundation; DFG [GZ: BI 1551/3-1]; Open Access
   Publishing Fund of University of Tubingen
FX The authors thank Prof. Dr. S. Kochanek (Department of Gene Therapy,
   University, Ulm) for providing us with human PEDF protein and Mrs. A.
   Burda for excellent technical assistance and Mrs. J. Birch for
   proofreading our manuscript (Division of Experimental Vitreoretinal
   Surgery, Centre for Ophthalmology, Institute for Ophthalmic Research,
   University of Tuebingen). Part of this study was funded by the Dr.
   Werner Jackstaedt Foundation and the DFG (GZ: BI 1551/3-1). We
   acknowledge support by Open Access Publishing Fund of University of
   Tubingen.
CR Awad AS, 2013, AM J PHYSIOL-RENAL, V305, pF891, DOI 10.1152/ajprenal.00149.2013
   Brook N, 2019, FREE RADICAL RES, V53, P1166, DOI 10.1080/10715762.2019.1697809
   Burger S, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22010369
   Campochiaro PA, 2015, PROG RETIN EYE RES, V49, P67, DOI 10.1016/j.preteyeres.2015.06.002
   Catalani E, 2007, EUR J NEUROSCI, V25, P1447, DOI 10.1111/j.1460-9568.2007.05419.x
   Cho HJ, 2016, GRAEF ARCH CLIN EXP, V254, P23, DOI 10.1007/s00417-015-2993-3
   Coassin M, 2010, BRIT J OPHTHALMOL, V94, P1678, DOI 10.1136/bjo.2009.168864
   Coleman DJ, 2013, BRIT J OPHTHALMOL, V97, P1020, DOI 10.1136/bjophthalmol-2013-303143
   Crespo-Garcia S, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0193961
   Cringle SJ, 2004, INVEST OPHTH VIS SCI, V45, P3223, DOI 10.1167/iovs.03-1364
   Dong A, 2009, J CELL PHYSIOL, V219, P544, DOI 10.1002/jcp.21698
   Fleckenstein M, 2021, NAT REV DIS PRIMERS, V7, DOI 10.1038/s41572-021-00265-2
   Gehlbach P, 2003, GENE THER, V10, P637, DOI 10.1038/sj.gt.3301931
   Gemenetzi M, 2017, EYE, V31, P1, DOI 10.1038/eye.2016.208
   Grunwald JE, 2005, INVEST OPHTH VIS SCI, V46, P1033, DOI 10.1167/iovs.04-1050
   Hanhart J, 2018, ACTA OPHTHALMOL, V96, pE732, DOI 10.1111/aos.13731
   Hanhart J, 2018, GRAEF ARCH CLIN EXP, V256, P651, DOI 10.1007/s00417-018-3917-9
   Hanhart J, 2017, BMC OPHTHALMOL, V17, DOI 10.1186/s12886-017-0586-0
   He XM, 2015, CLIN SCI, V128, P805, DOI 10.1042/CS20130463
   Hurst J, 2020, J CELL MOL MED, V24, P4312, DOI 10.1111/jcmm.15091
   Ibuki M, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21238940
   Jalilian E, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21103496
   Kang HM, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0224210
   Karovic O, 2007, BIOCHEM PHARMACOL, V73, P694, DOI 10.1016/j.bcp.2006.11.008
   Kaynak S, 2018, TURK OFTALMOL DERG, V48, P81, DOI 10.4274/tjo.27448
   Lavinsky D, 2006, GRAEF ARCH CLIN EXP, V244, P199, DOI 10.1007/s00417-005-0006-7
   Lee D, 2020, JOVE-J VIS EXP, DOI 10.3791/61865
   Lee D, 2020, EXP EYE RES, V201, DOI 10.1016/j.exer.2020.108275
   Lin CM, 2018, AM J PATHOL, V188, P2392, DOI 10.1016/j.ajpath.2018.06.020
   Mastrodimou N, 2005, N-S ARCH PHARMACOL, V371, P44, DOI 10.1007/s00210-004-1011-9
   Mori K, 2001, J CELL PHYSIOL, V188, P253, DOI 10.1002/jcp.1114
   Neo T, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0236928
   Ogata N, 2001, CURR EYE RES, V22, P245, DOI 10.1076/ceyr.22.4.245.5506
   Plyukhova A A, 2018, Vestn Oftalmol, V134, P289, DOI 10.17116/oftalma2018134051289
   Roy S, 2017, AM J PATHOL, V187, P9, DOI 10.1016/j.ajpath.2016.08.022
   Saishin Y, 2005, HUM GENE THER, V16, P473, DOI 10.1089/hum.2005.16.473
   Schraermeyer U, 2015, GRAEF ARCH CLIN EXP, V253, P681, DOI 10.1007/s00417-014-2733-0
   Schraermeyer U, 2012, GRAEF ARCH CLIN EXP, V250, P1303, DOI 10.1007/s00417-012-2055-z
   Schutze C, 2015, AM J OPHTHALMOL, V159, P1100, DOI 10.1016/j.ajo.2015.02.020
   SellesNavarro I, 1996, INVEST OPHTH VIS SCI, V37, P2002
   Semeraro F, 2015, CURR DRUG METAB, V16, P572, DOI 10.2174/1389200216666151001120831
   Shimada Y, 2021, J CLIN MED, V10, DOI 10.3390/jcm10020357
   Spooner KL, 2020, OPHTHALMOLOGY, V127, P1663, DOI 10.1016/j.ophtha.2020.06.019
   Stellmach V, 2001, P NATL ACAD SCI USA, V98, P2593, DOI 10.1073/pnas.031252398
   Takeyama M, 2015, BIOL RES, V48, DOI [10.1186/s40659-015-0034-7, 10.1186/S40659-015-0034-7]
   Tang MJ, 2017, BIOCHEM BIOPH RES CO, V484, P285, DOI 10.1016/j.bbrc.2017.01.102
   Tsai T, 2020, GRAEF ARCH CLIN EXP, V258, P2185, DOI 10.1007/s00417-020-04854-x
   Valiente-Soriano FJ, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21197242
   Wakabayashi T, 2010, BRIT J OPHTHALMOL, V94, P611, DOI 10.1136/bjo.2009.163535
   Yamamoto H, 2006, EXP EYE RES, V82, P767, DOI 10.1016/j.exer.2005.09.019
   Yu DY, 2001, PROG RETIN EYE RES, V20, P175, DOI 10.1016/S1350-9462(00)00027-6
   Zhang SX, 2006, J MOL ENDOCRINOL, V37, P1, DOI 10.1677/jme.1.02008
NR 52
TC 0
Z9 0
U1 1
U2 1
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 1942-0900
EI 1942-0994
J9 OXID MED CELL LONGEV
JI Oxidative Med. Cell. Longev.
PD AUG 5
PY 2022
VL 2022
AR 4199394
DI 10.1155/2022/4199394
PG 10
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA 5A3FH
UT WOS:000862775100005
PM 36035211
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Creer, RC
   Roberts, SA
   Aslam, TM
   Balaskas, K
   Chhabra, R
   Mahmood, S
   Turner, GS
   Harper, RA
AF Creer, Rosalind C.
   Roberts, Stephen A.
   Aslam, Tariq M.
   Balaskas, Konstantinos
   Chhabra, Ramandeep
   Mahmood, Sajjad
   Turner, George S.
   Harper, Robert A.
TI Treatment decisions of UK hospital optometrists and ophthalmologists in
   patients with nAMD: a vignette study
SO OPHTHALMIC AND PHYSIOLOGICAL OPTICS
LA English
DT Article
DE age-related macular degeneration; extended roles; hospital eye service;
   ophthalmologists; optometrists; optometry
ID MANAGEMENT; AGREEMENT; GLAUCOMA
AB Purpose A vignette study to examine treatment decisions made by UK hospital optometrists in patients with neovascular age-related macular degeneration (nAMD) and the effect of optometrists' experience on agreement. Methods Patients with nAMD attending Manchester Royal Eye Hospital, Manchester, UK were identified as potential candidates for the case series of vignettes. The cases were chosen to reflect a varied case-mix with respect to difficulty as well as ensuring good quality of the images. Each vignette included a history summary consisting of the number of previous injections given and visual acuity measurements at baseline, the previous visit, and the current visit. Images were compiled to show baseline fundus photographs and ocular coherence tomography (OCT) images with the current visit images on which the treatment decision was to be made along with the images from the previous visit. Hospital optometrists were recruited and asked to complete the series of vignettes, deciding if treatment was required at that visit and how confident they felt with that decision. Their responses were compared to the reference standard created by a consensus of consultant ophthalmologists with a sub-speciality interest in medical retina. Results Regarding treatment decision for optometrists, the percentage correct value was 75% with the sensitivity being 75.6% (95% CI 70.1-80.3) and the specificity as 75.1% (95% CI 72.1-77.8). No statistically significant difference was found between differing levels of experience. However, there was a significant difference in confidence levels between groups. Potentially sight threatening decisions accounted for 6.4% of the optometrists' decisions, 3.5% were made with a high confidence rating suggesting no discussion with an ophthalmologist was required. Conclusions Although the optometrists showed modest agreement with the reference standard in a series of cases that have higher than average complexity, the optometrists showed a similar amount of variability within their treatment decisions compared to the reference standard. The optometrists were therefore not inferior in their performance compared to the ophthalmologists and this can be seen as supporting evidence for their extended role within this clinical area. Experience did not have an effect on 'correct' treatment decisions although there was a statistically significant effect on increasing confidence of treatment decision.
C1 [Creer, Rosalind C.; Aslam, Tariq M.; Balaskas, Konstantinos; Chhabra, Ramandeep; Mahmood, Sajjad; Turner, George S.; Harper, Robert A.] Manchester Univ NHS Fdn Trust, Manchester Royal Eye Hosp, Manchester, Lancs, England.
   [Creer, Rosalind C.; Aslam, Tariq M.; Balaskas, Konstantinos; Chhabra, Ramandeep; Mahmood, Sajjad; Turner, George S.; Harper, Robert A.] Univ Manchester, Manchester Acad Hlth Sci Ctr, Manchester, Lancs, England.
   [Roberts, Stephen A.] Univ Manchester, Biostat Grp, Manchester, Lancs, England.
   [Aslam, Tariq M.; Harper, Robert A.] Univ Manchester, Div Optometry & Pharm, Manchester, Lancs, England.
C3 Manchester Royal Eye Hospital; University of Manchester; University of
   Manchester; University of Manchester
RP Creer, RC (通讯作者)，Manchester Univ NHS Fdn Trust, Manchester Royal Eye Hosp, Manchester, Lancs, England.; Creer, RC (通讯作者)，Univ Manchester, Manchester Acad Hlth Sci Ctr, Manchester, Lancs, England.
EM rosalind.creer@mft.nhs.uk
RI Mahmood, Sajjad/AAK-7645-2021; Balaskas, Konstantinos/ABD-5979-2020;
   Aslam, Tariq/A-8532-2016
OI Balaskas, Konstantinos/0000-0002-7690-6277; Harper,
   Robert/0000-0001-5437-2553; Aslam, Tariq/0000-0002-9739-7280
CR [Anonymous], 2018, NICE GUIDELINE NG82
   Banes MJ, 2006, BRIT J OPHTHALMOL, V90, P579, DOI 10.1136/bjo.2005.082388
   Barrett C, 2018, OPHTHAL PHYSL OPT, V38, P400, DOI 10.1111/opo.12446
   Ciulla TA, 2020, OPHTHALMOL RETINA, V4, P19, DOI 10.1016/j.oret.2019.05.017
   Creer R, 2010, OPTOMETRY PRACT, V11, P13
   Gale RP, 2019, EYE, V33, DOI 10.1038/s41433-018-0300-3
   Gray SF, 2000, BRIT J OPHTHALMOL, V84, P456, DOI 10.1136/bjo.84.5.456
   Harper R, 2016, OPHTHAL PHYSL OPT, V36, P197, DOI 10.1111/opo.12262
   LANDIS RJ, 1977, BIOMETRICS, V33, P59
   Marks JR, 2012, EYE, V26, P853, DOI 10.1038/eye.2012.58
   McHugh ML, 2012, BIOCHEM MEDICA, V22, P276, DOI 10.11613/bm.2012.031
   R Core Team, 2019, LANG ENV STAT COMP
   Reeves BC, 2016, BMJ OPEN, V6, DOI 10.1136/bmjopen-2015-010685
   Royal College of Ophthalmologists, AG REL MAC DEG GUID
   Solomon SD, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005139.pub3
   Tang Wan, 2015, Shanghai Arch Psychiatry, V27, P62, DOI 10.11919/j.issn.1002-0829.215010
NR 16
TC 1
Z9 1
U1 0
U2 1
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0275-5408
EI 1475-1313
J9 OPHTHAL PHYSL OPT
JI Ophthalmic Physiol. Opt.
PD NOV
PY 2019
VL 39
IS 6
BP 432
EP 440
DI 10.1111/opo.12644
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA JK2GQ
UT WOS:000494665700005
PM 31602674
DA 2022-11-30
ER

PT J
AU Chan, CK
   Abraham, P
   Meyer, CH
   Kokame, GT
   Kaiser, PK
   Rauser, ME
   Gross, JG
   Nuthi, ASD
   Lin, SG
   Daher, NS
AF Chan, Clement K.
   Abraham, Prema
   Meyer, Carsten H.
   Kokame, Gregg T.
   Kaiser, Peter K.
   Rauser, Michael E.
   Gross, Jeffrey G.
   Nuthi, Asha S. D.
   Lin, Steven G.
   Daher, Noha S.
TI OPTICAL COHERENCE TOMOGRAPHY-MEASURED PIGMENT EPITHELIAL DETACHMENT
   HEIGHT AS A PREDICTOR FOR RETINAL PIGMENT EPITHELIAL TEARS ASSOCIATED
   WITH INTRAVITREAL BEVACIZUMAB INJECTIONS
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE Avastin; bevacizumab; intravitreal injection; fibrovascular pigment
   epithelial detachment; optical coherence tomography; retinal pigment
   epithelial detachment; retinal pigment epithelial height; retinal
   pigment epithelial rip; retinal pigment epithelial tear; vascularized
   pigment epithelial detachment
ID CHOROIDAL NEOVASCULARIZATION SECONDARY; PROLIFERATIVE
   DIABETIC-RETINOPATHY; MACULAR DEGENERATION; PHOTODYNAMIC THERAPY;
   RANIBIZUMAB; VERTEPORFIN; AVASTIN; TRIAMCINOLONE; ANGIOGRAPHY; SIGN
AB Purpose: The purpose was to study preinjection optical coherence tomography-related factors in age-related macular degeneration eyes with retinal pigment epithelial detachment (PED) that may predispose retinal pigment epithelial (RPE) tears associated with intravitreal bevacizumab injections.
   Methods: This multicenter retrospective case series involving 9 retina specialists and 7 centers investigated Stratus optical coherence tomography (Carl Zeiss Meditec, Dublin, CA) parameters in eyes with vascularized PED (vPED) from February 2006 to February 2007. Of the 1,280 eyes in 1,255 patients receiving 2,890 intravitreal injections, there were 125 eyes with vPED. For every vPED eye that developed an RPE tear (Group 1), 3 or more vPED eyes without RPE tears (Group 2) were randomly selected in each study center during the same time period for comparison. The primary outcome measure was PED height (mu m), and the secondary measures included volume index (vPED height x surface area), total macular volume, subretinal fluid, cystoid macular edema, center-point thickness, central 1 mm, and pre- and postinjection best-corrected Snellen visual acuities.
   Results: Twenty-one vPED eyes in 21 patients among 125 vPED eyes (16.8% of all vPED eyes) developed RPE tears. The 21 Group 1 eyes were compared with the 78 randomly selected Group 2 eyes. The vPED height was significantly higher for Group 1 eyes in comparison to Group 2 eyes (mean: 648.9 +/- 245.0 vs. 338.1 +/- 201.6 mu m, P < 0.001). The same was true for the following: volume index (P = 0.001), subretinal fluid (P = 0.002), and total macular volume (P = 0.04). The mean preinjection and post-RPE tear best-corrected visual acuity were 0.92 logMAR (20/166) and 0.84 logMAR (20/137), respectively (P = 0.25). Multivariate analysis showed PED height to be the only significant risk factor associated with RPE tears in Group 1 eyes [odds ratio = 0.995 (95% confidence interval: 0.992-0.997), P < 0.001].
   Conclusion: Elevated preinjection vPED height is the single most significant predictor for RPE tears after bevacizumab injections for vPED eyes. A vPED height >400 mu m is associated with a significant risk for such a complication.
   RETINA 30: 203-211, 2010
C1 [Chan, Clement K.; Nuthi, Asha S. D.; Lin, Steven G.] So Calif Desert Retina Consultants, Palm Springs, CA USA.
   [Chan, Clement K.; Rauser, Michael E.] Loma Linda Univ, Dept Ophthalmol, Loma Linda, CA 92350 USA.
   [Abraham, Prema] Black Hills Reg Eye Inst, Rapid City, SD USA.
   [Meyer, Carsten H.] Univ Augenklin, Bonn, Germany.
   [Kokame, Gregg T.] Retina Ctr Pali Momi, Aiea, HI USA.
   [Kokame, Gregg T.] Univ Hawaii, John A Burns Sch Med, Honolulu, HI 96822 USA.
   [Kaiser, Peter K.] Cleveland Clin, Cole Eye Inst, Cleveland, OH 44106 USA.
   [Gross, Jeffrey G.] Carolina Retina Ctr, Columbia, SC USA.
   [Daher, Noha S.] Loma Linda Univ, Sch Allied Hlth Profess, Loma Linda, CA 92350 USA.
C3 Loma Linda University; University of Bonn; University of Hamburg;
   University Medical Center Hamburg-Eppendorf; University of Hawaii
   System; Cleveland Clinic Foundation; Loma Linda University
RP Chan, CK (通讯作者)，POB 2467, Palm Springs, CA 92263 USA.
EM Pschan@aol.com
RI Meyer, Carsten/A-3981-2017
OI Meyer, Carsten/0000-0002-0530-5298; Kaiser, Peter/0000-0001-5126-045X
CR Arevalo JF, 2008, BRIT J OPHTHALMOL, V92, P213, DOI 10.1136/bjo.2007.127142
   Arias L, 2007, EUR J OPHTHALMOL, V17, P992, DOI 10.1177/112067210701700622
   Arnold JJ, 2004, AM J OPHTHALMOL, V137, P683, DOI 10.1016/j.ajo.2003.11.059
   Bakri SJ, 2007, AM J OPHTHALMOL, V143, P505, DOI 10.1016/j.ajo.2006.11.047
   CANTRILL HL, 1983, ARCH OPHTHALMOL-CHIC, V101, P1074
   Carvounis PE, 2007, AM J OPHTHALMOL, V143, P504, DOI 10.1016/j.ajo.2006.11.028
   CASSWELL AG, 1985, BRIT J OPHTHALMOL, V69, P397, DOI 10.1136/bjo.69.6.397
   Chan CK, 2007, EUR J OPHTHALMOL, V17, P674, DOI 10.1177/112067210701700432
   Chan CK, 2007, RETINA-J RET VIT DIS, V27, P541, DOI 10.1097/IAE.0b013e3180cc2612
   Chang LK, 2007, RETINA-J RET VIT DIS, V27, P857, DOI 10.1097/IAE.0b013e3180342c42
   Chang LK, 2007, RETINA-J RET VIT DIS, V27, P523, DOI 10.1097/IAE.0b013e3180a032db
   Chiang A, 2008, RETINA-J RET VIT DIS, V28, P1265, DOI 10.1097/IAE.0b013e31817d5d03
   CHUANG EL, 1988, EYE, V2, P106, DOI 10.1038/eye.1988.22
   Cleary CA, 2008, EYE, V22, P82, DOI 10.1038/sj.eye.6702936
   Coscas F, 2007, AM J OPHTHALMOL, V144, P592, DOI 10.1016/j.ajo.2007.06.014
   COSCAS G, 1990, ARCH OPHTHALMOL-CHIC, V108, P1687, DOI 10.1001/archopht.1990.01070140041025
   Dhalla MS, 2006, AM J OPHTHALMOL, V141, P752, DOI 10.1016/j.ajo.2005.10.053
   Fung AE, 2006, BRIT J OPHTHALMOL, V90, P1344, DOI 10.1136/bjo.2006.099598
   Garg S, 2008, CLIN EXP OPHTHALMOL, V36, P252, DOI 10.1111/j.1442-9071.2008.01710.x
   GASS JDM, 1981, ARCH OPHTHALMOL-CHIC, V99, P1016, DOI 10.1001/archopht.1981.03930011016006
   GASS JDM, 1984, AM J OPHTHALMOL, V98, P700
   GASS JDM, 1984, BRIT J OPHTHALMOL, V68, P513, DOI 10.1136/bjo.68.8.513
   GASS JDM, 1984, RETINA-J RET VIT DIS, V4, P205, DOI 10.1097/00006982-198400440-00001
   Gelisken F, 2001, AM J OPHTHALMOL, V131, P518, DOI 10.1016/S0002-9394(00)00813-8
   Giovannini A, 2000, RETINA-J RET VIT DIS, V20, P37, DOI 10.1097/00006982-200001000-00007
   Giovannini A, 1999, ACTA OPHTHALMOL SCAN, V77, P83, DOI 10.1034/j.1600-0420.1999.770119.x
   Goldstein M, 2005, EYE, V19, P1315, DOI 10.1038/sj.eye.6701765
   HOSKIN A, 1981, BRIT J OPHTHALMOL, V65, P417, DOI 10.1136/bjo.65.6.417
   Kook D, 2008, OPHTHALMOLOGE, V105, P158, DOI 10.1007/s00347-007-1561-6
   Leitritz M, 2008, EYE, V22, P1504, DOI 10.1038/eye.2008.145
   Meyer CH, 2006, BRIT J OPHTHALMOL, V90, P1207, DOI 10.1136/bjo.2006.093732
   Michels S, 2006, AM J OPHTHALMOL, V141, P396, DOI 10.1016/j.ajo.2005.08.046
   Moradian S, 2008, GRAEF ARCH CLIN EXP, V246, P1699, DOI 10.1007/s00417-008-0914-4
   Pauleikhoff D, 2002, GRAEF ARCH CLIN EXP, V240, P533, DOI 10.1007/s00417-002-0505-8
   Pece A, 2001, RETINA-J RET VIT DIS, V21, P661, DOI 10.1097/00006982-200112000-00017
   Ronan SM, 2007, RETINA-J RET VIT DIS, V27, P535, DOI 10.1097/IAE.0b013e3180cc2645
   Sato T, 2004, RETINA-J RET VIT DIS, V24, P910, DOI 10.1097/00006982-200412000-00011
   Shah CP, 2006, AM J OPHTHALMOL, V142, P1070, DOI 10.1016/j.ajo.2006.07.037
   Shaikh Saad, 2007, Indian Journal of Ophthalmology, V55, P470
   Singh RP, 2006, AM J OPHTHALMOL, V142, P160, DOI 10.1016/j.ajo.2006.03.051
   Spandau UHM, 2006, AM J OPHTHALMOL, V142, P1068, DOI 10.1016/j.ajo.2006.06.048
   Srivastava SK, 2002, RETINA-J RET VIT DIS, V22, P669, DOI 10.1097/00006982-200210000-00027
   Sutter FK, 2007, KLIN MONATSBL AUGENH, V224, P297, DOI 10.1055/s-2007-962949
   YEO JH, 1988, OPHTHALMOLOGY, V95, P8
NR 44
TC 78
Z9 82
U1 0
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0275-004X
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD FEB
PY 2010
VL 30
IS 2
BP 203
EP 211
DI 10.1097/IAE.0b013e3181babda5
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 607ZY
UT WOS:000278547400002
PM 19952998
DA 2022-11-30
ER

PT J
AU Yanyali, A
   Celik, E
   Horozoglu, F
   Oner, S
   Nohutcu, AF
AF Yanyali, A
   Celik, E
   Horozoglu, F
   Oner, S
   Nohutcu, AF
TI 25-Gauge transconjunctival sutureless pars 14 plana vitrectomy
SO EUROPEAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE pars plana vitrectomy; transconjunctival sutureless vitrectomy; 25-gauge
   pars plana vitrectomy
ID SELF-SEALING SCLEROTOMIES; INTRAOCULAR-LENS IMPLANTATION; BLOOD-AQUEOUS
   BARRIER; COMPLICATIONS; SURGERY; SYSTEM
AB PURPOSE. To evaluate the effectiveness, feasibility, and safety of the transconjunctival sutureless vitrectomy (TSV) system for a variety of vitreoretinal diseases.
   METHODS. In this retrospective study, the authors evaluated 71 eyes of 63 patients who underwent pars plana vitrectomy (PPV) with the 25-gauge TSV system. The indications for surgical intervention were diabetic vitreous hemorrhage (29 eyes), diabetic macular edema (14 eyes), macular epiretinal membrane (13 eyes), endophthalmitis (5 eyes), vitreous opacities secondary to Behcet's disease (4 eyes), vitreous hemorrhage secondary to branch retinal vein occlusion (4 eyes), and vitreous hemorrhage secondary to age-related macular degeneration (2 eyes). Epiretinal membrane and internal limiting membrane removal, endolaser photocoagulation, and air-fluid exchange were performed when required.
   RESULTS. Mean follow-up was 3.6 months (range 1-8 months). Mean overall visual acuity (VA) was counting fingers (range light perception to 0.4) preoperatively and 0.2 (range 0.1 to 0.8) postoperatively (p=0.000). Statistically significant VA improvement was observed in eyes with vitreous hemorrhage, diabetic macular edema, and macular epiretinal membrane. VA improved postoperatively in all eyes with endophthalmitis and vitreous opacities secondary to Behcet's disease. The surgery was completed without conjunctival and scleral suturing in all eyes. Mean intraocular pressure (IOP) was 17.2 mmHg (range 10-26 mmHg) preoperatively, 12.4 mmHg (range 6-24 mmHg) on the first postoperative day, 16.6 mmHg (range 10-33 mmHg) at 1 week, and 15.4 mmHg (range 10-20 mmHg) at 1 month postoperatively. On the first postoperative day, IOP was below 10 mmHg (between 6 and 9 mmHg) in 12 eyes (16.9%). In these eyes, IOP was normalized within 1 week without affecting the visual outcome. Five eyes (7%) had transient increase of IOP controlled by topical antiglaucomatous medications. Vitreous washout using 25-gauge TSV system was performed in two eyes, in which vitreous hemorrhage recurred.
   CONCLUSIONS. The TSV system was observed to be feasible, effective, and safe for a variety of vitreoretinal diseases. This minimally invasive and completely sutureless (transconjunctival) technique appears to decrease the convalescence period, operating time, and postoperative inflammatory response, and improve patient comfort.
C1 Haydarpasa Numune Educ & Res Hosp, Dept Ophthalmol, Istanbul, Turkey.
C3 Istanbul Haydarpasa Numune Training & Research Hospital
RP Yanyali, A (通讯作者)，Topagac Sok Akarsu Apt 3-13, Istanbul, Turkey.
EM ayanyali@hotmail.com
RI Yanyali, Ates/AAW-7594-2020; Horozoglu, Fatih/AAM-4273-2021
CR Chen JC, 1996, ARCH OPHTHALMOL-CHIC, V114, P1273, DOI 10.1001/archopht.1996.01100140473024
   D'Amico DJ, 1994, PRINCIPLES PRACTICE, P1159
   DICK AD, 1994, BRIT J OPHTHALMOL, V78, P1, DOI 10.1136/bjo.78.1.1
   Fujii GY, 2002, OPHTHALMOLOGY, V109, P1814, DOI 10.1016/S0161-6420(02)01119-3
   Fujii GY, 2002, OPHTHALMOLOGY, V109, P1807, DOI 10.1016/S0161-6420(02)01179-X
   KAIYA T, 1990, J CATARACT REFR SURG, V16, P320, DOI 10.1016/S0886-3350(13)80702-X
   Kwok AKH, 1999, AM J OPHTHALMOL, V127, P731, DOI 10.1016/S0002-9394(98)00427-9
   Kwok AKH, 2001, AM J OPHTHALMOL, V132, P172, DOI 10.1016/S0002-9394(01)00973-4
   Lam DSC, 2000, ARCH OPHTHALMOL-CHIC, V118, P850
   MICHAELS GR, 1981, VITREOUS SURG, P209
   MIELER WF, 1992, DEV OPHTHALMOL, V23, P239
   Milibak T, 1998, ARCH OPHTHALMOL-CHIC, V116, P119
   Morris R, 1995, MASTER TECH OPHTHALM, P560
   NOLTHENIUS PAT, 1983, OPHTHALMOLOGICA, V186, P11
   OSHIKA T, 1992, J CATARACT REFR SURG, V18, P356, DOI 10.1016/S0886-3350(13)80071-5
   Rahman R, 2000, OPHTHALMIC SURG LAS, V31, P462
   SANDERS DR, 1983, ARCH OPHTHALMOL-CHIC, V101, P131
   TARDIF YM, 1977, ARCH OPHTHALMOL-CHIC, V95, P229, DOI 10.1001/archopht.1977.04450020031005
   Van Kuijk FJGM, 2001, RETINA-J RET VIT DIS, V21, P547, DOI 10.1097/00006982-200110000-00027
NR 19
TC 77
Z9 86
U1 0
U2 2
PU WICHTIG EDITORE
PI MILAN
PA 72/74 VIA FRIULI, 20135 MILAN, ITALY
SN 1120-6721
J9 EUR J OPHTHALMOL
JI Eur. J. Ophthalmol.
PD JAN-FEB
PY 2006
VL 16
IS 1
BP 141
EP 147
DI 10.1177/112067210601600123
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 017YG
UT WOS:000235728600023
PM 16496259
DA 2022-11-30
ER

PT J
AU Johnson, PT
   Lewis, GP
   Talaga, KC
   Brown, MN
   Kappel, PJ
   Fisher, SK
   Anderson, DH
   Johnson, LV
AF Johnson, PT
   Lewis, GP
   Talaga, KC
   Brown, MN
   Kappel, PJ
   Fisher, SK
   Anderson, DH
   Johnson, LV
TI Drusen-associated degeneration in the retina
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID AGE-RELATED MACULOPATHY; MACULAR DEGENERATION; PIGMENT EPITHELIUM;
   COMPLEMENT ACTIVATION; PHOTORECEPTOR DEATH; BRUCHS MEMBRANE; GRADING
   SYSTEM; C57BL/6J MOUSE; BETA-PEPTIDE; RISK-FACTORS
AB PURPOSE. Drusen are variably sized extracellular deposits that form between the retinal pigmented epithelium (RPE) and Bruch's membrane. They are commonly found in aged eyes, however, numerous and/or confluent drusen are a significant risk factor for age-related macular degeneration. The purpose of this study was to investigate the impact of drusen on overlying cells of the retina.
   METHODS. Tissue containing retina and RPE/choroid was dissected from human donor eyes, embedded in agarose, and sectioned at 100 mum using a vibratome. Sections were immunostained with a panel of antibodies that labeled glial cells, first-, second-, and third-order retinal neurons and processed for confocal microscopy.
   RESULTS. Retinal cells that overlie both soft and hard drusen exhibited numerous structural and molecular abnormalities. Normally detectable only in the outer segments of rod photoreceptors, rod opsin immunolabeling was also observed in the inner segment, cell body, axon, and axon terminal of photoreceptors that overlie drusen. Labeling with this antibody also revealed the deflection and shortening of rod inner and outer segments. Cone photoreceptors displayed similar structural abnormalities, as well as a decrease in cone opsin immunoreactivity. Drusen-associated abnormalities in the synaptic terminals of photoreceptor cells were also observed. In addition, an increase in intermediate filament protein immunoreactivity (vimentin and glial fibrillary acidic protein) was observed within Muller glial cells in areas of retina overlying drusen. Both soft and hard drusen were associated with a similar spectrum of effects in both macular and extramacular regions. Second- and third-order neurons, including bipolar, horizontal, amacrine, and ganglion cells all appeared unaffected. The structural and molecular abnormalities observed in photoreceptors and Muller glial cells were confined to retinal regions directly overlying and immediately adjacent to drusen; more distant retinal regions appeared unperturbed. Remarkably, significant abnormalities were observed over small subclinical drusen.
   CONCLUSIONS. Retinal cells overlying both soft and hard drusen exhibit structural and molecular abnormalities indicative of photoreceptor degeneration and Muller glial activation. These abnormalities resemble the degenerative effects common to many forms of retinal degeneration, but are confined to areas directly overlying drusen. This suggests that photoreceptor cell function is compromised as a consequence of drusen formation.
C1 Univ Calif Santa Barbara, Neurosci Res Inst, Ctr Study Macular Degenerat, Santa Barbara, CA 93106 USA.
   Univ Calif Santa Barbara, Dept Mol Cellular & Dev Biol, Santa Barbara, CA 93106 USA.
C3 University of California System; University of California Santa Barbara;
   University of California System; University of California Santa Barbara
RP Johnson, PT (通讯作者)，Univ Calif Santa Barbara, Neurosci Res Inst, Ctr Study Macular Degenerat, Santa Barbara, CA 93106 USA.
EM p_johnso@lifesci.ucsb.edu
FU NEI NIH HHS [EY 00-888, EY 11-527, EY 11-521] Funding Source: Medline;
   NATIONAL EYE INSTITUTE [R01EY011527, R01EY011521, R37EY000888,
   R01EY000888] Funding Source: NIH RePORTER
CR Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   Anderson DH, 2001, AM J OPHTHALMOL, V131, P767, DOI 10.1016/S0002-9394(00)00961-2
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Boulton M, 2001, EYE, V15, P384, DOI 10.1038/eye.2001.141
   BRESSLER NM, 1994, RETINA-J RET VIT DIS, V14, P130, DOI 10.1097/00006982-199414020-00006
   BRESSLER SB, 1990, ARCH OPHTHALMOL-CHIC, V108, P1442, DOI 10.1001/archopht.1990.01070120090035
   Burns R P, 1980, Trans Am Ophthalmol Soc, V78, P206
   Coblentz FE, 2003, EXP EYE RES, V76, P333, DOI 10.1016/S0014-4835(02)00305-6
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   Curcio CA, 1996, INVEST OPHTH VIS SCI, V37, P1236
   Curcio CA, 1998, INVEST OPHTH VIS SCI, V39, P1085
   Curcio CA, 2001, INVEST OPHTH VIS SCI, V42, P265
   Dunaief JL, 2002, ARCH OPHTHALMOL-CHIC, V120, P1435, DOI 10.1001/archopht.120.11.1435
   Evans JR, 2001, PROG RETIN EYE RES, V20, P227, DOI 10.1016/S1350-9462(00)00023-9
   FARKAS TG, 1971, AM J OPHTHALMOL, V71, P1196, DOI 10.1016/0002-9394(71)90963-9
   FISHER SK, 2001, RETINA, V3, P1961
   Graymore CN, 1969, EYE, VI, P601
   Green W R, 1999, Mol Vis, V5, P27
   Guidry C, 2002, INVEST OPHTH VIS SCI, V43, P267
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   HOGAN M J, 1972, Transactions of the American Academy of Ophthalmology and Oto-Laryngology, V76, P64
   ISHIBASHI T, 1986, AM J OPHTHALMOL, V101, P342, DOI 10.1016/0002-9394(86)90830-5
   Jen LS, 1998, NATURE, V392, P140, DOI 10.1038/32327
   Johnson LV, 2000, EXP EYE RES, V70, P441, DOI 10.1006/exer.1999.0798
   Johnson LV, 2001, EXP EYE RES, V73, P887, DOI 10.1006/exer.2001.1094
   Johnson LV, 2002, P NATL ACAD SCI USA, V99, P11830, DOI 10.1073/pnas.192203399
   Kim SY, 2002, RETINA-J RET VIT DIS, V22, P471, DOI 10.1097/00006982-200208000-00012
   Linsenmeier RA, 2000, INVEST OPHTH VIS SCI, V41, P3117
   MADIGAN MC, 1994, RETINA-J RET VIT DIS, V14, P65, DOI 10.1097/00006982-199401000-00014
   Medeiros NE, 2001, INVEST OPHTH VIS SCI, V42, P795
   Mervin K, 2002, EXP EYE RES, V75, P703, DOI 10.1006/exer.2002.2063
   Mervin K, 2002, EXP EYE RES, V75, P715, DOI 10.1006/exer.2002.2064
   Mervin K, 1999, AM J OPHTHALMOL, V128, P155, DOI 10.1016/S0002-9394(99)00104-X
   MIDENA E, 1994, DOC OPHTHALMOL, V88, P179, DOI 10.1007/BF01204616
   Owsley C, 2001, OPHTHALMOLOGY, V108, P1196, DOI 10.1016/S0161-6420(01)00580-2
   PAULEIKHOFF D, 1990, AM J OPHTHALMOL, V109, P38, DOI 10.1016/S0002-9394(14)75576-X
   Penfold PL, 2001, PROG RETIN EYE RES, V20, P385, DOI 10.1016/S1350-9462(00)00025-2
   PORTERACAILLIAU C, 1994, P NATL ACAD SCI USA, V91, P974, DOI 10.1073/pnas.91.3.974
   Ramirez JM, 2001, EXP EYE RES, V73, P601, DOI 10.1006/exer.2001.1061
   Sakai T, 2001, INVEST OPHTH VIS SCI, V42, P3264
   Sarks SH, 1999, BRIT J OPHTHALMOL, V83, P358, DOI 10.1136/bjo.83.3.358
   SARKS SH, 1982, AUST J OPHTHALMOL, V10, P91, DOI 10.1111/j.1442-9071.1982.tb00366.x
   SMITH VC, 1988, J OPT SOC AM A, V5, P2113, DOI 10.1364/JOSAA.5.002113
   SUNNESS JS, 1988, ARCH OPHTHALMOL-CHIC, V106, P1081, DOI 10.1001/archopht.1988.01060140237032
   Walsh DT, 2002, NEUROBIOL DIS, V10, P20, DOI 10.1006/nbdi.2002.0485
NR 45
TC 139
Z9 149
U1 0
U2 13
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD OCT
PY 2003
VL 44
IS 10
BP 4481
EP 4488
DI 10.1167/iovs.03-0436
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 727BT
UT WOS:000185636700041
PM 14507896
DA 2022-11-30
ER

PT J
AU Zhang, RH
   Liu, YM
   Dong, L
   Li, HY
   Li, YF
   Zhou, WD
   Wu, HT
   Wang, YX
   Wei, WB
AF Zhang, Rui-Heng
   Liu, Yue-Ming
   Dong, Li
   Li, He-Yan
   Li, Yi-Fan
   Zhou, Wen-Da
   Wu, Hao-Tian
   Wang, Ya-Xing
   Wei, Wen-Bin
TI Prevalence, Years Lived With Disability, and Time Trends for 16 Causes
   of Blindness and Vision Impairment: Findings Highlight Retinopathy of
   Prematurity
SO FRONTIERS IN PEDIATRICS
LA English
DT Article
DE prevalence; years lived with disability; blindness; visual impairment;
   retinopathy of prematurity
ID GLOBAL BURDEN; DISEASE; COUNTRIES; MORTALITY; MYOPIA
AB BackgroundCause-specific prevalence data of vision loss and blindness is fundamental for making public health policies and is essential for prioritizing scientific advances and industry research. MethodsCause-specific vision loss data from the Global Health Data Exchange was used. The burden of vision loss was measured by prevalence and years lived with disability (YLDs). FindingsIn 2019, uncorrected refractory error and cataract were the most common causes for vision loss and blindness globally. Women have higher rates of cataract, age-related macular degeneration (AMD), and diabetic retinopathy (DR) than men. In the past 30 years, the prevalence of moderate/severe vision loss and blindness due to neonatal disorders has increased by 13.73 and 33.53%, respectively. Retinopathy of prematurity (ROP) is the major cause of neonatal disorders related vision loss. In 2019, ROP caused 101.6 thousand [95% uncertainty intervals (UI) 77.5-128.2] cases of vision impairment, including 49.1 thousand (95% UI 28.1-75.1) moderate vision loss, 27.5 thousand (95% UI 19.3-36.60) severe vision loss and, 25.0 thousand (95% UI 14.6-35.8) blindness. The prevalence of new-onset ROP in Africa and East Asia was significantly higher than other regions. Variation of preterm birth prevalence can explain 49.8% geometry variation of ROP-related vision loss burden among 204 countries and territories. After adjusting for preterm prevalence, government health spending per total health spending (%), rather than total health spending per person, was associated with a reduced burden of ROP-related vision loss in 2019 (-0.19 YLDs for 10% increment). By 2050, prevalence of moderate, severe vision loss and blindness due to ROP is expected to reach 43.6 (95% UI 35.1-52.0), 23.2 (95% UI 19.4-27.1), 31.9 (95% UI 29.7-34.1) per 100,000 population. ConclusionThe global burden of vision loss and blindness highlights the prevalent of ROP, a major and avoidable cause for childhood vision loss. Advanced screening techniques and treatments have shown to be effective in preventing ROP-related vision loss and are urgently needed in regions with high ROP-related blindness rates, including Africa and East Asia.
C1 [Zhang, Rui-Heng; Liu, Yue-Ming; Dong, Li; Li, He-Yan; Li, Yi-Fan; Zhou, Wen-Da; Wu, Hao-Tian; Wei, Wen-Bin] Capital Med Univ, Beijing Tongren Hosp, Beijing Tongren Eye Ctr,Beijing Ophthalmology an, Beijing Key Lab Intraocular Tumor Diag & Treatmen, Beijing, Peoples R China.
   [Wang, Ya-Xing] Capital Med Univ, Beijing Tongren Hosp, Beijing Inst Ophthalmol & Beijing Ophthalmol, Beijing Tongren Eye Ctr,Visual Sci Key Lab, Beijing, Peoples R China.
C3 Capital Medical University; Capital Medical University
RP Wei, WB (通讯作者)，Capital Med Univ, Beijing Tongren Hosp, Beijing Tongren Eye Ctr,Beijing Ophthalmology an, Beijing Key Lab Intraocular Tumor Diag & Treatmen, Beijing, Peoples R China.
EM weiwenbintr@163.com
CR Abbafati C, 2020, LANCET, V396, P1204, DOI 10.1016/S0140-6736(20)30925-9
   Blencowe H, 2012, LANCET, V379, P2162, DOI 10.1016/S0140-6736(12)60820-4
   Bourne RRA, 2021, LANCET GLOB HEALTH, V9, pE130, DOI 10.1016/S2214-109X(20)30425-3
   Dong L, 2020, RETINA-J RET VIT DIS, V40, P399, DOI 10.1097/IAE.0000000000002590
   Fierson WM, 2018, PEDIATRICS, V142, DOI 10.1542/peds.2018-3061
   Gebrezgabiher G, 2019, INFECT DIS POVERTY, V8, DOI 10.1186/s40249-019-0567-z
   Holden BA, 2016, OPHTHALMOLOGY, V123, P1036, DOI 10.1016/j.ophtha.2016.01.006
   Jonas JB, 2017, LANCET, V390, P2183, DOI 10.1016/S0140-6736(17)31469-1
   Li HY, 2021, BMC PUBLIC HEALTH, V21, DOI 10.1186/s12889-021-11648-1
   Li JQ, 2020, BRIT J OPHTHALMOL, V104, P1077, DOI 10.1136/bjophthalmol-2019-314422
   Li YH, 2022, BRIT J OPHTHALMOL, V106, P633, DOI 10.1136/bjophthalmol-2020-317825
   Liu YC, 2017, LANCET, V390, P600, DOI 10.1016/S0140-6736(17)30544-5
   Micah AE, 2021, LANCET, V398, P1317, DOI 10.1016/S0140-6736(21)01258-7
   NCD RiskFactorCollaboration(NCD-RisC)., 2016, LANCET, V387, P1513, DOI [DOI 10.1016/S0140-6736(16)00618-8, 10.1016/S0140-6736(16)00618-8]
   Network GBoDC, 2020, GLOBAL BURDEN DIS ST
   Ruiz-Medrano J, 2019, PROG RETIN EYE RES, V69, P80, DOI 10.1016/j.preteyeres.2018.10.005
   Solebo AL, 2017, ARCH DIS CHILD, V102, P853, DOI 10.1136/archdischild-2016-310532
   Son J, 2020, OPHTHALMOLOGY, V127, P85, DOI 10.1016/j.ophtha.2019.05.029
   Steinmetz JD, 2021, LANCET GLOB HEALTH, V9, pE144, DOI 10.1016/S2214-109X(20)30489-7
   Stevens GA, 2015, LANCET GLOB HEALTH, V3, pE528, DOI 10.1016/S2214-109X(15)00039-X
   Stoll BJ, 2015, JAMA-J AM MED ASSOC, V314, P1039, DOI 10.1001/jama.2015.10244
   Taylor HR, 2014, LANCET, V384, P2142, DOI 10.1016/S0140-6736(13)62182-0
   Tekle AH, 2016, INFECT DIS POVERTY, V5, DOI 10.1186/s40249-016-0160-7
   Ting DSW, 2019, PROG RETIN EYE RES, V72, DOI 10.1016/j.preteyeres.2019.04.003
   Ting DSW, 2017, JAMA-J AM MED ASSOC, V318, P2211, DOI 10.1001/jama.2017.18152
   Ung L, 2020, AM J OPHTHALMOL, V224, P30, DOI 10.1016/j.ajo.2020.11.016
   Vollset SE, 2020, LANCET, V396, P1285, DOI 10.1016/S0140-6736(20)30677-2
   Wirth JP, 2017, NUTRIENTS, V9, DOI 10.3390/nu9030190
   Wong TY, 2016, NAT REV DIS PRIMERS, V2, DOI 10.1038/nrdp.2016.12
   Wong TY, 2014, AM J OPHTHALMOL, V157, P9, DOI 10.1016/j.ajo.2013.08.010
   Xu TL, 2020, LANCET PUBLIC HEALTH, V5, pE682, DOI 10.1016/S2468-2667(20)30254-1
NR 31
TC 1
Z9 1
U1 2
U2 4
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 2296-2360
J9 FRONT PEDIATR
JI Front. Pediatr.
PD MAR 11
PY 2022
VL 10
AR 735335
DI 10.3389/fped.2022.735335
PG 9
WC Pediatrics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pediatrics
GA 0E9YL
UT WOS:000777027400001
PM 35359888
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Guerra, MH
   Yumnamcha, T
   Ebrahim, AS
   Berger, EA
   Singh, LP
   Ibrahim, AS
AF Guerra, Michael H.
   Yumnamcha, Thangal
   Ebrahim, Abdul-Shukkur
   Berger, Elizabeth A.
   Singh, Lalit Pukhrambam
   Ibrahim, Ahmed S.
TI Real-Time Monitoring the Effect of Cytopathic Hypoxia on Retinal Pigment
   Epithelial Barrier Functionality Using Electric Cell-Substrate Impedance
   Sensing (ECIS) Biosensor Technology
SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
LA English
DT Article
DE age related macular degeneration (AMD); diabetic macular edema (DME);
   cytopathic hypoxia; retinal pigment epithelial cells (RPE); ARPE-19;
   CoCl2; seahorse; ECIS modeling; R-b resistance; alpha resistance;
   impedance; capacitance; barrier integrity
ID DIABETIC MACULAR EDEMA; GROWTH-FACTORS; DEGENERATION; EXPRESSION;
   MANAGEMENT; TRANSPORT; MEMBRANE; ADHESION; REGIMEN; TREAT
AB Disruption of retinal pigment epithelial (RPE barrier integrity is a hallmark feature of various retinal blinding diseases, including diabetic macular edema and age-related macular degeneration, but the underlying causes and pathophysiology are not completely well-defined. One of the most conserved phenomena in biology is the progressive decline in mitochondrial function with aging leading to cytopathic hypoxia, where cells are unable to use oxygen for energy production. Therefore, this study aimed to thoroughly investigate the role of cytopathic hypoxia in compromising the barrier functionality of RPE cells. We used Electric Cell-Substrate Impedance Sensing (ECIS) system to monitor precisely in real time the barrier integrity of RPE cell line (ARPE-19) after treatment with various concentrations of cytopathic hypoxia-inducing agent, Cobalt(II) chloride (CoCl2). We further investigated how the resistance across ARPE-19 cells changes across three separate parameters: R-b (the electrical resistance between ARPE-19 cells), alpha (the resistance between the ARPE-19 and its substrate), and C-m (the capacitance of the ARPE-19 cell membrane). The viability of the ARPE-19 cells and mitochondrial bioenergetics were quantified with 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-2H-tetrazolium bromide (MTT) assay and seahorse technology, respectively. ECIS measurement showed that CoCl2 reduced the total impedance of ARPE-19 cells in a dose dependent manner across all tested frequencies. Specifically, the ECIS program's modelling demonstrated that CoCl2 affected R-b as it begins to drastically decrease earlier than alpha or C-m, although ARPE-19 cells' viability was not compromised. Using seahorse technology, all three concentrations of CoCl2 significantly impaired basal, maximal, and ATP-linked respirations of ARPE-19 cells but did not affect proton leak and non-mitochondrial bioenergetic. Concordantly, the expression of a major paracellular tight junction protein (ZO-1) was reduced significantly with CoCl(2-)treatment in a dose-dependent manner. Our data demonstrate that the ARPE-19 cells have distinct dielectric properties in response to cytopathic hypoxia in which disruption of barrier integrity between ARPE-19 cells precedes any changes in cells' viability, cell-substrate contacts, and cell membrane permeability. Such differences can be used in screening of selective agents that improve the assembly of RPE tight junction without compromising other RPE barrier parameters.
C1 [Guerra, Michael H.; Yumnamcha, Thangal; Ebrahim, Abdul-Shukkur; Berger, Elizabeth A.; Singh, Lalit Pukhrambam; Ibrahim, Ahmed S.] Wayne State Univ, Sch Med, Dept Ophthalmol Visual & Anat Sci, 540 East Canfield,Gordon Scott Hall,Room 7133, Detroit, MI 48201 USA.
   [Ibrahim, Ahmed S.] Wayne State Univ, Sch Med, Dept Pharmacol, 540 East Canfield,Gordon Scott Hall,Room 7133, Detroit, MI 48201 USA.
   [Ibrahim, Ahmed S.] Mansoura Univ, Fac Pharm, Dept Biochem, Mansoura 35516, Egypt.
C3 Wayne State University; Wayne State University; Egyptian Knowledge Bank
   (EKB); Mansoura University
RP Ibrahim, AS (通讯作者)，Wayne State Univ, Sch Med, Dept Ophthalmol Visual & Anat Sci, 540 East Canfield,Gordon Scott Hall,Room 7133, Detroit, MI 48201 USA.; Ibrahim, AS (通讯作者)，Wayne State Univ, Sch Med, Dept Pharmacol, 540 East Canfield,Gordon Scott Hall,Room 7133, Detroit, MI 48201 USA.; Ibrahim, AS (通讯作者)，Mansoura Univ, Fac Pharm, Dept Biochem, Mansoura 35516, Egypt.
EM michael.guerra2@med.wayne.edu; gl5948@wayne.edu; ex8029@wayne.edu;
   eberger@med.wayne.edu; plsingh@med.wayne.edu; ahmed.ibrahim@wayne.edu
RI ; ibrahim, ahmed/D-5241-2017
OI Berger, Elizabeth/0000-0001-5371-1170; ibrahim,
   ahmed/0000-0001-8480-6252
FU American Heart Association Grant [18CDA34080403]; NIH [P30EY004068];
   NIH/NEI [EY023992]; Research to Prevent Blindness
FX This research was funded by the American Heart Association Grant
   18CDA34080403 (A.S.I.), NIH core grant P30EY004068 to the Department of
   Ophthalmology, Visual and Anatomical Sciences (OVAS), NIH/NEI EY023992
   to L.P.S. and a Research to Prevent Blindness unrestricted grant to the
   Department of OVAS, Wayne State University, Detroit, MI, USA.
CR Afshari FT, 2010, BRAIN, V133, P448, DOI 10.1093/brain/awp319
   Ahuja M, 2016, J NEUROSCI, V36, P6332, DOI 10.1523/JNEUROSCI.0426-16.2016
   Brody BL, 2001, OPHTHALMOLOGY, V108, P1893, DOI 10.1016/S0161-6420(01)00754-0
   Dranka BP, 2011, FREE RADICAL BIO MED, V51, P1621, DOI 10.1016/j.freeradbiomed.2011.08.005
   Eamegdool SS, 2020, FREE RADICAL BIO MED, V146, P357, DOI 10.1016/j.freeradbiomed.2019.11.018
   Feng JY, 2020, ANN TRANSL MED, V8, DOI 10.21037/atm-20-7145
   Fischer S, 2002, MICROVASC RES, V63, P70, DOI 10.1006/mvre.2001.2367
   Gehrs KM, 2006, ANN MED, V38, P450, DOI 10.1080/07853890600946724
   Gemenetzi M, 2017, OPHTHALMOL THER, V6, P79, DOI 10.1007/s40123-017-0087-5
   GIAEVER I, 1993, NATURE, V366, P591, DOI 10.1038/366591a0
   Gomes AP, 2013, CELL, V155, P1624, DOI 10.1016/j.cell.2013.11.037
   GREEN WR, 1993, OPHTHALMOLOGY, V100, P1519
   Grossniklaus HE, 2002, MOL VIS, V8, P119
   Gullapalli VK, 2008, EXP EYE RES, V86, P189, DOI 10.1016/j.exer.2007.10.009
   Hayreh SS, 2008, GRAEF ARCH CLIN EXP, V246, P353, DOI 10.1007/s00417-007-0678-2
   Hollborn M, 2012, MOL BIOL REP, V39, P7949, DOI 10.1007/s11033-012-1640-x
   Ibrahim AS, 2020, J CLIN MED, V9, DOI 10.3390/jcm9072293
   Ibrahim AS, 2015, BBA-MOL CELL BIOL L, V1851, P290, DOI 10.1016/j.bbalip.2014.12.017
   Kaarniranta K, 2017, CELL BIOL TOXICOL, V33, P113, DOI 10.1007/s10565-016-9371-8
   Kowluru RA, 2019, DIABETES, V68, P241, DOI 10.2337/dbi18-0016
   KURIHARA H, 1995, AM J PHYSIOL-RENAL, V268, pF514, DOI 10.1152/ajprenal.1995.268.3.F514
   Kurihara T, 2016, ELIFE, V5, DOI 10.7554/eLife.14319
   Lanza IR, 2010, PFLUG ARCH EUR J PHY, V459, P277, DOI 10.1007/s00424-009-0724-5
   Marmorstein AD, 2001, TRAFFIC, V2, P867, DOI 10.1034/j.1600-0854.2001.21202.x
   Miller JW, 2013, AM J OPHTHALMOL, V155, P1, DOI 10.1016/j.ajo.2012.10.018
   Mousa SA, 1999, J CELL BIOCHEM, V74, P135, DOI 10.1002/(SICI)1097-4644(19990701)74:1<135::AID-JCB15>3.0.CO;2-#
   Munoz-Sanchez J, 2019, J APPL TOXICOL, V39, P556, DOI 10.1002/jat.3749
   NEGI A, 1986, INVEST OPHTH VIS SCI, V27, P1564
   Nguyen QD, 2004, INVEST OPHTH VIS SCI, V45, P617, DOI 10.1167/iovs.03-0557
   Rajala RVS, 2020, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.00266
   Robilliard LD, 2018, BIOSENSORS-BASEL, V8, DOI 10.3390/bios8030064
   Rufai SR, 2017, EYE, V31, P1337, DOI 10.1038/eye.2017.67
   Sacconi R, 2017, OPHTHALMOL THER, V6, P69, DOI 10.1007/s40123-017-0086-6
   Schlaepfer DD, 1999, PROG BIOPHYS MOL BIO, V71, P435, DOI 10.1016/S0079-6107(98)00052-2
   Schlingemann RO, 2004, GRAEF ARCH CLIN EXP, V242, P91, DOI 10.1007/s00417-003-0828-0
   Tan J, 2013, J HUAZHONG U SCI-MED, V33, P137, DOI 10.1007/s11596-013-1086-y
   Utepbergenov DI, 1998, FEBS LETT, V424, P197, DOI 10.1016/S0014-5793(98)00173-2
   Vadlapatla RK, 2013, INT J PHARMACEUT, V454, P444, DOI 10.1016/j.ijpharm.2013.06.044
   Valko M, 2005, CURR MED CHEM, V12, P1161, DOI 10.2174/0929867053764635
   Yajima D, 2009, CELL BIOCHEM FUNCT, V27, P338, DOI 10.1002/cbf.1578
   Yau JWY, 2012, DIABETES CARE, V35, P556, DOI 10.2337/dc11-1909
   Yonekawa Y, 2015, J CLIN MED, V4, P343, DOI 10.3390/jcm4020343
NR 42
TC 6
Z9 6
U1 1
U2 5
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 1422-0067
J9 INT J MOL SCI
JI Int. J. Mol. Sci.
PD MAY
PY 2021
VL 22
IS 9
AR 4568
DI 10.3390/ijms22094568
PG 17
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA SC0DN
UT WOS:000650353700001
PM 33925448
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Campochiaro, PA
   Aiello, LP
   Rosenfeld, PJ
AF Campochiaro, Peter A.
   Aiello, Lloyd Paul
   Rosenfeld, Philip J.
TI Antie-Vascular Endothelial Growth Factor Agents in the Treatment of
   Retinal Disease From Bench to Bedside
SO OPHTHALMOLOGY
LA English
DT Article
ID PROLIFERATIVE DIABETIC-RETINOPATHY; MACULAR EDEMA SECONDARY;
   INTRAVITREAL AFLIBERCEPT INJECTION; OCCLUSION 12-MONTH OUTCOMES;
   BEVACIZUMAB AVASTIN THERAPY; LONG-TERM OUTCOMES; 2.0 MG RANIBIZUMAB;
   VEGF TRAP-EYE; VEIN OCCLUSION; CHOROIDAL NEOVASCULARIZATION
AB The association of retinal hypoxia with retinal neovascularization has been recognized for decades, causing Michaelson to postulate in 1948 that a factor secreted by hypoxic retina was involved. The isolation of vascular endothelial growth factor (VEGF), characterization of its angiogenic activity, and demonstration that its expression was increased in hypoxic tissue made it a prime candidate. Intraocular levels of VEGF are elevated in patients with retinal or iris neovascularization, and VEGF-specific antagonists markedly suppress retinal neovascularization in mice and primates with ischemic retinopathy. Vascular endothelial growth factor antagonists also suppress choroidal neovascularization, and transgenic expression of VEGF in the retina of mice causes subretinal neovascularization. Clinical trials using a VEGF antagonist that blocks all isoforms of VEGF-A in patients with neovascular age-related macular degeneration (nAMD) demonstrated dramatic benefit. Similar results have been obtained with 2 other VEGF antagonists. Retinal hypoxia also contributes to diabetic macular edema (DME), and because of the absence of good animal models, small clinical trials were used to test the role of VEGF. The results clearly implicated VEGF as a major contributor to DME and have been confirmed by several large multicenter trials. A similar strategy demonstrated that VEGF is a major contributor to macular edema resulting from retinal vein occlusion, also confirmed in multicenter trials. Secondary outcomes in these large clinical trials have shown that VEGF inhibition improves retinal hemorrhages, retinal vessel closure, and progression of nonproliferative diabetic retinopathy. Anti-VEGF agents also provide therapeutic benefits in proliferative diabetic retinopathy. Thus, the development of VEGF antagonists has revolutionized the treatment of nAMD, diabetic retinopathy, and other ischemic retinopathies, but in many patients, the upregulation of VEGF is prolonged. Although the molecular signaling by which hypoxia and some other insults lead to upregulation of VEGF has been elucidated, it has not yet led to a treatment that reliably reduces the production of VEGF, necessitating continued neutralization by repeated intraocular injections of VEGF antagonists in many patients. The next horizon in the evolution of anti-VEGF therapy is the development of longer-acting agents or delivery platforms that provide sustained neutralization with fewer injections. (C) 2016 by the American Academy of Ophthalmology.
C1 [Campochiaro, Peter A.] Johns Hopkins Univ, Wilmer Eye Inst, Sch Med, Baltimore, MD 21218 USA.
   [Aiello, Lloyd Paul] Harvard Med Sch, Joslin Diabet Ctr, Beetham Eye Inst, Boston, MA USA.
   [Rosenfeld, Philip J.] Univ Miami, Miller Sch Med, Bascom Palmer Eye Inst, Miami, FL 33136 USA.
C3 Johns Hopkins University; Johns Hopkins Medicine; Harvard University;
   Harvard Medical School; Joslin Diabetes Center, Inc.; Bascom Palmer Eye
   Institute; University of Miami
RP Campochiaro, PA (通讯作者)，Johns Hopkins Univ, Wilmer Eye Inst, 600 North Wolfe St,Maunenee 815, Baltimore, MD 21287 USA.
EM pcampo@jhmi.edu
FU AbbVie (North Chicago, IL); Allergan (Irvine, CA); Genentech/Roche;
   Genzyme (Cambridge, MA); GlaxoSmithKline (Philadelphia, PA); Oxford
   Biomedica (Oxford, UK); Regeneron; RegenX; Rxi Pharmaceuticals; Kalvista
   (Southampton, UK); Genentech; Merck; Apellis (Crestwood, KY); Carl Zeiss
   Meditec (Dublin, CA); Genentech/Roche GlaxoSmithKline; Neurotech
   (Cumberland, RI); Ocata Therapeutics; Acucela
FX The author(s) have made the following disclosure(s): P.A.C.: Consultant
   - Alimera (Alpharetta, GA); Applied Genetic Technologies (Gainesville,
   FL); Eleven Biotherapeutics (Cambridge, MA); AsclipiX (Baltimore, MD);
   Genentech/Roche (South San Francisco, CA); Kala Pharmaceuticals
   (Waltham, MA); Rxi Pharmaceuticals (Marlborough, MA); Aerpio
   (Cincinnati, OH); Regeneron (Tarrytown, NY); Allegro (San Juan
   Capistrano, CA); Intrexon (Germantown, MD); RegenX (Rockville, MD);
   Merck (Kenilworth, NJ); Financial support - AbbVie (North Chicago, IL);
   Allergan (Irvine, CA); Genentech/Roche; Genzyme (Cambridge, MA);
   GlaxoSmithKline (Philadelphia, PA); Oxford Biomedica (Oxford, UK);
   Regeneron; RegenX; Rxi Pharmaceuticals; Royalties - Graybug (Baltimore,
   MD); Equity owner - Alimera; Allegro; Graybug; L.P.A.: Financial support
   - Kalvista (Southampton, UK); Genentech; Merck; Patents - 8,841,259
   (Compositions and Methods for Treating Vascular Permeability); 8,658,685
   (Methods for Treatment of Kallikrein-Related Disorders); 6,114,320
   (Therapeutic Treatment for VEGF-Related Ocular Diseases); P.J.R.:
   Consultant - Achillion Pharmaceuticals (New Haven, CT); Acucela
   (Seattle, WA); Alcon (Fort Worth, TX); Boehringer-Ingelheim (Ridgefield,
   CT); Cell Cure Neurosciences (Jerusalem, Israel); Chengdu Kanghong
   Biotech (Chengdu, China); CoDa Therapeutics (San Diego, CA);
   Genentech/Roche Healios (Brewster, MA); MacRegen Inc. (Seoul, South
   Korea); NGM Biopharmaceuticals (South San Francisco, CA); Ocata
   Therapeutics (Marlborough, MA); Ocudyne (Plano, TX); Regeneron, Stealth
   BioTherapeutics (Newton, MA); Tyrogenex (Needham Heights, MA); Vision
   Medicine (Cambridge, MA); Financial support - Acucela, Apellis
   (Crestwood, KY); Carl Zeiss Meditec (Dublin, CA); Genentech/Roche
   GlaxoSmithKline; Neurotech (Cumberland, RI); Ocata Therapeutics,
   Tyrogenex Equity owner - Apellis, Digisight (Portola Valley, CA).
CR ADAMIS AP, 1994, AM J OPHTHALMOL, V118, P445, DOI 10.1016/S0002-9394(14)75794-0
   Adamis AP, 1996, ARCH OPHTHALMOL-CHIC, V114, P66, DOI 10.1001/archopht.1996.01100130062010
   AIELLO LP, 1995, P NATL ACAD SCI USA, V92, P10457, DOI 10.1073/pnas.92.23.10457
   AIELLO LP, 1994, NEW ENGL J MED, V331, P1480, DOI 10.1056/NEJM199412013312203
   ALON T, 1995, NAT MED, V1, P1024, DOI 10.1038/nm1095-1024
   ASHTON N, 1957, AM J OPHTHALMOL, V44, P7, DOI 10.1016/0002-9394(57)90426-9
   Avery R. L., 2014, BR J OPHTHALMOL, V98, P1543
   Avery RL, 2006, OPHTHALMOLOGY, V113, P1695, DOI 10.1016/j.ophtha.2006.05.064
   BAIRD A, 1985, BIOCHEMISTRY-US, V24, P7855, DOI 10.1021/bi00348a001
   Berg K, 2016, OPHTHALMOLOGY, V123, P51, DOI 10.1016/j.ophtha.2015.09.018
   Berg K, 2015, OPHTHALMOLOGY, V122, P146, DOI 10.1016/j.ophtha.2014.07.041
   Boyer D, 2012, OPHTHALMOLOGY, V119, P1024, DOI 10.1016/j.ophtha.2012.01.042
   Boyer D, 2010, OPHTHALMOLOGY, V117, P1860, DOI 10.1016/j.ophtha.2010.02.022
   Bressler SB, 2013, JAMA OPHTHALMOL, V131, P1033, DOI 10.1001/jamaophthalmol.2013.4154
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Brown DM, 2013, AM J OPHTHALMOL, V155, P429, DOI 10.1016/j.ajo.2012.09.026
   Brown DM, 2011, OPHTHALMOLOGY, V118, P1594, DOI 10.1016/j.ophtha.2011.02.022
   Busbee BG, 2013, OPHTHALMOLOGY, V120, P1046, DOI 10.1016/j.ophtha.2012.10.014
   Campochiaro PA, 2004, INVEST OPHTH VIS SCI, V45, P922, DOI 10.1167/iovs.03-0955
   Campochiaro PA, 2008, MOL THER, V16, P791, DOI 10.1038/mt.2008.10
   Campochiaro PA, 2015, PROG RETIN EYE RES, V49, P67, DOI 10.1016/j.preteyeres.2015.06.002
   Campochiaro PA, 2014, OPHTHALMOLOGY, V121, P1783, DOI 10.1016/j.ophtha.2014.03.021
   Campochiaro PA, 2014, OPHTHALMOLOGY, V121, P209, DOI 10.1016/j.ophtha.2013.08.038
   Campochiaro PA, 2013, OPHTHALMOLOGY, V120, P795, DOI 10.1016/j.ophtha.2012.09.032
   Campochiaro PA, 2011, OPHTHALMOLOGY, V118, P2041, DOI 10.1016/j.ophtha.2011.02.038
   Campochiaro PA, 2010, OPHTHALMOLOGY, V117, P1102, DOI 10.1016/j.ophtha.2010.02.021
   Chakravarthy U, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.04.015
   Channa R, 2015, AM J OPHTHALMOL, V159, P9, DOI 10.1016/j.ajo.2014.09.012
   Chen Y, 1999, J MOL BIOL, V293, P865, DOI 10.1006/jmbi.1999.3192
   DOBI ET, 1989, ARCH OPHTHALMOL-CHIC, V107, P264, DOI 10.1001/archopht.1989.01070010270035
   Elman MJ, 2010, OPHTHALMOLOGY, V117, P1064, DOI 10.1016/j.ophtha.2010.02.031
   Epstein DLJ, 2012, OPHTHALMOLOGY, V119, P1184, DOI 10.1016/j.ophtha.2012.01.022
   Erdol H, 2010, RETINA-J RET VIT DIS, V30, P570, DOI 10.1097/IAE.0b013e3181bf5ff0
   Ferrara N, 2005, BIOCHEM BIOPH RES CO, V333, P328, DOI 10.1016/j.bbrc.2005.05.132
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Gross JG, 2015, JAMA-J AM MED ASSOC, V314, P2137, DOI 10.1001/jama.2015.15217
   Grunwald JE, 2014, OPHTHALMOLOGY, V121, P150, DOI 10.1016/j.ophtha.2013.08.015
   Hanhart J, 2014, EYE, V28, P646, DOI 10.1038/eye.2014.94
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Ho AC, 2014, OPHTHALMOLOGY, V121, P2181, DOI 10.1016/j.ophtha.2014.05.009
   Holash J, 2002, P NATL ACAD SCI USA, V99, P11393, DOI 10.1073/pnas.172398299
   Holz FG, 2013, BRIT J OPHTHALMOL, V97, P278, DOI 10.1136/bjophthalmol-2012-301504
   Ip MS, 2012, ARCH OPHTHALMOL-CHIC, V130, P1145, DOI 10.1001/archophthalmol.2012.1043
   KECK PJ, 1989, SCIENCE, V246, P1309, DOI 10.1126/science.2479987
   Koh A, 2012, RETINA-J RET VIT DIS, V32, P1453, DOI 10.1097/IAE.0b013e31824f91e8
   Korobelnik JF, 2014, OPHTHALMOLOGY, V121, P2247, DOI 10.1016/j.ophtha.2014.05.006
   Korobelnik JF, 2014, OPHTHALMOLOGY, V121, P202, DOI 10.1016/j.ophtha.2013.08.012
   Krzystolik MG, 2002, ARCH OPHTHALMOL-CHIC, V120, P338
   Kwak N, 2000, INVEST OPHTH VIS SCI, V41, P3158
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Mendrinos E, 2009, ACTA OPHTHALMOL, V87, P683, DOI 10.1111/j.1755-3768.2008.01391.x
   Michaelson I.C., 1948, T OPHTHALMOL SOC, V68, P137
   Michels S, 2005, OPHTHALMOLOGY, V112, P1035, DOI 10.1016/j.ophtha.2005.02.007
   MILLER JW, 1994, AM J PATHOL, V145, P574
   Mir TA, 2016, OPHTHALMOLOGY, V123, P625, DOI 10.1016/j.ophtha.2015.10.030
   Mirshahi A, 2008, EUR J OPHTHALMOL, V18, P263, DOI 10.1177/112067210801800215
   MONTESANO R, 1986, P NATL ACAD SCI USA, V83, P7297, DOI 10.1073/pnas.83.19.7297
   Moshfeghi AA, 2006, OPHTHALMOLOGY, V113, P2002, DOI 10.1016/j.ophtha.2006.05.070
   Ng EWM, 2006, NAT REV DRUG DISCOV, V5, P123, DOI 10.1038/nrd1955
   Nguyen QD, 2004, INVEST OPHTH VIS SCI, V45, P617, DOI 10.1167/iovs.03-0557
   Nguyen QD, 2008, AM J OPHTHALMOL, V145, P257, DOI 10.1016/j.ajo.2007.09.025
   Nguyen QD, 2009, OPHTHALMOLOGY, V116, P2175, DOI 10.1016/j.ophtha.2009.04.023
   Nguyen QD, 2006, AM J OPHTHALMOL, V142, P961, DOI 10.1016/j.ajo.2006.06.068
   Okamoto N, 1997, AM J PATHOL, V151, P281
   Oshima Y, 2005, FASEB J, V19, P963, DOI 10.1096/fj.04-2209fje
   Ozaki H, 2000, AM J PATHOL, V156, P697, DOI 10.1016/S0002-9440(10)64773-6
   Ozaki H, 1999, INVEST OPHTH VIS SCI, V40, P182
   Ozaki H, 1997, EXP EYE RES, V64, P505, DOI 10.1006/exer.1996.0239
   PIERCE EA, 1995, P NATL ACAD SCI USA, V92, P905, DOI 10.1073/pnas.92.3.905
   PLATE KH, 1992, NATURE, V359, P845, DOI 10.1038/359845a0
   Nguyen QD, 2012, OPHTHALMOLOGY, V119, P789, DOI 10.1016/j.ophtha.2011.12.039
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rosenfeld PJ, 2005, OPHTHAL SURG LAS IM, V36, P331, DOI 10.3928/1542-8877-20050701-14
   RYAN SJ, 1982, ARCH OPHTHALMOL-CHIC, V100, P1804, DOI 10.1001/archopht.1982.01030040784015
   Saishin Y, 2003, J CELL PHYSIOL, V195, P241, DOI 10.1002/jcp.10246
   Semenza GL, 2000, J APPL PHYSIOL, V88, P1474, DOI 10.1152/jappl.2000.88.4.1474
   SENGER DR, 1983, SCIENCE, V219, P983, DOI 10.1126/science.6823562
   SHWEIKI D, 1992, NATURE, V359, P843, DOI 10.1038/359843a0
   SMITH LEH, 1994, INVEST OPHTH VIS SCI, V35, P101
   Sophie R, 2013, AM J OPHTHALMOL, V156, P693, DOI 10.1016/j.ajo.2013.05.039
   Tanaka E, 2015, OPHTHALMOLOGY, V122, P153, DOI 10.1016/j.ophtha.2014.07.046
   Tobe T, 1998, AM J PATHOL, V153, P1641, DOI 10.1016/S0002-9440(10)65753-7
   Tolentino MJ, 1996, ARCH OPHTHALMOL-CHIC, V114, P964, DOI 10.1001/archopht.1996.01100140172010
   Tolentino MJ, 1996, OPHTHALMOLOGY, V103, P1820, DOI 10.1016/S0161-6420(96)30420-X
   Tonello M, 2008, ACTA OPHTHALMOL, V86, P385, DOI 10.1111/j.1600-0420.2007.01056.x
   Vinores SA, 2006, J CELL PHYSIOL, V206, P749, DOI 10.1002/jcp.20525
   Virgili G, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007419.pub4
   Wells JA, 2016, OPHTHALMOLOGY, V123, P1351, DOI 10.1016/j.ophtha.2016.02.022
   Wells JA, 2015, NEW ENGL J MED, V372, P1193, DOI 10.1056/NEJMoa1414264
NR 93
TC 73
Z9 79
U1 2
U2 10
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD OCT
PY 2016
VL 123
IS 10
SU S
BP S78
EP S88
DI 10.1016/j.ophtha.2016.04.056
PG 11
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA EE3QJ
UT WOS:000389509400004
PM 27664289
DA 2022-11-30
ER

PT J
AU Rezende, FA
   Qian, CX
   Sapieha, P
AF Rezende, Flavio A.
   Qian, Cynthia X.
   Sapieha, Przemyslaw
TI Evaluation of the vitreous microbial contamination rate in office-based
   three-port microincision vitrectomy surgery using Retrector technology
SO BMC OPHTHALMOLOGY
LA English
DT Article
ID BACTERIAL-CONTAMINATION; 25-GAUGE VITRECTOMY; ANTERIOR-CHAMBER;
   ENDOPHTHALMITIS; 20-GAUGE; IRRIGATION; RETINITIS; DIAGNOSIS; 23-GAUGE;
   THERAPY
AB Background: To perform a microbiological contamination analysis of the vitreous during office-based micro-incision vitrectomy surgery (MIVS) assessing whether the bacteria detected correlated with patient's ocular conjunctival flora.
   Methods: This is a prospective, interventional, nonrandomized case series of patients undergoing office-based MIVS, anti-VEGF, and dexamethasone intravitreal injections (triple therapy) for the treatment of wet age-related macular degeneration (AMD) and diabetic macular edema (DME).
   All patients were operated at a small procedure room in an ambulatory clinic of the Department of Ophthalmology, University of Montreal, Quebec, Canada. Conjunctival samples were done before placing the sclerotomies. The MIVS was done with a 23-gauge retractable vitrector, a 27-gauge infusion line, and a 29-gauge chandelier. Undiluted and diluted vitreous were collected for aerobic, anaerobic and fungal cultures. Outcomes measured were bacterial species identification within samples collected from the conjunctiva and the vitreous.
   Results: Thirty-seven patients (37 eyes) were recruited and completed over 17 months of follow-up. Twenty-eight had wet AMD and nine had DME. There were 13 men and 24 women, with a mean age of 78 years. Eighteen patients (46%) had culture positive conjunctival flora. Twenty-six bacterial colonies were tabulated in total from the conjunctival swabs. All bacteria detected were gram-positive bacteria (100%), most commonly: Staphylococcus epidermitis in 11 (42%) and Corynebacterium sp. in 6 (23%). Only 1/18 patients had more than 3 species isolated, 6/18 patients had 2 species and 11/18 patients had 1 species identified on the conjunctival swab. Only 1 of the 37 undiluted midvitreous samples was culture positive, equating to a contamination rate of 2.7%. None of the diluted vitreous samples were culture positive. All cultures were negative for fungus. No serious postoperative complications occurred, including bacterial endophthalmitis, choroidal detachment, and retinal detachment.
   Conclusion: This preliminary study of office-based MIVS gives us insights on the ocular surface microbial profile and vitreous contamination rate of performing such procedures outside the OR-controlled environment. Our initial results seem to indicate that there is little risk of bacterial translocation and contamination from the conjunctiva into the vitreous. Therefore, if endophthalmitis occurs post-operatively, the source may likely arise after the procedure. Larger studies are needed to confirm our data.
C1 [Rezende, Flavio A.; Qian, Cynthia X.; Sapieha, Przemyslaw] Univ Montreal, Dept Ophthalmol, Montreal, PQ, Canada.
   [Rezende, Flavio A.] Pontificia Univ Catolica Rio de Janeiro, Dept Ophthalmol, Rio De Janeiro, Brazil.
   [Qian, Cynthia X.] Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Retina Serv,Dept Ophthalmol, Boston, MA USA.
   [Rezende, Flavio A.] Hop Maison Neuve Rosemont, Dept Ophthalmol, Montreal, PQ H1T 2M4, Canada.
C3 Universite de Montreal; Pontificia Universidade Catolica do Rio de
   Janeiro; Harvard University; Harvard Medical School; Massachusetts Eye &
   Ear Infirmary; Universite de Montreal
RP Rezende, FA (通讯作者)，Univ Montreal, Dept Ophthalmol, Montreal, PQ, Canada.
EM frezendef@hotmail.com
FU Fonds de Recherche en Ophtalmologie de l'Universite de Montreal (FROUM);
   University of Montreal, (Montreal, Quebec, Canada); Retina Foundation of
   Canada; Novartis Canada; Retina Foundation of Canada clinical research
   grant; Alcon Research Institute New Investigator Award; Canadian
   Institute of Health Research (CIHR); Canadian National Institute for the
   Blind (CNIB); Canadian Diabetes Association
FX Supported in part by a research grant from the Fonds de Recherche en
   Ophtalmologie de l'Universite de Montreal (FROUM), University of
   Montreal, (Montreal, Quebec, Canada), a research grant from Retina
   Foundation of Canada (clinical research grant to Dr. Rezende); and an
   instrument grant from Novartis Canada. The sponsors or funding
   organizations had no role in the design or conduct of this research. The
   authors report no financial conflict of interest. Dr. Rezende received a
   Retina Foundation of Canada clinical research grant. Dr. Sapieha is an
   Alcon Research Institute New Investigator Award recipient and has
   operating grants from the Canadian Institute of Health Research (CIHR),
   the Canadian National Institute for the Blind (CNIB), and the Canadian
   Diabetes Association.
CR Bahrani HM, 2010, SEMIN OPHTHALMOL, V25, P275, DOI 10.3109/08820538.2010.518109
   Bausz M, 2006, J CATARACT REFR SURG, V32, P1691, DOI 10.1016/j.jcrs.2006.05.019
   Chen JK, 2009, EYE, V23, P780, DOI 10.1038/eye.2008.160
   Chiquet C, 2008, INVEST OPHTH VIS SCI, V49, P1971, DOI 10.1167/iovs.07-1377
   Cornut PL, 2012, RETINA-J RET VIT DIS, V32, P549, DOI 10.1097/IAE.0b013e3182205996
   Davis JL, 2012, EYE, V26, P194, DOI 10.1038/eye.2011.299
   Egger S. F., 1996, Ophthalmologe, V93, P126
   Graham Joanna E, 2007, Invest Ophthalmol Vis Sci, V48, P5616
   Hilton GF, 2002, RETINA-J RET VIT DIS, V22, P725, DOI 10.1097/00006982-200212000-00007
   Hu AYH, 2009, OPHTHALMOLOGY, V116, P1360, DOI 10.1016/j.ophtha.2009.01.045
   KINGHAM JD, 1982, BRIT J OPHTHALMOL, V66, P569, DOI 10.1136/bjo.66.9.569
   Knox CM, 1998, OPHTHALMOLOGY, V105, P37, DOI 10.1016/S0161-6420(98)71127-2
   Koch FH, 2011, ARCH OPHTHALMOL-CHIC, V129, P1599, DOI 10.1001/archophthalmol.2011.341
   Koss MJ, 2012, ACTA OPHTHALMOL, V90, P580, DOI 10.1111/j.1755-3768.2010.01962.x
   Koss MJ, 2012, ACTA OPHTHALMOL, V90, pe98, DOI 10.1111/j.1755-3768.2011.02292.x
   Koss MJ, 2011, OPHTHALMOLOGICA, V226, P45, DOI 10.1159/000327702
   Kunimoto DY, 2007, OPHTHALMOLOGY, V114, P2133, DOI 10.1016/j.ophtha.2007.08.009
   MAY DR, 1983, AM J OPHTHALMOL, V96, P775, DOI 10.1016/S0002-9394(14)71923-3
   Melo GB, 2011, J CATARACT REFR SURG, V37, P1244, DOI 10.1016/j.jcrs.2011.01.025
   Oshima Y, 2010, AM J OPHTHALMOL, V150, P716, DOI 10.1016/j.ajo.2010.06.002
   Parmar P, 2006, AM J OPHTHALMOL, V141, P1160, DOI 10.1016/j.ajo.2006.01.046
   Parolini B, 2009, GRAEF ARCH CLIN EXP, V247, P895, DOI 10.1007/s00417-009-1063-0
   Pitcher JD, 2011, RETINA-J RET VIT DIS, V31, P1759, DOI 10.1097/IAE.0b013e31820d4034
   Scott IU, 2011, GRAEF ARCH CLIN EXP, V249, P377, DOI 10.1007/s00417-010-1505-8
   Shimada H, 2008, OPHTHALMOLOGY, V115, P2215, DOI 10.1016/j.ophtha.2008.07.015
   Shimada H, 2013, RETINA-J RET VIT DIS, V33, P143, DOI 10.1097/IAE.0b013e318261a6ce
   Shimada H, 2010, RETINA-J RET VIT DIS, V30, P1242, DOI 10.1097/IAE.0b013e3181cea6ab
   Shukla Salil, 2008, Retin Cases Brief Rep, V2, P264, DOI 10.1097/ICB.0b013e318074c2e7
   Sugita S, 2011, BRIT J OPHTHALMOL, V95, P345, DOI 10.1136/bjo.2009.171504
   Tominaga A, 2010, OPHTHALMOLOGY, V117, P811, DOI 10.1016/j.ophtha.2009.09.030
   Wu L, 2011, RETINA-J RET VIT DIS, V31, P673, DOI 10.1097/IAE.0b013e318203c183
NR 31
TC 3
Z9 3
U1 0
U2 5
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1471-2415
J9 BMC OPHTHALMOL
JI BMC Ophthalmol.
PD MAY 1
PY 2014
VL 14
AR 58
DI 10.1186/1471-2415-14-58
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AH5MO
UT WOS:000336174400001
PM 24886149
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Wittich, W
   Watanabe, DH
   Gagne, JP
AF Wittich, Walter
   Watanabe, Donald H.
   Gagne, Jean-Pierre
TI Sensory and demographic characteristics of deafblindness rehabilitation
   clients in Montreal, Canada
SO OPHTHALMIC AND PHYSIOLOGICAL OPTICS
LA English
DT Article
DE aging; dual sensory impairment; hearing loss; sensory rehabilitation;
   Usher syndrome; vision loss
ID HEARING IMPAIRMENT; VISUAL-ACUITY; DEAF-BLINDNESS; VISION; POPULATION;
   PREVALENCE; RISK
AB Purpose: Demographic changes are increasing the number of older adults with combined age-related vision and hearing loss, while medical advances increase the survival probability of children with congenital dual (or multiple) impairments due to pre-maturity or rare hereditary diseases. Rehabilitation services for these populations are highly in demand since traditional uni-sensory rehabilitation approaches using the other sense to compensate are not always utilizable. Very little is currently known about the client population characteristics with dual sensory impairment. The present study provides information about demographic and sensory variables of persons in the Montreal region that were receiving rehabilitation for dual impairment in December 2010. This information can inform researchers, clinicians, educators, as well as administrators about potential research and service delivery priorities. Method: A chart review of all client files across the three rehabilitation agencies that offer integrated dual sensory rehabilitation services in Montreal provided data on visual acuity, visual field, hearing detection thresholds, and demographic variables. Results: The 209 males and 355 females ranged in age from 4 months to 105 years (M = 71.9, S.D. = 24.6), indicating a prevalence estimate for dual sensory impairment at 15/100 000. Only 5.7% were under 18 years of age, while 69.1% were over the age of 65 years, with 43.1% over the age of 85 years. The diagnostic combination that accounted for 31% of the entire sample was age-related macular degeneration with presbycusis. Their visual and auditory measures indicated that older adults were likely to fall into moderate to severe levels of impairment on both measures. Individuals with Usher Syndrome comprised 20.9% (n = 118) of the sample. Conclusion: The age distribution in this sample of persons with dual sensory impairment indicates that service delivery planning will need to strongly consider the growing presence of older adults as the baby-boomers approach retirement age. The distribution of their visual and auditory limits indicates that the large majority of this client group has residual vision and hearing that can be maximized in the rehabilitation process in order to restore functional abilities and social participation. Future research in this area should identify the specific priorities in both rehabilitation and research in individuals affected with combined vision and hearing loss.
C1 [Wittich, Walter; Gagne, Jean-Pierre] Ctr Res Inst Univ Geriatrie Montreal, Montreal, PQ, Canada.
   [Watanabe, Donald H.] MAB Mackay Rehabil Ctr, Montreal, PQ, Canada.
RP Wittich, W (通讯作者)，Ctr Res Inst Univ Geriatrie Montreal, Montreal, PQ, Canada.
EM wwittich@ssss.gouv.qc.ca
RI Wittich, Walter/AAH-2145-2020
OI Wittich, Walter/0000-0003-2184-6139
FU Canadian Institutes for Health Research (CIHR) [MFE-104424]
FX Post-doctoral fellowship funding for WW provided by the Canadian
   Institutes for Health Research (CIHR) # MFE-104424.
CR American National Standards Institute, 1996, S361996 ANSI
   BOUGHMAN JA, 1983, J CHRON DIS, V36, P595, DOI 10.1016/0021-9681(83)90147-9
   Brabyn John A, 2007, Trends Amplif, V11, P219, DOI 10.1177/1084713807307410
   Brennan M, 2005, GERONTOLOGIST, V45, P337, DOI 10.1093/geront/45.3.337
   Brennan Mark, 2007, Trends Amplif, V11, P281, DOI 10.1177/1084713807308210
   Campbell VA, 1999, MMWR-MORBID MORTAL W, V48, P131
   Chou KL, 2004, INT J GERIATR PSYCH, V19, P825, DOI 10.1002/gps.1174
   Committee on Hearing and Bioacoustics and Biomechanics (CHABA), 1988, J ACOUST SOC AM, V83, P859, DOI [10.1121/1.395965, DOI 10.1121/1.395965]
   Dalby DM, 2009, J VISUAL IMPAIR BLIN, V103, P93, DOI 10.1177/0145482X0910300208
   Dalby DM, 2009, J VISUAL IMPAIR BLIN, V103, P7, DOI 10.1177/0145482X0910300103
   Damen GWJA, 2005, INT J REHABIL RES, V28, P309, DOI 10.1097/00004356-200512000-00003
   Davis A., 2010, EPIDEMIOLOGY AGING H
   Fellinger J, 2009, J INTELL DISABIL RES, V53, P874, DOI 10.1111/j.1365-2788.2009.01205.x
   Gagne JP., 2007, PRECIS PRATIQUE GERI, P527
   Grue EV, 2009, J CLIN NURS, V18, P3037, DOI 10.1111/j.1365-2702.2009.02856.x
   Haegerstrom-Portnoy G, 1999, OPTOMETRY VISION SCI, V76, P141, DOI 10.1097/00006324-199903000-00014
   Haegerstrom-Portnoy G., 2007, VISION AGING, P31
   Holladay JT, 1997, J REFRACT SURG, V13, P388
   Holladay JT, 2004, J CATARACT REFR SURG, V30, P287, DOI 10.1016/j.jcrs.2004.01.014
   Keller BK, 1999, J AM GERIATR SOC, V47, P1319, DOI 10.1111/j.1532-5415.1999.tb07432.x
   Lam BL, 2006, ARCH OPHTHALMOL-CHIC, V124, P95, DOI 10.1001/archopht.124.1.95
   LeJeune B., 2010, AER J RES PRACTICE V, V3, P146
   Lemke U, 2010, CHALLENGES AGING SEN
   Lieberman D, 2004, J REHABIL RES DEV, V41, P669, DOI 10.1682/JRRD.2003.11.0168
   McGraw C, 2011, INSIGHT RES PRACT VI, V4, P74
   Munroe S., 2001, DEV NATL VOLUNTEER R
   Oklahoma deaf-blind technical assistance project, 2009, MAJ CAUS DEAF BLINDN
   Overbury O, 2011, INVEST OPHTH VIS SCI, V52, P8933, DOI 10.1167/iovs.11-8116
   Regie de l'assurance maladie du Quebec, 2006, SERV COV QUEB VIS DE
   Regie de l'assurance maladie du Quebec, 2006, SERV COV QUEB HEAR D
   Resnikoff S, 2004, B WORLD HEALTH ORGAN, V82, P844
   Ronnberg J, 2002, INT J AUDIOL, V41, P136, DOI 10.3109/14992020209090404
   Saunders Gabrielle H, 2007, Trends Amplif, V11, P243, DOI 10.1177/1084713807308365
   Schulze-Bonsel K, 2006, INVEST OPHTH VIS SCI, V47, P1236, DOI 10.1167/iovs.05-0981
   Slaets J P J, 2007, Ned Tijdschr Geneeskd, V151, P1451
   Smith SL, 2008, J REHABIL RES DEV, V45, P597, DOI 10.1682/JRRD.2007.02.0023
   *STAT CAN, 2002, PROF DIS CAN 2001
   U. S. Public Health Service, 1978, INT CLASS DIS 9 REV
   VERNON M, 1969, J CHRON DIS, V22, P133, DOI 10.1016/0021-9681(69)90055-1
   Watters C., 2005, STUDY DEAFBLIND DEMO
   WEINSTEIN BE, 2000, GERIATRIC AUDIOLOGY
   World Health Organisation, 1991, REP INF WORK GROUP P
NR 42
TC 51
Z9 51
U1 0
U2 14
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0275-5408
EI 1475-1313
J9 OPHTHAL PHYSL OPT
JI Ophthalmic Physiol. Opt.
PD MAY
PY 2012
VL 32
IS 3
BP 242
EP 251
DI 10.1111/j.1475-1313.2012.00897.x
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Ophthalmology
GA 927UM
UT WOS:000302935700009
PM 22348651
DA 2022-11-30
ER

PT J
AU Renzi, LM
   Hammond, BR
   Dengler, M
   Roberts, R
AF Renzi, Lisa M.
   Hammond, Billy R., Jr.
   Dengler, Melissa
   Roberts, Richard
TI The relation between serum lipids and lutein and zeaxanthin in the serum
   and retina: results from cross-sectional, case-control and case study
   designs
SO LIPIDS IN HEALTH AND DISEASE
LA English
DT Article
DE Macular pigment; Lipoproteins; Statins; Lutein; Zeaxanthin
ID PIGMENT OPTICAL-DENSITY; AGE-RELATED MACULOPATHY; LONG-TERM INCIDENCE;
   MACULAR DEGENERATION; RISK-FACTORS; IN-VIVO; CARDIOVASCULAR-DISEASE;
   ALZHEIMERS-DISEASE; VITAMIN-A; CAROTENOIDS
AB Background: The xanthophyll carotenoids lutein (L) and zeaxanthin (Z) are found in and around the macula of the primate retina, where they are termed macular pigment (MP). Dietary L and Z are absorbed with fat in the gut and transported on lipoproteins to the retina. Both MP and serum lipoproteins have been related to risk for neurodegenerative diseases such as age-related macular degeneration (AMD). L and Z are carried on both HDL (related to reduced risk of AMD) and LDL (related to increased risk). The purpose of this set of studies was to analyze the relation between L and Z in the serum and retina with the circulating lipid profile.
   Methods: In all experiments, lipoproteins were measured enzymatically from plasma, and MP optical density (MPOD) was measured using customized heterochromatic flicker photometry. Experiment 1: Relations between serum L and Z, MPOD and lipoprotein levels. 108 young, healthy subjects (M = 23.2, SD = 4.12 years) participated. Lipoprotein levels and MPOD were measured. In a subset of 66 participants, serum L and Z levels were also measured using high-performance liquid chromatography. Experiment 2: Relations between lipoprotein levels and MPOD in statin users. 20 subjects (M = 58.05, SD = 11.08 years) taking statin medication and 20 subjects (M = 57.95, SD = 11.03 years) not taking satin were recruited for participation. MPOD and lipoprotein levels were measured. Experiment 3: lowering lipoprotein levels to impact MPOD. One individual (aged 41 years) with high MP density adhered first to an atorvastatin regimen, then, after a wash-out period, to a rosuvastatin regimen.
   Results: Experiment 1: HDL were significantly (p < 0.05) related to MPOD (r = 0.33), to serum L (r = 0.36) and to serum Z (r = 0.26). MPOD was also significantly related to total cholesterol (r = 0.19). Experiment 2: MPOD was not lower in statin users when compared to matched non-statin users, but MPOD decreased significantly with increased duration of statin use (r = -0.63). Experiment 3: Administration of a statin regimen reduced MPOD with atorvastatin (p < 0.05) but not with rosuvastatin.
   Conclusions: Serum xanthophylls, retinal xanthophylls and lipoprotein concentrations are significantly related, and changing lipoprotein levels may impact levels of retinal xanthophylls.
C1 [Renzi, Lisa M.; Hammond, Billy R., Jr.] Univ Georgia, Human Biofactors Lab, Athens, GA 30602 USA.
   [Renzi, Lisa M.; Hammond, Billy R., Jr.; Dengler, Melissa] Univ Georgia, Vis Sci Lab, Athens, GA 30602 USA.
   [Roberts, Richard] Kemin Hlth LC, Des Moines, IA 50309 USA.
C3 University System of Georgia; University of Georgia; University System
   of Georgia; University of Georgia
RP Renzi, LM (通讯作者)，Univ Georgia, Human Biofactors Lab, 601 Psychol Bldg, Athens, GA 30602 USA.
EM lrenzi@uga.edu
OI Renzi-Hammond, Lisa/0000-0003-4334-8202; Hammond,
   Billy/0000-0002-5762-0206
FU DSM Nutritional Products; Kemin Health, L.C.
FX The authors would like to thank DSM Nutritional Products and Kemin
   Health, L.C. for their generous financial support of this project. The
   authors would also like to acknowledge Laura Fletcher for coordinating
   the serum collection for Experiment 1.
CR Beatty S, 2001, INVEST OPHTH VIS SCI, V42, P439
   Bone RA, 1997, EXP EYE RES, V64, P211, DOI 10.1006/exer.1996.0210
   BONE RA, 1985, VISION RES, V25, P1531, DOI 10.1016/0042-6989(85)90123-3
   Bone RA, 2001, INVEST OPHTH VIS SCI, V42, P235
   Broekmans WMR, 2002, AM J CLIN NUTR, V76, P595, DOI 10.1093/ajcn/76.3.595
   Burke JD, 2005, J NUTR, V135, P1208, DOI 10.1093/jn/135.5.1208
   Cagnin A, 2007, J NEURAL TRANSM-SUPP, P175
   Cangemi Francis E, 2007, BMC Ophthalmol, V7, P3, DOI 10.1186/1471-2415-7-3
   Chakravarthy U, 2010, BMC OPHTHALMOL, V10, DOI 10.1186/1471-2415-10-31
   Chew BP, 2004, J NUTR, V134, p257S, DOI 10.1093/jn/134.1.257S
   Connor WE, 2007, INVEST OPHTH VIS SCI, V48, P4226, DOI 10.1167/iovs.06-1275
   Delcourt C, 2001, Ophthalmic Epidemiol, V8, P237, DOI 10.1076/opep.8.4.237.1613
   DemmigAdams B, 1996, FASEB J, V10, P403, DOI 10.1096/fasebj.10.4.8647339
   Dentchev T, 2003, MOL VIS, V9, P184
   Falsini B, 2003, OPHTHALMOLOGY, V110, P51, DOI 10.1016/S0161-6420(02)01547-6
   Goulinet S, 1997, ARTERIOSCL THROM VAS, V17, P786, DOI 10.1161/01.ATV.17.4.786
   Gross M, 2003, AM J CLIN NUTR, V77, P458, DOI 10.1093/ajcn/77.2.458
   Gruber M, 2004, J NUTR, V134, P2387, DOI 10.1093/jn/134.9.2387
   Grundy SM, 2002, CIRCULATION, V106, P3143, DOI 10.1161/circ.106.25.3143
   Hammond BR, 2005, OPTOMETRY VISION SCI, V82, P387, DOI 10.1097/01.OPX.0000162652.85875.D2
   Hammond BR, 1996, VISION RES, V36, P3003, DOI 10.1016/0042-6989(96)00008-9
   Handelman GJ, 2001, NUTRITION, V17, P818, DOI 10.1016/S0899-9007(01)00640-2
   Hartmann D, 2004, AM J CLIN NUTR, V79, P410
   Hyman L, 2000, ARCH OPHTHALMOL-CHIC, V118, P351, DOI 10.1001/archopht.118.3.351
   Izumi-Nagai K, 2007, ARTERIOSCL THROM VAS, V27, P2555, DOI 10.1161/ATVBAHA.107.151431
   Johnson LV, 2002, P NATL ACAD SCI USA, V99, P11830, DOI 10.1073/pnas.192203399
   Kirby ML, 2010, INVEST OPHTH VIS SCI, V51, P6722, DOI 10.1167/iovs.10-5344
   Klaver CCW, 1999, AM J EPIDEMIOL, V150, P963
   KRINSKY NI, 1991, AM J CLIN NUTR, V53, pS238, DOI 10.1093/ajcn/53.1.238S
   KRINSKY NI, 1992, P SOC EXP BIOL MED, V200, P248
   Lidebjer C, 2007, NUTR METAB CARDIOVAS, V17, P448, DOI 10.1016/j.numecd.2006.02.006
   Loane E, 2010, INVEST OPHTH VIS SCI, V51, P5897, DOI 10.1167/iovs.09-4878
   Maoka T, 2009, ARCH BIOCHEM BIOPHYS, V483, P191, DOI 10.1016/j.abb.2008.10.019
   Michikawa T, 2009, ASIA PAC J CLIN NUTR, V18, P1
   Moeller SM, 2006, ARCH OPHTHALMOL-CHIC, V124, P1151, DOI 10.1001/archopht.124.8.1151
   Namitha KK, 2010, CRIT REV FOOD SCI, V50, P728, DOI 10.1080/10408398.2010.499811
   Nowak M, 2005, CLIN EXP MED, V4, P183, DOI 10.1007/s10238-004-0054-z
   Panz V R, 2005, Cardiovasc J S Afr, V16, P112
   Parker RS, 1996, FASEB J, V10, P542, DOI 10.1096/fasebj.10.5.8621054
   Renzi LM, 2010, OPHTHAL PHYSL OPT, V30, P351, DOI 10.1111/j.1475-1313.2010.00720.x
   Reynolds R, 2010, OPHTHALMOLOGY, V117, P1989, DOI 10.1016/j.ophtha.2010.07.009
   Richer Stuart, 2004, Optometry, V75, P216, DOI 10.1016/S1529-1839(04)70049-4
   Rinaldi P, 2003, NEUROBIOL AGING, V24, P915, DOI 10.1016/S0197-4580(03)00031-9
   Sabbagh M, 2004, J ALZHEIMERS DIS, V6, P585
   SAHEKI A, 1994, PHARMACEUT RES, V11, P305, DOI 10.1023/A:1018975928974
   SanGiovanni JP, 2007, ARCH OPHTHALMOL-CHIC, V125, P1225, DOI 10.1001/archopht.125.9.1225
   Santee J, 2002, AM J HEALTH-SYST PH, V59, P1774, DOI 10.1093/ajhp/59.18.1774
   SCHMITZ HH, 1991, J NUTR, V121, P1613, DOI 10.1093/jn/121.10.1613
   Snow K K, 1999, Ophthalmic Epidemiol, V6, P125, DOI 10.1076/opep.6.2.125.1558
   Stringham JM, 2008, EXP EYE RES, V87, P445, DOI 10.1016/j.exer.2008.08.005
   Sun C, 2009, OPHTHALMOLOGY, V116, P1913, DOI 10.1016/j.ophtha.2009.03.046
   Tan JSL, 2008, OPHTHALMOLOGY, V115, P334, DOI 10.1016/j.ophtha.2007.03.083
   Tan JSL, 2007, OPHTHALMOLOGY, V114, P1143, DOI 10.1016/j.ophtha.2006.09.033
   Thomson LR, 2002, INVEST OPHTH VIS SCI, V43, P3538
   Tomany SC, 2004, OPHTHALMOLOGY, V111, P1280, DOI 10.1016/j.ophtha.2003.11.010
   Vershinin A, 1999, BIOFACTORS, V10, P99, DOI 10.1002/biof.5520100203
   Vine AK, 2005, OPHTHALMOLOGY, V112, P2076, DOI 10.1016/j.ophtha.2005.07.004
   Vishwanathan R, 2009, AM J CLIN NUTR, V90, P1272, DOI 10.3945/ajcn.2009.28013
   Wang W, 2008, J ALZHEIMERS DIS, V13, P31
   Wang W, 2007, AM J CLIN NUTR, V85, P762, DOI 10.1093/ajcn/85.3.762
   Wong TY, 2007, OPHTHALMOLOGY, V114, P86, DOI 10.1016/j.ophtha.2006.06.039
   Wooten BR, 1999, INVEST OPHTH VIS SCI, V40, P2481
   YEUM KJ, 1995, INVEST OPHTH VIS SCI, V36, P2756
   Yeum KJ, 1999, CURR EYE RES, V19, P502, DOI 10.1076/ceyr.19.6.502.5282
NR 64
TC 52
Z9 52
U1 1
U2 15
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1476-511X
J9 LIPIDS HEALTH DIS
JI Lipids Health Dis.
PD FEB 29
PY 2012
VL 11
AR 33
DI 10.1186/1476-511X-11-33
PG 10
WC Biochemistry & Molecular Biology; Nutrition & Dietetics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Nutrition & Dietetics
GA 918AO
UT WOS:000302221400001
PM 22375926
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Vujosevic, S
   Vaclavik, V
   Bird, AC
   Leung, I
   Dandekar, S
   Peto, T
AF Vujosevic, Stela
   Vaclavik, Veronika
   Bird, Alan C.
   Leung, Irene
   Dandekar, Samantha
   Peto, Tunde
TI Combined grading for choroidal neovascularisation: colour, fluorescein
   angiography and autofluorescence images
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE age-related macular degeneration; autofluorescence; fluorescein
   angiography; color fundus photos
ID AGE-RELATED MACULOPATHY; FUNDUS AUTOFLUORESCENCE; IN-VIVO; MACULAR
   DEGENERATION; LIPOFUSCIN; LESIONS; CLASSIFICATION; MEMBRANE; PATTERNS
AB Background Patients with age-related macular degeneration (ARMD) have several imaging techniques carried out regularly. In this study we introduce a new grading model of autofluorescence images (AF), compare it with fluorescein angiography (FFA) and digital colour fundus photos (COL) and test for inter- and intraobserver reliability.
   Methods A total of 71 eyes of 54 patients with bilateral or unilateral CNV had COL, FFA and AF, fulfilling the inclusion criterion of having all 3 types of imaging carried out on the same day or within 14 days. The grading of COL was performed by a trained grader based on the International ARM classification; FFA and AF images were independently graded by two trained retinal specialists in order to assess inter-observer reliability. Overall, 30% of all images were regraded after at least 14 days interval to assess intra-observer variability.
   Results The intergrader agreement was exact for classification of CNV (k=1.00); almost perfect for FFA features (k=0.83) and correspondence of decreased AF to COL (k=0.94); substantial for patterns of decreased and increased AF (k=0.80, k=0.78), correspondence of patterns of increased AF to FFA and to COL (k=0.78, k=0.74) and background AF (k=0.72); moderate for CNV diameter in FFA (k=0.45), FFA pattern (k=0.43), dimension of increased and decreased AF (k=0.5, k=0.56); fair for quality of FFA and AF images (k=0.21, k=0.26) respectively. The intragrader agreement varied from exact to substantial for all categories. Diffuse and reticular patterns of decreased AF and reticular pattern of increased AF correlated well, with visual acuity worse than 6/24.
   Conclusion The combined grading system was reliable for evaluating the three imaging techniques, and might be suitable for epidemiological studies and therapeutic trials where such grading is warranted. Certain AF patterns seem to predict VA outcome better than one might have predicted based on FFA. Further studies are needed to evaluate its usefulness in clinical settings for predicting outcomes for patients receiving therapy for end-stage disease.
C1 IRCCS, Fdn GB Bietti Oftalmol, I-00198 Rome, Italy.
   Moorfields Eye Hosp, London, England.
   Inst Ophthalmol, London, England.
C3 IRCCS - Fondazione "G.B. Bietti" per lo Studio e la Ricerca in
   Oftalmologia; University of London; University College London;
   Moorfields Eye Hospital NHS Foundation Trust; University of London;
   University College London
RP Vujosevic, S (通讯作者)，IRCCS, Fdn GB Bietti Oftalmol, Via Livenza 3, I-00198 Rome, Italy.
EM stelavu@hotmail.com
RI Vujosevic, Stela/AAI-4874-2020; Cerviño, Alejandro/L-5853-2014; Peto,
   Tunde/G-8812-2018
OI Cerviño, Alejandro/0000-0001-8014-3279; Peto, Tunde/0000-0001-6265-0381;
   Vujosevic, Stela/0000-0001-6773-9967
CR Age-Related Eye Dis Study Res Grp, 2001, AM J OPHTHALMOL, V132, P668
   BARTSCH DU, 1995, AM J OPHTHALMOL, V120, P642, DOI 10.1016/S0002-9394(14)72211-1
   Bindewald A, 2005, INVEST OPHTH VIS SCI, V46, P3309, DOI 10.1167/iovs.04-0430
   BIRD AC, 1986, T OPHTHAL SOC UK, V105, P674
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   CHAMBERLIN JA, 1989, OPHTHALMOLOGY, V96, P1526
   DELORI FC, 1995, INVEST OPHTH VIS SCI, V36, P718
   Hee MR, 1996, OPHTHALMOLOGY, V103, P1260, DOI 10.1016/S0161-6420(96)30512-5
   Holz FG, 2004, AM J OPHTHALMOL, V137, P504, DOI 10.1016/j.ajo.2003.11.026
   Holz FG, 1999, GRAEF ARCH CLIN EXP, V237, P145, DOI 10.1007/s004170050209
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Lois N, 2002, AM J OPHTHALMOL, V133, P341, DOI 10.1016/S0002-9394(01)01404-0
   Lois N, 1999, BRIT J OPHTHALMOL, V83, P276, DOI 10.1136/bjo.83.3.276
   Lois N, 2000, BRIT J OPHTHALMOL, V84, P741, DOI 10.1136/bjo.84.7.741
   PAULEIKHOFF D, 1990, OPHTHALMOLOGY, V97, P171
   PAULEIKHOFF D, 1992, OPHTHALMOLOGY, V99, P1548
   Scholl HPN, 2003, GRAEF ARCH CLIN EXP, V241, P39, DOI 10.1007/s00417-002-0602-8
   Schutt F, 2002, FEBS LETT, V528, P217, DOI 10.1016/S0014-5793(02)03312-4
   SHERAIDAH G, 1993, OPHTHALMOLOGY, V100, P47
   Spaide RF, 2003, OPHTHALMOLOGY, V110, P392, DOI 10.1016/S0161-6420(02)01756-6
   Spital G, 1998, KLIN MONATSBL AUGENH, V213, P23, DOI 10.1055/s-2008-1034939
   VONRUCKMANN A, 1995, BRIT J OPHTHALMOL, V79, P407, DOI 10.1136/bjo.79.5.407
   vonRuckmann A, 1997, INVEST OPHTH VIS SCI, V38, P478
   WING GL, 1978, INVEST OPHTH VIS SCI, V17, P601
NR 24
TC 13
Z9 14
U1 0
U2 3
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0721-832X
EI 1435-702X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD OCT
PY 2007
VL 245
IS 10
BP 1453
EP 1460
DI 10.1007/s00417-007-0574-9
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 209RJ
UT WOS:000249405400007
PM 17429674
DA 2022-11-30
ER

PT J
AU Mullins, RF
   Skeie, JM
   Malone, EA
   Kuehn, MH
AF Mullins, RF
   Skeie, JM
   Malone, EA
   Kuehn, MH
TI Macular and peripheral distribution of ICAM-1 in the human
   choriocapillaris and retina
SO MOLECULAR VISION
LA English
DT Article
ID INTERCELLULAR-ADHESION MOLECULE-1; CHOROIDAL NEOVASCULAR MEMBRANES;
   GLOMERULONEPHRITIS TYPE-II; GLYCATION END-PRODUCTS; FACTOR-H
   POLYMORPHISM; FUNDUS CHANGES; COMPLEMENT ACTIVATION; ENDOTHELIAL-CELLS;
   ATTACK COMPLEX; EXPRESSION
AB PURPOSE: In order to understand the extent of choriocapillary endothelial cell activation in different topographic regions of the eye, we sought to compare the localization of intercellular adhesion molecule-1 (ICAM-1) in macular and peripheral regions of human eyes.
   METHODS: Sections of sucrose-embedded human donor eyes that included the macula and ora serrata were evaluated for ICAM-1 and ICAM-2 immunoreactivity with monoclonal and polyclonal antibodies. Patterns of ICAM-1 labeling in peripheral and macular regions were examined in 20 eyes. Morphometric analyses of anti-ICAM-1 labeling intensity in the choriocapillaris were performed using ImageJ software on a series of macular and extramacular punches from nine eyes. Quantitative PCR analysis for ICAM-1 mRNA was performed on the RPE-choroid from the same regions from six of the same eyes, and Western blots of samples treated or untreated with N-glycosidase were performed to compare retinal and choroidal ICAM-1.
   RESULTS: ICAM-1 labeling of the choriocapillaris was typically more intense in the macula than in the peripheral choroid in human donor eyes (14/20). ICAM-2 was also detected in the choriocapillaris and retinal vessels. Morphometric measurements confirmed a significant macular-extramacular difference in ICAM-1 in six of nine eyes (p < 0.05), with 1 of 9 eyes showing the opposite pattern. This pattern was not noted for endogenous alkaline phosphatase or ICAM-2. The opposite pattern was noted in the external limiting membrane (ELM), which exhibited more intense ICAM-1 labeling in the far periphery than in the macula. On Western blots, choroidal ICAM-1 exhibited a greater molecular weight than the retinal form, with most of the apparent weight difference due to N-linked carbohydrate chains.
   CONCLUSIONS: The regional differences in ICAM-1 distribution in the choriocapillaris may indicate that this region is subject to increased leukocyte trafficking. In view of the role of inflammatory processes in age-related macular degeneration (AMD), we propose that the higher level of ICAM-1 protein in the macular choriocapillaris may impart greater susceptibility of the macula to immune cell-mediated damage in AMD.
C1 Univ Iowa, Carver Coll Med, Dept Ophthalmol & Visual Sci, Ctr Macular Degenerat, Iowa City, IA USA.
C3 University of Iowa
RP Mullins, RF (通讯作者)，4135E MERF,375 Newton Rd, Iowa City, IA 52242 USA.
EM robert-mullins@uiowa.edu
RI Mullins, Robert F/I-6717-2013
OI Kuehn, Markus/0000-0003-3940-198X; Mullins, Robert/0000-0002-5006-0891
FU NEI NIH HHS [R03 EY14563, F32 EY022280] Funding Source: Medline;
   NATIONAL EYE INSTITUTE [F32EY022280, R03EY014563] Funding Source: NIH
   RePORTER
CR Aird WC, 2003, CRIT CARE MED, V31, pS221, DOI 10.1097/01.CCM.0000057847.32590.C1
   Ambati J, 2003, NAT MED, V9, P1390, DOI 10.1038/nm950
   Bagnasco M, 1997, CLIN EXP ALLERGY, V27, P737
   BARTHEL LK, 1990, J HISTOCHEM CYTOCHEM, V38, P1383, DOI 10.1177/38.9.2201738
   Bora PS, 2005, J IMMUNOL, V174, P491, DOI 10.4049/jimmunol.174.1.491
   DASTGHEIB K, 1994, ARCH OPHTHALMOL-CHIC, V112, P813, DOI 10.1001/archopht.1994.01090180111045
   DIAMOND MS, 1991, CELL, V65, P961, DOI 10.1016/0092-8674(91)90548-D
   DUGUID IGM, 1991, AUST NZ J OPHTHALMOL, V19, P309, DOI 10.1111/j.1442-9071.1991.tb00678.x
   DUGUID IGM, 1992, CURR EYE RES, V11, P153, DOI 10.3109/02713689208999526
   DUVALLYOUNG J, 1989, BRIT J OPHTHALMOL, V73, P297, DOI 10.1136/bjo.73.4.297
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Espinosa-Heidmann DG, 2003, INVEST OPHTH VIS SCI, V44, P3586, DOI 10.1167/iovs.03-0038
   Grunwald JE, 1998, INVEST OPHTH VIS SCI, V39, P385
   GURNE DH, 1991, OPHTHALMOLOGY, V98, P602
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   HAYREH SS, 1975, BRIT J OPHTHALMOL, V59, P631, DOI 10.1136/bjo.59.11.631
   Jimenez D, 2005, J BIOL CHEM, V280, P5854, DOI 10.1074/jbc.M412104200
   Johnson LV, 2000, EXP EYE RES, V70, P441, DOI 10.1006/exer.1999.0798
   Johnson LV, 2001, EXP EYE RES, V73, P887, DOI 10.1006/exer.2001.1094
   Joussen AM, 2002, AM J PATHOL, V160, P501, DOI 10.1016/S0002-9440(10)64869-9
   KILGORE KS, 1995, J IMMUNOL, V155, P1434
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Kvietys PR, 1997, AM J PHYSIOL-GASTR L, V273, pG1189, DOI 10.1152/ajpgi.1997.273.6.G1189
   LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0
   LEYS A, 1991, GRAEF ARCH CLIN EXP, V229, P406, DOI 10.1007/BF00166300
   LOPEZ PF, 1991, AM J OPHTHALMOL, V112, P647, DOI 10.1016/S0002-9394(14)77270-8
   Lum H, 2001, AM J PHYSIOL-CELL PH, V280, pC719
   Lutty G, 1999, MOL VIS, V5
   Mamputu JC, 2004, J LEUKOCYTE BIOL, V75, P1062, DOI 10.1189/jlb.0603265
   MCLEOD DS, 1995, AM J PATHOL, V147, P642
   Moore TCB, 2003, INVEST OPHTH VIS SCI, V44, P4457, DOI 10.1167/iovs.02-1063
   Muller WA, 2001, J EXP MED, V194, pF47, DOI 10.1084/jem.194.9.f47
   Mullins RF, 2005, MOL VIS, V11, P509
   Mullins RF, 2001, EYE, V15, P390, DOI 10.1038/eye.2001.142
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   Pauleikhoff D, 1992, Ophthalmologe, V89, P39
   PENFOLD PL, 1985, GRAEF ARCH CLIN EXP, V223, P69, DOI 10.1007/BF02150948
   PENFOLD PL, 1990, GRAEF ARCH CLIN EXP, V228, P270, DOI 10.1007/BF00920033
   Rahman A, 2001, MOL CELL BIOL, V21, P5554, DOI 10.1128/MCB.21.16.5554-5565.2001
   RAINES MF, 1989, BRIT J OPHTHALMOL, V73, P907, DOI 10.1136/bjo.73.11.907
   Rayborn ME, 1997, DEGENERATIVE RETINAL DISEASES, P17
   Roebuck KA, 1999, J LEUKOCYTE BIOL, V66, P876, DOI 10.1002/jlb.66.6.876
   Ross RD, 1998, AM J OPHTHALMOL, V125, P71, DOI 10.1016/S0002-9394(99)80237-2
   Sakurai E, 2003, INVEST OPHTH VIS SCI, V44, P2743, DOI 10.1167/iovs.02-1246
   Sakurai E, 2003, INVEST OPHTH VIS SCI, V44, P3578, DOI 10.1167/iovs.03-0097
   Seddon JM, 2004, JAMA-J AM MED ASSOC, V291, P704, DOI 10.1001/jama.291.6.704
   Vandesompele J, 2002, GENOME BIOL, V3, DOI 10.1186/gb-2002-3-7-research0034
   vandeStolpe A, 1996, J MOL MED, V74, P13, DOI 10.1007/BF00202069
   Ware LB, 2000, NEW ENGL J MED, V342, P1334, DOI 10.1056/NEJM200005043421806
   Yeh DC, 2004, INVEST OPHTH VIS SCI, V45, P2368, DOI 10.1167/iovs.03-0981
   Zhao ZQ, 1996, AM J PHYSIOL-HEART C, V271, pH1456, DOI 10.1152/ajpheart.1996.271.4.H1456
NR 52
TC 59
Z9 60
U1 1
U2 2
PU MOLECULAR VISION
PI ATLANTA
PA C/O JEFF BOATRIGHT, LAB B, 5500 EMORY EYE CENTER, 1327 CLIFTON RD, N E,
   ATLANTA, GA 30322 USA
SN 1090-0535
J9 MOL VIS
JI Mol. Vis.
PD MAR 30
PY 2006
VL 12
IS 24-27
BP 224
EP 235
PG 12
WC Biochemistry & Molecular Biology; Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Ophthalmology
GA 031BI
UT WOS:000236678700002
PM 16604055
DA 2022-11-30
ER

PT J
AU Congdon, N
   O'Colmain, B
   Klaver, CCW
   Klein, R
   Munoz, B
   Friedman, DS
   Kempen, J
   Taylor, HR
   Mitchell, P
   Hyman, L
AF Congdon, N
   O'Colmain, B
   Klaver, CCW
   Klein, R
   Munoz, B
   Friedman, DS
   Kempen, J
   Taylor, HR
   Mitchell, P
   Hyman, L
CA Eye Dis Prevalence Res Grp
TI Causes and prevalence of visual impairment among adults in the United
   States
SO ARCHIVES OF OPHTHALMOLOGY
LA English
DT Article
ID BALTIMORE EYE SURVEY; DIABETIC-RETINOPATHY; MACULAR DEGENERATION;
   POPULATION; BLINDNESS; ACUITY; CATARACT; OLDER; AUSTRALIA; GLAUCOMA
AB Objectives: To estimate the cause-specific prevalence and distribution of blindness and low vision in the United States by age, race/ethnicity, and gender, and to estimate the change in these prevalence figures over the next 20 years.
   Methods: Summary prevalence estimates of blindness (both according to the US definition of less than or equal to6/60 [less than or equal to20/200] best-corrected visual acuity in the better-seeing eye and the World Health Organization standard of <6/120 [<20/400]) and low vision (<6/12 [<20/40] best-corrected vision in the better-seeing eye) were prepared separately for black, Hispanic, and white persons in 5-year age intervals starting at 40 years. The estimated prevalences were based on recent population-based studies in the United States, Australia, and Europe. These estimates were applied to 2000 US Census data, and to projected US population figures for 2020, to estimate the number of Americans with visual impairment. Cause-specific prevalences of blindness and low vision were also estimated for the different racial/ethnic groups.
   Results: Based on demographics from the 2000 US Census, an estimated 937000 (0.78%) Americans older than 40 years were blind (US definition). An additional 2.4 million Americans (1.98%) had low vision. The leading cause of blindness among white persons was age-related macular degeneration (54.4% of the cases), while among black persons, cataract and glaucoma accounted for more than 60% of blindness. Cataract was the leading cause of low vision, responsible for approximately 50% of bilateral vision worse than 6/12 (20/40) among white, black, and Hispanic persons. The number of blind persons in the US is projected to increase by 70% to 1.6 million by 2020, with a similar rise projected for low vision.
   Conclusions: Blindness or low vision affects approximately 1 in 28 Americans older than 40 years. The specific causes of visual impairment, and especially blindness, vary greatly by race/ethnicity. The prevalence of visual disabilities will increase markedly during the next 20 years, owing largely to the aging of the US population.
C1 Johns Hopkins Univ, Wilmer Eye Inst, Dana Ctr Prevent Ophthalmol, Baltimore, MD 21287 USA.
   Macro Int Inc, Calverton, MD USA.
   Erasmus MC, Dept Ophthalmol, Rotterdam, Netherlands.
   Univ Wisconsin, Dept Ophthalmol, Madison, WI USA.
   Univ Melbourne, Ctr Eye Res Australia, Melbourne, Vic, Australia.
   Westmead Hosp, Ctr Vis Res, Dept Ophthalmol, Westmead, NSW 2145, Australia.
   Univ Sydney, Dept Ophthalmol, Sydney, NSW 2006, Australia.
   SUNY Stony Brook, Dept Prevent Med, Stony Brook, NY 11794 USA.
C3 Johns Hopkins University; Johns Hopkins Medicine; Erasmus University
   Rotterdam; Erasmus MC; University of Wisconsin System; University of
   Wisconsin Madison; Centre for Eye Research Australia; University of
   Melbourne; University of Sydney; University of Sydney; State University
   of New York (SUNY) System; SUNY Community College; State University of
   New York (SUNY) Stony Brook
RP Congdon, N (通讯作者)，Johns Hopkins Univ, Wilmer Eye Inst, Dana Ctr Prevent Ophthalmol, Wilmer 120,600 N Wolfe St, Baltimore, MD 21287 USA.
EM ncongdon@jhmi.edu
RI Mitchell, Paul/P-1498-2014; Panchapakesan, Jai/E-4860-2016; Klaver,
   Caroline C.W./A-2013-2016; Wang, Jie Jin/P-1499-2014
OI Wang, Jie Jin/0000-0001-9491-4898; Klaver, Caroline/0000-0002-2355-5258;
   Friedman, David/0000-0002-2055-5797
CR Abou-Gareeb I, 2001, Ophthalmic Epidemiol, V8, P39, DOI 10.1076/opep.8.1.39.1540
   Arfken CL, 1998, DIABETES CARE, V21, P792, DOI 10.2337/diacare.21.5.792
   Attebo K, 1996, OPHTHALMOLOGY, V103, P357
   Devgan U, 2000, ARCH OPHTHALMOL-CHIC, V118, P253
   Diabet Control Complications Trial Res Grp, 1995, OPHTHALMOLOGY, V102, P647
   Ederer F, 2000, ARCH OPHTHALMOL-CHIC, V118, P1639
   ESCARCE JJ, 1993, MED CARE, V31, P1106, DOI 10.1097/00005650-199312000-00004
   Evans JR, 2002, BRIT J OPHTHALMOL, V86, P795, DOI 10.1136/bjo.86.7.795
   Friedman DS, 1999, OPHTHALMOLOGY, V106, P1049, DOI 10.1016/S0161-6420(99)90267-1
   Goldzweig CL, 1997, JAMA-J AM MED ASSOC, V277, P1765, DOI 10.1001/jama.277.22.1765
   Harris EL, 1999, DIABETES CARE, V22, P779, DOI 10.2337/diacare.22.5.779
   Hyman L, 2001, OPHTHALMOLOGY, V108, P1751, DOI 10.1016/S0161-6420(01)00590-5
   JETTE AM, 1985, J CHRON DIS, V38, P59, DOI 10.1016/0021-9681(85)90008-6
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Kempen AH, 2004, ARCH OPHTHALMOL-CHIC, V122, P495
   Klaver CCW, 1998, ARCH OPHTHALMOL-CHIC, V116, P653, DOI 10.1001/archopht.116.5.653
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1310
   Klein R, 1999, OPHTHALMOLOGY, V106, P1056, DOI 10.1016/S0161-6420(99)90255-5
   KRUEGER DE, 1984, NATL TECHNICAL INFOR
   Laforge R.G., 1992, J AGING HEALTH, V4, P126, DOI [10.1177/089826439200400108, DOI 10.1177/089826439200400108]
   Lam B L, 2000, Ophthalmic Epidemiol, V7, P73
   Lee DJ, 1998, OPHTHALMOLOGY, V105, P552, DOI 10.1016/S0161-6420(98)93042-1
   LEIBOWITZ H, 1973, SURV OPHTHALMOL, V24, P335
   Massof RW, 2002, OPTOMETRY VISION SCI, V79, P31, DOI 10.1097/00006324-200201000-00010
   McCarty CA, 2000, INVEST OPHTH VIS SCI, V41, P3720
   Moser CL, 2002, BRIT J OPHTHALMOL, V86, P257, DOI 10.1136/bjo.86.3.257
   Munoz B, 2000, ARCH OPHTHALMOL-CHIC, V118, P819, DOI 10.1001/archopht.118.6.819
   Munoz B, 2002, INVEST OPHTH VIS SCI, V43, P608
   PATZ A, 1985, ARCH OPHTHALMOL-CHIC, V103, P1796, DOI 10.1001/archopht.1985.01050120030015
   Rahmani B, 1996, OPHTHALMOLOGY, V103, P1721, DOI 10.1016/S0161-6420(96)30435-1
   Rodriguez J, 2002, OPHTHALMOLOGY, V109, P737, DOI 10.1016/S0161-6420(01)01008-9
   Schillinger D, 2002, JAMA-J AM MED ASSOC, V288, P475, DOI 10.1001/jama.288.4.475
   TIELSCH JM, 1991, JAMA-J AM MED ASSOC, V266, P369, DOI 10.1001/jama.266.3.369
   van der Pols JC, 2000, BRIT J OPHTHALMOL, V84, P165, DOI 10.1136/bjo.84.2.165
   VanNewkirk MR, 2001, OPHTHALMOLOGY, V108, P960, DOI 10.1016/S0161-6420(01)00554-1
   West SK, 1997, INVEST OPHTH VIS SCI, V38, P72
   1978, OPHTHALMOLOGY, V85, P82
NR 37
TC 1876
Z9 1932
U1 1
U2 143
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 0003-9950
EI 1538-3601
J9 ARCH OPHTHALMOL-CHIC
JI Arch. Ophthalmol.
PD APR
PY 2004
VL 122
IS 4
BP 477
EP 485
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 812GT
UT WOS:000220828700005
PM 15078664
DA 2022-11-30
ER

PT J
AU Le, A
   Mukesh, BN
   McCarty, CA
   Taylor, HR
AF Le, A
   Mukesh, BN
   McCarty, CA
   Taylor, HR
TI Risk factors associated with the incidence of open-angle glaucoma: The
   Visual Impairment Project
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID GENERAL ELDERLY POPULATION; BALTIMORE EYE SURVEY; BLUE-MOUNTAINS-EYE;
   BEAVER DAM EYE; INTRAOCULAR-PRESSURE; BARBADOS EYE; DIABETES-MELLITUS;
   OCULAR PRESSURE; PREVALENCE; PSEUDOEXFOLIATION
AB PURPOSE. To assess the relationship between potential risk factors and the development of open-angle glaucoma (OAG) in Australian residents aged 40 and or more years.
   METHODS. A total of 3271 participants were recruited at baseline from nine urban areas through cluster random sampling and subjected to comprehensive standardized interviews and ophthalmic examination, both at baseline and at 5-year follow-up. The participation rate at follow-up was 85% of the surviving baseline cohort. OAG was diagnosed with definite, probable, or possible certainty by a consensus panel of six ophthalmologists. Potential risk factors identified at baseline included various sociodemographic, anthropometric, dietary, familial, medical. and ocular characteristics of the participants. Risk factor analyses were performed for development of at least possible OAG (possible, probable, and definite OAG) and then at least probable OAG (probable and definite OAG) to represent a higher level of certainty. Univariate and multivariate analyses were performed.
   RESULTS. Increased age and increased intraocular pressure (IOP) were associated with increased risk of development of OAG, according to multivariate analyses. A family history of glaucoma (relative risk [RR] = 2.1, 95% confidence interval [CI] = 1.03-4.2), the presence of age-related macular degeneration (RR = 2.2, 95% CI = 1.2-3.9), the presence of pseudoexfoliation (RR = 9.4, 95% Cl = 2.6 - 34.4), and a cup-disc ratio (CDR) greater than 0.7 (RR = 7.9, 95% Cl = 4.4-14.1) were associated with greater risk of development of at least possible OAG. Having ever taken alpha-blockers (RR = 4.8, 95% Cl = 1.2-18.8), the presence of pseudoexfoliation (RR = 11.2, 95% Cl = 2.0-63.3), and a CDR higher than 0.7 (RR = 11.0, 95% CI = 4.6-26.8) also indicated significant risk of development of at least probable OAG.
   CONCLUSIONS. Certain nortmodifiable risk factors may be used to identify high-risk individuals, and increased IOP remains an important modifiable risk factor for OAG. However, more prospective studies on risk factors are required to clarify further the etiological picture of OAG.
C1 Univ Melbourne, Ctr Eye Res Australia, Melbourne, Vic 3002, Australia.
   Peter MacCallum Canc Inst, Melbourne, Vic, Australia.
   Marshfield Med Res Fdn, Marshfield, WI 54449 USA.
C3 Centre for Eye Research Australia; University of Melbourne; Peter
   Maccallum Cancer Center
RP Le, A (通讯作者)，Univ Melbourne, Ctr Eye Res Australia, 32 Gisbourne St, Melbourne, Vic 3002, Australia.
EM la@unimelb.edu.au
OI McCarty, Catherine/0000-0003-1089-0142; Taylor, Hugh/0000-0002-9437-784X
CR ARMALY MF, 1980, ARCH OPHTHALMOL-CHIC, V98, P2163, DOI 10.1001/archopht.1980.01020041015002
   BENGTSSON B, 1989, BRIT J OPHTHALMOL, V73, P483, DOI 10.1136/bjo.73.7.483
   Bonomi L, 2000, OPHTHALMOLOGY, V107, P1287, DOI 10.1016/S0161-6420(00)00138-X
   Broadway DC, 1998, BRIT J OPHTHALMOL, V82, P862, DOI 10.1136/bjo.82.8.862
   Budde W M, 2000, Curr Opin Ophthalmol, V11, P101, DOI 10.1097/00055735-200004000-00006
   CAREL RS, 1984, OPHTHALMOLOGY, V91, P311
   Cheng A. C. K., 2000, Hong Kong Medical Journal, V6, P195
   Coleman AL, 1999, LANCET, V354, P1803, DOI 10.1016/S0140-6736(99)04240-3
   Dielemans I, 1996, OPHTHALMOLOGY, V103, P1271, DOI 10.1016/S0161-6420(96)30511-3
   DIELEMANS I, 1994, OPHTHALMOLOGY, V101, P1851
   DIELEMANS I, 1995, OPHTHALMOLOGY, V102, P54
   Douglas G R, 1998, Curr Opin Ophthalmol, V9, P34, DOI 10.1097/00055735-199804000-00007
   EID TM, 2000, GLAUCOMAS CONCEPTS F, V1, P89
   EKSTROM C, 1993, ACTA OPHTHALMOL, V71, P189
   Ellis JD, 2000, BRIT J OPHTHALMOL, V84, P1218, DOI 10.1136/bjo.84.11.1218
   Gramer E, 1995, Curr Opin Ophthalmol, V6, P78
   Hayreh SS, 1994, CURR OPIN OPHTHALMOL, V5II, P26
   Hirvela H, 1996, OPHTHALMOLOGY, V103, P871, DOI 10.1016/S0161-6420(96)30593-9
   HOLLOWS FC, 1966, BRIT J OPHTHALMOL, V50, P570, DOI 10.1136/bjo.50.10.570
   Kaimbo DKW, 2001, J CLIN EPIDEMIOL, V54, P166, DOI 10.1016/S0895-4356(00)00291-2
   KLEIN BEK, 1994, OPHTHALMOLOGY, V101, P1173
   KLEIN BEK, 1993, OPHTHALMOLOGY, V100, P1609
   LESKE MC, 1995, ARCH OPHTHALMOL-CHIC, V113, P918, DOI 10.1001/archopht.1995.01100070092031
   Leske MC, 2001, ARCH OPHTHALMOL-CHIC, V119, P89
   Livingston P M, 1997, Ophthalmic Epidemiol, V4, P73
   Livingston P M, 1994, Ophthalmic Epidemiol, V1, P139, DOI 10.3109/09286589409047222
   McCarty CA, 1996, B WORLD HEALTH ORGAN, V74, P353
   McCarty CA, 2001, BRIT J OPHTHALMOL, V85, P322, DOI 10.1136/bjo.85.3.322
   Mitchell P, 1996, OPHTHALMOLOGY, V103, P1661, DOI 10.1016/S0161-6420(96)30449-1
   Mitchell P, 1999, ARCH OPHTHALMOL-CHIC, V117, P1319, DOI 10.1001/archopht.117.10.1319
   Mukesh BN, 2002, OPHTHALMOLOGY, V109, P1047, DOI 10.1016/S0161-6420(02)01040-0
   Musch DC, 2001, ARCH OPHTHALMOL-CHIC, V119, P117
   Nemesure B, 2001, AM J MED GENET, V103, P36, DOI 10.1002/ajmg.1498
   Palmberg P, 2001, ARCH OPHTHALMOL-CHIC, V119, P897
   Quigley HA, 1996, BRIT J OPHTHALMOL, V80, P389, DOI 10.1136/bjo.80.5.389
   Ritch R, 2000, Curr Opin Ophthalmol, V11, P78, DOI 10.1097/00055735-200004000-00002
   Rothman KJ, 1998, MODERN EPIDEMIOLOGY, P23
   SCHWARTZ JT, 1975, ARCH OPHTHALMOL-CHIC, V93, P776, DOI 10.1001/archopht.1975.01010020670002
   Schwartz M, 2000, Curr Opin Ophthalmol, V11, P107, DOI 10.1097/00055735-200004000-00007
   SMITH RJH, 1989, BRIT J OPHTHALMOL, V73, P481, DOI 10.1136/bjo.73.7.481
   Sommer A, 1996, Curr Opin Ophthalmol, V7, P93, DOI 10.1097/00055735-199604000-00016
   Spaeth G L, 1994, Surv Ophthalmol, V38 Suppl, pS9, DOI 10.1016/0039-6257(94)90042-6
   Stewart WC, 2000, AM J OPHTHALMOL, V130, P274, DOI 10.1016/S0002-9394(00)00487-6
   TAYLOR HR, 1977, BRIT J OPHTHALMOL, V61, P473, DOI 10.1136/bjo.61.7.473
   TIELSCH JM, 1995, OPHTHALMOLOGY, V102, P48
   TIELSCH JM, 1995, ARCH OPHTHALMOL-CHIC, V113, P216, DOI 10.1001/archopht.1995.01100020100038
   TIELSCH JM, 1994, ARCH OPHTHALMOL-CHIC, V112, P69, DOI 10.1001/archopht.1994.01090130079022
   Weih LM, 2001, OPHTHALMOLOGY, V108, P1966, DOI 10.1016/S0161-6420(01)00799-0
   Wensor MD, 1998, OPHTHALMOLOGY, V105, P733, DOI 10.1016/S0161-6420(98)94031-3
   West SK, 2000, EPIDEMIOL REV, V22, P64, DOI 10.1093/oxfordjournals.epirev.a018025
   Wheeler LA, 2001, EUR J OPHTHALMOL, V11, pS30
   Wolfs RCW, 1998, ARCH OPHTHALMOL-CHIC, V116, P1640, DOI 10.1001/archopht.116.12.1640
   Wu SY, 1997, ARCH OPHTHALMOL-CHIC, V115, P1572, DOI 10.1001/archopht.1997.01100160742012
NR 53
TC 217
Z9 221
U1 0
U2 12
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD SEP
PY 2003
VL 44
IS 9
BP 3783
EP 3789
DI 10.1167/iovs.03-0077
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 715WC
UT WOS:000184994900010
PM 12939292
DA 2022-11-30
ER

PT J
AU Ouyang, S
   Ji, D
   He, SK
   Xia, XB
AF Ouyang, Sha
   Ji, Dan
   He, Shikun
   Xia, Xiaobo
TI Endoplasmic reticulum stress as a novel target to inhibit
   transdifferentiation of human retinal pigment epithelial cell
SO FRONTIERS IN BIOSCIENCE-LANDMARK
LA English
DT Article
DE Endoplasmic reticulum stress; Epithelial-mesenchymal transition; Cell
   movements; TGF-beta signaling; Retinal pigment epithelial cells
ID TO-MESENCHYMAL TRANSITION; TGF-BETA; PROLIFERATIVE VITREORETINOPATHY;
   FIBROSIS; DIFFERENTIATION; DISEASES; MATRIX; SMAD3; GRP78
AB Background: The epithelial to mesenchymal transition (EMT) of retinal pigment epithelial (RPE) cells is a critical event in the pathogenesis of proliferative vitreoretinopathy and neovascular age-related macular degeneration, which are the leading causes of severe vision loss. Endoplasmic reticulum (ER) stress has been implicated in the EMT of many cell types and various ocular diseases. However, the relationship between ER stress and EMT in RPE cells remains unknown. Therefore, in the study, we explored the impact of ER stress on EMT in RPE cells. Methods: Different concentrations of tunicamycin (TM) and thapsigargin (TG) were used to induce ER stress in human RPE cells. The expression of epithelial marker, mesenchymal markers and some of genes/proteins involved in TGE-fl/Smad signaling were analized by qPCR, western blot or immunostaining at the condition with or without stimulation of TGF-beta 2 (10 ng/mL). Boyden chamber and scratch assay were used to evaluate the migration of RPE cells, while cell viability and apoptosis of RPE cells were measured by MTT and TUNEL assay, respectively. Results: Treatment of RPE cells with TM and TG (24 h) reduced the expression of alpha-SMA and FN, and increased the expression of Occludin in a dose dependent manner at protein level, which was highly associated with the expression of GRP78. Treatment with TGF-beta 2 significantly increased the expression of alpha-SMA and FN, and decreased the expression of Occludin both in protein and mRNA levels, which was significantly inhibited by a 4h pre-treatment with TM. In addition, the expression of TGE-beta RII and Smad2/3, and mRNAs of TGE-beta RII and Smad3 were also decreased by the TM treatment. TM-induced ER stress inhibited RPE cell migration, and high concentrations of TM and TG reduced cell viability and induced apoptosis of RPE cells. Conclusions: Chemical induction of ER stress inhibited EMT and migration in RPE cells, possibly by inactivation of TGF-beta signaling, suggesting that regulation of ER stress in RPE cells may be a new approach to prevent the development of intraocular fibrosis.
C1 [Ouyang, Sha] Cent South Univ, Xiangya Hosp 3, Dept Ophthalmol, Changsha 410000, Hunan, Peoples R China.
   [Ouyang, Sha; Ji, Dan; Xia, Xiaobo] Cent South Univ, Eye Ctr, Xiangya Hosp, Changsha 410008, Hunan, Peoples R China.
   [Ouyang, Sha; Ji, Dan; Xia, Xiaobo] Hunan Key Lab Ophthalmol, Changsha 410008, Hunan, Peoples R China.
   [Ouyang, Sha; He, Shikun] Univ Southern Calif, USC Roski Eye Inst, Dept Pathol, Keck Sch Med, Los Angeles, CA 90033 USA.
C3 Central South University; Central South University; University of
   Southern California
RP Xia, XB (通讯作者)，Cent South Univ, Eye Ctr, Xiangya Hosp, Changsha 410008, Hunan, Peoples R China.; Xia, XB (通讯作者)，Hunan Key Lab Ophthalmol, Changsha 410008, Hunan, Peoples R China.; He, SK (通讯作者)，Univ Southern Calif, USC Roski Eye Inst, Dept Pathol, Keck Sch Med, Los Angeles, CA 90033 USA.
EM shikunhe@usc.edu; xbxia21@csu.edu.cn
FU second Xiangya Hospital of Xiangya School of Medicine of Central South
   University for Research Abroad
FX The research is supported by a fellowship from the second Xiangya
   Hospital of Xiangya School of Medicine of Central South University for
   Research Abroad. The authors thank Christine K. Spee, Eric Barron and
   Ernesto Barron for technical assistance.
CR Chang JL, 2018, MOL MED REP, V18, P945, DOI 10.3892/mmr.2018.9061
   Chang YJ, 2015, TUMOR BIOL, V36, P1859, DOI 10.1007/s13277-014-2788-x
   Chen CL, 2017, DRUG DES DEV THER, V11, P163, DOI 10.2147/DDDT.S126743
   Chiu CS, 2019, CANCER LETT, V442, P113, DOI 10.1016/j.canlet.2018.10.026
   CONNOR TB, 1989, J CLIN INVEST, V83, P1661, DOI 10.1172/JCI114065
   Dongre A, 2019, NAT REV MOL CELL BIO, V20, P69, DOI 10.1038/s41580-018-0080-4
   Feng ZL, 2015, GRAEF ARCH CLIN EXP, V253, P875, DOI 10.1007/s00417-014-2922-x
   Frangogiannis NG, 2020, J EXP MED, V217, DOI 10.1084/jem.20190103
   Friedlander M, 2007, J CLIN INVEST, V117, P576, DOI 10.1172/JCI31030
   Fu L, 2021, ENVIRON POLLUT, V283, DOI 10.1016/j.envpol.2021.117134
   Gamulescu MA, 2006, EXP EYE RES, V83, P212, DOI 10.1016/j.exer.2005.12.007
   Geng XQ, 2020, ACTA PHARMACOL SIN, V41, P670, DOI 10.1038/s41401-019-0324-7
   Hiscott P, 1999, PROG RETIN EYE RES, V18, P167, DOI 10.1016/S1350-9462(98)00024-X
   Hsu HS, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-14612-5
   Huang CX, 2015, INVEST OPHTH VIS SCI, V56, P6196, DOI 10.1167/iovs.15-16795
   Ishikawa K, 2016, AM J PATHOL, V186, P859, DOI 10.1016/j.ajpath.2015.11.014
   Ishikawa K, 2016, EXP EYE RES, V142, P19, DOI 10.1016/j.exer.2015.03.009
   Ishikawa K, 2015, SCI REP-UK, V5, DOI 10.1038/srep16386
   Kalluri R, 2009, J CLIN INVEST, V119, P1420, DOI 10.1172/JCI39104
   Kita T, 2008, P NATL ACAD SCI USA, V105, P17504, DOI 10.1073/pnas.0804054105
   Kropski JA, 2018, J CLIN INVEST, V128, P64, DOI 10.1172/JCI93560
   Lee AS, 2005, METHODS, V35, P373, DOI 10.1016/j.ymeth.2004.10.010
   Liu DS, 2018, CELL PHYSIOL BIOCHEM, V46, P1821, DOI 10.1159/000489367
   Moon SY, 2014, NEPHRON EXP NEPHROL, V126, P127, DOI 10.1159/000362457
   Mudhar HS, 2020, EYE, V34, P246, DOI 10.1038/s41433-019-0724-4
   PFEFFER BA, 1994, EXP EYE RES, V59, P323, DOI 10.1006/exer.1994.1114
   Roberts AB, 2006, CYTOKINE GROWTH F R, V17, P19, DOI 10.1016/j.cytogfr.2005.09.008
   Saika S, 2004, LAB INVEST, V84, P1245, DOI 10.1038/labinvest.3700156
   Saika Shizuya, 2009, Front Biosci (Schol Ed), V1, P376, DOI 10.2741/e32
   Sharma M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069343
   Shin HS, 2015, LAB INVEST, V95, P1157, DOI 10.1038/labinvest.2015.91
   Sonoda S, 2009, NAT PROTOC, V4, P662, DOI 10.1038/nprot.2009.33
   Stone RC, 2016, CELL TISSUE RES, V365, P495, DOI 10.1007/s00441-016-2464-0
   Tai CJ, 2012, ANN SURG ONCOL, V19, P336, DOI 10.1245/s10434-011-1692-5
   Tamiya S, 2016, EXP EYE RES, V142, P26, DOI 10.1016/j.exer.2015.02.008
   Tenbrock L, CELL TISSUE RES, V2021
   Tosi GM, 2014, J CELL PHYSIOL, V229, P1577, DOI 10.1002/jcp.24606
   Xia W, 2017, ONCOTARGET, V8, P8512, DOI 10.18632/oncotarget.14337
   Xu J, 2009, CELL RES, V19, P156, DOI 10.1038/cr.2009.5
   Yi N, 2012, ANAT REC, V295, P1462, DOI 10.1002/ar.22539
   Yoshikawa T, 2011, CURR EYE RES, V36, P1153, DOI 10.3109/02713683.2011.606592
   Zhang H, 2019, EUR J PHARMACOL, V842, P329, DOI 10.1016/j.ejphar.2018.11.001
   Zhou M, 2020, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.00501
   Zhou S, 2020, MOL MED REP, V21, P173, DOI 10.3892/mmr.2019.10814
NR 44
TC 0
Z9 0
U1 0
U2 0
PU IMR PRESS
PI ROBINSON
PA 112 ROBINSON RD, ROBINSON, SINGAPORE
SN 2768-6701
EI 2768-6698
J9 FRONT BIOSCI-LANDMRK
JI Front. Biosci.
PD FEB 16
PY 2022
VL 27
IS 2
AR 038
DI 10.31083/j.fbl2702038
PG 9
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA ZY5WE
UT WOS:000772656600005
PM 35226981
OA gold
DA 2022-11-30
ER

PT J
AU Bikbov, MM
   Kazakbaeva, GM
   Gilmanshin, TR
   Zainullin, RM
   Nuriev, IF
   Zaynetdinov, AF
   Israfilova, GZ
   Panda-Jonas, S
   Arslangareeva, II
   Rakhimova, EM
   Rusakova, IA
   Jonas, JB
AF Bikbov, Mukharram M.
   Kazakbaeva, Gyulli M.
   Gilmanshin, Timur R.
   Zainullin, Rinat M.
   Nuriev, Ildar F.
   Zaynetdinov, Artur F.
   Israfilova, Gulnara Z.
   Panda-Jonas, Songhomitra
   Arslangareeva, Inga I.
   Rakhimova, Ellina M.
   Rusakova, Iulia A.
   Jonas, Jost B.
TI Prevalence and associated factors of cataract and cataract-related
   blindness in the Russian Ural Eye and Medical Study
SO SCIENTIFIC REPORTS
LA English
DT Article
ID VISION IMPAIRMENT; CLASSIFICATION; DISTANCE
AB To assess the prevalence of cataract and cataract surgery in a population from Russia, we conducted the population-based Ural Eye and Medical Study with 5899 participants (80.5% out of 7328 eligible individuals), with an age of 40+years as the eligibility criterion. In the phakic population, the prevalence of nuclear, cortical, subcapsular cataract and any cataract was 38.0% [95% confidence interval (CI) 36.6, 39.3], 14.5% (95% CI 13.5, 15.5), 0.6% (95% CI 0.4, 0.8) and 44.6% (95% CI 43.2, 46.0), respectively. A higher prevalence of nuclear cataract was associated with older age [odds ratio (OR) 1.10; 95% CI 1.10, 1.11], the female sex (OR 1.27; 95% CI 1.08, 1.50), urban region (OR 2.00; 95% CI 1.71, 2.33), a low educational level (OR 0.93; 95% CI 0.88, 0.98), a high diastolic blood pressure (OR 1.01; 95% CI 1.001, 1.02), a low serum concentration of high-density lipoproteins (OR 0.91; 95% CI 0.84, 0.98), more smoking package years (OR 1.01; 95% CI 1.01, 1.02), chronic kidney disease (OR 1.02; 95% CI 1.10, 1.03), a short axial length (OR 0.93; 95% CI 0.86, 0.99), and a low prevalence of age-related macular degeneration (OR 0.72; 95% CI 0.57, 0.92). The prevalence of previous cataract surgery conducted in 354/5885 individuals (6.0%; 95% CI 5.4, 6.6) increased from 0.4% (95% CI 0.0, 1.0) in the age group of 40-45 years to 37.6% (95% CI 30.9, 44.4) in the age group of 80+years. Cataract was the cause of moderate-to-severe vision impairment in 109 (1.8%) individuals and of blindness in three (0.05%) individuals. The prevalence of cataract and cataract-related MSVI and blindness were relatively high; subsequently, the prevalence of previous cataract surgery was relatively low in this population from Russia.
C1 [Bikbov, Mukharram M.; Kazakbaeva, Gyulli M.; Gilmanshin, Timur R.; Zainullin, Rinat M.; Nuriev, Ildar F.; Zaynetdinov, Artur F.; Israfilova, Gulnara Z.; Arslangareeva, Inga I.; Rakhimova, Ellina M.; Rusakova, Iulia A.] Ufa Eye Res Inst, 90 Pushkin St, Ufa 450077, Bashkortostan, Russia.
   [Panda-Jonas, Songhomitra; Jonas, Jost B.] Heidelberg Univ, Dept Ophthalmol, Med Fac Mannheim, Theodor Kutzerufer 1, D-68167 Mannheim, Germany.
C3 Ufa Eye Research Institute; Ruprecht Karls University Heidelberg
RP Bikbov, MM (通讯作者)，Ufa Eye Res Inst, 90 Pushkin St, Ufa 450077, Bashkortostan, Russia.; Jonas, JB (通讯作者)，Heidelberg Univ, Dept Ophthalmol, Med Fac Mannheim, Theodor Kutzerufer 1, D-68167 Mannheim, Germany.
EM bikbov.m@gmail.com; jost.jonas@medma.uni-heidelberg.de
RI Zainullin, Rinat/AAR-6362-2021; Bikbov, Mukharram/AAO-7624-2021
OI Kazakbaeva, Gyulli/0000-0002-0569-1264
FU Projekt DEAL
FX Open Access funding enabled and organized by Projekt DEAL.
CR Bikbov M, 2018, OPHTHAL EPIDEMIOL, V25, P187, DOI 10.1080/09286586.2017.1384504
   Bikbov MM, 2020, AM J OPHTHALMOL, V210, P158, DOI 10.1016/j.ajo.2019.10.003
   Bikbov MM, 2019, AM J OPHTHALMOL, V204, P130, DOI 10.1016/j.ajo.2019.02.030
   Bikbov MM, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0211186
   Bourne RRA, 2018, BRIT J OPHTHALMOL, V102, P575, DOI 10.1136/bjophthalmol-2017-311258
   Bourne RRA, 2017, LANCET GLOB HEALTH, V5, pE888, DOI 10.1016/S2214-109X(17)30293-0
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Flaxman SR, 2017, LANCET GLOB HEALTH, V5, pE1221, DOI 10.1016/S2214-109X(17)30393-5
   FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6
   Foster PJ, 2002, BRIT J OPHTHALMOL, V86, P238, DOI 10.1136/bjo.86.2.238
   Jonas JB, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0113550
   Kassoff A, 2001, AM J OPHTHALMOL, V131, P167
   Naidoo K, 2020, BR J OPHTHALMOL, V2020, P2019
   Nangia V, 2019, BRIT J OPHTHALMOL, V103, P871, DOI 10.1136/bjophthalmol-2018-312292
   Nangia V, 2011, J CATARACT REFR SURG, V37, P1932, DOI 10.1016/j.jcrs.2011.08.020
   PRINCE AM, 1987, ARCH OPHTHALMOL-CHIC, V105, P1076
   Stevens GA, 2016, LANCET, V388, pE19, DOI 10.1016/S0140-6736(16)30388-9
   Wang W, 2016, INVEST OPHTH VIS SCI, V57, P5872, DOI 10.1167/iovs.16-19894
   Wang YX, 2011, ACTA OPHTHALMOL, V89, pE210, DOI 10.1111/j.1755-3768.2009.01787.x
   Yan YN, 2015, OPHTHALMOLOGY, V122, P1873, DOI 10.1016/j.ophtha.2015.05.031
   ZUNG WWK, 1965, ARCH GEN PSYCHIAT, V12, P63, DOI 10.1001/archpsyc.1965.01720310065008
NR 21
TC 6
Z9 6
U1 1
U2 2
PU NATURE PORTFOLIO
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD OCT 23
PY 2020
VL 10
IS 1
AR 18157
DI 10.1038/s41598-020-75313-0
PG 9
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA ON1RO
UT WOS:000586487500004
PM 33097810
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Skeie, JM
   Mahajan, VB
AF Skeie, Jessica M.
   Mahajan, Vinit B.
TI Proteomic Landscape of the Human Choroid-Retinal Pigment Epithelial
   Complex
SO JAMA OPHTHALMOLOGY
LA English
DT Article
ID CENTRAL SEROUS CHORIORETINOPATHY; MACULAR DEGENERATION AMD; FACTOR-H
   POLYMORPHISM; OXIDATIVE STRESS; HIGH-RISK; PROTEIN IDENTIFICATION;
   EXPRESSION; VARIANT; DISEASE; GENES
AB IMPORTANCE Differences in geographical protein expression in the human choroid-retinal pigment epithelial (RPE) complexmay explain molecular predisposition of regions to ophthalmic diseases such as age-related macular degeneration.
   OBJECTIVE To characterize the proteome of the human choroid-RPE complex and to identify differentially expressed proteins in specific anatomic regions.
   DESIGN, SETTING, AND PARTICIPANTS Experimental study of choroid-RPE tissue from 3 nondiseased eyes. The choroid-RPE complex underwent biopsy from beneath the foveal, macular, and peripheral retina. Protein fractions were isolated and subjected to multidimensional liquid chromatography and tandem mass spectrometry. A bioinformatic pipeline matched peptide spectra to the human proteome, assigned gene ontology classification, and identified protein signaling pathways unique to each of the choroid-RPE regions.
   MAIN OUTCOMES AND MEASURES Mean number of mass spectra, statistically significant differentially expressed proteins, gene ontology classification, and pathway representation.
   RESULTS We identified a mean of 4403 unique proteins in each of the foveal, macular, and peripheral choroid-RPE tissues. Six hundred seventy-one differentially expressed proteins included previously known risk factors for retinal diseases related to oxidative stress, inflammation, and the complement cascade. Gene ontology analysis showed that unique categories in the foveal and macular regions included immune process proteins as well as protein complexes and plasma membrane proteins. The peripheral region contained unique antioxidant activity proteins. Many proteins had the highest expression in the foveal or macular regions, including inflammation-related proteins HLA-A, HLA-B, and HLA-C antigens; intercellular adhesion molecule 1 (ICAM-1); S100; transcription factor ERG; antioxidant superoxide dismutase 1 (SOD1); chloride intracellular channel 6 ion (CLIC6); activators of the complement cascade C1q, C6, and C8; and complement factor H. Proteins with higher expression in the periphery included bestrophin 1 (BEST1), transcription factor RNA binding motif protein 39 (RBM39), inflammatory mediator macrophage migration inhibitory factor, antioxidant SOD3, ion channel voltage-dependent anion-selective channel protein 3 (VDAC3), and complement inhibitor CD55. The complement activation was among the highest represented pathways (P < 7.5e-13).
   CONCLUSIONS AND RELEVANCE This proteomic data set identifies novel molecular signatures in anatomically sensitive regions of the choroid-RPE complex. The findings give mechanistic insight into choroid-RPE function, reveal important choroid-RPE processes, and prioritize new pathways for therapeutic targeting.
C1 [Skeie, Jessica M.; Mahajan, Vinit B.] Univ Iowa, Carver Coll Med, Dept Ophthalmol & Visual Sci, Omics Lab, Iowa City, IA 52242 USA.
C3 University of Iowa
RP Mahajan, VB (通讯作者)，Univ Iowa, Carver Coll Med, Dept Ophthalmol & Visual Sci, Omics Lab, 200 Hawkins Dr, Iowa City, IA 52242 USA.
EM vinit-mahajan@uiowa.edu
OI Mahajan, Vinit/0000-0003-1886-1741
FU Bright Focus Foundation; National Institutes of Health
   [1F32EY022280-01A1, K08EY020530]; NATIONAL EYE INSTITUTE [K08EY020530,
   F32EY022280] Funding Source: NIH RePORTER
FX This study was supported by the Bright Focus Foundation and by grants
   1F32EY022280-01A1 (Dr Skeie) and K08EY020530 (Dr Mahajan) from the
   National Institutes of Health.
CR AMALRIC P, 1983, INT OPHTHALMOL, V6, P149, DOI 10.1007/BF00127643
   Ambati J, 2013, NAT REV IMMUNOL, V13, P438, DOI 10.1038/nri3459
   Arima K, 2011, P NATL ACAD SCI USA, V108, P14914, DOI 10.1073/pnas.1106015108
   Barnett BR, 2013, GERONTOLOGY, V59, P297, DOI 10.1159/000346169
   Beavis Ronald C., 2006, V328, P217
   Bhutto I, 2012, MOL ASPECTS MED, V33, P295, DOI 10.1016/j.mam.2012.04.005
   Bjornson RD, 2008, J PROTEOME RES, V7, P293, DOI 10.1021/pr0701198
   Boon CJF, 2009, PROG RETIN EYE RES, V28, P187, DOI 10.1016/j.preteyeres.2009.04.002
   BOUT A, 1991, BIOCHIM BIOPHYS ACTA, V1090, P43, DOI 10.1016/0167-4781(91)90035-K
   Cipriani V, 2012, IMMUNOBIOLOGY, V217, P158, DOI 10.1016/j.imbio.2011.09.002
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   Craig R, 2006, J PROTEOME RES, V5, P1843, DOI 10.1021/pr0602085
   CURCIO CA, 1990, J COMP NEUROL, V292, P497, DOI 10.1002/cne.902920402
   Darbro BW, 2013, HUM MUTAT, V34, P1075, DOI 10.1002/humu.22351
   Donato R, 2013, CURR MOL MED, V13, P24, DOI 10.2174/156652413804486214
   Dong A, 2009, J CELL PHYSIOL, V219, P544, DOI 10.1002/jcp.21698
   Ebrahimi KB, 2013, J PATHOL, V229, P729, DOI 10.1002/path.4128
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Ekins S, 2007, METH MOL B, V356, P319
   Fagerness JA, 2009, EUR J HUM GENET, V17, P100, DOI 10.1038/ejhg.2008.140
   Friedli M, 2003, GENE, V320, P31, DOI 10.1016/S0378-1119(03)00830-8
   Fritsche LG, 2013, NAT GENET, V45, P433, DOI 10.1038/ng.2578
   Geer LY, 2004, J PROTEOME RES, V3, P958, DOI 10.1021/pr0499491
   Gemenetzi M, 2010, EYE, V24, P1743, DOI 10.1038/eye.2010.130
   Gincel D, 2002, INVEST OPHTH VIS SCI, V43, P2097
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Goverdhan SV, 2005, INVEST OPHTH VIS SCI, V46, P1726, DOI 10.1167/iovs.04-0928
   Haas P, 2011, AM J OPHTHALMOL, V152, P396, DOI 10.1016/j.ajo.2011.02.017
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Handa JT, 2012, MOL ASPECTS MED, V33, P418, DOI 10.1016/j.mam.2012.03.006
   HAYREH SS, 1983, INT OPHTHALMOL, V6, P85, DOI 10.1007/BF00127636
   HAYREH SS, 1975, BRIT J OPHTHALMOL, V59, P631, DOI 10.1136/bjo.59.11.631
   Hayward C, 2003, HUM MOL GENET, V12, P2657, DOI 10.1093/hmg/ddg289
   Helgason H, 2013, NAT GENET, V45, P1371, DOI 10.1038/ng.2740
   Holz FG, 2014, OPHTHALMOLOGY, V121, P1079, DOI 10.1016/j.ophtha.2013.11.023
   Johnson LR, 2000, IEEE ANN HIST COMPUT, V22, P70
   Kauppinen A, 2012, IMMUNOL LETT, V147, P29, DOI 10.1016/j.imlet.2012.05.005
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Li Y, 2010, RAPID COMMUN MASS SP, V24, P807, DOI 10.1002/rcm.4448
   Ma KN, 2010, INVEST OPHTH VIS SCI, V51, P6776, DOI 10.1167/iovs.10-5887
   MacLean B, 2006, BIOINFORMATICS, V22, P2830, DOI 10.1093/bioinformatics/btl379
   Maddox AS, 2003, MOL CELL, V11, P846, DOI 10.1016/S1097-2765(03)00151-5
   Mahajan VB, 2014, PROTEOM CLIN APPL, V8, P204, DOI 10.1002/prca.201300062
   Maller JB, 2007, NAT GENET, V39, P1200, DOI 10.1038/ng2131
   Mullins RF, 2007, INVEST OPHTH VIS SCI, V48, P3372, DOI 10.1167/iovs.06-0868
   Mullins RF, 2011, EXP EYE RES, V93, P565, DOI 10.1016/j.exer.2011.06.015
   Nicholson B, 2013, SURV OPHTHALMOL, V58, P103, DOI 10.1016/j.survophthal.2012.07.004
   Nozaki M, 2006, P NATL ACAD SCI USA, V103, P2328, DOI 10.1073/pnas.0408835103
   Radi ZA, 2001, J VET INTERN MED, V15, P516, DOI 10.1892/0891-6640(2001)015&lt;0516:CAMLTA&gt;2.3.CO;2
   Rappsilber J, 2003, ANAL CHEM, V75, P663, DOI 10.1021/ac026117i
   Rui HA, 2011, BIOPHYS J, V100, P602, DOI 10.1016/j.bpj.2010.12.3711
   Sarup V, 2013, SEMIN OPHTHALMOL, V28, P333, DOI 10.3109/08820538.2013.825282
   Seddon JM, 2013, NAT GENET, V45, P1366, DOI 10.1038/ng.2741
   Skeie JM, 2014, PROTEOM CLIN APPL, V8, P209, DOI 10.1002/prca.201300043
   Skeie JM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0082140
   Skeie JM, 2011, JOVE-J VIS EXP, DOI 10.3791/2455
   Skeie JM, 2010, INVEST OPHTH VIS SCI, V51, P5336, DOI 10.1167/iovs.10-5322
   Sparrow JR, 2012, MOL ASPECTS MED, V33, P436, DOI 10.1016/j.mam.2012.03.007
   Sparrrow JR, 2010, CURR MOL MED, V10, P802
   Strauss O, 2005, PHYSIOL REV, V85, P845, DOI 10.1152/physrev.00021.2004
   Sun QK, 2014, MED ONCOL, V31, DOI 10.1007/s12032-013-0786-2
   Valente L, 2007, AM J HUM GENET, V80, P44, DOI 10.1086/510559
   Wagner E, 2010, NAT REV DRUG DISCOV, V9, P43, DOI 10.1038/nrd3011
   Weismann D, 2011, NATURE, V478, P76, DOI 10.1038/nature10449
   Westerfeld Corey, 2008, Semin Ophthalmol, V23, P59, DOI 10.1080/08820530701745249
   Wisniewski JR, 2009, NAT METHODS, V6, P359, DOI [10.1038/nmeth.1322, 10.1038/NMETH.1322]
   Yan J, 2013, J HUM GENET, V58, P366, DOI 10.1038/jhg.2013.20
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
   Yoo BC, 2001, ELECTROPHORESIS, V22, P172, DOI 10.1002/1522-2683(200101)22:1<172::AID-ELPS172>3.0.CO;2-P
   Zamir E, 1997, GRAEF ARCH CLIN EXP, V235, P339, DOI 10.1007/BF00937280
NR 71
TC 30
Z9 33
U1 0
U2 12
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 2168-6165
EI 2168-6173
J9 JAMA OPHTHALMOL
JI JAMA Ophthalmol.
PD NOV
PY 2014
VL 132
IS 11
BP 1271
EP 1281
DI 10.1001/jamaophthalmol.2014.2065
PG 11
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AT8WO
UT WOS:000345210100002
PM 25058583
DA 2022-11-30
ER

PT J
AU Westeneng-van Haaften, SC
   Boon, CJF
   Cremers, FPM
   Hoefsloot, LH
   den Hollander, AI
   Hoyng, CB
AF Westeneng-van Haaften, Sarah C.
   Boon, Camiel J. F.
   Cremers, Frans P. M.
   Hoefsloot, Lies H.
   den Hollander, Anneke I.
   Hoyng, Carel B.
TI Clinical and Genetic Characteristics of Late-onset Stargardt's Disease
SO OPHTHALMOLOGY
LA English
DT Article
ID MACULAR DEGENERATION; FUNDUS FLAVIMACULATUS; ABCR ABCA4; CHOROIDAL
   NEOVASCULARIZATION; RETINAL DYSTROPHIES; BIOCHEMICAL DEFECTS; MOUSE
   MODEL; MUTATIONS; AUTOFLUORESCENCE; SUPPLEMENTATION
AB Objective: To describe the genotype and phenotype of patients with a late-onset Stargardt's disease (STGD1).
   Design: Retrospective case series.
   Participants: Twenty-one unrelated STGD1 patients with an age at onset of >= 45 years and >= 1 rare variant in the ABCA4 gene.
   Methods: Ophthalmologic examination, including best-corrected visual acuity (VA), Amsler grid testing, fundus photography, fluorescein angiography (FA), spectral-domain optical coherence tomography (OCT), fundus autofluorescence (FAF) imaging, full-field electroretinography (ERG), multifocal ERG, and central visual field testing. Analysis of the ABCA4 gene was performed using microarray analysis, sequencing, and multiplex ligation-dependent probe amplification. In addition, the PRPH2 and CFH genes were sequenced.
   Main Outcome Measures: Age at onset, VA, fundus appearance, FA, FAF, and OCT findings; ABCA4 mutations; and genotype-phenotype correlation.
   Results: The mean age at onset was 55 years (range, 45-72 years). Seven patients were diagnosed without visual symptoms (age range, 45-83 years). The VA was >= 20/40 in 24 eyes of 14 patients (59%) owing to foveal sparing. On ophthalmoscopy, late-onset STGD1 showed flavimaculatus flecks (15 patients), small flecks surrounding mottled foveal changes (3 patients), extensive chorioretinal atrophy (2 patients), or small yellowish spots in the macula (1 patient). The fundus flecks showed increased autofluorescence on FAF. The choroidal background fluorescence on FA was obscured in 16 patients (80%). We found a single heterozygous ABCA4 variant in 11 patients (52%), 2 compound heterozygous variants in 8 patients (38%), and a homozygous variant in 2 patients (10%). No PRPH2 or CFH mutations were detected.
   Conclusions: Late-onset STGD1 is at the mild end of the spectrum of retinal dystrophies caused by ABCA4 mutations. The VA is frequently preserved in late-onset STGD1 patients owing to foveal sparing. This phenotype may be caused by 1 or 2 ABCA4 variants. The differential diagnosis between late-onset STGD1 and age-related macular degeneration may be challenging. A thorough clinical and genetic analysis makes a distinction possible, which is important for clinical and genetic counseling.
   Financial Disclosure(s): The authors have no proprietary or commercial interest in any of the materials discussed in this article. Ophthalmology 2012;119:1199-1210 (C) 2012 by the American Academy of Ophthalmology.
C1 [Westeneng-van Haaften, Sarah C.; Boon, Camiel J. F.; den Hollander, Anneke I.; Hoyng, Carel B.] Radboud Univ Nijmegen, Med Ctr, Dept Ophthalmol, NL-6500 HB Nijmegen, Netherlands.
   [Cremers, Frans P. M.; Hoefsloot, Lies H.; den Hollander, Anneke I.] Radboud Univ Nijmegen, Med Ctr, Dept Human Genet, NL-6500 HB Nijmegen, Netherlands.
   [Cremers, Frans P. M.; den Hollander, Anneke I.] Radboud Univ Nijmegen, Med Ctr, Nijmegen Ctr Mol Life Sci, NL-6500 HB Nijmegen, Netherlands.
C3 Radboud University Nijmegen; Radboud University Nijmegen; Radboud
   University Nijmegen
RP Hoyng, CB (通讯作者)，Radboud Univ Nijmegen, Med Ctr, Dept Ophthalmol, POB 9101, NL-6500 HB Nijmegen, Netherlands.
RI Cremers, Frans/A-5625-2014; Hollander, Anneke den/N-4911-2014; Hoyng,
   C.B./H-8050-2014; Boon, CJF/P-7534-2014
OI Cremers, Frans/0000-0002-4954-5592; Boon, CJF/0000-0002-6737-7932
CR Allikmets R, 1997, NAT GENET, V15, P236, DOI 10.1038/ng0397-236
   Allikmets R, 2000, AM J HUM GENET, V67, P487, DOI 10.1086/303018
   Allikmets R, 1997, SCIENCE, V277, P1805, DOI 10.1126/science.277.5333.1805
   Armstrong JD, 1998, OPHTHALMOLOGY, V105, P448, DOI 10.1016/S0161-6420(98)93026-3
   Bindewald A, 2005, INVEST OPHTH VIS SCI, V46, P3309, DOI 10.1167/iovs.04-0430
   Biswas-Fiss EE, 2010, J BIOL CHEM, V285, P19372, DOI 10.1074/jbc.M110.112896
   Boon CJF, 2007, BRIT J OPHTHALMOL, V91, P1504, DOI 10.1136/bjo.2007.115659
   Boon CJF, 2009, OPHTHALMOLOGY, V116, P771, DOI 10.1016/j.ophtha.2008.12.019
   Boon CJF, 2008, PROG RETIN EYE RES, V27, P213, DOI 10.1016/j.preteyeres.2008.01.002
   BOTTONI F, 1992, GRAEF ARCH CLIN EXP, V230, P498, DOI 10.1007/BF00175941
   Cremers F P M, 2004, Novartis Found Symp, V255, P68
   Cremers FPM, 1998, HUM MOL GENET, V7, P355, DOI 10.1093/hmg/7.3.355
   DELORI FC, 1995, INVEST OPHTH VIS SCI, V36, P718
   Fishman GA, 1999, ARCH OPHTHALMOL-CHIC, V117, P504, DOI 10.1001/archopht.117.4.504
   Franceschetti A, 1965, Trans Am Acad Ophthalmol Otolaryngol, V69, P1048
   Guillausseau PJ, 2001, ANN INTERN MED, V134, P721, DOI 10.7326/0003-4819-134-9_Part_1-200105010-00008
   Guymer RH, 2001, ARCH OPHTHALMOL-CHIC, V119, P745, DOI 10.1001/archopht.119.5.745
   Holz FG, 2001, INVEST OPHTH VIS SCI, V42, P1051
   Hood DC, 2008, DOC OPHTHALMOL, V116, P1, DOI 10.1007/s10633-007-9089-2
   Jaakson K, 2003, HUM MUTAT, V22, P395, DOI 10.1002/humu.10263
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Klevering BJ, 2005, GRAEF ARCH CLIN EXP, V243, P90, DOI 10.1007/s00417-004-1079-4
   Lois N, 2001, ARCH OPHTHALMOL-CHIC, V119, P359, DOI 10.1001/archopht.119.3.359
   Marmor MF, 2009, DOC OPHTHALMOL, V118, P69, DOI 10.1007/s10633-008-9155-4
   Mata NL, 2001, INVEST OPHTH VIS SCI, V42, P1685
   Maugeri A, 2002, EUR J HUM GENET, V10, P197, DOI 10.1038/sj.ejhg.5200784
   Maugeri A, 1999, AM J HUM GENET, V64, P1024, DOI 10.1086/302323
   Michaelides M, 2008, ARCH OPHTHALMOL-CHIC, V126, P320, DOI 10.1001/archopht.126.3.320
   MILLER SA, 1988, NUCLEIC ACIDS RES, V16, P1215, DOI 10.1093/nar/16.3.1215
   Molday LL, 2000, NAT GENET, V25, P257, DOI 10.1038/77004
   NOBLE KG, 1979, ARCH OPHTHALMOL-CHIC, V97, P1281
   Pawlak D, 2006, J FR OPHTALMOL, V29, P188, DOI 10.1016/S0181-5512(06)73770-6
   Radu RA, 2004, P NATL ACAD SCI USA, V101, P5928, DOI 10.1073/pnas.0308302101
   Radu RA, 2008, INVEST OPHTH VIS SCI, V49, P3821, DOI 10.1167/iovs.07-1470
   Radu RA, 2011, J BIOL CHEM, V286, P18593, DOI 10.1074/jbc.M110.191866
   Rivera A, 2000, AM J HUM GENET, V67, P800, DOI 10.1086/303090
   Rosenberg T, 2007, MOL VIS, V13, P1962
   Rotenstreich Y, 2003, OPHTHALMOLOGY, V110, P1151, DOI 10.1016/S0161-6420(03)00333-6
   Schmitz-Valckenberg S, 2009, SURV OPHTHALMOL, V54, P96, DOI 10.1016/j.survophthal.2008.10.004
   Shroyer NF, 2001, HUM MOL GENET, V10, P2671, DOI 10.1093/hmg/10.23.2671
   Souied EH, 1999, INVEST OPHTH VIS SCI, V40, P2740
   Souied EH, 2005, AM J OPHTHALMOL, V140, P312
   Souied EH, 1999, AM J OPHTHALMOL, V128, P173, DOI 10.1016/S0002-9394(99)00145-2
   Sparrow JR, 2010, J LIPID RES, V51, P247, DOI 10.1194/jlr.R000687
   Stargardt K., 1909, GRAEFES ARCH CLIN EX, V71, P534, DOI DOI 10.1007/BF01961301
   Suarez T, 2002, J BIOL CHEM, V277, P21759, DOI 10.1074/jbc.M202053200
   Sun H, 2000, NAT GENET, V26, P242, DOI 10.1038/79994
   Tsybovsky Y, 2010, ADV EXP MED BIOL, V703, P105, DOI 10.1007/978-1-4419-5635-4_8
   van Driel MA, 1998, OPHTHALMIC GENET, V19, P117, DOI 10.1076/opge.19.3.117.2187
   Wiszniewski W, 2005, HUM MOL GENET, V14, P2769, DOI 10.1093/hmg/ddi310
   Yatsenko AN, 2001, HUM GENET, V108, P346, DOI 10.1007/s004390100493
   Zhong M, 2009, J BIOL CHEM, V284, P3640, DOI 10.1074/jbc.M806580200
NR 52
TC 119
Z9 120
U1 0
U2 6
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0161-6420
J9 OPHTHALMOLOGY
JI Ophthalmology
PD JUN
PY 2012
VL 119
IS 6
BP 1199
EP 1210
DI 10.1016/j.ophtha.2012.01.005
PG 12
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 951JP
UT WOS:000304717100016
PM 22449572
DA 2022-11-30
ER

PT J
AU Koto, T
   Nagai, N
   Mochimaru, H
   Kurihara, T
   Izumi-Nagai, K
   Satofuka, S
   Shinoda, H
   Noda, K
   Ozawa, Y
   Inoue, M
   Tsubota, K
   Oike, Y
   Ishida, S
AF Koto, Takashi
   Nagai, Norihiro
   Mochimaru, Hiroshi
   Kurihara, Toshihide
   Izumi-Nagai, Kanako
   Satofuka, Shingo
   Shinoda, Hajime
   Noda, Kousuke
   Ozawa, Yoko
   Inoue, Makoto
   Tsubota, Kazuo
   Oike, Yuichi
   Ishida, Susumu
TI Eicosapentaenoic acid is anti-inflammatory in preventing choroidal
   neovascularization in mice
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID POLYUNSATURATED FATTY-ACIDS; AGE-RELATED MACULOPATHY; ENDOTHELIAL
   GROWTH-FACTOR; DIETARY FISH-OIL; INTERCELLULAR-ADHESION MOLECULE-1;
   TUMOR-NECROSIS-FACTOR; C-REACTIVE PROTEIN; MACULAR DEGENERATION;
   RISK-FACTORS; INFLAMMATION
AB PURPOSE. To investigate the role of eicosapentaenoic acid (EPA), the major omega-3 polyunsaturated fatty acid (PUFA), in the development of choroidal neovascularization (CNV), together with underlying molecular mechanisms.
   METHODS. Six-week-old C57BL/ 6 mice were fed with laboratory chow with 5% EPA or the omega-6 PUFA linoleic acid ( LA) for 4 weeks. Laser photocoagulation was performed to induce CNV, and the volume of CNV tissue was evaluated by volumetric measurements. The expression and production of intercellular adhesion molecule (ICAM)-1, monocyte chemotactic protein (MCP)-1, vascular endothelial growth factor ( VEGF) and interleukin (IL)-6 in the retinal pigment epithelium (RPE)-choroid in vivo, and stimulated b-End3 endothelial cells and RAW264.7 macrophages in vitro were evaluated by RT-PCR and ELISA. Fatty acid composition in the serum and the RPE-choroid was analyzed by gas chromatography and high-performance liquid chromatography, respectively. Serum levels of C-reactive protein (CRP), IL-6, VEGF, MCP-1, and soluble ICAM-1 were examined by ELISA.
   RESULTS. The CNV volume in EPA-fed animals was significantly suppressed compared with that in control mice, whereas the LA-rich diet did not affect CNV. The mRNA expression and protein levels of ICAM- 1, MCP-1, VEGF, and IL- 6 after CNV induction were significantly reduced in EPA-supplemented mice. In vitro, EPA application led to significant inhibition of mRNA and protein levels of ICAM- 1 and MCP-1 in endothelial cells and VEGF and IL- 6 in macrophages. EPA- fed mice exhibited significantly higher levels of EPA and lower levels of the omega-6 PUFA arachidonic acid in the serum and the RPE-choroid than control animals. EPA supplementation also led to significant reduction of serum levels of IL- 6 and CRP after CNV induction.
   CONCLUSIONS. The present study demonstrates for the first time that an EPA- rich diet results in significant suppression of CNV and CNV-related inflammatory molecules in vivo and in vitro. These results suggest that frequent consumption of omega-3 PUFAs may prevent CNV and lower the risk of blindness due to age-related macular degeneration.
C1 Keio Univ, Sch Med, Dept Ophthalmol, Lab Retinal Cell Biol,Shinjuku Ku, Tokyo 1608582, Japan.
   Keio Univ, Sch Med, Lab Vasc Biol & Metab, Tokyo, Japan.
C3 Keio University; Keio University
RP Ishida, S (通讯作者)，Keio Univ, Sch Med, Dept Ophthalmol, Lab Retinal Cell Biol,Shinjuku Ku, 35 Shinanomachi, Tokyo 1608582, Japan.
EM ishidasu@sc.itc.keio.ac.jp
RI Kurihara, Toshihide/ABA-7058-2020; Ozawa, Yoko/AAH-9888-2020
OI Kurihara, Toshihide/0000-0002-5457-2720; 
CR AMIN R, 1994, INVEST OPHTH VIS SCI, V35, P3178
   Belluzzi A, 2002, P NUTR SOC, V61, P391, DOI 10.1079/PNS2002171
   Calder PC, 2006, AM J CLIN NUTR, V83, p1505S, DOI 10.1093/ajcn/83.6.1505S
   Caughey GE, 1996, AM J CLIN NUTR, V63, P116, DOI 10.1093/ajcn/63.1.116
   Cho E, 2001, AM J CLIN NUTR, V73, P209
   Ciubotaru I, 2003, J NUTR BIOCHEM, V14, P513, DOI 10.1016/S0955-2863(03)00101-3
   Cleland LG, 2000, J RHEUMATOL, V27, P2305
   CollieDuguid ESR, 1996, BIOCHEM BIOPH RES CO, V220, P969, DOI 10.1006/bbrc.1996.0516
   Covington MB, 2004, AM FAM PHYSICIAN, V70, P133
   De Caterina R, 2000, AM J CLIN NUTR, V71, p213S, DOI 10.1093/ajcn/71.1.213S
   ENDRES S, 1989, NEW ENGL J MED, V320, P265, DOI 10.1056/NEJM198902023200501
   Espinosa-Heidmann DG, 2003, INVEST OPHTH VIS SCI, V44, P3586, DOI 10.1167/iovs.03-0038
   FOLCH J, 1957, J BIOL CHEM, V226, P497
   Fosslien E, 2005, ANN CLIN LAB SCI, V35, P347
   GIBNEY MJ, 1993, EUR J CLIN NUTR, V47, P255
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Grossniklaus HE, 2002, MOL VIS, V8, P119
   Healy DA, 2000, LIPIDS, V35, P763, DOI 10.1007/s11745-000-0583-1
   Iniguez MA, 2003, TRENDS MOL MED, V9, P73, DOI 10.1016/S1471-4914(02)00011-4
   Ishibashi T, 1997, GRAEF ARCH CLIN EXP, V235, P159, DOI 10.1007/BF00941723
   Ishida S, 2003, INVEST OPHTH VIS SCI, V44, P2155, DOI 10.1167/iovs.02-0807
   IWATA T, 1992, BIOMED CHROMATOGR, V6, P120, DOI 10.1002/bmc.1130060304
   Izumi-Nagai K, 2007, AM J PATHOL, V170, P2149, DOI 10.2353/ajpath.2007.061018
   Jiang CY, 1998, NATURE, V391, P82, DOI 10.1038/34184
   KLEIN R, 1995, INVEST OPHTH VIS SCI, V36, P182
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   Klein R, 2003, OPHTHALMOLOGY, V110, P636, DOI 10.1016/S0161-6420(02)01448-3
   Koh KK, 2005, J AM COLL CARDIOL, V46, P1978, DOI 10.1016/j.jacc.2005.06.082
   Krzystolik MG, 2002, ARCH OPHTHALMOL-CHIC, V120, P338
   Ku KS, 1996, TRANSPLANTATION, V62, P735, DOI 10.1097/00007890-199609270-00006
   Kvanta A, 1996, INVEST OPHTH VIS SCI, V37, P1929
   LEE TH, 1985, NEW ENGL J MED, V312, P1217, DOI 10.1056/NEJM198505093121903
   Li H, 2005, KIDNEY INT, V67, P867, DOI 10.1111/j.1523-1755.2005.00151.x
   Lopez-Garcia E, 2004, J NUTR, V134, P1806, DOI 10.1093/jn/134.7.1806
   Luft FC, 1999, HYPERTENSION, V33, P212, DOI 10.1161/01.HYP.33.1.212
   Maguire MG, 1997, ARCH OPHTHALMOL-CHIC, V115, P741
   MARESPERLMAN JA, 1995, ARCH OPHTHALMOL-CHIC, V113, P743, DOI 10.1001/archopht.1995.01100060069034
   Miles EA, 2000, ATHEROSCLEROSIS, V152, P43, DOI 10.1016/S0021-9150(99)00446-3
   Miyamoto K, 2000, AM J PATHOL, V156, P1733, DOI 10.1016/S0002-9440(10)65044-4
   Miyazaki M, 2003, BRIT J OPHTHALMOL, V87, P469, DOI 10.1136/bjo.87.4.469
   Nagai N, 2006, ARTERIOSCL THROM VAS, V26, P2252, DOI 10.1161/01.ATV.0000240050.15321.fe
   Nagata M, 2003, INT ARCH ALLERGY IMM, V131, P7, DOI 10.1159/000070474
   Nohe B, 2002, SHOCK, V18, P217, DOI 10.1097/00024382-200209000-00003
   Oh H, 1999, INVEST OPHTH VIS SCI, V40, P1891
   Owen AJ, 2004, LIPIDS, V39, P955, DOI 10.1007/s11745-004-1317-0
   Rakic JM, 2003, INVEST OPHTH VIS SCI, V44, P3186, DOI 10.1167/iovs.02-1092
   Rodriguez A, 1998, J LIPID RES, V39, P1825
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Sakurai E, 2003, INVEST OPHTH VIS SCI, V44, P2743, DOI 10.1167/iovs.02-1246
   Sakurai E, 2003, INVEST OPHTH VIS SCI, V44, P3578, DOI 10.1167/iovs.03-0097
   SanGiovanni JP, 2005, PROG RETIN EYE RES, V24, P87, DOI 10.1016/j.preteyeres.2004.06.002
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P774, DOI 10.1001/archopht.123.6.774
   Seddon JM, 2001, ARCH OPHTHALMOL-CHIC, V119, P1191, DOI 10.1001/archopht.119.8.1191
   Seddon JM, 2006, ARCH OPHTHALMOL-CHIC, V124, P995, DOI 10.1001/archopht.124.7.995
   Selvaraj RK, 2006, J NUTR, V136, P1610, DOI 10.1093/jn/136.6.1610
   Smith W, 2000, ARCH OPHTHALMOL-CHIC, V118, P401, DOI 10.1001/archopht.118.3.401
   SPERLING RI, 1993, J CLIN INVEST, V91, P651, DOI 10.1172/JCI116245
   Tsutsumi C, 2003, J LEUKOCYTE BIOL, V74, P25, DOI 10.1189/jlb.0902436
   van Leeuwen R, 2003, INVEST OPHTH VIS SCI, V44, P3771, DOI 10.1167/iovs.03-0121
   YANNUZZI LA, 1992, ARCH OPHTHALMOL-CHIC, V110, P1701
   Yokoyama M, 2007, LANCET, V369, P1090, DOI 10.1016/S0140-6736(07)60527-3
   Zhao GX, 2004, J NUTR, V134, P2991, DOI 10.1093/jn/134.11.2991
NR 62
TC 64
Z9 71
U1 0
U2 7
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD SEP
PY 2007
VL 48
IS 9
BP 4328
EP 4334
DI 10.1167/iovs.06-1148
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 204RO
UT WOS:000249061900059
PM 17724224
DA 2022-11-30
ER

PT J
AU Pedersen, R
   Soliman, W
   Lund-Andersen, H
   Larsen, M
AF Pedersen, Robert
   Soliman, Wael
   Lund-Andersen, Henrik
   Larsen, Michael
TI Treatment of choroidal neovascularization using intravitreal bevacizumab
SO ACTA OPHTHALMOLOGICA SCANDINAVICA
LA English
DT Article
DE bevacizumab; choroidal neovascularization; age-related macular
   degeneration; angioid streaks; retinal angiomatous proliferation;
   peripapillary neovascularization
ID MACULAR DEGENERATION; AVASTIN; RANIBIZUMAB; VERTEPORFIN; THERAPY;
   PRECIPITATION; SECONDARY; INJECTION; SAFETY; OCCULT
AB Purpose This study aimed to assess the pharmacodynamic profile of intravitreal bevacizumab in relation to best corrected visual acuity (BCVA), foveal thickness, and other aspects of macular morphology after intravitreal injection of bevacizumab in eyes with subretinal choroidal neovascularization (CNV).
   Methods A retrospective observational, uncontrolled case series including 26 eyes in 25 patients followed for up to 6 months after intravitreal injection of bevacizumab 1 mg repeated as deemed necessary after monthly assessments by biomicroscopy, optical coherence tomography, colour fundus photography, fluorescein angiography and BCVA determination. At follow-up, cases were classified by morphological treatment response (reduction or elimination of pathological neovascular leakage, retinal thickening or serous retinal detachment) or absence of response (deterioration or lack of improvement). Primary disease entities included age-related macular degeneration (22 eyes, four of which had evidence of retinal angiomatous proliferation), idiopathic peripapillary neovascularization (one eye), and angioid streaks (three eyes in two patients).
   Results: One month after the first injection, apparent morphological improvement was observed in 24/26 eyes and mean BCVA had improved by 3.1 +/- 7.8 letters (p = 0.05). Of these 24 responders, which included all primary diagnoses, 11 (46%) demonstrated BCVA improvement of >= 5 letters. The two non-responders (7.7%) had lost > 3 lines of vision at 2 months follow-up. Overall, 18 eyes completed 6 months follow-up, with a mean BCVA improvement of 0.5 +/- 12.7 letters, and 22 eyes completed 3 months follow-up, with a mean BCVA improvement of 2.0 +/- 11.0 letters. Two months after the first injection, 11 (46%) of the 24 responders demonstrated signs of recurrent CNV activity, defined as decreased BCVA and/or increased retinal thickness and/or fluorescein angiographic CNV leakage. No serious drug-related adverse events were observed during the course of the study.
   Conclusions: Overall mean BCVA remained stable throughout the study. Morphological signs of reduced CNV activity were seen in the majority of eyes at 2-4 weeks after intravitreal bevacizumab injection. Half the responders showed signs of renewed CNV activity at 2 months after their first injection. All first-injection responders were also second-injection responders.
C1 Univ Copenhagen, Glostrup Cty Hosp, Dept Ophthalmol, DK-2600 Glostrup, Denmark.
   NEI, Copenhagen, Denmark.
C3 University of Copenhagen
RP Soliman, W (通讯作者)，Univ Copenhagen, Glostrup Cty Hosp, Dept Ophthalmol, Nodre Ringvej 57, DK-2600 Glostrup, Denmark.
EM waelsoliman73@yahoo.com
RI Larsen, Michael/E-9620-2010; Soliman, Wael/K-2456-2012
OI Larsen, Michael/0000-0002-5172-5891; Soliman, Wael/0000-0002-3548-8267
CR Avery RL, 2006, OPHTHALMOLOGY, V113, P363, DOI 10.1016/j.ophtha.2005.11.019
   Bashshur ZF, 2006, AM J OPHTHALMOL, V142, P1, DOI 10.1016/j.ajo.2006.02.037
   Beer PM, 2006, RETINA-J RET VIT DIS, V26, P871, DOI 10.1097/01.iae.0000233327.68433.02
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Christoffersen N, 1998, AM J OPHTHALMOL, V126, P454, DOI 10.1016/S0002-9394(98)00107-X
   Dhalla MS, 2006, AM J OPHTHALMOL, V141, P752, DOI 10.1016/j.ajo.2005.10.053
   Fung AE, 2006, BRIT J OPHTHALMOL, V90, P1344, DOI 10.1136/bjo.2006.099598
   Gaudreault J, 2005, INVEST OPHTH VIS SCI, V46, P726, DOI 10.1167/iovs.04-0601
   Kaiser PK, 2006, GRAEF ARCH CLIN EXP, V244, P1132, DOI 10.1007/s00417-005-0199-9
   Laud K, 2006, RETINA-J RET VIT DIS, V26, P960, DOI 10.1097/01.iae.0000240121.28034.c3
   Luke M, 2006, BRIT J OPHTHALMOL, V90, P1178, DOI 10.1136/bjo.2006.094995
   Manzano RPA, 2006, RETINA-J RET VIT DIS, V26, P257, DOI 10.1097/00006982-200603000-00001
   Maturi RK, 2006, RETINA-J RET VIT DIS, V26, P270, DOI 10.1097/00006982-200603000-00003
   Meyer CH, 2006, BRIT J OPHTHALMOL, V90, P1207, DOI 10.1136/bjo.2006.093732
   Michels S, 2005, OPHTHALMOLOGY, V112, P1035, DOI 10.1016/j.ophtha.2005.02.007
   Nguyen QD, 2005, BRIT J OPHTHALMOL, V89, P1368, DOI 10.1136/bjo.2005.066431
   Pieramici DJ, 2006, ARCH OPHTHALMOL-CHIC, V124, P660
   Rich RM, 2006, RETINA-J RET VIT DIS, V26, P495, DOI 10.1097/01.iae.0000225766.75009.3a
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rosenfeld PJ, 2006, AM J OPHTHALMOL, V142, P141, DOI 10.1016/j.ajo.2006.03.036
   Shahar J, 2006, RETINA-J RET VIT DIS, V26, P262, DOI 10.1097/00006982-200603000-00002
   Soliman W, 2006, ACTA OPHTHALMOL SCAN, V84, P707, DOI 10.1111/j.1600-0420.2006.00736.x
   Spaide RF, 2006, RETINA-J RET VIT DIS, V26, P383, DOI 10.1097/00006982-200604000-00001
   Taarnhoj NCBB, 2003, INVEST OPHTH VIS SCI, V44, P1680, DOI 10.1167/iovs.01-1132
   Yamamoto I, 2007, BRIT J OPHTHALMOL, V91, P157, DOI 10.1136/bjo.2006.096776
NR 25
TC 56
Z9 62
U1 0
U2 1
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1395-3907
J9 ACTA OPHTHALMOL SCAN
JI Acta Ophthalmol. Scand.
PD AUG
PY 2007
VL 85
IS 5
BP 526
EP 533
DI 10.1111/j.1600-0420.2007.00895.x
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 193OF
UT WOS:000248282700008
PM 17511757
DA 2022-11-30
ER

PT J
AU Peters, S
   Lamah, T
   Kokkinou, D
   Bartz-Schmidt, KU
   Schraermeyer, U
AF Peters, Swaantie
   Lamah, Thomas
   Kokkinou, Despina
   Bartz-Schmidt, Karl-Ulrich
   Schraermeyer, Ulrich
TI Melanin protects choroidal blood vessels against light toxicity
SO ZEITSCHRIFT FUR NATURFORSCHUNG C-A JOURNAL OF BIOSCIENCES
LA English
DT Article
DE melanin; RPE; light toxicity
ID MACULAR DEGENERATION; MECHANISM; RETINA; ALBINO; DAMAGE; RAT
AB Low ocular pigmentation and high long-term exposure to bright light are believed to increase the risk of developing age-related macular degeneration (ARMD). To investigate the role of pigmentation during bright light exposure, cell damage in retinae and choroids of pigmented and non-pigmented rats were compared. Pigmented Long Evans (LE) rats and non-pigmented (albino) Wistar rats were exposed to high intensity visible light from a cold light source with 140,000 lux for 30 min. Control animals of both strains were not irradiated. The animals had their pupils dilated to prevent light absorbance by iris pigmentation. 22 h after irradiation, the rats were sacrificed and their eyes enucleated. Posterior segments, containing retina and choroid, were prepared for light and electron microscopy. Twenty different sections of specified and equal areas were examined in every eye. In albino rats severe retinal damage was observed after light exposure, rod outer segments (ROS) were shortened and the thickness of the outer nuclear layer (ONL) was significantly diminished. Choriocapillaris blood vessels were obstructed. In wide areas the retinal pigment epithelium (RPE) was absent in albino rats after irradiation. In contrast, LE rats presented much less cell damage in the RPE and retina after bright light exposure, although intra-individual differences were observed. The thickness of the ONL was almost unchanged compared to controls. ROS were shortened in LE rats, but the effect was considerably less than that seen in the albinos. Only minimal changes were found in choroidal blood vessels of pigmented rats. The RPE showed certain toxic damage, but cells were not destroyed as in the non-pigmented animals. The number of melanin granules in the RPE of LE rats was reduced after irradiation. Ocular melanin protects the retina and choroid of pigmented eyes against light-induced cell toxicity. Physical protection of iris melanin, as possible in eyes with non-dilated pupils, does not seem to play a major role in our setup. Biochemical mechanisms, like reducing oxidative intracellular stress, are more likely to be responsible for melanin-related light protection in eyes with dilated lens aperture.
C1 Univ Tubingen, Ctr Ophthalmol, D-72076 Tubingen, Germany.
   Univ Cologne, Dept Anat 1, D-50931 Cologne, Germany.
C3 Eberhard Karls University of Tubingen; Eberhard Karls University
   Hospital; University of Cologne
RP Peters, S (通讯作者)，Univ Tubingen, Ctr Ophthalmol, Schleichstr 12, D-72076 Tubingen, Germany.
EM Swaantje.Peters@med.uni-tuebingen.de
CR BOETTNER EA, 1962, INVEST OPHTH VISUAL, V1, P776
   COLLIER RJ, 1989, INVEST OPHTH VIS SCI, V30, P631
   GLICKMAN RD, 1992, PHOTOCHEM PHOTOBIOL, V55, P191, DOI 10.1111/j.1751-1097.1992.tb04227.x
   Gorgels TGMF, 1998, EXP EYE RES, V66, P155, DOI 10.1006/exer.1997.0416
   GREGOR Z, 1978, BRIT J OPHTHALMOL, V62, P547, DOI 10.1136/bjo.62.8.547
   Kayatz P, 1999, INVEST OPHTH VIS SCI, V40, P2314
   KORYTOWSKI W, 1985, BIOCHEM BIOPH RES CO, V131, P659, DOI 10.1016/0006-291X(85)91288-4
   KUWABARA T, 1979, RETINAL PIGMENT EPIT, V17, P293
   Memoli S, 1997, BBA-LIPID LIPID MET, V1346, P61, DOI 10.1016/S0005-2760(97)00018-0
   Noell W K, 1966, Invest Ophthalmol, V5, P450
   PARVER LM, 1980, AM J OPHTHALMOL, V89, P641, DOI 10.1016/0002-9394(80)90280-9
   PUTTING BJ, 1994, EXP EYE RES, V58, P31, DOI 10.1006/exer.1994.1192
   RAPP LM, 1992, EXP EYE RES, V54, P55, DOI 10.1016/0014-4835(92)90069-5
   Rimbach G, 1996, Z ERNAHRUNGSWISS, V35, P123, DOI 10.1007/BF01622861
   SANYAL S, 1988, EXP EYE RES, V46, P731, DOI 10.1016/S0014-4835(88)80059-9
   SARNA T, 1992, J PHOTOCH PHOTOBIO B, V12, P215, DOI 10.1016/1011-1344(92)85027-R
   Undas A, 2005, THROMB HAEMOSTASIS, V94, P907, DOI 10.1160/TH05-05-0313
   WEITER JJ, 1985, AM J OPHTHALMOL, V99, P185, DOI 10.1016/0002-9394(85)90230-2
   YOUNG RW, 1988, SURV OPHTHALMOL, V32, P252, DOI 10.1016/0039-6257(88)90174-9
NR 19
TC 26
Z9 27
U1 1
U2 5
PU VERLAG Z NATURFORSCH
PI TUBINGEN
PA POSTFACH 2645, W-7400 TUBINGEN, GERMANY
SN 0939-5075
J9 Z NATURFORSCH C
JI Z.Naturforsch.(C)
PD MAY-JUN
PY 2006
VL 61
IS 5-6
BP 427
EP 433
PG 7
WC Biochemistry & Molecular Biology; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Pharmacology & Pharmacy
GA 069KH
UT WOS:000239444300020
PM 16869503
DA 2022-11-30
ER

PT J
AU Gross, N
   Bachmann, LM
   Islam, M
   Faes, L
   Schmid, MK
   Thiel, MA
   Schimel, A
   Sim, DA
AF Gross, Nico
   Bachmann, Lucas M.
   Islam, Meriam
   Faes, Livia
   Schmid, Martin K.
   Thiel, Michael A.
   Schimel, Andrew
   Sim, Dawn A.
TI Visual outcomes and treatment adherence of patients with macular
   pathology using a mobile hyperacuity home-monitoring app: a matched-pair
   analysis
SO BMJ OPEN
LA English
DT Article
DE diabetic retinopathy; medical retina; medical ophthalmology
ID RANDOMIZED-TRIAL; DEGENERATION; ACCURACY; SYSTEM
AB Objective We compared patients with neovascular age-related macular degeneration (nvAMD), diabetic macular oedema (DMO) and other macular pathologies testing their vision with the hyperacuity home-monitoring app Alleye to patients not performing home-monitoring regarding clinical outcomes and clinical management. Design Matched-pair analysis. Setting Retina Referral Centre, Switzerland. Participants For each eye using Alleye, we matched 2-4 controls not using home-monitoring based on age, gender, number of previous intravitreal injections (IVI), best corrected visual acuity (BCVA) (Early Treatment Diabetic Retinopathy Study letters), central macular thickness (CRT) and time point of enrolment, using the Mahalanobis distance matching algorithm. We included 514 eyes (288 patients); 107 eyes with nvAMD using home monitoring and 218 controls not using home monitoring, 25 eyes with DMO (n=52 controls) and 40 eyes with miscellaneous conditions (n=72 controls). 173 eyes (33.7%) received no IVI during follow-up. Main outcome measures Improvement of >= 5 letters, number of injection visits and treatment retention after correcting for differences in baseline characteristics with multivariate analyses. Results The mean follow-up duration was 809 days (range 147-1353) and the mean number of IVI/year among treated eyes was 6.7 (SD 3.1). Mean age at baseline was 70.4 years (SD 10.9), BCVA was 77.6 letters (SD 11.6) and CRT was 263.6 mu m (SD 86.7) and was similar between patients using and not using home monitoring. In multivariate analyses, patients using home monitoring had a higher chance to improve visual acuity by >= 5 letters (OR 1.67 (95% CI 1.01 to 2.76; p=0.044)) than controls. Treated eyes using home monitoring had less injection visits/year (-0.99 (95% CI -1.59 to -0.40; p=0.001)) and a longer treatment retention +69.2 days (95% CI 2.4 to 136.0; p=0.042). These effects were similar across retinal pathologies. Conclusions This data suggest that patients capable of performing mobile hyperacuity home monitoring benefit in terms of visual acuity and discontinue treatment less often than patients not using home monitoring.
C1 [Gross, Nico] Cantonal Hosp Lucerne, Eye Clin, Luzern, Switzerland.
   [Gross, Nico; Bachmann, Lucas M.] Univ Zurich, Fac Med, Zurich, Switzerland.
   [Bachmann, Lucas M.] Medignition AG, Res, Zurich, Switzerland.
   [Islam, Meriam] UCL, Inst Ophthalmol, London, England.
   [Islam, Meriam; Faes, Livia; Sim, Dawn A.] Moorfields Eye Hosp NHS Fdn Trust, Med Retina Dept, London, England.
   [Faes, Livia; Schmid, Martin K.; Thiel, Michael A.] Luzern Kantonsspital, Eye Clin, Luzern, Switzerland.
   [Schimel, Andrew] Univ Miami, Dept Ophthalmol, Ctr Excellence Eye Care, Miami, FL USA.
   [Sim, Dawn A.] Moorfields Eye Hosp NHS Fdn Trust, NIHR Biomed Res Ctr Ophthalmol, London, England.
C3 Lucerne Cantonal Hospital; University of Geneva; University of Zurich;
   University of London; University College London; University of London;
   University College London; Moorfields Eye Hospital NHS Foundation Trust;
   Lucerne Cantonal Hospital; University of Miami; University of London;
   University College London; Moorfields Eye Hospital NHS Foundation Trust
RP Bachmann, LM (通讯作者)，Univ Zurich, Fac Med, Zurich, Switzerland.; Bachmann, LM (通讯作者)，Medignition AG, Res, Zurich, Switzerland.
EM bachmann@medignition.ch
OI Sim, Dawn/0000-0002-6363-7805; , Lucas/0000-0002-9868-154X
CR [Anonymous], 2020, SELF CARE INTERVENTI
   Chew EY, 2014, CONTEMP CLIN TRIALS, V37, P294, DOI 10.1016/j.cct.2014.02.003
   Chew EY, 2014, OPHTHALMOLOGY, V121, P535, DOI 10.1016/j.ophtha.2013.10.027
   Faes L, 2021, EYE, V35, P3035, DOI 10.1038/s41433-020-01356-2
   Faes L, 2021, BRIT J OPHTHALMOL, V105, P1738, DOI 10.1136/bjophthalmol-2020-316882
   Faes L, 2020, EYE, V34, P1950, DOI 10.1038/s41433-020-0964-3
   FRYBACK DG, 1991, MED DECIS MAKING, V11, P88, DOI 10.1177/0272989X9101100203
   Islam M, 2021, BMJ HEALTH CARE INFO, V28, DOI 10.1136/bmjhci-2020-100310
   Jones PR, 2021, AM J OPHTHALMOL, V223, P42, DOI 10.1016/j.ajo.2020.08.039
   Kaiser PK, 2013, RETINA-J RET VIT DIS, V33, P1863, DOI 10.1097/IAE.0b013e3182899258
   Ko MW, 2020, J NEURO-OPHTHALMOL, V40, P378, DOI 10.1097/WNO.0000000000001038
   Letourneur D, 2021, ADV HEALTHC MATER, V10, DOI 10.1002/adhm.202001237
   Li JPO, 2021, PROG RETIN EYE RES, V82, DOI 10.1016/j.preteyeres.2020.100900
   Pawson R, 2019, J CLIN EPIDEMIOL, V107, P71, DOI 10.1016/j.jclinepi.2018.11.020
   Ravizza A, 2019, FRONT BIOENG BIOTECH, V7, DOI 10.3389/fbioe.2019.00313
   Rubin DB, 2006, MATCHED SAMPLING FOR CAUSAL EFFECTS, P1, DOI 10.2277/ 0521674360
   Schmid MK, 2019, EYE, V33, P1584, DOI 10.1038/s41433-019-0455-6
   Schmid MK, 2018, OPEN OPHTHALMOL J, V12, P19, DOI 10.2174/1874364101812010019
   Temesgen ZM, 2020, MAYO CLIN PROC, V95, pS66, DOI 10.1016/j.mayocp.2020.06.052
   WACHOLDER S, 1992, AM J EPIDEMIOL, V135, P1029, DOI 10.1093/oxfordjournals.aje.a116397
NR 20
TC 2
Z9 2
U1 0
U2 1
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 2044-6055
J9 BMJ OPEN
JI BMJ Open
PD DEC
PY 2021
VL 11
IS 12
AR e056940
DI 10.1136/bmjopen-2021-056940
PG 7
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA XX1AZ
UT WOS:000736039200015
PM 34949632
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Kim, HR
   Kim, S
   Lee, SW
   Sin, HS
   Kim, SY
AF Kim, Ha-Rim
   Kim, Sol
   Lee, Sang-Wang
   Sin, Hong-Sig
   Kim, Seon-Young
TI Protective Effects of Fermented Paprika (Capsicum annuum L.) on Sodium
   Iodate-Induced Retinal Damage
SO NUTRIENTS
LA English
DT Article
DE age-related macular degeneration; oxidative stress; Capsicum annuum L;
   (paprika); fermentation; antiiflammation
AB Diseases of the outer retina, including age-related macular degeneration (AMD), are major cause of permanent visual damage. The pathogenesis of AMD involves oxidative stress and damage of the retinal pigment epithelium. Capsicum annuum L. (paprika) fruits have been known as a source of vitamins, carotenoids, phenolic compounds, and metabolites with a well-known antioxidant activity, which have positive effects on human health and protection against AMD and cataracts. In this study, we investigated whether paprika (fermented (FP), yellow, and orange colored) fermented with Lactobacillus (L.) plantarum could increase the protective effect of retinal degeneration using in vitro and in vivo models. FP significantly increased cell survival and reduced levels of lactate dehydrogenase as well as intracellular reactive oxygen species (ROS) increase in SI (sodium iodate, NaIO3)-treated human retinal pigment epithelial (ARPE-19) cells. We developed a model of retinal damage in C57BL/6 mice using SI (30 mg/kg) via intraperitoneal injection. Seven days after SI administration, deformation and a decrease in thickness were observed in the outer nuclear layer, but improved by FP treatment. FP administration protected the SI-mediated reduction of superoxide dismutase and glutathione levels in the serum and ocular tissues of mice. The overproduction of cleaved poly(ADP-Ribose) Polymerase (PARP)1, caspase-3 and -8 proteins were significantly protected by FP in SI-treated cells and ocular tissues. In addition, we evaluated the potentiating effects of FP on antioxidants and their underlying mechanisms in RAW 264.7 cells. Lipopolysaccharide (LPS)-induced nitrite increase was markedly blocked by FP treatment in RAW 264.7 cells. Furthermore, FP reduced LPS-induced inducible nitric oxide synthase and cyclooxygenase-2 activation. The FP also enhanced the inhibitory effects on mitogen activated kinase signaling protein activation in ARPE-19 and RAW 264.7 cells and ocular tissues. There was no significant difference in total phenol and flavonoid content in paprika by fermentation, but the vitamin C content was increased in orange colored paprika, and protective effect against oxidative stress-mediated retinal damage was enhanced after fermentation. These results suggest that FP may be a potential candidate to protect against retinal degenerative diseases through the regulation of oxidative stress.
C1 [Kim, Ha-Rim; Kim, Sol; Kim, Seon-Young] Jeonju AgroBiomat Inst, Wonjangdong Gil 111-27, Jeonju Si 54810, Jeollabuk Do, South Korea.
   [Lee, Sang-Wang; Sin, Hong-Sig] Chebigen Co Ltd, Jeonju 54853, South Korea.
RP Kim, SY (通讯作者)，Jeonju AgroBiomat Inst, Wonjangdong Gil 111-27, Jeonju Si 54810, Jeollabuk Do, South Korea.
EM poshrim@jami.re.kr; sol0819@jami.re.kr; molegene74@hanmail.net;
   shsdo@hanmail.net; Seon02@jami.re.kr
FU Technology development Program - Ministry of SMEs and Startups (MSS,
   Korea) [S2653090]
FX This work was supported by the Technology development Program (S2653090)
   funded by the Ministry of SMEs and Startups (MSS, Korea).
CR ANDERSON RE, 1984, CURR EYE RES, V3, P223, DOI 10.3109/02713688408997203
   Ao J, 2018, CLIN EXP OPHTHALMOL, V46, P670, DOI 10.1111/ceo.13121
   Balmer J, 2015, INT J MOL SCI, V16, P15086, DOI 10.3390/ijms160715086
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Campagne MV, 2014, J PATHOL, V232, P151, DOI 10.1002/path.4266
   Chen CC, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0158662
   Chinskey ND, 2014, CURR OPIN OPHTHALMOL, V25, P228, DOI 10.1097/ICU.0000000000000043
   Due WW, 2018, OXID MED CELL LONGEV, V2018, DOI 10.1155/2018/1610751
   EIGLER A, 1995, J IMMUNOL, V154, P4048
   Enzmann V, 2006, EXP EYE RES, V82, P441, DOI 10.1016/j.exer.2005.08.002
   Faghiri Z, 2010, EXP EYE RES, V90, P718, DOI 10.1016/j.exer.2010.03.002
   Floegel A., 2010, FASEB J, V24, P535, DOI [10.1096/fasebj.24.1_supplement.535.9, DOI 10.1096/FASEBJ.24.1_SUPPLEMENT.535.9]
   Gastman BR, 2000, BLOOD, V95, P2015, DOI 10.1182/blood.V95.6.2015
   Hao YM, 2019, NUTRIENTS, V11, DOI 10.3390/nu11071515
   He L, 2017, CELL PHYSIOL BIOCHEM, V44, P532, DOI 10.1159/000485089
   Hur SJ, 2014, FOOD CHEM, V160, P346, DOI 10.1016/j.foodchem.2014.03.112
   Torino MI, 2013, FOOD CHEM, V136, P1030, DOI 10.1016/j.foodchem.2012.09.015
   Jabbehdari S, 2021, SURV OPHTHALMOL, V66, P423, DOI 10.1016/j.survophthal.2020.09.002
   Khan FA, 2014, NAT PROD RES, V28, P1267, DOI 10.1080/14786419.2014.895723
   Kim HR, 2019, NUTRIENTS, V11, DOI 10.3390/nu11102429
   Kyosseva SV, 2016, OPHTHALMOL EYE DIS, V8, P23, DOI 10.4137/OED.S32200
   Li ZX, 2019, MOLECULES, V24, DOI 10.3390/molecules24010051
   Liu CD, 1999, J NEUROSCI, V19, P4778
   Pujol-Lereis LM, 2016, ADV EXP MED BIOL, V854, P87, DOI 10.1007/978-3-319-17121-0_13
   Sanvicens N, 2004, J BIOL CHEM, V279, P39268, DOI 10.1074/jbc.M402202200
   Silva LR, 2013, FOOD CHEM TOXICOL, V53, P240, DOI 10.1016/j.fct.2012.11.036
   Singh PK, 2016, CELL DEATH DISCOV, V2, DOI 10.1038/cddiscovery.2016.34
   Stanisavljevic N, 2015, FOOD CHEM, V175, P516, DOI 10.1016/j.foodchem.2014.12.009
   Sun T, 2007, J FOOD SCI, V72, pS98, DOI 10.1111/j.1750-3841.2006.00245.x
   Wang JM, 2014, INVEST OPHTH VIS SCI, V55, P1941, DOI 10.1167/iovs.13-13075
   Wang Z, 2014, J MED BIOL ENG, V3, P67
   Wei XT, 2011, J AGR FOOD CHEM, V59, P3957, DOI 10.1021/jf1049535
   Yan YH, 2019, FOOD CHEM TOXICOL, V131, DOI 10.1016/j.fct.2019.05.049
   Yang M, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21197279
   Yang YP, 2016, SCI REP-UK, V6, DOI 10.1038/srep29546
NR 35
TC 3
Z9 3
U1 5
U2 9
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2072-6643
J9 NUTRIENTS
JI Nutrients
PD JAN
PY 2021
VL 13
IS 1
AR 25
DI 10.3390/nu13010025
PG 15
WC Nutrition & Dietetics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Nutrition & Dietetics
GA PW4KS
UT WOS:000610640600001
PM 33374795
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Duncan, RS
   Rohowetz, L
   Vogt, A
   Koulen, P
AF Duncan, R. Scott
   Rohowetz, Landon
   Vogt, Alex
   Koulen, Peter
TI Repeat exposure to polyinosinic:polycytidylic acid induces TLR3
   expression via JAK-STAT signaling and synergistically potentiates NF
   kappa B-RelA signaling in ARPE-19 cells
SO CELLULAR SIGNALLING
LA English
DT Article
DE Age-related macular degeneration; Retinal pigment epithelium; ARPE-19;
   Toll-like receptor; Nuclear factor kappa B; Innate immunity
ID PIGMENT EPITHELIAL-CELLS; INNATE IMMUNE-RESPONSE; NITRIC-OXIDE SYNTHASE;
   TOLL-LIKE RECEPTORS; GENE-EXPRESSION; RECOGNITION RECEPTORS;
   IKK-EPSILON; ACTIVATION; PROMOTER; INFLAMMATION
AB Dry age-related macular degeneration (AMD), accounting for approximately 90% of AMD cases, is characterized by photoreceptor death, retinal pigment epithelium (RPE) dysfunction and, ultimately, geographic atrophy - the localized death of RPE leading to loss of the center of the visual field. The pathological etiology of AMD is multifactorial, but innate immune signaling and inflammation are involved in early stages of the disease. Although numerous single-nucleotide polymorphisms in innate immune genes are associated with dry AMD, no single gene appears to cause dry AMD.
   Here, we hypothesized that activation of TLR3 potentiates expression of TLR3 itself and the NF kappa B-p65 (RelA) subunit as part of pro-inflammatory RPE signaling. Furthermore, we hypothesized that TLR3 activation can 'prime' cells to future RelA stimulation, leading to enhanced, persistent RelA expression and signaling following a second TLR3 activation. We used the human RPE-derived cell line ARPE-19 as a model system for RPE signaling and measured NF kappa B expression and activity in response to TLR3 stimulation with its ligand, poly-inosinic:polycytidylic acid (pl:C).
   Activation of TLR3 with pl:C led to increased TLR3 and RelA expression that was sustained for at least 24 h. Cells exposed for a second time to pl:C after an initial pl:C exposure displayed elevated RelA expression and RelA nuclear translocation above the level generated by individual primary or secondary exposures alone. Such an elevated response could also not be generated by a single application of higher concentrations of the agonist pI:C. Additionally, we determined the mechanism for TLR3 mediated TLR3 and RelA expression by using in-hibitors of canonical TLR3-TBK1-IKK epsilon and JAK-STAT signaling pathways.
   These data suggest that initial exposure of ARPE-19 cells to pI:C upregulates TLR3 and RelA signaling, leading to potentiated and persistent RelA signaling potentially generated by a positive feedback loop that may cause exacerbated inflammation in AMD. Furthermore, inhibition of JAK-STAT signaling may be a possible therapeutic treatment to prevent induction of TLR3 expression subsequent to pI:C exposure. Our results identify possible therapeutic targets to reduce the TLR3 positive feedback loop and subsequent overproduction of pro-in-flammatory cytokines in RPE cells.
C1 [Duncan, R. Scott; Rohowetz, Landon; Vogt, Alex; Koulen, Peter] Univ Missouri, Vis Res Ctr, Sch Med, Dept Ophthalmol, 2411 Holmes St, Kansas City, MO 64108 USA.
   [Koulen, Peter] Univ Missouri, Sch Med, Dept Biomed Sci, 2411 Holmes St, Kansas City, MO 64108 USA.
C3 University of Missouri System; University of Missouri Kansas City;
   University of Missouri System; University of Missouri Kansas City
RP Duncan, RS (通讯作者)，Univ Missouri, Vis Res Ctr, Sch Med, Dept Ophthalmol, 2411 Holmes St, Kansas City, MO 64108 USA.
EM duncanrs@umkc.edu
RI Rohowetz, Landon/AIC-4846-2022; Rohowetz, Landon/M-1167-2019
OI Rohowetz, Landon/0000-0002-5403-421X; Rohowetz,
   Landon/0000-0002-5403-421X
FU Felix and Carmen Sabates/Missouri Endowed Chair in Vision Research; UMKC
   Project ADVANCER (Academic Development Via Applied and Cutting-Edge
   Research) award; Sarah Morrison award (UMKC School of Medicine)
FX This work was funded by the Felix and Carmen Sabates/Missouri Endowed
   Chair in Vision Research (P-K), UMKC Project ADVANCER (Academic
   Development Via Applied and Cutting-Edge Research) award (L.R.) and
   Sarah Morrison award (UMKC School of Medicine) (L.R.).
CR Bach NS, 2014, TOXICOL LETT, V228, P42, DOI 10.1016/j.toxlet.2014.03.021
   Bode KA, 2009, J IMMUNOL, V182, P2176, DOI 10.4049/jimmunol.0802560
   Boivin N, 2008, J INFECT DIS, V198, P664, DOI 10.1086/590671
   Brosig A, 2015, MOL VIS, V21, P1000
   Brown EE, 2018, ADV EXP MED BIOL, V1074, P11, DOI 10.1007/978-3-319-75402-4_2
   Bsibsi M, 2002, J NEUROPATH EXP NEUR, V61, P1013, DOI 10.1093/jnen/61.11.1013
   Buschini E, 2015, CLIN OPHTHALMOL, V9, P563, DOI 10.2147/OPTH.S59724
   Changelian PS, 2003, SCIENCE, V302, P875, DOI 10.1126/science.1087061
   Chen M, 2016, CYTOKINE, V78, P94, DOI 10.1016/j.cyto.2015.09.014
   COGSWELL PC, 1993, J IMMUNOL, V150, P2794
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Dai XJ, 2006, J INVEST DERMATOL, V126, P1574, DOI 10.1038/sj.jid.5700294
   Detrick B, 1996, INVEST OPHTH VIS SCI, V37, P814
   Dokladny K, 2010, CELL STRESS CHAPERON, V15, P153, DOI 10.1007/s12192-009-0129-6
   Duncan RS, 2009, MOL NEURODEGENER, V4, DOI 10.1186/1750-1326-4-50
   Dunn KC, 2016, GLOBAL PUNK: RESISTANCE AND REBELLION IN EVERYDAY LIFE, P61
   Edwards AO, 2008, INVEST OPHTH VIS SCI, V49, P1652, DOI 10.1167/iovs.07-1378
   Ernst O, 2018, METHODS MOL BIOL, V1714, P67, DOI 10.1007/978-1-4939-7519-8_5
   Finnemann SC, 1997, P NATL ACAD SCI USA, V94, P12932, DOI 10.1073/pnas.94.24.12932
   Fitzgerald KA, 2003, NAT IMMUNOL, V4, P491, DOI 10.1038/ni921
   Fragale A, 2011, J IMMUNOL, V186, P1951, DOI 10.4049/jimmunol.1000918
   Gilad E, 1998, FASEB J, V12, P685, DOI 10.1096/fasebj.12.9.685
   Goodbourn S, 1990, Semin Cancer Biol, V1, P89
   GORDON WC, 1992, CURR EYE RES, V11, P73, DOI 10.3109/02713689209069169
   Heinz S, 2003, J BIOL CHEM, V278, P21502, DOI 10.1074/jbc.M301476200
   HISCOTT J, 1993, MOL CELL BIOL, V13, P6231, DOI 10.1128/MCB.13.10.6231
   Ishizuka EK, 2016, SCI REP-UK, V6, DOI 10.1038/srep32092
   Jamilloux Y, 2019, AUTOIMMUN REV, V18, DOI 10.1016/j.autrev.2019.102390
   Kaarniranta K, 2009, J MOL MED, V87, P117, DOI 10.1007/s00109-008-0418-z
   Kaarniranta K, 2019, BIOCHIMIE, V159, P49, DOI 10.1016/j.biochi.2018.07.010
   Kaja S, 2011, NEUROSCIENCE, V175, P281, DOI 10.1016/j.neuroscience.2010.11.010
   Kariko K, 2004, J BIOL CHEM, V279, P12542, DOI 10.1074/jbc.M310175200
   Kashani-Sabet M, 2004, J CLIN ONCOL, V22, P617, DOI 10.1200/JCO.2004.06.047
   Kaur I, 2006, INVEST OPHTH VIS SCI, V47, P3729, DOI 10.1167/iovs.05-1430
   Kawasaki M, 2014, J COSMOL ASTROPART P, DOI 10.1088/1475-7516/2014/02/001
   Kutty RK, 2013, MOL VIS, V19, P737
   KWON G, 1995, ENDOCRINOLOGY, V136, P4790, DOI 10.1210/en.136.11.4790
   LEBAIL O, 1993, EMBO J, V12, P5043, DOI 10.1002/j.1460-2075.1993.tb06197.x
   LENARDO MJ, 1989, CELL, V58, P227, DOI 10.1016/0092-8674(89)90833-7
   Liu P, 2007, J VIROL, V81, P1401, DOI 10.1128/JVI.01740-06
   Liu ZM, 2016, AM J TRANSL RES, V8, P4764
   Lv SH, 2017, CELL DEATH DIFFER, V24, P492, DOI 10.1038/cdd.2016.148
   Ma LH, 2016, SCI REP-UK, V6, DOI 10.1038/srep32702
   Makhoul M, 2012, ACTA OPHTHALMOL, V90, pE38, DOI 10.1111/j.1755-3768.2011.02241.x
   McCluskie K, 2004, J PHARMACOL EXP THER, V311, P625, DOI 10.1124/jpet.104.068890
   Mulfaul K, 2018, ADV EXP MED BIOL, V1074, P19, DOI 10.1007/978-3-319-75402-4_3
   Munoz-Erazo L, 2012, MOL VIS, V18, P730
   Murakami M, 2013, CELL REP, V3, P946, DOI 10.1016/j.celrep.2013.01.028
   Nava M, 2003, AM J PHYSIOL-RENAL, V284, pF447, DOI 10.1152/ajprenal.00264.2002
   de Diego RP, 2013, J ALLERGY CLIN IMMUN, V131, P1157, DOI 10.1016/j.jaci.2013.01.008
   Pestka J, 2006, TOXICOL SCI, V92, P445, DOI 10.1093/toxsci/kfl012
   Pomerantz JL, 1999, EMBO J, V18, P6694, DOI 10.1093/emboj/18.23.6694
   Reilly SM, 2013, NAT MED, V19, P313, DOI 10.1038/nm.3082
   Ren G, 2015, CELL BIOSCI, V5, DOI 10.1186/s13578-015-0007-0
   ROBBINS SG, 1992, INVEST OPHTH VIS SCI, V33, P60
   Rueden CT, 2017, BMC BIOINFORMATICS, V18, DOI 10.1186/s12859-017-1934-z
   SAIJO T, 1985, INT ARCH ALLER A IMM, V77, P315, DOI 10.1159/000233837
   Sarkar SN, 2004, NAT STRUCT MOL BIOL, V11, P1060, DOI 10.1038/nsmb847
   Sasai M, 2013, INT REV IMMUNOL, V32, P116, DOI 10.3109/08830185.2013.774391
   Schindelin J, 2012, NAT METHODS, V9, P676, DOI [10.1038/NMETH.2019, 10.1038/nmeth.2019]
   Schulz O, 2005, NATURE, V433, P887, DOI 10.1038/nature03326
   Sharma NK, 2014, MOL CELL BIOCHEM, V393, P1, DOI 10.1007/s11010-014-2040-4
   Sironi M, 2017, J INFECT DIS, V215, P1430, DOI 10.1093/infdis/jix166
   Srivastava T, 2013, J CELL COMMUN SIGNAL, V7, P49, DOI 10.1007/s12079-012-0184-0
   Stokely ME, 2007, J NEUROSCI METH, V166, P217, DOI 10.1016/j.jneumeth.2007.07.010
   Tanabe M, 2003, BIOCHEM BIOPH RES CO, V311, P39, DOI 10.1016/j.bbrc.2003.09.159
   Tatematsu M, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms2857
   TEN RM, 1992, EMBO J, V11, P195, DOI 10.1002/j.1460-2075.1992.tb05042.x
   Thompson MR, 2011, VIRUSES-BASEL, V3, P920, DOI 10.3390/v3060920
   Tichaczek-Goska D, 2012, ADV CLIN EXP MED, V21, P105
   Wornle M, 2011, INVEST OPHTH VIS SCI, V52, P6536, DOI 10.1167/iovs.10-6993
   XIE QW, 1994, J BIOL CHEM, V269, P4705
   Ye SM, 2001, J NEUROIMMUNOL, V117, P87, DOI 10.1016/S0165-5728(01)00316-2
   Yonekawa Y, 2015, CSH PERSPECT MED, V5, DOI 10.1101/cshperspect.a017178
   Zinkernagel MS, 2013, AM J PATHOL, V182, P875, DOI 10.1016/j.ajpath.2012.11.031
NR 75
TC 7
Z9 7
U1 0
U2 7
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0898-6568
EI 1873-3913
J9 CELL SIGNAL
JI Cell. Signal.
PD FEB
PY 2020
VL 66
AR 109494
DI 10.1016/j.cellsig.2019.109494
PG 10
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA KE7RB
UT WOS:000508747700024
PM 31809875
DA 2022-11-30
ER

PT J
AU Ding, Y
   Aredo, B
   Zhong, X
   Zhao, CX
   Ufret-Vincenty, RL
AF Ding, Yi
   Aredo, Bogale
   Zhong, Xin
   Zhao, Cynthia X.
   Ufret-Vincenty, Rafael L.
TI Increased susceptibility to fundus camera-delivered light-induced
   retinal degeneration in mice deficient in oxidative stress response
   proteins
SO EXPERIMENTAL EYE RESEARCH
LA English
DT Article
DE Light induced retinal degeneration; Oxidative stress; RPE65; Met450; OCT
   volume; RPE morphology; Retina
ID INDUCED PHOTORECEPTOR DEGENERATION; MACULAR DEGENERATION; INDUCED
   DAMAGE; CELL-DEATH; COMPLEMENT; PROTECTS; PARKIN; INFLAMMATION;
   EXPRESSION; MICROGLIA
AB Oxidative stress is an important contributor to the pathogenesis of many retinal diseases including age related macular degeneration and retinal dystrophies. Light-induced retinal degeneration (LIRD) can serve as a model in which to study the response of the retina to stress. Of note, many genetic mutant mice are in a C57BL/6 J background and are thus resistant to the usual LIRD models. We recently developed a new model of fundus camera-delivered light-induced retinal degeneration (FCD-LIRD) which is effective in strains of mice expressing the light-resistant variant of RPE65 (450Met), including C57BL/6 J. In this work we investigated whether FCD-LIRD would be useful as a model in which to test the effect of genetic mutations on the response of the retina to stress. Furthermore, we tested whether oxidative stress plays an important role in the setting of this new FCD-LIRD model. FCD-LIRD was applied to C57BL/6 J mice and to mice simultaneously deficient in three proteins that are important in the response of the retina to oxidative stress (SOD1, DJ-1 and Parkin). Using fundus photography, we found that retinal damage was dramatically increased in the SOD1/DJ-1/Parkin deficient mice compared to C57BL/6 J. Outer retinal OCT volume and RPE cell morphology analysis in ZO-1-stained flat mounts added support to these findings. Gene expression analysis confirmed a strong oxidative stress response after FCD-LIRD, which was differentially altered in the SOD1/-DJ1/Parkin deficient mice. We conclude that FCD-LIRD is useful to study the effect of genetic mutations on the response of the retina to light stress in light resistant strains of mice. Furthermore, oxidative stress seems to be an important component of FCD-LIRD. Finally, we have established protocols to quantify the effect of FCD-LIRD on the retina and RPE which will be useful for future studies. Further dissection of the mechanisms by which the retina responds to light induced oxidative stress may result in new strategies to modulate this response, which could lead to a reduction in retinal and RPE damage. (C) 2017 Elsevier Ltd. All rights reserved.
C1 [Ding, Yi; Aredo, Bogale; Zhong, Xin; Zhao, Cynthia X.; Ufret-Vincenty, Rafael L.] UT Southwestern Med Ctr, Dept Ophthalmol, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.
   [Ding, Yi] Huazhong Univ Sci & Technol, Tongji Med Coll, Cent Hosp Wuhan, Dept Ophthalmol, Wuhan 430014, Hubei, Peoples R China.
   [Zhong, Xin] Guangxi Med Univ, Affiliated Hosp 1, Dept Ophthalmol, Nanning 530021, Guangxi, Peoples R China.
C3 University of Texas System; University of Texas Southwestern Medical
   Center Dallas; Huazhong University of Science & Technology; Guangxi
   Medical University
RP Ufret-Vincenty, RL (通讯作者)，UT Southwestern Med Ctr, Dept Ophthalmol, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.
EM Rafael.Ufret-Vincenty@UTSouthwestern.edu
FU National Institutes of Health (Visual Science Core) [1R01EY022652,
   EY020799]; Research to Prevent Blindness; Patricia and Col. William
   Massad Retina Research Fund; David M. Crowley Foundation; NATIONAL EYE
   INSTITUTE [P30EY020799, R01EY022652] Funding Source: NIH RePORTER
FX This work was supported by the National Institutes of Health
   (1R01EY022652, and Visual Science Core Grant EY020799), an unrestricted
   grant from Research to Prevent Blindness, the Patricia and Col. William
   Massad Retina Research Fund and a grant from the David M. Crowley
   Foundation.
CR Aredo B, 2015, INVEST OPHTH VIS SCI, V56, P3427, DOI 10.1167/iovs.14-16089
   Aziz MK, 2014, BRIT J OPHTHALMOL, V98, P984, DOI 10.1136/bjophthalmol-2013-304515
   Boatright JH, 2015, MOL VIS, V21, P40
   Bonilha VL, 2017, FREE RADICAL BIO MED, V104, P226, DOI 10.1016/j.freeradbiomed.2017.01.018
   Bonilha VL, 2015, EXP EYE RES, V139, P22, DOI 10.1016/j.exer.2015.07.014
   Brantley MA, 2012, AM J OPHTHALMOL, V153, P460, DOI 10.1016/j.ajo.2011.08.033
   Bray Mark-Anthony, 2015, Curr Protoc Mol Biol, V109, DOI 10.1002/0471142727.mb1417s109
   Brennan L, 2017, BBA-MOL BASIS DIS, V1863, P21, DOI 10.1016/j.bbadis.2016.09.020
   Campochiaro PA, 2015, ANTIOXID REDOX SIGN, V23, P643, DOI 10.1089/ars.2015.6327
   Chalfoun J, 2014, BMC BIOINFORMATICS, V15, DOI 10.1186/s12859-014-0431-x
   Chen L, 2004, EXP EYE RES, V79, P239, DOI 10.1016/j.exer.2004.05.002
   Chen Y, 2013, J BIOL CHEM, V288, P7506, DOI 10.1074/jbc.M112.439935
   Collier RJ, 2011, INVEST OPHTH VIS SCI, V52, P8108, DOI 10.1167/iovs.10-6418
   Delcourt C, 2014, INVEST OPHTH VIS SCI, V55, P7619, DOI 10.1167/iovs.14-14471
   Ding XY, 2009, PROG RETIN EYE RES, V28, P1, DOI 10.1016/j.preteyeres.2008.10.001
   Dong A, 2006, J CELL PHYSIOL, V208, P516, DOI 10.1002/jcp.20683
   Dysli C, 2015, TRANSL VIS SCI TECHN, V4, DOI 10.1167/tvst.4.4.9
   Esteve-Rudd J, 2010, BRAIN RES, V1352, P70, DOI 10.1016/j.brainres.2010.07.019
   Fischer AJ, 2004, MOL CELL NEUROSCI, V27, P531, DOI 10.1016/j.mcn.2004.08.007
   Fragoso MA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046892
   Grimm Christian, 2013, Methods Mol Biol, V935, P87, DOI 10.1007/978-1-62703-080-9_6
   Hadziahmetovic M, 2012, INVEST OPHTH VIS SCI, V53, P5231, DOI 10.1167/iovs.12-10204
   Hashizume K, 2008, AM J PATHOL, V172, P1325, DOI 10.2353/ajpath.2008.070730
   Hollyfield JG, 2008, NAT MED, V14, P194, DOI 10.1038/nm1709
   Hwang M, 2014, ENDOCRINOL METAB, V29, P62, DOI 10.3803/EnM.2014.29.1.62
   Hyun DH, 2002, J BIOL CHEM, V277, P28572, DOI 10.1074/jbc.M200666200
   Imai S, 2010, EUR J PHARMACOL, V642, P77, DOI 10.1016/j.ejphar.2010.05.057
   Joly S, 2009, AM J PATHOL, V174, P2310, DOI 10.2353/ajpath.2009.090023
   Kast B, 2016, EXP EYE RES, V146, P60, DOI 10.1016/j.exer.2015.12.008
   Komeima K, 2006, P NATL ACAD SCI USA, V103, P11300, DOI 10.1073/pnas.0604056103
   Luhmann UFO, 2009, INVEST OPHTH VIS SCI, V50, P5934, DOI 10.1167/iovs.09-3462
   Mattapallil MJ, 2012, INVEST OPHTH VIS SCI, V53, P2921, DOI 10.1167/iovs.12-9662
   Monk TH, 2000, CHRONOBIOL INT, V17, P49, DOI 10.1081/CBI-100101031
   Natoli R, 2016, EXP EYE RES, V147, P114, DOI 10.1016/j.exer.2016.04.015
   O'Koren EG, 2016, SCI REP-UK, V6, DOI 10.1038/srep20636
   Organisciak DT, 1999, PHOTOCHEM PHOTOBIOL, V70, P261, DOI 10.1111/j.1751-1097.1999.tb07998.x
   Palacino JJ, 2004, J BIOL CHEM, V279, P18614, DOI 10.1074/jbc.M401135200
   Paskowitz DM, 2006, BRIT J OPHTHALMOL, V90, P1060, DOI 10.1136/bjo.2006.097436
   Punzo C, 2012, J BIOL CHEM, V287, P1642, DOI 10.1074/jbc.R111.304428
   Rohrer B, 2016, ADV EXP MED BIOL, V854, P793, DOI 10.1007/978-3-319-17121-0_106
   Rohrer B, 2007, INVEST OPHTH VIS SCI, V48, P5282, DOI 10.1167/iovs.07-0282
   Rutar M, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-014-0224-1
   Rutar M, 2011, INVEST OPHTH VIS SCI, V52, P5347, DOI 10.1167/iovs.10-7119
   Shadrach KG, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067983
   Shaw PX, 2012, P NATL ACAD SCI USA, V109, P13757, DOI 10.1073/pnas.1121309109
   Shen JK, 2007, HISTOL HISTOPATHOL, V22, P1301, DOI 10.14670/HH-22.1301
   Song DL, 2012, FREE RADICAL BIO MED, V53, P64, DOI 10.1016/j.freeradbiomed.2012.04.020
   Tanito M, 2005, INVEST OPHTH VIS SCI, V46, P3859, DOI 10.1167/iovs.05-0672
   Tomany SC, 2004, ARCH OPHTHALMOL-CHIC, V122, P750, DOI 10.1001/archopht.122.5.750
   Ueki Y, 2008, J NEUROCHEM, V105, P784, DOI 10.1111/j.1471-4159.2007.05180.x
   Ufret-Vincenty RL, 2010, INVEST OPHTH VIS SCI, V51, P5878, DOI 10.1167/iovs.09-4457
   Wang CXZ, 2012, EXP EYE RES, V102, P1, DOI 10.1016/j.exer.2012.06.003
   Weismann D, 2011, NATURE, V478, P76, DOI 10.1038/nature10449
   Wenzel A, 2005, PROG RETIN EYE RES, V24, P275, DOI 10.1016/j.preteyeres.2004.08.002
   Wenzel A, 2001, J NEUROSCI, V21, P53, DOI 10.1523/JNEUROSCI.21-01-00053.2001
   White DA, 2007, INVEST OPHTH VIS SCI, V48, P1942, DOI 10.1167/iovs.06-1131
   Xu J, 2012, ANGIOGENESIS, V15, P213, DOI 10.1007/s10456-012-9254-4
   Yang LP, 2008, J NEUROSCI RES, V86, P910, DOI 10.1002/jnr.21535
   Yang YX, 2006, EUR J NEUROSCI, V24, P1366, DOI 10.1111/j.1460-9568.2006.04998.x
   Zgheib Carlos, 2012, JAKSTAT, V1, P101, DOI 10.4161/jkst.19776
   Zhao XL, 2013, CANCER INVEST, V31, P555, DOI 10.3109/07357907.2013.834925
   Zhao ZY, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019456
   Zheng LX, 2006, INVEST OPHTH VIS SCI, V47, P5583, DOI 10.1167/iovs.06-0163
   Zhong X, 2016, INVEST OPHTH VIS SCI, V57, P5558, DOI 10.1167/iovs.16-19965
NR 64
TC 8
Z9 8
U1 0
U2 3
PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 0014-4835
EI 1096-0007
J9 EXP EYE RES
JI Exp. Eye Res.
PD JUN
PY 2017
VL 159
BP 58
EP 68
DI 10.1016/j.exer.2017.03.009
PG 11
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA EW6AV
UT WOS:000402588500007
PM 28336262
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Buhler, AD
   Bucher, F
   Augustynik, M
   Wohrl, J
   Martin, G
   Schlunck, G
   Agostini, H
   Bohringer, D
   Putz, G
   Stahl, A
AF Buehler, Anima D.
   Bucher, Felicitas
   Augustynik, Michael
   Woehrl, Jan
   Martin, Gottfried
   Schlunck, Guenther
   Agostini, Hansjuergen
   Boehringer, Daniel
   Puetz, Gerhard
   Stahl, Andreas
TI Systemic confounders affecting serum measurements of omega-3 and-6
   polyunsaturated fatty acids in patients with retinal disease
SO BMC OPHTHALMOLOGY
LA English
DT Article
DE AMD; DME; RVO; Lipid; Omega-3; PUFA
ID OMEGA-3-FATTY-ACIDS; RISK
AB Background: Omega-3 polyunsaturated fatty acids (PUFAs) have a highly anti-angiogenic effect in animal models. However, the clinical relevance of omega-3PUFAs in human retinal pathologies remains unclear. The ARED 2 study found no effect of omega-3 PUFA supplementation on progression of age related macular degeneration (AMD). The aim of this study was to compare serum levels of omega-3-and omega-6 PUFAs between patients with diabetic retinopathy (DR), AMD and retinal vein occlusion (RVO), and to identify potential confounders of serum level measurements.
   Methods: Venous blood samples were collected from 44 patients with DR, 25 with AMD, 12 with RVO and 27 controls. The lipid phase was extracted and analyzed using mass spectrometry. Retinal disease staging was done by indirect funduscopy and FAG where appropriate. Patient demographics and medical history including current medication and fasting state were acquired. Tukey contrasts for multiple comparisons of the mean and linear regression analysis were used for statistical analysis.
   Results: Our data revealed no significant differences in omega-6 PUFA serum levels between patients with AMD, DR, RVO and controls (p > 0.858). Uncorrected omega-3 PUFA levels were significantly higher in patients with AMD compared to DR but not compared to controls (p = 0.004). However, after correcting for possible confounders such as body mass index (BMI), age, sex, fasting and use of statins, no statistically significant difference remained for serum omega-3 PUFA levels. Fasting was identified as an independent confounder of total omega-6 PUFAs, three individual omega-6 PUFAs and one omega-3 PUFA(p < 0.0427). Statin use was identified as an independent confounder of a-linolenic acid (an omega-3PUFA; p = 0.0210).
   Conclusion: In this pilot study with relatively low patient numbers, we report significant differences in serum levels of omega-3PUFAs among patients with different types of retinal diseases. However, these differences were not robust for disease specificity after correction for possible confounders in our cohort. Our results demonstrate that serum lipid profiles need to be interpreted with caution since they are significantly altered by variables like fasting and medication use independent from the underlying disease. Correcting for respective confounders is thus necessary to compare serum lipid profiles in clinical studies.
C1 [Buehler, Anima D.; Bucher, Felicitas; Augustynik, Michael; Martin, Gottfried; Schlunck, Guenther; Agostini, Hansjuergen; Boehringer, Daniel; Stahl, Andreas] Univ Freiburg, Eye Ctr, Med Ctr, Fac Med, Killianstr 5, D-79106 Freiburg, Germany.
   [Woehrl, Jan; Puetz, Gerhard] Univ Freiburg, Med Ctr, Inst Clin Chem & Lab Med, Freiburg, Germany.
C3 University of Freiburg; University of Freiburg
RP Stahl, A (通讯作者)，Univ Freiburg, Eye Ctr, Med Ctr, Fac Med, Killianstr 5, D-79106 Freiburg, Germany.
EM andreas.stahl@uniklinik-freiburg.de
OI Bucher, Felicitas/0000-0003-0081-1420
FU DFG [STA 1102/5-1]; German Ophthalmic Society (DOG); Novartis Germany
FX AS is supported by the DFG (STA 1102/5-1) and the German Ophthalmic
   Society (DOG). This study was supported by a research grant from
   Novartis Germany.
CR [Anonymous], 1991, Ophthalmology, V98, P786
   Bazan NG, 2009, J LIPID RES, V50, pS400, DOI 10.1194/jlr.R800068-JLR200
   BUTTE W, 1983, J CHROMATOGR, V261, P142, DOI 10.1016/S0021-9673(01)87931-0
   Chew EY, 2013, JAMA-J AM MED ASSOC, V309, P2005, DOI 10.1001/jama.2013.4997
   Chong EWT, 2008, ARCH OPHTHALMOL-CHIC, V126, P826, DOI 10.1001/archopht.126.6.826
   Delyfer MN, 2012, INVEST OPHTH VIS SCI, V53, P1204, DOI 10.1167/iovs.11-8721
   Ejsing CS, 2009, P NATL ACAD SCI USA, V106, P2136, DOI 10.1073/pnas.0811700106
   Jeffrey BG, 2001, LIPIDS, V36, P859, DOI 10.1007/s11745-001-0796-3
   Kabasawa S, 2011, OPHTHALMOLOGY, V118, P1082, DOI 10.1016/j.ophtha.2010.10.012
   Lawrenson JG, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD010015.pub3
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Merle BMJ, 2014, INVEST OPHTH VIS SCI, V55, P2010, DOI 10.1167/iovs.14-13916
   Merle BMJ, 2013, J NUTR, V143, P505, DOI 10.3945/jn.112.171033
   NEURINGER M, 1984, J CLIN INVEST, V73, P272, DOI 10.1172/JCI111202
   Pinazo-Duran MD, 2014, J OPHTHALMOL, V2014, DOI 10.1155/2014/901686
   SanGiovanni JP, 2005, PROG RETIN EYE RES, V24, P87, DOI 10.1016/j.preteyeres.2004.06.002
   Sapieha P, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3001571
   Sasaki M, 2015, INVEST OPHTH VIS SCI, V56, P7473, DOI 10.1167/iovs.15-17485
   Sekikawa A, 2007, AM J EPIDEMIOL, V165, P617, DOI 10.1093/aje/kwk053
   Yau JWY, 2012, DIABETES CARE, V35, P556, DOI 10.2337/dc11-1909
   Zhang JJ, 1999, PREV MED, V28, P520, DOI 10.1006/pmed.1998.0472
NR 21
TC 2
Z9 2
U1 1
U2 11
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1471-2415
J9 BMC OPHTHALMOL
JI BMC Ophthalmol.
PD SEP 5
PY 2016
VL 16
AR 159
DI 10.1186/s12886-016-0335-9
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA DW3NY
UT WOS:000383549500001
PM 27596098
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Waldstein, SM
   Wright, J
   Warburton, J
   Margaron, P
   Simader, C
   Schmidt-Erfurth, U
AF Waldstein, Sebastian M.
   Wright, Jonathan
   Warburton, James
   Margaron, Philippe
   Simader, Christian
   Schmidt-Erfurth, Ursula
TI Predictive Value of Retinal Morphology for Visual Acuity Outcomes of
   Different Ranibizumab Treatment Regimens for Neovascular AMD
SO OPHTHALMOLOGY
LA English
DT Article
ID DEGENERATION TREATMENTS TRIALS; OPTICAL COHERENCE TOMOGRAPHY; MACULAR
   DEGENERATION; VITREOMACULAR INTERFACE; EXTEND PROTOCOL; THERAPY;
   DETACHMENT; VERTEPORFIN; RELEVANT; ADHESION
AB Purpose: To establish the predictive value of defined retinal morphologic parameters on visual outcomes and re-treatment needs in patients with neovascular age-related macular degeneration (nAMD) receiving ranibizumab treatment.
   Design: Post hoc analysis of a prospective, 12-month, multicenter, phase IIIb trial.
   Participants: Three hundred fifty-three treatment-naive patients with nAMD.
   Methods: Available data from 319 treatment-naive patients receiving ranibizumab 0.3 mg monthly (frequent regimen; n = 102) or ranibizumab 0.3 or 0.5 mg quarterly (pooled 0.3/0.5 mg = infrequent regimen; n = 217) were analyzed to assess the correlations between baseline retinal morphologic parameters and best-corrected visual acuity (BCVA) change (structure-function correlations). The BCVA was measured at monthly visits. Optical coherence tomography scans were acquired monthly for quantitative measures of the central retinal thickness and qualitative assessment of retinal morphologic features. Assessed morphologic parameters included intraretinal cystoid fluid (IRC), subretinal fluid (SRF), pigment epithelial detachment, and vitreomacular interface configuration classification comprising vitreomacular adhesion and posterior vitreous detachment (PVD). An analysis of covariance was conducted to evaluate the impact of retinal morphologic features on BCVA change at month 12.
   Main Outcome Measures: Change in BCVA from baseline to month 12 compared between frequent and infrequent treatment arms.
   Results: Relevant predictive factors for BCVA change at month 12 were baseline SRF (P = 0.05), PVD (P = 0.03), IRC (P = 0.05), treatment frequency (P < 0.01), and BCVA (P < 0.01). The presence of both SRF and PVD at baseline was associated with similar BCVA gains regardless of treatment frequency (mean difference in BCVA gains at month 12 of +2.6 letters in favor of infrequent treatment). Subretinal fluid was present in 71% of patients, and PVD was present in 64% of patients.
   Conclusions: In patients with both SRF and PVD at baseline, similar BCVA outcomes were observed regardless of treatment frequency. These patients may require less frequent treatments compared with patients without SRF, without PVD, or without either who may require more frequent injections for maintenance of vision. This finding may have implications in clinical practice by helping to tailor an individualized retreatment interval in nAMD patients. (C) 2016 by the American Academy of Ophthalmology.
C1 [Waldstein, Sebastian M.; Simader, Christian; Schmidt-Erfurth, Ursula] Vienna Reading Ctr, Christian Doppler Lab Ophthalm Image Anal, Dept Ophthalmol, Vienna, Austria.
   [Wright, Jonathan] Numerus Ltd, Wokingham, Berks, England.
   [Warburton, James; Margaron, Philippe] Novartis Pharma AG, Basel, Switzerland.
C3 Novartis
RP Schmidt-Erfurth, U (通讯作者)，Med Univ Vienna, Dept Ophthalmol, Vienna Reading Ctr, Christian Doppler Lab Ophthalm Image Anal, Spitalgasse 23, A-1090 Vienna, Austria.
EM ursula.schmidt-erfurth@meduniwein.ac.at
OI Schmidt-Erfurth, Ursula/0000-0002-7788-7311; Waldstein,
   Sebastian/0000-0003-2899-6279
FU Novartis Pharma AG, Basel, Switzerland
FX The authors thank Marie-Catherine Mousseau, Global Business Services,
   Novartis Ireland Limited, Dublin, Ireland, for medical writing services
   toward the development of this article, funded by Novartis Pharma AG,
   Basel, Switzerland.
CR Abedi F, 2014, RETINA-J RET VIT DIS, V34, P1531, DOI 10.1097/IAE.0000000000000134
   Abraham P, 2010, AM J OPHTHALMOL, V150, P315, DOI 10.1016/j.ajo.2010.04.011
   Berg K, 2015, OPHTHALMOLOGY, V122, P146, DOI 10.1016/j.ophtha.2014.07.041
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Busbee BG, 2013, OPHTHALMOLOGY, V120, P1046, DOI 10.1016/j.ophtha.2012.10.014
   Chakravarthy U, 2013, LANCET, V382, P1258, DOI 10.1016/S0140-6736(13)61501-9
   Cuilla TA, 2015, OPHTHALMOLOGY, V122, P1203, DOI 10.1016/j.ophtha.2015.02.031
   Grunwald JE, 2014, OPHTHALMOLOGY, V121, P150, DOI 10.1016/j.ophtha.2013.08.015
   Hariprasad SM, 2012, J OPHTHALMOL, V2012, DOI 10.1155/2012/690641
   Itakura H, 2013, JAMA OPHTHALMOL, V131, P1348, DOI 10.1001/jamaophthalmol.2013.4578
   Jaffe GJ, 2013, OPHTHALMOLOGY, V120, P1860, DOI 10.1016/j.ophtha.2013.01.073
   Jang LN, 2015, GRAEF ARCH CLIN EXP, V253, P1211, DOI 10.1007/s00417-014-2789-x
   Kim BJ, 2014, AM J OPHTHALMOL, V158, P128, DOI 10.1016/j.ajo.2014.04.004
   Kiss CG, 2009, INVEST OPHTH VIS SCI, V50, P2376, DOI 10.1167/iovs.08-2017
   Lee SJ, 2011, OPHTHALMOLOGY, V118, P101, DOI 10.1016/j.ophtha.2010.04.015
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Mayr-Sponer U, 2013, OPHTHALMOLOGY, V120, P2620, DOI 10.1016/j.ophtha.2013.05.032
   Mitchell P, 2010, BRIT J OPHTHALMOL, V94, P2, DOI 10.1136/bjo.2009.159160
   Mojana F, 2008, AM J OPHTHALMOL, V146, P218, DOI 10.1016/j.ajo.2008.04.027
   Ritter M, 2011, BRIT J OPHTHALMOL, V95, P381, DOI 10.1136/bjo.2009.175976
   Roberts P, 2014, INVEST OPHTH VIS SCI, V55, DOI 10.1167/iovs.14-14293
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Sakata LM, 2009, CLIN EXP OPHTHALMOL, V37, P90, DOI 10.1111/j.1442-9071.2009.02015.x
   Schmidt-Erfurth U, 2015, OPHTHALMOLOGY, V122, P822, DOI 10.1016/j.ophtha.2014.11.017
   Schmidt-Erfurth U, 2011, OPHTHALMOLOGY, V118, P831, DOI 10.1016/j.ophtha.2010.09.004
   Simader C, 2014, OPHTHALMOLOGY, V121, P1237, DOI 10.1016/j.ophtha.2013.12.029
   Takahashi H, 2015, BRIT J OPHTHALMOL, V99, P1065, DOI 10.1136/bjophthalmol-2014-306051
   Waldstein SM, 2014, AM J OPHTHALMOL, V158, P328, DOI 10.1016/j.ajo.2014.04.028
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Ying GS, 2014, JAMA OPHTHALMOL, V132, P915, DOI 10.1001/jamaophthalmol.2014.1019
NR 31
TC 73
Z9 78
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD JAN
PY 2016
VL 123
IS 1
BP 60
EP 69
DI 10.1016/j.ophtha.2015.09.013
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA CZ4GE
UT WOS:000367060700026
PM 26481821
OA Bronze
DA 2022-11-30
ER

PT J
AU Hoang, QV
   Mendonca, LS
   Della Torre, KE
   Jung, JJ
   Tsuang, AJ
   Freund, KB
AF Hoang, Quan V.
   Mendonca, Luis S.
   Della Torre, Kara E.
   Jung, Jesse J.
   Tsuang, Angela J.
   Freund, K. Bailey
TI Effect on Intraocular Pressure in Patients Receiving Unilateral
   Intravitreal Anti-Vascular Endothelial Growth Factor Injections
SO OPHTHALMOLOGY
LA English
DT Article
ID MACULAR DEGENERATION; BEVACIZUMAB; RANIBIZUMAB; PEGAPTANIB
AB Purpose: We assessed the frequency and predictive factors related to intraocular pressure (IOP) elevation in neovascular age-related macular degeneration (AMD) patients undergoing unilateral intravitreal ranibizumab and/or bevacizumab injections.
   Design: Retrospective cohort study.
   Participants: Charts of 207 patients with neovascular AMD who presented to a single physician at a retinal referral practice over a 6-month period were retrospectively reviewed.
   Methods: Data recorded included demographic information, clinical findings, total number of bevacizumab and ranibizumab injections received and IOP at each visit. Increases above baseline IOP of >5, >10, or >15 mmHg on > 2 consecutive visits while under treatment were noted.
   Main Outcome Measures: The frequency of IOP elevation was compared between treated and untreated eyes. In addition, among treated eyes, frequency and odds ratio of experiencing IOP elevation >5 mmHg above baseline on >= 2 consecutive visits was stratified by number of injections. For the main regression analysis, the outcome variable was IOP elevation >5 mmHg on >= 2 consecutive visits and the main independent variable was total number of injections.
   Results: On >= 2 consecutive visits, 11.6% of treated versus 5.3% of untreated/control eyes experienced IOP elevation of >5 mmHg. The mean number of injections was higher in those with (24.4; 95% confidence interval [CI], 20.9-28.0; range, 9-39) than without IOP elevation of >5 mmHg (20.4; 95% CI, 18.9-21.8; range, 3-48) on >= 2 consecutive visits. There was an increased odds ratio (5.75; 95% CI, 1.19-27.8; P = 0.03) of experiencing IOP elevation >5 mmHg on >= 2 consecutive visits in patients receiving >= 29 injections compared with <= 12 injections. Of the factors considered, only the total number of injections showed a statistically significant association with IOP elevation >5 mmHg above baseline on >= 2 consecutive visits in treated eyes (P = 0.05).
   Conclusions: A greater number of intravitreal anti-vasular endothelial growth factor injections is associated with an increased risk for IOP elevation >5 mmHg on >= 2 consecutive visits in eyes with neovascular AMD receiving intravitreal ranbizumab and/or bevacizumab.
   Financial Disclosure(s): Proprietary or commercial disclosure may be found after the references. Ophthalmology 2012; 119: 321-326 (C) 2012 by the American Academy of Ophthalmology.
C1 [Hoang, Quan V.; Mendonca, Luis S.; Della Torre, Kara E.; Freund, K. Bailey] Vitreous Retina Macula Consultants New York, New York, NY USA.
   [Hoang, Quan V.; Mendonca, Luis S.; Della Torre, Kara E.; Freund, K. Bailey] Manhattan Eye Ear & Throat Inst, LuEsther T Mertz Retinal Res Ctr, New York, NY USA.
   [Hoang, Quan V.; Freund, K. Bailey] Columbia Univ, Coll Phys & Surg, Edward S Harkness Eye Inst, New York, NY USA.
   [Hoang, Quan V.; Della Torre, Kara E.; Jung, Jesse J.; Tsuang, Angela J.; Freund, K. Bailey] NYU, Med Ctr, Dept Ophthalmol, New York, NY 10016 USA.
C3 Vitreous Retina Macula Consultants of New York; Columbia University; New
   York University
RP Freund, KB (通讯作者)，460 Pk Ave,5th Floor, New York, NY 10022 USA.
EM kbfnyf@aol.com
RI Freund, K. Bailey/V-7488-2018
OI Freund, K. Bailey/0000-0002-7888-9773
FU Genentech; Macula Foundation Inc.; LuEsther T. Mertz Retinal Research
   Center, Manhattan Eye, Ear, and Throat Institute
FX K. Bailey Freund - Consultant, Research Support - Genentech;
   Consultant-Alcon; Consultant - Regeneron; Consultant - Alimera.;
   Supported by the LuEsther T. Mertz Retinal Research Center, Manhattan
   Eye, Ear, and Throat Institute, and The Macula Foundation Inc. The
   funding organizations had no role in the design or conduct of this
   research.
CR Adelman RA, 2010, J OCUL PHARMACOL TH, V26, P105, DOI 10.1089/jop.2009.0076
   Bakri SJ, 2009, EYE, V23, P181, DOI 10.1038/sj.eye.6702938
   Bakri SJ, 2008, GRAEF ARCH CLIN EXP, V246, P955, DOI 10.1007/s00417-008-0819-2
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Choi DY, 2011, RETINA-J RET VIT DIS, V31, P1028, DOI 10.1097/IAE.0b013e318217ffde
   D'Amico DJ, 2006, OPHTHALMOLOGY, V113, P992, DOI 10.1016/j.ophtha.2006.02.027
   Engelbert M, 2009, RETINA-J RET VIT DIS, V29, P1424, DOI 10.1097/IAE.0b013e3181bfbd46
   Georgopoulos M, 2009, BRIT J OPHTHALMOL, V93, P457, DOI 10.1136/bjo.2008.138479
   Good TJ, 2011, BRIT J OPHTHALMOL, V95, P1111, DOI 10.1136/bjo.2010.180729
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Hollands H, 2007, CAN J OPHTHALMOL, V42, P807, DOI 10.3129/i07-172
   Jager RD, 2004, RETINA-J RET VIT DIS, V24, P676, DOI 10.1097/00006982-200410000-00002
   Kahook MY, 2009, OPHTHAL SURG LAS IM, V40, P293, DOI 10.3928/15428877-20090430-12
   Kernt M, 2007, OPHTHALMOLOGE, V104, P965, DOI 10.1007/s00347-007-1569-y
   Kim JE, 2008, AM J OPHTHALMOL, V146, P930, DOI 10.1016/j.ajo.2008.07.007
   Ladas JG, 2001, INVEST OPHTH VIS SCI, V42, P2584
   Liu L, 2011, INVEST OPHTH VIS SCI, V52, P1023, DOI 10.1167/iovs.10-6431
   Mojica G, 2008, BRIT J OPHTHALMOL, V92, P584, DOI 10.1136/bjo.2007.126193
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Sniegowski M, 2010, OPEN OPHTHALMOL J, V4, P28, DOI 10.2174/1874364101004010028
   Tseng JJ, 2011, J GLAUCOMA      0316
NR 21
TC 96
Z9 101
U1 0
U2 7
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0161-6420
J9 OPHTHALMOLOGY
JI Ophthalmology
PD FEB
PY 2012
VL 119
IS 2
BP 321
EP 326
DI 10.1016/j.ophtha.2011.08.011
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 887SO
UT WOS:000299950300020
PM 22054994
DA 2022-11-30
ER

PT J
AU Miyamoto, N
   Izumi, H
   Miyamoto, R
   Bin, H
   Kondo, H
   Tawara, A
   Sasaguri, Y
   Kohno, K
AF Miyamoto, Naoya
   Izumi, Hiroto
   Miyamoto, Rie
   Bin, Han
   Kondo, Hiroyuki
   Tawara, Akihiko
   Sasaguri, Yasuyuki
   Kohno, Kimitoshi
TI Transcriptional Regulation of Activating Transcription Factor 4 under
   Oxidative Stress in Retinal Pigment Epithelial ARPE-19/HPV-16 Cells
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID ENDOTHELIAL GROWTH-FACTOR; ENDOPLASMIC-RETICULUM STRESS; TRABECULAR
   MESHWORK CELLS; NAD(P)H OXIDASE; EXPRESSION; INCREASES; PROTEIN; GENE;
   NRF2; RETINOPATHY
AB PURPOSE. Oxidative stress plays an important role in the pathogenesis of various ocular diseases such as retinopathy, glaucoma, and age-related macular degeneration. Activating transcription factor 4 (ATF4) is induced by various stressors, including endoplasmic reticulum (ER) and oxidative stress, and ATF4 expression is regulated translationally through the PERK pathway of eIF2 alpha phosphorylation. Transcriptional regulation of the ATF4 gene under oxidative stress was investigated in human papillomavirus 16 (HPV-16)-transformed retinal pigment epithelial ARPE-19/HPV-16 cells.
   METHODS. Retinal pigment epithelial cells, trabecular meshwork cells, and corneal endothelial cells were treated with anoxia and thapsigargin (TG). Gene expression of ATF4 and nuclear factor (erythroid-derived 2)-like 2 (Nrf2) and transcription factors was investigated by Western blot analysis, reporter assays, chromatin immunoprecipitation (ChiP) assays, and small interfering (si)RNA strategies. Cellular sensitivity to oxidative stress was determined.
   RESULTS. The expression of two transcriptional factors, ATF4 and Nrf2, was significantly induced by anoxia and TG. The Nrf2 regulator Keap1 was downregulated by anoxia. Downregulation of Nrf2 abolished ATF4 expression. On the other hand, downregulation of Keap1 enhanced the expression of both Nrf2 and ATF4. The promoter activity of ATF4 was transactivated by the co-transfection of Nrf2 expression plasmids and reduced by the transfection of Nrf2-specific siRNA. The ChIP assays demonstrated that Nrf2 bound to the promoter of the ATF4 gene. Nrf2 downregulation nearly abolished the ATF4 induction by anoxia and TG. Consistent with these findings, the promoter activity of ATF4 was augmented by treatment with TG, HCA, H2O2, and anoxia. However, stress induction of ATF4 promoter activity was observed, even when a mutation was introduced into the antioxidant-responsive elements site. Furthermore, stress induction of the ATF4 promoter was completely abolished when the 5' untranslated region of the ATF4 gene was deleted. Downregulation of ATF4 rendered ARPE-19/HPV-16 cells sensitive to oxidative stress.
   CONCLUSIONS. These results suggest that the stress induction of ATF4 is significantly regulated transcriptionally through a Nrf2-dependent mechanism and may be a double-edged sword in the pathogenesis of various retinopathies. (Invest Ophthalmol Vis Set. 2011;52:1226 -1234) DOI:10.1.167/iovs.10-5775
C1 [Kohno, Kimitoshi] Univ Occupat & Environm Hlth, Dept Mol Biol, Sch Med, Yahatanishi Ku, Kitakyushu, Fukuoka 8078555, Japan.
   [Miyamoto, Naoya; Miyamoto, Rie; Kondo, Hiroyuki; Tawara, Akihiko] Univ Occupat & Environm Hlth, Dept Ophthalmol, Sch Med, Kitakyushu, Fukuoka 8078555, Japan.
   [Sasaguri, Yasuyuki] Univ Occupat & Environm Hlth, Dept Pathol & Cell Biol, Sch Med, Kitakyushu, Fukuoka 8078555, Japan.
C3 University of Occupational & Environmental Health - Japan; University of
   Occupational & Environmental Health - Japan; University of Occupational
   & Environmental Health - Japan
RP Kohno, K (通讯作者)，Univ Occupat & Environm Hlth, Dept Mol Biol, Sch Med, Yahatanishi Ku, 1-1 Iseigaoka, Kitakyushu, Fukuoka 8078555, Japan.
EM k-kohno@med.uoeh-u.ac.jp
FU Ministry for Education, Culture, Sports, Science and Technology of Japan
   [17016075]; UOEH; Vehicle Racing Commemorative Foundation
FX Supported in part by Grants-in-Aid for Scientific Research front the
   Ministry for Education, Culture, Sports, Science and Technology of Japan
   (17016075), UOEH Grant for Advanced Research, and The Vehicle Racing
   Commemorative Foundation.
CR Afonyushkin T, 2010, ARTERIOSCL THROM VAS, V30, P1007, DOI 10.1161/ATVBAHA.110.204354
   Blais JD, 2004, MOL CELL BIOL, V24, P7469, DOI 10.1128/MCB.24.17.7469-7482.2004
   Cano M, 2010, VISION RES, V50, P652, DOI 10.1016/j.visres.2009.08.018
   Chen WM, 2009, MOL CELL, V34, P663, DOI 10.1016/j.molcel.2009.04.029
   Cullinan SB, 2006, INT J BIOCHEM CELL B, V38, P317, DOI 10.1016/j.biocel.2005.09.018
   Fels DR, 2008, CANCER RES, V68, P9323, DOI 10.1158/0008-5472.CAN-08-2873
   Fernandes AF, 2009, MOL BIOL CELL, V20, P3690, DOI 10.1091/mbc.E08-10-1068
   Harding HP, 2003, MOL CELL, V11, P619, DOI 10.1016/S1097-2765(03)00105-9
   He CH, 2001, J BIOL CHEM, V276, P20858, DOI 10.1074/jbc.M101198200
   He Y, 2008, INVEST OPHTH VIS SCI, V49, P1447, DOI 10.1167/iovs.07-1361
   Igarashi T, 2007, ONCOGENE, V26, P4749, DOI 10.1038/sj.onc.1210289
   Izzotti A, 2006, MUTAT RES-REV MUTAT, V612, P105, DOI 10.1016/j.mrrev.2005.11.001
   Kaspar JW, 2009, FREE RADICAL BIO MED, V47, P1304, DOI 10.1016/j.freeradbiomed.2009.07.035
   Kim JH, 2010, INVEST OPHTH VIS SCI, V51, P561, DOI 10.1167/iovs.09-3774
   Kim YJ, 2007, CANCER RES, V67, P546, DOI 10.1158/0008-5472.CAN-06-2401
   Koritzinsky M, 2006, EMBO J, V25, P1114, DOI 10.1038/sj.emboj.7600998
   Koumenis C, 2002, MOL CELL BIOL, V22, P7405, DOI 10.1128/MCB.22.21.7405-7416.2002
   Kowluru RA, 2009, FREE RADICAL BIO MED, V46, P1677, DOI 10.1016/j.freeradbiomed.2009.03.024
   Leal EC, 2009, EXP EYE RES, V88, P983, DOI 10.1016/j.exer.2008.12.010
   Lee I, 2007, BIOSCI BIOTECH BIOCH, V71, P1203, DOI 10.1271/bbb.60657
   Li CQ, 2009, P NATL ACAD SCI USA, V106, P14547, DOI 10.1073/pnas.0907539106
   Liu LP, 2008, J BIOL CHEM, V283, P31153, DOI 10.1074/jbc.M805056200
   Liu LP, 2006, MOL CELL, V21, P521, DOI 10.1016/j.molcel.2006.01.010
   Maher P, 2005, INVEST OPHTH VIS SCI, V46, P749, DOI 10.1167/iovs.04-0883
   Miyamoto N, 2008, J BIOL CHEM, V283, P18218, DOI 10.1074/jbc.M802332200
   Miyamoto N, 2009, INVEST OPHTH VIS SCI, V50, P2777, DOI 10.1167/iovs.08-3061
   Munderloh UG, 2004, VET MICROBIOL, V101, P53, DOI 10.1016/j.vetmic.2004.02.011
   Nguyen T, 2009, J BIOL CHEM, V284, P13291, DOI 10.1074/jbc.R900010200
   Ogawa Y, 2008, FREE RADICAL RES, V42, P674, DOI 10.1080/10715760802277396
   Ohta T, 2008, CANCER RES, V68, P1303, DOI 10.1158/0008-5472.CAN-07-5003
   Oshikawa M, 2009, MOL VIS, V15, P482
   PANG IH, 1994, CURR EYE RES, V13, P51, DOI 10.3109/02713689409042398
   Roybal CN, 2005, J BIOL CHEM, V280, P20331, DOI 10.1074/jbc.M411275200
   Roybal CN, 2004, J BIOL CHEM, V279, P14844, DOI 10.1074/jbc.M312948200
   Rutkowski DT, 2003, DEV CELL, V4, P442, DOI 10.1016/S1534-5807(03)00100-X
   Sacca SC, 2007, EXP EYE RES, V84, P389, DOI 10.1016/j.exer.2006.10.008
   Saito Y, 2008, INVEST OPHTH VIS SCI, V49, P1591, DOI 10.1167/iovs.07-1356
   Saito Y, 2007, MOL VIS, V13, P840
   Shiota M, 2008, CANCER RES, V68, P98, DOI 10.1158/0008-5472.CAN-07-2981
   Tanabe M, 2003, CANCER RES, V63, P8592
   Yang P, 2006, INVEST OPHTH VIS SCI, V47, P4598, DOI 10.1167/iovs.06-0140
NR 41
TC 47
Z9 49
U1 0
U2 3
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD MAR
PY 2011
VL 52
IS 3
BP 1226
EP 1234
DI 10.1167/iovs.10-5775
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 742SR
UT WOS:000288965300005
PM 21087962
DA 2022-11-30
ER

PT J
AU Le, HM
   Souied, EH
   Querques, G
   Colantuono, D
   Borrelli, E
   Sacconi, R
   Amoroso, F
   Capuano, V
   Jung, C
   Miere, A
AF Le, Hoang Mai
   Souied, Eric H.
   Querques, Giuseppe
   Colantuono, Donato
   Borrelli, Enrico
   Sacconi, Riccardo
   Amoroso, Francesca
   Capuano, Vittorio
   Jung, Camille
   Miere, Alexandra
TI CHORIOCAPILLARIS FLOW IMPAIRMENT IN TYPE 3 MACULAR NEOVASCULARIZATION A
   Quantitative Analysis Using Swept-Source Optical Coherence Tomography
   Angiography
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE swept-source optical coherence tomography angiography; type 3 macular
   neovascularization; choriocapillaris flow; intermediate age-related
   macular degeneration
ID SPECTRAL-DOMAIN; CHOROIDAL NEOVASCULARIZATION; DEGENERATION; DRUSEN
AB Purpose: To quantitatively analyze choriocapillaris alterations using swept-source optical coherence tomography angiography in eyes presenting with Type 3 macular neovascularization (MNV) and to compare these alterations with eyes presenting with intermediate AMD (iAMD). Methods: Macular 3 x 3-mm swept-source optical coherence tomography angiography scans were retrospectively analyzed in eyes with Type 3 MNV and in eyes with iAMD. The choriocapillaris en face slabs were extracted from the swept-source optical coherence tomography angiography device after manual segmentation. En face choriocapillaris flow images were compensated with en face choriocapillaris structure images, followed by the Phansalkar local thresholding method using a window radius of 4 and 8 pixels. The percentage of flow deficits (FD%), the number, size, and total area of FDs were computed for comparison. A secondary analysis was performed in the four corners of the image to include equidistant regions in all eyes. Results: Twenty-six Type 3 MNV eyes of 21 patients and 26 iAMD eyes of 17 patients were included. Compared with iAMD eyes, eyes with Type 3 MNV displayed a higher FD% (41.37% +/- 14.74 vs. 19.80% +/- 9.63 using radius 4 pixels [P < 0.001]; 45.24% +/- 11.9 vs. 26.63% +/- 8.96 using radius 8 pixels [P < 0.001]). The average size of FDs was significantly larger in Type 3 MNV eyes compared with iAMD eyes (P < 0.001), whereas the number of FDs was significantly lower in Type 3 MNV compared with iAMD eyes (P < 0.001). Conclusion: Type 3 MNV eyes present with increased choriocapillaris flow impairment compared with iAMD eyes. Reduced choriocapillaris perfusion may contribute to Type 3 MNV development and pathogenesis.
C1 [Le, Hoang Mai; Souied, Eric H.; Querques, Giuseppe; Colantuono, Donato; Amoroso, Francesca; Capuano, Vittorio; Miere, Alexandra] Ctr Hosp Intercommunal Creteil, Dept Ophthalmol, 40 Ave Verdun, F-94000 Creteil, France.
   [Le, Hoang Mai] Sorbonne Univ, Fac Med, Paris, France.
   [Souied, Eric H.; Jung, Camille] Ctr Hosp Intercommunal Creteil, Clin Res Ctr, GRC Macula, Creteil, France.
   [Souied, Eric H.; Jung, Camille] Ctr Hosp Intercommunal Creteil, Biol Ressources Ctr, Creteil, France.
   [Querques, Giuseppe; Borrelli, Enrico; Sacconi, Riccardo] Univ Vita Salute San Raffaele, IRCCS San Raffaele Sci Inst, Dept Ophthalmol, Milan, Italy.
   [Miere, Alexandra] Univ Paris Est Creteil, Lab Images Signals & Intelligent Syst LISSI, EA 3956, Paris, France.
C3 Universite Paris-Est-Creteil-Val-de-Marne (UPEC); CHI Creteil;
   UDICE-French Research Universities; Sorbonne Universite; Universite de
   Franche-Comte; Universite Paris-Est-Creteil-Val-de-Marne (UPEC); CHI
   Creteil; Universite Paris-Est-Creteil-Val-de-Marne (UPEC); CHI Creteil;
   Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele;
   Universite Paris-Est-Creteil-Val-de-Marne (UPEC)
RP Miere, A (通讯作者)，Ctr Hosp Intercommunal Creteil, Dept Ophthalmol, 40 Ave Verdun, F-94000 Creteil, France.
EM alexandramiere@gmail.com
RI Miere, Alexandra/AIC-4074-2022
OI Miere, Alexandra/0000-0003-4123-8210; Querques,
   Giuseppe/0000-0002-3292-9581; Sacconi, Riccardo/0000-0003-2891-2012
CR Alagorie AR, 2019, AM J OPHTHALMOL, V205, P132, DOI 10.1016/j.ajo.2019.04.037
   Borrelli E, 2018, AM J OPHTHALMOL, V196, P34, DOI 10.1016/j.ajo.2018.08.014
   Borrelli E, 2018, PROG RETIN EYE RES, V67, P30, DOI 10.1016/j.preteyeres.2018.07.002
   Borrelli E, 2018, RETINA-J RET VIT DIS, V38, P1968, DOI 10.1097/IAE.0000000000002198
   Chu ZD, 2020, AM J OPHTHALMOL, V213, P161, DOI 10.1016/j.ajo.2020.02.003
   Chu ZD, 2019, AM J OPHTHALMOL, V208, P111, DOI 10.1016/j.ajo.2019.07.003
   Curcio CA, 2013, RETINA-J RET VIT DIS, V33, P265, DOI 10.1097/IAE.0b013e31827e25e0
   Freund KB, 2008, RETINA-J RET VIT DIS, V28, P201, DOI 10.1097/IAE.0b013e3181669504
   Freund KB, 2010, RETINA-J RET VIT DIS, V30, P1333, DOI 10.1097/IAE.0b013e3181e7976b
   Gass JDM, 2003, RETINA-J RET VIT DIS, V23, P741, DOI 10.1097/00006982-200312000-00001
   Govetto A, 2017, BRIT J OPHTHALMOL, V101, P764, DOI 10.1136/bjophthalmol-2016-309281
   Hartnett ME, 1996, OPHTHALMOLOGY, V103, P2042, DOI 10.1016/S0161-6420(96)30389-8
   Kuehlewein L, 2015, RETINA-J RET VIT DIS, V35, P2229, DOI 10.1097/IAE.0000000000000835
   Lane M, 2016, INVEST OPHTH VIS SCI, V57, pOCT585, DOI 10.1167/iovs.15-18915
   Li ML, 2018, OPHTHALMOLOGY, V125, P276, DOI 10.1016/j.ophtha.2017.08.019
   Lutty G, 1999, MOL VIS, V5
   Miere A, 2021, RETINA-J RET VIT DIS, V41, P135, DOI 10.1097/IAE.0000000000002815
   Miere A, 2015, RETINA-J RET VIT DIS, V35, P2236, DOI 10.1097/IAE.0000000000000834
   Miller AR, 2017, INVEST OPHTH VIS SCI, V58, P1499, DOI 10.1167/iovs.16-20969
   Mullins RE, 2011, INVEST OPHTH VIS SCI, V52, P1606, DOI 10.1167/iovs.10-6476
   Nagiel A, 2015, RETINA-J RET VIT DIS, V35, P638, DOI 10.1097/IAE.0000000000000488
   Nassisi M, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0212563
   Querques G, 2013, RETINA-J RET VIT DIS, V33, P1881, DOI 10.1097/IAE.0b013e3182923448
   Shimada H, 2007, GRAEF ARCH CLIN EXP, V245, P295, DOI 10.1007/s00417-006-0367-6
   Spaide RF, 2019, RETINA-J RET VIT DIS, V39, P1451, DOI 10.1097/IAE.0000000000002412
   Spaide RF, 2016, AM J OPHTHALMOL, V170, P58, DOI 10.1016/j.ajo.2016.07.023
   Su D, 2016, RETINA-J RET VIT DIS, V36, pS40, DOI 10.1097/IAE.0000000000001268
   Yannuzzi LA, 2001, RETINA-J RET VIT DIS, V21, P416, DOI 10.1097/00006982-200110000-00003
   Zhang QQ, 2018, INVEST OPHTH VIS SCI, V59, P203, DOI 10.1167/iovs.17-22953
   Zhang QQ, 2017, INVEST OPHTH VIS SCI, V58, P1506, DOI 10.1167/iovs.16-20977
NR 30
TC 5
Z9 5
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD SEP
PY 2021
VL 41
IS 9
BP 1819
EP 1827
DI 10.1097/IAE.0000000000003119
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA WN5QE
UT WOS:000711821200026
PM 33464024
DA 2022-11-30
ER

PT J
AU Tsai, CL
   Hsu, HC
   Wu, XC
   Chen, SJ
   Lin, WY
AF Tsai, Chia-Ling
   Hsu, Hung-Chuan
   Wu, Xin-Chang
   Chen, Shih-Jen
   Lin, Wei-Yang
TI Accurate Joint-Alignment of Indocyanine Green and Fluorescein Angiograph
   Sequences for Treatment of Subretinal Lesions
SO IEEE JOURNAL OF BIOMEDICAL AND HEALTH INFORMATICS
LA English
DT Article
DE Joint registration; multimodality; retinal angiography
ID POLYPOIDAL CHOROIDAL VASCULOPATHY; PHOTODYNAMIC THERAPY; REGISTRATION;
   IMAGES; ROBUST; NEOVASCULARIZATION; MOSAICS
AB In ophthalmology, aligning images in indocyanine green and fluorescein angiograph sequences is important for the treatment of subretinal lesions. This paper introduces an algorithm that is tailored to align jointly in a common reference space all the images in an angiogram sequence containing both modalities. To overcome the issues of low image contrast and low signal-to-noise ratio for late-phase images, the structural similarity between two images is enhanced using Gabor wavelet transform. Image pairs are pairwise registered and the transformations are simultaneously and globally adjusted for a mutually consistent joint alignment. The joint registration process is incremental and the success depends on the correctness of matches from the pairwise registration. To safeguard the joint process, our system performs the consistency test to exclude incorrect pairwise results automatically to ensure correct matches as more images are jointly aligned. Our dataset consists of 60 sequences of polypoidal choroidal vasculopathy collected by the EVEREST Study Group. On average, each sequence contains 20 images. Our algorithm successfully pairwise registered 95.04% of all image pairs, and joint registered 98.7% of all images, with an average alignment error of 1.58 pixels.
C1 [Tsai, Chia-Ling] Iona Coll, Dept Comp Sci, New Rochelle, NY 10801 USA.
   [Hsu, Hung-Chuan; Wu, Xin-Chang; Lin, Wei-Yang] Natl Chung Cheng Univ, Dept Comp Sci & Informat Engn, Chiayi 62102, Taiwan.
   [Chen, Shih-Jen] Taipei Vet Gen Hosp, Dept Ophthalmol, Taipei 11217, Taiwan.
C3 Iona College; National Chung Cheng University; Taipei Veterans General
   Hospital
RP Lin, WY (通讯作者)，Natl Chung Cheng Univ, Dept Comp Sci & Informat Engn, Chiayi 62102, Taiwan.
EM ctsai@iona.edu; hhc102m@csie.ccu.edu.tw; windy-lock@gmail.com;
   sjchen96@gmail.com; wylin@cs.ccu.edu.tw
FU Ministry of Science and Technology, Taiwan [102-2221-E-194-056,
   103-2811-E-194-003]
FX This work was supported in part by the Ministry of Science and
   Technology, Taiwan under Grants 102-2221-E-194-056 and
   103-2811-E-194-003.
CR Ayres FJ, 2005, SIBGRAPI 2005: XVIII BRAZILIAN SYMPOSIUM ON COMPUTER GRAPHICS AND IMAGE PROCESSING, CONFERENCE PROCEEDINGS, P147
   Becker DE, 1998, IEEE T BIO-MED ENG, V45, P105, DOI 10.1109/10.650362
   Can A, 2002, IEEE T PATTERN ANAL, V24, P347, DOI 10.1109/34.990136
   Can A, 2002, IEEE T PATTERN ANAL, V24, P412, DOI 10.1109/34.990145
   Choe TE, 2005, IEEE I CONF COMP VIS, P106
   Davis J, 1998, PROC CVPR IEEE, P354, DOI 10.1109/CVPR.1998.698630
   Dreo J, 2006, COMPUT MED IMAG GRAP, V30, P453, DOI 10.1016/j.compmedimag.2006.07.004
   Emmenlauer M., 2008, J MICROSC-OXFORD, V233, P42
   Gracias N, 2000, COMPUT VIS IMAGE UND, V79, P66, DOI 10.1006/cviu.2000.0848
   Hajnal J. V., 2001, MED IMAGE REGISTRATI
   HOLLAND PW, 1977, COMMUN STAT A-THEOR, V6, P813, DOI 10.1080/03610927708827533
   Iida T, 2007, BRIT J OPHTHALMOL, V91, P1103, DOI 10.1136/bjo.2007.116160
   IRANI M, 1995, FIFTH INTERNATIONAL CONFERENCE ON COMPUTER VISION, PROCEEDINGS, P605, DOI 10.1109/ICCV.1995.466883
   Koh A, 2012, RETINA-J RET VIT DIS, V32, P1453, DOI 10.1097/IAE.0b013e31824f91e8
   Koh AHC, 2013, RETINA-J RET VIT DIS, V33, P686, DOI 10.1097/IAE.0b013e3182852446
   Lester H, 1999, PATTERN RECOGN, V32, P129, DOI 10.1016/S0031-3203(98)00095-8
   Lim TH, 2010, EYE, V24, P483, DOI 10.1038/eye.2009.323
   Lowe DG, 2004, INT J COMPUT VISION, V60, P91, DOI 10.1023/B:VISI.0000029664.99615.94
   Maintz J B, 1998, Med Image Anal, V2, P1, DOI 10.1016/S1361-8415(01)80026-8
   Matsopoulos G K, 1999, IEEE Trans Inf Technol Biomed, V3, P47, DOI 10.1109/4233.748975
   Matsopoulos GK, 2004, IEEE T MED IMAGING, V23, P1557, DOI 10.1109/TMI.2004.836547
   Nunes JC, 2004, COMPUT VIS IMAGE UND, V95, P129, DOI 10.1016/j.cviu.2004.03.007
   Otani A, 2007, AM J OPHTHALMOL, V144, P7, DOI 10.1016/j.ajo.2007.03.014
   Perez-Rovira A, 2012, IEEE T MED IMAGING, V31, P140, DOI 10.1109/TMI.2011.2167517
   Pinz A, 1998, IEEE T MED IMAGING, V17, P606, DOI 10.1109/42.730405
   Pluim JPW, 2003, IEEE T MED IMAGING, V22, P986, DOI 10.1109/TMI.2003.815867
   Preibisch S, 2009, BIOINFORMATICS, V25, P1463, DOI 10.1093/bioinformatics/btp184
   Sawhney H. S., 1998, Computer Vision - ECCV'98. 5th European Conference on Computer Vision. Proceedings, P103
   Shum HY, 2000, INT J COMPUT VISION, V36, P101, DOI 10.1023/A:1008195814169
   Soares JVB, 2006, IEEE T MED IMAGING, V25, P1214, DOI 10.1109/TMI.2006.879967
   Sun CM, 2006, J MICROSC-OXFORD, V224, P158, DOI 10.1111/j.1365-2818.2006.01687.x
   Tamura H, 2007, BRIT J OPHTHALMOL, V91, P1152, DOI 10.1136/bjo.2006.112318
   Tsai C.-L., 2011, 2 ANN AMA IEEE MED T
   Tsai CL, 2011, J MICROSC-OXFORD, V243, P154, DOI 10.1111/j.1365-2818.2011.03489.x
   Tsai CL, 2010, IEEE T MED IMAGING, V29, P636, DOI 10.1109/TMI.2009.2030324
   Wilson M, 2003, INVEST OPHTH VIS SCI, V44, pU412
   Yang GH, 2007, IEEE T PATTERN ANAL, V29, P1973, DOI 10.1109/TPAMl.2007.1116.
NR 37
TC 2
Z9 2
U1 0
U2 8
PU IEEE-INST ELECTRICAL ELECTRONICS ENGINEERS INC
PI PISCATAWAY
PA 445 HOES LANE, PISCATAWAY, NJ 08855-4141 USA
SN 2168-2194
EI 2168-2208
J9 IEEE J BIOMED HEALTH
JI IEEE J. Biomed. Health Inform.
PD MAY
PY 2017
VL 21
IS 3
BP 785
EP 793
DI 10.1109/JBHI.2016.2538265
PG 9
WC Computer Science, Information Systems; Computer Science,
   Interdisciplinary Applications; Mathematical & Computational Biology;
   Medical Informatics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Computer Science; Mathematical & Computational Biology; Medical
   Informatics
GA EU5TN
UT WOS:000401096700022
PM 28113480
DA 2022-11-30
ER

PT J
AU Lejoyeux, R
   Behar-Cohen, F
   Mantel, I
   Ruiz-Medrano, J
   Mrejen, S
   Tadayoni, R
   Gaudric, A
   Bousquet, E
AF Lejoyeux, Raphael
   Behar-Cohen, Francine
   Mantel, Irmela
   Ruiz-Medrano, Jorge
   Mrejen, Sarah
   Tadayoni, Ramin
   Gaudric, Alain
   Bousquet, Elodie
TI Type one macular neovascularization in central serous chorioretinopathy:
   Short-term response to anti-vascular endothelial growth factor therapy
SO EYE
LA English
DT Article
ID OPTICAL COHERENCE TOMOGRAPHY; CHOROIDAL NEOVASCULARIZATION; PHOTODYNAMIC
   THERAPY; RANIBIZUMAB; ANGIOGRAPHY; VERTEPORFIN; EXUDATION
AB Purpose The aim of this study was to assess the short-term effect of anti-vascular endothelial growth factor (VEGF) treatment on type 1 macular neovascularization (MNV) secondary to central serous chorioretinopathy (CSCR) and to identify potential predictive factors for treatment response using multimodal imaging. Methods Retrospective, multicentre study in CSCR patients with MNV detected by OCT-angiography and treated with anti-VEGF injections. Clinical and multimodal imaging data before and after anti-VEGF injections was reviewed. Univariate and multivariate linear regression analyses were performed to evaluate associations between the change in central macular thickness (CMT) after anti-VEGF therapy and other factors. Results Forty patients were included. One month after receiving a mean number of 2.7 anti-VEGF intravitreal injections, visual acuity increased significantly from 0.46 +/- 0.3 logMAR at baseline to 0.38 +/- 0.4 logMAR (p = 0.04). The CMT and foveal serous retinal detachment (SRD) decreased significantly from 330 +/- 81.9 mu m at baseline to 261.7 +/- 63.1 mu m after treatment (p < 0.001) and from 145.1 +/- 98.8 mu m at baseline to 52.6 +/- 71.3 mu m (p < 0.001), respectively. Subretinal fluid and/or intraretinal fluid were still present in 18 eyes (45%) one month after treatment. In the multivariate analysis, a higher SRD height was associated with a greater CMT change (p = 0.002) and a lower CMT change with the presence of subretinal hyperreflective material (SHRM) (p = 0.04). Conclusion Fluid resorption was incomplete in about half of the patients with MNV secondary to CSCR after anti-VEGF injections. Shallower SRD or the presence of SHRM were predictors of poor response to anti-VEGF.
C1 [Lejoyeux, Raphael; Behar-Cohen, Francine; Bousquet, Elodie] Univ Paris, Hop Cochin, AP HP, Dept Ophthalmol,OphtalmoPole, Paris, France.
   [Lejoyeux, Raphael; Behar-Cohen, Francine; Bousquet, Elodie] Univ Paris, Ctr Rech Cordeliers, Team 17, INSERM U1138, Paris, France.
   [Lejoyeux, Raphael; Mantel, Irmela; Ruiz-Medrano, Jorge] Univ Lausanne, Fdn Asile Aveugles, Jules Gonin Eye Hosp, Dept Ophthalmol, Lausanne, Switzerland.
   [Lejoyeux, Raphael; Mrejen, Sarah] Univ Paris, Ctr Hosp Natl Quinze Vingts, Dept Ophthalmol, Paris, France.
   [Lejoyeux, Raphael; Tadayoni, Ramin; Gaudric, Alain] Univ Paris, Hop Lariboisiere, AP HP, Dept Ophthalmol, F-75010 Paris, France.
   [Lejoyeux, Raphael; Tadayoni, Ramin] Fdn Rothschild Hosp, Retina Dept, Paris, France.
C3 Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin
   - APHP; UDICE-French Research Universities; Universite Paris Cite;
   Institut National de la Sante et de la Recherche Medicale (Inserm);
   UDICE-French Research Universities; Sorbonne Universite; Universite
   Paris Cite; University of Lausanne; CHNO des Quinze-Vingts; UDICE-French
   Research Universities; Sorbonne Universite; Universite Paris Cite;
   Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire
   Lariboisiere-Fernand-Widal - APHP; UDICE-French Research Universities;
   Universite Paris Cite; Fondation Adolphe de Rothschild
RP Bousquet, E (通讯作者)，Univ Paris, Hop Cochin, AP HP, Dept Ophthalmol,OphtalmoPole, Paris, France.; Bousquet, E (通讯作者)，Univ Paris, Ctr Rech Cordeliers, Team 17, INSERM U1138, Paris, France.
EM elodie.bousquet@aphp.fr
RI ; Ruiz-Medrano, Jorge/N-6256-2016
OI behar cohen, francine/0000-0001-8571-9513; Ruiz-Medrano,
   Jorge/0000-0002-1105-9265
CR Ac, 2013, OPHTHALMOLOGY OPHTHA, V120
   Behar-Cohen F, 2019, DRUG DISCOV TODAY, V24, P1436, DOI 10.1016/j.drudis.2019.05.034
   Bousquet E, 2018, RETINA-J RET VIT DIS, V38, P629, DOI 10.1097/IAE.0000000000001580
   Bousquet E, 2015, RETINA-J RET VIT DIS, V35, P2505, DOI 10.1097/IAE.0000000000000614
   Bouzas EA, 2002, SURV OPHTHALMOL, V47, P431, DOI 10.1016/S0039-6257(02)00338-7
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Chen YC, 2020, BRIT J OPHTHALMOL, V104, P1561, DOI 10.1136/bjophthalmol-2019-315302
   Cheung CMG, 2019, EYE, V33, P14, DOI 10.1038/s41433-018-0158-4
   Dansingani KK, 2015, AM J OPHTHALMOL, V160, P1243, DOI 10.1016/j.ajo.2015.08.028
   Daruich A, 2015, PROG RETIN EYE RES, V48, P82, DOI 10.1016/j.preteyeres.2015.05.003
   Freund, 2015, OPHTHALMIC SURG LASE, V46
   GASS JDM, 1991, ARCH OPHTHALMOL-CHIC, V109, P677, DOI 10.1001/archopht.1991.01080050091036
   Imamura Y, 2009, RETINA-J RET VIT DIS, V29, P1469, DOI 10.1097/IAE.0b013e3181be0a83
   Ji SL, 2017, INT J CLIN PHARM-NET, V39, P514, DOI 10.1007/s11096-017-0460-4
   Lai TYY, 2018, RETINA-J RET VIT DIS, V38, P1464, DOI 10.1097/IAE.0000000000001744
   Maruko I, 2011, RETINA-J RET VIT DIS, V31, P759, DOI 10.1097/IAE.0b013e3181fbce8e
   Miki A, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0248760
   Mrejen S, 2019, OPHTHALMOLOGY, V126, P576, DOI 10.1016/j.ophtha.2018.12.048
   Nair U, 2012, CLIN OPHTHALMOL, V6, P1949, DOI 10.2147/OPTH.S38363
   PICCOLINO FC, 1994, RETINA-J RET VIT DIS, V14, P231, DOI 10.1097/00006982-199414030-00008
   Romano MR, 2020, ACTA OPHTHALMOL, V98, pE549, DOI 10.1111/aos.14319
   Romdhane K, 2020, BRIT J OPHTHALMOL, V104, P910, DOI 10.1136/bjophthalmol-2019-314625
   Sacconi R, 2019, EYE, V33, P1809, DOI 10.1038/s41433-019-0511-2
   Schworm B, 2020, GRAEF ARCH CLIN EXP, V258, P1013, DOI 10.1007/s00417-020-04623-w
   Shah VP, 2014, RETINA-J RET VIT DIS, V34, P1281, DOI 10.1097/IAE.0000000000000166
   Shiragami C, 2018, AM J OPHTHALMOL, V193, P80, DOI 10.1016/j.ajo.2018.06.009
   Siedlecki J, 2019, OPHTHALMOL RETINA, V3, P1013, DOI 10.1016/j.oret.2019.08.002
   Smretschnig E, 2016, EYE, V30, P805, DOI 10.1038/eye.2016.41
NR 29
TC 0
Z9 0
U1 1
U2 3
PU SPRINGERNATURE
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND
SN 0950-222X
EI 1476-5454
J9 EYE
JI Eye
PD OCT
PY 2022
VL 36
IS 10
BP 1945
EP 1950
DI 10.1038/s41433-021-01778-6
EA SEP 2021
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 4S0NN
UT WOS:000701604900006
PM 34584236
DA 2022-11-30
ER

PT J
AU Takeda, T
   Tsubaki, M
   Genno, S
   Matsuda, T
   Yamamoto, Y
   Kimura, A
   Shimizu, N
   Nishida, S
AF Takeda, Tomoya
   Tsubaki, Masanobu
   Genno, Shuji
   Matsuda, Takuya
   Yamamoto, Yuuta
   Kimura, Akihiro
   Shimizu, Nao
   Nishida, Shozo
TI Inhibition of yes-associated protein suppresses migration, invasion, and
   metastasis in non-small cell lung cancer in vitro and in vivo
SO CLINICAL AND EXPERIMENTAL MEDICINE
LA English
DT Article
DE Yes-associated protein (YAP); Non-small cell lung cancer (NSCLC);
   Migration; Invasion; Metastasis; Verteporfin
ID HIPPO PATHWAY; GROWTH; YAP; PROMOTES; TUMORIGENESIS; MOTILITY; YAP/TAZ
AB Non-small cell lung cancer (NSCLC) is a highly aggressive cancer with one of the most prevalent malignant tumors. Metastasis in NSCLC is the major cause of treatment failure and cancer-related deaths. Yes-associated protein (YAP) is a transcriptional coactivator regulated by the evolutionarily conserved Hippo signaling pathway that regulates organ size, growth, and regeneration. YAP is highly expressed in several malignant tumor types. Furthermore, YAP promotes tumor initiation and/or progression in various types of cancer. However, it is unclear whether YAP contributes to the metastasis in NSCLC and serves as a useful therapeutic target. Here, we investigated whether levels of YAP correlate with metastatic phenotype in NSCLC cells and serve as a useful therapeutic target. We found that high levels of YAP associate with high cell migration, invasion, and metastasis in NSCLC cell lines. Furthermore, YAP siRNA decreased the migration and invasion in NSCLC cells. Additionally, verteporfin, an agent used for the treatment of symptomatic polypoidal choroidal vasculopathy, decreased the expression of YAP and inhibited migration, invasion, and metastasis in NSCLC cells. Thus, the study suggests that targeting YAP may present a new avenue to develop therapeutics against metastasis in NSCLC and that verteporfin has potential molecular therapeutic strategy for the treatment of metastatic NSCLC.
C1 [Takeda, Tomoya; Tsubaki, Masanobu; Genno, Shuji; Matsuda, Takuya; Yamamoto, Yuuta; Kimura, Akihiro; Shimizu, Nao; Nishida, Shozo] Kindai Univ, Div Pharmacotherapy, Sch Pharm, 3-4-1 Kowakae, Higashiosaka, Osaka 5778502, Japan.
C3 Kindai University (Kinki University)
RP Nishida, S (通讯作者)，Kindai Univ, Div Pharmacotherapy, Sch Pharm, 3-4-1 Kowakae, Higashiosaka, Osaka 5778502, Japan.
EM nishida@phar.kindai.ac.jp
FU Japan Society for the Promotion of Science (JSPS)
FX This study was supported in part by a Grant-in-Aid for Young Scientists
   from the Japan Society for the Promotion of Science (JSPS).
CR Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492
   Dong L, 2018, INT J MED SCI, V15, P645, DOI 10.7150/ijms.23460
   Dong XM, 2019, CANCER MANAG RES, V11, P6245, DOI 10.2147/CMAR.S197921
   Halder G, 2011, DEVELOPMENT, V138, P9, DOI 10.1242/dev.045500
   Han YY, 2019, J TRANSL MED, V17, DOI 10.1186/s12967-019-1869-4
   Harvey K, 2007, NAT REV CANCER, V7, P182, DOI 10.1038/nrc2070
   Herbst RS, 2018, NATURE, V553, P446, DOI 10.1038/nature25183
   Hsu PC, 2020, CANCERS, V12, DOI 10.3390/cancers12061361
   Hsu PC, 2018, J CELL MOL MED, V22, P3073, DOI 10.1111/jcmm.13582
   Huang SH, 2020, PHYTOMEDICINE, V69, DOI 10.1016/j.phymed.2020.153210
   Huggett MT, 2014, BRIT J CANCER, V110, P1698, DOI 10.1038/bjc.2014.95
   Isago H, 2020, AM J RESP CELL MOL, V62, P256, DOI 10.1165/rcmb.2019-0218OC
   Johnson R, 2014, NAT REV DRUG DISCOV, V13, P63, DOI 10.1038/nrd4161
   Lang-Lazdunski L, 2013, EUR RESPIR REV, V22, P382, DOI 10.1183/09059180.00003913
   Liu-Chittenden Y, 2012, GENE DEV, V26, P1300, DOI 10.1101/gad.192856.112
   Lo Sardo F, 2018, CANCERS, V10, DOI 10.3390/cancers10050137
   Ma L, 2021, EXP LUNG RES, V47, P250, DOI 10.1080/01902148.2021.1916651
   Miao J, 2017, ONCOTARGET, V8, P89802, DOI 10.18632/oncotarget.21155
   Michels S, 2001, Semin Ophthalmol, V16, P201, DOI 10.1076/soph.16.4.201.10298
   Morgensztern D, 2010, J THORAC ONCOL, V5, P29, DOI 10.1097/JTO.0b013e3181c5920c
   Moroishi T, 2015, NAT REV CANCER, V15, P73, DOI 10.1038/nrc3876
   Pan DJ, 2007, GENE DEV, V21, P886, DOI 10.1101/gad.1536007
   Patel S, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02872
   Phan ANH, 2016, ONCOTARGET, V7, P54702, DOI 10.18632/oncotarget.10581
   Song JM, 2018, CARCINOGENESIS, V39, P911, DOI 10.1093/carcin/bgy049
   Takeda T, 2016, TOXICOL APPL PHARM, V306, P105, DOI 10.1016/j.taap.2016.07.005
   Thompson BJ, 2020, BIOESSAYS, V42, DOI 10.1002/bies.201900162
   Tsubaki M, 2021, BIOMEDICINES, V9, DOI 10.3390/biomedicines9010035
   Tsubaki M, 2016, BIOMED PHARMACOTHER, V78, P23, DOI 10.1016/j.biopha.2015.12.017
   Tsubaki M, 2015, AM J CANCER RES, V5, P168
   Tsubaki M, 2013, J EXP CLIN CANC RES, V32, DOI 10.1186/1756-9966-32-62
   Vigneswaran K, 2021, CLIN CANCER RES, V27, P1553, DOI 10.1158/1078-0432.CCR-20-0018
   Nguyen VHL, 2019, J OVARIAN RES, V12, DOI 10.1186/s13048-019-0596-z
   Wang B, 2020, AM J CANCER RES, V10, P1207
   Wang T, 2018, BBA-MOL BASIS DIS, V1864, P1744, DOI 10.1016/j.bbadis.2018.02.020
   Wang Y, 2010, CANCER SCI, V101, P1279, DOI 10.1111/j.1349-7006.2010.01511.x
   Warren JSA, 2018, CANCERS, V10, DOI 10.3390/cancers10040115
   Xie HJ, 2018, LIFE SCI, V214, P176, DOI 10.1016/j.lfs.2018.10.062
   Xu MZ, 2009, CANCER-AM CANCER SOC, V115, P4576, DOI 10.1002/cncr.24495
   Yang SP, 2015, ONCOTARGET, V6, P36019, DOI 10.18632/oncotarget.5935
   Yu T, 2015, ONCOGENE, V34, P413, DOI 10.1038/onc.2013.574
   Zanconato F, 2019, NAT REV CANCER, V19, P454, DOI 10.1038/s41568-019-0168-y
   Zanconato F, 2016, CANCER CELL, V29, P783, DOI 10.1016/j.ccell.2016.05.005
   Zhang L, 2015, MOL CELL BIOL, V35, P1350, DOI 10.1128/MCB.00102-15
   Zhou PJ, 2017, J EXP CLIN CANC RES, V36, DOI 10.1186/s13046-017-0609-y
NR 45
TC 0
Z9 0
U1 3
U2 5
PU SPRINGER-VERLAG ITALIA SRL
PI MILAN
PA VIA DECEMBRIO, 28, MILAN, 20137, ITALY
SN 1591-8890
EI 1591-9528
J9 CLIN EXP MED
JI Clin. Exper. Med.
PD MAY
PY 2022
VL 22
IS 2
BP 221
EP 228
DI 10.1007/s10238-021-00738-4
EA JUL 2021
PG 8
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA 1H4RC
UT WOS:000668808400002
PM 34196881
DA 2022-11-30
ER

PT J
AU Concilio, M
   Fossataro, F
   Montorio, D
   Giordano, M
   Cennamo, G
AF Concilio, Marina
   Fossataro, Federica
   Montorio, Daniela
   Giordano, Mariapaola
   Cennamo, Gilda
TI The role of quantitative deep capillary plexus in the pathogenesis of
   type 3 macular neovascularization: an optical coherence tomography
   angiography study
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE Type 3 MNV; Optical coherence tomography angiography; Deep capillary
   plexus; Vessel density; Reticular pseudodrusen
ID CLINICOPATHOLOGICAL CORRELATION; SPECTRUM; FEATURES
AB Purpose To quantitatively investigate the role of deep capillary plexus (DCP) in patients affected by type 3 macular neovascularization (MNV), compared to patients with reticular pseudodrusen (RPD) eyes and healthy controls, using optical coherence tomography angiography (OCTA).
   Methods In this prospective observational study, a total of seventy-eight eyes of 78 patients were included. Group 1 consisted of 40 eyes of 40 patients with stage 1 of type 3 MNV (22 males, 18 females, mean age 73.7, SD +/- 6.60) and group 2 included 38 eyes of 38 patients with RPD (17 males, 21 females, mean age 73.2, SD +/- 4.55). The control group included 40 eyes of 40 healthy subjects (20 males, 20 females, mean age 71.4, SD +/- 6.36 years). We evaluated the retinal vessel density (VD) of superficial capillary plexus (SCP) and deep capillary plexus (DCP) using OCTA.
   Results Patients with diagnosis of type 3 MNV showed statistically lower values of VD in DCP with respect to controls and to RPD group (p < 0.001), while there were no statistical differences between RPD and control group in macular region. No significant differences in VD of SCP were detected among the three study groups.
   Conclusion OCTA provides a reproducible, non-invasive detailed quantitative analysis of retinal vascular features and changing in early-stage type 3 MNV patients, which allowed to shed the light on the main role of DCP ischemia in the development of type 3 MNV.
C1 [Concilio, Marina; Fossataro, Federica; Montorio, Daniela; Giordano, Mariapaola] Univ Naples Federico II, Dept Neurosci Reprod Sci & Dent, Eye Clin, Via S Pansini 5, I-80131 Naples, Italy.
   [Cennamo, Gilda] Univ Naples Federico II, Dept Publ Hlth, Eye Clin, Naples, Italy.
C3 University of Naples Federico II; University of Naples Federico II
RP Cennamo, G (通讯作者)，Univ Naples Federico II, Dept Publ Hlth, Eye Clin, Naples, Italy.
EM xgilda@hotmail.com
RI Fossataro, Federica/AAU-9316-2021
OI Fossataro, Federica/0000-0001-5798-1899; CENNAMO,
   Gilda/0000-0003-4253-1929
CR Borrelli E, 2020, EYE, V34, P2264, DOI 10.1038/s41433-020-0804-5
   Borrelli E, 2018, RETINA-J RET VIT DIS, V38, P1968, DOI 10.1097/IAE.0000000000002198
   Cennamo, 2020, PHOTODIAGNOSIS PROTO, V33
   Colantuono D, 2021, EUR J OPHTHALMOL, V31, P2474, DOI 10.1177/1120672120968758
   Feigl B, 2009, PROG RETIN EYE RES, V28, P63, DOI 10.1016/j.preteyeres.2008.11.004
   Freund KB, 2008, RETINA-J RET VIT DIS, V28, P201, DOI 10.1097/IAE.0b013e3181669504
   Gass JDM, 2003, RETINA-J RET VIT DIS, V23, P741, DOI 10.1097/00006982-200312000-00001
   HARTNETT ME, 1992, GRAEF ARCH CLIN EXP, V230, P11, DOI 10.1007/BF00166756
   Huang D, 2016, DEV OPHTHALMOL, V56, P6, DOI 10.1159/000442770
   Jia YL, 2012, OPT EXPRESS, V20, P4710, DOI 10.1364/OE.20.004710
   Lafaut BA, 2000, BRIT J OPHTHALMOL, V84, P1269, DOI 10.1136/bjo.84.11.1269
   Martins A, 2018, OPHTHALMIC RES, V59, P88, DOI 10.1159/000481262
   Monson DM, 2008, ARCH OPHTHALMOL-CHIC, V126, P1664, DOI 10.1001/archopht.126.12.1664
   Nagiel A, 2015, RETINA-J RET VIT DIS, V35, P638, DOI 10.1097/IAE.0000000000000488
   Phasukkijwatana N, 2017, BRIT J OPHTHALMOL, V101, P597, DOI 10.1136/bjophthalmol-2016-308815
   Querques, 2021, RETINA-J RET VIT DIS, V12
   Querques G, 2016, DEV OPHTHALMOL, V56, P57, DOI 10.1159/000442779
   Sacconi R, 2021, BRIT J OPHTHALMOL, V105, P222, DOI 10.1136/bjophthalmol-2020-316054
   Sacconi R, 2018, OPHTHALMOL RETINA, V2, P1097, DOI 10.1016/j.oret.2018.04.016
   Savastano MC, 2015, RETINA-J RET VIT DIS, V35, P2196, DOI 10.1097/IAE.0000000000000635
   Sawa M, 2014, RETINA-J RET VIT DIS, V34, P761, DOI 10.1097/01.iae.0000434566.57189.37
   Silva N, 2020, CASE REP OPHTHALM, V11, P493, DOI 10.1159/000509139
   Spaide RF, 2016, AM J OPHTHALMOL, V170, P58, DOI 10.1016/j.ajo.2016.07.023
   Su D, 2016, RETINA-J RET VIT DIS, V36, pS40, DOI 10.1097/IAE.0000000000001268
   Yannuzzi LA, 2001, RETINA-J RET VIT DIS, V21, P416, DOI 10.1097/00006982-200110000-00003
NR 25
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0721-832X
EI 1435-702X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD FEB
PY 2022
VL 260
IS 2
BP 425
EP 430
DI 10.1007/s00417-021-05330-w
EA AUG 2021
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA YN7BB
UT WOS:000681163000002
PM 34350468
OA hybrid, Green Published
DA 2022-11-30
ER

PT J
AU Vossmerbaeumer, U
   Kuehl, S
   Kern, S
   Kluter, H
   Jonas, JB
   Bieback, K
AF Vossmerbaeumer, Urs
   Kuehl, Sandra
   Kern, Susanne
   Kluter, Harald
   Jonas, Jost B.
   Bieback, Karen
TI Induction of retinal pigment epithelium properties in ciliary margin
   progenitor cells
SO CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE age-related macular degeneration; cytoengineering; differentiation;
   ocular progenitor cell; retinal pigment epithelium
ID MICROTUBULE-ASSOCIATED PROTEIN; ADULT MAMMALIAN EYE; STEM-CELLS; MACULAR
   DEGENERATION; SUBRETINAL SPACE; BINDING-PROTEIN; MESSENGER-RNA;
   IN-VITRO; NESTIN; DIFFERENTIATION
AB Purpose: Degenerative processes in the retinal pigment epithelium (RPE) are known to play a pivotal role in the development of age-related maculopathy. Substitute RPE analogue cells could be used to preserve visual function. In this paper we investigate methods for the isolation, cultivation and RPE differentiation of undifferentiated cells from the ciliary marginal zone (CMZ) of rat eyes.
   Methods: The CMZ was isolated from enucleated rat eyes, cell spheres formed in serum-free suspension culture, Bromodeoxyuridine (BrdU) incorporation indicated mitotic activity. Following baseline differentiation status assessment, directional differentiation was induced by cultivating cells in RPE-conditioned medium and vasoactive intestinal peptide (VIP). The differentiation status was analysed by immunocytochemistry. Fluorescein isothiocyanate (FITC)-labelled latex beads were used for functional evaluation.
   Results: CMZ-derived cells were expanded for 6-12 months. Formation of spherical cellular conglomerates, subsphere formation and expression of nestin indicated progenitor cells. Baseline levels of markers MAP-2 for neuronal and GFAP for glial properties and baseline levels of bestrophin, cytokeratins 8 and 18 and RPE 65 for RPE properties were induced by serum culture, respectively. Culture in conditioned medium with addition of VIP significantly increased RPE marker expression and reduced neuronal features, uptake of latex beads indicated phagocytosis.
   Conclusions: We succeeded in isolating and cultivating cells from rodent CMZ with progenitor cell characteristics. Subsequently, these cells tested positive for neuronal, glial and RPE markers. Appropriate conditions significantly increased RPE marker expression. Unidirectional induction of differentiation makes the CMZ eligible as a source of regenerative ocular tissue for RPE-reconditioning therapy.
C1 [Vossmerbaeumer, Urs; Kuehl, Sandra; Jonas, Jost B.] Heidelberg Univ, Dept Ophthalmol, Mannheim Med Fac, Univ Augenklin,Univ Eye Hosp, D-68167 Mannheim, Germany.
   [Kuehl, Sandra; Kern, Susanne; Kluter, Harald; Bieback, Karen] Heidelberg Univ, Mannheim Med Fac, German Red Cross Blood Serv Baden Wuerttemberg He, Inst Transfus Med & Immunol, D-68167 Mannheim, Germany.
C3 Ruprecht Karls University Heidelberg; University of Hamburg; University
   Medical Center Hamburg-Eppendorf; Ruprecht Karls University Heidelberg
RP Vossmerbaeumer, U (通讯作者)，Heidelberg Univ, Dept Ophthalmol, Mannheim Med Fac, Univ Augenklin,Univ Eye Hosp, Theodor Kutzer Ufer 1-3, D-68167 Mannheim, Germany.
EM urs.vossmerbaeumer@augen.ma.uni-heidelberg.de
CR Abmad I, 2001, INVEST OPHTH VIS SCI, V42, P2743
   Ahmad I, 2000, BIOCHEM BIOPH RES CO, V270, P517, DOI 10.1006/bbrc.2000.2473
   Ahmad I, 1999, BRAIN RES, V831, P1, DOI 10.1016/S0006-8993(99)01376-1
   Algvere PV, 1997, GRAEF ARCH CLIN EXP, V235, P149, DOI 10.1007/BF00941722
   Chacko DM, 2000, BIOCHEM BIOPH RES CO, V268, P842, DOI 10.1006/bbrc.2000.2153
   Coles BLK, 2004, P NATL ACAD SCI USA, V101, P15772, DOI 10.1073/pnas.0401596101
   DAHLSTRAND J, 1995, DEV BRAIN RES, V84, P109, DOI 10.1016/0165-3806(94)00162-S
   DAHLSTRAND J, 1992, J CELL SCI, V103, P589
   Das AV, 2005, VISION RES, V45, P1653, DOI 10.1016/j.visres.2004.12.017
   Delcourt C, 2005, AM J OPHTHALMOL, V140, P924, DOI 10.1016/j.ajo.2005.05.002
   Engelhardt M, 2005, BRAIN RES, V1040, P98, DOI 10.1016/j.brainres.2005.01.075
   Engelmann K, 2004, GRAEF ARCH CLIN EXP, V242, P65, DOI 10.1007/s00417-003-0811-9
   Enzmann V, 2003, INVEST OPHTH VIS SCI, V44, P5417, DOI 10.1167/iovs.03-0468
   Ernst C, 2006, NEUROSCIENCE, V138, P183, DOI 10.1016/j.neuroscience.2005.10.065
   Fassbender K, 2004, FASEB J, V18, P203, DOI 10.1096/fj.03-0364fje
   FRANKE WW, 1981, J MOL BIOL, V153, P933, DOI 10.1016/0022-2836(81)90460-5
   Gu P, 2007, MOL VIS, V13, P1045
   Haruta M, 2004, INVEST OPHTH VIS SCI, V45, P1020, DOI 10.1167/iovs.03-1034
   Haynes T, 2004, CURR NEUROVASC RES, V1, P231, DOI 10.2174/1567202043362216
   HERNANDEZ MA, 1988, BIOCHIM BIOPHYS ACTA, V965, P195, DOI 10.1016/0304-4165(88)90056-6
   Klein R, 2005, AM J OPHTHALMOL, V140, P129, DOI 10.1016/j.ajo.2004.12.049
   Koh SWM, 2000, PROG RETIN EYE RES, V19, P669, DOI 10.1016/S1350-9462(00)00010-0
   Kubota R, 2002, DEV BRAIN RES, V134, P31, DOI 10.1016/S0165-3806(01)00287-5
   Leske MC, 2006, OPHTHALMOLOGY, V113, P29, DOI 10.1016/j.ophtha.2005.08.012
   MacLaren RE, 2005, OPHTHALMOLOGY, V112, P2081, DOI 10.1016/j.ophtha.2005.06.029
   Marmorstein AD, 2000, P NATL ACAD SCI USA, V97, P12758, DOI 10.1073/pnas.220402097
   Mata NL, 2004, J BIOL CHEM, V279, P635, DOI 10.1074/jbc.M310042200
   Means AL, 2005, DEVELOPMENT, V132, P3767, DOI 10.1242/dev.01925
   Medeiros NE, 2001, INVEST OPHTH VIS SCI, V42, P795
   Perron M, 2000, BIOESSAYS, V22, P685, DOI 10.1002/1521-1878(200008)22:8<685::AID-BIES1>3.0.CO;2-C
   Saigo Y, 2004, INVEST OPHTH VIS SCI, V45, P1996, DOI 10.1167/iovs.03-0777
   Spraul CW, 1998, OPHTHALMOLOGE, V95, P73, DOI 10.1007/s003470050240
   Tezel TH, 1997, GRAEF ARCH CLIN EXP, V235, P41, DOI 10.1007/BF01007836
   Tropepe V, 2000, SCIENCE, V287, P2032, DOI 10.1126/science.287.5460.2032
   Yan WH, 2005, CELL BIOL INT, V29, P153, DOI 10.1016/j.cellbi.2004.10.001
NR 35
TC 15
Z9 17
U1 0
U2 2
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1442-6404
EI 1442-9071
J9 CLIN EXP OPHTHALMOL
JI Clin. Exp. Ophthalmol.
PD MAY-JUN
PY 2008
VL 36
IS 4
BP 358
EP 366
DI 10.1111/j.1442-9071.2008.01770.x
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 323VH
UT WOS:000257476000013
PM 18700924
DA 2022-11-30
ER

PT J
AU Ortak, H
   Demir, S
   Ates, O
   Sogut, E
   Alim, S
   Benli, I
AF Ortak, Huseyin
   Demir, Selim
   Ates, Omer
   Sogut, Erkan
   Alim, Sait
   Benli, Ismail
TI Association of MMP2-1306C/T and TIMP2G-418C polymorphisms in retinal
   vein occlusion
SO EXPERIMENTAL EYE RESEARCH
LA English
DT Article
DE retinal vein occlusion; matrix metalloproteinase; polymorphisms
ID TISSUE INHIBITOR; METALLOPROTEINASE INHIBITORS; MATRIX
   METALLOPROTEINASES; PLATELET ACTIVATION; GENE POLYMORPHISMS;
   GELATINASE-A; MMP-2; PATHOGENESIS; POPULATION; EXPRESSION
AB Matrix metalloproteinases (MMPs) are large groups of zinc-dependent proteases that play an important role in many diseases and pathological processes such as cancer, angiogenesis, atherosclerosis, and vascular disease. Also, it was found that the expression of MMPs was high during the initial period of thrombosis in a rat model of traumatic deep vein thrombosis. Moreover, the presence of metalloproteinase activity and endogenous inhibitor activity in vitrectomy samples are associated with neovascularization of several retinal diseases such as exudative age related maculopathy, proliferative diabetic retinopathy, and central retinal vein occlusion. In this study, we aimed to investigate the possible association of the matrix metalloproteinase 2-1306C/T (rs 243865) and tissue inhibitors of matrix metalloproteinase 2 G-418C (rs 8179090) polymorphisms with the risk of retinal vein occlusion (RVO). Genomic DNA was extracted from peripheral leukocytes from ethylenediaminetetraacetic acid anticoagulated blood. Genotyping of the MMP2-1306C/T and TIMP2G-418C polymorphisms were performed using real-time polymerase chain reaction. The MMP2-1306 T allele carriers (CT + TT) had a significantly increased risk of RVO compared with the CC homozygotes (p < 0.001, odds ratio = 4.78; 95% CI = 2.85-8.09). After adjusting for hypertension, diabetes, hypertriglyceridemia, and hypercholesterolemia, MMP2-1306 T allele carriers (Cl' + TT) also had a significantly increased risk of RVO (B = 1.453; p < 0.001; odds ratio = 4.275; 95% CI:2.529-7.224). MMP2-1306C/T, but not TIMP2G-418C, gene variants are a risk factor for the development of retinal vein occlusion. (C) 2013 Elsevier Ltd. All rights reserved.
C1 [Ortak, Huseyin; Demir, Selim] Gaziosmanpasa Univ, Fac Med, Dept Ophthalmol, Tokat, Turkey.
   [Ates, Omer] Gaziosmanpasa Univ, Fac Med, Dept Med Biol, Tokat, Turkey.
   [Sogut, Erkan; Benli, Ismail] Gaziosmanpasa Univ, Fac Med, Dept Biochem, Tokat, Turkey.
   [Alim, Sait] Tokat State Hosp, Dept Ophthalmol, Tokat, Turkey.
C3 Gaziosmanpasa University; Gaziosmanpasa University; Gaziosmanpasa
   University; Tokat State Hospital
RP Ortak, H (通讯作者)，Gaziosmanpasa Univ, Fac Med, Dept Ophthalmol, Tokat, Turkey.
EM huseyin.ortak@hotmail.com
RI benli, ismail/A-7441-2016
FU Research Foundation of Gaziosmanpasa University [2012/22]
FX This work was partially supported by the Research Foundation of
   Gaziosmanpasa University 2012/22.
CR Amer Diabet Assoc, 2010, DIABETES CARE, V33, pS62, DOI 10.2337/dc10-s062
   Arakawa S, 2011, INVEST OPHTH VIS SCI, V52, P5905, DOI 10.1167/iovs.11-7775
   Basalyga DM, 2004, CIRCULATION, V110, P3480, DOI 10.1161/01.CIR.0000148367.08413.E9
   Benjamin Mina M, 2012, Exp Suppl, V103, P209, DOI 10.1007/978-3-0348-0364-9_7
   Bergmeier W, 2003, BLOOD, V102, P4229, DOI 10.1182/blood-2003-04-1305
   Brassart B, 1998, CLIN EXP METASTAS, V16, P489, DOI 10.1023/A:1006550503612
   Das A, 1999, INVEST OPHTH VIS SCI, V40, P809
   De la Paz MA, 1998, INVEST OPHTH VIS SCI, V39, P1256
   DECLERCK YA, 1994, GENE, V139, P185, DOI 10.1016/0378-1119(94)90753-6
   Falcinelli E, 2005, J THROMB HAEMOST, V3, P2526, DOI 10.1111/j.1538-7836.2005.01614.x
   Fernandez-Patron C, 1999, THROMB HAEMOSTASIS, V82, P1730, DOI 10.1055/s-0037-1614906
   HARSFALVI J, 1995, BLOOD, V85, P705, DOI 10.1182/blood.V85.3.705.bloodjournal853705
   Hirano K, 2001, EUR RESPIR J, V18, P748, DOI 10.1183/09031936.01.00102101
   Lambert V, 2003, FASEB J, V17, P2290, DOI 10.1096/fj.03-0113fje
   Leoncini G, 2007, THROMB HAEMOSTASIS, V97, P218, DOI 10.1160/TH06-05-0257
   Li ZH, 1996, AM J PATHOL, V148, P121
   Martinez A, 2001, Med Sci Monit, V7, P646
   Medley TL, 2004, ARTERIOSCL THROM VAS, V24, P1479, DOI 10.1161/01.ATV.0000135656.49158.95
   Ortak H, 2012, CLIN EXP OPHTHALMOL, V40, P743, DOI 10.1111/j.1442-9071.2012.02780.x
   PEPPER MS, 1990, CELL DIFFER DEV, V32, P319, DOI 10.1016/0922-3371(90)90046-Y
   Pocsai Z, 2003, CLIN CHIM ACTA, V332, P31, DOI 10.1016/S0009-8981(03)00083-4
   Price SJ, 2001, J BIOL CHEM, V276, P7549, DOI 10.1074/jbc.M010242200
   Rehak J, 2008, CURR EYE RES, V33, P111, DOI 10.1080/02713680701851902
   Rehak M, 2010, J THROMB HAEMOST, V8, P1886, DOI 10.1111/j.1538-7836.2010.03909.x
   Rogers S, 2010, OPHTHALMOLOGY, V117, P313, DOI [10.1016/j.ophtha.2009.07.017, 10.1016/j.ophtha.2010.01.060]
   Sawicki G, 1997, NATURE, V386, P616, DOI 10.1038/386616a0
   Srivastava P, 2012, ARCH MED RES, V43, P117, DOI 10.1016/j.arcmed.2012.02.006
   Steen B, 1998, INVEST OPHTH VIS SCI, V39, P2194
   Steinbrugger I, 2009, MOL VIS, V15, P609
   Wang Y, 2010, BIOCHEM BIOPH RES CO, V391, P113, DOI 10.1016/j.bbrc.2009.11.012
   Wong TY, 2010, NEW ENGL J MED, V363, P2135, DOI 10.1056/NEJMcp1003934
   Yu PK, 2012, INVEST OPHTH VIS SCI, V53, P1108, DOI 10.1167/iovs.11-8865
   Zhang BP, 1999, CIRCULATION, V99, P1788, DOI 10.1161/01.CIR.99.14.1788
   Zhang LY, 2011, ARCH MED RES, V42, P239, DOI 10.1016/j.arcmed.2011.04.013
   Zitka O, 2010, CURR MED CHEM, V17, P3751, DOI 10.2174/092986710793213724
NR 35
TC 11
Z9 12
U1 0
U2 14
PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 0014-4835
EI 1096-0007
J9 EXP EYE RES
JI Exp. Eye Res.
PD AUG
PY 2013
VL 113
BP 151
EP 155
DI 10.1016/j.exer.2013.06.009
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 198OH
UT WOS:000322931700020
PM 23791966
DA 2022-11-30
ER

PT J
AU Wang, YM
   Xie, MY
   Zhang, M
   Zhao, XH
   Zhu, XY
   Wang, YW
   Chen, YH
   Chen, JQ
   Sun, XD
AF Wang, Yimin
   Xie, Minyue
   Zhang, Min
   Zhao, Xiaohuan
   Zhu, Xinyue
   Wang, Yuwei
   Chen, Yuhong
   Chen, Jieqiong
   Sun, Xiaodong
TI Publication Trends of Research on Polypoidal Choroidal Vasculopathy
   During 2001-2020: A 20-Year Bibliometric Study
SO FRONTIERS IN MEDICINE
LA English
DT Article
DE polypoidal choroidal vasculopathy (PCV); age-related macular
   degeneration (AMD); bibliometric; anti-VEGF (vascular endothelial growth
   factor); pigment epithelial detachment
ID VERTEPORFIN PHOTODYNAMIC THERAPY; ANTI-VEGF APTAMER; MACULAR
   DEGENERATION; H-INDEX; RANIBIZUMAB; DIAGNOSIS; PEGAPTANIB; EFFICACY;
   CHINESE; SAFETY
AB IntroductionPolypoidal choroidal vasculopathy (PCV) is a special subtype of AMD, which is one of the leading threats to vision health worldwide. At this time, many aspects of PCV, from how it works to potential treatments, remain a mystery. In this study, we explored the frontier researches and revealed the study trends within the study of PCV. MethodsWe collected all the publications in this field from 2001 to 2020, analyzed trends within them, and defined the contributions of various countries/regions, institutions, authors, and journals. Additionally, VOSviewer software was used to define the hot keywords in this field. ResultsA total of 1,190 publications were ultimately examined; We found that PCV is becoming an increasingly relevant topic of research, and that Japan has contributed the most publications (428), the most citations (14,504 in total), and the highest H-index value (62) to the field. Our keywords analysis was classified into four clusters to show the hotspots within the study of PCV, namely mechanism-related, imaging-related, prognosis-related, and therapy-related topics. The average years in which the keywords appeared the most were also calculated, and we identified anti-VEGF therapy, anti-complement therapy and angiography as having been the main focus in recent years. ConclusionsThese results helped clarify the comprehensive research progress that has been made as well as the future trends in the study of PCV, which can assist and guide future research.
C1 [Wang, Yimin; Zhang, Min; Zhao, Xiaohuan; Zhu, Xinyue; Wang, Yuwei; Chen, Yuhong; Chen, Jieqiong; Sun, Xiaodong] Shanghai Jiao Tong Univ, Sch Med, Shanghai Gen Hosp, Shanghai, Peoples R China.
   [Wang, Yimin; Zhang, Min; Zhao, Xiaohuan; Zhu, Xinyue; Wang, Yuwei; Chen, Yuhong; Chen, Jieqiong; Sun, Xiaodong] Natl Clin Res Ctr Eye Dis, Shanghai, Peoples R China.
   [Wang, Yimin; Zhang, Min; Zhao, Xiaohuan; Zhu, Xinyue; Wang, Yuwei; Chen, Yuhong; Chen, Jieqiong; Sun, Xiaodong] Shanghai Key Lab Ocular Fundus Dis, Shanghai, Peoples R China.
   [Wang, Yimin; Zhang, Min; Zhao, Xiaohuan; Zhu, Xinyue; Wang, Yuwei; Chen, Yuhong; Chen, Jieqiong; Sun, Xiaodong] Shanghai Engn Ctr Visual Sci & Photomed, Shanghai, Peoples R China.
   [Xie, Minyue] Capital Med Univ, Beijing Tongren Hosp, Beijing, Peoples R China.
C3 Shanghai Jiao Tong University; Capital Medical University
RP Chen, JQ (通讯作者)，Shanghai Jiao Tong Univ, Sch Med, Shanghai Gen Hosp, Shanghai, Peoples R China.; Chen, JQ (通讯作者)，Natl Clin Res Ctr Eye Dis, Shanghai, Peoples R China.; Chen, JQ (通讯作者)，Shanghai Key Lab Ocular Fundus Dis, Shanghai, Peoples R China.; Chen, JQ (通讯作者)，Shanghai Engn Ctr Visual Sci & Photomed, Shanghai, Peoples R China.
EM chenjieqiong2011@163.com
FU National Natural Science Foundation of China [81730026, 82171076,
   8210041148]; National Science and Technology Major Project
   [2017YFA0105301]; Science and Technology Commission of Shanghai
   Municipality [20Z11900400]; Shanghai Hospital Development Center
   [SHDC2020CR2040B, SHDC2020CR5014]
FX This study was supported by the National Natural Science Foundation of
   China (81730026, 82171076, 8210041148) National Science and Technology
   Major Project (2017YFA0105301), Science and Technology Commission of
   Shanghai Municipality (20Z11900400) supported by Shanghai Hospital
   Development Center (SHDC2020CR2040B, SHDC2020CR5014).
CR Anantharaman G, 2018, INDIAN J OPHTHALMOL, V66, P896, DOI 10.4103/ijo.IJO_1136_17
   Anderson DH, 2010, PROG RETIN EYE RES, V29, P95, DOI 10.1016/j.preteyeres.2009.11.003
   Bertran K, 2020, POULTRY SCI, V99, P6503, DOI 10.1016/j.psj.2020.09.017
   Bo QY, 2019, JAMA OPHTHALMOL, V137, P642, DOI 10.1001/jamaophthalmol.2019.0449
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Byeon SH, 2008, JPN J OPHTHALMOL, V52, P57, DOI 10.1007/s10384-007-0498-2
   Casado-Aranda LA, 2021, ENVIRON RES, V193, DOI 10.1016/j.envres.2020.110416
   Cheung CMG, 2021, OPHTHALMOLOGY, V128, P443, DOI 10.1016/j.ophtha.2020.08.006
   Cheung CMG, 2018, OPHTHALMOLOGY, V125, P708, DOI 10.1016/j.ophtha.2017.11.019
   Cheung CMG, 2014, OPHTHALMOLOGY, V121, P1598, DOI 10.1016/j.ophtha.2014.02.004
   Cheung CMG, 2013, AM J OPHTHALMOL, V155, P295, DOI 10.1016/j.ajo.2012.08.002
   Ciardella AP, 2004, SURV OPHTHALMOL, V49, P25, DOI 10.1016/j.survophthal.2003.10.007
   Coscas G, 2014, AM J OPHTHALMOL, V158, P309, DOI 10.1016/j.ajo.2014.05.004
   Dansingani KK, 2018, CLIN EXP OPHTHALMOL, V46, P189, DOI 10.1111/ceo.13114
   Despriet DDG, 2009, OPHTHALMOLOGY, V116, P474, DOI 10.1016/j.ophtha.2008.09.055
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Fleckenstein M, 2021, NAT REV DIS PRIMERS, V7, DOI 10.1038/s41572-021-00265-2
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Izumi T, 2022, RETINA-J RET VIT DIS, V42, P123, DOI 10.1097/IAE.0000000000003264
   Jakobsdottir J, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002199
   Jensen EG, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21249752
   Kato Y, 2020, INVEST OPHTH VIS SCI, V61, DOI 10.1167/iovs.61.13.39
   Kim JY, 2016, GRAEF ARCH CLIN EXP, V254, P1505, DOI 10.1007/s00417-015-3228-3
   Koh A, 2017, JAMA OPHTHALMOL, V135, P1206, DOI 10.1001/jamaophthalmol.2017.4030
   Koh A, 2012, RETINA-J RET VIT DIS, V32, P1453, DOI 10.1097/IAE.0b013e31824f91e8
   Kumar-Singh R, 2019, EXP EYE RES, V184, P266, DOI 10.1016/j.exer.2019.05.006
   Leal S, 2010, RETINA-J RET VIT DIS, V30, P1197, DOI 10.1097/IAE.0b013e3181d37486
   Lee WK, 2018, JAMA OPHTHALMOL, V136, P786, DOI 10.1001/jamaophthalmol.2018.1804
   Li FJ, 2020, BIOMED RES INT, V2020, DOI 10.1155/2020/2428348
   Liu WH, 2021, AESTHET PLAST SURG, V45, P679, DOI 10.1007/s00266-020-01615-3
   Liu Y, 2007, GRAEF ARCH CLIN EXP, V245, P1441, DOI 10.1007/s00417-007-0575-8
   Mettu PS, 2021, PROG RETIN EYE RES, V82, DOI 10.1016/j.preteyeres.2020.100906
   Mitchell P, 2018, LANCET, V392, P1147, DOI 10.1016/S0140-6736(18)31550-2
   Nakashizuka H, 2008, INVEST OPHTH VIS SCI, V49, P4729, DOI 10.1167/iovs.08-2134
   Ng EWM, 2006, ANN NY ACAD SCI, V1082, P151, DOI 10.1196/annals.1348.062
   Ng EWM, 2006, NAT REV DRUG DISCOV, V5, P123, DOI 10.1038/nrd1955
   Nowak JK, 2018, CROAT MED J, V59, P25, DOI 10.3325/cmj.2018.59.25
   Nowak-Sliwinska P, 2013, PROG RETIN EYE RES, V37, P182, DOI 10.1016/j.preteyeres.2013.09.003
   Oishi A, 2014, OPHTHALMOLOGY, V121, P1151, DOI 10.1016/j.ophtha.2013.12.037
   Perrott-Reynolds R, 2019, EYE, V33, P274, DOI 10.1038/s41433-018-0229-6
   Sarwar S, 2016, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD011346.pub2
   Scharf J, 2021, J CLIN MED, V10, DOI 10.3390/jcm10040751
   Tamachi T, 2020, OPHTHALMOL THER, V9, P1069, DOI 10.1007/s40123-020-00312-3
   Wang YM, 2020, J OPHTHALMOL, V2020, DOI 10.1155/2020/4924053
   Wong CW, 2016, PROG RETIN EYE RES, V53, P107, DOI 10.1016/j.preteyeres.2016.04.002
   Wong CW, 2015, RETINA-J RET VIT DIS, V35, P1577, DOI 10.1097/IAE.0000000000000499
   Xiao H, 2021, BRIT J OPHTHALMOL, V105, P103, DOI 10.1136/bjophthalmol-2019-315763
   Xie MY, 2020, ANN TRANSL MED, V8, DOI 10.21037/atm-20-3700
   Yanagi Y, 2020, JPN J OPHTHALMOL, V64, P323, DOI 10.1007/s10384-020-00740-5
NR 50
TC 0
Z9 0
U1 10
U2 13
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
EI 2296-858X
J9 FRONT MED-LAUSANNE
JI Front. Med.
PD JAN 31
PY 2022
VL 8
AR 785126
DI 10.3389/fmed.2021.785126
PG 11
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA ZB0RA
UT WOS:000756559000001
PM 35174182
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Silvestri, G
   Williams, MA
   McAuley, C
   Oakes, K
   Sillery, E
   Henderson, DC
   Ferguson, S
   Silvestri, V
   Muldrew, KA
AF Silvestri, G.
   Williams, M. A.
   McAuley, C.
   Oakes, K.
   Sillery, E.
   Henderson, D. C.
   Ferguson, S.
   Silvestri, V.
   Muldrew, K. A.
TI Drusen prevalence and pigmentary changes in Caucasians aged 18-54 years
SO EYE
LA English
DT Article
DE age-related maculopathy; drusen; pigmentary changes; epidemiology;
   macula
ID MACULAR DEGENERATION; 5-YEAR INCIDENCE; FOLLOW-UP; MACULOPATHY;
   PROGRESSION; EYE; POPULATION; WISCONSIN
AB Aims and Purpose The aim of this study was to describe the prevalence and characteristics of drusen and pigmentary changes in a middle-aged population.
   Methods Retinal images from 500 individuals aged 18-54 years were included. The source of participants was two UK optometry practices. Retinal images were graded using the Wisconsin Age-Related Maculopathy Grading System. However, owing to the relatively young age of the population studied, a new category of drusen of smaller size (<31.5 mu m) was introduced.
   Results Drusen were identified within the central macular grid in 91.48% of all gradable eyes and in 444 subjects. Drusen sized <31.5 mu m were present in 89.7% of eyes, drusen sized >31.5 mu m and <63 mu m were present in 45.9% of all eyes and drusen >63 mu m and <125 mu m were present in only 1.7% of eyes. No eye had drusen larger or equal to 125 mu m. Very few eyes (1.2%) showed pigmentary changes within the grid. Drusen load increased with increasing age, P < 0.001.
   Conclusions The frequency of drusen in a younger Caucasian population aged 18-54 years is high, with 91.48% of all gradable eyes having drusen. The most frequent drusen subtype was hard distinct drusen <31.5 mu m. No druse greater or equal in size to 125 mu m was seen. Pigmentary changes are rare. Eye (2012) 26, 1357-1362; doi: 10.1038/eye.2012.165; published online 17 August 2012
C1 [Silvestri, G.; McAuley, C.; Oakes, K.; Sillery, E.; Silvestri, V.] Queens Univ Belfast, Royal Victoria Hosp, Ctr Vis & Vasc Sci, Belfast BT12 6BA, Antrim, North Ireland.
   [Silvestri, G.; Williams, M. A.] Belfast Hlth & Social Care Trust, Belfast, Antrim, North Ireland.
   [Muldrew, K. A.] Queens Univ Belfast, Cent Angiog Reading Facil, Ctr Vis & Vasc Sci, Belfast BT12 6BA, Antrim, North Ireland.
C3 Queens University Belfast; Queens University Belfast
RP Silvestri, G (通讯作者)，Queens Univ Belfast, Royal Victoria Hosp, Ctr Vis & Vasc Sci, Grosvenor Rd, Belfast BT12 6BA, Antrim, North Ireland.
EM g.silvestri@qub.ac.uk
OI Williams, Michael/0000-0002-5051-5921; McAuley,
   Ciaran/0000-0002-7036-8033; Silvestri, Giuliana/0000-0001-5662-5374
FU RD HPSS NI RRG [4.41]
FX We wish to acknowledge funding from R&D HPSS NI RRG 4.41.
CR Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   Augood CA, 2006, ARCH OPHTHALMOL-CHIC, V124, P529, DOI 10.1001/archopht.124.4.529
   BRESSLER NM, 1995, ARCH OPHTHALMOL-CHIC, V113, P301, DOI 10.1001/archopht.1995.01100030055022
   BRESSLER NM, 1989, ARCH OPHTHALMOL-CHIC, V107, P847, DOI 10.1001/archopht.1989.01070010869032
   Buch H, 2005, OPHTHALMOLOGY, V112, P787, DOI 10.1016/j.ophtha.2004.11.040
   Cruickshanks KJ, 1997, ARCH OPHTHALMOL-CHIC, V115, P242, DOI 10.1001/archopht.1997.01100150244015
   Dickinson AJ, 1997, EYE, V11, P301, DOI 10.1038/eye.1997.66
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Friedman DS, 1999, OPHTHALMOLOGY, V106, P1049, DOI 10.1016/S0161-6420(99)90267-1
   Gupta SK, 2007, INVEST OPHTH VIS SCI, V48, P1007, DOI 10.1167/iovs.06-0712
   Hogg RE, 2007, OPHTHALMOLOGY, V114, P1027
   Ikram MK, 2003, INVEST OPHTH VIS SCI, V44, P3778, DOI 10.1167/iovs.03-0120
   Jonasson F, 2005, OPHTHALMOLOGY, V112, P132, DOI 10.1016/j.ophtha.2004.07.020
   Klein R, 1997, OPHTHALMOLOGY, V104, P7, DOI 10.1016/S0161-6420(97)30368-6
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Klein R, 2007, OPHTHALMOLOGY, V114, P253, DOI 10.1016/j.ophtha.2006.10.040
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Mukesh BN, 2004, OPHTHALMOLOGY, V111, P1176, DOI 10.1016/j.ophtha.2003.08.042
   Munch IC, 2007, INVEST OPHTH VIS SCI, V48, P833, DOI 10.1167/iovs.06-0529
   Munoz B, 2005, ARCH OPHTHALMOL-CHIC, V123, P1575, DOI 10.1001/archopht.123.11.1575
   Sarks SH, 1999, BRIT J OPHTHALMOL, V83, P358, DOI 10.1136/bjo.83.3.358
   SCHACHAT AP, 1995, ARCH OPHTHALMOL-CHIC, V113, P728, DOI 10.1001/archopht.1995.01100060054032
   Sparrow JM, 1997, EYE, V11, P315, DOI 10.1038/eye.1997.67
   Tao Y, 2010, EYE, V24, P648, DOI 10.1038/eye.2009.160
   Tikellis G, 2007, EYE, V21, P169, DOI 10.1038/sj.eye.6702151
   Traboulsi EI, 2005, AM J OPHTHALMOL, V139, P908, DOI 10.1016/j.ajo.2005.01.045
   van Leeuwen R, 2003, ARCH OPHTHALMOL-CHIC, V121, P519, DOI 10.1001/archopht.121.4.519
   VanNewkirk MR, 2000, OPHTHALMOLOGY, V107, P1593, DOI 10.1016/S0161-6420(00)00175-5
   Varma R, 2004, OPHTHALMOLOGY, V111, P1288, DOI 10.1016/j.ophtha.2004.01.023
   VINGERLING JR, 1995, OPHTHALMOLOGY, V102, P205
   Wang JJ, 2007, OPHTHALMOLOGY, V114, P92, DOI 10.1016/j.ophtha.2006.07.017
   Wang Q, 1996, INVEST OPHTH VIS SCI, V37, P2234
   WANG Q, 1994, INVEST OPHTH VIS SCI, V35, P4344
NR 34
TC 10
Z9 10
U1 0
U2 7
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950-222X
EI 1476-5454
J9 EYE
JI Eye
PD OCT
PY 2012
VL 26
IS 10
BP 1357
EP 1362
DI 10.1038/eye.2012.165
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 022KO
UT WOS:000309958500012
PM 22899005
OA Green Published, Bronze
DA 2022-11-30
ER

PT J
AU Sasaki, H
   Kawakami, Y
   Ono, M
   Jonasson, F
   Shui, YB
   Cheng, HM
   Robman, L
   McCarty, C
   Chew, SJ
   Sasaki, K
AF Sasaki, H
   Kawakami, Y
   Ono, M
   Jonasson, F
   Shui, YB
   Cheng, HM
   Robman, L
   McCarty, C
   Chew, SJ
   Sasaki, K
TI Localization of cortical cataract in subjects of diverse races and
   latitude
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID POSTERIOR SUBCAPSULAR CATARACTS; BLUE MOUNTAINS EYE; LENS OPACIFICATION;
   SUNLIGHT EXPOSURE; REYKJAVIK EYE; RISK-FACTORS; PREVALENCE; NUCLEAR;
   ASSOCIATIONS; POPULATION
AB PURPOSE. To compare the characteristics of early cortical cataract localization in three groups in cataract epidemiologic surveys performed in Reykjavik, Melbourne, and Singapore.
   METHODS. Individuals who had right eyes with an area of cortical opacity less than 20% of the pupil when dilated 7 HIM or more were selected as subjects. This included 197 subjects from the Reykjavik Eye Study, 231 from the Vitamin E, Cataract, and Age-Related Maculopathy (VECAT) study in Melbourne, and 92 from the Singapore-Japan Cooperative Cataract Study, all showing early-stage cataract in pupils dilated to 7 mm or more. Scheimpflug and retroilluminated photographs were used to locate opacities. Localization of cortical cataract was determined by dividing the retroillumination image into seven concentric circles with diameters of 1 through 7 mm, and eight sections of 45degrees radial octants. The positive rate of opacification was then calculated for each quadrant.
   RESULTS. The highest positive rate of opacification was observed in the lower nasal quadrant in all groups. The relative risk of the prevalence of cortical opacity in the lower nasal oblique hemisphere to the upper temporal oblique hemisphere was the highest in the Singaporean subjects followed by those of Melbourne and then of Reykjavik.
   CONCLUSIONS. The prevalence of cortical cataract was higher in the lower nasal quadrant than in the other quadrants for all subjects of diverse race in three climatically different locations. This higher prevalence was most pronounced in subjects living at low latitude. These results support the view that solar UV exposure is a possible risk factor for development of human cortical cataract.
C1 Kanazawa Med Univ, Dept Ophthalmol, Uchinada, Ishikawa 9200293, Japan.
   Natl Inst Environm Studies, Tsukuba, Ibaraki, Japan.
   Univ Iceland, Dept Ophthalmol, Reykjavik, Iceland.
   Washington Univ, Sch Med, Dept Ophthalmol & Vis Sci, St Louis, MO USA.
   Schepens Retina Associates Fdn, Boston, MA USA.
   Univ Melbourne, Ctr Eue Res Australia, Melbourne, Vic, Australia.
   Marshfield Med Res Fdn, Marshfield Clin, Marshfield, WI 54449 USA.
   Singapore Eye Res Inst, Singapore, Singapore.
C3 Kanazawa Medical University; National Institute for Environmental
   Studies - Japan; University of Iceland; Washington University (WUSTL);
   University of Melbourne; Marshfield Clinic; National University of
   Singapore; Singapore National Eye Center
RP Sasaki, K (通讯作者)，Kanazawa Med Univ, Dept Ophthalmol, Uchinada, Ishikawa 9200293, Japan.
RI Jonasson, Fridbert/ABA-9889-2021
OI McCarty, Catherine/0000-0003-1089-0142
CR Asano K, 1997, DEV OPHTHALMOL, V27, P25
   BRILLIANT LB, 1983, AM J EPIDEMIOL, V118, P250, DOI 10.1093/oxfordjournals.aje.a113632
   COLLMAN GW, 1988, AM J PUBLIC HEALTH, V78, P1459, DOI 10.2105/AJPH.78.11.1459
   CORONEO MT, 1991, OPHTHALMIC SURG LAS, V22, P705
   CORONEO MT, 1993, BRIT J OPHTHALMOL, V77, P734, DOI 10.1136/bjo.77.11.734
   Cumming RG, 2000, AM J OPHTHALMOL, V130, P237, DOI 10.1016/S0002-9394(00)00479-7
   HILLER R, 1986, AM J EPIDEMIOL, V124, P916, DOI 10.1093/oxfordjournals.aje.a114481
   HOLLOWS F, 1981, LANCET, V2, P1249
   *JAP MET AG, 1998, 9 JAP MET AG
   Katoh N, 2001, ACTA OPHTHALMOL SCAN, V79, P154, DOI 10.1034/j.1600-0420.2001.079002154.x
   KLEIN BEK, 1992, OPHTHALMOLOGY, V99, P546
   MARAINI G, 1991, AM J EPIDEMIOL, V133, P541
   Mitchell P, 1997, OPHTHALMOLOGY, V104, P581, DOI 10.1016/S0161-6420(97)30266-8
   *NASA, ER UV EXP TOT OZ MAP
   Robman LD, 1999, AUST NZ J OPHTHALMOL, V27, P410
   SAKAMOTO Y, 1997, DEV OPHTHALMOL, V27, P63
   Sakamoto Yasuo, 1999, Nippon Ganka Gakkai Zasshi, V103, P379
   Sasaki H, 2000, OPHTHALMOLOGICA, V214, P412, DOI 10.1159/000027535
   Sasaki H, 2001, J Epidemiol, V11, P16
   Sasaki K, 1997, DEV OPHTHALMOL, V27, P42
   SASAKI K, 1987, JPN J CLIN OPHTHAL, V41, P763
   SCHEIN OD, 1994, INVEST OPHTH VIS SCI, V35, P363
   Sliney D H, 1994, Ophthalmic Epidemiol, V1, P107
   TAYLOR HR, 1988, NEW ENGL J MED, V319, P1429, DOI 10.1056/NEJM198812013192201
   West SK, 1998, JAMA-J AM MED ASSOC, V280, P714, DOI 10.1001/jama.280.8.714
   WONG L, 1993, J EPIDEMIOL COMMUN H, V47, P46, DOI 10.1136/jech.47.1.46
NR 26
TC 59
Z9 65
U1 0
U2 5
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD OCT
PY 2003
VL 44
IS 10
BP 4210
EP 4214
DI 10.1167/iovs.01-1221
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 727BT
UT WOS:000185636700008
PM 14507863
DA 2022-11-30
ER

PT J
AU Sun, LM
   Zhou, J
   Wang, K
   Wang, J
   Shang, L
   Zhang, JG
   Wu, JQ
   Cram, DS
AF Sun, Luming
   Zhou, Jia
   Wang, Kai
   Wang, Jian
   Shang, Ling
   Zhang, Jianguang
   Wu, Junqing
   Cram, David S.
TI Placental Up-Regulation of Leptin and ARMS2 is Associated with Growth
   Discordance in Monochorionic Diamniotic Twin Pregnancies
SO TWIN RESEARCH AND HUMAN GENETICS
LA English
DT Article
DE monochorionic diamniotic; placenta; growth discordance; RNA sequencing;
   leptin; ARMS2
ID GENE-EXPRESSION; RESTRICTION; RNA; DAMAGE
AB Fetal growth discordance is a relatively common complication of monochorionic diamniotic (MCDA) twin pregnancies and is caused by a combination of maternal and placental factors. The aim of the study was to survey placental gene expression patterns and identify genes associated with growth discordance. Clinical samples comprised eight growth-discordant MCDA twin placentas (31(+3)-34(+4) weeks gestational age) and six growth-concordant twin placentas (31(+2)-37 weeks gestational age). Gene expression libraries were constructed from placental biopsy samples and analyzed by RNA-sequencing. The distribution and relative abundance of mRNA transcripts expressed in the smaller and larger placentas from growth-discordant and concordant MCDA twins was remarkably similar. However, leptin (LEP) and age-related maculopathy susceptibility 2 (ARMS2) mRNA levels were exclusively up-regulated in all of the eight smaller growth-discordant twin placentas. Quantitative real-time PCR of independent biopsy samples confirmed the levels of differential mRNA expression for both genes. Immunohistochemical analysis of tissue sections from matching twin placentas showed increased leptin expression in 5-10% of blood vessel cells of the smaller placenta and marginally higher levels of ARMS2 expression in the microvillous membrane of the smaller placenta. Based on these findings, we speculate that up-regulation of leptin and ARMS2 forms part of an important survival mechanism to compensate for placental growth discordance. Since, leptin and ARMS2 are both expressed as soluble proteins, they may have clinical potential as measurable biomarkers for predicting the onset of growth discordance in MCDA twin pregnancies.
C1 [Sun, Luming; Zhou, Jia; Wang, Kai] Tongji Univ, Sch Med, Shanghai Matern & Infant Hosp 1, Fetal Med Unit,Dept Obstet, Shanghai, Peoples R China.
   [Sun, Luming; Zhou, Jia; Wang, Kai] Tongji Univ, Sch Med, Shanghai Matern & Infant Hosp 1, Prenatal Diag Ctr,Dept Obstet, Shanghai, Peoples R China.
   [Sun, Luming; Wang, Jian; Wu, Junqing] Fudan Univ, Sch Publ Hlth, Shanghai, Peoples R China.
   [Sun, Luming; Wang, Jian; Wu, Junqing] WHO Collaborating Ctr Human Reprod, Shanghai Inst Planned Parenthood Res, Shanghai, Peoples R China.
   [Shang, Ling; Zhang, Jianguang; Cram, David S.] Berry Genom Corp, Bldg 9,6 Court Jingshun East Rd, Beijing 100015, Peoples R China.
   [Cram, David S.] Monash Univ, Dept Anat & Dev Biol, Melbourne, Vic, Australia.
C3 Tongji University; Tongji University; Fudan University; Monash
   University
RP Cram, DS (通讯作者)，Berry Genom Corp, Bldg 9,6 Court Jingshun East Rd, Beijing 100015, Peoples R China.; Sun, LM (通讯作者)，Tongji Univ, Sch Med, Shanghai Matern & Infant Hosp 1, Pudong New Area, 2699 Gaoke West Rd, Shanghai 201204, Peoples R China.
EM luming_sun@163.com; david.cram@berrygenomics.com
FU Fund of Shanghai Municipal Science and Technology Commission
   [16411963100]
FX We thank the staff in the Fetal Medicine Unit and Prenatal Diagnosis
   Center, Department of Obstetrics in Shanghai First Maternity and Infant
   Hospital for their clinical support during the course of this research
   project. This work was supported by the Fund of Shanghai Municipal
   Science and Technology Commission to Dr Luming Sun (grant number
   16411963100).
CR Acosta-Rojas R, 2007, INT J GYNECOL OBSTET, V96, P98, DOI 10.1016/j.ijgo.2006.11.002
   Allison MB, 2014, J ENDOCRINOL, V223, pT25, DOI 10.1530/JOE-14-0404
   BEJAR R, 1990, AM J OBSTET GYNECOL, V162, P1230, DOI 10.1016/0002-9378(90)90024-2
   Bell JT, 2012, INT J EPIDEMIOL, V41, P140, DOI 10.1093/ije/dyr179
   Chang YL, 2009, PRENATAL DIAG, V29, P253, DOI 10.1002/pd.2193
   Cosmi E, 2013, TWIN RES HUM GENET, V16, P816, DOI 10.1017/thg.2013.33
   Fritsche LG, 2008, NAT GENET, V40, P892, DOI 10.1038/ng.170
   Gao Y, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033503
   Gordon L, 2011, EPIGENETICS-US, V6, P579, DOI 10.4161/epi.6.5.15072
   Gratacos E, 2007, ULTRASOUND OBST GYN, V30, P28, DOI 10.1002/uog.4046
   Hack KEA, 2008, PLACENTA, V29, P976, DOI 10.1016/j.placenta.2008.08.019
   Horie-Inoue K, 2014, BIOCHEM BIOPH RES CO, V452, P263, DOI 10.1016/j.bbrc.2014.08.013
   Huang XY, 2013, BMC GENOMICS, V14, DOI 10.1186/1471-2164-14-319
   Kaminsky ZA, 2009, NAT GENET, V41, P240, DOI 10.1038/ng.286
   Kim D, 2013, GENOME BIOL, V14, DOI 10.1186/gb-2013-14-4-r36
   Kim J, 2012, BMC GENOMICS, V13, DOI 10.1186/1471-2164-13-115
   Koh W, 2014, P NATL ACAD SCI USA, V111, P7361, DOI 10.1073/pnas.1405528111
   Kortvely E, 2010, INVEST OPHTH VIS SCI, V51, P79, DOI 10.1167/iovs.09-3850
   Lewi L, 2014, BEST PRACT RES CL OB, V28, P295, DOI 10.1016/j.bpobgyn.2013.12.003
   Lewi L, 2007, AM J OBSTET GYNECOL, V197, DOI 10.1016/j.ajog.2007.05.009
   Li MC, 2013, PLACENTA, V34, P288, DOI 10.1016/j.placenta.2012.12.014
   Liang DS, 2013, PRENATAL DIAG, V33, P409, DOI 10.1002/pd.4033
   MAFFEI M, 1995, NAT MED, V1, P1155, DOI 10.1038/nm1195-1155
   Marr Alexandra K, 2016, F1000Res, V5, P305, DOI 10.12688/f1000research.8210.2
   McCarthy C, 2007, AM J OBSTET GYNECOL, V196, P70, DOI 10.1016/j.ajog.2006.08.027
   Mortazavi A, 2008, NAT METHODS, V5, P621, DOI 10.1038/nmeth.1226
   Nishizawa H, 2011, REPROD BIOL ENDOCRIN, V9, DOI 10.1186/1477-7827-9-107
   Perez-Perez A, 2015, CLIN CHEM LAB MED, V53, P15, DOI 10.1515/cclm-2014-0387
   Ratnapriya R, 2013, CLIN GENET, V84, P160, DOI 10.1111/cge.12206
   Robinson MD, 2010, BIOINFORMATICS, V26, P139, DOI 10.1093/bioinformatics/btp616
   Sagawa N, 2002, PLACENTA, V23, pS80, DOI 10.1053/plac.2002.0814
   Schrey S, 2013, MOL HUM REPROD, V19, P764, DOI 10.1093/molehr/gat048
   Sierra-Honigmann MR, 1998, SCIENCE, V281, P1683, DOI 10.1126/science.281.5383.1683
   Simonazzi G, 2013, BJOG-INT J OBSTET GY, V120, P754, DOI 10.1111/1471-0528.12133
   Sitras V, 2009, REPROD SCI, V16, P701, DOI 10.1177/1933719109334256
   Sood R, 2006, P NATL ACAD SCI USA, V103, P5478, DOI 10.1073/pnas.0508035103
   Spornraft M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0107259
   Talavera-Adame D, 2008, J BIOMED OPT, V13, DOI 10.1117/1.3028010
   Tsui NBY, 2014, CLIN CHEM, V60, P954, DOI 10.1373/clinchem.2014.221648
   Valsky DV, 2010, SEMIN FETAL NEONAT M, V15, P342, DOI 10.1016/j.siny.2010.07.002
   Valsky DV, 2010, PRENATAL DIAG, V30, P719, DOI 10.1002/pd.2536
   Wang GF, 2012, EXP EYE RES, V94, P187, DOI 10.1016/j.exer.2011.11.005
   Yu CC, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047081
NR 43
TC 3
Z9 3
U1 0
U2 16
PU CAMBRIDGE UNIV PRESS
PI NEW YORK
PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA
SN 1832-4274
EI 1839-2628
J9 TWIN RES HUM GENET
JI Twin Res. Hum. Genet.
PD APR
PY 2017
VL 20
IS 2
BP 169
EP 179
DI 10.1017/thg.2017.11
PG 11
WC Genetics & Heredity; Obstetrics & Gynecology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity; Obstetrics & Gynecology
GA ER1OX
UT WOS:000398563000009
PM 28303777
OA Bronze
DA 2022-11-30
ER

PT J
AU Weeks, DE
   Conley, YP
   Ferrell, RE
   Mah, TS
   Gorin, MB
AF Weeks, DE
   Conley, YP
   Ferrell, RE
   Mah, TS
   Gorin, MB
TI A tale of two genotypes: Consistency between two high-throughput
   genotyping centers
SO GENOME RESEARCH
LA English
DT Article
ID LINKAGE ANALYSIS; BIPOLAR ILLNESS; ERRORS; IDENTIFICATION; LOCUS;
   CHROMOSOME-18; ALLELES; MARKERS; PROGRAM
AB Multiple genome-wide scans involving sib-pairs or limited pedigrees have been extensively used for a wide number of complex genetic conditions. Comparing data from two or more scans, as well as combining data, require an understanding of the sources of genotyping errors and data discrepancies. We have conducted two genome-wide scans for age-related maculopathy using the Center for Inherited Disease Research (CIDR) and the Mammalian Genotyping Service (MGS). Thirty individuals were typed in common, in order to allow for the alignment Of alleles and comparison of the data sets. The analysis of these 8914 genotypes distributed over 321 markers in common demonstrated excellent agreement between these two laboratories, which have low rates of internal errors. Under the assumption that within each genotype, the smaller MGS allele should correspond to the smaller CIDR allele, the alleles align well between the two centers, with only a small fraction (less than 0.65%) of the aligned alleles showing large differences in sizes. However, since called allele sizes are integer "labels" which may not directly reflect the true underlying allele sizes, it is important to carefully prepare in advance if one wishes to merge data from different laboratories. In particular, it would not suffice to attempt to align alleles by typing only one or two controls in common. Fortunately, for the purposes of linkage analysis, one can avoid merging difficulties by simply carrying out linkage analyses using laboratory-specific allele labels and allele frequencies for each laboratory-specific subset of the data.
C1 Univ Pittsburgh, Dept Human Genet, Pittsburgh, PA 15261 USA.
   Univ Pittsburgh, Sch Nursing, Dept Hlth Promot & Dev, Pittsburgh, PA 15261 USA.
   Univ Pittsburgh, Dept Ophthalmol, Pittsburgh, PA 15261 USA.
C3 Pennsylvania Commonwealth System of Higher Education (PCSHE); University
   of Pittsburgh; Pennsylvania Commonwealth System of Higher Education
   (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of
   Higher Education (PCSHE); University of Pittsburgh
RP Weeks, DE (通讯作者)，Univ Pittsburgh, Dept Human Genet, Crabtree Hall,Room A302A,130 DeSoto St, Pittsburgh, PA 15261 USA.
RI Weeks, Daniel E/B-2995-2012
OI Weeks, Daniel E/0000-0001-9410-7228
FU NEI NIH HHS [R01 EY009859, EY 09859] Funding Source: Medline; NHGRI NIH
   HHS [N01HG65403, N01 HG 65403] Funding Source: Medline; NHLBI NIH HHS
   [N01HV48141, N01 HV 48141] Funding Source: Medline; DIVISION OF HEART
   AND VASCULAR DISEASES [N01HV048141] Funding Source: NIH RePORTER;
   NATIONAL EYE INSTITUTE [R01EY009859] Funding Source: NIH RePORTER;
   NATIONAL HUMAN GENOME RESEARCH INSTITUTE [N01HG065403] Funding Source:
   NIH RePORTER
CR Abecasis GR, 2001, EUR J HUM GENET, V9, P130, DOI 10.1038/sj.ejhg.5200594
   Akey JM, 2001, AM J HUM GENET, V68, P1447, DOI 10.1086/320607
   BRZUSTOWICZ LM, 1993, AM J HUM GENET, V53, P1137
   Daly M, 1997, GENET EPIDEMIOL, V14, P599, DOI 10.1002/(SICI)1098-2272(1997)14:6<599::AID-GEPI8>3.0.CO;2-V
   Dorr DA, 1997, GENET EPIDEMIOL, V14, P617, DOI 10.1002/(SICI)1098-2272(1997)14:6<617::AID-GEPI11>3.0.CO;2-T
   Douglas JA, 2000, AM J HUM GENET, V66, P1287, DOI 10.1086/302861
   EASTON DF, 1993, AM J HUM GENET, V52, P678
   Ewen KR, 2000, AM J HUM GENET, V67, P727, DOI 10.1086/303048
   Ghosh S, 1997, GENOME RES, V7, P165, DOI 10.1101/gr.7.2.165
   Gordon D, 2001, AM J HUM GENET, V69, P371, DOI 10.1086/321981
   GORING HH, 2000, AM J HUM GENET, V66, P1472
   Goring HHH, 2000, AM J HUM GENET, V66, P1107, DOI 10.1086/302798
   Griffiths RAL, 1998, INT J LEGAL MED, V111, P267, DOI 10.1007/s004140050167
   Gudbjartsson DF, 2000, NAT GENET, V25, P12, DOI 10.1038/75514
   Gudbjartsson DF, 1999, AM J HUM GENET, V65, pA60
   Haberl M, 1999, MOL ECOL, V8, P1347, DOI 10.1046/j.1365-294X.1999.00692.x
   Idury RM, 1997, GENOME RES, V7, P1104, DOI 10.1101/gr.7.11.1104
   Li JL, 2001, GENOME RES, V11, P1304, DOI 10.1101/gr.159701
   LINCOLN SE, 1992, GENOMICS, V14, P604, DOI 10.1016/S0888-7543(05)80158-2
   MILLER SA, 1988, NUCLEIC ACIDS RES, V16, P1215, DOI 10.1093/nar/16.3.1215
   O'Connell JR, 1998, AM J HUM GENET, V63, P259, DOI 10.1086/301904
   OCONNELL JR, 1995, NAT GENET, V11, P402, DOI 10.1038/ng1295-402
   OTT J, 1999, ANAL HUMAN GENETIC L, P249
   Papp JC, 2000, AM J HUM GENET, V67, P301
   PUERS C, 1993, AM J HUM GENET, V53, P953
   SHIELDS DC, 1991, P NATL ACAD SCI USA, V88, P6501, DOI 10.1073/pnas.88.15.6501
   Sobel E, 2000, AM J HUM GENET, V67, P35
   Terwilliger JD, 1990, AM J HUM GENET S, V47, pA201
   Weber JL, 2001, ADV GENET, V42, P77, DOI 10.1016/S0065-2660(01)42016-5
   Weeks DE, 2000, HUM MOL GENET, V9, P1329, DOI 10.1093/hmg/9.9.1329
   WEEKS DE, 1995, TRENDS GENET, V11, P513, DOI 10.1016/S0168-9525(00)89163-5
   Weeks DE, 2001, AM J OPHTHALMOL, V132, P682, DOI 10.1016/S0002-9394(01)01214-4
   Xu JF, 2000, AM J HUM GENET, V66, P945, DOI 10.1086/302807
NR 33
TC 36
Z9 37
U1 0
U2 9
PU COLD SPRING HARBOR LAB PRESS
PI PLAINVIEW
PA 1 BUNGTOWN RD, PLAINVIEW, NY 11724 USA
SN 1088-9051
J9 GENOME RES
JI Genome Res.
PD MAR
PY 2002
VL 12
IS 3
BP 430
EP 435
DI 10.1101/gr.211502
PG 6
WC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
   Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
   Genetics & Heredity
GA 527DP
UT WOS:000174171300009
PM 11875031
OA Green Published, Bronze
DA 2022-11-30
ER

PT J
AU Rishi, P
   Das, A
   Sarate, P
   Rishi, E
AF Rishi, Pukhraj
   Das, Atheeswar
   Sarate, Pallavi
   Rishi, Ekta
TI Management of peripheral polypoidal choroidal vasculopathy with
   intravitreal bevacizumab and indocyanine green angiography-guided laser
   photocoagulation
SO INDIAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE Indocyanine green angiogram; intravitreal bevacizumab; laser
   photocoagulation; peripheral hemorrhagic exudative chorioretinopathy;
   polypoidal choroidal vasculopathy
AB A 69-year-old lady presented with complaints of decreased vision in left eye since one month. Best Corrected Visual Acuity (BCVA) was 6/18 in that eye. Fundus examination revealed non-central geographic atrophy and soft drusens at macula in both eyes. Temporal periphery of left eye revealed subretinal exudates with altered sub-RPE hemorrhage mimicking peripheral exudative hemorrhagic chorioretinopathy (PEHCR). Fundus Fluorescein Angiogram showed window defects at macula and blocked fluorescence at temporal periphery in left eye. However, Indocyanine green angiography (ICGA) revealed active peripheral choroidal polyps. The patient was successfully treated with intravitreal bevacizumab and ICGA-guided laser photocoagulation. 27 months after laser treatment, BCVA improved to 6/9. Rationale of consecutive anti-vascular endothelial growth factor (VEGF) treatment followed by more definitive laser photocoagulation is that anti-VEGF aids in resolution of subretinal fluid, thus making the polyp more amenable to focal laser photocoagulation which stabilizes the choroidal vasculature and prevents further leakage.
C1 [Rishi, Pukhraj; Das, Atheeswar; Sarate, Pallavi; Rishi, Ekta] Sankara Nethralaya, Shri Bhagwan Mahavir Vitreoretinal Serv, Madras 600006, Tamil Nadu, India.
RP Rishi, P (通讯作者)，Sankara Nethralaya, Shri Bhagwan Mahavir Vitreoretinal Serv, 18 Coll Rd, Madras 600006, Tamil Nadu, India.
EM docrishi@yahoo.co.in
RI Rishi, Pukhraj/AAZ-5296-2020
CR Anantharaman G, 2010, INDIAN J OPHTHALMOL, V58, P399, DOI 10.4103/0301-4738.67052
   Cackett P, 2009, RETINA-J RET VIT DIS, V29, P187, DOI 10.1097/IAE.0b013e318188c839
   Gomi F, 2008, CURR OPIN OPHTHALMOL, V19, P208, DOI 10.1097/ICU.0b013e3282fb7c33
   Lafaut BA, 2000, RETINA-J RET VIT DIS, V20, P650, DOI 10.1097/00006982-200011000-00010
   Mantel I, 2009, AM J OPHTHALMOL, V148, P932, DOI 10.1016/j.ajo.2009.06.032
   Shields JA, 2005, RETINA-J RET VIT DIS, V25, P767, DOI 10.1097/00006982-200509000-00013
   Yannuzzi LA, 1998, ARCH OPHTHALMOL-CHIC, V116, P382
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
NR 8
TC 8
Z9 8
U1 0
U2 1
PU MEDKNOW PUBLICATIONS & MEDIA PVT LTD
PI MUMBAI
PA B-9, KANARA BUSINESS CENTRE, OFF LINK RD, GHAKTOPAR-E, MUMBAI, 400075,
   INDIA
SN 0301-4738
J9 INDIAN J OPHTHALMOL
JI Indian J. Ophthalmol.
PD JAN-FEB
PY 2012
VL 60
IS 1
BP 60
EP U5
DI 10.4103/0301-4738.91351
PG 4
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 100AY
UT WOS:000315668300015
PM 22218251
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Hagag, AM
   Rasheed, R
   Chandra, S
   Jeffery, G
   Sivaprasad, S
AF Hagag, Ahmed M.
   Rasheed, Rajna
   Chandra, Shruti
   Jeffery, Glen
   Sivaprasad, Sobha
TI The Diagnostic Accuracy of Double-Layer Sign in Detection of Macular
   Neovascularization Secondary to Central Serous Chorioretinopathy
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID OPTICAL COHERENCE TOMOGRAPHY; PIGMENT EPITHELIAL DETACHMENTS; CHOROIDAL
   NEOVASCULARIZATION; RISK-FACTORS; ANGIOGRAPHY
AB PURPOSE: To investigate the diagnostic value of elevated retinal pigment epithelium (RPE) and double-layer sign (DLS) in identifying macular neovascularization (MNV) secondary to central serous chorioretinopathy (CSCR).
   DESIGN: Retrospective, cross-sectional study.
   METHODS: Patients with CSCR underwent optical coherence tomography (OCT) and OCT angiography (OCT-A) scanning at Moorfields Eye Hospital. OCT scans were reviewed to identify the presence/absence of an RPE elevation. The maximum length and maximum height of the elevated RPE were measured. A minimum length of 1000 mu m and a maximum height of 150 mu m were used to define the "double-layer sign." Other qualitative anatomical features were also graded from OCT scans. OCT-A was examined to confirm the presence/absence of MNV. Binary logistic regression analyses were used to assess the association between OCT features and the detection of MNV on OCT-A. Sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) were calculated to assess the diagnostic accuracy.
   RESULTS: One hundred sixty-three eyes from 132 patients were included. Elevated RPE was detected in 148 eyes (91%). OCT-A-confirmed MNV was detected in 54 eyes (33%). The sensitivity and specificity of RPE elevation were 100% and 13.8%, respectively. DLS was identified in 95 eyes (58%). The sensitivity and specificity of DLS for detecting MNV were 87% and 56%, respectively. Hyperreflectivity and nonhomogeneity of the sub-RPE space were independently associated with MNV within the DLS (odds ratio, 17.7 and 14.8, P < .001 and P = .02, respectively). None of the other demographic or anatomical features were associated with MNV. The presence of nonhomogeneous hyperreflective RPE elevation had a sensitivity and specificity of 98% and 67%, with PPV and NPV of 60% and 99%, respectively.
   CONCLUSIONS: Nonhomogeneous and hyperreflective space under an elevated RPE of any length or height indicates an eye with higher risk of MNV than DLS. OCT-A should at least be performed for these eyes to confirm the presence of MNV and treat accordingly. (C) 2021 Published by Elsevier Inc.
C1 [Hagag, Ahmed M.; Rasheed, Rajna; Chandra, Shruti; Sivaprasad, Sobha] Moorfields Eye Hosp NHS Fdn Trust, London, England.
   [Hagag, Ahmed M.; Rasheed, Rajna; Chandra, Shruti; Jeffery, Glen; Sivaprasad, Sobha] UCL Inst Ophthalmol, London, England.
C3 University of London; University College London; Moorfields Eye Hospital
   NHS Foundation Trust; University of London; University College London
RP Sivaprasad, S (通讯作者)，Moorfields Eye Hosp, 162 City Rd, London EV1V 2PD, England.
EM sobha.sivaprasad@nhs.net
OI Rasheed, Rajna/0000-0003-4080-0072; Chandra, Shruti/0000-0002-2634-9775;
   Hagag, Ahmed/0000-0002-3372-7885; Sivaprasad, Sobha/0000-0001-8952-0659
CR Bonini MA, 2015, JAMA OPHTHALMOL, V133, P899, DOI 10.1001/jamaophthalmol.2015.1320
   Borrelli E, 2021, AM J OPHTHALMOL, V223, P129, DOI 10.1016/j.ajo.2020.10.011
   Bossuyt PM, 2015, BMJ-BRIT MED J, V351, DOI [10.1136/bmj.h5527, 10.1373/clinchem.2015.246280, 10.1148/radiol.2015151516]
   Bousquet E, 2018, RETINA-J RET VIT DIS, V38, P629, DOI 10.1097/IAE.0000000000001580
   Breukink MB, 2017, CLIN OPHTHALMOL, V11, P39, DOI 10.2147/OPTH.S115685
   Daruich A, 2015, PROG RETIN EYE RES, V48, P82, DOI 10.1016/j.preteyeres.2015.05.003
   de Carlo TE, 2016, OSLI RETINA, V47, P128, DOI 10.3928/23258160-20160126-05
   FIRTH D, 1993, BIOMETRIKA, V80, P27, DOI 10.1093/biomet/80.1.27
   Guo JL, 2021, RETINA-J RET VIT DIS, V41, P199, DOI 10.1097/IAE.0000000000002791
   Hagag AM, 2020, J CLIN MED, V9, DOI 10.3390/jcm9061934
   Hagag Ahmed M, 2017, Taiwan J Ophthalmol, V7, P115, DOI 10.4103/tjo.tjo_31_17
   Hage R, 2015, AM J OPHTHALMOL, V159, P890, DOI 10.1016/j.ajo.2015.02.002
   Heinze G, 2002, STAT MED, V21, P2409, DOI 10.1002/sim.1047
   Imamura Y, 2009, RETINA-J RET VIT DIS, V29, P1469, DOI 10.1097/IAE.0b013e3181be0a83
   Kaye R, 2020, PROG RETIN EYE RES, V79, DOI 10.1016/j.preteyeres.2020.100865
   Kotsolis AI, 2010, BRIT J OPHTHALMOL, V94, P1506, DOI 10.1136/bjo.2009.159913
   Lee GI, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-40406-y
   Liu TT, 2021, BRIT J OPHTHALMOL, V105, P233, DOI 10.1136/bjophthalmol-2019-315318
   Montero JA, 2005, BRIT J OPHTHALMOL, V89, P562, DOI 10.1136/bjo.2004.049403
   Moussa M, 2017, J OPHTHALMOL, V2017, DOI 10.1155/2017/6913980
   Mrejen S, 2019, OPHTHALMOLOGY, V126, P576, DOI 10.1016/j.ophtha.2018.12.048
   Narita C, 2020, OPHTHALMOLOGY, V127, P637, DOI 10.1016/j.ophtha.2019.11.007
   Quaranta-El Maftouhi M, 2015, AM J OPHTHALMOL, V160, P581, DOI 10.1016/j.ajo.2015.06.016
   Sahoo NK, 2021, EUR J OPHTHALMOL, V31, P1892, DOI 10.1177/1120672120952678
   Sato T, 2007, RETINA-J RET VIT DIS, V27, P589, DOI 10.1097/01.iae.0000249386.63482.05
   Sheth J, 2018, INDIAN J OPHTHALMOL, V66, P1796, DOI 10.4103/ijo.IJO_377_18
   Shi YY, 2019, OPHTHALMOL RETINA, V3, P211, DOI 10.1016/j.oret.2018.10.012
   Shiragami C, 2018, AM J OPHTHALMOL, V193, P80, DOI 10.1016/j.ajo.2018.06.009
   Willoughby AS, 2015, OPHTHALMOLOGY, V122, P1846, DOI 10.1016/j.ophtha.2015.05.042
   YANNUZZI LA, 1984, OPHTHALMOLOGY, V91, P1554
NR 30
TC 1
Z9 1
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0002-9394
EI 1879-1891
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD APR
PY 2022
VL 236
BP 271
EP 280
DI 10.1016/j.ajo.2021.10.021
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 4X3ZY
UT WOS:000860785500029
PM 34699741
OA Green Published
DA 2022-11-30
ER

PT J
AU Jiang, JJ
   Huang, LZ
   Yu, WZ
   Wu, X
   Zhou, P
   Li, XX
AF Jiang, Jingjing
   Huang, Lvzhen
   Yu, Wenzhen
   Wu, Xi
   Zhou, Peng
   Li, Xiaoxin
TI Overexpression of HTRA1 Leads to Down-Regulation of Fibronectin and
   Functional Changes in RF/6A Cells and HUVECs
SO PLOS ONE
LA English
DT Article
ID POLYPOIDAL CHOROIDAL VASCULOPATHY; SERINE-PROTEASE HTRA1;
   RETINAL-PIGMENT EPITHELIUM; ENDOTHELIAL GROWTH-FACTOR; MACULAR
   DEGENERATION; GENE POLYMORPHISMS; JAPANESE PATIENTS; CHINESE PATIENTS;
   A1 HTRA1; EXPRESSION
AB Multiple genetic studies have suggested that high-temperature requirement serine protease (HTRA1) is associated with polypoidal choroidal vasculopathy (PCV). To date, no functional studies have investigated the biological effect of HTRA1 on vascular endothelial cells, essential vascular components involved in polypoidal vascular abnormalities and arteriosclerosis-like changes. In vitro studies were performed to investigate the effect of HTRA1 on the regulation of fibronectin, laminin, vascular endothelial growth factor (VEGF), platelet derived growth factor receptor (PDGFR) and matrix metalloparoteinases 2 (MMP-2) and the role of HTRA1 in choroid-retina endothelial (RF/6A) and human umbilical vein endothelial (HUVEC) cells. Lentivirus-mediated overexpression of HTRA1 was used to explore effects of the protease on RF/6A and HUVEC cells in vitro. HTRA1 overexpression inhibited the proliferation, cell cycle, migration and tube formation of RF/6A and HUVEC cells, effects that might contribute to the early stage of PCV pathological lesions. Fibronectin mRNA and protein levels were significantly down-regulated following the upregulation of HTRA1, whereas the expressions of laminin, VEGF and MMP-2 were unaffected by alterations in HTRA1 expression. The decreased biological function of vascular endothelial cells and the degradation of extracellular matrix proteins, such as fibronectin, may be involved in a contributory role for HTRA1 in PCV pathogenesis.
C1 [Jiang, Jingjing; Huang, Lvzhen; Yu, Wenzhen; Wu, Xi; Zhou, Peng; Li, Xiaoxin] Peking Univ, Peoples Hosp, Dept Ophthalmol, Beijing 100871, Peoples R China.
   [Jiang, Jingjing; Huang, Lvzhen; Yu, Wenzhen; Wu, Xi; Zhou, Peng; Li, Xiaoxin] Minist Educ, Key Lab Vis Loss & Restorat, Beijing, Peoples R China.
   [Jiang, Jingjing] China Japan Friendship Hosp, Dept Ophthalmol, Beijing, Peoples R China.
   [Zhou, Peng] Fudan Univ, Dept Ophthalmol, Eye & ENT Hosp, Shanghai 200433, Peoples R China.
C3 Peking University; China-Japan Friendship Hospital; Fudan University
RP Li, XX (通讯作者)，Peking Univ, Peoples Hosp, Dept Ophthalmol, Beijing 100871, Peoples R China.
EM drlixiaoxin@163.com
RI jiang, jun/GWC-9329-2022
OI Jiang, Qingwu/0000-0001-8921-3317; zhang, zhijie/0000-0002-1276-787X;
   Jiang, Jingjing/0000-0002-5077-1204; xu, wanghong/0000-0003-2045-2218
FU National Basic Research Program of China (973 Program) [2011CB510200]
FX This research was supported by the National Basic Research Program of
   China (973 Program (2011CB510200)). The funders had no role in study
   design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR An E, 2006, J PROTEOME RES, V5, P2599, DOI 10.1021/pr060121j
   An E, 2010, INVEST OPHTH VIS SCI, V51, P3379, DOI 10.1167/iovs.09-4853
   Austin BA, 2009, INVEST OPHTH VIS SCI, V50, P2896, DOI 10.1167/iovs.08-2495
   Bajenaru ML, 2002, MOL CELL BIOL, V22, P5100, DOI 10.1128/MCB.22.14.5100-5113.2002
   Canfield AE, 2007, BIOCHEM SOC T, V35, P669, DOI 10.1042/BST0350669
   Chan CC, 2007, T AM OPHTHAL SOC, V105, P97
   Chan Chi-Chao, 2007, Trans Am Ophthalmol Soc, V105, P92
   Chien J, 2004, ONCOGENE, V23, P1636, DOI 10.1038/sj.onc.1207271
   Chien J, 2009, MOL CELL BIOL, V29, P4177, DOI 10.1128/MCB.00035-09
   Chien J, 2009, CURR CANCER DRUG TAR, V9, P451, DOI 10.2174/156800909788486704
   Darribere T, 2000, MECH DEVELOP, V92, P239, DOI 10.1016/S0925-4773(00)00245-8
   De Luca A, 2003, J HISTOCHEM CYTOCHEM, V51, P1279, DOI 10.1177/002215540305101004
   DeAngelis MM, 2008, OPHTHALMOLOGY, V115, P1209, DOI 10.1016/j.ophtha.2007.10.032
   Gotoh N, 2010, JPN J OPHTHALMOL, V54, P609, DOI 10.1007/s10384-010-0865-2
   Hallmann R, 2005, PHYSIOL REV, V85, P979, DOI 10.1152/physrev.00014.2004
   Hara K, 2009, NEW ENGL J MED, V360, P1729, DOI 10.1056/NEJMoa0801560
   HARKER LA, 1976, J CLIN INVEST, V58, P731, DOI 10.1172/JCI108520
   Huang LZ, 2010, INVEST OPHTH VIS SCI, V51, P3193, DOI 10.1167/iovs.09-3779
   Huang LZ, 2009, MOL VIS, V15, P1057
   Jo N, 2006, AM J PATHOL, V168, P2036, DOI 10.2353/ajpath.2006.050588
   Jones A, 2011, P NATL ACAD SCI USA, V108, P14578, DOI 10.1073/pnas.1102853108
   Kondo N, 2007, AM J OPHTHALMOL, V144, P608, DOI 10.1016/j.ajo.2007.06.003
   Kwak N, 2000, INVEST OPHTH VIS SCI, V41, P3158
   Lafaut BA, 2000, GRAEF ARCH CLIN EXP, V238, P752, DOI 10.1007/s004170000180
   Laude A, 2010, PROG RETIN EYE RES, V29, P19, DOI 10.1016/j.preteyeres.2009.10.001
   Lee KY, 2008, INVEST OPHTH VIS SCI, V49, P2613, DOI 10.1167/iovs.07-0860
   Libby P, 2006, Handb Exp Pharmacol, P285
   Liu Y, 2007, GRAEF ARCH CLIN EXP, V245, P1441, DOI 10.1007/s00417-007-0575-8
   Maruko I, 2007, AM J OPHTHALMOL, V144, P15, DOI 10.1016/j.ajo.2007.03.047
   Matsuoka M, 2004, BRIT J OPHTHALMOL, V88, P809, DOI 10.1136/bjo.2003.032466
   Nakahara T, 2006, CANCER RES, V66, P1434, DOI 10.1158/0008-5472.CAN-05-0923
   Nakashizuka H, 2008, INVEST OPHTH VIS SCI, V49, P4729, DOI 10.1167/iovs.08-2134
   Ng TK, 2011, INVEST OPHTH VIS SCI, V52, P3706, DOI 10.1167/iovs.10-6773
   Oka C, 2004, DEVELOPMENT, V131, P1041, DOI 10.1242/dev.00999
   Park DH, 2012, JPN J OPHTHALMOL, V56, P60, DOI 10.1007/s10384-011-0089-0
   Patel N, 2003, J PHARMACOL EXP THER, V306, P838, DOI 10.1124/jpet.103.052167
   Stenzel D, 2011, DEVELOPMENT, V138, P4451, DOI 10.1242/dev.071381
   ten Dijke P, 2007, NAT REV MOL CELL BIO, V8, P857, DOI 10.1038/nrm2262
   Tiaden AN, 2012, J BIOL CHEM, V287, P21335, DOI 10.1074/jbc.M112.341032
   Tong Y, 2010, MOL VIS, V16, P1958
   Vierkotten S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022959
   Vigetti D, 2006, FASEB J, V20, P1118, DOI 10.1096/fj.05-4504com
   VLODAVSKY I, 1981, NATURE, V289, P304, DOI 10.1038/289304a0
   Yang ZL, 2006, SCIENCE, V314, P992, DOI 10.1126/science.1133811
   Yang ZL, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1000836
   Yannuzzi LA, 1997, ARCH OPHTHALMOL-CHIC, V115, P478, DOI 10.1001/archopht.1997.01100150480005
   Zhang L, 2012, J BIOL CHEM, V287, P1520, DOI 10.1074/jbc.M111.275990
   Zhou P, 2011, FASEB J, V25, P3489, DOI 10.1096/fj.11-189258
NR 48
TC 13
Z9 18
U1 0
U2 29
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD OCT 8
PY 2012
VL 7
IS 10
AR e46115
DI 10.1371/journal.pone.0046115
PG 8
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA 020RP
UT WOS:000309831500028
PM 23056244
OA gold, Green Submitted, Green Published
DA 2022-11-30
ER

PT J
AU Awwad, S
   Henein, C
   Ibeanu, N
   Khaw, PT
   Brocchini, S
AF Awwad, Sahar
   Henein, Christin
   Ibeanu, Nkiruka
   Khaw, Peng T.
   Brocchini, Steve
TI Preclinical challenges for developing long acting intravitreal medicines
SO EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS
LA English
DT Article
DE Vitreous; Pharmacokinetics; Drug delivery; Ocular; Posterior segment;
   Intravitreal
ID ENDOTHELIAL GROWTH-FACTOR; DIABETIC MACULAR EDEMA; AQUEOUS-HUMOR
   DYNAMICS; RETINAL-PIGMENT EPITHELIUM; DRUG-DELIVERY SYSTEMS; SILICONE
   OIL DROPLETS; AGE-RELATED-CHANGES; IN-VITRO DRUG; VITREOUS-HUMOR;
   INTRAOCULAR PHARMACOKINETICS
AB The majority of blinding conditions arise due to chronic pathologies in the retina. During the last two decades, antibody-based medicines administered by intravitreal injection directly into the back of the eye have revolutionised the treatment of chronic retinal diseases characterised by uncontrolled blood vessel growth, e.g. wet age-related macular degeneration (wAMD), diabetic retinopathy (DR) and choroidal neovascularisation (CNV). Although intravitreal injections have become a commonly performed ophthalmic procedure that provides a reproducible dose to maximise drug exposure in the back of the eye, there is a need to minimise the frequency and cumulative number of intravitreal injections. Developing longer acting intraocular therapies is one key strategy that is being pursued.
   Pharmaceutical preclinical development of intraocular medicines is heavily reliant on the use of animal models to determine ocular tolerability, pharmacokinetics, biodistribution and drug stability. Animal eyes are different from human eyes, such as the anatomy, organisation of vitreous macromolecular structure, aqueous outflow and immune response; all which impacts the ability to translate preclinical data into a clinical product. The development of longer acting protein formulations using animals is also limited because animals reject human proteins. Preclinical strategies also do not account for differences in the vitreous due to ageing and whether a vitrectomy has been performed. Intraocular formulations must reside and clear from the vitreous body, so there is a need for the formulation scientist to have knowledge about vitreous structure and physiology to facilitate preclinical development strategies.
   Preclinical pharmaceutical development paradigms used to create therapies for other routes of administration (e.g. oral, subcutaneous, pulmonary and intravenous) are grounded on the use of preclinical in vitro models. Analogous pharmaceutical strategies with appropriately designed in vitro models that can account for intraocular mass transfer to estimate pharmacokinetic profiles can be used to develop in vitro-in vivo correlations (IVIVCs) to accelerate the preclinical optimisation of long-acting intraocular formulations. Data obtained can then inform preclinical in vivo and clinical studies. With the now widespread use of intravitreal injections, it is also important during early preclinical studies to ensure there is a viable regulatory pathway for new therapies. Knowledge of the physiological, pharmaceutical and regulatory factors will help in the development of long-acting intravitreal medicines, which is rapidly evolving into a distinct pharmaceutical discipline.
C1 [Awwad, Sahar; Henein, Christin; Ibeanu, Nkiruka; Brocchini, Steve] UCL Sch Pharm, 29-39 Brunswick Sq, London WC1N 1AX, England.
   [Awwad, Sahar; Henein, Christin; Ibeanu, Nkiruka; Khaw, Peng T.; Brocchini, Steve] Moorfields Eye Hosp NHS Fdn Trust, Natl Inst Hlth Res NIHR Biomed Res Ctr, London EC1V 9EL, England.
   [Awwad, Sahar; Henein, Christin; Ibeanu, Nkiruka; Khaw, Peng T.; Brocchini, Steve] UCL Inst Ophthalmol, London EC1V 9EL, England.
C3 University of London; University College London; University of London;
   University College London; Moorfields Eye Hospital NHS Foundation Trust;
   University of London; University College London
RP Awwad, S (通讯作者)，UCL Sch Pharm, 29-39 Brunswick Sq, London WC1N 1AX, England.
EM s.awwad@ucl.ac.uk
OI Awwad, Sahar/0000-0002-4430-2508; Khaw, Sir Peng Tee/0000-0002-8087-2268
FU National Institute of Health Research (NIHR) Biomedical Research Centre
   at Moorfields Eye Hospital NHS Foundation Trust and UCL Institute of
   Ophthalmology; Moorfields; Helen Hamlyn Trust; Medical Research Council;
   Fight for Sight; Michael and Ilse Katz foundation; Santen Pharmaceutical
   Co., Ltd; MRC [G0801650] Funding Source: UKRI
FX We are grateful for funding from the National Institute of Health
   Research (NIHR) Biomedical Research Centre at Moorfields Eye Hospital
   NHS Foundation Trust and UCL Institute of Ophthalmology, Moorfields
   Special Trustees, the Helen Hamlyn Trust (in memory of Paul Hamlyn),
   Medical Research Council, Fight for Sight and the Michael and Ilse Katz
   foundation. NI is grateful Santen Pharmaceutical Co., Ltd for funding
   her PhD studies.
CR Aban IB, 2015, EXP NEUROL, V270, P82, DOI 10.1016/j.expneurol.2015.02.024
   Abrishami M, 2009, RETINA-J RET VIT DIS, V29, P699, DOI 10.1097/IAE.0b013e3181a2f42a
   Abu El-Asrar AM, 1998, EYE, V12, P1001, DOI 10.1038/eye.1998.257
   Acharya S, 2000, J BIOL CHEM, V275, P6945, DOI 10.1074/jbc.275.10.6945
   Adamson P, 2016, J CONTROL RELEASE, V244, P1, DOI 10.1016/j.jconrel.2016.10.026
   Adan A, 2013, RETINA-J RET VIT DIS, V33, P1435, DOI 10.1097/IAE.0b013e31827e247b
   Agrahari V, 2016, DRUG DELIV TRANSL RE, V6, P735, DOI 10.1007/s13346-016-0339-2
   Agu RU, 2011, EXPERT OPIN DRUG DEL, V8, P57, DOI 10.1517/17425247.2011.543896
   AGUILAR HE, 1995, RETINA-J RET VIT DIS, V15, P428
   Ahn J, 2013, J OCUL PHARMACOL TH, V29, P612, DOI 10.1089/jop.2013.0009
   Aiello LP, 2004, RETINA-J RET VIT DIS, V24, pS3, DOI 10.1097/00006982-200410001-00002
   Aihara M, 2003, INVEST OPHTH VIS SCI, V44, P5168, DOI 10.1167/iovs.03-0504
   Al-Khersan H, 2019, EXPERT OPIN PHARMACO, V20, P1879, DOI 10.1080/14656566.2019.1636031
   Ali SAM, 2011, J VET MED SCI, V73, P13, DOI 10.1292/jvms.10-0201
   Almubrad T, 2011, MOL VIS, V17, P2283
   Amos A F, 1997, Diabet Med, V14 Suppl 5, pS1
   Anand BS, 2004, INT J PHARMACEUT, V281, P79, DOI 10.1016/j.ijpharm.2004.05.028
   Angkawinitwong U, 2017, ACTA BIOMATER, V64, P126, DOI 10.1016/j.actbio.2017.10.015
   [Anonymous], 2018, LANCET, V392, P1090, DOI 10.1016/S0140-6736(18)32291-8
   [Anonymous], 1930, BR J OPHTHALMOL
   [Anonymous], 2003, GUIDANCE IND EXPOSUR
   Artunay O, 2009, EYE, V23, P2187, DOI 10.1038/eye.2009.7
   Atluri H, 2003, EXP EYE RES, V76, P315, DOI 10.1016/S0014-4835(02)00311-1
   Audren F, 2004, INVEST OPHTH VIS SCI, V45, P3435, DOI 10.1167/iovs.03-1110
   Avery RL, 2016, JAMA OPHTHALMOL, V134, P21, DOI 10.1001/jamaophthalmol.2015.4070
   Awwad S.S.H., 2016, VITREOUS DEPOT PROLO
   Awwad S, 2019, EUR J PHARM SCI, V137, DOI 10.1016/j.ejps.2019.104993
   Awwad S, 2018, PHARMACEUTICS, V10, DOI 10.3390/pharmaceutics10030083
   Awwad S, 2018, MACROMOL BIOSCI, V18, DOI 10.1002/mabi.201700255
   Awwad S, 2017, BRIT J PHARMACOL, V174, P4205, DOI 10.1111/bph.14024
   Awwad S, 2017, INT J PHARMACEUT, V522, P119, DOI 10.1016/j.ijpharm.2017.02.047
   Awwad S, 2015, J PHARM SCI-US, V104, P3330, DOI 10.1002/jps.24480
   BAARSMA GS, 1991, AM J OPHTHALMOL, V112, P147, DOI 10.1016/S0002-9394(14)76693-0
   Baino F, 2011, ACTA BIOMATER, V7, P921, DOI 10.1016/j.actbio.2010.10.030
   Bakri SJ, 2008, RETINA-J RET VIT DIS, V28, P996, DOI 10.1097/IAE.0b013e31816c6868
   Bakri SJ, 2008, GRAEF ARCH CLIN EXP, V246, P779, DOI 10.1007/s00417-007-0754-7
   Bakri SJ, 2007, OPHTHALMOLOGY, V114, P2179, DOI 10.1016/j.ophtha.2007.09.012
   Balasubramani M, 2010, MATRIX BIOL, V29, P471, DOI 10.1016/j.matbio.2010.04.002
   Balazs E.A., 1984, BIOMEDICAL FDN OPHTH, V1, P14
   BALAZS EA, 1959, J BIOL CHEM, V234, P422
   Banyard J, 2003, J BIOL CHEM, V278, P20989, DOI 10.1074/jbc.M210616200
   Barat A, 2006, SIMUL MODEL PRACT TH, V14, P857, DOI 10.1016/j.simpat.2006.03.003
   BARTELS SP, 1988, INVEST OPHTH VIS SCI, V29, P1498
   Baskakova A, 2016, INT J PHARMACEUT, V502, P208, DOI 10.1016/j.ijpharm.2016.02.015
   Beer PM, 2003, OPHTHALMOLOGY, V110, P681, DOI 10.1016/S0161-6420(02)01969-3
   Behar-Cohen F, 2019, EXPERT OPIN DRUG DEL, V16, P679, DOI 10.1080/17425247.2019.1618829
   BERMAN ER, 1964, EXP EYE RES, V3, P9, DOI 10.1016/S0014-4835(64)80003-8
   Bhatt N, 2016, DEV OPHTHALMOL, V55, P252, DOI 10.1159/000431201
   Bishop P, 1996, GRAEF ARCH CLIN EXP, V234, P710, DOI 10.1007/BF00292358
   Bishop P, 1996, EYE, V10, P664, DOI 10.1038/eye.1996.159
   BISHOP PN, 1994, BIOCHEM J, V299, P497, DOI 10.1042/bj2990497
   Bishop PN, 2004, INVEST OPHTH VIS SCI, V45, P1041, DOI 10.1167/iovs.03-1017
   Bishop PN, 2000, PROG RETIN EYE RES, V19, P323, DOI 10.1016/S1350-9462(99)00016-6
   Bonam M, 2008, AAPS PHARMSCITECH, V9, P404, DOI 10.1208/s12249-008-9045-9
   Bond-Taylor M, 2017, CLIN OPHTHALMOL, V11, P1689, DOI 10.2147/OPTH.S143898
   Bourne RRA, 2018, BRIT J OPHTHALMOL, V102, P575, DOI 10.1136/bjophthalmol-2017-311258
   Boyer DS, 2011, RETINA-J RET VIT DIS, V31, P915, DOI 10.1097/IAE.0b013e318206d18c
   Brinch KS, 2009, ANTIMICROB AGENTS CH, V53, P4794, DOI 10.1128/AAC.00440-09
   Brinks V, 2011, PHARM RES-DORDR, V28, P2379, DOI 10.1007/s11095-011-0523-5
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Brubaker R F, 1982, Trans Am Ophthalmol Soc, V80, P391
   Bu SC, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0134325
   Burden N, 2015, J AM ASSOC LAB ANIM, V54, P198
   BUSTAMANTE J, 1993, PIGM CELL RES, V6, P348, DOI 10.1111/j.1600-0749.1993.tb00612.x
   Campochiaro PA, 2019, OPHTHALMOLOGY, V126, P1141, DOI 10.1016/j.ophtha.2019.03.036
   Caruso A, 2020, MOL PHARMACEUT, V17, P695, DOI 10.1021/acs.molpharmaceut.9b01191
   Causin P, 2016, J MATH IND, V6, DOI 10.1186/s13362-016-0031-7
   Centre for Drug Evaluation and Research (CDER), 2014, FDA MED REV NDA20193
   Centre for Drug Evaluation and Research (CDER), 2006, FDA PHARM REV BLA AP
   Centre for Drug Evaluation and Research (CDER), 2011, FDA PHARM REV BLA AP
   Centre for Drug Evaluation and Research (CDER), 2009, FDA MED REV NDA02231
   Chakravarti S, 2003, INVEST OPHTH VIS SCI, V44, P2422, DOI 10.1167/iovs.02-0783
   Chapman K, 2016, MABS-AUSTIN, V8, P427, DOI 10.1080/19420862.2016.1145331
   Cheng LY, 2009, OPHTHALMOLOGY, V116, P1356, DOI 10.1016/j.ophtha.2009.01.039
   Cheruvu NPS, 2008, INVEST OPHTH VIS SCI, V49, P333, DOI 10.1167/iovs.07-0214
   Cheung N, 2012, AM J OPHTHALMOL, V153, P193, DOI 10.1016/j.ajo.2011.11.022
   Chin HS, 2005, RETINA-J RET VIT DIS, V25, P556, DOI 10.1097/00006982-200507000-00002
   Choonara YE, 2010, J PHARM SCI-US, V99, P2219, DOI 10.1002/jps.21987
   Christoforidis JB, 2013, RETINA-J RET VIT DIS, V33, P946, DOI 10.1097/IAE.0b013e3182753b12
   Christoforidis JB, 2012, CURR EYE RES, V37, P1171, DOI 10.3109/02713683.2012.727521
   Christoforidis JB, 2017, INVEST OPHTH VIS SCI, V58, P5636, DOI 10.1167/iovs.17-22431
   CINTRON C, 1988, INVEST OPHTH VIS SCI, V29, P760
   Clark JM, 2018, BRIT J NUTR, V120, pS1, DOI 10.1017/S0007114517002227
   Clemence M, 2016, PUBLIC ATTITUDES ANI
   Coco RM, 1998, J OCUL PHARMACOL TH, V14, P555, DOI 10.1089/jop.1998.14.555
   Corpuz LM, 1996, J BIOL CHEM, V271, P9759, DOI 10.1074/jbc.271.16.9759
   Couch SM, 2009, CLIN OPHTHALMOL, V3, P41
   Crowell SR, 2019, TRANSL VIS SCI TECHN, V8, DOI 10.1167/tvst.8.6.1
   Crumley WR, 2012, AM J VET RES, V73, P704, DOI 10.2460/ajvr.73.5.704
   Csaky K, 2009, AM J OPHTHALMOL, V148, P647, DOI 10.1016/j.ajo.2009.06.014
   Cunha-Vaz JG, 1997, DOC OPHTHALMOL, V93, P149, DOI 10.1007/BF02569055
   Dayhaw-Barker P, 2002, INT J TOXICOL, V21, P451, DOI 10.1080/10915810290169873
   de Oliveira Dias Joao Rafael, 2016, Int J Retina Vitreous, V2, P3, DOI 10.1186/s40942-016-0026-y
   de Zafra CLZ, 2017, REGUL TOXICOL PHARM, V86, P221, DOI 10.1016/j.yrtph.2017.03.013
   del Amo EM, 2017, PROG RETIN EYE RES, V57, P134, DOI 10.1016/j.preteyeres.2016.12.001
   del Amo EM, 2015, EXP EYE RES, V137, P111, DOI 10.1016/j.exer.2015.05.003
   Delplace V, 2019, J CONTROL RELEASE, V293, P10, DOI 10.1016/j.jconrel.2018.11.012
   Delplace V, 2015, J CONTROL RELEASE, V219, P652, DOI 10.1016/j.jconrel.2015.09.065
   Deng F., 2016, PHARM RES, V56, P1
   Do D.V., 2019, RETINA, V40, P643
   DOFT BH, 1985, OPHTHALMOLOGY, V92, P1601, DOI 10.1016/S0161-6420(85)33838-1
   Drapala PW, 2011, J BIOMAT SCI-POLYM E, V22, P59, DOI 10.1163/092050609X12578498952315
   Durairaj C, 2012, EXP EYE RES, V98, P23, DOI 10.1016/j.exer.2012.03.004
   Durham D G, 1970, Trans Am Ophthalmol Soc, V68, P462
   Medeiros MD, 2014, J OCUL PHARMACOL TH, V30, P709, DOI 10.1089/jop.2014.0010
   Edelhauser HF, 2010, INVEST OPHTH VIS SCI, V51, P5403, DOI 10.1167/iovs.10-5392
   Egbu R, 2018, EUR J PHARM BIOPHARM, V124, P95, DOI 10.1016/j.ejpb.2017.12.019
   Emami J, 2006, J PHARM PHARM SCI, V9, P169
   Endo K, 2004, INVEST OPHTH VIS SCI, V45, P1771, DOI 10.1167/iovs.03-0952
   Ethier CR, 2004, ANNU REV BIOMED ENG, V6, P249, DOI 10.1146/annurev.bioeng.6.040803.140055
   European Medical Agency, 2012, GUID IMM ASS MON ANT
   European Medicines Agency (EMA), 2014, ASS REP EYL INT NONP
   Falavarjani KG, 2013, EYE, V27, P787, DOI 10.1038/eye.2013.107
   Figueira JR., 2016, MULTIPLE CRITERIA DE, V2, pxix, DOI DOI 10.1016/B978-0-12-809847-9.02001-8
   FOTAKI N, 2005, DISSOLUT TECHNOL, V12, P17
   Fotaki N, 2011, DISSOLUT TECHNOL, V18, P46, DOI 10.14227/DT180411P46
   FOWLKS WL, 1963, INVEST OPHTH VISUAL, V2, P63
   Fraser JRE, 1997, J INTERN MED, V242, P27, DOI 10.1046/j.1365-2796.1997.00170.x
   FRIEDLAND AB, 1978, B MATH BIOL, V40, P223, DOI 10.1016/S0092-8240(78)80041-X
   Friedrich S, 1997, J OCUL PHARMACOL TH, V13, P445, DOI 10.1089/jop.1997.13.445
   G.B. Home Office, 2011, STAT SCI P REC ES LI
   Gandhi NS, 2008, CHEM BIOL DRUG DES, V72, P455, DOI 10.1111/j.1747-0285.2008.00741.x
   Gao QY, 2015, INT J OPHTHALMOL-CHI, V8, P437, DOI 10.3980/j.issn.2222-3959.2015.03.01
   Garcia-Quintanilla L, 2019, PHARMACEUTICS, V11, DOI 10.3390/pharmaceutics11080365
   Gaudana R, 2010, AAPS J, V12, P348, DOI 10.1208/s12248-010-9183-3
   Gaudreault J, 2005, INVEST OPHTH VIS SCI, V46, P726, DOI 10.1167/iovs.04-0601
   Gaudreault J, 2007, RETINA-J RET VIT DIS, V27, P1260, DOI 10.1097/IAE.0b013e318134eecd
   Gebauer M, 2009, CURR OPIN CHEM BIOL, V13, P245, DOI 10.1016/j.cbpa.2009.04.627
   Gelse K, 2003, ADV DRUG DELIVER REV, V55, P1531, DOI 10.1016/j.addr.2003.08.002
   Ghosh JG, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14837
   Giansanti F, 2009, INVEST OPHTH VIS SCI, V50, P5328, DOI 10.1167/iovs.09-3569
   Gil-Martinez M, 2020, CURR MED CHEM, V27, P583, DOI 10.2174/0929867326666190726121711
   Gilger BC, 2005, VET OPHTHALMOL, V8, P265, DOI 10.1111/j.1463-5224.2005.00401.x
   Goel M, 2010, OPEN OPHTHALMOL J, V4, P52, DOI 10.2174/1874364101004010052
   Goel VK, 2016, SPINE, V41, pA6, DOI 10.1097/BRS.0000000000001421
   Goldberg RA, 2013, OPHTHALMOLOGY, V120, P1448, DOI 10.1016/j.ophtha.2012.12.009
   Goldberg RA, 2012, AM J OPHTHALMOL, V153, P204, DOI 10.1016/j.ajo.2011.11.035
   Gomes RR, 2006, DIFFERENTIATION, V74, P53, DOI 10.1111/j.1432-0436.2005.00055.x
   Gooch N, 2013, J FUNCT BIOMATER, V4, P14, DOI 10.3390/jfb4010014
   Goswami S, 2013, ANTIBODIES, V2, P452, DOI 10.3390/antib2030452
   Grimshaw J, 1996, ELECTROPHORESIS, V17, P396, DOI 10.1002/elps.1150170218
   GRONNING K, 2020, BROLUCIZUMAB AND IMM, DOI DOI 10.1530/EDM-19-0131
   Haghjou N, 2013, PHARM RES-DORDR, V30, P41, DOI 10.1007/s11095-012-0847-9
   Haug Sara J, 2020, Am J Ophthalmol Case Rep, V18, P100680, DOI 10.1016/j.ajoc.2020.100680
   HAYREH SS, 1966, EXP EYE RES, V5, P123, DOI 10.1016/S0014-4835(66)80029-5
   Heier JS, 2011, OPHTHALMOLOGY, V118, P1098, DOI 10.1016/j.ophtha.2011.03.020
   Hellinen L, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-50324-8
   Henein C, 2019, PHARMACEUTICS, V11, DOI 10.3390/pharmaceutics11080371
   Hirano T, 2018, RETINA-J RET VIT DIS, V38, P1801, DOI 10.1097/IAE.0000000000002004
   HOBBS HE, 1959, LANCET, V2, P478
   Holz FG, 2015, BRIT J OPHTHALMOL, V99, P220, DOI 10.1136/bjophthalmol-2014-305327
   Hornof M, 2005, EUR J PHARM BIOPHARM, V60, P207, DOI 10.1016/j.ejpb.2005.01.009
   Hu CC, 2014, BIO-MED MATER ENG, V24, P1941, DOI 10.3233/BME-141003
   Hubschman JP, 2010, RETINA-J RET VIT DIS, V30, P167, DOI 10.1097/IAE.0b013e3181b094cf
   Huelsmann PM, 2017, Al, Fusion proteins for ophthalmology with increased eye retention, Patent No. [WO 2017/211731 Al, 2017211731]
   Hughes PM, 2005, ADV DRUG DELIVER REV, V57, P2010, DOI 10.1016/j.addr.2005.09.004
   Hutton-Smith LA, 2017, MOL PHARMACEUT, V14, P2690, DOI 10.1021/acs.molpharmaceut.7b00164
   ICH, INT COUNC HARM TECHN
   Ihanamaki T, 2004, PROG RETIN EYE RES, V23, P403, DOI 10.1016/j.preteyeres.2004.04.002
   Ihanamaki T, 2001, EXP EYE RES, V72, P423, DOI 10.1006/exer.2000.0972
   Inatani M, 2002, PROG RETIN EYE RES, V21, P429, DOI 10.1016/S1350-9462(02)00009-5
   Inatani M, 2001, INVEST OPHTH VIS SCI, V42, P1930
   Inatani M, 1999, INVEST OPHTH VIS SCI, V40, P1783
   International Conference on Harmonisation (ICH), 2009, GUIDELINE, V3, P31
   Ipsos, 2018, PUBL ATT AN RES 2018
   ISHIZAKI M, 1993, INVEST OPHTH VIS SCI, V34, P2680
   Jager RD, 2004, RETINA-J RET VIT DIS, V24, P676, DOI 10.1097/00006982-200410000-00002
   Jain Atul, 2020, Am J Ophthalmol Case Rep, V18, P100687, DOI 10.1016/j.ajoc.2020.100687
   JARUS G, 1985, OPHTHALMOLOGY, V92, P91
   Jones HM, 2011, CLIN PHARMACOKINET, V50, P331, DOI 10.2165/11539680-000000000-00000
   Jooybar E, 2014, MATH BIOSCI, V255, P11, DOI 10.1016/j.mbs.2014.06.008
   JUNQUEIRA LCU, 1983, ARCH HISTOL JAPON, V46, P589, DOI 10.1679/aohc.46.589
   Kakinoki M, 2012, INVEST OPHTH VIS SCI, V53, P5877, DOI 10.1167/iovs.12-10164
   Kamma-Lorger CS, 2010, J STRUCT BIOL, V169, P424, DOI 10.1016/j.jsb.2009.11.004
   Kathawate J, 2008, INT J HEAT MASS TRAN, V51, P5598, DOI 10.1016/j.ijheatmasstransfer.2008.04.053
   Keenan TDL, 2012, INVEST OPHTH VIS SCI, V53, P7528, DOI 10.1167/iovs.12-10797
   Khurana RN, 2017, JAMA OPHTHALMOL, V135, P800, DOI 10.1001/jamaophthalmol.2017.1815
   Kim H, 2005, ANN BIOMED ENG, V33, P150, DOI 10.1007/s10439-005-8974-7
   Kim HM, 2020, OPHTHALMIC RES, V63, P41, DOI 10.1159/000499529
   Kim H, 2006, EXP EYE RES, V82, P760, DOI 10.1016/j.exer.2005.09.018
   Kim JE, 2008, AM J OPHTHALMOL, V146, P930, DOI 10.1016/j.ajo.2008.07.007
   Kim MR, 2002, J CONTROL RELEASE, V80, P69, DOI 10.1016/S0168-3659(01)00557-0
   King H, 1998, DIABETES CARE, V21, P1414, DOI 10.2337/diacare.21.9.1414
   Kleinberg TT, 2011, SURV OPHTHALMOL, V56, P300, DOI 10.1016/j.survophthal.2010.09.001
   Koch M, 2003, J BIOL CHEM, V278, P43236, DOI 10.1074/jbc.M302112200
   Koch M, 2001, J BIOL CHEM, V276, P23120, DOI 10.1074/jbc.M009912200
   Kodama M., 2013, J BIOMED SCI ENG, V6, P739
   KOKENYESI R, 1994, J BIOL CHEM, V269, P12304
   Kompella UB, 2011, DRUG PRODUCT DEV BAC, V2
   KONOMI H, 1984, AM J PATHOL, V116, P417
   Krohne TU, 2008, AM J OPHTHALMOL, V146, P508, DOI 10.1016/j.ajo.2008.05.036
   Krohne TU, 2012, AM J OPHTHALMOL, V154, P682, DOI 10.1016/j.ajo.2012.03.047
   Kumar A, 2016, EYE, V30, P763, DOI 10.1038/eye.2015.281
   Kummer MP, 2007, P ANN INT IEEE EMBS, P6407
   Kurisawa M, 2005, CHEM COMMUN, P4312, DOI 10.1039/b506989k
   KWAK HW, 1992, ARCH OPHTHALMOL-CHIC, V110, P259, DOI 10.1001/archopht.1992.01080140115038
   Lai CH, 1996, TISSUE CELL, V28, P155, DOI 10.1016/S0040-8166(96)80004-8
   Larsen C, 2009, EXPERT OPIN DRUG DEL, V6, P1283, DOI 10.1517/17425240903307431
   Laude A, 2010, PROG RETIN EYE RES, V29, P466, DOI 10.1016/j.preteyeres.2010.04.003
   Laugesen CS, 2017, ACTA OPHTHALMOL, V95, P28, DOI 10.1111/aos.13160
   LAURENT TC, 1960, BIOCHIM BIOPHYS ACTA, V42, P476, DOI 10.1016/0006-3002(60)90826-X
   LAURENT UBG, 1983, EXP EYE RES, V36, P481, DOI 10.1016/0014-4835(83)90042-8
   Lave T, 2009, EXPERT OPIN DRUG MET, V5, P1039, DOI 10.1517/17425250903099649
   Le Goff MM, 2008, EYE, V22, P1214, DOI 10.1038/eye.2008.21
   Leach JB, 2005, BIOMATERIALS, V26, P125, DOI 10.1016/j.biomaterials.2004.02.018
   Lee SS, 2010, INVEST OPHTH VIS SCI, V51, P2135, DOI 10.1167/iovs.09-3582
   Leitritz MA, 2011, RETINA-J RET VIT DIS, V31, P810, DOI 10.1097/IAE.0b013e3182111743
   Licina A., 2016, COCHRANE DATABASE SY, V2016
   Liebsch M, 2011, ARCH TOXICOL, V85, P841, DOI 10.1007/s00204-011-0718-x
   Lin HJ, 2010, INVEST OPHTH VIS SCI, V51, P96, DOI 10.1167/iovs.09-3612
   Liu L, 2011, INVEST OPHTH VIS SCI, V52, P1023, DOI 10.1167/iovs.10-6431
   Loch C, 2012, BIOMED ENG-BIOMED TE, V57, P281, DOI 10.1515/bmt-2012-4106
   Loch C, 2014, J PHARM SCI-US, V103, P517, DOI 10.1002/jps.23808
   Longest PW, 2012, PHARM RES-DORDR, V29, P1670, DOI 10.1007/s11095-012-0691-y
   Los LI, 2004, J HISTOCHEM CYTOCHEM, V52, P789, DOI 10.1369/jhc.4A6267.2004
   Lotery A, 2017, EYE, V31, P1697, DOI 10.1038/eye.2017.143
   Lovett ML, 2015, EUR J PHARM BIOPHARM, V95, P271, DOI 10.1016/j.ejpb.2014.12.029
   LUTJENDRECOLL E, 1981, INVEST OPHTH VIS SCI, V21, P563
   Macha S, 2001, J OCUL PHARMACOL TH, V17, P485, DOI 10.1089/108076801753266866
   Macha S, 2001, EXP EYE RES, V72, P289, DOI 10.1006/exer.2000.0953
   Machinaga N, 2018, TRANSL VIS SCI TECHN, V7, DOI 10.1167/tvst.7.4.21
   Mains J., 2012, J OCUL PHARM THER
   MANDELL BA, 1993, AM J OPHTHALMOL, V115, P770, DOI 10.1016/S0002-9394(14)73646-3
   MARINKOVICH MP, 1992, J BIOL CHEM, V267, P17900
   Markham A, 2019, DRUGS, V79, P1997, DOI 10.1007/s40265-019-01231-9
   MARSHALL GE, 1992, EXP EYE RES, V54, P393, DOI 10.1016/0014-4835(92)90051-S
   MARSHALL GE, 1993, BRIT J OPHTHALMOL, V77, P515, DOI 10.1136/bjo.77.8.515
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Maurice D, 2001, J OCUL PHARMACOL TH, V17, P393, DOI 10.1089/108076801753162807
   May Christian Albrecht, 2012, ISRN Ophthalmol, V2012, P378641, DOI 10.5402/2012/378641
   Mayne R, 1999, BIOCHEM SOC T, V27, P832, DOI 10.1042/bst0270832
   Mc MASTER PHILIP R. B., 1967, INVEST OPHTHALMOL, V6, P84
   Mehta H, 2015, THER ADV CHRONIC DIS, V6, P234, DOI 10.1177/2040622315590319
   Mehta SC, 2019, DRUG DISCOV TODAY, V24, P1440, DOI 10.1016/j.drudis.2019.05.025
   MENON IA, 1992, J OCUL PHARMACOL, V8, P35, DOI 10.1089/jop.1992.8.35
   Meral I, 2011, AM J NEURORADIOL, V32, P1563, DOI 10.3174/ajnr.A2543
   Mermoud A, 1996, GRAEF ARCH CLIN EXP, V234, pS198, DOI 10.1007/BF02343072
   Messmer EM, 2012, ACTA OPHTHALMOL, V90, pe476, DOI 10.1111/j.1755-3768.2012.02481.x
   Meyer CH, 2011, RETINA-J RET VIT DIS, V31, P1877, DOI 10.1097/IAE.0b013e318217373c
   Milston R, 2016, SURV OPHTHALMOL, V61, P211, DOI 10.1016/j.survophthal.2015.11.008
   Missel P, 2010, J OCUL PHARMACOL TH, V26, P137, DOI 10.1089/jop.2009.0132
   Missel PJ, 2012, PHARM RES-DORDR, V29, P3251, DOI 10.1007/s11095-012-0721-9
   Miyake T, 2010, INVEST OPHTH VIS SCI, V51, P1606, DOI 10.1167/iovs.09-4140
   Modareszadeh A, 2013, BIOMECH MODEL MECHAN, V12, P281, DOI 10.1007/s10237-012-0398-3
   Modi YS, 2015, DRUG SAFETY, V38, P279, DOI 10.1007/s40264-015-0273-0
   MORRISON JC, 1994, INVEST OPHTH VIS SCI, V35, P838
   Myllyharju J, 2001, ANN MED, V33, P7, DOI 10.3109/07853890109002055
   Necas J, 2008, VET MED-CZECH, V53, P397, DOI 10.17221/1930-VETMED
   Ness T, 2010, RETINA-J RET VIT DIS, V30, P332, DOI 10.1097/IAE.0b013e3181baf691
   NEWSOME DA, 1982, INVEST OPHTH VIS SCI, V22, P376
   Ng SF, 2012, ARCH PHARM RES, V35, P579, DOI 10.1007/s12272-012-0401-7
   Nickerson CS, 2008, J BIOMECH, V41, P1840, DOI 10.1016/j.jbiomech.2008.04.015
   Niwa Y, 2015, INVEST OPHTH VIS SCI, V56, P6501, DOI 10.1167/iovs.15-17279
   Nomoto H, 2009, INVEST OPHTH VIS SCI, V50, P4807, DOI 10.1167/iovs.08-3148
   Noulas AV, 2004, BIOMED CHROMATOGR, V18, P457, DOI 10.1002/bmc.336
   Noulas AV, 2002, BIOCHIMIE, V84, P295, DOI 10.1016/S0300-9084(02)01389-5
   OHTORI A, 1994, BIOL PHARM BULL, V17, P283
   Osswald CR, 2017, CURR EYE RES, V42, P1293, DOI 10.1080/02713683.2017.1302590
   Pakulska MM, 2016, SCIENCE, V351, DOI 10.1126/science.aac4750
   Palmer JM, 2013, EYE, V27, P1090, DOI 10.1038/eye.2013.139
   Pan CK, 2011, J OCUL PHARMACOL TH, V27, P219, DOI 10.1089/jop.2010.0158
   Panova IG, 2009, PROC SPIE, V7163, DOI 10.1117/12.808400
   Parikh R, 2017, OPHTHALMOLOGY, V124, P352, DOI 10.1016/j.ophtha.2016.10.036
   Park J, 2005, J CONTROL RELEASE, V105, P279, DOI 10.1016/j.jconrel.2005.03.010
   Park SJ, 2015, EYE, V29, P561, DOI 10.1038/eye.2014.329
   Park SJ, 2016, INVEST OPHTH VIS SCI, V57, P2612, DOI 10.1167/iovs.16-19204
   Patel S, 2015, EUR J PHARM BIOPHARM, V95, P407, DOI 10.1016/j.ejpb.2015.04.033
   Pelkonen L, 2017, EUR J PHARM SCI, V109, P162, DOI 10.1016/j.ejps.2017.07.027
   Pepic I, 2014, DRUG DISCOV TODAY, V19, P31, DOI 10.1016/j.drudis.2013.08.002
   Petri AS, 2020, OPHTHALMOL THER, V9, P191, DOI 10.1007/s40123-020-00230-4
   Peynshaert K, 2019, CURR EYE RES, V44, P465, DOI 10.1080/02713683.2019.1565890
   Pitkanen L, 2005, INVEST OPHTH VIS SCI, V46, P641, DOI 10.1167/iovs.04-1051
   Poku E., 2012, BEVACIZUMAB EYE COND
   Ponsioen TL, 2008, INVEST OPHTH VIS SCI, V49, P4089, DOI 10.1167/iovs.07-1456
   Ponsioen TL, 2010, PROG RETIN EYE RES, V29, P580, DOI 10.1016/j.preteyeres.2010.07.001
   Ponsioen TL, 2005, EXP EYE RES, V80, P643, DOI 10.1016/j.exer.2004.11.014
   Popp S, 2004, EXP EYE RES, V79, P351, DOI 10.1016/j.exer.2004.05.016
   POTTS AM, 1964, INVEST OPHTH VISUAL, V3, P405
   Prasad PS, 2010, MATURITAS, V66, P46, DOI 10.1016/j.maturitas.2010.02.006
   Pulido JE, 2007, EXP DIABETES RES, DOI 10.1155/2007/36150
   Qin P, 1997, DEV DYNAM, V209, P367, DOI 10.1002/(SICI)1097-0177(199708)209:4<367::AID-AJA4>3.0.CO;2-G
   Nguyen QD, 2012, OPHTHALMOLOGY, V119, P789, DOI 10.1016/j.ophtha.2011.12.039
   Radenbaugh PA, 2006, INVEST OPHTH VIS SCI, V47, P4860, DOI 10.1167/iovs.06-0154
   Radhakrishnan K, 2017, DRUG DISCOV TODAY, V22, P416, DOI 10.1016/j.drudis.2016.10.015
   Raftery J, 2007, BRIT J OPHTHALMOL, V91, P1244, DOI 10.1136/bjo.2007.116616
   Raju JR, 2002, AM J OPHTHALMOL, V133, P564, DOI 10.1016/S0002-9394(01)01408-8
   Ramesh S, 2004, BRIT J OPHTHALMOL, V88, P697, DOI 10.1136/bjo.2003.031989
   Rankin AJ, 2012, AM J VET RES, V73, P1074, DOI 10.2460/ajvr.73.7.1074
   Ranta VP, 2006, ADV DRUG DELIVER REV, V58, P1164, DOI 10.1016/j.addr.2006.07.025
   Rauck BM, 2014, INVEST OPHTH VIS SCI, V55, P469, DOI 10.1167/iovs.13-13120
   Reardon A, 1998, MATRIX BIOL, V17, P325, DOI 10.1016/S0945-053X(98)90085-3
   REHNBERG M, 1987, BRIT J OPHTHALMOL, V71, P886, DOI 10.1136/bjo.71.12.886
   Repetto R, 2005, PHYS MED BIOL, V50, P4729, DOI 10.1088/0031-9155/50/19/021
   Rimpela AK, 2019, PHARMACEUTICS, V11, DOI 10.3390/pharmaceutics11010009
   Rimpela AK, 2018, J CONTROL RELEASE, V283, P261, DOI 10.1016/j.jconrel.2018.05.034
   Rittenhouse KD, 2000, ADV DRUG DELIVER REV, V45, P229, DOI 10.1016/S0169-409X(00)00112-5
   Robbie SJ, 2013, INVEST OPHTH VIS SCI, V54, P1490, DOI 10.1167/iovs.12-10169
   Robinson S, 2008, REGUL TOXICOL PHARM, V50, P345, DOI 10.1016/j.yrtph.2007.11.009
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rostami-Hodjegan A, 2007, NAT REV DRUG DISCOV, V6, P140, DOI 10.1038/nrd2173
   Rowe-Rendleman CL, 2014, INVEST OPHTH VIS SCI, V55, P2714, DOI 10.1167/iovs.13-13707
   SALAZAR M, 1976, INVEST OPHTH VISUAL, V15, P671
   Sandberg-Lall M, 2000, EXP EYE RES, V70, P401, DOI 10.1006/exer.1998.0826
   Sapino S, 2019, NANOMATERIALS-BASEL, V9, DOI 10.3390/nano9101461
   Sarao V, 2014, SCI WORLD J, DOI 10.1155/2014/989501
   Schargus M, 2018, RETINA-J RET VIT DIS, V38, P2088, DOI 10.1097/IAE.0000000000001809
   Schmitt M, 2019, MOL PHARMACEUT, V16, P4399, DOI 10.1021/acs.molpharmaceut.9b00679
   SCHOLES GN, 1985, ARCH OPHTHALMOL-CHIC, V103, P1567
   Schroeder RL, 2014, TOXICOL REP, V1, P963, DOI 10.1016/j.toxrep.2014.10.019
   Schuster J, 2020, PHARM RES-DORDR, V37, DOI 10.1007/s11095-019-2689-1
   SCOTT JE, 1992, EYE, V6, P553, DOI 10.1038/eye.1992.120
   SEBAG J, 1989, INVEST OPHTH VIS SCI, V30, P1867
   SEBAG J, 1987, EYE, V1, P254, DOI 10.1038/eye.1987.45
   SEBAG J, 1987, GRAEF ARCH CLIN EXP, V225, P89, DOI 10.1007/BF02160337
   Sertkaya A, 2016, CLIN TRIALS, V13, P117, DOI 10.1177/1740774515625964
   Shafaie S, 2018, INT J PHARMACEUT, V550, P207, DOI 10.1016/j.ijpharm.2018.07.070
   Shafaie S, 2016, BIORESEARCH OPEN ACC, V5, DOI 10.1089/biores.2016.0008
   Shalaby AK, 2016, EYE, V30, P1404, DOI 10.1038/eye.2016.154
   Shankar G, 2006, TRENDS BIOTECHNOL, V24, P274, DOI 10.1016/j.tibtech.2006.04.001
   Sharif-Kashani P, 2011, J BIOMECH, V44, P419, DOI 10.1016/j.jbiomech.2010.10.002
   Sharma A, 2019, EYE, V33, P1359, DOI 10.1038/s41433-019-0434-y
   Shatz W, 2019, EXPERT OPIN DRUG DEL, V16, P43, DOI 10.1080/17425247.2019.1553953
   Shatz W, 2016, MOL PHARMACEUT, V13, P2996, DOI 10.1021/acs.molpharmaceut.6b00345
   Sheyman AT, 2013, JAMA OPHTHALMOL, V131, P864, DOI 10.1001/jamaophthalmol.2013.88
   Shohin IE, 2016, DISSOLUT TECHNOL, V23, P6, DOI 10.14227/DT230316P6
   Short BG, 2008, TOXICOL PATHOL, V36, P49, DOI 10.1177/0192623307310955
   Siggers JH, 2012, ANNU REV FLUID MECH, V44, P347, DOI 10.1146/annurev-fluid-120710-101058
   Silva AF, 2017, RHEOL ACTA, V56, P377, DOI 10.1007/s00397-017-0997-0
   Sinapis CI, 2011, CLIN OPHTHALMOL, V5, P697, DOI 10.2147/OPTH.S19555
   SMITH GN, 1976, P NATL ACAD SCI USA, V73, P4420, DOI 10.1073/pnas.73.12.4420
   Sophie Raafay, 2012, Biol Ther, V2, P3, DOI 10.1007/s13554-012-0003-4
   Stay MS, 2003, PHARM RES-DORDR, V20, P96, DOI 10.1023/A:1022207026982
   Stewart MW, 2014, EXPERT REV CLIN PHAR, V7, P167, DOI 10.1586/17512433.2014.884458
   Stewart MW, 2012, RETINA-J RET VIT DIS, V32, P434, DOI 10.1097/IAE.0B013E31822C290F
   Stocchino A, 2007, PHYS MED BIOL, V52, P2021, DOI 10.1088/0031-9155/52/7/016
   Stokes WS, 2015, HUM EXP TOXICOL, V34, P1297, DOI 10.1177/0960327115598410
   SUGRUE SP, 1989, J CELL BIOL, V109, P939, DOI 10.1083/jcb.109.2.939
   Sun L, 2012, J PHARM SCI-US, V101, P4540, DOI 10.1002/jps.23317
   Suri S., 2006, TRENDS BIOMATER ARTI, V20, P72
   SWANN DA, 1972, INVEST OPHTH VISUAL, V11, P159
   TAKAHASHI T, 1993, J HISTOCHEM CYTOCHEM, V41, P1447, DOI 10.1177/41.10.8245404
   Talks J, 2019, SURV OPHTHALMOL, V64, P707, DOI 10.1016/j.survophthal.2019.02.008
   Tan LE, 2011, INVEST OPHTH VIS SCI, V52, P1111, DOI 10.1167/iovs.10-5813
   Tegtmeyer S, 2001, EUR J PHARM BIOPHARM, V51, P119, DOI 10.1016/S0939-6411(01)00123-0
   TENGROTH B, 1985, ACTA OPHTHALMOL, V63, P91
   Thackaberry EA, 2019, DRUG DISCOV TODAY, V24, P1539, DOI 10.1016/j.drudis.2019.05.032
   Thakur SS, 2020, EUR J PHARM BIOPHARM, V148, P118, DOI 10.1016/j.ejpb.2020.01.008
   Thakur SS, 2014, EXPERT OPIN DRUG DEL, V11, P1575, DOI 10.1517/17425247.2014.927864
   Thrimawithana T.R., 2011, DRUG DISCOV TODAY
   Thrimawithana TR, 2011, DRUG DISCOV TODAY, V16, P270, DOI 10.1016/j.drudis.2010.12.004
   Thulliez M, 2014, JAMA OPHTHALMOL, V132, P1317, DOI 10.1001/jamaophthalmol.2014.2333
   Tojo K, 2004, CHEM PHARM BULL, V52, P1290, DOI 10.1248/cpb.52.1290
   Tojo K, 2001, ADV DRUG DELIVER REV, V52, P17, DOI 10.1016/S0169-409X(01)00187-9
   Tolentino M, 2011, SURV OPHTHALMOL, V56, P95, DOI 10.1016/j.survophthal.2010.08.006
   Toris CB, 1999, AM J OPHTHALMOL, V127, P407, DOI 10.1016/S0002-9394(98)00436-X
   TRELSTAD RL, 1974, EXP EYE RES, V18, P395, DOI 10.1016/0014-4835(74)90117-1
   TSEN G, 1995, J BIOL CHEM, V270, P3392, DOI 10.1074/jbc.270.7.3392
   Tuori A, 1996, CORNEA, V15, P286, DOI 10.1097/00003226-199605000-00010
   Turturro SB, 2011, BIOMATERIALS, V32, P3620, DOI 10.1016/j.biomaterials.2011.01.058
   U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) Center for Biologics Evaluation and Research (CBER), 2018, GUID IND
   U.S. Food and Drug Administration, 2017, CAS HEM OCCL RET VAS
   U.S. Food and Drug Administration. FDA Center for Drug Evaluation and Research (CDER), 2015, GUID IND REV STAFF
   Uddin R, 2011, INT J CUR BIOMED PHA, V1, P201, DOI DOI 10.1081/DDC-120021777
   UMIHIRA J, 1994, INVEST OPHTH VIS SCI, V35, P486
   Unal M, 1999, RETINA-J RET VIT DIS, V19, P442, DOI 10.1097/00006982-199909000-00013
   Ung BC, 2019, OPHTHALMOL MANAGE, V2019
   URTTI A, 1984, INT J PHARM, V19, P53, DOI 10.1016/0378-5173(84)90132-7
   Urtti A, 2006, ADV DRUG DELIVER REV, V58, P1131, DOI 10.1016/j.addr.2006.07.027
   US Food and Drug Administration, DRUGS FDA FDA APPR D
   Vaajanen A, 2007, J OCUL PHARMACOL TH, V23, P124, DOI 10.1089/jop.2006.0057
   van Beers MMC, 2010, PHARM RES-DORDR, V27, P1812, DOI 10.1007/s11095-010-0172-0
   VanderBeek BL, 2015, JAMA OPHTHALMOL, V133, P1159, DOI 10.1001/jamaophthalmol.2015.2556
   Varela-Fernandez R, 2020, PHARMACEUTICS, V12, DOI 10.3390/pharmaceutics12030269
   Vidal Jean-Marc, 2010, Cytokine, V51, P213, DOI 10.1016/j.cyto.2010.04.008
   Vulic K, 2014, BIOMACROMOLECULES, V15, P3867, DOI 10.1021/bm501084u
   Waga J, 1999, J OCUL PHARMACOL TH, V15, P455, DOI 10.1089/jop.1999.15.455
   Wakshull E, 2017, AAPS J, V19, P1656, DOI 10.1208/s12248-017-0128-y
   Wang CH, 2012, BIOMACROMOLECULES, V13, P40, DOI 10.1021/bm2009558
   Wang Lan, 2006, J Huazhong Univ Sci Technolog Med Sci, V26, P475, DOI 10.1007/s11596-006-0426-6
   Wessel H, 1997, INVEST OPHTH VIS SCI, V38, P2408
   Wessels U, 2018, BIOANALYSIS, V10, P803, DOI 10.4155/bio-2018-0047
   Williams G., 2014, REV OPHTHALMOL
   Williams GA, 2008, EYE, V22, P1263, DOI 10.1038/eye.2008.20
   Xu J, 2000, PHARMACEUT RES, V17, P664, DOI 10.1023/A:1007517912927
   Xu L, 2013, INVEST OPHTH VIS SCI, V54, P1616, DOI 10.1167/iovs.12-10260
   Yamashiro K, 2010, RETINA-J RET VIT DIS, V30, P485, DOI 10.1097/IAE.0b013e3181bd2d51
   Yannuzzi NA, 2019, CLIN OPHTHALMOL, V13, P1323, DOI 10.2147/OPTH.S184706
   Yanyali A, 2007, AM J OPHTHALMOL, V144, P124, DOI 10.1016/j.ajo.2007.02.048
   Yashkin AP, 2016, OPHTHALMOLOGY, V123, P2225, DOI 10.1016/j.ophtha.2016.06.053
   Yu Jea H, 2018, Am J Ophthalmol Case Rep, V10, P142, DOI 10.1016/j.ajoc.2017.07.009
   Yu Y, 2015, TRANSL VIS SCI TECHN, V4, DOI 10.1167/tvst.4.2.5
   Zhang Y, 2018, INVEST OPHTH VIS SCI, V59, P5266, DOI 10.1167/iovs.17-23632
   Zhou MX, 2007, DISSOLUT TECHNOL, V14, P25, DOI 10.14227/DT140207P25
   Zhu Q, 2008, OPHTHALMOLOGY, V115, P1750, DOI 10.1016/j.ophtha.2008.04.023
NR 395
TC 12
Z9 12
U1 2
U2 16
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0939-6411
EI 1873-3441
J9 EUR J PHARM BIOPHARM
JI Eur. J. Pharm. Biopharm.
PD AUG
PY 2020
VL 153
BP 130
EP 149
DI 10.1016/j.ejpb.2020.05.005
PG 20
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA MK2BJ
UT WOS:000548590600012
PM 32445965
OA Green Published
DA 2022-11-30
ER

PT J
AU Rosenfeld, PJ
AF Rosenfeld, Philip J.
TI Lessons Learned From Avastin and OCT-The Great, the Good, the Bad, and
   the Ugly: The LXXV Edward Jackson Memorial Lecture
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID OPTICAL COHERENCE TOMOGRAPHY; INTRAVITREAL BEVACIZUMAB AVASTIN; 2.0 MG
   RANIBIZUMAB; MACULAR DEGENERATION; CLINICAL-TRIALS; TERM SAFETY;
   EFFICACY; PEGAPTANIB; INJECTION; THERAPY
AB PURPOSE: To describe the synergistic benefits and cost savings from the use of optical coherence tomography (OCT) and vascular endothelial growth factor (VEGF) inhibitors, particularly intravitreal bevacizumab, in the treatment of exudative age-related macular degeneration (AMD).
   DESIGN: Retrospective literature review and personal perspective.
   METHODS: Retrospective literature review and personal perspective.
   RESULTS: The introduction of the first clinically useful OCT instrument coincided with early-phase clinical trials of a drug that would become known as ranibizumab. OCT provided a noninvasive imaging strategy that unambiguously showed the macular fluid associated with exudative AMD and the ability of anti-VEGF therapy to resolve this fluid with concomitant visual acuity improvement. Clinicians came to embrace the use of OCT imaging as the basis for dosing with anti-VEGF drugs, rather than the fixed-interval dosing that was the standard in clinical trials and recommended by industry after approval. But, before ranibizumab was approved for the treatment of exudative AMD, intravenous bevacizumab was approved to treat cancer. Both drugs shared a common molecular lineage, and this led to a clinical trial using intravenous bevacizumab for the treatment of exudative AMD. Intravenous bevacizumab resulted in visual acuity and OCT improvements similar to ranibizumab, and this observation soon led to the intravitreal use of bevacizumab in 2005. Fortuitously, both ranibizumab and bevacizumab were packaged at similar molar concentrations, so similar volumes of both drugs when injected into an eye would result in similar anti-VEGF activity. With ranibizumab not yet commercially available, intravitreal bevacizumab rapidly became adopted worldwide for the treatment of VEGF-driven ocular diseases. Despite numerous attempts by industry and anonymous sources to discredit and prevent its use, bevacizumab spread globally owing to its availability; its low treatment cost, which was $5.50 per 1 mg in the United States; the evidence of efficacy based on OCT imaging and vision improvement; and its perceived safety. In the United States alone, the use of OCT-guided therapy and the use of bevacizumab for the treatment of exudative AMD has saved Medicare over $40 billion since 2008.
   CONCLUSIONS: The rapid adoption of OCT-guided therapy and the use of intravitreal bevacizumab by the global retinal community has prevented blindness from exudative and neovascular ocular diseases worldwide while saving healthcare providers and patients billions of dollars. (Am J Ophthalmol 2019;204:26-45. (C) 2019 Elsevier Inc. All rights reserved.)
C1 [Rosenfeld, Philip J.] Univ Miami, Miller Sch Med, Bascom Palmer Eye Inst, Dept Ophthalmol, Miami, FL 33136 USA.
C3 Bascom Palmer Eye Institute; University of Miami
RP Rosenfeld, PJ (通讯作者)，Bascom Palmer Eye Inst, 900 NW 17th St, Miami, FL 33136 USA.
EM prosenfeld@miami.edu
FU NEI NIH HHS [P30 EY014801] Funding Source: Medline; NATIONAL EYE
   INSTITUTE [P30EY014801] Funding Source: NIH RePORTER
CR Adamis AP, 1996, ARCH OPHTHALMOL-CHIC, V114, P66, DOI 10.1001/archopht.1996.01100130062010
   BerminghamMcDonogh O, 1996, DEVELOPMENT, V122, P1427
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Brechner RJ, 2011, AM J OPHTHALMOL, V151, P887, DOI 10.1016/j.ajo.2010.11.017
   Busbee BG, 2013, OPHTHALMOLOGY, V120, P1046, DOI 10.1016/j.ophtha.2012.10.014
   Chakravarthy U, 2006, OPHTHALMOLOGY, V113, P1508, DOI 10.1016/j.ophtha.2006.02.064
   Chakravarthy U, 2013, LANCET, V382, P1258, DOI 10.1016/S0140-6736(13)61501-9
   Chakravarthy U, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.04.015
   Chen Y, 1999, J MOL BIOL, V293, P865, DOI 10.1006/jmbi.1999.3192
   D'Amico DJ, 2006, OPHTHALMOLOGY, V113, P992, DOI 10.1016/j.ophtha.2006.02.027
   Feinsod M, 2004, OPHTHALMOLOGY, V111, P1801, DOI 10.1016/j.ophtha.2004.05.022
   Fujimoto J, 2016, INVEST OPHTH VIS SCI, V57, pOCT1, DOI 10.1167/iovs.16-19963
   Fung AE, 2006, BRIT J OPHTHALMOL, V90, P1344, DOI 10.1136/bjo.2006.099598
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Gonzalez S, 2012, AM J OPHTHALMOL, V153, P196, DOI 10.1016/j.ajo.2011.11.023
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Gregori NZ, 2008, RETINA-J RET VIT DIS, V28, P1325, DOI 10.1097/IAE.0b013e318188501f
   Gregori NZ, 2009, RETINA-J RET VIT DIS, V29, P913, DOI 10.1097/IAE.0b013e3181aa8dfe
   Han Dennis P, 2004, Trans Am Ophthalmol Soc, V102, P305
   Heier JS, 2006, OPHTHALMOLOGY, V113, P633, DOI 10.1016/j.ophtha.2005.10.052
   Ho AC, 2014, OPHTHALMOLOGY, V121, P2181, DOI 10.1016/j.ophtha.2014.05.009
   Klettner A, 2008, INVEST OPHTH VIS SCI, V49, P4523, DOI 10.1167/iovs.08-2055
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Michels S, 2005, OPHTHALMOLOGY, V112, P1035, DOI 10.1016/j.ophtha.2005.02.007
   Mordenti J, 1999, TOXICOL PATHOL, V27, P536, DOI 10.1177/019262339902700507
   Moshfeghi AA, 2006, OPHTHALMOLOGY, V113, P2002, DOI 10.1016/j.ophtha.2006.05.070
   Ng EWM, 2006, NAT REV DRUG DISCOV, V5, P123, DOI 10.1038/nrd1955
   Okada M, 2018, AM J OPHTHALMOL, V192, P184, DOI 10.1016/j.ajo.2018.05.026
   Rich RM, 2006, RETINA-J RET VIT DIS, V26, P495, DOI 10.1097/01.iae.0000225766.75009.3a
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rosenfeld PJ, 2018, OPHTHALMOLOGY, V125, P1488, DOI 10.1016/j.ophtha.2018.06.002
   Rosenfeld PJ, 2018, AM J OPHTHALMOL, V191, P135, DOI 10.1016/j.ajo.2018.04.008
   Rosenfeld PJ, 2016, INVEST OPHTH VIS SCI, V57, pOCT14, DOI 10.1167/iovs.16-19969
   Rosenfeld PJ, 2005, OPHTHALMOLOGY, V112, P1048, DOI 10.1016/j.ophtha.2005.01.043
   Rosenfeld PJ, 2006, OPHTHALMOLOGY, V113, P623, DOI 10.1016/j.ophtha.2006.01.027
   Rosenfeld PJ, 2005, OPHTHAL SURG LAS IM, V36, P336, DOI 10.3928/1542-8877-20050701-15
   Rosenfeld PJ, 2005, OPHTHAL SURG LAS IM, V36, P331, DOI 10.3928/1542-8877-20050701-14
   Shahar J, 2006, RETINA-J RET VIT DIS, V26, P262, DOI 10.1097/00006982-200603000-00002
   Stewart MW, 2012, RETINA-J RET VIT DIS, V32, P434, DOI 10.1097/IAE.0B013E31822C290F
   TAP Study Group, 1999, ARCH OPHTHALMOL-CHIC, V117, P4329
   Windsor MA, 2018, AM J OPHTHALMOL, V185, P115, DOI 10.1016/j.ajo.2017.09.027
NR 43
TC 8
Z9 9
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0002-9394
EI 1879-1891
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD AUG
PY 2019
VL 204
BP 26
EP 45
DI 10.1016/j.ajo.2019.02.036
PG 20
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA IN7KD
UT WOS:000478859400005
PM 30851267
DA 2022-11-30
ER

PT J
AU Kolomeyer, AM
   Sugino, IK
   Zarbin, MA
AF Kolomeyer, A. M.
   Sugino, I. K.
   Zarbin, M. A.
TI Characterization of the effects of retinal pigment
   epithelium-conditioned media on porcine and aged human retina
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE Retinal pigment epithelium; Retina; Conditioned medium; Cell-based
   therapy; Age-related macular degeneration
ID CILIARY NEUROTROPHIC FACTOR; HEPATOCYTE GROWTH-FACTOR; REGENERATION
   IN-VITRO; MACULAR DEGENERATION; AUTOLOGOUS TRANSLOCATION; PHOTORECEPTOR
   SURVIVAL; EXTRACELLULAR-MATRIX; NEURONAL SURVIVAL; GANGLION-CELLS;
   FINE-STRUCTURE
AB Retinal pigment epithelium (RPE) cells produce neurotrophic factors that rescue photoreceptors from degeneration. Previously, we showed that conditioned medium (CM) from fetal vs adult RPE cells resulted in significantly better porcine retinal preservation, and possessed significantly higher levels of hepatocyte growth factor (HGF) and pigment epithelium-derived factor (PEDF). This study aimed to further describe the effects of human fetal RPE-CM on porcine and aged human retina, and to characterize its effects biochemically.
   RPE-CM was harvested from passage-2 fetal RPE, 7 days after passage, 24-hours after exposure to basal medium. After culture in RPE-CM, porcine retinal morphology was assessed with confocal microscopy. The effects of RPE-CM on porcine and aged human retina survival were assessed by cytotoxicity and apoptosis biochemical assays. To characterize RPE-CM biochemically, effects of heating, digesting with proteinase-K, dilution, concentration, and fractionation were tested. Recombinant proteins and neutralizing antibodies were used to identify proteins that might contribute to the salutary effects of RPE-CM on porcine retina.
   Culturing porcine retina in RPE-CM significantly preserved outer nuclear layer width and the number of nuclei in cross-section, and significantly decreased photoreceptor axon retraction. RPE-CM decreased porcine retinal death by 17-34 % (p < 0.05) compared to basal medium. Human retina from age-related macular degeneration (AMD) and non-AMD donors responded similarly after culture in RPE-CM. Heating, proteinase-K digestion, and dilution significantly diminished RPE-CM-mediated preservation of porcine retina, whereas concentrating RPE-CM significantly enhanced its preservation of porcine retina. Molecular cut filtration identified retina-preserving activity in the 3-100 kDa filtrate. PEDF or HGF at 90 % receptor occupancy significantly improved retinal preservation over 48 h of culture compared to basal medium. Neutralizing PEDF in RPE-CM decreased its ability to reduce retinal apoptosis by 23-27 % (p < 0.05).
   RPE-CM reduced biochemically and histologically measured degeneration in porcine retinae. This effect was concentration-dependent, and can be attributed to a protein component(s) in a 3-100 kDa molecular cut fraction. Human retina (including non-AMD and AMD Caucasian and non-AMD African-American) responds to culture in RPE-CM similarly to porcine retina. Receptor occupancy calculations and retinal viability data indicate that PEDF may be one of the components that contribute to retina preservation by RPE-CM.
C1 [Kolomeyer, A. M.; Sugino, I. K.; Zarbin, M. A.] Univ Med & Dent New Jersey, New Jersey Med Sch, Inst Ophthalmol & Visual Sci, Newark, NJ 07101 USA.
C3 Rutgers State University New Brunswick; Rutgers State University Medical
   Center
RP Zarbin, MA (通讯作者)，Univ Med & Dent New Jersey, New Jersey Med Sch, Inst Ophthalmol & Visual Sci, 90 Bergen St,DOC6155, Newark, NJ 07101 USA.
EM zarbin@earthlink.net
OI Zarbin, Marco/0000-0002-7811-7132
FU Janice Mitchell Vassar and Ashby John Mitchell Fellowship; Joseph J. and
   Marguerite DiSepio Retina Research Fund; Research to Prevent Blindness;
   Research to Prevent Blindness Medical Student Fellowship; Midwest Eye
   Banks Student Stipend; American Foundation for Aging Research Graduate
   Student Fellowship
FX The Janice Mitchell Vassar and Ashby John Mitchell Fellowship (MAZ), the
   Joseph J. and Marguerite DiSepio Retina Research Fund (MAZ), an
   unrestricted grant from Research to Prevent Blindness (MAZ), Research to
   Prevent Blindness Medical Student Fellowship (AMK), Midwest Eye Banks
   Student Stipend (AMK), and American Foundation for Aging Research
   Graduate Student Fellowship (AMK).
CR Ablonczy Z, 2011, INVEST OPHTH VIS SCI, V52, P8614, DOI 10.1167/iovs.11-8021
   Algvere PV, 1999, EUR J OPHTHALMOL, V9, P217, DOI 10.1177/112067219900900310
   BEAUCHEMIN ML, 1974, A GRAEF ARCH KLIN EX, V190, P27, DOI 10.1007/BF00414333
   Beltran WA, 2005, MOL VIS, V11, P232
   Binder S, 2004, INVEST OPHTH VIS SCI, V45, P4151, DOI 10.1167/iovs.04-0118
   Bonnet D, 2004, BRAIN RES, V1007, P142, DOI 10.1016/j.brainres.2004.02.023
   BRAEKEVELT CR, 1983, GRAEF ARCH CLIN EXP, V220, P273, DOI 10.1007/BF00231355
   Brocco MA, 1999, DEV BRAIN RES, V118, P23, DOI 10.1016/S0165-3806(99)00120-0
   Cayouette M, 1997, HUM GENE THER, V8, P423, DOI 10.1089/hum.1997.8.4-423
   Cayouette M, 1999, NEUROBIOL DIS, V6, P523, DOI 10.1006/nbdi.1999.0263
   Chong NHV, 1999, INVEST OPHTH VIS SCI, V40, P1298
   Frasson M, 1999, INVEST OPHTH VIS SCI, V40, P2724
   Gullapalli VK, 2005, EXP EYE RES, V80, P235, DOI 10.1016/j.exer.2004.09.006
   He PM, 1998, BIOCHEM BIOPH RES CO, V249, P253, DOI 10.1006/bbrc.1998.9087
   Joussen AM, 2007, OPHTHALMOLOGY, V114, P551, DOI 10.1016/j.ophtha.2006.08.016
   Joussen AM, 2006, AM J OPHTHALMOL, V142, P17, DOI 10.1016/j.ajo.2006.01.090
   Khodair MA, 2003, INVEST OPHTH VIS SCI, V44, P4976, DOI 10.1167/iovs.03-0036
   Kolomeyer AM, 2011, INVEST OPHTH VIS SCI, V52, P5963, DOI 10.1167/iovs.10-6440
   Kolomeyer AM, 2011, INVEST OPHTH VIS SCI, V52, P5973, DOI 10.1167/iovs.10-6965
   Lenzi L, 2005, VISION RES, V45, P1491, DOI 10.1016/j.visres.2004.12.020
   LI AR, 1995, J NEUROSCI, V15, P385
   MARTINEZMORALES JR, 1995, NEUROSCIENCE, V68, P245, DOI 10.1016/0306-4522(95)00089-2
   Mekhoubad S, 2012, CELL STEM CELL, V10, P595, DOI 10.1016/j.stem.2012.02.014
   PEYMAN GA, 1991, OPHTHALMIC SURG LAS, V22, P102
   Sieving PA, 2006, P NATL ACAD SCI USA, V103, P3896, DOI 10.1073/pnas.0600236103
   STEINBERG RH, 1985, DOC OPHTHALMOL, V60, P327, DOI 10.1007/BF00158922
   Streichert LC, 1999, J NEUROBIOL, V39, P475, DOI 10.1002/(SICI)1097-4695(19990615)39:4<475::AID-NEU2>3.0.CO;2-#
   Tezel TH, 2007, AM J OPHTHALMOL, V143, P584, DOI 10.1016/j.ajo.2006.12.007
   Tonges L, 2011, J NEUROCHEM, V117, P892, DOI 10.1111/j.1471-4159.2011.07257.x
   Xiao M, 1999, BRIT J OPHTHALMOL, V83, P728, DOI 10.1136/bjo.83.6.728
   Zarbin MA, 2007, AM J OPHTHALMOL, V143, P681, DOI 10.1016/j.ajo.2007.01.024
NR 31
TC 5
Z9 6
U1 0
U2 10
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0721-832X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD JUN
PY 2013
VL 251
IS 6
BP 1515
EP 1528
DI 10.1007/s00417-013-2326-3
PG 14
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 150VP
UT WOS:000319419800010
PM 23575949
DA 2022-11-30
ER

PT J
AU Mirza, S
   Plafker, KS
   Aston, C
   Plafker, SM
AF Mirza, Saima
   Plafker, Kendra S.
   Aston, Christopher
   Plafker, Scott M.
TI Expression and distribution of the class III ubiquitin-conjugating
   enzymes in the retina
SO MOLECULAR VISION
LA English
DT Article
ID PIGMENT EPITHELIAL-CELLS; OXIDATIVE STRESS; MACULAR DEGENERATION;
   DAMAGED PROTEINS; NUCLEAR IMPORT; IDENTIFICATION; DEGRADATION; PATHWAY;
   NRF2; SYSTEM
AB Purpose: Mounting evidence implicates chronic oxidative stress as a significant pathogenic factor in the development and progression of retinopathies, including age-related macular degeneration (AMD). The age-dependent toxic accumulation of oxidatively damaged proteins, lipids, and DNA in susceptible cells of the retina arises, at least in part, from a decreased capacity to eliminate these damaged biomolecules. The goal of this study was to determine the expression patterns and function of class III ubiquitin-conjugating enzymes (UbcM3, UBE2E2, and UbcM2) in the retina. These enzymes have been implicated in the ubiquitin-dependent degradation of oxidatively damaged and misfolded proteins.
   Methods: Complementary western blotting and immunohistochemistry was performed with specific antibodies to determine the retinal cell expression pattern of each enzyme. Additional analyses using antibodies raised against UbcM2 were performed to determine the relative levels of the enzyme in lysates derived from various mouse organs as compared to the retina. An established light-damage model of oxidative stress-induced retinal degeneration was used to determine alterations in the susceptibility of mice harboring a single intact allele of UbcM2. Ubiquitin charging and auto-ubiquitylation assays were done to assess the catalytic state of UbcM2 following photo-oxidative stress.
   Results: Expression of the class III ubiquitin-conjugating enzymes in the retina, from highest to lowest, is UbcM2>UbcM3>UBE2E2. In addition to being the most robustly expressed, UbcM2 is further distinguished by its expression in photoreceptors and retinal pigment epithelial cells. UbcM2 is expressed in most mouse tissues analyzed and is most abundant in the retina. Studies using a bright-light-damage model of acute oxidative stress in mice harboring a single disrupted allele of UbcM2 revealed that a 58% reduction in enzyme levels did not increase the susceptibility of photoreceptors to acute photo-oxidative toxicity. This result may be explained by the observation that UbcM2 retained an intact and functional active site following exposure to acute bright light.
   Conclusions: The class III ubiquitin-conjugating enzymes, and in particular UbcM2, are expressed in the retina and may function to counter the accumulation of oxidatively damaged and misfolded proteins. A 58% reduction in UbcM2 does not increase the susceptibility of photoreceptors to an acute photo-oxidative stress, suggesting the existence of compensating enzymes and/or that the remaining UbcM2 activity is sufficient to target oxidatively damaged proteins for destruction.
C1 [Mirza, Saima; Plafker, Kendra S.; Plafker, Scott M.] Univ Oklahoma, Dept Cell Biol, Hlth Sci Ctr, Oklahoma City, OK 73104 USA.
   [Aston, Christopher] Univ Oklahoma, Gen Clin Res Ctr, Hlth Sci Ctr, Oklahoma City, OK 73104 USA.
C3 University of Oklahoma System; University of Oklahoma Health Sciences
   Center; University of Oklahoma System; University of Oklahoma Health
   Sciences Center
RP Plafker, SM (通讯作者)，Univ Oklahoma, Dept Cell Biol, Hlth Sci Ctr, 940 Stanton L Young Blvd,BMSB 538, Oklahoma City, OK 73104 USA.
EM scott-plafker@ouhsc.edu
FU National Institutes of Health/National Center For Research Resources
   (NIH/NCRR) [P20RR024215]; American Health Assistance Foundation (AHAF)
   [M2009095]; Oklahoma Center for the Advancement of Science and
   Technology (OCAST) [HR08-076]; Karl Kirchgessner Foundation; NATIONAL
   CENTER FOR RESEARCH RESOURCES [P20RR024215] Funding Source: NIH RePORTER
FX This study was supported in part by grant P20RR024215 from the National
   Institutes of Health/National Center For Research Resources (NIH/NCRR).
   Title: Mentoring Diabetes Research in Oklahoma. Additional funding to S.
   M. Plafker in support of this work was kindly provided by the American
   Health Assistance Foundation (AHAF; grant M2009095), The Oklahoma Center
   for the Advancement of Science and Technology (OCAST; HR08-076), and a
   Karl Kirchgessner Foundation Vision Research Grant.
CR Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Benisty R, 2010, BBA-MOL CELL BIOL L, V1801, P1098, DOI 10.1016/j.bbalip.2010.06.004
   Bertram KM, 2009, AM J PHYSIOL-CELL PH, V297, pC1200, DOI 10.1152/ajpcell.00126.2009
   BONFANTI L, 1992, J COMP NEUROL, V322, P35, DOI 10.1002/cne.903220104
   Christensen DE, 2007, NAT STRUCT MOL BIOL, V14, P941, DOI 10.1038/nsmb1295
   Demand J, 2001, CURR BIOL, V11, P1569, DOI 10.1016/S0960-9822(01)00487-0
   Doyle K, 2010, J BIOL CHEM, V285, P17417, DOI 10.1074/jbc.M109.089250
   Drinjakovic J, 2010, NEURON, V65, P341, DOI 10.1016/j.neuron.2010.01.017
   Dudek EJ, 2005, FASEB J, V19, P1707, DOI 10.1096/fj.05-4049fje
   Fang S, 2004, CELL MOL LIFE SCI, V61, P1546, DOI 10.1007/s00018-004-4129-5
   Friedman JS, 2009, AM J HUM GENET, V84, P792, DOI 10.1016/j.ajhg.2009.05.007
   Fujihara M, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003119
   Gao XQ, 2004, P NATL ACAD SCI USA, V101, P10446, DOI 10.1073/pnas.0403886101
   Goldberg AL, 2003, NATURE, V426, P895, DOI 10.1038/nature02263
   JahngenHodge J, 1997, J BIOL CHEM, V272, P28218, DOI 10.1074/jbc.272.45.28218
   Jensen JP, 1995, J BIOL CHEM, V270, P30408, DOI 10.1074/jbc.270.51.30408
   JENTSCH S, 1992, ANNU REV GENET, V26, P179, DOI 10.1146/annurev.ge.26.120192.001143
   Jiang JH, 2001, J BIOL CHEM, V276, P42938, DOI 10.1074/jbc.M101968200
   Johnson J, 2009, INVEST OPHTH VIS SCI, V50, P2398, DOI 10.1167/iovs.08-2088
   Kaganovich D, 2008, NATURE, V454, P1088, DOI 10.1038/nature07195
   Kong L, 2007, J NEUROCHEM, V101, P1041, DOI 10.1111/j.1471-4159.2007.04481.x
   Lane AE, 2010, BIOCHEM J, V430, P161, DOI 10.1042/BJ20100082
   Lorick KL, 1999, P NATL ACAD SCI USA, V96, P11364, DOI 10.1073/pnas.96.20.11364
   Mandal MNA, 2009, FREE RADICAL BIO MED, V46, P672, DOI 10.1016/j.freeradbiomed.2008.12.006
   Matuschewski K, 1996, J BIOL CHEM, V271, P2789, DOI 10.1074/jbc.271.5.2789
   Medicherla B, 2008, J CELL BIOL, V182, P663, DOI 10.1083/jcb.200803022
   Obin MS, 1996, J BIOL CHEM, V271, P14473, DOI 10.1074/jbc.271.24.14473
   Pitha-Rowe I, 2009, INVEST OPHTH VIS SCI, V50, P5339, DOI 10.1167/iovs.09-3648
   Plafker KS, 2010, J BIOL CHEM, V285, P23062, DOI 10.1074/jbc.M110.121913
   Plafker KS, 2009, BIOCHEMISTRY-US, V48, P3527, DOI 10.1021/bi801971m
   Plafker KS, 2008, INVEST OPHTH VIS SCI, V49, P5611, DOI 10.1167/iovs.08-1698
   Plafker SM, 2000, EMBO J, V19, P5502, DOI 10.1093/emboj/19.20.5502
   Plafker SM, 2004, J CELL BIOL, V167, P649, DOI 10.1083/jcb.200406001
   Rattner A, 2008, J NEUROSCI, V28, P9880, DOI 10.1523/JNEUROSCI.2401-08.2008
   Sano Y, 2006, AM J PATHOL, V169, P132, DOI 10.2353/ajpath.2006.060085
   Sas K, 2007, J NEUROL SCI, V257, P221, DOI 10.1016/j.jns.2007.01.033
   Schrader EK, 2009, NAT CHEM BIOL, V5, P815, DOI 10.1038/nchembio.250
   SEUFERT W, 1990, EMBO J, V9, P543, DOI 10.1002/j.1460-2075.1990.tb08141.x
   Shang F, 2001, EXP EYE RES, V73, P229, DOI 10.1006/exer.2001.1029
   Sherman MY, 2001, NEURON, V29, P15, DOI 10.1016/S0896-6273(01)00177-5
   Tanito M, 2008, EXP EYE RES, V87, P292, DOI 10.1016/j.exer.2008.06.002
   Tanito M, 2006, FREE RADICAL BIO MED, V41, P1847, DOI 10.1016/j.freeradbiomed.2006.09.012
   Tanito M, 2007, FREE RADICAL BIO MED, V42, P1838, DOI 10.1016/j.freeradbiomed.2007.03.018
   Uno K, 2010, EXP EYE RES, V90, P493, DOI 10.1016/j.exer.2009.12.012
   Wang AL, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004160
   WINKLER BS, 1972, VISION RES, V12, P1183, DOI 10.1016/0042-6989(72)90106-X
   Xu Z, 2008, BMC STRUCT BIOL, V8, DOI 10.1186/1472-6807-8-26
   Ye YH, 2009, NAT REV MOL CELL BIO, V10, P755, DOI 10.1038/nrm2780
   Yego ECK, 2010, J BIOL CHEM, V285, P3181, DOI 10.1074/jbc.M109.083907
NR 49
TC 12
Z9 12
U1 0
U2 2
PU MOLECULAR VISION
PI ATLANTA
PA C/O JEFF BOATRIGHT, LAB B, 5500 EMORY EYE CENTER, 1327 CLIFTON RD, N E,
   ATLANTA, GA 30322 USA
SN 1090-0535
J9 MOL VIS
JI Mol. Vis.
PD NOV 18
PY 2010
VL 16
IS 260-62
BP 2425
EP 2437
PG 13
WC Biochemistry & Molecular Biology; Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Ophthalmology
GA 688FD
UT WOS:000284834300001
PM 21139979
DA 2022-11-30
ER

PT J
AU Cao, XG
   Liu, M
   Tuo, JS
   Shen, DF
   Chan, CC
AF Cao, Xiaoguang
   Liu, Melissa
   Tuo, Jingsheng
   Shen, Defen
   Chan, Chi-Chao
TI The effects of quercetin in cultured human RPE cells under oxidative
   stress and in Ccl2/Cx3cr1 double deficient mice
SO EXPERIMENTAL EYE RESEARCH
LA English
DT Article
DE quercetin; RPE; age-related macular degeneration; oxidative stress;
   inflammation; apoptosis; AMD mouse model
ID RETINAL-PIGMENT EPITHELIUM; MITOCHONDRIAL-DNA DAMAGE; MACULAR
   DEGENERATION; HYDROGEN-PEROXIDE; IN-VITRO; LUNG INFLAMMATION; ACID
   HYDROPEROXIDE; LIPID-PEROXIDATION; GENE-EXPRESSION; OUTER SEGMENTS
AB Quercetin, a member of the flavonoid family, is one of the most prominent dietary antioxidants. This study investigates the mechanisms for the effects of quercetin on cultured human RPE cells and in Ccl2/Cx3cr1 double knock-out (DKO) mice, which spontaneously develop progressive retinal lesions mimicking age-related macular degeneration (AMD). In the in vitro experiment, cultured ARPE-19 cells were exposed to 1 mM H2O2 with or without 50 mu M quercetin for 2 h. Cellular viability, mitochondrial function, and apoptosis were assessed using crystal violet staining, MTT assay, and comet assay, respectively. Apoptotic molecular transcripts of BCL-2, BAX, MUD, CASPASE-3 and CASPASE-9 were measured by RQ-PCR. COX activity and nitric oxide (NO) level were determined in the supernatant of the culture medium. Quercetin treatment protected ARPE-19 cells from H2O2-induced oxidative injury, enhanced BCL-2 transcript levels, increased the BCL-2/BAX ratio, suppressed the transcription of proapoptotic factors such as BAX, FADD, CASPASE-3 and CASPASE-9, inhibited the transcription of inflammatory factors such as TNF-alpha, COX-2 and INOS, and decreased the levels of COX and NO in the culture medium. In the in vivo experiment, DKO and C57/B6 mice were treated with 25 mg/kg/day quercetin by intraperitoneal injection daily for two months. Funduscopy was performed monthly. After two months, serum was collected to measure NADP(+)/NADPH, COX, PGE-2, and NO levels. The eyes were harvested for histology and A2E measurement. Ocular transcripts of Bcl-2, Bax, Cox-2, Inos, Tnf-alpha, Fas, Fast and Caspase-3 were detected by RQ-PCR. Quercetin treatment did not reverse the progression of retinal lesions in DKO mice funduscopically or histologically. Although quercetin treatment could recover systemic anti-oxidative capacity, suppress the systemic expression of NO, COX and PGE-2, and decrease ocular A2E levels, it could not effectively suppress the transcripts of the ocular inflammatory factors Trif-a, Cox-2 and Inos, or the pro-apoptotic factors Fas, FasL and Caspase-3 in DKO mice. Our data demonstrate that quercetin can protect human RPE cells from oxidative stress in vitro via inhibition of pro-inflammatory molecules and direct inhibition of the intrinsic apoptosis pathway. However, quercetin (25 mg/kg/day) does not improve the retinal AMD-like lesions in the Ccl2(-/-)/Cx3cr1(-/-) mice, likely due to its insufficient suppression of the inflammatory and apoptosis pathways in the eye. Published by Elsevier Ltd.
C1 [Cao, Xiaoguang; Liu, Melissa; Tuo, Jingsheng; Shen, Defen; Chan, Chi-Chao] NEI, Immunopathol Sect, Immunol Lab, NIH, Bethesda, MD 20892 USA.
   [Cao, Xiaoguang] Peking Univ, Peoples Hosp, Dept Ophthalmol, Beijing 100044, Peoples R China.
C3 National Institutes of Health (NIH) - USA; NIH National Eye Institute
   (NEI); Peking University
RP Chan, CC (通讯作者)，NEI, Immunopathol Sect, Immunol Lab, NIH, 10 Ctr Dr,Bldg 10,Room 10N103, Bethesda, MD 20892 USA.
EM chanc@nei.nih.gov
OI Tuo, Jingsheng/0000-0002-1372-7810
FU National Eye Institute, NIH; NATIONAL EYE INSTITUTE [ZIAEY000222,
   T32EY007143, ZICEY000461] Funding Source: NIH RePORTER
FX The study was supported by the Intramural Research Program of the
   National Eye Institute, NIH.
CR Akeo K, 1996, CURR EYE RES, V15, P467, DOI 10.3109/02713689609000758
   Ansari MA, 2009, J NUTR BIOCHEM, V20, P269, DOI 10.1016/j.jnutbio.2008.03.002
   Antonicelli F, 2002, FREE RADICAL BIO MED, V32, P492, DOI 10.1016/S0891-5849(01)00820-6
   Antonsson B, 2000, EXP CELL RES, V256, P50, DOI 10.1006/excr.2000.4839
   Arts MJTJ, 2004, FOOD CHEM, V88, P567, DOI 10.1016/j.foodchem.2004.02.008
   Bailey TA, 2004, INVEST OPHTH VIS SCI, V45, P675, DOI 10.1167/iovs.03-0351
   Ballinger SW, 1999, EXP EYE RES, V68, P765, DOI 10.1006/exer.1998.0661
   Ballinger SW, 2000, CIRC RES, V86, P960, DOI 10.1161/01.RES.86.9.960
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Beatty S, 2001, INVEST OPHTH VIS SCI, V42, P439
   BEILKE MA, 1987, J LAB CLIN MED, V110, P91
   Ben-Shabat S, 2001, BIOORG MED CHEM LETT, V11, P1533, DOI 10.1016/S0960-894X(01)00314-6
   Binder S, 2007, PROG RETIN EYE RES, V26, P516, DOI 10.1016/j.preteyeres.2007.02.002
   Boots AW, 2008, EUR J PHARMACOL, V585, P325, DOI 10.1016/j.ejphar.2008.03.008
   Bureau G, 2008, J NEUROSCI RES, V86, P403, DOI 10.1002/jnr.21503
   Cai JY, 2000, PROG RETIN EYE RES, V19, P205, DOI 10.1016/S1350-9462(99)00009-9
   Cao XG, 2007, INVEST OPHTH VIS SCI, V48, P3714, DOI 10.1167/iovs.06-1304
   Chan CC, 2008, OPHTHALMIC RES, V40, P124, DOI 10.1159/000119862
   Chen Y, 2008, GRAEF ARCH CLIN EXP, V246, P373, DOI 10.1007/s00417-007-0728-9
   Coleman HR, 2008, LANCET, V372, P1835, DOI 10.1016/S0140-6736(08)61759-6
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Cushnie TPT, 2005, INT J ANTIMICROB AG, V26, P343, DOI 10.1016/j.ijantimicag.2005.09.002
   deVries JHM, 1997, CANCER LETT, V114, P141, DOI 10.1016/S0304-3835(97)04645-4
   DING AH, 1988, J IMMUNOL, V141, P2407
   Ding XY, 2009, INVEST OPHTH VIS SCI, V50, P4957, DOI 10.1167/iovs.09-3381
   Ding XY, 2009, PROG RETIN EYE RES, V28, P1, DOI 10.1016/j.preteyeres.2008.10.001
   Dunaief JL, 2002, ARCH OPHTHALMOL-CHIC, V120, P1435, DOI 10.1001/archopht.120.11.1435
   Eberle J, 2007, DRUG RESIST UPDATE, V10, P218, DOI 10.1016/j.drup.2007.09.001
   ESTERBAUER H, 1991, FREE RADICAL BIO MED, V11, P81, DOI 10.1016/0891-5849(91)90192-6
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P532
   GAILLARD ER, 1995, PHOTOCHEM PHOTOBIOL, V61, P448, DOI 10.1111/j.1751-1097.1995.tb02343.x
   Geraets L, 2007, J NUTR, V137, P2190, DOI 10.1093/jn/137.10.2190
   Guo B, 2001, J BIOL CHEM, V276, P2780, DOI 10.1074/jbc.M005889200
   HANASAKI Y, 1994, FREE RADICAL BIO MED, V16, P845, DOI 10.1016/0891-5849(94)90202-X
   Hanneken A, 2006, INVEST OPHTH VIS SCI, V47, P3164, DOI 10.1167/iovs.04-1369
   Heijnen CGM, 2001, TOXICOL IN VITRO, V15, P3, DOI 10.1016/S0887-2333(00)00053-9
   HERTOG MGL, 1993, NUTR CANCER, V20, P21, DOI 10.1080/01635589309514267
   Higgins GT, 2003, INVEST OPHTH VIS SCI, V44, P1775, DOI 10.1167/iovs.02-0742
   Iannolo G, 2008, CRIT REV ONCOL HEMAT, V66, P42, DOI 10.1016/j.critrevonc.2007.09.004
   Jin GF, 2001, CURR EYE RES, V23, P11, DOI 10.1076/ceyr.23.1.11.5423
   Kamaraj S, 2007, BIOL PHARM BULL, V30, P2268, DOI 10.1248/bpb.30.2268
   Kanter M, 2007, CELL BIOCHEM FUNCT, V25, P747, DOI 10.1002/cbf.1397
   Karan G, 2005, P NATL ACAD SCI USA, V102, P4164, DOI 10.1073/pnas.0407698102
   Kasahara E, 2005, INVEST OPHTH VIS SCI, V46, P3426, DOI 10.1167/iovs.05-0344
   Kayatz P, 1999, INVEST OPHTH VIS SCI, V40, P2314
   Kernt M, 2009, J CATARACT REFR SURG, V35, P354, DOI 10.1016/j.jcrs.2008.10.052
   King A, 2004, PHOTOCHEM PHOTOBIOL, V79, P470, DOI 10.1562/LE-03-17.1
   Klein R, 2008, OPHTHALMOLOGY, V115, P1742, DOI 10.1016/j.ophtha.2008.03.021
   Kook D, 2008, INVEST OPHTH VIS SCI, V49, P1712, DOI 10.1167/iovs.07-0477
   LILES MR, 1991, ARCH OPHTHALMOL-CHIC, V109, P1285, DOI 10.1001/archopht.1991.01080090111033
   Lorenzo HK, 2007, DRUG RESIST UPDATE, V10, P235, DOI 10.1016/j.drup.2007.11.001
   MacNee W, 2001, EUR J PHARMACOL, V429, P195, DOI 10.1016/S0014-2999(01)01320-6
   Mandavilli BS, 2000, BRAIN RES, V885, P45, DOI 10.1016/S0006-8993(00)02926-7
   Manjeet R, 1999, INT J IMMUNOPHARMACO, V21, P435, DOI 10.1016/S0192-0561(99)00024-7
   Meyers KJ, 2008, J AGR FOOD CHEM, V56, P830, DOI 10.1021/jf072358l
   Mollinedo F, 2006, DRUG RESIST UPDATE, V9, P51, DOI 10.1016/j.drup.2006.04.002
   Nair MP, 2006, CLIN VACCINE IMMUNOL, V13, P319, DOI 10.1128/CVI.13.3.319-328.2006
   NEWSOME DA, 1990, INVEST OPHTH VIS SCI, V31, P2508
   Nussenblatt RB, 2007, AM J OPHTHALMOL, V144, P618, DOI 10.1016/j.ajo.2007.06.025
   Oliver L, 2005, DRUG RESIST UPDATE, V8, P163, DOI 10.1016/j.drup.2005.05.001
   Orsolic N, 2004, J ETHNOPHARMACOL, V94, P307, DOI 10.1016/j.jep.2004.06.006
   Peet GW, 1999, J BIOL CHEM, V274, P32655, DOI 10.1074/jbc.274.46.32655
   Rahman I, 2002, BIOCHEM PHARMACOL, V64, P935, DOI 10.1016/S0006-2952(02)01153-X
   Rahman I, 2002, MOL CELL BIOCHEM, V234, P239, DOI 10.1023/A:1015905010086
   READ MA, 1995, AM J PATHOL, V147, P235
   Ross RJ, 2008, EXP EYE RES, V86, P675, DOI 10.1016/j.exer.2008.01.014
   ROZANOWSKA M, 1995, J BIOL CHEM, V270, P18825, DOI 10.1074/jbc.270.32.18825
   Saito A, 2004, BIOSCI BIOTECH BIOCH, V68, P271, DOI 10.1271/bbb.68.271
   Salazar JJ, 1997, MUTAT RES-DNA REPAIR, V385, P139, DOI 10.1016/S0921-8777(97)00047-5
   Sawyer DE, 2001, REDOX REP, V6, P182, DOI 10.1179/135100001101536157
   SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x
   SNODDERLY DM, 1995, AM J CLIN NUTR, V62, P1448
   Srivastava S, 1995, BIOCHEM BIOPH RES CO, V217, P741, DOI 10.1006/bbrc.1995.2835
   TATE DJ, 1995, INVEST OPHTH VIS SCI, V36, P1271
   TATE DJ, 1993, INVEST OPHTH VIS SCI, V34, P2348
   Tuo JS, 2007, INVEST OPHTH VIS SCI, V48, P3827, DOI 10.1167/iovs.07-0051
   Tuo JS, 2009, AM J PATHOL, V175, P799, DOI 10.2353/ajpath.2009.090089
   Tyni T, 2002, PEDIATR RES, V52, P595, DOI 10.1203/01.PDR.0000030874.20888.2D
   Ueda T, 1996, OPHTHALMIC RES, V28, P184, DOI 10.1159/000267901
   Valerio DA, 2009, J NAT PROD, V72, P1975, DOI 10.1021/np900259y
   VANACKER SABE, 1995, BIOCHEM BIOPH RES CO, V214, P755, DOI 10.1006/bbrc.1995.2350
   Williamson G, 2005, AM J CLIN NUTR, V81, p243S, DOI [10.1093/ajcn/81.1.243S, 10.1093/ajcn/81.1.230S]
   Winkler BS, 1999, MOL VIS, V5
   Wu GS, 1999, INVEST OPHTH VIS SCI, V40, P831
   Wu PC, 2008, J OCUL PHARMACOL TH, V24, P25, DOI 10.1089/jop.2007.0044
   Yakes FM, 1997, P NATL ACAD SCI USA, V94, P514, DOI 10.1073/pnas.94.2.514
   Yen GC, 2003, BIOSCI BIOTECH BIOCH, V67, P1215, DOI 10.1271/bbb.67.1215
   Zhang L, 2007, DRUG RESIST UPDATE, V10, P207, DOI 10.1016/j.drup.2007.08.002
   ZHAO ZF, 1987, PLANT PHYSIOL, V84, P987, DOI 10.1104/pp.84.4.987
NR 89
TC 53
Z9 56
U1 1
U2 15
PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 0014-4835
EI 1096-0007
J9 EXP EYE RES
JI Exp. Eye Res.
PD JUL
PY 2010
VL 91
IS 1
BP 15
EP 25
DI 10.1016/j.exer.2010.03.016
PG 11
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 611HP
UT WOS:000278804700003
PM 20361964
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Masuda, N
   Tsujinaka, H
   Hirai, H
   Yamashita, M
   Ueda, T
   Ogata, N
AF Masuda, Naonori
   Tsujinaka, Hiroki
   Hirai, Hiromasa
   Yamashita, Mariko
   Ueda, Tetsuo
   Ogata, Nahoko
TI Effects of concentration of amyloid (A) on viability of cultured retinal
   pigment epithelial cells
SO BMC OPHTHALMOLOGY
LA English
DT Article
DE Age-related macular degeneration; Amyloid beta; Retinal pigment
   epithelial cells; Vascular endothelial growth factor; Pigment
   epithelium-derived factor; Receptor for advanced glycation end products
ID MACULAR DEGENERATION; INTERMITTENT HYPOXIA; REGENERATION FACTOR;
   GROWTH-FACTOR; UP-REGULATION; BETA; REG; EXPRESSION; ALZHEIMERS;
   ACTIVATION
AB BackgroundAmyloid beta (A) is a constituent of drusen that is a common sign of age-related macular degeneration (AMD). The purpose of this study was to investigate the effect of A on human retinal pigment epithelial (RPE) cells in culture.MethodsCells from a human RPE cell line (ARPE-19) were exposed to 0 to 25M of A 1-40 for 48h, and the number of living cells was determined by WST-8 cleavage. Replicative DNA synthesis was measured by the incorporation of 5-bromo-2-deoxyuridine. The cell death pathway was investigated by the WST-8 cleavage assay after the addition of caspase-9 inhibitor, an anti-apoptotic factor. Real-time qRT-PCR was performed using A-exposed cellular RNA to determine the level of vascular endothelial growth factor (VEGF)-A and pigment epithelium derived factor (PEDF). To determine the effect of receptor-for-advanced glycation end products (RAGE), the siRNA for RAGE was inserted into ARPE-19 treated with A, and the levels of expression of VEGF-A and PEDF were determined.ResultsThe number of living ARPE-19 cells was increased by exposure to 5M A but was decreased by exposure to 25M of A. Replicative DNA synthesis by ARPE-19 cells exposed to 25M of A was significantly decreased indicating that 25M of A inhibited cell proliferation. Real-time RT-PCR showed that the level of the mRNA of PEDF was increased by exposure to 5M A, and the levels of the mRNAs of PEDF and VEGF-A were also increased by exposure to 25M A. The addition of an inhibitor of caspase-9 blocked the decrease the number of ARPE-19 cells exposed to 25M A. Exposure to si-RAGE attenuated the increase of VEGF-A and PEDF mRNA expression in ARPE-19 exposed to A.ConclusionsExposure of ARPE-19 cells to low concentrations of A increases the level of PEDF which then inhibits the apoptosis of ARPE-19 cells leading to RPE cell proliferation. Exposure to high concentrations of A induces RPE cell death and enhances the expression of the mRNA of VEGF-A in RPE cells. The A-RAGE pathway may lead to the expression VEGF-A and PEDF in RPE cells. These results suggest that A is strongly related to the pathogenesis of choroidal neovascularization.
C1 [Masuda, Naonori; Tsujinaka, Hiroki; Hirai, Hiromasa; Yamashita, Mariko; Ueda, Tetsuo; Ogata, Nahoko] Nara Med Univ, Dept Ophthalmol, 840 Shijo Cho, Kashihara, Nara 6348522, Japan.
C3 Nara Medical University
RP Ogata, N (通讯作者)，Nara Med Univ, Dept Ophthalmol, 840 Shijo Cho, Kashihara, Nara 6348522, Japan.
EM masuda828@naramed-u.ac.jp; ogata@naramed-u.ac.jp
OI Hirai, Hiromasa/0000-0002-7607-0975
FU Ministry of Education, Culture, Sports, Science and Technology, Japan
   [26931058]
FX This work was supported in part by Grants-in-Aid for Scientific Research
   from the Ministry of Education, Culture, Sports, Science and Technology,
   Japan (Grant-in-Aid for Encouragement of Scientists; KAKENHI Grant
   Number #26931058). However, the funder had no role in study design, data
   collection and analysis, decision to publish, or preparation of the
   manuscript.
CR Abdelsalam A, 1999, SURV OPHTHALMOL, V44, P1, DOI 10.1016/S0039-6257(99)00072-7
   Baruch-Suchodolsky R, 2009, BIOCHEMISTRY-US, V48, P4354, DOI 10.1021/bi802361k
   Chandra D, 2004, MOL CELL BIOL, V24, P6592, DOI 10.1128/mcb.24.15.6592-6607.2004
   Dahlgren KN, 2002, J BIOL CHEM, V277, P32046, DOI 10.1074/jbc.M201750200
   Green W R, 1977, Trans Am Ophthalmol Soc, V75, P180
   Haass C, 2007, NAT REV MOL CELL BIO, V8, P101, DOI 10.1038/nrm2101
   Hamley IW, 2012, CHEM REV, V112, P5147, DOI 10.1021/cr3000994
   Isas JM, 2010, INVEST OPHTH VIS SCI, V51, P1304, DOI 10.1167/iovs.09-4207
   Ishibashi Y, 2013, MICROVASC RES, V85, P54, DOI 10.1016/j.mvr.2012.10.007
   Kobayashi S, 2000, J BIOL CHEM, V275, P10723, DOI 10.1074/jbc.275.15.10723
   Kyotani Y, 2013, EXP CELL RES, V319, P3042, DOI 10.1016/j.yexcr.2013.08.014
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Liu RZT, 2014, EXP EYE RES, V127, P49, DOI 10.1016/j.exer.2014.07.003
   Liu RT, 2013, INVEST OPHTH VIS SCI, V54, P2225, DOI 10.1167/iovs.12-10849
   Luo Y, 2003, NEUROBIOL DIS, V14, P81, DOI 10.1016/S0969-9961(03)00104-9
   Lynn SA, 2017, NEURAL REGEN RES, V12, P538, DOI 10.4103/1673-5374.205083
   Ma WC, 2007, INVEST OPHTH VIS SCI, V48, P1355, DOI 10.1167/iovs.06-0738
   Masui T, 2013, ONCOL REP, V30, P573, DOI 10.3892/or.2013.2521
   Matsuoka M, 2004, BRIT J OPHTHALMOL, V88, P809, DOI 10.1136/bjo.2003.032466
   Murakami-Kawaguchi S, 2014, CELL TISSUE RES, V355, P303, DOI 10.1007/s00441-013-1741-4
   Nakagawa K, 2013, BBA-MOL CELL RES, V1833, P2988, DOI 10.1016/j.bbamcr.2013.08.004
   Ogata N, 2002, INVEST OPHTH VIS SCI, V43, P1168
   Ohno-Matsui K, 2011, PROG RETIN EYE RES, V30, P217, DOI 10.1016/j.preteyeres.2011.02.004
   Ota H, 2013, LIFE SCI, V93, P664, DOI 10.1016/j.lfs.2013.09.001
   Ota H, 2012, LIFE SCI, V90, P206, DOI 10.1016/j.lfs.2011.11.011
   Prasad T, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-03397-2
   Ratnayaka JA, 2015, EYE, V29, P1013, DOI 10.1038/eye.2015.100
   Saveljeva S, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2014.548
   Sevigny J, 2016, NATURE, V537, P50, DOI 10.1038/nature19323
   Shervani NJ, 2004, EUR J CLIN INVEST, V34, P752, DOI 10.1111/j.1365-2362.2004.01419.x
   Sun JR, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.502
   TOMBRANTINK J, 1991, EXP EYE RES, V53, P411, DOI 10.1016/0014-4835(91)90248-D
   Tsujinaka Hiroki, 2015, Biochem Biophys Rep, V2, P123, DOI 10.1016/j.bbrep.2015.05.005
   Wang JY, 2011, ARTERIOSCL THROM VAS, V31, pE11, DOI 10.1161/ATVBAHA.110.215517
   Wang YJ, 2013, ASN NEURO, V5, DOI 10.1042/AN20130028
   Witmer AN, 2003, PROG RETIN EYE RES, V22, P1, DOI 10.1016/S1350-9462(02)00043-5
   Yamamoto Y, 2001, J CLIN INVEST, V108, P261, DOI 10.1172/JCI200111771
   Yoshida T, 2005, J CLIN INVEST, V115, P2793, DOI 10.1172/JCI24635
   Yoshikawa T, 2011, CURR EYE RES, V36, P1153, DOI 10.3109/02713683.2011.606592
   Yoshimoto K, 2013, CLIN EXP IMMUNOL, V174, P1, DOI 10.1111/cei.12142
   Zou K, 2002, J NEUROSCI, V22, P4833, DOI 10.1523/JNEUROSCI.22-12-04833.2002
NR 41
TC 17
Z9 18
U1 1
U2 7
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1471-2415
J9 BMC OPHTHALMOL
JI BMC Ophthalmol.
PD MAR 8
PY 2019
VL 19
AR 70
DI 10.1186/s12886-019-1076-3
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA HO2WD
UT WOS:000460776500001
PM 30849957
OA Green Published, gold, Green Submitted
DA 2022-11-30
ER

PT J
AU Oderinlo, O
   Hassan, AO
   Oluyadi, FO
   Ogunro, AO
   Okonkwo, ON
   Ulaikere, MO
   Ashano, O
AF Oderinlo, O.
   Hassan, A. O.
   Oluyadi, F. O.
   Ogunro, A. O.
   Okonkwo, O. N.
   Ulaikere, M. O.
   Ashano, O.
TI Refractive aim and visual outcome after phacoemulsification: A 2-year
   review from a Tertiary Private Eye Hospital in Sub-Saharan Africa
SO NIGERIAN JOURNAL OF CLINICAL PRACTICE
LA English
DT Article
DE Best-corrected visual acuity; phacoemulsification; refractive aim
ID ELECTRONIC MULTICENTER AUDIT; POSTERIOR CAPSULE RUPTURE; AGE-RELATED
   CATARACT; OF-LIFE OUTCOMES; ULTRASOUND BIOMETRY; BENCHMARK STANDARDS;
   SURGERY; ACUITY; INTERFEROMETRY; PERFORMANCE
AB Aim: To review the short-term visual outcome of phacoemulsification in adults with uncomplicated cataracts in Eye Foundation Hospital, Lagos, Nigeria.
   Materials and Methods: A retrospective review of records of patients that had phacoemulsification between January 2012 and December 2013 in Eye Foundation Hospital, Lagos, Nigeria, was done. Preoperative visual acuity, refractive aim, intraoperative complications, postoperative unaided, and best-corrected visual acuity at 1 and 3 months were analyzed. Only eyes of adults that had phacoemulsification for uncomplicated cataracts were included in the study, all pediatric cataracts and eyes with ocular comorbidities were excluded. Common ocular comorbidities excluded were corneal opacity/corneal scar, glaucoma, uveitis, pseudo exfoliation syndrome, moderate and severe nonproliferative diabetic retinopathy, macula edema, proliferative diabetic retinopathy, eye trauma, age-related macular degeneration, previous corneal surgery, glaucoma surgery, and previous or simultaneous vitreoretinal surgery.
   Results: A total of 157 eyes of 119 patients who met the inclusion criteria were analyzed. There were 60 (50.4%) females and 59 (49.6%) males, with age range from 31 to 91 years and a mean of 65.3 +/- 11.10 years. Only eyes with available data were analyzed at 1 and 3 months postoperatively. In 112 eyes (85.7%), the refractive aim was met, 21 eyes (14.3%) did not meet their refractive aim, 20 eyes (12.7%) were excluded, the refractive aim could not be determined from the records as surgeons did not specify, and in 4 eyes, the required information was missing from the case files. An unaided visual acuity of 6/18 and better was achieved in 134 eyes (85.4%) at 1 month and 126 eyes (85.9%) at 3 months whereas best-corrected vision of 6/18 and better was achieved by 145 eyes (92.4%) at 1 month and 146 eyes (98.0%) at 3 months.
   Conclusion: Surgical outcomes after phacoemulsification are comparable with international benchmarks for good outcomes, with 85.4% of eyes achieving within 1 D of spherical equivalent of the refractive aim, 92.4% and 98.0% of eyes also achieving best-corrected visual acuities of 6/18 and better at 1 and 3 postoperative months, respectively. Unaided vision of 6/18 and better was also achieved in 85.4% and 85.9% at 1 and 3 postoperative months, respectively.
C1 [Oderinlo, O.; Hassan, A. O.; Oluyadi, F. O.; Ogunro, A. O.; Okonkwo, O. N.; Ulaikere, M. O.; Ashano, O.] Eye Fdn Hosp, Anterior Segment & Cataract Unit, Lagos, Nigeria.
RP Oderinlo, O (通讯作者)，Eye Fdn Hosp, 27 Isaac John St,Ikeja GRA, Lagos, Nigeria.
EM olufemi_oderinlo@yahoo.com
RI Oderinlo, Olufemi/P-6235-2019; OKONKWO, OGUGUA Ndubuisi/ABG-2537-2020
OI OKONKWO, OGUGUA Ndubuisi/0000-0002-6805-2427
CR Borasio E, 2006, J CATARACT REFR SURG, V32, P565, DOI 10.1016/j.jcrs.2005.12.104
   Bourne RRA, 2004, OPHTHALMOLOGY, V111, P679, DOI 10.1016/j.ophtha.2003.07.015
   Chen M, 2014, CLIN OPHTHALMOL, V8, P375, DOI 10.2147/OPTH.S57736
   Choi YJ, 2009, YONSEI MED J, V50, P368, DOI 10.3349/ymj.2009.50.3.368
   Conner-Spady BL, 2004, BRIT J OPHTHALMOL, V88, P1305, DOI 10.1136/bjo.2003.037721
   Eleftheriadis H, 2003, BRIT J OPHTHALMOL, V87, P960, DOI 10.1136/bjo.87.8.960
   Eye Care Work Group, 2007, PHYS PERF MEAS SET, P18
   Findl O, 2003, J CATARACT REFR SURG, V29, P1950, DOI 10.1016/S0886-3350(03)00243-8
   Findl O, 2001, J CATARACT REFR SURG, V27, P861, DOI 10.1016/S0886-3350(00)00699-4
   Frick KD, 2003, AM J OPHTHALMOL, V135, P471, DOI 10.1016/S0002-9394(02)02110-4
   Gale RP, 2009, EYE, V23, P149, DOI 10.1038/sj.eye.6702954
   Gale RP, 2006, EYE, V20, P25, DOI 10.1038/sj.eye.6701778
   Hahn U, 2011, OPHTHALMOLOGY, V118, P2105, DOI 10.1016/j.ophtha.2011.05.011
   Jaycock P, 2009, EYE, V23, P38, DOI 10.1038/sj.eye.6703015
   Johnston RL, 2010, EYE, V24, P888, DOI 10.1038/eye.2009.195
   Klein BEK, 2008, OPHTHALMOLOGY, V115, P477, DOI 10.1016/j.ophtha.2007.11.024
   Kyari F, 2009, INVEST OPHTH VIS SCI, V50, P2033, DOI 10.1167/iovs.08-3133
   Lau J, 2002, BRIT J OPHTHALMOL, V86, P12, DOI 10.1136/bjo.86.1.12
   Lundstrom M, 2002, ACTA OPHTHALMOL SCAN, V80, P248, DOI 10.1034/j.1600-0420.2002.800304.x
   Minassian DC, 2001, BRIT J OPHTHALMOL, V85, P822, DOI 10.1136/bjo.85.7.822
   Murphy C, 2002, J CATARACT REFR SURG, V28, P62, DOI 10.1016/S0886-3350(01)01027-6
   Mylonas G, 2011, ACTA OPHTHALMOL, V89, pe237, DOI 10.1111/j.1755-3768.2010.02042.x
   Narendran N, 2009, EYE, V23, P31, DOI 10.1038/sj.eye.6703049
   Park J, 2013, J CATARACT REFR SURG, V39, P1463, DOI 10.1016/j.jcrs.2013.04.033
   Percival SPB, 2002, EYE, V16, P309, DOI 10.1038/sj/eye/6700043
   Pokharel GP, 1998, BRIT J OPHTHALMOL, V82, P606, DOI 10.1136/bjo.82.6.606
   Rajan MS, 2002, EYE, V16, P552, DOI 10.1038/sj.eye.6700157
   Resnikoff S, 2004, B WORLD HEALTH ORGAN, V82, P844
   Russo CA, 2007, AHRQ PUBLICATION, piv
   Sheard R, 2014, EYE, V28, P118, DOI 10.1038/eye.2013.248
   Simon SS, 2014, OPHTHALMOLOGY, V121, P440, DOI 10.1016/j.ophtha.2013.09.022
   Sparrow JM, 2012, EYE, V26, P821, DOI 10.1038/eye.2012.51
   Ti SE, 2014, AM J OPHTHALMOL, V157, P180, DOI 10.1016/j.ajo.2013.08.022
NR 33
TC 2
Z9 2
U1 0
U2 0
PU MEDKNOW PUBLICATIONS & MEDIA PVT LTD
PI MUMBAI
PA B-9, KANARA BUSINESS CENTRE, OFF LINK RD, GHAKTOPAR-E, MUMBAI, 400075,
   INDIA
SN 1119-3077
J9 NIGER J CLIN PRACT
JI Niger. J. Clin. Pract.
PD FEB
PY 2017
VL 20
IS 2
BP 147
EP 152
DI 10.4103/1119-3077.183249
PG 6
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA EM6ED
UT WOS:000395404700004
PM 28091428
DA 2022-11-30
ER

PT J
AU de Carlo, TE
   Bonini, MA
   Chin, AT
   Adhi, M
   Ferrara, D
   Baumal, CR
   Witkin, AJ
   Reichel, E
   Duker, JS
   Waheed, NK
AF de Carlo, Talisa E.
   Bonini Filho, Marco A.
   Chin, Adam T.
   Adhi, Mehreen
   Ferrara, Daniela
   Baumal, Caroline R.
   Witkin, Andre J.
   Reichel, Elias
   Duker, Jay S.
   Waheed, Nadia K.
TI Spectral-Domain Optical Coherence Tomography Angiography of Choroidal
   Neovascularization
SO OPHTHALMOLOGY
LA English
DT Article
ID FLUORESCEIN ANGIOGRAPHY
AB Purpose: To describe the characteristics as well as the sensitivity and specificity of detection of choroidal neovascularization (CNV) on optical coherence tomography angiography (OCTA) using spectral-domain optical coherence tomography.
   Design: Observational, retrospective study.
   Participants: Seventy-two eyes of 61 subjects (48 eyes of 43 subjects with CNV, 24 eyes of 18 subjects without CNV).
   Methods: Patients imaged using the prototype AngioVue OCTA system (Optovue, Inc, Fremont, CA) between August 2014 and October 2014 at New England Eye Center were assessed. Patients in whom CNV was identified on OCTA were evaluated to define characteristics of CNV on OCTA: size using greatest linear dimension (small, <1 mm; medium, 1-2 mm; large, >2 mm), appearance (well-circumscribed, poorly circumscribed), and presence of subretinal and intraretinal fluid. Concurrently, an overlapping second cohort of patients who underwent same-day OCTA and fluorescein angiography (FA) for suspected CNV was evaluated to estimate sensitivity and specificity of OCTA in detecting CNV using FA as ground truth.
   Main Outcome Measures: Choroidal neovascularization appearance, CNV size, and presence of subretinal and intraretinal fluid.
   Results: In 48 eyes, CNV was visualized on OCTA. Thirty-one eyes had CNV associated with neovascular age-related macular degeneration. Size of CNV was small in 23% (7/31), medium in 42% (13/31), and large in 35% (11/31). Poorly circumscribed vessels, subretinal fluid, and intraretinal fluid each were seen in 71% (22/31). Seven eyes had CNV associated with central serous chorioretinopathy. Size of CNV was small in 71% (5/7) and large in 29% (2/7). Seventy-one percent (5/7) had well-circumscribed vessels, 86% (6/7) had subretinal fluid, and 14% (1/7) had intraretinal fluid. Thirty eyes with OCTA and same-day FA were evaluated to determine sensitivity and specificity of CNV detection on OCTA. Sensitivity was 50% (4/8) and specificity was 91% (20/22).
   Conclusions: Using OCTA allows the clinician to visualize CNV noninvasively and may provide a method for identifying and guiding treatment of CNV. The specificity of CNV detection on OCTA compared with FA seems to be high. Future studies with larger sample sizes are needed to elaborate better on the sensitivity and specificity of CNV detection and to illustrate clinical usefulness. (C) 2015 by the American Academy of Ophthalmology.
C1 [de Carlo, Talisa E.; Bonini Filho, Marco A.; Chin, Adam T.; Adhi, Mehreen; Ferrara, Daniela; Baumal, Caroline R.; Witkin, Andre J.; Reichel, Elias; Duker, Jay S.; Waheed, Nadia K.] Tufts Univ, New England Eye Ctr, Boston, MA 02111 USA.
   [de Carlo, Talisa E.; Bonini Filho, Marco A.; Chin, Adam T.; Adhi, Mehreen; Ferrara, Daniela; Baumal, Caroline R.; Witkin, Andre J.; Reichel, Elias; Duker, Jay S.; Waheed, Nadia K.] Tufts Univ, Tufts Med Ctr, Boston, MA 02111 USA.
   [de Carlo, Talisa E.; Adhi, Mehreen] MIT, Dept Elect Engn & Comp Sci, Cambridge, MA 02139 USA.
   [de Carlo, Talisa E.; Adhi, Mehreen] MIT, Elect Res Lab, Cambridge, MA 02139 USA.
   [Bonini Filho, Marco A.] Minist Educ Brazil, CAPES Fdn, Brasilia, DF, Brazil.
C3 Tufts University; Tufts Medical Center; Tufts University; Massachusetts
   Institute of Technology (MIT); Massachusetts Institute of Technology
   (MIT); Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior
   (CAPES)
RP Waheed, NK (通讯作者)，Tufts Med Ctr, New England Eye Ctr, 260 Tremont St,Biewend Bldg,9-11th Floor, Boston, MA 02116 USA.
EM nadiakwaheed@gmail.com
RI BONINI FILHO, MARCO/GLR-8943-2022; Adhi, Mehreen/AAS-9733-2021
OI BONINI FILHO, MARCO/0000-0003-0796-8025; Chin, Adam/0000-0002-8539-754X
FU Research to Prevent Blindness, Inc., New York, New York; Massachusetts
   Lions Eye Research Fund, Inc (New Bedford, MA)
FX Supported in part by an unrestricted grant form Research to Prevent
   Blindness, Inc., New York, New York, to the New England Eye
   Center/Department of Ophthalmology, Tufts University School of Medicine;
   and by the Massachusetts Lions Eye Research Fund, Inc (New Bedford, MA).
CR Ambati J, 2003, SURV OPHTHALMOL, V48, P257, DOI 10.1016/S0039-6257(03)00030-4
   Choi W, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0081499
   Coscas F, 2012, INVEST OPHTH VIS SCI, V53, P4147, DOI 10.1167/iovs.12-9878
   Do DV, 2013, CURR OPIN OPHTHALMOL, V24, P244, DOI 10.1097/ICU.0b013e32835fd7dd
   Do DV, 2012, OPHTHALMOLOGY, V119, P771, DOI 10.1016/j.ophtha.2011.10.019
   Ferrara D, 2014, OPHTHALMOLOGY, V121, P719, DOI 10.1016/j.ophtha.2013.10.014
   Giani A, 2011, INVEST OPHTH VIS SCI, V52, P5579, DOI 10.1167/iovs.10-6617
   Jia YL, 2014, OPHTHALMOLOGY, V121, P1435, DOI 10.1016/j.ophtha.2014.01.034
   Kim DY, 2013, P NATL ACAD SCI USA, V110, P14354, DOI 10.1073/pnas.1307315110
   Kotsolis AI, 2010, BRIT J OPHTHALMOL, V94, P1506, DOI 10.1136/bjo.2009.159913
   KWITEROVICH KA, 1991, OPHTHALMOLOGY, V98, P1139
   Liakopoulos S, 2008, INVEST OPHTH VIS SCI, V49, P5048, DOI 10.1167/iovs.08-1877
   Lopez-Saez MP, 1998, ANN ALLERG ASTHMA IM, V81, P428, DOI 10.1016/S1081-1206(10)63140-7
   Ryan SJ, 2013, RETINA, P1150
   Sadda SR, 2010, GRAEF ARCH CLIN EXP, V248, P175, DOI 10.1007/s00417-009-1193-4
   Schwartz DM, 2014, OPHTHALMOLOGY, V121, P180, DOI 10.1016/j.ophtha.2013.09.002
   Shah SM, 2006, INVEST OPHTH VIS SCI, V47, P5460, DOI 10.1167/iovs.06-0012
   Sulzbacher F, 2011, AM J OPHTHALMOL, V152, P799, DOI 10.1016/j.ajo.2011.04.011
   Yannuzzi LA, 2001, RETINA-J RET VIT DIS, V21, P416, DOI 10.1097/00006982-200110000-00003
NR 19
TC 284
Z9 285
U1 5
U2 45
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD JUN
PY 2015
VL 122
IS 6
BP 1228
EP 1238
DI 10.1016/j.ophtha.2015.01.029
PG 11
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA CI9OJ
UT WOS:000355099200029
PM 25795476
HC Y
HP N
DA 2022-11-30
ER

PT J
AU Wills, NK
   Ramanujam, VMS
   Kalariya, N
   Lewis, JR
   van Kuijk, FJGM
AF Wills, N. K.
   Ramanujam, V. M. Sadagopa
   Kalariya, N.
   Lewis, J. R.
   van Kuijk, F. J. G. M.
TI Copper and zinc distribution in the human retina: Relationship to
   cadmium accumulation, age, and gender
SO EXPERIMENTAL EYE RESEARCH
LA English
DT Article
DE zinc; copper; cadmium; human; neural retina; retinal pigment epithelium;
   choroid
ID MACULAR DEGENERATION; VITAMIN-E; DISEASE; DEFICIENCY; RATS; TISSUES;
   BETA; MICE; IRON
AB The essential metals copper and zinc play vital roles in retinal cell survival and are crucial for the normal functioning of antioxidant enzymes. Retinal zinc deficiencies and decreased cellular antioxidative capacity have been linked to human retinal diseases including age-related macular degeneration (AMD). We recently reported that cadmium (a toxic metal with no known physiological function that interferes with copper and zinc metabolism) accumulates in human retinal tissues during aging. Moreover, cadmium content was higher in specific retinal tissues of aged women compared to men. Since cadmium, zinc and copper bind to similar proteins, we hypothesized that Cu and Zn content of human retinal tissues change as functions of cadmium accumulation during aging. Thus, we assessed the distribution of zinc and copper in the neural retina, retinal pigment epithelium (RPE) and choroid (Bruch's membrane-choroid; BMC) in male and female donors aged 1.5-87 years. Two independent methods, graphite furnace atomic absorption spectrometry and inductively-coupled plasma mass spectrometry, were used to measure Cd, Zn, and Cu in retinal tissues in human eyes from donors aged 1.5 to 87 years and the resulting values were normalized to protein concentration. Zn levels were similar to 5 times higher than Cu levels in the same tissues. The relative tissue distributions of these metals were: BMC>RPE>neural retina (Zn) and BMC > RPE = neural retina (Cu). In the choroid, mean Cu and Zn levels were higher in aged donors ( 55 years old) than young donors (<55 years) and levels of these metals were strongly correlated with each other (r = 0.90). In the neural retina, Cu and Zn both significantly decreased as a function of age. Several sex-related differences were found in the RPE. Specifically, copper levels were significantly higher in males than in females. In addition, both Zn and Cu levels in males were positively correlated with cadmium content, whereas this association did not occur in females. The results are consistent with co-regulation of zinc and copper stores in retinal tissues and suggest that the balance of these metals is associated with cadmium accumulation and gender. Thus, the roles of cadmium and gender differences in retinal metal balance warrant further investigation as factors in age-related retinal disease. (C) 2008 Elsevier Ltd. All rights reserved.
C1 [Wills, N. K.; Lewis, J. R.] Univ Texas Med Branch, Dept Neurosci & Cell Biol, Galveston, TX 77555 USA.
   [Wills, N. K.; Kalariya, N.; van Kuijk, F. J. G. M.] Univ Texas Med Branch, Age Related Macular Degenerat AMD, Dept Ophthalmol & Visual Sci, Galveston, TX 77555 USA.
   [Ramanujam, V. M. Sadagopa] Univ Texas Med Branch, Dept Prevent Med & Community Hlth, Div Nutr, Galveston, TX 77555 USA.
C3 University of Texas System; University of Texas Medical Branch
   Galveston; University of Texas System; University of Texas Medical
   Branch Galveston; University of Texas System; University of Texas
   Medical Branch Galveston
RP Wills, NK (通讯作者)，Univ Texas Med Branch, Dept Neurosci & Cell Biol, 301 Univ Blvd, Galveston, TX 77554 USA.
EM nkwills@utmb.edu
FU Philip Morris USA Inc; Philip Morris International; Wilkins AMD Fund;
   University of Texas Medical Branch Human Nutrition Trace Metal
   Instrumentation Facility
FX The research described in this article was supported by Philip Morris
   USA Inc. and Philip Morris International, the Wilkins AMD Fund, and the
   University of Texas Medical Branch Human Nutrition Trace Metal
   Instrumentation Facility.
CR ALCOCK NW, 1987, BIOL TRACE ELEM RES, V13, P363, DOI 10.1007/BF02796647
   Bhattacharyya MH., 2000, MOL BIOL TOXICOLOGY, P34
   CHAN HM, 1993, P SOC EXP BIOL MED, V202, P420
   DINGLE J, 1978, ANN OPHTHALMOL, V10, P1227
   ECKHERT CD, 1983, EXP EYE RES, V37, P639, DOI 10.1016/0014-4835(83)90138-0
   Ellingsen DG, 2007, HANDBOOK ON THE TOXICOLOGY OF METALS, 3RD EDITION, P529, DOI 10.1016/B978-012369413-3/50081-1
   Erie JC, 2005, AM J OPHTHALMOL, V139, P888, DOI 10.1016/j.ajo.2004.12.007
   FRIEDRICHSON T, 1995, CURR EYE RES, V14, P693, DOI 10.3109/02713689508998497
   JOHNSON PE, 1992, AM J CLIN NUTR, V56, P917, DOI 10.1093/ajcn/56.5.917
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Krajacic P, 2006, INVEST OPHTH VIS SCI, V47, P3129, DOI 10.1167/iovs.05-1601
   Maynard CJ, 2005, INT J EXP PATHOL, V86, P147, DOI 10.1111/j.0959-9673.2005.00434.x
   Miceli MV, 1999, INVEST OPHTH VIS SCI, V40, P1238
   MORITA A, 1994, BIOL TRACE ELEM RES, V42, P165, DOI 10.1007/BF02785387
   MORRISON SA, 1978, AM J CLIN NUTR, V31, P276, DOI 10.1093/ajcn/31.2.276
   Newsome DA, 1995, J TRACE ELEM EXP MED, V8, P193
   PRASAD AS, 1991, AM J CLIN NUTR, V53, P403, DOI 10.1093/ajcn/53.2.403
   Ramanujam VMS, 1999, BIOL TRACE ELEM RES, V68, P143, DOI 10.1007/BF02784403
   Reeves PG, 2005, J NUTR, V135, P99, DOI 10.1093/jn/135.1.99
   Satarug S, 2004, TOXICOL LETT, V148, P177, DOI 10.1016/j.toxlet.2003.09.015
   Ugarte M, 2001, PROG NEUROBIOL, V64, P219, DOI 10.1016/S0301-0082(00)00057-5
   VANKUIJK FJGM, 1991, INVEST OPHTH VIS SCI, V32, P1962
   VANKUIJK FJGM, 1992, INVEST OPHTH VIS SCI, V33, P3493
   Waggoner DJ, 1999, NEUROBIOL DIS, V6, P221, DOI 10.1006/nbdi.1999.0250
   WASTNEY ME, 1992, AM J PHYSIOL, V263, pR1162, DOI 10.1152/ajpregu.1992.263.5.R1162
   Wills NK, 2008, EXP EYE RES, V86, P41, DOI 10.1016/j.exer.2007.09.005
NR 26
TC 49
Z9 50
U1 0
U2 11
PU ACADEMIC PRESS LTD ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 0014-4835
J9 EXP EYE RES
JI Exp. Eye Res.
PD AUG
PY 2008
VL 87
IS 2
BP 80
EP 88
DI 10.1016/j.exer.2008.04.013
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 340EM
UT WOS:000258628900002
PM 18579132
DA 2022-11-30
ER

PT J
AU Cheung, CSY
   Wong, AWT
   Lui, A
   Kertes, PJ
   Devenyi, RG
   Lam, WC
AF Cheung, Crystal S. Y.
   Wong, Amanda W. T.
   Lui, Alex
   Kertes, Peter J.
   Devenyi, Robert G.
   Lam, Wai-Ching
TI Incidence of Endophthalmitis and Use of Antibiotic Prophylaxis after
   Intravitreal Injections
SO OPHTHALMOLOGY
LA English
DT Article
ID TRIAMCINOLONE ACETONIDE; BEVACIZUMAB; RESISTANCE; RISK; RANIBIZUMAB
AB Purpose: To report the incidence of endophthalmitis in association with different antibiotic prophylaxis strategies after intravitreal injections of anti-vascular endothelial growth factors and triamcinolone acetonide.
   Design: Retrospective, comparative case series.
   Participants: Fifteen thousand eight hundred ninety-five intravitreal injections (9453 ranibizumab, 5386 bevacizumab, 935 triamcinolone acetonide, 121 pegaptanib sodium) were reviewed for 2465 patients between January 5, 2005, and August 31, 2010. The number of injections was determined from billing code and patient records.
   Methods: The indications for injection included age-related macular degeneration, diabetic macular edema, central and branch retinal vein occlusion, and miscellaneous causes. Three strategies of topical antibiotic prophylaxis were used by the respective surgeons: (1) antibiotics given for 5 days after each injection, (2) antibiotics given immediately after each injection, and (3) no antibiotics given.
   Main Outcome Measures: The primary outcome measures were the incidence of culture-positive endophthalmitis and culture-negative cases of suspected endophthalmitis.
   Results: Nine eyes of 9 patients with suspected endophthalmitis after injection were identified. Three of the 9 cases had culture-positive results. The overall incidence of endophthalmitis was 9 in 15 895. The incidence of culture-negative cases of suspected endophthalmitis and culture-proven endophthalmitis after injection was 6 in 15 895 and 3 in 15 895, respectively. Taking into account both culture-positive endophthalmitis and culture-negative cases of suspected endophthalmitis, the incidence per injection was 5 in 8259 for patients who were given antibiotics for 5 days after injection, 2 in 2370 for those who received antibiotics immediately after each injection, and 2 in 5266 who received no antibiotics. However, if considering culture-proven endophthalmitis alone, the use of topical antibiotics, given immediately or for 5 days after injection, showed lower rates of endophthalmitis compared with those without postinjection antibiotics. The risk of endophthalmitis after intravitreal injection varied among agents that were used. Among the 9 cases of clinically suspected endophthalmitis, regardless of prophylactic strategies used, the incidence of endophthalmitis per injection was 2 in 935 for triamcinolone acetonide, 3 in 9453 for ranibizumab, and 4 in 5386 for bevacizumab.
   Conclusions: The overall rate of intravitreal injection-related endophthalmitis is greater with the use of topical antibiotics, given immediately or for 5 days after the injection, compared with no antibiotics.
   Financial Disclosure(s): Proprietary or commercial disclosure may be found after the references. Ophthalmology 2012;119:1609-1614 (C) 2012 by the American Academy of Ophthalmology.
C1 [Cheung, Crystal S. Y.; Wong, Amanda W. T.; Lui, Alex; Devenyi, Robert G.; Lam, Wai-Ching] Toronto Western Hosp, Univ Hlth Network, Dept Ophthalmol & Vis Sci, Toronto, ON M5T 2S8, Canada.
   [Kertes, Peter J.] Sunnybrook Hlth Sci Ctr, Dept Ophthalmol & Vis Sci, John & Liz Tory Eye Ctr, Toronto, ON M4N 3M5, Canada.
C3 University of Toronto; University Toronto Affiliates; University Health
   Network Toronto; University of Toronto; Sunnybrook Research Institute;
   University Toronto Affiliates; Sunnybrook Health Science Center
RP Lam, WC (通讯作者)，Univ Toronto, Toronto Western Hosp, Dept Ophthalmol, 399 Bathurst St,EW 6-432, Toronto, ON M5T 2S8, Canada.
EM waiching.lam@utoronto.ca
RI CLIHON, Residencia Medica/K-4896-2013
OI CLIHON, Residencia Medica/0000-0001-6734-2513; Lam,
   Wai-Ching/0000-0003-2057-9374
FU Novartis; Snell Publishing
FX The author(s) have made the following disclosure(s): Wai-Ching Lam -
   Consultant - Allergan; Financial support - Novartis, Snell Publishing
CR Artunay O, 2009, EYE, V23, P2187, DOI 10.1038/eye.2009.7
   Bakri SJ, 2005, EYE, V19, P686, DOI 10.1038/sj.eye.6701602
   Bakri Sophie J, 2009, Retin Cases Brief Rep, V3, P316, DOI 10.1097/ICB.0b013e318199b086
   Bhatt SS, 2011, RETINA-J RET VIT DIS, V31, P2032, DOI 10.1097/IAE.0b013e31820f4b4f
   Bhavsar AR, 2007, AM J OPHTHALMOL, V144, P454, DOI 10.1016/j.ajo.2007.04.011
   Bhavsar AR, 2009, ARCH OPHTHALMOL-CHIC, V127, P1581, DOI 10.1001/archophthalmol.2009.304
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Pastor JC, 2008, RETINA-J RET VIT DIS, V28, P1247, DOI 10.1097/IAE.0b013e31817d5bf6
   Chiquet C, 2008, INVEST OPHTH VIS SCI, V49, P1971, DOI 10.1167/iovs.07-1377
   Costello P, 2006, RETINA-J RET VIT DIS, V26, P191, DOI 10.1097/00006982-200602000-00012
   de Kaspar HM, 2001, OPHTHALMOLOGY, V108, P470, DOI 10.1016/S0161-6420(00)00545-5
   Fung AE, 2006, BRIT J OPHTHALMOL, V90, P1344, DOI 10.1136/bjo.2006.099598
   Green-Simms AE, 2011, AM J OPHTHALMOL, V151, P329, DOI 10.1016/j.ajo.2010.08.039
   Hooper DC, 2002, LANCET INFECT DIS, V2, P530, DOI 10.1016/S1473-3099(02)00369-9
   Inman ZD, 2011, RETINA-J RET VIT DIS, V31, P669, DOI 10.1097/IAE.0b013e3181ef463d
   Jackson TL, 2003, SURV OPHTHALMOL, V48, P403, DOI 10.1016/S0039-6257(03)00054-7
   Jager RD, 2004, RETINA-J RET VIT DIS, V24, P676, DOI 10.1097/00006982-200410000-00002
   Kim SJ, 2011, OPHTHALMOLOGY, V118, P1358, DOI 10.1016/j.ophtha.2010.12.014
   Kim SJ, 2010, OPHTHALMOLOGY, V117, P2372, DOI 10.1016/j.ophtha.2010.03.034
   Mason JO, 2008, RETINA-J RET VIT DIS, V28, P564, DOI 10.1097/IAE.0b013e3181633fee
   McCannel CA, 2011, RETINA-J RET VIT DIS, V31, P654, DOI 10.1097/IAE.0b013e31820a67e4
   Mezad-Koursh D, 2010, RETINA-J RET VIT DIS, V30, P1051, DOI 10.1097/IAE.0b013e3181cd47ed
   Miller D, 2006, ARCH OPHTHALMOL-CHIC, V124, P479, DOI 10.1001/archopht.124.4.479
   Moshfeghi DM, 2003, AM J OPHTHALMOL, V136, P791, DOI 10.1016/S0002-9394(03)00483-5
   Moss JM, 2009, OPHTHALMOLOGY, V116, P1498, DOI 10.1016/j.ophtha.2009.02.024
   Nelson ML, 2003, RETINA-J RET VIT DIS, V23, P686, DOI 10.1097/00006982-200310000-00014
   Pilu S, 2008, AM J OPHTHALMOL, V145, P879, DOI 10.1016/j.ajo.2007.12.036
   Recchia FM, 2005, ARCH OPHTHALMOL-CHIC, V123, P341, DOI 10.1001/archopht.123.3.341
   Scott IU, 2007, RETINA-J RET VIT DIS, V27, P10, DOI 10.1097/IAE.0b013e3180307271
   SPEAKER MG, 1991, OPHTHALMOLOGY, V98, P1769
   Ta CN, 2002, OPHTHALMOLOGY, V109, P2036, DOI 10.1016/S0161-6420(02)01236-8
   Westfall AC, 2005, ARCH OPHTHALMOL-CHIC, V123, P1075, DOI 10.1001/archopht.123.8.1075
   Wickremasinghe SS, 2008, OPHTHALMOLOGY, V115, P1911, DOI 10.1016/j.ophtha.2008.05.007
   Yospaiboon Yosanan, 2005, Journal of the Medical Association of Thailand, V88, P639
NR 34
TC 137
Z9 144
U1 0
U2 11
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD AUG
PY 2012
VL 119
IS 8
BP 1609
EP 1614
DI 10.1016/j.ophtha.2012.02.014
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 982YA
UT WOS:000307080100018
PM 22480743
DA 2022-11-30
ER

PT J
AU Cheng, LN
   Lin, YX
   Liu, L
   Zhang, XH
   Xue, YQ
   Zhou, SD
   Liu, ZL
   Zhang, H
AF Cheng, Lu-Na
   Lin, Yu-Xi
   Liu, Lei
   Zhang, Xu-He
   Xue, Yan-Qi
   Zhou, Sheng-Di
   Liu, Zhe-Li
   Zhang, Han
TI Assessment of conbercept therapy for high myopia macular
   neovascularization by optical coherence tomography angiography
SO SCIENTIFIC REPORTS
LA English
DT Article
ID CHOROIDAL NEOVASCULARIZATION; GROWTH-FACTOR; SECONDARY; RANIBIZUMAB;
   PREVALENCE
AB This study aimed to evaluate the efficacy and safety of the intravitreal injection of conbercept in the treatment of macular neovascularization (MNV) secondary to high myopia and to observe the application of optical coherence tomography angiography (OCTA) in the treatment follow-up. We reviewed the medical records of 20 patients (21 eyes) with MNV secondary to high myopia who were enrolled in the Department of Ophthalmology of the First Hospital of China Medical University between May 2018 and January 2020. Each patient received one or more intravitreal injections of conbercept (0.5 mg/0.05 mL). The treatment was conducted according to a 1 + PRN (pro re nata) regimen. The changes of best corrected visual acuity (BCVA), central macular thickness (CMT), and selected MNV and flow areas measured by OCTA were observed over a 6-month follow-up period. The mean logarithm of the minimum angle of resolution (logMAR) BCVA was 1.03 +/- 0.61 before treatment and improved to 0.83 +/- 0.59 (P = 0.007), 0.78 +/- 0.62 (P = 0.001), 0.81 +/- 0.73 (P = 0.027), and 0.79 +/- 0.72 (P = 0.023) at 1 month, 2 months, 3 months, and 6 months after treatment, respectively. The mean CMT was 358.16 +/- 206.11 mu m before treatment and decreased to 295.38 +/- 178.70 mu m (P = 0.003), 288.34 +/- 165.60 mu m (P = 0.004), 284.36 +/- 163.07 mu m (P = 0.005), and 283.00 +/- 160.32 mu m (P = 0.004) at 1 month, 2 months, 3 months, and 6 months after treatment, respectively. Nineteen eyes (90.5%) had stable or improved vision at 6 months of follow-up. One month after conbercept injection, in OCTA images, the small-diameter blood vessels of the MNV decreased, the intertwined small blood vessels decreased or even disappeared, and the main or larger-diameter blood vessels were still present. The mean selected MNV and blood flow areas were 0.62 +/- 0.81 and 0.22 +/- 0.27 -mm(2), respectively, before treatment and decreased to 0.23 +/- 0.33 and 0.07 +/- 0.08 mm(2) (P = 0.04 for both), respectively, 1 month after treatment. No drug-related systemic or ocular adverse effects were observed. Our results suggest that conbercept can effectively and safely improve BCVA and reduce CMT in patients with myopic MVN (mMNV). OCTA can be used to observe MNV area, blood flow area, and MNV morphological changes after treatment with conbercept, thus providing a reference for treatment follow-up.
C1 [Cheng, Lu-Na; Lin, Yu-Xi; Liu, Lei; Zhang, Xu-He; Xue, Yan-Qi; Zhou, Sheng-Di; Liu, Zhe-Li; Zhang, Han] China Med Univ, Hosp 1, Dept Ophthalmol, 155 Nanjing North St, Shenyang 110001, Peoples R China.
   [Liu, Lei] China Med Univ, Hosp 1, Dept Publ Serv, Shenyang 110001, Peoples R China.
C3 China Medical University; China Medical University
RP Zhang, H (通讯作者)，China Med Univ, Hosp 1, Dept Ophthalmol, 155 Nanjing North St, Shenyang 110001, Peoples R China.
EM zhanghan0614@139.com
OI Zhang, Han/0000-0002-9338-0051
FU Liaoning Science and Technology Project [2013225303]
FX Liaoning Science and Technology Project (No. 2013225303, H. Z.)
   supported this work. However, the funder played no role in the study
   design, data assembly or analysis, publishing decision, or manuscript
   preparation.
CR Akagi-Kurashige Y, 2012, INVEST OPHTH VIS SCI, V53, P2349, DOI 10.1167/iovs.11-9405
   Attebo K, 1999, OPHTHALMOLOGY, V106, P1066, DOI 10.1016/S0161-6420(99)90251-8
   Bruyere E, 2017, RETINA-J RET VIT DIS, V37, P2095, DOI 10.1097/IAE.0000000000001456
   Chen YX, 2019, RETINA-J RET VIT DIS, V39, P1985, DOI 10.1097/IAE.0000000000002292
   Cheng Y, 2019, RETINA-J RET VIT DIS, V39, P712, DOI 10.1097/IAE.0000000000002005
   de Carlo TE, 2015, OPHTHALMOLOGY, V122, P1228, DOI 10.1016/j.ophtha.2015.01.029
   Haas AM, 2020, OCUL IMMUNOL INFLAMM, V28, P20, DOI 10.1080/09273948.2018.1540708
   Holden BA, 2016, OPHTHALMOLOGY, V123, P1036, DOI 10.1016/j.ophtha.2016.01.006
   Huang D, 2015, RETINA-J RET VIT DIS, V35, P2260, DOI 10.1097/IAE.0000000000000846
   Ikuno Y, 2015, OPHTHALMOLOGY, V122, P1220, DOI 10.1016/j.ophtha.2015.01.025
   Kim KJ, 2012, EXP MOL MED, V44, P10, DOI 10.3858/emm.2012.44.1.023
   Lin LLK, 2004, ANN ACAD MED SINGAP, V33, P27
   Lu XM, 2015, DRUG DES DEV THER, V9, DOI 10.2147/DDDT.S67536
   Lumbroso B, 2016, DEV OPHTHALMOL, V56, P77, DOI 10.1159/000442782
   Mi L, 2018, J OPHTHALMOL, V2018, DOI 10.1155/2018/4707832
   Miere A, 2019, RETINA-J RET VIT DIS, V39, P548, DOI 10.1097/IAE.0000000000001964
   Miyata M, 2016, AM J OPHTHALMOL, V165, P108, DOI 10.1016/j.ajo.2016.03.009
   Neelam K, 2012, PROG RETIN EYE RES, V31, P495, DOI 10.1016/j.preteyeres.2012.04.001
   Nguyen TT, 2015, EXPERT REV CLIN PHAR, V8, P541, DOI 10.1586/17512433.2015.1075879
   Ohno-Matsui K, 2003, BRIT J OPHTHALMOL, V87, P570, DOI 10.1136/bjo.87.5.570
   Querques L, 2017, BRIT J OPHTHALMOL, V101, P609, DOI 10.1136/bjophthalmol-2016-309162
   Ruiz-Moreno JM, 2015, RETINA-J RET VIT DIS, V35, P2450, DOI 10.1097/IAE.0000000000000632
   Tan NW, 2018, RETINA-J RET VIT DIS, V38, P2228, DOI 10.1097/IAE.0000000000001858
   Wolf S, 2014, OPHTHALMOLOGY, V121, P682, DOI 10.1016/j.ophtha.2013.10.023
   Yan M, 2019, ACTA OPHTHALMOL, V97, pE813, DOI 10.1111/aos.13632
   Yoshida T, 2003, OPHTHALMOLOGY, V110, P1926, DOI 10.1016/S0161-6420(03)00621-3
NR 26
TC 3
Z9 3
U1 3
U2 6
PU NATURE RESEARCH
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD OCT 12
PY 2020
VL 10
IS 1
AR 16959
DI 10.1038/s41598-020-74073-1
PG 8
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA OH6EW
UT WOS:000582683400013
PM 33046787
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Bai, JH
   Wan, ZQ
   Wang, ML
   Wu, X
   Wang, TY
   Zhang, YY
   Xue, YW
   Xu, H
   Peng, Q
AF Bai, Jianhao
   Wan, Zhongqi
   Wang, Minli
   Wu, Xue
   Wang, Tianyu
   Zhang, Yuanyuan
   Xue, Yawen
   Xu, Hong
   Peng, Qing
TI Association of cognitive function with Neurofilament light chain in the
   aqueous humor of human eye
SO FRONTIERS IN AGING NEUROSCIENCE
LA English
DT Article
DE age-related macular degeneration; cataract; Alzheimer's disease; aqueous
   humor; neurofilament light chain
ID ALZHEIMERS-DISEASE; CEREBROSPINAL-FLUID; MACULAR DEGENERATION;
   INTRAVITREAL INJECTION; OPTIC-NERVE; BIOMARKERS; DIAGNOSIS; DEMENTIA;
   RISK; ONSET
AB ObjectivesTo evaluate the predictive clinical role of neurofilament light chain (NfL), amyloid-beta (A beta), glial fibrillary acidic protein (GFAP), and phosphorylated tau at threonine 181 (p-tau181) proteins in human aqueous humor (AH) and quantify the retinal macular microvascular parameters by optical coherence tomography angiography (OCTA) as early diagnostic markers of Alzheimer's disease (AD). MethodsThis prospective, single-site, cross-sectional, cohort study enrolled 55 participants, including 38 patients with neovascular age-related macular degeneration (nAMD) and 17 individuals with senile cataracts. The single-molecule array platform was used to quantitatively measure the levels of AH NfL, A beta 40, A beta 42, GFAP, and p-tau181 proteins in AH. The mini-mental state examination (MMSE) score was used to assess the global cognitive function. OCTA scan with 6 x 6 mm macular area was used to quantify the retinal thickness and microvascular densities of superficial retinal capillary plexuses and deep retinal capillary plexuses. ResultsNfL, A beta 40, A beta 42, GFAP, and p-tau181 were detected in all AH samples by Simoa platform. Individuals with cataract had higher concentrations of NfL and p-tau181 but lower A beta 40 and A beta 42 and similar GFAP compared to those with nAMD. Lower MMSE scores showed a negative correlation with NfL concentration of AH not only in the nAMD group (p = 0.043), but also in the cataract group (p = 0.032). However, the MMSE scores were not associated with the levels of A beta 40, A beta 42, GFAP, or p-Tau181. Further analysis found that the A beta 40 and A beta 42 concentrations showed a strong positive correlation (p < 0.0001). In addition, the NfL concentration showed a mild positive correlation with that of GFAP in the cataract group (p = 0.021). Although it has not reached statistical significance, there was a correlation between the levels of NfL and A beta 42 in the nAMD group (p = 0.051). Moreover, the macular superficial vessel density values had a negative correlation with the concentration of NfL (p = 0.004) but a positive correlation with MMSE scores (p = 0.045). The macular deep vessel density values were negatively correlated with the concentration of p-tau181 (p = 0.031) and positively correlated with MMSE scores (p = 0.020). ConclusionThe examination of AD-related biomarkers in human AH and OCTA may improve the ocular-based AD detection methods and contribute to forestalling the progression of preclinical AD.
C1 [Bai, Jianhao; Wan, Zhongqi; Wang, Minli; Wang, Tianyu; Zhang, Yuanyuan; Xue, Yawen; Peng, Qing] Tongji Univ, Sch Med, Dept Ophthalmol, Shanghai Peoples Hosp 10, Shanghai, Peoples R China.
   [Wu, Xue; Xu, Hong] Shanghai Jiao Tong Univ, Sch Biomed Engn, Shanghai, Peoples R China.
C3 Tongji University; Shanghai Jiao Tong University
RP Peng, Q (通讯作者)，Tongji Univ, Sch Med, Dept Ophthalmol, Shanghai Peoples Hosp 10, Shanghai, Peoples R China.; Xu, H (通讯作者)，Shanghai Jiao Tong Univ, Sch Biomed Engn, Shanghai, Peoples R China.
EM xuhong@sjtu.edu.cn; pengqing@tongji.edu.cn
FU National Natural Science Foundation of China [81470025]; Shanghai
   Municipal Health Bureau [ZY (2018-2020)-ZWB-1001-CPJS10]; Three-Year
   Action Plan for Promoting Clinical Skills and Clinical Innovation in
   Municipal Hospitals [SHDC2020CR5014]
FX This work was supported by the National Natural Science Foundation of
   China [grant number 81470025); the Shanghai Municipal Health Bureau
   [grant number ZY (2018-2020)-ZWB-1001-CPJS10); and the Three-Year Action
   Plan for Promoting Clinical Skills and Clinical Innovation in Municipal
   Hospitals (grant number SHDC2020CR5014).
CR Agarwal Rachna, 2011, Int J Alzheimers Dis, V2011, P503293, DOI 10.4061/2011/503293
   Ashok A, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21197290
   Baker ML, 2009, ARCH OPHTHALMOL-CHIC, V127, P667, DOI 10.1001/archophthalmol.2009.30
   Blennow K, 2018, J INTERN MED, V284, P643, DOI 10.1111/joim.12816
   Colligris P, 2018, J OPHTHALMOL, V2018, DOI 10.1155/2018/8538573
   Silva MVF, 2019, J BIOMED SCI, V26, DOI 10.1186/s12929-019-0524-y
   Gaetani L, 2019, J NEUROL NEUROSUR PS, V90, P870, DOI 10.1136/jnnp-2018-320106
   Gaugler J, 2019, ALZHEIMERS DEMENT, V15, P321, DOI 10.1016/j.jalz.2019.01.010
   Guo L, 2021, CURR ALZHEIMER RES, V18, P89, DOI 10.2174/1567205018666210414113634
   Guo LY, 2014, EXP EYE RES, V129, P31, DOI 10.1016/j.exer.2014.10.012
   Haapalinna F, 2018, J ALZHEIMERS DIS, V62, P165, DOI 10.3233/JAD-170534
   Hampel H, 2018, ALZHEIMERS DEMENT, V14, P492, DOI 10.1016/j.jalz.2017.11.015
   Hersi M, 2017, NEUROTOXICOLOGY, V61, P143, DOI 10.1016/j.neuro.2017.03.006
   Hou KJ, 2022, SIGNAL TRANSDUCT TAR, V7, DOI 10.1038/s41392-022-00974-4
   Hou YJ, 2019, NAT REV NEUROL, V15, P565, DOI 10.1038/s41582-019-0244-7
   Hwang PH, 2021, ALZHEIMERS DEMENT, V17, P1442, DOI 10.1002/alz.12313
   Janelidze S, 2020, NAT MED, V26, P379, DOI 10.1038/s41591-020-0755-1
   Javaid FZ, 2016, FRONT NEUROL, V7, DOI 10.3389/fneur.2016.00055
   Jin M, 2019, FRONT AGING NEUROSCI, V11, DOI 10.3389/fnagi.2019.00254
   Kaeser PF, 2015, BMC OPHTHALMOL, V15, DOI 10.1186/s12886-015-0060-9
   Kamalden TA, 2011, OPHTHALMIC RES, V45, P65, DOI 10.1159/000313985
   Kerbage C, 2015, AM J ALZHEIMERS DIS, V30, P738, DOI 10.1177/1533317513520214
   Kuhle J, 2016, CLIN CHEM LAB MED, V54, P1655, DOI 10.1515/cclm-2015-1195
   Lee CS, 2019, ALZHEIMERS DEMENT, V15, P34, DOI 10.1016/j.jalz.2018.06.2856
   Levin J, 2016, DTSCH ARZTEBL INT, V113, P61, DOI 10.3238/arztebl.2016.0061
   Liu S S, 2017, Zhonghua Yan Ke Za Zhi, V53, P314, DOI 10.3760/cma.j.issn.0412-4081.2017.04.016
   London A, 2013, NAT REV NEUROL, V9, P44, DOI 10.1038/nrneurol.2012.227
   Mancino R, 2018, CURR NEUROPHARMACOL, V16, P971, DOI 10.2174/1570159X16666171206144045
   Marchesi N, 2021, CELLS-BASEL, V10, DOI 10.3390/cells10092394
   Mattsson N, 2017, JAMA NEUROL, V74, P557, DOI 10.1001/jamaneurol.2016.6117
   Melov S, 2005, FREE RADICAL BIO MED, V38, P258, DOI 10.1016/j.freeradbiomed.2004.10.023
   Modvig S, 2016, MULT SCLER J, V22, P590, DOI 10.1177/1352458515599074
   More SS, 2015, ACS CHEM NEUROSCI, V6, P306, DOI 10.1021/cn500242z
   O'Bryhim BE, 2018, JAMA OPHTHALMOL, V136, P1242, DOI 10.1001/jamaophthalmol.2018.3556
   Ohno-Matsui K, 2011, PROG RETIN EYE RES, V30, P217, DOI 10.1016/j.preteyeres.2011.02.004
   Olsson B, 2019, JAMA NEUROL, V76, P318, DOI 10.1001/jamaneurol.2018.3746
   Olsson B, 2016, LANCET NEUROL, V15, P673, DOI [10.1016/S1474-4422(16)00070-3, 10.1016/s1474-4422(16)00070-3]
   Ong SS, 2019, J NEUROL, V266, P1566, DOI 10.1007/s00415-018-9028-z
   Paquet C, 2018, J ALZHEIMERS DIS, V64, P889, DOI 10.3233/JAD-180240
   Prakasam A, 2010, J ALZHEIMERS DIS, V20, P1243, DOI 10.3233/JAD-2010-100210
   Prasad T, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-03397-2
   Reilly S, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD008345.pub2
   Salobrar-Garcia E, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0220535
   Sasaoka M, 2006, EXP EYE RES, V83, P629, DOI 10.1016/j.exer.2006.03.007
   Saxena S, 2019, INT J RETINA VITR, V5, DOI 10.1186/s40942-019-0157-z
   Schoonenboom NSM, 2012, NEUROLOGY, V78, P47, DOI 10.1212/WNL.0b013e31823ed0f0
   Sernagor E, 2001, PROG RETIN EYE RES, V20, P139, DOI 10.1016/S1350-9462(00)00024-0
   Shah TM, 2017, MOL PSYCHIATR, V22, P353, DOI 10.1038/mp.2016.251
   Subramanian ML, 2020, ALZHEIMERS RES THER, V12, DOI 10.1186/s13195-020-00677-4
   Taniguchi T, 2004, BRAIN RES, V1013, P241, DOI 10.1016/j.brainres.2004.04.023
   Thal LJ, 2006, ALZ DIS ASSOC DIS, V20, P6, DOI 10.1097/01.wad.0000191420.61260.a8
   Tsai DC, 2015, OPHTHALMOLOGY, V122, P2327, DOI 10.1016/j.ophtha.2015.07.033
   Tsai YC, 2014, INVEST OPHTH VIS SCI, V55, P523, DOI 10.1167/iovs.13-12888
   van Wijngaarden P, 2017, CLIN EXP OPHTHALMOL, V45, P54, DOI 10.1111/ceo.12872
   Xing L, 2014, CAN J OPHTHALMOL, V49, P261, DOI 10.1016/j.jcjo.2014.03.009
   Zhang JY, 2017, DIABETES RES CLIN PR, V124, P41, DOI 10.1016/j.diabres.2016.10.024
   Zhu JM, 2021, SEMIN OPHTHALMOL, V36, P9, DOI 10.1080/08820538.2021.1883679
NR 57
TC 0
Z9 0
U1 2
U2 2
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 1663-4365
J9 FRONT AGING NEUROSCI
JI Front. Aging Neurosci.
PD NOV 3
PY 2022
VL 14
AR 1027705
DI 10.3389/fnagi.2022.1027705
PG 11
WC Geriatrics & Gerontology; Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Geriatrics & Gerontology; Neurosciences & Neurology
GA 6I3CC
UT WOS:000886005400001
PM 36408096
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Hanovice, NJ
   Leach, LL
   Slater, K
   Gabriel, AE
   Romanovicz, D
   Shao, E
   Collery, R
   Burton, EA
   Lathrop, KL
   Link, BA
   Gross, JM
AF Hanovice, Nicholas J.
   Leach, Lyndsay L.
   Slater, Kayleigh
   Gabriel, Ana E.
   Romanovicz, Dwight
   Shao, Enhua
   Collery, Ross
   Burton, Edward A.
   Lathrop, Kira L.
   Link, Brian A.
   Gross, Jeffrey M.
TI Regeneration of the zebrafish retinal pigment epithelium after
   widespread genetic ablation
SO PLOS GENETICS
LA English
DT Article
ID SIGNALING PROMOTES REGENERATION; PENETRATING EYE INJURY; STEM-CELL;
   MACULAR DEGENERATION; SODIUM IODATE; FUNDUS AUTOFLUORESCENCE;
   NITROREDUCTASE ENZYME; HEART REGENERATION; MULLER GLIA; PROLIFERATION
AB The retinal pigment epithelium (RPE) is a specialized monolayer of pigmented cells within the eye that is critical for maintaining visual system function. Diseases affecting the RPE have dire consequences for vision, and the most prevalent of these is atrophic (dry) age-related macular degeneration (AMD), which is thought to result from RPE dysfunction and degeneration. An intriguing possibility for treating RPE degenerative diseases like atrophic AMD is the stimulation of endogenous RPE regeneration; however, very little is known about the mechanisms driving successful RPE regeneration in vivo. Here, we developed a zebrafish transgenic model (rpe65a:nfsB-eGFP) that enabled ablation of large swathes of mature RPE. RPE ablation resulted in rapid RPE degeneration, as well as degeneration of Bruch's membrane and underlying photoreceptors. Using this model, we demonstrate for the first time that zebrafish are capable of regenerating a functional RPE monolayer after RPE ablation. Regenerated RPE cells first appear at the periphery of the RPE, and regeneration proceeds in a peripheral-to-central fashion. RPE ablation elicits a robust proliferative response in the remaining RPE. Subsequently, proliferative cells move into the injury site and differentiate into RPE. BrdU incorporation assays demonstrate that the regenerated RPE is likely derived from remaining peripheral RPE cells. Pharmacological disruption using IWR-1, a Wnt signaling antagonist, significantly reduces cell proliferation in the RPE and impairs overall RPE recovery. These data demonstrate that the zebrafish RPE possesses a robust capacity for regeneration and highlight a potential mechanism through which endogenous RPE regenerate in vivo.
   Author summary Diseases resulting in retinal pigment epithelium (RPE) degeneration are among the leading causes of blindness worldwide, and no therapy exists that can replace RPE or restore lost vision. One intriguing possibility is the development of therapies focused on stimulating endogenous RPE regeneration. For this to be possible, we must first gain a deeper understanding of the mechanisms underlying RPE regeneration. Here, we develop a transgenic zebrafish system through which we ablate large swathes of mature RPE and demonstrate that zebrafish regenerate RPE after widespread injury. Injury-adjacent RPE proliferate and regenerate RPE, suggesting that they are the source of regenerated tissue. Finally, we demonstrate that Wnt signaling may be involved in RPE regeneration. These findings establish a versatile in vivo model through which the molecular and cellular underpinnings of RPE regeneration can be further characterized.
C1 [Hanovice, Nicholas J.; Leach, Lyndsay L.; Slater, Kayleigh; Gabriel, Ana E.; Lathrop, Kira L.; Gross, Jeffrey M.] Univ Pittsburgh, Sch Med, Dept Ophthalmol, Louis J Fox Ctr Vis Restorat, Pittsburgh, PA 15261 USA.
   [Romanovicz, Dwight] Univ Texas Austin, Ctr Biomed Res Support, Austin, TX 78712 USA.
   [Shao, Enhua; Burton, Edward A.] Univ Pittsburgh, Pittsburgh Inst Neurodegenerat Dis, Pittsburgh, PA USA.
   [Shao, Enhua; Burton, Edward A.] Univ Pittsburgh, Sch Med, Dept Neurol, Pittsburgh, PA 15261 USA.
   [Shao, Enhua] Tsinghua Univ, Sch Med, Beijing, Peoples R China.
   [Collery, Ross; Link, Brian A.] Med Coll Wisconsin, Dept Neurobiol & Anat, Milwaukee, WI 53226 USA.
   [Burton, Edward A.] Pittsburgh VA Healthcare Syst, Geriatr Res Educ & Clin Ctr, Pittsburgh, PA USA.
   [Lathrop, Kira L.] Univ Pittsburgh, Swanson Sch Engn, Dept Bioengn, Pittsburgh, PA USA.
   [Gross, Jeffrey M.] Univ Pittsburgh, Sch Med, Dept Dev Biol, Pittsburgh, PA 15213 USA.
C3 Pennsylvania Commonwealth System of Higher Education (PCSHE); University
   of Pittsburgh; University of Texas System; University of Texas Austin;
   Pennsylvania Commonwealth System of Higher Education (PCSHE); University
   of Pittsburgh; Pennsylvania Commonwealth System of Higher Education
   (PCSHE); University of Pittsburgh; Tsinghua University; Medical College
   of Wisconsin; Geriatric Research Education & Clinical Center;
   Pennsylvania Commonwealth System of Higher Education (PCSHE); University
   of Pittsburgh; Pennsylvania Commonwealth System of Higher Education
   (PCSHE); University of Pittsburgh
RP Gross, JM (通讯作者)，Univ Pittsburgh, Sch Med, Dept Ophthalmol, Louis J Fox Ctr Vis Restorat, Pittsburgh, PA 15261 USA.; Gross, JM (通讯作者)，Univ Pittsburgh, Sch Med, Dept Dev Biol, Pittsburgh, PA 15213 USA.
EM grossjm@pitt.edu
RI Burton, Edward/ABB-1324-2021; Burton, Edward/AAO-9677-2021
OI Burton, Edward/0000-0002-8072-4636; Slater,
   Kayleigh/0000-0001-5566-8399; Hanovice, Nicholas/0000-0003-0827-6071;
   Leach, Lyndsay/0000-0002-5138-1371; Collery, Ross/0000-0002-1550-299X;
   Gabriel, Ana/0000-0001-7282-5544
FU Macular Degeneration Research Program of the Bright Focus Foundation
   [M2016067]; Charles and Louella Snyder Retinal Regeneration Fund; E.
   Ronald Salvitti Chair in Ophthalmology Research; Martha Wandrisco Neff
   Research Award in Macular Degeneration; NIH CORE Grant [P30 EY08098];
   Eye and Ear Foundation of Pittsburgh; Research to Prevent Blindness, New
   York, NY; NATIONAL EYE INSTITUTE [P30EY008098] Funding Source: NIH
   RePORTER
FX This work was supported by a grant from the Macular Degeneration
   Research Program of the Bright Focus Foundation (M2016067), the Charles
   and Louella Snyder Retinal Regeneration Fund, and the E. Ronald Salvitti
   Chair in Ophthalmology Research to JMG, the Martha Wandrisco Neff
   Research Award in Macular Degeneration to NH and LLL. This work was also
   supported by NIH CORE Grant P30 EY08098 to the Department of
   Ophthalmology, the Eye and Ear Foundation of Pittsburgh, and from an
   unrestricted grant from Research to Prevent Blindness, New York, NY. The
   funders had no role in study design, data collection and analysis,
   decision to publish, or preparation of the manuscript.
CR Adler R, 1999, MOL VIS, V5
   Al-Hussaini H, 2009, EXP EYE RES, V88, P610, DOI 10.1016/j.exer.2008.09.021
   Al-Hussaini H, 2008, MOL VIS, V14, P1784
   ANDERSON DH, 1981, INVEST OPHTH VIS SCI, V21, P10
   Ban Y, 2000, DEV BRAIN RES, V121, P89
   Becker T, 1997, J COMP NEUROL, V377, P577, DOI 10.1002/(SICI)1096-9861(19970127)377:4<577::AID-CNE8>3.0.CO;2-#
   Bernardos RL, 2007, J NEUROSCI, V27, P7028, DOI 10.1523/JNEUROSCI.1624-07.2007
   Bhutto I, 2012, MOL ASPECTS MED, V33, P295, DOI 10.1016/j.mam.2012.04.005
   Biesemeier A, 2014, NEUROBIOL AGING, V35, P2562, DOI 10.1016/j.neurobiolaging.2014.05.003
   Binder S, 2007, PROG RETIN EYE RES, V26, P516, DOI 10.1016/j.preteyeres.2007.02.002
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Booij JC, 2010, PROG RETIN EYE RES, V29, P1, DOI 10.1016/j.preteyeres.2009.08.003
   Bridgewater JA, 1995, EUR J CANCER, V31A, P2362, DOI 10.1016/0959-8049(95)00436-X
   Briona LK, 2015, DEV BIOL, V403, P15, DOI 10.1016/j.ydbio.2015.03.025
   Pastor JC, 2016, PROG RETIN EYE RES, V51, P125, DOI 10.1016/j.preteyeres.2015.07.005
   Chen BZ, 2009, NAT CHEM BIOL, V5, P100, DOI 10.1038/nchembio.137
   Chera S, 2009, DEV CELL, V17, P279, DOI 10.1016/j.devcel.2009.07.014
   Choudhary P, 2017, STEM CELL TRANSL MED, V6, P490, DOI 10.5966/sctm.2016-0088
   CLEARY PE, 1979, BRIT J OPHTHALMOL, V63, P306, DOI 10.1136/bjo.63.5.306
   CLEARY PE, 1979, BRIT J OPHTHALMOL, V63, P312, DOI 10.1136/bjo.63.5.312
   Collery RF, 2016, INVEST OPHTH VIS SCI, V57, P6805, DOI 10.1167/iovs.16-19593
   Curado S, 2007, DEV DYNAM, V236, P1025, DOI 10.1002/dvdy.21100
   Curcio CA, 1996, INVEST OPHTH VIS SCI, V37, P1236
   da Cruz L, 2018, NAT BIOTECHNOL, V36, P1, DOI 10.1038/nbt.4114
   DELPRIORE LV, 1995, ARCH OPHTHALMOL-CHIC, V113, P939, DOI 10.1001/archopht.1995.01100070113034
   Dunaief JL, 2002, ARCH OPHTHALMOL-CHIC, V120, P1435, DOI 10.1001/archopht.120.11.1435
   Fausett BV, 2006, J NEUROSCI, V26, P6303, DOI 10.1523/JNEUROSCI.0332-06.2006
   Filali M, 2002, J BIOL CHEM, V277, P33398, DOI 10.1074/jbc.M107977200
   Fujimura N, 2009, DEV BIOL, V334, P31, DOI 10.1016/j.ydbio.2009.07.002
   Gestri G, 2012, DEV NEUROBIOL, V72, P302, DOI 10.1002/dneu.20919
   Goldman D, 2014, NAT REV NEUROSCI, V15, P431, DOI 10.1038/nrn3723
   GRIERSON I, 1994, EYE, V8, P255, DOI 10.1038/eye.1994.54
   Hamann S, 2002, INT REV CYTOL, V215, P395
   Han JW, 2015, INVEST OPHTH VIS SCI, V56, P8314, DOI 10.1167/iovs.15-18359
   Hanovice NJ, 2015, INVEST OPHTH VIS SCI, V56, P7535, DOI 10.1167/iovs.15-17704
   Haynes T, 2004, CURR NEUROVASC RES, V1, P231, DOI 10.2174/1567202043362216
   Heller JP, 2014, TRANSL VIS SCI TECHN, V3, DOI 10.1167/tvst.3.4.4
   HERGOTT GJ, 1993, INVEST OPHTH VIS SCI, V34, P2761
   Herman PE, 2018, SCI REP, V8, P1, DOI [10.1038/s41598-017-17765-529311619, DOI 10.1038/S41598-017-17765-5]
   Hiscott P, 1999, PROG RETIN EYE RES, V18, P167, DOI 10.1016/S1350-9462(98)00024-X
   Holz FG, 2007, AM J OPHTHALMOL, V143, P463, DOI 10.1016/j.ajo.2006.11.041
   Iyengar S, 2015, DEV CELL, V33, P631, DOI 10.1016/j.devcel.2015.04.025
   Jackson GR, 2002, AGEING RES REV, V1, P381, DOI 10.1016/S1568-1637(02)00007-7
   JOSEPH DP, 1991, J PHYSIOL-LONDON, V435, P439, DOI 10.1113/jphysiol.1991.sp018518
   JOWETT T, 1994, TRENDS GENET, V10, P73, DOI 10.1016/0168-9525(94)90220-8
   Kamao H, 2017, INVEST OPHTH VIS SCI, V58, P211, DOI 10.1167/iovs.16-19778
   Kannan R, 2014, NEURAL REGEN RES, V9, P2044, DOI 10.4103/1673-5374.147927
   Kashani AH, 2018, SCI TRANSL MED, V10, DOI 10.1126/scitranslmed.aao4097
   Kawakami Y, 2006, GENE DEV, V20, P3232, DOI 10.1101/gad.1475106
   Kiilgaard JF, 2007, INVEST OPHTH VIS SCI, V48, P355, DOI 10.1167/iovs.05-1565
   Kikuchi K, 2010, NATURE, V464, P601, DOI 10.1038/nature08804
   Kiuchi K, 2002, CURR EYE RES, V25, P373, DOI 10.1076/ceyr.25.6.373.14227
   Klein R, 2011, ARCH OPHTHALMOL-CHIC, V129, P75, DOI 10.1001/archophthalmol.2010.318
   KNOX RJ, 1988, BIOCHEM PHARMACOL, V37, P4661, DOI 10.1016/0006-2952(88)90335-8
   KORTE GE, 1984, INVEST OPHTH VIS SCI, V25, P1135
   Kroehne V, 2011, DEVELOPMENT, V138, P4831, DOI 10.1242/dev.072587
   Kwan KM, 2007, DEV DYNAM, V236, P3088, DOI 10.1002/dvdy.21343
   LARISON KD, 1990, DEVELOPMENT, V109, P567
   Leach LL, 2015, STEM CELLS, V33, P2363, DOI 10.1002/stem.2010
   Li Y, 2006, INVEST OPHTH VIS SCI, V47, P1646, DOI 10.1167/iovs.05-1092
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Longbottom R, 2009, P NATL ACAD SCI USA, V106, P18728, DOI 10.1073/pnas.0902593106
   LOPASHOV GV, 1972, J EMBRYOL EXP MORPH, V28, P521
   LOPEZ PF, 1995, ARCH OPHTHALMOL-CHIC, V113, P1437, DOI 10.1001/archopht.1995.01100110097032
   Luz-Madrigal A, 2014, BMC BIOL, V12, DOI 10.1186/1741-7007-12-28
   Machalinska A, 2013, EXP EYE RES, V112, P68, DOI 10.1016/j.exer.2013.04.004
   MACHEMER R, 1975, AM J OPHTHALMOL, V80, P1
   MACHEMER R, 1978, AM J OPHTHALMOL, V85, P181, DOI 10.1016/S0002-9394(14)75946-X
   Mandai M, 2017, NEW ENGL J MED, V376, P1038, DOI 10.1056/NEJMoa1608368
   Maves L, 2002, DEVELOPMENT, V129, P3825
   Meyers JR, 2012, NEURAL DEV, V7, DOI 10.1186/1749-8104-7-30
   Mitchell DM, 2018, J NEUROINFLAMM, V15, DOI 10.1186/s12974-018-1185-6
   Mizota A, 1997, VISION RES, V37, P1859, DOI 10.1016/S0042-6989(97)00015-1
   NEGI A, 1984, OPHTHALMOLOGY, V91, P1678
   NEGISHI K, 1982, J NEUROSCI RES, V7, P321, DOI 10.1002/jnr.490070310
   Neuhauss SCF, 1999, J NEUROSCI, V19, P8603
   NILSSON SEG, 1977, ACTA OPHTHALMOL, V55, P1027
   Orkin SH, 2008, CELL, V132, P631, DOI 10.1016/j.cell.2008.01.025
   Osakada F, 2007, J NEUROSCI, V27, P4210, DOI 10.1523/JNEUROSCI.4193-06.2007
   Poss KD, 2000, DEV DYNAM, V219, P282, DOI 10.1002/1097-0177(2000)9999:9999<::AID-DVDY1045>3.3.CO;2-3
   Poss KD, 2002, SCIENCE, V298, P2188, DOI 10.1126/science.1077857
   Ramachandran R, 2011, J BIOL CHEM, V518, P4196, DOI [10.1002/cne.22448.Conditional, DOI 10.1002/CNE.22448.CONDITI0NAL]
   Ramachandran R, 2011, P NATL ACAD SCI USA, V108, P15858, DOI 10.1073/pnas.1107220108
   Raymond PA, 2006, BMC DEV BIOL, V6, DOI 10.1186/1471-213X-6-36
   Redfern WS, 2011, J PHARMACOL TOXICOL, V63, P102, DOI 10.1016/j.vascn.2010.06.008
   Reinhardt R, 2015, EMBO J, P1
   ROIDER J, 1992, ARCH OPHTHALMOL-CHIC, V110, P1786, DOI 10.1001/archopht.1992.01080240126045
   Salero E, 2012, CELL STEM CELL, V10, P88, DOI 10.1016/j.stem.2011.11.018
   Scheetz SD, 2018, J NEUROSCI METH, V293, P329, DOI 10.1016/j.jneumeth.2017.10.012
   Schindelin J, 2012, NAT METHODS, V9, P676, DOI [10.1038/NMETH.2019, 10.1038/nmeth.2019]
   Scholl HPN, 2004, INVEST OPHTH VIS SCI, V45, P574, DOI 10.1167/iovs.03-0495
   Schwartz SD, 2015, LANCET, V385, P509, DOI 10.1016/S0140-6736(14)61376-3
   Schwartz SD, 2012, LANCET, V379, P713, DOI 10.1016/S0140-6736(12)60028-2
   Seritrakul P, 2017, PLOS GENET, V13, DOI 10.1371/journal.pgen.1006987
   Shim SH, 2017, JAMA OPHTHALMOL, V135, P287, DOI 10.1001/jamaophthalmol.2016.5824
   Sparrow JR, 2005, EXP EYE RES, V80, P595, DOI 10.1016/j.exer.2005.01.007
   Spence JR, 2007, MOL VIS, V13, P57
   Spence JR, 2004, DEVELOPMENT, V131, P4607, DOI 10.1242/dev.01298
   Steinberg JS, 2015, JAMA OPHTHALMOL, V133, P690, DOI 10.1001/jamaophthalmol.2015.0477
   Steinfeld J, 2013, DEVELOPMENT, V140, P4959, DOI 10.1242/dev.096990
   Stenkamp DL, 2001, J COMP NEUROL, V431, P363, DOI 10.1002/1096-9861(20010319)431:4<363::AID-CNE1076>3.0.CO;2-7
   Stern J, 2015, EXP BIOL MED, V240, P1079, DOI 10.1177/1535370215587530
   Stoick-Cooper CL, 2007, DEVELOPMENT, V134, P479, DOI 10.1242/dev.001123
   Strand NS, 2016, BIOCHEM BIOPH RES CO, V477, P952, DOI 10.1016/j.bbrc.2016.07.006
   Strauss O, 2005, PHYSIOL REV, V85, P845, DOI 10.1152/physrev.00021.2004
   TSO MOM, 1973, INVEST OPHTH VISUAL, V12, P17
   Uygun Basak E., 2009, Critical Reviews in Biomedical Engineering, V37, P355
   von Leithner PL, 2010, MOL VIS, V16, P570
   Wang H, 2003, INVEST OPHTH VIS SCI, V44, P2199, DOI 10.1167/iovs.02-0435
   WEINGEIST TA, 1982, ARCH OPHTHALMOL-CHIC, V100, P1108
   Westenskow P, 2009, DEVELOPMENT, V136, P2505, DOI 10.1242/dev.032136
   Westerfield M., 1993, GUIDE LAB USE ZEBRAF
   White DT, 2017, P NATL ACAD SCI USA, V114, pE3719, DOI 10.1073/pnas.1617721114
   White DT, 2013, METHODS, V62, P232, DOI 10.1016/j.ymeth.2013.03.017
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Xia HM, 2011, EXP EYE RES, V93, P862, DOI 10.1016/j.exer.2011.09.020
   Yazulla S, 2001, J NEUROCYTOL, V30, P551, DOI 10.1023/A:1016512617484
   Yokoyama H, 2007, DEV BIOL, V306, P170, DOI 10.1016/j.ydbio.2007.03.014
   Yoshii C, 2007, DEV BIOL, V303, P45, DOI 10.1016/j.ydbio.2006.11.024
   Zhang Liyun, 2010, J Vis Exp, DOI 10.3791/2028
NR 120
TC 18
Z9 19
U1 2
U2 4
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1553-7404
J9 PLOS GENET
JI PLoS Genet.
PD JAN
PY 2019
VL 15
IS 1
AR e1007939
DI 10.1371/journal.pgen.1007939
PG 35
WC Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity
GA HJ7RR
UT WOS:000457395500044
PM 30695061
OA Green Submitted, Green Published, gold
DA 2022-11-30
ER

PT J
AU Paranthan, RR
   Bargagna-Mohan, P
   Lau, DL
   Mohan, R
AF Paranthan, Riya R.
   Bargagna-Mohan, Paola
   Lau, Daniel L.
   Mohan, Royce
TI A robust model for simultaneously inducing corneal neovascularization
   and retinal gliosis in the mouse eye
SO MOLECULAR VISION
LA English
DT Article
ID FIBRILLARY ACIDIC PROTEIN; ENDOTHELIAL GROWTH-FACTOR; GLIAL SCAR;
   ANGIOGENESIS; DISEASE; CELL; VIMENTIN; TARGETS; INFLAMMATION; ACTIVATION
AB Purpose: To develop an animal model for simultaneously eliciting corneal angiogenesis and retinal gliosis that will enable the assessment of inhibitor efficacy on these two pathological processes in separate anatomic sites of the ocular globe.
   Methods: Four to six week-old mice in a C57BL/6J background were anesthetized and 0.15 N NaOH was applied to the cornea, followed by mechanical scraping of the epithelium from limbus and central cornea. After this injury, mice were treated with vehicle or with an inhibitor (withaferin A [WFA]), which were delivered by intraperitoneal injection, to assess the pharmacological effects on angiogenesis and/or gliosis. Mice were sacrificed after 14 days and tissues (corneas and retinas) were prepared for analysis of corneal neovascularization and retinal gliosis by immunohistochemistry and western blotting, respectively. This protocol was also suited for studying earlier disease end points, for assessment of drug dose efficacy or genetic influences and the entire procedure and this analysis was completed in 16-17 days.
   Results: Both corneal angiogenesis and retinal gliosis were maximally sustained at fourteen days following chemical and mechanical injury of the cornea. 1) Injured corneas showed abundant CD31(+) staining, with new blood vessels branching out from the limbus to the central cornea. WFA treatment potently inhibited corneal neovascularization. 2) Retinal gliosis in injured mice was associated with upregulated expression of glial fibrillary acidic protein (GFAP) that appeared as polymeric filaments and soluble forms expressed in reactive Muller glial cells. WFA treatment potently downregulated the expression of soluble and filamentous GFAP; the latter protein was fragmented.
   Conclusions: We have developed a mouse model for investigating retinal gliosis and corneal neovascularization. We used this model to demonstrate the simultaneous inhibitory effects of WFA on both of these disease processes. Retinal gliosis occurs in several major degenerative conditions of the eye, including age-related macular degeneration, where angiogenesis is also a prevailing pathological feature. Thus, inhibitors of both gliosis and angiogensis used as combination therapy are currently being explored for treatment of such complex diseases. The model presented here affords a very simple preclinical assay for screening combination of drugs or polypharmacological agents and reduces the numbers of animals because of the different anatomic sites of these pathologies. Finally, given that endogenous mediators elicit angiogenesis and gliosis in this model, the combination of genetics and pharmacology can be exploited to study drug mechanisms and for target validation in vivo.
C1 [Mohan, Royce] Univ Connecticut, Ctr Hlth, Lab Chem Biol & Drug Discovery, Dept Neurosci,John A & Florence Mattern Solomon C, Farmington, CT 06030 USA.
   [Paranthan, Riya R.; Lau, Daniel L.] Univ Kentucky, Lexington, KY USA.
C3 University of Connecticut; University of Kentucky
RP Mohan, R (通讯作者)，Univ Connecticut, Ctr Hlth, Lab Chem Biol & Drug Discovery, Dept Neurosci,John A & Florence Mattern Solomon C, E3032,263 Farmington Ave, Farmington, CT 06030 USA.
EM mohan@uchc.edu
RI Lau, Daniel L/O-5169-2014
OI Lau, Daniel L/0000-0003-1377-4622
FU NIH [R01EY016782, R01 CA131059]; John A. and Florence Mattern Solomon
   Chair endowment funds; NATIONAL CANCER INSTITUTE [R01CA131059] Funding
   Source: NIH RePORTER; NATIONAL EYE INSTITUTE [R01EY016782] Funding
   Source: NIH RePORTER
FX We thank A. Pearson and J. Ambati for useful discussions. This work is
   supported in part by NIH grants R01EY016782 and R01 CA131059 and John A.
   and Florence Mattern Solomon Chair endowment funds to R.M.
CR Adams RH, 2007, NAT REV MOL CELL BIO, V8, P464, DOI 10.1038/nrm2183
   Amano S, 1998, INVEST OPHTH VIS SCI, V39, P18
   Anderson OA, 2010, DRUG DISCOV TODAY, V15, P272, DOI 10.1016/j.drudis.2010.02.004
   Bargagna-Mohan P, 2007, CHEM BIOL, V14, P623, DOI 10.1016/j.chembiol.2007.04.010
   Bargagna-Mohan P, 2006, INVEST OPHTH VIS SCI, V47, P4138, DOI 10.1167/iovs.05-1452
   Bargagna-Mohan P, 2010, J BIOL CHEM, V285, P7657, DOI 10.1074/jbc.M109.093765
   Bates KA, 2002, NEUROSCIENCE, V113, P785, DOI 10.1016/S0306-4522(02)00230-0
   Carmeliet P, 2003, NAT REV GENET, V4, P710, DOI 10.1038/nrg1158
   Carmeliet P, 2000, NATURE, V407, P249, DOI 10.1038/35025220
   Dyer MA, 2000, NAT NEUROSCI, V3, P873, DOI 10.1038/78774
   FIGG WD, 2008, ANGIOGENESIS INTEGRA, P35
   Fisher SK, 2003, VISION RES, V43, P887, DOI 10.1016/S0042-6989(02)00680-6
   FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27
   Friedlander M, 2007, J CLIN INVEST, V117, P576, DOI 10.1172/JCI31030
   Ganesh BS, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018305
   Gariano RF, 2005, NATURE, V438, P960, DOI 10.1038/nature04482
   Guyton MK, 2010, J NEUROSCI RES, V88, P2398, DOI 10.1002/jnr.22408
   Kalaria RN, 2002, CEREBROVASC DIS, V13, P48, DOI 10.1159/000049150
   Knight ZA, 2007, CELL, V128, P425, DOI 10.1016/j.cell.2007.01.021
   Lewis GP, 2010, MOL VIS, V16, P1361
   Menet V, 2001, J NEUROSCI, V21, P6147
   Mohan Royce, 2004, Angiogenesis, V7, P115, DOI 10.1007/s10456-004-1026-3
   Pekny M, 2005, GLIA, V50, P427, DOI 10.1002/glia.20207
   Petrukhin K, 2007, EXPERT OPIN THER TAR, V11, P625, DOI 10.1517/14728222.11.5.625
   Ribatti D, 2008, ENDOTHELIUM-J ENDOTH, V15, P1, DOI 10.1080/10623320802092377
   Rogers MS, 2007, NAT PROTOC, V2, P2545, DOI 10.1038/nprot.2007.368
   Silver J, 2004, NAT REV NEUROSCI, V5, P146, DOI 10.1038/nrn1326
   Sueishi Katsuo, 1996, Polish Journal of Pharmacology, V48, P307
   Tonnesen MG, 2000, J INVEST DERM SYMP P, V5, P40, DOI 10.1046/j.1087-0024.2000.00014.x
   Wu KHC, 2003, BRIT J OPHTHALMOL, V87, P1159, DOI 10.1136/bjo.87.9.1159
NR 30
TC 17
Z9 18
U1 0
U2 1
PU MOLECULAR VISION
PI ATLANTA
PA C/O JEFF BOATRIGHT, LAB B, 5500 EMORY EYE CENTER, 1327 CLIFTON RD, N E,
   ATLANTA, GA 30322 USA
SN 1090-0535
J9 MOL VIS
JI Mol. Vis.
PD JUL 14
PY 2011
VL 17
IS 205-07
BP 1901
EP 1908
PG 8
WC Biochemistry & Molecular Biology; Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Ophthalmology
GA 792EY
UT WOS:000292724500003
PM 21850164
DA 2022-11-30
ER

PT J
AU Dong, L
   He, WJ
   Zhang, RH
   Ge, ZY
   Wang, YX
   Zhou, JQ
   Xu, J
   Shao, L
   Wang, Q
   Yan, YN
   Xie, Y
   Fang, LJ
   Wang, HW
   Wang, YA
   Zhu, XB
   Wang, JY
   Zhang, C
   Wang, H
   Wang, YN
   Chen, RT
   Wan, QQ
   Yang, JY
   Zhou, WD
   Li, HY
   Yao, X
   Yang, ZW
   Xiong, JH
   Wang, X
   Huang, YL
   Chen, YZ
   Wang, ZH
   Rong, C
   Gao, JX
   Zhang, HL
   Wu, SL
   Jonas, JB
   Wei, WB
AF Dong, Li
   He, Wanji
   Zhang, Ruiheng
   Ge, Zongyuan
   Wang, Ya Xing
   Zhou, Jinqiong
   Xu, Jie
   Shao, Lei
   Wang, Qian
   Yan, Yanni
   Xie, Ying
   Fang, Lijian
   Wang, Haiwei
   Wang, Yenan
   Zhu, Xiaobo
   Wang, Jinyuan
   Zhang, Chuan
   Wang, Heng
   Wang, Yining
   Chen, Rongtian
   Wan, Qianqian
   Yang, Jingyan
   Zhou, Wenda
   Li, Heyan
   Yao, Xuan
   Yang, Zhiwen
   Xiong, Jianhao
   Wang, Xin
   Huang, Yelin
   Chen, Yuzhong
   Wang, Zhaohui
   Rong, Ce
   Gao, Jianxiong
   Zhang, Huiliang
   Wu, Shouling
   Jonas, Jost B.
   Wei, Wen Bin
TI Artificial Intelligence for Screening of Multiple Retinal and Optic
   Nerve Diseases
SO JAMA NETWORK OPEN
LA English
DT Article
ID DIABETIC-RETINOPATHY; VALIDATION; SYSTEM
AB IMPORTANCE The lack of experienced ophthalmologists limits the early diagnosis of retinal diseases. Artificial intelligence can be an efficient real-time way for screening retinal diseases.
   OBJECTIVE To develop and prospectively validate a deep learning (DL) algorithm that, based on ocular fundus images, recognizes numerous retinal diseases simultaneously in clinical practice.
   DESIGN, SETTING, AND PARTICIPANTS This multicenter, diagnostic study at 65 public medical screening centers and hospitals in 19 Chinese provinces included individuals attending annual routine medical examinations and participants of population-based and community-based studies.
   EXPOSURES Based on 120 002 ocular fundus photographs, the Retinal Artificial Intelligence Diagnosis System (RAIDS) was developed to identify 10 retinal diseases. RAIDS was validated in a prospective collected data set, and the performance between RAIDS and ophthalmologists was compared in the data sets of the population-based Beijing Eye Study and the community-based Kailuan Eye Study.
   MAIN OUTCOMES AND MEASURES The performance of each classifier included sensitivity, specificity, accuracy, Fl score, and Cohen K score.
   RESULTS In the prospective validation data set of 208 758 images collected from 110 784 individuals (median [range] age, 42 [8-87] years; 115 443 [55.3%] female), RAIDS achieved a sensitivity of 89.8% (95% CI, 89.5%-90.1%) to detect any of 10 retinal diseases. RAIDS differentiated 10 retinal diseases with accuracies ranging from 95.3% to 99.9%, without marked differences between medical screening centers and geographical regions in China. Compared with retinal specialists, RAIDS achieved a higher sensitivity for detection of any retinal abnormality (RAIDS, 91.7% [95% CI, 90.6%-92.8%]; certified ophthalmologists. 83.7% [95% CI, 82.1%-85.1%]; junior retinal specialists, 86.4% [95% CI, 84.9%-87.7%]; and senior retinal specialists, 88.5% [95% CI, 87.1%-89.8%]). RAIDS reached a superior or similar diagnostic sensitivity compared with senior retinal specialists in the detection of 7 of 10 retinal diseases (ie, referral diabetic retinopathy, referral possible glaucoma, macular hole, epiretinal macular membrane, hypertensive retinopathy, myelinated fibers, and retinitis pigmentosa). It achieved a performance comparable with the performance by certified ophthalmologists in 2 diseases (ie, age-related macular degeneration and retinal vein occlusion). Compared with ophthalmologists, RAIDS needed 96% to 97% less time for the image assessment.
   CONCLUSIONS AND RELEVANCE In this diagnostic study, the DL system was associated with accurately distinguishing10 retinal diseases in real time. This technology may help overcome the lack of experienced ophthalmologists in underdeveloped areas.
C1 [Dong, Li; Zhang, Ruiheng; Zhou, Jinqiong; Shao, Lei; Wang, Qian; Yan, Yanni; Xie, Ying; Fang, Lijian; Wang, Haiwei; Wang, Yenan; Zhu, Xiaobo; Wang, Jinyuan; Zhang, Chuan; Wang, Heng; Wang, Yining; Chen, Rongtian; Yang, Jingyan; Zhou, Wenda; Li, Heyan; Wei, Wen Bin] Capital Med Univ, Beijing Tongren Hosp,Med Artificial Intelligence, Minist Ind & Informat Technol,Beijing Tongren Eye, Beijing Key Lab Intraocular Tumor Diag & Treatmen, Beijing, Peoples R China.
   [He, Wanji; Yao, Xuan; Yang, Zhiwen; Xiong, Jianhao; Wang, Xin; Huang, Yelin; Chen, Yuzhong] Beijing Airdoc Technol Co Ltd, Beijing, Peoples R China.
   [Ge, Zongyuan] Monash Univ, eRes Ctr, Melbourne, Vic, Australia.
   [Ge, Zongyuan] Monash Univ, Fac Engn, ECSE, Melbourne, Vic, Australia.
   [Wang, Ya Xing; Xu, Jie] Capital Med Univ, Beijing Tongren Hosp, Beijing Tongren Eye Ctr, Beijing Inst Ophthalmol,Beijing Ophthalmol & Visu, Beijing, Peoples R China.
   [Xie, Ying] Shanxi Prov Peoples Hosp, Dept Ophthalmol, Taiyuan, Peoples R China.
   [Fang, Lijian] Capital Med Univ, Beijing Liangxiang Hosp, Dept Ophthalmol, Beijing, Peoples R China.
   [Wang, Haiwei] Capital Med Univ, Fuxing Hosp, Dept Ophthalmol, Beijing, Peoples R China.
   [Wang, Yenan] Capital Med Univ, Xuanwu Hosp, Dept Ophthalmol, Beijing, Peoples R China.
   [Zhu, Xiaobo] Beijing Univ Chinese Med, Dongfang Hosp, Dept Ophthalmol, Beijing, Peoples R China.
   [Wan, Qianqian] Anhui Med Univ, Dept Ophthalmol, Affiliated Hosp 2, Hefei, Peoples R China.
   [Wang, Zhaohui; Rong, Ce; Gao, Jianxiong; Zhang, Huiliang] iKang Guobin Healthcare Grp Co Ltd, Beijing, Peoples R China.
   [Wu, Shouling] Kailuan Gen Hosp, Dept Cardiol, Tangshan, Hebei, Peoples R China.
   [Jonas, Jost B.] Heidelberg Univ, Med Fac Mannheim, Dept Ophthalmol, Mannheim, Germany.
   [Jonas, Jost B.] Inst Mol & Clin Ophthalmol Basel, Basel, Switzerland.
C3 Capital Medical University; Monash University; Monash University;
   Capital Medical University; Shanxi People's Hospital; Capital Medical
   University; Capital Medical University; Capital Medical University;
   Beijing University of Chinese Medicine; Anhui Medical University;
   Ruprecht Karls University Heidelberg
RP Wei, WB (通讯作者)，Beijing Tongren Eye Ctr, 1 Dong Jiao Min Lane, Beijing 100730, Peoples R China.
EM weiwenbintr@163.com
RI xu, jie/GQR-1913-2022; Xu, Jie/AIE-0524-2022
OI xu, jie/0000-0002-2039-7055; Ge, Zongyuan/0000-0002-5880-8673
FU Capital Health Research and Development of Special [2020-12052,
   Z201100005520045, Z181100001818003]; Science and Technology Project of
   Beijing Municipal Science and Technology Commission
FX This study was supported by the Capital Health Research and Development
   of Special (2020-12052); and grant Z201100005520045 and grant
   Z181100001818003 Science and Technology Project of Beijing Municipal
   Science and Technology Commission.
CR Bock R, 2010, MED IMAGE ANAL, V14, P471, DOI 10.1016/j.media.2009.12.006
   Brown JM, 2018, JAMA OPHTHALMOL, V136, P803, DOI 10.1001/jamaophthalmol.2018.1934
   Choi JY, 2017, PLOS ONE, V12, DOI [10.1371/journal.pone.0187338, 10.1371/journal.pone.0187336]
   Grassmann F, 2018, OPHTHALMOLOGY, V125, P1410, DOI 10.1016/j.ophtha.2018.02.037
   Gulshan V, 2016, JAMA-J AM MED ASSOC, V316, P2402, DOI 10.1001/jama.2016.17216
   He JJ, 2021, BIOMED SIGNAL PROCES, V63, DOI 10.1016/j.bspc.2020.102167
   Hemelings R, 2020, ACTA OPHTHALMOL, V98, pE94, DOI 10.1111/aos.14193
   Jiang P, 2020, TRANSL VIS SCI TECHN, V9, DOI 10.1167/tvst.9.2.39
   Kanclerz P, 2019, LANCET GLOB HEALTH, V7, pE1490, DOI 10.1016/S2214-109X(19)30395-X
   Keenan TD, 2019, OPHTHALMOLOGY, V126, P1533, DOI 10.1016/j.ophtha.2019.06.005
   Kim KM, 2021, J PERS MED, V11, DOI 10.3390/jpm11050321
   Lee AY, 2021, DIABETES CARE, V44, P1168, DOI 10.2337/dc20-1877
   Li B, 2022, BRIT J OPHTHALMOL, V106, P1079, DOI 10.1136/bjophthalmol-2020-316290
   Li ZX, 2018, DIABETES CARE, V41, P2509, DOI 10.2337/dc18-0147
   Li ZX, 2018, OPHTHALMOLOGY, V125, P1199, DOI 10.1016/j.ophtha.2018.01.023
   Lin DR, 2021, LANCET DIGIT HEALTH, V3, pE486, DOI 10.1016/S2589-7500(21)00086-8
   Mao JB, 2020, ACTA OPHTHALMOL, V98, pE339, DOI 10.1111/aos.14264
   Milea D, 2020, NEW ENGL J MED, V382, P1687, DOI 10.1056/NEJMoa1917130
   Peng YF, 2019, OPHTHALMOLOGY, V126, P565, DOI 10.1016/j.ophtha.2018.11.015
   Redd TK, 2019, BRIT J OPHTHALMOL, V103, P580, DOI 10.1136/bjophthalmol-2018-313156
   Redmon J., 2018, COMPUTER VISION PATT
   Resnikoff S, 2020, BRIT J OPHTHALMOL, V104, P588, DOI 10.1136/bjophthalmol-2019-314336
   Sayres R, 2019, OPHTHALMOLOGY, V126, P552, DOI 10.1016/j.ophtha.2018.11.016
   Selvaraju RR, 2020, INT J COMPUT VISION, V128, P336, DOI 10.1007/s11263-019-01228-7
   Son J, 2020, OPHTHALMOLOGY, V127, P85, DOI 10.1016/j.ophtha.2019.05.029
   Steinmetz JD, 2021, LANCET GLOB HEALTH, V9, pE144, DOI 10.1016/S2214-109X(20)30489-7
   Stevenson CH, 2019, CLIN EXP OPHTHALMOL, V47, P484, DOI 10.1111/ceo.13433
   Tan TE, 2021, LANCET DIGIT HEALTH, V3, pE317, DOI 10.1016/S2589-7500(21)00055-8
   Ting DSW, 2019, PROG RETIN EYE RES, V72, DOI 10.1016/j.preteyeres.2019.04.003
   Ting DSW, 2017, JAMA-J AM MED ASSOC, V318, P2211, DOI 10.1001/jama.2017.18152
   Varadarajan AV, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-019-13922-8
   Wong TY, 2018, OPHTHALMOLOGY, V125, P1608, DOI 10.1016/j.ophtha.2018.04.007
   Yan YN, 2018, OPHTHALMOLOGY, V125, P1253, DOI 10.1016/j.ophtha.2018.01.035
   Zhu XB, 2020, INVEST OPHTH VIS SCI, V61, DOI 10.1167/iovs.61.11.37
NR 34
TC 4
Z9 3
U1 2
U2 3
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 2574-3805
J9 JAMA NETW OPEN
JI JAMA Netw. Open
PD MAY 3
PY 2022
VL 5
IS 5
AR e229960
DI 10.1001/jamanetworkopen.2022.9960
PG 12
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA 1A0WP
UT WOS:000791487600003
PM 35503220
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Campbell, RJ
   Bell, CM
   Paterson, JM
   Bronskill, SE
   Moineddin, R
   Whitehead, M
   Gill, SS
AF Campbell, Robert J.
   Bell, Chaim M.
   Paterson, J. Michael
   Bronskill, Susan E.
   Moineddin, Rahim
   Whitehead, Marlo
   Gill, Sudeep S.
TI Stroke Rates after Introduction of Vascular Endothelial Growth Factor
   Inhibitors for Macular Degeneration: A Time Series Analysis
SO OPHTHALMOLOGY
LA English
DT Article
ID ARTERIAL THROMBOEMBOLIC EVENTS; MYOCARDIAL-INFARCTION; RANIBIZUMAB;
   INTERVENTIONS; BEVACIZUMAB; DISEASES; RISK
AB Objective: To assess whether stroke rates among patients with retinal disease were influenced by the rapid and sequential uptakes of bevacizumab and ranibizumab for age-related macular degeneration (AMD).
   Design: Population-based, time series analysis using encrypted, linked healthcare databases in Ontario, Canada.
   Participants: We included all patients aged 66 years or older with physician-diagnosed retinal disease in the previous 5 years between 2002 and 2010 (N = 116 388). A secondary analysis evaluated patients who had undergone photodynamic therapy (PDT) within the preceding year (N = 10 059).
   Methods: We used segmented regression analysis to evaluate changes in the rate of hospitalization for ischemic stroke associated with the introduction of bevacizumab and ranibizumab. The stroke rate was compared across 3 mutually exclusive periods: the period before the availability of bevacizumab or ranibizumab, the period of bevacizumab dominant AMD therapy, and the period of ranibizumab dominant AMD therapy.
   Main Outcome Measures: Hospitalizations for ischemic stroke.
   Results: Among patients with retinal disease, neither the trend nor the level of the stroke time series changed with the uptake of bevacizumab (trend change coefficient -0.0026 stroke hospitalizations/1000 subjects/month [95% confidence interval {CI}, -0.0066 to 0.0014; P = 0.20]; level change coefficient, 0.036 stroke hospitalizations/1000 subjects [95% CI, -0.070 to 0.14; P = 0.51]), or ranibizumab (trend change coefficient: -0.0011 stroke hospitalizations/1000 subjects/month [95% CI, -0.0087 to 0.0065; P = 0.78]; level change coefficient: -0.017 stroke hospitalizations/1000 subjects [95% CI, -0.14 to 0.11; P = 0.79]). Similar results were observed in the analysis restricted to patients with recent PDT and in analyses stratified on age, sex, history of stroke, and history of diabetes.
   Conclusions: The rapid uptake of vascular endothelial growth factor (VEGF) inhibitors for AMD was not associated with a change in the rate of hospitalization for stroke among Ontario seniors with retinal disease. Furthermore, stroke rates in the bevacizumab and ranibizumab periods were not different. These population-level results complement the findings of a recently published trial comparing bevacizumab and ranibizumab, and may assist clinicians and policy makers as they balance the comparative efficacy, safety, and cost of these 2 closely related treatments.
   Financial Disclosure(s): The author(s) have no proprietary or commercial interest in any materials discussed in this article. Ophthalmology 2012;119:1604-1608 (C) 2012 by the American Academy of Ophthalmology.
C1 [Campbell, Robert J.] Hop Hotel Dieu, Dept Ophthalmol, Kingston, ON K7L 5G2, Canada.
   [Campbell, Robert J.] Queens Univ, Dept Ophthalmol, Kingston, ON, Canada.
   [Gill, Sudeep S.] Queens Univ, Div Geriatr Med, Kingston, ON, Canada.
   [Bell, Chaim M.; Moineddin, Rahim] Univ Toronto, Dept Med, Toronto, ON, Canada.
   [Bell, Chaim M.; Paterson, J. Michael; Bronskill, Susan E.] Univ Toronto, Dept Hlth Policy Management & Evaluat, Toronto, ON, Canada.
   [Bell, Chaim M.] St Michaels Hosp, Keenan Res Ctr, Li Ka Shing Knowledge Inst, Toronto, ON M5B 1W8, Canada.
   [Bell, Chaim M.] St Michaels Hosp, Dept Med, Toronto, ON M5B 1W8, Canada.
   [Gill, Sudeep S.] St Marys Lake Hosp, Div Geriatr Med, Kingston, ON, Canada.
   [Moineddin, Rahim] Univ Toronto, Dept Family & Community Med, Toronto, ON M5S 1A1, Canada.
   [Paterson, J. Michael] McMaster Univ, Dept Family Med, Hamilton, ON L8S 4L8, Canada.
C3 Queens University - Canada; Queens University - Canada; Queens
   University - Canada; University of Toronto; University of Toronto;
   University of Toronto; Li Ka Shing Knowledge Institute; University
   Toronto Affiliates; Saint Michaels Hospital Toronto; University of
   Toronto; University Toronto Affiliates; Saint Michaels Hospital Toronto;
   University of Toronto; McMaster University
RP Campbell, RJ (通讯作者)，Hop Hotel Dieu, Dept Ophthalmol, 166 Brock St, Kingston, ON K7L 5G2, Canada.
EM rob.campbell@queensu.ca
RI Bell, Chaim/C-4611-2015
OI Bell, Chaim/0000-0002-3778-9469
FU Canadian Institutes of Health Research [MOP 106693]; Ontario Ministry of
   Health and Long-Term Care; Southeastern Ontario Academic Medical
   Organization; Canadian Institutes of Health Research from the Institute
   of Aging; Canadian Patient Safety Institute chair in Patient Safety and
   Continuity of Care; Institute for Clinical Evaluative Sciences
FX This study was funded by research grants from the Canadian Institutes of
   Health Research (Funding Reference Number: MOP 106693) and the Drug
   Innovation Fund of the Ontario Ministry of Health and Long-Term Care.
   Dr. Campbell is supported by a Clinician Scientist Award from the
   Southeastern Ontario Academic Medical Organization. Drs. Gill and
   Bronskill are supported by Canadian Institutes of Health Research New
   Investigator Awards from the Institute of Aging. Dr. Bell is supported
   by a Canadian Institutes of Health Research and Canadian Patient Safety
   Institute chair in Patient Safety and Continuity of Care.; The sponsors
   of this study had no role in the design and conduct of the study;
   collection, management, analysis, and interpretation of the data;
   preparation, review, or approval of the manuscript; and the decision to
   submit for publication. This study was supported by the Institute for
   Clinical Evaluative Sciences, which is funded by an annual grant from
   the Ontario Ministry of Health and Long-Term Care. The opinions,
   results, and conclusions reported in this article are those of the
   authors and are independent from the funding sources. No endorsement by
   the Institute for Clinical Evaluative Sciences or the Ontario Ministry
   of Health and Long-Term Care is intended or should be inferred.
CR Alexander SL, 2007, OPHTHALMOLOGY, V114, P2174, DOI 10.1016/j.ophtha.2007.09.017
   Campbell RJ, 2010, ARCH OPHTHALMOL-CHIC, V128, P359, DOI 10.1001/archophthalmol.2010.19
   Curtis LH, 2010, ARCH OPHTHALMOL-CHIC, V128, P1273, DOI 10.1001/archophthalmol.2010.223
   Duan YK, 2007, OPHTHALMOLOGY, V114, P732, DOI 10.1016/j.ophtha.2006.07.045
   Hoffmann F., 2011, ROCH BUS REP 2011, P66
   Hux JE, 2002, DIABETES CARE, V25, P512, DOI 10.2337/diacare.25.3.512
   Juurlink D., 2006, CANADIAN I HLTH INFO
   Klein R, 2003, OPHTHALMOLOGY, V110, P636, DOI 10.1016/S0161-6420(02)01448-3
   Kokotailo RA, 2005, STROKE, V36, P1776, DOI 10.1161/01.STR.0000174293.17959.a1
   Levy Adrian R, 2003, Can J Clin Pharmacol, V10, P67
   Mamdani M, 2005, BMJ-BRIT MED J, V330, P960, DOI 10.1136/bmj.330.7497.960
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   McLeod AI, 2008, ACCIDENT ANAL PREV, V40, P1244, DOI 10.1016/j.aap.2007.10.007
   Nguyen-Khoa BA, 2008, ARCH OPHTHALMOL-CHIC, V126, P1280, DOI 10.1001/archopht.126.9.1280
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Scappaticci FA, 2007, JNCI-J NATL CANCER I, V99, P1232, DOI 10.1093/jnci/djm086
   Sun C, 2009, OPHTHALMOLOGY, V116, P1913, DOI 10.1016/j.ophtha.2009.03.046
   Tu Karen, 2007, Open Med, V1, pe18
   Tufail A, 2010, BRIT MED J, V340, pc2459
   Ueta T, 2009, OPHTHALMOLOGY, V116, P362, DOI 10.1016/j.ophtha.2008.09.046
   Wagner AK, 2002, J CLIN PHARM THER, V27, P299, DOI 10.1046/j.1365-2710.2002.00430.x
   Williams J., 1996, PATTERNS HLTH CARE O, P339
   Wong TY, 2006, ANN INTERN MED, V145, P98, DOI 10.7326/0003-4819-145-2-200607180-00007
   Zhang F, 2011, J CLIN EPIDEMIOL, V64, P1252, DOI 10.1016/j.jclinepi.2011.02.007
NR 24
TC 35
Z9 35
U1 0
U2 6
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD AUG
PY 2012
VL 119
IS 8
BP 1604
EP 1608
DI 10.1016/j.ophtha.2012.05.028
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 982YA
UT WOS:000307080100017
PM 22717458
DA 2022-11-30
ER

PT J
AU Li, J
   Yu, SS
   Lu, X
   Cui, KX
   Tang, XY
   Xu, Y
   Liang, XL
AF Li, Jia
   Yu, Shanshan
   Lu, Xi
   Cui, Kaixuan
   Tang, Xiaoyu
   Xu, Yue
   Liang, Xiaoling
TI The phase changes of M1/M2 phenotype of microglia/macrophage following
   oxygen-induced retinopathy in mice
SO INFLAMMATION RESEARCH
LA English
DT Article
DE Microglia; macrophage polarization; Retinal neovascularization;
   Inflammation cytokines; Oxygen-induced retinopathy
ID MOUSE MODEL; ALTERNATIVE ACTIVATION; MICROGLIAL ACTIVATION; MACROPHAGES;
   CELLS; STAT3; NEOVASCULARIZATION; INFLAMMATION; EXPRESSION; SEVERITY
AB Objective Microglia/macrophage activation is previously reported to be involved in various ocular diseases. However, the separate role of M1/M2 phenotype microglia/macrophage in the pathological process of oxygen-induced retinopathy (OIR) remains unknown. In this research, we explored the role and regulatory mechanism of M1/M2 microglia/macrophage in OIR in C57BL/6J mice. Furthermore, we demonstrated the time phase of M1/M2 shifting of microglia/macrophage during the natural process of OIR, which is very essential for further investigations. Materials and methods C57BL/6j pups were exposed to hyperoxia environment from postnatal 7(P7) to P12 then returned to normoxia. The mice were then euthanized, and the eyes were harvested at a series of time points for further investigation. The M1/M2 phenotype microglia/macrophage activity was presented by immunofluorescent staining and real-time quantitative polymerase chain reaction (qPCR). The NF-kappa b-STAT3 signaling and IL-4-STAT6-PPAR-gamma signaling pathway activity was examined by western blot analysis. Results The microglia/macrophage were activated when the OIR model was set up after P12. The M1 microglia/macrophage activation was found in neovascularization (NV) tufts in both central and peripheral retina, which started from P12 when the mice were returned to normoxia environment and peaked at P17. During this period of time, the NF-kappa b-STAT3 signaling pathway was activated, resulting in the upregulated M1 phenotype microglia/macrophage polarization, along with the enhanced inflammatory cytokine expression including tumor necrosis factor-alpha (TNF-alpha), interleukin-6 (IL-6), and IL-1 beta. Consequently, the NV tufts were observed from P12 and the volume continued to increase until P17. However, the M2 phenotype microglia/macrophage activity took over during the late phase of OIR started from P17. The IL-4-STAT6-PPAR-gamma signaling activity was upregulated from P17 and peaked at P20, inducing M2 phenotype microglia polarization, which consequently led to the inhibition of inflammatory cytokines and spontaneous regression of NV tufts. Conclusions Microglia/macrophage participate actively in the natural process of OIR in mice, and two phenotypes exert different functions. Treatment modulating microglia/macrophage polarize toward M2 phenotype might be a novel and promising method for ocular neovascular diseases such as retinopathy of prematurity (ROP), wet age-related macular degeneration (wAMD), and diabetic retinopathy (DR).
C1 [Li, Jia; Yu, Shanshan; Lu, Xi; Cui, Kaixuan; Tang, Xiaoyu; Xu, Yue; Liang, Xiaoling] Sun Yat Sen Univ, Zhongshan Ophthalm Ctr, State Key Lab Ophthalmol, Guangzhou 510030, Guangdong, Peoples R China.
C3 Sun Yat Sen University
RP Xu, Y; Liang, XL (通讯作者)，Sun Yat Sen Univ, Zhongshan Ophthalm Ctr, State Key Lab Ophthalmol, Guangzhou 510030, Guangdong, Peoples R China.
EM xuyueeye@163.com; liangxlsums@qq.com
RI yu, shanshan/AIC-2220-2022
OI yu, shanshan/0000-0001-6182-8328
FU national natural science foundation of China [81870668]; Young Scientist
   Fund of the National Natural Science Foundation of China [81900864]
FX This research is supported by the national natural science foundation of
   China (No. 81870668), and the Young Scientist Fund of the National
   Natural Science Foundation of China (No. 81900864).
CR Balce DR, 2011, BLOOD, V118, P4199, DOI 10.1182/blood-2011-01-328906
   Bollrath J, 2009, CANCER CELL, V15, P91, DOI 10.1016/j.ccr.2009.01.002
   Bosco A, 2011, J COMP NEUROL, V519, P599, DOI 10.1002/cne.22516
   Brandenburg S, 2016, ACTA NEUROPATHOL, V131, P365, DOI 10.1007/s00401-015-1529-6
   Connor KM, 2007, NAT MED, V13, P868, DOI 10.1038/nm1591
   Dagkalis A, 2009, IMMUNOLOGY, V128, P25, DOI 10.1111/j.1365-2567.2009.03046.x
   Daniel B, 2018, NUCLEIC ACIDS RES, V46, P4425, DOI 10.1093/nar/gky157
   David S, 2011, NAT REV NEUROSCI, V12, P388, DOI 10.1038/nrn3053
   Dong HQ, 2017, MOL NEUROBIOL, V54, P997, DOI 10.1007/s12035-016-9720-x
   Egholm C, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02507
   Fischer F, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-120
   Gallego BI, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-92
   Ginhoux F, 2010, SCIENCE, V330, P841, DOI 10.1126/science.1194637
   Glass CK, 2016, NAT IMMUNOL, V17, P26, DOI 10.1038/ni.3306
   Grivennikov S, 2009, CANCER CELL, V15, P103, DOI 10.1016/j.ccr.2009.01.001
   Haage V, 2019, ACTA NEUROPATHOL COM, V7, DOI 10.1186/s40478-019-0665-y
   Han RR, 2016, J NEUROINFLAMM, V13, DOI 10.1186/s12974-016-0559-x
   Lange C, 2009, GRAEF ARCH CLIN EXP, V247, P1205, DOI 10.1007/s00417-009-1116-4
   Luo YM, 2006, J NEUROCHEM, V97, P435, DOI 10.1111/j.1471-4159.2006.03758.x
   Ma WX, 2019, ELIFE, V8, DOI 10.7554/eLife.42049
   Mantovani A, 2008, NATURE, V454, P436, DOI 10.1038/nature07205
   Mantovani A, 2013, J PATHOL, V229, P176, DOI 10.1002/path.4133
   Martinez FO, 2009, ANNU REV IMMUNOL, V27, P451, DOI 10.1146/annurev.immunol.021908.132532
   Michelucci A, 2009, J NEUROIMMUNOL, V210, P3, DOI 10.1016/j.jneuroim.2009.02.003
   Oh H, 2019, J AGR FOOD CHEM, V67, P10069, DOI 10.1021/acs.jafc.9b03926
   Okunuki Y, 2018, P NATL ACAD SCI USA, V115, pE6264, DOI 10.1073/pnas.1719601115
   Pisanu A, 2014, NEUROBIOL DIS, V71, P280, DOI 10.1016/j.nbd.2014.08.011
   Ransohoff RM, 2009, ANNU REV IMMUNOL, V27, P119, DOI 10.1146/annurev.immunol.021908.132528
   Rathnasamy G, 2019, PROG NEUROBIOL, V173, P18, DOI 10.1016/j.pneurobio.2018.05.006
   SMITH LEH, 1994, INVEST OPHTH VIS SCI, V35, P101
   Stahl A, 2010, AM J PATHOL, V177, P2715, DOI 10.2353/ajpath.2010.100526
   Szabo M, 2013, NEUROSCIENCE, V241, P280, DOI 10.1016/j.neuroscience.2013.03.033
   Takeda A, 2018, GLIA, V66, P2366, DOI 10.1002/glia.23475
   Telegina DV, 2018, BIOCHEMISTRY-MOSCOW+, V83, P1009, DOI 10.1134/S000629791809002X
   Villacampa P, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0179759
   Xu Y, 2020, J PINEAL RES, V69, DOI 10.1111/jpi.12660
   Xu Y, 2018, J PINEAL RES, V64, DOI 10.1111/jpi.12473
   Yang BY, 2016, INFLAMM RES, V65, P81, DOI 10.1007/s00011-015-0894-x
   Yin Z, 2018, J CELL BIOCHEM, V119, P9419, DOI 10.1002/jcb.27259
   Yu H, 2009, NAT REV CANCER, V9, P798, DOI 10.1038/nrc2734
   Zhang LJ, 2018, MOL THER, V26, P1953, DOI 10.1016/j.ymthe.2018.06.014
   Zhao QY, 2016, J NEUROINFLAMM, V13, DOI 10.1186/s12974-016-0728-y
   Zheng HD, 2020, MUCOSAL IMMUNOL, V13, P293, DOI 10.1038/s41385-019-0236-3
   ZHONG Z, 1994, SCIENCE, V264, P95, DOI 10.1126/science.8140422
NR 44
TC 17
Z9 17
U1 0
U2 7
PU SPRINGER BASEL AG
PI BASEL
PA PICASSOPLATZ 4, BASEL, 4052, SWITZERLAND
SN 1023-3830
EI 1420-908X
J9 INFLAMM RES
JI Inflamm. Res.
PD FEB
PY 2021
VL 70
IS 2
BP 183
EP 192
DI 10.1007/s00011-020-01427-w
EA JAN 2021
PG 10
WC Cell Biology; Immunology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Immunology
GA QD5QZ
UT WOS:000604087000001
PM 33386422
DA 2022-11-30
ER

PT J
AU Taylor, RL
   Poulter, JA
   Downes, SM
   McKibbin, M
   Khan, KN
   Inglehearn, CF
   Webster, AR
   Hardcastle, AJ
   Michaelides, M
   Bishop, PN
   Clark, SJ
   Black, GC
   Black, G
   Hall, G
   Ingram, S
   Taylor, R
   Manson, F
   Sergouniotis, P
   Webster, A
   Hardcastle, A
   Plagnol, V
   Pontikos, N
   Cheetham, M
   Arno, G
   Fiorentino, A
   Inglehearn, C
   Toomes, C
   Ali, M
   McKibbin, M
   Smith, C
   Khan, K
   Downes, S
   Yu, J
   Halford, S
   Broadgate, S
   van Heyningen, V
AF Taylor, Rachel L.
   Poulter, James A.
   Downes, Susan M.
   McKibbin, Martin
   Khan, Kamron N.
   Inglehearn, Chris F.
   Webster, Andrew R.
   Hardcastle, Alison J.
   Michaelides, Michel
   Bishop, Paul N.
   Clark, Simon J.
   Black, Graeme C.
   Black, Graeme
   Hall, Georgina
   Ingram, Stuart
   Taylor, Rachel
   Manson, Forbes
   Sergouniotis, Panagiotis
   Webster, Andrew
   Hardcastle, Alison
   Plagnol, Vincent
   Pontikos, Nikolas
   Cheetham, Michael
   Arno, Gavin
   Fiorentino, Alessia
   Inglehearn, Chris
   Toomes, Carmel
   Ali, Manir
   McKibbin, Martin
   Smith, Claire
   Khan, Kamron
   Downes, Susan
   Yu, Jing
   Halford, Stephanie
   Broadgate, Suzanne
   van Heyningen, Veronica
CA United Kingdom Inherited Retinal D
TI Loss-of-Function Mutations in the CFH Gene Affecting Alternatively
   Encoded Factor H-like 1 Protein Cause Dominant Early-Onset Macular
   Drusen
SO OPHTHALMOLOGY
LA English
DT Article
ID COMPLEMENT FACTOR-H; HEMOLYTIC-UREMIC SYNDROME; BRUCHS MEMBRANE; RARE
   VARIANTS; DEGENERATION; DISEASE; BINDING; DEFICIENCY;
   GLOMERULONEPHRITIS; POLYMORPHISM
AB Purpose: To characterize the molecular mechanism underpinning early-onset macular drusen (EOMD), a phenotypically severe subtype of age-related macular degeneration (AMD), in a subgroup of patients.
   Design: Multicenter case series, in vitro experimentation, and retrospective analysis of previously reported variants.
   Participants: Seven families with apparently autosomal dominant EOMD.
   Methods: Patients underwent a comprehensive ophthalmic assessment. Affected individuals from families A, B, and E underwent whole exome sequencing. The probands from families C, D, F, and G underwent Sanger sequencing analysis of the complement factor H (CFH) gene. Mutant recombinant factor H like-1 (FHL-1) proteins were expressed in HEK293 cells to assess the impact on FHL-1 expression and function. Previously reported EOMD-causing variants in CFH were reviewed.
   Main Outcome Measures: Detailed clinical phenotypes, genomic findings, in vitro characterization of mutation effect on protein function, and postulation of the pathomechanism underpinning EOMD.
   Results: All affected participants demonstrated bilateral drusen. The earliest reported age of onset was 16 years (median, 46 years). Ultra-rare (minor allele frequency [MAF], <= 0.0001) CFH variants were identified as the cause of disease in each family: CFH c.1243del, p.(Ala415ProfsTer39) het; c.350+1G -> T het; c.619+1G -> A het, c.380G -> A, p.(Arg127His) het; c.694C -> T p.(Arg232Ter) het (identified in 2 unrelated families in this cohort); and c.1291T -> A, p.(Cys431Ser). All mutations affect complement control protein domains 2 through 7, and thus are predicted to impact both FHL-1, the predominant isoform in Bruch's membrane (BrM) of the macula, and factor H (FH). In vitro analysis of recombinant proteins FHL-1(R127H), FHL-1(A)(415f/s), and FHL-1(C)(431s) demonstrated that they are not secreted, and thus are loss-of-function proteins. Review of 29 previously reported EOMD-causing mutations found that 75.8% (22/29) impact FHL-1 and FH. In total, 86.2% (25/29) of EOMD-associated variants cause haploinsufficiency of FH or FHL-1.
   Conclusions: Early-onset macular drusen is an under-recognized, phenotypically severe subtype of AMD. We propose that haploinsufficiency of FHL-1, the main regulator of the complement pathway in BrM, where drusen develop, is an important mechanism underpinning the development of EOMD in a number of cases. Understanding the molecular basis of EOMD will shed light on AMD pathogenesis given their pathologic similarities. (C) 2019 by the American Academy of Ophthalmology.
C1 [Taylor, Rachel L.; Bishop, Paul N.; Clark, Simon J.; Black, Graeme C.] Univ Manchester, Manchester Acad Hlth Sci Ctr, Fac Biol Med & Hlth, Div Evolut & Genom Sci,Sch Biol Sci, Manchester, Lancs, England.
   [Taylor, Rachel L.; Black, Graeme C.] Cent Manchester Univ Hosp NHS Fdn Trust, St Marys Hosp, Manchester Acad Hlth Sci Ctr, Manchester Ctr Genom Med, Manchester, Lancs, England.
   [Poulter, James A.; Khan, Kamron N.; Inglehearn, Chris F.] Univ Leeds, Leeds Inst Med Res, Sect Ophthalmol & Neurosci, Leeds, W Yorkshire, England.
   [Downes, Susan M.] NHS Fdn Trust, Oxford Univ Hosp, Oxford Eye Hosp, Oxford, England.
   [Downes, Susan M.] John Radcliffe Hosp, Nuffield Dept Clin Neurosci, Oxford, England.
   [McKibbin, Martin] St James Univ Hosp, Dept Ophthalmol, Leeds, W Yorkshire, England.
   [Webster, Andrew R.; Hardcastle, Alison J.; Michaelides, Michel] UCL, UCL Inst Ophthalmol, London, England.
   [Webster, Andrew R.; Michaelides, Michel] Moorfields Eye Hosp, London, England.
   [Bishop, Paul N.] Cent Manchester Univ Hosp NHS Fdn Trust, Manchester Acad Hlth Sci Ctr, Manchester Royal Eye Hosp, Manchester, Lancs, England.
   [Clark, Simon J.] Univ Manchester, Fac Biol Med & Hlth, Lydia Becker Inst Immunol & Inflammat, Manchester, Lancs, England.
C3 University of Manchester; University of Manchester; University of Leeds;
   Oxford University Hospitals NHS Foundation Trust; University of Oxford;
   Saint James's University Hospital; University of London; University
   College London; University of London; University College London;
   Moorfields Eye Hospital NHS Foundation Trust; Manchester Royal Eye
   Hospital; University of Manchester; University of Manchester
RP Black, GC (通讯作者)，Univ Manchester, Manchester Acad Hlth Sci Ctr, Fac Med & Human Sci, Manchester Ctr Genom Med,Inst Human Dev, Manchester M13 9WL, Lancs, England.
EM graeme.black@manchester.ac.uk
RI Fiorentino, Alessia/ABC-3638-2020; Halford, Stephanie/AAJ-1375-2020;
   Pontikos, Nikolas/U-3642-2018; Ali, Manir/ABE-5251-2020; VAN HEYNINGEN,
   Veronica/GYE-0531-2022; Poulter, James/A-8190-2013; Black,
   Graeme/K-7374-2015
OI Halford, Stephanie/0000-0003-2179-907X; Pontikos,
   Nikolas/0000-0003-1782-4711; Ali, Manir/0000-0003-3204-3788; Inglehearn,
   Christopher/0000-0002-5143-2562; van Heyningen,
   Veronica/0000-0003-0359-0141; Michaelides, Michel/0000-0002-1552-7046;
   broadgate, suzanne/0000-0001-8894-9242; Poulter,
   James/0000-0003-2048-5693; Fiorentino, Alessia/0000-0002-1403-4581;
   Clark, Simon/0000-0001-8394-8355; Cheetham, Michael/0000-0001-6429-654X;
   Hardcastle, Alison/0000-0002-0038-6770; Black,
   Graeme/0000-0001-8727-6592; Taylor, Rachel/0000-0002-1235-4303
FU Retgene; Bayer; Novartis; Roche; Medical Research Council, United
   Kingdom [MR/R042952/1]; Macular Society, UK; RP Fighting Blindness (RP
   Genome Project) [GR586]; Fight for Sight UK (RP Genome Project) [GR586];
   Moorfields Eye Hospital, London, United Kingdom; National Institute for
   Health Research Biomedical Research Centre at Moorfields Eye Hospital
   National Health Service Foundation Trust, London, United Kingdom; UCL
   Institute of Ophthalmology London, United Kingdom; Medical Research
   Council (RCUK/UKRI Innovation Fellowship) [MR/R024952/1, MR/K024418/1];
   Manchester Academic Health Science Centre; Manchester National Institute
   for Health Research Biomedical Research Centre; MRC [MR/K024418/1,
   MR/R024952/1] Funding Source: UKRI
FX The author(s) have made the following disclosure(s): S.M.D.: Financial
   support - Retgene, Bayer, Novartis, Roche.; Funded by the Medical
   Research Council, United Kingdom (grant no. MR/R042952/1), the Macular
   Society, UK (R.L.T., S.J.C., G.C.B.); RP Fighting Blindness and Fight
   for Sight UK (RP Genome Project GR586); Moorfields Eye Hospital Special
   Trustees, London, United Kingdom; National Institute for Health Research
   Biomedical Research Centre at Moorfields Eye Hospital National Health
   Service Foundation Trust, London, United Kingdom; and the UCL Institute
   of Ophthalmology London, United Kingdom (M.M., K.N.K., A.R.W., A.J.H.);
   and the Medical Research Council (RCUK/UKRI Innovation Fellowship nos.:
   MR/R024952/1 [R.L.T.]and MR/K024418/1 [S.J.C.]). The authors would also
   like to acknowledge the support of the Manchester Academic Health
   Science Centre and the Manchester National Institute for Health Research
   Biomedical Research Centre. The views expressed are those of the
   authors, and not necessarily those of the National Health Service, the
   National Institute for Health Research, or the Department of Health.
   Funding bodies did not have any specific role in the design and conduct
   of the study.
CR Albuquerque JAT, 2012, J IMMUNOL, V189, P3242, DOI 10.4049/jimmunol.1201418
   Boon CJE, 2008, AM J HUM GENET, V82, P516, DOI 10.1016/j.ajhg.2007.11.007
   Clark SJ, 2006, J BIOL CHEM, V281, P24713, DOI 10.1074/jbc.M605083200
   Clark SJ, 2018, SEMIN IMMUNOPATHOL, V40, P65, DOI 10.1007/s00281-017-0649-6
   Clark SJ, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01778
   Clark SJ, 2015, J CLIN MED, V4, P18, DOI 10.3390/jcm4010018
   Clark SJ, 2014, J IMMUNOL, V193, P4962, DOI 10.4049/jimmunol.1401613
   Clark SJ, 2013, J IMMUNOL, V190, P2049, DOI 10.4049/jimmunol.1201751
   Clark SJ, 2010, J BIOL CHEM, V285, P30192, DOI 10.1074/jbc.M110.103986
   Dragon-Durey MA, 2004, J AM SOC NEPHROL, V15, P787, DOI 10.1097/01.ASN.0000115702.28859.A7
   Duvvari MR, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0152047
   Duvvari MR, 2015, MOL VIS, V21, P285
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Falcao DA, 2008, SCAND J IMMUNOL, V68, P445, DOI 10.1111/j.1365-3083.2008.02152.x
   Ferrara D, 2015, JAMA OPHTHALMOL, V133, P785, DOI 10.1001/jamaophthalmol.2015.0814
   Ferreira VP, 2009, J IMMUNOL, V182, P7009, DOI 10.4049/jimmunol.0804031
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Fritsche LG, 2014, ANNU REV GENOM HUM G, V15, P151, DOI 10.1146/annurev-genom-090413-025610
   Fritsche LG, 2013, NAT GENET, V45, P433, DOI 10.1038/ng.2578
   Geerlings MJ, 2017, MOL IMMUNOL, V84, P65, DOI 10.1016/j.molimm.2016.11.016
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Hallam D, 2017, STEM CELLS, V35, P2305, DOI 10.1002/stem.2708
   Holers VM, 2008, IMMUNOL REV, V223, P300, DOI 10.1111/j.1600-065X.2008.00641.x
   HOURCADE D, 1989, ADV IMMUNOL, V45, P381, DOI 10.1016/S0065-2776(08)60697-5
   Hughes AE, 2016, ACTA OPHTHALMOL, V94, pE247, DOI 10.1111/aos.12822
   Kavanagh D, 2010, PEDIATR NEPHROL, V25, P2431, DOI 10.1007/s00467-010-1555-5
   Liszewski MK, 2017, ANNU REV PATHOL-MECH, V12, P25, DOI 10.1146/annurev-pathol-012615-044145
   Maller JB, 2007, NAT GENET, V39, P1200, DOI 10.1038/ng2131
   Mandal NA, 2006, INVEST OPHTH VIS SCI, V47, P4091, DOI 10.1167/iovs.05-1655
   Merinero HM, 2018, KIDNEY INT, V93, P470, DOI 10.1016/j.kint.2017.07.015
   McHarg S, 2015, MOL IMMUNOL, V67, P43, DOI 10.1016/j.molimm.2015.02.032
   Montes T, 2008, MOL IMMUNOL, V45, P2897, DOI 10.1016/j.molimm.2008.01.027
   Parente R, 2017, CELL MOL LIFE SCI, V74, P1605, DOI 10.1007/s00018-016-2418-4
   Pechtl IC, 2011, J BIOL CHEM, V286, P11082, DOI 10.1074/jbc.M110.211839
   Raychaudhuri S, 2011, NAT GENET, V43, P1232, DOI 10.1038/ng.976
   Saunders RE, 2007, HUM MUTAT, V28, P222, DOI 10.1002/humu.20435
   Schejbel L, 2011, GENES IMMUN, V12, P90, DOI 10.1038/gene.2010.63
   Schmidt BZ, 1999, J BIOL CHEM, V274, P11782, DOI 10.1074/jbc.274.17.11782
   Schramm EC, 2014, MOL IMMUNOL, V61, P118, DOI 10.1016/j.molimm.2014.06.032
   Servais A, 2012, KIDNEY INT, V82, P454, DOI 10.1038/ki.2012.63
   Swinkels M, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-017-18395-7
   Taylor RL, 2017, JAMA OPHTHALMOL, V135, P339, DOI 10.1001/jamaophthalmol.2017.0046
   Thurman JM, 2006, J IMMUNOL, V176, P1305, DOI 10.4049/jimmunol.176.3.1305
   Triebwasser MP, 2015, INVEST OPHTH VIS SCI, V56, P6873, DOI 10.1167/iovs.15-17432
   van de Ven JPH, 2012, ARCH OPHTHALMOL-CHIC, V130, P1038, DOI 10.1001/archophthalmol.2012.265
   Wagner EK, 2016, SCI REP-UK, V6, DOI 10.1038/srep31531
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Yu Y, 2014, HUM MOL GENET, V23, P5283, DOI 10.1093/hmg/ddu226
NR 48
TC 15
Z9 16
U1 0
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD OCT
PY 2019
VL 126
IS 10
BP 1410
EP 1421
DI 10.1016/j.ophtha.2019.03.013
PG 12
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA IY7XQ
UT WOS:000486608900020
PM 30905644
OA Green Published, hybrid, Green Accepted
DA 2022-11-30
ER

PT J
AU Hollborn, M
   Ackmann, C
   Kuhrt, H
   Doktor, F
   Kohen, L
   Wiedemann, P
   Bringmann, A
AF Hollborn, Margrit
   Ackmann, Charlotte
   Kuhrt, Heidrun
   Doktor, Fabian
   Kohen, Leon
   Wiedemann, Peter
   Bringmann, Andreas
TI Osmotic and hypoxic induction of the complement factor C9 in cultured
   human retinal pigment epithelial cells: Regulation of VEGF and NLRP3
   expression
SO MOLECULAR VISION
LA English
DT Article
ID MEMBRANE ATTACK COMPLEX; AGE-RELATED MACULOPATHY; MACULAR DEGENERATION;
   INFLAMMASOME ACTIVATION; CHOROIDAL NEOVASCULARIZATION; GENE-EXPRESSION;
   BLOOD-PRESSURE; DRUSEN; SODIUM; ANGIOGENESIS
AB Purpose: Variants of complement factor genes, hypoxia and oxidative stress of the outer retina, and systemic hypertension affect the risk of age-related macular degeneration Hypertension often results from the high intake of dietary salt that increases extracellular osmolarity We determined the effects of extracellular hyperosmolarity, hypoxia, and oxidative stress on the expression of complement genes in cultured (dedifferentiated) human RPE cells and investigated the effects of C9 siRNA and C9 protein on RPE cells.
   Methods: Hyperosmolarity was induced by adding 100 mM NaCl or sucrose to the culture medium Hypoxia was induced by culturing cells in 1% O-2 or by adding the hypoxia mimetic CoCl2. Oxidative stress was induced by adding H2O2. Gene and protein expression levels were determined with real-time RT-PCR, western blot, and ELISA analyses. The expression of the nuclear factor of activated T cell 5 (NFAT5) and complement factor (C9) was knocked down with siRNA.
   Results: Extracellular hyperosmolarity, hypoxia, and oxidative stress strongly increased the transcription of the C9 gene, while the expression of the C3, C5, CFH, and CFB genes was moderately altered or not altered at all Hyperosmolarity also induced a moderate increase in the cytosolic C9 protein level The hyperosmotic C9 gene expression was reduced by inhibitors of the p38 MAPK, ERK1/2, JNK, and PI3K signal transduction pathways and of the transcription factors STAT3 and NFAT5 The hypoxic C9 gene expression was reduced by a STAT3 inhibitor The knockdown of C9 with siRNA decreased the hypoxic vascular endothelial growth factor (VEGF) and NLRP3 gene expression, the hypoxic secretion of VEGF, and the hyperosmotic expression of the NLRP3 gene Exogenous C9 protein inhibited the hyperosmotic expression of the C9 gene, the hypoxic and hyperosmotic VEGF gene expression, and the hyperosmotic expression of the NLRP3 gene Both C9 siRNA and C9 protein inhibited mflammasome activation under hyperosmotic conditions, as indicated by the decrease in the cytosolic level of mature IL-1 beta.
   Conclusions: The expression of the C9 gene in cultured RPE cells is highly induced by extracellular hyperosmolarity, hypoxia, and oxidative stress. The data may support the assumption that C9 gene expression may stimulate the expression of inflammatory (NLRP3) and angiogenic growth factors (VEGF) in RPE cells. Extracellular C9 protein may attenuate this effect, in part via negative regulation of the C9 mRNA level.
C1 [Hollborn, Margrit; Ackmann, Charlotte; Doktor, Fabian; Kohen, Leon; Wiedemann, Peter; Bringmann, Andreas] Univ Leipzig, Dept Ophthalmol, Leipzig, Germany.
   [Hollborn, Margrit; Ackmann, Charlotte; Doktor, Fabian; Kohen, Leon; Wiedemann, Peter; Bringmann, Andreas] Univ Leipzig, Eye Hosp, Leipzig, Germany.
   [Kuhrt, Heidrun] Univ Leipzig, Inst Anat, Leipzig, Germany.
   [Kohen, Leon] Helios Klinikum Aue, Aue, Germany.
C3 Leipzig University; Leipzig University; Leipzig University; Helios
   Kliniken
RP Hollborn, M (通讯作者)，Univ Leipzig, Dept Ophthalmol, Fac Med, Liebigstr 10-14, D-04103 Leipzig, Germany.; Hollborn, M (通讯作者)，Univ Leipzig, Eye Hosp, Fac Med, Liebigstr 10-14, D-04103 Leipzig, Germany.
EM hollbm@medizin.uni-leipzig.de
FU Deutsche Forschungsgemeinschaft [KO 1547/7-1]; Geschwister Freter
   Stiftung (Hannover, Germany)
FX The authors thank Ute Weinbrecht for excellent technical assistance.
   This study was supported by a grant from the Deutsche
   Forschungsgemeinschaft (KO 1547/7-1 to L.K.) and the Geschwister Freter
   Stiftung (Hannover, Germany).
CR An WG, 1998, NATURE, V392, P405, DOI 10.1038/32925
   Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   Anderson DH, 2010, PROG RETIN EYE RES, V29, P95, DOI 10.1016/j.preteyeres.2009.11.003
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Bora NS, 2007, J IMMUNOL, V178, P1783, DOI 10.4049/jimmunol.178.3.1783
   Bringmann A, 2016, MOL VIS, V22, P1437
   Brosig A, 2015, MOL VIS, V21, P1000
   Bubeck D, 2014, BIOCHEMISTRY-US, V53, P1908, DOI 10.1021/bi500157z
   Cheung Chris Yk, 2013, J Mol Signal, V8, P5, DOI 10.1186/1750-2187-8-5
   Cook NR, 2007, BMJ-BRIT MED J, V334, P885, DOI 10.1136/bmj.39147.604896.55
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   Dmitrieva NI, 2004, P NATL ACAD SCI USA, V101, P2317, DOI 10.1073/pnas.0308463100
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Ferraris JD, 2006, CONTRIB NEPHROL, V152, P125, DOI 10.1159/000096320
   Fowler BJ, 2014, SCIENCE, V346, P1000, DOI 10.1126/science.1261754
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Gross O, 2011, IMMUNOL REV, V243, P136, DOI 10.1111/j.1600-065X.2011.01046.x
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   He FJ, 2005, HYPERTENSION, V45, P98, DOI 10.1161/01.HYP.0000149431.79450.a2
   Ho SN, 2003, ARCH BIOCHEM BIOPHYS, V413, P151, DOI 10.1016/S0003-9861(03)00130-9
   Hollborn M, 2015, MOL VIS, V21, P360
   Johnson LV, 2001, EXP EYE RES, V73, P887, DOI 10.1006/exer.2001.1094
   Kenney WL, 2001, MED SCI SPORT EXER, V33, P1524, DOI 10.1097/00005768-200109000-00016
   Kent DL, 2014, MOL VIS, V20, P46
   Kerur N, 2013, INVEST OPHTH VIS SCI, V54, P7395, DOI 10.1167/iovs.13-12500
   KHAW KT, 1988, CIRCULATION, V77, P53, DOI 10.1161/01.CIR.77.1.53
   Klegeris A, 2001, EXP GERONTOL, V36, P1179, DOI 10.1016/S0531-5565(00)00265-5
   Klein R, 2007, OPHTHALMOLOGY, V114, P253, DOI 10.1016/j.ophtha.2006.10.040
   Klein Ronald, 2003, Ophthalmology, V110, P1273, DOI 10.1016/S0161-6420(03)00599-2
   Kurihara T, 2016, ELIFE, V5, DOI 10.7554/eLife.14319
   Latz E, 2013, NAT REV IMMUNOL, V13, P397, DOI 10.1038/nri3452
   Lee K, 2007, J MED CHEM, V50, P1675, DOI 10.1021/jm0610292
   Lueck K, 2011, EYE, V25, P1074, DOI 10.1038/eye.2011.109
   Luo C, 2013, EXP EYE RES, V112, P93, DOI 10.1016/j.exer.2013.04.016
   Marneros AG, 2013, CELL REP, V4, P945, DOI 10.1016/j.celrep.2013.08.002
   Miller JW, 2010, JPN J OPHTHALMOL, V54, P523, DOI 10.1007/s10384-010-0863-4
   Natarajan K, 1996, P NATL ACAD SCI USA, V93, P9090, DOI 10.1073/pnas.93.17.9090
   Nishiguchi KM, 2012, INVEST OPHTH VIS SCI, V53, P508, DOI 10.1167/iovs.11-8425
   Nozaki M, 2006, P NATL ACAD SCI USA, V103, P2328, DOI 10.1073/pnas.0408835103
   Orgul S, 1993, Ger J Ophthalmol, V2, P436
   PODACK ER, 1982, J EXP MED, V156, P268, DOI 10.1084/jem.156.1.268
   Prager P, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0165653
   Roth F, 2004, GRAEF ARCH CLIN EXP, V242, P710, DOI 10.1007/s00417-004-0976-x
   Schust J, 2006, CHEM BIOL, V13, P1235, DOI 10.1016/j.chembiol.2006.09.018
   Seth A, 2008, INVEST OPHTH VIS SCI, V49, P743, DOI 10.1167/iovs.07-1072
   SPERDUTO RD, 1986, ARCH OPHTHALMOL-CHIC, V104, P216
   Tan LX, 2016, P NATL ACAD SCI USA, V113, P8789, DOI 10.1073/pnas.1523061113
   Tanhehco EJ, 2000, AM J PHYSIOL-HEART C, V279, pH195, DOI 10.1152/ajpheart.2000.279.1.H195
   Triantafilou K, 2013, J CELL SCI, V126, P2903, DOI 10.1242/jcs.124388
   Tseng WA, 2013, INVEST OPHTH VIS SCI, V54, P110, DOI 10.1167/iovs.12-10655
   Tuomilehto J, 2001, LANCET, V357, P848, DOI 10.1016/S0140-6736(00)04199-4
   van Leeuwen R, 2003, INVEST OPHTH VIS SCI, V44, P3771, DOI 10.1167/iovs.03-0121
   van Leeuwen R, 2003, EUR J EPIDEMIOL, V18, P845, DOI 10.1023/A:1025643303914
   Walker DG, 1998, BRAIN RES, V809, P31, DOI 10.1016/S0006-8993(98)00811-7
   Wang AL, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005304
   Winges A, 2016, GRAEF ARCH CLIN EXP, V254, P2387, DOI 10.1007/s00417-016-3492-x
   Witmer AN, 2003, PROG RETIN EYE RES, V22, P1, DOI 10.1016/S1350-9462(02)00043-5
   Woo SK, 2002, PFLUG ARCH EUR J PHY, V444, P579, DOI 10.1007/s00424-002-0849-2
   Yasojima K, 1998, CIRC RES, V82, P1224, DOI 10.1161/01.RES.82.11.1224
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
   Zhao HY, 2002, AM J PHYSIOL-RENAL, V282, pF710, DOI 10.1152/ajprenal.00303.2001
NR 61
TC 17
Z9 18
U1 0
U2 2
PU MOLECULAR VISION
PI ATLANTA
PA C/O JEFF BOATRIGHT, LAB B, 5500 EMORY EYE CENTER, 1327 CLIFTON RD, N E,
   ATLANTA, GA 30322 USA
SN 1090-0535
J9 MOL VIS
JI Mol. Vis.
PD JUL 28
PY 2018
VL 24
BP 518
EP 535
PG 18
WC Biochemistry & Molecular Biology; Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Ophthalmology
GA GO7KD
UT WOS:000440242500001
PM 30090015
DA 2022-11-30
ER

PT J
AU Reinisalo, M
   Putula, J
   Mannermaa, E
   Urtti, A
   Honkakoski, P
AF Reinisalo, Mika
   Putula, Jaana
   Mannermaa, Eliisa
   Urtti, Arto
   Honkakoski, Paavo
TI Regulation of the human tyrosinase gene in retinal pigment epithelium
   cells: the significance of transcription factor orthodenticle homeobox 2
   and its polymorphic binding site
SO MOLECULAR VISION
LA English
DT Article
ID MACULAR DEGENERATION; HUMAN RPE; PARKINSONS-DISEASE; ALZHEIMERS-DISEASE;
   IN-VIVO; SUBSTANTIA-NIGRA; EYE DEVELOPMENT; OCULAR MELANIN;
   LOCUS-CERULEUS; MITF GENE
AB Purpose: Tyrosinase is the rate-limiting enzyme responsible for melanin biosynthesis in the retinal pigment epithelium (RPE) of the eye. Melanin has an important role in retinal development, function, and protection against light-induced oxidative stress, and melanin levels are associated with age-related macular degeneration (AMD). Because the levels of and protection afforded by melanin seem to decline with increasing age, proper regulation of the human tyrosinase gene (TYR) in the RPE is an important but insufficiently understood process. Our purpose was to obtain detailed information on regulation of the TYR gene promoter in the human RPE and to specify the role of orthodenticle homeobox 2 (OTX2) and microphthalmia-associated transcription factor (MITF).
   Methods: We used luciferase reporter constructs to study regulation of the human TYR gene promoter in cultured human RPE cells. We further studied the role of OTX2 and MITF, their binding sites, and endogenous expression by using mutagenesis, electrophoretic mobility shift assay, yeast two-hybrid assay, RNA interference, and gene expression analyses.
   Results: In the RPE, OTX2 activated the human TYR gene promoter via direct trans-activation of novel OTX2 binding elements. In addition, we found that indirect activation by OTX2 via more proximal MITF binding sites, even in the absence of OTX2 sites, took place. These results are consistent with the physical interaction observed between OTX2 and MITF. Overexpression or knockdown of OTX2 in RPE cells resulted in corresponding changes in tyrosinase mRNA expression. Finally, we found that a single nucleotide polymorphism (SNP rs4547091) at the most proximal OTX2 binding site is associated with altered nuclear protein binding and a remarkable decrease in TYR promoter activity in RPE cells. This single nucleotide polymorphism (SNP) is more common in the European population in which AMD is also more prevalent.
   Conclusions: In the RPE, OTX2 activates the human TYR gene promoter by direct DNA binding and by interaction with MITF. Such synergistic interaction highlights the role of OTX2 as a potential coregulator of numerous MITF target genes in the eye. Genetic differences in OTX2 binding sites affect tyrosinase regulation. Collectively, these findings emphasize the role of OTX2 in regulating the human TYR gene, with implications for inter-individual differences in melanin synthesis, retinal development, and function as well as susceptibility to retinal degeneration associated with aging.
C1 [Reinisalo, Mika; Putula, Jaana; Mannermaa, Eliisa; Honkakoski, Paavo] Univ Eastern Finland, Sch Pharm, Kuopio, Finland.
   [Reinisalo, Mika; Putula, Jaana; Mannermaa, Eliisa; Honkakoski, Paavo] Univ Eastern Finland, Bioctr Kuopio, Kuopio, Finland.
   [Urtti, Arto] Univ Helsinki, Ctr Drug Res, FIN-00014 Helsinki, Finland.
C3 University of Eastern Finland; University of Eastern Finland; University
   of Helsinki
RP Reinisalo, M (通讯作者)，Yliopistonranta 1C,POB 1627, FIN-70211 Kuopio, Finland.
EM mika.reinisalo@uef.fi
RI Honkakoski, Paavo/AAJ-1278-2020
OI Honkakoski, Paavo/0000-0002-4332-3577
FU Academy of Finland [40440]
FX We thank Lea Pirskanen and Inkeri Djupsund for technical assistance. We
   are thankful for Prof. Shigeki Shibahara for donating the MITF
   expression vectors and for Prof. Giorgio Corte providing the
   OTX2-specific antibody. This work was supported by the Academy of
   Finland (grant 40440 to P.H.).
CR Al-Hussaini H, 2008, MOL VIS, V14, P1784
   Amae S, 1998, BIOCHEM BIOPH RES CO, V247, P710, DOI 10.1006/bbrc.1998.8838
   Beby F, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011673
   Bejjani R, 2005, MOL VIS, V11, P124
   Bharti K, 2008, DEVELOPMENT, V135, P1169, DOI 10.1242/dev.014142
   Bobola N, 1999, MECH DEVELOP, V82, P165, DOI 10.1016/S0925-4773(98)00162-2
   Burke JM, 2008, PROG RETIN EYE RES, V27, P579, DOI 10.1016/j.preteyeres.2008.08.002
   Bustin SA, 2002, J MOL ENDOCRINOL, V29, DOI 10.1677/jme.0.0290023
   Camacho-Hubner A, 2001, GENESIS, V29, P180, DOI 10.1002/gene.1022
   Chatelain G, 2006, J MOL MED, V84, P604, DOI 10.1007/s00109-006-0048-2
   Chiaverini C, 2008, J BIOL CHEM, V283, P12635, DOI 10.1074/jbc.M800130200
   Complications Age-Related Macular, 2008, OPHTHALMOLOGY, V115, P1474, DOI 10.1016/j.ophtha.2008.03.008
   DAVIS AA, 1995, INVEST OPHTH VIS SCI, V36, P955
   Double KL, 2006, J NEURAL TRANSM, V113, P751, DOI 10.1007/s00702-006-0450-5
   Dunn KC, 1996, EXP EYE RES, V62, P155, DOI 10.1006/exer.1996.0020
   Esumi N, 2007, J BIOL CHEM, V282, P1838, DOI 10.1074/jbc.M609517200
   Esumi N, 2009, HUM MOL GENET, V18, P128, DOI 10.1093/hmg/ddn323
   FEENEYBURNS L, 1984, INVEST OPHTH VIS SCI, V25, P195
   Frazer KA, 2009, NAT REV GENET, V10, P241, DOI 10.1038/nrg2554
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P532
   Giraldo P, 2003, NUCLEIC ACIDS RES, V31, P6290, DOI 10.1093/nar/gkg793
   Hahn P, 2003, ARCH OPHTHALMOL-CHIC, V121, P1099, DOI 10.1001/archopht.121.8.1099
   Halaban R, 1997, P NATL ACAD SCI USA, V94, P6210, DOI 10.1073/pnas.94.12.6210
   Hallsson JH, 2007, PIGM CELL RES, V20, P185, DOI 10.1111/j.1600-0749.2007.00373.x
   Hever AM, 2006, CLIN GENET, V69, P459, DOI 10.1111/j.1399-0004.2006.00619.x
   Hong L, 2007, J PHYS CHEM B, V111, P7938, DOI 10.1021/jp071439h
   HOOGENDIJK WJG, 1995, BRAIN, V118, P131, DOI 10.1093/brain/118.1.131
   Hu DN, 2008, PHOTOCHEM PHOTOBIOL, V84, P639, DOI 10.1111/j.1751-1097.2008.00316.x
   Jeffery G, 1997, TRENDS NEUROSCI, V20, P165, DOI 10.1016/S0166-2236(96)10080-1
   Kanuga N, 2002, INVEST OPHTH VIS SCI, V43, P546
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   Koike C, 2007, MOL CELL BIOL, V27, P8318, DOI 10.1128/MCB.01209-07
   LARSSON BS, 1993, PIGM CELL RES, V6, P127, DOI 10.1111/j.1600-0749.1993.tb00591.x
   Lavado A, 2006, FRONT BIOSCI-LANDMRK, V11, P743, DOI 10.2741/1832
   Levy C, 2006, TRENDS MOL MED, V12, P406, DOI 10.1016/j.molmed.2006.07.008
   Lopes VS, 2007, MOL BIOL CELL, V18, P3914, DOI 10.1091/mbc.E07-03-0268
   Makinen J, 2003, BIOCHEM J, V376, P465, DOI 10.1042/BJ20030553
   Mallamaci A, 1996, MECH DEVELOP, V58, P165, DOI 10.1016/S0925-4773(96)00571-0
   Martinez-Morales JR, 2004, BIOESSAYS, V26, P766, DOI 10.1002/bies.20064
   Martinez-Morales JR, 2003, J BIOL CHEM, V278, P21721, DOI 10.1074/jbc.M301708200
   McInerney-Leo A, 2004, J NATL MED ASSOC, V96, P974
   Memoli S, 1997, BBA-LIPID LIPID MET, V1346, P61, DOI 10.1016/S0005-2760(97)00018-0
   Muller PY, 2002, BIOTECHNIQUES, V32, P1372
   Murisier F, 2006, HISTOL HISTOPATHOL, V21, P567, DOI 10.14670/HH-21.567
   Murisier F, 2007, PIGM CELL RES, V20, P173, DOI 10.1111/j.1600-0749.2007.00368.x
   Pitkanen L, 2007, PHARM RES-DORDR, V24, P2063, DOI 10.1007/s11095-007-9342-0
   Prakash N, 2006, DEVELOPMENT, V133, P89, DOI 10.1242/dev.02181
   Prakash N, 2006, J PHYSIOL-LONDON, V575, P403, DOI 10.1113/jphysiol.2006.113464
   Rachel RA, 2002, J NEUROSCI, V22, P4249, DOI 10.1523/JNEUROSCI.22-11-04249.2002
   Ragge NK, 2005, AM J HUM GENET, V76, P1008, DOI 10.1086/430721
   Raposo G, 2007, NAT REV MOL CELL BIO, V8, P786, DOI 10.1038/nrm2258
   Reinisalo M, 2006, J CONTROL RELEASE, V110, P437, DOI 10.1016/j.jconrel.2005.10.003
   Reinisalo M, 2003, BBA-GENE STRUCT EXPR, V1628, P169, DOI 10.1016/S0167-4781(03)00140-4
   Rettie AE, 2006, MOL INTERV, V6, P223, DOI 10.1124/mi.6.4.8
   Reyes MG, 2003, NEUROL RES, V25, P179, DOI 10.1179/016164103101201166
   Rozanowski B, 2008, INVEST OPHTH VIS SCI, V49, P2838, DOI 10.1167/iovs.08-1700
   SANYAL S, 1988, EXP EYE RES, V46, P731, DOI 10.1016/S0014-4835(88)80059-9
   Sarangarajan R, 2005, OPHTHALMIC RES, V37, P136, DOI 10.1159/000085533
   Sarna T, 2003, EXP EYE RES, V76, P89, DOI 10.1016/S0014-4835(02)00247-6
   Sasaki M, 2006, NEUROREPORT, V17, P1215, DOI 10.1097/01.wnr.0000227984.84927.a7
   Schraermeyer U, 1999, PIGM CELL RES, V12, P219, DOI 10.1111/j.1600-0749.1999.tb00755.x
   Schraermeyer U, 2006, EXP EYE RES, V83, P315, DOI 10.1016/j.exer.2005.12.015
   SONG MK, 1990, J CELL PHYSIOL, V143, P196, DOI 10.1002/jcp.1041430127
   Sprong H, 2001, J CELL BIOL, V155, P369, DOI 10.1083/jcb.200106104
   Strunnikova NV, 2010, HUM MOL GENET, V19, P2468, DOI 10.1093/hmg/ddq129
   Takeda K, 2003, BIOCHEM BIOPH RES CO, V300, P908, DOI 10.1016/S0006-291X(02)02934-0
   TASSABEHJI M, 1994, NAT GENET, V8, P251, DOI 10.1038/ng1194-251
   Thompson CL, 2007, INVEST OPHTH VIS SCI, V48, P3005, DOI 10.1167/iovs.06-1325
   Tief K, 1998, MOL BRAIN RES, V53, P307, DOI 10.1016/S0169-328X(97)00301-X
   Urtti A, 2000, J DRUG TARGET, V7, P413, DOI 10.3109/10611860009102216
   Verma AS, 2007, ORPHANET J RARE DIS, V2, DOI 10.1186/1750-1172-2-47
   Waes JGV, 2008, EXP EYE RES, V86, P419, DOI 10.1016/j.exer.2007.11.015
   Wang N, 2006, PIGM CELL RES, V19, P3, DOI 10.1111/j.1600-0749.2005.00288.x
   Wang RS, 2006, P NATL ACAD SCI USA, V103, P353, DOI 10.1073/pnas.0509822102
   Watabe H, 2004, J BIOL CHEM, V279, P7971, DOI 10.1074/jbc.M309714200
   Westenskow P, 2009, DEVELOPMENT, V136, P2505, DOI 10.1242/dev.032136
   Yasumoto K, 1997, J BIOL CHEM, V272, P503
   YASUMOTO KI, 1994, MOL CELL BIOL, V14, P8058, DOI 10.1128/MCB.14.12.8058
   Yerger VB, 2006, NICOTINE TOB RES, V8, P487, DOI 10.1080/14622200600790039
   Zadlo A, 2007, PIGM CELL RES, V20, P52, DOI 10.1111/j.1600-0749.2006.00350.x
   Zakin L, 2000, P NATL ACAD SCI USA, V97, P14388, DOI 10.1073/pnas.011513398
   Zecca L, 2006, NEUROLOGY, V67, pS8, DOI 10.1212/WNL.67.7_suppl_2.S8
NR 82
TC 35
Z9 35
U1 0
U2 3
PU MOLECULAR VISION
PI ATLANTA
PA C/O JEFF BOATRIGHT, LAB B, 5500 EMORY EYE CENTER, 1327 CLIFTON RD, N E,
   ATLANTA, GA 30322 USA
SN 1090-0535
J9 MOL VIS
JI Mol. Vis.
PD JAN 10
PY 2012
VL 18
IS 4-6
BP 38
EP 54
PG 17
WC Biochemistry & Molecular Biology; Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Ophthalmology
GA 904YS
UT WOS:000301236600003
PM 22259223
DA 2022-11-30
ER

PT J
AU Sayegh, RG
   Simader, C
   Scheschy, U
   Montuoro, A
   Kiss, C
   Sacu, S
   Kreil, DP
   Pruunte, C
   Schmidt-Erfurth, U
AF Sayegh, Ramzi G.
   Simader, Christian
   Scheschy, Ulrike
   Montuoro, Alessio
   Kiss, Christopher
   Sacu, Stefan
   Kreil, David P.
   Pruente, Christian
   Schmidt-Erfurth, Ursula
TI A Systematic Comparison of Spectral-Domain Optical Coherence Tomography
   and Fundus Autofluorescence in Patients with Geographic Atrophy
SO OPHTHALMOLOGY
LA English
DT Article
ID RETINAL-PIGMENT EPITHELIUM; MACULAR DEGENERATION; JUNCTIONAL ZONE;
   VISUAL-ACUITY; RANIBIZUMAB; CLASSIFICATION; PATTERNS; DISEASE
AB Purpose: To evaluate spectral-domain optical coherence tomography (SD-OCT) in providing reliable and reproducible parameters for grading geographic atrophy (GA) compared with fundus autofluorescence (FAF) images acquired by confocal scanning laser ophthalmoscopy (cSLO).
   Design: Prospective observational study.
   Participants: A total of 81 eyes of 42 patients with GA.
   Methods: Patients with atrophic age-related macular degeneration (AMD) were enrolled on the basis of total GA lesion size ranging from 0.5 to 7 disc areas and best-corrected visual acuity of at least 20/200. A novel combined cSLO-SD-OCT system (Spectralis HRA-OCT, Heidelberg Engineering, Heidelberg, Germany) was used to grade foveal involvement and to manually measure disease extent at the level of the outer neurosensory layers and retinal pigment epithelium (RPE) at the site of GA lesions. Two readers of the Vienna Reading Center graded all obtained volume stacks (20 x 20 degrees), and the results were correlated to FAF.
   Main Outcome Measures: Choroidal signal enhancements and alterations of the RPE, external limiting membrane (ELM), and outer plexiform layer by SD-OCT. These parameters were compared with the lesion measured with severely decreased FAF.
   Results: Foveal involvement or sparing was definitely identified in 75 of 81 eyes based on SD-OCT by both graders (inter-grader agreement: kappa = 0.6, P < 0.01). In FAF, inter-grader agreement regarding foveal involvement was lower (48/81 eyes, inter-grader agreement: kappa = 0.3, P < 0.01). Severely decreased FAF was measured over a mean area of 8.97 mm(2) for grader 1 (G1) and 9.54 mm(2) for grader 2 (G2), consistent with the mean SD-OCT quantification of the sub-RPE choroidal signal enhancement (8.9 mm(2) [G1] -9.4 mm(2) [G2]) and ELM loss with 8.7 mm(2) (G1) -10.2 mm(2) (G2). In contrast, complete morphologic absence of the RPE layer by SD-OCT was significantly smaller than the GA size in FAF (R-2 = 0.400). Inter-reader agreement was highest regarding complete choroidal signal enhancement (0.98) and ELM loss (0.98).
   Conclusions: Absence of FAF in GA lesions is consistent with morphologic RPE loss or advanced RPE disruption and is associated with alterations of the outer retinal layers as identified by SD-OCT. Lesion size is precisely determinable by SD-OCT, and foveal involvement is more accurate by SD-OCT than by FAF.
C1 [Sayegh, Ramzi G.; Simader, Christian; Scheschy, Ulrike; Montuoro, Alessio; Kiss, Christopher; Sacu, Stefan; Pruente, Christian; Schmidt-Erfurth, Ursula] Med Univ Vienna, Dept Ophthalmol, Vienna, Austria.
   [Kreil, David P.] Boku Univ Vienna, Chair Bioinformat, Dept Biotechnol, Vienna, Austria.
C3 Medical University of Vienna; University of Natural Resources & Life
   Sciences, Vienna
RP Simader, C (通讯作者)，Med Univ Vienna, Dept Ophthalmol, Waehringer Guertel 18-20, Vienna, Austria.
EM chrisitan.simader@meduniwien.ac.at
RI Kreil, D/O-1783-2013
OI Kreil, D/0000-0001-7538-2056; Schmidt-Erfurth,
   Ursula/0000-0002-7788-7311; Simader, Christian/0000-0002-1784-2883
CR Bearelly S, 2009, OPHTHALMOLOGY, V116, P1762, DOI 10.1016/j.ophtha.2009.04.015
   Bindewald A, 2005, INVEST OPHTH VIS SCI, V46, P3309, DOI 10.1167/iovs.04-0430
   Bindewald A, 2005, BRIT J OPHTHALMOL, V89, P874, DOI 10.1136/bjo.2004.057794
   Brar M, 2009, AM J OPHTHALMOL, V148, P439, DOI 10.1016/j.ajo.2009.04.022
   BRESSLER NM, 1988, SURV OPHTHALMOL, V32, P375, DOI 10.1016/0039-6257(88)90052-5
   BYRT T, 1993, J CLIN EPIDEMIOL, V46, P423, DOI 10.1016/0895-4356(93)90018-V
   COHEN J, 1960, EDUC PSYCHOL MEAS, V20, P37, DOI 10.1177/001316446002000104
   Cukras C, 2010, EYE, V24, P775, DOI 10.1038/eye.2009.211
   DELORI FC, 1995, INVEST OPHTH VIS SCI, V36, P718
   Dreyhaupt J, 2005, OPHTHAL EPIDEMIOL, V12, P353, DOI 10.1080/09286580591005723
   Eckardt C, 2002, RETINA-J RET VIT DIS, V22, P786, DOI 10.1097/00006982-200212000-00017
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   Gehrs KM, 2006, ANN MED, V38, P450, DOI 10.1080/07853890600946724
   Green W R, 1977, Trans Am Ophthalmol Soc, V75, P180
   HYMAN LG, 1983, AM J EPIDEMIOL, V118, P213, DOI 10.1093/oxfordjournals.aje.a113629
   Kiss CG, 2009, INVEST OPHTH VIS SCI, V50, P2376, DOI 10.1167/iovs.08-2017
   Klein R, 2007, OPHTHALMOLOGY, V114, P253, DOI 10.1016/j.ophtha.2006.10.040
   Klein R, 2006, AM J OPHTHALMOL, V142, P539, DOI 10.1016/j.ajo.2006.06.015
   Lujan BJ, 2009, OPHTHAL SURG LAS IM, V40, P96, DOI 10.3928/15428877-20090301-16
   MAGUIRE P, 1986, AM J OPHTHALMOL, V102, P621, DOI 10.1016/0002-9394(86)90535-0
   Okemefuna AI, 2010, J BIOL CHEM, V285, P1053, DOI 10.1074/jbc.M109.044529
   Resnikoff S, 2004, B WORLD HEALTH ORGAN, V82, P844
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Sahel Jose-Alain, 2005, Retina, V25, pS38, DOI 10.1097/00006982-200512001-00015
   Sayanagi K, 2009, OPHTHALMOLOGY, V116, P947, DOI 10.1016/j.ophtha.2008.11.002
   SCHATZ H, 1989, OPHTHALMOLOGY, V96, P1541
   Schmidt-Erfurth U, 2005, INVEST OPHTH VIS SCI, V46, P3393, DOI 10.1167/iovs.05-0370
   Schmitz-Valckenberg S, 2004, INVEST OPHTH VIS SCI, V45, P4470, DOI 10.1167/iovs.03-1311
   Schmitz-Valckenberg S, 2009, INVEST OPHTH VIS SCI, V50, P3915, DOI 10.1167/iovs.08-2484
   Siegel S., 1988, NONPARAMETRIC STAT B, P284
   Sunness JS, 1999, MOL VIS, V5
   Sunness JS, 1999, OPHTHALMOLOGY, V106, P1768, DOI 10.1016/S0161-6420(99)90340-8
   Unterhuber A, 2005, OPT EXPRESS, V13, P3252, DOI 10.1364/OPEX.13.003252
   vonRuckmann A, 1997, INVEST OPHTH VIS SCI, V38, P478
   Witkin AJ, 2009, OPHTHALMOLOGY, V116, P956, DOI 10.1016/j.ophtha.2008.12.018
   Wolf-Schnurrbusch UEK, 2008, INVEST OPHTH VIS SCI, V49, P3095, DOI 10.1167/iovs.07-1460
NR 36
TC 83
Z9 84
U1 0
U2 5
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD SEP
PY 2011
VL 118
IS 9
BP 1844
EP 1851
DI 10.1016/j.ophtha.2011.01.043
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 814TD
UT WOS:000294479200022
PM 21496928
DA 2022-11-30
ER

PT J
AU Labiris, G
   Katsanos, A
   Fanariotis, M
   Tsirouki, T
   Pefkianaki, M
   Chatzoulis, D
   Tsironi, E
AF Labiris, Georgios
   Katsanos, Andreas
   Fanariotis, Michael
   Tsirouki, Theodora
   Pefkianaki, Maria
   Chatzoulis, Dimitrios
   Tsironi, Evangelia
TI Psychometric properties of the Greek version of the NEI-VFQ 25
SO BMC OPHTHALMOLOGY
LA English
DT Article
ID QUALITY-OF-LIFE; VISUAL FUNCTION QUESTIONNAIRE; MACULAR DEGENERATION;
   FUNCTIONING QUESTIONNAIRE; LOW-VISION; EYE; HEALTH; VALIDATION;
   GLAUCOMA; IMPACT
AB Background: To evaluate the reliability and construct validity of a Greek version of the NEI-VFQ-25 in patients with chronic ophthalmic diseases.
   Methods: We developed the Greek version of the instrument using forward and backward translation. One hundred-eighty-six patients responded to the questionnaire. To examine reliability, Cronbach's alpha for each subscale was used as an index of internal consistency. Test-retest reliability was evaluated with intraclass correlation coefficients. Regarding construct validity, both convergent and discriminant validities were calculated by means of multi-trait analysis. Rasch analysis was used to estimate the visual ability required by each item for a particular response, and each patient's visual ability. Correspondingly, instrument validity was evaluated by estimating the distribution of residuals for item and subject measures.
   Results: Four patient groups were studied, each including participants with a single cause of visual impairment. Group 1 consisted of 84 glaucoma subjects. Group 2 included 30 subjects with age-related macular degeneration (ARMD); group 3 included 25 subjects with dry-eye syndrome, whereas group 4 included 18 cataract patients. Twenty-nine healthy individuals comprised the control group. NEI-VFQ scores (mean +/- SD) for the glaucoma, ARMD, dry-eye, cataract and control groups were: 76.9 +/- 20.2, 70.9 +/- 20.2, 81.6 +/- 16.5, 73.5 +/- 24.0 and 93.7 +/- 8.9 respectively. Item analysis revealed no significant data skewing. Cronbach's alpha ranged from 0.678 to 0.926, with most subscales having high internal consistency. Intraclass correlation coefficient ranged from 0.717 to 0.910 for all subscales. All items passed the convergent and discriminant validity tests. Strong correlations were detected between visual acuity and "general vision", "distant activities" and "near activities" subscales. Significant correlations were also detected between visual field deficits and the "peripheral vision" and "general vision" subscales. Rasch analysis revealed potential weaknesses of the instrument that are associated with the assumptions of the model itself. Specifically, low precision of the "agreement" items was detected in the estimation of visual ability. Twenty-three percent of the subjects had fit statistics that fell outside the tolerance box.
   Conclusion: Although traditional validation methods indicated that the Greek version of the NEI-VFQ-25 is a valid and reliable instrument for VS-QoL assessment, Rasch analysis detected significant misfits to the model, especially of the "agreement" items. This means that results of the corresponding subscales should be interpreted with extreme caution.
C1 [Labiris, Georgios; Katsanos, Andreas; Tsirouki, Theodora; Pefkianaki, Maria; Chatzoulis, Dimitrios; Tsironi, Evangelia] Univ Thessaly, Ophthalmol Clin, Larisa, Greece.
   [Labiris, Georgios; Fanariotis, Michael] Intermed Network, Athens, Greece.
C3 University of Thessaly
RP Labiris, G (通讯作者)，Univ Thessaly, Ophthalmol Clin, Larisa, Greece.
EM labiris@usa.net; andreakatbp@hotmail.com; m_fanariotis@intermedico.org;
   tsirouki_theodora@yahoo.gr; pefkianaki@hotmail.com;
   dchatzoulis@hotmail.com; evangelia_tsironi@yahoo.gr
RI Fanariotis, Michael/AAA-8161-2020
OI Fanariotis, Michael/0000-0001-9670-7980
CR Anagnostopoulos F, 2005, QUAL LIFE RES, V14, P1959, DOI 10.1007/s11136-005-3866-8
   ANDERSEN EB, 1973, PSYCHOMETRIKA, V38, P123, DOI 10.1007/BF02291180
   ANDRICH D, 1978, PSYCHOMETRIKA, V43, P561, DOI 10.1007/BF02293814
   Baker RS, 2006, OPHTHALMOLOGY, V113, P1363, DOI 10.1016/j.ophtha.2006.01.073
   BERGNER M, 1981, MED CARE, V19, P787, DOI 10.1097/00005650-198108000-00001
   Biousse V, 2004, J NEUROL NEUROSUR PS, V75, P314, DOI 10.1136/jnnp.2003.010678
   Burstedt MSI, 2005, RETINA-J RET VIT DIS, V25, P317, DOI 10.1097/00006982-200504000-00011
   Cahill MT, 2005, OPHTHALMOLOGY, V112, P152, DOI 10.1016/j.ophtha.2004.06.036
   Cahill MT, 2005, OPHTHALMOLOGY, V112, P144, DOI 10.1016/j.ophtha.2004.06.035
   CAMPBELL DT, 1959, PSYCHOL BULL, V56, P81, DOI 10.1037/h0046016
   Chabert S, 2004, ACTA OPHTHALMOL SCAN, V82, P25, DOI 10.1046/j.1600-0420.2003.0210.x
   Cronbach LJ, 1951, PSYCHOMETRIKA, V16, P297
   Cusick M, 2005, AM J OPHTHALMOL, V139, P1042, DOI 10.1016/j.ajo.2005.01.008
   Hall TA, 2006, ARCH OPHTHALMOL-CHIC, V124, P116, DOI 10.1001/archopht.124.1.116
   Hirneiss C, 2006, OPHTHALMOLOGE, V103, P109, DOI 10.1007/s00347-005-1252-0
   Jacobs JM, 2005, AGING CLIN EXP RES, V17, P281
   Jampel HD, 2002, J GLAUCOMA, V11, P154, DOI 10.1097/00061198-200204000-00012
   Lamoureux EL, 2007, OPTOMETRY VISION SCI, V84, P683, DOI 10.1097/OPX.0b013e31812f755f
   Lamoureux EL, 2007, OPTOMETRY VISION SCI, V84, P789, DOI 10.1097/OPX.0b013e3181334b83
   MANGIONE CM, 1992, MED CARE, V30, P1111, DOI 10.1097/00005650-199212000-00004
   Mangione CM, 1998, ARCH OPHTHALMOL-CHIC, V116, P227
   Mangione CM, 2001, ARCH OPHTHALMOL-CHIC, V119, P1050, DOI 10.1001/archopht.119.7.1050
   Massof RW, 2007, OPHTHAL EPIDEMIOL, V14, P198, DOI 10.1080/09286580701487883
   Massof RW, 2001, VISION RES, V41, P397, DOI 10.1016/S0042-6989(00)00249-2
   Mitchell J, 2006, HEALTH QUAL LIFE OUT, V4, DOI 10.1186/1477-7525-4-97
   Nichols KK, 2002, CORNEA, V21, P578, DOI 10.1097/00003226-200208000-00009
   Nordmann JP, 2004, PHARMACOECONOMICS, V22, P197, DOI 10.2165/00019053-200422030-00005
   Nutheti R, 2006, INVEST OPHTH VIS SCI, V47, P4742, DOI 10.1167/iovs.06-0020
   Ringsdorf L, 2006, J GLAUCOMA, V15, P414, DOI 10.1097/01.ijg.0000212252.72207.c2
   Rossi GCM, 2003, J GLAUCOMA, V12, P213, DOI 10.1097/00061198-200306000-00006
   Stelmack JA, 2002, INVEST OPHTH VIS SCI, V43, P2859
   Suzukamo Yoshimi, 2005, Health Qual Life Outcomes, V3, P65, DOI 10.1186/1477-7525-3-65
   Toprak AB, 2005, OPHTHAL EPIDEMIOL, V12, P259, DOI 10.1080/09286580590967763
   Tripop Shutimaporn, 2005, Journal of the Medical Association of Thailand, V88, pS155
   Vitali C, 1996, ANN RHEUM DIS, V55, P116, DOI 10.1136/ard.55.2.116
   Ware JE, 1992, MED CARE, V31, P247
NR 36
TC 57
Z9 57
U1 0
U2 16
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1471-2415
J9 BMC OPHTHALMOL
JI BMC Ophthalmol.
PY 2008
VL 8
AR 4
DI 10.1186/1471-2415-8-4
PG 11
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA V18OK
UT WOS:000208013900004
PM 18325083
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Dabasia, PL
   Edgar, DF
   Garway-Heath, DF
   Lawrenson, JG
AF Dabasia, Priya L.
   Edgar, David F.
   Garway-Heath, David F.
   Lawrenson, John G.
TI A survey of current and anticipated use of standard and specialist
   equipment by UK optometrists
SO OPHTHALMIC AND PHYSIOLOGICAL OPTICS
LA English
DT Article
DE equipment; information technology; optical coherence tomography;
   optometrist; survey
ID OPEN-ANGLE GLAUCOMA; HOSPITAL EYE SERVICE; ELECTRONIC HEALTH RECORD;
   COMMUNITY OPTOMETRISTS; MACULAR DEGENERATION; SHARED CARE; OCULAR
   HYPERTENSION; OPHTHALMIC SERVICES; FUNDUS PHOTOGRAPHY; PATIENT SAFETY
AB Purpose: To investigate current and anticipated use of equipment and information technology (IT) in community optometric practice in the UK, and to elicit optometrists' views on adoption of specialist equipment and IT.
   Methods: An anonymous online questionnaire was developed, covering use of standard and specialist diagnostic equipment, and IT. The survey was distributed to a random sample of 1300 UK College of Optometrists members.
   Results: Four hundred and thirty-two responses were received (response rate = 35%). Enhanced (locally commissioned) or additional/separately contracted services were provided by 73% of respondents. Services included glaucoma repeat measures (30% of respondents), glaucoma referral refinement (22%), fast-track referral for wet age-related macular degeneration (48%), and direct cataract referral (40%). Most respondents (88%) reported using non-contact/pneumo tonometry for intra-ocular pressure measurement, with 81% using Goldmann or Perkins tonometry. The most widely used item of specialist equipment was the fundus camera (74% of respondents). Optical Coherence Tomography (OCT) was used by 15% of respondents, up from 2% in 2007. Notably, 43% of those anticipating purchasing specialist equipment in the next 12 months planned to buy an OCT. 'Paperless' records were used by 39% of respondents, and almost 80% of practices used an electronic patient record/practice management system. Variations in responses between parts of the UK reflect differences in the provision of the General Ophthalmic Services contract or community enhanced services. There was general agreement that specialised equipment enhances clinical care, permits increased involvement in enhanced services, promotes the practice and can be used as a defence in clinico-legal cases, but initial costs and ongoing maintenance can be a financial burden. Respondents generally agreed that IT facilitates administrative flow and secure exchange of health information, and promotes a state-of-the-art practice image. However, use of IT may not save examination time; its dynamic nature necessitates frequent updates and technical support; the need for adequate training is an issue; and security of data is also a concern.
   Conclusion: UK optometrists increasingly employ modern equipment and IT services to enhance patient care and for practice management. While the clinical benefits of specialist equipment and IT are appreciated, questions remain as to whether the investment is cost-effective, and how specialist equipment and IT may be used to best advantage in community optometric practice.
C1 [Dabasia, Priya L.; Edgar, David F.; Lawrenson, John G.] City Univ London, Sch Hlth Sci, Ctr Publ Hlth Res, London EC1V 0HB, England.
   [Garway-Heath, David F.] Moorfields Eye Hosp NHS Fdn Trust, Biomed Res Ctr, Natl Inst Hlth Res, London, England.
   [Garway-Heath, David F.] UCL Inst Ophthalmol, London, England.
C3 City University London; University of London; University College London;
   Moorfields Eye Hospital NHS Foundation Trust; University of London;
   University College London
RP Dabasia, PL (通讯作者)，City Univ London, Sch Hlth Sci, Ctr Publ Hlth Res, London EC1V 0HB, England.
EM priya.dabasia.3@city.ac.uk
OI Garway-Heath, David/0000-0003-2907-6992; Lawrenson,
   John/0000-0002-2031-6390
FU College of Optometrists
FX The authors thank the College of Optometrists for their support and
   cooperation with the distribution of the survey. We are also most
   grateful to members of the Advisory group, and the College Council for
   their assistance in piloting the survey, and members of the College who
   participated in the main survey. This study was commissioned by the
   College of Optometrists who provided a PhD studentship to Priya Dabasia
   to conduct this work.
CR Abdul SS, 2010, COMPUT METH PROG BIO, V100, P283, DOI 10.1016/j.cmpb.2010.04.003
   American Optometric Association, 2012, EX SUMM NEW TECHN EH
   Amin M, 2014, OPTOM PRACT, V15, P29
   Ang GS, 2009, EYE, V23, P351, DOI 10.1038/sj.eye.6703045
   Banes MJ, 2000, OPHTHAL PHYSL OPT, V20, P351, DOI 10.1016/S0275-5408(99)00091-5
   Bartholomew N, 2011, INT J THER REHABIL, V18, P558, DOI 10.12968/ijtr.2011.18.10.558
   Bartlett JE., 2001, INFORM TECHNOLOGY LE, V19, P1380, DOI DOI 10.1109/LPT.2009.2020494
   Bates DW, 2003, NEW ENGL J MED, V348, P2526, DOI 10.1056/NEJMsa020847
   Bell RWD, 1997, OPHTHAL PHYSL OPT, V17, P7
   Bengtsson B, 1997, ACTA OPHTHALMOL SCAN, V75, P368
   Borooah S, 2013, EYE, V27, P392, DOI 10.1038/eye.2012.278
   Bosanquet, 2010, LIBERATING NHS EYE C
   Bourne RRA, 2010, EYE, V24, P881, DOI 10.1038/eye.2009.190
   Bowling B, 2005, BRIT J OPHTHALMOL, V89, P1102, DOI 10.1136/bjo.2004.064378
   Cameron JR, 2009, EYE, V23, P1134, DOI 10.1038/eye.2008.196
   Carl Zeiss Meditec Inc, HFA 2 I GUID PROGR A
   Chan P, 2013, AM J OPHTHALMOL, V156, P165, DOI 10.1016/j.ajo.2013.02.010
   Chen J, 2007, CLIN EXP OPTOM, V90, P317, DOI 10.1111/j.1444-0938.2007.00151.x
   Chiang MF, 2008, OPHTHALMOLOGY, V115, P1591, DOI 10.1016/j.ophtha.2008.03.024
   Cole J., 2011, REV OPTOM, V148, P28
   College of Optometrists, 2013, COMM BETT EYE CAR CL
   College of Optometrists, 2013, BETT DAT BETT CAR OP
   College of Optometrists, 2014, HLTH EYES ALL OPT SE
   College of Optometrists and Royal College of Ophthalmologists, 2010, GUID REF GLAUC SUSP
   Davey CJ, 2011, OPHTHAL PHYSL OPT, V31, P23, DOI 10.1111/j.1475-1313.2010.00797.x
   de Silva SR, 2013, OPHTHAL PHYSL OPT, V33, P179, DOI 10.1111/opo.12030
   Department of Health, 2007, GEN OPTH SERV REV
   Dunstone D., 2013, OPTOM PRACT, V14, P45
   EDGAR D, 2009, OPTOM PRACT, V11, P31
   Edgar DF, 2007, GLAUCOMA IDENTIFICAT
   Edwards PJ, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.MR000008.pub4
   ERS Market Research & The College of Optometrists, 2001, COLL OPT CLIN PRACT
   General Optical Council, 2013, ANN REP 2011 12
   Gill FR, 2010, OPHTHAL PHYSL OPT, V30, P731, DOI 10.1111/j.1475-1313.2010.00790.x
   Gordon MO, 2002, ARCH OPHTHALMOL-CHIC, V120, P714
   HARDING SP, 1995, BMJ-BRIT MED J, V311, P1131, DOI 10.1136/bmj.311.7013.1131
   Harper R, 2011, OPHTHAL PHYSL OPT, V31, P327, DOI 10.1111/j.1475-1313.2011.00856.x
   Heidarian A, 2013, CLIN EXP OPTOM, V96, P557, DOI 10.1111/cxo.12059
   Heidelberg Engineering, MOORF REGR AN
   Henson DB, 2003, EYE, V17, P21, DOI 10.1038/sj.eye.6700261
   Hippisley-Cox J, 2003, BRIT MED J, V326, P1439, DOI 10.1136/bmj.326.7404.1439
   Ieong A, 2003, OPHTHAL PHYSL OPT, V23, P341, DOI 10.1046/j.1475-1313.2003.00124.x
   Jain S, 2006, EYE, V20, P471, DOI 10.1038/sj.eye.6701916
   Kelly SP, 2011, CLIN OPHTHALMOL, V5, P1673, DOI 10.2147/OPTH.S26753
   Khan S, 2012, OPHTHAL PHYSL OPT, V32, P472, DOI 10.1111/j.1475-1313.2012.00943.x
   Kotecha A, 2009, OPTOM PRACT, V10, P51
   Lawrenson J, 2013, OPHTHAL PHYSL OPT, V33, P3, DOI 10.1111/opo.12015
   Lawrenson JG, 2013, BMC PUBLIC HEALTH, V13, DOI 10.1186/1471-2458-13-564
   Lin DY, 2002, AM J OPHTHALMOL, V134, P204, DOI 10.1016/S0002-9394(02)01522-2
   Local Optical Committee Support Unit, 2013, ANN REP 2012 13 STAT
   Lockwood AJ, 2010, EYE, V24, P1515, DOI 10.1038/eye.2010.77
   Mandalos A, 2012, EYE, V26, P564, DOI 10.1038/eye.2011.350
   Marks J, 2007, OPTOM PRACT, V8, P57
   McVeigh Francis L, 2008, Optometry, V79, P43, DOI 10.1016/j.optm.2007.06.013
   Medix UK & The College of Optometrists, 2008, COLL OPT CLIN PRACT
   Menachemi N, 2006, J MED SYST, V30, P159, DOI 10.1007/s10916-005-7988-x
   Myint J, 2011, OPHTHAL PHYSL OPT, V31, P353, DOI 10.1111/j.1475-1313.2011.00844.x
   Myint J, 2010, OPHTHAL PHYSL OPT, V30, P847, DOI 10.1111/j.1475-1313.2010.00792.x
   National Institute for Health and Clinical Excellence, GLAUC DIAGN MAN CHRO
   Needle JJ, 2008, OPHTHAL PHYSL OPT, V28, P193, DOI 10.1111/j.1475-1313.2008.00551.x
   NHS Somerset, 2010, ANN REP 2009 10
   Nouri-Mahdavi K, 2011, GRAEF ARCH CLIN EXP, V249, P1593, DOI 10.1007/s00417-011-1787-5
   Optometry Scotland, ACH DAT
   Park JC, 2009, EYE, V23, P309, DOI 10.1038/sj.eye.6703075
   Parkins DJ, 2011, OPHTHAL PHYSL OPT, V31, P343, DOI 10.1111/j.1475-1313.2011.00853.x
   Pieper Bob, 2005, Optometry, V76, P544, DOI 10.1016/j.optm.2005.08.009
   Pirbhai A, 2005, AM J OPHTHALMOL, V139, P455, DOI 10.1016/j.ajo.2004.09.077
   Public Health England, 2013, KNOWL STRAT HARN POW
   Shah R, 2010, OPHTHAL PHYSL OPT, V30, P209, DOI 10.1111/j.1475-1313.2010.00713.x
   Shah S, 2011, OPHTHAL PHYSL OPT, V31, P339, DOI 10.1111/j.1475-1313.2011.00843.x
   Sheen NJL, 2009, BRIT J OPHTHALMOL, V93, P435, DOI 10.1136/bjo.2008.144329
   Soroka M, 2006, OPTOMETRY VISION SCI, V83, P625, DOI 10.1097/01.opx.0000236028.23657.76
   Spry PG, 2008, OPTOM PRACT, V9, P103
   Spry PGD, 1999, BRIT J OPHTHALMOL, V83, P707, DOI 10.1136/bjo.83.6.707
   Stein JD, 2012, OPHTHALMOLOGY, V119, P748, DOI 10.1016/j.ophtha.2011.09.045
   Stolee P, 2011, OPTOMETRY, V82, P166, DOI 10.1016/j.optm.2010.07.031
   Strouthidis NG, 2008, CURR OPIN OPHTHALMOL, V19, P141, DOI 10.1097/ICU.0b013e3282f4450b
   TechUK, 2014, DIG NHS 2018 ON YEAR
   The National Alliance for Health Information Technology, 2008, DEF KEY HLTH INF TEC
   Theodossiades J, 1999, OPHTHAL PHYSL OPT, V19, P62, DOI 10.1046/j.1475-1313.1999.00410.x
   Theodossiades J, 2012, OPHTHAL PHYSL OPT, V32, P234, DOI 10.1111/j.1475-1313.2012.00898.x
   Ting DSW, 2011, CLIN EXP OPHTHALMOL, V39, P230, DOI 10.1111/j.1442-9071.2010.02446.x
   TUCK M, 1989, HLTH TRENDS, V21, P131
   TUCK MW, 1994, OPHTHAL PHYSL OPT, V14, P347
   TUCK MW, 1994, OPHTHAL PHYSL OPT, V14, P227, DOI 10.1111/j.1475-1313.1994.tb00002.x
   Tuck MW, 1988, OPTICIAN, V195, P12
   Vernon SA, 2010, EYE, V24, P265, DOI 10.1038/eye.2009.118
   Vernon SA, 1998, EYE, V12, P854, DOI 10.1038/eye.1998.217
   Woodward EG., 2006, OPHTHAL PHYSL OPT, V26, P215
NR 89
TC 30
Z9 30
U1 0
U2 18
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0275-5408
EI 1475-1313
J9 OPHTHAL PHYSL OPT
JI Ophthalmic Physiol. Opt.
PD SEP
PY 2014
VL 34
IS 5
BP 592
EP 613
DI 10.1111/opo.12150
PG 22
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AO3SB
UT WOS:000341254500011
PM 25160893
OA hybrid, Green Accepted
DA 2022-11-30
ER

PT J
AU Mrejen, S
   Spaide, RF
AF Mrejen, Sarah
   Spaide, Richard F.
TI THE RELATIONSHIP BETWEEN PSEUDODRUSEN AND CHOROIDAL THICKNESS
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE age-related choroidal atrophy; age-related macular degeneration; drusen;
   choroidal thickness; high myopia; pseudodrusen; subretinal drusenoid
   deposits
ID SUBRETINAL DRUSENOID DEPOSITS; OPTICAL COHERENCE TOMOGRAPHY; HIGHLY
   MYOPIC EYES; RETICULAR PSEUDODRUSEN; MACULAR DEGENERATION; PREVALENCE
AB Purpose: To determine the relationship between pseudodrusen as evidenced by the presence of subretinal drusenoid deposits and choroidal thickness using a multimodal imaging approach.
   Methods: Two sets of data were analyzed. The first set was composed of consecutive patients older than 60 years with either high myopia or pseudodrusen. Correlations were calculated between the subfoveal choroidal thickness and the presence of pseudodrusen. The second set of data was obtained from a previously published data examining 90 consecutive eyes with nonexudative age-related macular degeneration so that the relationship between pseudodrusen and subfoveal choroidal thickness could be analyzed.
   Results: There were 96 eyes of 53 patients in the first data set, 36 (67.9%) were female and 17 (32.1%) were male. There were 34 patients (61 eyes) in the High Myopia group and 19 patients (35 eyes) in the Primary Pseudodrusen group. The mean age of the Primary Pseudodrusen group was 83.7 years and that of the High Myopia group was 74.9 years, a difference that was significant (P < 0.001). Of the 61 eyes in the High Myopia group, only 3 (4.9%) had pseudodrusen and 0 had conventional drusen. In the Primary Pseudodrusen group, all had pseudodrusen by definition, but 28 (80%) also had conventional drusen. The mean subfoveal choroidal thickness was 181.7 mu m (median, 147; interquartile range, 65-225 mu m) in the Primary Pseudodrusen group and 59 mu m (median, 36; interquartile range, 21-90 mu m) in the myopic group. Generalized estimating equation analysis showed that eyes with pseudodrusen had thicker subfoveal choroidal thickness than eyes without, a result driven by the High Myopia group. In the second set of data, while the absolute number of eyes with pseudodrusen had a choroidal thickness between 201 mu m and 250 mu m, the proportion with pseudodrusen was higher in eyes with thinner choroids, with a broad peak between 50 mu m and 100 mu m.
   Conclusion: Our results are not consistent with a simple cause or consequence relationship between pseudodrusen and choroidal thinning, but rather with a third yet unknown factor impacting both the pseudodrusen appearance and the choroidal thinning in susceptible populations. The reasons for the relative lack of drusen and pseudodrusen formation in high myopes need to be ascertained.
C1 [Mrejen, Sarah; Spaide, Richard F.] Vitreous Retina Macula Consultants New York, New York, NY 10022 USA.
   [Mrejen, Sarah; Spaide, Richard F.] Manhattan Eye Ear & Throat Hosp, LuEsther T Mertz Retinal Res Ctr, New York, NY 10021 USA.
C3 Vitreous Retina Macula Consultants of New York; Manhattan Eye Ear &
   Throat Hospital
RP Spaide, RF (通讯作者)，Vitreous Retina Macula Consultants New York, 460 Pk Ave,Fifth Floor, New York, NY 10022 USA.
EM rick.spaide@gmail.com
RI Spaide, Richard/ABD-7368-2020; Mrejen, Sarah/G-2089-2016
FU LuEsther T. Mertz Retinal Research Center; Topcon
FX Supported by the LuEsther T. Mertz Retinal Research Center.; R. F.
   Spaide is a consultant in Topcon and Bausch and Lomb and received
   Royalties from Topcon. S. Mrejen has no conflicting interests to
   disclose.
CR Alten F, 2013, INVEST OPHTH VIS SCI, V54, P3250, DOI 10.1167/iovs.13-11923
   ARNOLD JJ, 1995, RETINA-J RET VIT DIS, V15, P183, DOI 10.1097/00006982-199515030-00001
   Chou J, 2013, ARVO 2013 SEATTL WA
   Cohen SY, 2007, BRIT J OPHTHALMOL, V91, P354, DOI 10.1136/bjo.2006.101022
   Coscas G, 2012, EUR J OPHTHALMOL, V22, P992, DOI 10.5301/ejo.5000189
   Curcio CA, 2013, RETINA-J RET VIT DIS, V33, P265, DOI 10.1097/IAE.0b013e31827e25e0
   Curcio CA, 2010, J LIPID RES, V51, P451, DOI 10.1194/jlr.R002238
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Flores-Moreno I, 2013, AM J OPHTHALMOL, V155, P314, DOI 10.1016/j.ajo.2012.07.015
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Fujiwara T, 2009, AM J OPHTHALMOL, V148, P445, DOI 10.1016/j.ajo.2009.04.029
   Garg A, 2013, INVEST OPHTHALMOL VI
   Haans R, 2011, ARVO 2013 FORT LAUD
   Hamel CP, 2009, AM J OPHTHALMOL, V147, P609, DOI 10.1016/j.ajo.2008.10.022
   Ikuno Y, 2009, INVEST OPHTH VIS SCI, V50, P3876, DOI 10.1167/iovs.08-3325
   Lee MY, 2012, AM J OPHTHALMOL, V153, P530, DOI 10.1016/j.ajo.2011.08.012
   Margolis R, 2009, AM J OPHTHALMOL, V147, P811, DOI 10.1016/j.ajo.2008.12.008
   Maruko I, 2012, INVEST OPHTH VIS SCI, V53, P3834, DOI 10.1167/iovs.12-9811
   MIMOUN G, 1990, J FR OPHTALMOL, V13, P511
   Mrejen S, 2013, OPHTHALMOLOGY
   Nishida Y, 2012, RETINA-J RET VIT DIS, V32, P1229, DOI 10.1097/IAE.0b013e318242b990
   Ooto S, 2013, AM J OPHTHALMOL, V156, P1184, DOI 10.1016/j.ajo.2013.06.036
   Pan CW, 2013, OPHTHALMOLOGY, V120, P284, DOI 10.1016/j.ophtha.2012.07.065
   Querques G, 2014, RETINA-J RET VIT DIS, V34, P321, DOI 10.1097/IAE.0b013e3182993df1
   Querques G, 2013, OPHTHALMOLOGY, V120, P872, DOI 10.1016/j.ophtha.2012.12.007
   Querques G, 2012, INVEST OPHTH VIS SCI, V53, P1258, DOI 10.1167/iovs.11-8907
   Sarks J, 2011, BRIT J OPHTHALMOL, V95, P979, DOI 10.1136/bjo.2010.194977
   Smith RT, 2009, AM J OPHTHALMOL, V148, P733, DOI 10.1016/j.ajo.2009.06.028
   Sohrab M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0048631
   Sohrab MA, 2011, INVEST OPHTH VIS SCI, V52, P5743, DOI 10.1167/iovs.10-6942
   Spaide RF, 2008, AM J OPHTHALMOL, V146, P496, DOI 10.1016/j.ajo.2008.05.032
   Spaide RF, 2013, RETINA-J RET VIT DIS, V33, P1800, DOI 10.1097/IAE.0b013e31829c3765
   Spaide RF, 2010, RETINA-J RET VIT DIS, V30, P1441, DOI 10.1097/IAE.0b013e3181ee5ce8
   Spaide RF, 2010, RETINA-J RET VIT DIS, V30, P1163, DOI 10.1097/IAE.0b013e3181ed8d05
   Spaide RF, 2009, AM J OPHTHALMOL, V147, P801, DOI 10.1016/j.ajo.2008.12.010
   Switzer DW, 2012, RETINA-J RET VIT DIS, V32, P1265, DOI 10.1097/IAE.0b013e31824453ac
   Xu L, 2007, OPHTHALMOLOGY, V114, P121, DOI 10.1016/j.ophtha.2006.05.071
   Zweifel SA, 2010, OPHTHALMOLOGY, V117, P1775, DOI 10.1016/j.ophtha.2010.01.027
   Zweifel SA, 2010, OPHTHALMOLOGY, V117, P303, DOI 10.1016/j.ophtha.2009.07.014
NR 39
TC 37
Z9 37
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD AUG
PY 2014
VL 34
IS 8
BP 1560
EP 1566
DI 10.1097/IAE.0000000000000139
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AM7ZE
UT WOS:000340086600015
PM 24732697
DA 2022-11-30
ER

PT J
AU Eadie, BD
   Etminan, M
   Carleton, BC
   Maberley, DA
   Mikelberg, FS
AF Eadie, Brennan D.
   Etminan, Mahyar
   Carleton, Bruce C.
   Maberley, David A.
   Mikelberg, Frederick S.
TI Association of Repeated Intravitreous Bevacizumab Injections With Risk
   for Glaucoma Surgery
SO JAMA OPHTHALMOLOGY
LA English
DT Article
ID INTRAOCULAR-PRESSURE ELEVATION; DIABETIC MACULAR EDEMA; SUSTAINED
   ELEVATION; RANIBIZUMAB; PREDICTORS; SECONDARY
AB IMPORTANCE Intravitreous injections of anti-vascular endothelial growth factor (VEGF) agents are associated with a sustained increase in intraocular pressure. This sustained elevated intraocular pressure could lead to higher rates of glaucoma surgery to lower this pressure.
   OBJECTIVE To determine the risk of glaucoma surgery following repeated intravitreous bevacizumab injections.
   DESIGN, SETTING, PARTICIPANTS This nested, case-control study acquired and analyzed data from large, population-based, linked health databases supported by the British Columbia Ministry of Health in Canada. Study participants included all patients with ophthalmic issues in British Columbia, such as those of the Provincial Retinal Diseases Treatment Program, who had received intravitreous bevacizumab injections for exudative age-related macular degeneration between January 1, 2009, and December 31, 2013. Cases were identified using glaucoma surgical codes for trabeculectomy, complicated trabeculectomy, glaucoma drainage device, and cycloablative procedure. For each case, 10 controls were identified and matched for age, preexisting glaucoma, calendar time, and follow-up time. The number of intravitreous bevacizumab injections received per year-3 or fewer, 4 to 6, or 7 or more-was determined for both cases and controls. Data analysis was performed from February 23, 2016, to November 14, 2016.
   MAIN OUTCOMES AND MEASURES Risk of glaucoma surgery compared with the number of intravitreous bevacizumab injections per year in cases and controls. Rate ratios were adjusted for covariates (diabetes mellitus, myocardial infarction, stroke, and verteporfin use).
   RESULTS Seventy-four cases of glaucoma surgery and 740 controls were identified, with a mean (SD) age of 81.3 (8.4) years for cases and 81.4 (7.9) for controls. The case group had more males than the control group (38 [51.4%] vs 272 [36.8%]). The adjusted rate ratio of glaucoma surgery among those who received 7 or more injections per year was 2.48 (95% CI, 1.25-4.93). There was a 10.3% higher number of 7 or more injections among cases compared with controls. The adjusted rate ratio for those who received 4 to 6 injections per year compared with those who received 3 or fewer was 1.65%(95% CI, 0.84-3.23).
   CONCLUSIONS AND RELEVANCE Findings from this large, pharmacoepidemiologic study suggest that 7 or more intravitreous injections of bevacizumab annually is associated with a higher risk of glaucoma surgery and that 4 to 6 injections per year show a nonstatistically significant rate ratio in the same direction.
C1 [Eadie, Brennan D.; Etminan, Mahyar; Maberley, David A.; Mikelberg, Frederick S.] Univ British Columbia, Dept Ophthalmol & Visual Sci, Fac Med, Room 323-2550 Willow St, Vancouver, BC V5Z 3N9, Canada.
   [Carleton, Bruce C.] Univ British Columbia, Div Translat Therapeut, Dept Pediat, Fac Med, Vancouver, BC, Canada.
   [Carleton, Bruce C.] Univ British Columbia, Child & Family Res Inst, Vancouver, BC, Canada.
   [Carleton, Bruce C.] British Columbia Childrens Hosp, Pharmaceut Outcomes Programme, Vancouver, BC, Canada.
C3 University of British Columbia; University of British Columbia; Child &
   Family Research Institute; University of British Columbia; BC Childrens
   Hospital; University of British Columbia
RP Etminan, M (通讯作者)，Univ British Columbia, Dept Ophthalmol & Visual Sci, Fac Med, Room 323-2550 Willow St, Vancouver, BC V5Z 3N9, Canada.
EM etminanm@mail.ubc.ca
OI Carleton, Bruce/0000-0002-4485-4054
CR Adelman RA, 2010, J OCUL PHARMACOL TH, V26, P105, DOI 10.1089/jop.2009.0076
   Baek SU, 2016, CUTAN OCUL TOXICOL, V35, P310, DOI 10.3109/15569527.2015.1124886
   Bakri SJ, 2010, AAO ANN M OCT 15 201
   Bakri SJ, 2008, GRAEF ARCH CLIN EXP, V246, P955, DOI 10.1007/s00417-008-0819-2
   Boyer D, 2012, OPHTHALMOLOGY, V119, P1024, DOI 10.1016/j.ophtha.2012.01.042
   Boyer D, 2010, OPHTHALMOLOGY, V117, P1860, DOI 10.1016/j.ophtha.2010.02.022
   Bressler SB, 2015, JAMA OPHTHALMOL, V133, P589, DOI 10.1001/jamaophthalmol.2015.186
   British Columbia Ministry of Health, MED SERV PLAN MSP PA
   British Columbia Ministry of Health, PHARMANET
   British Columbia Ministry of Health, DISCH ABSTR DAT HOSP
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Campochiaro PA, 2010, OPHTHALMOLOGY, V117, P1102, DOI 10.1016/j.ophtha.2010.02.021
   Choi DY, 2011, RETINA-J RET VIT DIS, V31, P1028, DOI 10.1097/IAE.0b013e318217ffde
   Clark WL, 2016, OPHTHALMOLOGY, V123, P330, DOI 10.1016/j.ophtha.2015.09.035
   Etminan M, 2016, AM J OPHTHALMOL, V163, P53, DOI 10.1016/j.ajo.2015.11.030
   Etminan M, 2012, JAMA-J AM MED ASSOC, V307, P1414, DOI 10.1001/jama.2012.383
   Fielden M, 2011, ACTA OPHTHALMOL, V89, pe664, DOI 10.1111/j.1755-3768.2010.02054.x
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   General Assembly of the World Medical Association, 2014, J Am Coll Dent, V81, P14
   Good TJ, 2011, BRIT J OPHTHALMOL, V95, P1111, DOI 10.1136/bjo.2010.180729
   Heier JS, 2013, OPHTHALMOLOGY, V120, P209
   Hoang QV, 2013, RETINA-J RET VIT DIS, V33, P179, DOI 10.1097/IAE.0b013e318261a6f7
   Jalil A, 2007, EYE, V21, P1541, DOI 10.1038/sj.eye.6703018
   Kahook MY, 2009, OPHTHAL SURG LAS IM, V40, P293, DOI 10.3928/15428877-20090430-12
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   LANGHOLZ B, 1994, ENVIRON HEALTH PERSP, V102, P47, DOI 10.1289/ehp.94102s847
   Nguyen QD, 2009, OPHTHALMOLOGY, V116, P2175, DOI 10.1016/j.ophtha.2009.04.023
   Nguyen QD, 2012, OPHTHALMOLOGY, V119, P789, DOI 10.1016/j.ophtha.2011.12.039
   Ricca AM, 2015, J OCUL PHARMACOL TH, V31, P2, DOI 10.1089/jop.2014.0062
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Schisterman EF, 2009, EPIDEMIOLOGY, V20, P488, DOI 10.1097/EDE.0b013e3181a819a1
   Skalicky SE, 2012, OPHTHAL SURG LAS IM, V43, P328, DOI 10.3928/15428877-20120618-01
   SooHoo JR, 2014, CURR OPIN OPHTHALMOL, V25, P127, DOI 10.1097/ICU.0000000000000036
   Suissa S, 2012, DIABETES CARE, V35, P2665, DOI 10.2337/dc12-0788
   Wells JA, 2015, NEW ENGL J MED, V372, P1193, DOI 10.1056/NEJMoa1414264
   Yannuzzi NA, 2015, JAMA OPHTHALMOL, V133, P32, DOI 10.1001/jamaophthalmol.2014.3591
   Yannuzzi NA, 2014, AM J OPHTHALMOL, V158, P319, DOI 10.1016/j.ajo.2014.04.029
   Zhang TT, 2013, EUR J CLIN PHARMACOL, V69, P581, DOI 10.1007/s00228-012-1343-1
NR 38
TC 35
Z9 35
U1 0
U2 0
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 2168-6165
EI 2168-6173
J9 JAMA OPHTHALMOL
JI JAMA Ophthalmol.
PD APR 1
PY 2017
VL 135
IS 4
BP 363
EP 368
DI 10.1001/jamaophthalmol.2017.0059
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA ES3IQ
UT WOS:000399423700016
PM 28301639
OA Green Published
DA 2022-11-30
ER

PT J
AU Zhao, T
   Gao, JY
   Van, J
   To, E
   Wang, AK
   Cao, SJ
   Cui, JZ
   Guo, JP
   Lee, M
   McGeer, PL
   Matsubara, JA
AF Zhao, Tom
   Gao, Jiangyuan
   Van, Jenifer
   To, Eleanor
   Wang, Aikun
   Cao, Sijia
   Cui, Jing Z.
   Guo, Jian-Ping
   Lee, Moonhee
   McGeer, Patrick L.
   Matsubara, Joanne A.
TI Age-related increases in amyloid beta and membrane attack complex:
   evidence of inflammasome activation in the rodent eye
SO JOURNAL OF NEUROINFLAMMATION
LA English
DT Article
DE Age-related macular degeneration; Membrane attack complex; Amyloid beta;
   NLRP3 inflammasome; NF-kappa B; RPE/choroid
ID NF-KAPPA-B; RETINAL-PIGMENT EPITHELIUM; MACULAR-DEGENERATION; NLRP3
   INFLAMMASOME; A-BETA; CELLS; C3; PATHWAYS; DEPOSITS; PEPTIDE
AB Background: The membrane attack complex (MAC) is a key player in the pathogenesis of age-related macular degeneration (AMD) and is a putative activator of the NLRP3 inflammasome. Amyloid beta (A beta), a component of drusen deposits, has also been implicated in inflammasome activation by our work and those of others. However, the interactions of MAC and A beta are still poorly understood, especially their roles in aging and retinal degenerative pathologies. Since inflammasome activation may represent a key cellular pathway underlying age-related chronic inflammation in the eye, the purpose of this study is to identify the effects associated with MAC and inflammasome activation in the retinal pigment epithelium (RPE)/choroid and to evaluate the therapeutic merits of MAC suppression.
   Methods: Adult Long-Evans rats were divided into treatment and control groups. Treatment groups received oral aurin tricarboxylic acid complex (ATAC), a MAC inhibitor, in drinking-water, and control groups received drinking-water alone (No ATAC). Groups were sacrificed at 7.5 or 11.5 months, after approximately 40 days of ATAC treatment. To study age-related changes of A beta and MAC in RPE/choroid, naive animals were sacrificed at 2.5, 7.5, and 11.5 months. Eye tissues underwent immunohistochemistry and western blot analysis for MAC, A beta, NF-kappa B activation, as well as cleaved caspase-1 and IL-18. Vitreal samples were collected and assessed by multiplex assays for secreted levels of IL-18 and IL-1 beta. Statistical analyses were performed, and significance level was set at p <= 0.05.
   Results: In vivo studies demonstrated an age-dependent increase in MAC, A beta, and NF-kappa B activation in the RPE/choroid. Systemic ATAC resulted in a prominent reduction in MAC formation and a concomitant reduction in inflammasome activation measured by cleaved caspase-1 and secreted levels of IL-18 and IL-1 beta, but not in NF-kappa B activation. In vitro studies demonstrated A beta-induced MAC formation on RPE cells.
   Conclusions: Age-dependent increases in A beta and MAC are present in the rodent outer retina. Our results suggest that suppressing MAC formation and subsequent inflammasome activation in the RPE/choroid may reduce chronic low-grade inflammation associated with IL-18 and IL-1 beta in the outer retina.
C1 [Zhao, Tom; Gao, Jiangyuan; Van, Jenifer; To, Eleanor; Wang, Aikun; Cao, Sijia; Cui, Jing Z.; Matsubara, Joanne A.] Univ British Columbia, Dept Ophthalmol & Visual Sci, Fac Med, Vancouver, BC V5Z 3N9, Canada.
   [Guo, Jian-Ping; Lee, Moonhee; McGeer, Patrick L.] Univ British Columbia, Kinsmen Lab Neurol Res, Vancouver, BC V5Z 3N9, Canada.
C3 University of British Columbia; University of British Columbia
RP Matsubara, JA (通讯作者)，Univ British Columbia, Dept Ophthalmol & Visual Sci, Fac Med, 2550 Willow St, Vancouver, BC V5Z 3N9, Canada.
EM jms@mail.ubc.ca
FU CIHR [MOP 97806, MOP 126195]; VGH + UBC Hospital Foundation
FX CIHR (MOP 97806, MOP 126195) and VGH + UBC Hospital Foundation
CR Anderson DH, 2010, PROG RETIN EYE RES, V29, P95, DOI 10.1016/j.preteyeres.2009.11.003
   Ardeljan D, 2013, PROG RETIN EYE RES, V37, P68, DOI 10.1016/j.preteyeres.2013.07.003
   Boulton M, 2001, EYE, V15, P384, DOI 10.1038/eye.2001.141
   Cao SJ, 2013, AM J OPHTHALMOL, V156, P1176, DOI 10.1016/j.ajo.2013.08.003
   Cao SJ, 2013, MOL VIS, V19, P718
   Chen HY, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002339
   Chen M, 2010, INVEST OPHTH VIS SCI, V51, P5888, DOI 10.1167/iovs.09-5103
   Ferriani VPL, 1999, ACTA PAEDIATR, V88, P1062, DOI 10.1080/08035259950168081
   Gao JY, 2015, MEDIAT INFLAMM, V2015, DOI 10.1155/2015/690243
   GarzonRodriguez W, 1997, J BIOL CHEM, V272, P21037, DOI 10.1074/jbc.272.34.21037
   HAASS C, 1992, NATURE, V359, P322, DOI 10.1038/359322a0
   Huang Y, 2002, J IMMUNOL, V169, P2627, DOI 10.4049/jimmunol.169.5.2627
   Isas JM, 2010, INVEST OPHTH VIS SCI, V51, P1304, DOI 10.1167/iovs.09-4207
   Johnson LV, 2002, P NATL ACAD SCI USA, V99, P11830, DOI 10.1073/pnas.192203399
   Kam JH, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013127
   Kurji KH, 2010, INVEST OPHTH VIS SCI, V51, P1151, DOI 10.1167/iovs.09-3622
   Laudisi F, 2013, J IMMUNOL, V191, P1006, DOI 10.4049/jimmunol.1300489
   Lee M, 2013, NEUROBIOL AGING, V34, P1451, DOI 10.1016/j.neurobiolaging.2012.10.023
   Lee M, 2012, NEUROBIOL AGING, V33, P2237, DOI 10.1016/j.neurobiolaging.2011.12.005
   Lin H, 2001, FASEB J, V15, P2433, DOI 10.1096/fj.01-0377com
   Liu RZT, 2014, EXP EYE RES, V127, P49, DOI 10.1016/j.exer.2014.07.003
   Liu RT, 2013, INVEST OPHTH VIS SCI, V54, P2225, DOI 10.1167/iovs.12-10849
   Lueck K, 2011, EYE, V25, P1074, DOI 10.1038/eye.2011.109
   Moon MR, 1999, J SURG RES, V82, P48, DOI 10.1006/jsre.1998.5503
   Mullins RF, 2014, AM J PATHOL, V184, P3142, DOI 10.1016/j.ajpath.2014.07.017
   Mullins RF, 2011, EXP EYE RES, V93, P565, DOI 10.1016/j.exer.2011.06.015
   Perkins ND, 2012, NAT REV CANCER, V12, P121, DOI 10.1038/nrc3204
   Prakasam A, 2010, J ALZHEIMERS DIS, V20, P1243, DOI 10.3233/JAD-2010-100210
   Ricklin D, 2010, NAT IMMUNOL, V11, P785, DOI 10.1038/ni.1923
   Rodriguez-Muela N, 2013, AGING CELL, V12, P478, DOI 10.1111/acel.12072
   ROGERS J, 1992, P NATL ACAD SCI USA, V89, P10016, DOI 10.1073/pnas.89.21.10016
   Sarroukh R, 2011, CELL MOL LIFE SCI, V68, P1429, DOI 10.1007/s00018-010-0529-x
   Seth A, 2008, INVEST OPHTH VIS SCI, V49, P743, DOI 10.1167/iovs.07-1072
   Shen Y, 2013, TRANSL NEURODEGENER, V2, DOI 10.1186/2047-9158-2-21
   Stine WB, 2011, METHODS MOL BIOL, V670, P13, DOI 10.1007/978-1-60761-744-0_2
   Tarallo V, 2012, CELL, V149, P847, DOI 10.1016/j.cell.2012.03.036
   Triantafilou K, 2013, J CELL SCI, V126, P2903, DOI 10.1242/jcs.124388
   Valazquez P, 1997, NAT MED, V3, P77, DOI 10.1038/nm0197-77
   Whitmore SS, 2015, PROG RETIN EYE RES, V45, P1, DOI 10.1016/j.preteyeres.2014.11.005
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Xu HP, 2009, PROG RETIN EYE RES, V28, P348, DOI 10.1016/j.preteyeres.2009.06.001
   YU DY, 1989, J IMMUNOL, V143, P2395
NR 42
TC 31
Z9 33
U1 0
U2 8
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1742-2094
J9 J NEUROINFLAMM
JI J. Neuroinflamm.
PD JUN 24
PY 2015
VL 12
AR 121
DI 10.1186/s12974-015-0337-1
PG 14
WC Immunology; Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Immunology; Neurosciences & Neurology
GA CL6MB
UT WOS:000357080100001
PM 26104676
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Wang, SL
   Wang, BY
   Feng, Y
   Mo, MS
   Du, FY
   Li, HB
   Yu, XR
AF Wang, Shaolan
   Wang, Baoying
   Feng, Yan
   Mo, Mingshu
   Du, Fangying
   Li, Hongbo
   Yu, Xiaorui
TI 17 beta-Estradiol Ameliorates Light-Induced Retinal Damage in
   Sprague-Dawley Rats by Reducing Oxidative Stress
SO JOURNAL OF MOLECULAR NEUROSCIENCE
LA English
DT Article
DE Neuroprotection; 17 beta-estradiol; Retinal light damage; Oxidative
   stress; Intravitreal injection; Antioxidation
ID INTRAVITREAL INJECTIONS; PATHWAY; CELLS; NEUROPROTECTION; NEUROTOXICITY;
   COMPLICATIONS; DEGENERATION; MODULATION; ACTIVATION; EXPRESSION
AB Oxidative stress is considered as a major cause of light-induced retinal neurodegeneration. The protective role of 17 beta-estradiol (beta E2) in neurodegenerative disorders is well known, but its underlying mechanism remains unclear. Here, we utilized a light-induced retinal damage model to explore the mechanism by which beta E2 exerts its neuroprotective effect. Adult male and female ovariectomized (OVX) rats were exposed to 8,000 lx white light for 12 h to induce retinal light damage. Electroretinogram (ERG) assays and hematoxylin and eosin (H&E) staining revealed that exposure to light for 12 h resulted in functional damage to the rat retina, histological changes, and retinal neuron loss. However, intravitreal injection (IVI) of beta E2 significantly rescued this impaired retinal function in both female and male rats. Based on the level of malondialdehyde (MDA) production (a biomarker of oxidative stress), an increase in retinal oxidative stress followed light exposure, and beta E2 administration reduced this light-induced oxidative stress. Quantitative reverse-transcriptase (qRT)-PCR indicated that the messenger RNA (mRNA) levels of the antioxidant enzymes superoxide dismutase (SOD) and glutathione peroxidase (Gpx) were downregulated in female OVX rats but were upregulated in male rats after light exposure, suggesting a gender difference in the regulation of these antioxidant enzyme genes in response to light. However, beta E2 administration restored or enhanced the SOD and Gpx expression levels following light exposure. Although the catalase (CAT) expression level was insensitive to light stimulation, beta E2 also increased the CAT gene expression level in both female OVX and male rats. Further examination indicated that the antioxidant proteins thioredoxin (Trx) and nuclear factor erythroid 2-related factor 2 (Nrf2) are also involved in beta E2-mediated antioxidation and that the cytoprotective protein heme oxygenase-1 (HO-1) plays a key role in the endogenous defense mechanism against light exposure in a beta E2-independent manner. Taken together, we provide evidence that beta E2 protects against light-induced retinal damage via its antioxidative effect, and its underlying mechanism involves the regulation of the gene expression levels of antioxidant enzymes (SOD, CAT, and Gpx) and proteins (Trx and Nrf2). Our study provides conceptual evidence in support of estrogen replacement therapy for postmenopausal women to reduce the risk of age-related macular degeneration.
C1 [Wang, Shaolan; Wang, Baoying; Feng, Yan; Mo, Mingshu; Du, Fangying; Li, Hongbo; Yu, Xiaorui] Xi An Jiao Tong Univ, Sch Med, Dept Genet & Mol Biol, Xian 710049, Peoples R China.
   [Yu, Xiaorui] Xi An Jiao Tong Univ, Sch Med, Minist Educ, Key Lab Environm & Gene Related Dis, Xian 710049, Peoples R China.
C3 Xi'an Jiaotong University; Xi'an Jiaotong University
RP Yu, XR (通讯作者)，Xi An Jiao Tong Univ, Sch Med, Minist Educ, Key Lab Environm & Gene Related Dis, Xian 710049, Peoples R China.
EM xiaoruiy@mail.xjtu.edu.cn
RI Mo, Mingshu/S-1388-2019
FU National Natural Science Foundation of China [30672286, 81271013];
   National Research Foundation for the Doctoral Program of Higher
   Education of China [20120201110051]
FX This work was supported by the National Natural Science Foundation of
   China (no. 30672286 and no. 81271013) and the National Research
   Foundation for the Doctoral Program of Higher Education of China (no.
   20120201110051).
CR Amtul Z, 2010, NEUROSCIENCE, V169, P781, DOI 10.1016/j.neuroscience.2010.05.031
   Ba F, 2004, NEUROCHEM INT, V44, P401, DOI 10.1016/j.neuint.2003.08.004
   Blanchet PJ, 1999, NEUROLOGY, V53, P91, DOI 10.1212/WNL.53.1.91
   Chiu K, 2007, J VIS EXP, V313
   Desikan R, 2001, PLANT PHYSIOL, V127, P159, DOI 10.1104/pp.127.1.159
   Dong J, 2008, ANTIOXID REDOX SIGN, V10, P2023, DOI 10.1089/ars.2007.2019
   Feng Y, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0077218
   Garcia-Segura LM, 2001, PROG NEUROBIOL, V63, P29, DOI 10.1016/S0301-0082(00)00025-3
   Green PG, 1999, J NEUROSCI, V19, P4082
   Hertrampf T, 2006, PLANTA MED, V72, P484, DOI 10.1055/s-2006-931579
   Ishihara Y, 2014, LIFE SCI, V99, P24, DOI 10.1016/j.lfs.2014.01.061
   Jarrett SG, 2008, PROG RETIN EYE RES, V27, P596, DOI 10.1016/j.preteyeres.2008.09.001
   Jonas JB, 2004, GRAEF ARCH CLIN EXP, V242, P184, DOI 10.1007/s00417-003-0841-3
   KANG YH, 1975, J CELL BIOL, V64, P682, DOI 10.1083/jcb.64.3.682
   Kensler TW, 2007, ANNU REV PHARMACOL, V47, P89, DOI 10.1146/annurev.pharmtox.46.120604.141046
   Kim YC, 2003, ONCOGENE, V22, P1860, DOI 10.1038/sj.onc.1206369
   Li HB, 2013, J MOL NEUROSCI, V50, P482, DOI 10.1007/s12031-013-9968-9
   Mandal MNA, 2009, FREE RADICAL BIO MED, V46, P672, DOI 10.1016/j.freeradbiomed.2008.12.006
   Mitsuishi Y, 2012, CANCER CELL, V22, P66, DOI 10.1016/j.ccr.2012.05.016
   Mo MS, 2013, NEUROSCIENCE, V228, P1, DOI 10.1016/j.neuroscience.2012.10.002
   Noell W K, 1966, Invest Ophthalmol, V5, P450
   Peyman GA, 2009, RETINA-J RET VIT DIS, V29, P875, DOI 10.1097/IAE.0b013e3181a94f01
   Quintanilla RA, 2005, J BIOL CHEM, V280, P11615, DOI 10.1074/jbc.M411936200
   Ramezani A, 2011, PHARMACOL BIOCHEM BE, V100, P144, DOI 10.1016/j.pbb.2011.07.010
   Sampat KM, 2010, CURR OPIN OPHTHALMOL, V21, P178, DOI 10.1097/ICU.0b013e328338679a
   Semeraro F, 2014, EXPERT OPIN DRUG SAF, V13, P785, DOI 10.1517/14740338.2014.911284
   Stocker R, 2006, CIRCULATION, V114, P2178, DOI 10.1161/CIRCULATIONAHA.105.598698
   Taylor H R, 1990, Trans Am Ophthalmol Soc, V88, P163
   Taylor HR, 1990, T AM OPHTHAL SOC, V88, P173
   Tripanichkul W, 2007, BRAIN RES, V1164, P24, DOI 10.1016/j.brainres.2007.05.076
   Wang Chao-Yung, 2010, Chang Gung Med J, V33, P13
   Wang L, 2008, INVEST OPHTH VIS SCI, V49, P1671, DOI 10.1167/iovs.07-1099
   Watanabe R, 2010, PHARMACOL THERAPEUT, V127, P261, DOI 10.1016/j.pharmthera.2010.04.004
   Yu JJ, 2012, J BIOCHEM MOL TOXIC, V26, P264, DOI 10.1002/jbt.21417
   Yu XR, 2005, MECH AGEING DEV, V126, P1135, DOI 10.1016/j.mad.2005.05.005
   Yusifov, 2000, Pathophysiology, V7, P203, DOI 10.1016/S0928-4680(00)00051-1
   Zhang X, 2012, NEUROSCIENCE, V220, P191, DOI 10.1016/j.neuroscience.2012.06.027
NR 37
TC 21
Z9 21
U1 2
U2 22
PU HUMANA PRESS INC
PI TOTOWA
PA 999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA
SN 0895-8696
EI 1559-1166
J9 J MOL NEUROSCI
JI J. Mol. Neurosci.
PD JAN
PY 2015
VL 55
IS 1
BP 141
EP 151
DI 10.1007/s12031-014-0384-6
PG 11
WC Biochemistry & Molecular Biology; Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Neurosciences & Neurology
GA AZ6PM
UT WOS:000348341300015
PM 25038876
DA 2022-11-30
ER

PT J
AU Qin, Q
   Knapinska, A
   Dobri, N
   Madoux, F
   Chase, P
   Hodder, P
   Petrukhin, K
AF Qin, Qiong
   Knapinska, Anna
   Dobri, Nicoleta
   Madoux, Franck
   Chase, Peter
   Hodder, Peter
   Petrukhin, Konstantin
TI In Pursuit of Synthetic Modulators for the Orphan Retina-Specific
   Nuclear Receptor NR2E3
SO JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS
LA English
DT Article
ID S-CONE SYNDROME; THYROID-HORMONE; TR-FRET; ROD; IDENTIFICATION;
   AGONISTS; ASSAY; TRANSCRIPTION; DEGENERATION; MUTATIONS
AB Purpose: NR2E3 is an orphan nuclear receptor expressed exclusively in photoreceptor cells of the retina. NR2E3-specific modulators may prolong photoreceptor survival in patients with dry age-related macular degeneration and other forms of retinal degeneration. To definitively establish NR2E3 as a photoreceptor protection target, identification of small-molecule NR2E3 modulators and their testing in animal models of retinal degeneration are required. Development of the high-throughput screen (HTS)-compatible screen for small-molecule NR2E3 modulators is the first step toward this goal.
   Methods: Purification protocol for isolation of the functionally competent soluble NR2E3 protein after its expression in the insect Sf9 cells was developed. The time-resolved fluorescence energy-transfer (TR-FRET) assay assessing agonist-sensitive interaction between apo-NR2E3 and transcriptional corepressor RetCOR was used for characterization of the previously reported putative NR2E3 agonist, Compound 11a, and to conduct the HTS for novel small-molecule NR2E3 modulators (direct and inverse agonists). A counterscreen TR-FRET assay that measures the affect of test compounds on PPAR gamma interaction with corepressor NCOR was used for assessing the specificity of compounds identified in the HTS.
   Results: We developed the cell-free TR-FRET assay for small-molecule NR2E3 modulators, which is based on agonist-induced disruption of the interaction between GST-tagged apo-NR2E3 and MBP-tagged fragment of transcriptional corepressor RetCOR. Compound 11a, a putative NR2E3 agonist, did not affect the NR2E3-RetCOR interaction, as was established by its titration in the developed assay. The assay was miniaturized for an ultralow-volume 1,536-well format and automated into 3 simple pipetting steps. Consistent with excellent assay performance, the test runs established a Z'-score within the 0.6-0.8 range. Analysis of the mid-size National Institutes of Health collection of 315,001 structurally diverse drug-like compounds confirmed excellent assay performance, but did not reveal NR2E3-specific agonists or inverse agonists.
   Conclusions: A robust and reliable TR-FRET assay for small-molecule NR2E3-specific modulators suitable for the analysis of million compound-strong HTS libraries was developed. A previously described putative NR2E3 agonist, Compound 11a, is unlikely to represent a direct NR2E3 agonist. Application of the developed assay for screening of a more abundant and diverse compound collection be required for identification of synthetic NR2E3 ligands.
C1 [Qin, Qiong; Dobri, Nicoleta; Petrukhin, Konstantin] Columbia Univ, Med Ctr, Dept Ophthalmol, New York, NY 10032 USA.
   [Knapinska, Anna; Madoux, Franck; Chase, Peter; Hodder, Peter] Scripps Res Inst, Translat Res Inst, Mol Screening Ctr, Lead Identificat Div, Jupiter, FL USA.
   [Hodder, Peter] Scripps Florida, Dept Mol Therapeut, Jupiter, FL USA.
C3 Columbia University; Scripps Research Institute; State University System
   of Florida; University of Florida
RP Petrukhin, K (通讯作者)，Columbia Univ, Med Ctr, Dept Ophthalmol, 630 W 168th St, New York, NY 10032 USA.
EM kep4@columbia.edu
OI Petrukhin, Konstantin/0000-0002-5545-6924
FU NIH [1R21NS061718-01, P30 EY019007, U54 MH084512]; Research to Prevent
   Blindness (New York, NY); NATIONAL EYE INSTITUTE [P30EY019007] Funding
   Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [U54MH084512]
   Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL
   DISORDERS AND STROKE [R21NS061718] Funding Source: NIH RePORTER
FX The authors thank Pierre Baillargeon and Lina DeLuca (Lead
   Identification Division, Scripps Florida) for compound management. This
   research was supported by the NIH Grants 1R21NS061718-01 (K. P.), P30
   EY019007 (Core Support for Vision Research; Columbia University Medical
   Center), U54 MH084512 (A. K., F. M., P. C., P. H.), and unrestricted
   funds from Research to Prevent Blindness (New York, NY) to the
   Department of Ophthalmology, Columbia University. This research was also
   supported by gifts from The Burch Family Foundation, the Mary
   Jaharis-John Catsimatidis Scholarship Fund, the Eye Surgery Fund, and
   the Kaplen Foundation.
CR Akhmedov NB, 2000, P NATL ACAD SCI USA, V97, P5551, DOI 10.1073/pnas.97.10.5551
   Bondos SE, 2003, ANAL BIOCHEM, V316, P223, DOI 10.1016/S0003-2697(03)00059-9
   Chatterjee VKK, 2001, BIOCHEM SOC T, V29, P227, DOI 10.1042/bst0290227
   Chawla A, 2001, SCIENCE, V294, P1866, DOI 10.1126/science.294.5548.1866
   Chen JC, 2005, J NEUROSCI, V25, P118, DOI 10.1523/JNEUROSCI.3571-04.2005
   CHEN JD, 1995, NATURE, V377, P454, DOI 10.1038/377454a0
   Cheng H, 2004, HUM MOL GENET, V13, P1563, DOI 10.1093/hmg/ddh173
   Chin J, 2003, ASSAY DRUG DEV TECHN, V1, P777, DOI 10.1089/154065803772613417
   Coppieters F, 2007, AM J HUM GENET, V81, P147, DOI 10.1086/518426
   Escher P, 2009, HUM MUTAT, V30, P342, DOI 10.1002/humu.20858
   Francis GA, 2003, ANNU REV PHYSIOL, V65, P261, DOI 10.1146/annurev.physiol.65.092101.142528
   Fujmura T, 2006, BIOL PHARM BULL, V29, P423, DOI 10.1248/bpb.29.423
   Gerber S, 2000, HUM GENET, V107, P276, DOI 10.1007/s004390000350
   Glickman JF, 2002, J BIOMOL SCREEN, V7, P3, DOI 10.1177/108705710200700102
   Haider NB, 2000, NAT GENET, V24, P127, DOI 10.1038/72777
   Haider NB, 2001, HUM MOL GENET, V10, P1619, DOI 10.1093/hmg/10.16.1619
   Hilal T, 2010, J BIOMOL SCREEN, V15, P268, DOI 10.1177/1087057109359196
   HORLEIN AJ, 1995, NATURE, V377, P397, DOI 10.1038/377397a0
   Kapitskaya M, 2006, ASSAY DRUG DEV TECHN, V4, P253, DOI 10.1089/adt.2006.4.253
   Kobayashi M, 1999, P NATL ACAD SCI USA, V96, P4814, DOI 10.1073/pnas.96.9.4814
   Latchman D. S., 1993, TRANSCRIPTION FACTOR
   Madoux F, 2008, MOL PHARMACOL, V73, P1776, DOI 10.1124/mol.108.045963
   MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X
   Milam AH, 2002, P NATL ACAD SCI USA, V99, P473, DOI 10.1073/pnas.022533099
   Nakamura M, 2002, AM J OPHTHALMOL, V133, P575, DOI 10.1016/S0002-9394(01)01428-3
   O'Brien KMB, 2004, INVEST OPHTH VIS SCI, V45, P2807, DOI 10.1167/iovs.03-1317
   Peng GH, 2005, HUM MOL GENET, V14, P747, DOI 10.1093/hmg/ddi070
   Petrukhin K, 2007, EXPERT OPIN THER TAR, V11, P625, DOI 10.1517/14728222.11.5.625
   Sharon D, 2003, ARCH OPHTHALMOL-CHIC, V121, P1316, DOI 10.1001/archopht.121.9.1316
   Takezawa S, 2007, EMBO J, V26, P764, DOI 10.1038/sj.emboj.7601548
   Ueno S, 2005, EXP EYE RES, V81, P751, DOI 10.1016/j.exer.2005.04.013
   Webber AL, 2008, EXP EYE RES, V87, P35, DOI 10.1016/j.exer.2008.04.006
   Wolkenberg SE, 2006, BIOORG MED CHEM LETT, V16, P5001, DOI 10.1016/j.bmcl.2006.07.056
   Zhang JH, 1999, J BIOMOL SCREEN, V4, P67, DOI 10.1177/108705719900400206
NR 34
TC 12
Z9 12
U1 0
U2 12
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1080-7683
EI 1557-7732
J9 J OCUL PHARMACOL TH
JI J. Ocular Pharmacol. Ther.
PD APR
PY 2013
VL 29
IS 3
BP 298
EP 309
DI 10.1089/jop.2012.0135
PG 12
WC Ophthalmology; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology; Pharmacology & Pharmacy
GA 117IP
UT WOS:000316947100004
PM 23098562
OA Green Published
DA 2022-11-30
ER

PT J
AU Michels, S
   Schmidt-Erfurth, U
AF Michels, S
   Schmidt-Erfurth, U
TI Sequence of early vascular events after photodynamic therapy
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID CHOROIDAL NEOVASCULARIZATION; OCCLUSION
AB PURPOSE. To identify early vascular changes in choroidal neovascularization (CNV) and in adjacent normal choroid, after photodynamic therapy (PDT).
   METHODS. In a prospective study, 40 patients with predominantly classic CNV due to age-related macular degeneration (AMD) were treated with PDT performed with verteporfin. Verteporfin was administered intravenously at a dose of 6 mg/m(2) body surface area. A near infrared laser tight dose of 50 J/cm(2), an irradiance of 600 mW/cm(2) and a wavelength of 692 nm was applied. A scanning laser system was used to perform confocal fluorescein angiography (FA) and indocyanine green angiography (ICGA) before treatment and regularly at 5 hours, I day, I week, and 3 months after PDT. Images were analyzed for CNV size and leakage area as seen by FA and ICGA. Collateral damage within the surrounding choroid was documented based on the hypofluorescence in early- and late-phase ICGA.
   RESULTS. No immediate occlusion of the CNV complex was found angiographically, but a dynamic change over time was observed in the early perfusion patterns and late-phase hyper- and hypofluorescence. At 5 hours after treatment, large portions of the CNV lesion were still perfused. One day after PDT, CNV size in early FA and early ICGA reached its minimum, at 0.49 mm(2) (15.7%) and 0.78 mm(2) (31.1%) of the initial area, respectively. In late-phase FA and ICGA, however, an immediate massive exudation with a continuous increase in hyperfluorescence originated from the CNV and surrounding choroid, with a maximum in leakage area at 1 day. At 1 week PDT-induced exudation slowly resolved. Eyes in 36 patients showed some choroidal hypofluorescence by ICGA before treatment. A progressive increase of the hypofluorescent area surrounding the CNV was observed, which correlated with the size of the laser spot. Maximum hypofluorescence was noted at 1 week with an average size of 11.1 mm(2) in early- and late-phase ICGA.
   CONCLUSIONS. In contrast to findings in experimental animals, PDT in humans with classic CNV did not induce immediate thrombosis, but primarily caused a breakdown of vascular barriers. A characteristic sequence of vascular changes was observed with early, enhanced leakage from the CNV and normal choroid followed by nonperfusion later. Occlusion of the CNV lesions occurred 1 day after treatment, but closure of the adjacent choroidal vessels proceeded slowly over as long as 1 week.
C1 Univ Eye Hosp Lubeck, D-23538 Lubeck, Germany.
RP Michels, S (通讯作者)，Univ Eye Hosp Lubeck, Ratzeburger Allee 160, D-23538 Lubeck, Germany.
EM stmichels@web.de
CR Arnold J, 2001, OPHTHALMOLOGY, V108, P841
   Arnold J, 2001, AM J OPHTHALMOL, V131, P541
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Fingar V H, 1996, J Clin Laser Med Surg, V14, P323
   Fingar VH, 1999, BRIT J CANCER, V79, P1702, DOI 10.1038/sj.bjc.6690271
   Flower RW, 1999, RETINA-J RET VIT DIS, V19, P365
   FOGELMAN AM, 1988, SEMIN THROMB HEMOST, V14, P206, DOI 10.1055/s-2007-1002778
   GAFFNEY J, 1985, J CELL SCI, V79, P317
   HENDERSON BW, 1992, PHOTOCHEM PHOTOBIOL, V55, P145, DOI 10.1111/j.1751-1097.1992.tb04222.x
   Lanzetta P, 2002, OPHTHALMOLOGY, V109, P1098, DOI 10.1016/S0161-6420(02)01034-5
   LIN SC, 1994, CURR EYE RES, V13, P513, DOI 10.3109/02713689408999883
   Michels S, 2000, KLIN MONATSBL AUGENH, V217, P94, DOI 10.1055/s-2000-10391
   MILLER H, 1993, ARCH OPHTHALMOL-CHIC, V111, P855, DOI 10.1001/archopht.1993.01090060145039
   MILLER JW, 1995, ARCH OPHTHALMOL-CHIC, V113, P810, DOI 10.1001/archopht.1995.01100060136048
   Parodi MB, 2001, GRAEF ARCH CLIN EXP, V239, P900, DOI 10.1007/s00417-001-0387-1
   Peyman GA, 2000, OPHTHALMOLOGY, V107, P29, DOI 10.1016/S0161-6420(99)00012-3
   RODGERS MAJ, 1988, J PHOTOCH PHOTOBIO B, V1, P371, DOI 10.1016/1011-1344(88)85024-3
   Schmidt-Erfurth U, 2002, ARCH OPHTHALMOL-CHIC, V120, P835
   Schmidt-Erfurth U, 1999, ARCH OPHTHALMOL-CHIC, V117, P1177
   Schmidt-Erfurth U, 2002, INVEST OPHTH VIS SCI, V43, P830
   Schmidt-Erfurth U., 1994, Ophthalmologe, V91, P348
   Schmidt-Erfurth U, 1999, Semin Ophthalmol, V14, P35, DOI 10.3109/08820539909056061
   SCHMIDTERFURTH U, 1994, OPHTHALMOLOGY, V101, P1953
   SCHMIDTERFURTH U, 1994, OPHTHALMOLOGY, V101, P89
   SCHMIDTERFURTH U, 1995, LASER SURG MED, V17, P178, DOI 10.1002/lsm.1900170207
   Shiraga F, 2000, OPHTHALMOLOGY, V107, P600, DOI 10.1016/S0161-6420(99)00126-8
   STERNBERG P, 1991, ARCH OPHTHALMOL-CHIC, V109, P1242
NR 28
TC 142
Z9 150
U1 0
U2 8
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD MAY
PY 2003
VL 44
IS 5
BP 2147
EP 2154
DI 10.1167/iovs.02-0604
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 672CQ
UT WOS:000182503700050
PM 12714655
DA 2022-11-30
ER

PT J
AU Casillo, L
   Tricarico, S
   Contento, L
   Vingolo, EM
AF Casillo, Lorenzo
   Tricarico, Stefano
   Contento, Laura
   Vingolo, Enzo M.
TI Clinical Features, Prognosis, and Long-Term Response to Ranibizumab of
   Macular CNVs in Pattern Dystrophies Spectrum: A Pilot Study
SO JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID FOVEOMACULAR VITELLIFORM DYSTROPHY; SUBFOVEAL CHOROIDAL THICKNESS;
   OPTICAL COHERENCE TOMOGRAPHY; AGE; DEGENERATION; BEVACIZUMAB; EYES
AB Introduction. To analyze the morphological and functional features of choroidal neovascularizations (CNVs) in eyes affected by pattern dystrophies (PD), evaluating their long-term response to intravitreal ranibizumab, and comparing them with CNVs in age-related macular degeneration (AMD). The mean goal is to identify possible disease biomarkers and to evaluate the long-term prognosis of CNVs in PD. Materials and Methods. A retrospective study of 42 patients with naive CNV (26 PD and 16 AMD), for a total of 47 eyes (29 eyes in the PD group and 18 eyes in the AMD group). Each patient received a loading dose of ranibizumab (one monthly for three months) followed by pro re nata (PRN) reinjection protocol for a period of at least three years. Morphological OCT parameters (CRT, central retinal thickness; SRF, subretinal fluid; IRF, intraretinal fluid; SHRM, subretinal hyperreflective material; HRF, hyperreflective foci; HCD, hyperreflective crystalline deposits; cCT, central choroidal thickness; slCT, sublesional choroidal thickness; EZd, ellipsoid zone disruption; and best corrected visual acuity (BCVA in logMAR scale)) were reported at baseline and last follow-up. Results. At baseline, no significant differences were found between the two groups, except for choroidal thickness parameters that were significantly greater in the PD group (p=0.009). Longitudinal PD analysis demonstrated reduction in BCVA (p=0.009), decrease in CRT (p=0.046), resolution of SRF in 61.6% of cases (p=0.004) and SHRM in 30% (p=0.034), and choroidal thinning both centrally (p=0.004) and sublesional (p=0.011) compared to baseline. At 3 years, the PD group received significantly more injections than the AMD (p=0.011) and showed significantly thicker choroid (p=0.033) and more frequent HRF (p=0.006). Regarding the PD group, we found a negative correlation between age and choroidal thicknesses at baseline and at 3 years (p<0.05); significant positive correlations were found between baseline BCVA and at 3 years (p<0.001), BCVA at 3 years and IRF (p=0.003) and SHRM at 3 years (p=0.003); CRT baseline and CRT 3 years (p=0.017); HCD at 3 years was associated with greater CRT (p=0.04) and IRF at 3 years (p=0.019). Conclusions. Early and long-term morphofunctional features of CNVs in PD and in AMD are overlapping. CNVs in PD have poorer long-term response to ranibizumab and higher choroidal thickness suggesting different pathogenetic and evolutionary mechanisms.
C1 [Casillo, Lorenzo; Tricarico, Stefano; Contento, Laura; Vingolo, Enzo M.] Sapienza Univ Rome, UOC Ophthalmol, Osped A Fiorini Terracina, I-04120 Terracina, Italy.
C3 Sapienza University Rome
RP Casillo, L (通讯作者)，Sapienza Univ Rome, UOC Ophthalmol, Osped A Fiorini Terracina, I-04120 Terracina, Italy.
EM lorenzo.casillo@uniroma1.it
OI Casillo, Lorenzo/0000-0002-6265-5921
CR [Anonymous], 1997, DIAGNOSIS TREATMENT
   Cennamo G, 2012, J OCUL PHARMACOL TH, V28, P643, DOI 10.1089/jop.2011.0250
   Coscas F, 2014, INVEST OPHTH VIS SCI, V55, P64, DOI 10.1167/iovs.13-12931
   Fragiotta S, 2020, GRAEF ARCH CLIN EXP, V258, P491, DOI 10.1007/s00417-019-04565-y
   Fragiotta S, 2019, INVEST OPHTH VIS SCI, V60, P3100, DOI 10.1167/iovs.19-26589
   Francis PJ, 2005, BRIT J OPHTHALMOL, V89, P1115, DOI 10.1136/bjo.2004.062695
   Grenga PL, 2016, EUR J OPHTHALMOL, V26, P145, DOI 10.5301/ejo.5000687
   Imamura Y, 2009, RETINA-J RET VIT DIS, V29, P1469, DOI 10.1097/IAE.0b013e3181be0a83
   Kim SW, 2011, RETINA-J RET VIT DIS, V31, P1904, DOI 10.1097/IAE.0b013e31821801c5
   Koizumi H, 2011, GRAEF ARCH CLIN EXP, V249, P1123, DOI 10.1007/s00417-011-1620-1
   Maruko I, 2011, RETINA-J RET VIT DIS, V31, P1603, DOI 10.1097/IAE.0b013e31820f4b39
   Mimoun G, 2013, RETINA-J RET VIT DIS, V33, P513, DOI 10.1097/IAE.0b013e3182753adb
   Palacios Renato Menezes, 2016, Int J Retina Vitreous, V2, P5, DOI 10.1186/s40942-016-0031-1
   Pang CE, 2015, OPHTHALMOLOGY, V122, P2316, DOI 10.1016/j.ophtha.2015.07.008
   Parodi MB, 2010, INVEST OPHTH VIS SCI, V51, P4358, DOI 10.1167/iovs.10-5237
   Querques G, 2013, J FR OPHTALMOL, V36, pE1, DOI 10.1016/j.jfo.2012.04.013
   Roberts PK, 2019, INVEST OPHTH VIS SCI, V60, P304, DOI 10.1167/iovs.18-25189
   Tiosano L, 2014, EUR J OPHTHALMOL, V24, P890, DOI 10.5301/ejo.5000486
   Tuncer I, 2015, INT OPHTHALMOL, V35, P403, DOI 10.1007/s10792-014-9962-4
   Yiu G, 2015, AM J OPHTHALMOL, V159, P617, DOI 10.1016/j.ajo.2014.12.010
   Zhou H, 2020, OPHTHALMOL RETINA, V4, P204, DOI 10.1016/j.oret.2019.09.012
NR 21
TC 0
Z9 0
U1 0
U2 2
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 2090-004X
EI 2090-0058
J9 J OPHTHALMOL
JI J. Ophthalmol.
PD APR 17
PY 2021
VL 2021
DI 10.1155/2021/6698522
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA SV1HW
UT WOS:000663577300001
PM 33953968
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Ohayon, A
   Sacconi, R
   Semoun, O
   Corbelli, E
   Souied, EH
   Querques, G
AF Ohayon, Avi
   Sacconi, Riccardo
   Semoun, Oudy
   Corbelli, Eleonora
   Souied, Eric H.
   Querques, Giuseppe
TI CHOROIDAL NEOVASCULAR AREA AND VESSEL DENSITY COMPARISON BETWEEN TWO
   SWEPT-SOURCE OPTICAL COHERENCE TOMOGRAPHY ANGIOGRAPHY DEVICES
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE age-related macular degeneration; CNV area and vessel density
   comparison; comparison between OCTA devices; optical coherence
   tomography angiography
ID SPECTRAL-DOMAIN; REPRODUCIBILITY; REPEATABILITY; SECONDARY; EYES
AB Purpose: To compare choroidal neovascularization (CNV) area and vessel density (VD) measurements between two different swept-source optical coherence tomography angiography (SS-OCTA) devices. Methods: En face optical coherence tomography angiography (OCTA) images of patients affected by neovascular age-related macular degeneration were collected prospectively from two devices: Zeiss PLEX Elite 9000 (Carl Zeiss Meditec, Dublin, CA) and Topcon DRI OCT Triton SS-OCTA (Topcon, Tokyo, Japan). Choroidal neovascularization area and VD of images were measured and analyzed with ImageJ software by two readers to evaluate the agreement between two devices, with respect to different image size (3 x 3 and 6 x 6 mm) and different image segmentation (automatic vs. manual), and a Topcon equivalent Zeiss segmentation as control (i.e., the equivalent anatomical slab given by Topcon device on the Zeiss device). Results: A total of 30 eyes (30 patients) were analyzed. There was an excellent agreement between the two readers in CNV area measurements intraclass correlation coefficient >0.9 in all analyses. We found excellent agreement in CNV area measurements (manual and automatic segmentations) when comparing 3 x 3-mm or 6 x 6-mm images both for each single device and between the two devices (overall intraclass correlation coefficient > 0.9). Vessel density measurements between manual to automatic segmentation within the same device and same image size had a high intraclass correlation coefficient value, but there was a poor agreement in VD between different image sizes (3 x 3 mm vs. 6 x 6 mm) in the same device and also comparing the two devices (3 x 3 Topcon vs. 3 x 3 Zeiss; 6 x 6 Topcon vs. 6 x 6 Zeiss). There was a poor agreement between the Topcon equivalent Zeiss segmentation and all other segmentations. Conclusion: There was an excellent agreement in CNV area measurements for both swept-source optical coherence tomography angiography devices in automatic and manual segmentations. However, the Topcon equivalent Zeiss segmentation was not comparable with any of the preset segmentations of Topcon and Zeiss devices. There was a poor agreement in CNV VD between different image size and different devices. For these reasons, it seems that, for accurate longitudinal analysis of VD, it is better to use the same device for each individual, even if both devices can be used interchangeably for CNV area measurements using automatic or manual segmentations.
C1 [Ohayon, Avi; Semoun, Oudy; Souied, Eric H.; Querques, Giuseppe] Univ Paris Est Creteil, Ctr Hosp Intercommunal Creteil, Dept Ophthalmol, Creteil, France.
   [Sacconi, Riccardo; Corbelli, Eleonora; Querques, Giuseppe] Univ Vita Salute, Dept Ophthalmol, IRCCS Osped San Raffaele, Via Olgettina 60, I-20132 Milan, Italy.
   [Sacconi, Riccardo] Univ Verona, Dept Neurol, Biomed & Movement Sci, Eye Clin, Verona, Italy.
C3 Universite Paris-Est-Creteil-Val-de-Marne (UPEC); CHI Creteil;
   Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele;
   University of Verona
RP Querques, G (通讯作者)，Univ Vita Salute, Dept Ophthalmol, IRCCS Osped San Raffaele, Via Olgettina 60, I-20132 Milan, Italy.
EM giuseppe.querques@hotmail.it
RI Ohayon, Avi/R-2676-2018
OI Ohayon, Avi/0000-0002-4435-8659; Sacconi, Riccardo/0000-0003-2891-2012
CR Al-Sheikh M, 2018, RETINA-J RET VIT DIS, V38, P220, DOI 10.1097/IAE.0000000000001628
   Al-Sheikh M, 2017, BRIT J OPHTHALMOL, V101, P449, DOI 10.1136/bjophthalmol-2016-308764
   Bruyere E, 2017, RETINA-J RET VIT DIS, V37, P2095, DOI 10.1097/IAE.0000000000001456
   Chidambara L, 2016, BRIT J OPHTHALMOL, V100, P1482, DOI 10.1136/bjophthalmol-2015-307941
   Corbelli E, 2018, RETINA-J RET VIT DIS, V38, P2128, DOI 10.1097/IAE.0000000000001859
   Corvi F, 2018, AM J OPHTHALMOL, V186, P25, DOI 10.1016/j.ajo.2017.11.011
   Costanzo E, 2016, INVEST OPHTH VIS SCI, V57, pOCT307, DOI 10.1167/iovs.15-18830
   Costanzo E, 2015, J OPHTHALMOL, V2015, DOI 10.1155/2015/134783
   de Carlo TE, 2015, OPHTHALMOLOGY, V122, P1228, DOI 10.1016/j.ophtha.2015.01.029
   Guduru A, 2018, BRIT J OPHTHALMOL, V102, P444, DOI 10.1136/bjophthalmol-2017-310586
   Inoue M, 2016, INVEST OPHTH VIS SCI, V57, pOCT314, DOI 10.1167/iovs.15-18900
   Lei JQ, 2017, JAMA OPHTHALMOL, V135, P1092, DOI 10.1001/jamaophthalmol.2017.3431
   Miller AR, 2017, INVEST OPHTH VIS SCI, V58, P1499, DOI 10.1167/iovs.16-20969
   Novais EA, 2016, AM J OPHTHALMOL, V164, P80, DOI 10.1016/j.ajo.2016.01.011
   Querques G, 2016, BRIT J OPHTHALMOL, V100, P1724, DOI 10.1136/bjophthalmol-2016-308370
   Querques G, 2016, DEV OPHTHALMOL, V56, P101, DOI 10.1159/000442800
   Roisman L, 2016, OPHTHALMOLOGY, V123, P1309, DOI 10.1016/j.ophtha.2016.01.044
   Sacconi R, 2018, RETINA-J RET VIT DIS, V38, P2350, DOI 10.1097/IAE.0000000000001873
   Shahlaee A, 2016, AM J OPHTHALMOL, V161, P50, DOI 10.1016/j.ajo.2015.09.026
   Souied EH, 2016, DEV OPHTHALMOL, V56, P52, DOI 10.1159/000442777
   You QS, 2017, RETINA-J RET VIT DIS, V37, P1475, DOI 10.1097/IAE.0000000000001407
   Zahid S, 2017, RETINA-J RET VIT DIS, V37, P1451, DOI 10.1097/IAE.0000000000001381
   Zhang QQ, 2017, OPHTHALMOL RETINA, V1, P124, DOI 10.1016/j.oret.2016.08.005
   Zhang QQ, 2017, INVEST OPHTH VIS SCI, V58, P1506, DOI 10.1167/iovs.16-20977
NR 24
TC 13
Z9 14
U1 1
U2 5
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD MAR
PY 2020
VL 40
IS 3
BP 521
EP 528
DI 10.1097/IAE.0000000000002430
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA LA1RI
UT WOS:000523731700015
PM 30589664
DA 2022-11-30
ER

PT J
AU Lee, SY
   Stetson, PF
   Ruiz-Garcia, H
   Heussen, FM
   Sadda, SR
AF Lee, Sun Young
   Stetson, Paul F.
   Ruiz-Garcia, Humberto
   Heussen, Florian M.
   Sadda, SriniVas R.
TI Automated Characterization of Pigment Epithelial Detachment by Optical
   Coherence Tomography
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID FLUORESCEIN ANGIOGRAPHY; SUBANALYSIS
AB PURPOSE. To assess the accuracy of automated classification of pigment epithelial detachments (PED) by using a software algorithm applied to spectral-domain optical coherence tomography (SD-OCT) scans.
   METHODS. HD-OCT (Cirrus; Carl Zeiss Meditec, Dublin, CA) volume scans (512 x 128) were retrospectively collected from 46 eyes of 33 patients with evidence of PED in the setting of age-related macular degeneration (AMD, n = 28) or central serous chorioretinopathy (CSCR, n = 5). In these eyes, 168 PEDs were automatically detected with a system-associated tool (Cirrus HD-OCT RPE Elevation Analysis; Carl Zeiss Meditec). Two independent, certified Doheny Image Reading Center (DIRC) OCT graders classified these PEDs into three categories-serous, drusenoid, or fibrovascular-via inspection of the B-scans. Manual classification results served as the gold standard for comparisons with automated classification. For automated classification, interindividual variation in intensities was normalized in all images. Individual A-scans within the detected PEDs were then automatically classified into one of three categories based on the mean internal intensity and the standard deviation of the internal intensity: mean intensity <30 (serous type); mean intensity >= 30 but >= 60 or mean intensity >= 30 and SD >= 30 (fibrovascular type); or mean intensity >= 60 and SD < 30 (drusenoid type). Individual PEDs were then automatically classified into the same three categories based on the predominant type of A-scan within the PED. For mixed PEDs (many A-scans of each type), a risk index for neovascularization was computed based on the percentage of fibrovascular A-scans. In addition, a confidence index was computed for each PED based on its mathematical distance from the PED category boundaries.
   RESULTS. Among the 168 PEDs, the DIRC graders classified 16 as serous, 88 as fibrovascular, and 64 as drusenoid PEDs. The automated algorithm classified 14 as serous, 96 as fibrovascular, and 58 as drusenoid PEDs. The sensitivity and specificity values for automated classification according to type of PED were 88% and 100% for serous, 76% and 64% for fibrovascular, and 58% and 81% for drusenoid, respectively.
   CONCLUSIONS. Automated classification of PEDs using internal reflectivity characteristics appears to be sensitive for detecting serous and fibrovascular PEDs. Automated classification and quantification of PEDs may be a useful tool in future studies for stratifying PEDs according to risk and possibly predicting the risk of advanced AMD. (Invest Ophthalmol Vis Sci. 2012;53:164-170) DOI:10.1167/iovs.11-8188
C1 [Lee, Sun Young; Ruiz-Garcia, Humberto; Heussen, Florian M.; Sadda, SriniVas R.] Univ So Calif, Keck Sch Med, Doheny Eye Inst, Doheny Image Reading Ctr, Los Angeles, CA 90033 USA.
   [Stetson, Paul F.] Carl Zeiss Meditec, Dublin, CA USA.
C3 Doheny Eye Institute; University of Southern California; Carl Zeiss AG
RP Sadda, SR (通讯作者)，Doheny Eye Inst DEI 3602, 1450 San Pablo St, Los Angeles, CA 90033 USA.
EM sadda@usc.edu
OI Heussen, Florian Moritz/0000-0003-0536-9870
FU Research to Prevent Blindness
FX Supported in part by a Research to Prevent Blindness Physician Scientist
   Award.
CR Ahlers C, 2008, BRIT J OPHTHALMOL, V92, P197, DOI 10.1136/bjo.2007.120956
   Coscas F, 2007, AM J OPHTHALMOL, V144, P592, DOI 10.1016/j.ajo.2007.06.014
   Gupta Pawan, 2010, International Ophthalmology, V30, P175, DOI 10.1007/s10792-009-9302-2
   Joeres S, 2007, INVEST OPHTH VIS SCI, V48, P4300, DOI 10.1167/iovs.07-0179
   Khanifar AA, 2008, OPHTHALMOLOGY, V115, P1883, DOI 10.1016/j.ophtha.2008.04.041
   Krebs I, 2008, GRAEF ARCH CLIN EXP, V246, P811, DOI 10.1007/s00417-007-0755-6
   Liakopoulos S, 2008, INVEST OPHTH VIS SCI, V49, P5048, DOI 10.1167/iovs.08-1877
   Malamos P, 2009, INVEST OPHTH VIS SCI, V50, P4926, DOI 10.1167/iovs.09-3610
   Mavrofrides EC, 2004, OPTICAL COHERENCE TO, P243
   Ojima Y, 2009, RETINA-J RET VIT DIS, V29, P52, DOI 10.1097/IAE.0b013e3181884fbf
   Ouyang YL, 2010, INVEST OPHTH VIS SCI, V51, P5213, DOI 10.1167/iovs.09-4635
   Pauleikhoff D, 2002, GRAEF ARCH CLIN EXP, V240, P533, DOI 10.1007/s00417-002-0505-8
   Penha FM, 2011, AM J OPHTHALMOL
   POLINER LS, 1986, OPHTHALMOLOGY, V93, P543
   Roquet W, 2004, BRIT J OPHTHALMOL, V88, P638, DOI 10.1136/bjo.2003.017632
   Sadda SR, 2007, INVEST OPHTH VIS SCI, V48, P839, DOI 10.1167/iovs.06-0554
   Sadda SR, 2010, GRAEF ARCH CLIN EXP, V248, P175, DOI 10.1007/s00417-009-1193-4
   Sandhu SS, 2005, BRIT J OPHTHALMOL, V89, P967, DOI 10.1136/bjo.2004.060863
   Smretschnig E, 2010, GRAEF ARCH CLIN EXP, V248, P1693, DOI 10.1007/s00417-010-1415-9
   Spaide RF, 2009, AM J OPHTHALMOL, V147, P644, DOI 10.1016/j.ajo.2008.10.005
   Talks J, 2007, BRIT J OPHTHALMOL, V91, P600, DOI 10.1136/bjo.2006.108043
   van Velthoven MEJ, 2006, GRAEF ARCH CLIN EXP, V244, P1119, DOI 10.1007/s00417-005-0209-y
   Zayit-Soudry S, 2007, SURV OPHTHALMOL, V52, P227, DOI 10.1016/j.survophthal.2007.02.008
NR 23
TC 45
Z9 47
U1 0
U2 4
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD JAN
PY 2012
VL 53
IS 1
BP 164
EP 170
DI 10.1167/iovs.11-8188
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 924LY
UT WOS:000302694500027
PM 22159019
DA 2022-11-30
ER

PT J
AU Kook, D
   Wolf, AH
   Yu, AL
   Neubauer, AS
   Priglinger, SG
   Kampik, A
   Welge-Lussen, UC
AF Kook, Daniel
   Wolf, Armin H.
   Yu, Alice L.
   Neubauer, Aljoscha S.
   Priglinger, Siegfried G.
   Kampik, Anselm
   Welge-Luessen, Ulrich C.
TI The protective effect of quercetin against oxidative stress in the human
   RPE in vitro
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID RETINAL-PIGMENT EPITHELIUM; AGE-RELATED MACULOPATHY; ALPHA-B-CRYSTALLIN;
   MACULAR DEGENERATION; HUMAN-LYMPHOCYTES; MESSENGER-RNA; CANCER CELLS;
   DNA-DAMAGE; VITAMIN-C; FLAVONOIDS
AB PURPOSE. To investigate the possible protective effect of the dietary antioxidant quercetin on retinal pigment epithelial (RPE) cell dysfunction and cellular senescence occurring in age-related macular degeneration (AMD). The major flavonoid quercetin was studied on RPE cells in vitro.
   METHODS. Cultured human RPE cells were incubated with different concentrations of quercetin for 24 hours. Cells were then treated with 150 to 300 mu M hydrogen peroxide for 2 hours. Mitochondrial function was measured by using MTT assay and cell vitality by live-dead staining assay. Intracellular levels of glutathione were determined by using a glutathione assay kit. Apoptosis was quantified by a caspase-3 assay, and cellular senescence was quantified by beta-galactosidase staining. Expression of the senescence-associated transmembrane protein caveolin-1 was investigated by Northern and Western blot analyses.
   RESULTS. Hydrogen peroxide treatment caused significant decreases in mitochondrial function (52%) and in cell vitality (71%), whereas preincubation with 50 mu M quercetin diminished this decrease in a dose-dependent manner. Quercetin treatment did not show any notable effect on intracellular levels of glutathione in either used concentration of quercetin. Hydrogen peroxide-induced activation of caspase-3 was reduced by 50 mu M quercetin, from 1.9- to 1.4-fold, compared with untreated control (P < 0.001). Hydrogen peroxide caused a large (> 90%) dose-dependent increase in beta-galactosidase positive cells, whereas in the untreated control only single cells expressed this enzyme (< 5%). This increase in cellular senescence was significantly attenuated by quercetin in a dose-dependent manner. The highest attenuation was reached at 50 mu M quercetin. Quercetin caused a significant dose-dependent reduction of caveolin-1 mRNA 48 hours after treatment with hydrogen peroxide. After 96 hours of incubation, caveolin-1 protein levels were also reduced.
   CONCLUSIONS. The data demonstrate that quercetin is able to protect RPE cells from oxidative damage and cellular senescence in vitro in a dose-dependent manner. The authors suggest that this increase in antioxidative capacity is - among other mechanisms, such as the intracellular redox state - also mediated by inhibiting the upregulation of caveolin-1. Downregulation of caveolin-1 may be important for the retinal pigment epithelium to prevent apoptotic cell death in response to cellular stress, a condition implicated in the early pathogenesis of AMD. Therefore, the authors believe that the use of antioxidative dietary flavonoids such as quercetin is a promising approach in the prevention of early AMD.
C1 [Kook, Daniel; Wolf, Armin H.; Yu, Alice L.; Neubauer, Aljoscha S.; Priglinger, Siegfried G.; Kampik, Anselm; Welge-Luessen, Ulrich C.] Univ Munich, Dept Ophthalmol, D-80336 Munich, Germany.
C3 University of Munich
RP Kook, D (通讯作者)，Univ Munich, Dept Ophthalmol, Mathildenstr 8, D-80336 Munich, Germany.
EM daniel.kook@med.uni-muenchen.de
RI Daniel Kook, Kook/G-6071-2012; Kook, Daniel/AAU-8717-2021
CR AKIKO S, 2004, BIOSCI BIOTECH BIOCH, V68, P271
   Alge CS, 2002, INVEST OPHTH VIS SCI, V43, P3575
   Boadi WY, 2005, J APPL TOXICOL, V25, P82, DOI 10.1002/jat.1049
   Cao XG, 2007, INVEST OPHTH VIS SCI, V48, P3714, DOI 10.1167/iovs.06-1304
   Chen L, 2004, EXP EYE RES, V79, P239, DOI 10.1016/j.exer.2004.05.002
   Cho KA, 2005, MECH AGEING DEV, V126, P105, DOI 10.1016/j.mad.2004.09.029
   Cipak L, 2003, NEOPLASMA, V50, P443
   COFFEY AJH, 1986, AM J OPHTHALMOL, V102, P164, DOI 10.1016/0002-9394(86)90138-8
   DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363
   Dolnick E., 1990, HEALTH           MAY, P41
   Duthie SJ, 1997, MUTAT RES-GEN TOX EN, V393, P223, DOI 10.1016/S1383-5718(97)00107-1
   FLOOD MT, 1980, INVEST OPHTH VIS SCI, V19, P1309
   Formica JV, 1995, FOOD CHEM TOXICOL, V33, P1061, DOI 10.1016/0278-6915(95)00077-1
   Graefe EU, 2001, J CLIN PHARMACOL, V41, P492, DOI 10.1177/00912700122010366
   Hanneken A, 2006, INVEST OPHTH VIS SCI, V47, P3164, DOI 10.1167/iovs.04-1369
   Hawkins BS, 1999, MOL VIS, V5
   HERTOG MGL, 1992, J AGR FOOD CHEM, V40, P2379, DOI 10.1021/jf00024a011
   Hollman P C, 1998, Arch Toxicol Suppl, V20, P237
   Hollman PCH, 1997, FEBS LETT, V418, P152, DOI 10.1016/S0014-5793(97)01367-7
   Honda S, 2002, BRIT J OPHTHALMOL, V86, P159, DOI 10.1136/bjo.86.2.159
   Jayachandran M, 2001, AM J PHYSIOL-HEART C, V281, pH1327, DOI 10.1152/ajpheart.2001.281.3.H1327
   KAEKO M, 2004, J AGR FOOD CHEM, V52, P1907
   Kalayoglu MV, 2005, GRAEF ARCH CLIN EXP, V243, P1080, DOI 10.1007/s00417-005-1169-y
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Kennedy CJ, 1995, EYE, V9, P763, DOI 10.1038/eye.1995.192
   Kim JY, 2006, J BIOL CHEM, V281, P10865, DOI 10.1074/jbc.M513378200
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0
   LESCHEY KH, 1990, INVEST OPHTH VIS SCI, V31, P839
   Manach C, 2004, AM J CLIN NUTR, V79, P727, DOI 10.1093/ajcn/79.5.727
   MaresPerlman JA, 1996, ARCH OPHTHALMOL-CHIC, V114, P991, DOI 10.1001/archopht.1996.01100140199014
   Moon JH, 2000, AM J PHYSIOL-REG I, V279, pR461, DOI 10.1152/ajpregu.2000.279.2.R461
   Noroozi M, 1998, AM J CLIN NUTR, V67, P1210, DOI 10.1093/ajcn/67.6.1210
   Park C, 2003, BIOCHEM PHARMACOL, V66, P1287, DOI 10.1016/S0006-2952(03)00478-7
   Park CH, 2005, BIOCHEM BIOPH RES CO, V328, P227, DOI 10.1016/j.bbrc.2004.12.151
   Richer Stuart, 2004, Optometry, V75, P216, DOI 10.1016/S1529-1839(04)70049-4
   Rohrdanz E, 2003, ARCH TOXICOL, V77, P506, DOI 10.1007/s00204-003-0482-7
   Ross JA, 2002, ANNU REV NUTR, V22, P19, DOI 10.1146/annurev.nutr.22.111401.144957
   Spencer JPE, 2004, ARCH BIOCHEM BIOPHYS, V423, P148, DOI 10.1016/j.abb.2003.11.010
   Spraul CW, 1996, INVEST OPHTH VIS SCI, V37, P2724
   Swain T, 1986, Prog Clin Biol Res, V213, P1
   Szeto YT, 2002, FREE RADICAL RES, V36, P113, DOI 10.1080/10715760210161
   Torres VA, 2006, J CELL SCI, V119, P1812, DOI 10.1242/jcs.02894
   VINGERLING JR, 1995, OPHTHALMOLOGY, V102, P205
   Volonte D, 2002, MOL BIOL CELL, V13, P2502, DOI 10.1091/mbc.01-11-0529
   Wang Z, 2006, PHOTOCHEM PHOTOBIOL, V82, P474, DOI 10.1562/2005-10-21-RA-725
   Welge-Lussen U, 1999, INVEST OPHTH VIS SCI, V40, P2235
   Yamamoto H, 2006, DEV CELL, V11, P213, DOI 10.1016/j.devcel.2006.07.003
   Yen GC, 2003, BIOSCI BIOTECH BIOCH, V67, P1215, DOI 10.1271/bbb.67.1215
   YOUNG RW, 1988, SURV OPHTHALMOL, V32, P252, DOI 10.1016/0039-6257(88)90174-9
NR 50
TC 113
Z9 121
U1 3
U2 22
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD APR
PY 2008
VL 49
IS 4
BP 1712
EP 1720
DI 10.1167/iovs.07-0477
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 282ON
UT WOS:000254577200057
PM 18385095
DA 2022-11-30
ER

PT J
AU MacLaren, RE
   Groppe, M
   Barnard, AR
   Cottriall, CL
   Tolmachova, T
   Seymour, L
   Clark, KR
   During, MJ
   Cremers, FPM
   Black, GCM
   Lotery, AJ
   Downes, SM
   Webster, AR
   Seabra, MC
AF MacLaren, Robert E.
   Groppe, Markus
   Barnard, Alun R.
   Cottriall, Charles L.
   Tolmachova, Tanya
   Seymour, Len
   Clark, K. Reed
   During, Matthew J.
   Cremers, Frans P. M.
   Black, Graeme C. M.
   Lotery, Andrew J.
   Downes, Susan M.
   Webster, Andrew R.
   Seabra, Miguel C.
TI Retinal gene therapy in patients with choroideremia: initial findings
   from a phase 1/2 clinical trial
SO LANCET
LA English
DT Article
ID LEBERS CONGENITAL AMAUROSIS; DEGENERATION; MUTATIONS; EXPRESSION;
   DISEASE; CLONING; MODELS; CHM
AB Background Choroideremia is an X-linked recessive disease that leads to blindness due to mutations in the CHM gene, which encodes the Rab escort protein 1 (REP1). We assessed the effects of retinal gene therapy with an adeno-associated viral (AAV) vector encoding REP1 (AAV. REP1) in patients with this disease.
   Methods In a multicentre clinical trial, six male patients (aged 35-63 years) with choroideremia were administered AAV. REP1 (0.6-1.0 x 10(10) genome particles, subfoveal injection). Visual function tests included best corrected visual acuity, microperimetry, and retinal sensitivity tests for comparison of baseline values with 6 months after surgery. This study is registered with ClinicalTrials.gov, number NCT01461213.
   Findings Despite undergoing retinal detachment, which normally reduces vision, two patients with advanced choroideremia who had low baseline best corrected visual acuity gained 21 letters and 11 letters (more than two and four lines of vision). Four other patients with near normal best corrected visual acuity at baseline recovered to within one to three letters. Mean gain in visual acuity overall was 3.8 letters (SE 4.1). Maximal sensitivity measured with dark-adapted microperimetry increased in the treated eyes from 23.0 dB (SE 1.1) at baseline to 25.3 dB (1.3) after treatment (increase 2.3 dB [95% CI 0.8-3.8]). In all patients, over the 6 months, the increase in retinal sensitivity in the treated eyes (mean 1.7 [SE 1.0]) was correlated with the vector dose administered per mm(2) of surviving retina (r=0.82, p=0.04). By contrast, small non-significant reductions (p>0.05) were noted in the control eyes in both maximal sensitivity (-0.8 dB [1.5]) and mean sensitivity (-1.6 dB [0.9]). One patient in whom the vector was not administered to the fovea re-established variable eccentric fixation that included the ectopic island of surviving retinal pigment epithelium that had been exposed to vector.
   Interpretation The initial results of this retinal gene therapy trial are consistent with improved rod and cone function that overcome any negative effects of retinal detachment. These findings lend support to further assessment of gene therapy in the treatment of choroideremia and other diseases, such as age-related macular degeneration, for which intervention should ideally be applied before the onset of retinal thinning.
C1 [MacLaren, Robert E.; Groppe, Markus; Barnard, Alun R.; Downes, Susan M.] Univ Oxford, Dept Clin Neurosci, Nuffield Lab Ophthalmol, Oxford OX3 9DU, England.
   [MacLaren, Robert E.; Groppe, Markus; Cottriall, Charles L.; Downes, Susan M.] Oxford Univ Hosp NHS Trust, Oxford Eye Hosp, Oxford, England.
   [MacLaren, Robert E.; Groppe, Markus; Cottriall, Charles L.; Downes, Susan M.] NIHR Biomed Res Ctr, Oxford, England.
   [MacLaren, Robert E.; Groppe, Markus; Webster, Andrew R.] Moorfields Eye Hosp NHS Fdn Trust, London, England.
   [MacLaren, Robert E.; Groppe, Markus; Webster, Andrew R.] NIHR Ophthalmol Biomed Res Ctr, London, England.
   [Tolmachova, Tanya; Seabra, Miguel C.] Univ London Imperial Coll Sci Technol & Med, Natl Heart & Lung Inst, Mol Med Sect, London, England.
   [Seymour, Len] Univ Oxford, Dept Oncol, Oxford OX3 9DU, England.
   [Clark, K. Reed] Nationwide Childrens Hosp, Res Inst, Columbus, OH USA.
   [During, Matthew J.] Ohio State Univ, Med Ctr, Coll Med, Columbus, OH 43210 USA.
   [Cremers, Frans P. M.] Radboud Univ Nijmegen, Med Ctr, Dept Human Genet, Nijmegen, Netherlands.
   [Cremers, Frans P. M.] Radboud Univ Nijmegen, Med Ctr, Nijmegen Ctr Mol Life Sci, Nijmegen, Netherlands.
   [Black, Graeme C. M.] St Marys Hosp, Cent Manchester Univ Hosp NHS Fdn Trust, Manchester Acad Hlth Sci Ctr, Manchester Ctr Genom Med, Manchester M13 0JH, Lancs, England.
   [Lotery, Andrew J.] Univ Southampton, Fac Med, Clin Neurosci Grp, Southampton SO9 5NH, Hants, England.
   [Webster, Andrew R.] UCL Inst Ophthalmol, London, England.
   [Seabra, Miguel C.] Univ Nova Lisboa, Fac Ciencias Med, Chron Dis Res Ctr, P-1200 Lisbon, Portugal.
C3 University of Oxford; Oxford University Hospitals NHS Foundation Trust;
   University of Oxford; University of London; University College London;
   Moorfields Eye Hospital NHS Foundation Trust; Imperial College London;
   University of Oxford; University System of Ohio; Ohio State University;
   Nationwide Childrens Hospital; Research Institute at Nationwide
   Children's Hospital; University System of Ohio; Ohio State University;
   Radboud University Nijmegen; Radboud University Nijmegen; University of
   Manchester; University of Southampton; University of London; University
   College London; Universidade Nova de Lisboa
RP MacLaren, RE (通讯作者)，Univ Oxford, Dept Clin Neurosci, Nuffield Lab Ophthalmol, Oxford OX3 9DU, England.
EM enquiries@eye.ox.ac.uk
RI During, Matthew/AAC-1388-2020; Seabra, Miguel/AAC-3099-2019; Seabra,
   Miguel C/M-3280-2013; Cremers, Frans/A-5625-2014; Black,
   Graeme/K-7374-2015
OI Seabra, Miguel C/0000-0002-6404-4892; Cremers,
   Frans/0000-0002-4954-5592; Lotery, Andrew/0000-0001-5541-4305; Groppe,
   Markus/0000-0003-1963-3484; MacLaren, Robert/0000-0002-3096-4682; Black,
   Graeme/0000-0001-8727-6592; Tolmachova, Tanya/0000-0002-8841-0797;
   seymour, len/0000-0003-3825-0841
FU UK Department of Health; Wellcome Trust; Cancer Research UK [11339]
   Funding Source: researchfish; National Institute for Health Research
   [NF-SI-0509-10185] Funding Source: researchfish; Fight for Sight
   [1936/38, 1801/02] Funding Source: researchfish
FX Funding UK Department of Health and Wellcome Trust.
CR Arland V, 2003, VISION RES, V43, P919, DOI 10.1016/S0042-6989(02)00389-9
   Bennett J, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3002865
   Bennicelli J, 2008, MOL THER, V16, P458, DOI 10.1038/sj.mt.6300389
   Bowne SJ, 2011, EUR J HUM GENET, V19, P1074, DOI 10.1038/ejhg.2011.86
   Chen FK, 2009, INVEST OPHTH VIS SCI, V50, P3464, DOI 10.1167/iovs.08-2926
   Cideciyan AV, 2013, P NATL ACAD SCI USA, V110, pE517, DOI 10.1073/pnas.1218933110
   Cideciyan AV, 2009, NEW ENGL J MED, V361, P725, DOI 10.1056/NEJMc0903652
   CREMERS FPM, 1990, NATURE, V347, P674, DOI 10.1038/347674a0
   Endo K, 2000, ACTA OPHTHALMOL SCAN, V78, P483, DOI 10.1034/j.1600-0420.2000.078004483.x
   Jacobson SG, 2006, INVEST OPHTH VIS SCI, V47, P4113, DOI 10.1167/iovs.06-0424
   Jacobson SG, 2012, ARCH OPHTHALMOL-CHIC, V130, P9, DOI 10.1001/archophthalmol.2011.298
   KLEIN R, 1983, OPHTHALMOLOGY, V90, P1357
   LeWitt PA, 2011, LANCET NEUROL, V10, P309, DOI 10.1016/S1474-4422(11)70039-4
   Loeb JE, 1999, HUM GENE THER, V10, P2295, DOI 10.1089/10430349950016942
   MacLaren RE, 2009, CURR OPIN MOL THER, V11, P540
   Maguire AM, 2008, NEW ENGL J MED, V358, P2240, DOI 10.1056/NEJMoa0802315
   Maguire AM, 2009, LANCET, V374, P1597, DOI 10.1016/S0140-6736(09)61836-5
   Mauthner L., 1872, BERL NATUR MED VER I, V2, P191
   SANKILA EM, 1992, NAT GENET, V1, P109, DOI 10.1038/ng0592-109
   SEABRA MC, 1993, SCIENCE, V259, P377, DOI 10.1126/science.8380507
   Sieving PA, 2006, P NATL ACAD SCI USA, V103, P3896, DOI 10.1073/pnas.0600236103
   Syed R, 2013, INVEST OPHTH VIS SCI, V54, P950, DOI 10.1167/iovs.12-10707
   Tolmachova T, 2013, J MOL MED, V91, P825, DOI 10.1007/s00109-013-1006-4
   Tolmachova T, 2010, INVEST OPHTH VIS SCI, V51, P4913, DOI 10.1167/iovs.09-4892
   VANBOKHOVEN H, 1994, HUM MOL GENET, V3, P1041, DOI 10.1093/hmg/3.7.1041
   Vandenberghe L. H., 2011, SCI TRANSL MED, V3
   vandenHurk JAJM, 1997, HUM MUTAT, V9, P110, DOI 10.1002/(SICI)1098-1004(1997)9:2<110::AID-HUMU2>3.0.CO;2-D
NR 27
TC 531
Z9 571
U1 1
U2 77
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0140-6736
EI 1474-547X
J9 LANCET
JI Lancet
PD MAR 29
PY 2014
VL 383
IS 9923
BP 1129
EP 1137
DI 10.1016/S0140-6736(13)62117-0
PG 9
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA AE4MH
UT WOS:000333956000032
PM 24439297
OA Green Published, Green Accepted
HC Y
HP N
DA 2022-11-30
ER

PT J
AU Nakamura, Y
   Tomidokoro, A
   Sawaguchi, S
   Sakai, H
   Iwase, A
   Araie, M
AF Nakamura, Yuko
   Tomidokoro, Atsuo
   Sawaguchi, Shoichi
   Sakai, Hiroshi
   Iwase, Aiko
   Araie, Makoto
TI Prevalence and Causes of Low Vision and Blindness in a Rural Southwest
   Island of Japan The Kumejima Study
SO OPHTHALMOLOGY
LA English
DT Article
ID VISUAL IMPAIRMENT PROJECT; EYE SURVEY; ADULT-POPULATION;
   CATARACT-SURGERY; BEIJING EYE; GLAUCOMA; TAJIMI; OLDER; AUSTRALIA; URBAN
AB Purpose: To determine the prevalence and causes of low vision and blindness in an adult population on a rural southwest island of Japan.
   Design: Population-based, cross-sectional study.
   Participants: All residents of Kumejima Island, Japan, 40 years of age and older.
   Methods: Of the 4632 residents 40 years of age and older, 3762 (response rate, 81.2%) underwent a detailed ocular examination including measurement of the best-corrected visual acuity (BCVA) with a Landolt ring chart at 5 m. The age-and gender-specific prevalence rates of low vision and blindness were estimated and causes were identified.
   Main Outcome Measures: Low vision and blindness were defined, according to the definition of the World Health Organization, as a BCVA in the better eye below 20/60 to a lower limit of 20/400 and worse than 20/400, respectively.
   Results: The prevalence of bilateral low vision was 0.58% (95% confidence interval [CI], 0.38-0.89). The primary causes of low vision were cataract (0.11%), corneal opacity (0.08%), retinitis pigmentosa (RP; 0.06%), and diabetic retinopathy (0.06%). The prevalence of bilateral blindness was 0.39% (95% CI, 0.23-0.65). The primary causes of blindness were RP (0.17%) and glaucoma (0.11%). The primary causes of monocular low vision were cataract (0.65%), corneal opacity (0.16%), age-related macular degeneration (0.16%), and diabetic retinopathy (0.11%), whereas those of monocular blindness were cataract (0.29%), trauma (0.25%), and glaucoma (0.22%). Logistic analysis showed that female gender (P = 0.001; odds ratio [OR], 7.37; 95% CI, 2.20-24.71) and lower body weight (P = 0.015; OR, 0.94; 95% CI, 0.90-0.99) were associated significantly with visual impairment.
   Conclusions: The prevalences of low vision and blindness in the adult residents of an island in southwest Japan were 1.5 to 3 times higher than the prevalences reported in an urban city on the Japanese mainland. The prevalence of visual impairment caused by RP on this island was much higher than on the mainland, suggesting a genetic characteristic of the population. Furthermore, the prevalence of visual impairment resulting from cataract and corneal opacity was higher than that on the mainland. The prevalence of visual impairment resulting from myopic macular degeneration was less.
C1 [Tomidokoro, Atsuo] Univ Tokyo, Grad Sch Med, Dept Ophthalmol, Bunkyo Ku, Tokyo 1138655, Japan.
   [Nakamura, Yuko; Sawaguchi, Shoichi; Sakai, Hiroshi] Univ Ryukyus, Grad Sch Med, Dept Ophthalmol, Okinawa, Japan.
   [Iwase, Aiko] Tajimi Iwase Eye Clin, Gifu, Japan.
C3 University of Tokyo; University of Ryukyus
RP Tomidokoro, A (通讯作者)，Univ Tokyo, Grad Sch Med, Dept Ophthalmol, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1138655, Japan.
EM tomidokoro-tky@umin.ac.jp
FU Ministry of Health, Labour and Welfare of Japan, Tokyo, Japan
   [H18-Sensory-General-001]; Ministry of Education, Culture, Sports,
   Science and Technology, Tokyo, Japan [17591845]; Japan National Society
   for the Prevention of Blindness, Tokyo, Japan
FX Supported by a Grant-in-Aid for Scientific Research by the Ministry of
   Health, Labour and Welfare of Japan, Tokyo, Japan (no.:
   H18-Sensory-General-001); a Grant-in-Aid for Scientific Research from
   the Ministry of Education, Culture, Sports, Science and Technology,
   Tokyo, Japan (grant no.: (C) 17591845); and a fund from the Japan
   National Society for the Prevention of Blindness, Tokyo, Japan.
CR Attebo K, 1996, OPHTHALMOLOGY, V103, P357
   BAASANHU J, 1994, B WORLD HEALTH ORGAN, V72, P771
   Buch H, 2001, ACTA OPHTHALMOL SCAN, V79, P441, DOI 10.1034/j.1600-0420.2001.790503.x
   Casson RJ, 2007, OPHTHALMOLOGY, V114, P2302, DOI 10.1016/j.ophtha.2007.02.004
   Cedrone C, 2006, EYE, V20, P661, DOI 10.1038/sj.eye.6701934
   Cotter SA, 2006, OPHTHALMOLOGY, V113, P1574, DOI 10.1016/j.ophtha.2006.05.002
   Dandona L, 2001, INVEST OPHTH VIS SCI, V42, P908
   Edussuriya K, 2009, OPHTHALMOLOGY, V116, P52, DOI 10.1016/j.ophtha.2008.08.034
   Foster PJ, 2002, BRIT J OPHTHALMOL, V86, P238, DOI 10.1136/bjo.86.2.238
   Gunnlaugsdottir E, 2008, ACTA OPHTHALMOL, V86, P778, DOI 10.1111/j.1755-3768.2008.01191.x
   Hsu WM, 2004, OPHTHALMOLOGY, V111, P62, DOI 10.1016/j.ophtha.2003.05.011
   Hyman L, 2001, OPHTHALMOLOGY, V108, P1751, DOI 10.1016/S0161-6420(01)00590-5
   Iwase A, 2004, OPHTHALMOLOGY, V111, P1641, DOI 10.1016/j.ophtha.2004.03.029
   Iwase A, 2006, OPHTHALMOLOGY, V113, P1354, DOI 10.1016/j.ophtha.2006.04.022
   Klaver CCW, 1998, ARCH OPHTHALMOL-CHIC, V116, P653, DOI 10.1001/archopht.116.5.653
   Kyari F, 2009, INVEST OPHTH VIS SCI, V50, P2033, DOI 10.1167/iovs.08-3133
   Li SZ, 1999, OPHTHALMOLOGY, V106, P1602, DOI 10.1016/S0161-6420(99)90459-1
   Liang YB, 2008, OPHTHALMOLOGY, V115, P1965, DOI 10.1016/j.ophtha.2008.05.030
   *MIN HLTH LAB WELF, SURV MED FAC IS AR J
   Moser CL, 2002, BRIT J OPHTHALMOL, V86, P257, DOI 10.1136/bjo.86.3.257
   Murthy GVS, 2001, OPHTHALMOLOGY, V108, P679, DOI 10.1016/S0161-6420(00)00579-0
   Pascolini D, 2004, OPHTHAL EPIDEMIOL, V11, P67, DOI 10.1076/opep.11.2.67.28158
   Resnikoff S, 2004, B WORLD HEALTH ORGAN, V82, P844
   Rodriguez J, 2002, OPHTHALMOLOGY, V109, P737, DOI 10.1016/S0161-6420(01)01008-9
   Saw SM, 2004, OPHTHALMOLOGY, V111, P1161, DOI 10.1016/j.ophtha.2003.09.040
   Sawada A, 2008, OPHTHALMOLOGY, V115, P363, DOI 10.1016/j.ophtha.2007.03.075
   Shahriari HA, 2007, BRIT J OPHTHALMOL, V91, P579, DOI 10.1136/bjo.2006.105734
   SUZUMURA H, 1996, GANKA, V38, P1223
   Taylor HR, 1997, AM J OPHTHALMOL, V123, P328, DOI 10.1016/S0002-9394(14)70128-X
   Thulasiraj RD, 2003, OPHTHALMOLOGY, V110, P1491, DOI 10.1016/S0161-6420(03)00565-7
   TIELSCH JM, 1990, ARCH OPHTHALMOL-CHIC, V108, P286, DOI 10.1001/archopht.1990.01070040138048
   VanNewkirk MR, 2001, OPHTHALMOLOGY, V108, P960, DOI 10.1016/S0161-6420(01)00554-1
   Varma R, 2004, OPHTHALMOLOGY, V111, P1132, DOI 10.1016/j.ophtha.2004.02.002
   Vijaya L, 2006, BRIT J OPHTHALMOL, V90, P407, DOI 10.1136/bjo.2005.081406
   Wild JM, 1999, INVEST OPHTH VIS SCI, V40, P1152
   Wild JM, 1999, INVEST OPHTH VIS SCI, V40, P1998
   World Health Organization, WHO STAT INF SYST WH
   Xu L, 2006, AM J OPHTHALMOL, V141, P591, DOI 10.1016/j.ajo.2005.10.018
   Xu L, 2006, OPHTHALMOLOGY, V113, P1134, DOI 10.1016/j.ophtha.2006.01.035
   Yamamoto T, 2005, OPHTHALMOLOGY, V112, P1661, DOI 10.1016/j.ophtha.2005.05.012
   Zainal M, 2002, BRIT J OPHTHALMOL, V86, P951, DOI 10.1136/bjo.86.9.951
NR 41
TC 33
Z9 36
U1 0
U2 5
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0161-6420
J9 OPHTHALMOLOGY
JI Ophthalmology
PD DEC
PY 2010
VL 117
IS 12
BP 2315
EP 2321
DI 10.1016/j.ophtha.2010.03.043
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 688SI
UT WOS:000284872600015
PM 20591485
DA 2022-11-30
ER

PT J
AU Xu, L
   Wang, YX
   Li, YB
   Wang, Y
   Cui, TT
   Li, JJ
   Jonas, JB
AF Xu, Liang
   Wang, Yaxing
   Li, Yibin
   Wang, Yun
   Cui, Tongtong
   Li, Jianjun
   Jonas, Jost B.
TI Causes of blindness and visual impairment in urban and rural areas in
   Beijing - The Beijing eye study
SO OPHTHALMOLOGY
LA English
DT Article
ID CAUSE-SPECIFIC PREVALENCE; AGE-SPECIFIC PREVALENCE; BLUE MOUNTAINS EYE;
   CATARACT-SURGERY; REFRACTIVE ERROR; OLDER AMERICANS; NORTHERN CHINA;
   SHUNYI COUNTY; UNITED-STATES; POPULATION
AB Objective: To evaluate the causes of visual impairment and blindness in adult Chinese in an urban and rural region of Beijing, China.
   Design: Population-based prevalence survey.
   Participants: From a rural region and an urban region of Greater Beijing, 4439 of 5324 40-year-old invited subjects participated in the study (response rate, 83.4%). Using the World Health Organization (WHO) standard and the United States standard, blindness was defined as best-corrected visual acuity (BCVA) in the better-seeing eye of < 20/400 and of < 2/20, respectively, and visual impairment was defined as best-corrected vision of < 20/60 and >= 20/400, and of < 20/40 and >= 2/20, respectively.
   Methods: Determination of BCVA, pneumotonometry, frequency doubling perimetry, evaluation of photographs of the fundus and lens, and clinical examination.
   Main Outcome Measure: Causes of visual impairment and blindness.
   Results. Visual acuity measurements were available for 8816 eyes of 4409 subjects (99.3%). Using the WHO standard and the U.S. standard, 49 (1.1%) subjects and 95 (2.2%) subjects, respectively, had low vision, and 13 (0.3%) subjects and 15 (0.3%) subjects, respectively, were blind by definition. Taking the whole study population, the most frequent cause of low vision/blindness was cataract (36.7%/38.5%), followed by degenerative myopia (32.7%/7.7%), glaucoma (14.3%/7.7%), corneal opacity (6.1%/15.4%), and other optic nerve damage (2.0%/7.7%). Age-related macular degeneration (AMD) (2.0%/7.7%) and diabetic retinopathy (0%/7.7%) were responsible for a minority of cases. In subjects 40 to 49 years old, the most frequent cause of low vision and blindness was degenerative myopia. In the 50- to 59-year age group, the most frequent cause was cataract, followed by degenerative myopia. In the 60- to 69-year-old subjects and the >= 70-year group, the most frequent cause of low vision and blindness was cataract, followed by degenerative myopia and glaucoma.
   Conclusions: The most frequent cause of low vision and blindness in adult Chinese is cataract, followed by degenerative myopia and glaucomatous optic neuropathy, with degenerative myopia dominating in younger groups and cataract dominating in elder groups. In contrast to studies in Western countries, AMD and diabetic retinopathy appear to play a minor role as a cause of visual impairment in elderly Chinese.
C1 Univ Heidelberg, Augenklin, Fac Clin Med Mannheim, Dept Ophthalmol, D-68167 Mannheim, Germany.
   Tongren Hosp, Dept Ophthalmol, Beijing, Peoples R China.
   Tongren Hosp, Hosp Eye, Beijing, Peoples R China.
C3 Ruprecht Karls University Heidelberg; University of Hamburg; University
   Medical Center Hamburg-Eppendorf
RP Jonas, JB (通讯作者)，Univ Heidelberg, Augenklin, Fac Clin Med Mannheim, Dept Ophthalmol, Theodor Kutzer Ufer 1-3, D-68167 Mannheim, Germany.
EM Jost.Jonas@augen.ma.uni-heidelberg.de
RI wang, YA XING/K-9671-2016
OI wang, YA XING/0000-0003-2749-7793
CR Attebo K, 1996, OPHTHALMOLOGY, V103, P357
   Buch H, 2001, OPHTHALMOLOGY, V108, P2347, DOI 10.1016/S0161-6420(01)00823-5
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   DANA MR, 1990, JAMA-J AM MED ASSOC, V264, P2400, DOI 10.1001/jama.264.18.2400
   Dandona L, 2001, INVEST OPHTH VIS SCI, V42, P908
   Dunzhu S, 2003, BRIT J OPHTHALMOL, V87, P1443, DOI 10.1136/bjo.87.12.1443
   Fotouhi A, 2004, BRIT J OPHTHALMOL, V88, P740, DOI 10.1136/bjo.2003.031153
   Hsu WM, 2004, OPHTHALMOLOGY, V111, P62, DOI 10.1016/j.ophtha.2003.05.011
   Hyman L, 2001, OPHTHALMOLOGY, V108, P1751, DOI 10.1016/S0161-6420(01)00590-5
   Kassoff A, 2001, AM J OPHTHALMOL, V131, P167
   Klaver CCW, 1998, ARCH OPHTHALMOL-CHIC, V116, P653, DOI 10.1001/archopht.116.5.653
   KLEIN R, 1995, INVEST OPHTH VIS SCI, V36, P182
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1310
   Li SZ, 1999, OPHTHALMOLOGY, V106, P1602, DOI 10.1016/S0161-6420(99)90459-1
   Liu J H, 2001, Ophthalmic Epidemiol, V8, P339
   Michon JJ, 2002, BRIT J OPHTHALMOL, V86, P133, DOI 10.1136/bjo.86.2.133
   Munoz B, 2000, ARCH OPHTHALMOL-CHIC, V118, P819, DOI 10.1001/archopht.118.6.819
   Munoz B, 2002, INVEST OPHTH VIS SCI, V43, P608
   Ramrattan RS, 2001, ARCH OPHTHALMOL-CHIC, V119, P1788, DOI 10.1001/archopht.119.12.1788
   Reidy A, 1998, BRIT MED J, V316, P1643, DOI 10.1136/bmj.316.7145.1643
   Rodriguez J, 2002, OPHTHALMOLOGY, V109, P737, DOI 10.1016/S0161-6420(01)01008-9
   Rubin GS, 1997, INVEST OPHTH VIS SCI, V38, P557
   Saw SM, 2004, OPHTHALMOLOGY, V111, P1161, DOI 10.1016/j.ophtha.2003.09.040
   SOMMER A, 1991, NEW ENGL J MED, V325, P1412, DOI 10.1056/NEJM199111143252004
   Taylor HR, 1997, AM J OPHTHALMOL, V123, P328, DOI 10.1016/S0002-9394(14)70128-X
   Thulasiraj RD, 2003, OPHTHALMOLOGY, V110, P1491, DOI 10.1016/S0161-6420(03)00565-7
   TIELSCH JM, 1995, NEW ENGL J MED, V332, P1205, DOI 10.1056/NEJM199505043321806
   TIELSCH JM, 1990, ARCH OPHTHALMOL-CHIC, V108, P286, DOI 10.1001/archopht.1990.01070040138048
   VanNewkirk MR, 2001, OPHTHALMOLOGY, V108, P960, DOI 10.1016/S0161-6420(01)00554-1
   Varma R, 2004, OPHTHALMOLOGY, V111, P1132, DOI 10.1016/j.ophtha.2004.02.002
   Wang JJ, 2000, CLIN EXP OPHTHALMOL, V28, P268, DOI 10.1046/j.1442-9071.2000.00315.x
   Weih LM, 2000, ARCH OPHTHALMOL-CHIC, V118, P264
   West SK, 1997, INVEST OPHTH VIS SCI, V38, P72
   Xu L, 2005, AM J OPHTHALMOL, V140, P913, DOI 10.1016/j.ajo.2005.04.050
   Xu L, 2005, OPHTHALMOLOGY, V112, P1676, DOI 10.1016/j.ophtha.2005.05.015
   Xu L, 2005, BRIT J OPHTHALMOL, V89, P1089, DOI 10.1136/bjo.2005.068429
   YU XM, 1992, EPIDEMIOLOGICAL SURV, V28, P363
   Zhao JL, 1998, AM J OPHTHALMOL, V126, P515, DOI 10.1016/S0002-9394(98)00274-8
   Zhao JL, 1998, AM J OPHTHALMOL, V126, P506, DOI 10.1016/S0002-9394(98)00275-X
NR 39
TC 411
Z9 438
U1 1
U2 28
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD JUL
PY 2006
VL 113
IS 7
BP 1134
EP 1141
DI 10.1016/j.ophtha.2006.01.035
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 059IV
UT WOS:000238727400012
DA 2022-11-30
ER

PT J
AU Gao, JY
   Cui, JZ
   Wang, AK
   Chen, HHR
   Fong, A
   Matsubara, JA
AF Gao, Jiangyuan
   Cui, Jing Z.
   Wang, Aikun
   Chen, Hao Hang Rachel
   Fong, Alison
   Matsubara, Joanne A.
TI The reduction of XIAP is associated with inflammasome activation in RPE:
   implications for AMD pathogenesis
SO JOURNAL OF NEUROINFLAMMATION
LA English
DT Article
DE Age-related macular degeneration; XIAP; Caspase-1; Inflammasome;
   Pyroptosis; And retinal pigment epithelium
ID PIGMENT EPITHELIAL-CELLS; NF-KAPPA-B; NLRP3 INFLAMMASOME; ALU RNA;
   CASPASE-1 ACTIVATION; MACULAR DEGENERATION; GENE-EXPRESSION; P2X7
   RECEPTOR; DEATH; INHIBITOR
AB Background Age-related macular degeneration (AMD) is a multifactorial chronic disease of the eye. Several candidate pathways have been hypothesized to play a role in AMD pathogenesis. Our work and those of others suggests inflammasome activity as a mechanism associated with retinal pigment epithelial (RPE) cell demise. X-linked inhibitor of apoptosis protein (XIAP), an anti-apoptosis factor, has recently been shown to regulate inflammasome activity in non-ocular cells. The purpose of this study is to characterize XIAP's regulatory role in RPE. Methods Protein lysates of eye tissues from rats (vinpocetine- or aurin tricarboxylic acid complex-treated, ATAC, vs naive) and mice (wild type vs Caspase-4(-/-)) were utilized to analyze XIAP protein levels. Immunohistochemistry was used to detect NLRP3 levels in the RPE layer. In vitro inflammasome activation on RPE cells was achieved with L-leucyl-L-leucine methyl ester (Leu-Leu-OMe) stimulation. Levels of XIAP mRNA and 18S RNA were quantified by RT-PCR. Cell culture supernatants were tested directly for secreted IL-1 beta by ELISA or concentrated for the detection of secreted IL-18 by western blot. Protein lysates from RPE in cell culture were collected for the measurement of cleaved caspase-1 p20, XIAP, and GAPDH. Data are presented as Mean +/- SD. p < 0.05 is considered statistically significant. Results The XIAP protein level was significantly increased when the inflammasome was inhibited at the "activation" step by ATAC, but not the "priming" step, in vivo. Concomitantly, NLRP3 immunoreactivity was lower in the RPE layer of animals fed with ATAC. In mice where caspase-1 cleavage was impaired by the genetic deficiency in caspase-4, the XIAP protein level increased in eye tissues. In RPE cell culture, Leu-Leu-OMe stimulation led to caspase-1 cleavage, cytokine secretion, and XIAP reduction, which can be abolished by Z-YVAD-FMK. When XIAP siRNA was given as a pre-treatment to RPE in vitro, Leu-Leu-OMe induced IL-1 beta/IL-18 secretion was enhanced, whereas overexpressing XIAP reduced IL-1 beta secretion under inflammasome activation, both compared to controls cells. Conclusions Together, these data suggest XIAP-mediated inhibition of inflammasome activity in RPE may provide insights into the biological consequences of inflammasome activation in RPE and reveals the caspase-1/XIAP/IL-1 beta/IL-18 axis as a target for broader applications in AMD biology and treatment design.
C1 [Gao, Jiangyuan; Cui, Jing Z.; Wang, Aikun; Chen, Hao Hang Rachel; Fong, Alison; Matsubara, Joanne A.] Univ British Columbia, Dept Ophthalmol & Visual Sci, Fac Med, Eye Care Ctr, 2550 Willow St, Vancouver, BC V5Z 3N9, Canada.
C3 University of British Columbia
RP Matsubara, JA (通讯作者)，Univ British Columbia, Dept Ophthalmol & Visual Sci, Fac Med, Eye Care Ctr, 2550 Willow St, Vancouver, BC V5Z 3N9, Canada.
EM jygao@mail.ubc.ca; jms@mail.ubc.ca
OI Matsubara, Joanne A./0000-0002-3689-3117
FU Canadian Institutes of Health Research (CIHR); Natural Sciences and
   Engineering Research Council of Canada (NSERC)
FX The study was funded by Canadian Institutes of Health Research (CIHR)
   and Natural Sciences and Engineering Research Council of Canada (NSERC)
   grants to J.A.M. The funding body did not participate in the design of
   the study; collection, analysis, and interpretation of data; and writing
   the manuscript in any forms.
CR Arjamaa O, 2017, GRAEF ARCH CLIN EXP, V255, P1757, DOI 10.1007/s00417-017-3711-0
   Beug ST, 2012, TRENDS IMMUNOL, V33, P535, DOI 10.1016/j.it.2012.06.004
   Brandstetter C, 2015, J BIOL CHEM, V290, P31189, DOI 10.1074/jbc.M115.671180
   Brandstetter C, 2015, J MOL MED, V93, P905, DOI 10.1007/s00109-015-1275-1
   Cao SJ, 2013, MOL VIS, V19, P718
   Di Virgilio F, 2013, PHARMACOL REV, V65, P872, DOI 10.1124/pr.112.006171
   Eckelman BP, 2006, J BIOL CHEM, V281, P3254, DOI 10.1074/jbc.M510863200
   Ferretti M, 2009, ARTHRITIS RHEUM-US, V60, P3476, DOI 10.1002/art.24905
   Franchi L, 2007, J BIOL CHEM, V282, P18810, DOI 10.1074/jbc.M610762200
   Gao JY, 2018, J NEUROINFLAMM, V15, DOI 10.1186/s12974-018-1062-3
   Gelfand BD, 2015, CELL REP, V11, P1686, DOI 10.1016/j.celrep.2015.05.023
   Hirota JA, 2012, J ALLERGY CLIN IMMUN, V129, P1116, DOI 10.1016/j.jaci.2011.11.033
   Hu ZZ, 2019, J CELL PHYSIOL, V234, P18849, DOI 10.1002/jcp.28523
   Kahlenberg JM, 2005, J IMMUNOL, V175, P7611, DOI 10.4049/jimmunol.175.11.7611
   Kauppinen A, 2012, IMMUNOL LETT, V147, P29, DOI 10.1016/j.imlet.2012.05.005
   Kerur N, 2013, INVEST OPHTH VIS SCI, V54, P7395, DOI 10.1167/iovs.13-12500
   Kurji KH, 2010, INVEST OPHTH VIS SCI, V51, P1151, DOI 10.1167/iovs.09-3622
   Lawlor KE, 2017, CELL REP, V20, P668, DOI 10.1016/j.celrep.2017.06.073
   Licandro G, 2013, EUR J IMMUNOL, V43, P2126, DOI 10.1002/eji.201242918
   Liu RZT, 2014, EXP EYE RES, V127, P49, DOI 10.1016/j.exer.2014.07.003
   Lopez-Castejon G, 2012, EXPERT OPIN INV DRUG, V21, P995, DOI 10.1517/13543784.2012.690032
   Man SM, 2016, NAT REV IMMUNOL, V16, P7, DOI 10.1038/nri.2015.7
   Peeters PM, 2015, J IMMUNOL RES, V2015, DOI 10.1155/2015/828264
   Piippo N, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-25123-2
   Poudel B, 2018, J LEUKOC BIOL
   Riera CE, 2015, NAT MED, V21, P1400, DOI 10.1038/nm.4005
   Rigaud S, 2006, NATURE, V444, P110, DOI 10.1038/nature05257
   Santana PT, 2016, MICROBES INFECT, V18, P93, DOI 10.1016/j.micinf.2015.10.007
   Shi JJ, 2015, NATURE, V526, P660, DOI 10.1038/nature15514
   Tarallo V, 2012, CELL, V149, P847, DOI 10.1016/j.cell.2012.03.036
   Terman A, 2010, ANTIOXID REDOX SIGN, V12, P503, DOI 10.1089/ars.2009.2598
   Tseng WA, 2013, INVEST OPHTH VIS SCI, V54, P110, DOI 10.1167/iovs.12-10655
   Uchimoto T, 1999, APOPTOSIS, V4, P357, DOI 10.1023/A:1009695221038
   Vaccari JPDR, 2008, J NEUROSCI, V28, P3404, DOI 10.1523/JNEUROSCI.0157-08.2008
   Vince JE, 2012, IMMUNITY, V36, P215, DOI 10.1016/j.immuni.2012.01.012
   Wada T, 2014, CYTOKINE, V65, P74, DOI 10.1016/j.cyto.2013.09.007
   Wang LP, 2019, J MOL MED, V97, P523, DOI 10.1007/s00109-019-01753-5
   Wang XF, 2004, EXP EYE RES, V79, P209, DOI 10.1016/j.exer.2004.03.013
   Yabal M, 2014, CELL REP, V7, P1796, DOI 10.1016/j.celrep.2014.05.008
   Yao T, 2017, REPROD MED BIOL, V16, P99, DOI 10.1002/rmb2.12024
   Zhao T, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-015-0337-1
NR 41
TC 6
Z9 6
U1 0
U2 7
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1742-2094
J9 J NEUROINFLAMM
JI J. Neuroinflamm.
PD AUG 22
PY 2019
VL 16
IS 1
AR 171
DI 10.1186/s12974-019-1558-5
PG 13
WC Immunology; Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Immunology; Neurosciences & Neurology
GA IT7OG
UT WOS:000483064400001
PM 31438981
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Chew, EY
   Clemons, T
   SanGiovanni, JP
   Danis, R
   Domalpally, A
   McBee, W
   Sperduto, R
   Ferris, FL
AF Chew, Emily Y.
   Clemons, Traci
   SanGiovanni, John Paul
   Danis, Ronald
   Domalpally, Amitha
   McBee, Wendy
   Sperduto, Robert
   Ferris, Frederick L.
CA AREDS2 Res Grp
TI The Age-related Eye Disease Study 2 (AREDS2) Study Design and Baseline
   Characteristics (AREDS2 Report Number 1)
SO OPHTHALMOLOGY
LA English
DT Article
ID FATTY-ACID INTAKE; MACULAR DEGENERATION; FISH CONSUMPTION; RISK-FACTORS;
   DIETARY-FAT; VITAMIN-C; LUTEIN; ZEAXANTHIN; CAROTENOIDS; CATARACT
AB Purpose: The Age-Related Eye Disease Study (AREDS) demonstrated beneficial effects of oral supplementation with antioxidant vitamins and minerals on the development of advanced age-related macular degeneration (AMD) in persons with at least intermediate AMD (bilateral large drusen with or without pigment changes). Observational data suggest that other oral nutrient supplements might further reduce the risk of progression to advanced AMD. The primary purpose of the Age-Related Eye Disease Study 2 (AREDS2) is to evaluate the efficacy and safety of lutein plus zeaxanthin (L + Z) and/or omega-3 long-chain polyunsaturated fatty acid (LCPUFA) supplementation in reducing the risk of developing advanced AMD. The study also assesses the reduction in zinc and the omission of beta-carotene from original AREDS formulation.
   Design: Multicenter, phase III, randomized, controlled clinical trial.
   Participants: Persons aged 50 to 85 with bilateral intermediate AMD or advanced AMD in 1 eye.
   Methods: All participants were randomly assigned to placebo (n = 1012), L + Z (10 mg/2 mg; n = 1044), omega-3 LCPUFAs (eicosapentaenoic acid + docosahexaenoic acid [650 mg/350 mg]; n = 1069), or the combination of L + Z and omega-3 LCPUFAs (n = 1078). All participants were offered a secondary randomization to 1 of 4 variations of the original AREDS formulation keeping vitamins C (500 mg) and E (400 IU) and copper (2 mg) unchanged while varying zinc and beta-carotene as follows: Zinc remains at the original level (80 mg), lower only zinc to 25 mg, omit beta-carotene only, or lower zinc to 25 mg and omit beta-carotene.
   Main Outcome Measures: Progression to advanced AMD determined by centralized grading of annual fundus photographs.
   Results: We enrolled 4203 participants at 82 clinical centers located in the United States. Population characteristics at baseline were as follows: Mean age, 74 years; 57% female; 97% white; 7% current smokers; 19% with prior cardiovascular disease; and 44% and 50% taking statin-class cholesterol-lowering drugs and aspirin, respectively. Ocular characteristics include 59% with bilateral large drusen, 32% with advanced AMD in 1 eye and mean visual acuity of 20/32 in eyes without advanced AMD.
   Conclusions: This report presents the AREDS2 study design and the participants' baseline demographic and ocular characteristics.
   Financial Disclosure(s): Proprietary or commercial disclosure may be found after the references. Ophthalmology 2012;119:2282-2289 (C) 2012 by the American Academy of Ophthalmology.
C1 [Chew, Emily Y.; SanGiovanni, John Paul; Ferris, Frederick L.] NEI, Div Epidemiol & Clin Applicat, NIH, Bethesda, MD 20892 USA.
   [Clemons, Traci; McBee, Wendy; Sperduto, Robert] EMMES Corp, Rockville, MD USA.
   [Danis, Ronald; Domalpally, Amitha] Univ Wisconsin, Fundus Photograph Reading Ctr, Madison, WI USA.
C3 National Institutes of Health (NIH) - USA; NIH National Eye Institute
   (NEI); Emmes Corporation; University of Wisconsin System; University of
   Wisconsin Madison
RP Chew, EY (通讯作者)，NEI, Div Epidemiol & Clin Applicat, NIH, Bldg 10,CRC Room 3-2531,10 Ctr Dr,MSC 1204, Bethesda, MD 20892 USA.
EM echew@nei.nih.gov
RI Domalpally, Amitha/B-2367-2015; SanGiovanni, John Paul/AAU-3895-2020
OI Ferris, Frederick/0000-0002-4933-0639; Domalpally,
   Amitha/0000-0002-8145-9619
FU National Eye Institute/National Institutes of Health (NEI/NIH),
   Department of Health and Human Services, Bethesda, MD
   [HHS-N-260-2005-00007-C]; ADB Contract [N01-EY-5-0007]; NIH, Office of
   Dietary Supplements (ODS); NIH, National Center for Complementary and
   Alternative Medicine (NCCAM); NIH, National Institute on Aging (NIA);
   NIH, National Heart, Lung and Blood Institute (NHLBI); NIH, National
   Institute of Neurological Disorders and Stroke (NINDS); NATIONAL EYE
   INSTITUTE [ZIAEY000485] Funding Source: NIH RePORTER
FX This study is supported by the intramural program funds and contracts
   from the National Eye Institute/National Institutes of Health (NEI/NIH),
   Department of Health and Human Services, Bethesda, MD, Contract No.
   HHS-N-260-2005-00007-C and ADB Contract No. N01-EY-5-0007. Funds were
   generously contributed to these contracts by the following NIH
   institutes: Office of Dietary Supplements (ODS), National Center for
   Complementary and Alternative Medicine (NCCAM), National Institute on
   Aging (NIA), National Heart, Lung and Blood Institute (NHLBI), and
   National Institute of Neurological Disorders and Stroke (NINDS).
CR ALBANES D, 1995, AM J CLIN NUTR, V62, P1427, DOI 10.1093/ajcn/62.6.1427S
   [Anonymous], 1993, Arch Ophthalmol, V111, P104
   Arnal E, 2009, GRAEF ARCH CLIN EXP, V247, P115, DOI 10.1007/s00417-008-0935-z
   Augood C, 2008, AM J CLIN NUTR, V88, P398, DOI 10.1093/ajcn/88.2.398
   Chitchumroonchokchai C, 2004, J NUTR, V134, P3225, DOI 10.1093/jn/134.12.3225
   Chua B, 2006, ARCH OPHTHALMOL-CHIC, V124, P981, DOI 10.1001/archopht.124.7.981
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P487
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Delcourt C, 2006, INVEST OPHTH VIS SCI, V47, P2329, DOI 10.1167/iovs.05-1235
   Dherani M, 2008, INVEST OPHTH VIS SCI, V49, P3328, DOI 10.1167/iovs.07-1202
   Dorey CK, 2005, EXP EYE RES, V81, P464, DOI 10.1016/j.exer.2005.03.007
   Ferris FL, 2005, ARCH OPHTHALMOL-CHIC, V123, P1570
   FLIESLER SJ, 1983, PROG LIPID RES, V22, P79
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Goldman HB, 2009, GERIATRICS, V64, P19
   Hambidge M, 2003, J NUTR, V133, p1438S, DOI 10.1093/jn/133.5.1438S
   Institute of Medicine (US) Panel on Micronutrients, 2001, DIETARY REFERENCE IN, DOI 10.17226/10026
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1439, DOI 10.1001/archopht.119.10.1439
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Krinsky NI, 2003, ANNU REV NUTR, V23, P171, DOI 10.1146/annurev.nutr.23.011702.073307
   Landrum JT, 2001, ARCH BIOCHEM BIOPHYS, V385, P28, DOI 10.1006/abbi.2000.2171
   Lyle BJ, 1999, AM J EPIDEMIOL, V149, P801, DOI 10.1093/oxfordjournals.aje.a009895
   Mares-Perlman JA, 2001, AM J EPIDEMIOL, V153, P424, DOI 10.1093/aje/153.5.424
   Moeller SM, 2008, ARCH OPHTHALMOL-CHIC, V126, P354, DOI 10.1001/archopht.126.3.354
   Moeller SM, 2006, ARCH OPHTHALMOL-CHIC, V124, P1151, DOI 10.1001/archopht.124.8.1151
   Neuringer M, 1993, LIPIDS LEARNING BRAI, P134
   NEWSOME DA, 1988, ARCH OPHTHALMOL-CHIC, V106, P192
   Omenn GS, 1996, J NATL CANCER I, V88, P1550, DOI 10.1093/jnci/88.21.1550
   Renzi Lisa M., 2007, Journal of Nutrition for the Elderly, V26, P139, DOI 10.1300/J05052v26n03_07
   SanGiovanni JP, 2008, ARCH OPHTHALMOL-CHIC, V126, P1274, DOI 10.1001/archopht.126.9.1274
   SanGiovanni JP, 2007, ARCH OPHTHALMOL-CHIC, V125, P1225, DOI 10.1001/archopht.125.9.1225
   SanGiovanni JP, 2009, AM J CLIN NUTR, V90, P1601, DOI 10.3945/ajcn.2009.27594
   SanGiovanni JP, 2009, ARCH OPHTHALMOL-CHIC, V127, P110, DOI 10.1001/archophthalmol.2008.518
   SanGiovanni JP, 2005, PROG RETIN EYE RES, V24, P87, DOI 10.1016/j.preteyeres.2004.06.002
   SanGiovanni JP, 2010, ENCY DIETARY SUPPLEM, P493
   Seddon JM, 2003, ARCH OPHTHALMOL-CHIC, V121, P1728, DOI 10.1001/archopht.121.12.1728
   SEDDON JM, 1994, JAMA-J AM MED ASSOC, V272, P1413, DOI 10.1001/jama.272.18.1413
   Seddon JM, 2001, ARCH OPHTHALMOL-CHIC, V119, P1191, DOI 10.1001/archopht.119.8.1191
   Seddon JM, 2006, ARCH OPHTHALMOL-CHIC, V124, P995, DOI 10.1001/archopht.124.7.995
   Snellen ELM, 2002, ACTA OPHTHALMOL SCAN, V80, P368, DOI 10.1034/j.1600-0420.2002.800404.x
   Swenor BK, 2010, OPHTHALMOLOGY, V117, P2395, DOI 10.1016/j.ophtha.2010.03.058
   Tan JSL, 2008, OPHTHALMOLOGY, V115, P334, DOI 10.1016/j.ophtha.2007.03.083
   Vu HTV, 2006, INVEST OPHTH VIS SCI, V47, P3783, DOI 10.1167/iovs.05-0587
   WEI LJ, 1989, J AM STAT ASSOC, V84, P1065, DOI 10.2307/2290084
   YEUM KJ, 1995, INVEST OPHTH VIS SCI, V36, P2756
NR 45
TC 196
Z9 201
U1 0
U2 35
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD NOV
PY 2012
VL 119
IS 11
BP 2282
EP 2289
DI 10.1016/j.ophtha.2012.05.027
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 030OH
UT WOS:000310579500014
PM 22840421
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Koch, KR
   Muether, PS
   Hermann, MM
   Hoerster, R
   Kirchhof, B
   Fauser, S
AF Koch, Konrad R.
   Muether, Philipp S.
   Hermann, Manuel M.
   Hoerster, Robert
   Kirchhof, Bernd
   Fauser, Sascha
TI Subjective perception versus objective outcome after intravitreal
   ranibizumab for exudative AMD
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE Exudative AMD; Subjective perception; Ranibizumab treatment;
   Best-corrected visual acuity
ID OPTICAL COHERENCE TOMOGRAPHY; VISION-RELATED FUNCTION; QUALITY-OF-LIFE;
   MACULAR DEGENERATION; VISUAL-ACUITY; READING SPEED; CHOROIDAL
   NEOVASCULARIZATION; CLINICAL-TRIAL; EYE; REPRODUCIBILITY
AB The efficacy of ranibizumab in preserving visual acuity in exudative age-related macular degeneration (AMD) has been widely demonstrated. However, statistically significant improvements in outcome measures such as best-corrected visual acuity (BCVA) may not necessarily be clinically relevant. Clinical relevance can be assumed when the treatment success is perceivable for the patient. We therefore investigated the relation between subjective perception of the treatment success and the objective outcome after intravitreal ranibizumab treatment.
   In this prospective interventional case series, patients received three monthly ranibizumab injections for exudative AMD. To assess the subjective study outcome (SSO) 4 weeks after the third injection, patients had to grade the overall trend of visual quality in the treated eye since baseline. Objective changes of functional (BCVA measured with ETDRS reading charts; reading visual acuity (RVA) and reading speed measured with Radner reading charts) and morphological parameters (central retinal thickness measured with OCT) were evaluated. Agreement between SSO and objective parameters was assessed with nonparametric statistical tests.
   Seventy-four eyes of 74 patients were analyzed. Mean BCVA increased from 55 (SD +/- 13) ETDRS letters by +3.16 letters (SD +/- 11.99, p = 0.03). Mean RVA (measured as logRAD score) increased by -0.067 (SD +/- 0.294, p = 0.052). Fifty patients (68%) perceived a subjective improvement, 16 (21%) no change, and eight (11%) a worsening in the study eye (SSO). SSO was independent of whether treating the better- or worse-seeing eye (p = 0.83). SSO was significantly correlated with BCVA, RVA, and reading speed (as assessed using the critical print size (CPS)) changes (p = 0.002, p < 0.001, and p = 0.002), but showed no correlation to central retinal thickness changes (p = 0.783). Patients gaining a parts per thousand yenaEuro parts per thousand+5 ETDRS letters had a significantly better SSO (p = 0.001). The rate of subjective improvement increased distinctly to > 80% among patients gaining a parts per thousand yenaEuro parts per thousand+7 letters.
   In this study, 2/3 of patients reported a subjective improvement from ranibizumab injections. Patients' perception was significantly correlated with objective changes in BCVA and reading visual acuity. Our data indicate that the mean threshold for perceived improvement is a +5 to +7 letter gain, which might accordingly be considered clinically meaningful and relevant. Patients' perception was independent of whether the better- or worse-seeing eye was treated.
C1 [Koch, Konrad R.; Muether, Philipp S.; Hermann, Manuel M.; Hoerster, Robert; Kirchhof, Bernd; Fauser, Sascha] Univ Cologne, Ctr Ophthalmol, D-50924 Cologne, Germany.
C3 University of Cologne
RP Koch, KR (通讯作者)，Univ Cologne, Ctr Ophthalmol, D-50924 Cologne, Germany.
EM konikoch@web.de
FU Faculty of Medicine, University of Cologne
FX This study was supported by the Koeln Fortune Program, Faculty of
   Medicine, University of Cologne. The data were presented in part at the
   ARVO annual meeting 2011 [33]. The authors did not receive support from
   for-profit organizations. Clinical trials registration reference number:
   NCT 01213667
CR Ach T, 2007, KLIN MONATSBL AUGENH, V224, P180, DOI 10.1055/s-2007-963035
   Beck RW, 2003, AM J OPHTHALMOL, V135, P194, DOI 10.1016/S0002-9394(02)01825-1
   BLACKHURST DW, 1989, RETINA-J RET VIT DIS, V9, P163, DOI 10.1097/00006982-198909030-00001
   Bressler NM, 2010, OPHTHALMOLOGY, V117, P747, DOI 10.1016/j.ophtha.2009.09.002
   Bressler NM, 2009, ARCH OPHTHALMOL-CHIC, V127, P13, DOI 10.1001/archophthalmol.2008.562
   Bressler NM, 2003, ARCH OPHTHALMOL-CHIC, V121, P1621
   Bressler NM, 2010, OPHTHALMOLOGY, V117, pe4
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Burggraaff MC, 2010, GRAEF ARCH CLIN EXP, V248, P1631, DOI 10.1007/s00417-010-1402-1
   Ergun E, 2003, OPHTHALMOLOGY, V110, P65, DOI 10.1016/S0161-6420(02)01566-X
   Frennesson C, 2010, ACTA OPHTHALMOL, V88, P420, DOI 10.1111/j.1755-3768.2009.01576.x
   Gall C, 2010, GRAEF ARCH CLIN EXP, V248, P863, DOI 10.1007/s00417-009-1296-y
   Hazel CA, 2000, INVEST OPHTH VIS SCI, V41, P1309
   Joeres S, 2007, INVEST OPHTH VIS SCI, V48, P4300, DOI 10.1167/iovs.07-0179
   Kaiser PK, 2007, OPHTHALMOLOGY, V114, P1868, DOI 10.1016/j.ophtha.2007.04.030
   Keane PA, 2008, INVEST OPHTH VIS SCI, V49, P3115, DOI 10.1167/iovs.08-1689
   Keane PA, 2008, OPHTHALMOLOGY, V115, P2206, DOI 10.1016/j.ophtha.2008.08.016
   Kiss CG, 2009, INVEST OPHTH VIS SCI, V50, P2376, DOI 10.1167/iovs.08-2017
   Klein R, 1996, OPHTHALMOLOGY, V103, P1169, DOI 10.1016/S0161-6420(96)30526-5
   Koch KR, 2011, ARVO M, V52, P1662
   Maajwee K, 2008, OPTOMETRY VISION SCI, V85, P353, DOI 10.1097/OPX.0b013e31816bf58b
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   McClure ME, 2000, BRIT J OPHTHALMOL, V84, P244, DOI 10.1136/bjo.84.3.244
   Moutray T, 2008, BRIT J OPHTHALMOL, V92, P361, DOI 10.1136/bjo.2007.123976
   Radner T, 1998, KLIN MONATSBL AUGENH, V213, P174, DOI 10.1055/s-2008-1034969
   Radner W, 2002, GRAEF ARCH CLIN EXP, V240, P461, DOI 10.1007/s00417-002-0443-5
   Richter-Mueksch S, 2006, GRAEF ARCH CLIN EXP, V244, P154, DOI 10.1007/s00417-005-0063-y
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Roy MS, 2007, ARCH OPHTHALMOL-CHIC, V125, P1061, DOI 10.1001/archopht.125.8.1061
   Schumacher M, 2010, OPHTHALMOLOGY, V117, P1367, DOI 10.1016/j.ophtha.2010.03.061
   Singh RP, 2009, BRIT J OPHTHALMOL, V93, P1353, DOI 10.1136/bjo.2008.141879
   Stifter E, 2004, GRAEF ARCH CLIN EXP, V242, P31, DOI 10.1007/s00417-003-0776-8
   Stifter E, 2005, J CATARACT REFR SURG, V31, P2111, DOI 10.1016/j.jcrs.2005.03.080
   Suner IJ, 2009, INVEST OPHTH VIS SCI, V50, P3629, DOI 10.1167/iovs.08-3225
NR 34
TC 13
Z9 13
U1 0
U2 1
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0721-832X
EI 1435-702X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD FEB
PY 2012
VL 250
IS 2
BP 201
EP 209
DI 10.1007/s00417-011-1792-8
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 892MP
UT WOS:000300290600006
PM 21901296
DA 2022-11-30
ER

PT J
AU Sunness, JS
   El Annan, J
AF Sunness, Janet S.
   El Annan, Jaafar
TI Improvement of Visual Acuity by Refraction in a Low-Vision Population
SO OPHTHALMOLOGY
LA English
DT Article
ID BILATERAL GEOGRAPHIC ATROPHY; EYE; IMPAIRMENT
AB Purpose: Refraction often may be overlooked in low-vision patients, because the main cause of vision decrease is not refractive, but rather is the result of underlying ocular disease. This retrospective study was carried out to determine how frequently and to what extent visual acuity is improved by refraction in a low-vision population.
   Design: Cross-sectional study.
   Participants: Seven hundred thirty-nine low-vision patients seen for the first time.
   Methods: A database with all new low-vision patients seen from November 2005 through June 2008 recorded presenting visual acuity using an Early Treatment Diabetic Retinopathy Study chart; it also recorded the best-corrected visual acuity (BCVA) if it was 2 lines or more better than the presenting visual acuity. Retinoscopy was carried out on all patients, followed by manifest refraction.
   Main Outcome Measures: Improvement in visual acuity.
   Results: Median presenting acuity was 20/80(-2) (interquartile range, 20/50-20/200). There was an improvement of 2 lines or more of visual acuity in 81 patients (11% of all patients), with 22 patients (3% of all patients) improving by 4 lines or more. There was no significant difference in age or in presenting visual acuity between the group that did not improve by refraction and the group that did improve. When stratified by diagnosis, the only 2 diagnoses with a significantly higher rate of improvement than the age-related macular degeneration group were myopic degeneration and progressive myopia (odds ratio, 4.8; 95% confidence interval [CI], 3.0-6.7) and status post-retinal detachment (odds ratio, 7.1; 95% CI, 5.2-9.0). For 5 patients (6% of those with improvement), the eye that was 1 line or more worse than the fellow eye at presentation became the eye that was 1 line or more better than the fellow eye after refraction.
   Conclusions: A significant improvement in visual acuity was attained by refraction in 11% of the new low-vision patients. Improvement was seen across diagnoses and the range of presenting visual acuity. The worse-seeing eye at presentation may become the better-seeing eye after refraction, so that the eye behind a balance lens should be refracted as well.
   Financial Disclosure(s): Proprietary or commercial disclosure may be found after the references. Ophthalmology 2010; 117: 1442-1446 (C) 2010 by the American Academy of Ophthalmology.
C1 [Sunness, Janet S.; El Annan, Jaafar] Greater Baltimore Med Ctr, Dept Ophthalmol, Baltimore, MD 21204 USA.
   [Sunness, Janet S.] Greater Baltimore Med Ctr, Richard E Hoover Rehabil Serv Low Vis & Blindness, Baltimore, MD USA.
   [El Annan, Jaafar] Univ Louisville, Sch Med, Dept Ophthalmol, Louisville, KY 40292 USA.
C3 Greater Baltimore Medical Center; Greater Baltimore Medical Center;
   University of Louisville
RP Sunness, JS (通讯作者)，Greater Baltimore Med Ctr, Dept Ophthalmol, 6569 N Charles St,PPW 305, Baltimore, MD 21204 USA.
EM jsunness@gbmc.org
OI Sunness, Janet/0000-0001-8823-0780
CR *AM AC OPHTH, SMARTSIGHT ACAD IN V
   *AM AC OPHTH REFR, 2007, PREF PRACT PATT REFR, P7
   Bissell AJ, 2005, ACTA OPHTHALMOL SCAN, V83, P514, DOI 10.1111/j.1600-0420.2005.00441.x
   Crossland MD, 2005, OPTOMETRY VISION SCI, V82, P617, DOI 10.1097/01.opx.0000171336.40273.3f
   FAYE EE, 1970, LOW VISION PATIENT C, P196
   FONDA GE, 1994, OPHTHALMOLOGY, V101, P84
   Foran S, 2002, AM J OPHTHALMOL, V134, P712, DOI 10.1016/S0002-9394(02)01673-2
   Markowitz SN, 2006, CAN J OPHTHALMOL, V41, P289, DOI 10.1139/I06-027
   Munoz B, 2002, INVEST OPHTH VIS SCI, V43, P608
   Nilsson UL, 1998, OPTOMETRY VISION SCI, V75, P873, DOI 10.1097/00006324-199812000-00009
   SINGERMAN LJ, 1985, RETINA-J RET VIT DIS, V5, P135, DOI 10.1097/00006982-198500530-00001
   Sunness JS, 2000, RETINA-J RET VIT DIS, V20, P162, DOI 10.1097/00006982-200002000-00009
NR 12
TC 16
Z9 17
U1 0
U2 6
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0161-6420
J9 OPHTHALMOLOGY
JI Ophthalmology
PD JUL
PY 2010
VL 117
IS 7
BP 1442
EP 1446
DI 10.1016/j.ophtha.2009.11.017
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 619NF
UT WOS:000279436200024
PM 20231036
DA 2022-11-30
ER

PT J
AU Renno, RZ
   Terada, Y
   Haddadin, MJ
   Michaud, NA
   Gragoudas, ES
   Miller, JW
AF Renno, RZ
   Terada, Y
   Haddadin, MJ
   Michaud, NA
   Gragoudas, ES
   Miller, JW
TI Selective photodynamic therapy by targeted verteporfin delivery to
   experimental choroidal neovascularization mediated by a homing peptide
   to vascular endothelial growth factor receptor-2
SO ARCHIVES OF OPHTHALMOLOGY
LA English
DT Article
ID VIVO PROTEIN TRANSDUCTION; IN-VIVO; MACULAR DEGENERATION; FACTOR
   ANTIBODY; NORMAL RETINA; MODEL; VEGF; BENZOPORPHYRIN; ANGIOGENESIS;
   MOUSE
AB Objective: To evaluate the feasibility, efficacy, and selectivity of photodynamic therapy (PDT) using targeted delivery of verteporfin to choroidal neovascularization (CNV) in the rat laser-injury model of CNV.
   Methods: We performed PDT in rat eyes on experimental CNV and normal retina and choroid using verteporfin conjugates. A targeted verteporfin conjugate was made by conjugating verteporfin (after isolation from its liposomal formulation) to a modified polyvinyl alcohol (PVA) polymer (verteporfin-PVA) followed by linkage to the peptide ATWLPPR known to bind the receptor for vascular endothelial growth factor, VEGFR2. The verteporfin-PVA conjugate served as a control. We performed fluorescent fundus angiography to determine the optimal timing of light application for PDT using the conjugates. Closure of CNV was assessed angiographically and graded in a masked standardized fashion. We used standardized histological grading to compare the effects on normal retina and choroid.
   Results: The verteporfin-PVA conjugation ratio was on average 28:1. The conjugate retained typical emission/excitation spectra and photosensitizing activity and was as efficient as an equivalent amount of verteporfin. Peak intensity of targeted verteporfin in CNV was detected angiographically at 1 hour after intravenous injection. Photodynamic therapy using targeted verteporfin (3 or 4.5 mg/m(2)) with light application I hour after drug injection showed angiographic closure of all treated CNV (17/17) 1. day after treatment. Photodynamic therapy using verteporfin-PVA at the same drug dose achieved closure in 18 of 20 CNV. Histological examination after PDT of normal retina and choroid using targeted verteporfin and irradiation at I hour showed minimal effect on retinal pigment epithelium and no injury to photoreceptors, whereas PDT using verteporfin-PVA resulted in retinal pigment epithelium necrosis and mild damage to photoreceptors.
   Conclusions: Verteporfin bound to the targeting peptide, ATWLPPR, retained its spectral and photosensitizing properties. Angiography demonstrated localization of the targeted verteporfin I hour after injection. Photodynamic therapy using targeted verteporfin and the control conjugate were more effective in causing CNV closure than standard liposomal verteporfin. The targeted verteporfin resulted in more selective treatment than the control conjugate or standard verteporfin. These results suggest that targeted PDT strategies based on selective expression of receptors on CNV vasculature may improve current therapy.
   Clinical Relevance: Targeted PDT for CNV is feasible and may offer a qualitative improvement in current treatments for patients with age-related macular degeneration. This study provides the basis for further preclinical studies of targeted PDT strategies and subsequent clinical trials.
C1 Harvard Univ, Retina Serv, Angiogenesis & Laser Res Lab,Dept Ophthalmol, Massachusetts Eye & Ear Infirm,Sch Med, Boston, MA 02114 USA.
   Amer Univ Beirut, Dept Chem, Beirut, Lebanon.
C3 Harvard University; Harvard Medical School; Massachusetts Eye & Ear
   Infirmary; American University of Beirut
RP Miller, JW (通讯作者)，Harvard Univ, Retina Serv, Angiogenesis & Laser Res Lab,Dept Ophthalmol, Massachusetts Eye & Ear Infirm,Sch Med, 243 Charles St, Boston, MA 02114 USA.
EM jwmiller@meei.harvard.edu
CR AIELLO LP, 1995, P NATL ACAD SCI USA, V92, P10457, DOI 10.1073/pnas.92.23.10457
   Arap W, 1998, SCIENCE, V279, P377, DOI 10.1126/science.279.5349.377
   Arap W, 2002, P NATL ACAD SCI USA, V99, P1527, DOI 10.1073/pnas.241655998
   Binetruy-Tournaire R, 2000, EMBO J, V19, P1525, DOI 10.1093/emboj/19.7.1525
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Bressler NM, 2000, ARCH OPHTHALMOL-CHIC, V118, P488
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   DOBI ET, 1989, ARCH OPHTHALMOL-CHIC, V107, P264, DOI 10.1001/archopht.1989.01070010270035
   FOLLI S, 1994, CANCER RES, V54, P2643
   GAUTHIER D, 2002, SAFETY EFFICACY INTR
   Gilpin DA, 1996, BURNS, V22, P607, DOI 10.1016/S0305-4179(96)00064-2
   Husain D, 1999, INVEST OPHTH VIS SCI, V40, P2322
   Husain D, 1996, ARCH OPHTHALMOL-CHIC, V114, P978, DOI 10.1001/archopht.1996.01100140186012
   JIANG FN, 1990, J IMMUNOL METHODS, V134, P139, DOI 10.1016/0022-1759(90)90122-C
   Kim I, 1999, INVEST OPHTH VIS SCI, V40, P2115
   Kramer M, 1996, OPHTHALMOLOGY, V103, P427
   Krzystolik MG, 2002, ARCH OPHTHALMOL-CHIC, V120, P338
   Lange N, 2001, INVEST OPHTH VIS SCI, V42, P38
   Lindgren M, 2000, TRENDS PHARMACOL SCI, V21, P99, DOI 10.1016/S0165-6147(00)01447-4
   McLeod DS, 2002, INVEST OPHTH VIS SCI, V43, P474
   Miller JW, 1999, ARCH OPHTHALMOL-CHIC, V117, P1161
   MILLER JW, 1995, ARCH OPHTHALMOL-CHIC, V113, P810, DOI 10.1001/archopht.1995.01100060136048
   MILLER JW, 1994, AM J PATHOL, V145, P574
   MONNER DA, 1988, IMMUNOL LETT, V19, P261, DOI 10.1016/0165-2478(88)90152-6
   Murdter TE, 1997, CANCER RES, V57, P2440
   Pasqualini R, 1996, NATURE, V380, P364, DOI 10.1038/380364a0
   Reinke MH, 1999, OPHTHALMOLOGY, V106, P1915, DOI 10.1016/S0161-6420(99)90401-3
   Renno RZ, 2000, INVEST OPHTH VIS SCI, V41, P3963
   Schwarze SR, 1999, SCIENCE, V285, P1569, DOI 10.1126/science.285.5433.1569
   Schwarze SR, 2000, TRENDS PHARMACOL SCI, V21, P45, DOI 10.1016/S0165-6147(99)01429-7
   Sickenberg M, 2000, ARCH OPHTHALMOL-CHIC, V118, P327, DOI 10.1001/archopht.118.3.327
   STEELE KJ, 1989, P SPIE INT SOC OPT E, V1065, P73
   Tille JC, 2001, J PHARMACOL EXP THER, V299, P1073
   TOBE T, 1994, J JPN OPHTHALMOL SOC, V98, P837
   Tolentino MJ, 2000, ARCH OPHTHALMOL-CHIC, V118, P78
   Vocero-Akbani AM, 1999, NAT MED, V5, P29, DOI 10.1038/4710
   Wada M, 1999, CURR EYE RES, V18, P203, DOI 10.1076/ceyr.18.3.203.5368
   Zacks DN, 2002, INVEST OPHTH VIS SCI, V43, P2384
NR 38
TC 57
Z9 63
U1 3
U2 15
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 0003-9950
EI 1538-3601
J9 ARCH OPHTHALMOL-CHIC
JI Arch. Ophthalmol.
PD JUL
PY 2004
VL 122
IS 7
BP 1002
EP 1011
DI 10.1001/archopht.122.7.1002
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 838HF
UT WOS:000222703400008
PM 15249365
OA Bronze
DA 2022-11-30
ER

PT J
AU Marques, AP
   Ramke, J
   Cairns, J
   Butt, T
   Zhang, JH
   Jones, I
   Jovic, M
   Nandakumar, A
   Faal, H
   Taylor, H
   Bastawrous, A
   Braithwaite, T
   Resnikoff, S
   Khaw, PT
   Bourne, R
   Gordon, I
   Frick, K
   Burton, MJ
AF Marques, Ana Patricia
   Ramke, Jacqueline
   Cairns, John
   Butt, Thomas
   Zhang, Justine H.
   Jones, Iain
   Jovic, Marty
   Nandakumar, Allyala
   Faal, Hannah
   Taylor, Hugh
   Bastawrous, Andrew
   Braithwaite, Tasanee
   Resnikoff, Serge
   Khaw, Peng T.
   Bourne, Rupert
   Gordon, Iris
   Frick, Kevin
   Burton, Matthew J.
TI The economics of vision impairment and its leading causes: A systematic
   review
SO ECLINICALMEDICINE
LA English
DT Review
DE Ophthalmology; Public health; Health economics; Systematic review
ID HEALTH-CARE COSTS; BILATERAL CATARACT-SURGERY; VERTEPORFIN PHOTODYNAMIC
   THERAPY; DIABETES-RELATED COMPLICATIONS; OPEN-ANGLE GLAUCOMA;
   QUALITY-OF-LIFE; MACULAR DEGENERATION; VISUAL IMPAIRMENT; GLOBAL BURDEN;
   RESOURCE UTILIZATION
AB Vision impairment (VI) can have wide ranging economic impact on individuals, households, and health systems. The aim of this systematic review was to describe and summarise the costs associated with VI and its major causes. We searched MEDLINE (16 November 2019), National Health Service Economic Evaluation Database, the Database of Abstracts of Reviews of Effects and the Health Technology Assessment database (12 December 2019) for partial or full economic evaluation studies, published between 1 January 2000 and the search dates, reporting cost data for participants with VI due to an unspecified cause or one of the seven leading causes globally: cataract, uncorrected refractive error, diabetic retinopathy, glaucoma, age-related macular degeneration, corneal opacity, trachoma. The search was repeated on 20 January 2022 to identify studies published since our initial search. Included studies were quality appraised using the British Medical Journal Checklist for economic submissions adapted for cost of illness studies. Results were synthesized in a structured narrative. Of the 138 included studies, 38 reported cost estimates for VI due to an unspecified cause and 100 reported costs for one of the leading causes. These 138 studies provided 155 regional cost estimates. Fourteen studies reported global data; 103/155 (66%) regional estimates were from high-income countries. Costs were most commonly reported using a societal (n = 48) or healthcare system perspective (n = 25). Most studies included only a limited number of cost components. Large variations in methodology and reporting across studies meant cost estimates varied considerably. The average quality assessment score was 78% (range 35-100%); the most common weaknesses were the lack of sensitivity analysis and insufficient disaggregation of costs. There was substantial variation across studies in average treatment costs per patient for most conditions, including refractive error correction (range $12-$ 201 ppp), cataract surgery (range $54-$ 3654 ppp), glaucoma (range $351-$ 1354 ppp) and AMD (range $2209-$ 7524 ppp). Future cost estimates of the economic burden of VI and its major causes will be improved by the development and adoption of a reference case for eye health. This could then be used in regular studies, particularly in countries with data gaps, including low- and middle-income countries in Asia, Eastern Europe, Oceania, Latin America and sub-Saharan Africa. Copyright (C) 2022 The Authors. Published by Elsevier Ltd.
C1 [Marques, Ana Patricia; Ramke, Jacqueline; Cairns, John; Zhang, Justine H.; Bastawrous, Andrew] London Sch Hyg & Trop Med, Int Ctr Eye Hlth, London WC1E 7HT, England.
   [Ramke, Jacqueline] Univ Auckland, Sch Optometry & Vis Sci, Auckland, New Zealand.
   [Butt, Thomas] UCL, London, England.
   [Zhang, Justine H.] Royal Free Hosp, London, England.
   [Jones, Iain] Sightsavers, Haywards Heath, England.
   [Jovic, Marty] PricewaterhouseCoopers, Sydney, NSW, Australia.
   [Nandakumar, Allyala] Brandeis Univ, Heller Sch Social Policy & Management, Waltham, MA USA.
   [Faal, Hannah] Univ Calabar, Dept Ophthalmol, Calabar, Nigeria.
   [Faal, Hannah] Africa Vis Res Inst, Durban, Kwa Zulu Natal, South Africa.
   [Taylor, Hugh] Univ Melbourne, Melbourne Sch Populat & Global Hlth, Melbourne, Vic, Australia.
   [Braithwaite, Tasanee] Guys & St Thomas Hosp, Med Eye Unit, London, England.
   [Braithwaite, Tasanee] Kings Coll London, Sch Immunol & Microbiol, London, England.
   [Braithwaite, Tasanee] Kings Coll London, Sch Life Course Sci, London, England.
   [Resnikoff, Serge] Univ New South Wales, Brien Holden Vis Inst & SOVS, Sydney, NSW, Australia.
   [Khaw, Peng T.; Burton, Matthew J.] Moorfields Eye Hosp NHS Fdn Trust, Natl Inst Hlth Res Biomed Res Ctr, London, England.
   [Khaw, Peng T.; Burton, Matthew J.] UCL Inst Ophthalmol, London, England.
   [Bourne, Rupert; Gordon, Iris] Anglia Ruskin Univ, Sch Med, Vis & Eye Res Inst, Cambridge, England.
   [Frick, Kevin] Johns Hopkins Carey Business Sch, Baltimore, MD USA.
C3 University of London; London School of Hygiene & Tropical Medicine;
   University of Auckland; University of London; University College London;
   University of London; University College London; Royal Free London NHS
   Foundation Trust; UCL Medical School; Brandeis University; University of
   Calabar; University of Melbourne; Guy's & St Thomas' NHS Foundation
   Trust; University of London; King's College London; University of
   London; King's College London; University of New South Wales Sydney;
   University of London; University College London; Moorfields Eye Hospital
   NHS Foundation Trust; University of London; University College London;
   Anglia Ruskin University; University of Cambridge; Johns Hopkins
   University
RP Marques, AP (通讯作者)，London Sch Hyg & Trop Med, Int Ctr Eye Hlth, London WC1E 7HT, England.
EM Patricia.Marques@lshtm.ac.uk
RI Ramke, Jacqueline/I-8844-2019; Marques, Ana Patricia/V-9571-2017
OI Ramke, Jacqueline/0000-0002-5764-1306; Marques, Ana
   Patricia/0000-0001-8242-7021; Khaw, Sir Peng Tee/0000-0002-8087-2268
FU Queen Elizabeth Diamond Jubilee Trust; Wellcome Trust [207472/Z/17/Z];
   Moorfields Eye Charity [GR001061]; Sightsavers; Fred Hollows Foundation;
   SEVA Foundation; British Council for the Prevention of Blindness;
   Christian Blind Mission
FX We acknowledge funding support for The Lancet Global Health Commission
   on Global Eye Health from The Queen Elizabeth Diamond Jubilee Trust, The
   Wellcome Trust, Moorfields Eye Charity (GR001061), Sightsavers, The Fred
   Hollows Foundation, The SEVA Foundation, The British Council for the
   Prevention of Blindness, and Christian Blind Mission. MJB is supported
   by the Wellcome Trust (207472/Z/17/Z).
CR Adio AO, 2012, CLIN OPHTHALMOL, V6, P2023, DOI 10.2147/OPTH.S37145
   Agro KE, 1997, PHARMACOECONOMICS, V11, P75, DOI 10.2165/00019053-199711010-00009
   Alva ML, 2015, DIABETIC MED, V32, P459, DOI 10.1111/dme.12647
   Angell B, 2018, BMJ OPEN OPHTHALMOL, V3, DOI 10.1136/bmjophth-2017-000123
   Arieta Carlos Eduardo Leite, 2004, Cad. Saúde Pública, V20, P303, DOI 10.1590/S0102-311X2004000100048
   Athanasakis K, 2012, CLIN THER, V34, P446, DOI 10.1016/j.clinthera.2012.01.005
   Awan H, 2012, INDIAN J OPHTHALMOL, V60, P358, DOI 10.4103/0301-4738.100527
   Baltussen R, 2004, B WORLD HEALTH ORGAN, V82, P338
   Baltussen RMRM, 2005, OPHTHAL EPIDEMIOL, V12, P91, DOI 10.1080/09286580590932761
   Bandello F, 2008, DRUG AGING, V25, P255, DOI 10.2165/00002512-200825030-00007
   Bastawrous A, 2020, OPHTHAL EPIDEMIOL, V27, P115, DOI 10.1080/09286586.2019.1700532
   Bonastre J, 2003, PHARMACOECONOMICS, V21, P181, DOI 10.2165/00019053-200321030-00003
   Bourne RRA, 2021, LANCET GLOB HEALTH, V9, pE130, DOI 10.1016/S2214-109X(20)30425-3
   Brook RA, 2015, POSTGRAD MED, V127, P455, DOI 10.1080/00325481.2014.994468
   Brown GC, 2013, OPHTHALMOLOGY, V120, P2367, DOI 10.1016/j.ophtha.2013.04.030
   Brown MM, 2016, RETINA-J RET VIT DIS, V36, P285, DOI 10.1097/IAE.0000000000000717
   Burton MJ, 2021, LANCET GLOB HEALTH, V9, pE489, DOI 10.1016/S2214-109X(20)30488-5
   Chakravarthy U, 2017, OPHTHAL EPIDEMIOL, V24, P239, DOI 10.1080/09286586.2017.1281426
   Chou SL, 2006, OPHTHAL EPIDEMIOL, V13, P355, DOI 10.1080/09286580600966623
   Chuvarayan Y., 2019, EUR J HEALTH ECON
   Clarke P, 2003, DIABETIC MED, V20, P442, DOI 10.1046/j.1464-5491.2003.00972.x
   Coleman AL, 2008, OPHTHALMOLOGY, V115, P18, DOI 10.1016/j.ophtha.2007.04.016
   Crews JE, 2006, J VISUAL IMPAIR BLIN, V100, P824
   Cruess A, 2007, CAN J OPHTHALMOL, V42, P836, DOI 10.3129/i07-153
   Cruess AF, 2008, PHARMACOECONOMICS, V26, P57, DOI 10.2165/00019053-200826010-00006
   Cruess AF, 2011, CAN J OPHTHALMOL, V46, P315, DOI 10.1016/j.jcjo.2011.06.006
   Dakin HA, 2014, BMJ OPEN, V4, DOI 10.1136/bmjopen-2014-005094
   Dave H, 2010, ARCH OPHTHALMOL-CHIC, V128, P1050, DOI 10.1001/archophthalmol.2010.136
   Day S., 1994, MEDICARE COSTS NEOVA
   Dilokthornsakul P, 2014, INT J OPHTHALMOL-CHI, V7, P145, DOI 10.3980/j.issn.2222-3959.2014.01.27
   Drummond M, 2005, MED CARE, V43, P5
   Drummond M.F., 2005, METHODS EC EVALUATIO
   Drummond MF, 1996, BRIT MED J, V313, P275, DOI 10.1136/bmj.313.7052.275
   Eckert KA, 2015, OPHTHAL EPIDEMIOL, V22, P349, DOI 10.3109/09286586.2015.1066394
   Economics A, 2011, TUNN VIS EC IMP PRIM
   Economics A., 2010, CLEAR FOC EC IMP VIS
   Economics A, 2008, EC IMP DIAB EYE DIS
   Eye Care Comparative Effectiveness, 2011, JPN J OPHTHALMOL, V55, P333, DOI 10.1007/s10384-011-0041-3
   Fang JH, 2010, BMC PUBLIC HEALTH, V10, DOI 10.1186/1471-2458-10-543
   Fattore G, 2008, HEALTH ECON, V17, pS71, DOI 10.1002/hec.1324
   Fenter TC, 2006, AM J MANAG CARE, V12, pS90
   Flaxman SR, 2017, LANCET GLOB HEALTH, V5, pE1221, DOI 10.1016/S2214-109X(17)30393-5
   Frick K D, 2001, Ophthalmic Epidemiol, V8, P191, DOI 10.1076/opep.8.2.191.4163
   Frick KD, 2003, AM J TROP MED HYG, V69, P1
   Frick KD, 2003, OPHTHAL EPIDEMIOL, V10, P121, DOI 10.1076/opep.10.2.121.13899
   Frick KD, 2003, AM J OPHTHALMOL, V135, P471, DOI 10.1016/S0002-9394(02)02110-4
   Frick KD, 2008, OPHTHALMOLOGY, V115, P11, DOI 10.1016/j.ophtha.2007.02.007
   Frick KD, 2007, ARCH OPHTHALMOL-CHIC, V125, P544, DOI 10.1001/archopht.125.4.544
   Frick KD, 2015, OPHTHALMOLOGY, V122, P1706, DOI 10.1016/j.ophtha.2015.04.014
   Frick KD, 2010, INVEST OPHTH VIS SCI, V51, P1801, DOI 10.1167/iovs.09-4469
   Garattini Livio, 2004, Eur J Health Econ, V5, P22
   Gieser DK, 2006, J GLAUCOMA, V15, P419, DOI 10.1097/01.ijg.0000212250.95078.6f
   Gogate P, 2010, INT J OPHTHALMOL-CHI, V3, P182, DOI 10.3980/j.issn.2222-3959.2010.02.22
   Sirtoli MGGM, 2010, CLINICS, V65, P357, DOI 10.1590/S1807-59322010000400002
   Gordois A, 2012, GLOB PUBLIC HEALTH, V7, P465, DOI 10.1080/17441692.2011.634815
   Gordon KD, 2011, CAN J OPHTHALMOL, V46, P310, DOI 10.1016/j.jcjo.2011.07.001
   Gower EW, 2010, RETINA-J RET VIT DIS, V30, P212, DOI 10.1097/IAE.0b013e3181babd8e
   Gradin D, 2012, J PEDIAT OPHTH STRAB, V49, P139, DOI 10.3928/01913913-20110726-01
   Grieve R, 2009, OPHTHALMOLOGY, V116, P2471, DOI 10.1016/j.ophtha.2009.10.023
   Griffiths UK, 2015, OPHTHAL EPIDEMIOL, V22, P43, DOI 10.3109/09286586.2013.839800
   Guan XD, 2019, BMJ OPEN, V9, DOI 10.1136/bmjopen-2019-030561
   Gupta OP, 2010, OPHTHALMOLOGY, V117, P2134, DOI 10.1016/j.ophtha.2010.02.032
   Hagman J, 2013, ACTA OPHTHALMOL, V91, P1, DOI 10.1111/aos.12141
   Halliday Richard G, 2003, Appl Health Econ Health Policy, V2, P149
   Hanemoto T, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0189035
   Haynes R, 2001, SOC SCI MED, V53, P1631, DOI 10.1016/S0277-9536(00)00448-2
   Husereau D, 2013, VALUE HEALTH, V16, P231, DOI 10.1016/j.jval.2013.02.002
   Hutton DW, 2019, JAMA OPHTHALMOL, V137, P1424, DOI 10.1001/jamaophthalmol.2019.4284
   Ibrahim N, 2015, BMC HEALTH SERV RES, V15, DOI 10.1186/s12913-015-0831-2
   Iskedjian M, 2003, J GLAUCOMA, V12, P456, DOI 10.1097/00061198-200312000-00002
   Kaplan RI, 2015, JAMA OPHTHALMOL, V133, P560, DOI 10.1001/jamaophthalmol.2015.44
   Ke KM, 2010, EUR J HEALTH ECON, V11, P525, DOI 10.1007/s10198-009-0207-9
   Keeffe JE, 2009, ARCH OPHTHALMOL-CHIC, V127, P1377, DOI 10.1001/archophthalmol.2009.242
   Kim S, 2019, BMC HEALTH SERV RES, V19, DOI 10.1186/s12913-019-4666-0
   Koberlein J, 2013, BMJ OPEN, V3, DOI 10.1136/bmjopen-2013-003471
   Koopmanschap MA, 1998, PHARMACOECONOMICS, V14, P143, DOI 10.2165/00019053-199814020-00001
   Kruger SJ, 2015, OPHTHALMOLOGY, V122, P288, DOI 10.1016/j.ophtha.2014.08.037
   Kume A, 2016, OPHTHALMOLOGY, V123, P1263, DOI 10.1016/j.ophtha.2016.01.042
   Kuper H, 2008, PLOS MED, V5, P1716, DOI 10.1371/journal.pmed.0050244
   Lafuma A, 2006, PHARMACOECONOMICS, V24, P193, DOI 10.2165/00019053-200624020-00007
   Lafuma A, 2009, OPHTHAL EPIDEMIOL, V16, P218, DOI [10.1080/09286580902999421, 10.3109/09286580902999421]
   Langelaan M, 2007, OPHTHAL EPIDEMIOL, V14, P119, DOI 10.1080/09286580601139212
   Larg A, 2011, PHARMACOECONOMICS, V29, P653, DOI 10.2165/11588380-000000000-00000
   Loo Cheen-Yeng, 2004, International Ophthalmology, V25, P81, DOI 10.1023/B:INTE.0000031738.65787.e9
   Lundstrom M, 2000, ACTA OPHTHALMOL SCAN, V78, P335, DOI 10.1034/j.1600-0420.2000.078003335.x
   Malot J, 2011, J FR OPHTALMOL, V34, P10, DOI 10.1016/j.jfo.2010.10.014
   Mandrik O, 2020, VALUE HEALTH, V24, P463, DOI 10.1016/j.jval.2021.01.002
   Marques AP, 2020, BMJ OPEN, V10, DOI 10.1136/bmjopen-2019-036689
   Marques AP, 2019, OPHTHAL EPIDEMIOL, V26, P378, DOI 10.1080/09286586.2019.1632904
   Marques AP, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0198631
   Marques AP, 2015, BMJ OPEN, V5, DOI 10.1136/bmjopen-2015-009006
   Marques AP, 2021, ECLINICALMEDICINE, P35
   Meads C, 2003, BRIT J OPHTHALMOL, V87, P1201, DOI 10.1136/bjo.87.10.1201
   Minassian DC, 2001, BRIT J OPHTHALMOL, V85, P822, DOI 10.1136/bjo.85.7.822
   Mohammadi SF, 2018, INT J OPHTHALMOL-CHI, V11, P1013, DOI 10.18240/ijo.2018.06.20
   Mojon-Azzi SM, 2010, OPHTHALMOLOGICA, V224, P381, DOI 10.1159/000316688
   Molinier L, 2008, VALUE HEALTH, V11, P878, DOI 10.1111/j.1524-4733.2008.00327.x
   Muralikrishnan R, 2004, OPHTHAL EPIDEMIOL, V11, P369, DOI 10.1080/09286580490888762
   Naidoo KS, 2019, OPHTHALMOLOGY, V126, P338, DOI 10.1016/j.ophtha.2018.10.029
   Nghiem-Buffet MH, 2001, PRESSE MED, V30, P1924
   NICE International Health Intervention and Technology Assess-ment Program T Centre for Health Economics University of York Bill and Melinda Gates Foundation, 2014, METHODS EC EVALUATIO
   O'Brien JJ, 2010, CAN J OPHTHALMOL, V45, P596, DOI 10.3129/i10-094
   Guedes RAP, 2011, ARQ BRAS OFTALMOL, V74, P400, DOI 10.1590/S0004-27492011000600003
   Park HY, 2015, ASIA-PAC J PUBLIC HE, V27, P631, DOI 10.1177/1010539515588944
   Pezzullo L, 2018, BMC HEALTH SERV RES, V18, DOI 10.1186/s12913-018-2836-0
   Prager AJ, 2016, JAMA OPHTHALMOL, V134, P357, DOI 10.1001/jamaophthalmol.2015.5479
   Prajna VN, 2007, CORNEA, V26, P119, DOI 10.1097/ICO.0b013e31802b36dc
   Redekop WK, 2017, PLOS NEGLECT TROP D, V11, DOI 10.1371/journal.pntd.0005289
   Reich O, 2017, BMC OPHTHALMOL, V17, DOI 10.1186/s12886-017-0617-x
   Rein DB, 2006, ARCH OPHTHALMOL-CHIC, V124, P1754, DOI 10.1001/archopht.124.12.1754
   Rethlefsen ML, 2015, J CLIN EPIDEMIOL, V68, P617, DOI 10.1016/j.jclinepi.2014.11.025
   Roberts CB, 2010, ARCH OPHTHALMOL-CHIC, V128, P766, DOI 10.1001/archophthalmol.2010.86
   Ruiz-Moreno J M, 2016, Arch Soc Esp Oftalmol, V91, P265, DOI 10.1016/j.oftal.2016.01.013
   Ruiz-Moreno JM, 2008, CURR MED RES OPIN, V24, P2103, DOI [10.1185/03007990802214300 , 10.1185/03007990802214300]
   Saad Filho Roberto, 2005, Arq. Bras. Oftalmol., V68, P55, DOI 10.1590/S0004-27492005000100010
   Sach TH, 2007, BRIT J OPHTHALMOL, V91, P1675, DOI 10.1136/bjo.2007.118687
   Saxena N, 2016, OPHTHAL EPIDEMIOL, V23, P232, DOI 10.1080/09286586.2016.1193617
   Schakel W, 2018, INVEST OPHTH VIS SCI, V59, P1916, DOI 10.1167/iovs.17-23224
   Schmid MK, 2018, BMC OPHTHALMOL, V18, DOI 10.1186/s12886-018-0731-4
   Schmid MK, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0135050
   Schmier JK, 2007, RETINA-J RET VIT DIS, V27, P621, DOI 10.1097/01.iae.0000249577.92800.c0
   Schmier JK, 2012, AM J OPHTHALMOL, V154, P675, DOI 10.1016/j.ajo.2012.04.017
   Singh AJ, 2000, LANCET, V355, P180, DOI 10.1016/S0140-6736(99)07430-9
   Smith TST, 2009, B WORLD HEALTH ORGAN, V87, P431, DOI 10.2471/BLT.08.055673
   Spooner KL, 2018, CLIN OPHTHALMOL, V12, P2483, DOI 10.2147/OPTH.S185052
   Stein JD, 2013, AM J OPHTHALMOL, V155, P688, DOI 10.1016/j.ajo.2012.10.003
   Studnicka J, 2013, OPHTHALMOLOGICA, V230, P34, DOI 10.1159/000350802
   Taylor HR, 2006, BRIT J OPHTHALMOL, V90, P272, DOI 10.1136/bjo.2005.080986
   Teerawattananon Y, 2007, PHARMACOECONOMICS, V25, P467, DOI 10.2165/00019053-200725060-00003
   The World Bank, 2020, WORLD DEV IND PPP CO
   Thygesen J, 2008, CURR MED RES OPIN, V24, P1763, DOI 10.1185/03007990802111068
   Vassall A, 2017, REFERENCE CASE ESTIM
   Vitale S., 1999, COSTS REFRACTIVE COR
   Wang XZ, 2014, OPHTHALMOLOGY, V121, P1837, DOI 10.1016/j.ophtha.2014.03.017
   WDI, 2020, WORLD DEV IND
   Weyer-Wendl H, 2016, HEALTH ECON REV, V6, DOI 10.1186/s13561-016-0116-4
   Wilkinson T, 2016, VALUE HEALTH, V19, P921, DOI 10.1016/j.jval.2016.04.015
   Wittenborn JS, 2013, OPHTHALMOLOGY, V120, P1728, DOI 10.1016/j.ophtha.2013.01.068
   Wong EYH, 2008, OPHTHAL EPIDEMIOL, V15, P339, DOI 10.1080/09286580802227394
   Wood H, 2017, INT J TECHNOL ASSESS, V33, P25, DOI 10.1017/S0266462316000660
   World Health Organization, 2011, INT CLASS DIS ICD
   Yildirim S, 2018, TURK OFTALMOL DERG, V48, P27, DOI 10.4274/tjo.44370
   Zheng YF, 2013, INVEST OPHTH VIS SCI, V54, P7532, DOI 10.1167/iovs.13-12795
NR 143
TC 1
Z9 1
U1 3
U2 3
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
EI 2589-5370
J9 ECLINICALMEDICINE
JI EClinicalMedicine
PD APR
PY 2022
VL 46
AR 101354
DI 10.1016/j.eclinm.2022.101354
PG 20
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA 2S0KY
UT WOS:000821492000012
PM 35340626
OA Green Accepted, Green Published, gold
DA 2022-11-30
ER

PT J
AU Borchers, L
   Roider, J
   Klettner, A
AF Borchers, Laura
   Roider, Johann
   Klettner, Alexa
TI Differences in Uptake and Intracellular Fate between Bevacizumab and
   Aflibercept after Repetitive Long-Term Treatment in the Retinal Pigment
   Epithelium
SO OPHTHALMIC RESEARCH
LA English
DT Article
DE Bevacizumab; Aflibercept; Retinal pigment epithelium; Lamp2; Age-related
   macular degeneration
ID TISSUE-PLASMINOGEN ACTIVATOR; MACULAR DEGENERATION; FC-RECEPTOR;
   RANIBIZUMAB; GROWTH; COMPATIBILITY; ATROPHY
AB Introduction: Anti-VEGF therapy is repeatedly given for an extended period of time to patients when treated for age-related macular degeneration. While short-term effects of anti-VEGF agents on retinal pigment epithelial cells have been investigated, the effects of long-term and repeated treatment on these cells are scarce. In this study, we have investigated the effects of anti-VEGF treatment (bevacizumab and aflibercept) after long-term, repeated treatment on uptake, storage, and subcellular localization. Methods: Experiments were conducted in primary porcine retinal pigment epithelium (RPE) cells in first passage and in ARPE-19 cell line. Cells were treated with 250 mu g/mL bevacizumab, aflibercept, or, as a non-VEGF inhibiting antibody, rituximab once a week for 1 day, 7 days, 4, and 12 weeks. Cell survival was evaluated with methyl thiazolyl tetrazolium assay. Uptake and localization of compounds were investigated with immunofluorescence microscopy. Selective intracellular proteins were stained with specific respective primary antibodies; actin cytoskeleton was stained with phalloidin. For quantitative analysis, intracellular signals were normalized to light intensity and exposure time. Intracellular association with lysosomes (Lamp2) and exosomes (CD63) was also quantified. In addition, subcellular fractions (nucleus, plasma, membrane, and cytoskeleton) were generated and analyzed in Western blot. Results: Weekly treatment up to 12 weeks displayed no toxic effects on RPE cells in any substance tested. Intracellular signal of bevacizumab and aflibercept was strongest after 1 day, decreased after 1 and 4 weeks but increased again after 12 weeks. The signal of intracellular bevacizumab was significantly stronger than of aflibercept. In addition, in primary RPE, aflibercept was significantly more associated with Lamp2, indicating degradation of aflibercept. At all time points, the respective therapeutics could be detected at the cytoskeleton. In primary RPE cells, co-localization with exosome marker CD63 showed a maximum after 1 day for bevacizumab and after 12 weeks for aflibercept. Actin-encapsulated therapeutics can be found at any time point tested. Conclusion: Both bevacizumab and aflibercept display a distinctive time-dependent uptake in the RPE cells and are stored in actin-covered accumulations for extended periods of time. When normalized and quantified, less aflibercept can be found in RPE cells, while more aflibercept is co-localized with Lamp2. Our data suggest that bevacizumab is differently processed by RPE cells than aflibercept.
C1 [Borchers, Laura; Roider, Johann; Klettner, Alexa] Univ Kiel, Univ Med Ctr, Dept Ophthalmol, Rosalind Franklin St 9, DE-24109 Kiel, Germany.
C3 University of Kiel; Schleswig Holstein University Hospital
RP Klettner, A (通讯作者)，Univ Kiel, Univ Med Ctr, Dept Ophthalmol, Rosalind Franklin St 9, DE-24109 Kiel, Germany.
EM alexakarina.klettner@uksh.de
OI Klettner, Alexa/0000-0002-2709-1059
FU Stifterverband (Hermann-Wacker foundation)
FX This study was supported by the Stifterverband (Hermann-Wacker
   foundation).
CR Cohen SY, 2007, BRIT J OPHTHALMOL, V91, P1173, DOI 10.1136/bjo.2007.115501
   Dithmer M, 2016, EXP EYE RES, V145, P187, DOI 10.1016/j.exer.2015.12.013
   Dithmer M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0089150
   Dunn KC, 1996, EXP EYE RES, V62, P155, DOI 10.1006/exer.1996.0020
   Geisen P, 2006, CURR EYE RES, V31, P739, DOI 10.1080/02713680600837408
   Gerding H, 2016, KLIN MONATSBL AUGENH, V233, P471, DOI 10.1055/s-0041-111835
   Hillenkamp J, 2010, RETINA-J RET VIT DIS, V30, P1685, DOI 10.1097/IAE.0b013e3181d87eb4
   Klettner A, 2008, INVEST OPHTH VIS SCI, V49, P4523, DOI 10.1167/iovs.08-2055
   Klettner A, 2015, BRIT J OPHTHALMOL, V99, P864, DOI 10.1136/bjophthalmol-2014-306454
   Klettner A, 2014, GRAEF ARCH CLIN EXP, V252, P1593, DOI 10.1007/s00417-014-2719-y
   Klettner A, 2014, BRIT J OPHTHALMOL, V98, P1448, DOI 10.1136/bjophthalmol-2014-305105
   Klettner A, 2012, ARCH OPHTHALMOL-CHIC, V130, P875, DOI 10.1001/archophthalmol.2012.120
   Klettner A, 2010, GRAEF ARCH CLIN EXP, V248, P819, DOI 10.1007/s00417-010-1317-x
   Klettner AK, 2020, RETINAL PIGMENT EPITHELIUM IN HEALTH AND DISEASE, P295, DOI 10.1007/978-3-030-28384-1_17
   Klettner AK, 2009, GRAEF ARCH CLIN EXP, V247, P1601, DOI 10.1007/s00417-009-1136-0
   Lois N, 2013, RETINA-J RET VIT DIS, V33, P13, DOI 10.1097/IAE.0b013e3182657fff
   Malik D, 2014, BRIT J OPHTHALMOL, V98, P11, DOI 10.1136/bjophthalmol-2014-305302
   Middleton S, 2010, VET CLIN N AM-FOOD A, V26, P557, DOI 10.1016/j.cvfa.2010.09.002
   Naga SHA, 2015, EXP EYE RES, V131, P29, DOI 10.1016/j.exer.2014.12.010
   Ranjbar M, 2016, CELL PHYSIOL BIOCHEM, V38, P737, DOI 10.1159/000443030
   Riss T. L., 2004, ASSAY GUIDANCE MANUA, P295
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   Schmidt-Erfurth U, 2014, BRIT J OPHTHALMOL, V98, P1144, DOI 10.1136/bjophthalmol-2014-305702
   Schottler J, 2018, EXP EYE RES, V171, P1, DOI 10.1016/j.exer.2018.03.002
   Simister NE, 1997, BIOCHEM SOC T, V25, P481, DOI 10.1042/bst0250481
   Sobolewska Bianka, 2017, Int J Retina Vitreous, V3, P22, DOI 10.1186/s40942-017-0075-x
   Spitzer MS, 2006, BRIT J OPHTHALMOL, V90, P1316, DOI 10.1136/bjo.2006.095190
   van Bilsen K, 2011, BRIT J OPHTHALMOL, V95, P864, DOI 10.1136/bjo.2010.187930
   Vo TA, 2018, EXP EYE RES, V177, P112, DOI 10.1016/j.exer.2018.07.025
   Wiencke AK, 2003, ACTA OPHTHALMOL SCAN, V81, P170, DOI 10.1034/j.1600-0420.2003.00030.x
   Young M, 2014, RETINA-J RET VIT DIS, V34, P1308, DOI 10.1097/IAE.0000000000000081
NR 31
TC 2
Z9 2
U1 1
U2 1
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0030-3747
EI 1423-0259
J9 OPHTHALMIC RES
JI Ophthalmic Res.
PD JUN
PY 2021
VL 64
IS 3
BP 369
EP 388
DI 10.1159/000511960
PG 20
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA YL1JI
UT WOS:000745655100004
PM 33011724
OA Bronze
DA 2022-11-30
ER

PT J
AU Chen, X
   Chen, ZH
   Li, ZY
   Zhao, C
   Zeng, YX
   Zou, T
   Fu, CY
   Liu, XL
   Xu, HW
   Yin, ZQ
AF Chen, Xi
   Chen, Zehua
   Li, Zhengya
   Zhao, Chen
   Zeng, Yuxiao
   Zou, Ting
   Fu, Caiyun
   Liu, Xiaoli
   Xu, Haiwei
   Yin, Zheng Qin
TI Grafted c-kit(+)/ SSEA1(-) eye-wall progenitor cells delay retinal
   degeneration in mice by regulating neural plasticity and forming new
   graft-to-host synapses
SO STEM CELL RESEARCH & THERAPY
LA English
DT Article
DE Retinal degeneration; c-kit; Differentiation; Transplantation; Synapse
   formation; Neuroplasticity
ID C-KIT RECEPTOR; TRANSPLANTED PHOTORECEPTOR PRECURSORS; STEM-CELLS;
   RETINITIS-PIGMENTOSA; IN-VIVO; MOUSE RETINA; MACULAR DEGENERATION;
   GANGLION-CELLS; MULLER CELLS; INTEGRATION
AB Background: Despite diverse pathogenesis, the common pathological change observed in age-related macular degeneration and in most hereditary retinal degeneration (RD) diseases is photoreceptor loss. Photoreceptor replacement by cell transplantation may be a feasible treatment for RD. The major obstacles to clinical translation of stem cell-based cell therapy in RD remain the difficulty of obtaining sufficient quantities of appropriate and safe donor cells and the poor integration of grafted stem cell-derived photoreceptors into the remaining retinal circuitry.
   Methods: Eye-wall c-kit(+)/stage-specific embryonic antigen 1 (SSEA1)(-) cells were isolated via fluorescence-activated cell sorting, and their self-renewal and differentiation potential were detected by immunochemistry and flow cytometry in vitro. After labeling with quantum nanocrystal dots and transplantation into the subretinal space of rd1 RD mice, differentiation and synapse formation by daughter cells of the eye-wall c-kit(+)/SSEA1(-) cells were evaluated by immunochemistry and western blotting. Morphological changes of the inner retina of rd1 mice after cell transplantation were demonstrated by immunochemistry. Retinal function of rd1 mice that received cell grafts was tested via flash electroretinograms and the light/dark transition test.
   Results: Eye-wall c-kit(+)/SSEA1(-) cells were self-renewing and clonogenic, and they retained their proliferative potential through more than 20 passages. Additionally, eye-wall c-kit(+)/SSEA1(-) cells were capable of differentiating into multiple retinal cell types including photoreceptors, bipolar cells, horizontal cells, amacrine cells, Muller cells, and retinal pigment epithelium cells and of transdifferentiating into smooth muscle cells and endothelial cells in vitro. The levels of synaptophysin and postsynaptic density-95 in the retinas of eye-wall c-kit(+)/SSEA1(-) cell-transplanted rd1 mice were significantly increased at 4 weeks post transplantation. The c-kit(+)/SSEA1(-) cells were capable of differentiating into functional photoreceptors that formed new synaptic connections with recipient retinas in rd1 mice. Transplantation also partially corrected the abnormalities of inner retina of rd1 mice. At 4 and 8 weeks post transplantation, the rd1 mice that received c-kit(+)/SSEA1(-) cells showed significant increases in a-wave and b-wave amplitude and the percentage of time spent in the dark area.
   Conclusions: Grafted c-kit(+)/SSEA1(-) cells restored the retinal function of rd1 mice via regulating neural plasticity and forming new graft-to-host synapses.
C1 [Chen, Xi; Chen, Zehua; Li, Zhengya; Zhao, Chen; Zeng, Yuxiao; Zou, Ting; Fu, Caiyun; Xu, Haiwei; Yin, Zheng Qin] Third Mil Med Univ, Southwest Eye Hosp, Southwest Hosp, Chongqing 400038, Peoples R China.
   [Chen, Xi; Chen, Zehua; Li, Zhengya; Zhao, Chen; Zeng, Yuxiao; Zou, Ting; Fu, Caiyun; Xu, Haiwei; Yin, Zheng Qin] Key Lab Visual Damage & Regenerat & Restorat Chon, Chongqing 400038, Peoples R China.
   [Chen, Xi] Nankai Univ, Sch Med, Tianjin 300071, Peoples R China.
   [Chen, Xi; Liu, Xiaoli] Brigham & Womens Hosp, Dept Med, Div Pulm & Crit Care Med, 75 Francis St, Boston, MA 02115 USA.
   [Chen, Xi; Liu, Xiaoli] Harvard Med Sch, Boston, MA 02115 USA.
   [Liu, Xiaoli] Brigham & Womens Hosp, Dept Pediat Newborn Med, 75 Francis St, Boston, MA 02115 USA.
C3 Army Medical University; Nankai University; Harvard University; Brigham
   & Women's Hospital; Harvard University; Harvard Medical School; Harvard
   University; Brigham & Women's Hospital
RP Xu, HW; Yin, ZQ (通讯作者)，Third Mil Med Univ, Southwest Eye Hosp, Southwest Hosp, Chongqing 400038, Peoples R China.; Xu, HW; Yin, ZQ (通讯作者)，Key Lab Visual Damage & Regenerat & Restorat Chon, Chongqing 400038, Peoples R China.
EM haiweixu2001@163.com; qinzyin@aliyun.com
RI Xu, Haiwei/AAV-6591-2021; Xu, Haiwei/AFN-3524-2022
OI Xu, Haiwei/0000-0002-8840-7918; Xu, Haiwei/0000-0002-8840-7918; Liu,
   Xiaoli/0000-0003-2904-4413
FU National Basic Research Program of China (973 Program) [2013CB967002];
   National Natural Science Foundation of China [31271051]; Chinese
   Scholarship Council [201406200058]
FX This work was supported by the National Basic Research Program of China
   (973 Program, 2013CB967002) and partially supported by the National
   Natural Science Foundation of China (No. 31271051). XC was supported by
   the Chinese Scholarship Council (201406200058).
CR Abdouh M, 2006, EXP EYE RES, V83, P153, DOI 10.1016/j.exer.2005.11.016
   Baddour JA, 2012, BIRTH DEFECTS RES C, V96, P1, DOI 10.1002/bdrc.21006
   Barber AC, 2013, P NATL ACAD SCI USA, V110, P354, DOI 10.1073/pnas.1212677110
   Bartsch U, 2008, EXP EYE RES, V86, P691, DOI 10.1016/j.exer.2008.01.018
   Bolli R, 2011, LANCET, V378, P1847, DOI 10.1016/S0140-6736(11)61590-0
   Bunce C, 2010, EYE, V24, P1692, DOI 10.1038/eye.2010.122
   Carpentier PA, 2009, NEURON, V64, P79, DOI 10.1016/j.neuron.2009.08.038
   Chang B, 2002, VISION RES, V42, P517, DOI 10.1016/S0042-6989(01)00146-8
   Chen X, 2014, CELL PHYSIOL BIOCHEM, V34, P1109, DOI 10.1159/000366325
   Damiani D, 2012, J COMP NEUROL, V520, P1406, DOI 10.1002/cne.22802
   Das AV, 2004, DEV BIOL, V273, P87, DOI 10.1016/j.ydbio.2004.05.023
   Feng ZC, 2015, DIABETES, V64, P3852, DOI 10.2337/db15-0054
   Fukuda S, 2014, GRAEF ARCH CLIN EXP, V252, P411, DOI 10.1007/s00417-013-2551-9
   Gehrs KM, 2006, ANN MED, V38, P450, DOI 10.1080/07853890600946724
   Goel M, 2012, NEUROSCIENCE, V225, P152, DOI 10.1016/j.neuroscience.2012.08.066
   Goldstein BJ, 2015, J COMP NEUROL, V523, P15, DOI 10.1002/cne.23653
   Gonzalez-Cordero A, 2013, NAT BIOTECHNOL, V31, P741, DOI 10.1038/nbt.2643
   Guijarro P, 2013, DEV NEUROBIOL, V73, P871, DOI 10.1002/dneu.22107
   He YX, 2014, INT J MOL SCI, V15, P14456, DOI 10.3390/ijms150814456
   Hermann DM, 2014, FRONT CELL NEUROSCI, V8, DOI 10.3389/fncel.2014.00291
   Huang J, 2016, MOL NEUROBIOL, V53, P1031, DOI 10.1007/s12035-014-9052-7
   Jayakody SA, 2015, PROG RETIN EYE RES, V46, P31, DOI 10.1016/j.preteyeres.2015.01.003
   Jian Q, 2009, NEUROSCI LETT, V465, P41, DOI 10.1016/j.neulet.2009.07.083
   Jin K, 2002, J CLIN INVEST, V110, P311, DOI 10.1172/JCI200215251
   Jones BW, 2005, EXP EYE RES, V81, P123, DOI 10.1016/j.exer.2005.03.006
   Kajstura J, 2011, NEW ENGL J MED, V364, P1795, DOI 10.1056/NEJMoa1101324
   Kinouchi R, 2003, NAT NEUROSCI, V6, P863, DOI 10.1038/nn1088
   Kokaia Z, 2012, NAT NEUROSCI, V15, P1078, DOI 10.1038/nn.3163
   Koso H, 2007, DEV BIOL, V301, P141, DOI 10.1016/j.ydbio.2006.09.027
   Lee ES, 2011, ACTA HISTOCHEM CYTOC, V44, P213, DOI 10.1267/ahc.11009
   Li TQ, 2013, CELL RES, V23, P788, DOI 10.1038/cr.2013.48
   Li ZY, 2016, CYTOTHERAPY, V18, P771, DOI 10.1016/j.jcyt.2016.03.001
   Lin B, 2008, P NATL ACAD SCI USA, V105, P16009, DOI 10.1073/pnas.0806114105
   Liu XL, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9825
   Lu P, 2003, EXP NEUROL, V181, P115, DOI 10.1016/S0014-4886(03)00037-2
   MacLaren RE, 2006, NATURE, V444, P203, DOI 10.1038/nature05161
   Mazzoni F, 2008, J NEUROSCI, V28, P14282, DOI 10.1523/JNEUROSCI.4968-08.2008
   Minassian DC, 2011, BRIT J OPHTHALMOL, V95, P1433, DOI 10.1136/bjo.2010.195370
   MORII E, 1994, NEUROSCI LETT, V166, P168, DOI 10.1016/0304-3940(94)90477-4
   Moshiri A, 2004, J NEUROSCI, V24, P229, DOI 10.1523/JNEUROSCI.2980-03.2004
   Owen CG, 2012, BRIT J OPHTHALMOL, V96, P752, DOI 10.1136/bjophthalmol-2011-301109
   Pearson RA, 2012, NATURE, V485, P99, DOI 10.1038/nature10997
   Pearson RA, 2010, CELL TRANSPLANT, V19, P487, DOI 10.3727/096368909X486057
   Pearson RA, 2014, VISUAL NEUROSCI, V31, P333, DOI 10.1017/S0952523814000200
   Pearson RA, 2014, BIOTECHNOL ADV, V32, P485, DOI 10.1016/j.biotechadv.2014.01.001
   PEDERSEN OO, 1979, EXP EYE RES, V28, P569, DOI 10.1016/0014-4835(79)90044-7
   Pluchino S, 2005, NATURE, V436, P266, DOI 10.1038/nature03889
   Qiu GT, 2005, EXP EYE RES, V80, P515, DOI 10.1016/j.exer.2004.11.001
   Rafii S, 2003, NAT MED, V9, P702, DOI 10.1038/nm0603-702
   Ramsden CM, 2013, DEVELOPMENT, V140, P2576, DOI 10.1242/dev.092270
   Ryu JK, 2004, NEUROBIOL DIS, V16, P68, DOI 10.1016/j.nbd.2004.01.016
   Sachewsky N, 2014, STEM CELLS DEV, V23, P2469, DOI 10.1089/scd.2013.0646
   Sancho-Pelluz J, 2008, MOL NEUROBIOL, V38, P253, DOI 10.1007/s12035-008-8045-9
   Santos A, 1997, ARCH OPHTHALMOL-CHIC, V115, P511, DOI 10.1001/archopht.1997.01100150513011
   Strettoi E, 2000, P NATL ACAD SCI USA, V97, P11020, DOI 10.1073/pnas.190291097
   Verardo MR, 2008, INVEST OPHTH VIS SCI, V49, P3659, DOI 10.1167/iovs.07-1474
   Warre-Cornish K, 2014, STEM CELLS DEV, V23, P941, DOI 10.1089/scd.2013.0471
   West EL, 2008, EXP EYE RES, V86, P601, DOI 10.1016/j.exer.2008.01.004
   Yang P, 2002, EXP NEUROL, V177, P326, DOI 10.1006/exnr.2002.7955
   Zhou PY, 2015, J CELL SCI, V128, P2169, DOI 10.1242/jcs.169086
NR 60
TC 11
Z9 13
U1 0
U2 16
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1757-6512
J9 STEM CELL RES THER
JI Stem Cell Res. Ther.
PD DEC 30
PY 2016
VL 7
AR 191
DI 10.1186/s13287-016-0451-8
PG 16
WC Cell & Tissue Engineering; Cell Biology; Medicine, Research &
   Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Research & Experimental Medicine
GA EI1QV
UT WOS:000392253900004
PM 28038685
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Atas, M
   Baskan, B
   Ozkose, A
   Sariguzel, FM
   Demircan, S
   Pangal, E
AF Atas, Mustafa
   Baskan, Burhan
   Ozkose, Ayse
   Sariguzel, Fafma Mutlu
   Demircan, Suleyman
   Pangal, Emine
TI Effects of moxifloxacin exposure on the conjunctival flora and
   antibiotic resistance profile following repeated intravitreal injections
SO INTERNATIONAL JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE intravitreal injection; moxifloxacin; endopthalmitis
ID CATARACT-SURGERY; POVIDONE-IODINE; RISK-FACTORS; ENDOPHTHALMITIS;
   PROPHYLAXIS; COLONIZATION; RANIBIZUMAB; 0.5-PERCENT; OUTCOMES
AB AIM: To evaluate the effects of moxifloxacin exposure on the conjunctival flora and antibiotic resistance profile following repeated intravitreal injections.
   METHODS: Seventy-two eyes of 36 patients [36 eyes in control group, 36 eyes in intravitreal injection (IVI) group] were enrolled in the study. All the eyes had at least one IVI and had diabetic macular edema (DME) or age-related macular degeneration (ARMD). Moxifloxacin was prescribed to all the patients four times a day for five days following injection. Conjunctival cultures were obtained from the lower fornix via standardized technique with every possible effort made to minimize contamination from the lids, lashes, or skin. Before the application of any ophthalmic medication, conjunctival cultures were obtained from both eyes using sterile cotton culture. An automated microbiology system was used to identify the growing bacteria and determine antibiotic sensitivity.
   RESULTS: The bacterial cultures were isolated from 72 eyes of 36 patients, sixteen of whom patients (44.4%) were male and twenty (55.6%) were female. Average age was 68.4 +/- 9.0 (range 50-86). The average number of injections before taking cultures was 3.1+1.0. Forty-eight (66.7%) of 72 eyes had at least one significant organism. There was no bacterial growth in 8 (20.5%) of IVI eyes and in 16 (44.4%) of control eyes (P=0.03). Of the bacteria isolated from culture, 53.8% of coagulase negative staphylococci (CoNS) in IVI eyes and 47.2% CoNS in control eyes. This difference between IVI eyes and control eyes about bacteria isolated, from culture was not statistically significant (P=0.2). Eleven of 25 bacteria (44.0%) isolated from IVI eyes and 11 (57.9%) of 19 bacteria isolated from control eyes were resistant to oxacillin. The difference in frequency of moxifloxacine resistance between two groups was not statistically significant (12.0% in IVI eyes and 21.1% in control eyes) (P =0.44). There were no cases of resistance to vancomycin, teicoplanin and linezolid.
   CONCLUSION: There was no difference in species of bacteria isolated from cultures, or in the frequency of resistance to antibiotics between eyes that had recurrent IVI followed by moxifloxacin exposure compared with control eyes. However, the number of eyes that had bacterial growth was higher in IVI group than in the control group.
C1 [Atas, Mustafa; Baskan, Burhan; Ozkose, Ayse; Demircan, Suleyman; Pangal, Emine] Kayseri Educ & Res Hosp, Dept Ophthalmol, TR-38010 Kayseri, Turkey.
   [Sariguzel, Fafma Mutlu] Kayseri Educ & Res Hosp, Dept Microbiol, TR-38010 Kayseri, Turkey.
C3 Kayseri Training & Research Hospital; Kayseri Training & Research
   Hospital
RP Atas, M (通讯作者)，Kayseri Educ & Res Hosp, Dept Ophthalmol, TR-38010 Kayseri, Turkey.
EM atasmustafal2@hotmail.com
RI Atas, Mustafa/K-2319-2013
OI Atas, Mustafa/0000-0003-0545-184X
CR Aiello LP, 2004, RETINA-J RET VIT DIS, V24, pS3, DOI 10.1097/00006982-200410001-00002
   Alabiad CR, 2011, AM J OPHTHALMOL, V152, P999, DOI 10.1016/j.ajo.2011.05.026
   Bhatt SS, 2011, RETINA-J RET VIT DIS, V31, P2032, DOI 10.1097/IAE.0b013e31820f4b4f
   Bhavsar AR, 2009, ARCH OPHTHALMOL-CHIC, V127, P1581, DOI 10.1001/archophthalmol.2009.304
   Boyer D, 2010, OPHTHALMOLOGY, V117, P1860, DOI 10.1016/j.ophtha.2010.02.022
   Chang DF, 2007, J CATARACT REFR SURG, V33, P1801, DOI 10.1016/j.jcrs.2007.07.009
   Cheung CSY, 2012, OPHTHALMOLOGY, V119, P1609, DOI 10.1016/j.ophtha.2012.02.014
   Dave SB, 2013, OPHTHALMOLOGY, V120, P937, DOI 10.1016/j.ophtha.2012.11.005
   Dave SB, 2011, OPHTHALMOLOGY, V118, P2035, DOI 10.1016/j.ophtha.2011.03.017
   de Kaspar HM, 2001, OPHTHALMOLOGY, V108, P470, DOI 10.1016/S0161-6420(00)00545-5
   Deramo VA, 2006, AM J OPHTHALMOL, V142, P721, DOI 10.1016/j.ajo.2006.05.044
   Halachimi-Eyal O, 2009, J CATARACT REFR SURG, V35, P2109, DOI 10.1016/j.jcrs.2009.06.038
   HALBERT SP, 1952, AM J OPHTHALMOL, V35, P73, DOI 10.1016/0002-9394(52)90259-6
   Hariprasad SM, 2005, ARCH OPHTHALMOL-CHIC, V123, P39, DOI 10.1001/archopht.123.1.39
   Kim SJ, 2010, OPHTHALMOLOGY, V117, P2372, DOI 10.1016/j.ophtha.2010.03.034
   Lina G, 2003, APPL ENVIRON MICROB, V69, P18, DOI 10.1128/AEM.69.1.18-23.2003
   Lyall DAM, 2012, EYE, V26, P1517, DOI 10.1038/eye.2012.199
   Massin P, 2010, DIABETES CARE, V33, P2399, DOI 10.2337/dc10-0493
   McClellan KA, 1997, SURV OPHTHALMOL, V42, P233, DOI 10.1016/S0039-6257(97)00090-8
   Milder E, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.01.016
   Moshirfar M, 2007, OPHTHALMOLOGY, V114, P686, DOI 10.1016/j.ophtha.2006.08.038
   Moss JM, 2009, OPHTHALMOLOGY, V116, P1498, DOI 10.1016/j.ophtha.2009.02.024
   Pilu S, 2008, AM J OPHTHALMOL, V145, P879, DOI 10.1016/j.ajo.2007.12.036
   Pleyer U, 1997, OPHTHALMOLOGICA, V211, P2, DOI 10.1159/000310878
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Schimel AM, 2013, AM J OPHTHALMOL, V156, P50, DOI 10.1016/j.ajo.2013.01.027
   Scott IU, 2007, RETINA-J RET VIT DIS, V27, P10, DOI 10.1097/IAE.0b013e3180307271
   Shah CP, 2011, OPHTHALMOLOGY, V118, P2028, DOI 10.1016/j.ophtha.2011.02.034
   SINGER TR, 1988, BRIT J OPHTHALMOL, V72, P448, DOI 10.1136/bjo.72.6.448
   SPEAKER MG, 1991, OPHTHALMOLOGY, V98, P1769
   Storey P, 2014, OPHTHALMOLOGY, V121, P283, DOI 10.1016/j.ophtha.2013.08.037
NR 31
TC 4
Z9 4
U1 0
U2 6
PU IJO PRESS
PI XI AN
PA NO 269 YOUYI EAST RD, XI AN, 710054, PEOPLES R CHINA
SN 2222-3959
EI 2227-4898
J9 INT J OPHTHALMOL-CHI
JI Int. J. Ophthalmol.
PD OCT 18
PY 2014
VL 7
IS 5
BP 855
EP 859
DI 10.3980/j.issn.2222-3959.2014.05.21
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AR0PD
UT WOS:000343272900021
PM 25349806
DA 2022-11-30
ER

PT J
AU Xie, P
   Zhang, WW
   Yuan, ST
   Chen, ZQ
   Yang, Q
   Yuan, DQ
   Wang, F
   Liu, QH
AF Xie, Ping
   Zhang, WeiWei
   Yuan, Songtao
   Chen, Zhiqiang
   Yang, Qin
   Yuan, DongQing
   Wang, Feng
   Liu, QingHuai
TI Suppression of Experimental Choroidal Neovascularization by Curcumin in
   Mice
SO PLOS ONE
LA English
DT Article
ID ENDOTHELIAL GROWTH-FACTOR; RETINAL-PIGMENT EPITHELIUM; TNF-ALPHA;
   ADHESION MOLECULES; MACROPHAGE INFILTRATION; INFLAMMATORY RESPONSES;
   MACULAR DEGENERATION; MCP-1 SECRETION; DOWN-REGULATION; EXPRESSION
AB Purpose: To investigate the effects of curcumin on the development of experimental choroidal neovascularization (CNV) with underlying cellular and molecular mechanisms.
   Methods: C57BL/6N mice were pretreated with intraperitoneal injections of curcumin daily for 3 days prior to laser-induced CNV, and the drug treatments were continued until the end of the study. The CNV area was analyzed by fluorescein-labeled dextran angiography of retinal pigment epithelium (RPE)-choroid flat mounts on day 7 and 14, and CNV leakage was evaluated by fluorescein angiography (FA) on day 14 after laser photocoagulation. The infiltration of F4/80 positive macrophages and GR-1 positive granulocytes were evaluated by immunohistochemistry on RPE-choroid flat mounts on day 3. Their expression in RPE-choroid complex was quantified by real-time PCR (F4/80) and Western blotting (GR-1) on day 3. RPE-choroid levels of vascular endothelial growth factor (VEGF), tumor necrosis factor (TNF)-alpha, monocyte chemotactic protein (MCP)-1, and intercellular adhesion molecule (ICAM)-1 were examined by ELISA on day 3. Double immunostaining of F4/80 and VEGF was performed on cryo-sections of CNV lesions on day 3. The expression of nuclear factor (NF)-kappa B and hypoxia-inducible factor (HIF)-1 alpha in the RPE-choroid was determined by Western blotting.
   Results: Curcumin-treated mice had significantly less CNV area (P<0.05) and CNV leakage (P<0.001) than vehicle-treated mice. Curcumin treatment led to significant inhibition of F4/80 positive macrophages (P<0.05) and GR-1 positive granulocytes infiltration (P<0.05). VEGF mainly expressed in F4/80 positive macrophages in laser injury sites, which was suppressed by curcumin treatment (P<0.01). Curcumin inhibited the RPE-choroid levels of TNF-alpha (P<0.05), MCP-1 (P<0.05) and ICAM-1 (P<0.05), and suppressed the activation of NF-kappa B in nuclear extracts (P<0.05) and the activation of HIF-1 alpha (P<0.05).
   Conclusion: Curcumin treatment led to the suppression of CNV development together with inflammatory and angiogenic processes including NF-kappa B and HIF-1 alpha activation, the up-regulation of inflammatory and angiogenic cytokines, and infiltrating macrophages and granulocytes. This provides molecular and cellular evidence of the validity of curcumin supplementation as a therapeutic strategy for the suppression of age-related macular degeneration(AMD)-associated CNV.
C1 [Xie, Ping; Zhang, WeiWei; Yuan, Songtao; Yang, Qin; Yuan, DongQing; Wang, Feng; Liu, QingHuai] Nanjing Med Univ, Affiliated Hosp 1, Dept Ophthalmol, Nanjing, Jiangsu, Peoples R China.
   [Chen, Zhiqiang] JiangSu Prov Official Hosp, Dept Ophthalmol, Nanjing, Jiangsu, Peoples R China.
C3 Nanjing Medical University
RP Liu, QH (通讯作者)，Nanjing Med Univ, Affiliated Hosp 1, Dept Ophthalmol, Nanjing, Jiangsu, Peoples R China.
EM liuqh@njmu.edu.cn
OI Xie, Ping/0000-0003-4257-8970; Liu, Qinghuai/0000-0003-1605-1964
FU National Basic Research Program of China (973 Program) [2011CB510200];
   National Natural Science Foundation of China [81170855, 30973257]
FX This study is supported by National Basic Research Program of China (973
   Program, No. 2011CB510200 http://www.973.gov.cn/English/Index.aspx) and
   National Natural Science Foundation of China (No. 81170855 and No.
   30973257 http://www.nsfc.gov.cn/Portal0/default152.htm). The funders had
   no role in study design, data collection and analysis, decision to
   publish, or preparation of the manuscript.
CR Allegri P, 2010, CLIN OPHTHALMOL, V4, P1201, DOI 10.2147/OPTH.S13271
   Ambati J, 2003, NAT MED, V9, P1390, DOI 10.1038/nm950
   ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499
   Bae MK, 2006, ONCOL REP, V15, P1557
   Benny O, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012515
   Bian ZM, 1999, CURR EYE RES, V18, P349, DOI 10.1076/ceyr.18.5.349.5353
   Bian ZM, 2001, INVEST OPHTH VIS SCI, V42, P1660
   Caicedo A, 2005, EXP EYE RES, V81, P38, DOI 10.1016/j.exer.2005.01.013
   Chen D, 2008, PHARMACOLOGY, V82, P264, DOI 10.1159/000161127
   Chen HY, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002339
   Chen WH, 2005, CHINESE MED J-PEKING, V118, P2052
   Curry JM, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003405
   DEODHAR SD, 1980, INDIAN J MED RES, V71, P632
   ELNER SG, 1991, LAB INVEST, V64, P819
   ELNER SG, 1992, LAB INVEST, V66, P200
   Espinosa-Heidmann DG, 2005, EXP EYE RES, V80, P413, DOI 10.1016/j.exer.2004.10.008
   Espinosa-Heidmann DG, 2003, INVEST OPHTH VIS SCI, V44, P3586, DOI 10.1167/iovs.03-0038
   FERRARA N, 1992, ENDOCR REV, V13, P18, DOI 10.1210/er.13.1.18
   Fine SL, 2000, NEW ENGL J MED, V342, P483, DOI 10.1056/NEJM200002173420707
   FURIE MB, 1995, AM J PATHOL, V146, P1287
   Grossniklaus HE, 2002, MOL VIS, V8, P119
   Gukovsky I, 2003, AM J PHYSIOL-GASTR L, V284, pG85, DOI 10.1152/ajpgi.00138.2002
   Gupta SK, 2011, J OCUL PHARMACOL TH, V27, P123, DOI 10.1089/jop.2010.0123
   Hanai H, 2006, CLIN GASTROENTEROL H, V4, P1502, DOI 10.1016/j.cgh.2006.08.008
   Hangai M, 2006, J NEUROIMMUNOL, V171, P45, DOI 10.1016/j.jneuroim.2005.09.018
   Hara R, 2010, CURR EYE RES, V35, P1012, DOI 10.3109/02713683.2010.500112
   Hayden MS, 2008, CELL, V132, P344, DOI 10.1016/j.cell.2008.01.020
   Heng MCY, 2000, BRIT J DERMATOL, V143, P937, DOI 10.1046/j.1365-2133.2000.03767.x
   Holt PR, 2005, DIGEST DIS SCI, V50, P2191, DOI 10.1007/s10620-005-3032-8
   Inoue Y, 2007, BRIT J OPHTHALMOL, V91, P1720, DOI 10.1136/bjo.2006.111583
   Ishibashi T, 1997, GRAEF ARCH CLIN EXP, V235, P159, DOI 10.1007/BF00941723
   Itaya M, 2007, INVEST OPHTH VIS SCI, V48, P5677, DOI 10.1167/iovs.07-0156
   Izumi-Nagai K, 2007, ARTERIOSCL THROM VAS, V27, P2555, DOI 10.1161/ATVBAHA.107.151431
   Jackson JK, 2006, INFLAMM RES, V55, P168, DOI 10.1007/s00011-006-0067-z
   Jain SK, 2009, ANTIOXID REDOX SIGN, V11, P241, DOI 10.1089/ars.2008.2140
   Jung HJ, 2010, J BIOL CHEM, V285, P25867, DOI 10.1074/jbc.M110.135632
   Kent D, 2003, MOL VIS, V9, P747
   Kim JS, 2010, CURR EYE RES, V35, P274, DOI 10.3109/02713680903528345
   Kim YS, 2007, J CARDIOVASC PHARM, V50, P41, DOI 10.1097/FJC.0b013e31805559b9
   Kowluru RA, 2007, NUTR METAB, V4, DOI 10.1186/1743-7075-4-8
   Krzystolik MG, 2002, ARCH OPHTHALMOL-CHIC, V120, P338
   Kulkarni AD, 2005, ADV DRUG DELIVER REV, V57, P1994, DOI 10.1016/j.addr.2005.09.003
   Kumar A, 1998, BIOCHEM PHARMACOL, V55, P775, DOI 10.1016/S0006-2952(97)00557-1
   Kunnumakkara AB, 2008, CANCER LETT, V269, P199, DOI 10.1016/j.canlet.2008.03.009
   Kuwabara N, 2006, UROLOGY, V67, P440, DOI 10.1016/j.urology.2005.09.028
   Lal B, 2000, PHYTOTHER RES, V14, P443, DOI 10.1002/1099-1573(200009)14:6&lt;443::AID-PTR619&gt;3.0.CO;2-V
   Lal B, 1999, PHYTOTHER RES, V13, P318, DOI 10.1002/(SICI)1099-1573(199906)13:4&lt;318::AID-PTR445&gt;3.0.CO;2-7
   Larmonier CB, 2011, INFLAMM BOWEL DIS, V17, P503, DOI 10.1002/ibd.21391
   Lichtlen P, 2010, INVEST OPHTH VIS SCI, V51, P4738, DOI 10.1167/iovs.09-4890
   Lin MK, 2012, INVEST OPHTH VIS SCI, V53, P6197, DOI 10.1167/iovs.11-8936
   Luhmann UFO, 2009, INVEST OPHTH VIS SCI, V50, P5934, DOI 10.1167/iovs.09-3462
   Madan B, 2003, SHOCK, V19, P91, DOI 10.1097/00024382-200301000-00017
   Markomichelakis NN, 2005, AM J OPHTHALMOL, V139, P537, DOI 10.1016/j.ajo.2004.09.058
   Moghaddam SJ, 2009, CARCINOGENESIS, V30, P1949, DOI 10.1093/carcin/bgp229
   Mrudula T, 2007, BIOCHEM BIOPH RES CO, V361, P528, DOI 10.1016/j.bbrc.2007.07.059
   Nagai N, 2006, ARTERIOSCL THROM VAS, V26, P2252, DOI 10.1161/01.ATV.0000240050.15321.fe
   Oh H, 1999, INVEST OPHTH VIS SCI, V40, P1891
   Olson JL, 2007, ARCH OPHTHALMOL-CHIC, V125, P1221, DOI 10.1001/archopht.125.9.1221
   Pan Y, 2012, BRIT J PHARMACOL, V166, P1169, DOI 10.1111/j.1476-5381.2012.01854.x
   Regatieri CV, 2009, INVEST OPHTH VIS SCI, V50, P5487, DOI 10.1167/iovs.08-3171
   Sakurai E, 2003, INVEST OPHTH VIS SCI, V44, P2743, DOI 10.1167/iovs.02-1246
   Sakurai E, 2003, INVEST OPHTH VIS SCI, V44, P3578, DOI 10.1167/iovs.03-0097
   Sawatpanich Tarinee, 2010, J Med Assoc Thai, V93 Suppl 2, pS1
   Shen WY, 1998, BRIT J OPHTHALMOL, V82, P1063, DOI 10.1136/bjo.82.9.1063
   Sheridan CM, 2009, GRAEF ARCH CLIN EXP, V247, P1361, DOI 10.1007/s00417-009-1133-3
   Shi X, 2006, EXP EYE RES, V83, P1325, DOI 10.1016/j.exer.2006.07.007
   Shoskes D, 2005, TRANSPLANTATION, V80, P1556, DOI 10.1097/01.tp.0000183290.64309.21
   Sikora E, 2010, Immun Ageing, V7, P1, DOI 10.1186/1742-4933-7-1
   Singh S, 2007, CELL, V130, P765, DOI 10.1016/j.cell.2007.08.024
   Soetikno V, 2011, NUTR METAB, V8, DOI 10.1186/1743-7075-8-35
   Song SJ, 2008, OPHTHALMIC RES, V40, P35, DOI 10.1159/000111157
   Sugimoto H, 1997, DIABETES, V46, P2075, DOI 10.2337/diabetes.46.12.2075
   Takahashi M, 2007, MEDIAT INFLAMM, V2007, DOI 10.1155/2007/10767
   Takehana Y, 1999, INVEST OPHTH VIS SCI, V40, P459
   Theodossiadis PG, 2009, AM J OPHTHALMOL, V147, P825, DOI 10.1016/j.ajo.2008.12.004
   Tsutsumi C, 2003, J LEUKOCYTE BIOL, V74, P25, DOI 10.1189/jlb.0902436
   Woo HM, 2007, LIFE SCI, V80, P926, DOI 10.1016/j.lfs.2006.11.030
   Xiong M, 1998, AM J PATHOL, V153, P587, DOI 10.1016/S0002-9440(10)65601-5
   Yamada K, 2007, INVEST OPHTH VIS SCI, V48, P1839, DOI 10.1167/iovs.06-1085
   Yeh DC, 2004, INVEST OPHTH VIS SCI, V45, P2368, DOI 10.1167/iovs.03-0981
   Yoshida T, 2010, FASEB J, V24, P1759, DOI 10.1096/fj.09-145664
   Zhang Y, 2011, INT J MOL MED, V27, P87, DOI 10.3892/ijmm.2010.552
   Zhong F, 2011, BIOL PHARM BULL, V34, P226, DOI 10.1248/bpb.34.226
   Zhou HY, 2011, CURR DRUG TARGETS, V12, P332, DOI 10.2174/138945011794815356
   Zhou JH, 2005, MOL VIS, V11, P414
NR 85
TC 25
Z9 27
U1 0
U2 16
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD DEC 28
PY 2012
VL 7
IS 12
AR e53329
DI 10.1371/journal.pone.0053329
PG 12
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA 064DQ
UT WOS:000313051500136
PM 23285282
OA Green Published, Green Submitted, gold
DA 2022-11-30
ER

PT J
AU Ho, J
   Witkin, AJ
   Liu, J
   Chen, YL
   Fujimoto, JG
   Schuman, JS
   Duker, JS
AF Ho, Joseph
   Witkin, Andre J.
   Liu, Jonathan
   Chen, Yueli
   Fujimoto, James G.
   Schuman, Joel S.
   Duker, Jay S.
TI Documentation of Intraretinal Retinal Pigment Epithelium Migration via
   High-Speed Ultrahigh-Resolution Optical Coherence Tomography
SO OPHTHALMOLOGY
LA English
DT Article
ID MACULAR DEGENERATION; CELL-MIGRATION; RPE; MECHANISMS; MEMBRANE;
   ADHESION; DISEASE
AB Purpose: To describe the features of intraretinal retinal pigment epithelium (RPE) migration documented on a prototype spectral-domain, high-speed, ultrahigh-resolution optical coherence tomography (OCT) device in a group of patients with early to intermediate dry age-related macular degeneration (AMD) and to correlate intraretinal RPE migration on OCT to RPE pigment clumping on fundus photographs.
   Design: Retrospective, noncomparative, noninterventional case series.
   Participants: Fifty-five eyes of 44 patients seen at the New England Eye Center between December 2007 and June 2008 with early to intermediate dry AMD.
   Methods: Three-dimensional OCT scan sets from all patients were analyzed for the presence of intraretinal RPE migration, defined as small discreet hyperreflective and highly backscattering lesions within the neurosensory retina. Fundus photographs also were analyzed to determine the presence of RPE pigment clumping, defined as black, often spiculated, areas of pigment clumping within the macula. The en face OCT images were correlated with fundus photographs to demonstrate correspondence of intraretinal RPE migration on OCT and RPE clumping on fundus photography.
   Main Outcome Measures: Drusen, dry AMD, intraretinal RPE migration, and RPE pigment clumping.
   Results: On OCT scans, 54.5% of eyes (61.4% of patients) demonstrated intraretinal RPE migration. Of the fundus photographs, 56.4% demonstrated RPE pigment clumping. All eyes with intraretinal RPE migration on OCT had corresponding RPE pigment clumping on fundus photographs. The RPE pigment migrated most frequently into the outer nuclear layer (66.7% of eyes) and less frequently into more anterior retinal layers. Intraretinal RPE migration mainly occurred above areas of drusen (73.3% of eyes).
   Conclusions: The appearance of intraretinal RPE migration on OCT is a common occurrence in early to intermediate dry AMD, occurring in 54.5% of eyes, or 61.4% of patients. The area of intraretinal RPE migration on OCT always correlated to areas of pigment clumping on fundus photography. Conversely, all but 1 eye with RPE pigment clumping on fundus photography also had areas of intraretinal RPE migration on OCT. The high incidence of intraretinal RPE migration observed above areas of drusen suggests that drusen may play physical and catalytic roles in facilitating intraretinal RPE migration in dry AMD patients.
   Financial Disclosure(s): Proprietary or commercial disclosure may be found after the references. Ophthalmology 2011;118:687-693 (C) 2011 by the American Academy of Ophthalmology.
C1 [Ho, Joseph; Witkin, Andre J.; Duker, Jay S.] Tufts Med Ctr, Dept Ophthalmol, New England Eye Ctr, Boston, MA 02111 USA.
   [Ho, Joseph] Boston Univ, Sch Med, Boston, MA 02118 USA.
   [Liu, Jonathan; Chen, Yueli; Fujimoto, James G.] MIT, Dept Elect Engn & Comp Sci, Cambridge, MA 02139 USA.
   [Liu, Jonathan; Chen, Yueli; Fujimoto, James G.] MIT, Elect Res Lab, Cambridge, MA 02139 USA.
   [Schuman, Joel S.] Univ Pittsburgh, Inst Eye & Ear, Med Ctr, Ctr Eye, Pittsburgh, PA 15213 USA.
C3 Tufts Medical Center; Boston University; Massachusetts Institute of
   Technology (MIT); Massachusetts Institute of Technology (MIT);
   Pennsylvania Commonwealth System of Higher Education (PCSHE); University
   of Pittsburgh
RP Duker, JS (通讯作者)，Tufts Med Ctr, Dept Ophthalmol, New England Eye Ctr, 800 Washington St,Box 450, Boston, MA 02111 USA.
EM JDuker@tuftsmedicalcenter.org
RI Schuman, Joel S/K-7304-2012; Schuman, Joel S/M-2389-2019
OI Schuman, Joel S/0000-0002-8885-3766; Schuman, Joel S/0000-0002-8885-3766
FU Carl Zeiss Meditech, Inc.; Optovue, Inc.; Topcon Medical Systems, Inc.;
   Research to Prevent Blindness Inc., New York, New York; National
   Institutes of Health, Bethesda, Maryland [R01-EY11289-23,
   R01-EY13178-07, R01-EY013516-07]; Air Force Office of Scientific
   Research, Arlington, Virginia [FA9550-07-1-0101, FA9550-07-1-0014];
   NATIONAL EYE INSTITUTE [R01EY011289, R01EY013516, R01EY013178] Funding
   Source: NIH RePORTER
FX Jay S. Duker - Financial support - Carl Zeiss Meditech, Inc., Optovue,
   Inc., and Topcon Medical Systems, Inc.; Supported in part by a Research
   to Prevent Blindness Inc., New York, New York (challenge grant to the
   New England Eye Center/Department of Ophthalmology, Tufts University
   School of Medicine); the National Institutes of Health, Bethesda,
   Maryland (grant nos.: R01-EY11289-23, R01-EY13178-07, and
   R01-EY013516-07); and the Air Force Office of Scientific Research (grant
   nos.: FA9550-07-1-0101 and FA9550-07-1-0014), Arlington, Virginia. The
   sponsors had no role in the design or conduct of this research.
CR Afshari FT, 2009, EYE, V23, P1890, DOI 10.1038/eye.2008.411
   Ambati J, 2003, SURV OPHTHALMOL, V48, P257, DOI 10.1016/S0039-6257(03)00030-4
   Baumal CR, 2003, CLINICAL PATHWAYS IN VITREORETINAL DISEASE, P99
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Davis MD, 2005, ARCH OPHTHALMOL-CHIC, V123, P1484
   de Jong PTVM, 2006, NEW ENGL J MED, V355, P1474, DOI 10.1056/NEJMra062326
   Fleckenstein M, 2008, INVEST OPHTH VIS SCI, V49, P4137, DOI 10.1167/iovs.08-1967
   Han QH, 2001, GRAEF ARCH CLIN EXP, V239, P531, DOI 10.1007/s004170000212
   Hogg PA, 2002, INVEST OPHTH VIS SCI, V43, P2749
   HUANG D, 1991, SCIENCE, V254, P1178, DOI 10.1126/science.1957169
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Jin ML, 2000, INVEST OPHTH VIS SCI, V41, P4324
   Kim YH, 2009, GRAEF ARCH CLIN EXP, V247, P651, DOI 10.1007/s00417-009-1049-y
   Klein R, 2007, OPHTHALMOLOGY, V114, P253, DOI 10.1016/j.ophtha.2006.10.040
   Mitsuhiro MRKH, 2003, ACTA OPHTHALMOL SCAN, V81, P630, DOI 10.1111/j.1395-3907.2003.00170.x
   NGUYENTAN JQ, 1989, RETINA-J RET VIT DIS, V9, P203, DOI 10.1097/00006982-198909030-00008
   Pieroni CG, 2006, BRIT J OPHTHALMOL, V90, P191, DOI 10.1136/bjo.2005.076612
   Rodrigues EB, 2007, OPHTHALMOLOGICA, V221, P143, DOI 10.1159/000099293
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Sayanagi K, 2009, OPHTHALMOLOGY, V116, P947, DOI 10.1016/j.ophtha.2008.11.002
   Schneider S, 1998, DOC OPHTH P, V62, P69
   Schuman SG, 2009, OPHTHALMOLOGY, V116, P488, DOI 10.1016/j.ophtha.2008.10.006
   Wojtkowski M, 2005, OPHTHALMOLOGY, V112, P1734, DOI 10.1016/j.ophtha.2005.05.023
NR 23
TC 97
Z9 99
U1 1
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD APR
PY 2011
VL 118
IS 4
BP 687
EP 693
DI 10.1016/j.ophtha.2010.08.010
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 744DS
UT WOS:000289075200012
PM 21093923
OA Green Published, Green Accepted
DA 2022-11-30
ER

PT J
AU Lauermann, JL
   Woetzel, AK
   Treder, M
   Alnawaiseh, M
   Clemens, CR
   Eter, N
   Alten, F
AF Lauermann, J. L.
   Woetzel, A. K.
   Treder, M.
   Alnawaiseh, M.
   Clemens, C. R.
   Eter, N.
   Alten, Florian
TI Prevalences of segmentation errors and motion artifacts in
   OCT-angiography differ among retinal diseases
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE Age-related macular degeneration; OCT-angiography; Optical coherence
   tomography angiography; Spectral-domain optical coherence tomography;
   Eye tracking; Image artifacts; Motion artifacts; Image quality;
   Segmentation
ID OPTICAL COHERENCE TOMOGRAPHY; GLAUCOMA DIAGNOSTIC-ACCURACY; MACULAR
   DEGENERATION; PLAQUE RADIOTHERAPY; VEIN OCCLUSION; EYES;
   CHORIOCAPILLARIS; QUANTIFICATION; QUALITY; DRUSEN
AB To assess the prevalences of segmentation errors and motion artifacts in optical coherence tomography angiography (OCT-A) in different retinal diseases
   In a retrospective analysis, multimodal retinal imaging including OCT-A was performed in one eye of 57 healthy controls (50.96 +/- 22.4 years) and 149 patients (66.42 +/- 14.1 years) affected by different chorioretinal diseases: early/intermediate age-related macular degeneration (AMD; n = 26), neovascular AMD (nAMD; n = 22), geographic atrophy due to AMD (GA; n = 6), glaucoma (n = 28), central serous chorioretinopathy (CSC; n = 14), epiretinal membrane (EM; n = 26), retinal vein occlusion (RVO; n = 11), and retinitis pigmentosa (RP; n = 16). Central 3 x 3 mm(2) OCT-A imaging was performed with active eye-tracking (AngioVue, Optovue). Best-corrected visual acuity (BCVA) and signal strength index (SSI) were recorded. Images were independently evaluated by two graders using the OCT-A motion artifact score (MAS; scores I-IV) as well as a newly introduced segmentation accuracy score (SAS; score I-IIB).
   Mean SSI was 63.67 +/- 9.2 showing a negative correlation with increasing age (rSp = - 0.42, p < 0.001, n = 206). In the healthy cohort, mean MAS was 1.45 +/- 0.8 and segmentation was accurate (SAS I) in all eyes. In eyes with retinal pathologies, mean MAS was 2.1 +/- 0.9 (p < 0.001). Lowest MAS was observed in GA (2.67 +/- 0.5) and RVO (2.45 +/- 1.1). Compared to an accurate segmentation in 100% in healthy subjects, 34.2% (n = 51) of all patients showed highest segmentation quality (p < 0.001). 63.8% showed segmentation errors in more than 5% of all single b-scans in one (SAS IIA, n = 58) or at least two (SAS IIB, n = 40) segmentation boundaries. Highest percentages of inaccurate segmentation (SAS IIA or IIB) were observed in the nAMD group (90.1%). The inner plexiform layer was the segmentation boundary most prone to inaccurate segmentation in all pathologies compared to the inner limiting membrane (ILM) and retinal pigment epithelium (RPE) segmentation layer. Incorrect ILM segmentation was only seen in patients with EM.
   Prior to both qualitative and quantitative analysis, OCT-A images must be carefully reviewed as motion artifacts and segmentation errors in current OCT-A technology are frequent particularly in pathologically altered maculae.
C1 [Lauermann, J. L.; Woetzel, A. K.; Treder, M.; Alnawaiseh, M.; Clemens, C. R.; Eter, N.; Alten, Florian] Univ Munster, Dept Ophthalmol, Med Ctr, Domagkstr 15, D-48149 Munster, Germany.
C3 University of Munster
RP Alten, F (通讯作者)，Univ Munster, Dept Ophthalmol, Med Ctr, Domagkstr 15, D-48149 Munster, Germany.
EM jost.Lauermann@ukmuenster.de; ak.woetzel@gmail.com;
   maximilian.treder@ukmuenster.de; maged.alnawaiseh@ukmuenster.de;
   christoph.clemens@ukmuenster.de; nicole.eter@ukmuenster.de;
   florian.alten@ukmuenster.de
CR Al-Sheikh Mayss, 2017, Int J Retina Vitreous, V3, P13, DOI 10.1186/s40942-017-0068-9
   Alten F, 2017, GRAEF ARCH CLIN EXP, V255, P2347, DOI 10.1007/s00417-017-3813-8
   Bogunovic H, 2017, INVEST OPHTH VIS SCI, V58, P3240, DOI 10.1167/iovs.16-21053
   Cole ED, 2016, RETINA-J RET VIT DIS, V36, pS83, DOI 10.1097/IAE.0000000000001338
   de Sisternes L, 2017, BIOMED OPT EXPRESS, V8, P1926, DOI 10.1364/BOE.8.001926
   DeCroos FC, 2013, TRANSL VIS SCI TECHN, V2, DOI 10.1167/tvst.2.7.7
   Falavarjani KG, 2017, BRIT J OPHTHALMOL, V101, P564, DOI 10.1136/bjophthalmol-2016-309104
   Fenner BJ, 2018, BRIT J OPHTHALMOL, V102, P509, DOI 10.1136/bjophthalmol-2017-310700
   Han IC, 2010, OPHTHALMOLOGY, V117, P1177, DOI 10.1016/j.ophtha.2009.10.029
   Iida Y, 2017, AM J OPHTHALMOL, V182, P168, DOI 10.1016/j.ajo.2017.08.004
   Jeoung JW, 2013, INVEST OPHTH VIS SCI, V54, P4422, DOI 10.1167/iovs.12-11273
   Jia YL, 2015, P NATL ACAD SCI USA, V112, pE2395, DOI 10.1073/pnas.1500185112
   Kim HJ, 2016, INVEST OPHTH VIS SCI, V57, P4799, DOI 10.1167/iovs.16-19214
   Kraus MF, 2012, BIOMED OPT EXPRESS, V3, P1182, DOI 10.1364/BOE.3.001182
   Lang A, 2017, P SPIE INT SOC OPT E, V10137
   Lauermann JL, 2017, GRAEF ARCH CLIN EXP, V255, P1535, DOI 10.1007/s00417-017-3684-z
   Linderman R, 2017, TRANSL VIS SCI TECHN, V6, DOI 10.1167/tvst.6.3.16
   Louzada RN, 2017, CAN J OPHTHALMOL, V52, P419, DOI 10.1016/j.jcjo.2016.12.012
   Lumbroso B., 2015, CLIN OCT ANGIOGRAPHY
   Muftuoglu IK, 2018, RETINA-J RET VIT DIS, V38, P1478, DOI 10.1097/IAE.0000000000001759
   Mwanza JC, 2012, OPHTHALMOLOGY, V119, P1151, DOI 10.1016/j.ophtha.2011.12.014
   Nelis P, 2017, GRAEF ARCH CLIN EXP, V255, P1319, DOI 10.1007/s00417-017-3640-y
   Niu SJ, 2014, COMPUT BIOL MED, V54, P116, DOI 10.1016/j.compbiomed.2014.08.028
   Onishi AC, 2019, RETINA-J RET VIT DIS, V39, P1588, DOI 10.1097/IAE.0000000000002179
   Rogala J, 2015, INVEST OPHTH VIS SCI, V56, P1689, DOI 10.1167/iovs.14-16221
   Sadda SR, 2006, OPHTHALMOLOGY, V113, P285, DOI 10.1016/j.ophtha.2005.10.005
   Say EAT, 2017, RETINA-J RET VIT DIS, V37, P1660, DOI 10.1097/IAE.0000000000001414
   Shields CL, 2016, RETINA-J RET VIT DIS, V36, P1493, DOI 10.1097/IAE.0000000000001021
   Spaide RF, 2017, JAMA OPHTHALMOL, V135, P259, DOI 10.1001/jamaophthalmol.2016.5327
   Spaide RF, 2016, AM J OPHTHALMOL, V165, P133, DOI 10.1016/j.ajo.2016.02.037
   Spaide RF, 2015, RETINA-J RET VIT DIS, V35, P2163, DOI 10.1097/IAE.0000000000000765
   Treder M, 2018, GRAEF ARCH CLIN EXP, V256, P259, DOI 10.1007/s00417-017-3850-3
   Uji A, 2017, JAMA OPHTHALMOL, V135, P1197, DOI 10.1001/jamaophthalmol.2017.3904
   Wang J, 2017, BIOMED OPT EXPRESS, V8, P1536, DOI 10.1364/BOE.8.001536
   Zhang M, 2016, BIOMED OPT EXPRESS, V7, P816, DOI 10.1364/BOE.7.000816
NR 35
TC 59
Z9 60
U1 1
U2 14
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0721-832X
EI 1435-702X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD OCT
PY 2018
VL 256
IS 10
BP 1807
EP 1816
DI 10.1007/s00417-018-4053-2
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA GT7XF
UT WOS:000444744500003
PM 29982897
DA 2022-11-30
ER

PT J
AU Brown, GC
   Brown, MM
   Fischer, DH
AF Brown, Gary C.
   Brown, Melissa M.
   Fischer, David H.
TI Photopsias: A Key to Diagnosis
SO OPHTHALMOLOGY
LA English
DT Article
ID VISUAL HALLUCINATIONS; PHOTODYNAMIC THERAPY; MELANOMA; OBSTRUCTION;
   HEMANGIOMA; SECONDARY; SYMPTOMS; DISEASE; PATIENT
AB Purpose: To assess the character and cause of photopsias in vitreoretinal patients.
   Design: Cross-sectional study.
   Participants: A total of 169 consecutive patients (217 eyes) with vitreoretinal disease presenting with a history of photopsias.
   Methods: A total of 217 eyes with photopsias in 169 patients were evaluated. Photopsia assessment included (1) laterality (unilateral, bilateral but not simultaneous, bilateral, and simultaneous); (2) morphology (flash, zig-zag, strobe, scintillating scotoma, twinkling, other); (3) color (white, silver, yellow, combination, other); (4) location (temporal, central, other); (5) duration (quick, prolonged, constant, other); (6) frequency; (7) diurnal appearance (day, night, both); (8) stimuli (turning head or eyes, hypoglycemia, hyperglycemia, other); and (9) associated systemic or ocular signs and symptoms (headache, numbness, weakness, vertigo, syncope, diplopia, hypotension, floaters, other).
   Main Outcome Measures: Clinical photopsia features correlated with the causes of photopsias.
   Results: Thirty-two photopsia causes were identified. The top 16 included posterior vitreous detachment (PVD) in 39.7% of eyes; retinal tear in 8.9% of eyes; neovascular age-related macular degeneration (AMD) in 7.9% of eyes; rhegmatogenous retinal detachment (RRD) in 7.5% of eyes; classic and ophthalmic migraine in 6.5% of eyes; hypoglycemia in 2.8% of eyes; vertebrobasilar insufficiency in 2.8% of eyes; non-AMDchoroidal neovascularization in 2.3% of eyes; retinitis pigmentosa in 1.9% of eyes; severe cough in 1.9% of eyes; central serous chorioretinopathy in 1.4% of eyes; intraocular lens reflections in 0.9% of eyes; blue field entoptic phenomenon in 0.9% of eyes; Charles Bonnet syndrome in 0.9% of eyes; digitalis in 0.9% of eyes; and metastatic adenocarcinoma to the brain in 0.9% of eyes. The photopsias associated with PVD are typically quick (96%), with lightning/flash morphology (96%), white (87%), temporally located (86%), associated with new-onset floaters (85%), preferentially seen in dark (90%) rather than lighted environments (29%), and often initiated by head/eye movements (60%). Retinal detachment had a similar profile, but with more nontemporal photopsias (40%) (rho = 0.01). The photopsias from neovascular AMD are more centrally located (83%), quick and repetitive (79%), seen in light (73%) and dark (63%) environments, have no inciting stimuli (84%), and are more likely to be nonwhite (40%).
   Conclusions: A pointed history for photopsias can reveal a cause that may not initially seem apparent. Thus, the history can play a key role in management decisions. (C) 2015 by the American Academy of Ophthalmology.
C1 [Brown, Gary C.; Fischer, David H.] Thomas Jefferson Univ, Jefferson Med Coll, Wills Eye Hosp, Retina Serv, Philadelphia, PA 19107 USA.
   [Brown, Melissa M.] Thomas Jefferson Univ, Jefferson Med Coll, Wills Eye Hosp, Res Unit, Philadelphia, PA 19107 USA.
   [Brown, Gary C.; Fischer, David H.] Midatlantic Retina, Plymouth Meeting, PA 19462 USA.
   [Brown, Gary C.; Brown, Melissa M.] Eye Res Inst, Philadelphia, PA USA.
   [Brown, Gary C.; Brown, Melissa M.] Ctr Value Based Med, Flourtown, PA USA.
C3 Jefferson University; Jefferson University
RP Brown, GC (通讯作者)，Midatlantic Retina, 4060 Butler Pike, Plymouth Meeting, PA 19462 USA.
EM gbrown@valuebasedmedicine.com
CR Abazari A, 2012, AM J OPHTHALMOL, V153, P750, DOI 10.1016/j.ajo.2011.09.012
   Ah-Fat FG, 1998, EYE, V12, P781, DOI 10.1038/eye.1998.202
   Audo I, 2011, ARCH OPHTHALMOL-CHIC, V129, P703, DOI 10.1001/archophthalmol.2011.6
   Barile GR, 2013, DOC OPHTHALMOL, V127, P261, DOI 10.1007/s10633-013-9409-7
   Benson WE, 1988, DIABETES ITS OCULAR, P64
   Bokkon I, 2008, BIOSYSTEMS, V92, P168, DOI 10.1016/j.biosystems.2008.02.002
   BROWN GC, 1982, OPHTHALMOLOGY, V89, P14
   BROWN GC, 1992, ARCH OPHTHALMOL-CHIC, V110, P1251, DOI 10.1001/archopht.1992.01080210069027
   BROWN GC, 1981, OPHTHALMOLOGY, V88, P18
   BROWN GC, 1981, ANN OPHTHALMOL, V13, P1205
   Cabrera J, 2001, INT ANGIOL, V20, P322
   Cohen SY, 2003, BRIT J OPHTHALMOL, V87, P977, DOI 10.1136/bjo.87.8.977
   Danks JJ, 1998, BRIT J OPHTHALMOL, V82, P1309, DOI 10.1136/bjo.82.11.1309
   Demirci H, 2003, AM J OPHTHALMOL, V136, P264, DOI 10.1016/S0002-9394(03)00192-2
   Digre KB, 2009, HEADACHE, V49, P185, DOI 10.1111/j.1526-4610.2008.01324.x
   Goodfellow JFB, 2010, OPHTHAL PHYSL OPT, V30, P20, DOI 10.1111/j.1475-1313.2009.00685.x
   Haamann P, 2000, AM J OPHTHALMOL, V129, P552, DOI 10.1016/S0002-9394(99)00440-7
   Hazra M, 2006, J CLIN PSYCHOPHARM, V26, P546, DOI 10.1097/01.jcp.0000237949.88387.9e
   Heckenlively JR, 2008, SEMIN IMMUNOPATHOL, V30, P127, DOI 10.1007/s00281-008-0114-7
   Iankin V V, 1990, Klin Med (Mosk), V68, P33
   Inafuku T, 1994, Rinsho Shinkeigaku, V34, P484
   Kadikoy H, 2010, J OCUL PHARMACOL TH, V26, P387, DOI 10.1089/jop.2010.0046
   Kasten E, 1998, FORTSCHR NEUROL PSYC, V66, P49, DOI 10.1055/s-2007-995239
   Kuznik-Borkowska A, 2006, J FR OPHTALMOL, V29, P319, DOI 10.1016/S0181-5512(06)73790-1
   Kwon SI, 2008, JPN J OPHTHALMOL, V52, P331, DOI 10.1007/s10384-008-0561-7
   Law DZ, 2014, CASE REP OPHTHALMOL, V2014, DOI 10.1155/2014/156178
   Lommatzsch AP, 2014, KLIN MONATSBL AUGENH, V231, P909, DOI 10.1055/s-0034-1368372
   Morita Y, 2014, JPN J OPHTHALMOL, V58, P166, DOI 10.1007/s10384-013-0300-6
   Nagata T, 2001, Rinsho Shinkeigaku, V41, P498
   Nakaya-Onishi M, 2000, GRAEF ARCH CLIN EXP, V238, P200, DOI 10.1007/s004170050033
   Oishi A, 2006, CAN J OPHTHALMOL, V41, P603, DOI 10.1016/S0008-4182(06)80031-1
   Rayan M, 2011, ANADOLU KARDIYOL DER, V11, P402, DOI 10.5152/akd.2011.110
   Roos NM, 2012, OBSTET GYNECOL SURV, V67, P242, DOI 10.1097/OGX.0b013e318250a457
   Sagoo MS, 2007, ARCH OPHTHALMOL-CHIC, V125, P1202, DOI 10.1001/archopht.125.9.1202
   Schankin CJ, 2014, HEADACHE, V54, P957, DOI 10.1111/head.12378
   SEIDMAN AD, 1995, J CLIN ONCOL, V13, P2575, DOI 10.1200/JCO.1995.13.10.2575
   Shields CL, 2001, OPHTHALMOLOGY, V108, P2237, DOI 10.1016/S0161-6420(01)00812-0
   Silva RA, 2012, J OPHTHALMIC INFLAMM, V2, P109, DOI 10.1007/s12348-011-0051-9
   TAGUCHI K, 1980, ELECTROEN CLIN NEURO, V49, P162, DOI 10.1016/0013-4694(80)90362-4
   Tuncer S, 2009, EUR J OPHTHALMOL, V19, P159, DOI 10.1177/112067210901900127
   Urushitani M, 1996, Rinsho Shinkeigaku, V36, P481
   Verma Rajesh, 2012, BMJ Case Rep, V2012, DOI 10.1136/bcr.02.2012.5840
   Vongvaivanich K, 2014, CEPHALALGIA
   Wiaux C, 2007, KLIN MONATSBL AUGENH, V224, P334, DOI 10.1055/s-2007-962850
NR 44
TC 14
Z9 14
U1 0
U2 16
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD OCT
PY 2015
VL 122
IS 10
BP 2084
EP 2094
DI 10.1016/j.ophtha.2015.06.025
PG 11
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA CU4IP
UT WOS:000363491500025
PM 26249730
DA 2022-11-30
ER

PT J
AU Hennis, AJ
   Wu, SY
   Nemesure, B
   Hyman, L
   Schachat, AP
   Leske, MC
AF Hennis, Anselm J.
   Wu, Suh-Yuh
   Nemesure, Barbara
   Hyman, Leslie
   Schachat, Andrew P.
   Leske, M. Cristina
CA Barbados Eye Studies Grp
TI Nine-year Incidence of Visual Impairment in the Barbados Eye Studies
SO OPHTHALMOLOGY
LA English
DT Article
ID OPEN-ANGLE GLAUCOMA; BEAVER-DAM EYE; CAUSE-SPECIFIC PREVALENCE; BLUE
   MOUNTAINS EYE; QUALITY-OF-LIFE; CATARACT-SURGERY; LENS OPACITIES;
   RISK-FACTORS; URBAN-POPULATION; BLACK-POPULATION
AB Objective: To describe the 9-year incidence of visual impairment and primary causes of blindness among black participants of the Barbados Eye Studies (BES).
   Design: Population-based prospective cohort study.
   Participants: The BES followed a nationally representative cohort selected by simple random sampling, aged 40 to 84 years at baseline, with reexaminations after 4 years (Barbados Incidence Study of Eye Diseases [BISED]) and 9 years (BISED 11). BISED 11 included 2793 (81 %) of those eligible.
   Methods: Cumulative 9-year incidence rates were estimated by the Product-Limit approach. The study was reviewed and approved by the institutional review boards of collaborating institutions.
   Main Outcome Measures: Best-corrected visual acuity (VA) was assessed by the Ferris-Bailey chart, following a modified Early Treatment of Diabetic Retinopathy Study protocol. Low vision and blindness were defined by World Health Organization (WHO) criteria as VA <6/18 to 6/120, and <6/120, respectively, in the better eye, and by U.S. criteria as VA <= 20/40 and <= 20/200, respectively. Vision loss was defined as a decrease of 15 letters or more read correctly in the better eye between baseline and follow-up examinations.
   Results: The 9-year incidence was 1.0% and 2.1 % for blindness and 6.0% and 9.0% for low vision, by WHO and U.S. criteria, respectively. Older age at baseline was associated with higher incidence of low vision and blindness, reaching 23.0% (95% confidence interval [CI], 18.8-28.0) and 4.3% (95% CI, 2.7-6.9) at age 70 years or more, based on WHO criteria. The primary causes of incident bilateral blindness (U.S. criteria) in 126 eyes were age-related cataract (48.3%), open-angle glaucoma (OAG) (14.3%), combined cataract and OAG (6.3%), diabetic retinopathy (8.7%), and optic atrophy (7.1 %). Age-related macular degeneration (2.4%) rarely caused blindness.
   Conclusions: Incident visual impairment is exceedingly high in this population. Cataract, OAG, and diabetic retinopathy remain the major causes of blindness, underpinning the clinical and public health significance of these conditions in this and similar populations.
   Financial Disclosure(s): The author(s) have no proprietary or commercial interest in any materials discussed in this article. Ophthalmology 2009;116:1461-1468 (C) 2009 by the American Academy of Ophthalmology.
C1 [Hennis, Anselm J.] Univ W Indies, Chron Dis Res Ctr, Res Inst Trop Med, Bridgetown, Barbados.
   [Hennis, Anselm J.; Wu, Suh-Yuh; Nemesure, Barbara; Hyman, Leslie; Leske, M. Cristina] SUNY Stony Brook, Sch Med, Dept Prevent Med, Stony Brook, NY 11794 USA.
   [Hennis, Anselm J.] Minist Hlth, Bridgetown, Barbados.
   [Schachat, Andrew P.; Barbados Eye Studies Grp] Johns Hopkins Univ, Wilmer Inst, Baltimore, MD USA.
C3 University West Indies Mona Jamaica; University of the West Indies Open
   Campus; State University of New York (SUNY) System; SUNY Community
   College; State University of New York (SUNY) Stony Brook; Johns Hopkins
   University
RP Hennis, AJ (通讯作者)，Univ W Indies, Chron Dis Res Ctr, Res Inst Trop Med, Jemmotts Lane, Bridgetown, Barbados.
EM anselm.hennis@cavehill.uwi.edu
FU National Eye Institute, Bethesda, Maryland [EY07625, EY07617]; NATIONAL
   EYE INSTITUTE [U10EY007617, U10EY007625] Funding Source: NIH RePORTER
FX Supported by Grants EY07625 and EY07617 from the National Eye Institute,
   Bethesda, Maryland.
CR Attebo K, 1996, OPHTHALMOLOGY, V103, P357
   Berdeaux G, 2007, OPHTHAL EPIDEMIOL, V14, P80, DOI 10.1080/09286580600899691
   Bramley T, 2008, ARCH OPHTHALMOL-CHIC, V126, P849, DOI 10.1001/archopht.126.6.849
   Cedrone C, 2003, OPHTHALMOLOGY, V110, P584, DOI 10.1016/S0161-6420(02)01898-5
   Chia EM, 2004, INVEST OPHTH VIS SCI, V45, P71, DOI 10.1167/iovs.03-0661
   CHYLACK LT, 1989, ARCH OPHTHALMOL-CHIC, V107, P991, DOI 10.1001/archopht.1989.01070020053028
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   COX DR, 1972, J R STAT SOC B, V187, P220
   Foran S, 2002, ARCH OPHTHALMOL-CHIC, V120, P613, DOI 10.1001/archopht.120.5.613
   Gordon MO, 2002, ARCH OPHTHALMOL-CHIC, V120, P714
   Hennis A, 2002, INT J EPIDEMIOL, V31, P234, DOI 10.1093/ije/31.1.234
   Hennis A, 2007, OPHTHALMOLOGY, V114, P1816, DOI 10.1016/j.ophtha.2007.06.013
   Hsu WM, 2004, OPHTHALMOLOGY, V111, P62, DOI 10.1016/j.ophtha.2003.05.011
   Hyman L, 2001, OPHTHALMOLOGY, V108, P1751, DOI 10.1016/S0161-6420(01)00590-5
   KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868
   Klaver CCW, 1998, ARCH OPHTHALMOL-CHIC, V116, P653, DOI 10.1001/archopht.116.5.653
   Klein BEK, 2003, OPHTHALMOLOGY, V110, P644, DOI 10.1016/S0161-6420(02)01935-8
   Klein BEK, 1997, OPHTHALMOLOGY, V104, P573, DOI 10.1016/S0161-6420(97)30267-X
   Klein R, 2001, OPHTHALMOLOGY, V108, P1757, DOI 10.1016/S0161-6420(01)00769-2
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1310
   Klein R, 1996, OPHTHALMOLOGY, V103, P1169, DOI 10.1016/S0161-6420(96)30526-5
   Klein R, 2006, AM J OPHTHALMOL, V142, P539, DOI 10.1016/j.ajo.2006.06.015
   Leibowitz H M, 1980, Surv Ophthalmol, V24, P335
   Leske MC, 2008, OPHTHALMOLOGY, V115, P85, DOI 10.1016/j.ophtha.2007.03.017
   Leske MC, 2007, OPHTHALMOLOGY, V114, P1058, DOI 10.1016/j.ophtha.2006.08.051
   Leske MC, 1999, OPHTHALMOLOGY, V106, P35, DOI 10.1016/S0161-6420(99)90003-9
   Leske MC, 2004, OPHTHALMOLOGY, V111, P483, DOI 10.1016/j.ophtha.2003.06.016
   Leske MC, 2004, OPHTHALMOLOGY, V111, P118, DOI 10.1016/j.ophtha.2003.04.002
   LESKE MC, 1995, ARCH OPHTHALMOL-CHIC, V113, P918, DOI 10.1001/archopht.1995.01100070092031
   Leske MC, 2003, ARCH OPHTHALMOL-CHIC, V121, P48
   LESKE MC, 1994, ARCH OPHTHALMOL-CHIC, V112, P821, DOI 10.1001/archopht.1994.01090180121046
   Leske MC, 1999, OPHTHALMOLOGY, V106, P1893, DOI 10.1016/S0161-6420(99)90398-6
   Leske MC, 2001, ARCH OPHTHALMOL-CHIC, V119, P89
   LEUREDUPREE AE, 1981, INVEST OPHTH VIS SCI, V21, P1
   Limburg H, 2008, BRIT J OPHTHALMOL, V92, P315, DOI 10.1136/bjo.2007.125906
   Munoz B, 2000, ARCH OPHTHALMOL-CHIC, V118, P819, DOI 10.1001/archopht.118.6.819
   Nirmalan PK, 2002, BRIT J OPHTHALMOL, V86, P505, DOI 10.1136/bjo.86.5.505
   Nucci C, 2005, EYE, V19, P175, DOI 10.1038/sj.eye.6701444
   Rahmani B, 1996, OPHTHALMOLOGY, V103, P1721, DOI 10.1016/S0161-6420(96)30435-1
   Resnikoff S, 2004, B WORLD HEALTH ORGAN, V82, P844
   Rubin GS, 1997, INVEST OPHTH VIS SCI, V38, P557
   SOMMER A, 1991, NEW ENGL J MED, V325, P1412, DOI 10.1056/NEJM199111143252004
   Taylor HR, 1997, AM J OPHTHALMOL, V123, P328, DOI 10.1016/S0002-9394(14)70128-X
   THOMPSON JR, 1989, BRIT J OPHTHALMOL, V73, P95, DOI 10.1136/bjo.73.2.95
   Thulasiraj RD, 2003, OPHTHALMOLOGY, V110, P1491, DOI 10.1016/S0161-6420(03)00565-7
   THYLEFORS B, 1995, B WORLD HEALTH ORGAN, V73, P115
   TIELSCH JM, 1990, ARCH OPHTHALMOL-CHIC, V108, P286, DOI 10.1001/archopht.1990.01070040138048
   VanNewkirk MR, 2001, OPHTHALMOLOGY, V108, P960, DOI 10.1016/S0161-6420(01)00554-1
   West SK, 1997, INVEST OPHTH VIS SCI, V38, P72
   Wong TY, 2008, ARCH OPHTHALMOL-CHIC, V126, P1091, DOI 10.1001/archopht.126.8.1091
   Wu SY, 2008, INVEST OPHTH VIS SCI, V49, P1333, DOI 10.1167/iovs.07-1252
   Xu L, 2006, OPHTHALMOLOGY, V113, P1134, DOI 10.1016/j.ophtha.2006.01.035
NR 52
TC 35
Z9 37
U1 0
U2 6
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0161-6420
J9 OPHTHALMOLOGY
JI Ophthalmology
PD AUG
PY 2009
VL 116
IS 8
BP 1461
EP 1468
DI 10.1016/j.ophtha.2009.02.017
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 480CT
UT WOS:000268710200008
PM 19500851
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Boixadera, A
   Arumi, JG
   Martinez-Castillo, V
   Encinas, JL
   Elizalde, J
   Blanco-Mateos, G
   Caminal, J
   Capeans, C
   Armada, F
   Navea, A
   Olea, JL
AF Boixadera, Anna
   Garcia Arumi, Jose
   Martinez-Castillo, Vicente
   Luis Encinas, Jose
   Elizalde, Javier
   Blanco-Mateos, Gonzalo
   Caminal, Jose
   Capeans, Carmela
   Armada, Felix
   Navea, Amaparo
   Luis Olea, Jose
TI Prospective Clinical Trial Evaluating the Efficacy of Photodynamic
   Therapy for Symptomatic Circumscribed Choroidal Hemangioma
SO OPHTHALMOLOGY
LA English
DT Article
ID TRANSPUPILLARY THERMOTHERAPY; VERTEPORFIN
AB Purpose: To evaluate photodynamic therapy (PDT) for symptomatic circumscribed choroidal hemangioma (CCH).
   Design: Prospective, multicenter, nonrandomized clinical trial.
   Participants: Thirty-one eyes of 31 patients with posterior pole CCH and symptoms caused by exudation into the macular area.
   Intervention: Photodynamic therapy was applied by Zeiss laser. Intravenous verteporfin at 6 mg/m(2) body surface was administered before treatment, and light emitted at 689 nm for photosensitization. The treatment spot diameter was calculated on early-phase frames of pretreatment indocyanine green angiography. Fifteen minutes after starting the verteporfin infusion, the laser beam was applied to the retina at radiant exposure 50 J/cm(2) and exposure time 83 seconds. One to 4 treatments were applied at 12-week intervals over 1 year. Standardized evaluation was performed before and at 4-week intervals after each treatment, and at 3, 6, 9, and 12 months. All patients were followed for >= 12 months.
   Main Outcome Measures: The primary outcome measure was the absence of exudative retinal detachment at the 12-month follow-up visit on ophthalmoscopy, fluorescein angiography, and optical coherence tomography. Secondary measures were the visual acuity outcome, with best-corrected visual acuity determined by the Early Treatment for Diabetic Retinopathy Study chart, tumor thickness decrease on B-scan ultrasonography, and adverse events.
   Results: Among the total, 82.8% of patients required 1, 13.8% 2, and 3.4% 3 PDTs to eliminate exudative retinal detachment. Visual acuity increased from a mean of 20/60 to 20/35 (P<0.001). Sixty-nine percent of patients demonstrated visual recovery (P<0.001). Cystoid macular edema regressed in all cases and exudative macular detachment disappeared in all but 2 cases. The CCH thickness decreased in all cases from a mean of 3.0 to 1.7 mm, with the most intense effect seen after 4 weeks of treatment (P<0.001). Visual fields showed resolution of central scotomas. There were no severe adverse events.
   Conclusions: Combining PDT with the standard age-related macular degeneration protocol is an effective treatment for CCH in terms of resolution of exudative subretinal fluid and recovery of VA.
   Financial Disclosure(s): The authors have no proprietary or commercial interest in any materials discussed in this article. Ophthalmology 2009;116:100-105 (C) 2009 by the American Academy of Ophthalmology.
C1 [Boixadera, Anna; Garcia Arumi, Jose; Martinez-Castillo, Vicente] Hosp Gen Valle Hebron, Dept Ophthalmol, Barcelona, Spain.
   [Garcia Arumi, Jose] Inst Microcirugia Ocular, Barcelona, Spain.
   [Luis Encinas, Jose] Hosp Puerta de Hierro, Madrid, Spain.
   [Elizalde, Javier] Ctr Oftalmol Barraquer, Barcelona, Spain.
   [Blanco-Mateos, Gonzalo] Inst Oftalmobiol Aplicada, Valladolid, Spain.
   [Caminal, Jose] Bellvitge Hosp, Lhospitalet De Llobregat, Spain.
   [Capeans, Carmela] Hosp Conxo, Santiago De Compostela, Spain.
   [Armada, Felix] Hosp La Paz, Madrid, Spain.
   [Navea, Amaparo] Hosp La Fe, E-46009 Valencia, Spain.
   [Luis Olea, Jose] Hosp Son Dureta, Mallorca, Spain.
C3 Hospital Universitari Vall d'Hebron; Hospital Puerta de
   Hierro-Majadahonda; Institut d'Investigacio Biomedica de Bellvitge
   (IDIBELL); Bellvitge University Hospital; Hospital Universitario La Paz;
   Hospital Universitari i Politecnic La Fe; Hospital Universitari Son
   Espases; Hospital Universitari Son Dureta
RP Boixadera, A (通讯作者)，Paseo San Gervasio 78,5 3A, Barcelona 08022, Spain.
EM aboixadera@hotmail.com
RI Navea, Amparo/D-4577-2009
OI Navea, Amparo/0000-0002-9856-5370; Garcia-Arumi,
   Jose/0000-0001-8827-1160; Boixadera, Anna/0000-0003-2000-9478; Caminal,
   JM/0000-0001-9563-0344; OLEA, JOSE LUIS/0000-0002-3645-8262
CR ANAND R, 1989, ARCH OPHTHALMOL-CHIC, V107, P1338, DOI 10.1001/archopht.1989.01070020408045
   Augsburger J J, 1981, Retina, V1, P56
   Barbazetto I, 2000, GRAEF ARCH CLIN EXP, V238, P214, DOI 10.1007/s004170050346
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Garcia-Arumi J, 2000, OPHTHALMOLOGY, V107, P351, DOI 10.1016/S0161-6420(99)00046-9
   Gass JDM, 1974, DIFFERENTIAL DIAGNOS, P113
   Guagnini AP, 2006, J FR OPHTALMOL, V29, P1013, DOI 10.1016/S0181-5512(06)73889-X
   Gupta M, 2004, EYE, V18, P139, DOI 10.1038/sj.eye.6700597
   Jurklies B, 2003, BRIT J OPHTHALMOL, V87, P84, DOI 10.1136/bjo.87.1.84
   Kjeka O, 2002, ACTA OPHTHALMOL SCAN, V80, P557, DOI 10.1034/j.1600-0420.2002.800520.x
   Landau IME, 2002, ACTA OPHTHALMOL SCAN, V80, P531, DOI 10.1034/j.1600-0420.2002.800513.x
   Lanzetta P, 1996, INT OPHTHALMOL, V19, P239
   Madreperla SA, 1997, OPHTHALMOLOGY, V104, P1773, DOI 10.1016/S0161-6420(97)30027-X
   Madreperla SA, 2001, ARCH OPHTHALMOL-CHIC, V119, P1606
   Mennel S, 2007, OPHTHALMOLOGICA, V221, P216, DOI 10.1159/000101922
   Michels S, 2004, OPHTHALMOLOGE, V101, P569, DOI 10.1007/s00347-003-0914-z
   Michels S, 2005, RETINA-J RET VIT DIS, V25, P697, DOI 10.1097/00006982-200509000-00003
   Othmane IS, 1999, ARCH OPHTHALMOL-CHIC, V117, P136
   Porrini G, 2003, OPHTHALMOLOGY, V110, P674, DOI 10.1016/S0161-6420(02)01968-1
   Robertson DM, 2002, ARCH OPHTHALMOL-CHIC, V120, P1155
   SANBORN GE, 1982, OPHTHALMOLOGY, V89, P1374
   Schmidt-Erfurth UM, 2002, OPHTHALMOLOGY, V109, P2284, DOI 10.1016/S0161-6420(02)01454-9
   SCHMIDTERFURTH U, 1994, OPHTHALMOLOGY, V101, P1953
   SCHMIDTERFURTH U, 1994, OPHTHALMOLOGY, V101, P89
   Shields CL, 2001, OPHTHALMOLOGY, V108, P2237, DOI 10.1016/S0161-6420(01)00812-0
   Shields JA, 2004, OPHTHAL SURG LAS IM, V35, P383, DOI 10.3928/1542-8877-20040901-07
   Singh AD, 2004, BRIT J OPHTHALMOL, V88, P1414, DOI 10.1136/bjo.2004.044396
   Verbraak FD, 2003, GRAEF ARCH CLIN EXP, V241, P891, DOI 10.1007/s00417-003-0765-y
   Vicuna-Kojchen J, 2006, OPHTHALMOLOGICA, V220, P351, DOI 10.1159/000095859
NR 29
TC 71
Z9 77
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0161-6420
J9 OPHTHALMOLOGY
JI Ophthalmology
PD JAN
PY 2009
VL 116
IS 1
BP 100
EP 105
DI 10.1016/j.ophtha.2008.08.029
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 392BA
UT WOS:000262276700016
PM 18973950
OA Bronze
DA 2022-11-30
ER

PT J
AU Robinson, MR
   Baffi, J
   Yuan, P
   Sung, C
   Byrnes, G
   Cox, TA
   Csaky, KG
AF Robinson, MR
   Baffi, J
   Yuan, P
   Sung, C
   Byrnes, G
   Cox, TA
   Csaky, KG
TI Safety and pharmacokinetics of intravitreal 2-methoxyestradiol implants
   in normal rabbit and pharmacodynamics in a rat model of choroidal
   neovascularization
SO EXPERIMENTAL EYE RESEARCH
LA English
DT Article
DE 2-methoxyestradiol; implant; vitreous; drug release; age-related macular
   degeneration; choroidal neovascularization; animal model
ID ENDOGENOUS ESTROGEN METABOLITE; ENDOTHELIAL GROWTH-FACTOR; MACULAR
   DEGENERATION; INHIBITS ANGIOGENESIS; DELIVERY SYSTEM; TUMOR-GROWTH;
   EXPRESSION; RELEASE; CELLS
AB Choroidal neovascularization (CNV) is the leading cause of severe vision loss associated with age-related macular degeneration, As the pathogenesis of CNV formation is better understood, mechanism-based therapies, including the use of antiangiogenesis inhibitors, have been investigated, 2-methoxyestradiol (2ME2), an endogenous metabolite of estradiol, has been shown in the chick allantoic membrane model and the corneal micropocket assay to have antiangiogenic properties. The authors sought to determine the safety and pharmacokinetics of sustained-release intravitreal 2ME2 implants in normal rabbit and their efficacy in a rat model of CNV. 2ME2 implants were constructed using two designs: implant A, a silicone-based reservoir implant for the rabnbit eye, and implant B, a microimplant matrix design for the rat eye. In vitro release rates of both implants were determined. New Zealand white (NZW) rabbits had implant A placed in the vitreous cavity of one eye and the ocular toxicity was evaluated by clinical examination, serial electroretinography (ERG), and histopathology over a 28 week period. The steady state clearance of 2ME2 in the rabbit eye was calculated from in vivo release rates divided by steady state vitreous concentrations. A CNV model in the Brown-Norway rat was performed by injecting an adenoviral vector encoding human vascular endothelial growth factor in the subretinal space, Following the injection, a 2ME2 or sham (no drug) microimplant was placed in the vitreous cavity. Animals were killed over a 3 week period and the eyes examined for CNV by histopathology. Results showed that following a short burst, the release rate of implant A followed zero-order kinetics, typical of reservoir devices, and the cumulative release of implant B was proportional to the square root of time, as expected for a matrix delivery device. The safety studies in normal rabbit showed no ocular toxicities by clinical examination, ERG, and histopathology. Pharmacokinetic evaluation in the rabbit showed mean 2ME2 vitreous levels within the therapeutic range for the inhibition of endothelial cell proliferation. The experimental rat model showed a significant reduction in CNV in eyes treated with the 2ME2 implant. In conclusion, sustained-release 2ME2 intravitreal implants, which can be designed to deliver potentially therapeutic vitreous levels of 2ME2 for an extended period of time, appeared to be safe in normal rabbit and effective in a rat model of CNV. Sustained-release 2ME2 intravitreal implants may hold promise in the treatment of recurrent CNV refractory to standard therapy.
C1 NEI, NIH1, Bethesda, MD 20892 USA.
   NIH2, Ctr Clin, Dept Pharm, Bethesda, MD 20892 USA.
   NIH3, Bioengn & Phys Sci Div, ORS, Bethesda, MD 20892 USA.
C3 National Institutes of Health (NIH) - USA; NIH National Eye Institute
   (NEI); National Institutes of Health (NIH) - USA; NIH Clinical Center
   (CC)
RP Robinson, MR (通讯作者)，NEI, NIH, 10 Ctr Dr,Msc 1863,Bldg10,Room10N112, Bethesda, MD 20892 USA.
FU NATIONAL EYE INSTITUTE [Z01EY000327] Funding Source: NIH RePORTER
CR Abraham I, 1998, NEUROREPORT, V9, P1465, DOI 10.1097/00001756-199805110-00040
   Aiello LP, 1997, OPHTHALMIC RES, V29, P354, DOI 10.1159/000268033
   Baffi J, 2000, INVEST OPHTH VIS SCI, V41, P3582
   Baffi J, 2001, INVEST OPHTH VIS SCI, V42, pS227
   Baken RJ, 1987, CLIN MEASUREMENT SPE, P1
   Berkowitz BA, 1998, INVEST OPHTH VIS SCI, V39, P391
   BRESSLER NM, 1988, ARCH OPHTHALMOL-CHIC, V106, P1537, DOI 10.1001/archopht.1988.01060140705039
   Constantinides PP, 2000, PHARMACEUT RES, V17, P175, DOI 10.1023/A:1007565230130
   DAMATO RJ, 1994, P NATL ACAD SCI USA, V91, P3964, DOI 10.1073/pnas.91.9.3964
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   Fine SL, 2000, NEW ENGL J MED, V342, P483, DOI 10.1056/NEJM200002173420707
   FOTSIS T, 1994, NATURE, V368, P237, DOI 10.1038/368237a0
   FREIREICH EMIL J., 1966, CANCER CHEMOTHERAP REP, V50, P219
   GLASER BM, 1987, OPHTHALMOLOGY, V94, P780
   GREEN WR, 1993, OPHTHALMOLOGY, V100, P1519
   Jaffe GJ, 2000, INVEST OPHTH VIS SCI, V41, P3569
   Kajihara M, 2000, J CONTROL RELEASE, V66, P49, DOI 10.1016/S0168-3659(99)00257-6
   King BA, 2000, INVEST OPHTH VIS SCI, V41, pS770
   Klauber N, 1997, CANCER RES, V57, P81
   MILLER H, 1986, INVEST OPHTH VIS SCI, V27, P1644
   ONEILL WP, 1980, CONTROLLED RELEASE T, P129
   OReilly MS, 1997, CELL, V88, P277, DOI 10.1016/S0092-8674(00)81848-6
   Pearson PA, 1996, ARCH OPHTHALMOL-CHIC, V114, P311, DOI 10.1001/archopht.1996.01100130307014
   Pribluda VS, 1998, SCIENCE, V280, P987
   Pribluda VS, 2000, CANCER METAST REV, V19, P173, DOI 10.1023/A:1026543018478
   Ross ML, 2000, INVEST OPHTH VIS SCI, V41, pS770
   SHIPPY RL, 1973, J BIOMED MATER RES, V7, P95, DOI 10.1002/jbm.820070108
   THOMAS MA, 2001, INVEST OPHTH VIS SCI, V41, pS2809
   Velez G, 2001, ARCH OPHTHALMOL-CHIC, V119, P1518
   WELLING PG, 1986, ACS MONOGR SER, V185, P145
   Yue TL, 1997, MOL PHARMACOL, V51, P951, DOI 10.1124/mol.51.6.951
   ZIMMERMAN TJ, 1973, INVEST OPHTH VISUAL, V12, P777
NR 32
TC 36
Z9 41
U1 0
U2 3
PU ACADEMIC PRESS LTD ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 0014-4835
J9 EXP EYE RES
JI Exp. Eye Res.
PD FEB
PY 2002
VL 74
IS 2
BP 309
EP 317
DI 10.1006/exer.2001.1132
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 551AT
UT WOS:000175537800016
PM 11950241
DA 2022-11-30
ER

PT J
AU Llorian-Salvador, M
   Byrne, EM
   Szczepan, M
   Little, K
   Chen, M
   Xu, HP
AF Llorian-Salvador, Maria
   Byrne, Eimear M.
   Szczepan, Manon
   Little, Karis
   Chen, Mei
   Xu, Heping
TI Complement activation contributes to subretinal fibrosis through the
   induction of epithelial-to-mesenchymal transition (EMT) in retinal
   pigment epithelial cells
SO JOURNAL OF NEUROINFLAMMATION
LA English
DT Article
DE Age-related macular degeneration; Macular fibrosis; Inflammation;
   Complement system; Retinal pigment epithelial cell; C5a; C3a; Subretinal
   fibrosis; Epithelial-to-mesenchymal transition
ID MACULAR DEGENERATION; C5A; C3A; RECEPTOR; PATHOGENESIS; EXPRESSION;
   THERAPY; PATHWAY; GENE
AB Background We previously reported higher plasma levels of complement fragments C3a and C5a in neovascular Age-related Macular Degeneration (nAMD) patients with macular fibrosis. This study aimed to understand whether complement activation contributes to the development of macular fibrosis and the underlying mechanisms involved. Methods Complement activation was blocked using a C5 neutralizing antibody (BB5.1) in C57BL/6J mice after induction of subretinal fibrosis using the two-stage laser protocol. Fibrotic lesions were examined 10 days after the 2nd laser through fundus examination and immunohistochemistry. The expression of C5aR in fibrotic lesions and retinal pigment epithelial (RPE) cultures were examined by confocal microscopy. Primary murine RPE cells were treated with C3a or C5a (10-100 ng/mL) or TGF-beta 2 (10 ng/mL). Epithelial-to-mesenchymal transition (EMT) was assessed through various readouts. The expression of E-cadherin, vimentin, fibronectin, alpha-SMA, Slug, ERK/AKT and pSMAD2/3 were determined by Western blot and immunocytochemistry. Collagen contraction and wound-healing assays were used as functional readouts of EMT. The production of IL-6, TGF-beta 1, TGF-beta 2 and VEGF by RPE cells were determined by ELISA. PMX53 was used to block C5aR in RPE cultures and in vivo in mice with subretinal fibrosis. Results Extensive C5b-9 deposition was detected at the site of subretinal fibrosis. BB5.1 treatment completely abrogated complement activation and significantly reduced subretinal fibrosis. C5aR was detected in RPE and infiltrating MHC-II+ cells in subretinal fibrosis. In vitro, RPE cells constitutively express C5/C5a and C5aR, and their expression was increased by TGF-beta 2 treatment. C5a but not C3a increased fibronectin, alpha-SMA, vimentin and Slug expression, and decreased E-cadherin expression in RPE cells. C5a treatment also increased the contractility and migration of RPE cells and enhanced the production of VEGF and TGF-beta 1/2. C5a treatment induced pSmad2/3 and pERK1/2 expression in RPE cells and this was blocked by PMX53. PMX53 treatment significantly reduced sodium fluorescein leakage in the subretinal fibrosis model, while collagen-I+ lesions only mildly reduced. Conclusions Complement activation is critically involved in the development of subretinal fibrosis, partially through C5a-C5aR-mediated EMT in RPE cells. Targeting complement activation rather than C5a may be a novel approach for the management of macular fibrosis.
C1 [Llorian-Salvador, Maria; Byrne, Eimear M.; Szczepan, Manon; Little, Karis; Chen, Mei; Xu, Heping] Queens Univ Belfast, Sch Med Dent & Biomed Sci, Wellcome Wolfson Inst Expt Med, 97 Lisburn Rd, Belfast BT9 7BL, Antrim, North Ireland.
   [Llorian-Salvador, Maria] Univ Autonoma Barcelona, Vall dHebron Res Inst VHIR, Barcelona 08035, Spain.
   [Byrne, Eimear M.] Barcelona Inst Sci & Technol, Ctr Genom Regulat CRG, Barcelona 08003, Spain.
C3 Queens University Belfast; Autonomous University of Barcelona; Hospital
   Universitari Vall d'Hebron; Vall d'Hebron Institut de Recerca (VHIR);
   Barcelona Institute of Science & Technology; Pompeu Fabra University;
   Centre de Regulacio Genomica (CRG)
RP Xu, HP (通讯作者)，Queens Univ Belfast, Sch Med Dent & Biomed Sci, Wellcome Wolfson Inst Expt Med, 97 Lisburn Rd, Belfast BT9 7BL, Antrim, North Ireland.
EM heping.xu@qub.ac.uk
RI Llorian Salvador, Maria/GYV-1848-2022; Llorián-Salvador,
   Maía/HDM-6846-2022
OI Byrne, Eimear M./0000-0001-5064-3539; Xu, Heping/0000-0003-4000-931X
FU Fight for Sight [5057/5058, 5105/5106]
FX This study was supported by a grant from Fight for Sight (5057/5058;
   5105/5106).
CR Addis-Lieser E, 2005, J IMMUNOL, V175, P1894, DOI 10.4049/jimmunol.175.3.1894
   Ambati J, 2003, SURV OPHTHALMOL, V48, P257, DOI 10.1016/S0039-6257(03)00030-4
   Blasiak J., 2021, INT J MOL SCI, V22, P1
   Busch C, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00703
   Byrne EM., 2021, BIOMEDICINES, V9, P1
   Castellazzi G, 2018, FRONT NEUROL, V9, DOI 10.3389/fneur.2018.00690
   Chen M, 2008, INVEST OPHTH VIS SCI, V49, P3699, DOI 10.1167/iovs.07-1522
   Chen M, 2015, J LEUKOCYTE BIOL, V98, P713, DOI 10.1189/jlb.3RI0615-239R
   Chen M, 2008, EXP EYE RES, V87, P543, DOI 10.1016/j.exer.2008.09.005
   Chen SF, 2019, ADV EXP MED BIOL, V1165, P423, DOI 10.1007/978-981-13-8871-2_20
   Copland DA, 2010, CLIN EXP IMMUNOL, V159, P303, DOI 10.1111/j.1365-2249.2009.04070.x
   Fielding CA, 2014, IMMUNITY, V40, P40, DOI 10.1016/j.immuni.2013.10.022
   Friedlander M, 2007, J CLIN INVEST, V117, P576, DOI 10.1172/JCI31030
   Fukuoka Y, 2003, CLIN EXP IMMUNOL, V131, P248, DOI 10.1046/j.1365-2249.2003.02087.x
   Galarza TE, 2020, BIOCHEM PHARMACOL, V180, DOI 10.1016/j.bcp.2020.114177
   Gu HM, 2016, FASEB J, V30, P2336, DOI 10.1096/fj.201500044
   Gu HM, 2014, FASEB J, V28, P4223, DOI 10.1096/fj.13-247650
   Guo RF, 2005, ANNU REV IMMUNOL, V23, P821, DOI 10.1146/annurev.immunol.23.021704.115835
   Gurubaran IS, 2021, BIOLOGY-BASEL, V10, DOI 10.3390/biology10070622
   Hillebrandt S, 2005, NAT GENET, V37, P835, DOI 10.1038/ng1599
   Hornum L, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0189017
   Ishikawa K, 2016, EXP EYE RES, V142, P19, DOI 10.1016/j.exer.2015.03.009
   Katschke KJ, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-25557-8
   Kuiper EJ, 2007, INVEST OPHTH VIS SCI, V48, P4267, DOI 10.1167/iovs.06-0804
   Kumar V, 2020, ACS OMEGA, V5, P2345, DOI 10.1021/acsomega.9b03735
   Lechner J, 2016, IMMUN AGEING, V13, DOI 10.1186/s12979-016-0060-5
   Li L, 2015, METABOLISM, V64, P597, DOI 10.1016/j.metabol.2015.01.014
   Little K, 2020, J NEUROINFLAMM, V17, DOI 10.1186/s12974-020-02033-7
   Little K, 2020, TRANSL VIS SCI TECHN, V9, DOI 10.1167/tvst.9.4.3
   Little K, 2018, EBIOMEDICINE, V38, P283, DOI 10.1016/j.ebiom.2018.11.029
   Llorian-Salvador M, 2020, INVEST OPHTH VIS SCI, V61, DOI 10.1167/iovs.61.11.35
   Meng XM, 2016, NAT REV NEPHROL, V12, P325, DOI 10.1038/nrneph.2016.48
   Morgan BP, 2015, NAT REV DRUG DISCOV, V14, P857, DOI 10.1038/nrd4657
   Nozaki M, 2006, P NATL ACAD SCI USA, V103, P2328, DOI 10.1073/pnas.0408835103
   Papadopoulos Z, 2020, CURR MED SCI, V40, P851, DOI 10.1007/s11596-020-2253-6
   Parsons N, 2019, MOL IMMUNOL, V108, P8, DOI 10.1016/j.molimm.2019.02.001
   Peng Q, 2019, KIDNEY INT, V96, P117, DOI 10.1016/j.kint.2019.01.039
   Peng Q, 2012, J AM SOC NEPHROL, V23, P1474, DOI 10.1681/ASN.2011111072
   Piao CM, 2018, EXP CELL RES, V366, P127, DOI 10.1016/j.yexcr.2018.03.009
   Sendler M, 2015, GASTROENTEROLOGY, V149, P765, DOI 10.1053/j.gastro.2015.05.012
   Shu DY, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21124271
   Shu DY, 2017, PROG RETIN EYE RES, V60, P44, DOI 10.1016/j.preteyeres.2017.08.001
   Subramanian H, 2011, MOL PHARMACOL, V79, P1005, DOI 10.1124/mol.111.071472
   Tang ZY, 2009, J AM SOC NEPHROL, V20, P593, DOI 10.1681/ASN.2008040434
   Veerappan A, 2013, DNA CELL BIOL, V32, P206, DOI 10.1089/dna.2013.2005
   Vergunst CE, 2007, RHEUMATOLOGY, V46, P1773, DOI 10.1093/rheumatology/kem222
   Voigt AP, 2020, EXP EYE RES, V200, DOI 10.1016/j.exer.2020.108204
   Voigt AP, 2019, P NATL ACAD SCI USA, V116, P24100, DOI 10.1073/pnas.1914143116
   Ward PA, 2009, J CELL MOL MED, V13, P4154, DOI 10.1111/j.1582-4934.2009.00893.x
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Wu D, 2020, INVEST OPHTH VIS SCI, V61, DOI 10.1167/iovs.61.14.29
   Yiu WH, 2018, NEPHROL DIAL TRANSPL, V33, P1323, DOI 10.1093/ndt/gfx336
NR 52
TC 0
Z9 0
U1 2
U2 2
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1742-2094
J9 J NEUROINFLAMM
JI J. Neuroinflamm.
PD JUL 14
PY 2022
VL 19
IS 1
AR 182
DI 10.1186/s12974-022-02546-3
PG 17
WC Immunology; Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Immunology; Neurosciences & Neurology
GA 2W6JD
UT WOS:000824627500001
PM 35831910
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Browning, AC
   O'Brien, JM
   Vieira, RV
   Gupta, R
   Nenova, K
AF Browning, Andrew C.
   O'Brien, Jill M.
   Vieira, Rute V.
   Gupta, Rajen
   Nenova, Kapka
TI Intravitreal Aflibercept for Retinal Angiomatous Proliferation: Results
   of a Prospective Case Series at 96 Weeks
SO OPHTHALMOLOGICA
LA English
DT Article
DE Neovascular age-related macular degeneration; Aflibercept; Retinal
   angiomatous proliferation
ID ENDOTHELIAL GROWTH-FACTOR; MACULAR DEGENERATION; PHOTODYNAMIC THERAPY;
   GEOGRAPHIC ATROPHY; RISK-FACTORS; FELLOW EYE; RANIBIZUMAB;
   NEOVASCULARIZATION; TRIAMCINOLONE; VERTEPORFIN
AB Introduction: Retinal angiomatous proliferation (RAP) is a subtype of neovascular age-related macular degeneration (nAMD). Untreated, the lesions are thought to be aggressive and lead to a poor visual outcome. Despite some limitations, studies reporting the treatment of RAP lesions with the intravitreal anti-VEGF drugs ranibizumab and bevacizumab have demonstrated variable but generally favourable responses. More recently, aflibercept has been licensed for the treatment of nAMD and may offer some advantages over other agents. We present the visual and anatomical outcomes at 96 weeks of patients with RAP lesions who were treated with intravitreal aflibercept, according to the pivotal VIEW study nAMD treatment protocol. Methods: This is a prospective study of treatment-naive patients with Reading Centre-graded RAP lesions. The patients received aflibercept every 8 weeks, after 3 initial monthly injections, up to and including week 48. During weeks 52-96, patients received injections at least every 12 weeks, with monthly evaluations for interim injections if they fulfilled the retreatment criteria. At each visit, best-corrected visual acuity (BCVA) and optical coherence tomography (OCT) central macular thickness (CMT) were measured. Results: Forty-six patients reached study completion at week 96. Mean BCVA had improved by 6.0 (standard deviation [SD] 7.9) and 4.8 (SD 7.4) ETDRS letters at 52 (p = 0.003) and 96 (p = 0.02) weeks, respectively, from a baseline of 57.3 (SD 12.0) letters. At 52- and 96-week time points, 45/46 (98%) and 41/46 (89%) of patients, respectively, had maintained their vision (<15 letters of BCVA lost). At the 96-week time point, 13/46 (28%) of patients had gained >= 15 letters and also demonstrated a mean reduction in CMT of 162 mu m (SD 106) (p = <0.0001), with 72% of maculae being fluid-free. Using univariate analysis, we found no significant difference between any of the visual outcome measures in this study and the pivotal VIEW study; the mean number of injections required and change in CMT were also similar. Conclusions: In this study, we present the 96-week results, of the largest series to date, of patients treated prospectively with aflibercept for RAP using the VIEW protocol. We show that they benefited from treatment to a degree similar to those with type 1 and 2 nAMD. (c) 2019 S. Karger AG, Basel
C1 [Browning, Andrew C.; O'Brien, Jill M.; Vieira, Rute V.; Nenova, Kapka] Royal Victoria Infirm, Newcastle Eye Ctr, Newcastle Upon Tyne NE1 4LP, Tyne & Wear, England.
   [Gupta, Rajen] Univ Aberdeen, Inst Appl Hlth Sci, Polwarth Bldg, Aberdeen, Scotland.
C3 Newcastle University - UK; University of Aberdeen
RP Browning, AC (通讯作者)，Royal Victoria Infirm, Newcastle Eye Ctr, Newcastle Upon Tyne NE1 4LP, Tyne & Wear, England.
EM andrew.browning@nuth.nhs.uk
CR Age-Related Eye Dis Study Res Grp, 2001, AM J OPHTHALMOL, V132, P668
   Atmani K, 2010, EYE, V24, P1193, DOI 10.1038/eye.2010.9
   Baek J, 2016, INVEST OPHTH VIS SCI, V57, P1500, DOI 10.1167/iovs.15-18837
   Boscia F, 2006, GRAEF ARCH CLIN EXP, V244, P1224, DOI 10.1007/s00417-005-0205-2
   Bottoni F, 2005, ARCH OPHTHALMOL-CHIC, V123, P1644, DOI 10.1001/archopht.123.12.1644
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Campa C, 2010, EYE, V24, P1585, DOI 10.1038/eye.2010.88
   Caramoy A, 2014, ACTA OPHTHALMOL, V92, P745, DOI 10.1111/aos.12437
   Cho HJ, 2015, AM J OPHTHALMOL, V159, P285, DOI 10.1016/j.ajo.2014.10.035
   Cho HJ, 2016, GRAEF ARCH CLIN EXP, V254, P23, DOI 10.1007/s00417-015-2993-3
   Daniel E, 2016, OPHTHALMOLOGY, V123, P609, DOI 10.1016/j.ophtha.2015.10.034
   De Bats F, 2016, RETINA-J RET VIT DIS, V36, P46, DOI 10.1097/IAE.0000000000000648
   Engelbert M, 2009, RETINA-J RET VIT DIS, V29, P1424, DOI 10.1097/IAE.0b013e3181bfbd46
   Freund KB, 2008, RETINA-J RET VIT DIS, V28, P201, DOI 10.1097/IAE.0b013e3181669504
   Gharbiya M, 2014, RETINA-J RET VIT DIS, V34, P298, DOI 10.1097/IAE.0b013e3182979e62
   Gross NE, 2005, RETINA-J RET VIT DIS, V25, P713, DOI 10.1097/00006982-200509000-00005
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Johnson TM, 2006, RETINA-J RET VIT DIS, V26, P765, DOI 10.1097/01.iae.0000244264.98642.af
   Kim JH, 2018, RETINA-J RET VIT DIS, V38, P2356, DOI 10.1097/IAE.0000000000001876
   Kim JH, 2013, AM J OPHTHALMOL, V155, P743, DOI 10.1016/j.ajo.2012.11.001
   Kuroiwa S, 2003, RETINA-J RET VIT DIS, V23, P417, DOI 10.1097/00006982-200306000-00027
   Lafaut BA, 2000, BRIT J OPHTHALMOL, V84, P1269, DOI 10.1136/bjo.84.11.1269
   Lanzetta P, 2018, ACTA OPHTHALMOL, V96, pE911, DOI 10.1111/aos.13751
   Lim JH, 2012, AM J OPHTHALMOL, V153, P678, DOI 10.1016/j.ajo.2011.09.013
   Matsumoto H, 2016, RETINA-J RET VIT DIS, V36, P2282, DOI 10.1097/IAE.0000000000001104
   Montero JA, 2009, BRIT J OPHTHALMOL, V93, P166, DOI 10.1136/bjo.2008.141903
   National Institute for health and care Excellence, 2013, AFL SOL INJ TREAT RE
   Oishi A, 2015, AM J OPHTHALMOL, V159, P853, DOI 10.1016/j.ajo.2015.01.018
   Parodi MB, 2013, ACTA OPHTHALMOL, V91, P267, DOI 10.1111/j.1755-3768.2011.02265.x
   Peduzzi P, 1996, J CLIN EPIDEMIOL, V49, P1373, DOI 10.1016/S0895-4356(96)00236-3
   Reche-Frutos J, 2011, EUR J OPHTHALMOL, V21, P783, DOI 10.5301/EJO.2011.6526
   Rouvas AA, 2010, EYE, V24, P1633, DOI 10.1038/eye.2010.134
   Rouvas AA, 2012, RETINA-J RET VIT DIS, V32, P1181, DOI 10.1097/IAE.0b013e318235d8ce
   Sawa M, 2014, RETINA-J RET VIT DIS, V34, P761, DOI 10.1097/01.iae.0000434566.57189.37
   Schmidt-Erfurth U, 2014, OPHTHALMOLOGY, V121, P193, DOI 10.1016/j.ophtha.2013.08.011
   Shin JY, 2014, RETINA-J RET VIT DIS, V34, P2359, DOI 10.1097/IAE.0000000000000225
   Shiragami C, 2007, RETINA-J RET VIT DIS, V27, P198, DOI 10.1097/01.iae.0000224938.61915.f0
   Singh RP, 2018, AM J OPHTHAL CLIN TR, V1, DOI 10.25259/AJOCT-2-2018
   Slakter JS, 2000, OPHTHALMOLOGY, V107, P742, DOI 10.1016/S0161-6420(00)00009-9
   The National Institute for Health and Care Excellence, RAN PEG TREATM AG RE
   Tsaousis KT, 2015, GRAEF ARCH CLIN EXP, V253, P663, DOI 10.1007/s00417-014-2835-8
   Viola F, 2009, RETINA-J RET VIT DIS, V29, P732, DOI 10.1097/IAE.0b013e3181a395cb
   Wegscheider BJ, 2007, OPHTHALMOLOGY, V114, P738, DOI 10.1016/j.ophtha.2006.07.048
   Yamazaki T, 2014, RETINA-J RET VIT DIS, V34, P1316, DOI 10.1097/IAE.0000000000000086
   Yannuzzi LA, 2001, RETINA-J RET VIT DIS, V21, P416, DOI 10.1097/00006982-200110000-00003
   Yannuzzi LA, 2008, RETINA-J RET VIT DIS, V28, P375, DOI 10.1097/IAE.0b013e3181619c55
   Zarubina AV, 2016, OPHTHALMOLOGY, V123, P1090, DOI 10.1016/j.ophtha.2015.12.034
NR 47
TC 3
Z9 3
U1 0
U2 2
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0030-3755
EI 1423-0267
J9 OPHTHALMOLOGICA
JI Ophthalmologica
PD OCT
PY 2019
VL 242
IS 4
BP 239
EP 246
DI 10.1159/000500203
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA JH7RG
UT WOS:000492965000007
PM 31163436
OA Green Submitted
DA 2022-11-30
ER

PT J
AU Terasaki, H
   Sonoda, S
   Kakiuchi, N
   Shiihara, H
   Yamashita, T
   Sakamoto, T
AF Terasaki, Hiroto
   Sonoda, Shozo
   Kakiuchi, Naoko
   Shiihara, Hideki
   Yamashita, Takehiro
   Sakamoto, Taiji
TI Ability of MultiColor scanning laser ophthalmoscope to detect
   non-glaucomatous retinal nerve fiber layer defects in eyes with retinal
   diseases
SO BMC OPHTHALMOLOGY
LA English
DT Article
DE Non-glaucomatous NFLD; Scanning laser ophthalmoscope; Spectralis;
   MultiColor
ID OPTICAL COHERENCE TOMOGRAPHY; PANRETINAL PHOTOCOAGULATION;
   DIABETIC-RETINOPATHY; GEOGRAPHIC ATROPHY; ANGIOGRAPHY; THICKNESS
AB PurposeTo compare the ability of ocular fundus images obtained by Spectralis MultiColor scanning laser ophthalmoscope (MC-SLO) to that obtained by conventional color fundus images (CF) in detecting non-glaucomatous nerve fiber layer defects (NFLDs).MethodsA cross-sectional, retrospective study. Patients with retinal diseases who had ocular examination with both the MC-SLO and CF instruments at the Kagoshima University from December 2016 to February 2017 were studied. Eyes that had NFLDs with non-glaucomatous optic discs were analyzed. The visibility of the NFLDs was classified into three grades: grade 0, not visible; grade 1, barely visible; and grade 2, clearly visible. The NFLD grade for blue, green, and red scanning lights of the MC-SLO, merged images with three wavelengths and the color and red-free images were determined by two ophthalmologists. These scores were compared by Steel-Dwass tests.ResultsThirty-one eyes of 26 patients with a mean age of 63.111.2years were studied. There were 14 eyes with diabetic retinopathy, 11 eyes with age-related macular degeneration, 3 eyes with a branch retinal vein occlusion, and 3 eyes with an epiretinal membrane/macular hole. Both the intra-rater (0.631-0.790) and inter-rater (0.637-0.733) agreements were good. NFLDs were detected by the blue wavelength in all cases and by green wavelength and merged wavelengths in 90.3% of the images. The mean NFLD grade was 1.58 +/- 0.49 for blue light images, 1.13 +/- 0.54 for green light images, 0.07 +/- 0.24 for red light images, and 1.16 +/- 0.56 for merged images. The NFLD score for blue wavelength was significantly higher than that for green and red wavelength images (P<0.05 and P<0.01) but not significantly higher than that for the merged images. NFLDs were detected in 12 eyes (38.7%) in the color images and 16 eyes (51.6%) in the red-free images. The NFLD score for the CF and the red-free image was 0.41 +/- 0.55 and 0.70 +/- 0.67 which is significantly lower than that of blue MC-SLO images.Conclusion The images obtained by MC-SLO are superior to that obtained by CF in detecting NFLDs in eyes with retinal diseases. We recommend MC-SLO imaging to screen for NFLDs in eyes with retinal diseases.
C1 [Terasaki, Hiroto; Sonoda, Shozo; Kakiuchi, Naoko; Shiihara, Hideki; Yamashita, Takehiro; Sakamoto, Taiji] Kagoshima Univ, Grad Sch Med & Dent Sci, Dept Ophthalmol, 8-35-1 Sakuragaoka, Kagoshima 8908520, Japan.
C3 Kagoshima University
RP Sakamoto, T (通讯作者)，Kagoshima Univ, Grad Sch Med & Dent Sci, Dept Ophthalmol, 8-35-1 Sakuragaoka, Kagoshima 8908520, Japan.
EM tsakamot@m3.kufm.kagoshima-u.ac.jp
OI Sakamoto, Taiji/0000-0003-0287-3801
FU JSPS KAKENHI [15H04996]
FX This work was supported in part by JSPS KAKENHI grant (15H04996). The
   funders had no role in study design, data collection and analysis,
   decision to publish, or preparation of the manuscript.
CR Baba T, 2014, J OPHTHALMOL, V2014, DOI 10.1155/2014/372589
   Ben Moussa N, 2015, BRIT J OPHTHALMOL, V99, P842, DOI 10.1136/bjophthalmol-2014-305643
   CHIHARA E, 1993, OPHTHALMOLOGY, V100, P1147
   Feng Henry L, 2017, Retin Cases Brief Rep, V11, P198, DOI 10.1097/ICB.0000000000000330
   Fleckenstein M, 2008, INVEST OPHTH VIS SCI, V49, P4137, DOI 10.1167/iovs.08-1967
   Hassenstein A, 2009, CLIN EXP OPHTHALMOL, V37, P130, DOI 10.1111/j.1442-9071.2009.02017.x
   Hood DC, 2007, PROG RETIN EYE RES, V26, P688, DOI 10.1016/j.preteyeres.2007.08.001
   Inoue M, 2009, GRAEF ARCH CLIN EXP, V247, P325, DOI 10.1007/s00417-008-0999-9
   JONAS JB, 1994, GRAEF ARCH CLIN EXP, V232, P759, DOI 10.1007/BF00184280
   Kashani AH, 2015, RETINA-J RET VIT DIS, V35, P2323, DOI 10.1097/IAE.0000000000000811
   Kim AY, 2016, INVEST OPHTH VIS SCI, V57, pOCT362, DOI 10.1167/iovs.15-18904
   Kim CS, 2014, RETINA-J RET VIT DIS, V34, P525, DOI 10.1097/IAE.0b013e3182a2e746
   Lee SB, 2013, RETINA-J RET VIT DIS, V33, P188, DOI 10.1097/IAE.0b013e318261a710
   Lim MC, 2009, ARCH OPHTHALMOL-CHIC, V127, P857, DOI 10.1001/archophthalmol.2009.135
   Muftuoglu IK, 2018, RETINA-J RET VIT DIS, V38, P352, DOI 10.1097/IAE.0000000000001525
   Na KI, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0186032
   Oray M, 2015, AM J OPHTHALMOL, V159, P475, DOI 10.1016/j.ajo.2014.11.029
   QUIGLEY HA, 1982, ARCH OPHTHALMOL-CHIC, V100, P807
   QUIGLEY HA, 1982, ARCH OPHTHALMOL-CHIC, V100, P135, DOI 10.1001/archopht.1982.01030030137016
   Saidha S, 2011, MULT SCLER J, V17, P1449, DOI 10.1177/1352458511418630
   Toto L, 2016, RETINA-J RET VIT DIS, V36, P1566, DOI 10.1097/IAE.0000000000000962
   Xu L, 2013, AM J HYPERTENS, V26, P511, DOI 10.1093/ajh/hps081
NR 22
TC 8
Z9 8
U1 0
U2 0
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1471-2415
J9 BMC OPHTHALMOL
JI BMC Ophthalmol.
PD DEC 17
PY 2018
VL 18
AR 324
DI 10.1186/s12886-018-0995-8
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA HE6SC
UT WOS:000453541600004
PM 30558574
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Wanek, J
   Zelkha, R
   Lim, JI
   Shahid, M
AF Wanek, Justin
   Zelkha, Ruth
   Lim, Jennifer I.
   Shahid, Mahnaz
TI Feasibility of a Method for En Face Imaging of Photoreceptor Cell
   Integrity
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID OPTICAL COHERENCE TOMOGRAPHY; MACULAR HOLE SURGERY; CENTRAL SEROUS
   CHORIORETINOPATHY; RETINAL VEIN OCCLUSION; VISUAL-ACUITY;
   RETINITIS-PIGMENTOSA; LAYER; THICKNESS; PATHOLOGY; OUTCOMES
AB PURPOSE: To report a method for en face imaging of the photoreceptor inner and outer segment junction by spectral-domain optical coherence tomography (SD OCT) and to describe findings in normal subjects and patients with various retinal diseases.
   DESIGN: Observational case series.
   METHODS: SD OCT images were acquired from 6 normal subjects (mean age, 44 +/- 11 years) and from 5 subjects with retinal diseases (mean age, 66 +/- 22 years). A customized high-density SD OCT volume scan was acquired on the retina. SD OCT B-scan images were segmented automatically to extract intensity data along the inner and outer segment junction. Data obtained from the raster B-scans were combined to generate an inner and outer segment en face image in a 4.4 x 4.4-mm retinal area centered on the fovea. The foveal-to-parafoveal mean intensity ratio was measured, and repeatability was determined. An infrared scanning laser ophthalmoscope image was acquired and was cropped to provide a field of view similar to the inner and outer segment en face image.
   RESULTS: Inner and outer segment en face images generated in normal subjects provided clear visualization of the retinal vasculature, matching the vascular network observed in the infrared scanning laser ophthalmoscope image. In normal subjects, the foveal-to-parafoveal mean intensity ratio was 0.88 +/- 0.06, and repeatability of measurements was, on average, 7%. In macular hole, a dark circular region was observed in the inner and outer segment en face image, indicative of photoreceptor cell loss. In age-related macular degeneration, the en face image displayed nonuniform texture corresponding to topographic variations in the inner and outer segment junction. In central serous retinopathy, areas of lower intensity were visible on the en face image corresponding to regions of prior neurosensory elevation. In cystoid macular edema, reduced intensity was present in the inner and outer segment en face image in areas with increased retinal thickness. In diabetic retinopathy, the inner and outer segment en face image displayed regions of reduced intensity resulting from edema, laser scars, or both.
   CONCLUSIONS: Detection of intensity abnormalities in the inner and outer segment en face image is useful for monitoring the integrity of photoreceptor cells in the course of disease progression and therapeutic intervention. (Am J Ophthalmol 2011;152:807-814. (C) 2011 by Elsevier Inc. All rights reserved.)
C1 [Wanek, Justin; Zelkha, Ruth; Lim, Jennifer I.; Shahid, Mahnaz] Univ Illinois, Dept Ophthalmol & Visual Sci, Chicago, IL 60612 USA.
C3 University of Illinois System; University of Illinois Chicago;
   University of Illinois Chicago Hospital
RP Shahid, M (通讯作者)，Univ Illinois, Dept Ophthalmol & Visual Sci, 1855 W Taylor St, Chicago, IL 60612 USA.
EM mahnshah@uic.edu
FU National Institutes of Health, Bethesda, Maryland [EY14275, EY01792];
   Department of Veterans Affairs, Washington, DC; Research to Prevent
   Blindness, Inc, New York, New York; Cless Family Foundation, Cless
   Family Foundation; NATIONAL EYE INSTITUTE [P30EY001792, R01EY014275]
   Funding Source: NIH RePORTER
FX PUBLICATION OF THIS ARTICLE WAS SUPPORTED BY GRANTS EY14275 (M.S.) AND
   EY01792 (UNIVERSITY OF ILLINOIS AT Chicago) from the National Institutes
   of Health, Bethesda, Maryland; the Department of Veterans Affairs,
   Washington, DC; a senior scientific investigator award (M.S.) and an
   unrestricted departmental grant from Research to Prevent Blindness, Inc,
   New York, New York; and the Cless Family Foundation Fund for Retina
   Research, Chicago, Illinois. The authors indicate no financial conflict
   of interest. Involved in Design of study (M.S.); Conduct of study (J.W.,
   M.S.); Collection, management, analysis, and interpretation of data
   (R.Z., J.I.L., J.W., M.S.); and preparation, review, or approval of the
   manuscript (J.W., J.I.L., M.S.). The research study was approved by in
   institutional review board of the University of Illinois at Chicago.
   Informed consent according to the tenets of the Declaration of Helsinki
   for participation in the research and Health Insurance Portability and
   Accountability Act compliance were obtained.
CR Costa RA, 2004, INVEST OPHTH VIS SCI, V45, P2399, DOI 10.1167/iovs.04-0155
   CUNHAVAZ J, 2010, OPHTHALMOLOGICA, V224, P1, DOI DOI 10.1159/000244458
   Drexler W, 2003, ARCH OPHTHALMOL-CHIC, V121, P695, DOI 10.1001/archopht.121.5.695
   Eandi CM, 2005, RETINA-J RET VIT DIS, V25, P417, DOI 10.1097/00006982-200506000-00004
   Ergun E, 2005, INVEST OPHTH VIS SCI, V46, P310, DOI 10.1167/iovs.04-0212
   Forooghian F, 2010, RETINA-J RET VIT DIS, V30, P63, DOI 10.1097/IAE.0b013e3181bd2c5a
   Gloesmann M, 2003, INVEST OPHTH VIS SCI, V44, P1696, DOI 10.1167/iovs.02-0654
   Gorczynska I, 2009, BRIT J OPHTHALMOL, V93, P603, DOI 10.1136/bjo.2007.136101
   Hangai M, 2007, OPHTHALMOLOGY, V114, P763, DOI 10.1016/j.ophtha.2006.07.055
   Hayashi H, 2009, AM J OPHTHALMOL, V148, P83, DOI 10.1016/j.ajo.2009.01.017
   Inoue M, 2009, GRAEF ARCH CLIN EXP, V247, P325, DOI 10.1007/s00417-008-0999-9
   Maheshwary AS, 2010, AM J OPHTHALMOL, V150, P63, DOI 10.1016/j.ajo.2010.01.039
   Michalewska Z, 2008, GRAEF ARCH CLIN EXP, V246, P823, DOI 10.1007/s00417-007-0764-5
   Oh J, 2010, INVEST OPHTH VIS SCI, V51, P1651, DOI 10.1167/iovs.09-4420
   Ota M, 2008, AM J OPHTHALMOL, V145, P273, DOI 10.1016/j.ajo.2007.09.019
   Piccolino FC, 2005, AM J OPHTHALMOL, V139, P87, DOI 10.1016/j.ajo.2004.08.037
   Rangaswamy NV, 2010, INVEST OPHTH VIS SCI, V51, P4213, DOI 10.1167/iovs.09-4945
   SANDBERG MA, 2005, INVEST OPHTH VIS S S, V46, pNIL93
   Sayanagi K, 2008, AM J OPHTHALMOL, V145, P902, DOI 10.1016/j.ajo.2008.01.011
   Schmidt-Erfurth U, 2005, INVEST OPHTH VIS SCI, V46, P3393, DOI 10.1167/iovs.05-0370
   Shin HJ, 2011, ACTA OPHTHALMOL, V89, pE35, DOI 10.1111/j.1755-3768.2010.02063.x
   Srinivasan VJ, 2006, OPHTHALMOLOGY, V113, P2054, DOI 10.1016/j.ophtha.2006.05.046
   Suh MH, 2009, AM J OPHTHALMOL, V147, P473, DOI 10.1016/j.ajo.2008.09.020
   Wakabayashi T, 2010, OPHTHALMOLOGY, V117, P1815, DOI 10.1016/j.ophtha.2010.01.017
   Wakabayashi T, 2010, ACTA OPHTHALMOL, V88, pE177, DOI 10.1111/j.1755-3768.2010.01926.x
   Wojtkowski M, 2009, OPT EXPRESS, V17, P4189, DOI 10.1364/OE.17.004189
   1991, OPHTHALMOLOGY S, V98, P741
NR 27
TC 20
Z9 20
U1 0
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-9394
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD NOV
PY 2011
VL 152
IS 5
BP 807
EP 814
DI 10.1016/j.ajo.2011.04.027
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 840BK
UT WOS:000296413100016
PM 21764030
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Park, CH
   Toth, CA
AF Park, CH
   Toth, CA
TI Macular translocation surgery with 360-degree peripheral retinectomy
   following ocular photodynamic therapy of choroidal neovascularization
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID RANDOMIZED CLINICAL-TRIALS; VISUAL-ACUITY; DEGENERATION; VERTEPORFIN;
   RETINOTOMY; SECONDARY
AB Purpose: To determine the visual outcomes of eyes that underwent macular translocation surgery with 360 degrees peripheral retinectomy and silicone oil tamponade (MTS360) following ocular photodynamic therapy (OPT) with verteporfin for subfoveal choroidal neovascularization (CNV) associated with age,related macular degeneration (ARMD).
   Design: Observational case series.
   Methods: A retrospective review of patients who underwent MTS360 with silicone oil tamponade from August 5, 1998 through December 1, 2002. Patients who had at least one episode of OPT with verteporfin before surgery were identified. The number of OPT session, best-corrected Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity, complications (including postoperative CNV, retinal detachment [RD]), the presence or absence of cystoid macular edema (CME) by optical coherence tomography (OCT) were recorded.
   Results: Eight eyes of eight patients were identified that fulfilled the inclusion criteria. All eyes had at least one episode of OPT (mean, 1.5 treatments). All of these patients at the time of MTS360 demonstrated continued visual loss following the most recent OPT session. The mean preoperative visual acuity was 56 letters. Four of the eight eyes demonstrated CME by OCT on preoperative examination. There were no significant postoperative complications other than one eye that had a successful repair of an RD. At 3 months, the mean visual acuity was 54 letters. At last follow-up (mean, 10 months), the mean visual acuity was 61 letters (P=.5). The final mean visual acuity change for the patients who had only one prior OPT (five eyes) was +10 letters. The mean final visual acuity change for the patients who had multiple OPT sessions (three eyes) was -1 letter. Three of the four eyes that had preoperative CME continued to demonstrate CME at last follow,up. Two eyes that had concurrent cataract extraction surgery with MTS360 did not develop CME. No eyes developed a recurrent CNV during the postoperative period.
   Conclusions: MTS360 with silicone oil tamponade for CNV associated with ARMD appears to be a viable option for patients who are continuing to lose vision in their better seeing eye following OPT with verteporfin. MTS360 appears to be effective in stabilizing vision, especially in patients who had previously undergone only one OPT session. Further studies are indicated to evaluate the efficacy of MTS360 in this current era of OPT.
C1 Duke Univ, Ctr Eye, Med Ctr, Dept Ophthalmol,Vitreoretinal Serv, Durham, NC 27710 USA.
C3 Duke University
RP Toth, CA (通讯作者)，Duke Univ, Ctr Eye, Med Ctr, Dept Ophthalmol,Vitreoretinal Serv, Box 3802, Durham, NC 27710 USA.
RI Toth, Cynthia/L-5534-2019; toth, cynthia a/F-5614-2011
OI Toth, Cynthia/0000-0002-2324-0854; 
FU NATIONAL EYE INSTITUTE [P30EY005722] Funding Source: NIH RePORTER; NEI
   NIH HHS [P30EY05722] Funding Source: Medline
CR Aisenbrey S, 2002, ARCH OPHTHALMOL-CHIC, V120, P451
   *AM AC OPHTH, 2000, OPHTHALMOLOGY, V107, P1015
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Bressler NM, 2002, ARCH OPHTHALMOL-CHIC, V120, P1307
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   DEJUAN E, 1998, AM J OPHTHALMOL, V125, P698
   Eckardt C, 1999, GRAEF ARCH CLIN EXP, V237, P313, DOI 10.1007/s004170050239
   Lai JC, 2002, ARCH OPHTHALMOL-CHIC, V120, P1317, DOI 10.1001/archopht.120.10.1317
   MACHEMER R, 1993, GRAEF ARCH CLIN EXP, V231, P635, DOI 10.1007/BF00921957
   MAGUIRE MG, 1994, ARCH OPHTHALMOL-CHIC, V112, P480
   Pieramici DJ, 2000, AM J OPHTHALMOL, V130, P419, DOI 10.1016/S0002-9394(00)00533-X
   Rogers AH, 2002, AM J OPHTHALMOL, V134, P566, DOI 10.1016/S0002-9394(02)01566-0
   Ting TD, 2002, ARCH OPHTHALMOL-CHIC, V120, P731
   Toth CA, 2001, RETINA-J RET VIT DIS, V21, P293, DOI 10.1097/00006982-200108000-00001
   TOTH CA, 1999, AGE RELATED MACULAR, P353
   Wolf S, 1999, GRAEF ARCH CLIN EXP, V237, P51, DOI 10.1007/s004170050194
NR 16
TC 16
Z9 16
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-9394
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD NOV
PY 2003
VL 136
IS 5
BP 830
EP 835
DI 10.1016/S0002-9394(03)00723-2
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 735ZW
UT WOS:000186146000006
PM 14597033
DA 2022-11-30
ER

PT J
AU Ibrahim, MN
   Bashar, SB
   Rasheed, MA
   Selvam, A
   Sant, V
   Sahel, JA
   Chhablani, J
   Vupparaboina, KK
   Jana, S
AF Ibrahim, M. N.
   Bashar, S. Bin
   Rasheed, M. A.
   Selvam, A.
   Sant, V.
   Sahel, J. A.
   Chhablani, J.
   Vupparaboina, K. K.
   Jana, S.
TI Volumetric quantification of choroid and Haller?s sublayer using OCT
   scans: An accurate and unified approach based on stratified smoothing
SO COMPUTERIZED MEDICAL IMAGING AND GRAPHICS
LA English
DT Article
DE Optical coherence tomography (OCT); Choroid layer; Haller ?s sublayer;
   Exponential enhancement; Volumetric smoothing; Tensor voting and linear
   regression
ID OPTICAL COHERENCE TOMOGRAPHY; LOCALLY WEIGHTED REGRESSION; AUTOMATIC
   SEGMENTATION; VASCULARITY INDEX; THICKNESS; IMAGES; VASCULOPATHY;
   VASCULATURE; FUTURE; LAYER
AB Background and objective: The choroid, a dense vascular structure in the posterior segment of the eye, maintains the health of the retina by supplying oxygen and nutrients, and assumes clinical significance in screening ocular diseases including age-related macular degeneration (AMD) and central serous chorioretinopathy (CSCR). As a technological assist, algorithmic estimation of choroidal biomarkers has been suggested based on sectional (B scan) optical coherence tomography (OCT) images. However, most such 2D estimation techniques are compute intensive, yet enjoy limited accuracy and have only been validated on OCT image datasets of healthy eyes. Not surprisingly, fine-scale analyses, including those involving Haller's sublayer, remain relatively rare and unsophisticated. Against this backdrop, we propose an efficient algorithm to quantify desired biomarkers with improved accuracy based on volume OCT scans. Specifically, we attempted an accurate, computationally light volumetric segmentation method involving stratified smoothing to detect choroid and Haller's sublayer. Methods: For detecting the various boundaries of the choroid and the Haller's sublayer, we propose a common volumetric method that performs suitable exponential enhancement and maintains smooth spatial continuity across 2D B-scans. Further, we achieve suitable volumetric smoothing by primarily deploying light-duty linear regression, and sparingly using compute-intensive tensor voting, and hence significantly reduce overall complexity. The proposed methodology is tested on five health and five diseased OCT volumes considering various metrics including volumetric Dice coefficient and corresponding quotient measures to facilitate comparison vis-`a-vis intra-observer repeatability. Results: On five healthy and five diseased OCT volumes, respectively, the proposed method for choroid segmentation recorded volumetric Dice coefficients of 93.53 % and 93.30 %, which closely approximate the respective reference observer repeatability values of 95.60 % and 95.49 %. In terms of related quotient measures, our method achieved more than 50 % improvement over a recently reported method. In detecting Haller's sublayer as well, our algorithm records statistical performance closely matching that of reference manual method. Conclusion: Advancing the state-of-the-art, the proposed volumetric segmentation, tested on both healthy and diseased datasets, demonstrated close match with the manual reference. Our method assumes significance in accurate screening of chorioretinal diseases including AMD, CSCR and pachychoroid. Further, it enables generating accurate training data for developing deep learning models for improved detection of choroid and Haller's sublayer.
C1 [Ibrahim, M. N.; Jana, S.] Indian Inst Technol Hyderabad, Dept Elect Engg, Hyderabad, Telangana, India.
   [Bashar, S. Bin] L V Prasad Eye Inst, Hyderabad, Telangana, India.
   [Rasheed, M. A.] Univ Waterloo, Sch Optometry & Vis Sci, Waterloo, ON, Canada.
   [Selvam, A.] Univ Pittsburgh, Sch Med, Pittsburgh, PA USA.
   [Sant, V.] Fox Chapel Area High Sch, Pittsburgh, PA USA.
   [Ibrahim, M. N.; Sahel, J. A.; Chhablani, J.; Vupparaboina, K. K.] Univ Pittsburgh, Dept Ophthalmol, Pittsburgh, PA USA.
   [Vupparaboina, K. K.] Univ Pittsburgh, Eye & Ear Inst, 203 Lothrop St,Suite 800, Pittsburgh, PA 15213 USA.
C3 Indian Institute of Technology System (IIT System); Indian Institute of
   Technology (IIT) - Hyderabad; L. V. Prasad Eye Institute; University of
   Waterloo; Pennsylvania Commonwealth System of Higher Education (PCSHE);
   University of Pittsburgh; Pennsylvania Commonwealth System of Higher
   Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth
   System of Higher Education (PCSHE); University of Pittsburgh
RP Vupparaboina, KK (通讯作者)，Univ Pittsburgh, Eye & Ear Inst, 203 Lothrop St,Suite 800, Pittsburgh, PA 15213 USA.
EM kkv@pitt.edu
FU NIH CORE Grant [P30 EY08098]; Eye and Ear Foundation of Pitts-burgh;
   Research to Prevent Blind-ness, New York, NY
FX This work was supported by NIH CORE Grant P30 EY08098 to the Department
   of Ophthalmology, the Eye and Ear Foundation of Pitts-burgh, and from an
   unrestricted grant from Research to Prevent Blind-ness, New York, NY.
CR Adabi S, 2018, J BIOMED OPT, V23, DOI 10.1117/1.JBO.23.1.016013
   Adhi M, 2013, CURR OPIN OPHTHALMOL, V24, P213, DOI 10.1097/ICU.0b013e32835f8bf8
   Agrawal R, 2016, RETINA-J RET VIT DIS, V36, P1646, DOI 10.1097/IAE.0000000000001040
   Al-Bander B, 2017, I C DEV ESYST ENG, P182, DOI 10.1109/DeSE.2017.37
   Alonso-Caneiro D, 2013, BIOMED OPT EXPRESS, V4, P2795, DOI 10.1364/BOE.4.002795
   Chai ZJ, 2020, I S BIOMED IMAGING, P1966, DOI 10.1109/ISBI45749.2020.9098346
   Chen Q, 2018, COMPUT METH PROG BIO, V158, P161, DOI 10.1016/j.cmpb.2017.11.002
   Cheng X., 2020, MEDICAL IMAGING 2020
   Chhablani J, 2014, SAUDI J OPHTHALMOL, V28, P123, DOI 10.1016/j.sjopt.2014.03.004
   Chiu SJ, 2010, OPT EXPRESS, V18, P19413, DOI 10.1364/OE.18.019413
   Chung SE, 2011, OPHTHALMOLOGY, V118, P840, DOI 10.1016/j.ophtha.2010.09.012
   CLEVELAND WS, 1979, J AM STAT ASSOC, V74, P829, DOI 10.2307/2286407
   CLEVELAND WS, 1988, J AM STAT ASSOC, V83, P596, DOI 10.2307/2289282
   Danesh H, 2014, COMPUT MATH METHOD M, V2014, DOI 10.1155/2014/479268
   Daoud B, 2019, COMPUT MED IMAG GRAP, V77, DOI 10.1016/j.compmedimag.2019.101644
   De Fauw J, 2018, NAT MED, V24, P1342, DOI 10.1038/s41591-018-0107-6
   DICE LR, 1945, ECOLOGY, V26, P297, DOI 10.2307/1932409
   Endo H, 2020, AM J OPHTHALMOL, V218, P68, DOI 10.1016/j.ajo.2020.05.036
   Esmaeelpour M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0099690
   Esmaeelpour M, 2011, INVEST OPHTH VIS SCI, V52, P5311, DOI 10.1167/iovs.10-6875
   Ferrara D, 2016, PROG RETIN EYE RES, V52, P130, DOI 10.1016/j.preteyeres.2015.10.002
   Foo VHX, 2020, BMJ OPEN DIAB RES CA, V8, DOI 10.1136/bmjdrc-2020-001295
   Gattani VS, 2016, COMPUT BIOL MED, V69, P52, DOI 10.1016/j.compbiomed.2015.11.015
   George N., 2019, 2019 10 INT C COMPUT, P1
   George N, 2019, BIOCYBERN BIOMED ENG, V39, P686, DOI 10.1016/j.bbe.2019.05.012
   Girard MJA, 2011, INVEST OPHTH VIS SCI, V52, P7738, DOI 10.1167/iovs.10-6925
   Gonzalez R. C., 2003, DIGITAL IMAGE PROCES
   Gour N, 2020, MULTIMED TOOLS APPL, V79, P15679, DOI 10.1007/s11042-019-07999-y
   Haeker M, 2007, PROC SPIE, V6512, DOI 10.1117/12.710231
   He F, 2021, COMPUT MATH METHOD M, V2021, DOI 10.1155/2021/8882801
   Hu ZH, 2013, INVEST OPHTH VIS SCI, V54, P1722, DOI 10.1167/iovs.12-10578
   Ibrahim MN, 2017, 2017 IEEE EMBS INTERNATIONAL CONFERENCE ON BIOMEDICAL & HEALTH INFORMATICS (BHI), P113, DOI 10.1109/BHI.2017.7897218
   Indraswari R, 2019, PATTERN RECOGN LETT, V125, P791, DOI 10.1016/j.patrec.2019.08.003
   Jonas JB, 2014, RETINA-J RET VIT DIS, V34, P1149, DOI 10.1097/IAE.0000000000000035
   Koh LHL, 2017, ACTA OPHTHALMOL, V95, pE597, DOI 10.1111/aos.13399
   Lee WK, 2016, RETINA-J RET VIT DIS, V36, pS73, DOI 10.1097/IAE.0000000000001346
   Lejoyeux R., 2021, SCI REP-UK, V11, P1
   Li DQ, 2020, CURR OPIN OPHTHALMOL, V31, P199, DOI 10.1097/ICU.0000000000000653
   Li MXZ, 2017, BIOMED OPT EXPRESS, V8, P3903, DOI 10.1364/BOE.8.003903
   Linton Trevor, 2022, TENS VOT FRAM
   Lu HQ, 2013, IEEE ENG MED BIO, P5869, DOI 10.1109/EMBC.2013.6610887
   Masood S, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-39795-x
   Mazzaferri J, 2017, SCI REP-UK, V7, DOI 10.1038/srep42112
   Mo J, 2017, BMJ OPEN, V7, DOI 10.1136/bmjopen-2016-013571
   Nasar M, 2019, IEEE ENG MED BIO, P2041, DOI 10.1109/EMBC.2019.8857183
   Ng DSC, 2016, EYE, V30, P901, DOI 10.1038/eye.2016.47
   Phasukkijwatana N, 2018, RETINA-J RET VIT DIS, V38, P1652, DOI 10.1097/IAE.0000000000001907
   PIZER SM, 1987, COMPUT VISION GRAPH, V39, P355, DOI 10.1016/S0734-189X(87)80186-X
   Rasheed MA, 2018, INDIAN J OPHTHALMOL, V66, P530, DOI 10.4103/ijo.IJO_1160_17
   Regatieri C.V., 2016, INT J RETINA VITR, V2, P1
   Sacconi R., 2020, GRAEFEAS ARCH CLIN E, P1
   Sahoo NK, 2021, DIAGNOSTICS, V11, DOI 10.3390/diagnostics11050861
   Sakurada Y, 2020, RETINA-J RET VIT DIS, V40, P657, DOI 10.1097/IAE.0000000000002635
   Schindelin J, 2012, NAT METHODS, V9, P676, DOI [10.1038/NMETH.2019, 10.1038/nmeth.2019]
   Schmitt JM, 1999, J BIOMED OPT, V4, P95, DOI 10.1117/1.429925
   Singh SR, 2019, INDIAN J OPHTHALMOL, V67, P1121, DOI 10.4103/ijo.IJO_1757_18
   Singh SR, 2019, SURV OPHTHALMOL, V64, P312, DOI 10.1016/j.survophthal.2018.11.002
   Sui XD, 2017, NEUROCOMPUTING, V237, P332, DOI 10.1016/j.neucom.2017.01.023
   Tan KA, 2016, ACTA OPHTHALMOL, V94, pE612, DOI 10.1111/aos.13044
   Tan R, 2018, OSLI RETINA, V49, P191, DOI 10.3928/23258160-20180221-07
   Ting DSW, 2016, AM J OPHTHALMOL, V164, P128, DOI 10.1016/j.ajo.2015.12.024
   Tsuji S, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-57788-z
   Uppugunduri SR, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0193324
   Velaga SB, 2020, RETINA-J RET VIT DIS, V40, P612, DOI 10.1097/IAE.0000000000002667
   Vupparaboina KK, 2016, 2016 INTERNATIONAL CONFERENCE ON SIGNAL AND INFORMATION PROCESSING (ICONSIP)
   Vupparaboina KK, 2015, COMPUT MED IMAG GRAP, V46, P315, DOI 10.1016/j.compmedimag.2015.09.008
   Wang C, 2017, IEEE J BIOMED HEALTH, V21, P1694, DOI 10.1109/JBHI.2017.2675382
   Wang D, 2021, AM J OPHTHALMOL, V227, P125, DOI 10.1016/j.ajo.2021.02.025
   Wu H, 2021, INVEST OPHTH VIS SCI, V62, DOI 10.1167/iovs.62.1.8
   Zhang H., 2019, ARXIV1912050902019
   Zhang HH, 2020, IEEE J BIOMED HEALTH, V24, P3408, DOI 10.1109/JBHI.2020.3023144
   Zhao JY, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-22019-z
   Zhou H, 2018, BIOMED OPT EXPRESS, V9, P6067, DOI 10.1364/BOE.9.006067
NR 73
TC 0
Z9 0
U1 6
U2 6
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0895-6111
EI 1879-0771
J9 COMPUT MED IMAG GRAP
JI Comput. Med. Imaging Graph.
PD JUL
PY 2022
VL 99
AR 102086
DI 10.1016/j.compmedimag.2022.102086
PG 20
WC Engineering, Biomedical; Radiology, Nuclear Medicine & Medical Imaging
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Engineering; Radiology, Nuclear Medicine & Medical Imaging
GA 2L7BD
UT WOS:000817171700002
PM 35717830
DA 2022-11-30
ER

PT J
AU Karacorlu, M
   Ersoz, MG
   Arf, S
   Hocaoglu, M
   Muslubas, IS
AF Karacorlu, Murat
   Ersoz, M. Giray
   Arf, Serra
   Hocaoglu, Mumin
   Muslubas, Isil Sayman
TI Long-term follow-up of pachychoroid pigment epitheliopathy and lesion
   characteristics
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE Central serous chorioretinopathy; Choroidal hyperpermeability;
   Microbreak; Pachychoroid neovasculopathy; Pachychoroid pigment
   epitheliopathy; Polypoidal choroidal vasculopathy
ID CENTRAL SEROUS CHORIORETINOPATHY; OPTICAL COHERENCE TOMOGRAPHY
AB AimsTo investigate conversion of pachychoroid pigment epitheliopathy (PPE) lesions and the development of other pachychoroid spectrum diseases in patients with PPE during follow-up.MethodsWe retrospectively reviewed medical records of 46 eyes of 44 patients who had a diagnosis of PPE and were followed up for at least 3years.ResultsEyes with PPE (17.4%) developed central serous chorioretinopathy (CSC), and none developed pachychoroid neovasculopathy or polypoidal choroidal vasculopathy. Of 74 initial PPE lesions, 21.6% were retinal pigment epithelium (RPE) thickening, 36.5% were pigment epithelium detachment (PED), and 41.9% were RPE elevation with microbreak appearance (REwM). Five (62.5%) of the eight initial PPE lesions progressing to CSC were REwM. Two developed directly from the REwM and three REwMs transformed to PED first, and then progressed to CSC. Three initial PEDs progressed to CSC. REwMs can also transform to PED and RPE thickening. No initial PEDs or RPE thickenings transformed to a REwM. Of the new PPE lesions, 60% were REwM, 26.7% were PEDs, and 13.3% were RPE thickening.ConclusionThe smallest PPE lesion that can be detected is a REwM of RPE. It may be the precursor lesion for pachychoroid spectrum disease, but further large-scale prospective studies are required.
C1 [Karacorlu, Murat; Ersoz, M. Giray; Arf, Serra; Hocaoglu, Mumin; Muslubas, Isil Sayman] Istanbul Retina Inst, Hakki Yeten Cad Unimed Ctr 19-7 Fulya Sisli, TR-34349 Istanbul, Turkey.
C3 Istanbul Retina Enstitusu
RP Karacorlu, M (通讯作者)，Istanbul Retina Inst, Hakki Yeten Cad Unimed Ctr 19-7 Fulya Sisli, TR-34349 Istanbul, Turkey.
EM mkaracorlu@gmail.com
RI Hocaoglu, Mumin/B-5999-2017; Ersöz, Mehmet Giray/B-4195-2019; Karaçorlu,
   Murat/AAF-7763-2022; Karaçorlu, Murat/AFK-0782-2022; muslubas, isil
   sayman/B-3948-2019
OI Ersöz, Mehmet Giray/0000-0002-2336-0696; muslubas, isil
   sayman/0000-0002-5464-8713
CR Cheung CMG, 2019, EYE, V33, P14, DOI 10.1038/s41433-018-0158-4
   Dansingani KK, 2016, RETINA-J RET VIT DIS, V36, P499, DOI 10.1097/IAE.0000000000000742
   Ersoz MG, 2018, RETINA-J RET VIT DIS, V38, P1668, DOI 10.1097/IAE.0000000000001773
   Ersoz MG, 2018, BRIT J OPHTHALMOL, V102, P473, DOI 10.1136/bjophthalmol-2017-310724
   Ersoz MG, 2018, RETINA-J RET VIT DIS, V38, P957, DOI 10.1097/IAE.0000000000001655
   Ersoz MG, 2017, SURV OPHTHALMOL, V62, P493, DOI 10.1016/j.survophthal.2017.03.004
   Gallego-Pinazo Roberto, 2014, Med Hypothesis Discov Innov Ophthalmol, V3, P111
   GOLDSTEIN BG, 1987, BRIT J OPHTHALMOL, V71, P676, DOI 10.1136/bjo.71.9.676
   Gupta V, 2010, EYE, V24, P595, DOI 10.1038/eye.2009.193
   Ober Michael D, 2007, Retin Cases Brief Rep, V1, P271, DOI 10.1097/01.iae.0000243067.71211.88
   Pang CE, 2015, RETINA-J RET VIT DIS, V35, P1, DOI 10.1097/IAE.0000000000000331
   Roberts P, 2016, INVEST OPHTH VIS SCI, V57, P1595, DOI 10.1167/iovs.15-18494
   van Dijk EHC, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000003457
   Von Ruckmann A, 2002, AM J OPHTHALMOL, V133, P780, DOI 10.1016/S0002-9394(02)01428-9
   Warrow DJ, 2013, RETINA-J RET VIT DIS, V33, P1659, DOI 10.1097/IAE.0b013e3182953df4
NR 15
TC 13
Z9 13
U1 0
U2 3
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0721-832X
EI 1435-702X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD DEC
PY 2018
VL 256
IS 12
BP 2319
EP 2326
DI 10.1007/s00417-018-4144-0
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA GZ4RZ
UT WOS:000449389300006
PM 30238190
DA 2022-11-30
ER

PT J
AU Holtz, JK
   Larsson, JME
   Hansen, MS
   van Dijk, EHC
   Subhi, Y
AF Holtz, Jeppe K.
   Larsson, Janni M. E.
   Hansen, Michael S.
   van Dijk, Elon H. C.
   Subhi, Yousif
TI Pachychoroid Spectrum Diseases in Patients with Cushing's Syndrome: A
   Systematic Review with Meta-Analyses
SO JOURNAL OF CLINICAL MEDICINE
LA English
DT Review
DE central serous chorioretinopathy; Cushing's disease; meta-analysis;
   pachychoroid spectrum; polypoidal choroidal vasculopathy; systematic
   review
ID POLYPOIDAL CHOROIDAL VASCULOPATHY; CENTRAL SEROUS CHORIORETINOPATHY;
   CELLS
AB Cushing's syndrome is a rare disease with an endogenous cause of excess cortisol secretion. More evidence substantially links cortisol levels to the pachychoroid spectrum diseases. In this systematic review and meta-analysis, we summarize available evidence on pachychoroid spectrum diseases in patients with Cushing's syndrome. We performed a systematic literature search in 11 databases on 21 May 2022. Studies were considered eligible if they performed retinal examination of a consecutive group of patients with Cushing's syndrome using optical coherence tomography (OCT) scans. We extracted data on subfoveal choroidal thickness in patients with Cushing's syndrome compared to matched controls. We also extracted data on the prevalence of pachychoroid pigment epitheliopathy (PPE), central serous chorioretinopathy (CSC), and polypoidal choroidal vasculopathy (PCV). We identified six eligible studies with a total of 159 patients with Cushing's syndrome. On average, patients with Cushing's syndrome have 49.5 mu m thicker subfoveal choroidal thickness compared to matched healthy individuals. Pachychoroid spectrum diseases were relatively common in these patients: PPE in 20.8%, CSC in 7.7%, and PCV in 2.8%. We conclude that there should be low threshold to recommend ophthalmic examination to patients with Cushing's syndrome, and that a macular OCT is recommended during this examination.
C1 [Holtz, Jeppe K.] Odense Univ Hosp, Dept Ophthalmol, DK-5000 Odense, Denmark.
   [Holtz, Jeppe K.] Odense Univ Hosp, Dept Otolaryngol, DK-5000 Odense, Denmark.
   [Larsson, Janni M. E.; Hansen, Michael S.; Subhi, Yousif] Rigshospitalet, Dept Ophthalmol, DK-2600 Glostrup, Denmark.
   [van Dijk, Elon H. C.] Leiden Univ, Dept Ophthalmol, Med Ctr, NL-2300 RC Leiden, Netherlands.
   [Subhi, Yousif] Univ Southern Denmark, Dept Clin Res, DK-5230 Odense, Denmark.
C3 University of Southern Denmark; Odense University Hospital; University
   of Southern Denmark; Odense University Hospital; Rigshospitalet; Leiden
   University; Leiden University Medical Center (LUMC); Leiden University -
   Excl LUMC; University of Southern Denmark
RP Subhi, Y (通讯作者)，Rigshospitalet, Dept Ophthalmol, DK-2600 Glostrup, Denmark.; Subhi, Y (通讯作者)，Univ Southern Denmark, Dept Clin Res, DK-5230 Odense, Denmark.
EM jeppe.holtz@rsyd.dk; janni.margareta.ezban.larsson@regionh.dk;
   michael.stormly.hansen@regionh.dk; e.h.c.van_dijk@lumc.nl;
   ysubhi@gmail.com
RI Subhi, Yousif/ABG-6330-2020
OI Subhi, Yousif/0000-0001-6620-5365; van Dijk, Elon/0000-0002-6351-7942
CR Abalem MF, 2016, FRONT ENDOCRINOL, V7, DOI 10.3389/fendo.2016.00154
   Azad AD, 2021, OPHTHALMOLOGY, V128, P121, DOI [10.1016/j.ophtha.2020.06.056, 10.1016/j.opatha.2020.06.056]
   Barendregt JJ, 2013, J EPIDEMIOL COMMUN H, V67, P974, DOI 10.1136/jech-2013-203104
   Borgersen NJ, 2021, ACTA OPHTHALMOL, V99, P470, DOI 10.1111/aos.14655
   Borooah S, 2021, ACTA OPHTHALMOL, V99, pE806, DOI 10.1111/aos.14683
   Brinks J, 2022, PROG RETIN EYE RES, V87, DOI 10.1016/j.preteyeres.2021.100994
   Brinks J, 2022, J CLIN ENDOCR METAB, V107, P512, DOI 10.1210/clinem/dgab670
   Brinks J, 2022, ACTA OPHTHALMOL, V100, P946, DOI 10.1111/aos.15112
   Brinks J, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-82536-2
   Cheung CMG, 2019, EYE, V33, P14, DOI 10.1038/s41433-018-0158-4
   Cheung CMG, 2015, GRAEF ARCH CLIN EXP, V253, P2075, DOI 10.1007/s00417-015-2933-2
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Eymard P, 2021, ACTA OPHTHALMOL, V99, P533, DOI 10.1111/aos.14664
   Hakami OA, 2021, BEST PRACT RES CL EN, V35, DOI 10.1016/j.beem.2021.101521
   Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   Karaca C, 2017, RETINA-J RET VIT DIS, V37, P536, DOI 10.1097/IAE.0000000000001198
   Lassandro NV, 2022, GRAEF ARCH CLIN EXP, V260, P1535, DOI 10.1007/s00417-021-05524-2
   Li Y, 2016, ACTA OPHTHALMOL, V94, P386, DOI 10.1111/aos.12891
   Limumpornpetch P, 2022, J CLIN ENDOCR METAB, V107, P2377, DOI 10.1210/clinem/dgac265
   Nieman LK, 2015, EUR J ENDOCRINOL, V173, pM33, DOI 10.1530/EJE-15-0464
   Spaide RF, 2022, PROG RETIN EYE RES, V86, DOI 10.1016/j.preteyeres.2021.100973
   Subhi Y, 2019, INVEST OPHTH VIS SCI, V60, P2583, DOI 10.1167/iovs.19-26882
   Subhi Y, 2017, CASE REP OPHTHALMOL, V2017, DOI 10.1155/2017/9650287
   Subhi Y, 2016, AGEING RES REV, V29, P42, DOI 10.1016/j.arr.2016.05.013
   Van Dijk E.H.C., EUROPEAN PREVL UNPUB
   van Haalen FM, 2015, EUR J ENDOCRINOL, V172, pR143, DOI 10.1530/EJE-14-0556
   Wang EQ, 2019, RETINA-J RET VIT DIS, V39, P408, DOI 10.1097/IAE.0000000000001956
   Zeng Xiantao, 2015, J Evid Based Med, V8, P2, DOI 10.1111/jebm.12141
   Zhou XY, 2022, ACTA OPHTHALMOL, V100, pE1729, DOI 10.1111/aos.15194
NR 29
TC 0
Z9 0
U1 1
U2 1
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2077-0383
J9 J CLIN MED
JI J. Clin. Med.
PD AUG
PY 2022
VL 11
IS 15
AR 4437
DI 10.3390/jcm11154437
PG 13
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA 3R7OO
UT WOS:000839097700001
PM 35956052
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Xu, L
   Cao, WF
   Wang, YX
   Chen, CX
   Jonas, JB
AF Xu, Liang
   Cao, Wei Fang
   Wang, Ya Xing
   Chen, Chang Xi
   Jonas, Jost B.
TI Anterior chamber depth and chamber angle and their associations with
   ocular and general parameters: The Beijing eye study
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID OPTICAL COHERENCE TOMOGRAPHY; CENTRAL CORNEAL THICKNESS; HYPERTENSION
   TREATMENT; CLOSURE GLAUCOMA; NERVE HEAD; SEGMENT; POPULATION; PERIMETRY;
   SYSTEM; COUNT
AB PURPOSE: To investigate the normative data of anterior chamber depth (ACD) and angle width and their associations in Chinese adults.
   DESIGN: Population,based study.
   METHODS: The Beijing Eye Study 2006 included 3,251 subjects (73.3%) (aged 45+ years) out of 4,439 subjects who participated in the 2001 survey and who returned for reexamination. The subjects underwent an ophthalmologic examination including measurement of the anterior chamber dimensions by slit-lamp,based optical coherence tomography (OCT).
   RESULTS: Out of the 3,251 subjects, OCT measurements were available for 2,985 subjects (91.8%). Mean ACD measured 2.42 +/- L 034 mm and the mean anterior chamber angle (ACA) was 38.3 +/- 16.3 degrees. In multivariate analysis, a shallow chamber depth was significantly associated with age (P < .001), hyperopic refractive error (P < .001), female gender (P < .001), short body stature (P =.003), nuclear cataract (P =.03), central corneal thickness [CCT] (P < .001), large optic disk (P <.001), and presence of chronic angle-closure glaucoma (P <.001). Correspondingly, a narrow ACA was associated with age (P <.001), female gender (P <.001), hyperopia (P <.001), nuclear cataract (P <.001), short body stature (P =.001), large optic disk (P <.001), and angle,closure glaucoma (P <.001). Chamber depth and angle width were not associated with presence of age-related maculopathy and diabetic retinopathy.
   CONCLUSIONS: A shallow anterior chamber and a narrow chamber angle in Chinese adults are associated with age, female gender, hyperopia, nuclear cataract, small optic disk, short body stature, CCT, and chronic angle,closure glaucoma. These data may be helpful to explain anatomic relationships of the anterior segment of the eye, and to elucidate risk factors of angle-closure glaucoma.
C1 [Xu, Liang; Cao, Wei Fang; Wang, Ya Xing; Chen, Chang Xi; Jonas, Jost B.] Capital Med Univ, Beijing Tongren Hosp, Beijing Inst Ophthalmol, Beijing 100005, Peoples R China.
   [Jonas, Jost B.] Univ Heidelberg, Fac Clin Med Mannheim, Dept Ophthalmol, D-6800 Mannheim, Germany.
C3 Capital Medical University; Ruprecht Karls University Heidelberg
RP Jonas, JB (通讯作者)，Capital Med Univ, Beijing Tongren Hosp, Beijing Inst Ophthalmol, 17 Houhou St,Chong Wen Men, Beijing 100005, Peoples R China.
EM Jost.Jonas@augen.ma.uni-heidelberg.de
RI wang, YA XING/K-9671-2016
OI wang, YA XING/0000-0003-2749-7793
CR Brandt JD, 2001, OPHTHALMOLOGY, V108, P1779, DOI 10.1016/S0161-6420(01)00760-6
   Congdon NG, 1997, OPHTHALMOLOGY, V104, P1489, DOI 10.1016/S0161-6420(97)30112-2
   Devereux JG, 2000, ARCH OPHTHALMOL-CHIC, V118, P257
   Gordon MO, 2002, ARCH OPHTHALMOL-CHIC, V120, P714
   Herndon LW, 2004, ARCH OPHTHALMOL-CHIC, V122, P17, DOI 10.1001/archopht.122.1.17
   Jonas J B, 1994, Ger J Ophthalmol, V3, P179
   JONAS JB, 1989, INVEST OPHTH VIS SCI, V30, P908
   Jonas JB, 1999, SURV OPHTHALMOL, V43, P293, DOI 10.1016/S0039-6257(98)00049-6
   JONAS JB, 1992, INVEST OPHTH VIS SCI, V33, P2012
   Kassoff A, 2001, AM J OPHTHALMOL, V131, P167
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Koop N, 1997, OPHTHALMOLOGE, V94, P481, DOI 10.1007/s003470050143
   Leung CKS, 2005, INVEST OPHTH VIS SCI, V46, P891, DOI 10.1167/iovs.04-1107
   Medeiros FA, 2003, OPHTHALMOLOGY, V110, P1903, DOI 10.1016/S0161-6420(03)00734-6
   Nolan WP, 2007, OPHTHALMOLOGY, V114, P33, DOI 10.1016/j.ophtha.2006.05.073
   PANDAJONAS S, 1994, OPHTHALMOLOGY, V101, P519
   Radhakrishnan S, 2001, ARCH OPHTHALMOL-CHIC, V119, P1179, DOI 10.1001/archopht.119.8.1179
   Radhakrishnan Sunita, 2005, Ophthalmol Clin North Am, V18, P375, DOI 10.1016/j.ohc.2005.05.007
   Ramrattan RS, 1999, OPHTHALMOLOGY, V106, P1588, DOI 10.1016/S0161-6420(99)90457-8
   Thomas D, 2001, AM J OPHTHALMOL, V131, P734, DOI 10.1016/S0002-9394(01)00837-6
   VANHERICK W, 1969, AM J OPHTHALMOL, V68, P626, DOI 10.1016/0002-9394(69)91241-0
   Wirbelauer C, 2005, ARCH OPHTHALMOL-CHIC, V123, P179, DOI 10.1001/archopht.123.2.179
   Xu L, 2007, ACTA OPHTHALMOL SCAN, V85, P914, DOI 10.1111/j.1600-0420.2007.00966.x
   Xu L, 2007, OPHTHALMOLOGY, V114, P121, DOI 10.1016/j.ophtha.2006.05.071
   Xu LA, 2007, OPHTHALMOLOGY, V114, P216, DOI 10.1016/j.ophtha.2006.06.050
NR 25
TC 169
Z9 178
U1 0
U2 8
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-9394
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD MAY
PY 2008
VL 145
IS 5
BP 929
EP 936
DI 10.1016/j.ajo.2008.01.004
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 292YU
UT WOS:000255302800026
PM 18336789
DA 2022-11-30
ER

PT J
AU Zhang, J
   Wang, J
   Zheng, L
   Wang, M
   Lu, Y
   Li, Z
   Lian, C
   Mao, S
   Hou, X
   Li, S
   Xu, J
   Tian, H
   Jin, C
   Gao, F
   Zhang, J
   Wang, F
   Li, W
   Lu, L
   Xu, GT
AF Zhang, J.
   Wang, J.
   Zheng, L.
   Wang, M.
   Lu, Y.
   Li, Z.
   Lian, C.
   Mao, S.
   Hou, X.
   Li, S.
   Xu, J.
   Tian, H.
   Jin, C.
   Gao, F.
   Zhang, J.
   Wang, F.
   Li, W.
   Lu, L.
   Xu, G. -T.
TI miR-25 Mediates Retinal Degeneration Via Inhibiting ITGAV and PEDF in
   Rat
SO CURRENT MOLECULAR MEDICINE
LA English
DT Article
DE Retinal degeneration; miR-25; oxidative-stress; RPE cell; ITGAV; PEDF;
   STAT3
ID EPITHELIUM-DERIVED FACTOR; OUTER SEGMENT PHAGOCYTOSIS;
   PIGMENT-EPITHELIUM; OXIDATIVE STRESS; MACULAR DEGENERATION;
   NEUROPROTECTIN D1; SODIUM IODATE; ALPHA-V-BETA-5 INTEGRIN;
   ERYTHROPOIETIN GENE; CANCER CELLS
AB Background: Age-related macular degeneration (AMD) is the main cause of irreversible blindness in the elderly. Oxidative stress in retinal pigment epithelium (RPE) is deemed to play a pivotal role in the pathogenesis of AMD. miR-25 functions as an essential modulator in response to oxidative-stress in several cell types, but its function in RPE cells is poorly understood.
   Objective: To explore the roles of miR-25 in RPE cells and in the development of AMD.
   Methods: A rat model of retinal degeneration was induced by sodium iodate (SI). Subretinal injection of antagomiR-25 was performed for the intervention while the scramble as control. Visual responses were recorded with Electroretinogram (ERG). TUNEL assay was performed to detect apoptosis. Phagosome quantification in vivo was performed to evaluate RPE cell function. Oxygen-glucose deprivation treatment was performed to mimic in vitro oxidative stress. Gene expression at mRNA level and protein level were performed by quantitative polymerase chain reaction (qPCR) and Western Blot, respectively. The pigment epithelium derived factor (PEDF) level in the cultured medium was measured by Enzyme-linked immunosorbent assay (ELISA). The interaction between miR-25 and integrin alpha V (IGTAV)/PEDF 3'UTR was examined by dual luciferase assay. Chromatin immunoprecipitation (ChIP) assay was performed to examine its transcriptional regulation of miR-25.
   Results: Oxidative stress up-regulated miR-25 in RPE cells in very early stage, accompanied by decreased phagocytosis and reduced growth factor secretion in those cells. Such changes preceded RPE cell apoptosis and visual impairment in the SI-treated rats. Furthermore, antagomiR-25 intervention effectively rescued RPE cells from degeneration in such model. The increased miR-25 was confirmed to mediate RPE degeneration through direct targeting IGTAV and PEDF. On the other hand, upstream, miR-25 was found to be up-regulated by STAT3 signaling under oxidative stress in both in vivo and in vitro models.
   Conclusion: Our findings demonstrate that, in SI-treated rats, oxidative stress activates STAT3 signaling which up-regulates miR-25 expression, in a very early stage. The increased miR-25 then inhibits ITGAV and PEDF expressions, resulting in RPE phagocytosis dysfunction and then RPE apoptosis and visual impairment as observed in patients with AMD. These findings lead us to a better understanding of AMD pathogenesis, and suggest that miR-25 could be a potential therapeutic target for oxidative stress related RPE diseases, like AMD.
C1 [Zhang, J.; Wang, J.; Lu, Y.; Li, Z.; Lian, C.; Xu, J.; Tian, H.; Jin, C.; Gao, F.; Zhang, J.; Wang, F.; Lu, L.; Xu, G. -T.] Tongji Univ, Sch Med, Shanghai Peoples Hosp 10, Dept Ophthalmol, 1239 Siping Rd,Med Sch Bldg,Room 623, Shanghai 200092, Peoples R China.
   [Zhang, J.; Wang, J.; Lu, Y.; Li, Z.; Lian, C.; Xu, J.; Tian, H.; Jin, C.; Gao, F.; Zhang, J.; Wang, F.; Lu, L.; Xu, G. -T.] Tongji Univ, Sch Med, Tongji Eye Inst, 1239 Siping Rd,Med Sch Bldg,Room 623, Shanghai 200092, Peoples R China.
   [Zhang, J.; Wang, J.; Zheng, L.; Wang, M.; Lu, Y.; Li, Z.; Lian, C.; Mao, S.; Hou, X.; Li, S.; Xu, J.; Tian, H.; Jin, C.; Gao, F.; Zhang, J.; Wang, F.; Lu, L.; Xu, G. -T.] Tongji Univ, Sch Med, Dept Regenerat Med, Lab Clin Visual Sci, Shanghai, Peoples R China.
   [Zhang, J.; Wang, J.; Zheng, L.; Wang, M.; Lu, Y.; Li, Z.; Lian, C.; Mao, S.; Hou, X.; Li, S.; Xu, J.; Tian, H.; Jin, C.; Gao, F.; Zhang, J.; Wang, F.; Lu, L.; Xu, G. -T.] Tongji Univ, Sch Med, Stem Cell Res Ctr, Shanghai, Peoples R China.
   [Zhang, J.; Xu, G. -T.] Tongji Univ, Sch Med, Dept Physiol & Pharmacol, 1239 Siping Rd,Med Sch Bldg,Room 623, Shanghai 200092, Peoples R China.
   [Li, W.] Drexel Univ, Coll Med, Dept Ophthalmol, Philadelphia, PA 19104 USA.
   [Xu, G. -T.] Tongji Univ, Collaborat Innovat Ctr Brain Sci, Shanghai 200092, Peoples R China.
C3 Tongji University; Tongji University; Tongji University; Tongji
   University; Tongji University; Drexel University; Tongji University
RP Xu, GT (通讯作者)，Tongji Univ, Sch Med, Shanghai Peoples Hosp 10, Dept Ophthalmol, 1239 Siping Rd,Med Sch Bldg,Room 623, Shanghai 200092, Peoples R China.; Xu, GT (通讯作者)，Tongji Univ, Sch Med, Tongji Eye Inst, 1239 Siping Rd,Med Sch Bldg,Room 623, Shanghai 200092, Peoples R China.; Xu, GT (通讯作者)，Tongji Univ, Sch Med, Dept Physiol & Pharmacol, 1239 Siping Rd,Med Sch Bldg,Room 623, Shanghai 200092, Peoples R China.; Lu, L (通讯作者)，Tongji Univ, Sch Med, Dept Regenerat Med, Div Biochem & Mol Biol,Lab Clin Visual Sci, 1239 Siping Rd,Med Sch Bldg,Room 708, Shanghai 200092, Peoples R China.; Lu, L (通讯作者)，Tongji Univ, Sch Med, Tongji Eye Inst, 1239 Siping Rd,Med Sch Bldg,Room 708, Shanghai 200092, Peoples R China.
EM lulixia@tongji.edu.cn; gtxu@tongji.edu.cn
FU Ministry of Science and Technology of China [2017YFA0104100,
   2016YFA0101302]; National Natural Science Foundation [30700401,
   81100674, 91019929, 81570852, 31201084, 31201108, 81370999]; Shanghai
   Pujiang Program [15PJ1408700]; Shanghai Municipal Commission of Health
   and Family Planning project [20134222, 201640229]; Shanghai Science and
   Technology Committee Grant [17ZR1431300, 12ZR1450700]; Shanghai East
   Hospital [ZJ2014-ZD-002]
FX We would like to thank Prof. Siguang Li (TongJi University, Shanghai,
   China) for providing psiCHECK plasmid and valuable suggestions, and Dr.
   Xiujuan Shi (TongJi University, Shanghai, China) for kind technical
   support. This work was supported by the grants from the Ministry of
   Science and Technology of China (2017YFA0104100, 2016YFA0101302) and
   National Natural Science Foundation (30700401, 81100674, 91019929,
   81570852, 31201084, 31201108 and 81370999), Shanghai Pujiang Program
   (15PJ1408700), Shanghai Municipal Commission of Health and Family
   Planning project (20134222, 201640229), Shanghai Science and Technology
   Committee Grant (17ZR1431300, 12ZR1450700), as well as the grant from
   Shanghai East Hospital ZJ2014-ZD-002.
CR Baek D, 2008, NATURE, V455, P64, DOI 10.1038/nature07242
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Bhutto IA, 2006, EXP EYE RES, V82, P99, DOI 10.1016/j.exer.2005.05.007
   BOK D, 1971, J CELL BIOL, V49, P664, DOI 10.1083/jcb.49.3.664
   Boulton M, 2001, EYE, V15, P384, DOI 10.1038/eye.2001.141
   Brett JO, 2011, AGING-US, V3, P108, DOI 10.18632/aging.100285
   Cao W, 1999, J NEUROSCI RES, V57, P789, DOI 10.1002/(SICI)1097-4547(19990915)57:6<789::AID-JNR4>3.0.CO;2-M
   Carido M, 2014, INVEST OPHTH VIS SCI, V55, P5431, DOI 10.1167/iovs.14-14325
   CHANG CW, 1991, CURR EYE RES, V10, P1081, DOI 10.3109/02713689109020348
   Datta S, 2017, PROG RETIN EYE RES, V60, P201, DOI 10.1016/j.preteyeres.2017.03.002
   Enzmann V, 2006, EXP EYE RES, V82, P441, DOI 10.1016/j.exer.2005.08.002
   Falk G, 1995, BASIC AND CLINICAL PERSPECTIVES IN VISION RESEARCH, P95
   Finnemann SC, 2003, ADV EXP MED BIOL, V533, P337
   Finnemann SC, 2003, EMBO J, V22, P4143, DOI 10.1093/emboj/cdg416
   Gibbs D, 2003, P NATL ACAD SCI USA, V100, P6481, DOI 10.1073/pnas.1130432100
   Guan Y, 2013, CURR MOL MED, V13, P1419
   Haque R, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042542
   Holekamp NM, 2002, AM J OPHTHALMOL, V134, P220, DOI 10.1016/S0002-9394(02)01549-0
   HOOD DC, 1990, VISUAL NEUROSCI, V5, P379, DOI 10.1017/S0952523800000468
   Hynes RO, 2002, CELL, V110, P673, DOI 10.1016/S0092-8674(02)00971-6
   Kanan Y, 2015, CELL MOL NEUROBIOL, V35, P197, DOI 10.1007/s10571-014-0111-4
   Kiuchi K, 2002, CURR EYE RES, V25, P373, DOI 10.1076/ceyr.25.6.373.14227
   LAVAIL MM, 1976, SCIENCE, V194, P1071, DOI 10.1126/science.982063
   Li Q, 2013, CANCER LETT, V335, P168, DOI 10.1016/j.canlet.2013.02.029
   Li XJ, 2014, MED ONCOL, V31, DOI 10.1007/s12032-013-0781-7
   Liang FQ, 2003, EXP EYE RES, V76, P397, DOI 10.1016/S0014-4835(03)00023-X
   Lin H, 1998, INVEST OPHTH VIS SCI, V39, P1703
   Lin HJ, 2011, INVEST OPHTH VIS SCI, V52, P6308, DOI 10.1167/iovs.10-6632
   Ling SK, 2013, CELL SIGNAL, V25, P2840, DOI 10.1016/j.cellsig.2013.08.039
   Liu Jie, 2014, Shengli Xuebao, V66, P489
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   LOLLEY RN, 1976, EXP EYE RES, V22, P477, DOI 10.1016/0014-4835(76)90185-8
   Lu J, 2012, GENOME RES, V22, P1243, DOI 10.1101/gr.132514.111
   Lu L, 2006, J CELL PHYSIOL, V206, P119, DOI 10.1002/jcp.20439
   Makarev E, 2014, AGING-US, V6, P1064, DOI 10.18632/aging.100711
   Mao Yingyu, 2013, Methods Mol Biol, V935, P285, DOI 10.1007/978-1-62703-080-9_20
   MAYERSON PL, 1985, INVEST OPHTH VIS SCI, V26, P1599
   Menard C, 2016, ONCOTARGET, V7, P19171, DOI 10.18632/oncotarget.8280
   MILLER RF, 1970, J NEUROPHYSIOL, V33, P323, DOI 10.1152/jn.1970.33.3.323
   Mukherjee PK, 2007, P NATL ACAD SCI USA, V104, P13158, DOI 10.1073/pnas.0705963104
   Mukherjee PK, 2007, P NATL ACAD SCI USA, V104, P13152, DOI 10.1073/pnas.0705949104
   Murad N, 2014, FEBS J, V281, P5251, DOI 10.1111/febs.13066
   Nakamura R, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8847
   Nandrot EE, 2004, J EXP MED, V200, P1539, DOI 10.1084/jem.20041447
   Ogata N, 2001, CURR EYE RES, V22, P245, DOI 10.1076/ceyr.22.4.245.5506
   Olchawa MM, 2013, INVEST OPHTH VIS SCI, V54, P2276, DOI 10.1167/iovs.12-11154
   Pan L, 2015, INT J MOL SCI, V16, P5420, DOI 10.3390/ijms16035420
   Patel Amit K, 2013, JAKSTAT, V2, pe25434, DOI 10.4161/jkst.25434
   Petrocca F, 2008, CANCER RES, V68, P8191, DOI 10.1158/0008-5472.CAN-08-1768
   Pfeffer BA, 2014, EXP EYE RES, V126, P1, DOI 10.1016/j.exer.2014.07.010
   Polato F, 2016, ADV EXP MED BIOL, V854, P699, DOI 10.1007/978-3-319-17121-0_93
   Qin SF, 2012, EXP EYE RES, V94, P63, DOI 10.1016/j.exer.2011.11.007
   Roggia MF, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0134870
   Savita U, 2013, BIOCHEM BIOPH RES CO, V434, P841, DOI 10.1016/j.bbrc.2013.04.025
   Schraermeyer U, 1997, EXP EYE RES, V65, P277, DOI 10.1006/exer.1997.0339
   Sethna Saumil, 2013, Methods Mol Biol, V935, P245, DOI 10.1007/978-1-62703-080-9_17
   Shi Q, 2016, CELL DEATH DIFFER, V23, P496, DOI 10.1038/cdd.2015.117
   STEELE FR, 1993, P NATL ACAD SCI USA, V90, P1526, DOI 10.1073/pnas.90.4.1526
   Strauss O, 2005, PHYSIOL REV, V85, P845, DOI 10.1152/physrev.00021.2004
   Vlachos IS, 2012, NUCLEIC ACIDS RES, V40, pW498, DOI 10.1093/nar/gks494
   Wahlquist C, 2014, NATURE, V508, P531, DOI 10.1038/nature13073
   Wang JM, 2014, INVEST OPHTH VIS SCI, V55, P1941, DOI 10.1167/iovs.13-13075
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Xu H, 2014, INVEST OPHTH VIS SCI, V55, P1519, DOI 10.1167/iovs.13-13155
   Zeiss CJ, 2010, VET PATHOL, V47, P396, DOI 10.1177/0300985809359598
   Zhang ZH, 2007, FASEB J, V21, P3042, DOI 10.1096/fj.06-6914com
   Zhao HY, 2014, MOL CELL BIOCHEM, V385, P207, DOI 10.1007/s11010-013-1829-x
NR 67
TC 11
Z9 11
U1 0
U2 10
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 1566-5240
EI 1875-5666
J9 CURR MOL MED
JI Curr. Mol. Med.
PY 2017
VL 17
IS 5
BP 359
EP 374
DI 10.2174/1566524018666171205122540
PG 16
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA FS0HL
UT WOS:000419454600004
PM 29210651
DA 2022-11-30
ER

PT J
AU Yan, YN
   Wang, YX
   Xu, L
   Xu, J
   Wei, WB
   Jonas, JB
AF Yan, Yan Ni
   Wang, Ya Xing
   Xu, Liang
   Xu, Jie
   Wei, Wen Bin
   Jonas, Jost B.
TI Fundus Tessellation: Prevalence and Associated Factors The Beijing Eye
   Study 2011
SO OPHTHALMOLOGY
LA English
DT Article
ID ANGLE-CLOSURE GLAUCOMA; CHOROIDAL THICKNESS; EYES
AB Purpose: To examine the prevalence of fundus tessellation and its associated factors.
   Design: Population-based study.
   Participants: The Beijing Eye Study 2011 included 3468 individuals with a mean age of 64.6 +/- 9.8 years (range, 50-93 years).
   Methods: Participants underwent a comprehensive ophthalmic examination. By using 45 degrees color fundus photographs of the macula and optic disc, fundus tessellation, defined as variation in the visibility of the large choroidal vessels, was differentiated into 3 grades.
   Main Outcome Measures: Fundus tessellation.
   Results: Assessment of fundus tessellation was available for 3442 individuals (99.6%) or 6789 eyes (98.6%). In multivariate analysis, a higher degree of fundus tessellation (mean, 0.84 +/- 0.79) was associated with older age (P < 0.001; standardized correlation coefficient beta, 0.14), male sex (P < 0.001; beta, -0.08), lower body mass index (P = 0.04; beta, 0.03), worse best-corrected visual acuity (P < 0.001; beta, 0.05), thinner subfoveal choroidal thickness (P < 0.001; beta, -0.51), longer axial length (P < 0.001; beta, 0.11), larger parapapillary beta zone (P < 0.001; beta, 0.08), lower prevalence of intermediate age-related macular degeneration (AMD) (P = 0.02; beta, -0.04), and lower prevalence of late AMD (P = 0.007; beta, -0.04). If parapapillary beta zone was dropped, higher glaucoma prevalence (P = 0.003) was associated with a higher degree of fundus tessellation. Prevalence of diabetes mellitus and retinal vein occlusions, mean blood pressure, and intraocular pressure were not (P > 0.10) associated with fundus tessellation. In a reverse manner, thinner subfoveal choroidal thickness was associated with a higher degree of fundus tessellation (P < 0.001; beta, -0.49) in the multivariate analysis. Subfoveal choroidal thickness decreased from 322 +/- 90 mm (95% confidence interval [CI], 317-327) in eyes without fundus tessellation to 229 +/- 80 mm in eyes with grade 1, to 122 +/- 52 mm in eyes with grade 2, and to 81 +/- 37 mm in eyes with grade 3 of fundus tessellation.
   Conclusions: Fundus tessellation is a surrogate for choroidal thinness and may be a clinical sign for a leptochoroid. After adjusting for ocular and systemic parameters, fundus tessellation also is associated with a larger parapapillary beta zone and higher glaucoma prevalence, and a lower prevalence of intermediate and late AMD. Its association with lower visual acuity warrants further investigation. (C) 2015 by the American Academy of Ophthalmology.
C1 [Yan, Yan Ni; Wei, Wen Bin] Capital Med Univ, Beijing Tongren Hosp, Beijing Tongren Eye Ctr, Beijing, Peoples R China.
   [Wang, Ya Xing; Xu, Liang; Xu, Jie; Jonas, Jost B.] Capital Med Univ, Beijing Inst Ophthalmol, Beijing Tongren Hosp, Beijing Tongren Eye Ctr,Beijing Ophthalmol & Visu, Beijing, Peoples R China.
   [Jonas, Jost B.] Heidelberg Univ, Dept Ophthalmol, Med Fac Mannheim, Seegartenklin Heidelberg, Heidelberg, Germany.
C3 Capital Medical University; Capital Medical University; Ruprecht Karls
   University Heidelberg
RP Wei, WB (通讯作者)，Beijing Tongren Hosp, Beijing Tongren Eye Ctr, 1 Dong Jiao Min Lane, Beijing 100730, Peoples R China.
EM tr_weiwenbin@163.com
RI Xu, Jie/AIE-0524-2022; xu, jie/GQR-1913-2022; wang, YA XING/K-9671-2016
OI xu, jie/0000-0002-2039-7055; wang, YA XING/0000-0003-2749-7793
FU Natural Sciences Fund of Beijing government [81770890, 81272981]
FX Supported by Natural Sciences Fund of Beijing government (81770890;
   81272981).
CR Chen H, 2012, OPHTHAL PHYSL OPT, V32, P60, DOI 10.1111/j.1475-1313.2011.00861.x
   Dai Y, 2013, INVEST OPHTH VIS SCI, V54, P2013, DOI 10.1167/iovs.12-11255
   JONAS JB, 1992, GRAEF ARCH CLIN EXP, V230, P134, DOI 10.1007/BF00164651
   Jonas JB, 1996, GRAEF ARCH CLIN EXP, V234, P744, DOI 10.1007/BF00189355
   Jonas JB, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047237
   Koh VTC, 2013, ANN ACAD MED SINGAP, V42, P216
   PANDA S, 1992, INVEST OPHTH VIS SCI, V33, P2532
   SARKS SH, 1973, BRIT J OPHTHALMOL, V57, P98, DOI 10.1136/bjo.57.2.98
   Spaeth GL, 1992, THE OPTIC NERVE IN G, P79
   Spaide RF, 2009, AM J OPHTHALMOL, V147, P801, DOI 10.1016/j.ajo.2008.12.010
   Switzer DW, 2012, RETINA-J RET VIT DIS, V32, P1265, DOI 10.1097/IAE.0b013e31824453ac
   WANG Y, 2014, INT J DISTRIB SENS N, V2014, P9, DOI DOI 10.1371/J0URNAL.P0NE.0110024
   Warrow DJ, 2013, RETINA-J RET VIT DIS, V33, P1659, DOI 10.1097/IAE.0b013e3182953df4
   Wei WB, 2013, OPHTHALMOLOGY, V120, P175, DOI 10.1016/j.ophtha.2012.07.048
   Yoshihara N, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0103586
NR 15
TC 54
Z9 59
U1 1
U2 19
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD SEP
PY 2015
VL 122
IS 9
BP 1873
EP 1880
DI 10.1016/j.ophtha.2015.05.031
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA CP8BU
UT WOS:000360116900029
PM 26119000
DA 2022-11-30
ER

PT J
AU Fasih, U
   Shaikh, N
   Rahman, A
   Sultan, S
   Fehmi, MS
   Shaikh, A
AF Fasih, Uzma
   Shaikh, Nisar
   Rahman, Atiya
   Sultan, Sharjeel
   Fehmi, Mohammad Shafi
   Shaikh, Arshad
TI A one-year follow-up study of ocular and systemic complications of
   intravitreal injection of bevacizumab (Avastin)
SO JOURNAL OF THE PAKISTAN MEDICAL ASSOCIATION
LA English
DT Article
DE Visual aquity; Proliferative diabetic retinopathy; Retinal
   neovascularization; Best corrected visual acuity
ID CHOROIDAL NEOVASCULARIZATION SECONDARY; PROLIFERATIVE
   DIABETIC-RETINOPATHY; MACULAR DEGENERATION; SHORT-TERM; TRIAMCINOLONE;
   SAFETY
AB Objectives: To report systemic and ocular complications within a year of intravitreal injection of bevacizumab (Avastin) in ocular neovascularisation.
   Methods: The quasi-experimental (randomized without control) study was carried out at the Eye Department of Abbasi Shaheed Hospital, Karachi, from July 2008 to June 2010. It comprised 150 patients selected from the outpatient department with ocular neovascularisation through non-probability purposive sampling. After detailed history and examination, the patients were counseled for intravitreal injection Avastin (bevacizumab) which was injected into the vitreous cavity in sterile environment in the operation theatre using fully aseptic technique. The injection site was compressed for several seconds to avoid reflux when the needle was removed. Paracentesis was done following the injection as soon as possible. Patients were discharged on moxifloxcin eye drops and steroid antibiotic combination ointment at night time. They were followed up the very next day, after 2 weeks, 6 weeks, 3 months, 6 months and 1 year. Injection was repeated after 6 weeks if required and further repetition was done again after 6 weeks according to the need of the patient.
   Results: Of the 150 patients, 93 (62%) were males and 57 (38%) were females. Most commonly presenting age group was between 50-60 years (n=51; 34%) followed by 41-50 years (n=41; 27.4%). Most common indication for intravitreal injection Avastin (bevacizumab) was proliferative diabetic retinopathy in 134 (89.33%) patients, followed by age-related macular degeneration (wet type) in 5 (3.3%) patients. Most frequently presenting ocular complication was subconjunctival haemorrhage seen in 35 (23%) patients, followed by regurgitation of drug from the site of injection in 8 (5.3%) patients, transient rise of intraocular pressure in 7 (4.7%) patients, mild uveitis in 4 (2.7%) patients, lens injury in 3 (2%) patients, conjunctival chemosis and iatrogenic vitreous haemorrhage in 1 (0.7%) patients. Among the systemic complications were acute rise of blood pressure in 4 (2.7%) patients, and mild irritation and allergic reaction on skin in 1 (0.7%) patient.
   Conclusion: Avastin is generally a safe drug for treatment of ocular neovascularization. The complications reported were more associated with the technique of the procedure and not the drug itself and were easily manageable. Drug-related complications were limited, transient and easily managed with treatment.
C1 [Fasih, Uzma; Shaikh, Nisar; Rahman, Atiya; Sultan, Sharjeel; Fehmi, Mohammad Shafi; Shaikh, Arshad] Abbasi Shaheed Hosp, Karachi Med & Dent Coll, Eye Dept, Karachi, Pakistan.
RP Fasih, U (通讯作者)，Abbasi Shaheed Hosp, Karachi Med & Dent Coll, Eye Dept, Karachi, Pakistan.
EM yousufuzma@hotmail.com
CR Avery RL, 2006, OPHTHALMOLOGY, V113, P1695, DOI 10.1016/j.ophtha.2006.05.064
   Barron H, 2005, MEDWATCH GENENTECH I
   Fung AE, 2006, BRIT J OPHTHALMOL, V90, P1344, DOI 10.1136/bjo.2006.099598
   Gomi F, 2007, AM J OPHTHALMOL, V143, P507, DOI 10.1016/j.ajo.2006.10.050
   Hurwitz H, 2004, NEW ENGL J MED, V350, P2335, DOI 10.1056/NEJMoa032691
   Iturralde D, 2006, RETINA-J RET VIT DIS, V26, P279, DOI 10.1097/00006982-200603000-00005
   Johnson D, 2010, CAN J OPHTHALMOL, V45, P239, DOI 10.3129/i10-013
   Jonas JB, 2008, EYE, V22, P590, DOI 10.1038/eye.2008.10
   Khalili MR, 2009, CORNEA, V28, P360, DOI 10.1097/ICO.0b013e318189137a
   Kook D, 2008, OPHTHALMOLOGE, V105, P158, DOI 10.1007/s00347-007-1561-6
   Meyer CH, 2006, BRIT J OPHTHALMOL, V90, P1207, DOI 10.1136/bjo.2006.093732
   Michels S, 2005, OPHTHALMOLOGY, V112, P1035, DOI 10.1016/j.ophtha.2005.02.007
   Oshima Y, 2006, AM J OPHTHALMOL, V142, P155, DOI 10.1016/j.ajo.2006.02.015
   Rich RM, 2006, RETINA-J RET VIT DIS, V26, P495, DOI 10.1097/01.iae.0000225766.75009.3a
   Rosenfeld PJ, 2005, OPHTHAL SURG LAS IM, V36, P331, DOI 10.3928/1542-8877-20050701-14
   Sakaguchi H, 2007, BRIT J OPHTHALMOL, V91, P161, DOI 10.1136/bjo.2006.099887
   Shima C, 2008, ACTA OPHTHALMOL, V86, P372, DOI 10.1111/j.1600-0420.2007.01067.x
   Spaide RF, 2006, RETINA-J RET VIT DIS, V26, P383, DOI 10.1097/00006982-200604000-00001
   Yamashiro K, 2010, RETINA-J RET VIT DIS, V30, P485, DOI 10.1097/IAE.0b013e3181bd2d51
NR 19
TC 10
Z9 10
U1 0
U2 9
PU PAKISTAN MEDICAL ASSOC
PI KARACHI
PA PMA HOUSE, AGA KHAN III RD, KARACHI, 00000, PAKISTAN
SN 0030-9982
J9 J PAK MED ASSOC
JI J. Pak. Med. Assoc.
PD JUN
PY 2013
VL 63
IS 6
BP 707
EP 710
PG 4
WC Medicine, General & Internal; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine; Research & Experimental Medicine
GA 147ON
UT WOS:000319177000009
PM 23901669
DA 2022-11-30
ER

PT J
AU Keenan, TDL
   Chen, QY
   Peng, YF
   Domalpally, A
   Agron, E
   Hwang, CK
   Thavikulwat, AT
   Lee, DH
   Li, D
   Wong, WT
   Lu, ZY
   Chew, EY
AF Keenan, Tiarnan D. L.
   Chen, Qingyu
   Peng, Yifan
   Domalpally, Amitha
   Agron, Elvira
   Hwang, Christopher K.
   Thavikulwat, Alisa T.
   Lee, Debora H.
   Li, Daniel
   Wong, Wai T.
   Lu, Zhiyong
   Chew, Emily Y.
TI Deep Learning Automated Detection of Reticular Pseudodrusen from Fundus
   Autofluorescence Images or Color Fundus Photographs in AREDS2
SO OPHTHALMOLOGY
LA English
DT Article
ID MACULAR DEGENERATION; SEVERITY SCALE; EYE DISEASE; ATROPHY;
   CLASSIFICATION; TRIAL
AB Purpose: To develop deep learning models for detecting reticular pseudodrusen (RPD) using fundus auto-fluorescence (FAF) images or, alternatively, color fundus photographs (CFP) in the context of age-related macular degeneration (AMD).
   Design: Application of deep learning models to the Age-Related Eye Disease Study 2 (AREDS2) dataset.
   Participants: FAF and CFP images (n = 11 535) from 2450 AREDS2 participants. Gold standard labels from reading center grading of the FAF images were transferred to the corresponding CFP images.
   Methods: A deep learning model was trained to detect RPD in eyes with intermediate to late AMD using FAF images (FAF model). Using label transfer from FAF to CFP images, a deep learning model was trained to detect RPD from CFP (CFP model). Performance was compared with 4 ophthalmologists using a random subset from the full test set.
   Main Outcome Measures: Area under the receiver operating characteristic curve (AUC), kappa value, accuracy, and F1 score.
   Results: The FAF model had an AUC of 0.939 (95% confidence interval [CI], 0.927-0.950), a k value of 0.718 (95% CI, 0.685-0.751), and accuracy of 0.899 (95% CI, 0.887-0.911). The CFP model showed equivalent values of 0.832 (95% CI, 0.812-0.851), 0.470 (95% CI, 0.426-0.511), and 0.809 (95% CI, 0.793-0.825), respectively. The FAF model demonstrated superior performance to 4 ophthalmologists, showing a higher k value of 0.789 (95% CI, 0.675-0.875) versus a range of 0.367 to 0.756 and higher accuracy of 0.937 (95% CI, 0.907-0.963) versus a range of 0.696 to 0.933. The CFP model demonstrated substantially superior performance to 4 ophthalmologists, showing a higher k value of 0.471 (95% CI, 0.330-0.606) versus a range of 0.105 to 0.180 and higher accuracy of 0.844 (95% CI, 0.798-0.886) versus a range of 0.717 to 0.814.
   Conclusions: Deep learning-enabled automated detection of RPD presence from FAF images achieved a high level of accuracy, equal or superior to that of ophthalmologists. Automated RPD detection using CFP achieved a lower accuracy that still surpassed that of ophthalmologists. Deep learning models can assist, and even augment, the detection of this clinically important AMD-associated lesion. Published by Elsevier on behalf of the American Academy of Ophthalmology
C1 [Keenan, Tiarnan D. L.; Agron, Elvira; Hwang, Christopher K.; Thavikulwat, Alisa T.; Lee, Debora H.; Wong, Wai T.; Chew, Emily Y.] NEI, Div Epidemiol & Clin Applicat, NIH, Bethesda, MD 20892 USA.
   [Chen, Qingyu; Peng, Yifan; Li, Daniel; Lu, Zhiyong] Natl Lib Med, Natl Ctr Biotechnol Informat, NIH, Bethesda, MD 20894 USA.
   [Domalpally, Amitha] Univ Wisconsin, Fundus Photograph Reading Ctr, Madison, WI USA.
   [Wong, Wai T.] NEI, Sect Neuron Glia Interact Retinal Dis, Lab Retinal Cell & Mol Biol, Bethesda, MD 20892 USA.
C3 National Institutes of Health (NIH) - USA; NIH National Eye Institute
   (NEI); National Institutes of Health (NIH) - USA; NIH National Library
   of Medicine (NLM); University of Wisconsin System; University of
   Wisconsin Madison; National Institutes of Health (NIH) - USA; NIH
   National Eye Institute (NEI)
RP Lu, ZY (通讯作者)，Natl Lib Med, Natl Ctr Biotechnol Informat, NIH, Bethesda, MD 20894 USA.; Chew, EY (通讯作者)，NEI, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA.
EM zhiyong.lu@nih.gov
RI Chen, Qingyu/Q-8343-2019; Peng, Yifan/M-1605-2016
OI Chen, Qingyu/0000-0002-6036-1516; Peng, Yifan/0000-0001-9309-8331;
   Domalpally, Amitha/0000-0002-8145-9619
FU National Center for Biotechnology Information, National Library of
   Medicine, National Institutes of Health; National Eye Institute,
   National Institutes of Health, Bethesda, Maryland
   [HHS-N-260-2005-00007-C, N01-EY-5-0007, K99LM013001]; National
   Institutes of Health: Office of Dietary Supplements; National Institutes
   of Health: National Center for Complementary and Alternative Medicine;
   National Institutes of Health: National Institute on Aging; National
   Institutes of Health: National Heart, Lung, and Blood Institute;
   National Institutes of Health: National Institute of Neurological
   Disorders and Stroke; Heed Ophthalmic Foundation; NIH Medical Research
   Scholars Program; National Institutes of Health; Doris Duke Charitable
   Foundation [2014194]; American Association for Dental Research;
   Colgate-Palmolive Company; Genentech; Elsevier
FX Supported by the National Center for Biotechnology Information, National
   Library of Medicine, National Institutes of Health, and the National Eye
   Institute, National Institutes of Health, Bethesda, Maryland (grant
   nos.: HHS-N-260-2005-00007-C, N01-EY-5-0007, and K99LM013001). Funds
   were generously contributed to these contracts by the following National
   Institutes of Health institutes: Office of Dietary Supplements; National
   Center for Complementary and Alternative Medicine; National Institute on
   Aging; National Heart, Lung, and Blood Institute; and National Institute
   of Neurological Disorders and Stroke. The sponsor and funding
   organization participated in the design and conduct of the study; data
   collection, management, analysis, and interpretation; and the
   preparation, review and approval of the manuscript. Supported by the
   Heed Ophthalmic Foundation (C.K.H.); and the NIH Medical Research
   Scholars Program (D.H.L), a public-private partnership supported jointly
   by the National Institutes of Health and by contributions to the
   Foundation for the National Institutes of Health from the Doris Duke
   Charitable Foundation (grant no.: 2014194), the American Association for
   Dental Research, the Colgate-Palmolive Company, Genentech, Elsevier, and
   other private donors.
CR Abadi M., ARXIV160304467
   Abramoff MD, 2018, NPJ DIGIT MED, V1, DOI 10.1038/s41746-018-0040-6
   Age-Related Eye Disease Study 2 Research Group, 2013, JAMA, V309, P2005, DOI 10.1001/jama.2013.4997
   Alten F, 2014, GRAEF ARCH CLIN EXP, V252, P715, DOI 10.1007/s00417-013-2525-y
   American Academy of Ophthalmology, AG REL MAC DEG PREF
   [Anonymous], 2019, CLIN EXP OPTOM, DOI DOI 10.1111/cxo.12842
   Calaprice-Whitty D, 2020, THER INNOV REGUL SCI, V54, P69, DOI 10.1007/s43441-019-00030-4
   Chen Qingyu, 2019, AMIA Jt Summits Transl Sci Proc, V2019, P505
   Chew EY, 2014, OPHTHALMOLOGY, V121, P535, DOI 10.1016/j.ophtha.2013.10.027
   Chew EY, 2012, OPHTHALMOLOGY, V119, P2282, DOI 10.1016/j.ophtha.2012.05.027
   Chollet Francois, 2015, KERAS
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Davis MD, 2005, ARCH OPHTHALMOL-CHIC, V123, P1484
   Domalpally A, 2019, OPHTHALMOLOGY, V126, P1659, DOI 10.1016/j.ophtha.2019.07.022
   Domalpally A, 2019, OPHTHALMOL RETINA, V3, P326, DOI 10.1016/j.oret.2019.01.004
   Ferris FL, 2005, ARCH OPHTHALMOL-CHIC, V123, P1570
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Fleckenstein M, 2018, OPHTHALMOLOGY, V125, P369, DOI 10.1016/j.ophtha.2017.08.038
   Guymer RH, 2019, OPHTHALMOLOGY, V126, P829, DOI 10.1016/j.ophtha.2018.09.015
   He KM, 2016, PROC CVPR IEEE, P770, DOI 10.1109/CVPR.2016.90
   Huang G, 2022, IEEE T PATTERN ANAL, V44, P8704, DOI 10.1109/TPAMI.2019.2918284
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Keenan TD, 2019, OPHTHALMOLOGY, V126, P1533, DOI 10.1016/j.ophtha.2019.06.005
   Lawrenson JG, 2013, BMC PUBLIC HEALTH, V13, DOI 10.1186/1471-2458-13-564
   Peng YF, 2019, OPHTHALMOLOGY, V126, P565, DOI 10.1016/j.ophtha.2018.11.015
   Quartilho A, 2016, EYE, V30, P602, DOI 10.1038/eye.2015.288
   Rawat W, 2017, NEURAL COMPUT, V29, P2352, DOI [10.1162/NECO_a_00990, 10.1162/neco_a_00990]
   Sadda SR, 2018, OPHTHALMOLOGY, V125, P537, DOI 10.1016/j.ophtha.2017.09.028
   Schmitz-Valckenberg S, 2011, INVEST OPHTH VIS SCI, V52, P5009, DOI 10.1167/iovs.11-7235
   Simonyan K., 2013, ICLR 2014
   Simonyan K., 2014, PREPRINT, DOI DOI 10.48550/ARXIV.1409.1556
   Spaide RF, 2018, SURV OPHTHALMOL, V63, P782, DOI 10.1016/j.survophthal.2018.05.005
   Spaide RF, 2013, RETINA-J RET VIT DIS, V33, P1800, DOI 10.1097/IAE.0b013e31829c3765
   Suzuki M, 2014, AM J OPHTHALMOL, V157, P1005, DOI 10.1016/j.ajo.2014.01.025
   Szegedy C, 2016, PROC CVPR IEEE, P2818, DOI 10.1109/CVPR.2016.308
   Ueda-Arakawa N, 2013, RETINA-J RET VIT DIS, V33, P490, DOI 10.1097/IAE.0b013e318276e0ae
   van Grinsven MJJP, 2015, INVEST OPHTH VIS SCI, V56, P633, DOI 10.1167/iovs.14-15019
   Varadarajan AV, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-019-13922-8
   Wittenborn JS, 2017, JAMA OPHTHALMOL, V135, P452, DOI 10.1001/jamaophthalmol.2017.0255
NR 39
TC 10
Z9 10
U1 1
U2 17
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD DEC
PY 2020
VL 127
IS 12
BP 1674
EP 1687
DI 10.1016/j.ophtha.2020.05.036
PG 14
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA PH9SN
UT WOS:000600742900020
PM 32447042
DA 2022-11-30
ER

PT J
AU Li, F
   Chen, H
   Liu, Z
   Zhang, XD
   Wu, ZZ
AF Li, Feng
   Chen, Hua
   Liu, Zheng
   Zhang, Xuedian
   Wu, Zhizheng
TI Fully automated detection of retinal disorders by image-based deep
   learning
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE Age-related macular degeneration; Diabetic macular edema; Optical
   coherence tomography; Deep transfer learning; Visual geometry group 16
   network
ID DIABETIC MACULAR EDEMA; PREVALENCE; DEGENERATION; DIAGNOSIS
AB PurposeWith the aging population and the global diabetes epidemic, the prevalence of age-related macular degeneration (AMD) and diabetic macular edema (DME) diseases which are the leading causes of blindness is further increasing. Intravitreal injections with anti-vascular endothelial growth factor (anti-VEGF) medications are the standard of care for their indications. Optical coherence tomography (OCT), as a noninvasive imaging modality, plays a major part in guiding the administration of anti-VEGF therapy by providing detailed cross-sectional scans of the retina pathology. Fully automating OCT image detection can significantly decrease the tedious clinician labor and obtain a faithful pre-diagnosis from the analysis of the structural elements of the retina. Thereby, we explore the use of deep transfer learning method based on the visual geometry group 16 (VGG-16) network for classifying AMD and DME in OCT images accurately and automatically.MethodA total of 207,130 retinal OCT images between 2013 and 2017 were selected from retrospective cohorts of 5319 adult patients from the Shiley Eye Institute of the University of California San Diego, the California Retinal Research Foundation, Medical Center Ophthalmology Associates, the Shanghai First People's Hospital, and the Beijing Tongren Eye Center, with 109,312 images (37,456 with choroidal neovascularization, 11,599 with diabetic macular edema, 8867 with drusen, and 51,390 normal) for the experiment. After images preprocessing, 1000 images (250 images from each category) from 633 patients were selected as validation dataset while the rest images from another 4686 patients were used as training dataset. We used deep transfer learning method to fine-tune the VGG-16 network pre-trained on the ImageNet dataset, and evaluated its performance on the validation dataset. Then, prediction accuracy, sensitivity, specificity, and receiver-operating characteristic (ROC) were calculated.ResultsExperimental results proved that the proposed approach had manifested superior performance in retinal OCT images detection, which achieved a prediction accuracy of 98.6%, with a sensitivity of 97.8%, a specificity of 99.4%, and introduced an area under the ROC curve of 100%.ConclusionDeep transfer learning method based on the VGG-16 network shows significant effectiveness on classification of retinal OCT images with a relatively small dataset, which can provide assistant support for medical decision-making. Moreover, the performance of the proposed approach is comparable to that of human experts with significant clinical experience. Thereby, it will find promising applications in an automatic diagnosis and classification of common retinal diseases.
C1 [Li, Feng; Chen, Hua; Liu, Zheng; Zhang, Xuedian] Univ Shanghai Sci & Technol, Sch Opt Elect & Comp Engn, Shanghai 200093, Peoples R China.
   [Wu, Zhizheng] Shanghai Univ, Dept Precis Mech Engn, Shanghai 200072, Peoples R China.
C3 University of Shanghai for Science & Technology; Shanghai University
RP Chen, H (通讯作者)，Univ Shanghai Sci & Technol, Sch Opt Elect & Comp Engn, Shanghai 200093, Peoples R China.
EM 171655822@qq.com
FU National Key Research and Development Program of China [2016YFF0101400];
   National Natural Science Foundation of China [51675321]
FX This work was supported by the National Key Research and Development
   Program of China (2016YFF0101400) and the National Natural Science
   Foundation of China (51675321).
CR Abramoff Michael D, 2010, IEEE Rev Biomed Eng, V3, P169, DOI 10.1109/RBME.2010.2084567
   Abramoff MD, 2016, INVEST OPHTH VIS SCI, V57, P5200, DOI 10.1167/iovs.16-19964
   Alsaih K, 2016, CLASSIFICATION SD OC, DOI [10.1109/EMBC.2016.7590956, DOI 10.1109/EMBC.2016.7590956]
   Bourne RRA, 2017, LANCET GLOB HEALTH, V5, pE888, DOI 10.1016/S2214-109X(17)30293-0
   Bourne RRA, 2014, BRIT J OPHTHALMOL, V98, P629, DOI 10.1136/bjophthalmol-2013-304033
   Bressler NM, 2002, EARLY DETECTION TREA
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Burlina P, 2016, I S BIOMED IMAGING, P184, DOI 10.1109/ISBI.2016.7493240
   Ciulla TA, 2003, DIABETIC RETINOPATHY
   Drexler W, 2008, PROG RETIN EYE RES, V27, P45, DOI 10.1016/j.preteyeres.2007.07.005
   Ferrara N, 2010, VASCULAR ENDOTHELIAL
   Keane PA, 2012, SURV OPHTHALMOL, V57, P389, DOI 10.1016/j.survophthal.2012.01.006
   Kermany DS, 2018, CELL, V172, P1122, DOI 10.1016/j.cell.2018.02.010
   Koh JEW, 2018, COMPUT BIOL MED, V92, P204, DOI 10.1016/j.compbiomed.2017.11.019
   Lee JG, 2017, KOREAN J RADIOL, V18, P570, DOI 10.3348/kjr.2017.18.4.570
   Liu YY, 2011, MED IMAGE ANAL, V15, P748, DOI 10.1016/j.media.2011.06.005
   Mariotti SP, 2012, GLOBAL DATA VISUAL I
   PERONA P, 1990, IEEE T PATTERN ANAL, V12, P629, DOI 10.1109/34.56205
   Romero-Aroca P, 2013, WORLD J DIABETES, V4, P165, DOI 10.4239/wjd.v4.i5.165
   Schlegl T, 2018, OPHTHALMOLOGY, V125, P549, DOI 10.1016/j.ophtha.2017.10.031
   Srinivasan PP, 2014, BIOMED OPT EXPRESS, V5, P3568, DOI 10.1364/BOE.5.003568
   Varma R, 2014, JAMA OPHTHALMOL, V132, P1334, DOI 10.1001/jamaophthalmol.2014.2854
   Zhao BD, 2017, J SYST ENG ELECTRON, V28, P162, DOI 10.21629/JSEE.2017.01.18
NR 23
TC 63
Z9 64
U1 5
U2 56
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0721-832X
EI 1435-702X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD MAR
PY 2019
VL 257
IS 3
BP 495
EP 505
DI 10.1007/s00417-018-04224-8
PG 11
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA HM9FR
UT WOS:000459788800007
PM 30610422
DA 2022-11-30
ER

PT J
AU Qiu, M
   Wang, SY
   Singh, K
   Lin, SC
AF Qiu, Mary
   Wang, Sophia Y.
   Singh, Kuldev
   Lin, Shan C.
TI Association between Visual Field Defects and Quality of Life in the
   United States
SO OPHTHALMOLOGY
LA English
DT Article
ID OPEN-ANGLE GLAUCOMA; NUTRITION EXAMINATION SURVEY; OCULAR HYPERTENSION;
   NATIONAL-HEALTH; PREVALENCE
AB Purpose: To investigate the association between visual field defects and quality of life in the United States population.
   Design: Cross-sectional study.
   Participants: A total of 5186 participants in the 2005 through 2008 National Health and Nutrition Examination Survey 40 years of age and older without a self-reported history of age-related macular degeneration or prior refractive surgery who had undergone frequency doubling technology perimetric testing.
   Methods: Frequency doubling technology perimetry was performed in both eyes. Results from the better eye were used to categorize subjects as normal or having mild, moderate, or severe visual field loss. Subjects completed surveys about their visual and physical functioning ability.
   Main Outcome Measures: Disability pertaining to 6 vision-related activities, 2 visual function questions, and 5 physical functioning domains.
   Results: Eighty-one percent of subjects had normal visual fields and 10%, 7%, and 2% demonstrated mild, moderate, and severe visual field defects, respectively. Subjects with greater severity of visual field defects had greater difficulty with vision-related activities. Subjects with severe visual field defects demonstrated the greatest odds of difficulty with all 6 activities. The 2 activities impacted most adversely were daytime driving in familiar places (odds ratio [OR], 12.4; 95% confidence interval [CI], 6.1-25.1) and noticing objects off to the side when walking (OR, 7.7; 95% CI, 4.7-12.7). Subjects with severe visual field defects had greater odds of worrying about eyesight (OR, 3.4; 95% CI, 2.0-5.8) and being limited by vision in the time spent on daily activities (OR, 5.1; 95% CI, 3.0-8.5). Subjects with severe visual field defects demonstrated the greatest odds of difficulty with 3 physical function domains, including activities of daily living (OR, 2.45; 95% CI, 1.37-4.38), instrumental activities of daily living (OR, 2.45; 95% CI, 1.37-4.38), as well as leisure and social activities (OR, 3.29; 95% CI, 1.87-5.77).
   Conclusions: Greater severity of visual field abnormality was associated with significantly greater odds of disability with vision-related function and physical function. These findings support the necessity of routine screening to find those who may benefit from therapy to prevent progressive glaucomatous vision loss. (C) 2014 by the American Academy of Ophthalmology.
C1 [Qiu, Mary; Wang, Sophia Y.; Lin, Shan C.] Univ Calif San Francisco, Dept Ophthalmol, San Francisco, CA 94143 USA.
   [Singh, Kuldev] Stanford Univ, Dept Ophthalmol, Stanford, CA 94305 USA.
C3 University of California System; University of California San Francisco;
   Stanford University
RP Lin, SC (通讯作者)，Univ Calif San Francisco, Dept Ophthalmol, 10 Koret St,Room K301, San Francisco, CA 94143 USA.
EM lins@vision.ucsf.edu
OI Wang, Sophia/0000-0003-0916-9403
FU National Eye Institute, National Institutes of Health, Bethesda,
   Maryland [EY002162]; That Man May See, Inc, San Francisco, CA; Research
   to Prevent Blindness, Inc, New York, New York; National Center for
   Advancing Translational Sciences, Bethesda, MD; National Institutes of
   Health (UCSF-CTSI) [TL1 TR000144]; NATIONAL CENTER FOR ADVANCING
   TRANSLATIONAL SCIENCES [TL1TR000144] Funding Source: NIH RePORTER;
   NATIONAL EYE INSTITUTE [P30EY002162] Funding Source: NIH RePORTER
FX Supported by the National Eye Institute, National Institutes of Health,
   Bethesda, Maryland (core grant no.: EY002162); That Man May See, Inc,
   San Francisco, CA; Research to Prevent Blindness, Inc, New York, New
   York; and the National Center for Advancing Translational Sciences,
   Bethesda, MD; National Institutes of Health (UCSF-CTSI grant no.: TL1
   TR000144). The sponsor or funding organization had no role in the design
   or conduct of this research.
CR American Academy of Ophthalmology Glaucoma Panel, 2010, PREF PRACT PATT GUID, p[11, 17]
   Brusini P, 2003, J GLAUCOMA, V12, P417, DOI 10.1097/00061198-200310000-00004
   Heijl A, 2002, ARCH OPHTHALMOL-CHIC, V120, P1268, DOI 10.1001/archopht.120.10.1268
   Hochberg C, 2012, INVEST OPHTH VIS SCI, V53, P3201, DOI 10.1167/iovs.12-9469
   Jampel H D, 2001, Trans Am Ophthalmol Soc, V99, P301
   Kass MA, 2002, ARCH OPHTHALMOL-CHIC, V120, P701
   Kulkarni KM, 2012, AM J OPHTHALMOL, V154, P445, DOI 10.1016/j.ajo.2012.03.030
   Kuo HK, 2006, J GERONTOL A-BIOL, V61, P380, DOI 10.1093/gerona/61.4.380
   Lisboa R, 2013, JAMA OPHTHALMOL, V131, P486, DOI 10.1001/jamaophthalmol.2013.2602
   Mangione CM, 2001, ARCH OPHTHALMOL-CHIC, V119, P1050
   McKean-Cowdin R, 2008, OPHTHALMOLOGY, V115, P941, DOI 10.1016/j.ophtha.2007.08.037
   Mitchell P, 1996, OPHTHALMOLOGY, V103, P1661, DOI 10.1016/S0161-6420(96)30449-1
   National Center for Health Statistics, NHANES WEB TUT
   Nelson P, 2003, J GLAUCOMA, V12, P139, DOI 10.1097/00061198-200304000-00009
   Quigley HA, 1997, INVEST OPHTH VIS SCI, V38, P83
   Quigley HA, 2006, BRIT J OPHTHALMOL, V90, P262, DOI 10.1136/bjo.2005.081224
   Ramrattan RS, 2001, ARCH OPHTHALMOL-CHIC, V119, P1788, DOI 10.1001/archopht.119.12.1788
   Severn P, 2008, BMC OPHTHALMOL, V8, DOI 10.1186/1471-2415-8-2
   Spaeth G, 2006, AM J OPHTHALMOL, V141, pS3, DOI 10.1016/j.ajo.2005.07.075
   Terry AL, 2010, OPHTHAL EPIDEMIOL, V17, P411, DOI 10.3109/09286586.2010.528575
   The American Optometric Association, LOW VIS
   TIELSCH JM, 1991, JAMA-J AM MED ASSOC, V266, P369, DOI 10.1001/jama.266.3.369
   U.S. Preventive Services Task Force, SCREEN GLAUC CURR RE
   van Gestel A, 2010, EYE, V24, P1759, DOI 10.1038/eye.2010.133
   van Landingham SW, 2012, OPHTHALMOLOGY, V119, P2486, DOI 10.1016/j.ophtha.2012.06.034
   Varma R, 2004, OPHTHALMOLOGY, V111, P1439, DOI 10.1016/j.ophtha.2004.01.025
   Varma R, 2011, AM J OPHTHALMOL, V152, P515, DOI 10.1016/j.ajo.2011.06.004
   Ware JE, 1996, MED CARE, V34, P220, DOI 10.1097/00005650-199603000-00003
NR 28
TC 37
Z9 42
U1 0
U2 13
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD MAR
PY 2014
VL 121
IS 3
BP 733
EP 740
DI 10.1016/j.ophtha.2013.09.043
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AC3FT
UT WOS:000332401800024
PM 24342021
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Wachtlin, J
   Stroux, A
   Wehner, A
   Heimann, H
   Foerster, MH
AF Wachtlin, J
   Stroux, A
   Wehner, A
   Heimann, H
   Foerster, MH
TI Photodynamic therapy with verteporfin for choroidal neovascularisations
   in clinical routine outside the TAP study. One- and two-year results
   including juxtafoveal and extrafoveal CNV
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
ID MACULAR DEGENERATION; LASER PHOTOCOAGULATION; NEOVASCULARIZATION;
   TRIALS; MACULOPATHY; GUIDELINES; LESIONS
AB Introduction: The aim of this study was to analyse 1- and 2-year outcomes after photodynamic therapy (PDT) in clinical routine outside of the TAP [ treatment of age-related macular degeneration (AMD) with PDT] study. We analysed the functional results, possible influencing factors and the rate of side effects. Methods: We analysed the medical records of 210 consecutive patients between 50 and 93 years of age ( 73 +/- 9 years) who had been treated with PDT for active &GE; 50% classic CNV resulting from AMD. Only patients with a minimum follow-up of 1 year ( 127) were included; 52 patients completed 2 years of follow-up. Juxta- and extrafoveal CNV were also analysed. Treatment was given in accordance with TAP parameters and regular follow-up examinations were performed with standardised ETDRS visual acuity (VA) measurements and fluorescein angiography. Results: In the subfoveal group, in 63.6% (70/110) a loss of VA &GE; 3 lines could be prevented after 1 year, and in 51.1% (23/45) after 2 years. An improvement of &GE; 1 line was found in 31.8% ( 1 year) and in 22.2% of eyes ( 2 years). Severe VA loss of &GE; 6 lines occurred in 10.9% of cases after 1 year and in 15.6% after 2 years. The mean change of VA was - 1.7 +/- 3.4 lines ( 1 year) and - 2.5 +/- 3.9 lines ( 2 years). For the group of CNV with juxta-/ extrafoveal localisation, the mean change of VA was + 0.8 +/- 2.5 lines after 1 year and + 1.0 +/- 4.2 lines after 2 years. With regard to different CNV localisations, the results for juxta-/ extrafoveal CNV are statistical significantly better ( p= 0.005 and p= 0.035 after 1 and 2 years, respectively). A mean of 2.6 treatments were performed in the first year and 0.5 in the second year. Conclusions: The results obtained in a single institution compare favourably with the results of the TAP study. The results regarding functional visual outcome could be obtained with a lower number of treatments in clinical practice. Juxta- and extrafoveal CNV showed significantly better results than a subfoveal localisation of the CNV. In this subgroup a mean improvement of VA could be obtained after 1 or 2 years.
C1 Univ Med Berlin, Dept Ophthalmol, Charite, D-12200 Berlin, Germany.
   Univ Med Berlin, Dept Med Informat Biometry & Epidemiol, Charite, D-12200 Berlin, Germany.
C3 Free University of Berlin; Humboldt University of Berlin; Charite
   Universitatsmedizin Berlin; Free University of Berlin; Humboldt
   University of Berlin; Charite Universitatsmedizin Berlin
RP Wachtlin, J (通讯作者)，Univ Med Berlin, Dept Ophthalmol, Charite, Campus Benjamin Franklin,Hindenburgdamm 30, D-12200 Berlin, Germany.
EM joachim.wachtlin@charite.de
RI Heimann, Heinrich/AAP-8747-2020
OI Heimann, Heinrich/0000-0002-3298-4644
CR Axer-Siegel R, 2004, AM J OPHTHALMOL, V137, P258, DOI 10.1016/j.ajo.2003.08.009
   Barbazetto I, 2003, ARCH OPHTHALMOL-CHIC, V121, P1253
   Barnes RM, 2004, EYE, V18, P809, DOI 10.1038/sj.eye.6701329
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Blinder KJ, 2003, OPHTHALMOLOGY, V110, P667, DOI 10.1016/S0161-6420(02)01998-X
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Cohen SY, 2003, AM J OPHTHALMOL, V136, P371, DOI 10.1016/S0002-9394(03)00201-0
   FINE SL, 1982, ARCH OPHTHALMOL-CHIC, V100, P912
   GELISKEN F, 2004, GRAEFES ARCH CLIN EX
   HAWKINS BS, 1990, ARCH OPHTHALMOL-CHIC, V108, P816
   HAWKINS BS, 1986, ARCH OPHTHALMOL-CHIC, V104, P694
   SCHACHAT AP, 1994, ARCH OPHTHALMOL-CHIC, V112, P500
   Schmidt-Erfurth U, 1998, GRAEF ARCH CLIN EXP, V236, P365, DOI 10.1007/s004170050092
   STERNBERG P, 1991, ARCH OPHTHALMOL-CHIC, V109, P1242
   *VERT ROUNDT 2000, 2002, RETINA, V22, P6
   Wachtlin J, 2004, OPHTHALMOLOGE, V101, P489, DOI 10.1007/s00347-004-0993-5
   Wachtlin J, 2003, GRAEF ARCH CLIN EXP, V241, P899, DOI 10.1007/s00417-003-0734-5
NR 18
TC 11
Z9 12
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING STREET, NEW YORK, NY 10013 USA
SN 0721-832X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD MAY
PY 2005
VL 243
IS 5
BP 438
EP 445
DI 10.1007/s00417-004-1071-z
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 932UB
UT WOS:000229577900008
PM 15672299
DA 2022-11-30
ER

PT J
AU Stein, JD
   Brown, MM
   Brown, GC
   Hollands, H
   Sharma, S
AF Stein, JD
   Brown, MM
   Brown, GC
   Hollands, H
   Sharma, S
TI Quality patients, of life with macular degeneration: perceptions of
   clinicians, and community members
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID AGE-RELATED MACULOPATHY; OF-LIFE; HEALTH; PREFERENCES; ASSESSMENTS;
   UTILITIES; DISEASE
AB Background/aims: Age related macular degeneration (ARMD) is a common ophthalmological disorder that can significantly impair a patient's ability to function independently and potentially have a dramatic impact on health related quality of life. The aim of this study is to evaluate the quality of life of patients with ARMD, through the use of utility evaluation, and assess whether clinicians and healthy volunteers appreciate the impact of ARMD on health related quality of life.
   Methods: A standardised questionnaire using the time-tradeoff method of utility analysis was created to assess health related quality of life. This questionnaire was distributed to 115 patients with ARMD. A similar questionnaire was distributed to 142 healthy volunteers and 62 clinicians who were asked to assume that they had ARMD. Comparisons were made among the responses from the members of the three groups.
   Results: There was a significant difference in the utility scores among respondents with mild, moderate, and severe ARMD when compared to members of the general public and clinicians who were asked to assume they had each severity of ARMD. For mild ARMD the mean utility scores were 0.932, 0.960, and 0.832, for the general public, clinicians, and patients respectively (F=21.7; p<0.001). No significant difference was found between the community members and clinicians (p<0.166); however, the patient group differed significantly from the general public (p<0.001) and clinician (p<0.001) groups. The utility scores for moderate ARMD for the general public, clinicians, and patients were 0.918, 0.877, and 0.732, respectively. (F=34.6, p<0.001). There was no significant difference between the general public and clinicians (p<0.143); however, the patient group differed significantly compared with the general public (p<0.001) and clinician (p<0.001) groups. The utility scores, for people with severe ARMD in the general public, clinician, and patient groups were 0.857, 0.821, and 0.566, respectively (F=45.5; p<0.001). No significant difference was shown between the community members and clinicians (p<0.386); however, a significant difference was seen when comparing the patient group with the community member and clinician (p<0.001) groups.
   Conclusion: Clinicians and community members may greatly underestimate the impact of mild, moderate, and severe ARMD on health related quality of life.
C1 Ctr Evidence Based Hlth Care Econ, Flourtown, PA 19031 USA.
   Thomas Jefferson Univ, Jefferson Med Coll, Wills Eye Hosp, Retina Vasc Unit, Philadelphia, PA 19107 USA.
   Thomas Jefferson Univ, Jefferson Med Coll, Wills Eye Hosp, Cataract & Primary Eye Care Serv, Philadelphia, PA 19107 USA.
   NYU, Dept Ophthalmol, New York, NY 10016 USA.
   Queens Univ, Ocular Cost Effect Policy Unit, Kingston, ON, Canada.
C3 Jefferson University; Jefferson University; New York University; Queens
   University - Canada
RP Brown, MM (通讯作者)，Ctr Evidence Based Hlth Care Econ, Suite 210,1107 Bethlehem Pike, Flourtown, PA 19031 USA.
EM Lissa1011@aol.com
CR Brown G C, 1999, J Health Care Finance, V26, P14
   Brown GC, 2000, CAN J OPHTHALMOL, V35, P27
   Brown M M, 1999, Curr Opin Ophthalmol, V10, P221, DOI 10.1097/00055735-199906000-00012
   Brown MM, 2001, BRIT J OPHTHALMOL, V85, P327, DOI 10.1136/bjo.85.3.327
   Dandona L, 1998, ARCH OPHTHALMOL-CHIC, V116, P545, DOI 10.1001/archopht.116.4.514
   FROBERG DG, 1989, J CLIN EPIDEMIOL, V42, P459, DOI 10.1016/0895-4356(89)90136-4
   Gold MR., 1996, COST EFFECTIVENESS H
   Hazel CA, 2000, INVEST OPHTH VIS SCI, V41, P1309
   Jachuck S J, 1982, J R Coll Gen Pract, V32, P103
   KAHNEMAN D, 1984, AM PSYCHOL, V39, P341, DOI 10.1037/0003-066X.39.4.341
   KAPLAN RM, 1988, HEALTH SERV RES, V23, P203
   Lalonde L, 1999, QUAL LIFE RES, V8, P399, DOI 10.1023/A:1008991816278
   Lieberman JR, 1996, J BONE JOINT SURG AM, V78A, P835, DOI 10.2106/00004623-199606000-00005
   Mallery P, 2000, SPSS WINDOWS STEP ST
   Mangione CM, 1999, AM J OPHTHALMOL, V128, P45, DOI 10.1016/S0002-9394(99)00169-5
   MANGIONE CM, 1992, MED CARE, V30, P1111, DOI 10.1097/00005650-199212000-00004
   National Advisory Eye Council (U.S.), 1993, NIH PUBL
   NORUSIS MJ, 1997, SPSS 9 0 GUIDE DATA
   REDELMEIER DA, 1995, PRIMARY CARE, V22, P271
   Rothwell PM, 1997, BMJ-BRIT MED J, V314, P1580, DOI 10.1136/bmj.314.7094.1580
   Samsa GP, 1998, AM HEART J, V136, P703, DOI 10.1016/S0002-8703(98)70019-5
   Schrader GD, 1997, PSYCHOTHER PSYCHOSOM, V66, P258, DOI 10.1159/000289144
   Smith JP, 1997, J ADV NURS, V25, P1, DOI 10.1046/j.1365-2648.1997.1997025001.x
   Stein J D, 2002, J Clin Hypertens (Greenwich), V4, P181, DOI 10.1111/j.1524-6175.2002.00970.x
   Torrance G W, 1989, Int J Technol Assess Health Care, V5, P559
   TORRANCE GW, 1986, J HEALTH ECON, V5, P1, DOI 10.1016/0167-6296(86)90020-2
   VanNewkirk MR, 2000, OPHTHALMOLOGY, V107, P1593, DOI 10.1016/S0161-6420(00)00175-5
   Ware J.E., 1993, LINC RI QUAL METR IN
NR 28
TC 94
Z9 97
U1 0
U2 0
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
EI 1468-2079
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD JAN
PY 2003
VL 87
IS 1
BP 8
EP 12
DI 10.1136/bjo.87.1.8
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Ophthalmology
GA 631RN
UT WOS:000180180700004
PM 12488253
OA Green Published, Green Submitted, Bronze
DA 2022-11-30
ER

PT J
AU Dietrich, L
   Lucius, R
   Roider, J
   Klettner, A
AF Dietrich, Luisa
   Lucius, Ralph
   Roider, Johann
   Klettner, Alexa
TI Interaction of inflammatorily activated retinal pigment epithelium with
   retinal microglia and neuronal cells
SO EXPERIMENTAL EYE RESEARCH
LA English
DT Article
DE Toll-like receptors; Microglia; Retinal pigment epithelium;
   Lipopolysaccharide; IL-6; IL-8; IL-1 beta; TNF alpha
ID DOUBLE-STRANDED-RNA; TOLL-LIKE RECEPTOR-3; TNF-ALPHA; GENE-EXPRESSION;
   IN-VITRO; INFLAMMASOME ACTIVATION; CHOROIDAL NEOVASCULARIZATION;
   OXIDATIVE STRESS; ARPE-19 CELLS; KAPPA-B
AB In age-related macular degeneration, inflammatory events are presumed to contribute to disease development. A primary suspect of this contribution is the microglia, the innate immune cell of the retina. In addition, retinal pigment epithelium (RPE) cells can be inflammatorily activated. In this study, we investigate the effect of activated RPE cells on retinal microglia and on neuronal cells. RPE cells and microglia were harvested from porcine eyes. In addition, a neuronal cell line (SHSY-5Y) of human origin was used. For inflammatory activation, agonists of toll-like receptors in different concentrations were used: Pam2CSK4 (Pam; TLR-2), Polyinosinic: polycytidylic acid (Poly I:C; TLR-3) and lipopolysaccharid (LPS; TLR-4). Cell viability was investigated with an MTT assay. The secretion of cytokines was assessed in an ELISA and their expression in real-time PCR. There was no effect of the agonists on cell viability in RPE cells. All agonists induced the secretion of IL-6 and IL-8 in RPE cells with the strongest effect induced by LPS. In microglia, pro-inflammatory stimulation increased the metabolic activity. All agonists induced the secretion of IL-1 beta, IL-8, and TNF alpha in microglia cells while in real-time PCR, LPS and Pam induced the expression of IL-6, IL-1 beta and iNOS. Direct stimulation of SHSY-5Y with the agonists induced only minor alterations of viability. Stimulated RPE cell supernatant reduced the secretion of TNF alpha and IL-8 irrespective of the inducing agent in microglia cells. Additionally a slight induction of IL-1 beta was found in microglia treated with supernatant of RPE cells treated with Pam. In real time PCR, the supernatant of RPE cells stimulated with LPS significantly reduced the expression of iNOS and IL-6, but not of IL-1 beta. Of note, the expression of iNOS was also reduced by naive RPE cells. The treatment of the SHSY-5Y with supernatant of microglia previously treated with RPE conditioned medium significantly decreased SHSY-5Y viability with and without pro-inflammatory treatment. In conclusion, inflammatory activated RPE cells have a regulatory effect on the pm-inflammatory activation of microglia, stressing the importance of the interaction between these two retinal cell types. Microglia treated with RPE supernatant reduced viability of a neuronal cell line, indicating a neurotoxic effect.
C1 [Dietrich, Luisa; Roider, Johann; Klettner, Alexa] Univ Kiel, Univ Med Ctr, Dept Ophthalmol, Kiel, Germany.
   [Lucius, Ralph] Univ Kiel, Anat Inst, Kiel, Germany.
C3 University of Kiel; Schleswig Holstein University Hospital; University
   of Kiel
RP Klettner, A (通讯作者)，Univ Kiel, Univ Med Ctr, Quincke Res Ctr, Dept Ophthalmol, Rosalind Franklin Str 9, D-24105 Kiel, Germany.
EM AlexaKarina.Klettner@uksh.de
OI Klettner, Alexa/0000-0002-2709-1059
FU German Retinological Society; Hermann-Wacker foundation
FX This study was supported by the German Retinological Society (Dr. Gaide
   Award) and the Hermann-Wacker foundation. Parts of the study have been
   presented at the Meeting of the German Ophthalmological Society (DOG) in
   Berlin (Germany) 2019, and at the iSearch Meeting in Munster (Germany)
   in 2019.
CR Abcouwer SF., 2013, J CLIN CELL IMMUNOL, VSuppl 1, P1, DOI 10.4172/2155-9899
   Agarwal R, 2012, INDIAN J OPHTHALMOL, V60, P255, DOI 10.4103/0301-4738.98700
   Al-Gayyar MM, 2013, EUR CYTOKINE NETW, V24, P27, DOI 10.1684/ecn.2013.0334
   Alexopoulou L, 2001, NATURE, V413, P732, DOI 10.1038/35099560
   Aravalli RN, 2007, J NEUROIMMUNE PHARM, V2, P297, DOI 10.1007/s11481-007-9071-5
   Asensio-Sanchez V M, 2015, Arch Soc Esp Oftalmol, V90, P527, DOI 10.1016/j.oftal.2015.03.006
   Baptista F.I., 2017, MEDIAT INFLAMM
   BENSON MT, 1992, CURR EYE RES, V11, P173, DOI 10.3109/02713689208999529
   BIEDLER JL, 1978, CANCER RES, V38, P3751
   Chinnery HR, 2015, INVEST OPHTH VIS SCI, V56, P7377, DOI 10.1167/iovs.15-17587
   Chong DY, 2008, INVEST OPHTH VIS SCI, V49, P3193, DOI 10.1167/iovs.07-1641
   Chow JC, 1999, J BIOL CHEM, V274, P10689, DOI 10.1074/jbc.274.16.10689
   DEKOZAK Y, 1994, J NEUROIMMUNOL, V55, P1, DOI 10.1016/0165-5728(94)90141-4
   Detrick B, 2010, IMMUNOL RES, V47, P153, DOI 10.1007/s12026-009-8146-1
   Dick AD, 2004, PROG RETIN EYE RES, V23, P617, DOI 10.1016/j.preteyeres.2004.06.005
   Dithmer M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0089150
   Doktor F, 2018, PURINERG SIGNAL, V14, P471, DOI 10.1007/s11302-018-9631-6
   Ebert S, 2005, J NEUROIMMUNOL, V159, P87, DOI 10.1016/j.jneuroim.2004.10.005
   Ebihara N, 2007, OPHTHAL RES, V39, P155, DOI 10.1159/000103235
   Ehrlich LC, 1998, J IMMUNOL, V160, P1944
   ELNER VM, 1990, AM J PATHOL, V136, P745
   ELNER VM, 1992, EXP EYE RES, V54, P361, DOI 10.1016/0014-4835(92)90048-W
   FERRICK MR, 1991, INVEST OPHTH VIS SCI, V32, P1534
   Fischer AJ, 2015, GLIA, V63, P313, DOI 10.1002/glia.22752
   Fujimoto T, 2010, INVEST OPHTH VIS SCI, V51, P4694, DOI 10.1167/iovs.09-4464
   Ghasemi H, 2011, OCUL IMMUNOL INFLAMM, V19, P401, DOI 10.3109/09273948.2011.618902
   Gomes-Leal W, 2019, NEURAL REGEN RES, V14, P1499, DOI 10.4103/1673-5374.255359
   Graeber MB, 2010, ACTA NEUROPATHOL, V119, P89, DOI 10.1007/s00401-009-0622-0
   Hettich C, 2014, GRAEF ARCH CLIN EXP, V252, P1747, DOI 10.1007/s00417-014-2742-z
   Jakobs TC, 2014, CSH PERSPECT MED, V4, DOI 10.1101/cshperspect.a020636
   Jo DH, 2019, GLIA, V67, P321, DOI 10.1002/glia.23542
   Jonas JB, 2012, ACTA OPHTHALMOL, V90, pe381, DOI 10.1111/j.1755-3768.2012.02414.x
   Joussen AM, 2009, MOL VIS, V15, P1418
   Karlstetter M, 2015, PROG RETIN EYE RES, V45, P30, DOI 10.1016/j.preteyeres.2014.11.004
   Kauppinen A, 2012, IMMUNOL LETT, V147, P29, DOI 10.1016/j.imlet.2012.05.005
   Kern TS, 2007, EXP DIABETES RES, DOI 10.1155/2007/95103
   Klettner A, 2001, MOL BRAIN RES, V97, P21, DOI 10.1016/S0169-328X(01)00286-8
   Klettner A., 2015, RECENT ADV EYE RES, P31
   Klettner A., 2020, OPHTHALMOLOGIE
   Klettner A, 2008, INVEST OPHTH VIS SCI, V49, P4523, DOI 10.1167/iovs.08-2055
   Klettner A, 2014, ACTA OPHTHALMOL, V92, pe621, DOI 10.1111/aos.12472
   Klettner A, 2013, ACTA OPHTHALMOL, V91, pE211, DOI 10.1111/aos.12031
   Klettner AK, 2020, RETINAL PIGMENT EPITHELIUM IN HEALTH AND DISEASE, P295, DOI 10.1007/978-3-030-28384-1_17
   Kochan T, 2012, INFECT IMMUN, V80, P2076, DOI 10.1128/IAI.00149-12
   Kumar A, 2010, J INFECT DIS, V201, P255, DOI 10.1086/649589
   Kumar MV, 2004, J NEUROIMMUNOL, V153, P7, DOI 10.1016/j.jneuroim.2004.04.018
   Langmann T, 2007, J LEUKOCYTE BIOL, V81, P1345, DOI 10.1189/jlb.0207114
   Lavalette S, 2011, AM J PATHOL, V178, P2416, DOI 10.1016/j.ajpath.2011.01.013
   Lee HJ, 2007, INT J NEUROSCI, V117, P885, DOI 10.1080/00207450600592156
   Leibinger M, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.126
   Leung KW, 2009, MOL IMMUNOL, V46, P1374, DOI 10.1016/j.molimm.2008.12.001
   Liu Y, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0082061
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Ma WX, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007945
   Marinelli C, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-015-0458-6
   Mehrabadi ME, 2018, CAN J DIABETES, V42, P639, DOI 10.1016/j.jcjd.2018.03.008
   Murugeswari P, 2008, RETINA-J RET VIT DIS, V28, P817, DOI 10.1097/IAE.0b013e31816576d5
   NAGINENI CN, 1994, CLIN DIAGN LAB IMMUN, V1, P569, DOI 10.1128/CDLI.1.5.569-577.1994
   Nakazawa T, 2006, MOL VIS, V12, P867
   Natoli R, 2017, MOL NEURODEGENER, V12, DOI 10.1186/s13024-017-0175-y
   Nebel C, 2017, BIOCHEM BIOPH RES CO, V484, P681, DOI 10.1016/j.bbrc.2017.01.176
   Paeng SH, 2015, INT J MOL MED, V36, P808, DOI 10.3892/ijmm.2015.2266
   Perez VL, 2004, OCUL IMMUNOL INFLAMM, V12, P193, DOI 10.1080/092739490500282
   Piippo N, 2018, CELL PHYSIOL BIOCHEM, V49, P359, DOI 10.1159/000492886
   Rajalakshmy AR, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0125419
   Riss T. L., 2004, CELL VIABILITY ASSAY
   Rutar M, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-014-0224-1
   Sappington RM, 2006, INVEST OPHTH VIS SCI, V47, P2932, DOI 10.1167/iovs.05-1407
   Saxena S, 2009, OCUL IMMUNOL INFLAMM, V17, P201, DOI 10.1080/09273940902731015
   Shi HQ, 2015, BIOCHEM BIOPH RES CO, V463, P1071, DOI 10.1016/j.bbrc.2015.06.060
   Sivakumar V, 2011, J PATHOL, V224, P245, DOI 10.1002/path.2858
   Sonoi R, 2016, J BIOSCI BIOENG, V121, P220, DOI 10.1016/j.jbiosc.2015.05.019
   Stein-Streilein J, 2013, INT REV IMMUNOL, V32, P42, DOI 10.3109/08830185.2012.740535
   Stockert JC, 2018, ACTA HISTOCHEM, V120, P159, DOI 10.1016/j.acthis.2018.02.005
   Strauss O, 2005, PHYSIOL REV, V85, P845, DOI 10.1152/physrev.00021.2004
   Takeda A, 2018, GLIA, V66, P2366, DOI 10.1002/glia.23475
   Tang S, 2013, J DERMATOL SCI, V70, P42, DOI 10.1016/j.jdermsci.2013.01.008
   Tarassishin L, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-187
   ten Berge JC, 2019, ACTA OPHTHALMOL, V97, P185, DOI 10.1111/aos.13899
   Todd L, 2019, J NEUROINFLAMM, V16, DOI 10.1186/s12974-019-1505-5
   Town T, 2006, J IMMUNOL, V176, P3804, DOI 10.4049/jimmunol.176.6.3804
   Tsai T, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0194603
   Uebersax ED, 2000, EXP EYE RES, V70, P381, DOI 10.1006/exer.1999.0802
   van der Wijk AE, 2017, INVEST OPHTH VIS SCI, V58, P3496, DOI 10.1167/iovs.16-21091
   Wan CK, 2016, J IMMUNOL, V196, P543, DOI 10.4049/jimmunol.1502080
   Wornle M, 2011, INVEST OPHTH VIS SCI, V52, P6536, DOI 10.1167/iovs.10-6993
   Wu N, 2009, OPHTHALMIC RES, V42, P21, DOI 10.1159/000219681
   Xu YF, 2012, J INT MED RES, V40, P1438, DOI 10.1177/147323001204000422
   Yoshida S, 2004, GRAEF ARCH CLIN EXP, V242, P409, DOI 10.1007/s00417-004-0874-2
   Yuan ZH, 2019, MOL VIS, V25, P359
   Zhang YH, 2019, INT J OPHTHALMOL-CHI, V12, P1095, DOI 10.18240/ijo.2019.07.07
   Zheng QJ, 2019, INT IMMUNOPHARMACOL, V71, P313, DOI 10.1016/j.intimp.2019.03.029
   Zhou TWE, 2016, AM J PATHOL, V186, P3100, DOI 10.1016/j.ajpath.2016.08.004
NR 93
TC 6
Z9 6
U1 1
U2 3
PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 0014-4835
EI 1096-0007
J9 EXP EYE RES
JI Exp. Eye Res.
PD OCT
PY 2020
VL 199
AR 108167
DI 10.1016/j.exer.2020.108167
PG 12
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA OH0ED
UT WOS:000582245300006
PM 32735798
DA 2022-11-30
ER

PT J
AU Yumnamcha, T
   Devi, TS
   Singh, LP
AF Yumnamcha, Thangal
   Devi, Takhellembam Swornalata
   Singh, Lalit Pukhrambam
TI Auranofin Mediates Mitochondrial Dysregulation and Inflammatory Cell
   Death in Human Retinal Pigment Epithelial Cells: Implications of Retinal
   Neurodegenerative Diseases
SO FRONTIERS IN NEUROSCIENCE
LA English
DT Article
DE neurodegeneration; mitophagy; auranofin; Trx-TrxR; pyroptosis;
   inflammation; RPE
ID NUCLEAR-ENVELOPE RUPTURE; OXIDATIVE STRESS; DYSFUNCTION; METABOLISM;
   DAMAGE
AB Purpose: Photoreceptor degeneration occurs in various retinal diseases including age-related macular degeneration (AMD), Retinitis pigmentosa (RP), and diabetic retinopathy (DR). However, molecular mechanisms are not fully understood yet. The retinal pigment epithelium (RPE) forms the outer blood retinal barrier (oBRB) and supplies glucose, oxygen and nutrients from the fenestrated choriocapillaris to photoreceptors for visual function. Therefore, RPE dysfunction leads to photoreceptor injury/death and progression of blinding eye diseases. This study aims to understand the role of the thioredoxin (Trx) and its reductase (TrxR) redox signaling in human RPE dysfunction and cell death mechanism(s) in an in vitro system.
   Methods: A human RPE cell line (APRE-19) was cultured in DMEM/F12 medium and treated with auranofin (AF - 4 mu M, an inhibitor of TrxR) for 4 and 24 h. Mitochondrial and lysosomal function, cellular oxidative stress and NLRP3 inflammasome activity were measured using cell assays, Western blotting, and confocal microscopy. Antioxidants and anti-inflammatory compounds were tested for blocking AF effects on RPE damage. Cell death mechanisms (LDH release to culture media) were determined using necroptosis, ferroptosis and pyroptosis inhibitors. P < 0.05 was considered significant in statistical analysis.
   Results: Auranofin causes mitochondrial dysfunction (Delta psi m down arrow and ATP down arrow), oxidative stress (H2O2 up arrow) and mitophagic flux to lysosomes. Furthermore, the lysosomal enzyme (cathepsin L) activity is reduced while that of pro-inflammatory caspase-1 (NLRP3 inflammasome) is enhanced in ARPE-19. These effects of AF on ARPE-19 are inhibited by antioxidant N-acetylcysteine (5 mM, NAC) and significantly by a combination of SS31 (mitochondrial antioxidant) and anti-inflammatory drugs (amlexanox and tranilast). AF also causes cell death as measured by cytosolic LDH release/leakage, which is not inhibited by either ferrostatin-1 or necrostatin-1 (ferroptosis and necroptosis inhibitors, respectively). Conversely, AF-induced LDH release is significantly reduced by MCC950 and Ac-YVAD-cmk (NLRP3 and Caspase-1 inhibitors, respectively), suggesting a pro-inflammatory cell death by pyroptosis.
   Conclusion: The Trx/TrxR redox system is critical for RPE function and viability. We previously showed that thioredoxin-interacting protein (TXNIP) is strongly induced in DR inhibiting the Trx/TrxR system and RPE dysfunction. Therefore, our results suggest that the TXNIP-Trx-TrxR redox pathway may participate in RPE dysfunction in DR and other retinal neurodegenerative diseases.
C1 [Yumnamcha, Thangal; Devi, Takhellembam Swornalata; Singh, Lalit Pukhrambam] Wayne State Univ, Sch Med, Dept Ophthalmol Visual & Anat Sci OVAS, Detroit, MI 48202 USA.
C3 Wayne State University
RP Singh, LP (通讯作者)，Wayne State Univ, Sch Med, Dept Ophthalmol Visual & Anat Sci OVAS, Detroit, MI 48202 USA.
EM ak1157@wayne.edu
RI Yumnamcha, Thangal/AAV-1965-2020
FU Research to Prevent Blindness (RPB) [EY023992];  [P30 EY004068];
   NATIONAL EYE INSTITUTE [P30EY004068, R01EY023992] Funding Source: NIH
   RePORTER
FX This work was supported by the grants EY023992 (LS), Research to Prevent
   Blindness (RPB to OVAS), and Core Grant P30 EY004068 (OVAS).
CR Bapputty R, 2019, DIABETES, V68, P2004, DOI 10.2337/db19-0026
   Bergen AA, 2019, PROG RETIN EYE RES, V70, P55, DOI 10.1016/j.preteyeres.2018.12.003
   Biesemeier A, 2015, EXP EYE RES, V137, P39, DOI 10.1016/j.exer.2015.05.019
   Booty LM, 2019, CELL CHEM BIOL, V26, P449, DOI 10.1016/j.chembiol.2018.12.002
   Campbell M, 2013, ADV EXP MED BIOL, V763, P70
   Campbell MD, 2019, FREE RADICAL BIO MED, V134, P268, DOI 10.1016/j.freeradbiomed.2018.12.031
   Caspard H, 2018, DIABETES OBES METAB, V20, P667, DOI 10.1111/dom.13143
   Cheloni R, 2019, BMJ OPEN, V9, DOI 10.1136/bmjopen-2018-022188
   Chiquita S, 2019, MOL NEUROBIOL, V56, P5416, DOI 10.1007/s12035-018-1461-6
   Country MW, 2017, BRAIN RES, V1672, P50, DOI 10.1016/j.brainres.2017.07.025
   Cunha-Vaz J, 2011, EUR J OPHTHALMOL, V21, pS3, DOI 10.5301/EJO.2010.6049
   Devi TS, 2019, BIOL OPEN, V8, DOI 10.1242/bio.038521
   Devi TS, 2013, EXP CELL RES, V319, P1001, DOI 10.1016/j.yexcr.2013.01.012
   Devi TS, 2012, EXP DIABETES RES, DOI 10.1155/2012/438238
   Devi TS, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.190
   Di Carlo M, 2012, FREE RADICAL RES, V46, P1327, DOI 10.3109/10715762.2012.714466
   Di Paola S, 2019, METHODS MOL BIOL, V1925, P143, DOI 10.1007/978-1-4939-9018-4_12
   Dias Marina Franca, 2018, Prog Retin Eye Res, V63, P107, DOI 10.1016/j.preteyeres.2017.10.004
   Dubois H, 2019, PLOS PATHOG, V15, DOI 10.1371/journal.ppat.1007709
   Fivenson EM, 2017, NEUROCHEM INT, V109, P202, DOI 10.1016/j.neuint.2017.02.007
   Forcina GC, 2019, PROTEOMICS, V19, DOI 10.1002/pmic.201800311
   Forred BJ, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0168777
   Fu ZJ, 2018, EMBO MOL MED, V10, P76, DOI 10.15252/emmm.201707966
   Graham PS, 2018, BMC MED GENET, V19, DOI [10.1186/S12881-018-0587-8, 10.1186/s12881-018-0587-8]
   Handa JT, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-11262-1
   Hanus J, 2016, CELL DEATH DISCOV, V2, DOI 10.1038/cddiscovery.2016.54
   Harper MT, 2019, PLATELETS, V30, P98, DOI 10.1080/09537104.2017.1378809
   Hatch EM, 2016, J CELL BIOL, V215, P27, DOI 10.1083/jcb.201603053
   Huang Y, 2018, EMBO MOL MED, V10, DOI 10.15252/emmm.201708689
   Isobe Y, 2019, J BIOCHEM, V165, P75, DOI 10.1093/jb/mvy084
   Ivanova E, 2019, JCI INSIGHT, V4, DOI 10.1172/jci.insight.126747
   Jiang S, 2019, J IMMUNOL, V203, P1369, DOI 10.4049/jimmunol.1900383
   Jun SJ, 2019, EXP EYE RES, V181, P346, DOI 10.1016/j.exer.2018.09.023
   Kaarniranta K, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20102374
   Lammerding J, 2016, J CELL BIOL, V215, P5, DOI 10.1083/jcb.201609102
   Lill R, 2012, BBA-MOL CELL RES, V1823, P1491, DOI 10.1016/j.bbamcr.2012.05.009
   Lin MT, 2006, NATURE, V443, P787, DOI 10.1038/nature05292
   Liu HT, 2019, INVEST OPHTH VIS SCI, V60, P1538, DOI 10.1167/iovs.18-26433
   Maiorino M, 2018, ANTIOXID REDOX SIGN, V29, P61, DOI 10.1089/ars.2017.7115
   Manczak M, 2019, HUM MOL GENET, V28, P177, DOI 10.1093/hmg/ddy335
   Medina DL, 2015, NAT CELL BIOL, V17, P288, DOI 10.1038/ncb3114
   Moreno ML, 2018, FRONT PHYSIOL, V9, DOI 10.3389/fphys.2018.01008
   Napolitano G, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-05862-6
   Ni HM, 2015, REDOX BIOL, V4, P6, DOI 10.1016/j.redox.2014.11.006
   Oral EA, 2017, CELL METAB, V26, P157, DOI 10.1016/j.cmet.2017.06.006
   Pan HY, 2019, CELL MOL BIOL LETT, V24, DOI 10.1186/s11658-019-0159-8
   Pareek G, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-1213-6
   Perrone L, 2010, CELL DEATH DIS, V1, DOI 10.1038/cddis.2010.42
   Pronin A, 2019, FRONT MOL NEUROSCI, V12, DOI 10.3389/fnmol.2019.00036
   Ren XY, 2017, ANTIOXID REDOX SIGN, V27, P989, DOI 10.1089/ars.2016.6925
   Salma N, 2015, J CELL PHYSIOL, V230, P2330, DOI 10.1002/jcp.24978
   Samie MA, 2014, J LIPID RES, V55, P995, DOI 10.1194/jlr.R046896
   Settembre C, 2015, METHOD CELL BIOL, V126, P45, DOI 10.1016/bs.mcb.2014.11.011
   Shu WT, 2018, PHARMACEUTICALS-BASE, V11, DOI 10.3390/ph11040112
   Singh Lalit P, 2013, J Clin Exp Ophthalmol, V4, DOI 10.4172/2155-9570.1000287
   Spencer WJ, 2019, P NATL ACAD SCI USA, V116, P13087, DOI 10.1073/pnas.1906421116
   Stephenson J, 2018, IMMUNOLOGY, V154, P204, DOI 10.1111/imm.12922
   Tarchick MJ, 2019, EXP EYE RES, V180, P63, DOI 10.1016/j.exer.2018.11.020
   Warburton S, 2007, MOL VIS, V13, P318
   Wilkins HM, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00508
   Xia T, 2017, VISION RES, V139, P72, DOI 10.1016/j.visres.2017.02.006
   Yoshida M, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-10991-7
   Yoshihara E, 2014, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00514
   Zhao YY, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-09291-x
   Zhou BR, 2020, SEMIN CANCER BIOL, V66, P89, DOI 10.1016/j.semcancer.2019.03.002
NR 65
TC 35
Z9 36
U1 6
U2 21
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
EI 1662-453X
J9 FRONT NEUROSCI-SWITZ
JI Front. Neurosci.
PD OCT 10
PY 2019
VL 13
AR 1065
DI 10.3389/fnins.2019.01065
PG 15
WC Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology
GA JO4VR
UT WOS:000497578700001
PM 31649499
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Do, DV
   Gower, EW
   Cassard, SD
   Boyer, D
   Bressler, NM
   Bressler, SB
   Heier, JS
   Jefferys, JL
   Singerman, LJ
   Solomon, SD
AF Do, Diana V.
   Gower, Emily W.
   Cassard, Sandra D.
   Boyer, David
   Bressler, Neil M.
   Bressler, Susan B.
   Heier, Jeffrey S.
   Jefferys, Joan L.
   Singerman, Lawrence J.
   Solomon, Sharon D.
TI Detection of New-Onset Choroidal Neovascularization Using Optical
   Coherence Tomography The AMD DOC Study
SO OPHTHALMOLOGY
LA English
DT Article
ID MACULAR DEGENERATION; LESIONS; EYE
AB Purpose: To determine the sensitivity of time domain optical coherence tomography (OCT) in detecting conversion to neovascular age-related macular degeneration (AMD) in eyes at high risk for choroidal neovascularization (CNV), compared with detection using fluorescein angiography (FA) as the gold standard.
   Design: Prospective, multicenter, observational study.
   Participants: Individuals aged >= 50 years with nonneovascular AMD at high risk of progressing to CNV in the study eye and evidence of neovascular AMD in the fellow eye.
   Methods: At study entry and every 3 months through 2 years, participants underwent best-corrected visual acuity, supervised Amsler grid testing, preferential hyperacuity perimetry (PHP) testing, stereoscopic digital fundus photographs with FA, and OCT imaging. A central Reading Center graded all images.
   Main Outcomes Measures: The sensitivity of OCT in detecting conversion to neovascular AMD by 2 years, using FA as the reference standard. Secondary outcomes included comparison of sensitivity, specificity, positive predictive value, and negative predictive value of OCT, PHP, and supervised Amsler grid relative to FA for detecting incident CNV.
   Results: A total of 98 participants were enrolled; 87 (89%) of these individuals either completed the 24-month visit or exited the study after developing CNV. Fifteen (17%) study eyes had incident CNV confirmed on FA by the Reading Center. The sensitivity of each modality for detecting CNV was: OCT 0.40 (95% confidence interval [CI], 0.16-0.68), supervised Amsler grid 0.42 (95% CI, 0.15-0.72), and PHP 0.50 (95% CI, 0.23-0.77). Treatment for incident CNV was recommended by the study investigator in 13 study eyes. Sensitivity of the testing modalities for detection of CNV in these 13 eyes was 0.69 (95% CI, 0.39-0.91) for OCT, 0.50 (95% CI, 0.19-0.81) for supervised Amsler grid, and 0.70 (95% CI, 0.35-0.93) for PHP. Specificity of the OCT was higher than that of the Amsler grid and PHP.
   Conclusions: Time-domain OCT, supervised Amsler grid, and PHP have low to moderate sensitivity for detection of new-onset CNV compared with FA. Optical coherence tomography has greater specificity than Amsler grid or PHP. Among fellow eyes of individuals with unilateral CNV, FA remains the best method to detect new-onset CNV.
   Financial Disclosure(s): Proprietary or commercial disclosure may be found after the references. Ophthalmology 2012;119:771-778 (C) 2012 by the American Academy of Ophthalmology.
C1 [Do, Diana V.; Cassard, Sandra D.; Bressler, Neil M.; Bressler, Susan B.; Jefferys, Joan L.; Solomon, Sharon D.] Johns Hopkins Univ, Sch Med, Wilmer Eye Inst, Baltimore, MD 21205 USA.
   [Gower, Emily W.] Wake Forest Sch Med, Dept Epidemiol & Prevent, Winston Salem, NC USA.
   [Boyer, David] Retina Vitreous Associates Med Grp, Los Angeles, CA USA.
   [Heier, Jeffrey S.] Ophthalm Consultants Boston, Boston, MA USA.
   [Singerman, Lawrence J.] Retina Associates Cleveland, Cleveland, OH USA.
C3 Johns Hopkins University; Johns Hopkins Medicine; Wake Forest
   University; Retina Vitreous Associates Medical Group; Ophthalmic
   Consultants of Boston; Retina Associates of Cleveland, Inc.
RP Gower, EW (通讯作者)，Wake Forest Publ Hlth Sci, Med Ctr Blvd, Winston Salem, NC 27157 USA.
EM egower@wakehealth.edu
FU Research to Prevent Blindness; Lincy Foundation
FX The authors have made the following disclosures:; Emily W. Gower is the
   recipient of a Research to Prevent Blindness Ernest and Elizabeth
   Althouse Special Scholar's Award.; Funded by an unrestricted gift from
   the Lincy Foundation to the Johns Hopkins University.
CR ACHARD OA, 1995, AM J OPHTHALMOL, V120, P322, DOI 10.1016/S0002-9394(14)72162-2
   Alster Y, 2005, OPHTHALMOLOGY, V112, P1758, DOI 10.1016/j.ophtha.2005.06.008
   Barbazetto I, 2003, ARCH OPHTHALMOL-CHIC, V121, P1253
   Barbazetto IA, 2010, AM J OPHTHALMOL, V149, P939, DOI 10.1016/j.ajo.2010.01.007
   Bressler NM, 2008, AM J OPHTHALMOL, V145, P894, DOI 10.1016/j.ajo.2007.12.025
   Ferris FL, 2005, ARCH OPHTHALMOL-CHIC, V123, P1570
   FINE AM, 1986, ARCH OPHTHALMOL-CHIC, V104, P513
   Grossniklaus HE, 2005, ARCH OPHTHALMOL-CHIC, V123, P914
   HAWKINS BS, 1990, ARCH OPHTHALMOL-CHIC, V108, P816
   KAAS JH, 1990, SCIENCE, V248, P229, DOI 10.1126/science.2326637
   Khurana RN, 2010, OPHTHALMOLOGY, V117, P1376, DOI 10.1016/j.ophtha.2009.11.039
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   PIZZARELLO LD, 1987, OPHTHALMOLOGY, V94, P1191
   ROY MS, 1985, OPHTHALMOLOGICA, V191, P215, DOI 10.1159/000309590
   SCHUCHARD RA, 1993, ARCH OPHTHALMOL-CHIC, V111, P776, DOI 10.1001/archopht.1993.01090060064024
   WALL M, 1986, ARCH OPHTHALMOL-CHIC, V104, P520, DOI 10.1001/archopht.1986.01050160076015
   WESTHEIMER G, 1979, INVEST OPHTH VIS SCI, V18, P893
NR 17
TC 55
Z9 60
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0161-6420
J9 OPHTHALMOLOGY
JI Ophthalmology
PD APR
PY 2012
VL 119
IS 4
BP 771
EP 778
DI 10.1016/j.ophtha.2011.10.019
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 919UQ
UT WOS:000302355400016
PM 22297028
DA 2022-11-30
ER

PT J
AU Chou, R
   Dana, T
   Bougatsos, C
AF Chou, Roger
   Dana, Tracy
   Bougatsos, Christina
TI Screening Older Adults for Impaired Visual Acuity: A Review of the
   Evidence for the US Preventive Services Task Force
SO ANNALS OF INTERNAL MEDICINE
LA English
DT Article
ID QUALITY-OF-LIFE; EYE CATARACT-SURGERY; MACULAR DEGENERATION; REFRACTIVE
   ERROR; MICROBIAL KERATITIS; HEALTH-STATUS; RISK-FACTORS; VISION; FALLS;
   RANIBIZUMAB
AB Background: Impaired visual acuity is common in older adults. Screening for impaired visual acuity could lead to interventions to improve vision, function, and quality of life.
   Purpose: To update the 1996 U. S. Preventive Services Task Force evidence review on benefits and harms of screening for impaired visual acuity in primary care settings in adults age 65 years or older.
   Data Sources: MEDLINE and the Cochrane Central Register of Controlled Trials and the Cochrane Database of Systematic Reviews were searched for studies published in English from 1996 to July 2008.
   Study Selection: Randomized trials and controlled observational studies that directly evaluated screening for impaired visual acuity in older adults were selected. To evaluate indirect evidence on screening, investigators included studies of diagnostic test accuracy and systematic reviews, randomized trials, and controlled observational studies of treatments for uncorrected refractive errors, cataracts, and age-related macular degeneration (AMD).
   Data Extraction: Details were abstracted about the patient sample, study design, data analysis, follow-up, and results. Quality was assessed by using predefined criteria.
   Data Synthesis: Direct evidence on screening and evidence on accuracy of diagnostic tests were synthesized qualitatively. For benefits and harms of treatments, quantitative estimates for treatment effects from good-quality systematic reviews were reported or relative risks using a random-effects model were calculated. Direct evidence shows that screening for vision impairment in older adults in primary care settings is not associated with improved visual or other clinical outcomes and may be associated with unintended harms, such as increased falls. Effective treatments are available for uncorrected refractive error, cataracts, and AMD. A visual acuity test (for example, the Snellen eye chart) is the standard for screening for vision impairment in primary care, but its diagnostic accuracy is uncertain because no studies compare it against a clinically relevant reference standard. There remains no evidence on accuracy of funduscopic examination.
   Limitations: A relatively small number of primary studies and methodological shortcomings made it difficult to reach conclusions with a high degree of confidence. In addition, studies not published in English and studies of community- or home-based screening were not included.
   Conclusion: More research is needed to understand why direct evidence shows no benefits of screening, even though impaired visual acuity is common and effective treatments are available.
C1 [Chou, Roger; Dana, Tracy; Bougatsos, Christina] Oregon Hlth & Sci Ctr, Portland, OR USA.
C3 Oregon Health & Science University
RP Chou, R (通讯作者)，Oregon Hlth & Sci Univ, 3181 SW Sam Jackson Pk Rd,Mail Code BICC, Portland, OR 97239 USA.
EM chour@ohsu.edu
OI Chou, Roger/0000-0001-9889-8610
FU Agency for Healthcare Research and Quality [HHSA-290-2007-10057-I-EPC3]
FX By the Agency for Healthcare Research and Quality (contract
   HHSA-290-2007-10057-I-EPC3, Task Order No. 3).
CR Alpha-Tocopherol Beta Carotene Cancer Prevention Study Group, 1994, N Engl J Med, V330, P1029, DOI 10.1056/NEJM199404143301501
   [Anonymous], 1982, Br J Ophthalmol, V66, P745
   [Anonymous], 1991, Arch Ophthalmol, V109, P1220
   APPLEGATE WB, 1987, JAMA-J AM MED ASSOC, V257, P1064
   Ariyasu RG, 1996, OPHTHALMOLOGY, V103, P1751, DOI 10.1016/S0161-6420(96)30431-4
   Arnold J, 2001, OPHTHALMOLOGY, V108, P841
   Arnold J, 2001, AM J OPHTHALMOL, V131, P541
   Arnold JJ, 2004, AM J OPHTHALMOL, V137, P683, DOI 10.1016/j.ajo.2003.11.059
   AVERY RL, GOOD NEWS ANTIVEGF T
   Boyer DS, 2007, OPHTHALMOLOGY, V114, P246, DOI 10.1016/j.ophtha.2006.10.045
   Bressler NM, 2002, ARCH OPHTHALMOL-CHIC, V120, P1307
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Campbell MK, 2004, BMJ-BRIT MED J, V328, P702, DOI 10.1136/bmj.328.7441.702
   Chalmers RL, 2007, OPTOMETRY VISION SCI, V84, P573, DOI 10.1097/OPX.0b013e3180dc9a12
   Chang TS, 2007, ARCH OPHTHALMOL-CHIC, V125, P1460, DOI 10.1001/archopht.125.11.1460
   Cheng KH, 1999, LANCET, V354, P181, DOI 10.1016/S0140-6736(98)09385-4
   Chou R., 2009, AHRQ PUBLICATION
   Coleman AL, 2006, J AM GERIATR SOC, V54, P883, DOI 10.1111/j.1532-5415.2006.00817.x
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Cumming RG, 2007, J AM GERIATR SOC, V55, P175, DOI 10.1111/j.1532-5415.2007.01046.x
   D'Amico DJ, 2006, OPHTHALMOLOGY, V113, P992, DOI 10.1016/j.ophtha.2006.02.027
   Eekhof JAH, 2000, SCAND J PRIM HEALTH, V18, P203
   Eekhof JAH, 2000, FAM PRACT, V17, P329, DOI 10.1093/fampra/17.4.329
   Evans JR, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000253.pub2
   Feher J, 2005, OPHTHALMOLOGICA, V219, P154, DOI 10.1159/000085248
   FINE SL, 1982, ARCH OPHTHALMOL-CHIC, V100, P912
   FLEMING C, 2005, 34 AG HEALTHC RES QU
   Foss AJE, 2006, AGE AGEING, V35, P66, DOI 10.1093/ageing/afj005
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Greve MDJ, 2005, ARCH OPHTHALMOL-CHIC, V123, P448
   Harris RP, 2001, AM J PREV MED, V20, P21, DOI 10.1016/S0749-3797(01)00261-6
   Harwood RH, 2005, BRIT J OPHTHALMOL, V89, P53, DOI 10.1136/bjo.2004.049478
   HAWKINS BS, 1990, ARCH OPHTHALMOL-CHIC, V108, P816
   HILLER R, 1983, AM J PUBLIC HEALTH, V73, P93, DOI 10.2105/AJPH.73.1.93
   Ivers RQ, 1998, J AM GERIATR SOC, V46, P58
   Ivers RQ, 2001, OPHTHALMOLOGY, V108, P968, DOI 10.1016/S0161-6420(00)00649-7
   JAESCHKE R, 1994, JAMA-J AM MED ASSOC, V271, P703, DOI 10.1001/jama.271.9.703
   Johnson AR, 2007, J UROLOGY, V177, P639, DOI 10.1016/j.juro.2006.09.047
   KAISER HJ, 1995, OPHTHALMOLOGICA, V209, P302, DOI 10.1159/000310646
   Kaiser PK, 2006, GRAEF ARCH CLIN EXP, V244, P1132, DOI 10.1007/s00417-005-0199-9
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1439, DOI 10.1001/archopht.119.10.1439
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Kempen AH, 2004, ARCH OPHTHALMOL-CHIC, V122, P495
   Klein BEK, 2003, OPHTHALMOLOGY, V110, P644, DOI 10.1016/S0161-6420(02)01935-8
   Lee AG, 2001, J AM GERIATR SOC, V49, P673
   Leys A, 2008, EYE, V22, P792, DOI 10.1038/sj.eye.6702900
   Lonn E, 2005, JAMA-J AM MED ASSOC, V293, P1338, DOI 10.1001/jama.293.11.1338
   Lord SR, 2002, J AM GERIATR SOC, V50, P1760, DOI 10.1046/j.1532-5415.2002.50502.x
   Lundstrom M, 2000, J CATARACT REFR SURG, V26, P408, DOI 10.1016/S0886-3350(99)00418-6
   MANGIONE CM, 1994, ARCH OPHTHALMOL-CHIC, V112, P1419, DOI 10.1001/archopht.1994.01090230033017
   McDonnell PJ, 2003, OPHTHALMOLOGY, V110, P2302, DOI 10.1016/j.ophtha.2003.02.004
   McGwin G, 2000, ACCIDENT ANAL PREV, V32, P735, DOI 10.1016/S0001-4575(99)00123-2
   McGwin G, 2003, OPHTHAL EPIDEMIOL, V10, P303, DOI 10.1076/opep.10.5.303.17323
   McGwin G, 2003, OPHTHALMIC EPIDEMIOL, V10, P107, DOI 10.1076/opep.10.2.107.13900
   MCMURDO M E T, 1988, Health Bulletin (Edinburgh), V46, P327
   Meads C, 2003, Health Technol Assess, V7, pv
   Meads C, 2003, HEALTH TECHNOL ASSES, V7, p[v, 1], DOI [10.3310/hta7090, DOI 10.3310/hta7090]
   Moore AA, 1997, AM J MED, V102, P371, DOI 10.1016/S0002-9343(97)00089-2
   MURRAY A, 2005, SYSTEMATIC REV SAFET
   National Institute for Health and Clinical Excellence, 2006, GUID MAN
   Nilsson Sven Erik G., 1994, CLAO Journal, V20, P225
   NORRIS SL, 2008, 61 AG HEALTHC RES QU
   Omenn GS, 1996, NEW ENGL J MED, V334, P1150, DOI 10.1056/NEJM199605023341802
   Owsley C, 2002, JAMA-J AM MED ASSOC, V288, P841, DOI 10.1001/jama.288.7.841
   Owsley C, 2007, BRIT J OPHTHALMOL, V91, DOI 10.1136/bjo.2007.118547
   Owsley C, 2007, ARCH OPHTHALMOL-CHIC, V125, P1471, DOI 10.1001/archopht.125.11.1471
   OXMAN AD, 1991, J CLIN EPIDEMIOL, V44, P1271, DOI 10.1016/0895-4356(91)90160-B
   POWE NR, 1994, ARCH OPHTHALMOL-CHIC, V112, P239, DOI 10.1001/archopht.1994.01090140115033
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   Richer Stuart, 2004, Optometry, V75, P216, DOI 10.1016/S1529-1839(04)70049-4
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Schaumberg DA, 1998, OPHTHALMOLOGY, V105, P1213, DOI 10.1016/S0161-6420(98)97023-3
   SCHEIN OD, 1994, OPHTHALMOLOGY, V101, P1142
   Schein OD, 2001, J CATARACT REFR SURG, V27, P665, DOI 10.1016/S0886-3350(01)00844-6
   Schein OD, 2005, OPHTHALMOLOGY, V112, P2172, DOI 10.1016/j.ophtha.2005.09.014
   Smeeth L, 2003, BMJ-BRIT MED J, V327, P1027, DOI 10.1136/bmj.327.7422.1027
   STEINBERG EP, 1994, OPHTHALMOLOGY, V101, P1131
   STERNBERG P, 1991, ARCH OPHTHALMOL-CHIC, V109, P1232
   Taban M, 2005, ARCH OPHTHALMOL-CHIC, V123, P613, DOI 10.1001/archopht.123.5.613
   Tahzib NG, 2005, J CATARACT REFR SURG, V31, P1943, DOI 10.1016/j.jcrs.2005.08.022
   Taylor HR, 2004, INVEST OPHTH VIS SCI, V45, P2539, DOI 10.1167/iovs.03-1198
   Teh RCA, 2006, J AM GERIATR SOC, V54, P370, DOI 10.1111/j.1532-5415.2005.00592_4.x
   *US PREV SERV TASK, 1996, GUID CLIN PREV SERV, pCH33
   Vedula SS, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005139.pub2
   Virgili G, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004763.pub2
   Vitale S, 2006, JAMA-J AM MED ASSOC, V295, P2158, DOI 10.1001/jama.295.18.2158
   Wang F, 1998, Ophthalmic Epidemiol, V5, P69, DOI 10.1076/opep.5.2.69.1575
   West SK, 1997, INVEST OPHTH VIS SCI, V38, P72
   Whitlock EP, 2008, ANN INTERN MED, V148, P776, DOI 10.7326/0003-4819-148-10-200805200-00010
   Woods RL, 1998, OPHTHALMOLOGY, V105, P2318, DOI 10.1016/S0161-6420(98)91235-0
   Wormald R, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002030.pub3
NR 92
TC 33
Z9 34
U1 1
U2 2
PU AMER COLL PHYSICIANS
PI PHILADELPHIA
PA INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA
SN 0003-4819
EI 1539-3704
J9 ANN INTERN MED
JI Ann. Intern. Med.
PD JUL 7
PY 2009
VL 151
IS 1
BP 44
EP U81
DI 10.7326/0003-4819-151-1-200907070-00008
PG 25
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA 470BF
UT WOS:000267946100006
PM 19581646
DA 2022-11-30
ER

PT J
AU Panvini, AR
   Gvritishvili, A
   Galvan, H
   Nashine, SR
   Atilano, SR
   Kenney, MC
   Tombran-Tink, J
AF Panvini, Ana Rubin
   Gvritishvili, Anzor
   Galvan, Hannah
   Nashine, Sonali R.
   Atilano, Shari R.
   Kenney, M. Cristina
   Tombran-Tink, Joyce
TI Differential mitochondrial and cellular responses between H vs. J mtDNA
   haplogroup-containing human RPE transmitochondrial cybrid cells
SO EXPERIMENTAL EYE RESEARCH
LA English
DT Article
DE AMD; Age-related macular degeneration; Mitochondrial DNA haplogroups;
   mtDNA H haplogroup; mtDNA J haplogroup
ID HEREDITARY OPTIC NEUROPATHY; OXIDATIVE DAMAGE; MATRIX
   METALLOPROTEINASES; MACULAR DEGENERATION; DNA HAPLOGROUPS;
   SELENOPROTEIN-P; F-ACTIN; CALCIUM; STRESS; EXPRESSION
AB Mitochondrial dysfunction is associated with several retinal degenerative diseases including Age-related Macular Degeneration (AMD). Human mitochondrial DNA (mtDNA) haplogroups are inherited from a common ancestral clan and are defined by specific sets of genetic differences. The purpose of this study was to determine and compare the effects of mtDNA haplogroups H and J on transcriptome regulation and cellular resilience to oxidative stress in human RPE cytoplasmic hybrid (cybrid) cell lines in vitro.& nbsp;ARPE-19 cybrid cell lines containing mtDNA haplogroups H and J were created by fusing platelets obtained from normal individuals containing H and J haplogroups with mitochondria-deficient (Rho0) ARPE-19 cell lines. These cybrids were exposed to oxidative stress using 300 mu M hydrogen peroxide (H2O2), following which mitochondrial structural dynamics was studied at varying time points using the mitochondrial markers TOMM20 (Translocase of Outer Mitochondrial Membrane 20) and Mitotracker. To evaluate mitochondrial function, levels of ROS, delta psi m and [Ca2+]m were measured using flow cytometry, and ATP levels were measured using luminescence. The H and J cybrid cell transcriptomes were compared using RNAseq to determine how changes in mtDNA regulate gene expression. Inflammatory and angiogenic markers were measured using Luminex assay to understand how these mtDNAs influenced cellular response to oxidative stress. Actin filaments' morphology was examined using confocal microscopy.& nbsp;Following exposure to H2O2 stress, the J cybrids showed increased mitochondrial swelling and perinuclear localization, disturbed fission and fusion, increased calcium uptake (p < 0.05), and higher secreted levels of TNF alpha and VEGF (p < 0.001), compared to the H cybrids. Calcium uptake by J cybrids was reduced using an IP3R inhibitor. Thirteen genes involved in mitochondrial complex I and V function, fusion/fission events, cellular energy homeostasis, antioxidant defenses, and inflammatory responses, were significantly downregulated with log2 fold changes ranging between-1.5 and-5.1. Actin levels were also significantly reduced in stressed J cybrids (p < 0.001) and disruption in actin filaments was observed. Thirty-eight genes involved in mitochondrial and cellular support functions, were upregulated with log2 fold changes of +1.5 to +5.9 in J cybrids compared to H cybrids.& nbsp;Our results demonstrate significant structural and functional differences between mtDNA haplogroups H vs. J-containing cybrid cells. Our study suggests that the J mtDNA haplogroup can alter the transcriptome to increase cellular susceptibility to stress and retinal degenerations.
C1 [Panvini, Ana Rubin; Gvritishvili, Anzor; Galvan, Hannah; Atilano, Shari R.; Tombran-Tink, Joyce] Penn State Coll Med, Dept Neural & Behav Sci, Hershey, PA 17033 USA.
   [Atilano, Shari R.; Tombran-Tink, Joyce] Penn State Coll Med, Dept Ophthalmol, Hershey, PA 17033 USA.
   [Nashine, Sonali R.; Atilano, Shari R.; Kenney, M. Cristina] Univ Calif Irvine, Gavin Herbert Eye Inst, Dept Ophthalmol, Irvine, CA 92697 USA.
   [Atilano, Shari R.; Tombran-Tink, Joyce] Penn State Coll Med, Hershey, PA 17033 USA.
C3 Pennsylvania Commonwealth System of Higher Education (PCSHE);
   Pennsylvania State University; Penn State Health; Pennsylvania
   Commonwealth System of Higher Education (PCSHE); Pennsylvania State
   University; Penn State Health; University of California System;
   University of California Irvine; Pennsylvania Commonwealth System of
   Higher Education (PCSHE); Pennsylvania State University; Penn State
   Health
RP Tombran-Tink, J (通讯作者)，Penn State Coll Med, Dept Neural & Behav Sci, Hershey, PA 17033 USA.; Tombran-Tink, J (通讯作者)，Penn State Coll Med, Dept Ophthalmol, Hershey, PA 17033 USA.; Tombran-Tink, J (通讯作者)，Penn State Coll Med, Hershey, PA 17033 USA.
EM jxt57@psu.edu
CR Alge-Priglinger CS, 2009, INVEST OPHTH VIS SCI, V50, P5495, DOI 10.1167/iovs.08-3193
   Amer J, 2003, EUR J HAEMATOL, V70, P84, DOI 10.1034/j.1600-0609.2003.00011.x
   ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0
   Balaban RS, 2005, CELL, V120, P483, DOI 10.1016/j.cell.2005.02.001
   Bezprozvanny I, 2011, NEUROCHEM RES, V36, P1186, DOI 10.1007/s11064-010-0393-y
   Boldogh IR, 2006, BBA-MOL CELL RES, V1763, P450, DOI 10.1016/j.bbamcr.2006.02.014
   Brookes PS, 2004, AM J PHYSIOL-CELL PH, V287, pC817, DOI 10.1152/ajpcell.00139.2004
   Brown MD, 1997, AM J HUM GENET, V60, P381
   Cooper G. M., 2000, CELL MOL APPROACH, V2nd
   Egorova P, 2015, SEMIN CELL DEV BIOL, V40, P127, DOI 10.1016/j.semcdb.2015.03.010
   Egorova PA, 2018, FEBS J, V285, P3547, DOI 10.1111/febs.14366
   ERNSTER L, 1981, J CELL BIOL, V91, pS227, DOI 10.1083/jcb.91.3.227s
   Esposti MD, 2002, METHODS, V26, P335, DOI 10.1016/S1046-2023(02)00039-7
   Fehrenbacher KL, 2004, CURR BIOL, V14, P1996, DOI 10.1016/j.cub.2004.11.004
   Frank S, 2001, DEV CELL, V1, P515, DOI 10.1016/S1534-5807(01)00055-7
   FURUKAWA K, 1995, EXP NEUROL, V133, P153, DOI 10.1006/exnr.1995.1018
   GEIGER K, 1994, INVEST OPHTH VIS SCI, V35, P2667
   Guo L, 1999, INVEST OPHTH VIS SCI, V40, P2676
   Hamid MA, 2021, CELLS-BASEL, V10, DOI 10.3390/cells10040878
   He Y, 2008, INVEST OPHTH VIS SCI, V49, P4912, DOI 10.1167/iovs.08-2192
   Herrnstadt C, 2002, AM J HUM GENET, V70, P1152, DOI 10.1086/339933
   Hisatsune C, 2017, J NEUROCHEM, V141, P790, DOI 10.1111/jnc.13991
   Hudson G, 2007, AM J HUM GENET, V81, P228, DOI 10.1086/519394
   Ishii M, 2017, CELL DEATH DISCOV, V3, DOI 10.1038/cddiscovery.2016.71
   Jones MM, 2007, ARCH OPHTHALMOL-CHIC, V125, P1235, DOI 10.1001/archopht.125.9.1235
   Kaarniranta K, 2020, PROG RETIN EYE RES, V79, DOI 10.1016/j.preteyeres.2020.100858
   Kazuno AA, 2008, MITOCHONDRION, V8, P164, DOI 10.1016/j.mito.2007.12.002
   Kazuno AA, 2006, PLOS GENET, V2, P1167, DOI 10.1371/journal.pgen.0020128
   Kenney MC, 2014, HUM MOL GENET, V23, P3537, DOI 10.1093/hmg/ddu065
   Kenney MC, 2014, BBA-MOL BASIS DIS, V1842, P208, DOI 10.1016/j.bbadis.2013.10.016
   Kenney MC, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054339
   Kenney MC, 2013, BMC MED GENET, V14, DOI 10.1186/1471-2350-14-4
   Khan AH, 2022, EYE, V36, P2192, DOI 10.1038/s41433-021-01824-3
   Kim YS, 2012, BIOMOL THER, V20, P133, DOI 10.4062/biomolther.2012.20.2.133
   Kowluru RA, 2007, EXP DIABETES RES, DOI 10.1155/2007/43603
   Kvanta A, 1996, INVEST OPHTH VIS SCI, V37, P1929
   Lin MT, 2006, NATURE, V443, P787, DOI 10.1038/nature05292
   LINNANE AW, 1989, LANCET, V1, P642, DOI 10.1016/S0140-6736(89)92145-4
   Lustbader JW, 2004, SCIENCE, V304, P448, DOI 10.1126/science.1091230
   Malik D, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0099003
   Marshall WF, 2012, BMC BIOL, V10, DOI 10.1186/1741-7007-10-101
   MCCORMACK JG, 1993, DEV NEUROSCI-BASEL, V15, P165, DOI 10.1159/000111332
   Moore AS, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12886
   MORRIS RL, 1995, J CELL BIOL, V131, P1315, DOI 10.1083/jcb.131.5.1315
   Mueller EE, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030874
   Nagase H, 2006, CARDIOVASC RES, V69, P562, DOI 10.1016/j.cardiores.2005.12.002
   Olichon A, 2002, FEBS LETT, V523, P171, DOI 10.1016/S0014-5793(02)02985-X
   Osborne NN, 2010, EXP EYE RES, V90, P750, DOI 10.1016/j.exer.2010.03.008
   Pinton P, 2008, ONCOGENE, V27, P6407, DOI 10.1038/onc.2008.308
   RICHTER C, 1988, P NATL ACAD SCI USA, V85, P6465, DOI 10.1073/pnas.85.17.6465
   Rivero F, 1996, J CELL SCI, V109, P2679
   Rizzuto R, 2009, BBA-BIOENERGETICS, V1787, P1342, DOI 10.1016/j.bbabio.2009.03.015
   Rubin A, 2016, BMC GENOMICS, V17, DOI 10.1186/s12864-016-3199-8
   Santel A, 2001, J CELL SCI, V114, P867
   Sastre J, 2000, IUBMB LIFE, V49, P427
   Schapira AHV, 2008, LANCET NEUROL, V7, P97, DOI 10.1016/S1474-4422(07)70327-7
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P774, DOI 10.1001/archopht.123.6.774
   SHIGENAGA MK, 1994, P NATL ACAD SCI USA, V91, P10771, DOI 10.1073/pnas.91.23.10771
   Steinbrenner H, 2006, FREE RADICAL RES, V40, P936, DOI 10.1080/10715760600806248
   Steinbrenner H, 2006, FREE RADICAL BIO MED, V40, P1513, DOI 10.1016/j.freeradbiomed.2005.12.022
   Takemoto A.S., 2010, WINTER ETHN DIS, V20, P5
   Torroni A, 1997, AM J HUM GENET, V60, P1107
   Touhami S., 2018, THE J
   van Oven M, 2009, HUM MUTAT, V30, pE386, DOI 10.1002/humu.20921
   Wallace DC, 2005, ANNU REV GENET, V39, P359, DOI 10.1146/annurev.genet.39.110304.095751
   WALLACE DC, 1994, P NATL ACAD SCI USA, V91, P8739, DOI 10.1073/pnas.91.19.8739
   Wallace DC, SCIENCE, V92, P628
   Wang Y, 2002, J NEUROCHEM, V82, P945, DOI 10.1046/j.1471-4159.2002.01059.x
   Wilkins HM, 2014, REDOX BIOL, V2, P619, DOI 10.1016/j.redox.2014.03.006
   Wimmers S, 2007, INVEST OPHTH VIS SCI, V48, P5767, DOI 10.1167/iovs.07-0412
   WONG PC, 1995, NEURON, V14, P1105, DOI 10.1016/0896-6273(95)90259-7
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
NR 72
TC 2
Z9 2
U1 0
U2 0
PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 0014-4835
EI 1096-0007
J9 EXP EYE RES
JI Exp. Eye Res.
PD JUN
PY 2022
VL 219
AR 109013
DI 10.1016/j.exer.2022.109013
PG 11
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 0Y9XF
UT WOS:000790734800005
PM 35283109
DA 2022-11-30
ER

PT J
AU Zeried, F
   Ngozika, E
   Al-Anazi, M
   Mashige, K
   Osuagwu, U
AF Zeried, Ferial
   Ngozika, Ezinne
   Al-Anazi, Mana
   Mashige, Khathutshelo
   Osuagwu, Uchechukwu
TI Choroidal Thickness Measured by Ocular Coherence Tomography (SD-OCT) and
   Body Mass Index in Healthy Saudi Women: A Cross-sectional Controlled
   Study
SO CURRENT MEDICAL IMAGING
LA English
DT Article
DE Obesity; body mass index; choroidal thickness; spectral domain ocular
   coherence tomography; imaging; clinical diagnosis
ID AXIAL LENGTH; CHILDREN; OBESITY
AB Background: Obesity is one of the major public health problems globally, especially among women. Obesity is associated with glaucoma, cataract, age-related macular degeneration and diabetic retinopathy. Although it is clear that the anatomy and physiologic functions of the choroid may be affected by obesity, data investigating the effect of obesity on the choroid is limited and/or unavailable for the Saudi population.
   Objective: To assess Choroidal Thickness (CT) changes in a sample of healthy Saudi Arabian women with different Body Mass Index (BMI) using Spectral-domain Ocular Coherence Tomography (SD-OCT).
   Methods: A total of 140 healthy women aged 18-29 years (mean age +/- standard deviation SD, 24.5 +/- 1.7 years) with different BMI, axial length (AL) <= 24 +/- 1.0 mm, and spherical equivalent refraction (SER) of <= +/- 2.0 dioptres were enrolled for the study. The participants were age and refraction-matched, and grouped into underweight (BMI <= 18.0 kg/m2) (n = 30), normal (control group) (18.5-24.9 kg/m2) (n = 43), overweight (25.0-29.9 kg/m2) (n=37), and obese study groups (>= 30.0 kg/ m2) (n = 30). SD-OCT imaging was performed on one eye of each participant. Comparisons among groups for all locations and the associations between CT and other variables were examined.
   Results: The mean CT at the subfoveal region (285 +/- 31 mu m, range: 203 mu m to 399 mu m) was significantly greater, and it was the lowest in the nasal region (248 +/- 26 mu m, range 154 to 304) compared with other locations, across all the groups ( p < 0.05). Compared with the control, the subfoveal choroid was thinner in the obese group (mean difference: 22.6 mu m, 95% Confidence Interval; CI: 8.6 mu m to 36.6 mu m; p = 0.02) and across all locations (p < 0.05) but thicker at the temporal location in the underweight group (12.4 mu m, 95% CI: -23.7 mu m to -1.04 mu m; p = 0.01). No significant association of subfoveal CT with any of the measured parameters, including age (p-values ranged from 0.10 to 0.90), was found.
   Conclusion: BMI may have an influence on the CT of healthy individuals and could be a cofounder in research studies on CT. It is, therefore, recommended that BMI should be evaluated in the clinical diagnosis and management of conditions associated with choroid in healthy individuals.
C1 [Zeried, Ferial] King Saud Univ, Dept Optometry & Vis Sci, Coll Appl Med Sci, Ilesha, Saudi Arabia.
   [Ngozika, Ezinne] Univ West Indies, Optometry Unit, Dept Clin Surg Sci, St Augustine Campus, St Augustine, Trinidad Tobago.
   [Al-Anazi, Mana] Univ KwaZulu Natal, African Vis Res Inst, Discipline Optometry, Westville Campus, ZA-3629 Durban, South Africa.
   [Mashige, Khathutshelo] Western Sydney Univ, Diabet Obes & Metab Translat Res Unit, Campbelltown, NSW 2560, Australia.
   [Osuagwu, Uchechukwu] Western Sydney Univ, Translat Hlth Res Inst THRI, Sch Med, Campbelltown, NSW 2560, Australia.
C3 King Saud University; University West Indies Mona Jamaica; University
   West Indies Saint Augustine; University of Kwazulu Natal; University of
   Sydney; Western Sydney University; University of Sydney; Western Sydney
   University
RP Osuagwu, U (通讯作者)，Western Sydney Univ, Translat Hlth Res Inst THRI, Sch Med, Campbelltown, NSW 2560, Australia.
EM l.osuagwu@westernsydney.edu.au
RI osuagwu, Uchechukwu Levi/K-5236-2015
OI osuagwu, Uchechukwu Levi/0000-0002-1727-6914; Mashige,
   Khathutshelo/0000-0001-8199-0891; Ezinne, Ngozika/0000-0003-3138-0213
FU Research Centre of the Female Scientific and Medical Colleges, Deanship
   of Scientific Research at King Saud University
FX Hessa Almatter collected the data, drafted the first manuscript and
   participated in the review of the manuscript. The study is supported by
   the Research Centre of the Female Scientific and Medical Colleges,
   Deanship of Scientific Research at King Saud University.
CR Agawa T, 2011, GRAEF ARCH CLIN EXP, V249, P1485, DOI 10.1007/s00417-011-1708-7
   Akhtar Z, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0197457
   Al-Hanawi MK, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17072330
   Alonso-Caneiro D, 2016, BIOMED OPT EXPRESS, V7, P629, DOI 10.1364/BOE.7.000629
   Bhayana AA, 2019, INDIAN J OPHTHALMOL, V67, P252, DOI 10.4103/ijo.IJO_668_18
   Bulus AD, 2017, OSLI RETINA, V48, P10, DOI 10.3928/23258160-20161219-02
   Chakraborty R, 2011, INVEST OPHTH VIS SCI, V52, P5121, DOI 10.1167/iovs.11-7364
   DeNicola E, 2015, REV ENVIRON HEALTH, V30, P191, DOI 10.1515/reveh-2015-0008
   Ding XY, 2011, INVEST OPHTH VIS SCI, V52, P9555, DOI 10.1167/iovs.11-8076
   Entezari M, 2018, J OPHTHAL VIS RES, V13, P39, DOI 10.4103/jovr.jovr_148_16
   Gunes Alime, 2015, Korean J Ophthalmol, V29, P220, DOI 10.3341/kjo.2015.29.4.220
   Guyer DR, 2006, RETINA, P34, DOI DOI 10.1016/B978-0-323-02598-0.50009-4
   Han JC, 2010, LANCET, V375, P1737, DOI 10.1016/S0140-6736(10)60171-7
   Heirani M, 2020, J CURR OPHTHALMOL, V32, P58, DOI 10.1016/j.joco.2019.08.005
   Ikuno Y, 2010, INVEST OPHTH VIS SCI, V51, P2173, DOI 10.1167/iovs.09-4383
   Khan, 2014, 70 SAUDIS ARE OBESE
   Kopelman PG, 2000, NATURE, V404, P635, DOI 10.1038/35007508
   Lee Geun Young, 2017, Korean J Ophthalmol, V31, P151, DOI 10.3341/kjo.2017.31.2.151
   Li T, 2019, BMJ OPEN, V9, DOI 10.1136/bmjopen-2019-029896
   Manjunath V, 2010, AM J OPHTHALMOL, V150, P325, DOI 10.1016/j.ajo.2010.04.018
   Margolis R, 2009, AM J OPHTHALMOL, V147, P811, DOI 10.1016/j.ajo.2008.12.008
   Memish ZA, 2014, PREV CHRONIC DIS, V11, DOI 10.5888/pcd11.140236
   Michalewska Z., 2013, RETINA TODAY, V9, P50
   NEMETH J, 1992, INT OPHTHALMOL, V16, P355, DOI 10.1007/BF00917990
   Nishi T, 2014, BRIT J OPHTHALMOL, V98, P228, DOI 10.1136/bjophthalmol-2013-303938
   Ouyang YL, 2011, INVEST OPHTH VIS SCI, V52, P7019, DOI 10.1167/iovs.11-8046
   Panon N, 2019, CLIN OPHTHALMOL, V13, P763, DOI 10.2147/OPTH.S196622
   Park KA, 2013, RETINA-J RET VIT DIS, V33, P1971, DOI 10.1097/IAE.0b013e3182923477
   Read SA, 2013, INVEST OPHTH VIS SCI, V54, P7578, DOI 10.1167/iovs.13-12772
   Roberto CA, 2015, LANCET, V385, P2400, DOI 10.1016/S0140-6736(14)61744-X
   Ruiz-Moreno JM, 2013, INVEST OPHTH VIS SCI, V54, P353, DOI 10.1167/iovs.12-10863
   Ss M.A., 2016, J OBES EAT DISORD, V2, P1, DOI [10.21767/2471-8203.100025., DOI 10.21767/2471-8203.100025]
   Sun C, 2010, AM J OPHTHALMOL, V150, P909, DOI 10.1016/j.ajo.2010.06.028
   Tan CS, 2012, INVEST OPHTH VIS SCI, V53, P261, DOI 10.1167/iovs.11-8782
   Wang W, 2018, CURR EYE RES, V43, P796, DOI 10.1080/02713683.2018.1428995
   Wei WB, 2013, OPHTHALMOLOGY, V120, P175, DOI 10.1016/j.ophtha.2012.07.048
   WHO, 2021, WHO FACT SHEET
   Wong ACM, 2005, EYE, V19, P292, DOI 10.1038/sj.eye.6701466
   Xiong SY, 2020, AM J OPHTHALMOL, V213, P46, DOI 10.1016/j.ajo.2020.01.003
   Yilmaz I, 2015, RETINA-J RET VIT DIS, V35, P2085, DOI 10.1097/IAE.0000000000000582
   Yumusak E, 2016, BMC OPHTHALMOL, V16, DOI 10.1186/s12886-016-0227-z
   Zhang JM, 2015, INVEST OPHTH VIS SCI, V56, P7646, DOI 10.1167/iovs.15-17137
NR 42
TC 0
Z9 0
U1 0
U2 1
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 1573-4056
EI 1875-6603
J9 CURR MED IMAGING
JI Curr. Med. Imaging
PY 2022
VL 18
IS 6
BP 666
EP 673
DI 10.2174/1573405618666220131105957
PG 8
WC Radiology, Nuclear Medicine & Medical Imaging
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Radiology, Nuclear Medicine & Medical Imaging
GA 4F3WT
UT WOS:000848445600008
PM 35100959
DA 2022-11-30
ER

PT J
AU Stone, LG
   Devenport, A
   Stratton, IM
   Talks, JS
AF Stone, Lydia G.
   Devenport, Adele
   Stratton, Irene M.
   Talks, James S.
TI Macula service evaluation and assessing priorities for anti-VEGF
   treatment in the light of COVID-19
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE Macular; Anti-VEGF; Aflibercept; COVID-19
ID INTRAVITREAL AFLIBERCEPT; RANIBIZUMAB; EDEMA
AB Purpose To assess the treatment position of all patients who have had an anti-VEGF injection in 2020, prior to the UK lockdown on 23 March. To assess methods of service quality evaluation in setting benchmarks for comparison after the situation stabilized. To consider what proportion could be delayed based on national guidelines and varying vision parameters. Finally, to measure how many patients actually attended. Method A retrospective analysis of data collected from our electronic medical record was performed. Age, sex, reason for injection, visual acuity (VA) for both treated and untreated eyes and number of injections were recorded. The proportion of patients and eyes with >= 70 letters were calculated as an assessment of quality of service provision. The proportion of patients that could be delayed was estimated based on published guidelines and varying the parameters of difference between treated and untreated eyes. Finally, the number of patients who actually attended was recorded. Results About 3364 eyes (2229 neovascular age-related macular degeneration (nAMD), 427 diabetic macular oedema (DMO), 599 retinal vein occlusion (RVO) and 109 other) from 2924 patients were analysed. At the last appointment with injection, 64.4% of patients achieved >= 70 letters in their better-seeing eye. Mean VA of the treated eye was 61.5 letters, and 36.9% achieved >= 70. The mean number of injections was 16, 90% with aflibercept. Of the patients receiving treatment to one eye, 57.6% was receiving treatment to their worse seeing eye. In 18.2% this eye was > 20 letters worse and in 5.07% > 40 letters worse than the untreated eye. Using Royal College of Ophthalmologists (RCOphth) guidelines, (treat nAMD 8 weekly, delay majority of RVO and DMO) 24.8% would be delayed. From 2738 appointments during the first 4 weeks of lockdown (booked prior to lockdown), doctors rescheduled 1025 and patients did not attend 820, leaving 893 who were seen (33%). Conclusions Assessing the treatment position of patients prior to COVID-19 lockdown enables objective stratification for prioritization for continued treatment. If RCOphth guidelines were followed 24.8% could be delayed and if treating the worse seeing eye up to 57.6%. Many scheduled patients elected not to attend, with 67% not seen in the first 4 weeks. The impact of non-attendance and delays may be evaluated later.
C1 [Stone, Lydia G.; Devenport, Adele; Talks, James S.] Newcastle Upon Tyne Hosp NHS Fdn Trust, Newcastle Eye Ctr, Royal Victoria Infirm, Newcastle Upon Tyne NE1 4LP, Tyne & Wear, England.
   [Stratton, Irene M.] Cheltenham Gen Hosp, Gloucestershire Retinal Res Grp, Oakley Ward, Sandford Rd, Cheltenham GL53 7AN, Glos, England.
C3 Newcastle University - UK; Newcastle Upon Tyne Hospitals NHS Foundation
   Trust; Gloucestershire Hospitals NHS Foundation Trust; Cheltenham
   General Hospital
RP Stone, LG; Talks, JS (通讯作者)，Newcastle Upon Tyne Hosp NHS Fdn Trust, Newcastle Eye Ctr, Royal Victoria Infirm, Newcastle Upon Tyne NE1 4LP, Tyne & Wear, England.
EM lydia.stone1@nhs.net; james.talks@nhs.net
RI stratton, irene/AAZ-3627-2020
OI stratton, irene/0000-0003-1172-7865; Talks, James/0000-0001-6126-6476;
   Stone, Lydia/0000-0003-3034-7809
CR ANG JL, 2020, EYE 0420, DOI DOI 10.1038/S41433-020-0861-9
   Busbee BG, 2013, OPHTHALMOLOGY, V120, P1046, DOI 10.1016/j.ophtha.2012.10.014
   CHANDRA S, 2020, EYE 0407, DOI DOI 10.1038/S41433-020-0851-Y
   Ciulla TA, 2018, OPHTHALMOL RETINA, V2, P1179, DOI 10.1016/j.oret.2018.06.004
   Heier JS, 2016, OPHTHALMOLOGY, V123, P2376, DOI 10.1016/j.ophtha.2016.07.032
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Korobelnik JF, 2020, GRAEF ARCH CLIN EXP, V258, P1149, DOI 10.1007/s00417-020-04703-x
   Korobelnik JF, 2020, GRAEF ARCH CLIN EXP, V258, P1335, DOI 10.1007/s00417-020-04697-6
   Man REK, 2020, OPHTHALMOLOGY, V127, P1145, DOI 10.1016/j.ophtha.2020.01.056
   National Institute for Health and Clinical Excellence, 2012, RAN PEG TREATM AG RE
   Pushpoth S, 2012, BRIT J OPHTHALMOL, V96, P1469, DOI 10.1136/bjophthalmol-2012-302167
   Scanlon PH, 2015, DIABETIC MED, V32, P97, DOI 10.1111/dme.12593
   Talks JS, 2017, EYE, V31, P1613, DOI 10.1038/eye.2017.86
   Talks J, 2019, SURV OPHTHALMOL, V64, P707, DOI 10.1016/j.survophthal.2019.02.008
   Talks JS, 2016, OPHTHALMOLOGY, V123, P337, DOI 10.1016/j.ophtha.2015.09.039
   The Royal College of Ophthalmologists, 2020, MED RET MAN PLANS CO
   Wecker T, 2017, BRIT J OPHTHALMOL, V101, P353, DOI 10.1136/bjophthalmol-2016-308668
NR 17
TC 11
Z9 11
U1 0
U2 1
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0721-832X
EI 1435-702X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD DEC
PY 2020
VL 258
IS 12
BP 2639
EP 2645
DI 10.1007/s00417-020-04849-8
EA JUL 2020
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA OT7ND
UT WOS:000553091000001
PM 32712708
OA Green Published, Bronze
DA 2022-11-30
ER

PT J
AU Chakravarty, A
   Sivaswamy, J
AF Chakravarty, Arunava
   Sivaswamy, Jayanthi
TI A supervised joint multi-layer segmentation framework for retinal
   optical coherence tomography images using conditional random field
SO COMPUTER METHODS AND PROGRAMS IN BIOMEDICINE
LA English
DT Article
DE Optical coherence tomography; Conditional random field; Structured
   support vector machines; Diabetic macular edema; Age-Related macular
   degeneration
ID AUTOMATIC SEGMENTATION; LAYER SEGMENTATION; IDENTIFICATION; BOUNDARIES;
   BENCHMARK; DRUSEN; MODEL; SCANS
AB Background and Objective: Accurate segmentation of the intra-retinal tissue layers in Optical Coherence Tomography (OCT) images plays an important role in the diagnosis and treatment of ocular diseases such as Age-Related Macular Degeneration (AMD) and Diabetic Macular Edema (DME). The existing energy minimization based methods employ multiple, manually handcrafted cost terms and often fail in the presence of pathologies. In this work, we eliminate the need to handcraft the energy by learning it from training images in an end-to-end manner. Our method can be easily adapted to pathologies by re-training it on an appropriate dataset.
   Methods: We propose a Conditional Random Field (CRF) framework for the joint multi-layer segmentation of OCT B-scans. The appearance of each retinal layer and boundary is modeled by two convolutional filter banks and the shape priors are modeled using Gaussian distributions. The total CRF energy is linearly parameterized to allow a joint, end-to-end training by employing the Structured Support Vector Machine formulation.
   Results: The proposed method outperformed three benchmark algorithms on four public datasets. The NORMAL-1 and NORMAL-2 datasets contain healthy OCT B-scans while the AMD-1 and DME-1 dataset contain B-scans of AMD and DME cases respectively. The proposed method achieved an average unsigned boundary localization error (U-BLE) of 1.52 pixels on NORMAL-1, 1.11 pixels on NORMAL-2 and 2.04 pixels on the combined NORMAL-1 and DME-1 dataset across the eight layer boundaries, outperforming the three benchmark methods in each case. The Dice coefficient was 0.87 on NORMAL-1, 0.89 on NORMAL-2 and 0.84 on the combined NORMAL-1 and DME-1 dataset across the seven retinal layers. On the combined NORMAL-1 and AMD-1 dataset, we achieved an average U-BLE of 1.86 pixels on the ILM, inner and outer RPE boundaries and a Dice of 0.98 for the ILM-RPE in region and 0.81 for the RPE layer.
   Conclusion: We have proposed a supervised CRF based method to jointly segment multiple tissue layers in OCT images. It can aid the ophthalmologists in the quantitative analysis of structural changes in the retinal tissue layers for clinical practice and large-scale clinical studies. (c) 2018 Elsevier B.V. All rights reserved.
C1 [Chakravarty, Arunava; Sivaswamy, Jayanthi] Int Inst Informat Technol, Ctr Visual Informat Technol, Hyderabad 500032, India.
C3 International Institute of Information Technology Hyderabad
RP Chakravarty, A (通讯作者)，Int Inst Informat Technol, Ctr Visual Informat Technol, Hyderabad 500032, India.
EM arunava.chakravarty@research.iiit.ac.in; jsivaswamy@iiit.ac.in
RI Chakravarty, Arunava/AAS-1580-2020
OI Chakravarty, Arunava/0000-0003-3646-0650
FU Tata Consultancy Services
FX This research was supported in part by the doctoral fellowship provided
   by Tata Consultancy Services under their Research Scholarship Program.
CR Behbehani R, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0172120
   Ben-Cohen A, 2017, RETINAL LAYERS SEGME, P1
   Chakravarty A, 2017, COMM COM INF SC, V723, P3, DOI 10.1007/978-3-319-60964-5_1
   Chiu SJ, 2015, BIOMED OPT EXPRESS, V6, P1172, DOI 10.1364/BOE.6.001172
   Chiu SJ, 2012, INVEST OPHTH VIS SCI, V53, P53, DOI 10.1167/iovs.11-7640
   Chiu SJ, 2010, OPT EXPRESS, V18, P19413, DOI 10.1364/OE.18.019413
   Dufour PA, 2013, IEEE T MED IMAGING, V32, P531, DOI 10.1109/TMI.2012.2225152
   Fabritius T, 2009, OPT EXPRESS, V17, P15659, DOI 10.1364/OE.17.015659
   Fang LY, 2017, BIOMED OPT EXPRESS, V8, P2732, DOI 10.1364/BOE.8.002732
   Garvin MK, 2009, IEEE T MED IMAGING, V28, P1436, DOI 10.1109/TMI.2009.2016958
   Girish GN, 2018, COMPUT METH PROG BIO, V153, P105, DOI 10.1016/j.cmpb.2017.10.010
   Golzan SM, 2011, COMPUT METH PROG BIO, V104, P206, DOI 10.1016/j.cmpb.2011.08.005
   Haeker M., 2006, SEGMENTATION SURFACE, P800
   Huang G, 2017, PROC CVPR IEEE, P2261, DOI 10.1109/CVPR.2017.243
   Hussain MA, 2017, IEEE T BIO-MED ENG, V64, P1638, DOI 10.1109/TBME.2016.2619120
   Ishikawa H, 2005, INVEST OPHTH VIS SCI, V46, P2012, DOI 10.1167/iovs.04-0335
   Joachims T, 2008, P 25 INT C MACH LEAR, P304, DOI DOI 10.1145/1390156.1390195
   Kafieh Raheleh, 2013, J Med Signals Sens, V3, P45
   Kajic V, 2010, OPT EXPRESS, V18, P14730, DOI 10.1364/OE.18.014730
   Kolmogorov V, 2006, IEEE T PATTERN ANAL, V28, P1568, DOI 10.1109/TPAMI.2006.200
   Krizhevsky A, 2017, COMMUN ACM, V60, P84, DOI 10.1145/3065386
   Lacoste-Julien S., 2013, P 30 INT C MACH LEAR, P53
   Lee K., 2014, IOWA REFERENCE ALGOR
   Lee SM, 2005, COLOR RES APPL, V30, P265, DOI 10.1002/col.20122
   Mayer M., 2016, OCTSEG VERSION 4 0 P
   Mayer MA, 2010, BIOMED OPT EXPRESS, V1, P1358, DOI 10.1364/BOE.1.001358
   Niwas SI, 2016, COMPUT METH PROG BIO, V130, P65, DOI 10.1016/j.cmpb.2016.03.018
   Novosel J, 2017, IEEE T MED IMAGING, V36, P1276, DOI 10.1109/TMI.2017.2666045
   Novosel J, 2015, MED IMAGE ANAL, V26, P146, DOI 10.1016/j.media.2015.08.008
   Nyul LG, 2000, IEEE T MED IMAGING, V19, P143, DOI 10.1109/42.836373
   Pekala M., 2018, ARXIV180109749
   Ronneberger O, 2015, LECT NOTES COMPUT SC, V9351, P234, DOI 10.1007/978-3-319-24574-4_28
   Rossant F, 2015, PATTERN RECOGN, V48, P3857, DOI 10.1016/j.patcog.2015.06.009
   Roy AG, 2017, BIOMED OPT EXPRESS, V8, P3627, DOI 10.1364/BOE.8.003627
   Schlanitz FG, 2010, INVEST OPHTH VIS SCI, V51, P6715, DOI 10.1167/iovs.10-5288
   Shi F, 2015, IEEE T MED IMAGING, V34, P441, DOI 10.1109/TMI.2014.2359980
   Sidibe D, 2017, COMPUT METH PROG BIO, V139, P109, DOI 10.1016/j.cmpb.2016.11.001
   Syed AM, 2016, COMPUT METH PROG BIO, V137, P1, DOI 10.1016/j.cmpb.2016.09.004
   Teng P., 2013, CASEREL OPEN SOURCE
   Tian J, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0133908
   Varnousfaderani ES, 2016, COMPUT METH PROG BIO, V130, P93, DOI 10.1016/j.cmpb.2016.03.012
   Yazdanpanah A, 2011, IEEE T MED IMAGING, V30, P484, DOI 10.1109/TMI.2010.2087390
   Yu YJ, 2002, IEEE T IMAGE PROCESS, V11, P1260, DOI 10.1109/TIP.2002.804279
NR 43
TC 5
Z9 5
U1 1
U2 11
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0169-2607
EI 1872-7565
J9 COMPUT METH PROG BIO
JI Comput. Meth. Programs Biomed.
PD OCT
PY 2018
VL 165
BP 235
EP 250
DI 10.1016/j.cmpb.2018.09.004
PG 16
WC Computer Science, Interdisciplinary Applications; Computer Science,
   Theory & Methods; Engineering, Biomedical; Medical Informatics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Computer Science; Engineering; Medical Informatics
GA GX0CZ
UT WOS:000447378500022
PM 30337078
DA 2022-11-30
ER

PT J
AU Douillard, A
   Picot, MC
   Delcourt, C
   Lacroux, A
   Zanlonghi, X
   Puech, B
   Defoort-Dhelemmes, S
   Drumare, I
   Jozefowicz, E
   Bocquet, B
   Baudoin, C
   Marzouka, NAD
   Perez-Roustit, S
   Arsene, S
   Gissot, V
   Devin, F
   Arndt, C
   Wolff, B
   Mauget-Faysse, M
   Quaranta, M
   Mura, T
   Deplanque, D
   Oubraham, H
   Cohen, SY
   Gastaud, P
   Zambrowsky, O
   Creuzot-Garcher, C
   Said, SM
   Garavito, RB
   Souied, E
   Sahel, JA
   Audo, I
   Hamel, C
   Meunier, I
AF Douillard, Aymeric
   Picot, Marie-Christine
   Delcourt, Cecile
   Lacroux, Annie
   Zanlonghi, Xavier
   Puech, Bernard
   Defoort-Dhelemmes, Sabine
   Drumare, Isabelle
   Jozefowicz, Elsa
   Bocquet, Beatrice
   Baudoin, Corinne
   Marzouka, Nour Al-Dain
   Perez-Roustit, Sarah
   Arsene, Sophie
   Gissot, Valerie
   Devin, Francois
   Arndt, Carl
   Wolff, Benjamin
   Mauget-Faysse, Martine
   Quaranta, Maddalena
   Mura, Thibault
   Deplanque, Dominique
   Oubraham, Hassiba
   Cohen, Salomon Yves
   Gastaud, Pierre
   Zambrowsky, Olivia
   Creuzot-Garcher, Catherine
   Said, Saddek Mohand
   Garavito, Rocio Blanco
   Souied, Eric
   Sahel, Jose-Alain
   Audo, Isabelle
   Hamel, Christian
   Meunier, Isabelle
TI Clinical Characteristics and Risk Factors of Extensive Macular Atrophy
   with Pseudodrusen The EMAP Case-Control National Clinical Trial
SO OPHTHALMOLOGY
LA English
DT Article
ID SUBRETINAL DRUSENOID DEPOSITS; GEOGRAPHIC-ATROPHY; RETICULAR
   PSEUDODRUSEN; AGE; DEGENERATION; PROGRESSION; PREVALENCE; DISEASE;
   ASSOCIATION; COHORT
AB Purpose: To assess the association of clinical and biological factors with extensive macular atrophy with pseudodrusen (EMAP) characterized by bilateral macular atrophy occurring in patients aged 50 to 60 years and a rapid progression to legal blindness within 5 to 10 years.
   Design: A national matched case-control study.
   Participants: Participants were recruited in 10 French Departments of Ophthalmology and their associated clinical investigation centers. All 115 patients with EMAP had symptoms before the age of 55 years due to bilateral extensive macular atrophy with a larger vertical axis and diffuse pseudodrusen. Three controls without age-related macular degeneration (AMD) or retinal disease at fundus examination were matched for each patient with EMAP by gender, age, and geographic area (in total 415).
   Methods: Subjects and controls underwent an eye examination including color, red-free autofluorescent fundus photographs and spectral-domain optical coherence tomography with macular analysis. The interviews collected demographic, lifestyle, family and personal medical history, medications, and biological data. Associations of risk factors were estimated using conditional logistic regression.
   Main Outcome Measures: Extensive macular atrophy with pseudodrusen status (cases vs. controls).
   Results: Extensive macular atrophy with pseudodrusen most frequently affected women (70 women, 45 men). After multivariate adjustment, family history of glaucoma or AMD was strongly associated with EMAP (odds ratio [OR], 2.3, P = 0.008 and OR, 1.5, P = 0.01, respectively). No association was found with cardiac diseases or their risk factors. Mild and moderate kidney disease and higher neutrophil rate were associated with a reduced risk of EMAP (OR, 0.58, P = 0.04; OR, 0.34, P = 0.01; and OR, 0.59, P = 0.003, respectively). On the contrary, eosinophilia (OR, 1.6; P = 0.0002), lymphocytosis (OR, 1.84; P = 0.0002), increased erythrocyte sedimentation rate (OR, 6.5; P = 0.0005), decreased CH50 (P = 0.001), and high plasma C3 level (P = 0.023) were significantly associated with a higher risk of EMAP.
   Conclusions: This study documents an association between EMAP and family history of AMD and glaucoma, a clear female predominance, and a systemic inflammatory profile. The reduced CH50 and increased C3 plasma values could reflect a more severe complement pathway dysfunction than in AMD, leading to early pseudodrusen and rapid development of geographic atrophy. There is no association of EMAP with AMD cardiac diseases or cardiac risks, including cigarette smoking. (C) 2016 by the American Academy of Ophthalmology.
C1 [Douillard, Aymeric; Picot, Marie-Christine; Mura, Thibault] CHRU Montpellier, Clin Invest Ctr, Montpellier, France.
   [Douillard, Aymeric; Picot, Marie-Christine; Mura, Thibault] CHRU Montpellier, Clin Res & Epidemiol Unit, Montpellier, France.
   [Douillard, Aymeric; Picot, Marie-Christine] INSERM, CIC 1411, Montpellier, France.
   [Delcourt, Cecile] Univ Bordeaux, ISPED, Bordeaux, France.
   [Delcourt, Cecile] INSERM, Bordeaux Populat Hlth Res Ctr, U1219, Bordeaux, France.
   [Lacroux, Annie; Bocquet, Beatrice; Baudoin, Corinne; Marzouka, Nour Al-Dain; Perez-Roustit, Sarah; Hamel, Christian; Meunier, Isabelle] Hop Gui De Chauliac, Ctr Reference Malad Sensorielles Genet, Montpellier, France.
   [Lacroux, Annie; Bocquet, Beatrice; Baudoin, Corinne; Marzouka, Nour Al-Dain; Perez-Roustit, Sarah; Hamel, Christian; Meunier, Isabelle] Univ Montpellier, Montpellier, France.
   [Lacroux, Annie; Bocquet, Beatrice; Baudoin, Corinne; Marzouka, Nour Al-Dain; Perez-Roustit, Sarah; Hamel, Christian; Meunier, Isabelle] INSERM, U1051, Inst Neurosci Montpellier, Montpellier, France.
   [Zanlonghi, Xavier] Sourdille Jules Verne, Eye Clin, Nantes, France.
   [Puech, Bernard; Defoort-Dhelemmes, Sabine; Drumare, Isabelle] CHU Lille, Hop Robert Salengro, Serv Explorat Vis & Neuroophtalmol, Lille, France.
   [Jozefowicz, Elsa; Deplanque, Dominique] Univ Lille, INSERM, CHU Lille, CIC Ctr Invest Clin 1403, Lille, France.
   [Arsene, Sophie] CHRU Tours, Hop Tours, Eye Clin, Tours, France.
   [Gissot, Valerie] CHRU Tours, Ctr Invest Clin, Inserm 1415, Tours, France.
   [Devin, Francois] Monticelli, Ctr Paradis, Eye Clin, Marseille, France.
   [Arndt, Carl] CHRU Reims, Hop Robert Debre, Eye Clin, Reims, France.
   [Wolff, Benjamin] Maison Rouge, Eye Clin, Strasbourg, France.
   [Wolff, Benjamin; Mauget-Faysse, Martine; Sahel, Jose-Alain] Fdn Adolphe Rothschild, Paris, France.
   [Quaranta, Maddalena] Ctr Ophtalmol Rabelais, Lyon, France.
   [Oubraham, Hassiba; Cohen, Salomon Yves; Zambrowsky, Olivia; Garavito, Rocio Blanco; Souied, Eric] Hop Intercommunal Creteil, Eye Clin, Creteil, France.
   [Cohen, Salomon Yves] Ctr Imagerie Laser, Rue Antoine Bourdelle, Paris, France.
   [Gastaud, Pierre] CHU Nice, Hop St Roch, Eye Clin, Nice, France.
   [Creuzot-Garcher, Catherine] Hop Univ Dijon, Eye Clin, Dijon, France.
   [Creuzot-Garcher, Catherine] INRA, Eye Nutr & Signaling Grp, Dijon, France.
   [Said, Saddek Mohand; Sahel, Jose-Alain; Audo, Isabelle] UPMC Univ Paris 06, INSERM, CNRS, Sorborne Univ,Inst Vis, Paris, France.
   [Said, Saddek Mohand; Sahel, Jose-Alain; Audo, Isabelle] CHNO Quinze Vingts, DHU Sight Restore, INSERM DHOS CIC1423, Paris, France.
   [Sahel, Jose-Alain; Audo, Isabelle] UCL, Inst Ophthalmol, London, England.
   [Sahel, Jose-Alain] Inst France, Acad Sci, Paris, France.
C3 Universite de Montpellier; CHU de Montpellier; Universite de
   Montpellier; CHU de Montpellier; Institut National de la Sante et de la
   Recherche Medicale (Inserm); Universite de Montpellier; UDICE-French
   Research Universities; Universite de Bordeaux; Institut National de la
   Sante et de la Recherche Medicale (Inserm); UDICE-French Research
   Universities; Universite de Bordeaux; Universite de Montpellier; CHU de
   Montpellier; Universite de Montpellier; Institut National de la Sante et
   de la Recherche Medicale (Inserm); Universite de Montpellier; Universite
   de Lille - ISITE; CHU Lille; Institut National de la Sante et de la
   Recherche Medicale (Inserm); Universite de Lille - ISITE; CHU Lille;
   Universite de Lille; CHU Tours; CHU Tours; Institut National de la Sante
   et de la Recherche Medicale (Inserm); CHU de Reims; Universite de Reims
   Champagne-Ardenne; Fondation Adolphe de Rothschild; Universite
   Paris-Est-Creteil-Val-de-Marne (UPEC); CHI Creteil; CHU Nice; CHU Dijon
   Bourgogne; INRAE; Institut Agro; AgroSup Dijon; Universite de Bourgogne;
   Centre National de la Recherche Scientifique (CNRS); Institut National
   de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research
   Universities; Sorbonne Universite; Universite Paris Cite; CHNO des
   Quinze-Vingts; UDICE-French Research Universities; Sorbonne Universite;
   University of London; University College London
RP Meunier, I (通讯作者)，Hop Gui De Chauliac, Ctr Natl Reference, Malad Rares, Affect Sensorielles Genet, 80 Rue Auguste Fliche, F-34295 Montpellier 5, France.
EM isabelannemeunier@yahoo.fr
RI Mitchell, Paul/P-1498-2014; Sahel, Jose-Alain/F-3172-2017; Delcourt,
   Cecile/I-2627-2013; PICOT, Marie-Christine/AAK-4802-2020; mura,
   Thibault/X-7279-2019; Bocquet, Beatrice/AAY-8447-2020; Marzouka, Nour al
   dain/Y-5334-2019; Deplanque, Dominique/E-4901-2015
OI Sahel, Jose-Alain/0000-0002-4831-1153; Delcourt,
   Cecile/0000-0002-2099-0481; mura, Thibault/0000-0001-6420-1336; Bocquet,
   Beatrice/0000-0002-6369-4818; Marzouka, Nour al
   dain/0000-0002-9029-3702; Deplanque, Dominique/0000-0002-4995-584X;
   wolff, benjamin/0000-0003-4709-692X; Audo, Isabelle/0000-0003-0698-5309
FU Laboratoires Thea; Bayer; Novartis; Roche; Ophthotech; Allergan; PHRC;
   PHRC National; Thea
FX The author(s) have made the following disclosure(s): C.D.: Consultant -
   Allergan, Bausch & Lomb, Laboratoires Thea, Novartis; Grants and payment
   for manuscript preparation - Laboratoires Thea.; F.D.: Board member and
   payment for lectures - Bayer, Novartis, Roche, Ophthotech, Allergan.;
   R.B.G.: Grant - PHRC; Payment for lectures and travel expenses -
   Novartis, Bayer.; E.S.: Grant - PHRC National; Personal fees - Novartis,
   Bayer, Allergan, Thea.
CR Boddu S, 2014, AM J OPHTHALMOL, V157, P985, DOI 10.1016/j.ajo.2014.01.023
   Cascio C, 2015, STEROIDS, V103, P31, DOI 10.1016/j.steroids.2015.08.002
   Chakravarthy U, 2010, BMC OPHTHALMOL, V10, DOI 10.1186/1471-2415-10-31
   Chew EY, 2014, JAMA OPHTHALMOL, V132, P272, DOI 10.1001/jamaophthalmol.2013.6636
   Defay R, 2004, ANN EPIDEMIOL, V14, P202, DOI 10.1016/S1047-2797(03)00130-3
   Elliot S, 2008, EXP EYE RES, V86, P653, DOI 10.1016/j.exer.2008.01.010
   Elliot SJ, 2010, EXP EYE RES, V90, P10, DOI 10.1016/j.exer.2009.09.001
   Feskanich D, 2008, ARCH OPHTHALMOL-CHIC, V126, P519, DOI 10.1001/archopht.126.4.519
   Finger RP, 2016, OPHTHALMOLOGY, V123, P599, DOI 10.1016/j.ophtha.2015.10.029
   Finger RP, 2014, OPHTHALMOLOGY, V121, P1252, DOI 10.1016/j.ophtha.2013.12.034
   Fleckenstein M, 2014, INVEST OPHTH VIS SCI, V55, P2911, DOI 10.1167/iovs.13-13409
   Fleckenstein M, 2011, INVEST OPHTH VIS SCI, V52, P3761, DOI 10.1167/iovs.10-7021
   Fraser-Bell S, 2008, AM J OPHTHALMOL, V145, P308, DOI 10.1016/j.ajo.2007.10.007
   Grassmann F, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0126636
   Hamel CP, 2009, AM J OPHTHALMOL, V147, P609, DOI 10.1016/j.ajo.2008.10.022
   Holz FG, 2007, AM J OPHTHALMOL, V143, P463, DOI 10.1016/j.ajo.2006.11.041
   Joachim N, 2014, OPHTHALMOLOGY, V121, P917, DOI 10.1016/j.ophtha.2013.10.043
   Joachim N, 2013, OPHTHALMOLOGY, V120, P2042, DOI 10.1016/j.ophtha.2013.03.029
   Kaarniranta K, 2015, CURR EYE RES, V40, P226, DOI 10.3109/02713683.2014.925933
   Klein R, 2008, AM J OPHTHALMOL, V145, P317, DOI 10.1016/j.ajo.2007.09.008
   Korb CA, 2014, GRAEF ARCH CLIN EXP, V252, P1403, DOI 10.1007/s00417-014-2591-9
   Kovach JL, 2016, OPHTHALMOLOGY, V123, P921, DOI 10.1016/j.ophtha.2015.10.036
   Levey AS, 1999, ANN INTERN MED, V130, P461, DOI 10.7326/0003-4819-130-6-199903160-00002
   Lindner M, 2015, OPHTHALMOLOGY, V122, P1356, DOI 10.1016/j.ophtha.2015.03.027
   Marsiglia M, 2013, INVEST OPHTH VIS SCI, V54, P7362, DOI 10.1167/iovs.12-11073
   Martillo MA, 2012, MED HYPOTHESIS DISCO, V1, P37
   Rastogi N, 2016, SURV OPHTHALMOL, V61, P422, DOI 10.1016/j.survophthal.2015.10.003
   Rosen AM, 2010, ADV EXP MED BIOL, V703, P75, DOI 10.1007/978-1-4419-5635-4_6
   Rudnicka AR, 2012, OPHTHALMOLOGY, V119, P571, DOI 10.1016/j.ophtha.2011.09.027
   Schmitz-Valckenberg S, 2016, OPHTHALMOLOGY, V123, P361, DOI 10.1016/j.ophtha.2015.09.036
   Schmitz-Valckenberg S, 2011, INVEST OPHTH VIS SCI, V52, P5009, DOI 10.1167/iovs.11-7235
   Schmitz-Valckenberg S, 2009, INVEST OPHTH VIS SCI, V50, P3915, DOI 10.1167/iovs.08-2484
   Scholl HPN, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007418
   Seddon JM, 2006, ARCH OPHTHALMOL-CHIC, V124, P995, DOI 10.1001/archopht.124.7.995
   Seddon JM, 2015, INVEST OPHTH VIS SCI, V56, P2192, DOI 10.1167/iovs.14-15841
   Seddon JM, 2010, OPHTHALMOLOGY, V117, P1560, DOI 10.1016/j.ophtha.2009.11.020
   Seddon JM, 2009, INVEST OPHTH VIS SCI, V50, P2044, DOI 10.1167/iovs.08-3064
   Shahid H, 2012, BRIT J OPHTHALMOL, V96, P427, DOI 10.1136/bjophthalmol-2011-300193
   Smailhodzic D, 2012, OPHTHALMOLOGY, V119, P339, DOI 10.1016/j.ophtha.2011.07.056
   Smith W, 1997, AUST NZ J OPHTHALMOL, V25, pS13
   Spaide RF, 2013, RETINA-J RET VIT DIS, V33, P1800, DOI 10.1097/IAE.0b013e31829c3765
   Steinberg JS, 2015, BRIT J OPHTHALMOL, V99, P1289, DOI 10.1136/bjophthalmol-2014-306535
   Steinberg JS, 2015, OPHTHALMOLOGICA, V233, P35, DOI 10.1159/000368168
   Tan JSL, 2007, OPHTHALMOLOGY, V114, P1143, DOI 10.1016/j.ophtha.2006.09.033
   Xu LN, 2013, RETINA-J RET VIT DIS, V33, P1850, DOI 10.1097/IAE.0b013e31828991b2
   Zerbib J, 2014, GRAEF ARCH CLIN EXP, V252, P899, DOI 10.1007/s00417-013-2537-7
   Zweifel SA, 2010, OPHTHALMOLOGY, V117, P1775, DOI 10.1016/j.ophtha.2010.01.027
   Zweifel SA, 2010, OPHTHALMOLOGY, V117, P303, DOI 10.1016/j.ophtha.2009.07.014
NR 48
TC 4
Z9 5
U1 0
U2 18
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD SEP
PY 2016
VL 123
IS 9
BP 1865
EP 1873
DI 10.1016/j.ophtha.2016.05.018
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA EE3QE
UT WOS:000389508500015
PM 27320518
DA 2022-11-30
ER

PT J
AU Varga, BE
   Tatrai, E
   DeBuc, DC
   Somfai, GM
AF Varga, Boglarka Eniko
   Tatrai, Erika
   DeBuc, Delia Cabrera
   Somfai, Gabor Mark
TI The effect of incorrect scanning distance on boundary detection errors
   and macular thickness measurements by spectral domain optical coherence
   tomography: a cross sectional study
SO BMC OPHTHALMOLOGY
LA English
DT Article
DE Optical coherence tomography; Image segmentation; Imaging pitfalls;
   Diabetic retinopathy; Macular degeneration
ID SIGNAL QUALITY; ARTIFACTS; REPRODUCIBILITY; EDEMA; INSTRUMENTS;
   INDICATOR; IMAGES; EYES
AB Background: To investigate the influence of scan distance on retinal boundary detection errors (RBDEs) and retinal thickness measurements by spectral domain optical coherence tomography (SD-OCT).
   Methods: 10 eyes of healthy subjects, 10 eyes with diabetic macular edema (DME) and 10 eyes with neovascular age-related macular degeneration (AMD) were examined with RTVue SD-OCT. The MM5 protocol was used in two consecutive sessions to scan the macula. For the first session, the device was set 3.5 cm from the eye in order to obtain detectable signal with low fundus image quality (suboptimal setting) while in the second session a distance of 2.5 cm was set with a good quality fundus image. The signal strength (SSI) value was recorded. The score for retinal boundary detection errors (RBDE) was calculated for ten scans of each examination. RBDE scores were recorded for the whole scan and also for the peripheral 1.0 mm region. RBDE scores, regional retinal thickness values and SSI values between the two sessions were compared. The correlation between SSI and the number of RBDEs was also examined.
   Results: The SSI was significantly lower with suboptimal settings compared to optimal settings (63.9 +/- 12.0 vs. 68.3 +/- 12.2, respectively, p = 0.001) and the number of RBDEs was significantly higher with suboptimal settings in the "all-eyes" group along with the group of healthy subjects and eyes with DME (9.1 +/- 6.5 vs. 6.8 +/- 6.3, p = 0.007; 4.4 +/- 2.6 vs. 2.5 +/- 1.6, p = 0.035 and 9.7 +/- 3.3 vs. 5.1 +/- 3.7, p = 0.008, respectively). For these groups, significant negative correlation was found between the SSI and the number of RBDEs. In the AMD group, the number of RBDEs was markedly higher compared to the other groups and there was no difference in RBDEs between optimal and suboptimal settings with the errors being independent of the SSI. There were significantly less peripheral RBDEs with optimal settings in the "all-eyes" group and the DME subgroup (2.7 +/- 2.6 vs. 4.2 +/- 2.8, p = 0.001 and 1.4 +/- 1.7 vs. 4.1 +/- 2.2, p = 0.007, respectively). Retinal thickness in the two settings was significantly different only in the outer-superior region in DME.
   Conclusions: Optimal distance settings improve SD-OCT SSI with a decrease in RBDEs while retinal thickness measurements are independent of scanning distance.
C1 [Varga, Boglarka Eniko; Tatrai, Erika; Somfai, Gabor Mark] Semmelweis Univ, Fac Med, Dept Ophthalmol, H-1085 Budapest, Hungary.
   [DeBuc, Delia Cabrera; Somfai, Gabor Mark] Univ Miami, Miller Sch Med, Bascom Palmer Eye Inst, Miami, FL 33136 USA.
C3 Semmelweis University; Bascom Palmer Eye Institute; University of Miami
RP Somfai, GM (通讯作者)，Semmelweis Univ, Fac Med, Dept Ophthalmol, 39 Maria Str, H-1085 Budapest, Hungary.
EM somfaigm@yahoo.com
OI Cabrera DeBuc, Delia/0000-0002-4726-894X; Somfai, Gabor
   Mark/0000-0001-6329-442X
FU Zsigmond Diabetes Fund of the Hungarian Academy of Sciences; Eotvos
   Scholarship of the Hungarian Scholarship Fund; NATIONAL EYE INSTITUTE
   [R01EY020607] Funding Source: NIH RePORTER
FX This study was supported in part by the Zsigmond Diabetes Fund of the
   Hungarian Academy of Sciences and by an Eotvos Scholarship of the
   Hungarian Scholarship Fund. The authors thank Eva Szeles for her expert
   technical assistance.
CR Broecker Eric H, 2005, Optometry, V76, P79, DOI 10.1016/S1529-1839(05)70262-1
   Browning DJ, 2004, OPHTHALMOLOGY, V111, P712, DOI 10.1016/j.ophtha.2003.06.028
   Chen TC, 2006, AM J OPHTHALMOL, V141, P1165, DOI 10.1016/j.ajo.2006.01.086
   Chhablani J, 2014, SAUDI J OPHTHALMOL, V28, P81, DOI 10.1016/j.sjopt.2014.02.010
   Chin EK, 2012, OPHTHAL SURG LAS IM, V43, P97, DOI 10.3928/15428877-20111222-02
   Costa RA, 2005, AM J OPHTHALMOL, V140, P349, DOI 10.1016/j.ajo.2005.03.027
   Costa RA, 2004, INVEST OPHTH VIS SCI, V45, P2399, DOI 10.1167/iovs.04-0155
   Folio LS, 2010, INVEST OPHTH VIS SCI, V51
   Folio LS, 2012, BRIT J OPHTHALMOL, V96, P514, DOI 10.1136/bjophthalmol-2011-300044
   Forte R, 2009, EYE, V23, P2071, DOI 10.1038/eye.2008.363
   Garas A, 2010, OPHTHALMOLOGY, V117, P738, DOI 10.1016/j.ophtha.2009.08.039
   Giani A, 2010, AM J OPHTHALMOL, V150, P815, DOI 10.1016/j.ajo.2010.06.025
   Giani A, 2010, RETINA-J RET VIT DIS, V30, P607, DOI 10.1097/IAE.0b013e3181c2e09d
   Han IC, 2010, OPHTHALMOLOGY, V117, P1177, DOI 10.1016/j.ophtha.2009.10.029
   Hee MR, 2005, AM J OPHTHALMOL, V139, P154, DOI 10.1016/j.ajo.2004.08.066
   Hee MR, 1998, OPHTHALMOLOGY, V105, P360, DOI 10.1016/S0161-6420(98)93601-6
   Hee MR, 1996, OPHTHALMOLOGY, V103, P1260, DOI 10.1016/S0161-6420(96)30512-5
   HEE MR, 1995, ARCH OPHTHALMOL-CHIC, V113, P1019, DOI 10.1001/archopht.1995.01100080071031
   HEE MR, 1995, ARCH OPHTHALMOL-CHIC, V113, P325, DOI 10.1001/archopht.1995.01100030081025
   Ho J, 2009, OPHTHALMOLOGY, V116, P1960, DOI 10.1016/j.ophtha.2009.03.034
   Huang JJ, 2011, OPHTHAL SURG LAS IM, V42, P216, DOI 10.3928/15428877-20110324-01
   Huang JJ, 2009, RETINA-J RET VIT DIS, V29, P980, DOI 10.1097/IAE.0b013e3181a2c1a7
   Huang YJ, 1998, INVEST OPHTH VIS SCI, V39, P2405
   Kim JS, 2009, BRIT J OPHTHALMOL, V93, P1057, DOI 10.1136/bjo.2009.157875
   Leung CKS, 2007, OPHTHALMOLOGY, V114, P263, DOI 10.1016/j.ophtha.2006.06.059
   Massa GC, 2010, EYE, V24, P1498, DOI 10.1038/eye.2010.72
   Mylonas G, 2009, BRIT J OPHTHALMOL, V93, P1453, DOI 10.1136/bjo.2008.153643
   PULIAFITO CA, 1995, OPHTHALMOLOGY, V102, P217
   Puliafito Carmen A, 2010, Ophthalmic Surg Lasers Imaging, V41 Suppl, pS5, DOI 10.3928/15428877-20101031-20
   Ray R, 2005, AM J OPHTHALMOL, V139, P18, DOI 10.1016/j.ajo.2004.07.050
   Sadda SR, 2006, OPHTHALMOLOGY, V113, P285, DOI 10.1016/j.ophtha.2005.10.005
   Schneider M, 2010, OPHTHAL SURG LAS IM, V41, P54, DOI 10.3928/15428877-20091230-10
   Somfai GM, 2007, J BIOMED OPT, V12, DOI 10.1117/1.2774827
   Song Y, 2012, RETINA-J RET VIT DIS, V32, P569, DOI 10.1097/IAE.0b013e31821f5d69
   Sull AC, 2010, RETINA-J RET VIT DIS, V30, P235, DOI 10.1097/IAE.0b013e3181bd2c3b
   Tatrai E, 2011, J BIOMED OPT, V16, DOI 10.1117/1.3573817
NR 36
TC 5
Z9 5
U1 0
U2 4
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1471-2415
J9 BMC OPHTHALMOL
JI BMC Ophthalmol.
PD NOV 27
PY 2014
VL 14
AR 148
DI 10.1186/1471-2415-14-148
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA CA4HP
UT WOS:000348865700001
PM 25428608
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Bai, YJ
   Liang, ST
   Yu, WZ
   Zhao, M
   Huang, LZ
   Zhao, MW
   Li, XX
AF Bai, Yujing
   Liang, Shuting
   Yu, Wenzhen
   Zhao, Min
   Huang, Lvzhen
   Zhao, Mingwei
   Li, Xiaoxin
TI Semaphorin 3A blocks the formation of pathologic choroidal
   neovascularization induced by transforming growth factor beta
SO MOLECULAR VISION
LA English
DT Article
ID RECEPTOR SIGNALING PATHWAYS; PIGMENT EPITHELIAL-CELLS; MACULAR
   DEGENERATION; TGF-BETA; RETINAL NEOVASCULARIZATION; ANGIOGENESIS;
   EXPRESSION; THERAPY; NEUROPILINS; INHIBITION
AB Objective: Choroidal neovascularization (CNV) is a major cause of vision loss in retinal diseases such as age-related macular degeneration (AMD). Previously, we demonstrated that semaphorin3A (Sema3A), which is a chemorepellent guidance molecule, inhibited the formation of retina neovascularization. In the present study, we investigated the anti-angiogenic effects of Sema3A on transforming growth factor beta (TGF-beta) in vitro and in vivo.
   Methods: Enzyme-linked immunosorbent assays (ELISAs) were used to measure the TGF-beta levels in the vitreous humor of patients with AMD and controls. Human umbilical vein endothelial cells (HUVECs) were used for the in vitro study, and a laser-induced CNV mouse model was prepared for the in vivo study. The HUVECs were incubated with TGF-beta and Sema3A. The proliferation, migration, apoptosis, and tube formation of the cells were then measured using BrdU, Transwell, flow cytometry, and Matrigel assays, respectively, and the SMAD2/3 signaling pathways were analyzed using western blot analysis. The C57BL/6J mouse retina was exposed to a laser to induce choroidal neovascularization (CNV), and Sema3A was injected intravitreously. After 14 days, fundus fluorescein angiography was performed to evaluate the leakage area of the CNV. The vascular endothelial growth factor (VEGF) and TGF-beta concentrations in the retina-choroid complex were measured with ELISA. Components of the p38 mitogen-activated protein kinase (MAPK), extracellular signal-regulated kinase-1/2 (ERK1/2), c-Jun NH2-terminal kinase (JNK), and SMAD2/3 signaling pathways in the Sema3A-treated groups were analyzed using western blotting.
   Results: In this study, we first verified that the vitreous TGF-beta level was higher in patients with neovascular AMD than in the controls. We also showed that Sema3A inhibited TGF-beta-induced HUVEC proliferation, migration, and tube formation and inhibited the downstream SMAD2/3 signaling pathway. Sema3A also induced TGF-beta-stimulated HUVEC apoptosis and inhibited the response of TGF-beta in vitro. In vivo, the TGF-beta level was increased in the CNV mouse model. Sema3A not only inhibited laser-induced CNV formation but also inhibited the uptake of VEGF and TGF-beta. In the western blot analysis, Sema3A was shown to inhibit the phosphorylation of p38 MAPK, ERK1/2, and JNK and to inhibit the SMAD2/3 signaling pathway after Sema3A treatment in CNV mice.
   Conclusions: Sema3A can be applied as a useful, adjunctive therapeutic strategy for preventing CNV formation.
C1 [Bai, Yujing; Liang, Shuting; Yu, Wenzhen; Zhao, Min; Huang, Lvzhen; Zhao, Mingwei; Li, Xiaoxin] Peking Univ, Peoples Hosp, Dept Ophthalmol,Key Lab Vis Loss & Restorat,Minis, Key Lab Diag & Treatment Retinal & Choroid Dis, Beijing 100044, Peoples R China.
C3 Peking University
RP Yu, WZ (通讯作者)，Peking Univ, Peoples Hosp, Dept Ophthalmol, Key Lab Vis Loss & Restorat,Minist Educ, Beijing 100044, Peoples R China.
EM 41379226@qq.com
OI Zhao, Min/0000-0003-0521-9186
FU National Basic Research Program of China (973 Program) [2011CB510200];
   Beijing Nova Program [Z131102000413004]; National Natural Science
   Foundation of China Grant [81200690]; Peking University People's
   Hospital Research and Development Fund [RDB201320, RDB201224]
FX We thank Bin Wang for her help with the FACS analysis. This work was
   supported by the National Basic Research Program of China (973 Program,
   2011CB510200), the Beijing Nova Program (Z131102000413004), the National
   Natural Science Foundation of China Grant (81200690) and the Peking
   University People's Hospital Research and Development Fund (RDB201320,
   RDB201224). The funders had no role in the study design, data collection
   and analysis, decision to publish or preparation of the manuscript.
CR AMIN R, 1994, INVEST OPHTH VIS SCI, V35, P3178
   Bai YJ, 2012, J PHARMACOL EXP THER, V342, P131, DOI 10.1124/jpet.112.192575
   Bai YJ, 2013, INVEST OPHTH VIS SCI, V54, P6628, DOI 10.1167/iovs.13-12625
   Bian ZM, 2007, EXP EYE RES, V84, P812, DOI 10.1016/j.exer.2006.12.016
   Bierie B, 2010, CYTOKINE GROWTH F R, V21, P49, DOI 10.1016/j.cytogfr.2009.11.008
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Bressler NM, 2009, OPHTHALMOLOGY, V116, pS15, DOI 10.1016/j.ophtha.2009.06.048
   Bressler SB, 2009, OPHTHALMOLOGY, V116, pS1, DOI 10.1016/j.ophtha.2009.06.045
   Carmeliet P, 2011, NATURE, V473, P298, DOI 10.1038/nature10144
   Conidi A, 2011, CYTOKINE GROWTH F R, V22, P287, DOI 10.1016/j.cytogfr.2011.11.006
   Das A, 2003, PROG RETIN EYE RES, V22, P721, DOI 10.1016/j.preteyeres.2003.08.001
   Derijck AAHA, 2010, TRENDS CELL BIOL, V20, P568, DOI 10.1016/j.tcb.2010.06.007
   Ding XY, 2009, PROG RETIN EYE RES, V28, P1, DOI 10.1016/j.preteyeres.2008.10.001
   Do DV, 2009, OPHTHALMOLOGY, V116, pS24, DOI 10.1016/j.ophtha.2009.06.049
   Dobaczewski M, 2011, J MOL CELL CARDIOL, V51, P600, DOI 10.1016/j.yjmcc.2010.10.033
   Eichmann A, 2005, CURR OPIN NEUROBIOL, V15, P108, DOI 10.1016/j.conb.2005.01.008
   Gaur P, 2009, CLIN CANCER RES, V15, P6763, DOI 10.1158/1078-0432.CCR-09-1810
   Goshima Y, 2002, J CLIN INVEST, V109, P993, DOI 10.1172/JCI200215467
   Goumans MJ, 2009, CELL RES, V19, P116, DOI 10.1038/cr.2008.326
   Haller JA, 2013, OPHTHALMOLOGY, V120, pS3, DOI 10.1016/j.ophtha.2013.01.057
   Ikushima H, 2010, NAT REV CANCER, V10, P415, DOI 10.1038/nrc2853
   Joyal JS, 2011, BLOOD, V117, P6024, DOI 10.1182/blood-2010-10-311589
   Larsson J, 2001, EMBO J, V20, P1663, DOI 10.1093/emboj/20.7.1663
   Laude A, 2010, PROG RETIN EYE RES, V29, P466, DOI 10.1016/j.preteyeres.2010.04.003
   Nagineni CN, 2003, J CELL PHYSIOL, V197, P453, DOI 10.1002/jcp.10378
   Noble J, 2010, CAN MED ASSOC J, V182, P1759, DOI 10.1503/cmaj.090378
   Novack GD, 2008, ANNU REV PHARMACOL, V48, P61, DOI 10.1146/annurev.pharmtox.48.060607.174028
   Oh SP, 2000, P NATL ACAD SCI USA, V97, P2626, DOI 10.1073/pnas.97.6.2626
   Olsson AK, 2006, NAT REV MOL CELL BIO, V7, P359, DOI 10.1038/nrm1911
   Orlova VV, 2011, HISTOL HISTOPATHOL, V26, P1219, DOI 10.14670/HH-26.1219
   Pardali E, 2010, TRENDS CELL BIOL, V20, P556, DOI 10.1016/j.tcb.2010.06.006
   Parvani JG, 2011, J MAMMARY GLAND BIOL, V16, P127, DOI 10.1007/s10911-011-9207-3
   Prud'homme GJ, 2012, ONCOTARGET, V3, P921, DOI 10.18632/oncotarget.626
   Stone EM, 2007, ANNU REV MED, V58, P477, DOI 10.1146/annurev.med.58.111405.133335
   Suzuki Y, 2012, KIDNEY INT, V81, P865, DOI 10.1038/ki.2011.464
   Vadasz Z, 2010, AUTOIMMUN REV, V9, P825, DOI 10.1016/j.autrev.2010.07.014
   van Meeteren LA, 2011, CURR PHARM BIOTECHNO, V12, P2108
   Walshe TE, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005149
   Yu WZ, 2013, MOL VIS, V19, P1397
   Zarranz-Ventura J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0065434
   Zhang SX, 2007, PROG RETIN EYE RES, V26, P1, DOI 10.1016/j.preteyeres.2006.09.002
NR 41
TC 31
Z9 33
U1 1
U2 5
PU MOLECULAR VISION
PI ATLANTA
PA C/O JEFF BOATRIGHT, LAB B, 5500 EMORY EYE CENTER, 1327 CLIFTON RD, N E,
   ATLANTA, GA 30322 USA
SN 1090-0535
J9 MOL VIS
JI Mol. Vis.
PD SEP 19
PY 2014
VL 20
BP 1258
EP 1270
PG 13
WC Biochemistry & Molecular Biology; Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Ophthalmology
GA AP3LG
UT WOS:000341976900001
PM 25352735
DA 2022-11-30
ER

PT J
AU Karlsson, M
   Frennesson, C
   Gustafsson, T
   Brunk, UT
   Nilsson, SEG
   Kurz, T
AF Karlsson, Markus
   Frennesson, Christina
   Gustafsson, Therese
   Brunk, Ulf T.
   Nilsson, Sven Erik G.
   Kurz, Tino
TI Autophagy of iron-binding proteins may contribute to the oxidative
   stress resistance of ARPE-19 cells
SO EXPERIMENTAL EYE RESEARCH
LA English
DT Article
DE oxidative stress; ARPE-19; retinal pigment epithelium; iron;
   metallothionein; HSP70; ferritin; age-related macular degeneration
ID PIGMENT EPITHELIAL-CELLS; HEAT-SHOCK PROTEINS; INDUCED DNA-DAMAGE;
   REDOX-ACTIVE IRON; MACULAR DEGENERATION; METALLOTHIONEIN PROTECTS;
   INDUCED APOPTOSIS; INSULINOMA CELLS; LYSOSOMAL IRON; CYTOCHROME-C
AB The objective of this study was to elucidate possible reasons for the remarkable resistance of human retinal pigment epithelial (RPE) cells to oxidative stress. Much oxidative damage is due to hydrogen peroxide meeting redox-active iron in the acidic and reducing lysosomal environment, resulting in the production of toxic hydroxyl radicals that may oxidize intralysosomal content, leading to lipofuscin (LF) formation or, if more extensive, to permeabilization of lysosomal membranes. Formation of LF is a risk factor for age-related macular degeneration (AMD) and known to jeopardize normal autophagic rejuvenation of vital cellular biomolecules. Lysosomal membrane permeabilization causes release of lysosomal content (redox-active iron, lytic enzymes), which may then cause cell death. Total cellular and lysosomal low-mass iron of cultured, immortalized human RPE (ARPE-19) cells was compared to that of another professional scavenger cell line, J774, using atomic absorption spectroscopy and the cytochemical sulfide-silver method (SSM). It was found that both cell lines contained comparable levels of total as well as intralysosomal iron, suggesting that the latter is mainly kept in a non-redox-active state in ARPE-19 cells. Basal levels and capacity for upregulation of the iron-binding proteins ferritin, metallothionein and heat shock protein 70 were tested in both cell lines using immunoblotting. Compared to J774 cells, ARPE-19 cells were found to contain very high basal levels of all these proteins, which could be even further upregulated following appropriate stimulation. These findings suggest that a high basal expression of iron-binding stress proteins, which during their normal autophagic turnover in lysosomes may temporarily bind iron prior to their degradation, could contribute to the unusual oxidative stress-resistance of ARPE-19 cells. A high steady state influx of such proteins into lysosomes would keep the level of lysosomal redox-active iron permanently low. This, in turn, should delay intralysosomal accumulation of LF in RPE cells, which is known to reduce autophagic turnover as well as uptake and degradation of worn out photoreceptor tips. This may explain why severe LF accumulation and AMD normally do not develop until fairly late in life, in spite of RPE cells being continuously exposed to high levels of oxygen and light, as well as large amounts of lipid-rich material. (C) 2013 Elsevier Ltd. All rights reserved.
C1 [Karlsson, Markus; Frennesson, Christina; Gustafsson, Therese; Nilsson, Sven Erik G.] Linkoping Univ, Dept Clin & Expt Med, Div Ophthalmol, SE-58185 Linkoping, Sweden.
   [Brunk, Ulf T.; Kurz, Tino] Linkoping Univ, Dept Med & Hlth Sci, Div Drug Res, SE-58185 Linkoping, Sweden.
C3 Linkoping University; Linkoping University
RP Karlsson, M (通讯作者)，Linkoping Univ, Dept Clin & Expt Med, Div Ophthalmol, SE-58185 Linkoping, Sweden.
EM markus.karlsson@lio.se
OI Karlsson, Markus/0000-0003-1183-2526
FU Crown Princess Margareta's Foundation for the Visually Handicapped;
   Edvin Jordan Foundation for Ophthalmological Research; Linkoping
   University Hospital Research Fund (ALF)
FX The financial support by Crown Princess Margareta's Foundation for the
   Visually Handicapped, the Edvin Jordan Foundation for Ophthalmological
   Research and the Linkoping University Hospital Research Fund (ALF) is
   gratefully acknowledged. We are also grateful to Professor John W.
   Eaton, University of Louisville, KY, USA, for several helpful
   suggestions.
CR Antunes F, 2001, BIOCHEM J, V356, P549, DOI 10.1042/0264-6021:3560549
   Arosio P, 2010, BBA-GEN SUBJECTS, V1800, P783, DOI 10.1016/j.bbagen.2010.02.005
   Bailey TA, 2004, INVEST OPHTH VIS SCI, V45, P675, DOI 10.1167/iovs.03-0351
   Baird SK, 2006, BIOCHEM J, V394, P275, DOI 10.1042/BJ20051143
   BANERJI SS, 1984, MOL CELL BIOL, V4, P2437, DOI 10.1128/MCB.4.11.2437
   Bivik C, 2007, CARCINOGENESIS, V28, P537, DOI 10.1093/carcin/bgl152
   Boult J, 2008, CLIN CANCER RES, V14, P379, DOI 10.1158/1078-0432.CCR-07-1054
   BRIDGES KR, 1987, J BIOL CHEM, V262, P14773
   Brunk UT, 2002, FREE RADICAL BIO MED, V33, P611, DOI 10.1016/S0891-5849(02)00959-0
   Corna G, 2004, J BIOL CHEM, V279, P13738, DOI 10.1074/jbc.M310106200
   Creagh EM, 2000, EXP CELL RES, V257, P58, DOI 10.1006/excr.2000.4856
   Doulias PT, 2007, FREE RADICAL BIO MED, V42, P567, DOI 10.1016/j.freeradbiomed.2006.11.022
   Dunn KC, 1996, EXP EYE RES, V62, P155, DOI 10.1006/exer.1996.0020
   Erie JC, 2009, AM J OPHTHALMOL, V147, P276, DOI 10.1016/j.ajo.2008.08.014
   Hahn SH, 2001, EXP MOL MED, V33, P32, DOI 10.1038/emm.2001.7
   Jaattela M, 1999, ANN MED, V31, P261, DOI 10.3109/07853899908995889
   Julien S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0029245
   Kaarniranta K, 2013, AUTOPHAGY, V9, P973, DOI 10.4161/auto.24546
   Karlsson M, 2010, BIOCHEM J, V428, P183, DOI 10.1042/BJ20100208
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Kidane TZ, 2006, AM J PHYSIOL-CELL PH, V291, pC445, DOI 10.1152/ajpcell.00505.2005
   Kinnunen K, 2012, ACTA OPHTHALMOL, V90, P299, DOI 10.1111/j.1755-3768.2011.02179.x
   Kirkegaard T, 2010, NATURE, V463, P549, DOI 10.1038/nature08710
   Kurz T, 2008, HISTOCHEM CELL BIOL, V129, P389, DOI 10.1007/s00418-008-0394-y
   Kurz T, 2007, ARCH BIOCHEM BIOPHYS, V462, P220, DOI 10.1016/j.abb.2007.01.013
   Kurz T, 2011, FREE RADICAL BIO MED, V50, P1647, DOI 10.1016/j.freeradbiomed.2011.03.014
   Kurz T, 2009, AUTOPHAGY, V5, P494, DOI 10.4161/auto.5.4.7961
   Kurz T, 2009, AUTOPHAGY, V5, P93, DOI 10.4161/auto.5.1.7248
   Lei XG, 2011, ANTIOXID REDOX SIGN, V14, P489, DOI 10.1089/ars.2010.3416
   Linder MC, 2013, NUTRIENTS, V5, P4022, DOI 10.3390/nu5104022
   Lu HS, 2002, EXP EYE RES, V74, P83, DOI 10.1006/exer.2001.1101
   Martindale JL, 2002, J CELL PHYSIOL, V192, P1, DOI 10.1002/jcp.10119
   McAleer MF, 2001, IN VITRO MOL TOXICOL, V14, P219, DOI 10.1089/109793301753407975
   MELLOFILHO AC, 1988, BIOCHEM J, V256, P475, DOI 10.1042/bj2560475
   Mitter SK, 2012, ADV EXP MED BIOL, V723, P83, DOI 10.1007/978-1-4614-0631-0_12
   Mizzen CA, 1996, J BIOCHEM BIOPH METH, V32, P77, DOI 10.1016/0165-022X(95)00044-R
   Nylandsted J, 2004, J EXP MED, V200, P425, DOI 10.1084/jem.20040531
   Olejnicka BT, 1999, APMIS, V107, P747, DOI 10.1111/j.1699-0463.1999.tb01469.x
   Orino K, 2001, BIOCHEM J, V357, P241, DOI 10.1042/0264-6021:3570241
   Pedersen MO, 2009, PROG HISTOCHEM CYTO, V44, P29, DOI 10.1016/j.proghi.2008.10.001
   Reinecke F, 2006, BIOCHEM J, V395, P405, DOI 10.1042/BJ20051253
   Richardson DR, 2010, P NATL ACAD SCI USA, V107, P10775, DOI 10.1073/pnas.0912925107
   Romanucci M, 2008, CELL STRESS CHAPERON, V13, P253, DOI 10.1007/s12192-008-0030-8
   Ryhanen T, 2009, J CELL MOL MED, V13, P3616, DOI 10.1111/j.1582-4934.2008.00577.x
   Shimoda R, 2003, TOXICOL SCI, V73, P294, DOI 10.1093/toxsci/kfg095
   Sparrow JR, 2005, EXP EYE RES, V80, P595, DOI 10.1016/j.exer.2005.01.007
   Strauss O, 2005, PHYSIOL REV, V85, P845, DOI 10.1152/physrev.00021.2004
   Suemori S, 2006, INVEST OPHTH VIS SCI, V47, P3975, DOI 10.1167/iovs.06-0275
   Swindell WR, 2011, AGEING RES REV, V10, P132, DOI 10.1016/j.arr.2010.09.007
   Tenopoulou M, 2005, BIOCHEM J, V387, P703, DOI 10.1042/BJ20041650
   Terman A, 1999, EXP GERONTOL, V34, P943, DOI 10.1016/S0531-5565(99)00070-4
   Terman A, 1998, APMIS, V106, P265, DOI 10.1111/j.1699-0463.1998.tb01346.x
   Terman A, 2010, ANTIOXID REDOX SIGN, V12, P503, DOI 10.1089/ars.2009.2598
   TIMM F, 1958, Dtsch Z Gesamte Gerichtl Med, V46, P706, DOI 10.1007/BF00665092
   Viiri J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069563
   Winkler BS, 1999, MOL VIS, V5
   YOUNG RW, 1967, J CELL BIOL, V33, P61, DOI 10.1083/jcb.33.1.61
   Yu ZQ, 2003, FREE RADICAL BIO MED, V34, P1243, DOI 10.1016/S0891-5849(03)00109-6
   Zareba M, 2006, FREE RADICAL BIO MED, V40, P87, DOI 10.1016/j.freeradbiomed.2005.08.015
   ZDOLSEK JM, 1993, FREE RADICAL BIO MED, V15, P1, DOI 10.1016/0891-5849(93)90120-J
   ZHANG H, 1995, DIABETOLOGIA, V38, P635, DOI 10.1007/s001250050330
   Zhang YH, 2010, ANTIOXID REDOX SIGN, V13, P999, DOI 10.1089/ars.2010.3129
   Zhao M, 2003, EUR J BIOCHEM, V270, P3778, DOI 10.1046/j.1432-1033.2003.03765.x
NR 63
TC 23
Z9 23
U1 1
U2 15
PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 0014-4835
EI 1096-0007
J9 EXP EYE RES
JI Exp. Eye Res.
PD NOV
PY 2013
VL 116
BP 359
EP 365
DI 10.1016/j.exer.2013.10.014
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 259YP
UT WOS:000327562500041
PM 24416768
DA 2022-11-30
ER

PT J
AU Wagner, H
   Stifter, J
   Engesser, D
   Atzrodt, L
   Betancor, PK
   Bohringer, D
   Faessler, M
   Wuermeling, M
   Reinhard, T
AF Wagner, Helena
   Stifter, Julia
   Engesser, Diana
   Atzrodt, Lisa
   Betancor, Paola Kammrath
   Boehringer, Daniel
   Faessler, Markus
   Wuermeling, Martin
   Reinhard, Thomas
TI Ophthalmic Care in Nursing Homes for the Blind: A Growing Challenge
SO KLINISCHE MONATSBLATTER FUR AUGENHEILKUNDE
LA English
DT Article
DE blindness; visual impairment; low vision; care facility; home for the
   blind; care research
ID QUALITY-OF-LIFE; VISUAL IMPAIRMENT; OLDER-PEOPLE; VISION IMPAIRMENT;
   PERSONAL BURDEN; RISK-FACTORS; EYE DISEASE; HEALTH-CARE; PREVALENCE;
   IMPACT
AB Background The demographic change in Germany will lead to an increase in irreversible age-related eye diseases. This will increase the need for specialised care facilities for visually impaired people. Due to reduced mobility, residents in such facilities often do not receive adequate ophthalmological care. New concepts must therefore be considered for this group of patients. One approach is to set up an ophthalmological ex-amination unit within the facility combined with regular visits by an ophthalmologist. We now present the experience with such a model in a home for the blind.
   Patients and Methods The project was initiated in 2009. Since then there have been visits by medical staff of the Eye Center at Medical Center, University of Freiburg, every two weeks. All patient records (2010-2017) were reviewed systematically. The following data were extracted in a structured and anonymous way: Age at first presentation, gender, ophthalmological diagnoses and if a therapy was initiated. This data set was finally analysed descriptively.
   Results Out of 130 residents aged between 48 and 100 years, half were between 78 and 90 years old. The youngest resident was 48, the oldest 100 years old. The median visual acuity was 0.2. Sixty percent of the residents had at least mild visual impairment according to the WHO (visual acuity < 0.5; category 1-6). In one of 6-7 residents, visual acuity could not be determined using Snellen charts. The most frequent ophthalmological diagnoses included cataract (44%), age-related macular degeneration (36%) and glaucoma (29%). In 67 residents (52%), the ophthalmological examination lead to treatment, such as application of local therapy or planning an operation.
   Conclusion In every second resident, the ophthalmologist' s visit lead to treatment during the observation period. This underlines the difficulty of providing ophthalmological care even in specialised institutions for the blind and visually impaired, which is possibly due to the residents' mobility problems. The concept presented here has established a low-threshold, sustainable and high-quality ophthalmological service on site. These positive experiences indicate that corresponding measures may also be useful for other locations. However, in order to implement such a project on a larger scale, suitable financing and accounting modalities for the construction measures, the nursing staff and the ophthalmological procedure still need to be developed.
C1 [Wagner, Helena; Stifter, Julia; Engesser, Diana; Atzrodt, Lisa; Betancor, Paola Kammrath; Boehringer, Daniel; Reinhard, Thomas] Univ Klinikum Freiburg, Klin Augenheilkunde, Killianstr 5, D-79106 Freiburg, Germany.
   [Wagner, Helena; Stifter, Julia; Engesser, Diana; Atzrodt, Lisa; Betancor, Paola Kammrath; Boehringer, Daniel; Reinhard, Thomas] Albert Ludwigs Univ Freiburg, Med Fak, Freiburg, Germany.
   [Faessler, Markus] Blindenheim Freiburg, Leitung, Freiburg, Germany.
   [Wuermeling, Martin] Augennetz Sudbaden, Augenarztpraxis Titisee Neustadt, Titisee Neustadt, Germany.
C3 University of Freiburg; University of Freiburg
RP Wagner, H (通讯作者)，Univ Klinikum Freiburg, Klin Augenheilkunde, Killianstr 5, D-79106 Freiburg, Germany.
EM helena.wagner@uniklinik-freiburg.de
OI Kammrath Betancor, Paola/0000-0001-7654-6032; Siegel,
   Helena/0000-0001-8523-8832
CR Abdelhafiz AH, 2003, AGE AGEING, V32, P26, DOI 10.1093/ageing/32.1.26
   Brenowitz WD, 2019, J GERONTOL A-BIOL, V74, P890, DOI 10.1093/gerona/gly264
   Davies-Kershaw HR, 2018, J AM GERIATR SOC, V66, P1823, DOI 10.1111/jgs.15456
   Dev MK, 2014, CURR EYE RES, V39, P232, DOI 10.3109/02713683.2013.838973
   Elliott AF, 2009, BRIT J OPHTHALMOL, V93, P240, DOI 10.1136/bjo.2008.142356
   Elliott AF, 2010, J AGING HEALTH, V22, P504, DOI 10.1177/0898264310361368
   Fang PP, 2017, OPHTHALMOLOGE, V114, P818, DOI 10.1007/s00347-017-0557-0
   Finger RP, 2012, DTSCH ARZTEBL INT, V109, P484, DOI 10.3238/arztebl.2012.0484
   Finger RP, 2011, INVEST OPHTH VIS SCI, V52, P4381, DOI 10.1167/iovs.10-6987
   Friedman DS, 2002, INVEST OPHTH VIS SCI, V43, P2572
   Gaugler JE, 2009, MED CARE, V47, P191, DOI 10.1097/MLR.0b013e31818457ce
   JACK CIA, 1995, GERONTOLOGY, V41, P280
   Johansen A, 2003, ARCH GERONTOL GERIAT, V36, P289, DOI 10.1016/S0167-4943(02)00175-9
   Koski K, 1998, GERONTOLOGY, V44, P232, DOI 10.1159/000022017
   Lamoureux EL, 2009, INVEST OPHTH VIS SCI, V50, P4103, DOI 10.1167/iovs.08-3294
   Larsen PP, 2019, GRAEF ARCH CLIN EXP, V257, P363, DOI 10.1007/s00417-018-4196-1
   Lee ATC, 2020, J GERONTOL A-BIOL, V75, P2162, DOI 10.1093/gerona/glaa036
   MARX MS, 1990, INVEST OPHTH VIS SCI, V31, P593
   NEWELL SW, 1985, ANN OPHTHALMOL, V17, P186
   Owsley C, 2007, OPHTHAL EPIDEMIOL, V14, P188, DOI 10.1080/09286580701410315
   Schuster AK, 2019, OPHTHALMOLOGE, V116, P829, DOI 10.1007/s00347-019-0894-2
   Thederan L, 2016, DTSCH ARZTEBL INT, V113, P323, DOI 10.3238/arztebl.2016.0323
   Thibault L, 2016, OPHTHAL PHYSL OPT, V36, P566, DOI 10.1111/opo.12311
   Tromp AM, 2001, J CLIN EPIDEMIOL, V54, P837, DOI 10.1016/S0895-4356(01)00349-3
   van Nispen R, 2019, ACTA OPHTHALMOL, V97, P401, DOI 10.1111/aos.13956
   VanNewkirk MR, 2000, OPHTHALMOLOGY, V107, P2203, DOI 10.1016/S0161-6420(00)00459-0
   Varma R, 2016, JAMA OPHTHALMOL, V134, P802, DOI 10.1001/jamaophthalmol.2016.1284
   Vu HTV, 2005, BRIT J OPHTHALMOL, V89, P360, DOI 10.1136/bjo.2004.047498
   Waked N, 2007, J FR OPHTALMOL, V30, P497, DOI 10.1016/S0181-5512(07)89630-6
   West SK, 2003, OPHTHALMIC EPIDEMIOL, V10, P193, DOI 10.1076/opep.10.3.193.15081
   WHITMORE WG, 1989, OPHTHALMOLOGY, V96, P393, DOI 10.1016/S0161-6420(89)32880-6
   Wolfram C, 2019, DTSCH ARZTEBL INT, V116, P289, DOI 10.3238/arztebl.2019.0289
   World Health Organization, ICD 11 MORT MORB STA
   Zolotar O, 2019, KLIN MONATSBL AUGENH, V236, P1451, DOI 10.1055/a-0735-9708
NR 34
TC 0
Z9 0
U1 0
U2 3
PU GEORG THIEME VERLAG KG
PI STUTTGART
PA RUDIGERSTR 14, D-70469 STUTTGART, GERMANY
SN 0023-2165
EI 1439-3999
J9 KLIN MONATSBL AUGENH
JI Klinische Monatsblat. Augenheilkunde
PD NOV
PY 2020
VL 237
IS 11
BP 1326
EP 1333
DI 10.1055/a-1194-5381
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Ophthalmology
GA OS5JX
UT WOS:000590201200011
PM 32869245
DA 2022-11-30
ER

PT J
AU Nassisi, M
   Tepelus, T
   Nittala, MG
   Sadda, SR
AF Nassisi, Marco
   Tepelus, Tudor
   Nittala, Muneeswar Gupta
   Sadda, Srinivas R.
TI Choriocapillaris flow impairment predicts the development and
   enlargement of drusen
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE Age-related macular degeneration; Optical coherence tomography
   angiography; Drusen; Choriocapillaris
ID QUANTITATIVE FUNDUS AUTOFLUORESCENCE; AGE-RELATED MACULOPATHY; MACULAR
   DEGENERATION; MORPHOMETRIC-ANALYSIS; ADAPTIVE OPTICS; EYES; IMAGE;
   PROGRESSION; FEATURES; DENSITY
AB Purpose To evaluate the choriocapillaris flow in regions of enlarged or new incident drusen in patients with early and intermediate age-related macular degeneration (AMD). Methods We retrospectively reviewed and analyzed structural optical coherence tomography (OCT) and OCT angiography (OCTA) images of consecutive patients with early or intermediate AMD evaluated at the Doheny-UCLA Eye Centers between 2015 and 2018. All patients were imaged using a Cirrus OCT, and only one eye was included in the study. To be eligible for this analysis, patients were required to have a 3 x 3-mm OCTA scan acquired during the first visit (considered as baseline) and a fovea-centered 512 x 128 macular cube (6 x 6 mm) acquired at both the baseline visit and after a minimum of 1 year follow-up. The drusen maps generated from the macular cubes were used to generate a drusen area (DA) measurement and compute the difference between baseline and follow-up (Delta DA). After registering the structural OCTs to the baseline choriocapillaris (CC) OCTA, we analyzed and compared the baseline flow deficits (FD) within drusen-free region (FDDF), regions into which drusen enlarged or expanded at follow-up (FDEN), and regions in which new incident drusen (FDND) appeared at follow-up. Results Forty-six patients were eligible for the analysis and had a mean follow-up of 1.47 years. Twelve eyes of 12 subjects had a Delta DA < 0.1 mm(2). In these eyes, only the FDDF was calculated (40.37 +/- 2.29%) and it was not significantly different from the FDDF of eyes with Delta DA >= 0.1 mm(2) (40.25 +/- 4.37%, p = 0.849). When comparing the different regions within the eyes with Delta DA >= 0.1 mm(2), there was no significant difference between FDED and FDND (43.61 +/- 4.36% and 44.16 +/- 2.38%, p = 528), but both were significantly higher than FDDF (p = 0.001 and p < 0.001, respectively). Conclusions Significant CC flow impairment is present under regions of intact retinal pigment epithelium (RPE) where existing drusen will enlarge into or new drusen will appear within 2 years. These findings suggest that location of drusen may not be stochastic but may be driven by regional deficits in the choriocapillaris.
C1 [Nassisi, Marco; Tepelus, Tudor; Nittala, Muneeswar Gupta; Sadda, Srinivas R.] Doheny Eye Inst, Doheny Image Reading Ctr, 1350 San Pablo St,DVRC211, Los Angeles, CA 90033 USA.
   [Nassisi, Marco; Tepelus, Tudor; Nittala, Muneeswar Gupta; Sadda, Srinivas R.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Ophthalmol, Los Angeles, CA 90095 USA.
C3 Doheny Eye Institute; University of California System; University of
   California Los Angeles; University of California Los Angeles Medical
   Center; David Geffen School of Medicine at UCLA
RP Sadda, SR (通讯作者)，Doheny Eye Inst, Doheny Image Reading Ctr, 1350 San Pablo St,DVRC211, Los Angeles, CA 90033 USA.; Sadda, SR (通讯作者)，Univ Calif Los Angeles, David Geffen Sch Med, Dept Ophthalmol, Los Angeles, CA 90095 USA.
EM ssadda@doheny.org
RI Nittala, Muneeswar/AAT-7533-2020; Nassisi, Marco/P-9939-2019
OI Nassisi, Marco/0000-0002-9354-9005
CR Abdelfattah NS, 2016, INVEST OPHTH VIS SCI, V57, P1839, DOI 10.1167/iovs.15-18572
   Al-Sheikh M, 2017, OSLI RETINA, V48, P623, DOI 10.3928/23258160-20170802-04
   Armenti ST, 2016, JOVE-J VIS EXP, DOI 10.3791/53577
   Arya M, 2018, EYE VISION, V5, DOI 10.1186/s40662-018-0118-x
   Bearelly S, 2009, OPHTHALMOLOGY, V116, P1762, DOI 10.1016/j.ophtha.2009.04.015
   Bhutto I, 2012, MOL ASPECTS MED, V33, P295, DOI 10.1016/j.mam.2012.04.005
   Biesemeier A, 2014, NEUROBIOL AGING, V35, P2562, DOI 10.1016/j.neurobiolaging.2014.05.003
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Borrelli E, 2018, AM J OPHTHALMOL, V196, P34, DOI 10.1016/j.ajo.2018.08.014
   Borrelli E, 2018, PROG RETIN EYE RES, V67, P30, DOI 10.1016/j.preteyeres.2018.07.002
   Borrelli E, 2018, RETINA-J RET VIT DIS, V38, P1968, DOI 10.1097/IAE.0000000000002198
   Borrelli E, 2017, INVEST OPHTH VIS SCI, V58, P4792, DOI 10.1167/iovs.17-22360
   Burke TR, 2014, INVEST OPHTH VIS SCI, V55, P2841, DOI 10.1167/iovs.13-13624
   Cabrera AP, 2016, INVEST OPHTH VIS SCI, V57, P5910, DOI 10.1167/iovs.16-19727
   Cicinelli MV, 2017, BRIT J OPHTHALMOL, V101, P1193, DOI 10.1136/bjophthalmol-2016-309481
   Curcio CA, 2013, RETINA-J RET VIT DIS, V33, P265, DOI 10.1097/IAE.0b013e31827e25e0
   Dysli C, 2017, PROG RETIN EYE RES, V60, P120, DOI 10.1016/j.preteyeres.2017.06.005
   Eandi CM, 2017, INVEST OPHTH VIS SCI, V58, P2284, DOI 10.1167/iovs.16-20510
   Forte R, 2020, RETINA-J RET VIT DIS, V40, P333, DOI 10.1097/IAE.0000000000002376
   FRIEDMAN E, 1963, ARCH OPHTHALMOL-CHIC, V69, P220
   Gocho K, 2013, INVEST OPHTH VIS SCI, V54, P3673, DOI 10.1167/iovs.12-10672
   Klein R, 2014, JAMA OPHTHALMOL, V132, P446, DOI 10.1001/jamaophthalmol.2013.7671
   KORTE GE, 1984, INVEST OPHTH VIS SCI, V25, P1135
   Lei JQ, 2017, GRAEF ARCH CLIN EXP, V255, P1551, DOI 10.1007/s00417-017-3693-y
   Lengyel I, 2004, INVEST OPHTH VIS SCI, V45, P2886, DOI 10.1167/iovs.03-1083
   McLeod DS, 2009, INVEST OPHTH VIS SCI, V50, P4982, DOI 10.1167/iovs.09-3639
   Moult EM, 2016, RETINA-J RET VIT DIS, V36, pS2, DOI 10.1097/IAE.0000000000001287
   Mullins RE, 2011, INVEST OPHTH VIS SCI, V52, P1606, DOI 10.1167/iovs.10-6476
   Nassisi M, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0207638
   Nassisi M, 2019, BRIT J OPHTHALMOL, V103, P911, DOI 10.1136/bjophthalmol-2018-312643
   Nassisi M, 2018, INVEST OPHTH VIS SCI, V59, P3431, DOI 10.1167/iovs.18-24143
   Nassisi M, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18112468
   Nittala MG, 2012, INVEST OPHTH VIS SCI, V53, P8319, DOI 10.1167/iovs.12-10582
   Ouyang YL, 2013, OPHTHALMOLOGY, V120, P2656, DOI 10.1016/j.ophtha.2013.05.029
   Querques G, 2014, OPHTHALMIC RES, V52, P107, DOI 10.1159/000363187
   Querques G, 2014, OPHTHALMOLOGY, V121, P611, DOI 10.1016/j.ophtha.2013.10.006
   RAMRATTAN RS, 1994, INVEST OPHTH VIS SCI, V35, P2857
   Sacconi R, 2018, RETINA-J RET VIT DIS, V38, P2350, DOI 10.1097/IAE.0000000000001873
   Saksens NTM, 2016, JAMA OPHTHALMOL, V134, P287, DOI 10.1001/jamaophthalmol.2015.5592
   Sarks SH, 1999, BRIT J OPHTHALMOL, V83, P358, DOI 10.1136/bjo.83.3.358
   Sauer L, 2018, ACTA OPHTHALMOL, V96, P257, DOI 10.1111/aos.13587
   Schlingemann RO, 2004, GRAEF ARCH CLIN EXP, V242, P91, DOI 10.1007/s00417-003-0828-0
   Schneider CA, 2012, NAT METHODS, V9, P671, DOI 10.1038/nmeth.2089
   Seddon JM, 2016, JAMA OPHTHALMOL, V134, P1272, DOI 10.1001/jamaophthalmol.2016.3519
   Spaide RF, 2018, SURV OPHTHALMOL, V63, P782, DOI 10.1016/j.survophthal.2018.05.005
   Spaide RF, 2017, RETINA-J RET VIT DIS, V37, P2008, DOI 10.1097/IAE.0000000000001497
   Spaide RF, 2016, AM J OPHTHALMOL, V170, P58, DOI 10.1016/j.ajo.2016.07.023
   Uji A, 2017, JAMA OPHTHALMOL, V135, P1197, DOI 10.1001/jamaophthalmol.2017.3904
   Uji A, 2017, OPHTHALMOLOGY, V124, P944, DOI 10.1016/j.ophtha.2017.02.006
   Zarbin MA, 2010, RETINA-J RET VIT DIS, V30, P1350, DOI 10.1097/IAE.0b013e3181f57e30
NR 50
TC 30
Z9 30
U1 0
U2 3
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0721-832X
EI 1435-702X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD OCT
PY 2019
VL 257
IS 10
BP 2079
EP 2085
DI 10.1007/s00417-019-04403-1
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA JN2DL
UT WOS:000496711200002
PM 31263948
OA Green Submitted
DA 2022-11-30
ER

PT J
AU Djigo, AD
   Berube, J
   Landreville, S
   Proulx, S
AF Djigo, Aicha Dede
   Berube, Julie
   Landreville, Solange
   Proulx, Stephanie
TI Characterization of a tissue-engineered choroid
SO ACTA BIOMATERIALIA
LA English
DT Article
DE Choroid; Tissue engineering; Extracellular matrix; 3D choroidal/RPE
   tissue model
ID RETINAL-PIGMENT EPITHELIUM; IN-VITRO MODEL; HUMAN CORNEA; MATRIX
   METALLOPROTEINASES; CYTOKERATIN EXPRESSION; MACULAR DEGENERATION;
   ENDOTHELIAL-CELLS; STATISTICAL-MODEL; CHORIOCAPILLARIS; PROTEINS
AB The choroid of the eye is a vascularized and pigmented connective tissue lying between the retina and the sclera. Increasing evidence demonstrates that, beyond supplying nutrients to the outer retina, the different choroidal cells contribute to the retina's homeostasis, especially by paracrine signaling. However, the precise role of each cell type is currently unclear. Here, we developed a choroidal substitute using the self-assembly approach of tissue engineering. Retinal pigment epithelial (RPE) cells, as well as choroidal stromal fibroblasts, vascular endothelial cells and melanocytes, were isolated from human eye bank donor eyes. Fibroblasts were cultured in a medium containing serum and ascorbic acid. After six weeks, cells formed sheets of extracellular matrix (ECM), which were stacked to produce a tissue-engineered choroidal stroma (TECS). These stromal substitutes were then characterized and compared to the native choroid. Their ECM composition (collagens and proteoglycans) and biomechanical properties (ultimate tensile strength, strain and elasticity) were similar. Furthermore, RPE cells, human umbilical vein endothelial cells and choroidal melanocytes successfully repopulated the stromas. Physiological structures were established, such as a confluent monolayer of RPE cells, vascular-like structures and a pigmentation of the stroma. Our TECS thus recaptured the biophysical environment of the native choroid, and can serve as study models to understand the normal interactions between the RPE and choroidal cells, as well as their reciprocal exchanges with the ECM. This will consequently pave the way to derive accurate insight in the pathophysiological mechanisms of diseases affecting the choroid.
   Statement of significance
   The choroid is traditionally known for supplying blood to the avascular outer retina. There has been a renewed attention directed towards the choroid partly due to its implication in the development of age-related macular degeneration (AMD), the leading cause of blindness in industrialized countries. Since AMD involves the dysfunction of the choroid/retinal pigment epithelium (RPE) complex, a three-dimensional (3D) model of RPE comprising the choroid layer is warranted. We used human choroidal cells to engineer a choroidal substitute. Our approach takes advantage of the ability of cells to recreate their own environment, without exogenous materials. Our model could help to better understand the role of each choroidal cell type as well as to advance the development of new therapeutics for AMD. (C) 2018 Acta Materialia Inc. Published by Elsevier Ltd. All rights reserved.
C1 [Djigo, Aicha Dede; Berube, Julie; Landreville, Solange; Proulx, Stephanie] Univ Laval, Fac Med, Dept Ophtalmol, Quebec City, PQ, Canada.
   [Djigo, Aicha Dede; Berube, Julie; Landreville, Solange; Proulx, Stephanie] Univ Laval, Fac Med, ORL CCF, Quebec City, PQ, Canada.
   [Djigo, Aicha Dede; Berube, Julie; Landreville, Solange; Proulx, Stephanie] CHU Quebec UL, Ctr Rech, Axe Med Regeneratrice, Quebec City, PQ, Canada.
   [Djigo, Aicha Dede; Berube, Julie; Landreville, Solange; Proulx, Stephanie] Univ Laval, LOEX, Ctr Rech Organogenese Expt, Quebec City, PQ, Canada.
   [Berube, Julie; Landreville, Solange] Univ Laval, Ctr Rech Canc, Quebec City, PQ, Canada.
C3 Laval University; Laval University; Laval University; Laval University
RP Proulx, S (通讯作者)，Univ Laval, CHU Quebec, Ctr Rech, Hop St Sacrement, 1050 Chemin St Foy, Quebec City, PQ G1S 4L8, Canada.
EM stephanie.proulx@fmed.ulaval.ca
OI Proulx, Stephanie/0000-0002-1227-4039; Landreville,
   Solange/0000-0002-9164-0657
FU Foundation Fighting Blindness; Fondation du CHU de Quebec
FX This work was supported by the Foundation Fighting Blindness (S.P.).
   Procurement of eyes for research was possible thanks to the CUO Eye Bank
   and a Fonds de recherche du Quebec -Sante (FRQS) Vision Health Research
   Network Infrastructure Program (S.P.). S.P. and S.L. are Research
   Scholars of the FRQS (in partnership with the "Fondation Antoine Turmel"
   for S.P.). A.D.D. was a recipient of a Master Training Award from the
   Fondation du CHU de Quebec.
CR Ambati J, 2013, NAT REV IMMUNOL, V13, P438, DOI 10.1038/nri3459
   Ambati J, 2012, NEURON, V75, P26, DOI 10.1016/j.neuron.2012.06.018
   [Anonymous], 2016, CAR EFF HYP CHRON CH, P79
   Benedicto I, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15374
   Bhutto IA, 2004, INVEST OPHTH VIS SCI, V45, P1544, DOI 10.1167/iovs.03-0862
   Bhutto I, 2012, MOL ASPECTS MED, V33, P295, DOI 10.1016/j.mam.2012.04.005
   Biesemeier A, 2014, NEUROBIOL AGING, V35, P2562, DOI 10.1016/j.neurobiolaging.2014.05.003
   Blaauwgeers HGT, 1999, AM J PATHOL, V155, P421, DOI 10.1016/S0002-9440(10)65138-3
   Booij JC, 2010, PROG RETIN EYE RES, V29, P1, DOI 10.1016/j.preteyeres.2009.08.003
   Brazma A, 2001, NAT GENET, V29, P365, DOI 10.1038/ng1201-365
   Browning AC, 2012, BRIT J OPHTHALMOL, V96, P128, DOI 10.1136/bjophthalmol-2011-300572
   Burke JM, 1996, EXP EYE RES, V62, P63, DOI 10.1006/exer.1996.0008
   Cattan V, 2011, EUR UROL, V60, P1291, DOI 10.1016/j.eururo.2011.05.051
   Chang HY, 2002, P NATL ACAD SCI USA, V99, P12877, DOI 10.1073/pnas.162488599
   Cheung C. M. G., 2018, EYE LOND
   Chirco KR, 2017, ACTA BIOMATER, V57, P293, DOI 10.1016/j.actbio.2017.05.011
   Couture C, 2016, BIOMATERIALS, V78, P86, DOI 10.1016/j.biomaterials.2015.11.006
   DuFort CC, 2011, NAT REV MOL CELL BIO, V12, P308, DOI 10.1038/nrm3112
   Fan W, 2002, IN VITRO CELL DEV-AN, V38, P228
   Feigl B, 2013, ADV HEALTHC MATER, V2, P1056, DOI 10.1002/adhm.201200445
   FENYVES AM, 1993, J CELL SCI, V106, P879
   Galbraith T, 2017, ADV HEALTHC MATER, V6, DOI 10.1002/adhm.201600889
   Goyer B, 2018, TISSUE ENG PT A, V24, P607, DOI [10.1089/ten.TEA.2017.0128, 10.1089/ten.tea.2017.0128]
   Halper J, 2014, ADV EXP MED BIOL, V802, P31, DOI 10.1007/978-94-007-7893-1_3
   Hamilton RD, 2007, J ANAT, V211, P707, DOI 10.1111/j.1469-7580.2007.00812.x
   Havlis J, 2003, ANAL CHEM, V75, P1300, DOI 10.1021/ac026136s
   Hong L, 2006, PIGM CELL RES, V19, P465, DOI 10.1111/j.1600-0749.2006.00330.x
   Hu DN, 2008, PHOTOCHEM PHOTOBIOL, V84, P639, DOI 10.1111/j.1751-1097.2008.00316.x
   HU DN, 1993, INVEST OPHTH VIS SCI, V34, P2210
   Imbeault A, 2013, CUAJ-CAN UROL ASSOC, V7, pE4, DOI 10.5489/cuaj.12217
   Keenan TDL, 2012, INVEST OPHTH VIS SCI, V53, P7528, DOI 10.1167/iovs.12-10797
   Keller A, 2002, ANAL CHEM, V74, P5383, DOI 10.1021/ac025747h
   Kuznetsova AV, 2014, J OPHTHALMOL, V2014, DOI 10.1155/2014/801787
   L'Heureux N, 1998, FASEB J, V12, P47, DOI 10.1096/fasebj.12.1.47
   Lee S, 2007, J BIOCHEM MOL BIOL, V40, P226
   Leu ST, 2002, EXP EYE RES, V74, P141, DOI 10.1006/exer.2001.1112
   Liu ZP, 2014, BIOMATERIALS, V35, P2837, DOI 10.1016/j.biomaterials.2013.12.069
   MARSHALL GE, 1994, GRAEF ARCH CLIN EXP, V232, P133, DOI 10.1007/BF00176781
   MICHEL M, 1993, IN VITRO CELL DEV-AN, V29A, P834
   Midwood KS, 2009, J CELL COMMUN SIGNAL, V3, P287, DOI 10.1007/s12079-009-0075-1
   Mullins RE, 2011, INVEST OPHTH VIS SCI, V52, P1606, DOI 10.1167/iovs.10-6476
   Nesvizhskii AI, 2003, ANAL CHEM, V75, P4646, DOI 10.1021/ac0341261
   Nickla DL, 2010, PROG RETIN EYE RES, V29, P144, DOI 10.1016/j.preteyeres.2009.12.002
   Ohno-Matsui K, 2016, PROG RETIN EYE RES, V52, P156, DOI 10.1016/j.preteyeres.2015.12.001
   Peters S, 2006, Z NATURFORSCH C, V61, P427
   PIHLAJANIEMI T, 1991, J HEPATOL, V13, pS2, DOI 10.1016/0168-8278(91)90002-S
   Proulx S, 2010, MOL VIS, V16, P2192
   Proulx S, 2009, TISSUE ENG PT A, V15, P1709, DOI 10.1089/ten.tea.2008.0208
   RAMRATTAN RS, 1994, INVEST OPHTH VIS SCI, V35, P2857
   Rochon MH, 2010, TISSUE ENG PT A, V16, P1457, DOI [10.1089/ten.tea.2009.0090, 10.1089/ten.TEA.2009.0090]
   Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h
   Shokoohmand A, 2017, MACROMOL BIOSCI, V17, DOI 10.1002/mabi.201700221
   Sidney LE, 2015, INVEST OPHTH VIS SCI, V56, P7225, DOI 10.1167/iovs.15-17810
   SmithThomas L, 1996, CURR EYE RES, V15, P1079, DOI 10.3109/02713689608995139
   Summers JA, 2013, EXP EYE RES, V114, P120, DOI 10.1016/j.exer.2013.03.008
   TAMURA Y, 1991, INVEST OPHTH VIS SCI, V32, P2636
   Vermette M, 2007, BIOMATERIALS, V28, P2850, DOI 10.1016/j.biomaterials.2007.02.030
   VONKOSKULL H, 1987, J CELL PHYSIOL, V133, P321, DOI 10.1002/jcp.1041330216
   Waheed NK, 2016, DEV OPHTHALMOL, V56, P91, DOI 10.1159/000442784
   Warnke P. H., 2014, ACTA BIOMATER, V9, P3813
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Wystrychowski W, 2014, J VASC SURG, V60, P1353, DOI 10.1016/j.jvs.2013.08.018
   Xu X, 2014, BIOTECHNOL ADV, V32, P1256, DOI 10.1016/j.biotechadv.2014.07.009
   Zhu M, 1998, AUST NZ J OPHTHALMOL, V26, pS50, DOI 10.1111/j.1442-9071.1998.tb01371.x
NR 64
TC 11
Z9 11
U1 1
U2 14
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1742-7061
EI 1878-7568
J9 ACTA BIOMATER
JI Acta Biomater.
PD JAN 15
PY 2019
VL 84
BP 305
EP 316
DI 10.1016/j.actbio.2018.11.033
PG 12
WC Engineering, Biomedical; Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Engineering; Materials Science
GA HJ1DS
UT WOS:000456902700024
PM 30476582
DA 2022-11-30
ER

PT J
AU Richer, S
   Stiles, W
   Ulanski, L
   Carroll, D
   Podella, C
AF Richer, Stuart
   Stiles, William
   Ulanski, Lawrence
   Carroll, Donn
   Podella, Carla
TI Observation of Human Retinal Remodeling in Octogenarians with a
   Resveratrol Based Nutritional Supplement
SO NUTRIENTS
LA English
DT Article
DE macular degeneration; gene expression; epigenetics; RPE (retinal pigment
   epithelium) function; VEGF; pharmacogenomics
AB Purpose: Rare spontaneous remissions from age-related macular degeneration (AMD) suggest the human retina has large regenerative capacity, even in advanced age. We present examples of robust improvement of retinal structure and function using an OTC oral resveratrol (RV) based nutritional supplement called Longevinex (R) or L/RV (circa 2004, Resveratrol Partners, LLC, Las Vegas, NV, USA). RV, a polyphenolic phytoalexin caloric-restriction mimic, induces hormesis at low doses with widespread beneficial effects on systemic health. RV alone inhibits neovascularization in the murine retina. Thus far, published evidence includes L/RV mitigation of experimentally induced murine cardiovascular reperfusion injury, amelioration of human atherosclerosis serum biomarkers in a human Japanese randomized placebo controlled trial, modulation of micro RNA 20b and 539 that control hypoxia-inducing-factor (HIF-1) and vascular endothelial growth factor (VEGF) genes in the murine heart (RV inhibited micro RNA20b 189-fold, L/RV 1366-fold). Little is known about the effects of L/RV on human ocular pathology. Methods: Absent FDA IRB approval, but with permission from our Chief of Staff and medical center IRB, L/RV is reserved for AMD patients, on a case-by-case compassionate care basis. Patients include those who progress on AREDS II type supplements, refuse intra-vitreal anti-VEGF injections or fail to respond to Lucentis (R), Avastin (R) or Eylea (R). Patients are clinically followed traditionally as well as with multi-spectral retinal imaging, visual acuity, contrast sensitivity, cone glare recovery and macular visual fields. Three cases are presented. Results: Observed dramatic short-term anti-VEGF type effect including anatomic restoration of retinal structure with a suggestion of improvement in choroidal blood flow by near IR multispectral imaging. The visual function improvement mirrors the effect seen anatomically. The effect is bilateral with the added benefit of better RPE function. Effects have lasted for one year or longer when taken daily, at which point one patient required initiation of anti-VEGF agents. Unanticipated systemic benefits were observed. Conclusions: Preliminary observations support previous publications in animals and humans. Restoration of structure and visual function in octogenarians with daily oral consumption of L/RV is documented. Applications include failure on AREDS II supplements, refusing or failing conventional anti-VEGF therapy, adjunct therapy to improve RPE function, and compassionate use in medically underserved or economically depressed third-world countries.
C1 [Richer, Stuart; Stiles, William; Ulanski, Lawrence; Carroll, Donn; Podella, Carla] Captain James Lovell Fed Hlth Care Ctr, Eye Clin 112E, N Chicago, IL 60064 USA.
RP Richer, S (通讯作者)，Captain James Lovell Fed Hlth Care Ctr, Eye Clin 112E, 3001 Green Bay Rd, N Chicago, IL 60064 USA.
EM stuart.richer1@VA.Gov; ilovemabel@aol.com; larry.ulanski@gmail.com;
   donn.carroll@gmail.com; cjpstella63@gmail.com
FU Captain James Lovell Federal Health Care Facility, DVA-Naval Medical
   Center, North Chicago, IL, USA
FX These medical case reports are based on original clinical work supported
   by the Optometry/Ophthalmology sections of Captain James Lovell Federal
   Health Care Facility, DVA-Naval Medical Center, North Chicago, IL, USA.
   Further peer-reviewed scientific studies are available at [14].
CR [Anonymous], THE 2ND INTERNATIONA
   Barger JL, 2008, EXP GERONTOL, V43, P859, DOI 10.1016/j.exger.2008.06.013
   Fujitaka K, 2011, NUTR RES, V31, P842, DOI 10.1016/j.nutres.2011.09.028
   Harris G., 2012, FOOD AND NUTRIENTS I
   Juhasz B, 2010, EXP CLIN CARDIOL, V15, pE134
   Pezzuto JM, 2011, ANN NY ACAD SCI, V1215, P123, DOI 10.1111/j.1749-6632.2010.05849.x
   Richer S, 2009, OPTOMETRY, V80, P695, DOI 10.1016/j.optm.2009.03.018
   Richer SP, 2011, OPTOMETRY, V82, P667, DOI 10.1016/j.optm.2011.08.008
   Vang O, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019881
NR 9
TC 37
Z9 37
U1 0
U2 18
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2072-6643
J9 NUTRIENTS
JI Nutrients
PD JUN
PY 2013
VL 5
IS 6
BP 1989
EP 2005
DI 10.3390/nu5061989
PG 17
WC Nutrition & Dietetics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Nutrition & Dietetics
GA 169HS
UT WOS:000320771400009
PM 23736827
OA Green Published, Green Submitted, gold
DA 2022-11-30
ER

PT J
AU Brown, DM
   Chen, E
   Mariani, A
   Major, JC
AF Brown, David M.
   Chen, Eric
   Mariani, Angeline
   Major, James C., Jr.
CA SAVE Study Grp
TI Super-dose Anti-VEGF (SAVE) Trial: 2.0 mg Intravitreal Ranibizumab for
   Recalcitrant Neovascular Macular Degeneration-Primary End Point
SO OPHTHALMOLOGY
LA English
DT Article
ID TACHYPHYLAXIS; BEVACIZUMAB
AB Purpose: To determine whether a higher dose of intravitreal ranibizumab could improve the anatomy and best-corrected visual acuity (BCVA) in eyes with neovascular age-related macular degeneration (AMD) with persistent disease activity despite monthly intravitreal anti-vascular endothelial growth factor (VEGF) injections.
   Design: Phase I to II multicenter, open-label, controlled clinical trial.
   Participants: Eighty-seven patients with recalcitrant neovascular AMD, defined as having leakage on fundus fluorescein angiography or spectral domain optical coherence tomography (SD-OCT) despite monthly anti-VEGF injections.
   Methods: Patients were treated with 2.0-mg ranibizumab injections monthly for 3 doses and monitored with Early Treatment Diabetic Retinopathy Study (ETDRS) 4-m refractions, clinical examinations, and SD-OCT.
   Main Outcome Measures: The mean change in baseline visual acuity (VA), the percentage of patients who experienced a loss or gain of 15 or more letters in ETDRS BCVA, the mean change in central retinal thickness, and the incidence of adverse events.
   Results: Eighty-seven patients with an average of 24 injections before enrollment and a mean of 10.4 injections in the preceding 12 months had a mean refracted VA of 69.2 ETDRS letters (20/41 Snellen) and a mean central subfield of 422 mu m at baseline. Mean VA gain over baseline was +2.5 letters at day 7 (n = 82), +3.7 letters at month 1 (n = 87), +3.9 letters at month 2 (n = 87), and +3.3 letters at month 3 (20/36 Snellen; P = 0.001; n = 86). Anatomic outcomes showed a mean optical coherence tomography central subfield thickness improvement from baseline of -48.4 mu m at day 7 (n = 84), -37.5 mu m at month 1 (n = 87), -42.4 mu m at month 2 (n = 85), and -33.1 mu m at month 3 (P = 0.01; n = 86).
   Conclusions: Intravitreal injections of 2.0 mg ranibizumab led to statistically significant VA gains and anatomic improvement in patients with persistent intraretinal, subretinal, or subretinal pigment epithelial fluid during a previous regimen of chronic monthly 0.5-mg ranibizumab injections.
   Financial Disclosure(s): The author(s) have no proprietary or commercial interest in any materials discussed in this article. Ophthalmology 2013;120:349-354 (C) 2013 by the American Academy of Ophthalmology.
C1 [Brown, David M.; Chen, Eric; Mariani, Angeline; Major, James C., Jr.; SAVE Study Grp] Methodist Hosp, Retina Consultants Houston, Houston, TX 77030 USA.
C3 The Methodist Hospital System; The Methodist Hospital - Houston
RP Brown, DM (通讯作者)，6560 Fannin St,Suite 750, Houston, TX 77030 USA.
EM dmbmd@houstonretina.com
FU Genentech
FX Research grant from Genentech. The funding organization had no role in
   the design or conduct of this research.
CR Brown DM, 2007, AM J OPHTHALMOL, V144, P627, DOI 10.1016/j.ajo.2007.06.039
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Eghoj MS, 2012, BRIT J OPHTHALMOL, V96, P21, DOI 10.1136/bjo.2011.203893
   Gasperini JL, 2012, BRIT J OPHTHALMOL, V96, P14, DOI 10.1136/bjo.2011.204685
   Gregori NZ, 2010, RETINA-J RET VIT DIS, V30, P1046, DOI 10.1097/IAE.0b013e3181d87e04
   Keane PA, 2008, BRIT J OPHTHALMOL, V92, P1081, DOI 10.1136/bjo.2008.138891
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rosenfeld PJ, 2005, OPHTHALMOLOGY, V112, P1048, DOI 10.1016/j.ophtha.2005.01.043
   Rosenfeld PJ, 2006, OPHTHALMOLOGY, V113, P623, DOI 10.1016/j.ophtha.2006.01.027
   Schaal S, 2008, OPHTHALMOLOGY, V115, P2199, DOI 10.1016/j.ophtha.2008.07.007
NR 11
TC 58
Z9 62
U1 0
U2 8
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0161-6420
J9 OPHTHALMOLOGY
JI Ophthalmology
PD FEB
PY 2013
VL 120
IS 2
BP 349
EP 354
DI 10.1016/j.ophtha.2012.08.008
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 085WX
UT WOS:000314646100020
PM 23131717
DA 2022-11-30
ER

PT J
AU Xu, HP
   Chen, M
   Forrester, JV
AF Xu, Heping
   Chen, Mei
   Forrester, John V.
TI Para-inflammation in the aging retina
SO PROGRESS IN RETINAL AND EYE RESEARCH
LA English
DT Review
DE Retina; Aging; Oxidative stress; Inflammation; Para-inflammation;
   Age-related macular degeneration; Diabetic retinopathy; Glaucoma
ID PIGMENT EPITHELIAL-CELLS; NITRIC-OXIDE SYNTHASE; TOLL-LIKE-RECEPTORS;
   GLYCATION END-PRODUCTS; COMPLEMENT FACTOR-H; OPTIC-NERVE HEAD;
   NF-KAPPA-B; EXPERIMENTAL AUTOIMMUNE UVEITIS; OPEN-ANGLE GLAUCOMA;
   PHOTORECEPTOR OUTER SEGMENTS
AB Para-inflammation is a tissue adaptive response to noxious stress or malfunction and has characteristics that are intermediate between basal and inflammatory states (Medzhitov, 2008). The physiological purpose of para-inflammation is to restore tissue functionality and homeostasis. Para-inflammation may become chronic or turn into inflammation if tissue stress or malfunction persists for a sustained period. Chronic para-inflammation contributes to the initiation and progression of many human diseases including obesity, type 2 diabetes, atherosclerosis, and age-related neurodegenerative diseases. Evidence from our studies and the studies of some others suggests that para-inflammation also exists in the aging retina in physiological conditions and might contribute to age-related retinal pathologies. The purpose of this review is to introduce the notion of "para-inflammation" as a state between frank, overt destructive inflammation and the non-inflammatory removal of dead or dying cells by apoptosis, to the retinal community.
   In diabetes and atherosclerosis, leukocytes particularly monocytes and vascular endothelial cells are constantly under noxious stress due to glycaemic and/or lipiclaemic dysregulation. These blood-borne stresses trigger para-inflammatory responses in leukocytes and endothelial cells by up-regulating the expression of adhesion molecules or releasing cytokines/chemokines, which in turn cause abnormal leukocyte-endothelial interactions and ultimately vascular damage. In the aging retina, on the other hand, oxidized lipoproteins and free radicals are considered to be major causes of tissue stress and serve as local triggers for retinal para-inflammation. Microarray analysis has revealed the up-regulation of a large number of inflammatory genes, including genes involved in complement activation and inflammatory cytokine/chemokine production, in the aging retina. Para-inflammatory responses in the neuroretina of aged mice are characterized by microglial activation and subretinal migration, and breakdown of blood-retinal barrier. At the retinal/choroidal interface para-inflammation is manifested by complement activation in Bruch's membrane and RPE cells, and microglia accumulation in subretinal space. With age, para-inflammatory changes have also been observed in the choroidal tissue, evidenced by 1) increased thickness of choroid: 2) increased number of CD45(+)CRIg(+) macrophages; 3) morphological abnormalities in choroidal melanocytes; and 4) fibrosis in choroidal tissue. An increased knowledge of contribution of retinal para-inflammation to various pathological conditions is essential for the better understanding of the pathogenesis of various age-related retinal diseases including diabetic retinopathy, glaucoma and age-related macular degeneration. (C) 2009 Elsevier Ltd. All rights reserved.
C1 [Xu, Heping; Chen, Mei; Forrester, John V.] Univ Aberdeen, Sch Med, Div Appl Med, Foresterhill AB25 2ZD, Scotland.
C3 University of Aberdeen
RP Xu, HP (通讯作者)，Queens Univ Belfast, Royal Victoria Hosp, Ctr Vis & Vasc Sci, Grosvenor Rd, Belfast BT12 6BA, Antrim, North Ireland.
EM h.xu@abdn.ac.uk
RI Mohammed, Imran/J-8271-2012; Xu, Heping/A-4430-2008
OI Mohammed, Imran/0000-0002-8412-0768; Xu, Heping/0000-0003-4000-931X
FU NHS [07/66, 06/30]; Office of Science and Technology (OST);  [G08/03]; 
   [G06/13]
FX This project is supported in part by the American Health Assistance
   Foundation (AHAF) for Macular Degeneration Research, Tenovus Scotland
   (G08/03; G06/13), and NHS Endowment funds (07/66, 06/30). Dr Heping Xu
   thanks the Department of Trade and Industry (DTI) and Office of Science
   and Technology (OST) for supporting his Research Council UK (RCUK)
   fellowship. The authors thank Dr van Lookeren Campagne (Genentech) for
   providing anti mouse CRIg antibody.
CR Acosta J, 2000, P NATL ACAD SCI USA, V97, P5450, DOI 10.1073/pnas.97.10.5450
   Adamis AP, 2008, SEMIN IMMUNOPATHOL, V30, P65, DOI 10.1007/s00281-008-0111-x
   Akira S, 2004, CR BIOL, V327, P581, DOI 10.1016/j.crvi.2004.04.002
   Anderson DH, 2004, EXP EYE RES, V78, P243, DOI 10.1016/j.exer.2003.10.011
   Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   Antonetti D A, 1999, Semin Ophthalmol, V14, P240, DOI 10.3109/08820539909069543
   Ayalasomayajula SP, 2004, EUR J PHARMACOL, V498, P275, DOI 10.1016/j.ejphar.2004.07.046
   Bajetto A, 1999, ANN NY ACAD SCI, V876, P201, DOI 10.1111/j.1749-6632.1999.tb07640.x
   Banisadr G, 2005, J COMP NEUROL, V492, P178, DOI 10.1002/cne.20729
   Barile GR, 2007, CURR MOL MED, V7, P758, DOI 10.2174/156652407783220778
   Barouch FC, 2000, INVEST OPHTH VIS SCI, V41, P1153
   Barton GM, 2003, SCIENCE, V300, P1524, DOI 10.1126/science.1085536
   Besnard S, 2002, FEBS LETT, V511, P36, DOI 10.1016/S0014-5793(01)03275-6
   Bianchi ME, 2007, IMMUNOL REV, V220, P35, DOI 10.1111/j.1600-065X.2007.00574.x
   BIRD AC, 1986, T OPHTHAL SOC UK, V105, P674
   Bonifati DM, 2007, MOL IMMUNOL, V44, P999, DOI 10.1016/j.molimm.2006.03.007
   Bora NS, 2007, J IMMUNOL, V178, P1783, DOI 10.4049/jimmunol.178.3.1783
   Bora PS, 2005, J IMMUNOL, V174, P491, DOI 10.4049/jimmunol.174.1.491
   Bosco A, 2008, INVEST OPHTH VIS SCI, V49, P1437, DOI 10.1167/iovs.07-1337
   Cai JY, 2000, PROG RETIN EYE RES, V19, P205, DOI 10.1016/S1350-9462(99)00009-9
   Cantor Jerome O., 2006, Inflammation & Allergy Drug Targets, V5, P257, DOI 10.2174/187152806779010936
   Carmo A, 2000, NITRIC OXIDE-BIOL CH, V4, P590, DOI 10.1006/niox.2000.0312
   Cernadas MR, 1998, CIRC RES, V83, P279, DOI 10.1161/01.RES.83.3.279
   Chan-Ling T, 2007, MICROCIRCULATION, V14, P63, DOI 10.1080/10739680601073451
   Chen HY, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002339
   Chen M, 2007, EXP EYE RES, V84, P635, DOI 10.1016/j.exer.2006.11.015
   Chen M, 2008, EXP EYE RES, V87, P543, DOI 10.1016/j.exer.2008.09.005
   Cheon EW, 2002, NEUROSCI LETT, V330, P265, DOI 10.1016/S0304-3940(02)00804-2
   Cherepanoff S, 2006, CLIN EXP OPHTHALMOL, V34, P590, DOI 10.1111/j.1442-9071.2006.01281.x
   Cherra SJ, 2008, FUTUR NEUROL, V3, P309, DOI 10.2217/14796708.3.3.309
   Clynes R, 2007, CURR MOL MED, V7, P743
   COLE J, 2008, SERIALS LIBR, V53, P1, DOI DOI 10.1300/J123v53n04_01
   Combadiere C, 2007, J CLIN INVEST, V117, P2920, DOI 10.1172/JCI31692
   Copland DA, 2007, AM J PATHOL, V171, P580, DOI 10.2353/ajpath.2007.070272
   Coraci IS, 2002, AM J PATHOL, V160, P101, DOI 10.1016/S0002-9440(10)64354-4
   Corasaniti MT, 2001, NEUROSCI LETT, V312, P67, DOI 10.1016/S0304-3940(01)02191-7
   Cosentino F, 2006, AM J HYPERTENS, V19, P1213, DOI 10.1016/j.amjhyper.2006.06.002
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   Crack PJ, 2005, FREE RADICAL BIO MED, V38, P1433, DOI 10.1016/j.freeradbiomed.2005.01.019
   CURCIO CA, 1993, INVEST OPHTH VIS SCI, V34, P3278
   Cusi K, 2000, J CLIN INVEST, V105, P311, DOI 10.1172/JCI7535
   Davies CS, 2005, IMMUNOLOGY, V114, P280, DOI 10.1111/j.1365-2567.2004.02086.x
   De la Fuente M, 2000, LIFE SCI, V67, P2125, DOI 10.1016/S0024-3205(00)00799-2
   DELAFUENTE M, 1985, COMP BIOCHEM PHYS A, V81, P935, DOI 10.1016/0300-9629(85)90933-8
   Dick AD, 2003, J LEUKOCYTE BIOL, V74, P161, DOI 10.1189/jlb.1102535
   Donato AJ, 2008, AGING CELL, V7, P805, DOI 10.1111/j.1474-9726.2008.00438.x
   Du YP, 2002, J NEUROCHEM, V80, P771, DOI 10.1046/j.0022-3042.2001.00737.x
   Dumitriu IE, 2005, TRENDS IMMUNOL, V26, P381, DOI 10.1016/j.it.2005.04.009
   Dumitriu IE, 2005, EUR J IMMUNOL, V35, P2184, DOI 10.1002/eji.200526066
   Duncan KG, 2002, BIOCHEM BIOPH RES CO, V292, P1017, DOI 10.1006/bbrc.2002.6756
   Ebihara N, 2007, OPHTHAL RES, V39, P155, DOI 10.1159/000103235
   Edens HA, 2000, ADV DRUG DELIVER REV, V41, P315, DOI 10.1016/S0169-409X(00)00049-1
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   El-Asrar AM, 2001, AM J OPHTHALMOL, V132, P551, DOI 10.1016/S0002-9394(01)01127-8
   Fadok VA, 1998, J CLIN INVEST, V101, P890, DOI 10.1172/JCI1112
   Fadok VA, 1998, BIOCHEM SOC T, V26, P653, DOI 10.1042/bst0260653
   Felzien LK, 2001, BRAIN RES, V890, P137, DOI 10.1016/S0006-8993(00)03090-0
   Fernandes AF, 2008, J BIOL CHEM, V283, P20745, DOI 10.1074/jbc.M800268200
   Fernandez-Durango R, 2008, INVEST OPHTH VIS SCI, V49, P2506, DOI 10.1167/iovs.07-1363
   Forrester JV, 2005, BRIT J OPHTHALMOL, V89, P369, DOI 10.1136/bjo.2004.054197
   FORRESTER JV, 1994, INVEST OPHTH VIS SCI, V35, P64
   FORRESTER JV, 1990, CURR EYE RES, V9, P183, DOI 10.3109/02713689008999440
   FREEMAN BA, 1982, LAB INVEST, V47, P412
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P532
   GAO H, 1992, INVEST OPHTH VIS SCI, V33, P1
   GEHRMANN J, 1995, BRAIN RES REV, V20, P269, DOI 10.1016/0165-0173(94)00015-H
   Glabinski AR, 1999, J NEUROVIROL, V5, P623, DOI 10.3109/13550289909021291
   Glenn JV, 2009, INVEST OPHTH VIS SCI, V50, P441, DOI 10.1167/iovs.08-1724
   Gordon S, 2003, NAT REV IMMUNOL, V3, P23, DOI 10.1038/nri978
   Gorgani NN, 2008, J IMMUNOL, V181, P7902, DOI 10.4049/jimmunol.181.11.7902
   Goto R, 2005, JPN J OPHTHALMOL, V49, P363, DOI 10.1007/s10384-004-0213-5
   Griffiths M, 2007, INT REV NEUROBIOL, V82, P29, DOI 10.1016/S0074-7742(07)82002-2
   Gu XR, 2003, J BIOL CHEM, V278, P42027, DOI 10.1074/jbc.M305460200
   GURNE DH, 1991, OPHTHALMOLOGY, V98, P602
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Han M, 2007, J BIOMED OPT, V12, DOI 10.1117/1.2717522
   Handa JT, 1999, INVEST OPHTH VIS SCI, V40, P775
   Hansson GK, 2006, ANNU REV PATHOL-MECH, V1, P297, DOI 10.1146/annurev.pathol.1.110304.100100
   Harhaj NS, 2004, INT J BIOCHEM CELL B, V36, P1206, DOI 10.1016/j.biocel.2003.08.007
   HARMAN D, 1956, J GERONTOL, V11, P298, DOI 10.1093/geronj/11.3.298
   HARMAN D, 1981, P NATL ACAD SCI-BIOL, V78, P7124, DOI 10.1073/pnas.78.11.7124
   Harris MI, 1998, DIABETES CARE, V21, pC11, DOI 10.2337/diacare.21.3.C11
   Hayek MG, 1997, J IMMUNOL, V159, P2445
   He JL, 1997, NATURE, V385, P645, DOI 10.1038/385645a0
   Helmy KY, 2006, CELL, V124, P915, DOI 10.1016/j.cell.2005.12.039
   Herold K, 2007, J LEUKOCYTE BIOL, V82, P204, DOI 10.1189/jlb.1206751
   Herrero C, 2002, EXP GERONTOL, V37, P389, DOI 10.1016/S0531-5565(01)00205-4
   Higgins GT, 2003, INVEST OPHTH VIS SCI, V44, P1775, DOI 10.1167/iovs.02-0742
   Hollyfield JG, 1999, INVEST OPHTH VIS SCI, V40, P2767
   Hollyfield JG, 1998, EXP EYE RES, V66, P241, DOI 10.1006/exer.1997.0422
   Hollyfield JG, 2003, ADV EXP MED BIOL, V533, P83
   Hollyfield JG, 2008, NAT MED, V14, P194, DOI 10.1038/nm1709
   Howes KA, 2004, INVEST OPHTH VIS SCI, V45, P3713, DOI 10.1167/iovs.04-0404
   Hughes EH, 2003, INVEST OPHTH VIS SCI, V44, P2229, DOI 10.1167/iovs.02-0824
   ISCHIROPOULOS H, 1992, ARCH BIOCHEM BIOPHYS, V298, P431, DOI 10.1016/0003-9861(92)90431-U
   Jha P, 2006, INVEST OPHTH VIS SCI, V47, P1030, DOI 10.1167/iovs.05-1062
   Jha P, 2007, MOL IMMUNOL, V44, P3901, DOI 10.1016/j.molimm.2007.06.145
   Jiang DH, 2005, NAT MED, V11, P1173, DOI 10.1038/nm1315
   JIANG LQ, 1993, INVEST OPHTH VIS SCI, V34, P3347
   Jin MS, 2008, IMMUNITY, V29, P182, DOI 10.1016/j.immuni.2008.07.007
   Johnson EIM, 1999, CURR EYE RES, V18, P79, DOI 10.1076/ceyr.18.2.79.5386
   Joussen AM, 2002, AM J PATHOL, V160, P501, DOI 10.1016/S0002-9440(10)64869-9
   Joussen AM, 2001, AM J PATHOL, V158, P147, DOI 10.1016/S0002-9440(10)63952-1
   Ju WK, 2001, NEUROREPORT, V12, P4075, DOI 10.1097/00001756-200112210-00043
   Kawai T, 2007, TRENDS MOL MED, V13, P460, DOI 10.1016/j.molmed.2007.09.002
   Kawai T, 2007, SEMIN IMMUNOL, V19, P24, DOI 10.1016/j.smim.2006.12.004
   Kelly J, 2007, J CLIN INVEST, V117, P3421, DOI 10.1172/JCI32430
   Kezic J, 2008, INVEST OPHTH VIS SCI, V49, P1599, DOI 10.1167/iovs.07-0953
   Khare V, 1997, NAT IMMUN, V15, P285
   Khurana RN, 2008, INVEST OPHTH VIS SCI, V49, P3299, DOI 10.1167/iovs.07-1607
   Kim YH, 2009, GRAEFES ARCH CLIN EX
   King GL, 2008, J PERIODONTOL, V79, P1527, DOI 10.1902/jop.2008.080246
   KING PA, 1993, NUCLEIC ACIDS RES, V21, P2473, DOI 10.1093/nar/21.10.2473
   KLEIN CL, 1995, PATHOBIOLOGY, V63, P83, DOI 10.1159/000163938
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Kono H, 2008, NAT REV IMMUNOL, V8, P279, DOI 10.1038/nri2215
   Kowluru RA, 2004, BRIT J OPHTHALMOL, V88, P1343, DOI 10.1136/bjo.2003.038133
   Krady JK, 2005, DIABETES, V54, P1559, DOI 10.2337/diabetes.54.5.1559
   Krishnamoorthy RR, 1999, J BIOL CHEM, V274, P3734, DOI 10.1074/jbc.274.6.3734
   Kuehn MH, 2006, EXP EYE RES, V83, P620, DOI 10.1016/j.exer.2006.03.002
   Kumar MV, 2004, J NEUROIMMUNOL, V153, P7, DOI 10.1016/j.jneuroim.2004.04.018
   Ladeby R, 2005, BRAIN RES REV, V48, P196, DOI 10.1016/j.brainresrev.2004.12.009
   Lavi E, 1997, AM J PATHOL, V151, P1035
   Leal EC, 2007, INVEST OPHTH VIS SCI, V48, P5257, DOI 10.1167/iovs.07-0112
   Li GY, 2008, BRAIN RES, V1188, P35, DOI 10.1016/j.brainres.2007.10.073
   LIVERSIDGE J, 1994, IMMUNOLOGY, V83, P404
   LIVERSIDGE J, 1993, CELL IMMUNOL, V149, P315, DOI 10.1006/cimm.1993.1158
   Liversidge J, 2002, AM J PATHOL, V160, P905, DOI 10.1016/S0002-9440(10)64913-9
   Lloberas J, 2002, EXP GERONTOL, V37, P1325, DOI 10.1016/S0531-5565(02)00125-0
   Lopes KO, 2008, GLIA, V56, P1048, DOI 10.1002/glia.20678
   Ma NL, 1999, J IMMUNOL, V162, P4482
   Ma NL, 1998, INVEST OPHTH VIS SCI, V39, P2384
   Ma TY, 2004, AM J PHYSIOL-GASTR L, V286, pG367, DOI 10.1152/ajpgi.00173.2003
   Margrain TH, 2004, PROG RETIN EYE RES, V23, P523, DOI 10.1016/j.preteyeres.2004.05.001
   McGeer EG, 2005, NEUROBIOL AGING, V26, pS94, DOI 10.1016/j.neurobiolaging.2005.08.008
   McGeer PL, 2004, ANN NY ACAD SCI, V1035, P104, DOI 10.1196/annals.1332.007
   McKee CM, 1996, J CLIN INVEST, V98, P2403, DOI 10.1172/JCI119054
   McMenamin PG, 1999, BRIT J OPHTHALMOL, V83, P598, DOI 10.1136/bjo.83.5.598
   McMenamin PG, 1997, EYE, V11, P183, DOI 10.1038/eye.1997.49
   McMenamin PG, 1999, ANAT EMBRYOL, V200, P551, DOI 10.1007/s004290050303
   MCMENAMIN PG, 1990, ANAT REC, V227, P245, DOI 10.1002/ar.1092270213
   Medzhitov R, 2000, TRENDS MICROBIOL, V8, P452, DOI 10.1016/S0966-842X(00)01845-X
   Medzhitov R, 2000, SEMIN IMMUNOL, V12, P185, DOI 10.1006/smim.2000.0230
   Medzhitov R, 2002, SCIENCE, V296, P298, DOI 10.1126/science.1068883
   Medzhitov R, 1997, NATURE, V388, P394, DOI 10.1038/41131
   Medzhitov R, 2000, IMMUNOL REV, V173, P89, DOI 10.1034/j.1600-065X.2000.917309.x
   Medzhitov R, 2008, NATURE, V454, P428, DOI 10.1038/nature07201
   Mehdizadeh M, 2008, J GLAUCOMA, V17, P505, DOI 10.1097/IJG.0b013e318188b21f
   Mevorach D, 1998, J EXP MED, V188, P2313, DOI 10.1084/jem.188.12.2313
   Mevorach D, 2000, ANN NY ACAD SCI, V926, P226
   Miyake K, 2007, SEMIN IMMUNOL, V19, P3, DOI 10.1016/j.smim.2006.12.002
   Miyamoto K, 1998, INVEST OPHTH VIS SCI, V39, P2190
   Miyata T, 1996, J CLIN INVEST, V98, P1088, DOI 10.1172/JCI118889
   Moshfeghi DM, 2007, RETINA-J RET VIT DIS, V27, P269, DOI 10.1097/IAE.0b013e31802e3e9b
   Mozaffarieh M, 2008, MOL VIS, V14, P224
   Mrak RE, 2005, NEUROBIOL AGING, V26, P349, DOI 10.1016/j.neurobiolaging.2004.05.010
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   Naskar R, 2002, INVEST OPHTH VIS SCI, V43, P2962
   NAVEHFLOMAN N, 1984, CURR EYE RES, V3, P1135, DOI 10.3109/02713688409000813
   Neufeld AH, 1999, ARCH OPHTHALMOL-CHIC, V117, P1050
   Neufeld AH, 1999, SURV OPHTHALMOL, V43, pS129, DOI 10.1016/S0039-6257(99)00010-7
   NEWSOME DA, 1987, CURR EYE RES, V6, P1211, DOI 10.3109/02713688709025231
   Ng TF, 2001, INVEST OPHTH VIS SCI, V42, P3301
   Noble PW, 1996, J EXP MED, V183, P2373, DOI 10.1084/jem.183.5.2373
   Oppenheim JJ, 2005, J LEUKOCYTE BIOL, V77, P854, DOI 10.1189/jlb.1004623
   Osborne NN, 2004, PROG RETIN EYE RES, V23, P91, DOI 10.1016/j.preteyeres.2003.12.001
   Osborne NN, 2004, INVEST OPHTH VIS SCI, V45, P3787, DOI 10.1167/iovs.04-0147
   Osto E, 2007, CURR PHARM DESIGN, V13, P1053, DOI 10.2174/138161207780487566
   Osusky R, 1997, OPHTHALMIC RES, V29, P124, DOI 10.1159/000268006
   Osusky R, 1997, OPHTHALMIC RES, V29, P31, DOI 10.1159/000267988
   Park JS, 2006, AM J PHYSIOL-CELL PH, V290, pC917, DOI 10.1152/ajpcell.00401.2005
   Park SH, 2007, VISION RES, V47, P2732, DOI 10.1016/j.visres.2007.07.011
   Patel M, 2008, SEMIN IMMUNOPATHOL, V30, P97, DOI 10.1007/s00281-008-0112-9
   Patel N, 2005, IMMUNOLOGY, V115, P422, DOI 10.1111/j.1365-2567.2005.02173.x
   PENFOLD PL, 1990, GRAEF ARCH CLIN EXP, V228, P270, DOI 10.1007/BF00920033
   Penfold PL, 2001, PROG RETIN EYE RES, V20, P385, DOI 10.1016/S1350-9462(00)00025-2
   Plowden J, 2004, AGING CELL, V3, P161, DOI 10.1111/j.1474-9728.2004.00102.x
   Poulaki V, 2002, J CLIN INVEST, V109, P805, DOI 10.1172/JCI200213776
   Qin XB, 2004, DIABETES, V53, P2653, DOI 10.2337/diabetes.53.10.2653
   Quigley HA, 2006, BRIT J OPHTHALMOL, V90, P262, DOI 10.1136/bjo.2005.081224
   RADI R, 1991, ARCH BIOCHEM BIOPHYS, V288, P481, DOI 10.1016/0003-9861(91)90224-7
   RADI R, 1994, ARCH BIOCHEM BIOPHYS, V308, P89, DOI 10.1006/abbi.1994.1013
   RAMPRASAD MP, 1995, P NATL ACAD SCI USA, V92, P9580, DOI 10.1073/pnas.92.21.9580
   RAMRATTAN RS, 1994, INVEST OPHTH VIS SCI, V35, P2857
   Rattan SIS, 2006, FREE RADICAL RES, V40, P1230, DOI 10.1080/10715760600911303
   Renshaw M, 2002, J IMMUNOL, V169, P4697, DOI 10.4049/jimmunol.169.9.4697
   Richter V, 2003, GERONTOLOGY, V49, P293, DOI 10.1159/000071710
   Rock FL, 1998, P NATL ACAD SCI USA, V95, P588, DOI 10.1073/pnas.95.2.588
   Rock KL, 2008, ANNU REV PATHOL-MECH, V3, P99, DOI 10.1146/annurev.pathmechdis.3.121806.151456
   Rodrigues EB, 2007, OPHTHALMOLOGICA, V221, P143, DOI 10.1159/000099293
   Rohrer B, 2007, INVEST OPHTH VIS SCI, V48, P5282, DOI 10.1167/iovs.07-0282
   Rohrer B, 2009, INVEST OPHTH VIS SCI, V50, P3056, DOI 10.1167/iovs.08-2222
   Rungger-Brandle E, 2000, INVEST OPHTH VIS SCI, V41, P1971
   RYAN GB, 1977, AM J PATHOL, V86, P183
   Ryeom SW, 1996, J BIOL CHEM, V271, P20536, DOI 10.1074/jbc.271.34.20536
   Sanvicens N, 2004, J BIOL CHEM, V279, P39268, DOI 10.1074/jbc.M402202200
   Sappington RM, 2008, INVEST OPHTH VIS SCI, V49, P3004, DOI 10.1167/iovs.07-1355
   Saraswathy S, 2008, OPHTHALMIC RES, V40, P160, DOI 10.1159/000119869
   Schiffrin EL, 2001, J CARDIOVASC PHARM, V38, pS3, DOI 10.1097/00005344-200111002-00002
   SCHMIDT AM, 1994, P NATL ACAD SCI USA, V91, P8807, DOI 10.1073/pnas.91.19.8807
   SCHMIDT AM, 1995, J CLIN INVEST, V96, P1395, DOI 10.1172/JCI118175
   Schmidt AM, 2001, J CLIN INVEST, V108, P949, DOI 10.1172/JCI14002
   Scholl HPN, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002593
   SCHRODER S, 1991, AM J PATHOL, V139, P81
   SERRA AM, 2007, INVEST OPHTHALMOL VI, V48
   Shen Y, 2003, PROG NEUROBIOL, V70, P463, DOI 10.1016/j.pneurobio.2003.08.001
   Sheng JG, 1998, ACTA NEUROPATHOL, V95, P229, DOI 10.1007/s004010050792
   Sheng JG, 1998, NEUROPATH APPL NEURO, V24, P278
   Skeie JM, 2009, EYE, V23, P747, DOI 10.1038/eye.2008.206
   Sohn Jeong-Hyeon, 2007, Chem Immunol Allergy, V92, P105, DOI 10.1159/000099261
   Spiteller G, 2006, FREE RADICAL BIO MED, V41, P362, DOI 10.1016/j.freeradbiomed.2006.03.013
   Stadtman ER, 1997, CHEM RES TOXICOL, V10, P485, DOI 10.1021/tx960133r
   Stamatovic SM, 2003, J CELL SCI, V116, P4615, DOI 10.1242/jcs.00755
   Stasi K, 2006, INVEST OPHTH VIS SCI, V47, P1024, DOI 10.1167/iovs.05-0830
   Steinle JJ, 2008, J GERONTOL A-BIOL, V63, P135, DOI 10.1093/gerona/63.2.135
   Steinle JJ, 2009, J GERONTOL A-BIOL, V64, P325, DOI 10.1093/gerona/gln052
   Stern R, 2006, EUR J CELL BIOL, V85, P699, DOI 10.1016/j.ejcb.2006.05.009
   Streilein JW, 2002, VISION RES, V42, P487, DOI 10.1016/S0042-6989(01)00185-7
   Streit WJ, 2004, GLIA, V45, P208, DOI 10.1002/glia.10319
   Stumm R, 2007, J MOL ENDOCRINOL, V38, P377, DOI 10.1677/JME-06-0032
   Suematsu M, 2002, MICROCIRCULATION, V9, P259, DOI 10.1038/sj.mn.7800141
   Sugita S, 2008, J IMMUNOL, V181, P7525, DOI 10.4049/jimmunol.181.11.7525
   Sugita S, 2009, INVEST OPHTH VIS SCI, V50, P2862, DOI 10.1167/iovs.08-2846
   Swaroop A, 2007, HUM MOL GENET, V16, pR174, DOI 10.1093/hmg/ddm212
   Takeda K, 2002, J ENDOTOXIN RES, V8, P459, DOI 10.1179/096805102125001073
   Takizawa F, 1996, FEBS LETT, V397, P269, DOI 10.1016/S0014-5793(96)01197-0
   Terao A, 2002, J NEUROIMMUNOL, V132, P99, DOI 10.1016/S0165-5728(02)00317-X
   Tezel G, 2004, BRAIN RES BULL, V62, P473, DOI 10.1016/S0361-9230(03)00074-1
   Tezel G, 2004, ARCH OPHTHALMOL-CHIC, V122, P1348, DOI 10.1001/archopht.122.9.1348
   Tezel G, 2003, INVEST OPHTH VIS SCI, V44, P3025, DOI 10.1167/iovs.02-1136
   Thornton J, 2005, EYE, V19, P935, DOI 10.1038/sj.eye.6701978
   Tian J, 2005, P NATL ACAD SCI USA, V102, P11846, DOI 10.1073/pnas.0504759102
   Tsutsumi C, 2003, J LEUKOCYTE BIOL, V74, P25, DOI 10.1189/jlb.0902436
   Usui Y, 2008, EXP EYE RES, V86, P52, DOI 10.1016/j.exer.2007.09.007
   VanNewkirk MR, 2000, OPHTHALMOLOGY, V107, P1593, DOI 10.1016/S0161-6420(00)00175-5
   VERGANI S, 1986, BRIT J OPHTHALMOL, V70, P60, DOI 10.1136/bjo.70.1.60
   Vohra RS, 2006, TRENDS CARDIOVAS MED, V16, P60, DOI 10.1016/j.tcm.2005.12.001
   Voll RE, 1997, NATURE, V390, P350, DOI 10.1038/37022
   Walker DG, 2009, EXP NEUROL, V215, P5, DOI 10.1016/j.expneurol.2008.09.003
   Wang AL, 2008, MOL VIS, V14, P644
   Wang AL, 2009, AUTOPHAGY, V5, P563, DOI 10.4161/auto.5.4.8163
   Wang XF, 2004, EXP EYE RES, V79, P209, DOI 10.1016/j.exer.2004.03.013
   Wax MB, 2008, J NEUROSCI, V28, P12085, DOI 10.1523/JNEUROSCI.3200-08.2008
   Wax MB, 2009, EXP EYE RES, V88, P825, DOI 10.1016/j.exer.2009.02.005
   Wax MB, 2001, OPHTHALMOLOGY, V108, P296, DOI 10.1016/S0161-6420(00)00525-X
   Wenkel H, 2000, INVEST OPHTH VIS SCI, V41, P3467
   Wenkel H, 1999, INVEST OPHTH VIS SCI, V40, P3202
   Wong CHY, 2008, CURR MED CHEM, V15, P1
   Xu HP, 2008, AGING CELL, V7, P58, DOI 10.1111/j.1474-9726.2007.00351.x
   Xu HP, 2007, GLIA, V55, P1189, DOI 10.1002/glia.20535
   Xu HP, 2007, INVEST OPHTH VIS SCI, V48, P2162, DOI 10.1167/iovs.06-0783
   Xu HP, 2007, INVEST OPHTH VIS SCI, V48, P1701, DOI 10.1167/iovs.06-0697
   Xu HP, 2005, INVEST OPHTH VIS SCI, V46, P2487, DOI 10.1167/iovs.04-1333
   Yamada Y, 2006, EXP EYE RES, V82, P840, DOI 10.1016/j.exer.2005.10.005
   Yan SD, 2000, BBA-MOL BASIS DIS, V1502, P145, DOI 10.1016/S0925-4439(00)00041-7
   Yang Y, 2006, INT J OBESITY, V30, P439, DOI 10.1038/sj.ijo.0803173
   Yoshida A, 2001, INVEST OPHTH VIS SCI, V42, P1631
   Yuan L, 2000, GLIA, V32, P42, DOI 10.1002/1098-1136(200010)32:1<42::AID-GLIA40>3.0.CO;2-3
   Yuan LY, 2001, J NEUROSCI RES, V64, P523, DOI 10.1002/jnr.1104
   Zamiri Parisa, 2007, Chem Immunol Allergy, V92, P86, DOI 10.1159/000099259
   Zanon-Moreno V, 2008, J GLAUCOMA, V17, P263, DOI 10.1097/IJG.0b013e31815c3a7f
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
   Zeng HY, 2008, ARCH OPHTHALMOL-CHIC, V126, P227, DOI 10.1001/archophthalmol.2007.65
   Zhang A, 2002, DIABETES, V51, P3499
   Zhang FL, 2006, J CARDIOVASC PHARM, V48, P47, DOI 10.1097/01.fjc.0000242058.72471.0c
   Zhang Z, 2006, CELL MOL LIFE SCI, V63, P2901, DOI 10.1007/s00018-006-6189-1
   Zhou XH, 2005, J BIOL CHEM, V280, P31240, DOI 10.1074/jbc.M502641200
   Zhu YL, 2006, EXP EYE RES, V82, P153, DOI 10.1016/j.exer.2005.06.005
   Zissel G, 1999, J INVEST MED, V47, P51
NR 271
TC 460
Z9 476
U1 3
U2 82
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 1350-9462
EI 1873-1635
J9 PROG RETIN EYE RES
JI Prog. Retin. Eye Res.
PD SEP
PY 2009
VL 28
IS 5
BP 348
EP 368
DI 10.1016/j.preteyeres.2009.06.001
PG 21
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 487LL
UT WOS:000269275600003
PM 19560552
DA 2022-11-30
ER

PT J
AU Chou, R
   Bougatsos, C
   Jungbauer, R
   Grusing, S
   Blazina, I
   Selph, S
   Jonas, DE
   Tehrani, S
AF Chou, Roger
   Bougatsos, Christina
   Jungbauer, Rebecca
   Grusing, Sara
   Blazina, Ian
   Selph, Shelley
   Jonas, Daniel E.
   Tehrani, Shandiz
TI Screening for Impaired Visual Acuity in Older Adults Updated Evidence
   Report and Systematic Review for the US Preventive Services Task Force
SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
LA English
DT Review
ID BASE-LINE-CHARACTERISTICS; AGE-RELATED MACULOPATHY; MACULAR
   DEGENERATION; EYE DISEASE; CLINICAL-TRIAL; LUTEIN SUPPLEMENTATION;
   BETA-CAROTENE; ORAL ZINC; VITAMIN-E; VISION
AB IMPORTANCE A 2016 review for the US Preventive Services Task Force (USPSTF) found that effective treatments are available for refractive errors, cataracts, and wet (advanced neovascular) or dry (atrophic) age-related macular degeneration (AMD), but there were no differences between visual screening vs no screening on visual acuity or other outcomes.
   OBJECTIVE To update the 2016 review on screening for impaired visual acuity in older adults, to inform the USPSTF.
   DATA SOURCES Ovid MEDLINE, the Cochrane Central Register of Controlled Trials, and the Cochrane Database of Systematic Reviews (to February 2021); surveillance through January 21, 2022.
   STUDY SELECTION Randomized clinical trials and controlled observational studies on screening, vascular endothelial growth factor (VEGF) inhibitors (wet AMD), and antioxidant vitamins and minerals (dry AMD); studies on screening diagnostic accuracy.
   DATA EXTRACTION AND SYNTHESIS One investigator abstracted data and a second checked accuracy. Two investigators independently assessed study quality.
   RESULTS Twenty-five studies (N = 33 586) were included (13 trials, 11 diagnostic accuracy studies, and 1 systematic review [19 trials]). Four trials (n = 4819) found no significant differences between screening vs no screening in visual acuity or other outcomes. Visual acuity tests (3 studies; n = 6493) and screening question (3 studies; n = 5203) were associated with suboptimal diagnostic accuracy. For wet AMD, 4 trials (n = 2086) found VEGF inhibitors significantly associated with greater likelihood of 15 or more letters visual acuity gain (risk ratio [RR], 2.92 [95% CI, 1.20-7.12]; I-2 = 76%; absolute risk difference [ARD], 10%) and less than 15 letters visual acuity loss (RR, 1.46 [95% CI, 1.22-1.75]; I-2 = 80%; ARD, 27%) vs sham treatment, with no increased risk of serious harms. For dry AMD, a systematic review (19 trials) found antioxidant multivitamins significantly associated with decreased risk of progression to late AMD (3 trials, n = 2445; odds ratio [OR], 0.72 [95% CI, 0.58-0.90]) and 3 lines or more visual acuity loss (1 trial, n = 1791; OR, 0.77 [95% CI, 0.62-0.96]) vs placebo. Zinc was significantly associated with increased risk of genitourinary events and beta carotene with increased risk of lung cancer in former smokers; other serious harms were infrequent.
   CONCLUSIONS AND RELEVANCE This review found that effective treatments are available for common causes of impaired visual acuity in older adults. However, direct evidence found no significant association between vision screening vs no screening in primary care and improved visual outcomes.
C1 [Chou, Roger; Bougatsos, Christina; Jungbauer, Rebecca; Grusing, Sara; Blazina, Ian; Selph, Shelley] Oregon Hlth & Sci Univ, Northwest Evidence Based Practice Ctr, Dept Med Informat & Clin Epidemiol, Portland, OR 97201 USA.
   [Selph, Shelley] Oregon Hlth & Sci Univ, Dept Family Med, Portland, OR 97201 USA.
   [Jonas, Daniel E.] Ohio State Univ, Dept Internal Med, Columbus, OH 43210 USA.
   [Jonas, Daniel E.] Univ N Carolina, Evidence Based Practice Ctr, RTI Int, Chapel Hill, NC 27515 USA.
   [Tehrani, Shandiz] Oregon Hlth & Sci Univ, Casey Eye Inst, Dept Ophthalmol, Portland, OR 97201 USA.
C3 Oregon Health & Science University; Oregon Health & Science University;
   University System of Ohio; Ohio State University; Research Triangle
   Institute; University of North Carolina; University of North Carolina
   Chapel Hill; Oregon Health & Science University
RP Chou, R (通讯作者)，Oregon Hlth & Sci Univ, 3181 SW Sam Jackson Pk Rd,Mail Code BICC, Portland, OR 97239 USA.
EM chour@ohsu.edu
OI Blazina, Ian/0000-0003-0164-6674
FU Agency for Healthcare Research and Quality (AHRQ), US Department of
   Health and Human Services [HHSA-290-2015-00011-I, 75Q80119F32015]; US
   Preventive Services Task Force (USPSTF)
FX This research was funded under contract HHSA-290-2015-00011-I, Task
   Order 75Q80119F32015, from the Agency for Healthcare Research and
   Quality (AHRQ), US Department of Health and Human Services, under a
   contract to support the US Preventive Services Task Force (USPSTF).
CR Ariyasu RG, 1996, OPHTHALMOLOGY, V103, P1751, DOI 10.1016/S0161-6420(96)30431-4
   Arora KS, 2014, AM J OPHTHALMOL, V157, P1315, DOI 10.1016/j.ajo.2014.02.031
   Bartlett HE, 2007, EUR J CLIN NUTR, V61, P1121, DOI 10.1038/sj.ejcn.1602626
   Beatty S, 2013, OPHTHALMOLOGY, V120, P600, DOI 10.1016/j.ophtha.2012.08.040
   Berrow EJ, 2013, BRIT J NUTR, V109, P2008, DOI 10.1017/S0007114512004187
   Bressler NM, 2013, OPHTHALMOLOGY, V120, P160, DOI 10.1016/j.ophtha.2012.07.027
   Chang TS, 2007, ARCH OPHTHALMOL-CHIC, V125, P1460, DOI 10.1001/archopht.125.11.1460
   Chew EY, 2015, JAMA-J AM MED ASSOC, V314, P791, DOI 10.1001/jama.2015.9677
   Chew Emily Y, 2013, Ophthalmology, V120, P1604, DOI 10.1016/j.ophtha.2013.01.021
   Chew EY, 2014, JAMA OPHTHALMOL, V132, P272, DOI 10.1001/jamaophthalmol.2013.6636
   Chew EY, 2013, JAMA-J AM MED ASSOC, V309, P2005, DOI 10.1001/jama.2013.4997
   Chew EY, 2012, OPHTHALMOLOGY, V119, P2282, DOI 10.1016/j.ophtha.2012.05.027
   Chew EY, 2009, OPHTHALMOLOGY, V116, P297, DOI 10.1016/j.ophtha.2008.09.019
   Chou R, 2016, SCREENING IMPAIRED V
   Chou R., 2022, SCREENING IMPAIRED V
   Chou R., 2009, AHRQ PUBLICATION
   Chou R, 2016, JAMA-J AM MED ASSOC, V315, P915, DOI 10.1001/jama.2016.0783
   Chou R, 2009, ANN INTERN MED, V151, P44, DOI 10.7326/0003-4819-151-1-200907070-00008
   Clarke EL, 2018, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001054.pub3
   Clemons TE, 2015, INVEST OPHTH VIS SCI, V56
   D'Amico DJ, 2006, OPHTHALMOLOGY, V113, P992, DOI 10.1016/j.ophtha.2006.02.027
   Eekhof JAH, 2000, SCAND J PRIM HEALTH, V18, P203
   Eekhof JAH, 2000, FAM PRACT, V17, P329, DOI 10.1093/fampra/17.4.329
   Evans JR, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000253.pub2
   Evans JR, 2017, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000253.pub4
   Evans JR, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000254.pub3
   Gillies M, 2020, AM J OPHTHALMOL, V210, P116, DOI 10.1016/j.ajo.2019.10.007
   Gillies MC, 2020, OPHTHALMOLOGY, V127, P198, DOI 10.1016/j.ophtha.2019.08.023
   Gillies MC, 2019, JAMA OPHTHALMOL, V137, P372, DOI 10.1001/jamaophthalmol.2018.6776
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   HILLER R, 1983, AM J PUBLIC HEALTH, V73, P93, DOI 10.2105/AJPH.73.1.93
   Ho AC, 2018, OPHTHALMOL RETINA, V2, P676, DOI 10.1016/j.oret.2017.10.017
   Holz F., 1993, GER J OPHTHALMOL, V2, P391
   Huang YM, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/564738
   Ivers RQ, 2001, OPHTHALMOLOGY, V108, P968, DOI 10.1016/S0161-6420(00)00649-7
   Jee J, 2004, OPHTHAL EPIDEMIOL, V11, P427, DOI 10.1080/09286580490888807
   Jessa Z, 2012, OPHTHAL PHYSL OPT, V32, P332, DOI 10.1111/j.1475-1313.2012.00919.x
   Johnson AR, 2007, J UROLOGY, V177, P639, DOI 10.1016/j.juro.2006.09.047
   KAISER HJ, 1995, OPHTHALMOLOGICA, V209, P302, DOI 10.1159/000310646
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Ma L, 2012, OPHTHALMOLOGY, V119, P2290, DOI 10.1016/j.ophtha.2012.06.014
   MCMURDO M E T, 1988, Health Bulletin (Edinburgh), V46, P327
   Moore AA, 1997, AM J MED, V102, P371, DOI 10.1016/S0002-9343(97)00089-2
   Mueller YK, 2018, BMC GERIATR, V18, DOI 10.1186/s12877-018-0761-z
   Murray IJ, 2013, INVEST OPHTH VIS SCI, V54, P1781, DOI 10.1167/iovs.12-10715
   National Eye Institute, AREDS AREDS2 CLIN TR
   NEWSOME DA, 1988, ARCH OPHTHALMOL-CHIC, V106, P192
   Newsome DA, 2008, CURR EYE RES, V33, P591, DOI 10.1080/02713680802178437
   Piatti A, 2020, EUR J OPHTHALMOL, V30, P376, DOI 10.1177/1120672119836007
   Piermarocchi S, 2012, EUR J OPHTHALMOL, V22, P216, DOI 10.5301/ejo.5000069
   Pillay J., 2017, SCREENING IMPAIRED V
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   reviewofophthalmology, REV OPHTHALMOLOGY
   Richer S, 1996, J Am Optom Assoc, V67, P30
   Richer Stuart, 2004, Optometry, V75, P216, DOI 10.1016/S1529-1839(04)70049-4
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Saydah SH, 2020, JAMA OPHTHALMOL, V138, P479, DOI 10.1001/jamaophthalmol.2020.0273
   Siu AL, 2016, JAMA-J AM MED ASSOC, V315, P908, DOI 10.1001/jama.2016.0763
   Smeeth L, 2003, BMJ-BRIT MED J, V327, P1027, DOI 10.1136/bmj.327.7422.1027
   STONE DH, 1978, BRIT MED J, V2, P859, DOI 10.1136/bmj.2.6141.859
   Stur M, 1996, INVEST OPHTH VIS SCI, V37, P1225
   Swanson MW, 2009, J AM GERIATR SOC, V57, P486, DOI 10.1111/j.1532-5415.2008.02144.x
   SWENOR BK, 2021, LANCET GLOB HEALTH, V9, pE379, DOI DOI 10.1016/S2214-109X(21)00031-0
   Tanvetyanon T, 2008, CANCER-AM CANCER SOC, V113, P150, DOI 10.1002/cncr.23527
   Tao Y, 2016, TOHOKU J EXP MED, V240, P209, DOI 10.1620/tjem.240.209
   Tay T, 2006, CLIN EXP OPHTHALMOL, V34, P141, DOI 10.1111/j.1442-9071.2006.01139.x
   Taylor HR, 2002, BMJ-BRIT MED J, V325, P11, DOI 10.1136/bmj.325.7354.11
   Teh RCA, 2006, J AM GERIATR SOC, V54, P370, DOI 10.1111/j.1532-5415.2005.00592_4.x
   US Preventive Services Task Force, US PREV SERV TASK FO
   Waldstein SM, 2016, OPHTHALMOLOGY, V123, P1521, DOI 10.1016/j.ophtha.2016.03.037
   Wang F, 1998, Ophthalmic Epidemiol, V5, P69, DOI 10.1076/opep.5.2.69.1575
   Wang H., 2004, ZHONGGUO LINCHUANT K, V8, P1290
   Weigert G, 2011, INVEST OPHTH VIS SCI, V52, P8174, DOI 10.1167/iovs.11-7522
   Whitlock EP, 2008, ANN INTERN MED, V148, P776, DOI 10.7326/0003-4819-148-10-200805200-00010
   Woods RL, 1998, OPHTHALMOLOGY, V105, P2318, DOI 10.1016/S0161-6420(98)91235-0
   World Bank T, 2013, TURNING LIGHTS AFR
   Yaffe K, 2004, NEUROLOGY, V63, P1705, DOI 10.1212/01.WNL.0000142969.19465.8F
   Yashkin AP, 2016, OPHTHALMOLOGY, V123, P2225, DOI 10.1016/j.ophtha.2016.06.053
NR 79
TC 5
Z9 5
U1 6
U2 6
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 0098-7484
EI 1538-3598
J9 JAMA-J AM MED ASSOC
JI JAMA-J. Am. Med. Assoc.
PD JUN 7
PY 2022
VL 327
IS 21
BP 2129
EP 2140
DI 10.1001/jama.2022.6381
EA MAY 2022
PG 12
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA 2E5JY
UT WOS:000800638000002
PM 35608842
OA Bronze
DA 2022-11-30
ER

PT J
AU Sotoudeh-Paima, S
   Jodeiri, A
   Hajizadeh, F
   Soltanian-Zadeh, H
AF Sotoudeh-Paima, Saman
   Jodeiri, Ata
   Hajizadeh, Fedra
   Soltanian-Zadeh, Hamid
TI Multi-scale convolutional neural network for automated AMD
   classification using retinal OCT images
SO COMPUTERS IN BIOLOGY AND MEDICINE
LA English
DT Article
DE Age-related macular degeneration; Feature pyramid networks; Multi-scale
   convolutional neural networks; Deep learning; Optical coherence
   tomography (OCT)
ID OPTICAL COHERENCE TOMOGRAPHY; DIABETIC MACULAR EDEMA; GEOGRAPHIC
   ATROPHY; SEGMENTATION; DEGENERATION; RETINOPATHY; PATHOLOGY; DRUSEN;
   LAYERS; FLUID
AB Background and objective: Age-related macular degeneration (AMD) is the most common cause of blindness in developed countries, especially in people over 60 years of age. The workload of specialists and the healthcare system in this field has increased in recent years mainly due to three reasons: 1) increased use of retinal optical coherence tomography (OCT) imaging technique, 2) prevalence of population aging worldwide, and 3) chronic nature of AMD. Recent advancements in the field of deep learning have provided a unique opportunity for the development of fully automated diagnosis frameworks. Considering the presence of AMD-related retinal pa-thologies in varying sizes in OCT images, our objective was to propose a multi-scale convolutional neural network (CNN) that can capture inter-scale variations and improve performance using a feature fusion strategy across convolutional blocks.& nbsp;Methods: Our proposed method introduces a multi-scale CNN based on the feature pyramid network (FPN) structure. This method is used for the reliable diagnosis of normal and two common clinical characteristics of dry and wet AMD, namely drusen and choroidal neovascularization (CNV). The proposed method is evaluated on the national dataset gathered at Hospital (NEH) for this study, consisting of 12649 retinal OCT images from 441 patients, and the UCSD public dataset, consisting of 108312 OCT images from 4686 patients.& nbsp;Results: Experimental results show the superior performance of our proposed multi-scale structure over several well-known OCT classification frameworks. This feature combination strategy has proved to be effective on all tested backbone models, with improvements ranging from 0.4% to 3.3%. In addition, gradual learning has proved to be effective in improving performance in two consecutive stages. In the first stage, the performance was boosted from 87.2% +/- 2.5% to 92.0% +/- 1.6% using pre-trained ImageNet weights. In the second stage, another performance boost from 92.0% +/- 1.6% to 93.4% +/- 1.4% was observed as a result of fine-tuning the previous model on the UCSD dataset. Lastly, generating heatmaps provided additional proof for the effectiveness of our multi-scale structure, enabling the detection of retinal pathologies appearing in different sizes.& nbsp;Conclusion: The promising quantitative results of the proposed architecture, along with qualitative evaluations through generating heatmaps, prove the suitability of the proposed method to be used as a screening tool in healthcare centers assisting ophthalmologists in making better diagnostic decisions.
C1 [Sotoudeh-Paima, Saman; Jodeiri, Ata; Soltanian-Zadeh, Hamid] Univ Tehran, Coll Engn, Sch Elect & Comp Engn, Control & Intelligent Proc Ctr Excellence CIPCE, Tehran, Iran.
   [Jodeiri, Ata] Tabriz Univ Med Sci, Fac Adv Med Sci, Tabriz 51656, Iran.
   [Hajizadeh, Fedra] Noor Eye Hosp, Noor Ophthalmol Res Ctr, Tehran 19686, Iran.
   [Soltanian-Zadeh, Hamid] Henry Ford Hlth Syst, Med Image Anal Lab, Dept Radiol, Detroit, MI 48202 USA.
   [Soltanian-Zadeh, Hamid] Henry Ford Hlth Syst, Med Image Anal Lab, Dept Res Adm, Detroit, MI 48202 USA.
C3 University of Tehran; Tabriz University of Medical Science; Henry Ford
   Health System; Henry Ford Hospital; Henry Ford Health System; Henry Ford
   Hospital
RP Soltanian-Zadeh, H (通讯作者)，Univ Tehran, Coll Engn, Sch Elect & Comp Engn, Control & Intelligent Proc Ctr Excellence CIPCE, Tehran, Iran.; Hajizadeh, F (通讯作者)，Noor Eye Hosp, Noor Ophthalmol Res Ctr, Tehran 19686, Iran.
EM fedra_hajizadeh@yahoo.com; hszadeh@ut.ac.ir
RI Soltanian-Zadeh, Hamid/AAD-7027-2022
OI Soltanian-Zadeh, Hamid/0000-0002-7302-6856; Sotoudeh-Paima,
   Saman/0000-0003-0170-2541
CR Abdelsalam A, 1999, SURV OPHTHALMOL, V44, P1, DOI 10.1016/S0039-6257(99)00072-7
   Abramoff MD, 2016, INVEST OPHTH VIS SCI, V57, P5200, DOI 10.1167/iovs.16-19964
   Albarrak A., 2013, P 2013 INT C MED IM, p59?64
   Alsaih K, 2017, BIOMED ENG ONLINE, V16, DOI 10.1186/s12938-017-0352-9
   Bengio Y., 2009, P 26 ANN INT C MACHI, P41, DOI DOI 10.1145/1553374.1553380
   Burlina P, 2017, COMPUT BIOL MED, V82, P80, DOI 10.1016/j.compbiomed.2017.01.018
   Centers for Medicare & Medicaid Services, 2014, MED PROV UT PAYM DAT
   Chiu SJ, 2015, BIOMED OPT EXPRESS, V6, P1172, DOI 10.1364/BOE.6.001172
   Chiu SJ, 2012, INVEST OPHTH VIS SCI, V53, P53, DOI 10.1167/iovs.11-7640
   Das V, 2020, IEEE SIGNAL PROC LET, V27, P1025, DOI 10.1109/LSP.2020.3000933
   Das V, 2019, BIOMED SIGNAL PROCES, V54, DOI 10.1016/j.bspc.2019.101605
   Fang LY, 2019, IEEE T MED IMAGING, V38, P1959, DOI 10.1109/TMI.2019.2898414
   Fang LY, 2019, J VIS COMMUN IMAGE R, V59, P327, DOI 10.1016/j.jvcir.2019.01.022
   Fang LY, 2012, BIOMED OPT EXPRESS, V3, P927, DOI 10.1364/BOE.3.000927
   Farsiu S, 2014, OPHTHALMOLOGY, V121, P162, DOI 10.1016/j.ophtha.2013.07.013
   Garvin MK, 2008, IEEE T MED IMAGING, V27, P1495, DOI 10.1109/TMI.2008.923966
   Garvin MK, 2009, IEEE T MED IMAGING, V28, P1436, DOI 10.1109/TMI.2009.2016958
   Ghiasi G, 2019, PROC CVPR IEEE, P7029, DOI 10.1109/CVPR.2019.00720
   Gulshan V, 2016, JAMA-J AM MED ASSOC, V316, P2402, DOI 10.1001/jama.2016.17216
   Hassan T, 2021, IEEE J BIOMED HEALTH, V25, P108, DOI 10.1109/JBHI.2020.2982914
   Hassan T, 2019, COMPUT BIOL MED, V105, P112, DOI 10.1016/j.compbiomed.2018.12.015
   Hassan T, 2018, LECT NOTES COMPUT SC, V10882, P695, DOI 10.1007/978-3-319-93000-8_79
   He KM, 2016, PROC CVPR IEEE, P770, DOI 10.1109/CVPR.2016.90
   He XX, 2020, NEUROCOMPUTING, V405, P37, DOI 10.1016/j.neucom.2020.04.044
   Huang GL, 2017, IEEE ICC
   Huang LF, 2019, IEEE SIGNAL PROC LET, V26, P1026, DOI 10.1109/LSP.2019.2917779
   Hussain MA, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0198281
   Hwang DK, 2019, THERANOSTICS, V9, P232, DOI 10.7150/thno.28447
   Islam A., 2018, ARXIV PREPR ARXIV180
   Kaymak S, 2018, INT C INTELL COMP CO, P265, DOI 10.1109/ICCP.2018.8516635
   Kermany DS, 2018, CELL, V172, P1122, DOI 10.1016/j.cell.2018.02.010
   LeCun Y., 2015, NATURE, V521, P436, DOI DOI 10.1038/NATURE14539
   Lee CS, 2017, OPHTHALMOL RETINA, V1, P322, DOI 10.1016/j.oret.2016.12.009
   Lee CS, 2017, BIOMED OPT EXPRESS, V8, P3440, DOI 10.1364/BOE.8.003440
   Lemaitre G, 2016, J OPHTHALMOL, V2016, DOI 10.1155/2016/3298606
   Li F, 2019, GRAEF ARCH CLIN EXP, V257, P495, DOI 10.1007/s00417-018-04224-8
   Li XC, 2019, NEUROCOMPUTING, V369, P134, DOI 10.1016/j.neucom.2019.08.079
   Lin M, 2013, ARXIV13124400
   Lin TY, 2017, PROC CVPR IEEE, P936, DOI 10.1109/CVPR.2017.106
   Liu S, 2018, PROC CVPR IEEE, P8759, DOI 10.1109/CVPR.2018.00913
   Liu YY, 2011, MED IMAGE ANAL, V15, P748, DOI 10.1016/j.media.2011.06.005
   Qiu B, 2020, BIOMED OPT EXPRESS, V11, P817, DOI 10.1364/BOE.379551
   Rasti R, 2018, IEEE T MED IMAGING, V37, P1024, DOI 10.1109/TMI.2017.2780115
   Schlegl T, 2018, OPHTHALMOLOGY, V125, P549, DOI 10.1016/j.ophtha.2017.10.031
   Schmidt-Erfurth U, 2018, PROG RETIN EYE RES, V67, P1, DOI 10.1016/j.preteyeres.2018.07.004
   Selvaraju RR, 2020, INT J COMPUT VISION, V128, P336, DOI 10.1007/s11263-019-01228-7
   Serener A, 2019, 2019 SCIENTIFIC MEETING ON ELECTRICAL-ELECTRONICS & BIOMEDICAL ENGINEERING AND COMPUTER SCIENCE (EBBT)
   Simonyan K., 2015, 3 INT C LEARN REPR I
   Srinivasan PP, 2014, BIOMED OPT EXPRESS, V5, P3568, DOI 10.1364/BOE.5.003568
   Srinivasan PP, 2014, BIOMED OPT EXPRESS, V5, P348, DOI 10.1364/BOE.5.000348
   Sun YK, 2017, J BIOMED OPT, V22, DOI 10.1117/1.JBO.22.1.016012
   Tan MX, 2019, PR MACH LEARN RES, V97
   Taylor DJ, 2016, BMJ OPEN, V6, DOI 10.1136/bmjopen-2016-011504
   Thomas A, 2021, BIOMED SIGNAL PROCES, V67, DOI 10.1016/j.bspc.2021.102538
   Ting DSW, 2019, BRIT J OPHTHALMOL, V103, P167, DOI 10.1136/bjophthalmol-2018-313173
   Treder M, 2018, GRAEF ARCH CLIN EXP, V256, P259, DOI 10.1007/s00417-017-3850-3
   van Velthoven MEJ, 2007, PROG RETIN EYE RES, V26, P57, DOI 10.1016/j.preteyeres.2006.10.002
   Venhuizen FG, 2017, INVEST OPHTH VIS SCI, V58, P2318, DOI 10.1167/iovs.16-20541
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Xu RB, 2019, COMPUT BIOL MED, V105, P102, DOI 10.1016/j.compbiomed.2018.12.013
   Zhao QJ, 2019, AAAI CONF ARTIF INTE, P9259
   Zhou P, 2018, PROC CVPR IEEE, P528, DOI 10.1109/CVPR.2018.00062
NR 62
TC 1
Z9 1
U1 5
U2 11
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0010-4825
EI 1879-0534
J9 COMPUT BIOL MED
JI Comput. Biol. Med.
PD MAY
PY 2022
VL 144
AR 105368
DI 10.1016/j.compbiomed.2022.105368
PG 12
WC Biology; Computer Science, Interdisciplinary Applications; Engineering,
   Biomedical; Mathematical & Computational Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Life Sciences & Biomedicine - Other Topics; Computer Science;
   Engineering; Mathematical & Computational Biology
GA 1D0BL
UT WOS:000793475600006
PM 35259614
OA Green Submitted
DA 2022-11-30
ER

PT J
AU Bikbov, MM
   Kazakbaeva, GM
   Rakhimova, EM
   Rusakova, IA
   Gilmanshin, TR
   Zainullin, RM
   Panda-Jonas, S
   Fakhretdinova, AA
   Tuliakova, AM
   Safiullina, KR
   Bolshakova, NI
   Gizzatov, AV
   Ponomarev, IP
   Jonas, JB
AF Bikbov, Mukharram M.
   Kazakbaeva, Gyulli M.
   Rakhimova, Ellina M.
   Rusakova, Iuliia A.
   Gilmanshin, Timur R.
   Zainullin, Rinat M.
   Panda-Jonas, Songhomitra
   Fakhretdinova, Albina A.
   Tuliakova, Azaliia M.
   Safiullina, Kamilia R.
   Bolshakova, Natalia, I
   Gizzatov, Ainur, V
   Ponomarev, Ildar P.
   Jonas, Jost B.
TI Prevalence and determinants of reticular pseudodrusen in the Russian
   Ural Eye and Medical Study
SO ACTA OPHTHALMOLOGICA
LA English
DT Article
DE age-related macular degeneration; epidemiology; macula; myopia;
   population-based study; reticular pseudodrusen; retina; subretinal
   drusenoid deposits; Ural Eye and Medical Study
ID SUBRETINAL DRUSENOID DEPOSITS; AGE-RELATED MACULOPATHY; MACULAR
   DEGENERATION; RISK-FACTOR; POPULATION; CLASSIFICATION; EPIDEMIOLOGY;
   ATROPHY
AB Purpose: To assess the prevalence of reticular pseudodrusen (RPD) and their determinants.
   Methods: The Population-based Ural Eye and Medical Study conducted in Bashkortostan/Russia included 5899 participants aged 40+ years. Presence of RPDs was assessed on conventional colour fundus photographs, red-free fundus images and optical coherence tomographic images.
   Results: The study included 4914 (83.3%) individuals (mean age: 58.5 +/- 10.5 years; range: 40-94 years). Using two age limits (>55 years and 40+ years) for the definitions of RPD and AMD (age-related macular degeneration), RPD prevalence was 186/4914 (3.8%; 95% confidence interval (CI): 3.3, 4.3) and 246/4914 (5.0%, 95% CI: 4.4, 5.6), respectively, and the prevalence of any AMD without RPD was 182/4914 (3.7%: 95% CI: 3.2, 4.2) and 224/4914 (4.6%; 95% CI: 4.0, 5.1) respectively. Within the subgroup of early AMD, intermediate AMD and late AMD, RPD prevalence (age limit: 40+ years) was 55.1% (95% CI: 49.5, 60.8), 42.9% (95% CI: 33.8, 51.9) and 33.3% (95% CI: 16.4, 50.3) respectively. In multivariable analysis, higher RPD prevalence (age limit 40+ years) was associated with higher age (odds ratio (OR): 1.08; 95% CI: 1.07, 1.10; p < 0.001), rural region of habitation (OR: 3.81; 95% CI: 2.76, 5.24; p < 0.001) and lower percentage of lymphocytes on leukocyte counts (OR: 0.95; 95% CI: 0.93, 0.97; p < 0.001). Higher prevalence of any AMD without RPD was associated with urban region (OR: 1.58; 95% CI: 1.18, 2.11; p = 0.002), lower diabetes prevalence (OR: 0.55; 95% CI: 0.33, 0.90; p = 0.02) and shorter axial length (OR: 0.85; 95% CI: 0.74, 0.98; p = 0.03), after adjusting for age.
   Conclusions: Reticular pseudodrusen (mean prevalence: 3.8% (age limit >55 years); 5.0% (age limit 40+ years)) differs from AMD without RPD in its association with urban region (AMD without RPD: rural region), lower lymphocyte percentage (AMD without RPD: no association) and a lack of associations with axial length (AMD without RPD: shorter axial length) and with diabetes prevalence (AMD without RPD: lower diabetes prevalence).
C1 [Bikbov, Mukharram M.; Kazakbaeva, Gyulli M.; Rakhimova, Ellina M.; Rusakova, Iuliia A.; Gilmanshin, Timur R.; Zainullin, Rinat M.; Fakhretdinova, Albina A.; Tuliakova, Azaliia M.; Safiullina, Kamilia R.; Bolshakova, Natalia, I; Gizzatov, Ainur, V; Ponomarev, Ildar P.] Ufa Eye Res Inst, 90 Pushkin St, Ufa 450077, Bashkortostan, Russia.
   [Panda-Jonas, Songhomitra] Privatpraxis Prof Jonas & Dr Panda Jonas, Heidelberg, Germany.
   [Panda-Jonas, Songhomitra] Univ Hosp Heidelberg, Dept Ophthalmol, Heidelberg, Germany.
   [Jonas, Jost B.] Heidelberg Univ, Med Fac Mannheim, Dept Ophthalmol, Mannheim, Germany.
   [Jonas, Jost B.] Inst Mol & Clin Ophthalmol Basel, Basel, Switzerland.
C3 Ufa Eye Research Institute; Ruprecht Karls University Heidelberg;
   Ruprecht Karls University Heidelberg
RP Bikbov, MM (通讯作者)，Ufa Eye Res Inst, 90 Pushkin St, Ufa 450077, Bashkortostan, Russia.; Jonas, JB (通讯作者)，Med Fac Mannheim, Dept Ophthalmol, Theodor Kutzerufer 1, D-68167 Mannheim, Germany.
EM bikbov.m@gmail.com; jost.jonas@medma.uni-heidelberg.de
CR Alten F, 2012, RETINA-J RET VIT DIS, V32, P1727, DOI 10.1097/IAE.0b013e3182475b03
   [Anonymous], 2020, DEMOGRAPHICS RUSSIA
   Arnold JJ, 1997, AM J OPHTHALMOL, V124, P344, DOI 10.1016/S0002-9394(14)70826-8
   ARNOLD JJ, 1995, RETINA-J RET VIT DIS, V15, P183, DOI 10.1097/00006982-199515030-00001
   Bikbov MM, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-75313-0
   Bikbov MM, 2020, AM J OPHTHALMOL, V210, P146, DOI 10.1016/j.ajo.2019.10.004
   Bikbov MM, 2019, AM J OPHTHALMOL, V204, P130, DOI 10.1016/j.ajo.2019.02.030
   Buitendijk GHS, 2016, INVEST OPHTH VIS SCI, V57, P5593, DOI 10.1167/iovs.15-18816
   Chan H, 2016, INVEST OPHTH VIS SCI, V57, P3058, DOI 10.1167/iovs.16-19487
   Cheung CMG, 2012, ARCH OPHTHALMOL-CHIC, V130, P480, DOI 10.1001/archophthalmol.2011.376
   Domalpally A, 2019, OPHTHALMOLOGY, V126, P1659, DOI 10.1016/j.ophtha.2019.07.022
   Dutheil C, 2020, JAMA OPHTHALMOL, V138, P467, DOI 10.1001/jamaophthalmol.2020.0266
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Finger RP, 2014, OPHTHALMOLOGY, V121, P1252, DOI 10.1016/j.ophtha.2013.12.034
   FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6
   Foster PJ, 2002, BRIT J OPHTHALMOL, V86, P238, DOI 10.1136/bjo.86.2.238
   Gabrielle PH, 2019, INVEST OPHTH VIS SCI, V60, P4838, DOI 10.1167/iovs.19-27283
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Ikram MK, 2003, INVEST OPHTH VIS SCI, V44, P3778, DOI 10.1167/iovs.03-0120
   Joachim N, 2014, OPHTHALMOLOGY, V121, P917, DOI 10.1016/j.ophtha.2013.10.043
   Jonas JB, 2012, ACTA OPHTHALMOL, V90, pe185, DOI 10.1111/j.1755-3768.2011.02316.x
   Jonas JB, 2010, OPHTHALMOLOGY, V117, P2234, DOI 10.1016/j.ophtha.2009.12.006
   Klein R, 2008, AM J OPHTHALMOL, V145, P317, DOI 10.1016/j.ajo.2007.09.008
   Leisy HB, 2017, OPHTHALMOL RETINA, V1, P42, DOI 10.1016/j.oret.2016.08.011
   Morgan IG, 2012, LANCET, V379, P1739, DOI 10.1016/S0140-6736(12)60272-4
   Schmitz-Valckenberg S, 2010, OPHTHALMOLOGY, V117, P1169, DOI 10.1016/j.ophtha.2009.10.044
   Spaide RF, 2013, RETINA-J RET VIT DIS, V33, P1800, DOI 10.1097/IAE.0b013e31829c3765
   Stevens GA, 2016, PLOS MED, V13, DOI [10.1371/journal.pmed.1002056, 10.1371/journal.pmed.1002116]
   Wilde C, 2018, EYE, V32, P1130, DOI 10.1038/s41433-018-0049-8
   Xu L, 2006, BRIT J OPHTHALMOL, V90, P1087, DOI 10.1136/bjo.2006.096123
   ZUNG WWK, 1965, ARCH GEN PSYCHIAT, V12, P63, DOI 10.1001/archpsyc.1965.01720310065008
   Zweifel SA, 2010, OPHTHALMOLOGY, V117, P303, DOI 10.1016/j.ophtha.2009.07.014
NR 33
TC 1
Z9 1
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1755-375X
EI 1755-3768
J9 ACTA OPHTHALMOL
JI Acta Ophthalmol.
PD DEC
PY 2022
VL 100
IS 8
BP E1701
EP E1707
DI 10.1111/aos.15145
EA MAR 2022
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 6D4SX
UT WOS:000773628300001
PM 35343644
DA 2022-11-30
ER

PT J
AU Sreekumar, PG
   Reddy, ST
   Hinton, DR
   Kannan, R
AF Sreekumar, Parameswaran G.
   Reddy, Srinivasa T.
   Hinton, David R.
   Kannan, Ram
TI Mechanisms of RPE senescence and potential role of alpha B crystallin
   peptide as a senolytic agent in experimental AMD
SO EXPERIMENTAL EYE RESEARCH
LA English
DT Article
DE alpha B crystallin peptide; Mitochondrial dysfunction; Oxidative stress;
   Retinal pigment epithelium; SASP; Senescence; Senolytic drugs;
   Subretinal fibrosis
ID RETINAL-PIGMENT EPITHELIUM; INDUCED PREMATURE SENESCENCE; CELLULAR
   SENESCENCE; OXIDATIVE STRESS; MACULAR DEGENERATION; SECRETORY PHENOTYPE;
   REPLICATIVE SENESCENCE; SUBRETINAL FIBROSIS; INDUCED APOPTOSIS;
   UP-REGULATION
AB Oxidative stress in the retinal pigment epithelium (RPE) can cause mitochondrial dysfunction and is likely a causative factor in the pathogenesis of age-related macular degeneration (AMD). Under oxidative stress conditions, some of the RPE cells become senescent and a contributory role for RPE senescence in AMD pathology has been proposed. The purpose of this study is to 1) characterize senescence in human RPE; 2) investigate the effect of an alpha B Crystallin chaperone peptide (mini Cry) in controlling senescence, in particular by regulating mitochondrial function and senescence-associated secretory phenotype (SASP) production and 3) develop mouse models for studying the role of RPE senescence in dry and nAMD. Senescence was induced in human RPE cells in two ways. First, subconfluent cells were treated with 0.2 mu g/ml doxorubicin (DOX); second, subconfluent cells were treated with 500 mu M H2O2. Senescence biomarkers (senescence-associated beta-galactosidase (SA-beta gal), p21, p16) and mitochondrial proteins (Fis1, DRP1, MFN2, PGC1-alpha, mtTFA) were analyzed in control and experimental groups. The effect of mini Cry on mitochondrial bioenergetics, glycolysis and SASP was determined. In vivo, retinal degeneration was induced by intravenous injection of NaIO3 (20 mg/kg) and subretinal fibrosis by laser-induced choroidal neovascularization. Increased SA-beta gal staining and p16 and p21 expression was observed after DOX- or H2O2-induced senescence and mini Cry significantly decreased senescence-positive cells. The expression of mitochondrial biogenesis proteins PGC-1 and mTFA increased with senescence, and mini Cry reduced expression significantly. Senescent RPE cells were metabolically active, as evidenced by significantly enhanced oxidative phosphorylation and anaerobic glycolysis, mini Cry markedly reduced rates of respiration and glycolysis. Senescent RPE cells maintain a proinflammatory phenotype characterized by significantly increased production of cytokines (IFN-gamma, TNF-alpha, IL1-alpha IL1-beta, IL-6, IL-8, IL-10), and VEGF-A; mini Cry significantly inhibited their secretion. We identified and localized senescent RPE cells for the first time in NaIO3-induced retinal degeneration and laser-induced subretinal fibrosis mouse models. We conclude that mini Cry significantly impairs stress-induced senescence by modulating mitochondrial biogenesis and fission proteins in RPE cells. Characterization of senescence could provide further understanding of the metabolic changes that accompany the senescent phenotype in ocular disease. Future studies in vivo may better define the role of senescence in AMD and the therapeutic potential of mini Cry as a senotherapeutic.
C1 [Sreekumar, Parameswaran G.; Kannan, Ram] Doheny Eye Inst, Stephen J Ryan Initiat Macular Res RIMR, Los Angeles, CA 90033 USA.
   [Reddy, Srinivasa T.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Mol & Med Pharmacol, Los Angeles, CA 90095 USA.
   [Hinton, David R.] Univ Southern Calif, Keck Sch Med, USC Roski Eye Inst, Dept Pathol & Ophthalmol, Los Angeles, CA 90007 USA.
   [Kannan, Ram] Univ Calif Los Angeles, Geffen Sch Med, Stein Eye Inst, Los Angeles, CA 90095 USA.
C3 Doheny Eye Institute; University of California System; University of
   California Los Angeles; University of California Los Angeles Medical
   Center; David Geffen School of Medicine at UCLA; University of Southern
   California; University of California System; University of California
   Los Angeles; University of California Los Angeles Medical Center; David
   Geffen School of Medicine at UCLA
RP Kannan, R (通讯作者)，Doheny Eye Inst, Stephen J Ryan Initiat Macular Res RIMR, Los Angeles, CA 90033 USA.
EM sparameswaran@doheny.org; sreddy@mednet.ucla.edu; dhinton@usc.edu;
   rkannan@doheny.org
RI kannan, ram/ABB-7154-2020
OI kannan, ram/0000-0002-1583-3414; /0000-0002-9425-3986
FU NEI [R01 EY30141]; William Keck Foundation; Ryan Initiative for Macular
   Research
FX We sincerely thank Dr. Judith Campisi, Buck Institute for Research on
   Aging, Novato, CA, USA for helpful discussions. We acknowledge Christine
   Spee for culturing human RPE and Dr. Chandra Nagineni (NCI) for
   providing aged human donor RPE. Ernesto Barron is thanked for help with
   the confocal images. This work was supported by NEI R01 EY30141 (RK),
   William Keck Foundation (RK) and funds from the Ryan Initiative for
   Macular Research, DEI.
CR Ambati J, 2012, NEURON, V75, P26, DOI 10.1016/j.neuron.2012.06.018
   Bailey TA, 2004, INVEST OPHTH VIS SCI, V45, P675, DOI 10.1167/iovs.03-0351
   Baker DJ, 2011, NATURE, V479, P232, DOI 10.1038/nature10600
   Basisty N, 2020, PLOS BIOL, V18, DOI 10.1371/journal.pbio.3000599
   Bhutto I, 2012, MOL ASPECTS MED, V33, P295, DOI 10.1016/j.mam.2012.04.005
   Bhutto Imran A, 2018, Invest Ophthalmol Vis Sci, V59, pAMD143, DOI 10.1167/iovs.18-24245
   Bielak-Zmijewska A, 2014, BIOGERONTOLOGY, V15, P47, DOI 10.1007/s10522-013-9477-9
   Blasiak J, 2020, CELL MOL LIFE SCI, V77, P789, DOI 10.1007/s00018-019-03420-x
   Blasiak J, 2017, OXID MED CELL LONGEV, V2017, DOI 10.1155/2017/5293258
   Brew K, 2000, BBA-PROTEIN STRUCT M, V1477, P267, DOI 10.1016/S0167-4838(99)00279-4
   Burgess A, 2010, P NATL ACAD SCI USA, V107, P12564, DOI 10.1073/pnas.0914191107
   Campisi J, 1998, J Investig Dermatol Symp Proc, V3, P1
   Campisi J, 2019, NATURE, V571, P183, DOI 10.1038/s41586-019-1365-2
   Campisi J, 2013, ANNU REV PHYSIOL, V75, P685, DOI 10.1146/annurev-physiol-030212-183653
   Chae JB, 2021, GEROSCIENCE, V43, P2809, DOI [10.1007/s11357-021-00457-4, 10.1371/journal.pone.0101072, 10.3390/ijms21228840]
   Chaum E, 2015, MAMM GENOME, V26, P210, DOI 10.1007/s00335-015-9568-9
   Chen M, 2019, PROG RETIN EYE RES, V69, P159, DOI 10.1016/j.preteyeres.2018.10.003
   Childs BG, 2015, NAT MED, V21, P1424, DOI 10.1038/nm.4000
   Coppe JP, 2010, ANNU REV PATHOL-MECH, V5, P99, DOI 10.1146/annurev-pathol-121808-102144
   Correia-Melo C, 2015, BBA-BIOENERGETICS, V1847, P1373, DOI 10.1016/j.bbabio.2015.05.017
   Corso-Diaz X, 2018, PROG RETIN EYE RES, V65, P1, DOI 10.1016/j.preteyeres.2018.03.002
   Crespo-Garcia S, 2021, CELL METAB, V33, P818, DOI 10.1016/j.cmet.2021.01.011
   Datta S, 2017, PROG RETIN EYE RES, V60, P201, DOI 10.1016/j.preteyeres.2017.03.002
   Demaria M, 2017, CANCER DISCOV, V7, P165, DOI 10.1158/2159-8290.CD-16-0241
   Dimozi A, 2015, EUR CELLS MATER, V30, P89, DOI 10.22203/eCM.v030a07
   Dorr JR, 2013, NATURE, V501, P421, DOI 10.1038/nature12437
   Dou GR, 2012, FREE RADICAL BIO MED, V53, P1111, DOI 10.1016/j.freeradbiomed.2012.06.042
   Dridi S, 2012, P NATL ACAD SCI USA, V109, P13781, DOI 10.1073/pnas.1206494109
   Elgass K, 2013, BBA-MOL CELL RES, V1833, P150, DOI 10.1016/j.bbamcr.2012.05.002
   Enzbrenner A, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22179218
   Enzmann V, 2006, EXP EYE RES, V82, P441, DOI 10.1016/j.exer.2005.08.002
   Fan DNY, 2019, METHODS MOL BIOL, V1896, P93, DOI 10.1007/978-1-4939-8931-7_10
   Ferrington DA, 2017, REDOX BIOL, V13, P255, DOI 10.1016/j.redox.2017.05.015
   Fisher CR, 2018, INVEST OPHTH VIS SCI, V59, pAMD41, DOI 10.1167/iovs.18-24289
   Franco LM, 2009, INVEST OPHTH VIS SCI, V50, P4004, DOI 10.1167/iovs.08-2898
   Fu Z., TRENDS ENDOCRINOL ME, V32, P415
   Gericke A., SCI REP-UK, V11, P11532
   Ghasemi H, 2018, OCUL IMMUNOL INFLAMM, V26, P37, DOI 10.1080/09273948.2016.1277247
   Ghasemi H, 2011, OCUL IMMUNOL INFLAMM, V19, P401, DOI 10.3109/09273948.2011.618902
   Ghosh S, 2018, INVEST OPHTH VIS SCI, V59, P104, DOI 10.1167/iovs.18-24132
   Grenell A, 2019, P NATL ACAD SCI USA, V116, P3530, DOI 10.1073/pnas.1812941116
   Gureev AP, 2019, FRONT GENET, V10, DOI 10.3389/fgene.2019.00435
   Gutierrez-Fernandez A, 2015, EMBO J, V34, P1875, DOI 10.15252/embj.201490594
   Hara H, 2013, AM J PHYSIOL-LUNG C, V305, pL737, DOI 10.1152/ajplung.00146.2013
   Hernandez-Segura A, 2018, TRENDS CELL BIOL, V28, P436, DOI 10.1016/j.tcb.2018.02.001
   Hu CX, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18010144
   Idda ML, 2020, AGING-US, V12, P4052, DOI 10.18632/aging.102903
   Ishikawa K, 2016, AM J PATHOL, V186, P859, DOI 10.1016/j.ajpath.2015.11.014
   Jadeja RN, 2018, AGING-US, V10, P1306, DOI 10.18632/aging.101469
   Kamogashira T, 2017, NPJ AGING MECH DIS, V3, DOI 10.1038/s41514-017-0002-2
   Kandhaya-Pillai R, 2017, AGING-US, V9, P2411, DOI 10.18632/aging.101328
   Kannan R, 2016, BBA-GEN SUBJECTS, V1860, P258, DOI 10.1016/j.bbagen.2015.05.016
   Kannan R, 2014, NEURAL REGEN RES, V9, P2044, DOI 10.4103/1673-5374.147927
   Kannan R, 2012, PROG RETIN EYE RES, V31, P576, DOI 10.1016/j.preteyeres.2012.06.001
   Kanow MA, 2017, ELIFE, V6, DOI 10.7554/eLife.28899
   Kaplon J, 2013, NATURE, V498, P109, DOI 10.1038/nature12154
   Kase S, 2010, BLOOD, V115, P3398, DOI 10.1182/blood-2009-01-197095
   Kim EC, 2019, BMB REP, V52, P47, DOI 10.5483/BMBRep.2019.52.1.293
   Kim SJ, 2018, AGING-US, V10, P1239, DOI 10.18632/aging.101463
   Knickelbein Jared E, 2015, Int Ophthalmol Clin, V55, P63, DOI 10.1097/IIO.0000000000000073
   Kozlowski MR, 2012, MED HYPOTHESES, V78, P505, DOI 10.1016/j.mehy.2012.01.018
   Kukat C, 2013, TRENDS CELL BIOL, V23, P457, DOI 10.1016/j.tcb.2013.04.009
   Kurnellas MP, 2012, J BIOL CHEM, V287, P36423, DOI 10.1074/jbc.M112.371229
   Lagoumtzi SM, 2021, FREE RADICAL BIO MED, V171, P169, DOI 10.1016/j.freeradbiomed.2021.05.003
   LaPak KM, 2014, MOL CANCER RES, V12, P167, DOI 10.1158/1541-7786.MCR-13-0350
   Lee KS, 2021, J NEUROINFLAMM, V18, DOI 10.1186/s12974-021-02088-0
   Lopez-Luppo M, 2017, INVEST OPHTH VIS SCI, V58, P2832, DOI 10.1167/iovs.16-20312
   Macchioni L, 2021, ANTIOXIDANTS-BASEL, V10, DOI 10.3390/antiox10010025
   Maejima Y, 2008, AGING CELL, V7, P125, DOI 10.1111/j.1474-9726.2007.00358.x
   Marazita MC, 2016, REDOX BIOL, V7, P78, DOI 10.1016/j.redox.2015.11.011
   Martinez J, 2019, BIOCHEM J, V476, P2463, DOI 10.1042/BCJ20190405
   MILLIS AJT, 1992, EXP GERONTOL, V27, P425, DOI 10.1016/0531-5565(92)90076-C
   Mishima K, 1999, INVEST OPHTH VIS SCI, V40, P1590
   Nacarelli T, 2018, GEROSCIENCE, V40, P243, DOI 10.1007/s11357-018-0030-2
   Nacarelli T, 2016, FREE RADICAL BIO MED, V95, P133, DOI 10.1016/j.freeradbiomed.2016.03.008
   Nagineni CN, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22094835
   Nagineni CN, 2012, J CELL PHYSIOL, V227, P116, DOI 10.1002/jcp.22708
   Ortiz-Montero P, 2017, CELL COMMUN SIGNAL, V15, DOI 10.1186/s12964-017-0172-3
   Otera H, 2011, J BIOCHEM, V149, P241, DOI 10.1093/jb/mvr002
   Oubaha M, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aaf9440
   Parmeggiani F, 2012, MEDIAT INFLAMM, V2012, DOI 10.1155/2012/546786
   Passos JF, 2010, MOL SYST BIOL, V6, DOI 10.1038/msb.2010.5
   Quijano C, 2012, CELL CYCLE, V11, P1383, DOI 10.4161/cc.19800
   Rashid K, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-27209-3
   Rebbaa A, 2003, ONCOGENE, V22, P2805, DOI 10.1038/sj.onc.1206366
   Rickman CB, 2013, INVEST OPHTH VIS SCI, V54, pORSF68, DOI 10.1167/iovs.13-12757
   Roberts P, 2016, INVEST OPHTH VIS SCI, V57, P1699, DOI 10.1167/iovs.15-18694
   Rocha LR, 2020, AGING CELL, V19, DOI 10.1111/acel.13089
   Romashkan S, 2021, J GERONTOL A-BIOL, V76, P1144, DOI 10.1093/gerona/glab028
   Saraste M, 1999, SCIENCE, V283, P1488, DOI 10.1126/science.283.5407.1488
   Shang DS, 2020, FRONT NEUROL, V11, DOI 10.3389/fneur.2020.00929
   Singh KK, 1999, ONCOGENE, V18, P6641, DOI 10.1038/sj.onc.1203056
   SIPPY BD, 1995, CURR EYE RES, V14, P495, DOI 10.3109/02713689509003761
   Skowronska-Krawczyk D, 2015, MOL CELL, V59, P931, DOI 10.1016/j.molcel.2015.07.027
   Sonoda S, 2010, AGING-US, V2, P28, DOI 10.18632/aging.100111
   Sonoda S, 2009, NAT PROTOC, V4, P662, DOI 10.1038/nprot.2009.33
   Sreekumar PG, 2008, INVEST OPHTH VIS SCI, V49, P1210, DOI 10.1167/iovs.07-0667
   Sreekumar PG, 2020, ANTIOXIDANTS-BASEL, V9, DOI 10.3390/antiox9050411
   Sreekumar PG, 2020, OXID MED CELL LONGEV, V2020, DOI 10.1155/2020/2583601
   Sreekumar PG, 2018, J CONTROL RELEASE, V283, P94, DOI 10.1016/j.jconrel.2018.05.014
   Sreekumar PG, 2016, INVEST OPHTH VIS SCI, V57, P1238, DOI 10.1167/iovs.15-17053
   Sreekumar PG, 2013, INVEST OPHTH VIS SCI, V54, P2787, DOI 10.1167/iovs.12-11571
   Sreekumar PG, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033420
   Sreekumar PG, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012578
   Su F, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20194807
   Summer R, 2019, AM J PHYSIOL-LUNG C, V316, pL1049, DOI 10.1152/ajplung.00244.2018
   Takebayashi S, 2015, AGING CELL, V14, P689, DOI 10.1111/acel.12351
   Tan W, 2020, INT J BIOL SCI, V16, P2989, DOI 10.7150/ijbs.49890
   Tchkonia T, 2013, J CLIN INVEST, V123, P966, DOI 10.1172/JCI64098
   Vasileiou PVS, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8070686
   Vasko R, 2014, J AM SOC NEPHROL, V25, P276, DOI 10.1681/ASN.2013010069
   Vogt SD, 2011, EXP EYE RES, V93, P413, DOI 10.1016/j.exer.2011.06.002
   Wallace KB, 2020, CIRC RES, V126, P926, DOI 10.1161/CIRCRESAHA.119.314681
   Wan W., J INFLAMM RES, V14, P3129
   Wang W, 2014, J CONTROL RELEASE, V191, P4, DOI 10.1016/j.jconrel.2014.04.028
   WEST MD, 1989, EXP CELL RES, V184, P138, DOI 10.1016/0014-4827(89)90372-8
   Wiley CD, 2016, CELL METAB, V23, P1013, DOI 10.1016/j.cmet.2016.05.010
   Yang SQ, 2016, DRUG DES DEV THER, V10, P1857, DOI 10.2147/DDDT.S97653
   Yaung J, 2007, MOL VIS, V13, P566
   Yousefzadeh MJ, 2020, AGING CELL, V19, DOI 10.1111/acel.13094
   Yu B, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-16312-7
   Zhao C, 2011, J CLIN INVEST, V121, P369, DOI 10.1172/JCI44303
   Zhou P, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0098275
   Zhu DH, 2010, VISION RES, V50, P643, DOI 10.1016/j.visres.2009.09.002
   Zhu DH, 2009, J BIOL CHEM, V284, P9529, DOI 10.1074/jbc.M809393200
   Zhuge CC, 2014, INVEST OPHTH VIS SCI, V55, P4628, DOI 10.1167/iovs.13-13732
NR 126
TC 7
Z9 7
U1 1
U2 5
PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 0014-4835
EI 1096-0007
J9 EXP EYE RES
JI Exp. Eye Res.
PD FEB
PY 2022
VL 215
AR 108918
DI 10.1016/j.exer.2021.108918
PG 14
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA YL8ZM
UT WOS:000746175600003
PM 34986369
DA 2022-11-30
ER

PT J
AU Guerra, MH
   Yumnamcha, T
   Singh, LP
   Ibrahim, AS
AF Guerra, Michael H.
   Yumnamcha, Thangal
   Singh, Lalit P.
   Ibrahim, Ahmed S.
TI Relative Contribution of Different Mitochondrial Oxidative
   Phosphorylation Components to the Retinal Pigment Epithelium Barrier
   Function: Implications for RPE-Related Retinal Diseases
SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
LA English
DT Article
DE ECIS; ARPE-19; AMD; DR; RPE; mitochondria; oxidative phosphorylation;
   uncouplers
ID ATP SYNTHASE; DIABETIC-RETINOPATHY; ROS GENERATION; COMPLEX I; FCCP;
   PATHOGENESIS; AUTOPHAGY; STRESS; PERMEABILITY; DYSFUNCTION
AB Disruption of retinal pigment epithelial (RPE) barrier integrity is involved in the pathology of several blinding retinal diseases including age-related macular degeneration (AMD) and diabetic retinopathy (DR), but the underlying causes and pathophysiology are not completely well-defined. Mitochondria dysfunction has often been considered as a potential candidate implicated in such a process. In this study, we aimed to dissect the role of different mitochondrial components; specifically, those of oxidative phosphorylation (OxPhos), in maintaining the barrier functionality of RPE. Electric cell-substrate impedance sensing (ECIS) technology was used to collect multi-frequency electrical impedance data to assess in real-time the barrier formation of the RPE cells. For this purpose, the human retinal pigment epithelial cell line-ARPE-19-was used and treated with varying concentrations of specific mitochondrial inhibitors that target different steps in OxPhos: Rotenone for complex I (the largest protein complex in the electron transport chain (ETC)); oligomycin for ATP synthase; and carbonyl cyanide-p-trifluoromethoxyphenyl hydrazone (FCCP) for uncoupling ATP synthesis from the accompanying ETC. Furthermore, data were modeled using the ECIS-Z theta software to investigate in depth the effects of these inhibitors on three separate barrier parameters: cell-cell interactions (R-b), cell-matrix interactions (alpha), and the cell membrane capacitance (C-m). The viability of ARPE-19 cells was determined by lactate dehydrogenase (LDH) Cytotoxicity Assay. The ECIS program's modeling demonstrated that FCCP and thus OxPhos uncoupling disrupt the barrier function in the ARPE-19 cells across all three components of the total resistance (Rb, alpha, and C-m) in a dose-dependent manner. On the other hand, oligomycin and thus ATP synthase inhibition mostly affects the ARPE-19 cells' attachment to their substrate evident by a significant decrease in alpha resistance in a dose-dependent manner, both at the end and throughout the duration of the experiment. On the contrary, rotenone and complex I inhibition mostly affect the ARPE-19 paracellular resistance R-b in a dose-dependent manner compared to basolateral resistance alpha or C-m. Our results clearly demonstrate differential roles for different mitochondrial components in maintaining RPE cell functionality in which uncoupling of OxPhos is a major contributing factor to the disruption barrier function. Such differences can be used in investigating gene expression as well as for screening of selective agents that improve the OxPhos coupling efficiency to be used in the therapeutic approach for treating RPE-related retinal diseases.
C1 [Guerra, Michael H.; Yumnamcha, Thangal; Singh, Lalit P.; Ibrahim, Ahmed S.] Wayne State Univ, Sch Med, Dept Ophthalmol Visual & Anat Sci, 540 East Canfield, Detroit, MI 48201 USA.
   [Ibrahim, Ahmed S.] Wayne State Univ, Sch Med, Dept Pharmacol, 540 East Canfield, Detroit, MI 48201 USA.
   [Ibrahim, Ahmed S.] Mansoura Univ, Fac Pharm, Dept Biochem, Mansoura 35516, Egypt.
C3 Wayne State University; Wayne State University; Egyptian Knowledge Bank
   (EKB); Mansoura University
RP Ibrahim, AS (通讯作者)，Wayne State Univ, Sch Med, Dept Ophthalmol Visual & Anat Sci, 540 East Canfield, Detroit, MI 48201 USA.; Ibrahim, AS (通讯作者)，Wayne State Univ, Sch Med, Dept Pharmacol, 540 East Canfield, Detroit, MI 48201 USA.; Ibrahim, AS (通讯作者)，Mansoura Univ, Fac Pharm, Dept Biochem, Mansoura 35516, Egypt.
EM michael.guerra2@med.wayne.edu; gl5948@wayne.edu; plsingh@med.wayne.edu;
   ahmed.ibrahim@wayne.edu
RI ibrahim, ahmed/D-5241-2017
OI ibrahim, ahmed/0000-0001-8480-6252
FU American Heart Association [18CDA34080403]; NIH [P30EY004068]; NIH/NEI
   [EY023992]; Research to Prevent Blindness
FX This research was funded by the American Heart Association Grant
   18CDA34080403 (ASI), NIH core grant P30EY004068 to the Department of
   Ophthalmology, Visual and Anatomical Sciences (OVAS), NIH/NEI EY023992
   to LPS and a Research to Prevent Blindness unrestricted grant to the
   Department of OVAS, Wayne State University, Detroit, MI, USA.
CR Ambati J, 2013, NAT REV IMMUNOL, V13, P438, DOI 10.1038/nri3459
   Anchan A, 2019, BIOSENSORS-BASEL, V9, DOI 10.3390/bios9020056
   Barot M, 2011, CURR EYE RES, V36, P1069, DOI 10.3109/02713683.2011.607536
   Benedicto I, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15374
   Berezhnov AV, 2016, J BIOL CHEM, V291, P8701, DOI 10.1074/jbc.M115.691774
   BOK D, 1993, J CELL SCI, P189
   Boulton M, 2001, EYE, V15, P384, DOI 10.1038/eye.2001.141
   Brandt U, 2006, ANNU REV BIOCHEM, V75, P69, DOI 10.1146/annurev.biochem.75.103004.142539
   Brennan JP, 2006, CARDIOVASC RES, V72, P313, DOI 10.1016/j.cardiores.2006.07.019
   Chan YJ, 2018, EXP CELL RES, V369, P266, DOI 10.1016/j.yexcr.2018.05.025
   Cho MJ, 2019, EXP MOL MED, V51, DOI 10.1038/s12276-019-0327-y
   Davies KM, 2011, P NATL ACAD SCI USA, V108, P14121, DOI 10.1073/pnas.1103621108
   Detrick B, 2010, IMMUNOL RES, V47, P153, DOI 10.1007/s12026-009-8146-1
   Devi TS, 2019, BIOL OPEN, V8, DOI 10.1242/bio.038521
   Di Rosa M, 2016, CURR NEUROPHARMACOL, V14, P810, DOI 10.2174/1570159X14666160321122900
   Distelmaier F, 2009, BRAIN, V132, P833, DOI 10.1093/brain/awp058
   Ferrington DA, 2020, TRENDS MOL MED, V26, P105, DOI 10.1016/j.molmed.2019.10.008
   Fleckenstein M, 2018, OPHTHALMOLOGY, V125, P369, DOI 10.1016/j.ophtha.2017.08.038
   GIAEVER I, 1993, NATURE, V366, P591, DOI 10.1038/366591a0
   Guerra MH, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22094568
   Gullapalli VK, 2008, EXP EYE RES, V86, P189, DOI 10.1016/j.exer.2007.10.009
   Han YH, 2009, LUNG CANCER, V63, P201, DOI 10.1016/j.lungcan.2008.05.005
   He JY, 2020, P NATL ACAD SCI USA, V117, P29602, DOI 10.1073/pnas.2017987117
   He Y, 2019, INT J OPHTHALMOL-CHI, V12, P375, DOI 10.18240/ijo.2019.03.04
   Heng LZ, 2013, DIABETIC MED, V30, P640, DOI 10.1111/dme.12089
   Ibrahim AS, 2020, J CLIN MED, V9, DOI 10.3390/jcm9072293
   Kiamehr M, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20153773
   Lee SY, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.266
   LI CX, 1990, BIOCHIM BIOPHYS ACTA, V1030, P297, DOI 10.1016/0005-2736(90)90306-9
   Liang FQ, 2003, EXP EYE RES, V76, P397, DOI 10.1016/S0014-4835(03)00023-X
   Martin I.M., 2021, ATP ALLOSTERICALLY S, DOI [10.1101/2021.03.30.437490, DOI 10.1101/2021.03.30.437490]
   Masland RH, 2001, NAT NEUROSCI, V4, P877, DOI 10.1038/nn0901-877
   Millar TM, 2007, FREE RADICAL BIO MED, V42, P1165, DOI 10.1016/j.freeradbiomed.2007.01.015
   MITCHELL P, 1961, NATURE, V191, P144, DOI 10.1038/191144a0
   Mitter SK, 2014, AUTOPHAGY, V10, P1989, DOI 10.4161/auto.36184
   Mousa SA, 1999, J CELL BIOCHEM, V74, P135, DOI 10.1002/(SICI)1097-4644(19990701)74:1<135::AID-JCB15>3.0.CO;2-#
   Narimatsu T, 2013, INVEST OPHTH VIS SCI, V54, P4555, DOI 10.1167/iovs.12-11572
   Naylor A, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21010211
   Nowak JZ, 2006, PHARMACOL REP, V58, P353
   Onnela N, 2012, MED BIOL ENG COMPUT, V50, P107, DOI 10.1007/s11517-011-0850-z
   Park KS, 2002, PFLUG ARCH EUR J PHY, V443, P344, DOI 10.1007/s004240100703
   Rajasekaran SA, 2003, AM J PHYSIOL-CELL PH, V284, pC1497, DOI 10.1152/ajpcell.00355.2002
   Rao R, 2008, FRONT BIOSCI-LANDMRK, V13, P7210, DOI 10.2741/3223
   Rao RK, 2002, BIOCHEM J, V368, P471, DOI 10.1042/BJ20011804
   Sambongi Y, 1999, SCIENCE, V286, P1722, DOI 10.1126/science.286.5445.1722
   Sazanov LA, 2015, NAT REV MOL CELL BIO, V16, P375, DOI 10.1038/nrm3997
   Seth A, 2007, J BIOL CHEM, V282, P11487, DOI 10.1074/jbc.M610597200
   Simo R, 2010, J BIOMED BIOTECHNOL, DOI 10.1155/2010/190724
   Tenconi PE, 2019, EXP EYE RES, V184, P243, DOI 10.1016/j.exer.2019.04.028
   To CH, 1998, COMP BIOCHEM PHYS A, V121, P441, DOI 10.1016/S1095-6433(98)10156-3
   Turrens JF, 2003, J PHYSIOL-LONDON, V552, P335, DOI 10.1113/jphysiol.2003.049478
   Wang H, 2011, EYE BRAIN, V3, P19, DOI 10.2147/EB.S24951
   Winkler BS, 1999, MOL VIS, V5
   Xia T, 2017, VISION RES, V139, P72, DOI 10.1016/j.visres.2017.02.006
   Yuan YK, 2003, J PHYSIOL-LONDON, V549, P429, DOI 10.1113/jphysiol.2003.042341
   Yumnamcha T, 2019, FRONT NEUROSCI-SWITZ, V13, DOI 10.3389/fnins.2019.01065
   Zhao RZ, 2019, INT J MOL MED, V44, P3, DOI 10.3892/ijmm.2019.4188
   Zimmermann D, 2008, BIOCHEM BIOPH RES CO, V369, P1022, DOI 10.1016/j.bbrc.2008.02.153
   Zorov DB, 2000, J EXP MED, V192, P1001, DOI 10.1084/jem.192.7.1001
NR 59
TC 2
Z9 2
U1 3
U2 8
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 1422-0067
J9 INT J MOL SCI
JI Int. J. Mol. Sci.
PD AUG
PY 2021
VL 22
IS 15
AR 8130
DI 10.3390/ijms22158130
PG 19
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA TV6IE
UT WOS:000681824100001
PM 34360894
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Tonolli, PN
   Martins, WK
   Junqueira, HC
   Silva, MN
   Severino, D
   Santacruz-Perez, C
   Watanabe, I
   Baptista, MS
AF Tonolli, Paulo N.
   Martins, Waleska K.
   Junqueira, Helena C.
   Silva, Maryana N.
   Severino, Divinomar
   Santacruz-Perez, Carolina
   Watanabe, I
   Baptista, Mauricio S.
TI Lipofuscin in keratinocytes: Production, properties, and consequences of
   the photosensitization with visible light
SO FREE RADICAL BIOLOGY AND MEDICINE
LA English
DT Article
DE Autophagy; Mitophagy; DNA damage; Visible light; Singlet oxygen; Skin;
   Photoprotection
ID RETINAL-PIGMENT EPITHELIUM; SINGLET OXYGEN GENERATION; LYSOSOMAL AXIS
   THEORY; DNA-DAMAGE; OXIDATIVE STRESS; RPE LIPOFUSCIN; CATHEPSIN-B;
   CELLS; FLUORESCENCE; REPAIR
AB A dysfunction in the mitochondrial-lysosomal axis of cellular homeostasis is proposed to cause cells to age quicker and to accumulate lipofuscin. Typical protocols to mediate lipofuscinogenesis are based on the induction of the senescent phenotype either by allowing many consecutive cycles of cell division or by treating cells with physical/chemical agents such as ultraviolet (UV) light or hydrogen peroxide. Due to a direct connection with the physiopathology of age-related macular degeneration, lipofuscin that accumulates in retinal pigment epithelium (RPE) cells have been extensively studied, and the photochemical properties of RPE lipofuscin are considered as standard for this pigment. Yet, many other tissues such as the brain and the skin may prompt lipofuscinogenesis, and the properties of lipofuscin granules accumulated in these tissues are not necessarily the same as those of RPE lipofuscin. Here, we present a light-induced protocol that accelerates cell aging as judged by the maximization of lipofuscinogenesis. Photosensitization of cells previously incubated with nanomolar concentrations of 1,9-dimethyl methylene blue (DMMB), severely and specifically damages mitochondria and lysosomes, leading to a lipofuscin-related senescent phenotype. By applying this protocol in human immortalized non-malignant keratinocytes (HaCaT) cells, we observed a 2.5-fold higher level of lipofuscin accumulation compared to the level of lipofuscin accumulation in cells treated with a typical UV protocol. Lipofuscin accumulated in keratinocytes exhibited the typical red light emission, with excitation maximum in the blue wavelength region (similar to 450 nm). Fluorescence lifetime image microscopy data showed that the keratinocyte lipofuscin has an emission lifetime of similar to 1.7 ns. Lipofuscin-loaded cells (but not control cells) generated a substantial amount of singlet oxygen (O-1(2)) when irradiated with blue light (420 nm), but there was no O-1(2) generation when excitation was performed with a green light (532 nm). These characteristics were compared with those of RPE cells, considering that keratinocyte lipofuscin lacks the bisretinoids derivatives present in RPE lipofuscin. Additionally, we showed that lipofuscin-loaded keratinocytes irradiated with visible light presented critical DNA damages, such as double-strand breaks and Fpg-sensitive sites. We propose that the DMMB protocol is an efficient way to disturb the mitochondrial-lysosomal axis of cellular homeostasis, and consequently, it can be used to accelerate aging and to induce lipofuscinogenesis. We also discuss the consequences of the lipofuscin-induced genotoxicity of visible light in keratinocytes.
C1 [Tonolli, Paulo N.; Martins, Waleska K.; Junqueira, Helena C.; Severino, Divinomar; Santacruz-Perez, Carolina; Baptista, Mauricio S.] Univ Sao Paulo, Inst Quim, Dept Bioquim, Sao Paulo, SP, Brazil.
   [Martins, Waleska K.; Silva, Maryana N.] Univ Anhanguera Sao Paulo UNIAN SP, Sao Paulo, SP, Brazil.
   [Watanabe, I] Univ Sao Paulo, Inst Ciencias Biomet, Sao Paulo, SP, Brazil.
C3 Universidade de Sao Paulo; Universidade Anhanguera; Universidade de Sao
   Paulo
RP Baptista, MS (通讯作者)，Univ Sao Paulo, Inst Quim, Dept Bioquim, Sao Paulo, SP, Brazil.
EM baptista@iq.usp.br
RI Tonolli, Paulo Newton N/W-1829-2018; Martins, Waleska
   Kerllen/L-5187-2018; Baptista, Mauricio S/A-5140-2008; Baptista,
   Mauricio S/AAO-5749-2021; Severino, Divinomar/F-9029-2012
OI Tonolli, Paulo Newton N/0000-0002-9547-9477; Martins, Waleska
   Kerllen/0000-0003-1502-4606; Baptista, Mauricio S/0000-0001-7079-7666;
   Baptista, Mauricio S/0000-0001-7079-7666; Nascimento Silva,
   Maryana/0000-0003-2918-8169; Santacruz-Perez,
   Carolina/0000-0003-3712-486X; Severino, Divinomar/0000-0001-9483-6287
FU CAPES (Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior)
   Finance, Brazil [001]; FAPESP (Fundacao de Amparo a Pesquisa do Estado
   de Sao Paulo) [CEPID REDOXOMA 13/07937-8, 18/22922-0, 18/23257-0]; CNPq
FX The authors are grateful to Prof. Marisa Medeiros for instrumental
   support to the comet assay, Prof. Erick L Bastos for help with
   spectrofluorometer, and Sonia R.Y. Almeida for preparing the
   transmission electron microscopy samples. We also thank Alessandra A.
   Araujo de Sousa, Luana de Souza Barbosa, Laryssa Santos, and Larissa N.
   Xavier de Albuquerque for technical assistance in cell culture service;
   and Wilton J. R. Lima and Adriana Yamaguti Matsukuma for help with
   confocal microscopy and flow cytometry. We also acknowledge the support
   of CAPES (Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior)
   Finance Code 001, Brazil; and FAPESP (Fundacao de Amparo a Pesquisa do
   Estado de Sao Paulo) grants (CEPID REDOXOMA 13/07937-8, 18/22922-0, and
   18/23257-0) and CNPq.
CR Agnez-Lima LF, 2012, MUTAT RES-REV MUTAT, V751, P15, DOI 10.1016/j.mrrev.2011.12.005
   Aymard E, 2011, EXP DERMATOL, V20, P263, DOI 10.1111/j.1600-0625.2010.01157.x
   Bacellar IOL, 2018, J AM CHEM SOC, V140, P9606, DOI 10.1021/jacs.8b05014
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Ben-Shabat S, 2002, ANGEW CHEM INT EDIT, V41, P814, DOI 10.1002/1521-3773(20020301)41:5<814::AID-ANIE814>3.0.CO;2-2
   Biesemeier A, 2010, CELL TISSUE RES, V339, P551, DOI 10.1007/s00441-009-0920-9
   Bohr VA, 2002, GENE, V286, P127, DOI 10.1016/S0378-1119(01)00813-7
   BOUKAMP P, 1988, J CELL BIOL, V106, P761, DOI 10.1083/jcb.106.3.761
   BOULTON M, 1990, VISION RES, V30, P1291, DOI 10.1016/0042-6989(90)90003-4
   BOULTON M, 1985, EXP EYE RES, V41, P209, DOI 10.1016/0014-4835(85)90026-0
   Boulton ME, 2014, EXP EYE RES, V126, P61, DOI 10.1016/j.exer.2014.01.016
   BRUNK UT, 1992, MUTAT RES, V275, P395, DOI 10.1016/0921-8734(92)90042-N
   Brunk UT, 2002, FREE RADICAL BIO MED, V33, P611, DOI 10.1016/S0891-5849(02)00959-0
   Brunk UT, 2002, EUR J BIOCHEM, V269, P1996, DOI 10.1046/j.1432-1033.2002.02869.x
   Cadet J, 2013, CSH PERSPECT BIOL, V5, DOI 10.1101/cshperspect.a012559
   Cheng YS, 2019, EXP EYE RES, V181, P325, DOI 10.1016/j.exer.2018.09.012
   Chiarelli-Neto O, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0113266
   Chiarelli-Neto O, 2011, FREE RADICAL BIO MED, V51, P1195, DOI 10.1016/j.freeradbiomed.2011.06.013
   Chouinard N, 2002, BIOCHEM J, V365, P133, DOI 10.1042/BJ20020072
   Crouch RK, 2015, PROG MOL BIOL TRANSL, V134, P449, DOI 10.1016/bs.pmbts.2015.06.005
   Czarnecki D, 2016, J INVEST DERMATOL, V136, P1912, DOI 10.1016/j.jid.2016.04.028
   de Souza-Pinto N.C., 2013, BRENNERS ENCY GENET, DOI [10.1016/B978-0-12-374984-0.01296-1., DOI 10.1016/B978-0-12-374984-0.01296-1]
   Debacq-Chainiaux F, 2012, DERM-ENDOCRINOL, V4, DOI 10.4161/derm.23652
   DELORI FC, 1995, INVEST OPHTH VIS SCI, V36, P718
   Des Marais TL, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-13765-7
   Di Guardo G, 2015, FRONT MED-LAUSANNE, V2, DOI 10.3389/fmed.2015.00006
   Doicu A, 2010, SPRINGER-PRAX BOOKS, P1, DOI 10.1007/978-3-642-05439-6
   Donatello S, 2011, J EXP CLIN CANC RES, V30, DOI 10.1186/1756-9966-30-45
   ELDRED GE, 1988, EXP EYE RES, V47, P71, DOI 10.1016/0014-4835(88)90025-5
   ELDRED GE, 1982, SCIENCE, V216, P757, DOI 10.1126/science.7079738
   GAILLARD ER, 1995, PHOTOCHEM PHOTOBIOL, V61, P448, DOI 10.1111/j.1751-1097.1995.tb02343.x
   Georgakopoulou EA, 2013, AGING-US, V5, P37
   Godley BF, 2005, J BIOL CHEM, V280, P21061, DOI 10.1074/jbc.M502194200
   HALLIWELL B, 1991, FREE RADICAL BIO MED, V10, P439, DOI 10.1016/0891-5849(91)90052-5
   Hanasoge S, 2007, CARCINOGENESIS, V28, P2298, DOI 10.1093/carcin/bgm157
   Haque E, 2018, INT J BIOCHEM CELL B, V96, P90, DOI 10.1016/j.biocel.2018.01.014
   Henseleit U, 1997, J INVEST DERMATOL, V109, P722, DOI 10.1111/1523-1747.ep12340708
   Hohn A, 2010, FREE RADICAL BIO MED, V48, P1100, DOI 10.1016/j.freeradbiomed.2010.01.030
   HOMEWOOD CA, 1972, NATURE, V235, P50, DOI 10.1038/235050a0
   Hung CW, 2010, AGEING RES REV, V9, pS36, DOI 10.1016/j.arr.2010.08.006
   Jang YP, 2005, J BIOL CHEM, V280, P39732, DOI 10.1074/jbc.M504933200
   Jung T, 2010, METHODS MOL BIOL, V594, P173, DOI 10.1007/978-1-60761-411-1_13
   Kakimoto Y, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-40250-0
   Kielbassa C, 1997, CARCINOGENESIS, V18, P811, DOI 10.1093/carcin/18.4.811
   Kino K, 2001, CHEM BIOL, V8, P369, DOI 10.1016/S1074-5521(01)00019-9
   Kuo LJ, 2008, IN VIVO, V22, P305
   Lamore SD, 2013, J PHOTOCH PHOTOBIO B, V123, P1, DOI 10.1016/j.jphotobiol.2013.03.007
   LEHMAN TA, 1993, CARCINOGENESIS, V14, P833, DOI 10.1093/carcin/14.5.833
   Lemasters JJ, 2014, REDOX BIOL, V2, P749, DOI 10.1016/j.redox.2014.06.004
   Liebel F, 2012, J INVEST DERMATOL, V132, P1901, DOI 10.1038/jid.2011.476
   Marmorstein AD, 2002, INVEST OPHTH VIS SCI, V43, P2435
   Martins WK, 2019, AUTOPHAGY, V15, P259, DOI 10.1080/15548627.2018.1515609
   Martins WK, 2017, BBA-GEN SUBJECTS, V1861, P3129, DOI 10.1016/j.bbagen.2016.10.018
   Martins WK, 2015, SCI REP-UK, V5, DOI 10.1038/srep12425
   MCADOO MH, 1973, INFECT IMMUN, V7, P655, DOI 10.1128/IAI.7.4.655-665.1973
   Moreno-Garcia A, 2018, FRONT NEUROSCI-SWITZ, V12, DOI 10.3389/fnins.2018.00464
   Muller I, 2015, J INVEST DERMATOL, V135, P851, DOI 10.1038/jid.2014.481
   MUNTZING J, 1972, Z KREBSFORSCH KLIN O, V77, P166, DOI 10.1007/BF00304055
   Murdaugh LS, 2010, J MASS SPECTROM, V45, P1139, DOI 10.1002/jms.1795
   Narendra D, 2008, J CELL BIOL, V183, P795, DOI 10.1083/jcb.200809125
   Narendra DP, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000298
   Nilsson E, 1997, MECH AGEING DEV, V99, P61, DOI 10.1016/S0047-6374(97)00091-2
   OLIVE PL, 1990, RADIAT RES, V122, P86, DOI 10.2307/3577587
   Parish CA, 1998, P NATL ACAD SCI USA, V95, P14609, DOI 10.1073/pnas.95.25.14609
   Pattison DI, 2006, EXP SUPPL, V96, P131
   Perse M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059638
   Pfeiffer P, 1998, TOXICOL LETT, V96-7, P119, DOI 10.1016/S0378-4274(98)00058-7
   Randhawa M, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0130949
   Reszka K, 1995, PHOTOCHEM PHOTOBIOL, V62, P1005
   Rodgers K, 2016, J CELL PHYSIOL, V231, P15, DOI 10.1002/jcp.25053
   Rodrigues D, 2016, PHOTOCH PHOTOBIO SCI, V15, P334, DOI 10.1039/c5pp00409h
   Rozanowska M, 1998, FREE RADICAL BIO MED, V24, P1107, DOI 10.1016/S0891-5849(97)00395-X
   Schraermeyer U, 1999, PIGM CELL RES, V12, P219, DOI 10.1111/j.1600-0749.1999.tb00755.x
   Sharma A., 2012, METHODS MOL BIOL, P3, DOI [10.1007/978-1-61779-998, DOI 10.1007/978-1-61779-998-3-40.]
   SIES H, 1992, MUTAT RES, V275, P367, DOI 10.1016/0921-8734(92)90039-R
   Skoczynska A, 2017, POSTEP DERM ALERGOL, V34, P97, DOI 10.5114/ada.2017.67070
   Sparrow JR, 2014, J CLIN MED, V3, P1302, DOI 10.3390/jcm3041302
   Sparrow JR, 2005, EXP EYE RES, V80, P595, DOI 10.1016/j.exer.2005.01.007
   Sparrow JR, 2000, INVEST OPHTH VIS SCI, V41, P1981
   Steenken S, 1997, J AM CHEM SOC, V119, P617, DOI 10.1021/ja962255b
   Terman A, 2004, INT J BIOCHEM CELL B, V36, P1400, DOI 10.1016/j.biocel.2003.08.009
   Terman Alexei, 2006, Molecular Aspects of Medicine, V27, P471, DOI 10.1016/j.mam.2006.08.006
   Terman A, 2006, CHEM-BIOL INTERACT, V163, P29, DOI 10.1016/j.cbi.2006.04.013
   Terman A, 2010, ANTIOXID REDOX SIGN, V12, P503, DOI 10.1089/ars.2009.2598
   Tonolli PN, 2017, J INVEST DERMATOL, V137, P2447, DOI 10.1016/j.jid.2017.06.018
   TOWATARI T, 1991, FEBS LETT, V280, P311, DOI 10.1016/0014-5793(91)80319-X
   Tsubone T.M., 2020, ADV BIOCH BIOTECHNOL, V5, P1098, DOI [10.29011/2574-7258.001098, DOI 10.29011/2574-7258.001098]
   Tsubone TM, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-06788-7
   Uchoa AF, 2008, EUR BIOPHYS J BIOPHY, V37, P843, DOI 10.1007/s00249-008-0287-y
   vonZglinicki T, 1995, GERONTOLOGY, V41, P95
   WATANABE I, 1983, ARCH HISTOL JAPON, V46, P173, DOI 10.1679/aohc.46.173
   Wihlmark U, 1997, FREE RADICAL BIO MED, V22, P1229, DOI 10.1016/S0891-5849(96)00555-2
   Wihlmark U, 1996, APMIS, V104, P272, DOI 10.1111/j.1699-0463.1996.tb00717.x
   Wondrak GT, 2006, PHOTOCH PHOTOBIO SCI, V5, P215, DOI 10.1039/b504573h
   Yakovleva MA, 2017, DOKL BIOCHEM BIOPHYS, V472, P19, DOI 10.1134/S1607672917010069
   YOSHIMORI T, 1991, J BIOL CHEM, V266, P17707
   Zhang W, 2016, TOPOLOGY OPTIMIZATION IN ENGINEERING STRUCTURE DESIGN, P1
NR 97
TC 7
Z9 8
U1 0
U2 12
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0891-5849
EI 1873-4596
J9 FREE RADICAL BIO MED
JI Free Radic. Biol. Med.
PD NOV 20
PY 2020
VL 160
BP 277
EP 292
DI 10.1016/j.freeradbiomed.2020.08.002
PG 16
WC Biochemistry & Molecular Biology; Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Endocrinology & Metabolism
GA OY7FO
UT WOS:000594409300007
PM 32810634
DA 2022-11-30
ER

PT J
AU Alten, F
   Clemens, CR
   Heiduschka, P
   Eter, N
AF Alten, F.
   Clemens, C. R.
   Heiduschka, P.
   Eter, N.
TI Characterisation of reticular pseudodrusen and their central target
   aspect in multi-spectral, confocal scanning laser ophthalmoscopy
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE Age-related macular degeneration; Reticular drusen; Reticular
   pseudodrusen; Subretinal drusenoid deposits; Confocal scanning laser
   ophthalmoscopy; Multi-spectral confocal scanning laser ophthalmoscopy;
   Multi-colour confocal scanning laser ophthalmoscopy fundus
   autofluorescence; Infrared reflectance; Green reflectance; Blue
   reflectance
ID SUBRETINAL DRUSENOID DEPOSITS; MACULAR DEGENERATION; PREVALENCE
AB To analyse reticular pseudodrusen (RPD) in patients with age-related macular degeneration (AMD) using multi-spectral (MS), confocal scanning laser ophthalmoscopy (cSLO).
   cSLO images (blue fundus autofluorescence [FAF; exc., lambda = 488; em., lambda = 500-700 nm], near-infrared reflectance [IR; lambda = 820 nm], MS [blue reflectance (BR) lambda = 488 nm, green reflectance (GR) lambda = 515 nm, IR lambda = 820 nm], as well as colour fundus photographs (CFP) were taken of 200 eyes from 100 AMD patients suspected to show RPD on the basis of funduscopy or previous fundus imaging. FAF and IR images were graded by two independent readers. If both readers concordantly confirmed the presence of RPD in both modalities, eyes were subsequently also graded for RPD in MS, BR, GR, green-blue enhanced mode (GBE), and CFP. Besides, FAF, IR, and MS images were evaluated for the presence of a target aspect, which represents a common feature of RPD lesions.
   The presence of RPD was confirmed using FAF and IR images by both readers in 130 eyes of 76 patients. In those eyes, both readers concordantly diagnosed RPD in MS images in 124 (95.4 %) eyes (BR: 52 [40.0 %], GR: 63 [48.5 %], GBE: 101 [77.7 %], CF: 27 [20.8 %]). Cohen kappa statistics revealed excellent inter-observer agreement for MS (0.95) and GBE (0.85), substantial agreement for BR (0.75), GR (0.78), and moderate agreement for CFP (0.59). A target aspect within RPD lesions was detected in 45 of 130 (35.0 %) included eyes using FAF and IR. The presence of a target aspect improved the recognition of RPD lesions in all modalities. If a target aspect was present, RPD were diagnosed in 45 eyes (100 %) using MS (GBE: 42 eyes [93.3 %], BR: 30 eyes [66.7 %], GR: 37 eyes [82.2 %], CFP: 17 eyes [37.8 %]). Using MS cSLO, a target aspect could be identified in 75 of 130 (57.7 %) included eyes.
   MS cSLO imaging is equivalent to FAF and IR in identifying RPD in AMD patients. Higher identification rates in BR and GR of those RPD lesions featuring a target aspect confirm the current hypothesis of RPD localisation and its progression further into the photoreceptor layers. MS seems to be more sensitive in identifying a central target aspect in RPD lesions compared to blue FAF and IR.
C1 [Alten, F.; Clemens, C. R.; Heiduschka, P.; Eter, N.] Univ Munster, Med Ctr, Dept Ophthalmol, D-48149 Munster, Germany.
C3 University of Munster
RP Alten, F (通讯作者)，Univ Munster, Med Ctr, Dept Ophthalmol, Domagkstr 15, D-48149 Munster, Germany.
EM florian_alten@yahoo.de; christoph.clemens@ukmuenster.de;
   peter.heiduschka@ukmuenster.de; eter@uni-muenster.de
RI Heiduschka, Peter/AAX-3882-2021
CR ARNOLD JJ, 1995, RETINA-J RET VIT DIS, V15, P183, DOI 10.1097/00006982-199515030-00001
   Cohen SY, 2007, BRIT J OPHTHALMOL, V91, P354, DOI 10.1136/bjo.2006.101022
   Curcio CA, 2013, RETINA-J RET VIT DIS, V33, P265, DOI 10.1097/IAE.0b013e31827e25e0
   Forte R, 2012, ACTA OPHTHALMOL, V90, pE281, DOI 10.1111/j.1755-3768.2011.02331.x
   Klein R, 2008, AM J OPHTHALMOL, V145, P317, DOI 10.1016/j.ajo.2007.09.008
   Landa G, 2012, OPHTHALMIC RES, V47, P81, DOI 10.1159/000324988
   LANDIS JR, 1977, BIOMETRICS, V33, P159, DOI 10.2307/2529310
   Pumariega NM, 2011, OPHTHALMOLOGY, V118, P1619, DOI 10.1016/j.ophtha.2011.01.029
   Querques G, 2011, RETINA-J RET VIT DIS, V31, P518, DOI 10.1097/IAE.0b013e3181f04974
   Querques G, 2013, OPHTHALMOLOGY, V120, P872, DOI 10.1016/j.ophtha.2012.12.007
   Querques G, 2012, INVEST OPHTH VIS SCI, V53, P1264, DOI 10.1167/iovs.11-9063
   Sarks J, 2011, BRIT J OPHTHALMOL, V95, P979, DOI 10.1136/bjo.2010.194977
   Schmitz-Valckenberg S, 2011, INVEST OPHTH VIS SCI, V52, P5009, DOI 10.1167/iovs.11-7235
   Smith RT, 2009, AM J OPHTHALMOL, V148, P733, DOI 10.1016/j.ajo.2009.06.028
   Spaide RF, 2010, RETINA-J RET VIT DIS, V30, P1441, DOI 10.1097/IAE.0b013e3181ee5ce8
   Ueda-Arakawa N, 2013, AM J OPHTHALMOL, V155, P260, DOI 10.1016/j.ajo.2012.08.011
   Zweifel SA, 2010, OPHTHALMOLOGY, V117, P1775, DOI 10.1016/j.ophtha.2010.01.027
   Zweifel SA, 2010, OPHTHALMOLOGY, V117, P303, DOI 10.1016/j.ophtha.2009.07.014
NR 18
TC 28
Z9 32
U1 0
U2 4
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0721-832X
EI 1435-702X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD MAY
PY 2014
VL 252
IS 5
BP 715
EP 721
DI 10.1007/s00417-013-2525-y
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AG8HS
UT WOS:000335660000002
PM 24276561
DA 2022-11-30
ER

PT J
AU Patty, L
   Wu, C
   Torres, M
   Azen, S
   Varma, R
AF Patty, Lauren
   Wu, Cathy
   Torres, Mina
   Azen, Stanley
   Varma, Rohit
CA Los Angeles Latino Eye Study Grp
TI Validity of Self-reported Eye Disease and Treatment in a
   Population-based Study: The Los Angeles Latino Eye Study
SO OPHTHALMOLOGY
LA English
DT Article
ID MACULAR DEGENERATION; PREVALENCE; ACCURACY; CATARACT
AB Purpose: To examine the validity of self-reported eye disease, including cataract, age-related macular degeneration (AMD), glaucoma, and diabetic retinopathy (DR), and self-reported surgical treatment for cataract and DR in the Los Angeles Latino Eye Study (LALES).
   Design: Population-based, cross-sectional study.
   Participants: A total of 6357 Latinos aged 40+ years from the LALES.
   Methods: Participants underwent a detailed interview, including survey questions about ocular health, diagnoses, and timing of last eye examination, and a standardized clinical examination. Self-report was compared with examination to determine sensitivity and specificity by length of time since last eye examination. Stepwise logistic regression was used to determine factors associated with inaccurate self-report.
   Main Outcome Measures: Sensitivity and specificity were calculated for 4 self-reported eye diseases (cataract, AMD, glaucoma, and DR) and for surgical treatment of cataract and DR. Odds ratios (ORs) were determined for factors associated with inaccurate self-report underestimating eye disease and treatment.
   Results: For each disease, sensitivity and specificity in those who reported their last eye examination as <1 year ago were 36.8% and 92.5% for cataract, 37.7% and 96.3% for glaucoma, 5.1% and 98.9% for AMD, and 25.7% and 94.2% for DR, respectively. Self-report was less accurate with increasing time since last eye examination. Inaccurate self-report was independently associated with better visual acuity (OR, 2.4), <2 comorbidities (OR, 1.7), last eye examination/visit 1 to 5 years ago and >= 5 years ago (OR, 2.3 and 4.9, respectively), and less education (OR, 1.3 for 7-12 years and 1.7 for <7 years). Of 88 participants surgically treated for cataract who reported an eye examination <1 year ago, sensitivity and specificity of self-reported surgical history were 90.9% and 99.9%, respectively. Of the 31 participants treated for DR (laser/surgery) and reporting an eye examination <1 year ago, sensitivity and specificity of self-reported surgical history were 19.4% and 99.6%, respectively.
   Conclusions: Among Latinos, self-reporting of eye disease and surgical history provides a significant underestimate of the disease burden. This may lead to significant misclassification in vision research if self-report alone is used to identify persons with eye disease.
   Financial Disclosure(s): The author(s) have no proprietary or commercial interest in any materials discussed in this article. Ophthalmology 2012;119:1725-1730 (c) 2012 by the American Academy of Ophthalmology.
C1 [Patty, Lauren; Wu, Cathy; Azen, Stanley; Varma, Rohit] Univ So Calif, Doheny Eye Inst, Keck Sch Med, Los Angeles, CA 90033 USA.
   [Patty, Lauren; Wu, Cathy; Azen, Stanley; Varma, Rohit] Univ So Calif, Dept Ophthalmol, Keck Sch Med, Los Angeles, CA 90033 USA.
   [Torres, Mina; Varma, Rohit] Univ So Calif, Dept Prevent Med, Keck Sch Med, Los Angeles, CA 90033 USA.
C3 Doheny Eye Institute; University of Southern California; University of
   Southern California; University of Southern California
RP Varma, R (通讯作者)，Univ So Calif, Doheny Eye Inst, Keck Sch Med, Suite 4900,1450 San Pablo St, Los Angeles, CA 90033 USA.
EM rvarma@usc.edu
FU National Institutes of Health from the National Eye Institute, Bethesda,
   Maryland [EY-11753, EY-03040]; Research to Prevent Blindness, New York,
   New York; NATIONAL EYE INSTITUTE [U10EY011753, P30EY003040] Funding
   Source: NIH RePORTER
FX National Institutes of Health grants EY-11753 and EY-03040 from the
   National Eye Institute, Bethesda, Maryland, and an unrestricted grant
   from the Research to Prevent Blindness, New York, New York. Dr. Varma is
   a Research to Prevent Blindness Sybil B. Harrington Scholar. The
   sponsors or funding organizations had no role in the design or conduct
   of this research.
CR American Academy of Ophthalmology, 2010, PREF PRACT PATT COMP
   Bowie H, 2003, INVEST OPHTH VIS SCI, V44, P2905, DOI 10.1167/iovs.02-1055
   Cuellar IHL., 1980, HISPANIC J BEHAV SCI, V2, P199, DOI DOI 10.1177/07399863950173001
   Dietrich T, 2005, EUR J ORAL SCI, V113, P135, DOI 10.1111/j.1600-0722.2004.00196.x
   Grassi MA, 2009, AM J OPHTHALMOL, V147, P501, DOI 10.1016/j.ajo.2008.09.016
   HARLOW SD, 1989, AM J EPIDEMIOL, V129, P233, DOI 10.1093/oxfordjournals.aje.a115129
   LINTON KLP, 1991, AM J EPIDEMIOL, V134, P1438, DOI 10.1093/oxfordjournals.aje.a116049
   Lynch BM, 2008, J CLIN EPIDEMIOL, V61, P498, DOI 10.1016/j.jclinepi.2007.05.018
   Mawani Farah N, 2010, Health Rep, V21, P61
   U.S. Census Bureau, 2011, 2010 CENS HISP POP 2
   Varma R, 2004, OPHTHALMOLOGY, V111, P1439, DOI 10.1016/j.ophtha.2004.01.025
   Varma R, 2004, OPHTHALMOLOGY, V111, P1449, DOI 10.1016/j.ophtha.2004.01.024
   Varma R, 2004, OPHTHALMOLOGY, V111, P1298, DOI 10.1016/j.ophtha.2004.03.002
   Varma R, 2004, OPHTHALMOLOGY, V111, P1121, DOI 10.1016/j.ophtha.2004.02.001
   Varma R, 2004, OPHTHALMOLOGY, V111, P1288, DOI 10.1016/j.ophtha.2004.01.023
   Varma R, 2008, MED CARE, V46, P497, DOI 10.1097/MLR.0b013e31816080fe
NR 16
TC 47
Z9 47
U1 0
U2 7
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD SEP
PY 2012
VL 119
IS 9
BP 1725
EP 1730
DI 10.1016/j.ophtha.2012.02.029
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 030OY
UT WOS:000310581200002
PM 22537615
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Babizhayev, MA
AF Babizhayev, Mark A.
TI Bioactivation antioxidant and transglycating properties of
   N-acetylcarnosine autoinduction prodrug of a dipeptide L-carnosine in
   mucoadhesive drug delivery eye-drop formulation: powerful eye health
   application technique and therapeutic platform
SO DRUG TESTING AND ANALYSIS
LA English
DT Article
DE N-acetylcarnosine eye drops; prodrug formulations; hydrazide carnosine
   derivatives; age-related ophthalmic diseases; natural medicine; human
   biology
ID HISTIDINE-CONTAINING DIPEPTIDE; ALANYL-L-HISTIDINE; NATURAL HISTIDINE;
   SKELETAL-MUSCLE; CROSS-LINKING; CU,ZN-SUPEROXIDE DISMUTASE;
   LIPID-PEROXIDATION; PROTECTS PROTEINS; MASS-SPECTROMETRY; CLINICAL
   RESEARCH
AB A considerable interest in N-acetylcarnosine ocular drug design for eye health is based on clinical strategies to improve ocular drug delivery through metabolic enzymatic activation. Human biology aspects of ocular N-acetylcarnosine deacetylation during its pass through the cornea to the aqueous humor and dipeptide hydrolyzing enzymes are characterized. Novel approaches to ocular drug delivery increasing intraocular bioavailability of N-acetylcarnosine biologically activated metabolite carnosine become an integral development ensuring prolonged retention of the medication in the mucoadhesive precorneal area and facilitating transcorneal penetration of the natural dipeptide with the corneal promoters. A comprehensive list of techniques for peptide drug design, synthesis, purification, and biological analyses was considered: liquid chromatography (LC), high performance liquid chromatography (HPLC), 1H and 13C nuclear magnetic resonance (NMR), electrospray ionization (ESI) mass spectroscopy, and spectrophotometry. The antioxidant activity of therapeutics-targeted molecules was studied in aqueous solution and in a lipid membrane environment. A deglycation therapeutic system was developed involving removal, by transglycation of sugar or aldehyde moieties from Schiff bases by histidyl-hydrazide compounds or aldehyde scavenger L-carnosine. Clinical studies included ophthalmoscopy, visual acuity (VA), halometer disability glare tests, slit-image, and retro-illumination photography. N-acetylcarnosine 1% lubricant eye drops are considered as an auto-induction prodrug and natural ocular redox state balance therapies with implications in prevention and treatment of serious eye diseases that involve pathways of continuous oxidative damage to ocular tissues(cataracts, primary open-angle glaucoma, age-related macular degeneration) and sight-threatening glycosylation processes (diabetic retinopathy and consequent visual impairment) important for public health. The results of the study document that the therapeutic benefit in clinical trials is associated with the bioactivation universal antioxidant and transglycating properties of N-acetylcarnosine acting as the ophthalmic prodrug of L-carnosine, and depends on the nature of the specific drug delivery lubricant eye-drop formulation applied as the topical solution. The research highlights findings in N-acetylcarnosine prodrug activation, transport mechanisms, drug-to-drug interactions, and formulations in order to unlock the optimization of complicated ocular pharmacology of N-acetylcarnosine. Patented N-acetylcarnosine lubricant eye-drop formula was marketed as numerous human biological brands reaching important distribution networks on over 550 000 bottles sold. Nature Does Nothing Uselessly. -Aristotle Copyright (c) 2011 John Wiley & Sons, Ltd.
C1 [Babizhayev, Mark A.] Innovat Vis Prod Inc, Cty Of New Castle, DE USA.
RP Babizhayev, MA (通讯作者)，Innovat Vis Prod Inc, Moscow Div, Ivanovskaya 20,Suite 74, Moscow 127434, Russia.
EM markbabizhayev@mail.ru
FU Innovative Vision Products, Inc. (County of New Castle, DE, USA)
FX This work was planned, organized, and supported by Innovative Vision
   Products, Inc. (County of New Castle, DE, USA). Innovative Vision
   Products, Inc., holds the worldwide patent (including PCT International
   Publication No. WO 2004/028536 A1) for the application of
   N-acetylcarnosine for the treatment of ophthalmic disorders, including
   cataracts as well as (PCT International Publication No. WO 2004/064866
   PCT/JP2004/000351) protecting the therapeutic applications and
   formulations of carnosine and amino acid derivatives stabilizing
   carnosine from enzymatic hydrolysis by carnosinase (inhibited by a
   nonhydrolyzable substrate analog). Innovative Vision Products Inc., is a
   pharmaceutical and nanotechnology development company with a focus on
   innovative chemical entities, drug delivery systems, and unique medical
   devices to target specific biomedical applications. Over the last decade
   it has developed a track record in developing these technologies to
   effectively address the unmet needs of specific diseased populations.
CR Aldini G, 2002, BIOCHEM BIOPH RES CO, V298, P699, DOI 10.1016/S0006-291X(02)02545-7
   Aldini G, 2002, J MASS SPECTROM, V37, P1219, DOI 10.1002/jms.381
   [Anonymous], 2008, Community Eye Health, V21, P1
   Ansari NH, 1996, BIOCHEM MOL MED, V59, P68, DOI 10.1006/bmme.1996.0067
   Ansari NH, 1996, BIOCHEM MOL MED, V58, P25, DOI 10.1006/bmme.1996.0028
   BABIZHAEV MA, 1986, BIOFIZIKA+, V31, P109
   Babizhayev M. A., 1994, Patent No, Patent No. [WO 95/12581, 9512581]
   Babizhayev M. A., 2010, [US Patent No, PCT No. PCT/IB03/04259], Patent No. [US 7,795,203 B2, 7795203]
   Babizhayev M. A., 1994, Patent No, Patent No. [PCT/EP 94/03340 SCB 238 PCT, 94003340]
   Babizhayev M.A., 1994, Patent No. [Patent PCT/FR94/ 01272, 9401272]
   Babizhayev M.A., 1993, Italian Patent, Patent No. [A61K gruppo 37/00 20122 MI, 370020122]
   Babizhayev M.A., 1994, Patent No. [Patent PCT/FR94/00189, 9400189]
   Babizhayev M.A., 1994, WO, Patent No. [94/19325, 9419325]
   Babizhayev M.A., 1999, US Patent No, Patent No. [6,007,203, 6007203]
   BABIZHAYEV MA, 1989, BIOCHIM BIOPHYS ACTA, V1004, P363, DOI 10.1016/0005-2760(89)90085-4
   Babizhayev MA, 1996, BBA-MOL BASIS DIS, V1315, P87, DOI 10.1016/0925-4439(95)00091-7
   BABIZHAYEV MA, 1994, BBA-MOL BASIS DIS, V1225, P326, DOI 10.1016/0925-4439(94)90014-0
   Babizhayev MA, 1996, CLIN CHIM ACTA, V254, P1, DOI 10.1016/0009-8981(96)06356-5
   BABIZHAYEV MA, 1989, BIOCHIM BIOPHYS ACTA, V1004, P124, DOI 10.1016/0005-2760(89)90222-1
   BABIZHAYEV MA, 1988, MECH AGEING DEV, V44, P69, DOI 10.1016/0047-6374(88)90080-2
   Babizhayev MA, 2000, BIOCHEMISTRY-MOSCOW+, V65, P588
   Babizhayev MA, 2004, REJUV RES, V7, P186, DOI 10.1089/rej.2004.7.186
   Babizhayev MA, 2003, OPHTHALMIC RES, V35, P19, DOI 10.1159/000068199
   Babizhayev MA, 2001, PEPTIDES, V22, P979, DOI 10.1016/S0196-9781(01)00407-7
   Babizhayev MA, 1998, LETT PEPT SCI, V5, P163, DOI 10.1007/BF02443462
   BABIZHAYEV MA, 1994, BIOCHEM J, V304, P509, DOI 10.1042/bj3040509
   Babizhayev MA, 2000, J ANTI-AGING MED, V3, P43, DOI 10.1089/rej.1.2000.3.43
   BABIZHAYEV MA, 2006, J PHARM TOXICOL, V1, P201
   BABIZHAYEV MA, 2004, Patent No. 2004000351
   BABIZHAYEV MA, 2004, Patent No. 2004028536
   Babizhayev MA, 2004, Patent No. [2004064866, WO 2004/064866 PCT/JP2004/000351]
   Babizhayev MA, 2006, CURR DRUG THER, V1, P91, DOI 10.2174/157488506775268425
   Babizhayev MA, 2008, DRUG DEV IND PHARM, V34, P1071, DOI [10.1080/03639040801958413, 10.1080/03639040801958413 ]
   Babizhayev Mark A, 2004, Drugs R D, V5, P125, DOI 10.2165/00126839-200405030-00001
   Babizhayev Mark A, 2003, Clin Exp Optom, V86, P157
   Babizhayev Mark A, 2002, Drugs R D, V3, P87, DOI 10.2165/00126839-200203020-00004
   Babizhayev Mark A, 2010, Recent Pat Drug Deliv Formul, V4, P198
   BOLDYREV AA, 1987, BIOCHEM INT, V15, P1105
   BOLDYREV AA, 1990, ADV ENZYME REGUL, V30, P175
   Brownson C, 2000, FREE RADICAL BIO MED, V28, P1564, DOI 10.1016/S0891-5849(00)00270-7
   CARNEGIE PR, 1983, J CHROMATOGR, V261, P153, DOI 10.1016/S0021-9673(01)87933-4
   CRUSH KG, 1970, COMP BIOCHEM PHYSIOL, V34, P3, DOI 10.1016/0010-406X(70)90049-6
   FERRIS FL, 1982, AM J OPHTHALMOL, V94, P97, DOI 10.1016/0002-9394(82)90198-2
   FERRIS FL, 1982, AM J OPHTHALMOL, V94, P91, DOI 10.1016/0002-9394(82)90197-0
   FLANCBAUM L, 1990, LIFE SCI, V47, P1587, DOI 10.1016/0024-3205(90)90188-W
   GREENE SM, 1984, EUR J PHARMACOL, V99, P79, DOI 10.1016/0014-2999(84)90434-5
   Guiotto A, 2007, BIOORGAN MED CHEM, V15, P6158, DOI 10.1016/j.bmc.2007.06.029
   Gulewitsch W, 1900, BER DTSCH CHEM GES, V33, P1902, DOI 10.1002/cber.19000330275
   Ha JW, 2010, RAPID COMMUN MASS SP, V24, P2900, DOI 10.1002/rcm.4720
   Hipkiss AR, 1998, BBA-GEN SUBJECTS, V1380, P46, DOI 10.1016/S0304-4165(97)00123-2
   Hipkiss AR, 2005, MECH AGEING DEV, V126, P1034, DOI 10.1016/j.mad.2005.05.002
   HIPKISS AR, 1995, FEBS LETT, V371, P81, DOI 10.1016/0014-5793(95)00849-5
   Hipkiss AR, 2002, ANN NY ACAD SCI, V959, P285, DOI 10.1111/j.1749-6632.2002.tb02100.x
   HIPKISS AR, 1994, BIOCHEM SOC T, V22, pS399, DOI 10.1042/bst022399s
   Hipkiss AR, 1997, NEUROSCI LETT, V238, P135, DOI 10.1016/S0304-3940(97)00873-2
   Hipkiss AR, 1998, BIOCHEM BIOPH RES CO, V248, P28, DOI 10.1006/bbrc.1998.8806
   Hobart LJ, 2004, LIFE SCI, V75, P1379, DOI 10.1016/j.lfs.2004.05.002
   JAY JL, 1990, J PHYSL, V420, P155
   Kang JH, 2002, BBA-GEN SUBJECTS, V1570, P89, DOI 10.1016/S0304-4165(02)00158-7
   KUPFER C, 1994, PRINCIPLES PRACTICE, P1249
   MARGOLIS FL, 1974, SCIENCE, V184, P909, DOI 10.1126/science.184.4139.909
   Muranov K O, 2008, Vestn Oftalmol, V124, P3
   ODOWD JJ, 1988, BIOCHIM BIOPHYS ACTA, V967, P241, DOI 10.1016/0304-4165(88)90015-3
   Owsley C, 2001, ARCH OPHTHALMOL-CHIC, V119, P881
   Price DL, 2001, J BIOL CHEM, V276, P48967, DOI 10.1074/jbc.M108196200
   Seidler NW, 2004, ARCH BIOCHEM BIOPHYS, V427, P110, DOI 10.1016/j.abb.2004.04.024
   Szwergold BS, 2005, BIOCHEM BIOPH RES CO, V336, P36, DOI 10.1016/j.bbrc.2005.08.033
   Tianyang Z., 2010, J OCUL PHARM TH 0119
   Ukeda H, 2002, BIOSCI BIOTECH BIOCH, V66, P36, DOI 10.1271/bbb.66.36
   Yamagishi S, 2005, CURR DIABETES REV, V1, P93, DOI 10.2174/1573399052952631
   Zhou SY, 1999, J AGR FOOD CHEM, V47, P51, DOI 10.1021/jf980780j
NR 71
TC 5
Z9 7
U1 1
U2 37
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1942-7603
J9 DRUG TEST ANAL
JI Drug Test. Anal.
PD JUN
PY 2012
VL 4
IS 6
BP 468
EP 485
DI 10.1002/dta.265
PG 18
WC Biochemical Research Methods; Chemistry, Analytical; Pharmacology &
   Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry; Pharmacology & Pharmacy
GA 965UF
UT WOS:000305792100012
PM 21416634
DA 2022-11-30
ER

PT J
AU Miao, H
   Tao, Y
   Li, XX
AF Miao, Heng
   Tao, Yong
   Li, Xiao-xin
TI Inflammatory cytokines in aqueous humor of patients with choroidal
   neovascularization
SO MOLECULAR VISION
LA English
DT Article
ID ANTI-VEGF THERAPY; MACULAR DEGENERATION; BRUCHS MEMBRANE; VISION LOSS;
   RECEPTOR; DRUSEN; TRIAMCINOLONE; ACTIVATION; EDEMA; TRIAL
AB Objective: To investigate the correlations between aqueous concentrations of interleukin 1 beta, 6, 8, 10, 12p (IL-1 beta, IL-6, IL-8, IL-10, IL-12p), and tumor necrosis factor alpha (TNF-alpha) and the parameters of macular edema acquired by optical coherence tomography (OCT) in patients with choroidal neovascularization.
   Methods: IL-1 beta, IL-6, IL-8, IL-10, IL-12p, and TNF-alpha in the aqueous humor samples of 17 patients with exudative age-related macular degeneration (AMD), ten patients with pathological myopia (PM), seven patients with idiopathic choroidal neovascularization (CNV), and 14 patients with cataract and idiopathic epiretinal membrane or macular hole in the control group were measured with cytometric bead array. The maximum macular thickness and macular volume within 1 mm, 3 mm, and 6 mm were measured with OCT.
   Results: In the CNV groups, the aqueous levels of IL-6 and IL-8 were significantly associated with macular volume within 6 mm (p=0.011, p=0.008, respectively), while IL-1 beta, IL-10, IL-12p, and TNF-alpha showed no significant correlation with either the maximum macular thickness or the macular volume. By further selecting patients with CNV who had accepted their last intravitreal injection of bevacizumab within 3 months, the level of IL-6 still significantly correlated with the maximum macular thickness (p=0.019) and macular volume within 1 mm (p=0.018), 3 mm (p=0.018), and 6 mm (p=0.022). In patients with exudative AMD, the level of IL-6 was significantly associated with the maximum macular thickness (p=0.025) and macular volume within 1 mm (p=0.025), 3 mm (p=0.006), and 6 mm (p=0.002). The aqueous level of all cytokines did not vary significantly between the CNV patients who had accepted their last intravitreal injection of bevacizumab within 3 months and the other patients, nor was a difference found among patients with exudative AMD, PM, and idiopathic CNV, and the control group.
   Conclusions: Intraocular concentrations of IL-6 and IL-8 (particularly IL-6) are significantly associated with the volume of macular edema in patients with CNV. However, intravitreal injection of antivascular endothelial growth factor drugs did not change the intraocular level of these inflammation cytokines.
C1 [Miao, Heng; Tao, Yong; Li, Xiao-xin] Peking Univ, Peoples Hosp, Dept Ophthalmol, Beijing 100044, Peoples R China.
   [Miao, Heng; Tao, Yong; Li, Xiao-xin] Minist Educ, Key Lab Vis Loss & Restorat, Beijing, Peoples R China.
C3 Peking University
RP Li, XX (通讯作者)，Peking Univ, Peoples Hosp, Dept Ophthalmol, 11 Xizhimen S St, Beijing 100044, Peoples R China.
EM dr_lixiaoxin@163.com
OI Tao, Yong/0000-0003-1443-2667
FU National Basic Research Program of China (973 Program) [2011CB510200];
   National Natural Science Foundation of China [30901639]; EFSD/CDS/Lilly
   [90561]; Beijing Novel Program [2009B04]
FX Dr. Yong Tao (drtaoyong@163.com) and Dr. Xiao-xin Li contributed equally
   to the conduct of this research and are to be considered
   co-corresponding authors. This study was supported by National Basic
   Research Program of China (973 Program, No: 2011CB510200), National
   Natural Science Foundation of China (No: 30901639), an EFSD/CDS/Lilly
   grant (No: 90561) and Beijing Novel Program (No: 2009B04).
CR Aiello LP, 1997, DIABETES, V46, P1473, DOI 10.2337/diabetes.46.9.1473
   Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   Asato R, 2011, BRIT J OPHTHALMOL, V95, P1745, DOI 10.1136/bjophthalmol-2011-300139
   Chang TS, 2007, ARCH OPHTHALMOL-CHIC, V125, P1460, DOI 10.1001/archopht.125.11.1460
   Colquitt JL, 2008, HEALTH TECHNOL ASSES, V12, P1
   DASTGHEIB K, 1994, ARCH OPHTHALMOL-CHIC, V112, P813, DOI 10.1001/archopht.1994.01090180111045
   Ehlken C, 2011, AM J OPHTHALMOL, V152, P298, DOI 10.1016/j.ajo.2011.01.040
   Goverdhan SV, 2008, BRIT J OPHTHALMOL, V92, P537, DOI 10.1136/bjo.2007.123190
   Green W R, 1977, Trans Am Ophthalmol Soc, V75, P180
   GRINDLE CFJ, 1978, T OPHTHAL SOC UK, V98, P172
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Heimes B, 2011, OPHTHALMOLOGE, V108, P124, DOI 10.1007/s00347-010-2210-z
   Higgins GT, 2003, INVEST OPHTH VIS SCI, V44, P1775, DOI 10.1167/iovs.02-0742
   Izumi-Nagai K, 2007, AM J PATHOL, V170, P2149, DOI 10.2353/ajpath.2007.061018
   Johnson LV, 2001, EXP EYE RES, V73, P887, DOI 10.1006/exer.2001.1094
   Jonas JB, 2003, ARCH OPHTHALMOL-CHIC, V121, P57
   Jones LL, 2011, IMMUNOL RES, V51, P5, DOI 10.1007/s12026-011-8209-y
   Kawashima M, 2007, JPN J OPHTHALMOL, V51, P100, DOI 10.1007/s10384-006-0411-4
   KILLINGSWORTH MC, 1990, EYE, V4, P613, DOI 10.1038/eye.1990.86
   Klein R, 1997, OPHTHALMOLOGY, V104, P7, DOI 10.1016/S0161-6420(97)30368-6
   Koh A, 2011, SINGAP MED J, V52, P232
   Krause ML, 2011, CLIN IMMUNOL, V141, P67, DOI 10.1016/j.clim.2011.05.008
   Massin P, 2004, OPHTHALMOLOGY, V111, P218, DOI 10.1016/j.ophtha.2003.05.037
   Miller DG, 2006, OPTOMETRY VISION SCI, V83, P316, DOI 10.1097/01.opx.0000216019.88256.eb
   Olson JL, 2007, ARCH OPHTHALMOL-CHIC, V125, P1221, DOI 10.1001/archopht.125.9.1221
   Ouhadj O, 2010, J FR OPHTALMOL, V33, P649, DOI 10.1016/j.jfo.2010.09.004
   PENFOLD PL, 1985, GRAEF ARCH CLIN EXP, V223, P69, DOI 10.1007/BF02150948
   Roh MI, 2009, RETINA-J RET VIT DIS, V29, P523, DOI 10.1097/IAE.0b013e318195cb15
   Shen Y, 2011, EXPERT REV RESP MED, V5, P107, DOI [10.1586/ers.10.80, 10.1586/ERS.10.80]
   Szarka A, 2010, BMC IMMUNOL, V11, DOI 10.1186/1471-2172-11-59
   Tanaka T, 2012, ANNU REV PHARMACOL, V52, P199, DOI 10.1146/annurev-pharmtox-010611-134715
   Voykov B, 2011, KLIN MONATSBL AUGENH, V228, P762, DOI 10.1055/s-0031-1281583
   Wolf S, 2011, BRIT J OPHTHALMOL, V95, P1713, DOI 10.1136/bjophthalmol-2011-300471
   Yan Hua, 2009, Zhonghua Yan Ke Za Zhi, V45, P206
   Yong T, 2011, OPHTHALMOLOGICA, V225, P1, DOI 10.1159/000317909
NR 35
TC 62
Z9 69
U1 0
U2 5
PU MOLECULAR VISION
PI ATLANTA
PA C/O JEFF BOATRIGHT, LAB B, 5500 EMORY EYE CENTER, 1327 CLIFTON RD, N E,
   ATLANTA, GA 30322 USA
SN 1090-0535
J9 MOL VIS
JI Mol. Vis.
PD MAR 2
PY 2012
VL 18
IS 60-65
BP 574
EP 580
PG 7
WC Biochemistry & Molecular Biology; Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Ophthalmology
GA 905JT
UT WOS:000301269200003
PM 22419849
DA 2022-11-30
ER

PT J
AU Wang, HB
   Hartnett, ME
AF Wang, Haibo
   Hartnett, M. Elizabeth
TI Regulation of signaling events involved in the pathophysiology of
   neovascular AMD
SO MOLECULAR VISION
LA English
DT Article
ID RETINAL-PIGMENT EPITHELIUM; COHERENCE TOMOGRAPHY ANGIOGRAPHY; CHOROIDAL
   ENDOTHELIAL-CELLS; MACULAR DEGENERATION; NADPH OXIDASE; BRUCHS MEMBRANE;
   RETICULAR PSEUDODRUSEN; GEOGRAPHIC ATROPHY; NLRP3 INFLAMMASOME;
   OXIDATIVE STRESS
AB Neovascular age-related macular degeneration (AMD) is a complex disease in which an individual's genetic predisposition is affected by aging and environmental stresses, which trigger signaling pathways involving inflammation, oxidation, and/or angiogenesis in the RPE cells and choroidal endothelial cells (CECs), to lead to vision loss from choroidal neovascularization. Antiangiogenic therapies have greatly improved clinical outcomes in the last decade; however, vision improves in less than half of patients treated for neovascular AMD, and treatments remain inadequate for atrophic AMD. Many studies focus on genetic predisposition or the association of outcomes in trials of human neovascular AMD but are unable to evaluate the effects between different cell types involved in AMD and the signaling events that take place to cause pathologic biologic events. This manuscript complements other reviews in that it describes what is known generally in human AMD studies and clinical trials testing methods to inhibit vascular endothelial growth factor (VEGF inhibitors) and presents pathologic signaling events that develop in two important cell types, the RPE cells and the CECs, when stimulated by stresses or placed into conditions similar to what is currently understood to occur in neovascular AMD. This manuscript complements other reviews by discussing signaling events that are activated by cell-cell or cell-matrix interactions. These considerations are particularly important when considering growth factors, such as VEGF, which are important in physiologic and pathologic processes, or GTPases that are present but active only if GTP bound. In either case, it is essential to understand the role of signaling activation to distinguish what is pathologic from what is physiologic. Particularly important is the essential role of activated Rac1 in CEC transmigration of the RPE monolayer, an important step in blindness associated with neovascular AMD. Other concepts discussed include the importance of feed-forward loops that overwhelm mechanisms that seek to restore homeostasis in cells and the importance of regulating, instead of abolishing, signaling events in a chronic, complex disease, such as neovascular AMD. These concepts are important as we move to the next stages in developing treatments for neovascular AMD. A novel therapeutic strategy that will be discussed is activating an isoform of the GTPase, Rap1, which can regulate downstream signaling and a pathologic feed-forward loop leading to Rac1 activation and migration of CECs.
C1 [Wang, Haibo; Hartnett, M. Elizabeth] Univ Utah, John A Moran Eye Ctr, Salt Lake City, UT USA.
C3 Utah System of Higher Education; University of Utah
RP Hartnett, ME (通讯作者)，65 N Mario Capecchi Dr, Salt Lake City, UT 84132 USA.
EM ME.Hartnett@hsc.utah.edu
FU National Institutes of Health [P30EY014800, R01EY015130, R01EY017011];
   March of Dimes [6-FY13-75]; Research to Prevent Blindness, Inc., New
   York, NY; NATIONAL EYE INSTITUTE [R01EY015130, R01EY017011, P30EY014800]
   Funding Source: NIH RePORTER
FX This work was supported by the National Institutes of Health
   P30EY014800, R01EY015130, and R01EY017011 to M.E.H., a grant from the
   March of Dimes 6-FY13-75 to M.E.H, and an Unrestricted Grant from
   Research to Prevent Blindness, Inc., New York, NY, to the Department of
   Ophthalmology & Visual Sciences, University of Utah. Elsevier to use
   parts of Figure 18 from Prog Retin Eye Res. 2008 Jul;27(4):331-71,
   namely the OCT images used in Figure 1B, D.
CR Amaral J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056099
   Ambati J, 2011, INVEST OPHTH VIS SCI, V52, P2166, DOI 10.1167/iovs.11-7328
   ARNOLD JJ, 1995, RETINA-J RET VIT DIS, V15, P183, DOI 10.1097/00006982-199515030-00001
   Bhisitkul RB, 2015, AM J OPHTHALMOL, V159, P915, DOI 10.1016/j.ajo.2015.01.032
   Bhutto I, 2012, MOL ASPECTS MED, V33, P295, DOI 10.1016/j.mam.2012.04.005
   Bid HK, 2013, MOL CANCER THER, V12, P1925, DOI 10.1158/1535-7163.MCT-13-0164
   Bird AC, 2010, J CLIN INVEST, V120, P3033, DOI 10.1172/JCI42437
   Blaauwgeers HGT, 1999, AM J PATHOL, V155, P421, DOI 10.1016/S0002-9440(10)65138-3
   Blasiak J, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/768026
   Cai X, 2012, FRONT BIOSCI-LANDMRK, V17, P1976, DOI 10.2741/4033
   Chakravarthy U, 2015, HEALTH TECHNOL ASSES, V19, P1, DOI 10.3310/hta19780
   Chen Y, 2014, INVEST OPHTH VIS SCI, V55, DOI 10.1167/iovs.14-15029
   Chew EY, 2013, JAMA-J AM MED ASSOC, V309, P2005, DOI 10.1001/jama.2013.4997
   Cho HJ, 2015, AM J OPHTHALMOL, V159, P285, DOI 10.1016/j.ajo.2014.10.035
   Choi W, 2015, OPHTHALMOLOGY, V122, P2532, DOI 10.1016/j.ophtha.2015.08.029
   Chrzanowska-Wodnicka M, 2008, BLOOD, V111, P2647, DOI 10.1182/blood-2007-08-109710
   Coscas GJ, 2015, RETINA-J RET VIT DIS, V35, P2219, DOI 10.1097/IAE.0000000000000766
   Crabb JW, 2002, P NATL ACAD SCI USA
   Curcio CA, 2001, INVEST OPHTH VIS SCI, V42, P265
   Dansingani K, 2015, RETINA
   Dias JRD, 2011, BRIT J OPHTHALMOL, V95, P1631, DOI 10.1136/bjo.2010.186361
   Edwards MM, 2015, EXP EYE RES
   Espinosa-Heidmann DG, 2006, INVEST OPHTH VIS SCI, V47, P729, DOI 10.1167/iovs.05-0719
   Fei P, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0116423
   Fliesler SJ, 2015, J LIPID RES, V56, P1, DOI 10.1194/jlr.C056358
   Ford KM, 2011, INVEST OPHTH VIS SCI, V52, P9478, DOI 10.1167/iovs.11-8353
   Fritsche LG, 2014, ANNU REV GENOM HUM G, V15, P151, DOI 10.1146/annurev-genom-090413-025610
   Fujihara M, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003119
   Garrett TA, 2007, EXP CELL RES, V313, P3285, DOI 10.1016/j.yexcr.2007.05.027
   Gehrs KM, 2006, ANN MED, V38, P450, DOI 10.1080/07853890600946724
   Geisen P, 2006, EXP EYE RES, V82, P608, DOI 10.1016/j.exer.2005.08.021
   Gelfand BD, 2015, CELL REP, V11, P1686, DOI 10.1016/j.celrep.2015.05.023
   Geltzer A, 2013, COCHRANE DB SYST REV, V1
   Giehl K, 2008, AM J PHYSIOL-RENAL, V294, pF407, DOI 10.1152/ajprenal.00093.2007
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Green W R, 1977, Trans Am Ophthalmol Soc, V75, P180
   GREEN WR, 1993, OPHTHALMOLOGY, V100, P1519
   Grossniklaus HE, 1998, AM J OPHTHALMOL, V126, P59, DOI 10.1016/S0002-9394(98)00145-7
   Grossniklaus HE, 2004, AM J OPHTHALMOL, V137, P496, DOI 10.1016/j.ajo.2003.09.042
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Handa JT, 1999, INVEST OPHTH VIS SCI, V40, P775
   HARTNETT ME, 1992, GRAEF ARCH CLIN EXP, V230, P11, DOI 10.1007/BF00166756
   Hartnett ME, 1996, OPHTHALMOLOGY, V103, P58, DOI 10.1016/S0161-6420(96)30731-8
   Hartnett ME, 1996, OPHTHALMOLOGY, V103, P2042, DOI 10.1016/S0161-6420(96)30389-8
   HENKIND P, 1983, T OPHTHAL SOC UK, V103, P444
   Hirschi KK, 1997, TRANSPL IMMUNOL, V5, P177, DOI 10.1016/S0966-3274(97)80034-2
   Hirschi KK, 1999, CIRC RES, V84, P298, DOI 10.1161/01.RES.84.3.298
   Hu Y, 2013, INVEST OPHTH VIS SCI, V54, P141, DOI 10.1167/iovs.12-10281
   Ildefonso CJ, 2016, ADV EXP MED BIOL, V854, P59, DOI 10.1007/978-3-319-17121-0_9
   Indaram M, 2015, SCI REP-UK, V5, DOI 10.1038/srep09144
   Jaffe GJ, 2016, OPHTHALMOLOGY, V123, P78, DOI 10.1016/j.ophtha.2015.09.004
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Klettner Alexa, 2012, Front Biosci (Schol Ed), V4, P392
   KORTE GE, 1984, INVEST OPHTH VIS SCI, V25, P1135
   Kuehlewein L, 2015, RETINA-J RET VIT DIS, V35, P2229, DOI 10.1097/IAE.0000000000000835
   Lin CH, 2013, BRIT J PHARMACOL, V168, P920, DOI 10.1111/j.1476-5381.2012.02227.x
   Lukason M, 2011, MOL THER, V19, P260, DOI 10.1038/mt.2010.230
   Maharaj ASR, 2006, AM J PATHOL, V168, P639, DOI 10.2353/ajpath.2006.050834
   Marneros AG, 2016, ADV EXP MED BIOL, V854, P79, DOI 10.1007/978-3-319-17121-0_12
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   McLeod DS, 2009, INVEST OPHTH VIS SCI, V50, P4982, DOI 10.1167/iovs.09-3639
   Mitter SK, 2014, AUTOPHAGY, V10, P1989, DOI 10.4161/auto.36184
   Monaghan-Benson E, 2010, AM J PATHOL, V177, P2091, DOI 10.2353/ajpath.2010.090878
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   Nussenblatt RB, 2007, AM J OPHTHALMOL, V144, P618, DOI 10.1016/j.ajo.2007.06.025
   Parravano M, 2012, EUR J OPHTHALMOL, V22, P598, DOI 10.5301/ejo.5000087
   Peterson LJ, 2007, EXP EYE RES, V84, P737, DOI 10.1016/j.exer.2006.12.012
   POLINER LS, 1986, OPHTHALMOLOGY, V93, P543
   Poltorak Z, 1997, J BIOL CHEM, V272, P7151, DOI 10.1074/jbc.272.11.7151
   Radeke MJ, 2015, GENOME MED, V7, DOI 10.1186/s13073-015-0183-x
   Ramkumar HL, 2010, PROG RETIN EYE RES, V29, P169, DOI 10.1016/j.preteyeres.2010.02.002
   RODRIGUES MM, 1986, CAN J OPHTHALMOL, V21, P79
   Rodriguez IR, 2014, EXP EYE RES, V128, P151, DOI 10.1016/j.exer.2014.09.009
   Rodriguez IR, 2010, J LIPID RES, V51, P2847, DOI 10.1194/jlr.R004820
   Rudnicka AR, 2012, OPHTHALMOLOGY, V119, P571, DOI 10.1016/j.ophtha.2011.09.027
   Saint-Geniez M, 2006, INVEST OPHTH VIS SCI, V47, P3135, DOI 10.1167/iovs.05-1229
   Saint-Geniez M, 2009, P NATL ACAD SCI USA, V106, P18751, DOI 10.1073/pnas.0905010106
   Saint-Geniez M, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003554
   Sakurai E, 2003, INVEST OPHTH VIS SCI, V44, P3578, DOI 10.1167/iovs.03-0097
   Scott AW, 2013, CURR OPIN OPHTHALMOL, V24, P190, DOI 10.1097/ICU.0b013e32835fefee
   Seddon JM, 1996, JAMA-J AM MED ASSOC, V276, P1141, DOI 10.1001/jama.276.14.1141
   SEDDON JM, 1994, JAMA-J AM MED ASSOC, V272, P1413, DOI 10.1001/jama.272.18.1413
   Seddon JM, 2015, INVEST OPHTH VIS SCI, V56, P2192, DOI 10.1167/iovs.14-15841
   SINGERMAN LJ, 1989, GRAEF ARCH CLIN EXP, V227, P501, DOI 10.1007/BF02169440
   Singh RSJ, 2012, DRUG AGING, V29, P949, DOI 10.1007/s40266-012-0031-2
   Sobrin L, 2014, PROG RETIN EYE RES, V40, P1, DOI 10.1016/j.preteyeres.2013.12.004
   Sohn EH, 2014, INVEST OPHTH VIS SCI, V55, P1352, DOI 10.1167/iovs.13-13754
   Spaide RF, 2003, RETINA-J RET VIT DIS, V23, P595, DOI 10.1097/00006982-200310000-00001
   Sparrow JR, 2012, MOL ASPECTS MED, V33, P436, DOI 10.1016/j.mam.2012.03.007
   STERNBERG P, 1991, ARCH OPHTHALMOL-CHIC, V109, P1242
   Stevens TS, 1997, ARCH OPHTHALMOL-CHIC, V115, P345, DOI 10.1001/archopht.1997.01100150347006
   Sunness JS, 1999, OPHTHALMOLOGY, V106, P910, DOI 10.1016/S0161-6420(99)00509-6
   Takeda A, 2009, NATURE, V460, P225, DOI 10.1038/nature08151
   Terasaki H, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069994
   Toomey CB, 2015, P NATL ACAD SCI USA, V112, pE3040, DOI 10.1073/pnas.1424391112
   Tuo JS, 2015, J TRANSL MED, V13, DOI 10.1186/s12967-015-0683-x
   Ueda-Arakawa N, 2013, AM J OPHTHALMOL, V155, P260, DOI 10.1016/j.ajo.2012.08.011
   Ushio-Fukai M, 2004, MOL CELL BIOCHEM, V264, P85, DOI 10.1023/B:MCBI.0000044378.09409.b5
   Ushio-Fukai M, 2007, ANTIOXID REDOX SIGN, V9, P731, DOI 10.1089/ars.2007.1556
   Wang HB, 2015, AM J PATHOL, V185, P3316, DOI 10.1016/j.ajpath.2015.08.017
   Wang HB, 2014, FASEB J, V28, P265, DOI 10.1096/fj.13-240028
   Wang HB, 2011, INVEST OPHTH VIS SCI, V52, P8271, DOI 10.1167/iovs.11-8230
   Wang H, 2011, INVEST OPHTH VIS SCI, V52, P570, DOI 10.1167/iovs.10-5595
   Wilson CW, 2014, CELL ADHES MIGR, V8, P76, DOI 10.4161/cam.28115
   Wittchen ES, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0073070
   Wittchen Erika S, 2011, Small GTPases, V2, P65
   Wykoff CC, 2015, OPHTHALMOLOGY, V122, P2514, DOI 10.1016/j.ophtha.2015.08.009
   Xu HP, 2009, PROG RETIN EYE RES, V28, P348, DOI 10.1016/j.preteyeres.2009.06.001
   Yannuzzi LA, 2001, RETINA-J RET VIT DIS, V21, P416, DOI 10.1097/00006982-200110000-00003
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
   Ying GS, 2013, OPHTHALMOLOGY, V120, P122, DOI 10.1016/j.ophtha.2012.07.042
   Young M, 2014, RETINA-J RET VIT DIS, V34, P1308, DOI 10.1097/IAE.0000000000000081
   Zhang SX, 2015, PROG RETIN EYE RES, V45, P111, DOI 10.1016/j.preteyeres.2014.12.001
   Zhou T, 2010, INVEST OPHTH VIS SCI, V51, P4371, DOI 10.1167/iovs.09-4278
NR 115
TC 55
Z9 56
U1 0
U2 4
PU MOLECULAR VISION
PI ATLANTA
PA C/O JEFF BOATRIGHT, LAB B, 5500 EMORY EYE CENTER, 1327 CLIFTON RD, N E,
   ATLANTA, GA 30322 USA
SN 1090-0535
J9 MOL VIS
JI Mol. Vis.
PD FEB 27
PY 2016
VL 22
BP 189
EP 202
PG 14
WC Biochemistry & Molecular Biology; Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Ophthalmology
GA DF4JE
UT WOS:000371313000001
PM 27013848
DA 2022-11-30
ER

PT J
AU Kuper, H
   Mathenge, W
   Macleod, D
   Foster, A
   Gichangi, M
   Rono, H
   Wing, K
   Weiss, HA
   Bastawrous, A
   Burton, M
AF Kuper, Hannah
   Mathenge, Wanjiku
   Macleod, David
   Foster, Allen
   Gichangi, Michael
   Rono, Hillary
   Wing, Kevin
   Weiss, Helen Anne
   Bastawrous, Andrew
   Burton, Matthew
TI Mortality during 6 years of follow-up in relation to visual impairment
   and eye disease: results from a population-based cohort study of people
   aged 50 years and above in Nakuru, Kenya
SO BMJ OPEN
LA English
DT Article
ID OPEN-ANGLE GLAUCOMA; QUALITY-OF-LIFE; MACULAR DEGENERATION; VISION
   IMPAIRMENT; LENS OPACITIES; OLDER-PEOPLE; CATARACT; ASSOCIATION; RISK;
   SURVIVAL
AB Objective To estimate the association between (1) visual impairment (VI) and (2) eye disease and 6-year mortality risk within a cohort of elderly Kenyan people. Design, setting and participants The baseline of the Nakuru Posterior Segment Eye Disease Study was formed from a population-based survey of 4318 participants aged = 50 years, enrolled in 2007-2008. Ophthalmic and anthropometric examinations were undertaken on all participants at baseline, and a questionnaire was administered, including medical and ophthalmic history. Participants were retraced in 2013-2014 for a second examination. Vital status was recorded for all participants through information from community members. Cumulative incidence of mortality, and its relationship with baseline VI and types of eye disease was estimated. Inverse probability weighting was used to adjust for nonparticipation. Primary outcome measures Cumulative incidence of mortality in relation to VI level at baseline. Results Of the baseline sample, 2170 (50%) were re-examined at follow-up and 407 (10%) were known to have died (adjusted risk of 11.9% over 6 years). Compared to those with normal vision (visual acuity (VA) = 6/12, risk= 9.7%), the 6-year mortality risk was higher among people with VI (< 6/18 to = 6/60; risk= 28.3%; risk ratio (RR) 1.75, 95% CI 1.28 to 2.40) or severe VI (SVI)/ blindness (< 6/60; risk= 34.9%; RR 1.98, 95% CI 1.04 to 3.80). These associations remained after adjustment for non-communicable disease (NCD) risk factors (mortality: RR 1.56, 95% CI 1.14 to 2.15; SVI/blind: RR 1.46, 95% CI 0.80 to 2.68). Mortality risk was also associated with presence of diabetic retinopathy at baseline (RR 3.18, 95% CI 1.98 to 5.09), cataract (RR 1.26, 95% CI 0.95 to 1.66) and presence of both cataract and VI (RR 1.57, 95% CI 1.24 to 1.98). Mortality risk was higher among people with age-related macular degeneration at baseline (with or without VI), compared with those without (RR 1.42, 95% CI 0.91 to 2.22 and RR 1.34, 95% CI 0.99 to 1.81, respectively). Conclusions Visual acuity was related to 6-year mortality risk in this cohort of elderly Kenyan people, potentially because both VI and mortality are related to ageing and risk factors for NCD.
C1 [Kuper, Hannah; Foster, Allen; Rono, Hillary; Bastawrous, Andrew; Burton, Matthew] London Sch Hyg & Trop Med, Int Ctr Eye Hlth, Clin Res Dept, London, England.
   [Kuper, Hannah; Foster, Allen] London Sch Hyg & Trop Med, Int Ctr Evidence Disabil, Clin Res Dept, London, England.
   [Mathenge, Wanjiku] Rwanda Int Inst Ophthalmol, Kigali, Rwanda.
   [Mathenge, Wanjiku] Dr Agarwals Eye Hosp, Kigali, Rwanda.
   [Macleod, David; Weiss, Helen Anne] London Sch Hyg Trop Med, Dept Infect Dis Epidemiol, MRC Trop Epidemiol Grp, London, England.
   [Gichangi, Michael] Minist Hlth, Nairobi, Kenya.
   [Rono, Hillary] Minist Hlth Trans Nzoia Cty, Kitale Eye Unit, Kitale, Kenya.
   [Wing, Kevin] London Sch Hyg Trop Med, Dept Noncommunicable Dis Epidemiol, London, England.
C3 University of London; London School of Hygiene & Tropical Medicine;
   University of London; London School of Hygiene & Tropical Medicine;
   University of London; London School of Hygiene & Tropical Medicine;
   University of London; London School of Hygiene & Tropical Medicine
RP Kuper, H (通讯作者)，London Sch Hyg & Trop Med, Int Ctr Eye Hlth, Clin Res Dept, London, England.; Kuper, H (通讯作者)，London Sch Hyg & Trop Med, Int Ctr Evidence Disabil, Clin Res Dept, London, England.
EM hannah.kuper@lshtm.ac.uk
RI weiss, helen/ABC-7823-2021; MATHENGE, WANJIKU/W-3993-2019; Wing,
   Kevin/I-7807-2015
OI weiss, helen/0000-0003-3547-7936; Macleod, David/0000-0002-2371-5709;
   Wing, Kevin/0000-0003-2335-9641; Rono, Hillary/0000-0002-9843-4186;
   Foster, Allen/0000-0003-2368-4436; Burton, Matthew/0000-0003-1872-9169
FU Medical Research Council [G1001934, G0700837]; Fight for Sight [1310];
   British Council for the Prevention of Blindness; International Glaucoma
   Association; Wellcome Trust [098481/Z/12/Z]; Department for
   International Development; MRC [G1001934, MR/R010161/1, G0700837]
   Funding Source: UKRI
FX This study was supported by grant G1001934 from the Medical Research
   Council, grant 1310 from Fight for Sight, the British Council for the
   Prevention of Blindness, and the International Glaucoma Association (Dr
   Bastawrous). MB is supported by grant 098481/Z/12/Z from the Wellcome
   Trust. HAW is supported by grant G0700837 from the Medical Research
   Council and Department for International Development.
CR Agrawal Nilesh, 2011, Indian J Community Med, V36, P208, DOI 10.4103/0970-0218.86522
   Akbari M, 2009, ARCH OPHTHALMOL-CHIC, V127, P204, DOI 10.1001/archophthalmol.2008.571
   Banks LM, 2014, EC COSTS EXCLUSION G
   Bastawrous A, 2014, BMC OPHTHALMOL, V14, DOI 10.1186/1471-2415-14-60
   Boerma T, 2014, GLOBAL HEALTH ACTION, V7, DOI 10.3402/gha.v7.25931
   Borger PH, 2003, OPHTHALMOLOGY, V110, P1292, DOI 10.1016/S0161-6420(03)00450-0
   Bourne RRA, 2017, LANCET GLOB HEALTH, V5, pE888, DOI 10.1016/S2214-109X(17)30293-0
   Cimarolli VR, 2014, QUAL LIFE RES, V23, P1977, DOI 10.1007/s11136-014-0657-0
   Clemons TE, 2004, ARCH OPHTHALMOL-CHIC, V122, P716
   Cong RH, 2008, ANN EPIDEMIOL, V18, P647, DOI 10.1016/j.annepidem.2008.04.002
   Cugati S, 2007, ARCH OPHTHALMOL-CHIC, V125, P917, DOI 10.1001/archopht.125.7.917
   Fisher D, 2014, AGE AGEING, V43, P69, DOI 10.1093/ageing/aft122
   Fisher DE, 2015, OPHTHALMOLOGY, V122, P382, DOI 10.1016/j.ophtha.2014.08.006
   Foong AWP, 2008, OPHTHALMOLOGY, V115, P802, DOI 10.1016/j.ophtha.2007.04.066
   Freeman EE, 2005, INVEST OPHTH VIS SCI, V46, P4040, DOI 10.1167/iovs.05-0687
   Gopinath B, 2016, MATURITAS, V84, P63, DOI 10.1016/j.maturitas.2015.11.001
   Hennis A, 2001, OPHTHALMOLOGY, V108, P498, DOI 10.1016/S0161-6420(00)00542-X
   Karpa MJ, 2009, ARCH OPHTHALMOL-CHIC, V127, P1347, DOI 10.1001/archophthalmol.2009.240
   Khanna RC, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0078002
   KLEIN R, 1995, ARCH OPHTHALMOL-CHIC, V113, P333, DOI 10.1001/archopht.1995.01100030089026
   Knudtson MD, 2006, ARCH OPHTHALMOL-CHIC, V124, P243, DOI 10.1001/archopht.124.2.243
   Kuang TM, 2015, J CHIN MED ASSOC, V78, P177, DOI 10.1016/j.jcma.2014.11.006
   Kuper H, 2008, PLOS MED, V5, P1716, DOI 10.1371/journal.pmed.0050244
   Lam BL, 2006, ARCH OPHTHALMOL-CHIC, V124, P95, DOI 10.1001/archopht.124.1.95
   Lee AJ, 2006, OPHTHALMOLOGY, V113, P1069, DOI 10.1016/j.ophtha.2006.02.062
   Lee DJ, 2003, OPHTHALMOLOGY, V110, P1476, DOI 10.1016/S0161-6420(03)00408-1
   Li ZJ, 2011, OPHTHAL EPIDEMIOL, V18, P54, DOI 10.3109/09286586.2010.545503
   Liljas AEM, 2017, J EPIDEMIOL COMMUN H, V71, P1053, DOI 10.1136/jech-2017-209207
   Mathenge W, 2012, OPHTHALMOLOGY, V119, P2033, DOI 10.1016/j.ophtha.2012.04.019
   Mathenge W, 2010, BMC PUBLIC HEALTH, V10, DOI 10.1186/1471-2458-10-569
   MINASSIAN DC, 1992, B WORLD HEALTH ORGAN, V70, P219
   Mitoku K, 2016, BMC GERIATR, V16, DOI 10.1186/s12877-016-0286-2
   Ribeiro MVMR, 2015, ARQ BRAS OFTALMOL, V78, P197, DOI 10.5935/0004-2749.20150051
   Nucci C, 2004, GRAEF ARCH CLIN EXP, V242, P289, DOI 10.1007/s00417-003-0837-z
   Pathai S, 2013, MECH AGEING DEV, V134, P400, DOI 10.1016/j.mad.2013.08.002
   Pedula KL, 2015, J AM GERIATR SOC, V63, P910, DOI 10.1111/jgs.13405
   Polack S, 2008, BRIT J OPHTHALMOL, V92, P1026, DOI 10.1136/bjo.2007.134791
   Polack S, 2007, BRIT J OPHTHALMOL, V91, P927, DOI 10.1136/bjo.2006.110973
   Reidy A, 2002, BRIT J OPHTHALMOL, V86, P424, DOI 10.1136/bjo.86.4.424
   Seaman SR, 2013, STAT METHODS MED RES, V22, P278, DOI 10.1177/0962280210395740
   Siantar RG, 2015, SCI REP-UK, V5, DOI 10.1038/srep16304
   Song E, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0112054
   Thiagarajan M, 2005, ARCH OPHTHALMOL-CHIC, V123, P1397, DOI 10.1001/archopht.123.10.1397
   Turner AG, 1996, INT J EPIDEMIOL, V25, P198, DOI 10.1093/ije/25.1.198
   Wang JJ, 2001, ARCH OPHTHALMOL-CHIC, V119, P1186, DOI 10.1001/archopht.119.8.1186
   Williams SL, 2002, AM J EPIDEMIOL, V156, P127, DOI 10.1093/aje/kwf012
   Wong TY, 2007, OPHTHALMOLOGY, V114, P86, DOI 10.1016/j.ophtha.2006.06.039
   Zhu XR, 2017, MEDICINE, V96, DOI [10.1097/MD.0000000000005894, 10.1097/md.0000000000005894]
   2011, WORLD REP DIS, P1
NR 49
TC 8
Z9 9
U1 0
U2 0
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 2044-6055
J9 BMJ OPEN
JI BMJ Open
PD JUN
PY 2019
VL 9
IS 6
AR e029700
DI 10.1136/bmjopen-2019-029700
PG 10
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC General & Internal Medicine
GA IC7ZV
UT WOS:000471197000106
PM 31182456
OA Green Published, Green Accepted, gold
DA 2022-11-30
ER

PT J
AU Promsote, W
   Veeranan-Karmegam, R
   Ananth, S
   Shen, D
   Chan, CC
   Lambert, NA
   Ganapathy, V
   Martin, PM
AF Promsote, Wanwisa
   Veeranan-Karmegam, Rajalakshmi
   Ananth, Sudha
   Shen, Defen
   Chan, Chi-Chao
   Lambert, Nevin A.
   Ganapathy, Vadivel
   Martin, Pamela M.
TI L-2-oxothiazolidine-4-carboxylic acid attenuates oxidative stress and
   inflammation in retinal pigment epithelium
SO MOLECULAR VISION
LA English
DT Article
ID ENDOTHELIAL GROWTH-FACTOR; NF-KAPPA-B; MACULAR DEGENERATION; CYSTEINE
   PRODRUG; NICOTINIC-ACID; AQUEOUS-HUMOR; CELLS; EXPRESSION; GLUTATHIONE;
   RECEPTOR
AB Purpose: Oxidant-and inflammation-induced damage to retinal pigment epithelial (RPE) cells is central to the pathogenesis of age-related macular degeneration (AMD). Thus, developing novel strategies to protect these cells is important. We reported previously on the robust antioxidant and therefore cell-protective effects of the cysteine pro-drug L-2-oxothiazolidine-4-carboxylic acid (OTC) in cultured human RPE cells. New reports citing a novel anti-inflammatory role for OTC in addition to the known glutathione-stimulating and antioxidant properties emerged recently; however, this role has not been evaluated in RPE cells or in intact retina. Given the crucial causative roles of oxidative stress and inflammation in AMD pathogenesis, knowing whether OTC might exhibit a similar benefit in this cell and tissue type has high clinical relevance; thus, we evaluated OTC in the present study.
   Methods: ARPE-19 and primary RPE cells isolated from wild-type, Gpr109a(-/-), or Slc5a8(-/-) mouse eyes were exposed to TNF-alpha in the presence or absence of OTC, followed by analysis of IL-6 and Ccl2 expression with real-time quantitative polymerase chain reaction or enzyme-linked immunosorbent assay. Cellular and molecular markers of inflammation and oxidative stress (i.e., IL-1 beta, TGF-beta, ABCG1, ABCA1, reduced glutathione, and dihydroethidium) were evaluated in Ccl2(-/-)/Cx3cr1(-/-) double knockout mice on rd8 background (DKO rd8) treated with OTC (10 mg/ml) in drinking water for a period of 5 months.
   Results: OTC treatment significantly inhibited the expression and secretion of IL-6 and Ccl2 in TNF-alpha-stimulated ARPE-19 cells. Studies conducted using DKO rd8 animals treated with OTC in drinking water confirmed these findings. Cellular and molecular markers of inflammation were significantly suppressed in the retinas of the OTC-treated DKO rd8 animals. Subsequent in vitro and in vivo studies of the possible mechanism(s) to explain these actions revealed that although OTC is an agonist of the anti-inflammatory G-protein coupled receptor GPR109A and a transportable substrate of the sodium-coupled monocarboxylate transporter SMCT1 (SLC5A8), these properties may play a role but do not explain entirely the anti-inflammatory effects this compound elicits in cultured RPE cells and the intact mouse retina.
   Conclusions: This study represents, to our knowledge, the first report of the suppressive effects of OTC on inflammation in cultured RPE cells and on inflammation and oxidative stress in the retina in vivo.
C1 [Promsote, Wanwisa; Veeranan-Karmegam, Rajalakshmi; Ananth, Sudha; Ganapathy, Vadivel; Martin, Pamela M.] Georgia Regents Univ, Dept Biochem & Mol Biol, Augusta, GA 30912 USA.
   [Shen, Defen; Chan, Chi-Chao] NEI, Immunol Lab, NIH, Bethesda, MD 20892 USA.
   [Lambert, Nevin A.] Georgia Regents Univ, Dept Pharmacol & Toxicol, Augusta, GA 30912 USA.
   [Martin, Pamela M.] Dept Ophthalmol, Augusta, GA 30912 USA.
   [Martin, Pamela M.] Georgia Regents Univ, Augusta, GA 30912 USA.
   [Ganapathy, Vadivel; Martin, Pamela M.] Georgia Regents Univ, James & Jean Culver Vis Discovery Inst, Augusta, GA 30912 USA.
C3 University System of Georgia; Augusta University; National Institutes of
   Health (NIH) - USA; NIH National Eye Institute (NEI); University System
   of Georgia; Augusta University; University System of Georgia; Augusta
   University; University System of Georgia; Augusta University
RP Martin, PM (通讯作者)，Georgia Regents Univ, 1410 Laney Walker Blvd,CN-1160, Augusta, GA 30912 USA.
EM pmmartin@gru.edu
FU James and Jean Culver Vision Discovery Institute, Georgia Regents
   University, Augusta, GA; NATIONAL EYE INSTITUTE [R01EY022704,
   ZICEY000461, ZIAEY000222, ZIAEY000418] Funding Source: NIH RePORTER;
   NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM078319] Funding
   Source: NIH RePORTER
FX This work was supported by a Pilot Project Award from the James and Jean
   Culver Vision Discovery Institute, Georgia Regents University, Augusta,
   GA.
CR Adijanto J, 2012, CURR TOP MEMBR, V70, P275, DOI 10.1016/B978-0-12-394316-3.00009-0
   Ambati J, 2012, NEURON, V75, P26, DOI 10.1016/j.neuron.2012.06.018
   ANDERSON ME, 1989, FASEB J, V3, P1632, DOI 10.1096/fasebj.3.5.2920877
   Audet M, 2012, CELL, V151, P14, DOI 10.1016/j.cell.2012.09.003
   Babu E, 2011, INVEST OPHTH VIS SCI, V52, P5749, DOI 10.1167/iovs.10-6825
   Barditch-Crovo P, 1998, J CLIN PHARMACOL, V38, P357, DOI 10.1002/j.1552-4604.1998.tb04435.x
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Benyo Z, 2006, MOL PHARMACOL, V70, P1844, DOI 10.1124/mol.106.030833
   Bian QN, 2012, FREE RADICAL BIO MED, V53, P1298, DOI 10.1016/j.freeradbiomed.2012.06.024
   Bridges CC, 2002, CURR EYE RES, V24, P129, DOI 10.1076/ceyr.24.2.129.8167
   BRODEUR J, 1987, CAN J PHYSIOL PHARM, V65, P816, DOI 10.1139/y87-131
   Cai JY, 2000, PROG RETIN EYE RES, V19, P205, DOI 10.1016/S1350-9462(99)00009-9
   Cai X, 2012, FRONT BIOSCI-LANDMRK, V17, P1976, DOI 10.2741/4033
   Chu XK, 2013, BIOENGINEERED, V4, P130, DOI 10.4161/bioe.22949
   Colak E, 2012, AGING CLIN EXP RES, V24, P588, DOI 10.3275/8593
   Detrick B, 2010, IMMUNOL RES, V47, P153, DOI 10.1007/s12026-009-8146-1
   Ding XY, 2009, PROG RETIN EYE RES, V28, P1, DOI 10.1016/j.preteyeres.2008.10.001
   Evans JR, 2012, COCHRANE DB SYST REV, V11
   Fawcett JP, 1996, EXP NEPHROL, V4, P248
   Frank H, 2008, J BIOL CHEM, V283, P24729, DOI 10.1074/jbc.M802681200
   Gambhir D, 2012, INVEST OPHTH VIS SCI, V53, P2208, DOI 10.1167/iovs.11-8447
   Gamcsik M, 2011, NEUROCHEM RES, V36, P443, DOI 10.1007/s11064-010-0362-5
   Gaudana R, 2010, AAPS J, V12, P348, DOI 10.1208/s12248-010-9183-3
   Gnana-Prakasam JP, 2011, INVEST OPHTH VIS SCI, V52, P3751, DOI 10.1167/iovs.10-6722
   Hein TW, 2006, INVEST OPHTH VIS SCI, V47, P693, DOI 10.1167/iovs.05-1224
   Hollins B, 2009, CELL SIGNAL, V21, P1015, DOI 10.1016/j.cellsig.2009.02.017
   Holmes RP, 1997, J UROLOGY, V158, P34, DOI 10.1097/00005392-199707000-00008
   Jonas JB, 2012, ACTA OPHTHALMOL, V90, pe381, DOI 10.1111/j.1755-3768.2012.02414.x
   Jonas JB, 2010, ARCH OPHTHALMOL-CHIC, V128, P1281, DOI 10.1001/archophthalmol.2010.227
   Kauppinen A, 2012, IMMUNOL LETT, V147, P29, DOI 10.1016/j.imlet.2012.05.005
   Korybalska K, 2002, PERITON DIALYSIS INT, V22, P293
   Lakkaraju A, 2007, P NATL ACAD SCI USA, V104, P11026, DOI 10.1073/pnas.0702504104
   Lee JH, 2012, J DRUG DELIV, Vxxx
   Lee KS, 2005, MOL PHARMACOL, V68, P1281, DOI 10.1124/mol.105.016055
   Lee KS, 2006, MOL PHARMACOL, V70, P1184, DOI 10.1124/mol.106.024737
   Lee KS, 2006, EXP MOL MED, V38, P217, DOI 10.1038/emm.2006.27
   Li XY, 2010, BIOCHEM PHARMACOL, V80, P1450, DOI 10.1016/j.bcp.2010.07.023
   Martin PM, 2007, INVEST OPHTH VIS SCI, V48, P3356, DOI 10.1167/iovs.06-0888
   Martin PM, 2009, MOL VIS, V15, P362
   Mattapallil MJ, 2012, INVEST OPHTH VIS SCI, V53, P2921, DOI 10.1167/iovs.12-9662
   MESINA JE, 1989, BRAIN RES, V478, P181, DOI 10.1016/0006-8993(89)91494-7
   Miao H, 2012, MOL VIS, V18, P574
   Moberly JB, 1998, J AM SOC NEPHROL, V9, P1093
   MOSLEN MT, 1989, J PHARMACOL EXP THER, V248, P157
   Nagineni CN, 2003, J CELL PHYSIOL, V197, P453, DOI 10.1002/jcp.10378
   Park SJ, 2012, INT J MOL SCI, V13, P7915, DOI 10.3390/ijms13077915
   Penfold PL, 2001, PROG RETIN EYE RES, V20, P385, DOI 10.1016/S1350-9462(00)00025-2
   PORTA P, 1991, J PHARMACOL EXP THER, V257, P331
   Redmond HP, 1998, NUTRITION, V14, P599, DOI 10.1016/S0899-9007(98)00097-5
   Schuller-Levis GB, 2003, FEMS MICROBIOL LETT, V226, P195, DOI 10.1016/S0378-1097(03)00611-6
   Singh N, 2010, J BIOL CHEM, V285, P27601, DOI 10.1074/jbc.M110.102947
   Sparrrow JR, 2010, CURR MOL MED, V10, P802
   Tseng WA, 2013, INVEST OPHTH VIS SCI, V54, P110, DOI 10.1167/iovs.12-10655
   Tserentsoodol N, 2006, MOL VIS, V12, P1306
   Tunaru S, 2003, NAT MED, V9, P352, DOI 10.1038/nm824
   Vassilatis DK, 2003, P NATL ACAD SCI USA, V100, P4903, DOI 10.1073/pnas.0230374100
   Vita JA, 1998, J CLIN INVEST, V101, P1408, DOI 10.1172/JCI1155
   Wernerman J, 1999, Curr Opin Clin Nutr Metab Care, V2, P487, DOI 10.1097/00075197-199911000-00010
   WILLIAMSON JM, 1981, P NATL ACAD SCI-BIOL, V78, P936, DOI 10.1073/pnas.78.2.936
   WILLIAMSON JM, 1982, P NATL ACAD SCI-BIOL, V79, P6246, DOI 10.1073/pnas.79.20.6246
   Yokota H, 2011, INVEST OPHTH VIS SCI, V52, P8123, DOI 10.1167/iovs.11-8318
NR 61
TC 13
Z9 14
U1 0
U2 6
PU MOLECULAR VISION
PI ATLANTA
PA C/O JEFF BOATRIGHT, LAB B, 5500 EMORY EYE CENTER, 1327 CLIFTON RD, N E,
   ATLANTA, GA 30322 USA
SN 1090-0535
J9 MOL VIS
JI Mol. Vis.
PD JAN 7
PY 2014
VL 20
BP 73
EP 88
PG 16
WC Biochemistry & Molecular Biology; Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Ophthalmology
GA AB5JQ
UT WOS:000331825100001
PM 24426777
DA 2022-11-30
ER

PT J
AU Abebe, D
   Tsegaw, A
AF Abebe, Dagmawi
   Tsegaw, Asamere
TI Pattern of vitreo-retinal diseases at University of Gondar tertiary eye
   care and training center, North-West Ethiopia
SO PLOS ONE
LA English
DT Article
ID RETINAL DISEASES; PREVALENCE; SPECTRUM
AB ObjectiveVitreoretinal diseases are common causes of ocular morbidities and blindness. Data on the spectrum of vitreoretinal diseases needs to be studied and known in order to establish appropriate vitreoretinal care setups. The aim of this study was to determine the patterns of vitreoretinal diseases among patients who visited the vitreoretina clinic of University of Gondar Tertiary Eye Care and Training Center, NW Ethiopia (UoG-TECTC). MethodologyA hospital based cross sectional study was conducted from October/2017-September/2018. All patients who visited the vitreoretinal clinic for the first time during the study period were studied. Data were collected with standardized data extraction format entered into SPSS statistical package Version 20 and analyzed. ResultA total of 739 new patients who visited the vitreoretinal clinic were included in the study. The mean age was 50.26 +/- 19 years. The age group between 21-60 years accounted for 59.7% of study patients. Male's accounted for 63.1% and 58.7% of the participants were from urban areas. Bilateral disease was diagnosed in 504 (68.2%) of patients and 220 (29.7%) were bilaterally blind at presentation. Three hundred eighty nine (52.6%) of them had duration of illness six months and above.Diabetic Retinopathy (DR), Age Related Macular Degeneration (AMD) and Rhegmatoginous Retinal Detachment (RRD) were the top three retinal diseases accounting for 21.3%(196), 17.3% (128) and 12.4% (92) of diagnoses respectively. Systemic comorbidities were found in 44% (325) of the patients with diabetes mellitus, hypertension and hyperlipidemia being the commonest, occurring in 27.8%, 6.3% and 2.8% of study patients respectively. Cataract was the commonest ocular comorbidity seen in 33.5% of study participants. ConclusionVitreoretinal diseases affected a significant number of patients presented to our center and most of the study patients presented late with significant vision loss and blindness. Males were affected more than females and the age group between 21-60 years accounted nearly two-third of study patients. This is the working age group suffering from vision loss from vitreoretinal diseases. DR, AMD and RRD were the commonest retinal pathologies accounting for nearly half of the vitreoretinal diseases and these conditions are treatable either surgically or medically. However, available facilities for the management of these diseases are not adequate at the center. Strengthening the vitreoretinal services of UoG-TECTC with relevant equipment is recommended.
C1 [Abebe, Dagmawi; Tsegaw, Asamere] Univ Gondar, Coll Med & Hlth Sci, Dept Ophthalmol, Gondar, Ethiopia.
C3 University of Gondar
RP Tsegaw, A (通讯作者)，Univ Gondar, Coll Med & Hlth Sci, Dept Ophthalmol, Gondar, Ethiopia.
EM asameret@yahoo.com
CR [Anonymous], 2003, Community Eye Health, V16, P19
   Brilliant GEP R. P., 1981, EPIDEMIOLOGY BLINDNE
   Chauhan A., 2016, J MED SCI CLIN RES, V4
   Eze BI, 2010, MIDDLE EAST AFR J OP, V17, P246, DOI 10.4103/0974-9233.65491
   Fijalkowski N, 2013, OSLI RETINA, V44, P133, DOI 10.3928/23258160-20130313-06
   Furtado JM, 2012, SURV OPHTHALMOL, V57, P149, DOI 10.1016/j.survophthal.2011.07.002
   Hatef E, 2008, RETINA-J RET VIT DIS, V28, P755, DOI 10.1097/IAE.0b013e3181613463
   Khan A., 2011, PAK J OPHTHALMOL, V27, P155
   Li JQ., 2017, RETINAL DISEASESIN E
   Nwosu S N, 2000, Ophthalmic Epidemiol, V7, P41, DOI 10.1076/0928-6586(200003)7:1;1-2;FT041
   Onakpoya OH, 2008, J NATL MED ASSOC, V100, P1286, DOI 10.1016/S0027-9684(15)31506-6
   Teshome T, 2004, ETHIOPIAN MED J, V42, P185
   Thapa SS, 2013, BMC OPHTHALMOL, V13, DOI 10.1186/1471-2415-13-9
   Thapa SS, 2011, BMC OPHTHALMOL, V11, DOI 10.1186/1471-2415-11-2
   Uhumwangho O M, 2015, J West Afr Coll Surg, V5, P1
NR 15
TC 0
Z9 0
U1 0
U2 0
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PY 2022
VL 17
IS 4
AR e0267425
DI 10.1371/journal.pone.0267425
PG 10
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA 1F9GM
UT WOS:000795468200028
PM 35446916
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Dawczynski, J
   Jentsch, S
   Schweitzer, D
   Hammer, M
   Lang, GE
   Strobel, J
AF Dawczynski, Jens
   Jentsch, Susanne
   Schweitzer, Dietrich
   Hammer, Martin
   Lang, Gabriele E.
   Strobel, Jurgen
TI Long term effects of lutein, zeaxanthin and omega-3-LCPUFAs
   supplementation on optical density of macular pigment in AMD patients:
   the LUTEGA study
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE Age-related macular degeneration; Macular pigment; Lutein; Zeaxanthin;
   Omega-3-LCPUFAs
ID AGE-RELATED MACULOPATHY; VITAMIN-E; CAROTENOID LEVELS; VISUAL FUNCTION;
   PROTECTIVE ROLE; FATTY-ACIDS; DEGENERATION; RISK; SERUM; ASSOCIATION
AB The primary objective of LUTEGA is to determine the long-term effect of a supplementation with fixed combination of lutein, zeaxanthin, omega-3-longchain-polyunsaturated-fatty-acids (O-3-LCPUFAs) and antioxidants on macular pigment optical density (MPOD) in patients with non-exudative age-related macular degeneration (AMD).
   The LUTEGA study is a double-blind, placebo-controlled clinical trial. 172 patients with non-exudative AMD were enrolled and randomized to three treatment arms. Supplementation included either once (dosage D1) or twice daily (dosage D2) of 10 mg L / 1 mg Z/ O-3-LCPUFAs (thereof 100 mg DHA, 30 mg EPA)/ antioxidants, or placebo (P). After best-corrected visual acuity (BCVA) test, blood sample was collected and MPOD was measured using the 1-wavelength-reflection method and recording reflection images at 480 nm (modified Visucam(NM/FA), Carl Zeiss Meditec, Germany). During 1 year of intervention, AMD patients were followed up after 1, 3, 6 and 12 months. 145 AMD patients (D1 = 50, D2 = 55, P = 40) completed the study.
   After 12 months of intervention, the MPOD parameters (volume, area, maxOD, meanOD) increased significantly in treatment arms D1 and D2 (p < 0.001). Volume of MPOD showed the highest within-group difference and increased significantly in D1 and D2, and decreased significantly in P (p = 0.041). Between-group comparison of absolute changes of all MPOD parameters were significantly different between D1 and P as well as D2 and P with p < 0.001 at end point (t = 12). BCVA, measured in log MAR, improved in D1 and in D2 (p < 0.001). After 12 months of intervention, the mean improvement in BCVA was significant in D2 (p = 0.006) and D1 (p = 0.038) compared to P.
   The supplementation of L, Z, O-3-LCPUFAs and antioxidants resulted in considerable increase in MPOD. There was no difference in accumulation of MPOD between both dosages. Thus, we believe that the used supplementation with L and Z seems to reach a saturation level in retinal cell structure. Additionally, the constant supplementation of L, Z, O-3-LCPUFAs and antioxidants in AMD patients seems to be useful, because MPOD reduces without supplementation. We conclude that the supplementation caused an increase of MPOD, which results in an improvement and stabilization in BCVA in AMD patients. Thus, a protective effect on the macula in AMD patients is assumed.
C1 [Dawczynski, Jens] Univ Hosp Leipzig, Dept Ophthalmol, D-04103 Leipzig, Germany.
   [Jentsch, Susanne; Schweitzer, Dietrich; Hammer, Martin; Strobel, Jurgen] Univ Hosp Jena, Dept Ophthalmol, D-07743 Jena, Germany.
   [Lang, Gabriele E.] Univ Hosp Ulm, Dept Ophthalmol, D-89075 Ulm, Germany.
C3 Leipzig University; Friedrich Schiller University of Jena; Ulm
   University
RP Dawczynski, J (通讯作者)，Univ Hosp Leipzig, Dept Ophthalmol, Liebigstr 10-14, D-04103 Leipzig, Germany.
EM jens.dawczynski@medizin.uni-leipzig.de
FU Novartis Pharma GmbH
FX We would like to acknowledge Novartis Pharma GmbH, who supported this
   study.
CR Age-Related Eye Dis Study Res Grp, 2001, AM J OPHTHALMOL, V132, P668
   Arnold C, 2013, JAMA OPHTHALMOLOGY, P1, DOI [10.1001/jamaophthalmol.2013.2851, DOI 10.1001/JAMA0PHTHALM0L.2013.2851]
   Bartlett H, 2010, CLIN EXP OPTOM, V93, P300, DOI 10.1111/j.1444-0938.2010.00499.x
   Bazan NG, 2006, TRENDS NEUROSCI, V29, P263, DOI 10.1016/j.tins.2006.03.005
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Beatty S, 2001, INVEST OPHTH VIS SCI, V42, P439
   Berendschot TT, 2005, EXP EYE RES, V81, P602, DOI 10.1016/j.exer.2005.03.019
   Bernstein PS, 2010, VISION RES, V50, P716, DOI 10.1016/j.visres.2009.10.014
   Bernstein PS, 2002, OPHTHALMOLOGY, V109, P1780, DOI 10.1016/S0161-6420(02)01173-9
   Bhosale P, 2007, INVEST OPHTH VIS SCI, V48, P543, DOI 10.1167/iovs.06-0558
   Bone RA, 1997, EXP EYE RES, V64, P211, DOI 10.1006/exer.1996.0210
   BONE RA, 1988, INVEST OPHTH VIS SCI, V29, P843
   Bone RA, 2000, EXP EYE RES, V71, P239, DOI 10.1006/exer.2000.0870
   Brown M., 2005, CLIN REFRACT OPTOM, V16, P240
   Cangemi Francis E, 2007, BMC Ophthalmol, V7, P3, DOI 10.1186/1471-2415-7-3
   Chew EY, 2012, OPHTHALMOLOGY, V119, P2282, DOI 10.1016/j.ophtha.2012.05.027
   Chiu CJ, 2011, PROG RETIN EYE RES, V30, P18, DOI 10.1016/j.preteyeres.2010.09.001
   Chong EWT, 2008, ARCH OPHTHALMOL-CHIC, V126, P826, DOI 10.1001/archopht.126.6.826
   Cohen SY, 2010, J FR OPHTALMOL, V33, P234, DOI 10.1016/j.jfo.2010.01.015
   Coleman H, 2007, CURR OPIN OPHTHALMOL, V18, P220, DOI 10.1097/ICU.0b013e32814a586b
   Dawczynski J, 2011, KLIN MONATSBL AUGENH, V228, P57, DOI 10.1055/s-0029-1245353
   Garcia-Layana A, 2013, NUTRIENTS, V5, P543, DOI 10.3390/nu5020543
   Goodman GE, 1996, CANCER EPIDEM BIOMAR, V5, P815
   Green W R, 1999, Mol Vis, V5, P27
   Hartmann D, 2004, AM J CLIN NUTR, V79, P410
   Hunt S, 2007, OPHTHALMOLOGE, V104, P727, DOI 10.1007/s00347-007-1607-9
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Johnson EJ, 2010, J AM DIET ASSOC, V110, P1357, DOI 10.1016/j.jada.2010.06.009
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Kaya S, 2012, ACTA OPHTHALMOL, V90, pe399, DOI 10.1111/j.1755-3768.2012.02423.x
   Khachik F, 2006, INVEST OPHTH VIS SCI, V47, P5234, DOI 10.1167/iovs.06-0504
   Klaver CCW, 1998, ARCH OPHTHALMOL-CHIC, V116, P653, DOI 10.1001/archopht.116.5.653
   Klaver CCW, 1998, ARCH OPHTHALMOL-CHIC, V116, P1646, DOI 10.1001/archopht.116.12.1646
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   Krinsky NI, 2003, ANNU REV NUTR, V23, P171, DOI 10.1146/annurev.nutr.23.011702.073307
   Lengyel I, 2007, EXP EYE RES, V84, P772, DOI 10.1016/j.exer.2006.12.015
   LIM BP, 1992, BIOCHIM BIOPHYS ACTA, V1126, P178
   Ma L, 2012, OPHTHALMOLOGY, V119, P2290, DOI 10.1016/j.ophtha.2012.06.014
   Mares-Perlman JA, 2002, J NUTR, V132, p518S, DOI 10.1093/jn/132.3.518S
   Meyers KJ, 2013, INVEST OPHTH VIS SCI, V54, P2333, DOI [10.1167/iovs.12-10867, 10.1167/iovs.13-13216]
   Miller ER, 2005, ANN INTERN MED, V142, P37, DOI 10.7326/0003-4819-142-1-200501040-00110
   Mozaffarieh M, 2003, NUTR J, V2, DOI 10.1186/1475-2891-2-20
   Mukherjee PK, 2004, P NATL ACAD SCI USA, V101, P8491, DOI 10.1073/pnas.0402531101
   Murray IJ, 2013, INVEST OPHTH VIS SCI, V54, P1781, DOI 10.1167/iovs.12-10715
   Nebeling LC, 1997, J AM DIET ASSOC, V97, P991, DOI 10.1016/S0002-8223(97)00239-3
   NEURINGER M, 1986, P NATL ACAD SCI USA, V83, P4021, DOI 10.1073/pnas.83.11.4021
   Nolan JM, 2007, EXP EYE RES, V84, P61, DOI 10.1016/j.exer.2006.08.016
   Nolan JM, 2011, VISION RES, V51, P459, DOI 10.1016/j.visres.2010.12.016
   Obana A, 2008, OPHTHALMOLOGY, V115, P147, DOI 10.1016/j.ophtha.2007.02.028
   Ozawa Y, 2012, CURR PHARM DESIGN, V18, P51, DOI 10.2174/138161212798919101
   Ribaya-Mereado JD, 2004, J AM COLL NUTR, V23, p567S, DOI 10.1080/07315724.2004.10719427
   Richer Stuart, 2004, Optometry, V75, P216, DOI 10.1016/S1529-1839(04)70049-4
   Richer SP, 2011, OPTOMETRY, V82, P667, DOI 10.1016/j.optm.2011.08.008
   Sabour-Pickett S, 2012, MOL NUTR FOOD RES, V56, P270, DOI 10.1002/mnfr.201100219
   SanGiovanni JP, 2007, ARCH OPHTHALMOL-CHIC, V125, P671, DOI 10.1001/archopht.125.5.671
   SanGiovanni JP, 2009, AM J CLIN NUTR, V90, P1601, DOI 10.3945/ajcn.2009.27594
   SanGiovanni JP, 2005, PROG RETIN EYE RES, V24, P87, DOI 10.1016/j.preteyeres.2004.06.002
   Schwab JM, 2006, CURR OPIN PHARMACOL, V6, P414, DOI 10.1016/j.coph.2006.02.006
   Schweitzer D, 2010, J BIOMED OPT, V15, DOI 10.1117/1.3526358
   Seddon JM, 2003, ARCH OPHTHALMOL-CHIC, V121, P785, DOI 10.1001/archopht.121.6.785
   SEDDON JM, 1994, JAMA-J AM MED ASSOC, V272, P1413, DOI 10.1001/jama.272.18.1413
   Seddon JM, 2001, ARCH OPHTHALMOL-CHIC, V119, P1191, DOI 10.1001/archopht.119.8.1191
   Slatore CG, 2008, AM J RESP CRIT CARE, V177, P524, DOI 10.1164/rccm.200709-1398OC
   SNODDERLY DM, 1984, INVEST OPHTH VIS SCI, V25, P660
   Tan JSL, 2008, OPHTHALMOLOGY, V115, P334, DOI 10.1016/j.ophtha.2007.03.083
   Tan JSL, 2009, ARCH OPHTHALMOL-CHIC, V127, P656, DOI 10.1001/archophthalmol.2009.76
   Trevithick-Sutton CC, 2006, MOL VIS, V12, P1127
   van de Kraats J, 2008, INVEST OPHTH VIS SCI, V49, P5568, DOI 10.1167/iovs.08-1939
   Weigert G, 2011, INVEST OPHTH VIS SCI, V52, P8174, DOI 10.1167/iovs.11-7522
   Wenzel AJ, 2003, INVEST OPHTH VIS SCI, V44, P306, DOI 10.1167/iovs.01-1191
   Wolf S, 2006, GRAEF ARCH CLIN EXP, V244, P1562, DOI 10.1007/s00417-006-0336-0
NR 71
TC 62
Z9 64
U1 2
U2 56
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0721-832X
EI 1435-702X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD DEC
PY 2013
VL 251
IS 12
BP 2711
EP 2723
DI 10.1007/s00417-013-2376-6
PG 13
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 270US
UT WOS:000328345000007
PM 23695657
DA 2022-11-30
ER

PT J
AU Joussen, AM
   Joeres, S
   Fawzy, N
   Heussen, FMA
   Llacer, H
   van Meurs, JC
   Kirchhof, B
AF Joussen, Antonia M.
   Joeres, Sandra
   Fawzy, Nader
   Heussen, Florian M. A.
   Llacer, Helene
   van Meurs, Jan C.
   Kirchhof, Bernd
TI Autologous translocation of the choroid and retinal pigment epithelium
   in patients with geographic atrophy
SO OPHTHALMOLOGY
LA English
DT Article
ID AGE-RELATED MACULOPATHY; MACULAR DEGENERATION; FUNDUS AUTOFLUORESCENCE;
   SUBMACULAR SURGERY; VISUAL-LOSS; TRANSPLANTATION; RECURRENCE; REMOVAL;
   LESIONS; CELL
AB Purpose: To evaluate the functional and anatomical outcomes of autologous translocation of peripheral choroid and retinal pigment epithelium (RPE) in patients with geographic atrophy.
   Design: Prospective nonrandomized study.
   Participants: Twelve consecutive patients with geographic atrophy secondary to age-related macular degeneration presenting with recent loss of reading vision.
   Methods: An autologous peripheral full-thickness graft of RPE, Bruch's membrane, and choroid was positioned under the macula in patients with geographic atrophy.
   Main Outcome Measures: Functional tests included Early Treatment Diabetic Retinopathy Study distant vision, reading (Radner Test, measured as logarithm of the reading acuity determination [logRAD]), threshold static perimetry, and determination of the point of fixation. Fluorescein and indocyanine green angiography, autofluorescence, and optical coherence tomography served to evaluate the anatomical outcome in a 6-month follow-up (12 months in 7 patients).
   Results: Preoperative visual acuity (VA) ranged from 20/800 to 20/40 (mean, 0.6 +/- 0.4 logarithm of the minimum angle of resolution), and reading vision from 1.1 to 0.5 logRAD (mean, 0.8 +/- 0.2). Three patients were unable to read. Six months after surgery, VA ranged from hand movements to 20/32, with an increase of >= 5 letters in 2 eyes. Two patients without reading ability preoperatively were able to read after surgery. Reading was possible in a total of 8 patients after 6 months (1.3-0.4 logRAD). In 7 patients who were observed for 1 year, VA remained stable (+/- 1 line) in 5 eyes and decreased in 2 eyes between 6 months' and 1 year's follow-up. In all eyes but 2, revascularization was visible on indocyanine green angiography as early as 3 weeks after surgery. Autofluorescence of the RPE was independent of revascularization of the graft and persisted throughout follow-up. Four eyes had unstable fixation and/or extrafoveal fixation before surgery. Two of these eyes stabilized during follow-up. Areas overlying atrophic areas demonstrated low threshold sensitivities that persisted after translocation of a free graft with only limited recovery. Revisional surgery due to proliferative vitreoretinopathy was required in 5 eyes.
   Conclusions: The translocation of a full-thickness graft usually results in a vascularized and functioning graft in patients with geographic atrophy, although is associated with a high risk of complications and visual loss. Longer follow-up is necessary to learn about the long-term survival and functionality of the graft.
C1 Univ Dusseldorf, Dept Ophthalmol, D-40225 Dusseldorf, Germany.
   Univ Cologne, Ctr Opthalmol, Dept Vitreoeetinal Surg, D-5000 Cologne 41, Germany.
   Erasmus Univ, Rotterdam, Netherlands.
   RotterdamEye Hosp, Rotterdam, Netherlands.
C3 Heinrich Heine University Dusseldorf; University of Cologne; Erasmus
   University Rotterdam; Rotterdam Eye Hospital
RP Joussen, AM (通讯作者)，Univ Dusseldorf, Dept Ophthalmol, Moorenstr 5, D-40225 Dusseldorf, Germany.
EM Joussena@googlemail.com
RI Joussen, Antonia/AAA-6901-2022
OI Heussen, Florian Moritz/0000-0003-0536-9870; Fawzy,
   Nader/0000-0002-0916-5667
CR Algvere PV, 1997, GRAEF ARCH CLIN EXP, V235, P149, DOI 10.1007/BF00941722
   Bellmann C, 2002, ARCH OPHTHALMOL-CHIC, V120, P579, DOI 10.1001/archopht.120.5.579
   Cahill MT, 2005, ARCH OPHTHALMOL-CHIC, V123, P935, DOI 10.1001/archopht.123.7.935
   CHYLACK LT, 1993, ARCH OPHTHALMOL-CHIC, V111, P831, DOI 10.1001/archopht.1993.01090060119035
   Curcio CA, 2000, INVEST OPHTH VIS SCI, V41, P2015
   Eckardt C, 2002, RETINA-J RET VIT DIS, V22, P786, DOI 10.1097/00006982-200212000-00017
   Holz FG, 2001, INVEST OPHTH VIS SCI, V42, P1051
   Joussen AM, 2006, AM J OPHTHALMOL, V142, P17, DOI 10.1016/j.ajo.2006.01.090
   Khurana RN, 2005, OPHTHALMOLOGY, V112, P1586, DOI 10.1016/j.ophtha.2005.04.016
   Kim SY, 2002, RETINA-J RET VIT DIS, V22, P464, DOI 10.1097/00006982-200208000-00011
   Lappas A, 2004, GRAEF ARCH CLIN EXP, V242, P638, DOI 10.1007/s00417-003-0764-z
   Lappas A, 2000, GRAEF ARCH CLIN EXP, V238, P631, DOI 10.1007/s004170000149
   Maaijwee K, 2006, OPHTHALMOLOGY, V113, P1471, DOI 10.1016/j.ophtha.2006.04.011
   MacLaren RE, 2005, OPHTHALMOLOGY, V112, P2081, DOI 10.1016/j.ophtha.2005.06.029
   Owen CG, 2003, BRIT J OPHTHALMOL, V87, P312, DOI 10.1136/bjo.87.3.312
   PEYMAN GA, 1991, OPHTHALMIC SURG LAS, V22, P102
   SCHATZ H, 1989, OPHTHALMOLOGY, V96, P1541
   Schmitz-Valckenberg S, 2004, INVEST OPHTH VIS SCI, V45, P4470, DOI 10.1167/iovs.03-1311
   Scholl HPN, 2004, INVEST OPHTH VIS SCI, V45, P574, DOI 10.1167/iovs.03-0495
   Stanga PE, 2002, OPHTHALMOLOGY, V109, P1492, DOI 10.1016/S0161-6420(02)01099-0
   Sunness JS, 1999, OPHTHALMOLOGY, V106, P1768, DOI 10.1016/S0161-6420(99)90340-8
   Thumann G, 2000, ARCH OPHTHALMOL-CHIC, V118, P1350
   Van Meurs JC, 2003, AM J OPHTHALMOL, V136, P688, DOI 10.1016/S0002-9394(03)00384-2
   Weisz JM, 1999, RETINA-J RET VIT DIS, V19, P540, DOI 10.1097/00006982-199911000-00011
NR 24
TC 66
Z9 66
U1 0
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0161-6420
J9 OPHTHALMOLOGY
JI Ophthalmology
PD MAR
PY 2007
VL 114
IS 3
BP 551
EP 560
DI 10.1016/j.ophtha.2006.08.016
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 140US
UT WOS:000244532800023
PM 17324697
DA 2022-11-30
ER

PT J
AU Rosen, RB
   van Velthoven, MEJ
   Garcia, PMT
   Cucu, RG
   de Smet, MD
   Muldoon, TO
   Podoleanu, AG
AF Rosen, R. B.
   van Velthoven, M. E. J.
   Garcia, P. M. T.
   Cucu, R. G.
   de Smet, M. D.
   Muldoon, T. O.
   Podoleanu, A. Gh.
TI Ultrahigh-resolution combined coronal optical coherence tomography
   confocal scanning ophthalmoscope (OCT/SLO) : A pilot study
SO SPEKTRUM DER AUGENHEILKUNDE
LA English
DT Article
DE OCT ophthalmoscope; OCT/SLO; ultrahigh resolution OCT; coronal OCT
ID HUMAN RETINA; IN-VIVO; MACULAR PATHOLOGY; REPRODUCIBILITY; THICKNESS
AB Objective: To evaluate clinical images from a prototype ultrahigh resolution (UHR) combined coronal optical coherence tomography/confocal scanning ophthalmoscope (OCT/SLO) and to compare them to standard-resolution OCT/ SLO images on the same patients.
   Design: Cross-sectional pilot-study.
   Participants: Sixty-six eyes of 42 patients with various macular pathologies, such as age- related macular degeneration, macular edema, macular hole, central serous retinopathy, epiretinal membrane and posterior vitreous traction syndrome.
   Methods: Each subject was first scanned with a standardresolution OCT/ SLO that has an axial resolution of similar to 10 micron. Immediately following, patients were scanned with the prototype UHR OCT/SLO device. The UHR system employs a compact super luminescent diode (SLD) with a 150 nm bandwidth centered at 890 nm, which allows imaging of the retina with an axial resolution of 3 microns. Both coronal and longitudinal OCT scans were acquired with each system, and compared side-by-side. Scan quality was assessed for the observer's ability to visualize the vitreo- retinal interface and retinal layers - in particular of the outer retina/RPE/choroidal interface, increased discrimination of pathological changes, and better signal intensity.
   Main outcome measures: Ultrahigh and standard-resolution coronal and longitudinal OCT/ SLO images of macular pathologies.
   Results: In the side- by- side comparison with the commercial standard- resolution OCT/SLO images, the scans in the Ultrahigh resolution OCT/SLO images were superior in 85% of cases. Relatively poor quality images were attributed to lower signal-to-noise ratio, limited focusing, or media opacities. Several images that had a better signal intensity in the standard- resolution OCT/SLO system were found to show more retinal detail in the UHR system. In general, intraretinal layers in the UHR OCT/SLO images were better delineated in both coronal and longitudinal scans. Enhanced details were also seen in the outer retina/RPE/choroidal complex. The UHR OCT/SLO system produced better definition of morphological changes in several macular pathologies.
   Conclusions: Broadband SLD-based UHR OCT/SLO offers a compact, efficient, and economic enhancement to the currently available clinical OCT imaging systems. UHR OCT/SLO imaging enhanced the quality of the OCT C-scans, facilitated appreciation of vitreo-retinal pathologies, and improved sensitivity to small changes in the retina, and the outer retina/RPE/choroidal interface.
C1 [Rosen, R. B.; van Velthoven, M. E. J.; Garcia, P. M. T.; Muldoon, T. O.] New York Eye & Ear Infirm, Adv Retinal Imaging Lab, New York, NY 10003 USA.
   [van Velthoven, M. E. J.; de Smet, M. D.] Acad Med Ctr, Dept Ophthalmol, Amsterdam, Netherlands.
   [Cucu, R. G.; Podoleanu, A. Gh.] Univ Kent, Appl Opt Grp, Canterbury, Kent, England.
C3 New York Eye & Ear Infirmary of Mount Sinai; University of Amsterdam;
   Academic Medical Center Amsterdam; University of Kent
RP Rosen, RB (通讯作者)，New York Eye & Ear Infirm, Adv Retinal Imaging Lab, 310 E 14th St, New York, NY 10003 USA.
EM rrosen@nyee.edu
RI De Smet, Marc D./E-2451-2013; Podoleanu, Adrian/F-7094-2012
OI De Smet, Marc D./0000-0002-9217-5603; Podoleanu,
   Adrian/0000-0002-4899-9656
FU EPSRC [EP/D067081/1] Funding Source: UKRI; Engineering and Physical
   Sciences Research Council [EP/D067081/1] Funding Source: researchfish
CR *AM NAT STAND I, 2000, Z136I ANSI
   Cucu RG, 2006, OPT LETT, V31, P1684, DOI 10.1364/OL.31.001684
   Drexler W, 2003, ARCH OPHTHALMOL-CHIC, V121, P695, DOI 10.1001/archopht.121.5.695
   Drexler W, 2001, NAT MED, V7, P502, DOI 10.1038/86589
   Ergun E, 2005, INVEST OPHTH VIS SCI, V46, P310, DOI 10.1167/iovs.04-0212
   Gurses-Ozden R, 2004, J GLAUCOMA, V13, P238
   Hee MR, 2005, AM J OPHTHALMOL, V139, P154, DOI 10.1016/j.ajo.2004.08.066
   HEE MR, 1995, ARCH OPHTHALMOL-CHIC, V113, P325, DOI 10.1001/archopht.1995.01100030081025
   Hitzenberger CK, 2003, OPT EXPRESS, V11, P2753, DOI 10.1364/OE.11.002753
   HUANG D, 1991, SCIENCE, V254, P1178, DOI 10.1126/science.1957169
   Ko TH, 2005, OPHTHALMOLOGY, V112, P1922, DOI 10.1016/j.ophtha.2005.05.027
   Ko TH, 2004, OPT EXPRESS, V12, P2112, DOI 10.1364/OPEX.12.002112
   Ko TH, 2004, OPHTHALMOLOGY, V111, P2033, DOI 10.1016/j.ophtha.2004.05.021
   Leitgeb RA, 2004, OPT EXPRESS, V12, P2156, DOI 10.1364/OPEX.12.002156
   Nassif N, 2004, OPT LETT, V29, P480, DOI 10.1364/OL.29.000480
   Paunescu LA, 2006, OPHTHALMOLOGY, V113, P48, DOI 10.1016/j.ophtha.2005.08.016
   Paunescu LA, 2004, INVEST OPHTH VIS SCI, V45, P1716, DOI 10.1167/iovs.03-0514
   Pircher M, 2004, OPT EXPRESS, V12, P5940, DOI 10.1364/OPEX.12.005940
   Podoleanu AG, 1998, J BIOMED OPT, V3, P12, DOI 10.1117/1.429859
   Podoleanu AG, 2004, J BIOMED OPT, V9, P86, DOI 10.1117/1.1627778
   Podoleanu AG, 1998, LASERS LIGHT, V8, P187
   Sander B, 2005, BRIT J OPHTHALMOL, V89, P207, DOI 10.1136/bjo.2004.045989
   Schmidt-Erfurth U, 2005, INVEST OPHTH VIS SCI, V46, P3393, DOI 10.1167/iovs.05-0370
   SCHUMAN JS, 2004, OPTICAL COHERENCE TO
   Unterhuber A, 2004, PHYS MED BIOL, V49, P1235, DOI 10.1088/0031-9155/49/7/011
   Vabre L, 2002, OPT LETT, V27, P530, DOI 10.1364/OL.27.000530
   van Velthoven MEJ, 2005, BRIT J OPHTHALMOL, V89, P1483, DOI 10.1136/bjo.2005.073056
   Van Velthoven MEJ, 2006, RETINA-J RET VIT DIS, V26, P129, DOI 10.1097/00006982-200602000-00001
   van Velthoven Mirjam E J, 2005, BMC Ophthalmol, V5, P12, DOI 10.1186/1471-2415-5-12
   Wirtitsch MG, 2005, AM J OPHTHALMOL, V140, P976, DOI 10.1016/j.ajo.2005.06.029
   Witkin AJ, 2005, BRIT J OPHTHALMOL, V89, P1660, DOI 10.1136/bjo.2005.076570
NR 31
TC 2
Z9 2
U1 0
U2 7
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0930-4282
J9 SPEKTRUM AUGENHEILKD
JI Spektrum Augenheilkd.
PD MAR
PY 2007
VL 21
IS 1
BP 17
EP 28
DI 10.1007/s00717-007-0182-4
PG 12
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 326GH
UT WOS:000257646100004
DA 2022-11-30
ER

PT J
AU Johnson, AR
   Munoz, A
   Gottlieb, JL
   Jarrard, DF
AF Johnson, Aaron R.
   Munoz, Alejandro
   Gottlieb, Justin L.
   Jarrard, David F.
TI High dose zinc increases hospital admissions due to genitourinary
   complications
SO JOURNAL OF UROLOGY
LA English
DT Article
DE prostate; prostatic neoplasms; zinc; prostatic hyperplasia;
   complications
ID SUPPLEMENT USE; RISK; RECEPTOR; COPPER
AB Purpose: Zinc is a common dietary supplement that is widely believed to have beneficial health effects. To assess the impact of high dose supplemental zinc on genitourinary diseases we analyzed a recent randomized trial comparing zinc, antioxidants and their combination to placebo for complications related to the genitourinary tract.
   Materials and Methods: In a further analysis of the recent Age-related Eye Disease Study we examined the data pool for primary International Classification of Diseases, 9th revision codes given for hospital admissions related to urological problems. The Age-Related Eye Disease Study randomized 3,640 patients with age related macular degeneration to 1 of 4 study arms, including placebo, antioxidants (500 mg vitamin C, 400 IU vitamin E and 15 mg beta-carotene), 80 mg zinc and antioxidant plus zinc. Statistical analyses using Fisher's exact test were performed.
   Results: We found a significant increase in hospital admissions due to genitourinary causes in patients on zinc vs nonzinc formulations (11.1% vs 7.6%, p = 0.0003). The risk was greatest in male patients (RR 1.26, 95% Cl 1.07-1.50, p = 0.008). In the study group of 343 patients requiring hospital admission the most common primary International Classification of Diseases, 9th revision codes included benign prostatic hyperplasia/urinary retention (benign prostatic hyperplasia), urinary tract infection, urinary lithiasis and renal failure. When comparing zinc to placebo, significant increases in urinary tract infections were found (p = 0.004), especially in females (2.3% vs 0.4%, RR 5.77, 95% CI 1.30-25.66, p = 0.013). Admissions for urinary lithiasis approached significance in men on zinc compared to placebo (2.0% vs 0.5%, RR = 4.08, 95% Cl 0.87-19.10). There was no increase in prostate or other cancers with zinc supplementation. A significant decrease in prostate cancer diagnoses was seen in patients receiving antioxidants vs placebo (RR = 0.6, 95% Cl 0.49-0.86, p = 0.049). Subgroup analysis revealed that this finding was significant in men who smoked but not in nonsmokers.
   Conclusions: Zinc supplementation at high levels results in increased hospitalizations for urinary complications compared to placebo. These data support the hypothesis that high dose zinc supplementation has a negative effect on select aspects of urinary physiology.
C1 Univ Wisconsin, Ctr Clin Sci, Sch Med & Publ Hlth, Dept Surg,Div Urol, Madison, WI 53792 USA.
   Univ Wisconsin, Sch Med & Publ Hlth, Dept Ophthalmol & Visual Sci, Madison, WI 53792 USA.
   Univ Wisconsin, Ctr Comprehens Canc, Madison, WI USA.
C3 University of Wisconsin System; University of Wisconsin Madison;
   University of Wisconsin System; University of Wisconsin Madison;
   University of Wisconsin System; University of Wisconsin Madison
RP Jarrard, DF (通讯作者)，Univ Wisconsin, Ctr Clin Sci, Sch Med & Publ Hlth, Dept Surg,Div Urol, K6-527,600 Highland Ave, Madison, WI 53792 USA.
EM jarrard@surgery.wisc.edu
CR ALBANES D, 1995, AM J CLIN NUTR, V62, P1427, DOI 10.1093/ajcn/62.6.1427S
   Briefel RR, 2000, J NUTR, V130, p1367S, DOI 10.1093/jn/130.5.1367S
   CHANDRA RK, 1984, JAMA-J AM MED ASSOC, V252, P1443, DOI 10.1001/jama.252.11.1443
   Chavakis T, 1999, BLOOD, V93, P2976
   Clemons TE, 2004, ARCH OPHTHALMOL-CHIC, V122, P716
   Costello LC, 2004, JNCI-J NATL CANCER I, V96, P239, DOI 10.1093/jnci/djh045
   Costello LC, 1998, PROSTATE, V35, P285, DOI 10.1002/(SICI)1097-0045(19980601)35:4<285::AID-PROS8>3.0.CO;2-F
   DUCHATEAU J, 1981, AM J CLIN NUTR, V34, P88, DOI 10.1093/ajcn/34.1.88
   Jarrard DF, 2005, ARCH OPHTHALMOL-CHIC, V123, P102, DOI 10.1001/archopht.123.1.102
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Kristal AR, 1999, CANCER EPIDEM BIOMAR, V8, P887
   Lagiou P, 1999, UROLOGY, V54, P284, DOI 10.1016/S0090-4295(99)00096-5
   Leitzmann MF, 2003, J NATL CANCER I, V95, P1004, DOI 10.1093/jnci/95.13.1004
   Liang JY, 1999, PROSTATE, V40, P200
   MEYER JL, 1977, INVEST UROL, V14, P347
   Moyad Mark A, 2004, Urol Nurs, V24, P49
   Nemoto K, 2000, BIOCHEM PHARMACOL, V59, P401, DOI 10.1016/S0006-2952(99)00334-2
   Ozgurtas T, 2004, UROL INT, V72, P233, DOI 10.1159/000077122
   Prasad A S, 1985, Spec Top Endocrinol Metab, V7, P45
   RAJAGOPALAN S, 1995, J IMMUNOL, V155, P4143
   Rink L, 2000, P NUTR SOC, V59, P541, DOI 10.1017/S0029665100000781
   SAMMAN S, 1988, ATHEROSCLEROSIS, V70, P247, DOI 10.1016/0021-9150(88)90175-X
   SUTOR D J, 1970, British Journal of Urology, V42, P296, DOI 10.1111/j.1464-410X.1970.tb11923.x
   Zaichick V. Ye., 1997, International Urology and Nephrology, V29, P565, DOI 10.1007/BF02552202
NR 24
TC 61
Z9 63
U1 2
U2 6
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0022-5347
EI 1527-3792
J9 J UROLOGY
JI J. Urol.
PD FEB
PY 2007
VL 177
IS 2
BP 639
EP 643
DI 10.1016/j.juro.2006.09.047
PG 5
WC Urology & Nephrology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Urology & Nephrology
GA 125PI
UT WOS:000243453900049
PM 17222649
DA 2022-11-30
ER

PT J
AU Shang, F
   Dudek, E
   Liu, Q
   Boulton, ME
   Taylor, A
AF Shang, Fu
   Dudek, Edward
   Liu, Qing
   Boulton, Michael E.
   Taylor, Allen
TI Protein quality control by the ubiquitin proteolytic pathway: Roles in
   resistance to oxidative stress and disease
SO ISRAEL JOURNAL OF CHEMISTRY
LA English
DT Article
ID LENS EPITHELIAL-CELLS; IRON REGULATORY PROTEIN-2; PROTEASOME PATHWAY;
   CALORIE RESTRICTION; EYE LENS; DEPENDENT PROTEOLYSIS; CONJUGATING
   ENZYMES; HYDROGEN-PEROXIDE; DEGRADATION; SYSTEM
AB There is now consensus that the accumulation of oxidatively modified proteins is cytotoxic and causally related to several age-related diseases including the amyloid diseases and age-related cataracts. There is also general agreement that the ubiquitin proteolytic pathway (UPP) provides a quality control mechanism to limit accumulation of modified proteins. We asked if and how oxidative stress is related to the function of the ubiquitin proteolytic pathway, and vice versa, with the objective of obtaining information that can lead to the development of strategies to delay age-related "amyloid" or "protein precipitation" diseases such as cataracts and age-related macular degeneration. Elevated levels of ubiquitin conjugates were observed when human, rabbit, bovine, and rat tens, retina, liver cells or tissues were exposed to mild oxidative stress, which was created by exposure to paraquat, diamide, peroxide, light together with lipofuscin, and radiomimetic drugs. The increase in ubiquitin conjugates derived from an increase in substrates as well as by hyperactivation of E1, rather than inactivation of the proteasome. Using a novel glutathiolated substrate, gamma C-crystallin, we demonstrated that the UPP shows a previously unrecognized selectivity for such specifically oxidatively modified proteins. Selectivity of the pathway for other oxidatively modified proteins, specifically for protein carbonyls, was indicated in assays that employed the ubiquitin conjugation-competent, but degradation-resistant ubiquitin variant K6W-ubiquitin. These experiments showed that failure to execute ubiquitin-dependent proteolysis renders cells more susceptible to oxidative-stress-related cytotoxicity. Activity of the pathway is regulated in part by cellular redox status, specifically as affected by GSSG. Ubiquitination is enhanced when GSSG/GSH ratios are 0.02-0.15. Since there is potentiation of ubiquitination even when GSSG/GSH ratios are indistinguishable from basal levels, it appears that ubiquitination provides one of the most sensitive indicators of oxidative stress. Ubiquitination is attenuated when GSSG/GSH rises > 0.2 and does not occur when GSSG/GSH >= 2.9. The data indicate that inhibition of the pathway, which occurs upon aging, is associated with accumulation rather than the timely degradation of ubiquitin conjugates. They further suggest that if the system fails to keep up with production of substrates, high mass ubiquitin conjugates may accumulate and precipitate in cytotoxic aggregates such as are seen in many age-related syndromes, including lens cataracts or in lipofuscin and drusen in the aging retina.
C1 Tufts Univ, Lab Nutr & Vis Res, USDA, Human Nutr Res Ctr, Boston, MA 02111 USA.
   Univ Texas, Med Branch, AMD Ctr, Dept Ophthalmol & Visual Sci, Galveston, TX 77555 USA.
C3 Tufts University; United States Department of Agriculture (USDA);
   University of Texas System; University of Texas Medical Branch Galveston
RP Taylor, A (通讯作者)，Tufts Univ, Lab Nutr & Vis Res, USDA, Human Nutr Res Ctr, 711 Washington St, Boston, MA 02111 USA.
EM allen.taylor@tufts.edu
CR ADAMO AM, 1994, J NEUROSCI RES, V38, P358, DOI 10.1002/jnr.490380314
   Adamo AM, 1999, J NEUROSCI RES, V55, P523, DOI 10.1002/(SICI)1097-4547(19990215)55:4<523::AID-JNR12>3.3.CO;2-H
   Beal MF, 2002, FREE RADICAL BIO MED, V32, P797, DOI 10.1016/S0891-5849(02)00780-3
   Bence NF, 2001, SCIENCE, V292, P1552, DOI 10.1126/science.292.5521.1552
   Berlett BS, 1996, J BIOL CHEM, V271, P4177, DOI 10.1074/jbc.271.8.4177
   Bleau G, 1998, ANAL BIOCHEM, V263, P13, DOI 10.1006/abio.1998.2801
   Butterfield DA, 1999, LIFE SCI, V65, P1883, DOI 10.1016/S0024-3205(99)00442-7
   CIECHANOVER A, 1978, BIOCHEM BIOPH RES CO, V81, P1100, DOI 10.1016/0006-291X(78)91249-4
   Donaldson KM, 2003, P NATL ACAD SCI USA, V100, P8892, DOI 10.1073/pnas.1530212100
   DUDEK EJ, 2005, FASEB J
   DUNTEN RL, 1989, J BIOL CHEM, V264, P16739
   EDO K, 1991, CHEM PHARM BULL, V39, P170
   El-Agnaf OMA, 2002, BIOCHEM SOC T, V30, P559
   FIGUEIREDOPEREI.ME, 1997, MOL BIOL REP, V24, P25
   FINCH JS, 1990, NUCLEIC ACIDS RES, V18, P1907, DOI 10.1093/nar/18.7.1907
   Floyd RA, 2002, NEUROBIOL AGING, V23, P795, DOI 10.1016/S0197-4580(02)00019-2
   Forman HJ, 2002, AM J RESP CRIT CARE, V166, pS4, DOI 10.1164/rccm.2206007
   Frederikse PH, 1996, J BIOL CHEM, V271, P10169, DOI 10.1074/jbc.271.17.10169
   Gelman MS, 2002, J BIOL CHEM, V277, P11709, DOI 10.1074/jbc.M111958200
   Goellner GM, 2003, INT J BIOCHEM CELL B, V35, P562, DOI 10.1016/S1357-2725(02)00388-6
   Goldberg AL, 2003, NATURE, V426, P895, DOI 10.1038/nature02263
   Gomes-Marcondes MCC, 2002, CANCER LETT, V180, P69, DOI 10.1016/S0304-3835(02)00006-X
   GRAY DA, 2003, SCI AGING KNOWLEDGE, V34, pRE6
   Guo WM, 2004, INVEST OPHTH VIS SCI, V45, P1194, DOI 10.1167/iovs.03-0830
   He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509
   HERSHKO A, 1986, J BIOL CHEM, V261, P1992
   HUANG LL, 1993, BIOCHIM BIOPHYS ACTA, V1175, P181, DOI 10.1016/0167-4889(93)90021-G
   HUANG LL, 1995, EXP EYE RES, V61, P45, DOI 10.1016/S0014-4835(95)80057-3
   Hyun DH, 2002, J BIOL CHEM, V277, P28572, DOI 10.1074/jbc.M200666200
   Iwai K, 1998, P NATL ACAD SCI USA, V95, P4924, DOI 10.1073/pnas.95.9.4924
   JAHNGEN JH, 1986, J BIOL CHEM, V261, P3760
   JAHNGEN JH, 1990, ARCH BIOCHEM BIOPHYS, V276, P32, DOI 10.1016/0003-9861(90)90006-K
   JAHNGENHODGE J, 1992, EXP EYE RES, V55, P897, DOI 10.1016/0014-4835(92)90016-L
   JahngenHodge J, 1997, J BIOL CHEM, V272, P28218, DOI 10.1074/jbc.272.45.28218
   Johnston JA, 1998, J CELL BIOL, V143, P1883, DOI 10.1083/jcb.143.7.1883
   Kim BY, 2001, FREE RADICAL BIO MED, V30, P686, DOI 10.1016/S0891-5849(00)00514-1
   KOPITO RR, 1999, PHYSIOL REV, V79, P167
   Kwon YT, 1998, P NATL ACAD SCI USA, V95, P7898, DOI 10.1073/pnas.95.14.7898
   LaVaute T, 2001, NAT GENET, V27, P209, DOI 10.1038/84859
   Liu Q, 2004, EXP EYE RES, V78, P197, DOI 10.1016/j.exer.2003.11.009
   Loeffler KU, 1997, GRAEF ARCH CLIN EXP, V235, P248, DOI 10.1007/BF00941767
   MAYER RJ, 1991, J PATHOL, V163, P279, DOI 10.1002/path.1711630402
   Obin M, 1998, FASEB J, V12, P561, DOI 10.1096/fasebj.12.7.561
   Obin M, 1999, J BIOL CHEM, V274, P11789, DOI 10.1074/jbc.274.17.11789
   OLIVER CN, 1987, J BIOL CHEM, V262, P5488
   Pereira P, 2003, EXP EYE RES, V76, P623, DOI 10.1016/S0014-4835(03)00020-4
   Ramanathan M, 1999, NEUROREPORT, V10, P3797, DOI 10.1097/00001756-199912160-00014
   RUBINSZTEIN DC, 2003, SCI MAG SAGE KE, V37, P26
   Scrofano MM, 1998, MECH AGEING DEV, V105, P273, DOI 10.1016/S0047-6374(98)00097-9
   Scrofano MM, 1998, MECH AGEING DEV, V101, P277, DOI 10.1016/S0047-6374(97)00178-4
   Selkoe DJ, 2003, NATURE, V426, P900, DOI 10.1038/nature02264
   SHANG F, 1995, BIOCHEM J, V307, P297, DOI 10.1042/bj3070297
   Shang F, 2004, EXP EYE RES, V78, P1, DOI 10.1016/j.exer.2003.10.003
   Shang F, 1997, EXP EYE RES, V64, P21, DOI 10.1006/exer.1996.0176
   Shang F, 2001, EXP EYE RES, V73, P229, DOI 10.1006/exer.2001.1029
   Shang F, 1997, J BIOL CHEM, V272, P23086, DOI 10.1074/jbc.272.37.23086
   Shang F, 2005, J BIOL CHEM, V280, P20365, DOI 10.1074/jbc.M414356200
   SHANG F, 1994, CURR EYE RES, V13, P423, DOI 10.3109/02713689408999870
   Sitte N, 2000, FASEB J, V14, P2503, DOI 10.1096/fj.00-0210com
   Spector A, 1998, INVEST OPHTH VIS SCI, V39, P1188
   SPECTOR A, 1981, EXP EYE RES, V33, P673, DOI 10.1016/S0014-4835(81)80107-8
   SPECTOR A, 1995, FASEB J, V9, P1173, DOI 10.1096/fasebj.9.12.7672510
   Stadtman ER, 2006, FREE RADICAL RES, V40, P1250, DOI 10.1080/10715760600918142
   Taylor A, 2002, AM J CLIN NUTR, V75, P540, DOI 10.1093/ajcn/75.3.540
   Taylor A, 2001, NUTRITION, V17, P845, DOI 10.1016/S0899-9007(01)00655-4
   TAYLOR A, 1993, TOXICOL IND HEALTH, V9, P349, DOI 10.1177/0748233793009001-226
   Taylor A, 2002, ONCOGENE, V21, P4363, DOI 10.1038/sj.onc.1205557
   TAYLOR A, 1995, MECH AGEING DEV, V79, P33, DOI 10.1016/0047-6374(94)01541-S
   TAYLOR A, 1991, IN VITRO CELL DEV B, V27, P287, DOI 10.1007/BF02630905
   TAYLOR A, 1999, CRC MOD NUT, P1
   Taylor A, 1999, NUTR ENV INFLUENCES
   Terman A, 2002, ANN NY ACAD SCI, V973, P309, DOI 10.1111/j.1749-6632.2002.tb04657.x
   Tessier F, 1999, J BIOL CHEM, V274, P20796, DOI 10.1074/jbc.274.30.20796
   Vieira O, 2000, FASEB J, V14, P532, DOI 10.1096/fasebj.14.3.532
   Yamanaka K, 2003, NAT CELL BIOL, V5, P336, DOI 10.1038/ncb952
   Zanetti M, 2002, AM J PHYSIOL-HEART C, V283, pH2620, DOI 10.1152/ajpheart.00358.2001
NR 76
TC 7
Z9 7
U1 0
U2 10
PU WILEY-V C H VERLAG GMBH
PI WEINHEIM
PA POSTFACH 101161, 69451 WEINHEIM, GERMANY
SN 0021-2148
EI 1869-5868
J9 ISR J CHEM
JI Isr. J. Chem.
PY 2006
VL 46
IS 2
BP 145
EP 158
DI 10.1560/A8AA-Y8RP-9DRW-Y8AX
PG 14
WC Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Chemistry
GA 119QK
UT WOS:000243027600006
DA 2022-11-30
ER

PT J
AU Bikbov, MM
   Gilmanshin, TR
   Zainullin, RM
   Rakhimova, EM
   Rusakova, IA
   Fakhretdinova, AA
   Tuliakova, AM
   Kazakbaeva, GM
   Panda-Jonas, S
   Safiullina, KR
   Bolshakova, NI
   Gizzatov, AV
   Ponomarev, IP
   Nikitin, NA
   Baimukhametov, NE
   Jonas, JB
AF Bikbov, Mukharram M.
   Gilmanshin, Timur R.
   Zainullin, Rinat M.
   Rakhimova, Ellina M.
   Rusakova, Iuliia A.
   Fakhretdinova, Albina A.
   Tuliakova, Azaliia M.
   Kazakbaeva, Gyulli M.
   Panda-Jonas, Songhomitra
   Safiullina, Kamilia R.
   Bolshakova, Nataliia, I
   Gizzatov, Ainur, V
   Ponomarev, Ildar P.
   Nikitin, Nikolai A.
   Baimukhametov, Nail E.
   Jonas, Jost B.
TI Ankle-brachial index and ocular diseases in a Russian population
SO EYE
LA English
DT Article
ID ARTERIAL STIFFNESS; ASSOCIATION; PRESSURE; RISK; CLASSIFICATION;
   GLAUCOMA
AB Background To assess potential associations between the ankle-brachial blood pressure index (ABI) and ocular disorders. Methods In the population-based cross-sectional Russian Ural Eye and Medical Study including 5,899 (80.5%) out of 7328 eligible participants aged 40+ years, the participants underwent a series of ocular and medical examinations including measurement of ABI. Results Blood pressure measurements of both arms and ankles were available for 3187 (54.0%) individuals. The mean ABI was 1.26 +/- 0.19 (median:1.20; range: 0.61, 2.20). In multivariate analysis, a higher ABI was associated with younger age (P < 0.001; non-standardized regression coefficient B: -0.001; 95% confidence interval (CI): -0.002, -0.001), female sex (P < 0.001; B: 0.03; 95% CI: 0.02, 0.04), lower body mass index (P < 0.001; B: -0.004; 95% CI: -0.006, -0.003), lower waist-to-hip ratio (P = 0.01; B: -0.10; 95% CI: -0.17, -0.02), lower glucose serum concentration (P = 0.008; B: -0.005; 95% CI: -0.009, -0.001), lower prevalence of arterial hypertension (P < 0.001; B: -0.14; 95% CI: -0.16, -0.12), higher mean systolic blood pressure (P < 0.001; B: 0.003; 95% CI: 0.002, 0.003), and higher prevalence of any alcohol consumption (P < 0.001; B: 0.03; 95% CI: 0.02, 0.04). In that multivariate model, prevalence of glaucoma (P = 0.67) as a whole, open-angle glaucoma (P = 0.86) and angle-closure glaucoma (P = 0.54), stage of glaucomatous optic neuropathy (P = 0.57), prevalence of age-related macular degeneration (P = 0.88), prevalence and stage of diabetic retinopathy (P = 0.30, and P = 0.29, respectively), nuclear cataract (P = 0.32, and P = 0.41, resp.), cortical cataract (P = 0.33, and P = 0.92, resp.), subcapsular cataract (P = 0.74 and P = 0.60, resp.), and pseudoexfoliation (P = 0.44 and P = 0.47, resp.), intraocular pressure (P = 0.52), axial length (P = 0.20), and peripapillary retinal nerve fibre layer thickness (P = 0.55) were not significantly associated with the ABI. Conclusions In this ethnically mixed population from Russia, none of the major ocular diseases was associated with ABI suggesting that subclinical atherosclerosis is not markedly associated with the aetiology of these ocular disorders.
C1 [Bikbov, Mukharram M.; Gilmanshin, Timur R.; Zainullin, Rinat M.; Rakhimova, Ellina M.; Rusakova, Iuliia A.; Fakhretdinova, Albina A.; Tuliakova, Azaliia M.; Kazakbaeva, Gyulli M.; Safiullina, Kamilia R.; Bolshakova, Nataliia, I; Gizzatov, Ainur, V; Ponomarev, Ildar P.; Nikitin, Nikolai A.; Baimukhametov, Nail E.] Ufa Eye Res Inst, Ufa, Bashkortostan, Russia.
   [Panda-Jonas, Songhomitra] Privatpraxis Prof Jonas & Dr Panda Jonas, Heidelberg, Germany.
   [Jonas, Jost B.] Heidelberg Univ, Dept Ophthalmol, Med Fac Mannheim, Mannheim, Germany.
   [Jonas, Jost B.] Inst Mol & Clin Ophthalmol Basel, Basel, Switzerland.
C3 Ufa Eye Research Institute; Ruprecht Karls University Heidelberg
RP Bikbov, MM (通讯作者)，Ufa Eye Res Inst, Ufa, Bashkortostan, Russia.; Jonas, JB (通讯作者)，Heidelberg Univ, Dept Ophthalmol, Med Fac Mannheim, Mannheim, Germany.; Jonas, JB (通讯作者)，Inst Mol & Clin Ophthalmol Basel, Basel, Switzerland.
EM Bikbov.m@gmail.com; Jost.Jonas@medma.uni-heidelberg.de
FU Projekt DEAL
FX Open Access funding enabled and organized by Projekt DEAL.
CR Aboyans V, 2012, CIRCULATION, V126, P2890, DOI 10.1161/CIR.0b013e318276fbcb
   Agarwal I, 2015, ATHEROSCLEROSIS, V239, P539, DOI 10.1016/j.atherosclerosis.2015.02.020
   Bikbov MM, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.0567
   Bikbov MM, 2020, AM J OPHTHALMOL, V210, P158, DOI 10.1016/j.ajo.2019.10.003
   CARTER SA, 1969, J AMER MED ASSOC, V207, P1869, DOI 10.1001/jama.207.10.1869
   Chang YC, 2010, EYE, V24, P1037, DOI 10.1038/eye.2009.247
   Chen YW, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0122022
   Chen ZQ, 2014, SCI REP-UK, V4, DOI 10.1038/srep06685
   Chirinos JA, 2019, J AM COLL CARDIOL, V74, P1237, DOI 10.1016/j.jacc.2019.07.012
   Federal State Statistic Service, POP CENS
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Foster PJ, 2002, BRIT J OPHTHALMOL, V86, P238, DOI 10.1136/bjo.86.2.238
   Jeganathan VSE, 2009, ARCH OPHTHALMOL-CHIC, V127, P888, DOI 10.1001/archophthalmol.2009.136
   Jeon SJ, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-28985-8
   Kassoff A, 2001, AM J OPHTHALMOL, V131, P167
   Kawasaki R, 2011, OPHTHALMOLOGY, V118, P860, DOI 10.1016/j.ophtha.2010.08.040
   Levey AS, 2009, ANN INTERN MED, V150, P604, DOI 10.7326/0003-4819-150-9-200905050-00006
   Meyer ML, 2017, J ALZHEIMERS DIS, V57, P195, DOI 10.3233/JAD-161041
   Praveen MR, 2011, EYE, V25, P174, DOI 10.1038/eye.2010.175
   Roger VL, 2012, CIRCULATION, V125, pE2, DOI 10.1161/CIR.0b013e31823ac046
   Shiba T, 2017, GRAEF ARCH CLIN EXP, V255, P99, DOI 10.1007/s00417-016-3521-9
   Shiba T, 2012, GRAEF ARCH CLIN EXP, V250, P1275, DOI 10.1007/s00417-012-1952-5
   Shim SH, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/425835
   Stevens GA, 2016, PLOS MED, V13, DOI [10.1371/journal.pmed.1002056, 10.1371/journal.pmed.1002116]
   Tendera M, 2011, EUR HEART J, V32, P2851, DOI 10.1093/eurheartj/ehr211
   Terentes-Printzios D, 2017, HYPERTENSION, V70, P1057, DOI 10.1161/HYPERTENSIONAHA.117.09633
   Villela-Nogueira CA, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17040460
   Vlachopoulos C, 2012, HYPERTENSION, V60, P556, DOI 10.1161/HYPERTENSIONAHA.112.194779
   Weatherley Beth D, 2006, BMC Cardiovasc Disord, V6, P7, DOI 10.1186/1471-2261-6-7
   Whelton Paul K, 2018, Hypertension, V71, pe13, DOI [10.1016/j.jash.2018.06.010, 10.1161/HYP.0000000000000065]
   Wikipedia, DEM RUSS
   Wintergerst MWM, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-90900-5
NR 32
TC 0
Z9 0
U1 0
U2 0
PU SPRINGERNATURE
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND
SN 0950-222X
EI 1476-5454
J9 EYE
JI Eye
PD DEC
PY 2022
VL 36
IS 12
BP 2294
EP 2303
DI 10.1038/s41433-021-01846-x
EA NOV 2021
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 6H2ZZ
UT WOS:000723502900001
PM 34845354
OA Green Published, hybrid
DA 2022-11-30
ER

PT J
AU Thomas, A
   Sunija, AP
   Manoj, R
   Ramachandran, R
   Ramachandran, S
   Varun, PG
   Palanisamy, P
AF Thomas, Anju
   Sunija, A. P.
   Manoj, Rigved
   Ramachandran, Rajiv
   Ramachandran, Srikkanth
   Varun, P. Gopi
   Palanisamy, P.
TI RPE layer detection and baseline estimation using statistical methods
   and randomization for classification of AMD from retinal OCT
SO COMPUTER METHODS AND PROGRAMS IN BIOMEDICINE
LA English
DT Article
DE Retinal pigment epithelium; SD-OCT; Contrast enhancement; Pixel
   grouping; Randomization; Polynomial fitting
ID MACULAR DEGENERATION; AUTOMATIC SEGMENTATION; IMAGES; BOUNDARIES;
   DISEASE
AB Background and Objective: Age-related macular degeneration (AMD) is a condition of the eye that affects the aged people. Optical coherence tomography (OCT) is a diagnostic tool capable of analyzing and identifying the disease affected retinal layers with high resolution. The objective of this work is to extract the retinal pigment epithelium (RPE) layer and the baseline (natural eye curvature, particular to every patient) from retinal spectral-domain OCT (SD-OCT) images. It uses them to find the height of drusen (abnormalities) in the RPE layer and classify it as AMD or normal.
   Methods: In the proposed work, the contrast enhancement based adaptive denoising technique is used for speckle elimination. Pixel grouping and iterative elimination based on the knowledge of typical layer intensities and positions are used to obtain the RPE layer. Using this estimate, randomization techniques are employed, followed by polynomial fitting and drusen removal to arrive at a baseline estimate. The classification is based on the drusen height obtained by taking the difference between the RPE and baseline levels. We have used a patient, wise classification approach where a patient is classified diseased if more than a threshold number of patient images have drusen of more than a certain height. Since all slices of an affected patient will not show drusen, we are justified in adopting this technique
   Results: The proposed method is tested on a public data set of 2130 images/slices, which belonged to 30 patient volumes (15 AMD and 15 Normal) and achieved an overall accuracy of 96.66%, with no false positives. In comparison with existing works, the proposed method achieved higher overall accuracy and a better baseline estimate.
   Conclusions: The proposed work focuses on AMD/normal classification using a statistical approach. It does not require any training. The proposed method modifies the motion restoration paradigm to obtain an application-specific denoising algorithm. The existing RPE detection algorithm is modified significantly to make it robust and applicable even to images where the RPE is not very evident/there is a significant amount of perforations (drusen). The baseline estimation algorithm employs a powerful combination of randomization, iterative polynomial fitting, and pixel elimination in contrast to mere fitting techniques. The main highlight of this work is, it achieved an exact estimation of the baseline in the retinal image compared to the existing methods.
   (c) 2020 Elsevier B.V. All rights reserved.
C1 [Thomas, Anju; Sunija, A. P.; Manoj, Rigved; Ramachandran, Rajiv; Ramachandran, Srikkanth; Varun, P. Gopi; Palanisamy, P.] Natl Inst Technol Tiruchirappalli, Dept Elect & Commun Engn, Tiruchirappalli 620015, Tamil Nadu, India.
C3 National Institute of Technology (NIT System); National Institute of
   Technology Tiruchirappalli
RP Palanisamy, P (通讯作者)，Natl Inst Technol Tiruchirappalli, Dept Elect & Commun Engn, Tiruchirappalli 620015, Tamil Nadu, India.
EM anjukandathil.thomas@gmail.com; sunijaprabhakaran@gmail.com;
   rigvedmanoj1998@gmail.com; rrajiv9802@gmail.com; supersri04@gmail.com;
   varun@nitt.edu; palan@nitt.edu
RI Gopi, Varun P/S-3943-2019; PONNUSAMY, PALANISAMY/AAM-5285-2020; Thomas,
   Anju/ABF-6145-2021
OI Gopi, Varun P/0000-0001-5593-3949; PONNUSAMY,
   PALANISAMY/0000-0003-3687-5944; Thomas, Anju/0000-0002-2178-0531;
   Ramachandran, Srikkanth/0000-0003-2392-1999
CR Bagci AM, 2008, AM J OPHTHALMOL, V146, P679, DOI 10.1016/j.ajo.2008.06.010
   Curcio CA, 1996, INVEST OPHTH VIS SCI, V37, P1236
   Davis MD, 2005, ARCH OPHTHALMOL-CHIC, V123, P1484
   Duan WJ, 2018, IEEE ACCESS, V6, P25130, DOI 10.1109/ACCESS.2018.2825397
   Fang LY, 2017, BIOMED OPT EXPRESS, V8, P2732, DOI 10.1364/BOE.8.002732
   Jemshi KM, 2018, INT J COMPUT ASS RAD, V13, P1369, DOI 10.1007/s11548-018-1795-6
   Khalid S., 2017, INTERVIEW BASED ITER
   Khalid S, 2018, J DIGIT IMAGING, V31, P464, DOI 10.1007/s10278-017-0038-7
   Koprowski R., 2011, IMAGE PROCESSING OPT
   Kugelman J, 2018, BIOMED OPT EXPRESS, V9, P5759, DOI 10.1364/BOE.9.005759
   Motozawa N, 2019, OPHTHALMOL THER, V8, P527, DOI 10.1007/s40123-019-00207-y
   Mousavi E., 2019, ARXIV PREPRINT ARXIV
   Naz S., 2016, 2016 6 INT C IMAGE P, P1
   Niwas SI, 2015, J MED SYST, V39, DOI 10.1007/s10916-015-0199-1
   Niwas SI, 2016, COMPUT METH PROG BIO, V130, P13, DOI 10.1016/j.cmpb.2016.03.011
   Niwas SI, 2016, COMPUT METH PROG BIO, V130, P65, DOI 10.1016/j.cmpb.2016.03.018
   Niwas SI, 2016, IEEE J BIOMED HEALTH, V20, P343, DOI 10.1109/JBHI.2014.2387207
   Ravenscroft D, 2017, LECT NOTES COMPUT SC, V10617, P237, DOI 10.1007/978-3-319-70353-4_21
   Ravenscroft D, 2017, EUR SIGNAL PR CONF, P51, DOI 10.23919/EUSIPCO.2017.8081167
   Saha S, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-47390-3
   Srinivasan PP, 2014, BIOMED OPT EXPRESS, V5, P3568, DOI 10.1364/BOE.5.003568
   Sudeep PV, 2016, COMPUT BIOL MED, V71, P97, DOI 10.1016/j.compbiomed.2016.02.003
   Sugmk J, 2014, 7 2014 BIOM ENG INT, P1, DOI DOI 10.1109/BMEICON.2014.7017441
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Yaqoob Z, 2006, J BIOMED OPT, V11, DOI 10.1117/1.2360525
NR 25
TC 13
Z9 13
U1 0
U2 4
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0169-2607
EI 1872-7565
J9 COMPUT METH PROG BIO
JI Comput. Meth. Programs Biomed.
PD MAR
PY 2021
VL 200
AR 105822
DI 10.1016/j.cmpb.2020.105822
EA FEB 2021
PG 11
WC Computer Science, Interdisciplinary Applications; Computer Science,
   Theory & Methods; Engineering, Biomedical; Medical Informatics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Computer Science; Engineering; Medical Informatics
GA QO4KJ
UT WOS:000623111700009
PM 33190943
DA 2022-11-30
ER

PT J
AU Rodriguez, A
   Biarnes, M
   Coco-Martin, RM
   Sala-Puigdollers, A
   Mones, J
AF Rodriguez, Anabel
   Biarnes, Marc
   Coco-Martin, Rosa M.
   Sala-Puigdollers, Anna
   Mones, Jordi
TI Early Detection of Incipient Retinal Pigment Epithelium Atrophy
   Overlying Drusen with Fundus Autofluorescencevs. Spectral Domain Optical
   Coherence Tomography
SO JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID GEOGRAPHIC ATROPHY
AB Purpose. This study aims to find out which tool, fundus autofluorescence (FAF) or spectral domain optical coherence tomography (SD-OCT), is more sensitive in detecting retinal pigment epithelium (RPE) demise overlying drusen and can, therefore, help predict geographic atrophy (GA) appearance in Age-Related Macular Degeneration (AMD).Methods. A single-site, retrospective, observational, longitudinal study was conducted. Patients with intermediate AMD (iAMD) (large (>125 mu m) or intermediate (63-125 mu m) drusen with hyper/hypopigmentation) with a minimum follow-up of 18 months were included. Drusen with overlying incipient RPE atrophy were identified on SD-OCT defined as choroidal hypertransmission or nascent geographic atrophy (nGA). These selected drusen were, then, traced backwards in time to determine if incipient RPE atrophy overlying drusen was observed on FAF (well-demarcated region of absence of autofluorescence) before, simultaneously, or after having detected the first signs of incipient RPE atrophy on SD-OCT. The number of drusen in which signs of incipient RPE atrophy was detected earlier using FAF or SD-OCT was compared. The time elapsed from the identification with the more sensitive method to the other was recorded and analyzed.Results. One hundred and thirty-three drusen in 22 eyes of 22 patients were included. Of these, 112 (84.2%) drusen showed choroidal hypertransmission and 21(15.8%) nGA. Early signs of atrophy overlying drusen were found simultaneously on SD-OCT and FAF in 52 cases (39.1%, 95% CI 30.8-47.9%), earliest on FAF in 51 (38.3%, 95% CI 30.0-47.2%) and first on SD-OCT in 30 (22.6%, 95% CI 15.8-30.6%;p<0.05). Statistically significant differences were found between both techniques (p=0.005), with FAF detecting it earlier than SD-OCT. When RPE atrophy was found first on FAF, the median time to diagnosis with SD-OCT was 6.6 months (95% CI 5.5 to 8.6), while if detection occurred earlier on SD-OCT, the median time until identification with FAF was 12.6 months (95% CI 6.0 to 23.4;p=0.0003).Conclusions. In iAMD cases in which early atrophy overlying drusen is not detected simultaneously in FAF and SD-OCT, FAF was significantly more sensitive. Nevertheless, a multimodal approach is recommended and required to evaluate these patients.
C1 [Rodriguez, Anabel; Biarnes, Marc; Sala-Puigdollers, Anna; Mones, Jordi] Ctr Med Teknon, Inst Macula, Barcelona, Spain.
   [Rodriguez, Anabel; Biarnes, Marc; Mones, Jordi] Barcelona Macula Fdn, Barcelona, Spain.
   [Coco-Martin, Rosa M.] Univ Valladolid, Inst Oftalmobiol Aplicada IOBA, Valladolid, Spain.
   [Coco-Martin, Rosa M.] Inst Salud Carlos III, Red Temat Invest Cooperat Salud Oftalmol Oftared, Madrid, Spain.
   [Sala-Puigdollers, Anna] Hosp Clin Barcelona, Inst Clin Oftalmol ICOE, Barcelona, Spain.
C3 Universidad de Valladolid; Instituto de Salud Carlos III; University of
   Barcelona; Hospital Clinic de Barcelona
RP Coco-Martin, RM (通讯作者)，Univ Valladolid, Inst Oftalmobiol Aplicada IOBA, Valladolid, Spain.; Coco-Martin, RM (通讯作者)，Inst Salud Carlos III, Red Temat Invest Cooperat Salud Oftalmol Oftared, Madrid, Spain.
EM anabelrolo@gmail.com; marcmbp@gmail.com; rosa@ioba.med.uva.es;
   annasalapuigdollers@hotmail.com; jmones@institutmacula.com
RI Martin, Rosa Maria Coco/H-4511-2015; mones, jordi/CAJ-2963-2022
OI Martin, Rosa Maria Coco/0000-0002-1811-1417; mones,
   jordi/0000-0003-3685-2160; Sala-Puigdollers, Anna/0000-0001-5792-6937
CR Balaratnasingam C, 2017, OPHTHALMOLOGY, V124, P644, DOI 10.1016/j.ophtha.2016.12.034
   Batioglu F, 2014, OPTOMETRY VISION SCI, V91, P950, DOI 10.1097/OPX.0000000000000321
   Bearelly S, 2011, RETINA-J RET VIT DIS, V31, P81, DOI 10.1097/IAE.0b013e3181e0958b
   Bearelly S, 2009, OPHTHALMOLOGY, V116, P1762, DOI 10.1016/j.ophtha.2009.04.015
   Bindewald A, 2005, INVEST OPHTH VIS SCI, V46, P3309, DOI 10.1167/iovs.04-0430
   Coleman HR, 2008, LANCET, V372, P1835, DOI 10.1016/S0140-6736(08)61759-6
   Cukras C, 2010, OPHTHALMOLOGY, V117, P489, DOI 10.1016/j.ophtha.2009.12.002
   Dysli C, 2017, INVEST OPHTH VIS SCI, V58, P4856, DOI 10.1167/iovs.17-22184
   Fleckenstein M, 2011, INVEST OPHTH VIS SCI, V52, P3761, DOI 10.1167/iovs.10-7021
   Fleckenstein M, 2010, INVEST OPHTH VIS SCI, V51, P3846, DOI 10.1167/iovs.09-4533
   Giocanti-Auregan A, 2015, INVEST OPHTH VIS SCI, V56, P8325, DOI 10.1167/iovs.14-15480
   Guymer R., 2020, INVESTIGATIVE OPTHAL, P56
   Kellner U, 2010, RETINA-J RET VIT DIS, V30, P6, DOI 10.1097/IAE.0b013e3181b8348b
   Khanifar AA, 2012, RETINA-J RET VIT DIS, V32, P1884, DOI 10.1097/IAE.0b013e3182509778
   Lackner D, 2020, SOL RRL, V4, DOI 10.1002/solr.202000210
   Ly A, 2017, OPTOMETRY VISION SCI, V94, P246, DOI 10.1097/OPX.0000000000000997
   Mauschitz MM, 2012, INVEST OPHTH VIS SCI, V53, P4932, DOI 10.1167/iovs.12-9711
   Mones J, 2017, OPHTHALMOL RETINA, V1, P461, DOI 10.1016/j.oret.2017.02.006
   SARKS JP, 1994, EYE, V8, P269, DOI 10.1038/eye.1994.57
   Schaal KB, 2017, AM J OPHTHALMOL, V174, P145, DOI 10.1016/j.ajo.2016.11.002
   Steinberg JS, 2013, INVEST OPHTH VIS SCI, V54, P4054, DOI 10.1167/iovs.12-11538
   VANDERSCHAFT TL, 1992, OPHTHALMOLOGY, V99, P278
   Wu ZC, 2020, OPHTHALMOL RETINA, V4, P568, DOI 10.1016/j.oret.2019.12.011
   Wu ZC, 2015, INVEST OPHTH VIS SCI, V56, P1546, DOI 10.1167/iovs.14-16211
   Wu ZC, 2014, OPHTHALMOLOGY, V121, P2415, DOI 10.1016/j.ophtha.2014.06.034
   Xu LN, 2013, RETINA-J RET VIT DIS, V33, P1850, DOI 10.1097/IAE.0b013e31828991b2
   Xuan Yi, 2010, Zhonghua Yan Ke Za Zhi, V46, P708
NR 27
TC 1
Z9 1
U1 0
U2 1
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 2090-004X
EI 2090-0058
J9 J OPHTHALMOL
JI J. Ophthalmol.
PD SEP 16
PY 2020
VL 2020
AR 9457457
DI 10.1155/2020/9457457
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA NY1DO
UT WOS:000576139000003
PM 33014447
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Conner-Spady, BL
   Sanmugasunderam, S
   Courtright, P
   Mildon, D
   McGurran, JJ
   Noseworthy, TW
AF Conner-Spady, BL
   Sanmugasunderam, S
   Courtright, P
   Mildon, D
   McGurran, JJ
   Noseworthy, TW
CA Steering Comm Western Canada Waiti
TI Patient and physician perspectives of maximum acceptable waiting times
   for cataract surgery
SO CANADIAN JOURNAL OF OPHTHALMOLOGY-JOURNAL CANADIEN D OPHTALMOLOGIE
LA English
DT Article
DE priority criteria; maximum acceptable waiting times; cataract surgery;
   waiting list
ID WILLINGNESS-TO-PAY; OLDER-ADULTS; CANADA; LIST
AB Background: Lengthy waiting times for cataract surgery are an important issue in countries with publicly funded health care systems. To improve the fairness, timeliness, and certainty of waiting-time management, the Western Canada Waiting List Project has developed priority criteria scores (PCSs) related to urgency and linked to maximum acceptable waiting times (MAWTs).The purpose of our study was to compare patient and physician perspectives of MAWT for different levels of urgency. A second aim was to assess the determinants of patient and surgeon perspectives on MAWT
   Methods: Ophthalmologists assessed consecutive patients waitlisted for cataract surgery. Data included a MAWT, a visual analogue scale of urgency (VAS urgency), and the cataract PCS. Patients were mailed questionnaires to assess their perspectives of MAWT and VAS urgency.They were also sent a measure of visual function called the Visual Function Assessment. We used hierarchical linear regression to assess the determinants of MAWT
   Results: The mean age of the 213 patients was 73.9 years; 56.8% were female and 71.8% were booked for first eye surgery. Physician-rated MAWT was significantly longer than patient-rated MAWT (mean 15.1 vs. 9.9 weeks). Median physician MAWTs ranged from 12 (most urgent) to 20 (least urgent) weeks, and patient MAWTs, from 4 to 8 weeks. A 3-step hierarchical linear regression model showed that, after adjusting for age and sex, the priority criteria added significantly to the surgeon model (R2 change = 0.22). Significant predictors were ocular comorbidity, impairment in visual function, and ability to work or live independently or care for dependents. After the addition of VAS urgency, the final model explained 42% of the variance in surgeon MAWT. Significant predictors were age-related macular degeneration and VAS urgency. A 4-step hierarchical regression model for patient MAWT showed that after step 2, sex and visual acuity in the nonsurgery eye were significant predictors.The final model accounted for 11% of the variance in patient MAWT. Significant predictors were sex (males had lower MAWT) and VAS urgency.
   Interpretation: Patient and physician views on MAWT differ, yet both are critical to a fair process for developing standardized waiting times related to levels of urgency. Results from this study provide initial inputs to the formulation of benchmark waiting times for different levels of the cataract PCS.
C1 Univ Calgary, Calgary, AB T2N 4N1, Canada.
   Western Canada Waiting List Project, Calgary, AB, Canada.
   Univ British Columbia, Dept Ophthalmol, Vancouver, BC, Canada.
   Univ British Columbia, British Columbia Ctr Epidemiol & Int Ophthalmol, Vancouver, BC, Canada.
   Kilimanjaro Ctr Community Ophthalmol, Moshi, Tanzania.
C3 University of Calgary; University of British Columbia; University of
   British Columbia
RP Noseworthy, TW (通讯作者)，Univ Calgary, 3330 Hosp Dr NW, Calgary, AB T2N 4N1, Canada.
EM tnosewor@ucalgary.ca
CR Anderson G, 1997, HEALTH AFFAIR, V16, P181, DOI 10.1377/hlthaff.16.5.181
   Ballan L, 2001, CAN MED ASSOC J, V164, P1177
   Bishai DM, 2000, J HEALTH ECON, V19, P219, DOI 10.1016/S0167-6296(99)00024-7
   Churchill AJ, 2000, BRIT J OPHTHALMOL, V84, P429, DOI 10.1136/bjo.84.4.429
   Cohen J., 1983, APPL MULTIPLE REGRES, V2nd ed.
   Conner-Spady Barbara, 2005, J Health Serv Res Policy, V10, P84, DOI 10.1258/1355819053559155
   Desai P, 1999, BRIT J OPHTHALMOL, V83, P893, DOI 10.1136/bjo.83.8.893
   Dunn E, 1997, SOC SCI MED, V44, P1603, DOI 10.1016/S0277-9536(96)00251-1
   Edwards RT, 2003, HEALTH POLICY, V63, P229, DOI 10.1016/S0168-8510(02)00101-X
   ESMAIL N, 2003, WAITING YOUR TURN HO
   Glynn Peter A R, 2003, Hosp Q, V7, P44
   Hadjistavropoulos H D, 1998, Jt Comm J Qual Improv, V24, P407
   Hanning M, 1998, INT J TECHNOL ASSESS, V14, P180, DOI 10.1017/S026646230001062X
   Ivers RQ, 1998, J AM GERIATR SOC, V46, P58
   Ivers RQ, 2003, J AM GERIATR SOC, V51, P356, DOI 10.1046/j.1532-5415.2003.51109.x
   Naumann S, 2001, J Manag Med, V15, P376, DOI 10.1108/EUM0000000006184
   Noseworthy TW, 2003, J EVAL CLIN PRACT, V9, P23, DOI 10.1046/j.1365-2753.2003.00377.x
   Owsley C, 2002, JAMA-J AM MED ASSOC, V288, P841, DOI 10.1001/jama.288.7.841
   Pager CK, 2004, J CATARACT REFR SURG, V30, P591, DOI 10.1016/S0886-3350(03)00671-0
   Riley AF, 2001, CLIN EXP OPHTHALMOL, V29, P376, DOI 10.1046/j.1442-9071.2001.00457.x
   Romanchuk KG, 2002, CAN J OPHTHALMOL, V37, P145, DOI 10.1016/S0008-4182(02)80056-4
   THOMPSON AGH, 1995, INT J QUAL HEALTH C, V7, P127, DOI 10.1093/intqhc/7.2.127
   Wright CJ, 2002, CAN MED ASSOC J, V167, P461
NR 23
TC 19
Z9 19
U1 0
U2 3
PU CANADIAN OPHTHAL SOC
PI OTTAWA
PA 1525 CARLING AVE SUITE 610, OTTAWA, ONTARIO K1Z 8R9, CANADA
SN 0008-4182
EI 1715-3360
J9 CAN J OPHTHALMOL
JI Can. J. Opthalmol.-J. Can. Opthalmol.
PD AUG
PY 2005
VL 40
IS 4
BP 439
EP 447
DI 10.1016/S0008-4182(05)80003-1
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Ophthalmology
GA 964AN
UT WOS:000231848400003
PM 16116507
DA 2022-11-30
ER

PT J
AU Schlegl, T
   Waldstein, SM
   Bogunovic, H
   Endstrasser, F
   Sadeghipour, A
   Philip, AM
   Podkowinski, D
   Gerendas, BS
   Langs, G
   Schmidt-Erfurth, U
AF Schlegl, Thomas
   Waldstein, Sebastian M.
   Bogunovic, Hrvoje
   Endstrasser, Franz
   Sadeghipour, Amir
   Philip, Ana-Maria
   Podkowinski, Dominika
   Gerendas, Bianca S.
   Langs, Georg
   Schmidt-Erfurth, Ursula
TI Fully Automated Detection and Quantification of Macular Fluid in OCT
   Using Deep Learning
SO OPHTHALMOLOGY
LA English
DT Article
ID OPTICAL COHERENCE TOMOGRAPHY; VISUAL-ACUITY; DIABETIC-RETINOPATHY;
   ANATOMIC OUTCOMES; SUBRETINAL FLUID; DEGENERATION; EDEMA;
   IDENTIFICATION; SEGMENTATION; RANIBIZUMAB
AB Purpose: Development and validation of a fully automated method to detect and quantify macular fluid in conventional OCT images.
   Design: Development of a diagnostic modality.
   Participants: The clinical dataset for fluid detection consisted of 1200 OCT volumes of patients with neovascular age-related macular degeneration (AMD, n = 400), diabetic macular edema (DME, n = 400), or retinal vein occlusion (RVO, n = 400) acquired with Zeiss Cirrus (Carl Zeiss Meditec, Dublin, CA) (n = 600) or Heidelberg Spectralis (Heidelberg Engineering, Heidelberg, Germany) (n = 600) OCT devices.
   Methods: A method based on deep learning to automatically detect and quantify intraretinal cystoid fluid (IRC) and subretinal fluid (SRF) was developed. The performance of the algorithm in accurately identifying fluid localization and extent was evaluated against a manual consensus reading of 2 masked reading center graders.
   Main Outcome Measures: Performance of a fully automated method to accurately detect, differentiate, and quantify intraretinal and SRF using area under the receiver operating characteristics curves, precision, and recall.
   Results: The newly designed, fully automated diagnostic method based on deep learning achieved optimal accuracy for the detection and quantification of IRC for all 3 macular pathologies with a mean accuracy (AUC) of 0.94 (range, 0.91-0.97), a mean precision of 0.91, and a mean recall of 0.84. The detection and measurement of SRF were also highly accurate with an AUC of 0.92 (range, 0.86-0.98), a mean precision of 0.61, and a mean recall of 0.81, with superior performance in neovascular AMD and RVO compared with DME, which was represented rarely in the population studied. High linear correlation was confirmed between automated and manual fluid localization and quantification, yielding an average Pearson's correlation coefficient of 0.90 for IRC and of 0.96 for SRF.
   Conclusions: Deep learning in retinal image analysis achieves excellent accuracy for the differential detection of retinal fluid types across the most prevalent exudative macular diseases and OCT devices. Furthermore, quantification of fluid achieves a high level of concordance with manual expert assessment. Fully automated analysis of retinal OCT images from clinical routine provides a promising horizon in improving accuracy and reliability of retinal diagnosis for research and clinical practice in ophthalmology. (C) 2017 by the American Academy of Ophthalmology. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
C1 [Schlegl, Thomas; Bogunovic, Hrvoje; Endstrasser, Franz; Sadeghipour, Amir; Schmidt-Erfurth, Ursula] Med Univ Vienna, Dept Ophthalmol, Christian Doppler Lab Ophthalm Image Anal, Vienna, Austria.
   [Waldstein, Sebastian M.; Gerendas, Bianca S.; Schmidt-Erfurth, Ursula] Med Univ Vienna, Dept Ophthalmol, Spitalgasse 23, A-1090 Vienna, Austria.
   [Philip, Ana-Maria; Podkowinski, Dominika] Med Univ Vienna, Vienna Reading Ctr, Dept Ophthalmol, Vienna, Austria.
   [Schlegl, Thomas; Langs, Georg] Med Univ Vienna, Dept Biomed Imaging & Image Guided Therapy, Computat Imaging Res Lab, Vienna, Austria.
C3 Medical University of Vienna; Medical University of Vienna; Medical
   University of Vienna; Medical University of Vienna
RP Schmidt-Erfurth, U (通讯作者)，Med Univ Vienna, Dept Ophthalmol, Spitalgasse 23, A-1090 Vienna, Austria.
EM ursula.schmidt-erfurth@meduniwien.ac.at
RI Bogunovic, Hrvoje/J-3445-2014
OI Bogunovic, Hrvoje/0000-0002-9168-0894; Gerendas, Bianca
   S./0000-0001-8940-8130; Schlegl, Thomas/0000-0003-0706-7876;
   Sadeghipour, Amir/0000-0003-2379-7895; Schmidt-Erfurth,
   Ursula/0000-0002-7788-7311; Langs, Georg/0000-0002-5536-6873
FU Christian Doppler Research Association; Austrian Federal Ministry of
   Economy, Family and Youth; National Foundation of Research, Technology
   and Development; IBM; Austrian Federal Ministry of Science, Research and
   Economy; Novartis; Austrian Science Fund [I 2714-B31]
FX S.M.W.: Consultancy - Bayer, Novartis; Research support - Bayer,
   Genentech; Patent pending - WO 2016139183 A1.; T.S., S.M.W., H.B., F.E.,
   A. S., A.-M.P., D.P., B.S.G., G.L., and U.S.-E.: Grants - Christian
   Doppler Research Association.; A.-M.P.: Grants - Austrian Federal
   Ministry of Economy, Family and Youth, National Foundation of Research,
   Technology and Development.; This study received funding from IBM (TS:
   2016-2017 IBM PhD Fellowship Award), the Austrian Federal Ministry of
   Science, Research and Economy, Novartis, and the Austrian Science Fund
   (I 2714-B31). The sponsor or funding organizations had no role in the
   design or conduct of this research.
CR Abramoff MD, 2016, INVEST OPHTH VIS SCI, V57, P5200, DOI 10.1167/iovs.16-19964
   Arnold JJ, 2016, BMC OPHTHALMOL, V16, DOI 10.1186/s12886-016-0207-3
   Chakravarthy U, 2016, OPHTHALMOLOGY, V123, P1731, DOI 10.1016/j.ophtha.2016.04.005
   Chen XJ, 2012, INVEST OPHTH VIS SCI, V53, P8042, DOI 10.1167/iovs.12-10083
   Chetlur S, ARXIV141007592014 CO
   Chiu SJ, 2015, BIOMED OPT EXPRESS, V6, P1172, DOI 10.1364/BOE.6.001172
   Dieleman S., 2015, LASAGNE 1 RELEASE, V1
   Elman MJ, 2015, OPHTHALMOLOGY, V122, P375, DOI 10.1016/j.ophtha.2014.08.047
   Fernandez DC, 2005, IEEE T MED IMAGING, V24, P929, DOI 10.1109/TMI.2005.848655
   Freund KB, 2015, RETINA-J RET VIT DIS, V35, P1489, DOI 10.1097/IAE.0000000000000627
   Gargeya R, 2017, OPHTHALMOLOGY, V124, P962, DOI 10.1016/j.ophtha.2017.02.008
   Garvin MK, 2009, IEEE T MED IMAGING, V28, P1436, DOI 10.1109/TMI.2009.2016958
   Gerendas B, 2014, INVEST OPHTH VIS SCI, V55
   Giachetti Filho Richard Geraldo, 2016, Int J Retina Vitreous, V2, P6, DOI 10.1186/s40942-016-0029-8
   Gupta OP, 2010, OPHTHALMOLOGY, V117, P2134, DOI 10.1016/j.ophtha.2010.02.032
   HUANG D, 1991, SCIENCE, V254, P1178, DOI 10.1126/science.1957169
   James B, P PYTH SCI COMP C SC
   Lee CS, 2017, OPHTHALMOL RETINA, V1, P322, DOI 10.1016/j.oret.2016.12.009
   Maguire MG, 2016, OPHTHALMOLOGY, V123, P1751, DOI 10.1016/j.ophtha.2016.03.045
   Noh H, 2015, IEEE I CONF COMP VIS, P1520, DOI 10.1109/ICCV.2015.178
   Querques G, 2011, AM J OPHTHALMOL, V152, P100, DOI 10.1016/j.ajo.2011.01.027
   Schlegl Thomas, 2015, Inf Process Med Imaging, V24, P437, DOI 10.1007/978-3-319-19992-4_34
   Schmidt-Erfurth U, 2017, EYE, V31, P26, DOI 10.1038/eye.2016.227
   Schmidt-Erfurth U, 2016, PROG RETIN EYE RES, V50, P1, DOI 10.1016/j.preteyeres.2015.07.007
   Schmidt-Erfurth U, 2015, OPHTHALMOLOGY, V122, P822, DOI 10.1016/j.ophtha.2014.11.017
   Sharma S, 2016, OPHTHALMOLOGY, V123, P865, DOI 10.1016/j.ophtha.2015.12.002
   Sophie R, 2015, OPHTHALMOLOGY, V122, P1395, DOI 10.1016/j.ophtha.2015.02.036
   Toth CA, 2015, RETINA-J RET VIT DIS, V35, P1303, DOI 10.1097/IAE.0000000000000483
   Waldstein SM, 2016, OPHTHALMOLOGY, V123, P1521, DOI 10.1016/j.ophtha.2016.03.037
   Waldstein SM, 2016, JAMA OPHTHALMOL, V134, P182, DOI 10.1001/jamaophthalmol.2015.4948
   Wang J, 2016, BIOMED OPT EXPRESS, V7, P1577, DOI 10.1364/BOE.7.001577
   Wilkins GR, 2012, IEEE T BIO-MED ENG, V59, P1109, DOI 10.1109/TBME.2012.2184759
   Wu J, 2016, J OPHTHALMOL, V2016, DOI 10.1155/2016/3898750
   Xu XY, 2015, IEEE T MED IMAGING, V34, P1616, DOI 10.1109/TMI.2015.2408632
   YOUDEN WJ, 1950, CANCER-AM CANCER SOC, V3, P32, DOI 10.1002/1097-0142(1950)3:1<32::AID-CNCR2820030106>3.0.CO;2-3
NR 35
TC 232
Z9 240
U1 7
U2 57
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD APR
PY 2018
VL 125
IS 4
BP 549
EP 558
DI 10.1016/j.ophtha.2017.10.031
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA FZ9HE
UT WOS:000427920000023
PM 29224926
OA hybrid
HC Y
HP N
DA 2022-11-30
ER

PT J
AU Ying, GS
   Maguire, MG
   Daniel, E
   Ferris, FL
   Jaffe, GJ
   Grunwald, JE
   Toth, CA
   Huang, JY
   Martin, DF
AF Ying, Gui-shuang
   Maguire, Maureen G.
   Daniel, Ebenezer
   Ferris, Frederick L.
   Jaffe, Glenn J.
   Grunwald, Juan E.
   Toth, Cynthia A.
   Huang, Jiayan
   Martin, Daniel F.
CA Comparison Age-Related Macular
TI Association of Baseline Characteristics and Early Vision Response with
   2-Year Vision Outcomes in the Comparison of AMD Treatments Trials (CATT)
SO OPHTHALMOLOGY
LA English
DT Article
ID VISUAL-ACUITY LOSS; MACULAR DEGENERATION; RANIBIZUMAB; BEVACIZUMAB;
   AFLIBERCEPT; THERAPY
AB Purpose: To evaluate the association of baseline characteristics and early visual acuity (VA) response with visual outcomes at years 1 or 2 in the Comparison of Age-Related Macular Degeneration (AMD) Treatments Trials (CATT).
   Design: Secondary analysis of CATT.
   Participants: The 1185 CATT participants with baseline VA of 20/25 to 20/320. Methods: Participants were assigned to ranibizumab or bevacizumab and to 1 of 3 dosing regimens. Associations of baseline characteristics and early VA response (week 4 or 12) with VA response at years 1 or 2 were assessed by R-2 from linear regression analyses. Patients who had a poor initial response (VA 20/ 40 or worse with persistent fluid and without >= 1-line VA gain) were defined as candidates for changing treatment.
   Main Outcome Measures: Visual acuity change from baseline.
   Results: Statistically significant (P < 0.05) baseline predictors for less VA gain at year 2 were older age, VA of 20/40 or better, larger choroidal neovascularization area, presence of geographic atrophy, total foveal thickness <= 325 mu m or >= 425 mu m, and elevation of retinal pigment epithelium. Among 176 eyes gaining >= 3 lines at week 12, 78% had a >= 3-line gain at year 2, whereas among 113 eyes losing >= 1-line at week 12, 27% improved to a >= 1-line gain at year 2. Visual acuity response at week 12 was more predictive of VA response at year 2 (R-2 = 0.30) than VA response at week 4 (R-2 = 0.17) and baseline predictors (R-2 = 0.13; P < 0.0001). Among 126 candidates for changing treatment drug at week 12, mean VA improved by 2.8 letters (P = 0.050), mean total retinal thickness decreased 53 mu m (P < 0.0001), and fluid resolved in 33% (P < 0.0001) between week 12 and year 1 with continued use of the same drug and regimen. Similar improvements were observed among 83 candidates for changing drugs at week 24.
   Conclusions: Visual acuity response at week 12 is more predictive of 2-year vision outcomes than either several baseline characteristics or week 4 response. Eyes with poor initial response may benefit from continued treatment without switching to another drug. Ophthalmology 2015; 122:2523-2531 (C) 2015 by the American Academy of Ophthalmology.
C1 [Ying, Gui-shuang; Maguire, Maureen G.; Daniel, Ebenezer; Grunwald, Juan E.; Huang, Jiayan] Univ Penn, Dept Ophthalmol, Philadelphia, PA 19104 USA.
   [Ferris, Frederick L.] NEI, NIH, Bethesda, MD 20892 USA.
   [Jaffe, Glenn J.; Toth, Cynthia A.] Duke Univ, Dept Ophthalmol, Durham, NC USA.
   [Martin, Daniel F.] Cleveland Clin, Cole Eye Inst, Cleveland, OH 44106 USA.
C3 University of Pennsylvania; National Institutes of Health (NIH) - USA;
   NIH National Eye Institute (NEI); Duke University; Cleveland Clinic
   Foundation
RP Ying, GS (通讯作者)，Univ Penn, Dept Ophthalmol, 3535 Market St,Suite 700, Philadelphia, PA 19104 USA.
EM gsying@mail.med.upenn.edu
RI Toth, Cynthia/L-5534-2019
OI Toth, Cynthia/0000-0002-2324-0854; Maguire, Maureen/0000-0002-4249-2467;
   Grunwald, Juan/0000-0002-5973-6616; Ferris,
   Frederick/0000-0002-4933-0639
FU Bioptigen (Morrisville, NC); Genentech (San Francisco, CA); Physical
   Sciences Inc (Andover, MA); Consultant - Alcon Laboratories (Fort Worth,
   TX); Thrombogenics (Iselin, NJ); Consultant - Genentech (San Francisco,
   CA); National Eye Institute, National Institutes of Health, Bethesda,
   Maryland [U10 EY017823, U10 EY017825, U10 EY017826, U10 EY017828,
   R21EY023689]; NATIONAL EYE INSTITUTE [R21EY023689, U10EY017825] Funding
   Source: NIH RePORTER
FX The author(s) have no proprietary or commercial interest in any
   materials discussed in this article. G.-S. Y.: Consultant -Janssen
   (Titusville, NJ) C.A.T.: Financial Support - Bioptigen (Morrisville,
   NC), Genentech (San Francisco, CA), Physical Sciences Inc (Andover,
   MA).; Consultant - Alcon Laboratories (Fort Worth, TX), Thrombogenics
   (Iselin, NJ) M.G.M.: Consultant - Genentech (San Francisco, CA);
   Supported by the National Eye Institute, National Institutes of Health,
   Bethesda, Maryland (cooperative agreement nos.: U10 EY017823, U10
   EY017825, U10 EY017826, U10 EY017828, and R21EY023689).
CR Aslankurt M, 2013, EUR J OPHTHALMOL, V23, P553, DOI 10.5301/ejo.5000268
   Avery RL, 2006, OPHTHALMOLOGY, V113, P363, DOI 10.1016/j.ophtha.2005.11.019
   Bakall B, 2013, AM J OPHTHALMOL, V156, P15, DOI 10.1016/j.ajo.2013.02.017
   Beck RW, 2003, AM J OPHTHALMOL, V135, P194, DOI 10.1016/S0002-9394(02)01825-1
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Busbee BG, 2013, OPHTHALMOLOGY, V120, P1046, DOI 10.1016/j.ophtha.2012.10.014
   Chakravarthy U, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.04.015
   Cho H, 2013, BRIT J OPHTHALMOL, V97, P1032, DOI 10.1136/bjophthalmol-2013-303344
   DeCroos FC, 2012, OPHTHALMOLOGY, V119, P2549, DOI 10.1016/j.ophtha.2012.06.040
   Eadie JA, 2014, OPHTHAL SURG LAS IM, V9, P1
   Ehlken C, 2014, EYE, V28, P538, DOI 10.1038/eye.2014.64
   Finger RP, 2014, SURV OPHTHALMOL, V59, P1, DOI 10.1016/j.survophthal.2013.03.009
   Grunwald JE, 2012, OPHTHALMOLOGY, V119, P1634, DOI 10.1016/j.ophtha.2012.02.013
   Hagstrom SA, 2014, JAMA OPHTHALMOL, V132, P521, DOI 10.1001/jamaophthalmol.2014.109
   Hagstrom SA, 2013, OPHTHALMOLOGY, V120, P593, DOI 10.1016/j.ophtha.2012.11.037
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Kim BJ, 2014, AM J OPHTHALMOL, V158, P128, DOI 10.1016/j.ajo.2014.04.004
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   MENG XL, 1992, PSYCHOL BULL, V111, P172, DOI 10.1037/0033-2909.111.1.172
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rosenfeld PJ, 2005, OPHTHAL SURG LAS IM, V36, P331, DOI 10.3928/1542-8877-20050701-14
   Ying GS, 2014, JAMA OPHTHALMOL, V132, P915, DOI 10.1001/jamaophthalmol.2014.1019
   Ying GS, 2013, OPHTHALMOLOGY, V120, P122, DOI 10.1016/j.ophtha.2012.07.042
   Yonekawa Y, 2013, AM J OPHTHALMOL, V156, P29, DOI 10.1016/j.ajo.2013.03.030
NR 25
TC 66
Z9 68
U1 0
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD DEC
PY 2015
VL 122
IS 12
BP 2523
EP +
DI 10.1016/j.ophtha.2015.08.015
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA CZ4EZ
UT WOS:000367057500032
PM 26383996
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Thanos, S
   Bohm, MRR
   Horste, MMZ
   Prokosch-Willing, V
   Hennig, M
   Bauer, D
   Heiligenhaus, A
AF Thanos, Solon
   Boehm, Michael R. R.
   Hoerste, Melissa Meyer Zu
   Prokosch-Willing, Verena
   Hennig, Maren
   Bauer, Dirk
   Heiligenhaus, Arndt
TI Role of crystallins in ocular neuroprotection and axonal regeneration
SO PROGRESS IN RETINAL AND EYE RESEARCH
LA English
DT Article
DE Retina; Crystallins; Glaucoma injury; Axonal regrowth; Neuroprotection
ID ALPHA-B-CRYSTALLIN; RETINAL GANGLION-CELLS; HEAT-SHOCK-PROTEIN; LENS
   EPITHELIAL-CELLS; EXPERIMENTAL AUTOIMMUNE UVEITIS; OPTIC-NERVE
   REGENERATION; A-CRYSTALLIN; GENE-EXPRESSION; MACULAR DEGENERATION;
   IN-VITRO
AB Neuroprotection is an emerging challenge in ophthalmology due to the particularly exposed location of retinal neurons and to the steadily increasing rate of intraocular surgical and pharmacological treatments applied to various eye diseases. Within few decades neuroprotection has developed from strongly contested approaches to being recognized and introduced as a potentially clinical application. One of the groups of putative substances for neuroprotection comprises alpha A- and alpha B-crystallins, which are types of heat-shock proteins and are considered to be molecular chaperones. The beta/gamma-crystallins form their own superfamily and are characterized as proteins with a distinct structure containing four Greek key motifs. Besides being abundant in the ocular lens, crystallins are also expressed in both the developing and mature retina. Crystallins are dramatically up-regulated in numerous retinal pathologies, including mechanical injury, ischemic insults, age-related macular degeneration, uveoretinitis, and diabetic retinopathy. Crystallins of the alpha family are thought to play a crucial role in retinal neuron survival and inflammation. Crystallins of the beta/gamma superfamily are also small proteins with a possible emerging role in retinal tissue remodeling and repair. One of the typical retinal diseases associated with crystallins is the experimental glaucomatous neuropathy that is characterized by their expression. Another typical retinal disease is the atrophy that occurs after mechanical injury to the optic nerve, which is associated with the need to regrow retinal axons. We have shown in regenerative models in vivo and in vitro that beta B2-crystallin actively supports the regenerative growth of cut retinal axons, thereby offering targets for neuroprotective and regenerative treatments. In this review we discuss the discovery that beta B2-crystallin is clearly up-regulated in the regenerating retina in vitro. beta B2-Crystallin is produced and secreted during axon elongation, while beta/gamma-crystallins promote axon growth both in vivo and in vitro by acting either directly by uptake into cells, or indirectly by enhancing the production of ciliary neurotrophic factor from astrocytes to synergistically promote axon regrowth. We also discuss methods to induce the continuous production of crystallins at the site of injury and repair based on the use of transfected neural progenitor cells. This review ultimately leads to the conclusion that the postinjury fate of neurons cannot be seen merely as inevitable, but instead should be regarded as a challenge to shaping the neuroprotective and regenerative conditions that promote cell survival and axon repair. (C) 2014 Elsevier Ltd. All rights reserved.
C1 [Thanos, Solon; Boehm, Michael R. R.; Prokosch-Willing, Verena; Heiligenhaus, Arndt] Inst Expt Ophthalmol, Berlin, Germany.
   [Thanos, Solon; Boehm, Michael R. R.] Univ Munster, Sch Med, Ctr Excellence Cells In Mot CiM, D-48149 Munster, Germany.
   [Hoerste, Melissa Meyer Zu] Massachusetts Eye & Ear Infirm, Boston, MA 02114 USA.
   [Hoerste, Melissa Meyer Zu] Univ Essen Gesamthsch, Eye Clin, Essen, Germany.
   [Hennig, Maren; Bauer, Dirk; Heiligenhaus, Arndt] Franziskus Hosp Munster, Dept Ophthalmol, Munster, Germany.
C3 University of Munster; Harvard University; Massachusetts Eye & Ear
   Infirmary; University of Duisburg Essen; St. Franziskus-Hospital
RP Thanos, S (通讯作者)，Univ Munster, Sch Med, Inst Expt Ophthalmol, Albert Schweitzer Campus 1,D15, D-48149 Munster, Germany.
EM solon@uni-muenster.de
RI Kasper, Maren/AAS-1716-2021
FU Deutsche Forschungsgemeinschaft (DFG) [Th 386/20-1, ME 4162/1-1];
   Interdisciplinary Clinical Research Center (IZKF); Innovative Medical
   Research (IMF)
FX The authors are indebted to Magdalena Reis for typing the manuscript and
   Mechthild Wissing and Mechthild Langkamp-Flock for technical assistance.
   The work was supported by the Deutsche Forschungsgemeinschaft (DFG:
   Grant No. Th 386/20-1 to S.T.), the Interdisciplinary Clinical Research
   Center (IZKF), and the Innovative Medical Research (IMF). M.M.z.H. was
   supported by a DFG Fellowship to conduct research at MEEI (Grant No. ME
   4162/1-1). All tissue materials used for in vitro explants in this study
   were obtained from cadavers after the animals had died.
CR Adhikari AS, 2011, BBA-MOL CELL RES, V1813, P1532, DOI 10.1016/j.bbamcr.2011.04.009
   Alge CS, 2002, INVEST OPHTH VIS SCI, V43, P3575
   Andley UP, 2002, J BIOL CHEM, V277, P10178, DOI 10.1074/jbc.M109211200
   Andley UP, 2000, J BIOL CHEM, V275, P36823, DOI 10.1074/jbc.M004233200
   Andley UP, 2007, PROG RETIN EYE RES, V26, P78, DOI 10.1016/j.preteyeres.2006.10.003
   Aquilina JA, 2004, J BIOL CHEM, V279, P28675, DOI 10.1074/jbc.M403348200
   Arrigo AP, 2010, CURR MOL MED, V10, P776, DOI 10.2174/156652410793937804
   Beebe DC, 2011, PHILOS T R SOC B, V366, P1293, DOI 10.1098/rstb.2010.0228
   Benowitz LI, 2007, DEV NEUROBIOL, V67, P1148, DOI 10.1002/dneu.20515
   Bertrand J, 2007, NEUROBIOL DIS, V25, P65, DOI 10.1016/j.nbd.2006.08.008
   Bertrand J, 2005, J NEUROSCI, V25, P1113, DOI 10.1523/JNEUROSCI.3931-04.2005
   Bhat SP, 2004, DEV NEUROSCI-BASEL, V26, P328, DOI 10.1159/000082274
   BHAT SP, 1989, BIOCHEM BIOPH RES CO, V158, P319, DOI 10.1016/S0006-291X(89)80215-3
   Bhat Suraj P, 2011, Commun Integr Biol, V4, P739
   BLOEMENDAL H, 1991, PROG NUCLEIC ACID RE, V41, P259
   Bohm MRR, 2013, GRAEF ARCH CLIN EXP, V251, P63, DOI 10.1007/s00417-012-2157-7
   Bohm MRR, 2012, INVEST OPHTH VIS SCI, V53, P8265, DOI 10.1167/iovs.12-10334
   Brady JP, 1997, P NATL ACAD SCI USA, V94, P884, DOI 10.1073/pnas.94.3.884
   Brady JP, 2001, INVEST OPHTH VIS SCI, V42, P2924
   Cannata SM, 2008, J ANAT, V212, P621, DOI 10.1111/j.1469-7580.2008.00886.x
   Charalambous P, 2008, INVEST OPHTH VIS SCI, V49, P3513, DOI 10.1167/iovs.07-1473
   Chen L, 2008, INVEST OPHTH VIS SCI, V49, P4476, DOI 10.1167/iovs.08-1971
   Chen Y, 2013, PROG RETIN EYE RES, V33, P28, DOI 10.1016/j.preteyeres.2012.10.001
   CHERIAN M, 1995, BIOCHEM BIOPH RES CO, V208, P675, DOI 10.1006/bbrc.1995.1391
   Chierzi S, 2005, EUR J NEUROSCI, V21, P2051, DOI 10.1111/j.1460-9568.2005.04066.x
   Chiu K, 2010, J CELL BIOCHEM, V110, P311, DOI 10.1002/jcb.22539
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   Cvekl A, 2007, PROG RETIN EYE RES, V26, P555, DOI 10.1016/j.preteyeres.2007.07.002
   D'Anna C, 2011, PROTEOMICS, V11, P986, DOI 10.1002/pmic.201000561
   Day RC, 2011, BMC DEV BIOL, V11, DOI 10.1186/1471-213X-11-54
   Dong ZY, 2012, RETINA-J RET VIT DIS, V32, P1190, DOI 10.1097/IAE.0b013e318233ab9c
   Ethen CM, 2006, INVEST OPHTH VIS SCI, V47, P2280, DOI 10.1167/iovs.05-1395
   Fan W, 2005, MOL BRAIN RES, V139, P306, DOI 10.1016/j.molbrainres.2005.06.008
   Filbin MT, 2006, NAT NEUROSCI, V9, P715, DOI 10.1038/nn0606-715
   Fischer D, 2000, INVEST OPHTH VIS SCI, V41, P3943
   Fischer D, 2004, J NEUROSCI, V24, P8726, DOI 10.1523/JNEUROSCI.2774-04.2004
   Fischer D, 2001, EXP NEUROL, V172, P257, DOI 10.1006/exnr.2001.7822
   Fischer D, 2008, MOL CELL NEUROSCI, V37, P471, DOI 10.1016/j.mcn.2007.11.002
   Fort PE, 2011, EXP EYE RES, V92, P98, DOI 10.1016/j.exer.2010.11.008
   Fort PE, 2009, MOL CELL PROTEOMICS, V8, P767, DOI 10.1074/mcp.M800326-MCP200
   Gangalum RK, 2011, J BIOL CHEM, V286, P3261, DOI 10.1074/jbc.M110.160135
   Ganguly K, 2008, INVEST OPHTH VIS SCI, V49, P1533, DOI 10.1167/iovs.07-0788
   Graw J, 2009, EXP EYE RES, V88, P173, DOI 10.1016/j.exer.2008.10.011
   Hamann S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055372
   Hauk TG, 2008, EXP NEUROL, V209, P469, DOI 10.1016/j.expneurol.2007.09.020
   HEAD MW, 1995, EXP EYE RES, V61, P423, DOI 10.1016/S0014-4835(05)80137-X
   Heidelberger R, 2003, VISUAL NEUROSCI, V20, P37, DOI 10.1017/S095252380320105X
   Heise EA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0082520
   Holcakova J, 2008, INT J BIOL MARKER, V23, P48, DOI 10.1177/172460080802300108
   HORWITZ J, 1992, P NATL ACAD SCI USA, V89, P10449, DOI 10.1073/pnas.89.21.10449
   Horwitz J, 2003, EXP EYE RES, V76, P145, DOI 10.1016/S0014-4835(02)00278-6
   Huang YS, 2010, MOL VIS, V16, P341
   Imai H, 2010, INVEST OPHTH VIS SCI, V51, P3554, DOI 10.1167/iovs.09-3728
   Ito H, 1997, J BIOL CHEM, V272, P29934, DOI 10.1074/jbc.272.47.29934
   Ito K, 2001, J BIOL CHEM, V276, P5346, DOI 10.1074/jbc.M009004200
   IWAKI T, 1993, AM J PATHOL, V143, P487
   Jaenicke R, 2001, CRIT REV BIOCHEM MOL, V36, P435, DOI 10.1080/20014091074237
   Joachim SC, 2007, CURR EYE RES, V32, P501, DOI 10.1080/02713680701375183
   Johnson PT, 2005, INVEST OPHTH VIS SCI, V46, P4788, DOI 10.1167/iovs.05-0767
   Jones SE, 1998, NEUROREPORT, V9, P4161, DOI 10.1097/00001756-199812210-00030
   Jones SE, 1999, INVEST OPHTH VIS SCI, V40, P3017
   Kalesnykas G, 2008, NEUROSCIENCE, V155, P937, DOI 10.1016/j.neuroscience.2008.06.038
   Kamradt MC, 2005, J BIOL CHEM, V280, P11059, DOI 10.1074/jbc.M413382200
   Kandpal RP, 2012, MOL VIS, V18, P1123
   Kannan R, 2012, PROG RETIN EYE RES, V31, P576, DOI 10.1016/j.preteyeres.2012.06.001
   Kase S, 2012, MOL MED REP, V5, P395, DOI 10.3892/mmr.2011.653
   Kase S, 2011, INT J MOL MED, V28, P505, DOI 10.3892/ijmm.2011.708
   Kase S, 2010, BLOOD, V115, P3398, DOI 10.1182/blood-2009-01-197095
   Kataoka K, 2007, J BIOCHEM, V141, P775, DOI 10.1093/jb/mvm105
   Kim JY, 2012, NEUROCHEM RES, V37, P2135, DOI 10.1007/s11064-012-0835-9
   Kim JY, 2011, NEUROCHEM RES, V36, P76, DOI 10.1007/s11064-010-0266-4
   Kim YH, 2007, NEUROBIOL DIS, V28, P293, DOI 10.1016/j.nbd.2007.07.017
   Kim YH, 2012, DIABETOLOGIA, V55, P2835, DOI 10.1007/s00125-012-2625-y
   Klok EJ, 1998, J BIOL CHEM, V273, P17206, DOI 10.1074/jbc.273.27.17206
   Kovacs B, 2003, LIFE SCI, V73, P3213, DOI 10.1016/j.lfs.2003.05.005
   Kumar PA, 2005, ARCH BIOCHEM BIOPHYS, V444, P77, DOI 10.1016/j.abb.2005.09.021
   Kurimoto T, 2010, J NEUROSCI, V30, P15654, DOI 10.1523/JNEUROSCI.4340-10.2010
   Lampi KJ, 1998, EXP EYE RES, V67, P31, DOI 10.1006/exer.1998.0481
   Lee H, 2011, INT J BIOL MACROMOL, V48, P194, DOI 10.1016/j.ijbiomac.2010.11.006
   Leon S, 2000, J NEUROSCI, V20, P4615, DOI 10.1523/JNEUROSCI.20-12-04615.2000
   Liedtke T, 2007, MOL CELL PROTEOMICS, V6, P895, DOI 10.1074/mcp.M600245-MCP200
   Lima LH, 2010, RETINA-J RET VIT DIS, V30, P542, DOI 10.1097/IAE.0b013e3181c713e4
   Liu HQ, 2005, J BIOL CHEM, V280, P25071, DOI 10.1074/jbc.M502490200
   Liu JP, 2004, EXP EYE RES, V79, P393, DOI 10.1016/j.exer.2004.06.015
   Lorber B, 2005, EUR J NEUROSCI, V21, P2029, DOI 10.1111/j.1460-9568.2005.04034.x
   Losiewicz MK, 2011, INVEST OPHTH VIS SCI, V52, P5034, DOI 10.1167/iovs.10-6931
   Lu LL, 2013, J CELL PHYSIOL, V228, P251, DOI 10.1002/jcp.24133
   LUBSEN NH, 1988, PROG BIOPHYS MOL BIO, V51, P47, DOI 10.1016/0079-6107(88)90010-7
   Ma B, 2011, CELL DEATH DIS, V2, DOI 10.1038/cddis.2011.100
   Mackay DS, 2003, EUR J HUM GENET, V11, P784, DOI 10.1038/sj.ejhg.5201046
   Mackay DW, 2004, MOL VIS, V10, P155
   Maddala R, 2005, EXP CELL RES, V306, P203, DOI 10.1016/j.yexcr.2005.01.026
   Magabo KS, 2000, INVEST OPHTH VIS SCI, V41, P3056
   Mao YW, 2004, CELL DEATH DIFFER, V11, P512, DOI 10.1038/sj.cdd.4401384
   MEAKIN SO, 1987, MOL CELL BIOL, V7, P2671, DOI 10.1128/MCB.7.8.2671
   Medvedovic M, 2006, MOL VIS, V12, P422
   Mehlen P, 1996, EMBO J, V15, P2695, DOI 10.1002/j.1460-2075.1996.tb00630.x
   Miyara N, 2008, JPN J OPHTHALMOL, V52, P84, DOI 10.1007/s10384-007-0507-5
   Moore DL, 2009, SCIENCE, V326, P298, DOI 10.1126/science.1175737
   Morozov V, 2006, DEVELOPMENT, V133, P813, DOI 10.1242/dev.02262
   Mueller NH, 2013, INVEST OPHTH VIS SCI, V54, P2, DOI 10.1167/iovs.12-10947
   Munemasa Y, 2009, INVEST OPHTH VIS SCI, V50, P3869, DOI 10.1167/iovs.08-3138
   Mykkanen OT, 2012, MOL VIS, V18, P2338
   Nagaraj RH, 2005, ANN NY ACAD SCI, V1043, P158, DOI 10.1196/annals.1333.020
   Naskar R, 2006, MOL VIS, V12, P1199
   Nordgaard CL, 2006, INVEST OPHTH VIS SCI, V47, P815, DOI 10.1167/iovs.05-0976
   Organisciak D, 2011, PHOTOCHEM PHOTOBIOL, V87, P151, DOI 10.1111/j.1751-1097.2010.00844.x
   Ousman SS, 2007, NATURE, V448, P474, DOI 10.1038/nature05935
   Pangratz-Fuehrer S, 2011, EYE, V25, P809, DOI 10.1038/eye.2011.42
   Park KK, 2008, SCIENCE, V322, P963, DOI 10.1126/science.1161566
   Parthasarathy G, 2011, J MOL HISTOL, V42, P59, DOI 10.1007/s10735-010-9307-1
   PERRY RE, 1987, EXP EYE RES, V44, P269, DOI 10.1016/S0014-4835(87)80011-8
   PIATIGORSKY J, 1992, J BIOL CHEM, V267, P4277
   Piri N, 2007, BRAIN RES, V1141, P1, DOI 10.1016/j.brainres.2006.11.095
   Piri N, 2013, MOL NEUROBIOL, V48, P819, DOI 10.1007/s12035-013-8470-2
   Prokosch V, 2011, OPHTHALMOLOGE, V108, P372, DOI 10.1007/s00347-010-2298-1
   Prokosch V, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0049730
   Rao NA, 2008, INVEST OPHTH VIS SCI, V49, P1161, DOI 10.1167/iovs.07-1259
   Rao NA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033582
   RENKAWEK K, 1992, ACTA NEUROPATHOL, V83, P324, DOI 10.1007/BF00296796
   Renkawek K, 1999, NEUROREPORT, V10, P2273, DOI 10.1097/00001756-199908020-00009
   RENKAWEK K, 1994, ACTA NEUROPATHOL, V87, P155, DOI 10.1007/BF00296185
   Rose K, 2008, RESTOR NEUROL NEUROS, V26, P249
   Sakaguchi H, 2003, EXP EYE RES, V76, P131, DOI 10.1016/S0014-4835(02)00249-X
   Saraswathy S, 2010, INVEST OPHTH VIS SCI, V51, P3680, DOI 10.1167/iovs.09-4575
   Saraswathy S, 2009, INVEST OPHTH VIS SCI, V50, P5559, DOI 10.1167/iovs.08-2842
   Sax C M, 1994, Adv Enzymol Relat Areas Mol Biol, V69, P155
   Sinha D, 1998, Mol Vis, V4, P8
   Sinha D, 2012, TRANSGENIC RES, V21, P1033, DOI 10.1007/s11248-012-9608-0
   Sitterding SM, 2008, ANN DIAGN PATHOL, V12, P33, DOI 10.1016/j.anndiagpath.2007.02.004
   Skeie JM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0082140
   Sreekumar PG, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033420
   Sreekumar PG, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012578
   Srivastava OP, 1998, CURR EYE RES, V17, P1074, DOI 10.1076/ceyr.17.11.1074.5228
   Srivastava OP, 1998, BIOCHEM BIOPH RES CO, V253, P288, DOI 10.1006/bbrc.1998.9728
   Srivastava PK, 2000, DRUG NEWS PERSPECT, V13, P517, DOI 10.1358/dnp.2000.13.9.858479
   Srivastava SS, 2014, J BIOL CHEM, V289, P10958, DOI 10.1074/jbc.O113.539569
   Steele MR, 2006, INVEST OPHTH VIS SCI, V47, P977, DOI 10.1167/iovs.05-0865
   Stupp T, 2005, EXP EYE RES, V81, P530, DOI 10.1016/j.exer.2005.03.011
   Sun MX, 2013, MAMM GENOME, V24, P333, DOI 10.1007/s00335-013-9478-7
   SWAMY MS, 1993, EXP EYE RES, V56, P177, DOI 10.1006/exer.1993.1025
   Tezel G, 1998, INVEST OPHTH VIS SCI, V39, P2277
   Ullian EM, 2004, MOL CELL NEUROSCI, V26, P544, DOI 10.1016/j.mcn.2004.05.002
   Umeda S, 2005, FASEB J, V19, P1683, DOI 10.1096/fj.04-3525fje
   Vanita, 2001, J MED GENET, V38, P392, DOI 10.1136/jmg.38.6.392
   Vazquez-Chona F, 2004, INVEST OPHTH VIS SCI, V45, P2737, DOI 10.1167/iovs.03-1047
   VIDALSANZ M, 1987, J NEUROSCI, V7, P2894
   Wang XH, 2004, INVEST OPHTH VIS SCI, V45, P3608, DOI 10.1167/iovs.04-0423
   Wang YD, 2007, CURR EYE RES, V32, P891, DOI 10.1080/02713680701593702
   Wang YH, 2012, J MOL NEUROSCI, V46, P138, DOI 10.1007/s12031-011-9537-z
   Wang YH, 2011, OPHTHALMIC RES, V45, P164, DOI 10.1159/000319944
   Wang YH, 2009, OPHTHALMIC RES, V42, P29, DOI 10.1159/000219682
   Whiston EA, 2008, INFECT IMMUN, V76, P1781, DOI 10.1128/IAI.01285-07
   WIGLEY CB, 1988, DEV BRAIN RES, V42, P85, DOI 10.1016/0165-3806(88)90204-0
   WISTOW G, 1990, J MOL EVOL, V30, P140, DOI 10.1007/BF02099940
   WISTOW GJ, 1988, ANNU REV BIOCHEM, V57, P479, DOI 10.1146/annurev.bi.57.070188.002403
   Wong WK, 2006, NEUROREPORT, V17, P699, DOI 10.1097/01.wnr.0000215776.91850.96
   Yaung J, 2008, EXP EYE RES, V86, P355, DOI 10.1016/j.exer.2007.11.007
   Yin YQ, 2003, J NEUROSCI, V23, P2284
   Yin YQ, 2006, NAT NEUROSCI, V9, P843, DOI 10.1038/nn1701
   Yin YQ, 2009, P NATL ACAD SCI USA, V106, P19587, DOI 10.1073/pnas.0907085106
   Ying X, 2008, J MOL NEUROSCI, V35, P253, DOI 10.1007/s12031-007-9010-1
   Yoshimura N, 2003, INVEST OPHTH VIS SCI, V44, P2211, DOI 10.1167/iovs.02-0704
   Yu AL, 2007, EXP EYE RES, V84, P694, DOI 10.1016/j.exer.2006.12.008
   Zhan XQ, 2008, MOL CELL PROTEOMICS, V7, P864, DOI 10.1074/mcp.M700417-MCP200
   Zhang C, 2005, DEV DYNAM, V234, P36, DOI 10.1002/dvdy.20494
   Zhang J, 2008, INVEST OPHTH VIS SCI, V49, P5476, DOI 10.1167/iovs.08-2179
NR 167
TC 51
Z9 53
U1 3
U2 21
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 1350-9462
EI 1873-1635
J9 PROG RETIN EYE RES
JI Prog. Retin. Eye Res.
PD SEP
PY 2014
VL 42
BP 145
EP 161
DI 10.1016/j.preteyeres.2014.06.004
PG 17
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AO6NT
UT WOS:000341469500007
PM 24998680
DA 2022-11-30
ER

PT J
AU Vilares-Morgado, R
   Madeira, C
   Falcao, M
   Godinho, G
   Ribeiro, M
   Beato, J
   Pedrosa, AC
   Brandao, E
   Falcao-Reis, F
   Carneiro, A
AF Vilares-Morgado, Rodrigo
   Madeira, Carolina
   Falcao, Manuel
   Godinho, Goncalo
   Ribeiro, Margarida
   Beato, Joao
   Pedrosa, Ana Catarina
   Brandao, Elisete
   Falcao-Reis, Fernando
   Carneiro, Angela
TI Predicting retinal pigment epithelium remodelling and its functional
   impact
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE Age-related macular degeneration; Retinal pigment epithelium tear;
   Retinal pigment epithelium remodelling; Spectral-domain optical
   coherence tomography
ID GROWTH-FACTOR THERAPY; MACULAR DEGENERATION; CLINICOPATHOLOGICAL
   CORRELATION; FUNDUS AUTOFLUORESCENCE; TEARS; MECHANISM; PATHOGENESIS;
   REPAIR
AB Purpose To identify predictive factors for RPE tear remodelling and its correlation with functional and morphological outcomes.
   Methods Retrospective longitudinal study of patients with retinal pigment epithelium (RPE) tears secondary to age-related macular degeneration (AMD). Imaging was performed using spectral-domain optical coherence tomography (SD-OCT) and fundus autofluorescence (FAF). RPE layer integrity in the RPE-denuded area was examined with SD-OCT, and variation in the RPE-denuded homogeneous hypofluorescent area was examined with FAF over time for each case (eye). Patients were divided in two groups, according to the presence (Rem) or absence (No Rem) of evidence of RPE tear remodelling. Data were collected at three different time points: at baseline (at diagnosis of exudative AMD), at RPE tear diagnosis, and at the last available follow-up. Using SD-OCT, the following parameters were evaluated: type of CNV, type of PED and its dimensions, presence of subretinal (SRF) or intraretinal (IRF) fluid, central retinal thickness (CRT), presence and location of hyperreflective dots, and dimension and location of RPE tear.
   Results This study included 32 eyes from 31 patients (19 female and 12 male), with RPE tears secondary to AMD. RPE remodelling after tear development was evident in 17 (53.1%) eyes after 7 [1-59] months. Anatomical recovery was associated with a younger age at RPE tear diagnosis (73 +/- 7 vs. 81 +/- 7 years old, p=0.01), smaller and narrower retinal pigment epithelial detachment (PED) at tear diagnosis (height 369 vs. 602 mu m, p=0.02; width 2379 vs. 3378 mu m, p=0.04), and the presence of SRF at tear diagnosis (94% vs. 53%, p=0.02). After adjusting for other covariates, a younger age at RPE tear diagnosis maintained significant association with RPE tear remodelling. RPE tear remodelling did not correlate with a better visual outcome at last follow-up (43 +/- 22.8 vs. 34 +/- 23.8 ETDRS letters, p=0.30). Final VA was directly proportional to VA at tear diagnosis (r= 0.654; p<0.001) and correlated negatively with PED width at tear diagnosis (r = -0.388; p=0.03).
   Conclusion RPE remodelling was evident in half of our sample and was associated with a younger age, smaller and narrower PED at RPE tear diagnosis, and presence of SRF also at tear diagnosis. Nevertheless, this structural recovery did not result in a better functional outcome.
C1 [Vilares-Morgado, Rodrigo; Madeira, Carolina; Falcao, Manuel; Godinho, Goncalo; Ribeiro, Margarida; Beato, Joao; Pedrosa, Ana Catarina; Brandao, Elisete; Falcao-Reis, Fernando; Carneiro, Angela] Ctr Hosp Sao Joao Hosp, Dept Ophthalmol, Ave Prof Hernani Monteiro, P-4202451 Porto, Portugal.
   [Vilares-Morgado, Rodrigo; Falcao, Manuel; Falcao-Reis, Fernando; Carneiro, Angela] Univ Porto, Dept Surg & Physiol, Fac Med, Porto, Portugal.
   [Ribeiro, Margarida] Univ Porto, Dept Pharmacol & Therapeut, Fac Med, Porto, Portugal.
C3 Universidade do Porto; Universidade do Porto
RP Vilares-Morgado, R (通讯作者)，Ctr Hosp Sao Joao Hosp, Dept Ophthalmol, Ave Prof Hernani Monteiro, P-4202451 Porto, Portugal.; Vilares-Morgado, R (通讯作者)，Univ Porto, Dept Surg & Physiol, Fac Med, Porto, Portugal.
EM vilaresmorgador@gmail.com
RI Ribeiro, Margarida/HDM-9637-2022
OI Falcao, Manuel/0000-0003-4718-0910; Godinho,
   Goncalo/0000-0001-5303-0025; Ribeiro, Margarida/0000-0002-0196-3840
CR Asao K, 2014, RETINA-J RET VIT DIS, V34, P512, DOI 10.1097/IAE.0b013e31829f73eb
   Caramoy A, 2012, BRIT J OPHTHALMOL, V96, P1211, DOI 10.1136/bjophthalmol-2012-301750
   Chiang A, 2008, RETINA-J RET VIT DIS, V28, P1265, DOI 10.1097/IAE.0b013e31817d5d03
   CHUANG EL, 1988, EYE, V2, P106, DOI 10.1038/eye.1988.22
   CHUANG EL, 1988, AM J OPHTHALMOL, V105, P285, DOI 10.1016/0002-9394(88)90011-6
   Clemens CR, 2016, OPHTHALMOLOGICA, V235, P1, DOI 10.1159/000439445
   Clemens CR, 2014, ACTA OPHTHALMOL, V92, pE50, DOI 10.1111/aos.12234
   Del Priore LV, 2002, INVEST OPHTH VIS SCI, V43, P3312
   Ersoz MG, 2017, SURV OPHTHALMOL, V62, P493, DOI 10.1016/j.survophthal.2017.03.004
   GU X, 2012, PLOS ONE, V7
   Gutfleisch M, 2011, EYE, V25, P1181, DOI 10.1038/eye.2011.146
   Heimes B, 2016, RETINA-J RET VIT DIS, V36, P868, DOI 10.1097/IAE.0000000000000823
   HERIOT WJ, 1992, GRAEF ARCH CLIN EXP, V230, P91, DOI 10.1007/BF00166769
   Ho J, 2011, OPHTHALMOLOGY, V118, P687, DOI 10.1016/j.ophtha.2010.08.010
   HOSKIN A, 1981, BRIT J OPHTHALMOL, V65, P417, DOI 10.1136/bjo.65.6.417
   Invernizzi A, 2018, OPHTHALMOLOGY, V125, P237, DOI 10.1016/j.ophtha.2017.08.039
   Lafaut BA, 2001, BRIT J OPHTHALMOL, V85, P454, DOI 10.1136/bjo.85.4.454
   Leonard DS, 1997, INVEST OPHTH VIS SCI, V38, P1094
   Lesniak SP, 2011, EUR J OPHTHALMOL, V21, P73, DOI 10.5301/EJO.2010.2285
   Mendis R, 2014, GRAEF ARCH CLIN EXP, V252, P1059, DOI 10.1007/s00417-013-2549-3
   Meyer CH, 2001, GRAEF ARCH CLIN EXP, V239, P325, DOI 10.1007/s004170100259
   Mitchell P, 2018, LANCET, V392, P1147, DOI 10.1016/S0140-6736(18)31550-2
   Mukai R, 2015, RETINA-J RET VIT DIS, V35, P473, DOI 10.1097/IAE.0000000000000337
   Nagiel A, 2013, AM J OPHTHALMOL, V156, P981, DOI 10.1016/j.ajo.2013.06.024
   Oishi A, 2018, RETINA-J RET VIT DIS, V38, P1331, DOI 10.1097/IAE.0000000000001688
   Okada M, 2021, OPHTHALMOLOGY, V128, P234, DOI 10.1016/j.ophtha.2020.07.060
   Pece A, 2010, OPHTHALMOLOGICA, V224, P159, DOI 10.1159/000236910
   Salz, 2010, REV OPTHALMOL, V2010, P1866
   Sarraf D, 2010, RETINA-J RET VIT DIS, V30, P1039, DOI 10.1097/IAE.0b013e3181cdf366
   Spaide RF, 2009, AM J OPHTHALMOL, V147, P644, DOI 10.1016/j.ajo.2008.10.005
NR 30
TC 1
Z9 1
U1 0
U2 1
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0721-832X
EI 1435-702X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD SEP
PY 2021
VL 259
IS 9
BP 2583
EP 2595
DI 10.1007/s00417-021-05129-9
EA MAR 2021
PG 13
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA UD4CF
UT WOS:000624404400002
PM 33651204
DA 2022-11-30
ER

PT J
AU Zhang, Y
   Cross, SD
   Stanton, JB
   Marmorstein, AD
   Le, YZ
   Marmorstein, LY
AF Zhang, Youwen
   Cross, Samuel D.
   Stanton, James B.
   Marmorstein, Alan D.
   Le, Yun Zheng
   Marmorstein, Lihua Y.
TI Early AMD-like defects in the RPE and retinal degeneration in aged mice
   with RPE-specific deletion of Atg5 or Atg7
SO MOLECULAR VISION
LA English
DT Article
ID PIGMENT-EPITHELIUM; MACULAR DEGENERATION; OXIDATIVE STRESS; AUTOPHAGY;
   DRUSEN; DISEASE; PATHOGENESIS; DEGRADATION; PROGRESSION; IMPAIRMENT
AB Purpose: To examine the effects of autophagy deficiency induced by RPE-specific deletion of Atg5 or Atg7 in mice as a function of age.
   Methods: Conditional knockout mice with a floxed allele of Atg5 or Atg7 were crossed with inducible VMD2-rtTA/Cre transgenic mice. VMD2-directed RPE-specific Cre recombinase expression was induced with doxycycline feeding in the resulting mice. Cre-mediated deletion of floxed Atg5 or Atg7 resulted in RPE-specific inactivation of the Atg5 or Atg7 gene. Plastic and thin retinal sections were analyzed with light and electron microscopy for histological changes. Photoreceptor outer segment (POS) thickness in plastic sections was measured using the Adobe Photoshop CS4 extended ruler tool. Autophagic adaptor p62/SQSTM1 and markers for oxidatively damaged lipids, proteins, and DNA were examined with immunofluorescence staining of cryosections. Fluorescence signals were quantified using Image J software.
   Results: Accumulation of p62/SQSTM1 reflecting autophagy deficiency was observed in the RPE of the Atg5(Delta RPE) and Atg7(Delta RP)E mice. 3-nitrotyrosine, advanced glycation end products (AGEs), and 8-hydroxy-2'-deoxyguanosine (8-OHdG), markers for oxidatively damaged proteins and DNA, were also found to accumulate in the RPE of these mice. We observed retinal degeneration in 35% of the Atg5(Delta RPE) mice and 45% of the Atg7.RPE mice at 8 to 24 months old. Degeneration severity and the number of mice with degeneration increased with age. The mean POS thickness of these mice was 25 mu m at 8-12 months, 15 mu m at 13-18 months, and 3 mu m at 19-24 months, compared to 35 mu m, 30 mu m, and 24 aem in the wildtype mice, respectively. Early age-related macular degeneration (AMD)-like RPE defects were found in all the Atg5(Delta RPE) and Atg7.RPE mice 13 months old or older, including vacuoles, uneven RPE thickness, diminished basal infoldings, RPE hypertrophy/hypotrophy, pigmentary irregularities, and necrosis. The severity of the RPE defects increased with age and in the mice with retinal degeneration. RPE atrophy and choroidal neovascularization (CNV) were occasionally observed in the Atg5(Delta RPE) and Atg7(Delta RPE) mice with advanced age.
   Conclusions: Autophagy deficiency induced by RPE-specific deletion of Atg5 or Atg7 predisposes but does not necessarily drive the development of AMD-like phenotypes or retinal degeneration.
C1 [Zhang, Youwen; Cross, Samuel D.; Marmorstein, Alan D.; Marmorstein, Lihua Y.] Mayo Clin, Dept Ophthalmol, 200 1st St SW, Rochester, MN 55905 USA.
   [Stanton, James B.] Univ Arizona, Dept Ophthalmol & Vis Sci, Tucson, AZ USA.
   [Le, Yun Zheng] Univ Oklahoma, Hlth Sci Ctr, Dept Med, Oklahoma City, OK USA.
   [Le, Yun Zheng] Univ Oklahoma, Hlth Sci Ctr, Harold Hamm Diabet Ctr, Oklahoma City, OK USA.
C3 Mayo Clinic; University of Arizona; University of Oklahoma System;
   University of Oklahoma Health Sciences Center; University of Oklahoma
   System; University of Oklahoma Health Sciences Center
RP Marmorstein, LY (通讯作者)，Mayo Clin, Dept Ophthalmol, 200 1st St SW, Rochester, MN 55905 USA.
EM Marmorstein.Lihua@mayo.edu
FU NIH grant [R01EY0013847, R01EY0013160, R01EY0021153]; Mayo Foundation;
   Research to Prevent Blindness to the Department of Ophthalmology at the
   Mayo Clinic in Rochester, Minnesota; NATIONAL EYE INSTITUTE
   [R01EY013160, R01EY021153, R01EY013847] Funding Source: NIH RePORTER
FX We are grateful to Lori A. Bachman and Benjamin J. Gilles for assistance
   in mouse care, Dr. Adiv A. Johnson for technical assistance, and the
   staff in the electron microscopy core facility at the Mayo Clinic for
   their assistance with transmission electron microscopy. This work was
   supported by NIH grants R01EY0013847 (LYM), R01EY0013160 (ADM), and
   R01EY0021153 (ADM), Mayo Foundation, and an unrestricted grant from
   Research to Prevent Blindness to the Department of Ophthalmology at the
   Mayo Clinic in Rochester, Minnesota.
CR Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   Athanasiou D, 2013, FEBS LETT, V587, P2008, DOI 10.1016/j.febslet.2013.05.020
   Ayala A, 2014, OXID MED CELL LONGEV, V2014, DOI 10.1155/2014/360438
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Bjorkoy G, 2009, METHOD ENZYMOL, V452, P181, DOI 10.1016/S0076-6879(08)03612-4
   BOK D, 1993, J CELL SCI, P189
   Boya P, 2016, PROG RETIN EYE RES, V55, P206, DOI 10.1016/j.preteyeres.2016.08.001
   BRESSLER NM, 1994, RETINA-J RET VIT DIS, V14, P130, DOI 10.1097/00006982-199414020-00006
   Buschini E, 2011, PROG NEUROBIOL, V95, P14, DOI 10.1016/j.pneurobio.2011.05.011
   Cousins SW, 2002, EXP EYE RES, V75, P543, DOI 10.1006/exer.2002.2047
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   de Jong PTVM, 2006, NEW ENGL J MED, V355, P1474, DOI 10.1056/NEJMra062326
   Esumi N, 2004, J BIOL CHEM, V279, P19064, DOI 10.1074/jbc.M309881200
   Evans JR, 2004, OPHTHALMOLOGY, V111, P513, DOI 10.1016/j.ophtha.2003.07.012
   Feher J, 2006, NEUROBIOL AGING, V27, P983, DOI 10.1016/j.neurobiolaging.2005.05.012
   Fornai F, 2008, P NATL ACAD SCI USA, V105, P2052, DOI 10.1073/pnas.0708022105
   Green W R, 1999, Mol Vis, V5, P27
   Handa JT, 2017, BIOCHIM BIOPHYS ACTA, Vxxx, P430
   Hara T, 2006, NATURE, V441, P885, DOI 10.1038/nature04724
   HIRATA A, 1992, INVEST OPHTH VIS SCI, V33, P2079
   Kaarniranta K, 2013, AUTOPHAGY, V9, P973, DOI 10.4161/auto.24546
   Katsuragi Y, 2015, FEBS J, V282, P4672, DOI 10.1111/febs.13540
   Kim JY, 2013, CELL, V154, P365, DOI 10.1016/j.cell.2013.06.012
   Komatsu M, 2005, J CELL BIOL, V169, P425, DOI 10.1083/jcb.200412022
   Komatsu M, 2007, CELL, V131, P1149, DOI 10.1016/j.cell.2007.10.035
   Kuma A, 2004, NATURE, V432, P1032, DOI 10.1038/nature03029
   Le YZ, 2008, INVEST OPHTH VIS SCI, V49, P1248, DOI 10.1167/iovs.07-1105
   Levine B, 2008, CELL, V132, P27, DOI 10.1016/j.cell.2007.12.018
   Marmorstein AD, 2000, P NATL ACAD SCI USA, V97, P12758, DOI 10.1073/pnas.220402097
   Marmorstein LY, 2007, HUM MOL GENET, V16, P2423, DOI 10.1093/hmg/ddm199
   McLaughlin PJ, 2006, MOL CELL BIOL, V26, P1700, DOI 10.1128/MCB.26.5.1700-1709.2006
   McLaughlin PJ, 2007, HUM MOL GENET, V16, P3059, DOI 10.1093/hmg/ddm264
   Mitter SK, 2012, ADV EXP MED BIOL, V723, P83, DOI 10.1007/978-1-4614-0631-0_12
   Mizushima N, 2008, NATURE, V451, P1069, DOI 10.1038/nature06639
   Nishida Y, 2009, NATURE, V461, P654, DOI 10.1038/nature08455
   Noda NN, 2015, ANNU REV BIOPHYS, V44, P101, DOI 10.1146/annurev-biophys-060414-034248
   Pacher P, 2007, PHYSIOL REV, V87, P315, DOI 10.1152/physrev.00029.2006
   Perusek L, 2015, J BIOL CHEM, V290, P29035, DOI 10.1074/jbc.M115.682310
   Rubinszfein DC, 2005, AUTOPHAGY, V1, P11, DOI 10.4161/auto.1.1.1513
   Sarkar S, 2008, MOL BIOSYST, V4, P895, DOI 10.1039/b804606a
   Sarkar S, 2008, FEBS J, V275, P4263, DOI 10.1111/j.1742-4658.2008.06562.x
   Sarks SH, 2001, MED RETINA, VII, P1064
   Schutt F, 2003, INVEST OPHTH VIS SCI, V44, P3663, DOI 10.1167/iovs.03-0172
   Sinha D, 2016, EXP EYE RES, V144, P46, DOI 10.1016/j.exer.2015.08.018
   Stanton JB, 2017, INVEST OPHTH VIS SCI, V58, P1455, DOI 10.1167/iovs.16-20955
   Strauss O, 2005, PHYSIOL REV, V85, P845, DOI 10.1152/physrev.00021.2004
   Sukseree S, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0161640
   Umeda S, 2005, FASEB J, V19, P1683, DOI 10.1096/fj.04-3525fje
   Valavanidis A, 2009, J ENVIRON SCI HEAL C, V27, P120, DOI 10.1080/10590500902885684
   Vellai T, 2009, CELL DEATH DIFFER, V16, P94, DOI 10.1038/cdd.2008.126
   Vistoli G, 2013, FREE RADIC RES S, V47, P13
   Wang AL, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004160
   Xie ZP, 2007, NAT CELL BIOL, V9, P1102, DOI 10.1038/ncb1007-1102
NR 54
TC 39
Z9 39
U1 0
U2 3
PU MOLECULAR VISION
PI ATLANTA
PA C/O JEFF BOATRIGHT, LAB B, 5500 EMORY EYE CENTER, 1327 CLIFTON RD, N E,
   ATLANTA, GA 30322 USA
SN 1090-0535
J9 MOL VIS
JI Mol. Vis.
PD APR 14
PY 2017
VL 23
BP 228
EP 241
PG 14
WC Biochemistry & Molecular Biology; Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Ophthalmology
GA ES1LH
UT WOS:000399288600001
PM 28465655
DA 2022-11-30
ER

PT J
AU Parikh, R
   Ross, JS
   Sangaralingham, LR
   Adelman, RA
   Shah, ND
   Barkmeier, AJ
AF Parikh, Ravi
   Ross, Joseph S.
   Sangaralingham, Lindsey R.
   Adelman, Ron A.
   Shah, Nilay D.
   Barkmeier, Andrew J.
TI Trends of Anti-Vascular Endothelial Growth Factor Use in Ophthalmology
   Among Privately Insured and Medicare Advantage Patients
SO OPHTHALMOLOGY
LA English
DT Article
ID DIABETIC MACULAR EDEMA; INTRAVITREAL AFLIBERCEPT; RANIBIZUMAB;
   DEGENERATION; BEVACIZUMAB; INJECTION; TRIAL
AB Purpose: To characterize the first 10 years of intravitreal anti-vascular endothelial growth factor (VEGF) medication use for ophthalmic disease, including bevacizumab, ranibizumab, and aflibercept.
   Design: A retrospective cohort study using administrative claims data from January 1, 2006 to December 31, 2015.
   Subjects: Total of 124 835 patients 18 years of age or over in the United States.
   Methods: OptumLabs Data Warehouse, which includes administrative claims data for over 100 million commercially insured and Medicare Advantage individuals, was used to identify patients receiving intravitreal anti-VEGF injections based on Current Procedural Terminology codes.
   Main Outcome Measures: Total and annual numbers of intravitreal anti-VEGF injections, as well as injections per 1000 enrolled patients per general category of ophthalmic disease, overall and for each available medication.
   Results: There were 959 945 anti-VEGF injections among 124 835 patients from 2006 to 2015. Among all injections, 64.6% were of bevacizumab, 22.0% ranibizumab, and 13.4% aflibercept; 62.7% were performed to treat age-related macular degeneration (AMD), 16.1% to treat diabetic retinal diseases (including 0.9% of all injections that were for proliferative diabetic retinopathy), 8.3% to treat retinal vein occlusions, and 12.9% for all other uses. Use of bevacizumab and ranibizumab for AMD plateaued as of 2011/2012 and decreased thereafter (in 2006, 58.8 and 35.3 injections/1000 AMD patients, respectively; in 2015, 294.4 and 100.7 injections/1000), whereas use of aflibercept increased (1.1 injections/1000 AMD patients in 2011 to 183.0 injections/1000 in 2015). Bevacizumab use increased each year for diabetic retinal disease (2.4 injections/1000 patients with diabetic retinal disease in 2009 to 13.6 per 1000 in 2015) while that of ranibizumab initially increased significantly and then declined after 2014 (0.1 in 2009 to 4.0 in 2015). Aflibercept use increased each year in patients with diabetic retinal diseases and retinal vein occlusions (both < 0.1 per 1000 retinal vein occlusion patients in 2011, 5.6 and 140.2 in 2015).
   Conclusions: Intravitreal injections of anti-VEGF medications increased annually from 2006 to 2015. Bevacizumabwas the mostcommonmedication used, despite its lacking U. S. Food and Drug Administration approval to treat ophthalmic disease, and AMD was the most common condition treated. Ranibizumab use declined after 2014 while both the absolute and relative use of bevacizumab and aflibercept increased. (C) 2016 by the American Academy of Ophthalmology
C1 [Parikh, Ravi; Adelman, Ron A.] Yale Univ, Sch Med, Dept Ophthalmol & Visual Sci, New Haven, CT 06520 USA.
   [Parikh, Ravi; Adelman, Ron A.] Yale New Haven Med Ctr, New Haven, CT USA.
   [Ross, Joseph S.] Yale Sch Publ Hlth, Yale Sch Med, Dept Internal Med, Gen Internal Med Sect, New Haven, CT USA.
   [Ross, Joseph S.] Yale Sch Publ Hlth, Yale Sch Med, Dept Internal Med, Robert Wood Johnson Fdn Clin Scholars Program, New Haven, CT USA.
   [Ross, Joseph S.] Yale New Haven Med Ctr, Ctr Outcomes Res & Evaluat, New Haven, CT USA.
   [Sangaralingham, Lindsey R.; Shah, Nilay D.] Robert D Patricia E Kern Ctr Sci Hlth Care Delive, Mayo Clin, Rochester, MN USA.
   [Shah, Nilay D.] Mayo Clin, Dept Hlth Sci Res, Rochester, MN USA.
   [Shah, Nilay D.] OptumLabs, Cambridge, MA USA.
   [Barkmeier, Andrew J.] Mayo Clin, Dept Ophthalmol, Rochester, MN USA.
C3 Yale University; Yale University; Yale University; Robert Wood Johnson
   Foundation (RWJF); Yale University; Yale University; Mayo Clinic; Mayo
   Clinic; Optum; Mayo Clinic
RP Parikh, R (通讯作者)，40 Temple St,Suite 3A, New Haven, CT 06510 USA.
EM Ravi.Parikh@yale.edu
RI Barkmeier, Andrew/AAV-1021-2020
OI Parikh, Ravi/0000-0003-3369-4224; Ross, Joseph/0000-0002-9218-3320
FU Mayo Clinic Robert D. and Patricia E. Kern Center for the Science of
   Health Care Delivery (Rochester, MN); Research to Prevent Blindness,
   Inc., New York, NY; Leir Foundation (New York, NY); Newman's Own
   Foundation (Westport, CT); Yale University from Medtronic, Inc.; Johnson
   Johnson; Blue Cross Blue Shield Association (BCBSA); Centers of Medicare
   and Medicaid Services (CMS); Food and Drug Administration (FDA)
FX The author(s) have made the following disclosure(s): Funded in part by
   the Mayo Clinic Robert D. and Patricia E. Kern Center for the Science of
   Health Care Delivery (Rochester, MN). The Departments of Ophthalmology
   at both the Yale School of Medicine (New Haven, CT) and the Mayo Clinic
   (Rochester, MN) receive unrestricted grant funding from Research to
   Prevent Blindness, Inc., New York, NY. The Department Ophthalmology and
   Visual Sciences at Yale School of Medicine ( New Haven, CT) also
   received funding from the Leir Foundation (New York, NY) and Newman's
   Own Foundation (Westport, CT).; J.S.R.: Support - Yale University from
   Medtronic, Inc. and Johnson & Johnson to develop methods of clinical
   trial data sharing, from the Blue Cross Blue Shield Association (BCBSA)
   to better understand medical technology evidence generation, from the
   Centers of Medicare and Medicaid Services (CMS) to develop and maintain
   performance measures that are used for public reporting, and from the
   Food and Drug Administration (FDA) to develop methods for postmarket
   surveillance of medical devices.
CR Administration FaD, 2004, AV BEV LAB TEXT
   Administration FaD, AFL EYL PRESCR INF
   Clark WL, 2016, OPHTHALMOLOGY, V123, P330, DOI 10.1016/j.ophtha.2015.09.035
   Do DV, 2016, OPHTHALMOLOGY, V123, P850, DOI 10.1016/j.ophtha.2015.11.008
   Elman MJ, 2010, OPHTHALMOLOGY, V117, P1064, DOI 10.1016/j.ophtha.2010.02.031
   Erie JC, 2016, OPHTHALMOLOGY, V123, P1257, DOI 10.1016/j.ophtha.2016.02.015
   Gross JG, 2015, JAMA-J AM MED ASSOC, V314, P2137, DOI 10.1001/jama.2015.15217
   Gunther JB, 2009, SURV OPHTHALMOL, V54, P372, DOI 10.1016/j.survophthal.2009.02.004
   Heier JS, 2014, OPHTHALMOLOGY, V121, P1414, DOI 10.1016/j.ophtha.2014.01.027
   Korobelnik JF, 2014, OPHTHALMOLOGY, V121, P2247, DOI 10.1016/j.ophtha.2014.05.006
   la Cour M, 2002, DRUG AGING, V19, P101, DOI 10.2165/00002512-200219020-00003
   Lad EM, 2014, AM J OPHTHALMOL, V158, P537, DOI 10.1016/j.ajo.2014.05.014
   Martin DF, 2015, NEW ENGL J MED, V372, P1260, DOI 10.1056/NEJMe1500351
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Murdoch IE, 1998, BRIT J OPHTHALMOL, V82, P971, DOI 10.1136/bjo.82.8.971
   Ogura Y, 2014, AM J OPHTHALMOL, V158, P1032, DOI 10.1016/j.ajo.2014.07.027
   OptumLabs, OPT RES DAT ASS
   Pershing S, 2015, HEALTH AFFAIR, V34, P229, DOI 10.1377/hlthaff.2014.1032
   Nguyen QD, 2012, OPHTHALMOLOGY, V119, P789, DOI 10.1016/j.ophtha.2011.12.039
   Quan DN, 2010, OPHTHALMOLOGY, V117, P2146, DOI 10.1016/j.ophtha.2010.08.016
   Steinbrook R, 2006, NEW ENGL J MED, V355, P1409, DOI 10.1056/NEJMp068185
   Varma R, 2012, OPHTHALMOLOGY, V119, P2108, DOI 10.1016/j.ophtha.2012.05.017
   Wallace PJ, 2014, HEALTH AFFAIR, V33, P1187, DOI 10.1377/hlthaff.2014.0038
   Wells JA, 2016, OPHTHALMOLOGY, V123, P1351, DOI 10.1016/j.ophtha.2016.02.022
   Wells JA, 2015, NEW ENGL J MED, V372, P1193, DOI 10.1056/NEJMoa1414264
NR 26
TC 62
Z9 62
U1 0
U2 6
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD MAR
PY 2017
VL 124
IS 3
BP 352
EP 358
DI 10.1016/j.ophtha.2016.10.036
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA EQ1SB
UT WOS:000397848800033
PM 27890437
OA Bronze
DA 2022-11-30
ER

PT J
AU Toledano, S
   Lu, HY
   Palacio, A
   Kigel, B
   Kessler, O
   Allon, G
   Barak, Y
   Neufeld, G
   Schaal, S
AF Toledano, Shira
   Lu, Huayi
   Palacio, Agustina
   Kigel, Boaz
   Kessler, Ofra
   Allon, Gilad
   Barak, Yoreh
   Neufeld, Gera
   Schaal, Shlomit
TI A SEMA3E mutant resistant to cleavage by furins (UNCL-SEMA3E) inhibits
   choroidal neovascularization
SO EXPERIMENTAL EYE RESEARCH
LA English
DT Article
DE Choroidal neovascularization; Angiogenesis; Semaphorin; Age related
   macular degeneration
ID ENDOTHELIAL GROWTH-FACTOR; MACULAR DEGENERATION; SEMAPHORIN 3E;
   SCHEMATIC EYE; TUMOR-GROWTH; MOUSE; CELLS; ANGIOGENESIS; RANIBIZUMAB;
   NEUROPILIN-1
AB Abnormal subretinal choroidal neovascularization (CNV) is a major cause of blindness in exudative age related macular degeneration (AMD). Current anti-angiogenic treatments by VEGF sequestering agents have been successful, but a significant proportion of patients do not respond well to these treatments, and the response of others diminishes over time, suggesting that additional anti-angiogenic agents that function by separate mechanisms may be of use to such patients. We have previously found that a point mutated form of semaphorin-3E resistant to cleavage by furin like pro-protein convertases (UNCL-Sema3E) displays potent anti-angiogenic properties. We therefore determined if UNCL-Sema3E has potential as an inhibitor of CNV formation. We chose to study UNCL-Sema3E rather than wild type sema3E because unlike full length sema3E, the major p61-Sema3E peptide that is produced by cleavage of sema3E with furin like pro-protein convertases activates signal transduction mediated by the ErbB2 receptor and can promote tumor metastasis in addition to its anti-angiogenic activity. UNCL-Sema3E inhibited efficiently vascular endothelial growth factor-A (VEGF), platelet derived growth factor (PDGF) and basic fibroblast growth factor (bFGF) signaling in human umbilical vein derived endothelial cells (HUVEC) and to a lesser extent hepatocyte growth factor (HGF) signal transduction. CNV that was induced in the eyes of C57 black mice by laser photocoagulation was inhibited by 65% (P < 0.01) following a single bolus intra-vitreal injection of 5 mu g UNCL-Sema3E. This inhibitory effect was similar to the inhibition produced by a single bolus intra-vitreal injection of 5 mu g aflibercept. A similar inhibition of CNV was observed following the injection of UNCL-Sema3E into the eyes of Long-Evans rats. However, a higher dose of UNCL-Sema3E (125 mu g), partially due to the larger volume of the vitreous cavity of rats, was required to achieve maximal inhibition of CNV. Injection of UNCL-Sema3E into eyes of healthy mice did not have any adverse effect on retinal function as assessed by optic kinetic reflex (OKR) or by electroretinogram (ERG) assays nor did UNCL-Sema3E injection affect the structure of the retina as determined using histology. To conclude, our results suggest that UNCL-Sema3E may be useful for the treatment of exudative AMD, which does not respond well to conventional anti-VEGF therapy. (C) 2016 Elsevier Ltd. All rights reserved.
C1 [Toledano, Shira; Kigel, Boaz; Kessler, Ofra; Neufeld, Gera] Technion Israel Inst Technol, Canc Res & Vasc Biol Ctr, Bruce Rappaport Fac Med, Haifa, Israel.
   [Lu, Huayi] Jilin Univ, Hosp 2, Changchun 130041, Jilin Province, Peoples R China.
   [Lu, Huayi; Palacio, Agustina; Schaal, Shlomit] Univ Louisville, Dept Ophthalmol & Visual Sci, Louisville, KY 40292 USA.
   [Allon, Gilad; Barak, Yoreh] Rambam Med Ctr, Dept Ophthalmol, Haifa, Israel.
   [Schaal, Shlomit] Univ Massachusetts, Sch Med, Dept Ophthalmol & Visual Sci, Amherst, MA 01003 USA.
C3 Technion Israel Institute of Technology; Rappaport Faculty of Medicine;
   Jilin University; University of Louisville; Rambam Health Care Campus;
   Technion Israel Institute of Technology; University of Massachusetts
   System; University of Massachusetts Amherst
RP Neufeld, G (通讯作者)，Technion Israel Inst Technol, Canc Res & Vasc Biol Ctr, Bruce Rappaport Fac Med, Haifa, Israel.; Barak, Y (通讯作者)，Rambam Med Ctr, Dept Ophthalmol, Haifa, Israel.; Schaal, S (通讯作者)，Israel Inst Technol, Louisville, KY USA.
EM yorehb@gmail.com; gera@tx.technion.ac.il; s.schaal@umassmed.edu
RI Palacio, Agustina/ABD-7463-2021; Neufeld, Gera/F-1524-2019
OI Toledano, Shira/0000-0002-2590-6066; Barak, Yoreh/0000-0002-6941-862X
FU United States - Israel Binational Science Foundation (BSF); KAMIN grant
   from the Israel Ministry of Commerce; Israel Science Foundation
   [ISF_188_2016]; Rappaport Family Institute for Research in the Medical
   Sciences; Research to Prevent Blindness (RPB, USA)
FX This work was supported in part by a grant from the United States -
   Israel Binational Science Foundation (BSF) (YB and SS), by a KAMIN grant
   from the Israel Ministry of Commerce (GN), By a grant from the Israel
   Science Foundation (GN) (ISF_188_2016), by a grant from the Rappaport
   Family Institute for Research in the Medical Sciences (GN), and by an
   unrestricted institutional grant from Research to Prevent Blindness
   (RPB, USA) (SS).
CR Adams RH, 1997, EMBO J, V16, P6077, DOI 10.1093/emboj/16.20.6077
   Bassi DE, 2005, MOL CARCINOGEN, V44, P151, DOI 10.1002/mc.20134
   Bellon A, 2010, NEURON, V66, P205, DOI 10.1016/j.neuron.2010.04.006
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Brown MM, 2006, CURR OPIN OPHTHALMOL, V17, P257
   Bry M, 2014, PHYSIOL REV, V94, P779, DOI 10.1152/physrev.00028.2013
   Campa C, 2008, INVEST OPHTH VIS SCI, V49, P1178, DOI 10.1167/iovs.07-1194
   Campagne MV, 2014, J PATHOL, V232, P151, DOI 10.1002/path.4266
   Casazza A, 2012, EMBO MOL MED, V4, P234, DOI 10.1002/emmm.201100205
   Casazza A, 2010, J CLIN INVEST, V120, P2684, DOI 10.1172/JCI42118
   Chauvet S, 2007, NEURON, V56, P807, DOI 10.1016/j.neuron.2007.10.019
   Christensen C, 2005, CANCER RES, V65, P6167, DOI 10.1158/0008-5472.CAN-04-4309
   Christensen CRL, 1998, CANCER RES, V58, P1238
   Cohen T, 1992, GROWTH FACTORS, V7, P131, DOI 10.3109/08977199209046402
   Dias JRD, 2011, BRIT J OPHTHALMOL, V95, P1631, DOI 10.1136/bjo.2010.186361
   Ferrara N, 2006, RETINA-J RET VIT DIS, V26, P859, DOI 10.1097/01.iae.0000242842.14624.e7
   Frank RN, 1996, AM J OPHTHALMOL, V122, P393, DOI 10.1016/S0002-9394(14)72066-5
   Fukushima Y, 2011, J CLIN INVEST, V121, P1974, DOI 10.1172/JCI44900
   Gu CH, 2005, SCIENCE, V307, P265, DOI 10.1126/science.1105416
   Guttmann-Raviv N, 2007, J BIOL CHEM, V282, P26294, DOI 10.1074/jbc.M609711200
   HUGHES A, 1979, VISION RES, V19, P569, DOI 10.1016/0042-6989(79)90143-3
   Kim J, 2011, GENE DEV, V25, P1399, DOI 10.1101/gad.2042011
   Lally DR, 2012, CURR OPIN OPHTHALMOL, V23, P182, DOI 10.1097/ICU.0b013e328352411c
   Lopez PF, 1996, INVEST OPHTH VIS SCI, V37, P855
   Lu HY, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087530
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   NEUFELD G, 1988, J CELL PHYSIOL, V136, P537, DOI 10.1002/jcp.1041360321
   Neufeld G, 2016, CELL ADHES MIGR, V10, P1
   Neufeld G, 2008, NAT REV CANCER, V8, P632, DOI 10.1038/nrc2404
   Neufeld G, 2012, CSH PERSPECT MED, V2, DOI 10.1101/cshperspect.a006718
   Oh WJ, 2013, SEMIN CELL DEV BIOL, V24, P156, DOI 10.1016/j.semcdb.2012.12.001
   Pennesi ME, 2012, MOL ASPECTS MED, V33, P487, DOI 10.1016/j.mam.2012.06.003
   Prusky GT, 2004, INVEST OPHTH VIS SCI, V45, P4611, DOI 10.1167/iovs.04-0541
   REMTULLA S, 1985, VISION RES, V25, P21, DOI 10.1016/0042-6989(85)90076-8
   Sakurai A, 2010, MOL CELL BIOL, V30, P3086, DOI 10.1128/MCB.01652-09
   Scalabrino ML, 2015, HUM MOL GENET, V24, P6229, DOI 10.1093/hmg/ddv341
   Schaal S, 2008, OPHTHALMOLOGY, V115, P2199, DOI 10.1016/j.ophtha.2008.07.007
   Seidah NG, 2012, NAT REV DRUG DISCOV, V11, P367, DOI 10.1038/nrd3699
   Soker S, 1998, CELL, V92, P735, DOI 10.1016/S0092-8674(00)81402-6
   Soudry S, 2009, EXP EYE RES, V88, P1152, DOI 10.1016/j.exer.2009.02.002
   Suda K, 2014, INVEST OPHTH VIS SCI, V55, P4700, DOI 10.1167/iovs.14-14087
   TESSLER S, 1990, J CELL PHYSIOL, V145, P310, DOI 10.1002/jcp.1041450216
   Varshavsky A, 2008, CANCER RES, V68, P6922, DOI 10.1158/0008-5472.CAN-07-5408
NR 43
TC 4
Z9 5
U1 0
U2 6
PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 0014-4835
EI 1096-0007
J9 EXP EYE RES
JI Exp. Eye Res.
PD DEC
PY 2016
VL 153
BP 186
EP 194
DI 10.1016/j.exer.2016.10.004
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA EE0RX
UT WOS:000389287700022
PM 27725196
DA 2022-11-30
ER

PT J
AU Chang, JR
   Koo, E
   Agron, E
   Hallak, J
   Clemons, T
   Azar, D
   Sperduto, RD
   Ferris, FL
   Chew, EY
AF Chang, Jessica R.
   Koo, Euna
   Agron, Elvira
   Hallak, Joelle
   Clemons, Traci
   Azar, Dimitri
   Sperduto, Robert D.
   Ferris, Frederick L., III
   Chew, Emily Y.
CA Age-Related Eye Dis Study Grp
TI Risk Factors Associated with Incident Cataracts and Cataract Surgery in
   the Age-Related Eye Disease Study (AREDS) AREDS Report Number 32
SO OPHTHALMOLOGY
LA English
DT Article
ID ULTRAVIOLET-LIGHT EXPOSURE; ASPIRIN-LIKE ANALGESICS; LONG-TERM
   INCIDENCE; BODY-MASS INDEX; LENS OPACITIES; VISUAL IMPAIRMENT;
   CARDIOVASCULAR-DISEASE; VITAMIN SUPPLEMENTS; CIGARETTE-SMOKING; 5-YEAR
   INCIDENCE
AB Objective: To investigate potential risk factors associated with incident nuclear, cortical, and posterior subcapsular (PSC) cataracts and cataract surgery in participants in the Age-Related Eye Disease Study (AREDS).
   Design: Clinic-based prospective cohort study.
   Participants: Persons (n = 4425) 55 to 80 years of age enrolled in a controlled clinical trial of antioxidant vitamins and minerals, AREDS, for age-related macular degeneration and cataract.
   Methods: Lens photographs were graded centrally for nuclear, cortical, and PSC opacities using the AREDS system for classifying cataracts. Type-specific incident cataracts were defined as an increase in cataract grade from none or mild at baseline to a grade of moderate at follow-up, also with a grade of at least moderate at the final visit, or cataract surgery. Cox regression analyses were used to assess baseline risk factors associated with type-specific opacities and cataract surgery.
   Main Outcome Measures: Moderate cataract was defined as a grade of 4.0 or more for nuclear opacity, 10% or more involvement within the full visible lens for cortical opacity, and 5% or more involvement of the central 5-mm circle of the lens for PSC opacity. These were graded on baseline and annual lens photographs.
   Results: A clinic-based cohort of 4425 persons 55 to 80 years of age at baseline was followed up for an average of 9.8 +/- 2.4 years. The following associations were found: increasing age with increased risk of all types of cataract and cataract surgery; males with increased risk of PSC and decreased risk of cortical cataracts; nonwhite persons with increased risk of cortical cataract; hyperopia with decreased risk of PSC, nuclear cataract, and cataract surgery; Centrum (Wyeth Consumer Healthcare, Madison, NJ) use with decreased risk of nuclear cataract; diabetes with increased risk of cortical, PSC cataract, and cataract surgery; higher educational level with decreased risk of cortical cataract; and smoking with increased risk of cortical cataract and cataract surgery. Estrogen replacement therapy in female participants increased the risk of cataract surgery.
   Conclusions: These findings largely are consistent with the results of previous studies, providing further evidence for possible modifiable risk factors for age-related cataract.
   Financial Disclosure(s): The author(s) have no proprietary or commercial interest in any materials discussed in this article. Ophthalmology 2011;118:2113-2119 (C) 2011 by the American Academy of Ophthalmology.
C1 [Koo, Euna; Agron, Elvira; Ferris, Frederick L., III; Chew, Emily Y.] NEI, Clin Trials Branch, Div Epidemiol & Clin Applicat, NIH, Bethesda, MD 20892 USA.
   [Chang, Jessica R.] NEI, Neurobiol Neurodegenerat & Repair Lab, NIH, Bethesda, MD 20892 USA.
   [Hallak, Joelle; Azar, Dimitri] Univ Illinois, Dept Ophthalmol & Visual Sci, Chicago, IL USA.
   [Clemons, Traci; Sperduto, Robert D.] EMMES Corp, Rockville, MD USA.
C3 National Institutes of Health (NIH) - USA; NIH National Eye Institute
   (NEI); National Institutes of Health (NIH) - USA; NIH National Eye
   Institute (NEI); University of Illinois System; University of Illinois
   Chicago; University of Illinois Chicago Hospital; Emmes Corporation
RP Chew, EY (通讯作者)，NEI, Clin Trials Branch, Div Epidemiol & Clin Applicat, NIH, Bldg 10,CRC Room 3-2531,10 Ctr Dr,MSC 1204, Bethesda, MD 20892 USA.
EM echew@nei.nih.gov
OI Ferris, Frederick/0000-0002-4933-0639; Chang,
   Jessica/0000-0001-6663-2519
FU National Eye Institute/National Institutes of Health, Department of
   Health and Human Services, Bethesda, Maryland; Howard Hughes Medical
   Institute-National Institutes of Health; National Institutes of Health;
   Pfizer; NATIONAL EYE INSTITUTE [ZIEEY000487, ZIAEY000489, ZIAEY000485]
   Funding Source: NIH RePORTER
FX Supported by the intramural program funds and contracts from the
   National Eye Institute/National Institutes of Health, Department of
   Health and Human Services, Bethesda, Maryland; the Howard Hughes Medical
   Institute-National Institutes of Health Scholars Program (JRC); and the
   Clinical Research Training Program at the National Institutes of Health,
   a public-private partnership supported jointly by the NIH and Pfizer
   (EK).
CR Arnarsson A, 2002, DEV OPHTHALMOL, V35, P12
   BOCHOW TW, 1989, ARCH OPHTHALMOL-CHIC, V107, P369, DOI 10.1001/archopht.1989.01070010379027
   Caulfield LE, 1999, AM J CLIN NUTR, V69, P237
   Chang MA, 2005, OPHTHALMOLOGY, V112, P1395, DOI 10.1016/j.ophtha.2005.02.017
   CHEW EY, 1992, ARCH OPHTHALMOL-CHIC, V110, P339, DOI 10.1001/archopht.1992.01080150037023
   Christen W G, 1998, Ophthalmic Epidemiol, V5, P133, DOI 10.1076/opep.5.3.133.8368
   CHRISTEN WG, 1992, JAMA-J AM MED ASSOC, V268, P989
   Collett D, 1994, MODELLING SURVIVAL D, P78
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P487
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   COX DR, 1972, J R STAT SOC B, V34, P187
   CRUICKSHANKS KJ, 1992, AM J PUBLIC HEALTH, V82, P1658, DOI 10.2105/AJPH.82.12.1658
   Cumming RG, 1997, NEW ENGL J MED, V337, P8, DOI 10.1056/NEJM199707033370102
   Cumming RG, 1998, OPHTHALMOLOGY, V105, P1751, DOI 10.1016/S0161-6420(98)99049-2
   delCastillo JMB, 1997, OPHTHALMOLOGY, V104, P970
   Delcourt C, 2000, AM J EPIDEMIOL, V151, P497
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P1019, DOI 10.1001/archopht.122.7.1019
   GLYNN RJ, 1995, ARCH OPHTHALMOL-CHIC, V113, P1131, DOI 10.1001/archopht.1995.01100090057023
   HANKINSON SE, 1993, ARCH OPHTHALMOL-CHIC, V111, P503, DOI 10.1001/archopht.1993.01090040095040
   HARDING JJ, 1988, BRIT J OPHTHALMOL, V72, P809, DOI 10.1136/bjo.72.11.809
   Hennis A, 2004, ARCH OPHTHALMOL-CHIC, V122, P525, DOI 10.1001/archopht.122.4.525
   Hiller R, 1998, OPHTHALMOLOGY, V105, P1244, DOI 10.1016/S0161-6420(98)97029-4
   HILLER R, 1986, AM J EPIDEMIOL, V124, P916, DOI 10.1093/oxfordjournals.aje.a114481
   Hiller R, 1997, ARCH OPHTHALMOL-CHIC, V115, P1113, DOI 10.1001/archopht.1997.01100160283003
   Kanthan GL, 2008, OPHTHALMOLOGY, V115, P808, DOI 10.1016/j.ophtha.2007.07.008
   Kanthan GL, 2010, ACTA OPHTHALMOL, V88, P773, DOI 10.1111/j.1755-3768.2009.01565.x
   Kassoff A, 1999, CONTROL CLIN TRIALS, V20, P573
   Kassoff A, 2001, AM J OPHTHALMOL, V131, P167
   Klein BEK, 2008, OPHTHALMOLOGY, V115, P477, DOI 10.1016/j.ophtha.2007.11.024
   Klein BEK, 1998, AM J OPHTHALMOL, V126, P782, DOI 10.1016/S0002-9394(98)00280-3
   KLEIN BEK, 1994, ARCH OPHTHALMOL-CHIC, V112, P85, DOI 10.1001/archopht.1994.01090130095025
   Klein BEK, 2002, OPHTHALMOLOGY, V109, P2052, DOI 10.1016/S0161-6420(02)01249-6
   Klein BEK, 2001, OPHTHALMOLOGY, V108, P1670, DOI 10.1016/S0161-6420(01)00656-X
   Klein R, 2002, ARCH OPHTHALMOL-CHIC, V120, P1551, DOI 10.1001/archopht.120.11.1551
   KLEIN R, 1994, OPHTHALMOLOGY, V101, P1969
   KLEIN R, 1994, ARCH OPHTHALMOL-CHIC, V112, P191, DOI 10.1001/archopht.1994.01090140067025
   Kuzniarz M, 2001, AM J OPHTHALMOL, V132, P19, DOI 10.1016/S0002-9394(01)00922-9
   Leske MC, 1998, AM J EPIDEMIOL, V147, P36
   Leske MC, 1997, INT J EPIDEMIOL, V26, P1314, DOI 10.1093/ije/26.6.1314
   Leske MC, 1999, OPHTHALMOLOGY, V106, P35, DOI 10.1016/S0161-6420(99)90003-9
   Leske MC, 2004, OPHTHALMOLOGY, V111, P483, DOI 10.1016/j.ophtha.2003.06.016
   LESKE MC, 1991, ARCH OPHTHALMOL-CHIC, V109, P244, DOI 10.1001/archopht.1991.01080020090051
   Leske MC, 1998, OPHTHALMOLOGY, V105, P831, DOI 10.1016/S0161-6420(98)95021-7
   MARAINI G, 1991, AM J EPIDEMIOL, V133, P541
   Maraini G, 2008, OPHTHALMOLOGY, V115, P599, DOI 10.1016/j.ophtha.2008.01.005
   McCarty CA, 1999, AM J OPHTHALMOL, V128, P446, DOI 10.1016/S0002-9394(99)00218-4
   Milton RC, 2006, OPHTHALMOLOGY, V113, P1264, DOI 10.1016/j.ophtha.2006.02.054
   Pascolini D, 2004, OPHTHAL EPIDEMIOL, V11, P67, DOI 10.1076/opep.11.2.67.28158
   Rahmani B, 1996, OPHTHALMOLOGY, V103, P1721, DOI 10.1016/S0161-6420(96)30435-1
   Salm M, 2006, AM J OPHTHALMOL, V142, P976, DOI 10.1016/j.ajo.2006.07.057
   SEDDON JM, 1994, AM J PUBLIC HEALTH, V84, P788, DOI 10.2105/AJPH.84.5.788
   SPERDUTO RD, 1993, ARCH OPHTHALMOL-CHIC, V111, P1246, DOI 10.1001/archopht.1993.01090090098027
   Sperduto RD, 2001, OPHTHALMOLOGY, V108, P1400
   Tan JSL, 2008, OPHTHAL EPIDEMIOL, V15, P317, DOI 10.1080/09286580802105806
   VANHEYNINGEN R, 1986, LANCET, V1, P1111
   Wang J J, 1999, Ophthalmic Epidemiol, V6, P317, DOI 10.1076/opep.6.4.317.4182
   Wang JJ, 2009, OPHTHALMOLOGY, V116, P652, DOI 10.1016/j.ophtha.2008.12.001
   WEI LJ, 1989, J AM STAT ASSOC, V84, P1065, DOI 10.2307/2290084
   West SK, 1998, AM J EPIDEMIOL, V148, P1033
   West SK, 1998, JAMA-J AM MED ASSOC, V280, P714, DOI 10.1001/jama.280.8.714
   WEST SK, 1995, SURV OPHTHALMOL, V39, P323
   Wong TY, 2001, INVEST OPHTH VIS SCI, V42, P1449
   World Health Organization, 2009, VIS IMP BLINDN FACT
   Younan C, 2002, INVEST OPHTH VIS SCI, V43, P3625
NR 64
TC 108
Z9 108
U1 1
U2 17
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD NOV
PY 2011
VL 118
IS 11
BP 2113
EP 2119
DI 10.1016/j.ophtha.2011.03.032
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 842EG
UT WOS:000296573500003
PM 21684602
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Framme, C
   Panagakis, G
   Birngruber, R
AF Framme, Carsten
   Panagakis, Georgios
   Birngruber, Reginald
TI Effects on Choroidal Neovascularization after Anti-VEGF Upload Using
   Intravitreal Ranibizumab, as Determined by Spectral Domain-Optical
   Coherence Tomography
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID MACULAR DEGENERATION; THERAPY; VERTEPORFIN; OCT
AB PURPOSE. It is unclear whether anti-VEGF monotherapy in age-related macular degeneration (AMD) achieves morphologic CNV regression or only stops further CNV growth. In this study, spectral domain-optical coherence tomography (SD-OCT) was used to image CNV structure before and after anti-VEGF treatment.
   METHODS. Out of 107 consecutive patients, a prospective CNV evaluation was possible in 78 of them. Newly diagnosed CNV (classic CNV: n = 16; occult CNV: n = 54; minimal classic CNV: n = 8) due to AMD was imaged before and 4 weeks after anti-VEGF upload in three intravitreal injections of ranibizumab. Qualitative (structural changes) and quantitative measurements (diameter and thickness) of the CNV were obtained from the OCT images.
   RESULTS. Classic CNV components were observed above the RPE/photoreceptor complex, whereas occult CNVs stayed below. Of all postoperative OCTs, 59% revealed complete dry retinal structures, 27% showed reduced edema, and 14% showed edema remaining unchanged. Mean macular thickness decreased significantly from 427 to 303 mu m (P = 0.000). Qualitatively, overall CNV architecture appeared to be unchanged in 78%, was reduced in thickness in 18%, and became larger in 4%. Quantitatively, in all CNV subtypes, the diameter of the CNV lesions (preoperative, 2813 mu m; postoperative, 2804 mu m) did not change after treatment (classic CNV: P = 0.390; occult CNV: P = 0.405, minimal classic CNV: P = 0.092) independent of postoperative retinal edema. The overall thickness of the lesion, however, was reduced from 205 to 175 mu m (P = 0.000). Thickness reduction was significantly enhanced especially in CNV with classic components (n = 24; 252 to 197 mu m; P = 0.000; reduction, 22%), whereas reduction was smaller but also significant in occult CNV (183 to 164 mu m; P = 0.003; reduction, 10%).
   CONCLUSIONS. With SD-OCT, CNV size can be two-dimensionally determined and followed up after intravitreal anti-VEGF treatment. In only 4% of CNV was enlargement observed, whereas in 78%, CNV architecture appeared qualitatively unchanged, independent of retinal edema. Quantitative measurements underlined stable CNV diameters for all subtypes but revealed significant reduction of thickness especially for classic CNV components. In this series, ranibizumab monotherapy was able to morphologically stop further CNV growth but, in most patients, did not lead to a major regression of CNV, especially of its occult components. (Invest Ophthalmol Vis Sci. 2010;51:1671-1676) DOI:10.1167/iovs.09-4496
C1 [Framme, Carsten] Univ Eye Hosp Bern, CH-3010 Bern, Switzerland.
   [Framme, Carsten; Panagakis, Georgios] Univ Eye Hosp, Regensburg, Germany.
   [Birngruber, Reginald] Med Univ Lubeck, Inst Biomed Opt, D-23538 Lubeck, Germany.
C3 University of Bern; University Hospital of Bern; University of
   Regensburg; University of Lubeck
RP Framme, C (通讯作者)，Univ Eye Hosp Bern, Freiburgstr 10, CH-3010 Bern, Switzerland.
EM carsten.framme@insel.ch
RI Birngruber, Reginald/Q-2342-2016
FU Novartis Pharma GmbH, Nuremberg, Germany
FX Supported by Novartis Pharma GmbH, Nuremberg, Germany.
CR Ahlswede W, 2004, OPHTHALMOLOGE, V101, P675, DOI 10.1007/s00347-003-0943-7
   [Anonymous], 2009, OPHTHALMOLOGE, V106, P457
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Bolz M, 2008, OPHTHALMOLOGE, V105, P650, DOI 10.1007/s00347-007-1639-1
   Bressler Neil M, 2004, JAMA, V291, P1900, DOI 10.1001/jama.291.15.1900
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Framme C, 2009, CURR EYE RES, V34, P568, DOI 10.1080/02713680902964892
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   GOLBAZ I, OPHTHALMOLOGE
   Jo N, 2006, AM J PATHOL, V168, P2036, DOI 10.2353/ajpath.2006.050588
   Kaiser PK, 2007, OPHTHALMOLOGY, V114, P1868, DOI 10.1016/j.ophtha.2007.04.030
   Keane PA, 2008, INVEST OPHTH VIS SCI, V49, P3115, DOI 10.1167/iovs.08-1689
   Kiss CG, 2009, INVEST OPHTH VIS SCI, V50, P2376, DOI 10.1167/iovs.08-2017
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rothenbuehler SP, 2009, AM J OPHTHALMOL, V147, P831, DOI 10.1016/j.ajo.2008.12.005
   Sayanagi K, 2009, OPHTHALMOLOGY, V116, P947, DOI 10.1016/j.ophtha.2008.11.002
NR 17
TC 39
Z9 39
U1 0
U2 1
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD MAR
PY 2010
VL 51
IS 3
BP 1671
EP 1676
DI 10.1167/iovs.09-4496
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 563VW
UT WOS:000275164300060
PM 19875667
DA 2022-11-30
ER

PT J
AU Liu, YF
   Zhang, L
   Tang, XC
   Liu, FY
   Fu, JL
   Gong, XD
   Wang, L
   Nie, Q
   Xiang, JW
   Xiao, Y
   Liu, YZ
   Li, DWC
AF Liu, Yunfei
   Zhang, Lan
   Tang, Xiangcheng
   Liu, Fangyuan
   Fu, Jia-Ling
   Gong, Xiao-Dong
   Wang, Ling
   Nie, Qian
   Xiang, Jia-Wen
   Xiao, Yuan
   Liu, Yizhi
   Li, David Wan-Cheng
TI Determination of Expression Patterns of Seven De-sumoylation Enzymes in
   Major Ocular Cell Lines
SO CURRENT MOLECULAR MEDICINE
LA English
DT Article
DE SENP; FHL124; HLE; alpha TN4-1; N/N1003A; ARPE-19; De-sumoylation
ID PIGMENT EPITHELIAL-CELLS; SUMO PROTEASE SENP7; ALPHA-B-CRYSTALLIN;
   OXIDATIVE STRESS; GENE-EXPRESSION; TRANSCRIPTION FACTOR; SIGNALING
   PATHWAY; PLASMA-MEMBRANE; DOWN-REGULATION; INHIBITION
AB Purpose: Accumulated evidence have well established that protein sumoylation plays multiple roles in various cellular processes. In the vertebrate eye, we and others have demonstrated that sumoylation displays indispensable roles in regulating eye development. Various ocular cell lines including human embryonic cell line (FHL124), the SV40-large T-transformed human lens epithelial cell line (HLE), the SV40-large T-transformed mouse lens epithelial cell line (alpha TN4-1), the rabbit lens epithelial cell line (N/N1003A) and the human retina pigment epithelial cell line (ARPE-19) have been extensively used for studying various cellular functions and disease processes including sumoylation functions, and mechanisms for cataract and age-related macular degeneration (AMD). However, the sumoylation enzyme systems have not been well established.
   Methods: FHL124, HLE, alpha TN4-1, N/N1003A and ARPE-19 were cultured in Dulbecco's modified eagle medium (DMEM) containing 10% FBS and 1% penicillin & streptomycin. The expression levels of seven SENP mRNAs were analyzed with qRT-PCR, and the expression levels of seven SENP proteins were detected with Western blot analysis.
   Results: Using both qRT-PCR and Western blot analysis, we have obtained the followings: 1). The 3 human ocular cell lines, FHL124, HLE and ARPE-19 express all types of SENP mRNA and proteins. 2). In mouse lens epithelial cell line alpha TN4-1, and rabbit lens epithelial cells line N/N1003A, however, only the mRNAs for SENP1, 2, 3, 6 and 7 are expressed. At the protein level, SENP8 was absent in both alpha TN4-1 and N/N1003A cells; 3). Each cell line has different dominant SENP enzymes. For FHL124, SENP3, 5, 7 and 8 proteins are relatively dominant. SENP3, 5 and 6 are the major de-sumoylation enzymes in HLE cells. Different from human lens epithelial cells, FHL124 and HLE, human retina pigment epithelial cells (ARPE-19) have SENP3, 7, and 8 as the dominant forms of de-sumoylation enzymes. For mouse lens epithelial cells, SENP1, 3 and 7 are the major de-sumoylation enzymes. On the other hand, the rabbit lens epithelial cells have SENP1, 2 and 7 as the major isoforms.
   Conclusion: Our results for the first time defined the differential expression patterns of the seven types of de-sumoylation enzymes (SENPs) in 5 major ocular cell lines. These results help to establish the basis for the future study of sumoylation functions and the related mechanisms in vertebrate eye.
C1 [Liu, Yunfei; Zhang, Lan; Tang, Xiangcheng; Liu, Fangyuan; Fu, Jia-Ling; Gong, Xiao-Dong; Wang, Ling; Nie, Qian; Xiang, Jia-Wen; Xiao, Yuan; Liu, Yizhi; Li, David Wan-Cheng] Sun Yat Sen Univ, Zhongshan Ophthalm Ctr, State Key Lab Ophthalmol, 7 Jinsui Rd,Res Bldg,Room 602-5, Guangzhou 510230, Guangdong, Peoples R China.
C3 Sun Yat Sen University
RP Li, DWC (通讯作者)，Sun Yat Sen Univ, Zhongshan Ophthalm Ctr, State Key Lab Ophthalmol, 7 Jinsui Rd,Res Bldg,Room 602-5, Guangzhou 510230, Guangdong, Peoples R China.; Liu, YZ (通讯作者)，Sun Yat Sen Univ, Zhongshan Ophthalm Ctr, State Key Lab Ophthalmol, 7 Jinsui Rd,Res Bldg,Room 602-2, Guangzhou 510230, Guangdong, Peoples R China.
EM liuyizhi@gzzoc.com; liwancheng@gzzoc.com
RI LIU, Fangyuan/GRX-8688-2022; Li, David/AAN-9205-2021; liu,
   yi/GXE-9662-2022
FU National Natural Science Foundation of China [81570824, 81770910,
   81500738, 81500707, 81700821]; Fundamental Research Funds of the State
   Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun
   Yat-sen University
FX This study was supported in part by the grants from the National Natural
   Science Foundation of China (Grant Number #81570824, 81770910, 81500738,
   81500707 and 81700821), and the Fundamental Research Funds of the State
   Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun
   Yat-sen University. We thank all members of David W. Li's Laboratory in
   the State Key Laboratory of Ophthalmology in Zhongshan Ophthalmic Center
   of Sun Yat-sen University.
CR Alizadeh M, 2001, INVEST OPHTH VIS SCI, V42, P2706
   Anderson CA, 2013, EMBO J, V32, P1496, DOI 10.1038/emboj.2013.103
   Awasthi N, 2005, INVEST OPHTH VIS SCI, V46, P2082, DOI 10.1167/iovs.05-0002
   Barry R, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-05321-2
   Chen LH, 2003, ONCOGENE, V22, P5348, DOI 10.1038/sj.onc.1206851
   Cheng J, 2007, CELL, V131, P584, DOI 10.1016/j.cell.2007.08.045
   Cui CP, 2017, GUT, V66, P2149, DOI 10.1136/gutjnl-2016-313264
   Di Bacco A, 2006, CELL CYCLE, V5, P2310, DOI 10.4161/cc.5.20.3367
   Di Bacco A, 2006, MOL CELL BIOL, V26, P4489, DOI 10.1128/MCB.02301-05
   Dunn KC, 1996, EXP EYE RES, V62, P155, DOI 10.1006/exer.1996.0020
   Ehrentraut SF, 2016, MOL BIOL CELL
   Finnemann SC, 1997, P NATL ACAD SCI USA, V94, P12932, DOI 10.1073/pnas.94.24.12932
   Ganatra DA, 2015, EYE, V29, P828, DOI 10.1038/eye.2015.29
   Gao M, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.478
   Gao XQ, 2001, P NATL ACAD SCI USA, V98, P15221, DOI 10.1073/pnas.261572998
   Gareau JR, 2010, NAT REV MOL CELL BIO, V11, P861, DOI 10.1038/nrm3011
   Geiss-Friedlander R, 2007, NAT REV MOL CELL BIO, V8, P947, DOI 10.1038/nrm2293
   Gong L, 2016, CURR MOL MED, V16, P871, DOI 10.2174/1566524016666161223104915
   Gong LL, 2018, P NATL ACAD SCI USA, V115, pE3987, DOI 10.1073/pnas.1715237115
   Gong LL, 2014, P NATL ACAD SCI USA, V111, P5574, DOI 10.1073/pnas.1315034111
   Grocott T, 2007, NUCLEIC ACIDS RES, V35, P890, DOI 10.1093/nar/gkl1105
   Guo C, 2013, EMBO J, V32, P1514, DOI 10.1038/emboj.2013.65
   Hang J, 2002, J BIOL CHEM, V277, P19961, DOI 10.1074/jbc.M201799200
   Hendriks IA, 2016, NAT REV MOL CELL BIO, V17, P581, DOI 10.1038/nrm.2016.81
   Huang CJ, 2017, BBA-MOL CELL RES, V1864, P1195, DOI 10.1016/j.bbamcr.2017.03.005
   Huang M, 2015, BBA-MOL CELL RES, V1853, P1808, DOI 10.1016/j.bbamcr.2015.04.018
   Huang WD, 2011, NATURE, V470, P414, DOI 10.1038/nature09703
   Ibaraki N, 1998, EXP EYE RES, V67, P577, DOI 10.1006/exer.1998.0551
   Iriyama A, 2008, J BIOL CHEM, V283, P11947, DOI 10.1074/jbc.M708989200
   James C, 2005, INVEST OPHTH VIS SCI, V46, P925, DOI 10.1167/iovs.04-0523
   James ER, 2003, INVEST OPHTH VIS SCI, V44, P5269, DOI 10.1167/iovs.03-0401
   Juarez-Vicente F, 2016, BBA-MOL CELL RES, V1863, P1490, DOI 10.1016/j.bbamcr.2016.03.028
   Kadoya T, 2000, J BIOL CHEM, V275, P37030, DOI 10.1074/jbc.M005984200
   Kang X, 2010, ONCOGENE, V29, P5568, DOI 10.1038/onc.2010.297
   Kim KI, 2000, J BIOL CHEM, V275, P14102, DOI 10.1074/jbc.275.19.14102
   Klein UR, 2009, MOL BIOL CELL, V20, P410, DOI 10.1091/mbc.E08-05-0511
   Krausz E, 1996, INVEST OPHTH VIS SCI, V37, P2120
   Lee MH, 2011, MOL CELL, V43, P180, DOI 10.1016/j.molcel.2011.06.017
   Li DWC, 2006, ONCOGENE, V25, P3006, DOI 10.1038/sj.onc.1209334
   Li DWC, 2005, MOL BIOL CELL, V16, P4437, DOI 10.1091/mbc.E05-01-0010
   Li JS, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-03177-0
   Liu H. M, 2017, ACTA ECOLOGICA SINIC, V37, P1
   Liu H, 2013, INVEST OPHTH VIS SCI, V54, P5236, DOI 10.1167/iovs.13-11664
   Liu WB, 2008, MOL VIS, V14, P762
   Ma WC, 2006, FREE RADICAL BIO MED, V40, P335, DOI 10.1016/j.freeradbiomed.2005.08.032
   Maison C, 2012, NAT STRUCT MOL BIOL, V19, P458, DOI 10.1038/nsmb.2244
   Mao YW, 2004, CELL DEATH DIFFER, V11, P512, DOI 10.1038/sj.cdd.4401384
   Mao YW, 2001, J BIOL CHEM, V276, P43435, DOI 10.1074/jbc.M102195200
   Marcantonio JM, 2004, EXP EYE RES, V79, P437, DOI 10.1016/j.exer.2004.06.014
   Marmorstein AD, 2000, P NATL ACAD SCI USA, V97, P12758, DOI 10.1073/pnas.220402097
   Martina JA, 2014, SCI SIGNAL, V7, DOI 10.1126/scisignal.2004754
   MEAKIN SO, 1989, EXP EYE RES, V48, P131, DOI 10.1016/0014-4835(89)90026-2
   Mukhopadhyay D, 2010, J CELL BIOL, V188, P681, DOI 10.1083/jcb.200909008
   Nahomi RB, 2018, J CELL BIOCHEM, V119, P6814, DOI 10.1002/jcb.26877
   Nie Q, 2016, CURR MOL MED, V16, P906, DOI 10.2174/1566524016666161223105555
   Nishida T, 2000, EUR J BIOCHEM, V267, P6423, DOI 10.1046/j.1432-1327.2000.01729.x
   Nishida T, 2001, J BIOL CHEM, V276, P39060, DOI 10.1074/jbc.M103955200
   Onishi A, 2010, NAT NEUROSCI, V13, P1059, DOI 10.1038/nn.2618
   Onishi A, 2009, NEURON, V61, P234, DOI 10.1016/j.neuron.2008.12.006
   Park JH, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6483
   Park JI, 2012, PLOS ONE, V7, DOI [10.1371/journal.pone.0051377, 10.1371/journal.pone.0037010]
   Plant LD, 2010, P NATL ACAD SCI USA, V107, P10743, DOI 10.1073/pnas.1004712107
   Prudent J, 2015, MOL CELL, V59, P941, DOI 10.1016/j.molcel.2015.08.001
   Qi YT, 2014, J BIOL CHEM, V289, P3288, DOI 10.1074/jbc.M113.518282
   Qin JC, 2008, CANCER RES, V68, P4150, DOI 10.1158/0008-5472.CAN-08-0839
   Qiu C, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15426
   Rajan S, 2005, CELL, V121, P37, DOI 10.1016/j.cell.2005.01.019
   REDDAN JR, 1986, DIFFERENTIATION, V33, P168, DOI 10.1111/j.1432-0436.1986.tb00422.x
   Reddan JR, 1999, INVEST OPHTH VIS SCI, V40, pS970
   Roger JE, 2010, J BIOL CHEM, V285, P25637, DOI 10.1074/jbc.M110.142810
   Shao L, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9917
   Smith AJO, 2016, REDOX BIOL, V8, P354, DOI 10.1016/j.redox.2016.03.003
   Spector A, 2002, EXP EYE RES, V75, P573, DOI 10.1006/exer.2002.2045
   Spector A, 2002, INVEST OPHTH VIS SCI, V43, P3251
   Tong C, 2013, FASEB J, V27, P4332, DOI 10.1096/fj.12-216473
   Treins C, 2001, J BIOL CHEM, V276, P43836, DOI 10.1074/jbc.M106534200
   Wang LX, 2006, EXP CELL RES, V312, P1439, DOI 10.1016/j.yexcr.2006.01.004
   Wormstone IM, 2000, INVEST OPHTH VIS SCI, V41, P4216
   Wu YC, 2012, CANCER RES, V72, P4963, DOI 10.1158/0008-5472.CAN-12-0673
   Xiang H, 2002, ONCOGENE, V21, P3784, DOI 10.1038/sj.onc.1205455
   Xiang JW, 2016, CURR MOL MED, V16, P859, DOI 10.2174/1566524017666170109123238
   Xiao L, 2010, CELL DEATH DIFFER, V17, P1448, DOI 10.1038/cdd.2010.16
   Xirodimas DP, 2008, EMBO REP, V9, P280, DOI 10.1038/embor.2008.10
   Yan Q, 2007, J BIOL CHEM, V282, P13954, DOI 10.1074/jbc.M611476200
   Yan Q, 2010, P NATL ACAD SCI USA, V107, P21034, DOI 10.1073/pnas.1007866107
   Yates KE, 2008, AGING CELL, V7, P609, DOI 10.1111/j.1474-9726.2008.00411.x
   Yu LY, 2010, J EXP MED, V207, P1183, DOI 10.1084/jem.20092215
   Yuan YK, 2014, NEURON, V83, P996, DOI 10.1016/j.neuron.2014.08.026
   Yue XT, 2017, GENE DEV, V31, P1641, DOI 10.1101/gad.301564.117
   Zhang L, 2016, CURR MOL MED, V16, P877, DOI 10.2174/1566524016666161223110407
   Zhang L, 2016, CURR MOL MED, V16, P803, DOI 10.2174/1566524016666161128115453
   Zhang L, 2011, ANTIOXID REDOX SIGN, V15, P1, DOI 10.1089/ars.2010.3560
   Zhang XD, 2008, MOL CELL, V29, P729, DOI 10.1016/j.molcel.2008.01.013
   Zhou HJ, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-05812-2
   Zhou JL, 2006, P NATL ACAD SCI USA, V103, P16182, DOI 10.1073/pnas.0604255103
   Zhu XL, 2017, CIRC RES, V121, P636, DOI 10.1161/CIRCRESAHA.117.310696
   Zunino R, 2007, J CELL SCI, V120, P1178, DOI 10.1242/jcs.03418
   Zunino R, 2009, J BIOL CHEM, V284, P17783, DOI 10.1074/jbc.M901902200
NR 98
TC 2
Z9 2
U1 0
U2 6
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 1566-5240
EI 1875-5666
J9 CURR MOL MED
JI Curr. Mol. Med.
PY 2018
VL 18
IS 9
BP 584
EP 593
DI 10.2174/1566524019666190107153440
PG 10
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA HL7BM
UT WOS:000458892000002
PM 30621560
DA 2022-11-30
ER

PT J
AU Elsaid, N
   Jackson, TL
   Elsaid, Z
   Alqathania, A
   Somavarapu, S
AF Elsaid, Naba
   Jackson, Timothy L.
   Elsaid, Zeeneh
   Alqathania, Aljawharah
   Somavarapu, Satyanarayana
TI PLGA Microparticles Entrapping Chitosan-Based Nanoparticles for the
   Ocular Delivery of Ranibizumab
SO MOLECULAR PHARMACEUTICS
LA English
DT Article
DE chitosan; ranibizumab; age-related macular degeneration; sustained
   delivery; antiangiogenic; hyaluronic acid
ID ENDOTHELIAL GROWTH-FACTOR; IN-VITRO EVALUATION; HYALURONIC-ACID; MACULAR
   DEGENERATION; CONTROLLED-RELEASE; N-ACETYLCYSTEINE; PROTEIN DELIVERY;
   DRUG-DELIVERY; ABSORPTION ENHANCEMENT; INDUCED ANGIOGENESIS
AB Age-related macular degeneration (AMD) is the leading cause of certified vision loss worldwide. The standard treatment for neovascular AMD involves repeated intravitreal injections of therapeutic proteins directed against vascular endothelial growth factor, such as ranibizumab. Biodegradable polymers, such as poly(lactic-co-glycolic acid) (PLGA), form delivery vehicles which can be used to treat posterior segment eye diseases, but suffer from poor protein loading and release. This work describes a "system-within-system", PLGA micro particles incorporating chitosan-based nanoparticles, for improved loading and sustained intravitreal delivery of ranibizumab. Chitosan-N-acetyl-L-cysteine (CNAC) was synthesized and its synthesis confirmed using FT-IR and H-1 NMR. Chitosan-based nanoparticles composed of CNAC, CNAC/tripolyphosphate (CNAC/TPP), chitosan, chitosan/TPP (chit/TPP), or chit/TPP-hyaluronic acid (chit/TPP-HA) were incorporated in PLGA microparticles using a modified w/o/w double emulsion method. Nanoparticles and final nanoparticles-within-microparticles were characterized for their protein-nanoparticle interaction, size, zeta potential, morphology, protein loading, stability, in vitro release, in vivo antiangiogenic activity, and effects on cell viability. The prepared nanoparticles were 17-350 nm in size and had zeta potentials of -1.4 to +12 mV. Microscopic imaging revealed spherical nanoparticles on the surface of PLGA microparticles for preparations containing chit/TPP, CNAC, and CNAC/TPP. Ranibizumab entrapment efficiency in the preparations varied between 13 and 69% and was highest for the PLGA microparticles containing CNAC nanoparticles. This preparation also showed the slowest release with no initial burst release compared to all other preparations. Incorporation of TPP to this formulation increased the rate of protein release and reduced entrapment efficiency. PLGA microparticles containing chit/TPP-HA showed the fastest and near-complete release of ranibizumab. All of the prepared empty particles showed no effect on cell viability up to a concentration of 12.5 mg/mL. Ranibizumab released from all preparations maintained its structural integrity and in vitro activity. The chit/TPP-HA preparation enhanced antiangiogenic activity and may provide a potential biocompatible platform for enhanced antiangiogenic activity in combination with ranibizumab. In conclusion, the PLGA microparticles containing CNAC nanoparticles showed significantly improved ranibizumab loading and release profile. This novel drug delivery system may have potential for improved intravitreal delivery of therapeutic proteins, thereby reducing the frequency, risk, and cost of burdensome intravitreal injections.
C1 [Elsaid, Naba] Univ Hertfordshire, Hatfield, Herts, England.
   [Jackson, Timothy L.] Kings Coll London, London, England.
   [Elsaid, Zeeneh; Alqathania, Aljawharah; Somavarapu, Satyanarayana] UCL, Sch Pharm, London, England.
C3 University of Hertfordshire; University of London; King's College
   London; University of London; University College London; University of
   London School of Pharmacy
RP Elsaid, N (通讯作者)，Univ Hertfordshire, Hatfield, Herts, England.; Somavarapu, S (通讯作者)，UCL, Sch Pharm, London, England.
EM naba_elsaid@hotmail.com; s.somavarapu@ucl.ac.uk
OI Alqathama, Aljawharah/0000-0003-0855-2013; Jackson,
   Timothy/0000-0001-7618-1555
FU King's College Hospital NHS Foundation Trust Clinical Research and
   Development Investment Scheme [513843]; NeoVista; Novartis; Oraya
FX We wish to thank Dr. Paul Stapleton and David McCarthy for their
   assistance in the Live/Dead, TEM, and SEM procedures. We wish to also
   thank Robert Petrarca and Tasneem Kapadia for their contribution in the
   preliminary studies. This study was supported by King's College Hospital
   NHS Foundation Trust Clinical Research and Development Investment
   Scheme, Grant No. 513843. T.L.J. received research grant support from
   NeoVista, Novartis, and Oraya for unrelated projects. He has served as
   an advisor to Alcon, Bausch & Lomb, Thrombogenics and Allimera, but
   received no commercial support in relation to the work presented herein.
CR Aktas Y, 2005, INT J PHARMACEUT, V298, P378, DOI 10.1016/j.ijpharm.2005.03.027
   Allison SD, 2008, EXPERT OPIN DRUG DEL, V5, P615, DOI 10.1517/17425247.5.6.615 
   Aluigi MG, 2000, ANTICANCER RES, V20, P3183
   Amann LC, 2010, PHARM RES-DORDR, V27, P1730, DOI 10.1007/s11095-010-0152-4
   Anderson JM, 1997, ADV DRUG DELIVER REV, V28, P5, DOI 10.1016/S0169-409X(97)00048-3
   Arnaoutova I, 2010, NAT PROTOC, V5, P628, DOI 10.1038/nprot.2010.6
   Bakri SJ, 2007, OPHTHALMOLOGY, V114, P2179, DOI 10.1016/j.ophtha.2007.09.012
   Bernkop-Schnurch A, 2004, EUR J PHARM BIOPHARM, V57, P9, DOI 10.1016/s0939-6411(03)00147-4
   Bouissou C, 2006, PHARM RES-DORDR, V23, P1295, DOI 10.1007/s11095-006-0180-2
   Bozhokina E, 2013, J CELL BIOCHEM, V114, P1568, DOI 10.1002/jcb.24498
   Bunce C, 2015, PUBLIC HEALTH, V129, P138, DOI 10.1016/j.puhe.2014.12.018
   Calvo P, 1997, INT J PHARM, V153, P41, DOI 10.1016/S0378-5173(97)00083-5
   Carneiro A, 2009, EXP EYE RES, V88, P522, DOI 10.1016/j.exer.2008.11.011
   Carrasquillo KG, 2003, INVEST OPHTH VIS SCI, V44, P290, DOI 10.1167/iovs.01-1156
   Chandy T, 2000, J MICROENCAPSUL, V17, P625
   Chen YL, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.159
   Chereddy KK, 2014, J CONTROL RELEASE, V194, P138, DOI 10.1016/j.jconrel.2014.08.016
   Costa R, 2009, J CELL BIOCHEM, V108, P1410, DOI 10.1002/jcb.22378
   Crotts G, 1998, J MICROENCAPSUL, V15, P699, DOI 10.3109/02652049809008253
   D'Souza SS, 2006, PHARM RES-DORDR, V23, P460, DOI 10.1007/s11095-005-9397-8
   de la Fuente M, 2008, INVEST OPHTH VIS SCI, V49, P2016, DOI 10.1167/iovs.07-1077
   Dias JRD, 2011, BRIT J OPHTHALMOL, V95, P1631, DOI 10.1136/bjo.2010.186361
   Dhawan S, 2003, BIOTECH HISTOCHEM, V78, P243, DOI 10.1080/1052090310001602396
   Dounighi NM, 2012, J VENOM ANIM TOXINS, V18, P44, DOI 10.1590/S1678-91992012000100006
   Dunn KC, 1996, EXP EYE RES, V62, P155, DOI 10.1006/exer.1996.0020
   [EMEA] European Medicines Agency, 2007, SCI DISC
   FEINBERG RN, 1983, SCIENCE, V220, P1177, DOI 10.1126/science.6857242
   Feng L, 2005, AM J NEURORADIOL, V26, P1405
   Ferlay J, 2010, EUR J CANCER, V46, P765, DOI 10.1016/j.ejca.2009.12.014
   Ferrara N, 2006, RETINA-J RET VIT DIS, V26, P859, DOI 10.1097/01.iae.0000242842.14624.e7
   FOLKMAN J, 1987, SCIENCE, V235, P442, DOI 10.1126/science.2432664
   FOLKMAN J, 1985, ADV CANCER RES, V43, P175, DOI 10.1016/S0065-230X(08)60946-X
   Ghasemian E, 2013, DARU, V21, DOI 10.1186/2008-2231-21-68
   Giebel SJ, 2005, LAB INVEST, V85, P597, DOI 10.1038/labinvest.3700251
   Grenha A, 2007, EUR J PHARM SCI, V31, P73, DOI 10.1016/j.ejps.2007.02.008
   Grisanti S, 2010, OPHTHALMOLOGE, V107, P1123, DOI 10.1007/s00347-010-2299-0
   Harde H, 2015, PHARM RES-DORDR, V32, P122, DOI 10.1007/s11095-014-1449-5
   Hoeben A, 2004, PHARMACOL REV, V56, P549, DOI 10.1124/pr.56.4.3
   Hombach J, 2008, EUR J PHARM SCI, V33, P1, DOI 10.1016/j.ejps.2007.09.001
   Hong XY, 2013, INT J NANOMED, V8, P2433, DOI 10.2147/IJN.S45186
   Hornof M, 2005, EUR J PHARM BIOPHARM, V60, P207, DOI 10.1016/j.ejpb.2005.01.009
   Hotchkiss KA, 2002, MOL CANCER THER, V1, P1191
   Hrynyk M, 2010, INT J PHARMACEUT, V398, P146, DOI 10.1016/j.ijpharm.2010.07.052
   HSIEH DST, 1983, J PHARM SCI-US, V72, P17, DOI 10.1002/jps.2600720105
   Hua FJ, 2002, J BIOMED MATER RES, V63, P161, DOI 10.1002/jbm.10121
   Iriyama A, 2008, J BIOL CHEM, V283, P11947, DOI 10.1074/jbc.M708989200
   Ito T, 2004, KIDNEY INT, V65, P823, DOI 10.1111/j.1523-1755.2004.00457.x
   Jain GK, 2010, POLYM DEGRAD STABIL, V95, P2360, DOI 10.1016/j.polymdegradstab.2010.08.015
   Janes KA, 2001, ADV DRUG DELIVER REV, V47, P83, DOI 10.1016/S0169-409X(00)00123-X
   Jin SG, 2009, J KOREAN NEUROSURG S, V46, P472, DOI 10.3340/jkns.2009.46.5.472
   Kageyama T, 2014, BIOFABRICATION, V6, DOI 10.1088/1758-5082/6/2/025006
   Kahook MY, 2010, RETINA-J RET VIT DIS, V30, P887, DOI 10.1097/IAE.0b013e3181d50cea
   Kaja Simon, 2011, Human Antibodies, V20, P95, DOI 10.3233/HAB-2011-0244
   Khattar H, 2012, INT J DRUG DELIV, V4, P316
   Kievit FM, 2013, ADV HEALTHC MATER, V2, P1651, DOI 10.1002/adhm.201300092
   Kim MM, 2006, FEBS LETT, V580, P2661, DOI 10.1016/j.febslet.2006.04.015
   Klettner A, 2008, INVEST OPHTH VIS SCI, V49, P4523, DOI 10.1167/iovs.08-2055
   Kogan G, 2007, BIOTECHNOL LETT, V29, P17, DOI 10.1007/s10529-006-9219-z
   Lee ES, 2006, EUR J PHARM SCI, V29, P435, DOI 10.1016/j.ejps.2006.08.005
   Lee YS, 2013, EUR J PHARM BIOPHARM, V83, P168, DOI 10.1016/j.ejpb.2012.10.016
   Li FF, 2012, OPEN OPHTHALMOL J, V6, P54, DOI 10.2174/1874364101206010054
   Lian H, 2014, J NANOPART RES, V16, DOI 10.1007/s11051-014-2355-9
   Lin MT, 2003, MOL PHARMACOL, V64, P1029, DOI 10.1124/mol.64.5.1029
   Liu F, 2011, EUR J PHARM BIOPHARM, V78, P151, DOI 10.1016/j.ejpb.2011.01.001
   Liu G., 2010, Journal of Biomimetrics, Biomaterials, and Tissue Engineering, V6, P1, DOI 10.4028/www.scientific.net/JBBTE.6.1
   Liu HT, 2011, ACTA PHARMACOL SIN, V32, P478, DOI 10.1038/aps.2011.10
   Lu W, 1995, PDA J Pharm Sci Technol, V49, P13
   Luangtana-anan M, 2005, PHARM DEV TECHNOL, V10, P189, DOI 10.1081/PDT-200054388
   Manca ML, 2008, COLLOID SURFACE B, V62, P220, DOI 10.1016/j.colsurfb.2007.10.005
   Mao SR, 2007, INT J PHARM, V334, P137, DOI 10.1016/j.ijpharm.2006.10.036
   McBane JE, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0077538
   Medina RJ, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002584
   Mi FL, 1999, J APPL POLYM SCI, V74, P1093, DOI 10.1002/(SICI)1097-4628(19991031)74:5<1093::AID-APP6>3.0.CO;2-C
   Miklas JW, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0072956
   Murugeshu A, 2011, NANOMEDICINE-UK, V6, P1513, DOI [10.2217/nnm.11.44, 10.2217/NNM.11.44]
   Nasti A, 2009, PHARM RES-DORDR, V26, P1918, DOI 10.1007/s11095-009-9908-0
   National Institute for Health and Care Excellence (NICE), 2008, RAN PEG TREATM AG RE
   Oh EJ, 2010, J CONTROL RELEASE, V141, P2, DOI 10.1016/j.jconrel.2009.09.010
   Okamoto H, 2006, MOL VIS, V12, P156
   Okamoto Y, 2002, BIOMATERIALS, V23, P1975, DOI 10.1016/S0142-9612(01)00324-6
   Oliveira RC, 2012, CURR EYE RES, V37, P55, DOI 10.3109/02713683.2011.593722
   Pan CK, 2011, J OCUL PHARMACOL TH, V27, P219, DOI 10.1089/jop.2010.0158
   Pan Y, 2002, INT J PHARMACEUT, V249, P139, DOI 10.1016/S0378-5173(02)00486-6
   Parajo Y, 2010, DRUG DELIV, V17, P596, DOI 10.3109/10717544.2010.509357
   Pieper GM, 1998, J CARDIOVASC PHARM, V32, P101, DOI 10.1097/00005344-199807000-00016
   Ponedel'kina IY, 2008, DOKL CHEM, V419, P95, DOI 10.1134/S0012500808040046
   Prashanth KVH, 2005, BBA-GEN SUBJECTS, V1722, P22, DOI 10.1016/j.bbagen.2004.11.009
   Qi LF, 2004, CARBOHYD RES, V339, P2693, DOI 10.1016/j.carres.2004.09.007
   Ramchandani M, 1998, J CONTROL RELEASE, V54, P167, DOI 10.1016/S0168-3659(97)00113-2
   ROONEY P, 1993, DIFFERENTIATION, V54, P1
   Sampat KM, 2010, CURR OPIN OPHTHALMOL, V21, P178, DOI 10.1097/ICU.0b013e328338679a
   Schipper NGM, 1997, PHARMACEUT RES, V14, P923, DOI 10.1023/A:1012160102740
   Schmitz T, 2008, INT J PHARMACEUT, V347, P79, DOI 10.1016/j.ijpharm.2007.06.040
   Semete B, 2010, NANOMED-NANOTECHNOL, V6, P662, DOI 10.1016/j.nano.2010.02.002
   Shelke NB, 2011, DRUG DELIV TRANSL RE, V1, P76, DOI 10.1007/s13346-010-0009-8
   Silverstein R.M., 1981, SPECTROMETRIC IDENTI, V4th ed.
   Souza MCM, 2014, CURR EYE RES, V39, P99, DOI 10.3109/02713683.2013.819927
   Sturesson C, 2000, J CONTROL RELEASE, V67, P171, DOI 10.1016/S0168-3659(00)00205-4
   Talaei F, 2011, INT J NANOMED, V6, P1963, DOI 10.2147/IJN.S22731
   van de Weert M, 2000, PHARM RES-DORDR, V17, P1159, DOI 10.1023/A:1026498209874
   van der Meer AD, 2010, AM J PHYSIOL-HEART C, V298, pH719, DOI 10.1152/ajpheart.00933.2009
   Wadhwa S, 2010, J DRUG TARGET, V18, P292, DOI 10.3109/10611860903450023
   Wang Q, 2014, BIOMED MATER, V9, DOI 10.1088/1748-6041/9/1/015007
   Wang X, 2009, J BIOMED MATER RES B, V88B, P150, DOI 10.1002/jbm.b.31161
   Wang YC, 2013, AAPS PHARMSCITECH, V14, P585, DOI 10.1208/s12249-013-9943-3
   Wang Z, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.318
   Wen H, 2013, J PHARM SCI-US, V102, P892, DOI 10.1002/jps.23387
   Xu YL, 2009, ANTICANCER RES, V29, P5103
   Yandrapu SK, 2013, MOL PHARMACEUT, V10, P4676, DOI 10.1021/mp400487f
   Yang H., 2013, INT J ADV COMPUT TEC, V5, P585
   Yang MH, 2012, ANALYST, V137, P4921, DOI 10.1039/c2an35368g
   Ye ML, 2010, J CONTROL RELEASE, V146, P241, DOI 10.1016/j.jconrel.2010.05.011
   Yu WZ, 2013, MOL VIS, V19, P1397
   Zhu X, 2012, MOL VIS, V18, P1973
NR 114
TC 71
Z9 72
U1 6
U2 84
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1543-8384
J9 MOL PHARMACEUT
JI Mol. Pharm.
PD SEP
PY 2016
VL 13
IS 9
BP 2923
EP 2940
DI 10.1021/acs.molpharmaceut.6b00335
PG 18
WC Medicine, Research & Experimental; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine; Pharmacology & Pharmacy
GA DV1WV
UT WOS:000382713700008
PM 27286558
OA Green Submitted
DA 2022-11-30
ER

PT J
AU Indaram, M
   Agron, E
   Clemons, TE
   Sperduto, RD
   Wong, WT
   Ferris, FL
   Chew, EY
AF Indaram, Maanasa
   Agron, Elvira
   Clemons, Traci E.
   Sperduto, Robert D.
   Wong, Wai T.
   Ferris, Frederick L., III
   Chew, Emily Y.
CA Age Related Eye Dis Study Res Grp
TI Changes in Lens Opacities on the Age-Related Eye Disease Study Grading
   Scale Predict Progression to Cataract Surgery and Vision Loss
SO OPHTHALMOLOGY
LA English
DT Article
ID BLUE MOUNTAINS EYE; II LOCS-II; REGRESSION; AREDS
AB Purpose: To investigate whether the 2-year change in lens opacity severity on the Age-Related Eye Disease Study (AREDS) lens grading scale predicts progression to cataract surgery or loss of visual acuity by 5 years.
   Design: Prospective cohort study within a randomized clinical trial of oral supplements. Participants: The AREDS participants whose eyes were phakic at baseline and free of late age-related macular degeneration throughout the study.
   Methods: Baseline and annual lens photographs of AREDS participants (n = 3466/4757; 73%) were graded for severity of cataracts using the AREDS system for classifying cataracts from photographs. Clinical examinations conducted semiannually collected data on cataract surgery and visual acuity. Association of the change in lens opacities at 2 years with these outcomes at 5 years was analyzed with adjusted Cox proportional hazard models.
   Main Outcome Measurements: Progression of lens opacities on stereoscopic lens photographs at 2 years, cataract surgery, and visual acuity loss of 2 lines or more at 5 years.
   Results: The adjusted hazard ratios (HRs) for association of progression to cataract surgery at 5 years were: nuclear cataract increase of 1.0 unit or more compared with less than 1.0-unit change at 2 years, 2.77 (95% confidence interval [CI], 2.07-3.70; P < 0.001); cortical cataract increase of 5% or more in lens opacity in the central 5 mm of the lens compared with less than 5% increase at 2 years, 1.91 (95% CI, 1.27-2.87; P = 0.002); and posterior subcapsular cataract increase of 5% or more versus less than 5% in the central 5 mm of the lens, 8.25 (95% CI, 5.55-12.29; P < 0.001). Similarly, HRs of vision loss of 2 lines or more at 5 years for this degree of lens changes at 2 years were the following: nuclear, 1.83 (95% CI, 1.49-2.25; P < 0.001); cortical, 1.13 (95% CI, 0.78-1.65; P = 0.519); and posterior subcapsular cataract, 3.05 (95% CI, 1.79-5.19; P < 0.001).
   Conclusions: Two-year changes in severity of lens opacities on the AREDS lens grading scale are predictive of long-term clinically relevant outcomes, making them potential surrogate end points in follow-up studies. (C) 2015 by the American Academy of Ophthalmology.
C1 [Indaram, Maanasa; Agron, Elvira; Ferris, Frederick L., III; Chew, Emily Y.] NEI, Div Epidemiol & Clin Applicat, NIH, Bethesda, MD 20892 USA.
   [Clemons, Traci E.; Sperduto, Robert D.] EMMES Corp, Rockville, MD USA.
   [Wong, Wai T.] NEI, Unit Neuron Glia Interact Retinal Dis, NIH, Bethesda, MD 20892 USA.
C3 National Institutes of Health (NIH) - USA; NIH National Eye Institute
   (NEI); Emmes Corporation; National Institutes of Health (NIH) - USA; NIH
   National Eye Institute (NEI)
RP Chew, EY (通讯作者)，NEI, NIH, Bldg 10,CRC Room 3-2531,10 Ctr Dr,MSC 1204, Bethesda, MD 20892 USA.
EM echew@nei.nih.gov
RI SanGiovanni, John Paul/AAU-3895-2020; Wong, Wai/B-6118-2017
OI Wong, Wai/0000-0003-0681-4016; Indaram, Maanasa/0000-0001-6228-3307;
   Ferris, Frederick/0000-0002-4933-0639
FU National Eye Institute, National Institutes of Health, Bethesda,
   Maryland [NOI-EY-0-2127]; NATIONAL EYE INSTITUTE [ZIAEY000485,
   ZIAEY000489, N01EY002127] Funding Source: NIH RePORTER
FX Supported by the National Eye Institute, National Institutes of Health,
   Bethesda, Maryland (grant no.: NOI-EY-0-2127). Maanasa Indaram performed
   this work as part of the Howard Hughes Scholars Program at the National
   Institutes of Health.
CR ADAMSONS I, 1991, ARCH OPHTHALMOL-CHIC, V109, P993, DOI 10.1001/archopht.1991.01080070105046
   Age-Related Eye Disease Study Research Group, 2001, AM J OPHTHALMOL, V131, P67
   Chang JR, 2011, OPHTHALMOLOGY, V118, P2113, DOI 10.1016/j.ophtha.2011.03.032
   Chew EY, 2009, ARCH OPHTHALMOL-CHIC, V127, P1678, DOI 10.1001/archophthalmol.2009.312
   CHYLACK LT, 1989, ARCH OPHTHALMOL-CHIC, V107, P991, DOI 10.1001/archopht.1989.01070020053028
   FERRIS FL, 1982, AM J OPHTHALMOL, V94, P97, DOI 10.1016/0002-9394(82)90198-2
   Gonen M, 2005, BIOMETRIKA, V92, P965, DOI 10.1093/biomet/92.4.965
   Grewal DS, 2009, OPHTHALMOLOGY, V116, P1436, DOI 10.1016/j.ophtha.2009.03.002
   Kanthan GL, 2008, OPHTHALMOLOGY, V115, P808, DOI 10.1016/j.ophtha.2007.07.008
   Kassoff A, 1999, CONTROL CLIN TRIALS, V20, P573
   Klein BEK, 2008, OPHTHALMOLOGY, V115, P477, DOI 10.1016/j.ophtha.2007.11.024
   Klein BEK, 1997, OPHTHALMOLOGY, V104, P573, DOI 10.1016/S0161-6420(97)30267-X
   Leske MC, 2004, OPHTHALMOLOGY, V111, P483, DOI 10.1016/j.ophtha.2003.06.016
   MARAINI G, 1991, INVEST OPHTH VIS SCI, V32, P2400
   Sabanayagam C, 2011, INVEST OPHTH VIS SCI, V52, P2397, DOI 10.1167/iovs.10-6373
   Sperduto RD, 2008, AM J OPHTHALMOL, V145, P504, DOI 10.1016/j.ajo.2007.10.024
   Tan JSL, 2008, OPHTHAL EPIDEMIOL, V15, P317, DOI 10.1080/09286580802105806
   WEI LJ, 1989, J AM STAT ASSOC, V84, P1065, DOI 10.2307/2290084
NR 18
TC 9
Z9 11
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD MAY
PY 2015
VL 122
IS 5
BP 888
EP 896
DI 10.1016/j.ophtha.2014.12.037
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA CG5NB
UT WOS:000353337600013
PM 25682177
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Mitta, VP
   Christen, WG
   Glynn, RJ
   Semba, RD
   Ridker, PM
   Rimm, EB
   Hankinson, SE
   Schaumberg, DA
AF Mitta, Vinod P.
   Christen, William G.
   Glynn, Robert J.
   Semba, Richard D.
   Ridker, Paul M.
   Rimm, Eric B.
   Hankinson, Susan E.
   Schaumberg, Debra A.
TI C-Reactive Protein and the Incidence of Macular Degeneration Pooled
   Analysis of 5 Cohorts
SO JAMA OPHTHALMOLOGY
LA English
DT Article
ID COMPLEMENT FACTOR-H; AGE-RELATED MACULOPATHY; COMPONENT 2 C2; FACTOR-B
   BF; CARDIOVASCULAR-DISEASE; RISK-FACTORS; RANDOMIZED-TRIAL; Y402H
   VARIANT; UNITED-STATES; INFLAMMATION
AB Importance: This study adds to the evidence that elevated levels of high-sensitivity C-reactive protein (hsCRP) predict future risk of age-related macular degeneration (AMD). This information might shed light on underlying pathological mechanisms involving inflammation and could be of clinical utility in the identification of persons at high risk of AMD who may benefit from increased adherence to lifestyle recommendations, eye examination schedules, and therapeutic protocols.
   Objective: To investigate the relationship between hsCRP and future risk of AMD in US men and women.
   Design: Pooled analysis of prospective nested case-control data from the Women's Health Study and 4 other cohorts, the Physicians' Health Study, Women's Antioxidant and Folic Acid Cardiovascular Study, Nurses' Health Study, and Health Professionals Follow-up Study.
   Setting: A prospective nested case-control study within 5 large cohorts.
   Participants: Patients were initially free of AMD. We prospectively identified 647 incident cases of AMD and selected age-and sex-matched controls for each AMD case (2 controls for each case with dry AMD or 3 controls for each case of neovascular AMD).
   Main Outcome Measures: We measured hsCRP in baseline blood samples. We used conditional logistic regression models to examine the relationship between hsCRP and AMD and pooled findings using meta-analytic techniques.
   Results: After adjusting for cigarette smoking status, participants with high (>3 mg/L) compared with low (<1 mg/L) hsCRP levels had cohort-specific odds ratios (ORs) for incident AMD ranging from 0.94 (95% CI, 0.581.51) in the Physicians' Health Study to 2.59 (95% CI, 0.58-11.67) in the Women's Antioxidant and Folic Acid Cardiovascular Study. After testing for heterogeneity between studies (Q=5.61; P=.23), we pooled findings across cohorts and observed a significantly increased risk of incident AMD for high vs low hsCRP levels (OR, 1.49; 95% CI, 1.06-2.08). Risk of neovascular AMD was also increased among those with high hsCRP levels (OR, 1.84; 95% CI, 1.14-2.98).
   Conclusions and Relevance: Overall, these pooled findings from 5 prospective cohorts add further evidence that elevated levels of hsCRP predict greater future risk of AMD. This information might shed light on underlying mechanisms and could be of clinical utility in the identification of persons at high risk of AMD who may benefit from increased adherence to lifestyle recommendations, eye examination schedules, and therapeutic protocols.
C1 [Mitta, Vinod P.; Hankinson, Susan E.; Schaumberg, Debra A.] Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02215 USA.
   [Christen, William G.; Glynn, Robert J.; Ridker, Paul M.; Schaumberg, Debra A.] Harvard Univ, Sch Publ Hlth, Div Prevent Med, Boston, MA 02215 USA.
   Harvard Univ, Sch Med, Brigham & Womens Hosp, Cambridge, MA 02138 USA.
   [Hankinson, Susan E.] Brigham & Womens Hosp, Channing Lab, Dept Med, Boston, MA 02115 USA.
   Harvard Univ, Sch Med, Boston, MA 02215 USA.
   [Schaumberg, Debra A.] Harvard Univ, Sch Med, Schepens Eye Res Inst, Dept Ophthalmol, Boston, MA 02215 USA.
   [Semba, Richard D.] Johns Hopkins Univ, Wilmer Eye Inst, Sch Med, Baltimore, MD 21218 USA.
   [Schaumberg, Debra A.] Univ Utah, Dept Ophthalmol & Visual Sci, Salt Lake City, UT USA.
C3 Harvard University; Harvard T.H. Chan School of Public Health; Harvard
   University; Harvard T.H. Chan School of Public Health; Harvard
   University; Brigham & Women's Hospital; Harvard University; Brigham &
   Women's Hospital; Harvard University; Harvard Medical School; Harvard
   University; Harvard Medical School; Schepens Eye Research Institute;
   Johns Hopkins University; Johns Hopkins Medicine; Utah System of Higher
   Education; University of Utah
RP Schaumberg, DA (通讯作者)，Harvard Univ, Sch Med, Brigham & Womens Hosp, Div Prevent Med, 900 Commonwealth Ave E,3rd Floor, Boston, MA 02215 USA.
EM dschaumberg@rics.bwh.harvard.edu
OI Venkatasubramanian, Siddharth/0000-0002-5860-0768
FU National Institutes of Health [EY017362, EY013834, EY06633, EY009611,
   CA047988, HL043851, CA87969, CA49449, HL35464, CA34944, CA40360,
   HL26490, HL34595, HL046959]; NATIONAL CANCER INSTITUTE [R01CA047988,
   R01CA049449, P01CA087969, U01CA049449, R01CA040360] Funding Source: NIH
   RePORTER; NATIONAL EYE INSTITUTE [R01EY006633, R01EY017362, R01EY013834,
   R01EY009611] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND
   BLOOD INSTITUTE [R01HL034595, R01HL035464, R01HL046959, R01HL043851]
   Funding Source: NIH RePORTER
FX This work was supported by National Institutes of Health grants
   EY017362, EY013834, EY06633, EY009611, CA047988, HL043851, CA87969,
   CA49449, HL35464, CA34944, CA40360, HL26490, HL34595, and HL046959.
CR Ambati J, 2003, SURV OPHTHALMOL, V48, P257, DOI 10.1016/S0039-6257(03)00030-4
   Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   Bassuk SS, 2004, J WOMENS HEALTH, V13, P99, DOI 10.1089/154099904322836519
   BELANGER CF, 1978, AM J NURS, V78, P1039, DOI 10.2307/3462013
   Boekhoorn SS, 2007, ARCH OPHTHALMOL-CHIC, V125, P1396, DOI 10.1001/archopht.125.10.1396
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   de Cordoba SR, 2004, MOL IMMUNOL, V41, P355, DOI 10.1016/j.molimm.2004.02.005
   Donoso LA, 2006, SURV OPHTHALMOL, V51, P137, DOI 10.1016/j.survophthal.2005.12.001
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Everett BM, 2006, J AM COLL CARDIOL, V48, P2235, DOI 10.1016/j.jacc.2006.09.030
   Ferrucci L, 2005, BLOOD, V105, P2294, DOI 10.1182/blood-2004-07-2599
   Giannakis E, 2003, EUR J IMMUNOL, V33, P962, DOI 10.1002/eji.200323541
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   GROBBEE DE, 1990, NEW ENGL J MED, V323, P1026, DOI 10.1056/NEJM199010113231504
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   HENNEKENS CH, 1985, PREV MED, V14, P165, DOI 10.1016/0091-7435(85)90031-3
   Hong T, 2011, SURV OPHTHALMOL, V56, P184, DOI 10.1016/j.survophthal.2010.08.007
   Klein R, 2005, AM J OPHTHALMOL, V140, P35, DOI 10.1016/j.ajo.2005.01.051
   Klein R, 2003, OPHTHALMOLOGY, V110, P25, DOI 10.1016/S0161-6420(02)01565-8
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Maguire MG, 2009, OPHTHALMOLOGY, V116, P2381, DOI 10.1016/j.ophtha.2009.06.055
   McGwin G, 2005, BRIT J OPHTHALMOL, V89, P1166, DOI 10.1136/bjo.2005.067397
   Pearson TA, 2003, CIRCULATION, V107, P499, DOI 10.1161/01.CIR.0000052939.59093.45
   PENFOLD PL, 1986, INVEST OPHTH VIS SCI, V27, P364
   Penfold PL, 2001, PROG RETIN EYE RES, V20, P385, DOI 10.1016/S1350-9462(00)00025-2
   Perkins SJ, 2010, ADV EXP MED BIOL, V703, P25, DOI 10.1007/978-1-4419-5635-4_3
   Richardson AJ, 2009, INVEST OPHTH VIS SCI, V50, P540, DOI 10.1167/iovs.08-2423
   Ridker PM, 2005, JAMA-J AM MED ASSOC, V294, P326, DOI 10.1001/jama.294.3.326
   Ridker PM, 2002, NEW ENGL J MED, V347, P1557, DOI 10.1056/NEJMoa021993
   Ridker PM, 2005, NEW ENGL J MED, V352, P1293, DOI 10.1056/NEJMoa050613
   Ridker PM, 2000, NEW ENGL J MED, V342, P836, DOI 10.1056/NEJM200003233421202
   Roberts WL, 2001, CLIN CHEM, V47, P418
   Robman L, 2010, OPHTHALMOLOGY, V117, P1982, DOI 10.1016/j.ophtha.2010.02.003
   Rothman KJ, 1998, MODERN EPIDEMIOLOGY, P133
   Sarks S., 1985, RETINAL DIS, P87
   Schaumberg DA, 2001, ARCH OPHTHALMOL-CHIC, V119, P1259
   Schaumberg DA, 2007, ARCH OPHTHALMOL-CHIC, V125, P300, DOI 10.1001/archopht.125.3.300
   Schaumberg DA, 2007, ARCH OPHTHALMOL-CHIC, V125, P55, DOI 10.1001/archopht.125.1.55
   Schaumberg DA, 2006, INVEST OPHTH VIS SCI, V47, P2336, DOI 10.1167/iovs.05-1456
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P774, DOI 10.1001/archopht.123.6.774
   Seddon JM, 2004, JAMA-J AM MED ASSOC, V291, P704, DOI 10.1001/jama.291.6.704
   Spencer KL, 2007, HUM MOL GENET, V16, P1986, DOI 10.1093/hmg/ddm146
   Vine AK, 2005, OPHTHALMOLOGY, V112, P2076, DOI 10.1016/j.ophtha.2005.07.004
   Wilkins J, 1998, CLIN CHEM, V44, P1358
   Zareparsi S, 2005, AM J HUM GENET, V77, P149, DOI 10.1086/431426
NR 47
TC 43
Z9 46
U1 0
U2 7
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA
SN 2168-6165
J9 JAMA OPHTHALMOL
JI JAMA Ophthalmol.
PD APR
PY 2013
VL 131
IS 4
BP 507
EP 513
DI 10.1001/jamaophthalmol.2013.2303
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 163JH
UT WOS:000320331600013
PM 23392454
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Balaiya, S
   Malyapa, R
   Hsi, W
   Murthy, RK
   Chalam, KV
AF Balaiya, Sankarathi
   Malyapa, Robert
   Hsi, Wen
   Murthy, Ravi K.
   Chalam, Kakarla V.
TI Evaluation of proton beam radiation sensitivity of proliferating
   choroidal endothelial and retinal ganglion cells with clonogenic assay
SO CUTANEOUS AND OCULAR TOXICOLOGY
LA English
DT Article
DE AMD; proton beam; CEC; RGC; clonogenic assay
ID MACULAR DEGENERATION; RADIOTHERAPY; THERAPY; EXPOSURE; TRIAL
AB Context: Proton beam therapy offers the advantage of precise delivery with limited damage to the healthy tissue and is being tested in the management of exudative age-related macular degeneration (AMD). However, the dosages tested are empirical and not based on preclinical studies.
   Objective: In this study we evaluated the effects of varying doses of proton beam radiation on choroidal endothelial cells (CECs) and retinal ganglion cells (RGCs) using clonogenic assay to determine differential sensitivity.
   Materials and methods: Each cell type has different efficiency to replicate (plating efficiency (PE)). PE of CEC (RF/6A) and RGC (RGC-5) grown in culture flasks was determined by plating 250 cells each (without any treatment) and counting the number of colonies after 13 days. Radiation induced sensitivity was determined by exposing the semi-confluent RF/6A and RGC-5 cells to proton beam at the doses of 0 (control), 2, 4, 8 and 12 cobalt gray equivalent (CGE). The ability of the cells to repair and replicate to form colonies were analyzed 13 days after radiation with crystal violet stain and the survival ratio was calculated. The significance of survival was analyzed using ANOVA (Graphpad Instat.3).
   Results: The PE of CEC and RGC was 12.96 +/- 0.29% and 40.7 +/- 1.48%, respectively. A survival ratio of CEC at 2, 4, 8 and 12 CGE proton radiation was 66.0 +/- 8.6%, 44.3 +/- 6.5%, 7.6 +/- 0.3% and 1.14 +/- 0.06% on exposure to 2, 4, 8 and 12 CGE proton radiation, respectively, p < 0.01). Survival ratio of RGC was 71.1 +/- 22.4% (p = 0.05), 40.2 +/- 7.9%, 8.89 +/- 2.6% and 0.78 +/- 0.31% at 2, 4, 8 and 12 CGE dosages (p < 0.001).
   Discussion: CEC showed dose-dependent decrease in survival rate with values attaining significance at all radiation dosages. In contrast, RGC was comparatively radio resistant and were able to replicate at lower doses and sensitive at higher doses after proton beam radiation.
   Conclusion: Since CECs proliferate during neovascularization, this clonogenic assay is a useful assay to assess the sensitivity of CEC to radiation. This study identified that CEC were more sensitive to proton beam radiation than RGC at all doses. This may provide a therapeutic window for administration of proton beam radiation in the management of AMD.
C1 [Balaiya, Sankarathi; Murthy, Ravi K.; Chalam, Kakarla V.] Univ Florida, Dept Ophthalmol, Jacksonville, FL 32209 USA.
   [Malyapa, Robert; Hsi, Wen] Univ Florida, Proton Therapy Inst, Jacksonville, FL 32209 USA.
C3 State University System of Florida; University of Florida; State
   University System of Florida; University of Florida
RP Chalam, KV (通讯作者)，Univ Florida, Dept Ophthalmol, Jacksonville, FL 32209 USA.
EM kakarla.chalam@ufl.edu
RI ma, qi/G-3268-2011; Chalam, kakarla/K-7507-2019
OI Chalam, kakarla/0000-0001-9325-8665; Chalam, K V/0000-0002-0004-9416
CR [Anonymous], 1999, ARCH OPHTHALMOL, V17, P1329
   Bakirtzis G, 2000, RADIAT PROT DOSIM, V91, P77, DOI 10.1093/oxfordjournals.rpd.a033238
   Chalam KV, 2011, RETINA-J RET VIT DIS, V31, P169, DOI 10.1097/IAE.0b013e3181dee621
   Ciulla TA, 2002, AM J OPHTHALMOL, V134, P905, DOI 10.1016/S0002-9394(02)01821-4
   Coleman HR, 2008, LANCET, V372, P1835, DOI 10.1016/S0140-6736(08)61759-6
   DEGOWIN RL, 1974, J LAB CLIN MED, V84, P42
   Eter N, 2000, BRIT J OPHTHALMOL, V84, P757, DOI 10.1136/bjo.84.7.757
   Finger PT, 1998, ARCH OPHTHALMOL-CHIC, V116, P1507, DOI 10.1001/archopht.116.11.1507
   Franken NAP, 2006, NAT PROTOC, V1, P2315, DOI 10.1038/nprot.2006.339
   Fridrichsen E, 1995, INVEST OPHTHALMOL  S, V36, P224
   Green W R, 1999, Mol Vis, V5, P27
   Hall EJ, 1994, RADIOBIOLOGY RADIOBI, P30
   Hart PM, 2002, ARCH OPHTHALMOL-CHIC, V120, P1029
   Isola V, 2006, AM J OPHTHALMOL, V142, P680, DOI 10.1016/j.ajo.2006.04.028
   Laser photocoagulation of subfoveal neovascular lesions of age-related macular degeneration, 1993, ARCH OPHTHALMOL, V111, P1200
   RUBIN DB, 1984, RADIAT RES, V99, P420, DOI 10.2307/3576384
   Wood JPM, 2008, MOL VIS, V14, P334
NR 17
TC 4
Z9 4
U1 0
U2 1
PU INFORMA HEALTHCARE
PI LONDON
PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND
SN 1556-9527
J9 CUTAN OCUL TOXICOL
JI Cutan. Ocul. Toxicol.
PD MAR
PY 2012
VL 31
IS 1
BP 14
EP 19
DI 10.3109/15569527.2011.594697
PG 6
WC Ophthalmology; Toxicology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology; Toxicology
GA 888QU
UT WOS:000300019500003
PM 21861774
DA 2022-11-30
ER

PT J
AU Nickla, DL
   Wallman, J
AF Nickla, Debora L.
   Wallman, Josh
TI The multifunctional choroid
SO PROGRESS IN RETINAL AND EYE RESEARCH
LA English
DT Article
DE Myopia; Defocus; Emmetropization; Nitric oxide; Growth factors;
   Intrinsic choroidal neurons
ID NITRIC-OXIDE SYNTHASE; FORM-DEPRIVATION MYOPIA; SMOOTH-MUSCLE-CELLS;
   VASOACTIVE INTESTINAL POLYPEPTIDE; IMMUNOREACTIVE NERVE-FIBERS;
   RETINAL-PIGMENT EPITHELIUM; INDUCED REFRACTIVE ERRORS; GENE-RELATED
   PEPTIDE; BLOOD-FLOW; EYE GROWTH
AB The choroid of the eye is primarily a vascular structure supplying the outer retina. It has several unusual features: It contains large membrane-lined lacunae, which, at least in birds, function as part of the lymphatic drainage of the eye and which can change their volume dramatically, thereby changing the thickness of the choroid as much as four-fold over a few days (much less in primates). It contains non-vascular smooth muscle cells, especially behind the fovea, the contraction of which may thin the choroid, thereby opposing the thickening caused by expansion of the lacunae. It has intrinsic choroidal neurons, also mostly behind the central retina, which may control these muscles and may modulate choroidal blood flow as well. These neurons receive sympathetic, parasympathetic and nitrergic innervation.
   The choroid has several functions: Its vasculature is the major supply for the outer retina: impairment of the flow of oxygen from choroid to retina may cause Age-Related Macular Degeneration. The choroidal blood flow, which is as great as in any other organ, may also cool and warm the retina. In addition to its vascular functions, the choroid contains secretory cells, probably involved in modulation of vascularization and in growth of the sclera. Finally, the dramatic changes in choroidal thickness move the retina forward and back, bringing the photoreceptors into the plane of focus, a function demonstrated by the thinning of the choroid that occurs when the focal plane is moved back by the wearing of negative lenses, and, conversely, by the thickening that occurs when positive lenses are worn.
   In addition to focusing the eye, more slowly than accommodation and more quickly than emmetropization, we argue that the choroidal thickness changes also are correlated with changes in the growth of the sclera, and hence of the eye. Because transient increases in choroidal thickness are followed by a prolonged decrease in synthesis of extracellular matrix molecules and a slowing of ocular elongation, and attempts to decouple the choroidal and scleral changes have largely failed, it seems that the thickening of the choroid may be mechanistically linked to the scleral synthesis of macromolecules, and thus may play an important role in the homeostatic control of eye growth, and, consequently, in the etiology of myopia and hyperopia. (C) 2009 Elsevier Ltd. All rights reserved.
C1 [Nickla, Debora L.] New England Coll Optometry, Dept Biosci, Boston, MA 02115 USA.
   [Wallman, Josh] CUNY City Coll, Dept Biol, New York, NY 10031 USA.
C3 City University of New York (CUNY) System; City College of New York
   (CUNY)
RP Nickla, DL (通讯作者)，New England Coll Optometry, Dept Biosci, 424 Beacon St, Boston, MA 02115 USA.
EM nicklad@neco.edu
FU NIH [EY-013636, EY-02727, RR03060]; NATIONAL EYE INSTITUTE [R01EY013636,
   R01EY002727, R37EY002727] Funding Source: NIH RePORTER
FX Supported by: NIH-EY-013636 (DLN) and EY-02727 and RR03060 (JW).
CR Abelsdorff G., 1909, Archiv fuer Augenheilkunde Wiesbaden, V64
   ALM A, 1973, EXP EYE RES, V15, P15, DOI 10.1016/0014-4835(73)90185-1
   Alm A., 1992, ADLERS PHYSL EYE, P198
   Alm A, 2009, EXP EYE RES, V88, P760, DOI 10.1016/j.exer.2008.12.012
   ALM P, 1995, HISTOCHEM J, V27, P819
   Bar H, 2002, BASIC RES CARDIOL, V97, P9, DOI 10.1007/s395-002-8382-z
   Baumel, 1975, SISSON GROSSMANS ANA, P2019
   Bedrossian R H, 1971, Ann Ophthalmol, V3, P891
   Bergua A, 1996, ANAT EMBRYOL, V193, P239
   Bergua A., 2003, INVEST OPHTHALMOL VI, V44
   BERGUA A, 1998, EXP EYE RES, V67, P78
   BILL A, 1983, INT OPHTHALMOL, V6, P101, DOI 10.1007/BF00127638
   BILL A, 1980, T OPHTHAL SOC UK, V100, P332
   BILL A, 1991, EXP EYE RES, V53, P3, DOI 10.1016/0014-4835(91)90138-5
   BILL A, 1985, INVEST OPHTH VIS SCI, V26, P410
   BILL A, 1975, PHYSIOL REV, V55, P383, DOI 10.1152/physrev.1975.55.3.383
   BILL A, 1962, ARCH OPHTHALMOL-CHIC, V67, P336
   BILL A, 1976, EXP EYE RES, V23, P615, DOI 10.1016/0014-4835(76)90220-7
   Blaner William S., 1994, P229
   Brown JS, 2009, INVEST OPHTH VIS SCI, V50, P5, DOI 10.1167/iovs.08-1779
   Chiquet M, 2009, BBA-MOL CELL RES, V1793, P911, DOI 10.1016/j.bbamcr.2009.01.012
   CHRISTENSEN AM, 1991, INVEST OPHTH VIS SCI, V32, P2143
   Cottriall CL, 2000, INVEST OPHTH VIS SCI, V41, pS133
   Cottriall CL, 1996, INVEST OPHTH VIS SCI, V37, P1368
   Cuthbertson S, 1997, J COMP NEUROL, V386, P422
   Cuthbertson S, 1996, VISION RES, V36, P775, DOI 10.1016/0042-6989(95)00179-4
   DAWSON TM, 1994, J NEUROSCI, V14, P5147
   DE STEFANO ME, 1993, J NEUROCYTOL, V22, P868, DOI 10.1007/BF01186358
   de Stefano ME, 1997, INVEST OPHTH VIS SCI, V38, P1241
   Delaey C, 2000, OPHTHALMIC RES, V32, P249, DOI 10.1159/000055622
   DHILLON B, 2008, INVEST OPHTHALMOL VI
   EPSTEIN ML, 1988, NEUROSCIENCE, V25, P1053, DOI 10.1016/0306-4522(88)90058-9
   FINE BS, 1979, OCULAR HISTOLOGY, P195
   Fischer AJ, 1999, J COMP NEUROL, V405, P1, DOI 10.1002/(SICI)1096-9861(19990301)405:1<1::AID-CNE1>3.0.CO;2-U
   Fischer AJ, 1999, NAT NEUROSCI, V2, P706, DOI 10.1038/11167
   Fischer AJ, 1999, J NEUROCYTOL, V28, P597, DOI 10.1023/A:1007071406746
   Fischer AJ, 1998, BRAIN RES, V794, P48, DOI 10.1016/S0006-8993(98)00188-7
   Fitzgerald MEC, 1996, VISUAL NEUROSCI, V13, P655, DOI 10.1017/S0952523800008555
   FITZGERALD MEC, 1990, INVEST OPHTH VIS SCI, V31, P2483
   FLUGEL C, 1994, INVEST OPHTH VIS SCI, V35, P592
   FlugelKoch C, 1996, OPHTHALMOLOGICA, V210, P296
   Forrester JVDA., 2002, EYE BASIC SCI PRACTI, V2
   Geiser MH, 2000, CURR EYE RES, V21, P669, DOI 10.1076/0271-3683(200008)21:2;1-V;FT669
   GHEREZGHIHER T, 1990, EXP EYE RES, V50, P457, DOI 10.1016/0014-4835(90)90032-P
   GIENC J, 1985, Zoologica Poloniae, V32, P229
   Goldstein IM, 1996, VISION RES, V36, P2979, DOI 10.1016/0042-6989(96)00017-X
   GOMEZ DG, 1988, GRAEF ARCH CLIN EXP, V226, P1, DOI 10.1007/BF02172707
   GOTTLIEB MD, 1990, CURR EYE RES, V9, P1157, DOI 10.3109/02713689009003472
   GRAY DB, 1989, J NEUROSCI, V9, P1683
   GUGLIELMONE R, 1982, CELL TISSUE RES, V222, P417
   GUO SS, 1995, CURR EYE RES, V14, P385, DOI 10.3109/02713689508999936
   Haddad A, 2001, EXP EYE RES, V73, P345, DOI 10.1006/exer.2001.1042
   Hirata A, 1998, GRAEF ARCH CLIN EXP, V236, P132, DOI 10.1007/s004170050053
   Hirose A, 2007, CURR EYE RES, V32, P585, DOI 10.1080/02713680701391529
   Hogan MJ, 1971, HISTOLOGY HUMAN EYE
   HOLZER P, 1988, NEUROSCIENCE, V24, P739, DOI 10.1016/0306-4522(88)90064-4
   Howlett MHC, 2009, VISION RES, V49, P219, DOI 10.1016/j.visres.2008.10.008
   Hu WZ, 2009, EXP EYE RES, V88, P79, DOI 10.1016/j.exer.2008.10.014
   Hung LF, 2000, INVEST OPHTH VIS SCI, V41, P1259
   IRVING EL, 1992, OPHTHAL PHYSL OPT, V12, P448, DOI 10.1016/0275-5408(92)90175-V
   IUVONE PM, 1991, INVEST OPHTH VIS SCI, V32, P1674
   Janssen A, 2008, INVEST OPHTH VIS SCI, V49, P2812, DOI 10.1167/iovs.07-1444
   Jobling AI, 2009, EXP EYE RES, V88, P458, DOI 10.1016/j.exer.2008.10.022
   Junghans B. M., 1998, IOVS, V39, pS504
   Junghans BM, 1999, OPTOMETRY VISION SCI, V76, P796, DOI 10.1097/00006324-199911000-00028
   Kajikawa J., 1923, A VONGRAEFES ARCH OP, V112, P260, DOI DOI 10.1007/BF01861096
   Kee CS, 2007, INVEST OPHTH VIS SCI, V48, P957, DOI 10.1167/iovs.06-0743
   Kee CS, 2001, INVEST OPHTH VIS SCI, V42, P575
   Kennedy R H, 1995, Trans Am Ophthalmol Soc, V93, P755
   Kennedy R H, 2000, Binocul Vis Strabismus Q, V15, P281
   KIEL JW, 1992, INVEST OPHTH VIS SCI, V33, P2399
   KIRBY ML, 1978, ANAT REC, V191, P311, DOI 10.1002/ar.1091910304
   KREBS W, 1988, ARCH OPHTHALMOL-CHIC, V106, P1615, DOI 10.1001/archopht.1988.01060140783055
   Krebs W., 1991, PRIMATE RETINA CHORO
   Kusakari T, 2001, EXP EYE RES, V73, P533, DOI 10.1006/exer.2001.1064
   LEECH EM, 1995, OPHTHAL PHYSL OPT, V15, P351, DOI 10.1046/j.1475-1313.1995.9500074n.x
   LI XX, 1992, VISUAL NEUROSCI, V9, P483, DOI 10.1017/S0952523800011287
   Liang H, 2004, INVEST OPHTH VIS SCI, V45, P2463, DOI 10.1167/iovs.03-1009
   Lin MW, 1996, PSYCHIAT GENET, V6, pU3
   Lind GJ, 1998, INVEST OPHTH VIS SCI, V39, P2217
   LINSENMEIER RA, 1992, J GEN PHYSIOL, V99, P177, DOI 10.1085/jgp.99.2.177
   LINSENMEIER RA, 1981, EXP EYE RES, V32, P369, DOI 10.1016/S0014-4835(81)80016-4
   LIU O, 2007, MOL VIS, V13, P1234
   Lovasik JV, 2003, INVEST OPHTH VIS SCI, V44, P2126, DOI 10.1167/iovs.02-0825
   Luft WA, 2003, INVEST OPHTH VIS SCI, V44, P1330, DOI 10.1167/iovs.02-0796
   LUTTY GA, 1993, INVEST OPHTH VIS SCI, V34, P477
   Mammoto A, 2009, NATURE, V457, P1103, DOI 10.1038/nature07765
   MARMOR MF, 1980, INVEST OPHTH VIS SCI, V19, P893
   Marzani D, 1997, INVEST OPHTH VIS SCI, V38, P1726
   May CA, 2004, INVEST OPHTH VIS SCI, V45, P361, DOI 10.1167/iovs.03-0624
   May CA, 2005, J ANAT, V207, P381, DOI 10.1111/j.1469-7580.2005.00460.x
   May CA, 2003, CURR EYE RES, V27, P1, DOI 10.1076/ceyr.27.2.1.15459
   May CA, 1997, OPHTHALMOLOGICA, V211, P161
   MCBRIEN N, 2009, INVEST OPHTHALMOL VI
   McBrien NA, 2000, INVEST OPHTH VIS SCI, V41, P3713
   MCBRIEN NA, 1993, J PHYSIOL-LONDON, V469, P427, DOI 10.1113/jphysiol.1993.sp019821
   MCBRIEN NA, 1993, INVEST OPHTH VIS SCI, V34, P205
   McCarthy CS, 2007, EXP EYE RES, V84, P100, DOI 10.1016/j.exer.2006.09.018
   McFadden SA, 2004, VISION RES, V44, P643, DOI 10.1016/j.visres.2003.11.002
   MCKANNA JA, 1981, DOC OPHTHALMOL P SER, V28, P187
   McLeod DS, 2009, INVEST OPHTH VIS SCI, V50, P4982, DOI 10.1167/iovs.09-3639
   Melis MR, 1996, EUR J NEUROSCI, V8, P2056, DOI 10.1111/j.1460-9568.1996.tb00725.x
   MERINEY SD, 1987, J NEUROSCI, V7, P3827
   Mertz JR, 2000, EXP EYE RES, V70, P519, DOI 10.1006/exer.1999.0813
   MILLER AS, 1983, AUST J OPHTHALMOL, V11, P185, DOI 10.1111/j.1442-9071.1983.tb01077.x
   Moring AG, 2007, INVEST OPHTH VIS SCI, V48, P2947, DOI 10.1167/iovs.06-0906
   Mueller H, 1859, VEHR PHYS MED GES WU, V10, P179
   NAKANOME Y, 1995, EXP EYE RES, V60, P37, DOI 10.1016/S0014-4835(05)80081-8
   NAPPER GA, 1995, VISION RES, V35, P1337, DOI 10.1016/0042-6989(94)00226-C
   Nickel R., 1977, ANATOMY DOMESTIC BIR
   NICKLA D, 2003, INVEST OPHTHALMOL VI
   Nickla DL, 2007, EXP EYE RES, V84, P951, DOI 10.1016/j.exer.2007.01.017
   Nickla DL, 2006, EXP EYE RES, V83, P456, DOI 10.1016/j.exer.2006.01.029
   Nickla DL, 2006, J COMP PHYSIOL A, V192, P399, DOI 10.1007/s00359-005-0077-2
   Nickla DL, 2009, EXP EYE RES, V88, P1092, DOI 10.1016/j.exer.2009.01.012
   Nickla DL, 1997, CURR EYE RES, V16, P320, DOI 10.1076/ceyr.16.4.320.10697
   Nickla DL, 2004, OPTOMETRY VISION SCI, V81, P111, DOI 10.1097/00006324-200402000-00009
   Nickla DL, 2002, INVEST OPHTH VIS SCI, V43, P2519
   Nickla DL, 1998, EXP EYE RES, V66, P163, DOI 10.1006/exer.1997.0420
   Nickla DL, 1999, J COMP PHYSIOL A, V185, P81, DOI 10.1007/s003590050368
   Nickla DL, 2001, INVEST OPHTH VIS SCI, V42, P584
   Nickla DL, 2009, INVEST OPHTHALMOL VI
   Nilsson SFE, 1996, INVEST OPHTH VIS SCI, V37, P2110
   NISHI R, 1994, J NEUROBIOL, V25, P612, DOI 10.1002/neu.480250604
   NORTON T, 1995, VISION RES, P1271
   Norton Thomas T., 1999, ILAR J, V40, P59
   Papastergiou GI, 1998, EXP EYE RES, V66, P195, DOI 10.1006/exer.1997.0421
   Park TW, 2003, VISION RES, V43, P1519, DOI 10.1016/S0042-6989(03)00180-9
   PARVER L M, 1991, Eye (London), V5, P181
   PARVER LM, 1982, RETINA-J RET VIT DIS, V2, P117, DOI 10.1097/00006982-198200220-00008
   PARVER LM, 1982, ARCH OPHTHALMOL-CHIC, V100, P1327, DOI 10.1001/archopht.1982.01030040305021
   PARVER LM, 1983, ARCH OPHTHALMOL-CHIC, V101, P1604, DOI 10.1001/archopht.1983.01040020606021
   PARVER LM, 1980, AM J OPHTHALMOL, V89, P641, DOI 10.1016/0002-9394(80)90280-9
   Pendrak K, 2000, EXP EYE RES, V70, P629, DOI 10.1006/exer.2000.0825
   Pendrak K, 1997, CURR EYE RES, V16, P152, DOI 10.1076/ceyr.16.2.152.5090
   Pendrak K., 1998, IOVS, V39, pS504
   PETTIGREW JD, 1990, NATURE, V343, P362, DOI 10.1038/343362a0
   Polska E, 2007, INVEST OPHTH VIS SCI, V48, P3768, DOI 10.1167/iovs.07-0307
   Poukens V, 1998, INVEST OPHTH VIS SCI, V39, P1765
   Rada JA, 2000, INVEST OPHTH VIS SCI, V41, P2050
   RADA JA, 1992, CURR EYE RES, V11, P767, DOI 10.3109/02713689209000750
   RADA JA, 1991, DEV BIOL, V147, P303, DOI 10.1016/0012-1606(91)90288-E
   RADA JA, 1994, INVEST OPHTH VIS SCI, V35, P2436
   Rada JA, 2001, CURR EYE RES, V22, P121, DOI 10.1076/ceyr.22.2.121.5525
   Rada JAS, 2007, INVEST OPHTH VIS SCI, V48, P2957, DOI 10.1167/iovs.06-1051
   Rada JAS, 2009, MOL VIS, V15, P778
   RADA JS, 2009, INVEST OPHTHALMOL VI
   RAMRATTAN RS, 1994, INVEST OPHTH VIS SCI, V35, P2857
   RAVIOLA E, 1985, NEW ENGL J MED, V312, P1609, DOI 10.1056/NEJM198506203122505
   REINER A, 1991, VISUAL NEUROSCI, V6, P451, DOI 10.1017/S0952523800001310
   Reiner A, 2003, EXP EYE RES, V76, P273, DOI 10.1016/S0014-4835(02)00316-0
   REINER A, 1983, TRENDS NEUROSCI, V6, P140, DOI 10.1016/0166-2236(83)90068-1
   REINER A, 1987, INVEST OPHTH VIS SCI, V28, pS81
   Remington L.A., 2021, CLIN ANATOMY PHYSL V
   Riva CE, 1997, INVEST OPHTH VIS SCI, V38, P2338
   Riva CE, 1997, INVEST OPHTH VIS SCI, V38, P1752
   ROHRER B, 1994, EXP EYE RES, V58, P553, DOI 10.1006/exer.1994.1049
   ROHRER B, 1993, VISUAL NEUROSCI, V10, P447, DOI 10.1017/S0952523800004673
   Rucker FJ, 2008, VISION RES, V48, P1980, DOI 10.1016/j.visres.2008.06.003
   RUSKELL GL, 1971, EXP EYE RES, V12, P166, DOI 10.1016/0014-4835(71)90085-6
   Rymer J, 2005, VISUAL NEUROSCI, V22, P251, DOI 10.1017/S0952523805223015
   SCHAEFFEL F, 1990, VISUAL NEUROSCI, V4, P177, DOI 10.1017/S0952523800002327
   SCHAEFFEL F, 1994, VISION RES, V34, P143, DOI 10.1016/0042-6989(94)90327-1
   SCHAEFFEL F, 1995, VISION RES, V35, P1247, DOI 10.1016/0042-6989(94)00221-7
   Schmid KL, 2004, OPTOMETRY VISION SCI, V81, P137, DOI 10.1097/00006324-200402000-00012
   Schmid KL, 1996, VISION RES, V36, P1023, DOI 10.1016/0042-6989(95)00191-3
   Schrodl F, 2003, INVEST OPHTH VIS SCI, V44, P3705, DOI 10.1167/iovs.03-0232
   Schrodl F, 2001, CELL TISSUE RES, V304, P175, DOI 10.1007/s004410100362
   Schrodl F, 2001, EXP EYE RES, V72, P137, DOI 10.1006/exer.2000.0940
   Schrodl F, 2000, J COMP NEUROL, V425, P24
   SCHRODL F, 1998, EXP EYE RES S, V67, P78
   Schrodl F., 2009, NEUROPEPTIDES EYE, P169
   Schroedl F, 2004, EXP EYE RES, V78, P187, DOI 10.1016/j.exer.2003.11.007
   Schroedl F, 2008, INVEST OPHTH VIS SCI, V49, P5222, DOI 10.1167/iovs.08-1721
   Schrodl F, 2006, INVEST OPHTH VIS SCI, V47, P3225, DOI 10.1167/iovs.05-1279
   Schwahn HN, 2000, VISUAL NEUROSCI, V17, P165, DOI 10.1017/S0952523800171184
   SEKO Y, 1995, INVEST OPHTH VIS SCI, V36, P1183
   Shaikh AW, 1999, OPTOMETRY VISION SCI, V76, P308, DOI 10.1097/00006324-199905000-00019
   SHERMAN SM, 1977, BRAIN RES, V124, P154, DOI 10.1016/0006-8993(77)90872-1
   Shih YF, 1999, EXP EYE RES, V69, P9, DOI 10.1006/exer.1999.0692
   Shih YF, 1999, J OCUL PHARMACOL TH, V15, P85, DOI 10.1089/jop.1999.15.85
   Simon P, 2004, MOL VIS, V10, P588
   SMALLEY DM, 1994, INVEST OPHTH VIS SCI, V35, P48
   SNYDER SH, 1992, SCI AM, V266, P68, DOI 10.1038/scientificamerican0592-68
   SPERDUTO RD, 1983, ARCH OPHTHALMOL-CHIC, V101, P405, DOI 10.1001/archopht.1983.01040010405011
   Spraul CW, 1999, SURV OPHTHALMOL, V44, pS10, DOI 10.1016/S0039-6257(99)00086-7
   STEWART AG, 1994, MICROSURG, V15, P693, DOI 10.1002/micr.1920151006
   STJERNSCHANTZ J, 1976, INVEST OPHTHALMOL, V18, P99
   Stone RA, 2004, INVEST OPHTH VIS SCI, V45, P63, DOI 10.1167/iovs.03-0294
   STONE RA, 1989, P NATL ACAD SCI USA, V86, P704, DOI 10.1073/pnas.86.2.704
   STONE RA, 1991, EXP EYE RES, V52, P755, DOI 10.1016/0014-4835(91)90027-C
   STONE RA, 1987, EXPERIENTIA, V43, P791, DOI 10.1007/BF01945357
   STONE RA, 1988, INVEST OPHTH VIS SCI, V29, P305
   STONE RA, 1985, ARCH OPHTHALMOL-CHIC, V103, P1207
   STONE RA, 1986, INVEST OPHTH VIS SCI, V27, P951
   SUGITA A, 1992, JPN J OPHTHALMOL, V36, P436
   SUN JS, 1994, VISUAL NEUROSCI, V11, P13, DOI 10.1017/S0952523800011068
   Tian YB, 2006, INVEST OPHTH VIS SCI, V47, P4168, DOI 10.1167/iovs.05-1211
   Tigges M, 1999, OPTOMETRY VISION SCI, V76, P397, DOI 10.1097/00006324-199906000-00020
   Troilo D, 2000, INVEST OPHTH VIS SCI, V41, P1249
   Troilo D, 2006, INVEST OPHTH VIS SCI, V47, P1768, DOI 10.1167/iovs.05-0298
   UDDMAN R, 1980, INVEST OPHTH VIS SCI, V19, P878
   VANALPHEN GWHM, 1986, VISION RES, V26, P723, DOI 10.1016/0042-6989(86)90086-6
   vanderLoop FTL, 1996, J CELL BIOL, V134, P401, DOI 10.1083/jcb.134.2.401
   Wajer SD, 2000, MICROVASC RES, V60, P281, DOI 10.1006/mvre.2000.2270
   WALCOTT B, 1989, INVEST OPHTH VIS SCI, V30, P1666
   WALLMAN J, 1995, VISION RES, V35, P37, DOI 10.1016/0042-6989(94)E0049-Q
   WALLMAN J, 1993, PROG RETIN RES, V12, P133, DOI 10.1016/0278-4327(93)90007-G
   Wallman J, 2004, NEURON, V43, P447, DOI 10.1016/j.neuron.2004.08.008
   WALLMAN J, 1978, SCIENCE, V201, P1249, DOI 10.1126/science.694514
   Walls G. L., 1942, VERTEBRATE EYE ITS A, DOI 10.1097/00005053-194409000-00057
   WANG YF, 1995, INVEST OPHTH VIS SCI, V36, P1625
   Wangsa-Wirawan ND, 2003, ARCH OPHTHALMOL-CHIC, V121, P547, DOI 10.1001/archopht.121.4.547
   Watson PG, 2004, EXP EYE RES, V78, P609, DOI 10.1016/S0014-4835(03)00212-4
   WENTZEK LAF, 1993, J NEUROSCI, V13, P3143
   WIESEL TN, 1977, NATURE, V266, P66, DOI 10.1038/266066a0
   WILDSOET C, 1995, VISION RES, V35, P1175, DOI 10.1016/0042-6989(94)00233-C
   Winawer J, 2002, VISION RES, V42, P2651, DOI 10.1016/S0042-6989(02)00300-0
   WINGSTRAND KARL GEORG, 1965, BIOL SKR KONGELIGE DANSKE VIDENSKABERNES SELSK, V14, P1
   WOBIG JL, 1981, OPHTHALMIC ANATOMY, P77
   YAMAMOTO R, 1993, BRAIN RES, V631, P83, DOI 10.1016/0006-8993(93)91190-4
   YAMAMOTO R, 1993, NEUROSCIENCE, V54, P189, DOI 10.1016/0306-4522(93)90393-T
   YOUNG FA, 1965, AMER J OPT ARCH AM A, V42, P439
   Yu DY, 2001, PROG RETIN EYE RES, V20, P175, DOI 10.1016/S1350-9462(00)00027-6
   Yucel YH, 2009, EXP EYE RES, V89, P810, DOI 10.1016/j.exer.2009.08.010
   Zarbin MA, 1998, EUR J OPHTHALMOL, V8, P199, DOI 10.1177/112067219800800401
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
   Zhu XY, 2009, INVEST OPHTH VIS SCI, V50, P37, DOI 10.1167/iovs.08-2102
   Zhu XY, 2005, INVEST OPHTH VIS SCI, V46, P2238, DOI 10.1167/iovs.04-0956
NR 229
TC 987
Z9 1022
U1 1
U2 104
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 1350-9462
EI 1873-1635
J9 PROG RETIN EYE RES
JI Prog. Retin. Eye Res.
PD MAR
PY 2010
VL 29
IS 2
BP 144
EP 168
DI 10.1016/j.preteyeres.2009.12.002
PG 25
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 576LN
UT WOS:000276146100004
PM 20044062
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Demirel, S
   Begar, PG
   Yanik, O
   Batioglu, F
   Ozmert, E
AF Demirel, Sibel
   Begar, Pinar Guran
   Yanik, Ozge
   Batioglu, Figen
   Ozmert, Emin
TI Visualization of Type-1 Macular Neovascularization Secondary to
   Pachychoroid Spectrum Diseases: A Comparative Study for Sensitivity and
   Specificity of Indocyanine Green Angiography and Optical Coherence
   Tomography Angiography
SO DIAGNOSTICS
LA English
DT Article
DE flat irregular pigment epithelial detachment; indocyanine green
   angiography; optical coherence tomography angiography; pachychoroid
   neovasculopathy
ID CENTRAL SEROUS CHORIORETINOPATHY; PIGMENT EPITHELIAL DETACHMENTS;
   CHOROIDAL NEOVASCULARIZATION
AB Background: The aim of this study was to compare optical coherence tomography angiography (OCTA) and indocyanine green angiography (ICGA) in detecting type-1 macular neovascularization (MNV) in pachychoroid spectrum diseases. Methods: Patients with pachychoroid characteristics who had undergone ICGA and OCTA imaging at the same visit, were recruited. The diagnosis of MNV was made by a senior retina specialist using multimodal imaging techniques. Afterward, both ICGA and OCTA images were separately reviewed by a masked-independent senior retina specialist with regard to the presence of MNV. The specificity, sensitivity, positive, and negative predictive values of ICGA and OCTA were analyzed. Results: OCTA was able to detect MNV with 97.2% sensitivity, failing to detect MNV only in one eye. The sensitivity of ICGA to detect MNV was 66.76%. The negative predictive value of OCTA was 94.7%; however, this value was 60% for ICGA. Multimodal imaging and OCTA were in almost perfect agreement (kappa coefficient = 0.95). Conclusion: OCTA shows greater sensitivity when detecting type-1 MNV than ICGA in pachychoroid neovasculopathy cases. OCTA is a non-invasive and quick imaging modality that can be preferred to dye angiography in the visualization of type-1 MNV in pachychoroid neovasculopathy.
C1 [Demirel, Sibel; Begar, Pinar Guran; Yanik, Ozge; Batioglu, Figen; Ozmert, Emin] Ankara Univ, Dept Ophthalmol, Sch Med, TR-06620 Ankara, Turkey.
C3 Ankara University
RP Demirel, S (通讯作者)，Ankara Univ, Dept Ophthalmol, Sch Med, TR-06620 Ankara, Turkey.
EM drsibeldemireltr@yahoo.com.tr; pinar_guran_aaal@windowslive.com;
   oyanik05@hotmail.com; fbatioglu@gmail.com; eozmert56@gmail.com
RI DEMIREL, SIBEL/GQH-3232-2022; Yanık Odabaş, Özge/AAO-6777-2020
OI DEMIREL, SIBEL/0000-0002-2477-9974; Yanık Odabaş,
   Özge/0000-0002-1822-8703; Demirel, Sibel/0000-0002-6430-6565
CR Bonini MA, 2015, JAMA OPHTHALMOL, V133, P899, DOI 10.1001/jamaophthalmol.2015.1320
   Bousquet E, 2018, RETINA-J RET VIT DIS, V38, P629, DOI 10.1097/IAE.0000000000001580
   Carnevali A, 2017, OPHTHALMOL RETINA, V1, P328, DOI 10.1016/j.oret.2017.01.003
   Dansingani KK, 2015, AM J OPHTHALMOL, V160, P1243, DOI 10.1016/j.ajo.2015.08.028
   de Carlo TE, 2016, OSLI RETINA, V47, P128, DOI 10.3928/23258160-20160126-05
   Demirel S, 2017, GRAEF ARCH CLIN EXP, V255, P2317, DOI 10.1007/s00417-017-3793-8
   Fung AT, 2012, RETINA-J RET VIT DIS, V32, P1829, DOI 10.1097/IAE.0b013e3182680a66
   Gallego-Pinazo Roberto, 2014, Med Hypothesis Discov Innov Ophthalmol, V3, P111
   Hage R, 2015, AM J OPHTHALMOL, V159, P890, DOI 10.1016/j.ajo.2015.02.002
   Hwang H, 2020, RETINA-J RET VIT DIS, V40, P1724, DOI 10.1097/IAE.0000000000002662
   Loo RH, 2002, RETINA-J RET VIT DIS, V22, P19, DOI 10.1097/00006982-200202000-00004
   Matsumoto H, 2020, OPHTHALMOL RETINA, V4, P938, DOI 10.1016/j.oret.2020.03.024
   Miyake M, 2015, SCI REP-UK, V5, DOI 10.1038/srep16204
   Mudvari SS, 2007, RETINA-J RET VIT DIS, V27, P1168, DOI 10.1097/IAE.0b013e318156db8a
   Negida A, 2019, ADV J EMERG MED, V3, DOI 10.22114/ajem.v0i0.158
   Pang CE, 2015, RETINA-J RET VIT DIS, V35, P1, DOI 10.1097/IAE.0000000000000331
   Quaranta-El Maftouhi M, 2015, AM J OPHTHALMOL, V160, P581, DOI 10.1016/j.ajo.2015.06.016
   SCHATZ H, 1992, OPHTHALMOLOGY, V99, P63
   Song IS, 2012, AM J OPHTHALMOL, V154, P366, DOI 10.1016/j.ajo.2012.02.031
   Spaide RF, 1996, OPHTHALMOLOGY, V103, P2070, DOI 10.1016/S0161-6420(96)30386-2
   Terao N, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-28484-w
   Yang LH, 2013, INVEST OPHTH VIS SCI, V54, P4659, DOI 10.1167/iovs.12-10991
NR 22
TC 0
Z9 0
U1 1
U2 1
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2075-4418
J9 DIAGNOSTICS
JI Diagnostics
PD JUN
PY 2022
VL 12
IS 6
AR 1368
DI 10.3390/diagnostics12061368
PG 10
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA 2L9PM
UT WOS:000817345300001
PM 35741178
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Kang, HM
   Lee, NE
   Choi, JH
   Koh, HJ
   Lee, SC
AF Kang, Hae Min
   Lee, Na Eun
   Choi, Jeong Hoon
   Koh, Hyoung Jun
   Lee, Sung Chul
TI Prevalence of focal lamina cribrosa defects in eyes with pachychoroid
   disease spectrum
SO INTERNATIONAL JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE central serous chorioretinopathy; lamina cribrosa; pachychoroid;
   polypoidal choroidal vasculopathy
ID POLYPOIDAL CHOROIDAL VASCULOPATHY; OPTIC-NERVE HEAD; PATHOPHYSIOLOGY
AB AIM: To determine the prevalence of focal lamina cribrosa (LC) defect among patients with pachychoroid disease spectrum (PDS) in the absence of peripapillary retinoschisis.
   METHODS: This retrospective, cross-sectional study comprised of 180 patients with PDS, including polypoidal choroidal vasculopathy (PCV), central serous chorioretinopathy, and pachychoroidal neovasculopathy. Medical records and optic nerve head evaluations conducted using spectral-domain optical coherence tomography with enhanced depth imaging were reviewed. As a control group, 236 patients who underwent ophthalmologic evaluation for vitreous floaters, without obvious ocular disease, were also included.
   RESULTS: The mean age of the PDS group, which included 118 male patients (65. 6%), was 57.4 +/- 11.1y. There was no significant difference between the two groups in age (P=0.710) or sex (P=0.248). Six patients (3.3%) in the PDS group and none in the control group showed focal LC defect (P=0.318). Among the six patients with focal LC defect in the PDS group, four eyes had PCV, one eye was the fellow eye of a PCV eye, and one eye had pachychoroidal neovasculopathy.
   CONCLUSION: Focal LC defect can be defected in patients with PDS in the absence of peripapillary retinoschisis. However, the prevalence of focal LC defect was not different significantly between PDS patients and those who did not have PDS.
C1 [Kang, Hae Min] Harvard Sch Publ Hlth, Boston, MA 02115 USA.
   [Kang, Hae Min] Catholic Kwandong Univ, Incheon 22711, South Korea.
   [Lee, Na Eun] Gongdoek Seoul Eye Clin, Seoul 04214, South Korea.
   [Choi, Jeong Hoon] Choikang Seoul Eye Clin, Seoul 01110, South Korea.
   [Koh, Hyoung Jun] Yonsei Univ, Coll Med, Dept Ophthalmol, Inst Vis Res, Seoul 03722, South Korea.
   [Lee, Sung Chul] Konyang Univ Hosp, Daejeon 35365, South Korea.
C3 Harvard University; Harvard T.H. Chan School of Public Health; Catholic
   Kwandong University; Yonsei University; Yonsei University Health System;
   Konyang University; Konyang University Hospital
RP Kang, HM (通讯作者)，Catholic Kwandong Univ, Int St Marys Hosp, Dept Ophthalmol, 100 Simgok Ro, Incheon 22711, South Korea.
EM liebe05@naver.com
FU National Research Foundation of Korea (NRF) - Korean government (MSIT)
   [2018R1C1B5085620]; Korea Health Industry Development Institute (KHIDI)
   - Ministry of Health & Welfare, Republic of Korea [HI21C1251]
FX Supported by a National Research Foundation of Korea (NRF) grant funded
   by the Korean government (MSIT) (No.2018R1C1B5085620) ; the Korea Health
   Technology R & D Project through the Korea Health Industry Development
   Institute (KHIDI) funded by the Ministry of Health & Welfare, Republic
   of Korea (No.HI21C1251) .
CR Burgoyne CF, 2005, PROG RETIN EYE RES, V24, P39, DOI 10.1016/j.preteyeres.2004.06.001
   Ciardella AP, 2004, SURV OPHTHALMOL, V49, P25, DOI 10.1016/j.survophthal.2003.10.007
   Costa RA, 2005, PROG RETIN EYE RES, V24, P560, DOI 10.1016/j.preteyeres.2005.01.001
   Dansingani KK, 2016, RETINA-J RET VIT DIS, V36, P499, DOI 10.1097/IAE.0000000000000742
   Daruich A, 2015, PROG RETIN EYE RES, V48, P82, DOI 10.1016/j.preteyeres.2015.05.003
   GASS JDM, 1967, AM J OPHTHALMOL, V63, P573
   GUYER DR, 1994, ARCH OPHTHALMOL-CHIC, V112, P1057, DOI 10.1001/archopht.1994.01090200063023
   Kang HM, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0230293
   Kang HM, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0208254
   Kang HM, 2018, RETINA-J RET VIT DIS, V38, P1905, DOI 10.1097/IAE.0000000000001804
   Kiumehr S, 2012, ARCH OPHTHALMOL-CHIC, V130, P552, DOI 10.1001/archopthalmol.2011.1309
   Lee JH, 2016, OPHTHALMOLOGY, V123, P2066, DOI 10.1016/j.ophtha.2016.06.033
   Lee NE, 2019, INT J OPHTHALMOL-CHI, V12, P472, DOI 10.18240/ijo.2019.03.19
   Nicholson B, 2013, SURV OPHTHALMOL, V58, P103, DOI 10.1016/j.survophthal.2012.07.004
   Pang CE, 2015, RETINA-J RET VIT DIS, V35, P1, DOI 10.1097/IAE.0000000000000331
   Phasukkijwatana N, 2018, RETINA-J RET VIT DIS, V38, P1652, DOI 10.1097/IAE.0000000000001907
   Sigal IA, 2007, EXP EYE RES, V85, P312, DOI 10.1016/j.exer.2007.05.005
   Warrow DJ, 2013, RETINA-J RET VIT DIS, V33, P1659, DOI 10.1097/IAE.0b013e3182953df4
   Wong CW, 2016, PROG RETIN EYE RES, V53, P107, DOI 10.1016/j.preteyeres.2016.04.002
NR 19
TC 0
Z9 0
U1 1
U2 1
PU IJO PRESS
PI XI AN
PA NO 269 YOUYI EAST RD, XI AN, 710054, PEOPLES R CHINA
SN 2222-3959
EI 2227-4898
J9 INT J OPHTHALMOL-CHI
JI Int. J. Ophthalmol.
PD JAN 18
PY 2022
VL 15
IS 1
BP 77
EP 82
DI 10.18240/ijo.2022.01.12
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA YD8SS
UT WOS:000740705900012
PM 35047360
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Bo, QY
   Yan, Q
   Shen, MX
   Song, ML
   Sun, MS
   Yu, Y
   Rosenfeld, PJ
   Wang, FH
   Sun, XD
AF Bo, Qiyu
   Yan, Quan
   Shen, Mengxi
   Song, Minlu
   Sun, Mengsha
   Yu, Yang
   Rosenfeld, Philip J.
   Wang, Fenghua
   Sun, Xiaodong
TI Appearance of Polypoidal Lesions in Patients With Polypoidal Choroidal
   Vasculopathy Using Swept-Source Optical Coherence Tomographic
   Angiography
SO JAMA OPHTHALMOLOGY
LA English
DT Article
ID MACULAR DEGENERATION; RANIBIZUMAB; THERAPY; NEOVASCULARIZATION;
   VERTEPORFIN; BEVACIZUMAB; DIAGNOSIS; EVEREST
AB ImportancePolypoidal choroidal vasculopathy (PCV) is a major cause of visual loss worldwide, particularly in Asia, and the appropriate understanding of the structures in PCV previously described as polypoidal lesions is important for understanding their pathogenesis, diagnosis, and prognosis. ObjectiveTo report the morphologic characteristics of polypoidal lesions and their association with branching vascular networks (BVNs) in eyes with PCV using swept-source optical coherence tomographic angiography (SS-OCTA). Design, Setting, and ParticipantsThis cross-sectional observational study included 20 participants recruited from Shanghai General Hospital with a diagnosis of PCV based on the presence of focal hyperfluorescent spots on indocyanine green angiography (ICGA). Data were collected from December 1, 2017, to September 1, 2018, and analyzed from June 1 through September 30, 2018. Main Outcomes and MeasuresPolypoidal lesions in eyes with PCV were characterized using multimodal imaging that included fundus photography, fluorescein angiography, ICGA, SS-OCT, and SS-OCTA, and the images were anatomically aligned. Subfoveal choroidal thickness was manually measured as the distance between the Bruch membrane and the sclerochoroidal interface on the SS-OCT images. ResultsOf the 20 Asian patients, 5 (25%) were women and 15 (75%) were men. The mean (SD) age was 61.1 (7.6) years, and the mean (SD) logMAR visual acuity was 0.358 (0.294) (Snellen equivalent, 20/50 [20/40]). Twenty-three eyes underwent imaging and were diagnosed with PCV. Indocyanine green angiography identified 43 polypoidal lesions, and all corresponded to the structures that appeared as clusters of tangled vessels on SS-OCTA images. In addition, SS-OCTA detected 16 tangled vascular structures not seen on ICGA. Branching vascular networks were detected on SS-OCTA imaging in all eyes, but ICGA identified BVNs in only 17 of 23 eyes (74%). Of the 43 tangled vascular structures, 40 (93%) were located at the edge of a BVN and 3 (7%) were associated with type 2 neovascularization. Conclusions and RelevanceIn eyes with PCV undergoing SS-OCTA imaging, previously described polypoidal lesions may appear as tangled vascular structures associated with BVN or type 2 neovascularization. The identification of polypoidal lesions in patients with PCV as neovascular tangles rather than actual polypoidal lesions or aneurysmal dilatations may help facilitate understanding of their pathogenesis and response to treatment.
C1 [Bo, Qiyu; Yan, Quan; Shen, Mengxi; Song, Minlu; Sun, Mengsha; Yu, Yang; Wang, Fenghua; Sun, Xiaodong] Shanghai Jiao Tong Univ, Sch Med, Shanghai Peoples Hosp 1, Dept Ophthalmol,Shanghai Gen Hosp, 100 Haining Rd, Shanghai 200080, Peoples R China.
   [Bo, Qiyu; Yan, Quan; Shen, Mengxi; Song, Minlu; Sun, Mengsha; Wang, Fenghua; Sun, Xiaodong] Shanghai Key Lab Fundus Dis, Shanghai, Peoples R China.
   [Rosenfeld, Philip J.] Univ Miami, Miller Sch Med, Dept Ophthalmol, Bascom Palmer Eye Inst, Miami, FL 33136 USA.
   [Wang, Fenghua; Sun, Xiaodong] Shanghai Engn Ctr Visual Sci & Photomed, Shanghai, Peoples R China.
C3 Shanghai Jiao Tong University; Bascom Palmer Eye Institute; University
   of Miami
RP Wang, FH (通讯作者)，Shanghai Jiao Tong Univ, Sch Med, Shanghai Peoples Hosp 1, Dept Ophthalmol,Shanghai Gen Hosp, 100 Haining Rd, Shanghai 200080, Peoples R China.
EM shretina@sjtu.edu.cn
RI Sun, Mengsha/HCH-7851-2022; Shen, Mengxi/ABC-6941-2021
OI Shen, Mengxi/0000-0002-1336-1695
FU National Natural Science Foundation of China [81730026, 81470640];
   Frontier Project of Shanghai Hospital Development Center [SHDC12016105];
   National Major Scientific and Technological Special Project for
   "Significant New Drugs Development" during the Thirteenth Five-year Plan
   Period [2018ZX09301029001]; Science and Technology Commission of
   Shanghai Municipality [17411953000, 16411952900, 16dz2251500]
FX This study was supported by grants 81730026 (Dr X. Sun) and 81470640 (Dr
   Wang) from the National Natural Science Foundation of China, grant
   SHDC12016105 from the Frontier Project of Shanghai Hospital Development
   Center (Dr X. Sun), grant 2018ZX09301029001 from the National Major
   Scientific and Technological Special Project for "Significant New Drugs
   Development" during the Thirteenth Five-year Plan Period (Dr X. Sun),
   and grants 17411953000 (Dr X. Sun), 16411952900 (Dr Wang), and
   16dz2251500 (DrWang) from the Science and Technology Commission of
   Shanghai Municipality.
CR Akaza Eriko, 2006, Nippon Ganka Gakkai Zasshi, V110, P288
   Alshahrani ST, 2014, CLIN OPHTHALMOL, V8, P1689, DOI 10.2147/OPTH.S68471
   Balaratnasingam C, 2016, RETINA-J RET VIT DIS, V36, P1, DOI 10.1097/IAE.0000000000000774
   Chan SY, 2018, RETINA-J RET VIT DIS, V38, P1187, DOI 10.1097/IAE.0000000000001702
   Chen YT, 2018, LASER SURG MED, V50, P427, DOI 10.1002/lsm.22801
   Cheung CMG, 2019, RETINA-J RET VIT DIS, V39, P1655, DOI 10.1097/IAE.0000000000002228
   Cheung CMG, 2018, OPHTHALMOLOGY, V125, P708, DOI 10.1016/j.ophtha.2017.11.019
   Cheung CMG, 2017, RETINA-J RET VIT DIS, V37, P1464, DOI 10.1097/IAE.0000000000001391
   Cheung CMG, 2015, RETINA-J RET VIT DIS, V35, P1375, DOI 10.1097/IAE.0000000000000482
   Dansingani KK, 2015, AM J OPHTHALMOL, V160, P1243, DOI 10.1016/j.ajo.2015.08.028
   de Carlo TE, 2019, RETINA-J RET VIT DIS, V39, P1343, DOI 10.1097/IAE.0000000000002139
   Dias JRD, 2018, OPHTHALMOLOGY, V125, P255, DOI 10.1016/j.ophtha.2017.08.030
   Inoue M, 2015, RETINA-J RET VIT DIS, V35, P2265, DOI 10.1097/IAE.0000000000000777
   Koh A, 2012, RETINA-J RET VIT DIS, V32, P1453, DOI 10.1097/IAE.0b013e31824f91e8
   Kokame GT, 2014, OPHTHALMOLOGICA, V231, P94, DOI 10.1159/000354072
   Li ML, 2019, OPHTHALMOL RETINA, V3, P99, DOI 10.1016/j.oret.2018.08.008
   Liang ST, 2018, BRIT J OPHTHALMOL, V102, P1570, DOI 10.1136/bjophthalmol-2017-311518
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Nakashizuka H, 2008, INVEST OPHTH VIS SCI, V49, P4729, DOI 10.1167/iovs.08-2134
   Novais EA, 2016, AM J OPHTHALMOL, V164, P80, DOI 10.1016/j.ajo.2016.01.011
   Oishi A, 2013, AM J OPHTHALMOL, V156, P644, DOI 10.1016/j.ajo.2013.05.024
   Okubo A, 2002, BRIT J OPHTHALMOL, V86, P1093, DOI 10.1136/bjo.86.10.1093
   Peiretti E, 2019, RETINA-J RET VIT DIS, V39, P1693, DOI 10.1097/IAE.0000000000002234
   Rajendram R, 2012, ARCH OPHTHALMOL-CHIC, V130, P972, DOI 10.1001/archophthalmol.2012.393
   Ross RD, 1996, RETINA-J RET VIT DIS, V16, P105, DOI 10.1097/00006982-199616020-00003
   Terasaki H, 2002, BRIT J OPHTHALMOL, V86, P321, DOI 10.1136/bjo.86.3.321
   Ting DSW, 2015, CLIN EXP OPHTHALMOL, V43, P815, DOI 10.1111/ceo.12580
   Wang M, 2016, INVEST OPHTH VIS SCI, V57, pOCT526, DOI 10.1167/iovs.15-18955
   Watanabe G, 2008, JPN J OPHTHALMOL, V52, P175, DOI 10.1007/s10384-007-0521-7
   World Med Assoc, 2013, JAMA-J AM MED ASSOC, V310, P2191, DOI 10.1001/jama.2013.281053
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
   Yuzawa M, 2005, BRIT J OPHTHALMOL, V89, P602, DOI 10.1136/bjo.2004.049296
   Zhang QQ, 2017, OPHTHALMOL RETINA, V1, P124, DOI 10.1016/j.oret.2016.08.005
NR 34
TC 32
Z9 35
U1 1
U2 9
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 2168-6165
EI 2168-6173
J9 JAMA OPHTHALMOL
JI JAMA Ophthalmol.
PD JUN
PY 2019
VL 137
IS 6
BP 642
EP 650
DI 10.1001/jamaophthalmol.2019.0449
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA ID5XL
UT WOS:000471750500010
PM 30998817
OA Green Published, Bronze
DA 2022-11-30
ER

PT J
AU Wilde, C
   Poostchi, A
   Mehta, RL
   Hillman, JG
   MacNab, HK
   Messina, M
   Monaco, G
   Vernon, SA
   Amoaku, WM
AF Wilde, Craig
   Poostchi, Ali
   Mehta, Rajnikant L.
   Hillman, Jonathan G.
   MacNab, Hamish K.
   Messina, Marco
   Monaco, Gaspare
   Vernon, Stephen A.
   Amoaku, Winfried M.
TI Prevalence of peripapillary choroidal neovascular membranes (PPCNV) in
   an elderly UK population-the Bridlington eye assessment project (BEAP):
   a cross-sectional study (2002-2006)
SO EYE
LA English
DT Article
ID SUBRETINAL DRUSENOID DEPOSITS; MACULAR DEGENERATION; RETICULAR
   PSEUDODRUSEN
AB Purpose There is paucity of data on the epidemiology of peripapillary choroidal neovascularisartion (PPCNV). Our aim was to determine prevalence of PPCNV in the elderly UK population of Bridlington residents aged >= 65 years.
   Methods Eyes with PPCNV in the Bridlington eye assessment project (BEAP) database of 3475 participants were analysed. PPCNV outline was drawn, its area measured, and clock-hour involvement of disc circumference recorded. Location and shortest distance from the lesion edge to fovea were recorded. Masked grading for age-related maculopathy (ARM)/reticular pseudodrusen (RPD) within the ETDRS grid was assigned for each eye using a modified Rotterdam scale. Peripapillary retinal pigment epithelial (RPE) changes/drusen were recorded. Visual acuity (VA) and demographic details analysed separately were merged with grading data.
   Results PPCNV were identified in ten subjects, and were bilateral in two (20%), a population prevalence of 0.29%, and 0.06% bilaterality. Gender-specific prevalence were 0.36% and 0.19% for females and males, respectively. Age ranged from 66 to 85 years [mean 76.3 (SD 6.4)]. PPCNV were located nasal to disc in 41.7%, measuring 0.46-7.93 mm(2) [mean 2.81 mm(2) (SD 2.82)]. All PPCNV eyes had peripapillary RPE changes. One subject had no ARM, 1 angioid streaks, and 30% RPD. No direct foveal involvement, or reduced VA attributable to PPCNV was observed.
   Conclusion PPCNV were infrequent in this population, more common in females, and often located nasal to the disc, without foveal extension. Peripapillary degenerative changes were universal, and strong association with ARM was observed in eyes with PPCNV. Typically, PPCNV were asymptomatic with VA preservation.
C1 [Wilde, Craig; Poostchi, Ali; Messina, Marco; Monaco, Gaspare; Amoaku, Winfried M.] Univ Nottingham, EENT Ctr, Queens Med Ctr, Div Clin Neurosci,Ophthalmol & Vis Sci, B Floor, Nottingham, England.
   [Mehta, Rajnikant L.] Univ Nottingham, RDS EM, Sch Med, Nottingham Hlth Sci Partners,QMC, Nottingham NG7 2UH, England.
   [Hillman, Jonathan G.; MacNab, Hamish K.] Med Ctr, Stn Ave, Bridlington YO16 4LZ, England.
   [Vernon, Stephen A.] Univ Hosp, Queens Med Ctr, Nottingham, England.
   [Vernon, Stephen A.] Univ Nottingham, Ophthalmol, Nottingham, England.
C3 University of Nottingham; University of Nottingham; Nottingham
   University Hospital NHS Trust; University of Nottingham; University of
   Nottingham
RP Amoaku, WM (通讯作者)，Univ Nottingham, EENT Ctr, Queens Med Ctr, Div Clin Neurosci,Ophthalmol & Vis Sci, B Floor, Nottingham, England.
EM wma@nottingham.ac.uk
OI Mehta, Rajnikant/0000-0002-5341-5598; Amoaku,
   Winfried/0000-0001-5028-7984
FU Macular Society UK, Andover, Hants, UK; Pfizer; Pharmacia; Yorkshire
   Wolds and Coast Primary Care Trust; Lords Feoffees of Bridlington;
   Bridlington Hospital League of Friends; Hull and East Riding Charitable
   Trust; National Eye Research Centre (Yorkshire); Rotary Club of
   Bridlington; Alexander Pigott Wernher Memorial Trust; Bridlington Lions
   Club; Inner Wheel Club of Bridlington; Soroptimist International of
   Bridlington; Patricia and Donald Shepherd Charitable Trust
FX This research was funded in part by a Research Grant from the Macular
   Society UK, Andover, Hants, UK. The Bridlington Eye Assessment Project
   was funded by an unrestricted grant from Pfizer. We would also like to
   thank the following organisations for financial support of the Project:
   Pharmacia, Yorkshire Wolds and Coast Primary Care Trust, The Lords
   Feoffees of Bridlington, Bridlington Hospital League of Friends, The
   Hull and East Riding Charitable Trust, The National Eye Research Centre
   (Yorkshire), The Rotary Club of Bridlington, The Alexander Pigott
   Wernher Memorial Trust, Bridlington Lions Club, The Inner Wheel Club of
   Bridlington, Soroptimist International of Bridlington, and The Patricia
   and Donald Shepherd Charitable Trust. The authors thank Sheila MacNab
   (Project Manager), and Stephen Brown, Janet Button, Graham Langton, and
   Mark Kunz (Optometrists) for their work with the Project; John Bapty,
   Nigel Connell, Peter Jay, and Gillian Poole for their work as the
   charity trustees of the Bridlington Eye Assessment Project.
CR ARKFELD DF, 1985, RETINA-J RET VIT DIS, V5, P157, DOI 10.1097/00006982-198500530-00005
   BALLATORI N, 1982, SCIENCE, V216, P61, DOI 10.1126/science.7063871
   BERKOW JW, 1984, AM J OPHTHALMOL, V97, P143, DOI 10.1016/S0002-9394(14)76083-0
   Binder S, 2007, BRIT J OPHTHALMOL, V91, P990, DOI 10.1136/bjo.2007.114009
   Browning DJ, 2005, OPHTHALMOLOGY, V112, P1054, DOI 10.1016/j.ophtha.2004.11.062
   CANTRILL HL, 1980, AM J OPHTHALMOL, V89, P192, DOI 10.1016/0002-9394(80)90111-7
   Cohen SY, 2007, BRIT J OPHTHALMOL, V91, P354, DOI 10.1136/bjo.2006.101022
   Garcia CAD, 2008, ARQ BRAS OFTALMOL, V71, P890, DOI 10.1590/S0004-27492008000600026
   GASS JDM, 1973, ARCH OPHTHALMOL-CHIC, V90, P206
   Hogg RE, 2014, OPHTHALMOLOGY, V121, P1748, DOI 10.1016/j.ophtha.2014.03.015
   HOTCHKISS ML, 1981, AM J OPHTHALMOL, V91, P177, DOI 10.1016/0002-9394(81)90170-7
   Huisingh C, 2016, INVEST OPHTH VIS SCI, V57, P739, DOI 10.1167/iovs.15-18316
   JAMPOL LM, 1979, AM J OPHTHALMOL, V88, P683, DOI 10.1016/0002-9394(79)90665-2
   KIES JC, 1988, AM J OPHTHALMOL, V105, P11, DOI 10.1016/0002-9394(88)90114-6
   Kokame GT, 2005, RETINA-J RET VIT DIS, V25, P564, DOI 10.1097/00006982-200507000-00004
   LIM JI, 1993, AM J OPHTHALMOL, V116, P414, DOI 10.1016/S0002-9394(14)71398-4
   LOPEZ PF, 1992, RETINA-J RET VIT DIS, V12, P147, DOI 10.1097/00006982-199212020-00012
   MANSOUR AM, 1988, OPHTHALMOLOGICA, V197, P36, DOI 10.1159/000309915
   Mehta S, 2013, J OPHTHALMIC INFLAMM, V3, DOI 10.1186/1869-5760-3-13
   Oh KT, 2001, RETINA-J RET VIT DIS, V21, P182, DOI 10.1097/00006982-200104000-00017
   RUBEN S, 1994, ACTA OPHTHALMOL, V72, P118
   SARKS SH, 1973, BRIT J OPHTHALMOL, V57, P951, DOI 10.1136/bjo.57.12.951
   Shoughy SS, 2014, SAUDI J OPHTHALMOL, V28, P160, DOI 10.1016/j.sjopt.2014.02.007
   SILVESTRI G, 1993, EYE, V7, P398, DOI 10.1038/eye.1993.78
   Singerman L J, 1981, Retina, V1, P75
   Wilde C, 2015, EYE, V29, P602, DOI 10.1038/eye.2015.44
   Wilde C, 2017, EYE, V31, P1042, DOI 10.1038/eye.2017.30
   Wilde C, 2016, EUR J OPHTHALMOL, V26, P128, DOI 10.5301/ejo.5000661
   WOLF S, 1994, RETINA-J RET VIT DIS, V14, P465, DOI 10.1097/00006982-199414050-00014
   WYHINNY GJ, 1990, ARCH OPHTHALMOL-CHIC, V108, P1384, DOI 10.1001/archopht.1990.01070120030013
   Zarubina AV, 2016, OPHTHALMOLOGY, V123, P1090, DOI 10.1016/j.ophtha.2015.12.034
NR 31
TC 3
Z9 3
U1 0
U2 3
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950-222X
EI 1476-5454
J9 EYE
JI Eye
PD MAR
PY 2019
VL 33
IS 3
BP 451
EP 458
DI 10.1038/s41433-018-0232-y
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA HN9UD
UT WOS:000460544800018
PM 30315265
OA Green Published, Green Accepted, Bronze
DA 2022-11-30
ER

PT J
AU Huang, JD
   Presley, JB
   Chimento, MF
   Curcio, CA
   Johnson, M
AF Huang, Jiahn-Dar
   Presley, J. Brett
   Chimento, Melissa F.
   Curcio, Christine A.
   Johnson, Mark
TI Age-related changes in human macular Bruch's membrane as seen by
   quick-freeze/deep-etch
SO EXPERIMENTAL EYE RESEARCH
LA English
DT Article
DE age-related maculopathy; age-related macular degeneration; Bruch's
   membrane; lipids; lipoproteins; electron microscopy; extracellular
   matrix; ultrastructures
ID BASAL DEPOSITS; UNESTERIFIED CHOLESTEROL; OXIDATIVE MODIFICATIONS;
   HYDRAULIC CONDUCTIVITY; LIPID-ACCUMULATION; APOLIPOPROTEIN-B; AGING
   CHANGES; DRUSEN; DEGENERATION; INTIMA
AB Lipid-containing inclusions have been observed in human Bruch's membrane (BrM) and are postulated to be associated with age-related maculopathy (ARM), a major cause of legal blindness in developed countries. The dehydration associated with specimen preparation for thin-section transmission electron microscopy causes loss of these inclusions. Better preservation of the ultrastructure of the inclusions and tissue is achieved by using a quick-freeze/deep-etch preparation. We use this technique to examine normal human macular BrM in order to characterize the deposition of the lipid-rich inclusions and their age-related accumulation within different layers of the tissue. We find that various inclusions mentioned in other studies can be formed by combinations of three basic structures: lipoprotein-like particles (LLPs), small granules (SGs) and membrane-like structures. These inclusions are associated with collagen and elastic fibrils by fine filaments. In younger eyes, these inclusions are found mostly in the elastic (EL) and outer collageneous layer (OCL) and occupy a small fraction of the interfibrillar spacing. As age increases, LLPs and SGs gradually fill the interfibrillar spacing of the EL and inner collageneous layer (ICL) of the tissue, and later form a new sublayer, the lipid wall, within the boundary region between the basal lamina of retinal pigment epithelium (RPE) and ICL. Because the formation of the lipid wall only occurs after these inclusions fill the ICL, and it seems unlikely that the LLPs can pass through the packed layer, this result suggests a possible RPE origin of the LLPs that make up the lipid wall. (c) 2007 Elsevier Ltd. All rights reserved.
C1 NW Univ, Dept Biomed Engn, Evanston, IL 60208 USA.
   Univ Alabama Birmingham, Sch Med, Dept Ophthalmol, Birmingham, AL USA.
C3 Northwestern University; University of Alabama System; University of
   Alabama Birmingham
RP Johnson, M (通讯作者)，NW Univ, Dept Biomed Engn, 2145 Sheridan Rd, Evanston, IL 60208 USA.
EM m-johnson2@northwestern.edu
RI Johnson, Mark/B-6921-2009
FU NCRR NIH HHS [S10 RR016701-01] Funding Source: Medline; NEI NIH HHS
   [EY06109, R01 EY014662-01, R01 EY014662-02, EY014662, R01 EY014662, R01
   EY014662-04, R01 EY006109, R01 EY014662-03] Funding Source: Medline;
   NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR016701] Funding Source: NIH
   RePORTER; NATIONAL EYE INSTITUTE [R01EY006109, R01EY014662] Funding
   Source: NIH RePORTER
CR ANDERSON DH, 1978, INVEST OPHTH VIS SCI, V17, P117
   BIRD AC, 1986, T OPHTHAL SOC UK, V105, P674
   Bobryshev YV, 1999, ATHEROSCLEROSIS, V142, P121
   BOCAN TMA, 1988, ARTERIOSCLEROSIS, V8, P499, DOI 10.1161/01.ATV.8.5.499
   Chang MY, 2001, J LIPID RES, V42, P824
   CHEN JC, 1992, INVEST OPHTH VIS SCI, V33, P334
   Curcio CA, 2005, EXP EYE RES, V81, P731, DOI 10.1016/j.exer.2005.04.012
   Curcio CA, 2005, EXP EYE RES, V80, P761, DOI 10.1016/j.exer.2004.09.017
   Curcio CA, 1999, ARCH OPHTHALMOL-CHIC, V117, P329, DOI 10.1001/archopht.117.3.329
   Curcio CA, 2001, INVEST OPHTH VIS SCI, V42, P265
   FEENEYBURNS L, 1985, AM J OPHTHALMOL, V100, P686, DOI 10.1016/0002-9394(85)90625-7
   Foster A, 2005, EYE, V19, P1133, DOI 10.1038/sj.eye.6701973
   FRANK JS, 1989, J LIPID RES, V30, P967
   Giusto NM, 1997, NEUROCHEM RES, V22, P445, DOI 10.1023/A:1027359727263
   Gordiyenko N, 2004, INVEST OPHTH VIS SCI, V45, P2822, DOI 10.1167/iovs.04-0074
   GREEN WR, 1993, OPHTHALMOLOGY, V100, P1519
   GREEN WR, 1985, OPHTHALMOLOGY, V92, P615
   GRINDLE CFJ, 1978, T OPHTHAL SOC UK, V98, P172
   GUYTON JR, 1985, ARTERIOSCLEROSIS, V5, P644, DOI 10.1161/01.ATV.5.6.644
   GUYTON JR, 1988, J HISTOCHEM CYTOCHEM, V36, P1319, DOI 10.1177/36.10.2458408
   Hageman GS, 1999, MOL VIS, V5
   Handa JT, 1999, INVEST OPHTH VIS SCI, V40, P775
   HODGE AJ, 1960, P NATL ACAD SCI USA, V46, P186, DOI 10.1073/pnas.46.2.186
   HOGAN MJ, 1967, ARCH OPHTHALMOL-CHIC, V77, P410, DOI 10.1001/archopht.1967.00980020412022
   HOLZ FG, 1994, ARCH OPHTHALMOL-CHIC, V112, P402, DOI 10.1001/archopht.1994.01090150132035
   HUANG JD, 2007, THESIS NW U EVANSTON
   Hussain AA, 2002, J OPT SOC AM A, V19, P166, DOI 10.1364/JOSAA.19.000166
   KARWATOWSKI WSS, 1995, BRIT J OPHTHALMOL, V79, P944, DOI 10.1136/bjo.79.10.944
   KILLINGSWORTH MC, 1987, GRAEF ARCH CLIN EXP, V225, P406, DOI 10.1007/BF02334166
   Knupp C, 2002, J STRUCT BIOL, V139, P181, DOI 10.1016/S1047-8477(02)00534-8
   KORNZWEIG AL, 1977, ANN OPHTHALMOL, V9, P753
   KORTE GE, 1989, INT REV CYTOL, V114, P221
   KRAMSCH DM, 1973, J CLIN INVEST, V52, P236, DOI 10.1172/JCI107180
   Li CM, 2006, INVEST OPHTH VIS SCI, V47, P3119, DOI 10.1167/iovs.05-1446
   Li CM, 2005, INVEST OPHTH VIS SCI, V46, P2576, DOI 10.1167/iovs.05-0034
   Li CM, 2005, J LIPID RES, V46, P628, DOI 10.1194/jlr.M400428-JLR200
   Malek G, 2003, AM J PATHOL, V162, P413, DOI 10.1016/S0002-9440(10)63836-9
   Marshall J., 1998, RETINAL PIGMENT EPIT, P669
   MATSUMOTO B, 1987, PROC R SOC SER B-BIO, V230, P339, DOI 10.1098/rspb.1987.0023
   MEEK KM, 1979, J BIOL CHEM, V254, P710
   MOORE DJ, 1995, INVEST OPHTH VIS SCI, V36, P1290
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   NAKAIZUMI Y, 1964, ARCH OPHTHALMOL-CHIC, V72, P395, DOI 10.1001/archopht.1964.00970020395018
   NEWSOME DA, 1987, CURR EYE RES, V6, P1211, DOI 10.3109/02713688709025231
   Overby D, 2001, J BIOMECH ENG-T ASME, V123, P154, DOI 10.1115/1.1351888
   PAULEIKHOFF D, 1990, AM J OPHTHALMOL, V109, P38, DOI 10.1016/S0002-9394(14)75576-X
   PODET EJ, 1991, ARTERIOSCLER THROMB, V11, P116, DOI 10.1161/01.ATV.11.1.116
   RAMRATTAN RS, 1994, INVEST OPHTH VIS SCI, V35, P2857
   Ruberti JW, 2003, INVEST OPHTH VIS SCI, V44, P1753, DOI 10.1167/iovs.02-0496
   SABESIN SM, 1977, J LIPID RES, V18, P496
   SARKS JP, 1988, EYE, V2, P552, DOI 10.1038/eye.1988.106
   SARKS SH, 1976, BRIT J OPHTHALMOL, V60, P324, DOI 10.1136/bjo.60.5.324
   Sarks SH, 1999, BRIT J OPHTHALMOL, V83, P358, DOI 10.1136/bjo.83.3.358
   Sivaprasad S, 2005, CLIN EXP OPHTHALMOL, V33, P518, DOI 10.1111/j.1442-9071.2005.01074.x
   Skalen K, 2002, NATURE, V417, P750, DOI 10.1038/nature00804
   Starita C, 1997, INVEST OPHTH VIS SCI, V38, P762
   Starita C, 1996, EXP EYE RES, V62, P565, DOI 10.1006/exer.1996.0066
   Stocker R, 2004, PHYSIOL REV, V84, P1381, DOI 10.1152/physrev.00047.2003
   Ugarte M, 2006, BRIT J OPHTHALMOL, V90, P621, DOI 10.1136/bjo.2005.086579
   VANDERSCHAFT TL, 1992, OPHTHALMOLOGY, V99, P278
   VANDERSCHAFT TL, 1991, ARCH OPHTHALMOL-CHIC, V109, P420, DOI 10.1001/archopht.1991.01080030122052
   Vijayagopal P, 2005, ATHEROSCLEROSIS, V178, P75, DOI 10.1016/j.atherosclerosis.2004.08.028
   Wang XS, 2001, J PATHOL, V195, P244, DOI 10.1002/path.935
   WILLIAMS KJ, 1995, ARTERIOSCL THROM VAS, V15, P551, DOI 10.1161/01.ATV.15.5.551
   Yamada Y, 2006, EXP EYE RES, V82, P840, DOI 10.1016/j.exer.2005.10.005
NR 65
TC 69
Z9 72
U1 0
U2 2
PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 0014-4835
EI 1096-0007
J9 EXP EYE RES
JI Exp. Eye Res.
PD AUG
PY 2007
VL 85
IS 2
BP 202
EP 218
DI 10.1016/j.exer.2007.03.011
PG 17
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 201BV
UT WOS:000248807400005
PM 17586493
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Laitinen, A
   Laatikainen, L
   Harkanen, T
   Koskinen, S
   Reunanen, A
   Aromaa, A
AF Laitinen, Arja
   Laatikainen, Leila
   Harkanen, Tommi
   Koskinen, Seppo
   Reunanen, Antti
   Aromaa, Arpo
TI Prevalence of major eye diseases and causes of visual impairment in the
   adult Finnish population: a nationwide population-based survey
SO ACTA OPHTHALMOLOGICA
LA English
DT Article
DE epidemiology; eye diseases; population survey; prevalence; visual
   impairment
ID OPEN-ANGLE GLAUCOMA; BLUE MOUNTAINS EYE; BEAVER-DAM EYE; AGE-RELATED
   MACULOPATHY; COPENHAGEN CITY EYE; MACULAR DEGENERATION;
   DIABETIC-RETINOPATHY; LENS OPACITIES; REYKJAVIK EYE;
   INTRAOCULAR-PRESSURE
AB Purpose:
   To estimate the prevalence of cataract, glaucoma, age-related maculopathy (ARM) and diabetic retinopathy (DR) in the adult Finnish population.
   Methods:
   A representative cross-sectional sample of the Finnish population aged 30 years and older. Of the 7979 eligible people, 7413 (93%) were interviewed and/or examined. The interview included self-reported doctor-made diagnoses of cataract, glaucoma, degenerative fundus changes (mainly ARM) or DR. Information on self-reported eye diseases was complemented with data from national registers, and case records were gathered for non-participants and persons with visual acuity (VA) < 0.5 or reporting difficulties in vision or eye diseases without assessed VA.
   Results:
   Based on self-reported and/or register-based data the estimated total prevalences of cataract, glaucoma, ARM and DR in the study population were 10%, 5%, 4% and 1%, respectively. All these chronic eye diseases increased with age (p < 0.001). The corresponding prevalences for persons aged 65 and older were 34%, 13%, 12% and 2%, respectively. Cataract and glaucoma were more common in women than in men [odds ratio (OR) 1.55, 95% confidence interval (CI) 1.26-1.91; OR 1.57, 95% CI 1.24-1.98, respectively]. The most prevalent eye diseases in people with visual impairment (VA < 0.25) were ARM (37%), unoperated cataract (27%), glaucoma (22%) and DR (7%).
   Conclusion:
   The high prevalence of these mainly age-related eye diseases, together with increasing life expectancy, mean that continuous efforts are needed to identify and treat eye diseases in order to maintain patients' quality of life and to alleviate the social and economic burden of serious eye diseases.
C1 [Laitinen, Arja; Harkanen, Tommi; Koskinen, Seppo; Reunanen, Antti; Aromaa, Arpo] Natl Publ Hlth Inst, Dept Hlth & Funct Capac, FI-00300 Helsinki, Finland.
   [Laitinen, Arja; Laatikainen, Leila] Univ Helsinki, Dept Ophthalmol, FIN-00014 Helsinki, Finland.
C3 Finland National Institute for Health & Welfare; University of Helsinki
RP Laitinen, A (通讯作者)，Natl Publ Hlth Inst, Dept Hlth & Funct Capac, Mannerheimintie 166, FI-00300 Helsinki, Finland.
EM arja.laitinen@thl.fi
RI Härkänen, Tommi/G-4866-2019
OI Härkänen, Tommi/0000-0002-4577-1808
CR Arnarsson A, 2007, ACTA OPHTHALMOL SCAN, V85, P822, DOI 10.1111/j.1600-0420.2007.01051.x
   Aromaa A., 2004, HLTH FUNCTIONAL CAPA
   Astrom S, 2007, ACTA OPHTHALMOL SCAN, V85, P832, DOI 10.1111/j.1600-0420.2007.00980.x
   Astrom S, 2007, ACTA OPHTHALMOL SCAN, V85, P828, DOI 10.1111/j.1600-0420.2007.00992.x
   Backlund LB, 1997, DIABETIC MED, V14, P732, DOI 10.1002/(SICI)1096-9136(199709)14:9<732::AID-DIA474>3.0.CO;2-J
   Bjornsson OM, 2006, ACTA OPHTHALMOL SCAN, V84, P636, DOI 10.1111/j.1600-0420.2006.00696.x
   Bonomi L, 1998, OPHTHALMOLOGY, V105, P209, DOI 10.1016/S0161-6420(98)92665-3
   Buch H, 2001, ACTA OPHTHALMOL SCAN, V79, P441, DOI 10.1034/j.1600-0420.2001.790503.x
   Buch H, 2001, OPHTHALMOLOGY, V108, P2347, DOI 10.1016/S0161-6420(01)00823-5
   Chen PP, 2003, OPHTHALMOLOGY, V110, P726, DOI 10.1016/S0161-6420(02)01974-7
   DIELEMANS I, 1994, OPHTHALMOLOGY, V101, P1851
   Ekstrom C, 1996, ACTA OPHTHALMOL SCAN, V74, P107
   FERRIS FL, 1982, AM J OPHTHALMOL, V94, P91, DOI 10.1016/0002-9394(82)90197-0
   Fleiss J.L., 1981, STAT METHODS RATES P
   GIBSON JM, 1985, T OPHTHAL SOC UK, V104, P196
   Graubard BI, 1999, BIOMETRICS, V55, P652, DOI 10.1111/j.0006-341X.1999.00652.x
   HAKKINEN L, 1984, SCAND J SOC MED, P1
   HIRVELA H, 1995, OPHTHALMOLOGY, V102, P108
   HIRVELA H, 1994, INT OPHTHALMOL, V18, P299
   Hirvela H, 1997, BRIT J OPHTHALMOL, V81, P214, DOI 10.1136/bjo.81.3.214
   Jonasson F, 1987, Acta Ophthalmol Suppl, V182, P40
   Jonasson F, 2003, EYE, V17, P747, DOI 10.1038/sj.eye.6700374
   Keeffe JE, 2002, BRIT J OPHTHALMOL, V86, P24, DOI 10.1136/bjo.86.1.24
   KLEIN BEK, 1992, OPHTHALMOLOGY, V99, P1499
   KLEIN BEK, 1992, OPHTHALMOLOGY, V99, P546
   KLEIN R, 1986, AM J EPIDEMIOL, V124, P104, DOI 10.1093/oxfordjournals.aje.a114353
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Klein R, 2001, OPHTHALMOLOGY, V108, P1757, DOI 10.1016/S0161-6420(01)00769-2
   KRAUSE U, 1988, ACTA OPHTHALMOL, V66, P565
   LAATIKAINEN L, 1995, ACTA OPHTHALMOL SCAN, V73, P105
   LEE J, 1981, J CHRON DIS, V34, P415, DOI 10.1016/0021-9681(81)90040-0
   Leibowitz H M, 1980, Surv Ophthalmol, V24, P335
   LINTON KLP, 1991, AM J EPIDEMIOL, V134, P1438, DOI 10.1093/oxfordjournals.aje.a116049
   Livingston P M, 1997, Ophthalmic Epidemiol, V4, P73
   MARTINEZ GS, 1982, AM J OPHTHALMOL, V94, P181, DOI 10.1016/0002-9394(82)90073-3
   McCarty CA, 2000, CLIN EXP OPHTHALMOL, V28, P77, DOI 10.1046/j.1442-9071.2000.00276.x
   McKay R, 2000, BRIT J OPHTHALMOL, V84, P865, DOI 10.1136/bjo.84.8.865
   Mitchell P, 1996, OPHTHALMOLOGY, V103, P1661, DOI 10.1016/S0161-6420(96)30449-1
   Mitchell P, 1997, OPHTHALMOLOGY, V104, P581, DOI 10.1016/S0161-6420(97)30266-8
   Mitchell P, 1998, OPHTHALMOLOGY, V105, P406, DOI 10.1016/S0161-6420(98)93019-6
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   MITCHELL RA, 1993, J EPIDEMIOL COMMUN H, V47, P42, DOI 10.1136/jech.47.1.42
   Munoz B, 1999, ANN EPIDEMIOL, V9, P53, DOI 10.1016/S1047-2797(98)00026-X
   *NAT AG MED, 2002, FINN STAT MED 2001, P2001
   Nizankowska MH, 2005, OPHTHAL EPIDEMIOL, V12, P363, DOI 10.1080/09286580500212904
   OJAMO M, 2001, FINNISH REGISTER VIS, P2001
   Orr P, 1999, OPHTHALMOLOGY, V106, P904, DOI 10.1016/S0161-6420(99)00508-4
   Ostberg A, 2006, OPHTHALMOLOGY, V113, P970, DOI 10.1016/j.ophtha.2006.01.067
   Rahmani B, 1996, OPHTHALMOLOGY, V103, P1721, DOI 10.1016/S0161-6420(96)30435-1
   Reidy A, 1998, BRIT MED J, V316, P1643, DOI 10.1136/bmj.316.7145.1643
   RINGVOLD A, 1991, ACTA OPHTHALMOL, V69, P273
   RINGVOLD A, 1988, ACTA OPHTHALMOL, V66, P652
   Sasaki H, 2000, OPHTHALMOLOGICA, V214, P412, DOI 10.1159/000027535
   Tarkkanen A, 2008, ACTA OPHTHALMOL, V86, P697, DOI 10.1111/j.1600-0420.2007.01109.x
   TIELSCH JM, 1991, JAMA-J AM MED ASSOC, V266, P369, DOI 10.1001/jama.266.3.369
   Topouzis F, 2006, AM J OPHTHALMOL, V142, P1076, DOI 10.1016/j.ajo.2006.07.042
   VanNewkirk MR, 2001, OPHTHALMOLOGY, V108, P960, DOI 10.1016/S0161-6420(01)00554-1
   VINDING T, 1989, ACTA OPHTHALMOL, V67, P609
   VINGERLING JR, 1995, OPHTHALMOLOGY, V102, P205
   WANG F, 1994, ARCH INTERN MED, V154, P1821, DOI 10.1001/archinte.154.16.1821
   Wang JJ, 1999, AUST NZ J OPHTHALMOL, V27, P294, DOI 10.1046/j.1440-1606.1999.00227.x
   Weih LM, 2001, OPHTHALMOLOGY, V108, P1966, DOI 10.1016/S0161-6420(01)00799-0
   Wolfs RCW, 2000, INVEST OPHTH VIS SCI, V41, P3309
NR 63
TC 38
Z9 40
U1 0
U2 6
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1755-375X
EI 1755-3768
J9 ACTA OPHTHALMOL
JI Acta Ophthalmol.
PD JUN
PY 2010
VL 88
IS 4
BP 463
EP 471
DI 10.1111/j.1755-3768.2009.01566.x
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 603BD
UT WOS:000278182000015
PM 19878108
OA Bronze
DA 2022-11-30
ER

PT J
AU Stephan, H
   Boeloeni, R
   Eggert, A
   Bornfeld, N
   Schueler, A
AF Stephan, Harald
   Boeloeni, Reka
   Eggert, Angelika
   Bornfeld, Norbert
   Schueler, Andreas
TI Photodynamic therapy in retinoblastoma: Effects of verteporfin on
   retinoblastoma cell lines
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID DOSE-RESPONSE RELATIONSHIPS; RING-A BPD; INTRAOCULAR RETINOBLASTOMA;
   PHOTORADIATION THERAPY; PROTEIN EXPRESSION; ENDOTHELIAL-CELLS;
   P-GLYCOPROTEIN; LIGHT ENERGY; PHOTOFRIN-II; IN-VIVO
AB PURPOSE. In contrast to the excellent survival rates of the malignant childhood tumor retinoblastoma (RB), morbidity is high in patients with this disease because of the enucleation or loss of retinal areas caused by current bulb-saving therapies. The authors aimed to preclinically assess the effects of photochemotherapy using second-generation photochemotherapeutics as a prerequisite to develop a promising therapeutic alternative. This therapy implies intravenous application of a photosensitizer activated locally by light of the appropriate wavelength. Activation leads to the formation of free radicals, vascular occlusion, and death of affected cells in the area of irradiation. The photosensitizer verteporfin is approved for the therapy of neovascularizations, such as age-related maculopathy.
   METHODS. The uptake of verteporfin in RB cell lines was investigated. Established RB cell lines, an RB subline resistant to etoposide, and dissociated cells from a primary RB were incubated with verteporfin and irradiated with activating laser light. Proliferation was measured at different time points after application.
   RESULTS. All five RB cell lines investigated incorporated verteporfin, and nanomolar concentrations were sufficient for effective killing. At lower doses, surviving cells started to proliferate again after several days, but verteporfin 50 ng/mL and 100 J/cm(2) were sufficient for irreversible killing. High verteporfin concentrations caused cell death with little to no irradiation. Etoposide-resistant cells and primary tumor cells had a comparable susceptibility to photodynamic therapy (PDT) as established parental cell lines.
   CONCLUSIONS. PDT using verteporfin efficiently kills chemotherapy-resistant and nonresistant retinoblastoma cell lines and primary tumor cells in vitro, and it warrants further preclinical evaluation as a therapeutic option for the treatment of retinoblastoma.
C1 [Stephan, Harald; Eggert, Angelika] Univ Childrens Hosp, Dept Hematol & Oncol, Essen, Germany.
   [Boeloeni, Reka; Bornfeld, Norbert; Schueler, Andreas] Univ Childrens Hosp, Dept Ophthalmol, Essen, Germany.
C3 University of Duisburg Essen; University of Hamburg; University Medical
   Center Hamburg-Eppendorf; University of Duisburg Essen; University of
   Hamburg; University Medical Center Hamburg-Eppendorf
RP Stephan, H (通讯作者)，Univ Childrens Hosp, Dept Hematol & Oncol, Essen, Germany.
EM harald.stephan@uni-due.de
RI Eggert, Angelika/AAE-6907-2022; Stephan, Harald/AAT-6802-2021
OI Eggert, Angelika/0000-0003-3476-8184; 
CR ALLISON BA, 1994, BRIT J CANCER, V69, P833, DOI 10.1038/bjc.1994.162
   AVELINE B, 1994, PHOTOCHEM PHOTOBIOL, V59, P328, DOI 10.1111/j.1751-1097.1994.tb05042.x
   BENEDICT WF, 1980, MED PEDIATR ONCOL, V8, P397, DOI 10.1002/mpo.2950080412
   Brichard B, 2002, MED PEDIATR ONCOL, V38, P411, DOI 10.1002/mpo.1355
   DESMIDT PC, 1990, CRIT REV THER DRUG, V7, P99
   DiCiommo D, 2000, SEMIN CANCER BIOL, V10, P255, DOI 10.1006/scbi.2000.0326
   DOUGHERTY T J, 1986, Seminars in Surgical Oncology, V2, P24, DOI 10.1002/ssu.2980020104
   Ebrahim S, 2005, SURV OPHTHALMOL, V50, P167, DOI 10.1016/j.survophthal.2004.12.006
   ENG C, 1993, JNCI-J NATL CANCER I, V85, P1121, DOI 10.1093/jnci/85.14.1121
   FOGELMAN AM, 1988, SEMIN THROMB HEMOST, V14, P206, DOI 10.1055/s-2007-1002778
   GAFFNEY J, 1985, J CELL SCI, V79, P317
   GOMER CJ, 1985, CANCER RES, V45, P3718
   Gordiyenko N, 2004, INVEST OPHTH VIS SCI, V45, P2822, DOI 10.1167/iovs.04-0074
   Haimovici R, 1997, CURR EYE RES, V16, P83, DOI 10.1076/ceyr.16.2.83.5088
   HORSMAN MR, 1989, ACTA ONCOL, V28, P693, DOI 10.3109/02841868909092295
   Hunter DD, 2004, MOL CELL NEUROSCI, V27, P477, DOI 10.1016/j.mcn.2004.08.003
   JAMIESON CHM, 1990, LEUKEMIA RES, V14, P209, DOI 10.1016/0145-2126(90)90128-V
   Jin C, 1999, Yan Ke Xue Bao, V15, P1
   KARANOV S, 1990, J PHOTOCH PHOTOBIO B, V6, P175, DOI 10.1016/1011-1344(90)85087-D
   KOBAYASHI M, 1982, ACTA NEUROPATHOL, V57, P203, DOI 10.1007/BF00685390
   Krishnakumar S, 2004, BRIT J OPHTHALMOL, V88, P1521, DOI 10.1136/bjo.2004.047928
   Mohney BG, 1998, AM J OPHTHALMOL, V126, P269, DOI 10.1016/S0002-9394(98)00146-9
   Moppett J, 2001, EUR J RADIOL, V37, P95, DOI 10.1016/S0720-048X(00)00291-6
   MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4
   NOSKE DP, 1991, CLIN NEUROL NEUROSUR, V93, P293, DOI 10.1016/0303-8467(91)90094-6
   OHNISHI Y, 1986, JPN J OPHTHALMOL, V30, P409
   Rensen PCN, 2001, ADV DRUG DELIVER REV, V47, P251, DOI 10.1016/S0169-409X(01)00109-0
   Richter A M, 1996, J Clin Laser Med Surg, V14, P335
   RICHTER AM, 1993, PHOTOCHEM PHOTOBIOL, V57, P1000, DOI 10.1111/j.1751-1097.1993.tb02962.x
   Schmidt-Erfurth U, 2000, SURV OPHTHALMOL, V45, P195, DOI 10.1016/S0039-6257(00)00158-2
   SchmidtErfurth U, 1997, BRIT J CANCER, V75, P54, DOI 10.1038/bjc.1997.9
   SCHMIDTERFURTH U, 1995, LASER SURG MED, V17, P178, DOI 10.1002/lsm.1900170207
   Schouten-van Meeteren AYN, 2002, MED PEDIATR ONCOL, V38, P428, DOI 10.1002/mpo.1358
   Schuler AO, 2000, OPHTHALMOLOGE, V97, P207, DOI 10.1007/s003470050516
   SERY TW, 1979, CANCER RES, V39, P96
   SHIELDS JA, 1982, RETINA-J RET VIT DIS, V2, P206, DOI 10.1097/00006982-198202040-00003
   Souza JP, 2005, CLIN EXP OPHTHALMOL, V33, P279, DOI 10.1111/j.1442-9071.2005.00991.x
   Wilson MW, 2006, INVEST OPHTH VIS SCI, V47, P1269, DOI 10.1167/iovs.05-1321
   Winther J, 1987, Acta Ophthalmol Suppl, V182, P140
   WINTHER J, 1987, OPHTHALMIC PAED GEN, V8, P49, DOI 10.3109/13816818709028516
   WINTHER J, 1989, J CANCER RES CLIN, V115, P73, DOI 10.1007/BF00391603
   WINTHER J, 1989, ACTA OPHTHALMOL, V67, P44
   WINTHER J, 1989, BRIT J CANCER, V59, P869, DOI 10.1038/bjc.1989.184
   WINTHER J, 1988, ACTA OPHTHALMOL, V66, P69
   WINTHER J, 1988, PHOTOCHEM PHOTOBIOL, V47, P419
   WINTHER JB, 1990, ACTA OPHTHALMOL    S, V185, P1
   Yanagisawa Takaaki, 2004, Int J Clin Oncol, V9, P13, DOI 10.1007/s10147-003-0368-y
NR 47
TC 29
Z9 32
U1 0
U2 3
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD JUL
PY 2008
VL 49
IS 7
BP 3158
EP 3163
DI 10.1167/iovs.07-1016
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 318WR
UT WOS:000257124000049
PM 18579764
DA 2022-11-30
ER

PT J
AU Cohen, SY
   Vignal-Clermont, C
   Trinh, L
   Ohno-Matsui, K
AF Cohen, Salomon Yves
   Vignal-Clermont, Catherine
   Trinh, Liem
   Ohno-Matsui, Kyoko
TI Tilted disc syndrome (TDS): New hypotheses for posterior segment
   complications and their implications in other retinal diseases
SO PROGRESS IN RETINAL AND EYE RESEARCH
LA English
DT Review
DE Tilted disc syndrome; Inferior staphyloma; Macular serous retinal
   detachment; Wide-field imaging
ID OPTICAL COHERENCE TOMOGRAPHY; DOME-SHAPED MACULA; HIGHLY MYOPIC EYES;
   POLYPOIDAL CHOROIDAL VASCULOPATHY; INFERIOR STAPHYLOMA; CHORIORETINAL
   FOLDS; CORNEAL ASTIGMATISM; SUBRETINAL NEOVASCULARIZATION;
   INTRAPAPILLARY HEMORRHAGE; POPULATION PREVALENCE
AB Tilted disc syndrome (TDS) is considered a congenital anomaly due to a delayed closure of the embryonic fissure. It is characterized by an oblique orientation of the axis of the optic disc, associated with other posterior pole anomalies such as inferior crescent, situs inversus and inferior staphyloma. The aim of this review was to summarize the data supporting the current hypotheses for the pathogenesis of TDS, and its anatomical and functional clinical consequences. Recent imaging techniques, such as magnetic resonance imaging, wide-field fundus imaging, and 2- and 3-D optical coherence tomography have provided a new perspective on TDS and its complications. Different abnormalities have previously been reported, both in the anterior and posterior segments. The focus was on vision-threatening chorioretinal changes or complications, including choroidal neovascularization and serous retinal detachments and their therapeutic options. Based on clinical observations, assumptions were proposed to understand the occurrence of complications such as chorioretinal degenerative changes, choroidal neovascularization and polypoidal choroidal vasculopathy, macular serous retinal detachment, myopic foveoschisis and chorioretinal folds. These hypotheses could be referred to as the curvature "breaking point" hypothesis, the uneven growth "tractional" hypothesis, the "container-content" imbalance hypothesis, and the "choroidal funnel" hypothesis. Because these complications could also occur in other contexts, understanding the pathogenesis of TDS complications could help to understand their pathophysiology.
C1 [Cohen, Salomon Yves] Ophthalm Ctr Imaging & Laser, Paris, France.
   [Cohen, Salomon Yves] Univ Paris Est, Interc Hosp, Dept Ophthalmol, Creteil, France.
   [Vignal-Clermont, Catherine] Rothschild Fdn Hosp, Dept Ophthalmol, Paris, France.
   [Trinh, Liem] CHNO Quinze Vingts, IHU Foresight, INSERM DGOS C 1423, Paris, France.
   [Ohno-Matsui, Kyoko] Tokyo Med & Dent Univ, Dept Ophthalmol & Visual Sci, Tokyo, Japan.
C3 Universite Paris-Est-Creteil-Val-de-Marne (UPEC); CHI Creteil; Fondation
   Adolphe de Rothschild; CHNO des Quinze-Vingts; UDICE-French Research
   Universities; Sorbonne Universite; Tokyo Medical & Dental University
   (TMDU)
RP Cohen, SY (通讯作者)，Ophthalm Ctr Imaging & Laser, Paris, France.; Cohen, SY (通讯作者)，Univ Paris Est, Interc Hosp, Dept Ophthalmol, Creteil, France.
EM sycsyc75@gmail.com
OI vignal clermont, catherine/0000-0003-0292-8905
FU CIL-ASSOC
FX CIL-ASSOC, an association for education and research, without
   involvement in the study design, data collection, analysis and
   interpretation, writing of the report and decision to submit the article
   for publication.
CR Abalem MF, 2017, OSLI RETINA, V48, P760, DOI 10.3928/23258160-20170829-12
   Adams Matthew K, 2020, Retin Cases Brief Rep, V14, P289, DOI 10.1097/ICB.0000000000000765
   Apple D J, 1984, Int Ophthalmol Clin, V24, P109, DOI 10.1097/00004397-198402410-00009
   APPLE DJ, 1982, SURV OPHTHALMOL, V27, P3, DOI 10.1016/0039-6257(82)90111-4
   Arias L, 2010, CLIN OPHTHALMOL, V4, P227
   Astroz P, 2017, RETINA-J RET VIT DIS, V37, P154, DOI 10.1097/IAE.0000000000001135
   AVILA MP, 1984, OPHTHALMOLOGY, V91, P1573
   Baba T, 2003, AM J OPHTHALMOL, V135, P338, DOI 10.1016/S0002-9394(02)01937-2
   Bando H, 2005, AM J OPHTHALMOL, V139, P197, DOI 10.1016/j.ajo.2004.07.027
   Benhamou N, 2002, AM J OPHTHALMOL, V133, P794, DOI 10.1016/S0002-9394(02)01394-6
   BENSON WE, 1988, SURV OPHTHALMOL, V32, P297, DOI 10.1016/0039-6257(88)90093-8
   Booij JC, 2010, PROG RETIN EYE RES, V29, P1, DOI 10.1016/j.preteyeres.2009.08.003
   BOTTONI FG, 1990, EYE, V4, P504, DOI 10.1038/eye.1990.66
   Bozkurt B, 2002, CORNEA, V21, P458, DOI 10.1097/00003226-200207000-00005
   BRAZITIKOS PD, 1990, ARCH OPHTHALMOL-CHIC, V108, P1698, DOI 10.1001/archopht.1990.01070140052027
   BRODSKY MC, 1995, ARCH OPHTHALMOL-CHIC, V113, P624, DOI 10.1001/archopht.1995.01100050092036
   Caillaux V, 2013, AM J OPHTHALMOL, V156, P958, DOI 10.1016/j.ajo.2013.06.032
   Cankaya C, 2020, CLIN EXP OPTOM, V103, P192, DOI 10.1111/cxo.12897
   Cheung CMG, 2018, OPHTHALMOLOGY, V125, P708, DOI 10.1016/j.ophtha.2017.11.019
   Choi SY, 2015, GRAEF ARCH CLIN EXP, V253, P327, DOI 10.1007/s00417-014-2824-y
   Ciftci Suleyman, 2011, BMJ Case Rep, V2011, DOI 10.1136/bcr.06.2010.3126
   COCKBURN DM, 1982, AM J OPTOM PHYS OPT, V59, P760
   Coco RM, 2012, OPHTHALMOLOGICA, V228, P7, DOI 10.1159/000336910
   Cohen SY, 2008, RETINA-J RET VIT DIS, V28, P1361, DOI 10.1097/IAE.0b013e318180f66e
   Cohen SY, 2006, GRAEF ARCH CLIN EXP, V244, P1536, DOI 10.1007/s00417-006-0302-x
   Cohen SY, 2013, RETINA-J RET VIT DIS, V33, P1338, DOI 10.1097/IAE.0b013e3182831364
   Cohen SY, 2009, EUR J OPHTHALMOL, V19, P876
   Cohen SY, 1998, ARCH OPHTHALMOL-CHIC, V116, P1398, DOI 10.1001/archopht.116.10.1398
   Cohen SY, 1996, OPHTHALMOLOGY, V103, P1241, DOI 10.1016/S0161-6420(96)30515-0
   Cohen SY, 1998, OPHTHALMOLOGY, V105, P1831, DOI 10.1016/S0161-6420(98)91024-7
   Couturier A, 2015, RETINA-J RET VIT DIS, V35, P2384, DOI 10.1097/IAE.0000000000000859
   Curtin B J, 1977, Trans Am Ophthalmol Soc, V75, P67
   Dai Y, 2015, INVEST OPHTH VIS SCI, V56, P7076, DOI 10.1167/iovs.14-16033
   de Carlo TE, 2015, OPHTHALMOLOGY, V122, P1228, DOI 10.1016/j.ophtha.2015.01.029
   Dehghani C, 2010, OPTOMETRY, V81, P688, DOI 10.1016/j.optm.2010.03.009
   Denis D, 2019, J FR OPHTALMOL, V42, P778, DOI 10.1016/j.jfo.2018.09.011
   Deobhakta A, 2015, OSLI RETINA, V46, P391, DOI 10.3928/23258160-20150323-18
   Donati MC, 2013, EUR J OPHTHALMOL, V23, P267, DOI 10.5301/ejo.5000169
   Dormegny L, 2021, AM J OPHTHALMOL, V224, P18, DOI 10.1016/j.ajo.2020.11.013
   DORRELL D, 1978, BRIT J OPHTHALMOL, V62, P16, DOI 10.1136/bjo.62.1.16
   Ellabban AA, 2013, AM J OPHTHALMOL, V155, P320, DOI 10.1016/j.ajo.2012.08.007
   Ellabban AA, 2012, INVEST OPHTH VIS SCI, V53, P7735, DOI 10.1167/iovs.12-9952
   Elschnig A., 1900, A VONGRAEFES ARCH OP, V51, p391?430
   Fingler J, 2009, OPT EXPRESS, V17, P22190, DOI 10.1364/OE.17.022190
   Fuchs E., 1982, BEITRAG ANGEBORENEN
   Furuta M, 2013, RETINA-J RET VIT DIS, V33, P71, DOI 10.1097/IAE.0b013e318263ceb4
   Garcia-Ben A, 2020, Arch Soc Esp Oftalmol (Engl Ed), V95, P478, DOI 10.1016/j.oftal.2020.05.013
   Garcia-Ben A, 2014, OPTOMETRY VISION SCI, V91, P497, DOI 10.1097/OPX.0000000000000250
   Gass J.D.M., 1997, STEREOSCOPIC ATLAS M, Vfourth
   GASS JDM, 1981, ARCH OPHTHALMOL-CHIC, V99, P1016, DOI 10.1001/archopht.1981.03930011016006
   Gaucher D, 2008, AM J OPHTHALMOL, V145, P909, DOI 10.1016/j.ajo.2008.01.012
   Gaynon MW, 2018, RETINA-J RET VIT DIS, V38, pE36, DOI 10.1097/IAE.0000000000002147
   Gediz BS, 2020, TURK OFTALMOL DERG, V50, P190, DOI 10.4274/tjo.galenos.2020.98415
   Giocanti-Auregan Audrey, 2020, Am J Ophthalmol Case Rep, V19, P100747, DOI 10.1016/j.ajoc.2020.100747
   GIUFFRE G, 1985, J FR OPHTALMOL, V8, P565
   GIUFFRE G, 1986, DOC OPHTHALMOL, V62, P223
   Giuffre G, 2005, EUR J OPHTHALMOL, V15, P647, DOI 10.1177/112067210501500518
   GIUFFRE G, 1993, GRAEF ARCH CLIN EXP, V231, P41, DOI 10.1007/BF01681699
   GIUFFRE G, 1991, INT OPHTHALMOL, V15, P1, DOI 10.1007/BF00150971
   Gohil R, 2015, EYE, V29, P593, DOI 10.1038/eye.2014.311
   Gomez-Resa M, 2014, DEV OPHTHALMOL, V54, P204, DOI 10.1159/000360468
   Gunduz A, 2002, J CATARACT REFR SURG, V28, P1836, DOI 10.1016/S0886-3350(02)01424-4
   Gunduz A, 2016, ARQ BRAS OFTALMOL, V79, P285, DOI 10.5935/0004-2749.20160083
   Ha A., 2021, AM J OPHTHALMOL, DOI [10.1016/j.ajo.2021.06.003, 00325-1, DOI 10.1016/J.AJO.2021.06.003,00325-1]
   Hayashi K, 2010, OPHTHALMOLOGY, V117, P1595, DOI 10.1016/j.ophtha.2009.11.003
   Hirano Y, 2015, OSLI RETINA, V46, P384, DOI 10.3928/23258160-20150323-16
   Hirayama K, 2021, GRAEF ARCH CLIN EXP, V259, P387, DOI 10.1007/s00417-020-04931-1
   HITTNER HM, 1981, J PEDIAT OPHTH STRAB, V18, P15
   Hocaoglu M, 2019, GRAEF ARCH CLIN EXP, V257, P2357, DOI 10.1007/s00417-019-04449-1
   Hosseini H, 2013, AM J OPHTHALMOL, V156, P737, DOI 10.1016/j.ajo.2013.05.036
   How ACS, 2009, ARCH OPHTHALMOL-CHIC, V127, P894, DOI 10.1001/archophthalmol.2009.134
   Ikuno Y, 2008, RETINA-J RET VIT DIS, V28, P1124, DOI 10.1097/IAE.0b013e318174417a
   Ikuno Y, 2017, RETINA-J RET VIT DIS, V37, P2347, DOI 10.1097/IAE.0000000000001489
   Ikuno Y, 2015, OPHTHALMOLOGY, V122, P1220, DOI 10.1016/j.ophtha.2015.01.025
   Imamura Y, 2011, AM J OPHTHALMOL, V151, P297, DOI 10.1016/j.ajo.2010.08.014
   Ishida T, 2015, OPHTHALMOLOGY, V122, P215, DOI 10.1016/j.ophtha.2014.08.003
   JAIN IS, 1967, ARCH OPHTHALMOL-CHIC, V77, P59
   Jay WM, 2017, NEURO-OPHTHALMOLOGY, V41, P291, DOI 10.1080/01658107.2017.1331247
   Jeng-Miller KW, 2017, CURR OPIN OPHTHALMOL, V28, P579, DOI 10.1097/ICU.0000000000000425
   Jia YL, 2012, OPT EXPRESS, V20, P4710, DOI 10.1364/OE.20.004710
   Jonas JB, 2004, INVEST OPHTH VIS SCI, V45, P2660, DOI 10.1167/iovs.03-1363
   Jonas JB, 2003, INVEST OPHTH VIS SCI, V44, P5189, DOI 10.1167/iovs.03-0174
   Jonas JB, 1997, OPHTHALMOLOGY, V104, P1934, DOI 10.1016/S0161-6420(97)30004-9
   Kasai A, 2016, CASE REP OPHTHALM, V7, P285, DOI 10.1159/000444293
   Kashani AH, 2015, RETINA-J RET VIT DIS, V35, P2323, DOI 10.1097/IAE.0000000000000811
   KATZ B, 1995, OPHTHALMOLOGY, V102, P349
   Khairallah M, 1996, RETINA-J RET VIT DIS, V16, P449, DOI 10.1097/00006982-199616050-00017
   Kim Ji Ah, 2019, Korean J Ophthalmol, V33, P173, DOI 10.3341/kjo.2018.0084
   Kokame GT, 2004, OPHTHALMOLOGY, V111, P926, DOI 10.1016/j.ophtha.2003.08.040
   Kosekahya P, 2018, EYE CONTACT LENS, V44, pS33, DOI 10.1097/ICL.0000000000000406
   Kubota F, 2019, AM J OPHTHALMOL, V207, P313, DOI 10.1016/j.ajo.2019.05.027
   Kugler L, 2010, J CATARACT REFR SURG, V36, P1745, DOI 10.1016/j.jcrs.2010.05.014
   LEAHEY AB, 1993, ARCH OPHTHALMOL-CHIC, V111, P357, DOI 10.1001/archopht.1993.01090030075042
   Lee Eun Kyoung, 2019, Korean J Ophthalmol, V33, P228, DOI 10.3341/kjo.2018.0125
   Lee KS, 2014, OPHTHALMOLOGY, V121, P1013, DOI 10.1016/j.ophtha.2013.11.014
   Leys AM, 2002, RETINA-J RET VIT DIS, V22, P659, DOI 10.1097/00006982-200210000-00025
   Liang IC, 2015, OPHTHALMOLOGY, V122, P1591, DOI 10.1016/j.ophtha.2015.04.012
   Lim L, 2008, BRIT J OPHTHALMOL, V92, P1461, DOI 10.1136/bjo.2008.139113
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Limaiem R, 2012, J FR OPHTALMOL, V35, P277, DOI 10.1016/j.jfo.2011.09.011
   Lupidi M, 2021, SURV OPHTHALMOL, V66, P761, DOI 10.1016/j.survophthal.2021.01.014
   LUREAU MA, 1995, J FR OPHTALMOL, V18, P468
   Malinowski SM, 1996, ARCH OPHTHALMOL-CHIC, V114, P230, DOI 10.1001/archopht.1996.01100130224028
   Manfre L, 1999, AM J NEURORADIOL, V20, P1750
   MARGOLIS S, 1984, OPHTHALMOLOGY, V91, P1327
   Marmor MF, 2008, ARCH OPHTHALMOL-CHIC, V126, P907, DOI 10.1001/archopht.126.7.907
   Maruko I, 2011, INVEST OPHTH VIS SCI, V52, P8763, DOI 10.1167/iovs.11-8195
   Mateo Carlos, 2016, Retin Cases Brief Rep, V10, P327, DOI 10.1097/ICB.0000000000000261
   Mauget-Faysse M, 2006, AM J OPHTHALMOL, V142, P970, DOI 10.1016/j.ajo.2006.06.063
   Milani P, 2009, GRAEF ARCH CLIN EXP, V247, P1179, DOI 10.1007/s00417-009-1096-4
   Min Chan Hong, 2020, Korean J Ophthalmol, V34, P106, DOI 10.3341/kjo.2019.0113
   Miura G, 2006, JPN J OPHTHALMOL, V50, P566, DOI 10.1007/s10384-006-0360-y
   Moriyama M, 2012, INVEST OPHTH VIS SCI, V53, P4510, DOI 10.1167/iovs.12-9426
   Moriyama M, 2011, OPHTHALMOLOGY, V118, P1626, DOI 10.1016/j.ophtha.2011.01.018
   Moschos MM, 2009, DOC OPHTHALMOL, V119, P23, DOI 10.1007/s10633-009-9165-x
   Mrejen S, 2014, RETINA-J RET VIT DIS, V34, P1560, DOI 10.1097/IAE.0000000000000139
   Muller B, 2011, KLIN MONATSBL AUGENH, V228, P771, DOI 10.1055/s-0031-1281714
   Nagaoka N, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0138825
   Nakanishi H, 2008, RETINA-J RET VIT DIS, V28, P1493, DOI 10.1097/IAE.0b013e318183589c
   Ohno-Matsui K, 2003, BRIT J OPHTHALMOL, V87, P570, DOI 10.1136/bjo.87.5.570
   Ohno-Matsui K, 2016, ASIA-PAC J OPHTHALMO, V5, P415, DOI 10.1097/APO.0000000000000230
   Ohno-Matsui K, 2015, AM J OPHTHALMOL, V159, P877, DOI 10.1016/j.ajo.2015.01.022
   Ohno-Matsui K, 2014, OPHTHALMOLOGY, V121, P1798, DOI 10.1016/j.ophtha.2014.03.035
   Ohno-Matsui K, 2012, INVEST OPHTH VIS SCI, V53, P6046, DOI 10.1167/iovs.12-10161
   Ohno-Matsui K, 2011, JPN J OPHTHALMOL, V55, P171, DOI 10.1007/s10384-010-0920-z
   OhnoMatsui K, 1996, RETINA-J RET VIT DIS, V16, P29, DOI 10.1097/00006982-199616010-00006
   Olsen TW, 2014, AM J OPHTHALMOL, V157, P1038, DOI 10.1016/j.ajo.2014.02.021
   Orguc S, 2007, NEURORADIOL J, V20, P175, DOI 10.1177/197140090702000206
   Ornek K, 2008, OPTOMETRY VISION SCI, V85, P350, DOI 10.1097/OPX.0b013e31816bf578
   Ozsoy E, 2016, J OPHTHALMOL, V2016, DOI 10.1155/2016/5185207
   Pan CW, 2013, OPHTHALMOLOGY, V120, P284, DOI 10.1016/j.ophtha.2012.07.065
   Pardo-Lopez D, 2011, CASE REP OPHTHALM, V2, P111, DOI 10.1159/000326918
   Park HYL, 2015, INVEST OPHTH VIS SCI, V56, P4927, DOI 10.1167/iovs.14-15819
   Park YG, 2016, GRAEF ARCH CLIN EXP, V254, P1703, DOI 10.1007/s00417-015-3262-1
   Peiretti Enrico, 2008, Retin Cases Brief Rep, V2, P31, DOI 10.1097/01.iae.0000243064.91851.78
   Phu J, 2018, OPTOMETRY VISION SCI, V95, P959, DOI 10.1097/OPX.0000000000001286
   Pichi F, 2014, GRAEF ARCH CLIN EXP, V252, P1661, DOI 10.1007/s00417-014-2701-8
   Prost M, 1991, Klin Oczna, V93, P121
   PROST M, 1988, INT OPHTHALMOL, V12, P131, DOI 10.1007/BF00137139
   Qian YS, 2011, J REFRACT SURG, V27, P863, DOI 10.3928/1081597X-20110629-01
   Quaranta M, 2000, GRAEF ARCH CLIN EXP, V238, P101
   RAND LI, 1985, NEW ENGL J MED, V313, P1433, DOI 10.1056/NEJM198512053132302
   Roider J, 1999, ARCH OPHTHALMOL-CHIC, V117, P1028
   ROTHKOFF L, 1979, ACTA OPHTHALMOL, V57, P1091
   Ruiz-Medrano J, 2019, PROG RETIN EYE RES, V69, P80, DOI 10.1016/j.preteyeres.2018.10.005
   SHIELDS JA, 1992, OPHTHALMIC PLAST REC, V8, P62, DOI 10.1097/00002341-199203000-00011
   Shinohara K, 2013, EYE, V27, P1234, DOI 10.1038/eye.2013.202
   Shinohara K, 2018, OPHTHALMOLOGY, V125, P1575, DOI 10.1016/j.ophtha.2018.03.053
   Shinohara K, 2017, INVEST OPHTH VIS SCI, V58, P3750, DOI 10.1167/iovs.17-22319
   SINGH J, 1985, ANN OPHTHALMOL, V17, P382
   Small K W, 1997, Mol Vis, V3, P1
   Small KW, 2019, OPHTHALMOL RETINA, V3, P607, DOI 10.1016/j.oret.2019.03.002
   Small KW, 2016, OPHTHALMOLOGY, V123, P9, DOI 10.1016/j.ophtha.2015.10.006
   SMITH A, 1979, CLIN GENET, V16, P156
   Soudier G, 2020, OPHTHALMOLOGICA, V243, P129, DOI 10.1159/000504051
   Spaide R.F., 2014, PATHOLOGIC MYOPIA, V2nd, P139, DOI [10.1007/978-1-4614-8338-0, DOI 10.1007/978-1-4614-8338-0]
   STUR M, 1988, AM J OPHTHALMOL, V105, P98, DOI 10.1016/0002-9394(88)90135-3
   Sung MS, 2016, OPHTHALMOLOGY, V123, P1484, DOI 10.1016/j.ophtha.2016.03.040
   Sung MS, 2016, OPHTHALMOLOGY, V123, P400, DOI 10.1016/j.ophtha.2015.10.018
   Takahashi H, 2021, OPHTHALMOLOGY, V128, P256, DOI 10.1016/j.ophtha.2020.06.063
   Takahashi H, 2019, AM J OPHTHALMOL, V206, P102, DOI 10.1016/j.ajo.2019.03.011
   Takano M, 1999, AM J OPHTHALMOL, V128, P472, DOI 10.1016/S0002-9394(99)00186-5
   Tan ACS, 2017, RETINA-J RET VIT DIS, V37, P1544, DOI 10.1097/IAE.0000000000001402
   Tarver-Carr ME, 2006, J NEURO-OPHTHALMOL, V26, P282, DOI 10.1097/01.wno.0000249315.04239.20
   Tay E, 2005, AM J OPHTHALMOL, V139, P247, DOI 10.1016/j.ajo.2004.08.076
   TAYLOR D, 1982, BRIT J OPHTHALMOL, V66, P455, DOI 10.1136/bjo.66.7.455
   Teng Y, 2014, GRAEF ARCH CLIN EXP, V252, P241, DOI 10.1007/s00417-013-2459-4
   Tosti G, 1999, OPHTHALMOLOGY, V106, P1453, DOI 10.1016/S0161-6420(99)90472-4
   TSUBOI S, 1984, BRIT J OPHTHALMOL, V68, P869, DOI 10.1136/bjo.68.12.869
   Tsubota Y, 2017, CASE REP OPHTHALM, V8, P53, DOI 10.1159/000453605
   Ueno C, 2014, RETINA-J RET VIT DIS, V34, P497, DOI 10.1097/IAE.0b013e3182a1ca40
   Varenne F, 2017, J FR OPHTALMOL, V40, pE381, DOI 10.1016/j.jfo.2016.07.032
   Villegas VM, 2018, OSLI RETINA, V49, P251, DOI 10.3928/23258160-20180329-07
   Volcker H E, 1979, Mod Probl Ophthalmol, V20, P34
   Vongphanit J, 2002, AM J OPHTHALMOL, V133, P679, DOI 10.1016/S0002-9394(02)01339-9
   Vuori ML, 2007, ACTA OPHTHALMOL SCAN, V85, P648, DOI 10.1111/j.1600-0420.2007.00918.x
   Wang YX, 2021, PROG RETIN EYE RES, V83, DOI 10.1016/j.preteyeres.2020.100933
   Wang YX, 2020, AM J OPHTHALMOL, V217, P91, DOI 10.1016/j.ajo.2020.03.050
   WEITER JJ, 1977, AM J OPHTHALMOL, V83, P569, DOI 10.1016/0002-9394(77)90569-4
   Witmer MT, 2010, SURV OPHTHALMOL, V55, P403, DOI 10.1016/j.survophthal.2010.01.002
   Wolf S, 2014, OPHTHALMOLOGY, V121, P682, DOI 10.1016/j.ophtha.2013.10.023
   Wu PC, 2009, EYE, V23, P356, DOI 10.1038/sj.eye.6703038
   Xu L, 2007, OPHTHALMOLOGY, V114, P121, DOI 10.1016/j.ophtha.2006.05.071
   Xu MP, 2017, RETINA-J RET VIT DIS, V37, P305, DOI 10.1097/IAE.0000000000001140
   Yamagishi T, 2012, RETINA-J RET VIT DIS, V32, P1237, DOI 10.1097/IAE.0b013e318234cae6
   Yamashita T, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0122191
   Yan YN, 2018, OPHTHALMOLOGY, V125, P1253, DOI 10.1016/j.ophtha.2018.01.035
   YAO XY, 1992, ARCH OPHTHALMOL-CHIC, V110, P541, DOI 10.1001/archopht.1992.01080160119047
   Yasui A, 2017, GRAEF ARCH CLIN EXP, V255, P243, DOI 10.1007/s00417-016-3441-8
   Yoon Joo Young, 2019, Korean J Ophthalmol, V33, P520, DOI 10.3341/kjo.2019.0069
   You QS, 2008, EYE, V22, P728, DOI 10.1038/eye.2008.87
   YOUNG SE, 1976, AM J OPHTHALMOL, V82, P16, DOI 10.1016/0002-9394(76)90658-9
   Zhang Q, 2019, INVEST OPHTH VIS SCI, V60, P2591, DOI 10.1167/iovs.19-27331
NR 193
TC 1
Z9 1
U1 5
U2 5
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 1350-9462
EI 1873-1635
J9 PROG RETIN EYE RES
JI Prog. Retin. Eye Res.
PD MAY
PY 2022
VL 88
AR 101020
DI 10.1016/j.preteyeres.2021.101020
PG 28
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 1W4MI
UT WOS:000806748700001
PM 34800679
DA 2022-11-30
ER

PT J
AU Demirel, S
   Yanik, O
   Ozcan, G
   Batioglu, F
   Ozmert, E
AF Demirel, Sibel
   Yanik, Ozge
   Ozcan, Gokcen
   Batioglu, Figen
   Ozmert, Emin
TI A comparative study on the choroidal vascularity index and the
   determination of cut-off values in the pachychoroid spectrum diseases
SO JAPANESE JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE Choroidal vascularity index; Central serous chorioretinopathy;
   Pachychoroid neovasculopathy; Pachychoroid pigment epitheliopathy;
   Polypoidal choroidal vasculopathy
AB Purpose To determine the cut-off levels for choroidal thickness and choroidal vascularity index (CVI) to differentiate among pachychoroid spectrum diseases. Study design A retrospective comparative study Methods A total of 143 eyes were included. Of these 29 had uncomplicated pachychoroid (UCP), 29 had pachychoroid pigment epitheliopathy (PPE), 25 had pachychoroid neovasculopathy (PNV), 30 had central serous chorioretinopathy (CSC), and 30 had polypoidal choroidal vasculopathy (PCV). The choroidal areas were measured with ImageJ software. The CVI, the proportion of the luminal area to the total choroidal area, was assessed. Results The cut-off points of central choroidal thickness were determined as 360 mu m for the PPE and PCV group pair (p < 0.001), 422 mu m for the PNV and CSC group pair (p = 0.026), 271 mu m for the PNV and PCV group pair (p < 0.001), and 341 mu m for the CSC and PCV group pair (p < 0.001). The cut-off points of CVI were 72.7 for the PPE and PCV group pair (p < 0.001), 74.7 for the PNV and CSC group pair (p = 0.005), 72.6 for the PNV and PCV group pair (p = 0.001), and 73.6 for the CSC and PCV group pair (p < 0.001). Conclusion Pachychoroid spectrum may be composed of a combination of distinct choroidal diseases with different vascular and structural characteristics.
C1 [Demirel, Sibel; Yanik, Ozge; Ozcan, Gokcen; Batioglu, Figen; Ozmert, Emin] Ankara Univ, Mamak St Vehbi Koc Eye Hosp, Sch Med, Dept Ophthalmol, Ankara, Turkey.
C3 Ankara University
RP Demirel, S (通讯作者)，Ankara Univ, Mamak St Vehbi Koc Eye Hosp, Sch Med, Dept Ophthalmol, Ankara, Turkey.
EM drsibeldemireltr@yahoo.com.tr
RI Yanık Odabaş, Özge/AAO-6777-2020; özcan, gökçen/ABE-3976-2021; DEMIREL,
   SIBEL/GQH-3232-2022
OI Yanık Odabaş, Özge/0000-0002-1822-8703; özcan,
   gökçen/0000-0002-2616-5941; DEMIREL, SIBEL/0000-0002-2477-9974
CR Agrawal R, 2020, PROG RETIN EYE RES, V77, DOI 10.1016/j.preteyeres.2020.100829
   Agrawal R, 2016, RETINA-J RET VIT DIS, V36, P1646, DOI 10.1097/IAE.0000000000001040
   Agrawal R, 2016, SCI REP-UK, V6, DOI 10.1038/srep21090
   Ambiya Vikas, 2018, Int J Retina Vitreous, V4, P11, DOI 10.1186/s40942-018-0115-1
   Baek J, 2018, GRAEF ARCH CLIN EXP, V256, P2309, DOI 10.1007/s00417-018-4143-1
   Bakthavatsalam M, 2017, GRAEF ARCH CLIN EXP, V255, P935, DOI 10.1007/s00417-017-3591-3
   Bousquet E, 2018, RETINA-J RET VIT DIS, V38, P629, DOI 10.1097/IAE.0000000000001580
   Cheung CMG, 2019, EYE, V33, P14, DOI 10.1038/s41433-018-0158-4
   Cho SC, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-57747-8
   Chung SE, 2013, RETINA-J RET VIT DIS, V33, P834, DOI 10.1097/IAE.0b013e31826af540
   Dansingani KK, 2016, RETINA-J RET VIT DIS, V36, P499, DOI 10.1097/IAE.0000000000000742
   Demirel S, 2020, GRAEF ARCH CLIN EXP, V258, P1649, DOI 10.1007/s00417-020-04740-6
   Ellabban AA, 2013, AM J OPHTHALMOL, V156, P673, DOI 10.1016/j.ajo.2013.05.010
   Gupta P, 2017, RETINA-J RET VIT DIS, V37, P2269, DOI 10.1097/IAE.0000000000001481
   Imamura Y, 2009, RETINA-J RET VIT DIS, V29, P1469, DOI 10.1097/IAE.0b013e3181be0a83
   Karacorlu M, 2018, GRAEF ARCH CLIN EXP, V256, P2319, DOI 10.1007/s00417-018-4144-0
   Kim RY, 2020, RETINA-J RET VIT DIS, V40, P1395, DOI 10.1097/IAE.0000000000002585
   Kishi S, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0206646
   Koh A, 2012, RETINA-J RET VIT DIS, V32, P1453, DOI 10.1097/IAE.0b013e31824f91e8
   Lee K, 2020, GRAEF ARCH CLIN EXP, V258, P1157, DOI 10.1007/s00417-020-04620-z
   Lee M, 2018, INVEST OPHTH VIS SCI, V59, P4896, DOI 10.1167/iovs.18-25018
   Liu B, 2019, CLIN EXP OPHTHALMOL, V47, P631, DOI 10.1111/ceo.13467
   Loo RH, 2002, RETINA-J RET VIT DIS, V22, P19, DOI 10.1097/00006982-200202000-00004
   Matsumoto H, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-51268-9
   Pang CE, 2015, RETINA-J RET VIT DIS, V35, P1, DOI 10.1097/IAE.0000000000000331
   Phasukkijwatana N, 2018, RETINA-J RET VIT DIS, V38, P1652, DOI 10.1097/IAE.0000000000001907
   Sonoda S, 2015, AM J OPHTHALMOL, V159, P1123, DOI 10.1016/j.ajo.2015.03.005
   Sonoda S, 2014, INVEST OPHTH VIS SCI, V55, P3893, DOI 10.1167/iovs.14-14447
   Spaide RF, 1996, OPHTHALMOLOGY, V103, P2070, DOI 10.1016/S0161-6420(96)30386-2
   Spaide RF, 2008, AM J OPHTHALMOL, V146, P496, DOI 10.1016/j.ajo.2008.05.032
   Tan KA, 2015, AM J OPHTHALMOL, V160, P394, DOI 10.1016/j.ajo.2015.04.039
   Ting DSW, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-08276-4
   Yang LH, 2013, ACTA OPHTHALMOL, V91, pE358, DOI 10.1111/aos.12059
NR 33
TC 3
Z9 3
U1 2
U2 4
PU SPRINGER JAPAN KK
PI TOKYO
PA SHIROYAMA TRUST TOWER 5F, 4-3-1 TORANOMON, MINATO-KU, TOKYO, 105-6005,
   JAPAN
SN 0021-5155
EI 1613-2246
J9 JPN J OPHTHALMOL
JI Jpn. J. Ophthalmol.
PD JUL
PY 2021
VL 65
IS 4
BP 482
EP 491
DI 10.1007/s10384-021-00829-5
EA MAR 2021
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA SW0GG
UT WOS:000625751600001
PM 33675486
DA 2022-11-30
ER

PT J
AU Wolf-Schnurrbusch, UEK
   Roosli, N
   Weyermann, E
   Heldner, MR
   Hohne, K
   Wolf, S
AF Wolf-Schnurrbusch, Ute E. K.
   Roeoesli, Nicole
   Weyermann, Eva
   Heldner, Mirjam R.
   Hoehne, Katja
   Wolf, Sebastian
TI Ethnic differences in macular pigment density and distribution
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID AGE-RELATED MACULOPATHY; RISK-FACTORS; OPTICAL-DENSITY; VISUAL
   IMPAIRMENT; HEALTHY-SUBJECTS; HUMAN RETINA; DEGENERATION; LUTEIN;
   ZEAXANTHIN; CAROTENOIDS
AB PURPOSE. Many epidemiologic studies suggest a number of risk factors that may be associated with progression of age-related maculopathy ( ARM). In this study, the authors investigate ethnic differences in macular pigment density (MPD) and macular pigment ( MP) distribution.
   METHODS. Inclusion criteria were healthy subjects, aged 35 to 49 years, visual acuity >= 20/20,race ethnicity white non-Hispanic (WNH) or African. All subjects underwent the following examinations: best-corrected ETDRS visual acuity (VA), measurements of MPD, and spatial distribution of MP with a modified confocal scanning laser ophthalmoscope according to a standard protocol. MPD maps were calculated from autofluorescence images recorded at 488 nm and 514 nm. Central macular pigment density (MPDc) was quantified from MPD maps within 0.5 around the center of the fovea.
   RESULTS. In total, 118 healthy subjects ( 61 women, 57 men) aged 35 to 49 years (mean, 42.5 +/- 3.6 years) were recruited for the study. Sixty-seven healthy subjects were WNH and 51 were African. Visual acuity ranged from 20/20 to 20/16 in the study eye. Significant differences were found among MPDc between the group of WNH ( MPDc, 0.36 +/- 0.13 density units [DU]; P < 0.0001) and African subjects (MPDc, 0.59 +/- 0.14 DU). A parafoveal ring was significantly more frequent in African subjects than in WNH subjects (86% [African] vs. 68% [WNH]; P < 0.0001).
   CONCLUSIONS. This study demonstrates that ethnicity plays a role in MPD values and in MP distribution. The association of different distribution patterns and their relevance as possible prognostic factors for diseases leading to oxidative retinal damage requires further studies.
C1 Univ Med Berlin, Augenklin Charite, Berlin, Germany.
   Univ Bern, Klin & Poliklin Augenheikunde Inselspital, CH-3010 Bern, Switzerland.
C3 Free University of Berlin; Humboldt University of Berlin; Charite
   Universitatsmedizin Berlin; University of Bern
RP Wolf, S (通讯作者)，Univ Bern, Inselspital, Klin & Poliklin Augenheikunde, CH-3010 Bern, Switzerland.
EM sebastian.wolf@insel.ch
RI Wolf, Sebastian/B-8782-2008
OI Wolf, Sebastian/0000-0002-7467-7028; Heldner, Mirjam
   R/0000-0002-3594-2159
CR Beatty S, 1999, BRIT J OPHTHALMOL, V83, P867, DOI 10.1136/bjo.83.7.867
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Beatty S, 2001, INVEST OPHTH VIS SCI, V42, P439
   Berendschot TTJM, 2000, INVEST OPHTH VIS SCI, V41, P3322
   Berendschot TTJM, 2006, INVEST OPHTH VIS SCI, V47, P709, DOI 10.1167/iovs.05-0663
   Berendschot TTJM, 2002, ARCH OPHTHALMOL-CHIC, V120, P1732, DOI 10.1001/archopht.120.12.1732
   Berendschot TTJM, 2002, INVEST OPHTH VIS SCI, V43, P1928
   Bernstein PS, 1998, INVEST OPHTH VIS SCI, V39, P2003
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   BONE RA, 1992, VISION RES, V32, P105, DOI 10.1016/0042-6989(92)90118-3
   Cai JY, 2000, PROG RETIN EYE RES, V19, P205, DOI 10.1016/S1350-9462(99)00009-9
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   DELAPAZ MA, 1992, INVEST OPHTH VIS SCI, V33, P2091
   Delcourt C, 1999, ARCH OPHTHALMOL-CHIC, V117, P1384, DOI 10.1001/archopht.117.10.1384
   Delori FC, 2006, J OPT SOC AM A, V23, P521, DOI 10.1364/JOSAA.23.000521
   Delori FC, 2001, J OPT SOC AM A, V18, P1212, DOI 10.1364/JOSAA.18.001212
   Despriet DDG, 2006, JAMA-J AM MED ASSOC, V296, P301, DOI 10.1001/jama.296.3.301
   Evans JR, 2001, PROG RETIN EYE RES, V20, P227, DOI 10.1016/S1350-9462(00)00023-9
   HAM WT, 1976, NATURE, V260, P153, DOI 10.1038/260153a0
   Hammond BR, 1996, VISION RES, V36, P3003, DOI 10.1016/0042-6989(96)00008-9
   Hammond BR, 2001, ARCH BIOCHEM BIOPHYS, V385, P41, DOI 10.1006/abbi.2000.2184
   Hammond CJ, 2002, OPHTHALMOLOGY, V109, P730, DOI 10.1016/S0161-6420(01)01049-1
   Jahn C, 2005, GRAEF ARCH CLIN EXP, V243, P222, DOI 10.1007/s00417-004-0995-7
   K IGH, 1952, J OPT SOC AM, V42, P529
   Kardys I, 2006, J AM COLL CARDIOL, V47, P1568, DOI 10.1016/j.jacc.2005.11.076
   Khachik F, 1997, INVEST OPHTH VIS SCI, V38, P1802
   Kim SR, 2006, EXP EYE RES, V82, P828, DOI 10.1016/j.exer.2005.10.004
   Klein R, 1997, OPHTHALMOLOGY, V104, P1804, DOI 10.1016/S0161-6420(97)30023-2
   Krinsky NI, 2003, ANNU REV NUTR, V23, P171, DOI 10.1146/annurev.nutr.23.011702.073307
   Lam RF, 2005, CURR EYE RES, V30, P799, DOI 10.1080/02713680590968439
   Landrum JT, 1997, EXP EYE RES, V65, P57, DOI 10.1006/exer.1997.0309
   MARESPERLMAN JA, 1995, ARCH OPHTHALMOL-CHIC, V113, P743, DOI 10.1001/archopht.1995.01100060069034
   McCarty CA, 2001, ARCH OPHTHALMOL-CHIC, V119, P1455
   Milton RC, 2005, OPHTHALMOLOGY, V112, P533, DOI 10.1016/j.ophtha.2004.10.047
   PAULEIKHOFF D, 1990, AM J OPHTHALMOL, V109, P211, DOI 10.1016/S0002-9394(14)75989-6
   PAULEIKHOFF D, 1990, AM J OPHTHALMOL, V109, P38, DOI 10.1016/S0002-9394(14)75576-X
   Rapp LM, 2000, INVEST OPHTH VIS SCI, V41, P1200
   Robson AG, 2003, VISION RES, V43, P1765, DOI 10.1016/S0042-6989(03)00280-3
   SCHACHAT AP, 1995, ARCH OPHTHALMOL-CHIC, V113, P728, DOI 10.1001/archopht.1995.01100060054032
   Sharpe LT, 1998, VISION RES, V38, P3233, DOI 10.1016/S0042-6989(97)00457-4
   SNODDERLY DM, 1995, AM J CLIN NUTR, V62, P1448
   SOMMER A, 1991, NEW ENGL J MED, V325, P1412, DOI 10.1056/NEJM199111143252004
   Tang CY, 2004, OPHTHAL PHYSL OPT, V24, P586, DOI 10.1111/j.1475-1313.2004.00242.x
   van Leeuwen R, 2003, ARCH OPHTHALMOL-CHIC, V121, P519, DOI 10.1001/archopht.121.4.519
   Wustemeyer H, 2003, GRAEF ARCH CLIN EXP, V241, P647, DOI 10.1007/s00417-003-0730-9
   Wustemeyer H, 2002, GRAEF ARCH CLIN EXP, V240, P666, DOI 10.1007/s00417-002-0515-6
   YANNUZZI LA, 1992, ARCH OPHTHALMOL-CHIC, V110, P1701
   YOUNG RW, 1987, SURV OPHTHALMOL, V31, P291, DOI 10.1016/0039-6257(87)90115-9
NR 48
TC 58
Z9 59
U1 0
U2 3
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD AUG
PY 2007
VL 48
IS 8
BP 3783
EP 3787
DI 10.1167/iovs.06-1218
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 199VF
UT WOS:000248722600046
PM 17652752
DA 2022-11-30
ER

PT J
AU Remky, A
   Elsner, AE
AF Remky, A
   Elsner, AE
TI Blue on yellow perimetry with scanning laser ophthalmoscopy in patients
   with age related macular disease
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID WAVELENGTH AUTOMATED PERIMETRY; CONE PHOTOPIGMENT; FUNDUS PERIMETRY;
   CHOROIDAL NEOVASCULARIZATION; RETINAL SENSITIVITY; RETINITIS-PIGMENTOSA;
   FLICKER SENSITIVITY; OPTICAL-DENSITY; VISUAL FUNCTION; DEGENERATION
AB Background/aim: The loss of short wavelength sensitive (SWS) cone mechanism sensitivity is related to severe vision loss in patients with age related maculopathy (ARM). A case-control study of patients with ARM and age matched controls was performed, using blue on yellow static perimetry.
   Methods: A bright yellow background at 594 nm isolated the responses of short wavelength cone mechanisms to 458 nm targets. A scanning laser ophthalmoscope produced stimuli and provided real time, simultaneous fundus illumination. The macula was probed with 16 Goldmann IV targets, 1-10 degrees from fixation, using a staircase method.
   Results: 24 patients with non-exudative ARM were matched to 24 subjects with normal fundus appearance. SWS cone pathway sensitivity for macular targets was significantly reduced in the patients with ARM compared to normals-15.45 (SD 4.56) dB v 17.22 (0.28) dB, respectively (p<0.0005). There was not only a diffuse loss of sensitivity in ARM patients, but also a localised loss of sensitivity over drusen (p<0.025). Neither the mean age, 69 (8) years, nor the mean visual acuity differed between groups, logMAR 0.09 (0.10) v 0.05 (0.06) for ARM patients v normals, respectively. Patients with soft drusen had lower sensitivity than those with hard drusen (p<0.05).
   Conclusion: A loss of SWS cone pathway sensitivity occurred in most patients with early ARM, despite good visual acuity, demonstrating a loss of visual function that cannot be attributed to ageing changes. The loss of sensitivity, despite good visual acuity, included both a diffuse loss and localised losses.
C1 Rhein Westfal TH Aachen, Fak Med, Augenklin, D-52057 Aachen, Germany.
   Harvard Univ, Sch Med, Schepens Eye Res Inst, Boston, MA 02114 USA.
C3 RWTH Aachen University; RWTH Aachen University Hospital; University of
   Hamburg; University Medical Center Hamburg-Eppendorf; Harvard
   University; Harvard Medical School; Schepens Eye Research Institute
RP Remky, A (通讯作者)，Rhein Westfal TH Aachen, Fak Med, Augenklin, Pauwelsstr 30, D-52057 Aachen, Germany.
EM andreas.remky@post.rwth-aachen.de
FU NEI NIH HHS [R01 EY007624, EY007624] Funding Source: Medline; NATIONAL
   EYE INSTITUTE [R29EY007624, R01EY007624] Funding Source: NIH RePORTER
CR APPLEGATE RA, 1987, APPL OPTICS, V26, P1458, DOI 10.1364/AO.26.001458
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   BURNS SA, 1988, APPL OPTICS, V27, P1045, DOI 10.1364/AO.27.001045
   CHEN JF, 1992, CLIN VISION SCI, V7, P521
   CROGNALE MA, 1993, COLOUR VISION DEFICI, V11, P229
   EISNER A, 1991, INVEST OPHTH VIS SCI, V32, P8
   EISNER A, 1992, INVEST OPHTH VIS SCI, V33, P3091
   Elsner AE, 1998, INVEST OPHTH VIS SCI, V39, P2394
   ELSNER AE, 1992, APPL OPTICS, V31, P3697, DOI 10.1364/AO.31.003697
   Elsner AE, 1996, VISION RES, V36, P191, DOI 10.1016/0042-6989(95)00100-E
   Elsner AE, 2002, J OPT SOC AM A, V19, P215, DOI 10.1364/JOSAA.19.000215
   ELSNER AE, 1987, APPL OPTICS, V26, P1378, DOI 10.1364/AO.26.001378
   ELSNER AE, 1987, INVEST OPHTH VIS SCI, V28, P718
   ELSNER AE, 1989, 1989 TECHNICAL DIGES, V20
   ELSNER AE, 1998, VISION SCI ITS APPL, V1, P14
   Falsini B, 1999, GRAEF ARCH CLIN EXP, V237, P193, DOI 10.1007/s004170050218
   Falsini B, 2000, INVEST OPHTH VIS SCI, V41, P1498
   FLANAGAN JG, 1993, GRAEF ARCH CLIN EXP, V231, P465, DOI 10.1007/BF02044233
   Fletcher D. C., 1994, OPHTHALMOLOGY CLIN N, V7, P257
   FUNKHOUSER AT, 1992, GRAEF ARCH CLIN EXP, V230, P243, DOI 10.1007/BF00176298
   GREENSTEIN VC, 1989, INVEST OPHTH VIS SCI, V30, P1732
   HAEGERSTROMPORTNOY G, 1989, CLIN VISION SCI, V4, P165
   Hartnett ME, 1996, OPHTHALMOLOGY, V103, P58, DOI 10.1016/S0161-6420(96)30731-8
   Hartnett ME, 1996, OPHTHALMOLOGY, V103, P2042, DOI 10.1016/S0161-6420(96)30389-8
   JOHNSON CA, 1993, ARCH OPHTHALMOL-CHIC, V111, P645, DOI 10.1001/archopht.1993.01090050079034
   KUHN D, 1995, ARCH OPHTHALMOL-CHIC, V113, P1392, DOI 10.1001/archopht.1995.01100110052025
   Leibowitz H M, 1980, Surv Ophthalmol, V24, P335
   Li J, 2001, BRIT J OPHTHALMOL, V85, P287, DOI 10.1136/bjo.85.3.287
   Loewenstein A, 1998, AM J OPHTHALMOL, V125, P657, DOI 10.1016/S0002-9394(98)00014-2
   Maguire MG, 1997, ARCH OPHTHALMOL-CHIC, V115, P741
   Marre M, 1986, ERWORBENE STORUNGEN
   MAYER MJ, 1992, INVEST OPHTH VIS SCI, V33, P3136
   MAYER MJ, 1994, INVEST OPHTH VIS SCI, V35, P1138
   McKeefry DJ, 2003, INVEST OPHTH VIS SCI, V44, P2267, DOI 10.1167/iovs.02-0772
   Remky A, 1996, INVEST OPHTH VIS SCI, V37, P2350
   Remky A, 2001, J OPT SOC AM A, V18, P1425, DOI 10.1364/JOSAA.18.001425
   Remky A, 2001, BRIT J OPHTHALMOL, V85, P1432, DOI 10.1136/bjo.85.12.1432
   Remky A, 2000, INVEST OPHTH VIS SCI, V41, P274
   Rohrschneider K, 1997, BRIT J OPHTHALMOL, V81, P568, DOI 10.1136/bjo.81.7.568
   Rohrschneider K, 1995, Ger J Ophthalmol, V4, P197
   SAMPLE PA, 1990, INVEST OPHTH VIS SCI, V31, P1869
   SARKS SH, 1980, AUST J OPHTHALMOL, V8, P117, DOI 10.1111/j.1442-9071.1980.tb01670.x
   SCHUCHARD RA, 1992, CLIN VISION SCI, V7, P511
   Schuchard RA, 1994, CLIN EYE VISION CARE, V6, P101
   SMIDDY WE, 1984, OPHTHALMOLOGY, V91, P271
   SUNNESS JS, 1987, APPL OPTICS, V26, P1487, DOI 10.1364/AO.26.001487
   SUNNESS JS, 1995, INVEST OPHTH VIS SCI, V36, P1863
   SUNNESS JS, 1988, ARCH OPHTHALMOL-CHIC, V106, P1081, DOI 10.1001/archopht.1988.01060140237032
   Sunness JS, 1997, OPHTHALMOLOGY, V104, P1677, DOI 10.1016/S0161-6420(97)30079-7
   SUNNESS JS, 1989, OPHTHALMOLOGY, V96, P357
   Takamine Y, 1998, GRAEF ARCH CLIN EXP, V236, P285, DOI 10.1007/s004170050079
   TIMBERLAKE GT, 1986, INVEST OPHTH VIS SCI, V27, P1137
   Toonen F, 1995, Ger J Ophthalmol, V4, P311
NR 53
TC 25
Z9 26
U1 0
U2 1
PU B M J PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD APR
PY 2005
VL 89
IS 4
BP 464
EP 469
DI 10.1136/bjo.2004.050260
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 907JU
UT WOS:000227713800017
PM 15774925
OA Green Submitted, Bronze, Green Published, Green Accepted
DA 2022-11-30
ER

PT J
AU Giorio, G
   Yildirim, A
   Stigliani, AL
   D'Ambrosio, C
AF Giorio, Giovanni
   Yildirim, Arzu
   Stigliani, Adriana Lucia
   D'Ambrosio, Caterina
TI Elevation of lutein content in tomato: A biochemical tug-of-war between
   lycopene cyclases
SO METABOLIC ENGINEERING
LA English
DT Article
DE Tomato; Lutein; Lycopene cyclase; Relative cyclase activity ratio;
   Carotenoids; Genetically modified organisms
ID PERFORMANCE LIQUID-CHROMATOGRAPHY; CAROTENOID BIOSYNTHESIS;
   EPSILON-CYCLASE; ZEAXANTHIN SUPPLEMENTATION; LYCOPERSICON-ESCULENTUM;
   COLOR MUTATIONS; BETA-CAROTENE; FRUIT; PLANT; EXPRESSION
AB Lutein is becoming increasingly important in preventive medicine due to its possible role in maintaining good vision and in preventing age-related maculopathy. Average daily lutein intake in developed countries is often below suggested daily consumption levels, and lutein supplementation could be beneficial. Lutein is also valuable in the food and feed industries and is emerging in nutraceutical and pharmaceutical markets. Currently, lutein is obtained at high cost from marigold petals, and synthesis alternatives are thus desirable. Tomato constitutes a promising starting system for production as it naturally accumulates high levels of lycopene. To develop tomato for lutein synthesis, the tomato Red Setter cultivar was transformed with the tomato lycopene e-cyclase-encoding gene under the control of a constitutive promoter, and the HighDelta (HD) line, characterised by elevated lutein and delta-carotene content in ripe fruits, was selected. HD was crossed to the transgenic RC line and to RSB with the aim of converting all residual fruit delta-carotene to lutein. Fruits of both crosses were enriched in lutein and presented unusual carotenoid profiles. The unique genetic background of the crosses used in this study permitted an unprecedented analysis of the role and regulation of the lycopene cyclase enzymes in tomato.
   A new defined biochemical index, the relative cyclase activity ratio, was used to discern post-transcriptional regulation of cyclases, and will help in the study of carotenoid biosynthesis in photosynthetic plant species and particularly in those, like tomato, that have been domesticated for the production of food, feed or useful by (C) 2013 International Metabolic Engineering Society. Published by Elsevier Inc. All rights reserved
C1 [Giorio, Giovanni; Stigliani, Adriana Lucia; D'Ambrosio, Caterina] ALSIA Ctr Ric Metapontum Agrobios, I-75012 Metaponto, MT, Italy.
   [Yildirim, Arzu] Dept Bioengn, Bornova-Izmir, Turkey.
RP Giorio, G (通讯作者)，ALSIA Ctr Ric Metapontum Agrobios, SS Jonica Km 448-2, I-75012 Metaponto, MT, Italy.
EM giovanni.giorio@alsia.it
RI yıldırım, arzu/V-8702-2019; YILDIRIM, ARZU/ABF-2032-2022
OI YILDIRIM, ARZU/0000-0001-9836-3181; D'Ambrosio,
   Caterina/0000-0002-2984-5942; STIGLIANI, ADRIANA
   LUCIA/0000-0002-9989-6235
FU European Commission [244348]
FX This study was partially supported by the European Commission FP7
   program (project METAPRO, nr. 244348).
CR Aguilar F, 2011, EFSA J, V9, DOI 10.2903/j.efsa.2011.2144
   Alonso AP, 2011, METAB ENG, V13, P96, DOI 10.1016/j.ymben.2010.10.002
   Anunciato TP, 2012, J COSMET DERMATOL-US, V11, P51, DOI 10.1111/j.1473-2165.2011.00600.x
   Bai L, 2009, PLANT J, V59, P588, DOI 10.1111/j.1365-313X.2009.03899.x
   BEVAN M, 1984, NUCLEIC ACIDS RES, V12, P8711, DOI 10.1093/nar/12.22.8711
   Bone RA, 2010, ARCH BIOCHEM BIOPHYS, V504, P50, DOI 10.1016/j.abb.2010.06.019
   Britton G., 2004, CAROTENOIDS HDB, DOI 10.1080/10715760410001727849
   Bustin SA, 2009, CLIN CHEM, V55, P611, DOI 10.1373/clinchem.2008.112797
   Butelli E, 2008, NAT BIOTECHNOL, V26, P1301, DOI 10.1038/nbt.1506
   Cunningham FX, 1998, ANNU REV PLANT PHYS, V49, P557, DOI 10.1146/annurev.arplant.49.1.557
   D'Ambrosio C, 2004, PLANT SCI, V166, P207, DOI 10.1016/j.plantsci.2003.09.015
   D'Ambrosio C, 2011, TRANSGENIC RES, V20, P47, DOI 10.1007/s11248-010-9387-4
   DellaPenna D, 2006, ANNU REV PLANT BIOL, V57, P711, DOI 10.1146/annurev.arplant.56.032604.144301
   Dharmapuri S, 2002, FEBS LETT, V519, P30, DOI 10.1016/S0014-5793(02)02699-6
   ESHED Y, 1994, EUPHYTICA, V79, P175, DOI 10.1007/BF00022516
   Fernandez-Sevilla JM, 2010, APPL MICROBIOL BIOT, V86, P27, DOI 10.1007/s00253-009-2420-y
   Fraser PD, 2007, PLANT CELL, V19, P3194, DOI 10.1105/tpc.106.049817
   Fraser PD, 2000, PLANT J, V24, P551, DOI [10.1046/j.1365-313x.2000.00896.x, 10.1111/j.1365-313X.2000.00896.x]
   Galpaz N, 2006, PLANT CELL, V18, P1947, DOI 10.1105/tpc.105.039966
   Gao SS, 2011, MOL VIS, V17, P3180
   Giorio G, 2007, TRANSGENIC RES, V16, P15, DOI 10.1007/s11248-006-9025-3
   Giorio P, 2012, ENVIRON EXP BOT, V75, P1, DOI 10.1016/j.envexpbot.2011.08.009
   Harjes CE, 2008, SCIENCE, V319, P330, DOI 10.1126/science.1150255
   Huang JC, 2013, METAB ENG, V17, P59, DOI 10.1016/j.ymben.2013.02.005
   Hwang ES, 2012, J FOOD SCI, V77, pC1109, DOI 10.1111/j.1750-3841.2012.02909.x
   Johnson EJ, 2010, J AM DIET ASSOC, V110, P1357, DOI 10.1016/j.jada.2010.06.009
   Kachanovsky DE, 2012, P NATL ACAD SCI USA, V109, P19021, DOI 10.1073/pnas.1214808109
   Karppi J, 2012, BRIT J NUTR, V108, P148, DOI 10.1017/S0007114511005332
   Kijlstra A, 2012, PROG RETIN EYE RES, V31, P303, DOI 10.1016/j.preteyeres.2012.03.002
   Kim J, 2006, P NATL ACAD SCI USA, V103, P3474, DOI 10.1073/pnas.0511207103
   Kumar S, 2012, METAB ENG, V14, P19, DOI 10.1016/j.ymben.2011.11.005
   Li ZR, 2009, PLANT CELL, V21, P1798, DOI 10.1105/tpc.109.066571
   LOPEZGOMEZ R, 1992, HORTSCIENCE, V27, P440, DOI 10.21273/HORTSCI.27.5.440
   Ma L, 2012, AM J OPHTHALMOL, V154, P625, DOI 10.1016/j.ajo.2012.04.014
   Moco S, 2007, J EXP BOT, V58, P4131, DOI 10.1093/jxb/erm271
   Naqvi S, 2011, PLANT BIOTECHNOL J, V9, P384, DOI 10.1111/j.1467-7652.2010.00554.x
   Pan Y, 2013, PLANT PHYSIOL, V161, P1476, DOI 10.1104/pp.112.212654
   Pecker I, 1996, PLANT MOL BIOL, V30, P807, DOI 10.1007/BF00019013
   Peterson DG, 1997, PLANT MOL BIOL REP, V15, P148, DOI 10.1007/BF02812265
   Pogson B, 1996, PLANT CELL, V8, P1627, DOI 10.1105/tpc.8.9.1627
   Romer S, 2002, METAB ENG, V4, P263, DOI 10.1006/mben.2002.0234
   Ronen G, 2000, P NATL ACAD SCI USA, V97, P11102, DOI 10.1073/pnas.190177497
   Ronen G, 1999, PLANT J, V17, P341, DOI 10.1046/j.1365-313X.1999.00381.x
   Shegokar Ranjita, 2012, Journal of Dietary Supplements, V9, P183, DOI 10.3109/19390211.2012.708716
   Silletti MF, 2013, MOL BREEDING, V31, P665, DOI 10.1007/s11032-012-9824-6
   Stigliani AL, 2011, PLANT CELL PHYSIOL, V52, P851, DOI 10.1093/pcp/pcr037
   Sugiyama A, 2011, METAB ENG, V13, P629, DOI 10.1016/j.ymben.2011.07.003
   Taylor KL, 2006, J CHROMATOGR A, V1121, P83, DOI 10.1016/j.chroma.2006.04.033
   VANROEKEL JSC, 1993, PLANT CELL REP, V12, P644, DOI 10.1007/BF00232816
   Yu QJ, 2012, FEBS LETT, V586, P3415, DOI 10.1016/j.febslet.2012.07.060
NR 50
TC 28
Z9 30
U1 0
U2 54
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 1096-7176
EI 1096-7184
J9 METAB ENG
JI Metab. Eng.
PD NOV
PY 2013
VL 20
BP 167
EP 176
DI 10.1016/j.ymben.2013.10.007
PG 10
WC Biotechnology & Applied Microbiology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biotechnology & Applied Microbiology
GA 267ES
UT WOS:000328080100018
PM 24141052
DA 2022-11-30
ER

PT J
AU Tanaka, K
   Mori, R
   Wakatsuki, Y
   Onoe, H
   Kawamura, A
   Nakashizuka, H
AF Tanaka, Koji
   Mori, Ryusaburo
   Wakatsuki, Yu
   Onoe, Hajime
   Kawamura, Akiyuki
   Nakashizuka, Hiroyuki
TI Two-Thirds Dose Photodynamic Therapy for Pachychoroid Neovasculopathy
SO JOURNAL OF CLINICAL MEDICINE
LA English
DT Article
DE PNV; OCT angiography; 2; 3PDT
ID CENTRAL SEROUS CHORIORETINOPATHY; ONE-YEAR OUTCOMES; INTRAVITREAL
   AFLIBERCEPT; NEOVASCULARIZATION; VERTEPORFIN
AB Pachychoroid neovasculopathy (PNV) is treated with antivascular endothelial growth factor (VEGF) injection and photodynamic therapy (PDT), but no curative treatment has yet been established. We aimed to clarify the treatment results of a reduced dose of PDT for PNV. The subjects were 27 eyes of 27 patients (male:female = 20:7, mean age 58.9 years). PDT, at 2/3 of the conventional dose (2/3PDT), was administered once. The patients were then observed for one year. Eyes with polypoidal choroidal vasculopathy (PCV) were excluded. We investigated the associations among the central retinal thickness, choroidal thickness, and visual acuity changes before treatment and one, three, six and 12 months after PDT. When serous retinal detachment was increased or unchanged or new hemorrhages were observed, as compared with pretreatment findings, intravitreal injection of an anti-VEGF agent was performed. Visual acuity was significantly improved, as compared to before treatment, at three, six, and 12 months after 2/3PDT. Foveal retinal thickness was significantly decreased after versus before treatment in the 2/3PDT group (p < 0.001). Foveal choroidal thickness was also significantly reduced in the 2/3PDT group (p = 0.001). Additional intravitreal anti-VEGF agent injections were administered to three patients (11%), while 24 (89%) required no additional treatment during the one-year follow-up period. For PNV without polyps, 2/3PDT appears to be effective.
C1 [Tanaka, Koji; Mori, Ryusaburo; Wakatsuki, Yu; Onoe, Hajime; Kawamura, Akiyuki; Nakashizuka, Hiroyuki] Nihon Univ, Sch Med, Dept Ophthalmol, Tokyo 1018309, Japan.
C3 Nihon University
RP Tanaka, K (通讯作者)，Nihon Univ, Sch Med, Dept Ophthalmol, Tokyo 1018309, Japan.
EM tanaka.koji@nihon-u.ac.jp; mori.ryusaburo@nihon-u.ac.jp;
   wakatsuki.yu@nihon-u.ac.jp; onoe.hajime@nihon-u.ac.jp;
   kw-eye-c@xb3.so-net.ne.jp; nakashizuka.hiroyuki@nihon-u.ac.jp
OI Tanaka, Koji/0000-0003-3323-4148
CR Akaza E, 2011, JPN J OPHTHALMOL, V55, P39, DOI 10.1007/s10384-010-0886-x
   Cheung CMG, 2019, EYE, V33, P14, DOI 10.1038/s41433-018-0158-4
   Cho HJ, 2019, J OCUL PHARMACOL TH, V35, P174, DOI 10.1089/jop.2018.0107
   Fujita K, 2015, OPHTHALMOLOGY, V122, P555, DOI 10.1016/j.ophtha.2014.09.034
   Fung AT, 2012, RETINA-J RET VIT DIS, V32, P1829, DOI 10.1097/IAE.0b013e3182680a66
   Hata M, 2017, INVEST OPHTH VIS SCI, V58, P292, DOI 10.1167/iovs.16-20967
   Jung BJ, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-38504-y
   Kitajima Y, 2020, GRAEF ARCH CLIN EXP, V258, P1279, DOI 10.1007/s00417-020-04661-4
   Lai TYY, 2006, BRIT J OPHTHALMOL, V90, P869, DOI 10.1136/bjo.2006.090282
   Lee JH, 2016, RETINA-J RET VIT DIS, V36, P889, DOI 10.1097/IAE.0000000000000809
   Matsumoto H, 2020, JPN J OPHTHALMOL, V64, P203, DOI 10.1007/s10384-020-00722-7
   Matsumoto H, 2018, JPN J OPHTHALMOL, V62, P144, DOI 10.1007/s10384-018-0562-0
   Miyata M, 2019, BRIT J OPHTHALMOL, V103, P617, DOI 10.1136/bjophthalmol-2018-311963
   Pang CE, 2015, RETINA-J RET VIT DIS, V35, P1, DOI 10.1097/IAE.0000000000000331
   PICCOLINO FC, 1994, RETINA-J RET VIT DIS, V14, P231, DOI 10.1097/00006982-199414030-00008
   Shiragami C, 2018, AM J OPHTHALMOL, V193, P80, DOI 10.1016/j.ajo.2018.06.009
   Smretschnig E, 2016, EYE, V30, P805, DOI 10.1038/eye.2016.41
   Son BK, 2019, OPHTHALMOLOGICA, V241, P105, DOI 10.1159/000490773
   Spaide RF, 2002, RETINA-J RET VIT DIS, V22, P529, DOI 10.1097/00006982-200210000-00001
   Warrow DJ, 2013, RETINA-J RET VIT DIS, V33, P1659, DOI 10.1097/IAE.0b013e3182953df4
   Yamamoto A, 2015, OPHTHALMOLOGY, V122, P1866, DOI 10.1016/j.ophtha.2015.05.024
   Yanagi Y, 2018, RETINA-J RET VIT DIS, V38, P1509, DOI 10.1097/IAE.0000000000001758
NR 22
TC 1
Z9 1
U1 0
U2 0
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2077-0383
J9 J CLIN MED
JI J. Clin. Med.
PD MAY
PY 2021
VL 10
IS 10
AR 2168
DI 10.3390/jcm10102168
PG 9
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA SI6MA
UT WOS:000654940800001
PM 34067863
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Priya, BV
   Gupta, I
   Poornachandra, B
   Jayadev, C
   Pereira, A
   Mohapatra, A
   Krishna, SG
   Yadav, NK
AF Priya, B., V
   Gupta, Ishank
   Poornachandra, B.
   Jayadev, Chaitra
   Pereira, Arpitha
   Mohapatra, Ayushi
   Krishna, Santosh G.
   Yadav, Naresh K.
TI Morphological features of focal choroidal excavation and its association
   with macular pathology in Asian Indian eyes
SO INDIAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE Bowl shape; cone shape; conforming; focal choroidal excavation;
   nonconforming
AB Purpose: To study the characteristics of focal choroidal excavation (FCE) in Indian eyes based on spectral-domain optical coherence tomography (SD-OCT) findings and their association with macular pathologies. Methods: Retrospective study of 26 patients diagnosed with FCE. All patients' clinical and imaging data were reviewed. Results: There were eight females and 18 males aged between 24 and 85 years. FCE was noted in 31 eyes of 26 patients - unilateral in 21 and bilateral in 5. The conforming type was noted in 13 and nonconforming in 19 eyes. The location was extrafoveal in 16 and subfoveal in 15 eyes. The morphology was bowl-shaped in 24, cone-shaped in six eyes, and mixed type in one eye. Associated pathologies were central serous chorioretinopathy in nine eyes, choroidal neovascular membrane in seven eyes, Stargardt's disease in three eyes, Best disease in four eyes, other retinal dystrophies in two eyes, polypoidal choroidal vasculopathy and moderate non-proliferative diabetic retinopathy, each in one eye. The mean FCE width was 1667.2 +/- 817.7 mu, mean depth was 95.7 +/- 46.4 mu, and the mean choroidal thickness under the FCE was 234.8 +/- 85.9 mu. No abnormal choroidal tissue was found under any FCE. Conclusion: FCE is a relatively common entity and frequently associated with macular pathologies. The presence of an FCE did not alter the course or management of these conditions.
C1 [Priya, B., V; Gupta, Ishank; Poornachandra, B.; Jayadev, Chaitra; Pereira, Arpitha; Mohapatra, Ayushi; Krishna, Santosh G.; Yadav, Naresh K.] Narayana Nethralaya Eye Inst, Dept Vitreoretina, Bangalore, Karnataka, India.
RP Poornachandra, B (通讯作者)，Narayana Nethralaya Eye Inst, 121-C Chord Rd,1st R Block, Bangalore 560010, Karnataka, India.
EM punith.poorna@gmail.com
CR Chung CY, 2017, EYE, V31, P1373, DOI 10.1038/eye.2017.71
   Ellabban AA, 2013, AM J OPHTHALMOL, V156, P673, DOI 10.1016/j.ajo.2013.05.010
   Guo J, 2014, BMC OPHTHALMOL, V14, DOI 10.1186/1471-2415-14-63
   Jampol LM, 2006, RETINA-J RET VIT DIS, V26, P1072, DOI 10.1097/01.iae.0000248819.86737.a5
   Kobayashi W, 2012, CLIN OPHTHALMOL, V6, P1373, DOI 10.2147/OPTH.S33879
   Kuroda Y, 2014, INVEST OPHTH VIS SCI, V55, P6046, DOI 10.1167/iovs.14-14723
   Lee CS, 2014, OPHTHALMOLOGY, V121, P1029, DOI 10.1016/j.ophtha.2013.11.043
   Lim FPM, 2016, BRIT J OPHTHALMOL, V100, P918, DOI 10.1136/bjophthalmol-2015-307055
   Margolis R, 2011, ARCH OPHTHALMOL-CHIC, V129, P1320, DOI 10.1001/archophthalmol.2011.148
   Obata R, 2013, RETINA-J RET VIT DIS, V33, P1201, DOI 10.1097/IAE.0b013e31827b6452
   Say EAT, 2013, OPHTHAL SURG LAS IM, V44, P409, DOI 10.3928/23258160-20130715-12
   Shinojima A, 2014, RETINA-J RET VIT DIS, V34, P1407, DOI 10.1097/IAE.0000000000000108
   Suzuki M, 2014, RETINA-J RET VIT DIS, V34, P1216, DOI 10.1097/IAE.0000000000000045
   Wang Y, 2016, J OPHTHALMOL, V2016, DOI 10.1155/2016/7073083
   Xu HF, 2014, OPHTHALMOLOGY, V121, P246, DOI 10.1016/j.ophtha.2013.08.014
NR 15
TC 0
Z9 0
U1 0
U2 0
PU WOLTERS KLUWER MEDKNOW PUBLICATIONS
PI MUMBAI
PA WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2
   VILLAGE MAROL, ANDHERI EAST, MUMBAI, 400059, INDIA
SN 0301-4738
EI 1998-3689
J9 INDIAN J OPHTHALMOL
JI Indian J. Ophthalmol.
PD APR
PY 2021
VL 69
IS 4
BP 886
EP 889
DI 10.4103/ijo.IJO_569_20
PG 4
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA RF1YF
UT WOS:000634641100022
PM 33727453
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Baek, J
   Park, YH
AF Baek, Jiwon
   Park, Young-Hoon
TI Optical Density Ratio in the Subretinal Fluid: Differentiating Chronic
   Central Serous Chorioretinopathy and Polypodial Choroidal Vasculopathy
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID COHERENCE TOMOGRAPHY; RETINAL DETACHMENTS; ANGIOGRAPHY; FLUORESCEIN
AB PURPOSE: To investigate the differences in the optical density ratios between chronic central serous chorioretinopathy (CSC) and polypoidal choroidal vasculopathy (PCV) obtained from subretinal fluid (SRF) analyses to identify the diagnostic role of optical density ratios.
   DESIGN: Retrospective cohort study.
   METHODS: Patients with acute CSC (n = 36), chronic CSC (n = 38), and PCV (n = 32) were included in the study. Spectral-domain optical coherence tomography (SD OCT) images of SRF were analyzed. The optical density measurements were obtained by using ImageJ. The optical density ratios were calculated from the SRF to the vitreous, retinal pigment epithelium (RPE), and retinal nerve fiber layer (RNFL) reflectivity ratios.
   RESULTS: Optical density ratios of SRF to the vitreous, RPE, and RNFL were significantly higher in patients with PCV than in those with chronic CSC (P = .002, P = .001, P = .001). There was no significant difference between acute and chronic CSC (P = .358, P = .433, P = .774). RPE reflectivity was significantly different between groups (P = .002) but no significant difference in vitreous and RNFL reflectivity were detected between groups (P = .172, P = .171).
   CONCLUSIONS: The optical density ratio differs significantly between chronic CSC and PCV, but not between chronic and acute CSC. This suggests the usefulness of this parameter in differentiating between chronic CSC resembling PCV and PCV itself. (C) 2015 by Elsevier Inc. All rights reserved.
C1 [Baek, Jiwon; Park, Young-Hoon] Catholic Univ Korea, Coll Med, Dept Ophthalmol & Visual Sci, Seoul 137701, South Korea.
C3 Catholic University of Korea
RP Park, YH (通讯作者)，Catholic Univ Korea, Coll Med, Dept Ophthalmol & Visual Sci, 505 Banpo Dong, Seoul 137701, South Korea.
EM parkyh@catholic.ac.kr
OI Baek, Jiwon/0000-0001-6736-5379
CR Ahlers C, 2009, INVEST OPHTH VIS SCI, V50, P3417, DOI 10.1167/iovs.08-2759
   Ahn SJ, 2012, OPHTHAL SURG LAS IM, V43, P374, DOI 10.3928/15428877-20120628-01
   [Anonymous], 2008, SPECTR QUICKG SOFTW, V7, P11
   Dubois A, 2002, APPL OPTICS, V41, P805, DOI 10.1364/AO.41.000805
   GUYER DR, 1994, ARCH OPHTHALMOL-CHIC, V112, P1057, DOI 10.1001/archopht.1994.01090200063023
   HARA S, 1987, ARCH OPHTHALMOL-CHIC, V105, P260
   Hartig SM, 2013, CURR PROTOC MOL BIOL, V102
   Iida T, 1999, RETINA-J RET VIT DIS, V19, P508, DOI 10.1097/00006982-199911000-00005
   LEVINE R, 1989, OPHTHALMOLOGY, V96, P854
   Neudorfer M, 2012, INVEST OPHTH VIS SCI, V53, P3104, DOI 10.1167/iovs.11-8700
   Ooto S, 2010, GRAEF ARCH CLIN EXP, V248, P1077, DOI 10.1007/s00417-010-1338-5
   PICCOLINO FC, 1994, RETINA-J RET VIT DIS, V14, P231, DOI 10.1097/00006982-199414030-00008
   Prunte C, 1996, AM J OPHTHALMOL, V121, P26
   Sasahara M, 2006, AM J OPHTHALMOL, V142, P601, DOI 10.1016/j.ajo.2006.05.051
   SCHEIDER A, 1993, AM J OPHTHALMOL, V115, P50, DOI 10.1016/S0002-9394(14)73524-X
   Spaide RF, 1996, OPHTHALMOLOGY, V103, P2070, DOI 10.1016/S0161-6420(96)30386-2
   SPAIDE RF, 1996, OPHTHALMOLOGY, V103, P2079
   Srinivasan VJ, 2006, OPHTHALMOLOGY, V113, P2054, DOI 10.1016/j.ophtha.2006.05.046
   YANNUZZI LA, 1984, OPHTHALMOLOGY, V91, P1554
   Yannuzzi LA, 1997, ARCH OPHTHALMOL-CHIC, V115, P478, DOI 10.1001/archopht.1997.01100150480005
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
   Yannuzzi LA, 2000, OPHTHALMOLOGY, V107, P767, DOI 10.1016/S0161-6420(99)00173-6
NR 22
TC 14
Z9 14
U1 0
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-9394
EI 1879-1891
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD FEB
PY 2015
VL 159
IS 2
BP 386
EP 392
DI 10.1016/j.ajo.2014.11.011
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA CA0WM
UT WOS:000348634300022
PM 25447112
DA 2022-11-30
ER

PT J
AU Sheth, J
   Anantharaman, G
   Chandra, S
   Sivaprasad, S
AF Sheth, Jay
   Anantharaman, Giridhar
   Chandra, Shruti
   Sivaprasad, Sobha
TI "Double-layer sign" on spectral domain optical coherence tomography in
   pachychoroid spectrum disease
SO INDIAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE Branching vascular network; chronic central serous chorioretinopathy;
   double-layer sign; optical coherence tomography; polypoidal choroidal
   vasculopathy
ID POLYPOIDAL CHOROIDAL VASCULOPATHY; ANGIOGRAPHY; FEATURES
AB Purpose: The "double-layer sign (DLS)" describes the shallow and irregular elevation of the retinal pigment epithelium from the underlying intact Bruch's membrane visualized on the spectral domain optical coherence tomography. In this study, we evaluated the frequency, characteristics of the space within the double layer and other features in the pachychoroid spectrum to aid the clinical diagnosis of these variants. Methods: This retrospective study evaluated the features of the DLS on multimodal imaging in consecutive patients with a clinical diagnosis of one of the four variants of pachychoroid: pachychoroid pigment epitheliopathy (PPE), pachychoroid neovasculopathy (PCN), chronic central serous chorioretinopathy (CCSCR), and polypoidal choroidal vasculopathy (PCV). The features of the DLS were graded by two masked graders. Results: Overall, 102 eyes of 79 consecutive patients with pachychoroid spectrum were identified for grading. Sixteen eyes with PPE did not show any evidence of DLS. The DLS was identified in 15/16 (93.75%) eyes with PCN, 11/35 (31.43%) with CCSCR, and 32/35 (91.43%) with PCV (P < 0.001). The space within the DLS showed moderate hyperreflectivity in all eyes with PCV and PCN, while the space in the DLS in CCSCR showed uniform hyporeflectivity in 10/11 (%) eyes. Conclusion: The DLS sign was most frequent in polypoidal vasculopathy and PCN. A hyporeflective gap within the DLS favored the diagnosis of CCSCR.
C1 [Sheth, Jay; Anantharaman, Giridhar; Chandra, Shruti] Giridhar Eye Inst, Dept Vitreoretina, Ponneth Temple Rd, Kochi 682020, Kerala, India.
   [Sivaprasad, Sobha] NIHR Moorfields Biomed Res Ctr, London EC1V 2PD, England.
RP Sheth, J (通讯作者)，Giridhar Eye Inst, Dept Vitreoretina, Ponneth Temple Rd, Kochi 682020, Kerala, India.
EM drjay009@gmail.com
RI Sivaprasad, S./D-6876-2015; Sheth, Jay/AAZ-6612-2020
OI Sivaprasad, S./0000-0001-8952-0659; 
CR Anantharaman G, 2010, INDIAN J OPHTHALMOL, V58, P399, DOI 10.4103/0301-4738.67052
   Dansingani KK, 2016, RETINA-J RET VIT DIS, V36, P499, DOI 10.1097/IAE.0000000000000742
   Dansingani KK, 2015, AM J OPHTHALMOL, V160, P1243, DOI 10.1016/j.ajo.2015.08.028
   De Salvo G, 2014, AM J OPHTHALMOL, V158, P1228, DOI 10.1016/j.ajo.2014.08.025
   GUYER DR, 1994, ARCH OPHTHALMOL-CHIC, V112, P1057, DOI 10.1001/archopht.1994.01090200063023
   Liu R, 2016, RETINA-J RET VIT DIS, V36, P778, DOI 10.1097/IAE.0000000000000794
   Nicholson B, 2013, SURV OPHTHALMOL, V58, P103, DOI 10.1016/j.survophthal.2012.07.004
   Oishi A, 2011, EYE, V25, P1020, DOI 10.1038/eye.2011.110
   Ojima Y, 2009, RETINA-J RET VIT DIS, V29, P52, DOI 10.1097/IAE.0b013e3181884fbf
   Pang CE, 2015, RETINA-J RET VIT DIS, V35, P1, DOI 10.1097/IAE.0000000000000331
   Pang CE, 2014, AM J OPHTHALMOL, V158, P362, DOI 10.1016/j.ajo.2014.04.021
   Sato T, 2007, RETINA-J RET VIT DIS, V27, P589, DOI 10.1097/01.iae.0000249386.63482.05
   St Martin JM, 2013, OPTOMETRY VISION SCI, V90, pE293, DOI 10.1097/OPX.0000000000000079
   Warrow DJ, 2013, RETINA-J RET VIT DIS, V33, P1659, DOI 10.1097/IAE.0b013e3182953df4
   Yang LH, 2013, INVEST OPHTH VIS SCI, V54, P4659, DOI 10.1167/iovs.12-10991
NR 15
TC 16
Z9 16
U1 1
U2 1
PU WOLTERS KLUWER MEDKNOW PUBLICATIONS
PI MUMBAI
PA WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2
   VILLAGE MAROL, ANDHERI EAST, MUMBAI, 400059, INDIA
SN 0301-4738
EI 1998-3689
J9 INDIAN J OPHTHALMOL
JI Indian J. Ophthalmol.
PD DEC
PY 2018
VL 66
IS 12
BP 1796
EP 1801
DI 10.4103/ijo.IJO_377_18
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA HB0BS
UT WOS:000450676000022
PM 30451181
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Nagai, N
   Klimava, A
   Lee, WH
   Izumi-Nagai, K
   Handa, JT
AF Nagai, Norihiro
   Klimava, Alena
   Lee, Wen-Hsiang
   Izumi-Nagai, Kanako
   Handa, James T.
TI CTGF Is Increased in Basal Deposits and Regulates Matrix Production
   through the ERK (p42/p44(mapk)) MAPK and the p38 MAPK Signaling Pathways
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID TISSUE GROWTH-FACTOR; AGE-RELATED MACULOPATHY; LIPOPROTEIN-INDUCED
   EXPRESSION; PIGMENT EPITHELIAL-CELLS; MACULAR DEGENERATION; CHOROIDAL
   NEOVASCULARIZATION; ENDOTHELIAL-CELLS; BRUCHS MEMBRANE; MESANGIAL CELLS;
   LINEAR DEPOSIT
AB PURPOSE. Matrix expansion is an early change in age-related maculopathy. The aim of this study was to determine whether connective tissue growth factor (CTGF) regulates the production of extracellular matrix components by retinal pigmented epithelial (RPE) cells.
   METHODS. ARPE-19 cells were treated with CTGF and analyzed for fibronectin, laminin, and MMP-2 by RT-qPCR, Western blot analysis, or zymography. Cells were also pretreated with an MEK-1/2 inhibitor (PD98059) or a p38 inhibitor (SB203580) and an anti-CTGF antibody to analyze the signaling contributing to fibronectin, laminin, and MMP-2 production. Human maculas were analyzed for mRNA using laser capture microdissected RPE cells and by immunohistochemistry for the topographic distribution of CTGF.
   RESULTS. CTGF induced fibronectin mRNA (P = 0.006) and protein (P = 0.006), and laminin mRNA (P = 0.006) and protein (P = 0.02) by ARPE-19 cells. CTGF also induced MMP-2 mRNA (P = 0.002) and protein secretion (P = 0.04). Using zymography, CTGF increased the latent and active forms of MMP-2 compared to controls (P = 0.02). An anti-CTGF antibody inhibited fibronectin, laminin, and MMP- 2 after CTGF stimulation. CTGF increased the phosphorylation of p38 and ERK1/2. Fibronectin and MMP- 2 mRNA and protein were suppressed by a MEK-1/2 inhibitor, but not with a p38 inhibitor. Laminin expression was suppressed by both inhibitors. RTqPCR analysis showed that macular RPE cells from human donors express CTGF. Immunohistochemistry of human maculas showed strong labeling of CTGF in Bruch membrane, including basal deposits and drusen.
   CONCLUSIONS. CTGF is increased in basal deposits and drusen of AMD specimens, and it induces matrix protein production in ARPE-19 cells through the ERK (p42/p44(mapk)) and p38(mapk) signaling pathways. (Invest Ophthalmol Vis Sci. 2009; 50: 1903-1910) DOI: 10.1167/iovs.08-2383
C1 [Nagai, Norihiro; Klimava, Alena; Lee, Wen-Hsiang; Izumi-Nagai, Kanako; Handa, James T.] Johns Hopkins Sch Med, Wilmer Eye Inst, Baltimore, MD 21287 USA.
C3 Johns Hopkins University; Johns Hopkins Medicine
RP Handa, JT (通讯作者)，Johns Hopkins Sch Med, Wilmer Eye Inst, 1550 Orleans St,Room 144, Baltimore, MD 21287 USA.
EM jthanda@jhmi.edu
FU NEI [EY14005]; Research to Prevent Blindness (RPB); Clinician Scientist
   Award (JTH); Ric and Sandy Forsythe; Kwok family; Merlau Family; Aleda
   Wright; Bausch and Lomb Fellowship Award; Keio University Medical
   Science Fund; The Uehara Memorial Foundation; NATIONAL EYE INSTITUTE
   [R01EY014005] Funding Source: NIH RePORTER
FX Supported by NEI Grant EY14005 (JTH); Research to Prevent Blindness
   (RPB) Clinician Scientist Award (JTH); an unrestricted grant from RPB;
   and gifts from Ric and Sandy Forsythe, the Kwok family, the Merlau
   Family, and Aleda Wright. JTH is the Thomas Orton Jones Fellow in
   Age-Related Macular Degeneration. NN is the recipient of a Bausch and
   Lomb Fellowship Award and support from the Keio University Medical
   Science Fund and The Uehara Memorial Foundation.
CR An E, 2006, J PROTEOME RES, V5, P2599, DOI 10.1021/pr060121j
   Bhutto IA, 2004, INVEST OPHTH VIS SCI, V45, P1544, DOI 10.1167/iovs.03-0862
   Boylan S, 2001, LAB INVEST, V81, P1167, DOI 10.1038/labinvest.3780329
   BRADHAM DM, 1991, J CELL BIOL, V114, P1285, DOI 10.1083/jcb.114.6.1285
   Cameron DJ, 2007, CELL CYCLE, V6, P1122, DOI 10.4161/cc.6.9.4157
   Canfield AE, 2007, BIOCHEM SOC T, V35, P669, DOI 10.1042/BST0350669
   Curcio CA, 2005, EXP EYE RES, V80, P761, DOI 10.1016/j.exer.2004.09.017
   Curcio CA, 1999, ARCH OPHTHALMOL-CHIC, V117, P329, DOI 10.1001/archopht.117.3.329
   Curcio CA, 1998, INVEST OPHTH VIS SCI, V39, P1085
   Del Priore LV, 2002, INVEST OPHTH VIS SCI, V43, P3312
   DEWAN A, 2006, SCIENCE
   Dunaief JL, 2002, ARCH OPHTHALMOL-CHIC, V120, P1435, DOI 10.1001/archopht.120.11.1435
   Dunn KC, 1998, INVEST OPHTH VIS SCI, V39, P2744
   Dunn KC, 1996, EXP EYE RES, V62, P155, DOI 10.1006/exer.1996.0020
   Espinosa-Heidmann DG, 2006, INVEST OPHTH VIS SCI, V47, P729, DOI 10.1167/iovs.05-0719
   Farboud B, 1999, MOL VIS, V5, pU1
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P532
   Gao RP, 2003, HEPATOL RES, V27, P214, DOI 10.1016/S1386-6346(03)00241-9
   Gao XX, 2008, WOUND REPAIR REGEN, V16, P408, DOI 10.1111/j.1524-475X.2008.00380.x
   He S, 2003, ARCH OPHTHALMOL-CHIC, V121, P1283, DOI 10.1001/archopht.121.9.1283
   Honda S, 2001, INVEST OPHTH VIS SCI, V42, P2419
   Ishibashi K, 2004, INVEST OPHTH VIS SCI, V45, P3291, DOI 10.1167/iovs.04-0168
   Kimoto K, 2004, INVEST OPHTH VIS SCI, V45, P2431, DOI 10.1167/iovs.03-1276
   Kuiper EJ, 2007, J HISTOCHEM CYTOCHEM, V55, P1139, DOI 10.1369/jhc.7A7258.2007
   Kyriakis JM, 2001, PHYSIOL REV, V81, P807, DOI 10.1152/physrev.2001.81.2.807
   Leask A, 2003, BIOCHEM CELL BIOL, V81, P355, DOI 10.1139/O03-069
   Leu ST, 2002, EXP EYE RES, V74, P141, DOI 10.1006/exer.2001.1112
   Li CM, 2005, INVEST OPHTH VIS SCI, V46, P2576, DOI 10.1167/iovs.05-0034
   Liu HB, 2008, ENDOCRINOLOGY, V149, P1666, DOI 10.1210/en.2007-1415
   LOFFLER KU, 1986, GRAEF ARCH CLIN EXP, V224, P493, DOI 10.1007/BF02154735
   Malek G, 2003, AM J PATHOL, V162, P413, DOI 10.1016/S0002-9440(10)63836-9
   Mott JD, 1997, KIDNEY INT, V52, P1302, DOI 10.1038/ki.1997.455
   Nagase H, 1998, Cell Res, V8, P179
   NEWSOME DA, 1987, AM J OPHTHALMOL, V104, P373, DOI 10.1016/0002-9394(87)90227-3
   Nishida T, 2007, J CELL COMMUN SIGNAL, V1, P45, DOI 10.1007/s12079-007-0005-z
   Philp NJ, 2003, INVEST OPHTH VIS SCI, V44, P1716, DOI 10.1167/iovs.02-0287
   Sanchez-Lopez E, 2008, AM J PHYSIOL-RENAL, V294, pF149, DOI 10.1152/ajprenal.00129.2007
   SARKS SH, 1976, BRIT J OPHTHALMOL, V60, P324, DOI 10.1136/bjo.60.5.324
   Segarini PR, 2001, J BIOL CHEM, V276, P40659, DOI 10.1074/jbc.M105180200
   Shi-Wen X, 2008, CYTOKINE GROWTH F R, V19, P133, DOI 10.1016/j.cytogfr.2008.01.002
   Sohn M, 2006, AM J PHYSIOL-HEART C, V290, pH1624, DOI 10.1152/ajpheart.01233.2004
   Sohn M, 2005, KIDNEY INT, V67, P1286, DOI 10.1111/j.1523-1755.2005.00206.x
   VANDERSCHAFT TL, 1994, GRAEF ARCH CLIN EXP, V232, P40, DOI 10.1007/BF00176436
   Watanabe D, 2005, RETINA-J RET VIT DIS, V25, P911, DOI 10.1097/00006982-200510000-00015
   Wetzker R, 2003, NAT REV MOL CELL BIO, V4, P651, DOI 10.1038/nrm1173
   YAMADA Y, 2008, J NEUROCHEM
   Yamada Y, 2006, EXP EYE RES, V82, P840, DOI 10.1016/j.exer.2005.10.005
   Yang M, 2004, FASEB J, V18, P1920, DOI 10.1096/fj.04-2357fje
   Yang M, 2007, WOUND REPAIR REGEN, V15, P817, DOI 10.1111/j.1524-475X.2007.00284.x
   Yang ZL, 2006, SCIENCE, V314, P992, DOI 10.1126/science.1133811
   Yosimichi G, 2001, EUR J BIOCHEM, V268, P6058, DOI 10.1046/j.0014-2956.2001.02553.x
   Yosimichi G, 2006, BONE, V38, P853, DOI 10.1016/j.bone.2005.11.016
NR 52
TC 41
Z9 43
U1 1
U2 6
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD APR
PY 2009
VL 50
IS 4
BP 1903
EP 1910
DI 10.1167/iovs.08-2383
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 424CP
UT WOS:000264543400057
PM 19011018
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Panchapakesan, J
   Rochtchina, E
   Mitchell, P
AF Panchapakesan, J
   Rochtchina, E
   Mitchell, P
TI Five-year change in visual acuity following cataract surgery in an older
   community: the Blue Mountains Eye Study
SO EYE
LA English
DT Article
DE cataract; cataract surgery; visual acuity; age-related maculopathy
ID BEAVER DAM EYE; AGE-RELATED MACULOPATHY; POPULATION; PREVALENCE;
   AUSTRALIA; OUTCOMES; EXTRACTION; DISEASE
AB Aims To assess the change in visual acuity following cataract surgery in the Blue Mountains Eye Study (BMES) population. Change in visual acuity was assessed by age, sex, baseline cataract type, and baseline visual acuity.
   Methods A 5-year prospective follow-up of the population- based BMES cohort, who were initially examined in 1992. After 5 years, 2335 survivors of 3654 ( 75.1%) baseline BMES participants were re-examined. Slit-lamp and retro-illumination lens photographs were graded for the presence of incident cataract and evidence of cataract surgery. Visual acuity was measured using a logMAR chart, read at 2.4 m. The main outcome measure was change in the number of logMAR letters correctly identified by eyes that underwent cataract surgery during the 5-year follow-up period.
   Results In a multiple linear regression model, age (P<0.0001) and early age-related maculopathy ( ARM) at baseline ( P<0.0001) were found to affect adversely the postoperative visual acuity following the cataract surgery. As expected, eyes with any baseline cataract showed the greatest improvement in visual acuity after cataract surgery (right eyes: mean +/- s.e. change of 3.75 +/- 1.34 letters; left eyes: mean change +/- s.e. of 6.7 +/- 0.99 letters). There was also a statistically significant improvement in vision after cataract surgery in eyes with no significant lens opacity graded as present at baseline ( right eyes: mean +/- s.e. change of 3.78 +/- 1.85 letters; left eyes: mean change +/- s.e. of 2.68 +/- 1.33 letters).
   Conclusions Age and baseline cataract or ARM status, and baseline visual acuity were determinants of the postoperative visual outcome in older persons who underwent cataract surgery in this community.
C1 Univ Sydney, Dept Ophthalmol, Sydney, NSW 2006, Australia.
C3 University of Sydney
RP Mitchell, P (通讯作者)，Univ Sydney, Westmead Hosp, Ctr Vis Res, Dept Ophthalmol, Hawkesbury Rd, Westmead, NSW 2145, Australia.
EM paul_mitchell@wmi.usyd.edu.au
RI Mitchell, Paul/P-1498-2014; Panchapakesan, Jai/E-4860-2016
CR Attebo K, 1996, OPHTHALMOLOGY, V103, P357
   GRANEY MJ, 1988, AM J OPHTHALMOL, V105, P460, DOI 10.1016/0002-9394(88)90235-8
   HYMAN L, 1987, EYE, V1, P330, DOI 10.1038/eye.1987.53
   Ivers RQ, 2001, OPHTHALMOLOGY, V108, P968, DOI 10.1016/S0161-6420(00)00649-7
   Klein BEK, 1996, OPHTHALMOLOGY, V103, P1727, DOI 10.1016/S0161-6420(96)30434-X
   KLEIN BEK, 1990, OPHTHALMOLOGY, V97, P1428
   KLEIN BEK, 1992, OPHTHALMOLOGY, V99, P546
   Lau J, 2002, BRIT J OPHTHALMOL, V86, P12, DOI 10.1136/bjo.86.1.12
   Lundstrom M, 2000, J CATARACT REFR SURG, V26, P101, DOI 10.1016/S0886-3350(99)00324-7
   McCarty CA, 1999, BRIT J OPHTHALMOL, V83, P62, DOI 10.1136/bjo.83.1.62
   Mitchell P, 1997, OPHTHALMOLOGY, V104, P581, DOI 10.1016/S0161-6420(97)30266-8
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Murphy C, 2002, J CATARACT REFR SURG, V28, P62, DOI 10.1016/S0886-3350(01)01027-6
   Panchapakesan J, 1997, Ophthalmic Epidemiol, V4, P119
   Riley AF, 2002, BRIT J OPHTHALMOL, V86, P185, DOI 10.1136/bjo.86.2.185
   Saw SM, 2002, J CATARACT REFR SURG, V28, P445, DOI 10.1016/S0886-3350(01)01016-1
   Setty R, 2000, BRIT J OPHTHALMOL, V84, P1439
   Shuttleworth GN, 1998, BRIT J OPHTHALMOL, V82, P611, DOI 10.1136/bjo.82.6.611
   STEINBERG EP, 1993, ARCH OPHTHALMOL-CHIC, V111, P1041, DOI 10.1001/archopht.1993.01090080037016
   Wang JJ, 2003, OPHTHALMOLOGY, V110, P1960, DOI 10.1016/S0161-6420(03)00816-9
   Westcott MC, 2000, BRIT J OPHTHALMOL, V84, P1380, DOI 10.1136/bjo.84.12.1380
NR 21
TC 20
Z9 24
U1 0
U2 3
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950-222X
EI 1476-5454
J9 EYE
JI Eye
PD MAR
PY 2004
VL 18
IS 3
BP 278
EP 282
DI 10.1038/sj.eye.6700641
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 801FD
UT WOS:000220080900009
PM 15004577
OA Bronze
DA 2022-11-30
ER

PT J
AU Wang, L
   Clark, ME
   Crossman, DK
   Kojima, K
   Messinger, JD
   Mobley, JA
   Curcio, CA
AF Wang, Lan
   Clark, Mark E.
   Crossman, David K.
   Kojima, Kyoko
   Messinger, Jeffrey D.
   Mobley, James A.
   Curcio, Christine A.
TI Abundant Lipid and Protein Components of Drusen
SO PLOS ONE
LA English
DT Article
ID RETINAL-PIGMENT EPITHELIUM; AGE-RELATED MACULOPATHY; HUMAN BRUCHS
   MEMBRANE; HIGH-DENSITY-LIPOPROTEIN; MACULAR DEGENERATION; SCAVENGER
   RECEPTORS; BASAL DEPOSITS; UNESTERIFIED CHOLESTEROL; PROGRESSIVE STAGES;
   APOLIPOPROTEIN-E
AB Background: Drusen are extracellular lesions characteristic of aging and age-related maculopathy, a major retinal disease of the elderly. We determined the relative proportions of lipids and proteins in drusen capped with retinal pigment epithelium (RPE) and in RPE isolated from non-macular regions of 36 human retinas with grossly normal maculas obtained <6 hr after death.
   Methodology/Principal Findings: Druse pellets were examined by light and electron microscopy. Component proteins were extracted using novel methods for preserved tissues, separated, subjected to tryptic digestion and LC-MS(MS)(2) analysis using an ion trap mass spectrometer, and identified with reference to databases. Lipid classes were separated using thin layer chromatography and quantified by densitometry. Major druse components were esterified cholesterol (EC), phosphatidylcholine (PC), and protein (37.5 +/- 13.7, 36.9 +/- 12.9, and 43.0 +/- 11.5 ng/druse, respectively). Lipid-containing particles (median diameter, 77 nm) occupied 37-44% of druse volume. Major proteins include vitronectin, complement component 9, apoE, and clusterin, previously seen in drusen, and ATP synthase subunit beta, scavenger receptor B2, and retinol dehydrogenase 5, previously seen in RPE. Drusen and RPE had similar protein profiles, with higher intensities and greater variability in drusen. C8, part of the complement membrane attack complex, was localized in drusen by immunofluorescence.
   Conclusions/Significance: At least 40% of druse content is comprised by lipids dominated by EC and PC, 2 components that are potentially accounted for by just one pathway, the secretion of lipoproteins by RPE. Manipulating genes encoding apolipoprotein pathways would be a fruitful approach to producing drusen with high EC content in laboratory animals. Therapies that directly mitigate drusen should prepare for the substantial volume of neutral lipids. The catalog of major druse proteins is nearing completion.
C1 [Wang, Lan; Clark, Mark E.; Messinger, Jeffrey D.; Curcio, Christine A.] Univ Alabama, Dept Ophthalmol, Birmingham, AL 35294 USA.
   [Crossman, David K.] Univ Alabama, Dept Microbiol, Birmingham, AL 35294 USA.
   [Kojima, Kyoko] Univ Alabama, Dept Epidemiol, Birmingham, AL 35294 USA.
   [Mobley, James A.] Univ Alabama, Dept Surg, Birmingham, AL 35294 USA.
C3 University of Alabama System; University of Alabama Birmingham;
   University of Alabama System; University of Alabama Birmingham;
   University of Alabama System; University of Alabama Birmingham;
   University of Alabama System; University of Alabama Birmingham
RP Wang, L (通讯作者)，Univ Alabama, Dept Ophthalmol, Birmingham, AL 35294 USA.
EM curcio@uab.edu
OI mobley, james/0000-0002-3229-7975; Crossman, David/0000-0002-0981-169X
FU NIH [EY06109]; International Retinal Research Foundation; Research to
   Prevent Blindness, Inc.; EyeSight Foundation of Alabama; Roger Johnson
   Prize in Macular Degeneration Research (CAC); NIAID [T32AI007041-15];
   NATIONAL EYE INSTITUTE [R01EY006109] Funding Source: NIH RePORTER;
   NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI007041]
   Funding Source: NIH RePORTER
FX NIH grant EY06109, International Retinal Research Foundation,
   unrestricted funds to the Department of Ophthalmology from Research to
   Prevent Blindness, Inc., EyeSight Foundation of Alabama, and the 2002
   Roger Johnson Prize in Macular Degeneration Research (CAC); NIAID,
   T32AI007041-15 (DKC). The funders had no role in study design, data
   collection and analysis, decision to publish, or preparation of the
   manuscript.
CR Alcazar O, 2009, MOL CELL PROTEOMICS, V8, P2201, DOI 10.1074/mcp.M900203-MCP200
   Anderson DH, 2004, EXP EYE RES, V78, P243, DOI 10.1016/j.exer.2003.10.011
   Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   Anderson DH, 2001, AM J OPHTHALMOL, V131, P767, DOI 10.1016/S0002-9394(00)00961-2
   Binder S, 2007, PROG RETIN EYE RES, V26, P516, DOI 10.1016/j.preteyeres.2007.02.002
   Booij JC, 2009, BMC GENOMICS, V10, DOI 10.1186/1471-2164-10-164
   Bretillon L, 2008, INVEST OPHTH VIS SCI, V49, P1307, DOI 10.1167/iovs.07-0808
   Bretillon L, 2008, EXP EYE RES, V87, P521, DOI 10.1016/j.exer.2008.08.010
   CasaroliMarano RP, 1996, J LIPID RES, V37, P1037
   Chang AA, 2003, CLIN EXP OPHTHALMOL, V31, P300, DOI 10.1046/j.1442-9071.2003.00664.x
   Chung BH, 2005, BBA-MOL CELL BIOL L, V1733, P76, DOI 10.1016/j.bbalip.2004.12.002
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   Curcio CA, 2005, EXP EYE RES, V81, P731, DOI 10.1016/j.exer.2005.04.012
   Curcio CA, 2005, EXP EYE RES, V80, P761, DOI 10.1016/j.exer.2004.09.017
   Curcio CA, 1999, ARCH OPHTHALMOL-CHIC, V117, P329, DOI 10.1001/archopht.117.3.329
   Curcio CA, 2001, INVEST OPHTH VIS SCI, V42, P265
   Curcio CA, 2009, PROG RETIN EYE RES, V28, P393, DOI 10.1016/j.preteyeres.2009.08.001
   Decanini A, 2008, DIABETOLOGIA, V51, P1051, DOI 10.1007/s00125-008-0991-2
   Del Priore LV, 1998, ARCH OPHTHALMOL-CHIC, V116, P335, DOI 10.1001/archopht.116.3.335
   Dentchev T, 2003, MOL VIS, V9, P184
   DOWHAN W, 2002, BIOCH LIPIDS LIPOPRO, P1
   Duncan KG, 2002, BIOCHEM BIOPH RES CO, V292, P1017, DOI 10.1006/bbrc.2002.6756
   During A, 2008, J LIPID RES, V49, P1715, DOI 10.1194/jlr.M700580-JLR200
   Eckhardt ERM, 2004, J BIOL CHEM, V279, P14372, DOI 10.1074/jbc.M313793200
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Fagerness JA, 2009, EUR J HUM GENET, V17, P100, DOI 10.1038/ejhg.2008.140
   Fujihara M, 2009, EXP EYE RES, V88, P1115, DOI 10.1016/j.exer.2009.01.017
   GAMBLE W, 1978, J LIPID RES, V19, P1068
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Gouras P, 2009, GRAEF ARCH CLIN EXP, V247, P1051, DOI 10.1007/s00417-009-1091-9
   GREEN WR, 1993, OPHTHALMOLOGY, V100, P1519
   Gullapalli VK, 2008, EXP EYE RES, V86, P189, DOI 10.1016/j.exer.2007.10.009
   GUYTON JR, 1988, J HISTOCHEM CYTOCHEM, V36, P1319, DOI 10.1177/36.10.2458408
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haimovici R, 2001, INVEST OPHTH VIS SCI, V42, P1592
   HAYES KC, 1989, INVEST OPHTH VIS SCI, V30, P225
   Holm C, 1999, METH MOL B, V109, P109
   ISHIBASHI T, 1986, AM J OPHTHALMOL, V101, P342, DOI 10.1016/0002-9394(86)90830-5
   Johnson LV, 2000, EXP EYE RES, V70, P441, DOI 10.1006/exer.1999.0798
   Johnson LV, 2001, EXP EYE RES, V73, P887, DOI 10.1006/exer.2001.1094
   Kamei M, 2007, INVEST OPHTH VIS SCI, V48, P1801, DOI 10.1167/iovs.06-0699
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Klein R, 2007, OPHTHALMOLOGY, V114, P253, DOI 10.1016/j.ophtha.2006.10.040
   Kochounian H, 2009, EXP EYE RES, V88, P1129, DOI 10.1016/j.exer.2009.01.019
   Lakkaraju A, 2008, TRENDS CELL BIOL, V18, P199, DOI 10.1016/j.tcb.2008.03.002
   Lengyel I, 2004, INVEST OPHTH VIS SCI, V45, P2886, DOI 10.1167/iovs.03-1083
   Lengyel I, 2007, EXP EYE RES, V84, P772, DOI 10.1016/j.exer.2006.12.015
   Li CM, 2007, EXP EYE RES, V85, P192, DOI 10.1016/j.exer.2007.04.002
   Li CM, 2006, INVEST OPHTH VIS SCI, V47, P3119, DOI 10.1167/iovs.05-1446
   Li CM, 2005, INVEST OPHTH VIS SCI, V46, P2576, DOI 10.1167/iovs.05-0034
   Li CM, 2005, J LIPID RES, V46, P628, DOI 10.1194/jlr.M400428-JLR200
   Lin MY, 2007, MOL VIS, V13, P1203
   Loane E, 2008, SURV OPHTHALMOL, V53, P68, DOI 10.1016/j.survophthal.2007.10.008
   Luhmann UFO, 2009, INVEST OPHTH VIS SCI, V50, P5934, DOI 10.1167/iovs.09-3462
   Luibl V, 2006, J CLIN INVEST, V116, P378, DOI 10.1172/JCI25843
   Malek G, 2005, P NATL ACAD SCI USA, V102, P11900, DOI 10.1073/pnas.0503015102
   Malek G, 2003, AM J PATHOL, V162, P413, DOI 10.1016/S0002-9440(10)63836-9
   Moreira EF, 2009, INVEST OPHTH VIS SCI, V50, P523, DOI 10.1167/iovs.08-2373
   Mullins RF, 1999, J HISTOCHEM CYTOCHEM, V47, P1533, DOI 10.1177/002215549904701205
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   Ng KP, 2008, MOL CELL PROTEOMICS, V7, P1397, DOI 10.1074/mcp.M700525-MCP200
   Nickle B, 2007, CELL MOL LIFE SCI, V64, P2917, DOI 10.1007/s00018-007-7253-1
   Nordgaard CL, 2006, INVEST OPHTH VIS SCI, V47, P815, DOI 10.1167/iovs.05-0976
   Nordgaard CL, 2008, INVEST OPHTH VIS SCI, V49, P2848, DOI 10.1167/iovs.07-1352
   Oksjoki R, 2007, FRONT BIOSCI-LANDMRK, V12, P4696, DOI 10.2741/2419
   PAULEIKHOFF D, 1990, OPHTHALMOLOGY, V97, P171
   PAULEIKHOFF D, 1992, OPHTHALMOLOGY, V99, P1548
   Raoul W, 2008, OPHTHAL RES, V40, P115, DOI 10.1159/000119860
   Rudolf M, 2008, INVEST OPHTH VIS SCI, V49, P1200, DOI 10.1167/iovs.07-1466
   Sallo FB, 2009, EXP EYE RES, V89, P178, DOI 10.1016/j.exer.2009.03.006
   SARKS JP, 1988, EYE, V2, P552, DOI 10.1038/eye.1988.106
   SARKS SH, 1980, AUST J OPHTHALMOL, V8, P117, DOI 10.1111/j.1442-9071.1980.tb01670.x
   Schloendorn J, 2009, REJUV RES, V12, P411, DOI 10.1089/rej.2009.0917
   Schmidt-Erfurth U, 2008, INVEST OPHTH VIS SCI, V49, P390, DOI 10.1167/iovs.07-0227
   Schreck SF, 2000, BBA-PROTEIN STRUCT M, V1482, P199, DOI 10.1016/S0167-4838(00)00155-2
   Seth A, 2008, INVEST OPHTH VIS SCI, V49, P743, DOI 10.1167/iovs.07-1072
   Spaide RF, 1999, RETINA-J RET VIT DIS, V19, P141, DOI 10.1097/00006982-199902000-00010
   Suzuki M, 2007, MOL VIS, V13, P772
   Tezel TH, 2004, INVEST OPHTH VIS SCI, V45, P3337, DOI 10.1167/iovs.04-0193
   Tserentsoodol N, 2006, MOL VIS, V12, P1319
   VANDERSCHAFT TL, 1992, OPHTHALMOLOGY, V99, P278
   Wang AL, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004160
   Wang JJ, 2007, OPHTHALMOLOGY, V114, P92, DOI 10.1016/j.ophtha.2006.07.017
   Wang L, 2009, INVEST OPHTH VIS SCI, V50, P870, DOI 10.1167/iovs.08-2376
   Warburton S, 2007, MOL VIS, V13, P318
   Webb NR, 1998, J BIOL CHEM, V273, P15241, DOI 10.1074/jbc.273.24.15241
   West KA, 2003, MOL CELL PROTEOMICS, V2, P37, DOI 10.1074/mcp.D200001-MCP200
   White C Roger, 2009, Vasc Dis Prev, V6, P122
   WOLTER JR, 1962, ARCH OPHTHALMOL-CHIC, V68, P219
   Yamada Y, 2008, J NEUROCHEM, V105, P1187, DOI 10.1111/j.1471-4159.2008.05211.x
   Yamamoto H, 1999, NAT GENET, V22, P188, DOI 10.1038/9707
   Zerbib J, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007341
   [No title captured]
   [No title captured]
   [No title captured]
   [No title captured]
NR 97
TC 226
Z9 229
U1 1
U2 29
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD APR 23
PY 2010
VL 5
IS 4
AR e10329
DI 10.1371/journal.pone.0010329
PG 12
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA 588NU
UT WOS:000277079300016
PM 20428236
OA gold, Green Published, Green Submitted
DA 2022-11-30
ER

PT J
AU Sung, WH
   Tsao, YT
   Shen, CJ
   Tsai, CY
   Cheng, CM
AF Sung, Wei-Hsuan
   Tsao, Yu-Ting
   Shen, Ching-Ju
   Tsai, Chia-Ying
   Cheng, Chao-Min
TI Small-volume detection: platform developments for clinically-relevant
   applications
SO JOURNAL OF NANOBIOTECHNOLOGY
LA English
DT Review
ID NASAL-LAVAGE FLUID; EOSINOPHIL CATIONIC PROTEIN; TEAR GLUCOSE;
   CEREBROSPINAL-FLUID; CONTACT-LENS; CERVICOVAGINAL FLUID; ALLERGIC
   RHINITIS; GUNSHOT RESIDUES; ALPHA-SYNUCLEIN; CERVICAL FLUID
AB Biochemical analysis of human body fluids is a frequent and fruitful strategy for disease diagnosis. Point-of-care (POC) diagnostics offers the tantalizing possibility of providing rapid diagnostic results in non-laboratory settings. Successful diagnostic testing using body fluids has been reported on in the literature; however, small-volume detection devices, which offer remarkable advantages such as portability, inexpensiveness, capacity for mass production, and tiny sample volume requirements have not been thoroughly discussed. Here, we review progress in this research field, with a focus on developments since 2015. In this review article, we provide a summary of articles that have detailed the development of small-volume detection strategies using clinical samples over the course of the last 5 years. Topics covered include small-volume detection strategies in ophthalmology, dermatology or plastic surgery, otolaryngology, and cerebrospinal fluid analysis. In ophthalmology, advances in technology could be applied to examine tear or anterior chamber (AC) fluid for glucose, lactoferrin, interferon, or VEGF. These approaches could impact detection and care for diseases including diabetic mellitus, dry-eye disease, and age-related maculopathy. Early detection and easy monitoring are critical approaches for improving overall care and outcome. In dermatology or plastic surgery, small-volume detection strategies have been applied for passive or interactive wound dressing, wound healing monitoring, and blister fluid analysis for autoimmune disease diagnosis. In otolaryngology, the analysis of nasal secretions and mucosa could be used to differentiate between allergic responses and infectious diseases. Cerebrospinal fluid analysis could be applied in neurodegenerative diseases, central neural system infection and tumor diagnosis. Other small-volume fluids that have been analyzed for diagnostic and monitoring purposes include semen and cervico-vaginal fluids. We include more details regarding each of these fluids, associated collection and detection devices, and approaches in our review.
C1 [Sung, Wei-Hsuan; Tsao, Yu-Ting] Chang Gung Mem Hosp, Linkou Med Ctr, Taoyuan, Taiwan.
   [Sung, Wei-Hsuan; Tsao, Yu-Ting] Chang Gung Med Coll, Taoyuan, Taiwan.
   [Sung, Wei-Hsuan; Tsao, Yu-Ting] Chang Gung Univ, Taoyuan, Taiwan.
   [Shen, Ching-Ju] Kaohsiung Med Univ Hosp, Dept Obstet & Gynecol, Kaohsiung, Taiwan.
   [Tsai, Chia-Ying] Fu Jen Catholic Univ, Fu Jen Catholic Univ Hosp, Dept Ophthalmol, New Taipei, Taiwan.
   [Tsai, Chia-Ying] Fu Jen Catholic Univ, Coll Med, Sch Med, New Taipei, Taiwan.
   [Cheng, Chao-Min] Natl Tsing Hua Univ, Inst Biomed Engn, Hsinchu, Taiwan.
C3 Chang Gung Memorial Hospital; Chang Gung University; Chang Gung
   University; Kaohsiung Medical University; Kaohsiung Medical University
   Hospital; Fu Jen Catholic University; Fu Jen Catholic University
   Hospital; Fu Jen Catholic University; National Tsing Hua University
RP Tsai, CY (通讯作者)，Fu Jen Catholic Univ, Fu Jen Catholic Univ Hosp, Dept Ophthalmol, New Taipei, Taiwan.; Cheng, CM (通讯作者)，Natl Tsing Hua Univ, Inst Biomed Engn, Hsinchu, Taiwan.
EM chiaying131@gmail.com; chaomin@mx.nthu.edu.tw
FU Ministry of Science and Technology (MOST) [MOST 107-2628-E-007-001-MY3,
   MOST 109-2622-E-007-009-CC3]; Fu Jen Catholic University Hospital
   Research Grant [PL201908002V]
FX This paper is partially supported by the Ministry of Science and
   Technology (MOST) under MOST 107-2628-E-007-001-MY3 & MOST
   109-2622-E-007-009-CC3 and Fu Jen Catholic University Hospital Research
   Grant (PL201908002V).
CR Abdulrahman A., 2020, COMP SARS COV 2 NASA, DOI [10.1101/2020.11.10.20228973v2, DOI 10.1101/2020.11.10.20228973], 10.1101/2020.11.10.20228973]
   Alexeev VL, 2004, CLIN CHEM, V50, P2353, DOI 10.1373/clinchem.2004.039701
   Aliste M, 2016, FORENSIC SCI INT, V261, P14, DOI 10.1016/j.forsciint.2016.01.034
   Allen J, 2012, PEDIATR BLOOD CANCER, V59, P1180, DOI 10.1002/pbc.24097
   Amabebe E, 2018, J REPROD IMMUNOL, V126, P1, DOI 10.1016/j.jri.2018.01.001
   Amabebe E, 2016, FRONT MED-LAUSANNE, V3, DOI 10.3389/fmed2016.00048
   Amabebe E, 2016, METABOLOMICS, V12, DOI 10.1007/s11306-016-0985-x
   Anahtar MN, 2018, CELL HOST MICROBE, V23, P159, DOI 10.1016/j.chom.2018.01.013
   Appidi T, 2020, NANOSCALE ADV, V2, P5737, DOI 10.1039/d0na00686f
   Armenta S, 2013, ANAL CHEM, V85, P11382, DOI 10.1021/ac4023583
   Ascaso FJ, 2016, OPTOMETRY VISION SCI, V93, P426, DOI 10.1097/OPX.0000000000000698
   Baca JT, 2007, OCUL SURF, V5, P280, DOI 10.1016/S1542-0124(12)70094-0
   Badugu R, 2003, J FLUORESC, V13, P371, DOI 10.1023/A:1026103804104
   BENTLEY AM, 1992, J ALLERGY CLIN IMMUN, V89, P877, DOI 10.1016/0091-6749(92)90444-7
   Berends SE, 2019, BRIT J CLIN PHARMACO, V85, P1544, DOI 10.1111/bcp.13939
   Bhushan P, 2019, TOXICOL IN VITRO, V58, P170, DOI 10.1016/j.tiv.2019.03.034
   Bielen R, 2020, J VIRAL HEPATITIS, V27, P709, DOI 10.1111/jvh.13284
   BISGAARD H, 1990, J ALLERGY CLIN IMMUN, V85, P891, DOI 10.1016/0091-6749(90)90074-E
   Bowler PG, 2001, CLIN MICROBIOL REV, V14, P244, DOI 10.1128/CMR.14.2.244-269.2001
   Brown MS, 2018, FRONT BIOENG BIOTECH, V6, DOI 10.3389/fbioe.2018.00047
   Calabria D, 2017, BIOSENS BIOELECTRON, V94, P124, DOI 10.1016/j.bios.2017.02.053
   CASTELLS M, 1988, J ALLERGY CLIN IMMUN, V82, P348, DOI 10.1016/0091-6749(88)90005-X
   Chang H, 2017, ADV MATER, V29, DOI 10.1002/adma.201702243
   Chen R, 1996, J CAPILLARY ELECTROP, V3, P243
   Chen XS, 2017, ACS NANO, V11, P7938, DOI 10.1021/acsnano.7b02471
   Cheng CM, 2010, ANGEW CHEM INT EDIT, V49, P4771, DOI 10.1002/anie.201001005
   Choi SR, 2018, TAIWAN J OBSTET GYNE, V57, P407, DOI 10.1016/j.tjog.2018.04.014
   Chotiprasitsakul D, 2018, INFECT CONT HOSP EP, V39, P290, DOI 10.1017/ice.2017.308
   Chu MX, 2011, TALANTA, V83, P960, DOI 10.1016/j.talanta.2010.10.055
   Collier DA, 2020, CELL REP MED, V1, DOI 10.1016/j.xcrm.2020.100062
   Combs CA, 2015, AM J OBSTET GYNECOL, V212, DOI 10.1016/j.ajog.2015.02.007
   D'Elia V, 2016, TALANTA, V154, P367, DOI 10.1016/j.talanta.2016.03.077
   Dabiri G, 2016, ADV WOUND CARE, V5, P32, DOI 10.1089/wound.2014.0586
   DANJO Y, 1994, ACTA OPHTHALMOL, V72, P433
   DAUM KM, 1984, ACTA OPHTHALMOL, V62, P472
   Delacroix R, 2017, SCI REP-UK, V7, DOI 10.1038/srep39893
   Dhivya S, 2015, BIOMEDICINE-TAIWAN, V5, P24, DOI 10.7603/s40681-015-0022-9
   Eichinger A, 2019, INFECTION, V47, P51, DOI 10.1007/s15010-018-1212-7
   Eom G, 2019, ACS SENSORS, V4, P2282, DOI 10.1021/acssensors.9b00697
   Fairbairn S, 2018, CURR OPIN ALLERGY CL, V18, P167, DOI 10.1097/ACI.0000000000000449
   Fan SY, 2018, INT J INFECT DIS, V67, P20, DOI 10.1016/j.ijid.2017.11.028
   Francesko A, 2018, CURR MED CHEM, V25, P5782, DOI 10.2174/0929867324666170920161246
   Frykberg RG, 2015, ADV WOUND CARE, V4, P560, DOI 10.1089/wound.2015.0635
   Gabriel EFM, 2016, ANALYST, V141, P4749, DOI 10.1039/c6an00430j
   Garweg JG, 2000, J CLIN MICROBIOL, V38, P996, DOI 10.1128/JCM.38.3.996-1001.2000
   GASSET AR, 1968, AM J OPHTHALMOL, V65, P414, DOI 10.1016/0002-9394(68)93093-6
   Geelhoed-Duijvestijn Petronella, 2021, J Diabetes Sci Technol, V15, P1320, DOI 10.1177/1932296820964844
   Gentile DA, 2001, ANN ALLERG ASTHMA IM, V87, P496, DOI 10.1016/S1081-1206(10)62263-6
   Guan A, 2016, LAB CHIP, V16, P1152, DOI 10.1039/c6lc00034g
   Hansel TT, 2017, EBIOMEDICINE, V19, P128, DOI 10.1016/j.ebiom.2017.03.033
   Hansson KT., 2017, J VIS EXP, V130, P56244
   Hirvonen MR, 1999, AM J RESP CRIT CARE, V160, P1943, DOI 10.1164/ajrccm.160.6.9903023
   Ho EL, 2015, SEX TRANSM DIS, V42, P48, DOI 10.1097/OLQ.0000000000000222
   Hsu CK, 2014, ANAL CHEM, V86, P4605, DOI 10.1021/ac500835k
   Hsu MY, 2016, SCI REP-UK, V6, DOI 10.1038/srep34631
   Hsu MY, 2015, LAB CHIP, V15, P2357, DOI 10.1039/c4lc01052c
   Jankowska DA, 2017, BIOSENS BIOELECTRON, V87, P312, DOI 10.1016/j.bios.2016.08.072
   Jochems SP, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0169805
   Joo NS, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0116756
   Jung EY, 2016, J OBSTET GYNAECOL RE, V42, P158, DOI 10.1111/jog.12882
   Kacerovsky M, 2015, J MATERN-FETAL NEO M, V28, P392, DOI 10.3109/14767058.2014.917625
   Kacerovsky M, 2015, J MATERN-FETAL NEO M, V28, P134, DOI 10.3109/14767058.2014.908179
   Kamoun EA, 2017, J ADV RES, V8, P217, DOI 10.1016/j.jare.2017.01.005
   Kanakasabapathy MK, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aai7863
   Kandhavelu J, 2017, J PROTEOMICS, V152, P13, DOI 10.1016/j.jprot.2016.10.009
   Karsten SL, 2015, TALANTA, V145, P55, DOI 10.1016/j.talanta.2015.04.032
   Kim HJ, 2015, J KOREAN CHEM SOC, V59, P88, DOI 10.5012/jkcs.2015.59.1.88
   Kim S, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-65103-z
   Konig K, 2016, ALLERGY ASTHMA CL IM, V12, DOI 10.1186/s13223-016-0123-3
   Koev ST, 2010, LAB CHIP, V10, P3026, DOI [10.1039/c0lc00047g, 10.1039/c01c00047g]
   Kolluru C, 2019, BIOMED MICRODEVICES, V21, DOI 10.1007/s10544-019-0363-3
   Lane JD, 2006, CURR EYE RES, V31, P895, DOI 10.1080/02713680600976552
   Laniewski P, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-43849-5
   Lee SM, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0200311
   Lefrere B, 2017, J ROY ARMY MED CORPS, V163, P397, DOI 10.1136/jramc-2017-000778
   Lemp MA, 2007, OCUL SURF, V5, P75
   Liu XY, 2017, BIOSENS BIOELECTRON, V98, P189, DOI 10.1016/j.bios.2017.06.053
   Mak WC, 2017, PROC TECH, V27, P16, DOI 10.1016/j.protcy.2017.04.009
   Matsuura K, 2017, SCI REP-UK, V7, DOI 10.1038/srep46213
   Meng YF, 2018, LARYNGOSCOPE, V128, pE311, DOI 10.1002/lary.27120
   Merli D, 2016, INT J LEGAL MED, V130, P1045, DOI 10.1007/s00414-016-1375-7
   Miner JJ, 2016, CELL REP, V16, P3208, DOI 10.1016/j.celrep.2016.08.079
   Mirani B, 2017, ADV HEALTHC MATER, V6, DOI 10.1002/adhm.201700718
   Mitchell C, 2011, J CLIN MICROBIOL, V49, P735, DOI 10.1128/JCM.00991-10
   Mohammadi MH, 2016, ADV HEALTHC MATER, V5, P2459, DOI 10.1002/adhm.201600439
   Moncla BJ, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0127091
   Mostafalu P, 2018, SMALL, V14, DOI 10.1002/smll.201703509
   Musilova I., 2016, AM J OBSTET GYNECOL, VS00029378, P30438
   MYGIND N, 1976, ACTA OTO-LARYNGOL, V82, P219, DOI 10.3109/00016487609120888
   Nischwitz SP, 2019, BURNS, V45, P1336, DOI 10.1016/j.burns.2019.02.021
   Ogurtsova K, 2017, DIABETES RES CLIN PR, V128, P40, DOI 10.1016/j.diabres.2017.03.024
   Pal A, 2018, BIOSENS BIOELECTRON, V117, P696, DOI 10.1016/j.bios.2018.06.060
   Power G, 2017, J WOUND CARE, V26, P381, DOI 10.12968/jowc.2017.26.7.381
   Price CP, 2001, BMJ-BRIT MED J, V322, P1285, DOI 10.1136/bmj.322.7297.1285
   Qiao BB, 2020, BIOMATER SCI-UK, V8, P1649, DOI 10.1039/c9bm02060h
   Rajeev G, 2020, FRONT CHEM, V8, DOI 10.3389/fchem.2020.00155
   Rinaudo M, 2006, PROG POLYM SCI, V31, P603, DOI 10.1016/j.progpolymsci.2006.06.001
   Roda A, 2016, TRAC-TREND ANAL CHEM, V79, P317, DOI 10.1016/j.trac.2015.10.019
   Romano A, 1988, Metab Pediatr Syst Ophthalmol (1985), V11, P78
   Rousseau G, 2019, EUR J EMERG MED, V26, P41, DOI 10.1097/MEJ.0000000000000495
   RoyChoudhury S, 2018, J ELECTROCHEM SOC, V165, pB3168, DOI 10.1149/2.0231808jes
   Ryu A, 2013, ACTA OBSTET GYN SCAN, V92, P517, DOI 10.1111/aogs.12073
   Salvo P, 2018, SENSOR ACTUAT B-CHEM, V256, P976, DOI 10.1016/j.snb.2017.10.037
   Salvo P., 2015, WOUND MED, V8, P15, DOI DOI 10.1016/J.WNDM.2015.03.007
   Salvo P, 2017, SENSORS-BASEL, V17, DOI 10.3390/s17122952
   Salvo P, 2017, INT J NANOMED, V12, P949, DOI 10.2147/IJN.S121726
   Schleh C, 2013, J OCCUP MED TOXICOL, V8, DOI 10.1186/1745-6673-8-6
   SEN DK, 1980, BRIT J OPHTHALMOL, V64, P693, DOI 10.1136/bjo.64.9.693
   Sernicola A, 2019, MEDICINE, V98, DOI 10.1097/MD.0000000000014514
   Shahnawaz M, 2017, JAMA NEUROL, V74, P163, DOI 10.1001/jamaneurol.2016.4547
   Shams Naveed, 2006, Ophthalmol Clin North Am, V19, P335
   Sheybani R, 2017, BIOSENS BIOELECTRON, V92, P425, DOI 10.1016/j.bios.2016.10.084
   Shin YS, 2018, CURR OPIN ALLERGY CL, V18, P10, DOI 10.1097/ACI.0000000000000413
   Shukla SK, 2013, INT J BIOL MACROMOL, V59, P46, DOI 10.1016/j.ijbiomac.2013.04.043
   SIGURS N, 1994, ACTA PAEDIATR, V83, P1151
   Song C, 2018, NANOMED-NANOTECHNOL, V14, P1845, DOI 10.1016/j.nano.2018.05.013
   Sonobe H, 2019, OCUL SURF, V17, P160, DOI 10.1016/j.jtos.2018.11.001
   Su TW, 2010, ANAL CHEM, V82, P8307, DOI 10.1021/ac101845q
   Succar Eric F, 2018, F1000Res, V7, DOI 10.12688/f1000research.16222.1
   Sun F, 2020, LAB CHIP, V20, P1621, DOI 10.1039/d0lc00304b
   Taormina CR, 2007, J AM SOC MASS SPECTR, V18, P332, DOI 10.1016/j.jasms.2006.10.002
   Tsao YT, 2021, BIOENG TRANSL MED, V6, DOI 10.1002/btm2.10176
   Turetsky A, 2015, THERANOSTICS, V5, P796, DOI 10.7150/thno.11220
   Tyssen D, 2018, MSPHERE, V3, DOI 10.1128/mSphere.00055-18
   Vadlamani BS, 2020, SENSORS-BASEL, V20, DOI 10.3390/s20205871
   Vanderstichele H, 2017, ALZHEIMERS RES THER, V9, DOI 10.1186/s13195-017-0265-7
   Wake RM, 2018, JAIDS-J ACQ IMM DEF, V78, P574, DOI [10.1097/qai.0000000000001721, 10.1097/QAI.0000000000001721]
   Wisniewski NA, 2017, ADV EXP MED BIOL, V977, P377, DOI 10.1007/978-3-319-55231-6_49
   World Health Organization, 2020, WHO STAK WORKSH
   Xu M, 2019, ACS SENSORS, V4, P1040, DOI 10.1021/acssensors.9b00230
   Yam WC, 2013, J CLIN MICROBIOL, V51, P2869, DOI 10.1128/JCM.00488-13
   Yamada K, 2015, ACS APPL MATER INTER, V7, P24864, DOI 10.1021/acsami.5b08124
   Yamada K, 2014, ANALYST, V139, P1637, DOI 10.1039/c3an01926h
   Yang YR, 2019, CHEM SOC REV, V48, P1465, DOI 10.1039/c7cs00730b
   Yen TH, 2015, TALANTA, V144, P189, DOI 10.1016/j.talanta.2015.05.049
   Yetisen AK, 2019, ANGEW CHEM INT EDIT, V58, P10506, DOI 10.1002/anie.201904416
   Yetisen AK, 2017, LAB CHIP, V17, P1137, DOI 10.1039/c6lc01450j
   Yi HM, 2005, BIOMACROMOLECULES, V6, P2881, DOI 10.1021/bm050410l
   Yoo HN, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0180878
   Young S, 2021, J CLIN MICROBIOL, V59, DOI 10.1128/JCM.02338-20
NR 140
TC 4
Z9 4
U1 1
U2 7
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1477-3155
J9 J NANOBIOTECHNOL
JI J. Nanobiotechnol.
PD APR 21
PY 2021
VL 19
IS 1
AR 114
DI 10.1186/s12951-021-00852-1
PG 14
WC Biotechnology & Applied Microbiology; Nanoscience & Nanotechnology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biotechnology & Applied Microbiology; Science & Technology - Other
   Topics
GA RQ1GG
UT WOS:000642166800001
PM 33882955
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Fenner, BJ
   Cheung, CMG
   Sim, SS
   Lee, WK
   Staurenghi, G
   Lai, TYY
   Ruamviboonsuk, P
   Kokame, G
   Yanagi, Y
   Teo, KYC
AF Fenner, Beau J.
   Cheung, Chui Ming Gemmy
   Sim, Shaun S.
   Lee, Won Ki
   Staurenghi, Giovanni
   Lai, Timothy Y. Y.
   Ruamviboonsuk, Paisan
   Kokame, Gregg
   Yanagi, Yasuo
   Teo, Kelvin Y. C.
TI Evolving treatment paradigms for PCV
SO EYE
LA English
DT Review
ID POLYPOIDAL CHOROIDAL VASCULOPATHY; VERTEPORFIN PHOTODYNAMIC THERAPY;
   ENDOTHELIAL GROWTH-FACTOR; MACULAR DEGENERATION; INCREASED EXPRESSION;
   VISUAL-ACUITY; INTRAVITREAL AFLIBERCEPT; SUBMACULAR HEMORRHAGE;
   GEOGRAPHIC ATROPHY; EXTEND REGIMENS
AB Polypoidal choroidal vasculopathy (PCV) is a subtype of neovascular AMD (nAMD) that accounts for a significant proportion of nAMD cases worldwide, and particularly in Asia. Contemporary PCV treatment strategies have closely followed those used in typical nAMD, though there are significant gaps in knowledge on PCV management and it remains unclear if these strategies are appropriate. Current clinical trial data suggest intravitreal anti-vascular endothelial growth factor (VEGF) therapy alone or in combination with photodynamic therapy is effective in managing haemorrhage and exudation in PCV, although the optimal treatment interval, including as-needed and treat-and-extend approaches, is unclear. Newer imaging modalities, including OCT angiography and high-resolution spectral domain OCT have enabled characterisation of unique PCV biomarkers that may provide guidance on how and when treatment and re-treatment should be initiated. Treatment burden for PCV is a major focus of future therapeutic research and several newly developed anti-VEGF agents, including brolucizumab, faricimab, and new modes of drug delivery like the port delivery system, offer hope for dramatically reduced treatment burden for PCV patients. Beyond anti-VEGF therapy, recent developments in our understanding of PCV pathophysiology, in particular the role of choroidal anatomy and lipid mediators in PCV pathogenesis, offer new treatment avenues that may become clinically relevant in the future. This article explores the current management of PCV and more recent approaches to PCV treatment based on an improved understanding of this unique disease process.
C1 [Fenner, Beau J.; Cheung, Chui Ming Gemmy; Sim, Shaun S.; Teo, Kelvin Y. C.] Singapore Natl Eye Ctr, Singapore, Singapore.
   [Fenner, Beau J.; Cheung, Chui Ming Gemmy; Sim, Shaun S.; Teo, Kelvin Y. C.] Singapore Eye Res Inst, Singapore, Singapore.
   [Fenner, Beau J.; Cheung, Chui Ming Gemmy; Teo, Kelvin Y. C.] Natl Univ Singapore, Duke NUS Grad Med Sch, Singapore, Singapore.
   [Lee, Won Ki] Nune Eye Hosp, Seoul, South Korea.
   [Staurenghi, Giovanni] Univ Milan, Dept Biomed & Clin Sci Luigi Sacco, Eye Clin, Milan, Italy.
   [Lai, Timothy Y. Y.] Chinese Univ Hong Kong, Hong Kong Eye Hosp, Dept Ophthalmol & Visual Sci, Hong Kong, Peoples R China.
   [Ruamviboonsuk, Paisan] Rajavithi Hosp, Dept Ophthalmol, Bangkok, Thailand.
   [Kokame, Gregg] Univ Hawaii, Dept Surg, Div Ophthalmol, Sch Med, Honolulu, HI USA.
   [Yanagi, Yasuo] Yokohama City Univ, Dept Ophthalmol & Microtechnol, Yokohama, Kanagawa, Japan.
   [Teo, Kelvin Y. C.] Univ Sydney, Sydney, NSW, Australia.
C3 Singapore National Eye Center; National University of Singapore;
   Singapore National Eye Center; National University of Singapore;
   University of Milan; Luigi Sacco Hospital; Chinese University of Hong
   Kong; Rajavithi Hospital; University of Hawaii System; Yokohama City
   University; University of Sydney
RP Teo, KYC (通讯作者)，Singapore Natl Eye Ctr, Singapore, Singapore.; Teo, KYC (通讯作者)，Singapore Eye Res Inst, Singapore, Singapore.; Teo, KYC (通讯作者)，Natl Univ Singapore, Duke NUS Grad Med Sch, Singapore, Singapore.; Teo, KYC (通讯作者)，Univ Sydney, Sydney, NSW, Australia.
EM kelvin.teo.y.c@singhealth.com.sg
RI Yanagi, Yasuo/AAA-5441-2022
OI Teo, Kelvin/0000-0002-7458-7081; Fenner, Beau/0000-0002-5356-7604; Sim,
   Shaun/0000-0001-8940-4842; Lai, Timothy/0000-0002-7832-6428
CR Azuma K, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-65346-w
   Baek J, 2019, EYE, V33, P419, DOI 10.1038/s41433-018-0228-7
   Baumal CR, 2020, OPHTHALMOLOGY, V127, P1345, DOI 10.1016/j.ophtha.2020.04.017
   Bo QY, 2019, JAMA OPHTHALMOL, V137, P642, DOI 10.1001/jamaophthalmol.2019.0449
   Campochiaro PA, 2019, OPHTHALMOLOGY, V126, P1141, DOI 10.1016/j.ophtha.2019.03.036
   Chaikitmongkol V, 2022, OPHTHALMOL RETINA, V6, P21, DOI 10.1016/j.oret.2021.03.012
   Chakravarthy U, 2021, EYE, V35, P2983, DOI 10.1038/s41433-020-01354-4
   Chan WM, 2004, OPHTHALMOLOGY, V111, P1576, DOI 10.1016/j.ophtha.2003.12.056
   Chang Young Suk, 2018, Korean J Ophthalmol, V32, P361, DOI 10.3341/kjo.2017.0095
   Chang YC, 2020, RETINA-J RET VIT DIS, V40, P1403, DOI 10.1097/IAE.0000000000002583
   Cheong KX, 2021, CLIN EXP OPHTHALMOL, V49, P430, DOI 10.1111/ceo.13927
   Cheong KX, 2021, SURV OPHTHALMOL, V66, P68, DOI 10.1016/j.survophthal.2020.05.003
   Cheong KX, 2020, EYE, V34, P2257, DOI 10.1038/s41433-020-0803-6
   Cheung CMG, 2021, RETINA-J RET VIT DIS, V41, P2370, DOI 10.1097/IAE.0000000000003195
   Cheung CMG, 2021, RETINA-J RET VIT DIS, V41, P387, DOI 10.1097/IAE.0000000000002902
   Cheung CMG, 2019, OPHTHALMOL RETINA, V3, P1045, DOI 10.1016/j.oret.2019.06.002
   Cheung CMG, 2019, EYE, V33, P14, DOI 10.1038/s41433-018-0158-4
   Cheung CMG, 2018, OPHTHALMOLOGY, V125, P708, DOI 10.1016/j.ophtha.2017.11.019
   Cheung CMG, 2017, RETINA-J RET VIT DIS, V37, P1464, DOI 10.1097/IAE.0000000000001391
   Cho JH, 2016, AM J OPHTHALMOL, V169, P79, DOI 10.1016/j.ajo.2016.06.014
   Cho SC, 2021, ACTA OPHTHALMOL, V99, pE706, DOI 10.1111/aos.14676
   Ciardella AP, 2004, SURV OPHTHALMOL, V49, P25, DOI 10.1016/j.survophthal.2003.10.007
   Daniel E, 2018, OPHTHALMOLOGY, V125, P1037, DOI 10.1016/j.ophtha.2018.01.004
   Deng YH, 2021, AGING-US, V13, P13968, DOI 10.18632/aging.203006
   Dugel PU, 2021, OPHTHALMOLOGY, V128, P89, DOI [10.1016/j.opatha.2020.06.028, 10.1016/j.ophtha.2020.06.028]
   Dugel PU, 2020, OPHTHALMOLOGY, V127, P72, DOI 10.1016/j.ophtha.2019.04.017
   Evans RN, 2020, JAMA OPHTHALMOL, V138, P1043, DOI 10.1001/jamaophthalmol.2020.3001
   Fenner BJ, 2020, OPHTHALMOL RETINA, V4, P403, DOI 10.1016/j.oret.2019.10.019
   Freund KB, 2015, RETINA-J RET VIT DIS, V35, P1489, DOI 10.1097/IAE.0000000000000627
   Fujiwara K, 2018, SEMIN OPHTHALMOL, V33, P813, DOI 10.1080/08820538.2018.1506483
   Gillies M, 2020, AM J OPHTHALMOL, V210, P116, DOI 10.1016/j.ajo.2019.10.007
   Gomi F, 2015, RETINA-J RET VIT DIS, V35, P1569, DOI 10.1097/IAE.0000000000000526
   Gomi F, 2010, AM J OPHTHALMOL, V150, P48, DOI 10.1016/j.ajo.2010.02.008
   Grunwald JE, 2015, OPHTHALMOLOGY, V122, P809, DOI 10.1016/j.ophtha.2014.11.007
   Grunwald JE, 2014, OPHTHALMOLOGY, V121, P150, DOI 10.1016/j.ophtha.2013.08.015
   Guymer RH, 2019, OPHTHALMOLOGY, V126, P723, DOI 10.1016/j.ophtha.2018.11.025
   Heier JS, 2021, RETINA-J RET VIT DIS, V41, P1, DOI 10.1097/IAE.0000000000003003
   Hosokawa M, 2017, JPN J OPHTHALMOL, V61, P150, DOI 10.1007/s10384-016-0492-7
   Jaffe, 2019, AM ACAD OPHTH M SAN
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Jones A, 2011, P NATL ACAD SCI USA, V108, P14578, DOI 10.1073/pnas.1102853108
   Jordan-Yu JM, 2021, RETINA-J RET VIT DIS, V41, P1084, DOI 10.1097/IAE.0000000000002966
   Joussen AM, 2021, EYE, V35, P1305, DOI 10.1038/s41433-020-01377-x
   Kawamura A, 2013, ACTA OPHTHALMOL, V91, pe474, DOI 10.1111/aos.12110
   Keenan TDL, 2021, AM J OPHTHALMOL, V224, P267, DOI 10.1016/j.ajo.2020.12.012
   Kikushima W, 2021, J CLIN MED, V10, DOI 10.3390/jcm10051098
   Kim H, 2016, GRAEF ARCH CLIN EXP, V254, P1497, DOI 10.1007/s00417-015-3221-x
   Kim J, 2017, EYE, V31, P1678, DOI 10.1038/eye.2017.126
   Kim JH, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-72030-6
   Koh A, 2017, JAMA OPHTHALMOL, V135, P1206, DOI 10.1001/jamaophthalmol.2017.4030
   Koh A, 2012, RETINA-J RET VIT DIS, V32, P1453, DOI 10.1097/IAE.0b013e31824f91e8
   Koizumi H, 2013, AM J OPHTHALMOL, V155, P305, DOI 10.1016/j.ajo.2012.07.018
   Kokame GT, 2021, OPHTHALMOL RETINA, V5, P954, DOI 10.1016/j.oret.2021.05.009
   Kokame Gregg T, 2014, Trans Am Ophthalmol Soc, V112, P74
   Kokame GT, 2014, OPHTHALMOLOGICA, V231, P94, DOI 10.1159/000354072
   Kumar S, 2014, INVEST OPHTH VIS SCI, V55, P3842, DOI 10.1167/iovs.13-13111
   Lee SC, 2004, OPHTHALMOLOGICA, V218, P193, DOI 10.1159/000076844
   Lee WK, 2018, JAMA OPHTHALMOL, V136, P786, DOI 10.1001/jamaophthalmol.2018.1804
   Li ML, 2016, SCI REP-UK, V6, DOI 10.1038/srep38342
   Liew G, 2021, EYE, V35, P1011, DOI 10.1038/s41433-020-0834-z
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Lim TH, 2020, JAMA OPHTHALMOL, V138, P935, DOI 10.1001/jamaophthalmol.2020.2443
   Liu K, 2014, OPHTHALMOLOGY, V121, P911, DOI 10.1016/j.ophtha.2013.10.042
   Lorentzen TD, 2018, RETINA-J RET VIT DIS, V38, P2363, DOI 10.1097/IAE.0000000000001872
   Lu ZG, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0216808
   Maruko I, 2011, AM J OPHTHALMOL, V151, P594, DOI 10.1016/j.ajo.2010.10.030
   Matsumoto H, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-86014-7
   Ohji M, 2020, ADV THER, V37, P1173, DOI 10.1007/s12325-020-01236-x
   Oishi A, 2014, OPHTHALMOLOGY, V121, P1151, DOI 10.1016/j.ophtha.2013.12.037
   Oishi A, 2013, AM J OPHTHALMOL, V156, P644, DOI 10.1016/j.ajo.2013.05.024
   Okamoto N, 1997, AM J PATHOL, V151, P281
   Quaranta M, 2002, AM J OPHTHALMOL, V134, P277, DOI 10.1016/S0002-9394(02)01516-7
   Roche, NEW PHAS 3 DAT SHOW
   Rogers AH, 2003, OPHTHALMIC SUR LA IM, V34, P60, DOI 10.3928/1542-8877-20030101-14
   Rouvas A, 2021, EUR J OPHTHALMOL, V31, P2868, DOI 10.1177/11206721211014717
   Sharma S, 2016, OPHTHALMOLOGY, V123, P865, DOI 10.1016/j.ophtha.2015.12.002
   Sonoda S, 2013, BMC OPHTHALMOL, V13, DOI 10.1186/1471-2415-13-43
   Spaide RF, 2002, RETINA-J RET VIT DIS, V22, P529, DOI 10.1097/00006982-200210000-00001
   Spaide RF, 2021, RETINA-J RET VIT DIS, V41, P997, DOI 10.1097/IAE.0000000000003004
   Spaide RF, 2020, OPHTHALMOLOGY, V127, P616, DOI 10.1016/j.ophtha.2019.11.004
   Srour M, 2016, BRIT J OPHTHALMOL, V100, P1489, DOI 10.1136/bjophthalmol-2015-307892
   Tamachi T, 2020, OPHTHALMOL THER, V9, P1069, DOI 10.1007/s40123-020-00312-3
   Teo KYC, 2021, OPHTHALMOL RETINA, V5, P945, DOI 10.1016/j.oret.2021.04.002
   Teo KYC, 2022, BRIT J OPHTHALMOL, V106, P987, DOI 10.1136/bjophthalmol-2020-318354
   Teo KYC, 2020, RETINA-J RET VIT DIS, V40, P2285, DOI 10.1097/IAE.0000000000002779
   Teo KYC, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19092611
   Teo KYC, 2018, RETINA-J RET VIT DIS, V38, P1675, DOI 10.1097/IAE.0000000000001776
   Tom I, 2020, P NATL ACAD SCI USA, V117, P9952, DOI 10.1073/pnas.1917608117
   Warrow DJ, 2013, RETINA-J RET VIT DIS, V33, P1659, DOI 10.1097/IAE.0b013e3182953df4
   Wataru K, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0229231
   Wolff B, 2020, CLIN EXP OPHTHALMOL, V48, P636, DOI 10.1111/ceo.13742
   Wong TY, 2019, AM J OPHTHALMOL, V204, P80, DOI 10.1016/j.ajo.2019.02.027
   Wykoff CC, 2015, OPHTHALMOLOGY, V122, P2514, DOI 10.1016/j.ophtha.2015.08.009
   Xu ND, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0226763
   Yanagi Y, 2018, RETINA-J RET VIT DIS, V38, P1509, DOI 10.1097/IAE.0000000000001758
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
   You QS, 2021, JAMA OPHTHALMOL, V139, P734, DOI 10.1001/jamaophthalmol.2021.1275
NR 97
TC 4
Z9 4
U1 0
U2 1
PU SPRINGERNATURE
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND
SN 0950-222X
EI 1476-5454
J9 EYE
JI Eye
PD FEB
PY 2022
VL 36
IS 2
BP 257
EP 265
DI 10.1038/s41433-021-01688-7
EA JUL 2021
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA YQ7VR
UT WOS:000673436700003
PM 34262165
OA hybrid, Green Published
DA 2022-11-30
ER

PT J
AU Rothenbuehler, SP
   Wolf-Schnurrbusch, UEK
   Wolf, S
AF Rothenbuehler, Simon Paul
   Wolf-Schnurrbusch, Ute E. K.
   Wolf, Sebastian
TI Macular pigment density at the site of altered fundus autofluorescence
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE Macular pigment; Fundus autofluorescence; Age-related macular
   degeneration; Age-related maculopathy
ID OPTICAL-DENSITY; SPATIAL-DISTRIBUTION; RETINOID COMPONENT; GEOGRAPHIC
   ATROPHY; HEALTHY-SUBJECTS; RPE CELLS; DEGENERATION; LIPOFUSCIN; DISEASE;
   EPITHELIUM
AB Background The purpose of our study was to determine whether abnormalities of increased or decreased fundus autofluorescence (FAF) are associated with local changes in macular pigment (MP) optical density in patients with age-related maculopathy (ARM) and macular degeneration (ARMD).
   Methods FAF imaging and MP measurement was performed through dilated pupils using a modified confocal scanning laser ophthalmoscope (HRA, Heidelberg Engineering, Germany) according to a standard protocol. Two-wavelength autofluorescence method was employed for determination of local macular pigment optical density (LMPOD). Image analysis and measurement of LMPOD at the area of altered FAF was performed using Heidelberg Eye Explorer Software. Mean values of LMPOD at the site of FAF abnormality were compared to an adjacent location with normal background FAF of the same image.
   Results Sixty-three eyes of 63 patients (28 male, 35 female, mean age 75.8 +/- 8.8 years) were included in this analysis. Group 1 comprised 31 cases with focal increased FAF. Mean LMPOD in the area of increased FAF was 0.073 +/- 0.083 compared to 0.075 +/- 0.074 in the adjacent area of normal FAF. Group 2 comprised 32 cases of focal decreased FAF. Mean LMPOD in the area of decreased FAF was -0.004 +/- 0.088 compared 0.053 +/- 0.075 in the adjacent area of normal FAF. The site of increased FAF showed no significant difference in LMPOD (p=0.927) compared to adjacent areas of normal FAF, while areas of decreased FAF revealed significantly lower LMPOD (p=0.001) compared to adjacent areas of normal FAF.
   Conclusions Focal increases of FAF due to ARM or ARMD did not lead to change in LMPOD. Presumably, retinal layers containing MP are unaffected by these processes. For lesions exhibiting focal decreased FAF, a reduction of LMPOD cannot be excluded. Further studies are needed to investigate MP in the course of disease.
C1 [Wolf-Schnurrbusch, Ute E. K.; Wolf, Sebastian] Univ Hosp Bern, Univ Klinikum Augenheilkunde, Inselspital, CH-3010 Bern, Switzerland.
   [Rothenbuehler, Simon Paul] Univ Klinikum Augenheilkunde, Bern Photog Reading Ctr, Bern, Switzerland.
C3 University of Bern; University Hospital of Bern
RP Wolf, S (通讯作者)，Univ Hosp Bern, Univ Klinikum Augenheilkunde, Inselspital, CH-3010 Bern, Switzerland.
EM Sebastian.wolf@insel.ch
RI Wolf, Sebastian/B-8782-2008
OI Wolf, Sebastian/0000-0002-7467-7028; Rothenbuehler,
   Simon/0000-0002-5223-6483
FU SNF [SNF 3200 Bo-109962/1, Velux 303]
FX Grant support SNF 3200 Bo-109962/1 and Velux 303
CR Ambati J, 2003, SURV OPHTHALMOL, V48, P257, DOI 10.1016/S0039-6257(03)00030-4
   Beatty S, 2008, INVEST OPHTH VIS SCI, V49, P843, DOI 10.1167/iovs.07-1276
   Bindewald A, 2005, INVEST OPHTH VIS SCI, V46, P3309, DOI 10.1167/iovs.04-0430
   Bird A, 1996, BRIT J OPHTHALMOL, V80, P2, DOI 10.1136/bjo.80.1.2
   Bone RA, 1997, EXP EYE RES, V64, P211, DOI 10.1006/exer.1996.0210
   Boulton M, 2001, EYE, V15, P384, DOI 10.1038/eye.2001.141
   Delori FC, 2000, INVEST OPHTH VIS SCI, V41, P496
   Delori FC, 2001, J OPT SOC AM A, V18, P1212, DOI 10.1364/JOSAA.18.001212
   Delori FC, 2001, INVEST OPHTH VIS SCI, V42, P1855
   DELORI FC, 1995, INVEST OPHTH VIS SCI, V36, P718
   Einbock W, 2005, GRAEF ARCH CLIN EXP, V243, P300, DOI 10.1007/s00417-004-1027-3
   Gillies MC, 2009, OPHTHALMOLOGY, V116, P2422, DOI 10.1016/j.ophtha.2009.05.010
   Green W Richard, 2005, Retina, V25, P1519, DOI 10.1097/00006982-200507001-00015
   Helb HM, 2008, RETINA-J RET VIT DIS, V28, P808, DOI 10.1097/IAE.0b013e31816d81aa
   Holz FG, 1999, GRAEF ARCH CLIN EXP, V237, P145, DOI 10.1007/s004170050209
   Holz FG, 1999, INVEST OPHTH VIS SCI, V40, P737
   Holz FG, 2007, AM J OPHTHALMOL, V143, P463, DOI 10.1016/j.ajo.2006.11.041
   Issa PC, 2009, EXP EYE RES, V89, P25, DOI 10.1016/j.exer.2009.02.006
   Klaver CCW, 1998, ARCH OPHTHALMOL-CHIC, V116, P653, DOI 10.1001/archopht.116.5.653
   Klein R, 2007, OPHTHALMOLOGY, V114, P253, DOI 10.1016/j.ophtha.2006.10.040
   Mares JA, 2006, AM J CLIN NUTR, V84, P1107
   Nolan J, 2004, INVEST OPHTH VIS SCI, V45, P3940, DOI 10.1167/iovs.04-0273
   Richer Stuart, 2007, Optometry, V78, P213, DOI 10.1016/j.optm.2006.10.019
   Schmitz-Valckenberg S, 2009, SURV OPHTHALMOL, V54, P96, DOI 10.1016/j.survophthal.2008.10.004
   Schutt F, 2000, INVEST OPHTH VIS SCI, V41, P2303
   SNODDERLY DM, 1984, INVEST OPHTH VIS SCI, V25, P674
   Sommerburg Olaf, 2000, Biofactors, V11, P3
   Sparrow JR, 2010, INVEST OPHTH VIS SCI, V51, P4351, DOI 10.1167/iovs.10-5852
   Trieschmann M, 2008, EYE, V22, P132, DOI 10.1038/sj.eye.6702780
   Trieschmann M, 2007, EXP EYE RES, V84, P718, DOI 10.1016/j.exer.2006.12.010
   van der Veen RLP, 2010, OPHTHALMOLOGY, V117, P966, DOI 10.1016/j.ophtha.2009.10.019
   vonRuckmann A, 1997, INVEST OPHTH VIS SCI, V38, P478
   Wustemeyer H, 2003, GRAEF ARCH CLIN EXP, V241, P647, DOI 10.1007/s00417-003-0730-9
   Wustemeyer H, 2002, GRAEF ARCH CLIN EXP, V240, P666, DOI 10.1007/s00417-002-0515-6
NR 34
TC 8
Z9 8
U1 0
U2 2
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0721-832X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD APR
PY 2011
VL 249
IS 4
BP 499
EP 504
DI 10.1007/s00417-010-1528-1
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 756SJ
UT WOS:000290034700005
PM 20878175
OA Green Published, Green Submitted
DA 2022-11-30
ER

PT J
AU Abugreen, S
   Muldrew, KA
   Stevenson, MR
   VanLeeuwen, R
   Dejong, PTVM
   Chakravarthy, U
AF Abugreen, S
   Muldrew, KA
   Stevenson, MR
   VanLeeuwen, R
   Dejong, PTVM
   Chakravarthy, U
TI CNV subtype in first eyes predicts severity of ARM in fellow eyes
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID MACULAR DEGENERATION; DRUSEN; ABNORMALITIES; PROGNOSIS
AB Aim: To examine the relation between the type of choroidal neovascularisation (CNV) in the first eye and age related maculopathy (ARM) severity in the fellow eye.
   Methods: Colour fundus photographs and fluorescein angiograms from 67 subjects with a clinical diagnosis of CNV in one eye were scrutinised. CNV was classified as wholly classic, predominantly Classic, minimally classic, or occult based on the proportion of classic leakage within the lesion. ARM changes in the fellow eye were assigned a severity stage using the system described by the Rotterdam Eye Study. Logistic regression analysis was employed to examine the association between CNV subtype and ARM stage.
   Results: Of subjects with classic or predominantly classic CNV in the first eye 78% exhibited least no or early ARM features in the fellow eye. By contrast, 85% of subjects with minimally classic or occult CNV in the first eye exhibited more advanced ARM features in the fellow eye. Kruskall-Wallis one way ANOVA by ranks showed that this was highly significant (p = 0.002). Logistic regression analysis showed that as the proportion of occult CNV increased in the first eye, fellow eyes of subjects in this category were more likely to have been assigned to a higher ARM stage (p = 0.019). The area occupied by the CNV in the first eye also influenced severity of ARM changes in the fellow eye.
   Conclusion: The type and extent of CNV in the first affected eye has a distinct relation to ARM severity in the fellow eye. Fellow eyes of subjects with minimally classic or occult CNV in the first affected eye show widespread ARM changes suggestive of retinal pigment epithelial dysfunction. These findings suggest that classic CNV may be focal disease while occult CNV is essentially a more widespread retinal pigment epithelial disorder.
C1 Queens Univ Belfast, Belfast, Antrim, North Ireland.
   Royal Hosp, Belfast, Antrim, North Ireland.
   Erasmus MC, Dept Epidemiol & Biostat, Rotterdam, Netherlands.
   Netherlands Ophthalm Res Inst, KNAW, NL-1100 AC Amsterdam, Netherlands.
   Univ Amsterdam, Acad Med Ctr, Dept Ophthalmol, NL-1105 AZ Amsterdam, Netherlands.
C3 Queens University Belfast; Erasmus University Rotterdam; Erasmus MC;
   Royal Netherlands Academy of Arts & Sciences; Netherlands Institute for
   Neuroscience (NIN-KNAW); University of Amsterdam; Academic Medical
   Center Amsterdam
RP Chakravarthy, U (通讯作者)，Queens Univ Belfast, Belfast, Antrim, North Ireland.
EM u.chakravarthy@qub.ac.uk
OI Chakravarthy, Usha/0000-0002-2606-3734
CR Abdelsalam A, 1999, SURV OPHTHALMOL, V44, P1, DOI 10.1016/S0039-6257(99)00072-7
   Arnold J, 2001, AM J OPHTHALMOL, V131, P541
   BRESSLER NM, 1995, ARCH OPHTHALMOL-CHIC, V113, P301, DOI 10.1001/archopht.1995.01100030055022
   BRESSLER NM, 1988, RETINA-J RET VIT DIS, V8, P109, DOI 10.1097/00006982-198808020-00005
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   BRESSLER SB, 1990, ARCH OPHTHALMOL-CHIC, V108, P1442, DOI 10.1001/archopht.1990.01070120090035
   BURGESS DB, 1993, ARCH OPHTHALMOL-CHIC, V111, P1189
   Evans J, 1996, BRIT J OPHTHALMOL, V80, P9, DOI 10.1136/bjo.80.1.9
   GREGOR Z, 1977, BRIT J OPHTHALMOL, V61, P141, DOI 10.1136/bjo.61.2.141
   HOLZ FG, 1994, OPHTHALMOLOGY, V101, P1522
   *INT ARM EP STUD G, 1995, OLK, V39, P367
   KLAVER CCW, 2001, INVEST OPHTHALMOL, V72, P2237
   Klein R, 1997, OPHTHALMOLOGY, V104, P7, DOI 10.1016/S0161-6420(97)30368-6
   *MAC PHOT STUD GRO, 1977, ARCH OPHTHALMOL-CHIC, V115, P741
   *MAC PHOT STUD GRO, 1982, ARCH OPHTHALMOL-CHIC, V109, P912
   Maguire MG, 1997, ARCH OPHTHALMOL-CHIC, V115, P741
   PAULEIKHOFF D, 1990, AM J OPHTHALMOL, V109, P38, DOI 10.1016/S0002-9394(14)75576-X
   Pieramici D J, 1998, Curr Opin Ophthalmol, V9, P38, DOI 10.1097/00055735-199806000-00007
   ROY M, 1990, Eye (London), V4, P813
   SARKS SH, 1980, AUST J OPHTHALMOL, V8, P117, DOI 10.1111/j.1442-9071.1980.tb01670.x
   SCHACHAT AP, 1994, ARCH OPHTHALMOL-CHIC, V112, P500
   SCHAFT TL, 1992, OPHTHALMOLOGY, V99, P278
   STERNBERG P, 1991, ARCH OPHTHALMOL-CHIC, V109, P1242
   Sternberg P, 1996, ARCH OPHTHALMOL-CHIC, V114, P400
NR 24
TC 18
Z9 18
U1 0
U2 3
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
EI 1468-2079
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD MAR
PY 2003
VL 87
IS 3
BP 307
EP 311
DI 10.1136/bjo.87.3.307
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 652FE
UT WOS:000181368500016
PM 12598444
OA Green Published, Green Submitted, Bronze
DA 2022-11-30
ER

PT J
AU Wang, L
   Li, CM
   Rudolf, M
   Belyaeva, OV
   Chung, BH
   Messinger, JD
   Kedishvili, NY
   Curcio, CA
AF Wang, Lan
   Li, Chuan-Ming
   Rudolf, Martin
   Belyaeva, Olga V.
   Chung, Byung Hong
   Messinger, Jeffrey D.
   Kedishvili, Natalia Y.
   Curcio, Christine A.
TI Lipoprotein Particles of Intraocular Origin in Human Bruch Membrane: An
   Unusual Lipid Profile
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID B-CONTAINING LIPOPROTEINS; AGE-RELATED MACULOPATHY; HUMAN
   ATHEROSCLEROTIC PLAQUES; RETINAL-PIGMENT EPITHELIUM;
   LOW-DENSITY-LIPOPROTEIN; QUICK-FREEZE/DEEP-ETCH; APOLIPOPROTEIN-B;
   VITAMIN-A; STIMULATES SECRETION; MACULAR DEGENERATION
AB PURPOSE. Throughout adulthood, Bruch membrane (BrM) accumulates esterified cholesterol (EC) associated with abundant 60- to 80-nm-diameter lipoprotein-like particles (LLP), putative apolipoprotein B (apoB) lipoproteins secreted by the retinal pigment epithelium (RPE). In the present study, neutral lipid, phospholipids, and retinoid components of human BrM-LLP were assayed.
   METHODS. Particles isolated from paired choroids of human donors were subjected to comprehensive lipid profiling (preparative liquid chromatography [LC] gas chromatography [GC]), thin-layer chromatography (TLC), high-performance liquid chromatography (HPLC), Western blot analysis, and negative stain electron microscopy. Results were compared to plasma lipoproteins isolated from normolipemic volunteers and to conditioned medium from RPE-J cells supplemented with palmitate to induce particle synthesis and secretion.
   RESULTS. EC was the largest component (32.4 +/- 7.9 mol%) of BrM-LLP lipids. EC was 11.3-fold more abundant than triglyceride (TG), unlike large apoB lipoproteins in plasma. Of the fatty acids (FA) esterified to cholesterol, linoleate (18:2n6) was the most abundant (41.7 +/- 4.7 mol%). Retinyl ester (RE) was detectable at picomolar levels in BrM-LLP. Notably scarce in any BrM-LLP lipid class was the photoreceptor-abundant FA docosahexaenoate (DHA, 22:6n3). RPE-J cells synthesized apoB and numerous EC-rich spherical particles.
   CONCLUSIONS. BrM-LLP composition resembles plasma LDL more than it does photoreceptors. An EC-rich core is possible for newly synthesized lipoproteins as well as those processed in plasma. Abundant EC could contribute to a transport barrier in aging and lesion formation in age-related maculopathy (ARM). Analysis of BrM-LLP composition has revealed new aspects of retinal cholesterol and retinoid homeostasis. (Invest Ophthalmol Vis Sci. 2009; 50:870-877) DOI:10.1167/iovs.082376
C1 [Curcio, Christine A.] Univ Alabama Birmingham, Sch Med, Callahan Eye Fdn Hosp, Dept Ophthalmol, Birmingham, AL 35294 USA.
   [Belyaeva, Olga V.; Kedishvili, Natalia Y.] Univ Alabama Birmingham, Dept Biochem & Mol Genet, Birmingham, AL 35294 USA.
   [Chung, Byung Hong] Univ Alabama Birmingham, Dept Nutr Biochem & Genom, Birmingham, AL 35294 USA.
C3 University of Alabama System; University of Alabama Birmingham;
   University of Alabama System; University of Alabama Birmingham;
   University of Alabama System; University of Alabama Birmingham
RP Curcio, CA (通讯作者)，Univ Alabama Birmingham, Sch Med, Callahan Eye Fdn Hosp, Dept Ophthalmol, 700 S 18th St,Room H020, Birmingham, AL 35294 USA.
EM curcio@uab.edu
OI Kedishvili, Natalia/0000-0001-6917-4891; Beliaeva,
   Olga/0000-0003-2512-925X
FU National Institutes of Health (NIH) [EY06109]; EyeSight Foundation of
   Alabama; Macula Vision Research Foundation; Deutsche
   Forschungsgemeinschaft; NIH [AA12153]; Research to Prevent Blindness,
   Inc.; NATIONAL EYE INSTITUTE [R01EY006109] Funding Source: NIH RePORTER;
   NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R01AA012153] Funding
   Source: NIH RePORTER
FX Supported by National Institutes of Health (NIH) Grant EY06109 (CAC);
   the EyeSight Foundation of Alabama (CAC); the Macula Vision Research
   Foundation (CAC); Deutsche Forschungsgemeinschaft (MR); NIH grant
   AA12153 (NYK); and Research to Prevent Blindness, Inc. (CAC).
CR Anderson DH, 2001, AM J OPHTHALMOL, V131, P767, DOI 10.1016/S0002-9394(00)00961-2
   BAZAN NG, 1992, ADV EXP MED BIOL, V318, P295
   BIRD AC, 1986, T OPHTHAL SOC UK, V105, P674
   BJORKHEM I, 2004, ARTERIOSCLER THROMB, V5, P5
   BOESZEBATTAGLIA K, 1990, J BIOL CHEM, V265, P18867
   Bretillon L, 2008, INVEST OPHTH VIS SCI, V49, P1307, DOI 10.1167/iovs.07-0808
   CasaroliMarano RP, 1996, J LIPID RES, V37, P1037
   Chung BH, 2005, BBA-MOL CELL BIOL L, V1733, P76, DOI 10.1016/j.bbalip.2004.12.002
   CHUNG BH, 1994, ARTERIOSCLER THROMB, V14, P622, DOI 10.1161/01.ATV.14.4.622
   *COUNC NAE, 1999, VIS RES NAT PLAN 199
   Curcio CA, 2005, EXP EYE RES, V80, P761, DOI 10.1016/j.exer.2004.09.017
   Curcio CA, 2001, INVEST OPHTH VIS SCI, V42, P265
   DEMEL RA, 1977, BIOCHIM BIOPHYS ACTA, V465, P1, DOI 10.1016/0005-2736(77)90350-9
   Dithmar S, 2000, INVEST OPHTH VIS SCI, V41, P2035
   DIXON JL, 1991, J BIOL CHEM, V266, P5080
   During A, 2008, J LIPID RES, V49, P1715, DOI 10.1194/jlr.M700580-JLR200
   Edwards Albert O., 2007, Angiogenesis, V10, P119, DOI 10.1007/s10456-007-9064-2
   Elner Victor M, 2002, Trans Am Ophthalmol Soc, V100, P301
   FOLCH J, 1957, J BIOL CHEM, V226, P497
   Gibbons GF, 2004, BIOCHEM SOC T, V32, P59, DOI 10.1042/BST0320059
   Gordiyenko N, 2004, INVEST OPHTH VIS SCI, V45, P2822, DOI 10.1167/iovs.04-0074
   GRINDLE CFJ, 1978, T OPHTHAL SOC UK, V98, P172
   Gullapalli VK, 2008, EXP EYE RES, V86, P189, DOI 10.1016/j.exer.2007.10.009
   GUYTON JR, 1989, AM J PATHOL, V134, P705
   Haimovici R, 2001, INVEST OPHTH VIS SCI, V42, P1592
   Harrison EH, 2005, ANNU REV NUTR, V25, P87, DOI 10.1146/annurev.nutr.25.050304.092614
   HOLZ FG, 1994, ARCH OPHTHALMOL-CHIC, V112, P402, DOI 10.1001/archopht.1994.01090150132035
   Huang JD, 2008, INVEST OPHTH VIS SCI, V49, P2721, DOI 10.1167/iovs.07-1196
   Huang JD, 2007, EXP EYE RES, V85, P202, DOI 10.1016/j.exer.2007.03.011
   Ishida BY, 2004, J LIPID RES, V45, P263, DOI 10.1194/jlr.M300306-JLR200
   Jonas A., 2002, BIOCH LIPIDS LIPOPRO, P483
   Kawaguchi R, 2007, SCIENCE, V315, P820, DOI 10.1126/science.1136244
   Kliffen M, 2000, BRIT J OPHTHALMOL, V84, P1415, DOI 10.1136/bjo.84.12.1415
   KRASINSKI SD, 1990, METABOLISM, V39, P357, DOI 10.1016/0026-0495(90)90249-C
   Kruth HS, 1997, CURR OPIN LIPIDOL, V8, P246, DOI 10.1097/00041433-199710000-00002
   Li CM, 2007, EXP EYE RES, V85, P192, DOI 10.1016/j.exer.2007.04.002
   Li CM, 2006, INVEST OPHTH VIS SCI, V47, P3119, DOI 10.1167/iovs.05-1446
   Li CM, 2005, INVEST OPHTH VIS SCI, V46, P2576, DOI 10.1167/iovs.05-0034
   Li CM, 2005, J LIPID RES, V46, P628, DOI 10.1194/jlr.M400428-JLR200
   Liang JJ, 2004, J BIOL CHEM, V279, P44938, DOI 10.1074/jbc.M408507200
   Malek G, 2005, P NATL ACAD SCI USA, V102, P11900, DOI 10.1073/pnas.0503015102
   Malek G, 2003, AM J PATHOL, V162, P413, DOI 10.1016/S0002-9440(10)63836-9
   Marmorstein LHY, 2002, P NATL ACAD SCI USA, V99, P13067, DOI 10.1073/pnas.202491599
   McCarty WJ, 2008, J APPL PHYSIOL, V105, P621, DOI 10.1152/japplphysiol.01245.2007
   NABI IR, 1993, J CELL SCI, V104, P37
   PARK SW, 1985, ANAL BIOCHEM, V149, P275, DOI 10.1016/0003-2697(85)90505-6
   PAULEIKHOFF D, 1990, OPHTHALMOLOGY, V97, P171
   Qtaishat NM, 2003, INVEST OPHTH VIS SCI, V44, P1435, DOI 10.1167/iovs.02-0679
   Rapp LM, 2000, INVEST OPHTH VIS SCI, V41, P1200
   Ruberti JW, 2003, INVEST OPHTH VIS SCI, V44, P1753, DOI 10.1167/iovs.02-0496
   Rudolf M, 2005, BRIT J OPHTHALMOL, V89, P1627, DOI 10.1136/bjo.2005.071183
   SAARI JC, 1989, J BIOL CHEM, V264, P8636
   SARKS SH, 1976, BRIT J OPHTHALMOL, V60, P324, DOI 10.1136/bjo.60.5.324
   Smith E B, 1974, Adv Lipid Res, V12, P1
   SPARKS CE, 1981, CAN J BIOCHEM CELL B, V59, P693, DOI 10.1139/o81-096
   SPARKS JD, 1992, J CLIN INVEST, V89, P1418, DOI 10.1172/JCI115731
   Suzuki M, 2007, MOL VIS, V13, P772
   Temel RE, 2007, J LIPID RES, V48, P1618, DOI 10.1194/jlr.M700109-JLR200
   Tserentsoodol N, 2006, MOL VIS, V12, P1319
   Vance DE, 2008, CURR OPIN LIPIDOL, V19, P229, DOI 10.1097/MOL.0b013e3282fee935
   Yamada Y, 2008, J NEUROCHEM, V105, P1187, DOI 10.1111/j.1471-4159.2008.05211.x
   Zak Z, 2002, J LIPID RES, V43, P2164, DOI 10.1194/jlr.M200253-JLR200
NR 62
TC 75
Z9 76
U1 0
U2 3
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD FEB
PY 2009
VL 50
IS 2
BP 870
EP 877
DI 10.1167/iovs.08-2376
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 397MD
UT WOS:000262665900050
PM 18806290
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Chang, CJ
   Huang, YM
   Hsieh, MH
   Li, AF
   Chen, SJ
AF Chang, Chia-Jui
   Huang, Yi-Ming
   Hsieh, Ming-Hung
   Li, An-Fei
   Chen, Shih-Jen
TI Flow signal change in polyps after anti-vascular endothelial growth
   factor therapy
SO PLOS ONE
LA English
DT Article
ID POLYPOIDAL CHOROIDAL VASCULOPATHY; AMPLITUDE-DECORRELATION ANGIOGRAPHY;
   COHERENCE TOMOGRAPHY ANGIOGRAPHY; VERTEPORFIN PHOTODYNAMIC THERAPY;
   RANIBIZUMAB THERAPY; EFFICACY; EVEREST; SAFETY
AB Optical coherence tomography angiography (OCTA) is a novel, non-invasive imaging tool used to detect vascular flow. The absence of a flow signal in OCTA in polyps revealed by indocyanine green angiography (ICGA) in patients with polypoidal choroidal vasculopathy (PCV) may indicate slow or compromised filling of blood flow from choroidal vessels. Naive patients with PCV treated with intravitreal injections of aflibercept (IVI-A) were enrolled in this study to validate the hypothesis that baseline flow may affect the outcome of polyp regression in ICGA. The flow signal of polyps in OCTA was detected by manual segmentation in the corresponding location by ICGA. Polyps were defined as high-flow if both OCTA and ICGA showed positive findings, and low-flow if OCTA showed a negative flow signal in 3 consecutive horizontal scans at the polyp area shown in ICGA. A total of 24 polyps were identified in 13 PCV patients at baseline. Of these 24 polyps, 22 (91.7%) were high-flow and 2 (8.3%) were low-flow. After 3 monthly IVI-A, all low-flow polyps had complete regression in ICGA. Among 17 (77%) high-flow polyps at baseline that had regression after treatment, 10 (58.8%) became low-flow, while 5 (22.7%) persistent polyps remained high-flow. Flow signal of polyps as detected by OCTA could be a predictive factor for treatment response in patients with PCV. Monitoring changes in flow signal after treatment is clinically relevant.
C1 [Chang, Chia-Jui; Huang, Yi-Ming; Li, An-Fei; Chen, Shih-Jen] Taipei Vet Gen Hosp, Dept Ophthalmol, Taipei, Taiwan.
   [Hsieh, Ming-Hung] Taipei City Hosp, Hoping Branch, Taipei, Taiwan.
   [Li, An-Fei; Chen, Shih-Jen] Natl Yang Ming Univ, Sch Med, Taipei, Taiwan.
   [Li, An-Fei] Cheng Hsin Gen Hosp, Dept Ophthalmol, Taipei, Taiwan.
C3 Taipei Veterans General Hospital; Taipei City Hospital; National Yang
   Ming Chiao Tung University; Cheng Hsin General Hospital
RP Chen, SJ (通讯作者)，Taipei Vet Gen Hosp, Dept Ophthalmol, Taipei, Taiwan.; Chen, SJ (通讯作者)，Natl Yang Ming Univ, Sch Med, Taipei, Taiwan.
EM sjchen96@gamil.com
OI Chen, Shih-Jen/0000-0001-9798-1578
CR Bo QY, 2019, JAMA OPHTHALMOL, V137, P642, DOI 10.1001/jamaophthalmol.2019.0449
   Chen YT, 2018, LASER SURG MED, V50, P427, DOI 10.1002/lsm.22801
   Cho HJ, 2015, JPN J OPHTHALMOL, V59, P29, DOI 10.1007/s10384-014-0349-x
   Cho JH, 2020, RETINA-J RET VIT DIS, V40, P468, DOI 10.1097/IAE.0000000000002384
   Fukuyama H, 2018, OPHTHALMOL RETINA, V2, P803, DOI 10.1016/j.oret.2017.11.016
   Hikichi T, 2015, BRIT J OPHTHALMOL, V99, P817, DOI 10.1136/bjophthalmol-2014-305606
   Huang CH, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-018-37384-y
   Huang YM, 2017, J OPHTHALMOL, V2017, DOI 10.1155/2017/3479695
   Inoue M, 2015, RETINA-J RET VIT DIS, V35, P2265, DOI 10.1097/IAE.0000000000000777
   Jia YL, 2012, OPT EXPRESS, V20, P4710, DOI 10.1364/OE.20.004710
   Kim JY, 2016, GRAEF ARCH CLIN EXP, V254, P1505, DOI 10.1007/s00417-015-3228-3
   Koh A, 2017, JAMA OPHTHALMOL, V135, P1206, DOI 10.1001/jamaophthalmol.2017.4030
   Koh A, 2012, RETINA-J RET VIT DIS, V32, P1453, DOI 10.1097/IAE.0b013e31824f91e8
   Miura M, 2015, INVEST OPHTH VIS SCI, V56, P3179, DOI 10.1167/iovs.14-16252
   Rebhun CB, 2017, TRANSL VIS SCI TECHN, V6, DOI 10.1167/tvst.6.6.4
   SPAIDE RF, 1995, RETINA-J RET VIT DIS, V15, P100, DOI 10.1097/00006982-199515020-00003
   Suzuki M, 2016, AM J OPHTHALMOL, V166, P52, DOI 10.1016/j.ajo.2016.03.024
   Tan CS, 2015, BRIT J OPHTHALMOL, V99, P624, DOI 10.1136/bjophthalmol-2014-305674
   Tanaka K, 2017, BRIT J OPHTHALMOL, V101, P51, DOI 10.1136/bjophthalmol-2016-309264
   Tokayer J, 2013, BIOMED OPT EXPRESS, V4, P1909, DOI 10.1364/BOE.4.001909
   Tomiyasu T, 2016, INVEST OPHTH VIS SCI, V57, pOCT324, DOI 10.1167/iovs.15-18898
   Wang M, 2016, INVEST OPHTH VIS SCI, V57, pOCT526, DOI 10.1167/iovs.15-18955
   Wong TY, 2019, AM J OPHTHALMOL, V204, P80, DOI 10.1016/j.ajo.2019.02.027
NR 23
TC 2
Z9 2
U1 1
U2 1
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD OCT 23
PY 2020
VL 15
IS 10
AR e0241230
DI 10.1371/journal.pone.0241230
PG 10
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA ON4BV
UT WOS:000586649400057
PM 33095843
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Iesato, Y
   Tanaka, M
   Murata, M
   Kitahara, J
   Hirano, T
   Kurenuma, T
   Yoshida, N
   Murata, T
AF Iesato, Yasuhiro
   Tanaka, Masaaki
   Murata, Masako
   Kitahara, Junya
   Hirano, Takao
   Kurenuma, Taihei
   Yoshida, Noriko
   Murata, Toshinori
TI Complete regression of branching vascular network in polypoidal
   choroidal vasculopathy by ranibizumab and photodynamic therapy, two case
   reports
SO BMC OPHTHALMOLOGY
LA English
DT Article
DE Polypoidal choroidal vasculopathy; Branching vascular network;
   Polypoidal lesions; Ranibizumab; Photodynamic therapy; Optical coherence
   tomography angiography
ID INTRAVITREAL AFLIBERCEPT; VERTEPORFIN; EFFICACY; ANGIOGRAPHY; SAFETY
AB BackgroundPolypoidal choroidal vasculopathy (PCV) consists of polyps that potentially cause massive subretinal hemorrhage and their branching vascular network (BVN) of feeder vessels. Although conventional indocyanine green angiography (IA) has shown anti-vascular endothelial growth factor (VEGF) agents and/or photodynamic therapy (PDT) to successfully induce polyp closure, the BVN appears resistant to these therapies and serves as the origin of recurrent active polyps. Recently introduced optical coherence tomography angiography (OCT-A) enables more frequent angiographic evaluation of polyps and the BVN than does conventional IA since it does not require intravenous fluorescent dye injection and is thus considered non-invasive.Case presentationCase 1. A 70-year-old male with PCV in his left eye suffered from vision deterioration (20/40) due to persistent subretinal fluid despite 42 intravitreal injections of ranibizumab (IVRs) over 5years and 7months. PDT was performed as an adjunct therapy 3days after the 43rd IVR. IA at 3months after PDT showed successful polyp closure but persisting BVN. However, more frequent evaluation with OCT-A starting at 1week after PDT demonstrated complete regression of both the BVN and polyp. OCT-A at every subsequent outpatient visit depicted gradual re-perfusion of the BVN and the restoration of most of its original network at 3months, which was compatible with IA findings. Neither OCTA nor IA revealed polyp recurrence at 3months.Case 2. A 65-year-old female suffering from left vision deterioration due to PCV underwent 5 intravitreal injections of aflibercept. Since her subretinal fluid persisted, the treatment was switched to a combination of IVR and PDT. OCT-A revealed marked regression of the BVN and polyp at 2weeks, but the BVN had regained its original shape at 2months without any sign of polyp recurrence.ConclusionsDifferently from previous observations obtained by IA alone, more frequent non-invasive OCT-A examination revealed complete but transient regression of the BVN just after combination therapy with IVR and PDT.
C1 [Iesato, Yasuhiro; Tanaka, Masaaki; Kitahara, Junya; Hirano, Takao; Kurenuma, Taihei; Yoshida, Noriko; Murata, Toshinori] Shinshu Univ, Sch Med, Dept Ophthalmol, 3-1-1 Asahi, Matsumoto, Nagano 3908621, Japan.
   [Murata, Masako] Nar Hosp Organaizat, Matsumoto Med Ctr, Dept Ophthalmol, 2-20-30 Murai Minami, Matsumoto, Nagano 3908621, Japan.
C3 Shinshu University
RP Murata, T (通讯作者)，Shinshu Univ, Sch Med, Dept Ophthalmol, 3-1-1 Asahi, Matsumoto, Nagano 3908621, Japan.
EM murata@shinshu-u.ac.jp
OI Murata, Toshinori/0000-0001-6577-5032
CR Akaza E, 2008, RETINA-J RET VIT DIS, V28, P717, DOI 10.1097/IAE.0b013e31816577cb
   Azuma K, 2016, RETINA-J RET VIT DIS, V36, P2158, DOI 10.1097/IAE.0000000000001047
   Baek J, 2017, RETINA, V37, P1, DOI [10.1097/IAE.0000000000001870, DOI 10.1097/IAE.0000000000001870]
   Cheung CMG, 2018, OPHTHALMOLOGY, V125, P708, DOI 10.1016/j.ophtha.2017.11.019
   Dansingani KK, 2018, CLIN EXP OPHTHALMOL, V46, P189, DOI 10.1111/ceo.13114
   de Carlo TE, 2019, RETINA-J RET VIT DIS, V39, P1343, DOI 10.1097/IAE.0000000000002139
   Hikichi T, 2014, BRIT J OPHTHALMOL, V98, P1201, DOI 10.1136/bjophthalmol-2013-304555
   Imamura Y, 2010, SURV OPHTHALMOL, V55, P501, DOI 10.1016/j.survophthal.2010.03.004
   Inoue M, 2013, EYE, V27, P1013, DOI 10.1038/eye.2013.179
   Inoue M, 2015, RETINA-J RET VIT DIS, V35, P2265, DOI 10.1097/IAE.0000000000000777
   Koh A, 2017, JAMA OPHTHALMOL, V135, P1206, DOI 10.1001/jamaophthalmol.2017.4030
   Koh A, 2012, RETINA-J RET VIT DIS, V32, P1453, DOI 10.1097/IAE.0b013e31824f91e8
   Kokame GT, 2010, BRIT J OPHTHALMOL, V94, P297, DOI 10.1136/bjo.2008.150029
   Leal S, 2010, RETINA-J RET VIT DIS, V30, P1197, DOI 10.1097/IAE.0b013e3181d37486
   Lee JE, 2017, GRAEF ARCH CLIN EXP, V255, P493, DOI 10.1007/s00417-016-3489-5
   Lee WK, 2008, JPN J OPHTHALMOL, V52, P108, DOI 10.1007/s10384-007-0501-y
   Lee WK, 2012, AM J OPHTHALMOL, V154, P355, DOI 10.1016/j.ajo.2012.02.019
   Maruyama-Inoue M, 2017, RETINA, P1
   Michels S, 2003, INVEST OPHTH VIS SCI, V44, P2147, DOI 10.1167/iovs.02-0604
   OBANA A, 1994, AM J OPHTHALMOL, V118, P749, DOI 10.1016/S0002-9394(14)72554-1
   Oshima Y, 2017, OPHTHALMOLOGICA, V238, P163, DOI 10.1159/000477448
   Saito M, 2014, RETINA-J RET VIT DIS, V34, P2192, DOI 10.1097/IAE.0000000000000236
   Schmidt-Erfurth U, 2005, OPHTHALMOLOGY, V112, P2061, DOI 10.1016/j.ophtha.2005.09.007
   Wong CW, 2016, PROG RETIN EYE RES, V53, P107, DOI 10.1016/j.preteyeres.2016.04.002
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
NR 25
TC 3
Z9 3
U1 0
U2 3
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1471-2415
J9 BMC OPHTHALMOL
JI BMC Ophthalmol.
PD NOV 3
PY 2018
VL 18
AR 284
DI 10.1186/s12886-018-0952-6
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA GZ3HP
UT WOS:000449278000001
PM 30390650
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Alagappan, LP
   Koh, JEW
   Jahmunah, V
   Ramesh, A
   Bhende, M
   Raman, R
   Acharya, UR
   Mathavan, S
AF Alagappan, Lakshmi Priyankka
   Koh, Joel En Wei
   Jahmunah, V
   Ramesh, Adhithi
   Bhende, Muna
   Raman, Rajiv
   Acharya, U. Rajendra
   Mathavan, Sinnakaruppan
TI Development of an automated system for the detection of genotype in
   polypoidal choroidal vasculopathy using retinal image phenotype
SO COMPUTER METHODS AND PROGRAMS IN BIOMEDICINE
LA English
DT Article
ID MACULAR DEGENERATION; PROTEIN HERP; TEXTURE; DIAGNOSIS; VARIANTS;
   ASSOCIATIONS; INFORMATION; ARMS2/HTRA1; FEATURES; STRESS
C1 [Alagappan, Lakshmi Priyankka; Ramesh, Adhithi; Mathavan, Sinnakaruppan] Sankara Nethralaya Campus, SN ONGC Dept Genet & Mol Biol, Vis Res Fdn, Chennai 600006, Tamil Nadu, India.
   [Alagappan, Lakshmi Priyankka] SASTRA Univ, Sch Chem & Biotechnol, Tanjore 613401, India.
   [Bhende, Muna; Raman, Rajiv] Sankara Nethralaya, Shri Bhagwan Mahavir Dept Vitreo Retinal Serv, Med Res Fdn, Chennai 600006, Tamil Nadu, India.
   [Koh, Joel En Wei; Jahmunah, V; Acharya, U. Rajendra] Ngee Ann Polytech, Sch Engn, Singapore 599489, Singapore.
   [Acharya, U. Rajendra] Singapore Univ Social Sci, Sch Sci & Technol, Dept Biomed Engn, Singapore, Singapore.
   [Acharya, U. Rajendra] Asia Univ, Dept Bioinformat & Med Engn, Taichung, Taiwan.
C3 Shanmugha Arts, Science, Technology & Research Academy (SASTRA);
   Singapore University of Social Sciences (SUSS); Asia University Taiwan
RP Acharya, UR (通讯作者)，Ngee Ann Polytech, Sch Engn, Singapore 599489, Singapore.
EM aru@np.edu.sg
RI Acharya, Rajendra U/E-3791-2010
OI Acharya, Rajendra U/0000-0003-2689-8552; ALAGAPPAN, LAKSHMI
   PRIYANKKA/0000-0002-8151-2379
FU Bayer Zydus Pvt. Ltd, India; Medical Research Foundation, Sankara
   Nethralaya, Chennai-India; Vision Research Foundation, Chennai-India
FX This study was supported by Bayer Zydus Pvt. Ltd, India; Medical
   Research Foundation, Sankara Nethralaya, Chennai-India; Vision Research
   Foundation, Chennai-India. We express our gratitude to all patients who
   participated in this study. We also acknowledge Mr. N. Vishwanathan and
   Ms. Porkodi Periyasamy for their technical support.
CR Acharya UR, 2018, COMPUT METH PROG BIO, V161, P103, DOI 10.1016/j.cmpb.2018.04.012
   Acharya UR, 2018, FUTURE GENER COMP SY, V79, P952, DOI 10.1016/j.future.2017.08.039
   Acharya UR, 2011, IEEE T INF TECHNOL B, V15, P449, DOI 10.1109/TITB.2011.2119322
   Anantharaman G, 2018, INDIAN J OPHTHALMOL, V66, P896, DOI 10.4103/ijo.IJO_1136_17
   [Anonymous], [No title captured]
   [Anonymous], NEURAL COMPUT APPL
   [Anonymous], [No title captured]
   Belal C, 2012, HUM MOL GENET, V21, P963, DOI 10.1093/hmg/ddr502
   Caixinha M, 2017, CURR EYE RES, V42, P1, DOI 10.1080/02713683.2016.1175019
   Chen HY, 2012, MOL VIS, V18, P816
   Cheung CMG, 2018, OPHTHALMOLOGY, V125, P708, DOI 10.1016/j.ophtha.2017.11.019
   Choi JY, 2017, PLOS ONE, V12, DOI [10.1371/journal.pone.0187338, 10.1371/journal.pone.0187336]
   Darbellay GA, 2000, IEEE T INFORM THEORY, V46, P709, DOI 10.1109/18.825848
   Dinakaran S, 2017, INT J ARTIF INTELL T, V26, DOI 10.1142/S0218213017500075
   Dutta S, 2018, INT J GRID DISTRIB, V11, P89, DOI 10.14257/ijgdc.2018.11.1.09
   Galloway MM, 1975, COMPUT VISION GRAPH, V4, P172, DOI [10.1016/S0146-664X(75)80008-6, DOI 10.1016/S0146-664X(75)80008-6]
   Gao XT, 2015, IEEE T BIO-MED ENG, V62, P2693, DOI 10.1109/TBME.2015.2444389
   Gotoh N, 2009, AM J OPHTHALMOL, V147, P1037, DOI 10.1016/j.ajo.2008.12.036
   Grassmann F, 2018, OPHTHALMOLOGY, V125, P1410, DOI 10.1016/j.ophtha.2018.02.037
   HARALICK RM, 1973, IEEE T SYST MAN CYB, VSMC3, P610, DOI 10.1109/TSMC.1973.4309314
   He HB, 2008, IEEE IJCNN, P1322, DOI 10.1109/IJCNN.2008.4633969
   Honda S, 2014, OPHTHALMOLOGICA, V231, P59, DOI 10.1159/000355488
   Huang L, 2015, EYE, V29, P691, DOI 10.1038/eye.2015.32
   Jin EZ, 2015, INT J CLIN EXP PATHO, V8, P13928
   Kannathal N, 2005, COMPUT METH PROG BIO, V80, P187, DOI 10.1016/j.cmpb.2005.06.012
   Kondo N, 2007, AM J OPHTHALMOL, V144, P608, DOI 10.1016/j.ajo.2007.06.003
   Laude A, 2010, PROG RETIN EYE RES, V29, P19, DOI 10.1016/j.preteyeres.2009.10.001
   Lomnitz JG, 2015, NPJ SYST BIOL APPL, V1, DOI 10.1038/npjsba.2015.3
   Ma L, 2015, OPHTHALMOLOGY, V122, P1854, DOI 10.1016/j.ophtha.2015.05.012
   Nogalska A, 2006, J NEUROCHEM, V96, P1491, DOI 10.1111/j.1471-4159.2006.03668.x
   Oh SL, 2019, APPL SCI-BASEL, V9, DOI 10.3390/app9142870
   Park DH, 2012, JPN J OPHTHALMOL, V56, P60, DOI 10.1007/s10384-011-0089-0
   RAMER A, 1990, INT J GEN SYST, V17, P241, DOI 10.1080/03081079008935109
   Rimavicius T, 2018, SIGNAL IMAGE VIDEO P, V12, P1107, DOI 10.1007/s11760-018-1262-4
   Sakurada Y, 2009, RETINA-J RET VIT DIS, V29, P1522, DOI 10.1097/IAE.0b013e3181af0d72
   SHANNON CE, 1948, BELL SYST TECH J, V27, P379, DOI 10.1002/j.1538-7305.1948.tb01338.x
   Simonthomas S, 2015, INT J COMPUT SCI NET, V15, P53
   Singh M, 2018, INT J OPHTHALMOL-CHI, V11, P117, DOI 10.18240/ijo.2018.01.20
   Singh SR, 2019, INDIAN J OPHTHALMOL, V67, P1121, DOI 10.4103/ijo.IJO_1757_18
   Soh LK, 1999, IEEE T GEOSCI REMOTE, V37, P780, DOI 10.1109/36.752194
   STONE M, 1974, J R STAT SOC B, V36, P111, DOI 10.1111/j.2517-6161.1974.tb00994.x
   Tan JH, 2017, J COMPUT SCI-NETH, V20, P70, DOI 10.1016/j.jocs.2017.02.006
   Tanaka K, 2011, INVEST OPHTH VIS SCI, V52, P7441, DOI 10.1167/iovs.11-7546
   Tang XO, 1998, IEEE T IMAGE PROCESS, V7, P1602, DOI 10.1109/83.725367
   Xu DH, 2004, Proceedings of the Fourth IASTED International Conference on Visualization, Imaging, and Image Processing, P534
   Yannuzzi LA, 1999, ARCH OPHTHALMOL-CHIC, V117, P1503
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
   Zhao XY, 2018, GRAEF ARCH CLIN EXP, V256, P1101, DOI 10.1007/s00417-018-3980-2
   Zhou Nina, 2007, Genomics Proteomics & Bioinformatics, V5, P242, DOI 10.1016/S1672-0229(08)60011-X
   Zhu YL, 2012, PHYSCS PROC, V25, P601, DOI 10.1016/j.phpro.2012.03.132
NR 50
TC 1
Z9 1
U1 0
U2 6
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0169-2607
EI 1872-7565
J9 COMPUT METH PROG BIO
JI Comput. Meth. Programs Biomed.
PD AUG
PY 2020
VL 192
AR 105460
DI 10.1016/j.cmpb.2020.105460
PG 8
WC Computer Science, Interdisciplinary Applications; Computer Science,
   Theory & Methods; Engineering, Biomedical; Medical Informatics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Computer Science; Engineering; Medical Informatics
GA LY3WW
UT WOS:000540460600005
PM 32276189
DA 2022-11-30
ER

PT J
AU Wood, JM
   Black, AA
   Anstey, KJ
   Horswill, MS
AF Wood, Joanne M.
   Black, Alex A.
   Anstey, Kaarin J.
   Horswill, Mark S.
TI Hazard Perception in Older Drivers With Eye Disease
SO TRANSLATIONAL VISION SCIENCE & TECHNOLOGY
LA English
DT Article
DE older drivers; eye disease; hazard perception; driving safety; visual
   impairment
ID MOTION PERCEPTION; CRASH; AGE; PERFORMANCE; IMPAIRMENT; MOVEMENTS;
   GLAUCOMA; SAFETY; RISK
AB Purpose: Timely detection of hazards is a key driving skill; however, the hazard perception of drivers with eye disease and related visual changes and the visual predictors of hazard perception are poorly understood.
   Methods: Participants included drivers aged 65 years and older with a range of eye diseases, including cataract, age-related maculopathy (AMD), and glaucoma (n = 99; mean age, 75.4 ? 6.4 years) and controls (n = 118; mean age, 72.2 ? 5.5 years). Visual performance was assessed using clinical measures (visual acuity, contrast sensitivity, visual fields) and non-clinical measures (useful field of view, motion sensitivity). Participants completed a computer-based hazard perception test (HPT) that has been related to driving performance and crash risk.
   Results: Participants with eye disease exhibited a 0.73-second delay in HPT response times compared to controls (6.61 ? 1.62 seconds vs. 5.88 ? 1.38 seconds; age-adjusted P = 0.012). Participants with glaucoma exhibited significantly delayed responses compared to those with AMD (P = 0.038) and controls (P = 0.004). Poorer motion sensitivity (standardized 0 = 0.27; P < 0.001), visual acuity (0 = 0.21; P = 0.002), and bettereye mean defect (0 = ?0.17; P = 0.009) were most strongly associated with delayed HPT responses. Motion sensitivity remained significantly associated with HPT responses, adjusted for visual acuity and visual fields.
   Conclusions: HPT responses of older drivers with eye disease were delayed compared to controls and translate to an estimated 16-meter longer stopping distance when traveling at 80 km/hr. Decreased motion sensitivity was most strongly associated with delayed HPT responses.
   Translational Relevance: HPT tests can provide insight into difficulties regarding road hazard detection of older drivers with eye disease and provide a potential avenue for interventions to improve road safety.
C1 [Wood, Joanne M.; Black, Alex A.] Queensland Univ Technol, Ctr Vis & Eye Res, Sch Optometry & Vis Sci, Victoria Pk Rd, Brisbane, Qld 4059, Australia.
   [Anstey, Kaarin J.] Univ New South Wales, Sch Psychol, Sydney, NSW, Australia.
   [Anstey, Kaarin J.] Neurosci Res Australia, Sydney, NSW, Australia.
   [Anstey, Kaarin J.] Univ New South Wales, UNSW Ageing Futures Inst, Sydney, NSW, Australia.
   [Horswill, Mark S.] Univ Queensland, Sch Psychol, Brisbane, Qld, Australia.
C3 Queensland University of Technology (QUT); University of New South Wales
   Sydney; Neuroscience Research Australia; University of New South Wales
   Sydney; University of Queensland
RP Wood, JM (通讯作者)，Queensland Univ Technol, Ctr Vis & Eye Res, Sch Optometry & Vis Sci, Victoria Pk Rd, Brisbane, Qld 4059, Australia.
EM j.wood@qut.edu.au
RI Horswill, Mark/J-9029-2019; Black, Alex/I-9727-2012
OI Horswill, Mark/0000-0002-0286-6292; Black, Alex/0000-0002-8671-5167;
   Anstey, Kaarin Jane/0000-0002-9706-9316
FU National Health and Medical Research Council (NHMRC) [1008145, 1045024];
   NHMRC Fellowship [1102694]
FX Supported by grants from the National Health and Medical Research
   Council (NHMRC; 1008145, 1045024) . KJA is funded by a NHMRC Fellowship
   (1102694) .
CR BAILEY IL, 1976, AM J OPTOM PHYS OPT, V53, P740
   Ball KK, 2006, J AM GERIATR SOC, V54, P77, DOI 10.1111/j.1532-5415.2005.00568.x
   Bowers A, 2005, OPTOMETRY VISION SCI, V82, P657, DOI 10.1097/01.opx.0000175558.33268.b5
   BULLIMORE MA, 1993, INVEST OPHTH VIS SCI, V34, P3526
   Crabb DP, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009710
   Darby P, 2009, SAFETY SCI, V47, P436, DOI 10.1016/j.ssci.2008.05.004
   ELLIOTT DB, 1991, CLIN VISION SCI, V6, P471
   FOLSTEIN MF, 1983, ARCH GEN PSYCHIAT, V40, P812
   Glen FC, 2016, CLIN EXP OPTOM, V99, P469, DOI 10.1111/cxo.12435
   Glen FC, 2015, BRIT J OPHTHALMOL, V99, P613, DOI 10.1136/bjophthalmol-2014-305932
   Haymes SA, 2008, INVEST OPHTH VIS SCI, V49, P3035, DOI 10.1167/iovs.07-1609
   Hill A, 2019, ACCIDENT ANAL PREV, V122, P207, DOI 10.1016/j.aap.2018.08.030
   Horswill MS, 2008, J GERONTOL B-PSYCHOL, V63, pP212, DOI 10.1093/geronb/63.4.P212
   Horswill MS, 2016, CURR DIR PSYCHOL SCI, V25, P425, DOI 10.1177/0963721416663186
   Horswill MS, 2015, ACCIDENT ANAL PREV, V82, P213, DOI 10.1016/j.aap.2015.05.019
   Horswill MS, 2015, PSYCHOL AGING, V30, P62, DOI 10.1037/a0038671
   Horswill MS, 2010, J INT NEUROPSYCH SOC, V16, P939, DOI 10.1017/S135561771000055X
   Lacherez P, 2014, OPHTHAL PHYSL OPT, V34, P445, DOI 10.1111/opo.12140
   Lacherez P, 2014, ACTA OPHTHALMOL, V92, P88, DOI 10.1111/j.1755-3768.2012.02575.x
   Lee SSY, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0178876
   Lee SSY, 2016, OPTOMETRY VISION SCI, V93, P1137, DOI 10.1097/OPX.0000000000000903
   Marrington SA, 2008, OPTOMETRY VISION SCI, V85, P1121, DOI 10.1097/OPX.0b013e31818e8d00
   McKenna F.P., 1999, J INT ASS TRAFFIC SA, V23, P26
   Owsley C, 1998, JAMA-J AM MED ASSOC, V279, P1083, DOI 10.1001/jama.279.14.1083
   Queensland Government, STOPPING DISTANCE SP
   Underwood G, 2005, OPHTHAL PHYSL OPT, V25, P346, DOI 10.1111/j.1475-1313.2005.00290.x
   Wetton MA, 2010, ACCIDENT ANAL PREV, V42, P1232, DOI 10.1016/j.aap.2010.01.017
   Wetton MA, 2011, ACCIDENT ANAL PREV, V43, P1759, DOI 10.1016/j.aap.2011.04.007
   Wood JM, 2002, HUM FACTORS, V44, P482, DOI 10.1518/0018720024497664
   Wood JM, 2008, J AM GERIATR SOC, V56, P986, DOI 10.1111/j.1532-5415.2008.01709.x
   Wood JM, 2018, INVEST OPHTH VIS SCI, V59, P273, DOI 10.1167/iovs.17-22751
   Wood JM, 2016, CLIN EXP OPTOM, V99, P395, DOI 10.1111/cxo.12391
NR 32
TC 0
Z9 0
U1 0
U2 6
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 2164-2591
J9 TRANSL VIS SCI TECHN
JI Transl. Vis. Sci. Technol.
PD JAN
PY 2021
VL 10
IS 1
AR 31
DI 10.1167/tvst.10.1.31
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Ophthalmology
GA RC7IG
UT WOS:000632969400009
PM 33520426
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Zapata, MA
   Arcos, G
   Fonollosa, A
   Abraldes, M
   Olenik, A
   Gutierrez, E
   Garcia-Arumi, J
AF Zapata, Miguel A.
   Arcos, Gabriel
   Fonollosa, Alex
   Abraldes, Maximino
   Olenik, Andrea
   Gutierrez, Estanislao
   Garcia-Arumi, Jose
TI Telemedicine for a General Screening of Retinal Disease Using
   Nonmydriatic Fundus Cameras in Optometry Centers: Three-Year Results
SO TELEMEDICINE AND E-HEALTH
LA English
DT Article
DE commercial telemedicine; ophthalmology; technology; telemedicine
ID DIABETIC-RETINOPATHY; MACULAR DEGENERATION; EMERGENCY-DEPARTMENT;
   DIGITAL CAMERA; PHOTOGRAPHY; INTEROBSERVER; VISION; TRIAL
AB Purpose: Describe the first 3 years of highly specialized retinal screening through a web platform using a retinologists' network for image reading. Methods: All patients who came to centers in the network and consented to fundus photography were included. Images were evaluated by ophthalmologists. We describe number of patients, age, visual acuity, retinal abnormalities, medical recommendations, and factors associated with abnormal retinographies. Results: Fifty thousand three hundred eighty-four patients were included; mean age 52.3 years (range 3-99). Mean visual acuity 20/25. Of the total cohort, 75% had normal retinographies, 22% had abnormalities, 1% referred acute floaters, 1% referred acute symptoms with normal retinography, and 1% could not be assessed. Ophthalmological referral was recommended in 12,634 patients: 9% urgent visit, 11% preferential (2-3 weeks), and 80% an ordinary visit. Age-related maculopathy signs were the most common abnormalities (2,456 patients, 4.8%). Epiretinal membrane was the second (764 cases, 1.5%). Diabetic retinopathy was suspected in 543 patients (1%), and nevi in 358 patients (0.7%). Patients older than 50 years had significantly more retinal abnormalities (31.5%) than younger ones (11.1%) (p < 0.0001; odds ratio [OR] 2.47; confidence interval [CI] 2.37-2.57). Patients with almost one eye with a myopic defect greater than -5 spherical equivalent had a higher risk of presenting abnormalities (p < 0.001; OR 1.04; CI 1.03-1.05). Conclusions: A high rate of asymptomatic retinal abnormalities was detected in this general screening, justifying this practice. Many patients who visit optometrists in Spain are unaware that they would benefit from ophthalmological monitoring. The ophthalmic community should lead initiatives of the type presented to preserve and guarantee quality standards.
C1 [Zapata, Miguel A.; Arcos, Gabriel; Fonollosa, Alex; Abraldes, Maximino; Olenik, Andrea; Gutierrez, Estanislao] OPTretina, Barcelona, Spain.
   [Zapata, Miguel A.; Garcia-Arumi, Jose] Hosp Valle De Hebron, Passeig Roser 126, Barcelona 08195, Spain.
   [Fonollosa, Alex] Hosp Cruces, Bilbao, Pais Vasco, Spain.
   [Abraldes, Maximino] Complejo Hosp Univ Santiago de Compostela, Galicia, Spain.
   [Olenik, Andrea] Hosp Severo Ochoa, Madrid, Spain.
   [Gutierrez, Estanislao] Hosp Univ Virgen Macarena, Seville, Spain.
   [Garcia-Arumi, Jose] Univ Autonoma Barcelona, Bareclona, Spain.
C3 Hospital Universitari Vall d'Hebron; Hospital Universitario Cruces;
   Complexo Hospitalario Universitario de Santiago de Compostela; Severo
   Ochoa University Hospital; Hospital Universitario Virgen Macarena;
   Autonomous University of Barcelona
RP Zapata, MA (通讯作者)，Hosp Valle De Hebron, Passeig Roser 126, Barcelona 08195, Spain.
EM zapatavictori@hotmail.com
RI Fonollosa, Alex/Q-9545-2019; Zapata, Miguel Ángel/AAB-9552-2019;
   Sanchez, Estanislao Gutierrez/P-7776-2018; Blanco, Leire/O-5114-2017
OI Sanchez, Estanislao Gutierrez/0000-0003-4851-680X; Garcia-Arumi,
   Jose/0000-0001-8827-1160; Zapata, Miguel Angel/0000-0002-0096-4569
CR American Academy of Ophthalmology (AAO), 2010, PRIM OP ANGL GLAUC P
   Au A, 2011, CURR OPIN OPHTHALMOL, V22, P194, DOI 10.1097/ICU.0b013e3283459508
   Boucher MC, 2008, CAN J OPHTHALMOL, V43, P658, DOI 10.3129/i08-120
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Bruce BB, 2011, NEW ENGL J MED, V364, P387, DOI 10.1056/NEJMc1009733
   Chew EY, 2014, CONTEMP CLIN TRIALS, V37, P294, DOI 10.1016/j.cct.2014.02.003
   Chin EK, 2014, TELEMED E-HEALTH, V20, P102, DOI 10.1089/tmj.2013.0042
   De Bats F, 2014, OPHTHALMOLOGICA, V231, P172, DOI 10.1159/000356695
   Early Treatment Diabetic Retinopathy Study Res Grp, 1991, OPHTHALMOLOGY, V98, P766
   Gomez-Ulla F, 2008, TELEMED J E-HEALTH, V14, P912, DOI 10.1089/tmj.2008.0013
   Hilton GF, 1995, OPHTHALMOLOGY MONOGR, V1, P161
   Ho AC, 2014, OPHTHALMOLOGY
   Kanagasingam Y, 2014, PROG RETIN EYE RES, V38, P20, DOI 10.1016/j.preteyeres.2013.10.002
   Klein R, 2004, ARCH OPHTHALMOL-CHIC, V122, P1642, DOI 10.1001/archopht.122.11.1642
   Kocur I, 2002, BRIT J OPHTHALMOL, V86, P716, DOI 10.1136/bjo.86.7.716
   Le Tien V, 2008, AM J OPHTHALMOL, V146, P520, DOI 10.1016/j.ajo.2008.05.031
   Li HK, 2011, TELEMED E-HEALTH, V17, P814, DOI 10.1089/tmj.2011.0075
   Lin DY, 2002, AM J OPHTHALMOL, V134, P204, DOI 10.1016/S0002-9394(02)01522-2
   Maa AY, 2014, TELEMED E-HEALTH, V20, P318, DOI 10.1089/tmj.2013.0185
   Perez MA, 2012, NEUROLOGIST, V18, P350, DOI 10.1097/NRL.0b013e318272f7d7
   Pirbhai A, 2005, AM J OPHTHALMOL, V139, P455, DOI 10.1016/j.ajo.2004.09.077
   Rachapelle S, 2013, OPHTHALMOLOGY, V120, P566, DOI 10.1016/j.ophtha.2012.09.002
   Rahman R, 2014, EYE, V28, P410, DOI 10.1038/eye.2013.305
   Rice T A, 1982, Trans Pa Acad Ophthalmol Otolaryngol, V35, P24
   Ruamviboonsuk P, 2006, OPHTHALMOLOGY, V113, P826, DOI 10.1016/j.ophtha.2005.11.021
   Schmidt-Erfurth U, 2014, BRIT J OPHTHALMOL, V98, P1144, DOI 10.1136/bjophthalmol-2014-305702
   Silva PS, 2011, ARCH OPHTHALMOL-CHIC, V129, P236, DOI 10.1001/archophthalmol.2010.365
   Surendran Thandalam Sundararajan, 2014, J Diabetes Sci Technol, V8, P262
   Tan JCH, 2013, J TELEMED TELECARE, V19, P65, DOI 10.1177/1357633X13476233
   Thulasi P, 2013, NEUROLOGY, V80, P432, DOI 10.1212/WNL.0b013e31827f0f20
   Toffoli D, 2011, J AAPOS, V15, P567, DOI 10.1016/j.jaapos.2011.07.010
   Vujosevic S, 2009, AM J OPHTHALMOL, V148, P111, DOI 10.1016/j.ajo.2009.02.031
NR 32
TC 22
Z9 22
U1 0
U2 12
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1530-5627
EI 1556-3669
J9 TELEMED E-HEALTH
JI Telemed. e-Health
PD JAN
PY 2017
VL 23
IS 1
BP 31
EP 37
DI 10.1089/tmj.2016.0020
PG 7
WC Health Care Sciences & Services
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Health Care Sciences & Services
GA EH5XM
UT WOS:000391846400005
PM 27228051
DA 2022-11-30
ER

PT J
AU Chia, EM
   Wang, JJ
   Rochtchina, E
   Smith, W
   Cumming, RR
   Mitchell, P
AF Chia, EM
   Wang, JJ
   Rochtchina, E
   Smith, W
   Cumming, RR
   Mitchell, P
TI Impact of bilateral visual impairment on health-related quality of life:
   the Blue Mountains Eye Study
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID BEAVER DAM EYE; FUNCTIONAL STATUS; OLDER-PEOPLE; VISION; ACUITY;
   AUSTRALIA; CATARACT; QUESTIONNAIRE; MACULOPATHY; PREVALENCE
AB PURPOSE. To assess the impact of visual impairment on health-related quality of life (HRQOL) in an older population and compare it with the impact of major medical conditions.
   METHODS. Participants of the second cross-sectional Blue Mountains Eye Study (BMES; n = 3509; mean age, 66.7 years; 57% female) were asked to complete the self-administered 36-item Short-Form health survey (SF-36), a comprehensive interview, and an eye examination. Visual impairment was defined as visual acuity less than 20/40 (better eye).
   RESULTS. Of 3154 (89.9%) participants with complete data, 172 (5.5%) had visual impairment due to refractive errors (correctable visual impairment) and 66 (2.1%) due to eye conditions (noncorrectable visual impairment; 49 mild, 9 moderate, 8 severe). After adjustment for demographic and medical confounders, there was a trend toward lower SF-36 scores in participants with noncorrectable impairment than in those with correctable impairment (physical component score [PCS] P-trend = 0.01 and mental component score [MCS] P-trend = 0.02). Increasingly severe noncorrectable visual impairment was associated with significantly poorer SF-36 scores in all but two dimensions. The impact of noncorrectable visual impairment was comparable to that from major medical conditions (e.g., stroke) and had a greater impact on mental than physical domains (mean MCS = 46.2, PCS = 41). No significant differences in HRQOL were demonstrated between visual impairment cases caused by age-related maculopathy and cataract, after adjusting for severity of visual impairment.
   CONCLUSIONS. Noncorrectable visual impairment was associated with reduced functional status and well-being, with a magnitude comparable to major medical conditions. These data have implications for disability weights such as those developed by the Global Burden of Disease study.
C1 Univ Sydney, Dept Ophthalmol, Ctr Vis Res, Westmead, NSW 2145, Australia.
   Univ Sydney, Sch Publ Hlth, Westmead, NSW 2145, Australia.
   Univ Newcastle, Ctr Clin Epidemiol & Biostat, Newcastle, NSW 2308, Australia.
C3 University of Sydney; University of Sydney; University of Newcastle
RP Mitchell, P (通讯作者)，Univ Sydney, Dept Ophthalmol, Ctr Vis Res, Hawkesbury Rd, Westmead, NSW 2145, Australia.
EM paul_mitchell@wmi.usyd.edu.au
RI Mitchell, Paul/P-1498-2014; wang, jie/GRS-0942-2022; Wang, Jie
   Jin/P-1499-2014
OI Wang, Jie Jin/0000-0001-9491-4898
CR Attebo K, 1996, OPHTHALMOLOGY, V103, P357
   *AUSTR BUR STAT, 1997, AUSTR BUR STAT PUBL
   BERGNER M, 1981, MED CARE, V19, P787, DOI 10.1097/00005650-198108000-00001
   Boisjoly H, 1999, AM J OPHTHALMOL, V128, P38, DOI 10.1016/S0002-9394(99)00071-9
   Brown MM, 2002, ARCH OPHTHALMOL-CHIC, V120, P481
   Chia EM, 2003, BRIT J OPHTHALMOL, V87, P392, DOI 10.1136/bjo.87.4.392
   Foran S, 2002, AM J OPHTHALMOL, V134, P712, DOI 10.1016/S0002-9394(02)01673-2
   Foran S, 2000, CLIN EXP OPHTHALMOL, V28, P143, DOI 10.1046/j.1442-9071.2000.00292.x
   FRYBACK DG, 1993, MED DECIS MAKING, V13, P89, DOI 10.1177/0272989X9301300202
   GILL TM, 1994, JAMA-J AM MED ASSOC, V272, P619, DOI 10.1001/jama.272.8.619
   HUNT SM, 1981, SOC SCI MED-MED SOC, V15, P221, DOI 10.1016/0271-7123(81)90005-5
   Ivers RQ, 2000, AM J EPIDEMIOL, V152, P633, DOI 10.1093/aje/152.7.633
   Ivers RQ, 1998, J AM GERIATR SOC, V46, P58
   KLEIN R, 1995, ARCH OPHTHALMOL-CHIC, V113, P333, DOI 10.1001/archopht.1995.01100030089026
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1310
   Mangione CM, 1999, AM J OPHTHALMOL, V128, P45, DOI 10.1016/S0002-9394(99)00169-5
   MANGIONE CM, 1992, MED CARE, V30, P1111, DOI 10.1097/00005650-199212000-00004
   MANGIONE CM, 1994, ARCH OPHTHALMOL-CHIC, V112, P1419, DOI 10.1001/archopht.1994.01090230033017
   Mangione CM, 1998, ARCH OPHTHALMOL-CHIC, V116, P1496, DOI 10.1001/archopht.116.11.1496
   MATHERS C, 1999, PUBLICATION PHE, V17
   Mitchell P, 1997, OPHTHALMOLOGY, V104, P581, DOI 10.1016/S0161-6420(97)30266-8
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   MURRAY CJL, 1996, GLOBAL BURDEN DIS, V1
   Musch DC, 1997, AM J OPHTHALMOL, V124, P1
   *NAT ADV EY COUNC, 1993, VIS RES NAT PLAN 199, P305
   Parrish RK, 1997, ARCH OPHTHALMOL-CHIC, V115, P1447, DOI 10.1001/archopht.1997.01100160617016
   Rovner BW, 1996, J AM GERIATR SOC, V44, P181, DOI 10.1111/j.1532-5415.1996.tb02436.x
   Rubin GS, 2000, INVEST OPHTH VIS SCI, V41, P3327
   Salomon JA, 2002, SUMMARY MEASURES OF POPULATION HEALTH: CONCEPTS, ETHICS, MEASUREMENT AND APPLICATIONS, P487
   Sanson-Fisher RW, 1998, J CLIN EPIDEMIOL, V51, P961, DOI 10.1016/S0895-4356(98)00087-0
   Schiffman RM, 2001, ARCH OPHTHALMOL-CHIC, V119, P841
   Scott IU, 1999, AM J OPHTHALMOL, V128, P54, DOI 10.1016/S0002-9394(99)00108-7
   Sinclair AJ, 2000, AGE AGEING, V29, P335, DOI 10.1093/ageing/29.4.335
   Smeeth L, 1998, BRIT MED J, V316, P660, DOI 10.1136/bmj.316.7132.660
   STEINBERG EP, 1994, ARCH OPHTHALMOL-CHIC, V112, P630, DOI 10.1001/archopht.1994.01090170074026
   Stouthard MEA, 1997, DISABILITY WEIGHTS D
   TIELSCH JM, 1990, ARCH OPHTHALMOL-CHIC, V108, P286, DOI 10.1001/archopht.1990.01070040138048
   USTUN TB, 2000, 37 GPE WHO
   Wang JJ, 2001, ARCH OPHTHALMOL-CHIC, V119, P1186, DOI 10.1001/archopht.119.8.1186
   Wang JJ, 2003, OPHTHALMIC EPIDEMIOL, V10, P3, DOI 10.1076/opep.10.1.3.13773
   Wang JJ, 1999, INVEST OPHTH VIS SCI, V40, P12
   Wang JJ, 2000, INVEST OPHTH VIS SCI, V41, P49
   WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002
   Ware JE, 1994, PHYS MENTAL HLTH SUM
   WARE JE, 1993, HLTH SURVEY MANUAL I
   Wilson MR, 1998, OPHTHALMOLOGY, V105, P2112, DOI 10.1016/S0161-6420(98)91135-6
NR 46
TC 201
Z9 205
U1 1
U2 18
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD JAN
PY 2004
VL 45
IS 1
BP 71
EP 76
DI 10.1167/iovs.03-0661
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Ophthalmology
GA 761AF
UT WOS:000187875600011
PM 14691156
DA 2022-11-30
ER

PT J
AU Kim, BR
   Yoo, TK
   Kim, HK
   Ryu, IH
   Kim, JK
   Lee, IS
   Kim, JS
   Shin, DH
   Kim, YS
   Kim, BT
AF Kim, Bo Ram
   Yoo, Tae Keun
   Kim, Hong Kyu
   Ryu, Ik Hee
   Kim, Jin Kuk
   Lee, In Sik
   Kim, Jung Soo
   Shin, Dong-Hyeok
   Kim, Young-Sang
   Kim, Bom Taeck
TI Oculomics for sarcopenia prediction: a machine learning approach toward
   predictive, preventive, and personalized medicine
SO EPMA JOURNAL
LA English
DT Article
DE Oculomics; Predictive algorithm; Marker patterns; Predictive preventive
   personalized medicine (PPPM/3PM), Sarcopenia; Risk assessment;
   Predictive model for practitioners; Ophthalmologic examination;
   Demographic factors; Machine learning; Age-related macular degeneration;
   Blepharoptosis; Cataract
ID KOREA NATIONAL-HEALTH; PHYSICAL PERFORMANCE; FUNDUS PHOTOGRAPHS; MUSCLE
   STRENGTH; NUTRITION; RISK; BLEPHAROPTOSIS; POPULATION; RATIONALE;
   GLAUCOMA
AB Aims Sarcopenia is characterized by a gradual loss of skeletal muscle mass and strength with increased adverse outcomes. Recently, large-scale epidemiological studies have demonstrated a relationship between several chronic disorders and ocular pathological conditions using an oculomics approach. We hypothesized that sarcopenia can be predicted through eye examinations, without invasive tests or radiologic evaluations in the context of predictive, preventive, and personalized medicine (PPPM/3PM).
   Methods We analyzed data from the Korean National Health and Nutrition Examination Survey (KNHANES). The training set (80%, randomly selected from 2008 to 2010) data were used to construct the machine learning models. Internal (20%, randomly selected from 2008 to 2010) and external (from the KNHANES 2011) validation sets were used to assess the ability to predict sarcopenia. We included 8092 participants in the final dataset. Machine learning models (XGBoost) were trained on ophthalmological examinations and demographic factors to detect sarcopenia.
   Results In the exploratory analysis, decreased levator function (odds ratio [OR], 1.41; P value <0.001), cataracts (OR, 1.31; P value = 0.013), and age-related macular degeneration (OR, 1.38; P value = 0.026) were associated with an increased risk of sarcopenia in men. In women, an increased risk of sarcopenia was associated with blepharoptosis (OR, 1.23; P value = 0.038) and cataracts (OR, 1.29; P value = 0.010). The XGBoost technique showed areas under the receiver operating characteristic curves (AUCs) of 0.746 and 0.762 in men and women, respectively. The external validation achieved AUCs of 0.751 and 0.785 for men and women, respectively. For practical and fast hands-on experience with the predictive model for practitioners who may be willing to test the whole idea of sarcopenia prediction based on oculomics data, we developed a simple web-based calculator application (hutps://kilhanesoculomics.githubdo/sarcopenia) to predict the risk of sarcopenia and facilitate screening, based on the model established in this study.
   Conclusion Sarcopenia is treatable before the vicious cycle of sarcopenia-related deterioration begins. Therefore, early identification of individuals at a high risk of sarcopenia is essential in the context of PPPM. Our oculomics-based approach provides an effective strategy for sarcopenia prediction. The proposed method shows promise in significantly increasing the number of patients diagnosed with sarcopenia, potentially facilitating earlier intervention. Through patient oculometric monitoring, various pathological factors related to sarcopenia can be simultaneously analyzed, and doctors can provide personalized medical services according to each cause. Further studies are needed to confirm whether such a prediction algorithm can be used in real-world clinical settings to improve the diagnosis of sarcopenia.
C1 [Kim, Bo Ram] Hangil Eye Hosp, Dept Ophthalmol, Incheon, South Korea.
   [Yoo, Tae Keun; Ryu, Ik Hee; Kim, Jin Kuk; Lee, In Sik] B & VIIT Eye Ctr, B2 GT Tower,1317-23 Seocho Dong, Seoul, South Korea.
   [Yoo, Tae Keun; Ryu, Ik Hee; Kim, Jin Kuk; Kim, Jung Soo] VISUWORKS, Seoul, South Korea.
   [Kim, Hong Kyu] Dankook Univ, Dankook Univ Hosp, Dept Ophthalmol, Coll Med, Cheonan, South Korea.
   [Shin, Dong-Hyeok] Malgeun Seoul Family Clin, Seoul, South Korea.
   [Kim, Young-Sang] CHA Univ, CHA Bundang Med Ctr, Dept Family Med, Seongnam, South Korea.
   [Kim, Bom Taeck] Ajou Univ, Dept Family Practice & Community Hlth, Sch Med, Suwon 16499, Gyeonggi Do, South Korea.
C3 Dankook University; Dankook University Hospital; Pochon Cha University;
   Ajou University
RP Yoo, TK (通讯作者)，B & VIIT Eye Ctr, B2 GT Tower,1317-23 Seocho Dong, Seoul, South Korea.; Yoo, TK (通讯作者)，VISUWORKS, Seoul, South Korea.; Kim, BT (通讯作者)，Ajou Univ, Dept Family Practice & Community Hlth, Sch Med, Suwon 16499, Gyeonggi Do, South Korea.
EM eyetaekeunyoo@gmail.com; lovesong@ajou.ac.kr
RI Yoo, Tae Keun/Q-3620-2019
OI Yoo, Tae Keun/0000-0003-0890-8614; KIM, BOM TAECK/0000-0002-0395-0410
CR Abramoff MD, 2008, DIABETES CARE, V31, P193, DOI 10.2337/dc07-1312
   Arik SO, 2021, AAAI CONF ARTIF INTE, V35, P6679
   Asadi-Pooya AA, 2022, J PSYCHOSOM RES, V153, DOI 10.1016/j.jpsychores.2021.110703
   Babenko B, 2022, NAT BIOMED ENG, DOI 10.1038/s41551-022-00867-5
   Bahat G, 2016, EUR GERIATR MED, V7, P220, DOI 10.1016/j.eurger.2015.12.012
   Bao WX, 2020, AGING DIS, V11, P863, DOI 10.14336/AD.2019.1012
   Beaudart C, 2017, OSTEOPOROSIS INT, V28, P1817, DOI 10.1007/s00198-017-3980-9
   Beebe DC, 2010, OPHTHALMIC RES, V44, P155, DOI 10.1159/000316481
   Bertele N, 2021, EPMA J, V12, P507, DOI 10.1007/s13167-021-00255-0
   Bian AL, 2017, EUR J MED RES, V22, DOI 10.1186/s40001-017-0266-9
   Biolo G, 2014, CLIN NUTR, V33, P737, DOI 10.1016/j.clnu.2014.03.007
   Bruyere O, 2019, MATURITAS, V119, P61, DOI 10.1016/j.maturitas.2018.11.003
   Cesari M, 2012, J CACHEXIA SARCOPENI, V3, P181, DOI 10.1007/s13539-012-0078-2
   Chen TQ, 2016, KDD'16: PROCEEDINGS OF THE 22ND ACM SIGKDD INTERNATIONAL CONFERENCE ON KNOWLEDGE DISCOVERY AND DATA MINING, P785, DOI 10.1145/2939672.2939785
   Cohen LM, 2021, OPHTHAL PLAST RECONS, V37, P133, DOI 10.1097/IOP.0000000000001707
   Cruz-Jentoft AJ, 2019, LANCET, V393, P2636, DOI 10.1016/S0140-6736(19)31138-9
   Darvishi A, 2021, BMC PUBLIC HEALTH, V21, DOI 10.1186/s12889-021-10511-7
   Garnica O, 2021, EPMA J, V12, P365, DOI 10.1007/s13167-021-00252-3
   Golubnitschaja O, 2021, EPMA J, V12, P243, DOI 10.1007/s13167-021-00251-4
   Jeong S, 1999, ARCH OPHTHALMOL-CHIC, V117, P907
   Kim MH, 2017, EYE, V31, P940, DOI 10.1038/eye.2017.43
   Kim YS, 2020, NUTRIENTS, V12, DOI 10.3390/nu12092856
   Kweon S, 2014, INT J EPIDEMIOL, V43, P69, DOI 10.1093/ije/dyt228
   Lee K, 2019, KOREAN J RADIOL, V20, P205, DOI 10.3348/kjr.2018.0479
   Lee YH, 2015, J HEPATOL, V63, P486, DOI 10.1016/j.jhep.2015.02.051
   Lundberg SM, 2018, NAT BIOMED ENG, V2, P749, DOI 10.1038/s41551-018-0304-0
   McManus JR, 2013, CURR OPIN OPHTHALMOL, V24, P144, DOI 10.1097/ICU.0b013e32835cf078
   Mun S, 2022, EPMA J, V13, P125, DOI 10.1007/s13167-022-00273-6
   Oh E, 2015, INVEST OPHTH VIS SCI, V56, P3957, DOI 10.1167/iovs.15-16805
   Paik JS, 2020, BMC OPHTHALMOL, V20, DOI 10.1186/s12886-020-01350-y
   Park SJ, 2019, METAB SYNDR RELAT D, V17, P494, DOI 10.1089/met.2019.0059
   Poplin R, 2018, NAT BIOMED ENG, V2, P158, DOI 10.1038/s41551-018-0195-0
   Rim TH, 2021, LANCET DIGIT HEALTH, V3, pE306, DOI 10.1016/S2589-7500(21)00043-1
   Rim TH, 2020, LANCET DIGIT HEALTH, V2, pE526, DOI 10.1016/S2589-7500(20)30216-8
   Rodriguez-Acuna R, 2020, BMJ OPEN DIAB RES CA, V8, DOI 10.1136/bmjdrc-2020-001622
   Rossi AP, 2017, J NUTR HEALTH AGING, V21, P743, DOI 10.1007/s12603-017-0921-4
   Sabel BA, 2020, EPMA J, V11, P177, DOI 10.1007/s13167-020-00204-3
   Scharf G, 2012, J CACHEXIA SARCOPENI, V3, P145, DOI 10.1007/s13539-012-0081-7
   Shin J, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0239071
   Shwartz-Ziv R, 2022, INFORM FUSION, V81, P84, DOI 10.1016/j.inffus.2021.11.011
   Studenski SA, 2014, J GERONTOL A-BIOL, V69, P547, DOI 10.1093/gerona/glu010
   Tournadre A, 2019, JOINT BONE SPINE, V86, P309, DOI 10.1016/j.jbspin.2018.08.001
   Wagner SK, 2020, TRANSL VIS SCI TECHN, V9, DOI 10.1167/tvst.9.2.6
   Wang W, 2021, EPMA J, V12, P403, DOI 10.1007/s13167-021-00253-2
   Woo J, 2014, EUR GERIATR MED, V5, P155, DOI 10.1016/j.eurger.2014.04.003
   Wouters RJ, 2001, INVEST OPHTH VIS SCI, V42, P620
   Xiao W, 2021, LANCET DIGIT HEALTH, V3, pe88, DOI 10.1016/S2589-7500(20)30288-0
   Yadav Saumya, 2019, Community Eye Health, V32, pS1
   Yoo TK, 2021, PAIN MED, V22, P2525, DOI 10.1093/pm/pnab085
   Yoo TK, 2018, CURR EYE RES, V43, P1090, DOI 10.1080/02713683.2018.1484145
   Yoo YJ, 2018, INVEST OPHTH VIS SCI, V59
   Zhan XQ, 2021, EPMA J, V12, P449, DOI 10.1007/s13167-021-00265-y
   Zheng YL, 2022, EPMA J, V13, P285, DOI 10.1007/s13167-022-00283-4
NR 53
TC 2
Z9 2
U1 8
U2 8
PU SPRINGER INT PUBL AG
PI CHAM
PA GEWERBESTRASSE 11, CHAM, CH-6330, SWITZERLAND
SN 1878-5077
EI 1878-5085
J9 EPMA J
JI EPMA J.
PD SEP
PY 2022
VL 13
IS 3
SI SI
BP 367
EP 382
DI 10.1007/s13167-022-00292-3
EA AUG 2022
PG 16
WC Medicine, General & Internal; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine; Research & Experimental Medicine
GA 4F8GK
UT WOS:000837500600001
PM 36061832
DA 2022-11-30
ER

PT J
AU Santana-Garrido, A
   Reyes-Goya, C
   Fernandez-Bobadilla, C
   Blanca, AJ
   Andre, H
   Mate, A
   Vazquez, CM
AF Santana-Garrido, Alvaro
   Reyes-Goya, Claudia
   Fernandez-Bobadilla, Carmen
   Blanca, Antonio J.
   Andre, Helder
   Mate, Alfonso
   Vazquez, Carmen M.
TI NADPH oxidase-induced oxidative stress in the eyes of hypertensive rats
SO MOLECULAR VISION
LA English
DT Article
ID L-CARNITINE; NITRIC-OXIDE; ANTIOXIDANT ENZYMES; BLOOD-PRESSURE;
   INFLAMMATION; SUPEROXIDE; ACTIVATION; MECHANISMS; EXPRESSION;
   CATARACTOGENESIS
AB Purpose: Increased reactive oxygen species (ROS) released by NADPH oxidase and inflammation are associated with arterial hypertension and eye diseases associated with high blood pressure, including glaucoma, retinopathies (e.g., age-related macular degeneration), and choroidopathies affecting ocular function; however, the mechanisms underlying these adverse outcomes remain undefined. The present study was designed to highlight the importance of oxidative stress in severe hypertension-related eye damage.
   Methods: Male Wistar rats (n = 7, unless otherwise specified for specific experiments) were administered an oral dose of 30 mg of Nco-nitro-L-arginine methyl ester (L-NAME) per kilogram of bodyweight and day for 3 weeks; chronic administration with L-NAME is a validated experimental approach resulting in severe hypertension secondary to nitric oxide (NO) depletion and subsequent vasoconstriction in the systemic circulation. Upon treatment completion, histomorphometric studies, NADPH oxidase activity, and ROS production were measured in eyecup homogenates and paraffin-embedded sections from control and L-NAME-treated animals. In addition, immunohistofluorescence, western blotting, and real-time PCR (RT-qPCR) analyses were performed in the eye and the retina to evaluate the expression of i) NADPH oxidase main isoforms (NOX1, NOX2, and NOX4) and subunits (p22phox and p47phox); ii) glial fibrillary acidic protein (GFAP), as a marker of microglial activation in the retina; iii) antioxidant enzymes; and iv) endothelial constitutive (eNOS) and inflammation inducible (iNOS) nitric oxide synthase isoforms, and nitrotyrosine as a versatile biomarker of oxidative stress.
   Results: Increased activity of NADPH oxidase and superoxide anion production, accompanied by transcriptional up-regulation of this enzyme isoforms, was found in the retina and choroid of the hypertensive rats in comparison with the untreated controls. Histomorphometric analyses revealed a significant reduction in the thickness of the ganglion cell layer and the outer retinal layers in the hypertensive animals, which also showed a positive strong signal of GFAP in the retinal outer segment and plexiform layers. In addition, L-NAME-treated animals presented with upregulation of nitric oxide synthase (including inducible and endothelial isoforms) and abnormally elevated nitrotyrosine levels. Experiments on protein and mRNA expression of antioxidant enzymes revealed depletion of superoxide dismutase and glutathione peroxidase in the eyes of the hypertensive animals; however, glutathione reductase was significantly higher than in the normotensive controls.
   Conclusions: The present study demonstrated structural changes in the retinas of the L-NAME-treated hypertensive animals and strengthens the importance of NADPH oxidase as a major ROS-generating enzyme system in the oxidative and inflammatory processes surrounding hypertensive eye diseases. These observations might contribute to unveiling pathogenic mechanisms responsible for developing ocular disturbances in the context of severe hypertension.
C1 [Santana-Garrido, Alvaro; Reyes-Goya, Claudia; Fernandez-Bobadilla, Carmen; Blanca, Antonio J.; Mate, Alfonso; Vazquez, Carmen M.] Univ Seville, Fac Farm, Dept Fisiol, CL Prof Garcia Gonzalez 2, Seville 41012, Spain.
   [Andre, Helder] Karolinska Inst, Dept Clin Neurosci, St Erik Eye Hosp, Stockholm, Sweden.
   [Santana-Garrido, Alvaro; Mate, Alfonso; Vazquez, Carmen M.] Univ Seville, Consejo Super Invest Cient, Hosp Univ Virgen Rocio, Epidemiol Clin & Riesgo Cardiovasc,Inst Biomed Se, Avda Manuel Siurot S-N, Seville, Spain.
C3 University of Sevilla; Karolinska Institutet; Consejo Superior de
   Investigaciones Cientificas (CSIC); University of Sevilla; CSIC-JA-USE -
   Instituto de Biomedicina de Sevilla (IBIS); Virgen del Rocio University
   Hospital
RP Mate, A (通讯作者)，Univ Seville, Fac Farm, Dept Fisiol, CL Prof Garcia Gonzalez 2, Seville 41012, Spain.
EM mate@us.es
RI Mate, Alfonso/G-7418-2012; Garrido, Alvaro Santana/AAU-8611-2021;
   Vazquez, Carmen/GVT-8878-2022; VAZQUEZ, CARMEN CM/K-7058-2014
OI Mate, Alfonso/0000-0002-2719-8825; Garrido, Alvaro
   Santana/0000-0002-9469-3850; VAZQUEZ, CARMEN CM/0000-0002-2999-3582;
   Andre, Helder/0000-0002-2926-2376; Reyes-Goya,
   Claudia/0000-0002-1621-5335
FU Consejeria de Conocimiento, Investigacion y Universidad, Junta de
   Andalucia [2020/275]; FPU predoctoral fellowship from Ministerio de
   Ciencia, Innovacion y Universidades [FPU17/03465]; Ministerio de
   Ciencia, Innovacion y Universidades [PEJ2018-004474-A, PEJ2017-399]
FX We thank technical support from Centro de Innovacion, Tecnologia e
   Innovacion de la Universidad de Sevilla (CITIUS, Servicio de Biologia,
   Servicio de Microscopia). Author Contribution: Study design and data
   management: AM, CMV; data acquisition: AS, CR-G, CF-B, AJB;
   draft/revision of the article: AS, AJB, HA, AM, CMV. Funding: This study
   was supported by Consejeria de Conocimiento, Investigacion y
   Universidad, Junta de Andalucia (2020/275). AS is recipient of an FPU
   predoctoral fellowship from Ministerio de Ciencia, Innovacion y
   Universidades (FPU17/03465). CR-G was supported by Ministerio de
   Ciencia, Innovacion y Universidades, Ayudas para la Promocion de Empleo
   Joven e Implantacion de la Garantia Juvenil en I+D+i 2017-2020
   (PEJ2018-004474-A and CF-B Programa Operativo de Empleo Juvenil
   2014-2020 (PEJ2017-399).
CR Akay F, 2016, EUR J OPHTHALMOL, V26, P152, DOI 10.5301/ejo.5000675
   Al-Shabrawey M, 2005, AM J PATHOL, V167, P599, DOI 10.1016/S0002-9440(10)63001-5
   Al-Shabrawey M, 2008, INVEST OPHTH VIS SCI, V49, P3239, DOI 10.1167/iovs.08-1755
   Altmann C, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19010110
   Appukuttan B, 2018, CLIN EXP OPHTHALMOL, V46, P652, DOI 10.1111/ceo.13155
   Bhargava M, 2012, J HUM HYPERTENS, V26, P71, DOI 10.1038/jhh.2011.37
   Bhatia RP, 2006, ANN OPHTHALMOL, V38, P103, DOI 10.1385/AO:38:2:103
   Bhutto IA, 2010, EXP EYE RES, V90, P155, DOI 10.1016/j.exer.2009.10.004
   Blanca AJ, 2017, FOOD CHEM, V228, P356, DOI 10.1016/j.foodchem.2017.02.011
   Blanca AJ, 2016, J CELL BIOCHEM, V117, P2281, DOI 10.1002/jcb.25526
   BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3
   Brandes RP, 2014, FREE RADICAL BIO MED, V76, P208, DOI 10.1016/j.freeradbiomed.2014.07.046
   Calabro V, 2018, ARCH BIOCHEM BIOPHYS, V647, P47, DOI 10.1016/j.abb.2018.03.041
   Camargo LL, 2018, HYPERTENSION, V72, P235, DOI 10.1161/HYPERTENSIONAHA.118.10824
   Cammalleri M, 2017, NUTRIENTS, V9, DOI 10.3390/nu9101079
   Cao Y, 2014, PHARMACOLOGY, V94, P123, DOI 10.1159/000363062
   Chan EC, 2016, CLIN SCI, V130, P683, DOI 10.1042/CS20150103
   d'Azy CB, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0166915
   Dornas WC, 2011, J BIOSCIENCES, V36, P731, DOI 10.1007/s12038-011-9097-y
   Forrester JV, 2013, EYE, V27, P340, DOI 10.1038/eye.2012.265
   Fraser-Bell S, 2017, CLIN EXP OPHTHALMOL, V45, P45, DOI 10.1111/ceo.12905
   Garcia-Redondo AB, 2016, PHARMACOL RES, V114, P110, DOI 10.1016/j.phrs.2016.10.015
   Gomez-Amores L, 2006, LIFE SCI, V78, P1945, DOI 10.1016/j.lfs.2005.08.023
   Gomez-Guzman M, 2011, BRIT J NUTR, V106, P1337, DOI 10.1017/S0007114511004314
   Hernandez-Ramirez E, 2017, CELL PHYSIOL BIOCHEM, V42, P2353, DOI 10.1159/000480007
   Jarrett SG, 2012, MOL ASPECTS MED, V33, P399, DOI 10.1016/j.mam.2012.03.009
   Jeoung JW, 2017, J GLAUCOMA, V26, P1030, DOI 10.1097/IJG.0000000000000751
   Jose GS, 2008, CLIN SCI, V114, P173, DOI 10.1042/CS20070130
   Khan SA, 2016, J CURR OPHTHALMOL, V28, P123, DOI 10.1016/j.joco.2016.05.001
   Kiel JW, 2001, EXP EYE RES, V73, P355, DOI 10.1006/exer.2001.1050
   Kowluru A, 2014, BIOCHEM PHARMACOL, V88, P275, DOI 10.1016/j.bcp.2014.01.017
   Langman MJS, 2005, BRIT J OPHTHALMOL, V89, P960, DOI 10.1136/bjo.2004.053397
   Lei XG, 2016, PHYSIOL REV, V96, P307, DOI 10.1152/physrev.00010.2014
   Li JM, 2015, J DIABETES RES, V2015, DOI 10.1155/2015/963289
   Li YX, 2020, CURR EYE RES, V45, P1422, DOI 10.1080/02713683.2020.1752738
   Lim HB, 2019, AM J OPHTHALMOL, V199, P167, DOI 10.1016/j.ajo.2018.11.016
   Malchiodi-Albedi F, 2008, PPAR RES, V2008, DOI 10.1155/2008/295784
   Miguel-Carrasco JL, 2010, J INFLAMM-LOND, V7, DOI 10.1186/1476-9255-7-21
   Miguel-Carrasco JL, 2010, EUR J PHARMACOL, V632, P65, DOI 10.1016/j.ejphar.2010.01.017
   Minh VCN, 2012, BIOCHEM BIOPH RES CO, V419, P453, DOI 10.1016/j.bbrc.2012.01.136
   Miyazaki M, 2003, BRIT J OPHTHALMOL, V87, P469, DOI 10.1136/bjo.87.4.469
   Mohamed IN, 2012, MOL VIS, V18, P1457
   Nagano K, 2013, MOL MED REP, V7, P1371, DOI 10.3892/mmr.2013.1378
   O'Brien WJ, 2009, MOL VIS, V15, P2535
   O'Brien WJ, 2006, INVEST OPHTH VIS SCI, V47, P853, DOI 10.1167/iovs.05-1063
   Oduntan OA., 2011, S AFR OPTOM, V70, P191, DOI 10.4102/aveh.v70i4.116
   Opatrilova R, 2018, ACTA OPHTHALMOL, V96, P222, DOI 10.1111/aos.13384
   Pinto CC, 2007, FREE RADICAL RES, V41, P1151, DOI 10.1080/10715760701632816
   Ramirez-Montero C, 2020, EXP EYE RES, V193, DOI 10.1016/j.exer.2020.107981
   Roehlecke C, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0071570
   Rojas M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0084357
   Sabbatini M, 2002, CLIN EXP HYPERTENS, V24, P727, DOI 10.1081/CEH-120015348
   Sasaki M, 2010, DIABETOLOGIA, V53, P971, DOI 10.1007/s00125-009-1655-6
   Sicard P, 2007, BRIT J PHARMACOL, V151, P979, DOI 10.1038/sj.bjp.0707322
   Singh A, 2016, J PHARMACOPUNCT, V19, P137, DOI 10.3831/KPI.2016.19.015
   Singh L, 2016, INT J CLIN ONCOL, V21, P651, DOI 10.1007/s10147-016-0951-7
   Small HY, 2018, FREE RADICAL BIO MED, V125, P104, DOI 10.1016/j.freeradbiomed.2018.05.085
   Toda N, 2007, PROG RETIN EYE RES, V26, P205, DOI 10.1016/j.preteyeres.2007.01.004
   Tokarz P, 2013, BIOGERONTOLOGY, V14, P461, DOI 10.1007/s10522-013-9463-2
   Touyz RM, 2019, ANTIOXID REDOX SIGN, V30, P1027, DOI 10.1089/ars.2018.7583
   Wang HB, 2017, ANTIOXIDANTS-BASEL, V6, DOI 10.3390/antiox6020040
   Wang HB, 2015, AM J PATHOL, V185, P3316, DOI 10.1016/j.ajpath.2015.08.017
   Wang HB, 2014, FASEB J, V28, P265, DOI 10.1096/fj.13-240028
   Wang SB, 2017, CLIN EXP HYPERTENS, V39, P711, DOI 10.1080/10641963.2017.1313854
   Wilding LA, 2015, J AM ASSOC LAB ANIM, V54, P328
   Xiang Y, 2016, J OPHTHALMOL, V2016, DOI 10.1155/2016/1348347
   Yanai R, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0196037
   You IC, 2015, ARCH IMMUNOL THER EX, V63, P299, DOI 10.1007/s00005-015-0335-0
   Yu XN, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0114012
   Zambrano S, 2013, EUR J NUTR, V52, P1649, DOI 10.1007/s00394-012-0470-x
   Zambrano S, 2013, BIOCHEM PHARMACOL, V85, P937, DOI 10.1016/j.bcp.2012.12.021
   Zheng CW, 2015, MOL VIS, V21, P403
NR 72
TC 7
Z9 7
U1 0
U2 3
PU MOLECULAR VISION
PI ATLANTA
PA C/O JEFF BOATRIGHT, LAB B, 5500 EMORY EYE CENTER, 1327 CLIFTON RD, N E,
   ATLANTA, GA 30322 USA
SN 1090-0535
J9 MOL VIS
JI Mol. Vis.
PD APR 2
PY 2021
VL 27
BP 161
EP 178
PG 18
WC Biochemistry & Molecular Biology; Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Ophthalmology
GA TA5KJ
UT WOS:000667287600001
PM 33907371
DA 2022-11-30
ER

PT J
AU Parmeggiani, F
   Gemmati, D
   Costagliola, C
   Semeraro, F
   Perri, P
   D'Angelo, S
   Romano, MR
   De Nadai, K
   Sebastiani, A
   Incorvaia, C
AF Parmeggiani, Francesco
   Gemmati, Donato
   Costagliola, Ciro
   Semeraro, Francesco
   Perri, Paolo
   D'Angelo, Sergio
   Romano, Mario R.
   De Nadai, Katia
   Sebastiani, Adolfo
   Incorvaia, Carlo
TI Genetic Predictors of Response to Photodynamic Therapy
SO MOLECULAR DIAGNOSIS & THERAPY
LA English
DT Review
ID COMPLEMENT FACTOR-H; ENDOTHELIAL GROWTH-FACTOR; SUBFOVEAL CHOROIDAL
   NEOVASCULARIZATION; METHYLENETETRAHYDROFOLATE REDUCTASE GENE; ACTIVATED
   PROTEIN-C; INTRAVITREAL BEVACIZUMAB INJECTION; SINGLE-NUCLEOTIDE
   POLYMORPHISMS; RETINAL VASCULAR INFARCTION; FACTOR HY402H POLYMORPHISM;
   PROTHROMBIN MESSENGER-RNA
AB In Western countries, therapeutic management of patients affected by choroidal neovascularization (CNV) secondary to different typologies of macular degeneration represents a major health care problem. Age-related macular degeneration is the disease most frequently associated with CNV development. Schematically, CNVs can be distinguished into classic and occult subtypes, which are characterized by variable natural history and different responsiveness to some therapeutic procedures. At present, the dramatic vision loss due to CNV can be mainly treated by two interventional strategies, which are utilizable in either single or combined modalities: photodynamic therapy with verteporfin (PDT-V), and intravitreal administration of drugs acting against vascular endothelial growth factor. The combined use of PDT-V and anti-angiogenic drugs represents one of the most promising strategies against neovascular macular degeneration, but it unavoidably results in an expensive increase in health resource utilization. However, the positive data from several studies serve as a basis for reconsidering the role of PDT-V, which has undergone a renaissance prompted by the need for a more rational therapeutic approach toward CNV. New pharmacogenetic knowledge of PDT-V points to exploratory prospects to optimize the clinical application of this intriguing photothrombotic procedure. In fact, a Medline search provides data regarding the role of several single nucleotide polymorphisms (SNPs) as genetic predictors of CNV responsiveness to PDT-V. Specifically, correlations between SNPs and different levels of PDT-V efficacy have been detected by examining the gene variants influencing (i) thrombo-coagulative pathways, i.e. methylenetetrahydrofolate reductase (MTHFR) 677C>T (rs1801133), factor V (F5) 1691G>A (rs6025), prothrombin (F2) 20210G>A (rs1799963), and factor XIII-A (F13A1) 185G>T (rs5985); (ii) complement activation and/or inflammatory processes, i.e. complement factor H (CFH) 1277T>C (rs1061170), high-temperature requirement factor A1 (HTRA1) promoter -512G>A (rs11200638), and two variants of the C-reactive protein (CRP) gene (rs2808635 and rs876538); and (iii) production and bioavailability of vascular endothelial growth factor (VEGFA -2578C>A [rs699947] and rs2146323). This article critically evaluates both the clinical plausibility and the opportunity to utilize the most important SNP-response interactions of PDT-V for an effective upgrade of the current anti-CNV therapeutic scenario. In addition, the pharmacogenetics of a very severe post-PDT-V adverse event, i.e. a decrease in acute vision, is briefly discussed. A comprehensive appraisal of the findings reviewed in this article should be carefully considered to design future trials aimed at verifying (after proper genotypic stratification of the enrolled patients) whether these innovative pharmacogenetic approaches will be able to improve the multifaceted interventional management of neovascular macular degeneration.
C1 [Parmeggiani, Francesco; Perri, Paolo; D'Angelo, Sergio; Sebastiani, Adolfo; Incorvaia, Carlo] Univ Ferrara, Dept Ophthalmol, I-44100 Ferrara, Italy.
   [Gemmati, Donato] Univ Ferrara, Dept Hematol, Ctr Thrombosis & Hemostasis, I-44100 Ferrara, Italy.
   [Costagliola, Ciro; Romano, Mario R.] Univ Molise, Dept Hlth Sci, Campobasso, Italy.
   [Semeraro, Francesco] Univ Brescia, Dept Ophthalmol, Brescia, Italy.
   [De Nadai, Katia] Camposampiero Hosp, Ctr Retinitis Pigmentosa Veneto Reg, Unita Locale Socio Sanit Alta Padovana 15, Camposampiero, Italy.
C3 University of Ferrara; University of Ferrara; University of Molise;
   University of Brescia; ULSS 6 Euganea; Ospedale di Camposampiero
RP Parmeggiani, F (通讯作者)，Univ Ferrara, Sez Clin Oculist, Dipartimento Discipline Med Chirurg Comunicaz & C, Corso Giovecca 203, I-44100 Ferrara, Italy.
EM francesco.parmeggiani@unife.it
RI Romano, Mario R/I-8320-2012; Perri, Paolo/L-3047-2015; Semeraro,
   Francesco fs/K-8667-2016; Costagliola, Ciro/G-5707-2012
OI Perri, Paolo/0000-0003-4652-9842; Semeraro, Francesco
   fs/0000-0002-2275-4917; Costagliola, Ciro/0000-0001-8477-6188; Gemmati,
   Donato/0000-0001-6213-6120; D'Angelo, Sergio/0000-0003-1118-3845
CR Abugreen S, 2003, BRIT J OPHTHALMOL, V87, P307, DOI 10.1136/bjo.87.3.307
   Antoszyk AN, 2008, AM J OPHTHALMOL, V145, P862, DOI 10.1016/j.ajo.2007.12.029
   Ariens RAS, 2000, BLOOD, V96, P988, DOI 10.1182/blood.V96.3.988.015k57_988_995
   Ariens RAS, 2002, BLOOD, V100, P743, DOI 10.1182/blood.V100.3.743
   Arnold J, 2001, OPHTHALMOLOGY, V108, P841
   Arnold J, 2001, AM J OPHTHALMOL, V131, P541
   Arnold JJ, 2004, AM J OPHTHALMOL, V137, P683, DOI 10.1016/j.ajo.2003.11.059
   Austin RC, 2004, CELL DEATH DIFFER, V11, pS56, DOI 10.1038/sj.cdd.4401451
   Bakri SJ, 2004, EXPERT OPIN PHARMACO, V5, P195, DOI 10.1517/14656566.5.1.195
   Bashshur ZF, 2008, AM J OPHTHALMOL, V145, P249, DOI 10.1016/j.ajo.2007.09.031
   Beaumont P, 2004, ARCH OPHTHALMOL-CHIC, V122, P1546, DOI 10.1001/archopht.122.10.1546
   Bereczky Z, 2003, PATHOPHYSIOL HAEMO T, V33, P430, DOI 10.1159/000083841
   Bergeron-Sawitzke J, 2009, EUR J HUM GENET, V17, P1190, DOI 10.1038/ejhg.2009.23
   Bernardi F, 2002, PATHOPHYSIOL HAEMO T, V32, P335, DOI 10.1159/000076692
   BERTINA RM, 1994, NATURE, V369, P64, DOI 10.1038/369064a0
   Bhavsar A, 2004, RETINA-J RET VIT DIS, V24, P512
   Blinder KJ, 2003, OPHTHALMOLOGY, V110, P667, DOI 10.1016/S0161-6420(02)01998-X
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Bradley John, 2007, Angiogenesis, V10, P141, DOI 10.1007/s10456-007-9069-x
   Brantley MA, 2009, EYE, V23, P626, DOI 10.1038/eye.2008.28
   Brantley MA, 2007, AM J OPHTHALMOL, V144, P404, DOI 10.1016/j.ajo.2007.05.018
   Bressler NM, 2005, RETINA-J RET VIT DIS, V25, P119
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Brown GC, 2007, OPHTHALMOLOGY, V114, P1170, DOI 10.1016/j.ophtha.2006.09.019
   Brown GC, 2005, AM J OPHTHALMOL, V140, P679, DOI 10.1016/j.ajo.2005.04.061
   Brown MM, 2008, OPHTHALMOLOGY, V115, P1039, DOI 10.1016/j.ophtha.2007.08.033
   Brull DJ, 2003, ARTERIOSCL THROM VAS, V23, P2063, DOI 10.1161/01.ATV.0000084640.21712.9C
   Cai H, 2000, CIRC RES, V87, P840, DOI 10.1161/01.RES.87.10.840
   Campa C, 2010, MEDIAT INFLAMM, V2010, DOI 10.1155/2010/546826
   Campochiaro P A, 1999, Mol Vis, V5, P34
   Carter AM, 2002, THROMB HAEMOSTASIS, V87, P846, DOI 10.1055/s-0037-1613095
   Castoldi E, 2004, CURR OPIN HEMATOL, V11, P176, DOI 10.1097/01.moh.0000130315.41033.32
   Castro R, 2006, J INHERIT METAB DIS, V29, P3, DOI 10.1007/s10545-006-0106-5
   Ceelie H, 2004, J THROMB HAEMOST, V2, P119, DOI 10.1111/j.1538-7836.2003.00493.x
   Chakravarthy U, 2006, BRIT J OPHTHALMOL, V90, P1188, DOI 10.1136/bjo.2005.082255
   Chan WM, 2009, BRIT J OPHTHALMOL, V93, P150, DOI 10.1136/bjo.2008.145797
   Chan WM, 2006, JPN J OPHTHALMOL, V50, P161, DOI 10.1007/s10384-005-0259-z
   Chan WM, 2005, BRIT J OPHTHALMOL, V89, P1522, DOI 10.1136/bjo.2005.074716
   Chappelow AV, 2008, DRUGS, V68, P1029, DOI 10.2165/00003495-200868080-00002
   Chen YH, 2011, ARCH OPHTHALMOL-CHIC, V129, P344, DOI 10.1001/archophthalmol.2011.10
   Chowers I, 2008, MOL VIS, V14, P2263
   Chowers I, 2008, MOL VIS, V14, P1829
   Churchill AJ, 2006, HUM MOL GENET, V15, P2955, DOI 10.1093/hmg/ddl238
   Ciulla TA, 2009, CURR OPIN OPHTHALMOL, V20, P166, DOI 10.1097/ICU.0b013e328329d173
   Cohen SY, 2009, RETINA-J RET VIT DIS, V29, P1062, DOI 10.1097/IAE.0b013e3181b1bb1a
   Colquitt JL, 2008, HEALTH TECHNOL ASSES, V12, P1
   Coppola A, 2000, SEMIN THROMB HEMOST, V26, P243, DOI 10.1055/s-2000-8469
   Costagliola C, 2008, EUR J OPHTHALMOL, V18, P955, DOI 10.1177/112067210801800616
   Costagliola C, 2010, BRIT J OPHTHALMOL, V94, P180, DOI 10.1136/bjo.2009.159343
   Costagliola C, 2009, RETINA-J RET VIT DIS, V29, P1227, DOI 10.1097/IAE.0b013e3181b773e1
   Costagliola C, 2009, GRAEF ARCH CLIN EXP, V247, P1031, DOI 10.1007/s00417-009-1081-y
   Cruess AF, 2008, PHARMACOECONOMICS, V26, P57, DOI 10.2165/00019053-200826010-00006
   Dadgostar H, 2008, EYE, V22, P761, DOI 10.1038/eye.2008.86
   Dahlback B, 2008, BLOOD, V112, P19, DOI 10.1182/blood-2008-01-077909
   Danckwardt S, 2006, ACTA HAEMATOL-BASEL, V115, P192, DOI 10.1159/000090934
   Dardik R, 2006, J THROMB HAEMOST, V4, P19, DOI 10.1111/j.1538-7836.2005.01473.x
   Dardik R, 2003, ARTERIOSCL THROM VAS, V23, P1472, DOI 10.1161/01.ATV.0000081636.25235.C6
   de Lange M, 2006, ARTERIOSCL THROM VAS, V26, P1914, DOI 10.1161/01.ATV.0000231538.60223.92
   De Stefano V, 2000, SEMIN THROMB HEMOST, V26, P305, DOI 10.1055/s-2000-8473
   DEJONG PT, 2007, INVEST OPHTHALMOL VI, V48
   Ding XY, 2009, PROG RETIN EYE RES, V28, P1, DOI 10.1016/j.preteyeres.2008.10.001
   Donoso LA, 2010, SURV OPHTHALMOL, V55, P227, DOI 10.1016/j.survophthal.2009.11.001
   Dougherty TJ, 1998, JNCI-J NATL CANCER I, V90, P889, DOI 10.1093/jnci/90.12.889
   Droz I, 2008, BRIT J OPHTHALMOL, V92, P513, DOI 10.1136/bjo.2007.127811
   Du Clos TW, 2000, ANN MED, V32, P274, DOI 10.3109/07853890009011772
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Emerson MV, 2007, BIODRUGS, V21, P245, DOI 10.2165/00063030-200721040-00005
   Fang AM, 2009, MOL VIS, V15, P2710
   Feng XF, 2009, OPHTHALMOLOGY, V116, P1908, DOI 10.1016/j.ophtha.2009.03.011
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   Galan A, 2010, OPHTHALMOLOGY, V117, P1769, DOI 10.1016/j.ophtha.2010.01.030
   Gaynes Bruce I, 2004, Expert Opin Drug Saf, V3, P345, DOI 10.1517/14740338.3.4.345
   Gehring NH, 2001, NAT GENET, V28, P389, DOI 10.1038/ng578
   Gemmati D, 1999, ARTERIOSCL THROM VAS, V19, P1761, DOI 10.1161/01.ATV.19.7.1761
   Gemmati D, 2004, CANCER EPIDEM BIOMAR, V13, P787
   Gemmati D, 1999, HAEMATOLOGICA, V84, P824
   Gemmati D, 2007, HAEMATOLOGICA, V92, P478, DOI 10.3324/haematol.10587
   Goverdhan SV, 2008, EYE, V22, P849, DOI 10.1038/sj.eye.6702830
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   GREEN WR, 1986, OPHTHALMOLOGY, V93, P1169
   Greve MDJ, 2005, ARCH OPHTHALMOL-CHIC, V123, P448
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2006, INVEST OPHTH VIS SCI, V47, P329, DOI 10.1167/iovs.05-0116
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hasan T., 1997, CANC MED, P739
   Hayashi K, 2008, AM J OPHTHALMOL, V145, P518, DOI 10.1016/j.ajo.2007.10.032
   HEHLGANS S, 1999, THROMB HAEMOST, V81
   HENDERSON BW, 1992, PHOTOCHEM PHOTOBIOL, V55, P145, DOI 10.1111/j.1751-1097.1992.tb04222.x
   Hezard N, 2006, CLIN CHEM, V52, P665, DOI 10.1373/clinchem.2005.063339
   Holven KB, 2007, J THROMB HAEMOST, V5, P193, DOI 10.1111/j.1538-7836.2006.02275.x
   Holven KB, 2003, J NUTR, V133, P3588, DOI 10.1093/jn/133.11.3588
   Holz ER, 2003, ARCH OPHTHALMOL-CHIC, V121, P1649, DOI 10.1001/archopht.121.11.1649
   Howard TE, 2001, BLOOD, V98, p259A
   Ichinose A, 2001, THROMB HAEMOSTASIS, V86, P57
   Ilhan N, 2008, ARCH MED RES, V39, P125, DOI 10.1016/j.arcmed.2007.07.009
   Immonen I, 2010, OPHTHALMOLOGY, V117, P103, DOI 10.1016/j.ophtha.2009.06.037
   Incorvaia C, 2008, RETINA-J RET VIT DIS, V28, P289, DOI 10.1097/IAE.0b013e31813ffe90
   Isola V, 2006, AM J OPHTHALMOL, V142, P680, DOI 10.1016/j.ajo.2006.04.028
   Jalil A, 2009, EUR J OPHTHALMOL, V19, P490, DOI 10.1177/112067210901900330
   Jambor C, 2009, ANESTH ANALG, V109, P1023, DOI 10.1213/ANE.0b013e3181b5a263
   Kaiser PK, 2006, AM J OPHTHALMOL, V142, P660, DOI 10.1016/j.ajo.2006.05.061
   Kaiser PK, 2009, OPHTHALMOLOGY, V116, P747, DOI 10.1016/j.ophtha.2008.12.057
   Kanani PM, 1999, CIRCULATION, V100, P1161, DOI 10.1161/01.CIR.100.11.1161
   Kaur I, 2008, INVEST OPHTH VIS SCI, V49, P1771, DOI 10.1167/iovs.07-0560
   Kim IK, 2008, MOL VIS, V14, P1487
   Kim NR, 2008, INVEST OPHTH VIS SCI, V49, P2071, DOI 10.1167/iovs.07-1195
   Klais CM, 2005, ARCH OPHTHALMOL-CHIC, V123, P1149, DOI 10.1001/archopht.123.8.1149
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Kobbervig C, 2004, BIOPHYS CHEM, V112, P223, DOI 10.1016/j.bpc.2004.07.023
   Kohler HP, 1998, THROMB HAEMOSTASIS, V80, P704
   Koizumi H, 2010, ARCH OPHTHALMOL-CHIC, V128, P259, DOI 10.1001/archophthalmol.2009.369
   Kolling K, 2004, AM J CARDIOL, V93, P1201, DOI 10.1016/j.amjcard.2004.02.009
   Krebs I, 2005, AM J OPHTHALMOL, V140, P416, DOI 10.1016/j.ajo.2005.03.050
   Lai TYY, 2009, RETINA-J RET VIT DIS, V29, P750, DOI 10.1097/IAE.0b013e31819ed6bd
   Lam DSC, 2004, BRIT J OPHTHALMOL, V88, P1315, DOI 10.1136/bjo.2004.041624
   Landa G, 2009, OPHTHALMOLOGICA, V223, P370, DOI 10.1159/000227783
   Lane DA, 2000, BLOOD, V95, P1517, DOI 10.1182/blood.V95.5.1517.005k48_1517_1532
   Lazic R, 2007, OPHTHALMOLOGY, V114, P1179, DOI 10.1016/j.ophtha.2007.03.006
   Leveziel N, 2008, INVEST OPHTH VIS SCI, V49, P3090, DOI 10.1167/iovs.07-1540
   Lim BCB, 2003, LANCET, V361, P1424, DOI 10.1016/S0140-6736(03)13135-2
   Lin JM, 2008, AM J OPHTHALMOL, V145, P1045, DOI 10.1016/j.ajo.2008.01.027
   Ma J, 1999, CANCER EPIDEM BIOMAR, V8, P825
   Ma J, 1997, CANCER RES, V57, P1098
   Mao RF, 2008, CELL BIOCHEM FUNCT, V26, P352, DOI 10.1002/cbf.1450
   Maurer MC, 2006, ARCH BIOCHEM BIOPHYS, V445, P36, DOI 10.1016/j.abb.2005.11.009
   Michels S, 2003, INVEST OPHTH VIS SCI, V44, P2147, DOI 10.1167/iovs.02-0604
   Miller JW, 2010, JPN J OPHTHALMOL, V54, P523, DOI 10.1007/s10384-010-0863-4
   Miller Joan W, 2008, Trans Am Ophthalmol Soc, V106, P357
   Miller JW, 1999, ARCH OPHTHALMOL-CHIC, V117, P1161
   Mitchell P, 2010, BRIT J OPHTHALMOL, V94, P2, DOI 10.1136/bjo.2009.159160
   Mosesson MW, 2005, J THROMB HAEMOST, V3, P1894, DOI 10.1111/j.1538-7836.2005.01365.x
   Navea A, 2009, RETINA-J RET VIT DIS, V29, P13, DOI 10.1097/IAE.0b013e31818a1fd3
   Nicolaes GAF, 1997, BLOOD COAGUL FIBRIN, V8, P28, DOI 10.1097/00001721-199701000-00006
   Ormsby RJ, 2008, INVEST OPHTH VIS SCI, V49, P1763, DOI 10.1167/iovs.07-1297
   Parmeggiani F, 2006, OPHTHALMOLOGY, V113, P157
   Parmeggiani F, 2008, INVEST OPHTH VIS SCI, V49, P3100, DOI 10.1167/iovs.07-1654
   Parmeggiani F, 2007, PHARMACOGENET GENOM, V17, P1039, DOI 10.1097/FPC.0b013e3282f12a4e
   Parmeggiani F, 2011, CURR DRUG TARGETS, V12, P138, DOI 10.2174/138945011794182773
   Parmeggiani F, 2010, ARCH OPHTHALMOL-CHIC, V128, P1632, DOI 10.1001/archophthalmol.2010.285
   Parmeggiani Francesco, 2009, Recent Pat DNA Gene Seq, V3, P114
   Parmeggiani F, 2010, OPHTHALMOLOGY, V117, P517, DOI 10.1016/j.ophtha.2009.08.028
   Parmeggiani F, 2009, PHARMACOGENOMICS, V10, P81, DOI 10.2217/14622416.10.1.81
   PAULEIKHOFF D, 1990, AM J OPHTHALMOL, V109, P38, DOI 10.1016/S0002-9394(14)75576-X
   Pegaz B, 2006, J PHOTOCH PHOTOBIO B, V85, P216, DOI 10.1016/j.jphotobiol.2006.07.008
   Pollak ES, 2002, BLOOD, V100, P359, DOI 10.1182/blood-2002-02-0412
   Poort SR, 1996, BLOOD, V88, P3698, DOI 10.1182/blood.V88.10.3698.bloodjournal88103698
   Postea O, 2006, ARTERIOSCL THROM VAS, V26, P508, DOI 10.1161/01.ATV.0000201039.21705.dc
   Raftery J, 2007, BRIT J OPHTHALMOL, V91, P1244, DOI 10.1136/bjo.2007.116616
   Ranchod TM, 2008, RETINA-J RET VIT DIS, V28, P711, DOI 10.1097/IAE.0b013e31816079c3
   Richardson AJ, 2007, MOL VIS, V13, P2148
   Robman L, 2010, OPHTHALMOLOGY, V117, P1982, DOI 10.1016/j.ophtha.2010.02.003
   Rongioletti M, 2005, PLATELETS, V16, P185, DOI 10.1080/09537100400020187
   Rosendorff A, 2007, ARCH PATHOL LAB MED, V131, P866
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Sakurai K, 2003, J PHARMACOL SCI, V91, P182
   Schaumberg DA, 2006, INVEST OPHTH VIS SCI, V47, P2336, DOI 10.1167/iovs.05-1456
   Schlotzer-Schrehardt U, 2002, GRAEF ARCH CLIN EXP, V240, P748, DOI 10.1007/s00417-002-0517-4
   Schmidt-Erfurth U, 2000, SURV OPHTHALMOL, V45, P195, DOI 10.1016/S0039-6257(00)00158-2
   Schmidt-Erfurth U, 2005, OPHTHALMOLOGY, V112, P2061, DOI 10.1016/j.ophtha.2005.09.007
   Schmidt-Erfurth U, 1999, ARCH OPHTHALMOL-CHIC, V117, P1177
   Schmidt-Erfurth U, 2002, INVEST OPHTH VIS SCI, V43, P830
   Schmidt-Erfurth U, 1998, GRAEF ARCH CLIN EXP, V236, P365, DOI 10.1007/s004170050092
   Schmidt-Erfurth U, 2009, PROG RETIN EYE RES, V28, P145, DOI 10.1016/j.preteyeres.2009.01.001
   Schmidt-Erfurth UM, 2007, PROG RETIN EYE RES, V26, P437, DOI 10.1016/j.preteyeres.2007.03.002
   Schwahn B, 2001, Am J Pharmacogenomics, V1, P189, DOI 10.2165/00129785-200101030-00004
   Seddon JM, 2007, JAMA-J AM MED ASSOC, V297, P1793, DOI 10.1001/jama.297.16.1793
   Seddon JM, 2010, OPHTHALMOLOGY, V117, P1560, DOI 10.1016/j.ophtha.2009.11.020
   Seitsonen SP, 2007, EUR J OPHTHALMOL, V17, P943, DOI 10.1177/112067210701700612
   Shah GK, 2009, RETINA-J RET VIT DIS, V29, P133, DOI 10.1097/IAE.0b013e3181960a28
   Shastry B, 2010, GRAEF ARCH CLIN EXP, V248, P1057, DOI 10.1007/s00417-010-1333-x
   Shemirani AH, 2006, BBA-PROTEINS PROTEOM, V1764, P1420, DOI 10.1016/j.bbapap.2006.06.007
   SHEN L, 1994, J BIOL CHEM, V269, P18735
   Shima C, 2009, GRAEF ARCH CLIN EXP, V247, P899, DOI 10.1007/s00417-009-1067-9
   Shuler RK, 2008, OPHTHALMOLOGY, V115, P520, DOI 10.1016/j.ophtha.2007.06.021
   Simioni P, 2006, SEMIN THROMB HEMOST, V32, P700, DOI 10.1055/s-2006-951298
   SMITH SR, 2007, INVEST OPHTHALMOL VI, V48
   Soria JM, 2000, BLOOD, V95, P2780, DOI 10.1182/blood.V95.9.2780.009k36_2780_2785
   Soubrane G, 2008, SURV OPHTHALMOL, V53, P121, DOI 10.1016/j.survophthal.2007.12.004
   Soubrane G, 2007, ARCH OPHTHALMOL-CHIC, V125, P1249, DOI 10.1001/archopht.125.9.1249
   Spaide RF, 2006, AM J OPHTHALMOL, V141, P149, DOI 10.1016/j.ajo.2005.07.025
   Spilsbury K, 2000, AM J PATHOL, V157, P135, DOI 10.1016/S0002-9440(10)64525-7
   Stepien KE, 2009, RETINA-J RET VIT DIS, V29, P1067, DOI 10.1097/IAE.0b013e3181b1bb06
   Subramanian ML, 2009, AM J OPHTHALMOL, V148, P875, DOI 10.1016/j.ajo.2009.07.009
   *TAP VIP STUD GROU, 2004, RETINA, V24, P1
   Tong HP, 2006, CLIN BIOCHEM, V39, P267, DOI 10.1016/j.clinbiochem.2005.11.013
   Trumbo TA, 2000, J BIOL CHEM, V275, P20627, DOI 10.1074/jbc.M000209200
   Tsuchihashi T, 2011, OPHTHALMOLOGY, V118, P93, DOI 10.1016/j.ophtha.2010.04.007
   Varga EA, 2008, J THROMB THROMBOLYS, V25, P6, DOI 10.1007/s11239-007-0056-2
   Vargas A, 2009, Arch Soc Esp Oftalmol, V84, P169
   Vedula SS, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005139.pub2
   Volanti C, 2002, PHOTOCHEM PHOTOBIOL, V75, P36, DOI 10.1562/0031-8655(2002)075<0036:IOOSIN>2.0.CO;2
   Waisbourd M, 2007, DRUG AGING, V24, P643, DOI 10.2165/00002512-200724080-00003
   Wegscheider BJ, 2007, OPHTHALMOLOGY, V114, P738, DOI 10.1016/j.ophtha.2006.07.048
   Weiss N, 2005, CURR DRUG METAB, V6, P27, DOI 10.2174/1389200052997357
   Wickens J, 2006, DRUG SAFETY, V29, P189, DOI 10.2165/00002018-200629030-00003
   Wong T, 2008, OPHTHALMOLOGY, V115, P116, DOI 10.1016/j.ophtha.2007.03.008
   Wormald R, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002030.pub3
   Yang N, 2006, EYE, V20, P523, DOI 10.1038/sj.eye.6701991
   Zivelin A, 1998, BLOOD, V92, P1119, DOI 10.1182/blood.V92.4.1119.416k39_1119_1124
   Zuluaga MF, 2007, INVEST OPHTH VIS SCI, V48, P1767, DOI 10.1167/iovs.06-1224
NR 202
TC 7
Z9 8
U1 0
U2 7
PU ADIS INT LTD
PI NORTHCOTE
PA 5 THE WAREHOUSE WAY, NORTHCOTE 0627, AUCKLAND, NEW ZEALAND
SN 1177-1062
EI 1179-2000
J9 MOL DIAGN THER
JI Mol. Diagn. Ther.
PY 2011
VL 15
IS 4
BP 195
EP 210
DI 10.1007/BF03256411
PG 16
WC Genetics & Heredity; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity; Pharmacology & Pharmacy
GA 833PD
UT WOS:000295896500002
PM 21913742
DA 2022-11-30
ER

PT J
AU Eisner, A
AF Eisner, Alvin
TI Sex, Eyes, and Vision: Male/Female Distinctions in Ophthalmic Disorders
SO CURRENT EYE RESEARCH
LA English
DT Review
DE Estrogen; ophthalmology; sex; vision; women's health
ID MENOPAUSAL HORMONE-THERAPY; BREAST-CANCER; ESTROGEN; WOMEN; SOY;
   ISOFLAVONES; INTRACRINE; ANDROGENS; SOCIETY; BALANCE
AB There is growing recognition: (1) that sex (male and female) and sex hormones (androgens and estrogens) are important for physiologic functions outside those pertaining expressly to reproduction, and (2) that both classes of sex hormones are active in both sexes, and moreover are produced locally in non-gonadal tissues throughout the body. The visual system, in addition to being of tremendous inherent importance, is unique in a very distinctive way; it possesses an organ - the eye - having a window allowing its interior to be examined with exquisite precision and control in both laboratory and clinical settings. Plus, many diseases manifest in the eye or are exclusive to the eye. This special issue of Current Eye Research contains 12 review articles, each addressing a different topical area important for Sex, Eyes, and Vision: Male/Female Distinctions in Ophthalmic Disorders. Of course, the distinctions between topical areas are blurred, and the overlap between the various lines of knowledge and investigation likewise is substantial. Eye diseases can be both neurodegenerative and involve altered blood flow, for instance. In fact, the thematic overlap is greater yet, in that the articles for this special issue address matters of interest to clinicians and scientists who may identify more with women's health or sex & gender fields than with eye & vision fields. Nevertheless, because this special issue needs a home, the following 12 topical areas each have here their own dedicated review: age-related maculopathy, central nervous system function and cognition & perception, diabetic retinopathy, dry eye, glaucoma, inherited diseases, lens and cataract, neuro-ophthalmology, ocular blood flow, ocular inflammatory disorders, optical coherence tomography, and sex/gender eye care disparities. This overview article itself raises additional points expressly concerning: (1) the estrogen therapy timing hypothesis, and (2) breast cancer treatment with aromatase inhibitors.
C1 Current Eye Res Editorial Board, Portland, OR 97239 USA.
RP Eisner, A (通讯作者)，Current Eye Res Editorial Board, Portland, OR 97239 USA.
EM aeisnerphd@gmail.com
CR Anderson WF, 2011, J NATL CANCER I, V103, P1397, DOI 10.1093/jnci/djr257
   Barlow DH, 2010, HUM REPROD UPDATE, V16, P761, DOI 10.1093/humupd/dmq008
   Bringmann Andreas, 2013, Front Endocrinol (Lausanne), V4, P48, DOI 10.3389/fendo.2013.00048
   Burstein HJ, 2014, J CLIN ONCOL, V32, P2255, DOI 10.1200/JCO.2013.54.2258
   Carroll J, 2013, CURR EYE RES, V38, P709, DOI 10.3109/02713683.2013.784792
   Clarke BL, 2010, ARCH BIOCHEM BIOPHYS, V503, P118, DOI 10.1016/j.abb.2010.07.006
   Clayton JA, 2014, NATURE, V509, P282, DOI 10.1038/509282a
   Cowell CF, 2013, MOL ONCOL, V7, P859, DOI 10.1016/j.molonc.2013.07.005
   Eiermann W, 2013, ANN ONCOL, V24, P618, DOI 10.1093/annonc/mds512
   Eisner A, 2011, CURR EYE RES, V36, P867, DOI 10.3109/02713683.2011.594202
   Eisner A, 2011, ACTA OPHTHALMOL, V89, pe217, DOI 10.1111/j.1755-3768.2009.01799.x
   Ferraldeschi R, 2013, CLIN CANCER RES, V19, P3353, DOI 10.1158/1078-0432.CCR-12-0931
   Gameiro CM, 2010, MATURITAS, V67, P316, DOI 10.1016/j.maturitas.2010.08.003
   Gillies GE, 2010, PHARMACOL REV, V62, P155, DOI 10.1124/pr.109.002071
   Gomez FP, 2013, HORM BEHAV, V63, P315, DOI 10.1016/j.yhbeh.2012.10.014
   Greendale GA, 2011, OBSTET GYN CLIN N AM, V38, P519, DOI 10.1016/j.ogc.2011.05.007
   Kiernan DF, 2010, AM J OPHTHALMOL, V149, P18, DOI 10.1016/j.ajo.2009.08.037
   Kimura K, 2014, INVEST OPHTH VIS SCI, V55, P2621, DOI 10.1167/iovs.13-13501
   Krause DN, 2011, ACTA PHYSIOL, V203, P181, DOI 10.1111/j.1748-1716.2011.02323.x
   Kreatsoulas C, 2013, POL ARCH MED WEWN, V123, P112, DOI 10.20452/pamw.1625
   Kurzer MS, 2002, J NUTR, V132, p570S, DOI 10.1093/jn/132.3.570S
   Kwak HS, 2009, J KOREAN MED SCI, V24, P867, DOI 10.3346/jkms.2009.24.5.867
   Laurent M, 2014, ASIAN J ANDROL, V16, P213, DOI 10.4103/1008-682X.122356
   Li JH, 2014, J BIOL CHEM, V289, P747, DOI 10.1074/jbc.M113.534172
   Liu M, 2010, MINERVA ENDOCRINOL, V35, P127
   Lobo RA, 2011, MENOPAUSE, V18, P237, DOI [10.1097/gme.0b013e3181e9e538, 10.1097/gme.0b013e31821fc8e0]
   Manson JE, 2013, JAMA-J AM MED ASSOC, V310, P1353, DOI 10.1001/jama.2013.278040
   Markopoulos C, 2013, EXPERT REV ANTICANC, V13, P179, DOI [10.1586/era.12.174, 10.1586/ERA.12.174]
   Marshak DW, 2014, VISUAL NEUROSCI, V31, P111, DOI 10.1017/S0952523813000655
   McCarthy MM, 2011, BRAIN RES, V1379, P109, DOI 10.1016/j.brainres.2010.11.094
   Melcangi Roberto Cosimo, 2011, Front Endocrinol (Lausanne), V2, P104, DOI 10.3389/fendo.2011.00104
   Meyer MR, 2011, ACTA PHYSIOL, V203, P259, DOI 10.1111/j.1748-1716.2010.02237.x
   Miller VM, 2014, AM J PHYSIOL-HEART C, V306, pH781, DOI 10.1152/ajpheart.00994.2013
   Morgan JE, 2012, CLIN EXP OPHTHALMOL, V40, P364, DOI 10.1111/j.1442-9071.2012.02789.x
   Mott NN, 2013, ISRN ENDOCRINOL, DOI [10.1155/2013/814690, DOI 10.1155/2013/814690]
   Pollanen E, 2011, AGING CELL, V10, P650, DOI 10.1111/j.1474-9726.2011.00701.x
   Porola P, 2008, J RHEUMATOL, V35, P2229, DOI 10.3899/jrheum.080220
   Qin WY, 2009, NUTR CANCER, V61, P238, DOI 10.1080/01635580802404196
   Riva CE, 2001, INVEST OPHTH VIS SCI, V42, P756
   Rosner W, 2013, J CLIN ENDOCR METAB, V98, P1376, DOI 10.1210/jc.2012-3780
   Santen RJ, 2009, ENDOCR REV, V30, P343, DOI 10.1210/er.2008-0016
   Simpson ER, 2003, J STEROID BIOCHEM, V86, P225, DOI 10.1016/S0960-0760(03)00360-1
   Sorwell KG, 2012, NEUROBIOL AGING, V33, DOI 10.1016/j.neurobiolaging.2011.05.004
   Thomas MP, 2013, J STEROID BIOCHEM, V137, P27, DOI 10.1016/j.jsbmb.2012.12.014
   Truong S, 2014, CLIN EXP OPTOM, V97, P324, DOI 10.1111/cxo.12147
   Van LT, 2013, J STEROID BIOCHEM, V137, P176, DOI 10.1016/j.jsbmb.2013.05.017
   Vitale C, 2009, NAT REV CARDIOL, V6, P532, DOI 10.1038/nrcardio.2009.105
   Voogd AC, 2013, J COMP EFFECT RES, V2, P113, DOI [10.2217/cer.13.3, 10.2217/CER.13.3]
   Wang AT, 2014, PLOS ONE, V9, DOI [10.1371/journal.pone.0091399, 10.1371/journal.pone.0110985]
   Welch HG, 2014, JAMA INTERN MED, V174, P448, DOI 10.1001/jamainternmed.2013.13635
   Winters-Stone KM, 2011, ARCH PHYS MED REHAB, V92, P646, DOI 10.1016/j.apmr.2010.10.039
   Yarrow JF, 2012, MED SCI SPORT EXER, V44, P818, DOI 10.1249/MSS.0b013e31823bfcbf
   Zhong ZY, 2012, J VISION, V12, DOI 10.1167/12.6.3
   Zouboulis, 2013, J STEROID BIOCHEM, V137, P107, DOI [10.1016/.jsbmb.2013.02.006, DOI 10.1016/J.JSBMB.2013.02.006]
NR 54
TC 15
Z9 15
U1 1
U2 27
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0271-3683
EI 1460-2202
J9 CURR EYE RES
JI Curr. Eye Res.
PD FEB
PY 2015
VL 40
IS 2
BP 96
EP 101
DI 10.3109/02713683.2014.975368
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AZ4TB
UT WOS:000348214800002
PM 25329177
DA 2022-11-30
ER

PT J
AU Awwad, S
   Abubakre, A
   Angkawinitwong, U
   Khaw, PT
   Brocchini, S
AF Awwad, Sahar
   Abubakre, Abdullah
   Angkawinitwong, Ukrit
   Khaw, Peng T.
   Brocchini, Steve
TI In situ antibody-loaded hydrogel for intravitreal delivery
SO EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES
LA English
DT Article
DE Hyaluronic acid; Intraocular; Controlled release; Hydrogel; Ocular drug
   delivery; Antibody
ID HYALURONIC-ACID; DRUG-DELIVERY; MONOCLONAL-ANTIBODY; CONTROLLED-RELEASE;
   PROTEIN RELEASE; BEHAVIOR; PHASE; DEGRADATION; FORMULATION; EXCIPIENT
AB Therapeutic protein medicines have transformed the treatment of blinding diseases (e.g. age-related macular degeneration, AMD) during the last 1-2 decades. Many blinding conditions such as AMD are chronic; and require multiple intravitreal injections over a long period to achieve a high and reproducible dose needed for clinical benefit. Prolonging the duration of action of ophthalmic drugs is critical to reduce the frequency of injections. Thermoresponsive hydrogels (e.g. N-isopropylacrylamide, NIPAAM) that collapse in physiological conditions can entrap and sustain the release of a therapeutic protein. However, most NIPAAM hydrogels are not biodegradable and often requires invasive surgery to remove the depot. Here, we report the preparation of a hydrogel derived from NIPAAM and acrylated hyaluronic acid (Ac-HA) as a biodegradable, macromolecular crosslinker. Ac-HA was prepared by the acrylation of hyaluronic acid (HA). Antibody (infliximab (INF), 5.0 mg/mL or bevacizumab (BEVA), 12.5 mg/mL), NIPAAM (0.35 mmol) and Ac-HA (2.0-10.0 mg/mL, 40.0-200.0 nmol) were first mixed prior to redox polymerisation to ensure maximal protein mixing and to shorten the burst release. Hydrogels with lower amounts of Ac-HA (2.0-4.0 mg/mL, 40.0-80.0 nmol) showed favourable lower critical solution temperature (LCST) values and injectability (27-29G) than higher amounts of Ac-HA (> 4.0 mg/mL, > 80.0 nmol). These hydrogels were further characterised (swelling ratio (SR), water retention (WR) and rheology). All hydrogels degraded in presence of bovine testes hyaluronidase (0-50 U/mL, 37 degrees C, 100 rpm). Release studies of BEVA-loaded hydrogels were investigated in vitro using the PK-Eye (TM) model, which estimates the human clearance times of proteins from the back of the eye. Phosphate buffered saline (PBS, pH 7.4, 37 degrees C) was used rather than simulated vitreous to more effectively map trends between the formulations. A zero-order release profile was observed between days 5 to 50 with 43.3 +/- 9.5% protein released at day 50. Determining protein binding and functionality from a formulation is crucial to determine the optimal formulation prior to more detailed studies that might be necessary. BEVA showed binding to human vascular growth endothelial factor (VEGF(165)) throughout the study (two months) while still maintaining a therapeutic dose (123.5 +/- 45.6 ng) in the posterior cavity of the PK-Eye (TM) model. These encouraging results suggest that extended release of proteins in the vitreous can be achieved using injectable hydrogels derived from NIPAAM and HA.
C1 [Awwad, Sahar; Abubakre, Abdullah; Angkawinitwong, Ukrit; Brocchini, Steve] UCL Sch Pharm, 29-39 Brunswick Sq, London WC1N 1AX, England.
   [Awwad, Sahar; Khaw, Peng T.; Brocchini, Steve] Moorfields Eye Hosp NHS Fdn Trust, Biomed Res Ctr, NIHR, London EC1V 9EL, England.
   [Awwad, Sahar; Khaw, Peng T.; Brocchini, Steve] UCL Inst Ophthalmol, London EC1V 9EL, England.
C3 University of London; University College London; University of London;
   King's College London; University College London; Moorfields Eye
   Hospital NHS Foundation Trust; University of London; University College
   London
RP Awwad, S (通讯作者)，UCL Sch Pharm, 29-39 Brunswick Sq, London WC1N 1AX, England.
EM s.awwad@ucl.ac.uk
OI Khaw, Sir Peng Tee/0000-0002-8087-2268; Awwad, Sahar/0000-0002-4430-2508
FU National Institute for Health Research Biomedical Research Centre at
   Moorfields Eye Hospital NHS Foundation Trust and UCL Institute of
   Ophthalmology; Moorfields Special Trustees; Helen Hamlyn Trust; Medical
   Research Council; Fight for Sight UK; Michael and Ilse Katz Foundation
FX We are grateful for funding from the National Institute for Health
   Research Biomedical Research Centre at Moorfields Eye Hospital NHS
   Foundation Trust and UCL Institute of Ophthalmology, Moorfields Special
   Trustees, the Helen Hamlyn Trust (in memory of Paul Hamlyn), Medical
   Research Council, Fight for Sight UK and the Michael and Ilse Katz
   Foundation.
CR [Anonymous], 2012, J APPL RES CLIN EXP
   Awwad S, 2018, PHARMACEUTICS, V10, DOI 10.3390/pharmaceutics10030083
   Awwad S, 2018, MACROMOL BIOSCI, V18, DOI 10.1002/mabi.201700255
   Awwad S, 2017, INT J PHARMACEUT, V522, P119, DOI 10.1016/j.ijpharm.2017.02.047
   Awwad S, 2015, J PHARM SCI-US, V104, P3330, DOI 10.1002/jps.24480
   Ballios BG, 2010, BIOMATERIALS, V31, P2555, DOI 10.1016/j.biomaterials.2009.12.004
   Bhambhani A, 2012, J PHARM SCI-US, V101, P1120, DOI 10.1002/jps.23008
   Bishop PN, 2000, PROG RETIN EYE RES, V19, P323, DOI 10.1016/S1350-9462(99)00016-6
   Burdick JA, 2011, ADV MATER, V23, pH41, DOI 10.1002/adma.201003963
   Chakravarthy U, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.04.015
   Chen MH, 2017, ACS BIOMATER SCI ENG, V3, P3146, DOI 10.1021/acsbiomaterials.7b00734
   del Amo EM, 2008, DRUG DISCOV TODAY, V13, P135, DOI 10.1016/j.drudis.2007.11.002
   del Amo EM, 2015, EUR J PHARM BIOPHARM, V95, P215, DOI 10.1016/j.ejpb.2015.01.003
   Drapala PW, 2011, J BIOMAT SCI-POLYM E, V22, P59, DOI 10.1163/092050609X12578498952315
   Egbu R, 2018, EUR J PHARM BIOPHARM, V124, P95, DOI 10.1016/j.ejpb.2017.12.019
   Erbil C, 2004, EUR POLYM J, V40, P1145, DOI 10.1016/j.eurpolymj.2003.12.024
   Falconer RJ, 2011, J CHEM TECHNOL BIOT, V86, P942, DOI 10.1002/jctb.2657
   Filas BA, 2014, INVEST OPHTH VIS SCI, V55, P55, DOI 10.1167/iovs.13-13026
   Gandhi A, 2015, ASIAN J PHARM SCI, V10, P99, DOI 10.1016/j.ajps.2014.08.010
   Gaudana R, 2010, AAPS J, V12, P348, DOI 10.1208/s12248-010-9183-3
   Genentech, 2018, GEN UNV POS PHAS 2 R
   Ghosh JG, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14837
   Gokceoren AT, 2014, J POLYM RES, V21, DOI 10.1007/s10965-014-0370-2
   Guter M, 2017, EUR J PHARM BIOPHARM, V113, P34, DOI 10.1016/j.ejpb.2016.11.035
   Haddad A, 1998, EXP EYE RES, V66, P709, DOI 10.1006/exer.1997.0476
   Hamidi M, 2008, ADV DRUG DELIVER REV, V60, P1638, DOI 10.1016/j.addr.2008.08.002
   Hattori T, 2010, RETINA-J RET VIT DIS, V30, P761, DOI 10.1097/IAE.0b013e3181c70168
   Hwang W, 2013, J MED DEVICES, V7, DOI 10.1115/1.4024338
   JACOBSON B, 1984, EXP EYE RES, V39, P373, DOI 10.1016/0014-4835(84)90025-3
   Jager RD, 2004, RETINA-J RET VIT DIS, V24, P676, DOI 10.1097/00006982-200410000-00002
   Jain K, 2015, POLYM CHEM-UK, V6, P6819, DOI 10.1039/c5py00998g
   Jatav V. S., 2011, INT J RES PHARM BIOM, V2, P442
   Khunmanee S, 2017, J TISSUE ENG, V8, DOI 10.1177/2041731417726464
   Kim MR, 2002, J CONTROL RELEASE, V80, P69, DOI 10.1016/S0168-3659(01)00557-0
   Klouda L, 2015, EUR J PHARM BIOPHARM, V97, P338, DOI 10.1016/j.ejpb.2015.05.017
   Kogan G, 2007, BIOTECHNOL LETT, V29, P17, DOI 10.1007/s10529-006-9219-z
   Kurisawa M, 2005, CHEM COMMUN, P4312, DOI 10.1039/b506989k
   Lance KD, 2016, DRUG DELIV TRANSL RE, V6, P771, DOI 10.1007/s13346-016-0298-7
   Leach JB, 2005, BIOMATERIALS, V26, P125, DOI 10.1016/j.biomaterials.2004.02.018
   Lian S, 2012, INT J NANOMED, V7, P4893, DOI 10.2147/IJN.S32645
   Makino K, 2001, COLLOID SURFACE B, V20, P341, DOI 10.1016/S0927-7765(00)00201-0
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   MATSUO ES, 1988, J CHEM PHYS, V89, P1695, DOI 10.1063/1.455115
   Necas J, 2008, VET MED-CZECH, V53, P397, DOI 10.17221/1930-VETMED
   Osswald CR, 2017, CURR EYE RES, V42, P1293, DOI 10.1080/02713683.2017.1302590
   Prasannan A, 2014, J MATER CHEM B, V2, P1988, DOI 10.1039/c3tb21360a
   Ratanji KD, 2014, J IMMUNOTOXICOL, V11, P99, DOI 10.3109/1547691X.2013.821564
   RAUCK BM, 2013, INVESTIG OPHTHALMOL, V55, P469
   Regeneron, 2017, REG ANN FDA ACC SBLA
   Samanta HS, 2014, CARBOHYD POLYM, V99, P666, DOI 10.1016/j.carbpol.2013.09.004
   Schwartz DM, 1996, CURR EYE RES, V15, P1156, DOI 10.3109/02713689608995150
   SEBAG J, 1989, INVEST OPHTH VIS SCI, V30, P1867
   Shi YF, 2013, BIOMED MATER, V8, DOI 10.1088/1748-6041/8/5/055007
   Stile RA, 1999, MACROMOLECULES, V32, P7370, DOI 10.1021/ma990130w
   Turturro SB, 2011, BIOMATERIALS, V32, P3620, DOI 10.1016/j.biomaterials.2011.01.058
   Vermonden T, 2012, CHEM REV, V112, P2853, DOI 10.1021/cr200157d
   Wang W, 2007, J PHARM SCI-US, V96, P1, DOI 10.1002/jps.20727
   Wells LA, 2011, BIOMACROMOLECULES, V12, P923, DOI 10.1021/bm101233m
   Wu JY, 2005, J CONTROL RELEASE, V102, P361, DOI 10.1016/j.jconrel.2004.10.008
   Yoon JA, 2010, MACROMOLECULES, V43, P4791, DOI 10.1021/ma1004953
   Yu Y, 2015, TRANSL VIS SCI TECHN, V4, DOI 10.1167/tvst.4.2.5
NR 61
TC 16
Z9 16
U1 10
U2 60
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0928-0987
EI 1879-0720
J9 EUR J PHARM SCI
JI Eur. J. Pharm. Sci.
PD SEP 1
PY 2019
VL 137
AR 104993
DI 10.1016/j.ejps.2019.104993
PG 10
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA IS3WX
UT WOS:000482085700018
PM 31302214
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Williams, KM
   Bentham, GCG
   Young, IS
   McGinty, A
   McKay, GJ
   Hogg, R
   Hammond, CJ
   Chakravarthy, U
   Rahu, M
   Seland, J
   Soubrane, G
   Tomazzoli, L
   Topouzis, F
   Fletcher, AE
AF Williams, Katie M.
   Bentham, Graham C. G.
   Young, Ian S.
   McGinty, Ann
   McKay, Gareth J.
   Hogg, Ruth
   Hammond, Christopher J.
   Chakravarthy, Usha
   Rahu, Mati
   Seland, Johan
   Soubrane, Gisele
   Tomazzoli, Laura
   Topouzis, Fotis
   Fletcher, Astrid E.
TI Association Between Myopia, Ultraviolet B Radiation Exposure, Serum
   Vitamin D Concentrations, and Genetic Polymorphisms in Vitamin D
   Metabolic Pathways in a Multicountry European Study
SO JAMA OPHTHALMOLOGY
LA English
DT Article
ID AGE-RELATED MACULOPATHY; TIME SPENT OUTDOORS; MACULAR DEGENERATION;
   AXIAL LENGTH; RISK-FACTORS; PREVALENCE; LIGHT; CHILDREN; SUNLIGHT;
   LUTEIN
AB IMPORTANCE Myopia is becoming increasingly common globally and is associated with potentially sight-threatening complications. Spending time outdoors is protective, but the mechanism underlying this association is poorly understood.
   OBJECTIVE To examine the association of myopia with ultraviolet B radiation (UVB; directly associated with time outdoors and sunlight exposure), serum vitamin D concentrations, and vitamin D pathway genetic variants, adjusting for years in education.
   DESIGN, SETTING, AND PARTICIPANTS A cross-sectional, population-based random sample of participants 65 years and older was chosen from 6 study centers from the European Eye Study between November 6, 2000, to November 15, 2002. Of 4187 participants, 4166 attended an eye examination including refraction, gave a blood sample, and were interviewed by trained fieldworkers using a structured questionnaire. Myopia was defined as a mean spherical equivalent of -0.75 diopters or less. Exclusion criteria included aphakia, pseudophakia, late age-related macular degeneration, and vision impairment due to cataract, resulting in 371 participants with myopia and 2797 without.
   EXPOSURES Exposure to UVB estimated by combining meteorological and questionnaire data at different ages, single-nucleotide polymorphisms in vitamin D metabolic pathway genes, serum vitamin D-3 concentrations, and years of education.
   MAIN OUTCOMES AND MEASURES Odds ratios (ORs) of UVB, serum vitamin D3 concentrations, vitamin D single-nucleotide polymorphisms, and myopia estimated from logistic regression.
   RESULT Of the included 3168 participants, the mean (SD) age was 72.4 (5) years, and 1456 (46.0%) were male. An SD increase in UVB exposure at age 14 to 19 years (OR, 0.81; 95% CI, 0.71-0.92) and 20 to 39 years (OR, 0.7; 95% CI, 0.62-0.93) was associated with a reduced adjusted OR of myopia; those in the highest tertile of years of education had twice the OR of myopia (OR, 2.08; 95% CI, 1.41-3.06). No independent associations between myopia and serum vitamin D3 concentrations nor variants in genes associated with vitamin D metabolism were found. An unexpected finding was that the highest quintile of plasma lutein concentrations was associated with a reduced OR of myopia (OR, 0.57; 95% CI, 0.46-0.72).
   CONCLUSIONS AND RELEVANCE Increased UVB exposure was associated with reduced myopia, particularly in adolescence and young adulthood. The association was not altered by adjusting for education. We found no convincing evidence for a direct role of vitamin D in myopia risk. The relationship between high plasma lutein concentrations and a lower risk of myopia requires replication.
C1 [Williams, Katie M.; Hammond, Christopher J.] Kings Coll London, Dept Ophthalmol, London, England.
   [Williams, Katie M.] Kings Coll London, Dept Twin Res & Genet Epidemiol, London, England.
   [Bentham, Graham C. G.] Univ East Anglia, Sch Environm Sci, East Anglia, England.
   [Young, Ian S.; McGinty, Ann; McKay, Gareth J.] Queens Univ Belfast, Ctr Publ Hlth, Belfast, Antrim, North Ireland.
   [Hogg, Ruth; Chakravarthy, Usha] Queens Univ Belfast, Inst Clin Sci, Ctr Med Expt, Belfast, Antrim, North Ireland.
   [Rahu, Mati] Natl Inst Hlth Dev, Dept Epidemiol & Biostat, Tallinn, Estonia.
   [Seland, Johan] Univ Bergen, Eye Dept, Bergen, Norway.
   [Soubrane, Gisele] Paris Descartes Univ, Dept Ophthalmol, Hotel Dieu Paris, Paris, France.
   [Tomazzoli, Laura] Univ Verona, Ophthalmol Clin, Verona, Italy.
   [Topouzis, Fotis] Aristotle Univ Thessaloniki, Sch Med, Dept Ophthalmol, Thessaloniki, Greece.
   [Fletcher, Astrid E.] London Sch Hyg & Trop Med, Fac Epidemiol & Populat Hlth, Keppel St, London WC1E 7HT, England.
C3 University of London; King's College London; University of London;
   King's College London; Queens University Belfast; Queens University
   Belfast; National Institute for Health Development - Estonia; University
   of Bergen; Assistance Publique Hopitaux Paris (APHP); Hopital
   Universitaire Hotel-Dieu - APHP; UDICE-French Research Universities;
   Universite Paris Cite; University of Verona; Aristotle University of
   Thessaloniki; University of London; London School of Hygiene & Tropical
   Medicine
RP Fletcher, AE (通讯作者)，London Sch Hyg & Trop Med, Fac Epidemiol & Populat Hlth, Keppel St, London WC1E 7HT, England.
EM astrid.fletcher@lshtm.ac.uk
RI Hogg, Ruth E./ABC-9602-2020; McKay, Gareth/AAZ-2601-2020
OI Hogg, Ruth E./0000-0001-9413-2669; McKay, Gareth/0000-0001-8197-6280;
   Chakravarthy, Usha/0000-0002-2606-3734; Topouzis,
   Fotis/0000-0002-8966-537X; Young, Ian/0000-0003-3890-3152; Hammond,
   Christopher/0000-0002-3227-2620; Williams, Katie M/0000-0003-4596-3938
FU European Commission [QLK6-CT-1999-02094]; Macular Disease Society UK;
   Guide Dogs for the Blind [OR2011-05d]; MRC [MR/K023721/1] Funding
   Source: UKRI; Medical Research Council [MR/K023721/1, MC_CF023241]
   Funding Source: researchfish; National Institute for Health Research
   [SRF/01/010] Funding Source: researchfish
FX The European Eye Study was supported by the European Commission Vth
   Framework (QLK6-CT-1999-02094), with additional funding for cameras
   provided by the Macular Disease Society UK. Funding for serum vitamin D
   analyses was provided by Guide Dogs for the Blind (OR2011-05d).
CR Augood C, 2004, OPHTHAL EPIDEMIOL, V11, P117, DOI 10.1076/opep.11.2.117.28160
   Augood CA, 2006, ARCH OPHTHALMOL-CHIC, V124, P529, DOI 10.1001/archopht.124.4.529
   Bennett SE, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0074068
   Choi JA, 2014, INVEST OPHTH VIS SCI, V55, P2041, DOI [10.1167/iovs.13-12853, 10.1167/IOVS.13-12853]
   Dirani M, 2009, BRIT J OPHTHALMOL, V93, P997, DOI 10.1136/bjo.2008.150979
   FEISTER U, 1995, PHOTOCHEM PHOTOBIOL, V62, P736, DOI 10.1111/j.1751-1097.1995.tb08723.x
   Fletcher AE, 2008, ARCH OPHTHALMOL-CHIC, V126, P1396, DOI 10.1001/archopht.126.10.1396
   Flitcroft DI, 2012, PROG RETIN EYE RES, V31, P622, DOI 10.1016/j.preteyeres.2012.06.004
   FREDERICK JE, 1995, J APPL METEOROL, V34, P2755, DOI 10.1175/1520-0450(1995)034<2755:TTOSTC>2.0.CO;2
   French AN, 2013, EXP EYE RES, V114, P58, DOI 10.1016/j.exer.2013.04.018
   Guggenheim JA, 2014, INVEST OPHTH VIS SCI, V55, P8550, DOI 10.1167/iovs.14-15839
   Guggenheim JA, 2012, INVEST OPHTH VIS SCI, V53, P2856, DOI 10.1167/iovs.11-9091
   He MG, 2015, JAMA-J AM MED ASSOC, V314, P1142, DOI 10.1001/jama.2015.10803
   Heckman CJ, 2013, JOVE-J VIS EXP, DOI 10.3791/50175
   Holland B, 1991, MCCANCE WIDD COMP FO
   Ip JM, 2008, INVEST OPHTH VIS SCI, V49, P2903, DOI 10.1167/iovs.07-0804
   Johnson EJ, 2014, NUTR REV, V72, P605, DOI 10.1111/nure.12133
   Jones LA, 2007, INVEST OPHTH VIS SCI, V48, P3524, DOI 10.1167/iovs.06-1118
   Ma L, 2009, BRIT J NUTR, V102, P186, DOI 10.1017/S0007114508163000
   MADRONICH S, 1997, NATO ASI SER, V52, P23
   Mcknight CM, 2014, AM J OPHTHALMOL, V158, P1079, DOI 10.1016/j.ajo.2014.07.033
   Morgan IG, 2012, LANCET, V379, P1739, DOI 10.1016/S0140-6736(12)60272-4
   Mutti DO, 2011, INVEST OPHTH VIS SCI, V52, P3818, DOI 10.1167/iovs.10-6534
   Norton TT, 2013, EXP EYE RES, V114, P48, DOI 10.1016/j.exer.2013.05.004
   Pan CW, 2012, OPHTHAL PHYSL OPT, V32, P3, DOI 10.1111/j.1475-1313.2011.00884.x
   Purcell S, 2007, AM J HUM GENET, V81, P559, DOI 10.1086/519795
   Rahi JS, 2011, OPHTHALMOLOGY, V118, P797, DOI 10.1016/j.ophtha.2010.09.025
   Reins RY, 2015, EXP EYE RES, V134, P101, DOI 10.1016/j.exer.2015.02.019
   Rose KA, 2008, OPHTHALMOLOGY, V115, P1279, DOI 10.1016/j.ophtha.2007.12.019
   SanGiovanni JP, 2007, ARCH OPHTHALMOL-CHIC, V125, P671, DOI 10.1001/archopht.125.5.671
   Schmid KL, 2013, OPTOMETRY VISION SCI, V90, P148, DOI 10.1097/OPX.0b013e31827cda5b
   Sherwin JC, 2012, OPHTHALMOLOGY, V119, P2141, DOI 10.1016/j.ophtha.2012.04.020
   Smith EL, 2012, INVEST OPHTH VIS SCI, V53, P421, DOI 10.1167/iovs.11-8652
   Sonderman JS, 2012, AM J EPIDEMIOL, V176, P615, DOI 10.1093/aje/kws141
   STONE RA, 1989, P NATL ACAD SCI USA, V86, P704, DOI 10.1073/pnas.86.2.704
   Tideman JWL, 2016, EUR J EPIDEMIOL, V31, P491, DOI 10.1007/s10654-016-0128-8
   Tong NT, 2013, GRAEF ARCH CLIN EXP, V251, P1495, DOI 10.1007/s00417-012-2225-z
   Williams KM, 2015, OPHTHALMOLOGY, V122, P1489, DOI 10.1016/j.ophtha.2015.03.018
   Williams KM, 2013, OPHTHAL PHYSL OPT, V33, P339, DOI 10.1111/opo.12042
   Yazar S, 2014, INVEST OPHTH VIS SCI, V55, P4552, DOI 10.1167/iovs.14-14589
NR 40
TC 43
Z9 47
U1 2
U2 25
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 2168-6165
EI 2168-6173
J9 JAMA OPHTHALMOL
JI JAMA Ophthalmol.
PD JAN
PY 2017
VL 135
IS 1
BP 47
EP 53
DI 10.1001/jamaophthalmol.2016.4752
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA EK9PJ
UT WOS:000394256100011
PM 27918775
OA Green Published, Bronze, Green Accepted
DA 2022-11-30
ER

PT J
AU Jonas, RA
   Wang, YX
   Yang, H
   Li, JJ
   Xu, L
   Panda-Jonas, S
   Jonas, JB
AF Jonas, Rahul Arvo
   Wang, Ya Xing
   Yang, Hua
   Li, Jian Jun
   Xu, Liang
   Panda-Jonas, Songhomitra
   Jonas, Jost Bruno
TI Optic Disc - Fovea Distance, Axial Length and Parapapillary Zones. The
   Beijing Eye Study 2011
SO PLOS ONE
LA English
DT Article
ID SUBFOVEAL CHOROIDAL THICKNESS; MACULA DISTANCE; DIAMETER RATIO; RETINAL
   FEATURES; SIZE; ATROPHY; FUNDUS; DEGENERATION; GLAUCOMA; CHINA
AB Purpose
   To measure the distance between the optic disc center and the fovea (DFD) and to assess its associations.
   Methods
   The population-based cross-sectional Beijing Eye Study 2011 included 3468 individuals aged 50+ years. The DFD was measured on fundus photographs.
   Results
   Readable fundus photographs were available for 2836 (81.8%) individuals. Mean DFD was 4.76 +/- 0.34mm (median: 4.74 mm; range: 3.76-6.53mm). In multivariate analysis, longer DFD was associated with longer axial length (P<0.001; standardized correlation coefficient beta: 0.62), higher prevalence of axially high myopia (P<0.001; beta: 0.06), shallower anterior chamber depth (P<0.001; beta:-0.18), thinner lens thickness (P = 0.004; beta: -0.06), smaller optic disc-fovea angle (P = 0.02; beta: -0.04), larger parapapillary alpha zone (P = 0.008; beta: 0.05), larger parapapillary beta/gamma zone (P<0.001; beta: 0.11), larger optic disc area (P<0.001; beta: 0.08), lower degree of cortical cataract (P = 0.002; beta: -0.08), and lower prevalence of age-related macular degeneration (P = 0.001; beta: -0.06). Bruch's membrane opening-fovea distance (DFD minus disc radius minus parapapillary beta/gamma zone width) in non-glaucomatous eyes was not significantly (P = 0.60) related with axial length in emmetropic or axially myopic eyes (axial length >= 23.5 mm), while it increased significantly (P<0.001; r: 0.32) with longer axial length in eyes with an axial length of <23.5mm. Ratio of mean DFD to disc diameter was 2.65 +/- 0.30. If the ratio of disc-fovea distance to disc diameter was considered constant and if the individual disc diameter was calculated as the individual disc-fovea distance divided by the constant factor of 2.65, the resulting calculated disc diameter differed from the directly measured disc diameter by 0.16 +/- 0.13 mm (median: 0.13 mm, range: 0.00-0.89 mm) or 8.9 +/- 7.3% (median: 7.4%; range: 0.00-70%) of the measured disc diameter.
   Conclusions
   DFD (mean: 4.76mm) increases with longer axial length, larger parapapillary alpha zone and parapapillary beta/gamma zone, and larger disc area. The axial elongation associated increase in DFD was due to an enlargement of parapapillary beta/gamma zone while the Bruch's membrane opening-fovea distance did not enlarge with longer axial length. This finding may be of interest for the process of emmetropization and myopization. Due to its variability, the disc-fovea distance has only limited clinical value as a relative size unit for structures at the posterior pole.
C1 [Jonas, Rahul Arvo; Wang, Ya Xing; Yang, Hua; Li, Jian Jun; Xu, Liang; Jonas, Jost Bruno] Capital Med Univ, Beijing Inst Ophthalmol, Beijing Tongren Eye Ctr, Beijing Tongren Hosp,Beijing Ophthalmol & Visual, Beijing, Peoples R China.
   [Jonas, Rahul Arvo; Panda-Jonas, Songhomitra; Jonas, Jost Bruno] Heidelberg Univ, Med Fac Mannheim, Dept Ophthalmol, Mannheim, Germany.
C3 Capital Medical University; Ruprecht Karls University Heidelberg
RP Wang, YX (通讯作者)，Capital Med Univ, Beijing Inst Ophthalmol, Beijing Tongren Eye Ctr, Beijing Tongren Hosp,Beijing Ophthalmol & Visual, Beijing, Peoples R China.
EM yaxingw@gmail.com
RI Jonas, Rahul A/N-9304-2017; wang, YA XING/K-9671-2016
OI wang, YA XING/0000-0003-2749-7793; Jonas, Rahul/0000-0002-5389-3047
FU State Natural Sciences Fund [81041018]; Natural Sciences Fund of Beijing
   government [7092021, 7112031]; Consultant for Allergan Inc.; Merck Sharp
   & Dohme Co., Inc.; Alimera Co.; Boehringer Ingelheim Co.; Sanofi Co.
FX This work was supported by State Natural Sciences Fund (81041018) and
   the Natural Sciences Fund of Beijing government (7092021; 7112031). Jost
   B. Jonas has the following financial disclosures: Consultant for
   Allergan Inc.; Merck Sharp & Dohme Co., Inc.; Alimera Co.; Boehringer
   Ingelheim Co., Sanofi Co. Patent holder with CellMed AG, Alzenau,
   Germany.
CR Alvarez E, 1988, J Pediatr Ophthalmol Strabismus, V25, P151
   Barr DB, 1999, OPHTHAL PHYSL OPT, V19, P365, DOI 10.1046/j.1475-1313.1999.00463.x
   BENNETT AG, 1994, GRAEF ARCH CLIN EXP, V232, P361, DOI 10.1007/BF00175988
   Dai Y, 2013, INVEST OPHTH VIS SCI, V54, P2013, DOI 10.1167/iovs.12-11255
   De Silva DJ, 2006, INVEST OPHTH VIS SCI, V47, P4683, DOI 10.1167/iovs.06-0152
   JONAS JB, 1991, INVEST OPHTH VIS SCI, V32, P2942
   JONAS JB, 1988, GRAEF ARCH CLIN EXP, V226, P213, DOI 10.1007/BF02181183
   Jonas JB, 2000, PROG RETIN EYE RES, V19, P1, DOI 10.1016/S1350-9462(99)00002-6
   JONAS JB, 1989, AM J OPHTHALMOL, V107, P137, DOI 10.1016/0002-9394(89)90212-2
   Jonas JB, 2006, AM J OPHTHALMOL, V142, P168, DOI 10.1016/j.ajo.2006.01.068
   Jonas JB, 2014, ACTA OPHTHALMOL, V92, pE470, DOI 10.1111/aos.12372
   Jonas JB, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047237
   Jonas JB, 2012, ACTA OPHTHALMOL, V90, pe185, DOI 10.1111/j.1755-3768.2011.02316.x
   Knaapi L, 2015, ACTA OPHTHALMOL, V93, P339, DOI 10.1111/aos.12554
   Lee M, 2014, GRAEF ARCH CLIN EXP, V252, P307, DOI 10.1007/s00417-013-2513-2
   LITTMANN H, 1982, KLIN MONATSBL AUGENH, V180, P286, DOI 10.1055/s-2008-1055068
   Mok KH, 2002, J GLAUCOMA, V11, P392, DOI 10.1097/00061198-200210000-00004
   Pan CW, 2013, OPHTHALMOLOGY, V120, P2058, DOI 10.1016/j.ophtha.2013.03.028
   Panda-Jonas S, 2014, ACTA OPHTHALMOL, V92, P59, DOI 10.1111/j.1755-3768.2012.02570.x
   PAPASTATHOPOULOS KI, 1995, EXP EYE RES, V60, P459, DOI 10.1016/S0014-4835(05)80102-2
   Rohrschneider K, 2004, INVEST OPHTH VIS SCI, V45, P3257, DOI 10.1167/iovs.03-1157
   Shao L, 2015, INVEST OPHTH VIS SCI, V56, P810, DOI 10.1167/iovs.14-15736
   Shao L, 2014, AM J OPHTHALMOL, V158, P702, DOI 10.1016/j.ajo.2014.05.023
   van de Put MAJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062518
   Vurgese S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0029692
   WAKAKURA M, 1987, ACTA OPHTHALMOL, V65, P612
   Wang YX, 2015, OPHTHALMOLOGY, V122, P2022, DOI 10.1016/j.ophtha.2015.06.005
   Wang YX, 2010, AM J OPHTHALMOL, V150, P917, DOI 10.1016/j.ajo.2010.06.037
   Wei WB, 2013, OPHTHALMOLOGY, V120, P175, DOI 10.1016/j.ophtha.2012.07.048
   Xu J, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0111320
   Xu L, 2006, BRIT J OPHTHALMOL, V90, P1087, DOI 10.1136/bjo.2006.096123
   Xu L, 2007, AM J OPHTHALMOL, V144, P541, DOI 10.1016/j.ajo.2007.05.038
   Xu L, 2007, OPHTHALMOLOGY, V114, P121, DOI 10.1016/j.ophtha.2006.05.071
NR 33
TC 75
Z9 78
U1 0
U2 5
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD SEP 21
PY 2015
VL 10
IS 9
AR e0138701
DI 10.1371/journal.pone.0138701
PG 14
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA CS0ZM
UT WOS:000361791000052
PM 26390438
OA Green Published, gold, Green Submitted
DA 2022-11-30
ER

PT J
AU Heier, JS
   Boyer, D
   Nguyen, QD
   Marcus, D
   Roth, DB
   Yancopoulos, G
   Stahl, N
   Ingerman, A
   Vitti, R
   Berliner, AJ
   Yang, K
   Brown, DM
AF Heier, Jeffrey S.
   Boyer, David
   Quan Dong Nguyen
   Marcus, Dennis
   Roth, Daniel B.
   Yancopoulos, George
   Stahl, Neil
   Ingerman, Avner
   Vitti, Robert
   Berliner, Alyson J.
   Yang, Ke
   Brown, David M.
CA CLEAR-IT 2 Investigators
TI The 1-year Results of CLEAR-IT 2, a Phase 2 Study of Vascular
   Endothelial Growth Factor Trap-Eye Dosed As-needed After 12-week Fixed
   Dosing
SO OPHTHALMOLOGY
LA English
DT Article
ID MACULAR DEGENERATION; VEGF-TRAP; CHOROIDAL NEOVASCULARIZATION;
   BEVACIZUMAB AVASTIN; IN-VITRO; RANIBIZUMAB; BINDING; DISEASE; VIVO
AB Objective: To evaluate anatomic outcomes and vision, injection frequency, and safety during the as-needed (PRN) treatment phase of a study evaluating a 12-week fixed dosing period followed by PRN dosing to week 52 with vascular endothelial growth factor (VEGF) Trap-Eye for neovascular (wet) age-related macular degeneration (AMD).
   Design: Multicenter, randomized, double-masked trial.
   Participants: We included 159 patients with subfoveal choroidal neovascularization (CNV) secondary to wet AMD.
   Methods: Patients were randomly assigned to 1 of 5 intravitreal VEGF Trap-Eye treatment groups: 0.5 mg or 2 mg every 4 weeks or 0.5, 2, or 4 mg every 12 weeks during the fixed-dosing period (weeks 1-12). From weeks 16 to 52, patients were evaluated monthly and were retreated PRN with their assigned dose (0.5, 2, or 4 mg).
   Main Outcome Measures: Change in central retinal/lesion thickness (CR/LT), change in total lesion and CNV size, mean change in best-corrected visual acuity (BCVA), proportion of patients with 15-letter loss or gain, time to first PRN injection, reinjection frequency, and safety at week 52.
   Results: The decrease in CR/LT at week 12 versus baseline remained significant at weeks 12 to 52 (-130 mu m from baseline at week 52) and CNV size regressed from baseline by 2.21 mm(2) at 48 weeks. After achieving a significant improvement in BCVA during the 12-week, fixed-dosing phase for all groups combined, PRN dosing for 40 weeks maintained improvements in BCVA to 52 weeks (5.3-letter gain; P<0.0001). The most robust improvements and consistent maintenance of visual acuity generally occurred in patients initially dosed with 2 mg every 4 weeks for 12 weeks, demonstrating a gain of 9 letters at 52 weeks. Overall, a mean of 2 injections was administered after the 12-week fixed-dosing phase, and the mean time to first reinjection was 129 days; 19% of patients received no injections and 45% received 1 or 2 injections. Treatment with VEGF Trap-Eye was generally safe and well tolerated, with few ocular or systemic adverse events.
   Conclusions: PRN dosing with VEGF Trap-Eye at weeks 16-52 maintained the significant anatomic and vision improvements established during the 12-week fixed-dosing phase with a low frequency of reinjections. Repeated dosing with VEGF Trap-Eye was well tolerated over 52 weeks of treatment.
   Financial Disclosure(s): Proprietary or commercial disclosure may be found after the references. Ophthalmology 2011; 118: 1098-1106 (C) 2011 by the American Academy of Ophthalmology.
C1 [Brown, David M.] Retina Consultants Houston, Methodist Hosp, Houston, TX 77030 USA.
   [Yancopoulos, George; Stahl, Neil; Ingerman, Avner; Vitti, Robert; Berliner, Alyson J.; Yang, Ke] Regeneron Pharmaceut Inc, Tarrytown, NY 10591 USA.
   [Roth, Daniel B.] Retina Vitreous Ctr, New Brunswick, NJ USA.
   [Marcus, Dennis] SE Retina Ctr, Augusta, GA USA.
   [Quan Dong Nguyen] Johns Hopkins Univ, Sch Med, Wilmer Eye Inst, Baltimore, MD 21205 USA.
   [Boyer, David] Retina Vitreous Assoc Med Grp, Beverly Hills, CA USA.
   [Heier, Jeffrey S.] Ophthalm Consultants Boston, Boston, MA USA.
C3 The Methodist Hospital System; The Methodist Hospital - Houston;
   Regeneron; Johns Hopkins University; Johns Hopkins Medicine; Retina
   Vitreous Associates Medical Group; Ophthalmic Consultants of Boston
RP Brown, DM (通讯作者)，Retina Consultants Houston, Methodist Hosp, 6560 Fannin,Suite 750, Houston, TX 77030 USA.
EM dmbmd@houstonretina.com
FU Regeneron Pharmaceuticals, Inc.; Bayer HealthCare AG
FX Supported by Regeneron Pharmaceuticals, Inc. and Bayer HealthCare AG.
   The sponsors participated in the design of the study, conducting the
   study, data collection, data management, data analysis, interpretation
   of the data, and the preparation, review and approval of the manuscript.
CR AIELLO LP, 1994, NEW ENGL J MED, V331, P1480, DOI 10.1056/NEJM199412013312203
   Avery RL, 2006, OPHTHALMOLOGY, V113, P363, DOI 10.1016/j.ophtha.2005.11.019
   Boyer DS, 2007, OPHTHALMOLOGY, V114, P246, DOI 10.1016/j.ophtha.2006.10.045
   Boyer DS, 2009, OPHTHALMOLOGY, V116, P1731, DOI 10.1016/j.ophtha.2009.05.024
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Dixon JA, 2009, EXPERT OPIN INV DRUG, V18, P1573, DOI 10.1517/13543780903201684
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Grisanti S, 2008, PROG RETIN EYE RES, V27, P372, DOI 10.1016/j.preteyeres.2008.05.002
   Gunther JB, 2009, SURV OPHTHALMOL, V54, P372, DOI 10.1016/j.survophthal.2009.02.004
   Holash J, 2002, P NATL ACAD SCI USA, V99, P11393, DOI 10.1073/pnas.172398299
   Ip MS, 2008, OPHTHALMOLOGY, V115, P1837, DOI 10.1016/j.ophtha.2008.08.012
   Konner Jason, 2004, Clin Colorectal Cancer, V4 Suppl 2, pS81
   Krzystolik MG, 2002, ARCH OPHTHALMOL-CHIC, V120, P338
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Lee JH, 2005, P NATL ACAD SCI USA, V102, P18902, DOI 10.1073/pnas.0509069102
   Lowe J, 2007, EXP EYE RES, V85, P425, DOI 10.1016/j.exer.2007.05.008
   Maharaj ASR, 2007, MICROVASC RES, V74, P100, DOI 10.1016/j.mvr.2007.03.004
   Mitchell P, 2010, BRIT J OPHTHALMOL, V94, P2, DOI 10.1136/bjo.2009.159160
   Nguyen QD, 2009, OPHTHALMOLOGY, V116, P2141, DOI 10.1016/j.ophtha.2009.04.030
   Olsson AK, 2006, NAT REV MOL CELL BIO, V7, P359, DOI 10.1038/nrm1911
   PARK JE, 1994, J BIOL CHEM, V269, P25646
   Penn JS, 2008, PROG RETIN EYE RES, V27, P331, DOI 10.1016/j.preteyeres.2008.05.001
   Rakic JM, 2003, INVEST OPHTH VIS SCI, V44, P3186, DOI 10.1167/iovs.02-1092
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rudge JS, 2007, P NATL ACAD SCI USA, V104, P18363, DOI 10.1073/pnas.0708865104
   Spaide R, 2007, AM J OPHTHALMOL, V143, P679, DOI 10.1016/j.ajo.2007.02.024
   Stewart MW, 2008, BRIT J OPHTHALMOL, V92, P667, DOI 10.1136/bjo.2007.134874
   Tammela T, 2005, CARDIOVASC RES, V65, P550, DOI 10.1016/j.cardiores.2004.12.002
   van Wijngaarden P, 2008, CLIN EXP OPTOM, V91, P427, DOI 10.1111/j.1444-0938.2008.00305.x
   Waisbourd M, 2007, DRUG AGING, V24, P643, DOI 10.2165/00002512-200724080-00003
   Wong T, 2008, OPHTHALMOLOGY, V115, P116, DOI 10.1016/j.ophtha.2007.03.008
NR 33
TC 122
Z9 130
U1 0
U2 13
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD JUN
PY 2011
VL 118
IS 6
BP 1098
EP 1106
DI 10.1016/j.ophtha.2011.03.020
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 771JJ
UT WOS:000291152700015
PM 21640258
DA 2022-11-30
ER

PT J
AU Rim, TH
   Kawasaki, R
   Tham, YC
   Kang, SW
   Ruamviboonsuk, P
   Bikbov, MM
   Miyake, M
   Hao, J
   Fletcher, A
   Sasaki, M
   Nangia, V
   Sabanayagam, C
   Yu, M
   Fujiwara, K
   Thapa, R
   Wong, IY
   Kayama, T
   Chen, SJ
   Kuang, TM
   Yamashita, H
   Sundaresan, P
   Chan, JC
   van Rens, GHMB
   Sonoda, KH
   Wang, YX
   Panda-Jonas, S
   Harada, S
   Kim, R
   Ganesan, S
   Raman, R
   Yamashiro, K
   Gilmanshin, TR
   Jenchitr, W
   Park, KH
   Cheung, CMG
   Wong, TY
   Wang, NL
   Jonas, JB
   Chakravarthy, U
   Cheng, CY
   Yanagi, Y
AF Rim, Tyler Hyungtaek
   Kawasaki, Ryo
   Tham, Yih-Chung
   Kang, Se Woong
   Ruamviboonsuk, Paisan
   Bikbov, Mukharram M.
   Miyake, Masahiro
   Hao, Jie
   Fletcher, Astrid
   Sasaki, Mariko
   Nangia, Vinay
   Sabanayagam, Charumathi
   Yu, Marco
   Fujiwara, Kohta
   Thapa, Raba
   Wong, Ian Y.
   Kayama, Takamasa
   Chen, Shih-Jen
   Kuang, Tung-Mei
   Yamashita, Hidetoshi
   Sundaresan, Periasamy
   Chan, Jonathan C.
   van Rens, G. H. M. B.
   Sonoda, Koh-Hei
   Wang, Ya Xing
   Panda-Jonas, Songhomitra
   Harada, Sei
   Kim, Ramasamy
   Ganesan, Suganeswari
   Raman, Rajiv
   Yamashiro, Kenji
   Gilmanshin, Timur R.
   Jenchitr, Watanee
   Park, Kyu Hyung
   Cheung, Chui Ming Gemmy
   Wong, Tien Yin
   Wang, Ningli
   Jonas, Jost B.
   Chakravarthy, Usha
   Cheng, Ching-Yu
   Yanagi, Yasuo
CA Asian Eye Epidemiology Consortium
TI Prevalence and Pattern of Geographic Atrophy in Asia The Asian Eye
   Epidemiology Consortium
SO OPHTHALMOLOGY
LA English
DT Article
ID AGE-RELATED MACULOPATHY; MACULAR DEGENERATION PREVALENCE; RISK-FACTORS;
   CHINESE POPULATION; RETICULAR PSEUDODRUSEN; GLOBAL PREVALENCE;
   RURAL-POPULATION; ADULT CHINESE; INDIA; SINGAPORE
AB Purpose: Although there have been many population-based studies of age-related macular degeneration (AMD), only limited information is available in Asia on the epidemiology of geographic atrophy (GA). We aimed to determine the prevalence and patterns of GA through an analysis of multiple studies conducted within the Asian Eye Epidemiology Consortium (AEEC).
   Design: Cross-sectional meta-analyses.
   Participants: A total of 97 213 individuals aged 40 years and older.
   Methods: Data from 22 population-based studies from countries belonging to the AEEC were included. In all studies, AMD was defined on the basis of standardized grading systems. Geographic atrophy was defined as an area of pallor in the fundus with visibility of the underlying choroidal blood vessels and sharply defined borders. Random-effects meta-analysis was performed to estimate overall and age-, gender-, and region-specific pooled prevalence of GA.
   Main Outcome Measures: Prevalence of GA per 1000 persons.
   Results: The mean age was 60.8 +/- 10.0 years, and 42 673 (43.9%) were male. Overall, a total of 223 individuals (0.2%) had GA. The pooled overall prevalence of GA was 1.57 per 1000 persons (95% confidence interval [CI], 1.04-2.10), which was 3 times less than that of neovascular AMD of 5.20 per 1000 persons (95% CI, 3.97-6.43). Compared with those aged 50 to 59 years, the prevalence of GA increased from 0.34 per 1000 persons (95% CI, 0.07-0.62) to 2.90 per 1000 persons (95% CI, 1.55-4.25) in those aged >= 70 years. The GA prevalence per 1000 persons was similar between urban (2.22; 95% CI, 1.22-3.23) and rural residents (1.33; 95% CI, 0.70-1.96). Geographic atrophy was more prevalent in South Asia (based on studies from India and Nepal, 3.82 per 1000 persons; 95% CI, 1.72-5.93) compared with East Asia (based on studies from China, Korea, Hong Kong, Taiwan, and Japan, and the Singapore Chinese Eye Study, 0.76 per 1000 persons; 95% CI, 0.31-1.22, P = 0.005).
   Conclusions: Geographic atrophy is uncommon in Asian populations compared with those of European ancestry. Even within Asia, geographic differences in GA prevalence were seen. The findings of this meta-analysis suggest that better dissection of risk factors in the Asian population for GA may provide insights into the biological pathways that drive these late-stage manifestations, thus suggesting better targets for prevention. (C) 2020 by the American Academy of Ophthalmology
C1 [Rim, Tyler Hyungtaek; Tham, Yih-Chung; Sabanayagam, Charumathi; Yu, Marco; Cheung, Chui Ming Gemmy; Wong, Tien Yin; Cheng, Ching-Yu; Yanagi, Yasuo] Singapore Eye Res Inst, Singapore Natl Eye Ctr, Singapore, Singapore.
   [Rim, Tyler Hyungtaek; Tham, Yih-Chung; Sabanayagam, Charumathi; Cheung, Chui Ming Gemmy; Wong, Tien Yin; Cheng, Ching-Yu] Duke NUS Med Sch, Ophthalmol & Visual Sci Acad Clin Program Eye ACP, Singapore, Singapore.
   [Kawasaki, Ryo] Osaka Univ, Dept Ophthalmol, Grad Sch Med, Suita, Osaka, Japan.
   [Kawasaki, Ryo; Miyake, Masahiro; Sasaki, Mariko; Fujiwara, Kohta; Yanagi, Yasuo] Ganka Ekigaku Network, Osaka, Japan.
   [Kang, Se Woong] Sungkyunkwan Univ, Dept Ophthalmol Samsung Med Ctr, Sch Med, Seoul, South Korea.
   [Ruamviboonsuk, Paisan] Rajavithi Hosp, Dept Ophthalmol, Bangkok, Thailand.
   [Bikbov, Mukharram M.; Gilmanshin, Timur R.] Ufa Eye Res Inst, Ufa, Russia.
   [Miyake, Masahiro; Yamashiro, Kenji] Kyoto Univ, Dept Ophthalmol, Grad Sch Med, Kyoto, Japan.
   [Hao, Jie; Wang, Ya Xing; Wang, Ningli] Capital Med Univ, Beijing Tongren Hosp, Beijing Inst Ophthalmol, Beijing, Peoples R China.
   [Fletcher, Astrid] London Sch Hyg & Trop Med, London, England.
   [Sasaki, Mariko] Keio Univ, Dept Ophthalmol, Sch Med, Tokyo, Japan.
   [Nangia, Vinay] Suraj Eye Inst, Nagpur, Maharashtra, India.
   [Fujiwara, Kohta] Kyushu Univ, Grad Sch Med Sci, Dept Epidemiol & Publ Hlth, Fukuoka, Japan.
   [Thapa, Raba] Tilganga Inst Ophthalmol, Kathmandu, Nepal.
   [Wong, Ian Y.] Univ Hong Kong, Hong Kong Sanat & Hosp, Hong Kong, Peoples R China.
   [Kayama, Takamasa; Yamashita, Hidetoshi] Yamagata Univ, Fac Med, Yamagata, Japan.
   [Chen, Shih-Jen; Kuang, Tung-Mei] Natl Yang Ming Univ, Taipei Vet Gen Hosp, Sch Med, Dept Ophthalmol, Taipei, Taiwan.
   [Sundaresan, Periasamy] Aravind Med Res Fdn, Dept Mol Genet, Madurai, Tamil Nadu, India.
   [Chan, Jonathan C.] Univ Hong Kong, Dept Ophthalmol, LKS Fac Med, Hong Kong, Peoples R China.
   [van Rens, G. H. M. B.] Vrije Univ Amsterdam, Amsterdam Univ Med Ctr, Dept Ophthalmol, Amsterdam, Netherlands.
   [Sonoda, Koh-Hei] Kyushu Univ, Grad Sch Med Sci, Dept Ophthalmol, Fukuoka, Japan.
   [Panda-Jonas, Songhomitra] Augenpraxis Jonas, Heidelberg, Germany.
   [Harada, Sei] Keio Univ, Dept Prevent Med & Publ Hlth, Sch Med, Tokyo, Japan.
   [Kim, Ramasamy] Aravind Eye Hosp, Dept Ophthalmol, Madurai, Tamil Nadu, India.
   [Ganesan, Suganeswari; Raman, Rajiv] Med Res Fdn, Sankara Nethralaya, Chennai, Tamil Nadu, India.
   [Yamashiro, Kenji] Otsu Red Cross Hosp, Dept Ophthalmol, Otsu, Shiga, Japan.
   [Jenchitr, Watanee] Rangsit Univ, Rangsit Eye Ctr, Bangkok, Thailand.
   [Jenchitr, Watanee] Rangsit Univ, Fac Optometry, Bangkok, Thailand.
   [Park, Kyu Hyung] Seoul Natl Univ, Seoul Natl Univ Coll Med, Dept Ophthalmol, Bundang Hosp, Seoul, South Korea.
   [Jonas, Jost B.] Heidelberg Univ, Med Fac Mannheim, Dept Ophthalmol, Heidelberg, Germany.
   [Chakravarthy, Usha] Queens Univ Belfast, Belfast, Antrim, North Ireland.
   [Yanagi, Yasuo] Asahikawa Med Univ, Dept Ophthalmol, Asahikawa, Hokkaido, Japan.
C3 National University of Singapore; Singapore National Eye Center;
   National University of Singapore; Osaka University; Sungkyunkwan
   University (SKKU); Rajavithi Hospital; Ufa Eye Research Institute; Kyoto
   University; Capital Medical University; University of London; London
   School of Hygiene & Tropical Medicine; Keio University; Suraj Eye
   Institute; Kyushu University; University of Hong Kong; Yamagata
   University; National Yang Ming Chiao Tung University; Taipei Veterans
   General Hospital; University of Hong Kong; Vrije Universiteit Amsterdam;
   Kyushu University; Keio University; Rangsit University; Rangsit
   University; Seoul National University (SNU); Seoul National University
   Hospital; Ruprecht Karls University Heidelberg; Queens University
   Belfast; Asahikawa Medical College
RP Cheng, CY; Yanagi, Y (通讯作者)，Singapore Eye Res Inst, 20 Coll Rd,Acad,Level 6,Discovery Tower, Singapore 169856, Singapore.
EM chingyu.cheng@duke-nus.edu.sg; yasuo.yanagi.asahikawa@gmail.com
RI Cheng, Ching-Yu/Y-2229-2019; Chan, Jonathan/ABE-6588-2020; Kawasaki,
   Ryo/B-7266-2009; Chung, Yih/AIF-2414-2022; Sabanayagam,
   Charumathi/C-1294-2011; .P, Sundaresan/AAR-8426-2021; Wong, Tien
   Yin/AAC-9724-2020; Oh, Jaeryung/ABD-3090-2021; Bikbov,
   Mukharram/AAO-7624-2021; wang, YA XING/K-9671-2016; Yanagi,
   Yasuo/AAA-5441-2022
OI Cheng, Ching-Yu/0000-0003-0655-885X; Chan, Jonathan/0000-0002-0177-8178;
   Kawasaki, Ryo/0000-0002-7492-6303; Chung, Yih/0000-0002-6752-797X;
   Sabanayagam, Charumathi/0000-0002-4042-4719; Wong, Tien
   Yin/0000-0002-8448-1264; Oh, Jaeryung/0000-0002-1036-6562; wang, YA
   XING/0000-0003-2749-7793; george, ronnie/0000-0001-7368-0252;
   Kazakbaeva, Gyulli/0000-0002-0569-1264; Harada, Sei/0000-0003-2666-4932;
   Tsujikawa, Akitaka/0000-0003-0779-7799
FU National Medical Research Council of Singapore [NMRC/OFLCG/004a/2018,
   NMRC/CIRG/1488/2018, NMRC/CIRG/1417/2015]
FX Funded by the National Medical Research Council of Singapore
   (NMRC/OFLCG/004a/2018; NMRC/CIRG/1488/2018; NMRC/CIRG/1417/2015). The
   funding sources had no role in the design or conduct of the study;
   collection, management, analysis, and interpretation of the data;
   preparation, review, or approval of the manuscript; or the decision to
   submit the manuscript for publication.
CR Andersen MVN, 2008, OPHTHALMOLOGY, V115, P700, DOI 10.1016/j.ophtha.2007.12.013
   [Anonymous], [No title captured]
   [Anonymous], [No title captured]
   Balachandran A, 2020, J AGING HEALTH, V32, P340, DOI 10.1177/0898264318824180
   Bikbov M, 2018, OPHTHAL EPIDEMIOL, V25, P187, DOI 10.1080/09286586.2017.1384504
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Buitendijk GHS, 2016, INVEST OPHTH VIS SCI, V57, P5593, DOI 10.1167/iovs.15-18816
   Butt AL, 2011, OPHTHALMOLOGY, V118, P1380, DOI 10.1016/j.ophtha.2010.11.007
   Chen SJ, 2008, INVEST OPHTH VIS SCI, V49, P3126, DOI 10.1167/iovs.08-1803
   Cheung CMG, 2014, OPHTHALMOLOGY, V121, P1598, DOI 10.1016/j.ophtha.2014.02.004
   Cheung CMG, 2013, AM J OPHTHALMOL, V155, P764, DOI 10.1016/j.ajo.2012.10.013
   Cheung CMG, 2012, ARCH OPHTHALMOL-CHIC, V130, P480, DOI 10.1001/archophthalmol.2011.376
   Claessen H, 2012, EUR J EPIDEMIOL, V27, P519, DOI 10.1007/s10654-012-9705-7
   Colijn JM, 2017, OPHTHALMOLOGY, V124, P1753, DOI 10.1016/j.ophtha.2017.05.035
   Erke MG, 2012, OPHTHALMOLOGY, V119, P1737, DOI 10.1016/j.ophtha.2012.03.016
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Friedman DS, 1999, OPHTHALMOLOGY, V106, P1049, DOI 10.1016/S0161-6420(99)90267-1
   Fujiwara K, 2018, SEMIN OPHTHALMOL, V33, P813, DOI 10.1080/08820538.2018.1506483
   Cheung CM, 2018, OPHTHALMOL RETINA, V2, P1196, DOI 10.1016/j.oret.2018.06.014
   Gupta SK, 2007, INVEST OPHTH VIS SCI, V48, P1007, DOI 10.1167/iovs.06-0712
   HALDANE JBS, 1956, ANN HUM GENET, V20, P309
   Holden BA, 2016, OPHTHALMOLOGY, V123, P1036, DOI 10.1016/j.ophtha.2016.01.006
   Holz FG, 2017, OPHTHALMOLOGY, V124, P464, DOI 10.1016/j.ophtha.2016.12.002
   Hu DN, 2008, PHOTOCHEM PHOTOBIOL, V84, P639, DOI 10.1111/j.1751-1097.2008.00316.x
   Jenchitr W, 2011, OPHTHAL EPIDEMIOL, V18, P48, DOI 10.3109/09286586.2010.545502
   Jonasson F, 2011, OPHTHALMOLOGY, V118, P825, DOI 10.1016/j.ophtha.2010.08.044
   Kawasaki R, 2008, OPHTHALMOLOGY, V115, P1735, DOI 10.1016/j.ophtha.2008.02.012
   Kawasaki R, 2008, OPHTHALMOLOGY, V115, P1376, DOI 10.1016/j.ophtha.2007.11.015
   Kawasaki R, 2010, OPHTHALMOLOGY, V117, P921, DOI 10.1016/j.ophtha.2009.10.007
   Klein R, 2006, OPHTHALMOLOGY, V113, P373, DOI 10.1016/j.ophtha.2005.12.013
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Klein R, 2011, ARCH OPHTHALMOL-CHIC, V129, P75, DOI 10.1001/archophthalmol.2010.318
   Krishnan T, 2010, INVEST OPHTH VIS SCI, V51, P701, DOI 10.1167/iovs.09-4114
   Lindekleiv H, 2013, ACTA OPHTHALMOL, V91, P307, DOI 10.1111/j.1755-3768.2012.02399.x
   Mao FF, 2019, INVEST OPHTH VIS SCI, V60, P4966, DOI 10.1167/iovs.19-27325
   Mitchell P, 2002, ARCH OPHTHALMOL-CHIC, V120, P1357, DOI 10.1001/archopht.120.10.1357
   Munoz B, 2005, ARCH OPHTHALMOL-CHIC, V123, P1575, DOI 10.1001/archopht.123.11.1575
   Nakata I, 2013, AM J OPHTHALMOL, V156, P1002, DOI 10.1016/j.ajo.2013.06.007
   Nangia V, 2011, RETINA-J RET VIT DIS, V31, P1179, DOI 10.1097/IAE.0b013e3181f57ff2
   Nirmalan PK, 2004, ARCH OPHTHALMOL-CHIC, V122, P581, DOI 10.1001/archopht.122.4.581
   Obata R, 2018, BRIT J OPHTHALMOL, V102, P1047, DOI 10.1136/bjophthalmol-2016-309980
   Owen CG, 2012, BRIT J OPHTHALMOL, V96, P752, DOI 10.1136/bjophthalmol-2011-301109
   Park SJ, 2014, OPHTHALMOLOGY, V121, P1756, DOI 10.1016/j.ophtha.2014.03.022
   Raman R, 2016, EYE, V30, P688, DOI 10.1038/eye.2016.14
   Rein DB, 2009, ARCH OPHTHALMOL-CHIC, V127, P533, DOI 10.1001/archophthalmol.2009.58
   Rudnicka AR, 2012, OPHTHALMOLOGY, V119, P571, DOI 10.1016/j.ophtha.2011.09.027
   Sasaki M, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-017-18487-4
   Seddon JM, 2006, OPHTHALMOLOGY, V113, P260, DOI 10.1016/j.ophtha.2005.11.001
   Smith W, 1996, ARCH OPHTHALMOL-CHIC, V114, P1518, DOI 10.1001/archopht.1996.01100140716016
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Thapa R, 2017, CLIN OPHTHALMOL, V11, P963, DOI 10.2147/OPTH.S132338
   Varma R, 2004, OPHTHALMOLOGY, V111, P1288, DOI 10.1016/j.ophtha.2004.01.023
   WEITER JJ, 1985, AM J OPHTHALMOL, V99, P185, DOI 10.1016/0002-9394(85)90230-2
   Wilde C, 2018, EYE, V32, P1130, DOI 10.1038/s41433-018-0049-8
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Xu L, 2007, OPHTHALMOLOGY, V114, P121, DOI 10.1016/j.ophtha.2006.05.071
   Xu LA, 2006, AM J OPHTHALMOL, V142, P688, DOI 10.1016/j.ajo.2006.05.028
   Yang K, 2011, OPHTHALMOLOGY, V118, P1395, DOI 10.1016/j.ophtha.2010.12.030
   Ye HH, 2014, INVEST OPHTH VIS SCI, V55, P6374, DOI 10.1167/iovs.14-14899
   You QS, 2020, OPHTHAL EPIDEMIOL, V27, P354, DOI 10.1080/09286586.2020.1755444
NR 60
TC 13
Z9 14
U1 7
U2 10
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD OCT
PY 2020
VL 127
IS 10
BP 1371
EP 1381
DI 10.1016/j.ophtha.2020.04.019
PG 11
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA NT0HB
UT WOS:000572632200019
PM 32344073
DA 2022-11-30
ER

PT J
AU Cunha-Vaz, J
AF Cunha-Vaz, Jose
TI The Blood-Retinal Barrier in the Management of Retinal Disease: EURETINA
   Award Lecture
SO OPHTHALMOLOGICA
LA English
DT Article
DE Blood-retinal barrier; Macular edema; Retinal edema
ID OPTICAL COHERENCE TOMOGRAPHY; CYSTOID MACULAR EDEMA; FLUID ACCUMULATION;
   PERMEABILITY; ANGIOGRAPHY; BREAKDOWN; VESSELS; BRAIN; FLUORESCEIN; SPACE
AB Retinal diseases are the main causes of blindness in the Western world. Diabetic retinopathy and age-related macular degeneration continue to increase in prevalence and as main causes of vision loss. Intravitreal anti-VEGF and steroid injections have raised new expectations for their successful treatment. These agents act by stabilizing the blood-retinal barrier (BRB). Our group defined the BRB by identifying for the first time the tight junctions that unite retinal endothelial cells and are the basis for the inner BRB, an observation later confirmed in retinal pigment epithelial cells and in brain vessels. A major role of active transport processes was also identified. Today, the BRB is understood to play a fundamental role in retinal function in both health and disease. Retinal edema, an ubiquitous manifestation of retinal disease, is directly associated with breakdown of the BRB and with vision loss. In its most common form (i.e., vasogenic edema), due to breakdown of the BRB, Starling's law of capillary filtration may be used to interpret the mechanisms of fluid accumulation in the retina.The main factors involved in the development of retinal edema are BRB permeability, capillary hydrostatic pressure, tissue hydrostatic pressure, tissue osmotic pressure, and plasma osmotic pressure. In the clinical environment, breakdown of the BRB has been identified by fluorescein angiography and vitreous fluorometry, requiring the intravenous administration of fluorescein. An OCT-based method, OCT-Leakage, recently introduced by our group is capable of noninvasively identifying and quantifying sites of alteration of the BRB by mapping areas of lower-than-normal optical reflectivity, thus reflecting changes in the retinal extracellular fluid. We found good correspondence between the location of increased areas of low optical reflectivity identified by OCT-Leakage and the main sites of leakage on fluorescein angiography. Furthermore, with OCT-Leakage the areas of abnormal fluid accumulation can be identified in specific retinal layers, clearly offering more information than previously obtained with fluorescein angiography. OCT angiography has become available, replacing much of the information yielded by fluorescein angiography in a noninvasive manner. However, OCT angiography cannot visualize the leakage, i.e., the alteration of the BRB. OCT-Leakage is able to identify the locations of increases in extracellular fluid in the different layers of the retina. The complementarity of these 2 methods is of potential great interest for the diagnosis and management of several retinal diseases in which the presence and amount of fluid, as a marker of severity and activity, is paramount to treatment and management decisions in clinical practice. (C) 2017 S. Karger AG, Basel
C1 [Cunha-Vaz, Jose] AIBILI Assoc Innovat & Biomed Res Light & Image, Coimbra, Portugal.
   AIBILI, P-3000548 Coimbra, Portugal.
C3 Universidade de Coimbra; Universidade de Coimbra
RP Cunha-Vaz, J (通讯作者)，AIBILI, P-3000548 Coimbra, Portugal.
EM cunhavaz@aibili.pt
OI Cunha-Vaz, Jose/0000-0002-0947-9850
CR ASHTON N, 1965, ARCH OPHTHALMOL-CHIC, V73, P211
   CHEEK DB, 1978, PEDIATR RES, V12, P635, DOI 10.1203/00006450-197805000-00005
   Cunha-Vaz J, 1966, THESIS
   Cunha-Vaz J, 2016, INVEST OPHTH VIS SCI, V57, P6776, DOI 10.1167/iovs.16-19999
   CUNHAVAZ J, 1975, BRIT J OPHTHALMOL, V59, P649, DOI 10.1136/bjo.59.11.649
   CUNHAVAZ JG, 1967, J PHYSIOL-LONDON, V191, P467, DOI 10.1113/jphysiol.1967.sp008262
   CUNHAVAZ JG, 1966, BRIT J OPHTHALMOL, V50, P454, DOI 10.1136/bjo.50.8.454
   CUNHAVAZ JG, 1984, SURV OPHTHALMOL, V28, P485, DOI 10.1016/0039-6257(84)90230-3
   FATT I, 1971, EXP EYE RES, V12, P218, DOI 10.1016/0014-4835(71)90094-7
   Henkind P, 1980, BLOOD RETINA BARRIER, P251
   Hogan M, 1971, HISTOLOGY HUMAN EYE, P488
   Jia YL, 2015, P NATL ACAD SCI USA, V112, pE2395, DOI 10.1073/pnas.1500185112
   Jia YL, 2012, OPT EXPRESS, V20, P4710, DOI 10.1364/OE.20.004710
   KLATZO I, 1967, J NEUROPATH EXP NEUR, V26, P1, DOI 10.1097/00005072-196701000-00001
   Marmor MF, 1997, BRIT J OPHTHALMOL, V81, P812, DOI 10.1136/bjo.81.10.812
   Marmor MF, 1999, DOC OPHTHALMOL, V97, P239, DOI 10.1023/A:1002192829817
   Marmor MF., 1998, RETINAL PIGMENT EPIT, P420
   Miller JW, 2016, TRANSL VIS SCI TECHN, V5, DOI 10.1167/tvst.5.2.9
   Parikh VS, 2016, OPHTHALMOLOGY, V123, P664, DOI 10.1016/j.ophtha.2015.09.011
   REESE TS, 1967, J CELL BIOL, V34, P207, DOI 10.1083/jcb.34.1.207
   SHAKIB M, 1966, EXP EYE RES, V5, P229, DOI 10.1016/S0014-4835(66)80011-8
   Smelser GK, 1965, STRUCTURE EYE, P109
   Strauss O, 2005, PHYSIOL REV, V85, P845, DOI 10.1152/physrev.00021.2004
   TAKEUCHI A, 1995, INVEST OPHTH VIS SCI, V36, P1298
   YANNUZZI LA, 1986, OPHTHALMOLOGY, V93, P611
   Yau JWY, 2012, DIABETES CARE, V35, P556, DOI 10.2337/dc11-1909
NR 26
TC 45
Z9 47
U1 1
U2 6
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0030-3755
EI 1423-0267
J9 OPHTHALMOLOGICA
JI Ophthalmologica
PY 2017
VL 237
IS 1
BP 1
EP 10
DI 10.1159/000455809
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA EM5MW
UT WOS:000395356700001
PM 28152535
OA Bronze
DA 2022-11-30
ER

PT J
AU Golka, K
   Selinski, S
   Lehmann, ML
   Blaszkewicz, M
   Marchan, R
   Ickstadt, K
   Schwender, H
   Bolt, HM
   Hengstler, JG
AF Golka, Klaus
   Selinski, Silvia
   Lehmann, Marie-Louise
   Blaszkewicz, Meinolf
   Marchan, Rosemarie
   Ickstadt, Katja
   Schwender, Holger
   Bolt, Hermann M.
   Hengstler, Jan G.
TI Genetic variants in urinary bladder cancer: collective power of the
   "wimp SNPs"
SO ARCHIVES OF TOXICOLOGY
LA English
DT Review
DE Genome-wide association study; SNP chip comparison; Bladder cancer risk;
   Genetic variant; Enzyme polymorphism; Validation; GSTM1
ID GENOME-WIDE ASSOCIATION; SINGLE NUCLEOTIDE POLYMORPHISMS; MICROSOMAL
   EPOXIDE HYDROLASE; GLUTATHIONE S-TRANSFERASES; DNA-REPAIR GENES;
   HAPLOTYPE-PHASE INFERENCE; SQUAMOUS-CELL CARCINOMA; BREAST-CANCER;
   FUNCTIONAL POLYMORPHISMS; CONFERS SUSCEPTIBILITY
AB In recent years, genome-wide association studies (GWAS) have identified more than 300 validated associations between genetic variants and risk of approximately 70 common diseases. A small number of rare variants with a frequency of usually less than 1% are associated with a strongly enhanced risk, such as genetic variants of TP53, RB1, BRCA1, and BRCA2. Only a very small number of SNPs (with a frequency of more that 1% of the rare allele) have effects of a factor of two or higher. Examples include APOE4 in Alzheimer's disease, LOXL1 in exfoliative glaucoma, and CFH in age-related macular degeneration. However, the majority of all identified SNPs have odds ratios between 1.1 and 1.5. In the case of urinary bladder cancer, all known SNPs that have been validated in sufficiently large populations are associated with odds ratios smaller than 1.5. These SNPs are located next to the following genes: MYC, TP63, PSCA, the TERT-CLPTM1L locus, FGFR3, TACC3, NAT2, CBX6, APOBEC3A, CCNE1, and UGT1A. It is likely that these moderate risk or "wimp SNPs" interact, and because of their high number, collectively have a strong influence on whether an individual will develop cancer or not. It should be considered that variants identified so far explain only approximately 5-10% of the overall inherited risk. Possibly, the remaining variance is due to an even higher number of SNPs with odds ratios smaller than 1.1. Recent studies have provided the following information: (1) The functions of genes identified as relevant for bladder cancer focus on detoxification of carcinogens, control of the cell cycle and apoptosis, as well as maintenance of DNA integrity. (2) Many novel SNPs are far away from the protein coding regions, suggesting that these SNPs are located on distant-acting transcriptional enhancers. (3) The low odds ratio of each individual bladder cancer-associated SNP is too low to justify reasonable preventive measures. However, if the recently identified SNPs interact, they may collectively result in a substantial risk that is of preventive relevance. In addition to the "novel SNPs" identified by the recent GWAS, at least 163 further variants have been reported in relation to bladder cancer, although they have not been consistently validated in independent case-control series. Moreover, given that only 60 of these 163 "old SNPs" are covered by the SNP chips used in the recent GWAS, there are in principle 103 published variants still awaiting validation or disproval. In future, besides identifying novel disease-associated rare variants by deep sequencing, it will also be important to understand how the already identified variants interact.
C1 [Golka, Klaus; Selinski, Silvia; Lehmann, Marie-Louise; Blaszkewicz, Meinolf; Marchan, Rosemarie; Bolt, Hermann M.; Hengstler, Jan G.] Leibniz Res Ctr Working Environm & Human Factors, D-44139 Dortmund, Germany.
   [Ickstadt, Katja; Schwender, Holger] TU Dortmund Univ, Fac Stat, Dortmund, Germany.
C3 Dortmund University of Technology; Leibniz Institut for Arbeitsforschung
   an der TU Dortmund (IFADO); Dortmund University of Technology
RP Golka, K (通讯作者)，Leibniz Res Ctr Working Environm & Human Factors, Ardeystr 67, D-44139 Dortmund, Germany.
EM Golka@ifado.de; Hengstler@ifado.de
RI Hengstler, Jan G./O-1415-2013
OI Hengstler, Jan/0000-0002-1427-5246; Marchan,
   Rosemarie/0000-0003-4414-1633
CR Abbasi R, 2009, INT J CANCER, V125, P1431, DOI 10.1002/ijc.24442
   Abe H, 2009, HEPATOL RES, V39, P1159, DOI 10.1111/j.1872-034X.2009.00566.x
   Ahirwar DK, 2009, BJU INT, V104, P867, DOI 10.1111/j.1464-410X.2009.08549.x
   Ahirwar DK, 2010, ARCH MED RES, V41, P97, DOI 10.1016/j.arcmed.2010.03.005
   Alakus H, 2010, WORLD J SURG, V34, P2853, DOI 10.1007/s00268-010-0761-4
   Altshuler D, 2008, SCIENCE, V322, P881, DOI 10.1126/science.1156409
   Andrew AS, 2009, HUM GENET, V125, P527, DOI 10.1007/s00439-009-0645-6
   Arand M, 1996, ANAL BIOCHEM, V236, P184, DOI 10.1006/abio.1996.0153
   Arizono K, 2008, JPN J CLIN ONCOL, V38, P186, DOI 10.1093/jjco/hym176
   Aulchenko YS, 2007, BIOINFORMATICS, V23, P1294, DOI 10.1093/bioinformatics/btm108
   Begin P, 2007, AM J RESP CRIT CARE, V175, P1109, DOI 10.1164/rccm.200607-1012OC
   Berman DM, 2004, CANCER RES, V64, P6820, DOI 10.1158/0008-5472.CAN-04-1916
   Bezemer ID, 2007, ARCH INTERN MED, V167, P497, DOI 10.1001/archinte.167.5.497
   Bolt HM, 2006, CURR DRUG METAB, V7, P613, DOI 10.2174/138920006778017786
   Bolt HM, 2007, CRIT REV TOXICOL, V37, P521, DOI 10.1080/10408440701385671
   Brockmoller J, 1996, CANCER RES, V56, P3915
   Browning BL, 2009, AM J HUM GENET, V84, P210, DOI 10.1016/j.ajhg.2009.01.005
   Browning SR, 2007, AM J HUM GENET, V81, P1084, DOI 10.1086/521987
   Browning SR, 2008, HUM GENET, V124, P439, DOI 10.1007/s00439-008-0568-7
   Cadenas C, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2599
   Cai DW, 2009, J INT MED RES, V37, P1882, DOI 10.1177/147323000903700625
   Carmo H, 2006, PHARMACOGENET GENOM, V16, P789, DOI 10.1097/01.fpc.0000230419.05221.fc
   Carr SM, 2008, COMP BIOCHEM PHYS D, V3, P1, DOI 10.1016/j.cbd.2006.12.005
   Cascorbi I, 2001, CANCER RES, V61, P5051
   Castillejo A, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-406
   Chang CH, 2009, ANTICANCER RES, V29, P5121
   Chang CH, 2009, ANTICANCER RES, V29, P3903
   Chang CH, 2009, ANTICANCER RES, V29, P1777
   Chang CH, 2009, ANTICANCER RES, V29, P1275
   Chao C, 2006, CANCER EPIDEM BIOMAR, V15, P979, DOI 10.1158/1055-9965.EPI-05-0899
   Chen M, 2009, CARCINOGENESIS, V30, P2047, DOI 10.1093/carcin/bgp258
   Chen TP, 2004, INT J CANCER, V112, P420, DOI 10.1002/ijc.20419
   Chen WC, 2002, UROL ONCOL, V7, P63, DOI 10.1016/S1078-1439(01)00152-1
   Cheung ALM, 2008, FRONT BIOSCI-LANDMRK, V13, P2075, DOI 10.2741/2825
   Chiu CF, 2008, ORAL ONCOL, V44, P898, DOI 10.1016/j.oraloncology.2007.11.007
   Choi JY, 2003, PHARMACOGENETICS, V13, P349, DOI 10.1097/00008571-200306000-00006
   Choudhury A, 2008, BMC MED GENET, V9, DOI 10.1186/1471-2350-9-69
   COX DG, 2004, CANCER EPIDEM BIOMAR, P1821
   de Verdier PJ, 2010, MUTAT RES-FUND MOL M, V694, P39, DOI 10.1016/j.mrfmmm.2010.09.003
   Devi SS, 2008, CHEMOSPHERE, V70, P1835, DOI 10.1016/j.chemosphere.2007.08.008
   Dominguez-Sola D, 2007, NATURE, V448, P445, DOI 10.1038/nature05953
   Federico A, 2009, CANCER RES, V69, P7079, DOI 10.1158/0008-5472.CAN-09-1542
   Figueroa JD, 2008, CARCINOGENESIS, V29, P1955, DOI 10.1093/carcin/bgn163
   Figueroa JD, 2007, HUM GENET, V121, P233, DOI 10.1007/s00439-006-0294-y
   Florl AR, 2008, ARCH TOXICOL, V82, P173, DOI 10.1007/s00204-008-0280-3
   Frank B, 2005, CARCINOGENESIS, V26, P1975, DOI 10.1093/carcin/bgi164
   Galli P, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-137
   Gangwar R, 2011, SURGERY, V149, P126, DOI 10.1016/j.surg.2010.04.004
   Gangwar R, 2009, MUTAT RES-GEN TOX EN, V680, P56, DOI 10.1016/j.mrgentox.2009.09.008
   Gangwar R, 2009, ANN SURG ONCOL, V16, P2028, DOI 10.1245/s10434-009-0488-3
   Garcia-Closas M, 2006, CANCER EPIDEM BIOMAR, V15, P536, DOI 10.1158/1055-9965.EPI-05-0749
   Garcia-Closas M, 2005, LANCET, V366, P649, DOI 10.1016/S0140-6736(05)67137-1
   Garcia-Closas M, 2007, PLOS GENET, V3, P287, DOI 10.1371/journal.pgen.0030029
   Gaudet MM, 2005, CANCER CAUSE CONTROL, V16, P1225, DOI 10.1007/s10552-005-0375-6
   Golka K, 2004, TOXICOL LETT, V151, P203, DOI 10.1016/j.toxlet.2003.11.016
   Golka K, 1996, SCAND J WORK ENV HEA, V22, P332, DOI 10.5271/sjweh.150
   Golka K, 2009, PHARMACOGENET GENOM, V19, P903, DOI 10.1097/FPC.0b013e328331b554
   Gomez-Baldo L, 2010, CELL CYCLE, V9, P1143, DOI 10.4161/cc.9.6.11018
   Halperin E, 2009, NAT BIOTECHNOL, V27, P349, DOI 10.1038/nbt0409-349
   Halperin E, 2009, NAT BIOTECHNOL, V27, P255, DOI 10.1038/nbt0309-255
   Hao K, 2009, BMC GENET, V10, DOI 10.1186/1471-2156-10-27
   Haq I, 2010, BMC MED GENET, V11, DOI 10.1186/1471-2350-11-7
   Harries LW, 1997, CARCINOGENESIS, V18, P641, DOI 10.1093/carcin/18.4.641
   Hazra A, 2003, CANCER RES, V63, P1157
   Hebbring SJ, 2007, HUM MOL GENET, V16, P463, DOI 10.1093/hmg/ddl468
   Hellwig B, 2010, BMC BIOINFORMATICS, V11, DOI 10.1186/1471-2105-11-276
   Hengstler JG, 1998, RECENT RES CANCER, V154, P47
   Hengstler JG, 2000, DRUG METAB REV, V32, P81, DOI 10.1081/DMR-100100564
   Hewitt NJ, 2007, DRUG METAB REV, V39, P159, DOI 10.1080/03602530601093489
   Hindorff LA, 2009, P NATL ACAD SCI USA, V106, P9362, DOI 10.1073/pnas.0903103106
   Huang L, 2009, AM J HUM GENET, V84, P235, DOI 10.1016/j.ajhg.2009.01.013
   Hung RJ, 2004, INT J CANCER, V110, P598, DOI 10.1002/ijc.20157
   Johne A, 2003, CANCER EPIDEM BIOMAR, V12, P68
   KEEGAN K, 1991, P NATL ACAD SCI USA, V88, P1095, DOI 10.1073/pnas.88.4.1095
   Kempkes M, 1996, ARCH TOXICOL, V71, P123, DOI 10.1007/s002040050366
   Kiemeney LA, 2008, NAT GENET, V40, P1307, DOI 10.1038/ng.229
   Kiemeney LA, 2006, EUR J CANCER, V42, P3219, DOI 10.1016/j.ejca.2006.05.033
   Kiemeney LA, 2010, NAT GENET, V42, P415, DOI 10.1038/ng.558
   KOFF A, 1991, CELL, V66, P1217, DOI 10.1016/0092-8674(91)90044-Y
   Kotsopoulos J, 2009, CANCER CAUSE CONTROL, V20, P335, DOI 10.1007/s10552-008-9247-1
   Lee JM, 2009, AM J CARDIOL, V104, P46, DOI 10.1016/j.amjcard.2009.02.045
   Lefkimmiatis K, 2009, CANCER RES, V69, P8563, DOI 10.1158/0008-5472.CAN-09-0259
   Lehmann ML, 2010, ARCH TOXICOL, V84, P967, DOI 10.1007/s00204-010-0617-6
   Leibovici D, 2005, J CLIN ONCOL, V23, P5746, DOI 10.1200/JCO.2005.01.598
   Li CP, 2007, J TOXICOL ENV HEAL A, V70, P876, DOI 10.1080/15287390701285824
   Li CP, 2006, PHARMACOGENET GENOM, V16, P245, DOI 10.1097/01.fpc.0000194425.58511.a7
   Li DB, 2010, GENET MOL RES, V9, P1599, DOI 10.4238/vol9-3gmr882
   Li YH, 2010, AM J HEMATOL, V85, P213, DOI 10.1002/ajh.21608
   Li Y, 2010, GENET EPIDEMIOL, V34, P816, DOI 10.1002/gepi.20533
   Lin GF, 2005, TOXICOL SCI, V85, P502, DOI 10.1093/toxsci/kfi068
   Liu ZS, 2010, CARCINOGENESIS, V31, P1977, DOI 10.1093/carcin/bgq179
   Lo YL, 2009, CANCER EPIDEM BIOMAR, V18, P223, DOI 10.1158/1055-9965.EPI-08-0749
   Lu C, 2009, BREAST CANCER RES TR, V116, P571, DOI 10.1007/s10549-008-0195-y
   Maalej A, 2005, GENES IMMUN, V6, P707, DOI 10.1038/sj.gene.6364260
   Manchanda PK, 2006, UROL INT, V77, P81, DOI 10.1159/000092940
   Marchini J, 2008, AM J HUM GENET, V83, P535, DOI 10.1016/j.ajhg.2008.09.007
   Marchini J, 2007, NAT GENET, V39, P906, DOI 10.1038/ng2088
   Marsh HP, 2003, BRIT J CANCER, V89, P1096, DOI 10.1038/sj.bjc.6601165
   Mateuca RA, 2008, MUTAGENESIS, V23, P35, DOI 10.1093/mutage/gem040
   Mathias G, 2008, PHARMACOGENOMICS, V9, P969, DOI 10.2217/14622416.9.7.969
   Matullo G, 2005, CANCER EPIDEM BIOMAR, V14, P2569, DOI 10.1158/1055-9965.EPI-05-0189
   Michiels S, 2009, CARCINOGENESIS, V30, P763, DOI 10.1093/carcin/bgp046
   Mittal RD, 2007, BJU INT, V99, P933, DOI 10.1111/j.1464-410X.2007.06657.x
   Molle I, 2008, LEUKEMIA LYMPHOMA, V49, P1116, DOI 10.1080/10428190802074585
   Moore LE, 2007, INT J CANCER, V120, P2452, DOI 10.1002/ijc.22565
   Narter KF, 2010, GENET MOL RES, V9, P685, DOI 10.4238/vol9-2gmr829
   *NCBI, 2010, NCBI SINGL NUCL POL
   Nicolae DL, 2006, GENET EPIDEMIOL, V30, P718, DOI 10.1002/gepi.20182
   Nonomura N, 2006, INT J UROL, V13, P971, DOI 10.1111/j.1442-2042.2006.01450.x
   Nyquist PA, 2009, CEREBROVASC DIS, V28, P124, DOI 10.1159/000223437
   Onat OE, 2006, ANTICANCER RES, V26, P3473
   Oscarson M, 2001, DRUG METAB DISPOS, V29, P91
   Ott N, 2008, J CANCER RES CLIN, V134, P405, DOI 10.1007/s00432-007-0301-2
   Ouerhani S, 2007, CANCER GENET CYTOGEN, V176, P48, DOI 10.1016/j.cancergencyto.2007.03.007
   Pabalan N, 2010, BREAST CANCER RES TR, V124, P531, DOI 10.1007/s10549-010-0863-6
   Park J, 2009, CLIN CANCER RES, V15, P1794, DOI 10.1158/1078-0432.CCR-08-1770
   Park SL, 2010, CARCINOGENESIS, V31, P1264, DOI 10.1093/carcin/bgq096
   Parkin DM, 2008, SCAND J UROL NEPHROL, V42, P12, DOI 10.1080/03008880802285032
   Pavanello S, 2010, EUR J EPIDEMIOL, V25, P491, DOI 10.1007/s10654-010-9479-8
   Paz-y-Mino C, 2009, ONCOL RES, V18, P395, DOI 10.3727/096504010X12644422320780
   Pei YF, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010827
   Pei YF, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003551
   Pinto LA, 2010, RESP RES, V11, DOI 10.1186/1465-9921-11-23
   Pittman AM, 2008, BRIT J CANCER, V98, P1434, DOI 10.1038/sj.bjc.6604314
   Platek ME, 2009, CANCER EPIDEM BIOMAR, V18, P2453, DOI 10.1158/1055-9965.EPI-09-0159
   Prieto-Castello MJ, 2010, TOXICOL LETT, V192, P34, DOI 10.1016/j.toxlet.2009.01.011
   Purcell S, 2007, AM J HUM GENET, V81, P559, DOI 10.1086/519795
   Puthothu B, 2009, PEDIAT ALLERG IMM-UK, V20, P157, DOI 10.1111/j.1399-3038.2008.00751.x
   Rafnar T, 2009, NAT GENET, V41, P221, DOI 10.1038/ng.296
   Reddy B. M., 2006, International Journal of Human Genetics, V6, P309
   Reddy P, 2010, LUNG, V188, P409, DOI 10.1007/s00408-010-9246-3
   REIF DM, 2006, THESIS NASHVILLE TN
   Ricceri F, 2010, DNA REPAIR, V9, P191, DOI 10.1016/j.dnarep.2009.12.002
   Rothman N, 2010, NAT GENET, V42, P978, DOI 10.1038/ng.687
   Rouguieg K, 2010, DRUG METAB DISPOS, V38, P40, DOI 10.1124/dmd.109.029546
   SAFARINEJAD MR, 2010, MED ONCOL       1029
   SAFARINEJAD MR, 2011, ARCH TOXICO IN PRESS
   Sasaki T, 2008, JPN J CLIN ONCOL, V38, P634, DOI 10.1093/jjco/hyn081
   Savage SA, 2006, CANCER EPIDEM BIOMAR, V15, P589, DOI 10.1158/1055-9965.EPI-05-0887
   Sayan BS, 2007, P NATL ACAD SCI USA, V104, P10871, DOI 10.1073/pnas.0700761104
   Scheet P, 2006, AM J HUM GENET, V78, P629, DOI 10.1086/502802
   Schnakenberg E, 2000, CYTOGENET CELL GENET, V91, P234, DOI 10.1159/000056851
   Servin B, 2007, PLOS GENET, V3, P1296, DOI 10.1371/journal.pgen.0030114
   Shao JF, 2007, CANCER GENET CYTOGEN, V177, P30, DOI 10.1016/j.cancergencyto.2007.05.005
   Shi WX, 2004, WORLD J GASTROENTERO, V10, P1961, DOI 10.3748/wjg.v10.i13.463
   Shih CM, 2011, CLIN CHIM ACTA, V412, P194, DOI 10.1016/j.cca.2010.10.004
   Skjelbred CF, 2006, BMC CANCER, V6, DOI 10.1186/1471-2407-6-67
   Slattery ML, 2007, CANCER CAUSE CONTROL, V18, P1095, DOI 10.1007/s10552-007-9049-x
   Song DK, 2009, CANCER DETECT PREV, V32, P416, DOI 10.1016/j.cdp.2009.02.003
   Srivastava DS, 2008, ARCH TOXICOL, V82, P633, DOI 10.1007/s00204-007-0276-4
   Srivastava P, 2010, ANN SURG ONCOL, V17, P3068, DOI 10.1245/s10434-010-1153-6
   Srivastava P, 2010, DIS MARKERS, V29, P37, DOI [10.1155/2010/149651, 10.3233/DMA-2010-0724]
   Stern MC, 2009, CANCER RES, V69, P6857, DOI 10.1158/0008-5472.CAN-09-1091
   Strassburg CP, 2008, ARCH TOXICOL, V82, P415, DOI 10.1007/s00204-008-0314-x
   SU L, 2006, P AM ASSOC CANC RES, V47, P437
   Sun HM, 2010, CANCER SCI, V101, P1777, DOI 10.1111/j.1349-7006.2010.01608.x
   Sun P, 2009, CANCER EPIDEM BIOMAR, V18, P1821, DOI 10.1158/1055-9965.EPI-09-0140
   Tang TL, 2010, DNA CELL BIOL, V29, P9, DOI 10.1089/dna.2009.0937
   Tranah GJ, 2004, CARCINOGENESIS, V25, P1211, DOI 10.1093/carcin/bgh126
   Tsironi EE, 2009, MOL VIS, V15, P2890
   van Dijk BAC, 2001, EUR UROL, V40, P509, DOI 10.1159/000049827
   Varghese JS, 2010, CURR OPIN GENET DEV, V20, P201, DOI 10.1016/j.gde.2010.03.012
   Vartanian JP, 2008, SCIENCE, V320, P230, DOI 10.1126/science.1153201
   Verhaegh GW, 2008, EUR UROL, V54, P1118, DOI 10.1016/j.eururo.2008.01.060
   Verlaan M, 2004, ALCOHOL ALCOHOLISM, V39, P20, DOI 10.1093/alcalc/agh001
   Visel A, 2009, NATURE, V461, P199, DOI 10.1038/nature08451
   Wang HC, 2009, ANTICANCER RES, V29, P5251
   Wang M, 2010, ONCOGENE, V29, P1920, DOI 10.1038/onc.2009.484
   Wang ML, 2008, CLIN CANCER RES, V14, P3633, DOI 10.1158/1078-0432.CCR-07-5155
   Wang ML, 2010, DNA CELL BIOL, V29, P303, DOI 10.1089/dna.2009.0969
   Wang ML, 2009, CLIN CANCER RES, V15, P2567, DOI 10.1158/1078-0432.CCR-08-2829
   Wang ML, 2009, MUTAT RES-FUND MOL M, V661, P85, DOI 10.1016/j.mrfmmm.2008.11.009
   Wang SZ, 2010, CARCINOGENESIS, V31, P621, DOI 10.1093/carcin/bgp323
   Watabe T, 2002, P NATL ACAD SCI USA, V99, P401, DOI 10.1073/pnas.012574899
   Waterston RH, 2002, NATURE, V420, P520, DOI 10.1038/nature01262
   Wen H, 2009, INT UROL NEPHROL, V41, P855, DOI 10.1007/s11255-009-9560-y
   Wolf S, 2006, INT J CANCER, V118, P1831, DOI 10.1002/ijc.21502
   Wu XF, 2006, AM J HUM GENET, V78, P464, DOI 10.1086/500848
   Wu XF, 2009, NAT GENET, V41, P991, DOI 10.1038/ng.421
   Yang H, 2008, CLIN CANCER RES, V14, P2236, DOI 10.1158/1078-0432.CCR-07-1670
   Yang JJ, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-238
   Yang WJ, 2010, ANN SURG ONCOL, V17, P1453, DOI 10.1245/s10434-009-0882-x
   Yu ZX, 2007, HUM GENET, V122, P495, DOI 10.1007/s00439-007-0427-y
   Yuan L, 2010, DNA CELL BIOL, V29, P611, DOI 10.1089/dna.2010.1018
   Zhang YJ, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-256
   Zhang ZZ, 2008, CARCINOGENESIS, V29, P1973, DOI 10.1093/carcin/bgn183
   Zheng LZ, 2003, CANCER LETT, V202, P61, DOI 10.1016/j.canlet.2003.08.007
   Zhou P, 2011, BREAST CANCER RES TR, V126, P253, DOI 10.1007/s10549-010-1246-8
   2010, HUMAN ARYLAMINE N AC
   2010, PHARMACOGENOMICS KNO
NR 190
TC 55
Z9 60
U1 0
U2 21
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY
SN 0340-5761
EI 1432-0738
J9 ARCH TOXICOL
JI Arch. Toxicol.
PD JUN
PY 2011
VL 85
IS 6
BP 539
EP 554
DI 10.1007/s00204-011-0676-3
PG 16
WC Toxicology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Toxicology
GA 771MP
UT WOS:000291163000002
PM 21380501
DA 2022-11-30
ER

PT J
AU Korot, E
   Pontikos, N
   Drawnel, FM
   Jaber, A
   Fu, DJ
   Zhang, GY
   Miranda, MA
   Liefers, B
   Glinton, S
   Wagner, SK
   Struyven, R
   Kilduff, C
   Moshfeghi, DM
   Keane, PA
   Sim, DA
   Thomas, PBM
   Balaskas, K
AF Korot, Edward
   Pontikos, Nikolas
   Drawnel, Faye M.
   Jaber, Aljazy
   Fu, Dun Jack
   Zhang, Gongyu
   Miranda, Marco A.
   Liefers, Bart
   Glinton, Sophie
   Wagner, Siegfried K.
   Struyven, Robbert
   Kilduff, Caroline
   Moshfeghi, Darius M.
   Keane, Pearse A.
   Sim, Dawn A.
   Thomas, Peter B. M.
   Balaskas, Konstantinos
TI Enablers and Barriers to Deployment of Smartphone-Based Home Vision
   Monitoring in Clinical Practice Settings
SO JAMA OPHTHALMOLOGY
LA English
DT Article
ID SHAPE-DISCRIMINATION; RANDOMIZED-TRIAL; TELEHEALTH; HEALTH; DEVICE;
   SYSTEM
AB IMPORTANCE Telemedicine is accelerating the remote detection and monitoring of medical conditions, such as vision-threatening diseases. Meaningful deployment of smartphone apps for home vision monitoring should consider the barriers to patient uptake and engagement and address issues around digital exclusion in vulnerable patient populations.
   OBJECTIVE To quantify the associations between patient characteristics and clinical measures with vision monitoring app uptake and engagement.
   DESIGN, SETTING, AND PARTICIPANTS In this cohort and survey study, consecutive adult patients attending Moorfields Eye Hospital receiving intravitreal injections for retinal disease between May 2020 and February 2021 were included.
   EXPOSURES Patients were offered the Home Vision Monitor (HVM) smartphone app to self-test their vision. A patient survey was conducted to capture their experience. App data, demographic characteristics, survey results, and clinical data from the electronic health record were analyzed via regression and machine learning.
   MAIN OUTCOMES AND MEASURES Associations of patient uptake, compliance, and use rate measured in odds ratios (ORs).
   RESULTS Of 417 included patients, 236 (56.6%) were female, and the mean (SD) age was 72.8 (12.8) years. A total of 258 patients (61.9%) were active users. Uptake was negatively associated with age (OR, 0.98; 95% CI, 0.97-0.998; P =.02) and positively associated with both visual acuity in the better-seeing eye (OR, 1.02; 95% CI, 1.00-1.03; P =.01) and baseline number of intravitreal injections (OR, 1.01; 95% CI, 1.00-1.02; P =.02). Of 258 active patients, 166 (64.3%) fulfilled the definition of compliance. Compliance was associated with patients diagnosed with neovascular age-related macular degeneration (OR, 1.94; 95% CI, 1.07-3.53; P =.002), White British ethnicity (OR, 1.69; 95% CI, 0.96-3.01; P =.02), and visual acuity in the better-seeing eye at baseline (OR, 1.02; 95% CI, 1.01-1.04; P =.04). Use rate was higher with increasing levels of comfort with use of modern technologies (beta = 0.031; 95% CI, 0.007-0.055; P =.02). A total of 119 patients (98.4%) found the app either easy or very easy to use, while 96 (82.1%) experienced increased reassurance from using the app.
   CONCLUSIONS AND RELEVANCE This evaluation of home vision monitoring for patients with common vision-threatening disease within a clinical practice setting revealed demographic, clinical, and patient-related factors associated with patient uptake and engagement. These insights inform targeted interventions to address risks of digital exclusion with smartphone-based medical devices.
C1 [Korot, Edward; Moshfeghi, Darius M.] Stanford Univ, Byers Eye Inst, Palo Alto, CA 94304 USA.
   [Korot, Edward; Pontikos, Nikolas; Jaber, Aljazy; Fu, Dun Jack; Zhang, Gongyu; Liefers, Bart; Glinton, Sophie; Wagner, Siegfried K.; Struyven, Robbert; Kilduff, Caroline; Keane, Pearse A.; Sim, Dawn A.; Thomas, Peter B. M.; Balaskas, Konstantinos] Moorfields Eye Hosp NHS Fdn Trust, UCL Inst Ophthalmol, NIHR Biomed Res Ctr, 162 City Rd, London EC1V 2PD, England.
   [Korot, Edward; Pontikos, Nikolas; Fu, Dun Jack; Zhang, Gongyu; Miranda, Marco A.; Liefers, Bart; Glinton, Sophie; Wagner, Siegfried K.; Struyven, Robbert; Kilduff, Caroline; Keane, Pearse A.; Sim, Dawn A.; Thomas, Peter B. M.; Balaskas, Konstantinos] UCL Inst Ophthalmol, London, England.
   [Drawnel, Faye M.] F Hoffmann La Roche & Cie AG, Personalised Healthcare Ophthalmol, Basel, Switzerland.
   [Miranda, Marco A.] Roche Prod, Personalised Healthcare Ophthalmol, Welwyn Gardens City, England.
C3 Stanford University; University of London; University College London;
   Moorfields Eye Hospital NHS Foundation Trust; University of London;
   University College London; Roche Holding; Roche Holding
RP Balaskas, K (通讯作者)，Moorfields Eye Hosp NHS Fdn Trust, UCL Inst Ophthalmol, NIHR Biomed Res Ctr, 162 City Rd, London EC1V 2PD, England.
EM k.balaskas@nhs.net
RI Balaskas, Konstantinos/ABD-5979-2020
OI Balaskas, Konstantinos/0000-0002-7690-6277; Zhang,
   Gongyu/0000-0003-4760-359X; Korot, Edward/0000-0002-5687-1564;
   Moshfeghi, Darius Mohammad/0000-0003-2254-292X; Keane,
   Pearse/0000-0002-9239-745X
FU Roche Products
FX Roche Products provided financial support for the home vision monitoring
   service quality improvement initiative.
CR Anderson AJ, 2017, OPHTHALMOLOGY, V124, P1735, DOI 10.1016/j.ophtha.2017.06.028
   Angermann R, 2019, GRAEF ARCH CLIN EXP, V257, P2119, DOI 10.1007/s00417-019-04414-y
   Brucker J, 2019, OPHTHALMOL THER, V8, P461, DOI 10.1007/s40123-019-0203-9
   Chew EY, 2016, RETINA-J RET VIT DIS, V36, P1542, DOI 10.1097/IAE.0000000000000940
   Chew EY, 2014, CONTEMP CLIN TRIALS, V37, P294, DOI 10.1016/j.cct.2014.02.003
   Chew EY, 2014, OPHTHALMOLOGY, V121, P535, DOI 10.1016/j.ophtha.2013.10.027
   Chumbler NR, 2005, J TELEMED TELECARE, V11, P150, DOI 10.1258/1357633053688723
   Crossland M, 2007, BRIT J OPHTHALMOL, V91, P391, DOI 10.1136/bjo.2006.095315
   Dinesen B, 2012, J TELEMED TELECARE, V18, P221, DOI 10.1258/jtt.2012.110704
   Faes L, 2020, EYE, V34, P1950, DOI 10.1038/s41433-020-0964-3
   Finkelstein SM, 2006, TELEMED J E-HEALTH, V12, P128, DOI 10.1089/tmj.2006.12.128
   Gronvall E, 2013, UBICOMP'13: PROCEEDINGS OF THE 2013 ACM INTERNATIONAL JOINT CONFERENCE ON PERVASIVE AND UBIQUITOUS COMPUTING, P587, DOI 10.1145/2493432.2493495
   Hung K, 2004, P ANN INT IEEE EMBS, V26, P5384
   Islam M, 2021, BMJ HEALTH CARE INFO, V28, DOI 10.1136/bmjhci-2020-100310
   Jansen ME, 2018, OSLI RETINA, V49, P186, DOI 10.3928/23258160-20180221-06
   Kern C, 2020, BRIT J OPHTHALMOL, V104, P312, DOI 10.1136/bjophthalmol-2019-314161
   Koch S, 2006, INT J MED INFORM, V75, P565, DOI 10.1016/j.ijmedinf.2005.09.002
   Koshy E, 2008, BMC OPHTHALMOL, V8, DOI 10.1186/1471-2415-8-9
   Lebak JW, 2004, P ANN INT IEEE EMBS, V26, P3338
   Maloca P, 2018, TRANSL VIS SCI TECHN, V7, DOI 10.1167/tvst.7.4.8
   Saleem SM, 2020, AM J OPHTHALMOL, V216, P237, DOI 10.1016/j.ajo.2020.04.029
   Schmid MK, 2019, EYE, V33, P1584, DOI 10.1038/s41433-019-0455-6
   Smith Glenn E, 2007, Am J Alzheimers Dis Other Demen, V22, P20, DOI 10.1177/1533317506295888
   US Centers for Medicare & Medicaid Services, MED TEL HLTH CAR FAC
   Vazquez NP, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0207342
   Wang YZ, 2013, INVEST OPHTH VIS SCI, V54, P5497, DOI 10.1167/iovs.13-12037
   Wang YZ, 2002, INVEST OPHTH VIS SCI, V43, P2055
   Wild K, 2008, J APPL GERONTOL, V27, P181, DOI 10.1177/0733464807311435
NR 28
TC 4
Z9 4
U1 0
U2 1
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 2168-6165
EI 2168-6173
J9 JAMA OPHTHALMOL
JI JAMA Ophthalmol.
PD FEB
PY 2022
VL 140
IS 2
BP 153
EP 160
DI 10.1001/jamaophthalmol.2021.5269
EA DEC 2021
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA ZC4TY
UT WOS:000731128000006
PM 34913967
OA Green Published
DA 2022-11-30
ER

PT J
AU Qiu, M
   Shields, CL
AF Qiu, Mary
   Shields, Carol L.
TI Choroidal Nevus in the United States Adult Population Racial Disparities
   and Associated Factors in the National Health and Nutrition Examination
   Survey
SO OPHTHALMOLOGY
LA English
DT Article
ID ULTRAVIOLET-LIGHT EXPOSURE; UVEAL MELANOMA; VISUAL IMPAIRMENT;
   RISK-FACTORS; MELANOCYTIC NEVI; REFRACTIVE ERROR; PREVALENCE; EYE; AGE;
   TRANSFORMATION
AB Purpose: To describe the prevalence of choroidal nevus in the US population and identify possible associated factors.
   Design: Cross-sectional study.
   Participants: A total of 5575 participants aged >= 40 years from the 2005-2008 National Health and Nutrition Examination Survey (NHANES) who underwent retinal imaging examination.
   Methods: Predictor variables included a spectrum of demographic, ophthalmic, dermatologic, systemic, socioeconomic, or occupational factor variables available in NHANES.
   Main Outcome Measures: Choroidal nevus on retinal imaging.
   Results: The prevalence of choroidal nevus was 4.7% overall and increased with age (4.7%, 3.1%, 5.4%, 6.6%, and 7.5% in subjects aged 40-49, 50-59, 60-69, 70-79, and >= 80 years, respectively). The prevalence was 5.0% in men, 4.4% in women, 5.6% in whites, 2.7% in Hispanics, 0.6% in blacks, and 2.1% in others. After adjusting for age and race, the odds of choroidal nevus were 10-fold higher in whites than in blacks, 5-fold higher in Hispanics than in blacks, 4-fold higher in others than in blacks, and 2-fold higher in whites than in Hispanics. Choroidal nevus was associated with hypertension (odds ratio [OR], 1.40; 95% confidence interval [CI], 0.99-1.98); psoriasis (OR, 3.90; 95% CI, 1.57-9.66); lower high-density lipoprotein (OR, 0.99; 95% CI, 0.98-0.99); higher uric acid (OR, 1.13; 95% CI, 1.04-1.22); working in installation, maintenance, or repairs (OR,1.42; 95% CI, 1.03-1.96); and having never worked (OR, 1.56; 95% CI, 1.03-2.37; P = 0.04). There was no association with visual symptoms, visual functioning, visual acuity, refractive error, visual field, diabetic retinopathy, age-related macular degeneration, or elevated cup-to-disc ratio on retinal imaging. There was no association with skin melanoma, other cancers, lung/liver/kidney/thyroid disease, alcohol/drug use, income/education, hemoglobin A1C, C-reactive protein, lactate dehydrogenase, electrolytes, or urine albumin.
   Conclusions: Among US adults, the prevalence of choroidal nevus located within two 45 degrees areas centered on the macula and optic disc is 4.7%. The prevalence increases with age, is highest among whites (5.6%), is lowest among blacks (0.6%), and has been previously under-recognized among Hispanics (2.7%). Extrapolating to the entire fundus, the true prevalence of choroidal nevus is even higher but difficult to accurately estimate. Possible associations with cardiovascular, renal, autoimmune, and occupational risk factors warrant further investigation. (C) 2015 by the American Academy of Ophthalmology.
C1 [Qiu, Mary] Johns Hopkins Univ, Wilmer Eye Inst, Baltimore, MD 21218 USA.
   [Shields, Carol L.] Thomas Jefferson Univ, Wills Eye Hosp, Ocular Oncol Serv, Philadelphia, PA 19107 USA.
C3 Johns Hopkins University; Johns Hopkins Medicine; Jefferson University
RP Shields, CL (通讯作者)，Wills Eye Hosp & Res Inst, Ocular Oncol Serv, 840 Walnut St,Suite 1440, Philadelphia, PA 19107 USA.
EM carolshields@gmail.com
FU Eye Tumor Research Foundation, Philadelphia, Pennsylvania
FX C.L.S.: Support - Eye Tumor Research Foundation, Philadelphia,
   Pennsylvania The funders had no role in the design or conduct of the
   study; in the collection, analysis, and interpretation of the data; and
   in the preparation, review, or approval of the manuscript.
CR Alpsoy S, 2014, GIORN ITAL DERMAT V, V149, P167
   Balato N, 2011, BRIT J DERMATOL, V164, P1262, DOI 10.1111/j.1365-2133.2011.10271.x
   Centers for Disease Control and Prevention, 2010, NAT HLTH NUTR EX SUR
   Centers for Disease Control and Prevention, 2005, NAT HLTH NUTR EX DAT
   Chou CF, 2013, AM J PREV MED, V45, P29, DOI 10.1016/j.amepre.2013.02.018
   Di Cesare A, 2013, J AM ACAD DERMATOL, V69, P947, DOI 10.1016/j.jaad.2013.08.017
   Ge YR, 2012, ASIAN PAC J CANCER P, V13, P4927, DOI 10.7314/APJCP.2012.13.10.4927
   Gisondi P, 2014, DRUG DEVELOP RES, V75, pS70, DOI 10.1002/ddr.21201
   Gordon-Shaag A, 2014, OPHTHAL PHYSL OPT, V34, P94, DOI 10.1111/opo.12092
   Greenstein MB, 2011, OPHTHALMOLOGY, V118, P2468, DOI 10.1016/j.ophtha.2011.05.007
   Guenel P, 2001, CANCER CAUSE CONTROL, V12, P451, DOI 10.1023/A:1011271420974
   HACIYAKUPOGLU G, 1993, ACTA OPHTHALMOL, V71, P846
   HALE PN, 1965, ARCH OPHTHALMOL-CHIC, V74, P532
   HOLLY EA, 1990, CANCER RES, V50, P5773
   Jonas JB, 2008, OPHTHALMOLOGY, V115, P1102, DOI 10.1016/j.ophtha.2007.12.022
   Kaliki S, 2015, EYE MD ASS, V33, P1
   Klein R, 2011, ARCH OPHTHALMOL-CHIC, V129, P75, DOI 10.1001/archophthalmol.2010.318
   Ko F, 2012, JAMA-J AM MED ASSOC, V308, P2361, DOI 10.1001/jama.2012.85685
   LANG GK, 1982, KLIN MONATSBL AUGENH, V181, P493, DOI 10.1055/s-2008-1055279
   Lutz JM, 2005, CANCER CAUSE CONTROL, V16, P437, DOI 10.1007/s10552-004-5029-6
   Mangione CM, 2001, ARCH OPHTHALMOL-CHIC, V119, P1050
   Monarrez-Espino J, 2002, SCAND J WORK ENV HEA, V28, P270, DOI 10.5271/sjweh.675
   Nangia V, 2012, BRIT J OPHTHALMOL, V96, P1443, DOI 10.1136/bjophthalmol-2012-302164
   NAUMANN G, 1970, ADV OPHTHALMOL, V23, P187
   Ng CH, 2009, ARCH OPHTHALMOL-CHIC, V127, P314, DOI 10.1001/archophthalmol.2008.625
   Qiu M, 2014, INVEST OPHTH VIS SCI, V55, DOI 10.1167/iovs.13-12662
   Qiu M, 2014, OPHTHALMOLOGY, V121, P733, DOI 10.1016/j.ophtha.2013.09.043
   Qiu M, 2013, INVEST OPHTH VIS SCI, V54, P830, DOI 10.1167/iovs.12-11158
   Schmidt-Pokrzywniak A, 2009, OPHTHALMOLOGY, V116, P340, DOI 10.1016/j.ophtha.2008.09.040
   Shah CP, 2005, OPHTHALMOLOGY, V112, P1599, DOI 10.1016/j.ophtha.2005.04.020
   Sherrod CE, 2014, JAMA OPHTHALMOL, V132, P1239, DOI 10.1001/jamaophthalmol.2014.2213
   Shields CL, 2008, OPHTHALMOLOGY, V115, P546, DOI 10.1016/j.ophtha.2007.07.009
   Shields CL, 2007, ARCH OPHTHALMOL-CHIC, V125, P1501, DOI 10.1001/archopht.125.11.1501
   Shields CL, 2009, ARCH OPHTHALMOL-CHIC, V127, P981, DOI 10.1001/archophthalmol.2009.151
   Shields CL, 2000, ARCH OPHTHALMOL-CHIC, V118, P360, DOI 10.1001/archopht.118.3.360
   SHIELDS CL, 1995, OPHTHALMOLOGY, V102, P1351, DOI 10.1016/S0161-6420(95)30864-0
   Singh AD, 2005, OPHTHALMOLOGY, V112, P1784, DOI 10.1016/j.ophtha.2005.06.011
   Stang A, 2003, OPHTHAL EPIDEMIOL, V10, P293, DOI 10.1076/opep.10.5.293.17319
   Sumich P, 1998, ARCH OPHTHALMOL-CHIC, V116, P645, DOI 10.1001/archopht.116.5.645
   Swenor BK, 2013, JAMA INTERN MED, V173, P312, DOI 10.1001/jamainternmed.2013.1880
   Terry AL, 2010, OPHTHAL EPIDEMIOL, V17, P411, DOI 10.3109/09286586.2010.528575
   VANHEES CLM, 1994, J INVEST DERMATOL, V103, P202, DOI 10.1111/1523-1747.ep12392754
   Weis E, 2006, ARCH OPHTHALMOL-CHIC, V124, P54, DOI 10.1001/archopht.124.1.54
   WILDER H C, 1946, Mil Surg, V99, P459
   Willis JR, 2012, ARCH OPHTHALMOL-CHIC, V130, P329, DOI 10.1001/archopthalmol.2011.1773
   Zhang XZ, 2010, JAMA-J AM MED ASSOC, V304, P649, DOI 10.1001/jama.2010.1111
NR 46
TC 41
Z9 44
U1 1
U2 11
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD OCT
PY 2015
VL 122
IS 10
BP 2071
EP 2083
DI 10.1016/j.ophtha.2015.06.008
PG 13
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA CU4IP
UT WOS:000363491500024
PM 26255109
DA 2022-11-30
ER

PT J
AU Virgili, G
   Acosta, R
AF Virgili, G.
   Acosta, R.
TI Reading aids for adults with low vision
SO COCHRANE DATABASE OF SYSTEMATIC REVIEWS
LA English
DT Review
ID CLOSED-CIRCUIT TELEVISION; MACULAR DEGENERATION; VISUAL IMPAIRMENT;
   PERFORMANCE; REHABILITATION; PEOPLE; IMPACT; INTERFACE; DEVICES; FILTERS
AB Background The purpose of low vision rehabilitation is to allow people to resume or to continue to perform daily living tasks, reading being one of the most important. This is achieved by providing appropriate optical devices and special training in the use of residual vision and low vision aids, which range from simple optical magnifiers to high power video magnifiers.
   Objectives The objective of this review was to assess the effects of reading aids for adults with low vision.
   Search strategy We searched the Cochrane Central Register of Controlled Trials (CENTRAL) (which contains the Cochrane Eyes and Vision Group Trials Register) in The Cochrane Library, MEDLINE, EMBASE, SIGLE, LILACS, IndMed to July 2006 and the reference lists of relevant articles. We used the Science Citation Index to find articles that cited the included studies and contacted investigators and manufacturers of low vision aids. We handsearched the British Journal of Visual Impairment from 1983 to 1999 and the Journal of Visual Impairment and Blindness from 1976 to 1991.
   Selection criteria This review included randomised and quasi-randomised trials in which any device or aid used for reading had been compared to another device or aid in people aged 16 or over with low vision as defined by the study investigators.
   Data collection and analysis Each author independently assessed trial quality and extracted data.
   Main results Eight small studies with a cross-over design (221 people overall) and one three parallel-arm study (243 participants) were included in the review.
   The cross-over studies evaluated various types of aids. The quality of the studies was unclear in most cases, especially concerning carryover or period effects. In one study on 20 participants head-mounted electronic devices (four types) were worse than optical devices. We could not find any differences in comparisons among electronic devices when pooling 23 participants of two small studies. One study on 10 people found that overlay coloured filters were no better than a clear filter.
   A parallel-arm study including 243 patients with age-related macular degeneration found that custom or standard prism spectacles are not different from conventional near spectacles, but the estimated difference was not precise.
   Authors' conclusions Further research is needed on the comparison of different types of low vision aids. It will be also necessary to delineate patient's characteristics that predict performance with costly electronic devices as well as their sustained use in the long term compared to simpler and cheaper optical devices.
C1 Univ Florence, Dept Otoneuroophthalmol Surg Sci, Eye Clin 2, I-50134 Florence, Italy.
C3 University of Florence
RP Virgili, G (通讯作者)，Univ Florence, Dept Otoneuroophthalmol Surg Sci, Eye Clin 2, Via Morgagni 85, I-50134 Florence, Italy.
EM gianni.virgili@unifi.it
RI Virgili, Gianni/P-6607-2014
OI Virgili, Gianni/0000-0002-9960-2989
CR ALDERSON P, 2002, COCHRANE COLLABORATI
   BLASKEY P, 1990, J LEARN DISABIL, V23, P604, DOI 10.1177/002221949002301007
   Cheong AMY, 2005, OPTOMETRY VISION SCI, V82, P114, DOI 10.1097/01.OPX.0000153244.93582.FF
   COHEN JM, 1991, OPTOMETRY VISION SCI, V68, P795, DOI 10.1097/00006324-199110000-00007
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Congdon NG, 2003, JAMA-J AM MED ASSOC, V290, P2057, DOI 10.1001/jama.290.15.2057
   Culham LE, 2004, OPHTHAL PHYSL OPT, V24, P281, DOI 10.1111/j.1475-1313.2004.00193.x
   DEEKS JJ, 2005, COCHRANE HDB SYSTEMA
   Dickinson, 1998, LOW VISION PRINCIPLE
   Elbourne DR, 2002, INT J EPIDEMIOL, V31, P140, DOI 10.1093/ije/31.1.140
   Eperjesi F, 2004, ACTA OPHTHALMOL SCAN, V82, P695, DOI 10.1111/j.1600-0420.2004.00371.x
   Goodrich G L, 2001, Optometry, V72, P519
   GOODRICH GL, 1977, AM J OPTOM PHYS OPT, V54, P312
   Goodrich GL, 2004, J VISUAL IMPAIRMENT, V98, P148
   HIGGINS JPT, 2005, COCHRANE HDB SYSTEMA
   HUMPHRY RC, 1986, T OPHTHAL SOC UK, V105, P296
   JACOBS RJ, 1990, J VISUAL IMPAIR BLIN, V84, P569
   Kleweno CP, 2001, J REHABIL RES DEV, V38, P431
   LAWTON TB, 1989, OPHTHALMOLOGY, V96, P115
   LEAT SJ, 1994, OPTOMETRY VISION SCI, V71, P199, DOI 10.1097/00006324-199403000-00009
   LEGGE GE, 1991, OPTOMETRY VISION SCI, V68, P763, DOI 10.1097/00006324-199110000-00001
   LEGGE GE, 1989, CLIN VISION SCI, V4, P51
   Margrain TH, 1999, BRIT MED J, V318, P1504, DOI 10.1136/bmj.318.7197.1504
   Margrain TH, 2000, BRIT J OPHTHALMOL, V84, P919, DOI 10.1136/bjo.84.8.919
   Massof RW, 1998, OPTOMETRY VISION SCI, V75, P349, DOI 10.1097/00006324-199805000-00025
   NILSSON UL, 1990, CLIN VISION SCI, V6, P3
   Ortiz A, 1999, OPTOMETRY VISION SCI, V76, P755, DOI 10.1097/00006324-199911000-00024
   Peterson RC, 2003, AM J OPHTHALMOL, V136, P1129, DOI 10.1016/S0002-9394(03)00567-1
   Putt ME, 2002, CONTROL CLIN TRIALS, V23, P111, DOI 10.1016/S0197-2456(01)00207-0
   Reeves BC, 2004, BRIT J OPHTHALMOL, V88, P1443, DOI 10.1136/bjo.2003.037457
   Rohrschneider K, 1998, OPHTHALMOLOGE, V95, P110, DOI 10.1007/s003470050246
   Scott IU, 1999, AM J OPHTHALMOL, V128, P54, DOI 10.1016/S0002-9394(99)00108-7
   Scott IU, 2002, AM J OPHTHALMOL, V134, P857, DOI 10.1016/S0002-9394(02)01795-6
   SHUTTLEWORTH GN, 1995, BRIT J OPHTHALMOL, V79, P719, DOI 10.1136/bjo.79.8.719
   Sloan L L, 1971, Int Ophthalmol Clin, V11, P19
   SMITH HJ, 1950, ARCH OPHTHALMOL-CHIC, V123, P1042
   Spitzberg L A, 1995, J Am Optom Assoc, V66, P25
   Stelmack J, 1991, J Am Optom Assoc, V62, P53
   TIELSCH JM, 1990, ARCH OPHTHALMOL-CHIC, V108, P286, DOI 10.1001/archopht.1990.01070040138048
   VIRTANEN P, 1991, ACTA OPHTHALMOL, V69, P484
   *WHO, 1997, BLINDN VIS DIS FACT
NR 41
TC 16
Z9 17
U1 0
U2 8
PU JOHN WILEY & SONS LTD
PI CHICHESTER
PA THE ATRIUM, SOUTHERN GATE, CHICHESTER PO19 8SQ, W SUSSEX, ENGLAND
SN 1469-493X
J9 COCHRANE DB SYST REV
JI Cochrane Database Syst Rev.
PY 2006
IS 4
AR CD003303
DI 10.1002/14651858.CD003303.pub2
PG 30
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA 096OF
UT WOS:000241386000014
OA Green Published, Green Accepted
DA 2022-11-30
ER

PT J
AU Sevik, MO
   Aykut, A
   Ozkan, G
   Dericioglu, V
   Sahin, O
AF Sevik, Mehmet Orkun
   Aykut, Aslan
   Ozkan, Gamze
   Dericioglu, Volkan
   Sahin, Ozlem
TI The effect of COVID-19 pandemic restrictions on neovascular AMD patients
   treated with treat-and-extend protocol
SO INTERNATIONAL OPHTHALMOLOGY
LA English
DT Article
DE Coronavirus disease-2019; COVID-19; Neovascular age-related macular
   degeneration; nAMD; Treat-and-extend protocol
ID VISUAL-ACUITY; MANAGEMENT
AB Purpose To investigate the adherence rate of neovascular age-related macular degeneration (nAMD) patients in treat-and-extend (TAE) protocol to their anti-vascular endothelial growth factor (anti-VEGF) intravitreal injection (IVI) appointments and to evaluate the functional and anatomical outcomes of the patients who attended and did not attend their IVI appointments during the coronavirus disease 2019 (COVID-19) restriction period (RP). Methods The patients with nAMD having IVI appointments between March 16 and June 1, 2020 (RP in Turkey) were included in this retrospective study. For adherence analysis, the patients who attended (Group 1, n = 44) and who did not attend (Group 2, n = 60) their IVI appointment visits during the RP (V-RP) were evaluated according to their last visit before the RP (V-0). For outcome analysis, the patients who attend V-RP and have follow-up (Group 1a, 46 eyes) and who did not attend V-RP but later attended for follow-up (Group 2a, 33 eyes) were evaluated for functional (best-corrected visual acuity, BCVA [logMAR]) and anatomical (optical coherence tomography [OCT] disease activity) outcomes at the first visit after RP (V-1) and last visit within six months after RP (V-2). Patients received a complete ophthalmologic evaluation with anti-VEGF (Aflibercept) IVI administration at all visits. Results The adherence rate of the patients to V-RP was 42.3% (44/104). The patients in Group 1 were significantly younger (mean +/- SD years, 71.0 +/- 8.1 vs. 74.7 +/- 8.0, p = 0.024), had better median [IQR] BCVA at their first presentation (0.30 [0.54] vs. 0.61 [1.08], p = 0.023) and V-0 (0.40 [0.48] vs. 0.52 [0.70], p = 0.031), and had less hypertension (36.4% vs. 58.3%, p = 0.044) than Group 2. The mean +/- SD delay of planned IVI at V-RP in Group 2a was 13.9 +/- 6.2 weeks. Disease activity in OCT was significantly higher in Group 2a than Group 1a at V-1 (60.6% vs. 32.6%, p = 0.025). In Group 2a, the median (IQR) BCVA was significantly worse at V-1 (0.70 [0.58]) and V-2 (0.70 [0.59]) than V-0 (0.52 [0.40], p = 0.047 and p = 0.035, respectively). Conclusions More than half of the scheduled nAMD patients in TAE protocol missed their IVI visits during the RP, which resulted in a delay of their treatments. The delay of IVI treatment in those patients resulted in an increase in OCT disease activity and a decrease in BCVA.
C1 [Sevik, Mehmet Orkun; Aykut, Aslan; Ozkan, Gamze; Dericioglu, Volkan; Sahin, Ozlem] Marmara Univ, Sch Med, Dept Ophthalmol, Pendik Egitim & Arastirma Hastanesi,Oftalmol Serv, Muhsin Yazicioglu Cd 10,Kat 3, TR-34899 Istanbul, Turkey.
C3 Marmara University
RP Sevik, MO (通讯作者)，Marmara Univ, Sch Med, Dept Ophthalmol, Pendik Egitim & Arastirma Hastanesi,Oftalmol Serv, Muhsin Yazicioglu Cd 10,Kat 3, TR-34899 Istanbul, Turkey.
EM m.orkunsevik@gmail.com
RI Dericioğlu, Volkan/B-8795-2019
OI SEVIK, Mehmet Orkun/0000-0001-7130-4798; Ozkan,
   Gamze/0000-0002-5526-691X; DERICIOGLU, VOLKAN/0000-0001-6264-5304
CR American Academy of Ophthalmology, NEW RECOMMENDATIONS
   American Society of Retina Specialists, COVID 19 UPDATES RES
   [Anonymous], Turk Oftalmoloji Dernegi (2020) Pandemi Nedeni ile Acil Kabul Edilen Goz Ameliyatlari
   Antaki F, 2020, GRAEF ARCH CLIN EXP, V258, P1567, DOI 10.1007/s00417-020-04693-w
   Borrelli E, 2020, GRAEF ARCH CLIN EXP, V258, P2621, DOI 10.1007/s00417-020-04955-7
   Borrelli E, 2020, GRAEF ARCH CLIN EXP, V258, P2655, DOI 10.1007/s00417-020-04858-7
   Bourne RRA, 2013, LANCET GLOB HEALTH, V1, pE339, DOI 10.1016/S2214-109X(13)70113-X
   Campos A, 2020, CLIN OPHTHALMOL, V14, P2625, DOI 10.2147/OPTH.S267427
   Corazza P, 2020, INT J RETINA VITR, V6, DOI 10.1186/s40942-020-00226-z
   Corradetti G, 2020, OPHTHALMOL RETINA, V4, P757, DOI 10.1016/j.oret.2020.05.015
   Fang L, 2020, LANCET RESP MED, V8, pE21, DOI 10.1016/S2213-2600(20)30116-8
   Freund KB, 2015, RETINA-J RET VIT DIS, V35, P1489, DOI 10.1097/IAE.0000000000000627
   Fung THM, 2021, ACTA OPHTHALMOL, V99, pE285, DOI 10.1111/aos.14520
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Holladay JT, 1997, J REFRACT SURG, V13, P388
   Holz FG, 2016, BRIT J OPHTHALMOL, V100, P1623, DOI 10.1136/bjophthalmol-2015-308166
   Huang C., 2022, BIOL TRACE ELEM RES, DOI [DOI 10.1007/S12011-021-03084, DOI 10.1103/PHYSREVB.105.174502]
   Icisleri Bakanligi TC, 81 L VALILI INE CORO
   Iovino C, 2020, GRAEF ARCH CLIN EXP, V258, P2869, DOI 10.1007/s00417-020-04800-x
   Korobelnik JF, 2020, GRAEF ARCH CLIN EXP, V258, P1149, DOI 10.1007/s00417-020-04703-x
   Korobelnik JF, 2020, GRAEF ARCH CLIN EXP, V258, P1335, DOI 10.1007/s00417-020-04697-6
   Massamba N, 2015, EYE, V29, P1453, DOI 10.1038/eye.2015.128
   Mintz J, 2022, J TELEMED TELECARE, V28, P670, DOI 10.1177/1357633X20960636
   Mitchell P, 2018, LANCET, V392, P1147, DOI 10.1016/S0140-6736(18)31550-2
   Parravano M, 2020, OPHTHALMOL THER, V9, P231, DOI 10.1007/s40123-020-00251-z
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Sacconi R, 2021, EUR J OPHTHALMOL, V31, P849, DOI 10.1177/1120672120963448
   Schiffrin EL, 2020, AM J HYPERTENS, V33, P373, DOI 10.1093/ajh/hpaa057
   Schulze-Bonsel K, 2006, INVEST OPHTH VIS SCI, V47, P1236, DOI 10.1167/iovs.05-0981
   Solomon SD, 2019, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005139.pub4
   Spaide RF, 2020, OPHTHALMOLOGY, V127, P616, DOI 10.1016/j.ophtha.2019.11.004
   Teo KYC, 2021, EYE, V35, P2793, DOI 10.1038/s41433-020-01315-x
   The Royal College of Ophthalmologists, RCOPHTH MANAGEMENT O
   Toro MD, 2021, EUR J OPHTHALMOL, V31, P5, DOI 10.1177/1120672120960339
   Wasser Lauren M, 2020, SN Compr Clin Med, V2, P2546, DOI 10.1007/s42399-020-00614-4
   Wecker T, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-38934-8
   World Health Organization, 2021, WHO DIR GEN OP REM M
NR 37
TC 7
Z9 7
U1 0
U2 2
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0165-5701
EI 1573-2630
J9 INT OPHTHALMOL
JI Int. Ophthalmol.
PD SEP
PY 2021
VL 41
IS 9
BP 2951
EP 2961
DI 10.1007/s10792-021-01854-6
EA APR 2021
PG 11
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA UB2DC
UT WOS:000640858300001
PM 33864577
OA Bronze, Green Published
DA 2022-11-30
ER

PT J
AU Angkawinitwong, U
   Awwad, S
   Khaw, PT
   Brocchini, S
   Williams, GR
AF Angkawinitwong, Ukrit
   Awwad, Sahar
   Khaw, Peng T.
   Brocchini, Steve
   Williams, Gareth R.
TI Electrospun formulations of bevacizumab for sustained release in the eye
SO ACTA BIOMATERIALIA
LA English
DT Article
DE Coaxial electrospinning; Bevacizumab; Controlled release system;
   Core-shell fibers; Anti-VEGF; Poly-e-caprolactone
ID ENDOTHELIAL GROWTH-FACTOR; DRUG-DELIVERY; VITREOUS LEVELS;
   PHARMACOKINETICS; NANOFIBERS; SCAFFOLD; INJECTION; KINETICS; PLGA
AB Medicines based on vascular endothelial growth factor (VEGF) neutralising antibodies such as bevacizumab have revolutionized the treatment of age related macular degeneration (AMD), a common blinding disease, and have great potential in preventing scarring after surgery or accelerating the healing of corneal injuries. However, at present frequent invasive injections are required to deliver these antibodies. Such administration is uncomfortable for patients and expensive for health service providers. Much effort is thus focused on developing dosage forms that can be administered less frequently. Here we use electrospinning to prepare a solid form of bevacizumab designed for prolonged release while maintaining antibody stability. Electrospun fibers were prepared with bevacizumab encapsulated in the core, surrounded by a poly-epsilon-caprolactone sheath. The fibers were generated using aqueous bevacizumab solutions buffered at two different pH values: 6.2 (the pH of the commercial product; F-beva) and 8.3 (the isoelectric point of bevacizumab; F-bevap). The fibers had smooth and cylindrical morphologies, with diameters of ca. 500 nm. Both sets of bevacizumab loaded fibers gave sustained release profiles in an in vitro model of the subconjunctival space of the eye. F-beva displayed first order kinetics with tip of 11.4 +/- 4.4 days, while Fbevap comprises a zero-order reservoir type release system with tip of 52.9 +/- 14.8 days. Both SDS-PAGE and surface plasmon resonance demonstrate that the bevacizumab in F-bevap did not undergo degradation during fiber fabrication or release. In contrast, the antibody released from Fbeva had degraded, and failed to bind to VEGF. Our results demonstrate that pH control is crucial to maintain antibody stability during the fabrication of core/shell fibers and ensure release of functional protein.
   Statement of Significance
   Bevacizumab is a potent protein drug which is highly effective in the treatment of degenerative conditions in the eye. To be effective, frequent injections into the eye are required, which is deeply unpleasant for patients and expensive for healthcare providers. Alternative methods of administration are thus highly sought after. In our work, we use the electrospinning technique to prepare fiber-based formulations loaded with bevacizumab. By careful control of the experimental parameters we are able to stabilize the protein during processing and ensure a constant rate of release over more than two months in vitro. These fibers could thus be used to reduce the frequency of dosing required, reducing cost and improving patient outcomes. (C) 2017 Acta Materialia Inc. Published by Elsevier Ltd. All rights reserved.
C1 [Angkawinitwong, Ukrit; Awwad, Sahar; Brocchini, Steve; Williams, Gareth R.] UCL, UCL Sch Pharm, 29-39 Brunswick Sq, London WC1N 1AX, England.
   [Awwad, Sahar; Khaw, Peng T.; Brocchini, Steve] Moorfields Eye Hosp, NIHR Biomed Res Ctr, London EC1V 9EL, England.
   [Awwad, Sahar; Khaw, Peng T.; Brocchini, Steve] UCL, UCL Inst Ophthalmol, 11-43 Bath St, London EC1V 9EL, England.
C3 University of London; University College London; University of London;
   University College London; Moorfields Eye Hospital NHS Foundation Trust;
   University of London; University College London
RP Williams, GR (通讯作者)，UCL, UCL Sch Pharm, 29-39 Brunswick Sq, London WC1N 1AX, England.
EM g.williams@ucl.ac.uk
RI Williams, Gareth/A-5980-2013
OI Williams, Gareth/0000-0002-3066-2860; Awwad, Sahar/0000-0002-4430-2508;
   Khaw, Sir Peng Tee/0000-0002-8087-2268
FU UCL Overseas Research Student Fund; National Institute of Health
   Research (NIHR) Biomedical Research Centre at Moorfields Eye Hospital
   NHS Foundation Trust and UCL Institute of Ophthalmology; Moorfields
   Special Trustees; Helen Hamlyn Trust (in memory of Paul Hamlyn); Medical
   Research Council; Fight for Sight; Freemasons Grand Charity; National
   Institute for Health Research [NF-SI-0512-10101] Funding Source:
   researchfish
FX We thank David McCarthy and Kate Keen for SEM and TEM images, Dr. Asma
   Buanz for assistance with TGA experiments, and Mr John Frost for all his
   help to fabricating the rig models. S. A. gratefully acknowledges
   funding from the UCL Overseas Research Student Fund. We are further
   grateful for funding from: the National Institute of Health Research
   (NIHR) Biomedical Research Centre at Moorfields Eye Hospital NHS
   Foundation Trust and UCL Institute of Ophthalmology; Moorfields Special
   Trustees; the Helen Hamlyn Trust (in memory of Paul Hamlyn); the Medical
   Research Council; Fight for Sight; and, the Freemasons Grand Charity.
CR Awwad S, 2015, J PHARM SCI-US, V104, P3330, DOI 10.1002/jps.24480
   Beer PM, 2006, RETINA-J RET VIT DIS, V26, P871, DOI 10.1097/01.iae.0000233327.68433.02
   Bilati U, 2005, EUR J PHARM BIOPHARM, V59, P375, DOI 10.1016/j.ejpb.2004.10.006
   Brubaker R F, 1982, Trans Am Ophthalmol Soc, V80, P391
   Centola M, 2013, TISSUE ENG PT A, V19, P1960, DOI [10.1089/ten.tea.2012.0455, 10.1089/ten.TEA.2012.0455]
   Dash S, 2010, ACTA POL PHARM, V67, P217
   Fu Y, 2010, EXPERT OPIN DRUG DEL, V7, P429, DOI 10.1517/17425241003602259
   Gandhi M, 2009, MOL PHARMACEUT, V6, P641, DOI 10.1021/mp800160p
   Gast K, 1999, PROTEIN SCI, V8, P625
   Genentech, 2004, AV R BEV
   Greiner A, 2007, ANGEW CHEM INT EDIT, V46, P5670, DOI 10.1002/anie.200604646
   Haroosh HJ, 2014, J MATER SCI, V49, P6270, DOI 10.1007/s10853-014-8352-7
   Jager RD, 2004, RETINA-J RET VIT DIS, V24, P676, DOI 10.1097/00006982-200410000-00002
   Ji W, 2010, ACTA BIOMATER, V6, P4199, DOI 10.1016/j.actbio.2010.05.025
   Jiang HL, 2005, J CONTROL RELEASE, V108, P237, DOI 10.1016/j.jconrel.2005.08.006
   Kaja Simon, 2011, Human Antibodies, V20, P95, DOI 10.3233/HAB-2011-0244
   Khalili H., 2012, THESIS
   Khaw P., 2010, US patent, Patent No. 9186414
   Kim YC, 2014, J CONTROL RELEASE, V190, P172, DOI 10.1016/j.jconrel.2014.06.043
   Krohne T.U., 2016, PHARMACOKINETICS INT, P139, DOI [10.1007/978-3-319-24097-8_8, DOI 10.1007/978-3-319-24097-8_8]
   Kutlu C, 2014, J MICROENCAPSUL, V31, P700, DOI 10.3109/02652048.2014.913727
   Li FF, 2012, OPEN OPHTHALMOL J, V6, P54, DOI 10.2174/1874364101206010054
   Li ZQ, 2009, INVEST OPHTH VIS SCI, V50, P5217, DOI 10.1167/iovs.08-2662
   Luo CJ, 2014, MACROMOLECULES, V47, P7930, DOI 10.1021/ma5016616
   Luu YK, 2003, J CONTROL RELEASE, V89, P341, DOI 10.1016/S0168-3659(03)00097-X
   Meyer CH, 2011, RETINA-J RET VIT DIS, V31, P1877, DOI 10.1097/IAE.0b013e318217373c
   Moisseiev E, 2014, GRAEF ARCH CLIN EXP, V252, P331, DOI 10.1007/s00417-013-2495-0
   Patel Ashaben, 2013, World J Pharmacol, V2, P47
   RITGER P L, 1987, Journal of Controlled Release, V5, P23, DOI 10.1016/0168-3659(87)90034-4
   Siegel RA, 2012, ADV DEL SCI TECHNOL, P19, DOI 10.1007/978-1-4614-0881-9_2
   Siepmann J, 2008, INT J PHARMACEUT, V364, P328, DOI 10.1016/j.ijpharm.2008.09.004
   Solomon SD, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005139.pub3
   Sousa F, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-03959-4
   Sridhar R, 2015, CHEM SOC REV, V44, P790, DOI 10.1039/c4cs00226a
   Srikar R, 2008, LANGMUIR, V24, P965, DOI 10.1021/la702449k
   Sun XY, 2008, MACROMOL RAPID COMM, V29, P1455, DOI 10.1002/marc.200800163
   TA Instruments, DISC TGA US MAN
   Tang C, 2012, BIOMACROMOLECULES, V13, P1269, DOI 10.1021/bm2017146
   Toris CB, 1999, AM J OPHTHALMOL, V127, P407, DOI 10.1016/S0002-9394(98)00436-X
   Urtti A, 2006, ADV DRUG DELIVER REV, V58, P1131, DOI 10.1016/j.addr.2006.07.027
   Vlasak J, 2011, MABS-AUSTIN, V3, P253, DOI 10.4161/mabs.3.3.15608
   Vlckova M, 2008, J CHROMATOGR A, V1181, P145, DOI 10.1016/j.chroma.2007.12.046
   Wang CH, 2012, BIOMACROMOLECULES, V13, P40, DOI 10.1021/bm2009558
   Williams GR, 2012, THER DELIV, V3, P515, DOI 10.4155/tde.12.17
   Woodruff MA, 2010, PROG POLYM SCI, V35, P1217, DOI 10.1016/j.progpolymsci.2010.04.002
   Yarin A.L., 2014, FUNDAMENTALS APPL MI, P179
   Yu Y, 2015, TRANSL VIS SCI TECHN, V4, DOI 10.1167/tvst.4.2.5
   Zhang H, 2010, SCI CHINA CHEM, V53, P1246, DOI 10.1007/s11426-010-3180-3
   Zhu Q, 2008, OPHTHALMOLOGY, V115, P1750, DOI 10.1016/j.ophtha.2008.04.023
NR 49
TC 41
Z9 41
U1 2
U2 46
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1742-7061
EI 1878-7568
J9 ACTA BIOMATER
JI Acta Biomater.
PD DEC
PY 2017
VL 64
BP 126
EP 136
DI 10.1016/j.actbio.2017.10.015
PG 11
WC Engineering, Biomedical; Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Engineering; Materials Science
GA FO1DZ
UT WOS:000416498200012
PM 29030303
OA Green Submitted
DA 2022-11-30
ER

PT J
AU Tuulonen, A
   Salminen, H
   Linna, M
   Perkola, M
AF Tuulonen, Anja
   Salminen, Hannu
   Linna, Miika
   Perkola, Markku
TI The need and total cost of Finnish eyecare services: a simulation model
   for 2005-2040
SO ACTA OPHTHALMOLOGICA
LA English
DT Article
DE access to care; costs; healthcare resources; prioritization; supply;
   system dynamics
ID VISUAL IMPAIRMENT; ECONOMIC BURDEN; GLAUCOMA; MORTALITY; IMPACT
AB Purpose:
   The aims of this study were: (i) to create a structural simulation model capable of predicting the future need and cost of eyecare services in Finland; and (ii) to test and rank different policy alternatives for access to care and the required physician workforce.
   Methods:
   Using the system dynamics approach, the number and cost of patients with cataract, glaucoma, diabetic retinopathy and age-related macular degeneration (AMD) were described with causal-loop diagrams and were then translated into a set of mathematical equations to build a computer simulation model. Mathematically, the problem was formulated as a set of differential equations that were solved numerically with specialized software. The validity of the model was tested against prevalence and administrative historical data. The costs covered by the public sector in Finland were obtained from 2003 from the Finnish Hospital Discharge Register (including outpatient care), the Finnish Social Insurance Institution and a survey of hospital price lists. Different levels of access to public care were then simulated in four eye diseases, for which the model estimated the need for services and resources and their costs in the years 2005-2040.
   Results:
   The model forecasted that the adoption of the 2005 national 'access to care' criteria for cataract surgery would shorten waiting lists. If the workload of Finnish ophthalmologists were kept at the 2003 level, the graduation rate of new ophthalmologists would have to increase by 75% from the current level. If all glaucoma patients were followed in the public sector in future, even this increase in training would not meet the demand for physician workforce. The current model indicated that the screening frequency of diabetes can be increased without large sacrifices in terms of costs. AMD therapy has a significant role in the allocation of future resources in eyecare. The modelling study predicted that ageing alone will increase the costs of eyecare during the next four decades in Finland by about 1% per year in real terms (undiscounted and without inflation of unit costs). The increases in total yearly costs were on average 8.6% between 2001 and 2003.
   Conclusions:
   The results of this modelling study indicate that policy initiatives, such as defining criteria for access to care, can have substantial implications on the demand for care and waiting times whereas the effect of ageing alone was relatively small. Measures to control several other factors - such as the adoption and price level of new technologies, treatments and practice patterns - will be at least equally important in order to restrain healthcare costs effectively.
C1 [Tuulonen, Anja] Univ Oulu, Dept Ophthalmol, FI-90014 Oulu, Finland.
   [Salminen, Hannu; Perkola, Markku] Syst Thinking Europe Inc, Espoo, Finland.
   [Linna, Miika] CHESS, Helsinki, Finland.
C3 University of Oulu
RP Tuulonen, A (通讯作者)，Univ Oulu, Dept Ophthalmol, POB 5000, FI-90014 Oulu, Finland.
EM anja.tuulonen@pshp.fi
RI Salminen, Hannu/GLT-0498-2022; Salminen, Hannu M/P-2321-2015
OI Salminen, Hannu M/0000-0002-6019-8165
FU Academy of Finland; Juselius Foundation
FX This study was funded by the TER-TTU programme of the Academy of Finland
   and the Juselius Foundation.
CR Bojke L, 2008, MED DECIS MAKING, V28, P33, DOI 10.1177/0272989X07309638
   BROMMELS M, 2004, 200333 MIN SOC AFF H
   COLQUITT JL, 2006, RANIBIZUMAB BEVACIZU
   COYLE D, 1995, PHARMACOECONOMICS, V7, P484, DOI 10.2165/00019053-199507060-00003
   European Glaucoma Society, 2020, TERM GUID GLAUC
   EVANS RG, 1985, J HEALTH POLIT POLIC, V10, P439, DOI 10.1215/03616878-10-3-439
   Falck A, 2008, ACTA OPHTHALMOL, V86, P648, DOI 10.1111/j.1600-0420.2007.01118.x
   FORRESTER JW, 1995, MCKINSEY Q, V4, P6
   Frick KD, 2007, ARCH OPHTHALMOL-CHIC, V125, P544, DOI 10.1001/archopht.125.4.544
   GETZEN TE, 1992, J GERONTOL, V47, pS98, DOI 10.1093/geronj/47.3.S98
   Grodum K, 2002, ACTA OPHTHALMOL SCAN, V80, P627, DOI 10.1034/j.1600-0420.2002.800613.x
   HEALEY P, 2008, 5 WORLD GLAUC ASS CO, P40
   HIRVELA H, 1995, ACTA U OULUENSIS D, V327, pS86
   ISOLAURI J, 2000, 21 MIN SOC AFF HLTH
   Kobelt G, 2002, J GLAUCOMA, V11, P531, DOI 10.1097/00061198-200212000-00015
   Koskinen SVP, 1998, AM J PUBLIC HEALTH, V88, P765, DOI 10.2105/AJPH.88.5.765
   Ministry of Social Affairs and Health, 2005, HDB MIN SOC AFF HLTH, V6
   Morley AMS, 2006, BRIT J OPHTHALMOL, V90, P640, DOI 10.1136/bjo.2005.085522
   MUIR GJA, 2001, EVIDENCE BASED HLTH
   Mukesh BN, 2002, OPHTHALMOLOGY, V109, P1047, DOI 10.1016/S0161-6420(02)01040-0
   NEWHOUSE JP, 1992, J ECON PERSPECT, V6, P3, DOI 10.1257/jep.6.3.3
   PAJUNPAA H, 1999, ACTA U OULUENSIS MED, V522, pS115
   PALOSAARI T, 2008, FINNISH MED J, V24, P2229
   PUNNONEN H, 2000, STAT HOSP
   Raftery J, 2007, BRIT J OPHTHALMOL, V91, P1244, DOI 10.1136/bjo.2007.116616
   Rajala U, 2001, J CLIN EPIDEMIOL, V54, P470, DOI 10.1016/S0895-4356(00)00324-3
   Rein DB, 2006, ARCH OPHTHALMOL-CHIC, V124, P1754, DOI 10.1001/archopht.124.12.1754
   *SBU HLTH TECHN AS, 2008, RAN TREAT AG REL MAC
   Sterman J., 2010, BUSINESS DYNAMICS
   Sterman JD, 2002, SYST DYNAM REV, V18, P501, DOI 10.1002/sdr.261
   Taylor HR, 2006, BRIT J OPHTHALMOL, V90, P272, DOI 10.1136/bjo.2005.080986
   Tuulonen A, 2005, ACTA OPHTHALMOL SCAN, V83, P611, DOI 10.1111/j.1600-0420.2005.00530.x
   Tuulonen A, 2003, ACTA OPHTHALMOL SCAN, V81, P3, DOI 10.1034/j.1600-0420.2003.00021.x
   Tuulonen A, 1999, J GLAUCOMA, V8, P367
   TUULONEN A, 2008, FINNISH MED J, V24, P2219
   TUULONEN A, 2003, FINNISH MED J, V58, P2657
   Tuulonen A, 2006, ESSENT OPHTHALMOL, P123
   Vaahtoranta-Lehtonen H, 2007, ACTA OPHTHALMOL SCAN, V85, P508, DOI 10.1111/j.1600-0420.2007.00947.x
   Williams A, 1993, Health Econ, V2, P295, DOI 10.1002/hec.4730020402
NR 39
TC 25
Z9 25
U1 0
U2 10
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1755-375X
EI 1755-3768
J9 ACTA OPHTHALMOL
JI Acta Ophthalmol.
PD DEC
PY 2009
VL 87
IS 8
BP 820
EP 829
DI 10.1111/j.1755-3768.2009.01532.x
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Ophthalmology
GA 524RQ
UT WOS:000272161000003
PM 19740130
OA Bronze
DA 2022-11-30
ER

PT J
AU Burke, JM
AF Burke, Janice M.
TI Epithelial phenotype and the RPE: Is the answer blowing in the Wnt?
SO PROGRESS IN RETINAL AND EYE RESEARCH
LA English
DT Review
ID RETINAL-PIGMENT EPITHELIUM; ADHESION MOLECULE UVOMORULIN;
   GLYCOGEN-SYNTHASE KINASE-3; CADHERIN-CATENIN COMPLEXES; CELL-SURFACE
   DISTRIBUTION; TRANSCRIPTION FACTOR MITF; FRIZZLED-RELATED PROTEIN;
   ENDOGENOUS N-CADHERIN; NECTIN-LIKE MOLECULES; FACTOR-H POLYMORPHISM
AB Cells of the human retinal pigment epithelium (RPE) have a regular epithelial cell shape within the tissue in situ, but for reasons that remain elusive the RPE shows an incomplete and variable ability to re-develop an epithelial phenotype after propagation in vitro. In other epithelial cell cultures, formation of an adherens junction (AJ) composed of E-cadherin plays an important early inductive role in epithelial morphogenesis, but E-cadherin is largely absent from the RPE. In this review, the contribution of cadherins, both minor (E-cadherin) and major (N-cadherin), to RPE phenotype development is discussed. Emphasis is placed on the importance for future Studies of actin cytoskeletal remodeling during assembly of the AJ, which in epithelial cells results in an actin organization that is characteristically zonular. Other markers of RPE phenotype that are used to gauge the maturation state of RPE cultures including tissue-specific protein expression, protein polarity, and pigmentation are described. An argument is made that RPE epithelial phenotype, cadherin-based cell-cell adhesion and melanization are linked by a common signaling pathway: the Wnt/(beta-catenin pathway. Analyzing this pathway and its intersecting signaling networks is suggested as a useful framework for dissecting the steps in RPE morphogenesis.
   Also discussed is the effect of aging on RPE phenotype. Preliminary evidence is provided to suggest that light-induced sub-lethal oxidative stress to cultured ARPE-19 cells impairs organelle motility. Organelle translocation, which is mediated by stress-susceptible cytoskeletal scaffolds, is an essential process in cell phenotype development and retention. The observation of impaired organelle motility therefore raises the possibility that low levels of stress, which are believed to accompany RPE aging, may produce subtle disruptions of cell phenotype. Over time these would be expected to diminish the support functions performed by the RPE on behalf of photoreceptors, theoretically contributing to aging retinal disease such as age-related macular degeneration (AMD). Analyzing sub-lethal stress that produces declines in RPE functional efficiency rather than overt cell death is suggested as a useful future direction for understanding the effects of age on RPE organization and physiology. As for phenotype and pigmentation, a role for the Wnt/(beta-catenin pathway is also suggested in regulating the RPE response to oxidative stress. Exploration of this pathway in the RPE therefore may provide a unifying strategy for advancing our understanding of both RPE phenotype and the consequences of mild oxidative stress on RPE structure and function. (C) 2008 Elsevier Ltd. All rights reserved
C1 Med Coll Wisconsin, Inst Eye, Dept Ophthalmol, Milwaukee, WI 53226 USA.
C3 Medical College of Wisconsin
RP Burke, JM (通讯作者)，Med Coll Wisconsin, Inst Eye, Dept Ophthalmol, 925 N 87th St, Milwaukee, WI 53226 USA.
EM jburke@mcw.edu
FU University of Arizona; NIH [R01 EY015284, R01 EY013722, P30 EY01931];
   Milwaukee area donors and foundations; NATIONAL EYE INSTITUTE
   [R01EY013722, R01EY015284, P30EY001931, R01EY010832] Funding Source: NIH
   RePORTER
FX The author thanks Dr. Brian McKay, University of Arizona, for his
   helpful suggestions on the manuscript and Dr. Mariusz Zareba for
   assistance with the studies of organelle motility and with preparation
   of the figures. Support for research from the author's laboratory was
   provided by NIH grants R01 EY015284, R01 EY013722 and P30 EY01931, by an
   unrestricted grant from Research to Prevent Blindness, Inc., and by
   Milwaukee area donors and foundations supporting macular degeneration
   research.
CR Abe T, 1996, EXP EYE RES, V63, P201, DOI 10.1006/exer.1996.0109
   Abe T, 1998, CURR EYE RES, V17, P1103, DOI 10.1076/ceyr.17.12.1103.5126
   Abul-Hassan K, 2000, PIGM CELL RES, V13, P436, DOI 10.1034/j.1600-0749.2000.130605.x
   Agrawal RN, 2007, NAT PROTOC, V2, P67, DOI 10.1038/nprot.2007.4
   Akeo K, 2002, PIGM CELL RES, V15, P341, DOI 10.1034/j.1600-0749.2002.02054.x
   Algvere PV, 2006, ACTA OPHTHALMOL SCAN, V84, P4, DOI 10.1111/j.1600-0420.2005.00627.x
   Alonso SR, 2007, CANCER RES, V67, P3450, DOI 10.1158/0008-5472.CAN-06-3481
   Andarawewa KL, 2007, CANCER RES, V67, P8662, DOI 10.1158/0008-5472.CAN-07-1294
   ANDERSON DH, 1990, INVEST OPHTH VIS SCI, V31, P81
   Apodaca G, 2001, TRAFFIC, V2, P149, DOI 10.1034/j.1600-0854.2001.020301.x
   Asaria Riaz H Y, 2006, Compr Ophthalmol Update, V7, P179
   Aslan M, 2003, J BIOL CHEM, V278, P4194, DOI 10.1074/jbc.M208916200
   Bailey TA, 2004, INVEST OPHTH VIS SCI, V45, P675, DOI 10.1167/iovs.03-0351
   Ballhausen WG, 2000, ANN NY ACAD SCI, V910, P36
   Banan A, 2004, AM J PHYSIOL-CELL PH, V287, pC1139, DOI 10.1152/ajpcell.00146.2004
   Banan A, 2003, J PHARMACOL EXP THER, V305, P482, DOI 10.1124/jpet.102.047308
   Banan A, 2001, AM J PHYSIOL-GASTR L, V280, pG1234, DOI 10.1152/ajpgi.2001.280.6.G1234
   Barral DC, 2004, PIGM CELL RES, V17, P111, DOI 10.1111/j.1600-0749.2004.00138.x
   Basuroy S, 2003, J BIOL CHEM, V278, P11916, DOI 10.1074/jbc.M211710200
   Bazan NG, 2008, ADV EXP MED BIOL, V613, P39
   Bharti K, 2006, PIGM CELL RES, V19, P380, DOI 10.1111/j.1600-0749.2006.00318.x
   Binder S, 2007, PROG RETIN EYE RES, V26, P516, DOI 10.1016/j.preteyeres.2007.02.002
   Bok D., 1982, STRUCTURE EYE, P247
   Boldogh IR, 2007, TRENDS CELL BIOL, V17, P502, DOI 10.1016/j.tcb.2007.07.008
   Bonilha VL, 2001, INVEST OPHTH VIS SCI, V42, P3274
   Boulton M, 2001, EYE, V15, P384, DOI 10.1038/eye.2001.141
   BOULTON M, 1998, RETINAL PIGMENT EPIT, P68
   Bowerman B, 2005, SCIENCE, V308, P1119, DOI 10.1126/science.1113356
   Burke JM, 2006, INVEST OPHTH VIS SCI, V47, P3635, DOI 10.1167/iovs.06-0104
   Burke JM, 2005, MOL INTERV, V5, P241, DOI 10.1124/mi.5.4.7
   Burke JM, 1999, INVEST OPHTH VIS SCI, V40, P2963
   Burke JM, 2000, INVEST OPHTH VIS SCI, V41, P1945
   Burke JM, 1996, EXP EYE RES, V62, P63, DOI 10.1006/exer.1996.0008
   BURKE JM, 1993, EXP EYE RES, V57, P51, DOI 10.1006/exer.1993.1098
   BURKE JM, 1998, RETINAL PIGMENT EPIT, P86
   Cai JY, 2000, PROG RETIN EYE RES, V19, P205, DOI 10.1016/S1350-9462(99)00009-9
   Calnan DR, 2008, ONCOGENE, V27, P2276, DOI 10.1038/onc.2008.21
   CAMPOCHIARO PA, 1993, EXP EYE RES, V57, P539, DOI 10.1006/exer.1993.1158
   Chancy CD, 2000, J BIOL CHEM, V275, P20676, DOI 10.1074/jbc.M002328200
   Chang JHT, 1999, HUM MOL GENET, V8, P575, DOI 10.1093/hmg/8.4.575
   Chen HJ, 2007, INVEST OPHTH VIS SCI, V48, P1832, DOI 10.1167/iovs.06-0928
   Chen XY, 2003, J CELL BIOL, V163, P547, DOI 10.1083/jcb.200305137
   Chen YT, 1999, J CELL BIOL, V144, P687, DOI 10.1083/jcb.144.4.687
   Clevers H, 2006, CELL, V127, P469, DOI 10.1016/j.cell.2006.10.018
   Coudrier E, 2007, PIGM CELL RES, V20, P153, DOI 10.1111/j.1600-0749.2007.00376.x
   Dalle-Donne I, 2002, FREE RADICAL BIO MED, V32, P927, DOI 10.1016/S0891-5849(02)00799-2
   Dalle-Donne I, 2001, FREE RADICAL BIO MED, V31, P1624, DOI 10.1016/S0891-5849(01)00749-3
   Dalle-Donne I, 2001, FREE RADICAL BIO MED, V31, P1075, DOI 10.1016/S0891-5849(01)00690-6
   Daugherty RL, 2007, PHYSIOLOGY, V22, P303, DOI 10.1152/physiol.00020.2007
   DAVIS AA, 1995, INVEST OPHTH VIS SCI, V36, P955
   Davis MA, 2003, J CELL BIOL, V163, P525, DOI 10.1083/jcb.200307111
   de Heredia ML, 2004, CURR OPIN CELL BIOL, V16, P80, DOI 10.1016/j.ceb.2003.11.002
   Decanini A, 2007, AM J OPHTHALMOL, V143, P607, DOI 10.1016/j.ajo.2006.12.006
   Del Priore LV, 2002, INVEST OPHTH VIS SCI, V43, P3312
   Deora AA, 2005, P NATL ACAD SCI USA, V102, P16245, DOI 10.1073/pnas.0504419102
   Deora AA, 2004, MOL BIOL CELL, V15, P4148, DOI 10.1091/mbc.E04-01-0058
   Doble BW, 2007, CELLS TISSUES ORGANS, V185, P73, DOI 10.1159/000101306
   DOREY CK, 1990, EXP EYE RES, V50, P1, DOI 10.1016/0014-4835(90)90003-D
   DOREY CK, 1989, INVEST OPHTH VIS SCI, V30, P1691
   Drees F, 2005, CELL, V123, P903, DOI 10.1016/j.cell.2005.09.021
   Dunaief JL, 2002, ARCH OPHTHALMOL-CHIC, V120, P1435, DOI 10.1001/archopht.120.11.1435
   Dunn KC, 1996, EXP EYE RES, V62, P155, DOI 10.1006/exer.1996.0020
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Essers MAG, 2005, SCIENCE, V308, P1181, DOI 10.1126/science.1109083
   Esumi N, 2007, J BIOL CHEM, V282, P1838, DOI 10.1074/jbc.M609517200
   FEENEY L, 1978, INVEST OPHTH VIS SCI, V17, P583
   FEENEYBURNS L, 1990, AM J OPHTHALMOL, V109, P265, DOI 10.1016/S0002-9394(14)74549-0
   Fratelli M, 2003, PROTEOMICS, V3, P1154, DOI 10.1002/pmic.200300436
   Fukumoto Y, 2008, EXP CELL RES, V314, P52, DOI 10.1016/j.yexcr.2007.07.024
   Futter CE, 2006, PIGM CELL RES, V19, P104, DOI 10.1111/j.1600-0749.2006.00303.x
   Gamm DM, 2008, INVEST OPHTH VIS SCI, V49, P788, DOI 10.1167/iovs.07-0777
   GAO H, 1992, INVEST OPHTH VIS SCI, V33, P1
   Garg Tarun K, 2003, BMC Ophthalmol, V3, P5, DOI 10.1186/1471-2415-3-5
   Gavert N, 2007, J CELL BIOCHEM, V102, P820, DOI 10.1002/jcb.21505
   GEIGER B, 1992, ANNU REV CELL BIOL, V8, P307, DOI 10.1146/annurev.cb.08.110192.001515
   Geisen P, 2006, CURR EYE RES, V31, P739, DOI 10.1080/02713680600837408
   GOTTARDI CJ, 1993, SCIENCE, V260, P552, DOI 10.1126/science.8386395
   Grune T, 2002, FASEB J, V16, P1602, DOI 10.1096/fj.02-0015com
   GUMBINER BM, 1993, J CELL SCI, P155
   GUNDERSEN D, 1993, J CELL BIOL, V121, P335, DOI 10.1083/jcb.121.2.335
   GUNDERSEN D, 1991, J CELL BIOL, V112, P863, DOI 10.1083/jcb.112.5.863
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Halbleib JM, 2006, GENE DEV, V20, P3199, DOI 10.1101/gad.1486806
   HAMMERTON RW, 1991, SCIENCE, V254, P847, DOI 10.1126/science.1658934
   HATTA K, 1986, NATURE, V320, P447, DOI 10.1038/320447a0
   Hazan RB, 2004, ANN NY ACAD SCI, V1014, P155, DOI 10.1196/annals.1294.016
   HETH CA, 1987, CURR EYE RES, V6, P1007, DOI 10.3109/02713688709034872
   HINCK L, 1994, J CELL BIOL, V125, P1327, DOI 10.1083/jcb.125.6.1327
   HITT AL, 1994, CURR OPIN CELL BIOL, V6, P120, DOI 10.1016/0955-0674(94)90125-2
   Hjelmeland LM, 1999, MOL VIS, V5
   Ho TC, 2006, BIOCHEM BIOPH RES CO, V342, P372, DOI 10.1016/j.bbrc.2006.01.164
   Hu J, 2001, MOL VIS, V7, P14
   Huber MA, 2005, CURR OPIN CELL BIOL, V17, P548, DOI 10.1016/j.ceb.2005.08.001
   HUOTARI V, 1995, DIFFERENTIATION, V58, P205, DOI 10.1046/j.1432-0436.1995.5830205.x
   Imamura Y, 2006, P NATL ACAD SCI USA, V103, P11282, DOI 10.1073/pnas.0602131103
   Inoue T, 2007, NEUROSCI LETT, V424, P190, DOI 10.1016/j.neulet.2007.07.022
   Islam S, 1996, J CELL BIOL, V135, P1643, DOI 10.1083/jcb.135.6.1643
   Iwakiri R, 2005, EXP EYE RES, V81, P15, DOI 10.1016/j.exer.2005.01.004
   Jaitovich AA, 2006, SEMIN NEPHROL, V26, P386, DOI 10.1016/j.semnephrol.2006.07.002
   Jones SE, 2000, INVEST OPHTH VIS SCI, V41, P1297
   Kaida M, 2000, INVEST OPHTH VIS SCI, V41, P3215
   Kameya S, 2002, HUM MOL GENET, V11, P1879, DOI 10.1093/hmg/11.16.1879
   Kanuga N, 2002, INVEST OPHTH VIS SCI, V43, P546
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Katoh M, 2007, INT J MOL MED, V19, P529
   Katoh M, 2006, CANCER BIOL THER, V5, P1059, DOI 10.4161/cbt.5.9.3151
   Katsube T, 2007, BBA-MOL CELL RES, V1773, P794, DOI 10.1016/j.bbamcr.2007.03.002
   Kaufmann U, 1999, CELL TISSUE RES, V296, P191, DOI 10.1007/s004410051280
   Keshavarzian A, 2003, GUT, V52, P720, DOI 10.1136/gut.52.5.720
   Kivela T, 2000, CELL TISSUE RES, V301, P217, DOI 10.1007/s004410000225
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Klein R, 2008, ARCH OPHTHALMOL-CHIC, V126, P115, DOI 10.1001/archopht.126.1.115
   Kloc M, 2003, FOLIA HISTOCHEM CYTO, V41, P3
   Kociok N, 2007, GRAEF ARCH CLIN EXP, V245, P101, DOI 10.1007/s00417-006-0266-x
   Kooistra MRH, 2007, J CELL SCI, V120, P17, DOI 10.1242/jcs.03306
   Krizbai IA, 2005, CELL MOL NEUROBIOL, V25, P129, DOI 10.1007/s10571-004-1378-7
   Krugluger W, 2007, GRAEF ARCH CLIN EXP, V245, P1543, DOI 10.1007/s00417-007-0635-0
   LAGUNOWICH LA, 1991, DIFFERENTIATION, V47, P19, DOI 10.1111/j.1432-0436.1991.tb00217.x
   LAGUNOWICH LA, 1989, DEV BIOL, V135, P158, DOI 10.1016/0012-1606(89)90166-8
   Larue L, 2006, FRONT BIOSCI-LANDMRK, V11, P733, DOI 10.2741/1831
   Lee SC, 2001, OPHTHALMIC RES, V33, P80, DOI 10.1159/000055648
   Leterrier JF, 2001, CELL MOL BIOL, V47, P901
   Liang FQ, 2003, EXP EYE RES, V76, P397, DOI 10.1016/S0014-4835(03)00023-X
   Liu HJ, 2007, SCIENCE, V317, P803, DOI 10.1126/science.1143578
   Liu X, 1997, HISTOCHEM CELL BIOL, V108, P35, DOI 10.1007/s004180050144
   Loeffler KU, 1996, GRAEF ARCH CLIN EXP, V234, pS70, DOI 10.1007/BF02343051
   Low SH, 2002, J CELL SCI, V115, P4545, DOI 10.1242/jcs.00116
   LUNA EJ, 1992, SCIENCE, V258, P955, DOI 10.1126/science.1439807
   Maeda M, 2006, ONCOGENE, V25, P4595, DOI 10.1038/sj.onc.1209396
   Maeda M, 2005, J CELL SCI, V118, P873, DOI 10.1242/jcs.01634
   Maminishkis A, 2006, INVEST OPHTH VIS SCI, V47, P3612, DOI 10.1167/iovs.05-1622
   Mandal MNA, 2006, INVEST OPHTH VIS SCI, V47, P5514, DOI 10.1167/iovs.06-0449
   Mandell KJ, 2007, INVEST OPHTH VIS SCI, V48, P3928, DOI 10.1167/iovs.06-1536
   Manolagas SC, 2007, MOL ENDOCRINOL, V21, P2605, DOI 10.1210/me.2007-0259
   Marmorstein AD, 2001, TRAFFIC, V2, P867, DOI 10.1034/j.1600-0854.2001.21202.x
   Marmorstein AD, 1998, ANN NY ACAD SCI, V857, P1, DOI 10.1111/j.1749-6632.1998.tb10102.x
   Marmorstein AD, 2007, EXP EYE RES, V85, P423, DOI 10.1016/j.exer.2006.03.021
   MARRS JA, 1993, J CELL BIOL, V123, P149, DOI 10.1083/jcb.123.1.149
   MARRS JA, 1995, J CELL BIOL, V129, P507, DOI 10.1083/jcb.129.2.507
   Martinez-Morales JR, 2004, BIOESSAYS, V26, P766, DOI 10.1002/bies.20064
   Matsuyoshi N, 1997, BIOCHEM BIOPH RES CO, V235, P355, DOI 10.1006/bbrc.1997.6707
   MAYS RW, 1995, J CELL BIOL, V130, P1105, DOI 10.1083/jcb.130.5.1105
   MCKAY BS, 1994, EXP CELL RES, V213, P85, DOI 10.1006/excr.1994.1176
   McKay BS, 1997, EXP EYE RES, V65, P661, DOI 10.1006/exer.1997.0374
   MCNEILL H, 1993, J CELL BIOL, V120, P1217, DOI 10.1083/jcb.120.5.1217
   MCNEILL H, 1990, CELL, V62, P309, DOI 10.1016/0092-8674(90)90368-O
   Mecklenburg L, 2007, TOXICOL PATHOL, V35, P252, DOI 10.1080/01926230601178199
   Meshorer E, 2008, J CELL BIOL, V181, P9, DOI 10.1083/jcb.200802155
   Miranda KC, 2003, J BIOL CHEM, V278, P43480, DOI 10.1074/jbc.M305525200
   Miyoshi J, 2005, ADV DRUG DELIVER REV, V57, P815, DOI 10.1016/j.addr.2005.01.008
   Miyoshi J, 2008, BBA-BIOMEMBRANES, V1778, P670, DOI 10.1016/j.bbamem.2007.12.014
   Miyoshi J, 2007, AM J NEPHROL, V27, P590, DOI 10.1159/000108103
   Mochii M, 1998, DEV BIOL, V193, P47, DOI 10.1006/dbio.1997.8800
   Mora RC, 2006, AM J PHYSIOL-CELL PH, V290, pC832, DOI 10.1152/ajpcell.00405.2005
   Moustakas A, 2007, CANCER SCI, V98, P1512, DOI 10.1111/j.1349-7006.2007.00550.x
   Mullins RF, 2007, INVEST OPHTH VIS SCI, V48, P3372, DOI 10.1167/iovs.06-0868
   Murisier F, 2006, HISTOL HISTOPATHOL, V21, P567, DOI 10.14670/HH-21.567
   MURPHYERDOSH C, 1994, DEV BIOL, V161, P107, DOI 10.1006/dbio.1994.1013
   NABI IR, 1993, J CELL SCI, V104, P37
   NATHKE IS, 1993, J CELL SCI, P139
   Nelson W J, 1991, Semin Cell Biol, V2, P375
   Nelson WJ, 2004, SCIENCE, V303, P1483, DOI 10.1126/science.1094291
   NELSON WJ, 1990, J CELL BIOL, V110, P349, DOI 10.1083/jcb.110.2.349
   NELSON WJ, 1987, NATURE, V328, P533, DOI 10.1038/328533a0
   Nieman MT, 1999, J CELL BIOL, V147, P631, DOI 10.1083/jcb.147.3.631
   Ogita H, 2008, INT REV CYTOL, V265, P1, DOI 10.1016/S0074-7696(07)65001-3
   Ogita H, 2006, IUBMB LIFE, V58, P334, DOI 10.1080/15216540600719622
   Ohno-Matsui K, 2005, MOL VIS, V11, P1
   OKAMI T, 1990, J HISTOCHEM CYTOCHEM, V38, P1267, DOI 10.1177/38.9.2167328
   Oliveira SS, 2007, CELL MOL LIFE SCI, V64, P17, DOI 10.1007/s00018-006-6314-1
   Perez-Moreno M, 2006, DEV CELL, V11, P601, DOI 10.1016/j.devcel.2006.10.010
   PFEFFER BA, 1986, INVEST OPHTH VIS SCI, V27, P1031
   PLETJUSHKINA OJ, 1994, EXP CELL RES, V212, P201, DOI 10.1006/excr.1994.1135
   Polakis P, 2007, CURR OPIN GENET DEV, V17, P45, DOI 10.1016/j.gde.2006.12.007
   POULIOT Y, 1990, DEV BIOL, V141, P292, DOI 10.1016/0012-1606(90)90385-V
   Rajasekaran AK, 1996, J CELL BIOL, V132, P451, DOI 10.1083/jcb.132.3.451
   Rak DJ, 2006, EXP EYE RES, V82, P648, DOI 10.1016/j.exer.2005.09.002
   Rao RK, 2002, BIOCHEM J, V368, P471, DOI 10.1042/BJ20011804
   Rizzolo LJ, 2007, INT REV CYTOL, V258, P195, DOI 10.1016/S0074-7696(07)58004-6
   RIZZOLO LJ, 1990, EXP EYE RES, V51, P435, DOI 10.1016/0014-4835(90)90156-O
   Rodriguez-Boulan E, 2005, NAT REV MOL CELL BIO, V6, P233, DOI 10.1038/nrm1593
   RODRIGUEZBOULAN E, 1989, SCIENCE, V245, P718, DOI 10.1126/science.2672330
   Saenz-Morales D, 2006, EXP CELL RES, V312, P3711, DOI 10.1016/j.yexcr.2006.05.024
   SAIKA S, 2008, DRUG TARGETS, V8, P69
   Sakamoto Y, 2006, J BIOL CHEM, V281, P19631, DOI 10.1074/jbc.M600301200
   Sakisaka T, 2007, CURR OPIN CELL BIOL, V19, P593, DOI 10.1016/j.ceb.2007.09.007
   Schepsky A, 2006, MOL CELL BIOL, V26, P8914, DOI 10.1128/MCB.02299-05
   Schraermeyer U, 1999, PIGM CELL RES, V12, P219, DOI 10.1111/j.1600-0749.1999.tb00755.x
   Seabra MC, 2004, TRAFFIC, V5, P393, DOI 10.1111/j.1398-9219.2004.00190.x
   Shibahara S, 2001, J INVEST DERM SYMP P, V6, P99, DOI 10.1046/j.0022-202x.2001.00010.x
   Shibahara S, 2000, PIGM CELL RES, V13, P98, DOI 10.1034/j.1600-0749.13.s8.18.x
   Shin K, 2006, ANNU REV CELL DEV BI, V22, P207, DOI 10.1146/annurev.cellbio.22.010305.104219
   Simm A, 2008, BIOL CHEM, V389, P257, DOI 10.1515/BC.2008.034
   SONG MK, 1990, J CELL PHYSIOL, V143, P196, DOI 10.1002/jcp.1041430127
   Stebbings H, 2001, INT REV CYTOL, V211, P1, DOI 10.1016/S0074-7696(01)11016-8
   Steinberg R.H., 1979, RETINAL PIGMENT EPIT, P205
   Steingrimsson E, 2004, ANNU REV GENET, V38, P365, DOI 10.1146/annurev.genet.38.072902.092717
   STINSON AM, 1991, EXP EYE RES, V52, P213, DOI 10.1016/0014-4835(91)90261-C
   Strauss O, 2005, PHYSIOL REV, V85, P845, DOI 10.1152/physrev.00021.2004
   Sundin OH, 2005, P NATL ACAD SCI USA, V102, P9553, DOI 10.1073/pnas.0501451102
   Tachibana M, 2000, PIGM CELL RES, V13, P230, DOI 10.1034/j.1600-0749.2000.130404.x
   TAKEICHI M, 1991, SCIENCE, V251, P1451, DOI 10.1126/science.2006419
   TAKEICHI M, 1995, CURR OPIN CELL BIOL, V7, P619, DOI 10.1016/0955-0674(95)80102-2
   Tan JSL, 2008, OPHTHALMOLOGY, V115, P334, DOI 10.1016/j.ophtha.2007.03.083
   Tekotte H, 2002, TRENDS GENET, V18, P636, DOI 10.1016/S0168-9525(02)02819-6
   Thompson MD, 2007, HEPATOLOGY, V45, P1298, DOI 10.1002/hep.21651
   Tiret A, 1999, Curr Opin Ophthalmol, V10, P168, DOI 10.1097/00055735-199906000-00003
   Tugizov S, 1996, J GEN VIROL, V77, P61, DOI 10.1099/0022-1317-77-1-61
   Usatyuk PV, 2006, J BIOL CHEM, V281, P35554, DOI 10.1074/jbc.M607305200
   Van Aken EH, 2003, INVEST OPHTH VIS SCI, V44, P463, DOI 10.1167/iovs.01-1096
   Wahl JK, 2003, J BIOL CHEM, V278, P17269, DOI 10.1074/jbc.M211452200
   WANG AZ, 1990, J CELL SCI, V95, P137
   WATZKE RC, 1993, CURR EYE RES, V12, P133, DOI 10.3109/02713689308999481
   Wheelock MJ, 2003, CURR OPIN CELL BIOL, V15, P509, DOI 10.1016/S0955-0674(03)00101-7
   Wheelock MJ, 2003, ANNU REV CELL DEV BI, V19, P207, DOI 10.1146/annurev.cellbio.19.011102.111135
   White BD, 2007, CURR BIOL, V17, pR923, DOI 10.1016/j.cub.2007.08.062
   Wolfensberger TJ, 1998, DOC OPHTH P, V62, P1
   WOLLNER DA, 1992, J CELL SCI, V102, P185
   WOLLNER DA, 1992, J CELL BIOL, V116, P889, DOI 10.1083/jcb.116.4.889
   Wong RW, 2007, RETINA-J RET VIT DIS, V27, P997, DOI 10.1097/IAE.0b013e318074c290
   Wu JM, 2006, SURV OPHTHALMOL, V51, P461, DOI 10.1016/j.survophthal.2006.06.009
   Xu L, 2002, EXP EYE RES, V74, P753, DOI 10.1006/exer.2002.1175
   Yamada S, 2005, CELL, V123, P889, DOI 10.1016/j.cell.2005.09.020
   YONEMURA S, 1995, J CELL SCI, V108, P127
   Youn YH, 2005, EXP CELL RES, V303, P275, DOI 10.1016/j.yexcr.2004.09.023
   Youn YH, 2006, INVEST OPHTH VIS SCI, V47, P2675, DOI 10.1167/iovs.05-1335
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
   Zareba M, 2007, PHOTOCHEM PHOTOBIOL, V83, P925, DOI 10.1111/j.1751-1097.2007.00080.x
   ZURZOLO C, 1993, SCIENCE, V260, P550, DOI 10.1126/science.8386394
NR 230
TC 89
Z9 90
U1 0
U2 10
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 1350-9462
EI 1873-1635
J9 PROG RETIN EYE RES
JI Prog. Retin. Eye Res.
PD NOV
PY 2008
VL 27
IS 6
BP 579
EP 595
DI 10.1016/j.preteyeres.2008.08.002
PG 17
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 382RS
UT WOS:000261623700001
PM 18775790
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Van de Moere, A
   Sandhu, SS
   Kak, R
   Mitchell, KW
   Talks, SJ
AF Van de Moere, A
   Sandhu, SS
   Kak, R
   Mitchell, KW
   Talks, SJ
TI Effect of posterior juxtascleral triamcinolone acetonide on choroidal
   neovascular growth after photodynamic therapy with verteporfin
SO OPHTHALMOLOGY
LA English
DT Article
ID RANDOMIZED CLINICAL-TRIAL; MACULAR DEGENERATION; INTRAVITREAL
   TRIAMCINOLONE; INTRAOCULAR-PRESSURE; SUBTENON INJECTION; MACULOPATHY;
   PREVALENCE; EXPRESSION; UVEITIS; EYE
AB Objective: To assess if posterior juxtascleral application of 40 mg triamcinolone acetonide (TA), given at the same time as initial photodynamic therapy (PDT) for predominantly classic choroidal neovascularization (CNV) related to age-related macular degeneration affects lesion growth at 3 and 6 months.
   Design: Comparative (nonrandomized) interventional study.
   Participants: The study group consists of 38 eyes of 38 patients. The control group consists of 73 eyes of 73 patients.
   Methods: Comparison of 2 consecutive case series collected at different times. The study group had a posterior juxtascleral TA with their initial PDT treatment. The controls were treated with PDT alone. All patients were reviewed at 1, 3, and 6 months.
   Main Outcome Measures: Change in total lesion size; secondary outcomes: area of leak, best-corrected visual acuity, number of treatments, and intraocular pressure. mm(2); Results: There was significantly less growth of total lesion at 3 months (mean difference = 2.47 mm(2) 95% confidence interval (CI): +1.22 to +3.72 mm(2); p = 0.0002) and 6 months (mean difference = 2.88 mm(2); 95% CI: +0.61 to +5.15 mm(2); p = 0.0134) in patients given TA with PDT compared with PDT alone. There was also a significantly smaller residual area of leak at 3 months in the study group (mean difference = 1.07 mm(2); 95% CI: +0.16 to +1.97 mm(2); p = 0.02). At 6 months, the residual area of leak between the 2 groups became comparable (mean difference = 0.13 mm(2); 95% CI = -1.59 to +11.33 mm(2); p = 0.86). Mean number of letters lost on the logarithm of the minimum angle of resolution chart at 6 months was 9.1 letters (standard error of the mean [SEM] = 2.21) in the study group compared with 12.4 letters (SEM = 1.91) in the control group (P = 0.30). At 6 months, 10 of 36 eyes (27.8%) in the study group showed >= 15 letters loss, compared with 29 of 73 eyes (39.7%) in the control group. Intraocular pressure was raised in 4 of 38 eyes (10.5%). Fewer retreatments were required in the TA with PDT group (2.03 compared with 2.47 [P = 0.006]).
   Conclusions: Posterior juxtascleral placement of TA with PDT at baseline significantly reduces CNV growth at 3 and 6 months. Fewer retreatments were required. Visual outcome may be improved, although we did not show a statistically significant improvement with this sample size. A larger, randomized trial with longer follow-up is justified.
C1 Royal Victoria Infirm, Dept Ophthalmol, Newcastle Upon Tyne NE1 4LP, Tyne & Wear, England.
C3 Newcastle University - UK
RP Talks, SJ (通讯作者)，Royal Victoria Infirm, Dept Ophthalmol, Queen Victoria Rd, Newcastle Upon Tyne NE1 4LP, Tyne & Wear, England.
EM james.talks@ncl.ac.uk
CR ANTOSZYK AN, 1993, GRAEF ARCH CLIN EXP, V231, P34, DOI 10.1007/BF01681698
   Arroyo JG, 2003, ARCH OPHTHALMOL-CHIC, V121, P898, DOI 10.1001/archopht.121.6.898
   Blair MP, 2004, RETINA-J RET VIT DIS, V24, P501, DOI 10.1097/00006982-200408000-00001
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Ciulla TA, 2001, ARCH OPHTHALMOL-CHIC, V119, P399, DOI 10.1001/archopht.119.3.399
   Danis RP, 2000, RETINA-J RET VIT DIS, V20, P244, DOI 10.1097/00006982-200003000-00004
   Ergun E, 2003, OPHTHALMOLOGY, V110, P65, DOI 10.1016/S0161-6420(02)01566-X
   Gillies MC, 2003, ARCH OPHTHALMOL-CHIC, V121, P667, DOI 10.1001/archopht.121.5.667
   Gillies MC, 2004, ARCH OPHTHALMOL-CHIC, V122, P336, DOI 10.1001/archopht.122.3.336
   Grisanti S, 2004, AM J OPHTHALMOL, V137, P914, DOI 10.1016/j.ajo.2003.12.049
   HELM CJ, 1995, AM J OPHTHALMOL, V120, P55, DOI 10.1016/S0002-9394(14)73759-6
   ISHIBASHI T, 1985, ARCH OPHTHALMOL-CHIC, V103, P708
   Jonas JB, 2003, BRIT J OPHTHALMOL, V87, P24, DOI 10.1136/bjo.87.1.24
   Jonas JB, 2003, BRIT J OPHTHALMOL, V87, P462, DOI 10.1136/bjo.87.4.462
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Mueller AJ, 1998, AM J OPHTHALMOL, V125, P158, DOI 10.1016/S0002-9394(99)80085-3
   Penfold PL, 2000, CLIN EXP IMMUNOL, V121, P458, DOI 10.1046/j.1365-2249.2000.01316.x
   Rechtman E, 2004, BRIT J OPHTHALMOL, V88, P344, DOI 10.1136/bjo.2003.027177
   Schmidt-Erfurth U, 2002, INVEST OPHTH VIS SCI, V43, P830
   Schmidt-Erfurth U, 2003, INVEST OPHTH VIS SCI, V44, P4473, DOI 10.1167/iovs.02-1115
   Schmidt-Erfurth UM, 2004, OPHTHALMOLOGY, V111, P931, DOI 10.1016/j.ophtha.2003.12.025
   Spaide RF, 2005, OPHTHALMOLOGY, V112, P301, DOI 10.1016/j.ophtha.2004.08.012
   Spaide RF, 2003, OPHTHALMOLOGY, V110, P1517, DOI 10.1016/S0161-6420(03)00544-X
   STERNBERG P, 1991, ARCH OPHTHALMOL-CHIC, V109, P1242
   Tanner V, 1998, EYE, V12, P679, DOI 10.1038/eye.1998.168
NR 26
TC 30
Z9 32
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD NOV
PY 2005
VL 112
IS 11
BP 1897
EP 1903
DI 10.1016/j.ophtha.2005.06.018
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 980EW
UT WOS:000232998000007
DA 2022-11-30
ER

PT J
AU Quellec, G
   Russell, SR
   Abramoff, MD
AF Quellec, Gwenole
   Russell, Stephen R.
   Abramoff, Michael D.
TI Optimal Filter Framework for Automated, Instantaneous Detection of
   Lesions in Retinal Images
SO IEEE TRANSACTIONS ON MEDICAL IMAGING
LA English
DT Article
DE Drusen; factor analysis; lesion detection; microaneurysms; retinal
   diseases
ID COLOR FUNDUS PHOTOGRAPHS; DIABETIC-RETINOPATHY; CONTRAST NORMALIZATION;
   MACULAR DEGENERATION; RED LESIONS; MICROANEURYSMS; SEGMENTATION;
   DIAGNOSIS; DRUSEN; POPULATION
AB Automated detection of lesions in retinal images is a crucial step towards efficient early detection, or screening, of large at-risk populations. In particular, the detection of microaneurysms, usually the first sign of diabetic retinopathy (DR), and the detection of drusen, the hallmark of age-related macular degeneration (AMD), are of primary importance. In spite of substantial progress made, detection algorithms still produce 1) false positives-target lesions are mixed up with other normal or abnormal structures in the eye, and 2) false negatives-the large variability in the appearance of the lesions causes a subset of these target lesions to be missed. We propose a general framework for detecting and characterizing target lesions almost instantaneously. This framework relies on a feature space automatically derived from a set of reference image samples representing target lesions, including atypical target lesions, and those eye structures that are similar looking but are not target lesions. The reference image samples are obtained either from an expert-or a data-driven approach. Factor analysis is used to derive the filters generating this feature space from reference samples. Previously unseen image samples are then classified in this feature space. We tested this approach by training it to detect microaneurysms. On a set of images from 2739 patients including 67 with referable DR, DR detection area under the receiver-operating characteristic curve (AUC) was comparable (AUC = 0.927) to our previously published red lesion detection algorithm (AUC = 0.929). We also tested the approach on the detection of AMD, by training it to differentiate drusen from Stargardt's disease lesions, and achieved an AUC = 0.850 on a set of 300 manually detected drusen and 300 manually detected flecks. The entire image processing sequence takes less than a second on a standard PC compared to minutes in our previous approach, allowing instantaneous detection. Free-response receiver-operating characteristic analysis showed the superiority of this approach over a framework where false positives and the atypical lesions are not explicitly modeled. A greater performance was achieved by the expert-driven approach for DR detection, where the designer had sound expert knowledge. However, for both problems, a comparable performance was obtained for both expert- and data-driven approaches. This indicates that annotation of a limited number of lesions suffices for building a detection system for any type of lesion in retinal images, if no expert-knowledge is available. We are studying whether the optimal filter framework also generalizes to the detection of any structure in other domains.
C1 [Quellec, Gwenole; Russell, Stephen R.; Abramoff, Michael D.] Univ Iowa, Dept Ophthalmol & Visual Sci, Iowa City, IA 52242 USA.
   [Quellec, Gwenole] Univ Iowa, Dept Biomed Engn, Iowa City, IA 52242 USA.
   [Russell, Stephen R.; Abramoff, Michael D.] Iowa City VA Med Ctr, Dept Vet Affairs, Iowa City, IA 52242 USA.
   [Abramoff, Michael D.] Univ Iowa, Dept Elect & Comp Engn, Iowa City, IA 52242 USA.
C3 University of Iowa; University of Iowa; US Department of Veterans
   Affairs; Veterans Health Administration (VHA); Iowa City VA Health Care
   System; University of Iowa
RP Quellec, G (通讯作者)，Univ Iowa, Dept Ophthalmol & Visual Sci, Iowa City, IA 52242 USA.
EM gwenole-quellec@uiowa.edu; steve-russell@uiowa.edu;
   michael-abramoff@uiowa.edu
RI Quellec, Gwenole/L-9946-2015; Abramoff, Michael D/A-5836-2009
OI Quellec, Gwenole/0000-0003-1669-7140; Abramoff, Michael
   D/0000-0002-3490-0037; Russell, Stephen/0000-0003-3776-1367
FU National Institutes of Health [EY017066]; U.S. Department of Veterans
   Affairs; NATIONAL EYE INSTITUTE [R01EY017066] Funding Source: NIH
   RePORTER
FX Manuscript received March 20, 2010; revised August 08, 2010, October 13,
   2010; accepted October 14, 2010. Date of publication October 21, 2010;
   date of current version February 02, 2011. This work was supported in
   part by the National Institutes of Health (EY017066) and in part by the
   U.S. Department of Veterans Affairs. Asterisk indicates corresponding
   author.
CR Abramoff MD, 2005, TELEMED J E-HEALTH, V11, P668, DOI 10.1089/tmj.2005.11.668
   ABRAMOFF MD, 2010, IEEE REV BI IN PRESS
   Abramoff MD, 2007, INVEST OPHTH VIS SCI, V48, P1665, DOI 10.1167/iovs.06-1081
   Abramoff MD, 2010, OPHTHALMOLOGY, V117, P1147, DOI 10.1016/j.ophtha.2010.03.046
   Abramoff MD, 2008, DIABETES CARE, V31, P193, DOI 10.2337/dc07-1312
   [Anonymous], OPHTHALMOL TIMES
   ARYA S, 1993, PROCEEDINGS OF THE FOURTH ANNUAL ACM-SIAM SYMPOSIUM ON DISCRETE ALGORITHMS, P271
   Barthes A, 2001, MED PHYS, V28, P2410, DOI 10.1118/1.1420735
   Bell AJ, 1997, VISION RES, V37, P3327, DOI 10.1016/S0042-6989(97)00121-1
   Bethge M, 2006, J OPT SOC AM A, V23, P1253, DOI 10.1364/JOSAA.23.001253
   Brainard DH, 1997, J OPT SOC AM A, V14, P1393, DOI 10.1364/JOSAA.14.001393
   Bresnick GH, 2000, OPHTHALMOLOGY, V107, P19, DOI 10.1016/S0161-6420(99)00010-X
   BUNCH PC, 1978, J APPL PHOTOGR ENG, V4, P166
   Chaum E, 2008, RETINA-J RET VIT DIS, V28, P1463, DOI 10.1097/IAE.0b013e31818356dd
   Cree MJ, 1997, EYE, V11, P622, DOI 10.1038/eye.1997.166
   Early Treatment Diabetic Retinopathy Study Res Grp, 1991, OPHTHALMOLOGY, V98, P766
   Fleming AD, 2007, PHYS MED BIOL, V52, P7385, DOI 10.1088/0031-9155/52/24/012
   Fleming AD, 2006, IEEE T MED IMAGING, V25, P1223, DOI 10.1109/TMI.2006.879953
   Foracchia M, 2005, MED IMAGE ANAL, V9, P179, DOI 10.1016/j.media.2004.07.001
   Hipwell JH, 2000, DIABETIC MED, V17, P588, DOI 10.1046/j.1464-5491.2000.00338.x
   Jolliffe I., 2002, SPRINGER SERIES
   KINYOUN J, 1989, OPHTHALMOLOGY, V96, P746
   Klonoff DC, 2000, DIABETES CARE, V23, P390, DOI 10.2337/diacare.23.3.390
   Larsen M, 2003, INVEST OPHTH VIS SCI, V44, P761, DOI 10.1167/iovs.02-0418
   Luo G, 2001, COMP MED SY, P132, DOI 10.1109/CBMS.2001.941710
   Metz CE, 1998, STAT MED, V17, P1033, DOI 10.1002/(SICI)1097-0258(19980515)17:9<1033::AID-SIM784>3.0.CO;2-Z
   MIZUTANI A, 2001, P SPIE MED IMAGING 2, V7260
   Niemeijer M, 2005, IEEE T MED IMAGING, V24, P584, DOI 10.1109/TMI.2005.843738
   Niemeijer M, 2007, INVEST OPHTH VIS SCI, V48, P2260, DOI 10.1167/iovs.06-0996
   Niemeijer M, 2010, IEEE T MED IMAGING, V29, P185, DOI 10.1109/TMI.2009.2033909
   Niemeijer M, 2009, IEEE T MED IMAGING, V28, P775, DOI 10.1109/TMI.2008.2012029
   Quellec G, 2008, IEEE T MED IMAGING, V27, P1230, DOI 10.1109/TMI.2008.920619
   Rapantzikos K, 2003, MED IMAGE ANAL, V7, P95, DOI 10.1016/S1361-8415(02)00093-2
   Romeny B. t. H., 2003, FRONT END VISION MUL
   SANCHEZ CI, 2001, P SPIE MED IMAGING 2, V7260
   Sinthanayothin C, 2002, DIABETIC MED, V19, P105, DOI 10.1046/j.1464-5491.2002.00613.x
   Sluimer IC, 2006, MED PHYS, V33, P2610, DOI 10.1118/1.2207131
   Smith RT, 2005, ARCH OPHTHALMOL-CHIC, V123, P200, DOI 10.1001/archopht.123.2.200
   Spencer T, 1996, COMPUT BIOMED RES, V29, P284, DOI 10.1006/cbmr.1996.0021
   Teng T, 2002, MED BIOL ENG COMPUT, V40, P2, DOI 10.1007/BF02347689
   van Leeuwen R, 2003, ARCH OPHTHALMOL-CHIC, V121, P519, DOI 10.1001/archopht.121.4.519
   Walia S, 2009, OPHTHALMIC GENET, V30, P63, DOI 10.1080/13816810802695550
   Walter T, 2007, MED IMAGE ANAL, V11, P555, DOI 10.1016/j.media.2007.05.001
   Winder RJ, 2009, COMPUT MED IMAG GRAP, V33, P608, DOI 10.1016/j.compmedimag.2009.06.003
   ZHANG B, 2001, P SPIE MED IMAGING 2, V7260
NR 45
TC 71
Z9 77
U1 0
U2 13
PU IEEE-INST ELECTRICAL ELECTRONICS ENGINEERS INC
PI PISCATAWAY
PA 445 HOES LANE, PISCATAWAY, NJ 08855-4141 USA
SN 0278-0062
EI 1558-254X
J9 IEEE T MED IMAGING
JI IEEE Trans. Med. Imaging
PD FEB
PY 2011
VL 30
IS 2
BP 523
EP 533
DI 10.1109/TMI.2010.2089383
PG 11
WC Computer Science, Interdisciplinary Applications; Engineering,
   Biomedical; Engineering, Electrical & Electronic; Imaging Science &
   Photographic Technology; Radiology, Nuclear Medicine & Medical Imaging
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Computer Science; Engineering; Imaging Science & Photographic
   Technology; Radiology, Nuclear Medicine & Medical Imaging
GA 715YG
UT WOS:000286931000030
PM 21292586
DA 2022-11-30
ER

PT J
AU Yohe, S
   Maass, KF
   Horvath, J
   Rea, J
   Barteselli, G
   Ranade, SV
AF Yohe, Stefan
   Maass, Katie F.
   Horvath, Judit
   Rea, Jennifer
   Barteselli, Giulio
   Ranade, Shrirang V.
TI In-vitro characterization of ranibizumab release from the Port Delivery
   System
SO JOURNAL OF CONTROLLED RELEASE
LA English
DT Article
DE Controlled release; In vitro; Long-acting drug delivery system;
   Neovascular age-related macular degeneration; Port Delivery System;
   Ranibizumab
ID REAL-WORLD OUTCOMES; MACULAR DEGENERATION; THERAPY; PDS
AB The Port Delivery System with ranibizumab (PDS) consists of an implant that is a permanent, indwelling drug delivery device that can be refilled through a self-sealing septum and is designed to continuously release a customized formulation of ranibizumab into the vitreous by passive diffusion through a porous titanium release control element. Target release rates of ranibizumab via the implant used in studies of the PDS in patients with neovascular age-related macular degeneration were selected based on clinical and pharmacokinetic (PK) data from previously conducted intravitreal ranibizumab injection studies. In-vitro testing was performed to verify release rates with a range of ranibizumab concentrations before the phase II Ladder (NCT02510794) and phase III Archway (NCT03677934) trials of the PDS. Implants were filled with ranibizumab and were regularly transferred to new buffer-containing tubes to represent ocular ranibizumab clearance and release kinetics. Ranibizumab concentrations were measured and release rates calculated. Release rate data were fit to an exponential model and compared with expected release kinetics of diffusion. Release profiles of the implant releasing ranibizumab at concentrations of 10 mg/mL, 40 mg/mL, and 100 mg/mL were determined in the pre-phase II in-vitro studies. At day 3.5, mean (SD) ranibizumab release rates were 1.75 (0.07), 6.42 (0.35), and 16.69 (0.67) mu g/d for PDS 10 mg/mL, 40 mg/mL, and 100 mg/mL, respectively. At month 6, mean (SD) release rates were 1.68 (0.05) and 4.16 (0.05) mu g/d for PDS 40 mg/mL and 100 mg/mL, respectively. Measured release rates were within 90% of theoretical release rates during the course of drug release. PDS 100 mg/mL released 73% (SD, 1.92) of drug by month 6. In the pre-phase III in-vitro studies, mean (SD) release rates with PDS 100 mg/mL were 17.97 (0.90), 4.44 (0.11), and 2.45 (0.08) mu g/d at 3.5 days, 6 months, and 9 months, respectively. Cumulative release (SD) was 73% (1.92) by month 6 and 87% (1.88) by month 9. The sustained, continuous, and reproducible release from the PDS observed in the in-vitro studies was also observed in Ladder and Archway. In conclusion, in-vitro studies were a powerful tool for characterizing and verifying ranibizumab release from the PDS implant and supported clinical evaluation of the PDS. PDS 100 mg/mL, which was associated with the longest therapeutic-level delivery of ranibizumab among the concentrations tested, was selected for evaluation in the pivotal phase III Archway trial.
C1 [Yohe, Stefan; Maass, Katie F.; Horvath, Judit; Rea, Jennifer; Barteselli, Giulio; Ranade, Shrirang V.] Genentech Inc, 1 DNA Way, South San Francisco, CA 94080 USA.
C3 Roche Holding; Genentech
RP Ranade, SV (通讯作者)，Genentech Inc, Pharma Tech Dev, 1 DNA Way, South San Francisco, CA 94080 USA.
EM ranade.shrirang@gene.com
OI Maass, Katie/0000-0002-0493-2863
FU Genentech, Inc., a member of the Roche Group; Genentech, Inc.
FX Funding was provided by Genentech, Inc., a member of the Roche Group,
   for the study and third-party writing assistance, which was provided by
   Luke Carey, PhD, CMPP, of Envision Pharma Group.; Genentech, Inc.
   supported and contributed to all aspects of the studies, including
   design, analyses, data interpretation, report writing, and the decision
   to submit the manuscript for publication.
CR American Academy of Ophthalmology Retina/Vitreous Panel, PREF PRACT PATT GUID
   Campochiaro PA, 2021, INVEST OPHTH VIS SCI, V62
   Campochiaro PA, 2020, INVEST OPHTH VIS SCI, V61
   Campochiaro PA, 2019, OPHTHALMOLOGY, V126, P1141, DOI 10.1016/j.ophtha.2019.03.036
   Cao YQ, 2019, DRUG DISCOV TODAY, V24, P1694, DOI 10.1016/j.drudis.2019.05.031
   Caruso A, 2020, MOL PHARMACEUT, V17, P695, DOI 10.1021/acs.molpharmaceut.9b01191
   Ciulla TA, 2020, OPHTHALMOL RETINA, V4, P19, DOI 10.1016/j.oret.2019.05.017
   Ciulla TA, 2018, OPHTHALMOL RETINA, V2, P645, DOI 10.1016/j.oret.2018.01.006
   Ehlken C, 2020, GRAEF ARCH CLIN EXP, V258, P2077, DOI 10.1007/s00417-020-04798-2
   Ferrara N, 2006, RETINA-J RET VIT DIS, V26, P859, DOI 10.1097/01.iae.0000242842.14624.e7
   Gohil R, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0129361
   Holekamp NM, 2022, OPHTHALMOLOGY, V129, P295, DOI 10.1016/j.ophtha.2021.09.016
   Khanani AM, 2021, OPHTHALMOL RETINA, V5, P775, DOI 10.1016/j.oret.2020.11.004
   Kim LN, 2016, RETINA-J RET VIT DIS, V36, P1418, DOI 10.1097/IAE.0000000000001142
   Landers MB, 2012, RETINA-J RET VIT DIS, V32, P172, DOI 10.1097/IAE.0b013e31821c3ee0
   Lowe J, 2018, J IMMUNOL METHODS, V461, P44, DOI 10.1016/j.jim.2018.05.007
   Mones J., PHARMACOKINETIC PROF
   Prenner JL, 2015, AM J OPHTHALMOL, V160, P725, DOI 10.1016/j.ajo.2015.06.023
   Regillo C, PORT DELIVERY SYSTEM
   Schmidt-Erfurth U, 2014, BRIT J OPHTHALMOL, V98, P1144, DOI 10.1136/bjophthalmol-2014-305702
   Solomon SD, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005139.pub3
   Stewart JM, 2021, INVEST OPHTH VIS SCI, V62
   Varano M, 2015, CLIN OPHTHALMOL, V9, P2243, DOI 10.2147/OPTH.S92548
   Vukicevic M, 2016, EYE, V30, P413, DOI 10.1038/eye.2015.235
   Xu L, 2013, INVEST OPHTH VIS SCI, V54, P1616, DOI 10.1167/iovs.12-10260
NR 25
TC 5
Z9 5
U1 4
U2 4
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0168-3659
EI 1873-4995
J9 J CONTROL RELEASE
JI J. Control. Release
PD MAY
PY 2022
VL 345
BP 101
EP 107
DI 10.1016/j.jconrel.2022.03.005
PG 7
WC Chemistry, Multidisciplinary; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Chemistry; Pharmacology & Pharmacy
GA 0O9XY
UT WOS:000783878100004
PM 35248647
OA hybrid
DA 2022-11-30
ER

PT J
AU de Breuk, A
   Heesterbeek, TJ
   Bakker, B
   Verzijden, T
   Lechanteur, YTE
   Klaver, CCW
   den Hollander, AI
   Hoyng, CB
AF de Breuk, Anita
   Heesterbeek, Thomas J.
   Bakker, Bjorn
   Verzijden, Timo
   Lechanteur, Yara T. E.
   Klaver, Caroline C. W.
   den Hollander, Anneke, I
   Hoyng, Carel B.
TI Evaluating the Occurrence of Rare Variants in the Complement Factor H
   Gene in Patients With Early-Onset Drusen Maculopathy
SO JAMA OPHTHALMOLOGY
LA English
DT Article
ID AGE-RELATED MACULOPATHY; MACULAR DEGENERATION; HIGH-RISK;
   IDENTIFICATION; ASSOCIATION; FAMILIES; SYSTEM; CFI
AB IMPORTANCE Early-onset drusen maculopathy (EODM) is a severe disease and can lead to advanced macular degeneration early in life; however, genetic and phenotypic characteristics of individuals with EODM are not well studied.
   OBJECTIVE To identify genotypic and phenotypic characteristics of individuals with EODM.
   DESIGN, SETTING, AND PARTICIPANTS This case-control study collected data from the European Genetic Database from September 2004 to October 2019. A total of 89 patients with EODM diagnosed at 55 years or younger and 91 patients with age-related macular degeneration (AMD) diagnosed at 65 years or older were included.
   EXPOSURES Coding regions of CFH, CFI, C3, C9, CFB, ABCA4, PRPH2, TIMP3, and CTNNA1 genes were sequenced, genetic risk scores (GRS) were calculated based on 52 AMD-associated variants, and phenotypic characteristics on color fundus photographs were analyzed comparing patients with EODM and AMD.
   MAIN OUTCOMES AND MEASURES GRS, frequency of rare genetic complement variants, and phenotypic characteristics.
   RESULTS This case-control study included 89 patients with EODM (mean [SD] age, 51.8 [8.7] years; 58 [65.2%] were female) and 91 patients with AMD (mean [SD] age, 77.6 [6.1] years; 45 [49.5%] female). At a mean (SD) age of 56.4 (7.3) years, 40 of 89 patients with EODM (44.9%) were affected by geographic atrophy or choroidal neovascularization. A lower GRS was observed in patients with EODM compared with patients with AMD (1.03 vs 1.60; P = .002), and 27 of 89 patients with EODM (30.3%) carried rare variants in the CFH gene compared with 7 of 91 patients with AMD (7.7%). Carriership of a rare CFH variant was associated with EODM (odds ratio, 7.2; 95% CI, 2.7-19.6; P < .001). A large macular drusen area (more than 50% covered with drusen) was observed in patients with EODM (24 of 162 eyes [14.8%]) compared with patients with AMD (9 of 164 eyes [5.5%]) (odds ratio, 4.57; 95% CI, 1.5-14.1; P = .008).
   CONCLUSIONS AND RELEVANCE A large proportion of patients with EODM in this study carried rare CFH variants, with most of the identified CFH variants clustered in the first 7 complement control protein domains affecting factor H and factor H-like 1. Because EODM frequently leads to advanced macular degeneration at an early age and can result in many years of vision loss, this study supports targeting the complement system and sequencing the CFH gene in patients with EODM to improve genetic counseling and future treatments for AMD.
C1 [de Breuk, Anita; Heesterbeek, Thomas J.; Bakker, Bjorn; Lechanteur, Yara T. E.; den Hollander, Anneke, I; Hoyng, Carel B.] Donders Inst Brain Cognit & Behav, Nijmegen, Netherlands.
   [de Breuk, Anita; Heesterbeek, Thomas J.; Bakker, Bjorn; Lechanteur, Yara T. E.; Klaver, Caroline C. W.; den Hollander, Anneke, I; Hoyng, Carel B.] Radboud Univ Nijmegen Med Ctr, Dept Ophthalmol, Philips Van Leydenlaan 15, NL-6525 EX Nijmegen, Netherlands.
   [Verzijden, Timo; Klaver, Caroline C. W.] Erasmus MC, Dept Ophthalmol, Rotterdam, Netherlands.
   [Verzijden, Timo; Klaver, Caroline C. W.] Erasmus MC, Dept Epidemiol, Rotterdam, Netherlands.
   [Klaver, Caroline C. W.] Inst Mol & Clin Ophthalmol, Basel, Switzerland.
C3 Radboud University Nijmegen; Philips; Radboud University Nijmegen;
   Erasmus University Rotterdam; Erasmus MC; Erasmus University Rotterdam;
   Erasmus MC
RP Hoyng, CB (通讯作者)，Radboud Univ Nijmegen Med Ctr, Dept Ophthalmol, Philips Van Leydenlaan 15, NL-6525 EX Nijmegen, Netherlands.
EM carel.hoyng@radboudumc.nl
FU Dutch Research Council [016.Vici.170.024]; Oogfonds; Landelijke
   Stichting voor Blinden en Slechtzienden; Macula Fonds; Vereniging
   Bartimeus Sonneheerdt [Uitzicht 2016-02, 2016-26]
FX This research was supported by the Dutch Research Council
   (016.Vici.170.024 to Dr den Hollander) and Oogfonds, Landelijke
   Stichting voor Blinden en Slechtzienden, Macula Fonds, Vereniging
   Bartimeus Sonneheerdt (Uitzicht 2016-02 and 2016-26 to Drs den Hollander
   and Hoyng).
CR Anand-Apte B, 2019, J NEUROSCI RES, V97, P88, DOI 10.1002/jnr.24317
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Boon CJE, 2008, AM J HUM GENET, V82, P516, DOI 10.1016/j.ajhg.2007.11.007
   Clark SJ, 2014, J IMMUNOL, V193, P4962, DOI 10.4049/jimmunol.1401613
   Colijn JM, 2021, OPHTHALMOLOGY, V128, P1039, DOI 10.1016/j.ophtha.2020.11.024
   Colijn JM, 2017, OPHTHALMOLOGY, V124, P1753, DOI 10.1016/j.ophtha.2017.05.035
   Corominas J, 2018, OPHTHALMOLOGY, V125, P1433, DOI 10.1016/j.ophtha.2018.03.040
   De Bats Flore, 2013, ISRN Ophthalmol, V2013, P273085, DOI 10.1155/2013/273085
   de Breuk A, 2021, OPHTHALMOLOGY, V128, P1604, DOI 10.1016/j.ophtha.2020.07.037
   Duvvari MR, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0094165
   Finger RP, 2019, OPHTHALMOLOGICA, V241, P61, DOI 10.1159/000491402
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Geerlings MJ, 2018, CLIN GENET, V94, P330, DOI 10.1111/cge.13392
   Geerlings MJ, 2017, MOL IMMUNOL, V84, P65, DOI 10.1016/j.molimm.2016.11.016
   Guigui B, 2011, BRIT J OPHTHALMOL, V95, P238, DOI 10.1136/bjo.2009.178400
   Heesterbeek TJ, 2020, OPHTHAL PHYSL OPT, V40, P140, DOI 10.1111/opo.12675
   Hughes AE, 2016, ACTA OPHTHALMOL, V94, pE247, DOI 10.1111/aos.12822
   Kersten E, 2018, CLIN GENET, V94, P569, DOI 10.1111/cge.13447
   Kersten E, 2017, JAMA OPHTHALMOL, V135, P1037, DOI 10.1001/jamaophthalmol.2017.3195
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Klevering BJ, 2002, BRIT J OPHTHALMOL, V86, P91, DOI 10.1136/bjo.86.1.91
   Nathoo NA, 2014, AM J OPHTHALMOL, V158, P757, DOI 10.1016/j.ajo.2014.06.021
   Richards S, 2015, GENET MED, V17, P405, DOI 10.1038/gim.2015.30
   Saksens NTM, 2016, JAMA OPHTHALMOL, V134, P287, DOI 10.1001/jamaophthalmol.2015.5592
   Saksens NTM, 2014, PROG RETIN EYE RES, V39, P23, DOI 10.1016/j.preteyeres.2013.11.001
   Schein T., 2017, COMPLEMENT FACTSBOOK
   Seddon JM, 2013, NAT GENET, V45, P1366, DOI 10.1038/ng.2741
   Smailhodzic D, 2011, INVEST OPHTH VIS SCI, V52, P8908, DOI 10.1167/iovs.11-7926
   Taylor RL, 2019, OPHTHALMOLOGY, V126, P1410, DOI 10.1016/j.ophtha.2019.03.013
   Triebwasser MP, 2015, INVEST OPHTH VIS SCI, V56, P6873, DOI 10.1167/iovs.15-17432
   van de Ven JPH, 2013, NAT GENET, V45, P813, DOI 10.1038/ng.2640
   van de Ven JPH, 2012, ARCH OPHTHALMOL-CHIC, V130, P1038, DOI 10.1001/archophthalmol.2012.265
   van Leeuwen R, 2003, OPHTHALMOLOGY, V110, P1540, DOI 10.1016/S0161-6420(03)00501-3
   Wagner EK, 2016, SCI REP-UK, V6, DOI 10.1038/srep31531
   Yu Y, 2014, HUM MOL GENET, V23, P5283, DOI 10.1093/hmg/ddu226
   Zhan XW, 2013, NAT GENET, V45, P1375, DOI 10.1038/ng.2758
NR 36
TC 4
Z9 4
U1 0
U2 3
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 2168-6165
EI 2168-6173
J9 JAMA OPHTHALMOL
JI JAMA Ophthalmol.
PD NOV
PY 2021
VL 139
IS 11
BP 1218
EP 1226
DI 10.1001/jamaophthalmol.2021.4102
EA OCT 2021
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA XA2TC
UT WOS:000707428100006
PM 34647987
OA hybrid, Green Published
DA 2022-11-30
ER

PT J
AU Stewart, MW
   Rosenfeld, PJ
   Penha, FM
   Wang, FH
   Yehoshua, Z
   Bueno-Lopez, E
   Lopez, PF
AF Stewart, Michael W.
   Rosenfeld, Philip J.
   Penha, Fernando M.
   Wang, Fenghua
   Yehoshua, Zohar
   Bueno-Lopez, Elena
   Lopez, Pedro F.
TI PHARMACOKINETIC RATIONALE FOR DOSING EVERY 2 WEEKS VERSUS 4 WEEKS WITH
   INTRAVITREAL RANIBIZUMAB, BEVACIZUMAB, AND AFLIBERCEPT (VASCULAR
   ENDOTHELIAL GROWTH FACTOR TRAP-EYE)
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE intravitreal injection; pharmacokinetics; anti-VEGF therapy;
   ranibizumab; bevacizumab; VEGF Trap; dosing interval; biologic activity;
   aflibercept
ID MACULAR DEGENERATION; FACTOR THERAPY; VERTEPORFIN; LUCENTIS
AB Purpose: Monthly dosing with inhibitors of vascular endothelial growth factor (VEGF) results in stable or improved visual acuity in most patients with neovascular age-related macular degeneration. However, a minority of patients show little if any response to therapy with persistent or worsening macular fluid. Pharmacokinetic modeling was performed to determine if more frequent dosing with anti-VEGF drugs could be theoretically beneficial.
   Methods: A mathematical model comparing the time-dependent relative binding activities of ranibizumab, bevacizumab, and aflibercept (VEGF Trap-eye; VTE) was used to determine the theoretical peak and trough binding activities when the drugs were injected every 14 days and every 28 days. The intravitreal half-lives of ranibizumab, bevacizumab, and the VTE were estimated to be 3.2, 5.6, and 4.8 days, respectively. The relative molar binding activities of ranibizumab, bevacizumab, and the VTE used in the analyses were 1, 0.05 to 0.2, and 140, respectively. The expected peak and trough binding activities for ranibizumab, bevacizumab, and VTE were calculated. Dosing every 2 weeks was performed on selected patients who had a poor response to monthly therapy.
   Results: Dosing of a drug every 2 weeks resulted in markedly improved trough binding activity, but had little impact on the peak binding activity when calculated through Day 28. The dosing of bevacizumab every 2 weeks resulted in trough binding levels that were superior to monthly dosing with ranibizumab at a dose of 0.5 mg and potentially superior to the levels achieved when ranibizumab was dosed monthly at a dose of 2.0 mg. The VTE displayed superior binding levels for both peak and trough levels even when compared with ranibizumab doses given every 2 weeks. Two case reports demonstrate the clinical usefulness of dosing with anti-VEGF therapy every 2 weeks in eyes with VEGF-dependent macular fluid appearing to be refractory to monthly dosing.
   Conclusion: The theoretical increase in trough binding levels when anti-VEGF drugs are dosed every 2 weeks most likely explains the clinical benefit observed in patients who received biweekly injections after their poor response to monthly therapy. The short-term use of biweekly dosing may be an attractive treatment option for those eyes that show a treatment response within 2 weeks of an injection, but rebound with increased macular fluid after a month. In the future, VTE should provide higher trough levels of anti-VEGF binding activity and eliminate the need for biweekly dosing in those eyes with VEGF-mediated exudation that appear unresponsive to monthly ranibizumab or bevacizumab. RETINA 32: 434-457, 2012
C1 [Stewart, Michael W.] Mayo Clin, Dept Ophthalmol, Sch Med, Coll Med, Jacksonville, FL 32224 USA.
   [Rosenfeld, Philip J.; Penha, Fernando M.; Wang, Fenghua; Yehoshua, Zohar] Univ Miami, Miller Sch Med, Bascom Palmer Eye Inst, Miami, FL 33136 USA.
   [Wang, Fenghua] Shanghai Jiao Tong Univ, Dept Ophthalmol, Shanghai Peoples Hosp 1, Shanghai 200030, Peoples R China.
   [Bueno-Lopez, Elena; Lopez, Pedro F.] Baptist Hosp Miami, Ctr Excellence Eye Care, Miami, FL USA.
   [Bueno-Lopez, Elena; Lopez, Pedro F.] Florida Int Univ, Dept Ophthalmol, Herbert Wertheim Coll Med, Miami, FL 33199 USA.
C3 Mayo Clinic; Bascom Palmer Eye Institute; University of Miami; Shanghai
   Jiao Tong University; Baptist Hospital Miami; State University System of
   Florida; Florida International University
RP Stewart, MW (通讯作者)，Mayo Clin, Dept Ophthalmol, Sch Med, Coll Med, 4500 San Pablo Rd, Jacksonville, FL 32224 USA.
EM stewart.michael@mayo.edu
RI Penha, Fernando M/G-1784-2012
FU Research to Prevent Blindness, Inc; National Eye Institute core center
   [P30 EY014801]; NATIONAL EYE INSTITUTE [P30EY014801] Funding Source: NIH
   RePORTER
FX Supported by an unrestricted grant from Research to Prevent Blindness,
   Inc, and National Eye Institute core center grant P30 EY014801 to the
   University of Miami.
CR [Anonymous], STUDY RANIBIZUMAB AD
   [Anonymous], BAYER REGENERON REPO
   [Anonymous], COMPARISON AGE RELAT
   Brechner RJ, 2011, AM J OPHTHALMOL, V151, P887, DOI 10.1016/j.ajo.2010.11.017
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Ciulla TA, 2009, CURR OPIN OPHTHALMOL, V20, P166, DOI 10.1097/ICU.0b013e328329d173
   Ciulla TA, 2009, CURR OPIN OPHTHALMOL, V20, P158, DOI 10.1097/ICU.0b013e32832d25b3
   Fong DS, 2010, OPHTHALMOLOGY, V117, P298, DOI 10.1016/j.ophtha.2009.07.023
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Funk M, 2009, OPHTHALMOLOGY, V116, P2393, DOI 10.1016/j.ophtha.2009.05.039
   Funk M, 2009, INVEST OPHTH VIS SCI, V50, P1025, DOI 10.1167/iovs.08-2510
   Gupta OP, 2010, OPHTHALMOLOGY, V117, P2134, DOI 10.1016/j.ophtha.2010.02.032
   Heier JS, 2006, OPHTHALMOLOGY, V113, pe1, DOI DOI 10.1016/J.0PHTHA.2005.10.052)
   HEIER JS, 2006, OPHTHALMOLOGY, V113, P642
   Jyothi S, 2010, EYE, V24, P816, DOI 10.1038/eye.2009.219
   Krohne TU, 2008, AM J OPHTHALMOL, V146, P508, DOI 10.1016/j.ajo.2008.05.036
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Mitchell P, 2010, BRIT J OPHTHALMOL, V94, P2, DOI 10.1136/bjo.2009.159160
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rosenfeld PJ, 2011, OPHTHALMOLOGY, V118, P523, DOI 10.1016/j.ophtha.2010.07.011
   Rosenfeld PJ, 2005, OPHTHALMOLOGY, V112, P1048, DOI 10.1016/j.ophtha.2005.01.043
   Rosenfeld PJ, 2006, OPHTHALMOLOGY, V113, P623, DOI 10.1016/j.ophtha.2006.01.027
   Schmidt-Erfurth U, 2010, DEV OPHTHALMOL, V46, P21, DOI 10.1159/000320007
   Schouten JSAG, 2009, GRAEF ARCH CLIN EXP, V247, P1, DOI 10.1007/s00417-008-0952-y
   Stewart MW, 2008, BRIT J OPHTHALMOL, V92, P667, DOI 10.1136/bjo.2007.134874
   Stewart MW, 2007, RETINA-J RET VIT DIS, V27, P1196, DOI 10.1097/IAE.0b013e318158ea28
   Vascular Endothelial Growth Factor (VEGF), TRAP EY INV EFF SAF
   Zhu Q, 2008, OPHTHALMOLOGY, V115, P1750, DOI 10.1016/j.ophtha.2008.04.023
NR 29
TC 168
Z9 177
U1 1
U2 19
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD MAR
PY 2012
VL 32
IS 3
BP 434
EP 457
DI 10.1097/IAE.0B013E31822C290F
PG 24
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 900RU
UT WOS:000300907200004
PM 22374154
DA 2022-11-30
ER

PT J
AU Thapa, SS
   Thapa, R
   Paudyal, I
   Khanal, S
   Aujla, J
   Paudyal, G
   van Rens, G
AF Thapa, Suman S.
   Thapa, Raba
   Paudyal, Indira
   Khanal, Shankar
   Aujla, Jaskirat
   Paudyal, Govinda
   van Rens, Ger
TI Prevalence and pattern of vitreo-retinal diseases in Nepal: the
   Bhaktapur glaucoma study
SO BMC OPHTHALMOLOGY
LA English
DT Article
DE Vitreo-retinal disorders; Prevalence; Low vision; Blindness; Nepal
ID RETINAL VEIN OCCLUSION; AGE-RELATED MACULOPATHY; MACULAR DEGENERATION;
   CATARACT-SURGERY; VISUAL IMPAIRMENT; RISK-FACTORS; LOW-VISION;
   ADULT-POPULATION; RURAL-POPULATION; BLINDNESS
AB Background: Vitreo-retinal diseases are among the leading causes of visual impairment and blindness worldwide. This study reports the prevalence and pattern of vitreo-retinal diseases in the Bhaktapur Glaucoma Study (BGS), a population based study conducted in Nepal.
   Methods: BGS was a population based cross-sectional study involving 4800 subjects aged 40 years and over from Bhaktapur district. Subjects were selected using a cluster sampling methodology and a door-to-door enumeration. All subjects underwent a detailed ocular examination at the base hospital which included log MAR visual acuity, refraction, applanation tonometry and a dilated fundus examination. Fundus photography, optical coherence tomography and fundus fluorescein angiography were performed where indicated.
   Results: Complete data was available for 3966 (82.62%) out of the total of 4800 enumerated subjects. The mean age was 55.08 years (SD 11.51). The overall prevalence of vitreo-retinal disorders was 5.35% (95% CI, 4.67 - 6.09). Increasing age was associated with a higher prevalence of vitreo-retinal disorders (P < 0.001). The prevalence of diabetes mellitus was 7.69% (95% CI, 6.88 - 8.56). Age-related macular degeneration (AMD) was the most common vitreo-retinal disorder with a prevalence of 1.50% (95% CI, 1.15 - 1.94), increasing significantly with age. The prevalence of diabetic retinopathy among the study population was 0.78% (95% CI, 0.53 - 1.11) and among the diabetic population 10.16% (95% CI, 7.01 - 14.12). The population prevalence of other retinal disorders were hypertensive retinopathy 0.88%, macular scar 0.37%, retinal vein occlusion 0.50%, macular hole 0.20%, retinitis pigmentosa 0.12%. and retinal detachment 0.10%.
   The prevalence of low vision and blindness due to vitreo-retinal disorders was 1.53% (95% CI, 1.18 - 1.97) and 0.65% (95% CI, 0.43 - 0.96), respectively. The prevalence of low vision and blindness was 28.77% (95% CI, 22.78-35.37) and 12.26% (95% CI, 8.17-17.45), respectively among cases with vitreo-retinal disorders. Blindness was observed to be unilateral in 19 cases (73%), and bilateral in 7 cases (27%).
   Conclusions: The prevalence of vitreo-retinal disorders in this Nepalese population was 5.35%, which increased significantly with age. AMD was the predominant retinal condition followed by diabetic retinopathy. One fourth of the subjects with vitreo-retinal disorder had low vision. Taking into consideration the aging population and emerging systemic diseases such as diabetes mellitus and hypertension, vitreo-retinal disorders could be of future public health importance.
C1 [Thapa, Suman S.; Thapa, Raba; Paudyal, Indira; Khanal, Shankar; Aujla, Jaskirat; Paudyal, Govinda; van Rens, Ger] Tilganga Inst Ophthalmol, Nepal Glaucoma Eye Clin, Kathmandu, Nepal.
RP Thapa, SS (通讯作者)，Tilganga Inst Ophthalmol, Nepal Glaucoma Eye Clin, Kathmandu, Nepal.
EM suman.thapa@tilganga.org
OI Aujla, Jaskirat/0000-0003-3164-6077
CR *AM AC OPHTH, 1998, PREF PRACT PATT DIAB
   BENNETT S, 1991, World Health Statistics Quarterly, V44, P98
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Brilliant GE, 1988, EPIDEMIOLOGY BLINDNE
   Buch H, 2001, ACTA OPHTHALMOL SCAN, V79, P441, DOI 10.1034/j.1600-0420.2001.790503.x
   Central Bureau of statistics National Planning Commission Secretariat government of Nepal, 2001, 10 NPLCBSNPC GOV NEP, V01, P44
   Chakravarthy U, 2007, OPHTHALMOLOGY, V114, P1157, DOI 10.1016/j.ophtha.2006.09.022
   Chataut J, 2011, Kathmandu Univ Med J (KUMJ), V9, P13
   CHYLACK LT, 1989, ARCH OPHTHALMOL-CHIC, V107, P991, DOI 10.1001/archopht.1989.01070020053028
   Dandona L, 1998, LANCET, V351, P1312, DOI 10.1016/S0140-6736(97)09509-3
   Early Treatment Diabetic Retinopathy Study Research Group, 1981, OPHTHALMOLOGY, V98, P766
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Gilbert C, 2001, B WORLD HEALTH ORGAN, V79, P227
   Gupta SK, 2007, INVEST OPHTH VIS SCI, V48, P1007, DOI 10.1167/iovs.06-0712
   Hatef E, 2008, RETINA-J RET VIT DIS, V28, P755, DOI 10.1097/IAE.0b013e3181613463
   Hawkins BS, 1999, MOL VIS, V5
   Iwase A, 2006, OPHTHALMOLOGY, V113, P1354, DOI 10.1016/j.ophtha.2006.04.022
   Kempen JH, 2004, ARCH OPHTHALMOL-CHIC, V122, P552
   Klaver CCW, 1998, ARCH OPHTHALMOL-CHIC, V116, P653, DOI 10.1001/archopht.116.5.653
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Klein R, 2000, Trans Am Ophthalmol Soc, V98, P133
   Krishnaiah S, 2005, INVEST OPHTH VIS SCI, V46, P4442, DOI 10.1167/iovs.05-0853
   Kumar A, 1998, Indian J Ophthalmol, V46, P65
   Liang YB, 2008, OPHTHALMOLOGY, V115, P1965, DOI 10.1016/j.ophtha.2008.05.030
   Lim LL, 2008, BRIT J OPHTHALMOL, V92, P1316, DOI 10.1136/bjo.2008.140640
   Ministry of Health (HMG), 2002, HLTH SECT STRAT AG C
   Mitchell P, 1996, ARCH OPHTHALMOL-CHIC, V114, P1243, DOI 10.1001/archopht.1996.01100140443012
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Nirmalan PK, 2004, ARCH OPHTHALMOL-CHIC, V122, P581, DOI 10.1001/archopht.122.4.581
   Paudyal G, 2008, Nepal Med Coll J, V10, P160
   Raman R, 2009, OPHTHALMOLOGY, V116, P311, DOI 10.1016/j.ophtha.2008.09.010
   Resnikoff S, 2004, B WORLD HEALTH ORGAN, V82, P844
   Sapkota YD, 2006, BRIT J OPHTHALMOL, V90, P411, DOI 10.1136/bjo.2005.082503
   Sapkota YD, 2010, OPHTHAL EPIDEMIOL, V17, P82, DOI 10.3109/09286581003624947
   SCHACHAT AP, 1995, ARCH OPHTHALMOL-CHIC, V113, P728, DOI 10.1001/archopht.1995.01100060054032
   Sen P, 2008, OPHTHAL EPIDEMIOL, V15, P279, DOI 10.1080/09286580802105814
   Sen P, 2008, CLIN EXP OPHTHALMOL, V36, P257, DOI 10.1111/j.1442-9071.2008.01715.x
   Sharma Deewakar, 2006, Indian Heart J, V58, P34
   Soori H, 2011, J PAK MED ASSOC, V61, P544
   Thapa R, 2011, Kathmandu Univ Med J (KUMJ), V9, P165
   Thapa SS, 2011, CLIN EXP OPHTHALMOL, V39, P851, DOI 10.1111/j.1442-9071.2011.02576.x
   Thapa SS, 2011, BMC OPHTHALMOL, V11, DOI 10.1186/1471-2415-11-2
   Thapa SS, 2011, CLIN EXP OPHTHALMOL, V39, P126, DOI 10.1111/j.1442-9071.2010.02429.x
   Varma R, 2004, OPHTHALMOLOGY, V111, P1288, DOI 10.1016/j.ophtha.2004.01.023
   Wang FH, 2009, OPHTHALMOLOGY, V116, P461, DOI 10.1016/j.ophtha.2008.10.003
   Wang S, 2006, AM J OPHTHALMOL, V141, P589, DOI 10.1016/j.ajo.2005.10.021
   West S, 2001, B WORLD HEALTH ORGAN, V79, P244
   Wild S, 2004, DIABETES CARE, V27, P1047, DOI 10.2337/diacare.27.5.1047
   Wong TY, OPHTHALMOLOGY, V111, P1869
   World Health Organization, 2004, INT STAT CLASS DIS H
   WU LZ, 1987, JPN J OPHTHALMOL, V31, P349
   Yasuda M, 2010, INVEST OPHTH VIS SCI, V51, P3205, DOI 10.1167/iovs.09-4453
NR 52
TC 39
Z9 39
U1 0
U2 11
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1471-2415
J9 BMC OPHTHALMOL
JI BMC Ophthalmol.
PD MAR 28
PY 2013
VL 13
AR 9
DI 10.1186/1471-2415-13-9
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 122GW
UT WOS:000317307500001
PM 23537395
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Thumann, G
AF Thumann, Gabriele
TI Prospectives for Gene Therapy of Retinal Degenerations
SO CURRENT GENOMICS
LA English
DT Article
DE Adeno-associated viral vector; age-related macular degeneration;
   diabetic retinopathy; gene therapy; Leber congenital amaurosis; retinal
   degenerations; retinitis pigmentosa; Sleeping Beauty transposon;
   Stargardt disease
ID LEBER CONGENITAL AMAUROSIS; PIGMENT EPITHELIAL-CELLS; ENDOTHELIAL
   GROWTH-FACTOR; PLURIPOTENT STEM-CELLS; ROD OUTER SEGMENTS; MACULAR
   DEGENERATION; VISUAL FUNCTION; MOUSE MODEL; SLEEPING-BEAUTY; IN-VIVO
AB Retinal degenerations encompass a large number of diseases in which the retina and associated retinal pigment epithelial (RPE) cells progressively degenerate leading to severe visual disorders or blindness. Retinal degenerations can be divided into two groups, a group in which the defect has been linked to a specific gene and a second group that has a complex etiology that includes environmental and genetic influences. The first group encompasses a number of relatively rare diseases with the most prevalent being Retinitis pigmentosa that affects approximately 1 million individuals worldwide. Attempts have been made to correct the defective gene by transfecting the appropriate cells with the wild-type gene and while these attempts have been successful in animal models, human gene therapy for these inherited retinal degenerations has only begun recently and the results are promising. To the second group belong glaucoma, age-related macular degeneration (AMD) and diabetic retinopathy (DR). These retinal degenerations have a genetic component since they occur more often in families with affected probands but they are also linked to environmental factors, specifically elevated intraocular pressure, age and high blood sugar levels respectively. The economic and medical impact of these three diseases can be assessed by the number of individuals affected; AMD affects over 30 million, DR over 40 million and glaucoma over 65 million individuals worldwide. The basic defect in these diseases appears to be the relative lack of a neurogenic environment; the neovascularization that often accompanies these diseases has suggested that a decrease in pigment epithelium-derived factor (PEDF), at least in part, may be responsible for the neurodegeneration since PEDF is not only an effective neurogenic and neuroprotective agent but also a potent inhibitor of neovascularization. In the last few years inhibitors of vascularization, especially antibodies against vascular endothelial cell growth factors (VEGF), have been used to prevent the neovascularization that accompanies AMD and DR resulting in the amelioration of vision in a significant number of patients. In animal models it has been shown that transfection of RPE cells with the gene for PEDF and other growth factors can prevent or slow degeneration. A limited number of studies in humans have also shown that transfection of RPE cells in vivo with the gene for PEDF is effective in preventing degeneration and restore vision. Most of these studies have used virally mediated gene delivery with all its accompanying side effects and have not been widely used. New techniques using non-viral protocols that allow efficient delivery and permanent integration of the transgene into the host cell genome offer novel opportunities for effective treatment of retinal degenerations.
C1 Rhein Westfal TH Aachen, IZKF Aachen, Univ Augenklin, D-52074 Aachen, Germany.
C3 RWTH Aachen University; RWTH Aachen University Hospital; University of
   Hamburg; University Medical Center Hamburg-Eppendorf
RP Thumann, G (通讯作者)，Rhein Westfal TH Aachen, IZKF Aachen, Univ Augenklin, Pauwelsstr 30, D-52074 Aachen, Germany.
EM gthumann@googlemail.com
CR Abe T, 1999, CELL TRANSPLANT, V8, P501, DOI 10.1177/096368979900800505
   Acland GM, 2005, MOL THER, V12, P1072, DOI 10.1016/j.ymthe.2005.08.008
   Acland GM, 2001, NAT GENET, V28, P92, DOI 10.1038/ng0501-92
   Adelman RA, 2010, J OCUL PHARMACOL TH, V26, P105, DOI 10.1089/jop.2009.0076
   Aisenbrey S, 2006, ARCH OPHTHALMOL-CHIC, V124, P183, DOI 10.1001/archopht.124.2.183
   Ali M, 2009, AM J HUM GENET, V84, P664, DOI 10.1016/j.ajhg.2009.03.017
   Alikhani M, 2010, MOL VIS, V16, P408
   Allikmets R, 1997, NAT GENET, V15, P236, DOI 10.1038/ng0397-236
   ALSTROM CH, 1957, HEREDITAS, V43, P1
   Amaral J, 2010, INVEST OPHTH VIS SCI, V51, P1318, DOI 10.1167/iovs.09-4455
   ANDERSON KL, 1995, AM J HUM GENET, V57, P1351
   Antonetti DA, 1998, DIABETES, V47, P1953, DOI 10.2337/diabetes.47.12.1953
   Arnhold S, 2004, EXP NEUROL, V187, P410, DOI 10.1016/j.expneurol.2004.02.015
   Azarian SM, 1997, FEBS LETT, V409, P247, DOI 10.1016/S0014-5793(97)00517-6
   Bagley RG, 2011, MOL CANCER THER, V10, P404, DOI 10.1158/1535-7163.MCT-10-0813
   Bainbridge JWB, 2008, NEW ENGL J MED, V358, P2231, DOI 10.1056/NEJMoa0802268
   Bejjani BA, 1998, AM J HUM GENET, V62, P325, DOI 10.1086/301725
   Belay E, 2011, CURR GENE THER, V11, P406
   Belay E, 2010, STEM CELLS, V28, P1760, DOI 10.1002/stem.501
   Bennicelli J, 2008, MOL THER, V16, P458, DOI 10.1038/sj.mt.6300389
   Berson E L, 1990, Trans Am Ophthalmol Soc, V88, P355
   Bhutto IA, 2006, EXP EYE RES, V82, P99, DOI 10.1016/j.exer.2005.05.007
   Binder S, 2004, INVEST OPHTH VIS SCI, V45, P4151, DOI 10.1167/iovs.04-0118
   Binder S, 2002, AM J OPHTHALMOL, V133, P215, DOI 10.1016/S0002-9394(01)01373-3
   Binder S, 2007, PROG RETIN EYE RES, V26, P516, DOI 10.1016/j.preteyeres.2007.02.002
   Bixler GV, 2011, BMC MED GENOMICS, V4, DOI 10.1186/1755-8794-4-40
   Blacharski P.A., 1988, RETINAL DYSTROPHY DE, P135
   Boeri D, 2001, DIABETES, V50, P1432, DOI 10.2337/diabetes.50.6.1432
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Bull ND, 2009, INVEST OPHTH VIS SCI, V50, P4244, DOI 10.1167/iovs.08-3239
   Butterwick A, 2007, IEEE T BIO-MED ENG, V54, P2261, DOI 10.1109/TBME.2007.908310
   Campochiaro PA, 2006, HUM GENE THER, V17, P167, DOI 10.1089/hum.2006.17.167
   Carr AJ, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008152
   Chang B, 2002, VISION RES, V42, P517, DOI 10.1016/S0042-6989(01)00146-8
   Chen MF, 2010, INVEST OPHTH VIS SCI, V51, P5970, DOI 10.1167/iovs.09-4504
   Cideciyan AV, 2009, HUM GENE THER, V20, P999, DOI 10.1089/hum.2009.086
   Cideciyan AV, 2008, P NATL ACAD SCI USA, V105, P15112, DOI 10.1073/pnas.0807027105
   Cideciyan AV, 1998, P NATL ACAD SCI USA, V95, P7103, DOI 10.1073/pnas.95.12.7103
   Crafoord S, 2002, ACTA OPHTHALMOL SCAN, V80, P387, DOI 10.1034/j.1600-0420.2002.800408.x
   Cubeddu R, 1999, PHOTOCHEM PHOTOBIOL, V70, P172, DOI 10.1111/j.1751-1097.1999.tb07986.x
   Curtis TM, 2009, EYE, V23, P1496, DOI 10.1038/eye.2009.108
   Dalkara D, 2011, MOL THER, V19, P1602, DOI 10.1038/mt.2011.62
   Dandona L, 2001, INVEST OPHTH VIS SCI, V42, P908
   Davis RJ, 2008, INVEST OPHTH VIS SCI, V49, P5067, DOI 10.1167/iovs.07-1422
   Dejneka NS, 2004, MOL THER, V9, P182, DOI 10.1016/j.ymthe.2003.11.013
   den Hollander AI, 2008, PROG RETIN EYE RES, V27, P391, DOI 10.1016/j.preteyeres.2008.05.003
   Djalali-Talab Y., 2011, INVEST OPHTH VIS SCI, V52, P4380
   Downs MA, 2006, VISION RES, V46, P4442, DOI 10.1016/j.visres.2006.07.021
   Dreyer EB, 1998, J GLAUCOMA, V7, P62
   Dreyer EB, 1997, CLIN NEUROSCI, V4, P270
   Du HJ, 2011, SEMIN OPHTHALMOL, V26, P216, DOI 10.3109/08820538.2011.577498
   Eurell TE, 2003, VET OPHTHALMOL, V6, P237, DOI 10.1046/j.1463-5224.2003.00300.x
   Falkner-Radler CI, 2011, BRIT J OPHTHALMOL, V95, P370, DOI 10.1136/bjo.2009.176305
   FARRAR GJ, 1991, NATURE, V354, P478, DOI 10.1038/354478a0
   Frank RN, 2004, NEW ENGL J MED, V350, P48, DOI 10.1056/NEJMra021678
   Giacco F, 2010, CIRC RES, V107, P1058, DOI 10.1161/CIRCRESAHA.110.223545
   Ginn SL, 2010, MOL THER, V18, P965, DOI 10.1038/mt.2010.50
   Gould DB, 2004, MOL CELL BIOL, V24, P9019, DOI 10.1128/MCB.24.20.9019-9025.2004
   Gould DB, 2006, MOL CELL BIOL, V26, P8427, DOI 10.1128/MCB.01127-06
   Gouras P, 2002, INVEST OPHTH VIS SCI, V43, P3307
   Gu SM, 1997, NAT GENET, V17, P194, DOI 10.1038/ng1097-194
   Hamel CP, 2000, J FR OPHTALMOL, V23, P985
   Han JH, 2010, CLIN EXP OPHTHALMOL, V38, P620, DOI 10.1111/j.1442-9071.2010.02276.x
   Harper MM, 2011, INVEST OPHTH VIS SCI, V52, P4506, DOI 10.1167/iovs.11-7346
   Hartman ZC, 2007, VIROLOGY, V358, P357, DOI 10.1016/j.virol.2006.08.041
   Hartong DT, 2006, LANCET, V368, P1795, DOI 10.1016/S0140-6736(06)69740-7
   Hauswirth WW, 2008, HUM GENE THER, V19, P979, DOI 10.1089/hum.2008.107
   Holekamp NM, 2002, AM J OPHTHALMOL, V134, P220, DOI 10.1016/S0002-9394(02)01549-0
   Huang YM, 2011, STEM CELL REV REP, V7, P434, DOI 10.1007/s12015-010-9192-8
   Ideno J, 2007, INT J MOL MED, V19, P75
   Illing M, 1997, J BIOL CHEM, V272, P10303, DOI 10.1074/jbc.272.15.10303
   Ishikawa H, 2005, GENE THER, V12, P289, DOI 10.1038/sj.gt.3302277
   Ivics Z, 1997, CELL, V91, P501, DOI 10.1016/S0092-8674(00)80436-5
   Izsvak Z, 2010, BIOESSAYS, V32, P756, DOI 10.1002/bies.201000027
   Izsvak Z, 2009, METHODS, V49, P287, DOI 10.1016/j.ymeth.2009.07.001
   Jacobson SG, 2006, MOL THER, V13, P1074, DOI 10.1016/j.ymthe.2006.03.005
   Jacobson SG, 2012, ARCH OPHTHALMOL-CHIC, V130, P9, DOI 10.1001/archophthalmol.2011.298
   Johnen S., 2011, INVEST OPHTH VIS SCI, V52, P4379
   Johnson TV, 2010, INVEST OPHTH VIS SCI, V51, P2051, DOI 10.1167/iovs.09-4509
   Kachi S, 2005, GENE THER, V12, P843, DOI 10.1038/sj.gt.3302475
   Kaiser PK, 2006, GRAEF ARCH CLIN EXP, V244, P1132, DOI 10.1007/s00417-005-0199-9
   KAJIWARA K, 1991, NATURE, V354, P480, DOI 10.1038/354480a0
   Khalfaoui T, 2009, PATHOL BIOL, V57, P513, DOI 10.1016/j.patbio.2008.07.021
   Kim BS, 2001, MOL CELL BIOL, V21, P7707, DOI 10.1128/MCB.21.22.7707-7713.2001
   Klimanskaya I, 2004, CLONING STEM CELLS, V6, P217, DOI 10.1089/1536230042323420
   Kociok N, 1998, EXP EYE RES, V67, P237, DOI 10.1006/exer.1998.0517
   Kociok N, 2007, GRAEF ARCH CLIN EXP, V245, P101, DOI 10.1007/s00417-006-0266-x
   Kong J, 2008, GENE THER, V15, P1311, DOI 10.1038/gt.2008.78
   Kozulin P, 2010, INVEST OPHTH VIS SCI, V51, P4298, DOI 10.1167/iovs.09-4905
   Krishnan R, 2009, CLIN EXP OPHTHALMOL, V37, P384, DOI 10.1111/j.1442-9071.2009.02043.x
   Ku CA, 2011, HUM MOL GENET, V20, P4569, DOI 10.1093/hmg/ddr391
   Kwak N., 2004, INVEST OPHTH VIS SCI, V4, P3158
   Lai Chooi-May, 2004, Genet Vaccines Ther, V2, P3, DOI 10.1186/1479-0556-2-3
   Lamba DA, 2006, P NATL ACAD SCI USA, V103, P12769, DOI 10.1073/pnas.0601990103
   Lamba DA, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008763
   Lamba DA, 2009, CELL STEM CELL, V4, P73, DOI 10.1016/j.stem.2008.10.015
   Lappas A, 2004, GRAEF ARCH CLIN EXP, V242, P638, DOI 10.1007/s00417-003-0764-z
   Le Gat L, 2003, GENE THER, V10, P2098, DOI 10.1038/sj.gt.3302122
   Leber T., 1869, GRAEFES ARCH CLIN EX, V15, P13, DOI DOI 10.1007/BF02721213
   Lee CJ, 2007, BIOMATERIALS, V28, P2192, DOI 10.1016/j.biomaterials.2007.01.018
   Levin Leonard A, 2005, Ophthalmol Clin North Am, V18, P585
   Li TS, 1996, P NATL ACAD SCI USA, V93, P14176, DOI 10.1073/pnas.93.24.14176
   Li X, 2011, INVEST OPHTH VIS SCI, V52, P7, DOI 10.1167/iovs.10-6138
   Li Y, 2010, CELL REPROGRAM, V12, P237, DOI 10.1089/cell.2009.0103
   Li YW, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009495
   Liu GY, 2005, J MOL BIOL, V346, P161, DOI 10.1016/j.jmb.2004.09.086
   Lu B, 2009, STEM CELLS, V27, P2126, DOI 10.1002/stem.149
   Lund RD, 2006, CLONING STEM CELLS, V8, P189, DOI 10.1089/clo.2006.8.189
   MacLaren RE, 2006, NATURE, V444, P203, DOI 10.1038/nature05161
   Maguire AM, 2008, NEW ENGL J MED, V358, P2240, DOI 10.1056/NEJMoa0802315
   Maguire AM, 2009, LANCET, V374, P1597, DOI 10.1016/S0140-6736(09)61836-5
   Marlhens F, 1997, NAT GENET, V17, P139, DOI 10.1038/ng1097-139
   Mata NL, 2001, INVEST OPHTH VIS SCI, V42, P1685
   Mates L, 2009, NAT GENET, V41, P753, DOI 10.1038/ng.343
   Mathews MK, 1997, INVEST OPHTH VIS SCI, V38, P2729
   Merlak M, 2008, COLLEGIUM ANTROPOL, V32, P39
   Mihelec M, 2011, HUM GENE THER, V22, P1179, DOI 10.1089/hum.2011.069
   Milam AH, 1998, PROG RETIN EYE RES, V17, P175
   Millington-Ward S, 2011, MOL THER, V19, P642, DOI 10.1038/mt.2010.293
   Milne R., 2011, AMINO ACIDS
   Milton RC, 2005, OPHTHALMOLOGY, V112, P533, DOI 10.1016/j.ophtha.2004.10.047
   Miyazaki M, 2011, HUM GENE THER, V22, P559, DOI 10.1089/hum.2010.132
   Mordenti J, 1999, TOXICOL PATHOL, V27, P536, DOI 10.1177/019262339902700507
   Morissette J, 1998, NAT GENET, V19, P319, DOI 10.1038/1203
   Mozaffarieh M, 2008, SURV OPHTHALMOL, V53, P479, DOI 10.1016/j.survophthal.2008.06.006
   Mozaffarieh M, 2008, MOL VIS, V14, P224
   Mruthyunjaya P, 2004, OPHTHALMOLOGY, V111, P1715, DOI 10.1016/j.ophtha.2004.03.022
   Murakami Y, 2010, HUM GENE THER, V21, P199, DOI 10.1089/hum.2009.102
   Nusinowitz S, 2006, VISION RES, V46, P3926, DOI 10.1016/j.visres.2006.05.010
   Ohno-Matsui K, 2006, MOL VIS, V12, P1022
   Ohno-Matsui Kyoko, 2003, Nippon Ganka Gakkai Zasshi, V107, P657
   Okita K, 2007, NATURE, V448, P313, DOI 10.1038/nature05934
   Osakada F, 2008, NAT BIOTECHNOL, V26, P215, DOI 10.1038/nbt1384
   Pang JJ, 2006, MOL THER, V13, P565, DOI 10.1016/j.ymthe.2005.09.001
   Pang JJ, 2005, MOL VIS, V11, P152
   Parameswaran S, 2010, STEM CELLS, V28, P695, DOI 10.1002/stem.320
   Pawlyk BS, 2010, HUM GENE THER, V21, P993, DOI 10.1089/hum.2009.218
   Pechan P, 2009, GENE THER, V16, P10, DOI 10.1038/gt.2008.115
   Plasilova M, 1998, HUM HERED, V48, P30
   Quigley HA, 2006, BRIT J OPHTHALMOL, V90, P262, DOI 10.1136/bjo.2005.081224
   Ramirez M, 2011, INVEST OPHTH VIS SCI, V52, P8944, DOI 10.1167/iovs.11-8190
   Redmond TM, 1998, NAT GENET, V20, P344, DOI 10.1038/3813
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Santos JM, 2011, CURR PHARM BIOTECHNO, V12, P352
   SCHAPPERTKIMMIJSER J, 1959, ARCH OPHTHALMOL-CHIC, V61, P211
   Seiler MJ, 2010, J NEUROSCI METH, V188, P250, DOI 10.1016/j.jneumeth.2010.02.018
   Sen P, 2008, OPHTHAL EPIDEMIOL, V15, P279, DOI 10.1080/09286580802105814
   Sheikpranbabu S, 2011, DIABETES METAB, V37, P505, DOI 10.1016/j.diabet.2011.03.006
   Simonelli F, 2010, MOL THER, V18, P643, DOI 10.1038/mt.2009.277
   Singh MS, 2011, P ROY SOC B-BIOL SCI, V278, P3009, DOI 10.1098/rspb.2011.1028
   Singh SR, 2009, GENE THER, V16, P645, DOI 10.1038/gt.2008.185
   Spranger J, 2001, DIABETES, V50, P2641, DOI 10.2337/diabetes.50.12.2641
   Stargardt K., 1909, GRAEFES ARCH CLIN EX, V71, P534, DOI DOI 10.1007/BF01961301
   Stoilov I, 1997, HUM MOL GENET, V6, P641, DOI 10.1093/hmg/6.4.641
   Sun H, 1999, J BIOL CHEM, V274, P8269, DOI 10.1074/jbc.274.12.8269
   Suzuki Y, 2011, JPN J OPHTHALMOL, V55, P256, DOI 10.1007/s10384-011-0004-8
   Takahashi M, 1999, J VIROL, V73, P7812, DOI 10.1128/JVI.73.9.7812-7816.1999
   Tezcaner A, 2008, J BIOMED MATER RES A, V86A, P170, DOI 10.1002/jbm.a.31600
   Thomson HA, 2010, J BIOMED MATER RES A, V95A, P1233, DOI 10.1002/jbm.a.32940
   Thumann G, 2006, CURR EYE RES, V31, P241, DOI 10.1080/02713680600556966
   Thumann G, 1999, TRANSPLANTATION, V68, P195, DOI 10.1097/00007890-199907270-00006
   Thumann G, 1998, GRAEF ARCH CLIN EXP, V236, P753, DOI 10.1007/s004170050154
   Thumann G, 1999, GRAEF ARCH CLIN EXP, V237, P1046, DOI 10.1007/s004170050343
   Thumann G, 2009, GRAEF ARCH CLIN EXP, V247, P363, DOI 10.1007/s00417-008-0998-x
   Thumann G, 2009, BIOMATERIALS, V30, P287, DOI 10.1016/j.biomaterials.2008.09.039
   Tong JP, 2006, AM J OPHTHALMOL, V141, P456, DOI 10.1016/j.ajo.2005.10.012
   Tosi J, 2011, EXP BIOL MED, V236, P1211, DOI 10.1258/ebm.2011.011053
   Trudeau K, 2011, INVEST OPHTH VIS SCI, V52, P8657, DOI 10.1167/iovs.11-7934
   Tucker BA, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018992
   Tuo JS, 2012, NEUROBIOL AGING, V33, DOI 10.1016/j.neurobiolaging.2011.01.009
   Van Adel BA, 2003, HUM GENE THER, V14, P103, DOI 10.1089/104303403321070801
   Veske A, 1999, GENOMICS, V57, P57, DOI 10.1006/geno.1999.5754
   Wang NK, 2010, TRANSPLANTATION, V89, P911, DOI 10.1097/TP.0b013e3181d45a61
   Wang S., 2008, INVEST OPHTH VIS SCI, V49, P16
   Wang SM, 2005, INVEST OPHTH VIS SCI, V46, P2552, DOI 10.1167/iovs.05-0279
   Weng J, 1999, CELL, V98, P13, DOI 10.1016/S0092-8674(00)80602-9
   Xu L, 2006, EUR J OPHTHALMOL, V16, P865
   Yant SR, 2005, MOL CELL BIOL, V25, P2085, DOI 10.1128/MCB.25.6.2085-2094.2005
   Yoshida Takeshi, 2007, Nippon Ganka Gakkai Zasshi, V111, P881
   Yoshioka Y, 2006, INVEST OPHTH VIS SCI, V47, P745, DOI 10.1167/iovs.05-0398
   Zayed H, 2004, MOL THER, V9, P292, DOI 10.1016/j.ymthe.2003.11.024
   Zhang TR, 2009, INVEST OPHTH VIS SCI, V50, P2982, DOI 10.1167/iovs.08-2131
   Zhang XZ, 2010, JAMA-J AM MED ASSOC, V304, P649, DOI 10.1001/jama.2010.1111
   ZVYAGA TA, 1994, BIOCHEMISTRY-US, V33, P9753, DOI 10.1021/bi00198a046
NR 184
TC 17
Z9 21
U1 1
U2 28
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 1389-2029
EI 1875-5488
J9 CURR GENOMICS
JI Curr. Genomics
PD AUG
PY 2012
VL 13
IS 5
BP 350
EP 362
DI 10.2174/138920212801619214
PG 13
WC Biochemistry & Molecular Biology; Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Genetics & Heredity
GA 975FL
UT WOS:000306492900002
PM 23372421
OA Green Published, Green Submitted
DA 2022-11-30
ER

PT J
AU Loane, E
   Nolan, JM
   Mckay, GJ
   Beatty, S
AF Loane, Edward
   Nolan, John M.
   McKay, Gareth J.
   Beatty, Stephen
TI The association between macular pigment optical density and CFH, ARMS2,
   C2/BF, and C3 genotype
SO EXPERIMENTAL EYE RESEARCH
LA English
DT Article
DE age-related macular degeneration; age-related maculopathy
   susceptibility; 2 gene; carotenoids; Complement factor H; lutein;
   macular pigment; zeaxanthin
ID AGE-RELATED MACULOPATHY; COMPLEMENT FACTOR-H; RISK-FACTORS; PRIMATE
   RETINAS; PROTECTIVE ROLE; COMPONENT 2; DEGENERATION; CAROTENOIDS;
   LOC387715; VARIANT
AB Age-related macular degeneration (AMD) is the most common cause of blindness in older people in developed countries, and risk for this condition may be classified as genetic or environmental, with an interaction between such factors predisposing to this disease. This study investigated the relationship between AMD risk genes, macular pigment optical density (MPOD), which may protect against AMD, and serum concentrations of the macular carotenoids, lutein (L) and zeaxanthin (Z). This was a cross-sectional study of 302 healthy adult subjects. Dietary intake of L and Z was assessed by food frequency questionnaire, and MPOD was measured by customized heterochromatic flicker photometry. We also calculated MPOD Area as the area of MP under the spatial profile curve, to reflect MP across the macula. Serum L and Z were measured by HPLC. Genotyping of tag SNPs in the genes CFH, ARMS2, C3, C2 and BF was undertaken with multiplex polymerase chain reaction (PCR) and primer extension methodology (ABI Snapshot, ABI Warrington UK) on DNA extracted from peripheral blood. The mean +/- SD (range) age of the subjects in this study was 48 +/- 11(21-66) years. There was a statistically significant association between CFH genotype and family history of AMD, with subjects having two non-risk CFH haplotypes (n = 35), or one non-risk and one protective CFH haplotype (n = 33), being significantly more likely to have a negative family history of AMD (Pearson Chi square: p = 0.001). There was no significant association between the AMD risk genes investigated and either MPOD (One way ANOVA: p > 0.05) or serum concentrations of L or Z (One way ANOVA: p > 0.05, for both). Subjects who were homozygous for risk alleles of both CFH and ARMS2 (n = 4) had significantly lower MPOD at 0.5 degrees and 1 degrees retinal eccentricity (Independent samples t test: p < 0.05) and lower MPOD Area which approached statistical significance (Independent samples t test: p = 0.058), compared to other subjects (n = 291). In conclusion, this study did not detect an association between individual AMD risk genotypes and the putatively protective MP, or serum concentrations of its constituent carotenoids. However, the combination of homozygous risk alleles at both CFH and ARMS2 loci was associated with significantly lower MPOD centrally, despite comparable serum concentrations of the macular carotenoids. These findings suggest that the maculae of subjects at very high genetic risk of AMD represent a hostile environment for accumulation and/or stabilization of MP. (C) 2011 Elsevier Ltd. All rights reserved.
C1 [Loane, Edward; Nolan, John M.; Beatty, Stephen] Waterford Inst Technol, Dept Chem & Life Sci, Macular Pigment Res Grp, Waterford, Ireland.
   [Loane, Edward] St Vincents Univ Hosp, Dept Ophthalmol, Dublin 4, Ireland.
   [Nolan, John M.; Beatty, Stephen] Whitfield Clin, Inst Vis Res, Waterford, Ireland.
   [McKay, Gareth J.] Queens Univ Belfast, Ctr Publ Hlth, Belfast, Antrim, North Ireland.
   [Beatty, Stephen] Whitfield Clin, Inst Eye Surg, Waterford, Ireland.
C3 South East Technological University (SETU); University College Dublin;
   Saint Vincent's University Hospital; Queens University Belfast
RP Loane, E (通讯作者)，Waterford Inst Technol, Dept Chem & Life Sci, Macular Pigment Res Grp, Waterford, Ireland.
EM edwardloane@yahoo.com
RI McKay, Gareth/AAZ-2601-2020; Nolan, John/N-4921-2014
OI McKay, Gareth/0000-0001-8197-6280; Nolan, John/0000-0002-5503-7084
FU EU; Bausch Lomb, Ireland
FX Grant information: EU Strand 1 research grant; Bausch & Lomb, Ireland
   research grant.
CR Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Beatty S, 2001, INVEST OPHTH VIS SCI, V42, P439
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   BONE RA, 1992, VISION RES, V32, P105, DOI 10.1016/0042-6989(92)90118-3
   BONE RA, 1993, INVEST OPHTH VIS SCI, V34, P2033
   Bressler Neil M, 2004, JAMA, V291, P1900, DOI 10.1001/jama.291.15.1900
   Ciulla TA, 2001, OPHTHALMOLOGY, V108, P730, DOI 10.1016/S0161-6420(00)00655-2
   Congdon NG, 2003, JAMA-J AM MED ASSOC, V290, P2057, DOI 10.1001/jama.290.15.2057
   Conley YP, 2006, HUM MOL GENET, V15, P3206, DOI 10.1093/hmg/ddl396
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Fritsche LG, 2008, NAT GENET, V40, P892, DOI 10.1038/ng.170
   Gold B, 2006, NAT GENET, V38, P458, DOI 10.1038/ng1750
   Gotoh N, 2009, AM J OPHTHALMOL, V147, P1037, DOI 10.1016/j.ajo.2008.12.036
   HAEGERSTROMPORTNOY G, 1988, J OPT SOC AM A, V5, P2140, DOI 10.1364/JOSAA.5.002140
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   HAM WT, 1976, NATURE, V260, P153, DOI 10.1038/260153a0
   Hammond BR, 2000, INVEST OPHTH VIS SCI, V41, P1492
   Hoang QV, 2002, VISUAL NEUROSCI, V19, P395, DOI 10.1017/S0952523802194028
   Hollyfield JG, 2008, NAT MED, V14, P194, DOI 10.1038/nm1709
   Hughes AE, 2007, PLOS MED, V4, P1993, DOI 10.1371/journal.pmed.0040355
   Hughes AE, 2006, NAT GENET, V38, P1173, DOI 10.1038/ng1890
   Izumi-Nagai K, 2007, ARTERIOSCL THROM VAS, V27, P2555, DOI 10.1161/ATVBAHA.107.151431
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Jakobsdottir J, 2005, AM J HUM GENET, V77, P389, DOI 10.1086/444437
   Johnson EJ, 2005, INVEST OPHTH VIS SCI, V46, P692, DOI 10.1167/iovs.02-1192
   Johnson LV, 2000, EXP EYE RES, V70, P441, DOI 10.1006/exer.1999.0798
   Kanda A, 2007, P NATL ACAD SCI USA, V104, P16227, DOI 10.1073/pnas.0703933104
   Kim IK, 2008, MOL VIS, V14, P1487
   Kirby ML, 2009, INVEST OPHTH VIS SCI, V50, P1383, DOI 10.1167/iovs.08-2494
   KLEIN R, 1995, INVEST OPHTH VIS SCI, V36, P182
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   KRINSKY NI, 1982, J NATL CANCER I, V69, P205
   Leveziel N, 2007, MOL VIS, V13, P2153
   Liew SHM, 2005, INVEST OPHTH VIS SCI, V46, P4430, DOI 10.1167/iovs.05-0519
   LIM BP, 1992, BIOCHIM BIOPHYS ACTA, V1126, P178
   Loane E, 2008, BRIT J OPHTHALMOL, V92, P1163, DOI 10.1136/bjo.2007.135566
   Loane E, 2007, CURR EYE RES, V32, P555, DOI 10.1080/02713680701418405
   Loane E, 2010, INVEST OPHTH VIS SCI, V51, P2636, DOI 10.1167/iovs.09-4397
   Maller JB, 2007, NAT GENET, V39, P1200, DOI 10.1038/ng2131
   McKay GJ, 2009, INVEST OPHTH VIS SCI, V50, P533, DOI 10.1167/iovs.08-2275
   Mellerio J, 2002, CURR EYE RES, V25, P37, DOI 10.1076/ceyr.25.1.37.9961
   Nolan JM, 2008, INVEST OPHTH VIS SCI, V49, P2134, DOI 10.1167/iovs.07-0933
   Nolan JM, 2007, EXP EYE RES, V84, P61, DOI 10.1016/j.exer.2006.08.016
   Organisciak DT, 1999, PHOTOCHEM PHOTOBIOL, V70, P261, DOI 10.1111/j.1751-1097.1999.tb07998.x
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Ross RJ, 2007, INVEST OPHTH VIS SCI, V48, P1128, DOI 10.1167/iovs.06-0999
   Seddon JM, 2007, JAMA-J AM MED ASSOC, V297, P1793, DOI 10.1001/jama.297.16.1793
   Seddon JM, 2006, HUM HERED, V61, P157, DOI 10.1159/000094141
   Snodderly DM, 2004, INVEST OPHTH VIS SCI, V45, P531, DOI 10.1167/iovs.03-0762
   SNODDERLY DM, 1995, AM J CLIN NUTR, V62, P1448
   SNODDERLY DM, 1984, INVEST OPHTH VIS SCI, V25, P674
   Tomany SC, 2004, OPHTHALMOLOGY, V111, P1280, DOI 10.1016/j.ophtha.2003.11.010
   van Leeuwen R, 2003, EUR J EPIDEMIOL, V18, P845, DOI 10.1023/A:1025643303914
   Walport MJ, 2001, NEW ENGL J MED, V344, P1058, DOI 10.1056/NEJM200104053441406
   Wooten BR, 1999, INVEST OPHTH VIS SCI, V40, P2481
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
NR 59
TC 13
Z9 13
U1 0
U2 4
PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 0014-4835
J9 EXP EYE RES
JI Exp. Eye Res.
PD NOV
PY 2011
VL 93
IS 5
BP 592
EP 598
DI 10.1016/j.exer.2011.07.005
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 855AK
UT WOS:000297535700005
PM 21816153
DA 2022-11-30
ER

PT J
AU Goody, RJ
   Hu, WZ
   Shafiee, A
   Struharik, M
   Bartels, S
   Lopez, FJ
   Lawrence, MS
AF Goody, Robin J.
   Hu, Wenzheng
   Shafiee, Afshin
   Struharik, Michael
   Bartels, Stephen
   Lopez, Francisco J.
   Lawrence, Matthew S.
TI Optimization of laser-induced choroidal neovascularization in African
   green monkeys
SO EXPERIMENTAL EYE RESEARCH
LA English
DT Article
DE laser-induced choroidal neovascularization; age-related macular
   degeneration; nonhuman primate; African green monkey; Chlorocebus
   sabaeus; animal model; VEGF
ID GROWTH-FACTOR ANTIBODY; MACULAR DEGENERATION; INDUCED CNV; INTRAVITREAL
   INJECTION; VERTEPORFIN PDT; VEGF-A; RANIBIZUMAB; MODEL;
   PHOTOCOAGULATION; BEVACIZUMAB
AB We developed and validated a new nonhuman primate model of laser-induced choroidal neovascularization (CNV) that addresses study design limitations prevalent in laser-induced CNV-based efficacy studies. Laser-induced Bruch's membrane disruption triggers CNV and has been widely utilized in animals to model neovascular ("wet") age-related macular degeneration (AMD). Despite widespread use of the approach, detailed assessment of experimental parameters and their influence on pathophysiological endpoints critical for disease modeling has been extremely limited and largely based on anecdotal observations. We evaluated laser power parameters and endpoint measures to optimize methods for CNV formation and quantification to facilitate drug efficacy screening in African green monkeys. Six laser spots of 350, 550, 750, 950 or 1500 mW laser power were positioned bilaterally 1.5 disc diameters from the fovea, within the macula. Fluorescein angiograms were collected 3-5 weeks later and scored by trained masked investigators using graded (I-IV) and densitometric methods. Histopathology assessments were also performed, including determination of CNV area. Test system sensitivity to angiogenesis inhibition was subsequently assessed by evaluating the effect of intravitreal bevacizumab (Avastin) pretreatment (one day prior to laser photocoagulation) on incidence of CNV. Grade III and grade IV lesions were considered clinically relevant, demonstrating early hyperfluorescence and late leakage within or beyond the lesion borders. By 4 weeks post-laser all treatment groups demonstrated evidence of grade III lesions with greatest incidence observed in lesions induced by 750 and 950 mW laser power (72.9% and 69.4% respectively). Grade IV lesions were confined to eyes receiving 550 mW laser power or higher, with highest incidence of grade IV lesions observed in eyes receiving 950(19.4%) and 1500 mW (31%) laser spots, incidence peaking 4 weeks post-laser photocoagulation. Densitometric analyses of angiograms corroborated visual scoring. Bevacizumab completely abolished grade IV lesion development and significantly lowered lesion fluorescein signal intensity (P < 0.0001) and CNV area (P = 0.038) compared to vehicle-treated controls. Our studies demonstrate that laser power of 950-1500 mW and angiography analysis 4 weeks post-laser are optimal parameters to evaluate treatment effects on CNV induction following laser photocoagulation. Bevacizumab significantly attenuated CNV development, as determined by fluorescein angiography and histopathology assessments in this model, supporting the application of African green monkeys in preclinical modeling of CNV. Laser parameters and time points for therapeutic dosing and angiography endpoints are critical factors to the laser-induced CNV model and must be validated for robust assessment of efficacy. The newly optimized nonhuman primate model described will facilitate preclinical efficacy assessments of novel therapeutics for CNV. (C) 2011 Elsevier Ltd. All rights reserved.
C1 [Goody, Robin J.; Struharik, Michael; Lawrence, Matthew S.] RxGen Inc, Hamden, CT 06517 USA.
   [Hu, Wenzheng; Shafiee, Afshin; Bartels, Stephen; Lopez, Francisco J.] Bausch & Lomb Inc, Preclin Pharmacol, Rochester, NY 14603 USA.
C3 Bausch Health; Bausch + Lomb
RP Lawrence, MS (通讯作者)，RxGen Inc, 100 Deepwood Dr, Hamden, CT 06517 USA.
EM mlawrence@rx-gen.com
FU Bausch Lomb
FX WH, AS, SB, FJL were employees at Bausch & Lomb during the experimental
   analysis described in this manuscript. Bausch & Lomb develops and
   manufactures ophthalmic drugs and devices and provide financial support
   towards components of detailed model development.
CR BARANY E, 1963, INVEST OPHTH VISUAL, V2, P322
   BARANY EH, 1977, ACTA OPHTHALMOL, V55, P141
   Campa C, 2008, INVEST OPHTH VIS SCI, V49, P1178, DOI 10.1167/iovs.07-1194
   Carlsson HE, 2004, AM J PRIMATOL, V63, P225, DOI 10.1002/ajp.20054
   Ciulla TA, 2009, CURR OPIN OPHTHALMOL, V20, P158, DOI 10.1097/ICU.0b013e32832d25b3
   FRANCOIS J, 1975, AM J OPHTHALMOL, V79, P206, DOI 10.1016/0002-9394(75)90073-2
   Green W R, 1999, Mol Vis, V5, P27
   Hu WZ, 2009, EXP EYE RES, V88, P79, DOI 10.1016/j.exer.2008.10.014
   Husain D, 2005, ARCH OPHTHALMOL-CHIC, V123, P509, DOI 10.1001/archopht.123.4.509
   Kim IK, 2006, INVEST OPHTH VIS SCI, V47, P357, DOI 10.1167/iovs.04-0087
   Koh HJ, 2006, RETINA-J RET VIT DIS, V26, P202, DOI 10.1097/00006982-200602000-00014
   Krzystolik MG, 2002, ARCH OPHTHALMOL-CHIC, V120, P338
   Kwak N, 2000, INVEST OPHTH VIS SCI, V41, P3158
   Lai CC, 2001, INVEST OPHTH VIS SCI, V42, P2401
   Lichtlen P, 2010, INVEST OPHTH VIS SCI, V51, P4738, DOI 10.1167/iovs.09-4890
   Lu F, 2009, GRAEF ARCH CLIN EXP, V247, P171, DOI 10.1007/s00417-008-0936-y
   Marano RJ, 2006, BIOTECH HISTOCHEM, V81, P59, DOI 10.1080/10520290600799131
   Marano RJ, 2005, GENE THER, V12, P1544, DOI 10.1038/sj.gt.3302579
   Merrill NL, 2007, J MED PRIMATOL, V36, P33, DOI 10.1111/j.1600-0684.2006.00176.x
   MILLER JW, 1995, ARCH OPHTHALMOL-CHIC, V113, P810, DOI 10.1001/archopht.1995.01100060136048
   Ozkiris A, 2010, EXPERT OPIN THER PAT, V20, P103, DOI 10.1517/13543770902762885
   Resnikoff S, 2004, B WORLD HEALTH ORGAN, V82, P844
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Ryan S J, 1979, Trans Am Ophthalmol Soc, V77, P707
   RYAN SJ, 1982, ARCH OPHTHALMOL-CHIC, V100, P1804, DOI 10.1001/archopht.1982.01030040784015
   Shen WY, 2002, LAB INVEST, V82, P167, DOI 10.1038/labinvest.3780409
   Shen WY, 2004, ARCH OPHTHALMOL-CHIC, V122, P353, DOI 10.1001/archopht.122.3.353
   Takahashi H, 2006, J OCUL PHARMACOL TH, V22, P213, DOI 10.1089/jop.2006.22.213
   Tolentino MJ, 2000, ARCH OPHTHALMOL-CHIC, V118, P78
   Yanagi Y, 2002, INVEST OPHTH VIS SCI, V43, P3495
   Yu LL, 2008, INVEST OPHTH VIS SCI, V49, P522, DOI 10.1167/iovs.07-1175
   Zhang Ming, 2008, Sichuan Da Xue Xue Bao Yi Xue Ban, V39, P567
NR 32
TC 27
Z9 29
U1 0
U2 5
PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 0014-4835
EI 1096-0007
J9 EXP EYE RES
JI Exp. Eye Res.
PD JUN
PY 2011
VL 92
IS 6
BP 464
EP 472
DI 10.1016/j.exer.2011.03.006
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 774HL
UT WOS:000291376200005
PM 21414311
DA 2022-11-30
ER

PT J
AU Bressler, SB
   Hawkins, BS
   Marsh, MJ
   Bressler, NM
AF Bressler, Susan B.
   Hawkins, Barbara S.
   Marsh, Marta J.
   Bressler, Neil M.
TI Guidelines for interpreting retinal photographs and coding findings in
   the Submacular Surgery Trials (SST) - SST report no. 8
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
ID MACULAR DEGENERATION
AB Purpose: To describe the guidelines followed by the Submacular Surgery Trials (SST) Research Group in the interpretation of color fundus photographs and fluorescein angiograms of subfoveal choroidal neovascular lesions evaluated in the SST and to assist ophthalmologists in applying the results of the SST.
   Methods: Stereoscopic color fundus photographs and fluorescein angiograms of the study eye and nonstudy eye of 1,015 patients with subfoveal choroidal neovascular lesions secondary to age-related macular degeneration, ocular histoplasmosis syndrome, or idiopathic choroidal neovascularization (CNV) were obtained and graded by certified SST fundus photograph readers at the baseline examination in three randomized clinical trials comparing surgery with observation. Adherence to the inclusion and exclusion criteria and ocular features that might affect visual outcome were documented. Stereoscopic color fundus photography and fluorescein angiography were repeated 1 month after randomization for patients assigned to surgery to provide documentation that surgery was performed and to assess compliance with the surgery protocol. Photographs and fluorescein angiograms of both the study eye and the fellow eye in all patients then were obtained 3 months, 6 months, and 12 months after randomization and then annually up to 48 months. The K statistic was used to evaluate interobserver reliability of photograph gradings.
   Results: Lesion components at baseline included classic CNV, occult CNV, and features contiguous to CNV, including blood, fibrous tissue, hypofluorescence not corresponding to blood, serous detachment of the retinal pigment epithelium, and prior areas of laser photocoagulation. At follow-up, fluorescein leakage from CNV was assessed peripheral to or within the area of the retinal pigment epithelium abnormality after surgery. The lesion at follow-up could include any of the features identified at baseline as well as retinal pigment epithelium abnormalities, such as mottling of the retinal pigment epithelium with a subtle transition to normal retinal pigment epithelium or a very sharply demarcated, markedly hypopigmented area that was easily distinguished from the surrounding retinal pigment epithelium. K statistics for interobserver reliability ranged from good (0.47) to excellent (1.00) for features graded at baseline and follow-up.
   Conclusions: Although some of the definitions essential to the interpretation of the SST are similar to those used in the Macular Photocoagulation Study and randomized clinical trials of photodynamic therapy with verteporfin, this guideline provides new information regarding lesion components at baseline as well as standardized descriptions of lesions after submacular surgery. These descriptions from the SST assist in understanding what lesions were studied, when additional treatment was considered after surgery, and how anatomical results should be interpreted.
C1 Coordinating Ctr, Baltimore, MD 21287 USA.
RP Hawkins, BS (通讯作者)，Coordinating Ctr, 550 N Broadway,9th Floor, Baltimore, MD 21287 USA.
EM bhawkins@jhmi.edu
FU NATIONAL EYE INSTITUTE [U10EY011557, U10EY011547, U10EY011558] Funding
   Source: NIH RePORTER; NEI NIH HHS [EY11557, U10 EY011557-08, U10
   EY011558, U10 EY011547, EY11558, U10 EY011557, U10 EY011547-07, U10
   EY11547, U10 EY011558-07] Funding Source: Medline
CR [Anonymous], 1991, Arch Ophthalmol, V109, P1109
   Arnold J, 2002, RETINA-J RET VIT DIS, V22, P6
   Arnold J, 2001, AM J OPHTHALMOL, V131, P541
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   BRESSLER NM, 1987, ARCH OPHTHALMOL-CHIC, V105, P209
   FERRIS FL, 1983, AM J EPIDEMIOL, V118, P132, DOI 10.1093/oxfordjournals.aje.a113624
   FREUND KB, 1993, AM J OPHTHALMOL, V115, P786, DOI 10.1016/S0002-9394(14)73649-9
   HAWKINS BS, 1993, ARCH OPHTHALMOL-CHIC, V111, P1200
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   MOISSEIEV J, 1995, ARCH OPHTHALMOL-CHIC, V113, P185, DOI 10.1001/archopht.1995.01100020069031
   SCHACHAT AP, 1994, ARCH OPHTHALMOL-CHIC, V112, P500
   STERNBERG P, 1991, ARCH OPHTHALMOL-CHIC, V109, P1242
   *TREAT AG REL MAC, 2003, ARCH OPHTHALMOL-CHIC, V121, P12533
   2003, ARCH OPHTHAMOL, V121, P1621
NR 14
TC 7
Z9 7
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD APR-MAY
PY 2005
VL 25
IS 3
BP 253
EP 268
PG 16
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 100QT
UT WOS:000241684400002
PM 15805900
DA 2022-11-30
ER

PT J
AU Kim, JH
   Chang, YS
   Lee, TG
   Kim, CG
AF Kim, Jae Hui
   Chang, Young Suk
   Lee, Tae Gon
   Kim, Chul Gu
TI Choroidal Vascular Hyperpermeability and Punctate Hyperfluorescent Spot
   in Choroidal Neovascularization
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
DE AMD; choroidal vascular hyperpermeability; punctate hyperfluorescent
   spot; choroidal neovascularization; indocyanine green angiography
ID RETINAL ANGIOMATOUS PROLIFERATION; CENTRAL SEROUS CHORIORETINOPATHY;
   INDOCYANINE GREEN VIDEOANGIOGRAPHY; MACULAR DEGENERATION;
   PIGMENT-EPITHELIUM; THICKNESS CHANGES; VASCULOPATHY; RANIBIZUMAB; EYES;
   ANGIOGRAPHY
AB PURPOSE. To evaluate the prevalence of choroidal vascular hyperpermeability and punctate hyperfluorescent spots in eyes with choroidal neovascularization (CNV).
   METHODS. This retrospective, observational study included 382 eyes with typical exudative AMD (97 eyes), polypoidal choroidal vasculopathy (PCV, 163 eyes), retinal angiomatous proliferation (RAP, 37 eyes), or myopic CNV (86 eyes). The prevalence of choroidal vascular hyperpermeability and punctate hyperfluorescent spots was estimated based on available indocyanine green angiography (ICGA) images.
   RESULTS. Choroidal vascular hyperpermeability was noted in 12.4% (12 eyes) and 26.9% (42 eyes) of eyes with typical exudative AMD and PCV, respectively. Choroidal vascular hyperpermeability was not noted in any eye with RAP or myopic CNV. Punctate hyperfluorescent spots were noted in 43.3% (42 eyes), 72.4% (118 eyes), 10.8% (4 eyes), and 4.7% (4 eyes) of eyes with typical exudative AMD, PCV, RAP, and myopic CNV, respectively. Of the 56 eyes with choroidal vascular hyperpermeability, punctate hyperfluorescent spots were noted in 55 eyes (98.2%).
   CONCLUSIONS. Choroidal vascular hyperpermeability and punctate hyperfluorescent spots may have a common pathophysiology. Although choroidal vascular hyperpermeability and punctate hyperfluorescent spots have been thought to be associated with pathologic conditions, the markedly low prevalence of these findings in eyes with RAP and myopic CNV may not be a normal finding. It is possible that compromised choroidal perfusion, with or without associated with choroidal thinning, may lead the low prevalence of these abnormalities in eyes with these two disorders.
C1 [Kim, Jae Hui; Lee, Tae Gon; Kim, Chul Gu] Konyang Univ, Coll Med, Dept Ophthalmol, Kims Eye Hosp, Seoul, South Korea.
   [Chang, Young Suk] Konyang Univ, Coll Med, Dept Ophthalmol, Taejon, South Korea.
C3 Konyang University; Konyang University Hospital; Konyang University;
   Konyang University Hospital
RP Kim, JH (通讯作者)，Kims Eye Hosp, Dept Ophthalmol, 156 Youngdeungpo Dong 4ga, Seoul 150034, South Korea.
EM kimoph@gmail.com
FU Kim's Eye Hospital Research Center (Seoul, South Korea)
FX Supported by grants from Kim's Eye Hospital Research Center (Seoul,
   South Korea).
CR Arnold JJ, 1997, AM J OPHTHALMOL, V124, P344, DOI 10.1016/S0002-9394(14)70826-8
   Cao XS, 2014, RETINA-J RET VIT DIS, V34, P1554, DOI 10.1097/IAE.0000000000000122
   Cho HJ, 2013, AM J OPHTHALMOL, V156, P1192, DOI 10.1016/j.ajo.2013.07.001
   Chung SE, 2013, RETINA-J RET VIT DIS, V33, P834, DOI 10.1097/IAE.0b013e31826af540
   Chung SE, 2011, OPHTHALMOLOGY, V118, P840, DOI 10.1016/j.ophtha.2010.09.012
   Flores-Moreno I, 2013, BRIT J OPHTHALMOL, V97, P1010, DOI 10.1136/bjophthalmol-2012-302836
   Fujiwara T, 2009, AM J OPHTHALMOL, V148, P445, DOI 10.1016/j.ajo.2009.04.029
   Giovannini A, 1997, RETINA-J RET VIT DIS, V17, P286, DOI 10.1097/00006982-199707000-00002
   GUYER DR, 1994, ARCH OPHTHALMOL-CHIC, V112, P1057, DOI 10.1001/archopht.1994.01090200063023
   Iida T, 1999, RETINA-J RET VIT DIS, V19, P508, DOI 10.1097/00006982-199911000-00005
   Imamura Y, 2009, RETINA-J RET VIT DIS, V29, P1469, DOI 10.1097/IAE.0b013e3181be0a83
   Jirarattanasopa P, 2012, INVEST OPHTH VIS SCI, V53, P3663, DOI 10.1167/iovs.12-9619
   Kim JH, 2014, BRIT J OPHTHALMOL, V98, P1066, DOI 10.1136/bjophthalmol-2013-304405
   Kim JH, 2013, AM J OPHTHALMOL, V155, P743, DOI 10.1016/j.ajo.2012.11.001
   Kitaya N, 2003, BRIT J OPHTHALMOL, V87, P709, DOI 10.1136/bjo.87.6.709
   Koizumi H, 2008, GRAEF ARCH CLIN EXP, V246, P515, DOI 10.1007/s00417-007-0705-3
   Koizumi H, 2013, AM J OPHTHALMOL, V155, P305, DOI 10.1016/j.ajo.2012.07.018
   Lim SJ, 2010, RETINA-J RET VIT DIS, V30, P100, DOI 10.1097/IAE.0b013e3181bcf0b4
   Margolis R, 2009, AM J OPHTHALMOL, V147, P811, DOI 10.1016/j.ajo.2008.12.008
   Maruko I, 2011, AM J OPHTHALMOL, V151, P594, DOI 10.1016/j.ajo.2010.10.030
   McDonnell EC, 2014, EUR J OPHTHALMOL, V24, P897, DOI 10.5301/ejo.5000509
   Menchini U, 1997, INT OPHTHALMOL, V21, P57, DOI 10.1023/A:1005880129005
   Miyake M, 2014, INVEST OPHTH VIS SCI, V55, P3223, DOI 10.1167/iovs.14-14059
   Nishida Y, 2012, RETINA-J RET VIT DIS, V32, P1229, DOI 10.1097/IAE.0b013e318242b990
   Park SJ, 2014, AM J OPHTHALMOL, V158, P1155, DOI 10.1016/j.ajo.2014.08.010
   Park SJ, 2014, AM J OPHTHALMOL, V158, pe1
   Prunte C, 1996, AM J OPHTHALMOL, V121, P26
   Read SA, 2013, INVEST OPHTH VIS SCI, V54, P7578, DOI 10.1167/iovs.13-12772
   Sasahara M, 2006, AM J OPHTHALMOL, V142, P601, DOI 10.1016/j.ajo.2006.05.051
   Sizmaz S, 2014, EUR J OPHTHALMOL, V24, P904, DOI 10.5301/ejo.5000478
   Sonoda S, 2013, BMC OPHTHALMOL, V13, DOI 10.1186/1471-2415-13-43
   SPAIDE RF, 1995, RETINA-J RET VIT DIS, V15, P100, DOI 10.1097/00006982-199515020-00003
   Spaide RF, 2008, AM J OPHTHALMOL, V146, P496, DOI 10.1016/j.ajo.2008.05.032
   Spraul CW, 1996, INVEST OPHTH VIS SCI, V37, P2724
   Troilo D, 2000, INVEST OPHTH VIS SCI, V41, P1249
   Tsujikawa A, 2010, RETINA-J RET VIT DIS, V30, P801, DOI 10.1097/IAE.0b013e3181c72068
   Wakabayashi T, 2010, BRIT J OPHTHALMOL, V94, P611, DOI 10.1136/bjo.2009.163535
   Wood A, 2011, AM J OPHTHALMOL, V152, P1030, DOI 10.1016/j.ajo.2011.05.021
   Yamazaki T, 2014, RETINA-J RET VIT DIS, V34, P1316, DOI 10.1097/IAE.0000000000000086
   Yamazaki T, 2012, OPHTHALMOLOGY, V119, P1621, DOI 10.1016/j.ophtha.2012.02.022
   Yannuzzi LA, 2001, RETINA-J RET VIT DIS, V21, P416, DOI 10.1097/00006982-200110000-00003
NR 41
TC 22
Z9 22
U1 0
U2 0
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD MAR
PY 2015
VL 56
IS 3
BP 1909
EP 1915
DI 10.1167/iovs.14-16000
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA CE9BF
UT WOS:000352137600064
PM 25722216
DA 2022-11-30
ER

PT J
AU Sobolewska, B
   Golenko, J
   Poeschel, S
   Grimmel, C
   Gatsiou, A
   Sopova, K
   Biedermann, T
   Schenke-Layland, K
   Stellos, K
   Ziemssen, F
AF Sobolewska, B.
   Golenko, J.
   Poeschel, S.
   Grimmel, C.
   Gatsiou, A.
   Sopova, K.
   Biedermann, T.
   Schenke-Layland, K.
   Stellos, K.
   Ziemssen, F.
TI Influence of aflibercept on platelet activation profile
SO EXPERIMENTAL EYE RESEARCH
LA English
DT Article
DE Aflibercept; Arterial thromboembolic event; Platelet activation;
   Thrombin; Proteinase-activated receptor
ID ARTERIAL THROMBOEMBOLIC EVENTS; ADVANCED COLORECTAL-CANCER; RETINAL
   ENDOTHELIAL-CELLS; MACULAR DEGENERATION; POOLED ANALYSIS;
   RANDOMIZED-TRIAL; ADVERSE EVENTS; BEVACIZUMAB; VEGF; SAFETY
AB Aflibercept appears to accumulate in systemic circulation following intravitreal injections in therapy of neovascular age-related macular degeneration. This gives raise to the question of whether aflibercept affects platelets and their function such as activation and aggregation, which are substantial in the pathogenesis of an arterial thromboembolic event (ATE). In order to determine the effect of aflibercept in platelet activation, platelets from healthy volunteers were treated with aflibercept and its solvents at equal concentrations (0.04 mu g/mL - 4 mu g/mL - 40 mu g/mL - 400 mu g/mL - 4 mg/mL) for 10 and 30 min before addition of agonists. IgG1 antibody was used as a control. The surface expression of GPIIb/IIIa, P-selectin, and platelet-bound stromal-cell-derived factor-1, which are potential blood biomarkers for ATEs, was determined on resting and activated platelets by the multispectral imaging flow cytometry, combining the features of flow cytometry with fluorescence microscopy. Platelet aggregation was assessed with light transmission aggregometry. To determine whether aflibercept directly interacts with platelets, aflibercept was labeled with the fluorescence FITC.
   Co-treatment of platelets with thrombin or PAR-4-AP and aflibercept resulted in increased activation of the fibrinogen receptor GPIIb/IIIa in comparison to controls (P < 0.05). Interestingly, the expression of platelet-derived P-selectin and SDF-1 was not affected by aflibercept, except thrombin-activated CD62P with 0.04 mu g/mL aflibercept (aflibercept vs. its solvent: MSI = 1.54, IC = 1.201-1.879 vs. MSI = 1.37, IC = 1.136-1.604 [P = 0.0311) and SDF-1 with 4 mg/mL aflibercept (aflibercept vs. its solvent: MSI = 1.971, IC = 1.206-2.737 vs. MSI = 1.200, IC = 0.738-1.662 [P = 0.041]). Although the levels of platelet-bound aflibercept-FITC were significantly increased in all activated platelets, no effect was observed in platelet aggregation.
   Albeit no impact of aflibercept was found on platelet aggregation under the studied experimental conditions, the increased activation of the fibrinogen receptor GPIIb/IIIa and the presence of a direct interaction between aflibercept and platelets may partially explain the risk of ATE in patients under aflibercept treatment due to Fc gamma RIIa mediated alpha IIlb beta 3 outside-in integrin signaling and transport of aflibercept into platelets. Therefore, the Fc domain seems to be involved in interactions between aflibercept and platelets. Further research is needed to explain the role of Fc containing aflibercept in the pathogenesis of drug-associated vascular events involving platelets, coagulation cascade, extracellular matrix proteins and other cells.
C1 [Sobolewska, B.; Golenko, J.; Ziemssen, F.] Eberhard Karls Univ Tubingen, Ctr Ophthalmol, Schleichstr 12,Elfriede Aulhorn Str 7, D-72076 Tubingen, Germany.
   [Gatsiou, A.; Stellos, K.] JW Goethe Univ Frankfurt Main, Inst Cardiovasc Regenerat, Frankfurt, Germany.
   [Grimmel, C.; Biedermann, T.] Eberhard Karls Univ Tubingen, Dept Dermatol, Tubingen, Germany.
   [Sopova, K.; Stellos, K.] JW Goethe Univ Frankfurt Main, Dept Cardiol, Frankfurt, Germany.
   [Poeschel, S.; Schenke-Layland, K.] Eberhard Karls Univ Tubingen, Res Inst Womens Hlth, Dept Womens Hlth, Tubingen, Germany.
   [Stellos, K.] Newcastle Univ, Inst Med Genet, Newcastle Upon Tyne, Tyne & Wear, England.
C3 Eberhard Karls University of Tubingen; Eberhard Karls University
   Hospital; Goethe University Frankfurt; Eberhard Karls University of
   Tubingen; Eberhard Karls University Hospital; Goethe University
   Frankfurt; Eberhard Karls University of Tubingen; Newcastle University -
   UK
RP Sobolewska, B (通讯作者)，Eberhard Karls Univ Tubingen, Ctr Ophthalmol, Schleichstr 12,Elfriede Aulhorn Str 7, D-72076 Tubingen, Germany.
EM bianka.sob@gmx.de
RI Stellos, Konstantinos/AAF-2711-2020; Ziemssen, Focke/AAY-1686-2021;
   Sobolewska, Bianka/A-8492-2015; Stellos, Konstantinos/ABH-1523-2021;
   Schenke-Layland, Katja/E-5940-2013
OI Schenke-Layland, Katja/0000-0001-8066-5157; Gatsiou,
   Aikaterini/0000-0003-4144-4305; Stellos,
   Konstantinos/0000-0002-0194-0825
FU Galderma; Novartis; Santen
FX B. Sobolewska has received a travel grant from Galderma, Novartis, and
   Santen. F. Ziemssen has received consulting fees from Alimera, Allergan,
   Bayer HealthCare, Boehringer-Ingelheim, MSD and Novartis, and speaker
   fees from Alcon, Allergan, Bayer HealthCare, and Novartis.
CR Arman M, 2015, J THROMB HAEMOST, V13, P893, DOI 10.1111/jth.12905
   Avery RL, 2017, RETINA-J RET VIT DIS, V37, P1847, DOI 10.1097/IAE.0000000000001493
   Avery RL, 2016, JAMA OPHTHALMOL, V134, P21, DOI 10.1001/jamaophthalmol.2015.4070
   Avery RL, 2014, BRIT J OPHTHALMOL, V98, P1636, DOI 10.1136/bjophthalmol-2014-305252
   Boylan B, 2008, BLOOD, V112, P2780, DOI 10.1182/blood-2008-02-142125
   Chauhan AK, 2007, J THROMB HAEMOST, V5, P583, DOI 10.1111/j.1538-7836.2007.02361.x
   Ciombor KK, 2015, CURR COLORECT CANC R, V11, P378, DOI 10.1007/s11888-015-0292-3
   Ciombor KK, 2013, CLIN CANCER RES, V19, P1920, DOI 10.1158/1078-0432.CCR-12-2911
   Costagliola C, 2012, EXPERT OPIN BIOL TH, V12, P1299, DOI 10.1517/14712598.2012.707176
   Deissler HL, 2017, EXP EYE RES, V154, P39, DOI 10.1016/j.exer.2016.11.007
   Deissler HL, 2014, EXP EYE RES, V122, P20, DOI 10.1016/j.exer.2014.02.024
   Deissler HL, 2013, EXP EYE RES, V115, P162, DOI 10.1016/j.exer.2013.07.018
   Fateh-Moghadam S, 2007, THROMB HAEMOSTASIS, V97, P974, DOI 10.1160/TH06-12-0725
   Fehr M, 2011, SWISS MED WKLY, V141, DOI 10.4414/smw.2011.13243
   Gilbert MR, 2014, NEW ENGL J MED, V370, P699, DOI 10.1056/NEJMoa1308573
   Hasan N, 2012, BRIT J CLIN PHARMACO, V74, P230, DOI 10.1111/j.1365-2125.2012.04212.x
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Herrmann J, 2016, CIRCULATION, V133, P1272, DOI 10.1161/CIRCULATIONAHA.115.018347
   Hurwitz HI, 2013, ONCOLOGIST, V18, P1004, DOI 10.1634/theoncologist.2013-0107
   Isenberg JS, 2009, NAT REV CANCER, V9, P182, DOI 10.1038/nrc2561
   Jennings LK, 2009, THROMB HAEMOSTASIS, V102, P248, DOI 10.1160/TH09-03-0192
   Julien S, 2013, BRIT J OPHTHALMOL, V97, P511, DOI 10.1136/bjophthalmol-2012-302308
   Kabbinavar FF, 2009, J CLIN ONCOL, V27, P199, DOI 10.1200/JCO.2008.17.7931
   Klettner A, 2014, BRIT J OPHTHALMOL, V98, P1448, DOI 10.1136/bjophthalmol-2014-305105
   MacDonald DA, 2016, ANGIOGENESIS, V19, P389, DOI 10.1007/s10456-016-9515-8
   Meyer CH, 2011, EYE, V25, P661, DOI 10.1038/eye.2011.66
   Petrelli F, 2013, CLIN COLORECTAL CANC, V12, P145, DOI 10.1016/j.clcc.2013.04.006
   Scappaticci FA, 2007, JNCI-J NATL CANCER I, V99, P1232, DOI 10.1093/jnci/djm086
   Schmid MK, 2015, BRIT J OPHTHALMOL, V99, P141, DOI 10.1136/bjophthalmol-2014-305149
   Schmidt-Erfurth U, 2014, OPHTHALMOLOGY, V121, P193, DOI 10.1016/j.ophtha.2013.08.011
   Semeraro F, 2013, DRUG DES DEV THER, V7, P711, DOI 10.2147/DDDT.S40215
   Sobolewska B, 2015, OPHTHALMOLOGICA, V234, P195, DOI 10.1159/000437057
   Stellos K, 2012, J THROMB HAEMOST, V10, P49, DOI 10.1111/j.1538-7836.2011.04547.x
   Stellos K, 2010, J THROMB HAEMOST, V8, P205, DOI 10.1111/j.1538-7836.2009.03659.x
   Stellos K, 2010, SEMIN THROMB HEMOST, V36, P175, DOI 10.1055/s-0030-1251502
   Tebbutt NC, 2011, ANN ONCOL, V22, P1834, DOI 10.1093/annonc/mdq702
   Thulliez M, 2018, JAMA OPHTHALMOL, V136, P557, DOI 10.1001/jamaophthalmol.2018.0002
   Tuzovic Mirela, 2018, Curr Treat Options Cardiovasc Med, V20, P40, DOI 10.1007/s11936-018-0635-x
   Van Cutsem E, 2012, J CLIN ONCOL, V30, P3499, DOI 10.1200/JCO.2012.42.8201
   Verheu HMW, 2007, CLIN CANCER RES, V13, P5341, DOI 10.1158/1078-0432.CCR-07-0847
   Walraven M, 2018, ANGIOGENESIS, V21, P325, DOI 10.1007/s10456-018-9598-5
   Winnik S, 2013, INT J CARDIOL, V168, P2453, DOI 10.1016/j.ijcard.2013.03.010
   Wurster T, 2013, INT J CARDIOL, V164, P111, DOI 10.1016/j.ijcard.2011.06.082
   Yao J, 2011, P NATL ACAD SCI USA, V108, P11590, DOI 10.1073/pnas.1109029108
   Ziemssen F, 2016, EXPERT OPIN DRUG SAF, V15, P75, DOI 10.1517/14740338.2016.1121232
NR 45
TC 6
Z9 6
U1 0
U2 6
PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 0014-4835
EI 1096-0007
J9 EXP EYE RES
JI Exp. Eye Res.
PD OCT
PY 2018
VL 175
BP 166
EP 172
DI 10.1016/j.exer.2018.06.009
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA GX2TW
UT WOS:000447574000019
PM 29908884
DA 2022-11-30
ER

PT J
AU Fenwick, EK
   Ong, PG
   Man, REK
   Cheng, CY
   Sabanayagam, C
   Wong, TY
   Lamoureux, EL
AF Fenwick, Eva K.
   Ong, Peng Guan
   Man, Ryan Eyn Kidd
   Cheng, Ching-Yu
   Sabanayagam, Charumathi
   Wong, Tien Y.
   Lamoureux, Ecosse L.
TI Association of Vision Impairment and Major Eye Diseases With Mobility
   and Independence in a Chinese Population
SO JAMA OPHTHALMOLOGY
LA English
DT Article
ID QUALITY-OF-LIFE; SINGAPORE MALAY EYE; BLUE-MOUNTAINS-EYE; VISUAL
   IMPAIRMENT; OLDER-ADULTS; CATARACT-SURGERY; GLAUCOMA; IMPACT; HEALTH;
   AGE
AB IMPORTANCE Mobility limitations arising from vision impairment (VI) can result in loss of independence and reduced quality of life. However, few data are available on the association between VI and mobility limitations at a population-based level, particularly in Asian populations.
   OBJECTIVE To assess the association of VI and major eye diseases with mobility and independence (M&I) in a Chinese population.
   DESIGN, SETTING, AND PARTICIPANTS The Singapore Chinese Eye Study (February 9, 2009, to December 19, 2011) was a population-based, cross-sectional study of 3353 persons aged 40 to 80 years of Chinese ethnicity. Patients underwent visual acuity testing, and sociodemographic and medical data were collected from standardized questionnaires. Data analysis for this study was performed October 2015 to April 2016.
   EXPOSURES Presenting bilateral visual acuity (categorized as none, moderate, or severe VI) and major eye diseases (cataract, uncorrected refractive error, glaucoma, age-related macular degeneration, and diabetic retinopathy).
   MAIN OUTCOMES AND MEASURES Patients answered questions on the M&I scale of the Impact of Vision Impairment questionnaire, validated using Rasch analysis. The composite M&I score (score range, -4.47 to 7.48 logits; higher scores indicate better M&I) and 11 individual item scores were the main outcomes. The association between bilateral VI and eye conditions and the composite and individual M&I item scores was assessed using linear regression models.
   RESULTS Of the 3353 patients, the mean (SD) age was 59.7 (9.9) years, and 1662 (49.6%) were male. The mean (SD) presenting visual acuity values in the better and worse eyes were 0.20 (0.21) and 0.39 (0.42) logMAR, respectively. A total of 1432 patients (42.7%) and 114 patients (3.4%) had moderate and severe bilateral VI, respectively. Mobility and independence systematically worsened as the severity of bilateral VI increased. There was a clinically meaningful reduction in M&I (20%; beta, -1.44; 95% CI, -1.75 to -1.13) and all 11 M&I tasks in patients with severe bilateral VI compared with no VI. Glaucoma (13%; beta, -0.94; 95% CI, -1.82 to -0.06) and cataract (6%; beta, -0.43; 95% CI, -0.65 to -0.22) were independently associated with worse M&I, with patients with glaucoma particularly concerned about avoiding falling or tripping.
   CONCLUSIONS AND RELEVANCE Bilateral VI in this population was associated with substantial decrements in M&I, with glaucoma and cataract independently associated with worse M&I. Although these associations do not prove that preventing bilateral VI will improve M&I in this population, the results suggest that such interventions could be of tremendous value from this perspective.
C1 [Fenwick, Eva K.; Ong, Peng Guan; Man, Ryan Eyn Kidd; Cheng, Ching-Yu; Sabanayagam, Charumathi; Wong, Tien Y.; Lamoureux, Ecosse L.] Singapore Natl Eye Ctr, Singapore Eye Res Inst, Singapore, Singapore.
   [Fenwick, Eva K.] Univ Melbourne, Royal Victorian Eye & Ear Hosp, Ctr Eye Res Australia, Melbourne, Vic, Australia.
   [Fenwick, Eva K.; Cheng, Ching-Yu; Sabanayagam, Charumathi; Wong, Tien Y.; Lamoureux, Ecosse L.] Natl Univ Singapore, Duke NUS Med Sch, Singapore, Singapore.
   [Cheng, Ching-Yu; Wong, Tien Y.; Lamoureux, Ecosse L.] Natl Univ Singapore, Dept Ophthalmol, Singapore, Singapore.
   [Cheng, Ching-Yu; Wong, Tien Y.; Lamoureux, Ecosse L.] Natl Univ Hlth Syst, Singapore, Singapore.
C3 National University of Singapore; Singapore National Eye Center; Centre
   for Eye Research Australia; Royal Victorian Eye & Ear Hospital;
   University of Melbourne; National University of Singapore; National
   University of Singapore; National University of Singapore
RP Lamoureux, EL (通讯作者)，Singapore Eye Res Inst, 20 Coll Rd,Level 6, Singapore 169856, Singapore.
EM ecosse.lamoureux@seri.com.sg
RI Sabanayagam, Charumathi/C-1294-2011; Cheng, Ching-Yu/Y-2229-2019; Wong,
   Tien Yin/AAC-9724-2020; Lamoureux, Ecosse/Z-5482-2019
OI Sabanayagam, Charumathi/0000-0002-4042-4719; Cheng,
   Ching-Yu/0000-0003-0655-885X; Wong, Tien Yin/0000-0002-8448-1264; Man,
   Ryan/0000-0001-5028-605X
FU National Medical Research Council [STaR/0003/2008, CIRG/1417/2015];
   Singapore Bio Imaging Consortium [C-011/2006]; Biomedical Research
   Council [08/1/35/19/550]; Australian National Health and Medical
   Research Council Early Career Fellowship [1072987]; Victorian government
FX This study was supported by grant STaR/0003/2008 (Dr Wong) and grant
   CIRG/1417/2015 (Dr Cheng) from the National Medical Research Council,
   grant C-011/2006 from the Singapore Bio Imaging Consortium (Dr Wong),
   and grant 08/1/35/19/550 from the Biomedical Research Council (Dr Wong).
   Dr Fenwick is funded by grant 1072987 from the Australian National
   Health and Medical Research Council Early Career Fellowship. The Centre
   for Eye Research Australia receives Operational Infrastructure Support
   from the Victorian government.
CR [Anonymous], 1991, OPHTHALMOLOGY, V98, P786
   [Anonymous], 2006, REP AG POP
   Arun CS, 2003, DIABETIC MED, V20, P186, DOI 10.1046/j.1464-5491.2003.t01-1-00899.x
   Bressler Neil M, 2002, J Am Board Fam Pract, V15, P142
   Cheng CY, 2015, INVEST OPHTH VIS SCI, V56, P478, DOI 10.1167/iovs.14-15863
   Dolinis J, 1997, AUST NZ J PUBL HEAL, V21, P462, DOI 10.1111/j.1467-842X.1997.tb01736.x
   Eisele M, 2015, BRIT J GEN PRACT, V65, pE716, DOI 10.3399/bjgp15X687337
   Ekici F, 2015, JAMA OPHTHALMOL, V133, P1377, DOI 10.1001/jamaophthalmol.2015.3426
   Fenwick EK, 2016, QUAL LIFE RES, V25, P871, DOI 10.1007/s11136-015-1141-1
   Foster PJ, 2002, BRIT J OPHTHALMOL, V86, P238, DOI 10.1136/bjo.86.2.238
   Gothwal VK, 2011, J CATARACT REFR SURG, V37, P1208, DOI 10.1016/j.jcrs.2011.01.028
   GURALNIK JM, 1995, NEW ENGL J MED, V332, P556, DOI 10.1056/NEJM199503023320902
   Ivers RQ, 1998, J AM GERIATR SOC, V46, P58
   JOHNSON RJ, 1993, J HEALTH SOC BEHAV, V34, P105, DOI 10.2307/2137238
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Lahav K, 2011, ARCH OPHTHALMOL-CHIC, V129, P16, DOI 10.1001/archophthalmol.2010.332
   Lamoreux EL, 2008, INVEST OPHTH VIS SCI, V49, P528, DOI 10.1167/iovs.07-1036
   Lamoureux EL, 2008, OPHTHALMOLOGY, V115, P1973, DOI 10.1016/j.ophtha.2008.05.005
   Lamoureux EL, 2008, INVEST OPHTH VIS SCI, V49, P1298
   Lamoureux EL, 2011, CURR OPIN OPHTHALMOL, V22, P19, DOI 10.1097/ICU.0b013e3283414284
   Lamoureux EL, 2009, INVEST OPHTH VIS SCI, V50, P2614, DOI 10.1167/iovs.08-2164
   Lavanya R, 2009, OPHTHAL EPIDEMIOL, V16, P325, DOI 10.3109/09286580903144738
   Livengood HM, 2015, DISABIL REHABIL, V37, P1202, DOI 10.3109/09638288.2014.961651
   Ministry of Health, 2010, HPB MOH CLIN PRACT G
   Ng TP, 2009, AM J GERIAT PSYCHIAT, V17, P407, DOI 10.1097/JGP.0b013e31819a808e
   Nirmalan PK, 2005, INVEST OPHTH VIS SCI, V46, P2308, DOI 10.1167/iovs.04-0830
   Patel I, 2006, INVEST OPHTH VIS SCI, V47, P65, DOI 10.1167/iovs.05-0582
   Popescu ML, 2011, INVEST OPHTH VIS SCI, V52, P7168, DOI 10.1167/iovs.11-7564
   Rooney D, 2015, ACTA DIABETOL, V52, P73, DOI 10.1007/s00592-014-0602-2
   Swenor BK, 2015, J AM GERIATR SOC, V63, P46, DOI 10.1111/jgs.13183
   Swenor BK, 2013, INVEST OPHTH VIS SCI, V54, P7683, DOI 10.1167/iovs.13-12869
   United Nations, 2001, WORLD POP AG 1950 20
   Varma R, 2013, OPHTHAL EPIDEMIOL, V20, P335, DOI 10.3109/09286586.2013.823505
   Wang JJ, 2003, OPHTHALMIC EPIDEMIOL, V10, P3, DOI 10.1076/opep.10.1.3.13773
   Wang MY, 2012, INVEST OPHTH VIS SCI, V53, P7967, DOI 10.1167/iovs.12-10701
   Weih LM, 2002, INVEST OPHTH VIS SCI, V43, P927
   Yap, 2013, NATL SURVEY SENIOR C
   Yuki K, 2013, INVEST OPHTH VIS SCI, V54, P7739, DOI 10.1167/iovs.13-12079
NR 38
TC 28
Z9 31
U1 0
U2 4
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 2168-6165
EI 2168-6173
J9 JAMA OPHTHALMOL
JI JAMA Ophthalmol.
PD OCT 1
PY 2016
VL 134
IS 10
BP 1087
EP 1093
DI 10.1001/jamaophthalmol.2016.2394
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Ophthalmology
GA EA3FO
UT WOS:000386486900006
PM 27467140
OA Bronze
DA 2022-11-30
ER

PT J
AU Chu, CJ
   Johnston, RL
   Buscombe, C
   Sallam, AB
   Mohamed, Q
   Yang, YC
AF Chu, Colin J.
   Johnston, Robert L.
   Buscombe, Charlotte
   Sallam, Ahmed B.
   Mohamed, Queresh
   Yang, Yit C.
CA United Kingdom Pseudophakic
TI Risk Factors and Incidence of Macular Edema after Cataract Surgery A
   Database Study of 81 984 Eyes
SO OPHTHALMOLOGY
LA English
DT Article
ID NATIONAL OPHTHALMOLOGY DATABASE; VISUAL-ACUITY; DIABETIC-RETINOPATHY;
   PHACOEMULSIFICATION; THICKNESS; NEPAFENAC
AB Purpose: To define the incidence of pseudophakic macular edema (PME) after cataract surgery and to identify contributory risk factors.
   Design: Retrospective database study of electronic medical records (EMRs).
   Participants: A total of 81 984 eyes undergoing cataract surgery between December 2010 and December 2014 from 8 independent United Kingdom clinical sites.
   Methods: Structured clinical data mandated by the EMR were anonymized and extracted for each eye undergoing cataract surgery including: perioperative visual acuity, copathologic features, simultaneous surgical procedures, and the presence or absence of a specified list of intraoperative complications. Diabetic status with matched Early Treatment Diabetic Retinopathy Study (ETDRS) grading also was mandated by the EMR. Eyes receiving prophylactic nonsteroidal anti-inflammatory drugs were excluded.
   Main Outcome Measure: Diagnosis of cystoid macular edema or new-onset macular edema in patients with diabetes, recorded by a healthcare professional within 90 days of surgery.
   Results: Baseline incidence of PME in eyes without operative complications, diabetes, or risk factors was 1.17%. Eyes in which PME developed were more likely to be male, older, and to demonstrate risk factors. The relative risk (RR) was increased in eyes with capsule rupture with or without vitreous loss (RR, 2.61; 95% confidence interval [CI], 1.57-4.34), a previous diagnosis of epiretinal membrane (RR, 5.60; 95% CI, 3.45-9.07), uveitis (RR, 2.88; 95% CI, 1.50-5.51), retinal vein occlusion (RR, 4.47; 95% CI, 2.56-5.92), or retinal detachment repair (RR, 3.93; 95% CI, 2.60-5.92). High myopia, age-related macular degeneration, or prostaglandin analog use were not shown to increase risk. Eyes with PME on average had poorer postoperative visual acuity, which persisted to the latest time point assessed, up to 24 weeks. Eyes from patients with diabetes, even in the absence of retinopathy, had an increased RR (RR, 1.80; 95% CI, 1.36-2.36) of new macular edema after surgery. The risk was higher in the presence of any diabetic retinopathy (DR; RR, 6.23; 95% CI, 5.12-7.58) and rose proportionately with increasing severity of DR.
   Conclusions: Pseudophakic macular edema occurs commonly after phacoemulsification cataract surgery, even in the absence of complications and risk factors. This large retrospective study using structured EMR data quantified the RRs of PME and the risk with increasing ETDRS severity of DR. It highlights the need for prophylactic therapy, especially in those groups of eyes with the highest RRs. (C) 2016 by the American Academy of Ophthalmology.
C1 [Chu, Colin J.] Univ Bristol, Sch Clin Sci, Bristol, Avon, England.
   [Chu, Colin J.; Mohamed, Queresh] Bristol Eye Hosp, Bristol BS1 2LX, Avon, England.
   [Johnston, Robert L.; Buscombe, Charlotte; Sallam, Ahmed B.; Mohamed, Queresh] Cheltenham Gen Hosp, Gloucestershire Eye Unit, Cheltenham GL53 7AN, Glos, England.
   [Sallam, Ahmed B.] Univ Arkansas Med Sci, Jones Eye Inst, Little Rock, AR 72205 USA.
   [Yang, Yit C.] Royal Wolverhampton Hosp NHS Trust, Wolverhampton Eye Infirm, Wolverhampton, W Midlands, England.
   [Yang, Yit C.] Sandwell & West Birmingham NHS Trust, Birmingham, W Midlands, England.
C3 University of Bristol; Bristol Eye Hospital; Gloucestershire Hospitals
   NHS Foundation Trust; Cheltenham General Hospital; University of
   Arkansas System; University of Arkansas Medical Sciences
RP Johnston, RL (通讯作者)，Cheltenham Gen Hosp, Gloucestershire Eye Unit, Sandford Rd, Cheltenham GL53 7AN, Glos, England.
EM Rob.Johnston@glos.nhs.uk
RI Sallam, Ahmed/A-4791-2014
OI Sallam, Ahmed/0000-0001-7207-6782; Chu, Colin/0000-0003-2088-8310
FU National Institute for Health Research; Alcon (Fort Worth, TX); National
   Institute for Health Research [CL-2014-25-001] Funding Source:
   researchfish
FX Supported by the National Institute for Health Research (academic
   clinical lecturer support to C.J.C). Alcon (Fort Worth, TX) provided
   financial support with a research grant to cover the cost of data
   extraction and open access but did not play any role in the design or
   conduct of the study and did not have any input into the preparation and
   content of the manuscript. Robert Johnston is the Medical Director of
   Medisoft Limited, the EMR supplier to each contributing site and
   Medisoft was funded to perform the data extraction.
CR Altman DG, 1998, BRIT MED J, V317, P1309, DOI 10.1136/bmj.317.7168.1309
   Belair ML, 2009, AM J OPHTHALMOL, V148, P128, DOI 10.1016/j.ajo.2009.02.029
   Brito PN, 2015, RETINA-J RET VIT DIS, V35, P294, DOI 10.1097/IAE.0000000000000298
   Day AC, 2015, EYE, V29, P552, DOI 10.1038/eye.2015.3
   Flach A J, 1998, Trans Am Ophthalmol Soc, V96, P557
   Frisina R, 2015, GRAEF ARCH CLIN EXP, V253, P47, DOI 10.1007/s00417-014-2655-x
   Gulkilik G, 2006, CAN J OPHTHALMOL, V41, P699, DOI 10.1139/I06-062
   Henderson BA, 2007, J CATARACT REFR SURG, V33, P1550, DOI 10.1016/j.jcrs.2007.05.013
   Horozoglu F, 2011, RETINA-J RET VIT DIS, V31, P1095, DOI 10.1097/IAE.0b013e3181f98cd5
   Keenan TDL, 2013, EYE, V27, P1397, DOI 10.1038/eye.2013.196
   Kessel L, 2014, OPHTHALMOLOGY, V121, P1915, DOI 10.1016/j.ophtha.2014.04.035
   Kim SJ, 2015, OPHTHALMOLOGY, V122, P2159, DOI 10.1016/j.ophtha.2015.05.014
   Lobo C, 2012, OPHTHALMOLOGICA, V227, P61, DOI 10.1159/000331277
   Loewenstein A, 2010, DEV OPHTHALMOL, V47, P148, DOI 10.1159/000320078
   Mathys KC, 2010, EYE, V24, P90, DOI 10.1038/eye.2009.10
   Moroi SE, 1999, OPHTHALMOLOGY, V106, P1024, DOI 10.1016/S0161-6420(99)00528-X
   Packer M, 2012, J CATARACT REFR SURG, V38, P2108, DOI 10.1016/j.jcrs.2012.07.029
   Pascolini D, 2012, BRIT J OPHTHALMOL, V96, P614, DOI 10.1136/bjophthalmol-2011-300539
   Schmier JK, 2007, RETINA-J RET VIT DIS, V27, P621, DOI 10.1097/01.iae.0000249577.92800.c0
   Singh R, 2012, CLIN OPHTHALMOL, V6, P1259, DOI 10.2147/OPTH.S31902
   Warwar RE, 1998, OPHTHALMOLOGY, V105, P263, DOI 10.1016/S0161-6420(98)92977-3
   Wolf EJ, 2007, J CATARACT REFR SURG, V33, P1546, DOI 10.1016/j.jcrs.2007.05.018
   Yonekawa Y, 2012, CURR OPIN OPHTHALMOL, V23, P26, DOI 10.1097/ICU.0b013e32834cd5f8
NR 23
TC 211
Z9 230
U1 6
U2 106
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD FEB
PY 2016
VL 123
IS 2
BP 316
EP 323
DI 10.1016/j.ophtha.2015.10.001
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA DB2TK
UT WOS:000368362200023
PM 26681390
OA hybrid, Green Published
HC Y
HP N
DA 2022-11-30
ER

PT J
AU Slopsema, RL
   Mamalui, M
   Zhao, T
   Yeung, D
   Malyapa, R
   Li, Z
AF Slopsema, R. L.
   Mamalui, M.
   Zhao, T.
   Yeung, D.
   Malyapa, R.
   Li, Z.
TI Dosimetric properties of a proton beamline dedicated to the treatment of
   ocular disease
SO MEDICAL PHYSICS
LA English
DT Article
DE proton therapy; commissioning; eyeline; uveal melanoma; dose/MU model
ID MACULAR DEGENERATION; UVEAL MELANOMA; THERAPY; RADIOTHERAPY;
   IRRADIATION; TUMORS; BEAMS; PROTONTHERAPY; EYE
AB Purpose: A commercial proton eyeline has been developed to treat ocular disease. Radiotherapy of intraocular lesions (e.g., uveal melanoma, age-related macular degeneration) requires sharp dose gradients to avoid critical structures like the macula and optic disc. A high dose rate is needed to limit patient gazing times during delivery of large fractional dose. Dose delivery needs to be accurate and predictable, not in the least because current treatment planning algorithms have limited dose modeling capabilities. The purpose of this paper is to determine the dosimetric properties of a new proton eyeline. These properties are compared to those of existing systems and evaluated in the context of the specific clinical requirements of ocular treatments.
   Methods: The eyeline is part of a high-energy, cyclotron-based proton therapy system. The energy at the entrance of the eyeline is 105 MeV. A range modulator (RM) wheel generates the spread-out Bragg peak, while a variable range shifter system adjusts the range and spreads the beam laterally. The range can be adjusted from 0.5 up to 3.4 g/cm(2); the modulation width can be varied in steps of 0.3 g/cm(2) or less. Maximum field diameter is 2.5 cm. All fields can be delivered with a dose rate of 30 Gy/min or more. The eyeline is calibrated according to the IAEA TRS-398 protocol using a cylindrical ionization chamber. Depth dose distributions and dose/MU are measured with a parallel-plate ionization chamber; lateral profiles with radiochromic film. The dose/MU is modeled as a function of range, modulation width, and instantaneous MU rate with fit parameters determined per option (RM wheel).
   Results: The distal fall-off of the spread-out Bragg peak is 0.3 g/cm(2), larger than for most existing systems. The lateral penumbra varies between 0.9 and 1.4 mm, except for fully modulated fields that have a larger penumbra at skin. The source-to-axis distance is found to be 169 cm. The dose/MU shows a strong dependence on range (up to 4%/mm). A linear increase in dose/MU as a function of instantaneous MU rate is observed. The dose/MU model describes the measurements with an accuracy of +/- 2%. Neutron dose is found to be 146 +/- 102 mu Sv/Gy at the contralateral eye and 19 +/- 13 mu Sv/Gy at the chest.
   Conclusions: Measurements show the proton eyeline meets the requirements to effectively treat ocular disease. (C) 2014 American Association of Physicists in Medicine.
C1 [Slopsema, R. L.; Mamalui, M.; Yeung, D.; Malyapa, R.; Li, Z.] Univ Florida, Proton Therapy Inst, Jacksonville, FL 32205 USA.
   [Zhao, T.] Washington Univ, Sch Med, Dept Radiat Oncol, St Louis, MO 63110 USA.
C3 State University System of Florida; University of Florida; Washington
   University (WUSTL)
RP Slopsema, RL (通讯作者)，Univ Florida, Proton Therapy Inst, 2015 North Jefferson St, Jacksonville, FL 32205 USA.
EM rslopsema@floridaproton.org
CR Agosteo S, 1998, RADIOTHER ONCOL, V48, P293, DOI 10.1016/S0167-8140(98)00049-8
   [Anonymous], 2012, HADRON THERAPY PATIE
   Attix F.H, 2004, INTRO RADIOLOGICAL P, Vsecond
   Bonnett D., 1993, BRIT J RADIOL, V66, P907
   Calugaru V, 2011, INT J RADIAT ONCOL, V81, P1136, DOI 10.1016/j.ijrobp.2010.09.003
   Cirrone GAP, 2004, IEEE T NUCL SCI, V51, P860, DOI 10.1109/TNS.2004.829535
   Daartz J, 2009, MED PHYS, V36, P3205, DOI 10.1118/1.3152111
   Daftari IK, 1996, NUCL INSTRUM METH A, V380, P597, DOI 10.1016/0168-9002(96)00707-3
   Daftari IK, 2010, MED PHYS, V37, P5199, DOI 10.1118/1.3488891
   Damato B, 2005, INT J RADIAT ONCOL, V63, P109, DOI 10.1016/j.ijrobp.2005.01.050
   De Ruysscher D, 2012, RADIOTHER ONCOL, V103, P5, DOI 10.1016/j.radonc.2012.01.003
   GOITEIN M, 1983, MED PHYS, V10, P275, DOI 10.1118/1.595258
   GOTTSCHALK B, 1993, NUCL INSTRUM METH B, V74, P467, DOI 10.1016/0168-583X(93)95944-Z
   GRAGOUDAS ES, 1977, AM J OPHTHALMOL, V83, P665, DOI 10.1016/0002-9394(77)90133-7
   Hawkins BS, 2011, CLIN TRIALS, V8, P661, DOI 10.1177/1740774511419684
   Herault J, 2005, MED PHYS, V32, P910, DOI 10.1118/1.1871392
   International Atomic Energy Agency, 2000, TECHNICAL REPORTS SE
   International Committee on Radiological Protection, 1991, ANN ICRP, V21, P1
   Jongen Y., 2010, P 19 INT C CYCL THEI
   Kacperek A, 2009, APPL RADIAT ISOTOPES, V67, P378, DOI 10.1016/j.apradiso.2008.06.012
   Kacperek A., 2011, ION BEAM THERAPY FUN, P149
   Kooy HM, 2005, PHYS MED BIOL, V50, P5847, DOI 10.1088/0031-9155/50/24/006
   Levy-Gabriel C, 2009, RETINA-J RET VIT DIS, V29, P170, DOI 10.1097/IAE.0b013e31818bccfb
   Martisikova M, 2010, PHYS MED BIOL, V55, P5557, DOI 10.1088/0031-9155/55/18/019
   Michalec B, 2010, APPL RADIAT ISOTOPES, V68, P738, DOI 10.1016/j.apradiso.2009.11.001
   Moyers MF, 1999, MED PHYS, V26, P777, DOI 10.1118/1.598587
   Newhauser W, 2005, PHYS MED BIOL, V50, P5229, DOI 10.1088/0031-9155/50/22/002
   Newhauser WD, 2007, PHYS MED BIOL, V52, P3979, DOI 10.1088/0031-9155/52/13/021
   Paganetti H., 2012, PROTON THERAPY PHYS, P125
   Singh AD, 2011, OPHTHALMOLOGY, V118, P1881, DOI 10.1016/j.ophtha.2011.01.040
   Slopsema R., 2012, PROTON THERAPY PHYS, P125
   Trompier F, 2007, RADIAT PROT DOSIM, V125, P349, DOI 10.1093/rpd/ncm154
   Tsina EK, 2005, OPHTHALMOLOGY, V112, P337, DOI 10.1016/j.ophtha.2004.09.013
   WEINHOUS MS, 1984, MED PHYS, V11, P846, DOI 10.1118/1.595574
   Wuestemeyer H, 2006, GRAEF ARCH CLIN EXP, V244, P438, DOI 10.1007/s00417-005-0093-5
   Zambarakji HJ, 2006, OPHTHALMOLOGY, V113, P2012, DOI 10.1016/j.ophtha.2006.05.036
NR 36
TC 17
Z9 17
U1 0
U2 5
PU AMER ASSOC PHYSICISTS MEDICINE AMER INST PHYSICS
PI MELVILLE
PA STE 1 NO 1, 2 HUNTINGTON QUADRANGLE, MELVILLE, NY 11747-4502 USA
SN 0094-2405
J9 MED PHYS
JI Med. Phys.
PD JAN
PY 2014
VL 41
IS 1
AR 011707
DI 10.1118/1.4842455
PG 11
WC Radiology, Nuclear Medicine & Medical Imaging
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Radiology, Nuclear Medicine & Medical Imaging
GA 282OT
UT WOS:000329182200012
PM 24387499
DA 2022-11-30
ER

PT J
AU Qi, XP
   Ricart, K
   Ahmed, KA
   Patel, RP
   Boulton, ME
AF Qi, Xiaoping
   Ricart, Karina
   Ahmed, Khandaker A.
   Patel, Rakesh P.
   Boulton, Michael E.
TI Supplemental nitrite increases choroidal neovascularization in mice
SO NITRIC OXIDE-BIOLOGY AND CHEMISTRY
LA English
DT Article
DE Nitrate; Nitrite; Choroidal neovascularization; Age-related macular
   degeneration; Aging
ID SODIUM-NITRITE; DIETARY NITRATE; ISCHEMIA-REPERFUSION; MACULAR
   DEGENERATION; AGE; THERAPY; OXIDE; ANGIOGENESIS; SUPEROXIDE; INHIBITION
AB Low doses of nitrite, close to physiological levels, increase blood flow in normal and ischemic tissues through a nitric oxide (NO) dependent mechanism. Given that nitrite therapy and dietary supplementation with vegetables high in nitrate (e.g. beets) are gaining popularity we decided to determine if low doses of nitrite impact the development of choroidal neovascularization (CNV), a key feature of wet age related macular degeneration (AMD). Sodium nitrite (at 50 mg/L, 150 mg/L, and 300 mg/L), nitrate (1 g/L) or water alone were provided in the drinking water of C57BL/6 J mice aged 2 or 12 months. Mice were allowed to drink ad libitum for 1 week at which time laser-induced choroidal neovascularization (L-CNV) was induced. The mice continued to drink the supplemented water ad libitum for a further 14 days at which point optical coherence tomography (OCT) was performed to determine the volume of the CNV lesion. Blood was drawn to determine nitrite and nitrate levels and eyes taken for histology. CNV volume was 2.86 x 107 mu m3 (+/- 0.4 x 107) in young mice on water alone but CNV volume more than doubled to 6.9 x 107 mu m3 (+/- 0.8 x 107) in mice receiving 300 mg/L nitrite or 7.34 x 107 mu m3 (+/- 1.4 x 107) in 1 g/L nitrate (p < 0.01). A similar trend was observed in older mice. CNV volume was 5.3 x 107 mu m3 (+/- 0.5 x 107) in older mice on water alone but CNV volume almost doubled to approximately 9.3 x 107 mu m3 (+/- 1.1 x 107) in mice receiving 300 mg/L nitrite or 8.7 x 107 mu m3 (+/- 0.9 x 107) 1 g/L nitrate (p < 0.01). Plasma nitrite levels were highest in young mice receiving 150 mg/L in the drinking water with no changes in plasma nitrate observed. In older mice, drinking water nitrite did not significantly change plasma nitrite, but plasma nitrate was increased. Plasma nitrate was elevated in both young and old mice provided with nitrate supplemented drinking water. Our data demonstrate that the CNV lesion is larger in older mice compared to young and that therapeutic levels of oral nitrite increase the volume of CNV lesions in both young and older mice. Therapeutic nitrite or nitrate supplementation should be used with caution in the elderly population prone to CNV.
C1 [Qi, Xiaoping; Boulton, Michael E.] Univ Alabama Birmingham, Dept Ophthalmol & Visual Sci, Birmingham, AL 35294 USA.
   [Ricart, Karina; Ahmed, Khandaker A.; Patel, Rakesh P.] Univ Alabama Birmingham, Dept Pathol, Birmingham, AL 35294 USA.
   [Ricart, Karina; Ahmed, Khandaker A.; Patel, Rakesh P.] Univ Alabama Birmingham, Ctr Free Rad Biol, Birmingham, AL 35294 USA.
C3 University of Alabama System; University of Alabama Birmingham;
   University of Alabama System; University of Alabama Birmingham;
   University of Alabama System; University of Alabama Birmingham
RP Boulton, ME (通讯作者)，Univ Alabama Birmingham, Dept Ophthalmol & Visual Sci, Birmingham, AL 35294 USA.; Patel, RP (通讯作者)，Univ Alabama Birmingham, Dept Pathol, Birmingham, AL 35294 USA.; Patel, RP (通讯作者)，Univ Alabama Birmingham, Ctr Free Rad Biol, Birmingham, AL 35294 USA.
EM rakeshpatel@uabmc.edu; meboulton@uabmc.edu
OI Boulton, Michael/0000-0002-0796-1766; Patel, Rakesh/0000-0002-1526-4303
FU NEI Core grant [P30 EY03039]; Research to Prevent Blindness;
   (NCATS)National Center for Advancing Translational Sciences of the
   National Institutes of Health (NIH) [UL1TR001417]; NIH T90 grant
   [5T90DE022736-07]
FX This publication was made possible by: NEI Core grant P30 EY03039; an
   unrestricted grant from Research to Prevent Blindness; the UAB Center
   for Clinical and Translational Science Grant Number UL1TR001417 from the
   (NCATS)National Center for Advancing Translational Sciences of the
   National Institutes of Health (NIH); KA was supported by NIH T90 grant
   (5T90DE022736-07).
CR Ahmed KA, 2021, NITRIC OXIDE-BIOL CH, V108, P1, DOI 10.1016/j.niox.2020.12.001
   Allen JD, 2012, NITRIC OXIDE-BIOL CH, V26, P217, DOI 10.1016/j.niox.2012.03.003
   Bir SC, 2014, DIABETES, V63, P270, DOI 10.2337/db13-0890
   Blekkenhorst LC, 2018, J AM HEART ASSOC, V7, DOI 10.1161/JAHA.117.008391
   Campbell M, 2019, BIOCHEM PHARMACOL, V164, P321, DOI 10.1016/j.bcp.2019.04.029
   Carlstrom M, 2015, ANTIOXID REDOX SIGN, V23, P295, DOI 10.1089/ars.2013.5481
   Crawford JH, 2006, BLOOD, V107, P566, DOI 10.1182/blood-2005-07-2668
   DeMartino AW, 2019, BRIT J PHARMACOL, V176, P228, DOI 10.1111/bph.14484
   DeVan AE, 2016, J APPL PHYSIOL, V120, P416, DOI 10.1152/japplphysiol.00879.2015
   Dezfulian C, 2007, CARDIOVASC RES, V75, P327, DOI 10.1016/j.cardiores.2007.05.001
   Ding XY, 2009, PROG RETIN EYE RES, V28, P1, DOI 10.1016/j.preteyeres.2008.10.001
   Duranski MR, 2005, J CLIN INVEST, V115, P1232, DOI 10.1172/JCI200522493
   GANGOLLI SD, 1994, EUR J PHARM-ENVIRON, V292, P1, DOI 10.1016/0926-6917(94)90022-1
   Gopinath B, 2018, J ACAD NUTR DIET, V118, P2311, DOI 10.1016/j.jand.2018.07.012
   Greenway FL, 2012, DIABETES TECHNOL THE, V14, P552, DOI 10.1089/dia.2011.0291
   Grossniklaus HE, 2004, AM J OPHTHALMOL, V137, P496, DOI 10.1016/j.ajo.2003.09.042
   Guimaraes DD, 2019, HYPERTENSION, V73, P839, DOI 10.1161/HYPERTENSIONAHA.118.12425
   Hendgen-Cotta UB, 2012, CIRCULATION, V126, P1983, DOI 10.1161/CIRCULATIONAHA.112.112912
   Hezel M, 2016, FREE RADICAL BIO MED, V99, P87, DOI 10.1016/j.freeradbiomed.2016.07.025
   Joshipura KJ, 2017, NITRIC OXIDE-BIOL CH, V71, P14, DOI 10.1016/j.niox.2017.09.004
   Kelpke SS, 2012, KIDNEY INT, V82, P304, DOI 10.1038/ki.2012.116
   Kevil Christopher G, 2008, Expert Rev Cardiovasc Ther, V6, P1175, DOI 10.1586/14779072.6.9.1175
   Kumar D, 2008, P NATL ACAD SCI USA, V105, P7540, DOI 10.1073/pnas.0711480105
   Lahteenvuo J, 2012, CIRC RES, V110, P1252, DOI 10.1161/CIRCRESAHA.111.246116
   Lambert V, 2013, NAT PROTOC, V8, P2197, DOI 10.1038/nprot.2013.135
   Liu CH, 2017, FASEB J, V31, P4665, DOI 10.1096/fj.201700336R
   Lundberg JO, 2018, CELL METAB, V28, P9, DOI 10.1016/j.cmet.2018.06.007
   Lundberg JO, 2009, NAT CHEM BIOL, V5, P865, DOI 10.1038/nchembio.260
   Mohler ER, 2014, VASC MED, V19, P9, DOI 10.1177/1358863X13515043
   Peleli M, 2020, REDOX BIOL, V28, DOI 10.1016/j.redox.2019.101387
   Qi XP, 2012, INVEST OPHTH VIS SCI, V53, P574, DOI 10.1167/iovs.11-8728
   Rein DB, 2009, ARCH OPHTHALMOL-CHIC, V127, P533, DOI 10.1001/archophthalmol.2009.58
   Rivard A, 1999, CIRCULATION, V99, P111, DOI 10.1161/01.CIR.99.1.111
   Schiffer TA, 2020, BBA-MOL BASIS DIS, V1866, DOI 10.1016/j.bbadis.2020.165811
   Stapley R, 2015, FREE RADICAL BIO MED, V85, P207, DOI 10.1016/j.freeradbiomed.2015.04.025
   Sulaiman RS, 2015, J OCUL PHARMACOL TH, V31, P447, DOI 10.1089/jop.2015.0049
   Yeo NJY, 2019, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.01363
   Zhao YZ, 2015, J PHARMACOL SCI, V129, P83, DOI 10.1016/j.jphs.2015.09.002
   Ziche M, 2000, J NEURO-ONCOL, V50, P139, DOI 10.1023/A:1006431309841
NR 39
TC 0
Z9 0
U1 0
U2 0
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 1089-8603
EI 1089-8611
J9 NITRIC OXIDE-BIOL CH
JI Nitric Oxide-Biol. Chem.
PD DEC 1
PY 2021
VL 117
BP 7
EP 15
DI 10.1016/j.niox.2021.09.005
EA SEP 2021
PG 9
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA UY7ZX
UT WOS:000701738500002
PM 34537345
OA hybrid
DA 2022-11-30
ER

PT J
AU Papudesu, C
   Clemons, TE
   Agron, E
   Chew, EY
AF Papudesu, Chandana
   Clemons, Traci E.
   Agron, Elvira
   Chew, Emily Y.
CA Age-Related Eye Dis Study 2 Res
TI Association of Mortality with Ocular Diseases and Visual Impairment in
   the Age-Related Eye Disease Study 2 Age-Related Eye Disease Study 2
   Report Number 13
SO OPHTHALMOLOGY
LA English
DT Article
ID CORONARY-HEART-DISEASE; MACULAR DEGENERATION; CATARACT-SURGERY;
   CARDIOVASCULAR-DISEASE; DEPRESSIVE SYMPTOMS; LENS OPACITIES; TERM
   MORTALITY; SURVIVAL; ATHEROSCLEROSIS; HYPERTENSION
AB Purpose: To evaluate the association of mortality with visual acuity (VA) impairment, age-related macular degeneration (AMD), and cataract surgery.
   Design: Cohort study.
   Participants: Participants with at least intermediate AMD enrolled in a randomized controlled clinical trial of lutein/zeaxanthin and/or omega-3 fatty acids, the Age-Related Eye Disease Study 2 (AREDS2), for treatment of AMD and cataract.
   Methods: Baseline and annual eye examinations included best-corrected visual acuity (BCVA) assessments, slit-lamp examinations, and stereoscopic fundus photographs that were centrally graded for development of late AMD (central geographic atrophy or neovascular AMD) or pseudophakia. Cause-specific mortality was determined on the basis of the International Classification of Diseases 9th or 10th Revision codes. Risk of all-cause and cause-specific mortality was assessed with Cox proportional hazards models adjusted for age, sex, AMD severity, VA, history of cataract surgery, and assigned AREDS2 study treatment. Analyses included baseline covariates: race, education, smoking status, diabetes, and cardiovascular disease.
   Results: During follow-up (median 5 years), 368 (9%) of the 4203 AREDS2 participants died. Participants with neovascular AMD in 1 eye at baseline had a statistically significant increased risk for mortality compared with participants with no or few drusen (hazard ratio [HR], 1.56; 95% confidence interval [CI], 1.21-2.01; P < 0.001). Poorer survival was associated with bilateral cataract surgery before enrollment compared with baseline bilateral phakia (HR, 1.63; 95% CI, 1.29-2.07; P < 0.001) and with BCVA of less than 20/40 compared with participants with 20/40 or better (HR, 1.56; 95% CI, 1.06-2.30; P = 0.024), adjusted for age, sex, and statistically significant covariates. Participants who received antivascular endothelial growth factor therapies for neovascular AMD had decreased mortality compared with those who did not (HR, 0.71; 95% CI, 0.57-0.88; P = 0.002). The association between all-cause mortality and AREDS2 treatment whether assessing the main or individual treatment effect was not significantly different (omega-3 fatty acids main effect HR, 1.18; 95% CI, 0.96-1.45; P = 0.12; lutein/zeaxanthin main effect HR, 1.04; 95% CI, 0.85-1.28; P = 0.71).
   Conclusions: In AREDS2, the presence of late AMD, bilateral cataract surgery, and VA less than 20/40 was associated with decreased survival. However, oral supplementation with omega-3 fatty acids, lutein plus zeaxanthin, zinc, or beta-carotene had no statistically significant impact on mortality. Published by Elsevier on behalf of the American Academy of Ophthalmology
C1 [Papudesu, Chandana; Agron, Elvira; Chew, Emily Y.] NEI, Clin Trials Branch, Div Epidemiol & Clin Applicat, NIH, Bethesda, MD 20892 USA.
   [Clemons, Traci E.] EMMES Corp, Rockville, MD USA.
C3 National Institutes of Health (NIH) - USA; NIH National Eye Institute
   (NEI); Emmes Corporation
RP Chew, EY (通讯作者)，NIH, Bldg 10,CRC,Room 3-2531,10 Ctr Dr,MSC 1204, Bethesda, MD 20892 USA.
EM echew@nei.nih.gov
RI SanGiovanni, John Paul/AAU-3895-2020
FU National Eye Institute, National Institutes of Health, Department of
   Health and Human Services, Bethesda, Maryland [HHS-N-260-2005-00007-C,
   N01-EY-5-0007]; Office of Dietary Supplements; National Center for
   Complementary and Alternative Medicine; National Institute on Aging;
   National Heart, Lung, and Blood Institute; National Institute of
   Neurological Disorders and Stroke; NATIONAL EYE INSTITUTE [ZIAEY000489]
   Funding Source: NIH RePORTER
FX Supported by the intramural program funds and contracts from the
   National Eye Institute, National Institutes of Health, Department of
   Health and Human Services, Bethesda, Maryland (Contract
   HHS-N-260-2005-00007-C; ADB Contract N01-EY-5-0007). Funds were
   generously contributed to these contracts by the following National
   Institutes of Health institutes: Office of Dietary Supplements; National
   Center for Complementary and Alternative Medicine; National Institute on
   Aging; National Heart, Lung, and Blood Institute; and National Institute
   of Neurological Disorders and Stroke.
CR Age-Related Eye Dis Study Res Grp, 2001, AM J OPHTHALMOL, V132, P668
   Ariyo AA, 2000, CIRCULATION, V102, P1773
   BENSON WH, 1988, OPHTHALMOLOGY, V95, P1288
   Borger PH, 2003, OPHTHALMOLOGY, V110, P1292, DOI 10.1016/S0161-6420(03)00450-0
   Chew EY, 2013, JAMA-J AM MED ASSOC, V309, P2005, DOI 10.1001/jama.2013.4997
   Chew EY, 2012, OPHTHALMOLOGY, V119, P2282, DOI 10.1016/j.ophtha.2012.05.027
   Clemons TE, 2004, ARCH OPHTHALMOL-CHIC, V122, P716
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Cugati S, 2007, ARCH OPHTHALMOL-CHIC, V125, P917, DOI 10.1001/archopht.125.7.917
   EDERER F, 1993, AM J EPIDEMIOL, V137, P787, DOI 10.1093/oxfordjournals.aje.a116739
   Ferris FL, 2005, ARCH OPHTHALMOL-CHIC, V123, P1570
   Fisher DE, 2015, OPHTHALMOLOGY, V122, P382, DOI 10.1016/j.ophtha.2014.08.006
   Fong CSU, 2014, AM J OPHTHALMOL, V157, P163, DOI 10.1016/j.ajo.2013.08.018
   Fong CSU, 2013, OPHTHALMOLOGY, V120, P1720, DOI 10.1016/j.ophtha.2013.02.009
   French DD, 2011, RETINA-J RET VIT DIS, V31, P1036, DOI 10.1097/IAE.0b013e31821dc66f
   Ganguli M, 1998, J GERONTOL A-BIOL, V53, pM39, DOI 10.1093/gerona/53A.1.M39
   Hennis A, 2001, OPHTHALMOLOGY, V108, P498, DOI 10.1016/S0161-6420(00)00542-X
   HIRSCH RP, 1983, ARCH OPHTHALMOL-CHIC, V101, P1034
   Hyman L, 2000, ARCH OPHTHALMOL-CHIC, V118, P351, DOI 10.1001/archopht.118.3.351
   Knudtson MD, 2006, ARCH OPHTHALMOL-CHIC, V124, P243, DOI 10.1001/archopht.124.2.243
   Lee DJ, 2002, ARCH OPHTHALMOL-CHIC, V120, P1544, DOI 10.1001/archopht.120.11.1544
   McCarty CA, 2001, BRIT J OPHTHALMOL, V85, P322, DOI 10.1136/bjo.85.3.322
   NinnPedersen K, 1995, BRIT J OPHTHALMOL, V79, P1115, DOI 10.1136/bjo.79.12.1115
   Pedula KL, 2015, J AM GERIATR SOC, V63, P910, DOI 10.1111/jgs.13405
   Siantar RG, 2015, SCI REP-UK, V5, DOI 10.1038/srep16304
   Snow K K, 1999, Ophthalmic Epidemiol, V6, P125, DOI 10.1076/opep.6.2.125.1558
   SPERDUTO RD, 1986, ARCH OPHTHALMOL-CHIC, V104, P216
   STREET DA, 1992, AM J OPHTHALMOL, V113, P263, DOI 10.1016/S0002-9394(14)71577-6
   Tan JSL, 2008, BRIT J OPHTHALMOL, V92, P509, DOI 10.1136/bjo.2007.131706
   Taylor H R, 2000, Trans Am Ophthalmol Soc, V98, P91
   Thiagarajan M, 2005, ARCH OPHTHALMOL-CHIC, V123, P1397, DOI 10.1001/archopht.123.10.1397
   THOMPSON JR, 1989, AGE AGEING, V18, P83, DOI 10.1093/ageing/18.2.83
   Tseng VL, 2016, OPHTHALMOLOGY, V123, P1019, DOI 10.1016/j.ophtha.2015.12.033
   VINGERLING JR, 1995, AM J EPIDEMIOL, V142, P404, DOI 10.1093/oxfordjournals.aje.a117648
   WANG J, 2016, BIOMED RES INT, V2016, DOI DOI 10.1155/2016/8212063
   Wang JJ, 2001, ARCH OPHTHALMOL-CHIC, V119, P1186, DOI 10.1001/archopht.119.8.1186
   Wang YX, 2014, ACTA OPHTHALMOL, V92, pE424, DOI 10.1111/aos.12370
   West SK, 2000, ARCH OPHTHALMOL-CHIC, V118, P393, DOI 10.1001/archopht.118.3.393
   Whooley MA, 1998, ARCH INTERN MED, V158, P2129, DOI 10.1001/archinte.158.19.2129
   Wong TY, 2007, OPHTHALMOLOGY, V114, P86, DOI 10.1016/j.ophtha.2006.06.039
NR 40
TC 17
Z9 17
U1 0
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD APR
PY 2018
VL 125
IS 4
BP 512
EP 521
DI 10.1016/j.ophtha.2017.10.028
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA FZ9HE
UT WOS:000427920000018
PM 29153456
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Kitchens, JW
   Do, DV
   Boyer, DS
   Thompson, D
   Gibson, A
   Saroj, N
   Vitti, R
   Berliner, AJ
   Kaiser, PK
AF Kitchens, John W.
   Do, Diana V.
   Boyer, David S.
   Thompson, Desmond
   Gibson, Andrea
   Saroj, Namrata
   Vitti, Robert
   Berliner, Alyson J.
   Kaiser, Peter K.
TI Comprehensive Review of Ocular and Systemic Safety Events with
   Intravitreal Aflibercept Injection in Randomized Controlled Trials
SO OPHTHALMOLOGY
LA English
DT Review
ID RETINAL VEIN OCCLUSION; ENDOTHELIAL GROWTH-FACTOR; MACULAR EDEMA
   SECONDARY; VEGF TRAP-EYE; RANIBIZUMAB; BEVACIZUMAB; DEGENERATION;
   PREVALENCE
AB Purpose: To assess the ocular and systemic safety of intravitreal aflibercept injection (IAI) compared with controls in IAI trials in neovascular age-related macular degeneration (nAMD), macular edema following central retinal vein occlusion (MEfCRVO), macular edema following branch retinal vein occlusion (MEfBRVO), and diabetic macular edema (DME).
   Design: Comprehensive review of 10 phase II and III trials of IAI in retinal diseases.
   Participants: Patients were included from IAI trials in nAMD (CLEAR-IT 2 [52 weeks], VIEW 1 [96 weeks], VIEW 2 [96 weeks], VIEW 1 extension [208 weeks]); MEfCRVO (COPERNICUS [100 weeks], GALILEO [76 weeks]); MEfBRVO (VIBRANT [52 weeks]); and DME (DA VINCI [52 weeks], VIVID [100 weeks], VISTA [100 weeks]).
   Methods: Rates were calculated as events/100 person-years at risk (PYR). When applicable, rate ratios (RRs) and 95% confidence intervals (CIs) were provided.
   Main Outcome Measures: Outcomes included rates for intraocular inflammation, endophthalmitis, serious adverse events (SAEs), wound-healing complications, hypertension (HTN), adjudicated Anti-Platelet Trialists' Collaboration (APTC)-defined arterial thromboembolic events (ATEs) (nonfatal myocardial infarction, nonfatal stroke, and vascular death), and death from all causes.
   Results: More than 4000 patients contributed > 7000 PYR. For all outcomes, there were no meaningful differences between evaluated adverse event rates for IAI and controls. Overall intraocular inflammation rates were 2.37 (control) and 2.06 (IAI); overall RR was 0.87 (95% CI, 0.61-1.27). Overall endophthalmitis rates were 0.52 (control) and 0.22 (IAI); overall RR was 0.42 (95% CI, 0.18-1.03). Overall SAE rates were 23.09 (control) and 20.80 (IAI); overall RR was 0.90 (95% CI, 0.80-1.02). Overall rates of wound-healing complications were 0.17 (control) and 0.15 (IAI); overall RR was 0.85 (95% CI, 0.24-3.86). Overall HTN rates were 14.87 (control) and 11.27 (IAI), with an overall RR of 0.76 (95% CI, 0.65-0.89); HTN rates were highest in MEfBRVO and lowest in nAMD. For adjudicated APTC-defined ATEs, rates were 2.04 (control) and 2.19 (IAI), with an RR of 1.07 (95% CI, 0.73-1.61). Overall death rates were 1.16 (control) and 1.49 (IAI); overall RR was 1.28 (95% CI, 0.80-2.15).
   Conclusions: Rates of selected ocular and systemic adverse events with IAI were similar to those of controls and similar across disease states in evaluated IAI trials. Intravitreal aflibercept injection was generally well tolerated in the patients evaluated. (C) 2016 by the American Academy of Ophthalmology.
C1 [Kitchens, John W.] Retina Associates Kentucky, Lexington, KY USA.
   [Do, Diana V.] Univ Nebraska Med Ctr, Truhlsen Eye Inst, Omaha, NE USA.
   [Boyer, David S.] Retina Vitreous Associates Med Grp, Beverly Hills, CA USA.
   [Thompson, Desmond; Gibson, Andrea; Saroj, Namrata; Vitti, Robert; Berliner, Alyson J.] Regeneron Pharmaceut Inc, 777 Old Saw Mill River Rd, Tarrytown, NY 10591 USA.
   [Kaiser, Peter K.] Cole Eye Inst, 9500 Euclid Ave, Cleveland, OH 44195 USA.
C3 University of Nebraska System; University of Nebraska Medical Center;
   Retina Vitreous Associates Medical Group; Regeneron; Cleveland Clinic
   Foundation
RP Kaiser, PK (通讯作者)，Cole Eye Inst, 9500 Euclid Ave, Cleveland, OH 44195 USA.
EM pkkaiser@aol.com
OI Kaiser, Peter/0000-0001-5126-045X
FU Regeneron Pharmaceuticals, Inc., Tarrytown, New York; Bayer HealthCare,
   Berlin, Germany
FX Funded by Regeneron Pharmaceuticals, Inc., Tarrytown, New York, and
   Bayer HealthCare, Berlin, Germany. The sponsors participated in the
   design and conduct of the study, analysis of the data, and preparation
   of the manuscript.
CR ADAMIS AP, 1994, AM J OPHTHALMOL, V118, P445, DOI 10.1016/S0002-9394(14)75794-0
   AIELLO LP, 1994, NEW ENGL J MED, V331, P1480, DOI 10.1056/NEJM199412013312203
   Berg K, 2015, OPHTHALMOLOGY, V122, P146, DOI 10.1016/j.ophtha.2014.07.041
   Biswas P, 2011, INDIAN J OPHTHALMOL, V59, P191, DOI 10.4103/0301-4738.81023
   Boyer D, 2010, OPHTHALMOLOGY, V117, P1860, DOI 10.1016/j.ophtha.2010.02.022
   Bressler NM, 2012, RETINA-J RET VIT DIS, V32, P1821, DOI 10.1097/IAE.0b013e31825db6ba
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Brown DM, 2015, OPHTHALMOLOGY, V122, P2044, DOI 10.1016/j.ophtha.2015.06.017
   Brown DM, 2013, OPHTHALMOLOGY, V120, P2013, DOI 10.1016/j.ophtha.2013.02.034
   Brown DM, 2013, AM J OPHTHALMOL, V155, P429, DOI 10.1016/j.ajo.2012.09.026
   Campochiaro PA, 2015, OPHTHALMOLOGY, V122, P538, DOI 10.1016/j.ophtha.2014.08.031
   Campochiaro PA, 2010, OPHTHALMOLOGY, V117, P1102, DOI 10.1016/j.ophtha.2010.02.021
   Center for Disease Control and Prevention (CDC), 2014, NAT DIAB STAT REP
   Chakravarthy U, 2013, LANCET, V382, P1258, DOI 10.1016/S0140-6736(13)61501-9
   CLAYTON D, 1988, STAT MED, V7, P819, DOI 10.1002/sim.4780070802
   Ding J, 2012, CURR DIABETES REP, V12, P346, DOI 10.1007/s11892-012-0283-6
   Do DV, 2012, OPHTHALMOLOGY, V119, P1658, DOI 10.1016/j.ophtha.2012.02.010
   Epstein DLJ, 2012, OPHTHALMOLOGY, V119, P1184, DOI 10.1016/j.ophtha.2012.01.022
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Heier JS, 2011, OPHTHALMOLOGY, V118, P1098, DOI 10.1016/j.ophtha.2011.03.020
   HOLFORD TR, 1980, BIOMETRICS, V36, P299, DOI 10.2307/2529982
   Kjeldsen SE, 2001, BLOOD PRESSURE, V10, P190, DOI 10.1080/08037050152669684
   Klein R, 2011, ARCH OPHTHALMOL-CHIC, V129, P75, DOI 10.1001/archophthalmol.2010.318
   Kodjikian L, 2013, OPHTHALMOLOGY, V120, P2300, DOI 10.1016/j.ophtha.2013.06.020
   Korobelnik JF, 2014, OPHTHALMOLOGY, V121, P2247, DOI 10.1016/j.ophtha.2014.05.006
   Krebs I, 2013, BRIT J OPHTHALMOL, V97, P266, DOI 10.1136/bjophthalmol-2012-302391
   LAIRD N, 1981, J AM STAT ASSOC, V76, P231, DOI 10.2307/2287816
   Marcus DM, 2014, INVEST OPHTH VIS SCI, V55
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Mitchell P, 2011, OPHTHALMOLOGY, V118, P615, DOI 10.1016/j.ophtha.2011.01.031
   Moja L, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD011230.pub2
   Ogura Y, 2014, AM J OPHTHALMOL, V158, P1032, DOI 10.1016/j.ajo.2014.07.027
   Nguyen QD, 2012, OPHTHALMOLOGY, V119, P789, DOI 10.1016/j.ophtha.2011.12.039
   Rajendram R, 2012, ARCH OPHTHALMOL-CHIC, V130, P972, DOI 10.1001/archophthalmol.2012.393
   Rogers S, 2010, OPHTHALMOLOGY, V117, P313, DOI [10.1016/j.ophtha.2009.07.017, 10.1016/j.ophtha.2010.01.060]
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Schauwvlieghe ASME, 2014, INVEST OPHTH VIS SCI, V55
   Schmidt-Erfurth U, 2014, OPHTHALMOLOGY, V121, P193, DOI 10.1016/j.ophtha.2013.08.011
   Scott LJ, 2015, EXPERT OPIN DRUG SAF, V14, P379, DOI 10.1517/14740338.2015.991712
   Wells JA, 2015, NEW ENGL J MED, V372, P1193, DOI 10.1056/NEJMoa1414264
NR 40
TC 37
Z9 39
U1 0
U2 6
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD JUL
PY 2016
VL 123
IS 7
BP 1511
EP 1520
DI 10.1016/j.ophtha.2016.02.046
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA DP3KC
UT WOS:000378391100023
PM 27084563
DA 2022-11-30
ER

PT J
AU Grebe, R
   Mughal, I
   Bryden, W
   McLeod, S
   Edwards, M
   Hageman, GS
   Lutty, G
AF Grebe, Rhonda
   Mughal, Irum
   Bryden, William
   McLeod, Scott
   Edwards, Malia
   Hageman, Gregory S.
   Lutty, Gerard
TI Ultrastructural analysis of submacular choriocapillaris and its
   transport systems in AMD and aged control eyes
SO EXPERIMENTAL EYE RESEARCH
LA English
DT Article
DE Age-related macular degeneration; Caveolae; Choriocapillaris; Coated
   pits; Endothelial cells; Fenestrations; Transcytosis
ID ENDOTHELIAL GROWTH-FACTOR; VESICULO-VACUOLAR ORGANELLE; C-REACTIVE
   PROTEIN; MACULAR DEGENERATION; BRUCHS MEMBRANE; CHOROIDAL VASCULATURE;
   MORPHOMETRIC-ANALYSIS; FENESTRAL DIAPHRAGMS; HTRA1 GENE; PERMEABILITY
AB The choriocapillaris is the source of nutrients and oxygen for photoreceptors, which consume more oxygen per gram of tissue than any other cell in the body. The purpose of this study was to evaluate and compare the ultrastructure of the choriocapillaris and its transport systems in patients with and without age-related macular degeneration (AMD). Ultrastructural changes were also evaluated in subjects that were homozygous for polymorphisms in high risk CFH alleles (Pure 1) only or homozygous only for high risk ARMS2/HTRA1 (Pure 10) alleles. Tissue samples were obtained from the macular region of forty male (n = 24) and female (n = 16) donor eyes and prepared for ultrastructural studies with transmission electron microscopy (TEM). The average age of the aged donors was 74 +/- 7.2 (n = 30) and the young donors 31.7 +/- 11.25 (n = 10). There was no significant difference in average ages between the adult groups. TEM images of the capillaries in the choriocapillaris (CC) were taken at 4,000X and 25,000X and used to measure the area of endothelial cell somas, the number of fenestrations, and area of caveolae within the endothelial cells per length of Bruchs membrane (BrMb). The Student t-test and Wilcoxon sum rank test were used to determine significant differences. There was no significant difference between young subjects and aged controls in any of the morphological criteria assessed. There was a significant decrease in the number of fenestrations/mm of BrMb in atrophic areas of GA eyes (p = 0.007) when compared with aged control eyes. A significant increase was found in the caveolae area as a percent of the endothelial cell soma of capillaries from GA subjects as compared with the controls (p = 0.03). Loss of capillary segments in choriocapillaris was also evident, especially in areas of geographic atrophy and CNV. In eyes from patients with sequence variations, the capillary endothelial cells often appeared degenerative and exhibited atypical fenestrations and pericytes covering the blood vessels. Subjects that were homozygous for polymorphisms in high risk CFH alleles only had more fenestrations/mm of BrMb than subjects that were homozygous only for high risk ARMS2/HTRA1 alleles (p = 0.04), while the latter had greater caveolae area/endothelial cell area than the former (p = 0.007). This study demonstrated an attenuation of CC and a significant decline in the two major transport systems in CC endothelial cells in AMD. This may contribute to drusen deposition, nutrient transport, and vision loss in AMD subjects.
C1 [Grebe, Rhonda; Mughal, Irum; Bryden, William; McLeod, Scott; Edwards, Malia; Lutty, Gerard] Johns Hopkins Univ Hosp, Wilmer Ophthalmol Inst, Dept Ophthalmol, Baltimore, MD 21287 USA.
   [Hageman, Gregory S.] Univ Utah Sch Med, John A Moran Eye Ctr, Steele Ctr Translat Med, Dept Ophthalmol & Visual Sci, Salt Lake City, UT 84132 USA.
C3 Johns Hopkins University; Johns Hopkins Medicine; Utah System of Higher
   Education; University of Utah
RP Lutty, G (通讯作者)，Johns Hopkins Univ Hosp, Wilmer Ophthalmol Inst, M041 Smith Bldg, Baltimore, MD 21287 USA.
EM glutty@jhmi.edu
FU NIH [EY016151, EY01765]; Arnold and Mabel Beckman Foundation;
   Altsheler-Durell Foundation; Foundation Fighting Blindness; RPB
   Unrestricted Grant (Wilmer, Utah); Steele Center for Translational
   Medicine; NATIONAL EYE INSTITUTE [R01EY016151] Funding Source: NIH
   RePORTER
FX We acknowledge the support of NIH grants EY016151 (GL), and EY01765
   (Wilmer), Arnold and Mabel Beckman Foundation (GL), the Altsheler-Durell
   Foundation, Foundation Fighting Blindness, an RPB Unrestricted Grant
   (Wilmer, Utah), and the Steele Center for Translational Medicine (GH).
   The authors wish to acknowledge Tian Jing for assistance with
   statistical analysis and Marc Toso for assistance with tissue
   acquisition. The authors are grateful to the eye donors and their
   families for their generosity without which this study would not have
   been possible.
CR Anderson RGW, 1998, ANNU REV BIOCHEM, V67, P199, DOI 10.1146/annurev.biochem.67.1.199
   Baba T, 2009, INVEST OPHTH VIS SCI, V50, P3503, DOI 10.1167/iovs.08-2614
   BEARER EL, 1985, J CELL BIOL, V100, P418, DOI 10.1083/jcb.100.2.418
   Bhutto IA, 2016, BRIT J OPHTHALMOL, V100, P720, DOI 10.1136/bjophthalmol-2015-308290
   Bhutto IA, 2011, BRIT J OPHTHALMOL, V95, P1323, DOI 10.1136/bjo.2010.199216
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Bird AC, 2014, JAMA OPHTHALMOL, V132, P338, DOI 10.1001/jamaophthalmol.2013.5799
   Blaauwgeers HGT, 1999, AM J PATHOL, V155, P421, DOI 10.1016/S0002-9440(10)65138-3
   Chen Y, 2013, J INT MED RES, V41, P1445, DOI 10.1177/0300060513480926
   Chirco KR, 2017, EYE, V31, P10, DOI 10.1038/eye.2016.216
   Chirco KR, 2016, J PATHOL, V240, P173, DOI 10.1002/path.4766
   Chirco KR, 2016, EXP EYE RES, V146, P393, DOI 10.1016/j.exer.2015.09.003
   Curcio CA, 2011, BRIT J OPHTHALMOL, V95, P1638, DOI 10.1136/bjophthalmol-2011-300344
   Curcio CA, 2010, J LIPID RES, V51, P451, DOI 10.1194/jlr.R002238
   Curcio CA, 2009, METHODS MOL BIOL, V580, P267, DOI 10.1007/978-1-60761-325-1_15
   Di Donato I, 2017, CNS NEUROSCI THER, V23, P759, DOI 10.1111/cns.12722
   Dolz-Marco R, 2018, AM J OPHTHALMOL, V193, P166, DOI 10.1016/j.ajo.2018.06.020
   Dolz-Marco R, 2018, OPHTHALMOLOGY, V125, P1287, DOI 10.1016/j.ophtha.2018.02.036
   Dvorak AM, 1996, J LEUKOCYTE BIOL, V59, P100, DOI 10.1002/jlb.59.1.100
   Dvorak AM, 2001, J HISTOCHEM CYTOCHEM, V49, P419, DOI 10.1177/002215540104900401
   Edwards MM, 2017, INVEST OPHTH VIS SCI, V58, P1352, DOI 10.1167/iovs.16-21229
   Ethier CR, 2004, ANNU REV BIOMED ENG, V6, P249, DOI 10.1146/annurev.bioeng.6.040803.140055
   Federman J L, 1982, Trans Am Ophthalmol Soc, V80, P498
   Feng D, 1996, J EXP MED, V183, P1981, DOI 10.1084/jem.183.5.1981
   Feng D, 1999, MICROCIRCULATION, V6, P23, DOI 10.1038/sj.mn.7300055
   Feng YY, 1999, INVEST OPHTH VIS SCI, V40, P157
   Ferrara D, 2016, PROG RETIN EYE RES, V52, P130, DOI 10.1016/j.preteyeres.2015.10.002
   GEHRS KM, 1992, ARCH OPHTHALMOL-CHIC, V110, P833, DOI 10.1001/archopht.1992.01080180105036
   Grassmann F, 2017, GENETICS, V205, P919, DOI 10.1534/genetics.116.195966
   GREEN WR, 1993, OPHTHALMOLOGY, V100, P1519
   Grossniklaus HE, 2005, ARCH OPHTHALMOL-CHIC, V123, P914
   Guymer R, 1999, PROG RETIN EYE RES, V18, P59, DOI 10.1016/S1350-9462(98)00012-3
   Guymer RH, 2004, INVEST OPHTH VIS SCI, V45, P1660, DOI 10.1167/iovs.03-0913
   Heindl LM, 2015, INVEST OPHTH VIS SCI, V56, P6709, DOI 10.1167/iovs.15-17686
   Herrnberger L, 2012, EXP EYE RES, V105, P27, DOI 10.1016/j.exer.2012.09.011
   Hillman N, 2001, EYE, V15, P319, DOI 10.1038/eye.2001.103
   Hofman P, 2000, CURR EYE RES, V21, P637, DOI 10.1076/0271-3683(200008)21:2;1-V;FT637
   Huang JD, 2008, INVEST OPHTH VIS SCI, V49, P2721, DOI 10.1167/iovs.07-1196
   Hussain AA, 2002, J OPT SOC AM A, V19, P166, DOI 10.1364/JOSAA.19.000166
   Johnson M, 2007, CURR EYE RES, V32, P791, DOI 10.1080/02713680701550660
   Kami J, 2008, JPN J OPHTHALMOL, V52, P91, DOI 10.1007/s10384-007-0506-6
   KILLINGSWORTH MC, 1990, EYE, V4, P613, DOI 10.1038/eye.1990.86
   Kim SY, 2002, RETINA-J RET VIT DIS, V22, P471, DOI 10.1097/00006982-200208000-00012
   Koina ME, 2015, INVEST OPHTH VIS SCI, V56, P1310, DOI 10.1167/iovs.14-15705
   Lains I, 2017, AM J OPHTHALMOL, V180, P55, DOI 10.1016/j.ajo.2017.05.021
   LAZARUS HS, 1993, EXP EYE RES, V56, P531, DOI 10.1006/exer.1993.1067
   LOPEZ PF, 1991, AM J OPHTHALMOL, V112, P647, DOI 10.1016/S0002-9394(14)77270-8
   Lu LN, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000002967
   Lutty GA, 2010, EYE, V24, P408, DOI 10.1038/eye.2009.318
   McLeod DS, 2009, INVEST OPHTH VIS SCI, V50, P4982, DOI 10.1167/iovs.09-3639
   McLeod DS, 2002, INVEST OPHTH VIS SCI, V43, P1986
   MILICI AJ, 1985, CIRC RES, V56, P709, DOI 10.1161/01.RES.56.5.709
   MILLER JW, 1994, AM J PATHOL, V145, P574
   MOORE DJ, 1995, INVEST OPHTH VIS SCI, V36, P1290
   Nakanishi M, 2016, INVEST OPHTH VIS SCI, V57, P2213, DOI 10.1167/iovs.15-17934
   Nesper PL, 2017, RETINA, V38, P1289
   Pennington KL, 2016, EYE VISION, V3, DOI 10.1186/s40662-016-0063-5
   Podar K, 2006, CANCER LETT, V233, P10, DOI 10.1016/j.canlet.2005.02.035
   Predescu SA, 2007, AM J PHYSIOL-LUNG C, V293, pL823, DOI 10.1152/ajplung.00436.2006
   Rajani RM, 2017, CLIN SCI, V131, P369, DOI 10.1042/CS20160618
   ROBERTS WG, 1995, J CELL SCI, V108, P2369
   Saint-Geniez M, 2009, P NATL ACAD SCI USA, V106, P18751, DOI 10.1073/pnas.0905010106
   SARKS SH, 1976, BRIT J OPHTHALMOL, V60, P324, DOI 10.1136/bjo.60.5.324
   SCHNITZER JE, 1992, AM J PHYSIOL, V262, pH246, DOI 10.1152/ajpheart.1992.262.1.H246
   Schroedl F, 2008, INVEST OPHTH VIS SCI, V49, P5222, DOI 10.1167/iovs.08-1721
   Schroedl F, 2014, INVEST OPHTH VIS SCI, V55, P6440, DOI 10.1167/iovs.14-15638
   Seddon JM, 2016, JAMA OPHTHALMOL, V134, P1272, DOI 10.1001/jamaophthalmol.2016.3519
   Simionescu M, 2002, MICROSC RES TECHNIQ, V57, P269, DOI 10.1002/jemt.10086
   Sohn EH, 2014, INVEST OPHTH VIS SCI, V55, P1352, DOI 10.1167/iovs.13-13754
   Stan RV, 2007, J CELL MOL MED, V11, P621, DOI 10.1111/j.1582-4934.2007.00075.x
   Stan RV, 2006, AM J PHYSIOL-LUNG C, V290, pL806, DOI 10.1152/ajplung.00533.2005
   Stan RV, 1999, P NATL ACAD SCI USA, V96, P13203, DOI 10.1073/pnas.96.23.13203
   Stan RV, 2005, BBA-MOL CELL RES, V1746, P334, DOI 10.1016/j.bbamcr.2005.08.008
   Tkachenko E, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032655
   Verdura E, 2015, BRAIN, V138, P2347, DOI 10.1093/brain/awv155
   Wada M, 1999, CURR EYE RES, V18, P203, DOI 10.1076/ceyr.18.3.203.5368
   Wu XW, 2018, BRAZ J MED BIOL RES, V51, DOI [10.1590/1414-431x20176632, 10.1590/1414-431X20176632]
   YAMAMOTO T, 1994, JPN J OPHTHALMOL, V38, P129
   Yuan XL, 2010, MOL CELL PROTEOMICS, V9, P1031, DOI 10.1074/mcp.M900523-MCP200
   Zheng F, 2016, INVEST OPHTH VIS SCI, V57, P6256, DOI 10.1167/iovs.16-20161
NR 80
TC 13
Z9 13
U1 0
U2 7
PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 0014-4835
EI 1096-0007
J9 EXP EYE RES
JI Exp. Eye Res.
PD APR
PY 2019
VL 181
BP 252
EP 262
DI 10.1016/j.exer.2019.02.018
PG 11
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA HT5TJ
UT WOS:000464625900031
PM 30807744
DA 2022-11-30
ER

PT J
AU Kjellstrom, U
AF Kjellstrom, Ulrika
TI Reduced macular function in ABCA4 carriers
SO MOLECULAR VISION
LA English
DT Article
ID CONE-ROD DYSTROPHY; DISEASE GENE ABCR; RECESSIVE RETINITIS-PIGMENTOSA;
   ONSET STARGARDT DISEASE; TRANSPORTER GENE; VISUAL FUNCTION; RIM PROTEIN;
   MUTATIONS; DEGENERATION; PHENOTYPE
AB Purpose: To study retinal function and morphology in ABCA4 carriers to investigate if ABCA4 carriership is associated with any functional or morphological changes and, if so, to explore whether certain mutations may be associated with particularly severe alterations.
   Methods: Eighteen subjects were recruited by means of being the parents of 10 teenagers/young adults with genetically confirmed ABCA4-associated retinal degenerations. The teenagers/young adults are well-known patients and have been followed in our clinic for many years. The eighteen subjects underwent careful ophthalmological examinations, including fundus photography and autofluorescence imaging, Goldmann perimetry, optical coherence tomography (OCT), fullfield electroretinography (ffERG), multifocal electroretinography (mERG), and ABCA4 gene sequencing. The ffERG and mERG results were compared with those of healthy controls.
   Results: All subjects carried at least one ABCA4 mutation. Two subjects were compound heterozygous and therefore were excluded from the group-wise statistical analysis. Thirteen different ABCA4 mutations were found. C.2894 A>G (5/18) and c.768 G>T (4/18) were most common. Fourteen of 16 ABCA4 carriers demonstrated significantly altered mERG parameters (reduced amplitudes and/or delayed implicit times (ITs)) compared to normal values. In addition, the two subjects with compound heterozygous ABCA4 mutations had altered mERG parameters. A statistical comparison to the control group showed significantly reduced amplitudes and delayed ITs; p <= 0.003 for all mERG parameters. FfERG parameters were altered in two ABCA4 carriers and one of the subjects with compound heterozygous ABCA4 mutations (reduced amplitude and delayed IT for the 30 Hz flicker ERG). No significant alterations were found for the whole group of ABCA4 carriers compared to the ffERG control group. Fundus photographs showed subtle to extensive pigmentary changes in several ABCA4 carriers.
   Conclusions: In this study, ABCA4 carriers demonstrated reduced macular function measured by mERG along with none to subtle and even extensive morphological retinal changes. The c.768 G>T, c.5461-10 T>C, and c.319 C>T mutations were associated with the most deviant ERGs, including both significant reduction of mERG amplitudes and prolongation of mERG ITs, as well as with reduced amplitude or delayed IT for the 30 Hz flicker ffERG in a few cases. They may therefore be considered serious mutations. The c.5917delG and c.4469 G>A mutations were associated with milder or no macular alteration. Long-term follow-up of these and other ABCA4 carriers may be of importance to elucidate the role of ABCA4 mutations in age-related macular degeneration. Moreover, improved knowledge of separate ABCA4 mutations may help us to better understand their role in ABCA4-associated retinal degenerations.
C1 [Kjellstrom, Ulrika] Lund Univ, Dept Ophthalmol, Lund, Sweden.
C3 Lund University
RP Kjellstrom, U (通讯作者)，Skanes Univ Sjukhus Lund, Ogonkliniken, S-22185 Lund, Sweden.
EM ulrika.kjellstrom@med.lu.se
FU Skane County Council Research and Development Foundation; Stiftelsen for
   synskadade i fd Malmohuslan; Stiftelsen Synframjandets
   Forskningsfond/Ogonfonden; Cronqvists foundation; ARMEC Lindebergs
   stiftelse; Swedish Society of Medicine; Skane University Hospital
FX I thank Prof. Sten Andreasson for fruitful collaboration and Ing-Marie
   Holst and Boel Nilsson for skillful technical assistance. This study was
   supported by grants from Skane County Council Research and Development
   Foundation, Stiftelsen for synskadade i fd Malmohuslan, Stiftelsen
   Synframjandets Forskningsfond/Ogonfonden, the Cronqvists foundation,
   ARMEC Lindebergs stiftelse (2015-3), the Swedish Society of Medicine and
   Skane University Hospital foundations and donations. Disclosure: The
   author has full control of all primary data and agrees to allow the
   journal to review the data on request. The author has no conflict of
   interest to disclose.
CR Allikmets R, 2000, AM J HUM GENET, V67, P793, DOI 10.1086/303100
   Allikmets R, 1997, NAT GENET, V15, P236, DOI 10.1038/ng0397-236
   Allikmets R, 2000, AM J HUM GENET, V67, P487, DOI 10.1086/303018
   Azarian SM, 1997, FEBS LETT, V409, P247, DOI 10.1016/S0014-5793(97)00517-6
   Birch DG, 2001, EXP EYE RES, V73, P877, DOI 10.1006/exer.2001.1093
   Burke TR, 2011, OPHTHALMIC GENET, V32, P165, DOI 10.3109/13816810.2011.565397
   Cella W, 2009, EXP EYE RES, V89, P16, DOI 10.1016/j.exer.2009.02.001
   Cremers FPM, 1998, HUM MOL GENET, V7, P355, DOI 10.1093/hmg/7.3.355
   De La Paz MA, 1999, OPHTHALMOLOGY, V106, P1531, DOI 10.1016/S0161-6420(99)90449-9
   Ducroq D, 2006, EUR J HUM GENET, V14, P1269, DOI 10.1038/sj.ejhg.5201691
   Fishman GA, 2003, ARCH OPHTHALMOL-CHIC, V121, P851, DOI 10.1001/archopht.121.6.851
   Fritsche LG, 2012, INVEST OPHTH VIS SCI, V53, P2112, DOI 10.1167/iovs.11-8785
   Fujinami K, 2015, OPHTHALMOLOGY, V122, P326, DOI 10.1016/j.ophtha.2014.08.012
   Fujinami K, 2013, OPHTHALMOLOGY, V120, P2324, DOI 10.1016/j.ophtha.2013.04.016
   Fujinami K, 2013, AM J OPHTHALMOL, V156, P487, DOI 10.1016/j.ajo.2013.05.003
   Gerth C, 2002, GRAEF ARCH CLIN EXP, V240, P628, DOI 10.1007/s00417-002-0502-y
   Gomes NL, 2009, INVEST OPHTH VIS SCI, V50, P3953, DOI 10.1167/iovs.08-2657
   Hargitai J, 2005, INVEST OPHTH VIS SCI, V46, P4402, DOI 10.1167/iovs.05-0504
   Hollenstein K, 2007, CURR OPIN STRUC BIOL, V17, P412, DOI 10.1016/j.sbi.2007.07.003
   Hwang YH, 2012, CURR EYE RES, V37, P914, DOI 10.3109/02713683.2012.688163
   HYMAN LG, 1983, AM J EPIDEMIOL, V118, P213, DOI 10.1093/oxfordjournals.aje.a113629
   Jaakson K, 2003, HUM MUTAT, V22, P395, DOI 10.1002/humu.10263
   Jonsson F, 2013, EUR J HUM GENET, V21, P1266, DOI 10.1038/ejhg.2013.23
   Kim YJ, 2013, INVEST OPHTH VIS SCI, V54, P1303, DOI 10.1167/iovs.12-10149
   Kjellstrom U, 2014, MOL VIS, V20, P89
   Klevering BJ, 2005, GRAEF ARCH CLIN EXP, V243, P90, DOI 10.1007/s00417-004-1079-4
   Klevering BJ, 2002, INVEST OPHTH VIS SCI, V43, P1980
   Lewis RA, 1999, AM J HUM GENET, V64, P422, DOI 10.1086/302251
   Lois N, 2001, ARCH OPHTHALMOL-CHIC, V119, P359, DOI 10.1001/archopht.119.3.359
   Lupo S, 2011, AM J OPHTHALMOL, V151, P106, DOI 10.1016/j.ajo.2010.07.026
   Maia-Lopes S, 2008, INVEST OPHTH VIS SCI, V49, P1191, DOI 10.1167/iovs.07-1051
   Marmor MF, 2009, DOC OPHTHALMOL, V118, P69, DOI 10.1007/s10633-008-9155-4
   Martinez-Mir A, 1998, NAT GENET, V18, P11, DOI 10.1038/ng0198-11
   Mata NL, 2000, P NATL ACAD SCI USA, V97, P7154, DOI 10.1073/pnas.130110497
   Maugeri A, 1999, AM J HUM GENET, V64, P1024, DOI 10.1086/302323
   Michaelides M, 2003, J MED GENET, V40, P641, DOI 10.1136/jmg.40.9.641
   Molday LL, 2000, NAT GENET, V25, P257, DOI 10.1038/77004
   Mullins RF, 2012, INVEST OPHTH VIS SCI, V53, P1883, DOI 10.1167/iovs.12-9477
   Quazi F, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms1927
   Rivera A, 2000, AM J HUM GENET, V67, P800, DOI 10.1086/303090
   Rosenberg T, 2007, MOL VIS, V13, P1962
   Seddon JM, 1997, AM J OPHTHALMOL, V123, P199, DOI 10.1016/S0002-9394(14)71036-0
   Sun H, 1997, NAT GENET, V17, P15, DOI 10.1038/ng0997-15
   Testa F, 2014, BRIT J OPHTHALMOL, V98, P946, DOI 10.1136/bjophthalmol-2013-304082
   Testa F, 2012, INVEST OPHTH VIS SCI, V53, P4409, DOI 10.1167/iovs.11-8201
   Utz VM, 2014, BRIT J OPHTHALMOL, V98, P513, DOI 10.1136/bjophthalmol-2013-304270
   van Driel MA, 1998, OPHTHALMIC GENET, V19, P117, DOI 10.1076/opge.19.3.117.2187
   Webster AR, 2001, INVEST OPHTH VIS SCI, V42, P1179
   Weng J, 1999, CELL, V98, P13, DOI 10.1016/S0092-8674(00)80602-9
   Westeneng-van Haaften SC, 2012, OPHTHALMOLOGY, V119, P1199, DOI 10.1016/j.ophtha.2012.01.005
   Wiszniewski W, 2005, HUM MOL GENET, V14, P2769, DOI 10.1093/hmg/ddi310
   Yatsenko AN, 2001, HUM GENET, V108, P346, DOI 10.1007/s004390100493
NR 52
TC 12
Z9 12
U1 0
U2 7
PU MOLECULAR VISION
PI ATLANTA
PA C/O JEFF BOATRIGHT, LAB B, 5500 EMORY EYE CENTER, 1327 CLIFTON RD, N E,
   ATLANTA, GA 30322 USA
SN 1090-0535
J9 MOL VIS
JI Mol. Vis.
PD JUL 17
PY 2015
VL 21
BP 767
EP 782
PG 16
WC Biochemistry & Molecular Biology; Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Ophthalmology
GA CO2VU
UT WOS:000359015700001
PM 26261413
DA 2022-11-30
ER

PT J
AU Hanlon, J
   Chell, E
   Firpo, M
   Koruga, I
AF Hanlon, Justin
   Chell, Erik
   Firpo, Michael
   Koruga, Igor
TI ITAR: A modified TAR method to determine depth dose distribution for an
   ophthalmic device that performs kilovoltage x-ray pencil-beam stereotaxy
SO MEDICAL PHYSICS
LA English
DT Article
DE reference and relative dosimetry; tissue air ratio (TAR); age-related
   macular degeneration (AMD); stereotaxy; MCNPX
ID MACULAR DEGENERATION; RANIBIZUMAB THERAPY; RADIOSURGERY; RADIOTHERAPY;
   IRRADIATION; DOSIMETRY; AMD; OUTCOMES
AB Purpose: New technology has been developed to treat age-related macular degeneration (AMD) using 100 kVp pencil-beams that enter the patient through the radio-resistant sclera with a depth of interest between 1.6 and 2.6 cm. Measurement of reference and relative dose in a kilovoltage x-ray beam with a 0.42 cm diameter field size and a 15 cm source to axis distance (SAD) is a challenge that is not fully addressed in current guidelines to medical physicists. AAPM's TG-61 gives dosimetry recommendations for low and medium energy x-rays, but not all of them are feasible to follow for this modality.
   Methods: An investigation was conducted to select appropriate equipment for the application. PTW's Type 34013 Soft X-Ray Chamber (Freiburg, Germany) and CIRS's Plastic Water LR (Norfolk, VA) were found to be the best available options. Attenuation curves were measured with minimal scatter contribution and thus called Low Scatter Tissue Air Ratio (LSTAR). A scatter conversion coefficient (C-scat) was derived through Monte Carlo radiation transport simulation using MCNPX (LANL, Los Alamos, NM) to quantify the difference between a traditional TAR curve and the LSTAR curve. A material conversion coefficient (C-mat) was determined through experimentation to evaluate the difference in attenuation properties between water and Plastic Water LR. Validity of performing direct dosimetry measurements with a source to detector distance other than the treatment distance, and therefore a different field size due to a fixed collimator, was explored. A method-Integrated Tissue Air Ratio (ITAR)-has been developed that isolates each of the three main radiological effects (distance from source, attenuation, and scatter) during measurement, and integrates them to determine the dose rate to the macula during treatment.
   Results: LSTAR curves were determined to be field size independent within the range explored, indicating that direct dosimetry measurements may be performed with a source to detector distance of 20 cm even though the SAD is 15 cm during treatment. C-scat varied from 1.102 to 1.106 within the range of depths of interest. The experimental variance among repeated measurements of C-mat was larger than depth dependence, so C-mat was estimated as 1.019 for all depths of interest.
   Conclusions: Equipment selection, measurement techniques, and formalism for the determination of dose rate to the macula during stereotaxy for AMD have been determined and are strongly recommended by the authors of this paper to be used by clinical medical physicists. (C) 2014 American Association of Physicists in Medicine.
C1 [Hanlon, Justin; Chell, Erik; Firpo, Michael; Koruga, Igor] Oraya Therapeut Inc, Newark, CA 94560 USA.
RP Hanlon, J (通讯作者)，Oraya Therapeut Inc, Newark, CA 94560 USA.
EM jhanlon@orayainc.com
FU Oraya Therapeutics, Inc.
FX This work was supported by Oraya Therapeutics, Inc.
CR Cantley JL, 2013, PHYS MED BIOL, V58, P6887, DOI 10.1088/0031-9155/58/19/6887
   Canton VM, 2011, OPHTHAL SURG LAS IM, V42, P468, DOI 10.3928/15428877-20110804-01
   Cranley K., 1997, 78 I PHYS
   Gertner M, 2010, MED PHYS, V37, P600, DOI 10.1118/1.3291648
   Hanlon J, 2011, INVEST OPHTH VIS SCI, V52, P2334, DOI 10.1167/iovs.10-6421
   Hanlon J, 2009, MED PHYS, V36, P3671, DOI 10.1118/1.3168554
   Ibbott G, 2008, MED PHYS, V35, P1418, DOI 10.1118/1.2868765
   Jackson T., 2013, 13 EUR C HAMB GERM 2
   Jackson TL, 2013, OPHTHALMOLOGY, V120, P1893, DOI 10.1016/j.ophtha.2013.02.016
   Khan F.M., 2003, PHYS RAD THERAPY, V3rd ed
   Lee C, 2008, MED PHYS, V35, P5151, DOI 10.1118/1.2990780
   Ma CM, 2001, MED PHYS, V28, P868, DOI 10.1118/1.1374247
   Moshfeghi AA, 2011, OPHTHAL SURG LAS IM, V42, P460, DOI 10.3928/15428877-20110804-03
   Moshfeghi DM, 2011, BRIT J OPHTHALMOL, V95, P185, DOI 10.1136/bjo.2009.163907
   Taddei PJ, 2010, PHYS MED BIOL, V55, P7037, DOI 10.1088/0031-9155/55/23/S06
NR 15
TC 1
Z9 1
U1 0
U2 2
PU AMER ASSOC PHYSICISTS MEDICINE AMER INST PHYSICS
PI MELVILLE
PA STE 1 NO 1, 2 HUNTINGTON QUADRANGLE, MELVILLE, NY 11747-4502 USA
SN 0094-2405
J9 MED PHYS
JI Med. Phys.
PD FEB
PY 2014
VL 41
IS 2
AR 021729
DI 10.1118/1.4863482
PG 8
WC Radiology, Nuclear Medicine & Medical Imaging
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Radiology, Nuclear Medicine & Medical Imaging
GA AA6MV
UT WOS:000331213300032
PM 24506620
DA 2022-11-30
ER

PT J
AU Lafuma, A
   Brezin, A
   Lopatriello, S
   Hieke, K
   Hutchinson, J
   Mimaud, V
   Berdeaux, G
AF Lafuma, A
   Brezin, A
   Lopatriello, S
   Hieke, K
   Hutchinson, J
   Mimaud, V
   Berdeaux, G
TI Evaluation of non-medical costs associated with visual impairment in
   four European countries - France, Italy, Germany and the UK
SO PHARMACOECONOMICS
LA English
DT Article
ID GLOBAL BLINDNESS; LOW-VISION; PREVALENCE; BURDEN; POPULATION; GLAUCOMA
AB Introduction: Visual impairment is a severe disability that puts a heavy burden on individuals, families and society. In developed countries, the two major diseases leading to irreversible visual impairment are glaucoma and age-related macular degeneration. Their prevalence will increase dramatically with population aging. The economic consequences of visual impairment are considerable, but have rarely been documented, apart from some 'top-down' estimates based on national statistics. We estimated the non-medical costs related to visual impairment in four European countries: France, Italy, Germany and the UK.
   Methods: Prevalence rates of visual impairment, defined according to local regulations, were taken from national registers and, for France, from two recent nationwide surveys conducted by the French Institute for National Statistics and Economic Studies (Institut National de la Statistique et des Etudes Economiques [INSEE]). Estimates of the number of non-registered persons were obtained from the literature and expert opinion. Estimates of non-medical costs included institutional care, non-medical devices, residential adaptations, burden on carer, paid home help, loss of income and social allowances related to visual impairment. Unit costs (year 2004) were extracted from national databases and manufacturers. Healthcare professionals were interviewed to estimate the duration of assistance required by visually impaired persons. These durations were used to evaluate the cost of paid assistance at home in the four countries.
   Results: The numbers of visually impaired persons were 1.27 million in France, 0.73 million in Germany, 1.03 million in Italy and 1.11 million in the UK, including, respectively, 56%, 11%, 80% and 72% non-registered persons. The frequency of institutionalisation for visually impaired persons were, respectively, 7.8%, 9.6%, 10.9% and 10%. Total annual costs for visually impaired persons were estimated at EURO10 749 million in France, EURO9214 million in Germany, EURO12 069 million in Italy and EURO15 180 million in the UK. This translated into average annual costs per affected individual of EURO8434, EURO12 662, EURO11 701 and EURO13 674, respectively. The main cost components of visual impairment in the community were 'loss of income' (23-43% of community costs), 'burden on carer' (24-39%) and 'paid assistance' (13-29%).
   Conclusion: Total non-medical costs associated with visual impairment are considerable. The present analysis demonstrates that the preponderant economic consequences of visual impairment lie beyond healthcare systems, and that visual impairment has a considerable negative impact on productivity. Considering the non-medical social dimensions of visual impairment related to the consequent incapacity and dependency should encourage payers to finance health innovations that aim to preserve vision.
C1 Cemka Eval, Bourg La Reine, France.
   Hop Cochin, F-75674 Paris, France.
   PBE Consulting, Verona, Italy.
   NEOS Hlth, Binningen, Switzerland.
   Fourth Hurdle Consulting Ltd, London, England.
   Conservatoire Natl Arts & Metiers, Paris, France.
C3 Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin
   - APHP; UDICE-French Research Universities; Universite Paris Cite; heSam
   Universite; Conservatoire National Arts & Metiers (CNAM)
RP Berdeaux, G (通讯作者)，Alcon France, 4 Rue Henri St Claire, F-92563 Deville, France.
EM gilles.berdeaux@alconlabs.com
CR Berdeaux G, 2004, VALUE HEALTH, V7, P748, DOI 10.1016/S1098-3015(10)65988-8
   BOISSONNAT V, 2003, REV FRANCAISE AFFAIR, P1
   Bonastre J, 2002, Eur J Health Econ, V3, P94, DOI 10.1007/s10198-002-0104-y
   Bonastre J, 2003, PHARMACOECONOMICS, V21, P181, DOI 10.2165/00019053-200321030-00003
   Brezin Antoine Pierre, 2005, Health Qual Life Outcomes, V3, P27, DOI 10.1186/1477-7525-3-27
   Brezin AP, 2005, ARCH OPHTHALMOL-CHIC, V123, P1117, DOI 10.1001/archopht.123.8.1117
   Brezin AP, 2004, BRIT J OPHTHALMOL, V88, P1330, DOI 10.1136/bjo.2003.039180
   BRUCE I, 1991, BLIND PARTIALLY SIGH, V1
   Buch H, 2001, ACTA OPHTHALMOL SCAN, V79, P441, DOI 10.1034/j.1600-0420.2001.790503.x
   *CAISS NAT ASS MAL, 2000, IND STAT RES 2000 20
   CASTIGLIONI M, 2001, EUR POP C JUN 7 9 HE
   CHIANG YP, 1992, MILBANK Q, V70, P319, DOI 10.2307/3350062
   COFFEY M, 1993, BRIT J OPHTHALMOL, V77, P17, DOI 10.1136/bjo.77.1.17
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   *DEM, TAR BLEU BLANC ROUG
   Denis P, 2004, J GLAUCOMA, V13, P283, DOI 10.1097/00061198-200408000-00005
   *DEP HLTH ENGL GOV, NAT STAT
   ENGEL H, 2000, PUBLICATION SERIES G
   *EV KIRCH LUDW, PREISL DIAK SOZ
   Frick KD, 2003, AM J OPHTHALMOL, V135, P471, DOI 10.1016/S0002-9394(02)02110-4
   *GDBA, COSTS BLINDN AN COST
   *IRDES, 2004, OECD HLTH DAT DAT CD
   JACOBZONE S, 2000, OECD EC STUDIES, P149
   JONSSON B, 1999, PRIMARY OPEN ANGLE G
   Klaver CCW, 1998, ARCH OPHTHALMOL-CHIC, V116, P653, DOI 10.1001/archopht.116.5.653
   Kocur I, 2002, BRIT J OPHTHALMOL, V86, P716, DOI 10.1136/bjo.86.7.716
   MATHERS C, DEATHS DIS BURDEN CA
   Meads C, 2003, BRIT J OPHTHALMOL, V87, P1201, DOI 10.1136/bjo.87.10.1201
   *MIN SAN, TAR PREST ASS OSP AC
   *NAT I STAT, 2001, ISTAT
   National Institute for Clinical Excellence, 2004, GUID METH TECHN APPR
   Netten A, 2003, UNIT COST HLTH SOCIA
   NETTEN A, 2002, UNIT COSTS HLTH SOCI
   *NEXD, PORT IMM
   *OECD, 1996, 20 OECD
   QUEGINER P, 1988, B SOC OPHTALMOL FR, V88, P26
   Queguiner P, 1988, Bull Soc Ophtalmol Fr, V88, P21
   QUEGUINER P, 1988, B SOC OPHTHALMOL FR, V88, P25
   Resnikoff S, 2004, B WORLD HEALTH ORGAN, V82, P844
   ROBINSON R, 1994, BRIT J OPHTHALMOL, V78, P736, DOI 10.1136/bjo.78.10.736
   Smith AF, 1996, BRIT J OPHTHALMOL, V80, P276, DOI 10.1136/bjo.80.4.276
   *STAT BUND DEUTSCH, 2003, FACHS, V13
   TAYLOR H, 2004, EC IMPACT COST VISIO
   Thylefors B, 1995, Ophthalmic Epidemiol, V2, P5, DOI 10.3109/09286589509071448
   Thylefors B, 1995, OPHTHAL EPIDEMIOL, V2, P5
   Tinker A, 2003, BRIT DENT J, V194, P369, DOI 10.1038/sj.bdj.4809996
   *URL, COT IMM PRIX MARCH I
   *URL, GUID CRED CTR IND CR
   *URL, VISION 2020 RIGHT SI
   WORMALD R, 1994, BRIT J OPHTHALMOL, V78, P733, DOI 10.1136/bjo.78.10.733
   Wright SE, 2000, CLIN EXP OPHTHALMOL, V28, P140, DOI 10.1046/j.1442-9071.2000.00296.x
NR 51
TC 52
Z9 53
U1 0
U2 14
PU ADIS INT LTD
PI NORTHCOTE
PA 5 THE WAREHOUSE WAY, NORTHCOTE 0627, AUCKLAND, NEW ZEALAND
SN 1170-7690
EI 1179-2027
J9 PHARMACOECONOMICS
JI Pharmacoeconomics
PY 2006
VL 24
IS 2
BP 193
EP 205
DI 10.2165/00019053-200624020-00007
PG 13
WC Economics; Health Care Sciences & Services; Health Policy & Services;
   Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Business & Economics; Health Care Sciences & Services; Pharmacology &
   Pharmacy
GA 023YW
UT WOS:000236163100007
PM 16460138
OA Green Published
DA 2022-11-30
ER

PT J
AU Kelliher, C
   Kenny, D
   O'Brien, C
AF Kelliher, C
   Kenny, D
   O'Brien, C
TI Trends in blind registration in the adult population of the Republic of
   Ireland 1996-2003
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID VISUAL IMPAIRMENT
AB Background/aim: The Republic of Ireland has a centralised database of all registered, blind people in the country. The last study of the national blind register was undertaken in 1996. The current study sought, firstly, to investigate and identify any recent changes in the register composition. Secondly, there is concern that many eligible people are not appropriately registered. To examine this further, registration levels among patients attending an Irish outpatient ophthalmology clinic were determined.
   Methods: Criteria for blind registration in Ireland are ( 1) a best corrected visual acuity of 6/60 or less in the better eye, or ( 2) a visual field subtending an angle of 20 degrees or less. The National Council for the Blind in Ireland (NCBI) is the sole custodian of a national registration database recording all eligible, registered people. This computerised database was analysed to provide information on the demographics and blind registration condition of those on the register in 2003. This information was compared with the results of the 1996 study. To assess the accuracy of the current register, the registration status of eligible patients attending the outpatient clinic of a busy, tertiary referral ophthalmology department, over a 9 week period, was studied.
   Results: 6862 adults were registered as blind on the NCBI register in Ireland in 2003, representing an increase of 37% since 1996. The leading causes of registration were age related macular degeneration (ARMD) (25%), glaucoma (12%), and retinitis pigmentosa (7%). Comparing the 1996 and 2003 data, dramatic increases in the numbers registered caused by ARMD ( from 812 to 1729 people, a 113% increase) and diabetic retinopathy (DR) (from 147 people to 323 people, a 120% increase) were found. The numbers registered as a result of glaucoma were relatively stable (795 in 1996 and 811 in 2003). A substantial drop, of 53%, was noted in the number of people registered as a result of cataracts, from 561 people to 261. Of the 672 new cases registered in 2003, ARMD accounted for 44%, glaucoma 13%, and DR 7%. Over the 9 week study period 75 patients, out of a total 2320 patients who attended the outpatient department, fulfilled the blind registration criteria. It was found that 21% ( 16 of 75) of the eligible clinic outpatients had not been appropriately registered.
   Conclusion: An overall increase in adult blind registration of 37% in the Republic of Ireland was found between 1996 and 2003. There were large increases in registered blindness as a result of ARMD ( 113%) and DR ( 120%). A notable decrease in registration as a result of cataracts was discovered. Vigilance by clinicians is necessary to ensure that eligible patients are registered.
C1 Mater Misericordiae Univ Hosp, Dept Ophthalmol, Dublin, Ireland.
   Univ Coll Dublin, Conway Inst Biomol & Biomed Sci, Dublin 2, Ireland.
C3 Mater Misericordiae University Hospital; University College Dublin;
   University College Dublin
RP O'Brien, C (通讯作者)，Mater Misericordiae Univ Hosp, Dept Ophthalmol, Dublin, Ireland.
EM cobrien@mater.ie
CR Bamashmus MA, 2004, EYE, V18, P257, DOI 10.1038/sj.eye.6700606
   Barry RJ, 2005, BRIT J OPHTHALMOL, V89, P995, DOI 10.1136/bjo.2004.059915
   Bunce C, 1998, BRIT J OPHTHALMOL, V82, P72, DOI 10.1136/bjo.82.1.72
   Canavan YM, 1997, ULSTER MED J, V66, P92
   *CENTR STAT OFF, CENS 1996
   *CENTR STAT OFF, CENS 2002
   Evans J, 1996, BRIT J OPHTHALMOL, V80, P9, DOI 10.1136/bjo.80.1.9
   Farber MD, 2003, OPHTHAL EPIDEMIOL, V10, P267, DOI 10.1076/opep.10.4.267.15910
   Gillibrand W, 2004, MOL CELL BIOCHEM, V261, P183, DOI 10.1023/B:MCBI.0000028754.70862.13
   KANSKI JJ, 2003, CLIN OPHTHALMOLOGY S, P405
   Krumpaszky HG, 1999, OPHTHALMOLOGICA, V213, P176, DOI 10.1159/000027415
   KRUMPASZKY HG, 1992, KLIN MONATSBL AUGENH, V200, P142, DOI 10.1055/s-2008-1045729
   Long VW, 2005, IRISH J MED SCI, V174, P36, DOI 10.1007/BF03169127
   Munier A, 1998, BRIT J OPHTHALMOL, V82, P630, DOI 10.1136/bjo.82.6.630
   Resnikoff S, 2004, B WORLD HEALTH ORGAN, V82, P844
   ROBINSON R, 1994, BRIT J OPHTHALMOL, V78, P736, DOI 10.1136/bjo.78.10.736
   Rosenberg T, 1996, ACTA OPHTHALMOL SCAN, V74, P395
NR 17
TC 55
Z9 55
U1 0
U2 2
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
EI 1468-2079
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD MAR
PY 2006
VL 90
IS 3
BP 367
EP 371
DI 10.1136/bjo.2005.075861
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 013QS
UT WOS:000235424800032
PM 16488964
OA Green Published
DA 2022-11-30
ER

PT J
AU Haas, AM
   Ahmed, D
   Stattin, M
   Graf, A
   Krepler, K
   Ansari-Shahrezaei, S
AF Haas, Anna-Maria
   Ahmed, Daniel
   Stattin, Martin
   Graf, Alexandra
   Krepler, Katharina
   Ansari-Shahrezaei, Siamak
TI Comparison of macular neovascularization lesion size by the use of
   Spectral-Domain Optical Coherence Tomography Angiography and
   Swept-Source Optical Coherence Tomography Angiography versus Indocyanine
   Green Angiography
SO ACTA OPHTHALMOLOGICA
LA English
DT Article
DE age-related macular degeneration; indocyanine green angiography; macular
   neovascularization; optical coherence tomography angiography;
   spectral-domain; swept-source
ID CHOROIDAL NEOVASCULARIZATION; TYPE-1; GUIDELINES
AB Purpose To compare the lesion sizes of macular neovascularization (MNV) imaged with spectral-domain (SD) and swept-source (SS) optical coherence tomography angiography (OCTA) as well as indocyanine green angiography (ICGA). Methods In this prospective, observational case series, patients showing a secured diagnosis of MNV on ICGA or Fluorescein Angiography, were imaged by SD-OCTA and SS-OCTA on the same day. Lesion size was measured on 3 x 3-mm(2)and 6 x 6-mm(2)scans using the Maestro 2 SD-OCTA (Topcon Corporation, Tokyo Japan) and the Triton SS-OCTA device (Topcon Corporation, Tokyo Japan) and compared to ICGA (Spectralis HRA, Heidelberg, Germany). Results Twenty eyes from 20 patients (11 females, 55%) were enrolled. The neovascularization area measured on 6 x 6-mm(2)SD-OCTA was lower compared to that outlined on SS-OCTA, however, not reaching statistical significance (p = 0.094). Regarding 3 x 3-mm(2)measurements, the median lesion sizes between the two OCTA devices were comparable (p = 0.492). Indocyanine green angiography depicted a larger lesion area than both OCTA devices, however, not reaching statistical significance. Conclusion SD-OCTA tends to show smaller areas of MNV extension than SS-OCTA regarding 6 x 6 mm(2)scans. The lesion size of MNV can be very well compared between the different devices, emphasizing the use of OCTA for monitoring neovascular area. Lesion measurements on SS-OCTA correlate better with ICGA than SD-OCTA.
C1 [Haas, Anna-Maria; Ahmed, Daniel; Stattin, Martin; Krepler, Katharina; Ansari-Shahrezaei, Siamak] Karl Landsteiner Inst Retinal Res & Imaging, Vienna, Austria.
   [Haas, Anna-Maria; Ahmed, Daniel; Stattin, Martin; Krepler, Katharina; Ansari-Shahrezaei, Siamak] Rudolf Fdn Hosp, Dept Ophthalmol, Juchgasse 25, A-1030 Vienna, Austria.
   [Graf, Alexandra] Med Univ Vienna, Ctr Med Stat Informat & Intelligent Syst, Vienna, Austria.
   [Ansari-Shahrezaei, Siamak] Med Univ Graz, Dept Ophthalmol, Graz, Austria.
C3 Medical University of Vienna; Medical University of Graz
RP Ansari-Shahrezaei, S (通讯作者)，Rudolf Fdn Hosp, Dept Ophthalmol, Juchgasse 25, A-1030 Vienna, Austria.
EM siamak.ansarishahrezaei@wienkav.at
OI Graf, Alexandra/0000-0003-0035-2658; Ansari Shahrezaei,
   Siamak/0000-0001-8032-4686
FU Topcon Europe Medical BV
FX Each author certifies that he or she has made substantial contribution
   to the work reported in this manuscript to all of the following: (1)
   conception and design, acquisition of data or analysis and
   interpretation of data, (2) drafting the article, revising it critically
   for important intellectual content, (3) final approval of the version to
   be published (4) and agreement to be accountable for all aspects of the
   work in ensuring that all questions related to the accuracy and
   integrity of the work are appropriately investigated and resolved. All
   authors have completed and submitted the ICMJE Form for Disclosure of
   Potential Conflicts of Interest. The authors have not published or
   submitted any related papers from this study. Neither was the paper
   presented at a meeting. The Karl Landsteiner Institute for Retinal
   Research and Imaging currently receives a device support from Topcon
   Europe Medical BV.
CR Ahmed D, 2018, RETINA-J RET VIT DIS, V38, P2143, DOI 10.1097/IAE.0000000000001832
   Chakravarthy U, 2013, EYE, V27, P1429, DOI 10.1038/eye.2013.233
   Cicinelli MV, 2020, RETINA-J RET VIT DIS, V40, P499, DOI 10.1097/IAE.0000000000002452
   Costanzo E, 2016, INVEST OPHTH VIS SCI, V57, pOCT307, DOI 10.1167/iovs.15-18830
   de Carlo TE, 2015, OPHTHALMOLOGY, V122, P1228, DOI 10.1016/j.ophtha.2015.01.029
   Do DV, 2013, CURR OPIN OPHTHALMOL, V24, P244, DOI 10.1097/ICU.0b013e32835fd7dd
   Eandi CM, 2017, INVEST OPHTH VIS SCI, V58, P3690, DOI 10.1167/iovs.17-21941
   Inoue M, 2016, INVEST OPHTH VIS SCI, V57, pOCT314, DOI 10.1167/iovs.15-18900
   LIM JI, 1995, INT OPHTHALMOL CLIN, V35, P59, DOI 10.1097/00004397-199503540-00006
   LIPSON BK, 1989, INT OPHTHALMOL CLIN, V29, P200, DOI 10.1097/00004397-198902930-00011
   Makita S, 2006, OPT EXPRESS, V14, P7821, DOI 10.1364/OE.14.007821
   Miller AR, 2017, INVEST OPHTH VIS SCI, V58, P1499, DOI 10.1167/iovs.16-20969
   Moult E, 2014, OSLI RETINA, V45, P496, DOI 10.3928/23258160-20141118-03
   Novais EA, 2016, AM J OPHTHALMOL, V164, P80, DOI 10.1016/j.ajo.2016.01.011
   Roisman L, 2016, OPHTHALMOLOGY, V123, P1309, DOI 10.1016/j.ophtha.2016.01.044
   Schachat AP., 2018, RYANS RETINA, V6
   Schmidt-Erfurth U, 2014, BRIT J OPHTHALMOL, V98, P1144, DOI 10.1136/bjophthalmol-2014-305702
   Spaide RF, 2018, PROG RETIN EYE RES, V64, P1, DOI 10.1016/j.preteyeres.2017.11.003
   Ting DSW, 2015, CLIN EXP OPHTHALMOL, V43, P815, DOI 10.1111/ceo.12580
   Told R, 2016, SCI REP-UK, V6, DOI 10.1038/srep38132
   Told R, 2018, INVEST OPHTH VIS SCI, V59, P2393, DOI 10.1167/iovs.17-22902
   Wang R, 2019, BMC OPHTHALMOL, V19, DOI 10.1186/s12886-019-1163-5
   Yu SQ, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0204501
   Zhang QQ, 2017, INVEST OPHTH VIS SCI, V58, P1506, DOI 10.1167/iovs.16-20977
NR 24
TC 2
Z9 2
U1 1
U2 2
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1755-375X
EI 1755-3768
J9 ACTA OPHTHALMOL
JI Acta Ophthalmol.
PD MAR
PY 2021
VL 99
IS 2
BP E260
EP E266
DI 10.1111/aos.14572
EA AUG 2020
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA QT2FQ
UT WOS:000561940400001
PM 32833284
OA Bronze
DA 2022-11-30
ER

PT J
AU Zhao, ZZ
   Zhang, YM
   Zhang, CY
   Zhang, JT
   Luo, XT
   Qiu, QH
   Luo, DW
   Zhang, JF
AF Zhao, Zhenzhen
   Zhang, Yumeng
   Zhang, Chaoyang
   Zhang, Jingting
   Luo, Xueting
   Qiu, Qinghua
   Luo, Dawei
   Zhang, Jingfa
TI TGF-beta promotes pericyte-myofibroblast transition in subretinal
   fibrosis through the Smad2/3 and Akt/mTOR pathways
SO EXPERIMENTAL AND MOLECULAR MEDICINE
LA English
DT Article
ID MESENCHYMAL STEM-CELLS; MACULAR DEGENERATION; GROWTH-FACTOR; CHOROIDAL
   NEOVASCULARIZATION; MECHANISMS; RECEPTOR; ORIGIN; MTOR; SCAR
AB Subretinal fibrosis remains a major obstacle to the management of neovascular age-related macular degeneration. Choroidal pericytes were found to be a significant source of subretinal fibrosis, but the underlying mechanisms of pericyte-myofibroblast transition (PMT) remain largely unknown. The goal of this study was to explore the role and potential mechanisms by which PMT contributes to subretinal fibrosis. Choroidal neovascularization (CNV) was induced by laser photocoagulation in transgenic mice with the collagen1 alpha 1-green fluorescent protein (Col1 alpha 1-GFP) reporter, and recombinant adeno-associated virus 2 (rAAV2)-mediated TGF-beta 2 (rAAV2-TGF-beta 2) was administered intravitreally to further induce PMT. Primary mouse choroidal GFP-positive pericytes were treated with TGF-beta 2 in combination with siRNAs targeting Smad2/3, the Akt inhibitor MK2206 or the mTOR inhibitor rapamycin to examine cell proliferation, migration, and differentiation into myofibroblasts. The involvement of the Akt/mTOR pathway in PMT in subretinal fibrosis was further investigated in vivo. Intraocular TGF-beta 2 overexpression induced GFP-positive pericyte infiltration and PMT in subretinal fibrosis, which was mimicked in vitro. Knockdown of Smad2/3 or inhibition of Akt/mTOR decreased cell proliferation, PMT and migration in primary mouse pericytes. Combined inhibition of Smad2/3 and mTOR showed synergistic effects on attenuating alpha-smooth muscle actin (alpha-SMA) expression and cell proliferation. In mice with laser-induced CNV, the administration of the Akt/mTOR inhibitors suppressed pericyte proliferation and alleviated the severity of subretinal fibrosis. Our results showed that PMT plays a pivotal role in subretinal fibrosis, which was induced by TGF-beta 2 through the Smad2/3 and Akt/mTOR pathways. Thus, inhibiting PMT may be a novel strategy for the treatment of subretinal fibrosis.
   Eye disease: Revealing the mechanisms behind subretinal fibrosis The identification of a new cell type that plays a crucial role in causing fibrosis under the retina could improve treatment of eye disease. Effective treatments exist for diseases that cause impairment and loss of vision in elderly people, but success can be limited by the development of subretinal fibrosis. Jingfa Zhang at Shanghai Jiao Tong University, China, and co-workers used mice with laser-induced retinal damage to explore how subretinal fibrosis may result from transition of pericytes, multi-functional cells in the capillaries, into myofibroblasts, cells associated with fibrosis. The overexpression of a growth factor called TGF-beta 2 induced pericytes to infiltrate the subretinal area and pericyte-myofibroblast transition via two signalling pathways. Inhibiting these pathways may help to treat subretinal fibrosis, and one option is the use of inhibitors of AKT/mTOR which may slow the ageing process.
C1 [Zhao, Zhenzhen; Zhang, Yumeng; Zhang, Chaoyang; Zhang, Jingting; Luo, Xueting; Qiu, Qinghua; Luo, Dawei; Zhang, Jingfa] Shanghai Jiao Tong Univ, Sch Med, Shanghai Peoples Hosp 1, Dept Ophthalmol,Shanghai Gen Hosp, Shanghai, Peoples R China.
   [Zhao, Zhenzhen; Zhang, Yumeng; Zhang, Chaoyang; Zhang, Jingting; Luo, Xueting; Qiu, Qinghua; Luo, Dawei; Zhang, Jingfa] Natl Clin Res Ctr Eye Dis, Shanghai, Peoples R China.
   [Zhao, Zhenzhen; Zhang, Yumeng; Zhang, Chaoyang; Zhang, Jingting; Luo, Xueting; Qiu, Qinghua; Luo, Dawei; Zhang, Jingfa] Shanghai Key Lab Ocular Fundus Dis, Shanghai, Peoples R China.
   [Zhao, Zhenzhen; Zhang, Yumeng; Zhang, Chaoyang; Zhang, Jingting; Luo, Xueting; Qiu, Qinghua; Luo, Dawei; Zhang, Jingfa] Shanghai Engn Ctr Visual Sci & Photomed, Shanghai, Peoples R China.
   [Zhao, Zhenzhen; Zhang, Yumeng; Zhang, Chaoyang; Zhang, Jingting; Luo, Xueting; Qiu, Qinghua; Luo, Dawei; Zhang, Jingfa] Shanghai Engn Ctr Precise Diag & Treatment Eye Di, Shanghai, Peoples R China.
   [Qiu, Qinghua] Shigatse Peoples Hosp, Dept Ophthalmol, Xizang, Peoples R China.
C3 Shanghai Jiao Tong University
RP Zhang, JF (通讯作者)，Shanghai Jiao Tong Univ, Sch Med, Shanghai Peoples Hosp 1, Dept Ophthalmol,Shanghai Gen Hosp, Shanghai, Peoples R China.; Zhang, JF (通讯作者)，Natl Clin Res Ctr Eye Dis, Shanghai, Peoples R China.; Zhang, JF (通讯作者)，Shanghai Key Lab Ocular Fundus Dis, Shanghai, Peoples R China.; Zhang, JF (通讯作者)，Shanghai Engn Ctr Visual Sci & Photomed, Shanghai, Peoples R China.; Zhang, JF (通讯作者)，Shanghai Engn Ctr Precise Diag & Treatment Eye Di, Shanghai, Peoples R China.
EM jingfa.zhang@shgh.cn
FU National Natural Science Foundation of China [82171062, 81970810,
   81970811]; Natural Science Foundation of Shanghai [20ZR1472600];
   Domestic Science and Technology Cooperation Project of Shanghai
   Municipal Science and Technology Commission [21015800700]; Science and
   Technology Commission of Shanghai Municipality [19495800700]; National
   Major Scientific and Technological Special Project for "Significant New
   Drugs Development" [2019ZX09301113]; Interdisciplinary Program of
   Shanghai Jiao Tong University [ZH2018ZDA16]
FX This work was supported by grants from the National Natural Science
   Foundation of China (82171062, 81970810, 81970811), the Natural Science
   Foundation of Shanghai (20ZR1472600), the Domestic Science and
   Technology Cooperation Project of Shanghai Municipal Science and
   Technology Commission (21015800700), the Science and Technology
   Commission of Shanghai Municipality (19495800700), the National Major
   Scientific and Technological Special Project for "Significant New Drugs
   Development" during the Thirtieth Five-year Plan Period
   (2019ZX09301113); and the Interdisciplinary Program of Shanghai Jiao
   Tong University (ZH2018ZDA16).
CR Ambati J, 2012, NEURON, V75, P26, DOI 10.1016/j.neuron.2012.06.018
   AMIN R, 1994, INVEST OPHTH VIS SCI, V35, P3178
   Armulik A, 2005, CIRC RES, V97, P512, DOI 10.1161/01.RES.0000182903.16652.d7
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Chen XG, 2010, MOL CARCINOGEN, V49, P603, DOI 10.1002/mc.20628
   Crisan M, 2008, CELL STEM CELL, V3, P301, DOI 10.1016/j.stem.2008.07.003
   Daniel E, 2014, OPHTHALMOLOGY, V121, P656, DOI 10.1016/j.ophtha.2013.10.019
   Dejneka NS, 2004, MOL VIS, V10, P964
   Frangogiannis NG, 2020, J EXP MED, V217, DOI 10.1084/jem.20190103
   Friedlander M, 2007, J CLIN INVEST, V117, P576, DOI 10.1172/JCI31030
   Goritz C, 2011, SCIENCE, V333, P238, DOI 10.1126/science.1203165
   Hay N, 2004, GENE DEV, V18, P1926, DOI 10.1101/gad.1212704
   Hinz B, 2007, J INVEST DERMATOL, V127, P526, DOI 10.1038/sj.jid.5700613
   Kuppe C, 2021, NATURE, V589, P281, DOI 10.1038/s41586-020-2941-1
   Lawrence J, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19030778
   Lee J, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.244
   Lehmann GL, 2020, J EXP MED, V217, DOI 10.1084/jem.20190730
   Li YJ, 2021, BASIC RES CARDIOL, V116, DOI 10.1007/s00395-021-00867-7
   Lin SL, 2008, AM J PATHOL, V173, P1617, DOI 10.2353/ajpath.2008.080433
   Little K, 2020, J NEUROINFLAMM, V17, DOI 10.1186/s12974-020-02033-7
   Liu F, 2003, FRONT BIOSCI-LANDMRK, V8, pS1280, DOI 10.2741/1149
   Liu Y, 2020, J CLIN MED, V9, DOI 10.3390/jcm9072242
   Luo K, 2017, CSH PERSPECT BIOL, V9, DOI 10.1101/cshperspect.a022137
   Luo XT, 2018, DIS MODEL MECH, V11, DOI 10.1242/dmm.032060
   Ma J, 2016, INVEST OPHTH VIS SCI, V57, P3138, DOI 10.1167/iovs.15-18795
   Matsuda Y, 2019, MOL THER-NUCL ACIDS, V17, P819, DOI 10.1016/j.omtn.2019.07.018
   Melick CH, 2020, GENES-BASEL, V11, DOI 10.3390/genes11090989
   Meng XM, 2016, NAT REV NEPHROL, V12, P325, DOI 10.1038/nrneph.2016.48
   Miller JW, 2013, OPHTHALMOLOGY, V120, P106, DOI 10.1016/j.ophtha.2012.07.038
   Nussenblatt RB, 2010, RETINA-J RET VIT DIS, V30, P1579, DOI 10.1097/IAE.0b013e3181e7978e
   Park TK, 2017, MOL THER-NUCL ACIDS, V8, P26, DOI 10.1016/j.omtn.2017.05.012
   Saxton RA, 2017, CELL, V168, P960, DOI [10.1016/j.cell.2017.03.035, 10.1016/j.cell.2017.02.004]
   Shu DY, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21124271
   Spaide RF, 2020, OPHTHALMOLOGY, V127, P616, DOI 10.1016/j.ophtha.2019.11.004
   Sun W, 2017, INT J BIOCHEM CELL B, V88, P44, DOI 10.1016/j.biocel.2017.05.010
   Tai WL, 2020, J CELL PHYSIOL, V235, P1759, DOI 10.1002/jcp.29094
   ten Dijke P, 2004, TRENDS BIOCHEM SCI, V29, P265, DOI 10.1016/j.tibs.2004.03.008
   Tenbrock L, 2022, CELL TISSUE RES, V387, P361, DOI 10.1007/s00441-021-03514-8
   Tosi GM, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19113363
   Wang YC, 2019, EXP MOL MED, V51, DOI 10.1038/s12276-019-0228-0
   Willoughby AS, 2015, OPHTHALMOLOGY, V122, P1846, DOI 10.1016/j.ophtha.2015.05.042
   Wong SP, 2015, PHARMACOL THERAPEUT, V151, P107, DOI 10.1016/j.pharmthera.2015.03.006
   Xavier S, 2017, AM J PHYSIOL-RENAL, V312, pF516, DOI 10.1152/ajprenal.00604.2016
   Yang JY, 2019, CELL COMMUN SIGNAL, V17, DOI 10.1186/s12964-019-0380-0
   Zhang H, 2012, INT J OPHTHALMOL-CHI, V5, P307, DOI 10.3980/j.issn.2222-3959.2012.03.11
   Zhang L, 2013, TRENDS BIOCHEM SCI, V38, P612, DOI 10.1016/j.tibs.2013.10.001
   Zhang YE, 2009, CELL RES, V19, P128, DOI 10.1038/cr.2008.328
NR 47
TC 0
Z9 0
U1 5
U2 5
PU SPRINGERNATURE
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND
SN 1226-3613
EI 2092-6413
J9 EXP MOL MED
JI Exp. Mol. Med.
PD MAY
PY 2022
VL 54
IS 5
BP 673
EP 684
DI 10.1038/s12276-022-00778-0
EA MAY 2022
PG 12
WC Biochemistry & Molecular Biology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Research & Experimental Medicine
GA 1V1AR
UT WOS:000805511100003
PM 35624154
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Federici, TJ
AF Federici, Thomas J.
TI The non-antibiotic properties of tetracyclines: Clinical potential in
   ophthalmic disease
SO PHARMACOLOGICAL RESEARCH
LA English
DT Review
DE Chemically modified non-antibacterial tetracyclines; Choroidal
   neovascularization; Corneal neovascularization; Retinal
   neovascularization; Tetracycline
ID ENDOTHELIAL GROWTH-FACTOR; MATRIX-METALLOPROTEINASE ACTIVITY;
   MOLECULAR-WEIGHT HEPARIN; MACULAR DEGENERATION; OCULAR ROSACEA;
   CHOROIDAL NEOVASCULARIZATION; PHOTODYNAMIC THERAPY;
   DIABETIC-RETINOPATHY; CYTOKINE EXPRESSION; CHRONIC BLEPHARITIS
AB Introduction: Beyond their decades of long use as broad-spectrum antibiotics, tetracyclines and their derivatives have been shown to exhibit non-antimicrobial properties including their ability to interact with matrix metalloproteinases (MMP), tissue inhibitors of MMPs, growth factors and cytokines. As such, they are capable of affecting inflammation, immunomodulation, cell proliferation, and angiogenesis. Although they have been used to treat a variety of conditions including acne, cutaneous sarcoid, and rheumatoid arthritis, amongst others, their use in treating ophthalmologic disease is in its infancy.
   Materials and methods: A literature review on the role of non-antimicrobial properties of tetracyclines, semisynthetic tetracyclines, and chemically modified non-antibacterial tetracyclines (CMTs) and their clinical properties was performed. The effects of these compounds in relation to ophthalmic disease are presented.
   Results: Due to their non-antimicrobial properties, tetracyclines and their derivatives are capable of influencing a wide variety of ocular diseases in animal models. By affecting expression of MMP-9 and tumor necrosis factor (TNF)-alpha, these compounds decrease corneal permeability, improve corneal smoothness, and reduce meibomian gland dysfunction; this improves the tear film which in turn restores the optical quality of the tear film and cornea. Sterile corneal ulceration may be inhibited via anticollagenase activity; this has been demonstrated in both animal models and case reports. CMTs suppress cataractogenesis in a diabetic rat model, possibly by affecting MMPs. With respect to retinal disease, tetracyclines can inhibit both microglial-mediated cell death and retinal cell apoptosis as well as prevent retinal capillary damage via caspase inhibition thus preventing retinal neovascularization. Experimental choroidal neovascularization is reduced by inhibition of MMP-2 and MMP-9, elevation of pigment epithelial derived growth factor (PEDF), and reduction of vascular endothelial growth factor (VEGF) expression via Fas ligand.
   Discussion: Due to their non-antimicrobial properties, tetracyclines and their derivatives are capable of influencing a wide variety of ocular disease in animal models. Research suggests that they are able to reduce inflammation in the eyelid meibomian glands, improve optical clarity of the cornea, retard cataract formation, and limit ocular angiogenesis. They may have a role in treating the leading causes of vision loss: cataract, age-related macular degeneration, and diabetic retinopathy, all of which are anticipated to increase in incidence due to the aging population.
   Conclusions: Tetracyclines, semisynthetic tetracyclines, and CMTs may have a role in the treatment of several important ophthalmologic diseases; however, further research is required, including prospective multicenter clinical trials. (C) 2011 Elsevier Ltd. All rights reserved.
C1 SUNY Stony Brook, Dept Ophthalmol, Hlth Sci Ctr, Stony Brook, NY 11794 USA.
C3 State University of New York (SUNY) System; SUNY Community College;
   State University of New York (SUNY) Stony Brook
RP Federici, TJ (通讯作者)，SUNY Stony Brook, Dept Ophthalmol, Hlth Sci Ctr, Level 2,Room 152, Stony Brook, NY 11794 USA.
EM tfederici@gmail.com
CR Akpek EK, 1997, OPHTHALMOLOGY, V104, P1863, DOI 10.1016/S0161-6420(97)30015-3
   Ambati J, 2003, SURV OPHTHALMOL, V48, P257, DOI 10.1016/S0039-6257(03)00030-4
   [Anonymous], 1986, Arch Ophthalmol, V104, P694
   [Anonymous], 1981, OPHTHALMOLOGY, V88, P583
   Arnold J, 2001, AM J OPHTHALMOL, V131, P541
   Aronowicz JD, 2006, BRIT J OPHTHALMOL, V90, P856, DOI 10.1136/bjo.2006.091579
   Aydin E, 2008, CORNEA, V27, P446, DOI 10.1097/ICO.0b013e3181605ff9
   BARTHOLOMEW RS, 1982, BRIT J OPHTHALMOL, V66, P386, DOI 10.1136/bjo.66.6.386
   Beardsley RM, 2008, CORNEA, V27, P935, DOI 10.1097/ICO.0b013e3181757997
   Bhatt LK, 2010, AM J TRANSL RES, V2, P181
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Boyle JP, 2010, POPUL HEALTH METR, V8, DOI 10.1186/1478-7954-8-29
   Bressler NM, 2010, OPHTHALMOLOGY, V117, P747, DOI 10.1016/j.ophtha.2009.09.002
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Bron AJ, 2004, EXP EYE RES, V78, P347, DOI 10.1016/j.exer.2003.09.019
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Brown G C, 1999, Trans Am Ophthalmol Soc, V97, P473
   BROWNING DJ, 1986, SURV OPHTHALMOL, V31, P145, DOI 10.1016/0039-6257(86)90034-2
   BURNS FR, 1989, INVEST OPHTH VIS SCI, V30, P1569
   Carmeliet P, 1996, NATURE, V380, P435, DOI 10.1038/380435a0
   Cetinkaya A, 2006, AM J OPHTHALMOL, V142, P816, DOI 10.1016/j.ajo.2006.06.047
   CHISHOLM IH, 1982, BRIT J OPHTHALMOL, V66, P745
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P487
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Cox CA, 2010, OPHTHALMOLOGY, V117, P1782, DOI 10.1016/j.ophtha.2010.01.037
   Das A, 1999, INVEST OPHTH VIS SCI, V40, P809
   Das A, 1999, ARCH OPHTHALMOL-CHIC, V117, P498
   De Paiva CS, 2006, INVEST OPHTH VIS SCI, V47, P2847, DOI 10.1167/iovs.05-1281
   De Paiva CS, 2006, EXP EYE RES, V83, P526, DOI 10.1016/j.exer.2006.02.004
   Descamps FJ, 2005, FASEB J, V19, P29, DOI 10.1096/fj.04-1837com
   DOUGHERTY JM, 1991, INVEST OPHTH VIS SCI, V32, P2970
   Dwivedi DJ, 2006, AM J PATHOL, V168, P69, DOI 10.2353/ajpath.2006.041089
   Early Treatment Diabetic Retinopathy Study Res Grp, 1991, OPHTHALMOLOGY, V98, P766
   Fainaru O, 2008, FASEB J, V22, P3728, DOI 10.1096/fj.08-110494
   Ferguson TA, 2001, CELL DEATH DIFFER, V8, P771, DOI 10.1038/sj.cdd.4400891
   FERRARA N, 1991, J CELL BIOCHEM, V47, P211, DOI 10.1002/jcb.240470305
   FINE SL, 1982, ARCH OPHTHALMOL-CHIC, V100, P912
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Funatsu H, 2002, AM J OPHTHALMOL, V133, P70, DOI 10.1016/S0002-9394(01)01269-7
   Gilbard Jeffrey P, 2005, Ophthalmol Clin North Am, V18, P475
   GILBARD JP, 1978, ARCH OPHTHALMOL-CHIC, V96, P677
   GIULIAN D, 1995, J NEUROSCI, V15, P7712
   Golub L M, 1992, Curr Opin Dent, V2, P80
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   GREENWALD RA, 1992, J RHEUMATOL, V19, P927
   GRIFFITH TS, 1995, SCIENCE, V270, P1189, DOI 10.1126/science.270.5239.1189
   Hao F, 2003, ACTA PHARMACOL SIN, V24, P534
   Hennis A, 2004, ARCH OPHTHALMOL-CHIC, V122, P525, DOI 10.1001/archopht.122.4.525
   Hoffmann S, 2006, RETINA-J RET VIT DIS, V26, P454, DOI 10.1097/00006982-200604000-00012
   Ishibashi T, 1997, GRAEF ARCH CLIN EXP, V235, P159, DOI 10.1007/BF00941723
   Joussen AM, 2001, AM J PATHOL, V158, P147, DOI 10.1016/S0002-9440(10)63952-1
   Kaplan HJ, 1999, NAT MED, V5, P292, DOI 10.1038/6509
   Kim HS, 2005, INVEST OPHTH VIS SCI, V46, P840, DOI 10.1167/iovs.04-0929
   Klein BEK, 1998, AM J OPHTHALMOL, V126, P782, DOI 10.1016/S0002-9394(98)00280-3
   Kothari M, 2006, CYTOKINE, V35, P115, DOI 10.1016/j.cyto.2006.05.004
   Krady JK, 2005, DIABETES, V54, P1559, DOI 10.2337/diabetes.54.5.1559
   Krzystolik MG, 2002, ARCH OPHTHALMOL-CHIC, V120, P338
   Kvanta A, 2000, CURR EYE RES, V21, P684, DOI 10.1076/0271-3683(200009)21:3;1-R;FT684
   Kvanta A, 2000, EXP EYE RES, V70, P419, DOI 10.1006/exer.1999.0790
   Kvanta A, 2006, ACTA OPHTHALMOL SCAN, V84, P282, DOI 10.1111/j.1600-0420.2006.00659.x
   Kwak N, 2000, INVEST OPHTH VIS SCI, V41, P3158
   Lee CZ, 2006, J CEREBR BLOOD F MET, V26, P1157, DOI 10.1038/sj.jcbfm.9600268
   Lee HM, 2004, J PERIODONTOL, V75, P453, DOI 10.1902/jop.2004.75.3.453
   Lee HO, 2002, J IMMUNOL, V169, P4739, DOI 10.4049/jimmunol.169.9.4739
   Li DQ, 1981, INVEST OPHTHALMOL VI, V43
   Liang D, 2008, CURR EYE RES, V33, P653, DOI 10.1080/02713680802245772
   Luo LH, 2004, INVEST OPHTH VIS SCI, V45, P4293, DOI 10.1167/iovs.03-1145
   Luo Lihui, 2005, Eye Contact Lens, V31, P186, DOI 10.1097/01.ICL.0000162759.79740.46
   Macsai Marian S, 2008, Trans Am Ophthalmol Soc, V106, P336
   Mathers WD, 1996, CORNEA, V15, P110, DOI 10.1097/00003226-199603000-00002
   MCCULLEY JP, 1982, OPHTHALMOLOGY, V89, P1173
   Mohr S, 2004, EXPERT OPIN INV DRUG, V13, P189, DOI 10.1517/13543784.13.3.189
   Mohr S, 2002, DIABETES, V51, P1172, DOI 10.2337/diabetes.51.4.1172
   Nelson M L, 1998, Adv Dent Res, V12, P5
   Nicholson DW, 1997, TRENDS BIOCHEM SCI, V22, P299, DOI 10.1016/S0968-0004(97)01085-2
   Noda K, 2003, INVEST OPHTH VIS SCI, V44, P2163, DOI 10.1167/iovs.02-0662
   Nussenblatt RB, 2007, AM J OPHTHALMOL, V144, P618, DOI 10.1016/j.ajo.2007.06.025
   PERRY HD, 1986, OPHTHALMOLOGY, V93, P1320
   PERRY HD, 1985, ANN OPHTHALMOL, V17, P742
   Peyman GA, 2006, CORNEA, V25, P582, DOI 10.1097/01.ico.0000220767.73660.3a
   Qazi Y, 2009, J GENET, V88, P495, DOI 10.1007/s12041-009-0068-0
   Quaterman MJ, 1997, ARCH DERMATOL, V133, P49
   Ralph RA, 2000, CORNEA, V19, P274, DOI 10.1097/00003226-200005000-00003
   Riazi-Esfahani M, 2006, CORNEA, V25, P801, DOI 10.1097/01.ico.0000220768.11778.60
   Richiert DM, 1999, CURR EYE RES, V19, P269, DOI 10.1076/ceyr.19.3.269.5316
   ROBERTS WG, 1995, J CELL SCI, V108, P2369
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Roychoudhury J, 2010, INVEST OPHTH VIS SCI, V51, P3560, DOI 10.1167/iovs.09-3890
   Ryan ME, 1999, ANN NY ACAD SCI, V878, P311, DOI 10.1111/j.1749-6632.1999.tb07692.x
   Sachdev NH, 2004, INVEST OPHTH VIS SCI, V45, P4075, DOI 10.1167/iovs.03-1336
   Samtani S, 2009, INVEST OPHTH VIS SCI, V50, P5098, DOI 10.1167/iovs.08-3174
   Sapadin AN, 2006, J AM ACAD DERMATOL, V54, P258, DOI 10.1016/j.jaad.2005.10.004
   Schmidt-Erfurth U, 2003, INVEST OPHTH VIS SCI, V44, P4473, DOI 10.1167/iovs.02-1115
   Schubert HD, 2004, OPHTHALMOLOGY, P511
   SEEDOR JA, 1987, ARCH OPHTHALMOL-CHIC, V105, P268
   Seitsalo H, 2007, J NEGAT RESULTS BIOM, V6, DOI 10.1186/1477-5751-6-11
   SENGER DR, 1983, SCIENCE, V219, P983, DOI 10.1126/science.6823562
   Shine WE, 1996, CORNEA, V15, P340, DOI 10.1097/00003226-199607000-00002
   Singerman LJ, 2008, BRIT J OPHTHALMOL, V92, P1606, DOI 10.1136/bjo.2007.132597
   Sivaprasad S, 2011, OPHTHALMOLOGICA, V225, P200, DOI 10.1159/000322363
   Smith VA, 2004, BRIT J OPHTHALMOL, V88, P619, DOI 10.1136/bjo.2003.025551
   Souchier M, 2008, BRIT J OPHTHALMOL, V92, P819, DOI 10.1136/bjo.2007.133900
   Steen B, 1998, INVEST OPHTH VIS SCI, V39, P2194
   STEPHENS CR, 1954, J AM CHEM SOC, V76, P3568, DOI 10.1021/ja01642a064
   Stone DU, 2004, CORNEA, V23, P106, DOI 10.1097/00003226-200401000-00020
   STREIT WJ, 1989, J NEUROIMMUNOL, V21, P117, DOI 10.1016/0165-5728(89)90167-7
   STREIT WJ, 1988, J COMP NEUROL, V268, P248, DOI 10.1002/cne.902680209
   SZMYD L JR, 1986, Investigative Ophthalmology and Visual Science, V27, P208
   Tanzi EL, 2001, CUTIS, V68, P112
   Tolman EI, 1992, DERMATOLOGY, V2, P1477
   Uemura S, 2001, CIRC RES, V88, P1291, DOI 10.1161/hh1201.092042
   Vincent JA, 2007, DIABETES, V56, P224, DOI 10.2337/db06-0427
   Wang AL, 2005, NEUROCHEM INT, V47, P152, DOI 10.1016/j.neuint.2005.04.018
   West-Mays JA, 2007, EXPERT REV OPHTHALMO, V2, P931, DOI 10.1586/17469899.2.6.931
   Yi XJ, 1997, GRAEF ARCH CLIN EXP, V235, P313, DOI 10.1007/BF01739641
   Yoo Seo-Eun, 2005, Korean J Ophthalmol, V19, P258
   Zhang SX, 2007, PROG RETIN EYE RES, V26, P1, DOI 10.1016/j.preteyeres.2006.09.002
   Zhang XZ, 2010, JAMA-J AM MED ASSOC, V304, P649, DOI 10.1001/jama.2010.1111
NR 118
TC 47
Z9 49
U1 0
U2 22
PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 1043-6618
J9 PHARMACOL RES
JI Pharmacol. Res.
PD DEC
PY 2011
VL 64
IS 6
SI SI
BP 614
EP 623
DI 10.1016/j.phrs.2011.06.013
PG 10
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA 844OD
UT WOS:000296756000011
PM 21843641
DA 2022-11-30
ER

PT J
AU Taban, M
   Sharma, S
   Williams, DR
   Waheed, N
   Kaiser, PK
AF Taban, Mehran
   Sharma, Sumit
   Williams, Dawn R.
   Waheed, Nadia
   Kaiser, Peter K.
TI Comparing Retinal Thickness Measurements Using Automated Fast Macular
   Thickness Map versus Six-Radial Line Scans with Manual Measurements
SO OPHTHALMOLOGY
LA English
DT Article
ID OPTICAL COHERENCE TOMOGRAPHY; QUANTITATIVE ASSESSMENT; REPRODUCIBILITY;
   DEGENERATION; REPEATABILITY; SUBANALYSIS; EDEMA
AB Purpose: To compare automated retinal thickness values generated by the fast macular thickness maps (FMTM) and customized 6-radial line scans (RLS) versus manual retinal measurements on Stratus optical coherence tomography (OCT) (Carl Zeiss Meditec, Dublin, CA).
   Design: Prospective, observational case series.
   Participants: Patients with subfoveal choroidal neovascularization (CNV) caused by age-related macular degeneration (AMD), diabetic macular edema (DME), or branch/central retinal vein occlusion (RVO).
   Methods: Patients were prospectively imaged using the FMTM and customized RLS patterns on Stratus OCT at the same sitting. Each scan was evaluated for errors in retinal segmentation (i.e., correct retinal boundaries [CRB]). Automated values were recorded while central retinal thickness measurements were determined manually for both patterns. The presence or absence of epiretinal phenomenon, cystoid spaces, pigment epithelial detachment, and subretinal fluid was also noted.
   Main Outcome Measures: Errors in retinal segmentation at and outside the fovea (i.e., CRB) and percentage of automated values within a clinically acceptable margin (+/- 25 mu m) of the manual central retinal thickness.
   Results: A total of 147 eyes of 147 patients (95 eyes with exudative AMD, 41 eyes with DME, and 11 eyes with macular edema caused by RVO) were included. For wet AMD, the total number of CRB at the fovea and outside the fovea was 363 (63.7%) and 360 (63.2%), respectively, in FMTM and 428 (75.1%) and 426 (74.7%), respectively, in RLS (P<0.0001 for both). For DME and RVO, the total number of CRB at the fovea and outside the fovea was 274 (87.8%) and 256 (82.1%), respectively, in FMTM and 287 (92.0%) and 270 (86.5%), respectively, in RLS (P = 0.11, P = 0.15, respectively). Some 40% and 56% of automated foveal center point thicknesses on FMTM and RLS, respectively, were within +/- 25 mu m of the manual central retinal thickness for AMD (P = 0.042), versus 94% and 81% for DME and RVO, respectively (P = 0.07).
   Conclusions: For exudative AMD, the RLS protocol provides fewer segmentation errors than the FMTM protocol, and its automated retinal thickness values (e. g., foveal center point, central subfield) correlate better with manual retinal thickness measurement than FMTM. In DME and RVO, however, both protocols provide similar and low segmentation errors, and their automated results are close to manual measurements.
   Financial Disclosure(s): Proprietary or commercial disclosure may be found after the references. Ophthalmology 2009;116:964-970 (C) 2009 by the American Academy of Ophthalmology.
C1 [Kaiser, Peter K.] Cleveland Clin, Cole Eye Inst, Digital OCT Reading Ctr, Cleveland, OH 44195 USA.
C3 Cleveland Clinic Foundation
RP Kaiser, PK (通讯作者)，Cleveland Clin, Cole Eye Inst, Digital OCT Reading Ctr, 9500 Euclid Ave, Cleveland, OH 44195 USA.
EM pkkaiser@aol.com
OI Kaiser, Peter/0000-0001-5126-045X
CR Baumann M, 1998, OPHTHALMIC SURG LAS, V29, P280
   Chan A, 2006, ARCH OPHTHALMOL-CHIC, V124, P193, DOI 10.1001/archopht.124.2.193
   Joeres S, 2008, OPHTHALMOLOGY, V115, P347, DOI 10.1016/j.ophtha.2007.03.082
   Joeres S, 2007, INVEST OPHTH VIS SCI, V48, P4300, DOI 10.1167/iovs.07-0179
   Massin P, 2001, ARCH OPHTHALMOL-CHIC, V119, P1135, DOI 10.1001/archopht.119.8.1135
   Menke MN, 2005, OPHTHAL SURG LAS IM, V36, P310, DOI 10.3928/1542-8877-20050701-10
   Muscat S, 2002, INVEST OPHTH VIS SCI, V43, P490
   Paunescu LA, 2004, INVEST OPHTH VIS SCI, V45, P1716, DOI 10.1167/iovs.03-0514
   Polito A, 2005, ARCH OPHTHALMOL-CHIC, V123, P1330, DOI 10.1001/archopht.123.10.1330
   Ray R, 2005, AM J OPHTHALMOL, V139, P18, DOI 10.1016/j.ajo.2004.07.050
   Sadda SR, 2006, OPHTHALMOLOGY, V113, P285, DOI 10.1016/j.ophtha.2005.10.005
   Sadda SR, 2007, INVEST OPHTH VIS SCI, V48, P839, DOI 10.1167/iovs.06-0554
   SHAHIDI M, 1991, ARCH OPHTHALMOL-CHIC, V109, P1115, DOI 10.1001/archopht.1991.01080080075032
   Yang CS, 2001, ACTA OPHTHALMOL SCAN, V79, P266, DOI 10.1034/j.1600-0420.2001.790311.x
NR 14
TC 25
Z9 28
U1 0
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD MAY
PY 2009
VL 116
IS 5
BP 964
EP 970
DI 10.1016/j.ophtha.2008.12.033
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 508DI
UT WOS:000270907500022
PM 19410954
DA 2022-11-30
ER

PT J
AU Korobelnik, JF
   Rougier, MB
   Delyfer, MN
   Bron, A
   Merle, BMJ
   Savel, H
   Chene, G
   Delcourt, C
   Creuzot-Garcher, C
AF Korobelnik, Jean-Francois
   Rougier, Marie-Benedicte
   Delyfer, Marie-Noelle
   Bron, Alain
   Merle, Benedicte M. J.
   Savel, Helene
   Chene, Genevieve
   Delcourt, Cecile
   Creuzot-Garcher, Catherine
TI Effect of Dietary Supplementation With Lutein, Zeaxanthin, and omega-3
   on Macular Pigment A Randomized Clinical Trial
SO JAMA OPHTHALMOLOGY
LA English
DT Article
ID AGE-RELATED MACULOPATHY; OPTICAL-DENSITY; CONSTITUENT CAROTENOIDS;
   FAMILIAL AGGREGATION; DOCOSAHEXAENOIC ACID; EYE DISEASE; SERUM; WOMEN
AB IMPORTANCE Nutritional uptake of lutein, zeaxanthin, and omega-3 polyunsaturated fatty acids may increase macular pigment optical density (MPOD) and thereby protect against the development of age-related macular degeneration (AMD).
   OBJECTIVES To estimate the efficiency of dietary supplementation containing lutein, zeaxanthin, omega-3 polyunsaturated fatty acids, and vitamins to increase the density of macular pigment in first-generation offspring of parents with neovascular AMD.
   DESIGN, SETTING, AND PARTICIPANTS This study was a randomized clinical trial (Lutein Influence on Macula of Persons Issued From AMD Parents [LIMPIA]) with a 6-month treatment period, followed by a 6-month follow-up period. Analyses were based on the intent-to-treat principle. The setting was 2 university hospitals in France (at Bordeaux and Dijon) from January 2011 (first participant first visit) to February 2013 (last participant last visit). The analysis was conducted from January to November 2016. Participants were 120 individuals free of any retinal ocular disease. They were first-generation offspring of parents with neovascular AMD.
   INTERVENTIONS Participants were randomized in a 1:1 ratio to receive either 2 daily dietary supplementation capsules or placebo for 6 months.
   MAIN OUTCOMES AND MEASURES The primary assessment criterion was the evolution of MPOD after 6 months of supplementation (value of both eligible eyes) measured using the modified MPD-Visucam 200 (Carl Zeiss Meditec) and the modified Heidelberg Retina Angiograph (Heidelberg Engineering) (HRA) at 0.98 degrees eccentricity. The statistical analysis was adjusted for hospital and for risk factors.
   RESULTS Overall, 120 participants (60 in each group) were included, and 239 eyes were analyzed (119 in the lutein plus zeaxanthin [L + Z] group and 120 in the placebo group). Their mean (SD) age was 56.7 (6.6) years, and 71.7%(n = 86) were female. A statistically significant increase in plasma lutein and zeaxanthin was shown in the L + Z group after 3 months and 6 months of treatment compared with the placebo group. However, the difference between groups in the evolution of MPOD measured by HRA 0.98 degrees eccentricity between 6 months and baseline was 0.036 (95% CI, -0.037 to 0.110) (P = .33).
   CONCLUSIONS AND RELEVANCE Among first-generation offspring of parents with neovascular AMD in the LIMPIA trial, MPOD as measured with the modified HRA and the MPD-Visucam was not modified after 6 months of lutein and zeaxanthin dietary supplementation despite plasma levels showing continuous exposure to lutein and zeaxanthin. Further research is necessary to understand the mechanism of absorption and metabolism of these nutrients in the macula, the best way to measure MPOD, and the clinical benefit for the patients.
C1 [Korobelnik, Jean-Francois; Rougier, Marie-Benedicte; Delyfer, Marie-Noelle] CHU Bordeaux, Serv Ophtalmol, Bordeaux, France.
   [Korobelnik, Jean-Francois; Delyfer, Marie-Noelle; Merle, Benedicte M. J.; Chene, Genevieve; Delcourt, Cecile] Univ Bordeaux, INSERM, Bordeaux Populat Hlth Res Ctr, Team Lifelong Exposures Hlth & Aging LEHA,UMR 121, Bordeaux, France.
   [Bron, Alain] CHU Dijon, Serv Ophtalmol, Dijon, France.
   [Savel, Helene; Chene, Genevieve; Creuzot-Garcher, Catherine] CHU Bordeaux, Pole Sante Publ, Unite Soutien Methodol Rech Clin & Epidemiol, Bordeaux, France.
   [Savel, Helene; Chene, Genevieve; Creuzot-Garcher, Catherine] CHU Bordeaux, CIC 1401, EC, Bordeaux, France.
C3 CHU Bordeaux; Institut National de la Sante et de la Recherche Medicale
   (Inserm); UDICE-French Research Universities; Universite de Bordeaux;
   CHU Dijon Bourgogne; CHU Bordeaux; CHU Bordeaux; UDICE-French Research
   Universities; Universite de Bordeaux
RP Korobelnik, JF (通讯作者)，CHU Bordeaux, Serv Ophtalmol, Hop Pellegrin, Pl Amelie Raba Leon, F-33000 Bordeaux, France.
EM jean-francois.korobelnik@chu-bordeaux.fr
RI chene, genevieve/H-8665-2014; Merle, Benedicte MJ/F-1247-2015; Bron,
   Alain/AAP-8010-2020; KOROBELNIK, Jean-Francois/A-5448-2016; Merle,
   Benedicte MJ/AAQ-5021-2021; Delcourt, Cecile/I-2627-2013; Delyfer,
   Marie-Noelle/T-3304-2019
OI chene, genevieve/0000-0002-8368-6460; Merle, Benedicte
   MJ/0000-0003-1332-0954; Bron, Alain/0000-0002-7265-931X; Merle,
   Benedicte MJ/0000-0003-1332-0954; Delcourt, Cecile/0000-0002-2099-0481; 
FU Laboratoires Thea
FX The study was supported by Laboratoires Thea.
CR Age-Related Eye Disease Study Research Group, 2008, ARCH OPHTHALMOL-CHIC, V126, P1251
   Arnold C, 2013, JAMA OPHTHALMOL, V131, P564, DOI 10.1001/jamaophthalmol.2013.2851
   Chen YH, 2010, MOL INTERV, V10, P271, DOI 10.1124/mi.10.5.4
   CHYLACK LT, 1989, ARCH OPHTHALMOL-CHIC, V107, P991, DOI 10.1001/archopht.1989.01070020053028
   Creuzot-Garcher C, 2014, INVEST OPHTH VIS SCI, V55, P2941, DOI 10.1167/iovs.13-13568
   Dawczynski J, 2013, GRAEF ARCH CLIN EXP, V251, P2711, DOI 10.1007/s00417-013-2376-6
   Garcia-Layana A, 2013, NUTRIENTS, V5, P543, DOI 10.3390/nu5020543
   Hammond BR, 1996, VISION RES, V36, P2001, DOI 10.1016/0042-6989(95)00290-1
   Hammond CJ, 2012, INVEST OPHTH VIS SCI, V53, P4963, DOI 10.1167/iovs.12-9618
   Johnson EJ, 2008, AM J CLIN NUTR, V87, P1521, DOI 10.1093/ajcn/87.5.1521
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Klaver CCW, 1998, ARCH OPHTHALMOL-CHIC, V116, P1646, DOI 10.1001/archopht.116.12.1646
   Mares JA, 2006, AM J CLIN NUTR, V84, P1107
   Merle BMJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0079848
   Meyers KJ, 2013, INVEST OPHTH VIS SCI, V54, P2333, DOI [10.1167/iovs.12-10867, 10.1167/iovs.13-13216]
   Nolan JM, 2007, INVEST OPHTH VIS SCI, V48, P571, DOI 10.1167/iovs.06-0864
   Seddon JM, 1997, AM J OPHTHALMOL, V123, P199, DOI 10.1016/S0002-9394(14)71036-0
   Trieschmann M, 2007, EXP EYE RES, V84, P718, DOI 10.1016/j.exer.2006.12.010
   Widomska Justyna, 2014, J Clin Exp Ophthalmol, V5, P326
   Wolf-Schnurrbusch UEK, 2007, INVEST OPHTH VIS SCI, V48, P3783, DOI 10.1167/iovs.06-1218
NR 20
TC 30
Z9 30
U1 2
U2 30
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 2168-6165
EI 2168-6173
J9 JAMA OPHTHALMOL
JI JAMA Ophthalmol.
PD NOV
PY 2017
VL 135
IS 11
BP 1259
EP 1266
DI 10.1001/jamaophthalmol.2017.3398
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA FM2ER
UT WOS:000414798100024
PM 28973076
OA Green Published, Bronze
DA 2022-11-30
ER

PT J
AU Steinmetz, JD
   Bourne, RRA
   Briant, PS
   Flaxman, S
   Taylor, HR
   Jonas, JB
   Abdoli, A
   Abrha, WA
   Abualhasan, A
   Abu-Gharbieh, E
   Adal, TG
   Afshin, A
   Ahmadieh, H
   Alemayehu, W
   Alemzadeh, SA
   Alfaar, AS
   Alipour, V
   Androudi, S
   Arabloo, J
   Arditi, A
   Aregawi, BB
   Arrigo, A
   Ashbaugh, C
   Ashrafi, E
   Atnafu, DD
   Bagli, E
   Baig, AA
   Barnighausen, TW
   Parodi, MB
   Beheshti, M
   Bhagavathula, AS
   Bhardwaj, N
   Bhardwaj, P
   Bhattacharyya, K
   Bijani, A
   Bikbov, M
   Bottone, M
   Braithwaite, T
   Bron, AM
   Nagaraja, SB
   Butt, ZA
   dos Santos, FLC
   Carneiro, VLA
   Casson, RJ
   Cheng, CY
   Choi, JYJ
   Chu, DT
   Cicinelli, MV
   Coelho, JM
   Congdon, NG
   Couto, RAS
   Cromwell, EA
   Dahlawi, SMA
   Dai, XC
   Dana, R
   Dandona, L
   Dandona, R
   Del Monte, MA
   Molla, MD
   Dervenis, N
   Desta, AA
   Deva, JP
   Diaz, D
   Djalalinia, S
   Ehrlich, JR
   Elayedath, R
   Elhabashy, HR
   Ellwein, LB
   Emamian, MH
   Eskandarieh, S
   Farzadfar, F
   Fernandes, AG
   Fischer, F
   Friedman, DS
   Furtado, JM
   Gaidhane, S
   Gazzard, G
   Gebremichael, B
   George, R
   Ghashghaee, A
   Gilani, SA
   Golechha, M
   Hamidi, S
   Hammond, BR
   Hartnett, MER
   Hartono, RK
   Hashi, A
   Hay, SI
   Hayat, K
   Heidari, G
   Ho, HC
   Holla, R
   Househ, M
   Huang, JJ
   Ibitoye, SE
   Ilic, IM
   Ilic, MD
   Ingram, AD
   Irvani, SSN
   Islam, SMS
   Itumalla, R
   Jayaram, S
   Jha, RP
   Kahloun, R
   Kalhor, R
   Kandel, H
   Kasa, AS
   Kavetskyy, T
   Kayode, GA
   Kempen, JH
   Khairallah, M
   Khalilov, R
   Khan, EA
   Khanna, RC
   Khatib, MN
   Khoja, TAM
   Kim, GR
   Kim, JE
   Kim, YJ
   Kisa, A
   Kisa, S
   Kosen, S
   Koyanagi, A
   Bicer, BK
   Kulkarni, V
   Kurmi, OP
   Landires, I
   Lansingh, V
   Leasher, JL
   LeGrand, KE
   Leveziel, N
   Limburg, H
   Liu, XF
   Kunjathur, SM
   Maleki, S
   Manafi, N
   Mansouri, K
   McAlinden, C
   Meles, GG
   Mersha, AM
   Michalek, IM
   Miller, TR
   Misra, S
   Mohammad, Y
   Mohammadi, SF
   Mohammed, JA
   Mokdad, AH
   Moni, MA
   Al Montasir, A
   Morse, AR
   Mulaw, GF
   Naderi, M
   Naderifar, H
   Naidoo, KS
   Naimzada, MD
   Nangia, V
   Swamy, SN
   Naveed, M
   Negash, H
   Nguyen, HLT
   Nunez-Samudio, V
   Ogbo, FA
   Ogundimu, K
   Olagunju, AT
   Onwujekwe, OE
   Otstavnov, N
   Owolabi, MO
   Pakshir, K
   Panda-Jonas, S
   Parekh, U
   Park, EC
   Pasovic, M
   Pawar, S
   Pesudovs, K
   Peto, T
   Pham, HQ
   Pinheiro, M
   Podder, V
   Rahimi-Movaghar, V
   Rahman, MHU
   Ramulu, PY
   Rathi, P
   Rawaf, DL
   Rawaf, S
   Rawal, L
   Reinig, N
   Renzaho, AMN
   Rezapour, A
   Robin, AL
   Rossetti, L
   Sabour, S
   Safi, S
   Sahebkar, A
   Sahraian, MA
   Samy, AM
   Sathian, B
   Saya, GK
   Saylan, M
   Shaheen, AA
   Shaikh, MA
   Shen, TT
   Shibuya, K
   Shiferaw, WS
   Shigematsu, M
   Shin, JI
   Silva, JC
   Silvester, A
   Singh, JA
   Singhal, D
   Sitorus, RS
   Skiadaresi, E
   Skryabin, VY
   Skryabina, AA
   Soheili, A
   Sorrie, MB
   Sousa, RARC
   Sreeramareddy, CT
   Stambolian, D
   Tadesse, EG
   Tahhan, N
   Tareque, MI
   Topouzis, F
   Tran, BX
   Tsegaye, GW
   Tsilimbaris, MK
   Varma, R
   Virgili, G
   Vongpradith, A
   Vu, GT
   Wang, YX
   Wang, NL
   Weldemariam, AH
   West, SK
   Wondmeneh, TG
   Wong, TY
   Yaseri, M
   Yonemoto, N
   Yu, CH
   Zastrozhin, MS
   Zastrozhina, A
   Zhang, ZJ
   Zimsen, SRM
   Resnikoff, S
   Vos, T
AF Steinmetz, Jaimie D.
   Bourne, Rupert R. A.
   Briant, Paul Svitil
   Flaxman, Seth
   Taylor, Hugh R.
   Jonas, Jost B.
   Abdoli, Amir
   Abrha, Woldu Aberhe
   Abualhasan, Ahmed
   Abu-Gharbieh, Eman
   Adal, Tadele Girum
   Afshin, Ashkan
   Ahmadieh, Hamid
   Alemayehu, Wondu
   Alemzadeh, Sayyed Amirpooya
   Alfaar, Ahmed Samir
   Alipour, Vahid
   Androudi, Sofia
   Arabloo, Jalal
   Arditi, Aries
   Aregawi, Brhane Berhe
   Arrigo, Alessandro
   Ashbaugh, Charlie
   Ashrafi, Elham
   Atnafu, Desta Debalkie
   Bagli, Eleni
   Baig, Atif Amin
   Barnighausen, Till Winfried
   Parodi, Maurizio Battaglia
   Beheshti, Mahya
   Bhagavathula, Akshaya Srikanth
   Bhardwaj, Nikha
   Bhardwaj, Pankaj
   Bhattacharyya, Krittika
   Bijani, Ali
   Bikbov, Mukharram
   Bottone, Michele
   Braithwaite, Tasanee
   Bron, Alain M.
   Nagaraja, Sharath Burugina
   Butt, Zahid A.
   dos Santos, Florentino Luciano Caetano
   Carneiro, Vera L. A.
   Casson, Robert James
   Cheng, Ching-Yu
   Choi, Jee-Young Jasmine
   Chu, Dinh-Toi
   Cicinelli, Maria Vittoria
   Coelho, Joao M.
   Congdon, Nathan G.
   Couto, Rosa A. S.
   Cromwell, Elizabeth A.
   Dahlawi, Saad M. A.
   Dai, Xiaochen
   Dana, Reza
   Dandona, Lalit
   Dandona, Rakhi
   Del Monte, Monte A.
   Molla, Meseret Derbew
   Dervenis, Nikolaos
   Desta, Abebaw Alemayehu
   Deva, Jenny P.
   Diaz, Daniel
   Djalalinia, Shirin
   Ehrlich, Joshua R.
   Elayedath, Rajesh
   Elhabashy, Hala Rashad
   Ellwein, Leon B.
   Emamian, Mohammad Hassan
   Eskandarieh, Sharareh
   Farzadfar, Farshad
   Fernandes, Arthur G.
   Fischer, Florian
   Friedman, David S.
   Furtado, Joao M.
   Gaidhane, Shilpa
   Gazzard, Gus
   Gebremichael, Berhe
   George, Ronnie
   Ghashghaee, Ahmad
   Gilani, Syed Amir
   Golechha, Mahaveer
   Hamidi, Samer
   Hammond, Billy Randall
   Hartnett, Mary Elizabeth R.
   Hartono, Risky Kusuma
   Hashi, Abdiwahab
   Hay, Simon, I
   Hayat, Khezar
   Heidari, Golnaz
   Ho, Hung Chak
   Holla, Ramesh
   Househ, Mowafa
   Huang, John J.
   Ibitoye, Segun Emmanuel
   Ilic, Irena M.
   Ilic, Milena D.
   Ingram, April D.
   Irvani, Seyed Sina Naghibi
   Islam, Sheikh Mohammed Shariful
   Itumalla, Ramaiah
   Jayaram, Shubha
   Jha, Ravi Prakash
   Kahloun, Rim
   Kalhor, Rohollah
   Kandel, Himal
   Kasa, Ayele Semachew
   Kavetskyy, Taras
   Kayode, Gbenga A.
   Kempen, John H.
   Khairallah, Moncef
   Khalilov, Rovshan
   Khan, Ejaz Ahmad
   Khanna, Rohit C.
   Khatib, Mahalaqua Nazli
   Khoja, Tawfik Ahmed Muthafer
   Kim, Gyu Ri
   Kim, Judy E.
   Kim, Yun Jin
   Kisa, Adnan
   Kisa, Sezer
   Kosen, Soewarta
   Koyanagi, Ai
   Bicer, Burcu Kucuk
   Kulkarni, Vaman
   Kurmi, Om P.
   Landires, Ivan
   Lansingh, Van Charles
   Leasher, Janet L.
   LeGrand, Kate E.
   Leveziel, Nicolas
   Limburg, Hans
   Liu, Xuefeng
   Kunjathur, Shilpashree Madhava
   Maleki, Shokofeh
   Manafi, Navid
   Mansouri, Kaweh
   McAlinden, Colm
   Meles, Gebrekiros Gebremichael
   Mersha, Abera M.
   Michalek, Irmina Maria
   Miller, Ted R.
   Misra, Sanjeev
   Mohammad, Yousef
   Mohammadi, Seyed Farzad
   Mohammed, Jemal Abdu
   Mokdad, Ali H.
   Moni, Mohammad Ali
   Al Montasir, Ahmed
   Morse, Alan R.
   Mulaw, Getahun Fentaw
   Naderi, Mehdi
   Naderifar, Homa
   Naidoo, Kovin S.
   Naimzada, Mukhammad David
   Nangia, Vinay
   Swamy, Sreenivas Narasimha
   Naveed, Muhammad
   Negash, Hadush
   Huong Lan Thi Nguyen
   Nunez-Samudio, Virginia
   Ogbo, Felix Akpojene
   Ogundimu, Kolawole
   Olagunju, Andrew T.
   Onwujekwe, Obinna E.
   Otstavnov, Nikita
   Owolabi, Mayowa O.
   Pakshir, Keyvan
   Panda-Jonas, Songhomitra
   Parekh, Utsav
   Park, Eun-Cheol
   Pasovic, Maja
   Pawar, Shrikant
   Pesudovs, Konrad
   Peto, Tunde
   Pham, Hai Quang
   Pinheiro, Marina
   Podder, Vivek
   Rahimi-Movaghar, Vafa
   Rahman, Mohammad Hifz Ur
   Ramulu, Pradeep Y.
   Rathi, Priya
   Rawaf, David Laith
   Rawaf, Salman
   Rawal, Lal
   Reinig, Nickolas
   Renzaho, Andre M. N.
   Rezapour, Aziz
   Robin, Alan L.
   Rossetti, Luca
   Sabour, Siamak
   Safi, Sare
   Sahebkar, Amirhossein
   Sahraian, Mohammad Ali
   Samy, Abdallah M.
   Sathian, Brijesh
   Saya, Ganesh Kumar
   Saylan, Mete
   Shaheen, Amira A.
   Shaikh, Masood Ali
   Shen, Tueng T.
   Shibuya, Kenji
   Shiferaw, Wondimeneh Shibabaw
   Shigematsu, Mika
   Shin, Jae Il
   Silva, Juan Carlos
   Silvester, Alexander
   Singh, Jasvinder A.
   Singhal, Deepika
   Sitorus, Rita S.
   Skiadaresi, Eirini
   Skryabin, Valentin Yurievich
   Skryabina, Anna Aleksandrovna
   Soheili, Amin
   Sorrie, Muluken Bekele
   Sousa, Raul A. R. C.
   Sreeramareddy, Chandrashekhar T.
   Stambolian, Dwight
   Tadesse, Eyayou Girma
   Tahhan, Nina
   Tareque, Md Ismail
   Topouzis, Fotis
   Bach Xuan Tran
   Tsegaye, Gebiyaw Wudie
   Tsilimbaris, Miltiadis K.
   Varma, Rohit
   Virgili, Gianni
   Vongpradith, Avina
   Vu, Giang Thu
   Wang, Ya Xing
   Wang, Ningli
   Weldemariam, Abrha Hailay
   West, Sheila K.
   Wondmeneh, Temesgen Gebeyehu
   Wong, Tien Y.
   Yaseri, Mehdi
   Yonemoto, Naohiro
   Yu, Chuanhua
   Zastrozhin, Mikhail Sergeevich
   Zastrozhina, Anasthasia
   Zhang, Zhi-Jiang
   Zimsen, Stephanie R. M.
   Resnikoff, Serge
   Vos, Theo
CA Vision Loss Expert Grp Global Burd
TI Causes of blindness and vision impairment in 2020 and trends over 30
   years, and prevalence of avoidable blindness in relation to VISION 2020:
   the Right to Sight: an analysis for the Global Burden of Disease Study
SO LANCET GLOBAL HEALTH
LA English
DT Article
ID MACULAR DEGENERATION; PROJECTIONS; DISTANCE
AB Background Many causes of vision impairment can be prevented or treated. With an ageing global population, the demands for eye health services are increasing. We estimated the prevalence and relative contribution of avoidable causes of blindness and vision impairment globally from 1990 to 2020. We aimed to compare the results with the World Health Assembly Global Action Plan (WHA GAP) target of a 25% global reduction from 2010 to 2019 in avoidable vision impairment, defined as cataract and undercorrected refractive error.
   Methods We did a systematic review and meta-analysis of population-based surveys of eye disease from January, 1980, to October, 2018. We fitted hierarchical models to estimate prevalence (with 95% uncertainty intervals [UIs]) of moderate and severe vision impairment (MSVI; presenting visual acuity from <6/18 to 3/60) and blindness (<3/60 or less than 10 degrees visual field around central fixation) by cause, age, region, and year. Because of data sparsity at younger ages, our analysis focused on adults aged 50 years and older.
   Findings Global crude prevalence of avoidable vision impairment and blindness in adults aged 50 years and older did not change between 2010 and 2019 (percentage change -0.2% [95% UI -1.5 to 1.0]; 2019 prevalence 9.58 cases per 1000 people [9s% IU 8.51 to 10.8], 2010 prevalence 96.0 cases per 1000 people [86.0 to 107-0]). Age-standardised prevalence of avoidable blindness decreased by -15.4% [-16.8 to -14.3], while avoidable MSVI showed no change (0.5% [-0.8 to 1.6]). However, the number of cases increased for both avoidable blindness (10.8% [8.9 to 12.4]) and MSVI (31.5% [30.0 to 33.1]). The leading global causes of blindness in those aged 50 years and older in 2020 were cataract (15.2 million cases [9% IU 12.7-18.0]), followed by glaucoma (3.6 million cases [2-8-4.4]), undercorrected refractive error (2.3 million cases [1.8-2.8]), age-related macular degeneration (1.8 million cases [1.3-2.4]), and diabetic retinopathy (0.86 million cases [0.59-1.23]). Leading causes of MSVI were undercorrected refractive error (86.1 million cases [74.2-101.0]) and cataract (78.8 million cases [67.2-91.4]).
   Interpretation Results suggest eye care services contributed to the observed reduction of age-standardised rates of avoidable blindness but not of MSVI, and that the target in an ageing global population was not reached. Copyright (C) 2020 The Author(s). Published by Elsevier Ltd.
C1 [Steinmetz, Jaimie D.; Briant, Paul Svitil; Afshin, Ashkan; Ashbaugh, Charlie; Cromwell, Elizabeth A.; Dai, Xiaochen; Dandona, Lalit; Dandona, Rakhi; Hay, Simon, I; LeGrand, Kate E.; Mokdad, Ali H.; Pasovic, Maja; Reinig, Nickolas; Vongpradith, Avina; Zimsen, Stephanie R. M.; Vos, Theo] Univ Washington, Inst Hlth Metr & Evaluat, Seattle, WA USA.
   [Briant, Paul Svitil; Afshin, Ashkan; Cromwell, Elizabeth A.; Dandona, Rakhi; Hay, Simon, I; Mokdad, Ali H.; Vos, Theo] Univ Washington, Sch Med, Dept Hlth Metr Sci, Seattle, WA USA.
   [Shen, Tueng T.] Univ Washington, Dept Ophthalmol, Seattle, WA 98195 USA.
   [Bourne, Rupert R. A.; Silvester, Alexander] Anglia Ruskin Univ, Vis & Eye Res Inst, Cambridge CB1 1PT, England.
   [Flaxman, Seth] Imperial Coll London, Dept Math, London, England.
   [Rawaf, David Laith] Imperial Coll London, WHO Collaborating Ctr Publ Hlth Educ & Training, London, England.
   [Rawaf, Salman] Imperial Coll London, Dept Primary Care & Publ Hlth, London, England.
   [Taylor, Hugh R.] Univ Melbourne, Sch Populat & Global Hlth, Carlton, Vic, Australia.
   [Jonas, Jost B.; Panda-Jonas, Songhomitra] Heidelberg Univ, Dept Ophthalmol, Heidelberg, Germany.
   [Barnighausen, Till Winfried] Heidelberg Univ, Heidelberg Inst Global Hlth HIGH, Heidelberg, Germany.
   [Wang, Ya Xing] Beijing Tongren Hosp, Beijing Inst Ophthalmol, Beijing, Peoples R China.
   [Wang, Ningli] Beijing Tongren Hosp, Beijing Tongren Eye Ctr, Beijing, Peoples R China.
   [Abdoli, Amir] Jahrom Univ Med Sci, Dept Parasitol & Mycol, Jahrom, Iran.
   [Abrha, Woldu Aberhe; Weldemariam, Abrha Hailay] Aksum Univ, Dept Adult Hlth Nursing, Aksum, Ethiopia.
   [Abualhasan, Ahmed] Cairo Univ, Dept Neurol, Cairo, Egypt.
   [Elhabashy, Hala Rashad] Cairo Univ, Neurophysiol Unit, Cairo, Egypt.
   [Abu-Gharbieh, Eman] Univ Sharjah, Dept Clin Sci, Sharjah, U Arab Emirates.
   [Adal, Tadele Girum] Wolkite Univ, Dept Publ Hlth, Wolkite, Ethiopia.
   [Ahmadieh, Hamid; Safi, Sare; Yaseri, Mehdi] Shahid Beheshti Univ Med Sci, Ophthalm Res Ctr, Tehran, Iran.
   [Ahmadieh, Hamid] Shahid Beheshti Univ Med Sci, Dept Ophthalmol, Tehran, Iran.
   [Irvani, Seyed Sina Naghibi] Shahid Beheshti Univ Med Sci, Res Inst Endocrine Sci, Tehran, Iran.
   [Sabour, Siamak] Shahid Beheshti Univ Med Sci, Dept Epidemiol, Tehran, Iran.
   [Safi, Sare] Shahid Beheshti Univ Med Sci, Ophthalm Epidemiol Res Ctr, Tehran, Iran.
   [Desta, Abebaw Alemayehu] Fred Hollows Fdn, Sydney, NSW, Australia.
   [Alemayehu, Wondu] Berhan Publ Hlth & Eye Care Consultancy, Addis Ababa, Ethiopia.
   [Alemzadeh, Sayyed Amirpooya] Iran Univ Med Sci, Eye Res Ctr, Tehran, Iran.
   [Alipour, Vahid; Arabloo, Jalal; Ghashghaee, Ahmad; Rezapour, Aziz] Iran Univ Med Sci, Hlth Management & Econ Res Ctr, Tehran, Iran.
   [Alipour, Vahid] Iran Univ Med Sci, Hlth Econ Dept, Tehran, Iran.
   [Ghashghaee, Ahmad] Iran Univ Med Sci, Student Res Comm, Tehran, Iran.
   [Manafi, Navid] Iran Univ Med Sci, Sch Med, Tehran, Iran.
   [Alfaar, Ahmed Samir] Univ Leipzig Med Ctr, Dept Ophthalmol, Leipzig, Germany.
   [Alfaar, Ahmed Samir] Charite Med Univ Berlin, Dept Ophthalmol, Berlin, Germany.
   [Androudi, Sofia] Univ Thessaly, Dept Med, Volos, Greece.
   [Arditi, Aries] Visibil Metr LLC, Dept Res, Chappaqua, NY USA.
   [Aregawi, Brhane Berhe] Adigrat Univ, Coll Med & Hlth Sci, Adigrat, Ethiopia.
   [Negash, Hadush] Adigrat Univ, Dept Med Lab Sci, Adigrat, Ethiopia.
   [Arrigo, Alessandro] Osped San Raffaele, Dept Ophthalmol, Milan, Italy.
   [Arrigo, Alessandro] Univ Vita Salute San Raffaele, Dept Ophthalmol, Milan, Italy.
   [Ashrafi, Elham; Mohammadi, Seyed Farzad] Univ Tehran Med Sci, Translat Ophthalmol Res Ctr, Tehran, Iran.
   [Eskandarieh, Sharareh; Sahraian, Mohammad Ali] Univ Tehran Med Sci, Multiple Sclerosis Res Ctr, Tehran, Iran.
   [Farzadfar, Farshad] Univ Tehran Med Sci, Noncommunicable Dis Res Ctr, Tehran, Iran.
   [Rahimi-Movaghar, Vafa] Univ Tehran Med Sci, Sina Trauma & Surg Res Ctr, Tehran, Iran.
   [Yaseri, Mehdi] Univ Tehran Med Sci, Dept Epidemiol & Biostat, Tehran, Iran.
   [Atnafu, Desta Debalkie] Bahir Dar Univ, Dept Hlth Syst & Hlth Econ, Bahir Dar, Ethiopia.
   [Kasa, Ayele Semachew] Bahir Dar Univ, Dept Adult Hlth Nursing, Bahir Dar, Ethiopia.
   [Tsegaye, Gebiyaw Wudie] Bahir Dar Univ, Coll Med & Hlth Sci, Bahir Dar, Ethiopia.
   [Bagli, Eleni] Univ Hosp Ioannina, Dept Ophthalmol, Ioannina, Greece.
   [Bagli, Eleni] Fdn Res & Technol, Inst Mol Biol & Biotechnol, Ioannina, Greece.
   [Baig, Atif Amin] Sultan Zainal Abidin Univ, Unit Biochem, Kuala Terengganu, Malaysia.
   [Barnighausen, Till Winfried] Harvard Univ, TH Chan Sch Publ Hlth, Boston, MA 02115 USA.
   [Dana, Reza; Friedman, David S.; Kempen, John H.] Harvard Univ, Dept Ophthalmol, Boston, MA 02115 USA.
   [Beheshti, Mahya] NYU, Dept Phys Med & Rehabil, New York, NY USA.
   [Bhagavathula, Akshaya Srikanth] Charles Univ Prague, Dept Social & Clin Pharm, Hradec Kralova, Czech Republic.
   [Bhagavathula, Akshaya Srikanth] United Arab Emirates Univ, Inst Publ Hlth, Al Ain, U Arab Emirates.
   [Bhardwaj, Nikha] Govt Med Coll Pali, Dept Anat, Pali, India.
   [Bhardwaj, Pankaj] All India Inst Med Sci, Dept Community Med & Family Med, Jodhpur, Rajasthan, India.
   [Bhardwaj, Pankaj] All India Inst Med Sci, Sch Publ Hlth, Jodhpur, Rajasthan, India.
   [Misra, Sanjeev] All India Inst Med Sci, Dept Surg Oncol, Jodhpur, Rajasthan, India.
   [Bhattacharyya, Krittika] Natl Inst Biomed Genom, Dept Stat & Computat Genom, Kalyani, W Bengal, India.
   [Bhattacharyya, Krittika] Univ Calcutta, Dept Stat, Kolkata, India.
   [Bijani, Ali] Babol Univ Med Sci, Social Determinants Hlth Res Ctr, Babol, Iran.
   [Bikbov, Mukharram] Ufa Eye Res Inst, Epidemiol Dept, Ufa, Russia.
   [Braithwaite, Tasanee] Middlesex Univ London, Dept Comp Sci, London, England.
   [Braithwaite, Tasanee] Moorfields Eye Hosp NHS Fdn Trust, Ophthalmol Dept, London, England.
   [Braithwaite, Tasanee] London Sch Hyg & Trop Med, Int Ctr Eye Hlth, London, England.
   [Bron, Alain M.] Univ Hosp Dijon, Dept Ophthalmol, Dijon, France.
   [Bron, Alain M.] Univ Bourgogne Franche Comte, Eye & Nutr Res Grp, Dijon, France.
   [Nagaraja, Sharath Burugina] Employee State Insurance Post Grad Inst Med Sci &, Dept Community Med, Bangalore, Karnataka, India.
   [Butt, Zahid A.] Univ Waterloo, Sch Publ Hlth & Hlth Syst, Waterloo, ON, Canada.
   [Butt, Zahid A.] Shifa Trust Eye Hosp, Shifa Sch Publ Hlth, Rawalpindi, Pakistan.
   [dos Santos, Florentino Luciano Caetano] Fed Polytech Sch Lausanne, Inst Microengn, Lausanne, Switzerland.
   [Carneiro, Vera L. A.] Univ Minho, Sch Sci, Braga, Portugal.
   [Sousa, Raul A. R. C.] Assoc Licensed Optometry Profess, Direct Board, Linda A Velha, Portugal.
   [Casson, Robert James] Univ Adelaide, Dept Ophthalmol, Adelaide, SA, Australia.
   [Podder, Vivek] Univ Adelaide, Sch Publ Hlth, Adelaide, SA, Australia.
   [Cheng, Ching-Yu] Singapore Eye Res Inst, Ocular Epidemiol Res Grp, Singapore, Singapore.
   [Cheng, Ching-Yu] Ophthalmol & Visual Sci Acad Clin Program, Singapore, Singapore.
   [Wong, Tien Y.] Duke NUS Med Sch, Singapore, Singapore.
   [Choi, Jee-Young Jasmine] Seoul Natl Univ Hosp, Biomed Informat, Seoul, South Korea.
   [Chu, Dinh-Toi] Hanoi Natl Univ Educ, Fac Biol, Hanoi, Vietnam.
   [Cicinelli, Maria Vittoria] Ist Sci San Raffaele, Dept Ophthalmol, Milan, Italy.
   [Coelho, Joao M.] Univ Porto, Univ Hosp Ctr Porto, Porto, Portugal.
   [Couto, Rosa A. S.] Univ Porto, Dept Chem Sci, Porto, Portugal.
   [Casson, Robert James] Univ Porto, Dept Chem, Porto, Portugal.
   [Congdon, Nathan G.; Virgili, Gianni] Queens Univ, Ctr Publ Hlth, Belfast, Antrim, North Ireland.
   [Congdon, Nathan G.] Orbis Int, New York, NY USA.
   [Dahlawi, Saad M. A.] Imam Abdulrahman Bin Faisal Univ, Environm Hlth Dept, Dammam, Saudi Arabia.
   [Dandona, Lalit; Dandona, Rakhi] Publ Hlth Fdn India, Gurugram, India.
   [Dandona, Lalit] Indian Council Med Res, New Delhi, India.
   [Del Monte, Monte A.; Ehrlich, Joshua R.; Robin, Alan L.] Univ Michigan, Dept Ophthalmol & Visual Sci, Ann Arbor, MI USA.
   [Ehrlich, Joshua R.] Univ Michigan, Inst Hlth Care Policy & Innovat, Ann Arbor, MI USA.
   [Liu, Xuefeng] Univ Michigan, Dept Syst Populat & Leadership, Ann Arbor, MI 48109 USA.
   [Molla, Meseret Derbew] Univ Gondar, Dept Biochem, Gondar, Ethiopia.
   [Desta, Abebaw Alemayehu] Univ Gondar, Dept Surg Nursing, Gondar, Ethiopia.
   [Dervenis, Nikolaos] Royal Liverpool Univ Hosp, St Pauls Eye Unit, Liverpool, Merseyside, England.
   [Dervenis, Nikolaos] Aristotle Univ Thessaloniki, Dept Ophthalmol, Thessaloniki, Greece.
   [Topouzis, Fotis] Aristotle Univ Thessaloniki, Dept Ophthalmol 1, Thessaloniki, Greece.
   [Deva, Jenny P.] Univ Tunku Abdul Rahman, Dept Ophthalmol, Kajang, Malaysia.
   [Diaz, Daniel] Univ Nacl Autonoma Mexico, Ctr Complex Sci, Mexico City, DF, Mexico.
   [Djalalinia, Shirin] Autonomous Univ Sinaloa, Fac Vet Med & Zootech, Culiacan Rosales, Mexico.
   [Elayedath, Rajesh] Minist Hlth & Med Educ, Dev Res & Technol Ctr, Tehran, Iran.
   [Elayedath, Rajesh] Mahatma Gandhi Univ Med Sci & Technol, Sch Behav Sci, Kottayam, Kerala, India.
   [Ellwein, Leon B.] NEI, NIH, Bethesda, MD 20892 USA.
   [Emamian, Mohammad Hassan] Shahroud Univ Med Sci, Ophthalm Epidemiol Res Ctr, Shahroud, Iran.
   [Fernandes, Arthur G.] Univ Fed Sao Paulo, Dept Ophthalmol & Visual Sci, Sao Paulo, Brazil.
   [Fischer, Florian] Ravensburg Weingarten Univ Appl Sci, Inst Gerontol Hlth Serv & Nursing Res, Weingarten, Germany.
   [Furtado, Joao M.] Univ Sao Paulo, Div Ophthalmol, Ribeirao Preto, Brazil.
   [Gaidhane, Shilpa] Datta Meghe Inst Med Sci, Dept Med, Wardha, India.
   [Khatib, Mahalaqua Nazli] Datta Meghe Inst Med Sci, Global Evidence Synth Initiat, Wardha, India.
   [Singhal, Deepika] Datta Meghe Inst Med Sci, Dept Ophthalmol, Wardha, India.
   [Gazzard, Gus] UCL, Inst Ophthalmol, London, England.
   [Gebremichael, Berhe] Haramaya Univ, Sch Publ Hlth, Harar, Ethiopia.
   [George, Ronnie] Sankara Nethralaya Med Res Fdn, Glaucoma Serv, Chennai, Tamil Nadu, India.
   [Gilani, Syed Amir] Univ Lahore, Fac Allied Hlth Sci, Lahore, Pakistan.
   [Gilani, Syed Amir] Afro Asian Inst, Lahore, Pakistan.
   [Golechha, Mahaveer] Indian Inst Publ Hlth Gandhinagar, Hlth Syst & Policy Res, Gandhinagar, India.
   [Hamidi, Samer] Hamdan Bin Mohammed Smart Univ, Sch Hlth & Environm Studies, Dubai, U Arab Emirates.
   [Hammond, Billy Randall] Univ Georgia, Brain & Behav Sci Program, Athens, GA 30602 USA.
   [Hartnett, Mary Elizabeth R.] Univ Utah, Moran Eye Ctr, Salt Lake City, UT USA.
   [Hartono, Risky Kusuma] Indonesian Adv Coll Hlth Sci, Inst Publ Hlth Sci, Jakarta, Indonesia.
   [Hashi, Abdiwahab] Jigjiga Univ, Dept Publ Hlth, Jijiga, Ethiopia.
   [Hayat, Khezar] Univ Vet & Anim Sci, Inst Pharmaceut Sci, Lahore, Pakistan.
   [Hayat, Khezar] Xi An Jiao Tong Univ, Dept Pharm Adm & Clin Pharm, Xian, Peoples R China.
   [Ho, Hung Chak] Univ Hong Kong, Dept Urban Planning & Design, Hong Kong, Peoples R China.
   [Holla, Ramesh; Rathi, Priya] Manipal Acad Higher Educ, Kasturba Med Coll, Manipal, Karnataka, India.
   [Househ, Mowafa] Hamad Bin Khalifa Univ, Coll Sci & Engn, Doha, Qatar.
   [Huang, John J.] Yale Univ, Dept Ophthalmol & Visual Sci, New Haven, CT USA.
   [Pawar, Shrikant] Yale Univ, Dept Genet, New Haven, CT USA.
   [Ibitoye, Segun Emmanuel] Univ Ibadan, Dept Hlth Promot & Educ, Ibadan, Nigeria.
   [Owolabi, Mayowa O.] Univ Ibadan, Dept Med, Ibadan, Nigeria.
   [Ilic, Irena M.] Univ Belgrade, Fac Med, Belgrade, Serbia.
   [Ilic, Milena D.] Univ Kragujevac, Dept Epidemiol, Kragujevac, Serbia.
   [Islam, Sheikh Mohammed Shariful] Deakin Univ, Inst Phys Act & Nutr, Burwood, Vic, Australia.
   [Islam, Sheikh Mohammed Shariful] Univ Sydney, Sydney Med Sch, Sydney, NSW, Australia.
   [Kandel, Himal] Univ Sydney, Ophthalmol Dept, Sydney, NSW, Australia.
   [Itumalla, Ramaiah] Univ Hail, Dept Hlth Management, Hail, Saudi Arabia.
   [Itumalla, Ramaiah] Univ Hyderabad, Sch Management Studies, Hyderabad, India.
   [Jayaram, Shubha] Govt Med Coll, Dept Biochem, Mysuru, India.
   [Jha, Ravi Prakash] Dr Baba Saheb Ambedkar Med Coll & Hosp, Dept Community Med, Delhi, India.
   [Jha, Ravi Prakash] Banaras Hindu Univ, Dept Community Med, Varanasi, Uttar Pradesh, India.
   [Kahloun, Rim] Ophtalmologistes Associe Monastir, Monastir, Tunisia.
   [Kalhor, Rohollah] Qazvin Univ Med Sci, Inst Prevent Noncommunicable Dis, Qazvin, Iran.
   [Kalhor, Rohollah] Qazvin Univ Med Sci, Hlth Serv Management Dept, Qazvin, Iran.
   [Kandel, Himal] Sydney Local Hlth Dist, Ophthalmol Dept, Sydney, NSW, Australia.
   [Kavetskyy, Taras] John Paul II Catholic Univ Lublin, Dept Appl Phys, Lublin Voivodeship, Poland.
   [Kavetskyy, Taras] Drohobych Ivan Franko State Pedag Univ, Dept Biol & Chem, Drogobych, Ukraine.
   [Kayode, Gbenga A.] Int Res Ctr Excellence, Inst Human Virol Nigeria, Abuja, Nigeria.
   [Kayode, Gbenga A.] Univ Utrecht, Julius Ctr Hlth Sci & Primary Care, Utrecht, Netherlands.
   [Kempen, John H.] MyungSung Med Coll, Eye Unit, Addis Ababa, Ethiopia.
   [Khairallah, Moncef] Fattouma Bourguiba Univ Hosp, Dept Ophthalmol, Monastir, Tunisia.
   [Khalilov, Rovshan] Baku State Univ, Dept Biophys & Mol Biol, Baku, Azerbaijan.
   [Khalilov, Rovshan] Azerbaijan Natl Acad Sci, Inst Radiat Problems, Baku, Azerbaijan.
   [Khan, Ejaz Ahmad] Hlth Serv Acad, Dept Epidemiol & Biostat, Islamabad, Pakistan.
   [Khanna, Rohit C.] Allen Foster Community Eye Hlth Res Ctr, Prasad Eye Inst, Hyderabad, India.
   [Khanna, Rohit C.; Naidoo, Kovin S.; Pesudovs, Konrad; Tahhan, Nina; Resnikoff, Serge] UNSW, Sch Optometry & Vis Sci, Sydney, NSW, Australia.
   [Khoja, Tawfik Ahmed Muthafer] Hlth Ministers Council Gulf Cooperat Council Stat, Execut Board, Riyadh, Saudi Arabia.
   [Kim, Gyu Ri; Park, Eun-Cheol] Yonsei Univ, Dept Prevent Med, Seoul, South Korea.
   [Park, Eun-Cheol] Yonsei Univ, Inst Hlth Serv Res, Seoul, South Korea.
   [Shin, Jae Il] Yonsei Univ, Coll Med, Seoul, South Korea.
   [Kim, Judy E.] Med Coll Wisconsin, Dept Ophthalmol & Visual Sci, Milwaukee, WI 53226 USA.
   [Kim, Yun Jin] Xiamen Univ Malaysia, Sch Tradit Chinese Med, Sepang, Malaysia.
   [Kisa, Adnan] Kristiania Univ Coll, Sch Hlth Sci, Oslo, Norway.
   [Kisa, Adnan] Tulane Univ, Global Community Hlth & Behav Sci, New Orleans, LA 70118 USA.
   [Kisa, Sezer] Oslo Metropolitan Univ, Dept Nursing & Hlth Promot, Oslo, Norway.
   [Koyanagi, Ai] San Juan de Dios Sanitary Pk, Biomed Res Networking, Ctr Mental Hlth Network, St Boi De Llobregat, Spain.
   [Koyanagi, Ai] Catalan Inst Res & Adv Studies ICREA, Barcelona, Spain.
   [Bicer, Burcu Kucuk] Gazi Univ, Fac Med, Ankara, Turkey.
   [Kulkarni, Vaman] Manipal Acad Higher Educ, Dept Community Med, Mangalore, India.
   [Kurmi, Om P.] Coventry Univ, Fac Hlth & Life Sci, Coventry, W Midlands, England.
   [Kurmi, Om P.] McMaster Univ, Dept Med, Hamilton, ON, Canada.
   [Olagunju, Andrew T.] McMaster Univ, Dept Psychiat & Behav Neurosci, Hamilton, ON, Canada.
   [Landires, Ivan] Inst Med Sci, Unit Genet & Publ Hlth, Las Tablas, Panama.
   [Nunez-Samudio, Virginia] Inst Med Sci, Unit Microbiol & Publ Hlth, Las Tablas, Panama.
   [Nunez-Samudio, Virginia] Minist Hlth, Dept Publ Hlth, Herrera, Panama.
   [Lansingh, Van Charles] HelpMeSee, New York, NY USA.
   [Leasher, Janet L.] Mexican Inst Ophthalmol, Queretaro, Mexico.
   [Leasher, Janet L.] Nova Southeastern Univ, Coll Optometry, Ft Lauderdale, FL 33314 USA.
   [Leveziel, Nicolas] CHU Poitiers, Ophthalmol Dept, Poitiers, France.
   [Leveziel, Nicolas] Natl Inst Hlth & Med Res INSERM, Unit 1084, Poitiers, France.
   [Limburg, Hans] Hlth Informat Serv, Grootebroek, Netherlands.
   [Kunjathur, Shilpashree Madhava] BGS Global Inst Med Sci, Dept Biochem, Bengaluru, India.
   [Maleki, Shokofeh; Naderi, Mehdi] Kermanshah Univ Med Sci, Clin Res Dev Ctr, Kermanshah, Iran.
   [Manafi, Navid] Univ Manitoba, Sch Med, Winnipeg, MB, Canada.
   [Mansouri, Kaweh] Glaucoma Res Ctr, Montchoisi Clin, Lausanne, Switzerland.
   [Mansouri, Kaweh] Univ Colorado, Dept Ophthalmol, Denver, CO USA.
   [McAlinden, Colm] Singleton Hosp, Dept Ophthalmol, Swansea, W Glam, Wales.
   [Meles, Gebrekiros Gebremichael] Mekelle Univ, Sch Publ Hlth, Mekelle, Ethiopia.
   [Mersha, Abera M.] Arba Minch Univ, Dept Nursing, Arba Minch, Ethiopia.
   [Sorrie, Muluken Bekele] Arba Minch Univ, Dept Publ Hlth, Arba Minch, Ethiopia.
   [Tadesse, Eyayou Girma] Arba Minch Univ, Dept Biomed Sci, Arba Minch, Ethiopia.
   [Michalek, Irmina Maria] Lausanne Univ Hosp, Woman Mother Child Dept, Lausanne, Switzerland.
   [Miller, Ted R.] Pacific Inst Res & Evaluat, Calverton, MD USA.
   [Miller, Ted R.] Curtin Univ, Sch Publ Hlth, Perth, WA, Australia.
   [Mohammad, Yousef] King Saud Univ, Internal Med Dept, Riyadh, Saudi Arabia.
   [Mohammed, Jemal Abdu; Wondmeneh, Temesgen Gebeyehu] Samara Univ, Dept Publ Hlth, Samara, Ethiopia.
   [Moni, Mohammad Ali] World Hlth Org WHO Ctr eHlth, Sydney, NSW, Australia.
   [Al Montasir, Ahmed] TMSS Med Coll, Dept Med, Bogura, Bangladesh.
   [Morse, Alan R.] Sofia Ismail Mem Med Ctr, Dept Med, Bogura, Bangladesh.
   [Morse, Alan R.] Lighthouse Guild, New York, NY USA.
   [Morse, Alan R.] Columbia Univ, Harkness Eye Inst, New York, NY USA.
   [Mulaw, Getahun Fentaw] Woldia Univ, Dept Publ Hlth, Woldia, Ethiopia.
   [Naderifar, Homa] Hamadan Univ Med Sci, Dept Orgon, Hamadan, Hamadan, Iran.
   [Naidoo, Kovin S.] Univ KwaZulu Natal, Discipline Optometry, Durban, South Africa.
   [Naimzada, Mukhammad David; Otstavnov, Nikita] Moscow Inst Phys & Technol, Lab Publ Hlth Indicators Anal & Hlth Digitalizat, Dolgoprudnyi, Russia.
   [Naimzada, Mukhammad David] Kursk State Med Univ, Expt Surg & Oncol Lab, Kursk, Russia.
   [Nangia, Vinay] Suraj Eye Inst, Nagpur, Maharashtra, India.
   [Swamy, Sreenivas Narasimha] Govt Med Coll, Mysore Med Coll & Res Inst, Mysore, Karnataka, India.
   [Naveed, Muhammad] Univ Cent Punjab, Dept Biotechnol, Lahore, Pakistan.
   [Huong Lan Thi Nguyen] Duy Tan Univ, Inst Global Hlth Innovat, Hanoi, Vietnam.
   [Ogbo, Felix Akpojene] Western Sydney Univ, Translat Hlth Res Inst, Sydney, NSW, Australia.
   [Ogundimu, Kolawole] Sightsavers, Policy & Programme Syst, Haywards Heath, England.
   [Olagunju, Andrew T.] Univ Lagos, Dept Psychiat, Lagos, Nigeria.
   [Onwujekwe, Obinna E.] Univ Nigeria Nsukka, Dept Pharmacol & Therapeut, Enugu, Nigeria.
   [Owolabi, Mayowa O.] Univ Coll Hosp, Dept Med, Ibadan, Nigeria.
   [Pakshir, Keyvan] Shiraz Univ Med Sci, Dept Parasitol & Mycol, Shiraz, Iran.
   [Parekh, Utsav] Pramukhswami Med Coll, Dept Forens Med & Toxicol, Anand, Gujarat, India.
   [Peto, Tunde] Queens Univ Belfast, Ctr Publ Hlth, Belfast, Antrim, North Ireland.
   [Podder, Vivek] Tairunnessa Mem Med Coll & Hosp, Med Coll, Gazipur, Bangladesh.
   [Rahman, Mohammad Hifz Ur] Maharishi Markandeshwar Med Coll & Hosp, Dept Community Med, Solan, India.
   [Ramulu, Pradeep Y.; West, Sheila K.] Johns Hopkins Univ, Dept Ophthalmol, Baltimore, MD USA.
   [Robin, Alan L.] Johns Hopkins Univ, Wilmer Eye Inst, Baltimore, MD 21218 USA.
   [Rawaf, David Laith] Univ Coll London Hosp, London, England.
   [Rawaf, Salman] Publ Hlth England, Acad Publ Hlth England, London, England.
   [Rawal, Lal] CQ Univ, Sch Hlth Med & Appl Sci, Sydney, NSW, Australia.
   [Renzaho, Andre M. N.] Western Sydney Univ, Sch Social Sci & Psychol, Penrith, NSW, Australia.
   [Renzaho, Andre M. N.] Western Sydney Univ, Translat Hlth Res Inst, Penrith, NSW, Australia.
   [Rossetti, Luca] Univ Milan, Dept Ophthalmol, Milan, Italy.
   [Sahebkar, Amirhossein] Food & Drug Adm Islamic Republ Iran, Halal Res Ctr, Tehran, Iran.
   [Sahebkar, Amirhossein] Mashhad Univ Med Sci, Neurogen Inflammat Res Ctr, Mashhad, Razavi Khorasan, Iran.
   [Samy, Abdallah M.] Ain Shams Univ, Dept Entomol, Cairo, Egypt.
   [Sathian, Brijesh] Hamad Med Corp, Dept Geriatr & Long Term Care, Doha, Qatar.
   [Sathian, Brijesh] Bournemouth Univ, Fac Hlth & Social Sci, Bournemouth, Dorset, England.
   [Saya, Ganesh Kumar] Jawaharlal Inst Postgrad Med Educ & Res, Dept Prevent & Social Med, Pondicherry, India.
   [Saylan, Mete] Bayer, Market Access, Istanbul, Turkey.
   [Shaheen, Amira A.] Najah Natl Univ, Publ Hlth Div, Nablus, Palestine.
   [Shibuya, Kenji] Kings Coll London, Inst Populat Hlth, London, England.
   [Shiferaw, Wondimeneh Shibabaw] Debre Berhan Univ, Dept Nursing, Debre Berhan, Ethiopia.
   [Shigematsu, Mika] Natl Inst Infect Dis, Tokyo, Japan.
   [Silva, Juan Carlos] Pan Amer Hlth Org, Family Hlth Promot & Life Course Dept, Washington, DC USA.
   [Silvester, Alexander] SpaMedica, Ophthalmol Dept, Bolton, England.
   [Singh, Jasvinder A.] Univ Alabama Birmingham, Sch Med, Birmingham, AL USA.
   [Singh, Jasvinder A.] Us Dept Vet Affairs VA, Med Serv, Birmingham, AL USA.
   [Singhal, Deepika] Gmers Med Coll & Civil Hosp, Dept Ophthalmol, Ahmadabad, Gujarat, India.
   [Sitorus, Rita S.] Univ Indonesia, Dept Ophthalmol, Jakarta, Indonesia.
   [Sitorus, Rita S.] Cipto Mangunkusumo Natl Hosp, Dept Ophthalmol, Jakarta, Indonesia.
   [Skiadaresi, Eirini] Hywel Dda Univ Hlth Board, Dept Ophthalmol, Llanelli, England.
   [Skryabin, Valentin Yurievich] Moscow Res & Pract Ctr Addict, Dept 16, Moscow, Russia.
   [Zastrozhin, Mikhail Sergeevich] Moscow Res & Pract Ctr Addict, Lab Genet & Genom, Moscow, Russia.
   [Skryabina, Anna Aleksandrovna] Balashiha Cent Hosp, Therapeut Dept, Balashikha, Russia.
   [Soheili, Amin] Semnan Univ Med Sci, Nursing Care Res Ctr, Semnan, Iran.
   [Swamy, Sreenivas Narasimha] Int Med Univ, Div Community Med, Kuala Lumpur, Malaysia.
   [Stambolian, Dwight] Univ Penn, Dept Ophthalmol, Philadelphia, PA 19104 USA.
   [Tareque, Md Ismail] Univ Rajshahi, Dept Populat Sci & Human Resource Dev, Rajshahi, Bangladesh.
   [Bach Xuan Tran] Hanoi Med Univ, Dept Hlth Econ, Hanoi, Vietnam.
   [Tsilimbaris, Miltiadis K.] Univ Crete, Med Sch, Iraklion, Greece.
   [Varma, Rohit] Southern Calif Eye Inst, Los Angeles, CA USA.
   [Virgili, Gianni] Univ Florence, Area Farmaco & Salute Bambino, Psicol, NEUROFARBA Dipartimento Neurosci, Florence, Italy.
   [Vu, Giang Thu] Nguyen Tat Thanh Univ, Ctr Excellence Behav Med, Ho Chi Minh City, Vietnam.
   [Wong, Tien Y.] Singapore Natl Eye Ctr, Singapore Eye Res Inst, Singapore, Singapore.
   [Yonemoto, Naohiro] Natl Ctr Neurol & Psychiat, Dept Neuropsychopharmacol, Kodaira, Tokyo, Japan.
   [Yonemoto, Naohiro] Juntendo Univ, Dept Publ Hlth, Tokyo, Japan.
   [Yu, Chuanhua] Wuhan Univ, Dept Epidemiol & Biostat, Wuhan, Peoples R China.
   [Zhang, Zhi-Jiang] Wuhan Univ, Sch Med, Wuhan, Peoples R China.
   [Zastrozhin, Mikhail Sergeevich] Russian Med Acad Continuous Profess Educ, Addictol Dept, Moscow, Russia.
   [Zastrozhina, Anasthasia] Russian Med Acad Continuous Profess Educ, Pediat Dept, Moscow, Russia.
   [Resnikoff, Serge] Brien Holden Vis Inst, Sydney, NSW, Australia.
C3 Institute for Health Metrics & Evaluation; University of Washington;
   University of Washington Seattle; University of Washington; University
   of Washington Seattle; University of Washington; University of
   Washington Seattle; Anglia Ruskin University; Imperial College London;
   Imperial College London; Imperial College London; University of
   Melbourne; Ruprecht Karls University Heidelberg; Ruprecht Karls
   University Heidelberg; Capital Medical University; Capital Medical
   University; Egyptian Knowledge Bank (EKB); Cairo University; Egyptian
   Knowledge Bank (EKB); Cairo University; University of Sharjah; Shahid
   Beheshti University Medical Sciences; Shahid Beheshti University Medical
   Sciences; Shahid Beheshti University Medical Sciences; Shahid Beheshti
   University Medical Sciences; Shahid Beheshti University Medical
   Sciences; Iran University of Medical Sciences; Iran University of
   Medical Sciences; Iran University of Medical Sciences; Iran University
   of Medical Sciences; Iran University of Medical Sciences; Leipzig
   University; Free University of Berlin; Humboldt University of Berlin;
   Charite Universitatsmedizin Berlin; University of Thessaly; University
   of Gondar; Vita-Salute San Raffaele University; IRCCS Ospedale San
   Raffaele; Vita-Salute San Raffaele University; Tehran University of
   Medical Sciences; Tehran University of Medical Sciences; Tehran
   University of Medical Sciences; Tehran University of Medical Sciences;
   Tehran University of Medical Sciences; Bahir Dar University; Bahir Dar
   University; Bahir Dar University; University of Gondar; University
   Hospital Ioannina; Foundation for Research & Technology - Hellas
   (FORTH); Universiti Sultan Zainal Abidin; Harvard University; Harvard
   T.H. Chan School of Public Health; Harvard University; New York
   University; Charles University Prague; United Arab Emirates University;
   All India Institute of Medical Sciences (AIIMS) Jodhpur; All India
   Institute of Medical Sciences (AIIMS) Jodhpur; All India Institute of
   Medical Sciences (AIIMS) Jodhpur; Department of Biotechnology (DBT)
   India; National Institute of Biomedical Genomics (NIBMG); University of
   Calcutta; Babol University of Medical Sciences; Ufa Eye Research
   Institute; Middlesex University; University of London; University
   College London; Moorfields Eye Hospital NHS Foundation Trust; University
   of London; London School of Hygiene & Tropical Medicine; CHU Dijon
   Bourgogne; Institut Agro; AgroSup Dijon; Universite de Bourgogne;
   University of Waterloo; Universidade do Minho; University of Adelaide;
   University of Adelaide; National University of Singapore; Singapore
   National Eye Center; National University of Singapore; Seoul National
   University (SNU); Seoul National University Hospital; Hanoi National
   University of Education; Vita-Salute San Raffaele University; IRCCS
   Ospedale San Raffaele; Universidade do Porto; Universidade do Porto;
   Universidade do Porto; Queens University Belfast; Imam Abdulrahman Bin
   Faisal University; Public Health Foundation of India; Indian Council of
   Medical Research (ICMR); University of Michigan System; University of
   Michigan; University of Michigan System; University of Michigan;
   University of Michigan System; University of Michigan; University of
   Gondar; University of Gondar; Royal Liverpool & Broadgreen University
   Hospitals NHS Trust; Royal Liverpool University Hospital; University of
   Liverpool; Aristotle University of Thessaloniki; Aristotle University of
   Thessaloniki; Universiti Tunku Abdul Rahman (UTAR); Universidad Nacional
   Autonoma de Mexico; Ministry of Health & Medical Education (MOHME);
   National Institutes of Health (NIH) - USA; NIH National Eye Institute
   (NEI); Shahroud University Medical Sciences; Universidade Federal de Sao
   Paulo (UNIFESP); Universidade de Sao Paulo; Datta Meghe Institute of
   Medical Sciences - Deemed to be University; Jawaharlal Nehru Medical
   College Wardha; Datta Meghe Institute of Medical Sciences - Deemed to be
   University; Datta Meghe Institute of Medical Sciences - Deemed to be
   University; Jawaharlal Nehru Medical College Wardha; University of
   London; University College London; Haramaya University; University of
   Lahore; University System of Georgia; University of Georgia; Utah System
   of Higher Education; University of Utah; University of Veterinary &
   Animal Science - Pakistan; Xi'an Jiaotong University; University of Hong
   Kong; Manipal Academy of Higher Education (MAHE); Kasturba Medical
   College, Manipal; Hamad Bin Khalifa University-Qatar; Yale University;
   Yale University; University of Ibadan; University of Ibadan; University
   of Belgrade; University of Kragujevac; Deakin University; University of
   Sydney; University of Sydney; University Ha'il; University of Hyderabad;
   Banaras Hindu University (BHU); Qazvin University of Medical Sciences
   (QUMS); Qazvin University of Medical Sciences (QUMS); Catholic
   University of Lublin; Ministry of Education & Science of Ukraine;
   Drohobych Ivan Franko State Pedagogical University; Utrecht University;
   Universite de Monastir; Hopital Fattouma Bourguiba; Ministry of
   Education of Azerbaijan Republic; Baku State University; Azerbaijan
   National Academy of Sciences (ANAS); Institute of Radiation Problems of
   the Azerbaijan National Academy of Sciences; Health Services Academy; L.
   V. Prasad Eye Institute; University of New South Wales Sydney; Yonsei
   University; Yonsei University; Yonsei University; Yonsei University
   Health System; Medical College of Wisconsin; Xiamen University Malaysia
   Campus; Kristiania University College; Tulane University; Oslo
   Metropolitan University (OsloMet); ICREA; Gazi University; Manipal
   Academy of Higher Education (MAHE); Coventry University; McMaster
   University; McMaster University; Ministerio de Salud de la Republica de
   Panama; Nova Southeastern University; CHU Poitiers; Universite de
   Poitiers; Institut National de la Sante et de la Recherche Medicale
   (Inserm); Kermanshah University of Medical Sciences; University of
   Manitoba; University of Colorado System; University of Colorado Denver;
   Singleton Hospital; Mekelle University; Arba Minch University; Arba
   Minch University; Arba Minch University; University of Lausanne; Centre
   Hospitalier Universitaire Vaudois (CHUV); Pacific Institute for Research
   & Evaluation (PIRE); Curtin University; King Saud University; Columbia
   University; University of Kwazulu Natal; Moscow Institute of Physics &
   Technology; Kursk State Medical University; Suraj Eye Institute;
   University of Central Punjab; Duy Tan University; Western Sydney
   University; University of Lagos; University of Nigeria; University of
   Ibadan; University College Hospital, Ibadan; Shiraz University of
   Medical Science; Queens University Belfast; Maharishi Markandeshwar
   University; Johns Hopkins University; Johns Hopkins University; Johns
   Hopkins Medicine; University College London Hospitals NHS Foundation
   Trust; University of London; University College London; Public Health
   England; Central Queensland University; Western Sydney University;
   Western Sydney University; University of Milan; Mashhad University
   Medical Science; Egyptian Knowledge Bank (EKB); Ain Shams University;
   Hamad Medical Corporation; Bournemouth University; Jawaharlal Institute
   of Postgraduate Medical Education & Research; Bayer Turkey; An Najah
   National University; University of London; King's College London;
   National Institute of Infectious Diseases (NIID); Pan American Health
   Organization; University of Alabama System; University of Alabama
   Birmingham; University of Indonesia; University of Indonesia; Semnan
   University of Medical Sciences; International Medical University
   Malaysia; University of Pennsylvania; University of Rajshahi; Hanoi
   Medical University; University of Crete; University of Florence; Nguyen
   Tat Thanh University (NTTU); National University of Singapore; Singapore
   National Eye Center; National Center for Neurology & Psychiatry - Japan;
   Juntendo University; Wuhan University; Wuhan University; Brien Holden
   Vision Institute
RP Bourne, RRA (通讯作者)，Anglia Ruskin Univ, Vis & Eye Res Inst, Cambridge CB1 1PT, England.
EM rb@rupertbourne.co.uk
RI Arabloo, Jalal/K-1829-2019; Dervenis, Nikolaos/AAK-2376-2020; Naveed,
   Muhammad/E-4965-2013; Gaidhane, Shilpa/AAL-2089-2020; Bhagavathula,
   Akshaya/GQH-1302-2022; Khatib, Mahalaqua Nazli/E-7308-2010; Safi,
   Sare/AAW-4651-2020; Chu, Dinh-Toi/I-7414-2019; Skryabin,
   Valentin/B-6244-2019; Michalek, Irmina Maria/J-8448-2019; Cheng,
   Ching-Yu/Y-2229-2019; Gebremichael, Berhe/W-2874-2019; Shao,
   Ruitai/AAU-7642-2021; Wong, Tien Yin/AAC-9724-2020; Carneiro, Vera Lúcia
   Alves/AAS-6809-2020; Samy, Abdallah/B-4375-2010; Sathian,
   Brijesh/G-7576-2014; Androudi, Sofia/AAB-7618-2021; Kim, Yun
   Jin/AAE-8281-2019; Ahmed, Montasir Al/G-4680-2012; Bijani,
   Ali/B-1718-2017; Kisa, Adnan/Q-2081-2019; Koyanagi, Ai/D-3833-2018;
   Irvani, Seyed Sina Naghibi/O-2413-2018; cicinelli, maria
   vittoria/M-1611-2019; Onwujekwe, Obinna/O-6232-2014; SHIN, JAE
   IL/ABD-9660-2021; Kisa, Sezer/GPC-8200-2022; Ilic, Irena/T-8121-2019;
   Bhagavathula, Akshaya Srikanth/G-6649-2015; Diaz, Daniel/P-1916-2018;
   Caetano dos Santos, Florentino Luciano/D-3502-2015; Parekh,
   Utsav/AAQ-6583-2020; Kahloun, Rim/O-6421-2015; Dai,
   Xiaochen/ABG-4201-2020; Rahman, Mohammad Hifz Ur/GVU-3673-2022;
   Debalkie, Desta/AAA-1448-2022; Bikbov, Mukharram/AAO-7624-2021; Furtado,
   Joao M./AAB-5356-2022; wang, YA XING/K-9671-2016; Khan, Prof Dr
   Ejaz/GNP-1245-2022; Islam, Mohammed Shariful/B-1219-2011; Tsegaye,
   Gebiyaw Wudie/GOH-2644-2022; Kandel, Himal/Q-1031-2018; Itumalla,
   Ramaiah/AAR-8610-2021; Manafi, Navid/AAM-7393-2020; Jha, Ravi
   Prakash/ABC-6588-2020; Bhattacharyya, Krittika/AAA-8258-2021; Househ,
   Mowafa/GPX-8430-2022; Skryabina, Anna/ABH-7827-2020; Alipour,
   Vahid/K-5099-2019; Zastrozhin, Michael/O-8920-2017; Nagaraja, Sharath
   Burugina/ABD-7238-2021; Pawar, Shrikant/AAE-4462-2021; Syed,
   ZQ/K-2887-2018; Naimzada, Mukhammad David/A-1521-2016; Silva, Juan
   Carlos/N-9113-2019; Hashi, Abdiwahab/AAM-5480-2021; SHIN, JAE
   IL/J-6922-2017; Saya, Ganesh Kumar/AAT-5825-2020; Butt, Zahid
   Ahmad/W-4292-2017; Gaidhane, Abhay/AAK-7144-2020; Nagaraja, Sharath
   Burugina/ABD-7748-2021; Mokdad, Ali H./AAD-1232-2022; Bhardwaj,
   Pankaj/AAH-9451-2019; Sousa, Raul/D-1641-2011; Kisa,
   Sezer/GPC-8087-2022; Moni, Mohammad Ali/ABG-3606-2020; Hay, Simon
   I/F-8967-2015; Tejedor, Jaime/G-7728-2015; T., Olagunju
   Andrew/B-4746-2017; Kucuk Bicer, Burcu/G-4922-2017; ho, Hung
   Chak/W-3320-2017; Gilani, Syed Amir/A-9458-2019; Pakshir,
   Keyvan/U-6856-2017; Ahmadieh, Hamid/M-4853-2017; Alfaar, Ahmad
   Samir/C-8483-2011; Virgili, Gianni/P-6607-2014; Pinheiro,
   Marina/E-4451-2013; Yaseri, Mehdi/I-1645-2018; Rahimi-Movaghar,
   Vafa/T-7816-2017
OI Arabloo, Jalal/0000-0003-1223-4528; Dervenis,
   Nikolaos/0000-0002-7269-2785; Naveed, Muhammad/0000-0002-4333-8226;
   Gaidhane, Shilpa/0000-0002-3012-7438; Khatib, Mahalaqua
   Nazli/0000-0001-5875-8277; Chu, Dinh-Toi/0000-0002-4596-2022; Skryabin,
   Valentin/0000-0002-4942-8556; Michalek, Irmina
   Maria/0000-0001-8367-5916; Cheng, Ching-Yu/0000-0003-0655-885X;
   Gebremichael, Berhe/0000-0002-0669-8521; Wong, Tien
   Yin/0000-0002-8448-1264; Samy, Abdallah/0000-0003-3978-1134; Sathian,
   Brijesh/0000-0003-0851-4762; Androudi, Sofia/0000-0002-5303-7793; Kim,
   Yun Jin/0000-0001-8853-6587; Ahmed, Montasir Al/0000-0001-5222-7088;
   Bijani, Ali/0000-0003-2233-8726; Kisa, Adnan/0000-0001-7825-3436;
   Koyanagi, Ai/0000-0002-9565-5004; Irvani, Seyed Sina
   Naghibi/0000-0002-4566-7402; cicinelli, maria
   vittoria/0000-0003-2938-0409; Onwujekwe, Obinna/0000-0002-1214-4285;
   SHIN, JAE IL/0000-0003-2326-1820; Ilic, Irena/0000-0001-5347-3264;
   Bhagavathula, Akshaya Srikanth/0000-0002-0581-7808; Diaz,
   Daniel/0000-0003-2302-1982; Caetano dos Santos, Florentino
   Luciano/0000-0001-8151-3585; Parekh, Utsav/0000-0002-0548-7810; Dai,
   Xiaochen/0000-0002-0289-7814; Rahman, Mohammad Hifz
   Ur/0000-0002-0039-5837; Furtado, Joao M./0000-0003-2490-5747; wang, YA
   XING/0000-0003-2749-7793; Khan, Prof Dr Ejaz/0000-0002-7072-8035; Islam,
   Mohammed Shariful/0000-0001-7926-9368; Kandel,
   Himal/0000-0002-6745-6411; Itumalla, Ramaiah/0000-0002-6090-9641;
   Manafi, Navid/0000-0002-4610-402X; Jha, Ravi
   Prakash/0000-0001-5230-1436; Bhattacharyya,
   Krittika/0000-0002-9914-7031; Skryabina, Anna/0000-0002-2098-222X;
   Alipour, Vahid/0000-0003-1010-9571; Zastrozhin,
   Michael/0000-0003-0607-4812; Nagaraja, Sharath
   Burugina/0000-0002-6599-5753; Pawar, Shrikant/0000-0002-6157-2462; Syed,
   ZQ/0000-0002-1435-899X; Naimzada, Mukhammad David/0000-0002-7894-6029;
   Silva, Juan Carlos/0000-0003-4855-5008; SHIN, JAE
   IL/0000-0003-2326-1820; Saya, Ganesh Kumar/0000-0002-1495-9461; Butt,
   Zahid Ahmad/0000-0002-2486-4781; Gaidhane, Abhay/0000-0002-4814-2695;
   Nagaraja, Sharath Burugina/0000-0002-6599-5753; Mokdad, Ali
   H./0000-0002-4994-3339; Bhardwaj, Pankaj/0000-0001-9960-3060; Sousa,
   Raul/0000-0002-3166-1990; Kisa, Sezer/0000-0002-3969-9803; Hay, Simon
   I/0000-0002-0611-7272; T., Olagunju Andrew/0000-0003-1736-9886; Fentaw
   Mulaw, Getahun/0000-0002-4173-3759; Fernandes, Arthur
   Gustavo/0000-0002-7525-1838; Kucuk Bicer, Burcu/0000-0002-5615-264X;
   Kim, Gyu Ri/0000-0003-3624-3971; Bekele, Muluken/0000-0002-3464-2584;
   Gazzard, Gus/0000-0003-1982-5005; Molla, Meseret
   Derbew/0000-0002-2622-522X; Golechha, Mahaveer/0000-0002-6253-8274; ho,
   Hung Chak/0000-0002-6505-3504; Landires, Ivan/0000-0001-6323-1170; Park,
   Eun-Cheol/0000-0002-2306-5398; Ibitoye, Segun
   Emmanuel/0000-0002-5074-816X; Gilani, Syed Amir/0000-0002-2996-0764;
   george, ronnie/0000-0001-7368-0252; Steinmetz,
   Jaimie/0000-0003-2397-4070; Farzadfar, Farshad/0000-0001-8288-4046;
   Kurmi, Om Prakash/0000-0002-9518-4716; Naderifar,
   Homa/0000-0002-6693-0513; RENZAHO, ANDRE/0000-0002-6844-0833; Dreer,
   Laura/0000-0002-4728-5467; Battaglia Parodi,
   Maurizio/0000-0002-0385-7961; Emamian, Mohammad
   Hassan/0000-0002-1994-1105; Pakshir, Keyvan/0000-0001-7809-4690;
   Ahmadieh, Hamid/0000-0002-8139-2661; Alfaar, Ahmad
   Samir/0000-0002-0930-4583; Bhardwaj, Nikha/0000-0002-8081-9926; Zimsen,
   Stephanie Robin Marie/0000-0001-7660-4642; Virgili,
   Gianni/0000-0002-9960-2989; Tareque, Md Ismail/0000-0002-6507-1171;
   Nunez Samudio, Virginia/0000-0002-9625-1415; Pinheiro,
   Marina/0000-0002-6931-1355; Moni, Mohammad Ali/0000-0003-0756-1006;
   Pesudovs, Konrad/0000-0002-6322-9369; Carneiro, Vera
   L.A./0000-0001-7830-0095; Morse, Alan R./0000-0002-5285-7626; Otstavnov,
   Nikita/0000-0001-9818-4642; Yaseri, Mehdi/0000-0002-4066-873X; Miller,
   Ted/0000-0002-0958-2639; Tsegaye, Gebiyaw Wudie/0000-0002-8522-6193;
   Rahimi-Movaghar, Vafa/0000-0001-7347-8767; Tejedor Fraile,
   Jaime/0000-0001-5507-5622
FU Alexander von Humboldt Foundation through the Alexander von Humboldt
   Professor award - German Federal Ministry of Education and Research;
   NIHR [HTA 09/104/40]; Moorfields Eye Charity; British Council to Prevent
   Blindness; Fight for Sight; International Glaucoma Association; NIH [R01
   EY015130, R01 EY017011, EY014800]; Research to Prevent Blindness (NY,
   USA); National Health and Medical Research Council (NHMRC); National
   Heart Foundation; Massachusetts Eye and Ear Global Surgery Program;
   Sight for Souls; Research Management Centre, Xiamen University Malaysia
   [XMUMRF/2020-C6/ITCM/0004]; Secretaria Nacional de Ciencia, Tecnologia e
   Innovacion (SENACYT), Panama; Egyptian Fulbright Mission Program;
   National Eye Institute of the NIH [R01EY031209]
FX This manuscript was produced as part of the GBD Collaborator Network and
   in accordance with the GBD protocol. T W Barnighausen was supported by
   the Alexander von Humboldt Foundation through the Alexander von Humboldt
   Professor award, funded by the German Federal Ministry of Education and
   Research. R R A Bourne received institutional support from Anglia Ruskin
   University, Cambridge, UK. G Gazzard is employed by University College
   London (London, UK) and supported by grants from the NIHR (HTA
   09/104/40), Moorfields Eye Charity, British Council to Prevent
   Blindness, and Fight for Sight and the International Glaucoma
   Association. M E R Hartnett's work is supported by grants from NIH R01
   EY015130, NIH R01 EY017011, and NIH EY014800 Unrestricted Grant from
   Research to Prevent Blindness (NY, USA) to the Department of
   Ophthalmology & Visual Sciences, University of Utah (Salt Lake City, UT,
   USA). S M S Islam received funding from National Health and Medical
   Research Council (NHMRC) and National Heart Foundation. J H Kempen
   received support from the Massachusetts Eye and Ear Global Surgery
   Program; Sight for Souls. Y J Kim received support by the Research
   Management Centre, Xiamen University Malaysia
   [XMUMRF/2020-C6/ITCM/0004]. I Landires is a member of the Sistema
   Nacional de Investigacion (SNI), which is supported by the Secretaria
   Nacional de Ciencia, Tecnologia e Innovacion (SENACYT), Panama. A M Samy
   received support from a fellowship from the Egyptian Fulbright Mission
   Program. D Stambolia received research support from the National Eye
   Institute of the NIH under Award Number R01EY031209.
CR Abbafati C, 2020, LANCET, V396, P1204, DOI 10.1016/S0140-6736(20)30925-9
   Bloch SB, 2012, AM J OPHTHALMOL, V153, P209, DOI 10.1016/j.ajo.2011.10.016
   Bourne RRA, 2003, BRIT J OPHTHALMOL, V87, P813, DOI 10.1136/bjo.87.7.813
   Bourne RRA, 2021, LANCET GLOB HEALTH, V9, pE130, DOI 10.1016/S2214-109X(20)30425-3
   Bourne RRA, 2019, JAMA OPHTHALMOL, V137, P158, DOI 10.1001/jamaophthalmol.2018.5448
   Bourne RRA, 2017, LANCET GLOB HEALTH, V5, pE888, DOI 10.1016/S2214-109X(17)30293-0
   Ehrlich JR, 2019, JAMA OPHTHALMOL, V137, P146, DOI 10.1001/jamaophthalmol.2018.5449
   Flaxman SR, 2017, LANCET GLOB HEALTH, V5, pE1221, DOI 10.1016/S2214-109X(17)30393-5
   Garway-Heath DF, 2015, LANCET, V385, P1295, DOI 10.1016/S0140-6736(14)62111-5
   He MG, 2009, OPTOMETRY VISION SCI, V86, P40, DOI 10.1097/OPX.0b013e3181940719
   Hernandez RA, 2008, INT J TECHNOL ASSESS, V24, P203, DOI 10.1017/S0266462308080288
   Horton S, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0182951
   Jonas JB, 2018, LANCET, V392, P86
   Lansingh VC, 2007, OPHTHALMOLOGY, V114, P1670, DOI 10.1016/j.ophtha.2006.12.013
   Leasher JL, 2016, DIABETES CARE, V39, P1643, DOI 10.2337/dc15-2171
   Mehta MC, 2020, HEALTHCARE-J DEL SCI, V8, DOI 10.1016/j.hjdsi.2019.100408
   Ogurtsova K, 2017, DIABETES RES CLIN PR, V128, P40, DOI 10.1016/j.diabres.2017.03.024
   OMRAN AR, 1971, MILBANK MEML FUND Q, V49, P509, DOI 10.2307/3349375
   Pezzullo L, 2018, BMC HEALTH SERV RES, V18, DOI 10.1186/s12913-018-2836-0
   Reddy PA, 2018, LANCET GLOB HEALTH, V6, pE1019, DOI 10.1016/S2214-109X(18)30329-2
   Stevens GA, 2016, LANCET, V388, pE19, DOI 10.1016/S0140-6736(16)30388-9
   Tahhan N, 2013, OPHTHALMOLOGY, V120, P1736, DOI 10.1016/j.ophtha.2013.02.014
   Teo ZL, 2020, EYE, V34, P1255, DOI 10.1038/s41433-020-0776-5
   Tham YC, 2014, OPHTHALMOLOGY, V121, P2081, DOI 10.1016/j.ophtha.2014.05.013
   WHO, 2020, ENDING NEGLECT ATTAI
   WHO, 2013, UNIVERSAL EYE HLTH G
   WHO, 2019, WORLD REPORT VISION
   Wong TY, 2018, OPHTHALMOLOGY, V125, P1608, DOI 10.1016/j.ophtha.2018.04.007
   Wong TY, 2014, AM J OPHTHALMOL, V157, P9, DOI 10.1016/j.ajo.2013.08.010
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Yau JWY, 2012, DIABETES CARE, V35, P556, DOI 10.2337/dc11-1909
   Zheng P, 2019, ARXIV190910700MATHST
NR 32
TC 388
Z9 390
U1 42
U2 141
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 2214-109X
J9 LANCET GLOB HEALTH
JI Lancet Glob. Health
PD FEB
PY 2021
VL 9
IS 2
BP E144
EP E160
DI 10.1016/S2214-109X(20)30489-7
EA JAN 2021
PG 17
WC Public, Environmental & Occupational Health
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Public, Environmental & Occupational Health
GA RC6GZ
UT WOS:000632898500019
PM 33275949
OA Green Published, Green Accepted, gold
HC Y
HP Y
DA 2022-11-30
ER

PT J
AU Wang, JCC
   Cao, SJ
   Wang, AK
   To, E
   Law, G
   Gao, JY
   Zhang, D
   Cui, JZ
   Matsubara, JA
AF Wang, Jay Ching Chieh
   Cao, Sijia
   Wang, Aikun
   To, Eleanor
   Law, Geoffrey
   Gao, Jiangyuan
   Zhang, Dean
   Cui, Jing Z.
   Matsubara, Joanne A.
TI CFH Y402H polymorphism is associated with elevated vitreal GM-CSF and
   choroidal macrophages in the postmortem human eye
SO MOLECULAR VISION
LA English
DT Article
ID COMPLEMENT FACTOR-H; COLONY-STIMULATING FACTOR; PIGMENT
   EPITHELIAL-CELLS; MACULAR DEGENERATION; VISUAL IMPAIRMENT; ACTIVATION;
   RISK; CYTOKINE; MICROGLIA; GENOTYPES
AB Purpose: Age-related macular degeneration (AMD) is the leading cause of irreversible blindness in people 50 years of age or older in developed countries. The homozygous CC genotype in the complement factor H (CFH) Y402H single nucleotide polymorphism (SNP; rs1061170) is widely recognized as a risk factor for the development of AMD. In this study, we examined vitreal levels of granulocyte macrophage colony-stimulating factor (GM-CSF), a hematopoietic cytokine, and macrophages in the choroid of postmortem human eyes genotyped for the CFH Y402H SNP.
   Methods: Twenty-two pairs of postmortem, non-diseased, human donor eyes were obtained. The vitreous and retinal tissues of the left eyes were collected for GM-CSF level measurement and CFH Y402H genotyping, respectively. The right eyes were paraffin-embedded and sectioned for immunohistochemistry using a macrophage and microglia marker, CD68. Cell cultures of RPE cells were stimulated with complement C3a, C5a, 4-hydroxynonenal (HNE), or tumor necrosis factor alpha (TNF-alpha), and GM-CSF expression was measured with a suspension assay or quantitative PCR.
   Results: Eyes genotyped with the CC or the CT risk variant of the CFH Y402H SNP showed significantly increased levels of GM-CSF in the vitreous compared to eyes with the protective TT variant (mean +/- standard error of mean, 607.54 +/- 85.83 pg/ml or 656.32 +/- 15.20 pg/ml versus 286.69 +/- 81.96 pg/ml, p<0.05). The choroid of eye tissues genotyped with the CC variant showed higher levels of CD68 immunoreactivity than the tissues genotyped with the TT variant (p<0.05). The GM-CSF levels detected in the supernatant of RPE cells in culture treated with HNE or TNF-alpha were significantly higher compared to the non-treated control (145.88 +/- 5.06 pg/ml and 149.32 +/- 3.76 pg/ml versus 123.27 +/- 4.05 pg/ml, p<0.05). Furthermore, the gene expression of GM-CSF detected in the lysate of RPE cells stimulated with complement C3a or C5a showed significantly increased fold changes compared to the non-treated control (C3a: 2.38 +/- 0.31 fold, p<0.05; C5a: 2.84 +/- 0.54 fold, p<0.01).
   Conclusions: Our data showed a relationship between the CFH Y402H polymorphism and GM-CSF levels in the vitreous and accumulation of choroidal macrophages in the postmortem eye. These data suggest that the at-risk variant of the CFH gene may contribute to the dysregulation of proinflammatory cytokines locally in the eye.
C1 [Wang, Jay Ching Chieh; Cao, Sijia; Wang, Aikun; To, Eleanor; Law, Geoffrey; Gao, Jiangyuan; Zhang, Dean; Cui, Jing Z.; Matsubara, Joanne A.] Univ British Columbia, Dept Ophthalmol & Visual Sci, Vancouver, BC V5Z 1M9, Canada.
C3 University of British Columbia
RP Matsubara, JA (通讯作者)，Eye Care Ctr, Dept Ophthalmol & Visual Sci, 2550 Willow St, Vancouver, BC V5Z 3N9, Canada.
EM jms@mail.ubc.ca
FU Canadian Institute of Health Research (CIHR) [MOP-97806, MOP-126195]
FX The authors thank and acknowledge Meysam Abbasi from Bio-Rad for
   technical assistance, and support by Canadian Institute of Health
   Research (CIHR) grant (MOP-97806 and MOP-126195 to Dr. Joanne
   Matsubara). The authors have no proprietary or commercial interest in
   any materials discussed in this article. Part of this work was presented
   at 2013 ARVO and Canadian Ophthalmological Society annual meeting poster
   sessions.
CR Ambati J, 2013, NAT REV IMMUNOL, V13, P438, DOI 10.1038/nri3459
   Anderson DH, 2010, PROG RETIN EYE RES, V29, P95, DOI 10.1016/j.preteyeres.2009.11.003
   Bao LH, 2011, J AM SOC NEPHROL, V22, P285, DOI 10.1681/ASN.2010060647
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Brantley Jr MA, 2012, AM J OPHTHALMOL
   Cao SJ, 2013, AM J OPHTHALMOL, V156, P1176, DOI 10.1016/j.ajo.2013.08.003
   Cao SJ, 2013, MOL VIS, V19, P718
   Cherepanoff S, 2010, BRIT J OPHTHALMOL, V94, P918, DOI 10.1136/bjo.2009.165563
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   FISCHER HG, 1993, J NEUROIMMUNOL, V45, P193, DOI 10.1016/0165-5728(93)90180-7
   Fukuoka Y, 2003, CLIN EXP IMMUNOL, V131, P248, DOI 10.1046/j.1365-2249.2003.02087.x
   Grunin M, 2014, ADV EXP MED BIOL, V801, P199, DOI 10.1007/978-1-4614-3209-8_26
   Gupta N, 2003, EXP EYE RES, V76, P463, DOI 10.1016/S0014-4835(02)00332-9
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hamilton JA, 2008, NAT REV IMMUNOL, V8, P533, DOI 10.1038/nri2356
   Hecker LA, 2010, HUM MOL GENET, V19, P209, DOI 10.1093/hmg/ddp472
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Jashnani KD, 2010, J FORENSIC SCI, V55, P1523, DOI 10.1111/j.1556-4029.2010.01501.x
   Johnson PT, 2006, P NATL ACAD SCI USA, V103, P17456, DOI 10.1073/pnas.0606234103
   Kaarniranta K, 2011, J ALZHEIMERS DIS, V24, P615, DOI 10.3233/JAD-2011-101908
   Khandhadia S, 2012, ADV EXP MED BIOL, V724, P15, DOI 10.1007/978-1-4614-0653-2_2
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Kurji KH, 2010, INVEST OPHTH VIS SCI, V51, P1151, DOI 10.1167/iovs.09-3622
   LEE SC, 1994, GLIA, V12, P309, DOI 10.1002/glia.440120407
   Liu BY, 2011, J TRANSL MED, V9, DOI 10.1186/1479-5876-9-111
   Loyet KM, 2012, INVEST OPHTH VIS SCI, V53, P6628, DOI 10.1167/iovs.12-9587
   Maberley D, 2006, EYE, V20, P801, DOI 10.1038/sj.eye.6702011
   Mooijaart SP, 2007, EXP GERONTOL, V42, P1116, DOI 10.1016/j.exger.2007.08.001
   Mullins RF, 2011, EXP EYE RES, V93, P565, DOI 10.1016/j.exer.2011.06.015
   Murray PJ, 2011, NAT REV IMMUNOL, V11, P723, DOI 10.1038/nri3073
   Osuna E, 2005, FORENSIC SCI INT, V153, P189, DOI 10.1016/j.forsciint.2004.09.105
   Pascolini D, 2004, OPHTHAL EPIDEMIOL, V11, P67, DOI 10.1076/opep.11.2.67.28158
   PLANCK SR, 1993, CURR EYE RES, V12, P205, DOI 10.3109/02713689308999465
   Reynolds R, 2009, INVEST OPHTH VIS SCI, V50, P5818, DOI 10.1167/iovs.09-3928
   Ristau T, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0093459
   Rowan S, 2014, INVEST OPHTH VIS SCI, V55, P492, DOI 10.1167/iovs.13-12413
   RUEF C, 1990, REV INFECT DIS, V12, P41
   Scholl HPN, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002593
   Seth A, 2008, INVEST OPHTH VIS SCI, V49, P743, DOI 10.1167/iovs.07-1072
   Shaw PX, 2012, P NATL ACAD SCI USA, V109, P13757, DOI 10.1073/pnas.1121309109
   Smailhodzic D, 2012, OPHTHALMOLOGY, V119, P339, DOI 10.1016/j.ophtha.2011.07.056
   Swaroop A, 2009, ANNU REV GENOM HUM G, V10, P19, DOI 10.1146/annurev.genom.9.081307.164350
   Ufret-Vincenty RL, 2010, INVEST OPHTH VIS SCI, V51, P5878, DOI 10.1167/iovs.09-4457
   Wang JCC, 2012, MOL VIS, V18, P3049
   Zeng HY, 2008, ARCH OPHTHALMOL-CHIC, V126, P227, DOI 10.1001/archophthalmol.2007.65
NR 47
TC 16
Z9 16
U1 0
U2 1
PU MOLECULAR VISION
PI ATLANTA
PA C/O JEFF BOATRIGHT, LAB B, 5500 EMORY EYE CENTER, 1327 CLIFTON RD, N E,
   ATLANTA, GA 30322 USA
SN 1090-0535
J9 MOL VIS
JI Mol. Vis.
PD MAR 13
PY 2015
VL 21
BP 264
EP 272
PG 9
WC Biochemistry & Molecular Biology; Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Ophthalmology
GA CG1FR
UT WOS:000353019000001
PM 25814824
DA 2022-11-30
ER

PT J
AU Goldenberg, DT
   Giblin, FJ
   Cheng, M
   Chintala, SK
   Trese, MT
   Drenser, KA
   Ruby, AJ
AF Goldenberg, David T.
   Giblin, Frank J.
   Cheng, Mei
   Chintala, Shravan K.
   Trese, Michael T.
   Drenser, Kimberly A.
   Ruby, Alan J.
TI POSTERIOR VITREOUS DETACHMENT WITH MICROPLASMIN ALTERS THE RETINAL
   PENETRATION OF INTRAVITREAL BEVACIZUMAB (AVASTIN) IN RABBIT EYES
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE bevacizumab; Avastin; microplasmin; posterior vitreous detachment;
   retinal penetration
ID MACULAR DEGENERATION; CHOROIDAL NEOVASCULARIZATION; PHARMACOLOGICAL
   VITREOLYSIS; PLASMINOGEN-ACTIVATOR; BINDING-SITES; FIBRONECTIN;
   PHARMACOKINETICS; INJECTION; LOCALIZATION; MACULOPATHY
AB Purpose: Intravitreal bevacizumab (BV) (Avastin, Genentech Inc., South San Francisco, CA) is frequently used for the treatment of age-related macular degeneration. Previous studies have demonstrated full-thickness retinal penetration. Intravitreal recombinant microplasmin (MP) has been shown to successfully induce a posterior vitreous detachment (PVD) and vitreous liquefaction in animals. It has been suggested that a PVD may alter the retinal penetration of molecules in the vitreous cavity. The aim of this study was to compare BV retinal penetration in rabbit eyes with and without an MP-induced PVD.
   Methods: Twelve adult rabbits were injected with 0.1 mL (0.4 mg) of MP into the vitreous cavity of 1 eye. One week later, the rabbits were injected with 0.05 mL (1.25 mg) of BV into both eyes. Both eyes of 3 rabbits were harvested at 6 hours, 12 hours, 24 hours, and 72 hours after the BV injection. Frozen retinal cross sections were prepared, and BV retinal penetration was evaluated with immunohistochemistry using a fluorescence-labeled antibody against BV. Two eyes from one rabbit were not injected with either agent and used as controls to compare the background autofluorescence. Peripapillary retinal sections were recorded with a digital camera, and intraretinal BV fluorescence-labeled antibody was measured by qualitative photographic interpretation. Two additional rabbits received an intravitreal injection of 0.1 mL of MP in 1 eye. One week later, both eyes from each rabbit were enucleated, and frozen retinal sections were prepared and analyzed with light microscopy to evaluate histologic damage.
   Results: Full-thickness BV retinal penetration was observed throughout the retina in both eyes of each rabbit. All the MP-injected eyes exhibited increased antibody labeling in retinas evaluated at 6 hours, 12 hours, and 24 hours after BV injection when compared with the contralateral non-MP-injected eyes. By 3 days after BV injection, all eyes demonstrated decreased antibody labeling compared with earlier periods. At 3 days, 1 rabbit showed increased antibody labeling in the retina of the non-MP-injected eye compared with the contralateral MP-injected eye, and 2 rabbits exhibited similar antibody labeling in both eyes. When compared with control eyes, light microscopy demonstrated normal retinal histologic findings in eyes injected only with MP.
   Conclusion: Increased BV retinal penetration is observed initially in eyes with an MP-induced PVD, and the mechanism is likely multifactorial. By 3 days, retinal penetration is similar in eyes with and without a PVD. Although it is difficult to directly extrapolate to humans, our study suggests that a PVD may alter the retinal penetration of BV. RETINA 31: 393-400, 2011
C1 [Goldenberg, David T.; Trese, Michael T.; Drenser, Kimberly A.; Ruby, Alan J.] Retinal Consultants, Royal Oak, MI USA.
   [Giblin, Frank J.; Cheng, Mei; Chintala, Shravan K.; Trese, Michael T.; Drenser, Kimberly A.] Oakland Univ, Eye Res Inst, Rochester, MI USA.
C3 Oakland University
RP Goldenberg, DT (通讯作者)，Retinal Consultants Arizona, 1101 E Missouri Ave, Phoenix, AZ 85014 USA.
EM davidtgold@yahoo.com
FU ThromboGenics, Inc; Alliance for Vision Research; National Institutes of
   Health [EY02027, EY014803]; The Lincy Foundation; NATIONAL EYE INSTITUTE
   [R24EY014803, R01EY002027] Funding Source: NIH RePORTER
FX This research was partially supported by grants from the ThromboGenics,
   Inc, the Alliance for Vision Research, the National Institutes of Health
   (EY02027 and EY014803), and The Lincy Foundation.
CR Adamis AP, 2005, RETINA-J RET VIT DIS, V25, P111, DOI 10.1097/00006982-200502000-00001
   Arevalo JF, 2008, RETINA-J RET VIT DIS, V28, P1387, DOI 10.1097/IAE.0b013e3181884ff4
   Avery RL, 2006, OPHTHALMOLOGY, V113, P363, DOI 10.1016/j.ophtha.2005.11.019
   Bakri SJ, 2007, OPHTHALMOLOGY, V114, P855, DOI 10.1016/j.ophtha.2007.01.017
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Gandorfer A, 2004, INVEST OPHTH VIS SCI, V45, P641, DOI 10.1167/iovs.03-0930
   Gaudreault J, 2007, RETINA-J RET VIT DIS, V27, P1260, DOI 10.1097/IAE.0b013e318134eecd
   Giblin FJ, 2009, EXP EYE RES, V88, P286, DOI 10.1016/j.exer.2008.09.003
   Goldenberg D, 2008, EXPERT REV OPHTHALMO, V3, P273, DOI 10.1586/17469899.3.3.273
   Heiduschka P, 2007, INVEST OPHTH VIS SCI, V48, P2814, DOI 10.1167/iovs.06-1171
   Ip MS, 2008, OPHTHALMOLOGY, V115, P1837, DOI 10.1016/j.ophtha.2008.08.012
   Kamei M, 1999, AM J OPHTHALMOL, V128, P739, DOI 10.1016/S0002-9394(99)00239-1
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   KOHNO T, 1987, INVEST OPHTH VIS SCI, V28, P506
   Krebs I, 2007, AM J OPHTHALMOL, V144, P741, DOI 10.1016/j.ajo.2007.07.024
   LIOTTA LA, 1981, CANCER RES, V41, P4629
   MITTRA RA, 2008, 26 ANN ASRS M OCT 11
   Nagai N, 2003, J THROMB HAEMOST, V1, P307, DOI 10.1046/j.1538-7836.2003.00078.x
   Nomoto H, 2009, INVEST OPHTH VIS SCI, V50, P4807, DOI 10.1167/iovs.08-3148
   Ondes F, 2000, JPN J OPHTHALMOL, V44, P91, DOI 10.1016/S0021-5155(99)00174-4
   Peters S, 2008, BRIT J OPHTHALMOL, V92, P541, DOI 10.1136/bjo.2007.133496
   Quaranta-El Maftouhi M, 2006, EUR J OPHTHALMOL, V16, P134
   Quiram PA, 2007, RETINA-J RET VIT DIS, V27, P1090, DOI 10.1097/IAE.0b013e3180654229
   Rostagno A, 1996, MOL IMMUNOL, V33, P561, DOI 10.1016/0161-5890(95)00161-1
   ROSTAGNO AA, 1991, J IMMUNOL, V146, P2687
   ROSTAGNO AA, 1989, J IMMUNOL, V143, P3277
   Sakuma T, 2005, INVEST OPHTH VIS SCI, V46, P3295, DOI 10.1167/iovs.04-1517
   Sebag J, 2007, GRAEF ARCH CLIN EXP, V245, P576, DOI 10.1007/s00417-006-0394-3
   Sebag J, 2005, Trans Am Ophthalmol Soc, V103, P473
   Shahar J, 2006, RETINA-J RET VIT DIS, V26, P262, DOI 10.1097/00006982-200603000-00002
   Spaide RF, 2006, RETINA-J RET VIT DIS, V26, P383, DOI 10.1097/00006982-200604000-00001
   Stefansson E, 2009, GRAEF ARCH CLIN EXP, V247, P147, DOI 10.1007/s00417-008-0980-7
   TAKEUCHI A, 1994, INVEST OPHTH VIS SCI, V35, P3792
   Uemura A, 2005, ARCH OPHTHALMOL-CHIC, V123, P209, DOI 10.1001/archopht.123.2.209
   Wilkinson CP, 1997, MICHELS RETINAL DETA, P9
   Yoganathan P, 2006, RETINA-J RET VIT DIS, V26, P994, DOI 10.1097/01.iae.0000244380.34082.67
NR 37
TC 20
Z9 23
U1 0
U2 8
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0275-004X
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD FEB
PY 2011
VL 31
IS 2
BP 393
EP 400
DI 10.1097/IAE.0b013e3181e586b2
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 711JG
UT WOS:000286586500026
PM 21099453
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Essex, RW
   Qureshi, SH
   Cain, MS
   Harper, CA
   Guymer, RH
AF Essex, RW
   Qureshi, SH
   Cain, MS
   Harper, CA
   Guymer, RH
TI Photodynamic therapy in practice: a review of the results of the first
   12 months experience with verteporfin at the Royal Victorian Eye and Ear
   Hospital
SO CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE age-related macular degeneration; photochemotherapy; photodynamic
   therapy; triamcinolone; verteporfin
ID SUBFOVEAL CHOROIDAL NEOVASCULARIZATION; RANDOMIZED CLINICAL-TRIALS;
   MACULAR DEGENERATION
AB Purpose: To review the 12-month results of the first 136 eyes treated with photodynamic therapy (PDT) with verteporfin at a single institution, and to determine if this treatment when used in the broader community could reproduce the results achieved in the Treatment of Age-related Macular Degeneration (AMD) with PDT (TAP) study.
   Methods: A record of all patients who first received PDT with verteporfin at The Royal Victorian Eye and Ear Hospital between the time of its introduction in February 2000 and February 2001 was prospectively maintained. The medical charts of these cases were reviewed and fluorescein angiograms were graded. Eyes with AMD were classified into three groups: TAP comparable if they had predominantly classic subfoveal choroidal neovascularization (CNV) and visual acuity between 6/12 and 6/60; VIP comparable if they had occult but no classic subfoveal CNV and visual acuity better than 6/36; and PDT ineligible if they fell outside recommended eligibility guidelines of the TAP/VIP studies. The main outcome measure was visual acuity change, with total number of treatments a secondary outcome variable.
   Results: A total of 136 eyes of 130 patients began PDT during this period. The baseline angiogram and clinical data were available for 123 eyes (90%), and these were reviewed. Fourteen eyes had non-AMD related CNV, while 109 eyes of 105 patients had AMD. Of the 109 AMD related lesions, 72 (66%) were TAP comparable, six (5.5%) were VIP comparable and 31 (28%) were PDT ineligible. At the 12-month visit the proportion of TAP comparable eyes with same or better vision was 36/72 (50%), compared to 13/31 (42%) of the PDT ineligible eyes (P = 0.45). Only 30/72 (42%) of the TAP comparable eyes were still undergoing regular angiographic and clinical assessment (similar to the TAP protocol) at the time of the 12 month visit. The number of these who had same or better vision at 12 months was 17/30 (57%) compared to 19/42 (44%) TAP comparable eyes without regular angiographic follow up to 12 months (P = 0.37).
   Conclusions: When used according to the guidelines estab-lished by the TAP study, the visual acuity results with PDT approached those achieved in the TAP study. When eyes were either enrolled outside the TAP study eligibility guidelines, or were not actively followed up over the 12-month period as per TAP study guidelines, the visual outcome was similar to natural history of CNV secondary to AMD.
C1 Univ Melbourne, Ctr Eye Res Australia, Melbourne, Vic 8002, Australia.
   Royal Victorian Eye & Ear Hosp, Melbourne, Vic 3002, Australia.
C3 Centre for Eye Research Australia; University of Melbourne; Royal
   Victorian Eye & Ear Hospital
RP Guymer, RH (通讯作者)，Univ Melbourne, Ctr Eye Res Australia, Locked Bag 8, Melbourne, Vic 8002, Australia.
OI Essex, Rohan/0000-0001-5323-0334; Guymer, Robyn/0000-0002-9441-4356
CR Arnold J, 2001, AM J OPHTHALMOL, V131, P541
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Gillies MC, 2001, INVEST OPHTH VIS SCI, V42, pS522
NR 4
TC 12
Z9 12
U1 0
U2 2
PU BLACKWELL PUBLISHING ASIA
PI CARLTON
PA 54 UNIVERSITY ST, P O BOX 378, CARLTON, VICTORIA 3053, AUSTRALIA
SN 1442-6404
J9 CLIN EXP OPHTHALMOL
JI Clin. Exp. Ophthalmol.
PD DEC
PY 2003
VL 31
IS 6
BP 476
EP 481
DI 10.1046/j.1442-9071.2003.00714.x
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 745FM
UT WOS:000186678700005
PM 14641153
DA 2022-11-30
ER

PT J
AU Schutt, F
   Bergmann, M
   Holz, FG
   Kopitz, J
AF Schutt, F
   Bergmann, M
   Holz, FG
   Kopitz, J
TI Isolation of intact lysosomes from human RPE cells and effects of A2-E
   on the integrity of the lysosomal and other cellular membranes
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
ID PIGMENTED EPITHELIAL-CELLS; MACULAR DEGENERATION; LIPOFUSCIN
   FLUOROPHORE; RETINOID COMPONENT; APOPTOSIS; A2E; INVOLVEMENT;
   PHOTODAMAGE; DAMAGE; RATS
AB Background: Accumulation of lipofuscin in RPE cells occurs with age and in association with various retinal diseases. Lipofuscin and its major retinoid compound and fluorophore A2-E interfere with the cellular metabolism of RPE cells in various ways. One of these mechanisms is thought to be related to detergent properties of A2-E. Methods: We isolated pure and intact lysosomes from RPE cell cultures and investigated detergent-like effects of the lipofuscin compound A2-E on the integrity of lysosomal membrane and other cellular membranes, using latency measurements. A postnuclear supernatant prepared from cultured human RPE cells was used to isolate intact lysosomes by fractionation of cellular organelles in two sequential gradients. Destabilization of the lysosomal membrane was tested by incubating the purified lysosomal fraction in the presence of A2-E and subsequent measurement of the latency of the lysosomal luminal marker beta-hexosaminidase. In order to compare the effect of A2-E on other cellular membranes, latencies of the specific markers succinate dehydrogenase and UDP-galactosyltransferase were assessed using partially purified mitochondria and microsomes. Intactness of the plasma membrane was tested by including A2-E in the culture medium before leakage of lactate dehydrogenase into the medium was determined. Results: A more than 100-fold purification of the lysosomal fraction was achieved. Except for a minor activity of the mitochondrial marker, no contamination with other cell fractions was observed. Intactness of the purified lysosomes was well preserved upon incubations in isotonic media providing the base for investigations on a possible detergent-like action of A2-E on lysosomal integrity. At concentrations above 2 muM A2-E, progressive leakage of the lysosomal marker was observed. In comparison, leakage of the mitochondrial marker was induced at significantly lower concentrations (1 muM), whereas ER/Golgi membranes and the plasma membrane were relatively insensitive to a detergent effect of the retinoid. The described methodology to obtain highly purified and intact lysosomes from RPE cells provides a suitable tool for investigations on compounds affecting lysosomal structure. A2-E was shown to cause desintegration of the lysosomal membrane at relatively low concentrations, which may implicate an involvement of such mechanism in triggering lipofuscin-induced dysfunction of RPE in vivo. Secondary to disintegration of the lysosomal membrane, damage to mitochondria might be an additional pathogenic mechanism. Conclusions: Our data provide evidence for surfactant-like properties of A2-E on biomembranes which might be operative in retinal diseases associated with excessive lipofuscin-accumulation, such as age-related macular degeneration.
C1 Heidelberg Univ, Dept Ophthalmol, D-69120 Heidelberg, Germany.
   Heidelberg Univ, Dept Pathochem, D-69120 Heidelberg, Germany.
C3 Ruprecht Karls University Heidelberg; Ruprecht Karls University
   Heidelberg
RP Holz, FG (通讯作者)，Heidelberg Univ, Dept Ophthalmol, Neuenheimer Feld 400, D-69120 Heidelberg, Germany.
EM frank_holz@med.uni-heidelberg.de
CR Agha AM, 1995, PHARMACOL RES, V32, P279, DOI 10.1016/S1043-6618(05)80015-5
   BERGMANN M, 2001, EXP EYE RES, V72, P191
   BERGMEYER HU, 1974, METHODEN ENZYMATISCH, P2351
   BOK D, 1993, J CELL SCI, P189
   BRUNK UT, 1995, GERONTOLOGY S, V41, P2201
   ELDRED GE, 1993, RETINAL DEGENERATION, P15
   ELDRED GE, 1993, NATURE, V361, P724, DOI 10.1038/361724a0
   ELHIFNAWI E, 1994, ANN ANAT, V176, P505, DOI 10.1016/S0940-9602(11)80384-5
   FEENEYBURNS L, 1984, INVEST OPHTH VIS SCI, V25, P195
   FLEISCHER B, 1969, J CELL BIOL, V43, P59, DOI 10.1083/jcb.43.1.59
   Green W R, 1977, Trans Am Ophthalmol Soc, V75, P180
   HINTON RH, 1998, SUBCELLULAR FRACTION, P31
   HOLZ FG, 1994, OPHTHALMOLOGY, V101, P1522
   Holz FG, 1999, INVEST OPHTH VIS SCI, V40, P737
   Li W, 2000, FEBS LETT, V470, P35, DOI 10.1016/S0014-5793(00)01286-2
   Liu JH, 2000, J BIOL CHEM, V275, P29354, DOI 10.1074/jbc.M910191199
   LOFFLER KU, 1986, GRAEF ARCH CLIN EXP, V224, P493, DOI 10.1007/BF02154735
   LOWRY OH, 1951, J BIOL CHEM, V193, P265
   MARTINEZ CM, 1990, CELL BIOL INT REP, V14, P255, DOI 10.1016/S0309-1651(05)80008-6
   Mata NL, 2000, P NATL ACAD SCI USA, V97, P7154, DOI 10.1073/pnas.130110497
   Mata NL, 2001, INVEST OPHTH VIS SCI, V42, P1685
   PARISH EJ, 1998, RRD ORG CHEM 1, V2, P95
   Schutt F, 2000, INVEST OPHTH VIS SCI, V41, P2303
   Sparrow JR, 1999, INVEST OPHTH VIS SCI, V40, P2988
   Sparrow JR, 2001, INVEST OPHTH VIS SCI, V42, P1356
   Sparrow JR, 2000, INVEST OPHTH VIS SCI, V41, P1981
   Stoka V, 2001, J BIOL CHEM, V276, P3149, DOI 10.1074/jbc.M008944200
   STORRIE B, 1990, METHOD ENZYMOL, V182, P203
   Suter M, 2000, J BIOL CHEM, V275, P39625, DOI 10.1074/jbc.M007049200
   Wassell J, 1999, J BIOL CHEM, V274, P23828, DOI 10.1074/jbc.274.34.23828
   Yang AJ, 1998, J NEUROSCI RES, V52, P691, DOI 10.1002/(SICI)1097-4547(19980615)52:6<691::AID-JNR8>3.0.CO;2-3
   Zang Y, 2001, CELL DEATH DIFFER, V8, P477, DOI 10.1038/sj.cdd.4400843
   Zhang GJ, 1997, BBA-BIOMEMBRANES, V1326, P75, DOI 10.1016/S0005-2736(97)00009-6
   ZHANG H, 1992, APMIS, V100, P309, DOI 10.1111/j.1699-0463.1992.tb00877.x
NR 34
TC 69
Z9 74
U1 0
U2 7
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0721-832X
EI 1435-702X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD DEC
PY 2002
VL 240
IS 12
BP 983
EP 988
DI 10.1007/s00417-002-0558-8
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 639AD
UT WOS:000180604700004
PM 12483320
DA 2022-11-30
ER

PT J
AU Singh, R
   Yang, XM
AF Singh, Rohit
   Yang, Xinmai
TI A 3D finite element model to study the cavitation induced stresses on
   blood-vessel wall during the ultrasound-only phase of photo-mediated
   ultrasound therapy
SO AIP ADVANCES
LA English
DT Article
ID GRID LASER PHOTOCOAGULATION; SHEAR-STRESS; BRAIN-BARRIER; CORNEAL
   NEOVASCULARIZATION; CONTRAST AGENTS; IN-VIVO; BUBBLE; SONOPORATION;
   OSCILLATION; MECHANISMS
AB Photo-mediated ultrasound therapy (PUT) is a novel technique utilizing synchronized ultrasound and laser to generate enhanced cavitation inside blood vessels. The enhanced cavitation inside blood vessels induces bio-effects, which can result in the removal of micro-vessels and the reduction in local blood perfusion. These bio-effects have the potential to treat neovascularization diseases in the eye, such as age-related macular degeneration and diabetic retinopathy. Currently, PUT is in the preclinical stage, and various PUT studies on in vivo rabbit eye models have shown successful removal of micro-vessels. PUT is completely non-invasive and particle-free as opposed to current clinical treatments such as anti-vascular endothelial growth factor therapy and photodynamic therapy, and it precisely removes micro-vessels without damaging the surrounding tissue, unlike laser photocoagulation therapy. The stresses produced by oscillating bubbles during PUT are responsible for the induced bio-effects in blood vessels. In our previous work, stresses induced during the first phase of PUT due to combined ultrasound and laser irradiation were studied using a 2D model. In this work, stresses induced during the third or last phase of PUT due to ultrasound alone were studied using a 3D finite element method-based numerical model. The results showed that the circumferential and shear stress increased as the bubble moves from the center of the vessel toward the vessel wall with more than a 16 times increase in shear stress from 1.848 to 31.060 kPa as compared to only a 4 times increase in circumferential stress from 211 to 906 kPa for a 2 mu m bubble placed inside a 10 mu m vessel on the application of 1 MHz ultrasound frequency and 130 kPa amplitude. In addition, the stresses decreased as the bubble was placed in smaller sized vessels with a larger decrease in circumferential stress. The changes in shear stress were found to be more dependent on the bubble-vessel wall distance, and the changes in circumferential stress were more dependent on the bubble oscillation amplitude. Moreover, the bubble shape changed to an ellipsoidal with a higher oscillation amplitude in the vessel's axial direction as it was moved closer to the vessel wall, and the bubble oscillation amplitude decreased drastically as it was placed in vessels of a smaller size. (C) 2022 Author(s). All article content, except where otherwise noted, is licensed under a Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).& nbsp;
C1 Univ Kansas, Dept Mech Engn, Lawrence, KS 66045 USA.
C3 University of Kansas
RP Yang, XM (通讯作者)，Univ Kansas, Inst Bioengn Res, Lawrence, KS 66045 USA.
EM xmyang@ku.edu
FU National Institutes of Health (NIH) grant [R01EY029489]
FX This work was supported, in part, through a National Institutes of
   Health (NIH) grant, No. R01EY029489.
CR Agarwal A, 2016, MIDDLE EAST AFR J OP, V23, P27, DOI 10.4103/0974-9233.173133
   Blume E, 1983, JAMA, V249, P2434
   Blumenkranz MS, 2006, RETINA-J RET VIT DIS, V26, P370, DOI 10.1097/00006982-200603000-00024
   Brand CS, 2012, EYE, V26, pS1, DOI 10.1038/eye.2012.32
   Campochiaro PA, 2013, J MOL MED, V91, P311, DOI 10.1007/s00109-013-0993-5
   CHAUSSY C, 1984, UROL RADIOL, V6, P80, DOI 10.1007/BF02923707
   CHAUSSY CG, 1989, J UROLOGY, V141, P782, DOI 10.1016/S0022-5347(17)41010-X
   Chen H, 2011, ULTRASOUND MED BIOL, V37, P2139, DOI 10.1016/j.ultrasmedbio.2011.09.013
   Chen H, 2010, UROL RES, V38, P321, DOI 10.1007/s00240-010-0302-5
   CHURCH CC, 1990, ULTRASOUND MED BIOL, V16, P626, DOI 10.1016/0301-5629(90)90028-B
   CLARKE PR, 1970, J ACOUST SOC AM, V47, P649, DOI 10.1121/1.1911940
   CRUM LA, 1988, J UROLOGY, V140, P1587, DOI 10.1016/S0022-5347(17)42132-X
   Di Martino ES, 2006, J VASC SURG, V43, P570, DOI 10.1016/j.jvs.2005.10.072
   Duck FA., 1990, PHYS PROPERTIES TISS, P137, DOI 10.1016/B978-0-12-222800-1.50009-7
   Early Treatment Diabetic Retinopathy Study Res Grp, 1991, OPHTHALMOLOGY, V98, P766
   Folkman J, 2002, SEMIN ONCOL, V29, P15, DOI 10.1053/sonc.2002.37263
   FRY FJ, 1958, SCIENCE, V127, P83, DOI 10.1126/science.127.3289.83
   FRY WJ, 1955, SCIENCE, V122, P517, DOI 10.1126/science.122.3168.517
   FRY WJ, 1954, J NEUROSURG, V11, P471, DOI 10.3171/jns.1954.11.5.0471
   Gao FR, 2007, INT J SOLIDS STRUCT, V44, P7197, DOI 10.1016/j.ijsolstr.2007.04.005
   Greenleaf WJ, 1998, ULTRASOUND MED BIOL, V24, P587, DOI 10.1016/S0301-5629(98)00003-9
   GUYER DR, 1992, AM J OPHTHALMOL, V113, P652
   Hoffman HJ, 2000, J REFRACT SURG, V16, P90
   Hoger JH, 2002, P NATL ACAD SCI USA, V99, P7780, DOI 10.1073/pnas.102184999
   Hosseinkhah N, 2013, J ACOUST SOC AM, V134, P1875, DOI 10.1121/1.4817843
   Hosseinkhah N, 2012, PHYS MED BIOL, V57, P785, DOI 10.1088/0031-9155/57/3/785
   Hosseinkhah N, 2015, IEEE T BIO-MED ENG, V62, P1293, DOI 10.1109/TBME.2014.2385651
   Hu HH, 2001, J COMPUT PHYS, V169, P427, DOI 10.1006/jcph.2000.6592
   Hu ZZ, 2017, SCI REP-UK, V7, DOI 10.1038/srep40243
   Hynynen K, 2001, RADIOLOGY, V220, P640, DOI 10.1148/radiol.2202001804
   Jo JG, 2016, APPL PHYS LETT, V109, DOI 10.1063/1.4968509
   Karakatsani ME, 2019, MOVEMENT DISORD, V34, P1252, DOI 10.1002/mds.27804
   KELLER JB, 1980, J ACOUST SOC AM, V68, P628, DOI 10.1121/1.384720
   Kim HJ, 1996, HUM GENE THER, V7, P1339, DOI 10.1089/hum.1996.7.11-1339
   Klais CM, 2005, ARCH OPHTHALMOL-CHIC, V123, P1149, DOI 10.1001/archopht.123.8.1149
   Li SY, 2018, PHYS MED BIOL, V63, DOI 10.1088/1361-6560/aac7bc
   Li XQ, 2020, J NEUROL SCI, V416, DOI 10.1016/j.jns.2020.116998
   Lieu DK, 2004, AM J PHYSIOL-CELL PH, V286, pC1367, DOI 10.1152/ajpcell.00243.2003
   Liu XF, 2020, MICROMACHINES-BASEL, V11, DOI 10.3390/mi11030288
   Lu QL, 2003, GENE THER, V10, P396, DOI 10.1038/sj.gt.3301913
   Luo H, 1998, THROMB RES, V89, P171, DOI 10.1016/S0049-3848(98)00002-4
   Maguire MG, 2016, OPHTHALMOLOGY, V123, P1751, DOI 10.1016/j.ophtha.2016.03.045
   Martynov S, 2011, J ACOUST SOC AM, V130, P2700, DOI 10.1121/1.3646904
   Martynov S, 2009, J ACOUST SOC AM, V126, P2963, DOI 10.1121/1.3243292
   Miao H, 2008, J ACOUST SOC AM, V124, P2374, DOI 10.1121/1.2967488
   Miller DL, 1998, ULTRASONICS, V36, P947, DOI 10.1016/S0041-624X(98)00017-1
   Miller DL, 2011, J ACOUST SOC AM, V130, P3482, DOI 10.1121/1.3626127
   Miller MW, 2004, ULTRASOUND MED BIOL, V30, P1263, DOI 10.1016/j.ultrasmedbio.2004.07.005
   Neal CR, 1996, J PHYSIOL-LONDON, V492, P39, DOI 10.1113/jphysiol.1996.sp021287
   Ohl CD, 2003, BBA-GEN SUBJECTS, V1624, P131, DOI 10.1016/j.bbagen.2003.10.005
   Paltauf G, 1999, APPL PHYS A-MATER, V68, P525, DOI 10.1007/s003390050935
   Park J, 2011, J BIOMECH, V44, P164, DOI 10.1016/j.jbiomech.2010.09.003
   Paulus Y. M., 2020, PHOTOMEDIATED ULTRAS, P5244
   Porter TR, 1996, AM HEART J, V132, P964, DOI 10.1016/S0002-8703(96)90006-X
   Price RJ, 1998, CIRCULATION, V98, P1264, DOI 10.1161/01.CIR.98.13.1264
   PRIES AR, 1995, CIRC RES, V77, P1017, DOI 10.1161/01.RES.77.5.1017
   Qin SP, 2007, ULTRASOUND MED BIOL, V33, P1140, DOI 10.1016/j.ultrasmedbio.2006.12.009
   Qin Y, 2020, TRANSL VIS SCI TECHN, V9, DOI 10.1167/tvst.9.13.16
   Qin Y, 2020, IEEE T BIO-MED ENG, V67, P3363, DOI 10.1109/TBME.2020.2985648
   R. W. Wood and A. L. Loomis  London, 1927, EDINBURGH DUBLIN PHI, V4, P417, DOI [10.1080/14786440908564348, DOI 10.1080/14786440908564348]
   Reneman RS, 2008, MED BIOL ENG COMPUT, V46, P499, DOI 10.1007/s11517-008-0330-2
   Reneman RS, 2006, J VASC RES, V43, P251, DOI 10.1159/000091648
   Rezai AR, 2020, P NATL ACAD SCI USA, V117, P9180, DOI 10.1073/pnas.2002571117
   ROONEY JA, 1972, AM J PHYS, V40, P1825, DOI 10.1119/1.1987071
   Royer JJ, 2017, J PHYS CONF SER, V879, DOI 10.1088/1742-6596/879/1/012024
   SCHATZ H, 1991, ARCH OPHTHALMOL-CHIC, V109, P1549, DOI 10.1001/archopht.1991.01080110085041
   Singh R, 2020, AIP ADV, V10, DOI 10.1063/5.0020410
   Sramek C, 2009, J BIOMED OPT, V14, DOI 10.1117/1.3130282
   STRIPH GG, 1988, OPHTHALMOLOGY, V95, P1673
   Velazquez OC, 2007, J VASC SURG, V45, p39A, DOI 10.1016/j.jvs.2007.02.068
   Vogel A, 2003, CHEM REV, V103, P577, DOI 10.1021/cr010379n
   Wang SP, 2018, PHYS FLUIDS, V30, DOI 10.1063/1.5005534
   WEST JB, 1991, J APPL PHYSIOL, V70, P1731, DOI 10.1152/jappl.1991.70.4.1731
   WILLIAMS A R, 1989, Ultrasound in Medicine and Biology, V15, P53, DOI 10.1016/0301-5629(89)90132-4
   Wu JR, 2002, ULTRASOUND MED BIOL, V28, P125, DOI 10.1016/S0301-5629(01)00497-5
   Wu JR, 2002, J ACOUST SOC AM, V111, P1460, DOI 10.1121/1.1420389
   Ye T, 2006, J BIOMECH ENG-T ASME, V128, P554, DOI 10.1115/1.2206200
   Yu YX, 2020, INVEST OPHTH VIS SCI, V61
   Zhang HN, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-31045-w
   Zhong P, 2001, ULTRASOUND MED BIOL, V27, P119, DOI 10.1016/S0301-5629(00)00322-7
NR 80
TC 2
Z9 2
U1 2
U2 6
PU AIP Publishing
PI MELVILLE
PA 1305 WALT WHITMAN RD, STE 300, MELVILLE, NY 11747-4501 USA
EI 2158-3226
J9 AIP ADV
JI AIP Adv.
PD APR 1
PY 2022
VL 12
IS 4
AR 045020
DI 10.1063/5.0082429
PG 14
WC Nanoscience & Nanotechnology; Materials Science, Multidisciplinary;
   Physics, Applied
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics; Materials Science; Physics
GA 0Z7OK
UT WOS:000791262900004
PM 35465057
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Jackson, J
   Silvestri, G
   Stevenson, M
   Sinton, J
   Witherow, J
   McCann, R
   Moutray, T
   Cushley, L
AF Jackson, Jonathan
   Silvestri, Giuliana
   Stevenson, Michael
   Sinton, Janet
   Witherow, Jacqueline
   McCann, Roseleen
   Moutray, Tanya
   Cushley, Laura
TI COVID-19: The regional impact of COVID-19 on the certification of vision
   impairment in Northern Ireland
SO OPHTHALMIC AND PHYSIOLOGICAL OPTICS
LA English
DT Article
DE blindness; COVID-19; Northern Ireland; severe sight impairment; sight
   impairment; vision impairment
ID VISUAL IMPAIRMENT
AB Purpose In this paper we highlight the impact which the disruption of secondary care ophthalmic services, resulting from COVID-19, has had on Sight Impairment (SI) and Severe Sight Impairment (SSI) certification in Northern Ireland.
   Methods Regional data on SI and SSI certification in the period after the onset of the lockdown (19 March 2020-18 June 2020) were compared to the period immediately before lockdown (1 January 2020-18 March 2020) and to the same periods in 2019. Change documented was compared to post-lockdown reductions in primary and secondary ophthalmic care activity.
   Results In 2019, during the 3-month period (19 March 2019-18 June 2019), 115 individuals were certified as sight impaired (SI 36, SSI 75, unspecified 4). Of those certified, 65 were female, 49 male. Principal causes of certification were: Age-related macular degeneration (AMD) (N = 45), glaucoma (N = 20) and diabetic eye disease (DED) (N = 10). Mean VA, recorded from the better eye of those certified, was 0.96 LogMAR. In the 3 months following the onset of lockdown (19 March 2020-18 June 2020), only 37 individuals were certified (SI 6, SSI 31), 12 female and 25 male. AMD was the most frequent cause of sight impairment (N = 20). There were only two DED certifications and one due to glaucoma. Mean VA in the better eye of those certified was 1.15LogMAR. The numbers of CVI certifications completed following the introduction of COVID-19 lockdown fell by 68%, compared to the 2019 data. There was a significant reduction in the proportion of female certifications (p = 0.01), and in certifications due to glaucoma (p = 0.02). The proportion of those certified as SSI as opposed to SI in the period after the onset of lockdown rose from 68% in 2019 to 84% in 2020. The mean VA of those certified in the period after the onset of lockdown, when compared to those certified in the other three periods, was worse by between 0.21 and 0.19 LogMAR (p = 0.06). Reductions reflected change in overall primary and secondary ophthalmic care activity.
   Conclusions It is inconceivable that COVID-19 has reduced the incidence of sight-threatening eye disease. We must therefore assume that a flood of newly presenting sight loss will present once the pandemic has passed. New presentations will include those who would normally have attended during the lockdown period, and patients who, had they accessed ophthalmic care at the appropriate time, would have been saved from severe levels of blindness. The implications of the predicted increase in demand for medical, social and low vision related services are huge.
C1 [Jackson, Jonathan; Silvestri, Giuliana; McCann, Roseleen; Moutray, Tanya; Cushley, Laura] Belfast Hlth & Social Care Trust, Royal Victoria Hosp, Dept Ophthalmol, Belfast, Antrim, North Ireland.
   [Jackson, Jonathan] Dublin Technol Univ, Dublin, Ireland.
   [Silvestri, Giuliana] Univ Ulster, Coleraine, Londonderry, North Ireland.
   [Stevenson, Michael] Belfast Hlth & Social Care Trust, Belfast, Antrim, North Ireland.
   [Sinton, Janet] Western Hlth & Social Care Trust WHSCT, Altnagelvin Hosp, Dept Ophthalmol, Derry, Londonderry, North Ireland.
   [Witherow, Jacqueline] Royal Natl Inst Blind People RNIB, Belfast, Antrim, North Ireland.
   [Cushley, Laura] Queens Univ, Belfast, Antrim, North Ireland.
C3 Ulster University; Queens University Belfast
RP Jackson, J (通讯作者)，Belfast Hlth & Social Care Trust, Royal Victoria Hosp, Dept Ophthalmol, Belfast, Antrim, North Ireland.; Jackson, J (通讯作者)，Dublin Technol Univ, Dublin, Ireland.
EM profjackson_csa@yahoo.co.uk
RI Jackson, Jonathan/ABH-1264-2021; Cushley, Laura/AAE-4264-2022
OI Cushley, Laura/0000-0003-0697-8854; Silvestri,
   Giuliana/0000-0001-5662-5374; Jackson, Jonathan/0000-0003-4675-0272
CR [Anonymous], 2014, CARE SUPPORT SIGHT I
   Barry RJ, 2005, BRIT J OPHTHALMOL, V89, P995, DOI 10.1136/bjo.2004.059915
   Boyce T, 2014, BMJ OPEN, V4, DOI 10.1136/bmjopen-2013-004319
   Canavan YM, 1997, ULSTER MED J, V66, P92
   Certificate of Vision Impairment, EXPL NOT CONS OPHTH
   Department of Health, 2012, DEV EYE CAR PARTN IM
   Lu CW, 2020, LANCET, V395, pE39, DOI 10.1016/S0140-6736(20)30313-5
   Ohannessian R., 2015, EUROPEAN RES TELEMED, V4, P95
   Rahman F, 2020, EYE, V34, P1271, DOI 10.1038/s41433-020-0864-6
   Sorsby A., 1953, CAUSES BLINDNESS ENG
NR 10
TC 2
Z9 2
U1 2
U2 3
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0275-5408
EI 1475-1313
J9 OPHTHAL PHYSL OPT
JI Ophthalmic Physiol. Opt.
PD JAN
PY 2021
VL 41
IS 1
BP 136
EP 143
DI 10.1111/opo.12757
EA NOV 2020
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA QA8QH
UT WOS:000587473300001
PM 33165967
DA 2022-11-30
ER

PT J
AU Daruich, A
   Parcq, J
   Delaunay, K
   Naud, MC
   Le Rouzic, Q
   Picard, E
   Crisanti, P
   Vivien, D
   Berdugo, M
   Behar-Cohen, F
AF Daruich, Alejandra
   Parcq, Jerome
   Delaunay, Kimberley
   Naud, Marie-Christine
   Le Rouzic, Quentin
   Picard, Emilie
   Crisanti, Patricia
   Vivien, Denis
   Berdugo, Marianne
   Behar-Cohen, Francine
TI Retinal safety of intravitreal rtPA in healthy rats and under
   excitotoxic conditions
SO MOLECULAR VISION
LA English
DT Article
ID TISSUE-PLASMINOGEN-ACTIVATOR; THICK SUBMACULAR HEMORRHAGE; NITRIC-OXIDE
   SYNTHASE; GANGLION-CELL DEATH; MACULAR DEGENERATION; SUBRETINAL
   HEMORRHAGE; PNEUMATIC DISPLACEMENT; EXPANSILE GAS; INJECTION; TOXICITY
AB Purpose: Intravitreal recombinant tissue plasminogen activator (rtPA) is used off-label for the surgical management of submacular hemorrhage, a severe complication of neovascular age-related macular degeneration. rtPA is approved for coronary and cerebral thrombolysis. However, in ischemic stroke rtPA is known to increase excitotoxic neural cell death by interacting with the N-methyl-D-aspartate (NMDA) receptor. We therefore investigated the retinal toxicity of rtPA in healthy rats and in a model of NMDA-induced retinal excitotoxicity.
   Methods: First, rtPA at three different doses (2.16 mu g/5 mu l, 0.54 mu g/5 mu l, and 0.27 mu g/5 mu l) or vehicle (NaCl 0.9%) was injected intravitreally in healthy rat eyes. Electroretinograms (ERGs) were performed at 24 h or 7 days. Annexin V-fluorescein isothiocyanate (FITC)-labeled apoptotic retinal ganglion cells (RGCs) were counted on flatmounted retinas at 24 h or 7 days. Next, NMDA + vehicle or NMDA + rtPA (0.27 mu g/5 mu l) was injected intravitreally to generate excitotoxic conditions. Apoptotic annexin V-FITC-labeled RGCs and surviving Brn3a-labeled RGCs were quantified on flatmounted retinas and radial sections, 18 h after treatment.
   Results: In healthy rat eyes, the number of apoptotic RGCs was statistically significantly increased 24 h after the administration of rtPA at the highest dose (2.16 mu g/5 mu l; p = 0.0250) but not at the lower doses of 0.54 and 0.27 mu g/5 mu l (p = 0.36 and p = 0.20), compared to vehicle. At day 7, there was no difference in the apoptotic RGC count between the rtPA-and vehicle-injected eyes (p = 0.70, p = 0.52, p = 0.11). ERG amplitudes and implicit times were not modified at 24 h or 7 days after injection of any tested rtPA doses, compared to the baseline. Intravitreal administration of NMDA induced RGC death, but under these excitotoxic conditions, coadministration of rtPA did not increase the number of dead RGCs (p = 0.70). Similarly, the number of surviving RGCs on the flatmounted retinas and retinal sections did not differ between the eyes injected with NMDA + vehicle and NMDA + rtPA (p = 0.59 and p = 0.67).
   Conclusions: At low clinical equivalent doses corresponding to 25 mu g/0.1 ml in humans, intravitreal rtPA is not toxic for healthy rat retinas and does not enhance NMDA-induced excitotoxicity. Vitreal equivalent doses = 200 mu g/0.1 ml should be avoided in patients, due to potential RGC toxicity.
C1 [Daruich, Alejandra; Behar-Cohen, Francine] Univ Lausanne, Jules Gonin Eye Hosp, Dept Ophthalmol, Fdn Asile Aveugles, Ave France 15,Case Postale 5143, CH-1000 Lausanne 2, Switzerland.
   [Daruich, Alejandra; Delaunay, Kimberley; Naud, Marie-Christine; Le Rouzic, Quentin; Picard, Emilie; Crisanti, Patricia; Berdugo, Marianne; Behar-Cohen, Francine] Univ Paris 05, INSERM, U1138,Ctr Rech Cordeliers, Team 17,Physiopathol Ocular Dis Clin Dev,Sorbonne, Paris, France.
   [Parcq, Jerome; Vivien, Denis] Univ Caen Basse Normandie, INSERM, U919, Serine Proteases & Pathophysiol Neurovasc Unit,GI, Caen, France.
C3 University of Lausanne; Institut National de la Sante et de la Recherche
   Medicale (Inserm); UDICE-French Research Universities; Universite Paris
   Cite; Institut National de la Sante et de la Recherche Medicale
   (Inserm); Universite de Caen Normandie
RP Behar-Cohen, F (通讯作者)，Univ Lausanne, Jules Gonin Eye Hosp, Dept Ophthalmol, Fdn Asile Aveugles, Ave France 15,Case Postale 5143, CH-1000 Lausanne 2, Switzerland.
EM francine.behar@gmail.com
RI picard, Emilie/A-6919-2013
OI picard, Emilie/0000-0002-2689-0510; VIVIEN, DENIS/0000-0002-7636-2185;
   Parcq, Jerome/0000-0001-9713-327X
CR Baron A, 2010, CELL DEATH DIFFER, V17, P860, DOI 10.1038/cdd.2009.172
   Chen CY, 2007, RETINA-J RET VIT DIS, V27, P321, DOI 10.1097/01.iae.0000237586.48231.75
   Chen SN, 2003, OPHTHALMOLOGY, V110, P704, DOI 10.1016/S0161-6420(02)01979-6
   Crisanti P, 2006, APOPTOSIS, V11, P983, DOI 10.1007/s10495-006-6750-2
   Dureau P, 2001, CURR EYE RES, V22, P74, DOI 10.1076/ceyr.22.1.74.6974
   Echeverry R, 2010, J CLIN INVEST, V120, P2194, DOI 10.1172/JCI41722
   GLATT H, 1982, AM J OPHTHALMOL, V94, P762, DOI 10.1016/0002-9394(82)90301-4
   Guthoff R, 2011, RETINA-J RET VIT DIS, V31, P36, DOI 10.1097/IAE.0b013e3181e37884
   Haile WB, 2012, J CEREBR BLOOD F MET, V32, P57, DOI 10.1038/jcbfm.2011.106
   Hassan AS, 1999, OPHTHALMOLOGY, V106, P1900, DOI 10.1016/S0161-6420(99)90399-8
   Hattenbach LO, 2001, OPHTHALMOLOGY, V108, P1485, DOI 10.1016/S0161-6420(01)00648-0
   Haupert CL, 2001, AM J OPHTHALMOL, V131, P208, DOI 10.1016/S0002-9394(00)00734-0
   Hesse L, 1999, GRAEF ARCH CLIN EXP, V237, P273, DOI 10.1007/s004170050232
   Hillenkamp J, 2010, GRAEF ARCH CLIN EXP, V248, P5, DOI 10.1007/s00417-009-1158-7
   HOYLAERTS M, 1982, J BIOL CHEM, V257, P2912
   Hrach CJ, 2000, ARCH OPHTHALMOL-CHIC, V118, P659
   JOHNSON MW, 1990, ARCH OPHTHALMOL-CHIC, V108, P259, DOI 10.1001/archopht.1990.01070040111042
   KARSCHIN A, 1988, J NEUROSCI, V8, P2895
   Kiernan DF, 2010, RETINA-J RET VIT DIS, V30, P1573, DOI 10.1097/IAE.0b013e3181e2266d
   Koeberle PD, 1999, EXP NEUROL, V158, P366, DOI 10.1006/exnr.1999.7113
   Kumada M, 2005, INVEST OPHTH VIS SCI, V46, P1504, DOI 10.1167/iovs.04-0595
   Kumada M, 2004, TOXICOL APPL PHARM, V200, P48, DOI 10.1016/j.taap.2004.03.017
   Kwong JMK, 2000, EXP EYE RES, V71, P437, DOI 10.1006/exer.2000.0894
   Lam TT, 1997, J OCUL PHARMACOL TH, V13, P129, DOI 10.1089/jop.1997.13.129
   LEWIS H, 1994, AM J OPHTHALMOL, V118, P559, DOI 10.1016/S0002-9394(14)76571-7
   Lopez-Atalaya JP, 2008, J CEREBR BLOOD F MET, V28, P1212, DOI 10.1038/jcbfm.2008.14
   LOSCALZO J, 1988, J CLIN INVEST, V82, P1391, DOI 10.1172/JCI113743
   Mali RS, 2005, FASEB J, V19, P1280, DOI 10.1096/fj.04-3403com
   Meyer CH, 2008, ACTA OPHTHALMOL, V86, P490, DOI 10.1111/j.1600-0420.2007.01125.x
   Nicole O, 2001, NAT MED, V7, P59, DOI 10.1038/83358
   Nucci C, 2005, NEUROTOXICOLOGY, V26, P935, DOI 10.1016/j.neuro.2005.06.002
   Oh HS, 2005, CURR EYE RES, V30, P291, DOI 10.1080/02713680590923267
   Olivier S, 2004, OPHTHALMOLOGY, V111, P1201, DOI 10.1016/j.ophtha.2003.10.020
   Rowley SA, 2004, BRIT J OPHTHALMOL, V88, P573, DOI 10.1136/bjo.2003.027466
   Samson AL, 2008, J NEUROCHEM, V107, P1091, DOI 10.1111/j.1471-4159.2008.05687.x
   Schulze SD, 2002, GRAEF ARCH CLIN EXP, V240, P717, DOI 10.1007/s00417-002-0516-5
   Scupola A, 1999, OPHTHALMOLOGICA, V213, P97, DOI 10.1159/000027400
   SILIPRANDI R, 1992, VISUAL NEUROSCI, V8, P567, DOI 10.1017/S0952523800005666
   Thelwell C, 2007, J THROMB HAEMOST, V5, P804, DOI 10.1111/j.1538-7836.2007.02422.x
   TOTH CA, 1991, ARCH OPHTHALMOL-CHIC, V109, P723, DOI 10.1001/archopht.1991.01080050139046
   Treumer F, 2012, BRIT J OPHTHALMOL, V96, P708, DOI 10.1136/bjophthalmol-2011-300655
   TSIRKA SE, 1995, NATURE, V377, P340, DOI 10.1038/377340a0
   van Zeeburg EJT, 2013, OPHTHALMOLOGICA, V229, P1, DOI 10.1159/000343066
   Wu F, 2013, MOL CELL NEUROSCI, V52, P9, DOI 10.1016/j.mcn.2012.10.001
   YAMAMOTO R, 1993, BRAIN RES, V631, P83, DOI 10.1016/0006-8993(93)91190-4
   Yamamoto T, 2008, GRAEF ARCH CLIN EXP, V246, P509, DOI 10.1007/s00417-007-0670-x
NR 46
TC 5
Z9 5
U1 0
U2 2
PU MOLECULAR VISION
PI ATLANTA
PA C/O JEFF BOATRIGHT, LAB B, 5500 EMORY EYE CENTER, 1327 CLIFTON RD, N E,
   ATLANTA, GA 30322 USA
SN 1090-0535
J9 MOL VIS
JI Mol. Vis.
PD NOV 10
PY 2016
VL 22
BP 1332
EP 1341
PG 10
WC Biochemistry & Molecular Biology; Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Ophthalmology
GA EK4PF
UT WOS:000393908400002
PM 27881907
DA 2022-11-30
ER

PT J
AU Veltmann, M
   Hollborn, M
   Reichenbach, A
   Wiedemann, P
   Kohen, L
   Bringmann, A
AF Veltmann, Moritz
   Hollborn, Margrit
   Reichenbach, Andreas
   Wiedemann, Peter
   Kohen, Leon
   Bringmann, Andreas
TI Osmotic Induction of Angiogenic Growth Factor Expression in Human
   Retinal Pigment Epithelial Cells
SO PLOS ONE
LA English
DT Article
ID NACL-INDUCED ACTIVATION; VITREORETINAL PROLIFERATIVE DISEASE;
   TRANSCRIPTION FACTOR TONEBP/OREBP; OXYGEN SPECIES CONTRIBUTE; PATHOGENIC
   T(H)17 CELLS; MACULAR DEGENERATION; HB-EGF; GENE-EXPRESSION;
   RISK-FACTORS; AGE
AB Background
   Although systemic hypertension is a risk factor of age-related macular degeneration, antihypertensive medications do not affect the risk of the disease. One condition that induces hypertension is high intake of dietary salt resulting in increased blood osmolarity. In order to prove the assumption that, in addition to hypertension, high osmolarity may aggravate neovascular retinal diseases, we determined the effect of extracellular hyperosmolarity on the expression of angiogenic cytokines in cultured human retinal pigment epithelial (RPE) cells.
   Methodology/Principal Findings
   Hyperosmolarity was induced by the addition of 100 mM NaCI or sucrose to the culture medium. Hypoxia and oxidative stress were induced by the addition of the hypoxia mimetic CoCl2 and H2O2, respectively. Alterations in gene expression were determined with realtime RT-PCR. Secretion of bFGF was evaluated by ELISA. Cell viability was determined by trypan blue exclusion. Nuclear factor of activated T cell 5 (NFAT5) expression was knocked down with siRNA. Hyperosmolarity induced transcriptional activation of bFGF, HB-EGF, and VEGF genes, while the expression of other cytokines such as EGF, PDGF-A, TGF-01, HGF, and PEDF was not or moderately altered. Hypoxia induced increased expression of the HB-EGF, EGF, PDGF-A, TGF-01, and VEGF genes, but not of the bFGF gene. Oxidative stress induced gene expression of HB-EGF, but not of bFGF. The hyperosmotic expression of the bFGF gene was dependent on the activation of p38a/0 MAPK, JNK, P13K, and the transcriptional activity of NFAT5. The hyperosmotic expression of the HB-EGF gene was dependent on the activation of p38a/0 MAPK, ERK1/2, and JNK. The hyperosmotic expression of bFGF, HB-EGF, and VEGF genes was reduced by inhibitors of TGF-01 superfamily activin receptor-like kinase receptors and the FGF receptor kinase, respectively. Hyperosmolarity induced secretion of bFGF that was reduced by inhibition of autocrine/paracrine TGF-01 signaling and by NFAT5 siRNA, respectively. Hyperosmolarity decreased the viability of the cells; this effect was not altered by exogenous bFGF and HBEGF. Various vegetable polyphenols (luteolin, quercetin, apigenin) inhibited the hyperosmotic expression of bFGF, HB-EGF, and NFAT5 genes.
   Conclusion
   Hyperosmolarity induces transcription of bFGF and HB-EGF genes, and secretion of bFGF from RPE cells. This is in part mediated by autocrine/paracrine TGF-131 and FGF signaling. It is suggested that high intake of dietary salt resulting in osmotic stress may aggravate neovascular retinal diseases via stimulation of the production of angiogenic factors in RPE cells, independent of hypertension.
C1 [Veltmann, Moritz; Hollborn, Margrit; Wiedemann, Peter; Kohen, Leon; Bringmann, Andreas] Univ Leipzig, Dept Ophthalmol, D-04109 Leipzig, Germany.
   [Veltmann, Moritz; Hollborn, Margrit; Wiedemann, Peter; Kohen, Leon; Bringmann, Andreas] Univ Leipzig, Hosp Eye, D-04109 Leipzig, Germany.
   [Reichenbach, Andreas] Univ Leipzig, Paul Flechsig Inst Brain Res, D-04109 Leipzig, Germany.
   [Kohen, Leon] Helios Klinikum Aue, Aue, Germany.
C3 Leipzig University; Leipzig University; Leipzig University; Helios
   Kliniken
RP Hollborn, M (通讯作者)，Univ Leipzig, Dept Ophthalmol, D-04109 Leipzig, Germany.; Hollborn, M (通讯作者)，Univ Leipzig, Hosp Eye, D-04109 Leipzig, Germany.
EM hollbm@medizin.uni-leipzig.de
RI Reichenbach, Andreas/B-2510-2017
FU Deutsche Forschungsgemeinschaft [KO 1547/7-1, GRK 1097/1, RE 849/16-1];
   Geschwister Freter Stiftung (Hannover, Germany)
FX This work was supported by grants from the Deutsche
   Forschungsgemeinschaft (KO 1547/7-1 to L.K.; GRK 1097/1, RE 849/16-1, to
   A.R.) and the Geschwister Freter Stiftung (Hannover, Germany). The
   funders had no role in study design, data collection and analysis,
   decision to publish, or preparation of the manuscript.
CR ADAMIS AP, 1993, BIOCHEM BIOPH RES CO, V193, P631, DOI 10.1006/bbrc.1993.1671
   An WG, 1998, NATURE, V392, P405, DOI 10.1038/32925
   Asakawa H, 1996, CELL BIOCHEM FUNCT, V14, P181
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Bringmann A, 2009, PROG RETIN EYE RES, V28, P423, DOI 10.1016/j.preteyeres.2009.07.001
   Burg MB, 2007, PHYSIOL REV, V87, P1441, DOI 10.1152/physrev.00056.2006
   Burg MB, 1997, ANNU REV PHYSIOL, V59, P437, DOI 10.1146/annurev.physiol.59.1.437
   Chen R, 2014, MOL VIS, V20, P242
   Cheung Chris Yk, 2013, J Mol Signal, V8, P5, DOI 10.1186/1750-2187-8-5
   Dias JRD, 2011, BRIT J OPHTHALMOL, V95, P1631, DOI 10.1136/bjo.2010.186361
   Esposito E, 2002, NEUROBIOL AGING, V23, P719, DOI 10.1016/S0197-4580(02)00078-7
   FAKTOROVICH EG, 1992, J NEUROSCI, V12, P3554
   Fischer OM, 2004, MOL CELL BIOL, V24, P5172, DOI 10.1128/MCB.24.12.5172-5183.2004
   Fraser-Bell S, 2008, AM J OPHTHALMOL, V145, P308, DOI 10.1016/j.ajo.2007.10.007
   Granner T, 2013, BRIT J OPHTHALMOL, V97, P371, DOI 10.1136/bjophthalmol-2012-302002
   Guillonneau X, 1997, EXP CELL RES, V233, P198, DOI 10.1006/excr.1997.3542
   Harnett ME, 1999, INVEST OPHTH VIS SCI, V40, P2945
   He FJ, 2005, HYPERTENSION, V45, P98, DOI 10.1161/01.HYP.0000149431.79450.a2
   Hollborn M, 2005, MOL VIS, V11, P397
   Hollborn M, 2004, GRAEF ARCH CLIN EXP, V242, P414, DOI 10.1007/s00417-004-0879-x
   Hollborn M, 2006, CURR EYE RES, V31, P863, DOI 10.1080/02713680600888807
   Hollborn M, 2015, MOL VIS, V21, P360
   Hollborn M, 2009, INVEST OPHTH VIS SCI, V50, P4452, DOI 10.1167/iovs.08-3194
   Hollborn MR, 2004, LAB INVEST, V84, P963, DOI 10.1038/labinvest.3700121
   Hollyfield JG, 2008, NAT MED, V14, P194, DOI 10.1038/nm1709
   Hyman L, 2000, ARCH OPHTHALMOL-CHIC, V118, P351, DOI 10.1001/archopht.118.3.351
   Inoue Y, 2013, INVEST OPHTH VIS SCI, V54, P3815, DOI 10.1167/iovs.12-11236
   Irarrazabal CE, 2006, P NATL ACAD SCI USA, V103, P8882, DOI 10.1073/pnas.0602911103
   Izumi Y, 2014, PHYSIOL REP, V2, DOI 10.14814/phy2.12000
   Jo N, 2006, AM J PATHOL, V168, P2036, DOI 10.2353/ajpath.2006.050588
   Kawasaka K, 1977, JPN J OPHTHALMOL, V31, P23
   Kenney WL, 2001, MED SCI SPORT EXER, V33, P1524, DOI 10.1097/00005768-200109000-00016
   KHAW KT, 1988, CIRCULATION, V77, P53, DOI 10.1161/01.CIR.77.1.53
   Kippenberger S, 2005, FEBS LETT, V579, P207, DOI 10.1016/j.febslet.2004.11.077
   Klein R, 2007, OPHTHALMOLOGY, V114, P253, DOI 10.1016/j.ophtha.2006.10.040
   Klein R, 2010, ARCH OPHTHALMOL-CHIC, V128, P750, DOI 10.1001/archophthalmol.2010.92
   Kleinewietfeld M, 2013, NATURE, V496, P518, DOI 10.1038/nature11868
   Koh YH, 2001, J BIOCHEM-TOKYO, V130, P351, DOI 10.1093/oxfordjournals.jbchem.a002993
   Kuper C, 2014, FRONT PHYSIOL, V5, DOI 10.3389/fphys.2014.00293
   Lambert JD, 2010, ARCH BIOCHEM BIOPHYS, V501, P65, DOI 10.1016/j.abb.2010.06.013
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Lopez-Rodriguez C, 2001, IMMUNITY, V15, P47, DOI 10.1016/S1074-7613(01)00165-0
   Miller JW, 2010, JPN J OPHTHALMOL, V54, P523, DOI 10.1007/s10384-010-0863-4
   Miyakawa H, 1998, AM J PHYSIOL-RENAL, V274, pF753, DOI 10.1152/ajprenal.1998.274.4.F753
   Mousa SA, 1999, J CELL BIOCHEM, V74, P135, DOI 10.1002/(SICI)1097-4644(19990701)74:1<135::AID-JCB15>3.0.CO;2-#
   Nagineni CN, 2003, J CELL PHYSIOL, V197, P453, DOI 10.1002/jcp.10378
   Obika Lf O, 2013, Niger J Physiol Sci, V28, P83
   Orgul S, 1993, Ger J Ophthalmol, V2, P436
   Oshima Y, 2004, J CELL PHYSIOL, V201, P393, DOI 10.1002/jcp.20110
   Park SW, 2012, INVEST OPHTH VIS SCI, V53, P7718, DOI 10.1167/iovs.11-8790
   Peng PH, 2008, EXP EYE RES, V86, P637, DOI 10.1016/j.exer.2008.01.008
   Roth F, 2004, GRAEF ARCH CLIN EXP, V242, P710, DOI 10.1007/s00417-004-0976-x
   Schlingemann RO, 2009, PROG BRAIN RES, V175, P253, DOI 10.1016/S0079-6123(09)17517-9
   Schlingemann RO, 2004, GRAEF ARCH CLIN EXP, V242, P91, DOI 10.1007/s00417-003-0828-0
   SHIRAO Y, 1987, INVEST OPHTH VIS SCI, V28, P2015
   Silva KC, 2013, INVEST OPHTH VIS SCI, V54, P1325, DOI 10.1167/iovs.12-10647
   Sivakumar V, 2008, J NEUROSCI RES, V86, P702, DOI 10.1002/jnr.21519
   SOUBRANE G, 1994, CURR EYE RES, V13, P183, DOI 10.3109/02713689408995776
   Steinberg RH, 1985, PROG RETIN RES, V4, P33, DOI [10.1016/0278-4327(85)90004-5, DOI 10.1016/0278-4327(85)90004-5]
   Tranos P, 2013, DRUG DES DEV THER, V7, P485, DOI 10.2147/DDDT.S43470
   Van Leeuwen R, 2004, OPHTHALMOLOGY, V111, P1169, DOI 10.1016/j.ophtha.2003.10.024
   Wang H, 2015, AM J PHYSIOL-RENAL, V308, pF140, DOI 10.1152/ajprenal.00471.2014
   Weuste M, 2006, BIOCHEM BIOPH RES CO, V347, P310, DOI 10.1016/j.bbrc.2006.06.077
   Witmer AN, 2003, PROG RETIN EYE RES, V22, P1, DOI 10.1016/S1350-9462(02)00043-5
   Wu C, 2013, NATURE, V496, P513, DOI 10.1038/nature11984
   Yan Q, 2001, IN VITRO CELL DEV-AN, V37, P45
   Zhou XM, 2008, P NATL ACAD SCI USA, V105, P5620, DOI 10.1073/pnas.0801453105
   Zhou XM, 2006, AM J PHYSIOL-RENAL, V290, pF1169, DOI 10.1152/ajprenal.00378.2005
   Zhou XM, 2005, AM J PHYSIOL-RENAL, V289, pF377, DOI 10.1152/ajprenal.00463.2004
NR 69
TC 29
Z9 29
U1 1
U2 13
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JAN 22
PY 2016
VL 11
IS 1
AR e0147312
DI 10.1371/journal.pone.0147312
PG 21
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA DB6WB
UT WOS:000368655300092
PM 26800359
OA Green Published, Green Submitted, gold
DA 2022-11-30
ER

PT J
AU Framme, C
   Schweizer, P
   Imesch, M
   Wolf, S
   Wolf-Schnurrbusch, U
AF Framme, Carsten
   Schweizer, Paul
   Imesch, Manfred
   Wolf, Sebastian
   Wolf-Schnurrbusch, Ute
TI Behavior of SD-OCT-Detected Hyperreflective Foci in the Retina of
   Anti-VEGF-Treated Patients with Diabetic Macular Edema
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID OPTICAL COHERENCE TOMOGRAPHY; RANIBIZUMAB; DEGENERATION; THERAPY; AMD
AB PURPOSE. Hyperreflective foci (HFs) are observable within the neurosensory retina in diabetic macular edema (DME) using spectral domain optical coherence tomography (SD-OCT). HFs have also been seen in wet age-related macular degeneration (AMD), although the origin is still unknown; however, they reduced significantly during anti-VEGF (vascular endothelial growth factor) therapy, and their baseline amount seemed to correlate with treatment success. In this study the behavior of HFs was evaluated during anti-VEGF therapy for DME.
   METHODS. Fifty-one patients (mean age: 67 years) underwent SD-OCT before and one month after one anti-VEGF injection (ranibizumab: n = 30; bevacizumab: n = 21). The HFs were semiquantitatively counted, assigned to three groups (group A: HFs n = 1-10; group B: n = 11-20; group C: n > 20), and correlated to the course of visual acuity and foveal thickness (paired t-test). Additionally the baseline HbA1c was categorized and correlated to baseline HFs (Spearman Rho).
   RESULTS. In all eyes, HFs of various amounts were detected in the foveal and parafoveal area. The mean number of HFs reduced significantly from 16.02 to 14.32 in all patients (P = 0.000), whereas foveal thickness reduced from 445.5 to 373.9 mu m (P = 0.000) and visual acuity increased from 62.0 to 66.0 ETDRS letters (P = 0.003). Regarding the three HF groups, a reduction of the level stages was observed in 43.1% (stable: 54.9%; more: 2.0%). This reflects a HF distribution change from 31.4% to 62.7% (group A), from 45.1% to 31.4% (group B), and from 23.5% to 5.9% (group C). The HbA1c correlated significantly to the overall HF amount at baseline (0.880; P = 0.000); however, no distinct overall correlation was found between the HF reduction and the course of visual acuity or retinal thickness. Only in cases of complete edema resolution (25%) did HFs reduce significantly (P = 0.008).
   CONCLUSIONS. As in wet AMD, HFs are frequently found in DME and behave similarly under anti-VEGF therapy. Thus, a HF reduction was observable mainly in cases of complete edema resolution; however, no distinct correlation with visual acuity was noticed, presumably mainly due to the enhanced inhomogeneity in the disease progress of DME. Interestingly, the baseline HF amount seems to correlate positively with HbA1c values indicating the severity of disease. (Invest Ophthalmol Vis Sci. 2012;53:5814-5818) DOI:10.1167/iovs.12-9950
C1 [Framme, Carsten; Schweizer, Paul; Imesch, Manfred; Wolf, Sebastian; Wolf-Schnurrbusch, Ute] Inselspital Bern, Univ Eye Hosp Bern, CH-3010 Bern, Switzerland.
C3 University of Bern; University Hospital of Bern
RP Framme, C (通讯作者)，Inselspital Bern, Univ Eye Hosp Bern, Freiburgstr 10, CH-3010 Bern, Switzerland.
EM carsten.framme@insel.ch
RI Wolf, Sebastian/B-8782-2008
OI Wolf, Sebastian/0000-0002-7467-7028
CR Bolz M, 2009, OPHTHALMOLOGY, V116, P914, DOI 10.1016/j.ophtha.2008.12.039
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Framme C, 2012, ACTA OPHTHALMOL, V90, P49, DOI 10.1111/j.1755-3768.2010.01940.x
   Framme C, 2010, INVEST OPHTH VIS SCI, V51, P5965, DOI 10.1167/iovs.10-5779
   Haller JA, 2010, OPHTHALMOLOGY, V117, P1087, DOI 10.1016/j.ophtha.2009.10.040
   Kiss CG, 2009, INVEST OPHTH VIS SCI, V50, P2376, DOI 10.1167/iovs.08-2017
   Massin P, 2010, DIABETES CARE, V33, P2399, DOI 10.2337/dc10-0493
   Mitchell P, 2011, OPHTHALMOLOGY, V118, P615, DOI 10.1016/j.ophtha.2011.01.031
   Nowak JZ, 2006, PHARMACOL REP, V58, P353
   Ota M, 2010, OPHTHALMOLOGY, V117, P1996, DOI 10.1016/j.ophtha.2010.06.019
   Pauleikhoff D, 2011, GRAEF ARCH CLIN EXP, V249, P631, DOI 10.1007/s00417-011-1639-3
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rothenbuehler SP, 2009, AM J OPHTHALMOL, V147, P831, DOI 10.1016/j.ajo.2008.12.005
   Uji A, 2012, AM J OPHTHALMOL, V153, P710, DOI 10.1016/j.ajo.2011.08.041
   Wolf S, 2010, OPHTHALMOLOGICA, V224, P333, DOI 10.1159/000313814
NR 16
TC 85
Z9 88
U1 0
U2 8
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD AUG
PY 2012
VL 53
IS 9
BP 5814
EP 5818
DI 10.1167/iovs.12-9950
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 004QE
UT WOS:000308695400091
PM 22836760
DA 2022-11-30
ER

PT J
AU Lindeke-Myers, A
   Zhao, PYC
   Meyer, BI
   Liu, EA
   Levine, DA
   Bennett, OM
   Ji, S
   Newman-Casey, PA
   Rao, RC
   Jain, N
AF Lindeke-Myers, Aaron
   Zhao, Peter Yu Cheng
   Meyer, Benjamin I.
   Liu, Elaine A.
   Levine, David A.
   Bennett, Olivia M.
   Ji, Sunjong
   Newman-Casey, Paula Anne
   Rao, Rajesh C.
   Jain, Nieraj
TI Patient Perceptions of SARS-CoV-2 Exposure Risk and Association With
   Continuity of Ophthalmic Care
SO JAMA OPHTHALMOLOGY
LA English
DT Article
AB IMPORTANCE Patient perceptions regarding the risks of obtaining in-person ophthalmic care during the coronavirus disease 2019 (COVID-19) pandemic may affect adherence to recommended treatment plans and influence visual outcomes. A deeper understanding of patient perspectives will inform strategies to optimize adherence with vision-preserving therapies.
   OBJECTIVE To evaluate perceptions of COVID-19 exposure risk and their association with appointment attendance among patients at high risk of both reversible and irreversible vision loss from lapses in care. DESIGN, SETTING, AND PARTICIPANTS This survey study included a nonvalidated telephone survey designed in April and May of 2020 and a retrospective medical record review conducted in parallel with survey administration from May 22 to August 18, 2020. Participants were recruited from 2 tertiary eye care centers (Emory Eye Center in Atlanta, Georgia, and W.K. Kellogg Eye Center in Ann Arbor, Michigan). The study included a random sample of patients with diagnoses of exudative age-related macular degeneration (AMD) or diabetic retinopathy (DR) who received an intravitreal injection between January 6 and March 13, 2020, and were scheduled for a second injection between March 13 and May 6, 2020.
   MAIN OUTCOMES AND MEASURES Association between perceptions regarding COVID-19 risks and loss to follow-up.
   RESULTS Of 1004 eligible patients, 423 (42%) were successfully contacted, and 348 (82%) agreed to participate (participants' mean [SD] age, 75 [12] years; 195 women [56%]; 287 White [82%] patients). Respondents had a mean (SD) of 2.7 (1.1) comorbidities associated with severe COVID-19, and 77 (22%) knew someone with COVID-19. Of all respondents, 163 (47%) were very concerned or moderately concerned about vision loss from missed treatments during the pandemic. Although 208 (60%) believed the COVID-19 virus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), exposure at the eye clinic was extremely unlikely or unlikely, 49 (14%) believed it was extremely likely or likely. Seventy-eight participants (22%) were lost to follow-up. Concern regarding COVID-19 exposure during clinic visits (odds ratio [OR], 3.9; 95% CI, 1.8-8.4) and diagnosis of DR (vs AMD) (OR, 8.130; 95% CI, 3.367-20.408) were associated with an increase in likelihood of loss to follow-up.
   CONCLUSIONS AND RELEVANCE Among patients at high risk for vision loss from lapses in care, many expressed concerns regarding the effect of the pandemic on their ability to receive timely care. Survey results suggest that fear of SARS-CoV-2 exposure was associated with a roughly 4-fold increase in the odds of patient loss to follow-up. These results support the potential importance of clearly conveying infection-control measures.
C1 [Lindeke-Myers, Aaron; Meyer, Benjamin I.] Emory Univ, Sch Med, Atlanta, GA USA.
   [Zhao, Peter Yu Cheng; Newman-Casey, Paula Anne; Rao, Rajesh C.] Univ Michigan, WK Kellogg Eye Ctr, Dept Ophthalmol & Visual Sci, Ann Arbor, MI 48109 USA.
   [Liu, Elaine A.; Bennett, Olivia M.; Ji, Sunjong] Univ Michigan, Med Sch, Ann Arbor, MI 48109 USA.
   [Levine, David A.; Jain, Nieraj] Emory Univ, Sch Med, Dept Ophthalmol, 1365B Clifton Rd NE,Ste 2400, Atlanta, GA 30322 USA.
   [Rao, Rajesh C.] Univ Michigan, Dept Pathol, Ann Arbor, MI 48109 USA.
   [Rao, Rajesh C.] Univ Michigan, Dept Computat Med & Bioinformat, Ann Arbor, MI 48109 USA.
   [Rao, Rajesh C.] Univ Michigan, Comprehens Canc Ctr, Ann Arbor, MI 48109 USA.
   [Rao, Rajesh C.] Univ Michigan, A Alfred Taubman Med Res Inst, Ann Arbor, MI 48109 USA.
   [Rao, Rajesh C.] Vet Adm Ann Arbor Healthcare Syst, Sect Ophthalmol, Surg Serv, Ann Arbor, MI USA.
C3 Emory University; University of Michigan System; University of Michigan;
   University of Michigan System; University of Michigan; Emory University;
   University of Michigan System; University of Michigan; University of
   Michigan System; University of Michigan; University of Michigan System;
   University of Michigan; University of Michigan System; University of
   Michigan
RP Jain, N (通讯作者)，Emory Univ, Sch Med, Dept Ophthalmol, 1365B Clifton Rd NE,Ste 2400, Atlanta, GA 30322 USA.; Rao, RC (通讯作者)，Kellogg Eye Ctr, 1000 Wall St,Brehm Room 8333, Ann Arbor, MI 48105 USA.
EM rajeshr@umich.edu; nieraj.jain@emory.edu
RI Rao, Rajesh C./N-1107-2017
OI Rao, Rajesh C./0000-0002-5776-8366; Zhao, Peter/0000-0003-1430-1034
FU Foundation Fighting Blindness [CD-C-0918-0748-EEC]; Foundation Fighting
   Blindness Clinical/Research Fellowship [CD-CL-0619-0758-UMICH]; Heed
   Ophthalmic Foundation
FX This study was supported by award CD-C-0918-0748-EEC from the Foundation
   Fighting Blindness Career Development (Dr Jain), award
   CD-CL-0619-0758-UMICH from the Foundation Fighting Blindness
   Clinical/Research Fellowship (Dr Zhao), and funding from the Heed
   Ophthalmic Foundation (Dr Zhao).
CR American Academy of Ophthalmology, 2020, IMP COR UPD OPHTH
   American Academy of Ophthalmology, 2020, REC URG NON PAT CAR
   American Society of Retina Specialists, 2020, COVID 19 SURV JUL 14
   Bursac Z, 2008, SOURCE CODE BIOL MED, V3, DOI 10.1186/1751-0473-3-17
   Centers for Disease Control and Prevention (CDC), 2020, INF HEALTHC PROF COR
   Czeisler ME, 2020, MMWR-MORBID MORTAL W, V69, P1250, DOI 10.15585/mmwr.mm6936a4
   Elam AR, 2020, JAMA OPHTHALMOL, V138, P988, DOI 10.1001/jamaophthalmol.2020.3244
   Georgia Department of Public Health, 2020, GEORG DEP PUBL HLTH
   Hendrix MJ, 2020, MMWR-MORBID MORTAL W, V69, P930, DOI 10.15585/mmwr.mm6928e2
   Khurana R., 2020, CORONAVIRUS YOUR MAS
   Lang T, 2020, NATURE, V583, P333, DOI 10.1038/d41586-020-02004-1
   Mandavilli A., 2020, BIGGEST MONSTER IS S
   Mangione CM, 2001, ARCH OPHTHALMOL-CHIC, V119, P1050, DOI 10.1001/archopht.119.7.1050
   Mehrotra A., 2020, COMMONWEALTH FUND, DOI DOI 10.26099/2V5T-9Y63
   Michigan.gov, COR MICH DAT
   Morse AR, 2019, JAMA OPHTHALMOL, V137, P634, DOI 10.1001/jamaophthalmol.2019.0446
   Muller S, 2017, GRAEF ARCH CLIN EXP, V255, P2237, DOI 10.1007/s00417-017-3739-1
   Osterholm, 2020, COVID 19 CTR INFECT
   Ramakrishnan MS, 2020, JAMA OPHTHALMOL, V138, P237, DOI 10.1001/jamaophthalmol.2019.4577
   Romano F, 2020, OPHTHALMOL RETINA, V4, P1209, DOI 10.1016/j.oret.2020.06.027
   Saban O, 2020, GRAEF ARCH CLIN EXP, V258, P2271, DOI 10.1007/s00417-020-04790-w
   Smith KF, 2014, J R SOC INTERFACE, V11, DOI 10.1098/rsif.2014.0950
   United States Census Bureau, QUICKFACTS GEORG MIC
   Wong SCY, 2020, J HOSP INFECT, V105, P119, DOI 10.1016/j.jhin.2020.03.036
NR 24
TC 25
Z9 25
U1 1
U2 4
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 2168-6165
EI 2168-6173
J9 JAMA OPHTHALMOL
JI JAMA Ophthalmol.
PD MAY
PY 2021
VL 139
IS 5
BP 508
EP 515
DI 10.1001/jamaophthalmol.2021.0114
EA MAR 2021
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA SF2VX
UT WOS:000627901900002
PM 33704358
OA Green Published, Bronze
DA 2022-11-30
ER

PT J
AU Mitchell, P
   Bandello, F
   Schmidt-Erfurth, U
   Lang, GE
   Massin, P
   Schlingemann, RO
   Sutter, F
   Simader, C
   Burian, G
   Gerstner, O
   Weichselberger, A
AF Mitchell, Paul
   Bandello, Francesco
   Schmidt-Erfurth, Ursula
   Lang, Gabriele E.
   Massin, Pascale
   Schlingemann, Reinier O.
   Sutter, Florian
   Simader, Christian
   Burian, Gabriela
   Gerstner, Ortrud
   Weichselberger, Andreas
CA RESTORE Study Grp
TI The RESTORE Study Ranibizumab Monotherapy or Combined with Laser versus
   Laser Monotherapy for Diabetic Macular Edema
SO OPHTHALMOLOGY
LA English
DT Article
ID VISUAL IMPAIRMENT; MACULAR EDEMA; RETINOPATHY; LIFE
AB Objective: To demonstrate superiority of ranibizumab 0.5 mg monotherapy or combined with laser over laser alone based on mean average change in best-corrected visual acuity (BCVA) over 12 months in diabetic macular edema (DME).
   Design: A 12-month, randomized, double-masked, multicenter, laser-controlled phase III study.
   Participants: We included 345 patients aged >= 18 years, with type 1 or 2 diabetes mellitus and visual impairment due to DME.
   Methods: Patients were randomized to ranibizumab + sham laser (n = 116), ranibizumab + laser (n = 118), or sham injections + laser (n = 111). Ranibizumab/sham was given for 3 months then pro re nata (PRN); laser/sham laser was given at baseline then PRN (patients had scheduled monthly visits).
   Main Outcome Measures: Mean average change in BCVA from baseline to month 1 through 12 and safety.
   Results: Ranibizumab alone and combined with laser were superior to laser monotherapy in improving mean average change in BCVA letter score from baseline to month 1 through 12 (+6.1 and +5.9 vs +0.8; both P<0.0001). At month 12, a significantly greater proportion of patients had a BCVA letter score >= 15 and BCVA letter score level >73 (20/40 Snellen equivalent) with ranibizumab (22.6% and 53%, respectively) and ranibizumab + laser (22.9% and 44.9%) versus laser (8.2% and 23.6%). The mean central retinal thickness was significantly reduced from baseline with ranibizumab (-118.7 mu m) and ranibizumab + laser (-128.3 mu m) versus laser (-61.3 mu m; both P<0.001). Health-related quality of life, assessed through National Eye Institute Visual Function Questionnaire (NEI VFQ-25), improved significantly from baseline with ranibizumab alone and combined with laser (P<0.05 for composite score and vision-related subscales) versus laser. Patients received similar to 7 (mean) ranibizumab/sham injections over 12 months. No endophthalmitis cases occurred. Increased intraocular pressure was reported for 1 patient each in the ranibizumab arms. Ranibizumab monotherapy or combined with laser was not associated with an increased risk of cardiovascular or cerebrovascular events in this study.
   Conclusions: Ranibizumab monotherapy and combined with laser provided superior visual acuity gain over standard laser in patients with visual impairment due to DME. Visual acuity gains were associated with significant gains in VFQ-25 scores. At 1 year, no differences were detected between the ranibizumab and ranibizumab + laser arms. Ranibizumab monotherapy and combined with laser had a safety profile in DME similar to that in age-related macular degeneration.
   Financial Disclosure(s): Proprietary or commercial disclosure may be found after the references. Ophthalmology 2011; 118: 615-625 (C) 2011 by the American Academy of Ophthalmology.
C1 [Mitchell, Paul] Univ Sydney, Westmead Millennium Inst, Ctr Vis Res, Sydney, NSW 2006, Australia.
   [Bandello, Francesco] Univ Vita Salute, Inst Sci, Dept Ophthalmol, Milan, Italy.
   [Schmidt-Erfurth, Ursula] Univ Vienna, Univ Klin Augenheilkunde & Optometrie, Vienna, Austria.
   [Lang, Gabriele E.] Univ Eye Hosp Ulm, Dept Ophthalmol, Div Med Retina & Laser Surg, Ulm, Germany.
   [Massin, Pascale] Hop Lariboisiere, AP HP, Dept Ophthalmol, F-75475 Paris, France.
   [Schlingemann, Reinier O.] Univ Amsterdam, Acad Med Ctr, Dept Ophthalmol, NL-1105 AZ Amsterdam, Netherlands.
   [Sutter, Florian] Univ Zurich, Augenklin Nordtrakt 2, Zurich, Switzerland.
   [Simader, Christian] Med Univ Vienna, Dept Ophthalmol, Vienna Reading Ctr, Vienna, Austria.
   [Burian, Gabriela; Gerstner, Ortrud; Weichselberger, Andreas] Novartis Pharma AG, Basel, Switzerland.
C3 University of Sydney; Westmead Institute for Medical Research;
   Vita-Salute San Raffaele University; University of Vienna; Ulm
   University; Assistance Publique Hopitaux Paris (APHP); Hopital
   Universitaire Lariboisiere-Fernand-Widal - APHP; UDICE-French Research
   Universities; Universite Paris Cite; University of Amsterdam; Academic
   Medical Center Amsterdam; University of Zurich; Medical University of
   Vienna; Novartis
RP Mitchell, P (通讯作者)，Univ Sydney, Westmead Hosp, Ctr Vis Res, Sydney, NSW 2006, Australia.
EM paul.mitchell@sydney.edu.au
RI CLIHON, Residencia Medica/K-4896-2013; bandello,
   francesco/AAH-2405-2019; Mitchell, Paul/P-1498-2014
OI CLIHON, Residencia Medica/0000-0001-6734-2513; bandello,
   francesco/0000-0003-3238-9682; Simader, Christian/0000-0002-1784-2883;
   Schmidt-Erfurth, Ursula/0000-0002-7788-7311; Beare,
   Nicholas/0000-0001-8086-990X
FU Novartis Pharma AG, Switzerland
FX Sponsored by Novartis Pharma AG, Switzerland. The study is registered
   with www.clinicaltrial.gov under number NCT00687804.
CR AIELLO LP, 1994, NEW ENGL J MED, V331, P1480, DOI 10.1056/NEJM199412013312203
   Beck RW, 2009, ARCH OPHTHALMOL-CHIC, V127, P245, DOI 10.1001/archophthalmol.2008.610
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Chia EM, 2004, INVEST OPHTH VIS SCI, V45, P71, DOI 10.1167/iovs.03-0661
   *CLIN, NOV EFF SAF RAN 2 TR
   *CLIN, NOV EFF SAF RAN INTR
   *CLIN, GEN STUD RAN INJ SUB
   Elman MJ, 2010, OPHTHALMOLOGY, V117, P1064, DOI 10.1016/j.ophtha.2010.02.031
   Ferreira PL, 2008, QUAL LIFE RES, V17, P1031, DOI 10.1007/s11136-008-9368-8
   FERRIS FL, 1987, OPHTHALMOLOGY, V94, P761
   Ip MS, 2008, OPHTHALMOLOGY, V115, P1447, DOI 10.1016/j.ophtha.2008.06.015
   Klein R, 2009, OPHTHALMOLOGY, V116, P497, DOI 10.1016/j.ophtha.2008.10.016
   Massin P, 2010, DIABETES CARE, V33, P2399, DOI 10.2337/dc10-0493
   MOSS SE, 1994, OPHTHALMOLOGY, V101, P1061
   Owen Christopher G, 2006, BMC Ophthalmol, V6, P24, DOI 10.1186/1471-2415-6-24
   PATZ A, 1985, ARCH OPHTHALMOL-CHIC, V103, P1796, DOI 10.1001/archopht.1985.01050120030015
   Paulus YM, 2009, GERIATRICS-US, V64, P16
   Quan DN, 2010, OPHTHALMOLOGY, V117, P2146, DOI 10.1016/j.ophtha.2010.08.016
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Suner IJ, 2009, INVEST OPHTH VIS SCI, V50, P3629, DOI 10.1167/iovs.08-3225
   West SK, 2002, ARCH OPHTHALMOL-CHIC, V120, P774
NR 21
TC 946
Z9 1006
U1 1
U2 71
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD APR
PY 2011
VL 118
IS 4
BP 615
EP 625
DI 10.1016/j.ophtha.2011.01.031
PG 11
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 744DS
UT WOS:000289075200003
PM 21459215
OA hybrid
DA 2022-11-30
ER

PT J
AU de Gage, SB
   Bertrand, M
   Grimaldi, S
   Zureik, M
AF Billioti de Gage, Sophie
   Bertrand, Marion
   Grimaldi, Sebastien
   Zureik, Mahmoud
TI Intravitreal anti-VEGF use in France: a cross-sectional and longitudinal
   Nationwide observational study
SO ACTA OPHTHALMOLOGICA
LA English
DT Article
DE aflibercept; age-related macular degeneration; choroidal
   neovascularization; intravitreal anti-vascular endothelial (anti-VEGF)
   growth factor; longitudinal study; macular angiogenesis;
   pharmacoepidemiology; ranibizumab; real-world study
ID MACULAR DEGENERATION; NEOVASCULAR AMD; VISUAL-ACUITY; REAL-LIFE; AGE;
   RANIBIZUMAB; OUTCOMES; ASSOCIATION; AFLIBERCEPT; MANAGEMENT
AB Purpose To describe the sociodemographic, medical and management characteristics of patients using intravitreal (IVT) anti-vascular endothelial growth factors (VEGF) in France.
   Methods An observational study was conducted in patients treated with IVT ranibizumab or aflibercept, aged 18 years or older using the French National Health Insurance Databases covering 99% of the French population. Patients currently treated in 2018 were included in a cross-sectional approach to describe treatment history over the previous 6 years. Patients newly treated between 2014 and 2018 were included in a longitudinal approach to describe treatment management during up to 6 years of follow-up. Sociodemographic characteristics and medical history were described in both populations. The analyses were performed at the patient level, as no distinction between the eyes could be made.
   Results A total of 224 775 current users of IVT anti-VEGF in 2018 (mean age 78.1 +/- 11.3 years, 60% female) and 330 969 new users between 2014 and 2018 (mean age 75.9 +/- 12.0 years, 59% female) were included. In both populations cardiovascular comorbidities or risk factors were frequent and the main treatment indications were age-related macular degeneration and diabetic macular oedema. Among current users of IVT anti-VEGF in 2018, the mean number of years receiving a treatment was 2.9 +/- 2.0 years, with a mean of 13.7 +/- 11.8 dispensations. In the longitudinal approach, a 26% increase in IVT anti-VEGF initiation was observed between 2014 and 2018. For new users, the mean number of years receiving a treatment was 1.6 +/- 1.6 and 67% had at least three dispensations within the first three months. A treatment interruption was observed for 83% of new users and occurred on average of 6.1 +/- 8.1 months after initiation. The mean number of dispensations was 4.8 +/- 2.8 in the first year and 2.2 +/- 2.9 in the second year. The mean number of eye monitoring examinations was 6.5 +/- 4.7 in the first year and 4.6 +/- 4.4 in the second year.
   Conclusion This study described the real-world conditions of IVT anti-VEGF dispensing at the entire French population scale. Less frequent dispensations and surveillance examinations were observed than in monthly schemes applied in registration trials for IVT anti-VEGF. These results may indicate a lack of systematic monitoring associated with fewer injections and/or clinicians' preference for more flexible and personalized injection schemes than those originally recommended.
C1 [Billioti de Gage, Sophie; Bertrand, Marion; Zureik, Mahmoud] EPI PHARE French Natl Agcy Med & Hlth Prod Safety, 143 Blvd Anatole France, F-93200 St Denis, France.
   [Billioti de Gage, Sophie; Bertrand, Marion; Zureik, Mahmoud] French Natl Hlth Insurance CNAM, 143 Blvd Anatole France, F-93200 St Denis, France.
   [Grimaldi, Sebastien] Ophthalmol Ctr, Chatellerault, France.
   [Zureik, Mahmoud] Univ Paris Sud, Univ Paris Saclay, UVSQ, INSERM,Antiinfect Evas & Pharmacoepidemiol,CESP, Montigny Le Bretonneux, France.
C3 Institut National de la Sante et de la Recherche Medicale (Inserm);
   UDICE-French Research Universities; Universite Paris Saclay
RP de Gage, SB (通讯作者)，EPI PHARE French Natl Agcy Med & Hlth Prod Safety, 143 Blvd Anatole France, F-93200 St Denis, France.; de Gage, SB (通讯作者)，French Natl Hlth Insurance CNAM, 143 Blvd Anatole France, F-93200 St Denis, France.
EM sophie.billioti-de-gage@ansm.sante.fr
RI Zureik, Mahmoud/F-7855-2018
OI Zureik, Mahmoud/0000-0002-8393-4217
CR Bezin J, 2017, PHARMACOEPIDEM DR S, V26, P954, DOI 10.1002/pds.4233
   Bouillon K, 2018, JAMA-J AM MED ASSOC, V319, P375, DOI 10.1001/jama.2017.21269
   Bouillon K, 2015, LANCET HAEMATOL, V2, pE150, DOI 10.1016/S2352-3026(15)00027-7
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Cohen SY, 2013, RETINA-J RET VIT DIS, V33, P474, DOI 10.1097/IAE.0b013e31827b6324
   Cohen SY, 2009, AM J OPHTHALMOL, V148, P409, DOI 10.1016/j.ajo.2009.04.001
   European Medicine Agency, 2009, LUC RAN SUMM PROD CH
   European Medicine Agency, 2012, EYL AFL SUMM PROD CH
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Gillies MC, 2016, OPHTHALMOLOGY, V123, P2545, DOI 10.1016/j.ophtha.2016.08.016
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Holz FG, 2015, BRIT J OPHTHALMOL, V99, P220, DOI 10.1136/bjophthalmol-2014-305327
   Hufendiek K, 2018, KLIN MONATSBL AUGENH, V235, P930, DOI 10.1055/s-0042-122340
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Kiss S, 2020, OPHTHALMOLOGY, V127, P1179, DOI 10.1016/j.ophtha.2020.02.027
   Lambert NG, 2016, PROG RETIN EYE RES, V54, P64, DOI 10.1016/j.preteyeres.2016.04.003
   Lemaitre M, 2017, JAMA-J AM MED ASSOC, V318, P1679, DOI 10.1001/jama.2017.16071
   Li JQ, 2020, BRIT J OPHTHALMOL, V104, P1077, DOI 10.1136/bjophthalmol-2019-314422
   Lotery A, 2017, EYE, V31, P1697, DOI 10.1038/eye.2017.143
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Mehta H, 2020, CLIN OPHTHALMOL, V14, P3331, DOI 10.2147/OPTH.S275977
   Oubraham H, 2011, RETINA-J RET VIT DIS, V31, P26, DOI 10.1097/IAE.0b013e3181de5609
   Raguideau F, 2016, JAMA OPHTHALMOL, V134, P415, DOI 10.1001/jamaophthalmol.2015.6205
   Rey G, 2009, BMC PUBLIC HEALTH, V9, DOI 10.1186/1471-2458-9-33
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Sayanagi K, 2019, GRAEF ARCH CLIN EXP, V257, P749, DOI 10.1007/s00417-018-04214-w
   Semoun O, 2017, J FR OPHTALMOL, V40, P169, DOI 10.1016/j.jfo.2016.12.003
   Souied EH, 2015, ACTA OPHTHALMOL, V93, pE179, DOI 10.1111/aos.12517
   Spaide R, 2007, AM J OPHTHALMOL, V143, P679, DOI 10.1016/j.ajo.2007.02.024
   Weber M, 2019, BMJ OPEN OPHTHALMOL, V4, DOI 10.1136/bmjophth-2017-000109
   Weill A, 2016, BMJ-BRIT MED J, V353, DOI 10.1136/bmj.i2002
   Westborg I, 2017, ACTA OPHTHALMOL, V95, P787, DOI 10.1111/aos.13539
NR 32
TC 6
Z9 6
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1755-375X
EI 1755-3768
J9 ACTA OPHTHALMOL
JI Acta Ophthalmol.
PD MAR
PY 2022
VL 100
IS 2
BP E502
EP E511
DI 10.1111/aos.14929
EA JUN 2021
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA YX9MP
UT WOS:000661231000001
PM 34126649
OA Green Published
DA 2022-11-30
ER

PT J
AU Jiang, W
   Zhang, WY
   Chiou, GCY
AF Jiang, Wei
   Zhang, Wan-Yu
   Chiou, George C. Y.
TI Effects of hydralazine on NaIO3 -induced rat retinal pigment epithelium
   degeneration
SO INTERNATIONAL JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE retinal pigment epithelium; sodium iodate; age-related macular
   degeneration; hydralazine
ID SODIUM IODATE INJECTION; TISSUE BLOOD-FLOW; RABBIT; ADIPOSE; MODEL; MICE
AB AIM: To study the effects of 10g/L hydralazine eye drops on 35mg/kg NaIO3 -induced degeneration in rat eyes.
   METHODS: Various doses of NaIO3 and/or saline alone were injected into Brown Norway rats from hypoglossal vein. After 3, 7, 14 or 28 days of injection, ERG a-, b-, c-wave, fast oscillation (FO) and light peak (LP) were measured along with retinal colored pictures and fluorescein angiography (FA) taken. Some rats were chosen to study the histology of retinas by light microscopy and autofluorescence of retina flatmounts. Different concentrations of NaIO3 were given to RPE-19 cells, and cell proliferation rate was measured. For hydralazine study, 35mg/kg NaIO3 was injected into Brown Norway rat from hypoglossal vein. NaIO3 group was treated with saline alone after NaIO3 injection, 10g/L hydralazine+ NaIO3, group was treated with 10g/L hydralazine eyedrops after NaIO3 injection whereas normal group was treated with saline alone without NaIO3 injection. All eyedrops were instilled locally 3 times a day for 4 weeks and ERG c-wave was measured at the end of 2 and 4 weeks.
   RESULTS: After NaIO3 administration, the amplitude of all ERG waves fell markedly in large dose groups at 30, 40 or 60mg/kg NaIO3. Not many changes were observed in groups treated with <30mg/kg NaIO3. Some retinal necrosis appeared from 3 days post-injection (PI) in 30mg/kg NaIO3 group, which became more serious in larger dose groups or longer treatment time, but no apparent change was found in smaller dose groups. Similarly, on the retina flatmount, RPE monolayer showed necrosis from 3 days PI in the 30mg/kg NaIO3 and larger dose groups. On histological examination, no significant change was seen in 30mg/kg NaIO3 and lower concentration groups. In cell culture experiment, changes were found in RPE-19 cells proliferation rate with a concentration of NaIO3 at 30mg/L or higher. In hydralazine experiments, 4 weeks after injection of NaIO3, ERG c-wave fell markedly in NaIO3 group to 31% of control group(P<0.01). The ERG c-wave of hydralazine +NaIO3 group fell only to 50% of control group (P<0.05). This was a 61% reversal of the c-wave of NaIO3 treated group.
   CONCLUSION: Retinal pigment epithelium (RPE) degeneration induced by NaIO3 was both dose and time dependent Around 30 to 40mg/kg NaIO3 would be the optimal to be used as a non-exudative age-related macular degeneration (AMD) rat model. Hydralazine may postpone the development of non-exudative AMD.
C1 [Jiang, Wei; Zhang, Wan-Yu; Chiou, George C. Y.] Texas A&M Hlth Sci Ctr, Inst Ocular Pharmacol, Coll Med, College Stn, TX 77843 USA.
C3 Texas A&M University System; Texas A&M University College Station; Texas
   A&M Health Science Center
RP Chiou, GCY (通讯作者)，Texas A&M Hlth Sci Ctr, Inst Ocular Pharmacol, Coll Med, College Stn, TX 77843 USA.
EM chiou@medicine.tamhsc.edu
FU MacuClear, Inc.
FX The authors are grateful to Prof N.S. Peachey, J. Wu, and M. Yu for
   invaluable assistance in dc-ERG equipment assembling and measurement.
   Supported in party by MacuClear, Inc.
CR ASHBURN FS, 1980, INVEST OPHTH VIS SCI, V19, P1427
   Atmaca-Sonmez P, 2006, EXP EYE RES, V83, P1295, DOI 10.1016/j.exer.2006.07.013
   BAICH A, 1992, PIGM CELL RES, V5, P394, DOI 10.1111/j.1600-0749.1992.tb00568.x
   Borsheim E, 2000, METABOLISM, V49, P579, DOI 10.1016/S0026-0495(00)80031-1
   FLAGE T, 1982, EXP EYE RES, V34, P933, DOI 10.1016/0014-4835(82)90072-0
   Goossens GH, 2004, J CLIN ENDOCR METAB, V89, P2690, DOI 10.1210/jc.2003-032053
   GRIGNOLO A, 1966, EXP EYE RES, V5, P86, DOI 10.1016/S0014-4835(66)80024-6
   HOSODA L, 1993, ACTA OPHTHALMOL, V71, P616
   Kofuji P, 2000, J NEUROSCI, V20, P5733, DOI 10.1523/JNEUROSCI.20-15-05733.2000
   KORTE GE, 1993, EXP EYE RES, V56, P219, DOI 10.1006/exer.1993.1029
   Lamb TD, 1996, P NATL ACAD SCI USA, V93, P566, DOI 10.1073/pnas.93.2.566
   Mizota A, 1997, VISION RES, V37, P1859, DOI 10.1016/S0042-6989(97)00015-1
   NILSSON SEG, 1977, ACTA OPHTHALMOL, V55, P1027
   Obata R, 2005, EYE, V19, P464, DOI 10.1038/sj.eye.6701531
   Ohtaka K, 2006, CURR EYE RES, V31, P347, DOI 10.1080/02713680600629797
   SEN HA, 1992, INVEST OPHTH VIS SCI, V33, P3507
   SORSBY A, 1962, VISION RES, V2, P139, DOI 10.1016/0042-6989(62)90045-7
   SORSBY A, 1964, VISION RES, V4, P511, DOI 10.1016/0042-6989(64)90057-4
   STERN WH, 1980, AUST J OPHTHALMOL, V8, P281, DOI 10.1111/j.1442-9071.1980.tb00284.x
   2002, VIS NEUROSCI, V19, P693
NR 20
TC 2
Z9 2
U1 0
U2 1
PU IJO PRESS
PI XI AN
PA NO 269 YOUYI EAST RD, XI AN, 710054, PEOPLES R CHINA
SN 2222-3959
EI 2227-4898
J9 INT J OPHTHALMOL-CHI
JI Int. J. Ophthalmol.
PD JUN 18
PY 2009
VL 2
IS 2
BP 106
EP 112
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 664BL
UT WOS:000282933800002
DA 2022-11-30
ER

PT J
AU Keenan, TDL
   Clemons, TE
   Domalpally, A
   Elman, MJ
   Havilio, M
   Agron, E
   Benyamini, G
   Chew, EY
AF Keenan, Tiarnan D. L.
   Clemons, Traci E.
   Domalpally, Amitha
   Elman, Michael J.
   Havilio, Moshe
   Agron, Elvira
   Benyamini, Gidi
   Chew, Emily Y.
TI Retinal Specialist versus Artificial Intelligence Detection of Retinal
   Fluid from OCT Age-Related Eye Disease Study 2: 10-Year Follow-On Study
SO OPHTHALMOLOGY
LA English
DT Article
ID OPTICAL COHERENCE TOMOGRAPHY; MACULAR DEGENERATION; VISUAL-ACUITY;
   RANIBIZUMAB; SEGMENTATION; QUANTIFICATION; PREVALENCE; IDENTIFICATION;
   MORPHOLOGY; THERAPY
AB Purpose: To evaluate the performance of retinal specialists in detecting retinal fluid presence in spectral domain OCT (SD-OCT) scans from eyes with age-related macular degeneration (AMD) and compare performance with an artificial intelligence algorithm.
   Design: Prospective comparison of retinal fluid grades from human retinal specialists and the Notal OCT Analyzer (NOA) on SD-OCT scans from 2 common devices.
   Participants: A total of 1127 eyes of 651 Age-Related Eye Disease Study 2 10-year Follow-On Study (AREDS2-10Y) participants with SD-OCT scans graded by reading center graders (as the ground truth).
   Methods: The AREDS2-10Y investigators graded each SD-OCT scan for the presence/absence of intraretinal and subretinal fluid. Separately, the same scans were graded by the NOA.
   Main Outcome Measures: Accuracy (primary), sensitivity, specificity, precision, and F1-score.
   Results: Of the 1127 eyes, retinal fluid was present in 32.8%. For detecting retinal fluid, the investigators had an accuracy of 0.805 (95% confidence interval [CI], 0.780-0.828), a sensitivity of 0.468 (95% CI, 0.416-0.520), a specificity of 0.970 (95% CI, 0.955-0.981). The NOA metrics were 0.851 (95% CI, 0.829-0.871), 0.822 (95% CI, 0.779-0.859), 0.865 (95% CI, 0.839-0.889), respectively. For detecting intraretinal fluid, the investigator metrics were 0.815 (95% CI, 0.792-0.837), 0.403 (95% CI, 0.349-0.459), and 0.978 (95% CI, 0.966-0.987); the NOA metrics were 0.877 (95% CI, 0.857-0.896), 0.763 (95% CI, 0.713-0.808), and 0.922 (95% CI, 0.902-0.940), respectively. For detecting subretinal fluid, the investigator metrics were 0.946 (95% CI, 0.931-0.958), 0.583 (95% CI, 0.471-0.690), and 0.973 (95% CI, 0.962-0.982); the NOA metrics were 0.863 (95% CI, 0.842-0.882), 0.940 (95% CI, 0.867-0.980), and 0.857 (95% CI, 0.835-0.877), respectively.
   Conclusions: In this large and challenging sample of SD-OCT scans obtained with 2 common devices, retinal specialists had imperfect accuracy and low sensitivity in detecting retinal fluid. This was particularly true for intraretinal fluid and difficult cases (with lower fluid volumes appearing on fewer B-scans). Artificial intelligence based detection achieved a higher level of accuracy. This software tool could assist physicians in detecting retinal fluid, which is important for diagnostic, re-treatment, and prognostic tasks. Published by Elsevier on behalf of the American Academy of Ophthalmology
C1 [Keenan, Tiarnan D. L.; Agron, Elvira; Chew, Emily Y.] NEI, Div Epidemiol & Clin Applicat, NIH, Bethesda, MD 20892 USA.
   [Clemons, Traci E.] EMMES Co LLC, Rockville, MD USA.
   [Domalpally, Amitha] Univ Wisconsin, Fundus Photograph Reading Ctr, Madison, WI USA.
   [Elman, Michael J.] Elman Retina Grp, Baltimore, MD USA.
   [Havilio, Moshe; Benyamini, Gidi] Notal Vis Ltd, Tel Aviv, Israel.
C3 National Institutes of Health (NIH) - USA; NIH National Eye Institute
   (NEI); University of Wisconsin System; University of Wisconsin Madison
RP Keenan, TDL (通讯作者)，NIH, CRC, Bldg 10,Room 10D45,10 Ctr Dr,MSC 1204, Bethesda, MD 20892 USA.
EM tiarnan.keenan@nih.gov
OI Domalpally, Amitha/0000-0002-8145-9619; Benyamini,
   Gidi/0000-0003-4496-8462; Elman, Michael/0000-0001-7726-9508
FU Notal Vision Ltd.; National Eye Institute, National Institutes of
   Health, Department of Health and Human Services, Bethesda, Maryland
   [HHSN263201300005C]; EMMES Company, LLC
FX Financial support to the study was provided by Notal Vision Ltd.,
   through a service agreement with the EMMES Company, LLC. The AREDS2
   study was supported by intramural program funds and contracts from the
   National Eye Institute, National Institutes of Health, Department of
   Health and Human Services, Bethesda, Maryland (Contract Number
   HHSN263201300005C). The funding organizations participated in the design
   of the study, interpretation of the data, and preparation of the
   manuscript.
CR Arnold JJ, 2016, BMC OPHTHALMOL, V16, DOI 10.1186/s12886-016-0207-3
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Chakravarthy U, 2016, OPHTHALMOLOGY, V123, P1731, DOI 10.1016/j.ophtha.2016.04.005
   Chen XJ, 2012, INVEST OPHTH VIS SCI, V53, P8042, DOI 10.1167/iovs.12-10083
   Chew EY, 2012, OPHTHALMOLOGY, V119, P2282, DOI 10.1016/j.ophtha.2012.05.027
   Chiu SJ, 2015, BIOMED OPT EXPRESS, V6, P1172, DOI 10.1364/BOE.6.001172
   Colijn JM, 2017, OPHTHALMOLOGY, V124, P1753, DOI 10.1016/j.ophtha.2017.05.035
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   De Fauw J, 2018, NAT MED, V24, P1342, DOI 10.1038/s41591-018-0107-6
   DeCroos FC, 2012, OPHTHALMOLOGY, V119, P2549, DOI 10.1016/j.ophtha.2012.06.040
   Fernandez DC, 2005, IEEE T MED IMAGING, V24, P929, DOI 10.1109/TMI.2005.848655
   Flaxel CJ, 2020, OPHTHALMOLOGY, V127, P1, DOI DOI 10.1016/J.0PHTHA.2019.09.0242
   Fujimoto J, 2016, INVEST OPHTH VIS SCI, V57, pOCT1, DOI 10.1167/iovs.16-19963
   Gale RP, 2019, EYE, V33, DOI 10.1038/s41433-018-0300-3
   Goldstein M, 2019, AM AC OPHTH 2019 ANN
   Heidelberg Engineering, 2019, SPECTR MULT IM PLATF
   Heidelberg Engineering, 2019, HEID EYE EXPL NEXT G
   Keenan TD, 2020, OPHTHALMOL RETINA, V4, P3, DOI 10.1016/j.oret.2019.06.001
   Lee CS, 2017, BIOMED OPT EXPRESS, V8, P3440, DOI 10.1364/BOE.8.003440
   Lee H, 2018, AM J OPHTHALMOL, V191, P64, DOI 10.1016/j.ajo.2018.04.007
   Maloca P, 2018, TRANSL VIS SCI TECHN, V7, DOI 10.1167/tvst.7.4.8
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Mehta H, 2018, PROG RETIN EYE RES, V65, P127, DOI 10.1016/j.preteyeres.2017.12.002
   Motozawa N, 2019, OPHTHALMOL THER, V8, P527, DOI 10.1007/s40123-019-00207-y
   Nagendran M, 2020, BMJ-BRIT MED J, V368, DOI 10.1136/bmj.m689
   NIH U.S. National Library of Medicine ClinicalTrials.gov, BREAST ULTR IM REV A
   Quartilho A, 2016, EYE, V30, P602, DOI 10.1038/eye.2015.288
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Schlegl T, 2018, OPHTHALMOLOGY, V125, P549, DOI 10.1016/j.ophtha.2017.10.031
   Schmidt-Erfurth U, 2017, EYE, V31, P26, DOI 10.1038/eye.2016.227
   Schmidt-Erfurth U, 2018, OPHTHALMOL RETINA, V2, P24, DOI 10.1016/j.oret.2017.03.015
   Schmidt-Erfurth U, 2016, PROG RETIN EYE RES, V50, P1, DOI 10.1016/j.preteyeres.2015.07.007
   Sharma S, 2016, OPHTHALMOLOGY, V123, P865, DOI 10.1016/j.ophtha.2015.12.002
   Singer MA, 2012, OPHTHALMOLOGY, V119, P1175, DOI 10.1016/j.ophtha.2011.12.016
   Toth CA, 2015, RETINA-J RET VIT DIS, V35, P1303, DOI 10.1097/IAE.0000000000000483
   Tufail A, 2014, OPHTHALMOLOGY, V121, P1092, DOI 10.1016/j.ophtha.2013.11.031
   Venhuizen FG, 2018, BIOMED OPT EXPRESS, V9, P1545, DOI 10.1364/BOE.9.001545
   Waldstein SM, 2016, OPHTHALMOLOGY, V123, P1521, DOI 10.1016/j.ophtha.2016.03.037
   Wang J, 2016, BIOMED OPT EXPRESS, V7, P1577, DOI 10.1364/BOE.7.001577
   Wang P, 2019, GUT, V68, P1813, DOI 10.1136/gutjnl-2018-317500
   Wilkins GR, 2012, IEEE T BIO-MED ENG, V59, P1109, DOI 10.1109/TBME.2012.2184759
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Xu XY, 2015, IEEE T MED IMAGING, V34, P1616, DOI 10.1109/TMI.2015.2408632
NR 44
TC 27
Z9 27
U1 1
U2 10
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD JAN
PY 2021
VL 128
IS 1
BP 100
EP 109
DI 10.1016/j.opatha.2020.06.038
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA PH9UR
UT WOS:000600748500027
PM 32598950
DA 2022-11-30
ER

PT J
AU Foreman, J
   Xie, J
   Keel, S
   van Wijngaarden, P
   Sandhu, SS
   Soon, G
   Gaskin, JF
   Crowston, J
   Bourne, R
   Taylor, HR
   Dirani, M
AF Foreman, Joshua
   Xie, Jing
   Keel, Stuart
   van Wijngaarden, Peter
   Sandhu, Sukhpal Singh
   Soon, Ghee
   Gaskin, Jennifer Fan
   Crowston, Jonathan
   Bourne, Rupert
   Taylor, Hugh R.
   Dirani, Mohamed
TI The Prevalence and Causes of Vision Loss in Indigenous and
   Non-Indigenous Australians
SO OPHTHALMOLOGY
LA English
DT Article
ID EYE HEALTH SURVEY; VISUAL IMPAIRMENT PROJECT; BLUE MOUNTAINS EYE; OCULAR
   HEALTH; NATIONAL BLINDNESS; DIABETIC-RETINOPATHY; AVOIDABLE BLINDNESS;
   ADULT-POPULATION; CATARACT-SURGERY; RAPID ASSESSMENT
AB Purpose: To conduct a nationwide survey on the prevalence and causes of vision loss in Indigenous and non-Indigenous Australians. Design: Nationwide, cross-sectional, population-based survey. Participants: Indigenous Australians aged 40 years or older and non-Indigenous Australians aged 50 years and older.
   Methods: Multistage random-cluster sampling was used to select 3098 non-Indigenous Australians and 1738 Indigenous Australians from 30 sites across 5 remoteness strata (response rate of 71.5%). Sociodemographic and health data were collected using an interviewer-administered questionnaire. Trained examiners conducted standardized eye examinations, including visual acuity, perimetry, slit-lamp examination, intraocular pressure, and fundus photography. The prevalence and main causes of bilateral presenting vision loss (visual acuity < 6/12 in the better eye) were determined, and risk factors were identified.
   Main Outcome Measures: Prevalence and main causes of vision loss.
   Results: The overall prevalence of vision loss in Australia was 6.6% (95% confidence interval [CI], 5.4-7.8). The prevalence of vision loss was 11.2% (95% CI, 9.5-13.1) in Indigenous Australians and 6.5% (95% CI, 5.3-7.9) in non-Indigenous Australians. Vision loss was 2.8 times more prevalent in Indigenous Australians than in non-Indigenous Australians after age and gender adjustment (17.7%, 95% CI, 14.5-21.0 vs. 6.4%, 95% CI, 5.2-7.6, P < 0.001). In non-Indigenous Australians, the leading causes of vision loss were uncorrected refractive error (61.3%), cataract (13.2%), and age-related macular degeneration (10.3%). In Indigenous Australians, the leading causes of vision loss were uncorrected refractive error (60.8%), cataract (20.1%), and diabetic retinopathy (5.2%). In non-Indigenous Australians, increasing age (odds ratio [OR], 1.72 per decade) and having not had an eye examination within the past year (OR, 1.61) were risk factors for vision loss. Risk factors in Indigenous Australians included older age (OR, 1.61 per decade), remoteness (OR, 2.02), gender (OR, 0.60 for men), and diabetes in combination with never having had an eye examination (OR, 14.47).
   Conclusions: Vision loss is more prevalent in Indigenous Australians than in non-Indigenous Australians, highlighting that improvements in eye healthcare in Indigenous communities are required. The leading causes of vision loss were uncorrected refractive error and cataract, which are readily treatable. Other countries with Indigenous communities may benefit from conducting similar surveys of Indigenous and non-Indigenous populations. (C) 2017 by the American Academy of Ophthalmology
C1 [Foreman, Joshua; Xie, Jing; Keel, Stuart; van Wijngaarden, Peter; Sandhu, Sukhpal Singh; Soon, Ghee; Gaskin, Jennifer Fan; Crowston, Jonathan; Dirani, Mohamed] Royal Victorian Eye & Ear Hosp, Ctr Eye Res Australia, Melbourne, Vic, Australia.
   [Foreman, Joshua; van Wijngaarden, Peter; Sandhu, Sukhpal Singh; Crowston, Jonathan; Dirani, Mohamed] Univ Melbourne, Dept Surg, Ophthalmol, Melbourne, Vic, Australia.
   [Bourne, Rupert] Anglia Ruskin Univ, Postgrad Med Inst, Vis & Eye Res Unit, Cambridge, England.
   [Taylor, Hugh R.] Univ Melbourne, Melbourne Sch Populat & Global Hlth, Indigenous Eye Hlth Unit, Melbourne, Vic, Australia.
C3 Centre for Eye Research Australia; Royal Victorian Eye & Ear Hospital;
   University of Melbourne; Anglia Ruskin University; University of
   Melbourne
RP Foreman, J (通讯作者)，Ctr Eye Res Australia, Level 1,32 Gisborne St, East Melbourne, Vic 3002, Australia.
EM foreman.j@unimelb.edu.au
RI xie, jing/GRY-1689-2022
OI /0000-0001-6694-3587; Foreman, Joshua/0000-0002-3685-4054; van
   Wijngaarden, Peter/0000-0002-8800-7834
FU Commonwealth Government of Australia; Cranbourne Foundation; Novartis;
   Department of Health of the Australian Government; Novartis Australia;
   National Health and Medical Research Council Career Development
   Fellowship [1090466]; Australian Postgraduate Award scholarship;
   Australian Government Department of Health, Canberra, Australia; Peggy
   and Leslie Cranbourne Foundation
FX The author(s) have made the following disclosure(s): J.F., J.X., S.K.,
   P.vW., S.S.S., G.S.A., J.F.G., J.C., and M.D.: Grants and travel support
   - Commonwealth Government of Australia, Cranbourne Foundation, and
   Novartis.; The NEHS was funded by the Department of Health of the
   Australian Government and received financial contributions from Novartis
   Australia and in-kind support from our industry and sector partners:
   Optical Prescription Spectacle Makers, Carl Zeiss, Designs for Vision,
   the Royal Flying Doctor Service, Optometry Australia, and the Brien
   Holden Vision Institute. The authors acknowledge Optical Prescription
   Spectacle Makers, who donated sunglasses valued at $130 for each study
   participant. The CERA receives Operational Infrastructure Support from
   the Victorian Government. The Principal Investigator (M.D.) is supported
   by a National Health and Medical Research Council Career Development
   Fellowship (#1090466). A PhD student (J.F.) is supported by an
   Australian Postgraduate Award scholarship. Funded by The Australian
   Government Department of Health, Canberra, Australia, Novartis,
   Australia, and Peggy and Leslie Cranbourne Foundation. The funding
   organizations had no role in the design or conduct of this research.
CR Alves APX, 2002, OPHTHALMIC EPIDEMIOL, V9, P29
   Anderson I, 2016, LANCET, V388, P131, DOI 10.1016/S0140-6736(16)00345-7
   Anjou MD, 2013, CLIN EXP OPHTHALMOL, V41, P320, DOI 10.1111/j.1442-9071.2012.02886.x
   ARKELL SM, 1987, ARCH OPHTHALMOL-CHIC, V105, P482
   Attebo K, 1996, OPHTHALMOLOGY, V103, P357
   Australian Bureau of Statistics, 2014, AUSTR STAT GEOGR STA
   Australian Institute of Health and Welfare, 2015, HLTH SERV SER, V60
   Australian Institute of Health and Welfare, 2005, AUSTR I HLTH WELF B, V27
   BAASANHU J, 1994, B WORLD HEALTH ORGAN, V72, P771
   Bourne RRA, 2002, OPHTHAL EPIDEMIOL, V9, P119, DOI 10.1076/opep.9.2.119.1520
   Cubillan LDP, 2005, PHILIPP J OPHTHALMOL, V30, P100
   Department of Economic and Social Affairs, 2009, STAT WORLDS IND PEOP
   Diabetic Retinopathy Screening, 1981, 7 DRS, V21
   Dineen B, 2007, BRIT J OPHTHALMOL, V91, P1005, DOI 10.1136/bjo.2006.108035
   Duerksen R, 2003, OPHTHAL EPIDEMIOL, V10, P349, DOI 10.1076/opep.10.5.349.17326
   Faal H, 2000, BRIT J OPHTHALMOL, V84, P948, DOI 10.1136/bjo.84.9.948
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Foreman J, 2017, OPHTHAL EPIDEMIOL, P1
   Foreman J, 2017, CLIN EXP OPHTHALMOL, V45, P336, DOI 10.1111/ceo.12892
   Gracey M, 2009, LANCET, V374, P65, DOI 10.1016/S0140-6736(09)60914-4
   Isipradit S, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0114245
   Jimenez JR, 2004, JPN J OPHTHALMOL, V48, P163, DOI 10.1007/s10384-003-0041-z
   Jonas JB, 2014, AM J OPHTHALMOL, V158, P808, DOI 10.1016/j.ajo.2014.06.012
   Kelaher M, 2012, BMC OPHTHALMOL, V12, DOI 10.1186/1471-2415-12-51
   Kiely PM, 2011, CLIN EXP OPTOM, V94, P468, DOI 10.1111/j.1444-0938.2011.00590.x
   Kuper Hannah, 2006, Community Eye Health, V19, P68
   Kyari F, 2009, INVEST OPHTH VIS SCI, V50, P2033, DOI 10.1167/iovs.08-3133
   Laitinen A, 2005, OPHTHALMOLOGY, V112, P2227, DOI 10.1016/j.ophtha.2005.09.010
   Landers J, 2010, BRIT J OPHTHALMOL, V94, P1140, DOI 10.1136/bjo.2009.168146
   Landers J, 2011, CLIN EXP OPHTHALMOL, V39, P604, DOI 10.1111/j.1442-9071.2011.02532.x
   Landers J, 2010, CLIN EXP OPHTHALMOL, V38, P375, DOI 10.1111/j.1442-9071.2010.02255.x
   Landers J, 2010, CLIN EXP OPHTHALMOL, V38, P398, DOI 10.1111/j.1442-9071.2010.02288.x
   Landers J, 2010, CLIN EXP OPHTHALMOL, V38, P393, DOI 10.1111/j.1442-9071.2010.02256.x
   Lee ET, 2005, ARCH OPHTHALMOL-CHIC, V123, P1699, DOI 10.1001/archopht.123.12.1699
   Lepcha NT, 2013, OPHTHAL EPIDEMIOL, V20, P212, DOI 10.3109/09286586.2013.794902
   Mansberger SL, 2005, AM J PUBLIC HEALTH, V95, P881, DOI 10.2105/AJPH.2004.054221
   Mukesh BN, 2002, OPHTHALMOLOGY, V109, P1047, DOI 10.1016/S0161-6420(02)01040-0
   Newland H S, 1996, Ophthalmic Epidemiol, V3, P97, DOI 10.3109/09286589609080114
   NICOLOSI A, 1994, INT J EPIDEMIOL, V23, P359, DOI 10.1093/ije/23.2.359
   Pascolini D, 2012, BRIT J OPHTHALMOL, V96, P614, DOI 10.1136/bjophthalmol-2011-300539
   Paula JS, 2006, EYE, V20, P533, DOI 10.1038/sj.eye.6701917
   Paula JS, 2002, BRAZ J MED BIOL RES, V35, P1153, DOI 10.1590/S0100-879X2002001000007
   Rabiu MM, 2013, OPHTHAL EPIDEMIOL, V20, P26, DOI 10.3109/09286586.2012.746994
   Ramke J, 2012, CLIN EXP OPHTHALMOL, V40, P490, DOI 10.1111/j.1442-9071.2011.02749.x
   Ulldemolins AR, 2012, INDIAN J OPHTHALMOL, V60, P368, DOI 10.4103/0301-4738.100529
   Rochtchina E, 2003, CLIN EXP OPHTHALMOL, V31, P233, DOI 10.1046/j.1442-9071.2003.00635.x
   Schemann JF, 2006, OPHTHAL EPIDEMIOL, V13, P219, DOI 10.1080/09286580600681347
   Stevens GA, 2013, OPHTHALMOLOGY, V120, P2377, DOI 10.1016/j.ophtha.2013.05.025
   Taylor HR, 2005, MED J AUSTRALIA, V182, P565, DOI 10.5694/j.1326-5377.2005.tb06815.x
   TAYLOR HR, 1980, MED J AUSTRALIA, V1, P71, DOI 10.5694/j.1326-5377.1980.tb134630.x
   Taylor HR, 2012, MED J AUSTRALIA, V197, P613, DOI 10.5694/mja12.10544
   Taylor HR, 2010, MED J AUSTRALIA, V192, P312, DOI 10.5694/j.1326-5377.2010.tb03529.x
   Thorn F, 2005, OPTOMETRY VISION SCI, V82, P267, DOI 10.1097/01.OPX.0000159371.25986.67
   Turner AW, 2011, CLIN EXP OPHTHALMOL, V39, P598, DOI 10.1111/j.1442-9071.2011.02529.x
   United Nations Department of Economic and Social Affairs, 2015, WORLD POP PROSP 2015
   VANHERICK W, 1969, AM J OPHTHALMOL, V68, P626, DOI 10.1016/0002-9394(69)91241-0
   VanNewkirk MR, 2001, OPHTHALMOLOGY, V108, P960, DOI 10.1016/S0161-6420(01)00554-1
   Varma R, 2004, OPHTHALMOLOGY, V111, P1132, DOI 10.1016/j.ophtha.2004.02.002
   Wang JJ, 2000, CLIN EXP OPHTHALMOL, V28, P268, DOI 10.1046/j.1442-9071.2000.00315.x
   WHO simplified trachoma grading system, 2004, COMMUNITY EYE HLTH, V17, P68
   World Health Organization, 2001, RAP ASS CAT SURG SER
   World Health Organization, 2013, UN EY HLTH GLOB ACT
   Zainal M, 2002, BRIT J OPHTHALMOL, V86, P951, DOI 10.1136/bjo.86.9.951
   Zatic T, 2015, BRIT J OPHTHALMOL, V99, P832, DOI 10.1136/bjophthalmol-2014-305824
NR 64
TC 47
Z9 46
U1 0
U2 12
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD DEC
PY 2017
VL 124
IS 12
BP 1743
EP 1752
DI 10.1016/j.ophtha.2017.06.001
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA FM9JZ
UT WOS:000415586000013
PM 28689897
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Chew, EY
   Ferris, FL
   Csaky, KG
   Murphy, RP
   Agron, E
   Thompson, DJS
   Reed, GF
   Schachat, AP
AF Chew, EY
   Ferris, FL
   Csaky, KG
   Murphy, RP
   Agron, E
   Thompson, DJS
   Reed, GF
   Schachat, AP
TI The long-term effects of laser photocoagulation treatment in patients
   with diabetic retinopathy - The early treatment diabetic retinopathy
   follow-up study
SO OPHTHALMOLOGY
LA English
DT Article
AB Objectives: To evaluate the long-term natural history and effects of laser photocoagulation treatment in patients with diabetic retinopathy.
   Design: Follow-up study of the 214 surviving patients enrolled originally at the Johns Hopkins Clinical Center for the Early Treatment Diabetic Retinopathy Study (ETDRS), which was a clinical trial designed to evaluate the role of laser photocoagulation and aspirin treatment in patients with diabetic retinopathy.
   Methods: Early Treatment Diabetic Retinopathy Study patients enrolled in the Johns Hopkins Clinical Center had complete eye examinations, including best-corrected visual acuity measurements, fundus photographs, and medical questionnaires throughout the 7-year study. They had the same examinations at the final long-term follow-up visit at the National Eye Institute, National Institutes of Health, 13 to 19.5 years after the initial laser photocoagulation (median, 16.7 years).
   Main Outcome Measures: The major outcomes were mortality and the rates of moderate and severe vision loss. The secondary outcomes were progression of diabetic retinopathy and need for other eye surgery.
   Results: Of the 214 patients who were alive at the end of the original ETDRS in 1989, 130 (61%) were deceased at the time of the re-examination. Of the 84 who were alive, 71 (85%) were examined at their long-term follow-up visit at the National Institutes of Health. At the long-term follow-up examination, 42% had visual acuity of 20/20 or better, and 84% had visual acuity of 20/40 or better in the better eye. Compared with baseline, 20% of patients had moderate vision loss (loss of 3 lines or more vision) in the better eye at follow-up. Only one patient had visual acuity of 20/200 bilaterally. He had visual acuity loss secondary to age-related macular degeneration. No patient had severe vision loss (worse than 5/200). All the initially untreated eyes of patients who had severe nonproliferative diabetic retinopathy or worse by the time of the ETDRS closeout visit of the original study received scatter photocoagulation treatment. Focal photocoagulation was performed in 43% bilaterally and 22% unilaterally. Cataract surgery was performed in 31% of the patients, vitrectomy in 17%, and glaucoma surgery in one patient.
   Conclusions: As previously reported, the mortality rate of patients with diabetic retinopathy is much higher than that of the general population. For those who survived, aggressive follow-up, with treatment when indicated, seems to be associated with maintenance of good long-term visual acuity for most patients. The need for laser scatter photocoagulation with long-term follow-up seems to be high. (C) 2003 by the American Academy of Ophthalmology.
C1 NEI, NIH, Div Epidemiol & Clin Res, Bethesda, MD USA.
   NEI, NIH, Immunol Lab, Bethesda, MD 20892 USA.
   EMMES Corp, Rockville, MD USA.
   Johns Hopkins Med Inst, Wilmer Eye Inst, Baltimore, MD 21205 USA.
C3 National Institutes of Health (NIH) - USA; NIH National Eye Institute
   (NEI); National Institutes of Health (NIH) - USA; NIH National Eye
   Institute (NEI); Emmes Corporation; Johns Hopkins University; Johns
   Hopkins Medicine
RP Chew, EY (通讯作者)，NEI, Div Biometry & Epidemiol, NIH, Bldg 31,Room 6A52,31 Ctr Dr,MSC 2510, Bethesda, MD 20892 USA.
OI Ferris, Frederick/0000-0002-4933-0639
FU Intramural NIH HHS [Z99 EY999999] Funding Source: Medline
CR [Anonymous], 1991, OPHTHALMOLOGY, V98, P741
   [Anonymous], 1981, OPHTHALMOLOGY, V88, P583
   BEETHAM W P, 1963, Br J Ophthalmol, V47, P611, DOI 10.1136/bjo.47.10.611
   BLANKENSHIP GW, 1991, OPHTHALMOLOGY, V98, P125
   CAIRD FI, 1968, DIABETES, V17, P121, DOI 10.2337/diab.17.3.121
   DECKERT T, 1967, DIABETES, V16, P728, DOI 10.2337/diab.16.10.728
   *EARL TREATM DIAB, 1991, OPHTHALMOLOGY S, V98, P767
   *EARL TREATM DIAB, 1985, ARCH OPHTHALMOL-CHIC, V103, P1796, DOI DOI 10.1001/ARCHOPHT.1985.01050120030015
   Ferris F, 1996, Trans Am Ophthalmol Soc, V94, P505
   FERRIS FL, 1993, JAMA-J AM MED ASSOC, V269, P1290, DOI 10.1001/jama.269.10.1290
   Gu K, 1998, DIABETES CARE, V21, P1138, DOI 10.2337/diacare.21.7.1138
   Kassoff A, 2001, AM J OPHTHALMOL, V131, P167
   KLEIN R, 1984, OPHTHALMOLOGY, V91, P1
   KLEIN R, 1989, ARCH INTERN MED, V149, P266, DOI 10.1001/archinte.149.2.266
   SHAMOON H, 1993, NEW ENGL J MED, V329, P977, DOI 10.1056/nejm199309303291401
   The Diabetic Retinopathy Vitrectomy Study Research Group, 1985, ARCH OPHTHALMOL-CHIC, V103, P1644
NR 16
TC 103
Z9 109
U1 0
U2 9
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD SEP
PY 2003
VL 110
IS 9
BP 1683
EP 1689
DI 10.1016/S0161-6420(03)00579-7
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 715BG
UT WOS:000184950200003
PM 13129862
DA 2022-11-30
ER

PT J
AU Koskela, A
   Reinisalo, M
   Hyttinen, JMT
   Kaarniranta, K
   Karjalainen, RO
AF Koskela, Ali
   Reinisalo, Mika
   Hyttinen, Juha M. T.
   Kaarniranta, Kai
   Karjalainen, Reijo O.
TI Pinosylvin-mediated protection against oxidative stress in human retinal
   pigment epithelial cells
SO MOLECULAR VISION
LA English
DT Article
ID TRANSCRIPTION FACTOR NRF2; HEME OXYGENASE-1; KEAP1-NRF2 PATHWAY; GENE;
   ACTIVATION; EXPRESSION; AUTOPHAGY; SUPPRESSION; MECHANISMS; INDUCTION
AB Purpose: In this work, we investigated the ability of pinosylvin (PS), 3,5-dihydroxy-trans-stilbene, to modulate oxidative stress in human RPE cells. PS, a stilbenoid polyphenol, occurs in high concentrations in bark byproducts and therefore represents an attractive bioactive compound for health-promoting applications.
   Methods: First, we evaluated the toxicity range of PS by exposing ARPE-19 cells to 0.1-200 mu M concentrations of PS for 24 h followed by the cell viability test. In the next stage, the ARPE-19 cells were preincubated in PS for 24 h followed by hydroquinone (HQ) exposure without PS for another 24 h. The cell viability test was conducted after HQ exposure. To elucidate the potential mechanisms behind PS-mediated protection against oxidative stress, the ARPE-19 cells were treated with 5 M PS for 6 h, and mRNA was extracted at four time points (2 h, 6 h, 12 h, 24 h) to determine changes in the expression of nuclear factor-erythroid 2-related factor-2 (Nrf2), sequestosome 1 (p62/SQSTM1), heme oxygenase-1 (HO-1), and glutathione S-transferase pi 1 (GSTP1) genes. To clarify the molecular mechanism behind PS-mediated protection further, the ARPE-19 cells were transfected with p62 and Nrf2 siRNAs for 24 h, and the roles of p62, Nrf2, and its target gene HO-1 in conferring protection against oxidative stress were studied with quantitative real-time PCR (qRT-PCR) and the cell viability test.
   Results: PS treatment at concentrations of 5 and 10 M significantly enhanced cell survival from oxidative stress. The expression levels of an enzyme with antioxidative, anti-inflammatory, and immunomodulatory properties, HO-1, were increased by PS treatment and correlated strongly with cell survival. PS treatment did not elevate the expression levels of Nrf2 or its target genes, p62 or GSTP1, even though it had a clear effect on the expression of HO-1, another gene controlled by Nrf2. RNA interference analysis further confirmed the important role of Nrf2 and HO-1 in PS-mediated protection against oxidative stress whereas the role of p62 seemed to be insignificant at the gene expression and cell viability levels.
   Conclusions: Our results suggest that PS treatment conferred protection against oxidative stress through the induction of HO-1 in human RPE cells. Consequently, PS-stilbene compounds, which can be isolated in significant amounts from bark waste, may possess health-promoting properties against aging-related diseases associated with oxidative stress such as age-related macular degeneration (AMD) and Alzheimer's disease. These natural compounds may offer opportunities for high-value use of bark waste in diverse health-related applications.
C1 [Koskela, Ali; Reinisalo, Mika; Karjalainen, Reijo O.] Univ Eastern Finland, Dept Biol, Kuopio 70211, Finland.
   [Koskela, Ali; Reinisalo, Mika; Hyttinen, Juha M. T.; Kaarniranta, Kai] Univ Eastern Finland, Inst Clin Med, Dept Ophthalmol, Kuopio 70211, Finland.
   [Kaarniranta, Kai] Kuopio Univ Hosp, Dept Ophthalmol, SF-70210 Kuopio, Finland.
C3 University of Eastern Finland; University of Eastern Finland; Kuopio
   University Hospital; University of Eastern Finland
RP Karjalainen, RO (通讯作者)，Univ Eastern Finland, Dept Biol, POB 1627, Kuopio 70211, Finland.
EM reijo.karjalainen@uef.fi
OI Hyttinen, Juha/0000-0002-3414-4032; Kaarniranta, Kai/0000-0003-2600-8679
FU Foundation for Research of Natural Resources in Finland [1758/13];
   University of Eastern Finland spearhead project "Changing Climate and
   Biological Interactions Related to Forests, CABI"
FX We thank Dr. Ewen MacDonald for checking the language of the manuscript.
   This work was supported by a grant from Foundation for Research of
   Natural Resources in Finland ( grant number: 1758/13) and University of
   Eastern Finland spearhead project "Changing Climate and Biological
   Interactions Related to Forests, CABI."
CR Castilho AF, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042428
   Chen SY, 2012, FOOD CHEM TOXICOL, V50, P3025, DOI 10.1016/j.fct.2012.06.006
   Hanneken A, 2006, INVEST OPHTH VIS SCI, V47, P3164, DOI 10.1167/iovs.04-1369
   HANSEN MB, 1989, J IMMUNOL METHODS, V119, P203, DOI 10.1016/0022-1759(89)90397-9
   Ishii T, 2000, J BIOL CHEM, V275, P16023, DOI 10.1074/jbc.275.21.16023
   Ishikado A, 2013, FREE RADIC BIOL MED
   Jain A, 2010, J BIOL CHEM, V285, P22576, DOI 10.1074/jbc.M110.118976
   Jarrett SG, 2012, MOL ASPECTS MED, V33, P399, DOI 10.1016/j.mam.2012.03.009
   Jeong E, 2013, PHYTOTHER RES, V27, P610, DOI 10.1002/ptr.4770
   Johnson J, 2009, INVEST OPHTH VIS SCI, V50, P2398, DOI 10.1167/iovs.08-2088
   Kaarniranta K, 2011, J ALZHEIMERS DIS, V24, P615, DOI 10.3233/JAD-2011-101908
   Kansanen E, 2013, REDOX BIOL, V1, P45, DOI 10.1016/j.redox.2012.10.001
   Kim SW, 2013, FREE RADICAL BIO MED, V65, P468, DOI 10.1016/j.freeradbiomed.2013.07.028
   Kimura S, 2009, BIOCHEM BIOPH RES CO, V387, P109, DOI 10.1016/j.bbrc.2009.06.136
   Kokot A, 2009, ENDOCRINOLOGY, V150, P3197, DOI 10.1210/en.2008-1315
   Kook D, 2008, INVEST OPHTH VIS SCI, V49, P1712, DOI 10.1167/iovs.07-0477
   Lee J, 2006, PLANTA MED, V72, P801, DOI 10.1055/s-2006-941545
   Macickova T, 2010, NEUROENDOCRINOL LETT, V31, P91
   Maher P, 2005, INVEST OPHTH VIS SCI, V46, P4796, DOI 10.1167/iovs.05-0397
   Malinen M, 2008, NUCLEIC ACIDS RES, V36, P121, DOI 10.1093/nar/gkm913
   Milbury PE, 2007, INVEST OPHTH VIS SCI, V48, P2343, DOI 10.1167/iovs.06-0452
   Nezis IP, 2012, ANTIOXID REDOX SIGN, V17, P786, DOI 10.1089/ars.2011.4394
   Nguyen T, 2009, J BIOL CHEM, V284, P13291, DOI 10.1074/jbc.R900010200
   Paine A, 2010, BIOCHEM PHARMACOL, V80, P1895, DOI 10.1016/j.bcp.2010.07.014
   Park EJ, 2013, FOOD CHEM TOXICOL, V55, P424, DOI 10.1016/j.fct.2013.01.007
   Park EJ, 2012, J NUTR BIOCHEM, V23, P946, DOI 10.1016/j.jnutbio.2011.04.021
   Ren JW, 2011, NEUROCHEM RES, V36, P2352, DOI 10.1007/s11064-011-0561-8
   Saviranta NMM, 2011, FOOD RES INT, V44, P109, DOI 10.1016/j.foodres.2010.10.056
   Taguchi K, 2012, P NATL ACAD SCI USA, V109, P13561, DOI 10.1073/pnas.1121572109
   Taguchi K, 2011, GENES CELLS, V16, P123, DOI 10.1111/j.1365-2443.2010.01473.x
   Viiri J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069563
   Viiri J, 2010, MOL VIS, V16, P1399
   Wang RM, 2013, HIPPOCAMPUS, V23, P634, DOI 10.1002/hipo.22126
   Wignes JA, 2013, EXP EYE RES
   Woo JM, 2012, MOL VIS, V18, P901
   Zhang MJ, 2013, PROG NEUROBIOL, V100, P30, DOI 10.1016/j.pneurobio.2012.09.003
   Zheng Y, 2010, MOL VIS, V16, P1467
NR 37
TC 49
Z9 53
U1 1
U2 19
PU MOLECULAR VISION
PI ATLANTA
PA C/O JEFF BOATRIGHT, LAB B, 5500 EMORY EYE CENTER, 1327 CLIFTON RD, N E,
   ATLANTA, GA 30322 USA
SN 1090-0535
J9 MOL VIS
JI Mol. Vis.
PD JUN 2
PY 2014
VL 20
BP 760
EP 769
PG 10
WC Biochemistry & Molecular Biology; Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Ophthalmology
GA AK3JP
UT WOS:000338319700004
PM 24940030
DA 2022-11-30
ER

PT J
AU You, QS
   Xu, L
   Wang, YX
   Yang, H
   Ma, K
   Li, JJ
   Zhang, L
   Jonas, JB
AF You, Qi Sheng
   Xu, Liang
   Wang, Ya Xing
   Yang, Hua
   Ma, Ke
   Li, Jian Jun
   Zhang, Li
   Jonas, Jost B.
TI Pseudoexfoliation: Normative Data and Associations The Beijing Eye Study
   2011
SO OPHTHALMOLOGY
LA English
DT Article
ID OPEN-ANGLE GLAUCOMA; EXFOLIATION SYNDROME; INTRAOCULAR-PRESSURE;
   SOUTHERN INDIA; PREVALENCE; POPULATION; EYE
AB Objective: To assess the prevalence of pseudoexfoliation syndrome (PEX) and its associations in a population-based setting.
   Design: Population-based, cross-sectional cohort study.
   Participants: Of 4403 eligible subjects with an age of >= 50 years, 3468 individuals (78.8%) participated in the Beijing Eye Study 2011 (mean age, 64.6 +/- 9.8 years; range, 50-93 years).
   Methods: All study participants underwent a detailed ophthalmologic examination. After medical pupil dilation, PEX was assessed by an experienced ophthalmologist using slit-lamp-based biomicroscopy.
   Main Outcome Measures: Prevalence and associations of PEX.
   Results: Slit-lamp examination results were available for 3022 study participants (87.1%). Definite pseudoexfoliation was observed in 72 of the 3022 subjects, with a prevalence of 2.38% (95% confidence interval [CI], 1.84-2.93). Suspected PEX was detected in 104 of the subjects (3.44%; 95% CI, 2.8-4.1). The overall prevalence of PEX (definite and suspected) was 176 of 3022 or 5.82% (95% CI, 4.99-6.66). In 80 subjects (45.5%), PEX was detected in both eyes, whereas it was detected only in the right eye in 42 subjects (23.9%) and only in the left eye in 54 (30.7%). The prevalence of PEX increased from 1.1% in among those 50 to 54 years old, to 3.5%, 5.7%, and 11.8% among those 60 to 64 years, 70 to 74 years, and >= 80 years, respectively. In multivariate analysis, presence of PEX was significantly associated with older age (P<0.001; odds ratio [OR], 1.08; 95% CI, 1.04-1.10), shorter axial length (P = 0.03; OR, 0.82; 95% CI, 0.68,0.98), and shallower anterior chamber (P = 0.03; OR, 0.59; 95% CI, 0.36-0.95). We found that PEX was not associated (all P>0.05) with sex, diabetes mellitus, blood pressure, psychological depression, smoking, dyslipidemia, body mass index, central corneal thickness, corneal diameter, optic nerve head measurements, choroidal thickness, retinal vessel diameters, early age-related macular degeneration, or retinal vein occlusion.
   Conclusions: In a North Chinese population aged >= 50 years, the prevalence of definite PEX was 2.38% (95% CI, 1.84-2.93), suspect PEX was 3.4% (95% CI, 2.8-4.1) and overall PEX was 5.82% (95% CI, 4.99-6.66). We found PEX to be associated with older age, shorter axial length, and shallower anterior chamber. The relationship between PEX and glaucomatous optic neuropathy remained inconclusive among our population. (c) 2013 by the American Academy of Ophthalmology.
C1 [You, Qi Sheng; Xu, Liang; Wang, Ya Xing; Yang, Hua; Ma, Ke; Li, Jian Jun; Zhang, Li; Jonas, Jost B.] Capital Univ Med Sci, Beijing Tongren Hosp, Beijing Inst Ophthalmol, Beijing, Peoples R China.
   [Jonas, Jost B.] Heidelberg Univ, Med Fac Mannheim, Dept Ophthalmol, Univ Med Mannheim, Mannheim, Germany.
C3 Capital Medical University; Ruprecht Karls University Heidelberg
RP Xu, L (通讯作者)，Beijing Inst Ophthalmol, 17 Hougou Lane, Beijing 100005, Peoples R China.
EM xlbio1@163.com
RI You, Qisheng/AAG-7153-2020; wang, YA XING/K-9671-2016; You,
   Qisheng/A-3619-2014
OI You, Qisheng/0000-0003-0743-7320; wang, YA XING/0000-0003-2749-7793;
   You, Qisheng/0000-0003-0743-7320
FU Beijing Nova Program [2010B032]; National Natural Science Foundation of
   China [81170890]; National Key Technology R&D Program of the Ministry of
   Science and Technology [2011BAH15B08, 2012BAH05F05]
FX Supported by Beijing Nova Program (Nos. 2010B032), National Natural
   Science Foundation of China (No. 81170890) and National Key Technology
   R&D Program of the Ministry of Science and Technology (Nos. 2011BAH15B08
   and 2012BAH05F05).
CR Abdul-Rahman AM, 2008, BRIT J OPHTHALMOL, V92, P1325, DOI 10.1136/bjo.2008.141523
   Anastasopoulos E, 2011, J GLAUCOMA, V20, P160, DOI 10.1097/IJG.0b013e3181d9d8bd
   Arnarsson A, 2007, ACTA OPHTHALMOL SCAN, V85, P822, DOI 10.1111/j.1600-0420.2007.01051.x
   Arvind H, 2003, BRIT J OPHTHALMOL, V87, P1321, DOI 10.1136/bjo.87.11.1321
   Astrom S, 2007, ACTA OPHTHALMOL SCAN, V85, P828, DOI 10.1111/j.1600-0420.2007.00992.x
   Belovay GW, 2010, CURR OPIN OPHTHALMOL, V21, P25, DOI 10.1097/ICU.0b013e328332f814
   Forsman E, 2007, ACTA OPHTHALMOL SCAN, V85, P500, DOI 10.1111/j.1600-0420.2007.00978.x
   Foster PJ, 2005, BRIT J OPHTHALMOL, V89, P239, DOI 10.1136/bjo.2004.047605
   GROSS FJ, 1994, AM J OPHTHALMOL, V117, P333, DOI 10.1016/S0002-9394(14)73141-1
   HILLER R, 1982, ARCH OPHTHALMOL-CHIC, V100, P1080
   Kang JH, 2012, OPHTHALMOLOGY, V119, P27, DOI 10.1016/j.ophtha.2011.06.018
   Krishnadas R, 2003, AM J OPHTHALMOL, V135, P830, DOI 10.1016/S0002-9394(02)02271-7
   Krumbiegel M, 2010, J GLAUCOMA, V19, P561, DOI 10.1097/IJG.0b013e3181ca76c4
   Landers J, 2012, CLIN EXP OPHTHALMOL, V40, P454, DOI 10.1111/j.1442-9071.2011.02696.x
   Linner E, 2001, ACTA OPHTHALMOL SCAN, V79, P283, DOI 10.1034/j.1600-0420.2001.790314.x
   McCarty CA, 2000, AM J OPHTHALMOL, V129, P629, DOI 10.1016/S0002-9394(99)00466-3
   Miyazaki M, 2005, J GLAUCOMA, V14, P482, DOI 10.1097/01.ijg.0000185436.15675.b3
   Naumann GOH, 1998, OPHTHALMOLOGY, V105, P951, DOI 10.1016/S0161-6420(98)96020-1
   Nouri-Mahdavi K, 1999, ACTA OPHTHALMOL SCAN, V77, P581, DOI 10.1034/j.1600-0420.1999.770521.x
   Ritch R, 1994, J Glaucoma, V3, P176
   Ritch R, 2001, SURV OPHTHALMOL, V45, P265, DOI 10.1016/S0039-6257(00)00196-X
   Rotchford AP, 2003, ARCH OPHTHALMOL-CHIC, V121, P863, DOI 10.1001/archopht.121.6.863
   Rudkin AK, 2008, BRIT J OPHTHALMOL, V92, P1595, DOI 10.1136/bjo.2008.146407
   SCHLOTZERSCHREHARDT UM, 1992, ARCH OPHTHALMOL-CHIC, V110, P1752, DOI 10.1001/archopht.1992.01080240092038
   Stein JD, 2011, ARCH OPHTHALMOL-CHIC, V129, P1053, DOI 10.1001/archophthalmol.2011.191
   STREETEN BW, 1992, ARCH OPHTHALMOL-CHIC, V110, P1757, DOI 10.1001/archopht.1992.01080240097039
   Thomas R, 2005, INVEST OPHTH VIS SCI, V46, P1170, DOI 10.1167/iovs.04-1062
   Thorleifsson G, 2007, SCIENCE, V317, P1397, DOI 10.1126/science.1146554
   Topouzis F, 2011, AM J OPHTHALMOL, V152, P219, DOI 10.1016/j.ajo.2011.01.032
   Topouzis F, 2009, AM J OPHTHALMOL, V148, P606, DOI 10.1016/j.ajo.2009.03.024
   Viso E, 2010, OPHTHAL EPIDEMIOL, V17, P118, DOI 10.3109/09286581003624970
   Xu L, 2006, BRIT J OPHTHALMOL, V90, P1087, DOI 10.1136/bjo.2006.096123
   Xu L, 2012, BR J OPHTHALMOL
   Young AL, 2004, BRIT J OPHTHALMOL, V88, P193, DOI 10.1136/bjo.2003.021816
NR 34
TC 57
Z9 57
U1 0
U2 9
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD AUG
PY 2013
VL 120
IS 8
BP 1551
EP 1558
DI 10.1016/j.ophtha.2013.01.020
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 196LW
UT WOS:000322778000014
PM 23622877
DA 2022-11-30
ER

PT J
AU Murray, IJ
   Makridaki, M
   van der Veen, RLP
   Carden, D
   Parry, NRA
   Berendschot, TTJM
AF Murray, Ian J.
   Makridaki, Maria
   van der Veen, Rob L. P.
   Carden, David
   Parry, Neil R. A.
   Berendschot, Tos T. J. M.
TI Lutein Supplementation over a One-Year Period in Early AMD Might Have a
   Mild Beneficial Effect on Visual Acuity: The CLEAR Study
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID AGE-RELATED MACULOPATHY; PIGMENT OPTICAL-DENSITY; MACULAR PIGMENT;
   VITAMIN-E; CONSTITUENT CAROTENOIDS; DIETARY ANTIOXIDANTS; HUMAN RETINA;
   DEGENERATION; ZEAXANTHIN; PREVALENCE
AB PURPOSE. We investigated the effect of daily supplementation with lutein (L) capsules on macular pigment optical density (MPOD) and visual acuity (VA) in patients with early age-related macular degeneration (AMD).
   METHODS. A randomized, double-blind, placebo-controlled, two-center investigation of the effects of L supplementation in early AMD was conducted. The duration of the trial was 12 months. The centers were Manchester, United Kingdom and Maastricht, the Netherlands. L capsules (10 mg Ester) or a placebo (P) were taken daily. There were 72 patients (mean age 70.5 +/- 8.7) assigned randomly to either L (n = 36) or P (n = 36) groups. MPOD using a flicker-based technique (MPS9000) and best corrected VA (LogMAR) were measured at the beginning and at 4-month intervals over the duration of the 12-month supplementation period. Blood serum samples were collected to monitor compliance.
   RESULTS. At the end of the trial, an overall increase in the mean MPOD level was found for the L group from 0.38 +/- 0.19 to 0.53 +/- 0.22 optical density (OD) units. According to a mixed design ANOVA, this was statistically significant (P < 0.001). No change in MPOD was found for the P group. There was no significant change in VA in the L group (n = 36). The P group (n = 36) showed a statistically significant deterioration from 0.05 +/- 0.13 to 0.09 +/- 0.13 (P < 0.05). When comparing the change in VA over the supplementation period, there was a significant difference between the two groups (P < 0.05). To avoid ceiling effects, 2 subgroups of patients with VA worse than 0.06 at baseline were reanalyzed. In the L subgroup (n = 19) a mean improvement in VA from 0.23 +/- 0.12 at baseline to 0.16 +/- 0.10 at visit 4 was observed (P < 0.05). In the P subgroup (n = 14), there was a small deterioration from 0.18 +/- 0.13 to 0.19 +/- 0.12 (P = 0.70). The improvement in VA in the L subgroup was compared to the deterioration in VA in the P group and this effect reached statistical significance (P < 0.05).
   CONCLUSIONS. L supplementation increases MPOD levels in early stage AMD patients. According to the VA measurements, the progress of the disease might be slowed in some patients with augmented levels of MP. (ClinicalTrials. gov number NCT01042860.) (Invest Ophthalmol Vis Sci. 2013;54:1781-1788) DOI:10.1167/iovs.12-10715
C1 [Murray, Ian J.; Makridaki, Maria; Carden, David] Univ Manchester, Fac Life Sci, Manchester, Lancs, England.
   [van der Veen, Rob L. P.; Berendschot, Tos T. J. M.] Univ Eye Clin Maastricht, Maastricht, Netherlands.
   [Parry, Neil R. A.] Manchester Royal Eye Hosp, Vis Sci Ctr, Cent Manchester Univ Hosp NHS Fdn Trust, Manchester Acad Hlth Sci Ctr, Manchester M13 9WH, Lancs, England.
C3 University of Manchester; Maastricht University; Maastricht University
   Medical Centre (MUMC); Manchester Royal Eye Hospital; University of
   Manchester
RP Murray, IJ (通讯作者)，Fac Life Sci, Carys Bannister Bldg,Dover St, Manchester M13 9PL, Lancs, England.
EM Ian.j.murray@manchester.ac.uk
RI Berendschot, Tos TJM/M-8509-2016
OI Berendschot, Tos TJM/0000-0002-8101-939X
FU BASF; UK Medical Research Council; Manchester Biomedical Research
   Centre; Greater Manchester Comprehensive Local Research Network
FX Supported partly by BASF, the UK Medical Research Council, the
   Manchester Biomedical Research Centre, and the Greater Manchester
   Comprehensive Local Research Network.
CR Beatty S, 1999, BRIT J OPHTHALMOL, V83, P867, DOI 10.1136/bjo.83.7.867
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Beatty S, 2001, INVEST OPHTH VIS SCI, V42, P439
   Berendschot TTJM, 2000, INVEST OPHTH VIS SCI, V41, P3322
   Berendschot TTJM, 2002, INVEST OPHTH VIS SCI, V43, P1928
   Bernstein Paul S, 2002, Methods Mol Biol, V196, P321
   Bernstein PS, 2010, VISION RES, V50, P716, DOI 10.1016/j.visres.2009.10.014
   BONE RA, 1988, INVEST OPHTH VIS SCI, V29, P843
   Cai JY, 2000, PROG RETIN EYE RES, V19, P205, DOI 10.1016/S1350-9462(99)00009-9
   Chong EWT, 2007, BMJ-BRIT MED J, V335, P755, DOI 10.1136/bmj.39350.500428.47
   Dagnelie G, 2000, Optometry, V71, P147
   Kanis MJ, 2007, GRAEF ARCH CLIN EXP, V245, P767, DOI 10.1007/s00417-006-0478-0
   Kijlstra A, 2012, PROG RETIN EYE RES, V31, P303, DOI 10.1016/j.preteyeres.2012.03.002
   Klaver CCW, 1998, ARCH OPHTHALMOL-CHIC, V116, P653, DOI 10.1001/archopht.116.5.653
   Klein R, 1997, OPHTHALMOLOGY, V104, P7, DOI 10.1016/S0161-6420(97)30368-6
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Koh HH, 2004, EXP EYE RES, V79, P21, DOI 10.1016/j.exer.2004.03.001
   Kvansakul J, 2006, OPHTHAL PHYSL OPT, V26, P362, DOI 10.1111/j.1475-1313.2006.00387.x
   Ma L, 2012, OPHTHALMOLOGY, V119, P2290, DOI 10.1016/j.ophtha.2012.06.014
   Murray IJ, 2011, BRIT J OPHTHALMOL, V95, P431, DOI 10.1136/bjo.2010.195321
   Nolan JM, 2007, INVEST OPHTH VIS SCI, V48, P571, DOI 10.1167/iovs.06-0864
   Rein DB, 2009, ARCH OPHTHALMOL-CHIC, V127, P533, DOI 10.1001/archophthalmol.2009.58
   Richer Stuart, 2004, Optometry, V75, P216, DOI 10.1016/S1529-1839(04)70049-4
   Richer SP, 2011, OPTOMETRY, V82, P667, DOI 10.1016/j.optm.2011.08.008
   Rodriguez-Carmona M, 2006, OPHTHAL PHYSL OPT, V26, P137, DOI 10.1111/j.1475-1313.2006.00386.x
   Roodenburg AJC, 2000, AM J CLIN NUTR, V71, P1187
   SanGiovanni JP, 2007, ARCH OPHTHALMOL-CHIC, V125, P1225, DOI 10.1001/archopht.125.9.1225
   SanGiovanni JP, 2007, ARCH OPHTHALMOL-CHIC, V125, P671, DOI 10.1001/archopht.125.5.671
   Schalch W, 2007, ARCH BIOCHEM BIOPHYS, V458, P128, DOI 10.1016/j.abb.2006.09.032
   SEDDON JM, 1994, JAMA-J AM MED ASSOC, V272, P1413, DOI 10.1001/jama.272.18.1413
   Tan JSL, 2008, OPHTHALMOLOGY, V115, P334, DOI 10.1016/j.ophtha.2007.03.083
   Trieschmann M, 2007, EXP EYE RES, V84, P718, DOI 10.1016/j.exer.2006.12.010
   van de Kraats J, 2008, INVEST OPHTH VIS SCI, V49, P5568, DOI 10.1167/iovs.08-1939
   van der Veen RLP, 2009, J BIOMED OPT, V14, DOI 10.1117/1.3275481
   van der Veen RLP, 2009, OPHTHAL PHYSL OPT, V29, P127, DOI 10.1111/j.1475-1313.2008.00618.x
   van Herpen-Broekmans WMR, 2004, EUR J EPIDEMIOL, V19, P915, DOI 10.1007/s10654-004-5760-z
   van Leeuwen R, 2003, INVEST OPHTH VIS SCI, V44, P3771, DOI 10.1167/iovs.03-0121
   Weigert G, 2011, INVEST OPHTH VIS SCI, V52, P8174, DOI 10.1167/iovs.11-7522
NR 38
TC 68
Z9 71
U1 0
U2 43
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD MAR
PY 2013
VL 54
IS 3
BP 1781
EP 1788
DI 10.1167/iovs.12-10715
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 117GV
UT WOS:000316942400028
PM 23385792
DA 2022-11-30
ER

PT J
AU Biesemeier, A
   Schraermeyer, U
   Eibl, O
AF Biesemeier, Antje
   Schraermeyer, Ulrich
   Eibl, Oliver
TI Quantitative chemical analysis of ocular melanosomes in stained and
   non-stained tissues
SO MICRON
LA English
DT Review
DE Combined energy dispersive X-ray microanalysis and electron energy loss
   spectroscopy; Analytical electron microscopy; Melanosomes; Melanin type;
   Chemical composition; Rat; Sepia
ID X-RAY-MICROANALYSIS; RETINAL-PIGMENT EPITHELIUM; MELANIN; PHEOMELANIN;
   EUMELANIN; SPECIMENS; MELANOMAS; EYES
AB Energy-filtered Analytical Electron Microscopy (AEM) was used to image the ultrastructure and determine quantitatively the chemical composition of rat melanosomes of the choroid and the Retinal Pigment Epithelium (RPE). For the first time, the effect of staining in elemental analysis of melanosomes was investigated. Detection limits and accuracies of the applied methods were determined.
   Compared to previous work applying only quantitative Energy Dispersive X-ray microanalysis (EDX) in the TEM (Eibl. O., et al., 2006. Micron 37, 262), here we present a combined quantitative EDX and Electron Energy Loss Spectroscopy (EELS) analysis, including N. This yields the fraction of eumelanin and pheomelanin in melanosomes by the S/N mole fraction ratio. Melanosomes of the sepia ink sac, used as eumelanin standard, showed an S/N mole fraction ratio of < 0.004. Thus, they consist primarily of eumelanin as reported by degradation analysis. In contrast, melanosomes of the rats contained mixed melanin with significant amounts of pheomelanin (S/N 0.02) in the RPE and the choroid. Consistent with the previous publication, it was shown that oxygen mole fractions are especially large in melanosomes (7-10 at.%) compared to other cell compartments, e.g. 2-4 at.% oxygen in the cytoplasm. In the melanosomes of non-stained tissue, the oxygen mole fraction clearly correlated with the Ca mole fraction.
   EDX spectra used for quantitative analysis had about 15,000 net counts under the oxygen peak, which is necessary to obtain (i) a small statistical error for oxygen and (ii) optimum minimum detectable mole fractions for S, Ca and transition metals. The precise determination of the oxygen mole fraction in melanosomes is important for understanding metabolism. Therefore, a detailed analysis was carried out on the possible errors affecting quantification.
   While O, S, and N mole fractions yielded similar results in stained and non-stained ocular melanosomes of rats, transition metals can only be determined reliably in non-stained tissues. High-precision EDX analysis of melanosomes yielded minimum detectable mole fractions of less than 0.04 at.% for Cu and Zn, these elements were present in melanosomes with mole fractions of about 0.3 at.% and 0.1 at.%, respectively. Zn is of great importance for metabolism and for age related macular degeneration. Its mole fraction in melanosomes of rats is large enough to be detected and to be quantitatively analyzed by EDX spectroscopy. Ultrastructural information can now be correlated to the elemental composition. This is important to better understand the physical and chemical properties of melanosomal metabolism and turnover. (C) 2011 Elsevier Ltd. All rights reserved.
C1 [Biesemeier, Antje; Eibl, Oliver] Univ Tubingen, Inst Appl Phys, D-72076 Tubingen, Germany.
   [Biesemeier, Antje; Schraermeyer, Ulrich] Univ Eye Hosp, D-72076 Tubingen, Germany.
C3 Eberhard Karls University of Tubingen; Eberhard Karls University of
   Tubingen; Eberhard Karls University Hospital
RP Biesemeier, A (通讯作者)，Univ Tubingen, Inst Appl Phys, Morgenstelle 10, D-72076 Tubingen, Germany.
EM antje.biesemeier@uni-tuebingen.de;
   ulrich.schraermeyer@med.uni-tuebingen.de; oliver.eibl@uni-tuebingen.de
OI Biesemeier, Antje/0000-0002-3462-8803
CR Aronova MA, 2008, J STRUCT BIOL, V161, P322, DOI 10.1016/S1047-8477(08)00062-2
   Aronova MA, 2009, ULTRAMICROSCOPY, V109, P201, DOI 10.1016/j.ultramic.2008.10.003
   Birajdar B, 2006, SUPERCOND SCI TECH, V19, P916, DOI 10.1088/0953-2048/19/9/006
   Chen KG, 2006, P NATL ACAD SCI USA, V103, P9903, DOI 10.1073/pnas.0600213103
   Chen KG, 2009, JNCI-J NATL CANCER I, V101, P1259, DOI 10.1093/jnci/djp259
   Chi A, 2006, J PROTEOME RES, V5, P3135, DOI 10.1021/pr060363j
   Egerton R.F., 2011, ELECT ENERGY LOSS SP
   Eibl O, 2006, MICRON, V37, P262, DOI 10.1016/j.micron.2005.08.006
   Esivision S., 2002, SOFT IMAGING SYSTEMS
   Hong L, 2007, J PHYS CHEM B, V111, P7938, DOI 10.1021/jp071439h
   INCA, 2001, MICR SUIT
   ITO S, 1985, ANAL BIOCHEM, V144, P527, DOI 10.1016/0003-2697(85)90150-2
   Ito S, 2003, PIGM CELL RES, V16, P523, DOI 10.1034/j.1600-0749.2003.00072.x
   JIMBOW K, 1984, CANCER RES, V44, P1128
   Kokkinou D, 2005, GRAEF ARCH CLIN EXP, V243, P1050, DOI 10.1007/s00417-005-1197-7
   Laquerriere P, 2002, MICRON, V33, P597, DOI 10.1016/S0968-4328(02)00032-X
   LEAPMAN RD, 1992, J MICROSC-OXFORD, V165, P225, DOI 10.1111/j.1365-2818.1992.tb01482.x
   Liu Y, 2005, PHOTOCHEM PHOTOBIOL, V81, P510, DOI 10.1562/2004-10-19-RA-345.1
   Prota G, 2000, PIGM CELL RES, V13, P283, DOI 10.1034/j.1600-0749.2000.130412.x
   Prota G, 1998, EXP EYE RES, V67, P293, DOI 10.1006/exer.1998.0518
   SAMUELSON DA, 1993, EXP EYE RES, V56, P63, DOI 10.1006/exer.1993.1009
   SARNA T, 1992, J PHOTOCH PHOTOBIO B, V12, P215, DOI 10.1016/1011-1344(92)85027-R
   Schraermeyer U, 1999, PIGM CELL RES, V12, P219, DOI 10.1111/j.1600-0749.1999.tb00755.x
   Schraermeyer U, 1996, HISTOL HISTOPATHOL, V11, P445
   Schultz M, 1998, J MICROSC-OXFORD, V190, P293
   Simon JD, 2010, ACCOUNTS CHEM RES, V43, P1452, DOI 10.1021/ar100079y
   Sousa AA, 2008, J STRUCT BIOL, V162, P14, DOI 10.1016/j.jsb.2008.01.007
   Thirion S, 1997, J MICROSC-OXFORD, V186, P28, DOI 10.1046/j.1365-2818.1997.1980760.x
   Tribl F, 2005, MOL CELL PROTEOMICS, V4, P945, DOI 10.1074/mcp.M400117-MCP200
   VANDERSCHAFT TL, 1992, ARCH OPHTHALMOL-CHIC, V110, P389, DOI 10.1001/archopht.1992.01080150087034
   VINAYAGAMOORTHY T, 1993, MELANOMA RES, V3, P263
   Wakamatsu K, 2009, PIGM CELL MELANOMA R, V22, P474, DOI 10.1111/j.1755-148X.2009.00580.x
   WENDTGALLITELLI MF, 1982, Z NATURFORSCH C, V37, P712
   Williams D. D. B., 1996, TRANSMISSION ELECT M
   ZIEROLD K, 1989, ELECT PROBE MICROANA
NR 35
TC 15
Z9 15
U1 0
U2 14
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0968-4328
J9 MICRON
JI Micron
PD JUL
PY 2011
VL 42
IS 5
BP 461
EP 470
DI 10.1016/j.micron.2011.01.004
PG 10
WC Microscopy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Microscopy
GA 747MB
UT WOS:000289322900012
PM 21330141
DA 2022-11-30
ER

PT J
AU Abe, T
   Yoshida, M
   Yoshioka, Y
   Wakusawa, R
   Tokita-Ishikawa, Y
   Seto, H
   Tamai, M
   Nishida, K
AF Abe, Toshiaki
   Yoshida, Madoka
   Yoshioka, Yuki
   Wakusawa, Ryosuke
   Tokita-Ishikawa, Yumi
   Seto, Haruka
   Tamai, Makoto
   Nishida, Kohji
TI Iris pigment epithelial cell transplantation for degenerative retinal
   diseases
SO PROGRESS IN RETINAL AND EYE RESEARCH
LA English
DT Review
DE IPE; transplantation; retinal degenerative diseases; age-related macular
   degeneration; culture autologous IPE
ID MEDIATED GENE-TRANSFER; PHOTORECEPTOR-SPECIFIC PHENOTYPES; CILIARY
   NEUROTROPHIC FACTOR; FIBROBLAST GROWTH-FACTOR; CENTRAL-NERVOUS-SYSTEM;
   TERM IN-VIVO; MACULAR DEGENERATION; SUBRETINAL SPACE; RCS RATS;
   CHOROIDAL NEOVASCULARIZATION
AB The transplantation of different types of cells into the eye to treat retinal diseases has advanced in the past 20 years. One of the types of cells used for transplantation is the iris pigment epithelial (IPE) cell, because autologous IPE cells are easily obtained and their properties are similar to those of retinal pigment epithelial (RPE) cells and retinal cells. IPE cells are transplanted as; freshly isolated or cultured cells to replace defective or diseased RPE cells, genetically modified IPE cells for delivering target molecules to the retina or RPE, and retinal progenitor cells. IPE cells have also been transplanted for non-retinal disorders. The survival of the transplanted cells in the host is an important factor for the success of transplantation. Autologous IPE cells have been found in the transplanted subretinal space and were able to phagocytose rod outer segments even 6 months after transplantation. Allogeneic and xenogenic cells will not remain in the region longer than autologous cells. Allogenic cells transplanted into the subretinal space are rejected in humans. Thus, we have transplanted cultured autologous IPE cells in 56 patients with age-related macular degeneration. The long-term results (more than 2 years with a maximum of 8 years) showed that the visual acuity (VA) was significantly improved over the pre-transplantation VA, although a slight decrease of VA was observed 2 weeks after the transplantation. One patient showed a vasculitis-like lesion. IPE cells that were transduced with neurotrophic factors by plasmid or viral vectors have also been transplanted in animals. We have transduced several neurotrophic factor genes into IPE cells with a plasmid vector, adeno-associated virus, or adenovirus. Transplantation of these transduced IPE cells into the subretinal space rescued photoreceptor cells from several types of photoreceptor toxicities. In addition, transduction of a gene into the IPE cells suppressed the systemic dissemination of the viral genome. The neuroprotective effects of the IPE cells were different for the different types of neurotrophic factor, and some of the neurotrophic factors may enhance systemic immune reaction after transplantation. IPE cells have also been used as retinal progenital cells because they originate from the same cell lines that give rise to the neural retina and RPE cells. The transduction of the photoreceptor-related homeobox gene was reported to induce photoreceptor phenotypes in IPE cells. Furthermore, transplantations of IPE cells have been performed to treat central nervous system disorders. In this review, we summarize recent progress on IPE transplantation. (C) 2007 Elsevier Ltd. All rights reserved.
C1 Tohoku Univ, Grad Sch Med, CTAAR, Div Clin Cell Therapy, Sendai, Miyagi, Japan.
   Tohoku Univ, Grad Sch Med, Dept Ophthalmol & Visual Sci, Sendai, Miyagi, Japan.
   Tohoku Univ, Div Biofunct Sci, Biomed Engn Res Org, Sendai, Miyagi, Japan.
C3 Tohoku University; Tohoku University; Tohoku University
RP Abe, T (通讯作者)，Tohoku Univ, Grad Sch Med, CTAAR, Div Clin Cell Therapy, Sendai, Miyagi, Japan.
EM toshi@oph.med.tohoku.ac.jp
OI Nishida, Kohji/0000-0001-9069-3610
CR Abe T, 2006, ADV EXP MED BIOL, V572, P363
   Abe T, 2005, CELL TRANSPLANT, V14, P799, DOI 10.3727/000000005783982549
   Abe T, 2000, TOHOKU J EXP MED, V191, P7, DOI 10.1620/tjem.191.7
   Abe T, 2000, CURR EYE RES, V20, P268
   Abe T, 2003, INVEST OPHTH VIS SCI, V44, P4097, DOI 10.1167/iovs.02-0867
   Abe T, 1999, CELL TRANSPLANT, V8, P501, DOI 10.1177/096368979900800505
   Abe T, 1999, TOHOKU J EXP MED, V189, P295, DOI 10.1620/tjem.189.295
   Abe T, 2001, GRAEF ARCH CLIN EXP, V239, P927, DOI 10.1007/s00417-001-0393-3
   Abe T, 1999, TOHOKU J EXP MED, V189, P179, DOI 10.1620/tjem.189.179
   Abe Toshiaki, 2002, Nippon Ganka Gakkai Zasshi, V106, P778
   Acland GM, 2001, NAT GENET, V28, P92, DOI 10.1038/ng0501-92
   Adamus G, 2003, J AUTOIMMUN, V21, P121, DOI 10.1016/S0896-8411(03)00092-1
   Aisenbrey S, 2006, ARCH OPHTHALMOL-CHIC, V124, P183, DOI 10.1001/archopht.124.2.183
   Aitken ML, 2001, HUM GENE THER, V12, P1907, DOI 10.1089/104303401753153956
   Akagi T, 2005, INVEST OPHTH VIS SCI, V46, P3411, DOI 10.1167/iovs.04-1112
   Akagi T, 2004, INVEST OPHTH VIS SCI, V45, P4570, DOI 10.1167/iovs.04-0697
   Algvere PV, 1997, GRAEF ARCH CLIN EXP, V235, P149, DOI 10.1007/BF00941722
   Aloyz RS, 1998, J CELL BIOL, V143, P1691, DOI 10.1083/jcb.143.6.1691
   Angunawela RI, 2005, BRIT J OPHTHALMOL, V89, P386, DOI 10.1136/bjo.2004.050716
   Anosova NG, 2001, J CLIN INVEST, V108, P1175, DOI 10.1172/JCI12204
   Arnhold S, 2004, EXP NEUROL, V187, P410, DOI 10.1016/j.expneurol.2004.02.015
   Bainbridge JWB, 2003, GENE THER, V10, P1049, DOI 10.1038/sj.gt.3301945
   Bennett J, 1999, P NATL ACAD SCI USA, V96, P9920, DOI 10.1073/pnas.96.17.9920
   Bennett J, 1996, NAT MED, V2, P649, DOI 10.1038/nm0696-649
   BENNETT J, 1994, INVEST OPHTH VIS SCI, V35, P2535
   Bennett J, 1998, GENE THER, V5, P1156, DOI 10.1038/sj.gt.3300733
   BHATT NS, 1994, AM J OPHTHALMOL, V117, P214, DOI 10.1016/S0002-9394(14)73079-X
   Binder S, 2004, INVEST OPHTH VIS SCI, V45, P4151, DOI 10.1167/iovs.04-0118
   Blinder KJ, 2003, AM J OPHTHALMOL, V136, P407, DOI 10.1016/S0002-9394(03)00223-X
   Bordet T, 2001, HUM MOL GENET, V10, P1925, DOI 10.1093/hmg/10.18.1925
   Bringmann A, 2004, OPHTHALMIC RES, V36, P241, DOI 10.1159/000081203
   Campochiaro PA, 2006, HUM GENE THER, V17, P167, DOI 10.1089/hum.2006.17.167
   Cao YJ, 2002, GENE THER, V9, P415, DOI 10.1038/sj.gt.3301676
   Cashman SM, 2006, INVEST OPHTH VIS SCI, V47, P3496, DOI 10.1167/iovs.05-1610
   Cayouette M, 1997, HUM GENE THER, V8, P423, DOI 10.1089/hum.1997.8.4-423
   Cayouette M, 1998, J NEUROSCI, V18, P9282
   Chen Y, 2006, INVEST OPHTH VIS SCI, V47, P1177, DOI 10.1167/iovs.05-0965
   ChoiLundberg DL, 1997, SCIENCE, V275, P838, DOI 10.1126/science.275.5301.838
   CLAUDE P, 1973, J CELL BIOL, V58, P390, DOI 10.1083/jcb.58.2.390
   Coffey PJ, 2002, NAT NEUROSCI, V5, P53, DOI 10.1038/nn782
   Crafoord S, 2002, ACTA OPHTHALMOL SCAN, V80, P387, DOI 10.1034/j.1600-0420.2002.800408.x
   Crafoord S, 2000, ACTA OPHTHALMOL SCAN, V78, P122, DOI 10.1034/j.1600-0420.2000.078002122.x
   Crystal RG, 2004, HUM GENE THER, V15, P1131
   Dejneka NS, 2004, MOL THER, V9, P182, DOI 10.1016/j.ymthe.2003.11.013
   Del Priore LV, 2003, INVEST OPHTH VIS SCI, V44, P4044, DOI 10.1167/iovs.02-1175
   Del Priore LV, 2001, AM J OPHTHALMOL, V131, P472, DOI 10.1016/S0002-9394(00)00850-3
   DiLoreto D, 1996, EXP NEUROL, V140, P37
   During M J, 2001, Hum Gene Ther, V12, P1589
   FAKTOROVICH EG, 1990, NATURE, V347, P83, DOI 10.1038/347083a0
   Farrelly N, 1999, J CELL BIOL, V144, P1337, DOI 10.1083/jcb.144.6.1337
   FEALY MJ, 1995, TRANSPLANTATION, V59, P1475, DOI 10.1097/00007890-199505270-00020
   Finlay D, 2000, CELL DEATH DIFFER, V7, P302, DOI 10.1038/sj.cdd.4400652
   Flotte TR, 2004, HUM GENE THER, V15, P93
   FREDDO TF, 1984, INVEST OPHTH VIS SCI, V25, P1094
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Gartenhaus RB, 1996, P NATL ACAD SCI USA, V93, P265, DOI 10.1073/pnas.93.1.265
   GASS JDM, 1994, AM J OPHTHALMOL, V118, P285, DOI 10.1016/S0002-9394(14)72951-4
   Gauthier R, 2005, INVEST OPHTH VIS SCI, V46, P3383, DOI 10.1167/iovs.05-0362
   Geng LJ, 1999, EXP EYE RES, V69, P539, DOI 10.1006/exer.1999.0735
   Gouras P, 2002, INVEST OPHTH VIS SCI, V43, P3307
   Grisanti S, 1997, INVEST OPHTH VIS SCI, V38, P1619
   Gullapalli VK, 2005, EXP EYE RES, V80, P235, DOI 10.1016/j.exer.2004.09.006
   GUMBINER B, 1987, AM J PHYSIOL, V253, P749
   GURNE DH, 1991, OPHTHALMOLOGY, V98, P602
   Haase G, 1997, NAT MED, V3, P429, DOI 10.1038/nm0497-429
   HAMMER R M, 1991, Journal of Neural Transplantation and Plasticity, V2, P81
   Hartmann U, 1999, GRAEF ARCH CLIN EXP, V237, P940, DOI 10.1007/s004170050390
   Haruta M, 2001, NAT NEUROSCI, V4, P1163, DOI 10.1038/nn762
   Hawkins BS, 2004, OPHTHALMOLOGY, V111, P1967, DOI 10.1016/j.ophtha.2004.07.021
   Hendriks WTJ, 2004, PROG BRAIN RES, V146, P451
   Hennig AK, 2004, MOL THER, V10, P106, DOI 10.1016/j.ymthe.2004.03.018
   Hirose M, 2000, BIOMACROMOLECULES, V1, P377, DOI 10.1021/bm0002961
   Hojo M, 2004, INVEST OPHTH VIS SCI, V45, P3721, DOI 10.1167/iovs.04-0059
   Hong DH, 2005, INVEST OPHTH VIS SCI, V46, P435, DOI 10.1167/iovs.04-1065
   Hu DN, 1997, ARCH OPHTHALMOL-CHIC, V115, P89, DOI 10.1001/archopht.1997.01100150091015
   HU DN, 1992, INVEST OPHTH VIS SCI, V33, P2443
   Huang SP, 2004, J BIOMED SCI, V11, P37, DOI 10.1159/000075287
   Ito A, 2005, TISSUE ENG, V11, P489, DOI 10.1089/ten.2005.11.489
   JIANG LQ, 1994, INVEST OPHTH VIS SCI, V35, P4300
   JOMARY C, 1994, FEBS LETT, V347, P117, DOI 10.1016/0014-5793(94)00512-5
   Jordan JF, 2002, GRAEF ARCH CLIN EXP, V240, P403, DOI 10.1007/s00417-002-0436-4
   Joussen AM, 2006, AM J OPHTHALMOL, V142, P17, DOI 10.1016/j.ajo.2006.01.090
   Kamata Y, 2003, GENE THER, V10, P406, DOI 10.1038/sj.gt.3301869
   Kano T, 2002, INVEST OPHTH VIS SCI, V43, P3744
   Kato N, 2005, DIABETES, V54, P846, DOI 10.2337/diabetes.54.3.846
   Kay MA, 2000, NAT GENET, V24, P257, DOI 10.1038/73464
   Klein R, 2006, OPHTHALMOLOGY, V113, P373, DOI 10.1016/j.ophtha.2005.12.013
   Kociok N, 1998, EXP EYE RES, V67, P237, DOI 10.1006/exer.1998.0517
   Kohen L, 1997, OPHTHALMIC RES, V29, P298, DOI 10.1159/000268028
   KOZARSKY KF, 1993, CURR OPIN GENET DEV, V3, P499, DOI 10.1016/0959-437X(93)90126-A
   Kubota A, 2006, BIOMATERIALS, V27, P3639, DOI 10.1016/j.biomaterials.2006.02.018
   Kumar-Singh R, 1998, HUM MOL GENET, V7, P1893, DOI 10.1093/hmg/7.12.1893
   Lai CC, 2000, INVEST OPHTH VIS SCI, V41, P3134
   Lappas A, 2004, GRAEF ARCH CLIN EXP, V242, P638, DOI 10.1007/s00417-003-0764-z
   Lappas A, 2000, GRAEF ARCH CLIN EXP, V238, P631, DOI 10.1007/s004170000149
   LAVAIL MM, 1992, EXP EYE RES, V55, P555, DOI 10.1016/S0014-4835(05)80168-X
   Leone P, 2000, ANN NEUROL, V48, P27, DOI 10.1002/1531-8249(200007)48:1<27::AID-ANA6>3.0.CO;2-6
   LI L, 1991, EXP EYE RES, V52, P669, DOI 10.1016/0014-4835(91)90019-B
   Liu Y, 2005, PHOTOCHEM PHOTOBIOL, V81, P510, DOI 10.1562/2004-10-19-RA-345.1
   LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D
   Malik JMI, 2005, MOL THER, V11, P373, DOI 10.1016/j.ymthe.2004.11.014
   Marshall E, 1999, SCIENCE, V286, P2244, DOI 10.1126/science.286.5448.2244
   Martin KRG, 2003, INVEST OPHTH VIS SCI, V44, P4357, DOI 10.1167/iovs.02-1332
   MARTONE RL, 1988, BIOCHEM BIOPH RES CO, V157, P1078, DOI 10.1016/S0006-291X(88)80984-7
   MCKAY BS, 2006, EXP NEUROL
   Michel U, 2005, BIOCHEM BIOPH RES CO, V326, P307, DOI 10.1016/j.bbrc.2004.11.029
   Miyazaki M, 2005, INVEST OPHTH VIS SCI, V46, P1907, DOI 10.1167/iovs.04-0923
   Moss RB, 2004, CHEST, V125, P509, DOI 10.1378/chest.125.2.509
   NEWSOME DA, 1986, AM J OPHTHALMOL, V101, P354, DOI 10.1016/0002-9394(86)90831-7
   Nishida K, 2004, NEW ENGL J MED, V351, P1187, DOI 10.1056/NEJMoa040455
   Ohno-Matsui K, 2005, MOL VIS, V11, P1
   PENFOLD PL, 1990, GRAEF ARCH CLIN EXP, V228, P270, DOI 10.1007/BF00920033
   PEYMAN GA, 1991, OPHTHALMIC SURG LAS, V22, P102
   Prince JM, 2002, DEV DYNAM, V223, P497, DOI 10.1002/dvdy.10070
   Rabinowitz JE, 2002, J VIROL, V76, P791, DOI 10.1128/JVI.76.2.791-801.2002
   Raper SE, 2003, MOL GENET METAB, V80, P148, DOI 10.1016/j.ymgme.2003.08.016
   Redmond TM, 1998, NAT GENET, V20, P344, DOI 10.1038/3813
   Rezai KA, 1997, INVEST OPHTH VIS SCI, V38, P2662
   Rezai KA, 1997, INVEST OPHTH VIS SCI, V38, P2255
   Rezai KA, 1997, EXP EYE RES, V65, P23, DOI 10.1006/exer.1997.0307
   Rezai KA, 1997, GRAEF ARCH CLIN EXP, V235, P48, DOI 10.1007/BF01007837
   Rezai KA, 1997, GRAEF ARCH CLIN EXP, V235, P558, DOI 10.1007/BF00947084
   Rolling F, 2004, GENE THER, V11, pS26, DOI 10.1038/sj.gt.3302366
   Saigo Y, 2004, INVEST OPHTH VIS SCI, V45, P1996, DOI 10.1167/iovs.03-0777
   Saito A, 2004, J NEUROSCI, V24, P1584, DOI 10.1523/JNEUROSCI.5209-03.2004
   Sakuragi M, 2001, CURR EYE RES, V23, P185, DOI 10.1076/ceyr.23.3.185.5465
   Sandrock R, 2003, APOPTOSIS, V8, P209, DOI 10.1023/A:1022983012305
   Sapieha PS, 2003, MOL CELL NEUROSCI, V24, P656, DOI 10.1016/S1044-7431(03)00228-8
   Schmeer C, 2002, EUR J NEUROSCI, V15, P637, DOI 10.1046/j.1460-9568.2002.01893.x
   Schneeberger EE, 1992, AM J PHYSIOL, V262, P647
   Schraermeyer U, 1997, EXP EYE RES, V65, P277, DOI 10.1006/exer.1997.0339
   Schraermeyer U, 1999, PIGM CELL RES, V12, P219, DOI 10.1111/j.1600-0749.1999.tb00755.x
   Schraermeyer U, 1999, INVEST OPHTH VIS SCI, V40, P1545
   Schraermeyer U, 2000, GRAEF ARCH CLIN EXP, V238, P979, DOI 10.1007/s004170000194
   Semkova I, 2002, P NATL ACAD SCI USA, V99, P13090, DOI 10.1073/pnas.202486199
   SHEEDLO H J, 1991, Journal of Neural Transplantation and Plasticity, V2, P55
   SHEEDLO HJ, 1993, EXP EYE RES, V57, P753, DOI 10.1006/exer.1993.1183
   SHEEDLO HJ, 1995, IN VITRO CELL DEV-AN, V31, P330
   Smit NPM, 1998, ARCH DERMATOL RES, V290, P342, DOI 10.1007/s004030050315
   Smith AJ, 2003, MOL THER, V8, P188, DOI 10.1016/S1525-0016(03)00144-8
   Smith GM, 1996, EXP NEUROL, V139, P156, DOI 10.1006/exnr.1996.0090
   STOCKER KM, 1991, DEVELOPMENT, V111, P635
   Stover NP, 2005, ARCH NEUROL-CHICAGO, V62, P1833, DOI 10.1001/archneur.62.12.1833
   Streilein JW, 2002, VISION RES, V42, P487, DOI 10.1016/S0042-6989(01)00185-7
   Sugano E, 2003, EXP EYE RES, V77, P203, DOI 10.1016/S0014-4835(03)00115-5
   Sugita S, 2004, J IMMUNOL, V172, P4184, DOI 10.4049/jimmunol.172.7.4184
   Sugita S, 2003, J EXP MED, V198, P161, DOI 10.1084/jem.20030097
   Sun GW, 2006, DEV BIOL, V289, P243, DOI 10.1016/j.ydbio.2005.10.035
   Surace EM, 2003, J VIROL, V77, P7957, DOI 10.1128/JVI.77.14.7957-7963.2003
   Takita H, 2003, INVEST OPHTH VIS SCI, V44, P4497, DOI 10.1167/iovs.03-0052
   Tezel TH, 1997, GRAEF ARCH CLIN EXP, V235, P41, DOI 10.1007/BF01007836
   Thumann G, 2000, ARCH OPHTHALMOL-CHIC, V118, P1350
   Thumann G, 2006, CURR EYE RES, V31, P241, DOI 10.1080/02713680600556966
   Thumann G, 1997, CURR EYE RES, V16, P1236, DOI 10.1076/ceyr.16.12.1236.5031
   Thumann G, 1999, TRANSPLANTATION, V68, P195, DOI 10.1097/00007890-199907270-00006
   Thumann G, 1998, GRAEF ARCH CLIN EXP, V236, P753, DOI 10.1007/s004170050154
   Thumann G, 1999, GRAEF ARCH CLIN EXP, V237, P1046, DOI 10.1007/s004170050343
   Thumann G, 2001, SURV OPHTHALMOL, V45, P345, DOI 10.1016/S0039-6257(00)00195-8
   Tsukita S, 1997, SOC GEN PHY, V52, P69
   Van Meurs JC, 2003, AM J OPHTHALMOL, V136, P688, DOI 10.1016/S0002-9394(03)00384-2
   Vollrath D, 2001, P NATL ACAD SCI USA, V98, P12584, DOI 10.1073/pnas.221364198
   Wagner JA, 2002, HUM GENE THER, V13, P1349, DOI 10.1089/104303402760128577
   Wagner JA, 1999, LARYNGOSCOPE, V109, P266, DOI 10.1097/00005537-199902000-00017
   Wagner JA, 1999, J GENE MED, V1, P13, DOI 10.1002/(SICI)1521-2254(199901/02)1:1<13::AID-JGM6>3.3.CO;2-7
   Wang SM, 2005, INVEST OPHTH VIS SCI, V46, P2552, DOI 10.1167/iovs.05-0279
   Weisz JM, 1999, RETINA-J RET VIT DIS, V19, P540, DOI 10.1097/00006982-199911000-00011
   Wenkel H, 1999, INVEST OPHTH VIS SCI, V40, P3202
   Whiteley SJO, 1996, EXP NEUROL, V140, P100, DOI 10.1006/exnr.1996.0120
   Wolfensberger TJ, 2000, GRAEF ARCH CLIN EXP, V238, P76, DOI 10.1007/s004170050013
   Wu WC, 2004, MOL VIS, V10, P93
   YAMAMOTO S, 1993, INVEST OPHTH VIS SCI, V34, P3068
   Yamato M, 1999, J BIOMED MATER RES, V44, P44, DOI 10.1002/(SICI)1097-4636(199901)44:1<44::AID-JBM5>3.3.CO;2-O
   Yoshioka Y, 2006, INVEST OPHTH VIS SCI, V47, P745, DOI 10.1167/iovs.05-0398
   Zeng Y, 2004, INVEST OPHTH VIS SCI, V45, P3279, DOI 10.1167/iovs.04-0576
   Zhang XY, 1998, INVEST OPHTH VIS SCI, V39, P1021
NR 175
TC 39
Z9 43
U1 0
U2 8
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 1350-9462
J9 PROG RETIN EYE RES
JI Prog. Retin. Eye Res.
PD MAY
PY 2007
VL 26
IS 3
BP 302
EP 321
DI 10.1016/j.preteyeres.2007.01.003
PG 20
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 165DI
UT WOS:000246283700004
PM 17324604
DA 2022-11-30
ER

PT J
AU Jean-Charles, A
   Cohen, SY
   Merle, H
   Quentel, G
   Legargasson, JF
   Gaudric, A
AF Jean-Charles, Albert
   Cohen, Salomon Y.
   Merle, Harold
   Quentel, Gabriel
   Legargasson, Jean-Francois
   Gaudric, Alain
TI MARTINIQUE (WEST INDIES) CRINKLED RETINAL PIGMENT EPITHELIOPATHY
   Clinical Description
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE retinal pigment epithelium; dystrophy; spectral domain optical coherence
   tomography
ID POLYPOIDAL CHOROIDAL VASCULOPATHY; DYSTROPHY; FEATURES
AB Purpose: To report a previously undescribed pattern of crinkled retinal pigment epithelium (RPE), observed in a family of black patients originating from Martinique, an island in the French West Indies.
   Methods: Three generations were examined by visual acuity measurement and fundus photography. Autofluorescence photography, fluorescein and indocyanine green angiography, visual field testing, electrophysiology, and spectral domain optical coherence tomography were performed in certain patients.
   Results: One 86-year-old grandmother, her 7 children, her nephew, and 18 of her 22 grandchildren were examined. Nine patients were affected: five children, one nephew, and three grandchildren. An unrelated patient originating from the same area was also affected. In the third generation, fundus findings were whitish deep lines located in the posterior pole. Optical coherence tomography showed a crinkled pattern of a slightly elevated RPE. In the second generation, a scalloped crinkled RPE was observed in the posterior pole and midperiphery, giving an image of dry desert land in fluorescein and indocyanine green angiography. Optical coherence tomography showed that the RPE formed ripples, giving it a crinkled appearance. Complications were observed in six cases: they included RPE atrophy (one case), subretinal and sub-RPE hemorrhages because of polypoidal choroidal vasculopathy (four cases), and fibrovascular scarring (one case). The grandmother's fundi were characterized by peripheral pigmentary changes, with severe visual loss.
   Conclusion: The observed pattern appeared different from previously described dystrophies and could be referred to as Martinique crinkled retinal pigment epitheliopathy. RETINA 33: 1041-1048, 2013
C1 [Jean-Charles, Albert; Merle, Harold] Univ Hosp, Dept Ophthalmol, Fort De France, France.
   [Cohen, Salomon Y.; Quentel, Gabriel] Ctr Ophtalmol Imagerie & Laser, F-75015 Paris, France.
   [Cohen, Salomon Y.; Gaudric, Alain] Univ Paris Diderot, Lariboisiere Hosp, APHP, Dept Ophthalmol, Paris, France.
   [Legargasson, Jean-Francois] Univ Paris Diderot, Lariboisiere Hosp, APHP, Dept Funct Testing, Paris, France.
C3 CHU Martinique; Assistance Publique Hopitaux Paris (APHP); Hopital
   Universitaire Ambroise-Pare - APHP; Hopital Universitaire
   Lariboisiere-Fernand-Widal - APHP; UDICE-French Research Universities;
   Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP);
   Hopital Universitaire Ambroise-Pare - APHP; Hopital Universitaire
   Lariboisiere-Fernand-Widal - APHP; UDICE-French Research Universities;
   Universite Paris Cite
RP Cohen, SY (通讯作者)，Ctr Ophtalmol Imagerie & Laser, 11 Rue Antoine Bourdelle, F-75015 Paris, France.
EM sycsyc75@gmail.com
OI Gaudric, Alain/0000-0002-2486-4722
CR Agarwal A, 2005, ARCH OPHTHALMOL-CHIC, V123, P923, DOI 10.1001/archopht.123.7.923
   Agarwal A., 2011, GASS STEREOSCOPIC AT, P358
   Guyomarch J, 2008, J FR OPHTALMOL, V31, P579, DOI 10.1016/S0181-5512(08)75458-5
   Imamura Y, 2010, SURV OPHTHALMOL, V55, P501, DOI 10.1016/j.survophthal.2010.03.004
   JOHNSON BL, 1990, AM J OPHTHALMOL, V110, P504, DOI 10.1016/S0002-9394(14)77873-0
   Kellner U, 1998, ARCH OPHTHALMOL-CHIC, V116, P1307, DOI 10.1001/archopht.116.10.1307
   Khan S, 2012, RETINA-J RET VIT DIS, V32, P1057, DOI 10.1097/IAE.0b013e31823beb14
   Marmor MF, 2009, DOC OPHTHALMOL, V118, P69, DOI 10.1007/s10633-008-9155-4
   SNEED SR, 1991, AM J OPHTHALMOL, V112, P1
   STERN RM, 1985, AM J OPHTHALMOL, V100, P560, DOI 10.1016/0002-9394(85)90682-8
   STEUHL KP, 1985, OPHTHALMOLOGICA, V190, P219, DOI 10.1159/000309521
   Uyama M, 2002, AM J OPHTHALMOL, V133, P639, DOI 10.1016/S0002-9394(02)01404-6
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
NR 13
TC 4
Z9 4
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0275-004X
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD MAY
PY 2013
VL 33
IS 5
BP 1041
EP 1048
DI 10.1097/IAE.0b013e3182733ff3
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 131QY
UT WOS:000318011100022
PM 23370609
DA 2022-11-30
ER

PT J
AU Matsumoto, H
   Hoshino, J
   Arai, Y
   Mukai, R
   Nakamura, K
   Kikuchi, Y
   Kishi, S
   Akiyama, H
AF Matsumoto, Hidetaka
   Hoshino, Junki
   Arai, Yosuke
   Mukai, Ryo
   Nakamura, Kosuke
   Kikuchi, Yuka
   Kishi, Shoji
   Akiyama, Hideo
TI Quantitative measures of vortex veins in the posterior pole in eyes with
   pachychoroid spectrum diseases
SO SCIENTIFIC REPORTS
LA English
DT Article
ID CENTRAL SEROUS CHORIORETINOPATHY; OPTICAL COHERENCE TOMOGRAPHY
AB Pachychoroid spectrum diseases have attracted increasing attention, though their pathophysiology has yet to be fully elucidated. In this study, we assessed the vascular diameters of vortex veins in pachychoroid spectrum diseases such as central serous chorioretinopathy (CSC), pachychoroid neovasculopathy without polypoidal lesions (PNV), and pachychoroid neovasculopathy with polypoidal lesions (polypoidal choroidal vasculopathy: PCV). In a retrospective case series of 94 eyes with CSC, 60 eyes with PNV and 57 with PCV, we binarized en face optical coherence tomography (OCT) images of choroidal vortex veins and analyzed the mean diameter of vortex veins. The presence of anastomosis between the superior and inferior vortex veins and central choroidal thickness (CCT) were also evaluated using OCT images. CSC showed significantly larger mean diameter of vortex veins than PCV (P<0.05). Anastomosis between superior and inferior vortex veins was observed in over 90% of eyes with each pachychoroid spectrum disease. The patients with CSC were the youngest, followed by PNV patients, and then patients with PCV. The largest CCT values were observed in CSC eyes, followed by PNV eyes, and then PCV eyes. CCT correlated with the mean diameter of vortex veins (rs=0.51, P<0.01). These findings suggest that congestion of vortex veins might show gradual amelioration corresponding to the development of anastomosis between the superior and inferior vortex veins during the course of progression of pachychoroid spectrum diseases. Moreover, the mean diameter of vortex veins can be used as a parameter indicating choroidal congestion.
C1 [Matsumoto, Hidetaka; Hoshino, Junki; Arai, Yosuke; Mukai, Ryo; Nakamura, Kosuke; Kikuchi, Yuka; Kishi, Shoji; Akiyama, Hideo] Gunma Univ, Sch Med, Dept Ophthalmol, 3-39-15 Showa Machi, Maebashi, Gumma 3718511, Japan.
C3 Gunma University
RP Matsumoto, H (通讯作者)，Gunma Univ, Sch Med, Dept Ophthalmol, 3-39-15 Showa Machi, Maebashi, Gumma 3718511, Japan.
EM hide-m@gunma-u.ac.jp
CR Dansingani KK, 2016, RETINA-J RET VIT DIS, V36, P499, DOI 10.1097/IAE.0000000000000742
   Fung AT, 2012, RETINA-J RET VIT DIS, V32, P1829, DOI 10.1097/IAE.0b013e3182680a66
   Gallego-Pinazo Roberto, 2014, Med Hypothesis Discov Innov Ophthalmol, V3, P111
   Hiroe T, 2018, OPHTHALMOL RETINA, V2, P152, DOI 10.1016/j.oret.2017.05.013
   Iijima H, 2000, AM J OPHTHALMOL, V129, P21, DOI 10.1016/S0002-9394(99)00253-6
   Imamura Y, 2009, RETINA-J RET VIT DIS, V29, P1469, DOI 10.1097/IAE.0b013e3181be0a83
   Kishi S, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0206646
   Lee WK, 2016, RETINA-J RET VIT DIS, V36, pS73, DOI 10.1097/IAE.0000000000001346
   Matsumoto H, 2020, OPHTHALMOL RETINA, V4, P938, DOI 10.1016/j.oret.2020.03.024
   Matsumoto H, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-51268-9
   Miyake M, 2015, SCI REP-UK, V5, DOI 10.1038/srep16204
   Pang CE, 2015, RETINA-J RET VIT DIS, V35, P1, DOI 10.1097/IAE.0000000000000331
   Pang CE, 2014, AM J OPHTHALMOL, V158, P362, DOI 10.1016/j.ajo.2014.04.021
   Prunte C, 1996, AM J OPHTHALMOL, V121, P26
   Saito M, 2013, BRIT J OPHTHALMOL, V97, P775, DOI 10.1136/bjophthalmol-2012-302349
   Sakurada Y, 2020, RETINA-J RET VIT DIS, V40, P657, DOI 10.1097/IAE.0000000000002635
   Shiihara H, 2019, GRAEF ARCH CLIN EXP, V257, P1879, DOI 10.1007/s00417-019-04399-8
   Sonoda S, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0157190
   Warrow DJ, 2013, RETINA-J RET VIT DIS, V33, P1659, DOI 10.1097/IAE.0b013e3182953df4
   Yanai H., 2015, STATCEL USEFUL ADD I
   YOSHIOKA H, 1982, OPHTHALMOLOGICA, V185, P168, DOI 10.1159/000309239
NR 21
TC 14
Z9 14
U1 0
U2 1
PU NATURE RESEARCH
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD NOV 11
PY 2020
VL 10
IS 1
AR 19505
DI 10.1038/s41598-020-75789-w
PG 8
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA OZ3GM
UT WOS:000594818600012
PM 33177540
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Pauleikhoff, D
   Loffert, D
   Spital, G
   Radermacher, M
   Dohrmann, J
   Lommatzsch, A
   Bird, AC
AF Pauleikhoff, D
   Loffert, D
   Spital, G
   Radermacher, M
   Dohrmann, J
   Lommatzsch, A
   Bird, AC
TI Pigment epithelial detachment in the elderly - Clinical differentiation,
   natural course and pathogenetic implications
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
ID POLYPOIDAL CHOROIDAL VASCULOPATHY; INDOCYANINE GREEN VIDEOANGIOGRAPHY;
   BRUCHS MEMBRANE CHANGE; MACULAR DEGENERATION; AGE; TEARS;
   NEOVASCULARIZATION; ANGIOGRAPHY
AB Background: A prospective analysis was performed to characterize the angiographic appearance, natural course and prognosis of serous pigment epithelial detachments (PEDs) in elderly patients. The aim was to differentiate PEDs according to their angiographic characteristics and to analyze the specific clinical, visual and morphologic course of the different PEDs. Methods: Fluorescein and indocyanine green angiography were performed in 10 1 consecutive patients (53-87 years; 63 female, 38 male) with clinical signs of serous PED and drusen. Results: Different types of serous PED were identified: polypoidal choroidal vasculopathy (PCV)-associated PED in 14 patients (13.9%), vascular PED in 72 (71.2%), and avascular PED in 15 (14.9%). All PEDs resulted initially in similar visual loss. Avascular PEDs were smaller than vascular PEDs, and the latter were smaller than PCV-PEDs. During follow-up these differences were always present, but all PEDs enlarged initially followed by regression. This course was associated in all PEDs with progressive visual loss, accompanied by the development of RPE atrophy in avascular PEDs or disciform scars or RPE tears in the two other types. Conclusion: Despite different associations, all PEDs have a similar clinical course with respect to visual loss and enlargement or regression. This is compatible with the proposed common pathogenetic background with a hydrophobic barrier in Bruch's membrane causing fluid resulting from RPE pumping activity to accumulate between the pigment epithelium and Bruch's membrane.
C1 St Franziskus Hosp, Dept Ophthalmol, D-48145 Munster, Germany.
C3 St. Franziskus-Hospital
RP Pauleikhoff, D (通讯作者)，St Franziskus Hosp, Dept Ophthalmol, Hohenzollernring 74, D-48145 Munster, Germany.
CR Ahuja RM, 2000, BRIT J OPHTHALMOL, V84, P479, DOI 10.1136/bjo.84.5.479
   ALTMAN DG, 1999, PRACTICAL STAT MED R, P245
   [Anonymous], 1997, DIAGNOSIS TREATMENT
   Bandello F, 2000, OPHTHALMOLOGICA, V214, P362, DOI 10.1159/000027522
   BIRD AC, 1992, BRIT J OPHTHALMOL, V76, P166, DOI 10.1136/bjo.76.3.166
   BIRD AC, 1991, EYE, V5, P1
   BIRD AC, 1986, T OPHTHAL SOC UK, V105, P674
   CHUANG EL, 1988, BRIT J OPHTHALMOL, V72, P918, DOI 10.1136/bjo.72.12.918
   CHUANG EL, 1988, AM J OPHTHALMOL, V105, P285, DOI 10.1016/0002-9394(88)90011-6
   Curcio CA, 2001, INVEST OPHTH VIS SCI, V42, P265
   FISHER RF, 1987, EYE, V1, P184, DOI 10.1038/eye.1987.35
   FREDERICK AR, 1993, RETINA-J RET VIT DIS, V13, P3, DOI 10.1097/00006982-199313010-00002
   HOLZ FG, 1994, ARCH OPHTHALMOL-CHIC, V112, P402, DOI 10.1001/archopht.1994.01090150132035
   Kunze C, 1999, OPHTHALMOLOGY, V106, P1830, DOI 10.1016/S0161-6420(99)90364-0
   Lafaut BA, 2001, BRIT J OPHTHALMOL, V85, P454, DOI 10.1136/bjo.85.4.454
   MOORE DJ, 1995, INVEST OPHTH VIS SCI, V36, P1290
   Okubo A, 1999, INVEST OPHTH VIS SCI, V40, P443
   PAULEIKHOFF D, 1990, OPHTHALMOLOGY, V97, P171
   Pauleikhoff D, 1996, KLIN MONATSBL AUGENH, V209, P309, DOI 10.1055/s-2008-1035324
   Phillips WB, 1996, OPHTHALMIC SURG LAS, V27, P467
   POLINER LS, 1986, OPHTHALMOLOGY, V93, P543
   Schneider U, 1998, BRIT J OPHTHALMOL, V82, P98, DOI 10.1136/bjo.82.1.98
   SCHOEPPNER G, 1989, AM J OPHTHALMOL, V108, P683, DOI 10.1016/0002-9394(89)90861-1
   SPAIDE RF, 1995, RETINA-J RET VIT DIS, V15, P100, DOI 10.1097/00006982-199515020-00003
   Spaide RF, 1999, RETINA-J RET VIT DIS, V19, P141, DOI 10.1097/00006982-199902000-00010
   Spital G, 2000, OPHTHALMOLOGE, V97, P173, DOI 10.1007/s003470050509
   Starita C, 1997, INVEST OPHTH VIS SCI, V38, P762
   Starita C, 1996, EXP EYE RES, V62, P565, DOI 10.1006/exer.1996.0066
   Wolf S, 1994, Ger J Ophthalmol, V3, P224
   YANNUZZI LA, 1994, RETINA-J RET VIT DIS, V14, P99, DOI 10.1097/00006982-199414020-00003
   Yannuzzi LA, 1999, ARCH OPHTHALMOL-CHIC, V117, P1503
   YANNUZZI LA, 1992, RETINA-J RET VIT DIS, V12, P191, DOI 10.1097/00006982-199212030-00003
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
   YANNUZZI LA, 1997, ARCH OPHTHALMOL-CHIC, V10, P18
NR 34
TC 144
Z9 152
U1 0
U2 3
PU SPRINGER-VERLAG
PI NEW YORK
PA 175 FIFTH AVE, NEW YORK, NY 10010 USA
SN 0721-832X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD JUL
PY 2002
VL 240
IS 7
BP 533
EP 538
DI 10.1007/s00417-002-0505-8
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 583WJ
UT WOS:000177433600006
PM 12136282
DA 2022-11-30
ER

PT J
AU Serra, R
   Pinna, A
   Behar-Cohen, F
   Coscas, F
AF Serra, Rita
   Pinna, Antonio
   Behar-Cohen, Francine
   Coscas, Florence
TI OCT Angiography Fractal Analysis of Choroidal Neovessels Secondary to
   Central Serous Chorioretinopathy, in a Caucasian Cohort
SO JOURNAL OF CLINICAL MEDICINE
LA English
DT Article
DE central serous chorioretinopathy; fractal analysis; indocyanine green
   angiography; optical coherence tomography angiography; polypoidal
   choroidal vasculopathy; type 1 choroidal neovascularization
ID INDOCYANINE GREEN ANGIOGRAPHY; VASCULOPATHY; NEOVASCULARIZATION;
   DEGENERATION
AB Central serous chorioretinopathy (CSCR) can be complicated by different types of choroidal neovascularization (CNV). The purpose of this study was to investigate the incidence and quantitative optical coherence tomography angiography (OCT-A) features of CSCR-related CNVs. Methods: This was a retrospective multicenter study including 102 eyes of 102 Caucasian patients with acute or complex CSCR. All patients underwent a comprehensive ophthalmological examination. Quantitative OCT-A parameters, including vascular perfusion density (VPD), fractal dimension (FD), and lacunarity (LAC), were measured in CNV eyes. Results: Forty eyes (39.2%) had acute CSCR, whereas the remaining sixty-two (60.8%) had complex CSCR. CNV was observed in 37 (36.27%) eyes, all of which had the complex form. CNVs were classified as type 1 CNV in 11/37 (29.73%) cases and as polypoidal choroidal vasculopathy (PCV) in the remaining 26/37 (70.27%). Overall, the mean VPD, FD, and LAC of CSCR-related CNVs were 0.52 +/- 0.20%, 1.44 +/- 0.12, and 2.40 +/- 1.1, respectively. No significant difference between type 1 CNV and PCV was found. Conclusion: Complex CSCR is often complicated by type 1 CNV and PCV with similar neovascular architecture and branching complexity, a finding supporting the idea that they might be different stages of the same neovascular process. Future OCT-A fractal analysis-based studies that also include other relevant parameters, such as demographics, presentation, morphology on multimodal imaging, and response to treatment, are necessary before drawing any definitive conclusions.
C1 [Serra, Rita] Univ Sassari, Dept Biomed Sci, I-07100 Sassari, Italy.
   [Serra, Rita] Cittadella Univ Cagliari, CNR, Ist Ric Genet & Biomed IRGB, I-09042 Monserrato, Italy.
   [Serra, Rita; Coscas, Florence] Ctr Ophtalmol Odeon, 113 Bd St Germain, F-75006 Paris, France.
   [Pinna, Antonio] Univ Sassari, Ophthalmol Unit, Dept Med Surg & Expt Sci, I-07100 Sassari, Italy.
   [Behar-Cohen, Francine] Hop Cochin, AP HP, Ophtalmopole, Dept Ophthalmol, F-75014 Paris, France.
C3 University of Sassari; Consiglio Nazionale delle Ricerche (CNR);
   Istituto di Ricerca Genetica e Biomedica (IRGB-CNR); University of
   Sassari; Assistance Publique Hopitaux Paris (APHP); Hopital
   Universitaire Cochin - APHP; UDICE-French Research Universities;
   Universite Paris Cite
RP Serra, R (通讯作者)，Univ Sassari, Dept Biomed Sci, I-07100 Sassari, Italy.; Serra, R (通讯作者)，Cittadella Univ Cagliari, CNR, Ist Ric Genet & Biomed IRGB, I-09042 Monserrato, Italy.; Serra, R; Coscas, F (通讯作者)，Ctr Ophtalmol Odeon, 113 Bd St Germain, F-75006 Paris, France.
EM rita.serra@ymail.com; apinna@uniss.it; francine.behar@gmail.com;
   coscas.f@gmail.com
RI Pinna, Antonio/H-5067-2018
OI Pinna, Antonio/0000-0003-3052-2662; SERRA, RITA/0000-0002-6341-1435;
   behar cohen, francine/0000-0001-8571-9513
CR Ahuja RM, 2001, OPHTHALMOLOGY, V108, P1009, DOI 10.1016/S0161-6420(00)00614-X
   Al-Sheikh M, 2018, RETINA-J RET VIT DIS, V38, P220, DOI 10.1097/IAE.0000000000001628
   Anantharaman G, 2018, INDIAN J OPHTHALMOL, V66, P896, DOI 10.4103/ijo.IJO_1136_17
   Bicer O, 2018, TURK OFTALMOL DERG, V48, P262, DOI 10.4274/tjo.89166
   Bousquet E, 2021, J CLIN MED, V10, DOI 10.3390/jcm10194525
   Chhablani J, 2022, GRAEF ARCH CLIN EXP, V260, P1161, DOI 10.1007/s00417-021-05452-1
   Chhablani J, 2015, RETINA-J RET VIT DIS, V35, P2489, DOI 10.1097/IAE.0000000000000655
   Corvi F, 2020, RETINA-J RET VIT DIS, V40, P873, DOI 10.1097/IAE.0000000000002471
   Coscas F, 2019, BRIT J OPHTHALMOL, V103, P1342, DOI 10.1136/bjophthalmol-2018-313065
   Dansingani KK, 2016, RETINA-J RET VIT DIS, V36, P499, DOI 10.1097/IAE.0000000000000742
   Forte R, 2020, BRIT J OPHTHALMOL, V104, P1057, DOI 10.1136/bjophthalmol-2019-315189
   Fung AT, 2012, RETINA-J RET VIT DIS, V32, P1829, DOI 10.1097/IAE.0b013e3182680a66
   Garrity ST, 2018, INVEST OPHTH VIS SCI, V59, pAMD48, DOI 10.1167/iovs.18-24158
   GUYER DR, 1994, ARCH OPHTHALMOL-CHIC, V112, P1057, DOI 10.1001/archopht.1994.01090200063023
   Haimovici R, 2004, OPHTHALMOLOGY, V111, P244, DOI 10.1016/j.ophtha.2003.09.024
   Hua R, 2021, CURR EYE RES, V46, P1437, DOI 10.1080/02713683.2021.1942073
   Lafaut BA, 2000, GRAEF ARCH CLIN EXP, V238, P752, DOI 10.1007/s004170000180
   Lee GI, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-40406-y
   Lee WK, 2016, RETINA-J RET VIT DIS, V36, pS73, DOI 10.1097/IAE.0000000000001346
   Manayath George Joseph, 2018, Oman J Ophthalmol, V11, P103, DOI 10.4103/ojo.OJO_75_2017
   Mastropasqua R, 2020, TRANSL VIS SCI TECHN, V9, DOI 10.1167/tvst.9.11.6
   Munk MR, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0177059
   OTSU N, 1979, IEEE T SYST MAN CYB, V9, P62, DOI 10.1109/TSMC.1979.4310076
   Pece A, 2000, ARCH OPHTHALMOL-CHIC, V118, P630
   Piccolino FC, 2008, RETINA-J RET VIT DIS, V28, P1008, DOI 10.1097/IAE.0b013e31816b4b86
   Quaranta-El Maftouhi M, 2015, AM J OPHTHALMOL, V160, P581, DOI 10.1016/j.ajo.2015.06.016
   Rebhun CB, 2017, TRANSL VIS SCI TECHN, V6, DOI 10.1167/tvst.6.6.4
   Romdhane K, 2020, BRIT J OPHTHALMOL, V104, P910, DOI 10.1136/bjophthalmol-2019-314625
   Romdhane K, 2019, KLIN MONATSBL AUGENH, V236, P536, DOI 10.1055/a-0834-6118
   Sartini F, 2020, INT OPHTHALMOL, V40, P3577, DOI 10.1007/s10792-020-01522-1
   Savastano MC, 2021, RETINA-J RET VIT DIS, V41, P302, DOI 10.1097/IAE.0000000000002810
   Scassellati-Sforzolini B, 2001, RETINA-J RET VIT DIS, V21, P121, DOI 10.1097/00006982-200104000-00004
   Serra R, 2021, RETINA-J RET VIT DIS, V41, P93, DOI 10.1097/IAE.0000000000002807
   Serra R, 2021, BRIT J OPHTHALMOL, V105, P1421, DOI 10.1136/bjophthalmol-2020-317011
   Serra R, 2020, RETINA-J RET VIT DIS, V40, P1224, DOI 10.1097/IAE.0000000000002604
   Siedlecki J, 2019, OPHTHALMOL RETINA, V3, P1013, DOI 10.1016/j.oret.2019.08.002
   Spaide RF, 1996, OPHTHALMOLOGY, V103, P2070, DOI 10.1016/S0161-6420(96)30386-2
   Spaide RF, 2022, PROG RETIN EYE RES, V86, DOI 10.1016/j.preteyeres.2021.100973
   Spaide RF, 2020, OPHTHALMOLOGY, V127, P616, DOI 10.1016/j.ophtha.2019.11.004
   Wong CW, 2015, J CLIN MED, V4, P782, DOI 10.3390/jcm4050782
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
NR 41
TC 0
Z9 0
U1 0
U2 0
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2077-0383
J9 J CLIN MED
JI J. Clin. Med.
PD MAR
PY 2022
VL 11
IS 5
AR 1443
DI 10.3390/jcm11051443
PG 9
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA ZT1SX
UT WOS:000768936400001
PM 35268534
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Kang, HM
   Koh, HJ
AF Kang, Hae Min
   Koh, Hyoung Jun
TI Lack of Polypoidal Lesions in Patients With Myopic Choroidal
   Neovascularization as Evaluated by Indocyanine Green Angiography
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID OPTICAL COHERENCE TOMOGRAPHY; MACULAR DEGENERATION; PATHOLOGICAL MYOPIA;
   VASCULAR HYPERPERMEABILITY; CLINICOPATHOLOGICAL CORRELATION; CLINICAL
   CHARACTERISTICS; FLUORESCEIN ANGIOGRAPHY; POSTERIOR STAPHYLOMA; AXIAL
   LENGTH; VASCULOPATHY
AB OBJECTIVE: To investigate the prevalence of polypoidal choroidal vasculopathy (PCV) in patients with myopic choroidal neovascularization (CNV) using indocyanine green angiography (ICGA).
   DESIGN: Retrospective cross-sectional study.
   METHODS: A total of 297 eyes (255 patients) who presented with treatment-naive myopic CNV between January 2005 and December 2011 at Yonsei University Medical Center in Seoul, South Korea, were reviewed. Fluorescein angiography (FA) images obtained from the patients were analyzed to detect CNV presence and classify disease type. ICGA images were reviewed to detect polypoidal lesions. The main outcome measure was the prevalence of polypoidal lesions in patients with myopic CNV.
   RESULTS: All 297 eyes with myopic CNV were type 2 CNV, and mean age at diagnosis was 47.32 +/- 14.69 years. The mean refractive error was -11.95 +/- 5.88 diopters, and the mean axial length was 29.39 +/- 2.02 mm in the affected eyes. Among the myopic CNV eyes, 141 eyes (118 patients) were older than 50 years of age (mean 60.48 +/- 7.34 years). No eyes with myopic CNV showed polypoidal lesions on ICGA at initial presentation. After treatments for myopic CNV, 243 eyes (206 patients) completed at least 12 months of follow-up, and 86 eyes (35.4%) showed at least one recurrence of CNV during follow-up. The follow-up imaging studies, FA, and ICGA, showed no polypoidal lesions associated with recurred myopic CNV.
   CONCLUSIONS: ICGA analysis demonstrated no polypoidal component in myopic eyes with CNV. (C) 2014 by Elsevier Inc. All rights reserved.
C1 [Kang, Hae Min; Koh, Hyoung Jun] Yonsei Univ, Coll Med, Dept Ophthalmol, Inst Vis Res, Seoul 120752, South Korea.
C3 Yonsei University; Yonsei University Health System
RP Koh, HJ (通讯作者)，Yonsei Univ, Coll Med, Dept Ophthalmol, 134 Shinchon Dong, Seoul 120752, South Korea.
EM hjkoh@yuhs.ac
OI Koh, Hyoung Jun/0000-0002-5932-8516
CR Akyol N, 1996, CAN J OPHTHALMOL, V31, P113
   Byeon SH, 2008, JPN J OPHTHALMOL, V52, P57, DOI 10.1007/s10384-007-0498-2
   Chung SE, 2013, RETINA-J RET VIT DIS, V33, P834, DOI 10.1097/IAE.0b013e31826af540
   Chung SE, 2011, OPHTHALMOLOGY, V118, P840, DOI 10.1016/j.ophtha.2010.09.012
   Ciardella AP, 2004, SURV OPHTHALMOL, V49, P25, DOI 10.1016/j.survophthal.2003.10.007
   Dimitrova G, 2002, BRIT J OPHTHALMOL, V86, P771, DOI 10.1136/bjo.86.7.771
   Flores-Moreno I, 2013, AM J OPHTHALMOL, V155, P314, DOI 10.1016/j.ajo.2012.07.015
   Freund KB, 2010, RETINA-J RET VIT DIS, V30, P1333, DOI 10.1097/IAE.0b013e3181e7976b
   GASS JDM, 1994, AM J OPHTHALMOL, V118, P285, DOI 10.1016/S0002-9394(14)72951-4
   Hayashi K, 2010, OPHTHALMOLOGY, V117, P1595, DOI 10.1016/j.ophtha.2009.11.003
   Hsiang HW, 2008, AM J OPHTHALMOL, V146, P102, DOI 10.1016/j.ajo.2008.03.010
   Iida T, 2007, BRIT J OPHTHALMOL, V91, P1103, DOI 10.1136/bjo.2007.116160
   Imamura Y, 2010, SURV OPHTHALMOL, V55, P501, DOI 10.1016/j.survophthal.2010.03.004
   Jirarattanasopa P, 2012, INVEST OPHTH VIS SCI, V53, P3663, DOI 10.1167/iovs.12-9619
   Khan S, 2012, RETINA-J RET VIT DIS, V32, P1057, DOI 10.1097/IAE.0b013e31823beb14
   Kim SW, 2011, RETINA-J RET VIT DIS, V31, P1904, DOI 10.1097/IAE.0b013e31821801c5
   Koizumi H, 2013, AM J OPHTHALMOL, V155, P305, DOI 10.1016/j.ajo.2012.07.018
   Koizumi H, 2011, GRAEF ARCH CLIN EXP, V249, P1123, DOI 10.1007/s00417-011-1620-1
   Li XQ, 2011, INVEST OPHTH VIS SCI, V52, P8438, DOI 10.1167/iovs.11-8108
   Lima LH, 2010, OPHTHALMOLOGY, V117, P1567, DOI 10.1016/j.ophtha.2009.12.018
   Moriyama M, 2007, OPHTHALMOLOGY, V114, P1755, DOI 10.1016/j.ophtha.2006.11.034
   Nakanishi H, 2008, RETINA-J RET VIT DIS, V28, P1493, DOI 10.1097/IAE.0b013e318183589c
   Nakashizuka H, 2011, SURV OPHTHALMOL, V56, P278, DOI 10.1016/j.survophthal.2010.12.005
   Neelam K, 2012, PROG RETIN EYE RES, V31, P495, DOI 10.1016/j.preteyeres.2012.04.001
   Nishida Y, 2012, RETINA-J RET VIT DIS, V32, P1229, DOI 10.1097/IAE.0b013e318242b990
   Ohno-Matsui K, 2012, INVEST OPHTH VIS SCI, V53, P7290, DOI 10.1167/iovs.12-10371
   Okubo A, 2002, BRIT J OPHTHALMOL, V86, P1093, DOI 10.1136/bjo.86.10.1093
   Otsuji Tsuyoshi, 2006, Nippon Ganka Gakkai Zasshi, V110, P454
   Reynders S, 2002, GRAEF ARCH CLIN EXP, V240, P279, DOI 10.1007/s00417-002-0448-0
   Sasahara M, 2006, AM J OPHTHALMOL, V142, P601, DOI 10.1016/j.ajo.2006.05.051
   Silva R, 2012, OPHTHALMOLOGICA, V228, P197, DOI 10.1159/000339893
   SPAIDE RF, 1995, RETINA-J RET VIT DIS, V15, P100, DOI 10.1097/00006982-199515020-00003
   Sternberg P, 1996, ARCH OPHTHALMOL-CHIC, V114, P400
   STERNBERG P, 1991, ARCH OPHTHALMOL-CHIC, V109, P1220
   Tamura H, 2007, BRIT J OPHTHALMOL, V91, P1152, DOI 10.1136/bjo.2006.112318
   Tano Y, 2002, AM J OPHTHALMOL, V134, P645, DOI 10.1016/S0002-9394(02)01883-4
   Terasaki H, 2002, BRIT J OPHTHALMOL, V86, P321, DOI 10.1136/bjo.86.3.321
   Tong JP, 2006, AM J OPHTHALMOL, V141, P456, DOI 10.1016/j.ajo.2005.10.012
   Tsujikawa A, 2011, EYE, V25, P481, DOI 10.1038/eye.2010.232
   Uyama M, 1999, ARCH OPHTHALMOL-CHIC, V117, P1035
   Wakabayashi T, 2010, BRIT J OPHTHALMOL, V94, P611, DOI 10.1136/bjo.2009.163535
   Wong TY, 2000, INVEST OPHTH VIS SCI, V41, P2486
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
NR 43
TC 8
Z9 8
U1 0
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-9394
EI 1879-1891
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD FEB
PY 2014
VL 157
IS 2
BP 378
EP 383
DI 10.1016/j.ajo.2013.09.018
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 299SN
UT WOS:000330416100017
PM 24315295
DA 2022-11-30
ER

PT J
AU Battista, M
   Sacconi, R
   Borrelli, E
   Crepaldi, A
   Fantaguzzi, F
   Costanzo, E
   De Geronimo, D
   Parravano, M
   Bandello, F
   Querques, G
AF Battista, Marco
   Sacconi, Riccardo
   Borrelli, Enrico
   Crepaldi, Anna
   Fantaguzzi, Federico
   Costanzo, Eliana
   De Geronimo, Daniele
   Parravano, Mariacristina
   Bandello, Francesco
   Querques, Giuseppe
TI Discerning Between Macular Hemorrhages Due to Macular Neovascularization
   or Due to Spontaneous Bruch's Membrane Rupture in High Myopia: A
   Comparative Analysis Between OCTA and Fluorescein Angiography
SO OPHTHALMOLOGY AND THERAPY
LA English
DT Article
DE High myopia; Idiopathic macular hemorrhages; Myopic macular
   neovascularization; Optical coherence tomography-angiography
ID CHOROIDAL NEOVASCULARIZATION; SECONDARY
AB Introduction To evaluate the sensitivity and specificity of optical coherence tomography angiography (OCTA) in comparison to fluorescein angiography (FA) in discerning between macular hemorrhages due to myopic macular neovascularization (m-MNV) and idiopathic macular hemorrhage (IMH) in patients with high myopia (HM). Methods In this retrospective study, 14 eyes of 14 patients (mean age 60 +/- 16 years) affected by macular hemorrhage due to HM were included. All patients underwent OCTA and FA at the time of macular hemorrhage (i.e., baseline) and were followed for a 3-month follow-up. Results By means of FA, 8 out of 14 eyes with macular hemorrhage (57%) were diagnosed as type 2 m-MNV, whereas 6 eyes (43%) were diagnosed as IMH. Interestingly, OCTA displayed the presence of a neovascular network in all cases previously diagnosed as m-MNV using FA, and also excluded the presence of anomalous flow in all IMH eyes. This accounted for the high sensitivity and specificity of OCTA for m-MNV detection in HM cases with macular hemorrhage. After 3-month follow-up, BCVA improved from 0.39 +/- 0.15 to 0.21 +/- 0.14 logMAR (p = 0.006) in patients with m-MNV treated by a mean of 2.3 +/- 0.9 intravitreal anti-VEGF injections. Conversely, BCVA improved without treatment (from 0.55 +/- 0.48 to 0.17 +/- 0.08 logMAR, p = 0.112) in patients with IMH. Conclusions OCTA is able to differentiate with excellent reliability between the presence of m-MNV in patients with HM presenting with a new macular hemorrhage and an IMH. This could be of paramount relevance in the clinical setting for the diagnosis and treatment of patients with HM.
C1 [Battista, Marco; Sacconi, Riccardo; Borrelli, Enrico; Crepaldi, Anna; Fantaguzzi, Federico; Bandello, Francesco; Querques, Giuseppe] Univ Vita Salute San Raffaele, Sch Med, Milan, Italy.
   [Battista, Marco; Sacconi, Riccardo; Borrelli, Enrico; Crepaldi, Anna; Fantaguzzi, Federico; Bandello, Francesco; Querques, Giuseppe] IRCCS San Raffaele Sci Inst, Div Head & Neck, Ophthalmol Unit, Milan, Italy.
   [Costanzo, Eliana; De Geronimo, Daniele; Parravano, Mariacristina] Fdn GB Bietti IRCCS, Rome, Italy.
   [Querques, Giuseppe] Univ Vita Salute San Raffaele, Dept Ophthalmol, Via Olgettina 60, Milan, Italy.
C3 Vita-Salute San Raffaele University; Vita-Salute San Raffaele
   University; IRCCS Ospedale San Raffaele; IRCCS - Fondazione "G.B.
   Bietti" per lo Studio e la Ricerca in Oftalmologia; Vita-Salute San
   Raffaele University
RP Querques, G (通讯作者)，Univ Vita Salute San Raffaele, Dept Ophthalmol, Via Olgettina 60, Milan, Italy.
EM giuseppe.querques@hotmail.it
OI Sacconi, Riccardo/0000-0003-2891-2012; Querques,
   Giuseppe/0000-0002-3292-9581
CR Battista M, 2020, BRIT J OPHTHALMOL, V104, P1453, DOI 10.1136/bjophthalmol-2019-315482
   Bruyere E, 2017, RETINA-J RET VIT DIS, V37, P2095, DOI 10.1097/IAE.0000000000001456
   Carnevali A, 2018, OPHTHALMOL RETINA, V2, P922, DOI 10.1016/j.oret.2018.02.002
   Carnevali A, 2017, OPHTHALMOL RETINA, V1, P328, DOI 10.1016/j.oret.2017.01.003
   Cheung CMG, 2017, OPHTHALMOLOGY, V124, P1690, DOI 10.1016/j.ophtha.2017.04.028
   CURTIN BJ, 1971, AM J OPHTHALMOL, V71, P42, DOI 10.1016/0002-9394(71)91092-0
   Franqueira N, 2012, OPHTHALMOLOGICA, V227, P39, DOI 10.1159/000333213
   Giuffre C, 2017, EUR J OPHTHALMOL, V27, pE39, DOI 10.5301/ejo.5000875
   Gong JW, 2016, J OPHTHALMOL, V2016, DOI 10.1155/2016/7521478
   Huang YJ, 2012, INVEST OPHTH VIS SCI, V53, P2133, DOI 10.1167/iovs.11-8755
   Iacono P, 2021, EUR J OPHTHALMOL, V31, P149, DOI 10.1177/1120672119882333
   Ikuno Y, 2010, INVEST OPHTH VIS SCI, V51, P3721, DOI 10.1167/iovs.09-3493
   Kedhar SR, 2007, RETINA-J RET VIT DIS, V27, P1174, DOI 10.1097/IAE.0b013e318068de72
   Leveziel N, 2013, AM J OPHTHALMOL, V155, P913, DOI 10.1016/j.ajo.2012.11.021
   Liu B, 2018, J OPHTHALMOL, V2018, DOI 10.1155/2018/3150923
   Miyata M, 2016, AM J OPHTHALMOL, V165, P108, DOI 10.1016/j.ajo.2016.03.009
   Ohno-Matsui K, 2019, PROG RETIN EYE RES, V70, P99, DOI 10.1016/j.preteyeres.2018.12.001
   Ohno-Matsui K, 2016, AM J OPHTHALMOL, V166, P22, DOI 10.1016/j.ajo.2016.03.019
   Ohno-Matsui K, 2016, PROG RETIN EYE RES, V52, P156, DOI 10.1016/j.preteyeres.2015.12.001
   Ohno-Matsui K, 2015, AM J OPHTHALMOL, V159, P877, DOI 10.1016/j.ajo.2015.01.022
   OhnoMatsui K, 1996, RETINA-J RET VIT DIS, V16, P196, DOI 10.1097/00006982-199616030-00003
   Parodi MB, 2015, AM J OPHTHALMOL, V160, P322, DOI 10.1016/j.ajo.2015.04.030
   Querques G, 2015, AM J OPHTHALMOL, V160, P759, DOI 10.1016/j.ajo.2015.07.017
   Querques L, 2017, BRIT J OPHTHALMOL, V101, P609, DOI 10.1136/bjophthalmol-2016-309162
   Reichel E, 1995, OPHTHALMOLOGY, V102, P1871, DOI 10.1016/S0161-6420(95)30781-6
   Ren PF, 2020, GRAEF ARCH CLIN EXP, V258, P2661, DOI 10.1007/s00417-020-04778-6
   Ruiz-Medrano J, 2019, PROG RETIN EYE RES, V69, P80, DOI 10.1016/j.preteyeres.2018.10.005
   Sacconi R, 2021, BRIT J OPHTHALMOL, V105, P222, DOI 10.1136/bjophthalmol-2020-316054
   Sacconi R, 2019, EYE, V33, P1809, DOI 10.1038/s41433-019-0511-2
   Sacconi R, 2018, OPHTHALMOL RETINA, V2, P1097, DOI 10.1016/j.oret.2018.04.016
   Spaide RF, 2018, PROG RETIN EYE RES, V64, P1, DOI 10.1016/j.preteyeres.2017.11.003
   Wong TY, 2015, BRIT J OPHTHALMOL, V99, P289, DOI 10.1136/bjophthalmol-2014-305131
NR 32
TC 0
Z9 0
U1 2
U2 2
PU SPRINGER INT PUBL AG
PI CHAM
PA GEWERBESTRASSE 11, CHAM, CH-6330, SWITZERLAND
SN 2193-8245
EI 2193-6528
J9 OPHTHALMOL THER
JI OPHTHALMOL. THER.
PD APR
PY 2022
VL 11
IS 2
BP 821
EP 831
DI 10.1007/s40123-022-00484-0
EA FEB 2022
PG 11
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA ZU8LH
UT WOS:000758083300002
PM 35184253
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Kumar, S
   Berriochoa, Z
   Ambati, BK
   Fu, YB
AF Kumar, Sandeep
   Berriochoa, Zachary
   Ambati, Balamurali K.
   Fu, Yingbin
TI Angiographic Features of Transgenic Mice With Increased Expression of
   Human Serine Protease HTRA1 in Retinal Pigment Epithelium
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
DE polypoidal choroidal vasculopathy; HTRA1; indocyanine green angiography;
   late geographic hyperfluorescence; pigment epithelial detachment
ID POLYPOIDAL CHOROIDAL VASCULOPATHY; OPTICAL COHERENCE TOMOGRAPHY;
   INDOCYANINE GREEN ANGIOGRAPHY; INTRAVITREAL BEVACIZUMAB; PHOTODYNAMIC
   THERAPY; RANIBIZUMAB; IDENTIFICATION; INJECTIONS; VEGF
AB PURPOSE. Polypoidal choroidal vasculopathy (PCV) is characterized by a branching vascular network (BVN) of choroid that terminates in polypoidal dilations. We have previously reported the generation of the first PCV model by transgenically expressing human HTRA1 (hHTRA1(+)), a multifunctional serine protease, in mouse RPE. The purpose of this study was to perform a comprehensive examination of the PCV phenotypes (e. g., lesion type and distribution) of hHTRA1(+) mice by a variety of in vivo imaging techniques.
   METHODS. We generated improved hHTRA1(+) mice with a more consistent phenotype. Transgenic mice were examined by indocyanine green angiography (ICGA), fluorescein angiography, funduscopy, and spectral-domain optical coherence tomography. In particular, we performed ICGA by tail vein injection of ICG to obtain high-quality ICGA comparable to human studies in terms of the three phases (early, middle, and late) of angiography.
   RESULTS. The polyps can be detected in the early "fill-in" phase of ICGA, and most lesions become visible in the middle phase and are more distinct in the late phase with the fading of surrounding vessels. In addition to the two key features of PCV (polypoidal dilations and BVNs), hHTRA1(+) mice exhibit other features of PCV (i.e., late geographic hyperfluorescence, pigment epithelial detachment, and hyperfluorescent plaque). Polypoidal lesions appear as reddish orange nodules on funduscopy.
   CONCLUSIONS. Transgenic hHTRA1(+) mice exhibit a rich spectrum of "clinical" features that closely mimic human PCV. This animal model will serve as an invaluable tool for future mechanistic and translational studies of PCV and other forms of choroidal vasculopathies.
C1 [Kumar, Sandeep; Berriochoa, Zachary; Ambati, Balamurali K.; Fu, Yingbin] Univ Utah, Hlth Sci Ctr, Dept Ophthalmol & Visual Sci, Salt Lake City, UT 84132 USA.
   [Ambati, Balamurali K.; Fu, Yingbin] Univ Utah, Hlth Sci Ctr, Dept Neurobiol & Anat, Salt Lake City, UT 84132 USA.
C3 Utah System of Higher Education; University of Utah; Utah System of
   Higher Education; University of Utah
RP Fu, YB (通讯作者)，Univ Utah, Hlth Sci Ctr, Dept Ophthalmol, 65 Mario Capecchi Dr, Salt Lake City, UT 84132 USA.
EM yingbin.fu@hsc.utah.edu
OI kumar, sandeep/0000-0002-2918-8276
FU National Institutes of Health [1R01EY022901, 5P30EY014800]; Research to
   Prevent Blindness; Carl Marshall Reeves & Mildred Almen Reeves
   Foundation; NATIONAL EYE INSTITUTE [P30EY014800, R01EY022901] Funding
   Source: NIH RePORTER
FX Supported by National Institutes of Health Grants 1R01EY022901 and
   5P30EY014800, a Career Development Award from Research to Prevent
   Blindness, the Carl Marshall Reeves & Mildred Almen Reeves Foundation,
   and an unrestricted grant to the Department of Ophthalmology and Visual
   Sciences, University of Utah Health Sciences Center, from Research to
   Prevent Blindness.
CR Alex Anne F, 2013, Methods Mol Biol, V935, P41, DOI 10.1007/978-1-62703-080-9_3
   An E, 2010, INVEST OPHTH VIS SCI, V51, P3379, DOI 10.1167/iovs.09-4853
   Cackett P, 2009, RETINA-J RET VIT DIS, V29, P187, DOI 10.1097/IAE.0b013e318188c839
   Cho M, 2009, AM J OPHTHALMOL, V148, P70, DOI 10.1016/j.ajo.2009.02.012
   Ciardella Antonio P, 2002, Ophthalmol Clin North Am, V15, P537, DOI 10.1016/S0896-1549(02)00053-6
   Coppens G, 2011, Bull Soc Belge Ophtalmol, P39
   Coscas G, 2009, OCT AMD OPTICAL COHE
   Elliot SJ, 2010, EXP EYE RES, V90, P10, DOI 10.1016/j.exer.2009.09.001
   Esumi N, 2004, J BIOL CHEM, V279, P19064, DOI 10.1074/jbc.M309881200
   Gomi F, 2008, BRIT J OPHTHALMOL, V92, P70, DOI 10.1136/bjo.2007.122283
   Gomi F, 2007, GRAEF ARCH CLIN EXP, V245, P1421, DOI 10.1007/s00417-007-0564-y
   Grau S, 2006, J BIOL CHEM, V281, P6124, DOI 10.1074/jbc.M500361200
   Huber G, 2009, INVEST OPHTH VIS SCI, V50, P5888, DOI 10.1167/iovs.09-3724
   Imamura Y, 2010, SURV OPHTHALMOL, V55, P501, DOI 10.1016/j.survophthal.2010.03.004
   Janssen A, 2008, INVEST OPHTH VIS SCI, V49, P2812, DOI 10.1167/iovs.07-1444
   Jones A, 2011, P NATL ACAD SCI USA, V108, P14578, DOI 10.1073/pnas.1102853108
   Kang HM, 2014, AM J OPHTHALMOL, V157, P598, DOI 10.1016/j.ajo.2013.11.015
   Kang HM, 2013, AM J OPHTHALMOL, V156, P652, DOI 10.1016/j.ajo.2013.05.038
   Kang SW, 2009, BRIT J OPHTHALMOL, V93, P759, DOI 10.1136/bjo.2008.145862
   Khan S, 2012, RETINA-J RET VIT DIS, V32, P1057, DOI 10.1097/IAE.0b013e31823beb14
   Kim YT, 2012, BRIT J OPHTHALMOL, V96, P1217, DOI 10.1136/bjophthalmol-2012-301644
   Koh AHC, 2013, RETINA-J RET VIT DIS, V33, P686, DOI 10.1097/IAE.0b013e3182852446
   Kokame GT, 2010, BRIT J OPHTHALMOL, V94, P297, DOI 10.1136/bjo.2008.150029
   Kumar S, 2014, JOVE-J VIS EXP, DOI 10.3791/51061
   Kurihara T, 2012, J CLIN INVEST, V122, P4213, DOI 10.1172/JCI65157
   Lafaut BA, 2000, GRAEF ARCH CLIN EXP, V238, P752, DOI 10.1007/s004170000180
   Lai TYY, 2008, BRIT J OPHTHALMOL, V92, P661, DOI 10.1136/bjo.2007.135103
   Laude A, 2010, PROG RETIN EYE RES, V29, P19, DOI 10.1016/j.preteyeres.2009.10.001
   Marcus DM, 2013, RETINA-J RET VIT DIS, V33, P35, DOI 10.1097/IAE.0b013e3182618be0
   Saint-Geniez M, 2009, P NATL ACAD SCI USA, V106, P18751, DOI 10.1073/pnas.0905010106
   Sonoda S, 2013, BMC OPHTHALMOL, V13, DOI 10.1186/1471-2415-13-43
   SPAIDE RF, 1995, RETINA-J RET VIT DIS, V15, P100, DOI 10.1097/00006982-199515020-00003
   Spaide RF, 2011, RETINA-J RET VIT DIS, V31, P1609, DOI 10.1097/IAE.0b013e3182247535
   Stangos AN, 2010, AM J OPHTHALMOL, V150, P666, DOI 10.1016/j.ajo.2010.05.035
   Tiaden AN, 2012, J BIOL CHEM, V287, P21335, DOI 10.1074/jbc.M112.341032
   Tsujikawa A, 2007, AM J OPHTHALMOL, V143, P102, DOI 10.1016/j.ajo.2006.08.025
   Uyama M, 2002, AM J OPHTHALMOL, V133, P639, DOI 10.1016/S0002-9394(02)01404-6
   Vierkotten S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022959
   Yannuzzi LA, 2011, AM J OPHTHALMOL, V151, P745, DOI 10.1016/j.ajo.2011.01.043
   Znoiko SL, 2002, INVEST OPHTH VIS SCI, V43, P1604
NR 40
TC 17
Z9 22
U1 0
U2 4
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD JUN
PY 2014
VL 55
IS 6
BP 3842
EP 3850
DI 10.1167/iovs.13-13111
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AL9TX
UT WOS:000339485800058
PM 24854852
OA Green Published
DA 2022-11-30
ER

PT J
AU El Matri, K
   Bouraoui, R
   Falfoul, Y
   Chebil, A
   El Matri, L
AF El Matri, Khaled
   Bouraoui, Rim
   Falfoul, Yousra
   Chebil, Ahmed
   El Matri, Leila
TI Swept source OCT-Angiography assessing a case of aneurysmal type 1
   neovascularization secondary to high-myopic posterior staphyloma
SO EUROPEAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE Aneurysmal type 1 neovascularization; Polypoidal choroidal vasculopathy;
   pathologic myopia; staphyloma; retina; techniques of retinal
   examination; multimodal imaging; OCT-Angiography
ID COHERENCE TOMOGRAPHY ANGIOGRAPHY
AB Aim: To report an uncommon case of aneurysmal type 1 neovascularization (polypoidal choroidal vasculopathy) secondary to high-myopic staphyloma in a Caucasian patient, assessed with multimodal imaging including swept source OCT-Angiography. Methods: Observational case report Results: About 73-year-old Caucasian male patient with high myopia (axial length = 27.24 mm). Fundus examination showed a myopic conus and a deep orange-brownish nodular lesion at the edge of a deep haemorrhage and connected to a large choroidal vessel. ICGA showed a circular hyperfluorescent lesion in mid-phase, without any branching vascular network. OCT-Angiography could detect the aneurysmal lesion non-invasively as a small circular high-flow lesion in the outer retina slab, with a shadowing in the choriocapillaris slab. At the level of the aneurysmal lesion, structural OCT showed a high bilobed PED, without any subretinal fluid. A vascular flow was noted within the PED on cross-sectional OCT-A, confirming the vascular aneurysmal nature of this lesion. Additionally, swept source OCT highlighted the presence of an abrupt change in choroidal thickness, from 62 mu m in the peripapillary area to 120 mu m underneath the polypoidal lesion, with dilated choroidal vessels. Conclusion: To our knowledge, this is the first report of OCT-A findings in aneurysmal (polypoidal) dilation secondary to high-myopic staphyloma. We could demonstrate the usefulness of OCT-A detecting non-invasively the aneurysmal dilation and the usefulness of swept source OCT assessing the choroidal structure to better understand the pathophysiology of this uncommon finding.
C1 [El Matri, Khaled; Bouraoui, Rim; Falfoul, Yousra; Chebil, Ahmed; El Matri, Leila] Inst Hedi Rais Ophtalmol Tunis, Dept B, Tunis 1006, Tunisia.
   [El Matri, Khaled; Bouraoui, Rim; Falfoul, Yousra; Chebil, Ahmed; El Matri, Leila] Oculogenet Lab LR14SP01, Tunis, Tunisia.
   [El Matri, Khaled; Bouraoui, Rim; Falfoul, Yousra; Chebil, Ahmed; El Matri, Leila] Univ Tunis El Manar, Fac Med Tunis, Tunis, Tunisia.
C3 Universite de Tunis-El-Manar; Institut Hedi Raies d'ophtalmologie de
   Tunis; Universite de Tunis-El-Manar; Institut Hedi Raies d'ophtalmologie
   de Tunis; Universite de Tunis-El-Manar; Faculte de Medecine de Tunis
   (FMT)
RP El Matri, K (通讯作者)，Inst Hedi Rais Ophtalmol Tunis, Dept B, Tunis 1006, Tunisia.
EM khaled.elmatri@gmail.com
RI MATRI, KHALED EL/ABA-2835-2020
OI MATRI, KHALED EL/0000-0002-7939-3251; FALFOUL,
   YOUSRA/0000-0001-8922-2627
CR Dansingani KK, 2018, CLIN EXP OPHTHALMOL, V46, P189, DOI 10.1111/ceo.13114
   Fragiotta Serena, 2018, Int J Retina Vitreous, V4, P44, DOI 10.1186/s40942-018-0148-5
   Inoue M, 2015, RETINA-J RET VIT DIS, V35, P2265, DOI 10.1097/IAE.0000000000000777
   Miyata M, 2016, AM J OPHTHALMOL, V165, P108, DOI 10.1016/j.ajo.2016.03.009
   Nakanishi H, 2008, RETINA-J RET VIT DIS, V28, P1493, DOI 10.1097/IAE.0b013e318183589c
   Naysan Jonathan, 2015, Int J Retina Vitreous, V1, P8
   Querques L, 2017, BRIT J OPHTHALMOL, V101, P609, DOI 10.1136/bjophthalmol-2016-309162
   Srour M, 2016, BRIT J OPHTHALMOL, V100, P1489, DOI 10.1136/bjophthalmol-2015-307892
   Tan ACS, 2017, RETINA-J RET VIT DIS, V37, P1544, DOI 10.1097/IAE.0000000000001402
NR 9
TC 0
Z9 0
U1 0
U2 0
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1120-6721
EI 1724-6016
J9 EUR J OPHTHALMOL
JI Eur. J. Ophthalmol.
PD MAY
PY 2022
VL 32
IS 3
BP NP1
EP NP4
AR 1120672120984396
DI 10.1177/1120672120984396
EA DEC 2020
PG 4
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 1G7SZ
UT WOS:000678283700001
PM 33356524
DA 2022-11-30
ER

PT J
AU Walinjkar, JA
   Sharma, US
   Rishi, P
   Rishi, E
   Gopal, L
   Sharma, T
AF Walinjkar, Jaydeep Avinash
   Sharma, Unnati Shivshankar
   Rishi, Pukhraj
   Rishi, Ekta
   Gopal, Lingam
   Sharma, Tarun
TI Clinical features and treatment outcomes of vasoproliferative tumors in
   Indian participants
SO INDIAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE Clinical features; Indian participants; treatment outcome;
   vasoproliferative tumors
ID PERIPHERAL RETINAL ANGIOMA; OCULAR FUNDUS; TELANGIECTASIS; LESION
AB Purpose: The aim of the study was to describe the clinical features and treatment outcomes of vasoproliferative tumors (VPT) in Indian participants. Methods: This study design was a retrospective case series in a tertiary eye care center. Case records of patients diagnosed with VPT from 2011 to 2015 were reviewed, and their demographic details, clinical presentation, and treatment outcomes were documented. Baseline and follow-up visual acuity and tumor dimensions were statistically compared by applying paired t-test. Statistical analysis used SPSS version 14. Results: Twenty-two tumors from 19 eyes of 17 patients were included. Mean age at presentation was 43.5 years (range: 15-68 years). Mean presenting best-corrected visual acuity (BCVA) was + 1.10 logMAR. Sixty-eight percent eyes had secondary tumors. Most common association of secondary VPT was Coats disease followed by retinal vasculitis, polypoidal choroidal vasculopathy, familial exudative vitreoretinopathy, and traumatic chorioretinopathy. Ten tumors (45%) involved the inferior quadrant. Tumor-associated features were intra/subretinal exudates, vitritis, subretinal fluid, vitreous hemorrhage, preretinal fibrosis, epiretinal membrane, and subretinal blood. Treatment included cryotherapy, intravitreal or oral steroids, laser photocoagulation, cryotherapy with encirclage, cryotherapy with anti-vascular endothelial growth factor, and observation. Complications included tumor recurrence, retinal detachment, raised intraocular pressure, neovascularization of iris, and cataract. Ninety-five percent VPT regressed at mean 21 months (Median: 17 months; Range: 3-64 months). Mean final BCVA was + 1.21 logMAR. Conclusion: VPTs are commonly unilateral, unifocal, and located anterior to equator in inferior fundus. Secondary tumors are more common than primary tumors. Treatment achieves tumor regression in majority of cases.
C1 [Walinjkar, Jaydeep Avinash; Sharma, Unnati Shivshankar; Rishi, Pukhraj; Rishi, Ekta; Gopal, Lingam; Sharma, Tarun] Sankara Nethralaya, Shri Bhagwan Mahavir Vitreoretinal Serv, 18 Coll Rd, Madras 600006, Tamil Nadu, India.
RP Rishi, P (通讯作者)，Sankara Nethralaya, Shri Bhagwan Mahavir Vitreoretinal Serv, 18 Coll Rd, Madras 600006, Tamil Nadu, India.
EM docrishi@yahoo.co.in
RI Rishi, Pukhraj/AAZ-5296-2020
CR BAINES PS, 1982, T OPHTHAL SOC UK, V102, P487
   CAMPOCHIARO PA, 1988, ARCH OPHTHALMOL-CHIC, V106, P1409
   Heimann H, 2000, BRIT J OPHTHALMOL, V84, P1162, DOI 10.1136/bjo.84.10.1162
   HENKIND P, 1966, BRIT J OPHTHALMOL, V50, P2, DOI 10.1136/bjo.50.1.2
   Irvine F, 2000, ARCH OPHTHALMOL-CHIC, V118, P563
   LAATIKAINEN L, 1989, AM J OPHTHALMOL, V108, P563, DOI 10.1016/0002-9394(89)90434-0
   LAQUA H, 1983, OPHTHALMOLOGY, V90, P1284
   Makdoumi K, 2011, ACTA OPHTHALMOL, V89, P91, DOI 10.1111/j.1755-3768.2009.01662.x
   Murthy R, 2009, J AAPOS, V13, P97, DOI 10.1016/j.jaapos.2008.07.012
   Perry LJP, 2013, AM J OPHTHALMOL, V155, P593, DOI 10.1016/j.ajo.2012.09.002
   Rennie IG, 2010, EYE, V24, P468, DOI 10.1038/eye.2009.305
   Rundle P, 2000, EYE, V14, P105, DOI 10.1038/eye.2000.27
   Shields CL, 2013, JAMA OPHTHALMOL, V131, P328, DOI 10.1001/2013.jamaophthalmol.524
   SHIELDS CL, 1995, ARCH OPHTHALMOL-CHIC, V113, P615, DOI 10.1001/archopht.1995.01100050083035
   SHIELDS JA, 1983, OPHTHALMOLOGY, V90, P1292
   Wachtlin J, 2002, ARCH OPHTHALMOL-CHIC, V120, P860
NR 16
TC 6
Z9 6
U1 0
U2 1
PU MEDKNOW PUBLICATIONS & MEDIA PVT LTD
PI MUMBAI
PA B-9, KANARA BUSINESS CENTRE, OFF LINK RD, GHAKTOPAR-E, MUMBAI, 400075,
   INDIA
SN 0301-4738
EI 1998-3689
J9 INDIAN J OPHTHALMOL
JI Indian J. Ophthalmol.
PD FEB
PY 2018
VL 66
IS 2
BP 246
EP 251
AR PMID 29380768
DI 10.4103/ijo.IJO_210_17
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA FX8JQ
UT WOS:000426338700016
PM 29380768
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Sumnicht, AJ
   Chalam, KV
   Alset, AE
   Sierpina, DI
AF Sumnicht, Andrew J.
   V. Chalam, Kakarla
   Alset, Adel E.
   Sierpina, David I.
TI The role of oral steroids in the treatment of photodynamic
   therapy-associated exudative maculopathy, a case report and review of
   the literature
SO PHOTODIAGNOSIS AND PHOTODYNAMIC THERAPY
LA English
DT Review
DE Idiopathic polypoidal choroidal vasculopathy; Oral prednisone;
   Photodynamic therapy-induced acute exuda-tive maculopathy
ID POLYPOIDAL CHOROIDAL VASCULOPATHY; ENDOTHELIAL GROWTH-FACTOR;
   INTRAVITREAL INJECTION; MACULAR DEGENERATION; RANIBIZUMAB; COMBINATION;
   EFFICACY; SAFETY; VEGF
AB Background: Photodynamic therapy (PDT) is an effective treatment of pachychoroid spectrum disease. PDT can cause a rare complication known as PDT-associated exudative maculopathy (PAEM). Treatments including intravitreal anti-vascular endothelial growth factor (anti-VEGF) medications, local or systemic steroids, and observation have been attempted with variable success to address this complication. Methods: A thorough literature review was performed using the PubMed database on search terms aimed at treatments of PAEM. These cases were compared with each other and a novel case of PAEM in polypoidal choroidal vasculopathy (PCV) treated with oral prednisone by the authors. Results: Fifteen patients were compared; 11 were treated with anti-VEGF alone or in combination with intravitreal steroid and/or vitrectomy, one was treated with topical steroid, one was observed, one was treated with intravenous methylprednisolone, and one was treated with oral prednisone. The two cases treated with systemic steroids were given adjunctive sub-tenon's triamcinolone acetonide (STTA) after a favorable response was observed. Most cases had anatomic resolution of serous retinal detachment with stability of vision between 16 days and 2 months, with the most rapid resolution occurring in a patient with PCV treated with oral prednisone and STTA. Conclusions: Reported treatment of PAEM includes intravitreal anti-VEGF agents with or without local or systemic steroids. Oral steroids may be advantageous in cases where there is concern regarding the risk profile of periocular steroids, intravitreal steroids or anti-VEGF agents. However, data describing the various treatments of this rare complication is limited, precluding firm conclusions regarding relative safety and efficacy.
C1 [Sumnicht, Andrew J.; V. Chalam, Kakarla; Alset, Adel E.; Sierpina, David I.] Loma Linda Univ, Inst Eye, Loma Linda, CA 92350 USA.
C3 Loma Linda University
RP Sierpina, DI (通讯作者)，Loma Linda Univ, Inst Eye, Loma Linda, CA 92350 USA.
EM dsierpina@llu.edu
CR Al-Awadi A, 2017, CAN J OPHTHALMOL, V52, pE38, DOI 10.1016/j.jcjo.2016.08.001
   Chakurkar R, 2019, BMJ CASE REP, V12, DOI 10.1136/bcr-2019-231865
   Debefve E, 2007, VASC PHARMACOL, V46, P171, DOI 10.1016/j.vph.2006.09.006
   Figurska M, 2011, MED SCI MONITOR, V17, pCS75, DOI 10.12659/MSM.881799
   FINGAR VH, 1992, CANCER RES, V52, P4914
   Husain D, 1996, ARCH OPHTHALMOL-CHIC, V114, P978, DOI 10.1001/archopht.1996.01100140186012
   Kim Hyeong Min, 2015, Korean J Ophthalmol, V29, P143, DOI 10.3341/kjo.2015.29.2.143
   Koh A, 2017, JAMA OPHTHALMOL, V135, P1206, DOI 10.1001/jamaophthalmol.2017.4030
   Koh A, 2012, RETINA-J RET VIT DIS, V32, P1453, DOI 10.1097/IAE.0b013e31824f91e8
   Lafaut BA, 2000, GRAEF ARCH CLIN EXP, V238, P752, DOI 10.1007/s004170000180
   Mammo Zaid, 2017, Retin Cases Brief Rep, V11, P217, DOI 10.1097/ICB.0000000000000356
   Manayath GJ, 2020, RETINA-J RET VIT DIS, V40, P135, DOI 10.1097/IAE.0000000000002343
   Maruko I, 2007, AM J OPHTHALMOL, V144, P15, DOI 10.1016/j.ajo.2007.03.047
   Nowak-Sliwinska P, 2013, PROG RETIN EYE RES, V37, P182, DOI 10.1016/j.preteyeres.2013.09.003
   Ojima Y, 2009, RETINA-J RET VIT DIS, V29, P52, DOI 10.1097/IAE.0b013e3181884fbf
   Ross RD, 1996, RETINA-J RET VIT DIS, V16, P105, DOI 10.1097/00006982-199616020-00003
   Schmidt-Erfurth U, 2002, ARCH OPHTHALMOL-CHIC, V120, P835
   Schmidt-Erfurth U, 2003, INVEST OPHTH VIS SCI, V44, P4473, DOI 10.1167/iovs.02-1115
   SPAIDE RF, 1995, RETINA-J RET VIT DIS, V15, P100, DOI 10.1097/00006982-199515020-00003
   Tatar O, 2007, RETINA-J RET VIT DIS, V27, P713, DOI 10.1097/IAE.0b013e318042d3b0
   Wang EQ, 2019, RETINA-J RET VIT DIS, V39, P408, DOI 10.1097/IAE.0000000000001956
   Wang XY, 2014, AM J OPHTHALMOL, V158, P738, DOI 10.1016/j.ajo.2014.06.009
   Warrow DJ, 2013, RETINA-J RET VIT DIS, V33, P1659, DOI 10.1097/IAE.0b013e3182953df4
   Wong Raymond L M, 2013, J Ophthalmic Vis Res, V8, P359
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
   Zarbin MA, 2018, ASIA-PAC J OPHTHALMO, V7, P63, DOI 10.22608/APO.2017495
   Zehetner C, 2013, BRIT J OPHTHALMOL, V97, P454, DOI 10.1136/bjophthalmol-2012-302451
NR 27
TC 3
Z9 3
U1 2
U2 2
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 1572-1000
EI 1873-1597
J9 PHOTODIAGN PHOTODYN
JI Photodiagnosis Photodyn. Ther.
PD SEP
PY 2021
VL 35
AR 102390
DI 10.1016/j.pdpdt.2021.102390
EA JUL 2021
PG 4
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA UO8BE
UT WOS:000694915500009
PM 34119709
DA 2022-11-30
ER

PT J
AU Kang, HG
   Han, JY
   Kim, M
   Byeon, SH
   Kim, SS
   Koh, HJ
   Lee, CS
AF Kang, Hyun Goo
   Han, Jae Yong
   Kim, Min
   Byeon, Suk Ho
   Kim, Sung Soo
   Koh, Hyoung Jun
   Lee, Christopher Seungkyu
TI Pachydrusen, choroidal vascular hyperpermeability, and punctate
   hyperfluorescent spots
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE Indocyanine-green angiography; Optical coherence tomography angiography;
   Pachychoroid; Pachydrusen; Polypoidal choroidal vasculopathy
AB Purpose To investigate the relationship between pachydrusen and features of choroidal vascular hyperpermeability (CVH) and punctate hyperfluorescent spots (PHS) on serial imaging in patients with polypoidal choroidal vasculopathy (PCV) or pachychoroid neovasculopathy (PNV).
   Methods Patients diagnosed between January 2007 and June 2016 at 2 high-volume, tertiary hospitals were retrospectively reviewed with serial multimodal imaging assessment. The primary outcome was the association between drusen subtypes (hard/soft drusen, subretinal drusenoid droplets, or pachydrusen) with CVH and PHS, previously described in central serous chorioretinopathy.
   Results Among the 105 eyes (105 patients; mean age, 67.0 years), 87 (82.9%) were diagnosed with PCV and 18 (17.1%) with PNV. Pachydrusen was the most frequently identified subtype (54 eyes, 51.4%). CVH (72.2% vs 41.4%, P = 0.021) and PHS (72.2% vs 44.8%, P = 0.041) were observed with greater frequency in PNV eyes. Significant correlations were found between CVH and PHS (phi coefficient phi 0.30, P = 0.003), and PHS with pachydrusen (phi 0.20, P = 0.040). Over a mean follow-up of 74.8 months, new drusen co-localizing to PHS were noted in 22 (21.0%) eyes (phi 0.54, P < 0.001).
   Conclusion We observed a trend of pachydrusen appearing in conjunction with PHS in PCV or PNV. Frequent localization of new drusen to these choroidal lesions was observed over long-term follow-up. PHS may be a form of late-staining "forme fruste" drusen, possibly associated with micro-ischemic changes to the choriocapillaris.
C1 [Kang, Hyun Goo; Han, Jae Yong; Kim, Min] Yonsei Univ, Inst Vis Res, Gangnam Severance Hosp, Coll Med,Dept Ophthalmol, Eonjuro 211, Seoul, South Korea.
   [Kang, Hyun Goo] Yonsei Univ, Dept Biomed Syst Informat, Translat Genome Informat Lab, Coll Med, Yonsei Ro 50-1, Seoul, South Korea.
   [Byeon, Suk Ho; Kim, Sung Soo; Koh, Hyoung Jun; Lee, Christopher Seungkyu] Yonsei Univ, Severance Eye Hosp, Coll Med, Dept Ophthalmol,Inst Vis Res, 50-1 Yonse Iro, Seoul 03722, South Korea.
C3 Yonsei University; Yonsei University Health System; Yonsei University;
   Yonsei University Health System; Yonsei University; Yonsei University
   Health System
RP Lee, CS (通讯作者)，Yonsei Univ, Severance Eye Hosp, Coll Med, Dept Ophthalmol,Inst Vis Res, 50-1 Yonse Iro, Seoul 03722, South Korea.
EM sklee219@yuhs.ac
RI ; Kang, Hyun Goo/C-5569-2018
OI Lee, Christopher/0000-0001-5054-9470; Kang, Hyun
   Goo/0000-0001-8359-9618; Koh, Hyoung Jun/0000-0002-5932-8516; Kim,
   Min/0000-0003-1873-6959; Kim, Sung Soo/0000-0002-0574-7993; Byeon, suk
   ho/0000-0001-8101-0830
FU Basic Science Research Program through the National Research Foundation
   of Korea (NRF) [2019R1A2C2002393]
FX This research was supported by the Basic Science Research Program
   through the National Research Foundation of Korea (NRF) under
   2019R1A2C2002393 (CSL). The funding organization had no role in the
   design or conduct of this research.
CR Arya M, 2018, EYE VISION, V5, DOI 10.1186/s40662-018-0118-x
   Baek J, 2019, CLIN EXP OPHTHALMOL, V47, P498, DOI 10.1111/ceo.13438
   Balaratnasingam C, 2016, RETINA-J RET VIT DIS, V36, P1, DOI 10.1097/IAE.0000000000000774
   Boon CJF, 2013, PROG RETIN EYE RES, V37, P90, DOI 10.1016/j.preteyeres.2013.08.003
   Cheung CMG, 2019, EYE, V33, P14, DOI 10.1038/s41433-018-0158-4
   Cheung CMG, 2018, OPHTHALMOLOGY, V125, P708, DOI 10.1016/j.ophtha.2017.11.019
   Cho HJ, 2013, AM J OPHTHALMOL, V156, P1192, DOI 10.1016/j.ajo.2013.07.001
   Chung SE, 2011, OPHTHALMOLOGY, V118, P840, DOI 10.1016/j.ophtha.2010.09.012
   Dansingani KK, 2016, RETINA-J RET VIT DIS, V36, P499, DOI 10.1097/IAE.0000000000000742
   Guigui B, 2011, BRIT J OPHTHALMOL, V95, P238, DOI 10.1136/bjo.2009.178400
   Kang HG, 2022, OCUL IMMUNOL INFLAMM, V30, P81, DOI 10.1080/09273948.2020.1795206
   Kang HG, 2018, CLIN EXP OPHTHALMOL, V46, P916, DOI 10.1111/ceo.13198
   Kim H, 2015, OSLI RETINA, V46, P423, DOI 10.3928/23258160-20150422-04
   Koh A, 2017, JAMA OPHTHALMOL, V135, P1206, DOI 10.1001/jamaophthalmol.2017.4030
   Koizumi H, 2013, AM J OPHTHALMOL, V155, P305, DOI 10.1016/j.ajo.2012.07.018
   Lee J, 2019, RETINA-J RET VIT DIS, V39, P670, DOI 10.1097/IAE.0000000000002019
   Lee MY, 2012, AM J OPHTHALMOL, V153, P530, DOI 10.1016/j.ajo.2011.08.012
   Maruko I, 2011, AM J OPHTHALMOL, V151, P594, DOI 10.1016/j.ajo.2010.10.030
   Pang CE, 2015, RETINA-J RET VIT DIS, V35, P1, DOI 10.1097/IAE.0000000000000331
   Park SJ, 2014, AM J OPHTHALMOL, V158, P1155, DOI 10.1016/j.ajo.2014.08.010
   Sarks SH, 1999, BRIT J OPHTHALMOL, V83, P358, DOI 10.1136/bjo.83.3.358
   Sasahara M, 2006, AM J OPHTHALMOL, V142, P601, DOI 10.1016/j.ajo.2006.05.051
   Spaide RF, 1996, RETINA-J RET VIT DIS, V16, P203, DOI 10.1097/00006982-199616030-00004
   Spaide RF, 2018, RETINA-J RET VIT DIS, V38, P708, DOI 10.1097/IAE.0000000000001689
   Tan CS, 2015, BRIT J OPHTHALMOL, V99, P624, DOI 10.1136/bjophthalmol-2014-305674
   Tsujikawa A, 2010, RETINA-J RET VIT DIS, V30, P801, DOI 10.1097/IAE.0b013e3181c72068
   Warrow DJ, 2013, RETINA-J RET VIT DIS, V33, P1659, DOI 10.1097/IAE.0b013e3182953df4
   Wong CW, 2016, PROG RETIN EYE RES, V53, P107, DOI 10.1016/j.preteyeres.2016.04.002
   Yanagi Y, 2018, RETINA-J RET VIT DIS, V38, P1509, DOI 10.1097/IAE.0000000000001758
NR 29
TC 6
Z9 6
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0721-832X
EI 1435-702X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD AUG
PY 2021
VL 259
IS 8
BP 2391
EP 2400
DI 10.1007/s00417-021-05180-6
EA APR 2021
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA TX9FL
UT WOS:000644744200007
PM 33907882
DA 2022-11-30
ER

PT J
AU Schaumberg, DA
   Rose, L
   DeAngelis, MM
   Semba, RD
   Hageman, GS
   Chasman, DI
AF Schaumberg, Debra A.
   Rose, Lynda
   DeAngelis, Margaret M.
   Semba, Richard D.
   Hageman, Gregory S.
   Chasman, Daniel I.
TI Prospective Study of Common Variants in CX3CR1 and RISK of Macular
   Degeneration Pooled Analysis From 5 Long-term Studies
SO JAMA OPHTHALMOLOGY
LA English
DT Article
ID BASE-LINE CHARACTERISTICS; WOMENS ANTIOXIDANT; CIGARETTE-SMOKING;
   MICROGLIAL CELLS; RECEPTOR CX3CR1; DIETARY-FAT; DISEASE; ASSOCIATION;
   FRACTALKINE; HEALTH
AB IMPORTANCE The CX3CR1 gene is implicated as a candidate gene for age-related macular degeneration (AMD) through several lines of evidence. There is uncertainty, however, as to whether common genetic variants in CX3CR1 alter risk of AMD, since prior studies have been inconsistent and mostly limited to evaluation of 2 nonsynonymous variants, T280M (rs3732378) and V2491 (rs3732379).
   OBJECTIVE To determine if common variants in CX3CR1 predict future risk of AMD.
   DESIGN SETTING AND PARTICIPANTS Prospective nested case-control study within 5 large study populations with long-term follow-up. We measured genotypes for T280M, V2491, and 13 other common single-nucleotide polymorphisms (SNPs) of the CX3CR1 gene among people who developed AMD (n = 1110, including 369 with neovascular AMD) and 2532 age- and sex-matched controls.MAIN OUTCOMES AND MEASURES We determined the incidence rate ratios (RR) and 95% Cls for incidence of AMD for each variant and examined interactions with other AMD-associated variants and modifiable risk factors.
   RESULTS In additive genetic models, we identified nonsignificant associations with AMD for T280M (RR, 0.87; P =.07) and 3 other SNPs, rs2853707 (RR, 0.88; P =.07), rs12636547 (RR, 0.85; P =.10), and rs1877563 (RR, 0.84; P =.06),1 of which, rs2853707, is positioned in the CX3CR1 promoter region and was associated with neovascular AMD (RR, 0.75; P =.03). We observed that a recessive model was a better fit to the data for some SNPs, with associations between rs11715522 and AMD (RR, 1.27; P =.03) and between rs2669845 (RR, 3.10; P =.04), rs2853707 (RR, 0.48; P =.050), and rs9868689 (RR, 0.31; P =.02) and neovascular AMD. Moreover, in exploratory analyses, we identified a number of possible interactions including between V2491 and rs2669845 and dietary intake of u.)-3 fatty acids (P =.004 and P =.009, respectively) for AMD; between rs2669845 and obesity (P =.03) for neovascular AMD; between T280M and complement component 3 (C3) R102G for AMD (P =.03); between rs2669845 and Y402H in complement factor H for AMD (P =.04); and between rs2669845, rs2853707, and V2491 and C3 R102G for neovascular AMD (P =.008;.04; and.002, respectively).
   CONCLUSIONS AND RELEVANCE This study failed to identify significant associations between common CX3CR1 variants and AMD after considering the number of SNPs analyzed and multiple comparisons. However, we observed evidence consistent with recessive modes of association and that an effect of CX3CR1 variants may depend on other factors including dietary intake of co-3 fatty acids, obesity, and genotypes at CFH Y402H and C3 R102G. If replicated in other populations, these findings would support a role for CX3CR1 in AMD but also suggest that its role may involve mechanisms that are independent of the T280M/V2491 variations.
C1 [Schaumberg, Debra A.; Rose, Lynda; Chasman, Daniel I.] Brigham & Womens Hosp, Harvard Med Sch, Div Prevent Med, Dept Med, Boston, MA USA.
   [Schaumberg, Debra A.] Harvard Univ, Sch Med, Dept Ophthalmol, Schepens Eye Res Inst, Boston, MA USA.
   [Schaumberg, Debra A.] Harvard Univ, Sch Med, Dept Epidemiol, Boston, MA USA.
   [DeAngelis, Margaret M.; Hageman, Gregory S.] Univ Utah, John A Moran Eye Ctr, Salt Lake City, UT USA.
   [Semba, Richard D.] Johns Hopkins Univ, Sch Med, Wilmer Eye Inst, Baltimore, MD 21205 USA.
C3 Harvard University; Brigham & Women's Hospital; Harvard Medical School;
   Harvard University; Harvard Medical School; Schepens Eye Research
   Institute; Harvard University; Harvard Medical School; Utah System of
   Higher Education; University of Utah; Johns Hopkins University; Johns
   Hopkins Medicine
RP Schaumberg, DA (通讯作者)，Moran Ctr Translat Med, 65 N Mario Capecchi Dr, Salt Lake City, UT 84132 USA.
EM debra.schaumberg@utah.edu
RI DeAngelis, e/J-7863-2015
FU National Institutes of Health [EY017362, EY013834, EY009611, EY014458,
   CA87969, CA49449, HL35464, CA34944, CA40360, HL26490, HL34595, CA47988,
   HL43851, HL46959]; NATIONAL CANCER INSTITUTE [P01CA087969, R01CA040360,
   R01CA049449, U01CA049449, R01CA047988] Funding Source: NIH RePORTER;
   NATIONAL EYE INSTITUTE [P30EY014800, R01EY013834, R01EY009611,
   R01EY017362, R01EY014458] Funding Source: NIH RePORTER; NATIONAL HEART,
   LUNG, AND BLOOD INSTITUTE [R01HL035464, R01HL046959, R01HL043851,
   R01HL034595] Funding Source: NIH RePORTER
FX This work was supported by National Institutes of Health grants
   EY017362, EY013834, EY009611, EY014458, CA87969, CA49449, HL35464,
   CA34944, CA40360, HL26490, HL34595, CA47988, HL43851, and HL46959.
CR Abecasis GR, NATURE, V473, P544
   Akaike H., 1973, 2 INT S INF THEOR BU
   Altshuler D, 2010, NATURE, V467, P1061, DOI 10.1038/nature09534
   Barrett JC, 2005, BIOINFORMATICS, V21, P263, DOI 10.1093/bioinformatics/bth457
   Bassuk SS, 2004, J WOMENS HEALTH, V13, P99, DOI 10.1089/154099904322836519
   BELANGER CF, 1978, AM J NURS, V78, P1039, DOI 10.2307/3462013
   Brion M, 2011, ACTA OPHTHALMOL, V89, pE12, DOI 10.1111/j.1755-3768.2010.02040.x
   Chan CC, 2005, HISTOL HISTOPATHOL, V20, P857, DOI 10.14670/HH-20.857
   Cho E, 2001, AM J CLIN NUTR, V73, P209
   Cho EY, 2004, ARCH OPHTHALMOL-CHIC, V122, P883, DOI 10.1001/archopht.122.6.883
   Cho EY, 2000, ARCH OPHTHALMOL-CHIC, V118, P681, DOI 10.1001/archopht.118.5.681
   Christen WG, 1996, JAMA-J AM MED ASSOC, V276, P1147, DOI 10.1001/jama.276.14.1147
   Christen WG, 2009, ARCH INTERN MED, V169, P335, DOI 10.1001/archinternmed.2008.574
   Clark AK, 2011, CURR PHARM BIOTECHNO, V12, P1707
   COLDITZ GA, 1991, AM J CARDIOL, V67, P933, DOI 10.1016/0002-9149(91)90163-F
   Combadiere C, 2007, J CLIN INVEST, V117, P2920, DOI 10.1172/JCI31692
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Cook NR, 2005, JAMA-J AM MED ASSOC, V294, P47, DOI 10.1001/jama.294.1.47
   Damani MR, 2011, AGING CELL, V10, P263, DOI 10.1111/j.1474-9726.2010.00660.x
   Davis CN, 2006, J PHARMACOL EXP THER, V316, P356, DOI 10.1124/jpet.105.093039
   Farrell Kelly A, 2011, Front Biosci (Elite Ed), V3, P968
   Feigl B, 2011, CURR MED RES OPIN, V27, P1745, DOI 10.1185/03007995.2011.603301
   Hageman Gregory S., 2011, Human Genomics, V5, P420
   HENNEKENS CH, 1989, NEW ENGL J MED, V321, P129, DOI 10.1056/nejm198907203210301
   Ho L, 2011, ARCH OPHTHALMOL-CHIC, V129, P758, DOI 10.1001/archophthalmol.2011.141
   Jakobsdottir J, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000337
   Jun GG, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025775
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Lander ES, 1996, SCIENCE, V274, P536, DOI 10.1126/science.274.5287.536
   Lee S, 2010, AM J PATHOL, V177, P2549, DOI 10.2353/ajpath.2010.100265
   Liu MM, 2011, INVEST OPHTH VIS SCI, V52, P3129, DOI 10.1167/iovs.10-6735
   Prinz M, 2010, J NEUROIMMUNOL, V224, P80, DOI 10.1016/j.jneuroim.2010.05.015
   Raoul W, 2008, OPHTHAL RES, V40, P115, DOI 10.1159/000119860
   Raoul W, 2008, J NEUROIMMUNOL, V198, P56, DOI 10.1016/j.jneuroim.2008.04.014
   Raoul W, 2010, J NEUROINFLAMM, V7, DOI 10.1186/1742-2094-7-87
   Reich DE, 2001, TRENDS GENET, V17, P502, DOI 10.1016/S0168-9525(01)02410-6
   Rexrode KM, 2000, J WOMEN HEALTH GEN-B, V9, P19, DOI 10.1089/152460900318911
   Rothman KJ, 1998, MODERN EPIDEMIOLOGY, P133
   Savarin-Vuaillat C, 2007, NEUROTHERAPEUTICS, V4, P590, DOI 10.1016/j.nurt.2007.07.004
   Schaumberg DA, 2007, ARCH OPHTHALMOL-CHIC, V125, P300, DOI 10.1001/archopht.125.3.300
   Schaumberg DA, 2007, ARCH OPHTHALMOL-CHIC, V125, P55, DOI 10.1001/archopht.125.1.55
   Schaumberg DA, 2010, ARCH OPHTHALMOL-CHIC, V128, P1462, DOI 10.1001/archophthalmol.2010.261
   Seddon JM, 1996, JAMA-J AM MED ASSOC, V276, P1141, DOI 10.1001/jama.276.14.1141
   Seddon JM, 2001, ARCH OPHTHALMOL-CHIC, V119, P1191, DOI 10.1001/archopht.119.8.1191
   Shah R, 2011, DIABETES, V60, P1512, DOI 10.2337/db10-0956
   Sirois-Gagnon D, 2011, OBESITY, V19, P222, DOI 10.1038/oby.2010.125
   Suzuki F, 2012, ARTHRITIS RES THER, V14, DOI 10.1186/ar3761
   Tou JS, 2004, FASEB J, V18, P1297, DOI 10.1096/fj.04-1862fje
   Tremblay K, 2006, GENES IMMUN, V7, P632, DOI 10.1038/sj.gene.6364340
   Tuo JS, 2009, AM J PATHOL, V175, P799, DOI 10.2353/ajpath.2009.090089
   Wang JY, 2011, ARTERIOSCL THROM VAS, V31, pE11, DOI 10.1161/ATVBAHA.110.215517
   White GE, 2012, ARTERIOSCL THROM VAS, V32, P589, DOI 10.1161/ATVBAHA.111.237412
   Yang X, 2010, BRIT J OPHTHALMOL, V94, P1211, DOI 10.1136/bjo.2009.165811
   Zerbib J, 2011, EXP EYE RES, V93, P382, DOI 10.1016/j.exer.2011.05.005
   Zhang M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035446
   Zhou YD, 2011, EXP EYE RES, V93, P636, DOI 10.1016/j.exer.2011.07.017
NR 56
TC 19
Z9 20
U1 0
U2 6
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 2168-6165
EI 2168-6173
J9 JAMA OPHTHALMOL
JI JAMA Ophthalmol.
PD JAN
PY 2014
VL 132
IS 1
BP 84
EP 95
DI 10.1001/jamaophthalmol.2013.5506
PG 12
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 291TI
UT WOS:000329852300014
PM 24287500
OA Green Accepted, Bronze
DA 2022-11-30
ER

PT J
AU Bressler, NM
   Chang, TS
   Suner, IJ
   Fine, JT
   Dolan, CM
   Ward, J
   Ianchulev, T
AF Bressler, Neil M.
   Chang, Tom S.
   Suner, Ivan J.
   Fine, Jennifer T.
   Dolan, Chantal M.
   Ward, James
   Ianchulev, Tsontcho
CA MARINA Res Grp
   ANCHOR Res Grp
TI Vision-Related Function after Ranibizumab Treatment by Better- or
   Worse-Seeing Eye Clinical Trial Results from MARINA and ANCHOR
SO OPHTHALMOLOGY
LA English
DT Article
ID QUALITY-OF-LIFE; VISUAL FUNCTION QUESTIONNAIRE; SUBFOVEAL CHOROIDAL
   NEOVASCULARIZATION; MACULAR DEGENERATION; CATARACT-SURGERY; 2ND EYE;
   ACUITY; AREDS; RESPONSIVENESS; SECONDARY
AB Objective: To examine the effects of ranibizumab on the National Eye Institute Visual Function Questionnaire-25 (NEI VFQ-25) scores in neovascular age-related macular degeneration (AMD) according to whether the study eye was the better-or worse-seeing eye at baseline.
   Design: Within 2 randomized, double-masked clinical trials (MARINA and ANCHOR), the NEI VFQ-25 was administered at 0, 1, 2, 3, 6, 9, 12, 18, and 24 months.
   Participants: We included 646 MARINA and 379 ANCHOR patients.
   Intervention: Patients were randomized 1:1:1 to monthly intravitreal ranibizumab (0.3 or 0.5 mg) or control (sham injections for MARINA; photodynamic therapy [PDT] with verteporfin for ANCHOR).
   Main Outcome Measures: Mean change from baseline in NEI VFQ-25 scores at 12 and 24 months.
   Results: Across all treatment arms, 21% to 38% of enrolled eyes were the better-seeing eye. At the 24-month follow-up visit, mean change in composite scores with ranibizumab seemed to be better than control for both better-seeing eyes (8.4 [95% confidence interval (CI), 5.2-11.6], 7.5 [95% CI, 3.7-11.4], and -9.4 [95% CI, -12.5 to -6.3] for the 0.3-mg, 0.5-mg, and sham groups, respectively) and worse-seeing eyes (1.7 [95% CI, -1.1 to 4.4], 1.7 [95% CI, -0.7 to 4.1], and -5.4 [95% CI, -7.9 to -2.8] for the 0.3-mg, 0.5-mg, and sham groups, respectively) in MARINA, as well as the better-seeing eye in ANCHOR (11.3 [95% CI, 5.3-17.3], 13.3 [95% CI, 7.7-19.0], and -2.7 [95% CI, -9.0 to 3.7] for the 0.3-mg, 0.5-mg, and PDT groups, respectively). When the worse-seeing eye was treated in ANCHOR, such differences could not be detected at 24 months (1.3 [95% CI, -1.7 to 4.2], 2.6 [95% CI, -1.1 to 6.3], and 0.1 [95% CI, -3.5 to 3.7] for the 0.3-mg, 0.5-mg, and PDT groups, respectively).
   Conclusions: Analysis of patient perception of vision-related function in phase III trials evaluating ranibizumab for neovascular AMD demonstrates improved patient-reported outcomes regardless of whether the treated eye is the better-or worse-seeing eye at onset of treatment, and supports treatment of such lesions with ranibizumab, even those in the worse-seeing eye.
   Financial Disclosure(s): Proprietary or commercial disclosure may be found after the references. Ophthalmology 2010;117:747-756 (C) 2010 by the American Academy of Ophthalmology.
C1 [Bressler, Neil M.] Johns Hopkins Univ, Sch Med, Wilmer Eye Inst, Retina Div,Dept Ophthalmol, Baltimore, MD 21287 USA.
   [Chang, Tom S.] Retina Inst Calif, Pasadena, CA USA.
   [Suner, Ivan J.] Duke Univ, Sch Med, Durham, NC USA.
   [Fine, Jennifer T.; Dolan, Chantal M.; Ward, James; Ianchulev, Tsontcho] Genentech Inc, San Francisco, CA 94080 USA.
C3 Johns Hopkins University; Johns Hopkins Medicine; Duke University; Roche
   Holding; Genentech
RP Bressler, NM (通讯作者)，Johns Hopkins Univ, Sch Med, Wilmer Eye Inst, Retina Div,Dept Ophthalmol, Maumenee 7th Floor,600 N Wolfe St, Baltimore, MD 21287 USA.
EM nmboffice@jhmi.edu
FU Allergan, Bausch Lomb; Carl Zeiss Meditec; Genentech, Inc., South San
   Francisco, California; Notal Vision Inc.; Novartis Pharma AG, Basel,
   Switzerland; Othera; QLT; Regeneron; Steba Pharmaceuticals; Department
   of Ophthalmology
FX Neil M. Bressler's employer, the Johns Hopkins University (JHU), but not
   Dr. Bressler, receives funding from Allergan, Bausch & Lomb, Carl Zeiss
   Meditec, Genentech, Notal Vision Inc., Novartis, Othera, QLT, Regeneron,
   and Steba Pharmaceuticals for sponsored projects by the Department of
   Ophthalmology for the efforts of Dr Bressler. Dr Bressler receives
   salary support for these sponsored projects; the terms of these projects
   are negotiated and administered by JHU's Office of Research
   Administration. Under JHU's policy, support for the costs of research,
   administered by the institution, does not constitute a conflict of
   interest.; Supported financially by Genentech, Inc., South San
   Francisco, California, and by Novartis Pharma AG, Basel, Switzerland.
CR Beck RW, 2003, AM J OPHTHALMOL, V135, P194, DOI 10.1016/S0002-9394(02)01825-1
   Berdeaux GH, 2005, AM J OPHTHALMOL, V139, P271, DOI 10.1016/j.ajo.2004.09.028
   BLACKHURST DW, 1989, RETINA-J RET VIT DIS, V9, P163, DOI 10.1097/00006982-198909030-00001
   Bressler NM, 2009, ARCH OPHTHALMOL-CHIC, V127, P13, DOI 10.1001/archophthalmol.2008.562
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Cahill MT, 2005, OPHTHALMOLOGY, V112, P144, DOI 10.1016/j.ophtha.2004.06.035
   Castells X, 2006, J CLIN EPIDEMIOL, V59, P201, DOI 10.1016/j.jclinepi.2005.06.007
   Chang TS, 2007, ARCH OPHTHALMOL-CHIC, V125, P1460, DOI 10.1001/archopht.125.11.1460
   Clemons TE, 2003, ARCH OPHTHALMOL-CHIC, V121, P211
   Desai P, 1996, BRIT J OPHTHALMOL, V80, P868, DOI 10.1136/bjo.80.10.868
   Elliott DB, 2000, OPTOMETRY VISION SCI, V77, P13, DOI 10.1097/00006324-200001000-00009
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Lindblad AS, 2005, ARCH OPHTHALMOL-CHIC, V123, P1207
   Linder M, 1999, ARCH OPHTHALMOL-CHIC, V117, P1611
   Lundstrom M, 2001, J CATARACT REFR SURG, V27, P1553, DOI 10.1016/S0886-3350(01)00984-1
   Maguire MG, 1997, ARCH OPHTHALMOL-CHIC, V115, P741
   Mangione C., 2000, NATL EYE I 25 ITEM V
   Mangione CM, 2001, ARCH OPHTHALMOL-CHIC, V119, P1050, DOI 10.1001/archopht.119.7.1050
   Mangione CM, 1998, ARCH OPHTHALMOL-CHIC, V116, P1496, DOI 10.1001/archopht.116.11.1496
   Miskala PH, 2004, OPHTHALMOLOGY, V111, P1981, DOI 10.1016/j.ophtha.2004.07.022
   Miskala PH, 2003, ARCH OPHTHALMOL-CHIC, V121, P531
   Pomberg ML, 2004, AM J OPHTHALMOL, V138, P125, DOI 10.1016/j.ajo.2004.02.022
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Soubrane G, 2007, ARCH OPHTHALMOL-CHIC, V125, P1249, DOI 10.1001/archopht.125.9.1249
   Talic I, 2022, LEARN INSTR, V81, DOI [10.1016/j.learninstruc.2022.101594, 10.1016/j.ajo.2004.02.011]
NR 25
TC 102
Z9 106
U1 0
U2 5
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0161-6420
J9 OPHTHALMOLOGY
JI Ophthalmology
PD APR
PY 2010
VL 117
IS 4
BP 747
EP U124
DI 10.1016/j.ophtha.2009.09.002
PG 14
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 582YZ
UT WOS:000276638800016
PM 20189654
DA 2022-11-30
ER

PT J
AU Park, UC
   Kim, BH
   Choe, HR
   Yeon, DY
   Yu, HG
AF Park, Un Chul
   Kim, Bo Hee
   Choe, Hye Rim
   Yeon, Dong Yun
   Yu, Hyeong Gon
TI Long-term results of rescue photodynamic therapy for type 1
   neovascularization refractory to anti-vascular endothelial growth factor
SO ACTA OPHTHALMOLOGICA
LA English
DT Article
DE age&#8208; related macular degeneration; anti&#8208; VEGF; photodynamic
   therapy; polypoidal choroidal vasculopathy; refractory; rescue; type 1
   neovascularization
ID POLYPOIDAL CHOROIDAL VASCULOPATHY; MACULAR DEGENERATION; VERTEPORFIN;
   RANIBIZUMAB; ANGIOGRAPHY; COMBINATION; EFFICACY; SAFETY
AB Purpose To evaluate long-term results of photodynamic therapy (PDT) as a rescue treatment in patients with type 1 neovascularization refractory to intravitreal anti-vascular endothelial growth factor (VEGF).
   Methods Patients who underwent reduced-fluence PDT for refractory type 1 neovascularization, which showed persistent subretinal and/or intraretinal fluid after three or more consecutive anti-VEGF treatments, and were followed up for >= 24 months were reviewed.
   Results Seventy-eight eyes of 78 patients were included, and 37 (47%) were classified as polypoidal choroidal vasculopathy (PCV). The mean number of anti-VEGF injections before rescue PDT was 8.5 +/- 5.4, and the mean follow-up period after rescue PDT was 74.0 +/- 29.4 months. At 3 months after rescue PDT, exudation completely resolved in 55 (71%) patients and vision significantly improved (p = 0.021). Resolution of exudation was associated with choroidal vascular hyperpermeability [odds ratio (OR), 3.82; p = 0.031] and lower maximal height of pigment epithelial detachment (OR, 0.69; p = 0.018). In these patients, exudation recurred in 49 (89%) after mean period of 13.5 months. Vision significantly worsened at 24 months after rescue PDT, and thereafter, and the vision decrease was more prominent in patients with PCV. Rescue PDT could be repeated for recurrent or persistent exudation without increasing the risk of complications.
   Conclusion In patients with type 1 neovascularization refractory to anti-VEGF, reduced-fluence PDT is an effective and safe rescue treatment. Therapeutic efficacy wore off during long-term follow-up, but rescue PDT may be repeated safely.
C1 [Park, Un Chul; Kim, Bo Hee; Choe, Hye Rim; Yeon, Dong Yun; Yu, Hyeong Gon] Seoul Natl Univ, Coll Med, Dept Ophthalmol, 103 Daehak Ro, Seoul 110799, South Korea.
   [Park, Un Chul; Kim, Bo Hee; Choe, Hye Rim; Yeon, Dong Yun; Yu, Hyeong Gon] Seoul Natl Univ Hosp, Retinal Degenerat Res Lab, Biomed Res Inst, Seoul, South Korea.
   [Yu, Hyeong Gon] Seoul Natl Univ, Med Res Ctr, Inst Reprod Med & Populat, Seoul, South Korea.
C3 Seoul National University (SNU); Seoul National University (SNU); Seoul
   National University Hospital; Seoul National University (SNU)
RP Yu, HG (通讯作者)，Seoul Natl Univ, Coll Med, Dept Ophthalmol, 103 Daehak Ro, Seoul 110799, South Korea.
EM hgonyu@snu.ac.kr
OI Yu, Hyeong Gon/0000-0002-1795-202X
FU Korean Association of Retinal Degeneration Funding Source: Medline;
   Korea Health Technology R&D Project of the Korea Health Industry
   Development Institute [HI14C1277] Funding Source: Medline
CR Amoaku WM, 2015, EYE, V29, P721, DOI 10.1038/eye.2015.48
   Arnold J, 2001, AM J OPHTHALMOL, V131, P541
   Baek J, 2020, RETINA-J RET VIT DIS, V40, P2166, DOI 10.1097/IAE.0000000000002723
   Baek J, 2019, EYE, V33, P419, DOI 10.1038/s41433-018-0228-7
   Baek J, 2018, GRAEF ARCH CLIN EXP, V256, P2309, DOI 10.1007/s00417-018-4143-1
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Byon IS, 2014, OSLI RETINA, V45, P534, DOI 10.3928/23258160-20141118-08
   Dansingani KK, 2018, CLIN EXP OPHTHALMOL, V46, P189, DOI 10.1111/ceo.13114
   Fung AT, 2012, RETINA-J RET VIT DIS, V32, P1829, DOI 10.1097/IAE.0b013e3182680a66
   Jung BJ, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-38504-y
   Jung JJ, 2014, AM J OPHTHALMOL, V158, P769, DOI 10.1016/j.ajo.2014.07.006
   Khan S, 2012, RETINA-J RET VIT DIS, V32, P1057, DOI 10.1097/IAE.0b013e31823beb14
   Kikushima W, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-16476-1
   Kim JM, 2019, SEMIN OPHTHALMOL, V34, P168, DOI 10.1080/08820538.2019.1620791
   Kloos P, 2011, KLIN MONATSBL AUGENH, V228, P340, DOI 10.1055/s-0031-1273230
   Koh A, 2017, JAMA OPHTHALMOL, V135, P1206, DOI 10.1001/jamaophthalmol.2017.4030
   Koh A, 2012, RETINA-J RET VIT DIS, V32, P1453, DOI 10.1097/IAE.0b013e31824f91e8
   Lee JH, 2016, RETINA-J RET VIT DIS, V36, P889, DOI 10.1097/IAE.0000000000000809
   Lee WK, 2018, JAMA OPHTHALMOL, V136, P786, DOI 10.1001/jamaophthalmol.2018.1804
   Li JQ, 2018, J OPHTHALMOL, V2018, DOI 10.1155/2018/1425707
   Pang CE, 2015, RETINA-J RET VIT DIS, V35, P1, DOI 10.1097/IAE.0000000000000331
   Rishi P, 2013, EYE, V27, P1038, DOI 10.1038/eye.2013.106
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Schmidt-Erfurth U, 2000, SURV OPHTHALMOL, V45, P195, DOI 10.1016/S0039-6257(00)00158-2
   Schmidt-Erfurth U, 2014, OPHTHALMOLOGY, V121, P193, DOI 10.1016/j.ophtha.2013.08.011
   Tozer K, 2013, OPHTHALMOLOGY, V120, P2029, DOI 10.1016/j.ophtha.2013.03.016
   Yanagi Y, 2017, RETINA, V38, P1509
NR 28
TC 6
Z9 6
U1 0
U2 3
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1755-375X
EI 1755-3768
J9 ACTA OPHTHALMOL
JI Acta Ophthalmol.
PD SEP
PY 2021
VL 99
IS 6
BP E899
EP E907
DI 10.1111/aos.14719
EA DEC 2020
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA UO6TY
UT WOS:000603410600001
PM 33377608
DA 2022-11-30
ER

PT J
AU Hawkins, BS
   Miskala, PH
   Mangione, CM
   Bass, EB
   Bressler, NM
   Mann, AC
   Dong, LM
   Marsh, MJ
AF Hawkins, BS
   Miskala, PH
   Mangione, CM
   Bass, EB
   Bressler, NM
   Mann, AC
   Dong, LM
   Marsh, MJ
CA Submacular Surgery Trials Res Grp
TI Health- and vision-related quality of life among patients with ocular
   histoplasmosis or idiopathic choroidal neovascularization at enrollment
   in a randomized trial of submacular surgery - Submacular surgery trials
   report no.5
SO ARCHIVES OF OPHTHALMOLOGY
LA English
DT Article
ID VISUAL FUNCTION QUESTIONNAIRE; GENERAL HEALTH; DEPRESSION; ACUITY;
   SCORES
AB Objectives: To (1) summarize vision-targeted and general health-related quality-of-life scores at baseline and quantify the effect of the ophthalmic problem, (2) evaluate the strength of relations between visual acuity and inter-view scores, and (3) compare scores for patients who also had choroidal neovascular lesions in the fellow eye (bilateral cases) with those of patients who had choroidal neovascularization in only the study eye (unilateral cases) at time of enrollment in a randomized trial of surgical removal of subfoveal choroidal neovascularization, either associated with the ocular histoplasmosis syndrome or of idiopathic origin.
   Design: Eligible patients had subfoveal choroidal neovascularization (including some classic choroidal neovascularization) and a visual acuity of 20/50 to 20/800 (Snellen equivalent), inclusive, in the eye to be assigned randomly to surgery or observation. Interviews that incorporated the 39-item version of the National Eye Institute Visual Function Questionnaire (NEI-VFQ) and 2 other instruments were conducted by telephone by trained interviewers before patients enrolled and were assigned randomly to surgery or observation. Information from baseline clinical examinations and fluorescein angiograms interpreted centrally by masked readers was used to classify patients as unilateral or bilateral cases and to provide potential explanations for variability of interview responses using linear regression models.
   Results: The median overall NEI-VFQ score was 75 (interquartile range, 60-84). The median scores on individual subscales ranged from 55 (general vision) to 100 (color vision). The visual acuity of the better-seeing eye accounted for much of the variability in scores on most NEI-VFQ subscales; a 3-line difference in visual acuity was associated with a 10-point or greater difference in scores on 5 subscales after adjustment for other characteristics of patients and eyes. Scores on most scales of all 3 instruments differed between unilateral cases (n = 167) and bilateral cases (n = 58). Even after adjustment for visual acuity and reading speed of the better-seeing eye, age, gender, and scores on the other instruments, scores on the NEI-VFQ near and distance activities subscales differed by almost 13 and 10 points, respectively, between unilateral and bilateral cases. Neither age nor gender was an important independent explanatory variable for NEI-VFQ scores.
   Conclusions: Unilateral and bilateral cases had vision-targeted health-related quality-of-life scores worse than those published for a reference population without eye disease. Furthermore, despite younger age, better visual acuity, and better short-term visual prognosis, bilateral cases had NEI-VFQ scores at baseline similar to those published for 2 groups of patients with age-related macular degeneration. Unidentified factors, in addition to the visual acuity of the better-seeing eye, affected patients' perceptions of visual function.
C1 SST Coordinating Ctr, Baltimore, MD 21205 USA.
RP Hawkins, BS (通讯作者)，SST Coordinating Ctr, 550 N Broadway,9th Floor, Baltimore, MD 21205 USA.
EM bhawkins@jhmi.edu
FU NEI NIH HHS [EY11557, U10 EY011547-07, U10 EY011557-08, U10 EY011557,
   U10 EY011547, U10 EY011558, U01 EY11547, EY11558, U10 EY011558-07]
   Funding Source: Medline; NATIONAL EYE INSTITUTE [U10EY011558,
   U10EY011547, U10EY011557] Funding Source: NIH RePORTER
CR [Anonymous], 1991, Arch Ophthalmol, V109, P1220
   [Anonymous], 1987, ARCH OPHTHALMOL-CHIC, V105, P1499
   ARMITAGE P, 1987, STATISTICAL METHODS, P372
   Bass EB, 2004, ARCH OPHTHALMOL-CHIC, V122, P1856
   Brody BL, 2001, OPHTHALMOLOGY, V108, P1893, DOI 10.1016/S0161-6420(01)00754-0
   Clemons TE, 2003, ARCH OPHTHALMOL-CHIC, V121, P211
   Cole SR, 2000, INVEST OPHTH VIS SCI, V41, P1017
   Dandona L, 1998, ARCH OPHTHALMOL-CHIC, V116, P545, DOI 10.1001/archopht.116.4.514
   Dong LM, 2002, ARCH OPHTHALMOL-CHIC, V120, P1523, DOI 10.1001/archopht.120.11.1523
   DRAPER NR, 1966, APPLIED REGRESSION A, P44
   DRUMMOND MF, 1990, MEASURING QUALITY LI, P65
   EDWARDS LB, 1969, AM REV RESPIR DIS, V99, P1
   FEMAN SS, 1982, OPHTHALMOLOGY, V89, P1295, DOI 10.1016/S0161-6420(82)34630-8
   FINE SL, 1983, ARCH OPHTHALMOL-CHIC, V101, P1347, DOI 10.1001/archopht.1983.01040020349002
   FINE SL, 1983, ARCH OPHTHALMOL-CHIC, V101, P1358
   Gass J D, 1972, Trans Am Acad Ophthalmol Otolaryngol, V76, P672
   Keller S., 1994, SF36 PHYS MENTAL HLT
   MAKLEY TA, 1965, T AM ACAD OPHTHALMOL, P443
   Mangione CM, 2001, ARCH OPHTHALMOL-CHIC, V119, P1050, DOI 10.1001/archopht.119.7.1050
   Mangione CM, 1998, ARCH OPHTHALMOL-CHIC, V116, P1496, DOI 10.1001/archopht.116.11.1496
   MCDOWELL I, 1990, MEASURING QUALITY LI, P29
   Miskala PH, 2004, ARCH OPHTHALMOL-CHIC, V122, P758, DOI 10.1001/archopht.122.5.758
   Parrish RK, 1997, ARCH OPHTHALMOL-CHIC, V115, P1447, DOI 10.1001/archopht.1997.01100160617016
   PATRICK DL, 1993, QUALITY LIFE ASSESSM, P81
   PELLI DG, 1988, CLIN VISION SCI, V2, P187
   Schiffman RM, 2001, ARCH OPHTHALMOL-CHIC, V119, P841
   SCHLAEGEL TF, 1971, AM J OPHTHALMOL, V71, P1192, DOI 10.1016/0002-9394(71)90962-7
   Snedecor GW, 1980, STATISTICAL METHODS, p175/180
   SNEDECOR GW, 1980, STATISTICAL METHODS, P144
   *SUBM SURG TRIAL R, 1998, SUBM SURG TRIALS MAN
   *SUBM SURG TRIALS, 3 SST QOL
   *SUBM SURG TRIALS, 1998, SUBM SURG TRIALS FOR
   TUKEY JW, 1977, EXPLORATORY DATA ANA, P34
   VANMETRE TE, 1964, ARCH OPHTHALMOL-CHIC, V71, P314
   Ware J.E., 1993, LINC RI QUAL METR IN
   WARE JE, 1993, QUALITY LIFE ASSESSM
   Wilkinson CP, 1996, ARCH OPHTHALMOL-CHIC, V114, P677
   WOODS ALAN C, 1959, TRANS AMER OPHTHALMOL SOC, V57, P318
   ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x
NR 39
TC 19
Z9 20
U1 0
U2 1
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 0003-9950
EI 1538-3601
J9 ARCH OPHTHALMOL-CHIC
JI Arch. Ophthalmol.
PD JAN
PY 2005
VL 123
IS 1
BP 78
EP 88
PG 11
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 886RL
UT WOS:000226245900013
PM 15642816
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Ku, JY
   Milling, AF
   Vazquez, NP
   Knox, PC
AF Ku, Jae Y.
   Milling, Ashli F.
   Vazquez, Noelia Pitrelli
   Knox, Paul C.
TI Performance, usability and comparison of two versions of a new macular
   vision test: the handheld Radial Shape Discrimination test
SO PEERJ
LA English
DT Article
DE Macula; Vision testing; Acuity; Retina; Hyperacuity; Shape
   discrimination
ID VISUAL FUNCTION; DEGENERATION; HYPERACUITY; MACULOPATHY
AB Background. Central vision, critical for everyday tasks such as reading and driving, is impacted by age-related changes in the eye and by diseases such as age-related macular degeneration. The detection of changes in macular function is therefore important. The Radial Shape Discrimination (RSD) test measures the threshold at which distortions in a radial frequency pattern can be detected and there is evidence that it is more sensitive to macular pathology than visual acuity (VA). It also provides a more quantitative measure of macular function than the commonly available Amsler grid. Recently, handheld versions of the test (hRSD) in which stimuli are presented on mobile devices (e.g., Apple iPod Touch, iPhone) have been developed. We investigated the characteristics of the hRSD test in healthy participants.
   Methods. Data were collected using both three-alternative forced choice (3AFC) and 4AFC versions of the hRSD test, presented on an Apple iPod Touch. For the 3AFC version, data from a single test session were available for 186 (72 male; mean +/- SD age 42 +/- 17y; range 16-90y) healthy participants. Test-retest data were available for subgroups of participants (intra-session: N = 74; tests approximately 2 months apart: N = 30; tests 39 months apart: N = 15). The 3AFC and 4AFC versions were directly compared in 106 participants who also completed a usability questionnaire. Distance and near VA and Pelli Robson Contrast Sensitivity (CS) data were collected and undilated fundoscopy performed on the majority of participants.
   Results. Mean (+/- SD) 3AFC hRSD threshold was -0.77 +/- 0.14 logMAR, and was statistically significantly correlated with age (Pearson r = 0 : 35; p < 0 : 001). The linear regression of hRSD threshold on age had a slope of +0.0026 compared to +0.0051 for near VA (which also correlated with age: r = 0 : 51 I p < 0 : 001). There were no statistically significant differences in hRSD thresholds for any of the test-retest subgroups. We also observed no statistically significant difference between 3AFC (-0.82 +/- 0.11 logMAR) and 4AFC (-0.80 +/- 0.12 logMAR) hRSD thresholds (t = 1 : 85; p < 0 : 067) and participants reported excellent test usability with no strong preference expressed between the 3AFC and 4AFC versions of the test.
   Discussion. The 3AFC hRSD thresholds we report are consistent with a number of previous studies, as is its greater stability in ageing compared to VA. We have also shown that in the absence of pathology, thresholds are stable over short and long timescales. The 4AFC thresholds we have reported provide a baseline for future investigations, and we have confirmed that 3AFC and 4AFC thresholds are similar, providing a basis of comparisons between studies using the different versions. As the hRSD test is easy to use and relatively inexpensive, clinical studies are now required to establish its ability to detect and monitor macular pathologies.
C1 [Ku, Jae Y.; Vazquez, Noelia Pitrelli; Knox, Paul C.] Univ Liverpool, Eye & Vis Sci, Liverpool, Merseyside, England.
   [Milling, Ashli F.] Univ Liverpool, Directorate Orthopt & Vis Sci, Liverpool, Merseyside, England.
C3 University of Liverpool; University of Liverpool
RP Knox, PC (通讯作者)，Univ Liverpool, Eye & Vis Sci, Liverpool, Merseyside, England.
EM pcknox@liv.ac.uk
RI Knox, Paul/Q-1920-2019
OI Knox, Paul/0000-0002-2578-7335; Pitrelli Vazquez,
   Noelia/0000-0002-9800-8419
FU Dunhill Medical Trust [R283/0213]
FX Part of this work was funded by a grant from the Dunhill Medical Trust
   (R283/0213). The funders had no role in study design, data collection
   and analysis, decision to publish, or preparation of the manuscript.
CR AMSLER M, 1953, BRIT J OPHTHALMOL, V37, P521, DOI 10.1136/bjo.37.9.521
   Bennett LD, 2016, INVEST OPHTH VIS SCI, V57, P332, DOI 10.1167/iovs.15-18354
   Bunce C, 2014, BRIT J OPHTHALMOL, V98, P408, DOI 10.1136/bjophthalmol-2013-304587
   Dimitrov PN, 2011, INVEST OPHTH VIS SCI, V52, P9457, DOI 10.1167/iovs.10-7043
   Faes L, 2014, EYE, V28, P788, DOI 10.1038/eye.2014.104
   Hogg RE, 2006, PROG RETIN EYE RES, V25, P249, DOI 10.1016/j.preteyeres.2005.11.002
   Jakel F, 2006, J VISION, V6, P1307, DOI 10.1167/6.11.13
   Kaiser PK, 2013, RETINA-J RET VIT DIS, V33, P1863, DOI 10.1097/IAE.0b013e3182899258
   Keane PA, 2015, CLIN OPHTHALMOL, V9, P353, DOI 10.2147/OPTH.S59012
   KLEIN R, 1995, INVEST OPHTH VIS SCI, V36, P182
   Lott LA, 2015, INVEST OPHTHALMOL, V56, P2219
   Lott LA, 2016, INVEST OPHTH VIS SCI, V57
   Neelam K, 2009, SURV OPHTHALMOL, V54, P167, DOI 10.1016/j.survophthal.2008.12.003
   Pitrelli Vazquez N, 2014, OPHTHALMIC PHYSL OPT, V34
   Pitrelli Vazquez Noelia, 2015, Br Ir Orthopt J, V12, P9
   Wang Y-Z, 2012, INVESTIGATIVE OPHTHA, V53
   Wang YZ, 2013, INVEST OPHTH VIS SCI, V54, P5497, DOI 10.1167/iovs.13-12037
   Wang YZ, 2009, OPTOMETRY VISION SCI, V86, P695, DOI 10.1097/OPX.0b013e3181a7b0ff
   Wang YZ, 2002, INVEST OPHTH VIS SCI, V43, P2055
   Wilkinson F, 1998, VISION RES, V38, P3555, DOI 10.1016/S0042-6989(98)00039-X
NR 20
TC 6
Z9 6
U1 0
U2 4
PU PEERJ INC
PI LONDON
PA 341-345 OLD ST, THIRD FLR, LONDON, EC1V 9LL, ENGLAND
SN 2167-8359
J9 PEERJ
JI PeerJ
PD NOV 1
PY 2016
VL 4
AR e2650
DI 10.7717/peerj.2650
PG 12
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA EB2EA
UT WOS:000387169300010
PM 27833815
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Gu, LP
   Chen, H
   Tuo, JS
   Gao, XW
   Chen, L
AF Gu, Liping
   Chen, Hui
   Tuo, Jingsheng
   Gao, Xiaowei
   Chen, Li
TI Inhibition of experimental choroidal neovascularization in mice by
   anti-VEGFA/VEGFR2 or non-specific siRNA
SO EXPERIMENTAL EYE RESEARCH
LA English
DT Article
DE mouse model; choroidal neovascularization; siRNA; VEGFA; VEGFR
ID ENDOTHELIAL GROWTH-FACTOR; INTRAVITREAL BEVACIZUMAB;
   PLASMINOGEN-ACTIVATOR; MACULAR DEGENERATION; RNA; RECEPTOR; VEGF;
   ANGIOGENESIS; VERTEPORFIN; PATHWAY
AB Choroidal neovascularization (CNV) is one of the severe pathological consequences of the end-stage of age-related macular degeneration (AMD). Several lines of evidence implicate increased levels of vascular endothelial growth factor (VEGF) in the retinas of AMD patients. Current available agents for the inhibition of VEGF protein such as bevacizumab show significant promise for the treatment of exudative AMD. However, this compound still has limited efficacy and requires multiple administrations; thus, it is associated with a variety of ocular complications, including endophthalmitis and retinal detachment. In this study, we used anti-VEGFA/VEGFR2 or non-specific siRNA and evaluated their suppression of laser-induced choroidal neovascularization (CNV) in mice. Male adult C57BL/6J mice were used in the study. The mice were subjected to laser rupture of Bruch's membrane to induce CNV and then randomized to five groups with six mice per group. The five groups were blank control, vehicle control (5% glucose solution, GS), VEGFA.siRNA, VEGFR2.siRNA, and non-specific siRNA. Two days after laser photocoagulation, each group, with the exception of the blank control group, received 1 mu l of the appropriate agent by intravitreal injection to both eyes. Seven days later, after taking fundus photography and fundus fluorescein angiography (FFA), the mice were killed for tissue sampling. Six eyes from three mice in each group were used for choroidal flatmounts to examine CNV. Six eyes from three mice in each group were subjected to RNA extraction for VEGF mRNA quantification by qRT-PCR. Retinal tissue from 2 mice without laser treatment was harvested as the assay reference. The incidence of burns which showed fluorescein leakage was 80.0% in blank control, 75.0% in GS, 55.0% in VEGFA.siRNA, 40.0% in VEGFR2.siRNA and 30.0% in non-specific siRNA group. The flatmounted specimens showed that the retinal pigment epithelium (RPE) was visualized as a uniform hexagonal array in nonlasered areas. On day 7 after laser burn, well-defined isolectin-B4 labeled CNV networks were shown within the burn spots of the 2 control groups. The inhibitory effects of the 3 siRNAs on CNV formation were statistically significant as compared to the 2 control groups. Compared to the control groups, the ocular expression of VEGF mRNA was decreased significantly in the 3 siRNA treated groups. The areas of CNV correlated with the expression of VEGF mRNA. Anti-VEGFA/VEGFR2 or non-specific siRNA can inhibit CNV and attenuate VEGF mRNA expression in a laser-induced mouse model of CNV. We conclude that the siRNAs may be an option for treating patients with exudative AMD, and more studies are needed to test the possible side-effects of the treatment. (C) 2010 Elsevier Ltd. All rights reserved.
C1 [Chen, Li] Nantong Univ, Sch Med, Dept Pathol, Nantong 226001, Jiangsu, Peoples R China.
   [Gu, Liping; Chen, Hui; Tuo, Jingsheng] Nantong Univ, Affiliated Hosp, Dept Ophthalmol, Nantong 226001, Jiangsu, Peoples R China.
C3 Nantong University; Nantong University
RP Chen, L (通讯作者)，Nantong Univ, Sch Med, Dept Pathol, 19 Qi Xiu Rd, Nantong 226001, Jiangsu, Peoples R China.
EM kitty.lpgu@yahoo.com.cn
FU Nantong University, China
FX The study was supported by Nantong University, China. The authors thank
   Biomics Biotechnologies Co., Ltd. (Nantong, Jiangsu, China) for kindly
   providing the siRNAs.
CR [Anonymous], 1991, Arch Ophthalmol, V109, P1109
   ASHIKARI M, 2010, INVEST OPHTH VIS SCI, V10, P1167
   Beazley-Long N, 2010, FASEB J, V24
   Bora NS, 2007, J IMMUNOL, V178, P1783, DOI 10.4049/jimmunol.178.3.1783
   Bora NS, 2006, J IMMUNOL, V177, P1872, DOI 10.4049/jimmunol.177.3.1872
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Campos M, 2006, INVEST OPHTH VIS SCI, V47, P5163, DOI 10.1167/iovs.06-0156
   Chapman JA, 2006, ANN PHARMACOTHER, V40, P1322, DOI 10.1345/aph.1G604
   Ciulla TA, 2001, INVEST OPHTH VIS SCI, V42, P3337
   Costa RA, 2006, INVEST OPHTH VIS SCI, V47, P4569, DOI 10.1167/iovs.06-0433
   Das A, 2004, ARCH OPHTHALMOL-CHIC, V122, P1844, DOI 10.1001/archopht.122.12.1844
   Emerson MV, 2007, RETINA-J RET VIT DIS, V27, P439, DOI 10.1097/IAE.0b013e31804b3e15
   Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888
   Hannon GJ, 2002, NATURE, V418, P244, DOI 10.1038/418244a
   Kim B, 2004, AM J PATHOL, V165, P2177, DOI 10.1016/S0002-9440(10)63267-1
   Kleinman ME, 2008, NATURE, V452, P591, DOI 10.1038/nature06765
   Konopatskaya O, 2006, MOL VIS, V12, P626
   Lewis H, 1997, OPHTHALMOLOGY, V104, P1847, DOI 10.1016/S0161-6420(97)30018-9
   MATTHEWS W, 1991, P NATL ACAD SCI USA, V88, P9026, DOI 10.1073/pnas.88.20.9026
   QUINN TP, 1993, P NATL ACAD SCI USA, V90, P7533, DOI 10.1073/pnas.90.16.7533
   Reich S, 2003, MOL VIS, V9, P210
   Schmidt-Erfurth U, 1999, ARCH OPHTHALMOL-CHIC, V117, P1177
   Seo MS, 1999, AM J PATHOL, V154, P1743, DOI 10.1016/S0002-9440(10)65430-2
   SHIMA DT, 1995, FEBS LETT, V370, P203, DOI 10.1016/0014-5793(95)00831-S
   Tobe T, 1998, AM J PATHOL, V153, P1641, DOI 10.1016/S0002-9440(10)65753-7
   Tolentino MJ, 2004, RETINA-J RET VIT DIS, V24, P132, DOI 10.1097/00006982-200402000-00018
NR 26
TC 29
Z9 34
U1 3
U2 18
PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 0014-4835
EI 1096-0007
J9 EXP EYE RES
JI Exp. Eye Res.
PD SEP
PY 2010
VL 91
IS 3
BP 433
EP 439
DI 10.1016/j.exer.2010.06.019
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 645XY
UT WOS:000281500700014
PM 20599960
DA 2022-11-30
ER

PT J
AU Turner, K
AF Turner, K
TI Review of US patents in the field of organic process development
   published during May and June 2004
SO ORGANIC PROCESS RESEARCH & DEVELOPMENT
LA English
DT Article
AB This review of patents contains 20 from a selection of 255, and they cover a variety of topics that, it is hoped, will be of interest. The heart and obesity problems that are common in western society means there are a great many drugs already available or under development to treat these conditions. Hence, the statins continue to stimulate great interest in the treatment of obesity and heart problems. An improved drying process for one type of crystalline atorvastatin is disclosed. Other patents on statins describe two new polymorphs of orlistat and a new synthesis of fluvastatin. Another drug used to treat heart diseases is plavix, and a method of racemising the unwanted enantiomer has been described. The synthesis of a range of novel diazo compounds is described that can be used in the preservation of old manuscripts by deacidification. Atropisomers exhibit chirality due to hindered rotation, and a range of such pyridine derivatives is described that are used as chiral catalysts in asymmetric acylation reactions. A new route to the piperidine intermediates that are useful in preparing the antihistamine drug fexofenadine is disclosed. The importance of mixing raises its head again in a process for oxidation of alcohols using TEMPO. The procedure is a continuous process in which the reagents are fed separately to a tube where they are mixed with a static mixer. This is said to require short residence times and gives improved selectivity and productivity. The use of drugs in areas far removed from the original use brings an unusual finding. The drug eflornithine was developed to treat African sleeping sickness and has been found to be useful in the treatment of unwanted facial hair. Two patents cover a novel method of producing meso-zeaxanthin which is used to treat age-related macular degeneration. The chemistry covered in these patents is extensive and not clearly explained. Hence, the review here has merely scratched the surface; anyone who has a particular interest in this subject is strongly advised to consult the patents. Factor Xa is involved in the coagulation of blood, and two patents from different companies disclose details of compounds that can inhibit this. As is often the case, experimental details in patents may be lacking in detail. In this collection there are two patents that claim improved methods for preparing compounds and yet provide no experimental details to back up the claim. On the other hand two other patents give details of making substantial quantities of chemicals and provide an indication that the processes are capable of being used commercially. As usual, the advantages are those claimed in the patent unless this reviewer has personal knowledge, and there is no legal or commercial significance in the choice of patents for review.
C1 Kappa Tau Consulting, Stockton On Tees TS19 7EY, England.
RP Turner, K (通讯作者)，Kappa Tau Consulting, 12 Ave, Stockton On Tees TS19 7EY, England.
EM keith@kappa-tau.co.uk
NR 0
TC 0
Z9 0
U1 0
U2 9
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1083-6160
EI 1520-586X
J9 ORG PROCESS RES DEV
JI Org. Process Res. Dev.
PD SEP-OCT
PY 2004
VL 8
IS 5
BP 697
EP 707
DI 10.1021/op0498621
PG 11
WC Chemistry, Applied; Chemistry, Organic
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Chemistry
GA 855EA
UT WOS:000223954700003
DA 2022-11-30
ER

PT J
AU Douglas, VP
   Douglas, KAA
   Vavvas, DG
   Miller, JW
   Miller, JB
AF Douglas, Vivian Paraskevi
   Douglas, Konstantinos A. A.
   Vavvas, Demetrios G.
   Miller, Joan W.
   Miller, John B.
TI Short- and Long-Term Visual Outcomes in Patients Receiving Intravitreal
   Injections: The Impact of the Coronavirus 2019 Disease
   (COVID-19)-Related Lockdown
SO JOURNAL OF CLINICAL MEDICINE
LA English
DT Article
DE delay in care; anti-VEGF; nonadherence; nonpersistence; noncompliance;
   treatment discontinuation; pandemic
ID RETINAL VEIN OCCLUSION; ANTI-VEGF THERAPY; MACULAR DEGENERATION;
   FOLLOW-UP; RANIBIZUMAB; EDEMA; AFLIBERCEPT; BENEFITS
AB Purpose: To investigate the short- and long-term impact of COVID-19-related lockdown on the vision of patients requiring intravitreal injections (IVI) for neovascular Age-related Macular degeneration (nvAMD), diabetic retinopathy (DR), central retinal vein occlusion (CRVO), or branch retinal vein occlusion (BRVO). Methods: This is a retrospective study from the Retina department of three Mass Eye and Ear centers. Charts of patients age of >= 18 years with any of the abovementioned diagnoses who had a scheduled appointment anytime between 17 March 2020 until 18 May 2020 (lockdown period in Boston, Massachusetts) were reviewed at baseline (up to 12 weeks before the lockdown), at first available follow-up (=actual f/u) during or after the lockdown period, at 3 months, 6 months, and at last available completed appointment of 2020. Results: A total of 1001 patients met the inclusion criteria. Of those patients, 479 (47.9%) completed their intended f/u appointment, while 522 missed it (canceled and "no show"). The delay in care of those who missed it was 59.15 days [standard deviation (SD) +/- 49.6]. In these patients, significant loss of vision was noted at actual f/u [Best corrected visual acuity (BCVA) in LogMAR (Logarithm of the Minimum Angle of Resolution)-mean (+/- SD)-completed: 0.45 (+/- 0.46), missed: 0.53 (+/- 0.55); p = 0.01], which was more prominent in the DR group [Visual acuity (VA) change in LogMAR-mean (+/- SD); completed: 0.04 (+/- 0.28), missed: 0.18 (+/- 0.44); p = 0.02] and CRVO [completed: -0.06 (+/- 0.27), missed: 0.11 (+/- 0.35); p = <0.001] groups followed by nvAMD [completed: 0.006 (+/- 0.16), missed: 0.06 (+/- 0.27); p = 0.004] and BRVO [completed: -0.02 (+/- 0.1), missed: 0.03 (+/- 0.14); p = 0.02] ones. Overall, a higher percent of people who missed their intended f/u experienced vision loss of more than 15 letters at last f/u compared to those who completed it [missed vs. completed; 13.4% vs. 7.4% in nvAMD (p = 0.72), 7.8% vs. 6.3% in DR (0.84), 15.5% vs. 9.9% in CRVO (p < 0.001) and 9.6% vs. 2% in BRVO (p = 0.48)]. Conclusions: Delay in care of about 8.45 weeks can lead to loss of vision in patients who receive IVI with DR and CRVO patients being more vulnerable in the short-term, whereas in the long-term, CRVO patients followed by the nvAMD patients demonstrating the least vision recovery. BRVO patients were less likely to be affected by the delay in care. Adherence to treatment is key for maintaining and improving visual outcomes in patients who require IVI.
C1 [Douglas, Vivian Paraskevi; Douglas, Konstantinos A. A.; Vavvas, Demetrios G.; Miller, Joan W.; Miller, John B.] Harvard Med Sch, Retina Serv, Massachusetts Eye & Ear, Dept Ophthalmol, Boston, MA 02114 USA.
C3 Harvard University; Harvard Medical School; Massachusetts Eye & Ear
   Infirmary
RP Miller, JB (通讯作者)，Harvard Med Sch, Retina Serv, Massachusetts Eye & Ear, Dept Ophthalmol, Boston, MA 02114 USA.
EM douglasvivianp@gmail.com; douglaskonstantinos@gmail.com;
   demetrios_vavvas@meei.harvard.edu; joan_miller@meei.harvard.edu;
   john_miller@meei.harvard.edu
RI Miller, John J/GZG-5663-2022
CR Angermann R, 2019, GRAEF ARCH CLIN EXP, V257, P2119, DOI 10.1007/s00417-019-04414-y
   Boulanger-Scemama E, 2015, J FR OPHTALMOL, V38, P620, DOI 10.1016/j.jfo.2014.11.015
   Boyer D, 2010, OPHTHALMOLOGY, V117, P1860, DOI 10.1016/j.ophtha.2010.02.022
   Brown DM, 2011, OPHTHALMOLOGY, V118, P1594, DOI 10.1016/j.ophtha.2011.02.022
   Cucinotta Domenico, 2020, Acta Biomed, V91, P157, DOI 10.23750/abm.v91i1.9397
   Ehlken C, 2018, CLIN OPHTHALMOL, V12, P11, DOI 10.2147/OPTH.S151611
   Falk MK, 2013, AM J OPHTHALMOL, V155, P89, DOI 10.1016/j.ajo.2012.06.031
   Gao XX, 2019, OSLI RETINA, V50, P159, DOI 10.3928/23258160-20190301-05
   Giacomelli G, 2017, OPHTHALMOLOGICA, V238, P44, DOI 10.1159/000477498
   Giancipoli E, 2018, J OPHTHALMOL, V2018, DOI 10.1155/2018/5612342
   Haller JA, 2013, OPHTHALMOLOGY, V120, pS3, DOI 10.1016/j.ophtha.2013.01.057
   Kaiser Peter K, 2009, Trans Am Ophthalmol Soc, V107, P311
   Kim LN, 2016, RETINA-J RET VIT DIS, V36, P1418, DOI 10.1097/IAE.0000000000001142
   Kodjikian L, 2013, OPHTHALMOLOGY, V120, P2300, DOI 10.1016/j.ophtha.2013.06.020
   Mehta H, 2018, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD011599.pub2
   Naravane AV, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0247161
   Obeid A, 2018, JAMA OPHTHALMOL, V136, P1251, DOI 10.1001/jamaophthalmol.2018.3578
   Oishi A, 2011, EUR J OPHTHALMOL, V21, P777, DOI 10.5301/EJO.2011.7430
   Okada M, 2021, OPHTHALMOLOGY, V128, P234, DOI 10.1016/j.ophtha.2020.07.060
   Ozturk M, 2018, CLIN EXP OPHTHALMOL, V46, P407, DOI 10.1111/ceo.13085
   Pece A, 2016, GRAEF ARCH CLIN EXP, V254, P2327, DOI 10.1007/s00417-016-3396-9
   Qian T, 2017, J CLIN PHARM THER, V42, P519, DOI 10.1111/jcpt.12551
   Quan DN, 2010, OPHTHALMOLOGY, V117, P2146, DOI 10.1016/j.ophtha.2010.08.016
   Rahimzadeh M., 2021, PHYS, V6, P1, DOI [10.38192/1.6.3.10, DOI 10.38192/1.6.3.10]
   Ramakrishnan MS, 2020, JAMA OPHTHALMOL, V138, P237, DOI 10.1001/jamaophthalmol.2019.4577
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   Shikari H., 2016, J CLIN OPHTHALMOL RE, V4, P51, DOI [10.4103/2320-3897.174429, DOI 10.4103/2320-3897.174429]
   Sobolewska B, 2021, CLIN OPHTHALMOL, V15, P4317, DOI 10.2147/OPTH.S325763
   Song WL, 2021, OPHTHALMOL RETINA, V5, P975, DOI 10.1016/j.oret.2020.12.020
   Stokes EK, 2020, MMWR-MORBID MORTAL W, V69, P759, DOI 10.15585/mmwr.mm6924e2
   Stone LG, 2021, GRAEF ARCH CLIN EXP, V259, P1773, DOI 10.1007/s00417-021-05174-4
   Tiew S, 2020, EYE, V34, P2148, DOI 10.1038/s41433-020-0783-6
   Vaz-Pereira S, 2017, EUR J OPHTHALMOL, V27, P756, DOI 10.5301/ejo.5000943
   Ziemssen F, 2017, BMC OPHTHALMOL, V17, DOI 10.1186/s12886-017-0401-y
NR 34
TC 2
Z9 2
U1 1
U2 2
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2077-0383
J9 J CLIN MED
JI J. Clin. Med.
PD APR
PY 2022
VL 11
IS 8
AR 2097
DI 10.3390/jcm11082097
PG 16
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA 0S6FJ
UT WOS:000786366900001
PM 35456189
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Ciulla, TA
   Criswell, MH
   Danis, RP
   Fronheiser, M
   Yuan, P
   Cox, TA
   Csaky, KG
   Robinson, MR
AF Ciulla, TA
   Criswell, MH
   Danis, RP
   Fronheiser, M
   Yuan, P
   Cox, TA
   Csaky, KG
   Robinson, MR
TI Choroidal neovascular membrane inhibition in a laser treated rat model
   with intraocular sustained release triamcinolone acetonide microimplants
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID ENDOTHELIAL GROWTH-FACTOR; EXUDATIVE MACULAR DEGENERATION; INTRAVITREAL
   TRIAMCINOLONE; MESSENGER-RNA; EXPRESSION; STEROIDS
AB Aim: To determine if intravitreal microimplants containing triamcinolone acetonide ( TAAC) inhibit experimental fibrovascular proliferation ( FVP) induced by laser trauma in a rat as a model of choroidal neovascular membranes (CNVMs).
   Methods: 20 anaesthetised male Brown Norway rats received a series of eight krypton red laser lesions per eye (647 nm, 0.05 s, 50 mum, 150 mW). Three types of sterilised TAAC microimplant designs were evaluated: implant A consisting of 8.62% TAAC/20% polyvinyl alcohol (PVA) matrix ( by dry weight); implant B consisting of 3.62% TAAC/20% PVA matrix; and implant C consisting of a dual 8.62% TAAC/20% PVA matrix design combined with a central core (0.5 mm) of compressed TAAC to extend the implant release time. For each animal studied, one eye received one of the three aforementioned TAAC implant designs, while the fellow eye received a control implant consisting of PVA but without TAAC. The animals were sacrificed at day 35 and ocular tissues were processed for histological analysis. Serial histological specimens were methodically assessed in a masked fashion to analyse each laser lesion for the presence or absence of FVP; maximum FVP thickness for each lesion was measured from the choriocapillaris.
   Results: All three types of TAAC implants inhibited FVP relative to controls in a statistically significant fashion. In the eyes that received implant A (n = 8), the mean thickness of the recovered lesions ( n = 36) measured 32 (SD 22) mum, compared to 52 ( 30) mum ( p < 0.005) for the recovered lesions ( n = 40) from the fellow control eyes. In the eyes that received implant B ( n = 6), the mean thickness of the recovered lesions ( n = 31) measured 28 ( 15) &mu;m, compared to 50 ( 29) &mu;m ( p < 0.001) for the lesions ( n = 19) recovered from the fellow control eyes. In the eyes that received implant C ( n = 6), the mean thickness of the recovered lesions ( n = 21) measured 39 ( 24) mum, compared to 65 ( 30) mum ( p < 0.001) for the lesions ( n = 39) recovered from the fellow control eyes.
   Conclusions: All three of the tested TAAC microimplant designs produced potent inhibition of FVP in a rat model of CNVMs. There were no differences in inhibition of FVP between the three different types of implants evaluated. This study provides evidence that: ( 1) corroborates previous investigations that propose TAAC as a potential treatment for CNVMs in humans, and ( 2) demonstrates TAAC can be effectively delivered via long acting sustained release intraocular microimplants. It should be noted, however, that the FVP observed in this rat laser trauma may not reflect the CNVM observed in human with exudative age related macular degeneration (AMD).
C1 Indiana Univ, Dept Ophthalmol, Sch Med, Retina Serv,Res Labs, Indianapolis, IN 46260 USA.
   NIH, Bioengn & Phys Sci Div, ORS, Bethesda, MD 20892 USA.
   NIH, Dept Pharm, Ctr Clin, Bethesda, MD USA.
   NEI, NIH, Bethesda, MD 20892 USA.
C3 Indiana University System; Indiana University-Purdue University
   Indianapolis; National Institutes of Health (NIH) - USA; National
   Institutes of Health (NIH) - USA; NIH Clinical Center (CC); National
   Institutes of Health (NIH) - USA; NIH National Eye Institute (NEI)
RP Ciulla, TA (通讯作者)，Indiana Univ, Dept Ophthalmol, Sch Med, Retina Serv,Res Labs, 702 Rotary Circle, Indianapolis, IN 46260 USA.
RI Ciulla, Thomas/AAA-1299-2020
OI Ciulla, Thomas/0000-0001-5557-6777
CR AMIN R, 1994, INVEST OPHTH VIS SCI, V35, P3178
   Baker R., 1987, CONTROLLED RELEASE B
   Challa JK, 1998, AUST NZ J OPHTHALMOL, V26, P277, DOI 10.1111/j.1442-9071.1998.tb01330.x
   Ciulla TA, 2001, ARCH OPHTHALMOL-CHIC, V119, P399, DOI 10.1001/archopht.119.3.399
   Danis RP, 1996, OPHTHALMOLOGY, V103, P2099, DOI 10.1016/S0161-6420(96)30383-7
   Danis RP, 2000, RETINA-J RET VIT DIS, V20, P244, DOI 10.1097/00006982-200003000-00004
   DOBI ET, 1989, ARCH OPHTHALMOL-CHIC, V107, P264, DOI 10.1001/archopht.1989.01070010270035
   Edelman JL, 2000, EXP EYE RES, V71, P523, DOI 10.1006/exer.2000.0907
   FOLKMAN J, 1987, ANN SURG, V206, P374, DOI 10.1097/00000658-198709000-00016
   Frank RN, 1997, OPHTHALMIC RES, V29, P341, DOI 10.1159/000268032
   GILETBAZELI E, 1996, INVEST OPHTHALMOL  S, V37, P405
   HUGHES A, 1979, VISION RES, V19, P569, DOI 10.1016/0042-6989(79)90143-3
   ISHIBASHI T, 1985, ARCH OPHTHALMOL-CHIC, V103, P708
   KLIFFEN M, 1996, INVEST OPHTHALMOL  S, V37, P203
   KVANTA A, 1995, CURR EYE RES, V14, P1015, DOI 10.3109/02713689508998523
   Lopez PF, 1996, INVEST OPHTH VIS SCI, V37, P855
   Martidis A, 1999, J OCUL PHARMACOL TH, V15, P425, DOI 10.1089/jop.1999.15.425
   Ogata N, 1997, CURR EYE RES, V16, P9, DOI 10.1076/ceyr.16.1.9.5121
   Ogata N, 1996, CURR EYE RES, V15, P1008, DOI 10.3109/02713689609017649
   OGATA N, 1996, INVEST OPHTHALMOL  S, V37, P124
   Penfold PL, 1995, AUST NZ J OPHTHALMOL, V23, P293, DOI 10.1111/j.1442-9071.1995.tb00179.x
   Penn JS, 2001, INVEST OPHTH VIS SCI, V42, P283
   REDDY VM, 1995, AM J OPHTHALMOL, V120, P291, DOI 10.1016/S0002-9394(14)72158-0
   SCHLAEGEL TF, 1977, OCULAR HISTOPLASMOSI
   Shen WY, 1998, BRIT J OPHTHALMOL, V82, P1063, DOI 10.1136/bjo.82.9.1063
   TOBE T, 1994, J JPN OPHTHALMOL SOC, V98, P837
   Tobe Takao, 1995, Nippon Ganka Gakkai Zasshi, V99, P784
   Wada M, 1999, CURR EYE RES, V18, P203, DOI 10.1076/ceyr.18.3.203.5368
   WELLING PG, 1986, ACS MONOGR SER, V185, P145
   Yi XJ, 1997, GRAEF ARCH CLIN EXP, V235, P313, DOI 10.1007/BF01739641
   ZHANG NL, 1993, INVEST OPHTH VIS SCI, V34, P2412
NR 31
TC 63
Z9 72
U1 0
U2 2
PU BRITISH MED JOURNAL PUBL GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD AUG
PY 2003
VL 87
IS 8
BP 1032
EP 1037
DI 10.1136/bjo.87.8.1032
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 704NU
UT WOS:000184346400026
PM 12881350
OA Green Published, Bronze, Green Submitted
DA 2022-11-30
ER

PT J
AU Bikbov, MM
   Gilmanshin, TR
   Zainullin, RM
   Kazakbaeva, GM
   Iakupova, EM
   Fakhretdinova, AA
   Tuliakova, AM
   Panda-Jonas, S
   Arslangareeva, II
   Zinnatullin, AA
   Gilemzianova, LI
   Khakimov, DA
   Jonas, JB
AF Bikbov, Mukharram M.
   Gilmanshin, Timur R.
   Zainullin, Rinat M.
   Kazakbaeva, Gyulli M.
   Iakupova, Ellina M.
   Fakhretdinova, Albina A.
   Tuliakova, Azaliia M.
   Panda-Jonas, Songhomitra
   Arslangareeva, Inga I.
   Zinnatullin, Ainur A.
   Gilemzianova, Leisan, I
   Khakimov, Dinar A.
   Jonas, Jost B.
TI Macular pigment optical density and its determinants in a Russian
   population: the ural eye and medical study
SO ACTA OPHTHALMOLOGICA
LA English
DT Article
DE macula; macular pigment; Ufa eye and medical study; zeaxanthin;
   meso-zeaxanthin
ID SERUM CONCENTRATIONS; LUTEIN; DEGENERATION; ZEAXANTHIN; CLASSIFICATION
AB Purpose To assess the macular pigment optical density (MPOD) and its associations with ocular and systemic parameters and diseases. Methods The population-based study Ural Eye and Medical Study included 5899 (80.5%) out of 7328 eligible individuals. As part of ophthalmological and systemic examinations, MPOD was measured by reflectometry. Results Macular pigment optical density (MPOD) data were available for 4889 (82.9%) individuals (mean age:57.8 +/- 10.1 years;range: 40-94). Mean values for MOPD, maximal MOPD, macular pigment (MP) area and MP volume were 0.13 +/- 0.04 d.u. (density units), 0.36 +/- 0.09 d.u., 60 791 +/- 14 826 pixel and 8033 +/- 2888 d.u.pixel, respectively. A higher MP density was correlated (regression coefficient r: 0.63) with older age (standardized regression coefficient beta: 0.59; non-standardized regression coefficient B: 0.23; 95% confidence interval (CI): 0.22, 0.23; p < 0.001), female sex (beta: 0.08; B:0.63; 95%CI: 0.44, 0.83; p < 0.001), rural region of habitation (beta: 0.13; B: 1.02; 95%CI: 0.83, 1.22; p < 0.001), lower body mass index (beta: -0.04; B: -0.03; 95%CI: -0.05, 0.01; p = 0.004), lower prevalence of chronic obstructive pulmonary disorder (beta: -0.03; B: -0.43; 95%CI: -0.79, -0.08; p = 0.02), higher erythrocyte sedimentation rate (beta: 0.03; B: 0.01; 95%CI: 0.002, 0.02; p = 0.03), lower leukocyte cell count (beta: -0.04; B: -0.10; 95%CI: -0.16, -0.03; p = 0.003), thinner temporal parafoveal retinal thickness (beta: -0.06; B: -0.01;95%CI: -0.01, -0.003; p < 0.001), thinner central corneal thickness (beta: -0.06; B: -0.006; 95%CI: -0.009, -0.004; p < 0.001), higher prevalence of pseudophakia (beta: 0.09;B:2.08; 95%CI: 1.50, 2.65; p < 0.001) and reticular pseudo drusen (RPD) (beta: 0.03; B: 0.56; 95%CI: 0.13, 0.98; p = 0.01) and lower stage of open-angle glaucoma (beta: -0.03; B: -0.39; 95%CI: -0.74, -0.04; p = 0. 03). Prevalence (p = 0.44; beta: -0.01) and degree (p = 0.70; beta: -0.01) of angle-closure glaucoma, prevalence (p = 0.31; beta: 0.01) of age-related macular degeneration (AMD) without RPD and prevalence (p = 0.95; beta: 0.001) of diabetic retinopathy were not significantly associated with the mean MP density in that model. Conclusions A higher RPD prevalence and lower stage of open-angle glaucoma were ophthalmological disorders associated with a higher MPOD in a multivariable analysis, including parameters of older age, pseudophakia, female sex, rural region, lower body mass index and lower perifoveal retinal thickness.
C1 [Bikbov, Mukharram M.; Gilmanshin, Timur R.; Zainullin, Rinat M.; Kazakbaeva, Gyulli M.; Iakupova, Ellina M.; Fakhretdinova, Albina A.; Tuliakova, Azaliia M.; Arslangareeva, Inga I.; Zinnatullin, Ainur A.; Gilemzianova, Leisan, I; Khakimov, Dinar A.] Ufa Eye Res Inst, 90 Pushkin St, Ufa 450077, Russia.
   [Kazakbaeva, Gyulli M.] Ufa Eye Inst, Ufa, Russia.
   [Panda-Jonas, Songhomitra; Jonas, Jost B.] Privatpraxis Prof Jonas & Dr Panda Jonas, Heidelberg, Germany.
   [Panda-Jonas, Songhomitra; Jonas, Jost B.] Heidelberg Univ, Med Fac Mannheim, Dept Ophthalmol, Mannheim, Germany.
   [Panda-Jonas, Songhomitra; Jonas, Jost B.] Inst Mol & Clin Ophthalmol Basel, Basel, Switzerland.
C3 Ufa Eye Research Institute; Ruprecht Karls University Heidelberg
RP Bikbov, MM (通讯作者)，Ufa Eye Res Inst, 90 Pushkin St, Ufa 450077, Russia.; Jonas, JB (通讯作者)，Med Fac Mannheim, Dept Ophthalmol, D-168167 Mannheim, Germany.
EM bikbov.m@gmail.com; jost.jonas@medma.uni-heidelberg.de
CR Akuffo KO, 2017, INVEST OPHTH VIS SCI, V58, P5347, DOI 10.1167/iovs.16-21192
   Alassane S, 2016, INVEST OPHTH VIS SCI, V57, P1160, DOI 10.1167/iovs.15-18007
   Berendschot TT, 2005, EXP EYE RES, V81, P602, DOI 10.1016/j.exer.2005.03.019
   Berendschot TTJM, 2002, INVEST OPHTH VIS SCI, V43, P1928
   Bikbov MM, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.0567
   Bikbov MM, 2019, AM J OPHTHALMOL, V204, P130, DOI 10.1016/j.ajo.2019.02.030
   Bone RA, 1997, EXP EYE RES, V64, P211, DOI 10.1006/exer.1996.0210
   Broekmans WMR, 2002, AM J CLIN NUTR, V76, P595, DOI 10.1093/ajcn/76.3.595
   Chew EY, 2014, JAMA OPHTHALMOL, V132, P142, DOI 10.1001/jamaophthalmol.2013.7376
   Chew EY, 2013, JAMA-J AM MED ASSOC, V309, P2005, DOI 10.1001/jama.2013.4997
   Creuzot-Garcher C, 2014, INVEST OPHTH VIS SCI, V55, P2941, DOI 10.1167/iovs.13-13568
   Davey PG, 2020, THER ADV OPHTHALMOL, V12, DOI 10.1177/2515841420924167
   Dietzel M, 2011, INVEST OPHTH VIS SCI, V52, P3452, DOI 10.1167/iovs.10-6713
   El-Agamey A, 2004, ARCH BIOCHEM BIOPHYS, V430, P37, DOI 10.1016/j.abb.2004.03.007
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Foster PJ, 2002, BRIT J OPHTHALMOL, V86, P238, DOI 10.1136/bjo.86.2.238
   Green-Gomez M, 2021, INVEST OPHTH VIS SCI, V62, DOI 10.1167/iovs.62.9.18
   Ji YY, 2015, ACTA OPHTHALMOL, V93, pE550, DOI 10.1111/aos.12645
   Kamoshita M, 2016, SCI REP-UK, V6, DOI 10.1038/srep30226
   Kaya S, 2012, ACTA OPHTHALMOL, V90, pe399, DOI 10.1111/j.1755-3768.2012.02423.x
   Kim SR, 2006, EXP EYE RES, V82, P828, DOI 10.1016/j.exer.2005.10.004
   Ma L, 2016, NUTRIENTS, V8, DOI 10.3390/nu8070426
   Merle BMJ, 2017, ACTA OPHTHALMOL, V95, pe763, DOI 10.1111/aos.13408
   Nolan JM, 2016, INVEST OPHTH VIS SCI, V57, P3429, DOI 10.1167/iovs.16-19520
   Puell MC, 2013, ACTA OPHTHALMOL, V91, pE298, DOI 10.1111/aos.12067
   Remington LA., 2012, CLIN ANATOMY PHYSL V, P61, DOI DOI 10.1016/B978-1-4377-1926-0.10004-9
   Sasaki M, 2009, INVEST OPHTH VIS SCI, V50, P1433, DOI 10.1167/iovs.08-2493
   Sasamoto Y, 2011, INVEST OPHTH VIS SCI, V52, P927, DOI 10.1167/iovs.10-5664
   Schweitzer D, 2010, J BIOMED OPT, V15, DOI 10.1117/1.3526358
   Siah WF, 2015, OPHTHALMOLOGY, V122, P2029, DOI 10.1016/j.ophtha.2015.06.028
   SNODDERLY DM, 1984, INVEST OPHTH VIS SCI, V25, P660
   Srinivasan R, 2020, TRANSL VIS SCI TECHN, V9, DOI 10.1167/tvst.9.8.40
   Stevens GA, 2016, PLOS MED, V13, DOI [10.1371/journal.pmed.1002056, 10.1371/journal.pmed.1002116]
   Stringham JM, 2015, INVEST OPHTH VIS SCI, V56, P2459, DOI 10.1167/iovs.14-15716
   Sujak A, 1999, ARCH BIOCHEM BIOPHYS, V371, P301, DOI 10.1006/abbi.1999.1437
   Trieschmann M, 2007, EXP EYE RES, V84, P718, DOI 10.1016/j.exer.2006.12.010
   Yoshizako H, 2016, ACTA OPHTHALMOL, V94, pE411, DOI 10.1111/aos.13106
   Yu J, 2012, INVEST OPHTH VIS SCI, V53, P2106, DOI 10.1167/iovs.11-8518
NR 38
TC 0
Z9 0
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1755-375X
EI 1755-3768
J9 ACTA OPHTHALMOL
JI Acta Ophthalmol.
PD DEC
PY 2022
VL 100
IS 8
BP E1691
EP E1700
DI 10.1111/aos.15131
EA MAR 2022
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 6D4SX
UT WOS:000773539200001
PM 35343640
DA 2022-11-30
ER

PT J
AU Lin, XY
   Wang, QL
   He, MG
AF Lin, Xingyan
   Wang, Qilin
   He, Mingguang
TI Repeated retinal photocoagulation in monkeys for the optimization of a
   laser-induced choroidal neovascularization model
SO EXPERIMENTAL EYE RESEARCH
LA English
DT Article
DE Laser; Choroidal neovascularization; Monkey
ID PENETRATING EYE INJURY; VEGF; BEVACIZUMAB; RANIBIZUMAB; INJECTION;
   EFFICACY
AB The laser-induced choroidal neovascularization (CNV) model in nonhuman primates has played a critical role in the development of new therapies for neovascular age-related macular degeneration. The widespread use of this model, however, has been limited by its high costs, mainly due to the lower efficiency of animal use. We optimized the CNV model by administering repeated photocoagulation treatments to the same eye of each animal, and preliminarily evaluated this model using an assessment of the efficacy of an anti-vascular endothelial growth factor (VEGF) agent to address this problem. Seven rhesus monkeys were included and divided into two groups, which were named the laser-only and laser-bevacizumab groups. Each animal underwent 3 retinal photocoagulation sessions in the same eye at 4-week intervals to induce CNV. Three weeks after the first laser treatment, the animals in the laser-bevacizumab group were administered an intravitreal injection of bevacizumab. Fluorescein angiography (FA) was performed in all animals at multiple time points within 12 weeks to assess the severity and development of CNV following each laser treatment. The laser lesions produced in each photocoagulation session were analysed separately using grading and densitometry methods, and CNV severity was represented by the CNV incidence and the mean integrated fluorescence intensity (MIFI), respectively. Our results showed that in the animals in the laser-only group, the average CNV incidence rates were 62.5%, 42% and 50% at 2 weeks after each laser treatment, and the average MIFI values (x10(5)) were 3.83 +/- 2.36, 2.66 +/- 1.42 and 2.52 +/- 0.18, respectively. No significant differences were found among treatments. After week 2, the CNVs progressed or regressed continuously over 2-6 weeks before stabilization, and the time course of CNV development in each animal was generally the same after each photocoagulation session. In the laser-bevacizumab group, however, the average CNV incidence rates of each laser treatment at week 2 were 50%, 0 and 37.5%, respectively, and the average MIFI values were 3.79 +/- 0.47, 1.09 +/- 0.35 and 2.37 +/- 1.35, respectively. The differences between treatments 1 and 2 were statistically significant. Meanwhile, the CNV5 induced by laser treatment 1, which progressed during weeks 2-3, were reduced after bevacizumab administration. The average CNV incidence decreased from 50% at week 3 to 4.2% at week 4, and the average MIFI decreased from 4.62 +/- 1.15 to 1.76 +/- 0.81, both of which were statistically significant. On the other hand, the CNV5 induced by treatments 2 and 3 did not show any significant changes over time. Our study demonstrated that repeated retinal photocoagulation in the monkey eye produces relatively consistent CNV5, which can be used to assess the efficacies of anti-angiogenic agents more efficiently.
C1 [Lin, Xingyan; Wang, Qilin; He, Mingguang] Sun Yat Sen Univ, Zhongshan Ophthalm Ctr, State Key Lab Ophthalmol, Guangzhou, Guangdong, Peoples R China.
C3 Sun Yat Sen University
RP He, MG (通讯作者)，Sun Yat Sen Univ, Zhongshan Ophthalm Ctr, State Key Lab Ophthalmol, Guangzhou, Guangdong, Peoples R China.
EM mingguang.he@unimelb.edu.cn
RI He, Mingguang/AAY-5239-2020
OI He, Mingguang/0000-0002-6912-2810; Wang, Qilin/0000-0001-6967-6197
FU National Natural Science Foundation of China [81420108008]
FX This work was supported by the National Natural Science Foundation of
   China (grant number: 81420108008).
CR Adamson P, 2016, J CONTROL RELEASE, V244, P1, DOI 10.1016/j.jconrel.2016.10.026
   Avery RL, 2006, OPHTHALMOLOGY, V113, P363, DOI 10.1016/j.ophtha.2005.11.019
   CLEARY PE, 1979, AM J OPHTHALMOL, V88, P221, DOI 10.1016/0002-9394(79)90469-0
   CLEARY PE, 1979, AM J OPHTHALMOL, V88, P212, DOI 10.1016/0002-9394(79)90468-9
   Falavarjani KG, 2013, EYE, V27, P787, DOI 10.1038/eye.2013.107
   Goody RJ, 2011, EXP EYE RES, V92, P464, DOI 10.1016/j.exer.2011.03.006
   Ji WW, 2017, EUR J PHARM SCI, V109, P624, DOI 10.1016/j.ejps.2017.09.021
   Jia YL, 2014, OPHTHALMOLOGY, V121, P1435, DOI 10.1016/j.ophtha.2014.01.034
   Kovach JL, 2012, J OPHTHALMOL, V2012, DOI 10.1155/2012/786870
   Krzystolik MG, 2002, ARCH OPHTHALMOL-CHIC, V120, P338
   Lichtlen P, 2010, INVEST OPHTH VIS SCI, V51, P4738, DOI 10.1167/iovs.09-4890
   Liew G, 2007, NEW ENGL J MED, V356, P747
   Lukason M, 2011, MOL THER, V19, P260, DOI 10.1038/mt.2010.230
   Pan CK, 2011, J OCUL PHARMACOL TH, V27, P219, DOI 10.1089/jop.2010.0158
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Schmidt-Erfurth U, 2014, BRIT J OPHTHALMOL, V98, P1144, DOI 10.1136/bjophthalmol-2014-305702
NR 16
TC 4
Z9 4
U1 0
U2 5
PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 0014-4835
EI 1096-0007
J9 EXP EYE RES
JI Exp. Eye Res.
PD JUL
PY 2019
VL 184
BP 1
EP 7
DI 10.1016/j.exer.2019.03.020
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA IF3ND
UT WOS:000472986600001
PM 30928489
DA 2022-11-30
ER

PT J
AU Ko, F
   Foster, PJ
   Strouthidis, NG
   Shweikh, Y
   Yang, Q
   Reisman, CA
   Muthy, ZA
   Chakravarthy, U
   Lotery, AJ
   Keane, PA
   Tufail, A
   Grossi, CM
   Patel, PJ
AF Ko, Fang
   Foster, Paul J.
   Strouthidis, Nicholas G.
   Shweikh, Yusrah
   Yang, Qi
   Reisman, Charles A.
   Muthy, Zaynah A.
   Chakravarthy, Usha
   Lotery, Andrew J.
   Keane, Pearse A.
   Tufail, Adnan
   Grossi, Carlota M.
   Patel, Praveen J.
CA Uk Biobank Eye Vision Consortium
TI Associations with Retinal Pigment Epithelium Thickness Measures in a
   Large Cohort Results from the UK Biobank
SO OPHTHALMOLOGY
LA English
DT Article
ID OPTICAL COHERENCE TOMOGRAPHY; AGE-SPECIFIC PREVALENCE; MACULAR
   DEGENERATION; VISUAL IMPAIRMENT; GLOBAL PREVALENCE; OXIDATIVE STRESS;
   LAYER THICKNESS; BRUCHS MEMBRANE; POPULATION; BLINDNESS
AB Purpose: To describe associations of ocular and systemic factors with retinal pigment epithelium (RPE)- Bruch's membrane (BM) complex thickness as measured by spectral-domain (SD) optical coherence tomography (OCT).
   Design: Multisite community-based study. This research has been conducted using the UK Biobank Resource.
   Participants: Sixty-seven thousand three hundred eighteen people 40 to 69 years old received questionnaires, physical examination, and eye examination, including macular SD OCT. Systematic selection process identified 34 652 eyes with high-quality SD OCT images from normal individuals for analysis.
   Methods: We included people with no self-reported ocular disease, diabetes, or neurologic disorders; visual acuity of >= 20/25; refraction between -6 diopters (D) to 6 D, and IOP of 6 to 21 mmHg. Only high-quality, well-centered SD OCT images with central, stable fixation were included. Descriptive statistics, t tests, and regression analyses were performed. Multivariate regression modeling was used to adjust for covariates and to identify relationships between RPE-BM thickness and ocular and systemic features.
   Main Outcome Measures: Retinal pigment epithelium-BM thickness, as measured by SD OCT segmentation using Topcon Advanced Boundary Segmentation at 9 Early Treatment of Diabetic Retinopathy Study subfields.
   Results: Mean RPE-BM thickness was 26.3 mu m (standard deviation, 4.8 mu m) at central subfield. Multivariate regression with age stratification showed that RPE thinning became apparent after age 45. Among those aged <= 45, RPE-BM was significantly thicker among those of black or mixed/other race (+3.61 and +1.77 mm vs. white, respectively; P < 0.001) and higher hyperopia (+0.4 mm/D; P < 0.001), but not for other variables considered. Among those age > 45, RPE-BM was significantly thinner with older age (-0.10 mu m/year; P < 0.001), Asian ethnicity (-0.45 mu m vs. white; P = 0.02), taller height (-0.02 mm/cm; P < 0.001), higher IOP (-0.03 mu m/mmHg; P < 0.001), and regular smoking (-0.27 mu m vs. nonsmokers; P = 0.02). In contrast, RPE-BM was significantly thicker among black or mixed/other race (+3.29 mu m and +0.81 mu m vs. white, respectively; P < 0.001) and higher hyperopia (+0.28 mu m/D; P < 0.001). There was no significant association with sex or Chinese ethnicity.
   Conclusions: We describe novel findings of RPEeBM thickness in normal individuals, a structure that varies with age, ethnicity, refraction, IOP, and smoking. The significant association with IOP is especially interesting and may have relevance for the etiology of glaucoma, while the association between age and smoking may have relevance for the etiology of age-related macular degeneration. (C) 2016 by the American Academy of Ophthalmology
C1 [Ko, Fang; Foster, Paul J.; Strouthidis, Nicholas G.; Shweikh, Yusrah; Muthy, Zaynah A.; Keane, Pearse A.; Tufail, Adnan; Grossi, Carlota M.; Patel, Praveen J.] Moorfields Eye Hosp NHS Fdn Trust, NIHR Biomed Res Ctr, London, England.
   [Ko, Fang; Foster, Paul J.; Strouthidis, Nicholas G.; Shweikh, Yusrah; Muthy, Zaynah A.; Keane, Pearse A.; Tufail, Adnan; Grossi, Carlota M.; Patel, Praveen J.] UCL, UCL Inst Ophthalmol, London, England.
   [Yang, Qi; Reisman, Charles A.] Topcon Adv Biomed Imaging Lab, Oakland, NJ USA.
   [Chakravarthy, Usha] Queens Univ Belfast, Optometry & Vis Sci, Belfast, Antrim, North Ireland.
   [Lotery, Andrew J.] Southampton Gen Hosp, Dept Ophthalmol, Southampton, Hants, England.
C3 University of London; University College London; Moorfields Eye Hospital
   NHS Foundation Trust; University of London; University College London;
   Queens University Belfast; University of Southampton
RP Patel, PJ (通讯作者)，Moorfields Eye Hosp NHS Fdn Trust, 162 City Rd, London EC1V 2PD, England.
EM praveen.patel@moorfields.nhs.uk
RI Keane, Pearse/AAE-5709-2019; Foster, Paul/V-7288-2019
OI Keane, Pearse/0000-0002-9239-745X; Foster, Paul/0000-0002-4755-177X;
   Chakravarthy, Usha/0000-0002-2606-3734; Grossi,
   carlota/0000-0003-3722-5425; Tufail, Adnan/0000-0001-6131-7640; Khaw,
   Sir Peng Tee/0000-0002-8087-2268
FU Alcon (Fort Worth, TX); Allergan (Marlow, Buckinghamshire, UK); Roche;
   Allergan; Bayer UK (Newbury, Berkshire, UK); Medical Research Council
   [MC_qA137853] Funding Source: researchfish; National Institute for
   Health Research [NF-SI-0512-10101, CL-2010-18-004, CS-2014-14-023]
   Funding Source: researchfish
FX P.J.F.: Consultant - Zeiss (Oberkochen, Germany) Financial support -
   Alcon (Fort Worth, TX); Allergan (Marlow, Buckinghamshire, UK); Lecturer
   - Allergan; Board membership - Allergan; Expert testimony - Alcon,
   Allergan, Zeiss.; N.G.S.: Lecturer - Allergan; Alcon; Novartis
   (Camberley, Surrey, UK); Heidelberg Engineering (Hemel Hempstead,
   Hertfordshire, UK); Financial support - Allergan; U.C.: Consultant -
   Novartis; Bayer; Allergan; Roche (Basel, Switzerland); Financial support
   (to institution) - Roche; P.A.K.: Lecturer - Allergan; Novartis; Bayer
   (Leverkusen, Germany); Topcon; Heidelberg; Financial support - Allergan;
   P.J.P.: Consultant - Thrombogenics (to institution) (Leuven, Belgium);
   Bayer; Novartis; Merck (Kenilworth, NJ); Financial support - Bayer UK
   (Newbury, Berkshire, UK); Bayer; Salutaris MD (Tuscan, AZ); Lecturer -
   Bayer; Heidelberg Engineering; Topcon; Allergan; Alcon
CR Ach T, 2015, INVEST OPHTH VIS SCI, V55, P4832
   Cense B, 2004, OPT EXPRESS, V12, P2435, DOI 10.1364/OPEX.12.002435
   Curcio CA, 2011, INVEST OPHTH VIS SCI, V52, P3943, DOI 10.1167/iovs.10-6377
   Demirkaya N, 2013, INVEST OPHTH VIS SCI, V54, P4934, DOI 10.1167/iovs.13-11913
   Farsiu S, 2014, OPHTHALMOLOGY, V121, P162, DOI 10.1016/j.ophtha.2013.07.013
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Grossniklaus H, 2013, INVEST OPHTH VIS SCI, V54
   HUANG D, 1991, SCIENCE, V254, P1178, DOI 10.1126/science.1957169
   Jonas JB, 2014, LANCET GLOB HEALTH, V2, pE65, DOI 10.1016/S2214-109X(13)70163-3
   Karampelas M, 2013, BRIT J OPHTHALMOL, V97, P1256, DOI 10.1136/bjophthalmol-2013-303219
   Klaver CCW, 1998, ARCH OPHTHALMOL-CHIC, V116, P653, DOI 10.1001/archopht.116.5.653
   Kunchithapautham K, 2014, J BIOL CHEM, V289, P14534, DOI 10.1074/jbc.M114.564674
   Li YG, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0111707
   Liang FQ, 2003, EXP EYE RES, V76, P397, DOI 10.1016/S0014-4835(03)00023-X
   Munoz B, 2000, ARCH OPHTHALMOL-CHIC, V118, P819, DOI 10.1001/archopht.118.6.819
   Nassif NA, 2004, OPT EXPRESS, V12, P367, DOI 10.1364/OPEX.12.000367
   Patel PJ, 2016, OPHTHALMOLOGY, V123, P829, DOI 10.1016/j.ophtha.2015.11.009
   RAMRATTAN RS, 1994, INVEST OPHTH VIS SCI, V35, P2857
   Schuman JS, 1996, OPHTHALMOLOGY, V103, P1889, DOI 10.1016/S0161-6420(96)30410-7
   Staurenghi G, 2014, OPHTHALMOLOGY, V121, P1572, DOI 10.1016/j.ophtha.2014.02.023
   Strauss O, 2005, PHYSIOL REV, V85, P845, DOI 10.1152/physrev.00021.2004
   Wang JJ, 2000, CLIN EXP OPHTHALMOL, V28, P268, DOI 10.1046/j.1442-9071.2000.00315.x
   WING GL, 1978, INVEST OPHTH VIS SCI, V17, P601
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Woodell A, 2014, ADV EXP MED BIOL, V801, P301, DOI 10.1007/978-1-4614-3209-8_38
   Yang Q, 2010, OPT EXPRESS, V18, P21293, DOI 10.1364/OE.18.021293
NR 26
TC 30
Z9 30
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD JAN
PY 2017
VL 124
IS 1
BP 105
EP 117
DI 10.1016/j.ophtha.2016.07.033
PG 13
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA EK4KZ
UT WOS:000393896900029
PM 27720551
OA Bronze
DA 2022-11-30
ER

PT J
AU Chou, R
   Dana, T
   Bougatsos, C
   Grusing, S
   Blazina, I
AF Chou, Roger
   Dana, Tracy
   Bougatsos, Christina
   Grusing, Sara
   Blazina, Ian
TI Screening for Impaired Visual Acuity in Older Adults Updated Evidence
   Report and Systematic Review for the US Preventive Services Task Force
SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
LA English
DT Review
ID QUALITY-OF-LIFE; MACULAR DEGENERATION; CATARACT-SURGERY; REFRACTIVE
   ERROR; MICROBIAL KERATITIS; BETA-CAROTENE; RISK-FACTORS; VISION; AGE;
   FALLS
AB IMPORTANCE Impaired visual acuity is common among older adults and can adversely affect function and quality of life.
   OBJECTIVE To update a 2009 systematic review on screening for impaired visual acuity among older adults for the US Preventive Services Task Force (USPSTF).
   DATA SOURCES Ovid MEDLINE (2008 to January 2016), Cochrane Central Register of Controlled Trials, and Cochrane Database of Systematic Reviews.
   STUDY SELECTION Randomized clinical trials of screening; diagnostic accuracy studies of screening tests in primary care settings; and randomized clinical trials of treatment vs placebo or no treatment for uncorrected refractive errors, cataracts, and dry (atrophic) or wet (exudative) age-related macular degeneration (AMD). Studies of screening and diagnostic accuracy were limited to asymptomatic adults 65 years or older; studies of treatment included asymptomatic adults of any age.
   DATA EXTRACTION AND SYNTHESIS One investigator abstracted data, a second checked data for accuracy, and 2 investigators independently assessed study quality using predefined criteria. Random-effects meta-analysis was used to estimate the relative and absolute benefits of vascular endothelial growth factor inhibitors (anti-VEGF) for wet AMD.
   MAIN OUTCOMES AND MEASURES Visual acuity, vision-related function, functional capacity, harms, and diagnostic accuracy.
   RESULTS Three trials (n = 4728) from the 2009 USPSTF review found that screening for impaired visual acuity was not associated with improved visual or clinical outcomes. In 1 good-quality trial (n = 3346), universal screening identified 27% of persons with impaired visual acuity and correctable impairment vs 3.1% with targeted screening, but there was no difference in the likelihood of visual acuity worse than 20/60 after 3 to 5 years (37% vs 35%; relative risk [RR], 1.07; 95% CI, 0.84-1.36). The 2009 review found that effective treatments are available for uncorrected refractive errors and cataracts. Ten-year trial results of dry AMD found an antioxidant/zinc combination was associated with decreased risk of visual acuity loss (46% vs 54%; odds ratio, 0.71; 95% CI, 0.57-0.88). An updated meta-analysis found anti-VEGF for wet AMD was associated with greater likelihood of having vision 20/200 or better vs sham injection (4 trials; RR, 1.47; 95% CI, 1.30-1.66; 12 = 42%; absolute risk difference, 24%; 95%O. 12%-37% after 1 year). New evidence on the diagnostic accuracy of visual acuity screening tests was limited and consistent with previous findings that screening questions or a visual acuity test was associated with suboptimal accuracy.
   CONCLUSIONS AND RELEVANCE Screening can identify persons with impaired visual acuity, and effective treatments are available for common causes of impaired visual acuity, such as uncorrected refractive error, cataracts, and dry or wet AMD. However, direct evidence found no significant difference between vision screening in older adults in primary care settings vs no screening for improving visual acuity or other clinical outcomes.
C1 [Chou, Roger] Oregon Hlth & Sci Univ, Dept Med, Pacific Northwest Evidence Based Practice Ctr, Portland, OR 97201 USA.
   [Chou, Roger] Oregon Hlth & Sci Univ, Dept Med Informat & Clin Epidemiol, Portland, OR 97201 USA.
   [Dana, Tracy; Bougatsos, Christina; Grusing, Sara; Blazina, Ian] Oregon Hlth & Sci Univ, Pacific Northwest Evidence Based Practice Ctr, Portland, OR 97201 USA.
C3 Oregon Health & Science University; Oregon Health & Science University;
   Oregon Health & Science University
RP Chou, R (通讯作者)，Mail Code BICC, 3181 SW Sam Jackson Pk Rd, Portland, OR 97239 USA.
EM chour@ohsu.edu
OI Chou, Roger/0000-0001-9889-8610; Blazina, Ian/0000-0003-0164-6674
FU Agency for Healthcare Research and Quality (AHRQ)
FX This research was funded by the Agency for Healthcare Research and
   Quality (AHRQ) under a contract to support the USPSTF.
CR [Anonymous], SUMM HLTH STAT US AD
   Ariyasu RG, 1996, OPHTHALMOLOGY, V103, P1751, DOI 10.1016/S0161-6420(96)30431-4
   Bressler NM, 2013, OPHTHALMOLOGY, V120, P160, DOI 10.1016/j.ophtha.2012.07.027
   Calonge N, 2009, ANN INTERN MED, V151, P37, DOI 10.7326/0003-4819-151-1-200907070-00007
   Chang TS, 2007, ARCH OPHTHALMOL-CHIC, V125, P1460, DOI 10.1001/archopht.125.11.1460
   Cheng KH, 1999, LANCET, V354, P181, DOI 10.1016/S0140-6736(98)09385-4
   Chew EY, 2013, OPHTHALMOLOGY, V120, P1604, DOI 10.1016/j.ophtha.2013.01.021
   Chou R, 2009, ANN INTERN MED, V1511, pW11
   Chou R, 2016, AHRQ PUBLICATION
   Chou R., 2009, AHRQ PUBLICATION
   Chou R, 2009, ANN INTERN MED, V151, P44, DOI 10.7326/0003-4819-151-1-200907070-00008
   Coleman AL, 2006, J AM GERIATR SOC, V54, P883, DOI 10.1111/j.1532-5415.2006.00817.x
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Cumming RG, 2007, J AM GERIATR SOC, V55, P175, DOI 10.1111/j.1532-5415.2007.01046.x
   Eekhof JAH, 2000, SCAND J PRIM HEALTH, V18, P203
   Eekhof JAH, 2000, FAM PRACT, V17, P329, DOI 10.1093/fampra/17.4.329
   Elliott AF, 2009, J AM GERIATR SOC, V57, P202, DOI 10.1111/j.1532-5415.2008.02099.x
   Evans JR, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000253.pub2
   Evans JR, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000254.pub3
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Guymer RH, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0083759
   Hall TA, 2005, J AM GERIATR SOC, V53, P2140, DOI 10.1111/j.1532-5415.2005.00499.x
   Harwood RH, 2005, BRIT J OPHTHALMOL, V89, P53, DOI 10.1136/bjo.2004.049478
   HEINONEN OP, 1994, NEW ENGL J MED, V330, P1029
   HILLER R, 1983, AM J PUBLIC HEALTH, V73, P93, DOI 10.2105/AJPH.73.1.93
   Ivers RQ, 1998, J AM GERIATR SOC, V46, P58
   Ivers RQ, 2001, OPHTHALMOLOGY, V108, P968, DOI 10.1016/S0161-6420(00)00649-7
   Jessa Z, 2012, OPHTHAL PHYSL OPT, V32, P332, DOI 10.1111/j.1475-1313.2012.00919.x
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Lonn E, 2005, JAMA-J AM MED ASSOC, V293, P1338, DOI 10.1001/jama.293.11.1338
   Lord SR, 2002, J AM GERIATR SOC, V50, P1760, DOI 10.1046/j.1532-5415.2002.50502.x
   Lord SR, 2001, J AM GERIATR SOC, V49, P508, DOI 10.1046/j.1532-5415.2001.49107.x
   Ma L, 2012, OPHTHALMOLOGY, V119, P2290, DOI 10.1016/j.ophtha.2012.06.014
   McDonnell PJ, 2003, OPHTHALMOLOGY, V110, P2302, DOI 10.1016/j.ophtha.2003.02.004
   McGwin G, 2000, ACCIDENT ANAL PREV, V32, P735, DOI 10.1016/S0001-4575(99)00123-2
   MCMURDO M E T, 1988, Health Bulletin (Edinburgh), V46, P327
   Moore AA, 1997, AM J MED, V102, P371, DOI 10.1016/S0002-9343(97)00089-2
   Morrison A, 2012, INT J TECHNOL ASSESS, V28, P138, DOI 10.1017/S0266462312000086
   Murray A, 2005, SYSTEMATIC REV SAFET, P149
   Murray IJ, 2013, INVEST OPHTH VIS SCI, V54, P1781, DOI 10.1167/iovs.12-10715
   Nilsson Sven Erik G., 1994, CLAO Journal, V20, P225
   Omenn GS, 1996, NEW ENGL J MED, V334, P1150, DOI 10.1056/NEJM199605023341802
   Owsley C, 1999, J GERONTOL A-BIOL, V54, pM203, DOI 10.1093/gerona/54.4.M203
   Owsley C, 2007, BRIT J OPHTHALMOL, V91, DOI 10.1136/bjo.2007.118547
   Owsley C, 2007, ARCH OPHTHALMOL-CHIC, V125, P1471, DOI 10.1001/archopht.125.11.1471
   POWE NR, 1994, ARCH OPHTHALMOL-CHIC, V112, P239, DOI 10.1001/archopht.1994.01090140115033
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Schaumberg DA, 1998, OPHTHALMOLOGY, V105, P1213, DOI 10.1016/S0161-6420(98)97023-3
   Schein OD, 2001, J CATARACT REFR SURG, V27, P665, DOI 10.1016/S0886-3350(01)00844-6
   Schein OD, 2005, OPHTHALMOLOGY, V112, P2172, DOI 10.1016/j.ophtha.2005.09.014
   Sims RV, 1998, J AM GERIATR SOC, V46, P556, DOI 10.1111/j.1532-5415.1998.tb01070.x
   Smeeth L, 2003, BMJ-BRIT MED J, V327, P1027, DOI 10.1136/bmj.327.7422.1027
   Souied EH, 2013, OPHTHALMOLOGY, V120, P1619, DOI 10.1016/j.ophtha.2013.01.005
   Sterne JAC, 2011, BMJ-BRIT MED J, V343, DOI 10.1136/bmj.d4002
   STONE DH, 1978, BRIT MED J, V2, P859, DOI 10.1136/bmj.2.6141.859
   Swamy B, 2009, BRIT J OPHTHALMOL, V93, P736, DOI 10.1136/bjo.2007.134650
   Swanson MW, 2009, J AM GERIATR SOC, V57, P486, DOI 10.1111/j.1532-5415.2008.02144.x
   Taban M, 2005, ARCH OPHTHALMOL-CHIC, V123, P613, DOI 10.1001/archopht.123.5.613
   Tahzib NG, 2005, J CATARACT REFR SURG, V31, P1943, DOI 10.1016/j.jcrs.2005.08.022
   Teh RCA, 2006, J AM GERIATR SOC, V54, P370, DOI 10.1111/j.1532-5415.2005.00592_4.x
   US Preventive Services Task Force, 2009, ANN INTERN MED, V151, pW10
   Vedula SS, 2008, COCHRANE DB SYST REV, V2
   Wang F, 1998, Ophthalmic Epidemiol, V5, P69, DOI 10.1076/opep.5.2.69.1575
   Williams MA, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD009300.pub2
   Woods RL, 1998, OPHTHALMOLOGY, V105, P2318, DOI 10.1016/S0161-6420(98)91235-0
NR 66
TC 60
Z9 60
U1 0
U2 15
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 0098-7484
EI 1538-3598
J9 JAMA-J AM MED ASSOC
JI JAMA-J. Am. Med. Assoc.
PD MAR 1
PY 2016
VL 315
IS 9
BP 915
EP 933
DI 10.1001/jama.2016.0783
PG 19
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC General & Internal Medicine
GA DF1DB
UT WOS:000371077500022
PM 26934261
OA Bronze
DA 2022-11-30
ER

PT J
AU Demir, N
   Sevincli, S
   Kayhan, B
   Sonmez, M
AF Demir, Nur
   Sevincli, Sukru
   Kayhan, Belma
   Sonmez, Murat
TI Anatomical effects of intravitreal anti-vascular endothelial growth
   factor injections on inner layers of the lesion-free retina
SO CUTANEOUS AND OCULAR TOXICOLOGY
LA English
DT Article
DE Anti-vascular endothelial growth factor; ganglion cell layer; inner
   retinal layers; inner nuclear layer; lesion-free retina; neovascular
   age-related macular degeneration; retinal nerve fiber&#160; layer
AB Purpose The primary aim of the study was to investigate the effects of anti-vascular endothelial growth factor (VEGF) injections on the inner retinal layer anatomy of the lesion-free retina in eyes treated for neovascular age-related macular degeneration (nAMD). The secondary aim was to compare the changes of inner retinal layers in the lesion-free region of treated eyes with the same region of the untreated, fellow eyes and, thus, to elucidate any adverse effect of anti-VEGF treatments independently of 1-year aging changes. Methods This was a retrospective, longitudinal, case-control study of 50 eyes of 25 patients. Twenty-five eyes with nAMD comprised the study group (16 eyes treated with aflibercept and 9 eyes treated with ranibizumab) and 25 fellow eyes with dry AMD (16 eyes in AREDS 2 and 9 eyes in AREDS 3) comprised the fellow eye group. Spectral-domain optical coherence tomography (SD-OCT) measurements were done at pre-treatment, 1 month after three loading anti-VEGF injections and at the end of 1 year. The retinal nerve fiber layer (RNFL), ganglion cell layer (GCL), inner plexiform layer (IPL), inner nuclear layer (INL) thicknesses and total retinal thickness in the macula were measured. Thicknesses of inner retinal layers which were lesion-free in the outer nasal subfield of ETDRS grid were analysed and the changes in thicknesses during the follow-up period were compared between study and fellow eye groups. Paired t-test for normally distributed variables was applied for analyses of differences for the comparison of the results across the pre-and the post-. A p value of less than 0.05 was considered statistically significant. Results The mean number of injections was 5.76 +/- 1.26 in the study group in 1 year. The mean decrease in total retinal thickness was significant with 6.08 +/- 9.05 mu m (p= 0.003) in nAMD group and was insignificant with 0.32 +/- 1.03 mu m (p> 0.05) in fellow eye group with dry AMD. Most of the retinal thickness decrease was during first three injections in nAMD group. Total retinal thickness and GCL thickness were thinner in the study group at every follow-up examination, but the difference between groups was not statistically significant (p> 0.05). RNFL, GCL, IPL, and INL thicknesses did not demonstrate a statistically significant change in both study and fellow eye groups during 1 year follow-up period (p> 0.05). Conclusions Repeated anti-VEGF injections in nAMD appear to have no significant effect on the RNFL, GCL, IPL, and INL thicknesses of the lesion-free retina. Additionally, there was no significant difference in inner retinal layer changes between in eyes treated with anti-VEGF injections for nAMD and fellow eye group during 1-year follow-up.
C1 [Demir, Nur; Sevincli, Sukru; Kayhan, Belma; Sonmez, Murat] Univ Hlth Sci, Sultan 2 Abdulhamid Han Training & Res Hosp, Ophthalmol Dept, Istanbul, Turkey.
C3 University of Health Sciences Turkey
RP Kayhan, B (通讯作者)，Acibadem, Almondhill Sitesi,B15 Blok,D 8, TR-34660 Istanbul, Turkey.
EM drbelmakayhan@gmail.com
OI Demir, Nur/0000-0003-0738-7212; SONMEZ, MURAT/0000-0003-4231-7797
CR Avery RL, 2017, RETINA-J RET VIT DIS, V37, P1847, DOI 10.1097/IAE.0000000000001493
   Bakri SJ, 2007, OPHTHALMOLOGY, V114, P2179, DOI 10.1016/j.ophtha.2007.09.012
   Beck M, 2016, AM J OPHTHALMOL, V167, P10, DOI 10.1016/j.ajo.2016.04.003
   Cheng CK, 2009, RETINA-J RET VIT DIS, V29, P306, DOI 10.1097/IAE.0b013e3181909404
   D'Amore PA, 2007, AM J PATHOL, V171, P14, DOI 10.2353/ajpath.2007.070385
   Ferrara N, 2016, NAT REV DRUG DISCOV, V15, P385, DOI 10.1038/nrd.2015.17
   FERRIS FL, 1984, ARCH OPHTHALMOL-CHIC, V102, P1640
   Froger N, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-68488-z
   Gilbert RE, 1998, LAB INVEST, V78, P1017
   Horsley MB, 2010, AM J OPHTHALMOL, V150, P558, DOI 10.1016/j.ajo.2010.04.029
   Inan UU, 2019, INT OPHTHALMOL, V39, P2721, DOI 10.1007/s10792-019-01116-6
   Kim I, 1999, INVEST OPHTH VIS SCI, V40, P2115
   Kim Se Young, 2020, Korean J Ophthalmol, V34, P11, DOI 10.3341/kjo.2019.0081
   Kurihara T, 2012, J CLIN INVEST, V122, P4213, DOI 10.1172/JCI65157
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Martinez-de-la-Casa JM, 2012, INVEST OPHTH VIS SCI, V53, P6214, DOI 10.1167/iovs.12-9875
   Nieves-Moreno M, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0194169
   Nishijima K, 2007, AM J PATHOL, V171, P53, DOI 10.2353/ajpath.2007.061237
   Nishimura T, 2012, CLIN OPHTHALMOL, V6, P1073, DOI 10.2147/OPTH.S31674
   Romano MR, 2012, BRAIN RES, V1478, P55, DOI 10.1016/j.brainres.2012.08.014
   Rosenfeld PJ, 2011, OPHTHALMOLOGY, V118, P523, DOI 10.1016/j.ophtha.2010.07.011
   Saint-Geniez M, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003554
   Sondell M, 1999, J NEUROSCI, V19, P5731, DOI 10.1523/JNEUROSCI.19-14-05731.1999
   Storkebaum E, 2004, BIOESSAYS, V26, P943, DOI 10.1002/bies.20092
   Tokunaga CC, 2014, INVEST OPHTH VIS SCI, V55, P1884, DOI 10.1167/iovs.13-13397
   Velez-Montoya R, 2009, RETINA-J RET VIT DIS, V29, P20, DOI 10.1097/IAE.0b013e318186c64e
   Yang XJ, 1996, J NEUROSCI, V16, P6089
   Zinkernagel MS, 2015, INVEST OPHTH VIS SCI, V56, P1894, DOI 10.1167/iovs.14-16204
NR 28
TC 2
Z9 2
U1 0
U2 2
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 1556-9527
EI 1556-9535
J9 CUTAN OCUL TOXICOL
JI Cutan. Ocul. Toxicol.
PD APR 3
PY 2021
VL 40
IS 2
BP 135
EP 139
DI 10.1080/15569527.2021.1919136
EA MAY 2021
PG 5
WC Ophthalmology; Toxicology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology; Toxicology
GA SN8BA
UT WOS:000646904400001
PM 33944638
DA 2022-11-30
ER

PT J
AU Stringham, JM
   Stringham, NT
AF Stringham, James M.
   Stringham, Nicole T.
TI Serum and retinal responses to three different doses of macular
   carotenoids over 12 weeks of supplementation
SO EXPERIMENTAL EYE RESEARCH
LA English
DT Article
DE Lutein; Zeaxanthin; Mesozeaxanthin; Macular pigment; Macular
   carotenoids; Age-related macular degeneration
ID PIGMENT OPTICAL-DENSITY; VISUAL PERFORMANCE; LUTEIN SUPPLEMENTATION;
   SPATIAL-DISTRIBUTION; ZEAXANTHIN; AGE; AUGMENTATION
AB The macular carotenoids lutein (L), zeaxanthin (Z), and mesozeaxanthin (MZ) have been shown to have neuroprotective and visual performance benefits once deposited in retinal tissues. The purpose of this 12-week trial was to determine biweekly the absorption kinetics, efficiency of retinal deposition, and effects on the spatial profile of macular pigment for three levels of L + Z + MZ supplement.
   This study was a double-blind, placebo-controlled 12-week trial. Twenty-eight healthy subjects, aged 18-25 yrs participated. Subjects were randomly assigned to one of four daily supplementation groups: placebo (safflower oil; n = 5), 7.44 mg total macular carotenoid (n = 7), 13.13 mg total macular carotenoid (n = 8), and 27.03 (n = 8) mg total macular carotenoid. Ratios of the three carotenoids were virtually identical for the three levels of supplement (83% L, 10% Z, 7% MZ). At baseline and every two weeks thereafter over the 12-week study period, a fasting blood draw was conducted and, via heterochromatic flicker photometry, spatial profiles of macular pigment optical density (MPOD) were determined.
   Compared to placebo, serum concentrations of both L and total Z, for each of the supplement levels, were found to increase significantly from baseline after two weeks of daily ingestion (p < 0.001). Likewise, MPOD increased significantly in all treatment groups (p < 0.001) compared to placebo. Serum responses (L, Z, and L + Z) were linearly related to dose (p < 0.001 for all), but not to retinal response. L: Z serum response ratios decreased exponentially with increases in dose (p = 0.008). The ratio of MPOD change: total serum response was found to be highest for the 13.13 mg level of supplement (p = 0.021), followed by 27.03- and 7.44-mg doses. The very center of the spatial profile of MPOD increased in a fashion commensurate with dose level.
   Although L serum responses increased with dose, the slope of increase was shallower than for Z. Given the higher levels of L in the supplements, this is suggestive of a compressed response with relatively high doses of L Although all three doses significantly augmented MPOD, the 13.13 mg/day L + Z supplement level was the most efficient in doing so. The data regarding efficiency may inform recommendations regarding macular carotenoid supplementation for age-related macular degeneration. Lastly (although not statistically significant), the shift toward a more pronounced central peak in the spatial profile of MPOD in all treatment groups suggests that central retinal deposition of Z and MZ was efficient and can be seen after a short period of supplementation, especially with higher (e.g. 27.03 mg) daily doses of macular carotenoids. (C) 2016 Elsevier Ltd. All rights reserved.
C1 [Stringham, James M.] Univ Georgia, Dept Physiol & Pharmacol, Nutr Neurosci Lab, Athens, GA 30602 USA.
   [Stringham, Nicole T.] Univ Georgia, Biomed Hlth Sci Inst, Interdisciplinary Neurosci Program, Athens, GA 30602 USA.
C3 University System of Georgia; University of Georgia; University System
   of Georgia; University of Georgia
RP Stringham, JM (通讯作者)，Univ Georgia, Dept Physiol & Pharmacol, Nutr Neurosci Lab, Athens, GA 30602 USA.
EM psychjim@uga.edu; ntwood@uga.edu
FU OmniActive Health Technologies, Inc. [049393-01]
FX We gratefully acknowledge the contribution of our research participants
   to this study. This study was funded by OmniActive Health Technologies,
   Inc. (049393-01) provided the supplements and placebos.
CR Berendschot TTJM, 2006, INVEST OPHTH VIS SCI, V47, P709, DOI 10.1167/iovs.05-0663
   Bone RA, 2003, J NUTR, V133, P992, DOI 10.1093/jn/133.4.992
   BONE RA, 1993, INVEST OPHTH VIS SCI, V34, P2033
   Bone RA, 2010, ARCH BIOCHEM BIOPHYS, V504, P50, DOI 10.1016/j.abb.2010.06.019
   Buzzi F., 1782, OPUSCOLI SCELTI SCI, V5, P87
   Chew EY, 2013, JAMA-J AM MED ASSOC, V309, P2005, DOI 10.1001/jama.2013.4997
   Ciulla TA, 2001, OPHTHALMOLOGY, V108, P730, DOI 10.1016/S0161-6420(00)00655-2
   Connolly EE, 2010, CURR EYE RES, V35, P335, DOI 10.3109/02713680903521951
   CURCIO CA, 1990, J COMP NEUROL, V292, P497, DOI 10.1002/cne.902920402
   Fletcher LM, 2014, OPTOMETRY VISION SCI, V91, P1089, DOI 10.1097/OPX.0000000000000355
   Gallagher JC, 2012, ANN INTERN MED, V156, P425, DOI 10.7326/0003-4819-156-6-201203200-00005
   Hammond BR, 2013, INVEST OPHTH VIS SCI, V54, P476, DOI 10.1167/iovs.12-10411
   Hammond BR, 1997, INVEST OPHTH VIS SCI, V38, P1795
   Hammond Jr B.R., 1997, JAMA-J AM MED ASSOC, V8, P622
   Johnson EJ, 2010, J AM DIET ASSOC, V110, P1357, DOI 10.1016/j.jada.2010.06.009
   Klaver CCW, 1998, ARCH OPHTHALMOL-CHIC, V116, P653, DOI 10.1001/archopht.116.5.653
   Krinsky NI, 2003, ANNU REV NUTR, V23, P171, DOI 10.1146/annurev.nutr.23.011702.073307
   Kvansakul J, 2006, OPHTHAL PHYSL OPT, V26, P362, DOI 10.1111/j.1475-1313.2006.00387.x
   Landrum JT, 2001, ARCH BIOCHEM BIOPHYS, V385, P28, DOI 10.1006/abbi.2000.2171
   Loughman J, 2012, INVEST OPHTH VIS SCI, V53, P7871, DOI 10.1167/iovs.12-10690
   Neuringer M, 2004, INVEST OPHTH VIS SCI, V45, P3234, DOI 10.1167/iovs.02-1243
   Nolan John M, 2014, J Food Process Technol, V5, P335
   Nolan JM, 2012, EXP EYE RES, V101, P9, DOI 10.1016/j.exer.2012.05.006
   Nolan JM, 2011, VISION RES, V51, P459, DOI 10.1016/j.visres.2010.12.016
   Ruban AV, 2002, J BIOL CHEM, V277, P42937, DOI 10.1074/jbc.M207823200
   Sasamoto Y, 2011, GRAEF ARCH CLIN EXP, V249, P1847, DOI 10.1007/s00417-011-1780-z
   Sato Y, 2013, J PHARM PHARM SCI, V16, P494, DOI 10.18433/J33K61
   SEDDON JM, 1994, JAMA-J AM MED ASSOC, V272, P1413, DOI 10.1001/jama.272.18.1413
   Smollon WE, 2015, J BIOMED OPT, V20, DOI 10.1117/1.JBO.20.11.115004
   SNODDERLY DM, 1984, INVEST OPHTH VIS SCI, V25, P660
   SNODDERLY DM, 1984, INVEST OPHTH VIS SCI, V25, P674
   Sommerburg O, 1998, BRIT J OPHTHALMOL, V82, P907, DOI 10.1136/bjo.82.8.907
   Stringham JM, 2008, EXP EYE RES, V87, P445, DOI 10.1016/j.exer.2008.08.005
   Stringham JM, 2008, OPTOMETRY VISION SCI, V85, P82, DOI 10.1097/OPX.0b013e318162266e
   Stringham JM, 2011, INVEST OPHTH VIS SCI, V52, P7406, DOI 10.1167/iovs.10-6699
   Tian Y, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0073387
   Trieschmann M, 2007, EXP EYE RES, V84, P718, DOI 10.1016/j.exer.2006.12.010
   Vachali P, 2012, ARCH BIOCHEM BIOPHYS, V519, P32, DOI 10.1016/j.abb.2012.01.006
   WALD G, 1945, SCIENCE, V101, P653, DOI 10.1126/science.101.2635.653
   Wang YM, 2010, EUR J NUTR, V49, P327, DOI 10.1007/s00394-009-0089-8
   Wenzel AJ, 2007, OPHTHAL PHYSL OPT, V27, P329, DOI 10.1111/j.1475-1313.2007.00495.x
   WIEGAND RD, 1983, INVEST OPHTH VIS SCI, V24, P1433
   Wooten BR, 2005, OPTOMETRY VISION SCI, V82, P378, DOI 10.1097/01.OPX.0000162654.32112.A1
   Wooten BR, 1999, INVEST OPHTH VIS SCI, V40, P2481
   Yao Y, 2013, NUTRITION, V29, P958, DOI 10.1016/j.nut.2012.10.017
NR 45
TC 13
Z9 13
U1 0
U2 12
PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 0014-4835
EI 1096-0007
J9 EXP EYE RES
JI Exp. Eye Res.
PD OCT
PY 2016
VL 151
BP 1
EP 8
DI 10.1016/j.exer.2016.07.005
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA DZ1OI
UT WOS:000385607300001
PM 27426932
DA 2022-11-30
ER

PT J
AU Delcourt, C
   Korobelnik, JF
   Barberger-Gateau, P
   Delyfer, MN
   Rougier, MB
   Le Goff, M
   Malet, F
   Colin, J
   Dartigues, JF
AF Delcourt, C.
   Korobelnik, J. -F.
   Barberger-Gateau, P.
   Delyfer, M. -N.
   Rougier, M. -B.
   Le Goff, M.
   Malet, F.
   Colin, J.
   Dartigues, J. -F.
TI NUTRITION AND AGE-RELATED EYE DISEASES: THE ALIENOR (ANTIOXYDANTS,
   LIPIDES ESSENTIELS, NUTRITION ET MALADIES OCULAIRES) STUDY
SO JOURNAL OF NUTRITION HEALTH & AGING
LA English
DT Article
DE Macular degeneration; glaucoma; nutrition; antioxidants; fatty acids;
   epidemiology
ID OPEN-ANGLE GLAUCOMA; PLASMA EICOSAPENTAENOIC ACID; BLUE MOUNTAINS EYE;
   MACULAR DEGENERATION; DRY EYE; VISUAL IMPAIRMENT; OXIDATIVE STRESS;
   UNITED-STATES; DEPRESSIVE SYMPTOMATOLOGY; CARDIOVASCULAR HEALTH
AB Background: Worldwide, degenerative eye diseases (age-related maculopathy (ARM), cataract, glaucoma) are the main causes of visual impairment and blindness, which contribute to disability in the elderly. Mainly three types of nutritional factors are investigated for their potential protection against eye ageing: antioxidants; lutein and zeaxanthin (carotenoids which accumulate specifically in the eye); omega 3 polyunsaturated fatty acids. Few epidemiological studies have been conducted in this field, particularly in Europe. Objective: The Alienor (Antioxydants, Lipides Essentiels, Nutrition et maladies OculaiRes) Study aims at assessing the associations of eye diseases with nutritional factors, determined from plasma measurements and estimation of dietary intakes. Design, setting and participants: Subjects were recruited in Bordeaux (France) from the ongoing population-based 3C study. In 2006-2008, 963 subjects from the 3C Study, aged 73 years or more, had an eye examination and will have follow-up eye examinations every 2 years. Measurements: Vascular, genetic and nutritional factors were assessed at baseline (1999-2001) and follow-up examinations of the 3C Study. Eye diseases were classified according to international classifications. Results: Nutritional status and vascular disease and risk factors were similar between participants and non participants, except for a slight difference in plasma triglycerides and HDL-cholesterol. As expected, the prevalence of eye diseases was high: early and late ARM (28.4 % and 5.6 %, respectively), open-angle glaucoma and treated ocular hypertension (4.8 % and 10.0 %, respectively), cataract extraction (45.2 %), retinopathy (8.4 %), retinal vein occlusion (1.1 %), epiretinal membrane (3.9 %), current use of artificial tears (17.3 %). Conclusions: This study confirms the high prevalence of eye diseases in the elderly. Its main strength is the combination of nutritional, vascular and genetic information, collected over a 7 year period of time before the first eye examination. It may help design future interventional studies, which might be common with other age-related disorders, because of common nutritional factors.
C1 [Delcourt, C.; Korobelnik, J. -F.; Barberger-Gateau, P.; Le Goff, M.; Dartigues, J. -F.] Univ Victor Segalen Bordeaux 2, INSERM, U897, F-33076 Bordeaux, France.
   [Korobelnik, J. -F.; Delyfer, M. -N.; Rougier, M. -B.; Malet, F.; Colin, J.] CHU Bordeaux, Serv Ophtalmol, F-33000 Bordeaux, France.
C3 Institut National de la Sante et de la Recherche Medicale (Inserm);
   UDICE-French Research Universities; Universite de Bordeaux; CHU Bordeaux
RP Delcourt, C (通讯作者)，Univ Victor Segalen Bordeaux 2, INSERM, U897, 146 Rue Leo Saignat, F-33076 Bordeaux, France.
EM cecile.delcourt@isped.u-bordeaux2.fr
RI Delcourt, Cecile/I-2627-2013; LE GOFF, Mélanie/A-3541-2016; DARTIGUES,
   Jean François/T-4513-2019; Delyfer, Marie-Noelle/T-3304-2019;
   KOROBELNIK, Jean-Francois/A-5448-2016
OI Delcourt, Cecile/0000-0002-2099-0481; LE GOFF,
   Melanie/0000-0003-2848-6287
FU Laboratoires Thea (Clermont-Ferrand, France); Zeiss
FX This study received financial support from Laboratoires Thea
   (Clermont-Ferrand, France). This sponsor participated in the design of
   the study, but not in the collection, management, statistical analysis
   and interpretation of the data, nor in the preparation, review or
   approval of the present manuscript. Cecile Delcourt had full access to
   all the data in the study and takes responsibility for the integrity of
   the data and the accuracy of the data analysis.; C Delcourt: consultant
   for Bausch&Lomb, Novartis, Pfizer; JF Korobelnik: consultant for Alcon,
   Novartis, Bayer, Bausch & Lomb, Allergan; P Barberger-Gateau: lecture
   fees for Lesieur, Danone, Bausch & Lomb; J Colin: consultant for
   Addition Technologies Inc, Alcon, Abbott AMO, Optical Express, Horus
   Pharma, Gene Signal SAS; F Malet : consultant for Abbott Medical Optics
   France, Cibavision; MB Rougier : lecture fees from Zeiss; MN Delyfer, M
   Le Goff, JF Dartigues : none
CR [Anonymous], 2003, NEUROEPIDEMIOLOGY, V22, P316
   Augood CA, 2006, ARCH OPHTHALMOL-CHIC, V124, P529, DOI 10.1001/archopht.124.4.529
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Boscia F, 2000, INVEST OPHTH VIS SCI, V41, P2461
   Breslow JL, 2006, AM J CLIN NUTR, V83, p1477S, DOI 10.1093/ajcn/83.6.1477S
   CARBONNEAU MA, 1991, CLIN CHEM, V37, P1423
   Cheung N, 2007, SURV OPHTHALMOL, V52, P180, DOI 10.1016/j.survophthal.2006.12.003
   Chiu CJ, 2007, EXP EYE RES, V84, P229, DOI 10.1016/j.exer.2006.05.015
   Chong EWT, 2008, ARCH OPHTHALMOL-CHIC, V126, P826, DOI 10.1001/archopht.126.6.826
   Chylack LT, 2002, OPHTHAL EPIDEMIOL, V9, P49
   Cigolle CT, 2007, ANN INTERN MED, V147, P156, DOI 10.7326/0003-4819-147-3-200708070-00004
   Coleman AL, 2008, AM J OPHTHALMOL, V145, P1081, DOI 10.1016/j.ajo.2008.01.022
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Favier JC, 1995, REPERTOIRE GEN ALIME
   Feart C, 2008, AM J CLIN NUTR, V87, P1156, DOI 10.1093/ajcn/87.5.1156
   Feart C, 2007, BRIT J NUTR, V98, P1046, DOI 10.1017/S0007114507756520
   Foster PJ, 2002, BRIT J OPHTHALMOL, V86, P238, DOI 10.1136/bjo.86.2.238
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P532
   Helmer C, 2003, EUR J CLIN NUTR, V57, P1555, DOI 10.1038/sj.ejcn.1601724
   Kang JH, 2003, AM J EPIDEMIOL, V158, P337, DOI 10.1093/aje/kwg167
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Klaver CCW, 2001, INVEST OPHTH VIS SCI, V42, P2237
   KLEIN R, 1994, ARCH OPHTHALMOL-CHIC, V112, P92, DOI 10.1001/archopht.1994.01090130102026
   Klein R, 2006, OPHTHALMOLOGY, V113, P373, DOI 10.1016/j.ophtha.2005.12.013
   Klein R, 2000, Trans Am Ophthalmol Soc, V98, P133
   Klein R, 2000, T AM OPHTHAL SOC, V98, P133
   Laitinen A, 2007, OPHTHAL EPIDEMIOL, V14, P333, DOI 10.1080/01658100701473713
   Lambert JC, 2009, NAT GENET, V41, P1094, DOI 10.1038/ng.439
   Larrieu S, 2004, J Nutr Health Aging, V8, P497
   McCarty CA, 1998, OPHTHALMOLOGY, V105, P1114, DOI 10.1016/S0161-6420(98)96016-X
   McCarty CA, 2002, DEV OPHTHALMOL, V35, P21
   McCarty DJ, 2005, AM J OPHTHALMOL, V140, P288, DOI 10.1016/j.ajo.2005.03.032
   Mitchell P, 2002, ARCH OPHTHALMOL-CHIC, V120, P1357, DOI 10.1001/archopht.120.10.1357
   Mitchell P, 1997, OPHTHALMOLOGY, V104, P1033, DOI 10.1016/S0161-6420(97)30190-0
   Moss SE, 2000, ARCH OPHTHALMOL-CHIC, V118, P1264
   Renaud S., 1979, TABLE COMPOSITION AL, P105
   Resnikoff S, 2004, B WORLD HEALTH ORGAN, V82, P844
   Sacca SC, 2007, EXP EYE RES, V84, P389, DOI 10.1016/j.exer.2006.10.008
   Samieri C, 2008, AM J CLIN NUTR, V88, P714, DOI 10.1093/ajcn/88.3.714
   Samieri C, 2008, J AM DIET ASSOC, V108, P1461, DOI 10.1016/j.jada.2008.06.437
   SanGiovanni JP, 2005, PROG RETIN EYE RES, V24, P87, DOI 10.1016/j.preteyeres.2004.06.002
   Schaumberg DA, 2009, ARCH OPHTHALMOL-CHIC, V127, P763, DOI 10.1001/archophthalmol.2009.103
   Schein OD, 1997, AM J OPHTHALMOL, V124, P723, DOI 10.1016/S0002-9394(14)71688-5
   Schiffman RM, 2000, ARCH OPHTHALMOL-CHIC, V118, P615, DOI 10.1001/archopht.118.5.615
   Scholl HPN, 2007, MOL VIS, V13, P196
   SIMERMANN J, 2007, 25 ANN C SFNEP CLIN
   Solberg Y, 1998, SURV OPHTHALMOL, V42, P535, DOI 10.1016/S0039-6257(98)00002-2
   Souci SW., 2000, FOOD COMPOSITION NUT
   Viso E, 2009, OPHTHAL EPIDEMIOL, V16, P15, DOI 10.1080/09286580802228509
   Weinreb RN, 2004, LANCET, V363, P1711, DOI 10.1016/S0140-6736(04)16257-0
   Whitehead AJ, 2006, ARCH OPHTHALMOL-CHIC, V124, P1038, DOI 10.1001/archopht.124.7.1038
   Willcox BJ, 2008, AM J CARDIOL, V101, p75D, DOI 10.1016/j.amjcard.2008.02.012
   Wong T, 2007, LANCET, V369, P425, DOI 10.1016/S0140-6736(07)60198-6
   Wong TY, 2003, OPHTHALMOLOGY, V110, P658, DOI 10.1016/S0161-6420(02)01931-0
   Yates JRW, 2007, NEW ENGL J MED, V357, P553, DOI 10.1056/NEJMoa072618
   Yeum KJ, 1999, CURR EYE RES, V19, P502, DOI 10.1076/ceyr.19.6.502.5282
   Yu T, 1998, ARCH OPHTHALMOL-CHIC, V116, P83, DOI 10.1001/archopht.116.1.83
   Zanon-Moreno V, 2008, J GLAUCOMA, V17, P263, DOI 10.1097/IJG.0b013e31815c3a7f
NR 60
TC 67
Z9 69
U1 0
U2 25
PU SPRINGER FRANCE
PI PARIS
PA 22 RUE DE PALESTRO, PARIS, 75002, FRANCE
SN 1279-7707
J9 J NUTR HEALTH AGING
JI J. Nutr. Health Aging
PD DEC
PY 2010
VL 14
IS 10
BP 854
EP 861
DI 10.1007/s12603-010-0131-9
PG 8
WC Geriatrics & Gerontology; Nutrition & Dietetics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Geriatrics & Gerontology; Nutrition & Dietetics
GA 708YR
UT WOS:000286400700010
PM 21125205
OA Green Submitted, Green Accepted
DA 2022-11-30
ER

PT J
AU Hall, MA
   Wallace, J
   Lucas, AM
   Bradford, Y
   Verma, SS
   Muller-Myhsok, B
   Passero, K
   Zhou, J
   McGuigan, J
   Jiang, BB
   Pendergrass, SA
   Zhang, YF
   Peissig, P
   Brilliant, M
   Sleiman, P
   Hakonarson, H
   Harley, JB
   Kiryluk, K
   Van Steen, K
   Moore, JH
   Ritchie, MD
AF Hall, Molly A.
   Wallace, John
   Lucas, Anastasia M.
   Bradford, Yuki
   Verma, Shefali S.
   Mueller-Myhsok, Bertram
   Passero, Kristin
   Zhou, Jiayan
   McGuigan, John
   Jiang, Beibei
   Pendergrass, Sarah A.
   Zhang, Yanfei
   Peissig, Peggy
   Brilliant, Murray
   Sleiman, Patrick
   Hakonarson, Hakon
   Harley, John B.
   Kiryluk, Krzysztof
   Van Steen, Kristel
   Moore, Jason H.
   Ritchie, Marylyn D.
TI Novel EDGE encoding method enhances ability to identify genetic
   interactions
SO PLOS GENETICS
LA English
DT Article
ID GENOME-WIDE ASSOCIATION; ELECTRONIC MEDICAL-RECORDS; BREAST-CANCER RISK;
   ISCHEMIC-STROKE; EMERGE NETWORK; LOCUS; SUSCEPTIBILITY; POLYMORPHISM;
   DISEASE; TOOLS
AB Assumptions are made about the genetic model of single nucleotide polymorphisms (SNPs) when choosing a traditional genetic encoding: additive, dominant, and recessive. Furthermore, SNPs across the genome are unlikely to demonstrate identical genetic models. However, running SNP-SNP interaction analyses with every combination of encodings raises the multiple testing burden. Here, we present a novel and flexible encoding for genetic interactions, the elastic data-driven genetic encoding (EDGE), in which SNPs are assigned a heterozygous value based on the genetic model they demonstrate in a dataset prior to interaction testing. We assessed the power of EDGE to detect genetic interactions using 29 combinations of simulated genetic models and found it outperformed the traditional encoding methods across 10%, 30%, and 50% minor allele frequencies (MAFs). Further, EDGE maintained a low false-positive rate, while additive and dominant encodings demonstrated inflation. We evaluated EDGE and the traditional encodings with genetic data from the Electronic Medical Records and Genomics (eMERGE) Network for five phenotypes: age-related macular degeneration (AMD), age-related cataract, glaucoma, type 2 diabetes (T2D), and resistant hypertension. A multi-encoding genome-wide association study (GWAS) for each phenotype was performed using the traditional encodings, and the top results of the multi-encoding GWAS were considered for SNP-SNP interaction using the traditional encodings and EDGE. EDGE identified a novel SNP-SNP interaction for age-related cataract that no other method identified: rs7787286 (MAF: 0.041; intergenic region of chromosome 7)-rs4695885 (MAF: 0.34; intergenic region of chromosome 4) with a Bonferroni LRT p of 0.018. A SNP-SNP interaction was found in data from the UK Biobank within 25 kb of these SNPs using the recessive encoding: rs60374751 (MAF: 0.030) and rs6843594 (MAF: 0.34) (Bonferroni LRT p: 0.026). We recommend using EDGE to flexibly detect interactions between SNPs exhibiting diverse action.
   Author summary Although traditional genetic encodings are widely implemented in genetics research, including in genome-wide association studies (GWAS) and epistasis, each method makes assumptions that may not reflect the underlying etiology. Here, we introduce a novel encoding method that estimates and assigns an individualized data-driven encoding for each single nucleotide polymorphism (SNP): the elastic data-driven genetic encoding (EDGE). With simulations, we demonstrate that this novel method is more accurate and robust than traditional encoding methods in estimating heterozygous genotype values, reducing the type I error, and detecting SNP-SNP interactions. We further applied the traditional encodings and EDGE to biomedical data from the Electronic Medical Records and Genomics (eMERGE) Network for five phenotypes, and EDGE identified a novel interaction for age-related cataract not detected by traditional methods, which replicated in data from the UK Biobank. EDGE provides an alternative approach to understanding and modeling diverse SNP models and is recommended for studying complex genetics in common human phenotypes.
C1 [Hall, Molly A.; Wallace, John; Zhou, Jiayan; McGuigan, John] Penn State Univ, Coll Agr Sci, Dept Vet & Biomed Sci, University Pk, PA 16802 USA.
   [Hall, Molly A.; Passero, Kristin] Penn State Univ, Huck Inst Life Sci, University Pk, PA 16802 USA.
   [Hall, Molly A.] Penn State Univ, Penn State Canc Inst, University Pk, PA 16802 USA.
   [Lucas, Anastasia M.; Bradford, Yuki; Verma, Shefali S.; Moore, Jason H.; Ritchie, Marylyn D.] Univ Penn, Dept Genet, Inst Biomed Informat, Philadelphia, PA 19104 USA.
   [Mueller-Myhsok, Bertram; Jiang, Beibei] Max Planck Inst Psychiat, Dept Translat Res Psychiat, Munich, Germany.
   [Mueller-Myhsok, Bertram; Jiang, Beibei] Munich Cluster Syst Neurol SyNergy, Munich, Germany.
   [Mueller-Myhsok, Bertram; Jiang, Beibei] Univ Liverpool, Inst Translat Med, Liverpool, Merseyside, England.
   [Pendergrass, Sarah A.] Genentech Inc, San Francisco, CA USA.
   [Zhang, Yanfei] Geisinger Hlth Syst, Genom Med Inst, Danville, PA USA.
   [Peissig, Peggy; Brilliant, Murray] Marshfield Clin Res Inst, Ctr Precis Med Res, Marshfield, WI USA.
   [Sleiman, Patrick; Hakonarson, Hakon] Childrens Hosp Penn, Ctr Appl Genom, Dept Pediat, Philadelphia, PA USA.
   [Harley, John B.] Cincinnati Childrens Hosp Med Ctr, Ctr Autoimmune Genom & Etiol CAGE, Cincinnati, OH 45229 USA.
   [Harley, John B.] Univ Cincinnati, Coll Med, Dept Pediat, Cincinnati, OH USA.
   [Harley, John B.] US Dept Vet Affairs Med Ctr, Cincinnati, OH USA.
   [Kiryluk, Krzysztof] Columbia Univ Coll Phys & Surg, Dept Med, Div Nephrol, New York, NY USA.
   [Van Steen, Kristel] Univ Liege, GIGA R Med Genom BIO3, WELBIO, Liege, Belgium.
   [Van Steen, Kristel] Univ Leuven, Dept Human Genet, Leuven, Belgium.
C3 Pennsylvania Commonwealth System of Higher Education (PCSHE);
   Pennsylvania State University; Pennsylvania State University -
   University Park; Pennsylvania Commonwealth System of Higher Education
   (PCSHE); Pennsylvania State University; Pennsylvania State University -
   University Park; Pennsylvania Commonwealth System of Higher Education
   (PCSHE); Pennsylvania State University; Penn State Health; Pennsylvania
   State University - University Park; University of Pennsylvania; Max
   Planck Society; University of Munich; University of Liverpool; Roche
   Holding; Genentech; Geisinger Health System; University of Pennsylvania;
   Pennsylvania Medicine; Childrens Hospital of Philadelphia; Cincinnati
   Children's Hospital Medical Center; University System of Ohio;
   University of Cincinnati; University System of Ohio; University of
   Cincinnati; US Department of Veterans Affairs; Veterans Health
   Administration (VHA); Cincinnati VA Medical Center; Columbia University;
   University of Liege; WELBIO; KU Leuven
RP Hall, MA (通讯作者)，Penn State Univ, Coll Agr Sci, Dept Vet & Biomed Sci, University Pk, PA 16802 USA.; Hall, MA (通讯作者)，Penn State Univ, Huck Inst Life Sci, University Pk, PA 16802 USA.; Hall, MA (通讯作者)，Penn State Univ, Penn State Canc Inst, University Pk, PA 16802 USA.
EM mah546@psu.edu
RI Moore, Jason H./AAV-9645-2021
OI Moore, Jason H./0000-0002-5015-1099; McGuigan, John/0000-0003-4149-875X;
   Muller-Myhsok, Bertram/0000-0002-0719-101X; Hall,
   Molly/0000-0001-7740-401X; Zhou, Jiayan/0000-0001-5974-087X; Verma,
   Shefali/0000-0001-5216-4670
FU NIH [LM010098, AI116794]; Fonds de la Recherche Scientifique (FNRS);
   NHGRI [U01HG006828, U01HG006830, U01HG006389, U01HG006382, U01HG006375,
   U01HG006379, U01HG006380, U01HG006378, U01HG006385, U01HG004438,
   U01HG004424]; USDA National Institute of Food and Agriculture [PEN04275,
   1018544]; College of Agricultural Sciences, Pennsylvania State
   University; Dr. Frances Keesler Graham Early Career Professorship from
   the Social Science Research Institute, Pennsylvania State University
FX The project described was partially supported by NIH grants LM010098 and
   AI116794 to JHM. KVS acknowledges funding from the Fonds de la Recherche
   Scientifique (FNRS) and opportunities offered by the interuniversity
   research institute WELBIO. The eMERGE Network was initiated and funded
   by NHGRI through the following grants: U01HG006828 (Cincinnati
   Children's Hospital Medical Center/Boston Children's Hospital) to JBH;
   U01HG006830 (Children's Hospital of Philadelphia) to HH; U01HG006389
   (Essentia Institute of Rural Health, Marshfield Clinic Research
   Foundation and Pennsylvania State University); U01HG006382 (Geisinger
   Clinic); U01HG006375 (Group Health Cooperative/University of
   Washington); U01HG006379 (Mayo Clinic); U01HG006380 (Icahn School of
   Medicine at Mount Sinai); U01HG006388 (Northwestern University);
   U01HG006378 (Vanderbilt University Medical Center); and U01HG006385
   (Vanderbilt University Medical Center serving as the Coordinating
   Center); U01HG004438 (CIDR) and U01HG004424 (the Broad Institute)
   serving as Genotyping Centers; and the PGRNSeq dataset (eMERGE PGx) for
   data collection. This work was additionally supported by the USDA
   National Institute of Food and Agriculture and Hatch Appropriations
   under Project #PEN04275 and Accession #1018544, startup funds from the
   College of Agricultural Sciences, Pennsylvania State University
   (https://agsci.psu.edu/), and the Dr. Frances Keesler Graham Early
   Career Professorship from the Social Science Research Institute,
   Pennsylvania State University (https://ssri.psu.edu/) to MAH. The
   funders had no role in study design, data collection and analysis,
   decision to publish, or preparation of the manuscript.
CR Abbott S, 2016, GENETICS, V204, P407, DOI 10.1534/genetics.116.195198
   Anderson DH, 2010, PROG RETIN EYE RES, V29, P95, DOI 10.1016/j.preteyeres.2009.11.003
   Arking DE, 2006, NAT GENET, V38, P644, DOI 10.1038/ng1790
   Bierut LJ, 2007, HUM MOL GENET, V16, P24, DOI 10.1093/hmg/ddl441
   Breiman L, 2001, MACH LEARN, V45, P5, DOI 10.1023/A:1010933404324
   Burton PR, 2007, NATURE, V447, P661, DOI 10.1038/nature05911
   Bush WS, 2012, PLOS COMPUT BIOL, V8, DOI 10.1371/journal.pcbi.1002822
   Bycroft C, 2018, NATURE, V562, P203, DOI 10.1038/s41586-018-0579-z
   Carroll RJ, 2014, BIOINFORMATICS, V30, P2375, DOI 10.1093/bioinformatics/btu197
   Cipriani V, 2012, HUM MOL GENET, V21, P4138, DOI 10.1093/hmg/dds225
   Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807
   Enquobahrie DA, 2008, AM J CARDIOL, V101, P1683, DOI 10.1016/j.amjcard.2008.02.052
   Fung HC, 2006, LANCET NEUROL, V5, P911, DOI 10.1016/S1474-4422(06)70578-6
   Hall MA, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00802-2
   Hall MA, 2016, TRENDS GENET, V32, P470, DOI 10.1016/j.tig.2016.06.001
   Han W, 2012, CANCER-AM CANCER SOC, V118, P594, DOI 10.1002/cncr.26220
   Holzinger ER, 2014, BIOINFORMATICS, V30, P698, DOI 10.1093/bioinformatics/btt572
   Jiao XY, 2011, CARCINOGENESIS, V32, P496, DOI 10.1093/carcin/bgq250
   John JMM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0029594
   Juran BD, 2011, SEMIN LIVER DIS, V31, P215, DOI 10.1055/s-0031-1276641
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Kooperberg C, 2007, AM J EPIDEMIOL, V165, P334, DOI 10.1093/aje/kwk006
   Kopplin LJ, 2010, GENES IMMUN, V11, P609, DOI 10.1038/gene.2010.39
   Lencz T, 2007, MOL PSYCHIATR, V12, P572, DOI 10.1038/sj.mp.4001983
   Lettre G, 2007, GENET EPIDEMIOL, V31, P358, DOI 10.1002/gepi.20217
   Li RW, 2016, BIODATA MIN, V9, DOI 10.1186/s13040-016-0094-4
   Li WT, 2000, HUM HERED, V50, P334, DOI 10.1159/000022939
   Ma L, 2008, BMC BIOINFORMATICS, V9, DOI 10.1186/1471-2105-9-315
   Maraganore DM, 2005, AM J HUM GENET, V77, P685, DOI 10.1086/496902
   Matarin M, 2007, LANCET NEUROL, V6, P414, DOI 10.1016/S1474-4422(07)70081-9
   McCarty CA, 2011, BMC MED GENOMICS, V4, DOI 10.1186/1755-8794-4-13
   Motsinger AA, 2006, PROCEEDINGS OF THE 2006 IEEE SYMPOSIUM ON COMPUTATIONAL INTELLIGENCE IN BIOINFORMATICS AND COMPUTATIONAL BIOLOGY, P263
   Naj AC, 2013, ANN HUM GENET, V77, P215, DOI 10.1111/ahg.12011
   Neale BM, 2010, P NATL ACAD SCI USA, V107, P7395, DOI 10.1073/pnas.0912019107
   Neuhausen SL, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2414
   Ritchie MD, 2014, MOL VIS, V20, P1281
   Ritchie MD, 2001, AM J HUM GENET, V69, P138, DOI 10.1086/321276
   Schymick JC, 2007, LANCET NEUROL, V6, P322, DOI 10.1016/S1474-4422(07)70037-6
   Singmann P, 2009, OBESITY FACTS, V2, P235, DOI 10.1159/000227288
   Sladek R, 2007, NATURE, V445, P881, DOI 10.1038/nature05616
   Uda M, 2008, P NATL ACAD SCI USA, V105, P1620, DOI 10.1073/pnas.0711566105
   Urbanowicz RJ, 2013, J AM MED INFORM ASSN, V20, P603, DOI 10.1136/amiajnl-2012-001574
   Verma SS, 2014, FRONT GENET, V5, DOI 10.3389/fgene.2014.00370
   Vujkovic M, 2020, NAT GENET, V52, P680, DOI 10.1038/s41588-020-0637-y
   Wallace C, 2008, AM J HUM GENET, V82, P139, DOI 10.1016/j.ajhg.2007.11.001
   Wang HW, 2019, SCI ADV, V5, DOI 10.1126/sciadv.aaw3538
   Williams FMK, 2013, ANN NEUROL, V73, P16, DOI 10.1002/ana.23838
   Zhang H, 2008, BMC MED GENET, V9, DOI 10.1186/1471-2350-9-51
   Zheng XW, 2012, BIOINFORMATICS, V28, P3326, DOI 10.1093/bioinformatics/bts606
   Ziegler A, 2008, BIOMETRICAL J, V50, P8, DOI 10.1002/bimj.200710398
NR 50
TC 0
Z9 0
U1 0
U2 7
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1553-7404
J9 PLOS GENET
JI PLoS Genet.
PD JUN
PY 2021
VL 17
IS 6
AR e1009534
DI 10.1371/journal.pgen.1009534
PG 34
WC Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity
GA SW2NQ
UT WOS:000664356500001
PM 34086673
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Tan, GSW
   Liu, ZP
   Ilmarinen, T
   Barathi, VA
   Chee, CK
   Lingam, G
   Su, XY
   Stanzel, BV
AF Tan, Gavin S. W.
   Liu, Zengping
   Ilmarinen, Tanja
   Barathi, Veluchamy A.
   Chee, Caroline K.
   Lingam, Gopal
   Su, Xinyi
   Stanzel, Boris V.
TI Hints for Gentle Submacular Injection in Non-Human Primates Based on
   Intraoperative OCT Guidance
SO TRANSLATIONAL VISION SCIENCE & TECHNOLOGY
LA English
DT Article
DE submacular surgery; fovea; non-human primates; intraoperative OCT;
   Advanced Therapy Medicinal Products
AB Purpose: Delivery of Advanced Therapy Medicinal Products to the submacular space is increasingly evolving into a therapeutic modality. Cell replacement for age-related macular degeneration (AMD) and gene therapy for RPE65 are recent successful examples. Herein, a nonhuman primate (NHP) model was used to investigate surgical means to detach the macula. Methods: Sixteen eyes of 13 healthy macaques underwent a 25-gauge vitrectomy and subretinal injection of balanced salt solution monitored by microscope-integrated intraoperative optical coherence tomography (miOCT). The animals were followed with OCT and histology. Results: The miOCT monitoring allowed a more precise definition of surgical trauma ranging from an initial full-thickness foveal tear, or induction of a cystoid macular edema (CME), until no foveal defect was discernible, as the technique improved. However, as the subretinal fluid wave detached the fovea, the aforementioned lesions formed, whereas persistent retinal adhesion reproducibly proved to remain in the distal parafoveal semi annulus. Measures to reduce foveal trauma during submacular fluid injection included reducing intraocular pressure, injection volume, and velocity, as well as the retinal location for bleb initiation, use of a vitreous tamponade, and a dual-bore subretinal cannula. Conclusions: A stable very low intraocular pressure and careful subretinal injection may avoid tangential macular stretching or mechanical CME formation, while vitreous tamponade may facilitate a more lamellar subretinal flow, all thereby reducing foveal trauma during submacular injection in NHP. Translational Relevance: These results can be relevant to any submacular surgery procedure used today, as they synergistically reduce the risk of compromising foveal integrity.
   ABSTRACT Conclusions: A stable very low intraocular pressure and careful subretinal injection may avoid tangential macular stretching or mechanical CME formation, while vitreous tamponade may facilitate a more lamellar subretinal flow, all thereby reducing foveal trauma during submacular injection in NHP. Translational Relevance: These results can be relevant to any submacular surgery procedure used today, as they synergistically reduce the risk of compromising foveal integrity.
   ABSTRACT Methods: Sixteen eyes of 13 healthy macaques underwent a 25-gauge vitrectomy and subretinal injection of balanced salt solution monitored by microscope-integrated intraoperative optical coherence tomography (miOCT). The animals were followed with OCT and histology. Results: The miOCT monitoring allowed a more precise definition of surgical trauma ranging from an initial full-thickness foveal tear, or induction of a cystoid macular edema (CME), until no foveal defect was discernible, as the technique improved. However, as the subretinal fluid wave detached the fovea, the aforementioned lesions formed, whereas persistent retinal adhesion reproducibly proved to remain in the distal parafoveal semiannulus. Measures to reduce foveal trauma during submacular fluid injection included reducing intraocular pressure, injection volume, and velocity, as well as the retinal location for bleb initiation, use of a vitreous tamponade, and a dual-bore subretinal cannula.
C1 [Tan, Gavin S. W.; Stanzel, Boris V.] Singapore Natl Eye Ctr, Singapore, Singapore.
   [Tan, Gavin S. W.; Liu, Zengping; Barathi, Veluchamy A.; Chee, Caroline K.; Lingam, Gopal; Su, Xinyi] Singapore Eye Res Inst, Singapore, Singapore.
   [Liu, Zengping; Barathi, Veluchamy A.; Chee, Caroline K.; Lingam, Gopal; Stanzel, Boris V.] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Ophthalmol, Singapore, Singapore.
   [Liu, Zengping; Su, Xinyi] A STAR Agcy Sci Res & Technol, Inst Mol & Cell Biol, Singapore, Singapore.
   [Ilmarinen, Tanja] Tampere Univ, Fac Med & Hlth Technol, Tampere, Finland.
   [Tan, Gavin S. W.; Barathi, Veluchamy A.] Duke NUS Med Sch, Ophthalmol Acad Clin Res Program, Singapore, Singapore.
   [Chee, Caroline K.; Lingam, Gopal; Su, Xinyi] Natl Univ Singapore Hosp, Dept Ophthalmol, Singapore, Singapore.
   [Stanzel, Boris V.] Knappschaft Hosp Saar, Eye Clin Sulzbach, Sulzbach, Saar, Germany.
C3 Singapore National Eye Center; National University of Singapore;
   Singapore National Eye Center; National University of Singapore; Agency
   for Science Technology & Research (A*STAR); A*STAR - Institute of
   Molecular & Cell Biology (IMCB); Tampere University; National University
   of Singapore; National University of Singapore
RP Stanzel, BV (通讯作者)，Eye Clin Sulzbach, Klin 10, D-66280 Sulzbach, Germany.
EM boris.stanzel@kksaar.de
RI Stanzel, Boris/AAG-7010-2022; Liu, Zengping/GQO-9030-2022; Stanzel,
   Boris/ADP-9221-2022
OI Stanzel, Boris/0000-0002-4316-1539; Stanzel, Boris/0000-0002-4316-1539;
   Liu, Zengping/0000-0002-2578-293X; Ilmarinen, Tanja/0000-0002-4609-8897
FU Academy of Finland; Vision Funds (SNEC), Singapore; HREF (SNEC),
   Singapore [R1467/50/2017]; Academic Clinical Programme, Singapore;
   NMRC/MOH, Singapore [TA/MOH-0055/2017]; NUHS Clinical Scientist Program
   (NCSP), Singapore; INCEPTOR/Pre-Clinical Core Platform/2017_SERI;
   NMRC/CG/C010APreClinical/2017
FX Supported by grants from the Academy of Finland (TI); Vision Funds
   (SNEC), Singapore (BS); HREF (SNEC, R1467/50/2017), Singapore (GSWT,
   BS); Academic Clinical Programme (Singhealth, R1378/64/2016), Singapore
   (BS, GSWT); TA/MOH-0055/2017, NMRC/MOH, Singapore (GSWT); NUHS Clinical
   Scientist Program (NCSP), Singapore (XS); INCEPTOR/Pre-Clinical Core
   Platform/2017_SERI; NMRC/CG/C010APreClinical/2017.
CR Al-Nawaiseh S, 2016, JOVE-J VIS EXP, DOI 10.3791/53927
   Binder S, 2002, AM J OPHTHALMOL, V133, P215, DOI 10.1016/S0002-9394(01)01373-3
   Birch DG, 2018, RETINA-J RET VIT DIS, V38, P364, DOI 10.1097/IAE.0000000000001536
   Bressler NM, 2004, OPHTHALMOLOGY, V111, P1993, DOI 10.1016/j.ophtha.2004.07.023
   Bringmann A, 2018, PROG RETIN EYE RES, V66, P49, DOI 10.1016/j.preteyeres.2018.03.006
   Chang W, 2014, AM J OPHTHALMOL, V157, P1250, DOI 10.1016/j.ajo.2014.02.007
   Childs AL, 2004, OPHTHALMOLOGY, V111, P2007, DOI 10.1016/j.ophtha.2004.07.024
   Chung H, 2017, SURV OPHTHALMOL, V62, P506, DOI 10.1016/j.survophthal.2017.03.003
   da Cruz L, 2018, NAT BIOTECHNOL, V36, P1, DOI 10.1038/nbt.4114
   Davis JL, 2019, RETINA-J RET VIT DIS, V39, P2, DOI 10.1097/IAE.0000000000002609
   Davis JL, 2018, AM J OPHTHALMOL, V196, pXXV, DOI 10.1016/j.ajo.2018.08.038
   Ehlers JP, 2018, OPHTHALMOLOGY, V125, P1014, DOI 10.1016/j.ophtha.2017.12.037
   Ehlers JP, 2015, OSLI RETINA, V46, P327, DOI 10.3928/23258160-20150323-05
   Falkner CI, 2007, GRAEF ARCH CLIN EXP, V245, P490, DOI 10.1007/s00417-005-0184-3
   Gregori NZ, 2019, RETINA-J RET VIT DIS, V39, P9, DOI 10.1097/IAE.0000000000001646
   Grzybowski A, 2018, OPHTHALMOLOGICA, V239, P181, DOI 10.1159/000486145
   Kaplan H, 1996, BRIT J OPHTHALMOL, V80, P101, DOI 10.1136/bjo.80.2.101
   Kashani AH, 2020, OPHTHALMOL RETINA, V4, P264, DOI 10.1016/j.oret.2019.09.017
   Kashani AH, 2018, SCI TRANSL MED, V10, DOI 10.1126/scitranslmed.aao4097
   Kimura S, 2015, AM J OPHTHALMOL, V159, P683, DOI 10.1016/j.ajo.2014.12.020
   Kumar JB, 2018, OPHTHALMOL RETINA, V2, P1041, DOI 10.1016/j.oret.2018.02.013
   Loewenstein A, 1997, OPHTHALMIC SURG LAS, V28, P774
   Maguire AM, 2008, NEW ENGL J MED, V358, P2240, DOI 10.1056/NEJMoa0802315
   Maguire AM, 2009, LANCET, V374, P1597, DOI 10.1016/S0140-6736(09)61836-5
   Margo Jordan A, 2016, Retin Cases Brief Rep, V10, P48, DOI 10.1097/ICB.0000000000000175
   Meyer CH, 2020, GRAEF ARCH CLIN EXP, V258, P2151, DOI 10.1007/s00417-020-04735-3
   Meyer Carsten H, 2017, Int J Retina Vitreous, V3, P44, DOI 10.1186/s40942-017-0094-7
   Ochakovski GA, 2017, INVEST OPHTH VIS SCI, V58, P4155, DOI 10.1167/iovs.17-22402
   Ochakovski GA, 2017, FRONT NEUROSCI-SWITZ, V11, DOI 10.3389/fnins.2017.00174
   Peng YQ, 2017, OPHTHALMIC RES, V58, P217, DOI 10.1159/000479157
   PEYMAN GA, 1991, OPHTHALMIC SURG LAS, V22, P102
   Rachitskaya AV, 2016, OSLI RETINA, V47, P999, DOI 10.3928/23258160-20161031-03
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Russell S, 2017, LANCET, V390, P849, DOI 10.1016/S0140-6736(17)31868-8
   SCHEIN SJ, 1988, J COMP NEUROL, V269, P479, DOI 10.1002/cne.902690403
   Schwartz SD, 2015, LANCET, V385, P509, DOI 10.1016/S0140-6736(14)61376-3
   Sharma R, 2019, SCI TRANSL MED, V11, DOI 10.1126/scitranslmed.aat5580
   Stanzel B, 2019, ADV EXP MED BIOL, V1186, P141, DOI 10.1007/978-3-030-28471-8_6
   Stanzel BV, 2012, INVEST OPHTH VIS SCI, V53, P490, DOI 10.1167/iovs.11-8260
   Takahashi K, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0209996
   VALENTINO TL, 1995, ARCH OPHTHALMOL-CHIC, V113, P932, DOI 10.1001/archopht.1995.01100070106033
   Xue K, 2017, EYE, V31, P1308, DOI 10.1038/eye.2017.158
   Xue KM, 2018, NAT MED, V24, P1507, DOI 10.1038/s41591-018-0185-5
   Yee P, 2021, BRIT J OPHTHALMOL, V105, P403, DOI 10.1136/bjophthalmol-2020-316045
   Yu Q, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/250323
NR 45
TC 6
Z9 6
U1 0
U2 0
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 2164-2591
J9 TRANSL VIS SCI TECHN
JI Transl. Vis. Sci. Technol.
PD JAN
PY 2021
VL 10
IS 1
DI 10.1167/tvst.10.1.10
PG 13
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA RF6JV
UT WOS:000634949300010
PM 33510949
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Gross, N
   Ranjbar, M
   Evers, C
   Hua, J
   Martin, G
   Schulze, B
   Michaelis, U
   Hansen, LL
   Agostini, HT
AF Gross, Nikolai
   Ranjbar, Mahdy
   Evers, Charlotte
   Hua, Jing
   Martin, Gottfried
   Schulze, Brita
   Michaelis, Uwe
   Hansen, Lutz L.
   Agostini, Hansjuergen T.
TI Choroidal neovascularization reduced by targeted drug delivery with
   cationic liposome-encapsulated paclitaxel or targeted photodynamic
   therapy with verteporfin encapsulated in cationic liposomes
SO MOLECULAR VISION
LA English
DT Article
ID IMPROVES ANTITUMORAL EFFICACY; MACULAR DEGENERATION; PROLIFERATIVE
   VITREORETINOPATHY; RAT MODEL; ANGIOGENESIS; TAXOL; RANIBIZUMAB;
   INHIBITION; GROWTH; MOUSE
AB Purpose: Intravitreal antivascular endothelial growth factor (anti-VEGF) application has revolutionized the treatment of choroidal neovascularization (CNV), a hallmark of wet age-related macular degeneration. However, additional treatment options are desirable as not all CNV lesions respond to anti-VEGF injections. Here, we assessed the feasibility of targeted delivery of cationic liposome-encapsulated paclitaxel (EndoTAG-1) in treating CNV. Furthermore, we investigated whether a new formulation of verteporfin encapsulated in cationic liposomes (CL-VTP) enhances the effect of photodynamic therapy (PDT).
   Methods: EndoTAG-1, LipoSPA, and CL-VTP were produced by encapsulating paclitaxel, succinyl-paclitaxel, or verteporfin in cationic liposomes (CL). Mice underwent argon laser coagulations at day 0 (D0) to induce CNV. EndoTAG-1 and LipoSPA were injected into the tail vein at D1, D3, D5, D7, and D9. Taxol, CL, or trehalose buffer alone was injected in control animals. At D10, all animals were perfused with fluorescein isothiocyanate (FITC)-dextran. Flatmounts comprising the retinal pigment epithelium, choroid, and sclera were prepared for quantifying the CNV by measuring the area of lesions perfused with FITC-dextran. For PDT, mice received an injection with CL-VTP or Visudyne at D10. One eye was treated with PDT while the other served as a control. Evaluation of RPE-choroid-scleral and retinal flatmounts was performed at D12, D14, or D17. Perfusion with FITC-dextran and tetramethylrhodamine-5-(and 6)-isothiocyanate-lectin staining was used to distinguish between perfused and non-perfused choroidal vessels.
   Results: EndoTAG-1 or LipoSPA significantly reduced CNV size to 15% compared to trehalose controls. The mean CNV area of mice treated with CL was reduced (though not significantly) to about one-half of the value of the trehalose control group. The same was observed for paclitaxel. Thus, the reduction in the CNV size between treatment with CL and treatment with EndoTAG-1 or LipoSPA was 40%, which was not significant. PDT using either CL-VTP or Visudyne reduced CNV size to 65% (D17) of trehalose control size. CNV size was further diminished to 56% with Visudyne and 53% with CL-VTP when PDT was repeated twice. Most importantly, PDT-associated retinal damage was less pronounced using CL-VTP compared to Visudyne.
   Conclusions: Systemic intravenous injection of paclitaxel (EndoTAG-1)- or succinyl-paclitaxel (LipoSPA)- loaded CL had a significant antiangiogenic effect in a CNV mouse model. PDT with CL-VTP was as effective as Visudyne in neovascular obliteration but induced less tissue damage. Our data suggest that systemic application of cationic liposome formulations may serve to treat ocular neovascular diseases. This approach may reduce the need for intraocular injections and may benefit patients with neovascular lesions irresponsive to anti-VEGF treatment.
C1 [Gross, Nikolai; Ranjbar, Mahdy; Evers, Charlotte; Hua, Jing; Martin, Gottfried; Hansen, Lutz L.; Agostini, Hansjuergen T.] Univ Freiburg Klinikum, Augenklin, Freiburg, Germany.
   [Schulze, Brita; Michaelis, Uwe] MediGene AG, Martinsried, Germany.
C3 University of Freiburg; University of Hamburg; University Medical Center
   Hamburg-Eppendorf
RP Agostini, HT (通讯作者)，Univ Augenklin Freiburg, Killianstr 5, D-79106 Freiburg, Germany.
EM hansjuergen.agostini@uniklinik-freiburg.de
FU BMBF (Bundesministerium fur Bildung und Forschung) [0,313,744]
FX This research was supported by a grant from the BMBF (Bundesministerium
   fur Bildung und Forschung, Grant no. 0,313,744). The authors wish to
   thank Christiane Fingerhut (MediGene AG) as well as Anne Mattes, Beatrix
   Flugel, and Marc Leinweber for excellent technical support. Disclosure:
   N. Gross, None; M. Ranjbar, None; C. Evers, None; J. Hua, None; B.
   Schulze, former employee of MediGene AG; U. Michaelis, former employee
   of MediGene AG; L.L. Hansen, None; G. Martin, None; H.T. Agostini, None
CR ALLISON BA, 1994, BRIT J CANCER, V69, P833, DOI 10.1038/bjc.1994.162
   Chan WM, 2010, GRAEF ARCH CLIN EXP, V248, P613, DOI 10.1007/s00417-010-1307-z
   DANIELS SA, 1990, GRAEF ARCH CLIN EXP, V228, P513, DOI 10.1007/BF00918482
   Das RA, 2011, CURR DRUG TARGETS, V12, P182
   Ebrahim S, 2005, SURV OPHTHALMOL, V50, P167, DOI 10.1016/j.survophthal.2004.12.006
   Eichhorn ME, 2007, CANCER BIOL THER, V6, P920, DOI 10.4161/cbt.6.6.4207
   Eichhorn ME, 2006, CANCER BIOL THER, V5, P89, DOI 10.4161/cbt.5.1.2346
   Ferrara N, 2006, RETINA-J RET VIT DIS, V26, P859, DOI 10.1097/01.iae.0000242842.14624.e7
   Haimovici R, 1997, CURR EYE RES, V16, P83, DOI 10.1076/ceyr.16.2.83.5088
   Herber-Jonat S, 2011, INFLAMM RES, V60, P245, DOI 10.1007/s00011-010-0260-y
   Houle JM, 2002, J CLIN PHARMACOL, V42, P547, DOI 10.1177/00912700222011607
   Hua J, 2012, MOL VIS, V18, P1045
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Ju M, 2008, INVEST OPHTH VIS SCI, V49, P662, DOI 10.1167/iovs.07-0195
   Klauber N, 1997, CANCER RES, V57, P81
   Koudelka S, 2012, J CONTROL RELEASE, V163, P322, DOI 10.1016/j.jconrel.2012.09.006
   Kourlas H, 2007, CLIN THER, V29, P1850, DOI 10.1016/j.clinthera.2007.09.008
   Koz OG, 2007, J GLAUCOMA, V16, P610, DOI 10.1097/IJG.0b013e31815c89b9
   Kramer M, 1996, OPHTHALMOLOGY, V103, P427
   Krasnici S, 2003, INT J CANCER, V105, P561, DOI 10.1002/ijc.11108
   Kunstfeld R, 2003, J INVEST DERMATOL, V120, P476, DOI 10.1046/j.1523-1747.2003.12057.x
   Lu F, 2009, INVEST OPHTH VIS SCI, V50, P3890, DOI 10.1167/iovs.08-2833
   Odergren A, 2006, CURR EYE RES, V31, P765, DOI 10.1080/02713680600865045
   Schmitt-Sody M, 2003, CLIN CANCER RES, V9, P2335
   Strieth S, 2008, CLIN CANCER RES, V14, P4603, DOI 10.1158/1078-0432.CCR-07-4738
   Strieth S, 2008, INT J CANCER, V122, P452, DOI 10.1002/ijc.23088
   Thurston G, 1998, J CLIN INVEST, V101, P1401, DOI 10.1172/JCI965
   Tobe T, 1998, AM J PATHOL, V153, P1641, DOI 10.1016/S0002-9440(10)65753-7
   VANBOCKXMEER FM, 1985, INVEST OPHTH VIS SCI, V26, P1140
   Zacks DN, 2002, INVEST OPHTH VIS SCI, V43, P2384
NR 30
TC 33
Z9 34
U1 1
U2 26
PU MOLECULAR VISION
PI ATLANTA
PA C/O JEFF BOATRIGHT, LAB B, 5500 EMORY EYE CENTER, 1327 CLIFTON RD, N E,
   ATLANTA, GA 30322 USA
SN 1090-0535
J9 MOL VIS
JI Mol. Vis.
PD JAN 10
PY 2013
VL 19
BP 54
EP 61
PG 8
WC Biochemistry & Molecular Biology; Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Ophthalmology
GA 089KH
UT WOS:000314908900001
PM 23335851
DA 2022-11-30
ER

PT J
AU Trieschmann, M
   Spital, G
   Lommatzsch, A
   van Kuijk, E
   Fitzke, F
   Bird, AC
   Pauleikhoff, D
AF Trieschmann, M
   Spital, G
   Lommatzsch, A
   van Kuijk, E
   Fitzke, F
   Bird, AC
   Pauleikhoff, D
TI Macular pigment: quantitative analysis on autofluorescence images
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
ID AGE-RELATED MACULOPATHY; FUNDUS AUTOFLUORESCENCE; OPTICAL-DENSITY;
   GRADING SYSTEM; IN-VIVO; ZEAXANTHIN; LUTEIN; DEGENERATION; CAROTENOIDS;
   EYES
AB Background: Macular pigment (MP) reduces oxidative damage in the central retina and can be quantified by flicker-photometric analysis (HFP) of MP optical density. These analyses demonstrate a very good correlation with central absorption by MP on autofluorescence (AF) images. With these techniques different types of MP-distribution have been described. In the present study a quantification analysis of MP in AF images was developed to verify these MP types and to compare MP distribution patterns between healthy individuals and those with age-related macular degeneration (AMD). Methods: AF images (HRA) were analysed with respect to the area of central and paracentral absorption in 400 eyes with a computerised analysis program of MP optical density. The patients were between 41 and 90 years old (mean 67.2 years); 168 were male and 232 female, and 253 had early AMD and 147 showed no AMD characteristics. The central MP concentrations (peak) were measured, the amount of MP values within the first 8-pixel radius ("C"), the total amount of MP within a 120-pixel radius ("T") were calculated as the volume of the MP values over the regarded radius and the C/T ratio was registered. Results: Four types of MP distribution (type 1, intense central and paracentral MP; type 2, less intense central and paracentral MP; type 3, only central MP; type 4, only paracentral MP) were identified. The differences in MP distribution were confirmed and clearly characterised by quantitative analyses of peak, total MP ("T"), central MP ("C") and C/T ratio: mean peak in type 1, 0.65; type 2, 0.42; type 3, 0.42; type 4, 0.29; mean total amount of MP in 120-pixel radius ("T") in type 1, 5829.0; type 2, 4412.5; type 3, 2709; type 4, 4302.8. MP types with lower levels of MP were significantly more often observed in the AMD group (AMD: type 1, 120=47.4%; types 2-4, 133=52.6%; healthy eyes: type 1, 112=76.2%; types 2-4, 35=23.8%) (P<0.0001) Conclusions: Analysis of MP on AF images is a quantitative method for investigation of MR With this method a wide variation in concentration and distribution of MP could be seen in the population. Four different types of MP distribution could be characterised and quantitatively distinguished. Reduced levels of MP seem to be associated with a higher risk of development of AMD as they were significantly more often observed in the AMD group. This strategy of quantitative MP analysis on AF images is easily practicable and may be used in further studies to investigate the role of MP as a potential risk factor for AMD.
C1 St Franziskus Hosp, Dept Ophthalmol, D-48145 Munster, Germany.
   Univ Texas, Med Branch, Galveston, TX 77550 USA.
   Inst Ophthalmol, Dept Visual Sci, London WC1H 9QS, England.
   Moorfields Eye Hosp, London, England.
C3 St. Franziskus-Hospital; University of Texas System; University of Texas
   Medical Branch Galveston; University of London; University College
   London; University of London; University College London; Moorfields Eye
   Hospital NHS Foundation Trust
RP Pauleikhoff, D (通讯作者)，St Franziskus Hosp, Dept Ophthalmol, Hohenzollernring 74, D-48145 Munster, Germany.
EM dapauleikhoff@muenster.de
RI Fitzke, Fred/C-3535-2008
CR Beatty S, 1999, BRIT J OPHTHALMOL, V83, P867, DOI 10.1136/bjo.83.7.867
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Beatty S, 2000, OPHTHAL PHYSL OPT, V20, P105, DOI 10.1016/S0275-5408(99)00039-3
   Beatty S, 2001, INVEST OPHTH VIS SCI, V42, P439
   Berendschot TTJM, 2002, INVEST OPHTH VIS SCI, V43, P1928
   Berendschot TTJM, 2001, J OPT SOC AM A, V18, P1445, DOI 10.1364/JOSAA.18.001445
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Bone RA, 1997, EXP EYE RES, V64, P211, DOI 10.1006/exer.1996.0210
   BONE RA, 1985, VISION RES, V25, P1531, DOI 10.1016/0042-6989(85)90123-3
   Bone RA, 2001, INVEST OPHTH VIS SCI, V42, P235
   BONE RA, 1988, INVEST OPHTH VIS SCI, V29, P843
   CIULLA TA, 2001, OPHTHALMOLOGY, V108, P350
   Curcio CA, 1998, INVEST OPHTH VIS SCI, V39, P1085
   Delori FC, 2001, J OPT SOC AM A, V18, P1212, DOI 10.1364/JOSAA.18.001212
   Hammond BR, 1997, INVEST OPHTH VIS SCI, V38, P1795
   HAMMOND BR, 1992, INVEST OPHTH VIS SCI, V33, P350
   Hammond BR, 1996, EXP EYE RES, V62, P713
   Hammond BR, 2000, INVEST OPHTH VIS SCI, V41, P1492
   KIRSCHFELD K, 1982, PROC R SOC SER B-BIO, V216, P71, DOI 10.1098/rspb.1982.0061
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Landrum J T, 1997, Adv Pharmacol, V38, P537
   LANDRUM JT, 1995, INVEST OPHTHALMOL  S, V36, P857
   Leung IYF, 2001, INVEST OPHTH VIS SCI, V42, P466
   Lois N, 2000, BRIT J OPHTHALMOL, V84, P741, DOI 10.1136/bjo.84.7.741
   Moreland J. D., 1984, DOC OPHTHALMOL P SER, P127
   Moreland JD, 1998, VISION RES, V38, P3241, DOI 10.1016/S0042-6989(98)00013-3
   Nussbaum J J, 1981, Retina, V1, P296, DOI 10.1097/00006982-198101040-00007
   PAULEIKHOFF D, 2002, INVEST OPHTHALMOL  S, pS102
   PEASE PL, 1987, VISION RES, V27, P705, DOI 10.1016/0042-6989(87)90067-8
   Rapp LM, 2000, INVEST OPHTH VIS SCI, V41, P1200
   Robson AG, 2003, VISION RES, V43, P1765, DOI 10.1016/S0042-6989(03)00280-3
   SEDDON JM, 1994, JAMA-J AM MED ASSOC, V272, P1413, DOI 10.1001/jama.272.18.1413
   SNODDERLY DM, 1984, INVEST OPHTH VIS SCI, V25, P660
   SNODDERLY DM, 1991, INVEST OPHTH VIS SCI, V32, P268
   SNODDERLY DM, 1995, AM J CLIN NUTR, V62, P1448
   Sommerburg O, 1999, CURR EYE RES, V19, P491, DOI 10.1076/ceyr.19.6.491.5276
   SPERDUTO RD, 1993, ARCH OPHTHALMOL-CHIC, V111, P104
   VANKUIJK FJG, INVEST OPHTHALMOL S, pS102
   VIENOT F, 1997, 14 S IRGCVD
   von Ruckmann A, 1999, GRAEF ARCH CLIN EXP, V237, P1, DOI 10.1007/s004170050186
   VONRUCKMANN A, 1995, BRIT J OPHTHALMOL, V79, P407, DOI 10.1136/bjo.79.5.407
   vonRuckmann A, 1997, INVEST OPHTH VIS SCI, V38, P478
NR 42
TC 74
Z9 80
U1 0
U2 4
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0721-832X
EI 1435-702X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD DEC
PY 2003
VL 241
IS 12
BP 1006
EP 1012
DI 10.1007/s00417-003-0796-4
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 767AC
UT WOS:000188400600008
PM 14618343
DA 2022-11-30
ER

PT J
AU Guigou, S
   Michel, T
   Merite, PY
   Coupier, L
   Meyer, F
AF Guigou, S.
   Michel, T.
   Merite, P-Y
   Coupier, L.
   Meyer, F.
TI Home vision monitoring in patients with nnaculopathy: Real-life study of
   the OdySight application
SO JOURNAL FRANCAIS D OPHTALMOLOGIE
LA English
DT Article
DE AMD; Home monitoring; Telemedicine; Smartphone; Amsler grid; App;
   m-Health; Remote monitoring
ID DEVICE
AB Introduction. - The goal of the present study was to analyze the implementation and clinical efficacy of OdySight, a mobile medical application for the remote monitoring of patients with maculopathy.
   Materials and methods. - In all, 60 patients with edematous maculopathies receiving traditional clinical treatment (PRN or Treat & Extend) were provided with OdySight to detect changes in visual acuity from home. To determine both the feasibility and reliability of the application, its use by patients (both testing and game play), as well as the processing of alerts by the clinical team, were analyzed during the first year.
   Results. - The female-to-male ratio was 3:2, with a mean age of 64 years. 52% of patients presented with age-related macular degeneration, 31% with high myopia, 11% with retinal vein occlusion, and 6% with diabetic maculopathy. The conversion rate (defined as the percentage of patients completing at least one test following prescription) and the nine-month retention rate (percentage of active patients) were 61% and 24% respectively. Patients aged 50 to 70 years and those whose use of the app included game play represent 75% of active patients at 9 months. The 22 active patients performed 483 visual acuity tests, completed 1,667 game sessions, and underwent 77 in-person consultations. During the trial period, the clinical team processed 19 alerts, on average in fewer than 6 days. Decreases in visual acuity were detected with a sensitivity of 92% and specificity of 99%.
   Discussion. - The use of connected and mobile devices today is widespread, as is interest in mobile medical applications. Long-term treatments for maculopathies can be a difficult burden to bear, both for patients and healthcare practitioners. Overcoming the challenges associated with the successful remote detection of recurrences thus represents a significant opportunity for improving patient care. The implementation of novel digital tools requires the cooperation of the clinical team as a whole, to both inform and motivate patients. OdySight demonstrates satisfactory detection rates, thanks to reliable and reproducible home testing, and can thus serve as a supplementary tool for patients whose consultations are often spaced several months apart. Implementation can be nonetheless improved by facilitating alert processing, a goal which necessitates active adaptation of clinical practices. In general, active patients were very satisfied with this personalized service.
   Conclusion. - Improved medical support, plus the amusing nature of the tests and games, both bolster long-term use of the OdySight app. The application allows for the remote monitoring of changes in visual acuity and affords patients and practitioners an added level of protection, particularly during long intervals between treatments and at the end of a treatment course. To ensure proper implementation, clinics should focus on reinforcing and modernizing the clinical pathway, from patient intake to the injection room. (C) 2021 Elsevier Masson SAS. All rights reserved.
C1 [Guigou, S.; Merite, P-Y; Meyer, F.] Aix Vis, Collectif P1,5,44, F-13090 Aix En Provence, France.
   [Michel, T.; Coupier, L.] Ctr Hosp Pays Aix, Serv Ophtalmol, Aix En Provence, France.
RP Guigou, S (通讯作者)，Aix Vis, Collectif P1,5,44, F-13090 Aix En Provence, France.
EM s.guigou@wanadoo.fr
CR Brucker J, 2019, OPHTHALMOL THER, V8, P461, DOI 10.1007/s40123-019-0203-9
   Chakravarthy U, 2016, OPHTHALMOLOGY, V123, P1731, DOI 10.1016/j.ophtha.2016.04.005
   Chamard C, 2019, J FR OPHTALMOL, V42, P1049, DOI 10.1016/j.jfo.2019.02.017
   Chew EY, 2014, CONTEMP CLIN TRIALS, V37, P294, DOI 10.1016/j.cct.2014.02.003
   Maloca P, 2018, TRANSL VIS SCI TECHN, V7, DOI 10.1167/tvst.7.4.8
   Parfitt A, 2019, BMJ OPEN OPHTHALMOL, V4, DOI 10.1136/bmjophth-2019-000276
   Razavi H, 2018, CLIN EXP OPHTHALMOL, V46, P480, DOI 10.1111/ceo.13097
   Schmid MK, 2019, EYE, V33, P1584, DOI 10.1038/s41433-019-0455-6
   Ward E, 2021, EYE, V35, P592, DOI 10.1038/s41433-020-0910-4
   Williams AM, 2020, OPHTHALMOL THER, DOI 10.1007/s40123-020-00255-9
NR 10
TC 2
Z9 2
U1 1
U2 3
PU MASSON EDITEUR
PI MOULINEAUX CEDEX 9
PA 21 STREET CAMILLE DESMOULINS, ISSY, 92789 MOULINEAUX CEDEX 9, FRANCE
SN 0181-5512
EI 1773-0597
J9 J FR OPHTALMOL
JI J. Fr. Ophthamol.
PD JUN
PY 2021
VL 44
IS 6
BP 873
EP 881
DI 10.1016/j.jfo.2020.09.034
EA JUN 2021
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA SQ4BM
UT WOS:000660303700030
PM 34024655
DA 2022-11-30
ER

PT J
AU Nunez-Alvarez, C
   Suarez-Barrio, C
   Aguado, SD
   Osborne, NN
AF Nunez-Alvarez, Claudia
   Suarez-Barrio, Carlota
   del Olmo Aguado, Susana
   Osborne, Neville N.
TI Blue light negatively affects the survival of ARPE19 cells through an
   action on their mitochondria and blunted by red light
SO ACTA OPHTHALMOLOGICA
LA English
DT Article
DE ARPE19 cells; blue light toxicity; mitochondria; neuroprotection; red
   light; trans-epithelial membrane resistance
ID RETINAL-PIGMENT EPITHELIUM; CYTOCHROME-C RELEASE; NEAR-INFRARED LIGHT;
   AGE-RELATED-CHANGES; OXIDATIVE STRESS; HEME OXYGENASE-1; VISIBLE-LIGHT;
   HUMAN RPE; INDUCED APOPTOSIS; TIGHT JUNCTIONS
AB Purpose To ascertain whether red light, known to enhance mitochondrial function, can blunt a blue light insult to ARPE19 cells in culture. Methods Semi-confluent ARPE19 cells cultured in 10% FBS were subjected to various regimes of treatment with blue (465-475 nm, 800 lux, 26 W/m(2)) and red (625-635 nm, 950 lux, 6.5 W/m(2)) light, as well as with toxins that inactivate specific enzymes associated with mitochondrial oxidative phosphorylation. Cultures were then analysed for cell viability (MTT assay), mitochondrial status (JC-1), ROS formation, immunocytochemistry and the activation of specific proteins by electrophoresis/Western blotting. In addition, ARPE19 cells were cultured in polycarbonate membrane inserts in culture medium containing 1% FBS. Such cultures were exposed to cycles of red, blue or a combination of red and blue light for up to 6 weeks. Culture medium was changed and the trans-epithelium membrane resistance (TER) of the inserts-containing cells was measured twice weekly. Results ARPE19 cells in culture are affected negatively when exposed to blue light. This is indicated by a loss of viability, a depolarization of their mitochondria and a stimulation of ROS. Moreover, blue light causes an up-regulation of HO-1 and phospho-p-38-MAPK and a cleavage of apoptosis inhibitory factor, proteins which are all known to be activated during cell death. All of these negative effects of blue light are significantly blunted by the red light administered after the blue light insult in each case. ARPE19 cell loss of viability and mitochondrial potential caused by toxins that inhibit specific mitochondrial enzyme complexes was additive to an insult delivered by blue light in each case. After a time, ARPE19 cells in culture express the tight junction protein ZO-1, which is affected by blue light. The development of tight junctions between ARPE19 cells grown in inserts reached a steady peak of resistance after about 40 days and then increased very slightly over the next 40 days when still in darkness. However, maximum resistance was significantly attenuated, when cultures were treated with cycles of blue light after the initial 40 days in the dark and counteracted significantly when the blue light cycle insult was combined with red light. Conclusion Blue light affects mitochondrial function and also the development tight junctions between ARPE19 cells, which results in a loss of cell viability. Importantly, red light delivered after a blue light insult is significantly blunted. These findings argue for the therapeutic use of red light as a noninvasive procedure to attenuate insults caused by blue light and other insults to retinal pigment epithelial cell mitochondria that are likely to occur in age-related macular degeneration.
C1 [Nunez-Alvarez, Claudia; Suarez-Barrio, Carlota; del Olmo Aguado, Susana; Osborne, Neville N.] Ophthalmol Res Fdn, Avda Doctores Fernandez Vega 34, E-33012 Oviedo, Asturias, Spain.
RP Osborne, NN (通讯作者)，Ophthalmol Res Fdn, Avda Doctores Fernandez Vega 34, E-33012 Oviedo, Asturias, Spain.
EM Neville.osborne@eye.ox.ac.uk
RI Núñez-Álvarez, Claudia/AAF-6528-2021; del Olmo Aguado,
   Susana/AAY-3497-2021
OI Núñez-Álvarez, Claudia/0000-0001-5287-4058; del Olmo Aguado,
   Susana/0000-0002-2867-7254
FU Fundacion BBVA; Catedra de Biomedicina (Chair in Biomedicine)
FX Financial support is gratefully acknowledged from the Fundacion BBVA.
   NNO has a Catedra de Biomedicina (Chair in Biomedicine).
CR Algvere PV, 2006, ACTA OPHTHALMOL SCAN, V84, P4, DOI 10.1111/j.1600-0420.2005.00627.x
   Amersi F, 1999, J CLIN INVEST, V104, P1631, DOI 10.1172/JCI7903
   ANDLEY UP, 1990, PHOTODERMATOL PHOTO, V7, P98
   Artus C, 2010, EMBO J, V29, P1585, DOI 10.1038/emboj.2010.43
   Balogun E, 2003, BIOCHEM J, V371, P887, DOI 10.1042/BJ20021619
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Beckman KB, 1998, ANN NY ACAD SCI, V854, P118, DOI 10.1111/j.1749-6632.1998.tb09897.x
   Begum R, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057828
   Bennett MC, 1996, J NEUROCHEM, V66, P2606
   Boulton M, 2001, J PHOTOCH PHOTOBIO B, V64, P144, DOI 10.1016/S1011-1344(01)00227-5
   BOULTON M, 1990, VISION RES, V30, P1291, DOI 10.1016/0042-6989(90)90003-4
   Canter JA, 2008, PHARMACOGENOMICS J, V8, P71, DOI 10.1038/sj.tpj.6500470
   Chen Q, 2003, CELL DEATH DIFFER, V10, P323, DOI 10.1038/sj.cdd.4401148
   CHEN XY, 1993, PHOTOCHEM PHOTOBIOL, V58, P425, DOI 10.1111/j.1751-1097.1993.tb09585.x
   Cuadrado A, 2010, BIOCHEM J, V429, P403, DOI 10.1042/BJ20100323
   Dai CS, 2016, FOOD CHEM TOXICOL, V95, P52, DOI 10.1016/j.fct.2016.06.025
   Datta S, 2017, PROG RETIN EYE RES, V60, P201, DOI 10.1016/j.preteyeres.2017.03.002
   Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264-6021:3510095
   del Olmo-Aguado S, 2016, NEUROCHEM RES, V41, P2324, DOI 10.1007/s11064-016-1946-5
   del Olmo-Aguado S, 2012, PHOTOCHEM PHOTOBIOL, V88, P1346, DOI 10.1111/j.1751-1097.2012.01120.x
   Delavallee L, 2011, IUBMB LIFE, V63, P221, DOI 10.1002/iub.432
   Dunn KC, 1996, EXP EYE RES, V62, P155, DOI 10.1006/exer.1996.0020
   Eells JT, 2016, ADV EXP MED BIOL, V854, P437, DOI 10.1007/978-3-319-17121-0_58
   Egorov SY, 1999, BIOCHEMISTRY-MOSCOW+, V64, P1117
   FEENEYBURNS L, 1984, INVEST OPHTH VIS SCI, V25, P195
   Feher J, 2006, NEUROBIOL AGING, V27, P983, DOI 10.1016/j.neurobiolaging.2005.05.012
   Feigl B, 2009, PROG RETIN EYE RES, V28, P63, DOI 10.1016/j.preteyeres.2008.11.004
   Fitzgerald M, 2013, REV NEUROSCIENCE, V24, P205, DOI 10.1515/revneuro-2012-0086
   GarciaSilva MT, 1997, PEDIATR NEUROL, V17, P165, DOI 10.1016/S0887-8994(97)00048-9
   Godley BF, 2005, J BIOL CHEM, V280, P21061, DOI 10.1074/jbc.M502194200
   Gorgidze LA, 1998, BIOSCIENCE REP, V18, P215, DOI 10.1023/A:1020104914726
   GORN RA, 1967, ARCH OPHTHALMOL-CHIC, V77, P115, DOI 10.1001/archopht.1967.00980020117025
   Gouras P, 2016, GRAEF ARCH CLIN EXP, V254, P1221, DOI 10.1007/s00417-016-3342-x
   GRIGNOLO A, 1969, OPHTHALMOLOGICA, V157, P43, DOI 10.1159/000305619
   Hanus J, 2015, AGEING RES REV, V24, P286, DOI 10.1016/j.arr.2015.09.002
   HARMAN D, 1981, P NATL ACAD SCI-BIOL, V78, P7124, DOI 10.1073/pnas.78.11.7124
   He MH, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0084800
   Heiskanen KM, 1999, J BIOL CHEM, V274, P5654, DOI 10.1074/jbc.274.9.5654
   Himori N, 2014, J NEUROSCI RES, V92, P1134, DOI 10.1002/jnr.23398
   Hockberger PE, 1999, P NATL ACAD SCI USA, V96, P6255, DOI 10.1073/pnas.96.11.6255
   Huang LY, 2012, LASER SURG MED, V44, P490, DOI 10.1002/lsm.22045
   Ivandic BT, 2008, PHOTOMED LASER SURG, V26, P241, DOI 10.1089/pho.2007.2132
   Jarrett SG, 2007, OPHTHALMIC RES, V39, P213, DOI 10.1159/000104683
   Ji D, 2011, APOPTOSIS, V16, P425, DOI 10.1007/s10495-011-0574-4
   JUNG DW, 1990, BIOCHEMISTRY-US, V29, P4121, DOI 10.1021/bi00469a015
   Karu TI, 2005, PHOTOMED LASER SURG, V23, P355, DOI 10.1089/pho.2005.23.355
   Karu TI, 2004, PHOTOCHEM PHOTOBIOL, V80, P366, DOI 10.1562/2004-03-25-RA-123.1
   Karunadharma PP, 2010, INVEST OPHTH VIS SCI, V51, P5470, DOI 10.1167/iovs.10-5429
   King A, 2004, PHOTOCHEM PHOTOBIOL, V79, P470, DOI 10.1562/LE-03-17.1
   Klein BEK, 2007, AM J OPHTHALMOL, V144, P961, DOI 10.1016/j.ajo.2007.08.016
   Knels L, 2011, EUR J NEUROSCI, V34, P548, DOI 10.1111/j.1460-9568.2011.07790.x
   Krigel A, 2016, NEUROSCIENCE, V339, P296, DOI 10.1016/j.neuroscience.2016.10.015
   Kuse Y, 2014, SCI REP-UK, V4, DOI 10.1038/srep05223
   KUWABARA T, 1968, ARCH OPHTHALMOL-CHIC, V79, P69, DOI 10.1001/archopht.1968.03850040071019
   Lane N, 2006, NATURE, V443, P901, DOI 10.1038/443901a
   Leary SC, 2002, J BIOL CHEM, V277, P11321, DOI 10.1074/jbc.M112303200
   Li GY, 2008, BRAIN RES, V1188, P35, DOI 10.1016/j.brainres.2007.10.073
   Liang HL, 2006, NEUROSCIENCE, V139, P639, DOI 10.1016/j.neuroscience.2005.12.047
   Lin HJ, 2011, INVEST OPHTH VIS SCI, V52, P3521, DOI 10.1167/iovs.10-6163
   Margrain TH, 2004, PROG RETIN EYE RES, V23, P523, DOI 10.1016/j.preteyeres.2004.05.001
   Marino S, 2007, NEUROTOXICOLOGY, V28, P622, DOI 10.1016/j.neuro.2007.01.005
   Mellerio J., 1994, PRINCIPLES PRACTICE, V1, P1326
   Merry GF, 2017, ACTA OPHTHALMOL, V95, pE270, DOI 10.1111/aos.13354
   MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4
   Noell W K, 1966, Invest Ophthalmol, V5, P450
   NOELL WK, 1979, PHOTOCHEM PHOTOBIOL, V29, P717, DOI 10.1111/j.1751-1097.1979.tb07756.x
   Nunez-Alvarez C, 2017, EXP EYE RES, V161, P106, DOI 10.1016/j.exer.2017.06.008
   Ono K, 2000, CELL SIGNAL, V12, P1, DOI 10.1016/S0898-6568(99)00071-6
   Organisciak DT, 2010, PROG RETIN EYE RES, V29, P113, DOI 10.1016/j.preteyeres.2009.11.004
   Organisciak DT, 1998, INVEST OPHTH VIS SCI, V39, P1107
   Orrenius S, 2007, ANNU REV PHARMACOL, V47, P143, DOI 10.1146/annurev.pharmtox.47.120505.105122
   Osborne NN, 2008, J NEUROCHEM, V105, P2013, DOI 10.1111/j.1471-4159.2008.05320.x
   Osborne NN, 2016, EUR J PHARMACOL, V787, P127, DOI 10.1016/j.ejphar.2016.04.032
   Osborne NN, 2014, DRUG DISCOV TODAY, V19, P1613, DOI 10.1016/j.drudis.2014.05.010
   OSTEEN WK, 1972, Z ZELLFORSCH MIK ANA, V127, P306, DOI 10.1007/BF00306875
   Ott M, 2007, APOPTOSIS, V12, P913, DOI 10.1007/s10495-007-0756-2
   Pang JJ, 1998, GRAEF ARCH CLIN EXP, V236, P696, DOI 10.1007/s004170050143
   PASSARELLA S, 1984, FEBS LETT, V175, P95, DOI 10.1016/0014-5793(84)80577-3
   Peng SM, 2012, INVEST OPHTH VIS SCI, V53, P5016, DOI 10.1167/iovs.11-8311
   Perelman A, 2012, CELL DEATH DIS, V3, DOI 10.1038/cddis.2012.171
   Perez VL, 2015, TRENDS IMMUNOL, V36, P354, DOI 10.1016/j.it.2015.04.003
   Polster BM, 2013, NEUROCHEM INT, V62, P695, DOI 10.1016/j.neuint.2012.12.002
   Qamirani E, 2006, AM J PHYSIOL-HEART C, V290, pH1617, DOI 10.1152/ajpheart.00746.2005
   Qin SF, 2010, EXP EYE RES, V91, P818, DOI 10.1016/j.exer.2010.10.007
   Quirk BJ, 2011, PHOTOMED LASER SURG, V29, P143, DOI 10.1089/pho.2011.3014
   Rizzolo LJ, 2011, PROG RETIN EYE RES, V30, P296, DOI 10.1016/j.preteyeres.2011.06.002
   Roehlecke C, 2009, MOL VIS, V15, P1929
   Rozanowska M, 2005, PHOTOCHEM PHOTOBIOL, V81, P1305, DOI 10.1562/2004-11-13-IR-371
   Safiulina D, 2006, J CELL PHYSIOL, V206, P347, DOI 10.1002/jcp.20476
   SanGiovanni JP, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005508
   SARNA T, 1992, J PHOTOCH PHOTOBIO B, V12, P215, DOI 10.1016/1011-1344(92)85027-R
   Schipper HM, 2000, NEUROLOGY, V54, P1297, DOI 10.1212/WNL.54.6.1297
   SLINEY DH, 1988, INT OPHTHALMOL CLIN, V28, P246, DOI 10.1097/00004397-198802830-00017
   Sosna J, 2014, CELL MOL LIFE SCI, V71, P331, DOI 10.1007/s00018-013-1381-6
   Sui GY, 2013, BRIT J OPHTHALMOL, V97, P389, DOI 10.1136/bjophthalmol-2012-302281
   Tang ZH, 2014, J ENDOCRINOL INVEST, V37, P1165, DOI 10.1007/s40618-014-0172-8
   Ursu ON, 2014, CELL PHYSIOL BIOCHEM, V33, P52, DOI 10.1159/000356649
   Wataha JC, 2004, J DENT RES, V83, P104, DOI 10.1177/154405910408300204
   Wong-Riley MTT, 2005, J BIOL CHEM, V280, P4761, DOI 10.1074/jbc.M409650200
   Wood JPM, 2008, MOL VIS, V14, P334
   Yacout SM, 2017, PHOTOCHEM PHOTOBIOL, V93, P590, DOI 10.1111/php.12683
   Yang P, 2007, INVEST OPHTH VIS SCI, V48, P3341, DOI 10.1167/iovs.06-1340
   Ying R, 2008, BRAIN RES, V1243, P167, DOI 10.1016/j.brainres.2008.09.057
   Youn HY, 2009, J PHOTOCH PHOTOBIO B, V95, P64, DOI 10.1016/j.jphotobiol.2009.01.001
NR 104
TC 21
Z9 21
U1 2
U2 12
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1755-375X
EI 1755-3768
J9 ACTA OPHTHALMOL
JI Acta Ophthalmol.
PD FEB
PY 2019
VL 97
IS 1
BP E103
EP E115
DI 10.1111/aos.13812
PG 13
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA HJ0SF
UT WOS:000456872000028
PM 30198155
OA Bronze
DA 2022-11-30
ER

PT J
AU Hadley, D
   Orlin, A
   Brown, G
   Brucker, AJ
   Ho, AC
   Regillo, CD
   Donoso, LA
   Tian, LF
   Kaderli, B
   Stambolian, D
AF Hadley, Dexter
   Orlin, Anton
   Brown, Gary
   Brucker, Alexander J.
   Ho, Allen C.
   Regillo, Carl D.
   Donoso, Larry A.
   Tian, Lifeng
   Kaderli, Brian
   Stambolian, Dwight
TI Analysis of Six Genetic Risk Factors Highly Associated with AMD in the
   Region Surrounding ARMS2 and HTRA1 on Chromosome 10, Region q26
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID AGE-RELATED MACULOPATHY; COMPLEMENT FACTOR-H; BLUE MOUNTAINS EYE; BEAVER
   DAM EYE; MACULAR DEGENERATION; VISUAL IMPAIRMENT; SUSCEPTIBILITY GENES;
   CIGARETTE-SMOKING; POOLED FINDINGS; 3 CONTINENTS
AB PURPOSE. To determine the relationship of six genetic variants (rs10490924, rs3750848, del443ins54, rs3793917, rs11200638, and rs932275) localized to the ARMS2-HTRA1 region of chromosome 10, region q26, as risk factors for age-related macular degeneration (AMD), to define the haplotype structure of these six loci, and to confirm their genetic association with the disease.
   METHODS. Caucasian patients (n = 482) were stratified into categories based on AREDS (Age-Related Eye Disease Study) grading criteria (groups 0 and 1 served as the control, groups 3 and 4 contained subjects with AMD, and group 2 was excluded from the analysis). The six genetic variants in the ARMS2-HTRA1 region were genotyped and analyzed both independently and as a joint haplotype for association in subjects with disease (n = 291) compared with the control (n = 191).
   RESULTS. The six high-risk alleles all showed a statistically significant association with AMD (the most significant SNP was rs10490924 [P <= 3.31 x 10(-5), OR = 1.86]; the least significant SNP was rs932275 [P <= 9.15 x 10(-5), OR = 1.78]). Multi-marker analysis revealed that all six markers were in strong linkage disequilibrium with each other, and the two major haplotypes that captured > 98% of the genetic variation in the region were both significantly associated with the disease: One increased the risk of AMD and contained only risk alleles (P <= 2.20 x 10(-5)), and the other haplotype decreased the risk of AMD and contained only wild-type alleles (P <= 6.81 x 10(-5)). Furthermore, 36 individuals comprising both cases and controls were identified outside of these two major haplotypes, with at least one discordant marker.
   CONCLUSIONS. The results replicate the previously reported association between the high-risk alleles and AMD and independently confirm, for the first time, an association with AMD and the indel (del443ins54) polymorphism in a Caucasian population. Two major haplotypes that are associated with AMD and many minor novel haplotypes were identified. The novel haplotypes, identified from 36 cases and controls with discordant alleles spanning the ARMS2-HTRA1 region provide unique opportunities to gauge the relative phenotypic contributions of each of these genetic risk factors. With the identification of more discordant patients in the future, it may be possible to resolve the ongoing controversy as to which of the risk alleles and genes (ARMS2 vs. HTRA1) has the greatest impact on disease susceptibility. Future work should include the analysis of larger and more diverse populations, to further define the linkage structure of the region with a focus on phenotypic effects on AMD of the various haplotypes involving 10q26, as well as a functional analysis of the normal ARMS2 protein. (Invest Ophthalmol Vis Sci. 2010;51:2191-2196) DOI:10.1167/iovs.09-3798
C1 [Hadley, Dexter; Orlin, Anton; Brucker, Alexander J.; Tian, Lifeng; Kaderli, Brian; Stambolian, Dwight] Scheie Eye Inst, Dept Ophthalmol, Philadelphia, PA 19104 USA.
   [Hadley, Dexter; Tian, Lifeng; Kaderli, Brian; Stambolian, Dwight] Univ Penn, FM Kirby Ctr Mol Ophthalmol, Philadelphia, PA 19104 USA.
   [Brown, Gary; Ho, Allen C.; Regillo, Carl D.] Mid Atlantic Retina, Cherry Hill, NJ USA.
   [Brown, Gary; Ho, Allen C.; Regillo, Carl D.] Thomas Jefferson Univ, Wills Eye Hosp, Dept Ophthalmol, Philadelphia, PA 19107 USA.
   [Donoso, Larry A.] Philadelphia Retina Endowment Fund, Philadelphia, PA USA.
C3 University of Pennsylvania; Pennsylvania Medicine; University of
   Pennsylvania; Pennsylvania Medicine; Jefferson University
RP Orlin, A (通讯作者)，Scheie Eye Inst, Dept Ophthalmol, 51 N 39th St, Philadelphia, PA 19104 USA.
EM aorlin@gmail.com
RI Hadley, Dexter/ABB-7568-2021
OI Hadley, Dexter/0000-0003-0990-4674; Ho, Allen/0000-0003-3921-608X
FU Gilroy and Lillian P. Roberts Charitable Foundation (AJB)
FX Supported by funding from the Gilroy and Lillian P. Roberts Charitable
   Foundation (AJB).
CR Barrett JC, 2005, BIOINFORMATICS, V21, P263, DOI 10.1093/bioinformatics/bth457
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Bressler NM, 2003, ARCH OPHTHALMOL-CHIC, V121, P1621
   BRESSLER NM, 1989, ARCH OPHTHALMOL-CHIC, V107, P847, DOI 10.1001/archopht.1989.01070010869032
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Cruickshanks KJ, 1997, ARCH OPHTHALMOL-CHIC, V115, P242, DOI 10.1001/archopht.1997.01100150244015
   Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Ferris FL, 2005, ARCH OPHTHALMOL-CHIC, V123, P1570
   Francis PJ, 2008, HUM MOL GENET, V17, P2673, DOI 10.1093/hmg/ddn167
   Friedman DS, 1999, OPHTHALMOLOGY, V106, P1049, DOI 10.1016/S0161-6420(99)90267-1
   Fritsche LG, 2008, NAT GENET, V40, P892, DOI 10.1038/ng.170
   Grau S, 2006, J BIOL CHEM, V281, P6124, DOI 10.1074/jbc.M500361200
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   HEIBA IM, 1994, GENET EPIDEMIOL, V11, P51, DOI 10.1002/gepi.1370110106
   Jakobsdottir J, 2005, AM J HUM GENET, V77, P389, DOI 10.1086/444437
   Kanda A, 2007, P NATL ACAD SCI USA, V104, P16227, DOI 10.1073/pnas.0703933104
   Khan JC, 2006, BRIT J OPHTHALMOL, V90, P75, DOI 10.1136/bjo.2005.073643
   Klaver CCW, 1998, ARCH OPHTHALMOL-CHIC, V116, P653, DOI 10.1001/archopht.116.5.653
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Klein R, 2007, AM J OPHTHALMOL, V144, P1, DOI 10.1016/j.ajo.2007.02.047
   Lau LI, 2006, INVEST OPHTH VIS SCI, V47, P3242, DOI 10.1167/iovs.05-1532
   Lotery A, 2007, HUM GENET, V122, P219, DOI 10.1007/s00439-007-0406-3
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Oka C, 2004, DEVELOPMENT, V131, P1041, DOI 10.1242/dev.00999
   Purcell S, 2003, BIOINFORMATICS, V19, P149, DOI 10.1093/bioinformatics/19.1.149
   Purcell S, 2007, AM J HUM GENET, V81, P559, DOI 10.1086/519795
   *R, 2008, LANG ENV STAT COMP
   Resnikoff S, 2004, B WORLD HEALTH ORGAN, V82, P844
   Rivera A, 2005, HUM MOL GENET, V14, P3227, DOI 10.1093/hmg/ddi353
   Rozen S, 2000, Methods Mol Biol, V132, P365
   Schmidt S, 2006, AM J HUM GENET, V78, P852, DOI 10.1086/503822
   Seddon JM, 2005, ARCH OPHTHALMOL-CHIC, V123, P321, DOI 10.1001/archopht.123.3.321
   Seddon JM, 1997, AM J OPHTHALMOL, V123, P199, DOI 10.1016/S0002-9394(14)71036-0
   Simonelli F, 2006, BRIT J OPHTHALMOL, V90, P1142, DOI 10.1136/bjo.2006.096487
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Smith W, 1998, AUST NZ J OPHTHALMOL, V26, P203, DOI 10.1111/j.1442-9071.1998.tb01311.x
   Tomany SC, 2004, OPHTHALMOLOGY, V111, P1280, DOI 10.1016/j.ophtha.2003.11.010
   VanNewkirk MR, 2000, OPHTHALMOLOGY, V107, P1593, DOI 10.1016/S0161-6420(00)00175-5
   Vingerling JR, 1996, ARCH OPHTHALMOL-CHIC, V114, P1193, DOI 10.1001/archopht.1996.01100140393005
   Yang ZL, 2006, SCIENCE, V314, P992, DOI 10.1126/science.1133811
   Zareparsi S, 2005, AM J HUM GENET, V77, P149, DOI 10.1086/431426
NR 44
TC 26
Z9 27
U1 0
U2 1
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD APR
PY 2010
VL 51
IS 4
BP 2191
EP 2196
DI 10.1167/iovs.09-3798
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 574ND
UT WOS:000275995800052
PM 19933195
DA 2022-11-30
ER

PT J
AU Chew, EY
   Clemons, TE
   Agron, E
   Launer, LJ
   Grodstein, F
   Bernstein, PS
AF Chew, Emily Y.
   Clemons, Traci E.
   Agron, Elvira
   Launer, Lenore J.
   Grodstein, Francine
   Bernstein, Paul S.
CA Age-Related Eye Disease Study 2
TI Effect of Omega-3 Fatty Acids, Lutein/Zeaxanthin, or Other Nutrient
   Supplementation on Cognitive Function The AREDS2 Randomized Clinical
   Trial
SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
LA English
DT Article
ID DOCOSAHEXAENOIC ACID; BETA-CAROTENE; ALZHEIMERS-DISEASE; EYE DISEASE;
   ANTIOXIDANTS; CANCER
AB IMPORTANCE Observational data have suggested that high dietary intake of saturated fat and low intake of vegetables may be associated with increased risk of Alzheimer disease.
   OBJECTIVE To test the effects of oral supplementation with nutrients on cognitive function.
   DESIGN, SETTING, AND PARTICIPANTS In a double-masked randomized clinical trial (the Age-Related Eye Disease Study 2 [AREDS2]), retinal specialists in 82 US academic and community medical centers enrolled and observed participants who were at risk for developing late age-related macular degeneration (AMD) from October 2006 to December 2012. In addition to annual eye examinations, several validated cognitive function tests were administered via telephone by trained personnel at baseline and every 2 years during the 5-year study.
   INTERVENTIONS Long-chain polyunsaturated fatty acids (LCPUFAs) (1 g) and/or lutein (10mg)/zeaxanthin (2mg) vs placebo were tested in a factorial design. All participants were also given varying combinations of vitamins C, E, beta carotene, and zinc.
   MAIN OUTCOMES AND MEASURES The main outcome was the yearly change in composite scores determined from a battery of cognitive function tests from baseline. The analyses, which were adjusted for baseline age, sex, race, history of hypertension, education, cognitive score, and depression score, evaluated the differences in the composite score between the treated vs untreated groups. The composite score provided an overall score for the battery, ranging from -22 to 17, with higher scores representing better function.
   RESULTS A total of 89%(3741/4203) of AREDS2 participants consented to the ancillary cognitive function study and 93.6%(3501/3741) underwent cognitive function testing. The mean (SD) age of the participants was 72.7 (7.7) years and 57.5% were women. There were no statistically significant differences in change of scores for participants randomized to receive supplements vs those who were not. The yearly change in the composite cognitive function score was -0.19 (99% CI, -0.25 to -0.13) for participants randomized to receive LCPUFAs vs -0.18 (99% CI, -0.24 to -0.12) for those randomized to no LCPUFAs (difference in yearly change, -0.03 [99% CI, -0.20 to 0.13]; P = .63). Similarly, the yearly change in the composite cognitive function score was -0.18 (99% CI, -0.24 to -0.11) for participants randomized to receive lutein/zeaxanthin vs -0.19 (99% CI, -0.25 to -0.13) for those randomized to not receive lutein/zeaxanthin (difference in yearly change, 0.03 [99% CI, -0.14 to 0.19]; P = .66). Analyses were also conducted to assess for potential interactions between LCPUFAs and lutein/zeaxanthin and none were found to be significant.
   CONCLUSIONS AND RELEVANCE Among older persons with AMD, oral supplementation with LCPUFAs or lutein/zeaxanthin had no statistically significant effect on cognitive function.
C1 [Chew, Emily Y.; Agron, Elvira] NEI, Div Epidemiol & Clin Applicat, Clin Trials Branch, NIH, Bethesda, MD 20892 USA.
   [Clemons, Traci E.] EMMES Corp, Rockville, MD USA.
   [Launer, Lenore J.] NIA, Neuroepidemiol Sect, NIH, Bethesda, MD 20892 USA.
   [Grodstein, Francine] Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Med, Boston, MA 02115 USA.
   [Grodstein, Francine] Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA.
   [Bernstein, Paul S.] Univ Utah, Moran Eye Ctr, Salt Lake City, UT USA.
C3 National Institutes of Health (NIH) - USA; NIH National Eye Institute
   (NEI); Emmes Corporation; National Institutes of Health (NIH) - USA; NIH
   National Institute on Aging (NIA); Harvard University; Brigham & Women's
   Hospital; Harvard Medical School; Harvard University; Harvard T.H. Chan
   School of Public Health; Utah System of Higher Education; University of
   Utah
RP Chew, EY (通讯作者)，BG 10-CRC Room 3-2531,10 Ctr Dr MSC1204, Bethesda, MD 20892 USA.
EM echew@nei.nih.gov
FU NIH; National Eye Institute (NEI)/NIH, Department of Health and Human
   Services [HHS-N-260-2005-00007-C]; NIH, Office of Dietary Supplements
   (ODS); NIH, National Center for Complementary and Alternative Medicine
   (NCCAM); NIH, National Institute on Aging (NIA); NIH, National Heart,
   Lung, and Blood Institute (NHLBI); NIH, National Institute of
   Neurological Disorders and Stroke (NINDS);  [N01-EY-5-0007]; NATIONAL
   EYE INSTITUTE [N01EY002127, ZIAEY000485, ZIAEY000489] Funding Source:
   NIH RePORTER
FX This study was sponsored by the NIH; by the intramural program funds and
   contracts from the National Eye Institute (NEI)/NIH, Department of
   Health and Human Services, contract HHS-N-260-2005-00007-C. ADB and
   contract N01-EY-5-0007. Funds were generously contributed to these
   contracts by the following NIH institutes: Office of Dietary Supplements
   (ODS), National Center for Complementary and Alternative Medicine
   (NCCAM), National Institute on Aging (NIA), National Heart, Lung, and
   Blood Institute (NHLBI), and National Institute of Neurological
   Disorders and Stroke (NINDS).
CR ALBANES D, 1995, AM J CLIN NUTR, V62, P1427, DOI 10.1093/ajcn/62.6.1427S
   Bonds DE, 2014, JAMA INTERN MED, V174, P763, DOI 10.1001/jamainternmed.2014.328
   Chew EY, 2014, JAMA OPHTHALMOL, V132, P142, DOI 10.1001/jamaophthalmol.2013.7376
   Chew EY, 2013, JAMA-J AM MED ASSOC, V309, P2005, DOI 10.1001/jama.2013.4997
   Chew EY, 2012, OPHTHALMOLOGY, V119, P2282, DOI 10.1016/j.ophtha.2012.05.027
   Dangour AD, 2009, J NUTR HEALTH AGING, V13, P198, DOI 10.1007/s12603-009-0057-2
   Dangour AD, 2010, AM J CLIN NUTR, V91, P1725, DOI 10.3945/ajcn.2009.29121
   Evans DA, 2011, ALZHEIMERS DEMENT, V7, P110, DOI 10.1016/j.jalz.2010.11.008
   Grodstein F, 2003, AM J CLIN NUTR, V77, P975, DOI 10.1093/ajcn/77.4.975
   Grodstein F, 2007, ARCH INTERN MED, V167, P2184, DOI 10.1001/archinte.167.20.2184
   Jama JW, 1996, AM J EPIDEMIOL, V144, P275, DOI 10.1093/oxfordjournals.aje.a008922
   Johnson EJ, 2008, NUTR NEUROSCI, V11, P75, DOI 10.1179/147683008X301450
   Kalmijn S, 1997, AM J EPIDEMIOL, V145, P33, DOI 10.1093/oxfordjournals.aje.a009029
   Kang JH, 2006, ARCH INTERN MED, V166, P2462, DOI 10.1001/archinte.166.22.2462
   Kang JH, 2003, NEUROLOGY, V60, P1591
   Lopez Oscar L, 2010, Neuroepidemiology, V34, P63, DOI 10.1159/000264678
   MYERSON J, 1990, PSYCHOL REV, V97, P475, DOI 10.1037/0033-295X.97.4.475
   NEWMAN CW, 1991, EAR HEARING, V12, P355, DOI 10.1097/00003446-199110000-00009
   Omenn GS, 1996, J NATL CANCER I, V88, P1550, DOI 10.1093/jnci/88.21.1550
   Quinn JF, 2010, JAMA-J AM MED ASSOC, V304, P1903, DOI 10.1001/jama.2010.1510
   RADLOFF L S, 1977, Applied Psychological Measurement, V1, P385, DOI 10.1177/014662167700100306
   Rankin MW, 2005, OPHTHAL EPIDEMIOL, V12, P271, DOI 10.1080/09286580591003815
   ROSEN W G, 1980, Journal of Clinical Neuropsychology, V2, P135, DOI 10.1080/01688638008403788
   Samieri C, 2013, EPIDEMIOLOGY, V24, P490, DOI 10.1097/EDE.0b013e318294a065
   Samra SK, 2007, STROKE, V38, P1864, DOI 10.1161/STROKEAHA.106.477448
   Thies W, 2013, ALZHEIMERS DEMENT, V9, P208, DOI 10.1016/j.jalz.2013.02.003
   Tully AM, 2003, BRIT J NUTR, V89, P483, DOI 10.1079/BJN2002804
   Wechsler D, 1945, J PSYCHOL, V19, P87, DOI 10.1080/00223980.1945.9917223
   Yaffe K, 2004, NEUROLOGY, V63, P1705, DOI 10.1212/01.WNL.0000142969.19465.8F
NR 29
TC 117
Z9 119
U1 3
U2 48
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 0098-7484
EI 1538-3598
J9 JAMA-J AM MED ASSOC
JI JAMA-J. Am. Med. Assoc.
PD AUG 25
PY 2015
VL 314
IS 8
BP 791
EP 801
DI 10.1001/jama.2015.9677
PG 11
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA CP6SA
UT WOS:000360017200019
PM 26305649
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Yuan, DQ
   Shen, H
   Yuan, ST
   Liu, XY
   Xia, X
   Xie, P
   Li, WG
   Hu, JL
   Liu, QH
   Xu, HM
AF Yuan, Dongqing
   Shen, Hong
   Yuan, Songtao
   Liu, Xiaoyi
   Xia, Xin
   Xie, Ping
   Li, Weiguang
   Hu, Jialiang
   Liu, Qinghuai
   Xu, Hanmei
TI Pharmacokinetics of HM-3 After Intravitreal Administration in Mice
SO CURRENT EYE RESEARCH
LA English
DT Article
DE Blood retinal barrier; choroidal neovascularization; fluid flow; HM-3;
   intravitreal administration; pharmacokinetics
ID MACULAR DEGENERATION; VITREOUS-HUMOR; DRUG-DELIVERY; IN-VIVO; INJECTION;
   THERAPY; RETINA; MODELS; NEOVASCULARIZATION; ANGIOGENESIS
AB Purpose: HM-3, an RGD-modified endostatin-derived polypeptide, is a potent angiogenesis inhibitor synthesized in our laboratory. This study investigated the HM-3 pharmacokinetics of intravitreally administered in mice eyes as an anti-angiogenesis drug for age-related macular degeneration.
   Materials and methods: A total of 288 C57BL/6J mice were evaluated and divided into four groups. Each mouse in different groups received single bilateral intravitreal injection with HM-3. The concentrations of HM-3 in choroid/sclera, retina and serum were determined by indirect competitive enzyme-linked immunosorbent assay.
   Results: After intravitreal administration of doses of 0, 10, 20 and 40 mu g/eye HM-3, the observed maximum concentration (C-max) was 12.98 +/- 1.42, 27.87 +/- 3.64 and 55.96 +/- 11.94 ng/mg, respectively; and the total area under the curve (AUC(tot)) was 739.23 +/- 190.32, 1171.74 +/- 528.75 and 1777.71 +/- 511.64 h ng/mg; the elimination half-life (T-1/2) in retina was 104.85 +/- 36.90, 107.42 +/- 35.25 and 101.12 +/- 15.82 h; the mean residence time (MRT) was 172.46 +/- 63.80, 164.70 +/- 52.72 and 181.32 +/- 26.01 h, respectively. In choroid/sclera, the C-max was 5.29 +/- 0.34, 6.29 +/- 1.87 and 8.14 +/- 0.71 ng/mg, respectively; AUC(tot) was 579.03 +/- 56.50, 762.20 +/- 201.09 and 720.91 +/- 243.87 h ng/mg; T-1/2 was 54.04 +/- 25.99, 59.33 +/- 24.46 and 47.10 +/- 10.00 h, respectively; MRT was 139.98 +/- 23.93, 155.43 +/- 17.81 and 136.45 +/- 18.17 h, respectively. But in serum, the C-max was 482.00 +/- 38.97, 493.94 +/- 97.64 and 1033.10 +/- 276.33 ng/ml, respectively; AUC(tot) was 21128.55 +/- 4683.68, 53444.57 +/- 16963.99 and 53164.84 +/- 1535.06 h ng/ml; T-1/2 was 48.39 +/- 14.89, 47.96 +/- 12.97 and 49.98 +/- 30.07 h, respectively; MRT was 108.6 +/- 47.17, 159.76 +/- 18.82 and 125.33 +/- 21.41 h, respectively.
   Conclusions: The pharmacokinetic profiles of intravitreal administration HM-3 provide the basis for the development of reasonable dosing regimens of clinical choroidal neovascularization (CNV) treatment. However, the vitreous and blood retinal barrier might be barriers to drug distribution and diffusion. In addition, fluid flow for the anterior transport and choroidal blood circulation might play important roles for multiple peaking. Carrying out the research into pharmacokinetics of HM-3 provides the information for laying down drug delivery scheme in mice model of CNV.
C1 [Yuan, Dongqing; Yuan, Songtao; Liu, Xiaoyi; Xia, Xin; Xie, Ping; Liu, Qinghuai] Nanjing Med Univ, Dept Ophthalmol, Affiliated Hosp 1, Nanjing 210029, Jiangsu, Peoples R China.
   [Shen, Hong; Li, Weiguang; Hu, Jialiang; Xu, Hanmei] China Pharmaceut Univ, Dept Marine Pharm, Coll Life Sci & Technol, Nanjing 210009, Jiangsu, Peoples R China.
   [Shen, Hong] Nanjing Med Univ, Nanjing Brain Hosp, Neuropsychiat Inst, Nanjing 210029, Jiangsu, Peoples R China.
C3 Nanjing Medical University; China Pharmaceutical University; Nanjing
   Medical University
RP Liu, QH (通讯作者)，Nanjing Med Univ, Dept Ophthalmol, Affiliated Hosp 1, 300 Guangzhou Rd, Nanjing 210029, Jiangsu, Peoples R China.
EM liuqh@njmu.edu.cn; xuhanmei@cpu.edu.cn
OI Xie, Ping/0000-0003-4257-8970; Liu, Qinghuai/0000-0003-1605-1964
FU National Basic Research Program of China (973 Program) [2012CB066300,
   2011CB510200]; General Project of the National Natural Science Fund
   [81170855, 81070743]; Research and Innovation Project for College
   Graduates of Jiangsu Province [CXZZ12_0586]
FX This research project was supported by National Basic Research Program
   of China (973 Program, No. 2012CB066300 and No.2011CB510200,
   http://www.973.gov.cn/AreaAppl.aspx), General Project of the National
   Natural Science Fund (No. 81170855 and No. 81070743,
   http://www.nsfc.gov.cn/Portal0/default152.htm) and Research and
   Innovation Project for College Graduates of Jiangsu Province (No.
   CXZZ12_0586).. The funders had no role in study design, data collection
   and analysis, decision to publish or preparation of the manuscript. The
   authors report no conflicts of interest. The authors alone are
   responsible for the content and writing of the paper.
CR Akkoyun I, 2012, ACTA OPHTHALMOL, V90, P564, DOI 10.1111/j.1755-3768.2010.01963.x
   Cloutier F, 2012, INVEST OPHTH VIS SCI, V53, P1195, DOI 10.1167/iovs.11-9064
   Cunha-Vaz JG, 2004, EXP EYE RES, V78, P715, DOI 10.1016/S0014-4835(03)00213-6
   Dixon JA, 2009, EXPERT OPIN INV DRUG, V18, P1573, DOI 10.1517/13543780903201684
   Fine SL, 2000, NEW ENGL J MED, V342, P483, DOI 10.1056/NEJM200002173420707
   FOULDS WS, 1985, BRIT J OPHTHALMOL, V69, P529, DOI 10.1136/bjo.69.7.529
   Friedrich S, 1997, CURR EYE RES, V16, P663, DOI 10.1076/ceyr.16.7.663.5061
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Grisanti S, 2008, PROG RETIN EYE RES, V27, P372, DOI 10.1016/j.preteyeres.2008.05.002
   Gutfleisch M, 2011, EYE, V25, P1181, DOI 10.1038/eye.2011.146
   Heckmann D, 2008, CHEMBIOCHEM, V9, P1397, DOI 10.1002/cbic.200800045
   HEEGAARD S, 1986, GRAEF ARCH CLIN EXP, V224, P355, DOI 10.1007/BF02150029
   Heiduschka P, 2007, INVEST OPHTH VIS SCI, V48, P2814, DOI 10.1167/iovs.06-1171
   Kim SJ, 2008, RETINA-J RET VIT DIS, V28, P595, DOI 10.1097/IAE.0b013e31815e98a5
   Kociok N, 2007, GRAEF ARCH CLIN EXP, V245, P101, DOI 10.1007/s00417-006-0266-x
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Liu ZD, 2012, CURR PHARM DESIGN, V18, P1655, DOI 10.2174/138161212799958620
   Missel PJ, 2002, PHARMACEUT RES, V19, P1636, DOI 10.1023/A:1020940927675
   Mitchell P, 2011, CURR MED RES OPIN, V27, P1465, DOI 10.1185/03007995.2011.585394
   Park J, 2005, J CONTROL RELEASE, V105, P279, DOI 10.1016/j.jconrel.2005.03.010
   Peeters L, 2005, INVEST OPHTH VIS SCI, V46, P3553, DOI 10.1167/iovs.05-0165
   Pitkanen Leena, 2004, AAPS J, V6, pe25
   Sampat KM, 2010, CURR OPIN OPHTHALMOL, V21, P178, DOI 10.1097/ICU.0b013e328338679a
   Santulli RJ, 2008, J PHARMACOL EXP THER, V324, P894, DOI 10.1124/jpet.107.131656
   Seddon JM, 2011, OPHTHALMOLOGY, V118, P2203, DOI 10.1016/j.ophtha.2011.04.029
   Steuer H, 2004, BRAIN RES PROTOC, V13, P26, DOI 10.1016/j.brainresprot.2003.12.002
   Tolentino MJ, 2009, CURR MOL MED, V9, P973, DOI 10.2174/156652409789712783
   Xu HM, 2008, BIOCONJUGATE CHEM, V19, P1980, DOI 10.1021/bc800132p
   Xu HM, 2006, China Patent, Patent No. 1830487
   Xu J, 2000, PHARMACEUT RES, V17, P664, DOI 10.1023/A:1007517912927
   Zeng ZZ, 2009, TRANSL ONCOL, V2, P8, DOI 10.1593/tlo.08187
   Zhou K, 2009, BIOCONJUGATE CHEM, V20, P932, DOI 10.1021/bc900070r
   [朱蓓莉 Zhu Beili], 2010, [药物生物技术, Pharmaceutical Biotechnology], V17, P499
   Zhu BL, 2010, J BIOCHEM, V148, P341, DOI 10.1093/jb/mvq070
NR 34
TC 5
Z9 6
U1 0
U2 15
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0271-3683
EI 1460-2202
J9 CURR EYE RES
JI Curr. Eye Res.
PD AUG
PY 2014
VL 39
IS 8
BP 837
EP 844
DI 10.3109/02713683.2014.883411
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AM8ET
UT WOS:000340105500009
PM 24559456
DA 2022-11-30
ER

PT J
AU Chiang, PPC
   Zheng, YF
   Wong, TY
   Lamoureux, EL
AF Chiang, Peggy P. C.
   Zheng, Yingfeng
   Wong, Tien Y.
   Lamoureux, Ecosse L.
TI Vision Impairment and Major Causes of Vision Loss Impacts on
   Vision-Specific Functioning Independent of Socioeconomic Factors
SO OPHTHALMOLOGY
LA English
DT Article
ID QUALITY-OF-LIFE; VISUAL IMPAIRMENT; EYE DISEASES; HEALTH; POPULATION;
   BLINDNESS; VF-14; FALLS; QUESTIONNAIRE; PERFORMANCE
AB Purpose: To quantify the eye disease-specific impact of unilateral and bilateral vision impairment (VI) on vision-specific functioning (VF).
   Design: The Singapore Indian Eye population-based study.
   Participants: Ethnic Indians older than 40 years of age living in Singapore.
   Methods: Participants underwent standardized ophthalmic assessments for VI and blindness, defined using presenting visual acuity (United States definition). Sociodemographic data were recorded using a standardized questionnaire. Rasch analysis was used to validate the Visual Function Index 11 and to determine its psychometric properties. The major causes of VI (i.e., cataract, refractive error, age-related macular degeneration, diabetic retinopathy [DR], and glaucoma) were determined by ophthalmologists on examination. Multivariate linear regression analysis was performed to assess the impact of VI on the overall VF Rasch score.
   Main Outcome Measures: Vision-specific functioning.
   Results: Three thousand three hundred ninety-six persons were analyzed. Participants with VI had a systematic reduction in VF score compared with those with normal vision in both eyes, ranging from -11.2% normal vision in one eye and low vision in the other eye (95% confidence interval [CI], -12.2% to -10.3%; P<0.001), to -12.7% blindness in one eye and normal vision in the other eye (CI, -15.1% to -10.4%; P<0.001), to -19.4% low vision in both eyes (CI, -20.8% to -18.1%; P<0.001), to -52.9% blindness in one eye and low vision in other eye (CI, -55.3% to -50.4%; P<0.001), to -77.2% blindness in both eyes (CI, -82.4% to 72.0%; P<0.001). The impact of VI on VF score varied across different major causes of vision loss, regardless of socioeconomic factors. Vision impairment attributed to cataract in one or both eyes had a significant decrease in VF score by 17.7% and 22.3%, respectively, compared with those with normal vision in both eyes (P<0.001). The impact of unilateral and bilateral VI on VF score was greater in participants with glaucoma (32.2% in unilateral cases and 35.9% in bilateral cases; P<0.001) and DR (29.4% in unilateral cases and 33.3% in bilateral cases; P<0.001).
   Conclusions: Vision impairment and major age-related eye diseases such as cataract, DR, and glaucoma are associated significantly with worse deterioration in VF, regardless of education level, literacy adequacy, or immigration pattern. Glaucoma and DR seemed to have a greater negative impact on VF score compared with cataract. This study highlights the importance of disease-specific interventions in reducing the adverse impact of VI on daily activities.
   Financial Disclosure(s): The author(s) have no proprietary or commercial interest in any materials discussed in this article. Ophthalmology 2013;120:415-422 (C) 2013 by the American Academy of Ophthalmology.
C1 [Chiang, Peggy P. C.; Zheng, Yingfeng; Wong, Tien Y.; Lamoureux, Ecosse L.] Singapore Eye Res Inst, Singapore 168751, Singapore.
   [Chiang, Peggy P. C.] Duke NUS Grad Med Sch, Singapore, Singapore.
   [Wong, Tien Y.; Lamoureux, Ecosse L.] Univ Melbourne, Ctr Eye Res Australia, Melbourne, Vic, Australia.
   [Wong, Tien Y.] Natl Univ Singapore, Dept Ophthalmol, Singapore 117548, Singapore.
C3 National University of Singapore; Singapore National Eye Center;
   National University of Singapore; Centre for Eye Research Australia;
   University of Melbourne; National University of Singapore
RP Chiang, PPC (通讯作者)，Singapore Eye Res Inst, Level 5,11 3rd Hosp Ave, Singapore 168751, Singapore.
EM peggy.chiang.p.c@seri.com.sg
RI Zheng, Yingfeng/AAE-2983-2022; Wong, Tien Yin/AAC-9724-2020; Lamoureux,
   Ecosse/Z-5482-2019; Zheng, Yingfeng/CAE-9225-2022
OI Wong, Tien Yin/0000-0002-8448-1264; Zheng, Yingfeng/0000-0002-0914-7864
FU Biomedical Research Council, Singapore, Republic of Singapore
   [08/1/35/19/550]; National Medical Research Council, Singapore, Republic
   of Singapore [Star/0003/2008]
FX Supported by the Biomedical Research Council, Singapore, Republic of
   Singapore (grant no.: 08/1/35/19/550); and the National Medical Research
   Council, Singapore, Republic of Singapore (grant no.: Star/0003/2008).
CR [Anonymous], 1991, Ophthalmology, V98, P786
   [Anonymous], 2010, SING FIG 2010, P5
   Boisjoly H, 2002, AM J OPHTHALMOL, V134, P166, DOI 10.1016/S0002-9394(02)01529-5
   Broman AT, 2002, INVEST OPHTH VIS SCI, V43, P3393
   Chia EM, 2004, INVEST OPHTH VIS SCI, V45, P71, DOI 10.1167/iovs.03-0661
   Choi JK, 2011, ARCH OPHTHALMOL-CHIC, V129, P196, DOI 10.1001/archophthalmol.2010.355
   Coyne KS, 2004, FAM PRACT, V21, P447, DOI 10.1093/fampra/cmh417
   Dandona R, 2001, BRIT J OPHTHALMOL, V85, P1484, DOI 10.1136/bjo.85.12.1484
   de Boer MR, 2006, OPHTHAL PHYSL OPT, V26, P535, DOI 10.1111/j.1475-1313.2006.00424.x
   Delcourt C, 2000, AM J EPIDEMIOL, V151, P497
   Gothwal VK, 2011, J CATARACT REFR SURG, V37, P1208, DOI 10.1016/j.jcrs.2011.01.028
   Hirneiss C, 2003, OPHTHALMOLOGE, V100, P1091, DOI 10.1007/s00347-003-0884-1
   Ivers RQ, 1998, J AM GERIATR SOC, V46, P58
   Klein BEK, 1998, OPHTHALMOLOGY, V105, P160, DOI 10.1016/S0161-6420(98)91911-X
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Lamoreux EL, 2008, INVEST OPHTH VIS SCI, V49, P528, DOI 10.1167/iovs.07-1036
   Lamoureux E, 2011, AM J OPHTHALMOL, V151, P195, DOI 10.1016/j.ajo.2010.09.020
   Lamoureux EL, 2008, OPHTHALMOLOGY, V115, P1973, DOI 10.1016/j.ophtha.2008.05.005
   Lamoureux EL, 2007, INVEST OPHTH VIS SCI, V48, P1476, DOI 10.1167/iovs.06-0610
   Lavanya R, 2009, OPHTHAL EPIDEMIOL, V16, P325, DOI 10.3109/09286580903144738
   Linder M, 1999, ARCH OPHTHALMOL-CHIC, V117, P1611
   Livingston PM, 1997, BRIT J OPHTHALMOL, V81, P574, DOI 10.1136/bjo.81.7.574
   MACINTYRE S, 1993, J SOC POLICY, V22, P213, DOI 10.1017/S0047279400019310
   Maharajah KR, 2008, CLIN EXP OPHTHALMOL, V36, P222, DOI 10.1111/j.1442-9071.2008.01719.x
   Margolis MK, 2002, PHARMACOECONOMICS, V20, P791, DOI 10.2165/00019053-200220120-00001
   Marmot M, 2001, NEW ENGL J MED, V345, P134, DOI 10.1056/NEJM200107123450210
   Marmot M, 2005, LANCET, V365, P1099, DOI 10.1016/S0140-6736(05)74234-3
   Nirmalan PK, 2005, INVEST OPHTH VIS SCI, V46, P2308, DOI 10.1167/iovs.04-0830
   Nutheti R, 2004, INVEST OPHTH VIS SCI, V45, P3458, DOI 10.1167/iovs.04-0243
   Nutheti R, 2007, OPHTHALMOLOGY, V114, P1552, DOI 10.1016/j.ophtha.2006.11.012
   Sabri K, 2006, INVEST OPHTH VIS SCI, V47, P4386, DOI 10.1167/iovs.05-1365
   Saw SM, 2004, OPHTHALMOLOGY, V111, P1161, DOI 10.1016/j.ophtha.2003.09.040
   Sloan Jeff A, 2005, COPD, V2, P57
   TIELSCH JM, 1990, ARCH OPHTHALMOL-CHIC, V108, P286, DOI 10.1001/archopht.1990.01070040138048
   Tuomilehto J, 2003, DIABETES CARE, V26, P1770
   Varma R, 2006, OPHTHALMOLOGY, V113, P1846, DOI 10.1016/j.ophtha.2006.04.028
   Vu HTV, 2005, BRIT J OPHTHALMOL, V89, P360, DOI 10.1136/bjo.2004.047498
   Weisinger HS, 2009, CLIN EXP OPHTHALMOL, V37, P241, DOI 10.1111/j.1442-9071.2009.02011.x
   Wong TY, 2008, ARCH OPHTHALMOL-CHIC, V126, P1091, DOI 10.1001/archopht.126.8.1091
   Zhao JL, 1998, AM J OPHTHALMOL, V126, P515, DOI 10.1016/S0002-9394(98)00274-8
   Zheng YF, 2011, INVEST OPHTH VIS SCI, V52, P7634, DOI 10.1167/iovs.11-7725
   Zheng YF, 2011, OPHTHALMOLOGY, V118, P1798, DOI 10.1016/j.ophtha.2011.02.014
NR 42
TC 28
Z9 29
U1 0
U2 15
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD FEB
PY 2013
VL 120
IS 2
BP 415
EP 422
DI 10.1016/j.ophtha.2012.07.077
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 085WX
UT WOS:000314646100029
PM 23149127
DA 2022-11-30
ER

PT J
AU Christensen, DRG
   Brown, FE
   Cree, AJ
   Ratnayaka, JA
   Lotery, AJ
AF Christensen, David R. G.
   Brown, Ffion E.
   Cree, Angela J.
   Ratnayaka, J. Arjuna
   Lotery, Andrew J.
TI Sorsby fundus dystrophy - A review of pathology and disease mechanisms
SO EXPERIMENTAL EYE RESEARCH
LA English
DT Review
DE Retinal pigment epithelium; Induced pluripotent stem cells; Tissue
   inhibitor of matrix; metalloproteinases-3; Sorsby fundus dystrophy; AMD;
   Cell culture; Disease modelling
ID RETINAL-PIGMENT EPITHELIUM; PLURIPOTENT STEM-CELLS; UNUSUAL
   CLINICAL-FEATURES; GROWTH-FACTOR SECRETION; HUMAN TISSUE INHIBITOR;
   TIMP-3 MESSENGER-RNA; N-TERMINAL DOMAIN; MACULAR DEGENERATION;
   METALLOPROTEINASES-3 TIMP3; EXTRACELLULAR-MATRIX
AB Sorsby fundus dystrophy (SFD) is an autosomal dominant macular dystrophy with an estimated prevalence of 1 in 220,000 and an onset of disease around the 4th to 6th decade of life. Similar to age-related macular degeneration (AMD), ophthalmoscopy reveals accumulation of protein/lipid deposits under the retinal pigment epithelium (RPE), referred to as drusen, in the eyes of patients with SFD.
   SFD is caused by variants in the gene for tissue inhibitor of metalloproteinases-3 (TIMP3), which has been found in drusen-like deposits of SFD patients. TIMP3 is constitutively expressed by RPE cells and, in healthy eyes, resides in Bruch's membrane. Most SFD-associated TIMP3 variants involve the gain or loss of a cysteine residue. This suggests the protein aberrantly forms intermolecular disulphide bonds, resulting in the formation of TIMP3 dimers. It has been demonstrated that SFD-associated TIMP3 variants are more resistant to turnover, which is thought to be a result of dimerisation and thought to explain the accumulation of TIMP3 in drusen-like deposits at the level of Bruch's membrane.
   An important function of TIMP3 within the outer retina is to regulate the thickness of Bruch's membrane. TIMP3 performs this function by inhibiting the activity of matrix metalloproteinases (MMPs), which have the function of catalysing breakdown of the extracellular matrix. TIMP3 has an additional function to inhibit vascular endothelial growth factor (VEGF) signalling and thereby to inhibit angiogenesis. However, it is unclear whether SFD-associated TIMP3 variant proteins retain these functions. In this review, we discuss the current understanding of the potential mechanisms underlying development of SFD and summarise all known SFD-associated TIMP3 variants.
   Cell culture models provide an invaluable way to study disease and identify potential treatments. These allow a greater understanding of RPE physiology and pathophysiology, including the ability to study the blood-retinal barrier as well as other RPE functions such as phagocytosis of photoreceptor outer segments. This review describes some examples of such recent in vitro studies and how they might provide new insights into degenerative diseases like SFD.
   Thus far, most studies on SFD have been performed using ARPE-19 cells or other, less suitable, cell types. Now, induced pluripotent stem cell (iPSC) technologies allow the possibility to non-invasively collect somatic cells, such as dermal fibroblast cells and reprogram those to produce iPSC5. Subsequent differentiation of iPSC5 can generate patient-derived RPE cells that carry the same disease associated variant as RPE cells in the eyes of the patient. Use of these patient-derived RPE cells in novel cell culture systems should increase our understanding of how SFD and similar macular dystrophies develop. (C) 2017 Elsevier Ltd. All rights reserved.
C1 [Christensen, David R. G.; Brown, Ffion E.; Cree, Angela J.; Ratnayaka, J. Arjuna; Lotery, Andrew J.] Univ Southampton, Univ Hosp Southampton, Fac Med, Clin & Expt Sci, MP806,Tremona Rd, Southampton SO16 6YD, Hants, England.
   [Lotery, Andrew J.] Univ Hosp Southampton, Univ Hosp Southampton NHS Fdn Trust, Southampton Eye Unit, Southampton SO16 6YD, Hants, England.
C3 University of Southampton; University of Southampton; University
   Hospital Southampton NHS Foundation Trust
RP Ratnayaka, JA; Lotery, AJ (通讯作者)，Univ Southampton, Univ Hosp Southampton, Fac Med, Clin & Expt Sci, MP806,Tremona Rd, Southampton SO16 6YD, Hants, England.
EM J.Ratnayaka@soton.ac.uk; A.J.Lotery@soton.ac.uk
OI Ratnayaka, J. Arjuna/0000-0002-1027-6938; Cree,
   Angela/0000-0002-1987-8900; Christensen, David/0000-0003-4018-3537;
   Lotery, Andrew/0000-0001-5541-4305
FU Rosetrees Trust [M124-F1]; RP Fighting Blindness [GR590]; National
   Institute for Health Research [NF-SI-0515-10020] Funding Source:
   researchfish
FX The authors would like to acknowledge and thank the patients affected
   with Sorsby Fundus Dystrophy who have attended AL's clinics and
   contributed to this research and also the Gift of Sight Appeal,
   Rosetrees Trust (M124-F1), and RP Fighting Blindness (GR590) for grant
   support for this work. AL is a NIHR Senior Investigator.
CR Ablonczy Z, 2007, EXP EYE RES, V85, P762, DOI 10.1016/j.exer.2007.08.010
   Ablonczy Z, 2011, INVEST OPHTH VIS SCI, V52, P8614, DOI 10.1167/iovs.11-8021
   ALBERT DM, 1972, ARCH OPHTHALMOL-CHIC, V88, P63
   AMES A, 1992, J NEUROSCI, V12, P840, DOI 10.1523/jneurosci.12-03-00840.1992
   Amour A, 1998, FEBS LETT, V435, P39, DOI 10.1016/S0014-5793(98)01031-X
   APTE SS, 1995, J BIOL CHEM, V270, P14313, DOI 10.1074/jbc.270.24.14313
   Arris CE, 2003, BBA-MOL BASIS DIS, V1638, P20, DOI 10.1016/S0925-4439(03)00036-X
   Bailey TA, 2001, EXP EYE RES, V73, P851, DOI 10.1006/exer.2001.1089
   Bakall B, 2014, INVEST OPHTH VIS SCI, V55
   Baker AH, 1998, J CLIN INVEST, V101, P1478, DOI 10.1172/JCI1584
   Balaskas K, 2013, EYE, V27, P101, DOI 10.1038/eye.2012.221
   Ban Y, 1997, Mol Vis, V3, P18
   Barbazetto IA, 2005, ARCH OPHTHALMOL-CHIC, V123, P542, DOI 10.1001/archopht.123.4.542
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Becerra SP, 2004, EXP EYE RES, V78, P223, DOI 10.1016/j.exer.2003.10.013
   Blaauwgeers HGT, 1999, AM J PATHOL, V155, P421, DOI 10.1016/S0002-9440(10)65138-3
   BLODI CF, 1990, OPHTHALMIC PAED GEN, V11, P49
   Bond M, 2000, J BIOL CHEM, V275, P41358, DOI 10.1074/jbc.M007929200
   Brandl C, 2015, J CLIN MED, V4, P282, DOI 10.3390/jcm4020282
   Brandl C, 2014, NEUROMOL MED, V16, P551, DOI 10.1007/s12017-014-8308-8
   Brew K, 2010, BBA-MOL CELL RES, V1803, P55, DOI 10.1016/j.bbamcr.2010.01.003
   Buchholz DE, 2009, STEM CELLS, V27, P2427, DOI 10.1002/stem.189
   BURN RA, 1950, BRIT J OPHTHALMOL, V34, P393, DOI 10.1136/bjo.34.7.393
   CAPON MRC, 1988, EYE, V2, P114, DOI 10.1038/eye.1988.23
   Carr AJ, 2009, MOL VIS, V15, P283
   Carr R E, 1977, Trans Am Ophthalmol Soc, V75, P255
   CarreroValenzuela RD, 1996, ARCH OPHTHALMOL-CHIC, V114, P737, DOI 10.1001/archopht.1996.01100130729016
   Chong NHV, 2000, INVEST OPHTH VIS SCI, V41, P898
   Chong NHV, 2003, AM J OPHTHALMOL, V136, P954, DOI 10.1016/S0002-9394(03)00482-3
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   Dardik R, 2010, INVEST OPHTH VIS SCI, V51, P6188, DOI 10.1167/iovs.09-5095
   Della NG, 1996, INVEST OPHTH VIS SCI, V37, P1921
   DOWLING JE, 1960, NATURE, V188, P114, DOI 10.1038/188114a0
   Dunn KC, 1996, EXP EYE RES, V62, P155, DOI 10.1006/exer.1996.0020
   EVANS MJ, 1981, NATURE, V292, P154, DOI 10.1038/292154a0
   Fariss RN, 1998, BRIT J OPHTHALMOL, V82, P1329, DOI 10.1136/bjo.82.11.1329
   Fariss RN, 1997, AM J PATHOL, V150, P323
   FEENEY L, 1976, EXP EYE RES, V22, P533, DOI 10.1016/0014-4835(76)90190-1
   Felbor U, 1996, J MED GENET, V33, P233, DOI 10.1136/jmg.33.3.233
   FELBOR U, 1995, HUM MOL GENET, V4, P2415, DOI 10.1093/hmg/4.12.2415
   Felbor U, 1997, ARCH OPHTHALMOL-CHIC, V115, P1569, DOI 10.1001/archopht.1997.01100160739011
   Finnemann SC, 1997, P NATL ACAD SCI USA, V94, P12932, DOI 10.1073/pnas.94.24.12932
   FISHMAN GA, 1993, OPHTHALMOLOGY, V100, P1665
   Fogarasi M, 2008, MATRIX BIOL, V27, P381, DOI 10.1016/j.matbio.2008.01.008
   Fung Adrian T, 2013, Retin Cases Brief Rep, V7, P71, DOI 10.1097/ICB.0b013e318267101e
   Garcia TY, 2015, INVEST OPHTH VIS SCI, V56, P7480, DOI 10.1167/iovs.15-17251
   Gemenetzi Maria K, 2011, Retin Cases Brief Rep, V5, P132, DOI 10.1097/ICB.0b013e3181cc216b
   Gliem M, 2015, INVEST OPHTH VIS SCI, V56, P2664, DOI 10.1167/iovs.14-15733
   Golestaneh N, 2016, J TRANSL MED, V14, DOI 10.1186/s12967-016-1101-8
   Gourier HCY, 2015, J CLIN MED, V4, P874, DOI 10.3390/jcm4050874
   Hamilton RD, 2007, J ANAT, V211, P707, DOI 10.1111/j.1469-7580.2007.00812.x
   HAMILTON WK, 1989, OPHTHALMOLOGY, V96, P1755
   Handsley MM, 2005, INT J CANCER, V115, P849, DOI 10.1002/ijc.20945
   Hirami Y, 2009, NEUROSCI LETT, V458, P126, DOI 10.1016/j.neulet.2009.04.035
   Ho TC, 1997, EXP EYE RES, V64, P133, DOI 10.1006/exer.1996.0199
   HOSKIN A, 1981, BRIT J OPHTHALMOL, V65, P859, DOI 10.1136/bjo.65.12.859
   Idelson M, 2009, CELL STEM CELL, V5, P396, DOI 10.1016/j.stem.2009.07.002
   Jacobson SG, 2002, ARCH OPHTHALMOL-CHIC, V120, P376
   JACOBSON SG, 1995, NAT GENET, V11, P27, DOI 10.1038/ng0995-27
   Janssen A, 2008, INVEST OPHTH VIS SCI, V49, P2812, DOI 10.1167/iovs.07-1444
   Johnson LV, 2011, P NATL ACAD SCI USA, V108, P18277, DOI 10.1073/pnas.1109703108
   Juuti-Uusitalo K, 2013, INVEST OPHTH VIS SCI, V54, P3510, DOI 10.1167/iovs.13-11800
   Kamei M, 1999, INVEST OPHTH VIS SCI, V40, P2367
   Kashiwagi M, 2001, J BIOL CHEM, V276, P12501, DOI 10.1074/jbc.C000848200
   Kawasaki H, 2002, P NATL ACAD SCI USA, V99, P1580, DOI 10.1073/pnas.032662199
   Kaye R, 2017, INVEST OPHTH VIS SCI, V58
   KELLY J. P., 2014, RETINAL CASES BRIEF, P1
   Klenotic PA, 2004, J BIOL CHEM, V279, P30469, DOI 10.1074/jbc.M403026200
   Klimanskaya I, 2004, CLONING STEM CELLS, V6, P217, DOI 10.1089/1536230042323420
   Kokkinaki M, 2011, STEM CELLS, V29, P825, DOI 10.1002/stem.635
   Langton KP, 1998, J BIOL CHEM, V273, P16778, DOI 10.1074/jbc.273.27.16778
   Langton KP, 2000, J BIOL CHEM, V275, P27027
   Langton KP, 2005, HUM MOL GENET, V14, P3579, DOI 10.1093/hmg/ddi385
   Leach LL, J OCUL PHARM THER, V32, P317
   LECO KJ, 1994, J BIOL CHEM, V269, P9352
   Lee MH, 2007, J BIOL CHEM, V282, P6887, DOI 10.1074/jbc.M610490200
   Lee MH, 2001, BIOCHEM BIOPH RES CO, V280, P945, DOI 10.1006/bbrc.2000.4192
   Li Zheng, 2005, Expert Reviews in Molecular Medicine, V7, P1, DOI 10.1017/S1462399405010045
   Liao JL, 2010, HUM MOL GENET, V19, P4229, DOI 10.1093/hmg/ddq341
   Lin RJ, 2006, AM J OPHTHALMOL, V142, P839, DOI 10.1016/j.ajo.2006.06.003
   Lukovic D, 2015, SCI REP-UK, V5, DOI 10.1038/srep12910
   Lynn SA, 2017, TISSUE CELL, V49, P447, DOI 10.1016/j.tice.2017.06.003
   Macario AJL, 2002, AGEING RES REV, V1, P295, DOI 10.1016/S1568-1637(01)00005-8
   Malemud CJ, 2006, FRONT BIOSCI-LANDMRK, V11, P1696, DOI 10.2741/1915
   Maminishkis A, 2006, INVEST OPHTH VIS SCI, V47, P3612, DOI 10.1167/iovs.05-1622
   MANNAGH J, 1973, INVEST OPHTH VISUAL, V12, P52
   Marchler-Bauer A, 2017, NUCLEIC ACIDS RES, V45, pD200, DOI 10.1093/nar/gkw1129
   Marmorstein LHY, 2002, P NATL ACAD SCI USA, V99, P13067, DOI 10.1073/pnas.202491599
   McCafferty CL, 2016, SCI DATA, V3, DOI 10.1038/sdata.2016.112
   Meunier I, 2016, SCI REP-UK, V6, DOI 10.1038/srep32544
   Moshfegh Y, 2016, HUM MOL GENET, V25, P2672, DOI 10.1093/hmg/ddw126
   Mullins RF, 2001, EYE, V15, P390, DOI 10.1038/eye.2001.142
   MURPHY G, 1991, BIOCHEMISTRY-US, V30, P8097, DOI 10.1021/bi00247a001
   Nagase H, 1999, J BIOL CHEM, V274, P21491, DOI 10.1074/jbc.274.31.21491
   Navratilova Z, 2016, ARCH IMMUNOL THER EX, V64, P177, DOI 10.1007/s00005-015-0375-5
   OKA MS, 1984, EXP CELL RES, V154, P537, DOI 10.1016/0014-4827(84)90178-2
   Osakada F, 2009, J CELL SCI, V122, P3169, DOI 10.1242/jcs.050393
   Parfitt DA, 2016, CELL STEM CELL, V18, P769, DOI 10.1016/j.stem.2016.03.021
   Paschen W, 2001, J NEUROCHEM, V79, P719, DOI 10.1046/j.1471-4159.2001.00623.x
   Pettersen EF, 2004, J COMPUT CHEM, V25, P1605, DOI 10.1002/jcc.20084
   Puech B., 2014, INHERITED CHORIORECT
   Qi JH, 2003, NAT MED, V9, P407, DOI 10.1038/nm846
   Qi JH, 2002, J BIOL CHEM, V277, P13394, DOI 10.1074/jbc.M110870200
   Qi JH, 2015, APOPTOSIS, V20, P523, DOI 10.1007/s10495-014-1076-y
   Qi JH, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055667
   Qi JH, 2009, J BIOL CHEM, V284, P19927, DOI 10.1074/jbc.M109.013763
   Ratnayaka J. A., 2015, INVEST OPHTHALMOL VI, V56
   Rizzolo LJ, 2014, EXP EYE RES, V126, P16, DOI 10.1016/j.exer.2013.12.018
   Saihan Z, 2009, MOL VIS, V15, P1218
   Schoenberger SD, 2013, RETINA-J RET VIT DIS, V33, P429, DOI 10.1097/IAE.0b013e318263d3b4
   Schwartz SD, 2012, LANCET, V379, P713, DOI 10.1016/S0140-6736(12)60028-2
   Singh R, 2013, HUM MOL GENET, V22, P593, DOI 10.1093/hmg/dds469
   Sivaprasad S, 2008, AM J OPHTHALMOL, V146, P228, DOI 10.1016/j.ajo.2008.03.024
   Smith MR, 1997, CYTOKINE, V9, P770, DOI 10.1006/cyto.1997.0233
   SORSBY A, 1949, BRIT J OPHTHALMOL, V33, P67, DOI 10.1136/bjo.33.2.67
   Spiro RG, 2002, GLYCOBIOLOGY, V12, p43R, DOI 10.1093/glycob/12.4.43R
   Stamer WD, 2003, INVEST OPHTH VIS SCI, V44, P2803, DOI 10.1167/iovs.03-0001
   Stone EM, 1999, NAT GENET, V22, P199, DOI 10.1038/9722
   Tabata Y, 1998, HUM GENET, V103, P179, DOI 10.1007/s004390050803
   Takahashi K, 2006, CELL, V126, P663, DOI 10.1016/j.cell.2006.07.024
   Thomson JA, 1998, SCIENCE, V282, P1145, DOI 10.1126/science.282.5391.1145
   Vaajasaari H, 2011, MOL VIS, V17, P558
   Vranka JA, 1997, CURR EYE RES, V16, P102, DOI 10.1076/ceyr.16.2.102.5086
   Vugler A, 2008, EXP NEUROL, V214, P347, DOI 10.1016/j.expneurol.2008.09.007
   Warwick A, 2016, EYE, V30, P488, DOI 10.1038/eye.2015.204
   Weber BHF, 2002, INVEST OPHTH VIS SCI, V43, P2732
   WEBER BHF, 1994, NAT GENET, V8, P352, DOI 10.1038/ng1294-352
   Williams CD, 1997, ANAT RECORD, V249, P380, DOI 10.1002/(SICI)1097-0185(199711)249:3<380::AID-AR9>3.0.CO;2-Y
   WILLIAMSON RA, 1990, BIOCHEM J, V268, P267, DOI 10.1042/bj2680267
   Xiao QH, 2010, PFLUG ARCH EUR J PHY, V460, P559, DOI 10.1007/s00424-010-0821-5
   Yeow KM, 2002, MATRIX BIOL, V21, P75, DOI 10.1016/S0945-053X(01)00180-9
   YOUNG RW, 1969, J CELL BIOL, V42, P392, DOI 10.1083/jcb.42.2.392
NR 132
TC 28
Z9 28
U1 0
U2 8
PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 0014-4835
EI 1096-0007
J9 EXP EYE RES
JI Exp. Eye Res.
PD DEC
PY 2017
VL 165
BP 35
EP 46
DI 10.1016/j.exer.2017.08.014
PG 12
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA FQ4GL
UT WOS:000418315600005
PM 28847738
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Frennesson, CI
   Nilsson, SEG
AF Frennesson, Christina I.
   Nilsson, Sven Erik G.
TI A three-year follow-up of ranibizumab treatment of exudative AMD: impact
   on the outcome of carrying forward the last acuity observation in
   drop-outs
SO ACTA OPHTHALMOLOGICA
LA English
DT Article
DE drop-outs; long-term results; ranibizumab treatment; exudative AMD
ID CHOROIDAL NEOVASCULARIZATION SECONDARY; MACULAR DEGENERATION
AB Abstract.
   Purpose: To analyse a 3-year clinical patient cohort of ranibizumab treatment of exudative age-related macular degeneration (AMD), to investigate the impact on visual outcome of carrying forward the last acuity observation in drop-outs and to explore possible differences between the early and the late phase of the study.
   Methods: A retrospective study of 312 eyes with neovascular AMD. The patients were followed up monthly, received three initial monthly injections of 0.5 mg ranibizumab and were re-treated pro re nata (PRN). Time-domain optical coherence tomography (TD-OCT) was used until spectral-domain (SD)-OCT was introduced during the last year of enrolment. Sixty-five patients were discontinued from the study. Primary outcome: change in best corrected visual acuity (BCVA).
   Results: Best corrected visual acuity was 58.4 (CI 56.9-59.9) ETDRS (Early Treatment Diabetic Retinopathy Study) letters. At three months, it had increased by 4.1 letters (p = 0.0004), at 12 months by 1.8 letters, at 24 months by 1.0 letter and at 36 months by 0.1 letter. However, if the last available acuity of drop-outs was carried forward one step and included, acuity had increased by 3.9 letters at 3 months (p < 0.0001) and by 1.0 letter at 12 months but had decreased by 3.8 letters at 24 months (p = 0.019) and by 4.1 letters (p = 0.003) at 36 months. At 24 months, the result was significantly (p = 0.030) less favourable when drop-outs were included. In patients enrolled during the late phase, BCVA was 59.3 (CI 56.7-62.0). It had increased by 5.7 letters (p < 0.0001) at three months and by 5.8 letters at 12 months (p = 0.0016). In patients enrolled during the early phase, BCVA was 57.9 (CI 55.0-60.8). At three months, it had increased by 3.5 letters (p = 0.0008), but at 12 months, it had decreased by 2.3 letters (ns). The result at 12 months was significantly (p = 0.0033) better for the late than for the early phase. The number of injections was also significantly (p = 0.011) higher in the late phase. Adverse events were similar to those in earlier clinical trials.
   Conclusions: The results of this 3-year cohort showed that the initial average acuity could be maintained over 36 months, which was comparable to those of many other clinical cohorts. However, if the last available acuity of drop-outs was carried forward one step and included, the acuity figures would have fallen significantly. The results in patients enrolled during the late phase of the study were fairly similar to those in clinical trials.
C1 [Frennesson, Christina I.; Nilsson, Sven Erik G.] Linkoping Univ, Dept Ophthalmol, SE-58185 Linkoping, Sweden.
C3 Linkoping University
RP Frennesson, CI (通讯作者)，Linkoping Univ, Dept Ophthalmol, SE-58185 Linkoping, Sweden.
EM christina.frennesson@lio.se
CR Bandukwala T, 2010, CAN J OPHTHALMOL, V45, P590, DOI 10.3129/i10-082
   Bloch SB, 2011, ACTA OPHTHALMOL
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Cohen SY, 2009, AM J OPHTHALMOL, V148, P409, DOI 10.1016/j.ajo.2009.04.001
   Dadgostar H, 2009, OPHTHALMOLOGY, V116, P1740, DOI 10.1016/j.ophtha.2009.05.033
   Gerding H, 2011, GRAEF ARCH CLIN EXP, V249, P653, DOI 10.1007/s00417-011-1636-6
   Heimes B, 2011, GRAEF ARCH CLIN EXP, V249, P639, DOI 10.1007/s00417-010-1524-5
   Hjelmqvist L, 2011, J OPHTHALMOL, V2011, DOI 10.1155/2011/405724
   Holz FG, 2010, INVEST OPHTH VIS SCI, V51, P405, DOI 10.1167/iovs.09-3813
   Katz G, 2012, RETINA-J RET VIT DIS, V32, P293, DOI 10.1097/IAE.0b013e31821e20b0
   Lala C, 2012, ACTA OPHTHALMOL
   Michalova K, 2009, EYE, V23, P1633, DOI 10.1038/eye.2009.175
   Mitchell P, 2010, BRIT J OPHTHALMOL, V94, P2, DOI 10.1136/bjo.2009.159160
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Singer MA, 2012, OPHTHALMOLOGY, V119, P1175, DOI 10.1016/j.ophtha.2011.12.016
NR 15
TC 20
Z9 20
U1 0
U2 2
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1755-375X
EI 1755-3768
J9 ACTA OPHTHALMOL
JI Acta Ophthalmol.
PD MAY
PY 2014
VL 92
IS 3
BP 216
EP 220
DI 10.1111/aos.12091
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AF2HJ
UT WOS:000334532900011
PM 23452436
DA 2022-11-30
ER

PT J
AU Fang, IM
   Yang, CH
   Yang, CM
   Chen, MS
AF Fang, I-Mo
   Yang, Chang-Hao
   Yang, Chung-May
   Chen, Muh-Shy
TI Overexpression of integrin alpha(6) and beta(4) enhances adhesion and
   proliferation of human retinal pigment epithelial cells on layers of
   porcine Bruch's membrane
SO EXPERIMENTAL EYE RESEARCH
LA English
DT Article
DE age-related macular degeneration; integrin alpha(6)beta(4); retinal
   pigment epithelium transplantation; Bruch's membrane
ID JUNCTIONAL EPIDERMOLYSIS-BULLOSA; MACULAR DEGENERATION; CHOROIDAL
   NEOVASCULARIZATION; ALPHA-6-BETA-4 INTEGRIN; EXTRACELLULAR-MATRIX;
   PYLORIC ATRESIA; CLINICOPATHOLOGICAL CORRELATION; TRANSPLANTATION;
   BINDING; RPE
AB Transplantation of retinal pigment epithelium (RPE) following removal of choroidal neovascular membranes has been attempted in patients with age-related macular degeneration (AMD). However, inability of transplanted RPE to initially attach and subsequently proliferate on Bruch's membrane may lead to failure of RPE transplants and poor visual outcomes. Integrin alpha(6)beta(4) functions as a receptor for laminin, the major component of Bruch's membrane, and mediates the stable attachment of most epithelial cells to the underlying basement membrane. To improve adhesion and proliferation of transplanted RPE on Bruch's membrane, we elucidated the roles of integrin alpha(6)beta(4) in RPE adhesion to extracellular matrix and investigated whether ex vivo gene transfer of integrin alpha(6) and beta(4) in RPE could promote adhesion and proliferation of transplanted RPE on Bruch's membrane. The expression of integrin alpha(6) and beta(4) mRNA and surface protein in ARPE-19 cells was analyzed by reverse transcription-polymerase chain reaction (RT-PCR) and flow cytometric analysis. We generated point mutation in the ligand binding domain of integrin alpha(6) and beta(4) by using site-directed mutagenesis and transfected these mutated constructs into ARPE-19 cells. Adhesion assay was used to determine the roles of integrin alpha(6) and beta(4) in RPE adhesion to extracellular matrix. In addition, we transfected full-length alpha(6) cDNA or beta(4) cDNA into ARPE-19 cells. The reattachment and proliferation ratios of alpha(6)-cDNA- or beta(4)-cDNA-transfected ARPE-19 cells on different layers of Bruch's membrane were determined by cell adhesion and proliferation assays. Cell morphology and surface coverage were evaluated by scanning electron microscopy 7 days after plating on various layers of Bruch's membrane. We found that integrin alpha(6) and beta(4) mRNA and proteins were constitutively expressed in ARPE-19 cells. Decreased endogenous integrin alpha(6) and beta(4) expression by selective mutation of amino acid residues caused a significant reduction in adhesion of ARPE-19 cells to laminin 5. Modification of integrin expression by transfection of alpha(6) cDNA into ARPE-19 cells induced a significant increase in cell adhesion to laminin 5, fibronectin, whereas transfection with beta(4) cDNA caused increased adhesion only to laminin 5. alpha(6)-cDNA-transfectants increased cell attachment and proliferation on all layers of Bruch's membrane, whereas beta(4)-CDNA-transfectants enhanced adhesion and proliferation on basal lamina and inner collagenous layers. These data indicate that integrin alpha(6) and beta(4) play a role in adhesion of ARPE-19 cells to extracellular matrix. Modification of integrin expression by ex vivo genetic manipulation in RPE might be an alternative strategy to increase the success of RPE transplantation. (C) 2008 Elsevier Ltd. All rights reserved.
C1 [Fang, I-Mo; Yang, Chang-Hao; Yang, Chung-May; Chen, Muh-Shy] Natl Taiwan Univ Hosp, Dept Ophthalmol, Taipei, Taiwan.
   [Fang, I-Mo] Taipei City Hosp, Dept Ophthalmol, ZhongXiao Branch, Taipei, Taiwan.
C3 National Taiwan University; National Taiwan University Hospital; Taipei
   City Hospital
RP Yang, CH (通讯作者)，Natl Taiwan Univ Hosp, Dept Ophthalmol, 7 Chung Shan S Rd, Taipei, Taiwan.
EM chyangoph@ntu.edu.tw
RI Yang, Chung-May/AAV-3737-2020; Yang, Chang-Hao/AAR-3759-2021
OI YANG, CHANG-HAO/0000-0002-4328-8716; YANG, CHUNG-MAY/0000-0003-4082-420X
FU National Science Council, Executive Yuan, Republic of China [NSC
   96-2628-B-002-032-MY3]; Department of Health, Taipei City Government
   [95002-62-054]
FX This study was supported by grant NSC 96-2628-B-002-032-MY3 from the
   National Science Council, Executive Yuan, Republic of China and grant
   95002-62-054 from the Department of Health, Taipei City Government.
CR Aisenbrey S, 2006, INVEST OPHTH VIS SCI, V47, P5537, DOI 10.1167/iovs.05-1590
   Algvere PV, 1999, EUR J OPHTHALMOL, V9, P217, DOI 10.1177/112067219900900310
   ALGVERE PV, 1994, GRAEF ARCH CLIN EXP, V232, P707, DOI 10.1007/BF00184273
   Allegra M, 2003, J INVEST DERMATOL, V121, P1336, DOI 10.1111/j.1523-1747.2003.12625.x
   Arnaout MA, 2007, CURR OPIN CELL BIOL, V19, P495, DOI 10.1016/j.ceb.2007.08.002
   Ashton GHS, 2001, BRIT J DERMATOL, V144, P408, DOI 10.1046/j.1365-2133.2001.04038.x
   AVERY RL, 1986, ARCH OPHTHALMOL-CHIC, V104, P1220
   Berman A E, 2000, Membr Cell Biol, V13, P207
   Binder S, 2002, AM J OPHTHALMOL, V133, P215, DOI 10.1016/S0002-9394(01)01373-3
   Binder S, 2007, PROG RETIN EYE RES, V26, P516, DOI 10.1016/j.preteyeres.2007.02.002
   BRAEKEVELT CR, 1986, ANAT HISTOL EMBRYOL, V15, P205, DOI 10.1111/j.1439-0264.1986.tb00712.x
   Castellarin AA, 1998, BRIT J OPHTHALMOL, V82, P480, DOI 10.1136/bjo.82.5.480
   Castellarin AA, 1998, RETINA-J RET VIT DIS, V18, P143, DOI 10.1097/00006982-199818020-00008
   CHU PG, 1991, INVEST OPHTH VIS SCI, V32, P1763
   DAS A, 1990, ARCH OPHTHALMOL-CHIC, V108, P421, DOI 10.1001/archopht.1990.01070050119045
   Del Priore LV, 2006, PROG RETIN EYE RES, V25, P539, DOI 10.1016/j.preteyeres.2006.08.001
   Del Priore LV, 1998, ARCH OPHTHALMOL-CHIC, V116, P335, DOI 10.1001/archopht.116.3.335
   Del Priore LV, 2001, AM J OPHTHALMOL, V131, P472, DOI 10.1016/S0002-9394(00)00850-3
   DELPRIORE LV, 1995, ARCH OPHTHALMOL-CHIC, V113, P939, DOI 10.1001/archopht.1995.01100070113034
   Geng L, 2000, INVEST OPHTH VIS SCI, V41, pS857
   Geng L, 2001, INVEST OPHTH VIS SCI, V42, pS932
   Grossniklaus HE, 1998, ARCH OPHTHALMOL-CHIC, V116, P745, DOI 10.1001/archopht.116.6.745
   Gullapalli Vamsi K, 2004, Trans Am Ophthalmol Soc, V102, P123
   Gullapalli VK, 2008, EXP EYE RES, V86, P189, DOI 10.1016/j.exer.2007.10.009
   Gullapalli VK, 2005, EXP EYE RES, V80, P235, DOI 10.1016/j.exer.2004.09.006
   Ho TC, 1997, INVEST OPHTH VIS SCI, V38, P1110
   Hynes RO, 2002, CELL, V110, P673, DOI 10.1016/S0092-8674(02)00971-6
   Kiilgaard JF, 2005, ACTA OPHTHALMOL SCAN, V83, P697, DOI 10.1111/j.1600-0420.2005.00566.x
   Kikkawa Y, 2000, J CELL SCI, V113, P869
   Klein R, 1997, OPHTHALMOLOGY, V104, P7, DOI 10.1016/S0161-6420(97)30368-6
   Lassota N, 2006, GRAEF ARCH CLIN EXP, V244, P394, DOI 10.1007/s00417-005-0061-0
   Levinson H, 2002, J CELL PHYSIOL, V193, P219, DOI 10.1002/jcp.10164
   Lund RD, 2001, P NATL ACAD SCI USA, V98, P9942, DOI 10.1073/pnas.171266298
   Mercurio AM, 2001, SEMIN CANCER BIOL, V11, P129, DOI 10.1006/scbi.2000.0364
   Mercurio AM, 2001, CURR OPIN CELL BIOL, V13, P541, DOI 10.1016/S0955-0674(00)00249-0
   Merrill PT, 1999, OPHTHALMOLOGY, V106, P782, DOI 10.1016/S0161-6420(99)90167-7
   MILI H, 1975, INVEST OPHTH VIS SCI, V14, P712
   MITCHELL P, 1995, OPHTHALMOLOGY, V102, P1450
   Mousa SA, 1999, J CELL BIOCHEM, V74, P135, DOI 10.1002/(SICI)1097-4644(19990701)74:1<135::AID-JCB15>3.0.CO;2-#
   NAKAIZUMI Y, 1964, ARCH OPHTHALMOL-CHIC, V72, P380, DOI 10.1001/archopht.1964.00970020380016
   NIESSEN CM, 1994, EXP CELL RES, V211, P360, DOI 10.1006/excr.1994.1099
   PEYMAN GA, 1991, OPHTHALMIC SURG LAS, V22, P102
   Ruzzi L, 1997, J CLIN INVEST, V99, P2826, DOI 10.1172/JCI119474
   Saigo Y, 2004, INVEST OPHTH VIS SCI, V45, P1996, DOI 10.1167/iovs.03-0777
   Shiragami C, 1998, BRIT J OPHTHALMOL, V82, P1056, DOI 10.1136/bjo.82.9.1056
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   SONNENBERG A, 1991, J CELL BIOL, V113, P907, DOI 10.1083/jcb.113.4.907
   STEPP MA, 1990, P NATL ACAD SCI USA, V87, P8970, DOI 10.1073/pnas.87.22.8970
   Sun H, 1998, CANCER RES, V58, P2224
   Tezel TH, 1997, GRAEF ARCH CLIN EXP, V235, P41, DOI 10.1007/BF01007836
   Tezel TH, 1999, INVEST OPHTH VIS SCI, V40, P467
   Tsuruta D, 2003, J BIOL CHEM, V278, P38707, DOI 10.1074/jbc.M301637200
   van der Flier A, 2001, CELL TISSUE RES, V305, P285, DOI 10.1007/s004410100417
   Verwaerde C, 2003, GENE THER, V10, P1970, DOI 10.1038/sj.gt.3302101
   West SK, 2000, EPIDEMIOL REV, V22, P64, DOI 10.1093/oxfordjournals.epirev.a018025
   Zarbin Marco A, 2003, Trans Am Ophthalmol Soc, V101, P499
NR 56
TC 25
Z9 26
U1 0
U2 10
PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 0014-4835
J9 EXP EYE RES
JI Exp. Eye Res.
PD JAN
PY 2009
VL 88
IS 1
BP 12
EP 21
DI 10.1016/j.exer.2008.09.019
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 393TL
UT WOS:000262395800003
PM 18955047
DA 2022-11-30
ER

PT J
AU Cestari, DM
   Gaier, ED
   Bouzika, P
   Blachley, TS
   De Lott, LB
   Rizzo, JF
   Wiggs, JL
   Kang, JH
   Pasquale, LR
   Stein, JD
AF Cestari, Dean M.
   Gaier, Eric D.
   Bouzika, Peggy
   Blachley, Taylor S.
   De Lott, Lindsey B.
   Rizzo, Joseph F.
   Wiggs, Janey L.
   Kang, Jae H.
   Pasquale, Louis R.
   Stein, Joshua D.
TI Demographic, Systemic, and Ocular Factors Associated with Nonarteritic
   Anterior Ischemic Optic Neuropathy
SO OPHTHALMOLOGY
LA English
DT Article
ID RETINAL VEIN OCCLUSION; RISK-FACTORS; UNITED-STATES; ASPIRIN; IMPACT;
   NAION; CARE
AB Objective: Nonarteritic anterior ischemic optic neuropathy (NAION) is a devastating ocular condition causing permanent vision loss. Little is known about risk factors for developing this disease. We assessed demographic, systemic, and ocular factors associated with NAION.
   Design: Retrospective longitudinal cohort study.
   Participants: Beneficiaries between 40 and 75 years old without NAION at baseline enrolled in a large U.S. managed care network.
   Methods: Enrollees were monitored continuously for >= 2 years between 2001 and 2014 to identify those newly diagnosed with NAION (International Classification of Diseases, 9th Revision, Clinical Modification [ICD-9-CM] code 377.41). All persons were under ophthalmic surveillance and all cases had >= 1 confirmatory ICD-9-CM code for NAION during follow-up.
   Main Outcome Measures: Multivariable Cox regression modeling was used to generate hazard ratios (HRs) with 95% confidence intervals (CIs) to describe the statistical relationship between selected demographic characteristics, systemic and ocular conditions, and the hazard of developing NAION.
   Results: Of 1 381 477 eligible enrollees, 977 (0.1%) developed NAION during a mean +/- standard deviation (SD) follow-up of 7.8+/-3.1 years. The mean +/- SD age for NAION cases at the index date was 64.0+/-9.2 years vs. 58.4+/-9.4 years for the remainder of the beneficiaries. After adjustment for confounding factors, each additional year older was associated with a 2% increased hazard of NAION (HR = 1.02; 95% CI: 1.01-1.03). Female subjects had a 36% decreased hazard of developing NAION (HR = 0.64; 95% CI: 0.55-0.74) compared with male subjects. Compared with whites, Latinos had a 46% decreased hazard of developing NAION (HR = 0.54; 95% CI: 0.36-0.82), whereas African ancestry was not significantly associated with NAION (HR = 0.91; 95% CI: 0.72-1.15). Systemic diseases associated with NAION included hypertension (HR = 1.62; 95% CI: 1.26-2.07) and hypercoagulable states (HR = 2.46; 95% CI: 1.51-4.00). Although diabetes mellitus (DM) was not significantly associated with NAION compared with those without DM (P = 0.45), patients with end-organ involvement from DM had a 27% increased hazard of NAION relative to those with uncomplicated DM (HR = 1.27; 95% CI: 1.01-1.59). Ocular diseases associated with NAION were age-related macular degeneration (HR = 1.29; 95% CI: 1.08-1.54) and retinal vein occlusion (HR = 3.94; 95% CI: 3.11-4.99).
   Conclusions: Our study identified several modifiable risk factors that may be associated with NAION. Should future studies confirm these findings, they may offer opportunities to prevent or treat this debilitating condition. (C) 2016 by the American Academy of Ophthalmology
C1 [Cestari, Dean M.; Gaier, Eric D.; Bouzika, Peggy; Rizzo, Joseph F.; Wiggs, Janey L.; Pasquale, Louis R.] Harvard Med Sch, Dept Ophthalmol, Boston, MA USA.
   [Blachley, Taylor S.; De Lott, Lindsey B.; Stein, Joshua D.] Univ Michigan, Sch Med, Dept Ophthalmol & Visual Sci, Ann Arbor, MI USA.
   [Kang, Jae H.; Pasquale, Louis R.] Harvard Med Sch, Brigham & Womens Hosp, Dept Med, Channing Div Network Med, Boston, MA USA.
   [Stein, Joshua D.] Univ Michigan, Sch Publ Hlth, Dept Hlth Management & Policy, Ann Arbor, MI 48109 USA.
   [Stein, Joshua D.] Univ Michigan, Inst Healthcare Policy & Innovat, Ann Arbor, MI 48109 USA.
C3 Harvard University; Harvard Medical School; University of Michigan
   System; University of Michigan; Harvard University; Brigham & Women's
   Hospital; Harvard Medical School; University of Michigan System;
   University of Michigan; University of Michigan System; University of
   Michigan
RP Cestari, DM (通讯作者)，Mass Eye & Ear, Dept Ophthalmol, 243 Charles St, Boston, MA 02114 USA.
EM Dean_Cestari@meei.harvard.edu
OI De Lott, Lindsey/0000-0003-2403-0207; Stein, Joshua/0000-0003-2937-6987
FU Allergan, Parsippany, NJ; Merck, Kenilworth, NJ; Research to Prevent
   Blindness (New York, NY); W.K. Kellogg Foundation (Battle Creek, MI)
FX The author(s) have made the following disclosure(s): L.R.P.: Consultant
   - Bausch & Lomb, Rochester, NY; and Novartis, Basel, Switzerland;
   Speaker fee - Allergan, Parsippany, NJ; Unrestricted grant - Merck,
   Kenilworth, NJ; Travel support - The Glaucoma Foundation, New York City,
   NY; Aerie Pharmaceuticals, Inc., Bedminster, NJ; and Glaukos, Laguna
   Hills, CA.; J.D.S.: Support - Research to Prevent Blindness (New York,
   NY) and W.K. Kellogg Foundation (Battle Creek, MI).
CR Arnold AC, 2003, J NEURO-OPHTHALMOL, V23, P157, DOI 10.1097/00041327-200306000-00012
   Beck RW, 1997, AM J OPHTHALMOL, V123, P212, DOI 10.1016/S0002-9394(14)71038-4
   Biousse V, 2015, NEW ENGL J MED, V372, P2428, DOI 10.1056/NEJMra1413352
   Botelho PJ, 1996, AM J OPHTHALMOL, V121, P450, DOI 10.1016/S0002-9394(14)70448-9
   CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8
   Chen PL, 2006, NEUROLOGY, V67, P1056, DOI 10.1212/01.wnl.0000237526.32692.67
   Chen T, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076653
   CHUNG SM, 1994, OPHTHALMOLOGY, V101, P779
   Dai Yuxiang, 2012, Thrombosis, V2012, P245037, DOI 10.1155/2012/245037
   FONG ACO, 1992, RETINA-J RET VIT DIS, V12, P3, DOI 10.1097/00006982-199212010-00002
   Gedik S, 2007, EYE, V21, P129, DOI 10.1038/sj.eye.6702445
   Giambene B, 2009, GRAEF ARCH CLIN EXP, V247, P693, DOI 10.1007/s00417-008-0981-6
   Gulati S, 2014, JAMA PEDIATR, V168, P850, DOI 10.1001/jamapediatrics.2014.946
   GUYER DR, 1985, ARCH OPHTHALMOL-CHIC, V103, P1136
   Hattenhauer MG, 1997, AM J OPHTHALMOL, V123, P103, DOI 10.1016/S0002-9394(14)70999-7
   HAYREH SS, 1994, AM J OPHTHALMOL, V118, P766, DOI 10.1016/S0002-9394(14)72557-7
   HOSMER DW, 1989, BIOMETRICS, V45, P1265, DOI 10.2307/2531779
   Jacobson DM, 1997, ARCH OPHTHALMOL-CHIC, V115, P1403, DOI 10.1001/archopht.1997.01100160573008
   JOHNSON LN, 1994, J NEURO-OPHTHALMOL, V14, P38
   JONAS JB, 1993, INVEST OPHTH VIS SCI, V34, P2260
   Kupersmith MJ, 1997, J NEURO-OPHTHALMOL, V17, P250
   Lee MS, 2011, OPHTHALMOLOGY, V118, P959, DOI 10.1016/j.ophtha.2011.01.054
   Li A, 2015, WORLD NEUROSURG, V84, P2010, DOI 10.1016/j.wneu.2015.08.030
   Lind L, 2015, CLIN PHYSL FUNCT IMA
   Newman NJ, 1996, ARCH OPHTHALMOL-CHIC, V114, P1366
   Newman-Casey PA, 2014, OPHTHALMOLOGY, V121, P1939, DOI 10.1016/j.ophtha.2014.04.045
   Palombi K, 2006, BRIT J OPHTHALMOL, V90, P879, DOI 10.1136/bjo.2005.087452
   Parsa CF, 2015, OPHTHALMOLOGY, V122, P439, DOI 10.1016/j.ophtha.2014.11.011
   REPKA MX, 1983, AM J OPHTHALMOL, V96, P478, DOI 10.1016/S0002-9394(14)77911-5
   Sacco RL, 1997, STROKE, V28, P1507, DOI 10.1161/01.STR.28.7.1507
   SACCO SE, 1991, STROKE, V22, P1236, DOI 10.1161/01.STR.22.10.1236
   Salomon O, 1999, OPHTHALMOLOGY, V106, P739, DOI 10.1016/S0161-6420(99)90159-8
   Stein JD, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0123682
   Stein JD, 2015, JAMA OPHTHALMOL, V133, P290, DOI 10.1001/jamaophthalmol.2014.5103
   Stem MS, 2013, OPHTHALMOLOGY, V120, P362, DOI 10.1016/j.ophtha.2012.07.080
   Stenborg A, 2006, J INTERN MED, V259, P569, DOI 10.1111/j.1365-2796.2006.01635.x
   TALKS SJ, 1995, EYE, V9, P85, DOI 10.1038/eye.1995.13
   Timmins CL, 2002, J MIDWIFERY WOM HEAL, V47, P80, DOI 10.1016/S1526-9523(02)00218-0
   Tsai C S, 1995, J Glaucoma, V4, P248
   Yao FJ, 2016, GRAEF ARCH CLIN EXP, V254, P977, DOI 10.1007/s00417-015-3212-y
NR 40
TC 47
Z9 50
U1 0
U2 14
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD DEC
PY 2016
VL 123
IS 12
BP 2446
EP 2455
DI 10.1016/j.ophtha.2016.08.017
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA EE3YZ
UT WOS:000389539900011
PM 27659545
DA 2022-11-30
ER

PT J
AU Harju, N
AF Harju (ex-Bhattarai), Niina
TI Regulation of oxidative stress and inflammatory responses in human
   retinal pigment epithelial cellsAvainsanat
SO ACTA OPHTHALMOLOGICA
LA English
DT Article
DE ARPE-19 cell; AMD; RPE cell; hydroquinone; Resvega; ROS; NLRP3;
   cytokines; VEGF; PEDF
ID MACULAR DEGENERATION AMD; GROWTH-FACTOR VEGF; INDUCED DNA-DAMAGE; NLRP3
   INFLAMMASOME; CELL-DEATH; GASDERMIN-D; CHOROIDAL NEOVASCULARIZATION;
   MOLECULAR-MECHANISMS; CIGARETTE-SMOKING; GENE-EXPRESSION
AB Age-related macular degeneration (AMD) is an eye disease, which causes impaired vision that can lead to blindness. The incidence of AMD increases with age. Retinal pigment epithelial (RPE) cells maintain retinal homeostasis and support the functionality of photoreceptors. In the pathogenesis of AMD, the degeneration of the RPE cells precedes photoreceptor cell death. RPE cells are susceptible to oxidative stress, and chronic inflammation involving nucleotide-binding domain, leucine-rich repeat and pyrin domain 3 (NLRP3) inflammasome activation and impaired autophagy are challenges faced by aged RPE cells in AMD. There are two types of AMD, dry (85-90%) and wet (10-15%) disease forms. Choroidal neovascularization is typical for wet AMD, and anti-vascular endothelial growth factor (anti-VEGF) injections are used to prevent the progression of the disease but there is no curative treatment. There is no cure for the dry disease form, but antioxidants have been proposed as a potential treatment option. Ageing is the most important risk factor of AMD, and tobacco smoke is the most important environmental risk factor that can be controlled. Hydroquinone is a cytotoxic, immunotoxic, carcinogenic and pro-oxidative component of tobacco smoke. The aim of this PhD thesis was to study hydroquinone-induced oxidative stress and NLRP3 inflammasome activation in human RPE cells (ARPE-19 cells). An age-related eye disease study (AREDS) formulation (incl. omega-3 fatty acids, vitamin C and E, copper, zinc, lutein and zeaxanthin), which is clinically investigated p.o. dosing combination of dietary supplements for AMD patients, has been evaluated as a possible treatment and restraining option for AMD. Resvega (4.1.1, Table 2) is a similar kind of product to AREDS with added resveratrol, and many of the components incorporated within Resvega can be considered as belonging to the normal antioxidative defence system of the retina. Another aim was to evaluate the effects of Resvega on hydroquinone-induced oxidative stress or NLRP3 inflammasome activation induced by impaired protein clearance. The results of this study reveal that hydroquinone elevated the activity of NADPH oxidase which subsequently mediated the production of reactive oxygen species (ROS) and predisposed RPE cells to degeneration by reducing levels of vascular endothelial growth factor (VEGF) and pigment epithelium-derived factor (PEDF). Hydroquinone induced an NLRP3-independent IL-18 release and NLRP3 accumulation inside the IL-1 alpha-primed cells. Resvega treatment reduced the extent of hydroquinone-induced ROS production and NLRP3 inflammasome activation evoked by impaired protein clearance. Thus, Resvega alleviated hydroquinone- and impaired protein clearance-induced stress in human RPE cells, but more studies are needed, for example, to reveal the most optimal route of administration for targeting the cells in the retina, since both oxidative stress and NLRP3 inflammasome activation are important contributors to the development of AMD and represent significant treatment targets.
C1 [Harju (ex-Bhattarai), Niina] Univ Eastern Finland, Sch Pharm, Kuopio, Finland.
C3 University of Eastern Finland
RP Harju, N (通讯作者)，Univ Eastern Finland, Sch Pharm, Publicat Univ Eastern Finland, Dissertat Hlth Sci, Kuopio, Finland.
EM niina.harju@uef.fi
OI Harju (ex-Bhattarai), Niina/0000-0001-9031-5353
FU University of Eastern Finland; Kuopio University Hospital
FX University of Eastern Finland; Kuopio University Hospital
CR Abdelsalam A, 1999, SURV OPHTHALMOL, V44, P1, DOI 10.1016/S0039-6257(99)00072-7
   Ablonczy Z, 2007, EXP EYE RES, V85, P762, DOI 10.1016/j.exer.2007.08.010
   Ablonczy Z, 2009, J BIOL CHEM, V284, P30177, DOI 10.1074/jbc.M109.032391
   Abokyi S, 2020, OXID MED CELL LONGEV, V2020, DOI 10.1155/2020/7901270
   Ivanescu AA, 2015, NUTRIENTS, V7, P5423, DOI 10.3390/nu7075229
   Afonina IS, 2015, IMMUNITY, V42, P991, DOI 10.1016/j.immuni.2015.06.003
   Aho J, 2016, PURINERG SIGNAL, V12, P575, DOI 10.1007/s11302-016-9508-5
   Alcazar O, 2007, INVEST OPHTH VIS SCI, V48, P5662, DOI 10.1167/iovs.07-0392
   Alfonso-Loeches S, 2014, FRONT CELL NEUROSCI, V8, DOI 10.3389/fncel.2014.00216
   Algvere PV, 2016, ACTA OPHTHALMOL, V94, P427, DOI 10.1111/aos.13011
   Amano S, 2005, MICROVASC RES, V69, P45, DOI 10.1016/j.mvr.2004.11.001
   Ambati J, 2012, NEURON, V75, P26, DOI 10.1016/j.neuron.2012.06.018
   Amores-Iniesta J, 2017, CELL REP, V21, P3414, DOI 10.1016/j.celrep.2017.11.079
   Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   Andreyev AI, 2005, BIOCHEMISTRY-MOSCOW+, V70, P200, DOI 10.1007/s10541-005-0102-7
   Ao J, 2018, CLIN EXP OPHTHALMOL, V46, P670, DOI 10.1111/ceo.13121
   Aon MA, 2010, BBA-BIOENERGETICS, V1797, P865, DOI 10.1016/j.bbabio.2010.02.016
   Ardeljan CP, 2014, J CLIN MED, V3, P1542, DOI 10.3390/jcm3041542
   Arjamaa O, 2017, GRAEF ARCH CLIN EXP, V255, P1757, DOI 10.1007/s00417-017-3711-0
   Armento A, 2021, CELL MOL LIFE SCI, V78, P4487, DOI 10.1007/s00018-021-03796-9
   Badham HJ, 2010, CHEM-BIOL INTERACT, V184, P218, DOI 10.1016/j.cbi.2009.11.005
   Baroja-Mazo A, 2014, NAT IMMUNOL, V15, P738, DOI 10.1038/ni.2919
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Bertram KM, 2009, AM J PHYSIOL-CELL PH, V297, pC1200, DOI 10.1152/ajpcell.00126.2009
   Bhisitkul RB, 2006, BRIT J OPHTHALMOL, V90, P1542, DOI 10.1136/bjo.2006.098426
   Bhutto IA, 2006, EXP EYE RES, V82, P99, DOI 10.1016/j.exer.2005.05.007
   Bhutto I, 2012, MOL ASPECTS MED, V33, P295, DOI 10.1016/j.mam.2012.04.005
   Bian ZM, 2018, EXP EYE RES, V172, P10, DOI 10.1016/j.exer.2018.03.015
   Biesemeier A, 2014, NEUROBIOL AGING, V35, P2562, DOI 10.1016/j.neurobiolaging.2014.05.003
   Bir SC, 2013, FREE RADICAL BIO MED, V63, P135, DOI 10.1016/j.freeradbiomed.2013.05.015
   Biswal MR, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0203816
   Bjorkoy G, 2009, METHOD ENZYMOL, V452, P181, DOI 10.1016/S0076-6879(08)03612-4
   Blasiak J, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21228840
   Blasiak J, 2017, OXID MED CELL LONGEV, V2017, DOI 10.1155/2017/5293258
   Bolton JL, 2000, CHEM RES TOXICOL, V13, P135, DOI 10.1021/tx9902082
   Bonilha VL, 2014, EXP EYE RES, V126, P38, DOI 10.1016/j.exer.2013.09.015
   Bonilha VL, 2008, CLIN OPHTHALMOL, V2, P413
   Bonilha VL, 1999, J CELL BIOL, V147, P1533, DOI 10.1083/jcb.147.7.1533
   Boucher D, 2018, J EXP MED, V215, P827, DOI 10.1084/jem.20172222
   Boulton M, 2001, EYE, V15, P384, DOI 10.1038/eye.2001.141
   Boulton ME, 2014, EXP EYE RES, V126, P61, DOI 10.1016/j.exer.2014.01.016
   Boyer NP, 2012, J BIOL CHEM, V287, P22276, DOI 10.1074/jbc.M111.329235
   BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3
   Brandes RP, 2014, FREE RADICAL BIO MED, V76, P208, DOI 10.1016/j.freeradbiomed.2014.07.046
   Brandstetter C, 2016, J PHOTOCH PHOTOBIO B, V161, P177, DOI 10.1016/j.jphotobiol.2016.05.018
   Bringmann A, 2018, PROG RETIN EYE RES, V66, P49, DOI 10.1016/j.preteyeres.2018.03.006
   Broz P, 2020, NAT REV IMMUNOL, V20, P143, DOI 10.1038/s41577-019-0228-2
   Broz P, 2016, NAT REV IMMUNOL, V16, P407, DOI 10.1038/nri.2016.58
   Bus P, 2017, DIABETOLOGIA, V60, P1813, DOI 10.1007/s00125-017-4322-3
   Campa C, 2013, EUR J OPHTHALMOL, V23, P690, DOI 10.5301/ejo.5000248
   Castro JP, 2019, REDOX BIOL, V21, DOI 10.1016/j.redox.2019.101108
   Chalam KV, 2014, J OPHTHALMOL, V2014, DOI 10.1155/2014/502174
   Chatziralli I., 2019, ACTA OPHTHALMOL, V97
   Chen HW, 2004, CHEM-BIOL INTERACT, V150, P233, DOI 10.1016/j.cbi.2004.09.014
   Chen M, 2015, J LEUKOCYTE BIOL, V98, P713, DOI 10.1189/jlb.3RI0615-239R
   Chen PM, 2011, CELL BIOSCI, V1, DOI 10.1186/2045-3701-1-10
   Chew EY, 2013, JAMA-J AM MED ASSOC, V309, P2005, DOI 10.1001/jama.2013.4997
   Chiras D, 2015, CRIT REV CL LAB SCI, V52, P12, DOI 10.3109/10408363.2014.968703
   Cho JY, 2008, MEDIAT INFLAMM, V2008, DOI 10.1155/2008/298010
   Chong DY, 2008, INVEST OPHTH VIS SCI, V49, P3193, DOI 10.1167/iovs.07-1641
   Chua SYL, 2022, BRIT J OPHTHALMOL, V106, P705, DOI 10.1136/bjophthalmol-2020-316218
   Clague MJ, 2010, CELL, V143, P682, DOI 10.1016/j.cell.2010.11.012
   Cohen I, 2010, P NATL ACAD SCI USA, V107, P2574, DOI 10.1073/pnas.0915018107
   Cohen T, 1996, J BIOL CHEM, V271, P736, DOI 10.1074/jbc.271.2.736
   Cordeiro RM, 2014, BBA-BIOMEMBRANES, V1838, P438, DOI 10.1016/j.bbamem.2013.09.016
   Curcio CA, 1996, INVEST OPHTH VIS SCI, V37, P1236
   Curcio Christine A, 2018, Invest Ophthalmol Vis Sci, V59, pAMD160, DOI 10.1167/iovs.18-24882
   Curcio CA, 2011, BRIT J OPHTHALMOL, V95, P1638, DOI 10.1136/bjophthalmol-2011-300344
   de Guimaraes TAC, 2022, BRIT J OPHTHALMOL, V106, P297, DOI 10.1136/bjophthalmol-2020-318452
   Deisinger PJ, 1996, J TOXICOL ENV HEALTH, V47, P31, DOI 10.1080/009841096161915
   Detwiler PB, 2018, YALE J BIOL MED, V91, P49
   Dib B, 2015, BBA-MOL CELL RES, V1853, P2897, DOI 10.1016/j.bbamcr.2015.08.012
   Dikalov S, 2011, FREE RADICAL BIO MED, V51, P1289, DOI 10.1016/j.freeradbiomed.2011.06.033
   Dinarello CA, 2006, AM J CLIN NUTR, V83, p447S
   Dinarello CA, 1999, METHODS, V19, P121, DOI 10.1006/meth.1999.0837
   Dinarello CA, 2018, IMMUNOL REV, V281, P8, DOI 10.1111/imr.12621
   Dinarello CA, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00289
   Doughan AK, 2008, CIRC RES, V102, P488, DOI 10.1161/CIRCRESAHA.107.162800
   Doyle SL, 2012, NAT MED, V18, P791, DOI 10.1038/nm.2717
   Elahy M, 2014, J ENDOCRINOL, V222, pR129, DOI 10.1530/JOE-14-0065
   Enguita FJ, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/542168
   Erlank H, 2011, FREE RADICAL BIO MED, V51, P2319, DOI 10.1016/j.freeradbiomed.2011.09.033
   Evavold CL, 2018, IMMUNITY, V48, P35, DOI 10.1016/j.immuni.2017.11.013
   Fahey E, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01426
   Fan Y, 2017, MOL MED REP, V16, P5195, DOI 10.3892/mmr.2017.7236
   Fernandes-Alnemri T, 2009, NATURE, V458, P509, DOI 10.1038/nature07710
   Ferrara N, 2016, TRANSL VIS SCI TECHN, V5, DOI 10.1167/tvst.5.2.10
   Ferrington DA, 2016, PROG RETIN EYE RES, V51, P69, DOI 10.1016/j.preteyeres.2015.09.002
   Finnemann SC, 2002, P NATL ACAD SCI USA, V99, P3842, DOI 10.1073/pnas.052025899
   Fisher CR, 2018, INVEST OPHTH VIS SCI, V59, pAMD41, DOI 10.1167/iovs.18-24289
   Ford KM, 2011, INVEST OPHTH VIS SCI, V52, P9478, DOI 10.1167/iovs.11-8353
   Fujihara M, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003119
   Gaidt MM, 2016, EMBO J, V35, P2167, DOI 10.15252/embj.201695415
   Garrido-Urbani S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0014665
   Gehrs KM, 2006, ANN MED, V38, P450, DOI 10.1080/07853890600946724
   Gemenetzi M, 2017, EYE, V31, P1, DOI 10.1038/eye.2016.208
   Ghasemi H, 2011, OCUL IMMUNOL INFLAMM, V19, P401, DOI 10.3109/09273948.2011.618902
   Ghose P, 2011, J IMMUNOL, V187, P1333, DOI 10.4049/jimmunol.1100092
   Gimenez-Xavier P, 2008, INT J MOL MED, V22, P781, DOI 10.3892/ijmm_00000085
   Golestaneh N, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2016.453
   Gong XM, 2017, ANTIOXIDANTS-BASEL, V6, DOI 10.3390/antiox6040100
   Gong Y, 2010, CELL TISSUE RES, V339, P437, DOI 10.1007/s00441-009-0908-5
   Gritsenko A, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.565924
   Guha S, 2014, ADV EXP MED BIOL, V801, P105, DOI 10.1007/978-1-4614-3209-8_14
   Hammond BR, 1996, VISION RES, V36, P3003, DOI 10.1016/0042-6989(96)00008-9
   Handa JT, 2017, BBA-MOL CELL BIOL L, V1862, P430, DOI 10.1016/j.bbalip.2016.07.013
   HANDELMAN GJ, 1988, INVEST OPHTH VIS SCI, V29, P850
   Hatano M, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0218632
   He Y, 2014, INVEST OPHTH VIS SCI, V55, DOI 10.1167/iovs.14-14696
   He Yuan, 2010, J Ocul Biol Dis Infor, V3, P92, DOI 10.1007/s12177-011-9061-y
   Heesterbeek TJ, 2020, INVEST OPHTH VIS SCI, V61, DOI 10.1167/iovs.61.3.18
   Heilig R, 2018, EUR J IMMUNOL, V48, P584, DOI 10.1002/eji.201747404
   Holmes DIR, 2005, GENOME BIOL, V6, DOI 10.1186/gb-2005-6-2-209
   Huang CX, 2015, J BIOL CHEM, V290, P5367, DOI 10.1074/jbc.M114.603738
   Huang QT, 2015, CELL PHYSIOL BIOCHEM, V35, P1654, DOI 10.1159/000373979
   Hurst J, 2017, ATLA-ALTERN LAB ANIM, V45, P11, DOI 10.1177/026119291704500105
   Hyttinen JMT, 2013, BBA-MOL CELL RES, V1833, P503, DOI 10.1016/j.bbamcr.2012.11.018
   Ichimura Y, 2018, FRONT ONCOL, V8, DOI 10.3389/fonc.2018.00210
   Intartaglia D, 2022, FEBS J, V289, P7199, DOI 10.1111/febs.16018
   Istrate Marina, 2020, Rom J Ophthalmol, V64, P100
   Jaclyn L, 2012, J OPHTHALMOL, V2012, P1
   Jang HH, 2018, J CANCER PREV, V23, P153, DOI 10.15430/JCP.2018.23.4.153
   Jiang F, 2011, PHARMACOL REV, V63, P218, DOI 10.1124/pr.110.002980
   Jiang L, 2016, BIOMED PHARMACOTHER, V84, P130, DOI 10.1016/j.biopha.2016.09.020
   Johansson A, 2015, CIRC-CARDIOVASC GENE, V8, P498, DOI 10.1161/CIRCGENETICS.114.000724
   Joharapurkar A, 2021, EUR J PHARMACOL, V899, DOI 10.1016/j.ejphar.2021.174032
   Josifovska N, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21030813
   Jundi K, 2015, BIOMOLECULES, V5, P1386, DOI 10.3390/biom5031386
   Kaarniranta K, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20102374
   Kaarniranta K, 2017, CELL BIOL TOXICOL, V33, P113, DOI 10.1007/s10565-016-9371-8
   Kaarniranta K, 2013, AUTOPHAGY, V9, P973, DOI 10.4161/auto.24546
   Kaarniranta K, 2011, J ALZHEIMERS DIS, V24, P615, DOI 10.3233/JAD-2011-101908
   Kaarniranta K, 2009, AGEING RES REV, V8, P128, DOI 10.1016/j.arr.2009.01.001
   Kagan DB, 2012, CLIN OPHTHALMOL, V6, P1471, DOI 10.2147/OPTH.S35139
   Kamoshita M, 2016, SCI REP-UK, V6, DOI 10.1038/srep30226
   Kassoff A, 1999, CONTROL CLIN TRIALS, V20, P573
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Katsuragi Yoshinori, 2016, Current Opinion in Toxicology, V1, P54, DOI 10.1016/j.cotox.2016.09.005
   Kauppinen A, 2016, CELL MOL LIFE SCI, V73, P1765, DOI 10.1007/s00018-016-2147-8
   Kauppinen A, 2012, IMMUNOL LETT, V147, P29, DOI 10.1016/j.imlet.2012.05.005
   Kauppinen Kaarniranta Salminen., 2020, FRONT IMMUNOL, V11, P1
   Kaushik S, 2018, NAT REV MOL CELL BIO, V19, P365, DOI 10.1038/s41580-018-0001-6
   Kay P, 2013, J CELL MOL MED, V17, P833, DOI 10.1111/jcmm.12070
   Kayagaki N, 2015, NATURE, V526, P666, DOI 10.1038/nature15541
   Kelley N, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20133328
   Khan JC, 2006, BRIT J OPHTHALMOL, V90, P75, DOI 10.1136/bjo.2005.073643
   Kim E, 2005, IMMUNOL LETT, V99, P24, DOI 10.1016/j.imlet.2004.11.025
   Kim J.Y., 2021, CELL, V10, P1
   Kim YE, 2013, ANNU REV BIOCHEM, V82, P323, DOI 10.1146/annurev-biochem-060208-092442
   Kinnunen K, 2017, J CELL COMMUN SIGNAL, V11, P275, DOI 10.1007/s12079-017-0396-4
   Kinnunen K, 2012, ACTA OPHTHALMOL, V90, P299, DOI 10.1111/j.1755-3768.2011.02179.x
   Knickelbein Jared E, 2015, Int Ophthalmol Clin, V55, P63, DOI 10.1097/IIO.0000000000000073
   Knodler LA, 2014, CELL HOST MICROBE, V16, P249, DOI 10.1016/j.chom.2014.07.002
   Korhonen E, 2021, EXP EYE RES, V209, DOI 10.1016/j.exer.2021.108687
   Korhonen E, 2020, FASEB J, V34, P6437, DOI 10.1096/fj.201902355RR
   Koskela A, 2016, NUTRIENTS, V8, DOI 10.3390/nu8050284
   Kubicz A., 2016, ACTA OPHTHALMOL, V94
   Kubicz A, 2019, ACTA OPHTHALMOL, V97, DOI 10.1111/j.1755-3768.2019.5449
   Kumar A, 2016, TRANSPL IMMUNOL, V35, P40, DOI 10.1016/j.trim.2016.02.003
   Kurihara T, 2016, ELIFE, V5, DOI 10.7554/eLife.14319
   Lafuente M, 2021, ANTIOXIDANTS-BASEL, V10, DOI 10.3390/antiox10030386
   Lakkaraju A, 2020, PROG RETIN EYE RES, V78, DOI 10.1016/j.preteyeres.2020.100846
   Lancon A., 2012, ACTA OPHTHALMOL, V90
   Lancon A, 2016, MOLECULES, V21, DOI 10.3390/molecules21030304
   Lee H, 2018, BIOMOL THER, V26, P417, DOI 10.4062/biomolther.2017.167
   Leemans JC, 2014, NAT REV NEPHROL, V10, P398, DOI 10.1038/nrneph.2014.91
   Leonard SS, 2003, BIOCHEM BIOPH RES CO, V309, P1017, DOI 10.1016/j.bbrc.2003.08.105
   Li FE, 2019, NEURAL DEV, V14, DOI 10.1186/s13064-019-0137-x
   Li HS, 2016, MITOCHONDRION, V28, P67, DOI 10.1016/j.mito.2016.03.005
   Li LR, 2014, CHEM-BIOL INTERACT, V209, P56, DOI 10.1016/j.cbi.2013.12.005
   Li Q, 1997, FUND APPL TOXICOL, V38, P158, DOI 10.1006/faat.1997.2346
   Li QH, 2008, MOL THER, V16, P1688, DOI 10.1038/mt.2008.164
   Li XY, 2013, J HEMATOL ONCOL, V6, DOI 10.1186/1756-8722-6-19
   Li YB, 2015, THERANOSTICS, V5, P1363, DOI 10.7150/thno.13181
   Li Y, 2008, EXP GERONTOL, V43, P1114, DOI 10.1016/j.exger.2008.08.052
   Licandro G, 2013, EUR J IMMUNOL, V43, P2126, DOI 10.1002/eji.201242918
   Ling XX, 2016, BIOMED ENVIRON SCI, V29, P80, DOI 10.3967/bes2016.008
   Liu HJ, 2017, MOL MED REP, V16, P2069, DOI 10.3892/mmr.2017.6838
   Liu KF, 2017, NAT CELL BIOL, V19, P732, DOI 10.1038/ncb3531
   Liu XD, 2005, AM J RESP CELL MOL, V33, P121, DOI 10.1165/rcmb.2003-0341OC
   Liu YZ, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0116792
   Liu Y, 2014, BASIC RES CARDIOL, V109, DOI 10.1007/s00395-014-0415-z
   Long Y, 2020, ECOTOX ENVIRON SAFE, V189, DOI 10.1016/j.ecoenv.2019.109937
   Lopez-Garcia J, 2014, J FUNCT BIOMATER, V5, P43, DOI 10.3390/jfb5020043
   Lu LL, 2009, ANTIOXID REDOX SIGN, V11, P715, DOI 10.1089/ARS.2008.2171
   Lugrin J, 2018, IMMUNOL REV, V281, P99, DOI 10.1111/imr.12618
   Luo LH, 2008, CHEM-BIOL INTERACT, V173, P1, DOI 10.1016/j.cbi.2008.02.002
   Luo X, 2012, GENE DEV, V26, P417, DOI 10.1101/gad.183509.111
   Ma QY, 2014, ANN NEUROL, V75, P209, DOI 10.1002/ana.24070
   Maloney JP, 2015, MEDIAT INFLAMM, V2015, DOI 10.1155/2015/387842
   Mammadzada P, 2020, CELL MOL LIFE SCI, V77, P819, DOI 10.1007/s00018-019-03422-9
   Marasco MR, 2018, DIABETES, V67, P1576, DOI 10.2337/db17-1280
   Marin-Castano ME, 2006, INVEST OPHTH VIS SCI, V47, P4098, DOI 10.1167/iovs.05-1230
   Martinon F, 2008, J LEUKOCYTE BIOL, V83, P507, DOI 10.1189/jlb.0607362
   Masland RH, 2012, NEURON, V76, P266, DOI 10.1016/j.neuron.2012.10.002
   Mayor A, 2007, NAT IMMUNOL, V8, P497, DOI 10.1038/ni1459
   Mazat JP, 2020, CELL MOL LIFE SCI, V77, P455, DOI 10.1007/s00018-019-03381-1
   Mazzoni F, 2014, EXP EYE RES, V126, P51, DOI 10.1016/j.exer.2014.01.010
   McKee CM, 2020, J LEUKOCYTE BIOL, V108, P937, DOI 10.1002/JLB.3MR0720-513R
   McLeod DS, 2009, INVEST OPHTH VIS SCI, V50, P4982, DOI 10.1167/iovs.09-3639
   Mehta H, 2008, INFLAMM RES, V57, P497, DOI 10.1007/s00011-008-8078-6
   Meyers AK, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9081808
   Michalska-Malecka K, 2015, EUR GERIATR MED, V6, P69, DOI 10.1016/j.eurger.2014.09.007
   Nguyen MVC, 2013, BIOCHEM PHARMACOL, V85, P1644, DOI 10.1016/j.bcp.2013.03.023
   Mitchell P., 2013, J AMER MED ASSOC, V309, P2005
   Mitter SK, 2014, AUTOPHAGY, V10, P1989, DOI 10.4161/auto.36184
   Mortimer L, 2016, NAT IMMUNOL, V17, P1176, DOI 10.1038/ni.3538
   Mousavi M., 2013, J OPTOM, V6, P176, DOI [10.1016/j.optom.2013.07.002, DOI 10.1016/j.optom.2013.07.002]
   Moustafa MT, 2017, J OCUL PHARMACOL TH, V33, P610, DOI 10.1089/jop.2016.0129
   Muftuoglu IK, 2018, GRAEF ARCH CLIN EXP, V256, P2035, DOI 10.1007/s00417-018-4093-7
   Murphy AJ, 2016, CELL METAB, V23, P155, DOI 10.1016/j.cmet.2015.09.024
   Nakahira K, 2011, NAT IMMUNOL, V12, P222, DOI 10.1038/ni.1980
   Nicolas MG, 1996, EXP EYE RES, V62, P399, DOI 10.1006/exer.1996.0045
   Nikota JK, 2014, J IMMUNOL, V193, P3134, DOI 10.4049/jimmunol.1302412
   Ohno-Matsui K, 2003, BIOCHEM BIOPH RES CO, V303, P962, DOI 10.1016/S0006-291X(03)00446-7
   Olmiere C, 2013, ACTA OPHTHALMOL, V91, DOI 10.1111/j.1755-3768.2013.F015.x
   Omoto Y, 2006, J IMMUNOL, V177, P8315, DOI 10.4049/jimmunol.177.12.8315
   Oster SF, 2004, SEMIN CELL DEV BIOL, V15, P125, DOI 10.1016/j.semcdb.2003.09.006
   Pages G, 2005, CARDIOVASC RES, V65, P564, DOI 10.1016/j.cardiores.2004.09.032
   Pascal JM, 2018, DNA REPAIR, V71, P177, DOI 10.1016/j.dnarep.2018.08.022
   Payne AJ, 2014, INT J MOL SCI, V15, P1865, DOI 10.3390/ijms15021865
   Pellegrini C, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00036
   Peng HH, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-16778-4
   Pennington KL, 2016, EYE VISION, V3, DOI 10.1186/s40662-016-0063-5
   Pereira CA, 2020, FRONT PHYSIOL, V10, DOI 10.3389/fphys.2019.01557
   Petrukhin Konstantin, 2013, Drug Discov Today Ther Strateg, V10, pe11
   Piippo N, 2018, CELL PHYSIOL BIOCHEM, V49, P359, DOI 10.1159/000492886
   Piippo N, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-25123-2
   Piippo N, 2014, BBA-MOL CELL RES, V1843, P3038, DOI 10.1016/j.bbamcr.2014.09.015
   Pons M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016722
   Profumo E, 2018, OXID MED CELL LONGEV, V2018, DOI 10.1155/2018/2373167
   Prokopiou E, 2019, BMJ OPEN OPHTHALMOL, V4, DOI 10.1136/bmjophth-2019-000326
   Provis Jan M, 2005, Clin Exp Optom, V88, P269
   Pryor WA, 1997, ENVIRON HEALTH PERSP, V105, P875, DOI 10.2307/3433297
   Pyatt DW, 1998, TOXICOL APPL PHARM, V149, P178, DOI 10.1006/taap.1998.8369
   Qazi BS, 2011, INT J INFLAMM, V2011, DOI 10.4061/2011/908468
   Qiao H, 2004, LAB INVEST, V84, P973, DOI 10.1038/labinvest.3700115
   Qin S, 2008, J INFLAMM RES, V1, P49
   Qiu FF, 2017, ONCOTARGET, V8, P268, DOI 10.18632/oncotarget.13613
   Querques G, 2011, J NUTR METAB, V2011, DOI 10.1155/2011/748361
   Rajapakse D, 2017, OXID MED CELL LONGEV, V2017, DOI 10.1155/2017/6926485
   Ramirez C, 2016, J OCUL PHARMACOL TH, V32, P102, DOI 10.1089/jop.2015.0083
   Ramirez C, 2013, NEUROTOXICOLOGY, V39, P102, DOI 10.1016/j.neuro.2013.08.004
   Rastogi R, 2017, FRONT CELL NEUROSCI, V10, DOI 10.3389/fncel.2016.00301
   Ratsimandresy RA, 2017, CELL MOL IMMUNOL, V14, P127, DOI 10.1038/cmi.2016.35
   Razani B, 2012, CELL METAB, V15, P534, DOI 10.1016/j.cmet.2012.02.011
   Roberts JS, 2015, INT J MOL SCI, V16, P23337, DOI 10.3390/ijms161023337
   Rodriguez-Menendez S., 2018, NUTRIENTS, V10, P1
   Roos-Mattjus P, 2004, ANN MED, V36, P285, DOI 10.1080/07853890310016324
   Ruhl S, 2016, ONCOTARGET, V7, P57481, DOI 10.18632/oncotarget.11421
   Ryhanen T, 2009, J CELL MOL MED, V13, P3616, DOI 10.1111/j.1582-4934.2008.00577.x
   Saint-Geniez M, 2009, P NATL ACAD SCI USA, V106, P18751, DOI 10.1073/pnas.0905010106
   Saito Y, 2018, REDOX BIOL, V19, P354, DOI 10.1016/j.redox.2018.09.004
   Saitoh T, 2016, J ALLERGY CLIN IMMUN, V138, P28, DOI 10.1016/j.jaci.2016.05.009
   Salven P, 2002, FASEB J, V16, P1471, DOI 10.1096/fj.02-0134fje
   Sanchez-Aranguren LC, 2018, FRONT PHYSIOL, V9, DOI 10.3389/fphys.2018.00083
   Sang X., 2016, INFLAMMASOME, V2, P13, DOI [10.1515/infl-2016-0001, DOI 10.1515/INFL-2016-0001]
   Sarna T, 2003, EXP EYE RES, V76, P89, DOI 10.1016/S0014-4835(02)00247-6
   Satoh E, 2011, J TOXICOL SCI, V36, P741, DOI 10.2131/jts.36.741
   Scheller J, 2011, BBA-MOL CELL RES, V1813, P878, DOI 10.1016/j.bbamcr.2011.01.034
   Schlanitz FG, 2017, BRIT J OPHTHALMOL, V101, P198, DOI 10.1136/bjophthalmol-2016-308422
   Schneider BE, 2010, EUR J IMMUNOL, V40, P396, DOI 10.1002/eji.200939583
   Schwarz A, 2006, J IMMUNOL, V176, P2896, DOI 10.4049/jimmunol.176.5.2896
   Shahandeh A., 2015, J ANTIOXIDANT ACTIVI, V1, P29
   Shao LY, 2020, FASEB J, V34, P1497, DOI 10.1096/fj.201901653R
   Sharma A, 2012, INDIAN J OPHTHALMOL, V60, P189, DOI 10.4103/0301-4738.95869
   Shi JJ, 2015, NATURE, V526, P660, DOI 10.1038/nature15514
   Shibuya M, 2006, EXP CELL RES, V312, P549, DOI 10.1016/j.yexcr.2005.11.012
   Shibuya Masabumi, 2011, Genes Cancer, V2, P1097, DOI 10.1177/1947601911423031
   Shimada K, 2012, IMMUNITY, V36, P401, DOI 10.1016/j.immuni.2012.01.009
   Shin SM, 2009, MOL PHARMACOL, V76, P884, DOI 10.1124/mol.109.058479
   Sinha D, 2016, EXP EYE RES, V144, P46, DOI 10.1016/j.exer.2015.08.018
   Sivaprasad S, 2006, EYE, V20, P867, DOI 10.1038/sj.eye.6702176
   Snyder A.N, 2022, HISTOLOGY LIPOFUSCIN
   SNYDER R, 1993, ENVIRON HEALTH PERSP, V100, P293, DOI 10.2307/3431535
   Sohn EH, 2019, AM J PATHOL, V189, P1473, DOI 10.1016/j.ajpath.2019.04.005
   Sommerburg O, 1999, CURR EYE RES, V19, P491, DOI 10.1076/ceyr.19.6.491.5276
   Song N, 2017, MOL CELL, V68, P185, DOI 10.1016/j.molcel.2017.08.017
   Sousa FG, 2012, CARCINOGENESIS, V33, P1433, DOI 10.1093/carcin/bgs132
   Sparrow JR, 2005, EXP EYE RES, V80, P595, DOI 10.1016/j.exer.2005.01.007
   Spindler J, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0203337
   Stahl A, 2020, DTSCH ARZTEBL INT, V117, P513, DOI 10.3238/arztebl.2020.0513
   Strunnikova N, 2004, INVEST OPHTH VIS SCI, V45, P3767, DOI 10.1167/iovs.04-0311
   Sugawara S, 2001, J IMMUNOL, V167, P6568, DOI 10.4049/jimmunol.167.11.6568
   Sun SY, 2010, CANCER BIOL THER, V9, P109, DOI 10.4161/cbt.9.2.10583
   Suzuki M, 2012, J CELL SCI, V125, P2407, DOI 10.1242/jcs.097683
   Szaflik JP, 2009, MUTAT RES-FUND MOL M, V669, P169, DOI 10.1016/j.mrfmmm.2009.06.008
   Talhout R, 2011, INT J ENV RES PUB HE, V8, P613, DOI 10.3390/ijerph8020613
   Tan W, 2020, INT J BIOL SCI, V16, P2989, DOI 10.7150/ijbs.49890
   Tanaka T, 2000, J MOL CELL CARDIOL, V32, P1955, DOI 10.1006/jmcc.2000.1228
   Tanida I, 2004, INT J BIOCHEM CELL B, V36, P2503, DOI 10.1016/j.biocel.2004.05.009
   Tanida I, 2005, AUTOPHAGY, V1, P84, DOI 10.4161/auto.1.2.1697
   Tanito M, 2009, CLIN LIPIDOL, V4, P821, DOI 10.2217/CLP.09.65
   Tarallo V, 2012, CELL, V149, P847, DOI 10.1016/j.cell.2012.03.036
   Terman A, 1998, APMIS, V106, P265, DOI 10.1111/j.1699-0463.1998.tb01346.x
   Tonelli C, 2018, ANTIOXID REDOX SIGN, V29, P1727, DOI 10.1089/ars.2017.7342
   Torres PMM, 2001, J NEUROIMMUNOL, V117, P43, DOI 10.1016/S0165-5728(01)00303-4
   Triantafilou K, 2013, J CELL SCI, V126, P2903, DOI 10.1242/jcs.124388
   Tseng WA, 2013, INVEST OPHTH VIS SCI, V54, P110, DOI 10.1167/iovs.12-10655
   Tsutsui H, 1999, IMMUNITY, V11, P359, DOI 10.1016/S1074-7613(00)80111-9
   Vega R, 2021, BIOMEDICINES, V9, DOI 10.3390/biomedicines9020224
   Velilla S, 2013, J OPHTHALMOL, V2013, DOI 10.1155/2013/895147
   Vidal-Vanaclocha F, 2000, P NATL ACAD SCI USA, V97, P734, DOI 10.1073/pnas.97.2.734
   Viiri J, 2010, MOL VIS, V16, P1399
   Vincenti V, 1996, CIRCULATION, V93, P1493, DOI 10.1161/01.CIR.93.8.1493
   Voronov E, 2003, P NATL ACAD SCI USA, V100, P2645, DOI 10.1073/pnas.0437939100
   Wan P, 2019, FASEB J, V33, P5793, DOI 10.1096/fj.201801681R
   Wang AL, 2009, AUTOPHAGY, V5, P563, DOI 10.4161/auto.5.4.8163
   Wang HB, 2016, MOL VIS, V22, P116
   Wang X., 2013, TAIWAN J OPHTHALMOL, V3, P128, DOI [10.1016/j.tjo.2013.09.002, DOI 10.1016/J.TJO.2013.09.002]
   Wang XF, 2005, INVEST OPHTH VIS SCI, V46, P1508, DOI 10.1167/iovs.04-0951
   Wang X, 2019, MOL MED REP, V19, P59, DOI 10.3892/mmr.2018.9645
   Wang Y., 2016, INT J MOL SCI, V17, P1
   Wang YJ, 2019, DNA REPAIR, V81, DOI 10.1016/j.dnarep.2019.102651
   Wang YJ, 2013, ASN NEURO, V5, DOI 10.1042/AN20130028
   Weaver AN, 2013, FRONT ONCOL, V3, DOI 10.3389/fonc.2013.00290
   Wei RN, 2019, SAGE OPEN, V9, DOI 10.1177/2158244019850035
   Williams-Bey Y, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0097957
   Wojdasiewicz P, 2014, MEDIAT INFLAMM, V2014, DOI 10.1155/2014/561459
   Wong HS, 2019, FREE RADICAL BIO MED, V130, P140, DOI 10.1016/j.freeradbiomed.2018.10.448
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Wooff Y, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01618
   World Health Organization International Programme on Chemical Safety United Nations Environment Programme International Labour Organization, 1996, HYDR HLTH SAF GUID
   Wruck CJ, 2011, J BIOL CHEM, V286, P4493, DOI 10.1074/jbc.M110.162008
   Wu JL, 2019, DRUG DES DEV THER, V13, P2413, DOI 10.2147/DDDT.S206355
   Wu W, 2014, SCI WORLD J, DOI 10.1155/2014/502134
   Yang P., 2020, INVESTIGATIVE OPHTHA, V61, P1
   Yang S., 2021, EVID-BASED COMPL ALT, V2021, P1
   Yildirim Z, 2012, INT J GERONTOL, V6, P101, DOI 10.1016/j.ijge.2012.01.018
   Yusupov M, 2017, BBA-GEN SUBJECTS, V1861, P839, DOI 10.1016/j.bbagen.2017.01.030
   Zajac-Pytrus HM, 2015, ADV CLIN EXP MED, V24, P1099, DOI 10.17219/acem/27093
   Zapata MA, 2021, GRAEF ARCH CLIN EXP, V259, P1993, DOI 10.1007/s00417-021-05093-4
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
   Zeng SM, 2012, INVEST OPHTH VIS SCI, V53, P1041, DOI 10.1167/iovs.11-8531
   Zhang SX, 2006, J MOL ENDOCRINOL, V37, P1, DOI 10.1677/jme.1.02008
   Zhou RB, 2010, NAT IMMUNOL, V11, P136, DOI 10.1038/ni.1831
   Zhu QF, 2017, J IMMUNOL, V198, P4210, DOI 10.4049/jimmunol.1700352
NR 337
TC 0
Z9 0
U1 1
U2 1
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1755-375X
EI 1755-3768
J9 ACTA OPHTHALMOL
JI Acta Ophthalmol.
PD NOV
PY 2022
VL 100
SU 273
SI SI
BP 3
EP 59
DI 10.1111/aos.15275
PG 57
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 5Y8RF
UT WOS:000879548200002
PM 36343937
DA 2022-11-30
ER

PT J
AU Ahmed, CM
   Biswal, MR
   Li, H
   Han, PY
   Ildefonso, CJ
   Lewin, AS
AF Ahmed, Chulbul M.
   Biswal, Manas R.
   Li, Hong
   Han, Pingyang
   Ildefonso, Cristhian J.
   Lewin, Alfred S.
TI Repurposing an orally available drug for the treatment of geographic
   atrophy
SO MOLECULAR VISION
LA English
DT Article
ID MITOCHONDRIAL OXIDATIVE STRESS; RETINAL-PIGMENT EPITHELIUM; MACULAR
   DEGENERATION; 5-HT1A RECEPTORS; SR 57746A; ACTIVATION; AGONIST; CELLS;
   XALIPRODEN; SEROTONIN
AB Purpose: Chronic oxidative stress and subacute inflammation have been implicated as causes of age-related macular degeneration (AMD). In this study, we tested whether an orally available 5-OH-tryptamine (5HT) 1a receptor agonist, xaliproden, could protect against retinal pigment epithelium (RPE) cell damage in culture and in a mouse model of geographic atrophy.
   Methods: Paraquat was used to create mitochondrial oxidative stress in ARPE-19 cells, and tumor necrosis factor-alpha (TNF-alpha) was used to stimulate the production of inflammatory cytokines in these cells. The production of antioxidant proteins, metallothionein, and inflammatory cytokines was assayed with quantitative real-time PCR. Cell survival was analyzed with microscopy and a cell titer assay. Integrity of the RPE monolayer was determined by measuring the transepithelial electrical resistance (TEER) and with immunocytochemistry with zona occludens protein 1 (ZO-1) antibody. RPE atrophy was studied in mice deleted for Sod2 (the gene for mitochondrial superoxide dismutase) specifically in the RPE. The mice were treated orally with daily doses of xaliproden at 0.5 and 3 mg/kg for 4 months. The retinal structure was analyzed with spectral domain optical coherence tomography (SD-OCT) and with light and electron microscopy. Retinal function was assessed with full-field electroretinography (ERG) and with optokinetic measurements.
   Results: Xaliproden led to a dose-dependent increase in cell survival following treatment with paraquat. Synthesis of the antioxidant response genes NqO1, GSTM1, CAT, HO-1, and Nrf2 was increased in response to the drug, as was the zinc chaperone metallothionein. Treatment of cells with TNF-alpha led to increased production of IL-1 beta, IL-6, chemokine (C-C motif) ligand 20 (CCL20), and vascular endothelial growth factor (VEGF) by ARPE-19 cells, and this response was attenuated by treatment with xaliproden. TNF-alpha also led to a decrease in the TEER that was prevented by treatment with the 5HT1a agonist. Daily gavage with xaliproden at either dose induced the production of protective enzymes in the mouse retina, and treatment of the Sod2-deleted mice with the drug showed improved thickness of the outer nuclear layer and improved visual acuity relative to the control-treated mice. There was no significant difference in full-field scotopic ERG among the treatment groups, however. Vacuolization of the RPE and disorganization of the photoreceptor outer segments were reduced at both dose levels of xaliproden.
   Conclusions: Xaliproden protected RPE cells from oxidative and inflammatory insults and protected the mouse RPE and retina from RPE atrophy in the face of excess mitochondrial oxidative stress. These results suggest that this drug, which had a reasonable safety profile in clinical trials, may be used to prevent the progression of geographic atrophy in humans.
C1 [Ahmed, Chulbul M.; Biswal, Manas R.; Li, Hong; Han, Pingyang; Ildefonso, Cristhian J.; Lewin, Alfred S.] Univ Florida, Dept Mol Genet & Microbiol, 1200 Newell Dr, Gainesville, FL 32610 USA.
C3 State University System of Florida; University of Florida
RP Lewin, AS (通讯作者)，Univ Florida, Dept Mol Genet & Microbiol, 1200 Newell Dr, Gainesville, FL 32610 USA.
EM lewin@ufl.edu
RI Ildefonso, Cristhian/AAC-3576-2021; Mitchell, Paul/P-1498-2014
OI Ildefonso, Cristhian/0000-0001-6179-720X; Biswal,
   Manas/0000-0002-9685-2923; Lewin, Alfred/0000-0002-4192-9727
FU BrightFocus Foundation [M2012029]; NEI [P30 EY02172]; Shaler Richardson
   Professorship endowment
FX Grant support came from the BrightFocus Foundation (M2012029) and from
   the NEI core grant to the University of Florida (P30 EY02172). Initial
   support for the mouse model came from the Macula Vision Research
   Foundation. Funding was also provided by the Shaler Richardson
   Professorship endowment. We thank Dr. Eduardo Candelario-Jalil for
   allowing us to use his voltohmmeter to measure transepithelial
   resistance and to Dr. John Crabb for the gift of CEP antibodies.
CR Andoh T, 2013, EUR J PHARMACOL, V721, P231, DOI 10.1016/j.ejphar.2013.09.030
   Appert-Collin A, 2005, INT J IMMUNOPATH PH, V18, P233, DOI 10.1177/039463200501800206
   Azkona G, 2014, NEUROPHARMACOLOGY, V79, P726, DOI 10.1016/j.neuropharm.2013.11.024
   Bibbiani F, 2001, NEUROLOGY, V57, P1829, DOI 10.1212/WNL.57.10.1829
   Biswal MR, 2015, EXP EYE RES, V140, P94, DOI 10.1016/j.exer.2015.07.022
   Bourrie B, 1999, P NATL ACAD SCI USA, V96, P12855, DOI 10.1073/pnas.96.22.12855
   Castello PR, 2007, J BIOL CHEM, V282, P14186, DOI 10.1074/jbc.M700827200
   CERVO L, 1994, EUR J PHARMACOL, V253, P139, DOI 10.1016/0014-2999(94)90768-4
   Cholkar K, 2015, AAPS PHARMSCITECH, V16, P610, DOI 10.1208/s12249-014-0244-2
   Collier RJ, 2011, INVEST OPHTH VIS SCI, V52, P8108, DOI 10.1167/iovs.10-6418
   Collier RJ, 2011, INVEST OPHTH VIS SCI, V52, P2118, DOI 10.1167/iovs.10-6304
   Cowen DS, 2007, J NEUROCHEM, V101, P1161, DOI 10.1111/j.1471-4159.2006.04420.x
   Douglas RM, 2005, VISUAL NEUROSCI, V22, P677, DOI 10.1017/S0952523805225166
   Ebrahem Q, 2006, P NATL ACAD SCI USA, V103, P13480, DOI 10.1073/pnas.0601552103
   FOURNIER J, 1993, NEUROSCIENCE, V55, P629, DOI 10.1016/0306-4522(93)90429-J
   Fujihara M, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003119
   Gu JY, 2010, ADV EXP MED BIOL, V664, P411, DOI 10.1007/978-1-4419-1399-9_47
   Hollyfield JG, 2008, NAT MED, V14, P194, DOI 10.1038/nm1709
   Hong GL, 2013, EXP CELL RES, V319, P2845, DOI 10.1016/j.yexcr.2013.08.005
   Hu P, 2013, P NATL ACAD SCI USA, V110, pE4069, DOI 10.1073/pnas.1307574110
   Hwang AB, 2014, P NATL ACAD SCI USA, V111, pE4458, DOI 10.1073/pnas.1411199111
   Jin ML, 2000, INVEST OPHTH VIS SCI, V41, P4324
   Justilien V, 2007, INVEST OPHTH VIS SCI, V48, P4407, DOI 10.1167/iovs.07-0432
   Klein R, 2014, JAMA OPHTHALMOL, V132, P446, DOI 10.1001/jamaophthalmol.2013.7671
   Lavoie J, 2014, BIOL PSYCHIAT, V75, P479, DOI 10.1016/j.biopsych.2012.11.024
   Le YZ, 2008, INVEST OPHTH VIS SCI, V49, P1248, DOI 10.1167/iovs.07-1105
   Leibinger M, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.126
   Madhavan L, 2003, J PHARMACOL EXP THER, V304, P913, DOI 10.1124/jpet.102.044370
   Mao HY, 2014, INVEST OPHTH VIS SCI, V55, P4613, DOI 10.1167/iovs.14-14633
   Martel JC, 2009, BRIT J PHARMACOL, V158, P232, DOI 10.1111/j.1476-5381.2009.00249.x
   McGill TJ, 2007, INVEST OPHTH VIS SCI, V48, P1906, DOI 10.1167/iovs.06-1117
   McGill TJ, 2012, INVEST OPHTH VIS SCI, V53, P6232, DOI 10.1167/iovs.12-9569
   Meininger V, 2004, AMYOTROPH LATERAL SC, V5, P107, DOI 10.1080/14660820410019602
   Miao WM, 2005, J BIOL CHEM, V280, P20340, DOI 10.1074/jbc.M412081200
   Mo CF, 2014, ANTIOXID REDOX SIGN, V20, P574, DOI 10.1089/ars.2012.5116
   Nagineni CN, 2012, J CELL PHYSIOL, V227, P116, DOI 10.1002/jcp.22708
   Nash MS, 1997, INVEST OPHTH VIS SCI, V38, P510
   Ohta K, 2000, INVEST OPHTH VIS SCI, V41, P2591
   Pang J, 2010, GENE THER, V17, P815, DOI 10.1038/gt.2010.29
   Perez VL, 2015, TRENDS IMMUNOL, V36, P354, DOI 10.1016/j.it.2015.04.003
   Reagan-Shaw S, 2008, FASEB J, V22, P659, DOI 10.1096/fj.07-9574LSF
   Renganathan K, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076325
   Rowe-Rendleman CL, 2014, INVEST OPHTH VIS SCI, V55, P2714, DOI 10.1167/iovs.13-13707
   Saruhashi Y, 2002, SPINAL CORD, V40, P519, DOI 10.1038/sj.sc.3101331
   Seo SJ, 2012, EXP EYE RES, V101, P60, DOI 10.1016/j.exer.2012.05.013
   Smith VM, 2014, EUR J NEUROSCI, V40, P3512, DOI 10.1111/ejn.12712
   Strassburger M, 2005, FREE RADICAL BIO MED, V38, P1458, DOI 10.1016/j.freeradbiomed.2005.02.009
   Terasaki H, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069994
   Thampi P, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034468
   Ueki Y, 2008, J NEUROCHEM, V105, P784, DOI 10.1111/j.1471-4159.2007.05180.x
   Wilkes GM, 2015, ONCOLOGY NURSING DRU
   WOLFRUM U, 1991, CELL TISSUE RES, V266, P231, DOI 10.1007/BF00318178
   Yamada N, 2016, DEV OPHTHALMOL, V55, P71, DOI 10.1159/000431193
   Yang W, 2010, TOXICOL LETT, V199, P239, DOI 10.1016/j.toxlet.2010.09.005
   Zhao ZY, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019456
   Zhong YM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038616
   Zimmermann K, 2015, FREE RADICAL BIO MED, V88, P417, DOI 10.1016/j.freeradbiomed.2015.03.030
NR 57
TC 8
Z9 8
U1 0
U2 5
PU MOLECULAR VISION
PI ATLANTA
PA C/O JEFF BOATRIGHT, LAB B, 5500 EMORY EYE CENTER, 1327 CLIFTON RD, N E,
   ATLANTA, GA 30322 USA
SN 1090-0535
J9 MOL VIS
JI Mol. Vis.
PD APR 2
PY 2016
VL 22
BP 294
EP 310
PG 17
WC Biochemistry & Molecular Biology; Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Ophthalmology
GA DI4EV
UT WOS:000373454100002
PM 27110092
DA 2022-11-30
ER

PT J
AU Im, L
   Allingham, RR
   Singh, I
   Stinnett, S
   Fekrat, S
AF Im, Lily
   Allingham, R. Rand
   Singh, Inder
   Stinnett, Sandra
   Fekrat, Sharon
TI A prospective study of early intraocular pressure changes after a single
   intravitreal triamcinolone injection
SO JOURNAL OF GLAUCOMA
LA English
DT Article
DE intravitreal Kenalog; intraocular pressure; gonioscopy; steroid response
ID DIABETIC MACULAR EDEMA; RETINAL VEIN OCCLUSION; ACETONIDE INJECTION;
   OCULAR HYPERTENSION; SAFETY; EFFICACY; TRIAL
AB Purpose: To prospectively monitor intraocular pressure (IOP) and gonioscopy changes within the first month after a single 4-mg intravitreal injection of triamcinolone acetonide (IVK) (Kenalog, Briston-Meyers Squibb, New York).
   Design: Prospective comparative interventional case series.
   Methods: A consecutive series of 28 eyes of 14 patients with no prior intravitreal injections or history of glaucoma were prospectively enrolled. After baseline evaluation in both eyes, including IOP, gonioscopy, and optic nerve evaluation, a single 4-mg IVK was given in a standard sterile fashion in the eye to be treated. Eyes received IVK for macular edema associated with retinal vein occlusions and in conjunction with photodynamic therapy for choroidal neovascularization secondary to age-related macular degeneration, ocular histoplasmosis, and high myopia. The fellow eye served as the control. After the injection, IOP and gonioscopy were repeated at 1, 2, and 4-week intervals in both eyes.
   Results: Of the 14 patients, the 5 women and 9 men had a mean age of 67.6 years. Mean baseline IOP of the treated and fellow control eyes were similar at 15.9 versus 16.6 mm Hg, respectively. The control eyes maintained a small IOP range (15.6 to 16.6 mm Hg) during the 1-month follow-up period. In the treated eyes, the mean maximum IOP was 54% above baseline during follow-up, compared with 11% for control eyes. Six of 14 (43%) treated eyes had IOP elevation to 24mm Hg or higher with mean change of 8.6mm Hg and a mean maximum IOP of 32.1 mm Hg. There was no correlation between IOP rise and age, sex, diagnosis, or optic nerve appearance. However, during the course of the study, 4 of 6 (67%) of the treated eyes that required topical drops for the IOP elevation had documented abnormal inferior angle changes characterized by pigmented particulate matter in the inferior angle not present at the baseline exam. The most frequent time point for an IOP elevation that required treatment was at 2-week postinjection. No eyes required surgical management of IOP during the course of this 4-week study.
   Conclusions: We observed a significant IOP rise in eyes after a single intravitreal injection of 4mg of triamcinolone within I month of injection. In this study, the most frequent time point that required IOP treatment was at 2-week postinjection, suggesting that early and frequent monitoring of IOP should be considered. Two-thirds of eyes that required medical control of IOP developed gonioscopy changes, characterized by particulate matter in the inferior angle, not present at baseline. Eyes that developed gonioscopic changes were 5 times more likely to be treated for IOP elevation than those without gonioscopic findings.
C1 [Im, Lily] Univ Maryland, Dept Ophthalmol & Visual Sci, Baltimore, MD 21201 USA.
   [Allingham, R. Rand; Singh, Inder; Stinnett, Sandra; Fekrat, Sharon] Duke Univ, Med Ctr, Ctr Eye, Albert Eye Res Inst, Durham, NC 27710 USA.
C3 University System of Maryland; University of Maryland Baltimore; Duke
   University
RP Im, L (通讯作者)，419 W,Redwood St 462, Baltimore, MD 21201 USA.
EM lim@som.umaryland.edu
OI Stinnett, Sandra/0000-0001-7192-0195
CR Androudi S, 2005, OCUL IMMUNOL INFLAMM, V13, P205, DOI 10.1080/09273940590933511
   Bakri SJ, 2003, OPHTHALMIC SUR LA IM, V34, P386
   Challa JK, 1998, AUST NZ J OPHTHALMOL, V26, P277, DOI 10.1111/j.1442-9071.1998.tb01330.x
   Gillies MC, 2005, OPHTHALMOLOGY, V112, P139, DOI 10.1016/j.ophtha.2004.07.017
   Gillies MC, 2004, ARCH OPHTHALMOL-CHIC, V122, P336, DOI 10.1001/archopht.122.3.336
   Jonas J, 2005, J GLAUCOMA, V14, P168, DOI 10.1097/01.ijg.0000151880.22479.d7
   Jonas JB, 2006, EUR J OPHTHALMOL, V16, P566, DOI 10.1177/112067210601600411
   Jonas JB, 2005, PROG RETIN EYE RES, V24, P587, DOI 10.1016/j.preteyeres.2005.01.004
   Jonas JB, 2004, AM J OPHTHALMOL, V138, P158, DOI 10.1016/j.ajo.2004.02.025
   Jonas JB, 2005, OPHTHALMOLOGY, V112, P593, DOI 10.1016/j.ophtha.2004.10.042
   Kaushik S, 2004, AM J OPHTHALMOL, V137, P758, DOI 10.1016/j.ajo.2003.09.039
   Lee EW, 2007, AM J OPHTHALMOL, V143, P365, DOI 10.1016/j.ajo.2006.08.033
   Machemer R, 1979, Trans Am Ophthalmol Soc, V77, P171
   Massin P, 2004, OPHTHALMOLOGY, V111, P218, DOI 10.1016/j.ophtha.2003.05.037
   Ozkiris A, 2005, CAN J OPHTHALMOL, V40, P63, DOI 10.1016/S0008-4182(05)80119-X
   Ozkiris A, 2004, EUR J OPHTHALMOL, V14, P543
   Park CH, 2003, AM J OPHTHALMOL, V136, P419, DOI 10.1016/S0002-9394(03)00228-9
   Park Hye Young, 2005, Korean J Ophthalmol, V19, P122
   Rhee DJ, 2006, BRIT J OPHTHALMOL, V90, P999, DOI 10.1136/bjo.2006.090340
   Singh IP, 2004, AM J OPHTHALMOL, V138, P286, DOI 10.1016/j.ajo.2004.03.001
   Smithen LM, 2004, AM J OPHTHALMOL, V138, P740, DOI 10.1016/j.ajo.2004.06.067
   Spaide RF, 2005, RETINA-J RET VIT DIS, V25, P685, DOI 10.1097/00006982-200509000-00001
   Yang CS, 2005, OPHTHALMOLOGICA, V219, P413, DOI 10.1159/000088388
   Young S, 2001, CLIN EXP OPHTHALMOL, V29, P2, DOI 10.1046/j.1442-9071.2001.00360.x
NR 24
TC 16
Z9 16
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1057-0829
EI 1536-481X
J9 J GLAUCOMA
JI J. Glaucoma
PD MAR
PY 2008
VL 17
IS 2
BP 128
EP 132
DI 10.1097/IJG.0b013e31814b9948
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 280FZ
UT WOS:000254412400008
PM 18344759
DA 2022-11-30
ER

PT J
AU Qidwai, U
   Qidwai, U
   Raja, M
   Burton, B
AF Qidwai, Uvais
   Qidwai, Umair
   Raja, Muhammad
   Burton, Ben
TI Smart AMD prognosis through cellphone: an innovative localized AI-based
   prediction system for anti-VEGF treatment prognosis in nonagenarians and
   centenarians
SO INTERNATIONAL OPHTHALMOLOGY
LA English
DT Article
DE Wet AMD (Age-relate Macular Degeneration); Vascular Endothelial Cell
   Growth Factor (VEGF) Treatment; Repeated-intravitreal injections;
   Anti-VEGF-agents; Adaptive Neuro Fuzzy System (ANFIS); Outcome
   Prognosis; AI based App
ID MACULAR DEGENERATION; RANIBIZUMAB; AFLIBERCEPT; BEVACIZUMAB; OUTCOMES
AB Background and objective Age-related macular degeneration (AMD) is one of the most common reasons for blindness in the world today. The most common treatment for wet AMD is the intravitreal injections for inhibiting vascular-endothelial-derived growth factor (VEGF). This treatment usually involves multiple injections and thus multiple clinic visits, which not only causes increased cost on national health services but also causes exposure to the hospital environment, which is sometimes high risk considering current COVID crisis. The treatment, in spite of the above concerns, is usually effective. However, in some cases, either the medicine fails to produce the anticipated favourable outcome, resulting in waste of time, medication, efforts, and above all, psychological distress to the patients. Hence, early predictability of anatomical as well as functional effectiveness of the treatment appears to be a very desirable capability to have.
   Method A machine learning approach using adaptive neuro-fuzzy inference system (ANFIS) of two-sample prediction model has been presented that requires only the baseline measurements and changes in visual acuity (VA) as well as macular thickness (MAC) after four months of treatment to estimate the values of VA and MAC at 8 and 12 months. In contrast to most of the AI techniques, ANFIS approach has shown the capability of the algorithm to work with very small dataset as well, which makes it a perfect candidate for the presented solution.
   Results The presented model has shown to have a very high accuracy (> 92%) and works in near-real-time scenarios. It has been converted into a smart phone App, Ophnosis(AMD), for convenient usage. With this App, the clinician can visualize the progression of the patient for a specific treatment and can decide on continuing or changing the treatment accordingly. The complete AI engine developed with the ANFIS algorithm is localized to the phone through the App, implying that there is no need for intemet or cloud connectivity for this App to function. This makes it ideal for remote usage, especially under the current COVID scenarios.
   Conclusions With a smart AI-based App on their fingertips, the presented system provides ample opportunity to the doctors to make a better decision based on the estimated progression, if the same drug is continued with (good/fair prognosis) or alternate treatment should be sought (bad prognosis). From a functional point of view, a prediction algorithm is triggered through simple entry of the relevant parameters (baseline and 4 months only). No internet/cloud connectivity is needed since the algorithm and the trained network are fully embedded in the App locally. Hence, using the App in remote and/or non-connected isolated areas is possible, especially in the secluded patients during the COVID scenarios.
   [GRAPHICS]
   .
C1 [Qidwai, Uvais; Qidwai, Umair] Qatar Univ, Dept Comp Sci & Engn, POB 2713, Doha, Qatar.
   [Qidwai, Uvais; Qidwai, Umair; Raja, Muhammad; Burton, Ben] James Paget Univ Hosp, Dept Ophthalmol, Great Yarmouth, England.
C3 Qatar University
RP Qidwai, U (通讯作者)，Qatar Univ, Dept Comp Sci & Engn, POB 2713, Doha, Qatar.; Qidwai, U (通讯作者)，James Paget Univ Hosp, Dept Ophthalmol, Great Yarmouth, England.
EM uqidwai@qu.edu.qa
OI Qidwai, Uvais/0000-0002-9924-590X; Burton, Ben/0000-0001-9579-9078
CR Agurto C, 2011, INVEST OPHTH VIS SCI, V52, P5862, DOI 10.1167/iovs.10-7075
   Antonieta Martinez-Velasco A, 2017, LNCS, V10632, P257
   Arcinue CA, 2015, AM J OPHTHALMOL, V159, P426, DOI 10.1016/j.ajo.2014.11.022
   Berg K, 2015, OPHTHALMOLOGY, V122, P146, DOI 10.1016/j.ophtha.2014.07.041
   Binder S, 2013, INVEST OPHTH VIS SCI, V54
   Browning DJ, 2012, AM J OPHTHALMOL, V154, P222, DOI 10.1016/j.ajo.2012.04.020
   Burlina PM, 2017, JAMA OPHTHALMOL, V135, P1170, DOI 10.1001/jamaophthalmol.2017.3782
   Chakravarthy U, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.04.015
   Colijn JM, 2017, OPHTHALMOLOGY, V124, P1753, DOI 10.1016/j.ophtha.2017.05.035
   Grassmann F, 2018, OPHTHALMOLOGY, V125, P1410, DOI 10.1016/j.ophtha.2018.02.037
   JANG JSR, 1993, IEEE T SYST MAN CYB, V23, P665, DOI 10.1109/21.256541
   Karaboga D, 2019, ARTIF INTELL REV, V52, P2263, DOI 10.1007/s10462-017-9610-2
   Kodjikian L, 2013, OPHTHALMOLOGY, V120, P2300, DOI 10.1016/j.ophtha.2013.06.020
   Kubicek J, 2016, IFMBE PROC, V57, P239, DOI 10.1007/978-3-319-32703-7_48
   Lateh MA, 2017, J PHYS CONF SER, V892, DOI 10.1088/1742-6596/892/1/012016
   Lotery A, 2017, EYE, V31, P1697, DOI 10.1038/eye.2017.143
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Mulyukov Z, 2018, CPT-PHARMACOMET SYST, V7, P660, DOI 10.1002/psp4.12322
   Pead E, 2019, SURV OPHTHALMOL, V64, P498, DOI 10.1016/j.survophthal.2019.02.003
   Rudnicka AR, 2015, AM J OPHTHALMOL, V160, P85, DOI 10.1016/j.ajo.2015.04.003
   Stein JD, 2014, OPHTHALMOLOGY, V121, P936, DOI 10.1016/j.ophtha.2013.10.037
   Stewart MW, 2013, EXPERT REV CLIN PHAR, V6, P103, DOI [10.1586/ECP.12.81, 10.1586/ecp.12.81]
   Szabo SM, 2015, CURR MED RES OPIN, V31, P2031, DOI 10.1185/03007995.2015.1084909
   Tabaraki R, 2020, J MOL GRAPH MODEL, V100, DOI 10.1016/j.jmgm.2020.107698
   Thulliez M, 2014, JAMA OPHTHALMOL, V132, P1317, DOI 10.1001/jamaophthalmol.2014.2333
   Zhao TK, 2018, NPJ COMPUT MATER, V4, DOI 10.1038/s41524-018-0069-8
NR 26
TC 0
Z9 0
U1 1
U2 1
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0165-5701
EI 1573-2630
J9 INT OPHTHALMOL
JI Int. Ophthalmol.
PD JUN
PY 2022
VL 42
IS 6
BP 1749
EP 1762
DI 10.1007/s10792-021-02171-8
EA JAN 2022
PG 14
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 1S4GR
UT WOS:000748307200007
PM 35094227
OA Green Submitted
DA 2022-11-30
ER

PT J
AU Nolan, JM
   O'Reilly, P
   Loughman, J
   Stack, J
   Loane, E
   Connolly, E
   Beatty, S
AF Nolan, John M.
   O'Reilly, Philip
   Loughman, James
   Stack, Jim
   Loane, Edward
   Connolly, Eithne
   Beatty, Stephen
TI Augmentation of Macular Pigment following Implantation of Blue
   Light-Filtering Intraocular Lenses at the Time of Cataract Surgery
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID AGE-RELATED MACULOPATHY; BEAVER DAM EYE; OPTICAL-DENSITY; CONTRAST
   SENSITIVITY; RISK-FACTORS; SUNLIGHT EXPOSURE; COLOR-PERCEPTION; SPATIAL
   PROFILE; SCOTOPIC VISION; VISUAL FUNCTION
AB PURPOSE. (Photo)-oxidative stress is believed to play a role in the pathogenesis of age-related macular degeneration (AMD), with the threshold for retinal damage being lowest for short-wavelength (blue) light. Macular pigment (MP), consisting of the carotenoids lutein (L), zeaxanthin (Z) and meso-Z, has a maximum absorption at 460 nm and protects the retina from (photo)-oxidative injury. This study was designed to investigate whether the blue light-filtering properties of the Alcon AcrySof Natural intraocular lens (ANIOL) implanted during cataract surgery affects MP optical density (MPOD).
   METHODS. Forty-two patients scheduled for cataract surgery were recruited for the study. These patients all had a preoperative best corrected visual acuity rating (BCVAR) of at least 0.5 (logMAR) in the study eye. The patients were randomized to have either the standard Alcon AcrySof three-piece acrylic intraocular lens (AIOL) (controls) or the ANIOL implanted at the time of cataract surgery. The spatial profile of MPOD (i. e., at 0.25 degrees, 0.5 degrees, 1.0 degrees, and 1.75 degrees eccentricity) was measured with customized heterochromatic flicker photometry (cHFP) 1 week before and 1 week after surgery, and at 3, 6, and 12 months after surgery. Serum concentrations of L and Z were also measured at each study visit.
   RESULTS. There was a highly significant and positive correlation between all MPODs (e. g., at 0.25 degrees) recorded 1 week before and after surgery in eyes with an AIOL implant (r = 0.915, P < 0.01; paired samples t-test, P = 0.631) and in those ANIOL implants (r = 0.868, P < 0.01; paired samples t-test, P = 0.719). Average MPOD across the retina increased significantly with time (after 3 months) in the ANIOL group (repeatedmeasures, general linear model, P < 0.05), but remained stable in the AIOL group (repeated-measures, general linear model, P > 0.05). There were no significant time or lens effects observed for serum L over the study period (P > 0.05). There was a significant time effect for serum Z over the study period (P < 0.05), but not a significant time/lens interaction (P > 0.05).
   CONCLUSIONS. Customized HFP can reliably measure the MPOD spatial profile in the presence of lens opacity, and cataract surgery does not artifactually alter MPOD readings. This study also provides evidence that implanting an IOL that filters blue light is associated with augmentation of MPOD in the absence of raised serum concentrations of L and Z. However, further and longitudinal study is needed to assess whether the observed increase in MPOD after implantation of blue-filtering IOLs is associated with reduced risk of AMD development and/or progression. (Invest Ophthalmol Vis Sci. 2009;50:4777-4785) DOI: 10.1167/iovs.08-3277
C1 [Nolan, John M.; O'Reilly, Philip; Stack, Jim; Loane, Edward; Connolly, Eithne; Beatty, Stephen] Waterford Inst Technol, Macula Pigment Res Grp, Dept Chem & Life Sci, Watford, England.
   [Loughman, James] Dublin Inst Technol, Macula Pigment Res Grp, Dept Optometry, Sch Phys, Dublin, Ireland.
C3 South East Technological University (SETU); Technological University
   Dublin
RP Nolan, JM (通讯作者)，Waterford Inst Technol, Macula Pigment Res Grp, Dept Chem & Life Sci, Cork Rd, Watford, England.
EM jnolan@wit.ie
RI Nolan, John/N-4921-2014
OI Nolan, John/0000-0002-5503-7084; Loughman, James/0000-0003-3130-8991
FU Alcon Laboratories Inc., Fort Worth, Texas
FX Supported in full by Alcon Laboratories Inc., Fort Worth, Texas.
   Submitted for publication December 8, 2008; revised March 18, 2009;
   accepted August 21, 2009.
CR Aharonoff GB, 1998, CLIN ORTHOP RELAT R, P10
   Algvere PV, 2006, ACTA OPHTHALMOL SCAN, V84, P4, DOI 10.1111/j.1600-0420.2005.00627.x
   Barisic A, 2007, COLLEGIUM ANTROPOL, V31, P57
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Bhattacharjee H, 2006, J CATARACT REFR SURG, V32, P451, DOI 10.1016/j.jcrs.2005.12.136
   Bockelbrink A, 2008, SURV OPHTHALMOL, V53, P359, DOI 10.1016/j.survophthal.2008.04.001
   Brockmann C, 2008, J CATARACT REFR SURG, V34, P1161, DOI 10.1016/j.jcrs.2008.03.039
   Buch H, 2005, ACTA OPHTHALMOL SCAN, V83, P409, DOI 10.1111/J.1600-0420.2005.00492.x
   Cionni RJ, 2006, J CATARACT REFR SURG, V32, P236, DOI 10.1016/j.jcrs.2005.12.129
   Ciulla TA, 2001, INVEST OPHTH VIS SCI, V42, P1338
   CRUICKSHANKS KJ, 1993, ARCH OPHTHALMOL-CHIC, V111, P514, DOI 10.1001/archopht.1993.01090040106042
   Darzins P, 1997, OPHTHALMOLOGY, V104, P770, DOI 10.1016/S0161-6420(97)30235-8
   Dillon J, 2004, EXP EYE RES, V79, P753, DOI 10.1016/j.exer.2004.06.025
   Espindle D, 2005, J CATARACT REFR SURG, V31, P1952, DOI 10.1016/j.jcrs.2005.03.060
   Falsini B, 2000, INVEST OPHTH VIS SCI, V41, P1498
   FEENEYBURNS L, 1984, INVEST OPHTH VIS SCI, V25, P195
   Fletcher AE, 2008, ARCH OPHTHALMOL-CHIC, V126, P1396, DOI 10.1001/archopht.126.10.1396
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Hammond BR, 2005, OPTOMETRY VISION SCI, V82, P387, DOI 10.1097/01.OPX.0000162652.85875.D2
   Hammond BR, 2000, INVEST OPHTH VIS SCI, V41, P1492
   Hammond BR, 1997, J OPT SOC AM A, V14, P1187, DOI 10.1364/JOSAA.14.001187
   Hayashi K, 2006, BRIT J OPHTHALMOL, V90, P1019, DOI 10.1136/bjo.2006.090712
   Hirakawa M, 2008, BRIT J OPHTHALMOL, V92, P630, DOI 10.1136/bjo.2007.130575
   Junghans A, 2001, ARCH BIOCHEM BIOPHYS, V391, P160, DOI 10.1006/abbi.2001.2411
   Khan JC, 2006, BRIT J OPHTHALMOL, V90, P29, DOI 10.1136/bjo.2005.073825
   Klein R, 2002, ARCH OPHTHALMOL-CHIC, V120, P1551, DOI 10.1001/archopht.120.11.1551
   Krishnaiah S, 2005, INVEST OPHTH VIS SCI, V46, P4442, DOI 10.1167/iovs.05-0853
   Landers J, 2007, CLIN EXP OPHTHALMOL, V35, P152, DOI 10.1111/j.1442-9071.2006.01434.x
   Leibovitch I, 2006, ACTA OPHTHALMOL SCAN, V84, P95, DOI 10.1111/j.1600-0420.2005.00607.x
   LIU IY, 1989, AM J PUBLIC HEALTH, V79, P765, DOI 10.2105/AJPH.79.6.765
   Loane E, 2008, BRIT J OPHTHALMOL, V92, P1163, DOI 10.1136/bjo.2007.135566
   Loane E, 2007, CURR EYE RES, V32, P555, DOI 10.1080/02713680701418405
   Mainster MA, 2003, BRIT J OPHTHALMOL, V87, P1523, DOI 10.1136/bjo.87.12.1523
   Mainster MA, 2003, BRIT J OPHTHALMOL, V87, P113, DOI 10.1136/bjo.87.1.113
   Marshall J, 2005, J CATARACT REFR SURG, V31, P2319, DOI 10.1016/j.jcrs.2004.11.061
   Mayer S, 2006, KLIN MONATSBL AUGENH, V223, P142, DOI 10.1055/s-2005-858867
   Muftuoglu O, 2007, J CATARACT REFR SURG, V33, P658, DOI 10.1016/j.jcrs.2006.12.018
   Niwa K, 1996, OPHTHAL PHYSL OPT, V16, P297, DOI 10.1046/j.1475-1313.1996.95001182.x
   Nolan JM, 2006, CURR EYE RES, V31, P199, DOI 10.1080/02713680500514677
   Nolan JM, 2008, INVEST OPHTH VIS SCI, V49, P2134, DOI 10.1167/iovs.07-0933
   Norton R, 1997, J AM GERIATR SOC, V45, P1108, DOI 10.1111/j.1532-5415.1997.tb05975.x
   Phipps JA, 2004, INVEST OPHTH VIS SCI, V45, P3355, DOI 10.1167/iovs.04-0253
   Pierre A, 2007, J CATARACT REFR SURG, V33, P1248, DOI 10.1016/j.jcrs.2007.03.024
   Pollack A, 1996, OPHTHALMOLOGY, V103, P1546, DOI 10.1016/S0161-6420(96)30464-8
   Resnikoff S, 2004, B WORLD HEALTH ORGAN, V82, P844
   Rodriguez-Galietero A, 2005, J CATARACT REFR SURG, V31, P1736, DOI 10.1016/j.jcrs.2005.02.039
   Roodenburg AJC, 2000, AM J CLIN NUTR, V71, P1187
   ROZANOWSKA M, 1995, J BIOL CHEM, V270, P18825, DOI 10.1074/jbc.270.32.18825
   Schmidinger G, 2008, J CATARACT REFR SURG, V34, P769, DOI 10.1016/j.jcrs.2007.12.034
   Schwiegerling J, 2006, J CATARACT REFR SURG, V32, P141, DOI 10.1016/j.jcrs.2005.11.021
   Snodderly DM, 2004, INVEST OPHTH VIS SCI, V45, P531, DOI 10.1167/iovs.03-0762
   SNODDERLY DM, 1984, INVEST OPHTH VIS SCI, V25, P674
   Snodderly DM, 2005, INVEST OPHTH VIS SCI, V46, P1766
   Sparrow JR, 2004, J CATARACT REFR SURG, V30, P873, DOI 10.1016/j.jcrs.2004.01.031
   Sparrow JR, 2001, INVEST OPHTH VIS SCI, V42, P1356
   Stringham JM, 2006, OPTOMETRY VISION SCI, V83, P887, DOI 10.1097/01.opx.0000249976.00534.2d
   Taylor H R, 1990, Trans Am Ophthalmol Soc, V88, P163
   Taylor HR, 1990, T AM OPHTHAL SOC, V88, P173
   Tomany SC, 2004, ARCH OPHTHALMOL-CHIC, V122, P750, DOI 10.1001/archopht.122.5.750
   Trieschmann M, 2008, EYE, V22, P132, DOI 10.1038/sj.eye.6702780
   TYLER CW, 1989, J OPT SOC AM A, V6, P481, DOI 10.1364/JOSAA.6.000481
   Unlu NZ, 2005, J NUTR, V135, P431, DOI 10.1093/jn/135.3.431
   VETTER NJ, 1992, BMJ-BRIT MED J, V304, P888, DOI 10.1136/bmj.304.6831.888
   Wang JJ, 2003, OPHTHALMOLOGY, V110, P1960, DOI 10.1016/S0161-6420(03)00816-9
   Wenzel AJ, 2003, INVEST OPHTH VIS SCI, V44, P306, DOI 10.1167/iovs.01-1191
   Werner JS, 2005, BRIT J OPHTHALMOL, V89, P1518, DOI 10.1136/bjo.2005.073734
   WERNER JS, 1987, VISION RES, V27, P257, DOI 10.1016/0042-6989(87)90188-X
   WEST SK, 1989, ARCH OPHTHALMOL-CHIC, V107, P875, DOI 10.1001/archopht.1989.01070010897038
   Witmer AN, 2003, PROG RETIN EYE RES, V22, P1, DOI 10.1016/S1350-9462(02)00043-5
   Wooten BR, 1999, INVEST OPHTH VIS SCI, V40, P2481
   Yanagi Y, 2006, J CATARACT REFR SURG, V32, P1540, DOI 10.1016/j.jcrs.2006.04.012
NR 72
TC 36
Z9 49
U1 0
U2 10
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD OCT
PY 2009
VL 50
IS 10
BP 4777
EP 4785
DI 10.1167/iovs.08-3277
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 497XE
UT WOS:000270097200035
PM 19628740
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Kaji, Y
   Oshika, T
   Takazawa, Y
   Fukayama, M
   Takata, T
   Fujii, N
AF Kaji, Yuichi
   Oshika, Tetsuro
   Takazawa, Yutaka
   Fukayama, Masashi
   Takata, Takumi
   Fujii, Noriko
TI Localization of D-beta-aspartic acid-containing proteins in human eyes
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID ALPHA-A-CRYSTALLIN; HUMAN LENS; SIMULTANEOUS STEREOINVERSION; BRUCHS
   MEMBRANE; LAMINA-CRIBROSA; ELASTIC FIBERS; RACEMIZATION; RESIDUES; AGE;
   ISOMERIZATION
AB PURPOSE. Biologically uncommon D-beta-aspartic acid (D-beta-Asp) has been detected in proteins from various human tissues in elderly donors. Previous studies have identified D-beta-Asp residues at four different specific sites in alpha-crystallin from aged human lenses and an increased amount of D-beta-Asp residues with age. D-beta-Asp is formed as a result of racemization and accumulates with age; therefore, it is thought to be a potential marker of aging. To reveal the role of the D-beta-Asp formation in the aging process of eyes, immunohistochemical localization of D-beta-Asp was investigated in ocular samples of various ages.
   METHODS. Polyclonal antibody to the D-beta-Asp-containing peptide was prepared. To confirm the specificity of the antibody, SDS-PAGE and Western blotting analyses of lens were performed. To detect the locality of the D-beta-Asp-containing protein, immunohistochemical staining using the antibody was carried out in ocular samples obtained from nine donors 18 to 88 years of age and two fetuses.
   RESULTS. The antibody to the D-beta-Asp-containing peptide reacted with the lens peptide of the aged donors around 20 kDa that was compatible with alpha-A crystallin. In addition, the binding of the antibody to the alpha-A crystallin was almost completely blocked with the addition of the excess D-beta-Asp-containing peptide. The antibody showed a negative reaction with any of the tissues in the eye of human fetuses and in donors younger than 18 years. In contrast, relatively strong immunoreactivity to the D-beta-Asp-containing peptides was seen in the nuclei of the lens, in nonpigmented ciliary epithelial cells, in drusen, and in the sclera of elderly donors. In addition, moderate to weak immunoreactivity was seen in the cortex of the lens, in the blood vessels of the retina, in the optic nerve head, and in the lamina cribrosa of elderly donors. Furthermore, the immuno-reactions were almost completely blocked with the addition of the excess D-beta-Asp-containing peptide in the reaction mixture.
   CONCLUSIONS. The D-beta-Asp-containing proteins appeared in various ocular tissues with age. This study clearly demonstrated that the D-beta-Asp-containing proteins are more widespread in aged tissues than previously thought. The formation of D-beta-Asp in protein can cause major changes in its structure because different side chain orientations can induce an abnormal peptide backbone, and the main chain of the peptide can then become elongated by the beta linkage. Therefore, this modification can be the result of the partial unfolding of protein, leading to various age-related ocular diseases. In particular, D-beta-Asp would provide a new aspect of the molecular mechanisms of age-related macular degeneration because drusen is positive for D-beta-Asp.
C1 Univ Tsukuba, Inst Clin Med, Dept Ophthalmol, Tsukuba, Ibaraki 3058575, Japan.
   Univ Tokyo, Grad Sch Med, Dept Pathol, Tokyo, Japan.
   Osaka Univ, Inst Res Reactor, Osaka, Japan.
C3 University of Tsukuba; University of Tokyo; Osaka University
RP Kaji, Y (通讯作者)，Univ Tsukuba, Inst Clin Med, Dept Ophthalmol, Tennoudai 1-1-1, Tsukuba, Ibaraki 3058575, Japan.
EM sanken-tky@umin.ac.jp
OI Takata, Takumi/0000-0003-3208-3704
CR ALBON J, 1995, BRIT J OPHTHALMOL, V79, P368, DOI 10.1136/bjo.79.4.368
   Albon J, 2000, BRIT J OPHTHALMOL, V84, P318, DOI 10.1136/bjo.84.3.318
   Dunlevy JR, 2004, INVEST OPHTH VIS SCI, V45, P3849, DOI 10.1167/iovs.04-0496
   Fujii N, 1999, BIOCHEM BIOPH RES CO, V263, P322, DOI 10.1006/bbrc.1999.1279
   Fujii N, 2000, MOL VIS, V6, P1
   Fujii N, 2003, MOL VIS, V9, P315
   FUJII N, 1994, J BIOCHEM-TOKYO, V116, P663, DOI 10.1093/oxfordjournals.jbchem.a124577
   Fujii N, 2002, BIOCHEM BIOPH RES CO, V294, P1047, DOI 10.1016/S0006-291X(02)00597-1
   FUJII N, 1994, BBA-PROTEIN STRUCT M, V1204, P157, DOI 10.1016/0167-4838(94)90003-5
   Fujii N, 1999, MECH AGEING DEV, V107, P347, DOI 10.1016/S0047-6374(98)00129-8
   HERNANDEZ MR, 1989, AM J OPHTHALMOL, V107, P476, DOI 10.1016/0002-9394(89)90491-1
   HOENDERS HJ, 1983, J GERONTOL, V38, P278, DOI 10.1093/geronj/38.3.278
   Ida H, 2004, INVEST OPHTH VIS SCI, V45, P2348, DOI 10.1167/iovs.03-1337
   Kuge K, 2004, AMINO ACIDS, V27, P193, DOI 10.1007/s00726-004-0107-3
   MASTERS PM, 1983, CALCIFIED TISSUE INT, V35, P43, DOI 10.1007/BF02405005
   MASTERS PM, 1977, NATURE, V268, P71, DOI 10.1038/268071a0
   MCFADDEN PN, 1982, P NATL ACAD SCI-BIOL, V79, P2460, DOI 10.1073/pnas.79.8.2460
   Miura Y, 2004, J CUTAN PATHOL, V31, P51, DOI 10.1046/j.0303-6987.2004.0144.x
   Ohtani S, 1998, GROWTH DEVELOP AGING, V62, P141
   POWELL JT, 1992, ATHEROSCLEROSIS, V97, P201, DOI 10.1016/0021-9150(92)90132-Z
   RAMRATTAN RS, 1994, INVEST OPHTH VIS SCI, V35, P2857
   Ritz-Timme S, 2003, INT J LEGAL MED, V117, P96, DOI 10.1007/s00414-002-0355-2
   SHAPIRA R, 1987, BIOCHEM BIOPH RES CO, V146, P1342, DOI 10.1016/0006-291X(87)90797-2
   SHAPIRO SD, 1991, J CLIN INVEST, V87, P1828, DOI 10.1172/JCI115204
   Takata T, 2006, BIOCHEM BIOPH RES CO, V344, P263, DOI 10.1016/j.bbrc.2006.03.126
NR 25
TC 42
Z9 44
U1 0
U2 0
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD SEP
PY 2007
VL 48
IS 9
BP 3923
EP 3927
DI 10.1167/iovs.06-1284
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 204RO
UT WOS:000249061900003
PM 17724168
DA 2022-11-30
ER

PT J
AU Umeda, S
   Suzuki, MT
   Okamoto, H
   Ono, F
   Mizota, A
   Terao, K
   Yoshikawa, Y
   Tanaka, Y
   Iwata, T
AF Umeda, S
   Suzuki, MT
   Okamoto, H
   Ono, F
   Mizota, A
   Terao, K
   Yoshikawa, Y
   Tanaka, Y
   Iwata, T
TI Molecular composition of drusen and possible involvement of anti-retinal
   autoimmunity in two different forms of macular degeneration in
   cynomolgus monkey (Macaca fascicularis)
SO FASEB JOURNAL
LA English
DT Article
DE liquid chromatography tandem mass spectroscopy
ID HIGH-FAT DIET; BRUCHS MEMBRANE; ANIMAL-MODEL; ANNEXIN-V; ANTIBODIES;
   PROTEINS; AUTOANTIBODIES; PATHOGENESIS; MACULOPATHY; EXPRESSION
AB We have previously reported a cynomolgus monkey (Macaca fascicularis) pedigree with early onset macular degeneration that develops drusen at 2 yr after birth (1). In this study, the molecular composition of drusen in monkeys affected with late onset and early onset macular degeneration was both characterized. Involvement of anti-retinalautoimmunity in the deposition of drusen and the pathogenesis of the disease was also evaluated. Funduscopic and histological examinations were performed on 278 adult monkeys (mean age = 16.94 yr) for late onset macular degeneration. The molecular composition of drusen was analyzed by immunohistochemistry and/or direct proteome analysis using liquid chromatography tandem mass spectroscopy (LC-MS/ MS). Anti-retinal autoantibodies in sera were screened in 20 affected and 10 age-matched control monkeys by Western blot techniques. Immunogenic molecules were identified by 2D electrophoresis and LC-MS/ MS. Relative antibody titer against each antigen was determined by ELISA in sera from 42 affected (late onset) and 41 normal monkeys. Yellowish-white spots in the macular region were observed in 90 (32%) of the late onset monkeys that were examined. Histological examination demonstrated that drusen or degenerative retinal pigment epithelium (RPE) cells were associated with the pigmentary abnormalities. Drusen in both late and early onset monkeys showed immunoreactivities for apolipoprotein E, amyloid P component, complement component C5, the terminal C5b-9 complement complex, vitronectin, and membrane cofactor protein. LC-MS/MS analyses identified 60 proteins as constituents of drusen, including a number of common components in drusen of human age-related macular degeneration (AMD), such as annexins, crystallins, immunoglobulins, and complement components. Half of the affected monkeys had single or multiple autoantibodies against 38, 40, 50, and 60 kDa retinal proteins. The reacting antigens of 38 and 40 kDa were identified as annexin II and mu-crystallin, respectively. Relative antibody titer against annexin II in affected monkeys was significantly higher than control animals (P<0.01). Significant difference was not observed in antibody titer against mu-crystallin; however, several affected monkeys showed considerably elevated titer (360-610%) compared with the mean for unaffected animals. Monkey drusen both in late and early onset forms of macular degeneration had common components with drusen in human AMD patients, indicating that chronic inflammation mediated by complement activation might also be involved in the formation of drusen in these affected monkeys. The high prevalence of anti-retinalautoantibodies in sera from affected monkeys demonstrated an autoimmune aspect of the pathogenesis of the disease. Although further analyses are required to determine whether and how autoantibodies against annexin II or mu-crystallin relate to the pathogenesis of the disease, it could be hypothesized that immune responses directed against these antigens might trigger chronic activation of the complement cascade at the site of drusen formation.
C1 Natl Hosp Org, Tokyo Med Ctr, Natl Inst Sensory Organs, Meguro Ku, Tokyo 1528902, Japan.
   Univ Tokyo, Grad Sch Agr & Life Sci, Dept Biomed Sci, Tokyo 1138657, Japan.
   Corp Prod & Res Lab Primates, Tsukuba 3050843, Japan.
   Juntendo Univ, Urayasu Hosp, Dept Ophthalmol, Chiba 2790021, Japan.
   Natl Inst Biomed Innovat, Tsukuba Primate Res Ctr, Tsukuba 3050843, Japan.
C3 University of Tokyo; Juntendo University; National Institute of Health
   Sciences - Japan
RP Iwata, T (通讯作者)，Natl Hosp Org, Tokyo Med Ctr, Natl Inst Sensory Organs, Meguro Ku, 2-5-1 Higashikgaoka, Tokyo 1528902, Japan.
EM iwatatakeshi@kankakuki.go.jp
CR Ambati J, 2003, NAT MED, V9, P1390, DOI 10.1038/nm950
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   BRESSLER NM, 1989, ARCH OPHTHALMOL-CHIC, V107, P847, DOI 10.1001/archopht.1989.01070010869032
   Chen L, 2003, MOL VIS, V9, P151
   CIRINO G, 1989, P NATL ACAD SCI USA, V86, P3428, DOI 10.1073/pnas.86.9.3428
   COMERA C, 1995, BRIT J PHARMACOL, V115, P1043, DOI 10.1111/j.1476-5381.1995.tb15916.x
   Cousins SW, 2002, EXP EYE RES, V75, P543, DOI 10.1006/exer.2002.2047
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   Dithmar S, 2001, ARCH OPHTHALMOL-CHIC, V119, P1643, DOI 10.1001/archopht.119.11.1643
   Dithmar S, 2000, INVEST OPHTH VIS SCI, V41, P2035
   DUBOIS T, 1995, J RHEUMATOL, V22, P1230
   DUMONDE DC, 1982, LANCET, V2, P787
   GALBRAITH GMP, 1986, J CLIN INVEST, V78, P865, DOI 10.1172/JCI112672
   Gerke V, 2002, PHYSIOL REV, V82, P331, DOI 10.1152/physrev.00030.2001
   GREGORY CY, 1992, EXP EYE RES, V54, P843, DOI 10.1016/0014-4835(92)90147-K
   GURNE DH, 1991, OPHTHALMOLOGY, V98, P602
   Hageman GS, 1999, FASEB J, V13, P477, DOI 10.1096/fasebj.13.3.477
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   HOPE GM, 1992, BRIT J OPHTHALMOL, V76, P11, DOI 10.1136/bjo.76.1.11
   ISHIBASHI T, 1986, INVEST OPHTH VIS SCI, V27, P184
   Johnson LV, 2000, EXP EYE RES, V70, P441, DOI 10.1006/exer.1999.0798
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Kaufman M, 1996, BIOCHEM J, V316, P35, DOI 10.1042/bj3160035
   KIM RY, 1992, P NATL ACAD SCI USA, V89, P9292, DOI 10.1073/pnas.89.19.9292
   Liu H, 1998, J BIOL CHEM, V273, P12858, DOI 10.1074/jbc.273.21.12858
   Liu H, 1997, J BIOL CHEM, V272, P21751, DOI 10.1074/jbc.272.35.21751
   Majji AB, 2000, INVEST OPHTH VIS SCI, V41, P3936
   MONACO WA, 1990, OPTOMETRY VISION SCI, V67, P532, DOI 10.1097/00006324-199007000-00011
   Mullins RF, 2001, EYE, V15, P390, DOI 10.1038/eye.2001.142
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   NEWSOME DA, 1986, INVEST OPHTH VIS SCI, V27, P1675
   Nicolas MG, 1996, EXP EYE RES, V62, P399, DOI 10.1006/exer.1996.0045
   Nicolas MG, 1996, EXP EYE RES, V62, P211, DOI 10.1006/exer.1996.0026
   PENFOLD PL, 1990, GRAEF ARCH CLIN EXP, V228, P270, DOI 10.1007/BF00920033
   Rakoczy PE, 2002, AM J PATHOL, V161, P1515, DOI 10.1016/S0002-9440(10)64427-6
   RodriguezGarcia MI, 1996, ANN RHEUM DIS, V55, P895, DOI 10.1136/ard.55.12.895
   Stafford T J, 1974, Mod Probl Ophthalmol, V12, P214
   STAFFORD TJ, 1984, OPHTHALMOLOGY, V91, P513
   Suzuki MT, 2003, PRIMATES, V44, P291, DOI 10.1007/s10329-002-0016-6
   SUZUKI MT, 1985, EXP ANIM TOKYO, V34, P131, DOI 10.1538/expanim1978.34.2_131
   Thirkill CE, 2000, OCUL IMMUNOL INFLAMM, V8, P25, DOI 10.1076/0927-3948(200003)8:1;1-S;FT025
   Umeda S, 2005, INVEST OPHTH VIS SCI, V46, P683, DOI 10.1167/iovs.04-1031
   Vingerling JR, 1995, EPIDEMIOL REV, V17, P347, DOI 10.1093/oxfordjournals.epirev.a036198
   Weng J, 1999, CELL, V98, P13, DOI 10.1016/S0092-8674(00)80602-9
   WISTOW G, 1991, J MOL EVOL, V32, P262, DOI 10.1007/BF02342749
   Yang YH, 1997, INFLAMMATION, V21, P583, DOI 10.1023/A:1027330021479
NR 46
TC 125
Z9 133
U1 0
U2 10
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0892-6638
EI 1530-6860
J9 FASEB J
JI Faseb J.
PD AUG
PY 2005
VL 19
IS 10
BP 1683
EP +
DI 10.1096/fj.04-3525fje
PG 24
WC Biochemistry & Molecular Biology; Biology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other
   Topics; Cell Biology
GA 963YW
UT WOS:000231843700018
PM 16099945
DA 2022-11-30
ER

PT J
AU Berkowitz, ST
   Groth, SL
   Gangaputra, S
   Patel, S
AF Berkowitz, Sean T.
   Groth, Sylvia L.
   Gangaputra, Sapna
   Patel, Shriji
TI Racial/Ethnic Disparities in Ophthalmology Clinical Trials Resulting in
   US Food and Drug Administration Drug Approvals From 2000 to 2020
SO JAMA OPHTHALMOLOGY
LA English
DT Article
ID OPEN-ANGLE GLAUCOMA; MACULAR DEGENERATION; DIABETIC-RETINOPATHY;
   RACIAL-DIFFERENCES; UNITED-STATES; BARBADOS-EYE; PREVALENCE; POPULATION;
   INJECTION; SUBGROUP
AB IMPORTANCE Diverse, representative enrollment in pivotal clinical trials is vital to sufficiently power subgroup analyses and ensure equity and validity of trial results.
   OBJECTIVE To evaluate the racial/ethnic representation, trends, and disparities in clinical trials leading to US Food and Drug Administration (FDA) ophthalmology drug approvals from 2000 to 2020.
   DESIGN, SETTING, AND PARTICIPANTS This cohort study used data from participants in clinical trials of drugs for neovascular age-related macular degeneration (AMD), open-angle glaucoma (OAG), and expanded indications for diabetic retinopathy (DR) from January 1, 2000, to December 31, 2020. Trial data were sourced from FDA reviews, ClinicalTrials.gov, and relevant linked studies. National expected racial/ethnic proportions were sourced from public National Eye Institute prevalence data as well as published rates scaled using US Census Bureau data.
   MAIN OUTCOMES AND MEASURES The primary outcome measures were the distribution of and change over time in the racial/ethnic proportion of participants in clinical trials leading to FDA approval of drugs for AMD, OAG, and DR.
   RESULTS During the 20-year period, 31 clinical trials were identified for 13 medications with 18 410 participants. The distribution of trial participants was different from the expected trial distribution for most approvals with regard to race/ethnicity (12 drugs) and sex (10 drugs). Compared with the first decade (2000-2010), trials conducted in the second decade (2011-2020) showed increases in enrollment of Asian (odds ratio [OR], 2.30; 95% CI, 1.97-2.68; P < .001) and Hispanic or Latinx participants (OR, 1.74; 95% CI, 1.49-2.03; P < .001) for AMD, Asian participants (OR, 2.21; 95% CI, 1.46-3.42; P < .001) for DR, and Black (OR, 1.60; 95% CI, 1.43-1.78; P < .001) and Hispanic or Latinx participants (OR, 10.31; 95% CI, 8.05-13.35; P < .001) for OAG. There was a decrease in Black participants in DR trials (OR, 0.58; 95% CI, 0.42-0.79; P < .001). Based on these trends, the enrollment incidence ratio is expected to worsen by 2050, with overrepresentation of white participants vs underrepresentation of Black and Hispanic or Latinx participants in trials of drugs for AMD (1.08 vs 0.04 vs 0.77), DR (1.83 vs 0.87 vs 0.59), and OAG (1.62 vs 0.90 vs 0.37).
   CONCLUSIONS AND RELEVANCE In this cohort study, Black, Hispanic or Latinx, and other non-White participants were underrepresented in clinical trials leading to FDA ophthalmology drug approvals compared with the expected disease burden and racial/ethnic distribution in the US. Although there was meaningful improvement from 2000 to 2020, further efforts to increase minority enrollment in clinical trials seem to be warranted.
C1 [Berkowitz, Sean T.] Vanderbilt Univ, Sch Med, Nashville, TN 37232 USA.
   [Groth, Sylvia L.; Gangaputra, Sapna; Patel, Shriji] Vanderbilt Univ, Vanderbilt Eye Inst, Med Ctr, Nashville, TN 37232 USA.
C3 Vanderbilt University; Vanderbilt University
RP Patel, S (通讯作者)，Vanderbilt Univ, Med Ctr, 2311 Pierce Ave, Nashville, TN 37232 USA.
EM shriji.patel@vumc.org
OI Berkowitz, Sean/0000-0002-9763-7192
FU Research to Prevent Blindness, Inc.
FX This study was supported in part by an unrestricted departmental award
   from Research to Prevent Blindness, Inc.
CR [Anonymous], 2001, B WORLD HEALTH ORGAN, V79, P373
   Birnbaum FA, 2018, J NATL MED ASSOC, V110, P473, DOI 10.1016/j.jnma.2017.12.004
   Bressler SB, 2008, ARCH OPHTHALMOL-CHIC, V126, P241, DOI 10.1001/archophthalmol.2007.53
   Canevelli M, 2019, NEUROSCI BIOBEHAV R, V101, P122, DOI 10.1016/j.neubiorev.2019.03.020
   Friedman DS, 2006, ARCH OPHTHALMOL-CHIC, V124, P1625, DOI 10.1001/archopht.124.11.1625
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P564
   Friedman DS, 2004, ARCH OPHTHALMOL-CHIC, V122, P532
   Friedman DS, 1999, OPHTHALMOLOGY, V106, P1049, DOI 10.1016/S0161-6420(99)90267-1
   Gopal AD, 2021, OPHTHALMOLOGY, V128, P332, DOI 10.1016/j.ophtha.2020.07.028
   Kempen JH, 2004, ARCH OPHTHALMOL-CHIC, V122, P552
   Klein R, 2006, OPHTHALMOLOGY, V113, P373, DOI 10.1016/j.ophtha.2005.12.013
   Klein R, 2011, ARCH OPHTHALMOL-CHIC, V129, P75, DOI 10.1001/archophthalmol.2010.318
   Ko F, 2016, INVEST OPHTH VIS SCI, V57, P2152, DOI 10.1167/iovs.15-18373
   Leske MC, 2006, OPHTHALMOLOGY, V113, P29, DOI 10.1016/j.ophtha.2005.08.012
   LESKE MC, 1994, ARCH OPHTHALMOL-CHIC, V112, P821, DOI 10.1001/archopht.1994.01090180121046
   Leske MC, 1999, OPHTHALMOLOGY, V106, P1893, DOI 10.1016/S0161-6420(99)90398-6
   Loree JM, 2019, JAMA ONCOL, V5, DOI 10.1001/jamaoncol.2019.1870
   Moore DB, 2020, JAMA OPHTHALMOL, V138, P903, DOI 10.1001/jamaophthalmol.2020.2107
   Munoz B, 2005, ARCH OPHTHALMOL-CHIC, V123, P1575, DOI 10.1001/archopht.123.11.1575
   Munoz B, 2000, ARCH OPHTHALMOL-CHIC, V118, P819, DOI 10.1001/archopht.118.6.819
   National Eye Institute, 2020, EYE HLTH DATA STAT
   National Institutes of Health, 2001, AMENDMENT NIH POLICY
   National Institutes of Health, 2015, RACIAL ETHNIC CATEGO
   National Institutes of Health, NIH POLICY GUIDELINE
   National Institutes of Health, 2000, AMENDMENT NIH POLICY
   NIH, 2017, NIH POL GUID INCL WO
   Ogura Y, 2015, BRIT J OPHTHALMOL, V99, P92, DOI 10.1136/bjophthalmol-2014-305076
   Okada M, 2021, OPHTHALMOLOGY, V128, P234, DOI 10.1016/j.ophtha.2020.07.060
   Patel S, 2020, OPHTHALMOL RETINA, V4, P754, DOI 10.1016/j.oret.2020.03.011
   Patel S, 2020, JAMA OPHTHALMOL, V138, P242, DOI 10.1001/jamaophthalmol.2019.4644
   PREVENTZA O, 2020, ANN THORAC SURG
   Price KN, 2020, BRIT J DERMATOL, V183, P378, DOI 10.1111/bjd.18938
   Quigley HA, 2001, ARCH OPHTHALMOL-CHIC, V119, P1819, DOI 10.1001/archopht.119.12.1819
   Roy MS, 2004, ARCH OPHTHALMOL-CHIC, V122, P546, DOI 10.1001/archopht.122.4.546
   Salowe Rebecca, 2015, J Clin Exp Ophthalmol, V6
   Senft N, 2020, JAMA ONCOL, V6, P1773, DOI 10.1001/jamaoncol.2020.3697
   SOARES R, 2020, OPHTHALMOL RETINA
   Spielman DB, 2021, LARYNGOSCOPE, V131, P1722, DOI 10.1002/lary.29371
   Stein JD, 2011, OPHTHALMOLOGY, V118, P1031, DOI 10.1016/j.ophtha.2010.10.024
   TIELSCH JM, 1991, JAMA-J AM MED ASSOC, V266, P369, DOI 10.1001/jama.266.3.369
   U.S. Food and Drug Administration, 2020, ENHANCING DIVERSITY
   Unger Joseph M, 2016, Am Soc Clin Oncol Educ Book, V35, P185, DOI 10.14694/EDBK_156686
   US Census Bureau, 2021, MODIFIED RACE DATA 2
   US Food and Drug Administration, FDASIA SECTION 907 I
   US Food and Drug Administration US Department of Health and Human Services ., 2013, FDA REPORT COLLECTIO
   VanderBeek BL, 2011, AM J OPHTHALMOL, V152, P273, DOI 10.1016/j.ajo.2011.02.004
   Varma R, 2004, OPHTHALMOLOGY, V111, P1439, DOI 10.1016/j.ophtha.2004.01.025
   Varma R, 2004, OPHTHALMOLOGY, V111, P1298, DOI 10.1016/j.ophtha.2004.03.002
   Varma R, 2004, OPHTHALMOLOGY, V111, P1288, DOI 10.1016/j.ophtha.2004.01.023
   Varma R, 2016, JAMA OPHTHALMOL, V134, P571, DOI 10.1001/jamaophthalmol.2016.0588
   Vitale S, 2017, JAMA OPHTHALMOL, V135, P732, DOI 10.1001/jamaophthalmol.2017.1063
   Webster-Clark M, 2020, J CLIN EPIDEMIOL, V126, P65, DOI 10.1016/j.jclinepi.2020.06.020
   West SK, 2001, DIABETES CARE, V24, P1204, DOI 10.2337/diacare.24.7.1204
   Wong CW, 2016, PROG RETIN EYE RES, V53, P107, DOI 10.1016/j.preteyeres.2016.04.002
   Wong TY, 2006, AM J OPHTHALMOL, V141, P446, DOI 10.1016/j.ajo.2005.08.063
   Zhang XZ, 2010, JAMA-J AM MED ASSOC, V304, P649, DOI 10.1001/jama.2010.1111
NR 56
TC 8
Z9 8
U1 1
U2 2
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 2168-6165
EI 2168-6173
J9 JAMA OPHTHALMOL
JI JAMA Ophthalmol.
PD JUN
PY 2021
VL 139
IS 6
BP 629
EP 637
DI 10.1001/jamaophthalmol.2021.0857
EA APR 2021
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA SU3EJ
UT WOS:000642585100004
PM 33885724
OA Green Published
DA 2022-11-30
ER

PT J
AU Lei, JQ
   Durbin, MK
   Shi, Y
   Uji, A
   Balasubramanian, S
   Baghdasaryan, E
   Al-Sheikh, M
   Sadda, SR
AF Lei, Jianqin
   Durbin, Mary K.
   Shi, Yue
   Uji, Akihito
   Balasubramanian, Siva
   Baghdasaryan, Elmira
   Al-Sheikh, Mayss
   Sadda, Srinivas R.
TI Repeatability and Reproducibility of Superficial Macular Retinal Vessel
   Density Measurements Using Optical Coherence Tomography Angiography En
   Face Images
SO JAMA OPHTHALMOLOGY
LA English
DT Article
ID DIABETIC-RETINOPATHY; MICROVASCULAR DENSITY; VASCULAR DENSITY; SIGNAL
   STRENGTH; QUANTIFICATION; MORPHOLOGY; EYES
AB IMPORTANCE The repeatability and reproducibility of quantitative metrics from optical coherence tomographic angiography (OCTA) must be assessed before these data can be confidently interpreted in clinical research and practice.
   OBJECTIVE To evaluate the repeatability and reproducibility of OCTA-derived retinal vascular quantitative metrics.
   DESIGN, SETTING AND PARTICIPANTS In this cross-sectional study, 21 healthy volunteers (42 eyes) and 22 patients with retinal disease (22 eyes), including 14 with age-related macular degeneration, 3 with epiretinal membrane, 2 with diabetic retinopathy, 2 with myopic macular degeneration, and 1 with retinal vein occlusion, were enrolled. Participants were recruited from September 1 through November 31, 2016. Each eye underwent 3 repeated scans with 3 instruments for a total of 9 acquisitions. Eyes were randomly assigned to scanning with a 3 x 3-mm or 6 x 6-mm pattern. Eyes were excluded from subsequent analysis if any acquisition had a signal strength of less than 7. Repeatability (defined as the agreement in measurements within a device) and reproducibility (defined as the agreement between devices of the same type) were assessed by intraclass correlation coefficient (ICC) and coefficient of variation. EXPOSURES All eyes underwent scanning using 3 separate devices.
   MAIN OUTCOMES AND MEASURES Vessel length density (VLD) and perfusion density (PD) of the superficial retinal vasculature.
   RESULTS A total of 21 healthy volunteers (8 men and 13 women; mean [SD] age, 36 [6] years) and 22 patients with retinal disease (15 men and 7 women; mean [SD] age, 79 [9] years) underwent evaluation. Of these, 40 of 42 normal eyes and 15 of 22 eyes with retinal disease met signal strength criteria and were included in this analysis. The ICC among the 3 consecutive scans ranged from 0.82 to 0.98 for VLD and from 0.83 to 0.95 for PD. The coefficient of variation (CV) ranged from 2.2% to 5.9% for VLD and from 2.4% to 5.9% for PD. For reproducibility, the ICC ranged from 0.62 to 0.95 and the CV was less than 6% in all groups. The agreement was highest for the 3 x 3-mm pattern in the inner ring (ICC range, 0.92 [95% CI, 0.85-0.96] to 0.96 [95% CI, 0.93-0.98]) and 6 x 6-mm pattern in the outer ring (ICC range, 0.93 [95% CI, 0.86-0.97] to 0.96 [95% CI, 0.92-0.98]).
   CONCLUSIONS AND RELEVANCE Vessel length density and PD of the superficial retinal vasculature can be obtained from OCTA images with high levels of repeatability and reproducibility but can vary with scan pattern and location.
C1 [Lei, Jianqin; Shi, Yue; Uji, Akihito; Balasubramanian, Siva; Baghdasaryan, Elmira; Al-Sheikh, Mayss; Sadda, Srinivas R.] Doheny Eye Inst, Doheny Image Reading Ctr, 1350 San Pablo St,Room DVRC211, Los Angeles, CA 90033 USA.
   [Lei, Jianqin; Shi, Yue; Uji, Akihito; Balasubramanian, Siva; Baghdasaryan, Elmira; Al-Sheikh, Mayss; Sadda, Srinivas R.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Ophthalmol, Los Angeles, CA 90095 USA.
   [Lei, Jianqin] Xi An Jiao Tong Univ, Affiliated Hosp 1, Dept Ophthalmol, Xian, Shaanxi, Peoples R China.
   [Durbin, Mary K.] Carl Zeiss Meditec Inc, Res & Dev, Dublin, CA USA.
   [Al-Sheikh, Mayss] Univ Zurich, Univ Zurich Hosp, Dept Ophthalmol, Zurich, Switzerland.
C3 Doheny Eye Institute; University of California System; University of
   California Los Angeles; University of California Los Angeles Medical
   Center; David Geffen School of Medicine at UCLA; Xi'an Jiaotong
   University; Carl Zeiss AG; University of Zurich; University Zurich
   Hospital
RP Sadda, SR (通讯作者)，Doheny Eye Inst, Doheny Image Reading Ctr, 1350 San Pablo St,Room DVRC211, Los Angeles, CA 90033 USA.
EM ssadda@doheny.org
FU Sadda
FX Sadda.
CR Agemy SA, 2015, RETINA-J RET VIT DIS, V35, P2353, DOI 10.1097/IAE.0000000000000862
   Al-Sheikh M, 2017, BRIT J OPHTHALMOL, V101, P449, DOI 10.1136/bjophthalmol-2016-308764
   Chen CL, 2015, INVEST OPHTH VIS SCI, V56, P3810, DOI 10.1167/iovs.15-16502
   Cheung CYL, 2008, OPHTHALMOLOGY, V115, P1347, DOI 10.1016/j.ophtha.2007.11.027
   Cnaan A, 1997, STAT MED, V16, P2349, DOI 10.1002/(SICI)1097-0258(19971030)16:20<2349::AID-SIM667>3.0.CO;2-E
   Coscas F, 2016, INVEST OPHTH VIS SCI, V57, pOCT211, DOI 10.1167/iovs.15-18793
   Durbin MK, 2017, JAMA OPHTHALMOL, V135, P370, DOI 10.1001/jamaophthalmol.2017.0080
   Gao SS, 2016, INVEST OPHTH VIS SCI, V57, P4485, DOI 10.1167/iovs.16-20080
   Giani A, 2012, RETINA-J RET VIT DIS, V32, P1007, DOI 10.1097/IAE.0b013e31822f5660
   Hwang TS, 2016, JAMA OPHTHALMOL, V134, P367, DOI 10.1001/jamaophthalmol.2015.5658
   Kim AY, 2016, INVEST OPHTH VIS SCI, V57, pOCT362, DOI 10.1167/iovs.15-18904
   Pechauer AD, 2015, INVEST OPHTH VIS SCI, V56, P3287, DOI 10.1167/iovs.15-16655
   Savastano MC, 2015, RETINA-J RET VIT DIS, V35, P2196, DOI 10.1097/IAE.0000000000000635
   Shahlaee A, 2016, AM J OPHTHALMOL, V165, P39, DOI 10.1016/j.ajo.2016.02.018
   Spaide RF, 2015, JAMA OPHTHALMOL, V133, P45, DOI 10.1001/jamaophthalmol.2014.3616
   World Med Assoc, 2013, JAMA-J AM MED ASSOC, V310, P2191, DOI 10.1001/jama.2013.281053
   You QS, 2017, RETINA-J RET VIT DIS, V37, P1475, DOI 10.1097/IAE.0000000000001407
NR 17
TC 136
Z9 139
U1 0
U2 14
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 2168-6165
EI 2168-6173
J9 JAMA OPHTHALMOL
JI JAMA Ophthalmol.
PD OCT
PY 2017
VL 135
IS 10
BP 1092
EP 1098
DI 10.1001/jamaophthalmol.2017.3431
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA FJ6LL
UT WOS:000412869200020
PM 28910435
OA Green Published, Green Accepted
DA 2022-11-30
ER

PT J
AU Cohen, SY
   Dubois, L
   Ayrault, S
   Dourmad, P
   Delahaye-Mazza, C
   Fajnkuchen, F
   Nghiem-Buffet, S
   Quentel, G
   Tadayoni, R
AF Cohen, Salomon Y.
   Dubois, Lise
   Ayrault, Sandrine
   Dourmad, Pauline
   Delahaye-Mazza, Corinne
   Fajnkuchen, Franck
   Nghiem-Buffet, Sylvia
   Quentel, Gabriel
   Tadayoni, Ramin
TI Ranibizumab for exudative AMD in a clinical setting: differences between
   2007 and 2010
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE Exudative age-related macular degeneration; Ranibizumab; Real-life
   retrospective study
ID MACULAR DEGENERATION; INTRAVITREAL RANIBIZUMAB; DOSING REGIMEN;
   NEOVASCULARIZATION; THERAPY; TREAT
AB Visual results of ranibizumab given pro re nata in clinical settings depend greatly from the achievement of the monthly follow-up. In 2007, a previous study performed in our tertiary care showed a mean visual gain of only + 0.7 ETDRS chart letters, probably because of insufficient number of follow-up visits and injections. We report a second retrospective study of patients whose eyes were treated in the same setting, and whose first injection was performed after April 1 2010. The aim was to check if the changes in the management of AMD patients between 2010 and 2007 achieved better visual results.
   One hundred and twenty-two patients (125 eyes) with exudative age-related macular degeneration (AMD) were included. Age, gender, side, type of CNV, VA measured on an ETDRS chart at baseline and at 52 +/- 6 weeks, the number of IVT performed, and follow-up visits were recorded. The series was compared to our former series of the year 2007. Results are expressed as means +/- standard deviation. Mann-Whitney's non-parametric test was used to compare the statistical distribution of the parameters measured. Fisher's exact test was used for 2 x 2 categorical variables, and the chi-square test for others.
   In the 2010 series, the mean visual gain was +6.0 +/- 11.0 l (-35 to + 34). During this period, the eyes had 5.0 +/- 1.8 IVT and 7.8 +/- 1.4 follow-up visits. No correlation was found between the change in VA and gender, type of CNV, age, or the numbers of IVT and visits. There was a reverse correlation between baseline VA and VA changes (r = -0.413, p < 0.0001): i.e., the higher the VA at presentation, the smaller the gain. Comparison between 2010 and 2007 showed that in 2010, patients were older (82.2 +/- 7.0 vs 78.3 +/- 7.0 y, p < 0.0001), had a better baseline VA (60.6 +/- 12.7 vs 56.1 +/- 14.6 l, p = 0.0191) and, despite the reverse correlation between change in VA and VA at presentation, visual results were better: +6.0 +/- 11.0 vs +0.7 +/- 11.99 l, p = 0.0003. In 2010, eyes received more injections: 5.0 +/- 1.8 vs 3.8 +/- 1.4 in 2007, p < 0.0001. However, the series did not differ for the number of visits, gender, side or type of CNV.
   In 2010, monotherapy with ranibizumab for exudative AMD achieved better visual results than in 2007 in our clinical setting, despite the treatment of older patients with better baseline VA. This is probably due to the greater number of IVT performed. Alternate strategies, such as "inject and extend" or maintenance therapy, may also account for the better visual results.
C1 [Cohen, Salomon Y.; Dubois, Lise; Ayrault, Sandrine; Dourmad, Pauline; Delahaye-Mazza, Corinne; Fajnkuchen, Franck; Nghiem-Buffet, Sylvia; Quentel, Gabriel] Ctr Ophtalmol Imagerie & Laser, F-75015 Paris, France.
   [Cohen, Salomon Y.; Tadayoni, Ramin] Univ Paris Diderot, Hop Lariboisiere, APHP, Sorbonne Paris Cite,Dept Ophthalmol, Paris, France.
C3 Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire
   Ambroise-Pare - APHP; Hopital Universitaire Lariboisiere-Fernand-Widal -
   APHP; UDICE-French Research Universities; Universite Paris Cite
RP Cohen, SY (通讯作者)，Ctr Ophtalmol Imagerie & Laser, 11 Rue Antoine Bourdelle, F-75015 Paris, France.
EM sycsyc75@gmail.com
FU CIL-ASSOC, Association for Education and Research, Centre
   Ophtalmologique d'Imagerie et de Laser, Paris, France
FX Supported by CIL-ASSOC, Association for Education and Research, Centre
   Ophtalmologique d'Imagerie et de Laser, Paris, France.
CR Arias L, 2011, RETINA-J RET VIT DIS, V31, P1261, DOI 10.1097/IAE.0b013e318207d152
   Bandukwala T, 2010, CAN J OPHTHALMOL, V45, P590, DOI 10.3129/i10-082
   Biarnes M, 2011, EUR J OPHTHALMOL, V21, P282, DOI 10.5301/EJO.2010.5766
   Bloch SB, 2013, ACTA OPHTHALMOL, V91, P42, DOI 10.1111/j.1755-3768.2011.02268.x
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Cohen SY, 2013, RETINA-J RET VIT DIS, V33, P474, DOI 10.1097/IAE.0b013e31827b6324
   Cohen SY, 2009, AM J OPHTHALMOL, V148, P409, DOI 10.1016/j.ajo.2009.04.001
   Dadgostar H, 2009, OPHTHALMOLOGY, V116, P1740, DOI 10.1016/j.ophtha.2009.05.033
   Engelbert M, 2010, RETINA-J RET VIT DIS, V30, P1368, DOI 10.1097/IAE.0b013e3181d50cbf
   Engelbert M, 2009, RETINA-J RET VIT DIS, V29, P1424, DOI 10.1097/IAE.0b013e3181bfbd46
   Fung AE, 2007, AM J OPHTHALMOL, V143, P566, DOI 10.1016/j.ajo.2007.01.028
   Gerding H, 2011, GRAEF ARCH CLIN EXP, V249, P653, DOI 10.1007/s00417-011-1636-6
   Gupta OP, 2010, OPHTHALMOLOGY, V117, P2134, DOI 10.1016/j.ophtha.2010.02.032
   Hjelmqvist L, 2011, J OPHTHALMOL, V2011, DOI 10.1155/2011/405724
   Ip MS, 2008, OPHTHALMOLOGY, V115, P1837, DOI 10.1016/j.ophtha.2008.08.012
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Oubraham H, 2011, RETINA-J RET VIT DIS, V31, P26, DOI 10.1097/IAE.0b013e3181de5609
   Querques G, 2010, BRIT J OPHTHALMOL, V94, P292, DOI 10.1136/bjo.2009.170670
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rothenbuehler SP, 2009, AM J OPHTHALMOL, V147, P831, DOI 10.1016/j.ajo.2008.12.005
   Rotsos T, 2010, CLIN OPHTHALMOL, V4, P1271, DOI 10.2147/OPTH.S14684
   Spaide R, 2007, AM J OPHTHALMOL, V143, P679, DOI 10.1016/j.ajo.2007.02.024
   Spaide RF, 2009, AM J OPHTHALMOL, V148, P1, DOI 10.1016/j.ajo.2009.04.010
NR 24
TC 19
Z9 20
U1 0
U2 6
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0721-832X
EI 1435-702X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD NOV
PY 2013
VL 251
IS 11
BP 2499
EP 2503
DI 10.1007/s00417-013-2338-z
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 239VB
UT WOS:000326052700001
PM 23604514
DA 2022-11-30
ER

PT J
AU Babizhayev, MA
AF Babizhayev, Mark A.
TI Biomarkers and special features of oxidative stress in the anterior
   segment of the eye linked to lens cataract and the trabecular meshwork
   injury in primary open-angle glaucoma: challenges of dual combination
   therapy with N-acetylcarnosine lubricant eye drops and oral formulation
   of nonhydrolyzed carnosine
SO FUNDAMENTAL & CLINICAL PHARMACOLOGY
LA English
DT Review
DE age-related ophthalmic diseases; cataract; primary open-angle glaucoma;
   biomarkers; blindness prevention; lens and trabecular meshwork of
   anterior eye segment; mechanism of degenerative alterations;
   N-acetylcarnosine lubricant eye drops; oral supplement of nonhydrolyzed
   carnosine; oxidative stress
ID LIPID-PEROXIDATION PRODUCTS; INNER-WALL ENDOTHELIUM; AQUEOUS-HUMOR
   OUTFLOW; AGE-RELATED-CHANGES; INDUCED DNA-DAMAGE;
   PHOSPHOLIPID-MALONDIALDEHYDE-ADDUCT; GLUTATHIONE-S-TRANSFERASE; SYSTEMIC
   HUMAN-DISEASES; DIQUAT-INDUCED CATARACT; OPTIC-NERVE ISCHEMIA
AB The implication of oxidative stress associated with increased oxidant production in mammalian and human cells characterized by the release of free radicals, resulting in cellular degeneration, is involved in many ocular diseases, such as age-related macular degeneration, retinopathy of prematurity, retinal light damage, primary open-angle glaucoma (POAG), and cataract. Cataract is the leading cause of blindness, accounting for 50% of blindness worldwide. Glaucoma, the leading cause of irreversible blindness, is considered as a progressive optic neuropathy often caused by elevated intraocular pressure (IOP) consequent to abnormally high resistance to aqueous humor (AH) drainage via the trabecular meshwork (TM) and Schlemms canal. Morphological and biochemical analyses of the TM of patients with POAG revealed the loss of cells, increased accumulation of extracellular matrix proteins (ECM), changes in the cytoskeleton, cellular senescence, and the process of subclinical inflammation. The TM is the target tissue of glaucoma in the anterior chamber, and the development and progression of glaucoma are accompanied by the accumulation of oxidative damage in this tissue. The separate studies were conducted to comparatively evaluate the sensitivity to oxidative stress and lipid peroxidation (LPO) of anterior chamber tissues including TM. Accumulation of the primary, secondary, and end products of LPO (diene and triene conjugates, Schiffs bases) was noted in the studied extracts. Significant differences in the levels of all mentioned LPO products in comparison with the control were observed. The data may be considered as an evidence of LPO participation in the destruction of the trabecule and Schlemms canal in POAG. Treatment of TM cells with oxidative stress induced POAG-typical changes such as ECM accumulation, cell death, disarrangement of the cytoskeleton, advanced senescence, and the release of inflammatory markers. By pretreatment with antioxidants, prostaglandin analogs, beta-blockers, or local carbonic anhydrase inhibitors, these effects were markedly reduced. Oxidative stress can induce characteristic glaucomatous TM changes, and these oxidative stressinduced TM changes can be minimized by the use of antioxidants and IOP-lowering substances. It is tempting to speculate that the prevention of oxidative stress exposure to the TM may help to reduce the progression of POAG. The authors laboratory has developed and patented the dual combination therapy with N-acetylcarnosine lubricant eye drops and oral formulation of nonhydrolyzed carnosine in ripe cataracts and POAG. The specific regimen for the treatment in each stage of age-related ophthalmic disease has been taken up. In the treatment of POAG, this dual therapy can be combined with conventional antiglaucoma therapy with beta-blocking and/or adrenergic agonist medicines providing the significant IOP-lowering effect and significant increase in outflow facility. The developed therapy is a prominent management care of the glaucomatous neurodegeneration.
C1 [Babizhayev, Mark A.] Innovative Vis Prod Inc, Cty New Castle, DE 19810 USA.
   [Babizhayev, Mark A.] Moscow Helmholtz Res Inst Eye Dis, Moscow 103064, Russia.
C3 Helmholtz National Medical Research Center of Eye Diseases
RP Babizhayev, MA (通讯作者)，Innovative Vis Prod Inc, 3511 Silverside Rd,Suite 105, Cty New Castle, DE 19810 USA.
EM markbabizhayev@mail.ru
FU Innovative Vision Products, Inc. (County of New Castle, DE, USA)
FX This work was planned, organized, and supported by Innovative Vision
   Products, Inc. (County of New Castle, DE, USA). Innovative Vision
   Products, Inc. is a holder of the worldwide patent (including PCT
   International Publication Number WO 2004/028536 A1) for the application
   of N-acetylcarnosine for the treatment of ophthalmic disorders,
   including cataracts as well as (PCT International Publication Number WO
   2004/064866 PCT/JP2004/000351) protecting the described in the article
   therapeutic applications. Innovative Vision Products Inc. is a
   Pharmaceutical and Nanotechnology Development Company with a focus on
   innovative chemical entities, drug delivery systems, and unique medical
   devices to target specific biomedical applications. Over the last
   decade, IVP has developed a track record in developing these
   technologies to effectively address the unmet needs of specific diseased
   populations.
CR Acott TS, 2008, EXP EYE RES, V86, P543, DOI 10.1016/j.exer.2008.01.013
   Alberti G, 1996, INVEST OPHTH VIS SCI, V37, P1167
   ALCAIN FJ, 1994, J BIOENERG BIOMEMBR, V26, P393, DOI 10.1007/BF00762780
   ALLINGHAM RR, 1992, INVEST OPHTH VIS SCI, V33, P1661
   ALVARADO J, 1981, INVEST OPHTH VIS SCI, V21, P714
   ALVARADO J, 1984, OPHTHALMOLOGY, V91, P564
   Alvarado J, 1984, RECENT ADV GLAUCOMA, P3
   Alvarado JA, 2005, BRIT J OPHTHALMOL, V89, P1500, DOI 10.1136/bjo.2005.081307
   Alvarado JA, 2004, AM J PHYSIOL-CELL PH, V286, pC621, DOI 10.1152/ajpcell.00108.2003
   Alvarado JA, 2005, T AM OPHTHAL SOC, V103, P162
   Alvarado Jorge A, 2005, Trans Am Ophthalmol Soc, V103, P148
   ANDLEY UP, 1987, PHOTOCHEM PHOTOBIOL, V46, P1057, DOI 10.1111/j.1751-1097.1987.tb04893.x
   [Anonymous], 2008, Community Eye Health, V21, P1
   Apple DJ, 2000, SURV OPHTHALMOL, V45, pS5
   Ates O, 2010, ACTA OPHTHALMOL, V88, P891, DOI 10.1111/j.1755-3768.2009.01583.x
   BABIZHAEV M A, 1986, Byulleten' Eksperimental'noi Biologii i Meditsiny, V102, P158
   BABIZHAYEV MA, 1989, MECH AGEING DEV, V47, P145, DOI 10.1016/0047-6374(89)90017-1
   BABIZHAYEV MA, 1989, ACTA OPHTHALMOL, V67, P371
   BABIZHAYEV MA, 1989, BIOCHIM BIOPHYS ACTA, V1004, P363, DOI 10.1016/0005-2760(89)90085-4
   BABIZHAYEV MA, 1994, BBA-MOL BASIS DIS, V1225, P326, DOI 10.1016/0925-4439(94)90014-0
   BABIZHAYEV MA, 1989, BIOCHIM BIOPHYS ACTA, V1004, P124, DOI 10.1016/0005-2760(89)90222-1
   BABIZHAYEV MA, 1988, MECH AGEING DEV, V44, P69, DOI 10.1016/0047-6374(88)90080-2
   BABIZHAYEV MA, 1992, BIOCHIM BIOPHYS ACTA, V1138, P11, DOI 10.1016/0925-4439(92)90145-D
   BABIZHAYEV MA, 1992, MECH AGEING DEV, V64, P133, DOI 10.1016/0047-6374(92)90102-J
   BABIZHAYEV MA, 1989, GRAEF ARCH CLIN EXP, V227, P384, DOI 10.1007/BF02169418
   BABIZHAYEV MA, 1989, ACTA OPHTHALMOL, V67, P281
   Babizhayev MA, 2006, CURR DRUG THER, V1, P91, DOI 10.2174/157488506775268425
   Babizhayev Mark A, 2005, Drugs R D, V6, P345, DOI 10.2165/00126839-200506060-00004
   Babizhayev Mark A, 2010, Recent Pat Drug Deliv Formul, V4, P198
   Babizhayev MA, 2009, CLIN INTERV AGING, V4, P31
   Babizhayev Mark A, 2009, Recent Pat Drug Deliv Formul, V3, P229
   Babizhayev MA, 2009, AM J THER, V16, P517, DOI 10.1097/MJT.0b013e318195e327
   Babizhayev MA, 2009, CURR CLIN PHARMACOL, V4, P4, DOI 10.2174/157488409787236074
   Babizhayev MA, 2009, J DRUG TARGET, V17, P36, DOI [10.1080/10611860802438736, 10.1080/10611860802438736 ]
   Baetz NW, 2009, EXP EYE RES, V89, P95, DOI 10.1016/j.exer.2009.02.018
   BARKSDALE S, 1986, Investigative Ophthalmology and Visual Science, V27, P210
   BECKER B, 1979, AM J OPHTHALMOL, V97, P1667
   BHUYAN DK, 1991, FREE RADICAL RES COM, V12-3, P621
   BHUYAN KC, 1992, FREE RADICAL BIO MED, V12, P251, DOI 10.1016/0891-5849(92)90112-T
   BHUYAN KC, 1991, ARCH BIOCHEM BIOPHYS, V288, P525, DOI 10.1016/0003-9861(91)90230-G
   BHUYAN KC, 1977, BIOCHIM BIOPHYS ACTA, V497, P641, DOI 10.1016/0304-4165(77)90284-7
   BHUYAN KC, 1984, CURR EYE RES, V3, P67, DOI 10.3109/02713688408997188
   BHUYAN KC, 1986, LIFE SCI, V38, P1463, DOI 10.1016/0024-3205(86)90559-X
   BHUYAN KC, 1991, FREE RADICAL RES COM, V12-3, P609, DOI 10.3109/10715769109145837
   BHUYAN KC, 1986, MECH AGEING DEV, V34, P289, DOI 10.1016/0047-6374(86)90080-1
   BHUYAN KC, 1978, BIOCHIM BIOPHYS ACTA, V542, P28, DOI 10.1016/0304-4165(78)90229-5
   BILL A, 1975, INVEST OPHTH VISUAL, V14, P1
   BORCHMAN D, 1989, CURR EYE RES, V8, P939
   BORCHMAN D, 1989, INVEST OPHTH VIS SCI, V30, P1633
   BORCHMAN D, 1992, LIPIDS, V27, P261, DOI 10.1007/BF02536472
   BORCHMAN D, 1993, EXP EYE RES, V57, P199, DOI 10.1006/exer.1993.1115
   Bunin A Ia, 2000, Vestn Oftalmol, V116, P24
   Caballero M, 2003, BIOCHEM BIOPH RES CO, V308, P346, DOI 10.1016/S0006-291X(03)01385-8
   Chauhan BC, 2004, INVEST OPHTH VIS SCI, V45, P144, DOI 10.1167/iovs.03-0687
   Cioffi GA, 1995, CURR EYE RES, V14, P1147, DOI 10.3109/02713689508995821
   CLAYTON RM, 1982, T OPHTHAL SOC UK, V102, P331
   COSTAGLIOLA C, 1990, EXP EYE RES, V51, P631, DOI 10.1016/0014-4835(90)90046-W
   COSTAGLIOLA C, 1988, OPHTHALMIC RES, V20, P308, DOI 10.1159/000266734
   DelaPaz MA, 1996, INVEST OPHTH VIS SCI, V37, P1849
   Dong QY, 2008, EUR J OPHTHALMOL, V18, P94, DOI 10.1177/112067210801800116
   DWIVEDI RS, 1987, OPHTHALMIC RES, V19, P41, DOI 10.1159/000265469
   EGOROV SY, 1987, BIOFIZIKA+, V32, P169
   Ellwein LB, 1995, B WORLD HEALTH ORGAN, V73, P681
   EPSTEIN DL, 1991, INVEST OPHTH VIS SCI, V32, P160
   EPSTEIN DL, 1990, EXP EYE RES, V50, P785, DOI 10.1016/0014-4835(90)90129-I
   Ethier CR, 2004, BIOPHYS J, V87, P2828, DOI 10.1529/biophysj.103.038133
   Ethier CR, 2001, INVEST OPHTH VIS SCI, V42, P1795
   ETHIER CR, 1995, INVEST OPHTH VIS SCI, V36, P2466
   FECONDO JV, 1983, EXP EYE RES, V36, P15, DOI 10.1016/0014-4835(83)90085-4
   Ferreira SM, 2004, AM J OPHTHALMOL, V137, P62, DOI 10.1016/S0002-9394(03)00788-8
   FERRER JV, 1990, BIOCHEM J, V269, P531, DOI 10.1042/bj2690531
   Fishbein S L, 1972, Ann Ophthalmol, V4, P487
   Flammer J, 1994, Surv Ophthalmol, V38 Suppl, pS3, DOI 10.1016/0039-6257(94)90041-8
   Flammer J, 1999, J GLAUCOMA, V8, P212
   FLOYD RA, 1990, CARCINOGENESIS, V11, P1447, DOI 10.1093/carcin/11.9.1447
   Foster A, 2001, BRIT J OPHTHALMOL, V85, P635, DOI 10.1136/bjo.85.6.635
   FREEDMAN SF, 1985, INVEST OPHTH VIS SCI, V26, P1330
   Fris M, 2008, GRAEF ARCH CLIN EXP, V246, P551, DOI 10.1007/s00417-007-0747-6
   Gabelt BT, 2005, PROG RETIN EYE RES, V24, P612, DOI 10.1016/j.preteyeres.2004.10.003
   GERHARD JP, 1966, DOC OPHTHALMOL, V20, P104
   Ghanem AA, 2010, CURR EYE RES, V35, P295, DOI 10.3109/02713680903548970
   Gierhart D.L., 2006, [No title captured], Patent No. [US20060039954, 20060039954]
   GOOSEY JD, 1984, INVEST OPHTH VIS SCI, V25, P608
   GOOSEY JD, 1981, INVEST OPHTH VIS SCI, V20, P679
   GOOSEY JD, 1980, SCIENCE, V208, P1278, DOI 10.1126/science.7375939
   GRIERSON I, 1987, EYE, V1, P204, DOI 10.1038/eye.1987.38
   Haefliger IO, 1999, SURV OPHTHALMOL, V43, pS51, DOI 10.1016/S0039-6257(99)00026-0
   Halliwell B., 1985, FREE RADICAL BIO MED, P123
   HARDING JJ, 1970, BIOCHEM J, V117, P957, DOI 10.1042/bj1170957
   HARDING JJ, 1976, EXP EYE RES, V22, P1, DOI 10.1016/0014-4835(76)90033-6
   Harding JJ, 1984, EYE B, V1b, P207
   HARMAN D, 1965, J GERONTOL, V20, P151, DOI 10.1093/geronj/20.2.151
   Hassel B, 2007, VET OPHTHALMOL, V10, P38, DOI 10.1111/j.1463-5224.2007.00519.x
   Hockwin O., 1981, MOL CELLULAR BIOL EY, P367
   Hogg P, 2000, INVEST OPHTH VIS SCI, V41, P1091
   Huang L, 2006, FREE RADICAL BIO MED, V41, P1425, DOI 10.1016/j.freeradbiomed.2006.07.022
   Huang L, 2006, FREE RADICAL BIO MED, V41, P926, DOI 10.1016/j.freeradbiomed.2006.05.023
   Irshad M., 2002, Indian Journal of Experimental Biology, V40, P1233
   Izzotti A, 2006, MUTAT RES-REV MUTAT, V612, P105, DOI 10.1016/j.mrrev.2005.11.001
   Izzotti A, 2003, AM J MED, V114, P638, DOI 10.1016/S0002-9343(03)00114-1
   Izzotti Alberto, 2006, Recenti Prog Med, V97, P37
   Izzotti A, 2010, ARCH OPHTHALMOL-CHIC, V128, P724, DOI 10.1001/archophthalmol.2010.87
   Izzotti A, 2009, INVEST OPHTH VIS SCI, V50, P5251, DOI 10.1167/iovs.09-3871
   Javitt JC, 1996, ANNU REV PUBL HEALTH, V17, P159
   Johnson M, 2002, INVEST OPHTH VIS SCI, V43, P2950
   Johnson M, 2006, EXP EYE RES, V82, P545, DOI 10.1016/j.exer.2005.10.011
   Johnstone MA, 2004, J GLAUCOMA, V13, P421, DOI 10.1097/01.ijg.0000131757.63542.24
   KAGAN VE, 1988, LIPID PEROXIDATION B, P181
   KAHN MG, 1983, INVEST OPHTH VIS SCI, V24, P1283
   KIKUGAWA K, 1991, BIOCHIM BIOPHYS ACTA, V1096, P108, DOI 10.1016/0925-4439(91)90047-D
   KLEIMAN NJ, 1993, CURR EYE RES, V12, P423, DOI 10.3109/02713689309024624
   KLEIMAN NJ, 1990, CURR EYE RES, V9, P1185, DOI 10.3109/02713689009003475
   KLEIMAN NJ, 1990, MUTAT RES, V240, P35, DOI 10.1016/0165-1218(90)90006-N
   Knepper PA, 1996, INVEST OPHTH VIS SCI, V37, P1360
   Knepper PA, 1996, INVEST OPHTH VIS SCI, V37, P2414
   LINNER E, 1969, ACTA OPHTHALMOL, V47, P685
   Lipton SA, 1999, CELL DEATH DIFFER, V6, P943, DOI 10.1038/sj.cdd.4400580
   Liton PB, 2009, EXP EYE RES, V88, P724, DOI 10.1016/j.exer.2008.11.002
   LOFT S, 1993, J TOXICOL ENV HEALTH, V40, P391, DOI 10.1080/15287399309531806
   Lutjen-Drecoll E, 2005, EXP EYE RES, V81, P1, DOI 10.1016/j.exer.2005.02.008
   Lutjen-Drecoll E., 1996, GLAUCOMAS, P89
   MAEPEA O, 1992, EXP EYE RES, V54, P879, DOI 10.1016/0014-4835(92)90151-H
   MARTINEZCAYUELA M, 1995, BIOCHIMIE, V77, P147, DOI 10.1016/0300-9084(96)88119-3
   McCarty MF, 1998, MED HYPOTHESES, V51, P483, DOI 10.1016/S0306-9877(98)90068-8
   MIBU H, 1994, EXP EYE RES, V58, P85, DOI 10.1006/exer.1994.1197
   MILLARD CB, 1987, EXP EYE RES, V45, P623, DOI 10.1016/S0014-4835(87)80071-4
   MIYAZAKI M, 1987, JPN J OPHTHALMOL, V31, P558
   Murthy GVS, 2008, INDIAN J OPHTHALMOL, V56, P489, DOI 10.4103/0301-4738.42774
   NATH R, 1969, INDIAN J EXP BIOL, V7, P25
   Navajas EV, 2005, EXP EYE RES, V80, P853, DOI 10.1016/j.exer.2004.12.016
   NGUYEN KPV, 1985, INVEST OPHTH VIS SCI, V26, P887
   NISHIGORI H, 1986, CURR EYE RES, V5, P37, DOI 10.3109/02713688608995163
   Noske W, 1997, GRAEF ARCH CLIN EXP, V235, P551, DOI 10.1007/BF00947082
   NOTO R, 1983, ACTA DIABETOL LAT, V20, P81, DOI 10.1007/BF02629133
   Ohira Akihiro, 2008, Nippon Ganka Gakkai Zasshi, V112, P22
   Orgul S, 1999, SURV OPHTHALMOL, V43, pS17, DOI 10.1016/S0039-6257(99)00009-0
   Orgul S, 1996, J GLAUCOMA, V5, P135
   Ottonello S, 2000, OPHTHALMOLOGICA, V214, P78, DOI 10.1159/000027474
   Overby DR, 2009, EXP EYE RES, V88, P656, DOI 10.1016/j.exer.2008.11.033
   Padgaonkar V, 1994, J Glaucoma, V3, P123
   PARK JW, 1992, FREE RADICAL BIO MED, V12, P245, DOI 10.1016/0891-5849(92)90111-S
   PIRIE A, 1965, BIOCHEM J, V96, P244, DOI 10.1042/bj0960244
   PIRIE A, 1965, NATURE, V205, P500, DOI 10.1038/205500a0
   Potau J M, 2000, Arch Soc Esp Oftalmol, V75, P159
   Potau J M, 2000, Arch Soc Esp Oftalmol, V75, P21
   Prasanna G, 2005, PHARMACOL RES, V51, P41, DOI 10.1016/j.phrs.2004.04.006
   RAO GN, 1983, OPHTHALMIC RES, V15, P173, DOI 10.1159/000265254
   RATHBUN WB, 1989, GLUTATHIONE CHEM B B, P467
   REDDY VN, 1990, EXP EYE RES, V50, P771, DOI 10.1016/0014-4835(90)90127-G
   Reddy VN, 1998, INVEST OPHTH VIS SCI, V39, P344
   Resch H, 2009, INVEST OPHTH VIS SCI, V50, P358, DOI 10.1167/iovs.08-2460
   Rink H, 1984, Monogr Dev Biol, V17, P94
   Ronziere MC, 2003, BIOMATERIALS, V24, P851, DOI 10.1016/S0142-9612(02)00418-0
   RUSSELL P, 1989, EXP EYE RES, V48, P251, DOI 10.1016/S0014-4835(89)80074-0
   Russell P, 1996, J GLAUCOMA, V5, P317
   Sacca SC, 2008, PROG BRAIN RES, V173, P385, DOI 10.1016/S0079-6123(08)01127-8
   Sacca SC, 2005, ARCH OPHTHALMOL-CHIC, V123, P458, DOI 10.1001/archopht.123.4.458
   Sacca SC, 2007, EXP EYE RES, V84, P389, DOI 10.1016/j.exer.2006.10.008
   SAEZ G, 1982, BIOCHIM BIOPHYS ACTA, V719, P24, DOI 10.1016/0304-4165(82)90302-6
   Sawada H, 2009, CURR EYE RES, V34, P36, DOI 10.1080/02713680802500960
   SCHACHTSCHABEL DO, 1993, Z GERONTOL, V26, P243
   SCHARF J, 1987, GRAEF ARCH CLIN EXP, V225, P133, DOI 10.1007/BF02160345
   SCHWAB L, 1990, INT OPHTHALMOL CLIN, V30, P16, DOI 10.1097/00004397-199030010-00006
   SCOTT DR, 1984, INVEST OPHTH VIS SCI, V25, P599
   Scott PA, 2009, EXP EYE RES, V89, P942, DOI 10.1016/j.exer.2009.08.002
   Shin AH, 2006, ARCH PHARM RES, V29, P577, DOI 10.1007/BF02969268
   SIMONELLI F, 1989, EXP EYE RES, V49, P181, DOI 10.1016/0014-4835(89)90088-2
   Sit AJ, 1997, INVEST OPHTH VIS SCI, V38, P1517
   SPECTOR A, 1981, EXP EYE RES, V33, P673, DOI 10.1016/S0014-4835(81)80107-8
   SPECTOR A, 1995, FASEB J, V9, P1173, DOI 10.1096/fasebj.9.12.7672510
   SPECTOR A, 1984, INVEST OPHTH VIS SCI, V25, P130
   SPECTOR A, 1993, CURR EYE RES, V12, P163, DOI 10.3109/02713689308999484
   SPECTOR A, 1993, P NATL ACAD SCI USA, V90, P7485, DOI 10.1073/pnas.90.16.7485
   SPECTOR A, 1989, EXP EYE RES, V49, P685, DOI 10.1016/S0014-4835(89)80063-6
   Srivastava SK, 1996, CURR EYE RES, V15, P749, DOI 10.3109/02713689609003458
   Stamer WD, 1995, CURR EYE RES, V14, P1095, DOI 10.3109/02713689508995815
   Stamer WD, 2001, INVEST OPHTH VIS SCI, V42, P1803
   Tabin G, 2008, CURR OPIN OPHTHALMOL, V19, P55, DOI 10.1097/ICU.0b013e3282f154bd
   Tamm ER, 1996, INVEST OPHTH VIS SCI, V37, P2402
   TAMM ER, 1998, NITRIC OXIDE ENDOTHE, P158
   Tamm ER, 2007, SURV OPHTHALMOL, V52, pS101, DOI 10.1016/j.survophthal.2007.08.002
   Tamm ER, 2009, EXP EYE RES, V88, P648, DOI 10.1016/j.exer.2009.02.007
   Tektas OY, 2009, EXP EYE RES, V88, P769, DOI 10.1016/j.exer.2008.11.025
   Tian BH, 2000, INVEST OPHTH VIS SCI, V41, P619
   Truscott RJW, 2005, EXP EYE RES, V80, P709, DOI 10.1016/j.exer.2004.12.007
   Underwood JL, 1999, AM J PHYSIOL-CELL PH, V277, pC330, DOI 10.1152/ajpcell.1999.277.2.C330
   VARMA SD, 1979, P NATL ACAD SCI USA, V76, P3504, DOI 10.1073/pnas.76.7.3504
   Virno M, 1967, Boll Ocul, V46, P259
   WANNEMACHER CF, 1968, EXP EYE RES, V7, P623, DOI 10.1016/S0014-4835(68)80018-1
   Watkins Rodney, 2002, Clin Exp Optom, V85, P59
   Welge-Lussen U, 2010, KLIN MONATSBL AUGENH, V227, P99, DOI 10.1055/s-0029-1245171
   Welge-Lussen U, 1999, INVEST OPHTH VIS SCI, V40, P2235
   Wiederholt M., 1998, NITRIC OXIDE ENDOTHE, P168
   Williams DL, 2008, VET CLIN N AM-SMALL, V38, P179, DOI 10.1016/j.cvsm.2007.10.006
   Williams DL, 2008, VET CLIN N AM-SMALL, V38, pvii
   WOLFF SP, 1987, EXP EYE RES, V45, P777, DOI 10.1016/S0014-4835(87)80095-7
   WuDunn D, 2009, EXP EYE RES, V88, P718, DOI 10.1016/j.exer.2008.11.008
   YAGI K, 1985, Journal of Applied Biochemistry, V7, P202
   YAN DB, 1991, INVEST OPHTH VIS SCI, V32, P2515
   Yorio T, 2002, J GLAUCOMA, V11, P259, DOI 10.1097/00061198-200206000-00016
   Yue BYJT, 1996, SURV OPHTHALMOL, V40, P379
   Zhou LL, 1999, J CELL PHYSIOL, V180, P182, DOI 10.1002/(SICI)1097-4652(199908)180:2<182::AID-JCP6>3.0.CO;2-X
   Zigler Jr J.S., 1985, ARCH BIOCH BIOPHYS I, V241, P163
   ZIGLER JS, 1985, EXP EYE RES, V41, P67, DOI 10.1016/0014-4835(85)90095-8
   ZIGLER JS, 1983, INVEST OPHTH VIS SCI, V24, P651
   ZIGLER JS, 1989, FREE RADICAL BIO MED, V7, P499
   ZIGLER JS, 1983, ARCH BIOCHEM BIOPHYS, V225, P149, DOI 10.1016/0003-9861(83)90018-8
   ZIGMAN S, 1973, EXP EYE RES, V15, P255, DOI 10.1016/0014-4835(73)90145-0
   Zoric Lepsa, 2003, Srp Arh Celok Lek, V131, P137
NR 209
TC 41
Z9 43
U1 0
U2 27
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0767-3981
EI 1472-8206
J9 FUND CLIN PHARMACOL
JI Fundam. Clin. Pharmacol.
PD FEB
PY 2012
VL 26
IS 1
BP 86
EP 117
DI 10.1111/j.1472-8206.2011.00969.x
PG 32
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA 873JF
UT WOS:000298878000012
PM 21883446
DA 2022-11-30
ER

PT J
AU Chang, HM
   Hung, KH
   Hsu, CC
   Lin, TC
   Chen, SY
AF Chang, Hua-Ming
   Hung, Kuo-Hsuan
   Hsu, Chih-Chien
   Lin, Tai-Chi
   Chen, Szu-Yu
TI Using induced pluripotent stem cell-derived conditional medium to
   attenuate the light-induced photodamaged retina of rats
SO JOURNAL OF THE CHINESE MEDICAL ASSOCIATION
LA English
DT Article
DE conditional medium; induced pluripotent stem cell; light damage of
   retina
ID NEUROTROPHIC FACTOR; UP-REGULATION; PROTECTION; INJURY; DAMAGE; MODEL;
   DIFFERENTIATION; TRANSPLANTATION; DEGENERATION; SECRETION
AB Background: Light injury to photoreceptor cells and retinal pigment epithelium may lead to oxidative stress and irreversible degeneration of retina, especially degeneration of the high energy-demanded macula. The model of retinal photodamage could be applied to age-related macular degeneration and other degenerative retinal diseases for exploring new treatments. Based on broadly investigated induced pluripotent stem cells (iPSC) in the field of retinal degeneration, we aimed to clarify further how the interaction progresses between iPSC-conditional medium (CM) and light-damaged retina.
   Methods: iPSCs were generated from murine embryonic fibroblasts of C57/B6 mice by retroviral transfection of three factors: Oct4, Sox2, and KIf4. Cytokine array was performed to analyze the components of CM. Sprague-Dawley rats receiving white light exposure to retina were viewed as an animal model of light injury. The rats were divided into four subgroups: light-injured rats receiving intravitreal injection of iPSC-CM, apoptotic iPSC-CM, or sodium phosphate buffer (PBS); and a control group without light damage. The electroretinography and thickness of outer nuclear layer were measured to document the therapeutic effects in each condition. Apoptosis arrays for detecting annexin V and caspase 3 were performed in the retinal tissues from each group.
   Results: Murine embryonic fibroblasts were induced into iPSCs and expressed the marker genes similar to embryonic stem cells. These iPSCs can differentiate into Embryoid bodies (EBs), three germ layers in vitro and develop teratoma in severe combined immunodeficiency mice. The quantitative polymerase chain reaction of our iPSC-CM showed significantly elevated fibroblast growth factor-2, glial cell-derived neurotrophic factor, and insulin-like growth factor-binding proteins-1, -2, and -3. Compared to rats without photodamage, the light-injured rats receiving iPSC-CM had less reduction of outer nuclear layer thickness on Day 21 than other groups treated with either PBS or apoptotic iPSC-CM. In the same animal model, both a- and b-waves of electroretinography measurement in the group treated with iPSC-CM were significantly maintained compared to the control group and others with apoptotic iPSC-CM or PBS treatment. The apoptosis assay also demonstrated lower levels of annexin V and caspase 3 in the group with iPSC-CM treatment than in other groups presenting increasing apoptotic markers.
   Conclusion: The conditional medium of iPSCs contains plenty of cytoprotective, immune-modulative and rescue chemicals, contributing to the maintenance of neuronal function and retinal layers in light-damaged retina compared with apoptotic iPSC-CM and PBS. The antiapoptotic effect of iPSC-CM also shows promise in restoring damaged neurons. This result demonstrates that iPSC-CM may serve as an alternative to cell therapy alone to treat retinal light damage and maintain functional and structural integrity of the retina. Copyright (C) 2014 Elsevier Taiwan LLC and the Chinese Medical Association. All rights reserved.
C1 [Chang, Hua-Ming; Chen, Szu-Yu] Natl Cent Univ, Dept Opt & Photon, Chungli 32054, Taiwan.
   [Chang, Hua-Ming] Bade Vet Home, Taoyuan 334, Taiwan.
   [Hung, Kuo-Hsuan; Hsu, Chih-Chien; Lin, Tai-Chi] Natl Yang Ming Univ, Inst Clin Med, Taipei 112, Taiwan.
   [Hung, Kuo-Hsuan] Natl Yang Ming Univ Hosp, Div Ophthalmol, Ilan, Taiwan.
   [Hsu, Chih-Chien; Lin, Tai-Chi] Taipei Vet Gen Hosp, Dept Ophthalmol, Taipei, Taiwan.
C3 National Central University; National Yang Ming Chiao Tung University;
   Taipei Veterans General Hospital
RP Chang, HM (通讯作者)，Bade Vet Home, 1100 Rongxing Rd, Taoyuan 334, Taiwan.
EM huamingchang@gmail.com
CR Abe T, 2005, CELL TRANSPLANT, V14, P799, DOI 10.3727/000000005783982549
   Chen SJ, 2010, STEM CELLS DEV, V19, P1757, DOI 10.1089/scd.2009.0452
   Dalkara D, 2011, MOL THER, V19, P1602, DOI 10.1038/mt.2011.62
   Grote K, 2013, EUR CELLS MATER, V26, P66, DOI 10.22203/eCM.v026a05
   How CK, 2013, SHOCK, V39, P261, DOI 10.1097/SHK.0b013e318285f2e2
   Hwang JC, 2011, OPHTHAL SURG LAS IM, V42, DOI 10.3928/15428877-20100924-01
   Inoue Y, 2007, EXP EYE RES, V85, P234, DOI 10.1016/j.exer.2007.04.007
   John S, 2013, J OPHTHALMOL, V2013, DOI 10.1155/2013/465169
   Kao CL, 2010, STEM CELLS DEV, V19, P247, DOI 10.1089/scd.2009.0186
   Kvanta A, 2014, ACTA OPHTHALMOL, V92, P21, DOI 10.1111/aos.12185
   Lewallen Michelle, 2013, J Glaucoma, V22 Suppl 5, pS42, DOI 10.1097/IJG.0b013e3182934b45
   Li HY, 2011, BIOMATERIALS, V32, P5994, DOI 10.1016/j.biomaterials.2011.05.009
   Li Y, 2012, MOL MED, V18, P1312, DOI 10.2119/molmed.2012.00242
   Liang XT, 2014, CELL TRANSPLANT, V23, P1045, DOI 10.3727/096368913X667709
   O'Driscoll C, 2008, J NEUROCHEM, V105, P524, DOI 10.1111/j.1471-4159.2007.05189.x
   Okita K, 2007, NATURE, V448, P313, DOI 10.1038/nature05934
   Peng CH, 2011, BIOMATERIALS, V32, P9077, DOI 10.1016/j.biomaterials.2011.08.008
   Peng YJ, 2010, BIOMATERIALS, V31, P1773, DOI 10.1016/j.biomaterials.2009.11.039
   Satarian L, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0071855
   Sugitani S, 2013, EXP EYE RES, V116, P254, DOI 10.1016/j.exer.2013.09.013
   Takahashi K, 2007, CELL, V131, P861, DOI 10.1016/j.cell.2007.11.019
   Takahashi K, 2006, CELL, V126, P663, DOI 10.1016/j.cell.2006.07.024
   UNOKI K, 1994, INVEST OPHTH VIS SCI, V35, P907
   Valter K, 2005, INVEST OPHTH VIS SCI, V46, P1748, DOI 10.1167/iovs.04-0657
   Wang L, 2013, CNS NEUROSCI THER, V19, P945, DOI 10.1111/cns.12150
   Wenzel A, 2005, PROG RETIN EYE RES, V24, P275, DOI 10.1016/j.preteyeres.2004.08.002
   Wu WC, 2004, MOL VIS, V10, P93
   Xu W, 2013, ARQ BRAS OFTALMOL, V76, P105, DOI 10.1590/S0004-27492013000200010
   Yang KY, 2011, CHEST, V140, P1243, DOI 10.1378/chest.11-0539
   Yu JY, 2007, SCIENCE, V318, P1917, DOI 10.1126/science.1151526
   Zhang Y, 2010, INVEST OPHTH VIS SCI, V51, P3742, DOI 10.1167/iovs.08-3314
NR 31
TC 10
Z9 10
U1 1
U2 14
PU ELSEVIER TAIWAN
PI TAIPEI
PA RM N-412, 4F, CHIA HSIN BUILDING 11, NO 96, ZHONG SHAN N ROAD SEC 2,
   TAIPEI, 10449, TAIWAN
SN 1726-4901
EI 1728-7731
J9 J CHIN MED ASSOC
JI J. Chin. Med. Assoc.
PD MAR
PY 2015
VL 78
IS 3
BP 169
EP 176
DI 10.1016/j.jcma.2014.08.017
PG 8
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA CD7BX
UT WOS:000351246300007
PM 25557467
OA hybrid
DA 2022-11-30
ER

PT J
AU Chung, CY
   Li, SH
   Li, KKW
AF Chung, C. Y.
   Li, S. H.
   Li, K. K. W.
TI Focal choroidal excavation-morphological features and clinical
   correlation
SO EYE
LA English
DT Article
ID OPTICAL COHERENCE TOMOGRAPHY; CENTRAL SEROUS CHORIORETINOPATHY; MACULAR
   DEGENERATION; NEOVASCULARIZATION; EYES
AB Purpose To describe and correlate the morphological and clinical features of focal choroidal excavation (FCE).
   Methods This is a consecutive case series from the review of the 4436 optical coherence tomography scans performed by Kowloon East Cluster Ophthalmic Service from 1 August 2014-31 January 2016. Statistical analysis was performed on SPSS 18.0 (SPSS, Chicago, IL, USA). A significance level of P < 0.05 was taken.
   Results All 16 patients with FCE had unilateral involvement. The mean age of diagnosis was 52.56 +/- 14.00. The mean greatest linear dimension (GLD) of FCE was 636.25 +/- 265.11 mu m. The mean choroidal thickness was 183.63 +/- 52.39 mu m. Fourteen FCEs (87.5%) were conforming and two were non-conforming (12.5%). In the eyes with FCE, concurrent macular pathology was present in four cases (25.0%). Tractional pathologies of macular pucker and macular scar corresponded to the two non-conforming FCEs in the series. Polypoidal choroidal vasculopathy (PCV) and lacquer crack had a close topographic relationship with the FCE. The mean GLD was significantly larger in eyes with concurrent macular pathology than those without (878.00 vs 555.67 mu m, P = 0.029). In the fellow eyes, concurrent macular pathology was present in 5 cases (31.3%): PCV in 3 cases and chronic central serous chorioretinopathy in 2 cases.
   Conclusion As a significant proportion of FCE is associated with concurrent macular pathology in the involved or fellow eye, angiography for both eyes is recommended even for asymptomatic cases. The GLD of FCE may have clinical value in risk stratification.
C1 [Chung, C. Y.; Li, S. H.; Li, K. K. W.] United Christian Hosp, Dept Ophthalmol, 130 Hip Wo St, Kowloon, Hong Kong, Peoples R China.
   [Chung, C. Y.; Li, S. H.; Li, K. K. W.] Tseung Kwan O Hosp, Dept Ophthalmol, Kowloon, Hong Kong, Peoples R China.
   [Chung, C. Y.; Li, S. H.; Li, K. K. W.] Univ Hong Kong, LKS Fac Med, Dept Ophthalmol, Hong Kong, Hong Kong, Peoples R China.
C3 United Christian Hospital; University of Hong Kong
RP Chung, CY (通讯作者)，United Christian Hosp, Dept Ophthalmol, 130 Hip Wo St, Kowloon, Hong Kong, Peoples R China.
EM chungchungyee@gmail.com
OI Chung, Chung Yee/0000-0002-4927-0410
CR Cheung CMG, 2012, CLIN EXP OPHTHALMOL, V40, P727, DOI 10.1111/j.1442-9071.2012.02765.x
   Ellabban AA, 2013, AM J OPHTHALMOL, V156, P673, DOI 10.1016/j.ajo.2013.05.010
   Guo J, 2014, BMC OPHTHALMOL, V14, DOI 10.1186/1471-2415-14-63
   Hashimoto Y, 2014, BMC OPHTHALMOL, V14, DOI 10.1186/1471-2415-14-135
   Jampol LM, 2006, RETINA-J RET VIT DIS, V26, P1072, DOI 10.1097/01.iae.0000248819.86737.a5
   Kobayashi W, 2012, CLIN OPHTHALMOL, V6, P1373, DOI 10.2147/OPTH.S33879
   Kuroda Y, 2014, INVEST OPHTH VIS SCI, V55, P6046, DOI 10.1167/iovs.14-14723
   Lee CS, 2014, OPHTHALMOLOGY, V121, P1029, DOI 10.1016/j.ophtha.2013.11.043
   Lee JH, 2014, AM J OPHTHALMOL, V157, P710, DOI 10.1016/j.ajo.2013.12.011
   Lim FPM, 2014, EYE, V28, P1088, DOI 10.1038/eye.2014.78
   Luk FOJ, 2015, EYE, V29, P454, DOI 10.1038/eye.2015.31
   Margolis R, 2011, ARCH OPHTHALMOL-CHIC, V129, P1320, DOI 10.1001/archophthalmol.2011.148
   Obata R, 2013, RETINA-J RET VIT DIS, V33, P1201, DOI 10.1097/IAE.0b013e31827b6452
   Shinojima A, 2014, RETINA-J RET VIT DIS, V34, P1407, DOI 10.1097/IAE.0000000000000108
   Suzuki M, 2014, RETINA-J RET VIT DIS, V34, P1216, DOI 10.1097/IAE.0000000000000045
   Wakabayashi Y, 2010, ACTA OPHTHALMOL, V88, pe87, DOI 10.1111/j.1755-3768.2010.01895.x
   Xu HF, 2014, OPHTHALMOLOGY, V121, P246, DOI 10.1016/j.ophtha.2013.08.014
NR 17
TC 13
Z9 14
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950-222X
EI 1476-5454
J9 EYE
JI Eye
PD SEP
PY 2017
VL 31
IS 9
SI SI
BP 1373
EP 1379
DI 10.1038/eye.2017.71
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA FG7JZ
UT WOS:000410594600019
PM 28452991
OA Green Published, Bronze
DA 2022-11-30
ER

PT J
AU Eymard, P
   Gerardy, M
   Bouys, L
   Mehanna, C
   Bertherat, JM
   Behar-Cohen, F
   Bousquet, E
AF Eymard, Pauline
   Gerardy, Melvin
   Bouys, Lucas
   Mehanna, Chadi
   Bertherat, Jerome
   Behar-Cohen, Francine
   Bousquet, Elodie
TI Choroidal imaging in patients with Cushing syndrome
SO ACTA OPHTHALMOLOGICA
LA English
DT Article
DE choroid; Cushing syndrome; pachychoroid; pachychoroid pigment
   epitheliopathy; optical coherence tomography
ID CENTRAL SEROUS CHORIORETINOPATHY; SERUM CORTISOL
AB Aims Glucocorticoid intake is a well-established risk factor for central serous chorioretinopathy that belongs to the pachychoroid spectrum disease (PSD). The study aimed to assess the prevalence of PSD and analyse the choroidal phenotype in patients with Cushing syndrome.
   Methods A cross-sectional study was performed in Ophtalmopole hopital Cochin, Paris, France, with a systematic evaluation of hospitalized patients with Cushing syndrome, between November 2017 and July 2018. 56 eyes from 28 Cushing syndrome patients and 56 eyes of 28 age and gender-matched, and close spherical equivalent healthy participants were included. All patients underwent a complete ophthalmic examination including Enhanced-Depth Imaging (EDI)-Optical Coherence Tomography (OCT). Measures of subfoveal, 1000 mu m nasal and 1000 mu m temporal choroidal thicknesses were realized, and the presence of choroidal pachyvessels was evaluated. Hormonal tests evaluated the corticotropic axis.
   Results The number of eyes with PSD was significantly higher in Cushing syndrome patients as compared to controls (21.4% versus 3.6%, p = 0.004). In Cushing patients' eyes, 17.9% had a pachychoroid pigment epitheliopathy (PPE) and 3.6% had a polypoidal choroidal vasculopathy. Pachyvessels were more common in Cushing syndrome patients than in healthy subjects (71.4% versus 42.9%, p = 0.002). Mean subfoveal choroidal thickness was 331 +/- 110 mu m in Cushing patients, with no statistical difference between the two groups. There was no correlation between choroidal thickness and urinary and salivary cortisol levels.
   Conclusion Patients with Cushing syndrome have a higher prevalence of PDS. An ophthalmologic specialized follow-up of these patients with EDI-OCT could detect chorioretinal abnormalities and adapt the surveillance of these patients.
C1 [Eymard, Pauline; Gerardy, Melvin; Mehanna, Chadi; Behar-Cohen, Francine; Bousquet, Elodie] Univ Paris 05, Dept Ophthalmol, OphtalmoPole, Hop Cochin,AP HP,Sorbonne Paris Cite, Paris, France.
   [Bouys, Lucas; Bertherat, Jerome] Univ Paris 05, Dept Endocrinol, Hop Cochin, AP HP,Sorbonne Paris Cite, Paris, France.
   [Mehanna, Chadi] Hop Necker Enfants Malad, AP HP, Dept Biostat, Paris, France.
   [Behar-Cohen, Francine; Bousquet, Elodie] Univ Paris, INSERM, U1138, Team 17,Ctr Rech Cordeliers,Sorbonne Paris Cite, Paris, France.
C3 Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin
   - APHP; UDICE-French Research Universities; Universite Paris Cite;
   Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin
   - APHP; UDICE-French Research Universities; Universite Paris Cite;
   Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire
   Necker-Enfants Malades - APHP; UDICE-French Research Universities;
   Universite Paris Cite; Institut National de la Sante et de la Recherche
   Medicale (Inserm); UDICE-French Research Universities; Sorbonne
   Universite; Universite Paris Cite
RP Behar-Cohen, F (通讯作者)，Hop Cochin, OphtalmoPole, 8 Rue Mechain, F-75014 Paris, France.
EM francine.behar@gmail.com
OI Bouys, Lucas/0000-0003-1743-1598; behar cohen,
   francine/0000-0001-8571-9513
CR Abalem MF, 2016, FRONT ENDOCRINOL, V7, DOI 10.3389/fendo.2016.00154
   Akkaya S, 2018, INT OPHTHALMOL, V38, P2239, DOI 10.1007/s10792-017-0666-4
   Bousquet E, 2015, RETINA-J RET VIT DIS, V35, P2505, DOI 10.1097/IAE.0000000000000614
   BOUZAS EA, 1993, ARCH OPHTHALMOL-CHIC, V111, P1229, DOI 10.1001/archopht.1993.01090090081024
   Canonica J, 2019, EXP EYE RES, V187, DOI 10.1016/j.exer.2019.107747
   Carvalho-Recchia CA, 2002, OPHTHALMOLOGY, V109, P1834, DOI 10.1016/S0161-6420(02)01117-X
   Cheung CMG, 2019, EYE, V33, P14, DOI 10.1038/s41433-018-0158-4
   Clarke C, 2017, CAN J OPHTHALMOL, V52, pE77, DOI 10.1016/j.jcjo.2016.09.002
   Fujiwara T, 2009, AM J OPHTHALMOL, V148, P445, DOI 10.1016/j.ajo.2009.04.029
   Garg SP, 1997, BRIT J OPHTHALMOL, V81, P962, DOI 10.1136/bjo.81.11.962
   Karaca C, 2017, RETINA-J RET VIT DIS, V37, P536, DOI 10.1097/IAE.0000000000001198
   Karahan E, 2015, CLIN EXP OPTOM, V98, P362, DOI 10.1111/cxo.12254
   Liu B, 2016, RETINA-J RET VIT DIS, V36, P9, DOI 10.1097/IAE.0000000000000837
   Margolis R, 2009, AM J OPHTHALMOL, V147, P811, DOI 10.1016/j.ajo.2008.12.008
   Nickla DL, 2010, PROG RETIN EYE RES, V29, P144, DOI 10.1016/j.preteyeres.2009.12.002
   Nieman LK, 2019, ENDOCRIN METAB CLIN, V48, P717, DOI 10.1016/j.ecl.2019.08.005
   Pivonello R, 2016, LANCET DIABETES ENDO, V4, P611, DOI 10.1016/S2213-8587(16)00086-3
   Thoelen AM, 2000, RETINA-J RET VIT DIS, V20, P98, DOI 10.1097/00006982-200001000-00020
   van Haalen FM, 2018, FRONT ENDOCRINOL, V9, DOI 10.3389/fendo.2018.00039
   Wang EQ, 2019, RETINA-J RET VIT DIS, V39, P408, DOI 10.1097/IAE.0000000000001956
   Zakir SM, 2009, INDIAN J OPHTHALMOL, V57, P419, DOI 10.4103/0301-4738.57143
NR 21
TC 6
Z9 6
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1755-375X
EI 1755-3768
J9 ACTA OPHTHALMOL
JI Acta Ophthalmol.
PD AUG
PY 2021
VL 99
IS 5
BP 533
EP 537
DI 10.1111/aos.14664
EA NOV 2020
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA UD5RN
UT WOS:000589513500001
PM 33196148
DA 2022-11-30
ER

PT J
AU Kishi, S
   Matsumoto, H
AF Kishi, Shoji
   Matsumoto, Hidetaka
TI A new insight into pachychoroid diseases: Remodeling of choroidal
   vasculature
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Review
DE Central serous chorioretinopathy; Pachychoroid disease; Pachyvessel;
   Venous anastomosis; Vortex vein; Watershed zone
ID VORTEX VEIN; VASCULOPATHY
AB Purpose Pachychoroid spectrum diseases are regarded as being different manifestations of a common pathogenic process. We suggest that pachychoroid diseases are consequences of chronic vortex vein stasis.
   Methods We describe how we came to this conclusion based on our own recent reports as well as a search of the related literature.
   Results Central serous chorioretinopathy (CSC) is the first stage of pachychoroid spectrum diseases. CSC is caused by congestion of choroidal veins, which are branches of the vortex veins. The venous outflow tract of the choroid is divided into four quadrants, based on horizontal and vertical watershed zones, with one or two vortex veins in each quadrant being independently responsible for venous outflow. In acute CSC, vortex vein stasis frequently causes asymmetric dilatation of the vortex veins in the horizontal watershed. The area of geographic filling delay in the choriocapillaris coincides with the area of this asymmetrically dilated vortex veins. With chronic stasis of the vortex veins, venous anastomosis occurs in the watershed zone as a means of compensating for the stasis, and the choriocapillaris becomes occluded in the area of filling delay. The anastomotic vessels dilate, becoming often hyperpermeable, and are then recognizable as pachyvessels. With the development of choriocapillaris ischemia, choroidal neovascularization (CNV) occurs at the site of pachyvessels. This is termed pachychoroid neovasculopathy (PNV). Polypoidal choroidal vasculopathy is regarded as a variant of PNV.
   Conclusions Intervortex venous anastomosis is among the key factors underlying the development of pachychoroid diseases. Remodeling of the venous drainage route though the anastomosis across the watershed zones is apparently a common response to chronic vortex vein stasis.
C1 [Kishi, Shoji] Maebashi Cent Eye Clin, 2-54-5 Shimokoide, Maebashi, Gunma 3710031, Japan.
   [Kishi, Shoji; Matsumoto, Hidetaka] Gunma Univ, Dept Ophthalmol, Grad Sch Med, 3-39-15 Showa, Maebashi, Gunma 3718511, Japan.
C3 Gunma University
RP Kishi, S (通讯作者)，Maebashi Cent Eye Clin, 2-54-5 Shimokoide, Maebashi, Gunma 3710031, Japan.; Kishi, S (通讯作者)，Gunma Univ, Dept Ophthalmol, Grad Sch Med, 3-39-15 Showa, Maebashi, Gunma 3718511, Japan.
EM shojikishi@gunma-u.ac.jp
CR Cheung CMG, 2021, RETINA-J RET VIT DIS, V41, P2370, DOI 10.1097/IAE.0000000000003195
   Cheung CMG, 2019, EYE, V33, P14, DOI 10.1038/s41433-018-0158-4
   Fung AT, 2012, RETINA-J RET VIT DIS, V32, P1829, DOI 10.1097/IAE.0b013e3182680a66
   Gal-Or O, 2018, RETINA-J RET VIT DIS, V38, P1984, DOI 10.1097/IAE.0000000000002051
   GUYER DR, 1994, ARCH OPHTHALMOL-CHIC, V112, P1057, DOI 10.1001/archopht.1994.01090200063023
   HAYREH SS, 1975, BRIT J OPHTHALMOL, V59, P631, DOI 10.1136/bjo.59.11.631
   Hiroe T, 2018, OPHTHALMOL RETINA, V2, P152, DOI 10.1016/j.oret.2017.05.013
   Hogan MJ., 1971, HISTOLOGY HUMAN EYE
   Hoshino J, 2021, GRAEF ARCH CLIN EXP, V259, P2175, DOI 10.1007/s00417-021-05130-2
   Iida T, 1999, RETINA-J RET VIT DIS, V19, P508, DOI 10.1097/00006982-199911000-00005
   Imanaga N, 2021, OPHTHALMOL RETINA, V5, P285, DOI 10.1016/j.oret.2020.07.011
   Kishi S, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0206646
   Lee WK, 2016, RETINA-J RET VIT DIS, V36, pS73, DOI 10.1097/IAE.0000000000001346
   Matsumoto H, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-95904-9
   Matsumoto H, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-94412-0
   Matsumoto H, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-75789-w
   Matsumoto H, 2020, OPHTHALMOL RETINA, V4, P938, DOI 10.1016/j.oret.2020.03.024
   Matsumoto H, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-51268-9
   Pang CE, 2015, RETINA-J RET VIT DIS, V35, P1, DOI 10.1097/IAE.0000000000000331
   Pang CE, 2014, AM J OPHTHALMOL, V158, P362, DOI 10.1016/j.ajo.2014.04.021
   Phasukkijwatana N, 2018, RETINA-J RET VIT DIS, V38, P1652, DOI 10.1097/IAE.0000000000001907
   Quaranta-El Maftouhi M, 2015, AM J OPHTHALMOL, V160, P581, DOI 10.1016/j.ajo.2015.06.016
   Sasahara M, 2006, AM J OPHTHALMOL, V142, P601, DOI 10.1016/j.ajo.2006.05.051
   Shiihara H, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-66858-1
   Spaide RF, 2022, PROG RETIN EYE RES, V86, DOI 10.1016/j.preteyeres.2021.100973
   Spaide RF, 2021, RETINA-J RET VIT DIS, V41, P997, DOI 10.1097/IAE.0000000000003004
   Sutoh N, 1996, RETINA-J RET VIT DIS, V16, P497, DOI 10.1097/00006982-199616060-00005
   Takahashi K, 1998, AM J OPHTHALMOL, V125, P367, DOI 10.1016/S0002-9394(99)80148-2
   Takahashi K, 2000, AM J OPHTHALMOL, V129, P191, DOI 10.1016/S0002-9394(99)00425-0
   Takahashi K., 2019, NIPPON GANKA GAKKAI, V123, P284
   Terao Nobuhiro, 2021, Ophthalmol Sci, V1, P100071, DOI 10.1016/j.xops.2021.100071
   Toyama T, 2014, EYE, V28, P992, DOI 10.1038/eye.2014.132
   Ueta T, 2009, OPHTHALMOLOGY, V116, P2400, DOI 10.1016/j.ophtha.2009.06.013
   Verma A, 2021, CLIN OPHTHALMOL, V15, P3321, DOI 10.2147/OPTH.S324245
   Warrow DJ, 2013, RETINA-J RET VIT DIS, V33, P1659, DOI 10.1097/IAE.0b013e3182953df4
   YANNUZZI LA, 1987, RETINA-J RET VIT DIS, V7, P111, DOI 10.1097/00006982-198700720-00009
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
NR 37
TC 2
Z9 2
U1 3
U2 3
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0721-832X
EI 1435-702X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD NOV
PY 2022
VL 260
IS 11
BP 3405
EP 3417
DI 10.1007/s00417-022-05687-6
EA MAY 2022
PG 13
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 5L3BJ
UT WOS:000796329200002
PM 35575932
OA Green Published, hybrid
DA 2022-11-30
ER

PT J
AU Li, FJ
   Ma, AH
   Zhao, BJ
AF Li, Fengjiao
   Ma, Aihua
   Zhao, Bojun
TI Comparison of the Efficacy of Three Loading Doses of Intravitreal
   Injection of Conbercept with Injection Combined with PDT for the
   Treatment of PCV
SO BIOMED RESEARCH INTERNATIONAL
LA English
DT Article
ID POLYPOIDAL CHOROIDAL VASCULOPATHY; PHOTODYNAMIC THERAPY; RANIBIZUMAB;
   VERTEPORFIN; MONOTHERAPY; DIAGNOSIS; OUTCOMES
AB Purpose. To compare the efficacy between initial 3-monthly intravitreal conbercept monotherapy and combination intravitreal conbercept with photodynamic therapy (PDT) for polypoidal choroidal vasculopathy (PCV). Methods. This is a retrospective, comparative study which involved 65 PCV eyes of 65 patients. According to the therapeutic regimen, the PCV patients were divided into two groups: 32 eyes with naive PCV received a PDT after the first intravitreal injection of conbercept (IVC) followed by pro re nata (prn) retreatment (combination group), and 33 eyes with naive PCV received 3-monthly IVC monotherapy followed by prn regimen (IVC monotherapy group). All patients completed at least 6 months of monthly follow-up. Results. At month 6, best-corrected visual acuity (BCVA) improved significantly (P<0.05) in both groups compared with that at baseline; the mean changes of BCVA between the IVC monotherapy group and combination group have no significant difference (-0.22 +/- 0.22 vs. -0.17 +/- 0.22 LogMAR, P=0.38). The central retinal thickness (CRT) decreased significantly in the two groups (P<0.05), with no difference between the two groups (P=0.24). The complete regression rate of polyps was 58.6% (17 out of 29 eyes) in the IVC monotherapy group and 80.65% (25 out of 31 eyes) in the combination group, respectively (P=0.09, chi-squared test). The combination group required significantly fewer injections than the IVC monotherapy group (3.09 +/- 0.89 vs. 3.67 +/- 0.74, P=0.006). Conclusion. Conbercept monotherapy significantly improved visual acuity and effectively regressed polyps during 6-month follow-up time in the treatment of PCV.
C1 [Li, Fengjiao; Zhao, Bojun] Shandong Univ, Dept Ophthalmol, Shandong Prov Hosp, Jinan, Peoples R China.
   [Ma, Aihua] Shandong First Med Univ, Shandong Prov Hosp, Dept Pediat, Jinan, Peoples R China.
C3 Shandong First Medical University & Shandong Academy of Medical
   Sciences; Shandong University; Shandong First Medical University &
   Shandong Academy of Medical Sciences
RP Zhao, BJ (通讯作者)，Shandong Univ, Dept Ophthalmol, Shandong Prov Hosp, Jinan, Peoples R China.; Ma, AH (通讯作者)，Shandong First Med Univ, Shandong Prov Hosp, Dept Pediat, Jinan, Peoples R China.
EM 153466243@qq.com; aihuama@hotmail.co.uk; zhaobojun0708@163.com
FU Shandong Natural Foundation, China [ZR2019MH111, ZR2017MH021]
FX This work was supported by Shandong Natural Foundation, China, to Prof.
   Bojun Zhao (ZR2019MH111) and Aihua Ma (ZR2017MH021).
CR Cheng Y, 2016, CHINESE MED J-PEKING, V129, P2610, DOI 10.4103/0366-6999.192779
   Cheung CMG, 2018, OPHTHALMOLOGY, V125, P708, DOI 10.1016/j.ophtha.2017.11.019
   Cheung CMG, 2015, GRAEF ARCH CLIN EXP, V253, P2075, DOI 10.1007/s00417-015-2933-2
   Cho HJ, 2016, AM J OPHTHALMOL, V165, P1, DOI 10.1016/j.ajo.2016.02.019
   Gomi F, 2015, RETINA-J RET VIT DIS, V35, P1569, DOI 10.1097/IAE.0000000000000526
   Hikichi T, 2018, BRIT J OPHTHALMOL, V102, P97, DOI 10.1136/bjophthalmol-2017-310448
   Huang Z, 2019, RETINA-J RET VIT DIS, V39, P889, DOI 10.1097/IAE.0000000000002035
   Kikushima W, 2017, GRAEF ARCH CLIN EXP, V255, P311, DOI 10.1007/s00417-016-3467-y
   Koh A, 2017, JAMA OPHTHALMOL, V135, P1206, DOI 10.1001/jamaophthalmol.2017.4030
   Koh AHC, 2013, RETINA-J RET VIT DIS, V33, P686, DOI 10.1097/IAE.0b013e3182852446
   Lee WK, 2018, JAMA OPHTHALMOL, V136, P786, DOI 10.1001/jamaophthalmol.2018.1804
   Lu XM, 2015, DRUG DES DEV THER, V9, DOI 10.2147/DDDT.S67536
   Marcus DM, 2013, RETINA-J RET VIT DIS, V33, P35, DOI 10.1097/IAE.0b013e3182618be0
   Oishi A, 2013, AM J OPHTHALMOL, V156, P644, DOI 10.1016/j.ajo.2013.05.024
   Peng YT, 2018, DRUG DES DEV THER, V12, P339, DOI 10.2147/DDDT.S158368
   Qi HJ, 2019, INT J OPHTHALMOL-CHI, V12, P51, DOI 10.18240/ijo.2019.01.08
   Qu JF, 2016, RETINA-J RET VIT DIS, V36, P926, DOI 10.1097/IAE.0000000000000875
   Takayama K, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0176100
   Uyama M, 2002, AM J OPHTHALMOL, V133, P639, DOI 10.1016/S0002-9394(02)01404-6
NR 19
TC 3
Z9 3
U1 1
U2 3
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 2314-6133
EI 2314-6141
J9 BIOMED RES INT
JI Biomed Res. Int.
PD APR 24
PY 2020
VL 2020
AR 2428348
DI 10.1155/2020/2428348
PG 5
WC Biotechnology & Applied Microbiology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biotechnology & Applied Microbiology; Research & Experimental Medicine
GA LM5LP
UT WOS:000532290300006
PM 32382537
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Hong, YJ
   Miura, M
   Makita, S
   Ju, MJ
   Lee, BH
   Iwasaki, T
   Yasuno, Y
AF Hong, Young-Joo
   Miura, Masahiro
   Makita, Shuichi
   Ju, Myeong Jin
   Lee, Byeong Ha
   Iwasaki, Takuya
   Yasuno, Yoshiaki
TI Noninvasive Investigation of Deep Vascular Pathologies of Exudative
   Macular Diseases by High-Penetration Optical Coherence Angiography
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
DE noninvasive angiography; choroid; vasculature; Doppler; optical
   coherence tomography
ID RETINAL-BLOOD-FLOW; POLYPOIDAL CHOROIDAL VASCULOPATHY; DOPPLER
   TOMOGRAPHY; RISK-FACTORS; HUMAN SKIN; DEGENERATION; VELOCITY; SPEED;
   EYE; NM
AB PURPOSE. A newly developed high-penetration Doppler optical coherence angiography (HP-OCA) with a 1-mu m probe beam for noninvasive investigation of vascular pathology of exudative macular diseases is introduced. A descriptive case series is presented to discuss the clinical utility of HP-OCA.
   METHODS. Eleven eyes of 10 subjects with exudative macular disease, including two eyes with myopic choroidal neovascularization (mCNV); four eyes with AMD; and five eyes with polypoidal choroidal vasculopathy (PCV) were investigated. Two Doppler scanning modes (bidirectional and high-sensitive) of HP-OCA were used for the investigation. HP-OCA provides depth-resolved and en face angiograms and a structural OCT noninvasively. The HP-OCA images were compared with fluorescein angiography (FA); indocyanine green angiography (ICGA); and color fundus images.
   RESULTS. The abnormal vasculature patterns observed with high-sensitive HP-OCA presented high similarity to the midphase of ICGA. Several abnormal Doppler signals were observed in the en face high-sensitive HP-OCA and were colocated with FA leakage. This colocation was found in one eye with mCNV, four eyes with AMD, and one eye with PCV. Doppler tomogram of the bidirectional mode showed abnormal Doppler signals in three of five PCV cases beneath the pigment epithelium detachment. With the high-sensitive mode, Doppler signals were found beneath the elevated retinal pigment epithelium in all untreated cases.
   CONCLUSIONS. HP-OCA revealed depth-resolved abnormal vasculatures in exudative macular diseases. The en face HP-OCA images showed high similarity with FA and ICGA images. These results suggest HP-OCA can be used for noninvasive and three-dimensional angiography in a clinical routine.
C1 [Hong, Young-Joo; Makita, Shuichi; Yasuno, Yoshiaki] Univ Tsukuba, Computat Opt Grp, Tsukuba, Ibaraki 3058571, Japan.
   [Hong, Young-Joo; Miura, Masahiro; Makita, Shuichi; Yasuno, Yoshiaki] Computat Opt & Ophthalmol Grp, Tsukuba, Ibaraki, Japan.
   [Miura, Masahiro; Iwasaki, Takuya] Tokyo Med Univ, Ibaraki Med Ctr, Dept Ophthalmol, Ami, Ibaraki, Japan.
   [Ju, Myeong Jin; Lee, Byeong Ha] Gwangju Inst Sci & Technol, Sch Informat & Commun, Kwangju, South Korea.
C3 University of Tsukuba; Tokyo Medical University; Gwangju Institute of
   Science & Technology (GIST)
RP Yasuno, Y (通讯作者)，Univ Tsukuba, Computat Opt Grp, 1-1-1 Tennoudai, Tsukuba, Ibaraki 3058571, Japan.
EM yasuno@optlab2.bk.tsukuba.ac.jp
RI Lee, Byeong Ha/T-3397-2019; Yasuno, Yoshiaki/F-2586-2011; Makita,
   Shuichi/G-3806-2011
OI Yasuno, Yoshiaki/0000-0003-1645-7948; Makita,
   Shuichi/0000-0002-6614-3640; JU, MYEONG JIN/0000-0002-4907-3732; Lee,
   Byeong Ha/0000-0003-4544-1232
FU Japan Science and Technology Agency through a contract from the
   Development of Systems and Technology for Advanced Measurement and
   Analysis; Japan Society for the Promotion of Science (JSPS) KAKENHI
   [11J01600, 24592682]; Research Fellowships of the JSPS for Young
   Scientists
FX Supported by the Japan Science and Technology Agency through a contract
   from the Development of Systems and Technology for Advanced Measurement
   and Analysis, and in part by the Japan Society for the Promotion of
   Science (JSPS) KAKENHI Grants 11J01600 and 24592682. Supported by the
   Research Fellowships of the JSPS for Young Scientists (Y-JH).
CR An L, 2008, OPT EXPRESS, V16, P11438, DOI 10.1364/OE.16.011438
   Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   Baumann B, 2011, BIOMED OPT EXPRESS, V2, P1539, DOI 10.1364/BOE.2.001539
   Braaf B, 2011, OPT EXPRESS, V19, P20886, DOI 10.1364/OE.19.020886
   BRESSLER NM, 1988, SURV OPHTHALMOL, V32, P375, DOI 10.1016/0039-6257(88)90052-5
   Chen ZP, 1997, OPT LETT, V22, P1119, DOI 10.1364/OL.22.001119
   de Bruin DM, 2008, INVEST OPHTH VIS SCI, V49, P4545, DOI 10.1167/iovs.07-1553
   Hong YJ, 2012, OPT EXPRESS, V20, P2740, DOI 10.1364/OE.20.002740
   HOPEROSS M, 1994, OPHTHALMOLOGY, V101, P529
   HUANG D, 1991, SCIENCE, V254, P1178, DOI 10.1126/science.1957169
   Ikuno Y, 2010, INVEST OPHTH VIS SCI, V51, P3721, DOI 10.1167/iovs.09-3493
   Ikuno Y, 2009, INVEST OPHTH VIS SCI, V50, P3876, DOI 10.1167/iovs.08-3325
   Kim DY, 2011, BIOMED OPT EXPRESS, V2, P1504, DOI 10.1364/BOE.2.001504
   Leitgeb RA, 2004, OPT LETT, V29, P171, DOI 10.1364/OL.29.000171
   Leitgeb RA, 2003, OPT EXPRESS, V11, P3116, DOI 10.1364/OE.11.003116
   Makita S, 2008, OPT LETT, V33, P836, DOI 10.1364/OL.33.000836
   Makita S, 2006, OPT EXPRESS, V14, P7821, DOI 10.1364/OE.14.007821
   Makita S, 2011, OPT EXPRESS, V19, P1271, DOI 10.1364/OE.19.001271
   Miura M, 2011, INVEST OPHTH VIS SCI, V52, P2689, DOI 10.1167/iovs.10-6282
   Szkulmowska A, 2009, OPT EXPRESS, V17, P10584, DOI 10.1364/OE.17.010584
   Tsujikawa A, 2007, AM J OPHTHALMOL, V143, P102, DOI 10.1016/j.ajo.2006.08.025
   Unterhuber A, 2005, OPT EXPRESS, V13, P3252, DOI 10.1364/OPEX.13.003252
   WANG XJ, 1995, OPT LETT, V20, P1337, DOI 10.1364/OL.20.001337
   Wang YM, 2008, J BIOMED OPT, V13, DOI 10.1117/1.2998480
   Wehbe H, 2007, OPT EXPRESS, V15, P15193, DOI 10.1364/OE.15.015193
   White BR, 2003, OPT EXPRESS, V11, P3490, DOI 10.1364/OE.11.003490
   YANNUZZI LA, 1986, OPHTHALMOLOGY, V93, P611
   Yannuzzi LA, 1999, ARCH OPHTHALMOL-CHIC, V117, P1503
   Yannuzzi LA, 2010, RETINAL ATLAS
   Yasuno Y, 2009, INVEST OPHTH VIS SCI, V50, P405, DOI 10.1167/iovs.08-2272
   Zhao YH, 2000, OPT LETT, V25, P1358, DOI 10.1364/OL.25.001358
   Zhao YH, 2000, OPT LETT, V25, P114, DOI 10.1364/OL.25.000114
NR 32
TC 31
Z9 34
U1 0
U2 5
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD MAY
PY 2013
VL 54
IS 5
BP 3621
EP 3631
DI 10.1167/iovs.12-11184
PG 11
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 173YC
UT WOS:000321118300063
PM 23633664
OA Green Submitted
DA 2022-11-30
ER

PT J
AU Lee, JH
   Park, HYL
   Baek, J
   Lee, WK
AF Lee, Jae Hyung
   Park, Hae-Young Lopilly
   Baek, Jiwon
   Lee, Won Ki
TI Alterations of the Lamina Cribrosa Are Associated with Peripapillary
   Retinoschisis in Glaucoma and Pachychoroid Spectrum Disease
SO OPHTHALMOLOGY
LA English
DT Article
ID OPEN-ANGLE GLAUCOMA; OPTIC-NERVE HEAD; CENTRAL SEROUS CHORIORETINOPATHY;
   NORMAL-TENSION GLAUCOMA; BLOOD-BRAIN-BARRIER; INTRAOCULAR-PRESSURE;
   COHERENCE TOMOGRAPHY; THICKNESS; DEFECTS; PIT
AB Purpose: To describe the findings of enhanced depth imaging (EDI) optical coherence tomography (OCT) of the lamina cribrosa (LC) in glaucoma and pachychoroid spectrum diseases associated with peripapillary retinoschisis.
   Design: Retrospective, observational case series.
   Participants: A total of 16 patients from 1 institution.
   Methods: Detailed medical case histories, optic disc and retinal imaging with EDI using the Spectralis OCT (Heidelberg Engineering, Heidelberg, Germany), and clinical course were reviewed for patients with peripapillary retinoschisis without a known predisposing condition.
   Main Outcome Measures: Clinical features and findings of the EDI OCT.
   Results: Among the 16 eyes with peripapillary retinoschisis that had abnormal findings on EDI of the LC, 8 had glaucoma and 8 had pachychoroid spectrum diseases, including chronic central serous chorioretinopathy (CSC) (6 eyes), small pigment epithelium detachment (1 eye), and polypoidal choroidal vasculopathy (PCV) (1 eye). The abnormal LC findings were central or peripheral focal LC defects in eyes with glaucoma and LC disinsertions or peripheral focal LC defects in eyes with pachychoroid spectrum diseases. Central LC defects were related to inner layer retinoschisis, whereas LC disinsertions and peripheral LC defects were related to outer layer retinoschisis. The peripapillary retinoschisis did not show a topographic association with the underlying chronic CSC-or PCV-associated lesions. In 6 treated eyes with pachychoroid, peripapillary retinoschisis resolved along with subretinal fluid after antievascular endothelial growth factor injection in 4 eyes, whereas retinoschisis persisted after the resolution of subretinal fluid in 2 eyes.
   Conclusions: Enhanced depth imaging OCT of the LC demonstrated alterations associated with peripapillary retinoschisis, pachychoroid spectrum diseases, and glaucoma. (C) 2016 by the American Academy of Ophthalmology.
C1 [Lee, Jae Hyung; Park, Hae-Young Lopilly; Baek, Jiwon; Lee, Won Ki] Catholic Univ Korea, Dept Ophthalmol & Visual Sci, Seoul St Marys Hosp, Coll Med, 505 Banpo Dong, Seoul 137701, South Korea.
C3 Catholic University of Korea; Seoul St. Mary's Hospital
RP Lee, WK (通讯作者)，Catholic Univ Korea, Dept Ophthalmol & Visual Sci, Seoul St Marys Hosp, Coll Med, 505 Banpo Dong, Seoul 137701, South Korea.
EM weklee@catholic.ac.kr
OI Baek, Jiwon/0000-0001-6736-5379
FU Novartis; Bayer; Allergan; Alcon; Santen
FX The author(s) have made the following disclosure(s): W.K.L: Advisory
   boards for and received consultant fees - Novartis, Bayer, Allergan,
   Alcon, and Santen; Payments for lectures - Novartis, Bayer, Allergan,
   and Alcon.
CR Burgoyne CF, 2005, PROG RETIN EYE RES, V24, P39, DOI 10.1016/j.preteyeres.2004.06.001
   Choi YJ, 2014, OPHTHALMOLOGY, V121, P2098, DOI 10.1016/j.ophtha.2014.06.005
   COHEN AI, 1973, INVEST OPHTH VISUAL, V12, P513
   Farjad H, 2010, OPTOMETRY VISION SCI, V87, pE205, DOI 10.1097/OPX.0b013e3181d1dad5
   FLAGE T, 1975, ACTA OPHTHALMOL, V53, P801
   GASS JDM, 1967, AM J OPHTHALMOL, V63, P573
   GRAYSON MC, 1971, ARCH OPHTHALMOL-CHIC, V85, P600, DOI 10.1001/archopht.1971.00990050602014
   Grieshaber MC, 2007, SURV OPHTHALMOL, V52, pS115, DOI 10.1016/j.survophthal.2007.08.005
   GUYER DR, 1994, ARCH OPHTHALMOL-CHIC, V112, P1057, DOI 10.1001/archopht.1994.01090200063023
   Inoue M, 2015, ACTA OPHTHALMOL, V93, pE317, DOI 10.1111/aos.12568
   Jain N, 2014, AM J OPHTHALMOL, V158, P423, DOI 10.1016/j.ajo.2014.06.001
   Jirarattanasopa P, 2012, OPHTHALMOLOGY, V119, P1666, DOI 10.1016/j.ophtha.2012.02.021
   Kahook MY, 2007, AM J OPHTHALMOL, V143, P697, DOI 10.1016/j.ajo.2006.10.054
   Kiumehr S, 2012, ARCH OPHTHALMOL-CHIC, V130, P552, DOI 10.1001/archopthalmol.2011.1309
   Lee EJ, 2014, INVEST OPHTH VIS SCI, V55, P2805, DOI 10.1167/iovs.13-12742
   Lee EJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0090129
   Orazbekov L, 2015, OSLI RETINA, V46, P107, DOI 10.3928/23258160-20150101-21
   Ornek N, 2013, BMJ CASE REP, V2013
   Pang CE, 2015, RETINA-J RET VIT DIS, V35, P1, DOI 10.1097/IAE.0000000000000331
   Park HYL, 2014, INVEST OPHTH VIS SCI, V55, P233, DOI 10.1167/iovs.12-10329
   Park HYL, 2013, OPHTHALMOLOGY, V120, P745, DOI 10.1016/j.ophtha.2012.09.051
   Park HYL, 2012, OPHTHALMOLOGY, V119, P10, DOI 10.1016/j.ophtha.2011.07.033
   Park SC, 2013, INVEST OPHTH VIS SCI, V54, P8401, DOI 10.1167/iovs.13-13014
   Pautler SE, 2015, CLIN OPHTHALMOL, V9, P43, DOI 10.2147/OPTH.S75448
   Prinzi Robert A, 2015, BMJ Case Rep, V2015, DOI 10.1136/bcr-2015-211036
   RADIUS RL, 1978, BRIT J OPHTHALMOL, V62, P389, DOI 10.1136/bjo.62.6.389
   Rath EZ, 2007, CAN J OPHTHALMOL, V42, P339, DOI 10.3129/canjophthalmol.i07-027
   Razavi S, 2014, AM J OPHTHALMOL, V157, P852, DOI 10.1016/j.ajo.2013.12.029
   Shah Sejal D, 2014, Int Ophthalmol Clin, V54, P61, DOI 10.1097/IIO.0000000000000025
   Sigal IA, 2007, EXP EYE RES, V85, P312, DOI 10.1016/j.exer.2007.05.005
   Song In Seok, 2011, Korean J Ophthalmol, V25, P455, DOI 10.3341/kjo.2011.25.6.455
   Tatham AJ, 2014, OPHTHALMOLOGY, V121, P110, DOI 10.1016/j.ophtha.2013.08.018
   TSO MOM, 1975, ARCH OPHTHALMOL-CHIC, V93, P815
   Warrow DJ, 2013, RETINA-J RET VIT DIS, V33, P1659, DOI 10.1097/IAE.0b013e3182953df4
   Yoshitake T, 2014, JPN J OPHTHALMOL, V58, P435, DOI 10.1007/s10384-014-0330-8
NR 35
TC 27
Z9 29
U1 0
U2 5
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD OCT
PY 2016
VL 123
IS 10
BP 2066
EP 2076
DI 10.1016/j.ophtha.2016.06.033
PG 11
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA EE3QI
UT WOS:000389509100005
PM 27506483
DA 2022-11-30
ER

PT J
AU Ohba, N
   Nakao, K
AF Ohba, Norio
   Nakao, Kumiko
TI Sleeping beauties in ophthalmology
SO SCIENTOMETRICS
LA English
DT Article
DE Citation history; Delayed recognition; Sleeping beauties; Ophthalmology
ID POLYPOIDAL CHOROIDAL VASCULOPATHY; AMNIOTIC MEMBRANE TRANSPLANTATION;
   FREQUENTLY CITED ARTICLES; RETINAL NECROSIS SYNDROME; JOURNAL IMPACT
   FACTORS; PHOTORECEPTOR DEGENERATION; SURFACE RECONSTRUCTION; CORNEAL
   THICKNESS; CITATION ANALYSIS; TOXIN INJECTION
AB To identify delayed recognition publications, or 'Sleeping Beauties' (SBs), that are scarcely cited in the years or decades following their publication, but then go on to become highly cited, we screened citation histories of 184,606 articles in 52 ophthalmology journals using the Science Citation Index-Expanded (Thomson Reuters). Nine articles were identified as SBs, which accounted for 0.005% of basic materials. The SBs were published in Archives of Ophthalmology (n = 3), American Journal of Ophthalmology (n = 3), Acta Ophthalmologica (n = 1), Investigative Ophthalmology and Visual Science (n = 1), and Japanese Journal of Clinical Ophthalmology (n = 1). For citation histories according to the conjuring SB from the fairy tale, the sleep duration ranged from 7 to 59 years with mean of 19.7 years, the depth of sleep as evaluated by the average citations per year during the sleeping period ranged from 0.09 to 0.82 with mean of 0.45 citations, and the awake intensity as determined by the average citations per year during the first 5 years period following awakening ranged from 3.60 to 17.80 with mean of 8.51 citations. The number of total citations up to 2010 ranged from 109 to 375 with mean of 176.3 citations. Topics of the SBs covered description of new clinical diseases including acute retinal necrosis syndrome, cancer-associated retinopathy, and polypoidal choroidal vasculopathy, correlate of central corneal thickness with intraocular pressure readings, inadvertent eyeball perforation in retrobulbar anesthesia, pharmacologic weakening of extraocular muscles, amniotic membrane graft for ocular surface reconstruction, and refractive surgery. These data provide a perspective of rare but interesting delayed citation articles in ophthalmology.
C1 [Ohba, Norio] Aichishukutoku Univ, Div Visual Sci, Nagoya, Aichi, Japan.
   [Nakao, Kumiko] Kagoshima Univ, Dept Ophthalmol, Grad Sch Med & Dent Sci, Kagoshima 890, Japan.
C3 Kagoshima University
RP Ohba, N (通讯作者)，Asahigaoka 109, Minamisakaemachi, Owariasahishi 4880046, Japan.
EM ohbanm@gctv.ne.jp
CR Braun T, 2010, RES EVALUAT, V19, P195, DOI 10.3152/095820210X514210;
   CANO V, 1991, SCIENTOMETRICS, V22, P297, DOI 10.1007/BF02020003
   Cartwright VA, 2005, J CATARACT REFR SURG, V31, P1999, DOI 10.1016/j.jcrs.2005.10.031
   CULBERTSON WW, 1986, OPHTHALMOLOGY, V93, P559
   CULBERTSON WW, 1982, OPHTHALMOLOGY, V89, P1317
   de Rotth A, 1940, ARCH OPHTHALMOL-CHIC, V23, P522
   EHLERS N, 1975, ACTA OPHTHALMOL, V53, P34
   Fan JC, 2008, CLIN EXP OPHTHALMOL, V36, P54, DOI 10.1111/j.1442-9071.2008.01674.x
   FEIBEL RM, 1985, SURV OPHTHALMOL, V30, P102, DOI 10.1016/0039-6257(85)90078-5
   FYODOROV SN, 1979, ANN OPHTHALMOL, V11, P1885
   GARFIELD E, 1980, CURR CONTENTS, P5
   Glanzel W, 2003, SCIENTOMETRICS, V58, P571, DOI 10.1023/B:SCIE.0000006881.30700.ea
   Glanzel W., 1995, J INF SCI, V21, P37
   JOHNSON M, 1978, ARCH OPHTHALMOL-CHIC, V96, P664
   KELTNER JL, 1983, ARCH OPHTHALMOL-CHIC, V101, P564, DOI 10.1001/archopht.1983.01040010564006
   KIM JC, 1995, CORNEA, V14, P473
   Lange Lydia L, 2005, Hist Psychol, V8, P194, DOI 10.1037/1093-4510.8.2.194
   Lee SH, 1997, AM J OPHTHALMOL, V123, P303, DOI 10.1016/S0002-9394(14)70125-4
   Levitt JM, 2008, SCIENTOMETRICS, V77, P41, DOI 10.1007/s11192-007-1946-y
   Ohba N, 2007, ARCH OPHTHALMOL-CHIC, V125, P952, DOI 10.1001/archopht.125.7.952
   Ohba N, 2010, ARCH OPHTHALMOL-CHIC, V128, P1610, DOI 10.1001/archophthalmol.2010.308
   Ohba Norio, 2007, Nippon Ganka Gakkai Zasshi, V111, P849
   RAMSAY RC, 1978, AM J OPHTHALMOL, V86, P61, DOI 10.1016/0002-9394(78)90016-8
   Redner S, 2005, PHYS TODAY, V58, P49, DOI 10.1063/1.1996475
   SATO T, 1953, AM J OPHTHALMOL, V36, P823, DOI 10.1016/0002-9394(53)90183-4
   SAWYER RA, 1976, AM J OPHTHALMOL, V81, P606, DOI 10.1016/0002-9394(76)90125-2
   SCOTT AB, 1973, INVEST OPHTH VISUAL, V12, P924
   SCOTT AB, 1980, OPHTHALMOLOGY, V87, P1044
   SCOTT AB, 1985, ARCH OPHTHALMOL-CHIC, V103, P347
   Shimazaki J, 1997, OPHTHALMOLOGY, V104, P2068, DOI 10.1016/S0161-6420(97)30057-8
   Sims JL, 2003, CLIN EXP OPHTHALMOL, V31, P14, DOI 10.1046/j.1442-9071.2003.00610.x
   THIRKILL CE, 1987, ARCH OPHTHALMOL-CHIC, V105, P372
   Tsubota K, 1996, AM J OPHTHALMOL, V122, P38, DOI 10.1016/S0002-9394(14)71962-2
   Urayama A, 1971, JPN J CLIN OPHTHALMO, V25, P607
   van Raan AFJ, 2004, SCIENTOMETRICS, V59, P467, DOI 10.1023/B:SCIE.0000018543.82441.f1
   WHITACRE MM, 1993, SURV OPHTHALMOL, V38, P1, DOI 10.1016/0039-6257(93)90053-A
   YAMAGUCHI T, 1982, AM J OPHTHALMOL, V93, P600, DOI 10.1016/S0002-9394(14)77375-1
   Yannuzzi LA, 1997, ARCH OPHTHALMOL-CHIC, V115, P478, DOI 10.1001/archopht.1997.01100150480005
   YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001
NR 39
TC 33
Z9 35
U1 1
U2 59
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0138-9130
EI 1588-2861
J9 SCIENTOMETRICS
JI Scientometrics
PD NOV
PY 2012
VL 93
IS 2
BP 253
EP 264
DI 10.1007/s11192-012-0667-z
PG 12
WC Computer Science, Interdisciplinary Applications; Information Science &
   Library Science
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC Computer Science; Information Science & Library Science
GA 025XL
UT WOS:000310230400002
DA 2022-11-30
ER

PT J
AU Baumal, CR
   Sarraf, D
   Bryant, T
   Gui, W
   Muakkassa, N
   Pichi, F
   Querques, G
   Choudhry, N
   Teke, MY
   Govetto, A
   Invernizzi, A
   Eliott, D
   Gaudric, A
   de Souza, EC
   Naysan, J
   Lembo, A
   Lee, GC
   Freund, KB
AF Baumal, Caroline R.
   Sarraf, David
   Bryant, Tara
   Gui, Wei
   Muakkassa, Nora
   Pichi, Francesco
   Querques, Giuseppe
   Choudhry, Netan
   Teke, Mehmet Yasin
   Govetto, Andrea
   Invernizzi, Alessandro
   Eliott, Dean
   Gaudric, Alain
   de Souza, Eduardo Cunha
   Naysan, Jonathan
   Lembo, Andrea
   Lee, Grace C.
   Freund, K. Bailey
TI Henle fibre layer haemorrhage: clinical features and pathogenesis
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE imaging; retina; macula; anatomy
AB Background
   To describe the clinical presentation and characteristic imaging features of deep retinal haemorrhages primarily located in the Henle fibre layer (HFL) of the macula. The spectrum of aetiologies and a comprehensive theory of pathogenesis are presented.
   Methods
   This is a retrospective, multicentre case series evaluating eyes with retinal haemorrhage in HFL. Clinical features, underlying aetiology, systemic and ocular risk factors, visual acuity, and multimodal imaging including fundus photography and cross-sectional and en face optical coherence tomography (OCT) are presented.
   Results
   Retinal haemorrhages localised to HFL in 33 eyes from 23 patients were secondary to acute blunt trauma to the head (n=2), eye (n=1) and trunk (n=1), ruptured intracranial aneurysm (Terson's syndrome, n=3), general anaesthesia (n=1), epidural anaesthesia (n=1), hypertension with anaemia (n=1), decompression retinopathy (n=1), postvitrectomy with intraocular gas (n=1), retinal vein occlusion (n=7), myopic degeneration (n=2), macular telangiectasia type 2 (n=1), and polypoidal choroidal vasculopathy (n=1). Defining clinical features included deep retinal haemorrhage with feathery margin and petaloid pattern radiating from the fovea. OCT demonstrated characteristic hyper-reflectivity from the haemorrhage delineated by obliquely oriented fibres in the Henle layer. Spontaneous resolution of HFL haemorrhage occurred after 3 months in 15 patients with follow-up.
   Conclusion
   The characteristic petaloid-shaped, deep intraretinal haemorrhage with a feathery margin localised to HFL is associated with various disorders. The terminology 'Henle fiber layer hemorrhage (HH)' is proposed to describe the clinical and OCT findings, which may result from abnormal retinal venous pressure from systemic or local retinovascular disorders affecting the deep capillary plexus or from choroidal vascular abnormalities.
C1 [Baumal, Caroline R.; Bryant, Tara; Muakkassa, Nora] New England Eye Ctr, Ophthalmol, Boston, MA 02111 USA.
   [Sarraf, David; Gui, Wei] Univ Calif Los Angeles, Jules Stein Eye Inst, Retina Dept, Los Angeles, CA 90024 USA.
   [Pichi, Francesco; Lembo, Andrea] San Giuseppe Hosp, Univ Eye Clin, Milan, Italy.
   [Querques, Giuseppe] Osped San Raffaele, 0Phthalmol, Milan, Italy.
   [Choudhry, Netan] Herzig Eye Inst, Vitreoretinal Surg, Toronto, ON, Canada.
   [Teke, Mehmet Yasin] Ulucanlar Eye Educ & Res Hosp, Dept Ophthalmol, Ankara, Turkey.
   [Govetto, Andrea] Jules Stein Eye Inst, Retina Dept, Los Angeles, CA 90024 USA.
   [Invernizzi, Alessandro] Univ Milan, Eye Clin, Dept Clin Sci, Luigi Sacco Hosp, Milan, Italy.
   [Eliott, Dean] Massachusetts Eye & Ear Infirm, Retina Dept, Boston, MA 02114 USA.
   [Gaudric, Alain] Univ Paris 07, Lariboisiere Hosp, Dept Ophthalmol, Paris, France.
   [de Souza, Eduardo Cunha] Univ Sao Paulo, Dept Ophthalmol, Sao Paulo, Brazil.
   [Naysan, Jonathan] North Shore Long Isl Jewish, Ophthalmol, Great Neck, NY USA.
   [Lee, Grace C.] Kaiser Permanente, Dept Ophthalmol, Woodland Hills, CA USA.
   [Freund, K. Bailey] Vitreous Retina Macula Consultants New York, Retina Dept, New York, NY USA.
C3 University of California System; University of California Los Angeles;
   Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele; Ankara
   Ulucanlar Eye Training & Research Hospital; University of Milan; Luigi
   Sacco Hospital; Harvard University; Massachusetts Eye & Ear Infirmary;
   Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire
   Lariboisiere-Fernand-Widal - APHP; UDICE-French Research Universities;
   Universite Paris Cite; Universidade de Sao Paulo; Northwell Health;
   Kaiser Permanente; Vitreous Retina Macula Consultants of New York
RP Baumal, CR (通讯作者)，New England Eye Ctr, Ophthalmol, Boston, MA 02111 USA.
EM cbaumal@gmail.com
RI ; Freund, K. Bailey/V-7488-2018
OI Govetto, Andrea/0000-0003-2192-810X; Lembo, Andrea/0000-0001-7232-6593;
   Freund, K. Bailey/0000-0002-7888-9773; baumal,
   caroline/0000-0002-3651-8210; Querques, Giuseppe/0000-0002-3292-9581
FU Research to Prevent Blindness
FX This study was funded by Research to Prevent Blindness.
CR Adhi M, 2016, INVEST OPHTH VIS SCI, V57, pOCT486, DOI 10.1167/iovs.15-18907
   Agarwal A., 2011, GASSATLAS MACULAR DI, V5, P726
   Amirikia A, 2000, ARCH OPHTHALMOL-CHIC, V118, P287
   [Anonymous], 1997, DIAGNOSIS TREATMENT
   Au A, 2018, JAMA OPHTHALMOL, V136, P1182, DOI 10.1001/jamaophthalmol.2018.2979
   Bakhoum MF, 2018, AM J OPHTHALMOL, V195, P143, DOI 10.1016/j.ajo.2018.07.031
   BOVINO JA, 1984, ARCH OPHTHALMOL-CHIC, V102, P1151
   Bozeman WP, 2005, J TRAUMA, V58, P278, DOI 10.1097/01.TA.0000152536.71932.85
   Byeon SH, 2010, ACTA OPHTHALMOL, V88, P660, DOI 10.1111/j.1755-3768.2009.01517.x
   Campbell JP, 2017, SCI REP-UK, V7, DOI 10.1038/srep42201
   Chan JW, 2004, EYE, V18, P752, DOI 10.1038/sj.eye.6701302
   Chen Xuejing, 2021, Retin Cases Brief Rep, V15, P536, DOI 10.1097/ICB.0000000000000845
   Chen XJ, 2015, AM J OPHTHALMOL, V160, P26, DOI 10.1016/j.ajo.2015.04.004
   Chu S, 2018, INVEST OPHTH VIS SCI, V59, P2913, DOI 10.1167/iovs.18-24112
   Curcio CA, 2017, INVEST OPHTH VIS SCI, V58, P211, DOI 10.1167/iovs.17-21872
   Dansingani KK, 2015, EYE, V29, P1620, DOI 10.1038/eye.2015.180
   Dhrami-Gavazi Elona, 2015, Int J Retina Vitreous, V1, P14
   Falavarjani KG, 2017, AM J OPHTHALMOL, V177, P131, DOI 10.1016/j.ajo.2017.02.015
   Fawzi AA, 2012, RETINA-J RET VIT DIS, V32, P1500, DOI 10.1097/IAE.0b013e318263d0c3
   Freund KB, 2018, JAMA OPHTHALMOL, V136, P1262, DOI 10.1001/jamaophthalmol.2018.3586
   Garrity ST, 2017, INVEST OPHTH VIS SCI, V58, P5548, DOI 10.1167/iovs.17-22036
   Garrity ST, 2017, RETINA-J RET VIT DIS, V37, P1809, DOI 10.1097/IAE.0000000000001784
   Graversen VAK, 2014, RETINA-J RET VIT DIS, V34, P483, DOI 10.1097/IAE.0b013e3182a48759
   HENDRICKSON AE, 1984, OPHTHALMOLOGY, V91, P603
   Hogan MJ, 1971, HISTOLOGY HUMAN EYE
   Kim JH, 2016, JPN J OPHTHALMOL, V60, P466, DOI 10.1007/s10384-016-0466-9
   Kuriakose RK, 2019, CASE REP OPHTHALM, V10, P1, DOI 10.1159/000496144
   KUSHNER FH, 1995, ARCH OPHTHALMOL-CHIC, V113, P309, DOI 10.1001/archopht.1995.01100030065023
   Lee GD, 2014, RETINA-J RET VIT DIS, V34, P2388, DOI 10.1097/IAE.0000000000000397
   Li ML, 2018, RETINA-J RET VIT DIS, V38, P1937, DOI 10.1097/IAE.0000000000002182
   LING C, 1993, BRIT J OPHTHALMOL, V77, P316, DOI 10.1136/bjo.77.5.316
   Lujan BJ, 2011, INVEST OPHTH VIS SCI, V52, P1486, DOI 10.1167/iovs.10-5946
   Mena OJ, 2011, AM J FOREN MED PATH, V32, P55, DOI 10.1097/PAF.0b013e3181edee5b
   Mrejen S, 2016, OSLI RETINA, V47, P20, DOI 10.3928/23258160-20151214-03
   Nemiroff Julia, 2018, Retin Cases Brief Rep, V12 Suppl 1, pS12, DOI 10.1097/ICB.0000000000000706
   Nemiroff J, 2016, AM J OPHTHALMOL, V162, P121, DOI 10.1016/j.ajo.2015.10.026
   Okubo A, 2005, OPHTHALMOLOGY, V112, P1436, DOI 10.1016/j.ophtha.2005.03.017
   Otani T, 2011, RETINA-J RET VIT DIS, V31, P497, DOI 10.1097/IAE.0b013e3181ed8dae
   Park JJ, 2016, RETINA-J RET VIT DIS, V36, P2039, DOI 10.1097/IAE.0000000000001077
   Patel YP., RETINA-J RET VIT DIS, V10, P259
   Prabhakar H, 2007, MINIM INVAS NEUROSUR, V50, P98, DOI 10.1055/s-2007-982505
   Rabiolo Alessandro, 2018, Retin Cases Brief Rep, V12 Suppl 1, pS46, DOI 10.1097/ICB.0000000000000640
   Rahimy Ehsan, 2014, JAMA Ophthalmol, V132, P1413, DOI 10.1001/jamaophthalmol.2014.581
   Raper DMS, 2017, J NEUROINTERV SURG, V9, P986, DOI 10.1136/neurintsurg-2017-012984
   REYES ME, 1994, RETINA-J RET VIT DIS, V14, P14, DOI 10.1097/00006982-199401000-00004
   Sarraf D, 2013, JAMA OPHTHALMOL, V131, P1275, DOI 10.1001/jamaophthalmol.2013.4056
   Staurenghi G, 2014, OPHTHALMOLOGY, V121, P1572, DOI 10.1016/j.ophtha.2014.02.023
   Stiebel-Kalish H, 2004, RETINA-J RET VIT DIS, V24, P36, DOI 10.1097/00006982-200402000-00006
   Tabandeh H, 2000, AM J OPHTHALMOL, V129, P688, DOI 10.1016/S0002-9394(99)00470-5
   Uber-Zak LD, 2002, ARCH PHYS MED REHAB, V83, P278, DOI 10.1053/apmr.2002.27378
   YUODELIS C, 1986, VISION RES, V26, P847, DOI 10.1016/0042-6989(86)90143-4
NR 51
TC 5
Z9 5
U1 0
U2 1
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
EI 1468-2079
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD MAR
PY 2021
VL 105
IS 3
BP 374
EP 380
DI 10.1136/bjophthalmol-2019-315443
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA QP8GB
UT WOS:000624068000014
PM 32376610
DA 2022-11-30
ER

PT J
AU Doi, S
   Kimura, S
   Morizane, Y
   Shiode, Y
   Hosokawa, M
   Hirano, M
   Hosogi, M
   Fujiwara, A
   Miyamoto, K
   Shiraga, F
AF Doi, Shinichiro
   Kimura, Shuhei
   Morizane, Yuki
   Shiode, Yusuke
   Hosokawa, Mio
   Hirano, Masayuki
   Hosogi, Mika
   Fujiwara, Atsushi
   Miyamoto, Kazuhisa
   Shiraga, Fumio
TI Successful displacement of a traumatic submacular hemorrhage in a
   13-year-old boy treated by vitrectomy, subretinal injection of tissue
   plasminogen activator and intravitreal air tamponade: a case report
SO BMC OPHTHALMOLOGY
LA English
DT Article
DE Traumatic submacular hemorrhage; Vitrectomy; Subretinal injection;
   Recombinant tissue plasminogen activator; Air tamponade; Choroidal
   rupture
ID CHOROIDAL RUPTURE; PNEUMATIC DISPLACEMENT; MACULAR DEGENERATION;
   SECONDARY
AB Background: The natural course of submacular hemorrhage resulting from traumatic choroidal rupture generally has a poor outcome unless treated. The intravitreal injection of gas only or gas with recombinant tissue plasminogen activator (rt-PA) has been reported to be effective, but has also been reported to induce severe complications such as retinal detachment and vitreous hemorrhage. Recently, we reported a safe and effective procedure for treating submacular hemorrhage due to polypoidal choroidal vasculopathy (PCV) with a low dose of rt-PA. Here we report the application of this procedure to a case of traumatic submacular hemorrhage in a 13-year-old boy, which achieved a good visual outcome.
   Case presentation: A 13-year-old Japanese boy presented with a thick submacular hemorrhage in his left eye as a result of blunt trauma from being hit by a sinker. Best-corrected visual acuity (BCVA) was assessed as only able to perceive hand motions. We carried out a vitrectomy, subretinal injection of 4,000 IU rt-PA (6.9 mu g) and air tamponade. The day after surgery, most of the submacular hemorrhage had moved to the inferior periphery. One month after the surgery, we observed cataract formation, thin remnants of the submacular hemorrhage and juxtafoveal choroidal rupture. We carried out cataract surgery and injected bevacizumab intravitreally to prevent the development of choroidal neovascularization. Two months after the second surgery, the submacular hemorrhage had totally disappeared and the patient had a BCVA of 20/40.
   Conclusion: Vitrectomy, subretinal injection of rt-PA, and intravitreal air tamponade may be a promising strategy for treating traumatic submacular hemorrhage in young patients.
C1 [Doi, Shinichiro; Kimura, Shuhei; Morizane, Yuki; Shiode, Yusuke; Hosokawa, Mio; Hirano, Masayuki; Hosogi, Mika; Fujiwara, Atsushi; Shiraga, Fumio] Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Ophthalmol, Okayama, Japan.
   [Miyamoto, Kazuhisa] Sumitomo Bessi Hosp, Dept Ophthalmol, Niihama, Japan.
C3 Okayama University
RP Morizane, Y (通讯作者)，Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Ophthalmol, 2-5-1 Shikata Cho Kita Ku, Okayama, Japan.
EM moriza-y@okayama-u.ac.jp
CR Abdul-Salim I, 2013, CLIN OPHTHALMOL, V7, P703, DOI 10.2147/OPTH.S42208
   Ament CS, 2006, ARCH OPHTHALMOL-CHIC, V124, P957, DOI 10.1001/archopht.124.7.957
   Fine HF, 2010, RETINA-J RET VIT DIS, V30, P1588, DOI 10.1097/IAE.0b013e3181e2263c
   GLATT H, 1982, AM J OPHTHALMOL, V94, P762, DOI 10.1016/0002-9394(82)90301-4
   Goldman DR, 2014, RETINA-J RET VIT DIS, V34, P1258, DOI 10.1097/IAE.0000000000000019
   Haupert CL, 2001, AM J OPHTHALMOL, V131, P208, DOI 10.1016/S0002-9394(00)00734-0
   Hillenkamp J, 2010, GRAEF ARCH CLIN EXP, V248, P5, DOI 10.1007/s00417-009-1158-7
   Hochman MA, 1997, SURV OPHTHALMOL, V42, P195, DOI 10.1016/S0039-6257(97)00089-1
   Holland D, 2004, OPHTHALMOLOGICA, V218, P64, DOI 10.1159/000074569
   JOHNSON MW, 1990, ARCH OPHTHALMOL-CHIC, V108, P259, DOI 10.1001/archopht.1990.01070040111042
   Kimura S, 2015, AM J OPHTHALMOL, V159, P683, DOI 10.1016/j.ajo.2014.12.020
   Ohji M, 1998, ARCH OPHTHALMOL-CHIC, V116, P1326, DOI 10.1001/archopht.116.10.1326
   Secretan M, 1998, RETINA-J RET VIT DIS, V18, P62
   WYSZYNSKI RE, 1988, RETINA-J RET VIT DIS, V8, P237, DOI 10.1097/00006982-198808040-00003
   Yang Po-Min, 2005, Chang Gung Med J, V28, P852
NR 15
TC 6
Z9 6
U1 0
U2 1
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1471-2415
J9 BMC OPHTHALMOL
JI BMC Ophthalmol.
PD AUG 7
PY 2015
VL 15
AR 94
DI 10.1186/s12886-015-0090-3
PG 4
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA CO3HH
UT WOS:000359046900002
PM 26250101
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Maloney, MH
   Payne, SR
   Herrin, J
   Sangaralingham, LR
   Shah, ND
   Barkmeier, AJ
AF Maloney, Maya H.
   Payne, Stephanie R.
   Herrin, Jeph
   Sangaralingham, Lindsey R.
   Shah, Nilay D.
   Barkmeier, Andrew J.
TI Risk of Systemic Adverse Events after Intravitreal Bevacizumab,
   Ranibizumab, and Aflibercept in Routine Clinical Practice
SO OPHTHALMOLOGY
LA English
DT Article
DE anti-VEGF; aflibercept; ranibizumab; bevacizumab; age-related macular
   degeneration; diabetic retinopathy; retinal vein occlusion
AB Purpose: Intravitreal anti-vascular endothelial growth factor (VEGF) pharmacotherapy plays a central role in the management of neovascular age-related macular degeneration (nAMD), diabetic retinal disease (DRD), and retinal venous occlusive disease (RVO). Within clinical trials, rates of systemic serious adverse events (SAES) after anti-VEGF treatment have been low. However, the comparative systemic safety profile of common anti-VEGF agents remains incompletely understood. The goal of this study was to compare the systemic safety of intravitreal bevacizumab, ranibizumab, and aflibercept in real-world practice.
   Design: Retrospective cohort study.
   Participants: Using a large U.S. administrative claims database of commercially insured and Medicare Advantage enrollees, we identified adult cohorts receiving initial anti-VEGF injections for nAMD, DRD, and RVO between January 1, 2007, and June 30, 2018. We included patients with 1 year of insurance coverage before initial treatment.
   Methods: We compared predefined systemic outcomes between anti-VEGF agents occurring within 180 days of treatment initiation using propensity score-weighted Cox proportional hazards models. Patients were censored upon treatment with a different anti-VEGF medication or termination of health plan coverage.
   Main Outcome Measures: Primary outcomes were acute myocardial infarction (MI), acute cerebrovascular disease (CVD), major bleeding, and all-cause hospitalization.
   Results: A total of 87 844 patients received initial anti-VEGF injections for nAMD, DRD, and RVO between January 1, 2007, and June 30, 2018 (69 007 bevacizumab; 10 895 ranibizumab; 7942 aflibercept). Postinjection 180-day event rates per 100 patients for MI, CVD, major bleeding, and all-cause hospitalization were similar for bevacizumab (0.64, 0.59, 0.34, and 10.41, respectively), ranibizumab (0.62, 0.53, 0.40, and 9.44, respectively), and aflibercept (0.63, 0.60, 0.20, and 9.88, respectively). No differences were identified for the risk of MI, CVD, major bleeding, or all-cause hospitalization when comparing the risk-adjusted effect of treatment initiation with bevacizumab versus ranibizumab (hazard ratio [HR], 0.96 [95% confidence interval {CI}, 0.74-1.25]; HR, 1.04 [95% CI, 0.78-1.38]; HR, 0.85 [95% CI, 0.61-1.19]; HR, 1.03 [95% CI, 0.96-1.10], all P > 0.05), bevacizumab versus aflibercept (HR, 0.95 [95% CI, 0.68-1.33], HR, 0.99 [95% CI, 0.71-1.38], HR, 1.02 [95% CI, 0.60-1.74], HR, 1.01 [95% CI, 0.93-1.10], all P > 0.05), or aflibercept versus ranibizumab (HR, 0.91 [95% CI, 0.62-1.35], HR, 1.12 [95% CI, 0.74-1.69], HR, 0.96 [95% CI, 0.53-1.73], HR, 1.02 [95% CI, 0.92-1.13], all P > 0.05).
   Conclusions: We observed no differences in the risk of acute MI, CVD, major bleeding, or all-cause hospitalization after treatment initiation with intravitreal bevacizumab, ranibizumab, or aflibercept during routine clinical practice. (C) 2020 by the American Academy of Ophthalmology
C1 [Maloney, Maya H.; Barkmeier, Andrew J.] Mayo Clin, Dept Ophthalmol, 200 First St SW, Rochester, MN 55905 USA.
   [Maloney, Maya H.] Kaiser Permanente, Dept Ophthalmol, Vacaville, CA USA.
   [Payne, Stephanie R.] Mayo Clin, Biomed Stat & Informat, Rochester, MN USA.
   [Herrin, Jeph] Yale Univ, Yale Sch Med, New Haven, CT USA.
   [Sangaralingham, Lindsey R.; Shah, Nilay D.] Mayo Clin, Kern Ctr Sci Hlth Care Delivery, Rochester, MN USA.
   [Shah, Nilay D.] Mayo Clin, Div Hlth Care Policy & Res, Dept Hlth Sci Res, Rochester, MN USA.
   [Shah, Nilay D.] OptumLabs, Cambridge, MA USA.
C3 Mayo Clinic; Kaiser Permanente; Mayo Clinic; Yale University; Mayo
   Clinic; Mayo Clinic; Optum
RP Barkmeier, AJ (通讯作者)，Mayo Clin, Dept Ophthalmol, 200 First St SW, Rochester, MN 55905 USA.
EM barkmeier.andrew@mayo.edu
RI Barkmeier, Andrew/AAV-1021-2020
FU Mayo Clinic Robert D. and Patricia E. Kern Center for the Science of
   Health Care Delivery; Mayo Clinic from the FDA to establish Yale-Mayo
   Clinic Center for Excellence in Regulatory Science and Innovation
   program [U01FD005938]; Centers of Medicare and Medicaid Innovation under
   the Transforming Clinical Practice Initiative; Agency for Healthcare
   Research and Quality [U19HS024075, R01HS025164, R01HS025402,
   R03HS025517, K12HS026379]; National Heart, Lung, and Blood Institute;
   National Institute for Aging of the National Institutes of Health
   [R56HL130496, R01HL131535, R01AG062823]; National Science Foundation;
   Patient Centered Outcomes Research Institute to develop a Clinical Data
   Research Network
FX Funded in part by the Mayo Clinic Robert D. and Patricia E. Kern Center
   for the Science of Health Care Delivery.; In the last 36 months, NDS has
   received research support through Mayo Clinic from the FDA to establish
   Yale-Mayo Clinic Center for Excellence in Regulatory Science and
   Innovation program (U01FD005938); the Centers of Medicare and Medicaid
   Innovation under the Transforming Clinical Practice Initiative; the
   Agency for Healthcare Research and Quality (U19HS024075; R01HS025164;
   R01HS025402; R03HS025517; K12HS026379); the National Heart, Lung, and
   Blood Institute and National Institute for Aging of the National
   Institutes of Health (R56HL130496; R01HL131535; R01AG062823); the
   National Science Foundation; and the Patient Centered Outcomes Research
   Institute to develop a Clinical Data Research Network.
CR Arnason T, 2006, THROMB RES, V118, P253, DOI 10.1016/j.thromres.2005.06.015
   Avery RL, 2014, BRIT J OPHTHALMOL, V98, P1636, DOI 10.1136/bjophthalmol-2014-305252
   Berg K, 2015, OPHTHALMOLOGY, V122, P146, DOI 10.1016/j.ophtha.2014.07.041
   Berkowitz ST, 2019, JAMA OPHTHALMOL, V137, P921, DOI 10.1001/jamaophthalmol.2019.1971
   Brown DM, 2013, OPHTHALMOLOGY, V120, P2013, DOI 10.1016/j.ophtha.2013.02.034
   Chakravarthy U, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.04.015
   Cunningham A, 2011, PHARMACOEPIDEM DR S, V20, P560, DOI 10.1002/pds.2109
   Curtis LH, 2010, ARCH OPHTHALMOL-CHIC, V128, P1273, DOI 10.1001/archophthalmol.2010.223
   Daien V, 2019, BMC OPHTHALMOL, V19, DOI 10.1186/s12886-019-1208-9
   Do DV, 2012, OPHTHALMOLOGY, V119, P1658, DOI 10.1016/j.ophtha.2012.02.010
   Elman MJ, 2012, OPHTHALMOLOGY, V119, P2312, DOI 10.1016/j.ophtha.2012.08.022
   Heier JS, 2016, OPHTHALMOLOGY, V123, P2376, DOI 10.1016/j.ophtha.2016.07.032
   Holz FG, 2015, BRIT J OPHTHALMOL, V99, P220, DOI 10.1136/bjophthalmol-2014-305327
   Hykin P, 2019, JAMA OPHTHALMOL, V137, P1256, DOI 10.1001/jamaophthalmol.2019.3305
   Kiss S, 2014, CLIN OPHTHALMOL, V8, P1611, DOI 10.2147/OPTH.S60893
   Kitchens JW, 2016, OPHTHALMOLOGY, V123, P1511, DOI 10.1016/j.ophtha.2016.02.046
   Kodjikian L, 2013, OPHTHALMOLOGY, V120, P2300, DOI 10.1016/j.ophtha.2013.06.020
   Kokotailo RA, 2005, STROKE, V36, P1776, DOI 10.1161/01.STR.0000174293.17959.a1
   Lavallee PC, 2007, LANCET NEUROL, V6, P953, DOI 10.1016/S1474-4422(07)70248-X
   Maloney MH, 2019, OPHTHALMOLOGY, V126, P1007, DOI 10.1016/j.ophtha.2018.09.040
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   Massin P, 2010, DIABETES CARE, V33, P2399, DOI 10.2337/dc10-0493
   Parikh R, 2019, OPHTHALMOL RETINA, V3, P16, DOI 10.1016/j.oret.2018.08.002
   Parikh R, 2017, OPHTHALMOLOGY, V124, P352, DOI 10.1016/j.ophtha.2016.10.036
   Rajendram R, 2012, ARCH OPHTHALMOL-CHIC, V130, P972, DOI 10.1001/archophthalmol.2012.393
   Rosenfeld PJ, 2005, OPHTHAL SURG LAS IM, V36, P336, DOI 10.3928/1542-8877-20050701-15
   Rosenfeld PJ, 2005, OPHTHAL SURG LAS IM, V36, P331, DOI 10.3928/1542-8877-20050701-14
   Schmidt-Erfurth U, 2014, OPHTHALMOLOGY, V121, P1045, DOI 10.1016/j.ophtha.2013.11.041
   Scott IU, 2007, OPHTHALMOLOGY, V114, P1860, DOI 10.1016/j.ophtha.2007.05.062
   Scott IU, 2017, JAMA-J AM MED ASSOC, V317, P2072, DOI 10.1001/jama.2017.4568
   Stone TW HP, ASRS 2019 PREFERENCE
   Thigpen JL, 2015, CIRC-CARDIOVASC QUAL, V8, P8, DOI 10.1161/CIRCOUTCOMES.113.000371
   Tirschwell DL, 2002, STROKE, V33, P2465, DOI 10.1161/01.STR.0000032240.28636.BD
   Virgili G, 2018, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007419.pub6
   Wells JA, 2016, OPHTHALMOLOGY, V123, P1351, DOI 10.1016/j.ophtha.2016.02.022
   Wu L, 2008, GRAEF ARCH CLIN EXP, V246, P81, DOI 10.1007/s00417-007-0660-z
   Zarbin MA, 2018, OPHTHALMOL RETINA, V2, P1087, DOI 10.1016/j.oret.2018.04.018
NR 37
TC 18
Z9 18
U1 2
U2 8
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD MAR
PY 2021
VL 128
IS 3
BP 417
EP 424
DI 10.1016/j.ophtha.2020.07.062
EA FEB 2021
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA QY6YQ
UT WOS:000630184400012
PM 32781110
DA 2022-11-30
ER

PT J
AU Chiu, CJ
   Taylor, A
AF Chiu, Chung-Jung
   Taylor, Allen
TI Dietary hyperglycemia, glycemic index and metabolic retinal diseases
SO PROGRESS IN RETINAL AND EYE RESEARCH
LA English
DT Article
ID GLYCATION END-PRODUCTS; ENDOTHELIAL GROWTH-FACTOR; HYPOXIA-INDUCIBLE
   FACTOR; PROTEIN-KINASE-C; PIGMENT EPITHELIAL-CELLS;
   LOW-CARBOHYDRATE-DIET; FACTOR-KAPPA-B; CARDIOVASCULAR RISK-FACTORS;
   AGE-RELATED MACULOPATHY; CORONARY-HEART-DISEASE
AB The glycemic index (Cl) indicates how fast blood glucose is raised after consuming a carbohydrate-containing food. Human metabolic studies indicate that GI is related to patho-physiological responses after meals. Compared with a low-GI meal, a high-GI meal is characterized with hyperglycemia during the early postprandial stage (0-2 h) and a compensatory hyperlipidemia associated with counter-regulatory hormone responses during late postprandial stage (4-6 h). Over the past three decades, several human health disorders have been related to Cl. The strongest relationship suggests that consuming low-GI foods prevents diabetic complications. Diabetic retinopathy (DR) is a complication of diabetes. In this aspect, Cl appears to be useful as a practical guideline to help diabetic people choose foods. Abundant epidemiological evidence also indicates positive associations between Cl and risk for type 2 diabetes, cardiovascular disease, and more recently, age-related macular degeneration (AMD) in people without diabetes. Although data from randomized controlled intervention trials are scanty, these observations are strongly supported by evolving molecular mechanisms which explain the pathogenesis of hyperglycemia. This wide range of evidence implies that dietary hyperglycemia is etiologically related to human aging and diseases, including DR and AMD. In this context, these diseases can be considered as metabolic retinal diseases.
   Molecular theories that explain hyperglycemic pathogenesis involve a mitochondria-associated pathway and four glycolysis-associated pathways, including advanced glycation end products formation, protein kinase C activation, polyol pathway, and hexosamine pathway. While the four glycolysis-associated pathways appear to be universal for both normoxic and hypoxic conditions, the mitochondria-associated mechanism appears to be most relevant to the hyperglycemic, normoxic pathogenesis. For diseases that affect tissues with highly active metabolism and that frequently face challenge from low oxygen tension, such as retina in which metabolism is determined by both glucose and oxygen homeostases, these theories appear to be insufficient. Several lines of evidence indicate that the retina is particularly vulnerable when hypoxia coincides with hyperglycemia. We propose a novel hyperglycemic, hypoxia-inducible factor (HIF) pathway, to complement the current theories regarding hyperglycemic pathogenesis. HIF is a transcription complex that responds to decrease oxygen in the cellular environment. In addition to playing a significant role in the regulation of glucose metabolism, under hyperglycemia HIF has been shown to increase the expression of HIF-inducible genes, such as vascular endothelial growth factor (VEGF) leading to angiogenesis. To this extent, we suggest that HIF can also be described as a hyperglycemia-inducible factor.
   In summary, while management of dietary Cl appears to be an effective intervention for the prevention of metabolic diseases, specifically AMD and DR, more interventional data is needed to evaluate the efficacy of Cl management. There is an urgent need to develop reliable biomarkers of exposure, surrogate endpoints, as well as susceptibility for Cl. These insights would also be helpful in deciphering the detailed hyperglycemia-related biochemical mechanisms for the development of new therapeutic agents. (C) 2010 Elsevier Ltd. All rights reserved.
C1 [Chiu, Chung-Jung; Taylor, Allen] Tufts Univ, Jean Mayer United States Dept Agr, Human Nutr Res Ctr Aging, Dept Ophthalmol,Sch Med, Boston, MA 02111 USA.
C3 Tufts University; United States Department of Agriculture (USDA)
RP Chiu, CJ (通讯作者)，Tufts Univ, Jean Mayer United States Dept Agr, Human Nutr Res Ctr Aging, Dept Ophthalmol,Sch Med, 711 Washington St, Boston, MA 02111 USA.
EM cj.chiu@tufts.edu
FU U.S. Department of Agriculture [1950-5100-060-01A, R01-13250,
   R03-EY014183-01A2]; National Institutes of Health; Ross Aging
   Initiative; NATIONAL EYE INSTITUTE [R03EY014183, R01EY013250] Funding
   Source: NIH RePORTER
FX Financial support for this project has been provided by the U.S.
   Department of Agriculture under agreements, 1950-5100-060-01A (CJC, AT)
   and R01-13250 and R03-EY014183-01A2 from the National Institutes of
   Health (AT), and to CJC from the Ross Aging Initiative.
CR Abdallah Walid, 2009, Int Ophthalmol Clin, V49, P95, DOI 10.1097/IIO.0b013e31819fd84a
   Abordo EA, 1997, IMMUNOL LETT, V58, P139, DOI 10.1016/S0165-2478(97)00080-1
   Aiello LP, 1997, DIABETES, V46, P1473, DOI 10.2337/diabetes.46.9.1473
   AIELLO LP, 1994, NEW ENGL J MED, V331, P1480, DOI 10.1056/NEJM199412013312203
   Aisenbrey S, 2006, INVEST OPHTH VIS SCI, V47, P5537, DOI 10.1167/iovs.05-1590
   Allen DA, 2005, J NUTR BIOCHEM, V16, P705, DOI 10.1016/j.jnutbio.2005.06.007
   Allen NE, 2009, JNCI-J NATL CANCER I, V101, P296, DOI 10.1093/jnci/djn514
   Alnemri ES, 1996, CELL, V87, P171, DOI 10.1016/S0092-8674(00)81334-3
   Alnemri ES, 1997, J CELL BIOCHEM, V64, P33, DOI 10.1002/(SICI)1097-4644(199701)64:1<33::AID-JCB6>3.0.CO;2-0
   Anderson DH, 2002, AM J OPHTHALMOL, V134, P411, DOI 10.1016/S0002-9394(02)01624-0
   ANDERSON DH, 2009, PROG RETIN EYE RES
   Anil E, 2007, P NUTR SOC, V66, P60, DOI 10.1017/S0029665107005307
   Antonetti DA, 1999, J BIOL CHEM, V274, P23463, DOI 10.1074/jbc.274.33.23463
   Appel LJ, 2005, JAMA-J AM MED ASSOC, V294, P2455, DOI 10.1001/jama.294.19.2455
   Arany Z, 2008, NATURE, V451, P1008, DOI 10.1038/nature06613
   Arjamaa O, 2006, EXP EYE RES, V83, P473, DOI 10.1016/j.exer.2006.01.016
   Arjamaa O, 2009, AGEING RES REV, V8, P349, DOI 10.1016/j.arr.2009.06.002
   ARNOLD L, 1994, ATHEROSCLEROSIS, V108, P167, DOI 10.1016/0021-9150(94)90111-2
   Assero G, 2001, BBA-MOL CELL BIOL L, V1533, P128, DOI 10.1016/S1388-1981(01)00151-2
   Atkinson FS, 2008, DIABETES CARE, V31, P2281, DOI 10.2337/dc08-1239
   Aziz A, 2009, J AOAC INT, V92, P879
   Balkau B, 1998, DIABETES CARE, V21, P360, DOI 10.2337/diacare.21.3.360
   Barclay AW, 2008, AM J CLIN NUTR, V87, P627, DOI 10.1093/ajcn/87.3.627
   BAZAN NG, 1982, VISION RES, V22, P1539, DOI 10.1016/0042-6989(82)90221-8
   Becerra SP, 2002, NEW ENGL J MED, V347, P1968, DOI 10.1056/NEJMcibr022629
   Beckman KB, 1998, PHYSIOL REV, V78, P547, DOI 10.1152/physrev.1998.78.2.547
   BelAiba RS, 2007, MOL BIOL CELL, V18, P4691, DOI 10.1091/mbc.E07-04-0391
   Bellot G, 2009, MOL CELL BIOL, V29, P2570, DOI 10.1128/MCB.00166-09
   Bento CF, 2010, EXP PHYSIOL, V95, P955, DOI 10.1113/expphysiol.2010.053561
   BERTELSEN J, 1993, DIABETES CARE, V16, P4, DOI 10.2337/diacare.16.1.4
   Beulens JWJ, 2007, J AM COLL CARDIOL, V50, P14, DOI 10.1016/j.jacc.2007.02.068
   Bianchi R, 2004, P NATL ACAD SCI USA, V101, P823, DOI 10.1073/pnas.0307823100
   Bierhaus A, 2005, ANN NY ACAD SCI, V1043, P676, DOI 10.1196/annals.1333.077
   Bishara NB, 2002, J CELL PHYSIOL, V193, P80, DOI 10.1002/jcp.10153
   Boden G, 2005, ANN INTERN MED, V142, P403, DOI 10.7326/0003-4819-142-6-200503150-00006
   Bolanos JP, 1999, BBA-BIOENERGETICS, V1411, P415, DOI 10.1016/S0005-2728(99)00030-4
   Bonello S, 2007, ARTERIOSCL THROM VAS, V27, P755, DOI 10.1161/01.ATV.0000258979.92828.bc
   Bonora E, 2001, DIABETES CARE, V24, P2023, DOI 10.2337/diacare.24.12.2023
   BORNET FRJ, 1987, AM J CLIN NUTR, V45, P588, DOI 10.1093/ajcn/45.3.588
   Botero D, 2009, OBESITY, V17, P1664, DOI 10.1038/oby.2009.203
   BOULTON M, 1994, BRIT J OPHTHALMOL, V78, P125, DOI 10.1136/bjo.78.2.125
   Boulton M, 2004, PHOTOCH PHOTOBIO SCI, V3, P759, DOI 10.1039/b400108g
   BOULTON M, 1986, BRIT J OPHTHALMOL, V70, P808, DOI 10.1136/bjo.70.11.808
   BOULTON M, 1989, INVEST OPHTH VIS SCI, V30, P82
   Brahimi-Horn MC, 2007, CURR OPIN CELL BIOL, V19, P223, DOI 10.1016/j.ceb.2007.02.003
   Brahimi-Horn MC, 2005, INT REV CYTOL, V242, P157
   BRAND JC, 1991, DIABETES CARE, V14, P95, DOI 10.2337/diacare.14.2.95
   Brand-Miller J, 2003, DIABETES CARE, V26, P2261, DOI 10.2337/diacare.26.8.2261
   Bravata DM, 2003, JAMA-J AM MED ASSOC, V289, P1837, DOI 10.1001/jama.289.14.1837
   BRAY GA, 1972, J CLIN INVEST, V51, P537, DOI 10.1172/JCI106842
   Brehm BJ, 2003, J CLIN ENDOCR METAB, V88, P1617, DOI 10.1210/jc.2002-021480
   Bressler NM, 2009, OPHTHALMOLOGY, V116, pS15, DOI 10.1016/j.ophtha.2009.06.048
   Bressler SB, 2009, OPHTHALMOLOGY, V116, pS1, DOI 10.1016/j.ophtha.2009.06.045
   Brouns F, 2005, NUTR RES REV, V18, P145, DOI 10.1079/NRR2005100
   BROWNLEE M, 1995, ANNU REV MED, V46, P223, DOI 10.1146/annurev.med.46.1.223
   Brownlee M, 2001, NATURE, V414, P813, DOI 10.1038/414813a
   BROWNLEE M, 1992, DIABETES CARE, V15, P1835, DOI 10.2337/diacare.15.12.1835
   Brownlee M, 2005, DIABETES, V54, P1615, DOI 10.2337/diabetes.54.6.1615
   Brune B, 2007, CARDIOVASC RES, V75, P275, DOI 10.1016/j.cardiores.2007.03.005
   BRUN JF, 1995, DIABETOLOGIA, V38, P494
   BURG MB, 1988, J CLIN INVEST, V81, P635, DOI 10.1172/JCI113366
   Busik JV, 2008, DIABETES, V57, P1952, DOI 10.2337/db07-1520
   Buyken AE, 2010, DIABETOLOGIA, V53, P406, DOI 10.1007/s00125-009-1629-8
   Buyken AE, 2001, AM J CLIN NUTR, V73, P574
   Buyken AE, 2010, AM J CLIN NUTR, V92, P634, DOI 10.3945/ajcn.2010.29390
   Cahill G F Jr, 1970, N Engl J Med, V282, P668, DOI 10.1056/NEJM197003052821026
   Cai JY, 2000, PROG RETIN EYE RES, V19, P205, DOI 10.1016/S1350-9462(99)00009-9
   Carey VJ, 2005, CLIN TRIALS, V2, P529, DOI 10.1191/1740774505cn123oa
   Ceriello A, 1998, DIABETES CARE, V21, P1529, DOI 10.2337/diacare.21.9.1529
   Chanmugam P, 2003, J AM DIET ASSOC, V103, P867, DOI 10.1016/S0002-8223(03)00381-X
   CHARONIS AS, 1990, DIABETES, V39, P807, DOI 10.2337/diabetes.39.7.807
   Cherepanoff S, 2009, BR J OPHTHALMOL
   CHEW I, 1988, AM J CLIN NUTR, V47, P53, DOI 10.1093/ajcn/47.1.53
   Chiarelli F, 1999, J PEDIATR-US, V134, P486, DOI 10.1016/S0022-3476(99)70208-8
   Chiasson JL, 2002, LANCET, V359, P2072, DOI 10.1016/S0140-6736(02)08905-5
   Chibber R, 1997, DIABETOLOGIA, V40, P156, DOI 10.1007/s001250050657
   Chin CJ, 2005, AM J CLIN NUTR, V81, P1411
   Chiu CJ, 2009, BRIT J OPHTHALMOL, V93, P1241, DOI 10.1136/bjo.2008.143412
   Chiu CJ, 2007, AM J CLIN NUTR, V86, P1210, DOI 10.1093/ajcn/86.4.1210
   Chiu CJ, 2007, EXP EYE RES, V84, P229, DOI 10.1016/j.exer.2006.05.015
   Chiu CJ, 2007, AM J CLIN NUTR, V86, P180, DOI 10.1093/ajcn/86.1.180
   Chiu CJ, 2006, AM J CLIN NUTR, V83, P1177, DOI 10.1093/ajcn/83.5.1177
   Chiu CJ, 2010, INVEST OPHTH VIS SCI, V51, P2897, DOI 10.1167/iovs.08-2824
   Chiu CJ, 2009, OPHTHALMOLOGY, V116, P939, DOI 10.1016/j.ophtha.2008.12.025
   Chiu CJ, 2006, AM J CLIN NUTR, V83, P880, DOI 10.1093/ajcn/83.4.880
   Chuang DM, 2005, ANNU REV PHARMACOL, V45, P269, DOI 10.1146/annurev.pharmtox.45.120403.095902
   Cingle KA, 1996, CURR EYE RES, V15, P433, DOI 10.3109/02713689608995834
   Clarke M, 2007, BEST PRACT RES CL EN, V21, P573, DOI 10.1016/j.beem.2007.09.007
   Cockman ME, 2000, J BIOL CHEM, V275, P25733, DOI 10.1074/jbc.M002740200
   Coffe V, 2006, NEUROCHEM RES, V31, P103, DOI 10.1007/s11064-005-9236-7
   COHEN LH, 1965, BIOCH RETINA
   COHN C, 1964, FED PROC, V23, P76
   Collier GR., 1988, DIABETES NUTR METAB, V1, P11
   Craven PA, 1997, DIABETES, V46, P671, DOI 10.2337/diabetes.46.4.671
   Crider JY, 1997, J OCUL PHARMACOL TH, V13, P337, DOI 10.1089/jop.1997.13.337
   D'Souza YB, 2009, MOL VIS, V15, P906
   DAMICO DJ, 1994, NEW ENGL J MED, V331, P95, DOI 10.1056/NEJM199407143310207
   Decanini A, 2007, AM J OPHTHALMOL, V143, P607, DOI 10.1016/j.ajo.2006.12.006
   DEFRONZO RA, 1992, DIABETES CARE, V15, P318, DOI 10.2337/diacare.15.3.318
   Degenhardt TP, 1998, CELL MOL BIOL, V44, P1139
   Dehne N, 2009, EXP CELL RES, V315, P1791, DOI 10.1016/j.yexcr.2009.03.019
   Delcourt C, 2001, Ophthalmic Epidemiol, V8, P237, DOI 10.1076/opep.8.4.237.1613
   DENT MT, 1991, DIABETIC MED, V8, P439, DOI 10.1111/j.1464-5491.1991.tb01628.x
   DERUBERTIS FR, 1994, DIABETES, V43, P1, DOI 10.2337/diabetes.43.1.1
   Diabetes Control and Complications Trial Research Group, 1993, DIABETES, V46, P271
   Dickinson S, 2005, CURR OPIN LIPIDOL, V16, P69, DOI 10.1097/00041433-200502000-00012
   Dickinson S, 2008, AM J CLIN NUTR, V87, P1188
   Diederen RMH, 2006, INVEST OPHTH VIS SCI, V47, P2726, DOI 10.1167/iovs.06-0076
   DOI T, 1992, P NATL ACAD SCI USA, V89, P2873, DOI 10.1073/pnas.89.7.2873
   DolhoferBliesener R, 1996, EUR J CLIN CHEM CLIN, V34, P355
   Du XL, 2000, P NATL ACAD SCI USA, V97, P12222, DOI 10.1073/pnas.97.22.12222
   Du XL, 2001, J CLIN INVEST, V108, P1341, DOI 10.1172/JCI11235
   Du YP, 2003, FREE RADICAL BIO MED, V35, P1491, DOI 10.1016/j.freeradbiomed.2003.08.018
   Ebbeling C B, 2001, Adv Pediatr, V48, P179
   Ebbeling CB, 2005, AM J CLIN NUTR, V81, P976
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Ehlermann P, 2006, CARDIOVASC DIABETOL, V5, DOI 10.1186/1475-2840-5-6
   Elman MJ, 2010, OPHTHALMOLOGY, V117, P1064, DOI 10.1016/j.ophtha.2010.02.031
   Enaida H, 1999, Fukushima J Med Sci, V45, P77
   ENGERMAN RL, 1986, METABOLISM, V35, P20, DOI 10.1016/0026-0495(86)90182-4
   Erickson Kathryn K., 2007, Angiogenesis, V10, P103, DOI 10.1007/s10456-007-9067-z
   FABRY P, 1970, AM J CLIN NUTR, V23, P1059
   Fang IM, 2009, EXP EYE RES, V88, P12, DOI 10.1016/j.exer.2008.09.019
   Farboud B, 1999, MOL VIS, V5, pU1
   FARKAS TG, 1971, AM J OPHTHALMOL, V71, P1196, DOI 10.1016/0002-9394(71)90963-9
   Febbraio MA, 2000, J APPL PHYSIOL, V89, P1845, DOI 10.1152/jappl.2000.89.5.1845
   Feener EP, 1996, CONTRIB NEPHROL, V118, P180
   Festa A, 2006, DIABETES, V55, P1114, DOI 10.2337/diabetes.55.04.06.db05-1100
   Fiers W, 1999, ONCOGENE, V18, P7719, DOI 10.1038/sj.onc.1203249
   Fillmore KM, 2009, MOL NUTR FOOD RES, V53, P240, DOI 10.1002/mnfr.200800122
   Fong DS, 2004, DIABETES CARE, V27, P2540, DOI 10.2337/diacare.27.10.2540
   Fontvieille AM., 1988, DIABETES NUTR METAB, V1, P139
   Ford ES, 2001, ARCH INTERN MED, V161, P572, DOI 10.1001/archinte.161.4.572
   Forooghian F, 2007, BRIT J OPHTHALMOL, V91, DOI 10.1136/bjo.2007.123125
   Foster GD, 2003, NEW ENGL J MED, V348, P2082, DOI 10.1056/NEJMoa022207
   Foster-Powell K, 2002, AM J CLIN NUTR, V76, P5, DOI 10.1093/ajcn/76.1.5
   FOULDS WS, 1990, EYE, V4, P243, DOI 10.1038/eye.1990.35
   Frank RN, 2004, NEW ENGL J MED, V350, P48, DOI 10.1056/NEJMra021678
   Fraser-Bell S, 2008, AM J OPHTHALMOL, V145, P308, DOI 10.1016/j.ajo.2007.10.007
   Frede S, 2005, CANCER RES, V65, P4690, DOI 10.1158/0008-5472.CAN-04-3877
   Frede S, 2007, METHOD ENZYMOL, V435, P405, DOI 10.1016/S0076-6879(07)35021-0
   Frost G, 1996, METABOLISM, V45, P669, DOI 10.1016/S0026-0495(96)90129-8
   Frost G, 1998, METABOLISM, V47, P1245, DOI 10.1016/S0026-0495(98)90331-6
   Frost G, 1999, LANCET, V353, P1045, DOI 10.1016/S0140-6736(98)07164-5
   FROST G, 1994, DIABETIC MED, V11, P397, DOI 10.1111/j.1464-5491.1994.tb00292.x
   Fukumura D, 2001, CANCER RES, V61, P6020
   Gannon MC, 2004, DIABETES, V53, P2375, DOI 10.2337/diabetes.53.9.2375
   Gao ZQ, 2008, GEN PHYSIOL BIOPHYS, V27, P152
   Garcia-Ramirez M, 2008, DIABETES CARE, V31, P1189, DOI 10.2337/dc07-2075
   Gardner TA, 2003, J PATHOL, V201, P328, DOI 10.1002/path.1429
   GARG A, 1988, NEW ENGL J MED, V319, P829, DOI 10.1056/NEJM198809293191304
   Giacco R, 2000, DIABETES CARE, V23, P1461, DOI 10.2337/diacare.23.10.1461
   Giacco R, 2001, BRIT J NUTR, V85, P33, DOI 10.1079/BJN2000218
   GIARDINO I, 1994, J CLIN INVEST, V94, P110, DOI 10.1172/JCI117296
   Gilbertson HR, 2001, DIABETES CARE, V24, P1137, DOI 10.2337/diacare.24.7.1137
   Giugliano D, 2008, AM J CLIN NUTR, V87, p217S, DOI 10.1093/ajcn/87.1.217S
   Glenn JV, 2009, BBA-GEN SUBJECTS, V1790, P1109, DOI 10.1016/j.bbagen.2009.04.016
   Glenn JV, 2009, INVEST OPHTH VIS SCI, V50, P441, DOI 10.1167/iovs.08-1724
   Goldberg HJ, 2002, J BIOL CHEM, V277, P33833, DOI 10.1074/jbc.M112331200
   GOLDBERG J, 1988, AM J EPIDEMIOL, V128, P700, DOI 10.1093/oxfordjournals.aje.a115023
   Goodenough DA, 1996, ANNU REV BIOCHEM, V65, P475, DOI 10.1146/annurev.bi.65.070196.002355
   Gottlieb E, 2005, NAT REV CANCER, V5, P857, DOI 10.1038/nrc1737
   Granfeldt Y, 2006, EUR J CLIN NUTR, V60, P104, DOI 10.1038/sj.ejcn.1602273
   Grimm C, 2002, NAT MED, V8, P718, DOI 10.1038/nm723
   Grimm C, 2006, ADV EXP MED BIOL, V588, P119
   Grune T, 2004, INT J BIOCHEM CELL B, V36, P2519, DOI 10.1016/j.biocel.2004.04.020
   Hageman GS, 1999, FASEB J, V13, P477, DOI 10.1096/fasebj.13.3.477
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   HALES CN, 1963, LANCET, V1, P790
   Halton TL, 2008, AM J CLIN NUTR, V87, P339, DOI 10.1093/ajcn/87.2.339
   Halton TL, 2006, NEW ENGL J MED, V355, P1991, DOI 10.1056/NEJMoa055317
   Hammes HP, 1999, DIABETOLOGIA, V42, P728, DOI 10.1007/s001250051221
   Hammes HP, 1996, LAB INVEST, V75, P325
   HAMMES HP, 1994, DIABETOLOGIA, V37, P32
   Hammes HP, 2005, HORM METAB RES, V37, pS39, DOI 10.1055/s-2005-861361
   Hammes HP, 2003, NAT MED, V9, P294, DOI 10.1038/nm834
   Hammes HP, 1999, INVEST OPHTH VIS SCI, V40, P1855
   Hammond EM, 2005, BIOCHEM BIOPH RES CO, V331, P718, DOI 10.1016/j.bbrc.2005.03.154
   Handa J. T., 1998, IOVS, V39, pS370
   Handa JT, 1999, INVEST OPHTH VIS SCI, V40, P775
   Handa JT, 1998, EXP EYE RES, V66, P411, DOI 10.1006/exer.1997.0442
   Hansen SH, 2001, DIABETES-METAB RES, V17, P330, DOI 10.1002/dmrr.229
   Hare-Bruun H, 2008, NUTR REV, V66, P569, DOI 10.1111/j.1753-4887.2008.00108.x
   Harhaj NS, 2004, INT J BIOCHEM CELL B, V36, P1206, DOI 10.1016/j.biocel.2003.08.007
   Hart GW, 1997, ANNU REV BIOCHEM, V66, P315, DOI 10.1146/annurev.biochem.66.1.315
   Hata Y, 1999, DIABETES, V48, P1145, DOI 10.2337/diabetes.48.5.1145
   Hellwig-Burgel T, 1999, BLOOD, V94, P1561, DOI 10.1182/blood.V94.5.1561.417a06_1561_1567
   HENKIND P, 1980, T OPHTHAL SOC UK, V100, P425
   Henkind P, 1981, Trans Ophthalmol Soc N Z, V33, P46
   Henry DN, 2000, INVEST OPHTH VIS SCI, V41, P1554
   Hodge AM, 2004, DIABETES CARE, V27, P2701, DOI 10.2337/diacare.27.11.2701
   Hoffmann S, 2002, GRAEF ARCH CLIN EXP, V240, P996, DOI 10.1007/s00417-002-0568-6
   Hokanson J E, 1996, J Cardiovasc Risk, V3, P213, DOI 10.1097/00043798-199604000-00014
   Hollyfield JG, 2003, ADV EXP MED BIOL, V533, P83
   Horiuchi S, 1996, DIABETES, V45, pS73, DOI 10.2337/diab.45.3.S73
   Howes KA, 2004, INVEST OPHTH VIS SCI, V45, pU906
   Hu FB, 2000, NEW ENGL J MED, V343, P530, DOI 10.1056/NEJM200008243430802
   Hu FB, 2001, DIABETOLOGIA, V44, P805, DOI 10.1007/s001250100547
   Hu YQ, 2006, AM J CLIN NUTR, V84, P70, DOI 10.1093/ajcn/84.1.70
   Huang LE, 1998, P NATL ACAD SCI USA, V95, P7987, DOI 10.1073/pnas.95.14.7987
   Hyman L, 2000, ARCH OPHTHALMOL-CHIC, V118, P351, DOI 10.1001/archopht.118.3.351
   Ido Y, 1997, INVEST OPHTH VIS SCI, V38, P1467
   Ikeda K, 1996, BIOCHEMISTRY-US, V35, P8075, DOI 10.1021/bi9530550
   Ishibashi, 2000, Jpn J Ophthalmol, V44, P323, DOI 10.1016/S0021-5155(00)00165-9
   Ishibashi T, 1998, ARCH OPHTHALMOL-CHIC, V116, P1629, DOI 10.1001/archopht.116.12.1629
   ISHIBASHI T, 1986, INVEST OPHTH VIS SCI, V27, P184
   ISHIBASHI T, 1986, AM J OPHTHALMOL, V101, P342, DOI 10.1016/0002-9394(86)90830-5
   Ishii H, 1996, SCIENCE, V272, P728, DOI 10.1126/science.272.5262.728
   Iwai K, 1999, P NATL ACAD SCI USA, V96, P12436, DOI 10.1073/pnas.96.22.12436
   Iyer NV, 1998, GENOMICS, V52, P159, DOI 10.1006/geno.1998.5416
   JANANNATHAN SN, 1964, AM J CLIN NUTR, V15, P90
   Januszewski AS, 2003, BIOCHEM SOC T, V31, P1413
   Jardeleza MSR, 2009, SEMIN OPHTHALMOL, V24, P87, DOI 10.1080/08820530902800330
   Jarrett SG, 2008, PROG RETIN EYE RES, V27, P596, DOI 10.1016/j.preteyeres.2008.09.001
   Jarvi AE, 1999, DIABETES CARE, V22, P10, DOI 10.2337/diacare.22.1.10
   Jenkins DJA, 2008, JAMA-J AM MED ASSOC, V300, P2742, DOI 10.1001/jama.2008.808
   JENKINS DJA, 1981, AM J CLIN NUTR, V34, P362, DOI 10.1093/ajcn/34.3.362
   JENKINS DJA, 1987, AM J CLIN NUTR, V46, P968, DOI 10.1093/ajcn/46.6.968
   JENKINS DJA, 1982, AM J CLIN NUTR, V35, P1339, DOI 10.1093/ajcn/35.6.1339
   JENKINS DJA, 1990, DIABETES, V39, P775, DOI 10.2337/diabetes.39.7.775
   Jenkins DJA, 2002, AM J CLIN NUTR, V76, p266S, DOI 10.1093/ajcn/76.1.266S
   JENKINS DJA, 1988, AM J CLIN NUTR, V48, P248, DOI 10.1093/ajcn/48.2.248
   JENKINS DJA, 1987, AM J CLIN NUTR, V46, P66, DOI 10.1093/ajcn/46.1.66
   JENKINS DJA, 1989, NEW ENGL J MED, V321, P929, DOI 10.1056/NEJM198910053211403
   JENKINS DJA, 1992, AM J CLIN NUTR, V55, P461, DOI 10.1093/ajcn/55.2.461
   Johnson PT, 2003, INVEST OPHTH VIS SCI, V44, pU403
   JONES PJH, 1993, AM J CLIN NUTR, V57, P868, DOI 10.1093/ajcn/57.6.868
   Joussen AM, 2004, FASEB J, V18, P1450, DOI 10.1096/fj.03-1476fje
   Junk AK, 2002, P NATL ACAD SCI USA, V99, P10659, DOI 10.1073/pnas.152321399
   Juntunen KS, 2003, AM J CLIN NUTR, V77, P385
   Justilien V, 2007, INVEST OPHTH VIS SCI, V48, P4407, DOI 10.1167/iovs.07-0432
   Kaarniranta K, 2009, J MOL MED, V87, P117, DOI 10.1007/s00109-008-0418-z
   KADONAGA JT, 1988, SCIENCE, V242, P1566, DOI 10.1126/science.3059495
   Kaelin WG, 2008, MOL CELL, V30, P393, DOI 10.1016/j.molcel.2008.04.009
   KALFA TA, 1995, INVEST OPHTH VIS SCI, V36, P2358
   Kamura T, 2000, P NATL ACAD SCI USA, V97, P10430, DOI 10.1073/pnas.190332597
   Kanwar M, 2007, INVEST OPHTH VIS SCI, V48, P3805, DOI 10.1167/iovs.06-1280
   Kanwar M, 2009, DIABETES, V58, P227, DOI 10.2337/db08-1025
   Kasahara E, 2005, INVEST OPHTH VIS SCI, V46, P3426, DOI 10.1167/iovs.05-0344
   Kasajima H, 2001, VIRCHOWS ARCH, V439, P46, DOI 10.1007/s004280100444
   Kasper M, 1999, BIOCHEM BIOPH RES CO, V261, P175, DOI 10.1006/bbrc.1999.0902
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Kaur C, 2008, PROG RETIN EYE RES, V27, P622, DOI 10.1016/j.preteyeres.2008.09.003
   Kaushik S, 2008, AM J CLIN NUTR, V88, P1104, DOI 10.1093/ajcn/88.4.1104
   Keogh RJ, 1997, METABOLISM, V46, P41, DOI 10.1016/S0026-0495(97)90165-7
   Kern TS, 2000, INVEST OPHTH VIS SCI, V41, P3972
   Kiens B, 1996, AM J CLIN NUTR, V63, P47, DOI 10.1093/ajcn/63.1.47
   Kim JW, 2006, CANCER RES, V66, P8927, DOI 10.1158/0008-5472.CAN-06-1501
   Kim JW, 2006, CELL METAB, V3, P177, DOI 10.1016/j.cmet.2006.02.002
   Kim WY, 2006, EMBO J, V25, P4650, DOI 10.1038/sj.emboj.7601300
   Kim WY, 2004, J CLIN ONCOL, V22, P4991, DOI 10.1200/JCO.2004.05.061
   Kim YS, 2007, J ETHNOPHARMACOL, V112, P166, DOI 10.1016/j.jep.2007.02.017
   KIRSTEIN M, 1992, J CLIN INVEST, V90, P439, DOI 10.1172/JCI115879
   Klein R, 1997, OPHTHALMOLOGY, V104, P1804, DOI 10.1016/S0161-6420(97)30023-2
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P1527
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Klein R, 2008, AM J OPHTHALMOL, V145, P317, DOI 10.1016/j.ajo.2007.09.008
   Knowler WC, 2002, NEW ENGL J MED, V346, P393, DOI 10.1056/NEJMoa012512
   Kobayashi S, 2007, BIOL PHARM BULL, V30, P133, DOI 10.1248/bpb.30.133
   Kociok N, 1998, EXP EYE RES, V67, P237, DOI 10.1006/exer.1998.0517
   Koh MY, 2008, TRENDS BIOCHEM SCI, V33, P526, DOI 10.1016/j.tibs.2008.08.002
   Kohner EM, 1998, ARCH OPHTHALMOL-CHIC, V116, P297, DOI 10.1001/archopht.116.3.297
   Kohner EM, 2001, DIABETIC MED, V18, P178
   Kolm-Litty V, 1998, J CLIN INVEST, V101, P160, DOI 10.1172/JCI119875
   Kopp W, 2006, PREV MED, V42, P336, DOI 10.1016/j.ypmed.2006.02.003
   KOROLCHUK VI, 2009, FEBS LETT
   Korshunov SS, 1997, FEBS LETT, V416, P15, DOI 10.1016/S0014-5793(97)01159-9
   Koukourakis MI, 2005, CLIN EXP METASTAS, V22, P25, DOI 10.1007/s10585-005-2343-7
   Kowluru RA, 2005, ANTIOXID REDOX SIGN, V7, P1581, DOI 10.1089/ars.2005.7.1581
   Koya D, 2000, FASEB J, V14, P439, DOI 10.1096/fasebj.14.3.439
   Koya D, 1997, J CLIN INVEST, V100, P115, DOI 10.1172/JCI119503
   Koya D, 1998, DIABETES, V47, P859, DOI 10.2337/diabetes.47.6.859
   Krishnan S, 2007, ARCH INTERN MED, V167, P2304, DOI 10.1001/archinte.167.21.2304
   Kuboki K, 2000, CIRCULATION, V101, P676, DOI 10.1161/01.CIR.101.6.676
   Kuhla B, 2005, ANN NY ACAD SCI, V1043, P211, DOI 10.1196/annals.1333.026
   Kunt T, 1998, EXP CLIN ENDOCR DIAB, V106, P183, DOI 10.1055/s-0029-1211974
   Kusner LL, 2004, INVEST OPHTH VIS SCI, V45, P1553, DOI 10.1167/iovs.03-1294
   Laaksonen DE, 2005, AM J CLIN NUTR, V82, P1218, DOI 10.1093/ajcn/82.6.1218
   Lafrance L, 1998, DIABETIC MED, V15, P972, DOI 10.1002/(SICI)1096-9136(1998110)15:11<972::AID-DIA704>3.0.CO;2-2
   LAL S, 1995, ARCH BIOCHEM BIOPHYS, V318, P191, DOI 10.1006/abbi.1995.1220
   Lando D, 2002, SCIENCE, V295, P858, DOI 10.1126/science.1068592
   Lau C, 2005, DIABETES CARE, V28, P1397, DOI 10.2337/diacare.28.6.1397
   LEAHY JL, 1992, DIABETES CARE, V15, P442, DOI 10.2337/diacare.15.3.442
   Lee AYW, 1999, FASEB J, V13, P23, DOI 10.1096/fasebj.13.1.23
   Lee SH, 2000, NEW ENGL J MED, V342, P626, DOI 10.1056/NEJM200003023420904
   Leske MC, 2006, OPHTHALMOLOGY, V113, P29, DOI 10.1016/j.ophtha.2005.08.012
   LEVRAN A, 1981, DIABETES, V30, P996, DOI 10.2337/diabetes.30.12.996
   Li YM, 1997, NEUROSCI LETT, V226, P155
   Li YM, 1996, P NATL ACAD SCI USA, V93, P11047, DOI 10.1073/pnas.93.20.11047
   Liese AD, 2005, DIABETES CARE, V28, P2832, DOI 10.2337/diacare.28.12.2832
   Lipton SA, 2004, NEW ENGL J MED, V350, P2516, DOI 10.1056/NEJMcibr041121
   Lisy K, 2008, CELL DEATH DIFFER, V15, P642, DOI 10.1038/sj.cdd.4402315
   Lisztwan J, 1999, GENE DEV, V13, P1822, DOI 10.1101/gad.13.14.1822
   Liu SM, 2002, AM J CLIN NUTR, V75, P492, DOI 10.1093/ajcn/75.3.492
   Liu SM, 2000, AM J CLIN NUTR, V71, P1455
   Liu SM, 2002, J AM COLL NUTR, V21, P298, DOI 10.1080/07315724.2002.10719227
   Liu SM, 2001, CURR OPIN LIPIDOL, V12, P395, DOI 10.1097/00041433-200108000-00005
   Lohwasser C, 2006, J INVEST DERMATOL, V126, P291, DOI 10.1038/sj.jid.5700070
   Lorenzi M, 2001, DIABETOLOGIA, V44, P791, DOI 10.1007/s001250100544
   Louie JL, 2002, EXP EYE RES, V75, P271, DOI 10.1006/exer.2002.2022
   Lu M, 1998, J CLIN INVEST, V101, P1219, DOI 10.1172/JCI1277
   Ludwig DS, 2007, LANCET, V369, P890, DOI 10.1016/S0140-6736(07)60427-9
   Ludwig DS, 2002, JAMA-J AM MED ASSOC, V287, P2414, DOI 10.1001/jama.287.18.2414
   Ludwig DS, 1999, PEDIATRICS, V103, DOI 10.1542/peds.103.3.e26
   Luscombe ND, 1999, EUR J CLIN NUTR, V53, P473, DOI 10.1038/sj.ejcn.1600779
   Luthra S, 2006, INVEST OPHTH VIS SCI, V47, P5569, DOI 10.1167/iovs.06-0333
   LYONS TJ, 1991, DIABETES, V40, P1010, DOI 10.2337/diabetes.40.8.1010
   Ma WC, 2007, INVEST OPHTH VIS SCI, V48, P1355, DOI 10.1167/iovs.06-0738
   MacKenzie ED, 2007, MOL CELL BIOL, V27, P3282, DOI 10.1128/MCB.01927-06
   Madsen-Bouterse SA, 2008, REV ENDOCR METAB DIS, V9, P315, DOI 10.1007/s11154-008-9090-4
   Maeda A, 2005, BIOCHEMISTRY-US, V44, P480, DOI 10.1021/bi048016f
   Mahon PC, 2001, GENE DEV, V15, P2675, DOI 10.1101/gad.924501
   Malfait M, 2001, J MEMBRANE BIOL, V181, P31, DOI 10.1007/s0023200100082
   Mamputu JC, 2004, J LEUKOCYTE BIOL, V75, P1062, DOI 10.1189/jlb.0603265
   Mariathasan S, 2004, NATURE, V430, P213, DOI 10.1038/nature02664
   Masson E, 2005, GLYCOBIOLOGY, V15, P585, DOI 10.1093/glycob/cwi039
   Masson E, 2005, DIABETES, V54, P220, DOI 10.2337/diabetes.54.1.220
   McAuley KA, 2005, DIABETOLOGIA, V48, P8, DOI 10.1007/s00125-004-1603-4
   McFarlane S, 2005, BRIT J OPHTHALMOL, V89, P107, DOI 10.1136/bjo.2004.045914
   McKeown NM, 2009, J AM COLL NUTR, V28, P150, DOI 10.1080/07315724.2009.10719766
   McKeown NM, 2004, DIABETES CARE, V27, P538, DOI 10.2337/diacare.27.2.538
   McMillan-Price J, 2006, ARCH INTERN MED, V166, P1466, DOI 10.1001/archinte.166.14.1466
   Mensink RP, 2003, AM J CLIN NUTR, V77, P1146, DOI 10.1093/ajcn/77.5.1146
   Mente A, 2009, ARCH INTERN MED, V169, P659, DOI 10.1001/archinternmed.2009.38
   Mettler S, 2007, EUR J CLIN NUTR, V61, P19, DOI 10.1038/sj.ejcn.1602480
   Meyer KA, 2000, AM J CLIN NUTR, V71, P921
   MICELI MV, 1990, INVEST OPHTH VIS SCI, V31, P277
   Miller CK, 2006, J AM DIET ASSOC, V106, P745, DOI 10.1016/j.jada.2006.02.003
   Milton RC, 2005, OPHTHALMOLOGY, V112, P533, DOI 10.1016/j.ophtha.2004.10.047
   Mitchell P, 1999, AUST NZ J OPHTHALMOL, V27, P197, DOI 10.1046/j.1440-1606.1999.00211.x
   Miyamoto K, 1999, Semin Ophthalmol, V14, P233, DOI 10.3109/08820539909069542
   Miyata S, 1997, J BIOL CHEM, V272, P4037, DOI 10.1074/jbc.272.7.4037
   Miyata T, 2001, KIDNEY INT, V60, P2351, DOI 10.1046/j.1523-1755.2001.00051.x
   Mizutani M, 1996, J CLIN INVEST, V97, P2883, DOI 10.1172/JCI118746
   Mohr S, 2004, EXPERT OPIN INV DRUG, V13, P189, DOI 10.1517/13543784.13.3.189
   Mohr S, 2002, DIABETES, V51, P1172, DOI 10.2337/diabetes.51.4.1172
   Monnier L, 2003, DIABETES CARE, V26, P881, DOI 10.2337/diacare.26.3.881
   MONNIER VM, 1992, DIABETES, V41, P36, DOI 10.2337/diab.41.2.S36
   MOORE DJ, 1995, INVEST OPHTH VIS SCI, V36, P1290
   Moore DJ, 2001, INVEST OPHTH VIS SCI, V42, P2970
   Moore TCB, 2003, INVEST OPHTH VIS SCI, V44, P4457, DOI 10.1167/iovs.02-1063
   Morcos M, 2008, AGING CELL, V7, P260, DOI 10.1111/j.1474-9726.2008.00371.x
   Mousa SA, 1999, J CELL BIOCHEM, V74, P135, DOI 10.1002/(SICI)1097-4644(19990701)74:1<135::AID-JCB15>3.0.CO;2-#
   Mowat FM, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011103
   Mulder DJ, 2010, BRIT J OPHTHALMOL, V94, P622, DOI 10.1136/bjo.2009.162990
   Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835
   Murata T, 1997, DIABETOLOGIA, V40, P764, DOI 10.1007/s001250050747
   Nakashima E, 2005, ANTIOXID REDOX SIGN, V7, P1530, DOI 10.1089/ars.2005.7.1530
   NEEPER M, 1992, J BIOL CHEM, V267, P14998
   Nishikawa T, 2000, NATURE, V404, P787, DOI 10.1038/35008121
   Nishikawa Takaehi, 2008, Rinsho Byori, V56, P712
   Node K, 2009, CARDIOVASC DIABETOL, V8, DOI 10.1186/1475-2840-8-23
   Nordmann AJ, 2006, ARCH INTERN MED, V166, P285, DOI 10.1001/archinte.166.3.285
   Nyengaard JR, 2004, DIABETES, V53, P2931, DOI 10.2337/diabetes.53.11.2931
   Obrosova IG, 2001, EXP NEUROL, V172, P211, DOI 10.1006/exnr.2001.7789
   Ohgami N, 2002, J DIABETES COMPLICAT, V16, P56, DOI 10.1016/S1056-8727(01)00208-2
   Ohh M, 2000, NAT CELL BIOL, V2, P423, DOI 10.1038/35017054
   Okubo A, 1999, INVEST OPHTH VIS SCI, V40, P443
   Okubo A, 2000, INVEST OPHTH VIS SCI, V41, P4305
   Ola MS, 2006, AM J PHYSIOL-ENDOC M, V290, pE1057, DOI 10.1152/ajpendo.00323.2005
   Ono Y, 1998, DIABETES RES CLIN PR, V41, P131, DOI 10.1016/S0168-8227(98)00074-6
   Onorato JM, 2000, J BIOL CHEM, V275, P21177, DOI 10.1074/jbc.M003263200
   Osborne NN, 2004, PROG RETIN EYE RES, V23, P91, DOI 10.1016/j.preteyeres.2003.12.001
   Paget C, 1998, FREE RADICAL BIO MED, V25, P121, DOI 10.1016/S0891-5849(98)00071-9
   Pala V, 2006, NUTR METAB CARDIOVAS, V16, P186, DOI 10.1016/j.numecd.2005.05.009
   Papandreou I, 2006, CELL METAB, V3, P187, DOI 10.1016/j.cmet.2006.01.012
   Parillo M, 1985, Diabet Med, V2, P374
   Parillo M, 1996, DIABETES CARE, V19, P498, DOI 10.2337/diacare.19.5.498
   Park EJ, 2006, CELL CYCLE, V5, P1847, DOI 10.4161/cc.5.16.3019
   Park YK, 2008, MOL PHARMACOL, V74, P236, DOI 10.1124/mol.108.045278
   PASCUZZO GJ, 1980, EXP EYE RES, V30, P53, DOI 10.1016/0014-4835(80)90123-2
   Patel AV, 2007, CANCER CAUSE CONTROL, V18, P287, DOI 10.1007/s10552-006-0081-z
   Pawlak AM, 2008, ANN NY ACAD SCI, V1126, P59, DOI 10.1196/annals.1433.066
   Pawlak DB, 2004, LANCET, V364, P778, DOI 10.1016/S0140-6736(04)16937-7
   Pearl LH, 2008, BIOCHEM J, V410, P439, DOI 10.1042/BJ20071640
   PECORARO RE, 1982, DIABETES CARE, V5, P592, DOI 10.2337/diacare.5.6.592
   Pereira MA, 2002, AM J CLIN NUTR, V75, P848, DOI 10.1093/ajcn/75.5.848
   Pichiule P, 2007, J BIOL CHEM, V282, P36330, DOI 10.1074/jbc.M706407200
   POPBUSUI R, 1999, DIABETES, V47, pA229
   Portilla D, 2000, AM J PHYSIOL-RENAL, V278, pF667, DOI 10.1152/ajprenal.2000.278.4.F667
   Pouyssegur J, 2006, BIOL CHEM, V387, P1337, DOI 10.1515/BC.2006.167
   Prow TW, 2008, VISION RES, V48, P478, DOI 10.1016/j.visres.2007.09.019
   Pugliese G, 2001, FASEB J, V15, P2471, DOI 10.1096/fj.01-0006com
   Queisser MA, 2010, DIABETES, V59, P670, DOI 10.2337/db08-1565
   Radulian G, 2009, NUTR J, V8, DOI 10.1186/1475-2891-8-5
   Rakoczy PE, 1996, EXP EYE RES, V63, P159, DOI 10.1006/exer.1996.0104
   Ramana KV, 2005, DIABETES, V54, P818, DOI 10.2337/diabetes.54.3.818
   Rao AV, 1999, NUTR RES, V19, P305, DOI 10.1016/S0271-5317(98)00193-6
   Rapino C, 2005, AGING CELL, V4, P177, DOI 10.1111/j.1474-9726.2005.00161.x
   Rarnanathan A, 2005, P NATL ACAD SCI USA, V102, P5992, DOI 10.1073/pnas.0502267102
   READ NW, 1986, BRIT J NUTR, V55, P43, DOI 10.1079/BJN19860008
   REAVEN GM, 1988, DIABETES, V37, P1020, DOI 10.2337/diabetes.37.8.1020
   REDDY S, 1995, BIOCHEMISTRY-US, V34, P10872, DOI 10.1021/bi00034a021
   Riccardi G, 2008, AM J CLIN NUTR, V87, p269S, DOI 10.1093/ajcn/87.1.269S
   RIDDLE MC, 1990, DIABETES CARE, V13, P676, DOI 10.2337/diacare.13.6.676
   Ridker PM, 2000, NEW ENGL J MED, V342, P836, DOI 10.1056/NEJM200003233421202
   RITZ P, 1991, AM J CLIN NUTR, V54, P855, DOI 10.1093/ajcn/54.5.855
   Rizkalla SW, 2004, DIABETES CARE, V27, P1866, DOI 10.2337/diacare.27.8.1866
   Rodriguez-Fontal M, 2009, CURR DIABETES REV, V5, P47, DOI 10.2174/157339909787314239
   Rohlfing CL, 2002, DIABETES CARE, V25, P275, DOI 10.2337/diacare.25.2.275
   RuggieroLopez D, 1997, DIABETES RES CLIN PR, V34, P135, DOI 10.1016/S0168-8227(96)01352-6
   Rumble JR, 1997, J CLIN INVEST, V99, P1016, DOI 10.1172/JCI119229
   Ryhanen T, 2009, J CELL MOL MED, V13, P3616, DOI 10.1111/j.1582-4934.2008.00577.x
   Sahyoun NR, 2008, AM J CLIN NUTR, V87, P126, DOI 10.1093/ajcn/87.1.126
   Saishin Y, 2003, J CELL PHYSIOL, V195, P210, DOI 10.1002/jcp.10238
   Salmeron J, 1997, JAMA-J AM MED ASSOC, V277, P472, DOI 10.1001/jama.277.6.472
   Salmeron J, 1997, DIABETES CARE, V20, P545, DOI 10.2337/diacare.20.4.545
   Salminen A, 2009, TRENDS MOL MED, V15, P217, DOI 10.1016/j.molmed.2009.03.004
   Samaha FF, 2003, NEW ENGL J MED, V348, P2074, DOI 10.1056/NEJMoa022637
   Sandau KB, 2001, J BIOL CHEM, V276, P39805, DOI 10.1074/jbc.M107689200
   SanGiovanni John Paul, 2008, Arch Ophthalmol, V126, P1274, DOI 10.1001/archopht.126.9.1274
   SanGiovanni JP, 2005, PROG RETIN EYE RES, V24, P87, DOI 10.1016/j.preteyeres.2004.06.002
   Sano H, 1999, MECH AGEING DEV, V107, P333, DOI 10.1016/S0047-6374(99)00011-1
   Sarks SH, 1999, BRIT J OPHTHALMOL, V83, P358, DOI 10.1136/bjo.83.3.358
   Sato E, 2001, DIABETES CARE, V24, P479, DOI 10.2337/diacare.24.3.479
   SATO S, 1993, EXP EYE RES, V57, P235, DOI 10.1006/exer.1993.1119
   Sawa A, 1997, P NATL ACAD SCI USA, V94, P11669, DOI 10.1073/pnas.94.21.11669
   Schalkwijk CG, 1999, DIABETES, V48, pA386
   SCHMIDT AM, 1994, ARTERIOSCLER THROMB, V14, P1521, DOI 10.1161/01.ATV.14.10.1521
   SCHMIDT AM, 1995, J CLIN INVEST, V96, P1395, DOI 10.1172/JCI118175
   Schmidt AM, 2000, BBA-MOL CELL RES, V1498, P99, DOI 10.1016/S0167-4889(00)00087-2
   Schmitz HD, 2001, EUR J CELL BIOL, V80, P419, DOI 10.1078/0171-9335-00174
   Schofield CJ, 2004, NAT REV MOL CELL BIO, V5, P343, DOI 10.1038/nrm1366
   Schulze MB, 2004, AM J CLIN NUTR, V80, P348, DOI 10.1093/ajcn/80.2.348
   Schutt F, 2003, INVEST OPHTH VIS SCI, V44, P3663, DOI 10.1167/iovs.03-0172
   Scribner KB, 2008, AM J PHYSIOL-ENDOC M, V295, pE1126, DOI 10.1152/ajpendo.90487.2008
   Scribner KB, 2007, OBESITY, V15, P2190, DOI 10.1038/oby.2007.260
   Sebekova K, 1998, CELL MOL BIOL, V44, P1051
   Seko Y, 1999, INVEST OPHTH VIS SCI, V40, P3287
   SELL DR, 1992, DIABETES, V41, P1286, DOI 10.2337/diabetes.41.10.1286
   Semba RD, 2009, AM J KIDNEY DIS, V53, P51, DOI 10.1053/j.ajkd.2008.06.018
   Semenza GL, 2000, GENE DEV, V14, P1983
   SEMENZA GL, 1992, MOL CELL BIOL, V12, P5447, DOI 10.1128/MCB.12.12.5447
   Semenza GL, 2003, NAT REV CANCER, V3, P721, DOI 10.1038/nrc1187
   Shah VO, 1997, J CLIN ENDOCR METAB, V82, P2294, DOI 10.1210/jc.82.7.2294
   SHAMOON H, 1993, NEW ENGL J MED, V329, P977, DOI 10.1056/nejm199309303291401
   Shannon H, 2000, NEW ENGL J MED, V342, P381
   SHARMA NK, 1985, AM J OPHTHALMOL, V100, P51, DOI 10.1016/S0002-9394(14)74982-7
   Shikany JM, 2010, NUTRITION, V26, P641, DOI 10.1016/j.nut.2009.08.014
   Shinohara M, 1998, J CLIN INVEST, V101, P1142, DOI 10.1172/JCI119885
   Shukla A, 1996, EXPERIENTIA, V52, P136, DOI 10.1007/BF01923358
   Simo R, 2009, DIABETES CARE, V32, P1556, DOI 10.2337/dc09-0565
   Singh Ajay, 2009, Int Ophthalmol Clin, V49, P1, DOI 10.1097/IIO.0b013e31819fd164
   SKOLNIK EY, 1991, J EXP MED, V174, P931, DOI 10.1084/jem.174.4.931
   Smedsrod B, 1997, BIOCHEM J, V322, P567, DOI 10.1042/bj3220567
   Smith RT, 2006, INVEST OPHTH VIS SCI, V47, P5495, DOI 10.1167/iovs.05-1318
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Snow K K, 1999, Ophthalmic Epidemiol, V6, P125, DOI 10.1076/opep.6.2.125.1558
   Sone H, 1996, BIOCHEM BIOPH RES CO, V221, P193, DOI 10.1006/bbrc.1996.0568
   Stecyk JAW, 2004, SCIENCE, V306, P77, DOI 10.1126/science.1100763
   Stern L, 2004, ANN INTERN MED, V140, P778, DOI 10.7326/0003-4819-140-10-200405180-00007
   Steven J, 2002, DIABETES CARE, V25, P1715, DOI 10.2337/diacare.25.10.1715
   Stevens M. J., 1997, Diabetologia, V40, pA491
   Stevens MJ, 1999, AM J PHYSIOL-ENDOC M, V277, pE760, DOI 10.1152/ajpendo.1999.277.4.E760
   STEVENS MJ, 1997, CLIN MANAGEMENT DIAB, P13
   Stitt Alan W., 2000, Molecular Cell Biology Research Communications, V3, P380, DOI 10.1006/mcbr.2000.0243
   Stitt AW, 1999, BIOCHEM BIOPH RES CO, V256, P549, DOI 10.1006/bbrc.1999.0291
   Stitt AW, 2005, ANN NY ACAD SCI, V1043, P582, DOI 10.1196/annals.1338.066
   Stitt AW, 2005, DIABETES, V54, P785, DOI 10.2337/diabetes.54.3.785
   Stitt AW, 2004, DIABETOLOGIA, V47, P1735, DOI 10.1007/s00125-004-1523-3
   Stitt AW, 2001, BRIT J OPHTHALMOL, V85, P746, DOI 10.1136/bjo.85.6.746
   Stitt AW, 1997, AM J PATHOL, V150, P523
   Strauss O, 2005, PHYSIOL REV, V85, P845, DOI 10.1152/physrev.00021.2004
   STUDER RK, 1993, DIABETES, V42, P118, DOI 10.2337/diabetes.42.1.118
   Sugiyama S, 1998, J AM SOC NEPHROL, V9, P1681
   Sun Q, 2010, ARCH INTERN MED, V170, P961, DOI 10.1001/archinternmed.2010.109
   Sun X M, 2001, Sheng Wu Gong Cheng Xue Bao, V17, P698
   Suzuki H, 2005, METABOLISM, V54, P1593, DOI 10.1016/j.metabol.2005.06.006
   Suzuma K, 2000, J BIOL CHEM, V275, P40725, DOI 10.1074/jbc.M006509200
   Swamy-Mruthinti S, 2002, CURR EYE RES, V25, P139, DOI 10.1076/ceyr.25.3.139.13480
   SWINBURN BA, 1991, J CLIN ENDOCR METAB, V73, P156, DOI 10.1210/jcem-73-1-156
   Szweda PA, 2003, AGEING RES REV, V2, P383, DOI 10.1016/S1568-1637(03)00028-X
   Tabaton M, 1997, NEUROREPORT, V8, P907, DOI 10.1097/00001756-199703030-00018
   TAI MM, 1991, AM J CLIN NUTR, V54, P783, DOI 10.1093/ajcn/54.5.783
   Takahashi A, 2004, BRAIN RES BULL, V62, P497, DOI 10.1016/j.brainresbull.2003.07.009
   Takeuchi M, 2008, CURR PHARM DESIGN, V14, P973, DOI 10.2174/138161208784139693
   Tan JSL, 2007, OPHTHALMOLOGY, V114, P1143, DOI 10.1016/j.ophtha.2006.09.033
   Tanimoto K, 2000, EMBO J, V19, P4298, DOI 10.1093/emboj/19.16.4298
   Taylor CT, 2008, J PHYSIOL-LONDON, V586, P4055, DOI 10.1113/jphysiol.2008.157669
   Terman A, 2007, J PATHOL, V211, P134, DOI 10.1002/path.2094
   Tessier F, 1999, J BIOL CHEM, V274, P20796, DOI 10.1074/jbc.274.30.20796
   Thangarajah H, 2010, CELL CYCLE, V9, P75, DOI 10.4161/cc.9.1.10371
   Thangarajah H, 2009, P NATL ACAD SCI USA, V106, P13505, DOI 10.1073/pnas.0906670106
   Thiel VE, 2001, ANTIOXID REDOX SIGN, V3, P273, DOI 10.1089/152308601300185223
   Thomas D, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006296.pub2
   Thomas DD, 2008, FREE RADICAL BIO MED, V45, P18, DOI 10.1016/j.freeradbiomed.2008.03.020
   THORNALLEY PJ, 1993, MOL ASPECTS MED, V14, P287, DOI 10.1016/0098-2997(93)90002-U
   Thornalley PJ, 2003, BIOCHEM SOC T, V31, P1372, DOI 10.1042/BST0311372
   Thornalley PJ, 1999, BIOCHEM J, V344, P109, DOI 10.1042/0264-6021:3440109
   Thorpe SR, 2003, AMINO ACIDS, V25, P275, DOI 10.1007/s00726-003-0017-9
   To C H, 1998, Yan Ke Xue Bao, V14, P126
   Tomany SC, 2004, OPHTHALMOLOGY, V111, P1280, DOI 10.1016/j.ophtha.2003.11.010
   Topouzis F, 2009, BRIT J OPHTHALMOL, V93, P1037, DOI 10.1136/bjo.2008.146316
   Treins C, 2001, J BIOL CHEM, V276, P43836, DOI 10.1074/jbc.M106534200
   TRUMPOWER BL, 1990, J BIOL CHEM, V265, P11409
   Tumosa N, 2008, CLIN GERIATR MED, V24, P515, DOI 10.1016/j.cger.2008.03.002
   TURNER RC, 1991, DIABETOLOGIA, V34, P877
   Turner RC, 1998, LANCET, V352, P854, DOI 10.1016/s0140-6736(98)07037-8
   YANNUZZI LA, 1992, ARCH OPHTHALMOL-CHIC, V110, P1701
   Centers for Disease Control and Prevention (CDC), 2004, MMWR Morb Mortal Wkly Rep, V53, P80
   Tuomilehto J, 2001, NEW ENGL J MED, V344, P1343, DOI 10.1056/NEJM200105033441801
   van Bakel MME, 2009, J NUTR, V139, P568, DOI 10.3945/jn.108.097121
   van Dam RM, 2000, EUR J CLIN NUTR, V54, P726, DOI 10.1038/sj.ejcn.1601086
   van Uden P, 2008, BIOCHEM J, V412, P477, DOI 10.1042/BJ20080476
   Vega-Lopez S, 2009, CURR DIABETES REP, V9, P379, DOI 10.1007/s11892-009-0059-9
   Venn BJ, 2007, EUR J CLIN NUTR, V61, pS122, DOI 10.1038/sj.ejcn.1602942
   Vilchis C, 1996, NEUROCHEM INT, V28, P213, DOI 10.1016/0197-0186(95)00068-2
   Villegas R, 2007, ARCH INTERN MED, V167, P2310, DOI 10.1001/archinte.167.21.2310
   Vincent JA, 2007, DIABETES, V56, P224, DOI 10.2337/db06-0427
   VINORES SA, 1993, HISTOCHEM J, V25, P648, DOI 10.1007/BF00157879
   VINORES SA, 1993, EXP EYE RES, V57, P723, DOI 10.1006/exer.1993.1180
   VINORES SA, 1989, EXP EYE RES, V49, P495, DOI 10.1016/0014-4835(89)90057-2
   VINORES SA, 1988, DIABETES, V37, P1658, DOI 10.2337/diabetes.37.12.1658
   VLASSARA H, 1995, MOL MED, V1, P634, DOI 10.1007/BF03401604
   Vlassara H, 2001, DIABETES-METAB RES, V17, P436, DOI 10.1002/dmrr.233
   VLASSARA H, 1988, SCIENCE, V240, P1546, DOI 10.1126/science.3259727
   Vordermark D, 2005, CANCER LETT, V230, P122, DOI 10.1016/j.canlet.2004.12.040
   Wagner Z, 2001, AM J KIDNEY DIS, V38, P785, DOI 10.1053/ajkd.2001.27695
   WALLACE DC, 1992, ANNU REV BIOCHEM, V61, P1175, DOI 10.1146/annurev.bi.61.070192.005523
   Wang AL, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004160
   Wang DT, 2010, J IMMUNOL, V184, P582, DOI 10.4049/jimmunol.0902352
   WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510
   Wang XQ, 2009, AM J OPHTHALMOL, V148, P883, DOI 10.1016/j.ajo.2009.07.007
   Wang Z, 2007, MOL CELL PROTEOMICS, V6, P1365, DOI 10.1074/mcp.M600453-MCP200
   WARBURG O, 1956, SCIENCE, V123, P309, DOI 10.1126/science.123.3191.309
   Watanabe D, 2005, NEW ENGL J MED, V353, P782, DOI 10.1056/NEJMoa041773
   Watkinson S, 2008, Nurs Stand, V22, P51
   WATKINSON S, 2008, NURS STAND, V22, P58
   Wautier JL, 2004, CIRC RES, V95, P233, DOI 10.1161/01.RES.0000137876.28454.64
   Willett W, 2002, AM J CLIN NUTR, V76, p274S, DOI 10.1093/ajcn/76.1.274S
   Williams R, 2004, EYE, V18, P963, DOI 10.1038/sj.eye.6701476
   WILLIAMSON JR, 1993, DIABETES, V42, P801, DOI 10.2337/diabetes.42.6.801
   WILSON TM, 1973, EXP EYE RES, V16, P421, DOI 10.1016/0014-4835(73)90099-7
   Wolever T M, 1990, World Rev Nutr Diet, V62, P120
   Wolever TMS, 2008, DIABETOLOGIA, V51, P1607, DOI 10.1007/s00125-008-1093-x
   Wolever TMS, 2008, AM J CLIN NUTR, V87, p247S, DOI 10.1093/ajcn/87.1.247S
   Wolever TMS, 2008, AM J CLIN NUTR, V87, P114, DOI 10.1093/ajcn/87.1.114
   Wolever TMS, 2003, EUR J CLIN NUTR, V57, P475, DOI 10.1038/sj.ejcn.1601551
   Wolever TMS, 1996, J NUTR, V126, P2807
   WOLEVER TMS, 1988, AM J CLIN NUTR, V48, P1041, DOI 10.1093/ajcn/48.4.1041
   WOLEVER TMS, 1995, DIABETES CARE, V18, P962, DOI 10.2337/diacare.18.7.962
   Wolever TMS, 2002, BRIT J NUTR, V87, P477, DOI 10.1079/BJN2002568
   WOLEVER TMS, 1994, AM J CLIN NUTR, V59, P1265, DOI 10.1093/ajcn/59.6.1265
   WOLEVER TMS, 1986, AM J CLIN NUTR, V43, P167, DOI 10.1093/ajcn/43.1.167
   WOLEVER TMS, 1992, DIABETIC MED, V9, P451, DOI 10.1111/j.1464-5491.1992.tb01816.x
   WOLEVER TMS, 1985, DIABETES CARE, V8, P418, DOI 10.2337/diacare.8.5.418
   WOLEVER TMS, 1992, DIABETES CARE, V15, P562, DOI 10.2337/diacare.15.4.562
   Wood JPM, 2001, ARCH OPHTHALMOL-CHIC, V119, P81
   Xi X, 2005, BIOCHEM BIOPH RES CO, V326, P548, DOI 10.1016/j.bbrc.2004.11.064
   XIA P, 1994, DIABETES, V43, P1122, DOI 10.2337/diabetes.43.9.1122
   Xiao Qing, 2006, J Huazhong Univ Sci Technolog Med Sci, V26, P463, DOI 10.1007/s11596-006-0422-x
   Yamada Y, 2006, EXP EYE RES, V82, P840, DOI 10.1016/j.exer.2005.10.005
   Yamagishi S, 2002, BIOCHEM BIOPH RES CO, V290, P973, DOI 10.1006/bbrc.2001.6312
   Yamagishi S, 1999, BIOCHEM BIOPH RES CO, V258, P353, DOI 10.1006/bbrc.1999.0625
   Yamagishi S, 2008, CURR PHARM DESIGN, V14, P962, DOI 10.2174/138161208784139729
   Yamaguchi M, 1998, DIABETIC MED, V15, P458, DOI 10.1002/(SICI)1096-9136(199806)15:6<458::AID-DIA601>3.0.CO;2-Q
   Yan SF, 2007, CURR MOL MED, V7, P699
   Yang P, 2007, INVEST OPHTH VIS SCI, V48, P3341, DOI 10.1167/iovs.06-1340
   Yao DC, 2010, DIABETES, V59, P249, DOI 10.2337/db09-0801
   Yao Yi, 2003, Zhonghua Yi Xue Za Zhi, V83, P1989
   Yego ECK, 2010, J BIOL CHEM, V285, P3181, DOI 10.1074/jbc.M109.083907
   Yin DZ, 1996, FREE RADICAL BIO MED, V21, P871, DOI 10.1016/0891-5849(96)00175-X
   YOUNG RW, 1969, J CELL BIOL, V42, P392, DOI 10.1083/jcb.42.2.392
   Young TA, 2005, EXP EYE RES, V80, P651, DOI 10.1016/j.exer.2004.11.015
   Yu RK, 2004, J LIPID RES, V45, P783, DOI 10.1194/jlr.R3000020-JLR200
   Yuan G, 2008, J CELL PHYSIOL, V217, P674, DOI 10.1002/jcp.21537
   ZADUNAISKY JA, 1976, EXP EYE RES, V23, P191, DOI 10.1016/0014-4835(76)90202-5
   Zeng GC, 2008, CURR DRUG TARGETS, V9, P317, DOI 10.2174/138945008783954925
   Zhang CL, 2006, DIABETES CARE, V29, P2223, DOI 10.2337/dc06-0266
   Zhang HF, 2008, J BIOL CHEM, V283, P10892, DOI 10.1074/jbc.M800102200
   Zhang P, 2007, OPHTHALMOLOGICA, V221, P411, DOI 10.1159/000107502
   Zhang XY, 2008, INVEST OPHTH VIS SCI, V49, P3622, DOI 10.1167/iovs.07-1559
   Zhou J, 2003, MOL BIOL CELL, V14, P2216, DOI 10.1091/mbc.E02-09-0598
   Zhou JL, 2005, EXP EYE RES, V80, P567, DOI 10.1016/j.exer.2004.11.009
NR 575
TC 97
Z9 102
U1 2
U2 21
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 1350-9462
EI 1873-1635
J9 PROG RETIN EYE RES
JI Prog. Retin. Eye Res.
PD JAN
PY 2011
VL 30
IS 1
BP 18
EP 53
DI 10.1016/j.preteyeres.2010.09.001
PG 36
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 710WQ
UT WOS:000286548100002
PM 20868767
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Holfinger, S
   Miller, AG
   Rao, LJ
   Rowland, DY
   Hornik, JH
   Miller, DG
AF Holfinger, Steven
   Miller, Alexander G.
   Rao, Llewelyn J.
   Rowland, Douglas Y.
   Hornik, Joan H.
   Miller, David G.
TI Effect of Regulatory Requirement for Patient-Specific Prescriptions for
   Off-label Medications on the Use of Intravitreal Bevacizumab
SO JAMA OPHTHALMOLOGY
LA English
DT Article
ID COST-EFFECTIVENESS; RANIBIZUMAB; AFLIBERCEPT; SAFETY
AB IMPORTANCE Requirements regulating pharmaceutical prescriptions can affect physicians' choice of therapy in a clinical setting.
   OBJECTIVE To evaluate the change in bevacizumab use after the regulatory requirement for patient-specific prescriptions (PSPs) for off-label medications in Ohio.
   DESIGN, SETTING, AND PARTICIPANTS This study retrospectively reviewed the aggregate data from the billing records of patients receiving 1.25-mg injections of bevacizumab, 0.3-or 0.5-mg injections of ranibizumab, or 2.0-mg injections of aflibercept for age-related macular degeneration or diabetic macular edema in a 9-member retinal specialty private practice. The review assessed 4488 intravitreal injections in the 3-month period before (May 1 to July 30, 2012) and 5253 injections in the 3-month period after (May 1 to July 30, 2013) the Ohio Board of Pharmacy's requirement of PSPs for bevacizumab. Relative proportions of the drugs used for intravitreal injections were calculated and frequencies were compared. A Likert scale survey was conducted among the 9 physicians to identify reasons for their change in prescription of bevacizumab. The survey inquired about (1) the burden of PSPs, (2) concern about differences in efficacy, and (3) concern about differences in safety.
   MAIN OUTCOMES AND MEASURES Difference in drug use before and after the PSP requirement for bevacizumab and the physicians' reasons for change in their drug use.
   RESULTS Bevacizumab use decreased from 2752 of 4488 pre-PSP injections (61.3%) to 1503 of 5253 post-PSP injections (28.6%), a change of -32.7%(95% CI, -34.6% to -30.8%; P < .001). Use of 0.5-mg ranibizumab injections increased from 1122 of 4488 pre-PSP injections (25.0%) to 1838 of 5253 post-PSP injections (35.0%), a change of 10.0%(95% CI, 8.2% to 11.8%; P < .001). Use of 0.3-mg ranibizumab injections increased from 0 of 4488 (before US Food and Drug Administration approval) to 429 of 5253 post-PSP injections (8.2%), a change of 8.2%(95% CI, 7.4% to 8.9%; P < .001). Use of aflibercept injections increased from 614 of 4488 pre-PSP injections (13.7%) to 1483 of 5253 post-PSP injections (28.2%), a change of 14.6%(95% CI, 13.0%-16.1%; P < .001). In the survey of the 9 physicians concerning their reasons for decreased use of bevacizumab, 7 (78%) strongly agreed and 1 (11%) agreed that the burden of PSPs changed their choice of drug used for injection.
   CONCLUSIONS AND RELEVANCE Use of bevacizumab was reduced by 32.7% 1 year after the regulatory requirement for PSPs for compounded (repackaged) medications. This change seemed to have more association with the requirement for PSPs than with a known change in efficacy or safety concerns. Although this study was based on a single US practice, regulation of repackaged medication for safety concerns should also consider the evaluation of treatment burden, cost, and adherence.
C1 [Holfinger, Steven] Riverside Methodist Hosp, Columbus, OH 43214 USA.
   [Miller, Alexander G.; Rao, Llewelyn J.; Hornik, Joan H.; Miller, David G.] Retina Associates Cleveland, 3401 Enterprise Pkwy,Ste 300, Cleveland, OH 44122 USA.
   [Rowland, Douglas Y.] DY Rowland Associates, Cleveland Hts, OH USA.
   [Rowland, Douglas Y.] Case Western Reserve Univ, Sch Med, Dept Epidemiol & Biostat, Cleveland, OH 44106 USA.
C3 Retina Associates of Cleveland, Inc.; Case Western Reserve University
RP Miller, DG (通讯作者)，Retina Associates Cleveland, 3401 Enterprise Pkwy,Ste 300, Cleveland, OH 44122 USA.
EM retina@retina-assoc.com
RI Holfinger, Steven/AAI-4629-2021
OI Holfinger, Steven/0000-0002-2851-9504
CR [Anonymous], 2015, DRUGS COMP DIR ADM P
   [Anonymous], 2006, PRIOR NDA BLA APPR 2
   [Anonymous], 2013, HR 3204
   [Anonymous], FEE SCHED REIMB B
   Braithwaite T, 2014, COCHRANE DB SYST REV, V5
   Dugel PU, 2013, RETINA TIMES, V31, P24
   Elshout M, 2014, GRAEF ARCH CLIN EXP, V252, P1911, DOI 10.1007/s00417-014-2641-3
   Fung AE, 2006, BRIT J OPHTHALMOL, V90, P1344, DOI 10.1136/bjo.2006.099598
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Moja L, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD011230.pub2
   Pershing S, 2014, ANN INTERN MED, V160, P18, DOI 10.7326/M13-0768
   Regeneron, 2014, EYLEA AFL INJ REC FD
   Rich RM, 2006, RETINA-J RET VIT DIS, V26, P495, DOI 10.1097/01.iae.0000225766.75009.3a
   Solomon SD, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005139.pub3
   Stein JD, 2014, OPHTHALMOLOGY, V121, P936, DOI 10.1016/j.ophtha.2013.10.037
   Stein JD, 2013, OPHTHALMOLOGY, V120, P1835, DOI 10.1016/j.ophtha.2013.02.002
   Thomas M, 2013, CLIN OPHTHALMOL, V7, P495, DOI 10.2147/OPTH.S29974
   Thompson JT, 2013, RETINA TIMES, V31, P7
   Virgili G, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007419.pub4
NR 19
TC 6
Z9 6
U1 0
U2 0
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 2168-6165
EI 2168-6173
J9 JAMA OPHTHALMOL
JI JAMA Ophthalmol.
PD JAN
PY 2016
VL 134
IS 1
BP 45
EP 48
DI 10.1001/jamaophthalmol.2015.4331
PG 4
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA DH1IS
UT WOS:000372538200013
PM 26540671
OA Bronze
DA 2022-11-30
ER

PT J
AU Johnson, EJ
   Vishwanathan, R
   Rasmussen, HM
   Lang, JC
AF Johnson, Elizabeth J.
   Vishwanathan, Rohini
   Rasmussen, Helen M.
   Lang, John C.
TI Bioavailability of AREDS1 micronutrients from softgel capsules and
   tablets: a pilot study
SO MOLECULAR VISION
LA English
DT Article
ID BLOOD IONIZED CALCIUM; SERUM ZINC; MACULAR DEGENERATION;
   CIRCADIAN-RHYTHMS; DRUG RELEASE; EYE DISEASE; ABSORPTION; CAROTENOIDS;
   HUMANS; WOMEN
AB Purpose: The benefits of antioxidant micronutrients in slowing progression to advanced stages of age-related macular degeneration (AMD) was supported by the 4/day tablet form investigated in the Age-related Eye Disease Study 1 (AREDS1) and the 2/day softgel form in the Age-related Eye Disease Study 2 (AREDS2). However, the choices of excipient, dosage form, and ingredient chemistry as well as the patient physiologies and pathologies can influence bioavailability and efficacy. The objective of the study was to explore the influence of dosage form on the bioavailability of the five primary AREDS1 and Tier-2 AREDS2 micronutrients: the metals zinc and copper, beta-carotene, and vitamins E and C. The intent was to establish by chemical analysis the relative bioavailabilities of these five micronutrients in plasma, or serum for the metals, as well as to identify any opportunities for improvements.
   Methods: A total of 15 healthy men (5) and women (10) were recruited for a controlled, randomized, three-arm, crossover trial of the AREDS1 micronutrients. The study investigated responses in bioabsorption to a single dose of either four tablets or two softgels at the full dose level, or one softgel at the half-dose level. The bioavailability of each micronutrient was based on the pharmacokinetic profiles established through 15 samplings for each ingredient/dosage form in plasma/serum over the course of one week.
   Results: Bioavailability was estimated using model-independent and model-dependent procedures. A statistical advantage of the dosage form was observed in only two cases from the exaggerated effects using the half-dose softgel and for the tablet dosage form for beta-carotene and vitamin E. An unanticipated complexity was suggested by the bimodal absorption of zinc. For these micronutrients, no disadvantage (though potential advantage) was inferred for the water-soluble components presented in a softgel formulation. Increased fractional absorption was observed for the smaller dose (one capsule versus two), but it was not sufficient to reach the level achieved by the full dose of either four tablets or two softgels. A model-dependent analysis permitted an estimation of the percentage of micronutrients absorbed, with zinc, the single most important ingredient, absorbed at about a 10% level.
   Conclusions: The results suggest modestly contradictory requirements in the dosage form for water-soluble and lipid-soluble ingredients, as based on a goal of improved bioavailability. Comparative consistency in bioavailability was observed across dosage forms, and most nutrients between AREDS1 and AREDS2 (full dose) formulations relative to the significant variations observed within this controlled population. The results emphasize the importance of defining the requisite bioavailability of each micronutrient and the influence of the dosage form that provides it. With the recognition of global and population-specific micronutrient deficiencies, notably in the elderly populations afflicted with AMD and their significant metabolic and health consequences, establishing efficient means of supplementation are of continuing epidemiologic interest.
C1 [Johnson, Elizabeth J.; Vishwanathan, Rohini; Rasmussen, Helen M.] Tufts Univ, Jean Mayer USDA Human Nutr Res Ctr Aging, Boston, MA 02111 USA.
   [Lang, John C.] Univ Texas Arlington, Dept Chem & Biochem, Arlington, TX 76019 USA.
C3 Tufts University; United States Department of Agriculture (USDA);
   University of Texas System; University of Texas Arlington
RP Lang, JC (通讯作者)，Univ Texas Arlington, Dept Chem & Biochem, CRB 311, Arlington, TX 76019 USA.
EM jclangj66@gmail.com
FU US Department of Agriculture grant [1950-512000-073]; Alcon Research Ltd
FX This research was supported by a US Department of Agriculture grant
   (1950-512000-073). The authors thank Alcon Research Ltd for partial
   support of this research. The authors thank the women and men who
   participated in this study, the staff of Metabolic Research Unit and the
   Nutrition Evaluation Laboratory at the Nutrition Center, and the study
   physician, Dr. Joel Mason. The authors' responsibilities were as
   follows: HMR performed the blinded randomization and was responsible for
   the design of the dietary intervention; EJJ and RV acquired the data;
   JCL and RV analyzed the data and performed the statistical analysis;
   EJJ, RV, and JCL drafted the manuscript; EJJ and JCL share primary
   responsibility for final content. All authors were involved in the study
   concept and design and in the revision of the manuscript. None of the
   authors had a financial disclosure.
CR Abrams SA, 2013, AM J CLIN NUTR, V98, P1373, DOI 10.3945/ajcn.113.076489
   Benezeth P, 2002, J SOLUTION CHEM, V31, P947, DOI 10.1023/A:1021866025627
   BIERER TL, 1995, J NUTR, V125, P1569
   BLOCK G, 1986, AM J EPIDEMIOL, V124, P453, DOI 10.1093/oxfordjournals.aje.a114416
   BLOCK G, 1993, HHHQ DIETSYS ANAL SO
   BRESKIN MW, 1983, AM J CLIN NUTR, V38, P943, DOI 10.1093/ajcn/38.6.943
   Chew EY, 2013, JAMA-J AM MED ASSOC, V309, P2005, DOI 10.1001/jama.2013.4997
   Danis RP, 2013, INVEST OPHTH VIS SCI, V54, P4548, DOI 10.1167/iovs.13-11804
   EMES JH, 1975, P SOC EXP BIOL MED, V148, P86, DOI 10.3181/00379727-148-38481
   Ervin RB, 1999, VITAL HLTH STAT, V11, p[i, 1]
   EVANS DF, 1988, GUT, V29, P1035, DOI 10.1136/gut.29.8.1035
   EVERALL NC, 1989, J FISH BIOL, V35, P881, DOI 10.1111/j.1095-8649.1989.tb03039.x
   Ferris FL, 2005, ARCH OPHTHALMOL-CHIC, V123, P1570
   Garg S, 2012, ARCH INTERN MED, V172, P1677, DOI 10.1001/archinternmed.2012.4372
   Gibaldi M., 1982, PHARMACOKINETICS, V2nd ed., P409
   IoMPoD Antioxidants, 2000, ANT IOMPOD COMP R DI
   ISHIDA M, 1983, SCAND J CLIN LAB INV, V43, P83
   Johnson EJ, 2000, AM J CLIN NUTR, V71, P1555
   Kankanahalli S, 2013, INVEST OPHTH VIS SCI, V54, P1789, DOI 10.1167/iovs.12-10928
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Klein EA, 2011, JAMA-J AM MED ASSOC, V306, P1549, DOI 10.1001/jama.2011.1437
   LEE W, 1982, CLIN CHEM, V28, P2165
   Lindfield G. R, 2012, NUMERICAL METHODS US
   LUCAS M, 1983, GUT, V24, P734, DOI 10.1136/gut.24.8.734
   MAHE S, 1992, AM J CLIN NUTR, V56, P410, DOI 10.1093/ajcn/56.2.410
   MARKOWITZ H, 1955, J CLIN INVEST, V34, P1498, DOI 10.1172/JCI103201
   MARKOWITZ M, 1981, SCIENCE, V213, P672, DOI 10.1126/science.7256269
   MARKOWITZ ME, 1985, AM J CLIN NUTR, V41, P689, DOI 10.1093/ajcn/41.4.689
   MELDRUM SJ, 1972, BRIT MED J, V2, P104
   MELIA CD, 1989, ALIMENT PHARM THERAP, V3, P513
   MELIA CD, 1989, ALIMENT PHARM THERAP, V3, P223
   Meydani SN, 2007, AM J CLIN NUTR, V86, P1167, DOI 10.1093/ajcn/86.4.1167
   Meyers KJ, 2014, INVEST OPHTH VIS SCI, V55, P587, DOI 10.1167/iovs.13-13216
   Meyers KJ, 2013, INVEST OPHTH VIS SCI, V54, P2333, DOI [10.1167/iovs.12-10867, 10.1167/iovs.13-13216]
   Mursu J, 2011, ARCH INTERN MED, V171, P1625, DOI 10.1001/archinternmed.2011.445
   NEVE J, 1992, BIOL TRACE ELEM RES, V32, P201, DOI 10.1007/BF02784604
   Palmer D.A., 2004, P 14 INT C PROP WAT, P491
   Palmer DA, 2000, TRANSPORT CHEM COPPE
   Prasad AS, 2013, ADV NUTR, V4, P176, DOI 10.3945/an.112.003210
   PRASAD AS, 1993, J TRACE ELEM EXP MED, V6, P109
   Rajkumar S, 2013, INVEST OPHTH VIS SCI, V54, P6224, DOI 10.1167/iovs.13-11935
   Roe JH, 1943, J BIOL CHEM, V147, P399
   ROE JOSEPH H., 1942, SCIENCE, V95, P77, DOI 10.1126/science.95.2455.77
   Soinio M, 2007, DIABETES CARE, V30, P523, DOI 10.2337/dc06-1682
   Spence B, 2008, ENV SERIES
   Taylor A, 2012, MOL ASPECTS MED, V33, P291, DOI 10.1016/j.mam.2012.04.002
   TURNLUND JR, 1989, AM J CLIN NUTR, V49, P870, DOI 10.1093/ajcn/49.5.870
   Unlu NZ, 2005, J NUTR, V135, P431, DOI 10.1093/jn/135.3.431
NR 48
TC 5
Z9 5
U1 0
U2 7
PU MOLECULAR VISION
PI ATLANTA
PA C/O JEFF BOATRIGHT, LAB B, 5500 EMORY EYE CENTER, 1327 CLIFTON RD, N E,
   ATLANTA, GA 30322 USA
SN 1090-0535
J9 MOL VIS
JI Mol. Vis.
PD SEP 11
PY 2014
VL 20
BP 1228
EP 1242
PG 15
WC Biochemistry & Molecular Biology; Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Ophthalmology
GA AP3KZ
UT WOS:000341976200001
PM 25352732
DA 2022-11-30
ER

PT J
AU Li, J
   Lan, BF
   Li, XL
   Sun, SM
   Lu, P
   Cheng, LY
AF Li, Jie
   Lan, Bifei
   Li, Xiaoli
   Sun, Shumao
   Lu, Ping
   Cheng, Lingyun
TI Effect of intraocular pressure (IOP) and choroidal circulation on
   controlled episcleral drug delivery to retina/vitreous
SO JOURNAL OF CONTROLLED RELEASE
LA English
DT Article
DE Intraocular pressure; Choroidal circulation; Episcleral-controlled
   release of triamcinolone; Transscleral drug delivery; Episcleral
   drug-film
ID DIABETIC MACULAR EDEMA; INTRAVITREAL TRIAMCINOLONE ACETONIDE; HUMAN
   SCLERAL PERMEABILITY; SUBTENON TRIAMCINOLONE; TRANSSCLERAL DELIVERY;
   THERAPEUTIC APPROACH; SUSTAINED-RELEASE; ETHYLENE-OXIDE; CLINICAL-TRIAL;
   RISK-FACTORS
AB Transscleral drug delivery may become a safe alternative to the intravitreal injection for chronic retinal diseases such as age-related macular degeneration or diabetic macular edema. However, the drug delivered onto the sclera subjects to vigorous clearance by episcleral and choroidal circulation; in addition, the penetration from episclera to retina needs to overcome counter-directional ocular fluid current driven by intraocular pressure (IOP) as well as unfavorable drug disposition exerted by drug transporters before the drug reach retina. It is imperative to understand these processes and quantitate their influence for efficient designing of a sustained formulation or device to achieve efficient transscleral drug delivery. The current study was focused on the effects of intraocular pressure (IOP) and choroidal circulation on transscleral drug delivery using triamcinolone acetonide (TA) as a model drug. Rabbit eye IOP was modulated through cannulation in ex vivo study or through cryopexy of ciliary body in vivo studies before subtenon TA injection or episcleral TA-film implantation. In a subgroup of the rabbit eyes, localized choroid atrophy was induced by cryopexy before TA-film implantation. Each condition had a concurrent control group. The vitreous TA concentration was quantitated by ultra-performance liquid chromatography coupled with tandem mass spectrometry (UPLC/MS/MS). The vitreous TA concentration was compared between the study and control groups for effect of IOP or choroid circulation. For ex vivo studies, higher IOP was a significant effect against TA penetration from episclera towards vitreous. TA was 8.5 +/- 5 ng/mL in receptor chamber with a cross pressure of 50 mm Hg versus 15.9 +/- 10 ng/mL with the cross pressure of 5 mm Hg; p = 0.001, t-test. A multivariate regression demonstrated each mm Hg of IOP increase would result in 3 ng/mL lower concentration in the receptor chamber. Similar IOP effect was also identified in a 3-hour study using euthanized rabbit eyes whose IOP was controlled at 10 or 40 mm Hg by cannulation (3261 +/- 1821 ng/mL vs. 755 +/- 763 ng/mL; p = 0.013, Wilcoxon test). However, the effect of IOP was not significant in alive animal with the same IOP setting. In vivo chronic study using low IOP (7.7 mm Hg) versus normal IOP (14.4 mm Hg), vitreous TA was not statistically significant (154 +/- 200 ng/mL vs. 80 +/- 130 ng/mL, p = 0.17, Wilcoxon test). However, removing of choroidal circulation by local cryopexy significantly enhanced the TA penetration from episclera to vitreous (mean 163 +/- 129.8 ng/mL for choroidal cryopexy vs. 81.8 +/- 37.2 ng/mL for ciliary cryopexy or 75.5 +/- 36 ng/mL for control group, p = 0.007, regression analysis). In conclusion, the effect of IOP on transscleral drug delivery was not a significant effect in alive rabbit eyes; however, choroidal circulation seems to be a significant effect to affect TA penetration from episclera towards retina and vitreous. (C) 2016 Elsevier B.V. All rights reserved.
C1 [Li, Jie; Lan, Bifei; Li, Xiaoli; Sun, Shumao; Lu, Ping; Cheng, Lingyun] Wenzhou Med Univ, Inst Ocular Pharmacol, Sch Ophthalmol & Optometry, 270 Xueyuan Rd, Wenzhou 325027, Zhejiang, Peoples R China.
   [Li, Jie] Fuyang Peoples Hosp, Dept Ophthalmol, Fuyang 236000, Anhui, Peoples R China.
   [Lan, Bifei] Ningbo Eye Hosp, Ningbo 315040, Zhejiang, Peoples R China.
   [Cheng, Lingyun] Univ Calif San Diego, Jacobs Retina Ctr, Dept Ophthalmol, Shiley Eye Inst, 9415 Campus Point Dr, La Jolla, CA 92037 USA.
C3 Wenzhou Medical University; University of California System; University
   of California San Diego
RP Cheng, LY (通讯作者)，Wenzhou Med Coll, Inst Ocular Pharmacol, Sch Ophthalmol & Optometry, 270 Xueyuan Rd, Wenzhou 325027, Zhejiang, Peoples R China.
EM l1cheng@ucsd.edu
RI Li, Xiaoli/GYQ-7384-2022
FU National Natural Science Foundation of China [31271022]
FX National Natural Science Foundation of China, grant no. 31271022.
CR Amrite AC, 2008, MOL VIS, V14, P150
   Aref AA, 2015, JAMA OPHTHALMOL, V133, P1022, DOI 10.1001/jamaophthalmol.2015.1823
   Armentano I, 2010, POLYM DEGRAD STABIL, V95, P2126, DOI 10.1016/j.polymdegradstab.2010.06.007
   Balachandran RK, 2008, PHARM RES-DORDR, V25, P2685, DOI 10.1007/s11095-008-9691-3
   Blondeau P, 2001, J GLAUCOMA, V10, P18, DOI 10.1097/00061198-200102000-00005
   Bucolo C, 2015, J OCUL PHARMACOL TH, V31, P228, DOI 10.1089/jop.2014.0094
   Chan JE, 2010, EXP EYE RES, V90, P501, DOI 10.1016/j.exer.2010.01.001
   Chen H, 2013, INVEST OPHTH VIS SCI, V54, P2178, DOI 10.1167/iovs.12-11460
   Chew E, 2007, OPHTHALMOLOGY, V114, P1190, DOI 10.1016/j.ophtha.2007.02.010
   Cruysberg LPJ, 2005, INVEST OPHTH VIS SCI, V46, P3790, DOI 10.1167/iovs.04-1414
   Cruysberg LPJ, 2002, J OCUL PHARMACOL TH, V18, P559, DOI 10.1089/108076802321021108
   D'Amico DJ, 2004, INVEST OPHTH VIS SCI, V45, pU924
   Day S, 2011, AM J OPHTHALMOL, V152, P266, DOI 10.1016/j.ajo.2011.01.053
   Du WN, 2013, J OCUL PHARMACOL TH, V29, P633, DOI 10.1089/jop.2012.0226
   Geroski DH, 2001, ADV DRUG DELIVER REV, V52, P37, DOI 10.1016/S0169-409X(01)00193-4
   Gillies MC, 2014, OPHTHALMOLOGY, V121, P2473, DOI 10.1016/j.ophtha.2014.07.002
   Hooper KA, 1997, J APPL POLYM SCI, V63, P1499, DOI 10.1002/(SICI)1097-4628(19970314)63:11<1499::AID-APP12>3.0.CO;2-Y
   Ibrahim MA, 2015, TRANSL VIS SCI TECHN, V4, DOI 10.1167/tvst.4.2.4
   Khurana RN, 2014, OPHTHALMOLOGY, V121, P67, DOI 10.1016/j.ophtha.2013.06.033
   Kim H, 2004, INVEST OPHTH VIS SCI, V45, P2722, DOI 10.1167/iovs.04-0091
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Krispel C, 2013, WORLD J DIABETES, V4, P310, DOI 10.4239/wjd.v4.i6.310
   Lee SB, 2004, EXP EYE RES, V78, P599, DOI 10.1016/S0014-4835(03)00211-2
   Lee SJ, 2008, INVEST OPHTH VIS SCI, V49, P4506, DOI 10.1167/iovs.08-1989
   Li SK, 2004, PHARM RES-DORDR, V21, P2175, DOI 10.1007/s11095-004-7669-3
   Li YL, 2012, RETINA-J RET VIT DIS, V32, P364, DOI 10.1097/IAE.0b013e31821e1f7c
   Liu XL, 2012, RETINA-J RET VIT DIS, V32, P1838, DOI 10.1097/IAE.0b013e31824fd384
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Meng YC, 2014, ACTA BIOMATER, V10, P126, DOI 10.1016/j.actbio.2013.09.022
   Nan KH, 2010, BRIT J OPHTHALMOL, V94, P654, DOI 10.1136/bjo.2009.172106
   Nuutinen JP, 2002, J BIOMAT SCI-POLYM E, V13, P1325, DOI 10.1163/15685620260449723
   OLSEN TW, 1995, INVEST OPHTH VIS SCI, V36, P1893
   Osaadon P, 2014, EYE, V28, P510, DOI 10.1038/eye.2014.13
   Petrou PA, 2015, INVEST OPHTH VIS SCI, V56, P330, DOI 10.1167/iovs.14-15877
   Ranta VP, 2010, J CONTROL RELEASE, V148, P42, DOI 10.1016/j.jconrel.2010.08.028
   Robinson MR, 2006, EXP EYE RES, V82, P479, DOI 10.1016/j.exer.2005.08.007
   Rudnick DE, 1999, INVEST OPHTH VIS SCI, V40, P3054
   Shen L., 2015, ACTA OPHTHALMOL
   Shen LJ, 2015, OPHTHALMOLOGY, V122, P649, DOI 10.1016/j.ophtha.2014.09.027
   Silva PS, 2009, OCUL IMMUNOL INFLAMM, V17, P216, DOI 10.1080/09273940802687838
   Sohn HJ, 2011, AM J OPHTHALMOL, V152, P686, DOI 10.1016/j.ajo.2011.03.033
   Sun SM, 2016, ACTA BIOMATER, V37, P143, DOI 10.1016/j.actbio.2016.04.014
   Vigil EM, 2015, J OPHTHALMIC INFLAMM, V5, DOI 10.1186/s12348-015-0044-1
   Weijtens O, 1997, AM J OPHTHALMOL, V123, P358, DOI 10.1016/S0002-9394(14)70131-X
   Weiner AL, 2010, VET OPHTHALMOL, V13, P395, DOI 10.1111/j.1463-5224.2010.00835.x
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Yang Q, 2011, VET OPHTHALMOL, V14, P353, DOI 10.1111/j.1463-5224.2011.00881.x
NR 47
TC 8
Z9 8
U1 0
U2 8
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0168-3659
EI 1873-4995
J9 J CONTROL RELEASE
JI J. Control. Release
PD DEC 10
PY 2016
VL 243
BP 78
EP 85
DI 10.1016/j.jconrel.2016.10.001
PG 8
WC Chemistry, Multidisciplinary; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Chemistry; Pharmacology & Pharmacy
GA EI2BB
UT WOS:000392290000007
PM 27717742
DA 2022-11-30
ER

PT J
AU Elbaz-Hayoun, S
   Rinsky, B
   Hagbi-Levi, S
   Grunin, M
   HayaYedid, T
   Chowers, I
AF Elbaz-Hayoun, Sarah
   Rinsky, Batya
   Hagbi-Levi, Shira
   Grunin, Michelle
   HayaYedid, Tammy
   Chowers, Itay
TI Evaluation of antioxidant treatments for the modulation of macrophage
   function in the context of retinal degeneration
SO MOLECULAR VISION
LA English
DT Article
ID PERIPHERAL-BLOOD MONOCYTES; PHOTORECEPTOR DEGENERATION; OXIDATIVE
   STRESS; M2 MACROPHAGES; BETA-CAROTENE; CARNOSIC ACID; ACTIVATION;
   POLARIZATION; DAMAGE; CELLS
AB Purpose: Oxidative stress and macrophages have been implicated in the pathogenesis of atrophic and neovascular age-related macular degeneration (aAMD and nvAMD). It is unclear whether oxidative injury mediates macrophage involvement in AMD. We aimed to investigate the effect of antioxidant treatments on human monocyte-derived macrophages (hMDMs) from patients with AMD in models for the disease.
   Methods: Four antioxidant treatments were evaluated (G1: lutein + zeaxanthin, G2: lutein + zeaxanthin and zinc, G3: lutein + zeaxanthin, zinc, Lyc-O-Mato, and carnosic acid, G4: lutein + zeaxanthin, carnosic acid, and beta-carotene, G5: olive oil as vehicle control). The compounds were added to the culture medium of M1 (interferon-gamma [IFN-gamma] and lipopolysaccharide [LPS]) and M2a (interleukin-13 [IL-13] and IL-4) hMDMs from patients with AMD (n=7 and n=8, respectively). Mouse choroidal tissue was cultured with supernatants from treated M1/M2a hMDMs, to evaluate the effect of treatments on the angiogenic properties of macrophages with choroidal sprouting assay (CSA). Mouse retinal explants were cultured with treated hMDMs for 18 h, and evaluated for photoreceptor apoptosis using terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) labeling. Adult BALB/c mice (n=8) were exposed to 8,000 lux bright light for 3 h, and treated orally with antioxidant supplements for 7 days that preceded light injury and following it. Oxidative stress was assessed using an anti-4 hydroxynonenal (4-HNE) antibody. Retinal function and the thickness of the outer nuclear layer were evaluated with electroretinography (ERG) and histological analysis, respectively.
   Results: The G3 treatment reduced M2a hMDMs-associated sprouting in the CSA compared to the untreated group (n=7, -1.52-fold, p=0.05). Conversely, the G2 treatment was associated with an increased neurotoxic effect of M2a hMDMs in the retinal explant assay compared to the control group (n=7, 1.37-fold, p=0.047), as well as compared to the G3 treatment group (1.46-fold, p=0.01). The G4 treatment was also associated with increased cytotoxicity compared to the control group (1.48-fold, p=0.004), and compared to the G3 treatment group (1.58-fold, p=0.001). In the in vivo light damage model, mice (n=8) supplemented with G2, G3, and G4 had decreased levels of oxidative injury assessed using 4-HNE labeling (-2.32-fold, -2.17-fold, and -2.18-fold, respectively, p<0.05 for all comparisons). None of the treatments were associated with reduced photoreceptor cell loss, as shown with histology and ERG.
   Conclusions: Antioxidant treatment modulates M2a hMDMs at the functional level. In particular, we found that the G3 combination has a beneficial effect on M2a macrophages in reducing their angiogenic and neurotoxic capacity ex vivo. In addition, antioxidant treatments considerably reduced the oxidative stress level in light-damaged retinas. Further research is required to assess whether such therapies may curb macrophage-driven photoreceptor loss and neovascularization in AMD.
C1 [Elbaz-Hayoun, Sarah; Rinsky, Batya; Hagbi-Levi, Shira; Grunin, Michelle; HayaYedid, Tammy; Chowers, Itay] Hadassah Hebrew Univ, Dept Ophthalmol, Med Ctr, POB 12000, IL-91120 Jerusalem, Israel.
   [Elbaz-Hayoun, Sarah; Rinsky, Batya; Hagbi-Levi, Shira; Grunin, Michelle; HayaYedid, Tammy; Chowers, Itay] Hebrew Univ Jerusalem, Hadassah Sch Med, Jerusalem, Israel.
C3 Hebrew University of Jerusalem; Hadassah University Medical Center;
   Hebrew University of Jerusalem
RP Chowers, I (通讯作者)，Hadassah Hebrew Univ, Dept Ophthalmol, Med Ctr, POB 12000, IL-91120 Jerusalem, Israel.
EM chowers@hadassah.org.il
RI Grunin, Michelle/O-6044-2019
OI Grunin, Michelle/0000-0002-3155-2858
FU Hadassah Medical Center [22-03.08.07]; Hadassah-France
FX The research was supported by a generous research grant from
   Hadassah-France. Experimental protocols and for the study involving
   human subjects were approved by the local committee on Research
   Involving Human Subjects of the Hadassah Medical Center (File
   #22-03.08.07). All patients and controls signed informed consent forms
   that adhered to the tenets of the Declaration of Helsinki before
   participating in the study. Ethical approval for all protocols involving
   animals were obtained by the Authority for Biologic and Biomedical
   Models (ABBM) and the University Ethics Committee for the Care and Use
   of Laboratory Animals in Hebrew University, which is certified by the
   Association for Assessment and Accreditation of Laboratory Animal Care
   (AAALAC; ethical approval number: MD-15-14240-4, NIH approval number:
   OPRR-A01-5011). All researchers working with laboratory animals
   underwent approval by the ethics committee of the ABBM to allow them to
   ethically work with laboratory animals. All guidelines with regards to
   human and ethical treatment of laboratory animals (from ARVO) were
   followed.
CR Allavena P, 1998, EUR J IMMUNOL, V28, P359, DOI 10.1002/(SICI)1521-4141(199801)28:01<359::AID-IMMU359>3.0.CO;2-4
   Ambati J, 2012, NEURON, V75, P26, DOI 10.1016/j.neuron.2012.06.018
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Bouhlel MA, 2007, CELL METAB, V6, P137, DOI 10.1016/j.cmet.2007.06.010
   Cai JY, 2000, PROG RETIN EYE RES, V19, P205, DOI 10.1016/S1350-9462(99)00009-9
   Chang B, 2013, INVEST OPHTH VIS SCI, V54, P4974, DOI 10.1167/iovs.13-12289
   Chew EY, 2014, JAMA OPHTHALMOL, V132, P142, DOI 10.1001/jamaophthalmol.2013.7376
   Collins TJ, 2007, BIOTECHNIQUES, V43, P25, DOI 10.2144/000112517
   Cruz-Guilloty F, 2013, INT J INFLAMM, V2013, DOI 10.1155/2013/503725
   Gelinas L, 2011, J RENIN-ANGIO-ALDO S, V12, P295, DOI 10.1177/1470320310391332
   Grimm Christian, 2013, Methods Mol Biol, V935, P87, DOI 10.1007/978-1-62703-080-9_6
   Grunin M, 2012, INVEST OPHTH VIS SCI, V53, P5292, DOI 10.1167/iovs.11-9165
   Hadad N, 2012, FREE RADICAL BIO MED, V53, P1381, DOI 10.1016/j.freeradbiomed.2012.07.078
   Hagbi-Levi S, 2017, NEUROBIOL AGING, V51, P71, DOI 10.1016/j.neurobiolaging.2016.11.018
   Jiao HH, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0143952
   Jonas JB, 2010, ARCH OPHTHALMOL-CHIC, V128, P1281, DOI 10.1001/archophthalmol.2010.227
   Kaarniranta K, 2009, J MOL MED, V87, P117, DOI 10.1007/s00109-008-0418-z
   Kamoshita M, 2016, SCI REP-UK, V6, DOI 10.1038/srep30226
   Kassoff A, 1999, CONTROL CLIN TRIALS, V20, P573
   Khandhadia S, 2010, EXPERT REV MOL MED, V12, DOI 10.1017/S146239941000164X
   Lowe GM, 1999, FREE RADICAL RES, V30, P141, DOI 10.1080/10715769900300151
   Mantovani A, 2004, TRENDS IMMUNOL, V25, P677, DOI 10.1016/j.it.2004.09.015
   Mantovani A, 2002, TRENDS IMMUNOL, V23, P549, DOI 10.1016/S1471-4906(02)02302-5
   Martinez Fernando O, 2014, F1000Prime Rep, V6, P13, DOI 10.12703/P6-13
   Martinez Fernando O, 2009, J Biol, V8, P99, DOI 10.1186/jbiol206
   Martinez FO, 2008, FRONT BIOSCI-LANDMRK, V13, P453, DOI 10.2741/2692
   Mattapallil MJ, 2012, INVEST OPHTH VIS SCI, V53, P2921, DOI 10.1167/iovs.12-9662
   Mills CD, 2012, CRIT REV IMMUNOL, V32, P463, DOI 10.1615/CritRevImmunol.v32.i6.10
   Ni YQ, 2008, INVEST OPHTH VIS SCI, V49, P2589, DOI 10.1167/iovs.07-1173
   PATEL M, 2008, SEMIN IMMUNOPATHOL, P35
   Pelegrin P, 2009, EMBO J, V28, P2114, DOI 10.1038/emboj.2009.163
   PENFOLD P, 1984, AUST J OPHTHALMOL, V12, P23
   Penfold PL, 2001, PROG RETIN EYE RES, V20, P385, DOI 10.1016/S1350-9462(00)00025-2
   Rezaie T, 2012, INVEST OPHTH VIS SCI, V53, P7847, DOI 10.1167/iovs.12-10793
   Rinsky B, 2017, MOL VIS, V23, P889
   SARKS SH, 1980, T OPHTHAL SOC UK, V100, P414
   Sasaki M, 2012, J NUTR BIOCHEM, V23, P423, DOI 10.1016/j.jnutbio.2011.01.006
   Sennlaub F, 2013, EMBO MOL MED, V5, P1775, DOI 10.1002/emmm.201302692
   Shao A, 2006, REGUL TOXICOL PHARM, V45, P289, DOI 10.1016/j.yrtph.2006.05.007
   Shao Z, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069552
   Sica A, 2014, HEPATOLOGY, V59, P2034, DOI 10.1002/hep.26754
   Wenzel A, 2003, INVEST OPHTH VIS SCI, V44, P2798, DOI 10.1167/iovs.02-1134
   Winkler B S, 1999, Mol Vis, V5, P32
   Zhang M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035446
NR 44
TC 3
Z9 3
U1 0
U2 2
PU MOLECULAR VISION
PI ATLANTA
PA C/O JEFF BOATRIGHT, LAB B, 5500 EMORY EYE CENTER, 1327 CLIFTON RD, N E,
   ATLANTA, GA 30322 USA
SN 1090-0535
J9 MOL VIS
JI Mol. Vis.
PD SEP 5
PY 2019
VL 25
BP 479
EP 488
PG 10
WC Biochemistry & Molecular Biology; Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Ophthalmology
GA IX9CY
UT WOS:000485986100001
PM 31588172
DA 2022-11-30
ER

PT J
AU Gouras, P
   Brown, K
   Ivert, L
   Neuringer, M
AF Gouras, Peter
   Brown, Kristy
   Ivert, Lena
   Neuringer, Martha
TI A novel melano-lysosome in the retinal epithelium of rhesus monkeys
SO EXPERIMENTAL EYE RESEARCH
LA English
DT Article
DE retinal pigment epithelium; melanosomes; lysosomes; phagosomes; rhesus
   monkeys; age related macular degeneration
ID PIGMENT EPITHELIUM; MACULAR DEGENERATION; HUMAN RPE; DRUSENOID
   MACULOPATHY; LIPOFUSCIN; CELLS; AGE; DEGRADATION; PHAGOCYTOSIS;
   PATHOGENESIS
AB The large phagocytic load that confronts the retinal pigment epithelium (RPE) is thought to play a possible role in the pathogenesis of age related macular degeneration (AMD) that afflicts both humans and monkeys. Our knowledge of how RPE degrades phagosomes and other intra-cellular material by lysosomal action is still rudimentary. In this paper we examine organelles that play a role in this process, melanosome, lysosomes and phagosomes, in the RPE of young and old rhesus monkeys in order to better understand lysosomal autophagy and heterophagy in the RPE and its possible role in AMD.
   We used electron microscopy to detect and describe the characteristics of melanosomes and lysosome-like organelles in the macular RPE of rhesus monkeys (Macaca mulatto) that were 1, 6, 24, 24, 26 and 35 years of age. The measurements include the number, shape and size of these organelles located in the basal, middle and apical regions of RPE cells. Phaagosomes were also examined but not counted or measured for size or shape because of their rarity.
   Melanosomes were homogeneously dark with a circular or elliptical shape and decreased in number with age. Smaller melanosomes were more common at the basal side of the RPE. Among the small melanosomes, we found an organelle that was losing melanin in varying degrees; in some cases was nearly devoid of melanin. Because of the melanin loss, we considered this organelle to be a unique type of autophagic melano-lysosome, which we called a Type 1 lysosome. We found another organelle, more canonically lysosomal, which we called a Type 2 lysosome. This organelle was composed of a light matrix containing melanosomes in various stages of degradation. Type 2 lysosomes without melanosomes were rare. Type 2 lysosomes increased while Type 1 decreased in number with age. Phagosomes were rare in both young and old monkeys. They made close contact with Type 2 lysosomes which we considered responsible for their degradation.
   Melanosomes are being lost from monkey RPE with age. Much of this loss is carried out by two types of lysosomes. One, not defined as unique before, appears to be autophagic in digesting its own melanin; it has been called a Type 1 lysosome. The other, a more canonical lysosome, is both heterophagic in digesting phagosomes and autophagic in digesting local melanosomes; it has been called a Type 2 lysosome. Type 1 lysosomes decrease while type 2 lysosomes increase with age. The loss of melanin is considered to be detrimental to the RPE since it reduces melanin's protective action against light toxicity and oxidative stress. Phagosomes appear to be degraded by membrane contacts with Type 2 lysosomes. The loss of melanin and the buildup of Type 2 lysosomes occur at an earlier age in monkeys than humans implying that a greater vulnerability to senescence accelerates the rate of AMD in monkeys. (C) 2011 Elsevier Ltd. All rights reserved.
C1 [Gouras, Peter] Columbia Univ, Dept Ophthalmol, New York, NY 10032 USA.
   [Brown, Kristy] Columbia Univ, Dept Pathol, New York, NY 10032 USA.
   [Ivert, Lena] St Erik Eye Hosp, Stockholm, Sweden.
   [Neuringer, Martha] Oregon Hlth & Sci Univ, Div Neurosci, Oregon Natl Primate Res Ctr, Beaverton, OR 97006 USA.
C3 Columbia University; Columbia University; Oregon Health & Science
   University; Oregon National Primate Research Center
RP Gouras, P (通讯作者)，Columbia Univ, Dept Ophthalmol, 630 W 168th St, New York, NY 10032 USA.
EM pg10@columbia.edu
FU NEI [EY015293, RR00163]; Foundation Fighting Blindness; Research to
   Prevent Blindness Inc.; NATIONAL CENTER FOR RESEARCH RESOURCES
   [P51RR000163, K01RR000163] Funding Source: NIH RePORTER; NATIONAL EYE
   INSTITUTE [R01EY015293] Funding Source: NIH RePORTER
FX We were supported by NEI grants EY015293 and RR00163, the Foundation
   Fighting Blindness and Research to Prevent Blindness Inc.
CR Bergmann M, 2004, FASEB J, V18, P562, DOI 10.1096/fj.03-0289fje
   BOSCH E, 1993, J HISTOCHEM CYTOCHEM, V41, P253, DOI 10.1177/41.2.8419462
   BRANDES D, 1969, J GERONTOL, V24, P55, DOI 10.1093/geronj/24.1.55
   Burke JM, 1998, INVEST OPHTH VIS SCI, V39, P1478
   Damek-Poprawa M, 2009, J BIOL CHEM, V284, P10877, DOI 10.1074/jbc.M808857200
   DIMENT S, 1995, J BIOL CHEM, V270, P4213, DOI 10.1074/jbc.270.9.4213
   FEENEY L, 1978, INVEST OPHTH VIS SCI, V17, P583
   FEENEYBURNS L, 1984, INVEST OPHTH VIS SCI, V25, P195
   Finnemann SC, 2002, P NATL ACAD SCI USA, V99, P3842, DOI 10.1073/pnas.052025899
   Gouras P, 2008, GRAEF ARCH CLIN EXP, V246, P1395, DOI 10.1007/s00417-008-0910-8
   Gouras P, 2008, GRAEF ARCH CLIN EXP, V246, P1403, DOI 10.1007/s00417-008-0911-7
   Gouras P, 2010, GRAEF ARCH CLIN EXP, V248, P973, DOI 10.1007/s00417-010-1325-x
   Hogan MJ, 1971, HISTOLOGY HUMAN EYE
   Kim I T, 1998, Korean J Ophthalmol, V12, P85
   Lopes VS, 2007, MOL BIOL CELL, V18, P3914, DOI 10.1091/mbc.E07-03-0268
   ORLOW SJ, 1995, J INVEST DERMATOL, V105, P3, DOI 10.1111/1523-1747.ep12312291
   Radu RA, 2004, P NATL ACAD SCI USA, V101, P5928, DOI 10.1073/pnas.0308302101
   Sarangarajan R, 2005, MOL VIS, V11, P482
   Sarna T, 2003, EXP EYE RES, V76, P89, DOI 10.1016/S0014-4835(02)00247-6
   SCHMIDT SY, 1986, INVEST OPHTH VIS SCI, V27, P1063
   Schraermeyer U, 1999, EXP EYE RES, V68, P237, DOI 10.1006/exer.1998.0596
   Schutt F, 2001, OPHTHALMOLOGE, V98, P721, DOI 10.1007/s003470170078
   Schutt F, 2000, INVEST OPHTH VIS SCI, V41, P2303
   Sparrow JR, 2005, EXP EYE RES, V80, P595, DOI 10.1016/j.exer.2005.01.007
   Strauss O, 2005, PHYSIOL REV, V85, P845, DOI 10.1152/physrev.00021.2004
   Sundelin SP, 2001, FREE RADICAL BIO MED, V30, P74, DOI 10.1016/S0891-5849(00)00444-5
   Wasmeier C, 2008, J CELL SCI, V121, P3995, DOI 10.1242/jcs.040667
   WEITER JJ, 1986, INVEST OPHTH VIS SCI, V27, P145
   Yin DZ, 1996, FREE RADICAL BIO MED, V21, P871, DOI 10.1016/0891-5849(96)00175-X
NR 29
TC 14
Z9 14
U1 0
U2 7
PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 0014-4835
J9 EXP EYE RES
JI Exp. Eye Res.
PD DEC
PY 2011
VL 93
IS 6
BP 937
EP 946
DI 10.1016/j.exer.2011.10.011
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 859UZ
UT WOS:000297902600019
PM 22056912
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Foreman, J
   Xie, J
   Keel, S
   Ang, GS
   Lee, PY
   Bourne, R
   Crowston, JG
   Taylor, HR
   Dirani, M
AF Foreman, Joshua
   Xie, Jing
   Keel, Stuart
   Ang, Ghee Soon
   Lee, Pei Ying
   Bourne, Rupert
   Crowston, Jonathan G.
   Taylor, Hugh R.
   Dirani, Mohamed
TI Prevalence and Causes of Unilateral Vision Impairment and Unilateral
   Blindness in Australia The National Eye Health Survey
SO JAMA OPHTHALMOLOGY
LA English
DT Article
ID BLUE MOUNTAINS EYE; QUALITY-OF-LIFE; VISUAL IMPAIRMENT; INDIGENOUS
   AUSTRALIANS; DIABETIC-RETINOPATHY; GLOBAL COST; POPULATION; CATARACT;
   GLAUCOMA; ROADMAP
AB IMPORTANCE This study determines the prevalence of unilateral vision impairment (VI) and unilateral blindness to assist in policy formulation for eye health care services.
   OBJECTIVE To determine the prevalence and causes of unilateral VI and unilateral blindness in Australia.
   DESIGN, SETTING, AND PARTICIPANTS This cross-sectional population-based survey was conducted from March 2015 to April 2016 at 30 randomly selected sites across all strata of geographic remoteness in Australia. A total of 1738 indigenous Australians 40 years or older and 3098 nonindigenous Australians 50 years or older were included.
   MAIN OUTCOMES AND MEASURES The prevalence and causes of unilateral vision impairment and blindness, defined as presenting visual acuity worse than 6/12 and 6/60, respectively, in the worse eye, and 6/12 or better in the better eye.
   RESULTS Of the 1738 indigenous Australians, mean (SD) age was 55.0 (10.0) years, and 1024 participants (58.9%) were female. Among the 3098 nonindigenous Australians, mean (SD) age was 66.6 (9.7) years, and 1661 participants (53.6%) were female. The weighted prevalence of unilateral VI in indigenous Australians was 12.5%(95% CI, 11.0%-14.2%) and the prevalence of unilateral blindness was 2.4%(95% CI, 1.7%-3.3%), respectively. In nonindigenous Australians, the prevalence of unilateral VI was 14.6%(95% CI, 13.1%-16.3%) and unilateral blindness was found in 1.4%(95% CI, 1.0%-1.8%). The age-adjusted and sex-adjusted prevalence of unilateral vision loss was higher in indigenous Australians than nonindigenous Australians (VI: 18.7% vs 14.5%; P = .02; blindness: 2.9% vs 1.3%; P = .02). Risk factors for unilateral vision loss included older age (odds ratio [OR], 1.60 for each decade of age for indigenous Australians; 95% CI, 1.39-1.86; OR, 1.65 per decade for nonindigenous Australians; 95% CI, 1.38-1.96), very remote residence (OR, 1.65; 95% CI, 1.01-2.74) and self-reported diabetes (OR, 1.52; 95% CI, 1.12-2.07) for indigenous Australians, and having not undergone an eye examination in the past 2 years for nonindigenous Australians (OR, 1.54; 95% CI, 1.04-2.27). Uncorrected refractive error and cataract were leading causes of unilateral VI in both populations (70%-75%). Corneal pathology (16.7%) and cataract (13.9%) were leading causes of unilateral blindness in indigenous Australians, while amblyopia (18.8%), trauma (16.7%), and age-related macular degeneration (10.4%) were major causes of unilateral blindness in nonindigenous Australians.
   CONCLUSIONS AND RELEVANCE Unilateral vision loss is prevalent in indigenous and nonindigenous Australians; however, most cases are avoidable. As those with unilateral vision loss caused by cataract and posterior segment diseases may be at great risk of progressing to bilateral blindness, national blindness prevention programs may benefit from prioritizing examination and treatment of those with unilateral vision loss.
C1 [Foreman, Joshua; Xie, Jing; Keel, Stuart; Ang, Ghee Soon; Lee, Pei Ying; Crowston, Jonathan G.; Dirani, Mohamed] Royal Victorian Eye & Ear Hosp, Ctr Eye Res Australia, Melbourne, Vic, Australia.
   [Foreman, Joshua; Xie, Jing; Keel, Stuart; Ang, Ghee Soon; Lee, Pei Ying; Crowston, Jonathan G.] Univ Melbourne, Dept Surg, Ophthalmol Sect, Melbourne, Vic, Australia.
   [Bourne, Rupert] Anglia Ruskin Univ, Postgrad Med Inst, Vis & Eye Res Unit, Cambridge, England.
   [Taylor, Hugh R.] Univ Melbourne, Melbourne Sch Populat & Global Hlth, Indigenous Eye Hlth Unit, Melbourne, Vic, Australia.
   [Dirani, Mohamed] Singapore Natl Eye Ctr, Singapore Eye Res Inst, Singapore, Singapore.
C3 Centre for Eye Research Australia; Royal Victorian Eye & Ear Hospital;
   University of Melbourne; Anglia Ruskin University; University of
   Melbourne; National University of Singapore; Singapore National Eye
   Center
RP Foreman, J (通讯作者)，Ctr Eye Res Australia, Level 7,32 Gisborne St, East Melbourne, Vic 3002, Australia.
EM foreman.j@unimelb.edu.au
RI xie, jing/GRY-1689-2022
OI /0000-0001-6694-3587
FU Department of Health of the Australian Government; Peggy and Leslie
   Cranbourne Foundation; Novartis Australia; National Health and Medical
   Research Council Career Development Fellowship [1090466]; Australian
   Postgraduate Award scholarship
FX The National Eye Health Survey was funded by the Department of Health of
   the Australian Government, and also received financial contributions
   from the Peggy and Leslie Cranbourne Foundation and Novartis Australia.
   In-kind support was received from our industry and sector partners,
   Optical Prescription Spectacle Makers (OPSM), Carl Zeiss, Designs for
   Vision, the Royal Flying Doctor Service, Optometry Australia and the
   Brien Holden Vision Institute. The Centre for Eye Research Australia
   receives Operational Infrastructure Support from the Victorian
   Government. The work is further supported by National Health and Medical
   Research Council Career Development Fellowship grant 1090466 (Dr Dirani)
   and Australian Postgraduate Award scholarship (Mr Foreman).
CR Anjou MD, 2013, CLIN EXP OPHTHALMOL, V41, P320, DOI 10.1111/j.1442-9071.2012.02886.x
   [Anonymous], 1981, Invest Ophthalmol Vis Sci, V21, P1
   Attebo K, 1996, OPHTHALMOLOGY, V103, P357
   Australian Bureau of Statistics, 2014, AUSTR STAT GEOGR STA
   Australian Institute of Health andWelfare, 2005, VIS PROBL AM OLD AUS, V27
   Bourne RRA, 2013, LANCET GLOB HEALTH, V1, pE339, DOI 10.1016/S2214-109X(13)70113-X
   Buch H, 2001, ACTA OPHTHALMOL SCAN, V79, P441, DOI 10.1034/j.1600-0420.2001.790503.x
   Chia EM, 2003, BRIT J OPHTHALMOL, V87, P392, DOI 10.1136/bjo.87.4.392
   Chua BE, 2004, EYE, V18, P765, DOI 10.1038/sj.eye.6701366
   Creedy J, 1993, Aust Econ Rev, P56
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Fielder AR, 1996, EYE, V10, P233, DOI 10.1038/eye.1996.51
   Foreman J., 2016, NATL EYE HLTH SURVEY
   Foreman J, NATL EYE HLTH SURVEY
   Foreman J, 2017, OPHTHALMOLOGY, V124, P1743, DOI 10.1016/j.ophtha.2017.06.001
   Foreman J, 2017, OPHTHAL EPIDEMIOL, V24, P353, DOI 10.1080/09286586.2017.1296166
   Foreman J, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0175353
   Fotouhi A, 2004, BRIT J OPHTHALMOL, V88, P740, DOI 10.1136/bjo.2003.031153
   Fricke TR, 2012, B WORLD HEALTH ORGAN, V90, P728, DOI 10.2471/BLT.12.104034
   Gunnlaugsdottir E, 2008, ACTA OPHTHALMOL, V86, P778, DOI 10.1111/j.1755-3768.2008.01191.x
   Keel S, 2017, OPHTHALMOLOGY, V124, P977, DOI 10.1016/j.ophtha.2017.02.004
   KEENEY AH, 1981, AM J OPHTHALMOL, V91, P801, DOI 10.1016/0002-9394(81)90020-9
   Kyari F, 2009, INVEST OPHTH VIS SCI, V50, P2033, DOI 10.1167/iovs.08-3133
   Laitinen A, 2005, OPHTHALMOLOGY, V112, P2227, DOI 10.1016/j.ophtha.2005.09.010
   Landers J, 2010, BRIT J OPHTHALMOL, V94, P1140, DOI 10.1136/bjo.2009.168146
   Lansingh VC, 2007, OPHTHALMOLOGY, V114, P1670, DOI 10.1016/j.ophtha.2006.12.013
   Magliano DJ, 2008, DIABETOLOGIA, V51, P2179, DOI 10.1007/s00125-008-1150-5
   Magliano DJ, 2009, AUST NZ J PUBL HEAL, V33, P540, DOI 10.1111/j.1753-6405.2009.00450.x
   Mohamed Q, 2007, JAMA-J AM MED ASSOC, V298, P902, DOI 10.1001/jama.298.8.902
   Mukesh BN, 2002, OPHTHALMOLOGY, V109, P1047, DOI 10.1016/S0161-6420(02)01040-0
   Newland H S, 1996, Ophthalmic Epidemiol, V3, P97, DOI 10.3109/09286589609080114
   NEWLAND HS, 1992, B WORLD HEALTH ORGAN, V70, P369
   Ngondi J, 2006, PLOS MED, V3, P2416, DOI 10.1371/journal.pmed.0030477
   Pascolini D, 2012, BRIT J OPHTHALMOL, V96, P614, DOI 10.1136/bjophthalmol-2011-300539
   Ramke J, 2007, BRIT J OPHTHALMOL, V91, P1117, DOI 10.1136/bjo.2006.106559
   Schemann JF, 2006, OPHTHAL EPIDEMIOL, V13, P219, DOI 10.1080/09286580600681347
   Stevens GA, 2013, OPHTHALMOLOGY, V120, P2377, DOI 10.1016/j.ophtha.2013.05.025
   Tapp RJ, 2013, DIABETIC MED, V30, P1145, DOI 10.1111/dme.12215
   Taylor H R, 2000, Trans Am Ophthalmol Soc, V98, P91
   Taylor HR, 2017, MED J AUSTRALIA, V206, P8, DOI 10.5694/mja16.00647
   Taylor HR, 2012, MED J AUSTRALIA, V197, P613, DOI 10.5694/mja12.10544
   Taylor HR, 2010, MED J AUSTRALIA, V192, P312, DOI 10.5694/j.1326-5377.2010.tb03529.x
   Turner AW, 2011, CLIN EXP OPHTHALMOL, V39, P344, DOI 10.1111/j.1442-9071.2010.02474.x
   Vijaya L, 2006, BRIT J OPHTHALMOL, V90, P407, DOI 10.1136/bjo.2005.081406
   Vu HTV, 2005, BRIT J OPHTHALMOL, V89, P360, DOI 10.1136/bjo.2004.047498
   Wang JJ, 2001, ARCH OPHTHALMOL-CHIC, V119, P1186, DOI 10.1001/archopht.119.8.1186
   Wang JJ, 2000, CLIN EXP OPHTHALMOL, V28, P268, DOI 10.1046/j.1442-9071.2000.00315.x
   Wilson M R, 1996, Ophthalmic Epidemiol, V3, P23, DOI 10.3109/09286589609071598
NR 48
TC 15
Z9 15
U1 0
U2 8
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 2168-6165
EI 2168-6173
J9 JAMA OPHTHALMOL
JI JAMA Ophthalmol.
PD MAR
PY 2018
VL 136
IS 3
BP 240
EP 248
DI 10.1001/jamaophthalmol.2017.6457
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA FY6TC
UT WOS:000426994200005
PM 29372249
OA Bronze, Green Published
DA 2022-11-30
ER

PT J
AU Frampton, GK
   Kalita, N
   Payne, L
   Colquitt, J
   Loveman, E
AF Frampton, Geoff K.
   Kalita, Neelam
   Payne, Liz
   Colquitt, Jill
   Loveman, Emma
TI Accuracy of fundus autofluorescence imaging for the diagnosis and
   monitoring of retinal conditions: a systematic review
SO HEALTH TECHNOLOGY ASSESSMENT
LA English
DT Review
ID CENTRAL SEROUS CHORIORETINOPATHY; CYSTOID MACULAR EDEMA; OPTICAL
   COHERENCE TOMOGRAPHY; GEOGRAPHIC-ATROPHY; RETICULAR PSEUDODRUSEN;
   RETINITIS-PIGMENTOSA; CHOROIDAL-NEOVASCULARIZATION; CLINICAL
   CHARACTERISTICS; DIABETIC-RETINOPATHY; PREDICTIVE FACTOR
AB Background: Natural fluorescence in the eye may be increased or decreased by diseases that affect the retina. Imaging methods based on confocal scanning laser ophthalmoscopy (cSLO) can detect this 'fundus autofluorescence' (FAF) by illuminating the retina using a specific light 'excitation wavelength'. FAF imaging could assist the diagnosis or monitoring of retinal conditions. However, the accuracy of the method for diagnosis or monitoring is unclear.
   Objective: To conduct a systematic review to determine the accuracy of FAF imaging using cSLO for the diagnosis or monitoring of retinal conditions, including monitoring of response to therapy.
   Data sources: Electronic bibliographic databases; scrutiny of reference lists of included studies and relevant systematic reviews; and searches of internet pages of relevant organisations, meetings and trial registries. Databases included MEDLINE, EMBASE, The Cochrane Library, Web of Science and the Medion database of diagnostic accuracy studies. Searches covered 1990 to November 2014 and were limited to the English language.
   Review methods: References were screened for relevance using prespecified inclusion criteria to capture a broad range of retinal conditions. Two reviewers assessed titles and abstracts independently. Full-text versions of relevant records were retrieved and screened by one reviewer and checked by a second. Data were extracted and critically appraised using the Quality Assessment of Diagnostic Accuracy Studies criteria (QUADAS) for assessing risk of bias in test accuracy studies by one reviewer and checked by a second. At all stages any reviewer disagreement was resolved through discussion or arbitration by a third reviewer.
   Results: Eight primary research studies have investigated the diagnostic accuracy of FAF imaging in retinal conditions: choroidal neovascularisation (one study), reticular pseudodrusen (three studies), cystoid macular oedema (two studies) and diabetic macular oedema (two studies). Sensitivity of FAF imaging using an excitation wavelength of 488 nm was generally high (range 81-100%), but was lower (55% and 32%) in two studies using longer excitation wavelengths (514 nm and 790 nm, respectively). Specificity ranged from 34% to 100%. However, owing to limitations of the data, none of the studies provide conclusive evidence of the diagnostic accuracy of FAF imaging.
   Limitations: No studies on the accuracy of FAF imaging for monitoring the progression of retinal conditions or response to therapy were identified. Owing to study heterogeneity, pooling of diagnostic outcomes in meta-analysis was not conducted. All included studies had high risk of bias. In most studies the patient spectrum was not reflective of those who would present in clinical practice and no studies adequately reported how FAF images were interpreted.
   Conclusions: Although already in use in clinical practice, it is unclear whether or not FAF imaging is accurate, and whether or not it is applied and interpreted consistently for the diagnosis and/or monitoring of retinal conditions. Well-designed prospective primary research studies, which conform to the paradigm of diagnostic test accuracy assessment, are required to investigate the accuracy of FAF imaging in diagnosis and monitoring of inherited retinal dystrophies, early age-related macular degeneration, geographic atrophy and central serous chorioretinopathy.
C1 [Frampton, Geoff K.; Kalita, Neelam; Payne, Liz] Univ Southampton, SHTAC, Southampton, Hants, England.
   [Colquitt, Jill; Loveman, Emma] Effect Evidence LLP, Eastleigh, England.
C3 University of Southampton
RP Frampton, GK (通讯作者)，Univ Southampton, SHTAC, Southampton, Hants, England.
EM G.K.Frampton@soton.ac.uk
RI Payne, Liz/AAZ-5506-2020; Frampton, Geoff/B-5818-2017
OI Payne, Liz/0000-0002-6594-5668; Frampton, Geoff/0000-0003-2005-0497;
   Kalita, Neelam/0000-0002-0973-0160; Loveman, Emma/0000-0001-8226-2634;
   Colquitt, Jillian Leigh/0000-0001-5962-2689
FU National Institute for Health Research Health Technology Assessment
   programme
FX The National Institute for Health Research Health Technology Assessment
   programme.
CR Adackapara CA, 2008, RETINA-J RET VIT DIS, V28, P103, DOI 10.1097/IAE.0b013e31809862aa
   Agange N, 2010, J OPHTHALMOL, V2010, DOI 10.1155/2010/690707
   Ahn SJ, 2013, JAMA OPHTHALMOL, V131, P880, DOI 10.1001/jamaophthalmol.2013.172
   Aizawa S, 2010, CLIN EXP OPHTHALMOL, V38, P597, DOI 10.1111/j.1442-9071.2010.02321.x
   Alfaro V, 2006, AGE RELATED MACULAR
   Alten F, 2015, BRIT J OPHTHALMOL, V99, P717, DOI 10.1136/bjophthalmol-2014-305339
   Asao K, 2014, RETINA-J RET VIT DIS, V34, P512, DOI 10.1097/IAE.0b013e31829f73eb
   Batioglu F, 2014, OPTOMETRY VISION SCI, V91, P950, DOI 10.1097/OPX.0000000000000321
   Bearelly S, 2010, ADV EXP MED BIOL, V664, P395, DOI 10.1007/978-1-4419-1399-9_45
   Bindewald A, 2005, INVEST OPHTH VIS SCI, V46, P3309, DOI 10.1167/iovs.04-0430
   Bindewald A, 2005, BRIT J OPHTHALMOL, V89, P874, DOI 10.1136/bjo.2004.057794
   Bossuyt, 2010, COCHRANE HDB SYSTEMA
   Bossuyt P., 2013, COCHRANE HDB SYSTEMA
   Bossuyt PM, 2006, BRIT MED J, V332, P1089, DOI 10.1136/bmj.332.7549.1089
   Bossuyt PM, 2003, ANN INTERN MED, V138, P40, DOI 10.7326/0003-4819-138-1-200301070-00010
   Boyle J, 2015, PSYCHOL HEALTH MED, V20, P296, DOI 10.1080/13548506.2014.936886
   BRESSLER NM, 1995, ARCH OPHTHALMOL-CHIC, V113, P301, DOI 10.1001/archopht.1995.01100030055022
   Brito PN, 2014, RETINA-J RET VIT DIS, V34, P273, DOI 10.1097/IAE.0b013e3182999a02
   Cachulo L, 2011, OPHTHALMOLOGICA, V225, P144, DOI 10.1159/000321064
   Centre for Reviews and Dissemination, 2009, SYSTEMATIC REVIEWS C
   Chakravarthy U, 2010, BMC OPHTHALMOL, V10, DOI 10.1186/1471-2415-10-31
   Cho H, 2009, J INFLAMM RES, V2, P37
   Chopdar A, 2003, BRIT MED J, V326, P485, DOI 10.1136/bmj.326.7387.485
   Clemens CR, 2014, RETINA-J RET VIT DIS, V34, P24, DOI 10.1097/IAE.0b013e3182947811
   Daiger SP, 2015, CSH PERSPECT MED, V5, DOI 10.1101/cshperspect.a017129
   Dandekar SS, 2005, ARCH OPHTHALMOL-CHIC, V123, P1507, DOI 10.1001/archopht.123.11.1507
   DELORI FC, 1994, APPL OPTICS, V33, P7439, DOI 10.1364/AO.33.007439
   Dinc UA, 2010, RETINA, V18, P12
   Fenwick EK, 2012, QUAL LIFE RES, V21, P1771, DOI 10.1007/s11136-012-0110-1
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Finger RP, 2014, OPHTHALMOLOGY, V121, P1252, DOI 10.1016/j.ophtha.2013.12.034
   Flahault A, 2005, J CLIN EPIDEMIOL, V58, P859, DOI 10.1016/j.jclinepi.2004.12.009
   Flynn MF, 2001, RETINA-J RET VIT DIS, V21, P639, DOI 10.1097/00006982-200112000-00012
   Framme C, 2005, ACTA OPHTHALMOL SCAN, V83, P161, DOI 10.1111/j.1600-0420.2005.00442.x
   Framme C, 2002, BRIT J OPHTHALMOL, V86, P1099, DOI 10.1136/bjo.86.10.1099
   Framme C, 2001, OPHTHALMIC SURG LAS, V32, P383
   Frank RN, 2004, NEW ENGL J MED, V350, P48, DOI 10.1056/NEJMra021678
   Fung A, 2012, CLIN EXP OPHTHALMOL, V40, P49
   Gemenetzi M, 2010, EYE, V24, P1743, DOI 10.1038/eye.2010.130
   Hajali M, 2009, EYE, V23, P915, DOI 10.1038/eye.2008.110
   Hamblion EL, 2012, BRIT J OPHTHALMOL, V96, P360, DOI 10.1136/bjo.2010.201178
   Hamel CP, 2007, ORPHANET J RARE DIS, V2, DOI 10.1186/1750-1172-2-7
   Hogg RE, 2014, OPHTHALMOLOGY, V121, P1748, DOI 10.1016/j.ophtha.2014.03.015
   Hogg RE, 2014, OPTOMETRY VISION SCI, V91, P854, DOI 10.1097/OPX.0000000000000287
   Holz FG, 2007, AM J OPHTHALMOL, V143, P463, DOI 10.1016/j.ajo.2006.11.041
   Holz FG, 2015, GRAEF ARCH CLIN EXP, V253, P7, DOI 10.1007/s00417-014-2858-1
   Ilginis T, 2014, BRIT MED BULL, V111, P77, DOI 10.1093/bmb/ldu022
   Jarc-Vidmar M, 2003, KLIN MONATSBL AUGENH, V220, P861
   Jeong YJ, 2014, EYE, V28, P209, DOI 10.1038/eye.2013.275
   Kellner S, 2014, BRIT J OPHTHALMOL, V98, P200, DOI 10.1136/bjophthalmol-2013-303897
   Kellner U, 2010, RETINA-J RET VIT DIS, V30, P6, DOI 10.1097/IAE.0b013e3181b8348b
   KLEIN R, 1994, ARCH OPHTHALMOL-CHIC, V112, P1217, DOI 10.1001/archopht.1994.01090210105023
   Knottnerus JA, 2002, BMJ-BRIT MED J, V324, P477, DOI 10.1136/bmj.324.7335.477
   Koyama M, 2004, OPHTHALMOLOGICA, V218, P107, DOI 10.1159/000076145
   Kumar N, 2013, OPHTHALMOLOGY, V120, P334, DOI 10.1016/j.ophtha.2012.07.076
   Laviers H, 2014, GRAEF ARCH CLIN EXP, V252, P1871, DOI 10.1007/s00417-014-2840-y
   Lee JY, 2013, INVEST OPHTH VIS SCI, V54, P7812, DOI 10.1167/iovs.13-12284
   Liegl R, 2014, OPHTHALMOLOGICA, V232, P65, DOI 10.1159/000360014
   Liew G, 2013, CLIN EXP OPHTHALMOL, V41, P201, DOI 10.1111/j.1442-9071.2012.02848.x
   Lois N, 2009, FUNDUS AUTOFLUORESCE
   McBain VA, 2008, BRIT J OPHTHALMOL, V92, P946, DOI 10.1136/bjo.2007.129957
   Mehta H, 2012, CLIN EXP OPHTHALMOL, V40, P49
   Mesquida M, 2014, RETINA-J RET VIT DIS, V34, P2121, DOI 10.1097/IAE.0000000000000197
   Michaelides M, 2006, SURV OPHTHALMOL, V51, P232, DOI 10.1016/j.survophthal.2006.02.007
   Minassian DC, 2012, BRIT J OPHTHALMOL, V96, P345, DOI 10.1136/bjo.2011.204040
   Moher D, 2009, BMJ-BRIT MED J, V339, DOI [10.1186/2046-4053-4-1, 10.1136/bmj.b2535, 10.1136/bmj.i4086]
   Moore T, 2008, GENETIC OPHTHALMOLOG
   Owen CG, 2012, BRIT J OPHTHALMOL, V96, P752, DOI 10.1136/bjophthalmol-2011-301109
   Owsley C, 2008, J VISUAL IMPAIR BLIN, V102, P621, DOI 10.1177/0145482X0810201007
   Ozmert E, 2009, OPHTHALMOLOGICA, V223, P263, DOI 10.1159/000210386
   Parodi MB, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006537.pub2
   Peng XJ, 2011, CHINESE MED J-PEKING, V124, P253, DOI 10.3760/cma.j.issn.0366-6999.2011.02.019
   Petrou PA, 2015, INVEST OPHTH VIS SCI, V56, P330, DOI 10.1167/iovs.14-15877
   Pilotto E, 2013, BRIT J OPHTHALMOL, V97, P622, DOI 10.1136/bjophthalmol-2012-302633
   Reeves BC, 2011, COCHRANE HANDBOOK FO
   Reitsma JB., 2009, COCHRANE HDB SYSTEMA
   Robson AG, 2012, INVEST OPHTH VIS SCI, V53, P6187, DOI 10.1167/iovs.12-10195
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   Rotsos TG, 2008, CLIN OPHTHALMOL, V2, P919
   Royal College of Ophthalmologists, 2010, INTERIM GUIDELINES F
   Saksens NTM, 2014, INVEST OPHTH VIS SCI, V55, P7085, DOI 10.1167/iovs.14-14659
   Salvatore S, 2013, SURV OPHTHALMOL, V58, P560, DOI 10.1016/j.survophthal.2012.11.006
   Schachar IH, 2013, JAMA OPHTHALMOL, V131, P1009, DOI 10.1001/jamaophthalmol.2013.4014
   Schmitz-Valckenberg S, 2008, RETINA-J RET VIT DIS, V28, P385, DOI 10.1097/IAE.0b013e318164a907
   Schmitz-Valckenberg S, 2006, INVEST OPHTH VIS SCI, V47, P2648, DOI 10.1167/iovs.05-0892
   Senra H, 2015, OPHTHALMOLOGY, V122, P851, DOI 10.1016/j.ophtha.2014.10.022
   Sepah YJ, 2014, SAUDI J OPHTHALMOL, V28, P111, DOI 10.1016/j.sjopt.2014.03.008
   Simader C, 2014, AM J OPHTHALMOL, V158, P557, DOI 10.1016/j.ajo.2014.05.026
   Sivaprasad S, 2012, COCHRANE DB SYST REV, V2
   Slade J, 2014, EYE HEALTH DATA SUMM
   Smith RT, 2006, INVEST OPHTH VIS SCI, V47, P5495, DOI 10.1167/iovs.05-1318
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Sohrab MA, 2011, INVEST OPHTH VIS SCI, V52, P5743, DOI 10.1167/iovs.10-6942
   Southampton Health Technology Assessments Centre (SHTAC), 2014, THE USE OF FUNDUS AU
   Testa F, 2014, OPHTHALMOLOGY, V121, P2399, DOI 10.1016/j.ophtha.2014.06.032
   The Royal College of Ophthalmologists, 2012, DIABETIC RETINOPATHY
   The Royal College of Ophthalmologists, 2013, AGE RELATED MACULAR
   Ueda-Arakawa N, 2013, RETINA-J RET VIT DIS, V33, P490, DOI 10.1097/IAE.0b013e318276e0ae
   Vaz F, 2014, GEOGRAPHIC ATROPHY
   Velez-Montoya R, 2013, RETINA-J RET VIT DIS, V33, P1487, DOI 10.1097/IAE.0b013e318271f265
   Viera AJ, 2005, FAM MED, V37, P360
   Virgili G, 2014, COCHRANE DB SYST REV, V10, DOI DOI 10.1002/14651858.CD007419.PUB4
   Virgili G, 2011, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD008081.pub2
   Viswanathan M, 2013, ASSESSING RISK OF BI
   Vujosevic S, 2012, ACTA OPHTHALMOL, V90, pe374, DOI 10.1111/j.1755-3768.2012.02410.x
   Vujosevic S, 2010, RETINA-J RET VIT DIS, V30, P908, DOI 10.1097/IAE.0b013e3181c96986
   Vukicevic M, 2012, CLIN EXP OPHTHALMOL, V40, P282, DOI 10.1111/j.1442-9071.2011.02638.x
   Waldstein SM, 2012, EYE, V26, P1078, DOI 10.1038/eye.2012.100
   Walia S, 2009, OPHTHALMIC GENET, V30, P63, DOI 10.1080/13816810802695550
   WEBB RH, 1987, APPL OPTICS, V26, P1492, DOI 10.1364/AO.26.001492
   Whiting Penny, 2003, BMC Med Res Methodol, V3, P25, DOI 10.1186/1471-2288-3-25
NR 111
TC 5
Z9 5
U1 3
U2 14
PU NIHR JOURNALS LIBRARY
PI SOUTHAMPTON
PA UNIV SOUTHAMPTON, EVALUATION, TRIALS & STUDIES COORDINATING CENTRE,
   ALPHA HOUSE, ENTERPRISE RD, SOUTHAMPTON, SO16 7NS, ENGLAND
SN 1366-5278
EI 2046-4924
J9 HEALTH TECHNOL ASSES
JI Health Technol. Assess.
PD APR
PY 2016
VL 20
IS 31
BP 1
EP +
DI 10.3310/hta20310
PG 109
WC Health Care Sciences & Services
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Health Care Sciences & Services
GA DK6DE
UT WOS:000375011300001
PM 27115052
OA Green Accepted, Green Published, gold
DA 2022-11-30
ER

PT J
AU Ozkaya, D
   Shu, XH
   Naziroglu, M
AF Ozkaya, Dilek
   Shu, Xinhua
   Naziroglu, Mustafa
TI Deletion of Mitochondrial Translocator Protein (TSPO) Gene Decreases
   Oxidative Retinal Pigment Epithelial Cell Death via Modulation of TRPM2
   Channel
SO BIOLOGY-BASEL
LA English
DT Article
DE ARPE19 cells; cell death; mitochondrial translocator protein;
   mitochondrial oxidative cytotoxicity; TRPM2 channel
ID ADP-RIBOSE; STRESS; ACTIVATION; RESPIRATION; METABOLISM; MECHANISMS;
   ARPE-19
AB Simple Summary
   18 kDa mitochondrial translocator protein (TSPO) is a mitochondria protein of the cellular outer membrane in the mitochondria of several cells, including ARPE19 is TSPO. Accumulating evince indicates that the presence of TSPO participated the modulations of Ca2+ homeostasis and mitochondrial free reactive oxygen species (fROS) generation. The deletion of TSPO gene provides to study the action of TSPO on the levels of apoptosis, ADP-ribose (ADPR), mitochondria-fROS (Mito-fROS), and apoptosis via the stimulation of Ca2+ permeable channels in the models of cell culture. The stimulations of oxidative stress and ADPR induce the activation of TRPM2 in the ARPE19. For clarifying the involvement of TSPO in retinal human diseases, we used the ARPE19 human cell culture model. The current results demonstrated that the deletion of TSPO induces the regulation of TRPM2 in the TSPO gene knockout ARPE19 (ARPE19-KO) In fact, the present results show that the presence of TSPO increased the upregulations of apoptosis and mitochondria oxidative cytotoxicity values via stimulation of TRPM2 in the ARPE19. Nevertheless, the blockages of PARP-1 (PJ34 and DPQ) and TRPM2 (2APB and ACA) downregulated the values of cell death and oxidative cytotoxicity in the ARPE19. In summary, present results clearly demonstrate that the deletion of TSPO decreases mitochondrial oxidative cytotoxicity-mediated cell death via the modulation of TRPM2 in the ARPE19.
   The current results indicated the possible protective actions of 18 kDa mitochondrial translocator protein (TSPO) deletion on TRPM2 stimulation, mitochondrial free ROS (Mito-fROS) and apoptotic harmful actions in the cells of adult retinal pigment epithelial19 (ARPE19). There was a direct relationship between TSPO and the disease of age-related macular degeneration. The nature of TSPO implicates upregulation of Mito-fROS and apoptosis via the activation of Ca2+ channels in ARPE19, although deletion of TSPO gene downregulates the activation. The decrease of oxidative cytotoxicity and apoptosis might induce in TSPO gene deleted cells by the inhibition of Mito-fROS and PARP-1 activation-induced TRPM2 cation channel activation. The ARPE19 cells were divided into two main groups as TSPO expressing (ARPE19) and non-expressing cells (ARPE19-KO). The levels of caspase -3 (Casp -3), caspase -9 (Casp -9), apoptosis, Mito-fROS, TRPM2 current and intracellular free Ca2+ were upregulated in the ARPE19 by the stimulations of H2O2 and ADP-ribose, although their levels were downregulated in the cells by the modulators of PARP-1 (DPQ and PJ34), TRPM2 (ACA and 2APB) and glutathione. However, the H2O2 and ADP-ribose-mediated increases were not observed in the ARPE19-KO. The expression levels of Bax, Casp -3, Casp -9 and PARP-1 were higher in the ARPE19 group as compared to the ARPE19-KO group. In summary, current results confirmed that TRPM2-mediated cell death and oxidative cytotoxicity in the ARPE19 cells were occurred by the presence of TSPO. The deletion of TSPO may be considered as a therapeutic way to TRPM2 activation-mediated retinal oxidative injury.
C1 [Ozkaya, Dilek] Suleyman Demirel Univ, Fac Med, Dept Ophthalmol, TR-32260 Isparta, Turkey.
   [Shu, Xinhua] Glasgow Caledonian Univ, Dept Biol & Biomed Sci, Glasgow G4 0BA, Lanark, Scotland.
   [Shu, Xinhua] Glasgow Caledonian Univ, Dept Vis Sci, Glasgow G4 0BA, Lanark, Scotland.
   [Shu, Xinhua] Shaoyang Univ, Sch Basic Med Sci, Shaoyang 422000, Peoples R China.
   [Naziroglu, Mustafa] Suleyman Demirel Univ, Neurosci Res Ctr, TR-32260 Isparta, Turkey.
   [Naziroglu, Mustafa] BSN Hlth Anal Innovat Consultancy Org Agr Ltd, Drug Discovery Unit, TR-32260 Isparta, Turkey.
C3 Suleyman Demirel University; Glasgow Caledonian University; Glasgow
   Caledonian University; Shaoyang University; Suleyman Demirel University
RP Naziroglu, M (通讯作者)，Suleyman Demirel Univ, Neurosci Res Ctr, TR-32260 Isparta, Turkey.; Naziroglu, M (通讯作者)，BSN Hlth Anal Innovat Consultancy Org Agr Ltd, Drug Discovery Unit, TR-32260 Isparta, Turkey.
EM drdilekozkaya@yahoo.com; xinhua.shu@gcu.ac.uk;
   mustafanaziroglu@sdu.edu.tr
OI NAZIROGLU, Mustafa/0000-0003-0887-6974; Shu, Xinhua/0000-0003-3760-3019;
   OZKAYA, DILEK/0000-0002-3523-8479
FU BSN Health [2019-07]
FX The current study was carried out with financial support from the
   company (BSN Health). (Project No.: 2019-07. Project owner: Dilek
   Ozkaya).
CR Akyuva Y, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-63577-5
   Alamri A, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20061387
   Armagan HH, 2021, NEUROTOX RES, V39, P618, DOI 10.1007/s12640-020-00314-w
   Bardak H, 2017, PHYSIOL INT, V104, P301, DOI 10.1556/2060.104.2017.4.3
   Biswas L, 2017, HUM MOL GENET, V26, P4327, DOI 10.1093/hmg/ddx319
   Cano M, 2011, AM J PATHOL, V179, P850, DOI 10.1016/j.ajpath.2011.04.010
   Cao SC, 2019, J CELL MOL MED, V23, P6897, DOI 10.1111/jcmm.14573
   Carrasco C, 2015, TURK J BIOL, V39, P822, DOI 10.3906/biy-1504-26
   Chen SJ, 2014, J BIOL CHEM, V289, P36284, DOI 10.1074/jbc.M114.620922
   Choi J, 2011, GLIA, V59, P219, DOI 10.1002/glia.21091
   Cougnard-Gregoire A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0090973
   Dimitrova-Shumkovska J, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9040870
   Du YY, 2020, OXID MED CELL LONGEV, V2020, DOI 10.1155/2020/2684672
   Dunn KC, 1996, EXP EYE RES, V62, P155, DOI 10.1006/exer.1996.0020
   Fan JJ, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22010252
   Fan JJ, 2018, ENDOCRINOLOGY, V159, P1130, DOI 10.1210/en.2017-03065
   Gatliff J, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.186
   Han DM, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-33552-2
   He Y, 2010, ADV EXP MED BIOL, V664, P165, DOI 10.1007/978-1-4419-1399-9_20
   Kim SY, 2021, EXP EYE RES, V203, DOI 10.1016/j.exer.2020.108391
   Klee K, 2019, EXP EYE RES, V188, DOI 10.1016/j.exer.2019.107816
   Koc F, 2018, E MEDITERR HEALTH J, V24, P161, DOI [10.26719/2018.24.2.161, 10.26]
   McHugh D, 2003, J BIOL CHEM, V278, P11002, DOI 10.1074/jbc.M210810200
   Garcia RM, 2016, EBIOMEDICINE, V7, P35, DOI 10.1016/j.ebiom.2016.03.048
   Meng Y, 2020, BIOMED PHARMACOTHER, V121, DOI 10.1016/j.biopha.2019.109588
   Milenkovic VM, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20133359
   Mortadza SS, 2017, SCI REP-UK, V7, DOI 10.1038/srep45032
   Naziroglu M, 2008, NEUROCHEM RES, V33, P1256, DOI 10.1007/s11064-007-9577-5
   Naziroglu M, 2007, NEUROCHEM RES, V32, P1990, DOI 10.1007/s11064-007-9386-x
   Naziroglu M, 2017, J MOL NEUROSCI, V61, P425, DOI 10.1007/s12031-017-0882-4
   Naziroglu M, 2012, J RECEPT SIG TRANSD, V32, P134, DOI 10.3109/10799893.2012.672994
   Naziroglu M, 2011, NEUROCHEM RES, V36, P355, DOI 10.1007/s11064-010-0347-4
   Oz A, 2016, MOL MEMBR BIOL, V33, P76, DOI 10.1080/09687688.2017.1318224
   Ozkaya D, 2021, GRAEF ARCH CLIN EXP, V259, P1539, DOI 10.1007/s00417-021-05074-7
   Ozkaya D, 2021, BIOL TRACE ELEM RES, V199, P1356, DOI 10.1007/s12011-020-02556-3
   Pennington KL, 2016, EYE VISION, V3, DOI 10.1186/s40662-016-0063-5
   Perraud AL, 2001, NATURE, V411, P595, DOI 10.1038/35079100
   Qu SC, 2020, OXID MED CELL LONGEV, V2020, DOI 10.1155/2020/1740943
   Rashid K, 2020, BIOCHEM BIOPH RES CO, V528, P261, DOI 10.1016/j.bbrc.2020.05.114
   Rueda CB, 2016, BBA-BIOENERGETICS, V1857, P1158, DOI 10.1016/j.bbabio.2016.04.003
   Scholz R, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-015-0422-5
   Schriewer JM, 2013, J AM HEART ASSOC, V2, DOI 10.1161/JAHA.113.000159
   Shoshan-Barmatz V, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20133348
   Sileikyte J, 2011, J BIOL CHEM, V286, P1046, DOI 10.1074/jbc.M110.172486
   Sreekumar PG, 2020, REDOX BIOL, V37, DOI 10.1016/j.redox.2020.101663
   Sun YY, 2018, MOL NEUROBIOL, V55, P409, DOI 10.1007/s12035-016-0338-9
   Tuzcu M, 2017, BMC OPHTHALMOL, V17, DOI 10.1186/s12886-017-0524-1
   Wolf A, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-16400-8
   Zeineh N, 2020, BIOMEDICINES, V8, DOI 10.3390/biomedicines8050106
   Zhao AH, 2016, J BIOL CHEM, V291, P1591, DOI 10.1074/jbc.M115.686360
NR 50
TC 4
Z9 4
U1 0
U2 4
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2079-7737
J9 BIOLOGY-BASEL
JI Biology-Basel
PD MAY
PY 2021
VL 10
IS 5
AR 382
DI 10.3390/biology10050382
PG 18
WC Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Life Sciences & Biomedicine - Other Topics
GA SG4NH
UT WOS:000653417500001
PM 33924902
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU AnandBabu, K
   Sen, P
   Angayarkanni, N
AF AnandBabu, Kannadasan
   Sen, Parveen
   Angayarkanni, Narayanasamy
TI Oxidized LDL, homocysteine, homocysteine thiolactone and advanced
   glycation end products act as pro-oxidant metabolites inducing cytokine
   release, macrophage infiltration and pro-angiogenic effect in ARPE-19
   cells
SO PLOS ONE
LA English
DT Article
ID LOW-DENSITY-LIPOPROTEIN; RETINAL-PIGMENT EPITHELIUM; GROWTH-FACTOR
   EXPRESSION; MACULAR DEGENERATION; OXIDATIVE DAMAGE; APOPTOSIS; STRESS;
   PARAOXONASE; ACTIVATION; SECRETION
AB Age-related Macular Degeneration (AMD) is one of the major vision-threatening diseases of the eye. Oxidative stress is one of the key factors in the onset and progression of AMD. In this study, metabolites associated with AMD pathology more so at the systemic level namely, oxidized LDL (oxLDL), homocysteine (Hcy), homocysteine thiolactone (HCTL), advanced glycation end product (AGE) were evaluated for their pro-oxidant nature in a localized ocular environment based on in vitro studies in human retinal pigment epithelial cells (ARPE-19 cells). Human ARPE-19 cells were treated with pro-oxidants 50 pg/mL oxLDL, 500 pM Hcy, 500 nM HCTL, 100 pg/mL AGE, 200 pM H202 and 200 pM H2O2 with and without pre-treatment of 5 mM N-acetyl cysteine (NAC). The cytokines IL-6, IL-8 and vascular endothelial growth factor (VEGF) secreted from ARPE-19 cells exposed to pro-oxidants were estimated by ELISA. In vitro angiogenesis assay was performed with conditioned media of the pro-oxidant treated ARPE-19 cells in Geltrex-Matrigel coated 96-well plate. The human acute monocytic leukemia cell line (THP-1) was differentiated into macrophages and its migration in response to conditioned media of ARPE-19 cells insulted with the pro oxidants was studied by transwell migration assay. Western blot was performed to detect the protein expression of Bax, Bcl-2 and NF-KB to assess apoptotic changes. The compounds involved in the study showed a significant increase in reactive oxygen species (ROS) generation in ARPE-19 cells (oxLDL; Hcy; AGE: p < 0.001 and HCTL: p < 0.05). NAC pre-treatment significantly lowered the oxidative stress brought about by pro-oxidants as seen by lowered ROS and MDA levels in the cells. Treatment with pro-oxidants significantly increased the secretion of IL-6 (oxLDL: p < 0.05; Hcy, HCTL and AGE: p < 0.01) and IL-8 cytokines (oxLDL: p < 0.05; HCTL: p <. 001 and AGE: p < 0.01) in ARPE-19 cells. Serum samples of AMD patients (n = 23) revealed significantly higher IL-6 and IL-8 levels compared to control subjects (n = 23) (IL6: p < 0.01 and IL8: p < 0.05). The pro-oxidants also promoted VEGF secretion by ARPE-19 cells compared to untreated control (oxLDL: p< 0.001; Hcy: p < 0.01; HCTL and AGE: p < 0.05). In vitro angiogenesis assay showed that the conditioned media significantly increased the tube formation in RF/6A endothelial cells. Transwell migration assay revealed significant infiltration of macrophages in response to pro-oxidants. We further demonstrated that the pro-oxidants increased the Bax/Bc1-2 ratio and increased the NF-KB activation resulting in pro-apoptotic changes in ARPE-19 cells. Thus, oxLDL, Hcy, HCTL and AGE act as pro-oxidant metabolites in RPE that promote AMD through oxidative stress, inflammation, chemotaxis and neovascularization.
C1 [AnandBabu, Kannadasan; Angayarkanni, Narayanasamy] Sankara Nethralaya, RS Mehta Jain Dept Biochem & Cell Biol, KBIRVO, Vis Res Fdn, Chennai, Tamil Nadu, India.
   [AnandBabu, Kannadasan] SASTRA Univ, Sch Chem & Biotechnol, Thanjavur, India.
   [Sen, Parveen] Sankara Nethralaya, Shri Bhagwan Mahavir Vitreoretinal Serv, Chennai, Tamil Nadu, India.
C3 Shanmugha Arts, Science, Technology & Research Academy (SASTRA)
RP Angayarkanni, N (通讯作者)，Sankara Nethralaya, RS Mehta Jain Dept Biochem & Cell Biol, KBIRVO, Vis Res Fdn, Chennai, Tamil Nadu, India.
EM drak@snmail.org
RI K, Anand Babu/AAN-8619-2020; Narayanasamy, Angayarkanni/ABD-8584-2020;
   Sen, Parveen/W-4707-2019
OI K, Anand Babu/0000-0002-9910-2044; narayanasamy,
   angayarkanni/0000-0002-8147-1589
FU Indian Council of Medical Research (ICMR)
   [BMS/FW/BIOCHEM/2015-21610/JUN-2015/15/TN/PVT]; Dept. of Biotechnology
   [BT/PR13630/BRB/10/776/2010]
FX Financial support from Indian Council of Medical Research (ICMR), Govt.
   of India (Grant Number: BMS/FW/BIOCHEM/2015-21610/JUN-2015/15/TN/PVT)
   and Dept. of Biotechnology, Govt. of India (Grant number:
   BT/PR13630/BRB/10/776/2010) is acknowledged. The funders had no role in
   study design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR AnandBabu K, 2016, EXP EYE RES, V152, P100, DOI 10.1016/j.exer.2016.09.009
   Arnaoutova I, 2010, NAT PROTOC, V5, P628, DOI 10.1038/nprot.2010.6
   Barathi S, 2010, DIABETES CARE, V33, P2031, DOI 10.2337/dc10-0132
   Bharathselvi M, 2016, INDIAN J MED RES, V143, P756, DOI 10.4103/0971-5916.192026
   Boullier A, 2001, ANN NY ACAD SCI, V947, P214
   Bourquain D, 2013, VIRUS RES, V171, P161, DOI 10.1016/j.virusres.2012.11.013
   BUCALA R, 1994, P NATL ACAD SCI USA, V91, P9441, DOI 10.1073/pnas.91.20.9441
   Cai JY, 2000, PROG RETIN EYE RES, V19, P205, DOI 10.1016/S1350-9462(99)00009-9
   Chan CM, 2016, J CELL MOL MED, V20, P1749, DOI 10.1111/jcmm.12893
   Cheng YS, 2019, EXP EYE RES, V181, P325, DOI 10.1016/j.exer.2018.09.012
   Chiu CJ, 2011, PROG RETIN EYE RES, V30, P18, DOI 10.1016/j.preteyeres.2010.09.001
   Coral K, 2006, EYE, V20, P203, DOI 10.1038/sj.eye.6701853
   Davies IG, 2003, CLIN CHEM, V49, P1865, DOI 10.1373/clinchem.2003.023366
   Doyle SL, 2012, NAT MED, V18, P791, DOI 10.1038/nm.2717
   Espinosa-Heidmann DG, 2003, INVEST OPHTH VIS SCI, V44, P3586, DOI 10.1167/iovs.03-0038
   Falcone C, 2013, DIS MARKERS, V2013, P135, DOI 10.1155/2013/129360
   Ferlazzo N, 2008, BMC NEUROSCI, V9, DOI 10.1186/1471-2202-9-62
   Ghosh SG, 2018, PHYS REV D, V97, DOI 10.1103/PhysRevD.97.104050
   Glenn JV, 2009, BBA-GEN SUBJECTS, V1790, P1109, DOI 10.1016/j.bbagen.2009.04.016
   Glenn JV, 2009, INVEST OPHTH VIS SCI, V50, P441, DOI 10.1167/iovs.08-1724
   Holtkamp GM, 1998, CLIN EXP IMMUNOL, V112, P34
   Huang PR, 2015, SCI REP-UK, V5, DOI 10.1038/srep10585
   Ibrahim AS, 2016, ONCOTARGET, V7, P8532, DOI 10.18632/oncotarget.7384
   Inoue M, 2001, ARTERIOSCL THROM VAS, V21, P560, DOI 10.1161/01.ATV.21.4.560
   Ishibashi T, 1998, ARCH OPHTHALMOL-CHIC, V116, P1629, DOI 10.1001/archopht.116.12.1629
   Itabe H, 2012, J CLIN BIOCHEM NUTR, V51, P1, DOI 10.3164/jcbn.11-00020R1
   Jakubowski H, 2011, ADV CLIN CHEM, V55, P81, DOI 10.1016/B978-0-12-387042-1.00005-8
   Jarrett SG, 2012, MOL ASPECTS MED, V33, P399, DOI 10.1016/j.mam.2012.03.009
   Jasna JM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0101380
   Javadzadeh A, 2010, MOL VIS, V16, P2578
   Jenkins AJ, 2000, DIABETES, V49, P2160, DOI 10.2337/diabetes.49.12.2160
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   KLEINVELD HA, 1992, CLIN CHEM, V38, P2066
   Krilis M, 2017, ONCOTARGET, V8, P49016, DOI 10.18632/oncotarget.14940
   Lan KC, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0124418
   Lee D, 2015, BMB REP, V48, P636, DOI 10.5483/BMBRep.2015.48.11.112
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Maeda M, 2003, BBA-GEN SUBJECTS, V1623, P41, DOI 10.1016/S0304-4165(03)00161-2
   MCCULLY KS, 1993, ANN CLIN LAB SCI, V23, P477
   Nassar K, 2015, GRAEF ARCH CLIN EXP, V253, P699, DOI 10.1007/s00417-014-2738-8
   Nowotny K, 2015, BIOMOLECULES, V5, P194, DOI 10.3390/biom5010194
   PALINSKI W, 1990, ARTERIOSCLEROSIS, V10, P325, DOI 10.1161/01.ATV.10.3.325
   Penfold PL, 2001, PROG RETIN EYE RES, V20, P385, DOI 10.1016/S1350-9462(00)00025-2
   Pennington KL, 2016, EYE VISION, V3, DOI 10.1186/s40662-016-0063-5
   Peppa Melpomeni, 2004, Curr Diab Rep, V4, P31, DOI 10.1007/s11892-004-0008-6
   Pertynska-Marczewska M, 2004, CYTOKINE, V28, P35, DOI 10.1016/j.cyto.2004.06.006
   Picard E, 2010, AGING-US, V2, P981, DOI 10.18632/aging.100218
   Pinna A, 2018, ACTA OPHTHALMOL, V96, pE269, DOI 10.1111/aos.13343
   Qiu YT, 2015, CURR EYE RES, V40, P415, DOI 10.3109/02713683.2014.927507
   Ran WX, 2017, DISCRETE DYN NAT SOC, V2017, DOI 10.1155/2017/9470943
   Ryu J, 2015, MAR DRUGS, V13, P4721, DOI 10.3390/md13084721
   Sabanayagam C, 2017, INVEST OPHTH VIS SCI, V58, P2538, DOI 10.1167/iovs.16-21263
   Sakurai E, 2003, INVEST OPHTH VIS SCI, V44, P3578, DOI 10.1167/iovs.03-0097
   Schmittgen TD, 2008, NAT PROTOC, V3, P1101, DOI 10.1038/nprot.2008.73
   Sibrian-Vazquez M, 2010, P NATL ACAD SCI USA, V107, P551, DOI 10.1073/pnas.0909737107
   Singh M, 2017, INT J OPHTHALMOL-CHI, V10, P696, DOI 10.18240/ijo.2017.05.06
   Spindler J, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0203337
   STEINBRECHER UP, 1987, J BIOL CHEM, V262, P3603
   VIDAL M, 1986, BIOCHIMIE, V68, P723, DOI 10.1016/S0300-9084(86)80166-3
   Wang AL, 2008, MOL VIS, V14, P644
   Wang XT, 2016, SCI REP-UK, V6, DOI 10.1038/srep27866
   Xu QY, 2018, LIPIDS HEALTH DIS, V17, DOI 10.1186/s12944-017-0647-7
   Yamada Y, 2008, J NEUROCHEM, V105, P1187, DOI 10.1111/j.1471-4159.2008.05211.x
   Yan GG, 2017, INT J CLIN EXP PATHO, V10, P1619
   YOKODE M, 1988, J CLIN INVEST, V81, P720, DOI 10.1172/JCI113377
   Zandi S, 2015, CELL REP, V10, P1173, DOI 10.1016/j.celrep.2015.01.050
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
   ZIMMERMAN GA, 1995, P NATL ACAD SCI USA, V92, P3744, DOI 10.1073/pnas.92.9.3744
   2009, ATHEROSCLEROSIS, V204, P47, DOI DOI 10.1016/J.ATHEROSCLEROSIS.2008.08.004
   2018, REDOX BIOL, V15, P1, DOI DOI 10.1016/J.REDOX.2017.11.017
NR 70
TC 18
Z9 18
U1 2
U2 6
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAY 14
PY 2019
VL 14
IS 5
AR e0216899
DI 10.1371/journal.pone.0216899
PG 18
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA HY0ZM
UT WOS:000467843000044
PM 31086404
OA Green Submitted, Green Published, gold
DA 2022-11-30
ER

PT J
AU Hutton-Smith, LA
   Gaffney, EA
   Byrne, HM
   Caruso, A
   Maini, PK
   Mazer, NA
AF Hutton-Smith, Laurence A.
   Gaffney, Eamonn A.
   Byrne, Helen M.
   Caruso, Antonello
   Maini, Philip K.
   Mazer, Norman A.
TI Theoretical Insights into the Retinal Dynamics of Vascular Endothelial
   Growth Factor in Patients Treated with Ranibizumab, Based on an Ocular
   Pharmacokinetic/Pharmacodynamic Model
SO MOLECULAR PHARMACEUTICS
LA English
DT Article
DE retina; intravitreal; ranibizumab pharmacokinetics; VEGF
   pharmacodynamics; permeability; mechanistic modeling; neovascular
   age-related macular degeneration
ID AGING HUMAN-EYE; MACULAR DEGENERATION; INTRAVITREAL INJECTION; BINDING;
   PHARMACOKINETICS; BEVACIZUMAB; SUPPRESSION; THERAPY; VEGF; MECHANISMS
AB Neovascular age-related macular degeneration (wet AMD) results from the pathological angiogenesis of choroidal which leak fluid within or below the capillaries, macular region of the retina. The current standard of care for treating wet AMD utilizes intravitreal injections of anti-VEGF antibodies or antibody fragments to suppress ocular vascular endothelial growth factor (VEGF) levels. While VEGF suppression has been demonstrated in wet AMD by serial measurements of free-VEGF concentrations in aqueous Time (days) Time (days) humor samples, it is presumed that anti-VEGF molecules also permeate across the inner limiting membrane (ILM) of the retina as well as the retinal pigmented epithelium (RPE) and suppress VEGF levels in the retina and/or choroidal regions. The latter effects are inferred from serial optical coherence tomography (OCT) measurements of fluid in the retinal and sub-retinal spaces. In order to gain theoretical insights to the dynamics of retinal levels of free-VEGF following intravitreal injection of anti-VEGF molecules, we have extended our previous two-compartment pharmacokinetic/pharmacodynamic (PK/PD) model of ranibizumab-VEGF suppression in vitreous and aqueous humors to a three-compartment model that includes the retinal compartment. In the new model, reference values for the macromolecular permeability coefficients between retina and vitreous (p(ILM)) and between retina and choroid (p(RPE)) were estimated from PK data obtained in rabbit. With these values, the three-compartment model was used to re-analyze the aqueous humor levels of free-VEGF obtained in wet AMD patients treated with ranibizumab and to compare them to the simulated retinal levels of free-VEGF, including the observed variability in PK and PD. We have also used the model to explore the impact of varying p(ILM) and p(RPE) to assess the case in which an anti-VEGF molecule is impermeable to the ILM and to assess the potential effects of AMD pathology on the RPE barrier. Our simulations show that, for the reference values of p(ILM) and p(RPE), the simulated duration of VEGF suppression in the retina is approximately 50% shorter than the observed duration of VEGF suppression in the aqueous humor, a finding that may explain the short duration of suppressed disease activity in the "high anti-VEGF demand" patients reported by Fauser and Muether (Br. J. Ophthalmol. 2016, 100, 1494-1498). At 10-fold lower values of p(RPE), the durations of VEGF suppression in the retina and aqueous humor are comparable. Lastly we have used the model to explore the impact of dose and binding parameters on the duration and depth of VEGF suppression in the aqueous and retinal compartments. Our simulations with the three-compartment PK/PD model provide new insights into inter-patient variability in response to anti-VEGF therapy and offer a mechanistic framework for developing treatment regimens and molecules that may prolong the duration of retinal VEGF suppression.
C1 [Hutton-Smith, Laurence A.; Gaffney, Eamonn A.; Byrne, Helen M.; Maini, Philip K.] Univ Oxford, Radcliffe Observ Quarter, Math Inst, Wolfson Ctr Math Biol, Woodstock Rd,Andrew Wiles Bldg, Oxford OX2 6GG, England.
   [Caruso, Antonello; Mazer, Norman A.] F Hoffmann La Roche Ltd, Roche Innovat Ctr Basel, Roche Pharma Res & Early Dev, Pharmaceut Sci, Grenzacherstr 124, CH-4070 Basel, Switzerland.
C3 University of Oxford; Roche Holding
RP Hutton-Smith, LA (通讯作者)，Univ Oxford, Radcliffe Observ Quarter, Math Inst, Wolfson Ctr Math Biol, Woodstock Rd,Andrew Wiles Bldg, Oxford OX2 6GG, England.; Mazer, NA (通讯作者)，F Hoffmann La Roche Ltd, Roche Innovat Ctr Basel, Roche Pharma Res & Early Dev, Pharmaceut Sci, Grenzacherstr 124, CH-4070 Basel, Switzerland.
EM laurence.hutton-smith@pmb.ox.ac.uk; norman.mazer@roche.com
OI Caruso, Antonello/0000-0001-5832-3636; Byrne, Helen/0000-0003-1771-5910;
   Gaffney, Eamonn/0000-0002-6888-4362
FU Engineering and Physical Sciences Research Council (EPSRC); Medical
   Research Council (MRC) [EP/L016044/1]; Roche Pharma Research and Early
   Development; EPSRC [EP/I017909/1] Funding Source: UKRI
FX This work was supported by funding from the Engineering and Physical
   Sciences Research Council (EPSRC) and the Medical Research Council (MRC)
   [grant number EP/L016044/1]. Additional funding was provided by Roche
   Pharma Research and Early Development. The authors thank Dietmar Schwab
   for careful reading of this manuscript and helpful suggestions.
CR Ambati J, 2012, NEURON, V75, P26, DOI 10.1016/j.neuron.2012.06.018
   [Anonymous], 2015, MATLAB US GUID R2015
   Bolton S., 2004, PHARM STAT PRACTICAL
   Brown DM, 2013, OPHTHALMOLOGY, V120, P349, DOI 10.1016/j.ophtha.2012.08.008
   Campagne MV, 2014, J PATHOL, V232, P151, DOI 10.1002/path.4266
   Fauser S, 2016, BRIT J OPHTHALMOL, V100, P1494, DOI 10.1136/bjophthalmol-2015-308264
   Ferrara N, 2006, RETINA-J RET VIT DIS, V26, P859, DOI 10.1097/01.iae.0000242842.14624.e7
   Ferrara N, 2010, NAT MED, V16, P1107, DOI 10.1038/nm1010-1107
   FONTANA ST, 1980, ARCH OPHTHALMOL-CHIC, V98, P1803
   Gadkar K, 2015, INVEST OPHTH VIS SCI, V56, P5390, DOI 10.1167/iovs.15-17108
   Halfter W, 2008, EYE, V22, P1207, DOI 10.1038/eye.2008.19
   Heiduschka P, 2007, INVEST OPHTH VIS SCI, V48, P2814, DOI 10.1167/iovs.06-1171
   Ho AC, 2014, OPHTHALMOLOGY, V121, P2181, DOI 10.1016/j.ophtha.2014.05.009
   Hutton-Smith LA, 2017, MOL PHARMACEUT, V14, P2690, DOI 10.1021/acs.molpharmaceut.7b00164
   Hutton-Smith LA, 2016, MOL PHARMACEUT, V13, P2941, DOI 10.1021/acs.molpharmaceut.5b00849
   Krohne TU, 2008, AM J OPHTHALMOL, V146, P508, DOI 10.1016/j.ajo.2008.05.036
   Leppanen VM, 2010, P NATL ACAD SCI USA, V107, P2425, DOI 10.1073/pnas.0914318107
   Missel PJ, 2012, PHARM RES-DORDR, V29, P3251, DOI 10.1007/s11095-012-0721-9
   Moja L, 2014, COCHRANE DB SYST REV, V7
   Muether PS, 2013, AM J OPHTHALMOL, V156, P989, DOI 10.1016/j.ajo.2013.06.020
   Muether PS, 2012, OPHTHALMOLOGY, V119, P2082, DOI 10.1016/j.ophtha.2012.07.041
   Pai SS, 2011, BIOCONJUGATE CHEM, V22, P2317, DOI 10.1021/bc2003583
   Papadopoulos N, 2012, ANGIOGENESIS, V15, P171, DOI 10.1007/s10456-011-9249-6
   Penn JS, 2008, PROG RETIN EYE RES, V27, P331, DOI 10.1016/j.preteyeres.2008.05.001
   Pitkanen L, 2005, INVEST OPHTH VIS SCI, V46, P641, DOI 10.1167/iovs.04-1051
   QUINN TP, 1993, P NATL ACAD SCI USA, V90, P7533, DOI 10.1073/pnas.90.16.7533
   Saunders DJ, 2015, BRIT J OPHTHALMOL, V99, P1554, DOI 10.1136/bjophthalmol-2015-306771
   Tasman W., 2013, DUANES OPHTHALMOLOGY
   Toris CB, 1999, AM J OPHTHALMOL, V127, P407, DOI 10.1016/S0002-9394(98)00436-X
   WALTENBERGER J, 1994, J BIOL CHEM, V269, P26988
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Yang JH, 2014, MOL PHARMACEUT, V11, P3421, DOI 10.1021/mp500160v
   Zhu Q, 2008, OPHTHALMOLOGY, V115, P1750, DOI 10.1016/j.ophtha.2008.04.023
NR 33
TC 19
Z9 20
U1 1
U2 8
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1543-8384
J9 MOL PHARMACEUT
JI Mol. Pharm.
PD JUL
PY 2018
VL 15
IS 7
BP 2770
EP 2784
DI 10.1021/acs.molpharmaceut.8b00280
PG 15
WC Medicine, Research & Experimental; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine; Pharmacology & Pharmacy
GA GY3XK
UT WOS:000448490100027
PM 29734810
DA 2022-11-30
ER

PT J
AU Jones, RGA
   Martino, A
AF Jones, Russell G. A.
   Martino, Angela
TI Targeted localized use of therapeutic antibodies: a review of
   non-systemic, topical and oral applications
SO CRITICAL REVIEWS IN BIOTECHNOLOGY
LA English
DT Review
DE antibody; disease; clinical; antitoxin; peroral; Antibiotic resistance;
   immunoglobulin; polyclonal; monoclonal; gastrointestinal
ID NECROSIS-FACTOR-ALPHA; DIFFICILE-ASSOCIATED DIARRHEA; BOVINE
   IMMUNOGLOBULIN CONCENTRATE; PSEUDOMONAS-AERUGINOSA INFECTIONS;
   ROTAVIRUS-ASSOCIATED DIARRHEA; INFLAMMATORY-BOWEL-DISEASE; ENHANCED
   PEPSIN DIGESTION; EGG-YOLK IMMUNOGLOBULIN; SINGLE-CHAIN ANTIBODY;
   MONOCLONAL-ANTIBODY
AB Therapeutic antibodies provide important tools in the "medicine chest" of today's clinician for the treatment of a range of disorders. Typically monoclonal or polyclonal antibodies are administered in large doses, either directly or indirectly into the circulation, via a systemic route which is well suited for disseminated ailments. Diseases confined within a specific localized tissue, however, may be treated more effectively and at reduced cost by a delivery system which targets directly the affected area. To explore the advantages of the local administration of antibodies, we reviewed current alternative, non-systemic delivery approaches which are in clinical use, being trialed or developed. These less conventional approaches comprise: (a) local injections, (b) topical and (c) peroral administration routes. Local delivery includes intra-ocular injections into the vitreal humor (i.e. Ranibizumab for age-related macular degeneration), subconjunctival injections (e.g. Bevacizumab for corneal neovascularization), intra-articular joint injections (i.e. anti-TNF alpha antibody for persistent inflammatory monoarthritis) and intratumoral or peritumoral injections (e.g. Ipilimumab for cancer). A range of other strategies, such as the local use of antibacterial antibodies, are also presented. Local injections of antibodies utilize doses which range from 1/10th to 1/100th of the required systemic dose therefore reducing both side-effects and treatment costs. In addition, any therapeutic antibody escaping from the local site of disease into the systemic circulation is immediately diluted within the large blood volume, further lowering the potential for unwanted effects. Needle-free topical application routes become an option when the condition is restricted locally to an external surface. The topical route may potentially be utilized in the form of eye drops for infections or corneal neovascularization or be applied to diseased skin for psoriasis, dermatitis, pyoderma gangrenosum, antibiotic resistant bacterial infections or ulcerated wounds. Diseases confined to the gastrointestinal tract can be targeted directly by applying antibody via the injection-free peroral route. The gastrointestinal tract is unusual in that its natural immuno-tolerant nature ensures the long-term safety of repeatedly ingesting heterologous antiserum or antibody materials. Without the stringent regulatory, purity and clean room requirements of manufacturing parenteral (injectable) antibodies, production costs are minimal, with the potential for more direct low-cost targeting of gastrointestinal diseases, especially with those caused by problematic antibiotic resistant or toxigenic bacteria (e.g. Clostridium difficile, Helicobacter pylori), viruses (e.g. rotavirus, norovirus) or inflammatory bowel disease (e.g. ulcerative colitis, Crohn's disease). Use of the oral route has previously been hindered by excessive antibody digestion within the gastrointestinal tract; however, this limitation may be overcome by intelligently applying one or more strategies (i.e. decoy proteins, masking therapeutic antibody cleavage sites, pH modulation, enzyme inhibition or encapsulation). These aspects are additionally discussed in this review and novel insights also provided. With the development of new applications via local injections, topical and peroral routes, it is envisaged that an extended range of ailments will increasingly fall within the clinical scope of therapeutic antibodies further expanding this market.
C1 [Jones, Russell G. A.; Martino, Angela] Univ Warwick, Dept Chem, Coventry CV4 7AL, W Midlands, England.
C3 University of Warwick
RP Jones, RGA (通讯作者)，Univ Warwick, Dept Chem, Coventry CV4 7AL, W Midlands, England.
EM russellgajones@gmail.com
RI Jones, Russell/E-9817-2013
OI Jones, Russell/0000-0002-7015-5740; Martino, Angela/0000-0003-3646-140X
CR Abbott WM, 2013, BIOSCIENCE REP, V33, P655, DOI 10.1042/BSR20130044
   Ali T, 2013, DRUG HEALTHC PATIENT, V5, P79, DOI 10.2147/DHPS.S28801
   ANFINSEN CB, 1972, BIOCHEM J, V128, P737, DOI 10.1042/bj1280737
   ARHEM K, 1989, ANTHROPOS, V84, P1
   Ashcroft GS, 2012, WOUND REPAIR REGEN, V20, P38, DOI 10.1111/j.1524-475X.2011.00748.x
   Asteria CR, 2006, SCAND J GASTROENTERO, V41, P1064, DOI 10.1080/00365520600609941
   Atreya R, 2014, NAT MED, V20, P313, DOI 10.1038/nm.3462
   Attia EAS, 2014, WOUND REPAIR REGEN, V22, P52, DOI 10.1111/wrr.12122
   Balsari A, 2001, BRIT J CANCER, V85, P1964, DOI 10.1054/bjoc.2001.2188
   BALSARI AL, 1994, FASEB J, V8, P226, DOI 10.1096/fasebj.8.2.8119493
   Barde C, 2011, DERMATOLOGY, V222, P212, DOI 10.1159/000328403
   Barekzi NA, 2002, PHARMACEUT RES, V19, P1801, DOI 10.1023/A:1021481122011
   BARNES GL, 1982, LANCET, V1, P1371
   Bartelds GM, 2011, JAMA-J AM MED ASSOC, V305, P1460, DOI 10.1001/jama.2011.406
   Bashshur ZF, 2006, AM J OPHTHALMOL, V142, P1, DOI 10.1016/j.ajo.2006.02.037
   Berdugo M, 2012, ANTIMICROB AGENTS CH, V56, P1390, DOI 10.1128/AAC.05145-11
   Berghman LR, 2005, POULTRY SCI, V84, P660, DOI 10.1093/ps/84.4.660
   Berry JD, 2011, NEW BIOTECHNOL, V28, P489, DOI 10.1016/j.nbt.2011.03.018
   Bhol KC, 2013, INFLAMM BOWEL DIS, V19, P2273, DOI 10.1097/MIB.0b013e3182a11958
   Bhol KC, 2014, GASTROENTEROLOGY, V146
   BLUM PM, 1981, PEDIATR RES, V15, P1256, DOI 10.1203/00006450-198109000-00006
   Boirie Y, 1997, P NATL ACAD SCI USA, V94, P14930, DOI 10.1073/pnas.94.26.14930
   Boushaba R, 2003, BIOTECHNOL PROGR, V19, P1176, DOI 10.1021/bp034037+
   BRAEGGER CP, 1992, LANCET, V339, P89, DOI 10.1016/0140-6736(92)90999-J
   Brereton HM, 2005, BRIT J OPHTHALMOL, V89, P1205, DOI 10.1136/bjo.2005.066225
   BROWN WE, 1973, BIOCHEMISTRY-US, V12, P835, DOI 10.1021/bi00729a008
   BRUNSER O, 1992, J PEDIATR GASTR NUTR, V15, P63, DOI 10.1097/00005176-199207000-00010
   BRUSSOW H, 1987, J CLIN MICROBIOL, V25, P982
   BUREKKOZLOWSKA A, 1994, INT ARCH ALLERGY IMM, V104, P104, DOI 10.1159/000236716
   Carlander D, 2000, IMMUNOL RES, V21, P1, DOI 10.1385/IR:21:1:1
   Casadevall A, 2004, NAT REV MICROBIOL, V2, P695, DOI 10.1038/nrmicro974
   Casadevall A, 1999, CLIN IMMUNOL, V93, P5, DOI 10.1006/clim.1999.4768
   Casadevall A, 2002, EMERG INFECT DIS, V8, P833, DOI 10.3201/eid0808.010516
   Casadevall A, 2012, CELL HOST MICROBE, V11, P447, DOI 10.1016/j.chom.2012.04.004
   Casswall TH, 2000, SCAND J GASTROENTERO, V35, P711, DOI 10.1080/003655200750023372
   Chames P, 2009, BRIT J PHARMACOL, V157, P220, DOI 10.1111/j.1476-5381.2009.00190.x
   Chan AC, 2010, NAT REV IMMUNOL, V10, P301, DOI 10.1038/nri2761
   CHARLES F, 1995, MAYO CLIN PROC, V70, P113, DOI 10.4065/70.2.113
   Church D, 2006, CLIN MICROBIOL REV, V19, P403, DOI 10.1128/CMR.19.2.403-434.2006
   COLLINS PJ, 1991, GUT, V32, P615, DOI 10.1136/gut.32.6.615
   COPELAN EA, 1994, BONE MARROW TRANSPL, V13, P87
   Couzin-Frankel J, 2013, SCIENCE, V342, P1432, DOI 10.1126/science.342.6165.1432
   Crabb JH, 1998, ADV PARASIT, V40, P121, DOI 10.1016/S0065-308X(08)60119-0
   Crawford LM, 2002, FINAL RULE FED REG, V67, P37988
   Cumberlege GI, 1911, BRIT MED J, V1911, P108, DOI 10.1136/bmj.2.2637.108
   CUNNINGHAMRUNDLES C, 1992, J IMMUNOL METHODS, V152, P177, DOI 10.1016/0022-1759(92)90139-K
   da Cunha AP, 2012, CLIN DEV IMMUNOL, DOI 10.1155/2012/425021
   DAVIDSON GP, 1989, LANCET, V2, P709, DOI 10.1016/S0140-6736(89)90771-X
   Degen LP, 1996, GUT, V39, P299, DOI 10.1136/gut.39.2.299
   den Hoed CM, 2011, CAN J GASTROENTEROL, V25, P207, DOI 10.1155/2011/672093
   DIXON FJ, 1959, J IMMUNOL, V83, P437
   Dumoulin M, 2002, PROTEIN SCI, V11, P500, DOI 10.1110/ps.34602
   Dvorackova K, 2010, ACTA POL PHARM, V67, P191
   EBINA T, 1985, MED MICROBIOL IMMUN, V174, P177, DOI 10.1007/BF02123694
   EIBL MM, 1988, NEW ENGL J MED, V319, P1, DOI 10.1056/NEJM198807073190101
   Ermolenko DN, 2004, BIOCHEMISTRY-MOSCOW+, V69, P1233, DOI 10.1007/s10541-005-0069-4
   Evans CH, 2014, NAT REV RHEUMATOL, V10, P11, DOI 10.1038/nrrheum.2013.159
   Evenepoel P, 1998, J NUTR, V128, P1716, DOI 10.1093/jn/128.10.1716
   Farag N, 2013, EUR J CLIN MICROBIOL, V32, P1149, DOI 10.1007/s10096-013-1861-5
   Faria AMC, 2005, IMMUNOL REV, V206, P232, DOI 10.1111/j.0105-2896.2005.00280.x
   Felts AG, 2000, J TRAUMA, V49, P873, DOI 10.1097/00005373-200011000-00014
   Felts AG, 1999, BURNS, V25, P415, DOI 10.1016/S0305-4179(99)00017-0
   Ferrara N, 2006, RETINA-J RET VIT DIS, V26, P859, DOI 10.1097/01.iae.0000242842.14624.e7
   Ferrari G, 2013, INVEST OPHTH VIS SCI, V54, P1680, DOI 10.1167/iovs.12-10782
   Fioravanti A, 2009, RHEUMATOL INT, V29, P961, DOI 10.1007/s00296-009-0872-0
   Fisher BAC, 2006, J RHEUMATOL, V33, P1934
   Florescu DF, 2008, PEDIATR TRANSPLANT, V12, P372, DOI 10.1111/j.1399-3046.2007.00875.x
   Florescu DF, 2011, PEDIATR TRANSPLANT, V15, P718, DOI 10.1111/j.1399-3046.2011.01556.x
   Fong AHC, 2013, CLIN INTERV AGING, V8, P467, DOI 10.2147/CIA.S36811
   Fontana A, 2004, ACTA BIOCHIM POL, V51, P299
   Ford AC, 2013, AM J GASTROENTEROL, V108, P1268, DOI 10.1038/ajg.2013.138
   Fransen MF, 2013, CLIN CANCER RES, V19, P5381, DOI 10.1158/1078-0432.CCR-12-0781
   Furrer E, 2009, INVEST OPHTH VIS SCI, V50, P771, DOI 10.1167/iovs.08-2370
   Galloway JB, 2011, RHEUMATOLOGY, V50, P124, DOI 10.1093/rheumatology/keq242
   Gomez HF, 1999, ACAD EMERG MED, V6, P1195, DOI 10.1111/j.1553-2712.1999.tb00133.x
   GUARINO A, 1994, PEDIATRICS, V93, P12
   HAMMARSTROM L, 1994, IMMUNOL REV, V139, P43, DOI 10.1111/j.1600-065X.1994.tb00856.x
   HAMMARSTROM V, 1993, LANCET, V341, P1036, DOI 10.1016/0140-6736(93)91136-A
   Hansen S, 2013, BIOCENTURY, V9, P7
   Harmsen MM, 2007, APPL MICROBIOL BIOT, V77, P13, DOI 10.1007/s00253-007-1142-2
   Harmsen MM, 2006, APPL MICROBIOL BIOT, V72, P544, DOI 10.1007/s00253-005-0300-7
   HILPERT H, 1987, J INFECT DIS, V156, P158, DOI 10.1093/infdis/156.1.158
   Hodi FS, 2010, NEW ENGL J MED, V363, P711, DOI 10.1056/NEJMoa1003466
   Horie K, 2004, J DAIRY SCI, V87, P4073, DOI 10.3168/jds.S0022-0302(04)73549-3
   Hurwitz H, 2004, NEW ENGL J MED, V350, P2335, DOI 10.1056/NEJMoa032691
   HUSBY S, 1994, J IMMUNOL, V152, P4663
   Hussack Greg, 2012, Methods Mol Biol, V911, P417, DOI 10.1007/978-1-61779-968-6_25
   Hussack G, 2010, TOXINS, V2, P998, DOI 10.3390/toxins2050998
   Hussack G, 2011, J BIOL CHEM, V286, P8961, DOI 10.1074/jbc.M110.198754
   Ibekwe VC, 2008, PHARM RES-DORDR, V25, P1828, DOI 10.1007/s11095-008-9580-9
   Ibrahim ESM, 2008, VACCINE, V26, P2073, DOI 10.1016/j.vaccine.2008.02.046
   IMOTO T, 1986, J MOL BIOL, V190, P647, DOI 10.1016/0022-2836(86)90250-0
   Jackson JE, 2012, WOUND REPAIR REGEN, V20, P523, DOI 10.1111/j.1524-475X.2012.00802.x
   JEMMERSON R, 1986, SCIENCE, V232, P1001, DOI 10.1126/science.2422757
   Jones RGA, 1999, BRIT J PHARMACOL, V126, P581, DOI 10.1038/sj.bjp.0702286
   Jones RGA, 2003, J IMMUNOL METHODS, V275, P239, DOI 10.1016/S0022-1759(03)00005-X
   Jones RGA, 2002, J IMMUNOL METHODS, V263, P57, DOI 10.1016/S0022-1759(02)00031-5
   Jones RGA, 2013, J MED MICROBIOL, V62, P828, DOI 10.1099/jmm.0.053124-0
   KANFER EJ, 1994, BONE MARROW TRANSPL, V14, P651
   Keizer RJ, 2010, CLIN PHARMACOKINET, V49, P493, DOI 10.2165/11531280-000000000-00000
   Kelly CP, 1997, ANTIMICROB AGENTS CH, V41, P236, DOI 10.1128/AAC.41.2.236
   KITAMURA K, 1992, CANCER RES, V52, P6323
   KLAGER AJ, 1993, OPHTHALMOLOGICA, V207, P78
   KOBAYASHI T, 1991, BIOCHIM BIOPHYS ACTA, V1077, P11, DOI 10.1016/0167-4838(91)90519-6
   Kollberg H, 2003, PEDIATR PULM, V35, P433, DOI 10.1002/ppul.10290
   Kopecki Z, 2012, J INVEST DERMATOL, V132, pS9, DOI 10.1038/jid.2012.457
   Kovacs-Nolan J, 2005, J IMMUNOL METHODS, V296, P199, DOI 10.1016/j.jim.2004.11.017
   Kovacs-Nolan J, 2012, ANNU REV FOOD SCI T, V3, P163, DOI 10.1146/annurev-food-022811-101137
   Kozuch PL, 2008, WORLD J GASTROENTERO, V14, P354, DOI 10.3748/wjg.14.354
   Krizova D, 2014, J OPHTHALMOL, V2014, DOI 10.1155/2014/178132
   KROGDAHL A, 1981, J NUTR, V111, P2045, DOI 10.1093/jn/111.12.2045
   Kumpalume P, 2002, FOOD BIOPROD PROCESS, V80, P88, DOI 10.1205/09603080252938726
   LALAZAR A, 1979, P NATL ACAD SCI USA, V76, P318, DOI 10.1073/pnas.76.1.318
   Landon J, 2003, J TOXICOL-TOXIN REV, V22, P15, DOI 10.1081/TXR-120019017
   Larsson A, 2003, UPSALA J MED SCI, V108, P129
   Lebwohl M, 2005, ANN RHEUM DIS, V64, P83, DOI 10.1136/ard.2004.030791
   Lichtlen P, 2010, INVEST OPHTH VIS SCI, V51, P4738, DOI 10.1167/iovs.09-4890
   Liu F, 2010, J CONTROL RELEASE, V147, P242, DOI 10.1016/j.jconrel.2010.07.105
   Liu F, 2010, EUR J PHARM BIOPHARM, V74, P311, DOI 10.1016/j.ejpb.2009.11.008
   LOSONSKY GA, 1985, J CLIN INVEST, V76, P2362, DOI 10.1172/JCI112248
   MacLennan C, 2004, LANCET, V363, P1509, DOI 10.1016/S0140-6736(04)16150-3
   MADSEN JL, 1992, DIGEST DIS SCI, V37, P1548, DOI 10.1007/BF01296501
   Mahe S, 1996, AM J CLIN NUTR, V63, P546, DOI 10.1093/ajcn/63.4.546
   MANCA F, 1991, J EXP MED, V173, P37, DOI 10.1084/jem.173.1.37
   Marabelle A, 2014, CLIN CANCER RES, V20, P1747, DOI 10.1158/1078-0432.CCR-13-2116
   Marabelle A, 2013, CLIN CANCER RES, V19, P5261, DOI 10.1158/1078-0432.CCR-13-1923
   Marabelle A, 2013, J CLIN INVEST, V123, P2447, DOI 10.1172/JCI64859
   Marasco WA, 2007, NAT BIOTECHNOL, V25, DOI 10.1038/nbt1363
   Mattila E, 2008, SCAND J INFECT DIS, V40, P702, DOI 10.1080/00365540801964960
   Mayberry JF, 2013, ALIMENT PHARM THER, V37, P195, DOI 10.1111/apt.12102
   Meddeb-Mouelhi F, 2003, TOXICON, V42, P785, DOI 10.1016/j.toxicon.2003.10.021
   Meyer T, 2012, EXP MOL PATHOL, V93, P449, DOI 10.1016/j.yexmp.2012.10.002
   MHRA, 2014, RUL GUID PHARM MAN D
   MIETENS C, 1979, EUR J PEDIATR, V132, P239, DOI 10.1007/BF00496847
   MOJAVERIAN P, 1985, GASTROENTEROLOGY, V89, P392, DOI 10.1016/0016-5085(85)90342-7
   Morelli D, 1996, CANCER RES, V56, P2082
   Moshfeghi AA, 2006, OPHTHALMOLOGY, V113, P2002, DOI 10.1016/j.ophtha.2006.05.070
   Neri P, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026526
   Newcombe C, 2007, J CHROMATOGR B, V848, P2, DOI 10.1016/j.jchromb.2006.07.004
   NICE, 2008, AD TREATM AD PSOR TA
   NICE, 2009, RHEUM ARTHR CG79
   Nikas SN, 2004, ANN RHEUM DIS, V63, P102, DOI 10.1136/ard.2003.006981
   Nilsson E, 2008, PEDIATR PULM, V43, P892, DOI 10.1002/ppul.20875
   Nilsson E, 2007, J MED FOOD, V10, P375, DOI 10.1089/jmf.2006.214
   NORD J, 1990, AIDS, V4, P581, DOI 10.1097/00002030-199006000-00015
   Numan SC, 2007, GUT, V56, P888, DOI 10.1136/gut.2006.119016
   Ohtani S, 2003, PHARM RES-DORDR, V20, P611, DOI 10.1023/A:1023298816392
   Ohtani T, 2012, J ORAL PATHOL MED, V41, P96, DOI 10.1111/j.1600-0714.2011.01056.x
   Okhuysen PC, 1998, CLIN INFECT DIS, V26, P1324, DOI 10.1086/516374
   Ottiger M, 2009, INVEST OPHTH VIS SCI, V50, P779, DOI 10.1167/iovs.08-2372
   Pacyna J, 2001, J PEDIATR GASTR NUTR, V32, P162, DOI 10.1097/00005176-200102000-00013
   Pant N, 2006, J INFECT DIS, V194, P1580, DOI 10.1086/508747
   Paton D M, 1906, Br Med J, V1, P1032
   PETSCHOW BW, 1994, J PEDIATR GASTR NUTR, V19, P228, DOI 10.1097/00005176-199408000-00014
   Petsoglou C, 2013, BRIT J OPHTHALMOL, V97, P28, DOI 10.1136/bjophthalmol-2012-302137
   Pinho E, 2014, CRIT REV BIOTECHNOL, V34, P328, DOI 10.3109/07388551.2013.794413
   PLAYFORD RJ, 1993, LANCET, V341, P843, DOI 10.1016/0140-6736(93)93057-8
   POCKLINGTON T, 1969, BIOCHEM J, V112, P331, DOI 10.1042/bj1120331
   Poelstra KA, 2000, TISSUE ENG, V6, P401, DOI 10.1089/107632700418100
   PORTER RR, 1959, BIOCHEM J, V73, P119, DOI 10.1042/bj0730119
   Powers J C, 1977, Adv Exp Med Biol, V95, P141
   Rahman S, 2012, VACCINE, V30, P4661, DOI 10.1016/j.vaccine.2012.04.091
   Rao RK, 1998, PEPTIDES, V19, P495, DOI 10.1016/S0196-9781(97)00462-2
   Reichert JM, 2012, MABS-AUSTIN, V4, P413, DOI 10.4161/mabs.19931
   Reichert JM, 2011, MABS-AUSTIN, V3, P76, DOI 10.4161/mabs.3.1.13895
   Reseland JE, 1996, J NUTR, V126, P634, DOI 10.1093/jn/126.3.634
   ROOS N, 1995, J NUTR, V125, P1238
   Roy FH, 2008, ROY FRAUNFELDERS CUR
   Ruzehaji N, 2014, DIABETOLOGIA, V57, P402, DOI 10.1007/s00125-013-3107-6
   Salemi S, 2015, INT REV IMMUNOL, V34, P202, DOI 10.3109/08830185.2013.863304
   Sandin LC, 2014, ONCOIMMUNOLOGY, V3, DOI 10.4161/onci.27614
   Sandin LC, 2014, CANCER IMMUNOL RES, V2, P80, DOI 10.1158/2326-6066.CIR-13-0067
   Sands BE, 2004, NEW ENGL J MED, V350, P876, DOI 10.1056/NEJMoa030815
   Sarker SA, 2001, J PEDIATR GASTR NUTR, V32, P19, DOI 10.1097/00005176-200101000-00009
   Sarker SA, 2013, GASTROENTEROLOGY, V145, P740, DOI 10.1053/j.gastro.2013.06.053
   Schade K, 2005, ATLA-ALTERN LAB ANIM, V33, P129, DOI 10.1177/026119290503300208
   SCHLAMOWITZ M, 1959, J BIOL CHEM, V234, P3137
   SCHMIDT P, 1989, J VET MED B, V36, P619, DOI 10.1111/j.1439-0450.1989.tb00653.x
   Schreiber S, 2007, NEW ENGL J MED, V357, P239, DOI 10.1056/NEJMoa062897
   Scott Andrew M, 2012, Cancer Immun, V12, P14
   Shone C, 2014, Antibodies to Clostridium difficile toxins, Patent No. [US8709428 B2, 8709428]
   Shone C, 2013, Patent application, Patent No. [US20130004561 A1, 20130004561]
   SPLITTGERBER AG, 1983, J CHEM EDUC, V60, P651, DOI 10.1021/ed060p651
   Steinbrook R, 2006, NEW ENGL J MED, V355, P1409, DOI 10.1056/NEJMp068185
   Stevens NE, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068895
   Stevenson W, 2012, OCUL SURF, V10, P67, DOI 10.1016/j.jtos.2012.01.005
   Streit Markus, 2006, Int Wound J, V3, P171, DOI 10.1111/j.1742-481X.2006.00233.x
   SUCKAU D, 1990, P NATL ACAD SCI USA, V87, P9848, DOI 10.1073/pnas.87.24.9848
   Suzuki H, 2004, ALIMENT PHARM THER, V20, P185, DOI 10.1111/j.1365-2036.2004.02027.x
   Syed A, 2013, AM J GASTROENTEROL, V108, P583, DOI 10.1038/ajg.2012.464
   TACKET CO, 1992, AM J TROP MED HYG, V47, P276, DOI 10.4269/ajtmh.1992.47.276
   TACKET CO, 1988, NEW ENGL J MED, V318, P1240, DOI 10.1056/NEJM198805123181904
   Tappenden P, 2007, HEALTH TECHNOL ASSES, V11, P1
   Taxonera C, 2009, WORLD J GASTROENTERO, V15, P4263, DOI 10.3748/wjg.15.4263
   Teh YHA, 2010, TRANSGENIC RES, V19, P575, DOI 10.1007/s11248-009-9338-0
   Teich N, 2014, J CROHNS COLITIS, V8, P85, DOI 10.1016/j.crohns.2013.06.003
   Thakral S, 2013, EXPERT OPIN DRUG DEL, V10, P131, DOI 10.1517/17425247.2013.736962
   Thiel MA, 2002, CLIN EXP IMMUNOL, V128, P67, DOI 10.1046/j.1365-2249.2002.01808.x
   Thiel MA, 2013, OPHTHALMOLOGY, V120, P1403, DOI 10.1016/j.ophtha.2012.12.015
   TJELLSTROM B, 1993, LANCET, V341, P701, DOI 10.1016/0140-6736(93)90477-X
   Tjellstrom B, 1997, ACTA PAEDIATR, V86, P221, DOI 10.1111/j.1651-2227.1997.tb08873.x
   Tollemar J, 1999, BONE MARROW TRANSPL, V23, P283, DOI 10.1038/sj.bmt.1701560
   Tonelli F, 2012, DIS COLON RECTUM, V55, P870, DOI 10.1097/DCR.0b013e31825af532
   Urech DM, 2010, ANN RHEUM DIS, V69, P443, DOI 10.1136/ard.2008.105775
   van Dissel JT, 2005, J MED MICROBIOL, V54, P197, DOI 10.1099/jmm.0.45773-0
   Vandenbroucke K, 2010, MUCOSAL IMMUNOL, V3, P49, DOI 10.1038/mi.2009.116
   von Behring E., 1901, NOBEL LECT SERUM THE
   Waaga-Gasser AM, 2009, INT J CLIN PHARM TH, V47, P421
   Wang W, 2008, CLIN PHARMACOL THER, V84, P548, DOI 10.1038/clpt.2008.170
   Warny M, 1999, GUT, V44, P212, DOI 10.1136/gut.44.2.212
   Weiner C, 1999, CLIN EXP IMMUNOL, V116, P193
   West RL, 2008, ALIMENT PHARM THER, V28, P1122, DOI 10.1111/j.1365-2036.2008.03828.x
   WICHER K, 1992, INFECT IMMUN, V60, P3217, DOI 10.1128/IAI.60.8.3217-3223.1992
   Williams KA, 2013, DISCOV MED, V15, P291
   Worledge KL, 2000, DIGEST DIS SCI, V45, P2298, DOI 10.1023/A:1005554900286
   XIAN CJ, 1995, J ENDOCRINOL, V146, P215, DOI 10.1677/joe.0.1460215
   Xu ZQ, 2014, EXPERT OPIN INV DRUG, V23, P163, DOI 10.1517/13543784.2014.848853
   Zaidi TS, 2012, INFECT IMMUN, V80, P3706, DOI 10.1128/IAI.00249-12
NR 218
TC 18
Z9 22
U1 1
U2 70
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 0738-8551
EI 1549-7801
J9 CRIT REV BIOTECHNOL
JI Crit. Rev. Biotechnol.
PD MAY 3
PY 2016
VL 36
IS 3
BP 506
EP 520
DI 10.3109/07388551.2014.992388
PG 15
WC Biotechnology & Applied Microbiology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biotechnology & Applied Microbiology
GA DI9JP
UT WOS:000373819200010
PM 25600465
DA 2022-11-30
ER

PT J
AU Taylor-Walker, G
   Lynn, SA
   Keeling, E
   Munday, R
   Johnston, DA
   Page, A
   Scott, JA
   Goverdhan, S
   Lotery, AJ
   Ratnayaka, JA
AF Taylor-Walker, George
   Lynn, Savannah A.
   Keeling, Eloise
   Munday, Rosie
   Johnston, David A.
   Page, Anton
   Scott, Jennifer A.
   Goverdhan, Srini
   Lotery, Andrew J.
   Ratnayaka, J. Arjuna
TI The Alzheimer's-related amyloid beta peptide is internalised by R28
   neuroretinal cells and disrupts the microtubule associated protein 2
   (MAP-2)
SO EXPERIMENTAL EYE RESEARCH
LA English
DT Article
DE Amyloid beta (A beta); Neuroretina; R28 cells; Retinal degeneration;
   MAP-2
ID PIGMENT EPITHELIAL-CELLS; MACULAR DEGENERATION; RAT RETINA; CONE
   PHOTORECEPTORS; GEOGRAPHIC ATROPHY; PRECURSOR PROTEIN; DRUSEN DEPOSITS;
   MOUSE RETINA; DISEASE; NEURONS
AB Age-related Macular Degeneration (AMD) is a common, irreversible blinding condition that leads to the loss of central vision. AMD has a complex aetiology with both genetic as well as environmental risks factors, and share many similarities with Alzheimer's disease. Recent findings have contributed significantly to unravelling its genetic architecture that is yet to be matched by molecular insights. Studies are made more challenging by observations that aged and AMD retinas accumulate the highly pathogenic Alzheimer's-related Amyloid beta (A beta) group of peptides, for which there appears to be no clear genetic basis. Analyses of human donor and animal eyes have identified retinal A beta aggregates in retinal ganglion cells (RGC), the inner nuclear layer, photoreceptors as well as the retinal pigment epithelium. A beta is also a major drusen constituent; found correlated with elevated drusen-load and age, with a propensity to aggregate in retinas of advanced AMD. Despite this evidence, how such a potent driver of neurodegeneration might impair the neuroretina remains incompletely understood, and studies into this important aspect of retinopathy remains limited. In order to address this we exploited R28 rat retinal cells which due to its heterogeneous nature, offers diverse neuroretinal cell-types in which to study the molecular pathology of A beta. R28 cells are also unaffected by problems associated with the commonly used RGC-5 immortalised cell-line, thus providing a well-established model in which to study dynamic All effects at single-cell resolution. Our findings show that R28 cells express key neuronal markers calbindin, protein kinase C and the microtubule associated protein-2 (MAP-2) by confocal immunofluorescence which has not been shown before, but also calretinin which has not been reported previously. For the first time, we reveal that retinal neurons rapidly internalised A beta(1-42), the most cytotoxic and aggregate prone amongst the A beta family. Furthermore, exposure to physiological amounts of A beta(1-42) for 24 h correlated with impairment to neuronal MAP-2, a cytoskeletal protein which regulates microtubule dynamics in axons and dendrites. Disruption to MAP-2 was transient, and had recovered by 48 h, although internalised A beta persisted as discrete puncta for as long as 72 h. To assess whether A beta could realistically localise to living retinas to mediate such effects, we subretinally injected nanomolar levels of oligomeric A beta(1-42) into wildtype mice. Confocal microscopy revealed the presence of focal All deposits in RGC, the inner nuclear and the outer plexiform layers 8 days later, recapitulating naturally-occurring patterns of A beta aggregation in aged retinas. Our novel findings describe how retinal neurons internalise A beta to transiently impair MAP-2 in a hitherto unreported manner. MAP-2 dysfunction is reported in AMD retinas, and is thought to be involved in remodelling and plasticity of post-mitotic neurons. Our insights suggest a molecular pathway by which this could occur in the senescent eye leading to complex diseases such as AMD. (C) 2016 The Author(s). Published by Elsevier Ltd.
C1 [Taylor-Walker, George; Lynn, Savannah A.; Keeling, Eloise; Munday, Rosie; Scott, Jennifer A.; Goverdhan, Srini; Lotery, Andrew J.; Ratnayaka, J. Arjuna] Univ Southampton, Fac Med, Clin & Expt Sci, SGH, MP806,Tremona Rd, Southampton SO16 6YD, Hants, England.
   [Johnston, David A.; Page, Anton] Univ Southampton, Biomed Imaging Unit, SGH, MP12,Tremona Rd, Southampton SO16 6YD, Hants, England.
   [Lotery, Andrew J.] Univ Southampton NHS Trust, Eye Unit, Southampton SO16 6YD, Hants, England.
C3 University of Southampton; University of Southampton; University of
   Southampton
RP Ratnayaka, JA (通讯作者)，Univ Southampton, Fac Med, Clin & Expt Sci, SGH, MP806,Tremona Rd, Southampton SO16 6YD, Hants, England.
EM J.Ratnayaka@soton.ac.uk
OI Ratnayaka, J. Arjuna/0000-0002-1027-6938; Lotery,
   Andrew/0000-0001-5541-4305; Munday, Rosie/0000-0003-2529-2735; Johnston,
   David/0000-0001-6703-6014
FU National Centre for the Replacement, Refinement and Reduction of Animals
   in Research (NOR) [NC/L001152/1]; Fight for Sight [1485]; Gift of Sight
   Appeal; Hampshire and Isle of Wight Community Foundation; Macular
   Society UK; National Centre for the Replacement [NC/L001152/1] Funding
   Source: researchfish; Fight for Sight [1485/86] Funding Source:
   researchfish
FX This work was supported by the National Centre for the Replacement,
   Refinement and Reduction of Animals in Research (NOR: grant #
   NC/L001152/1), the Macular Society UK, Fight for Sight (grant # 1485),
   the Gift of Sight Appeal and the Hampshire and Isle of Wight Community
   Foundation. The authors are grateful to Professor Louise C. Serpell
   (University of Sussex, UK) for advice and reading of the manuscript.
CR Al-Hilaly YK, 2013, ACTA NEUROPATHOL COM, V1, DOI 10.1186/2051-5960-1-83
   Anderson DH, 2004, EXP EYE RES, V78, P243, DOI 10.1016/j.exer.2003.10.011
   Benilova I, 2012, NAT NEUROSCI, V15, P349, DOI 10.1038/nn.3028
   Bird AC, 2014, JAMA OPHTHALMOL, V132, P338, DOI 10.1001/jamaophthalmol.2013.5799
   Bodur E, 2011, BIOCHIMIE, V93, P469, DOI 10.1016/j.biochi.2010.10.020
   Broersen K, 2011, PROTEIN ENG DES SEL, V24, P743, DOI 10.1093/protein/gzr020
   Cao LN, 2013, INVEST OPHTH VIS SCI, V54, P3738, DOI 10.1167/iovs.13-11612
   Catchpole I, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0065518
   Chiu CJ, 2014, AM J OPHTHALMOL, V158, P118, DOI 10.1016/j.ajo.2014.04.016
   Citron M, 1997, NAT MED, V3, P67, DOI 10.1038/nm0197-67
   Dal Pra I, 2011, J ALZHEIMERS DIS, V24, P335, DOI [10.3233/JAD-2010-101626, 10.3233/JAD-2011-101626]
   Dasari B, 2011, BMC OPHTHALMOL, V11, DOI 10.1186/1471-2415-11-22
   Dehmelt L, 2005, GENOME BIOL, V6
   Ding JD, 2011, P NATL ACAD SCI USA, V108, pE279, DOI 10.1073/pnas.1100901108
   Do TD, 2014, J PHYS CHEM B, V118, P11220, DOI 10.1021/jp506258g
   Dutescu RM, 2009, GRAEF ARCH CLIN EXP, V247, P1213, DOI 10.1007/s00417-009-1060-3
   Fritsche LG, 2016, NAT GENET, V48, P134, DOI 10.1038/ng.3448
   Fritsche LG, 2013, NAT GENET, V45, P433, DOI 10.1038/ng.2578
   GABRIEL R, 1992, CELL TISSUE RES, V269, P175, DOI 10.1007/BF00384738
   Gordois A, 2012, GLOB PUBLIC HEALTH, V7, P465, DOI 10.1080/17441692.2011.634815
   Grandel H, 2006, DEV BIOL, V295, P263, DOI 10.1016/j.ydbio.2006.03.040
   Grunwald JE, 2015, OPHTHALMOLOGY, V122, P809, DOI 10.1016/j.ophtha.2014.11.007
   Guo L, 2007, P NATL ACAD SCI USA, V104, P13444, DOI 10.1073/pnas.0703707104
   Harada A, 2002, J CELL BIOL, V158, P541, DOI 10.1083/jcb.200110134
   Hoh K.J., 2010, PLOS ONE, V5
   Howlett DR, 2011, EXP BRAIN RES, V214, P185, DOI 10.1007/s00221-011-2819-4
   Hykin P, 2016, CLIN OPHTHALMOL, V10, P87, DOI 10.2147/OPTH.S92627
   Isas JM, 2010, INVEST OPHTH VIS SCI, V51, P1304, DOI 10.1167/iovs.09-4207
   Johnson LV, 2002, P NATL ACAD SCI USA, V99, P11830, DOI 10.1073/pnas.192203399
   Kauppinen A, 2016, CELL MOL LIFE SCI, V73, P1765, DOI 10.1007/s00018-016-2147-8
   Khandhadia S, 2012, ADV EXP MED BIOL, V724, P15, DOI 10.1007/978-1-4614-0653-2_2
   Kharlamov A, 2009, J NEUROSCI METH, V182, P205, DOI 10.1016/j.jneumeth.2009.06.014
   Kipfer-Kauer A, 2010, CURR EYE RES, V35, P828, DOI 10.3109/02713683.2010.494240
   Koronyo-Hamaoui M, 2011, NEUROIMAGE, V54, pS204, DOI 10.1016/j.neuroimage.2010.06.020
   Koyama Y, 2008, INVEST OPHTH VIS SCI, V49, P2376, DOI 10.1167/iovs.07-1067
   Krishnamoorthy RR, 2013, INVEST OPHTH VIS SCI, V54, P5712, DOI 10.1167/iovs.13-12085
   Krishnamoorthy RR, 2001, MOL BRAIN RES, V86, P1, DOI 10.1016/S0169-328X(00)00224-2
   Lingwood BE, 2008, J NEUROSCI METH, V171, P140, DOI 10.1016/j.jneumeth.2008.02.011
   Lois N, 2013, RETINA-J RET VIT DIS, V33, P13, DOI 10.1097/IAE.0b013e3182657fff
   Lotery A, 2008, EYE, V22, P739, DOI 10.1038/sj.eye.6703035
   Luibl V, 2006, J CLIN INVEST, V116, P378, DOI 10.1172/JCI25843
   Mazzoni F, 2014, EXP EYE RES, V126, P51, DOI 10.1016/j.exer.2014.01.010
   McLean CA, 1999, ANN NEUROL, V46, P860, DOI 10.1002/1531-8249(199912)46:6<860::AID-ANA8>3.0.CO;2-M
   OKABE S, 1989, BRAIN RES, V483, P335, DOI 10.1016/0006-8993(89)90178-9
   Pikuleva I.A., 2014, PROG RETIN EYE RES
   Pow DV, 2007, EXP EYE RES, V84, P850, DOI 10.1016/j.exer.2007.01.005
   Prakasam A, 2010, J ALZHEIMERS DIS, V20, P1243, DOI 10.3233/JAD-2010-100210
   Ratnayaka A, 2011, NAT COMMUN, V2, DOI 10.1038/ncomms1534
   Ratnayaka J.A., 2015, EYE LOND
   Reye P, 2002, J COMP NEUROL, V447, P323, DOI 10.1002/cne.10218
   Rich KA, 1997, J COMP NEUROL, V388, P47
   Sanchez-Mut J, 2015, FRONT BEHAV NEUROSCI, V9, DOI 10.3389/fnbeh.2015.00347
   Sato N, 2013, FRONT AGING NEUROSCI, V5, DOI 10.3389/fnagi.2013.00064
   Seigel GM, 2014, MOL VIS, V20, P301
   Seigel GM, 1996, IN VITRO CELL DEV-AN, V32, P66
   Seigel GM, 2004, CURR EYE RES, V28, P257, DOI 10.1076/ceyr.28.4.257.27831
   Sippl C, 2014, ADV EXP MED BIOL, V801, P145, DOI 10.1007/978-1-4614-3209-8_19
   Smith JD, 2008, J COMP PATHOL, V138, P12, DOI 10.1016/j.jcpa.2007.09.002
   Song MS, 2011, NEUROSCIENCE, V178, P181, DOI 10.1016/j.neuroscience.2010.12.055
   Soura V, 2012, BIOCHEM J, V441, P579, DOI 10.1042/BJ20110749
   Sudo H, 2010, J NEUROSCI, V30, P7215, DOI 10.1523/JNEUROSCI.0048-10.2010
   Sullivan RKP, 2007, INVEST OPHTH VIS SCI, V48, P2782, DOI 10.1167/iovs.06-1283
   Teng JL, 2001, J CELL BIOL, V155, P65, DOI 10.1083/jcb.200106025
   Tucker R P, 1988, Brain Res, V466, P313
   TUCKER RP, 1988, DEV BIOL, V130, P423, DOI 10.1016/0012-1606(88)90338-7
   Vaillant AR, 2002, NEURON, V34, P985, DOI 10.1016/S0896-6273(02)00717-1
   Van Bergen NJ, 2009, INVEST OPHTH VIS SCI, V50, P4267, DOI 10.1167/iovs.09-3484
   Walsh DT, 2005, NEUROPATH APPL NEURO, V31, P491, DOI 10.1111/j.1365-2990.2005.00666.x
   Wang JQ, 2011, ANAT REC, V294, P1401, DOI 10.1002/ar.21438
   Wang JY, 2008, J IMMUNOL, V181, P712, DOI 10.4049/jimmunol.181.1.712
   Wang JY, 2012, BIOCHEM BIOPH RES CO, V424, P704, DOI 10.1016/j.bbrc.2012.07.014
   Wang JY, 2012, BIOCHEM BIOPH RES CO, V423, P73, DOI 10.1016/j.bbrc.2012.05.085
   Williams TL, 2011, FEBS J, V278, P3905, DOI 10.1111/j.1742-4658.2011.08228.x
   Williams TL, 2011, BIOCHEM J, V439, P67, DOI 10.1042/BJ20110750
   Williams TL, 2010, LANGMUIR, V26, P17260, DOI 10.1021/la101581g
   Wu FB, 2009, AGEING RES REV, V8, P147, DOI 10.1016/j.arr.2009.03.002
   Yan J, 2010, BRAIN RES, V1347, P132, DOI 10.1016/j.brainres.2010.05.074
   Yoshida T, 2005, J CLIN INVEST, V115, P2793, DOI 10.1172/JCI24635
   Zhang H, 2008, BMC MED GENET, V9, DOI 10.1186/1471-2350-9-51
NR 79
TC 13
Z9 14
U1 0
U2 6
PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 0014-4835
EI 1096-0007
J9 EXP EYE RES
JI Exp. Eye Res.
PD DEC
PY 2016
VL 153
BP 110
EP 121
DI 10.1016/j.exer.2016.10.013
PG 12
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA EE0RX
UT WOS:000389287700013
PM 27751744
OA hybrid, Green Published, Green Accepted
DA 2022-11-30
ER

PT J
AU Brown, GC
   Brown, MM
   Chaudhry, I
   Stein, JD
AF Brown, Gary C.
   Brown, Melissa M.
   Chaudhry, Imtiaz
   Stein, Joshua D.
TI Opportunities to Reduce Potential Bias in Ophthalmic Cost-Utility
   Analysis
SO JAMA OPHTHALMOLOGY
LA English
DT Article
AB IMPORTANCE Select research methods in cost-utility analysis (incremental cost-effectiveness analysis) might potentially bias against patient value (quality-adjusted life-year [QALY]) gain and cost-effectiveness associated with common ophthalmic interventions in disabled, elderly, and African American populations.
   OBJECTIVE To ascertain whether using nonpatient vision utilities and/or a maximum limit model constraining vision utility gain to the systemic comorbidity utility level biases against ophthalmic cost-utility outcomes.
   DESIGN, SETTING, AND PARTICIPANTS This economic evaluation predominantly used data from the Center for Value-Based Medicine database to perform preference-based comparative effectiveness and cost-utility analyses for cataract surgery and intravitreal ranibizumab therapy for neovascular age-related macular degeneration (NVAMD) using vision utilities acquired from patients with ophthalmic disease (ophthalmic patient utilities) and from surrogate individuals (nonophthalmic patient vision utilities) with and without integrating systemic comorbidity utility limits on vision utility gain. Ophthalmic patient data were collected from January 1, 2000, to December 31, 2016, and analyzed from April 1 to July 1, 2020.
   INTERVENTIONS Cost-utility analysis with 3% discount rate in 2018 US dollars. MAIN
   OUTCOMES AND MEASURES QALY gains and dollars expended per QALY gain (the cost-utility ratio).
   RESULTS A total of 309 participants in the nonophthalmic patient cohort and 505 patients in the ophthalmic patient cohort were included. A reference case of first-eye cataract surgery using ophthalmic patient vision utilities and no systemic comorbidity utility limits yielded a 2.574 (34.2%) QALY gain vs observation. Substituting nonophthalmic patient utilities resulted in a 1.502 (15.5%) QALY gain, whereas using the 0.76 patient systemic comorbidity utility to limit cataract surgery vision utility gain yielded a 1.337 (17.8%) QALY gain. Using both nonophthalmic patient utilities and systemic comorbidity utility limits yielded a 0.839 (8.7%) QALY gain. The substitutions decreased cataract surgery cost-effectiveness by 71.3%(95% CI, 70.6%-72.1%) for nonophthalmic patient utilities, 92.5%(95% CI, 51.9%-133.1%) for patient systemic comorbidity utility, and 206.8%(95% CI, 202.6%-211.2%) for both. The NVAMD ranibizumab therapy reference case yielded a 1.339 (26.1%) QALY gain. Similar substitutions resulted in QALY gains of 1.164 (22.7%) for nonophthalmic patient utilities while reducing cost-effectiveness by 16.4%, 1.001 (19.5%) for systematic-limiting comorbidity utility while reducing cost-effectiveness by 33.8%, and 0.971 (18.9%) for both while reducing cost-effectiveness by 37.9%.
   CONCLUSIONS AND RELEVANCE Using nonophthalmic patient vision utilities and/or the maximum limit model of limiting patient utility gains to the population systemic comorbidity utility level resulted in large decreases in patient value (QALY) gain and cost-effectiveness for common ophthalmic interventions. Ophthalmologists should realize these phenomena and consider correcting the potential discrimination against disabled, elderly, and African American populations. This negative potential bias could theoretically result in beneficial intervention denial, less research dollars, curbed therapeutic advances, and decreased interventional reimbursement.
C1 [Brown, Gary C.; Brown, Melissa M.] Ctr Value Based Med, POB 3417, Hilton Head Isl, SC 29928 USA.
   [Brown, Gary C.; Brown, Melissa M.] Thomas Jefferson Med Univ, Wills Eye Hosp, Philadelphia, PA USA.
   [Brown, Gary C.; Brown, Melissa M.] Emory Univ, Sch Med, Dept Ophthalmol, Atlanta, GA 30322 USA.
   [Chaudhry, Imtiaz] Aria Jefferson Hlth, Dept Ophthalmol, Philadelphia, PA USA.
   [Stein, Joshua D.] Univ Michigan, Kellogg Eye Ctr, Glaucoma Serv, Ann Arbor, MI 48109 USA.
C3 Jefferson University; Emory University; University of Michigan System;
   University of Michigan
RP Brown, GC (通讯作者)，Ctr Value Based Med, POB 3417, Hilton Head Isl, SC 29928 USA.
EM gbrown@valuebasedmedicine.com
CR Diez JMB, 2020, MED CLIN-BARCELONA, V154, P254, DOI 10.1016/j.medcli.2019.06.021
   Bajwa ZH, 2004, KIDNEY INT, V66, P1561, DOI 10.1111/j.1523-1755.2004.00921.x
   Brazier J, 2019, VALUE HEALTH, V22, P267, DOI 10.1016/j.jval.2019.01.004
   Brown, 2020, AM J OPHTHALMOL
   Brown G C, 1999, Trans Am Ophthalmol Soc, V97, P473
   Brown GC, 2020, AM J OPHTHALMOL, V218, P225, DOI 10.1016/j.ajo.2020.05.029
   Brown GC, 2019, J CATARACT REFR SURG, V45, P927, DOI 10.1016/j.jcrs.2019.02.006
   Brown GC, 2019, SURV OPHTHALMOL, V64, P345, DOI 10.1016/j.survophthal.2018.11.001
   Brown GC, 2018, OPHTHALMOLOGY, V125, P965, DOI 10.1016/j.ophtha.2017.12.033
   Brown GC, 2000, CAN J OPHTHALMOL, V35, P127, DOI 10.1016/S0008-4182(00)80005-8
   Brown MM, 2002, BRIT J OPHTHALMOL, V86, P8, DOI 10.1136/bjo.86.1.8
   Brown MM, 2001, BRIT J OPHTHALMOL, V85, P327, DOI 10.1136/bjo.85.3.327
   Brown MM, 2005, EVIDENCE BASED VALUE, P151
   Center for Medicare & Medicaid Services, PHYS FEE SCHED SEARC
   Centers for Disease Control and Prevention, NAT DIAB STAT REP 20
   Centers for Medicare and Medicaid Services, HLTH OUTC SURV HOS
   Chaudry I, 2015, CAN J OPHTHALMOL, V50, P217, DOI 10.1016/j.jcjo.2015.02.004
   Christ SL, 2014, JAMA OPHTHALMOL, V132, P1400, DOI 10.1001/jamaophthalmol.2014.2847
   Espallargues M, 2005, INVEST OPHTH VIS SCI, V46, P4016, DOI 10.1167/iovs.05-0072
   Feeny D, 2017, COST EFFECTIVENESS H, P167
   FRYBACK DG, 1993, MED DECIS MAKING, V13, P89, DOI 10.1177/0272989X9301300202
   Haagsma JA, 2011, POPUL HEALTH METR, V9, DOI 10.1186/1478-7954-9-10
   Health Utilities Inc, MULT HLTH STAT CLASS
   Heffler E, 2019, J ALLER CL IMM-PRACT, V7, P1462, DOI 10.1016/j.jaip.2018.10.016
   Hollands H, 2001, CAN J OPHTHALMOL, V36, P202, DOI 10.1016/S0008-4182(01)80041-7
   Maguire MG, 2016, OPHTHALMOLOGY, V123, P1751, DOI 10.1016/j.ophtha.2016.03.045
   National Institute of Health and Care Excellence, 2014, DEV NICE GUID MAN
   Owens, 2017, COST EFFECTIVENESS H, P75
   Park B, 2020, QUAL LIFE RES, V29, P2475, DOI 10.1007/s11136-020-02514-5
   Pearson Isobel, 2013, J Med Econ, V16, P1307, DOI 10.3111/13696998.2013.839946
   Quinones AR, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0218462
   Real FJ, 2008, BRIT J OPHTHALMOL, V92, P770, DOI 10.1136/bjo.2007.127407
   Sanders GD, 2016, JAMA-J AM MED ASSOC, V316, P1093, DOI 10.1001/jama.2016.12195
   Shah AR, 2007, AM J OPHTHALMOL, V143, P83, DOI 10.1016/j.ajo.2006.09.043
   Sharma S, 2002, BRIT J OPHTHALMOL, V86, P493, DOI 10.1136/bjo.86.5.493
   Stein JD, 2003, BRIT J OPHTHALMOL, V87, P8, DOI 10.1136/bjo.87.1.8
   World Med Assoc, 2013, JAMA-J AM MED ASSOC, V310, P2191, DOI 10.1001/jama.2013.281053
   Zhao Y, 2018, J MED ECON, V21, P85, DOI 10.1080/13696998.2017.1387118
NR 38
TC 4
Z9 4
U1 0
U2 3
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 2168-6165
EI 2168-6173
J9 JAMA OPHTHALMOL
JI JAMA Ophthalmol.
PD APR
PY 2021
VL 139
IS 4
BP 389
EP 397
DI 10.1001/jamaophthalmol.2020.6591
EA FEB 2021
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA RQ8AR
UT WOS:000614935200004
PM 33538789
OA Bronze, Green Published
DA 2022-11-30
ER

PT J
AU Ting, DSW
   Cheung, CYL
   Lim, G
   Tan, GSW
   Quang, ND
   Gan, A
   Hamzah, H
   Garcia-Franco, R
   Yeo, IYS
   Lee, SY
   Wong, EYM
   Sabanayagam, C
   Baskaran, M
   Ibrahim, F
   Tan, NC
   Finkelstein, EA
   Lamoureux, EL
   Wong, IY
   Bressler, NM
   Sivaprasad, S
   Varma, R
   Jonas, JB
   He, MG
   Cheng, CY
   Cheung, GCM
   Aung, T
   Hsu, W
   Lee, ML
   Wong, TY
AF Ting, Daniel Shu Wei
   Cheung, Carol Yim-Lui
   Lim, Gilbert
   Tan, Gavin Siew Wei
   Quang, Nguyen D.
   Gan, Alfred
   Hamzah, Haslina
   Garcia-Franco, Renata
   Yeo, Ian Yew San
   Lee, Shu Yen
   Wong, Edmund Yick Mun
   Sabanayagam, Charumathi
   Baskaran, Mani
   Ibrahim, Farah
   Tan, Ngiap Chuan
   Finkelstein, Eric A.
   Lamoureux, Ecosse L.
   Wong, Ian Y.
   Bressler, Neil M.
   Sivaprasad, Sobha
   Varma, Rohit
   Jonas, Jost B.
   He, Ming Guang
   Cheng, Ching-Yu
   Cheung, Gemmy Chui Ming
   Aung, Tin
   Hsu, Wynne
   Lee, Mong Li
   Wong, Tien Yin
TI Development and Validation of a Deep Learning System for Diabetic
   Retinopathy and Related Eye Diseases Using Retinal Images From
   Multiethnic Populations With Diabetes
SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
LA English
DT Article
ID MAJOR RISK-FACTORS; MACULAR DEGENERATION; SINGAPORE EPIDEMIOLOGY;
   AUTOMATED DETECTION; GLOBAL PREVALENCE; TELEMEDICINE; CHALLENGES;
   MANAGEMENT; BARRIERS; COHORT
AB IMPORTANCE A deep learning system (DLS) is a machine learning technology with potential for screening diabetic retinopathy and related eye diseases.
   OBJECTIVE To evaluate the performance of a DLS in detecting referable diabetic retinopathy, vision-threatening diabetic retinopathy, possible glaucoma, and age-related macular degeneration (AMD) in community and clinic-based multiethnic populations with diabetes.
   DESIGN, SETTING, AND PARTICIPANTS Diagnostic performance of a DLS for diabetic retinopathy and related eye diseases was evaluated using 494 661 retinal images. A DLS was trained for detecting diabetic retinopathy (using 76 370 images), possible glaucoma (125 189 images), and AMD(72 610 images), and performance of DLS was evaluated for detecting diabetic retinopathy (using 112 648 images), possible glaucoma (71 896 images), and AMD(35 948 images). Training of the DLS was completed in May 2016, and validation of the DLS was completed in May 2017 for detection of referable diabetic retinopathy (moderate nonproliferative diabetic retinopathy or worse) and vision-threatening diabetic retinopathy (severe nonproliferative diabetic retinopathy orworse) using a primary validation data set in the Singapore National Diabetic Retinopathy Screening Program and 10 multiethnic cohorts with diabetes.
   EXPOSURES Use of a deep learning system.
   MAIN OUTCOMES AND MEASURES Area under the receiver operating characteristic curve (AUC) and sensitivity and specificity of the DLS with professional graders (retinal specialists, general ophthalmologists, trained graders, or optometrists) as the reference standard.
   RESULTS In the primary validation dataset (n = 14 880 patients; 71 896 images; mean [SD] age, 60.2 [2.2] years; 54.6% men), the prevalence of referable diabetic retinopathy was 3.0%; vision-threatening diabetic retinopathy, 0.6%; possible glaucoma, 0.1%; and AMD, 2.5%. The AUC of the DLS for referable diabetic retinopathy was 0.936 (95% CI, 0.925-0.943), sensitivity was 90.5%(95% CI, 87.3%-93.0%), and specificity was 91.6% (95% CI, 91.0%-92.2%). For vision-threatening diabetic retinopathy, AUC was 0.958 (95% CI, 0.956-0.961), sensitivity was 100% (95% CI, 94.1%-100.0%), and specificity was 91.1% (95% CI, 90.7%-91.4%). For possible glaucoma, AUC was 0.942 (95% CI, 0.929-0.954), sensitivity was 96.4%(95% CI, 81.7%-99.9%), and specificity was 87.2%(95% CI, 86.8%-87.5%). For AMD, AUC was 0.931 (95% CI, 0.928-0.935), sensitivity was 93.2%(95% CI, 91.1%-99.8%), and specificity was 88.7%(95% CI, 88.3%-89.0%). For referable diabetic retinopathy in the 10 additional datasets, AUC range was 0.889 to 0.983 (n = 40 752 images).
   CONCLUSIONS AND RELEVANCE In this evaluation of retinal images from multiethnic cohorts of patients with diabetes, the DLS had high sensitivity and specificity for identifying diabetic retinopathy and related eye diseases. Further research is necessary to evaluate the applicability of the DLS in health care settings and the utility of the DLS to improve vision outcomes.
C1 [Ting, Daniel Shu Wei; Cheung, Carol Yim-Lui; Tan, Gavin Siew Wei; Quang, Nguyen D.; Gan, Alfred; Hamzah, Haslina; Yeo, Ian Yew San; Lee, Shu Yen; Wong, Edmund Yick Mun; Sabanayagam, Charumathi; Baskaran, Mani; Lamoureux, Ecosse L.; Cheng, Ching-Yu; Cheung, Gemmy Chui Ming; Aung, Tin; Wong, Tien Yin] Singapore Natl Eye Ctr, Singapore Eye Res Inst, Singapore, Singapore.
   [Ting, Daniel Shu Wei; Tan, Gavin Siew Wei; Yeo, Ian Yew San; Lee, Shu Yen; Wong, Edmund Yick Mun; Sabanayagam, Charumathi; Baskaran, Mani; Ibrahim, Farah; Tan, Ngiap Chuan; Lamoureux, Ecosse L.; Cheng, Ching-Yu; Cheung, Gemmy Chui Ming; Aung, Tin; Wong, Tien Yin] Natl Univ Singapore, Duke NUS Med Sch, Singapore, Singapore.
   [Cheung, Carol Yim-Lui] Chinese Univ Hong Kong, Dept Ophthalmol & Visual Sci, Hong Kong, Hong Kong, Peoples R China.
   [Lim, Gilbert; Hsu, Wynne; Lee, Mong Li] Natl Univ Singapore, Sch Comp, Singapore, Singapore.
   [Garcia-Franco, Renata] IAP, Inst Mexicano Oftalmol, Queretaro, Mexico.
   [Tan, Ngiap Chuan] Singapore Hlth Serv, SingHlth Polyclin, Singapore, Singapore.
   [Finkelstein, Eric A.] Duke NUS Grad Med Sch, Lien Ctr Palliat Care, Hlth Serv & Syst Res Program, Singapore, Singapore.
   [Wong, Ian Y.] Univ Hong Kong, Dept Ophthalmol, Hong Kong, Hong Kong, Peoples R China.
   [Bressler, Neil M.] Johns Hopkins Wilmer Eye Inst, Baltimore, MD USA.
   [Sivaprasad, Sobha] Natl Hlth Serv Fdn Trust, Moorfields Eye Hosp, London, England.
   [Varma, Rohit] Univ Southern Calif, Gayle & Edward Roski Eye Inst, Los Angeles, CA USA.
   [Jonas, Jost B.] Heidelberg Univ, Dept Ophthalmol, Heidelberg, Germany.
   [He, Ming Guang] Sun Yatsen Univ, State Key Lab Ophthalmol, Zhongshan Ophthalm Ctr, Guangzhou, Guangdong, Peoples R China.
C3 National University of Singapore; Singapore National Eye Center;
   National University of Singapore; Chinese University of Hong Kong;
   National University of Singapore; National University of Singapore;
   University of Hong Kong; Johns Hopkins University; Johns Hopkins
   Medicine; University of London; University College London; Moorfields
   Eye Hospital NHS Foundation Trust; University of Southern California;
   Ruprecht Karls University Heidelberg; Sun Yat Sen University
RP Wong, TY (通讯作者)，Singapore Natl Eye Ctr, 11 Third Hosp Ave, Singapore 168751, Singapore.
EM wong.tien.yin@snec.com.sg
RI He, Mingguang/AAY-5239-2020; Cheung, Carol/AAF-1101-2020; Lim,
   Gilbert/N-7322-2017; Wong, Tien Yin/AAC-9724-2020; Sabanayagam,
   Charumathi/C-1294-2011; Cheung, Carol Y./G-7895-2016; Sivaprasad,
   S./D-6876-2015; Cheng, Ching-Yu/Y-2229-2019; Lamoureux,
   Ecosse/Z-5482-2019; Mani, Baskaran/GWZ-8299-2022; Nguyen, Duc
   Quang/AHC-6430-2022
OI He, Mingguang/0000-0002-6912-2810; Cheung, Carol/0000-0002-9672-1819;
   Lim, Gilbert/0000-0002-5381-9250; Wong, Tien Yin/0000-0002-8448-1264;
   Sabanayagam, Charumathi/0000-0002-4042-4719; Sivaprasad,
   S./0000-0001-8952-0659; Cheng, Ching-Yu/0000-0003-0655-885X; Nguyen, Duc
   Quang/0000-0001-6919-5211; Tan, Ngiap-Chuan/0000-0002-5946-1149; Hsu,
   Wynne/0000-0002-4142-8893; Cheung, Chui Ming Gemmy/0000-0003-3358-3516;
   Lee, Mong Li/0000-0002-9636-388X; Bidwai, Pooja
   Vishal/0000-0002-3077-4395
FU Singapore National Health Innovation Center (NHIC) [NHIC-I2D-1409022];
   SingHealth Foundation Research Grant [SHF/FG648S/2015]; Tanoto
   Foundation; NMRC, MOH [0796/2003, IRG07nov013, IRG09nov014,
   STaR/0003/2008, STaR/2013, CG/SERI/2010]; Biomedical Research Council
   [08/1/35/19/550, 09/1/35/19/616]; MOH, Singapore
   [AIC/RPDD/SIDRP/SERI/FY2013/0018, AIC/HPD/FY2016/0912]; National Medical
   Research Council (NMRC), Ministry of Health (MOH)
FX This project received funding from National Medical Research Council
   (NMRC), Ministry of Health (MOH), Singapore National Health Innovation
   Center (NHIC), Innovation to Develop Grant (NHIC-I2D-1409022);
   SingHealth Foundation Research Grant (SHF/FG648S/2015), and the Tanoto
   Foundation; unrestricted donations to the Retina Division, Johns Hopkins
   University School of Medicine. For the Singapore Epidemiology of Eye
   Diseases (SEED) study, we received funding from NMRC, MOH (grants
   0796/2003, IRG07nov013, IRG09nov014, STaR/0003/2008 and STaR/2013;
   CG/SERI/2010) and Biomedical Research Council (grants 08/1/35/19/550 and
   09/1/35/19/616). The Singapore Diabetic Retinopathy Program received
   funding from the MOH, Singapore (grants AIC/RPDD/SIDRP/SERI/FY2013/0018
   and AIC/HPD/FY2016/0912).
CR Abramoff MD, 2010, OPHTHALMOLOGY, V117, P1147, DOI 10.1016/j.ophtha.2010.03.046
   Abramoff MD, 2010, EXPERT REV MED DEVIC, V7, P287, DOI 10.1586/ERD.09.76
   Abramoff MD, 2008, DIABETES CARE, V31, P193, DOI 10.2337/dc07-1312
   Abramoff MD, 2016, INVEST OPHTH VIS SCI, V57, P5200, DOI 10.1167/iovs.16-19964
   Bhargava M, 2012, SINGAP MED J, V53, P715
   Burgess PI, 2013, BMC MED, V11, DOI 10.1186/1741-7015-11-157
   Chakrabarti R, 2012, EXPERT REV OPHTHALMO, V7, P417, DOI 10.1586/EOP.12.52
   Cheung CMG, 2012, CLIN EXP OPHTHALMOL, V40, P727, DOI 10.1111/j.1442-9071.2012.02765.x
   Cheung CMG, 2014, OPHTHALMOLOGY, V121, P1598, DOI 10.1016/j.ophtha.2014.02.004
   Cheung N, 2010, LANCET, V376, P124, DOI 10.1016/S0140-6736(09)62124-3
   Chew EY, 2015, OPHTHALMOLOGY, V122, P2155, DOI 10.1016/j.ophtha.2015.08.007
   Chong YH, 2017, OPHTHALMOLOGY, V124, P336, DOI 10.1016/j.ophtha.2016.11.016
   Chua J, 2015, JAMA OPHTHALMOL, V133, P938, DOI 10.1001/jamaophthalmol.2015.1478
   Frcophth AT, 2017, OPHTHALMOLOGY, V124, P343, DOI 10.1016/j.ophtha.2016.11.014
   Gargeya R, 2017, OPHTHALMOLOGY, V124, P962, DOI 10.1016/j.ophtha.2017.02.008
   Gulshan V, 2016, JAMA-J AM MED ASSOC, V316, P2402, DOI 10.1001/jama.2016.17216
   Hazin R, 2011, AM J OPHTHALMOL, V152, P723, DOI 10.1016/j.ajo.2011.06.022
   Huang OS, 2015, BRIT J OPHTHALMOL, V99, P1614, DOI 10.1136/bjophthalmol-2014-306492
   Jonas JB, 2009, ACTA OPHTHALMOL, V87, P247, DOI 10.1111/j.1755-3768.2008.01385.x
   Klein R, 1991, OPHTHALMOLOGY, V98, P1134
   Lamoureux EL, 2012, CLIN EXP OPHTHALMOL, V40, P73, DOI 10.1111/j.1442-9071.2011.02697.x
   LeCun Y, 2015, NATURE, V521, P436, DOI 10.1038/nature14539
   Lim G, 2014, MAIHA WORKSH 28 AAAI, P34
   National Health Service (NHS) Diabetic Eye Screening Programme and Population Screening Programmes, 2015, DIAB EYE SCREEN COMM
   Nguyen HV, 2016, OPHTHALMOLOGY, V123, P2571, DOI 10.1016/j.ophtha.2016.08.021
   Ren SQ, 2010, J APPL STAT, V37, P1487, DOI 10.1080/02664760903046102
   Shi Y, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0175966
   Sivaprasad S, 2012, SURV OPHTHALMOL, V57, P347, DOI 10.1016/j.survophthal.2012.01.004
   Tang FY, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-02767-0
   Ting DSW, 2011, CLIN EXP OPHTHALMOL, V39, P230, DOI 10.1111/j.1442-9071.2010.02446.x
   Ting DSW, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-08276-4
   Ting DSW, 2017, JAMA OPHTHALMOL, V135, P722, DOI 10.1001/jamaophthalmol.2017.1257
   Ting DSW, 2016, CLIN EXP OPHTHALMOL, V44, P260, DOI 10.1111/ceo.12696
   Ting DSW, 2016, AM J OPHTHALMOL, V164, P128, DOI 10.1016/j.ajo.2015.12.024
   Varma R., 2017, AFRICAN AM EYE DIS S
   Wang LZZ, 2017, BRIT J OPHTHALMOL, V101, P1352, DOI 10.1136/bjophthalmol-2016-310002
   Wilkinson CP, 2003, OPHTHALMOLOGY, V110, P1677, DOI 10.1016/S0161-6420(03)00475-5
   Wong TY, 2008, OPHTHALMOLOGY, V115, P1869, DOI 10.1016/j.ophtha.2008.05.014
   Wong TY, 2016, JAMA-J AM MED ASSOC, V316, P2366, DOI 10.1001/jama.2016.17563
   Yau JWY, 2012, DIABETES CARE, V35, P556, DOI 10.2337/dc11-1909
NR 40
TC 876
Z9 919
U1 42
U2 270
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 0098-7484
EI 1538-3598
J9 JAMA-J AM MED ASSOC
JI JAMA-J. Am. Med. Assoc.
PD DEC 12
PY 2017
VL 318
IS 22
BP 2211
EP 2223
DI 10.1001/jama.2017.18152
PG 13
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA FP7NR
UT WOS:000417822700019
PM 29234807
OA Green Published, Bronze
HC Y
HP N
DA 2022-11-30
ER

PT J
AU Schneider, K
   Chwa, M
   Atilano, SR
   Shao, ZX
   Park, J
   Karageozian, H
   Karageozian, V
   Kenney, MC
AF Schneider, Kevin
   Chwa, Marilyn
   Atilano, Shari R.
   Shao, Zixuan
   Park, John
   Karageozian, Hampar
   Karageozian, Vicken
   Kenney, M. Cristina
TI Differential effects of risuteganib and bevacizumab on AMD cybrid cells
SO EXPERIMENTAL EYE RESEARCH
LA English
DT Article
DE Risuteganib; Bevacizumab; Age-related macular degeneration; Cybrids
AB Purpose: Intravitreal injections of anti-vascular endothelial growth factor (VEGF) treatments are currently used to treat wet age-related macular degeneration (AMD), diabetic retinopathy, and macular edema. Chronic, repetitive treatments with anti-VEGF may have unintended consequences beyond the inhibition of angiogenesis. Most recently, clinical trials have been conducted with risuteganib (RSG, Luminate (R)), which is anti-angiogenic and has neuroprotective and anti-inflammatory properties. Mitochondrial damage and dysfunction play a major role in development of AMD. Transmitochondrial cybrids are cell lines established by fusing human retinal pigment epithelial (RPE) cells that are Rho0 (lacking mtDNA) with platelets isolated from AMD subjects or age-matched normal subjects. Cybrid cell lines have identical nuclei but mitochondria from different subjects, enabling investigation of the functional consequences of damaged AMD mitochondria. The present study compares the responses of AMD cybrids treated with bevacizumab (Bmab, Avastin (R)) versus risuteganib (RSG, Luminate (R)).
   Methods: Cybrids were created by fusing mtDNA depleted ARPE-19 cells with platelets from AMD or age-matched normal patients. AMD (n = 5) and normal (n = 3) cybrids were treated for 48 h with or without 1x clinical dose of 1.25 mg/50 mu l (25,000 mu g/ml) of Bmab or 1.0 mg/50 mu l (20,000 mu g/ml) of RSG. Cultures were analyzed for levels of cleaved caspase 3/7 and NucLight Rapid Red staining (IncuCyte (R) Live Cell Imager), mitochondrial membrane potential (Delta psi m, JC1 assay) or reactive oxygen species (ROS, H2DCFDA assay). Expression levels of genes related to the following pathways were analyzed with qRT-PCR: Apoptosis (BAX, BCL2L13, CASP-3,-7,-9); angiogenesis (VEGFA, HIF1 alpha, PDGF); integrins (ITGB-1,-3,-5, ITGA-3,-5,-V); mitochondrial biogenesis (PGC1 alpha, POLG); oxidative stress (SOD2, GPX3, NOX4); inflammation (IL-6,-18,-1 beta, IFN-beta 1); and signaling (P3KCA, PI3KR1). Statistical analyses were performed using GraphPad Prism software.
   Results: The untreated AMD cybrids had significantly higher levels of cleaved caspase 3/7 compared to the untreated normal cybrids. The Bmab-treated AMD cybrids showed elevated levels of cleaved caspase 3/7 compared to untreated AMD or RSG-treated AMD cybrids. The Bmab-treated cybrids had lower Delta psi m compared to untreated AMD or RSG-treated AMD cybrids. The ROS levels were not changed with Bmab or RSG treatment. Results showed that Bmab-treated cybrids had higher expression levels of inflammatory (IL-6, IL1-beta), oxidative stress (NOX4) and angiogenesis (VEGFA) genes compared to untreated AMD, while RSG-treated cybrids had lower expression levels of apoptosis (BAX), angiogenesis (VEGFA) and integrin (ITGB1) genes.
   Conclusions: These data suggest that the mechanism(s) of action of RSG, an integrin regulator, and Bmab, a recombinant monoclonal antibody, affect the AMD RPE cybrid cells differently, with the former having more anti-apoptosis properties, which may be desirable in treating degenerative ocular diseases.
C1 [Schneider, Kevin; Chwa, Marilyn; Atilano, Shari R.; Kenney, M. Cristina] Univ Calif Irvine, Gavin Herbert Eye Inst, Irvine, CA 92697 USA.
   [Shao, Zixuan; Park, John; Karageozian, Hampar; Karageozian, Vicken] Allegro Ophthalm LLC, San Juan Capistrano, CA USA.
   [Kenney, M. Cristina] Univ Calif Irvine, Dept Pathol & Lab Med, Irvine, CA 92697 USA.
C3 University of California System; University of California Irvine;
   University of California System; University of California Irvine
RP Kenney, MC (通讯作者)，Univ Calif Irvine, Gavin Herbert Eye Inst, Ophthalmol Res Lab, Hewitt Hall,Room 2028 843 Hlth Sci Rd, Irvine, CA 92697 USA.
EM mkenney@uci.edu
OI Chwa, Marilyn/0000-0002-1874-6041; shao, zixuan/0000-0002-4676-6023
FU Arnold and Mabel Beckman Foundation; Discovery Eye Foundation; NEI [R01
   EY0127363]; Research to Prevent Blindness; Institute for Clinical and
   Translational Science (ICTS) at University of California Irvine
FX We wish to thank the subjects who participated in this study. This work
   was supported by the Arnold and Mabel Beckman Foundation, Discovery Eye
   Foundation, Polly and Michael Smith, Edith and Roy Carver, and NEI R01
   EY0127363 (MCK). Supported in part by an Unrestricted Departmental Grant
   from Research to Prevent Blindness. We acknowledge the support of the
   Institute for Clinical and Translational Science (ICTS) at University of
   California Irvine.
CR Ablonczy Z, 2011, INVEST OPHTH VIS SCI, V52, P8614, DOI 10.1167/iovs.11-8021
   Alidzanovic L, 2016, ONCOTARGET, V7, P57197, DOI 10.18632/oncotarget.11084
   Beltran MA, 2018, INVEST OPHTH VIS SCI, V59
   Byzova TV, 2000, MOL CELL, V6, P851, DOI 10.1016/S1097-2765(05)00076-6
   Caceres-del-Carpio J, 2020, EXP EYE RES, V191, DOI 10.1016/j.exer.2019.107903
   Chakravarthy U, 2013, LANCET, V382, P1258, DOI 10.1016/S0140-6736(13)61501-9
   Chomyn A., 1996, PLATELET MEDIATED TR
   Feher J, 2005, OPHTHALMOLOGICA, V219, P154, DOI 10.1159/000085248
   Feher J, 2003, OPHTHALMOLOGICA, V217, P351, DOI 10.1159/000071351
   Feher J, 2006, NEUROBIOL AGING, V27, P983, DOI 10.1016/j.neurobiolaging.2005.05.012
   Forooghian F, 2010, INVEST OPHTH VIS SCI, V51, P2388, DOI 10.1167/iovs.09-4065
   FRIEDLANDER M, 1995, SCIENCE, V270, P1500, DOI 10.1126/science.270.5241.1500
   Friedlander M, 1996, P NATL ACAD SCI USA, V93, P9764, DOI 10.1073/pnas.93.18.9764
   Gillies MC, 2020, OPHTHALMOLOGY, V127, P198, DOI 10.1016/j.ophtha.2019.08.023
   Gonzalez V., 2016, RETINA TODAY, P76
   Gonzalez-Salinas R, 2018, SEMIN OPHTHALMOL, V33, P634, DOI 10.1080/08820538.2017.1388411
   Grunwald JE, 1998, AM J OPHTHALMOL, V125, P731
   Grunwald JE, 2014, OPHTHALMOLOGY, V121, P150, DOI 10.1016/j.ophtha.2013.08.015
   Guo B, 2010, MOL VIS, V16, P793
   Jeon S, 2012, CYTOKINE, V60, P535, DOI 10.1016/j.cyto.2012.07.005
   Kaiser P, 2019, AM SOC RET SPEC ANN
   Kaiser P, 2013, INVEST OPHTH VIS SCI, V54
   Karunadharma PP, 2010, INVEST OPHTH VIS SCI, V51, P5470, DOI 10.1167/iovs.10-5429
   Kenney M.C., 2014, HUM MOL GENET
   Kenney MC, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054339
   Klettner A, 2010, GRAEF ARCH CLIN EXP, V248, P819, DOI 10.1007/s00417-010-1317-x
   Kuppermann B.D., 2019, RETIN PHYS
   Li Y, 2016, BBA-GEN SUBJECTS, V1860, P2137, DOI 10.1016/j.bbagen.2016.05.031
   Lugano R, 2018, J CLIN INVEST, V128, P3280, DOI 10.1172/JCI97459
   Malik D, 2014, BRIT J OPHTHALMOL, V98, P11, DOI 10.1136/bjophthalmol-2014-305302
   Manousaridis K, 2012, BRIT J OPHTHALMOL, V96, P179, DOI 10.1136/bjophthalmol-2011-301087
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Milner R, 2002, MOL CELL NEUROSCI, V20, P616, DOI 10.1006/mcne.2002.1151
   Mueller EE, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030874
   Nashine S, 2019, AGING-US, V11, P6691, DOI 10.18632/aging.102179
   Nashine S, 2019, AGING-US, V11, P1177, DOI 10.18632/aging.101820
   Nashine S, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-33290-5
   Nashine S, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.348
   Nashine S, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0159828
   Nicholls TJ, 2014, EXP GERONTOL, V56, P175, DOI 10.1016/j.exger.2014.03.027
   Nordgaard CL, 2006, INVEST OPHTH VIS SCI, V47, P815, DOI 10.1167/iovs.05-0976
   Radonic A, 2004, BIOCHEM BIOPH RES CO, V313, P856, DOI 10.1016/j.bbrc.2003.11.177
   Shiose A, 2001, J BIOL CHEM, V276, P1417, DOI 10.1074/jbc.M007597200
   Simon T, 2014, NEUROMOL MED, V16, P752, DOI 10.1007/s12017-014-8324-8
   Simons M, 2016, NAT REV MOL CELL BIO, V17, P611, DOI 10.1038/nrm.2016.87
   Spitzer MS, 2007, GRAEF ARCH CLIN EXP, V245, P1837, DOI 10.1007/s00417-007-0568-7
   West XZ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031071
   Yang P, 2019, INVEST OPHTH VIS SCI, V60
   Zahn G, 2010, INVEST OPHTH VIS SCI, V51, P1028, DOI 10.1167/iovs.09-3575
NR 49
TC 5
Z9 5
U1 1
U2 6
PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 0014-4835
EI 1096-0007
J9 EXP EYE RES
JI Exp. Eye Res.
PD FEB
PY 2021
VL 203
AR 108287
DI 10.1016/j.exer.2020.108287
EA FEB 2021
PG 12
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA QG8HN
UT WOS:000617822500003
PM 33075294
OA hybrid, Green Accepted
DA 2022-11-30
ER

PT J
AU Klettner, A
   Kaya, L
   Flach, J
   Lassen, J
   Treumer, F
   Roider, J
AF Klettner, Alexa
   Kaya, Leyla
   Flach, Janina
   Lassen, Jens
   Treumer, Felix
   Roider, Johann
TI Basal and apical regulation of VEGF-A and placenta growth factor in the
   RPE/choroid and primary RPE
SO MOLECULAR VISION
LA English
DT Article
ID RETINAL-PIGMENT EPITHELIUM; IN-VITRO; OXIDATIVE-STRESS; MACULAR
   DEGENERATION; FACTOR SECRETION; INHIBITOR; KINASE; CELLS; TRANSCRIPTION;
   CONTRIBUTES
AB Purpose: Members of the vascular endothelial growth factor (VEGF) family are strongly involved in pathological processes in the retina, such as age-related macular degeneration and diabetic retinopathy. Cells of the retinal pigment epithelium (RPE) constitutively secrete VEGF-A, and the secretion of placental growth factor (PlGF) has also been described. RPE cells are strongly polarized cells with different secretome at the apical and basal side. In this study, we evaluated the basal and apical regulation of VEGF-A and PlGF secretion in RPE/choroid explants and primary RPE cells.
   Methods: RPE/choroid tissue explants were prepared from porcine eyes and cultivated in modified Ussing chambers, separating apical (RPE) and basal (choroid) supernatant. Primary RPE cells were also prepared from porcine eyes and cultivated on Transwell plates. Explants and cells were treated with inhibitors for VEGFR-2 (SU1498), p38 (SB203580), and the transcription factors nuclear factor-kappa B (NF-kappa B) and SP-1 (mithramycin), respectively. VEGF-A and PlGF content was evaluated with enzyme-linked immunosorbent assay (ELISA). In addition, western blots were performed.
   Results: In the RPE/choroid, VEGF-A can initially be found on the apical and basal sides with significantly more pronounced secretion on the basal side. VEGF-A secretion is differentially regulated on the apical and basal sides, with the inhibition of SP-1 and NF-kappa B showing strong effects apically and basally after 24 h and 48 h, the inhibition of p38 displaying its effect mainly on the basal side with some effect apically after 48 h, and the inhibition of VEGFR-2 reducing the secretion of VEGF only on the apical side at 24 h and 48 h. In the RPE cell culture, similar effects were found, with inhibition of NF-kappa B or SP-1 displaying a strong decrease in VEGF-A on both sides, and p38 inhibition displaying only an inhibitory effect on the basal side. In contrast, an apical effect of VEGFR-2 inhibition was not found. However, the western blot experiments exhibited a significant decrease in the VEGF-A protein under SU1498 treatment. In the RPE/choroid organ cultures, PlGF was initially found mainly on the basal site with only minute amounts of PlGF found apically. NF-kappa B and SP-1 were strongly involved in PlGF regulation apically and basally, while VEGFR2 and to a lesser degree p38 displayed some regulation at the basal site. In the primary RPE cell culture, PlGF was not found on the apical or basal side.
   Conclusions: VEGF-A and PlGF were constitutively secreted and regulated by the RPE/choroid complex, with PlGF secreted mainly by the choroid. Although the transcription factors NF-kappa B and SP-1 were involved in apical and basal regulation of both growth factors, VEGFR-2 displayed a strong polarity, with regulation of apical VEGF-A and basal PlGF secretion.
C1 [Klettner, Alexa; Kaya, Leyla; Flach, Janina; Lassen, Jens; Treumer, Felix; Roider, Johann] Univ Kiel, Univ Med Ctr, Dept Ophthalmol, D-24105 Kiel, Germany.
C3 University of Kiel; Schleswig Holstein University Hospital
RP Klettner, A (通讯作者)，Univ Kiel, Univ Med Ctr, Dept Ophthalmol, Arnold Heller Str 3,Haus 25, D-24105 Kiel, Germany.
EM aklettner@auge.uni-kiel.de
RI Lassen, Jens Flensted/AAY-2127-2021; Klettner, Alexa Karina/M-8344-2018
OI Lassen, Jens Flensted/0000-0001-7972-9192; Klettner,
   Alexa/0000-0002-2709-1059
FU Herman-Wacker Fond; Novartis Pharma
FX The authors thank Serap Luick for her excellent technical assistance.
   This study was partly funded by the Herman-Wacker Fond. Parts of the
   data presented here were presented at the ARVO conference 2012 and at
   the Biochemical Society Meeting 2014. No conflict of interest exists
   regarding this study. Independently of this study, AK has been a
   consultant for and received lecture fees and travel grants from Novartis
   Pharma.
CR ADAMIS AP, 1993, BIOCHEM BIOPH RES CO, V193, P631, DOI 10.1006/bbrc.1993.1671
   Autiero M, 2003, NAT MED, V9, P936, DOI 10.1038/nm884
   Becerra SP, 2004, EXP EYE RES, V78, P223, DOI 10.1016/j.exer.2003.10.013
   Bhutto I, 2012, MOL ASPECTS MED, V33, P295, DOI 10.1016/j.mam.2012.04.005
   Blaauwgeers HGT, 1999, AM J PATHOL, V155, P421, DOI 10.1016/S0002-9440(10)65138-3
   Byeon SH, 2010, INVEST OPHTH VIS SCI, V51, P1190, DOI 10.1167/iovs.09-4144
   Carmeliet P, 2001, NAT MED, V7, P575, DOI 10.1038/87904
   Carmeliet P, 1996, NATURE, V380, P435, DOI 10.1038/380435a0
   Chun YS, 2001, BIOCHEM PHARMACOL, V61, P947, DOI 10.1016/S0006-2952(01)00564-0
   Cramer M, 2005, BIOL CHEM, V386, P865, DOI 10.1515/BC.2005.101
   Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264-6021:3510095
   De Falco S, 2012, EXP MOL MED, V44, P1, DOI 10.3858/emm.2012.44.1.025
   Deacon K, 2012, J BIOL CHEM, V287, DOI 10.1074/jbc.M112.397042
   DeNiro M, 2010, MOL PHARMACOL, V77, P348, DOI 10.1124/mol.109.061366
   Dithmer M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0089150
   Faby H, 2014, GRAEF ARCH CLIN EXP, V252, P1737, DOI 10.1007/s00417-014-2750-z
   Ferrara N, 1996, NATURE, V380, P439, DOI 10.1038/380439a0
   HARDENBOL P, 1992, BIOCHEM BIOPH RES CO, V185, P553, DOI 10.1016/0006-291X(92)91660-I
   Hollborn M, 2006, GRAEF ARCH CLIN EXP, V244, P732, DOI 10.1007/s00417-005-0154-9
   Kannan R, 2006, MOL VIS, V12, P1649
   Kay P, 2013, J CELL MOL MED, V17, P833, DOI 10.1111/jcmm.12070
   Klettner A, 2009, MINI-REV MED CHEM, V9, P1127, DOI 10.2174/138955709788922665
   Klettner A., 2013, VASCULAR ENDOTHELIAL, P117
   Klettner A, 2008, INVEST OPHTH VIS SCI, V49, P4523, DOI 10.1167/iovs.08-2055
   Klettner A, 2013, MOL VIS, V19, P281
   Klettner A, 2012, OXID STRESS APPL BAS, P277, DOI 10.1007/978-1-61779-606-7_13
   Klettner Alexa, 2012, Front Biosci (Schol Ed), V4, P392
   Klettner A, 2009, GRAEF ARCH CLIN EXP, V247, P1487, DOI 10.1007/s00417-009-1139-x
   Kunchithapautham K, 2011, J BIOL CHEM, V286, P23717, DOI 10.1074/jbc.M110.214593
   Lisnock JM, 1998, BIOCHEMISTRY-US, V37, P16573, DOI 10.1021/bi981591x
   Lu Ming, 2006, Ophthalmol Clin North Am, V19, P323
   Maminishkis A, 2006, INVEST OPHTH VIS SCI, V47, P3612, DOI 10.1167/iovs.05-1622
   Miura Y, 2010, INVEST OPHTH VIS SCI, V51, P4848, DOI 10.1167/iovs.09-4699
   Miura Y, 2010, OPHTHAL RES, V43, P122, DOI 10.1159/000252979
   Nagineni CN, 2012, J CELL PHYSIOL, V227, P116, DOI 10.1002/jcp.22708
   PARK JE, 1994, J BIOL CHEM, V269, P25646
   Rakic JM, 2003, INVEST OPHTH VIS SCI, V44, P3186, DOI 10.1167/iovs.02-1092
   Roberts NA, 2004, BIOCHEM PHARMACOL, V68, P1923, DOI 10.1016/j.bcp.2004.07.040
   Saint-Geniez M, 2009, P NATL ACAD SCI USA, V106, P18751, DOI 10.1073/pnas.0905010106
   Saint-Geniez M, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003554
   Scholl S, 2010, OPHTHALMOLOGICA, V224, P8, DOI 10.1159/000315155
   Schust J, 2006, CHEM BIOL, V13, P1235, DOI 10.1016/j.chembiol.2006.09.018
   Shaw JH, 2012, MICROVASC RES, V84, P155, DOI 10.1016/j.mvr.2012.05.009
   Sleiman SF, 2011, J NEUROSCI, V31, P6858, DOI 10.1523/JNEUROSCI.0710-11.2011
   Strawn LM, 1996, CANCER RES, V56, P3540
   Terasaki H, 2014, CURR EYE RES, V13, P1
   Tobe M, 2003, BIOORGAN MED CHEM, V11, P383, DOI 10.1016/S0968-0896(02)00440-6
   TOULLEC D, 1991, J BIOL CHEM, V266, P15771
   Treumer F, 2012, EXP EYE RES, V97, P63, DOI 10.1016/j.exer.2012.02.011
   VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241
NR 50
TC 30
Z9 31
U1 0
U2 4
PU MOLECULAR VISION
PI ATLANTA
PA C/O JEFF BOATRIGHT, LAB B, 5500 EMORY EYE CENTER, 1327 CLIFTON RD, N E,
   ATLANTA, GA 30322 USA
SN 1090-0535
J9 MOL VIS
JI Mol. Vis.
PD JUL 10
PY 2015
VL 21
BP 736
EP 748
PG 13
WC Biochemistry & Molecular Biology; Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Ophthalmology
GA CO2VO
UT WOS:000359015100002
PM 26167115
DA 2022-11-30
ER

PT J
AU Iwami, H
   Pruessner, J
   Shiraki, K
   Brinkmann, R
   Miura, Y
AF Iwami, Hisashi
   Pruessner, Joachim
   Shiraki, Kunihiko
   Brinkmann, Ralf
   Miura, Yoko
TI Protective effect of a laser-induced sub-lethal temperature rise on RPE
   cells from oxidative stress
SO EXPERIMENTAL EYE RESEARCH
LA English
DT Article
DE sub-lethal thermal laser; retinal pigment epithelium; oxidative stress;
   age-related macular degeneration
ID RETINAL-PIGMENT EPITHELIUM; ENDOTHELIAL GROWTH-FACTOR; DOSE
   TRANSPUPILLARY THERMOTHERAPY; LIPID-PEROXIDATION; MACULAR DEGENERATION;
   CHOROIDAL NEOVASCULARIZATION; ADAPTIVE RESPONSE; LIVER-INJURY;
   GLUTATHIONE; PHOTOCOAGULATION
AB Recently introduced new technologies that enable temperature-controlled laser irradiation on the RPE allowed us to investigate temperature-resolved RPE cell responses. In this study we aimed primarily to establish an experimental setup that can realize laser irradiation on RPE cell culture with the similar temperature distribution as in the clinical application, with a precise time/temperature history. With this setup, we conducted investigations to elucidate the temperature-dependent RPE cell biochemical responses and the effect of transient hyperthermia on the responses of RPE cells to the secondary-exposed oxidative stress. Porcine RPE cells cultivated in a culture dish (inner diameter = 30 mm) with culture medium were used, on which laser radiation (lambda = 1940 nm, spot diameter = 30 mm) over 10 s was applied as a heat source. The irradiation provides a radially decreasing temperature profile which is close to a Gaussian shape with the highest temperature in the center. Power setting for irradiation was determined such that the peak temperature (T-max) in the center of the laser spot at the cells reaches from 40 degrees C to 58 degrees C (40, 43, 46, 50, 58 degrees C). Cell viability was investigated with ethidium homodimer III staining at the time points of 3 and 24 h following laser irradiation. Twenty four hours after laser irradiation the cells were exposed to hydrogen peroxide (H2O2) for 5 h, followed by the measurement of intracellular glutathione, intracellular 4-hydroxynonenal (HNE) protein adducts, and secreted vascular endothelial growth factor (VEGF). The mean temperature threshold for RPE cell death after 3 h was found to be around 52 degrees C, and for 24 h around 50 degrees C with the current irradiation setting. A sub-lethal preconditioning on T-max = 43 degrees C significantly induced the reduced glutathione (GSH)/oxidized glutathione (GSSG) ratio, and decreased H2O2-induced increase of intracellular 4-HNE protein adducts. Although sub-lethal hyperthermia (T-max = 40 degrees C, 43 degrees C, and 46 degrees C) caused a slight increase of VEGF secretion in 6 h directly following irradiation, secondary exposed H2O2-induced VEGF secretion was significantly reduced in the sub-lethally preheated groups, where the largest effect was seen following the irradiation with T-max = 43 degrees C. In summary, the current results suggest that sub-lethal thermal laser irradiation on the RPE at T-max = 43 degrees C for 10 s enhances cell defense system against oxidative stress, with increasing the GSH/GSSG ratio. Together with the results that the decreased amount of H2O2-induced 4-HNE in sub-lethally preheated RPE cells was accompanied by the lower secretion of VEGF, it is also strongly suggested that the sub-lethal hyperthermia may modify RPE cell functionality to protect RPE cells from oxidative stress and associated functional decrease, which are considered to play a significant role in the pathogenesis of age-related macular degeneration and other chorioretinal degenerative diseases. (C) 2014 Elsevier Ltd. All rights reserved.
C1 [Iwami, Hisashi; Shiraki, Kunihiko] Osaka City Univ, Grad Sch Med, Dept Ophthalmol & Visual Sci, Osaka 558, Japan.
   [Pruessner, Joachim; Brinkmann, Ralf; Miura, Yoko] Univ Lubeck, Inst Biomed Opt, D-23562 Lubeck, Germany.
   [Brinkmann, Ralf] Med Laser Ctr Luebeck, Lubeck, Germany.
   [Miura, Yoko] Univ Lubeck, Dept Ophthalmol, D-23562 Lubeck, Germany.
C3 Osaka Metropolitan University; University of Lubeck; University of
   Lubeck
RP Miura, Y (通讯作者)，Univ Lubeck, Inst Biomed Opt, Peter Monnik Weg 4, D-23562 Lubeck, Germany.
EM miura@bmo.uni-luebeck.de
RI Miura, Yoko/B-5588-2015; Brinkmann, Ralf/E-6701-2012; Brinkmann,
   Ralf/HDL-7611-2022
OI Brinkmann, Ralf/0000-0002-0445-8102; Pruessner,
   Jens/0000-0002-8582-2980; Miura, Yoko/0000-0003-1896-7634
FU German federal ministry of education and research (BMBF) [01EZ0733]
FX Authors would like to thank Veit Danicke for his technical support. This
   study was supported by German federal ministry of education and research
   (BMBF), grant #. 01EZ0733.
CR ADAMIS AP, 1993, BIOCHEM BIOPH RES CO, V193, P631, DOI 10.1006/bbrc.1993.1671
   Agnieszka Kubicka-Trzaska, 2010, Klin Oczna, V112, P289
   Avery RL, 2006, OPHTHALMOLOGY, V113, P363, DOI 10.1016/j.ophtha.2005.11.019
   Bailey TA, 2004, INVEST OPHTH VIS SCI, V45, P675, DOI 10.1167/iovs.03-0351
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Bettaieb A, 2005, J CELL PHYSIOL, V205, P47, DOI 10.1002/jcp.20386
   BRAMBILLA G, 1986, MUTAT RES, V171, P169, DOI 10.1016/0165-1218(86)90051-0
   Brinkmann R, 2012, J BIOMED OPT, V17, DOI 10.1117/1.JBO.17.6.061219
   Byeon SH, 2010, INVEST OPHTH VIS SCI, V51, P1190, DOI 10.1167/iovs.09-4144
   Cai JY, 2000, PROG RETIN EYE RES, V19, P205, DOI 10.1016/S1350-9462(99)00009-9
   Cencioni C, 2013, INT J MOL SCI, V14, P17643, DOI 10.3390/ijms140917643
   Chakraborty S, 2013, INT J MOL SCI, V14, P23103, DOI 10.3390/ijms141123103
   Chen HY, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002339
   Cordeiro S, 2010, INVEST OPHTH VIS SCI, V51, P6001, DOI 10.1167/iovs.09-4720
   CRAWFORD DR, 1994, ENVIRON HEALTH PERSP, V102, P25, DOI 10.2307/3432208
   Davies S, 2001, FREE RADICAL BIO MED, V31, P256, DOI 10.1016/S0891-5849(01)00582-2
   Denton M.L, 2009, P SOC PHOTO-OPT INS
   Denton ML, 2006, INVEST OPHTH VIS SCI, V47, P3065, DOI 10.1167/iovs.05-1066
   Denton ML, 2011, J BIOMED OPT, V16, DOI 10.1117/1.3548881
   ESTERBAUER H, 1991, FREE RADICAL BIO MED, V11, P81, DOI 10.1016/0891-5849(91)90192-6
   GITTER KA, 1975, AM J OPHTHALMOL, V79, P578, DOI 10.1016/0002-9394(75)90795-3
   HAVENER WH, 1964, AM J OPHTHALMOL, V58, P38, DOI 10.1016/0002-9394(64)90589-6
   Ikeda Y, 2006, EXP EYE RES, V83, P1031, DOI 10.1016/j.exer.2006.05.007
   JANSEN ED, 1994, LASER SURG MED, V14, P258, DOI 10.1002/lsm.1900140308
   JEGGO P, 1977, MOL GEN GENET, V157, P1, DOI 10.1007/BF00268680
   Kaemmerer E, 2007, INVEST OPHTH VIS SCI, V48, P1342, DOI 10.1167/iovs.06-0549
   Kandulla J, 2006, J BIOMED OPT, V11, DOI 10.1117/1.2236301
   Kauppinen A, 2012, IMMUNOL LETT, V147, P29, DOI 10.1016/j.imlet.2012.05.005
   Kikusato M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0064412
   Klettner A., 2012, ACTA OPHTHALMOL S249, V90
   Klettner A, 2013, MOL VIS, V19, P281
   Koinzer S, 2012, INVEST OPHTH VIS SCI, V53, P3605, DOI 10.1167/iovs.11-8588
   Kosower N S, 1978, Int Rev Cytol, V54, P109, DOI 10.1016/S0074-7696(08)60166-7
   Krohne TU, 2010, EXP EYE RES, V90, P465, DOI 10.1016/j.exer.2009.12.011
   Krohne TU, 2010, EXP EYE RES, V90, P261, DOI 10.1016/j.exer.2009.10.014
   LIN PS, 1991, RADIAT RES, V126, P43, DOI 10.2307/3578169
   Magenta A, 2013, INT J MOL SCI, V14, P17319, DOI 10.3390/ijms140917319
   Maher E.F., 1979, TRANSMISSION ABSORPT
   Mainster MA, 2000, OPHTHALMIC SURG LAS, V31, P359
   MEISTER A, 1983, ANNU REV BIOCHEM, V52, P711, DOI 10.1146/annurev.bi.52.070183.003431
   MEISTER A, 1994, CANCER RES, V54, pS1969
   Mettu PS, 2012, MOL ASPECTS MED, V33, P376, DOI 10.1016/j.mam.2012.04.006
   MEYER-SCHWICKERATH G, 1954, Albrecht Von Graefes Arch Ophthalmol, V156, P2, DOI 10.1007/BF00703328
   Ming Y, 2004, INVEST OPHTH VIS SCI, V45, P1969, DOI 10.1167/iovs.03-1329
   Miura Y., 2009, INVEST OPHTH VIS SCI, V50, P201
   Miura Y, 2010, OPHTHAL RES, V43, P122, DOI 10.1159/000252979
   Miura Y, 2009, GRAEF ARCH CLIN EXP, V247, P641, DOI 10.1007/s00417-009-1041-6
   Muller HH, 2012, BIOMED OPT EXPRESS, V3, P1025, DOI 10.1364/BOE.3.001025
   Nivon M, 2009, AUTOPHAGY, V5, P766, DOI 10.4161/auto.8788
   Nowak JZ, 2013, PHARMACOL REP, V65, P288, DOI 10.1016/S1734-1140(13)71005-3
   Nowak MS, 2012, MED SCI MONITOR, V18, pCR374, DOI 10.12659/MSM.882907
   Obin M, 1998, FASEB J, V12, P561, DOI 10.1096/fasebj.12.7.561
   Odergren A, 2008, BRIT J OPHTHALMOL, V92, P757, DOI 10.1136/bjo.2007.133561
   Oka Y, 2013, ANTICANCER RES, V33, P2887
   Pallepati P, 2011, FREE RADICAL BIO MED, V50, P667, DOI 10.1016/j.freeradbiomed.2010.11.022
   Qin SF, 2010, EXP EYE RES, V91, P818, DOI 10.1016/j.exer.2010.10.007
   Reichel E, 1999, OPHTHALMOLOGY, V106, P1908, DOI 10.1016/S0161-6420(99)90400-1
   Roth F, 2004, GRAEF ARCH CLIN EXP, V242, P710, DOI 10.1007/s00417-004-0976-x
   Routt SM, 2011, INT J HYPERTHER, V27, P435, DOI 10.3109/02656736.2011.578607
   Rudolf M, 2008, INVEST OPHTH VIS SCI, V49, P1200, DOI 10.1167/iovs.07-1466
   Schafer FQ, 2001, FREE RADICAL BIO MED, V30, P1191, DOI 10.1016/S0891-5849(01)00480-4
   Schlingemann RO, 2004, GRAEF ARCH CLIN EXP, V242, P91, DOI 10.1007/s00417-003-0828-0
   Schlott K, 2012, J BIOMED OPT, V17, DOI 10.1117/1.JBO.17.6.061223
   Schutt F, 2000, INVEST OPHTH VIS SCI, V41, P2303
   Sekiyama E, 2012, FASEB J, V26, P567, DOI 10.1096/fj.11-184127
   Sharma A, 2008, ARCH BIOCHEM BIOPHYS, V480, P85, DOI 10.1016/j.abb.2008.09.016
   Shrestha R, 2011, SENSORS-BASEL, V11, P8826, DOI 10.3390/s110908826
   SINGHAL SS, 1995, INVEST OPHTH VIS SCI, V36, P142
   Soderberg AC, 2012, BRIT J OPHTHALMOL, V96, P714, DOI 10.1136/bjophthalmol-2011-300721
   SPITZ DR, 1991, FREE RADICAL BIO MED, V11, P415, DOI 10.1016/0891-5849(91)90159-Z
   SPITZ DR, 1987, J CELL PHYSIOL, V131, P364, DOI 10.1002/jcp.1041310308
   Sramek C, 2011, J BIOMED OPT, V16, DOI 10.1117/1.3542045
   Sramek C, 2011, INVEST OPHTH VIS SCI, V52, P1780, DOI 10.1167/iovs.10-5917
   Stefansson E, 2006, SURV OPHTHALMOL, V51, P364, DOI 10.1016/j.survophthal.2006.04.005
   STERNBERG P, 1993, INVEST OPHTH VIS SCI, V34, P3661
   Theisen-Kunde D, 2011, LASER MED SCI, V26, P509, DOI 10.1007/s10103-010-0873-y
   Waldeck AR, 1996, CHEM RES TOXICOL, V9, P954, DOI 10.1021/tx960057s
   Yanagihara N, 1996, INVEST OPHTH VIS SCI, V37, P1975
   YOSHIMURA N, 1995, INVEST OPHTH VIS SCI, V36, P1686
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
   Zhang HJ, 2003, FASEB J, V17, P2293, DOI 10.1096/fj.03-0139fje
   Zhou B, 2006, EXP EYE RES, V83, P615, DOI 10.1016/j.exer.2006.02.010
NR 82
TC 28
Z9 28
U1 0
U2 12
PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 0014-4835
EI 1096-0007
J9 EXP EYE RES
JI Exp. Eye Res.
PD JUL
PY 2014
VL 124
BP 37
EP 47
DI 10.1016/j.exer.2014.04.014
PG 11
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AK2TV
UT WOS:000338273300006
PM 24800654
DA 2022-11-30
ER

PT J
AU Cao, K
   Wang, BS
   Friedman, DS
   Hao, J
   Zhang, Y
   Hu, AL
   Wang, NL
AF Cao, Kai
   Wang, Bingsong
   Friedman, David S.
   Hao, Jie
   Zhang, Ye
   Hu, Ailian
   Wang, Ningli
CA Handan Eye Study Grp
TI Diabetic Retinopathy, Visual Impairment, and the Risk of Six-Year Death:
   A Cohort Study of a Rural Population in China
SO OPHTHALMIC RESEARCH
LA English
DT Article
DE Diabetic retinopathy; Risk; Death; Cohort study; Epidemiology
ID ALL-CAUSE MORTALITY; 10-YEAR MORTALITY; ADULT-POPULATION; PREVALENCE;
   EDUCATION; CATARACT; TYPE-1
AB Purpose: The aim of this study was to explore the association between diabetic retinopathy (DR) and the risk of 6-year death, as well as the association between visual impairment (VI) and the risk of 6-year death in a rural Chinese population of age >= 30 years. Methods: This was a population-based cohort study. In 2006-2007, 6,830 subjects aged >= 30 years were recruited from 13 villages in Northern China through clustered randomization. In 2012-2013, a 6-year follow-up was further done. Six different proportional hazards models, with different confounders adjusted, were used to explore the association between baseline DR and risk of death. Results: 5,570 subjects were included in this study by our inclusion and exclusion criteria. Four hundred and ten (7.36%) subjects died by follow-up. The median ages of the dead subjects and survived subjects were 67 (interquartile range [IQR]: 58-72) years and 52 (IQR: 42-58) years (Z = 21.979, p < 0.001). Male accounted for 62.20 and 44.92% among the dead and survived subjects (chi(2) = 45.591, p < 0.001). Besides, compared with those survived, the dead were found to be with lower education (chi(2) = 109.981, p < 0.001), lower marriage rate (chi(2) = 101.341, p < 0.001), lower income (chi(2) = 123.763, p < 0.001), higher proportion of smoking (chi(2) = 8.869, p = 0.003), higher systolic blood pressure (Z = 10.411, p < 0.001), lower body mass index (Z = -3.302, p = 0.001), larger spherical equivalent error (Z = 4.248, p < 0.001), lower intraocular pressure (Z = -4.912, p < 0.001), smaller anterior chamber depth (Z = -9.186, p < 0.001), larger length thickness (Z = 11.069, p < 0.001), higher fast blood glucose level (Z = 5.650, p < 0.001), higher total cholesterols (Z = 2.015, p = 0.044), higher low-density lipoprotein (Z = 2.024, p = 0.043), and higher proportion of drug usage (chi(2) = 56.108, p < 0.001). Besides, the dead subjects were more likely to be with VI, glaucoma, cataract, age-related macular degeneration, diabetes, and DR. Hundred and forty-eight subjects were diagnosed with DR at baseline, and 33 (22.30%) of them were dead before follow-up. By adjusting all relative confounders in a proportional hazards model, DR was found to be a risk factor of 6-year death, the hazard ratio was 1.739 (95% confidence intervals: 1.080, 2.803). Another 5 different statistical models with different confounders adjusted also revealed a statistically significant association between DR and 6-year death. The association between VI and 6-year death was not statistically significant. Conclusions: DR increased the risk of 6-year death in a rural Chinese population aged >= 30 years, while VI did not. (c) 2020 S. Karger AG, Basel
C1 [Cao, Kai; Hao, Jie; Hu, Ailian; Wang, Ningli] Capital Med Univ, Beijing Tongren Hosp, Beijing Inst Ophthalmol, Beijing, Peoples R China.
   [Wang, Bingsong; Zhang, Ye; Wang, Ningli] Capital Med Univ, Beijing Tongren Hosp, Beijing Tongren Eye Ctr, Beijing, Peoples R China.
   [Friedman, David S.] Harvard Med Sch, Massachusetts Eye & Ear Glaucoma Ctr Excellence, Boston, MA 02115 USA.
C3 Capital Medical University; Capital Medical University; Harvard
   University; Harvard Medical School
RP Wang, NL (通讯作者)，Capital Med Univ, Beijing Tongren Hosp, Beijing Inst Ophthalmol, Beijing, Peoples R China.; Wang, NL (通讯作者)，Capital Med Univ, Beijing Tongren Hosp, Beijing Tongren Eye Ctr, Beijing, Peoples R China.
EM wningli@vip.163.com
FU Ministry of Science and Technology of China [2007CB512201]; Key
   Technologies RD Program
FX This study was supported by the grants from the Ministry of Science and
   Technology of China (No. 2007CB512201) and from the Key Technologies R&D
   Program.
CR Bonaccio M, 2016, INT J PUBLIC HEALTH, V61, P765, DOI 10.1007/s00038-016-0822-z
   Buckles K, 2016, J HEALTH ECON, V50, P99, DOI 10.1016/j.jhealeco.2016.08.002
   Cao K, 2019, CHINESE MED J-PEKING, V132, P2157, DOI 10.1097/CM9.0000000000000418
   Cheung N, 2010, LANCET, V376, P124, DOI 10.1016/S0140-6736(09)62124-3
   Cugati S, 2007, ARCH OPHTHALMOL-CHIC, V125, P917, DOI 10.1001/archopht.125.7.917
   Duan XR, 2013, GRAEF ARCH CLIN EXP, V251, P203, DOI 10.1007/s00417-012-2012-x
   Estevez J, 2018, CLIN EXP OPHTHALMOL, V46, P18, DOI 10.1111/ceo.13009
   Flaxman SR, 2017, LANCET GLOB HEALTH, V5, pE1221, DOI 10.1016/S2214-109X(17)30393-5
   Foong AWP, 2008, OPHTHALMOLOGY, V115, P802, DOI 10.1016/j.ophtha.2007.04.066
   Garofolo M, 2019, CARDIOVASC DIABETOL, V18, DOI 10.1186/s12933-019-0961-7
   Kramer CK, 2011, DIABETES CARE, V34, P1238, DOI 10.2337/dc11-0079
   Le Y, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0123320
   Li ZJ, 2011, OPHTHAL EPIDEMIOL, V18, P54, DOI 10.3109/09286586.2010.545503
   Liang YB, 2011, INVEST OPHTH VIS SCI, V52, P8250, DOI 10.1167/iovs.11-7472
   Liang YB, 2009, OPHTHAL EPIDEMIOL, V16, P115, DOI 10.1080/09286580902738159
   Pascolini D, 2012, BRIT J OPHTHALMOL, V96, P614, DOI 10.1136/bjophthalmol-2011-300539
   Sabanayagam C, 2019, JAMA NETW OPEN, V2, DOI 10.1001/jamanetworkopen.2019.1540
   Siantar RG, 2015, SCI REP-UK, V5, DOI 10.1038/srep16304
   Soedamah-Muthu SS, 2008, DIABETES CARE, V31, P1360, DOI 10.2337/dc08-0107
   Van Oyen H, 2013, INT J PUBLIC HEALTH, V58, P143, DOI 10.1007/s00038-012-0361-1
   Wang FH, 2009, OPHTHALMOLOGY, V116, P461, DOI 10.1016/j.ophtha.2008.10.003
   Wang YX, 2014, ACTA OPHTHALMOL, V92, pE424, DOI 10.1111/aos.12370
NR 22
TC 2
Z9 2
U1 2
U2 3
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0030-3747
EI 1423-0259
J9 OPHTHALMIC RES
JI Ophthalmic Res.
PD DEC
PY 2021
VL 64
IS 6
BP 983
EP 990
DI 10.1159/000512667
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA ZC4VR
UT WOS:000757520400011
PM 33120387
OA Bronze
DA 2022-11-30
ER

PT J
AU Strunz, T
   Kiel, C
   Grassmann, F
   Ratnapriya, R
   Kwicklis, M
   Karlstetter, M
   Fauser, S
   Arend, N
   Swaroop, A
   Langmann, T
   Wolf, A
   Weber, BHF
AF Strunz, Tobias
   Kiel, Christina
   Grassmann, Felix
   Ratnapriya, Rinki
   Kwicklis, Madeline
   Karlstetter, Marcus
   Fauser, Sascha
   Arend, Nicole
   Swaroop, Anand
   Langmann, Thomas
   Wolf, Armin
   Weber, Bernhard H. F.
TI A mega-analysis of expression quantitative trait loci in retinal tissue
SO PLOS GENETICS
LA English
DT Article
ID RNAS ASSOCIATE; ANNOTATION; THOUSANDS
AB Author summary The retina is a multilayered and highly specified neural tissue crucial for high-resolution visual perception and spatial orientation. Environmental and genetic insults to the retina result in many blinding diseases, such as age-related macular degeneration or glaucoma. Commonly, many of these diseases are age-related suggesting that minor changes are accumulating over a life-time, with little or no contribution of strong individual effects. Specifically, this is true for genetic factors known to underlie the etiology of complex diseases including the prevalent eye diseases. In our study, we searched for effects on gene expression due to genetic variation using 311 healthy post-mortem retinal tissue samples. We show that 3,007 of the 16,766 genes investigated are regulated in the retina by genetic variations. Of these, 80 genes are potentially associated to one or more of twelve complex eye diseases or retinal traits tested. Interestingly, 10 genes appear to be involved in the development of several eye traits suggesting that cellular mechanisms may act at a common point in the disease process. Consequently, our study provides the basis to further explore retinal disease pathways and is likely to highlight target molecules for future therapeutic applications.
   Significant association signals from genome-wide association studies (GWAS) point to genomic regions of interest. However, for most loci the causative genetic variant remains undefined. Determining expression quantitative trait loci (eQTL) in a disease relevant tissue is an excellent approach to zoom in on disease- or trait-associated association signals and hitherto on relevant disease mechanisms. To this end, we explored regulation of gene expression in healthy retina (n = 311) and generated the largest cis-eQTL data set available to date. Genotype- and RNA-Seq data underwent rigorous quality control protocols before FastQTL was applied to assess the influence of genetic markers on local (cis) gene expression. Our analysis identified 403,151 significant eQTL variants (eVariants) that regulate 3,007 genes (eGenes) (Q-Value < 0.05). A conditional analysis revealed 744 independent secondary eQTL signals for 598 of the 3,007 eGenes. Interestingly, 99,165 (24.71%) of all unique eVariants regulate the expression of more than one eGene. Filtering the dataset for eVariants regulating three or more eGenes revealed 96 potential regulatory clusters. Of these, 31 harbour 130 genes which are partially regulated by the same genetic signal. To correlate eQTL and association signals, GWAS data from twelve complex eye diseases or traits were included and resulted in identification of 80 eGenes with potential association. Remarkably, expression of 10 genes is regulated by eVariants associated with multiple eye diseases or traits. In conclusion, we generated a unique catalogue of gene expression regulation in healthy retinal tissue and applied this resource to identify potentially pleiotropic effects in highly prevalent human eye diseases. Our study provides an excellent basis to further explore mechanisms of various retinal disease etiologies.
C1 [Strunz, Tobias; Kiel, Christina; Grassmann, Felix; Weber, Bernhard H. F.] Univ Regensburg, Inst Human Genet, Regensburg, Germany.
   [Grassmann, Felix] Univ Aberdeen, Inst Med Sci, Aberdeen, Scotland.
   [Ratnapriya, Rinki; Kwicklis, Madeline; Swaroop, Anand] NEI, Neurobiol Neurodegenerat & Repair Lab, Bethesda, MD 20892 USA.
   [Karlstetter, Marcus; Langmann, Thomas] Fac Med, Dept Ophthalmol, Lab Expt Immunol Eye, Cologne, Germany.
   [Karlstetter, Marcus; Langmann, Thomas] Univ Hosp Cologne, Cologne, Germany.
   [Fauser, Sascha] F Hoffmann La Roche Ltd, Roche Innovat Ctr Basel, Basel, Switzerland.
   [Arend, Nicole] Ludwig Maximilians Univ Munchen, Dept Ophthalmol, Munich, Germany.
   [Wolf, Armin] Univ Ulm, Dept Ophthalmol, Ulm, Germany.
   [Weber, Bernhard H. F.] Univ Hosp Regensburg, Inst Clin Human Genet, Regensburg, Germany.
C3 University of Regensburg; University of Aberdeen; National Institutes of
   Health (NIH) - USA; NIH National Eye Institute (NEI); University of
   Cologne; University of Cologne; Roche Holding; University of Munich; Ulm
   University; University of Regensburg
RP Weber, BHF (通讯作者)，Univ Regensburg, Inst Human Genet, Regensburg, Germany.; Weber, BHF (通讯作者)，Univ Hosp Regensburg, Inst Clin Human Genet, Regensburg, Germany.
EM bweb@klinik.uni-regensburg.de
RI Strunz, Tobias/ABB-6300-2020; Strunz, Tobias/ABD-9798-2021
OI Strunz, Tobias/0000-0002-3744-9595; Swaroop, Anand/0000-0002-1975-1141;
   Grassmann, Felix/0000-0003-1390-7528; Kiel,
   Christina/0000-0003-3154-4847; Ratnapriya, Rinki/0000-0002-0469-4631;
   Reis, AlessanRSS/0000-0001-8486-7469
FU Institute of Human Genetics Regensburg, Germany [TG77]; Helmut Ecker
   Foundation (Ingolstadt, Germany) [05/17]; Hans and Marlies Stock
   Foundation [01042012]; Intramural Research Program of the National Eye
   Institute, USA [ZIAEY000450, ZIAEY000546]
FX The work has been supported in part by institutional funds (TG77) of the
   Institute of Human Genetics Regensburg, Germany, and by a grant from the
   Helmut Ecker Foundation (Ingolstadt, Germany) to BHFW (No. 05/17). TL
   received funding from the Hans and Marlies Stock Foundation (01042012).
   AS was supported by the Intramural Research Program of the National Eye
   Institute, USA (ZIAEY000450 and ZIAEY000546). The funders had no role in
   study design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR Aguet F, 2020, SCIENCE, V369, P1318, DOI 10.1126/science.aaz1776
   Altshuler DM, 2015, NATURE, V526, P68, DOI 10.1038/nature15393
   Altshuler DM, 2012, NATURE, V491, P56, DOI 10.1038/nature11632
   Andersson R, 2014, NATURE, V507, P455, DOI 10.1038/nature12787
   [Anonymous], 2014, Cancer Discov, V4, pOF5, DOI 10.1158/2159-8290.CD-NB2013-178
   Bolger AM, 2014, BIOINFORMATICS, V30, P2114, DOI 10.1093/bioinformatics/btu170
   Boyle AP, 2012, GENOME RES, V22, P1790, DOI 10.1101/gr.137323.112
   Boyle EA, 2017, CELL, V169, P1177, DOI 10.1016/j.cell.2017.05.038
   Braschi B, 2019, NUCLEIC ACIDS RES, V47, pD786, DOI 10.1093/nar/gky930
   Buniello A, 2019, NUCLEIC ACIDS RES, V47, pD1005, DOI 10.1093/nar/gky1120
   Cabili MN, 2011, GENE DEV, V25, P1915, DOI 10.1101/gad.17446611
   Cannon ME, 2018, AM J HUM GENET, V103, P637, DOI 10.1016/j.ajhg.2018.10.001
   Chakravarthy U, 2010, BMJ-BRIT MED J, V340, DOI 10.1136/bmj.c981
   Chiang JJ, 2018, NAT IMMUNOL, V19, P53, DOI 10.1038/s41590-017-0005-y
   Cookson W, 2009, NAT REV GENET, V10, P184, DOI 10.1038/nrg2537
   Crowder M., 2011, INT STAT REV, V79, P134
   Dekker J, 2002, SCIENCE, V295, P1306, DOI 10.1126/science.1067799
   Delaneau O, 2012, NAT METHODS, V9, P179, DOI [10.1038/NMETH.1785, 10.1038/nmeth.1785]
   Dobin A, 2013, BIOINFORMATICS, V29, P15, DOI 10.1093/bioinformatics/bts635
   Ewels P, 2016, BIOINFORMATICS, V32, P3047, DOI 10.1093/bioinformatics/btw354
   GERMAIN RN, 1993, ANNU REV IMMUNOL, V11, P403, DOI 10.1146/annurev.iy.11.040193.002155
   Giambartolomei C, 2014, PLOS GENET, V10, DOI 10.1371/journal.pgen.1004383
   Giannuzzi G, 2013, GENOME RES, V23, P46, DOI 10.1101/gr.138842.112
   Howie B, 2011, G3-GENES GENOM GENET, V1, P457, DOI 10.1534/g3.111.001198
   Johnson WE, 2007, BIOSTATISTICS, V8, P118, DOI 10.1093/biostatistics/kxj037
   Khalil AM, 2009, P NATL ACAD SCI USA, V106, P11667, DOI 10.1073/pnas.0904715106
   Kikuchi M, 2019, BMC MED GENOMICS, V12, DOI 10.1186/s12920-019-0574-8
   Kovalenko TF, 2018, BIOCHEMISTRY-MOSCOW+, V83, P1332, DOI 10.1134/S0006297918110044
   Kundaje A, 2015, NATURE, V518, P317, DOI 10.1038/nature14248
   Lai F, 2013, NATURE, V494, P497, DOI 10.1038/nature11884
   Li B, 2011, BMC BIOINFORMATICS, V12, DOI 10.1186/1471-2105-12-323
   Ongen H, 2016, BIOINFORMATICS, V32, P1479, DOI 10.1093/bioinformatics/btv722
   R Team Core, 2017, R FDN STAT COMP, P2017
   Raposo G, 2007, NAT REV MOL CELL BIO, V8, P786, DOI 10.1038/nrm2258
   Ratnapriya R, 2019, NAT GENET, V51, P606, DOI 10.1038/s41588-019-0351-9
   Robinson MD, 2010, BIOINFORMATICS, V26, P139, DOI 10.1093/bioinformatics/btp616
   Rosenbloom KR, 2015, NUCLEIC ACIDS RES, V43, pD670, DOI 10.1093/nar/gku1177
   Springelkamp H, 2017, HUM MOL GENET, V26, P438, DOI 10.1093/hmg/ddw399
   Storey JD, 2003, P NATL ACAD SCI USA, V100, P9440, DOI 10.1073/pnas.1530509100
   Strunz T, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-58510-9
   Strunz T, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-24219-z
   Weinreb RN, 2014, JAMA-J AM MED ASSOC, V311, P1901, DOI 10.1001/jama.2014.3192
   Wolf AH, 2009, CORNEA, V28, P524, DOI 10.1097/ICO.0b013e3181901dde
   Yates A, 2016, NUCLEIC ACIDS RES, V44, pD710, DOI 10.1093/nar/gkv1157
   Yengo L, 2018, HUM MOL GENET, V27, P3641, DOI 10.1093/hmg/ddy271
   Zheng XW, 2012, BIOINFORMATICS, V28, P3326, DOI 10.1093/bioinformatics/bts606
NR 46
TC 9
Z9 9
U1 0
U2 1
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1553-7404
J9 PLOS GENET
JI PLoS Genet.
PD SEP
PY 2020
VL 16
IS 9
AR e1008934
DI 10.1371/journal.pgen.1008934
PG 18
WC Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity
GA NN6BE
UT WOS:000568870800001
PM 32870927
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Babizhayev, MA
   Micans, P
   Guiotto, A
   Kasus-Jacobi, A
AF Babizhayev, Mark A.
   Micans, Philip
   Guiotto, Andrea
   Kasus-Jacobi, Anne
TI N-Acetylcarnosine Lubricant Eyedrops Possess All-In-One Universal
   Antioxidant Protective Effects of L-Carnosine in Aqueous and Lipid
   Membrane Environments, Aldehyde Scavenging, and Transglycation
   Activities Inherent to Cataracts: A Clinical Study of the New
   Vision-Saving Drug N-Acetylcarnosine Eyedrop Therapy in a Database
   Population of Over 50,500 Patients
SO AMERICAN JOURNAL OF THERAPEUTICS
LA English
DT Article
DE age-related ophthalmic diseases; aldehyde scavenging; cataracts;
   hydrazide carnosine derivatives; L-carnosine; N-acetylcarnosine
   lubricant eyedrops; transglycation
ID HISTIDINE-CONTAINING DIPEPTIDE; NATURAL HISTIDINE; CRYSTALLINE LENS;
   SCHIFF-BASES; PEROXIDATION; ANSERINE; DRIVERS; ACT
AB The antioxidant activity of L-carnosine (beta-alanyl-L-histidine, bioactivated in ocular tissues) versus N-acetylcarnosine (N-acetyl-beta-alanyl-L-histidine, ocular-targeted small dipeptide molecules) was studied in aqueous solution and in a lipid environment, employing liposomes as a model of lipid membranes. Reactive oxygen species (ROS) were generated by an iron/ascorbate promoter system for induction of lipid peroxidation (LPO). L-carnosine, which is stabilized from enzymatic hydrolysis, operates as a universal aldehyde and ROS scavenger in both aqueous and lipid environments and is effective at preventing ROS-induced damage to biomolecules. Second-generation carnosine analogs bearing the histidyl-hydrazide moiety were synthesized and tested versus L-camosine for their ability to reverse the glycation process, also known as the Maillard reaction, and reverse the stable intermolecular cross-links, monitored in the glucose-ethylamine Schiff base model, ultimately resulting in the formation of the advanced glycation end products (AGES) from nonenzymatic glycation, accumulating in numerous body tissues and fluids. The obtained data demonstrate the transglycation properties of the ophthalmically stabilized L-camosine and L-carnosine histidyl-hydrazide derivatives tested and can be used to decrease or predict the occurrence of long-term complications of AGE formation and improve therapeutically the quality of vision and length of life for diabetes mellitus patients and survivors with early aging. Scientists at Innovative Vision Products, Inc. (IVP), developed lubricant eyedrops designed as a sustained-release 1% N-acetylcarnosine prodrug of L-camosine. The eyedrops contain a mucoadhesive cellulose-based compound combined with corneal absorption promoters and glycerine in a drug-delivery system. Anti-aging therapeutics with the ophthalmic drug eyedrop formula including N-acetylcarnosine showed efficacy in the nonsurgical treatment of age-related cataracts for enrolled participants in the prospective, randomized, double-masked, placebo-controlled crossover clinical trial after controlling for age, gender, and daily activities. In a cohort in excess of 50,500 various patients seeking cutting-edge medical care, the N-acetylcamosine topical eyedrops target therapy was demonstrated to have significant efficacy, safety, and good tolerability for the prevention and treatment of visual impairment in this older population with relatively stable patterns of causes for blindness and visual impairment. Overall, accumulated study data demonstrate that the IVP-designed new vision-saving drugs, including N-acetylcarnosine eyedrops, promote health vision and prevent vision disability from senile cataracts, primary open-angle glaucoma, age-related macular degeneration, diabetic retinopathy, and aging. N-acetylcarnosine eyedrop therapy is the crown jewel of the anti-aging medical movement and revolutionizes early detection, treatment, and rejuvenation of aging-related eye-disabling disorders. N-acetylcarnosine, as an innovative medical science tool and component of the home medicine and alternative medicine approaches, has the potential to alleviate visual impairment and its associated social, economic, and political woes for an aging population.
   The real voyage of discovery consists not in seeking new landscapes but in having new eyes. -Marcel Proust
C1 [Babizhayev, Mark A.] Innovat Vis Prod, Delaware, OH USA.
   [Guiotto, Andrea] CNR, Inst Biomol Chem, Padova Unit, Padua, Italy.
   [Kasus-Jacobi, Anne] Univ Oklahoma, Hlth Sci Ctr, Dept Ophthalmol, Dean A McGee Eye Inst, Oklahoma City, OK USA.
C3 Consiglio Nazionale delle Ricerche (CNR); University of Oklahoma System;
   University of Oklahoma Health Sciences Center
RP Babizhayev, MA (通讯作者)，Innovat Vis Prod Inc, Moscow Div, Ivanovskaya 20,Suite 74, Moscow 127434, Russia.
EM markbabizhayev@mail.ru
RI KASUS-JACOBI, Anne/V-7799-2019
OI KASUS-JACOBI, Anne/0000-0003-3844-0450
CR Aldini G, 2002, BIOCHEM BIOPH RES CO, V298, P699, DOI 10.1016/S0006-291X(02)02545-7
   Ansari NH, 1996, BIOCHEM MOL MED, V58, P25, DOI 10.1006/bmme.1996.0028
   Babizhayev M.A., 1994, Pharmaceutical compositions containing N-acetylcarnosine for the treatment of cataract, Patent No. [PCT/EP 94/03340 SCB 238 PCT, 9403340]
   Babizhayev M.A., 1993, Italian Patent, Patent No. [A61K gruppo 37/00 20122 MI, 370020122]
   Babizhayev M.A., 1999, US Patent No, Patent No. [6,007,203, 6007203]
   BABIZHAYEV MA, 1989, BIOCHIM BIOPHYS ACTA, V1004, P363, DOI 10.1016/0005-2760(89)90085-4
   BABIZHAYEV MA, 1994, BBA-MOL BASIS DIS, V1225, P326, DOI 10.1016/0925-4439(94)90014-0
   Babizhayev MA, 1996, CLIN CHIM ACTA, V254, P1, DOI 10.1016/0009-8981(96)06356-5
   BABIZHAYEV MA, 1989, BIOCHIM BIOPHYS ACTA, V1004, P124, DOI 10.1016/0005-2760(89)90222-1
   BABIZHAYEV MA, 1988, MECH AGEING DEV, V44, P69, DOI 10.1016/0047-6374(88)90080-2
   Babizhayev MA, 2004, REJUV RES, V7, P186, DOI 10.1089/rej.2004.7.186
   Babizhayev MA, 2003, OPHTHALMIC RES, V35, P19, DOI 10.1159/000068199
   Babizhayev MA, 2001, PEPTIDES, V22, P979, DOI 10.1016/S0196-9781(01)00407-7
   BABIZHAYEV MA, 1994, BIOCHEM J, V304, P509, DOI 10.1042/bj3040509
   Babizhayev MA, 2000, J ANTI-AGING MED, V3, P43, DOI 10.1089/rej.1.2000.3.43
   BABIZHAYEV MA, 2006, J PHARM TOXICOL, V1, P201
   BABIZHAYEV MA, 2008, CLIN INTERVENTION AG, V4, P31
   BABIZHAYEV MA, 2004, Patent No. 2004000351
   BABIZHAYEV MA, 2004, Patent No. 2004028536
   Babizhayev MA, 2004, Patent No. [2004064866, WO 2004/064866 PCT/JP2004/000351]
   Babizhayev MA, 2006, CURR DRUG THER, V1, P91, DOI 10.2174/157488506775268425
   Babizhayev Mark A, 2004, Drugs R D, V5, P125, DOI 10.2165/00126839-200405030-00001
   Babizhayev Mark A, 2003, Clin Exp Optom, V86, P157
   Babizhayev Mark A, 2002, Drugs R D, V3, P87, DOI 10.2165/00126839-200203020-00004
   BOLDYREV AA, 1987, BIOCHEM INT, V15, P1105
   FERRIS FL, 1982, AM J OPHTHALMOL, V94, P97, DOI 10.1016/0002-9394(82)90198-2
   FERRIS FL, 1982, AM J OPHTHALMOL, V94, P91, DOI 10.1016/0002-9394(82)90197-0
   Ganley JP, 1983, DHHS PUBLICATION, V83-1678
   Guiotto A, 2007, BIOORGAN MED CHEM, V15, P6158, DOI 10.1016/j.bmc.2007.06.029
   Hipkiss AR, 2000, BIOGERONTOLOGY, V1, P217, DOI 10.1023/A:1010057412184
   Hipkiss AR, 1997, NEUROSCI LETT, V238, P135, DOI 10.1016/S0304-3940(97)00873-2
   Hobart LJ, 2004, LIFE SCI, V75, P1379, DOI 10.1016/j.lfs.2004.05.002
   Kang JH, 2002, BBA-GEN SUBJECTS, V1570, P89, DOI 10.1016/S0304-4165(02)00158-7
   Owsley C, 2001, ARCH OPHTHALMOL-CHIC, V119, P881
   Price DL, 2001, J BIOL CHEM, V276, P48967, DOI 10.1074/jbc.M108196200
   Seidler NW, 2004, ARCH BIOCHEM BIOPHYS, V427, P110, DOI 10.1016/j.abb.2004.04.024
   Shao L, 2004, BIOCHEM BIOPH RES CO, V324, P931, DOI 10.1016/j.bbrc.2004.09.136
   ShmuelyDulitzki Y, 1997, AM J GERIAT PSYCHIAT, V5, P216, DOI 10.1097/00019442-199700530-00005
   Szwergold BS, 2005, BIOCHEM BIOPH RES CO, V336, P36, DOI 10.1016/j.bbrc.2005.08.033
   Yamagishi S, 2005, CURR DIABETES REV, V1, P93, DOI 10.2174/1573399052952631
   Yu TZ, 2006, P NATL ACAD SCI USA, V103, P2653, DOI 10.1073/pnas.0511154103
NR 41
TC 27
Z9 29
U1 0
U2 18
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1075-2765
J9 AM J THER
JI Am. J. Ther.
PD NOV-DEC
PY 2009
VL 16
IS 6
BP 517
EP 533
DI 10.1097/MJT.0b013e318195e327
PG 17
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA 529RW
UT WOS:000272535900011
PM 19487926
DA 2022-11-30
ER

PT J
AU Owen, JP
   Blazes, M
   Lacy, M
   Yanagihara, RT
   Van Gelder, RN
   Lee, AY
   Lee, CS
AF Owen, Julia P.
   Blazes, Marian
   Lacy, Megan
   Yanagihara, Ryan T.
   Van Gelder, Russell N.
   Lee, Aaron Y.
   Lee, Cecilia S.
CA IRIS Res Analytic Ctr Consortium
TI Refractive Outcomes After Immediate Sequential vs Delayed Sequential
   Bilateral Cataract Surgery
SO JAMA OPHTHALMOLOGY
LA English
DT Article
ID VISION HEALTH; 1ST EYE; PREVALENCE; ERROR; DISPARITIES; ENDOPHTHALMITIS;
   STABILIZATION; PREDICTION; PATIENT; ADULTS
AB IMPORTANCE Approximately 2 million cataract operations are performed annually in the US, and patterns of cataract surgery delivery are changing to meet the increasing demand. Therefore, a comparative analysis of visual acuity outcomes after immediate sequential bilateral cataract surgery (ISBCS) vs delayed sequential bilateral cataract surgery (DSBCS) is important for informing future best practices.
   OBJECTIVE To compare refractive outcomes of patients who underwent ISBCS, short-interval (1-14 days between operations) DSBCS (DSBCS-14), and long-interval (15-90 days) DSBCS (DSBCS-90) procedures.
   DESIGN, SETTING, AND PARTICIPANTS This retrospective cohort study used population-based data from the American Academy of Ophthalmology Intelligent Research in Sight (IRIS) Registry. A total of 1 824 196 IRIS Registry participants with bilateral visual acuity measurements who underwent bilateral cataract surgery were assessed.
   EXPOSURES Participants were divided into 3 groups (DSBCS-90, DSBCS-14, and ISBCS groups) based on the timing of the second eye surgery. Univariable and multivariable linear regression models were used to analyze the refractive outcomes of the first and second surgery eye.
   MAIN OUTCOMES AND MEASURES Mean postoperative uncorrected visual acuity (UCVA) and best-corrected visual acuity (BCVA) after cataract surgery.
   RESULTS This study analyzed data from 1824 196 patients undergoing bilateral cataract surgery (mean [SD] age for those <87 years, 70.03 [7.77]; 684 916 [37.5%] male). Compared with the DSBCS-90 group, after age, self-reported race, insurance status, history of age-related macular degeneration, diabetic retinopathy, and glaucoma were controlled for, the UCVA of the first surgical eye was higher by 0.41 (95% CI, 0.36-0.45; P < .001) letters, and the BCVA was higher by 0.89 (95% CI, 0.86-0.92; P < .001) letters in the DSBCS-14 group, whereas in the ISBCS group, the UCVA was lower by 2.79 (95% CI, -2.95 to -2.63; P < .001) letters and the BCVA by 1.64 (95% CI, -1.74 to -1.53; P < .001) letters. Similarly, compared with the DSBCS-90 group for the second eye, in the DSBCS-14 group, the UCVA was higher by 0.79 (95% CI, 0.74-0.83; P < .001) letters and the BCVA by 0.48 (95% CI, 0.45-0.51; P < .001) letters, whereas in the ISBCS group, the UCVA was lower by -1.67 (95% CI, -1.83 to -1.51; P < .001) letters and the BCVA by -1.88 (95% CI, -1.98 to -1.78; P < .001) letters.
   CONCLUSIONS AND RELEVANCE The results of this cohort study of patients in the IRIS Registry suggest that compared with DSBCS-14 or DSBCS-90, ISBCS is associated with worse visual outcomes, which may or may not be clinically relevant, depending on patients' additional risk factors. Nonrandom surgery group assignment, confounding factors, and large sample size could account for the small but statistically significant differences noted. Further studies are warranted to determine whether these factors should be considered clinically relevant when counseling patients before cataract surgery.
C1 [Owen, Julia P.; Blazes, Marian; Lacy, Megan; Yanagihara, Ryan T.; Van Gelder, Russell N.; Lee, Aaron Y.; Lee, Cecilia S.] Univ Washington, Dept Ophthalmol, 325 Ninth Ave,POB 359608, Seattle, WA 98104 USA.
   [Van Gelder, Russell N.; Lee, Aaron Y.; Lee, Cecilia S.] Karalis Johnson Retina Ctr, Seattle, WA USA.
C3 University of Washington; University of Washington Seattle
RP Lee, CS (通讯作者)，Univ Washington, Dept Ophthalmol, 325 Ninth Ave,POB 359608, Seattle, WA 98104 USA.
EM leecs2@uw.edu
RI Van Gelder, Russell/ABB-4225-2021
OI Van Gelder, Russell/0000-0001-5368-3659; Lee, Aaron/0000-0002-7452-1648;
   Yanagihara, Ryan/0000-0001-6898-9335
FU National Eye Institute [K23EY029246]; National Institute on Aging
   [R01AG060942]; Latham Vision Innovation Award; Research to Prevent
   Blindness
FX This research was supported by grant K23EY029246 from the National Eye
   Institute (Dr A.Y. Lee), grant R01AG060942 from the National Institute
   on Aging (Dr C.S. Lee), a Latham Vision Innovation Award (Dr A.Y. Lee),
   and an unrestricted grant from Research to Prevent Blindness (Drs C.S.
   Lee and A.Y. Lee).
CR Ahmed IIK, 2021, OPHTHALMOLOGY, V128, P13, DOI 10.1016/j.ophtha.2020.08.028
   American Academy of Ophthalmology, IRIS REG
   Aristodemou P, 2011, OPHTHALMOLOGY, V118, P1701, DOI 10.1016/j.ophtha.2011.05.010
   Arshinoff SA, 2012, OPHTHALMOLOGY, V119, P2646, DOI 10.1016/j.ophtha.2012.07.055
   Arshinoff SA, 2011, J CATARACT REFR SURG, V37, P2105, DOI 10.1016/j.jcrs.2011.06.036
   Bell CM, 2007, OPHTHALMOLOGY, V114, P405, DOI 10.1016/j.ophtha.2006.08.036
   Caglar C, 2017, SEMIN OPHTHALMOL, V32, P412, DOI 10.3109/08820538.2015.1115089
   Chung JK, 2009, JPN J OPHTHALMOL, V53, P107, DOI 10.1007/s10384-008-0627-6
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P487
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Grzybowski A, 2016, SAUDI J OPHTHALMOL, V30, P244, DOI 10.1016/j.sjopt.2016.09.001
   Guber I, 2015, EYE VISION, V2, DOI 10.1186/s40662-015-0023-5
   Han MM, 2020, OPHTHALMOL RETINA, V4, P351, DOI 10.1016/j.oret.2019.12.018
   Herrinton LJ, 2017, OPHTHALMOLOGY, V124, P1126, DOI 10.1016/j.ophtha.2017.03.034
   Jabbour J, 2006, J CATARACT REFR SURG, V32, P2091, DOI 10.1016/j.jcrs.2006.08.030
   Jeon Sohee, 2011, Korean J Ophthalmol, V25, P84, DOI 10.3341/kjo.2011.25.2.84
   Jivrajka RV, 2012, OPHTHALMOLOGY, V119, P1097, DOI 10.1016/j.ophtha.2012.01.008
   Kessel L, 2015, J OPHTHALMOL, V2015, DOI 10.1155/2015/912481
   Lamoureux EL, 2011, CURR OPIN OPHTHALMOL, V22, P19, DOI 10.1097/ICU.0b013e3283414284
   Lee CS, 2020, OPHTHALMOL GLAUCOMA, V3, P253, DOI 10.1016/j.ogla.2020.03.008
   Lee YH, 2018, JAMA OPHTHALMOL, V136, P622, DOI 10.1001/jamaophthalmol.2018.0813
   Li O, 2014, AM J OPHTHALMOL, V157, P749, DOI 10.1016/j.ajo.2014.01.002
   Liu LY, 2019, J CATARACT REFR SURG, V45, P404, DOI 10.1016/j.jcrs.2018.11.002
   Lundstrom M, 2006, J CATARACT REFR SURG, V32, P826, DOI 10.1016/j.jcrs.2006.01.075
   Lundstrom M, 2002, BRIT J OPHTHALMOL, V86, P1330, DOI 10.1136/bjo.86.12.1330
   Mahr MA, 2018, J CATARACT REFR SURG, V44, P140, DOI 10.1016/j.jcrs.2017.10.049
   Manoharan N, 2018, J CATARACT REFR SURG, V44, P348, DOI 10.1016/j.jcrs.2017.12.024
   Medeiros S., 2014, CATARACT SURG INFOGR
   Modjtahedi BS, 2019, OPHTHALMOLOGY, V126, P355, DOI 10.1016/j.ophtha.2018.10.030
   Mundy KM, 2016, SEMIN OPHTHALMOL, V31, P358, DOI 10.3109/08820538.2016.1154178
   Nassiri N, 2009, EYE, V23, P89, DOI 10.1038/sj.eye.6702989
   National Eye Institute, CAT DAT STAT
   Neel ST, 2014, JAMA OPHTHALMOL, V132, P1282, DOI 10.1001/jamaophthalmol.2014.2074
   O'Brien JJ, 2010, CAN J OPHTHALMOL, V45, P596, DOI 10.3129/i10-094
   Rich WL, 2018, OPHTHALMOLOGY, V125, P782, DOI 10.1016/j.ophtha.2017.11.033
   Rush SW, 2015, J CATARACT REFR SURG, V41, P732, DOI 10.1016/j.jcrs.2014.07.034
   Sarikkola AU, 2011, J CATARACT REFR SURG, V37, P992, DOI 10.1016/j.jcrs.2011.01.019
   Serrano-Aguilar P, 2012, J CATARACT REFR SURG, V38, P1734, DOI 10.1016/j.jcrs.2012.05.024
   Shahbazi S, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0142459
   SOMMER A, 1991, NEW ENGL J MED, V325, P1412, DOI 10.1056/NEJM199111143252004
   Stock MV, 2015, INVEST OPHTH VIS SCI, V56, P2536, DOI 10.1167/iovs.14-16069
   Sugar A, 2001, J CATARACT REFR SURG, V27, P1741, DOI 10.1016/S0886-3350(01)00894-X
   Turnbull AMJ, 2019, J CATARACT REFR SURG, V45, P1239, DOI 10.1016/j.jcrs.2019.04.008
   Varma R, 2017, AM J OPHTHALMOL, V175, P201, DOI 10.1016/j.ajo.2016.10.002
   Wang W, 2017, INVEST OPHTH VIS SCI, V58, P3669, DOI 10.1167/iovs.17-21489
   Wen G, 2013, OPHTHALMOLOGY, V120, P2109, DOI 10.1016/j.ophtha.2013.06.039
   Wesolosky JD, 2013, CAN J OPHTHALMOL, V48, P471, DOI 10.1016/j.jcjo.2013.07.001
   World Med Assoc, 2013, JAMA-J AM MED ASSOC, V310, P2191, DOI 10.1001/jama.2013.281053
   Zambelli-Weiner A, 2012, AM J OPHTHALMOL, V154, pS23, DOI 10.1016/j.ajo.2012.03.018
   Zetterberg M, 2020, OPHTHALMOLOGY, V127, P305, DOI 10.1016/j.ophtha.2019.10.007
   Zhang XZ, 2012, AM J OPHTHALMOL, V154, pS53, DOI 10.1016/j.ajo.2011.08.045
NR 51
TC 9
Z9 9
U1 4
U2 6
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 2168-6165
EI 2168-6173
J9 JAMA OPHTHALMOL
JI JAMA Ophthalmol.
PD AUG
PY 2021
VL 139
IS 8
BP 876
EP 885
DI 10.1001/jamaophthalmol.2021.2032
EA JUL 2021
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA UC7WJ
UT WOS:000669019300006
PM 34196667
OA Green Published
DA 2022-11-30
ER

PT J
AU Bourne, RRA
   Dineen, BP
   Ali, SM
   Huq, DMN
   Johnson, GJ
AF Bourne, RRA
   Dineen, BP
   Ali, SM
   Huq, DMN
   Johnson, GJ
TI Outcomes of cataract surgery in Bangladesh: results from a population
   based nationwide survey
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID VISUAL-ACUITY; PREVALENCE; EYE; BLINDNESS; ADULTS; INDIA
AB Aim: To evaluate the outcome of cataract surgery in the population of Bangladesh.
   Methods: Data were collected by the National Blindness and Low Vision Prevalence Survey of Bangladesh, a cross sectional, nationally representative sample (12 782 subjects) of the population aged greater than or equal to30 years. An interview recorded socioeconomic data. Each subject was tested for logMAR visual acuity (VA) of each eye, autorefracted, and then underwent optic disc examination. Those with <6/12 VA on presentation in either eye were retested with their refractive correction, dilated, and examined for anterior and posterior segment disease. In aphakic and pseudophakic subjects the date, location and operating conditions (eye camp/hospital), and type of operation(s) were recorded.
   Results: 11 624 eligible subjects were examined (90.9% response rate) in the survey. 162 subjects, 77 men and 85 women, had undergone cataract surgery in one or both eyes. 199 (88%) eyes had undergone intracapsular cataract extraction (ICCE), and 22 (10%) extracapsular surgery with intraocular lens (ECCE+IOL); surgical technique(s) in four cases were not identified. Presenting VA for the 226 operated eyes were: 68 eyes (30.1%) were 6/12 or better, 31 (13.7%) <6/12 greater than or equal to6/18, 63 (27.9%) 6/18 to 6/60, 8 (3.5%) <6/60 >= 3/60, and 56 (24.8%) <3/60. With "best" refractive correction these values were 114 (50.4%), 31 (13.7%), 51 (22.6%), 5 (2.2%), and 25 (11.1%), respectively. Of the 158 eyes with VA of 6/12 or worse on presentation, 44 (28%) were the result of coincident disease (principally age related macular degeneration), 95 (60%) refractive error (44 of these had uncorrected aphakia), and 19 (12%) operative complications. ICCE was more likely to result in a VA of <6/18 (OR: 4.26, p = 0.01) than ECCE+IOL. Likewise, eye camp surgery was more likely to result in a VA of <6/60 (OR: 1.98, p = 0.04). No significant association was found between time since surgery and VA outcome, nor was there a sex difference for postoperative vision. Literate subjects were significantly less likely to have an outcome of <6/18 (OR: 2.38, p < 0.01) or < 6/60 (OR: 2.87, p < 0.01). Following ICCE (199 eyes), 56 (37%) of the 151 eyes with an aphakic spectacle correction achieved 6/12 or better. Females, eye camp surgeries, illiterate subjects, and rural dwellers were less likely to wear their aphakic correction. The ratio of ICCE: ECCE+IOL has reduced in the past 3 years (3.8:1) compared to greater than or equal to4 years before the survey (25: 1). Hospital based ECCE+IOL surgeries were associated with a better outcome, yet 36% of these eyes were <6/12 postoperatively, after excluding coincident disease.
   Conclusion: This evaluative research study into cataract surgery outcomes in Bangladesh highlights the need for an improvement in quality and increased quantity of surgery with a more balanced distribution of services.
C1 UCL, Inst Ophthalmol, Int Ctr Eye Hlth, Dept Epidemiol & Int Eye Hlth, London EC1V 9EL, England.
   Natl Inst Ophthalmol, Dhaka, Bangladesh.
C3 University of London; London School of Hygiene & Tropical Medicine;
   University College London
RP Bourne, RRA (通讯作者)，UCL, Inst Ophthalmol, Int Ctr Eye Hlth, Dept Epidemiol & Int Eye Hlth, 31-43 Bath St, London EC1V 9EL, England.
EM rupert_bourne@hotmail.com
OI Dineen, Brendan/0000-0002-9619-8044
CR *BANGL BUR STAT, 1997, BANGL POP CENS 1991, V3
   Bourne RRA, 2002, OPHTHAL EPIDEMIOL, V9, P119, DOI 10.1076/opep.9.2.119.1520
   Dandona L, 1999, AM J OPHTHALMOL, V127, P650, DOI 10.1016/S0002-9394(99)00044-6
   Dineen BP, 2003, BRIT J OPHTHALMOL, V87, P820, DOI 10.1136/bjo.87.7.820
   Dunn G., 1989, DESIGN ANAL RELIABIL
   He MG, 1999, OPHTHALMOLOGY, V106, P1609, DOI 10.1016/S0161-6420(99)90460-8
   Johnson GJ, 2000, LANCET, V355, P158, DOI 10.1016/S0140-6736(99)00404-3
   KANSKI JJ, 1986, EYE SYSTEMIC DIS
   Kapoor H, 1999, BRIT J OPHTHALMOL, V83, P343, DOI 10.1136/bjo.83.3.343
   Khan M J, 2000, Community Eye Health, V13, P24
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   LESKE MC, 1981, AM J EPIDEMIOL, V113, P606, DOI 10.1093/oxfordjournals.aje.a113138
   MEHRA V, 1988, BRIT J OPHTHALMOL, V72, P801, DOI 10.1136/bjo.72.11.801
   Murthy GVS, 2001, OPHTHALMOLOGY, V108, P686, DOI 10.1016/S0161-6420(00)00578-9
   Pokharel GP, 1998, BRIT J OPHTHALMOL, V82, P600, DOI 10.1136/bjo.82.6.600
   REIDY A, 1991, BRIT J OPHTHALMOL, V75, P102, DOI 10.1136/bjo.75.2.102
   Rosser DA, 2001, BRIT J OPHTHALMOL, V85, P432, DOI 10.1136/bjo.85.4.432
   *WHO, 1999, EL AV BLINDN S E AS
NR 18
TC 46
Z9 48
U1 0
U2 3
PU B M J PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD JUL
PY 2003
VL 87
IS 7
BP 813
EP 819
DI 10.1136/bjo.87.7.813
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 690ZZ
UT WOS:000183581500005
PM 12812874
OA Green Submitted, Green Published, Bronze
DA 2022-11-30
ER

PT J
AU Lee, H
   Bae, K
   Kang, SW
   Woo, SJ
   Ryoo, NK
   Kim, SJ
   Han, G
AF Lee, Hoyoung
   Bae, Kunho
   Kang, Se Woong
   Woo, Se Joon
   Ryoo, Na-Kyung
   Kim, Sang Jin
   Han, Gyule
TI Morphologic Characteristics of Choroid in the Major Choroidal Thickening
   Diseases, Studied by Optical Coherence Tomography
SO PLOS ONE
LA English
DT Article
ID CENTRAL SEROUS CHORIORETINOPATHY; KOYANAGI-HARADA-DISEASE; INDOCYANINE
   GREEN VIDEOANGIOGRAPHY; VASCULAR HYPERPERMEABILITY; THICKNESS
   MEASUREMENTS; MACULAR DEGENERATION; VASCULOPATHY; FEATURES; EYES;
   REPRODUCIBILITY
AB We investigated morphologic features of choroid in the choroidal thickening diseases, including central serous chorioretinopathy (CSC), polypoidal choroidal vasculopathy (PCV), and Vogt-Koyanagi-Harada disease (VKH), by a novel tomographic classification system of the choroid. This cross-sectional study involved 30 patients with active CSC, 30 patients with active PCV, and 27 patients with active VKH, and 30 normal controls. Utilizing enhanced depth imaging optical coherence tomography, we classified the morphology of the choroid into five categories: 1) Standard (S), 2) Dilated outer layer and Attenuated inner layer (DA), 3) Darkened (D), 4) Marbled (M), and 5) Pauci-Vascular (PV) types. Additional tomographic characteristics of the choroid such as choroidal vascular dilation, convolution, scleral invisibility, and choroidal hyper-or hypo-thickening were identified as well. The distribution of five choroidal tomographic morphology and additional tomographic characteristics in each group were analyzed. The DA type was observed in the CSC group more frequently than in the normal control group (53.3% vs 3.3%, P < 0.001). Additional tomographic characteristics, such as choroidal vascular dilation (76.7%), and choroidal hyper-thickening (36.7%), were more prevalent in the CSC group than in the control group. The PCV group showed higher prevalence of DA type (33.3% vs. 3.3%, P = 0.006) than the control group. The VKH group showed a significantly higher frequency of the D type (63.0%), convolution (40.7%), and scleral invisibility (70.4%) than controls (0% for all three findings). In conclusion, CSC and PCV shared common morphologic characteristics of choroid, including dilated outer vascular layer and focally attenuated innermost layer. Dense hypo-reflectivity and convolution of choroid were the specific tomographic markers for acute VKH. A new tomographic classification system of choroid may provide discrimination ability and insight into major pachychoroidopathies.
C1 [Lee, Hoyoung; Bae, Kunho; Kang, Se Woong; Kim, Sang Jin; Han, Gyule] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Ophthalmol, Seoul, South Korea.
   [Woo, Se Joon; Ryoo, Na-Kyung] Seoul Natl Univ, Coll Med, Bundang Hosp, Dept Ophthalmol, Songnam, South Korea.
C3 Sungkyunkwan University (SKKU); Samsung Medical Center; Seoul National
   University (SNU)
RP Kang, SW (通讯作者)，Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Ophthalmol, Seoul, South Korea.
EM swkang@skku.edu
CR Adhi M, 2013, JAMA OPHTHALMOL, V131, P1267, DOI 10.1001/jamaophthalmol.2013.4321
   Ahuja RM, 2001, OPHTHALMOLOGY, V108, P1009, DOI 10.1016/S0161-6420(00)00614-X
   Branchini L, 2012, OPHTHALMOLOGY, V119, P119, DOI 10.1016/j.ophtha.2011.07.002
   Branchini LA, 2013, OPHTHALMOLOGY, V120, P1901, DOI 10.1016/j.ophtha.2013.01.066
   Chung SE, 2011, OPHTHALMOLOGY, V118, P840, DOI 10.1016/j.ophtha.2010.09.012
   Ferrara D, 2014, OPHTHALMOLOGY, V121, P719, DOI 10.1016/j.ophtha.2013.10.014
   Fong AHC, 2011, RETINA-J RET VIT DIS, V31, P502, DOI 10.1097/IAE.0b013e3182083beb
   Fujiwara A, 2012, JPN J OPHTHALMOL, V56, P230, DOI 10.1007/s10384-012-0128-5
   Gupta V, 2009, AM J OPHTHALMOL, V147, P148, DOI 10.1016/j.ajo.2008.07.028
   GUYER DR, 1994, ARCH OPHTHALMOL-CHIC, V112, P1057, DOI 10.1001/archopht.1994.01090200063023
   HEE MR, 1995, AM J OPHTHALMOL, V120, P65, DOI 10.1016/S0002-9394(14)73760-2
   Hirata M, 2011, INVEST OPHTH VIS SCI, V52, P4971, DOI 10.1167/iovs.11-7729
   Hosoda Y, 2014, AM J OPHTHALMOL, V157, P1056, DOI 10.1016/j.ajo.2014.01.015
   Iida T, 1999, RETINA-J RET VIT DIS, V19, P508, DOI 10.1097/00006982-199911000-00005
   Ikuno Y, 2011, INVEST OPHTH VIS SCI, V52, P5536, DOI 10.1167/iovs.10-6811
   Imamura Y, 2009, RETINA-J RET VIT DIS, V29, P1469, DOI 10.1097/IAE.0b013e3181be0a83
   Ishihara K, 2009, OPHTHALMOLOGY, V116, P1799, DOI 10.1016/j.ophtha.2009.04.002
   Kato Y, 2013, JPN J OPHTHALMOL, V57, P90, DOI 10.1007/s10384-012-0212-x
   Kim JH, 2013, AM J OPHTHALMOL, V155, P743, DOI 10.1016/j.ajo.2012.11.001
   Kim YT, 2011, EYE, V25, P1635, DOI 10.1038/eye.2011.258
   Koizumi H, 2013, AM J OPHTHALMOL, V155, P305, DOI 10.1016/j.ajo.2012.07.018
   Lee CS, 2014, OPHTHALMOLOGY, V121, P1029, DOI 10.1016/j.ophtha.2013.11.043
   Lehmann M, 2013, BRIT J OPHTHALMOL, V97, P1181, DOI 10.1136/bjophthalmol-2012-302974
   Lin DS, 2014, BMC OPHTHALMOL, V14, DOI 10.1186/1471-2415-14-87
   Margolis R, 2009, AM J OPHTHALMOL, V147, P811, DOI 10.1016/j.ajo.2008.12.008
   Maruko I, 2011, RETINA-J RET VIT DIS, V31, P510, DOI 10.1097/IAE.0b013e3181eef053
   Nakashizuka H, 2008, INVEST OPHTH VIS SCI, V49, P4729, DOI 10.1167/iovs.08-2134
   Okunuki Y, 2015, JPN J OPHTHALMOL, V59, P103, DOI 10.1007/s10384-014-0367-8
   Ozawa S, 2009, RETINA-J RET VIT DIS, V29, P793, DOI 10.1097/IAE.0b013e3181a3b7d9
   Pang CE, 2015, RETINA-J RET VIT DIS, V35, P1, DOI 10.1097/IAE.0000000000000331
   Park SJ, 2014, AM J OPHTHALMOL, V158, P1155, DOI 10.1016/j.ajo.2014.08.010
   PICCOLINO FC, 1994, RETINA-J RET VIT DIS, V14, P231, DOI 10.1097/00006982-199414030-00008
   Prunte C, 1996, AM J OPHTHALMOL, V121, P26
   Rao Narsing A., 2007, International Ophthalmology, V27, P81, DOI 10.1007/s10792-006-9029-2
   Read RW, 2001, AM J OPHTHALMOL, V131, P647, DOI 10.1016/S0002-9394(01)00925-4
   Ruiz-Medrano J, 2015, AM J OPHTHALMOL, V160, P596, DOI 10.1016/j.ajo.2015.05.027
   Sasahara M, 2006, AM J OPHTHALMOL, V142, P601, DOI 10.1016/j.ajo.2006.05.051
   Spaide RF, 2003, RETINA-J RET VIT DIS, V23, P820, DOI 10.1097/00006982-200312000-00013
   Spaide RF, 1996, RETINA-J RET VIT DIS, V16, P203, DOI 10.1097/00006982-199616030-00004
   Spaide RF, 2008, AM J OPHTHALMOL, V146, P496, DOI 10.1016/j.ajo.2008.05.032
   Spaide RF, 2009, AM J OPHTHALMOL, V147, P801, DOI 10.1016/j.ajo.2008.12.010
   Spitznas M., 1986, CLIN EXP OPHTHALMOL, V224, P321
   Warrow DJ, 2013, RETINA-J RET VIT DIS, V33, P1659, DOI 10.1097/IAE.0b013e3182953df4
   Wu WJ, 2007, AM J OPHTHALMOL, V143, P900, DOI 10.1016/j.ajo.2006.11.050
   Yannuzzi LA, 2010, AM J OPHTHALMOL, V149, P361, DOI 10.1016/j.ajo.2009.11.017
NR 45
TC 10
Z9 11
U1 1
U2 3
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JAN 14
PY 2016
VL 11
IS 1
AR e0147139
DI 10.1371/journal.pone.0147139
PG 15
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA DB4CC
UT WOS:000368459300071
PM 26766530
OA Green Published, gold, Green Submitted
DA 2022-11-30
ER

PT J
AU Hua, R
   Zhang, MX
AF Hua, Rui
   Zhang, Meixia
TI Imaging Characteristics of Neovascular and Atrophic Pachychoroidal
   Spectrum Diseases
SO FRONTIERS IN MEDICINE
LA English
DT Article
DE pachychoroid spectrum diseases; optical coherence tomography
   angiography; choroidal vascular index; atrophic; aneurysmal polypoidal
   lesions
ID POLYPOIDAL CHOROIDAL VASCULOPATHY; CENTRAL SEROUS CHORIORETINOPATHY;
   COHERENCE TOMOGRAPHY ANGIOGRAPHY; MACULAR DEGENERATION; RISK-FACTORS;
   CLASSIFICATION; BINARIZATION; SECONDARY; OCT
AB BackgroundThis study qualitatively and quantitatively compared imaging characteristics between neovascular and atrophic pachychoroid spectrum disease (PSD) by optical coherence tomography (OCT), and OCT angiography (OCTA). MethodsThe subtypes of PSD were identified by multi-modality imaging approaches. Subfoveal choroidal thickness (SFCT), choroidal vascular index (CVI), and vascular density of choroidal neovascularization (CNV) were measured. ResultsThe CVI and SFCT of 174 PSD eyes were 67.6% +/- 5.48% and 362.2 +/- 131.88 mu m, respectively. After adjustment for age, linear regression indicated that SFCT was positively associated with CVI (p < 0.001), and patched hyper-reflective lesions in choriocapillaris layers (p = 0.009). Compared with neovascular PSD eyes, atrophic PSD eyes had similar patient age (57.1 +/- 16.72 years, p = 0.639), SFCT (332.0 +/- 111.00 mu m, p = 0.51), and CVI (67.6% +/- 3.94%, p = 0.527). There were no differences between polypoidal choroidal vasculopathy (PCV) eyes with aneurysmal polypoidal lesions and PCV eyes with tangled polypoidal lesions in terms of age, CVI, SFCT, vascular density, or the occurrence of double layer signs (DLSs, all p > 0.05). Logistic regression indicated that age (p = 0.003), SFCT (p = 0.003), patched hyper-reflective lesions in choriocapillaris layers (p = 0.009), and DLSs (p < 0.001) were predictive factors for CNV progression in PSD eyes (all p < 0.05). ConclusionsOur study highlighted the similarities in SFCT and CVI between neovascular and atrophic PSD, both of which were late stage lesions. Besides, age, SFCT, patched hyper-reflective lesions in choriocapillaris layers, and DLSs were risk factors for CNV in PSD. Our results showed that atrophic PSD is an important change in the late stage of PSD disease, which is helpful for in-depth understanding of the pathological mechanism of PSD and corresponding intervention.
C1 [Hua, Rui] China Med Univ, Dept Ophthalmol, Hosp 1, Shenyang, Peoples R China.
   [Hua, Rui; Zhang, Meixia] Sichuan Univ, West China Hosp, Dept Ophthalmol, Chengdu, Peoples R China.
   [Hua, Rui; Zhang, Meixia] Sichuan Univ, West China Hosp, Res Lab Macular Dis, Chengdu, Peoples R China.
C3 China Medical University; Sichuan University; Sichuan University
RP Zhang, MX (通讯作者)，Sichuan Univ, West China Hosp, Dept Ophthalmol, Chengdu, Peoples R China.; Zhang, MX (通讯作者)，Sichuan Univ, West China Hosp, Res Lab Macular Dis, Chengdu, Peoples R China.
EM zhangmeixia@scu.edu.cn
CR Bakthavatsalam M, 2017, GRAEF ARCH CLIN EXP, V255, P935, DOI 10.1007/s00417-017-3591-3
   Balaratnasingam C, 2016, RETINA-J RET VIT DIS, V36, P1, DOI 10.1097/IAE.0000000000000774
   Bo QY, 2019, JAMA OPHTHALMOL, V137, P642, DOI 10.1001/jamaophthalmol.2019.0449
   Borooah S, 2021, ACTA OPHTHALMOL, V99, pE806, DOI 10.1111/aos.14683
   Cakir B, 2019, OPHTHALMOL THER, V8, P75, DOI 10.1007/s40123-018-0159-1
   Cavichini M, 2021, BRIT J OPHTHALMOL, V105, P983, DOI 10.1136/bjophthalmol-2020-316622
   Chang YC, 2020, RETINA-J RET VIT DIS, V40, P1403, DOI 10.1097/IAE.0000000000002583
   Chen YT, 2018, LASER SURG MED, V50, P427, DOI 10.1002/lsm.22801
   Chen ZY, 2019, GRAEF ARCH CLIN EXP, V257, P2111, DOI 10.1007/s00417-019-04374-3
   Cheung CMG, 2019, EYE, V33, P14, DOI 10.1038/s41433-018-0158-4
   Chung HW, 2017, RETINA-J RET VIT DIS, V37, P199, DOI 10.1097/IAE.0000000000001345
   Coscas GJ, 2015, RETINA-J RET VIT DIS, V35, P2219, DOI 10.1097/IAE.0000000000000766
   Dansingani KK, 2018, CLIN EXP OPHTHALMOL, V46, P189, DOI 10.1111/ceo.13114
   Demirel S, 2021, JPN J OPHTHALMOL, V65, P482, DOI 10.1007/s10384-021-00829-5
   Demirel S, 2020, GRAEF ARCH CLIN EXP, V258, P1649, DOI 10.1007/s00417-020-04740-6
   Demirel S, 2021, EUR J OPHTHALMOL, V31, P184, DOI 10.1177/1120672119887095
   Dolz-Marco R, 2018, OPHTHALMOLOGY, V125, P1287, DOI 10.1016/j.ophtha.2018.02.036
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Fleckenstein M, 2018, OPHTHALMOLOGY, V125, P369, DOI 10.1016/j.ophtha.2017.08.038
   Freund KB, 2020, OSLI RETINA, V51, P206, DOI 10.3928/23258160-20200326-01
   Fujita A, 2020, RETINA-J RET VIT DIS, V40, P2296, DOI 10.1097/IAE.0000000000002760
   Hua R, 2021, CURR EYE RES, V46, P1437, DOI 10.1080/02713683.2021.1942073
   Hua R, 2017, J OPHTHALMOL, V2017, DOI 10.1155/2017/5498125
   Hua R, 2014, PHOTODIAGN PHOTODYN, V11, P365, DOI 10.1016/j.pdpdt.2014.07.001
   Invernizzi A, 2018, INVEST OPHTH VIS SCI, V59, P3836, DOI 10.1167/iovs.18-23960
   Jampol LM, 2006, RETINA-J RET VIT DIS, V26, P1072, DOI 10.1097/01.iae.0000248819.86737.a5
   Japanese Study Group of Polypoidal Choroidal Vasculopathy, 2005, Nippon Ganka Gakkai Zasshi, V109, P417
   Kim JH, 2013, AM J OPHTHALMOL, V156, P974, DOI 10.1016/j.ajo.2013.06.013
   Kocak N, 2021, INT OPHTHALMOL, V41, P825, DOI 10.1007/s10792-020-01636-6
   Koizumi H, 2013, AM J OPHTHALMOL, V155, P305, DOI 10.1016/j.ajo.2012.07.018
   Kuroiwa S, 2004, CLIN EXP OPHTHALMOL, V32, P297, DOI 10.1111/j.1442-9071.2004.00827.x
   Lee A, 2020, GRAEF ARCH CLIN EXP, V258, P1921, DOI 10.1007/s00417-020-04772-y
   Lee GI, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-40406-y
   Lee GW, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-83650-x
   Lee K, 2020, GRAEF ARCH CLIN EXP, V258, P1157, DOI 10.1007/s00417-020-04620-z
   Lee MW, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0229134
   Lee M, 2018, INVEST OPHTH VIS SCI, V59, P4896, DOI 10.1167/iovs.18-25018
   Lee WJ, 2016, EYE, V30, P1336, DOI 10.1038/eye.2016.113
   Lee WJ, 2017, BRIT J OPHTHALMOL, V101, P580, DOI 10.1136/bjophthalmol-2016-308428
   Lehmann M, 2015, RETINA-J RET VIT DIS, V35, P10, DOI 10.1097/IAE.0000000000000287
   Li ML, 2019, OPHTHALMOL RETINA, V3, P99, DOI 10.1016/j.oret.2018.08.008
   Lim HB, 2021, ACTA OPHTHALMOL, V99, pE117, DOI 10.1111/aos.14522
   Mitchell P, 2018, LANCET, V392, P1147, DOI 10.1016/S0140-6736(18)31550-2
   Nakashizuka H, 2008, INVEST OPHTH VIS SCI, V49, P4729, DOI 10.1167/iovs.08-2134
   Ng DSC, 2017, INVEST OPHTH VIS SCI, V58, DOI 10.1167/iovs.16-20519
   Querques G, 2016, INVEST OPHTH VIS SCI, V57, P2578, DOI 10.1167/iovs.16-19083
   Rochepeau C, 2018, AM J OPHTHALMOL, V194, P26, DOI 10.1016/j.ajo.2018.07.004
   Saito M, 2015, INVEST OPHTH VIS SCI, V56, P6515, DOI 10.1167/iovs.15-17246
   Sakurada Y, 2018, RETINA-J RET VIT DIS, V38, P1977, DOI 10.1097/IAE.0000000000002294
   Shahlaee A, 2016, AM J OPHTHALMOL, V165, P39, DOI 10.1016/j.ajo.2016.02.018
   Shi YY, 2019, OPHTHALMOL RETINA, V3, P211, DOI 10.1016/j.oret.2018.10.012
   Siedlecki J, 2019, OPHTHALMOL RETINA, V3, P1013, DOI 10.1016/j.oret.2019.08.002
   Smith W, 2001, OPHTHALMOLOGY, V108, P697, DOI 10.1016/S0161-6420(00)00580-7
   Takahashi A, 2018, OPHTHALMOL RETINA, V2, P295, DOI 10.1016/j.oret.2017.08.016
   Warrow DJ, 2013, RETINA-J RET VIT DIS, V33, P1659, DOI 10.1097/IAE.0b013e3182953df4
   Wei X, 2018, INVEST OPHTH VIS SCI, V59, P1206, DOI 10.1167/iovs.17-22720
   Yang LH, 2013, INVEST OPHTH VIS SCI, V54, P4659, DOI 10.1167/iovs.12-10991
   Yuan MZ, 2020, INT J OPHTHALMOL-CHI, V13, P93, DOI 10.18240/ijo.2020.01.14
   Zhang XY, 2021, EYE, V35, P121, DOI 10.1038/s41433-020-01265-4
NR 59
TC 0
Z9 0
U1 0
U2 0
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
EI 2296-858X
J9 FRONT MED-LAUSANNE
JI Front. Med.
PD JUL 4
PY 2022
VL 9
AR 891397
DI 10.3389/fmed.2022.891397
PG 10
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA 3B6ZM
UT WOS:000828086500001
PM 35860744
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Chen, L
   Zhang, XZ
   Liu, B
   Mi, L
   Wen, F
AF Chen, Ling
   Zhang, Xiongze
   Liu, Bing
   Mi, Lan
   Wen, Feng
TI Age-related scattered hypofluorescent spots on late-phase indocyanine
   green angiography: the multimodal imaging and relevant factors
SO CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE age-related hypofluorescent spots; fundus aging; indocyanine green
   angiography; multimodal imaging; polypoidal choroidal vasculopathy
ID POLYPOIDAL CHOROIDAL VASCULOPATHY; BRUCHS MEMBRANE; MACULAR
   DEGENERATION; HYDRAULIC CONDUCTIVITY; ACCUMULATION; EYES
AB Importance Fundus aging and its imaging features. Background Design To characterize the demographic and multimodal-imaging features of age-related scattered hypofluorescent spots on late-phase indocyanine green angiography (ASHS-LIA). A hospital-based retrospective study. Participants Methods Eight hundred and seventy-five normal fundi fellow eyes from 875 patients underwent indocyanine green angiography (ICGA), fluorescence angiography (FA), autofluorescence (AF) and spectral-domain optical coherence tomography (OCT). Demographic information, medical records and multimodal imaging data were reviewed. Main Outcome Measures Results Diameter of ASHS-LIA and its grade, subfoveal choroidal thickness (SFCT). ASHS-LIA was identified in 233 patients (26.6%) aged 33 to 87 years (mean: 65.8 +/- 8.4 years). Patients with ASHS-LIA were significantly older and had a higher male proportion than those without ASHS-LIA (both P < 0.001). The occurrence and grade of ASHS-LIA increased with age (all P < 0.001). Age (OR = 1.093) and male gender (OR = 1.550) were the independent relevant factors of ASHS-LIA (P < 0.001, and P = 0.002, respectively). The incidence of ASHS-LIA in polypoidal choroidal vasculopathy (PCV) patients (53.2%) was the highest (all P < 0.001). ASHS-LIA mainly located in macular region (diameter: 100-500 mu m), and could be confluent. No corresponding abnormalities were detected via multimodal imaging, including FA, AF and OCT. The mean SFCT had no significant difference between eyes with and without ASHS-LIA (P = 0.221). Conclusions and Relevance ASHS-LIA was observed on late-phase ICGA, mainly located in macular region. No corresponding abnormalities were detected by other multimodal imaging, including FA, AF and OCT. The occurrence and grade of ASHS-LIA increased with age. Moreover, ASHS-LIA might be not correlated with SFCT, but correlated with PCV.
C1 [Chen, Ling; Zhang, Xiongze; Liu, Bing; Mi, Lan; Wen, Feng] Sun Yat Sen Univ, State Key Lab Ophthalmol, Zhongshan Ophthalm Ctr, 54 South Xianlie Rd, Guangzhou 510060, Guangdong, Peoples R China.
C3 Sun Yat Sen University
RP Wen, F (通讯作者)，Sun Yat Sen Univ, State Key Lab Ophthalmol, Zhongshan Ophthalm Ctr, 54 South Xianlie Rd, Guangzhou 510060, Guangdong, Peoples R China.
EM wenfeng208@foxmail.com
OI Chen, Ling/0000-0002-5552-4667
FU National Natural Science Foundation of China [81470647]
FX This investigation was supported by grants from the National Natural
   Science Foundation of China (grant numbers: 81470647).
CR BIRD AC, 1992, BRIT J OPHTHALMOL, V76, P166, DOI 10.1136/bjo.76.3.166
   Chang AA, 1998, OPHTHALMOLOGY, V105, P1060, DOI 10.1016/S0161-6420(98)96008-0
   Chang AA, 2005, INVEST OPHTH VIS SCI, V46, P1463, DOI 10.1167/iovs.04-0825
   Cheung CMG, 2014, OPHTHALMOLOGY, V121, P1598, DOI 10.1016/j.ophtha.2014.02.004
   Chorlay A, 2018, BIOPHYS J, V114, P631, DOI 10.1016/j.bpj.2017.12.014
   Curcio CA, 2005, EXP EYE RES, V81, P731, DOI 10.1016/j.exer.2005.04.012
   Curcio CA, 2011, BRIT J OPHTHALMOL, V95, P1638, DOI 10.1136/bjophthalmol-2011-300344
   Curcio CA, 2010, J LIPID RES, V51, P451, DOI 10.1194/jlr.R002238
   Curcio CA, 2009, PROG RETIN EYE RES, V28, P393, DOI 10.1016/j.preteyeres.2009.08.001
   Daruich A, 2015, PROG RETIN EYE RES, V48, P82, DOI 10.1016/j.preteyeres.2015.05.003
   FEENEYBURNS L, 1985, AM J OPHTHALMOL, V100, P686, DOI 10.1016/0002-9394(85)90625-7
   Huang JD, 2008, INVEST OPHTH VIS SCI, V49, P2721, DOI 10.1167/iovs.07-1196
   Johnson M, 2007, CURR EYE RES, V32, P791, DOI 10.1080/02713680701550660
   Jung Jesse J, 2014, Retin Cases Brief Rep, V8, P141, DOI 10.1097/ICB.0000000000000026
   Koizumi H, 2011, GRAEF ARCH CLIN EXP, V249, P1123, DOI 10.1007/s00417-011-1620-1
   Matsubara Takashi, 1999, Nippon Ganka Gakkai Zasshi, V103, P497
   McCarty WJ, 2008, J APPL PHYSIOL, V105, P621, DOI 10.1152/japplphysiol.01245.2007
   MOORE DJ, 1995, INVEST OPHTH VIS SCI, V36, P1290
   Opremcak E Mitchel, 2013, Insight, V38, P21
   Ruberti JW, 2003, INVEST OPHTH VIS SCI, V44, P1753, DOI 10.1167/iovs.02-0496
   Shiraki Kunihiko, 1999, International Ophthalmology, V23, P105, DOI 10.1023/A:1026571327117
   Wong CW, 2016, PROG RETIN EYE RES, V53, P107, DOI 10.1016/j.preteyeres.2016.04.002
NR 22
TC 5
Z9 5
U1 0
U2 1
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1442-6404
EI 1442-9071
J9 CLIN EXP OPHTHALMOL
JI Clin. Exp. Ophthalmol.
PD NOV
PY 2018
VL 46
IS 8
BP 908
EP 915
DI 10.1111/ceo.13306
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA HA2JT
UT WOS:000450064600010
PM 29675907
OA hybrid, Green Published
DA 2022-11-30
ER

PT J
AU Tao, JW
   Wu, HF
   Chen, YQ
   Mao, JB
   Cheng, D
   Lin, JJ
   Shen, LJ
AF Tao, Jiwei
   Wu, Hanfei
   Chen, Yiqi
   Mao, Jianbo
   Cheng, Dan
   Lin, Jingjing
   Shen, Lijun
TI Use of iOCT in Vitreoretinal Surgery for Dense Vitreous Hemorrhage in a
   Chinese Population
SO CURRENT EYE RESEARCH
LA English
DT Article
DE Intraoperative optical coherence tomography; vitreous hemorrhage;
   surgical management; best corrected visual acuity; pars plana vitrectomy
ID OPTICAL COHERENCE TOMOGRAPHY; INTRAOPERATIVE OCT; MACULAR HOLE;
   VITRECTOMY; DYNAMICS; UTILITY
AB Purpose: To evaluate the feasibility and utility of intraoperative optical coherence tomography (iOCT) during pars plana vitrectomy (PPV) surgery for dense vitreous hemorrhage (VH). Methods: A retrospective, consecutive, interventional case series. A total of 68 dense VH patients (71 eyes) were enrolled, and the patients were divided into two groups. The control group (43 eyes) did not receive iOCT and the experimental group (28 eyes) did. All patients with macular structures that could not be assessed by preoperative OCT underwent PPV for dense VH. iOCT images were qualitatively evaluated for retinal abnormalities that might affect intraoperative management. The assessment of iOCT utility was evaluated by the surgeon. Intraoperative membrane peeling, postoperative macular structure, and postoperative visual acuity were compared between the two groups. Results: There were no significant differences in sex, age, different etiologies of VH, or best corrected visual acuity between the two groups at baseline. In the experimental group, iOCT revealed macular edema (eight eyes, 28.6%), epiretinal membranes (ERM, five eyes, 17.9%), macular atrophy (one eye, 3.6%), lamellar macular hole (one eye, 3.6%), polypoidal choroidal vasculopathy (one eye, 3.6%), and the existence of both macular edema with ERM (one eye, 3.6%). Eight cases showed macular abnormalities on the iOCT images that were inconsistent with the surgeon's judgment without iOCT. iOCT imaging affected the surgical plan for seven of the eight cases. Significantly more iOCT eyes had intraoperative membrane peeling than control eyes (P = 0.01), while significantly fewer iOCT eyes had postoperative ERMs (P = 0.04). Conclusions: iOCT during PPV for VH may provide the surgeon with clinically relevant information that influences surgical management. The iOCT group had a higher incidence of ERM peeling intraoperatively and lower incidence of ERM postoperatively compared with the control group.
C1 [Tao, Jiwei; Wu, Hanfei; Chen, Yiqi; Mao, Jianbo; Cheng, Dan; Lin, Jingjing; Shen, Lijun] Wenzhou Med Univ, Dept Retina Ctr, Affiliated Eye Hosp, 618 Fengqi Rd, Hangzhou 310000, Zhejiang, Peoples R China.
C3 Wenzhou Medical University
RP Shen, LJ (通讯作者)，Wenzhou Med Univ, Dept Retina Ctr, Affiliated Eye Hosp, 618 Fengqi Rd, Hangzhou 310000, Zhejiang, Peoples R China.
EM ljshenysg@163.com
OI Cheng, Dan/0000-0002-7190-3907
FU Medical Health and Science Technology Projects of Zhejiang Province
   [2016KYB207]
FX This work was supported by the Medical Health and Science Technology
   Projects of Zhejiang Province [(2016KYB207)].
CR Binder S, 2011, RETINA-J RET VIT DIS, V31, P1332, DOI 10.1097/IAE.0b013e3182019c18
   Dayani PN, 2009, RETINA-J RET VIT DIS, V29, P1457, DOI 10.1097/IAE.0b013e3181b266bc
   Ehlers JP, 2016, EYE, V30, P193, DOI 10.1038/eye.2015.255
   Ehlers JP, 2015, RETINA-J RET VIT DIS, V35, P2537, DOI 10.1097/IAE.0000000000000660
   Ehlers JP, 2015, INVEST OPHTH VIS SCI, V56, P7324, DOI 10.1167/iovs.15-17526
   Ehlers JP, 2014, RETINA-J RET VIT DIS, V34, P1341, DOI 10.1097/IAE.0000000000000123
   Ehlers JP, 2014, RETINA-J RET VIT DIS, V34, P213, DOI 10.1097/IAE.0b013e318297daf3
   Ehlers JP, 2013, RETINA-J RET VIT DIS, V33, P1428, DOI 10.1097/IAE.0b013e31828396b7
   Ehlers JP, 2013, RETINA-J RET VIT DIS, V33, P232, DOI 10.1097/IAE.0b013e31826e86f5
   Falkner-Radler CI, 2015, RETINA-J RET VIT DIS, V35, P2100, DOI 10.1097/IAE.0000000000000596
   Hahn P, 2013, RETINA-J RET VIT DIS, V33, P1328, DOI 10.1097/IAE.0b013e3182831293
   Hayashi A, 2011, CASE REP OPHTHALM, V2, P149, DOI 10.1159/000328752
   Khan M, 2016, CURR OPIN OPHTHALMOL, V27, P201, DOI 10.1097/ICU.0000000000000258
   Leisser C, 2016, OSLI RETINA, V47, P328, DOI 10.3928/23258160-20160324-04
   Mura M, 2016, ACTA OPHTHALMOL, V94, P246, DOI 10.1111/aos.12961
   Pfau M, 2015, OSLI RETINA, V46, P1001, DOI 10.3928/23258160-20151027-03
   Pichi Francesco, 2012, Ophthalmic Surg Lasers Imaging, V43, pS54, DOI 10.3928/15428877-20121001-08
   Smith AG, 2015, OSLI RETINA, V46, P964, DOI 10.3928/23258160-20151008-10
   Spraul CW, 1997, SURV OPHTHALMOL, V42, P3, DOI 10.1016/S0039-6257(97)84041-6
   Tao YKK, 2010, OPT LETT, V35, P3315, DOI 10.1364/OL.35.003315
   Toygar O, 2016, EYE, V30, P23, DOI 10.1038/eye.2015.230
   Wykoff CC, 2010, OPHTHAL SURG LAS IM, V41, P7, DOI 10.3928/15428877-20091230-01
NR 22
TC 5
Z9 6
U1 0
U2 4
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0271-3683
EI 1460-2202
J9 CURR EYE RES
JI Curr. Eye Res.
PD FEB 1
PY 2019
VL 44
IS 2
BP 219
EP 224
DI 10.1080/02713683.2018.1533982
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA HK5CV
UT WOS:000457983500014
PM 30299988
DA 2022-11-30
ER

PT J
AU Hayashida, M
   Miki, A
   Nakai, S
   Matsumiya, W
   Imai, H
   Kusuhara, S
   Honda, S
   Nakamura, M
AF Hayashida, Mayuka
   Miki, Akiko
   Nakai, Shunichiro
   Matsumiya, Wataru
   Imai, Hisanori
   Kusuhara, Sentaro
   Honda, Shigeru
   Nakamura, Makoto
TI Genetic factors associated with treatment response to reduced-fluence
   photodynamic therapy for chronic central serous chorioretinopathy
SO MOLECULAR VISION
LA English
DT Article
ID VARIANTS; GENOTYPE
AB Purpose: Reduced-fluence photodynamic therapy (RFPDT) has proven effective for some patients with chronic central serous chorioretinopathy (cCSC). Several clinicodemographic factors influencing treatment response have been identified, but associations with genetic factors have not been examined. Therefore, we investigated the associations of single nucleotide polymorphisms (SNPs) implicated in cCSC pathogenesis with clinical outcome following RFPDT.
   Methods: This was a retrospective study of 87 eyes from 87 patients with cCSC who underwent RFPDT and were followed up for more than 12 months. Patients were divided into a good response group (53 patients) and a poor response group (34 patients) based on either persistence or recurrence of subretinal fluid detected with spectral domain optical coherence tomography after the first application of RFPDT. SNPs in the genes encoding age-related maculopathy susceptibility protein 2 (ARMS2, SNP rs10490924) and complement factor H (CFH, SNP rs800292) were genotyped using TaqMan technology.
   Results: There were no statistically significant differences in the baseline characteristics between the response groups except the degree of hyperfluorescence on indocyanine green angiography (ICGA; p = 0.011). The minor (T) allele frequency of ARMS2 (rs10490924) were statistically significantly lower in the good response group than in the poor response group (24.0% versus 41.0%, p = 0.021). Further, the good response frequency was statistically significantly lower in patients with at least one minor allele (GT or TT) compared to the homozygous major allele group (GG; p<0.05). The baseline best-corrected visual acuity (BCVA) at 12 months after RFPDT was statistically significantly better in the GG carriers than in the GT or TT carriers (p<0.01). Logistic regression analysis showed less intense hyperfluorescence on ICGA, and the T allele of ARMS2 (rs10490924) was statistically significantly associated with poor response to PDT treatment (p = 0.012, p = 0.039, respectively).
   Conclusions: Carriers of the ARMS2 rs10490924 minor allele (GT or TT) demonstrated a higher subretinal fluid persistence or recurrence rate and poorer visual outcome following RFPDT. In addition to the ICGA findings, genotyping of ARMS2 (rs10490924) may assist in the selection of patients with cCSC most likely to benefit from RFPDT.
C1 [Hayashida, Mayuka; Miki, Akiko; Nakai, Shunichiro; Matsumiya, Wataru; Imai, Hisanori; Kusuhara, Sentaro; Nakamura, Makoto] Kobe Univ, Grad Sch Med, Div Ophthalmol, Dept Surg, Kobe, Hyogo, Japan.
   [Honda, Shigeru] Osaka City Univ, Grad Sch Med, Dept Ophthalmol & Visual Sci, Osaka, Japan.
C3 Kobe University; Osaka Metropolitan University
RP Miki, A (通讯作者)，Kobe Univ, Grad Sch Med, Dept Surg, Div Ophthalmol,Chuo Ku, 7-5-2 Kusunoki Cho, Kobe, Hyogo 6500017, Japan.
EM acacyey@med.kobe-u.ac.jp
FU Mishima Saiichi Memorial Ophthalmic Research Japan Foundation
FX We want to thank Megumi Kitamura for helping our study. Our research is
   supported by Mishima Saiichi Memorial Ophthalmic Research Japan
   Foundation.
CR Chan WM, 2008, OPHTHALMOLOGY, V115, P1756, DOI 10.1016/j.ophtha.2008.04.014
   Daruich A, 2015, PROG RETIN EYE RES, V48, P82, DOI 10.1016/j.preteyeres.2015.05.003
   de Jong EK, 2015, OPHTHALMOLOGY, V122, P562, DOI 10.1016/j.ophtha.2014.09.026
   Haga F, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0181479
   Inoue R, 2010, AM J OPHTHALMOL, V149, P441, DOI 10.1016/j.ajo.2009.10.011
   Kondo N, 2007, AM J OPHTHALMOL, V144, P608, DOI 10.1016/j.ajo.2007.06.003
   Liu HY, 2016, AM J OPHTHALMOL, V167, P57, DOI 10.1016/j.ajo.2016.04.001
   Miki A, 2014, OPHTHALMOLOGY, V121, P1067, DOI 10.1016/j.ophtha.2013.11.020
   Nakai S, 2017, MOL VIS, V23, P514
   Sakurada Y, 2010, RETINA-J RET VIT DIS, V30, P1616, DOI 10.1097/IAE.0b013e3181e587e3
   Sakurada Y, 2009, RETINA-J RET VIT DIS, V29, P1522, DOI 10.1097/IAE.0b013e3181af0d72
   van Rijssen TJ, 2018, GRAEF ARCH CLIN EXP, V256, P1395, DOI 10.1007/s00417-018-4003-z
   Yoneyama S, 2016, RETINA-J RET VIT DIS, V36, P1535, DOI 10.1097/IAE.0000000000000964
NR 13
TC 1
Z9 1
U1 0
U2 0
PU MOLECULAR VISION
PI ATLANTA
PA C/O JEFF BOATRIGHT, LAB B, 5500 EMORY EYE CENTER, 1327 CLIFTON RD, N E,
   ATLANTA, GA 30322 USA
SN 1090-0535
J9 MOL VIS
JI Mol. Vis.
PD JUL 4
PY 2020
VL 26
BP 505
EP 509
PG 5
WC Biochemistry & Molecular Biology; Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Ophthalmology
GA MG3RL
UT WOS:000545951100001
PM 32774081
DA 2022-11-30
ER

PT J
AU Rosen, RB
   Hathaway, M
   Rogers, J
   Pedro, J
   Garcia, P
   Dobre, GM
   Podoleanu, AG
AF Rosen, Richard B.
   Hathaway, Mark
   Rogers, John
   Pedro, Justin
   Garcia, Patricia
   Dobre, George M.
   Podoleanu, Adrian Gh.
TI Simultaneous OCT/SLO/ICG Imaging
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID OPTICAL COHERENCE TOMOGRAPHY; INDOCYANINE GREEN ANGIOGRAPHY; RETINA
AB PURPOSE. To evaluate how information from combined coronal optical coherence tomography (OCT) and confocal laser scanning ophthalmoscopy (SLO) with integrated simultaneous indocyanine green (ICG) dye angiography can be used in the diagnosis of a variety of macular diseases.
   METHODS. A compact chin-rest-based OCT/confocal imaging system was used to produce the OCT image and excite the fluorescence in the ICG dye. The same eye fundus area can be visualized with coronal (C-scans, en face) OCT and ICG angiography simultaneously. Fast T scanning (transverse scanning, en face) was used to build B- or C-scan OCT images along with confocal SLO views, with and without ICG filtration. The OCT, confocal SLO and ICG fluorescence images were simultaneously presented in a three-screen format. A live mixing channel overlaid the ICG sequence on the coronal OCT slices in a fourth panel for immediate comparison.
   RESULTS. Thirty eyes were imaged. The pathologic conditions studied included classic and occult neovascular membranes, vascularized RPE detachments, polypoidal choroidal vasculopathy, traumatic choroidal rupture, diabetic maculopathy, central serous retinopathy, and macular drusen. Images were evaluated with special attention toward identifying novel relationships between morphology and function revealed by the superimposition of the studies.
   CONCLUSIONS. Simultaneous visualization of an en face (coronal, C-scan) OCT image and of an ICG angiogram, displayed side by side and superimposed, permits more precise correlations between late fluorescence accumulation with structures deep to the retinal surface at the retina-choroid interface. The multiplanar scanning also permits immediate B-scan OCT cross-sectional views of regions of abnormal fluorescence. The paper demonstrates the synergy between the two types of studies, functional and anatomic, in providing a more complete view of the pathologic condition. (Invest Ophthalmol Vis Sci. 2009;50:851-860) DOI:10.1167/iovs.08-1855
C1 [Rosen, Richard B.; Garcia, Patricia] New York Eye & Ear Infirm, Adv Retinal Imaging Ctr, New York, NY 10003 USA.
   [Rosen, Richard B.; Garcia, Patricia] New York Med Coll, Valhalla, NY 10595 USA.
   [Hathaway, Mark; Rogers, John; Pedro, Justin] Ophthalm Technol Inc, Toronto, ON, Canada.
   [Dobre, George M.; Podoleanu, Adrian Gh.] Univ Kent, Appl Opt Grp, Canterbury, Kent, England.
C3 New York Eye & Ear Infirmary of Mount Sinai; New York Medical College;
   University of Kent
RP Rosen, RB (通讯作者)，New York Eye & Ear Infirm, Adv Retinal Imaging Ctr, 310 E 14th St, New York, NY 10003 USA.
EM rrosen@nyee.edu
RI Dobre, George M/I-7673-2016; Podoleanu, Adrian/F-7094-2012
OI Dobre, George M/0000-0002-5695-2591; Podoleanu,
   Adrian/0000-0002-4899-9656
FU Department of Ophthalmology, the New York Eye and Ear Infirmary;
   Ophthalmic Technologies Inc., Toronto, Canada; Superlum, Moscow, Russia
FX Supported by the Leon Lane-sponsored ARIBA Fund of the Department of
   Ophthalmology, the New York Eye and Ear Infirmary (RR, GD), Ophthalmic
   Technologies Inc., Toronto, Canada (RR, GD, AGP), and Superlum, Moscow,
   Russia (AGP).
CR Andrade RE, 2002, ACTA OPHTHALMOL SCAN, V80, P216, DOI 10.1034/j.1600-0420.2002.800218.x
   COSCAS G, 2003, J FR OPHTALMOL, V27
   de Boer JF, 2003, OPT LETT, V28, P2067, DOI 10.1364/OL.28.002067
   Dobre GM, 2005, OPT LETT, V30, P58, DOI 10.1364/OL.30.000058
   GEERAETS WJ, 1968, AM J OPHTHALMOL, V66, P15, DOI 10.1016/0002-9394(68)91780-7
   Giovannini A, 1999, ACTA OPHTHALMOL SCAN, V77, P83, DOI 10.1034/j.1600-0420.1999.770119.x
   Huber R, 2007, OPT LETT, V32, P2049, DOI 10.1364/OL.32.002049
   Krebs I, 2007, GRAEF ARCH CLIN EXP, V245, P376, DOI 10.1007/s00417-006-0424-1
   Makita S, 2006, OPT EXPRESS, V14, P7821, DOI 10.1364/OE.14.007821
   Masters BR, 1998, OPT EXPRESS, V3, P356, DOI 10.1364/OE.3.000356
   Mori K, 2005, RETINA-J RET VIT DIS, V25, P430, DOI 10.1097/00006982-200506000-00006
   Podoleanu AG, 2008, PROG RETIN EYE RES, V27, P464, DOI 10.1016/j.preteyeres.2008.03.002
   Podoleanu AG, 1998, J BIOMED OPT, V3, P12, DOI 10.1117/1.429859
   Podoleanu AG, 1998, OPT LETT, V23, P147, DOI 10.1364/OL.23.000147
   Podoleanu AG, 2005, BRIT J RADIOL, V78, P976, DOI 10.1259/bjr/55735832
   Podoleanu AG, 2004, J BIOMED OPT, V9, P86, DOI 10.1117/1.1627778
   Podoleanu AG, 1998, ELECTRON LETT, V34, P1088, DOI 10.1049/el:19980793
   SCHEIDER A, 1989, AM J OPHTHALMOL, V108, P458, DOI 10.1016/S0002-9394(14)73325-2
   Wojtkowski M, 2005, OPHTHALMOLOGY, V112, P1734, DOI 10.1016/j.ophtha.2005.05.023
   YANNUZZI LA, 1994, RETINA-J RET VIT DIS, V14, P99, DOI 10.1097/00006982-199414020-00003
   YANUZZI LA, 1997, INDOCYANINE GREEN AN
NR 21
TC 36
Z9 37
U1 0
U2 4
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD FEB
PY 2009
VL 50
IS 2
BP 851
EP 860
DI 10.1167/iovs.08-1855
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 397MD
UT WOS:000262665900048
PM 18952928
DA 2022-11-30
ER

PT J
AU Nolan, JM
   Stack, J
   O'Connell, E
   Beatty, S
AF Nolan, John M.
   Stack, Jim
   O'Connell, Eamonn
   Beatty, Stephen
TI The relationships between macular pigment optical density and its
   constituent carotenoids in diet and serum
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID AGE-RELATED MACULOPATHY; FOOD-FREQUENCY QUESTIONNAIRE; ANTIOXIDANT
   STATUS; RISK-FACTORS; LUTEIN; ZEAXANTHIN; PLASMA; DEGENERATION;
   POPULATION; IDENTIFICATION
AB PURPOSE. Lutein ( L) and zeaxanthin ( Z) are two dietary carotenoids that accumulate at the macula, where they are collectively known as macular pigment ( MP). There is a biologically plausible rationale, with some supporting evidence, that MP may protect against age-related maculopathy ( ARM). This study was undertaken to investigate the relationship between dietary intake of L and Z, serum concentrations of these carotenoids, and MP optical density in 828 healthy Irish subjects.
   METHODS. Dietary intake of L and Z was assessed with a validated food-frequency questionnaire, and serum concentrations of these carotenoids were quantified by high-performance liquid chromatography. MP optical density was measured psychophysically, using heterochromatic flicker photometry. Demographic data, lifestyle data, and general health status, were also recorded by questionnaire, with particular attention directed toward risk-factors ( established and putative) for ARM.
   RESULTS. The relationships between MP optical density, serum concentrations of L ( and Z), and dietary intake of L ( and Z) were positive and statistically significant when analyzed for the entire study group ( r = 0.136-0.303; P < 0.01 for all). Subjects with a clinically confirmed family history of ARM, current heavy cigarette smokers, subjects aged more than 53 years, and subjects with a body mass index ( BMI) > 27, did not demonstrate a positive and significant relationship between MP optical density and serum concentrations of Z ( r = 0.041, r = 0.001, r = 0.074 and r = 0.082, respectively; P > 0.05 for all). However, there was a positive and significant relationship between MP optical density and serum concentrations of L in the presence of all these risk factors ( r = 0.165 to 0.257), except for current heavy smokers ( r = 0.042; P > 0.05).
   CONCLUSIONS. For subjects at increased risk of ARM ( e. g., subjects with a clinically confirmed family history of ARM, current heavy cigarette smokers, subjects aged > 53 years and subjects with a BMI > 27) retinal capture and/or retinal stabilization of Z appears to be compromised, whereas retinal uptake and/or stabilization of L appears to be compromised in current heavy smokers only. Given the lack of MP in association with risk for ARM, the findings indicate that a retina predisposed to this condition may have an impaired ability to accumulate circulating Z.
C1 Waterford Inst Technol, Macular Pigment Res Grp, Dept Chem & Life Sci, Waterford, Ireland.
   Waterford Inst Technol, Dept Phys & Quantitat Sci, Waterford, Ireland.
   Waterford Reg Hosp, Dept Ophthalmol, Waterford, Ireland.
C3 South East Technological University (SETU); South East Technological
   University (SETU)
RP Nolan, JM (通讯作者)，Waterford Inst Technol, Macular Pigment Res Grp, Dept Chem & Life Sci, Cork Rd, Waterford, Ireland.
EM jnolan@wit.ie
RI Nolan, John/N-4921-2014
OI Nolan, John/0000-0002-5503-7084
CR Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Bhosale P, 2004, J BIOL CHEM, V279, P49447, DOI 10.1074/jbc.M405334200
   BLUMENKRANZ MS, 1986, OPHTHALMOLOGY, V93, P552
   Bodner CH, 1998, J HUM NUTR DIET, V11, P373, DOI 10.1046/j.1365-277X.1998.00119.x
   Bone RA, 1997, EXP EYE RES, V64, P211, DOI 10.1006/exer.1996.0210
   BONE RA, 1988, INVEST OPHTH VIS SCI, V29, P843
   BONE RA, 1993, INVEST OPHTH VIS SCI, V34, P2033
   Bone RA, 2000, EXP EYE RES, V71, P239, DOI 10.1006/exer.2000.0870
   Brady WE, 1996, J NUTR, V126, P129, DOI 10.1093/jn/126.1.129
   Broekmans WMR, 2002, AM J CLIN NUTR, V76, P595, DOI 10.1093/ajcn/76.3.595
   Burke JD, 2005, J NUTR, V135, P1208, DOI 10.1093/jn/135.5.1208
   Carroll YL, 1999, EUR J CLIN NUTR, V53, P644, DOI 10.1038/sj.ejcn.1600827
   Cho EY, 2004, ARCH OPHTHALMOL-CHIC, V122, P883, DOI 10.1001/archopht.122.6.883
   Ciulla TA, 2001, OPHTHALMOLOGY, V108, P730, DOI 10.1016/S0161-6420(00)00655-2
   CLEVIDENCE BA, 1993, METHOD ENZYMOL, V214, P33
   Curran-Celentano J, 2001, AM J CLIN NUTR, V74, P796
   Delcourt C, 1999, ARCH OPHTHALMOL-CHIC, V117, P1384, DOI 10.1001/archopht.117.10.1384
   Flood V, 2002, OPHTHALMOLOGY, V109, P2272, DOI 10.1016/S0161-6420(02)01263-0
   *FOODS STAND AG, 2002, MCC WIDD COMP FOODS
   Gale CR, 2003, INVEST OPHTH VIS SCI, V44, P2461, DOI 10.1167/iovs.02-0929
   GOLDBERG J, 1988, AM J EPIDEMIOL, V128, P700, DOI 10.1093/oxfordjournals.aje.a115023
   Hammond BR, 2005, OPTOMETRY VISION SCI, V82, P387, DOI 10.1097/01.OPX.0000162652.85875.D2
   Hammond BR, 1996, VISION RES, V36, P2001, DOI 10.1016/0042-6989(95)00290-1
   Hammond BR, 1996, VISION RES, V36, P3003, DOI 10.1016/0042-6989(96)00008-9
   Hammond BR, 2002, INVEST OPHTH VIS SCI, V43, P47
   Hammond BR, 1997, INVEST OPHTH VIS SCI, V38, P1795
   HAMMOND BR, 1995, INVEST OPHTH VIS SCI, V36, P2531
   Handelman GJ, 1996, AM J CLIN NUTR, V63, P559, DOI 10.1093/ajcn/63.4.559
   Holland B., 1991, MCCANCE WIDDOWSONS C, V5
   Khachik F, 1997, INVEST OPHTH VIS SCI, V38, P1802
   Klaver CCW, 1998, ARCH OPHTHALMOL-CHIC, V116, P653, DOI 10.1001/archopht.116.5.653
   KLEIN R, 1995, INVEST OPHTH VIS SCI, V36, P182
   KRINSKY NI, 1990, J NUTR, V120, P1654, DOI 10.1093/jn/120.12.1654
   Landrum JT, 1997, EXP EYE RES, V65, P57, DOI 10.1006/exer.1997.0309
   Landrum JT, 2001, ARCH BIOCHEM BIOPHYS, V385, P28, DOI 10.1006/abbi.2000.2171
   Mares-Perlman JA, 2001, AM J EPIDEMIOL, V153, P424, DOI 10.1093/aje/153.5.424
   MaresPerlman JA, 1996, ARCH OPHTHALMOL-CHIC, V114, P991, DOI 10.1001/archopht.1996.01100140199014
   MARESPERLMAN JA, 1995, ARCH OPHTHALMOL-CHIC, V113, P1518, DOI 10.1001/archopht.1995.01100120048007
   Masson LF, 2003, PUBLIC HEALTH NUTR, V6, P313, DOI 10.1079/PHN2002429
   Mellerio J, 2002, CURR EYE RES, V25, P37, DOI 10.1076/ceyr.25.1.37.9961
   Michaud DS, 1998, CANCER EPIDEM BIOMAR, V7, P283
   Neelam K, 2005, INVEST OPHTH VIS SCI, V46, P1023, DOI 10.1167/iovs.04-1032
   Neuringer M, 2004, INVEST OPHTH VIS SCI, V45, P3234, DOI 10.1167/iovs.02-1243
   Nolan J, 2004, INVEST OPHTH VIS SCI, V45, P3940, DOI 10.1167/iovs.04-0273
   O'Neill ME, 2001, BRIT J NUTR, V85, P499, DOI 10.1079/BJN2000284
   OLMEDILLA B, 1994, AM J CLIN NUTR, V60, P106, DOI 10.1093/ajcn/60.1.106
   RAND WM, 1987, FOOD COMPOSITION DAT
   Rock C, 2004, J NUTR, V132, p525s
   ROCK CL, 1993, METHOD ENZYMOL, V214, P116
   SEDDON JM, 1994, JAMA-J AM MED ASSOC, V272, P1413, DOI 10.1001/jama.272.18.1413
   Smith W, 1999, OPHTHALMOLOGY, V106, P761, DOI 10.1016/S0161-6420(99)90164-1
   Smith W, 1997, AM J OPHTHALMOL, V124, P838, DOI 10.1016/S0002-9394(14)71702-7
   Snellen ELM, 2002, ACTA OPHTHALMOL SCAN, V80, P368, DOI 10.1034/j.1600-0420.2002.800404.x
   SNODDERLY DM, 1991, INVEST OPHTH VIS SCI, V32, P268
   SNODDERLY DM, 1984, INVEST OPHTH VIS SCI, V25, P674
   Sommerburg O, 1998, BRIT J OPHTHALMOL, V82, P907, DOI 10.1136/bjo.82.8.907
   SPERDUTO RD, 1993, ARCH OPHTHALMOL-CHIC, V111, P104
   Stuerenburg HJ, 2005, NEUROENDOCRINOL LETT, V26, P261
   VandenLangenberg GM, 1998, AM J EPIDEMIOL, V148, P204, DOI 10.1093/oxfordjournals.aje.a009625
   WILLETT WC, 2006, NUTR EPIDEMIOLOGY, P321
   YANNUZZI LA, 1992, ARCH OPHTHALMOL-CHIC, V110, P1701
   Yemelyanov AY, 2001, EXP EYE RES, V72, P381, DOI 10.1006/exer.2000.0965
   [No title captured]
NR 65
TC 63
Z9 67
U1 0
U2 15
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD FEB
PY 2007
VL 48
IS 2
BP 571
EP 582
DI 10.1167/iovs.06-0864
PG 12
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 129KV
UT WOS:000243729300015
PM 17251452
DA 2022-11-30
ER

PT J
AU Greenstein, MB
   Myers, CE
   Meuer, SM
   Klein, BEK
   Cotch, MF
   Wong, TY
   Klein, R
AF Greenstein, Max B.
   Myers, Chelsea E.
   Meuer, Stacy M.
   Klein, Barbara E. K.
   Cotch, Mary Frances
   Wong, Tien Y.
   Klein, Ronald
TI Prevalence and Characteristics of Choroidal Nevi: The Multi-Ethnic Study
   of Atherosclerosis
SO OPHTHALMOLOGY
LA English
DT Article
ID MALIGNANT-MELANOMA; UVEAL MELANOMA; CUTANEOUS MELANOMA; CILIARY BODY;
   RISK-FACTORS; EPIDEMIOLOGIC ASPECTS; WHITE-POPULATION; BLACK PATIENTS;
   FOLLOW-UP; GROWTH
AB Objective: To describe the prevalence of choroidal nevi in 4 racial or ethnic groups (white, black, Hispanic, and Chinese) in the United States.
   Design: Cross-sectional study.
   Participants: Participants of the second examination of the Multi-Ethnic Study of Atherosclerosis (MESA), involving 6176 persons 44 to 84 years of age without clinical cardiovascular disease at baseline selected from 6 United States communities.
   Methods: Fundus images were taken using a 45 degrees digital camera through dark-adapted pupils and were graded for choroidal nevi using the modified Wisconsin Age-Related Maculopathy Grading System and the Blue Mountains Eye Study protocol.
   Main Outcome Measures: Choroidal nevi.
   Results: The overall prevalence of choroidal nevi in the whole cohort was 2.1%, with prevalences higher in whites (4.1%) than blacks (0.7%), Hispanics (1.2%), and Chinese (0.4%; P<0.001 for any differences among groups). The lowest prevalence of choroidal nevi occurred in those 75 to 84 years of age. The nevi were subfoveal in 4% of eyes with nevi and were not associated with a decrease in visual acuity. Characteristics of the nevi (size, shape, location, color, drusen on surface) did not differ among racial or ethnic groups. With the exception of associations with higher C-reactive protein levels (odds ratio [OR] per mg/dl on the logarithmic scale, 1.23; 95% confidence interval [CI], 1.06-1.43; P = 0.01) and lower systolic blood pressure (OR per 10 mmHg, 0.90; 95% CI, 0.82-0.99; P = 0.04), choroidal nevi were not associated with other potential risk factors (e. g., gender, smoking status, alcohol consumption, lipid levels, coagulation factors, or kidney disease).
   Conclusions: Low prevalences of choroidal nevi were found in the 4 groups participating in the MESA cohort, with whites having higher prevalence than the other racial or ethnic groups. The higher prevalence in whites than in other groups was not explained by any of the factors studied. When choroidal nevi were present, their characteristics did not differ among racial or ethnic groups.
   Financial Disclosure(s): The author(s) have no proprietary or commercial interest in any materials discussed in this article. Ophthalmology 2011; 118: 2468-2473 (C) 2011 by the American Academy of Ophthalmology.
C1 [Greenstein, Max B.; Myers, Chelsea E.; Meuer, Stacy M.; Klein, Barbara E. K.; Klein, Ronald] Univ Wisconsin, Dept Ophthalmol & Visual Sci, Sch Med & Publ Hlth, Madison, WI 53726 USA.
   [Cotch, Mary Frances] NEI, Div Epidemiol & Clin Applicat, NIH, Bethesda, MD 20892 USA.
   [Wong, Tien Y.] Natl Univ Singapore, Singapore Eye Res Inst, Singapore 117548, Singapore.
   [Wong, Tien Y.] Univ Melbourne, Ctr Eye Res Australia, Melbourne, Vic, Australia.
C3 University of Wisconsin System; University of Wisconsin Madison;
   National Institutes of Health (NIH) - USA; NIH National Eye Institute
   (NEI); National University of Singapore; Singapore National Eye Center;
   Centre for Eye Research Australia; University of Melbourne
RP Klein, R (通讯作者)，Univ Wisconsin, Dept Ophthalmol & Visual Sci, Sch Med & Publ Hlth, 610 N Walnut St,4th Floor WARF, Madison, WI 53726 USA.
EM kleinr@epi.ophth.wisc.edu
RI Wong, Tien Yin/AAC-9724-2020
OI Wong, Tien Yin/0000-0002-8448-1264; Klein, Ronald/0000-0002-4428-6237;
   Cotch, Mary Frances/0000-0002-2046-4350
FU National Heart, Lung, and Blood Institute, National Institutes of
   Health, Bethesda, Maryland [N01-HC-95159, N01-HC-95160, N01-HC-95161,
   N01-HC-95162, N01-HC-95163, N01-HC-95164, N01-HC-95165, N01-HC-95169];
   National Institutes of Health, National Eye Institute, Bethesda,
   Maryland [Z01 EY000403]; National Institutes of Health [HL69979-03];
   DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS [N01HC095164,
   N01HC095163, N01HC095165, N01HC095159, N01HC095161, N01HC095162,
   N01HC095169, N01HC095160] Funding Source: NIH RePORTER; NATIONAL EYE
   INSTITUTE [Z01EY000403, ZIAEY000403] Funding Source: NIH RePORTER;
   NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R43HL095169, R01HL069979,
   R44HL095169, R21HL095165] Funding Source: NIH RePORTER
FX Supported by the National Heart, Lung, and Blood Institute, National
   Institutes of Health, Bethesda, Maryland (grant nos.: N01-HC-95159
   through N01-HC-95165 and N01-HC-95169). The authors thank the other
   investigators, the staff, and the participants of the MESA study for
   their valuable contributions. A full list of participating MESA
   investigators and institutions can be found at
   http://www.mesa-nhlbi.org. This research was supported, in part, by the
   Intramural Research Program of the National Institutes of Health,
   National Eye Institute, Bethesda, Maryland (grant no.: Z01 EY000403).
   Additional support was provided by National Institutes of Health grant
   HL69979-03 (RK, TYW). The content is solely the responsibility of the
   authors and does not necessarily reflect the official views of the
   National Heart, Lung, and Blood Institute, the National Eye Institute,
   or the National Institutes of Health. The funding organizations had no
   role in the design or conduct of this research.
CR Albers EC, 1940, AM J OPHTHALMOL, V23, P779, DOI 10.1016/S0002-9394(40)92379-0
   ALBERT D M, 1980, International Ophthalmology Clinics, V20, P71, DOI 10.1097/00004397-198002020-00007
   ALBERT DM, 1983, AM J OPHTHALMOL, V95, P474, DOI 10.1016/0002-9394(83)90267-2
   [Anonymous], 2007, MULT ETHN STUD ATH F, P153
   Bataille V, 2000, JNCI-J NATL CANCER I, V92, P457, DOI 10.1093/jnci/92.6.457
   Bild DE, 2002, AM J EPIDEMIOL, V156, P871, DOI 10.1093/aje/kwf113
   BUTLER P, 1994, OPHTHALMOLOGY, V101, P710
   Cormier JN, 2006, ARCH INTERN MED, V166, P1907, DOI 10.1001/archinte.166.17.1907
   Cress RD, 1997, CANCER CAUSE CONTROL, V8, P246, DOI 10.1023/A:1018432632528
   de Wijn RS, 2010, J PLAST RECONSTR AES, V63, P906, DOI 10.1016/j.bjps.2009.02.090
   Deichmann M, 2004, BRIT J CANCER, V91, P699, DOI 10.1038/sj.bjc.6602043
   EASTON DF, 1991, BRIT J CANCER, V64, P1164, DOI 10.1038/bjc.1991.483
   EGAN KM, 1988, SURV OPHTHALMOL, V32, P239, DOI 10.1016/0039-6257(88)90173-7
   GANLEY JP, 1973, AM J OPHTHALMOL, V76, P19, DOI 10.1016/0002-9394(73)90003-2
   Gass J D, 1977, Trans Sect Ophthalmol Am Acad Ophthalmol Otolaryngol, V83, P19
   Gottlieb JL, 2006, RETINA, V1, P679
   Gutmann G, 1895, ARCH AUGENHEILKD, V31, P158
   HALE PN, 1965, ARCH OPHTHALMOL-CHIC, V74, P532
   Hu DN, 2005, AM J OPHTHALMOL, V140, P612, DOI 10.1016/j.ajo.2005.05.034
   Jonas JB, 2008, OPHTHALMOLOGY, V115, P1102, DOI 10.1016/j.ophtha.2007.12.022
   Klein R, 2004, ARCH OPHTHALMOL-CHIC, V122, P1642, DOI 10.1001/archopht.122.11.1642
   KLEIN R, 1991, OPHTHALMOLOGY, V98, P1128
   Kounalakis Nicole, 2005, Curr Oncol Rep, V7, P377, DOI 10.1007/s11912-005-0065-2
   LANG GK, 1982, KLIN MONATSBL AUGENH, V181, P493, DOI 10.1055/s-2008-1055279
   LYNCH HT, 1968, CANCER, V21, P119, DOI 10.1002/1097-0142(196801)21:1<119::AID-CNCR2820210118>3.0.CO;2-W
   MARGO CE, 1984, ARCH OPHTHALMOL-CHIC, V102, P77
   Margo CE, 1998, OPHTHALMOLOGY, V105, P1087, DOI 10.1016/S0161-6420(98)96012-2
   McLaughlin CC, 2005, CANCER-AM CANCER SOC, V103, P1000, DOI 10.1002/cncr.20866
   Melia BM, 1997, ARCH OPHTHALMOL-CHIC, V115, P1537
   MILLER B, 1981, BRIT J OPHTHALMOL, V65, P720, DOI 10.1136/bjo.65.10.720
   MIMS JL, 1978, OPHTHALMOLOGY, V85, P929
   Molven A, 2005, GENE CHROMOSOME CANC, V44, P10, DOI 10.1002/gcc.20202
   NAUMANN G, 1970, ADV OPHTHALMOL, V23, P187
   NAUMANN G, 1966, ARCH OPHTHALMOL-CHIC, V76, P784, DOI 10.1001/archopht.1966.03850010786004
   Nelson J, 2006, AM J EPIDEMIOL, V163, P903, DOI 10.1093/aje/kwj140
   NEUGUT AI, 1994, AM J PUBLIC HEALTH, V84, P1828, DOI 10.2105/AJPH.84.11.1828
   Ng CH, 2009, ARCH OPHTHALMOL-CHIC, V127, P314, DOI 10.1001/archophthalmol.2008.625
   Paul E.V., 1962, INT OPHTHALMOL CLIN, V2, P387, DOI [10.1097/00004397-196206000-00007, DOI 10.1097/00004397-196206000-00007]
   PHILLPOTTS BA, 1995, J NATL MED ASSOC, V87, P709
   RODRIGUEZSAINS RS, 1986, OPHTHALMOLOGY, V93, P661
   SCOTTO J, 1976, J NATL CANCER I, V56, P489, DOI 10.1093/jnci/56.3.489
   SEREGARD S, 1992, ACTA OPHTHALMOL, V70, P289
   Shields CL, 2008, OPHTHALMOLOGY, V115, P546, DOI 10.1016/j.ophtha.2007.07.009
   Shields CL, 2000, ARCH OPHTHALMOL-CHIC, V118, P360, DOI 10.1001/archopht.118.3.360
   SHIELDS CL, 1995, OPHTHALMOLOGY, V102, P1351, DOI 10.1016/S0161-6420(95)30864-0
   Singh AD, 2005, OPHTHALMOLOGY, V112, P1784, DOI 10.1016/j.ophtha.2005.06.011
   Singh AD, 2003, OPHTHALMOLOGY, V110, P956, DOI 10.1016/S0161-6420(03)00078-2
   Smith JH, 2007, OPHTHALMOLOGY, V114, P774, DOI 10.1016/j.ophtha.2006.08.041
   SMITH RE, 1972, AM J OPHTHALMOL, V74, P1126, DOI 10.1016/0002-9394(72)90732-5
   Sumich P, 1998, ARCH OPHTHALMOL-CHIC, V116, P645, DOI 10.1001/archopht.116.5.645
   TAMLER E, 1959, ARCH OPHTHALMOL-CHIC, V62, P196
   TAMLER E, 1970, ARCH OPHTHALMOL-CHIC, V84, P29, DOI 10.1001/archopht.1970.00990040031008
   Tsai T, 2005, MELANOMA RES, V15, P213, DOI 10.1097/00008390-200506000-00012
   WILDER H C, 1946, Mil Surg, V99, P459
   Wong TY, 2006, INVEST OPHTH VIS SCI, V47, P2341, DOI 10.1167/iovs.05-1539
   YANOFF M, 1967, CANCER, V20, P493, DOI 10.1002/1097-0142(1967)20:4<493::AID-CNCR2820200406>3.0.CO;2-U
NR 56
TC 26
Z9 29
U1 0
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD DEC
PY 2011
VL 118
IS 12
BP 2468
EP 2473
DI 10.1016/j.ophtha.2011.05.007
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 863BO
UT WOS:000298138000024
PM 21820181
OA Green Accepted
DA 2022-11-30
ER

PT J
AU Sirks, MJ
   van Dijk, EHC
   Rosenberg, N
   Hollak, CEM
   Aslanis, S
   Cheung, CMG
   Chowers, I
   Eandi, CM
   Freund, KB
   Holz, FG
   Kaiser, PK
   Lotery, AJ
   Ohno-Matsui, K
   Querques, G
   Subhi, Y
   Tadayoni, R
   Wykoff, CC
   Zur, D
   Diederen, RMH
   Boon, CJF
   Schlingemann, RO
AF Sirks, Marc J.
   van Dijk, Elon H. C.
   Rosenberg, Noa
   Hollak, Carla E. M.
   Aslanis, Stamatios
   Cheung, Chui Ming Gemmy
   Chowers, Itay
   Eandi, Chiara M.
   Freund, K. Bailey
   Holz, Frank G.
   Kaiser, Peter K.
   Lotery, Andrew J.
   Ohno-Matsui, Kyoko
   Querques, Giuseppe
   Subhi, Yousif
   Tadayoni, Ramin
   Wykoff, Charles C.
   Zur, Dinah
   Diederen, Roselie M. H.
   Boon, Camiel J. F.
   Schlingemann, Reinier O.
TI Clinical impact of the worldwide shortage of verteporfin (Visudyne (R))
   on ophthalmic care
SO ACTA OPHTHALMOLOGICA
LA English
DT Article
DE age-related macular degeneration; central serous chorioretinopathy;
   choroidal haemangioma; photodynamic therapy; polypoidal choroidal
   vasculopathy; verteporfin
ID POLYPOIDAL CHOROIDAL VASCULOPATHY; CENTRAL SEROUS CHORIORETINOPATHY;
   PHOTODYNAMIC THERAPY; MACULAR DEGENERATION; INDOCYANINE GREEN;
   RANIBIZUMAB; NEOVASCULARIZATION; PHOTOSENSITIZERS; HEMANGIOMA; EFFICACY
AB Introduction Since July 2021, a worldwide shortage of verteporfin (Visudyne (R)) occurred: an essential medicine required for photodynamic therapy (PDT). PDT with verteporfin has a broad range of indications in ophthalmology, including chronic central serous chorioretinopathy, polypoidal choroidal vasculopathy and choroidal haemangioma. For these disorders, PDT is either the first-choice treatment or regarded as a major treatment option. Materials and methods A questionnaire was sent to key opinion leaders in the field of medical retina throughout the world, to assess the role of PDT in their country and the effects of the shortage of verteporfin. In addition, information on the application of alternative treatments during shortage of verteporfin was obtained, to further assess the impact of the shortage. Results Our questionnaire indicated that the shortage of verteporfin had a major impact on ophthalmic care worldwide and was regarded to be a serious problem by most of our respondents. However, even though there is ample evidence to support the use of PDT in several chorioretinal diseases, we found notable differences in its use in normal patient care throughout the world. Various alternative management strategies were noted during the verteporfin shortage, including lowering the dose of verteporfin per patient, the use of alternative treatment strategies and the use of a centralized system for allocating the remaining ampoules of verteporfin in some countries. Conclusion The shortage of verteporfin has had a large effect on the care of ophthalmic patients across the world and may have resulted in significant and irreversible vision loss. Mitigation strategies should be developed in consultation with all stakeholders to avoid future medication shortages of verteporfin and other unique ophthalmic medications. These strategies may include mandatory stock keeping, compulsory licensing to an alternative manufacturer or incentivizing the development of competition, for example through novel public-private partnerships.
C1 [Sirks, Marc J.; Diederen, Roselie M. H.; Boon, Camiel J. F.; Schlingemann, Reinier O.] Univ Amsterdam, Amsterdam Univ Med Ctr, Dept Ophthalmol, Amsterdam, Netherlands.
   [van Dijk, Elon H. C.; Boon, Camiel J. F.] Leiden Univ, Dept Ophthalmol, Med Ctr, Leiden, Netherlands.
   [Rosenberg, Noa; Hollak, Carla E. M.] Univ Amsterdam, Med Soc, Platform Amsterdam Univ Med Ctr, Amsterdam, Netherlands.
   [Rosenberg, Noa; Hollak, Carla E. M.] Univ Amsterdam, Dept Endocrinol & Metab, Amsterdam UMC, Amsterdam, Netherlands.
   [Hollak, Carla E. M.] Amsterdam Lysosome Ctr, Sphinx, Amsterdam, Netherlands.
   [Aslanis, Stamatios] St Erik Eye Hosp, Stockholm, Sweden.
   [Cheung, Chui Ming Gemmy] Singapore Natl Eye Ctr, Singapore, Singapore.
   [Cheung, Chui Ming Gemmy] Singapore Eye Res Inst, Singapore, Singapore.
   [Chowers, Itay] Hadassah Med Ctr, Dept Ophthalmol, Jerusalem, Israel.
   [Chowers, Itay] Hebrew Univ Jerusalem, Fac Med, Jerusalem, Israel.
   [Eandi, Chiara M.; Schlingemann, Reinier O.] Univ Lausanne, Jules Gonin Eye Hosp, Fdn Asile Des Aveugles, Dept Ophthalmol, Lausanne, Switzerland.
   [Eandi, Chiara M.] Univ Turin, Dept Surg Sci, Turin, Italy.
   [Freund, K. Bailey] Vitreous Retina Macula Consultants New York, New York, NY USA.
   [Freund, K. Bailey] NYU, Dept Ophthalmol, Grossman Sch Med, 550 1St Ave, New York, NY 10016 USA.
   [Holz, Frank G.] Univ Bonn, Dept Ophthalmol, Bonn, Germany.
   [Kaiser, Peter K.] Cole Eye Inst, Cleveland, OH USA.
   [Lotery, Andrew J.] Univ Southampton, Fac Med, Southampton, Hants, England.
   [Ohno-Matsui, Kyoko] Tokyo Med & Dent Univ, Tokyo, Japan.
   [Querques, Giuseppe] Univ Vita Salute San Raffaele, IRCCS San Raffaele Sci Inst, Milan, Italy.
   [Subhi, Yousif] Rigshosp, Dept Opthalmol, Glostrup, Denmark.
   [Subhi, Yousif] Univ Southern Denmark, Dept Clin Res, Odense, Denmark.
   [Tadayoni, Ramin] Univ Paris, Paris, France.
   [Tadayoni, Ramin] Hop Lariboisiere, AP HP, Paris, France.
   [Tadayoni, Ramin] Hop Fdn Adolphe de Rothschild, Paris, France.
   [Wykoff, Charles C.] Retina Consultants Amer, Retina Consultants Texas, Houston, TX USA.
   [Wykoff, Charles C.] Houston Methodist Hosp, Blanton Eye Inst, Houston, TX 77030 USA.
   [Zur, Dinah] Tel Aviv Med Ctr & Sch Med, Ophthalmol Div, Tel Aviv, Israel.
   [Zur, Dinah] Tel Aviv Univ, Sackler Fac Med, Tel Aviv, Israel.
C3 University of Amsterdam; Leiden University; Leiden University Medical
   Center (LUMC); Leiden University - Excl LUMC; University of Amsterdam;
   University of Amsterdam; Singapore National Eye Center; National
   University of Singapore; Singapore National Eye Center; Hebrew
   University of Jerusalem; Hadassah University Medical Center; Hebrew
   University of Jerusalem; University of Lausanne; University of Turin;
   Vitreous Retina Macula Consultants of New York; New York University;
   University of Bonn; University of Southampton; Tokyo Medical & Dental
   University (TMDU); Vita-Salute San Raffaele University; IRCCS Ospedale
   San Raffaele; Rigshospitalet; University of Southern Denmark;
   UDICE-French Research Universities; Universite Paris Cite; Assistance
   Publique Hopitaux Paris (APHP); Hopital Universitaire
   Lariboisiere-Fernand-Widal - APHP; UDICE-French Research Universities;
   Universite Paris Cite; The Methodist Hospital System; The Methodist
   Hospital - Houston; Tel Aviv University; Sackler Faculty of Medicine;
   Tel Aviv University; Sackler Faculty of Medicine
RP Schlingemann, RO (通讯作者)，Amsterdam Univ Med Ctr, Dept Ophthalmol, Meibergdreef 9, NL-1105 AZ Amsterdam, Netherlands.
EM r.o.schlingemann@amsterdamumc.nl
RI Subhi, Yousif/ABG-6330-2020; Freund, K. Bailey/V-7488-2018
OI Subhi, Yousif/0000-0001-6620-5365; van Dijk, Elon/0000-0002-6351-7942;
   Eandi, Chiara Maria/0000-0003-3656-1689; Rosenberg,
   Noa/0000-0002-9586-6135; Freund, K. Bailey/0000-0002-7888-9773; Cheung,
   Chui Ming Gemmy/0000-0003-3358-3516; diederen,
   roselie/0000-0001-9708-2898; Sirks, Marc/0000-0002-8788-7753; Aslanis,
   Stamatios/0000-0001-9407-0541
FU Nationale Postcode Loterij
FX NR and CEMH are members of the platform `Medicijn voor de Maatschappij',
   an academic initiative that aims to support sustainable access to
   medicines for rare diseases, funded by the Nationale Postcode Loterij.
CR Abels C, 1998, BRIT J CANCER, V77, P1021, DOI 10.1038/bjc.1998.168
   Allison RR, 2010, FUTURE ONCOL, V6, P929, DOI 10.2217/FON.10.51
   ANAND R, 1989, ARCH OPHTHALMOL-CHIC, V107, P1338, DOI 10.1001/archopht.1989.01070020408045
   BATLLE AMD, 1993, J PHOTOCH PHOTOBIO B, V20, P5
   Beall RF, 2020, J LAW MED ETHICS, V48, P789, DOI 10.1177/1073110520979391
   Boixadera A, 2009, OPHTHALMOLOGY, V116, P100, DOI 10.1016/j.ophtha.2008.08.029
   Bressler NM, 1999, ARCH OPHTHALMOL-CHIC, V117, P1329
   Broekers-Knol A., 2021, KAMERBRIEF MELDING M
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Canadian Ophthalmological Society, 2021, GUIDELINES SUPPLY TR
   Chaikitmongkol V, 2020, ASIA-PAC J OPHTHALMO, V9, P260, DOI 10.1097/01.APO.0000656992.00746.48
   Cheplapharm Arzneimittel GmbH, 2020, VISUDYNE VERTEPORFIN
   Cheplapharm Arzneimittel GmbH, 2021, STATEMENT PROLONGED
   Cheung CMG, 2021, OPHTHALMOLOGY, V128, P443, DOI 10.1016/j.ophtha.2020.08.006
   Cheung CMG, 2019, EYE, V33, P14, DOI 10.1038/s41433-018-0158-4
   Ciulla TA, 2005, BRIT J OPHTHALMOL, V89, P113, DOI 10.1136/bjo.2004.043075
   Dansingani KK, 2018, CLIN EXP OPHTHALMOL, V46, P189, DOI 10.1111/ceo.13114
   DIAMOND I, 1972, LANCET, V2, P1175
   Dolmans DEJGJ, 2003, NAT REV CANCER, V3, P380, DOI 10.1038/nrc1071
   EU, 2001, OFFICIAL J, VL311, P67
   European Medicines Agency, 2021, GUIDANCE DETECTION N
   European Medicines Agency, 2021, SHORTAGE VISUDYNE VE
   European Medicines Agency, 2020, SUMMARY PRODUCT CHAR
   FIGGE FHJ, 1948, P SOC EXP BIOL MED, V68, P640
   Hollak CEM, 2010, BLOOD CELL MOL DIS, V44, P41, DOI 10.1016/j.bcmd.2009.09.006
   HURST LC, 1982, MED HIST, V26, P179, DOI 10.1017/S0025727300041156
   International Society for Pharmaceutical Engineering, 2014, ISPE DRUG SHORTAGES
   Karimi Saeed, 2015, J Ophthalmic Vis Res, V10, P320, DOI 10.4103/2008-322X.170353
   Koh A, 2012, RETINA-J RET VIT DIS, V32, P1453, DOI 10.1097/IAE.0b013e31824f91e8
   Koninklijke Nederlandse Maatschappij ter Bevordering der Pharmacie, 2020, KNMP ACHTERGRONDINFO
   Koninklijke Nederlandse Maatschappij ter Bevordering der Pharmacie, 2021, STAATSSECRETARIS BLO
   Kwiatkowski S, 2018, BIOMED PHARMACOTHER, V106, P1098, DOI 10.1016/j.biopha.2018.07.049
   Lee WK, 2018, JAMA OPHTHALMOL, V136, P786, DOI 10.1001/jamaophthalmol.2018.1804
   Lim TH, 2020, JAMA OPHTHALMOL, V138, P935, DOI 10.1001/jamaophthalmol.2020.2443
   Lotery A, 2020, LANCET, V395, P294, DOI 10.1016/S0140-6736(19)32981-2
   Mehta PH, 2017, BRIT J OPHTHALMOL, V101, P587, DOI 10.1136/bjophthalmol-2016-309247
   Mohabati D, 2018, CLIN OPHTHALMOL, V12, P2167, DOI 10.2147/OPTH.S174573
   Nederlands Oogheelkundig Gezelschap, 2021, ERNSTIG TEKORT VISUD
   Niazi FH, 2020, PHOTODIAGN PHOTODYN, V29, DOI 10.1016/j.pdpdt.2020.101665
   Nyst HJ, 2009, PHOTODIAGN PHOTODYN, V6, P3, DOI 10.1016/j.pdpdt.2009.03.002
   Ozog DM, 2016, DERMATOL SURG, V42, P804, DOI 10.1097/DSS.0000000000000800
   Quhill H, 2021, BRIT J OPHTHALMOL, V105, P794, DOI 10.1136/bjophthalmol-2020-316616
   Raizada K., 2021, PHOTODYNAMIC THERAPY
   Royal College of Ophthalmologists, 2021, MED SUPPLY NOTIFICAT
   Sachdeva R, 2010, ACTA OPHTHALMOL, V88, pe334, DOI 10.1111/j.1755-3768.2010.02008.x
   Saito M, 2012, AM J OPHTHALMOL, V153, P504, DOI 10.1016/j.ajo.2011.08.038
   Santosa V, 2008, INDONES J CHEM, V8, P279
   Schmidt-Erfurth UM, 2002, OPHTHALMOLOGY, V109, P2284, DOI 10.1016/S0161-6420(02)01454-9
   Soci?t? Fran?aise d'Ophtalmologie, 2021, RATIONALISATION LUTI
   Spaide RF, 2022, PROG RETIN EYE RES, V86, DOI 10.1016/j.preteyeres.2021.100973
   't Hoen Ellen F M, 2017, J Pharm Policy Pract, V10, P19, DOI 10.1186/s40545-017-0107-9
   Tomas MC, 2017, PHARM PAT ANAL, V6, P161, DOI 10.4155/ppa-2017-0010
   Tsipursky MS, 2011, SURV OPHTHALMOL, V56, P68, DOI 10.1016/j.survophthal.2010.08.002
   Tweede Kamer der Staten-Generaal, 2021, KAMERSTUKKEN 2 29, V477, P1
   van Dijk EHC, 2021, PROG RETIN EYE RES, V84, DOI 10.1016/j.preteyeres.2021.100955
   van Dijk EHC, 2021, GRAEF ARCH CLIN EXP, V259, P351, DOI 10.1007/s00417-020-04844-z
   van Dijk EHC, 2020, OPHTHALMOL THER, V9, P329, DOI 10.1007/s40123-020-00250-0
   van Dijk EHC, 2018, OPHTHALMOLOGY, V125, P1547, DOI 10.1016/j.ophtha.2018.04.021
   van Rijssen TJ, 2022, AM J OPHTHALMOL, V233, P101, DOI 10.1016/j.ajo.2021.06.020
   van Rijssen TJ, 2020, AM J OPHTHALMOL, V216, P80, DOI 10.1016/j.ajo.2020.04.007
   van Rijssen TJ, 2019, PROG RETIN EYE RES, V73, DOI 10.1016/j.preteyeres.2019.07.003
   Van Rijssen TJ, 2019, AM J OPHTHALMOL, V205, P1, DOI 10.1016/j.ajo.2019.03.025
   Von Tappeiner H., 1903, MUNCH MED WOCHENSCHR, V1, P2042
   Werkgroep Medische Retina van het Nederlands Oogheelkundig Gezelschap, 2021, TRIAGE PATI NTEN FOT
   Wong CW, 2016, PROG RETIN EYE RES, V53, P107, DOI 10.1016/j.preteyeres.2016.04.002
   Wong IY, 2018, RETINA-J RET VIT DIS, V38, P725, DOI 10.1097/IAE.0000000000001614
   Wong TW, 2019, J CLIN MED, V8, DOI 10.3390/jcm8030411
   Ziemssen F, 2012, EXPERT OPIN DRUG MET, V8, P1023, DOI 10.1517/17425255.2012.701617
NR 68
TC 7
Z9 7
U1 1
U2 2
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1755-375X
EI 1755-3768
J9 ACTA OPHTHALMOL
JI Acta Ophthalmol.
PD NOV
PY 2022
VL 100
IS 7
BP E1522
EP E1532
DI 10.1111/aos.15148
EA APR 2022
PG 11
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 5E2FF
UT WOS:000778748200001
PM 35388619
OA Green Published
DA 2022-11-30
ER

PT J
AU Evans, JR
   Lawrenson, JG
AF Evans, Jennifer R.
   Lawrenson, John G.
TI Antioxidant vitamin andmineral supplements for slowing the progression
   of age-relatedmacular degeneration
SO COCHRANE DATABASE OF SYSTEMATIC REVIEWS
LA English
DT Review
DE Antioxidants [*therapeutic use]; Dietary Supplements; Macular
   Degeneration [*prevention & control]; Minerals [*therapeutic use];
   Randomized Controlled Trials as Topic; Vitamins [*therapeutic use];
   Aged; Humans
ID PIGMENT OPTICAL-DENSITY; DIFFERING CAROTENOID FORMULATIONS; MACULAR
   DEGENERATION; LUTEIN SUPPLEMENTATION; EYE DISEASE; RANDOMIZED-TRIAL;
   VISUAL FUNCTION; ZEAXANTHIN SUPPLEMENTATION; DIETARY SUPPLEMENTATION;
   NUTRITIONAL SUPPLEMENTS
AB Background
   It has been proposed that antioxidants may prevent cellular damage in the retina by reacting with free radicals that are produced in the process of light absorption. Higher dietary levels of antioxidant vitamins and minerals may reduce the risk of progression of age-related macular degeneration (AMD).
   Objectives
   The objective of this review was to assess the effects of antioxidant vitamin or mineral supplementation on the progression of AMD in people with AMD.
   Search methods
   We searched CENTRAL (2017, Issue 2), MEDLINE Ovid (1946 to March 2017), Embase Ovid (1947 to March 2017), AMED (1985 to March 2017), OpenGrey (System for Information on Grey Literature in Europe, the ISRCTN registry (www. isrctn. com/editAdvancedSearch), ClinicalTrials. gov (www. clinicaltrials. gov) and theWHOInternationalClinical TrialsRegistry Platform(ICTRP) (www. who. int/ictrp/search/en). We did not use any date or language restrictions in the electronic searches for trials. We last searched the electronic databases on 29 March 2017.
   Selection criteria
   We included randomised controlled trials (RCTs) that compared antioxidant vitamin or mineral supplementation (alone or in combination) to placebo or no intervention, in people with AMD.
   Data collection and analysis
   Both review authors independently assessed risk of bias in the included studies and extracted data. One author entered data into RevMan 5; the other author checked the data entry. We graded the certainty of the evidence using GRADE.
   Main results
   We included 19 studies conducted in USA, Europe, China, and Australia. We judged the trials that contributed data to the review to be at low or unclear risk of bias.
   Nine studies compared multivitamins with placebo (7 studies) or no treatment (2 studies) in people with early and moderate AMD. The duration of supplementation and follow-up ranged from nine months to six years; one trial followed up beyond two years. Most evidence came from the Age-Related Eye Disease Study (AREDS) in the USA. People taking antioxidant vitamins were less likely to progress to late AMD (odds ratio (OR) 0.72, 95% confidence interval (CI) 0.58 to 0.90; 2445 participants; 3 RCTs; moderatecertainty evidence). In people with very early signs of AMD, who are at low risk of progression, this would mean that there would be approximately 4 fewer cases of progression to late AMD for every 1000 people taking vitamins (1 fewer to 6 fewer cases). In people at high risk of progression (i. e. people with moderate AMD) this would correspond to approximately 8 fewer cases of progression for every 100 people taking vitamins (3 fewer to 13 fewer). In one study of 1206 people, there was a lower risk of progression for both neovascular AMD (OR 0.62, 95% CI 0.47 to 0.82; moderate-certainty evidence) and geographic atrophy (OR 0.75, 95% CI 0.51 to 1.10; moderate-certainty evidence) and a lower risk of losing 3 or more lines of visual acuity (OR 0.77, 95% CI 0.62 to 0.96; 1791 participants; moderate-certainty evidence). Low-certainty evidence from one study of 110 people suggested higher quality of life scores (National Eye Institute Visual Function Questionnaire) in treated compared with the non-treated people after 24 months (mean difference (MD) 12.30, 95% CI 4.24 to 20.36).
   Six studies compared lutein (with or without zeaxanthin) with placebo. The duration of supplementation and follow-up ranged fromsix months to five years. Most evidence came from the AREDS2 study in the USA. People taking lutein or zeaxanthin may have similar or slightly reduced risk of progression to late AMD(RR 0.94, 95% CI 0.87 to 1.01; 6891 eyes; low-certainty evidence), neovascular AMD (RR 0.92, 95% CI 0.84 to 1.02; 6891 eyes; low-certainty evidence), and geographic atrophy (RR 0.92, 95% CI 0.80 to 1.05; 6891 eyes; low-certainty evidence). A similar risk of progression to visual loss of 15 or more letters was seen in the lutein and control groups (RR 0.98, 95% CI 0.91 to 1.05; 6656 eyes; low-certainty evidence). Quality of life (measured with Visual Function Questionnaire) was similar between groups in one study of 108 participants (MD 1.48, 95% -5.53 to 8.49, moderate-certainty evidence).
   One study, conducted in Australia, compared vitamin E with placebo. This study randomised 1204 people to vitamin E or placebo, and followed up for four years. Participants were enrolled from the general population; 19% had AMD. The number of late AMD events was low (N = 7) and the estimate of effect was uncertain (RR 1.36, 95% CI 0.31 to 6.05, very low-certainty evidence). There were no data on neovascular AMD or geographic atrophy. There was no evidence of any effect of treatment on visual loss (RR 1.04, 95% CI 0.74 to 1.47, low-certainty evidence). There were no data on quality of life.
   Five studies compared zinc with placebo. The duration of supplementation and follow-up ranged from six months to seven years. People taking zinc supplements may be less likely to progress to late AMD (OR 0.83, 95% CI 0.70 to 0.98; 3790 participants; 3 RCTs; low-certainty evidence), neovascular AMD (OR 0.76, 95% CI 0.62 to 0.93; 2442 participants; 1 RCT; moderate-certainty evidence), geographic atrophy (OR 0.84, 95% CI 0.64 to 1.10; 2442 participants; 1 RCT; moderate-certainty evidence), or visual loss (OR 0.87, 95% CI 0.75 to 1.00; 3791 participants; 2 RCTs; moderate-certainty evidence). There were no data reported on quality of life.
   Very low-certainty evidence was available on adverse effects because the included studies were underpowered and adverse effects inconsistently reported.
   Authors' conclusions
   People with AMD may experience some delay in progression of the disease with multivitamin antioxidant vitamin and mineral supplementation. This finding was largely drawn from one large trial, conducted in a relatively well-nourished American population. We do not know the generalisability of these findings to other populations. Although generally regarded as safe, vitamin supplements may have harmful effects. A systematic review of the evidence on harms of vitamin supplements is needed. Supplements containing lutein and zeaxanthin are heavily marketed for people with age-related macular degeneration but our review shows they may have little or no effect on the progression of AMD.
C1 [Evans, Jennifer R.] London Sch Hyg & Trop Med, Cochrane Eyes & Vis, ICEH, Keppel St, London WC1E 7HT, England.
   [Lawrenson, John G.] City Univ London, Sch Hlth Sci, Ctr Appl Vis Res, London, England.
C3 University of London; London School of Hygiene & Tropical Medicine; City
   University London
RP Evans, JR (通讯作者)，London Sch Hyg & Trop Med, Cochrane Eyes & Vis, ICEH, Keppel St, London WC1E 7HT, England.
EM jennifer.evans@lshtm.ac.uk
OI Lawrenson, John/0000-0002-2031-6390
FU Moorfields Eye Hospital NHS Trust, UK; Department of Health by the NIHR;
   UCL Institute of Ophthalmology for a Specialist Biomedical Research
   Centre for Ophthalmology; NIHR; Guide Dogs for the Blind Association,
   UK; National Institute for Health Research (NIHR), UK
FX Internal sources; Moorfields Eye Hospital NHS Trust, UK.; External
   sources; Guide Dogs for the Blind Association, UK.; National Institute
   for Health Research (NIHR), UK.; Richard Wormald, Co-ordinating Editor
   for Cochrane Eyes and Vision (CEV) acknowledges financial support for
   his CEV research sessions from the Department of Health through the
   award made by the NIHR to Moorfields Eye Hospital NHS Foundation Trust
   and UCL Institute of Ophthalmology for a Specialist Biomedical Research
   Centre for Ophthalmology.; This review was supported by the NIHR, via
   Cochrane Infrastructure funding to the CEV UK editorial base which funds
   part of Jennifer Evans's salary. The views and opinions expressed
   therein are those of the authors and do not necessarily reflect those of
   the Systematic Reviews Programme, NIHR, NHS or the Department of Health.
CR Abba K, 2011, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD008122.pub2
   Age-Related Eye Dis Study Res Grp, 2001, AM J OPHTHALMOL, V132, P668
   Akuffo KO, 2015, EYE, V29, P902, DOI 10.1038/eye.2015.64
   Akuffo KO, 2014, OPHTHAL EPIDEMIOL, V21, P111, DOI 10.3109/09286586.2014.888085
   Alpha-Tocopherol Beta Carotene Cancer Prevention Study Group, 1994, N Engl J Med, V330, P1029, DOI 10.1056/NEJM199404143301501
   Andreatta W, 2014, OPHTHALMOLOGICA, V231, P185, DOI 10.1159/000357528
   Angelo G, 2015, CRIT REV FOOD SCI, V55, P1968, DOI 10.1080/10408398.2014.912199
   Anonymous, 2015, AUST J PHARM, V96, P60
   Arnold C, 2013, JAMA OPHTHALMOL, V131, P564, DOI 10.1001/jamaophthalmol.2013.2851
   Bahrami Hossein, 2006, BMC Ophthalmol, V6, P23, DOI 10.1186/1471-2415-6-23
   Barakat MR, 2006, CURR EYE RES, V31, P629, DOI 10.1080/02713680600760501
   Bartlett HE, 2007, EUR J CLIN NUTR, V61, P1121, DOI 10.1038/sj.ejcn.1602626
   Bartlett H, 2003, NUTR J, V2, DOI 10.1186/1475-2891-2-12
   Beatty S, 2013, OPHTHALMOLOGY, V120, P600, DOI 10.1016/j.ophtha.2012.08.040
   Beatty S, 2013, OPHTHALMOLOGY, V120, P645, DOI 10.1016/j.ophtha.2012.09.013
   Benzie IFF, 2006, BRIT J NUTR, V96, P154, DOI 10.1079/BJN20061796
   Berrow EJ, 2013, BRIT J NUTR, V109, P2008, DOI 10.1017/S0007114512004187
   Bjelakovic G, 2012, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD007176.pub2, 10.1590/1516-3180.20151332T1]
   Bonds DE, 2014, JAMA INTERN MED, V174, P763, DOI 10.1001/jamainternmed.2014.328
   Bone RA, 2007, NUTR METAB, V4, DOI 10.1186/1743-7075-4-12
   Broadhead GK, 2015, NUTR REV, V73, P448, DOI 10.1093/nutrit/nuv005
   Bunce C, 2010, EYE, V24, P1692, DOI 10.1038/eye.2010.122
   Buschini E, 2015, CLIN OPHTHALMOL, V9, P563, DOI 10.2147/OPTH.S59724
   Cangemi Francis E, 2007, BMC Ophthalmol, V7, P3, DOI 10.1186/1471-2415-7-3
   Carneiro A, 2017, OXID MED CELL LONGEV, V2017, DOI 10.1155/2017/6469138
   Chew EY, 2014, OPHTHALMOLOGY, V121, P2173, DOI 10.1016/j.ophtha.2014.05.008
   Chew EY, 2014, JAMA OPHTHALMOL, V132, P665, DOI 10.1001/jamaophthalmol.2014.643
   Chew EY, 2014, JAMA OPHTHALMOL, V132, P272, DOI 10.1001/jamaophthalmol.2013.6636
   Chew EY, 2014, JAMA OPHTHALMOL, V132, P142, DOI 10.1001/jamaophthalmol.2013.7376
   Chew EY, 2013, OPHTHALMOLOGY, V120, P1604, DOI 10.1016/j.ophtha.2013.01.021
   Chew EY, 2013, JAMA-J AM MED ASSOC, V309, P2005, DOI 10.1001/jama.2013.4997
   Chew EY, 2012, OPHTHALMOLOGY, V119, P2282, DOI 10.1016/j.ophtha.2012.05.027
   Christen WG, 1996, ANN EPIDEMIOL, V6, P60, DOI 10.1016/1047-2797(95)00094-1
   Christen WG, 2007, ARCH OPHTHALMOL-CHIC, V125, P333, DOI 10.1001/archopht.125.3.333
   Christen WG, 2014, OPHTHALMOLOGY, V121, P525, DOI 10.1016/j.ophtha.2013.09.038
   Christen WG, 2012, OPHTHALMOLOGY, V119, P1642, DOI 10.1016/j.ophtha.2012.01.053
   Clemons TE, 2004, ARCH OPHTHALMOL-CHIC, V122, P716
   Connolly EE, 2011, INVEST OPHTH VIS SCI, V52, P9207, DOI 10.1167/iovs.11-8025
   Cumurcu T, 2006, TRACE ELEM ELECTROLY, V23, P103
   Dawczynski J, 2012, KLIN MONATSBL AUGENH, V229, P69, DOI 10.1055/s-0031-1273339
   Dawczynski J, 2013, GRAEF ARCH CLIN EXP, V251, P2711, DOI 10.1007/s00417-013-2376-6
   Downie LE, 2014, OPTOMETRY VISION SCI, V91, P821, DOI 10.1097/OPX.0000000000000285
   ETDRS 1980 Early Treatment Diabetic Retinopathy Study Research Group, 1980, EARL TREATM DIAB RET
   Evans JR, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000254.pub2
   Evans JR, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000254.pub3
   Evans JR, 2017, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD000253.pub4, DOI 10.1002/14651858.CD000253.PUB4]]
   Falsini B, 2010, INVEST OPHTH VIS SCI, V51, P6118, DOI 10.1167/iovs.09-4995
   Franciose JL, 2006, CURR TOP NUTRACEUT R, V4, P69
   Garrett S K, 1999, Ophthalmic Epidemiol, V6, P195, DOI 10.1076/opep.6.3.195.1500
   Garrett SKM, 2000, J CLIN EPIDEMIOL, V53, P541, DOI 10.1016/S0895-4356(99)00153-5
   Glanville JM, 2006, J MED LIBR ASSOC, V94, P130
   Goodrow EF, 2006, J NUTR, V136, P2519, DOI 10.1093/jn/136.10.2519
   GRADE Working Group McMaster University, 2014, GRADEPRO
   Grover AK, 2014, MOL CELL BIOCHEM, V388, P173, DOI 10.1007/s11010-013-1908-z
   Hanus J, 2016, BRIT J OPHTHALMOL, V100, P122, DOI 10.1136/bjophthalmol-2015-306972
   Higgins J, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.ED000049
   Holz F., 1993, GER J OPHTHALMOL, V2, P391
   Huang HY, 2006, ANN INTERN MED, V145, P372, DOI 10.7326/0003-4819-145-5-200609050-00135
   Huang YM, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/564738
   Huang YM, 2015, BRIT J OPHTHALMOL, V99, P371, DOI 10.1136/bjophthalmol-2014-305503
   Huang YM, 2013, NUTRITION, V29, P387, DOI 10.1016/j.nut.2012.06.009
   Hubbard LD, 2008, INVEST OPHTH VIS SCI, V49, P3269, DOI 10.1167/iovs.07-1267
   Johnson AR, 2007, J UROLOGY, V177, P639, DOI 10.1016/j.juro.2006.09.047
   KAISER HJ, 1995, OPHTHALMOLOGICA, V209, P302, DOI 10.1159/000310646
   Kamburoglu G, 2006, GRAEF ARCH CLIN EXP, V244, P565, DOI 10.1007/s00417-005-0108-2
   Kassoff A, 1999, CONTROL CLIN TRIALS, V20, P573
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Khachik F, 2006, INVEST OPHTH VIS SCI, V47, P5234, DOI 10.1167/iovs.06-0504
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Kolber MR, 2013, CAN FAM PHYSICIAN, V59, P503
   Kopsell DA, 2006, J AGR FOOD CHEM, V54, P7998, DOI 10.1021/jf0614802
   Kvansakul J, 2006, OPHTHAL PHYSL OPT, V26, P362, DOI 10.1111/j.1475-1313.2006.00387.x
   Lai YH, 2011, RETINA-J RET VIT DIS, V31, P1620, DOI 10.1097/IAE.0b013e31820d3ed1
   Landrum J, 2012, ACTA BIOCHIM POL, V59, P167
   Lim JI, 2006, RETINA-J RET VIT DIS, V26, P314, DOI 10.1097/00006982-200603000-00010
   Liu R, 2016, INVEST OPHTHALMOL, V56, P252
   Lonn E, 2005, JAMA-J AM MED ASSOC, V293, P1338, DOI 10.1001/jama.293.11.1338
   Ma L, 2012, OPHTHALMOLOGY, V119, P2290, DOI 10.1016/j.ophtha.2012.06.014
   Ma L, 2012, AM J OPHTHALMOL, V154, P625, DOI 10.1016/j.ajo.2012.04.014
   Manikandan R, 2016, FITOTERAPIA, V109, P58, DOI 10.1016/j.fitote.2015.12.009
   McBee WL, 2011, CLIN TRIALS C 32 M S
   Meagher K, 2013, EUR J OPHTHALMOL, V23, P612
   Moeller SM, 2006, ARCH OPHTHALMOL-CHIC, V124, P1151, DOI 10.1001/archopht.124.8.1151
   Moriarty-Craige SE, 2007, AM J OPHTHALMOL, V143, P206, DOI 10.1016/j.ajo.2006.09.056
   Murray IJ, 2013, INVEST OPHTH VIS SCI, V54, P1781, DOI 10.1167/iovs.12-10715
   Neelam K, 2008, OPHTHAL EPIDEMIOL, V15, P389, DOI 10.1080/09286580802154275
   NEWSOME DA, 1988, ARCH OPHTHALMOL-CHIC, V106, P192
   Newsome DA, 2008, CURR EYE RES, V33, P591, DOI 10.1080/02713680802178437
   NICE, MAC DEG NICE GUID
   Nolan JM, 2006, CURR EYE RES, V31, P199, DOI 10.1080/02713680500514677
   Nolan JM, 2007, EXP EYE RES, V84, P61, DOI 10.1016/j.exer.2006.08.016
   Nolan JM, 2012, EXP EYE RES, V101, P9, DOI 10.1016/j.exer.2012.05.006
   Nussenblatt RB, 2006, AM J OPHTHALMOL, V141, P193, DOI 10.1016/j.ajo.2005.07.036
   Omenn GS, 1996, NEW ENGL J MED, V334, P1150, DOI 10.1056/NEJM199605023341802
   Owsley C, 2006, INVEST OPHTH VIS SCI, V47, P1310, DOI 10.1167/iovs.05-1292
   Piermarocchi S, 2012, EUR J OPHTHALMOL, V22, P216, DOI 10.5301/ejo.5000069
   Prasad AS, 2014, J TRACE ELEM MED BIO, V28, P364, DOI 10.1016/j.jtemb.2014.07.019
   RICHER S, 1996, J AM OPTOMETRIC ASS, V0067
   Richer S, 1996, J Am Optom Assoc, V67, P30
   Richer Stuart, 2004, Optometry, V75, P216, DOI 10.1016/S1529-1839(04)70049-4
   Richer Stuart, 2007, Optometry, V78, P213, DOI 10.1016/j.optm.2006.10.019
   Robman LD, 1999, AUST NZ J OPHTHALMOL, V27, P410
   Rodriguez-Carmona M, 2006, OPHTHAL PHYSL OPT, V26, P137, DOI 10.1111/j.1475-1313.2006.00386.x
   Rosenthal JM, 2006, INVEST OPHTH VIS SCI, V47, P5227, DOI 10.1167/iovs.05-1513
   Rudnicka AR, 2012, OPHTHALMOLOGY, V119, P571, DOI 10.1016/j.ophtha.2011.09.027
   Sabour-Pickett S, 2014, RETINA-J RET VIT DIS, V34, P1757, DOI 10.1097/IAE.0000000000000174
   Sacconi R, 2017, OPHTHALMOL THER, V6, P69, DOI 10.1007/s40123-017-0086-6
   Sasamoto Y, 2011, GRAEF ARCH CLIN EXP, V249, P1847, DOI 10.1007/s00417-011-1780-z
   Scalinci SZ, 2002, CAN J OPHTHALMOL, V37, P399
   Schalch W, 2007, ARCH BIOCHEM BIOPHYS, V458, P128, DOI 10.1016/j.abb.2006.09.032
   Schmetterer L, 2013, EUR J OPHTHALMOL, V23, P605
   Schmidl D, 2011, J CLIN PHARM
   Schmidl D, 2015, ACTA OPHTHALMOL, V93, P105, DOI 10.1111/aos.12650
   Schtinemann HJ, 2011, COCHRANE HDB SYSTEMA
   Scorolli L, 2002, CAN J OPHTHALMOL, V37, P399, DOI 10.1016/S0008-4182(02)80042-4
   Soubrane, 1998, ZINC SUPPLEMENTATION
   Souied EH, 2013, OPHTHALMOLOGY, V120, P1619, DOI 10.1016/j.ophtha.2013.01.005
   Stur M, 1996, INVEST OPHTH VIS SCI, V37, P1225
   Taylor HR, 2001, INVEST OPHTH VIS SCI, V42, pS311
   The Nordic Cochrane Centre, 2014, REV MAN 5 REVMAN 5 V
   Tian Y, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0073387
   Tikellis G, 1999, Ophthalmic Epidemiol, V6, P181, DOI 10.1076/opep.6.3.181.1502
   Told R, 2015, INVEST OPHTH VIS SCI, V56, P403, DOI 10.1167/iovs.14-15581
   Told R, 2014, INVEST OPHTH VIS SCI, V55, P2220, DOI 10.1167/iovs.13-13784
   Trieschmann M, 2007, EXP EYE RES, V84, P718, DOI 10.1016/j.exer.2006.12.010
   VANNAS S, 1958, Acta Ophthalmol (Copenh), V36, P601
   Veritas Health Innovation, 2016, VER HLTH INN COV SYS
   Vidal K, 2011, CLIN NUTR
   Wang H., 2004, ZHONGGUO LINCHUANT K, V8, P1290
   Wang W, 2007, AM J CLIN NUTR, V85, P762, DOI 10.1093/ajcn/85.3.762
   Weigert G, 2011, INVEST OPHTH VIS SCI, V52, P8174, DOI 10.1167/iovs.11-7522
   Wenzel AJ, 2006, J NUTR, V136, P2568, DOI 10.1093/jn/136.10.2568
   Wolf-Schnurrbusch UEK, 2015, INVEST OPHTH VIS SCI, V56, P8069, DOI 10.1167/iovs.15-17586
   Wong WT, 2010, INVEST OPHTH VIS SCI, V51, P6131, DOI 10.1167/iovs.10-5637
   Zampatti S, 2014, NUTR RES, V34, P95, DOI 10.1016/j.nutres.2013.10.011
   Zeimer M, 2012, INVEST OPHTH VIS SCI, V53, P4852, DOI 10.1167/iovs.12-9713
   Zhao DY, 2006, CURR TOP NUTRACEUT R, V4, P53
NR 137
TC 49
Z9 50
U1 0
U2 19
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1469-493X
EI 1361-6137
J9 COCHRANE DB SYST REV
JI Cochrane Database Syst Rev.
PY 2017
IS 7
AR CD000254
DI 10.1002/14651858.CD000254.pub4
PG 131
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA FC4SO
UT WOS:000406831100047
PM 28756618
OA Green Published, Green Accepted
DA 2022-11-30
ER

PT J
AU Okubo, A
   Unoki, K
   Sameshima, M
   Sakamoto, T
AF Okubo, Akiko
   Unoki, Kazuhiko
   Sameshima, Munefumi
   Sakamoto, Taiji
TI Focal choroidal excavation with changes in shape and alterations of
   inner retina during long follow-up in an eye with polypoidal choroidal
   vasculopathy
SO CLINICAL AND EXPERIMENTAL OPTOMETRY
LA English
DT Article
ID OPTICAL COHERENCE TOMOGRAPHY
C1 [Okubo, Akiko; Unoki, Kazuhiko] Unoki Eye Clin, Kagoshima, Japan.
   [Sameshima, Munefumi; Sakamoto, Taiji] Kagoshima Univ, Grad Sch Med & Dent Sci, Dept Ophthalmol, Kagoshima 890, Japan.
C3 Kagoshima University
RP Okubo, A (通讯作者)，Unoki Eye Clin, Kagoshima, Japan.
EM akiko@m2.kufm.kagoshima-u.ac.jp
CR Ellabban AA, 2013, AM J OPHTHALMOL, V156, P673, DOI 10.1016/j.ajo.2013.05.010
   FRYCZKOWSKI AW, 1994, INT OPHTHALMOL, V18, P131, DOI 10.1007/BF00915961
   HAYREH SS, 1983, INT OPHTHALMOL, V6, P139, DOI 10.1007/BF00127642
   Husain D, 1999, INVEST OPHTH VIS SCI, V40, P2322
   Jampol LM, 2006, RETINA-J RET VIT DIS, V26, P1072, DOI 10.1097/01.iae.0000248819.86737.a5
   Kobayashi W, 2012, CLIN OPHTHALMOL, V6, P1373, DOI 10.2147/OPTH.S33879
   Lee CS, 2014, OPHTHALMOLOGY, V121, P1029, DOI 10.1016/j.ophtha.2013.11.043
   Margolis R, 2011, ARCH OPHTHALMOL-CHIC, V129, P1320, DOI 10.1001/archophthalmol.2011.148
   Obata R, 2013, RETINA-J RET VIT DIS, V33, P1201, DOI 10.1097/IAE.0b013e31827b6452
   Say EAT, 2013, OPHTHAL SURG LAS IM, V44, P409, DOI 10.3928/23258160-20130715-12
   Shinojima A, 2014, RETINA-J RET VIT DIS, V34, P1407, DOI 10.1097/IAE.0000000000000108
   Xu HF, 2014, OPHTHALMOLOGY, V121, P246, DOI 10.1016/j.ophtha.2013.08.014
NR 12
TC 4
Z9 4
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0816-4622
EI 1444-0938
J9 CLIN EXP OPTOM
JI Clin. Exp. Optom.
PD SEP
PY 2015
VL 98
IS 5
BP 478
EP 480
DI 10.1111/cxo.12265
PG 3
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA CS7UE
UT WOS:000362291200012
PM 25786518
DA 2022-11-30
ER

PT J
AU Chen, ZL
   Sun, Y
   Huang, P
   Yang, XX
   Zhou, XP
AF Chen, Zhi-Long
   Sun, Yun
   Huang, Peng
   Yang, Xiao-Xia
   Zhou, Xing-Ping
TI Studies on Preparation of Photosensitizer Loaded Magnetic Silica
   Nanoparticles and Their Anti-Tumor Effects for Targeting Photodynamic
   Therapy
SO NANOSCALE RESEARCH LETTERS
LA English
DT Article
DE Targeting photodynamic therapy; Photosensitizer; Silica; Magnetic
   nanoparticles; Tumor
ID SINGLET OXYGEN; PARTICLES; DELIVERY; DRUGS; CARRIER; SPHERES; SYSTEM;
   GROWTH
AB As a fast developing alternative of traditional therapeutics, photodynamic therapy (PDT) is an effective, noninvasive, nontoxic therapeutics for cancer, senile macular degeneration, and so on. But the efficacy of PDT was compromised by insufficient selectivity and low solubility. In this study, novel multifunctional silica-based magnetic nanoparticles (SMNPs) were strategically designed and prepared as targeting drug delivery system to achieve higher specificity and better solubility. 2,7,12,18-Tetramethyl-3,8-di-(1-propoxyethyl)-13,17-bis-(3-hydroxypropyl) porphyrin, shorted as PHPP, was used as photosensitizer, which was first synthesized by our lab with good PDT effects. Magnetite nanoparticles (Fe3O4) and PHPP were incorporated into silica nanoparticles by microemulsion and sol-gel methods. The prepared nanoparticles were characterized by transmission electron microscopy, X-ray diffraction, Fourier transform infrared spectroscopy and fluorescence spectroscopy. The nanoparticles were approximately spherical with 20-30 nm diameter. Intense fluorescence of PHPP was monitored in the cytoplasm of SW480 cells. The nanoparticles possessed good biocompatibility and could generate singlet oxygen to cause remarkable photodynamic anti-tumor effects. These suggested that PHPP-SMNPs had great potential as effective drug delivery system in targeting photodynamic therapy, diagnostic magnetic resonance imaging and magnetic hyperthermia therapy.
C1 [Chen, Zhi-Long; Sun, Yun; Huang, Peng; Yang, Xiao-Xia; Zhou, Xing-Ping] Donghua Univ, Dept Pharmaceut Sci & Technol, Coll Chem & Biol, Shanghai 201620, Peoples R China.
C3 Donghua University
RP Chen, ZL (通讯作者)，Donghua Univ, Dept Pharmaceut Sci & Technol, Coll Chem & Biol, Shanghai 201620, Peoples R China.
EM zlchen1967@yahoo.com; xpzhou@dhu.edu.cn
RI Huang, Peng/R-2480-2016; sun, yun/C-2739-2014; Huang, Peng/H-9985-2013;
   zhou, xt/GWZ-9212-2022; Chen, Zhi-long/AGF-6157-2022
OI Huang, Peng/0000-0003-3651-7813; sun, yun/0000-0002-2652-3040; 
FU National Natural Science Foundation of China [30070862, 30271534];
   Shanghai Municipal Foundation [05ZR14002, 06PJ14001, 064319020]
FX This work was supported by National Natural Science Foundation of China
   ( grant nos. 30070862, 30271534), Shanghai Municipal Foundation ( grant
   nos. 05ZR14002, 06PJ14001, 064319020).
CR ALEX R, 1990, J MICROENCAPSUL, V7, P347, DOI 10.3109/02652049009021845
   Chen ZL, 1998, HETEROCYCLES, V48, P1739, DOI 10.3987/COM-98-8203
   CHEN ZL, 1998, CHIN J MED CHEM, V8, P1
   Choi Y, 2006, CANCER RES, V66, P7225, DOI 10.1158/0008-5472.CAN-06-0448
   Cinteza LO, 2006, MOL PHARMACEUT, V3, P415, DOI 10.1021/mp060015p
   Corr SA, 2008, NANOSCALE RES LETT, V3, P87, DOI 10.1007/s11671-008-9122-8
   De Gao R. R., 2006, NANO LETT, V6, P2383, DOI DOI 10.1021/NL0617179
   Derycke ASL, 2004, ADV DRUG DELIVER REV, V56, P17, DOI 10.1016/j.addr.2003.07.014
   DOUGHERTY TJ, 1987, PHOTOCHEM PHOTOBIOL, V45, P879, DOI 10.1111/j.1751-1097.1987.tb07898.x
   Inbaraj JJ, 2003, J APPL POLYM SCI, V89, P3925, DOI 10.1002/app.12610
   Jain TK, 2008, MOL PHARMACEUT, V5, P316, DOI 10.1021/mp7001285
   Jain TK, 1998, J AM CHEM SOC, V120, P11092, DOI 10.1021/ja973849x
   Kim J, 2006, J AM CHEM SOC, V128, P688, DOI 10.1021/ja0565875
   Kim Y, 2006, CURR APPL PHYS, V6, P248, DOI 10.1016/j.cap.2005.07.050
   Konan YN, 2002, J PHOTOCH PHOTOBIO B, V66, P89, DOI 10.1016/S1011-1344(01)00267-6
   KRALJIC I, 1978, PHOTOCHEM PHOTOBIOL, V28, P577, DOI 10.1111/j.1751-1097.1978.tb06972.x
   Lai CW, 2008, SMALL, V4, P218, DOI 10.1002/smll.200700283
   Levy JG, 1996, PHOTOCHEM PHOTOBIOL, V64, P737, DOI 10.1111/j.1751-1097.1996.tb01828.x
   MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4
   Paul BK, 2001, CURR SCI INDIA, V80, P990
   Potter R., 1974, US Patent, V786, Patent No. 3
   Quarta A, 2007, IEEE T NANOBIOSCI, V6, P298, DOI 10.1109/TNB.2007.908989
   Roy I, 2003, J AM CHEM SOC, V125, P7860, DOI 10.1021/ja0343095
   Snyder JW, 2005, J AM CHEM SOC, V127, P14558, DOI 10.1021/ja055342p
   STOBER W, 1968, J COLLOID INTERF SCI, V26, P62, DOI 10.1016/0021-9797(68)90272-5
   Tada DB, 2007, LANGMUIR, V23, P8194, DOI 10.1021/la700883y
   van Nostrum CF, 2004, ADV DRUG DELIVER REV, V56, P9, DOI 10.1016/j.addr.2003.07.013
   Wang SZ, 2004, J MATER CHEM, V14, P487, DOI 10.1039/b311429e
   Zhou XP, 2007, CURR NANOSCI, V3, P259
NR 29
TC 63
Z9 66
U1 1
U2 54
PU SPRINGEROPEN
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND
SN 1931-7573
EI 1556-276X
J9 NANOSCALE RES LETT
JI Nanoscale Res. Lett.
PD MAY
PY 2009
VL 4
IS 5
BP 400
EP 408
DI 10.1007/s11671-009-9254-5
PG 9
WC Nanoscience & Nanotechnology; Materials Science, Multidisciplinary;
   Physics, Applied
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics; Materials Science; Physics
GA 423HQ
UT WOS:000264487800002
PM 20596490
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Le, JT
   Qureshi, R
   Twose, C
   Rosman, L
   Han, GN
   Fapohunda, K
   Saldanha, IJ
   Scherer, RW
   Lum, F
   Al-Rajhi, A
   Musch, DC
   Hawkins, BS
   Dickersin, K
   Li, TJ
AF Le, Jimmy T.
   Qureshi, Riaz
   Twose, Claire
   Rosman, Lori
   Han, Genie
   Fapohunda, Kolade
   Saldanha, Ian J.
   Scherer, Roberta W.
   Lum, Flora
   Al-Rajhi, Ali
   Musch, David C.
   Hawkins, Barbara S.
   Dickersin, Kay
   Li, Tianjing
TI Evaluation of Systematic Reviews of Interventions for Retina and
   Vitreous Conditions
SO JAMA OPHTHALMOLOGY
LA English
DT Review
ID SETTING PRIORITIES; GUIDELINES; OPHTHALMOLOGY; FRAMEWORK; QUALITY
AB This cross-sectional study of systematic reviews assesses the reliability of systematic reviews on interventions for 7 retina and vitreous conditions.
   Importance Patient care and clinical practice guidelines should be informed by evidence from reliable systematic reviews. The reliability of systematic reviews related to forthcoming guidelines for retina and vitreous conditions is unknown. Objectives To summarize the reliability of systematic reviews on interventions for 7 retina and vitreous conditions, describe characteristics of reliable and unreliable systematic reviews, and examine the primary area in which they appeared to be lacking. Design, Setting, and Participants A cross-sectional study of systematic reviews was conducted. Systematic reviews of interventions for retina- and vitreous-related conditions in a database maintained by the Cochrane Eyes and Vision United States Satellite were identified. Databases that the reviewers searched, whether any date or language restrictions were applied, and bibliographic information, such as year and journal of publication, were documented. The initial search was conducted in March 2007, and the final update was performed in July 2018. The conditions of interest were age-related macular degeneration; diabetic retinopathy; idiopathic epiretinal membrane and vitreomacular traction; idiopathic macular hole; posterior vitreous detachment, retinal breaks, and lattice degeneration; retinal and ophthalmic artery occlusions; and retinal vein occlusions. The reliability of each review was evaluated using prespecified criteria. Data were extracted by 2 research assistants working independently, with disagreements resolved through discussion or by 1 research assistant with verification by a senior team member. Main Outcomes and Measures Proportion of reviews that meet all of the following criteria: (1) defined eligibility criteria for study selection, (2) described conducting a comprehensive literature search, (3) reported assessing risk of bias in included studies, (4) described using appropriate methods for any meta-analysis performed, and (5) provided conclusions consistent with review findings. Results A total of 327 systematic reviews that addressed retina and vitreous conditions were identified; of these, 131 reviews (40.1%) were classified as reliable and 196 reviews (59.9%) were classified as not reliable. At least 1 reliable review was found for each of the 7 retina and vitreous conditions. The most common reason that a review was classified as not reliable was lack of evidence that a comprehensive literature search for relevant studies had been conducted (149 of 196 reviews [76.0%]). Conclusion and Relevance The findings of this study suggest that most systematic reviews that addressed interventions for retina and vitreous conditions were not reliable. Systematic review teams and guideline developers should work with information professionals who can help navigate sophisticated and varied syntaxes required to search different resources.
   Question What is the reliability of existing systematic reviews addressing interventions for 7 retina and vitreous conditions? Findings In this cross-sectional study of 327 systematic reviews of interventions for retina and vitreous conditions, 131 reviews (40.1%) were classified as reliable using prespecified criteria. Of the 196 reviews (59.9%) classified as not reliable, 149 reviews (76.0%) did not conduct a comprehensive literature search. Meaning Most systematic reviews on interventions for retina and vitreous conditions were unreliable; systematic review teams should routinely include information professionals as members to aid development and execution of search strategies appropriate to the goals of the review.
C1 [Le, Jimmy T.; Qureshi, Riaz; Han, Genie; Fapohunda, Kolade; Scherer, Roberta W.; Dickersin, Kay; Li, Tianjing] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, 615 N Wolfe St,Ste E6140, Baltimore, MD 21205 USA.
   [Twose, Claire; Rosman, Lori] Johns Hopkins Univ, Welch Med Lib, Baltimore, MD USA.
   [Saldanha, Ian J.] Brown Univ, Sch Publ Hlth, Dept Hlth Serv Policy & Practice Primary, Providence, RI 02912 USA.
   [Saldanha, Ian J.] Brown Univ, Sch Publ Hlth, Dept Epidemiol Joint, Providence, RI 02912 USA.
   [Lum, Flora; Al-Rajhi, Ali] Amer Acad Ophthalmol, San Francisco, CA USA.
   [Musch, David C.] Univ Michigan, Dept Ophthalmol & Visual Sci, Ann Arbor, MI 48109 USA.
   [Musch, David C.] Univ Michigan, Dept Epidemiol, Ann Arbor, MI 48109 USA.
   [Hawkins, Barbara S.] Johns Hopkins Sch Med, Wilmer Eye Inst, Baltimore, MD USA.
C3 Johns Hopkins University; Johns Hopkins Bloomberg School of Public
   Health; Johns Hopkins University; Brown University; Brown University;
   University of Michigan System; University of Michigan; University of
   Michigan System; University of Michigan; Johns Hopkins University; Johns
   Hopkins Medicine
RP Li, TJ (通讯作者)，Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, 615 N Wolfe St,Ste E6140, Baltimore, MD 21205 USA.
EM tli19@jhu.edu
OI Rosman, Lori/0000-0002-6935-1672; Musch, David/0000-0002-4164-3841
FU National Eye Institute (National Institutes of Health); United States
   Department of Health and Human Services [UG1EY020522]; NATIONAL
   INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK092926]
   Funding Source: NIH RePORTER
FX This project was supported by the National Eye Institute (National
   Institutes of Health) and the United States Department of Health and
   Human Services (UG1EY020522, Dr Li).
CR [Anonymous], THE COCHRANE COLLABO, DOI DOI 10.1016/J.JPEDS.2013.01.022
   Berger VW, 2009, REV RECENT CLIN TRIA, V4, P79, DOI 10.2174/157488709788186021
   Critical Appraisal Skills Programme (CASP), 2006, CASP CHECKL
   DICKERSIN K, 1994, BMJ-BRIT MED J, V309, P1286, DOI 10.1136/bmj.309.6964.1286
   Downie LE, 2018, JAMA OPHTHALMOL, V136, P1051, DOI 10.1001/jamaophthalmol.2018.2620
   Egger M, 2003, Health Technol Assess, V7, P1
   Glasziou P, 2018, BMJ-BRIT MED J, V363, DOI 10.1136/bmj.k4645
   Golozar A, 2018, JAMA OPHTHALMOL, V136, P514, DOI 10.1001/jamaophthalmol.2018.0786
   Goodman S, 2011, ANN INTERN MED, V155, P61, DOI 10.7326/0003-4819-155-1-201107050-00010
   GRADE, WELC GRADE WORK GROU
   Institute of Medicine, 2011, FIND WHAT WORKS HLTH
   Institute of Medicine, 2011, CLIN PRACTICE GUIDEL
   Jadad AR, 2009, TRANSPL INT, V22, P1028, DOI 10.1111/j.1432-2277.2009.00919.x
   Jap J, 2019, RES SYNTH METHODS, V10, P2, DOI 10.1002/jrsm.1326
   Le JT, 2017, OPHTHALMOL RETINA, V1, P94, DOI 10.1016/j.oret.2016.10.003
   Li TJ, 2014, OPHTHALMOLOGY, V121, P438, DOI 10.1016/j.ophtha.2013.10.003
   Li TJ, 2012, ANN INTERN MED, V156, P367, DOI 10.7326/0003-4819-156-5-201203060-00009
   Lindsley K, 2016, OPHTHALMOLOGY, V123, P884, DOI 10.1016/j.ophtha.2015.12.004
   Macdonald Geraldine, 2012, Cochrane Database Syst Rev, pCD001930, DOI 10.1002/14651858.CD001930.pub3
   Mayo-Wilson E, 2017, BMC OPHTHALMOL, V17, DOI 10.1186/s12886-017-0561-9
   McGowan J, 2005, J MED LIBR ASSOC, V93, P74
   Meert D, 2016, J MED LIBR ASSOC, V104, P267, DOI 10.3163/1536-5050.104.4.004
   Metzendorf MI, 2016, J EUROPEAN ASS HLTH, V12, P6
   Moher David, 2009, BMJ, V339, pb2535, DOI [10.1016/j.ijsu.2010.02.007, 10.1136/bmj.b2535]
   Rethlefsen ML, 2015, J CLIN EPIDEMIOL, V68, P617, DOI 10.1016/j.jclinepi.2014.11.025
   Ross JS, 2009, PLOS MED, V6, DOI 10.1371/journal.pmed.1000144
   Saldanha IJ, 2019, JAMA OPHTHALMOL, V137, P775, DOI 10.1001/jamaophthalmol.2019.1063
   Scherer RW, 2013, BMC MED RES METHODOL, V13, DOI 10.1186/1471-2288-13-79
   Shea BJ, 2007, BMC MED RES METHODOL, V7, DOI 10.1186/1471-2288-7-10
   Siontis KC, 2018, CIRC-CARDIOVASC QUAL, V11, DOI 10.1161/CIRCOUTCOMES.118.005212
   Tse T, 2018, BMJ-BRIT MED J, V361, DOI 10.1136/bmj.k1452
   Yu T, 2015, J GLAUCOMA, V24, P348, DOI 10.1097/IJG.0b013e31829e5616
NR 32
TC 11
Z9 12
U1 2
U2 6
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 2168-6165
EI 2168-6173
J9 JAMA OPHTHALMOL
JI JAMA Ophthalmol.
PD DEC
PY 2019
VL 137
IS 12
BP 1399
EP 1405
DI 10.1001/jamaophthalmol.2019.4016
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA JZ6BQ
UT WOS:000505186800011
PM 31600387
OA Bronze, Green Published
DA 2022-11-30
ER

PT J
AU Bastawrous, A
   Burgess, PI
   Mahdi, AM
   Kyari, F
   Burton, MJ
   Kuper, H
AF Bastawrous, Andrew
   Burgess, Philip I.
   Mahdi, Abdull M.
   Kyari, Fatima
   Burton, Matthew J.
   Kuper, Hannah
TI Posterior segment eye disease in sub-Saharan Africa: review of recent
   population-based studies
SO TROPICAL MEDICINE & INTERNATIONAL HEALTH
LA English
DT Article
DE glaucoma; diabetic retinopathy; age-related macular degeneration;
   posterior segment eye disease; prevalence; incidence; blindness; visual
   impairment; Africa
ID OPEN-ANGLE GLAUCOMA; AGE-RELATED MACULOPATHY; CATARACT SURGICAL
   SERVICES; CAUSE-SPECIFIC PREVALENCE; VISUAL IMPAIRMENT SURVEY;
   CROSS-SECTIONAL SURVEY; COPENHAGEN CITY EYE; SOUTH-WEST PROVINCE;
   ANGELES LATINO EYE; MACULAR DEGENERATION
AB ObjectiveTo assess the burden of posterior segment eye diseases (PSEDs) in sub-Saharan Africa (SSA).
   MethodsWe reviewed published population-based data from SSA and other relevant populations on the leading PSED, specifically glaucoma, diabetic retinopathy and age-related macular degeneration, as causes of blindness and visual impairment in adults. Data were extracted from population-based studies conducted in SSA and elsewhere where relevant.
   ResultsPSEDs, when grouped or as individual diseases, are a major contributor to blindness and visual impairment in SSA. PSED, grouped together, was usually the second leading cause of blindness after cataract, ranging as a proportion of blindness from 13 to 37%.
   ConclusionsPSEDs are likely to grow in importance as causes of visual impairment and blindness in SSA in the coming years as populations grow, age and become more urban in lifestyle. African-based cohort studies are required to help estimate present and future needs and plan services to prevent avoidable blindness.
   ObjectifEvaluer la charge des maladies du segment posterieur de l'OEil (MSPO) en Afrique subsaharienne (ASS).
   MethodesNous avons examine les donnees d'etudes basee sur la population, publiees pour l'ASS et d'autres populations concernees sur les principaux MSPO, en particulier le glaucome, la retinopathie diabetique et la degenerescence maculaire liee a l'age, comme causes de cecite et de deficience visuelle chez les adultes. Les donnees ont ete extraites des etudes de populations menees en ASS et ailleurs, le cas echeant.
   ResultatsLes MSPO, lorsque regroupees ou comme maladies individuelles, sont un contributeur majeur a la cecite et aux deficiences visuelles en ASS. Les MSPO, regroupees ensembles, constituaient habituellement la seconde cause de cecite apres le cataracte, dans une proportion de la cecite allant de 13 a 37%.
   ConclusionsLes MSPO sont susceptibles de croitre en importance en tant que causes de deficience visuelle et de cecite en ASS dans les annees a venir, avec la population qui augmente, vieillie et devient plus urbaine dans le style de vie. Des etudes de cohorte africaines sont necessaires pour aider a estimer les besoins actuels et futurs et pour planifier les services de prevention de la cecite evitable.
   ObjetivoEvaluar la carga de la enfermedad del segmento posterior del ojo (ESPO) en africa Subsahariana (ASS).
   MetodosHemos revisado datos publicados de estudios poblacionales de ASS y otras poblaciones relevantes en las principales ESPO, especificamente glaucoma, retinopatia diabetica y degeneracion macular relacionada con la edad, como causa de ceguera y discapacidad visual en adultos. Se extrajeron datos de estudios poblacionales realizado en ASS, y en otros lugares cuando era relevante.
   ResultadosLas ESPO, bien agrupadas o como enfermedad individual, contribuyen de forma importante a la ceguera y a la discapacidad visual entre adultos en ASS. Las ESPO, agrupadas, eran generalmente la segunda causa de ceguera despues de las cataratas, con un rango de proporcion de ceguera del 13 al 37%.
   ConclusionesLas ESPO podrian aumentar en importancia como causa de discapacidad visual y ceguera en ASS en los proximos anos, a medida que las poblaciones crecen, aumentan en edad y se adopta un estilo de vida mas urbano. Se requieren estudios de cohortes en africa para calcular las necesidades presentes y futuras y planear servicios que eviten la ceguera prevenible.
C1 [Bastawrous, Andrew; Mahdi, Abdull M.; Kyari, Fatima; Burton, Matthew J.; Kuper, Hannah] Univ London London Sch Hyg & Trop Med, Int Ctr Eye Hlth, London WC1E 7HT, England.
   [Burgess, Philip I.] Queen Elizabeth Cent Hosp, Malawi Liverpool Wellcome Trust Clin Res Programm, Blantyre, Malawi.
   [Mahdi, Abdull M.] Abubakar Tafawa Balewa Univ, Dept Ophthalmol, Teaching Hosp, Bauchi, Nigeria.
   [Kyari, Fatima] Univ Abuja, Coll Hlth Sci, Dept Ophthalmol, Abuja, Nigeria.
   [Burton, Matthew J.] Moorfields Eye Hosp, London, England.
   [Kuper, Hannah] Univ London London Sch Hyg & Trop Med, Int Ctr Evidence Disabil, London WC1E 7HT, England.
C3 University of London; London School of Hygiene & Tropical Medicine;
   University of Malawi; University of London; University College London;
   Moorfields Eye Hospital NHS Foundation Trust; University of London;
   London School of Hygiene & Tropical Medicine
RP Bastawrous, A (通讯作者)，Univ London London Sch Hyg & Trop Med, Fac Infect & Trop Dis, Int Ctr Eye Hlth, Dept Clin Res, Keppel St, London WC1E 7HT, England.
EM Andrew.Bastawrous@lshtm.ac.uk
RI Abdull, Mohammed Mahdi/D-6338-2011
OI Abdull, Mohammed Mahdi/0000-0003-1577-9291; Kyari,
   Fatima/0000-0002-5080-2154; Burton, Matthew/0000-0003-1872-9169
FU MRC [G1001934] Funding Source: UKRI; Medical Research Council [G1001934]
   Funding Source: Medline; Wellcome Trust [100890, 100714, 101113] Funding
   Source: Medline
CR Abdull MM, 2009, INVEST OPHTH VIS SCI, V50, P4114, DOI 10.1167/iovs.09-3507
   Adegbehingbe B. O., 2006, Indian Journal of Ophthalmology, V54, P59
   [Anonymous], 2007, WHOICD10
   Arnarsson A, 2006, AM J OPHTHALMOL, V142, P419, DOI 10.1016/j.ajo.2006.04.015
   Bastawrous A, 2012, BRIT J OPHTHALMOL, V96, P1357, DOI 10.1136/bjophthalmol-2012-302088
   BENGTSSON B, 1991, ACTA OPHTHALMOL, V69, P288
   Boutayeb A, 2006, T ROY SOC TROP MED H, V100, P191, DOI 10.1016/j.trstmh.2005.07.021
   Bowler GS, 2012, BRIT J OPHTHALMOL, V96, P1046, DOI 10.1136/bjophthalmol-2011-301241
   Buch H, 2005, ACTA OPHTHALMOL SCAN, V83, P409, DOI 10.1111/J.1600-0420.2005.00492.x
   Buch H, 2005, ACTA OPHTHALMOL SCAN, V83, P400, DOI [10.1111/j.1600-0420.2005.00474.x, 10.1111/j.1600-0420.2005.thesis.x]
   Budenz DL, 2012, OPHTHALMOLOGY, V119, P1744, DOI 10.1016/j.ophtha.2012.04.017
   Buhrmann RR, 2000, INVEST OPHTH VIS SCI, V41, P40
   Burgess PI, 2013, DIABETIC MED, V30, P399, DOI 10.1111/j.1464-5491.2012.03756.x
   Cedrone C, 2012, J GLAUCOMA, V21, P1, DOI 10.1097/IJG.0b013e3182027796
   Chandrasekaran S, 2006, OPHTHALMOLOGY, V113, P417, DOI 10.1016/j.ophtha.2005.10.050
   Chen SJ, 2008, INVEST OPHTH VIS SCI, V49, P3126, DOI 10.1167/iovs.08-1803
   Chiang PPC, 2006, LANCET, V368, P365, DOI 10.1016/S0140-6736(06)69105-8
   Choudhury F, 2011, AM J OPHTHALMOL, V152, P385, DOI 10.1016/j.ajo.2011.02.025
   Cook C, 2009, J GLAUCOMA, V18, P124, DOI 10.1097/IJG.0b013e318189158c
   Cruickshanks KJ, 2001, ARCH OPHTHALMOL-CHIC, V119, P246
   de Voogd S, 2005, OPHTHALMOLOGY, V112, P1487, DOI 10.1016/j.ophtha.2005.04.018
   DF, 2009, DIABETES ATLAS
   Dimitrov PN, 2003, INVEST OPHTH VIS SCI, V44, P5075, DOI 10.1167/iovs.02-0457
   Dineen B, 2006, OPHTHAL EPIDEMIOL, V13, P31, DOI 10.1080/09286580500473787
   Dineen B, 2008, BMC OPHTHALMOL, V8, DOI 10.1186/1471-2415-8-17
   Distiller LA, 2010, DIABETIC MED, V27, P197, DOI 10.1111/j.1464-5491.2009.02907.x
   Dowse GK, 1998, AM J EPIDEMIOL, V147, P448, DOI 10.1093/oxfordjournals.aje.a009470
   Evans JR, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000254.pub2
   Evans JR, 2012, COCHRANE DB SYST REV, V6, DOI DOI 10.1002/14651858.CD000253.PUB3
   Foster PJ, 2002, BRIT J OPHTHALMOL, V86, P238, DOI 10.1136/bjo.86.2.238
   Gill GV, 2005, DIABETIC MED, V22, P1642, DOI 10.1111/j.1464-5491.2005.01712.x
   GILL GV, 1995, DIABETIC MED, V12, P546, DOI 10.1111/j.1464-5491.1995.tb00539.x
   GILL GV, 1984, S AFR MED J, V65, P815
   Glover SJ, 2012, BRIT J OPHTHALMOL, V96, P156, DOI 10.1136/bjo.2010.196071
   Guzek J P, 2005, Ghana Med J, V39, P55
   Habiyakire C, 2010, OPHTHAL EPIDEMIOL, V17, P90, DOI 10.3109/09286580903453514
   Heijl A, 2002, ARCH OPHTHALMOL-CHIC, V120, P1268, DOI 10.1001/archopht.120.10.1268
   Herman WH, 1998, DIABETIC MED, V15, P1045, DOI 10.1002/(SICI)1096-9136(1998120)15:12<1045::AID-DIA696>3.0.CO;2-L
   Kalk WJ, 1997, J INTERN MED, V241, P31, DOI 10.1046/j.1365-2796.1997.70892000.x
   Kalua K, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019226
   Kandeke L, 2012, OPHTHAL EPIDEMIOL, V19, P211, DOI 10.3109/09286586.2012.690493
   Kanski J., 2007, CLIN OPHTHALMOLOGY S
   Kikira Susan, 2007, Community Eye Health, V20, P71
   King H, 1998, DIABETES CARE, V21, P1414, DOI 10.2337/diacare.21.9.1414
   Kyari Fatima, 2013, Middle East Afr J Ophthalmol, V20, P111, DOI 10.4103/0974-9233.110605
   Leske MC, 2007, OPHTHALMOLOGY, V114, P1058, DOI 10.1016/j.ophtha.2006.08.051
   Leske MC, 2006, OPHTHALMOLOGY, V113, P29, DOI 10.1016/j.ophtha.2005.08.012
   Leske MC, 2004, OPHTHALMOLOGY, V111, P706, DOI 10.1016/j.ophtha.2003.07.003
   LESKE MC, 1994, ARCH OPHTHALMOL-CHIC, V112, P821, DOI 10.1001/archopht.1994.01090180121046
   Leske MC, 2001, ARCH OPHTHALMOL-CHIC, V119, P89
   Lopez AD, 2006, LANCET, V367, P1747, DOI 10.1016/S0140-6736(06)68770-9
   Mash B, 2007, SAMJ S AFR MED J, V97, P1284
   MASON RP, 1989, OPHTHALMOLOGY, V96, P1363
   Mathenge W, 2007, PLOS MED, V4, P1187, DOI 10.1371/journal.pmed.0040217
   Mathenge W, 2007, OPHTHALMOLOGY, V114, P599, DOI 10.1016/j.ophtha.2006.06.057
   Mathenge W, 2013, PLOS MED, V10, DOI 10.1371/journal.pmed.1001393
   Mathenge W, 2012, OPHTHALMOLOGY, V119, P2033, DOI 10.1016/j.ophtha.2012.04.019
   Mathers CD, 2006, PLOS MED, V3, DOI 10.1371/journal.pmed.0030442
   Mbulaiteye SM, 2003, BRIT J OPHTHALMOL, V87, P829, DOI 10.1136/bjo.87.7.829
   Mbulaiteye SM, 2002, OPHTHAL EPIDEMIOL, V9, P251, DOI 10.1076/opep.9.4.251.1509
   Moser CL, 2002, BRIT J OPHTHALMOL, V86, P257, DOI 10.1136/bjo.86.3.257
   Muller A, 2011, OPHTHAL EPIDEMIOL, V18, P103, DOI 10.3109/09286586.2010.545932
   Munoz B, 2005, ARCH OPHTHALMOL-CHIC, V123, P1575, DOI 10.1001/archopht.123.11.1575
   Ngondi J, 2006, PLOS MED, V3, P2416, DOI 10.1371/journal.pmed.0030477
   Ntim-Amponsah CT, 2004, EYE, V18, P491, DOI 10.1038/sj.eye.6700674
   Oye JE, 2006, BRIT J OPHTHALMOL, V90, P538, DOI 10.1136/bjo.2005.082271
   Oye JE, 2007, BRIT J OPHTHALMOL, V91, P1435, DOI 10.1136/bjo.2007.115840
   Pascolini D, 2012, BRIT J OPHTHALMOL, V96, P614, DOI 10.1136/bjophthalmol-2011-300539
   Quigley HA, 2006, BRIT J OPHTHALMOL, V90, P262, DOI 10.1136/bjo.2005.081224
   Quigley HA, 2000, BRIT J OPHTHALMOL, V84, P860, DOI 10.1136/bjo.84.8.860
   Rabiu M Mansur, 2008, West Afr J Med, V27, P238
   Rabiu MM, 2008, OPHTHAL EPIDEMIOL, V15, P359, DOI 10.1080/09286580802399078
   Resnikoff S, 2012, BRIT J OPHTHALMOL, V96, P783, DOI 10.1136/bjophthalmol-2011-301378
   Rotchford AP, 2003, OPHTHALMOLOGY, V110, P376, DOI 10.1016/S0161-6420(02)01568-3
   Rotchford AP, 2002, ARCH OPHTHALMOL-CHIC, V120, P471, DOI 10.1001/archopht.120.4.471
   Rotchford AP, 2002, SAMJ S AFR MED J, V92, P536
   Rotimi Charles, 2003, Ethnicity & Disease, V13
   SALMON JF, 1994, S AFR MED J, V84, P623
   SHAMOON H, 1993, NEW ENGL J MED, V329, P977, DOI 10.1056/nejm199309303291401
   SOMMER A, 1991, NEW ENGL J MED, V325, P1412, DOI 10.1056/NEJM199111143252004
   Tapp RJ, 2006, DIABETES RES CLIN PR, V73, P298, DOI 10.1016/j.diabres.2006.02.009
   TIELSCH JM, 1991, JAMA-J AM MED ASSOC, V266, P369, DOI 10.1001/jama.266.3.369
   TIELSCH JM, 1991, AM J EPIDEMIOL, V134, P1102, DOI 10.1093/oxfordjournals.aje.a116013
   Varma R, 2010, AM J OPHTHALMOL, V149, P741, DOI 10.1016/j.ajo.2010.01.009
   Vingerling JR, 1996, ARCH OPHTHALMOL-CHIC, V114, P1193, DOI 10.1001/archopht.1996.01100140393005
   Williams R, 2004, EYE, V18, P963, DOI 10.1038/sj.eye.6701476
   World Health Organization, 1988, COD INSTR WHO PBL EY, V88, P1
   Yasuda M, 2009, OPHTHALMOLOGY, V116, P2135, DOI 10.1016/j.ophtha.2009.04.017
   Yemane Berhane, 2007, Ethiopian Journal of Health Development, V21, P204
NR 89
TC 16
Z9 16
U1 0
U2 17
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1360-2276
EI 1365-3156
J9 TROP MED INT HEALTH
JI Trop. Med. Int. Health
PD MAY
PY 2014
VL 19
IS 5
BP 600
EP 609
DI 10.1111/tmi.12276
PG 10
WC Public, Environmental & Occupational Health; Tropical Medicine
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Public, Environmental & Occupational Health; Tropical Medicine
GA AE4VS
UT WOS:000333984600015
PM 24479434
OA Green Published, Green Accepted, hybrid
DA 2022-11-30
ER

PT J
AU Biesemeier, A
   Schraermeyer, U
   Eibl, O
AF Biesemeier, Antje
   Schraermeyer, Ulrich
   Eibl, Oliver
TI Chemical composition of melanosomes, lipofuscin and melanolipofuscin
   granules of human RPE tissues
SO EXPERIMENTAL EYE RESEARCH
LA English
DT Article
DE chemical composition; melanolipofuscin; lipofuscin; melanosome;
   energy-dispersive X-ray microanalysis; electron energy loss
   spectroscopy; energy-filtered TEM
ID RETINAL-PIGMENT EPITHELIUM; X-RAY-MICROANALYSIS; AGE PIGMENT; OCULAR
   MELANIN; VITAMIN-E; FLUORESCENCE; CELLS; EYES; PHOTOTOXICITY;
   ACCUMULATION
AB Energy-filtered analytical transmission electron microscopy was used to image the ultrastructure and determine quantitatively the chemical composition of pigment granules of the choroid and retinal pigment epithelium of two healthy human donors, aged 68 and 85 years. The electron microscopy preparation procedure did not affect the autofluorescence of melanolipofuscin and lipofuscin granules, since staining was omitted during sample preparation. Oval melanosomes, melanolipofuscin and lipofuscin granules were observed, having sizes of about 1.5 mu m x 0.5 mu m, and were analyzed using energy-dispersive X-ray microanalysis and electron energy loss spectroscopy. Up to now, these pigments could only be identified by scattering contrast in bright field images, with melanosomes having dark contrast and lipofuscin being much brighter. High-precision energy-dispersive X-ray microanalysis of pigment granules (>15,000 integrated counts in the oxygen K(alpha) peak) yielded minimum detectable mole fractions of about 0.02 at% for copper and zinc. For the first time, quantitative analytical electron microscopy yielded the chemical composition of the different pigments without prior isolation from the tissue. This is important to better understand physical and chemical properties of the pigments and their metabolism and turnover.
   The composition of melanosomes and lipofuscin can clearly be distinguished by the applied methods. Melanosomes were the pigments with largest oxygen (about 5 at%) and nitrogen (about 10 at%) mole fractions. The S/N ratio determination demonstrated a high pheomelanin content of the melanosomes. Lipofuscin had a significantly smaller oxygen mole fraction (about 4 at%) and nitrogen was found to be only slightly above the limit of detection (0.4 at%). For comparison, the cytoplasm contained oxygen and nitrogen mole fractions of 3 at% and 0.8 at%. Bright field images showed melanolipofuscin granules having a core-shell structure with a dark inner and a bright outer fraction. The dark fraction had a chemical composition close to the melanosomes and the composition of the bright fraction could be distinguished from that of lipofuscin due to a significantly increased nitrogen mole fraction in the melanolipofuscin granule. For all pigments observed the oxygen mole fraction yielded a positive correlation with the calcium mole fraction as previously established for melanosomes. Only lipofuscin contained measurable phosphorus mole fractions, which also correlated positively with oxygen.
   In lipofuscin, mole fractions of nitrogen were significantly smaller than in melanosomes and only indicated a small fraction of proteins. In contrast, the phosphorus mole fraction was significantly larger indicating the presence of significant amounts of phospholipids.
   Copper and zinc mole fractions were larger than 0.1 at% in the melanosomes, but were below the detection limit in the lipofuscin granules. Compared to melanosomes of monkeys and rats analyzed beforehand, human retinal pigment epithelium melanosomes contained the highest amount of zinc, which even exceeded the calcium mole fraction. Trace elements like zinc are of great importance for metabolism and anti-oxidative mechanisms and also play a role in the progression of age related macular degeneration. They can now be investigated by quantitative analytical electron microscopy. (C) 2011 Elsevier Ltd. All rights reserved.
C1 [Biesemeier, Antje; Eibl, Oliver] Univ Tubingen, Inst Appl Phys, D-72076 Tubingen, Germany.
   [Biesemeier, Antje] Univ Eye Hosp, Dept Expt Vitreoretinal Surg, D-72076 Tubingen, Germany.
C3 Eberhard Karls University of Tubingen; Eberhard Karls University of
   Tubingen; Eberhard Karls University Hospital
RP Biesemeier, A (通讯作者)，Univ Eye Hosp, Dept Expt Vitreoretinal Surg, Schleichstr 12-1, D-72076 Tubingen, Germany.
EM antje.biesemeier@uni-tuebingen.de;
   ulrich.schraermeyer@med.uni-tuebingen.de; oliver.eibl@uni-tuebingen.de
OI Biesemeier, Antje/0000-0002-3462-8803
FU fortune program [1957-0-0]
FX Special thanks to Sigrid Schultheiss for excellent technical assistance.
   This work was funded by the fortune program (1957-0-0).
CR BAZAN HEP, 1990, INVEST OPHTH VIS SCI, V31, P1433
   BIESEMEIER A, 2011, MICRON          0125
   BJORKERUD S, 1964, Adv Gerontol Res, V21, P257
   Boulton M, 2004, GRAEF ARCH CLIN EXP, V242, P76, DOI 10.1007/s00417-003-0812-8
   Brunk UT, 2002, FREE RADICAL BIO MED, V33, P611, DOI 10.1016/S0891-5849(02)00959-0
   Bush WD, 2007, PIGM CELL RES, V20, P134, DOI 10.1111/j.1600-0749.2007.00362.x
   Chen KG, 2006, P NATL ACAD SCI USA, V103, P9903, DOI 10.1073/pnas.0600213103
   Chi A, 2006, J PROTEOME RES, V5, P3135, DOI 10.1021/pr060363j
   DELORI FC, 1995, INVEST OPHTH VIS SCI, V36, P718
   Egerton R.F., 2011, ELECT ENERGY LOSS SP
   Eibl O, 2006, MICRON, V37, P262, DOI 10.1016/j.micron.2005.08.006
   ELDRED GE, 1989, FREE RADICAL BIO MED, V7, P157, DOI 10.1016/0891-5849(89)90007-5
   ELDRED GE, 1993, NATURE, V361, P724, DOI 10.1038/361724a0
   ELDRED GE, 1982, SCIENCE, V216, P757, DOI 10.1126/science.7079738
   FEENEYBURNS L, 1984, INVEST OPHTH VIS SCI, V25, P195
   FEENEYBURNS L, 1988, INVEST OPHTH VIS SCI, V29, P708
   FEENEYBURNS L, 1983, T OPHTHAL SOC UK, V103, P416
   Framme C, 2004, CURR EYE RES, V29, P287, DOI 10.1080/02713680490516846
   Haralampus-Grynaviski NM, 2001, PHOTOCHEM PHOTOBIOL, V74, P364, DOI 10.1562/0031-8655(2001)074<0364:PTSDOT>2.0.CO;2
   HESS HH, 1975, EXP EYE RES, V21, P471, DOI 10.1016/0014-4835(75)90128-1
   Holz FG, 1999, OPHTHALMOLOGE, V96, P781, DOI 10.1007/s003470050496
   Hong L, 2007, J PHYS CHEM B, V111, P7938, DOI 10.1021/jp071439h
   INCA, 2001, MICR SUIT
   ITO S, 1985, ANAL BIOCHEM, V144, P527, DOI 10.1016/0003-2697(85)90150-2
   JELLINGER K, 1992, J NEUROCHEM, V59, P1168, DOI 10.1111/j.1471-4159.1992.tb08362.x
   JIMBOW K, 1984, CANCER RES, V44, P1128
   Jolly RD, 1995, GERONTOLOGY, V41, P283
   Jung T, 2007, ANN NY ACAD SCI, V1119, P97, DOI 10.1196/annals.1404.008
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1439, DOI 10.1001/archopht.119.10.1439
   KATZ ML, 1986, EXP EYE RES, V43, P561, DOI 10.1016/S0014-4835(86)80023-9
   KATZ ML, 1989, MECH AGEING DEV, V49, P23, DOI 10.1016/0047-6374(89)90065-1
   KATZ ML, 1989, ADV EXP MED BIOL, V266, P109
   KATZ ML, 1984, MECH AGEING DEV, V25, P149, DOI 10.1016/0047-6374(84)90137-4
   KATZ ML, 1989, ADV EXP MED BIOL, V266, P116
   Lengyel I, 2007, EXP EYE RES, V84, P772, DOI 10.1016/j.exer.2006.12.015
   Liu Y, 2005, PHOTOCHEM PHOTOBIOL, V81, P510, DOI 10.1562/2004-10-19-RA-345.1
   Ng KP, 2008, MOL CELL PROTEOMICS, V7, P1397, DOI 10.1074/mcp.M700525-MCP200
   NOVELLINO E, 1981, FEBS LETT, V125, P101, DOI 10.1016/0014-5793(81)81006-X
   PANESSA BJ, 1981, EXP EYE RES, V32, P593, DOI 10.1016/S0014-4835(81)80008-5
   Prota G, 1998, EXP EYE RES, V67, P293, DOI 10.1006/exer.1998.0518
   Roberts JE, 2002, INT J TOXICOL, V21, P491, DOI 10.1080/10915810290169918
   Rozanowski B, 2008, PHOTOCHEM PHOTOBIOL, V84, P650, DOI 10.1111/j.1751-1097.2007.00259.x
   SALCEDA R, 1990, PIGM CELL RES, V3, P141, DOI 10.1111/j.1600-0749.1990.tb00278.x
   SAMUELSON DA, 1993, EXP EYE RES, V56, P63, DOI 10.1006/exer.1993.1009
   SARNA T, 1992, J PHOTOCH PHOTOBIO B, V12, P215, DOI 10.1016/1011-1344(92)85027-R
   SCHRAERMEYER U, 1994, CELL TISSUE RES, V276, P273, DOI 10.1007/BF00306113
   Schutt F, 2003, INVEST OPHTH VIS SCI, V44, P3663, DOI 10.1167/iovs.03-0172
   Schutt F, 2002, FEBS LETT, V528, P217, DOI 10.1016/S0014-5793(02)03312-4
   SEALY RC, 1982, SCIENCE, V217, P545, DOI 10.1126/science.6283638
   Simon JD, 2010, ACCOUNTS CHEM RES, V43, P1452, DOI 10.1021/ar100079y
   *SOFT IM SYST GMBH, 2002, ES S
   Sparrow JR, 2010, J LIPID RES, V51, P247, DOI 10.1194/jlr.R000687
   ULSHAFER RJ, 1990, ARCH OPHTHALMOL-CHIC, V108, P113, DOI 10.1001/archopht.1990.01070030119041
   VANDERSCHAFT TL, 1992, ARCH OPHTHALMOL-CHIC, V110, P389, DOI 10.1001/archopht.1992.01080150087034
   Warburton S, 2005, MOL VIS, V11, P1122
   Warburton S, 2007, MOL VIS, V13, P318
   Ward WC, 2007, PIGM CELL RES, V20, P61, DOI 10.1111/j.1600-0749.2006.00357.x
   Williams D.B., 2009, TRANSMISSION ELECT M, VII
   Wong RW, 2007, RETINA-J RET VIT DIS, V27, P997, DOI 10.1097/IAE.0b013e318074c290
   Yin DZ, 1996, FREE RADICAL BIO MED, V21, P871, DOI 10.1016/0891-5849(96)00175-X
   YIN DZ, 1991, MECH AGEING DEV, V59, P95, DOI 10.1016/0047-6374(91)90076-C
   Zecca L, 2008, P NATL ACAD SCI USA, V105, P17567, DOI 10.1073/pnas.0808768105
   ZUMGOTTESBERGE AMM, 1988, PIGM CELL RES, V1, P238
NR 63
TC 39
Z9 40
U1 0
U2 16
PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 0014-4835
J9 EXP EYE RES
JI Exp. Eye Res.
PD JUL
PY 2011
VL 93
IS 1
BP 29
EP 39
DI 10.1016/j.exer.2011.04.004
PG 11
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 796HK
UT WOS:000293042200004
PM 21524648
DA 2022-11-30
ER

PT J
AU Wang, HB
   Han, XK
   Wittchen, ES
   Hartnett, ME
AF Wang, Haibo
   Han, Xiaokun
   Wittchen, Erika S.
   Hartnett, M. Elizabeth
TI TNF-alpha mediates choroidal neovascularization by upregulating VEGF
   expression in RPE through ROS-dependent beta-catenin activation
SO MOLECULAR VISION
LA English
DT Article
ID MACULAR DEGENERATION; NADPH OXIDASE; MODEL; MACROPHAGES; CELLS
AB Purpose: Inflammation, oxidative stress, and angiogenesis have been proposed to interact in age-related macular degeneration. It has been postulated that external stimuli that cause oxidative stress can increase production of vascular endothelial growth factor (VEGF) in retinal pigment epithelial (RPE) cells. In this study, we tested the hypothesis that the inflammatory cytokine, tumor necrosis factor alpha (TNF-alpha), contributed to choroidal neovascularization (CNV) by upregulating VEGF in RPE through intracellular reactive oxygen species (ROS)-dependent signaling and sought to understand the mechanisms involved.
   Methods: In a murine laser-induced CNV model, 7 days after laser treatment and intravitreal neutralizing mouse TNF-alpha antibody or isotype immunoglobulin G (IgG) control, the following measurements were made: 1) TNF-alpha protein and VEGF protein in RPE/choroids with western blot, 2) CNV volume in RPE/choroidal flatmounts, and 3) semiquantification of oxidized phospholipids stained with E06 antibody within CNV with immunohistochemistry (IHC). In cultured human RPE cells treated with TNF-alpha or PBS control, 1) ROS generation was measured using the 2',7'-dichlorodihydrofluorescein diacetate (DCFDA) fluorescence assay, and 2) NOX4 protein and VEGF protein or mRNA were measured with western blot or quantitative real-time PCR in cells pretreated with apocynin or nicotinamide adenine dinucleotide phosphate-oxidase (NADPH) inhibitor, VAS 2870, or transfected with p22phox siRNA, and each was compared to its appropriate control. Western blots of phosphorylated p65 (p-p65), total p65 and beta-actin, and quantitative real-time PCR of VEGF mRNA were measured in human RPE cells treated with TNF-alpha and pretreatment with the nuclear factor kappa B inhibitor, Bay 11-7082 or control. Western blots of beta-catenin, VEGF, and p22phox and coimmunoprecipitation of beta-catenin and T-cell transcriptional factor were performed in human RPE cells treated with TNF-alpha following pretreatment with beta-catenin transcriptional inhibitors, XAV939 or JW67, or transfection with p22phox siRNA and compared to appropriate controls.
   Results: Compared to the non-lasered control, TNF-alpha and VEGF protein were increased in the RPE/choroids in a murine laser-induced CNV model (p<0.05). An intravitreal neutralizing antibody to mouse TNF-alpha reduced CNV volume, and VEGF protein in the RPE/choroids (p<0.01) and oxidized phospholipids within CNV compared to IgG control (p<0.05). In cultured RPE cells and compared to controls, TNF-alpha induced ROS generation and increased activation of NOX4, an isoform of NADPH oxidase; both were prevented by pretreatment with the apocynin or VAS2870 or knockdown of p22phox, a subunit of NADPH oxidase. TNF-alpha treatment increased VEGF expression (p<0.001) and the formation of a transcriptional complex of beta-catenin and T-cell transcriptional factor; both were prevented by pretreatment with apocynin or knockdown of p22phox. Inhibition of beta-catenin by XAV939, but not the nuclear factor kappa B inhibitor, Bay 11-7082, prevented TNF-alpha-induced VEGF upregulation.
   Conclusions: Our results support the thinking that TNF-alpha contributes to CNV by upregulating VEGF production in RPE cells through ROS-dependent activation of beta-catenin signaling. These results provide mechanisms of crosstalk between inflammatory mediator, TNF-alpha, and ROS in RPE cells.
C1 [Wang, Haibo; Han, Xiaokun; Hartnett, M. Elizabeth] Univ Utah, John Moran Eye Ctr, Salt Lake City, UT USA.
   [Wittchen, Erika S.] Univ N Carolina, Cell Biol & Physiol, Chapel Hill, NC USA.
   [Han, Xiaokun] China Med Univ, Affiliated Hosp 4, Dept Ophthalmol, Shenyang 110001, Peoples R China.
C3 Utah System of Higher Education; University of Utah; University of North
   Carolina; University of North Carolina Chapel Hill; China Medical
   University
RP Hartnett, ME (通讯作者)，65 N Mario Capecchi Dr, Salt Lake City, UT 84132 USA.
EM ME.Hartnett@hsc.utah.edu
FU National Institutes of Health [EY014800, R01EY015130, R01EY017011];
   March of Dimes [6-FY13-75]; Knights Templar Eye Foundation, Inc.;
   Research to Prevent Blindness, Inc., New York, NY; NATIONAL EYE
   INSTITUTE [R01EY015130, R01EY017011, P30EY014800] Funding Source: NIH
   RePORTER
FX This work was supported by the National Institutes of Health EY014800,
   R01EY015130 and R01EY017011 to M.E.H., a grant from the March of Dimes
   6-FY13-75 to M.E.H, a grant from the Knights Templar Eye Foundation,
   Inc. to H.W and an Unrestricted Grant from Research to Prevent
   Blindness, Inc., New York, NY, to the Department of Ophthalmology &
   Visual Sciences, University of Utah.
CR Apte RS, 2006, PLOS MED, V3, P1371, DOI 10.1371/journal.pmed.0030310
   Bazan NG, 1999, INVEST OPHTH VIS SCI, V40, pS10
   Bird AC, 2010, J CLIN INVEST, V120, P3033, DOI 10.1172/JCI42437
   Blasiak J, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/768026
   Gehrs KM, 2006, ANN MED, V38, P450, DOI 10.1080/07853890600946724
   Geltzer A, 2013, COCHRANE DB SYST REV, V1
   Hageman GS, 2005, P NATL ACAD SCI USA, V102, P7227, DOI 10.1073/pnas.0501536102
   Haller JA, 2013, OPHTHALMOLOGY, V120, pS3, DOI 10.1016/j.ophtha.2013.01.057
   Hartnett ME, 1996, OPHTHALMOLOGY, V103, P58, DOI 10.1016/S0161-6420(96)30731-8
   Holekamp NM, 2014, AM J OPHTHALMOL, V157, P825, DOI 10.1016/j.ajo.2013.12.018
   Huang SMA, 2009, NATURE, V461, P614, DOI 10.1038/nature08356
   Joussen AM, 2009, DTSCH ARZTEBL INT, V106, P312, DOI 10.3238/arztebl.2009.0312
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Li QH, 2008, MOL THER, V16, P1688, DOI 10.1038/mt.2008.164
   Lichtlen P, 2010, INVEST OPHTH VIS SCI, V51, P4738, DOI 10.1167/iovs.09-4890
   Markomichelakis NN, 2005, AM J OPHTHALMOL, V139, P537, DOI 10.1016/j.ajo.2004.09.058
   Monaghan-Benson E, 2010, AM J PATHOL, V177, P2091, DOI 10.2353/ajpath.2010.090878
   Oh H, 1999, INVEST OPHTH VIS SCI, V40, P1891
   Sakurai E, 2003, INVEST OPHTH VIS SCI, V44, P3578, DOI 10.1167/iovs.03-0097
   Semenza GL, 1999, ANN NY ACAD SCI, V874, P262, DOI 10.1111/j.1749-6632.1999.tb09241.x
   Telander DG, 2011, SEMIN OPHTHALMOL, V26, P192, DOI 10.3109/08820538.2011.570849
   Terasaki H, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069994
   Theodossiadis PG, 2009, AM J OPHTHALMOL, V147, P825, DOI 10.1016/j.ajo.2008.12.004
   Valenta T, 2012, EMBO J, V31, P2714, DOI 10.1038/emboj.2012.150
   Waaler J, 2011, CANCER RES, V71, P197, DOI 10.1158/0008-5472.CAN-10-1282
   Wang HB, 2014, MOL VIS, V20, P231
   Wang H, 2011, INVEST OPHTH VIS SCI, V52, P570, DOI 10.1167/iovs.10-5595
   Zhou T, 2010, INVEST OPHTH VIS SCI, V51, P4371, DOI 10.1167/iovs.09-4278
NR 28
TC 83
Z9 89
U1 1
U2 14
PU MOLECULAR VISION
PI ATLANTA
PA C/O JEFF BOATRIGHT, LAB B, 5500 EMORY EYE CENTER, 1327 CLIFTON RD, N E,
   ATLANTA, GA 30322 USA
SN 1090-0535
J9 MOL VIS
JI Mol. Vis.
PD FEB 3
PY 2016
VL 22
BP 116
EP 128
PG 13
WC Biochemistry & Molecular Biology; Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Ophthalmology
GA DC4GK
UT WOS:000369178500001
PM 26900328
DA 2022-11-30
ER

PT J
AU Trieschmann, M
   Beatty, S
   Nolan, JM
   Hense, HW
   Heimes, B
   Austermann, U
   Fobker, M
   Pauleikhoff, D
AF Trieschmann, Meike
   Beatty, Stephen
   Nolan, John M.
   Hense, Hans Werner
   Heimes, Britta
   Austermann, Ulrike
   Fobker, Manfred
   Pauleikhoff, Daniel
TI Changes in macular pigment optical density and serum concentrations of
   its constituent carotenoids following supplemental lutein and
   zeaxanthin: The LUNA study
SO EXPERIMENTAL EYE RESEARCH
LA English
DT Article
DE age-related macular degeneration; lutein; macular pigment; Ocuvite
   Lutein (TM); zeaxanthin
ID AGE-RELATED MACULOPATHY; 3RD NATIONAL-HEALTH; IN-VIVO; TISSUE
   CONCENTRATIONS; PLASMA; DEGENERATION; DIET; NUTRITION; ANTIOXIDANTS;
   POPULATION
AB Macular pigment (MP), consisting of lutein (L) and zeaxanthin (Z), is believed to protect the retina from photo-oxidative damage. The current study investigates, in terms of MP optical density (MPOD) and serum concentrations of its constituent carotenoids, response to supplemental L and Z, and co-antioxidants. An intervention (I) group, consisting of 108 subjects (mean [+/- SD] age: 71.5 [+/- 7.1] years), of which 92.6% exhibited features of age-related macular degeneration (AMD), received a daily supplement consisting of 12 mg L and 1 mg Z, both provided as ester 120 mg vitamin C, 17.6 mg vitamin E, 10 mg zinc, 40 mu g selenium (Ocuvite Lutein (TM)) for a period of 6 months. MPOD was measured, by 2-wavelength autofluorescence (AF), on five occasions during the period of supplementation, and once again 3 months following discontinuation of the supplement. A control (C) group of 28 subjects (mean [+/- SD] age: 71.0 [+/- 8.1] years), who received no dietary supplementation or modification, was examined at baseline and once again after a mean of 29.4 (+/- 9.3) weeks. At baseline, mean (+/- SD) MPOD (at 0.5 degrees) was 0.504 (+/- 0.197) and 0.525 (+/- 0.189) in the I and C groups, respectively. There was a statistically significant increase in MPOD (at 0.5 degrees) for the I group (0.1 [+/- 0.009]; p < 0.0008), whereas no significant increase was seen in the C group (0.03 [+/- 0.02]; p > 0.05), over the period of supplementation. In order to classify supplemented subjects into quartiles, in terms of MPOD response, we calculated the difference between MPOD (at 0.5 degrees) at visit 6 and at baseline (visit 1). Quartile 1 (the "non-responder" quartile) displayed no increase in MPOD (at 0.5 degrees), in spite of rises seen in serum concentrations of L and Z. The three "responder" quartiles reached similar final plateaus of MPOD (at 0.5 degrees), reflected in final mean (+/- SEM) values of 0.59 (+/- 0.04) optical density unit (ODU), 0.64 (+/- 0.03) ODU and 0.64 (+/- 0.03) ODU for quartiles 2, 3 and 4, respectively. Subjects with low baseline MPOD were more likely to exhibit a dramatic rise in MPOD, or to exhibit no rise in MPOD, in response to supplements than subjects with medium to high baseline MPOD values. Supplementation with 12 mg L and I mg Z, combined with co-antioxidants, resulted in an increase of MPOD at 0.5 degrees eccentricity in a majority of subjects, including those afflicted with AMD. However, there remains a substantial proportion of subjects for whom, in spite of rises in serum concentrations of L and Z in these subjects, MPOD augmentation in response to supplemental L, Z and co-antioxidants could not be detected over the study period, thus indicating that intestinal malabsorption of these carotenoids is not responsible for the lack of a macular response to such supplements. Further, our results suggest that saturable mechanisms play a role in the retinal capture and/or stabilisation of the macular carotenoids. (c) 2007 Elsevier Ltd. All rights reserved.
C1 St Franziskus Hosp, Inst Ophthalmol, D-48145 Munster, Germany.
   Waterford Inst Technol, Dept Chem & Life Sci, Macular Pigment Res Grp, Waterford, Ireland.
   Univ Munster, Inst Epidemiol, Munster, Germany.
   Univ Munster, Cent Labs, Munster, Germany.
C3 St. Franziskus-Hospital; South East Technological University (SETU);
   University of Munster; University of Munster
RP Trieschmann, M (通讯作者)，St Franziskus Hosp, Inst Ophthalmol, Hohenzollernring 74, D-48145 Munster, Germany.
EM meiketri@aol.com
RI Nolan, John/N-4921-2014
OI Nolan, John/0000-0002-5503-7084; Heimes-Bussmann,
   Britta/0000-0003-3898-1679
CR Alves-Rodrigues A, 2004, TOXICOL LETT, V150, P57, DOI 10.1016/j.toxlet.2003.10.031
   Beatty S, 2000, SURV OPHTHALMOL, V45, P115, DOI 10.1016/S0039-6257(00)00140-5
   Beatty S, 2001, INVEST OPHTH VIS SCI, V42, P439
   Berendschot TTJM, 2000, INVEST OPHTH VIS SCI, V41, P3322
   Bernstein PS, 1997, INVEST OPHTH VIS SCI, V38, P167
   BONE RA, 1992, VISION RES, V32, P105, DOI 10.1016/0042-6989(92)90118-3
   Bone RA, 2003, J NUTR, V133, P992, DOI 10.1093/jn/133.4.992
   BONE RA, 1988, INVEST OPHTH VIS SCI, V29, P843
   BONE RA, 1984, VISION RES, V24, P103, DOI 10.1016/0042-6989(84)90094-4
   Bone RA, 2000, EXP EYE RES, V71, P239, DOI 10.1006/exer.2000.0870
   Brady WE, 1996, J NUTR, V126, P129, DOI 10.1093/jn/126.1.129
   Broekmans WMR, 2002, AM J CLIN NUTR, V76, P595, DOI 10.1093/ajcn/76.3.595
   Burke JD, 2005, J NUTR, V135, P1208, DOI 10.1093/jn/135.5.1208
   Cardinault N, 2005, CLIN CHIM ACTA, V357, P34, DOI 10.1016/j.cccn.2005.01.030
   Ciulla TA, 2004, AM J OPHTHALMOL, V138, P582, DOI 10.1016/j.ajo.2004.05.057
   Ciulla TA, 2001, OPHTHALMOLOGY, V108, P730, DOI 10.1016/S0161-6420(00)00655-2
   Curran-Celentano J, 2001, AM J CLIN NUTR, V74, P796
   Dachtler M, 2001, ANAL CHEM, V73, P667, DOI 10.1021/ac000635g
   Dasch B, 2005, GRAEF ARCH CLIN EXP, V243, P1028, DOI 10.1007/s00417-005-1176-z
   Delori FC, 2004, ARCH BIOCHEM BIOPHYS, V430, P156, DOI 10.1016/j.abb.2004.05.016
   Delori FC, 2001, J OPT SOC AM A, V18, P1212, DOI 10.1364/JOSAA.18.001212
   Delori FC, 2001, INVEST OPHTH VIS SCI, V42, P1855
   FRANKE AA, 1994, CANCER LETT, V79, P17, DOI 10.1016/0304-3835(94)90057-4
   FRIEDEWALD WT, 1972, CLIN CHEM, V18, P499
   Gale CR, 2003, INVEST OPHTH VIS SCI, V44, P2461, DOI 10.1167/iovs.02-0929
   Gellermann W, 2002, J OPT SOC AM A, V19, P1172, DOI 10.1364/JOSAA.19.001172
   Goulinet S, 1997, ARTERIOSCL THROM VAS, V17, P786, DOI 10.1161/01.ATV.17.4.786
   Gruber M, 2004, J NUTR, V134, P2387, DOI 10.1093/jn/134.9.2387
   Hammond BR, 1996, VISION RES, V36, P2001, DOI 10.1016/0042-6989(95)00290-1
   Hammond BR, 1996, VISION RES, V36, P3003, DOI 10.1016/0042-6989(96)00008-9
   Hammond BR, 1996, EXP EYE RES, V62, P293, DOI 10.1006/exer.1996.0035
   Hammond BR, 2002, INVEST OPHTH VIS SCI, V43, P47
   Hammond BR, 1997, INVEST OPHTH VIS SCI, V38, P1795
   HAMMOND BR, 1995, INVEST OPHTH VIS SCI, V36, P2531
   Jahn C, 2006, OPHTHALMOLOGE, V103, P136, DOI 10.1007/s00347-005-1282-7
   Jahn C, 2005, GRAEF ARCH CLIN EXP, V243, P222, DOI 10.1007/s00417-004-0995-7
   Johnson EJ, 2000, AM J CLIN NUTR, V71, P1555
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Klaver CCW, 1998, ARCH OPHTHALMOL-CHIC, V116, P653, DOI 10.1001/archopht.116.5.653
   Koh HH, 2004, EXP EYE RES, V79, P21, DOI 10.1016/j.exer.2004.03.001
   Landrum JT, 1997, EXP EYE RES, V65, P57, DOI 10.1006/exer.1997.0309
   Liew SHM, 2005, INVEST OPHTH VIS SCI, V46, P4430, DOI 10.1167/iovs.05-0519
   MALINOW MR, 1980, INVEST OPHTH VIS SCI, V19, P857
   Mares-Perlman JA, 2001, AM J EPIDEMIOL, V153, P424, DOI 10.1093/aje/153.5.424
   MARESPERLMAN JA, 1995, ARCH OPHTHALMOL-CHIC, V113, P1518, DOI 10.1001/archopht.1995.01100120048007
   Neuringer M, 2004, INVEST OPHTH VIS SCI, V45, P3234, DOI 10.1167/iovs.02-1243
   Nolan J, 2004, INVEST OPHTH VIS SCI, V45, P3940, DOI 10.1167/iovs.04-0273
   Nolan JM, 2006, CURR EYE RES, V31, P199, DOI 10.1080/02713680500514677
   Parker RS, 1999, P NUTR SOC, V58, P155, DOI 10.1079/PNS19990021
   Richer Stuart, 2004, Optometry, V75, P216, DOI 10.1016/S1529-1839(04)70049-4
   Rock CL, 2002, J NUTR, V132, p525S, DOI 10.1093/jn/132.3.525S
   SEDDON JM, 1994, JAMA-J AM MED ASSOC, V272, P1413, DOI 10.1001/jama.272.18.1413
   Snellen ELM, 2002, ACTA OPHTHALMOL SCAN, V80, P368, DOI 10.1034/j.1600-0420.2002.800404.x
   Sommerburg O, 1999, CURR EYE RES, V19, P491, DOI 10.1076/ceyr.19.6.491.5276
   Stockman A, 2000, METHOD ENZYMOL, V316, P626
   Trieschmann M, 2006, GRAEF ARCH CLIN EXP, V244, P1565, DOI 10.1007/s00417-006-0289-3
   VandenLangenberg GM, 1998, AM J EPIDEMIOL, V148, P204, DOI 10.1093/oxfordjournals.aje.a009625
   Wolf S, 2006, GRAEF ARCH CLIN EXP, V244, P1562, DOI 10.1007/s00417-006-0336-0
   Wustemeyer H, 2003, GRAEF ARCH CLIN EXP, V241, P647, DOI 10.1007/s00417-003-0730-9
   Wustemeyer H, 2002, GRAEF ARCH CLIN EXP, V240, P666, DOI 10.1007/s00417-002-0515-6
   Yemelyanov AY, 2001, EXP EYE RES, V72, P381, DOI 10.1006/exer.2000.0965
NR 61
TC 162
Z9 172
U1 0
U2 33
PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 0014-4835
EI 1096-0007
J9 EXP EYE RES
JI Exp. Eye Res.
PD APR
PY 2007
VL 84
IS 4
BP 718
EP 728
DI 10.1016/j.exer.2006.12.010
PG 11
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 158VC
UT WOS:000245822200014
PM 17306793
DA 2022-11-30
ER

PT J
AU Schottler, J
   Randoll, N
   Lucius, R
   Caliebe, A
   Roider, J
   Klettner, A
AF Schottler, Johann
   Randoll, Niklas
   Lucius, Ralph
   Caliebe, Amke
   Roider, Johann
   Klettner, Alexa
TI Long-term treatment with anti-VEGF does not induce cell aging in primary
   retinal pigment epithelium
SO EXPERIMENTAL EYE RESEARCH
LA English
DT Article
DE Bevacizumab; Ranibizumab; Aflibercept; Rituximab; RPE; Senescence; Aging
ID GROWTH-FACTOR-BETA; MACULAR DEGENERATION; OXIDATIVE STRESS; INTRAVITREAL
   AFLIBERCEPT; ARPE-19 CELLS; AMYLOID-BETA; TGF-BETA; BEVACIZUMAB;
   RANIBIZUMAB; SENESCENCE
AB Anti-Vascular Endothelial Growth Factor (VEGF) therapy is given repeatedly for an extended period of time to patients when treated for age-related macular degeneration. While short-term effects of anti-VEGF agents on retinal pigment epithelial (RPE) cells have been investigated, the effects of long-term and repeated treatment on these cells are scarce. In this study, we have investigated the effects of anti-VEGF treatment after long-term, repeated treatment on cell aging and morphology. The experiments were conducted in primary porcine RPE cells passage one and two. Cells were treated with 125 mu g/ml bevacizumab, ranibizumab, aflibercept or rituximab once a week for 1 day, 4 days, 7 days, 4 weeks and 12 weeks. Cell survival was evaluated with 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide tetrazolium (MTT) and trypan blue exclusion assay. Activity of beta-galactosidase was assessed in a commercially available assay. Influence of these compounds was investigated on the expression of cathepsin D and amyloid B, and the expression and phosphorylation of mechanistic target of rapamycin (mTOR), all proteins involved in senescence and aging, in Western blot. The secretion of Pigment Epithelium Derived Factor (PEDF) and Transforming Growth Factor (TGF)-beta was investigated in Enzyme-linked Immunosorbent Assay (ELISA). The cellular morphology was investigated with electron microscopy, investigating the number and area of mitochondria and autophagosomes. Statistical analysis was conducted using a mixed linear model. Weekly treatment up to 12 weeks displayed no toxic effects on RPE cells in any of the substances tested. Ranibizumab showed a significant increase in beta-galactosidase signal on day 4 (p < 0.05) and 7 (p < 0.05) after treatment. In long-term, however, ranibizumab displayed no significant difference to untreated cells. Bevacizumab displayed a significant reduction of the beta-galactosidase signal after 12 weeks (p < 0.05). Aflibercept significantly decreased beta-galactosidase after 1 day (p < 0.01) and 12 weeks (p < 0.05). Rituximab and bevacizumab also decreased beta-galactosidase signal after 12 weeks (p < 0.05). The expression of mTOR, phospho-mTOR, amyloid beta and cathepsin D was not significantly altered by any of the compounds tested. RPE cells secreted considerate amounts of TGF-beta. Bevacizumab treated cells showed significantly lower TGF-beta secretion than ranibizumab and rituximab (p < 0.05). In contrast, only small amounts of PEDF were secreted which were not altered by any substance tested. Ultrastructural analysis showed no alterations in mitochondria after long-term treatment with either substance. Autophagosomes were not reduced by long-term anti-VEGF treatment compared to control. However, the area of autophagosomes in bevacizumab and aflibercept treated cells was significantly less compared to both ranibizumab and rituximab treated cells (all p < 0.05). Taken together, weekly treatment with VEGF-antagonists up to 3 months does not induce premature aging in primary RPE cells in any tested compound. A significant difference can be found between bevacizumab and aflibercept on the one hand, and ranibizumab (and rituximab) on the other hand, with more autophagosomal area in ranibizumab and (rituximab). Taken together, our data provide indications for long-term safety of anti-VEGF compounds. Further research is warranted.
C1 [Schottler, Johann; Randoll, Niklas; Roider, Johann; Klettner, Alexa] Univ Kiel, Univ Med Ctr, Dept Ophthalmol, Arnold Heller Str 3,Haus 25, D-24105 Kiel, Germany.
   [Lucius, Ralph] Univ Kiel, Dept Anat, Kiel, Germany.
   [Caliebe, Amke] Univ Kiel, Biomed Stat, Kiel, Germany.
C3 University of Kiel; Schleswig Holstein University Hospital; University
   of Kiel; University of Kiel
RP Klettner, A (通讯作者)，Univ Kiel, Univ Med Ctr, Dept Ophthalmol, Arnold Heller Str 3,Haus 25, D-24105 Kiel, Germany.
EM AlexaKarina.Klettner@uksh.de
RI Klettner, Alexa Karina/M-8344-2018; Lucius, Ralph/B-1614-2010
OI Caliebe, Amke/0000-0003-0340-9154; Klettner, Alexa/0000-0002-2709-1059
FU Novartis Pharma research grant; Hermann-Wacker foundation
FX This study was funded by a Novartis Pharma research grant. AK is funded
   by the Hermann-Wacker foundation.
CR Abdelfattah NS, 2016, RETINA-J RET VIT DIS, V36, P1843, DOI 10.1097/IAE.0000000000001059
   Akkoyun I, 2012, ACTA OPHTHALMOL, V90, P564, DOI 10.1111/j.1755-3768.2010.01963.x
   Anderson DH, 2004, EXP EYE RES, V78, P243, DOI 10.1016/j.exer.2003.10.011
   [Anonymous], 2021, R LANGUAGE ENV STAT
   Arevalo J. F., 2016, BR J OPHTHALMOL, DOI [10.1136/bjophthalmo1-2015-307950, DOI 10.1136/BJOPHTHALMO1-2015-307950]
   Arevalo JF, 2016, RETINA-J RET VIT DIS, V36, P859, DOI 10.1097/IAE.0000000000000827
   Bai H, 2017, STEM CELL TRANSL MED, V6, P589, DOI 10.5966/sctm.2016-0089
   Barnstable CJ, 2004, PROG RETIN EYE RES, V23, P561, DOI 10.1016/j.preteyeres.2004.05.002
   Benjamini Y, 2006, BIOMETRIKA, V93, P491, DOI 10.1093/biomet/93.3.491
   Bergamini E, 2007, ANN NY ACAD SCI, V1114, P69, DOI 10.1196/annals.1396.020
   Bhisitkul RB, 2015, AM J OPHTHALMOL, V159, P915, DOI 10.1016/j.ajo.2015.01.032
   Blagosklonny MV, 2006, CELL CYCLE, V5, P2087, DOI 10.4161/cc.5.18.3288
   Brown DM, 2013, OPHTHALMOLOGY, V120, P2013, DOI 10.1016/j.ophtha.2013.02.034
   Byun HO, 2009, CANCER RES, V69, P4638, DOI 10.1158/0008-5472.CAN-08-4042
   Cao LN, 2013, INVEST OPHTH VIS SCI, V54, P3738, DOI 10.1167/iovs.13-11612
   Cedikova M, 2016, PHYSIOL RES, V65, pS519, DOI 10.33549/physiolres.933538
   Chen Y, 2010, INVEST OPHTH VIS SCI, V51, P5314, DOI 10.1167/iovs.10-5280
   Cho S, 2012, MOL CELLS, V33, P597, DOI 10.1007/s10059-012-0042-1
   Coppe JP, 2008, PLOS BIOL, V6, P2853, DOI 10.1371/journal.pbio.0060301
   De Cilla S, 2017, CELL PHYSIOL BIOCHEM, V42, P1725, DOI 10.1159/000479441
   DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363
   Ding JD, 2011, P NATL ACAD SCI USA, V108, pE279, DOI 10.1073/pnas.1100901108
   Dithmer M, 2016, EXP EYE RES, V145, P187, DOI 10.1016/j.exer.2015.12.013
   Feher J, 2006, NEUROBIOL AGING, V27, P983, DOI 10.1016/j.neurobiolaging.2005.05.012
   Gerding H, 2016, KLIN MONATSBL AUGENH, V233, P471, DOI 10.1055/s-0041-111835
   Glotin AL, 2008, FREE RADICAL BIO MED, V44, P1348, DOI 10.1016/j.freeradbiomed.2007.12.023
   Gu XR, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038673
   Halicka HD, 2012, AGING-US, V4, P952, DOI 10.18632/aging.100521
   He Y, 2014, INVEST OPHTH VIS SCI, V55, DOI 10.1167/iovs.14-14696
   He Y, 2010, ADV EXP MED BIOL, V664, P165, DOI 10.1007/978-1-4419-1399-9_20
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Hillenkamp J, 2010, RETINA-J RET VIT DIS, V30, P1685, DOI 10.1097/IAE.0b013e3181d87eb4
   Holtkamp GM, 2001, PROG RETIN EYE RES, V20, P29, DOI 10.1016/S1350-9462(00)00017-3
   Hwang ES, 2009, CELL MOL LIFE SCI, V66, P2503, DOI 10.1007/s00018-009-0034-2
   Inan UU, 2007, INVEST OPHTH VIS SCI, V48, P1773, DOI 10.1167/iovs.06-0828
   Johnson LV, 2002, P NATL ACAD SCI USA, V99, P11830, DOI 10.1073/pnas.192203399
   Kivinen N., 2014, J BIOCHM PHARM RES, V2, P44
   Klein R, 2004, AM J OPHTHALMOL, V137, P486, DOI 10.1016/j.ajo.2003.11.069
   Klettner A, 2001, MOL BRAIN RES, V97, P21, DOI 10.1016/S0169-328X(01)00286-8
   Klettner A, 2008, INVEST OPHTH VIS SCI, V49, P4523, DOI 10.1167/iovs.08-2055
   Klettner A, 2014, GRAEF ARCH CLIN EXP, V252, P1593, DOI 10.1007/s00417-014-2719-y
   Klettner A, 2014, BRIT J OPHTHALMOL, V98, P1448, DOI 10.1136/bjophthalmol-2014-305105
   Klettner A, 2010, GRAEF ARCH CLIN EXP, V248, P819, DOI 10.1007/s00417-010-1317-x
   Klettner AK, 2009, GRAEF ARCH CLIN EXP, V247, P1601, DOI 10.1007/s00417-009-1136-0
   Korobelnik JF, 2014, OPHTHALMOLOGY, V121, P2247, DOI 10.1016/j.ophtha.2014.05.006
   Kozlowski MR, 2012, MED HYPOTHESES, V78, P505, DOI 10.1016/j.mehy.2012.01.018
   KVANTA A, 1994, OPHTHALMIC RES, V26, P361, DOI 10.1159/000267502
   Li YF, 2006, J BIOENERG BIOMEMBR, V38, P283, DOI 10.1007/s10863-006-9052-z
   Li ZY, 2016, AGING-US, V8, P2337, DOI 10.18632/aging.101050
   Lois N, 2013, RETINA-J RET VIT DIS, V33, P13, DOI 10.1097/IAE.0b013e3182657fff
   Malik D, 2014, BRIT J OPHTHALMOL, V98, P11, DOI 10.1136/bjophthalmol-2014-305302
   Matsunaga H, 1999, INVEST OPHTH VIS SCI, V40, P197
   Mishima K, 1999, INVEST OPHTH VIS SCI, V40, P1590
   Mitchell P, 2014, AM J OPHTHALMOL, V157, P505, DOI 10.1016/j.ajo.2013.11.012
   Mitter SK, 2014, AUTOPHAGY, V10, P1989, DOI 10.4161/auto.36184
   Naga SHA, 2015, EXP EYE RES, V131, P29, DOI 10.1016/j.exer.2014.12.010
   Nave BT, 1999, BIOCHEM J, V344, P427, DOI 10.1042/0264-6021:3440427
   Ohno-Matsui K, 2001, J CELL PHYSIOL, V189, P323, DOI 10.1002/jcp.10026
   Pollard K. S., 2005, BIOINFORMATICS COMPU, P251, DOI DOI 10.1007/0-387-29362-0_15
   Rodier F, 2011, J CELL BIOL, V192, P547, DOI 10.1083/jcb.201009094
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Saenz-de-Viteri M, 2016, BIOCHEM PHARMACOL, V103, P129, DOI 10.1016/j.bcp.2015.12.017
   Saxton RA, 2017, CELL, V168, P960, DOI [10.1016/j.cell.2017.03.035, 10.1016/j.cell.2017.02.004]
   Schmidt-Erfurth U, 2014, BRIT J OPHTHALMOL, V98, P1144, DOI 10.1136/bjophthalmol-2014-305702
   Schnichels S, 2013, BRIT J OPHTHALMOL, V97, P917, DOI 10.1136/bjophthalmol-2013-303130
   Sheu SJ, 2015, ACTA OPHTHALMOL, V93, pE631, DOI 10.1111/aos.12745
   Smith CP, 2007, EXP EYE RES, V85, P817, DOI 10.1016/j.exer.2007.08.017
   Spitzer MS, 2007, GRAEF ARCH CLIN EXP, V245, P1837, DOI 10.1007/s00417-007-0568-7
   Steinle JJ, 2008, J GERONTOL A-BIOL, V63, P135, DOI 10.1093/gerona/63.2.135
   TANIHARA H, 1993, INVEST OPHTH VIS SCI, V34, P413
   Terzi MY, 2016, MOL BIOL REP, V43, P1213, DOI 10.1007/s11033-016-4065-0
   TOMBRANTINK J, 1995, J NEUROSCI, V15, P4992
   Van Kirk CA, 2011, MOL VIS, V17, P1261
   Wakabayashi T, 2002, J CELL MOL MED, V6, P497, DOI 10.1111/j.1582-4934.2002.tb00452.x
   Wang JY, 2012, BIOCHEM BIOPH RES CO, V423, P73, DOI 10.1016/j.bbrc.2012.05.085
   Wiencke AK, 2003, ACTA OPHTHALMOL SCAN, V81, P170, DOI 10.1034/j.1600-0420.2003.00030.x
   Xu SH, 2014, AGING DIS, V5, P263, DOI 10.14336/AD.2014.0500263
   Yoshida T, 2005, J CLIN INVEST, V115, P2793, DOI 10.1172/JCI24635
   Young M, 2014, RETINA-J RET VIT DIS, V34, P1308, DOI 10.1097/IAE.0000000000000081
   Yu AL, 2009, INVEST OPHTH VIS SCI, V50, P926, DOI 10.1167/iovs.07-1003
   Yu B, 2014, INVEST OPHTH VIS SCI, V55, P8638, DOI 10.1167/iovs.14-14758
   Zamiri P, 2005, INVEST OPHTH VIS SCI, V46, P908, DOI 10.1167/iovs.04-0362
   Zhang J, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.330
NR 84
TC 11
Z9 11
U1 0
U2 7
PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 0014-4835
EI 1096-0007
J9 EXP EYE RES
JI Exp. Eye Res.
PD JUN
PY 2018
VL 171
BP 1
EP 11
DI 10.1016/j.exer.2018.03.002
PG 11
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA GH7PN
UT WOS:000433646000001
PM 29522724
DA 2022-11-30
ER

PT J
AU Organisciak, DT
   Darrow, RM
   Rapp, CM
   Smuts, JP
   Armstrong, DW
   Lang, JC
AF Organisciak, Daniel T.
   Darrow, R. M.
   Rapp, C. M.
   Smuts, J. P.
   Armstrong, D. W.
   Lang, J. C.
TI Prevention of retinal light damage by zinc oxide combined with rosemary
   extract
SO MOLECULAR VISION
LA English
DT Article
ID FACTOR-H POLYMORPHISM; OXIDATIVE STRESS; VISIBLE-LIGHT; CARNOSIC ACID;
   VITAMIN-C; DEGENERATION; ANTIOXIDANT; INFLAMMATION; RETINOPATHY;
   INHIBITION
AB Purpose: Zinc oxide effectively reduces visual cell loss in rats exposed to intense visible light and is known to slow the rate of disease progression in advanced stages of age-related macular degeneration. Our goal was to determine the efficacy of zinc oxide in combination with novel and well-established antioxidants in an animal model of light-induced oxidative retinal damage.
   Methods: One group of male Sprague-Dawley rats was pretreated with zinc oxide with or without a detergent extract of rosemary powder and then exposed to intense visible light for 4-24 h. Another group of animals received zinc oxide combined with rosemary oil diluted with a mixture of polyunsaturated fatty acids (ROPUFA) and a third group was given an antioxidant mineral mix containing zinc oxide, as recommended by the Age Related Eye Disease Study group's first clinical trial (AREDS1). Visual cell survival was determined 2 weeks after intense light treatment by measuring rhodopsin and photoreceptor cell DNA levels and confirmed by retinal histology and agarose gel electrophoresis of DNA. Western analysis was used to determine the effects of zinc and antioxidants on the oxidative stress markers, glial fibrillary acidic protein (GFAP), heme-oxygenase-1 (HO-1), and carboxyethylpyrrole (CEP). Rod and cone opsin and arrestin levels were used as markers of photoreceptor cell function.
   Results: Dark-reared rats treated with 1.3 mg/kg zinc oxide and 17 mg/kg rosemary extract, or with one-half those doses, and exposed to moderate intensity green light retained 75%-85% of the rhodopsin and retinal DNA measured in unexposed rats. These levels were significantly higher than found for zinc oxide or rosemary treatment alone. Rosemary oil was also effective when combined with zinc oxide, but ROPUFA alone was no more effective than the detergent vehicle. Prolonged intense green light led to increases in retinal GFAP and HO-1 levels and to decreases in cone cell opsin and rod and cone arrestins. Rosemary plus zinc treatment reduced the expression of oxidative stress protein markers and enhanced visual cell survival, as shown by improved photoreceptor cell morphology and by decreased retinal DNA degradation. Using higher intensity white light for exposures in cyclic light-reared rats, treatment with an AREDS antioxidant/mineral mixture was found to be ineffective, whereas rosemary extract plus an equivalent dose of zinc oxide was significantly more effective in preserving visual cells. CEP protein adduct formation was reduced by all antioxidant treatments, but rosemary plus zinc oxide also prevented the loss of cone cell opsin and arrestin more effectively than AREDS.
   Conclusions: In the rat model of acute retinal light damage, zinc oxide combined with a detergent extract of rosemary powder or rosemary oil is more effective than treatment with either component alone and significantly more effective than an AREDS mixture containing a comparable dose of zinc oxide. Light-induced oxidative stress in animal models of retinal degeneration can be a useful preclinical paradigm for screening novel antioxidants and for testing potential therapeutics designed to slow the progression of age-related ocular disease.
C1 [Organisciak, Daniel T.; Darrow, R. M.; Rapp, C. M.] Wright State Univ, Boonshoft Sch Med, Dept Biochem & Mol Biol, Petticrew Res Lab, Dayton, OH 45435 USA.
   [Smuts, J. P.; Armstrong, D. W.; Lang, J. C.] Univ Texas Arlington, Dept Chem & Biochem, Arlington, TX 76019 USA.
C3 University System of Ohio; Wright State University Dayton; University of
   Texas System; University of Texas Arlington
RP Organisciak, DT (通讯作者)，Wright State Univ, Dept Biochem & Mol Biol, Petticrew Res Lab, 3640 Colonel Glenn Highway, Dayton, OH 45435 USA.
EM dto@wright.edu
RI Armstrong, Daniel/AGX-7301-2022
FU Alcon Research Ltd. Fort Worth TX; Ohio Lions Eye Research Foundation,
   Columbus, OH; International Retina Research Foundation, Birmingham, AL;
   Petticrew Research Laboratory
FX This work was supported by Alcon Research Ltd. Fort Worth TX, the Ohio
   Lions Eye Research Foundation, Columbus, OH, the International Retina
   Research Foundation, Birmingham, AL and funding from the Petticrew
   Research Laboratory. Thanks to Drs. John Crabb, Cheryl Craft, Larry
   Donoso and Krzysztof Palczewski for their generous gifts of antibodies
   used in this study. Special thanks to Linda Barsalou for her help with
   DNA gel electrophoresis. Part of this data was presented (abstract
   #2560) at the ARVO meeting held in Fort Lauderdale, FL in May 2012.
CR ARUOMA OI, 1992, XENOBIOTICA, V22, P257, DOI 10.3109/00498259209046624
   Berrow EJ, 2011, EUR OPHTHAL REV, V5, P143
   Blom AM, 2003, ARCH BIOCHEM BIOPHYS, V418, P108, DOI 10.1016/j.abb.2003.08.018
   Christen WG, 2011, ARCH OPHTHALMOL-CHIC, V129, P921, DOI 10.1001/archophthalmol.2011.34
   Collier RJ, 2011, INVEST OPHTH VIS SCI, V52, P8108, DOI 10.1167/iovs.10-6418
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   Donoso LA, 2006, SURV OPHTHALMOL, V51, P137, DOI 10.1016/j.survophthal.2005.12.001
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Eye Disease Case-Control Study Group, ARCH OPHTHALMOL, V110, p[1992, 1701]
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Hollyfield JG, 2008, NAT MED, V14, P194, DOI 10.1038/nm1709
   Imamura Y, 2006, P NATL ACAD SCI USA, V103, P11282, DOI 10.1073/pnas.0602131103
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Komeima K, 2006, P NATL ACAD SCI USA, V103, P11300, DOI 10.1073/pnas.0604056103
   Kowluru RA, 2008, ARCH OPHTHALMOL-CHIC, V126, P1266, DOI 10.1001/archopht.126.9.1266
   Kowluru RA, 2011, INVEST OPHTH VIS SCI, V52, P8665, DOI 10.1167/iovs.10-6768
   KUTTY RK, 1995, P NATL ACAD SCI USA, V92, P1177, DOI 10.1073/pnas.92.4.1177
   Lederer DE, 2010, OCULAR DIS MECH MANA, P536
   Marc RE, 2008, MOL VIS, V14, P782
   Nakata K, 2005, EXP EYE RES, V80, P821, DOI 10.1016/j.exer.2004.12.011
   Noell W K, 1966, Invest Ophthalmol, V5, P450
   Organisciak D, 2012, PHOTOCHEM PHOTOBIOL, V88, P1396, DOI 10.1111/j.1751-1097.2012.01134.x
   Organisciak DT, 2010, PROG RETIN EYE RES, V29, P113, DOI 10.1016/j.preteyeres.2009.11.004
   Organisciak DT, 2000, INVEST OPHTH VIS SCI, V41, P3694
   Organisciak DT, 2010, ARVO ANN M MAY 2 6 F
   Rezaie T, 2012, INVEST OPHTH VIS SCI, V53, P7847, DOI 10.1167/iovs.12-10793
   Rozanowska M, PHOTOBIOLOGY RETINA
   Rozanowska M, 2012, PHOTOCHEM PHOTOBIOL, V88, P1408, DOI 10.1111/j.1751-1097.2012.01228.x
   Rutar M, 2011, INVEST OPHTH VIS SCI, V52, P5347, DOI 10.1167/iovs.10-7119
   SanGiovanni JP, 2009, AM J CLIN NUTR, V90, P1601, DOI 10.3945/ajcn.2009.27594
   SEDDON JM, 1994, JAMA-J AM MED ASSOC, V272, P1413, DOI 10.1001/jama.272.18.1413
   Slamenova D, 2002, CANCER LETT, V177, P145, DOI 10.1016/S0304-3835(01)00784-4
   Ugarte M, 2001, PROG NEUROBIOL, V64, P219, DOI 10.1016/S0301-0082(00)00057-5
   Wada M, 2004, FOOD CHEM, V87, P261, DOI 10.1016/j.foodchem.2003.11.017
   Weismann D, 2011, NATURE, V478, P76, DOI 10.1038/nature10449
   WINKLER BS, 1972, VISION RES, V12, P1183, DOI 10.1016/0042-6989(72)90106-X
   Wood JPM, 2003, NEUROCHEM RES, V28, P1525, DOI 10.1023/A:1025622425501
   Zarbin M, 2010, OCULAR DIS MECH MANA, P527
   Zhang Y, 2012, J AGR FOOD CHEM, V60, P9305, DOI 10.1021/jf302179c
   Ziess CJ, 2011, VET PATHOL, V47, P396
NR 41
TC 13
Z9 14
U1 1
U2 9
PU MOLECULAR VISION
PI ATLANTA
PA C/O JEFF BOATRIGHT, LAB B, 5500 EMORY EYE CENTER, 1327 CLIFTON RD, N E,
   ATLANTA, GA 30322 USA
SN 1090-0535
J9 MOL VIS
JI Mol. Vis.
PD JUN 27
PY 2013
VL 19
BP 1433
EP 1445
PG 13
WC Biochemistry & Molecular Biology; Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Ophthalmology
GA 175BX
UT WOS:000321205400006
PM 23825923
DA 2022-11-30
ER

PT J
AU Gong, YB
   Wang, XC
   Wang, YCA
   Hao, P
   Wang, H
   Guo, YT
   Zhang, W
AF Gong, Yibo
   Wang, Xuechun
   Wang, Yuchuan
   Hao, Peng
   Wang, Hao
   Guo, Yatu
   Zhang, Wei
TI The effect of a chrysanthemum water extract in protecting the retina of
   mice from light damage
SO BMC COMPLEMENTARY MEDICINE AND THERAPIES
LA English
DT Article
DE Light-damaged retina; Chrysanthemum; Antioxidant; ROS; NF-kappa B;
   TNF-alpha; Apoptosis
ID MACULAR DEGENERATION; OXIDATIVE STRESS; AGE; ANTIOXIDANT; COMBINATION;
   AUTOPHAGY; RPE
AB Background: Oxidative stress can induce age-related diseases. Age-related retinal diseases, such as age-related macular degeneration (AMD), are difficult to cure owing to their complicated mechanisms. Although anti-neovascular therapeutics are used to treat wet AMD, vision cannot always be completely restored, and disease progression cannot always be inhibited. Therefore, determining a method to prevent or slow retinal damage is important. This study aimed to investigate the protective effect of a chrysanthemum water extract rich in flavone on the oxidatively stressed retina of mice.
   Methods: Light damage was induced to establish oxidative stress mouse models. For in vitro experiments, ARPE-19 cells were cultured and divided into four groups: control, light-damaged, and low- and high-dose chrysanthemum extract. No treatment was administered in the control group. The light-damaged and low- and high-dose chrysanthemum extract groups were exposed to a similar white light level. The chrysanthemum extract was added at a low dose of 0.4 mg/mL or a high dose of 1.0 mg/mL before cell exposure to 2500-lx white light. Reactive oxygen species (ROS) level and cellular viability were measured using MTT and immunofluorescence staining. For in vivo experiments, C57BL/6 J mice were divided into the same four groups. Low- (0.23 g/kg/day) and high-dose (0.38 g/kg/day) chrysanthemum extracts were continuously intragastrically administered for 8 weeks before mouse exposure to 10,000-lx white light. Retinal function was evaluated using electroretinography. In vivo optical coherence tomography and in vitro haematoxylin and eosin staining were performed to observe the pathological retinal changes in each group after light damage. Fluorescein fundus angiography of the arteriovenous vessel was performed, and the findings were analysed using the AngioTool software. TUNEL immunofluorescence staining was used to assess isolated retinal apoptosis.
   Results: In vitro, increased ROS production and decreased ARPE-19 cell viability were found in the light-damaged group. Improved ARPE-19 cell viability and reduced ROS levels were observed in the chrysanthemum extract treatment groups. In vivo, dysfunctional retinas and abnormal retinal structures were found in the light-damaged group, as well as increased apoptosis in the retinal ganglion cells (RGCs) and inner and outer nuclear layers. The apoptosis rate in the same layers was lower in the chrysanthemum extract treatment groups than in the light-damaged group. The production of antioxidant enzymes, including superoxide dismutase (SOD), catalase (CAT), and glutathione peroxidase (GSH-Px), increased in the treatment groups. NF-kappa B in the nucleus and TNF-alpha were more highly expressed in the light-damaged group than in the low- and high-dose chrysanthemum extract groups.
   Conclusions: Light damage-induced retinal oxidative stress can lead to ROS accumulation in the retinal tissues. Herein, RGC and photoreceptor layer apoptosis was triggered, and NF-kappa B in the nucleus and TNF-alpha were highly expressed in the light-damaged group. Preventive chrysanthemum extract administration decreased ROS production by increasing SOD, CAT, and GSH-Px activities and reversing the negative changes, demonstrating a potential protective effect on the retina.
C1 [Gong, Yibo; Wang, Xuechun; Wang, Yuchuan; Hao, Peng; Guo, Yatu; Zhang, Wei] Tianjin Eye Hosp, Tianjin Eye Inst, Tianjin Key Lab Ophthalmol & Visual Sci, 4 Gansu Rd, Tianjin, Peoples R China.
   [Gong, Yibo; Wang, Xuechun; Zhang, Wei] Tianjin Med Univ, 22 Qixiangtai Rd, Tianjin, Peoples R China.
   [Wang, Yuchuan; Hao, Peng; Guo, Yatu; Zhang, Wei] Nankai Univ, Affiliated Eye Hosp, 4 Gansu Rd, Tianjin, Peoples R China.
   [Wang, Hao] Tianjin Univ Sci & Technol, State Key Lab Food Nutr & Safety, Tianjin, Peoples R China.
C3 Tianjin Medical University; Tianjin Medical University; Nankai
   University; Tianjin University Science & Technology
RP Guo, YT; Zhang, W (通讯作者)，Tianjin Eye Hosp, Tianjin Eye Inst, Tianjin Key Lab Ophthalmol & Visual Sci, 4 Gansu Rd, Tianjin, Peoples R China.; Zhang, W (通讯作者)，Tianjin Med Univ, 22 Qixiangtai Rd, Tianjin, Peoples R China.; Guo, YT; Zhang, W (通讯作者)，Nankai Univ, Affiliated Eye Hosp, 4 Gansu Rd, Tianjin, Peoples R China.
EM yatuguo@163.com; zhangwei3067@163.com
FU National Natural Science Foundation of China [81300791]; Natural Science
   Foundation of Tianjin [18JCYBJC26500]; Tianjin Science and Technology
   Support Key Project [19YFZCSY00990]; Tianjin Municipal Health Science
   and Technology Project [TJWJ2021MS042]; Key Project of Tianjin Eye
   Hospital [YKZD2004]; 3rd Tianjin Talent Development Program; Tianjin Key
   Medical Discipline (Specialty) Construction Project
FX This study was supported by the National Natural Science Foundation of
   China (No. 81300791), Natural Science Foundation of Tianjin (No.
   18JCYBJC26500), Tianjin Science and Technology Support Key Project (No.
   19YFZCSY00990), Tianjin Municipal Health Science and Technology Project
   (No. TJWJ2021MS042), Key Project of Tianjin Eye Hospital (No. YKZD2004),
   3rd Tianjin Talent Development Program and High-Level Talents Program in
   TJHS, Tianjin Key Medical Specialty Construction Project, and Tianjin
   Key Medical Discipline (Specialty) Construction Project.
CR Ahmed CM, 2016, MOL VIS, V22, P294
   Boyer NP, 2012, J BIOL CHEM, V287, P22276, DOI 10.1074/jbc.M111.329235
   Cano M, 2010, VISION RES, V50, P652, DOI 10.1016/j.visres.2009.08.018
   Cao XP, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-75576-7
   Chakravarthy U, 2010, BMC OPHTHALMOL, V10, DOI 10.1186/1471-2415-10-31
   Chen Jia-Min, 2021, Zhongguo Zhong Yao Za Zhi, V46, P907, DOI 10.19540/j.cnki.cjcmm.20201122.102
   Chung YR, 2017, J DIABETES RES, V2017, DOI 10.1155/2017/1763292
   Cuenca N, 2020, PROG RETIN EYE RES, V77, DOI 10.1016/j.preteyeres.2019.100828
   Devarajan G, 2016, CURR EYE RES, V41, P1235, DOI 10.3109/02713683.2015.1109129
   Ferrington DA, 2016, PROG RETIN EYE RES, V51, P69, DOI 10.1016/j.preteyeres.2015.09.002
   Guo H, 2019, POLYMERS-BASEL, V11, DOI 10.3390/polym11020215
   Hanus J, 2015, AGEING RES REV, V24, P286, DOI 10.1016/j.arr.2015.09.002
   Hyttinen JMT, 2017, AGEING RES REV, V36, P64, DOI 10.1016/j.arr.2017.03.006
   Jager RD, 2008, NEW ENGL J MED, V358, P2606, DOI 10.1056/NEJMra0801537
   Jing CL, 2019, BIOMOLECULES, V9, DOI 10.3390/biom9100518
   Jonasson F, 2014, OPHTHALMOLOGY, V121, P1766, DOI 10.1016/j.ophtha.2014.03.013
   Kim IS, 2009, J ETHNOPHARMACOL, V126, P447, DOI 10.1016/j.jep.2009.09.017
   Kyrylkova Kateryna, 2012, Methods Mol Biol, V887, P41, DOI 10.1007/978-1-61779-860-3_5
   Li RC, 2019, FREE RADICAL BIO MED, V135, P116, DOI 10.1016/j.freeradbiomed.2019.02.005
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Liu YL, 2018, FRONT AGING NEUROSCI, V10, DOI 10.3389/fnagi.2018.00389
   Long T, 2022, J CHROMATOGR SCI, V60, P465, DOI 10.1093/chromsci/bmac009
   Mitter SK, 2014, AUTOPHAGY, V10, P1989, DOI 10.4161/auto.36184
   Renganathan K, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076325
   Sitte N, 2000, FASEB J, V14, P1490, DOI 10.1096/fj.14.11.1490
   Song DL, 2016, EXP EYE RES, V145, P1, DOI 10.1016/j.exer.2015.10.005
   Song DL, 2012, FREE RADICAL BIO MED, V53, P64, DOI 10.1016/j.freeradbiomed.2012.04.020
   Sun SJ, 2016, CYTOTECHNOLOGY, V68, P229, DOI 10.1007/s10616-014-9773-5
   Tachtsis B, 2020, FRONT PHYSIOL, V11, DOI 10.3389/fphys.2020.00563
   Tanaka J, 2011, J AGR FOOD CHEM, V59, P528, DOI 10.1021/jf103186a
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Wu J L, 2021, Zhonghua Yan Ke Za Zhi, V57, P601, DOI 10.3760/cma.j.cn112142-20210413-00173
   YAMASHITA H, 1992, RETINA-J RET VIT DIS, V12, P59, DOI 10.1097/00006982-199212010-00012
   Zhang N, 2019, FOOD RES INT, V116, P810, DOI 10.1016/j.foodres.2018.09.015
   Zheng L, 2017, J PLANT PHYSIOL, V213, P66, DOI 10.1016/j.jplph.2017.03.005
   Zudaire E, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027385
NR 36
TC 0
Z9 0
U1 1
U2 1
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 2662-7671
J9 BMC COMPLEMENT MED
JI BMC Complement. Med. Ther.
PD AUG 26
PY 2022
VL 22
IS 1
AR 224
DI 10.1186/s12906-022-03701-2
PG 18
WC Integrative & Complementary Medicine
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Integrative & Complementary Medicine
GA 4A3FO
UT WOS:000844991900003
PM 36028853
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Mukai, R
   Kishi, S
   Sato, T
   Watanabe, G
   Matsumoto, H
AF Mukai, Ryo
   Kishi, Shoji
   Sato, Taku
   Watanabe, Goro
   Matsumoto, Hidetaka
TI Protective Effect of Intravitreal Bevacizumab and Sub-Tenon
   Triamcinolone Acetonide against Occlusion of Choriocapillaris Induced by
   Photodynamic Therapy
SO OPHTHALMOLOGICA
LA English
DT Article
DE Choriocapillaris occlusion; Hypofluorescence; Intravitreal bevacizumab;
   Photodynamic therapy; Triamcinolone acetonide
ID INDOCYANINE GREEN ANGIOGRAPHY; CHOROIDAL NEOVASCULARIZATION;
   VERTEPORFIN; INJECTION; HYPOPERFUSION; EFFICACY; AVASTIN; RETINA; CELLS;
   VEGF
AB Purpose: To evaluate the protective effect of intravitreal bevacizumab (IVB) and sub-Tenon triamcinolone acetonide (TA) against choriocapillaris occlusion induced by photodynamic therapy (PDT). Methods: This prospective, nonrandomized, consecutive study included 80 eyes of 80 patients with polypoidal choroidal vasculopathy who underwent an initial PDT. The posttherapeutic follow-up periods were more than 3 months (mean, 9.3 months). Patients were divided into three groups consecutively: the PDT group included 21 eyes of 21 patients treated with only PDT, the TA group included 32 eyes of 32 patients treated with PDT and a sub-Tenon injection of 20 mg TA, and the IVB group included 27 eyes of 27 patients treated with PDT and an intravitreal injection of 1.25 mg bevacizumab. Indocyanine green angiography (ICGA) was performed before and 3 months after PDT. The degree of choriocapillaris occlusion was assessed in the marginal zone of the PDT area based on the background hypofluorescence seen on ICGA quantified by densitometry (Imagenet). Results: ICGA at 1 and 5 min showed hypofluorescence in the marginal zone in all eyes 3 months after PDT. The hypofluorescence became indistinguishable from the background fluorescence 15 min after treatment in some eyes; however, the relative hypofluorescence persisted in some cases. The rates of fluorescence intensity in the marginal zone compared to those in the untreated area, i.e. the percentage of baseline fluorescence, were 0.60, 0.65 and 0.73 at 1, 5 and 15 min after dye injection in the PDT group, respectively, 0.64, 0.68 and 0.82 in the TA group, and 0.64, 0.73 and 0.90 in the IVB group. The intensity of the fluorescence was significantly (p < 0.05) higher in the TA group at 15 min and in the IVB group at 1, 5 and 15 min compared with the PDT group. Conclusions: IVB and TA reduced choriocapillaris occlusion after PDT. IVB appeared to have a stronger protective effect than TA in this therapeutic regimen. Copyright (C) 2010 S. Karger AG, Basel
C1 [Mukai, Ryo; Kishi, Shoji; Sato, Taku; Watanabe, Goro; Matsumoto, Hidetaka] Gunma Univ, Sch Med, Dept Ophthalmol, Maebashi, Gunma 371, Japan.
C3 Gunma University
RP Mukai, R (通讯作者)，Gunma Univ Med Sci, 3-39-15 Showamachi, Gunma 3718511, Japan.
EM r-mukai@fd5.so-net.ne.jp
CR Bakri SJ, 2006, AM J OPHTHALMOL, V142, P162, DOI 10.1016/j.ajo.2006.03.058
   Costa RA, 2003, RETINA-J RET VIT DIS, V23, P159, DOI 10.1097/00006982-200304000-00004
   Dhalla MS, 2006, RETINA-J RET VIT DIS, V26, P988, DOI 10.1097/01.iae.0000247164.70376.91
   Edelman JL, 2005, EXP EYE RES, V80, P249, DOI 10.1016/j.exer.2004.09.013
   Fong DS, 2000, OPHTHALMOLOGY, V107, P2314
   Freund KB, 2006, ARCH OPHTHALMOL-CHIC, V124, P487, DOI 10.1001/archopht.124.4.487
   Giovannini A, 1996, BRIT J OPHTHALMOL, V80, P536, DOI 10.1136/bjo.80.6.536
   Gomi F, 2008, BRIT J OPHTHALMOL, V92, P70, DOI 10.1136/bjo.2007.122283
   Heiduschka P, 2008, RETINA-J RET VIT DIS, V28, P46, DOI 10.1097/IAE.0b013e31815e9368
   Heiduschka P, 2007, INVEST OPHTH VIS SCI, V48, P2814, DOI 10.1167/iovs.06-1171
   Holz ER, 2003, ARCH OPHTHALMOL-CHIC, V121, P1649, DOI 10.1001/archopht.121.11.1649
   HOWE LJ, 1995, OPHTHALMOLOGY, V102, P790, DOI 10.1016/S0161-6420(95)30955-4
   Husain D, 1999, INVEST OPHTH VIS SCI, V40, P2322
   Iriyama A, 2008, GRAEF ARCH CLIN EXP, V246, P339, DOI 10.1007/s00417-007-0667-5
   Ishida S, 2003, J EXP MED, V198, P483, DOI 10.1084/jem.20022027
   Ishikawa K, 2007, INVEST OPHTH VIS SCI, V48, P2254, DOI 10.1167/iovs.06-1277
   Jain RK, 2005, SCIENCE, V307, P58, DOI 10.1126/science.1104819
   Jonas JB, 2005, ACTA OPHTHALMOL SCAN, V83, P645, DOI 10.1111/j.1600-0420.2005.00592.x
   Jonas JB, 2009, OPHTHALMIC RES, V41, P21, DOI 10.1159/000162113
   Kaplan MJ, 1998, J SURG ONCOL, V67, P121, DOI 10.1002/(SICI)1096-9098(199802)67:2<121::AID-JSO9>3.3.CO;2-R
   Kiss C, 2006, RETINA-J RET VIT DIS, V26, P877, DOI 10.1097/01.iae.0000237080.10627.b7
   Luthra S, 2006, RETINA-J RET VIT DIS, V26, P512, DOI 10.1097/01.iae.0000222547.35820.52
   Maruko I, 2007, AM J OPHTHALMOL, V144, P15, DOI 10.1016/j.ajo.2007.03.047
   Matsuda S, 2005, INVEST OPHTH VIS SCI, V46, P1062, DOI 10.1167/iovs.04-0761
   Michels S, 2003, INVEST OPHTH VIS SCI, V44, P2147, DOI 10.1167/iovs.02-0604
   Miller D, 2004, AGE-RELATED MACULAR DEGENERATION, P199
   Miyamoto K, 2000, AM J PATHOL, V156, P1733, DOI 10.1016/S0002-9440(10)65044-4
   Nauck M, 1998, EUR J PHARMACOL, V341, P309, DOI 10.1016/S0014-2999(97)01464-7
   Obana A, 1996, RETINA-J RET VIT DIS, V16, P97, DOI 10.1097/00006982-199616020-00002
   Otani A, 2007, AM J OPHTHALMOL, V144, P7, DOI 10.1016/j.ajo.2007.03.014
   Ozdemir H, 2006, AM J OPHTHALMOL, V141, P574, DOI 10.1016/j.ajo.2005.09.031
   Peters S, 2007, AM J OPHTHALMOL, V143, P995, DOI 10.1016/j.ajo.2007.03.007
   SACU S, 2009, EYE
   Schmidt-Erfurth U, 2000, SURV OPHTHALMOL, V45, P195, DOI 10.1016/S0039-6257(00)00158-2
   Schmidt-Erfurth U, 2002, ARCH OPHTHALMOL-CHIC, V120, P835
   Schmidt-Erfurth U, 2002, INVEST OPHTH VIS SCI, V43, P830
   Schmidt-Erfurth U, 2003, INVEST OPHTH VIS SCI, V44, P4473, DOI 10.1167/iovs.02-1115
   SCHMIDTERFURTH U, 1994, OPHTHALMOLOGY, V101, P1953
   SchmidtErfurth U, 1997, BRIT J CANCER, V75, P54, DOI 10.1038/bjc.1997.9
   Shimomura Y, 2009, GRAEF ARCH CLIN EXP, V247, P1089, DOI 10.1007/s00417-009-1054-1
   Spaide RF, 2003, OPHTHALMOLOGY, V110, P1517, DOI 10.1016/S0161-6420(03)00544-X
   YANNUZZI LA, 1997, INDOCYANINE GREEN AN, P50
NR 42
TC 18
Z9 20
U1 0
U2 0
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0030-3755
EI 1423-0267
J9 OPHTHALMOLOGICA
JI Ophthalmologica
PY 2010
VL 224
IS 5
BP 267
EP 273
DI 10.1159/000287348
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 633QT
UT WOS:000280519700001
PM 20185940
DA 2022-11-30
ER

PT J
AU Park, SY
   Kim, SM
   Song, YM
   Sung, J
   Ham, DI
AF Park, Sung Yong
   Kim, Sung Min
   Song, Yun-Mi
   Sung, Joohon
   Ham, Don-Il
TI Retinal Thickness and Volume Measured With Enhanced Depth Imaging
   Optical Coherence Tomography
SO AMERICAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID KOYANAGI-HARADA-DISEASE; CHOROIDAL THICKNESS; RETICULAR PSEUDODRUSEN;
   MACULAR THICKNESS; HEALTHY-SUBJECTS; AXIAL LENGTH; REPRODUCIBILITY; AGE;
   SEGMENTATION; EDEMA
AB PURPOSE: To evaluate the retinal thickness and volume measured with the enhanced depth imaging (EDI) method compared with those measured with the conventional method using spectral-domain optical coherence tomography (OCT).
   DESIGN: Retrospective, observational, case-control study.
   METHODS: Clinical records of 20 healthy subjects and those of 35 patients with chorioretinopathy (central serous chorioretinopathy, polypoidal choroidal vasculopathy, Vogt-Koyanagi-Harada disease, and reticular pseudodrusen) were analyzed retrospectively. All subjects underwent spectral-domain OCT using both the conventional and the EDI OCT raster scan protocols. The raster scan was composed of 31 B-scans that were 9.0 mm in length and 240 pm apart. Retinal thickness and volume of 9 Early Treatment Diabetic Retinopathy Study subfields were investigated. Intraclass correlation coefficients, Bland-Altman plots, and Wilcoxon signed-rank test results were used for the analysis.
   RESULTS: Sixty-five eyes of 35 patients with chorioretinal diseases and 40 eyes of 20 normal healthy subjects were evaluated. The automatically measured retinal thickness and volume of 9 Early Treatment Diabetic Retinopathy Study subfields with conventional and EDI raster scan showed an intraclass correlation coefficient of 0.861 to 0.995 and 0.873 to 0.995, respectively. The 95% limits of agreement between the 2 protocols in the measurement of central subfield were -14.52 to 12.88 mu m in retinal thickness and -0.014 to 0.013 mm(3) in retinal volume. The differences of segmentation error rate between the 2 protocols were statistically insignificant (P > .05), except in eyes with reticular pseudodrusen in the subgroup analysis (P = .006). No significant differences were observed in measured values between healthy eyes and unaffected fellow eyes.
   CONCLUSIONS: The EDI OCT raster scan showed high agreement with conventional OCT in the measurement of retinal thickness and volume and could be used to evaluate both the retina and choroid in normal eyes and in eyes with some forms of chorioretinal disorder. ((C) 2013 by Elsevier Inc. All rights reserved.)
C1 [Park, Sung Yong; Kim, Sung Min; Ham, Don-Il] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Ophthalmol, Seoul 135710, South Korea.
   [Song, Yun-Mi] Sungkyunkwan Univ, Sch Med, Dept Family Med, Samsung Med Ctr, Seoul 135710, South Korea.
   [Song, Yun-Mi] Sungkyunkwan Univ, Sch Med, Samsung Biomed Res Inst, Clin Res Ctr, Seoul 135710, South Korea.
   [Sung, Joohon] Seoul Natl Univ, Dept Epidemiol, Seoul, South Korea.
   [Sung, Joohon] Seoul Natl Univ, Sch Publ Hlth, Inst Environm & Hlth, Seoul, South Korea.
   [Sung, Joohon] Seoul Natl Univ, Med Res Ctr, Genom Med Inst, Seoul, South Korea.
C3 Sungkyunkwan University (SKKU); Samsung Medical Center; Sungkyunkwan
   University (SKKU); Samsung Medical Center; Samsung; Sungkyunkwan
   University (SKKU); Samsung Medical Center; Seoul National University
   (SNU); Seoul National University (SNU); Seoul National University (SNU)
RP Ham, DI (通讯作者)，Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Ophthalmol, 50 Irwon Dong, Seoul 135710, South Korea.
EM oculus@naver.com
CR Barteselli G, 2012, OPHTHALMOLOGY, V119, P2572, DOI 10.1016/j.ophtha.2012.06.065
   Branchini L, 2012, OPHTHALMOLOGY, V119, P119, DOI 10.1016/j.ophtha.2011.07.002
   Chhablani J, 2012, INVEST OPHTH VIS SCI, V53, P2274, DOI 10.1167/iovs.12-9435
   da Silva FT, 2013, BRIT J OPHTHALMOL, V97, P70, DOI 10.1136/bjophthalmol-2012-302089
   Domalpally Amitha, 2010, Ophthalmic Surg Lasers Imaging, V41 Suppl, pS34, DOI 10.3928/15428877-20100325-01
   Esmaeelpour M, 2011, INVEST OPHTH VIS SCI, V52, P5311, DOI 10.1167/iovs.10-6875
   Fujiwara T, 2009, AM J OPHTHALMOL, V148, P445, DOI 10.1016/j.ajo.2009.04.029
   Grover S, 2009, AM J OPHTHALMOL, V148, P266, DOI 10.1016/j.ajo.2009.03.006
   Hefner L, 2012, KLIN MONATSBL AUGENH, V229, P403, DOI 10.1055/s-0031-1299212
   Iannetti L, 2012, ACTA OPHTHALMOL, V90, pe490, DOI 10.1111/j.1755-3768.2011.02322.x
   Imamura Y, 2009, RETINA-J RET VIT DIS, V29, P1469, DOI 10.1097/IAE.0b013e3181be0a83
   Kajic V, 2012, BIOMED OPT EXPRESS, V3, P86, DOI 10.1364/BOE.3.000086
   Koizumi H, 2011, GRAEF ARCH CLIN EXP, V249, P1123, DOI 10.1007/s00417-011-1620-1
   Krebs I, 2011, INVEST OPHTH VIS SCI, V52, P6925, DOI 10.1167/iovs.10-6612
   Lammer J, 2011, RETINA-J RET VIT DIS, V31, P48, DOI 10.1097/IAE.0b013e3181e095a4
   Lee MY, 2012, BRIT J OPHTHALMOL, V96, P1222, DOI 10.1136/bjophthalmol-2011-301207
   Margolis R, 2009, AM J OPHTHALMOL, V147, P811, DOI 10.1016/j.ajo.2008.12.008
   Maul EA, 2011, OPHTHALMOLOGY, V118, P1571, DOI 10.1016/j.ophtha.2011.01.016
   PATZ A, 1985, ARCH OPHTHALMOL-CHIC, V103, P1796, DOI 10.1001/archopht.1985.01050120030015
   Pierro L, 2010, AM J OPHTHALMOL, V150, P199, DOI 10.1016/j.ajo.2010.03.015
   Querques G, 2012, INVEST OPHTH VIS SCI, V53, P1258, DOI 10.1167/iovs.11-8907
   Read RW, 2001, AM J OPHTHALMOL, V131, P647, DOI 10.1016/S0002-9394(01)00925-4
   Song WK, 2010, INVEST OPHTH VIS SCI, V51, P3913, DOI 10.1167/iovs.09-4189
   Spaide RF, 2008, AM J OPHTHALMOL, V146, P496, DOI 10.1016/j.ajo.2008.05.032
   Spaide RF, 2009, AM J OPHTHALMOL, V147, P801, DOI 10.1016/j.ajo.2008.12.010
   Sull AC, 2010, RETINA-J RET VIT DIS, V30, P235, DOI 10.1097/IAE.0b013e3181bd2c3b
   Tian J, 2013, BIOMED OPT EXPRESS, V4, P397, DOI 10.1364/BOE.4.000397
   Yeoh J, 2010, GRAEF ARCH CLIN EXP, V248, P1719, DOI 10.1007/s00417-010-1437-3
NR 28
TC 17
Z9 17
U1 0
U2 15
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-9394
EI 1879-1891
J9 AM J OPHTHALMOL
JI Am. J. Ophthalmol.
PD SEP
PY 2013
VL 156
IS 3
BP 557
EP 566
DI 10.1016/j.ajo.2013.04.027
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 214RM
UT WOS:000324153500018
PM 23769194
DA 2022-11-30
ER

PT J
AU Lassandro, NV
   Nicolai, M
   Arnaldi, G
   Franceschi, A
   Pelliccioni, P
   Cantini, L
   Gesuita, R
   Faragalli, A
   Mariotti, C
AF Lassandro, Nicola Vito
   Nicolai, Michele
   Arnaldi, Giorgio
   Franceschi, Alessandro
   Pelliccioni, Paolo
   Cantini, Luca
   Gesuita, Rosaria
   Faragalli, Andrea
   Mariotti, Cesare
TI Pachychoroid spectrum disease and choriocapillary flow analysis in
   patients with Cushing disease: an optical coherence tomography
   angiography study
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE Choroid; Cortisol; Cushing; Multimodal imaging; Neovasculopathy;
   Pachychoroid
ID CENTRAL SEROUS CHORIORETINOPATHY; MINERALOCORTICOID RECEPTOR
AB Purpose To investigate the presence of pachychoroid spectrum disease (PSD) in patients with Cushing disease (CD) and to evaluate subfoveal choroidal thickness (SFCT) and choriocapillary flow using spectral domain OCT (SD-OCT) with the enhanced depth imaging (EDI) and optical coherence tomography angiography (OCT-A).
   Methods Thirty-two patients with CD and 32 age- and sex-matched healthy volunteers were enrolled in this observational study. All participants had a complete ophthalmic examination including SD-OCT with EDI and OCT-A, and were subjected to the Perceived Stress Scale test (PSS). All patients with CD had hormone test including 24-h urinary-free cortisol (UFC) and plasma adrenocorticotropic hormone (ACTH). We compared SFCT and choriocapillary vessel density (CVD) between the two groups and evaluated the presence of PSD. We investigated the association of hormone level, SFTC, CVD with the presence of CD; the association between the hormone level, SFTC, CVD, the CD disease activity, and duration with the presence of PSD in CD patients; and the association between SFTC and CVD with the hormone level, the CD disease activity, and duration in CD patients.
   Results Higher values of SFCT and CVD were associated with CD (beta: 0.028, 95% CI: 0.014; 0.041; beta: 0.912, 95%CI: 0.205; 1.62, respectively). Twelve patients with CD (37.5%) reported a PSD in at least one eye, whereas no subject was found in control group (p < 0.001); in particular, 11 CD patients (34%) presented pachychoroid pigment epitheliopathy (PPE) and 1 CD patient (3%) presented polypoidal choroidal vasculopathy/aneurysmal type 1 neovascularization (PCV/AT1). In patients with CD, a significant positive association between SFCT and PSD was found (beta: 0.010, 95% CI 0.001; 0.019).
   Conclusion A chronic state of hypercortisolism may have direct implications on the choroid. Patients with CD had higher SFCT values and a significant change in the choriocapillary flow compared to healthy controls. Moreover, PSD was observed only in CD patients.
C1 [Lassandro, Nicola Vito; Nicolai, Michele; Franceschi, Alessandro; Pelliccioni, Paolo; Mariotti, Cesare] Polytech Univ Marche, Eye Clin, AOU Osped Riuniti Ancona, Via Conca 61, I-60126 Ancona, Italy.
   [Arnaldi, Giorgio] Polytech Univ Marche, Div Endocrinol, AOU Osped Riuniti Ancona, Ancona, Italy.
   [Cantini, Luca] Polytech Univ Marche, Clin Oncol, AOU Osped Riuniti Ancona, Ancona, Italy.
   [Gesuita, Rosaria; Faragalli, Andrea] Polytech Univ Marche, Ctr Epidemiol Biostat & Med Informat Technol, Ancona, Italy.
C3 Marche Polytechnic University; Marche Polytechnic University; Marche
   Polytechnic University; Marche Polytechnic University
RP Franceschi, A (通讯作者)，Polytech Univ Marche, Eye Clin, AOU Osped Riuniti Ancona, Via Conca 61, I-60126 Ancona, Italy.
EM a.franceschi.md@gmail.com
OI Pelliccioni, Paolo/0000-0002-6024-0183; franceschi,
   alessandro/0000-0001-8867-4488
CR Abalem MF, 2016, FRONT ENDOCRINOL, V7, DOI 10.3389/fendo.2016.00154
   Akkaya S, 2018, INT OPHTHALMOL, V38, P2239, DOI 10.1007/s10792-017-0666-4
   Baek J, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-42052-w
   Bousquet E, 2013, RETINA-J RET VIT DIS, V33, P2096, DOI 10.1097/IAE.0b013e318297a07a
   BOUZAS EA, 1993, ARCH OPHTHALMOL-CHIC, V111, P1229, DOI 10.1001/archopht.1993.01090090081024
   Bouzas EA, 2002, SURV OPHTHALMOL, V47, P431, DOI 10.1016/S0039-6257(02)00338-7
   Cheung CMG, 2019, EYE, V33, P14, DOI 10.1038/s41433-018-0158-4
   Cushing H, 1994, Obes Res, V2, P486
   Dansingani KK, 2016, RETINA-J RET VIT DIS, V36, P499, DOI 10.1097/IAE.0000000000000742
   Dansingani KK, 2015, AM J OPHTHALMOL, V160, P1243, DOI 10.1016/j.ajo.2015.08.028
   Daruich A, 2015, PROG RETIN EYE RES, V48, P82, DOI 10.1016/j.preteyeres.2015.05.003
   Demirel S, 2021, EUR J OPHTHALMOL, V31, P184, DOI 10.1177/1120672119887095
   Eymard P, 2021, ACTA OPHTHALMOL, V99, P533, DOI 10.1111/aos.14664
   Gal-Or O, 2018, RETINA-J RET VIT DIS, V38, P1984, DOI 10.1097/IAE.0000000000002051
   Garg SP, 1997, BRIT J OPHTHALMOL, V81, P962, DOI 10.1136/bjo.81.11.962
   Giovansili I, 2013, ENDOCR PRACT, V19, pE129, DOI 10.4158/EP12389.CR
   Haimovici R, 2003, OPHTHALMOLOGY, V110, P698, DOI 10.1016/S0161-6420(02)01975-9
   Karaca C, 2017, RETINA-J RET VIT DIS, V37, P536, DOI 10.1097/IAE.0000000000001198
   Mrejen S, 2013, SURV OPHTHALMOL, V58, P387, DOI 10.1016/j.survophthal.2012.12.001
   ?ner A., 2014, RETINA VITREUS, V22, P204
   Nieman LK, 2008, J CLIN ENDOCR METAB, V93, P1526, DOI 10.1210/jc.2008-0125
   Siedlecki J, 2019, OPHTHALMOL RETINA, V3, P1013, DOI 10.1016/j.oret.2019.08.002
   Teussink MM, 2015, INVEST OPHTH VIS SCI, V56, P5229, DOI 10.1167/iovs.15-17140
   Vallejo MA, 2018, FRONT PSYCHOL, V9, DOI 10.3389/fpsyg.2018.00037
   Wang EQ, 2019, RETINA-J RET VIT DIS, V39, P408, DOI 10.1097/IAE.0000000000001956
   Warrow DJ, 2013, RETINA-J RET VIT DIS, V33, P1659, DOI 10.1097/IAE.0b013e3182953df4
   Wei WB, 2013, OPHTHALMOLOGY, V120, P175, DOI 10.1016/j.ophtha.2012.07.048
   WILLIAMS RB, 1982, SCIENCE, V218, P483, DOI 10.1126/science.7123248
   Yannuzzi Lawrence A, 2012, Retina, V32 Suppl 1, P709
   Zhao M, 2012, J CLIN INVEST, V122, P2672, DOI 10.1172/JCI61427
NR 30
TC 1
Z9 1
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0721-832X
EI 1435-702X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD MAY
PY 2022
VL 260
IS 5
BP 1535
EP 1542
DI 10.1007/s00417-021-05524-2
EA JAN 2022
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 0M9EN
UT WOS:000745765000003
PM 35067771
DA 2022-11-30
ER

PT J
AU Cinhuseyinoglu, N
   Celik, L
   Yaman, A
   Arikan, G
   Kaynak, T
   Kaynak, S
AF Cinhuseyinoglu, Necdet
   Celik, Lider
   Yaman, Aylin
   Arikan, Gul
   Kaynak, Tulin
   Kaynak, Suleyman
TI Microincisional cataract surgery and Thinoptx rollable intraocular lens
   implantation
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE microincisional cataract surgery; Thinoptx; rollable IOL
ID SILICONE; FORMULA; PHACOEMULSIFICATION; INCISION
AB Microincisional cataract surgery is a safe procedure with a very short learning period for an experienced cataract surgeon and rollable ultrathin intraocular lenses eliminate the need for enlargement of corneal incision. The purpose of the study was to evaluate the safety and efficacy of cataract surgery through a corneal microincision and implantation of rollable ultrathin intraocular lenses. The setting was Dokuz Eylul University Medical Faculty, Ophthalmology Department, Izmir, Turkey and SSK Okmeydani Hospital, Ophthalmology Clinic, Istanbul, Turkey.
   Ninety eyes in 85 patients were operated on through clear corneal microincisions with sleeveless phacoemulsification and rollable intraocular lenses were implanted. Forty-six of the patients were men and 39 were women between the ages of 27 and 83, with a mean of 51 years. Two eyes had atrophic senile macular degeneration, 4 eyes had nonspecific retinal pigment epithelial changes with chorioretinal atrophy, and 4 patients had diabetes mellitus without retinopathy. Three eyes had posterior capsular opacifications of unknown etiology. Two eyes had primary open angle glaucoma (PAAG) with cup to disc ratios of about 0.5. Three eyes had dense nuclear sclerosis of grade 4 with very low visibility of retinal structures. Other patients had no ocular or systemic pathology other than nuclear/corticonuclear cataract of grade 2-3. Uncorrected and best spectacle-corrected distance and near visual acuities, keratometric values, and refractive status were noted preoperatively and 1 week, 1 month, and 6 months postoperatively. Statistical analysis of keratometric changes between preoperative and postoperative findings was performed using the paired samples t test.
   At 6 months postoperatively, 1 patient had a best spectacle-corrected visual acuity (BSCVA) of 0.2, the patient with atrophic senile macular degeneration. The rest of the eyes achieved a BSCVA of 0.63 or better. At 6 months postoperatively, 55 (61.11%) eyes had uncorrected visual acuities (UCVA) equal to or better than 0.8 and 83 (92.22%) eyes had BSCVA equal to or better than 0.8 according to the Snellen chart. The mean postoperative corneal astigmatisms at 1 week, 1 month, and 6 months were 0.69 +/- 0.43 D, 0.66 +/- 0.46 D and 0.65 +/- 0.48 D respectively. Statistical analysis revealed a significant change in corneal astigmatisms at the 1st week visit (p < 0.05), but not at the 1st and 6th month visits (p > 0.05) compared with preoperative findings.
   Based on the limited data in the literature and in this study, it is not possible to make concrete decisions about the benefits and disadvantages of the ThinOptx IOL for longer durations. Intraoperatively, this IOL apparently eliminates the need for enlargement of the corneal incision during implantation. However, the statistical insignificance of induced astigmatisms after microincisions and classical phacoincisions should also be taken into consideration. We conclude that ThinOptx IOL is a pioneering intraocular lens implant that will contribute to the exciting future of cataract refractive surgical procedures. However, both clinical and laboratory investigations are needed to clearly describe the long-term effectiveness of this new rollable IOL.
C1 Retina Goz Merkezi, TR-35220 Izmir, Turkey.
   SSK Okmeydani Hosp, Ophthalmol Clin, Istanbul, Turkey.
   Retina Eye Ctr, Izmir, Turkey.
   Dokuz Eylul Univ, Dept Ophthalmol, Fac Med, Izmir, Turkey.
C3 Private Retina Eye Health Services & Materials Supply Ltd Co; Istanbul
   Okmeydani Training & Research Hospital; Dokuz Eylul University
RP Celik, L (通讯作者)，Retina Goz Merkezi, 1488 Sk 3, TR-35220 Izmir, Turkey.
EM lidercelik@retina-gm.com
CR ALIO JL, 2004, MICS MICROINCISIONAL
   Apple DJ, 2000, FOLDABLE INTRAOCULAR
   AUER C, 1995, KLIN MONATSBL AUGENH, V206, P293, DOI 10.1055/s-2008-1035444
   Dogru M, 2004, J CATARACT REFR SURG, V30, P558, DOI 10.1016/j.jcrs.2003.12.027
   ELMAGHRABY A, 1993, J CATARACT REFR SURG, V19, P494, DOI 10.1016/S0886-3350(13)80613-X
   Fine IH, 2002, J CATARACT REFR SURG, V28, P1054, DOI 10.1016/S0886-3350(02)01399-8
   Gills James P, 2002, Curr Opin Ophthalmol, V13, P2, DOI 10.1097/00055735-200202000-00002
   GIMBEL HV, 1990, J CATARACT REFR SURG, V16, P31, DOI 10.1016/S0886-3350(13)80870-X
   GRABOW HB, 1993, EUR J IMPLANT REF SU, V5, P200
   HOFFER KJ, 1993, J CATARACT REFR SURG, V19, P700, DOI 10.1016/S0886-3350(13)80338-0
   HOLLADAY JT, 1986, ARCH OPHTHALMOL-CHIC, V104, P539
   KOHNEN T, 1995, J CATARACT REFR SURG, V21, P417, DOI 10.1016/S0886-3350(13)80532-9
   Linebarger EJ, 1999, SURV OPHTHALMOL, V44, P123, DOI 10.1016/S0039-6257(99)00085-5
   Nishi O, 1998, J CATARACT REFR SURG, V24, P975, DOI 10.1016/S0886-3350(98)80054-0
   Pandey SK, 2002, J CATARACT REFR SURG, V28, P1710, DOI 10.1016/S0886-3350(02)01593-6
   RETZLAFF JA, 1990, J CATARACT REFR SURG, V16, P333, DOI 10.1016/S0886-3350(13)80705-5
   RETZLAFF JA, 1990, J CATARACT REFR SURG, V16, P528
   SANDERS DR, 1988, J CATARACT REFR SURG, V14, P136, DOI 10.1016/S0886-3350(88)80087-7
   Subramaniam S, 2001, J CATARACT REFR SURG, V27, P330, DOI 10.1016/S0886-3350(00)00557-5
NR 19
TC 6
Z9 7
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING STREET, NEW YORK, NY 10013 USA
SN 0721-832X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD JUL
PY 2006
VL 244
IS 7
BP 802
EP 807
DI 10.1007/s00417-005-0158-5
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 065GO
UT WOS:000239148000006
PM 16315046
DA 2022-11-30
ER

PT J
AU Li, D
   Yuan, DQ
   Shen, H
   Mao, XY
   Yuan, ST
   Liu, QH
AF Li, Duo
   Yuan, Dongqing
   Shen, Han
   Mao, Xiying
   Yuan, Songtao
   Liu, Qinghuai
TI Gremlin-1: An endogenous BMP antagonist induces epithelial-mesenchymal
   transition and interferes with redifferentiation in fetal RPE cells with
   repeated wounds
SO MOLECULAR VISION
LA English
DT Article
ID MACULAR DEGENERATION; STEM-CELL; BONE; CHICK
AB Purpose: To investigate the role of Gremlin-1, which is an endogenous antagonist of the bone morphogenetic protein (BMP) signaling pathway, in inducing epithelium-mesenchymal transition (EMT) in fetal RPE cells after repeated wounds.
   Methods: Subconfluent repetitive passages in fetal RPE cells were regarded as a model of repeated wounds. A phase contrast microscope was used to observe the morphology and pigment formation in cells. The expression of GREM1 (Gene ID: 26585; OMIM 603054) and EMT- or RPE-related genes in cells was evaluated with quantitative PCR (qPCR). Recombinant human protein Gremlin-1 (0.1 mu g/ml) was added every day to investigate the molecular effects of Gremlin-1 on fetal RPE cells. The cell migration rate was investigated using a cell wound scratch assay, and western blotting was used to analyze the representative proteins (P-cadherin, ZO-1, vimentin, Smad4, and phosphorylated-Smads). In addition, transfection of siRNA was used to explore the rescue effects on EMT cells through the downregulation of GREW1. Finally, LDN193189, which is a type of pan-inhibitor of BMP receptors, was used to verify whether complete blocking of the BMP pathway interferes with the redifferentiation in low-passage fetal cells, even if the cells were treated with transforming growth factor beta 1 (TGF-beta) inhibitors.
   Results: In fetal RPE cells, the expression of GREM1 were gradually upregulated with repetitive passages, and at the same time, the function-specific genes in fetal RPE cells (TJP1, PMEL, BEST1, RPE65, and MERTK) were downregulated while the EMT-specific genes were upregulated. In addition, GREW had a similar expression pattern as SNAI1, which is a key transcription factor to trigger EMT. Recombinant human Gremlin-1 promoted EMT with the upregulation of SNAI1 and elevated the cell migration rate in a cell scratch assay, as well as decreased the expression of two key transcription factors of RPE embryonic development (MITF and OTX2) and the RPE marker, RPE65. Furthermore, the EMT marker, vimentin, and the TGF-beta pathway downstream transcription factor phosphorylated-Smad2 (p-Smad2) increased, but the epithelial marker, ZO-1, was reduced. Additionally, Smad4, which plays a role as a Snail1 cooperator by binding Smad3, was also increased. In contrast, GREM1 silencing increased the expression of MITF and OTX2, which means there was better redifferentiation in subconfluent fetal RPE cells, but it had little influence on p-Smad2 compared to the negative control group. Finally, by adding LDN193189, the BMP signaling pathway was blocked, and this block led to poor redifferentiation in low-passage cells, although the cells were treated with TGF-beta inhibitors. In addition, as positive feedback to block the BMP pathway, GREM1 was subsequently upregulated.
   Conclusions: In fetal RPE cells, Gremlin-1 induces EMT and inhibits redifferentiation by promoting the TGF-beta pathway and inhibiting the BMP pathway. GREM1 silencing alleviates EMT and increases the redifferentiation of cells by relieving the blockade of the BMP pathway. However, GREM1 silencing has no effects on the TGF-beta pathway. Thus, Gremlin-1 may serve as a novel target to treat proliferative vitreoretinopathy (PVR) and inhibit subretinal fibrosis, which is a risk factor for influencing the therapeutic effects of anti-vascular endothelial growth factor (anti-VEGF) on neovascular age-related macular degeneration (nAMD).
C1 [Li, Duo; Yuan, Dongqing; Shen, Han; Mao, Xiying; Yuan, Songtao; Liu, Qinghuai] Nan Jing Med Univ, Affiliated Hosp 1, Dept Ophthalmol, Nanjing, Jiangsu, Peoples R China.
RP Liu, QH (通讯作者)，Nanjing Med Univ, Affiliated Hosp 1, Dept Ophthalmol, 300 Guangzhou Rd, Nanjing 210029, Jiangsu, Peoples R China.
EM liuqh@njmu.edu.cn
OI Liu, Qinghuai/0000-0003-1605-1964
FU National Key Research and Development Project of China [2017YFA0104101];
   National Natural Science Funds of China [81,870,694]; Jiangsu Natural
   Science Foundation [BK20151586]
FX Prof. Qinghuai Liu and Prof. Songtao Yuan are co-corresponding authors
   for this article. This research was supported by grants from the
   National Key Research and Development Project of China (2017YFA0104101),
   the National Natural Science Funds of China (81,870,694) and the Jiangsu
   Natural Science Foundation (BK20151586). We thank the Center of
   Reproductive Medicine at the First Affiliated Hospital of Nanjing
   Medical University for providing the fetal RPE cells.
CR Nieto MA, 2016, CELL, V166, P21, DOI 10.1016/j.cell.2016.06.028
   Brazil DP, 2015, TRENDS CELL BIOL, V25, P249, DOI 10.1016/j.tcb.2014.12.004
   Cohen SY, 2012, RETINA-J RET VIT DIS, V32, P1480, DOI 10.1097/IAE.0b013e318240a516
   Daniel E, 2018, OPHTHALMOLOGY, V125, P1037, DOI 10.1016/j.ophtha.2018.01.004
   Daniel E, 2014, OPHTHALMOLOGY, V121, P656, DOI 10.1016/j.ophtha.2013.10.019
   Friedlander M, 2007, J CLIN INVEST, V117, P576, DOI 10.1172/JCI31030
   Gamm DM, 2008, INVEST OPHTH VIS SCI, V49, P788, DOI 10.1167/iovs.07-0777
   Gonzalez DM, 2014, SCI SIGNAL, V7, DOI 10.1126/scisignal.2005189
   Guo X, 2009, CELL RES, V19, P71, DOI 10.1038/cr.2008.302
   Ishikawa K, 2016, EXP EYE RES, V142, P19, DOI 10.1016/j.exer.2015.03.009
   Lamouille S, 2014, NAT REV MOL CELL BIO, V15, P178, DOI 10.1038/nrm3758
   Mitola S, 2010, BLOOD, V116, P3677, DOI 10.1182/blood-2010-06-291930
   Muller F, 2007, DEVELOPMENT, V134, P3483, DOI 10.1242/dev.02884
   Nowak JZ, 2014, ACTA POL PHARM, V71, P900
   Radeke MJ, 2015, GENOME MED, V7, DOI 10.1186/s13073-015-0183-x
   Rodrigues-Diez R, 2012, NEPHRON EXP NEPHROL, V122, P62, DOI 10.1159/000346575
   Scheel C, 2011, CELL, V145, P926, DOI 10.1016/j.cell.2011.04.029
   Shih YH, 2017, INVEST OPHTH VIS SCI, V58, P430, DOI 10.1167/iovs.16-20018
   Singh R, 2013, INVEST OPHTH VIS SCI, V54, P6767, DOI 10.1167/iovs.13-11943
   Staloch D, 2015, J MOL MED, V93, P1085, DOI 10.1007/s00109-015-1308-9
   Steinfeld J, 2013, DEVELOPMENT, V140, P4959, DOI 10.1242/dev.096990
   Tamiya S, 2016, EXP EYE RES, V142, P26, DOI 10.1016/j.exer.2015.02.008
   Worthley DL, 2015, CELL, V160, P269, DOI 10.1016/j.cell.2014.11.042
   Yao H, 2016, SCI REP, V6
   Yin M, 2017, ONCOTARGET, V8, P98280, DOI 10.18632/oncotarget.21550
   Zeisberg M, 2005, J BIOL CHEM, V280, P8094, DOI 10.1074/jbc.M413102200
NR 26
TC 8
Z9 8
U1 0
U2 10
PU MOLECULAR VISION
PI ATLANTA
PA C/O JEFF BOATRIGHT, LAB B, 5500 EMORY EYE CENTER, 1327 CLIFTON RD, N E,
   ATLANTA, GA 30322 USA
SN 1090-0535
J9 MOL VIS
JI Mol. Vis.
PD OCT 21
PY 2019
VL 25
BP 625
EP 635
PG 11
WC Biochemistry & Molecular Biology; Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Ophthalmology
GA JH9KZ
UT WOS:000493088400001
PM 31700227
DA 2022-11-30
ER

PT J
AU Koster, C
   Wever, KE
   Wagstaff, PE
   van den Hurk, KT
   Hooijmans, CR
   Bergen, AA
AF Koster, Celine
   Wever, Kimberley E.
   Wagstaff, Philip E.
   van den Hurk, Koen T.
   Hooijmans, Carlijn R.
   Bergen, Arthur A.
TI A Systematic Review on Transplantation Studies of the Retinal Pigment
   Epithelium in Animal Models
SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
LA English
DT Review
DE retinal degenerative diseases; retinal pigment epithelium (RPE); cell
   therapy; systematic review; meta-analysis; transplantation
ID EMBRYONIC STEM-CELLS; LONG-TERM SAFETY; HUMAN FETAL RPE; RCS RATS;
   VISUAL FUNCTION; ROYAL-COLLEGE; PHOTORECEPTOR DEGENERATION; MACULAR
   DEGENERATION; SUBRETINAL INJECTION; FUNCTIONAL RESCUE
AB The retinal pigment epithelium (RPE) and the adjacent light-sensitive photoreceptors form a single functional unit lining the back of the eye. Both cell layers are essential for normal vision. RPE degeneration is usually followed by photoreceptor degeneration and vice versa. There are currently almost no effective therapies available for RPE disorders such as Stargardt disease, specific types of retinitis pigmentosa, and age-related macular degeneration. RPE replacement for these disorders, especially in later stages of the disease, may be one of the most promising future therapies. There is, however, no consensus regarding the optimal RPE source, delivery strategy, or the optimal experimental host in which to test RPE replacement therapy. Multiple RPE sources, delivery methods, and recipient animal models have been investigated, with variable results. So far, a systematic evaluation of the (variables influencing) efficacy of experimental RPE replacement parameters is lacking. Here we investigate the effect of RPE transplantation on vision and vision-based behavior in animal models of retinal degenerated diseases. In addition, we aim to explore the effect of RPE source used for transplantation, the method of intervention, and the animal model which is used. Methods: In this study, we systematically identified all publications concerning transplantation of RPE in experimental animal models targeting the improvement of vision (e.g., outcome measurements related to the morphology or function of the eye). A variety of characteristics, such as species, gender, and age of the animals but also cell type, number of cells, and other intervention characteristics were extracted from all studies. A risk of bias analysis was performed as well. Subsequently, all references describing one of the following outcomes were analyzed in depth in this systematic review: a-, b-, and c-wave amplitudes, vision-based, thickness analyses based on optical coherence tomography (OCT) data, and transplant survival based on scanning laser ophthalmoscopy (SLO) data. Meta-analyses were performed on the a- and b-wave amplitudes from electroretinography (ERG) data as well as data from vision-based behavioral assays. Results: original research articles met the inclusion criteria after two screening rounds. Overall, most studies were categorized as unclear regarding the risk of bias, because many experimental details were poorly reported. Twenty-three studies reporting one or more of the outcome measures of interest were eligible for either descriptive (thickness analyses based on OCT data; n = 2) or meta-analyses. RPE transplantation significantly increased ERG a-wave (Hedges' g 1.181 (0.471-1.892), n = 6) and b-wave (Hedges' g 1.734 (1.295-2.172), n = 42) amplitudes and improved vision-based behavior (Hedges' g 1.018 (0.826-1.209), n = 96). Subgroup analyses revealed a significantly increased effect of the use of young and adolescent animals compared to adult animals. Moreover, transplanting more cells (in the range of 10(5) versus in the range of 10(4)) resulted in a significantly increased effect on vision-based behavior as well. The origin of cells mattered as well. A significantly increased effect was found on vision-based behavior when using ARPE-19 and OpRegen((R)) RPE. Conclusions: This systematic review shows that RPE transplantation in animal models for retinal degeneration significantly increases a- and b- wave amplitudes and improves vision-related behavior.
   These effects appear to be more pronounced in young animals, when the number of transplanted cells is larger and when ARPE-19 and OpRegen((R)) RPE cells are used. We further emphasize that there is an urgent need for improving the reporting and methodological quality of animal experiments, to make such studies more comparable.
C1 [Koster, Celine; Wagstaff, Philip E.; van den Hurk, Koen T.; Bergen, Arthur A.] Univ Amsterdam, Locat Acad Med Ctr AMC, Amsterdam Univ Med Ctr AUMC, Dept Clin Genet, NL-1105 AZ Amsterdam, Netherlands.
   [Wever, Kimberley E.; Hooijmans, Carlijn R.] Radboud Univ Nijmegen, Systemat Review Ctr Lab Anim Expt SYRCLE, Dept Hlth Evidence, Radboud Inst Hlth Sci,Med Ctr, NL-6525 GA Nijmegen, Netherlands.
   [Hooijmans, Carlijn R.] Radboud Univ Nijmegen, Med Ctr, Dept Anesthesiol Pain & Palliat Med, NL-6525 GA Nijmegen, Netherlands.
   [Bergen, Arthur A.] UvA, AMC, AUMC, Dept Ophthalmol, NL-1105 AZ Amsterdam, Netherlands.
   [Bergen, Arthur A.] Netherlands Inst Neurosci NIN KNAW, Dept Ophthalmogenet, NL-1105 BA Amsterdam, Netherlands.
C3 University of Amsterdam; Radboud University Nijmegen; Radboud University
   Nijmegen; University of Amsterdam; Academic Medical Center Amsterdam;
   Royal Netherlands Academy of Arts & Sciences; Netherlands Institute for
   Neuroscience (NIN-KNAW)
RP Bergen, AA (通讯作者)，Univ Amsterdam, Locat Acad Med Ctr AMC, Amsterdam Univ Med Ctr AUMC, Dept Clin Genet, NL-1105 AZ Amsterdam, Netherlands.; Bergen, AA (通讯作者)，UvA, AMC, AUMC, Dept Ophthalmol, NL-1105 AZ Amsterdam, Netherlands.; Bergen, AA (通讯作者)，Netherlands Inst Neurosci NIN KNAW, Dept Ophthalmogenet, NL-1105 BA Amsterdam, Netherlands.
EM c.koster@amsterdamumc.nl; kim.wever@radboudumc.nl;
   p.e.wagstaff@amsterdamumc.nl; k.t.vandenk@amsterdamumc.nl;
   carlijn.hooijmans@radboudumc.nl; aabergen@amsterdamumc.nl
RI Hooijmans, C.R./L-4390-2015; Wever, Kimberley/D-9705-2016
OI Hooijmans, C.R./0000-0001-6435-5714; Koster, Celine/0000-0002-0936-3970;
   Bergen, Arthur/0000-0002-6333-9576; Wever,
   Kimberley/0000-0003-3635-3660; Wagstaff, Philip/0000-0001-5413-8820
FU ZonMw [ZonMw 114024111]
FX This research was funded by ZonMw, grant number ZonMw 114024111.
CR Abe T, 2008, INVEST OPHTH VIS SCI, V49, P3631, DOI 10.1167/iovs.07-0947
   Arya M, 2018, EYE VISION, V5, DOI 10.1186/s40662-018-0118-x
   Ben M'Barek K, 2018, ADV EXP MED BIOL, V1074, P625, DOI 10.1007/978-3-319-75402-4_76
   Ben M'Barek K, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aai7471
   Bergen AA, 2019, PROG RETIN EYE RES, V70, P55, DOI 10.1016/j.preteyeres.2018.12.003
   BHATT NS, 1994, AM J OPHTHALMOL, V117, P214, DOI 10.1016/S0002-9394(14)73079-X
   Binder S, 2007, PROG RETIN EYE RES, V26, P516, DOI 10.1016/j.preteyeres.2007.02.002
   Booij JC, 2010, PROG RETIN EYE RES, V29, P1, DOI 10.1016/j.preteyeres.2009.08.003
   Carido M, 2014, INVEST OPHTH VIS SCI, V55, P5431, DOI 10.1167/iovs.14-14325
   Carr AJ, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008152
   Cheung GCM, 2017, ASIA-PAC J OPHTHALMO, V6, P527, DOI 10.22608/APO.2017260
   Coffey PJ, 2002, NAT NEUROSCI, V5, P53, DOI 10.1038/nn782
   Curcio CA, 1996, INVEST OPHTH VIS SCI, V37, P1236
   Dang YL, 2015, CLIN INTERV AGING, V10, P255, DOI 10.2147/CIA.S73705
   Davis RJ, 2017, STEM CELL REP, V9, P42, DOI 10.1016/j.stemcr.2017.05.016
   de Vries RBM, 2014, LAB ANIM-UK, V48, P88, DOI 10.1177/0023677213494374
   Drukker M, 2006, STEM CELLS, V24, P221, DOI 10.1634/stemcells.2005-0188
   Duan PX, 2017, INT J CLIN EXP PATHO, V10, P5274
   Engelhardt M, 2012, VISUAL NEUROSCI, V29, P83, DOI 10.1017/S0952523812000041
   Enzmann V, 1998, ACTA ANAT, V162, P178
   Figueroa AG, 2019, ADV EXP MED BIOL, V1185, P15, DOI 10.1007/978-3-030-27378-1_3
   Gabrielian K, 1999, GRAEF ARCH CLIN EXP, V237, P326, DOI 10.1007/s004170050240
   Delgado ABG, 2019, TISSUE ENG PT A, V25, P799, DOI [10.1089/ten.tea.2019.0007, 10.1089/ten.TEA.2019.0007]
   Girman SV, 2003, VISION RES, V43, P1817, DOI 10.1016/S0042-6989(03)00276-1
   Gouras P, 2002, INVEST OPHTH VIS SCI, V43, P3307
   Guziewicz KE, 2017, PROG RETIN EYE RES, V58, P70, DOI 10.1016/j.preteyeres.2017.01.005
   Haruta M, 2004, INVEST OPHTH VIS SCI, V45, P1020, DOI 10.1167/iovs.03-1034
   Hooijmans CR, 2014, BMC MED RES METHODOL, V14, DOI 10.1186/1471-2288-14-43
   Hooijmans CR, 2010, LAB ANIM-UK, V44, P170, DOI 10.1258/la.2010.009117
   Hussain RM, 2018, EXPERT OPIN BIOL TH, V18, P1049, DOI 10.1080/14712598.2018.1513486
   Idelson M, 2018, STEM CELL REP, V11, P681, DOI 10.1016/j.stemcr.2018.07.009
   Ilmarinen T, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0143669
   JIANG LQ, 1994, INVEST OPHTH VIS SCI, V35, P4300
   Jones MK, 2017, PROG RETIN EYE RES, V58, P1, DOI 10.1016/j.preteyeres.2017.01.004
   Kamao H, 2014, STEM CELL REP, V2, P205, DOI 10.1016/j.stemcr.2013.12.007
   Khanna S, 2019, BMJ OPEN OPHTHALMOL, V4, DOI 10.1136/bmjophth-2019-000398
   Klassen H, 2001, EXP NEUROL, V169, P114, DOI 10.1006/exnr.2000.7617
   Kole C, 2018, MOL THER, V26, P219, DOI 10.1016/j.ymthe.2017.09.007
   Koss MJ, 2016, GRAEF ARCH CLIN EXP, V254, P1553, DOI 10.1007/s00417-016-3386-y
   Lane A, 2014, STEM CELL TRANSL MED, V3, P1295, DOI 10.5966/sctm.2014-0094
   Lee E, 2011, BRIT J OPHTHALMOL, V95, P445, DOI 10.1136/bjo.2009.171918
   LI L, 1991, EXP EYE RES, V52, P669, DOI 10.1016/0014-4835(91)90019-B
   LI LX, 1988, EXP EYE RES, V47, P911, DOI 10.1016/0014-4835(88)90073-5
   Li Y, 2012, MOL MED, V18, P1312, DOI 10.2119/molmed.2012.00242
   Little CW, 1998, EXP NEUROL, V149, P151, DOI 10.1006/exnr.1997.6642
   Little CW, 1996, INVEST OPHTH VIS SCI, V37, P204
   Lu B, 2009, STEM CELLS, V27, P2126, DOI 10.1002/stem.149
   Lund RD, 2006, CLONING STEM CELLS, V8, P189, DOI 10.1089/clo.2006.8.189
   Lund RD, 2001, P NATL ACAD SCI USA, V98, P9942, DOI 10.1073/pnas.171266298
   Luo MY, 2018, INT J OPHTHALMOL-CHI, V11, P150, DOI 10.18240/ijo.2018.01.23
   Maeda T, 2013, J BIOL CHEM, V288, P34484, DOI 10.1074/jbc.M113.518571
   McGill TJ, 2004, VISION RES, V44, P2559, DOI 10.1016/j.visres.2004.05.025
   McGill TJ, 2017, TRANSL VIS SCI TECHN, V6, DOI 10.1167/tvst.6.3.17
   Moher D, 2009, PLOS MED, V6, DOI [10.1136/bmj.b4037, 10.1371/journal.pmed.1000097]
   Muller-Jensen K, 1975, Mod Probl Ophthalmol, V15, P228
   Nazari H, 2015, PROG RETIN EYE RES, V48, P1, DOI 10.1016/j.preteyeres.2015.06.004
   PAULEIKHOFF D, 1990, OPHTHALMOLOGY, V97, P171
   Peng CH, 2016, ONCOTARGET, V7, P64631, DOI 10.18632/oncotarget.11502
   Petrus-Reurer S, 2018, JOVE-J VIS EXP, DOI 10.3791/56702
   Phillips SJ, 2003, CURR EYE RES, V26, P81, DOI 10.1076/ceyr.26.2.81.14508
   Pinilla I, 2007, EXP EYE RES, V85, P381, DOI 10.1016/j.exer.2007.06.002
   Sauve Y, 2006, VISION RES, V46, P1459, DOI 10.1016/j.visres.2005.11.009
   Sauve Y, 2004, VISION RES, V44, P9, DOI 10.1016/j.visres.2003.08.015
   Schatz P, 2011, OPHTHALMOLOGY, V118, P888, DOI 10.1016/j.ophtha.2010.09.005
   Shah M, 2019, PHARM RES-DORDR, V36, DOI 10.1007/s11095-019-2588-5
   Sharma R, 2019, SCI TRANSL MED, V11, DOI 10.1126/scitranslmed.aat5580
   Sohn EH, 2015, SCI REP-UK, V5, DOI 10.1038/srep11791
   Sparrrow JR, 2010, CURR MOL MED, V10, P802
   Stanzel B, 2019, ADV EXP MED BIOL, V1186, P141, DOI 10.1007/978-3-030-28471-8_6
   Stanzel BV, 2012, INVEST OPHTH VIS SCI, V53, P490, DOI 10.1167/iovs.11-8260
   Talib M, 2019, TRANSL VIS SCI TECHN, V8, DOI 10.1167/tvst.8.4.24
   Tang ZM, 2017, J TRANSL MED, V15, DOI 10.1186/s12967-017-1183-y
   Thomas BB, 2018, GRAEF ARCH CLIN EXP, V256, P2113, DOI 10.1007/s00417-018-4134-2
   Thomas BB, 2016, INVEST OPHTH VIS SCI, V57, P2877, DOI 10.1167/iovs.16-19238
   Tsang SH, 2018, ADV EXP MED BIOL, V1085, P183, DOI 10.1007/978-3-319-95046-4_37
   van Meurs J.C., 2018, RYANS RETINA, P2254
   van Meurs JC, 2004, BRIT J OPHTHALMOL, V88, P110, DOI 10.1136/bjo.88.1.110
   Van Meurs JC, 2003, AM J OPHTHALMOL, V136, P688, DOI 10.1016/S0002-9394(03)00384-2
   Wang NK, 2010, TRANSPLANTATION, V89, P911, DOI 10.1097/TP.0b013e3181d45a61
   Wang SM, 2008, INVEST OPHTH VIS SCI, V49, P3201, DOI 10.1167/iovs.08-1831
   Wang SM, 2008, INVEST OPHTH VIS SCI, V49, P416, DOI 10.1167/iovs.07-0992
   Weed Lindsey S, 2017, Stem Cell Investig, V4, P65, DOI 10.21037/sci.2017.07.02
   Wu HX, 2018, DOC OPHTHALMOL, V137, P71, DOI 10.1007/s10633-018-9648-8
   Wu W, 2016, ONCOTARGET, V7, P22819, DOI 10.18632/oncotarget.8185
   YAMAMOTO S, 1993, INVEST OPHTH VIS SCI, V34, P3068
   Zwetsloot PP, 2017, ELIFE, V6, DOI 10.7554/eLife.24260
NR 86
TC 10
Z9 10
U1 1
U2 6
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 1422-0067
J9 INT J MOL SCI
JI Int. J. Mol. Sci.
PD APR
PY 2020
VL 21
IS 8
AR 2719
DI 10.3390/ijms21082719
PG 24
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA LR3AC
UT WOS:000535565300061
PM 32295315
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU Zamora, DO
   Riviere, M
   Choi, D
   Pan, YZ
   Planck, SR
   Rosenbaum, JT
   David, LL
   Smith, JR
AF Zamora, David O.
   Riviere, Michael
   Choi, Dongseok
   Pan, Yuzhen
   Planck, Stephen R.
   Rosenbaum, James T.
   David, Larry L.
   Smith, Justine R.
TI Proteomic profiling of human retinal and choroidal endothelial cells
   reveals molecular heterogeneity related to tissue of origin
SO MOLECULAR VISION
LA English
DT Article
ID EXPERIMENTAL AUTOIMMUNE UVEITIS; MACULAR DEGENERATION; LEUKOCYTE
   TRAFFICKING; SHOTGUN PROTEOMICS; GROWTH-FACTOR; CATHEPSIN-B; IN-VITRO;
   EXPRESSION; MODEL; NEOVASCULARIZATION
AB Purpose: The ocular vascular endothelium plays a key role in the development of several leading retinal causes of blindness in Western nations. Choroidal endothelial cells are integral to the subretinalneovascular lesions that characterize the exudative form of late age-related macular degeneration (AMD), and retinal endothelial cells participate in the initiation of diabetic retinopathy and posterior uveitis. Vascular endothelial cells at different sites exhibit considerable molecular diversity. This diversity has implications for understanding the pathogenesis of tissue-specific diseases and for the development of targeted therapies to treat these conditions. Previous work from our group has identified significant differences in the gene transcript profiles of human retinal and choroidal endothelial cells. Because the proteome ultimately determines the behavior of any given cell, however, it is critical to determine whether molecular differences exist at the level of protein expression.
   Methods: Retinal and choroidal endothelial cells were separately isolated from five sets of human eyes by enzymatic digestion with type II collagenase followed by anti-CD31 antibody-conjugated magnetic bead separation. Cells were washed to remove serum peptides in the culture medium, and lysed by sonication in buffer containing 2% sodium dodecyl sulfate. Protein was then precipitated with acetone. Retinal and choroidal endothelial samples from each donor were labeled with Cy3 and Cy5, respectively, mixed with a Cy2-labeled pooled protein sample to facilitate spot matching across gels, and separated by two-dimensional difference gel electrophoresis (2D-DIGE). Following a global normalization, differentially abundant protein spots that were visible in at least four of five donor gels were detected by the significance analysis of microarrays method, with false discovery rate set at 5%. Corresponding spots were excised from additional DIGE-labeled or Coomassie-stained 2D electrophoretic gels. Protein identification was performed by liquid chromatography and tandem mass spectrometry.
   Results: Of 123 protein spots detected by 2D-DIGE that qualified for statistical analysis, we found 31 spots that demonstrated a significant difference in abundance between retinal endothelial samples versus choroidal endothelial samples. For 17 proteins, over 50% of the spectral counts could be matched to a single protein in the digested spot. Eleven proteins were more abundant in retinal endothelial cells (i. e., inorganic pyrophosphatase, protein disulfide isomerase A3, calreticulin, peroxiredoxin-4, protein disulfide isomerase, serpin B9, F-actin capping protein subunit beta, coactosin-like protein, vimentin, cathepsin B, and a high molecular weight form of annexin A3). Six proteins were more abundant in choroidal endothelial cells (i. e., glutathione peroxidase 1, ubiquitin carboxyl-terminal hydrolase isozyme L1 (UCH-L1), heat-shock protein beta-1, superoxide dismutase (Cu-Zn), nucleoside diphosphate kinase A, and a low molecular weight form of annexin 3).
   Conclusions: Our data indicate that the proteomes of retinal and choroidal vascular endothelial cells are different. Several differentially expressed proteins are implicated in the regulation of angiogenesis; these include cathepsin B and UCH-L1, proteins with transcripts that were also differently expressed according to microarray. Our observations further suggest that angiogenesis within the retina, a component of severe diabetic retinopathy and posterior uveitis, may be controlled by different mechanisms to those regulating choroidal neovascularization, as occur in exudative AMD. Future studies to establish the role of these angiogenic proteins in disease may suggest potential new targets for tissue-specific therapies.
C1 [Planck, Stephen R.; Rosenbaum, James T.; Smith, Justine R.] Oregon Hlth & Sci Univ, Dept Cell & Dev Biol, Portland, OR 97239 USA.
   [Zamora, David O.; Pan, Yuzhen; Planck, Stephen R.; Rosenbaum, James T.; Smith, Justine R.] Oregon Hlth & Sci Univ, Casey Eye Inst, Dept Biochem & Mol Biol, Portland, OR 97239 USA.
   [Riviere, Michael; David, Larry L.] Oregon Hlth & Sci Univ, Dept Publ Hlth & Prevent Med, Div Biostat, Portland, OR 97239 USA.
   [Planck, Stephen R.; Rosenbaum, James T.] Oregon Hlth & Sci Univ, Dept Med, Div Arthritis & Rheumat Dis, Portland, OR 97239 USA.
C3 Oregon Health & Science University; Oregon Health & Science University;
   Oregon Health & Science University; Oregon Health & Science University
RP Smith, JR (通讯作者)，Oregon Hlth & Sci Univ, Dept Cell & Dev Biol, Biomed Res Bldg,L467 AD,3181 SW Sam Jackson Pk Rd, Portland, OR 97239 USA.
EM smithjus@ohsu.edu
RI Pan, YZ/GVS-2269-2022; Zamora, David/B-9889-2011
OI Zamora, David/0000-0002-7003-5933; Choi, Dongseok/0000-0002-1552-4072
FU NEI NIH HHS [EY014909, EY010572] Funding Source: Medline; NATIONAL EYE
   INSTITUTE [P30EY010572, R01EY014909] Funding Source: NIH RePORTER
CR Ambati J, 2003, NAT MED, V9, P1390, DOI 10.1038/nm950
   Bargagna-Mohan P, 2006, INVEST OPHTH VIS SCI, V47, P4138, DOI 10.1167/iovs.05-1452
   BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x
   Bruneel A, 2003, PROTEOMICS, V3, P714, DOI 10.1002/pmic.200300409
   Campochiaro PA, 2006, INVEST OPHTH VIS SCI, V47, P462, DOI 10.1167/iovs.05-1494
   Chen YR, 2006, J PROTEOME RES, V5, P2727, DOI 10.1021/pr060212g
   Chi JT, 2003, P NATL ACAD SCI USA, V100, P10623, DOI 10.1073/pnas.1434429100
   Congdon NG, 2003, JAMA-J AM MED ASSOC, V290, P2057, DOI 10.1001/jama.290.15.2057
   Cox B, 2005, METHODS, V35, P303, DOI 10.1016/j.ymeth.2004.08.021
   DAY INM, 1988, BIOCHEM SOC T, V16, P454, DOI 10.1042/bst0160454
   de Jong PTVM, 2006, NEW ENGL J MED, V355, P1474, DOI 10.1056/NEJMra062326
   Gritz DC, 2004, OPHTHALMOLOGY, V111, P491, DOI 10.1016/j.ophtha.2003.06.014
   Hendrickx J, 2004, PHYSIOL GENOMICS, V19, P198, DOI 10.1152/physiolgenomics.00143.2004
   Holmen C, 2005, AM J RESP CELL MOL, V32, P18, DOI 10.1165/rcmb.2004-0253OC
   Im E, 2005, MOL BIOL CELL, V16, P3488, DOI 10.1091/mbc.E04-11-1029
   Ke QD, 2006, MOL PHARMACOL, V70, P1469, DOI 10.1124/mol.106.027029
   Kempen JH, 2004, ARCH OPHTHALMOL-CHIC, V122, P552
   Klein R, 2007, OPHTHALMOLOGY, V114, P253, DOI 10.1016/j.ophtha.2006.10.040
   Kreil DP, 2004, BIOINFORMATICS, V20, P2026, DOI 10.1093/bioinformatics/bth193
   Lakka SS, 2005, BRAIN PATHOL, V15, P327
   Lampi KJ, 2002, INVEST OPHTH VIS SCI, V43, P216
   Lebherz C, 2005, DIABETES, V54, P1141, DOI 10.2337/diabetes.54.4.1141
   Li R, 2006, ONCOGENE, V25, P2628, DOI 10.1038/sj.onc.1209289
   Liu HB, 2004, ANAL CHEM, V76, P4193, DOI 10.1021/ac0498563
   Luchansky SJ, 2006, BIOCHEMISTRY-US, V45, P14717, DOI 10.1021/bi061406c
   MOSS SE, 1994, OPHTHALMOLOGY, V101, P1061
   Nesvizhskii AI, 2003, ANAL CHEM, V75, P4646, DOI 10.1021/ac0341261
   Nivinskas H, 1996, BIOTECHNIQUES, V20, P380
   NIVINSKAS H, 1996, BIOTECHNIQUES, V20, P384
   Ohno-Matsui K, 2002, AM J PATHOL, V160, P711, DOI 10.1016/S0002-9440(10)64891-2
   Parnaby-Price A, 1998, J LEUKOCYTE BIOL, V64, P434, DOI 10.1002/jlb.64.4.434
   Premzl A, 2006, J CELL BIOCHEM, V97, P1230, DOI 10.1002/jcb.20720
   Rothova A, 1996, BRIT J OPHTHALMOL, V80, P332, DOI 10.1136/bjo.80.4.332
   Seliger B, 2007, CLIN CANCER RES, V13, P27, DOI 10.1158/1078-0432.CCR-06-0824
   Silverman MD, 2001, INVEST OPHTH VIS SCI, V42, P2861
   Smith JR, 2007, INVEST OPHTH VIS SCI, V48, P2676, DOI 10.1167/iovs.06-0598
   Storey JD, 2002, J ROY STAT SOC B, V64, P479, DOI 10.1111/1467-9868.00346
   Tusher VG, 2001, P NATL ACAD SCI USA, V98, P10515
   Wang DJ, 2004, J PROTEOME RES, V3, P627, DOI 10.1021/pr049976r
   Wang JS, 2006, CELL MOL IMMUNOL, V3, P255
   Wautier JL, 2004, CIRC RES, V95, P233, DOI 10.1161/01.RES.0000137876.28454.64
   Wu CC, 2002, CURR OPIN MOL THER, V4, P242
   Xu HP, 2003, INVEST OPHTH VIS SCI, V44, P226, DOI 10.1167/iovs.01-1202
NR 43
TC 44
Z9 49
U1 0
U2 6
PU MOLECULAR VISION
PI ATLANTA
PA C/O JEFF BOATRIGHT, LAB B, 5500 EMORY EYE CENTER, 1327 CLIFTON RD, N E,
   ATLANTA, GA 30322 USA
SN 1090-0535
J9 MOL VIS
JI Mol. Vis.
PD OCT 30
PY 2007
VL 13
IS 233
BP 2058
EP 2065
PG 8
WC Biochemistry & Molecular Biology; Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Ophthalmology
GA 310QN
UT WOS:000256545200001
PM 18079679
DA 2022-11-30
ER

PT J
AU Pilotto, E
   Convento, E
   Guidolin, F
   Abalsamo, CK
   Longhin, E
   Parrozzani, R
   Midena, E
AF Pilotto, Elisabetta
   Convento, Enrica
   Guidolin, Francesca
   Abalsamo, Clelia Karine
   Longhin, Evelyn
   Parrozzani, Raffaele
   Midena, Edoardo
TI Microperimetry Features of Geographic Atrophy Identified With En Face
   Optical Coherence Tomography
SO JAMA OPHTHALMOLOGY
LA English
DT Article
ID FUNDUS AUTOFLUORESCENCE; MACULAR DEGENERATION; RETINAL SENSITIVITY;
   PROGRESSION
AB IMPORTANCE Progressive geographic atrophy (GA) of the retinal pigment epithelium leads to loss of central vision. To identify GA in age-related macular degeneration and assess treatment, correlation of function observed on microperimetry with structure observed on optical coherence tomographic (OCT) images may be of value.
   OBJECTIVE To characterize the microperimetric function of GA as identified from en face OCT imaging.
   DESIGN, SETTING, AND PARTICIPANTS In a case-series study, 20 patients (22 eyes) entered the study at the University of Padova according to preplanned conditions. From March 1 to July 30, 2014, en face OCT images were obtained at the outer retinal layer and choroidal layer levels. The microperimetry sensitivity map was superimposed on the en face OCT images, which had been used to measure GA areas. Relative and dense scotoma rates were calculated in the GA areas. After data collection, the study eyes were divided into 3 groups according to the macular residual mean sensitivity.
   MAIN OUTCOMES AND MEASURES Retinal sensitivity measured by microperimetry within areas of GA identified by en face OCT images.
   RESULTS Twenty patients (5 men and 15 women) were included in the study, with a mean (SD) age of 79.5 (7.0) years (range, 69-98 years). Macular residual mean retinal sensitivity was less than 5 dB in 7 eyes (group 1), 5 to 10 dB in 9 eyes (group 2), and greater than 10 dB in 6 eyes (group 3). Mean (SD) GA area differed among the groups at the outer retinal (13.13 [5.03] mm(2) [range, 5.75-21.04 mm(2)] in group 1; 7.80 [3.25] mm(2) [range, 3.31-13.52 mm(2)] in group 2; and 3.94 [2.35] mm(2) [range, 1.46-7.90 mm(2)] in group 3; P = .001) and choroidal (11.83 [5.55] mm(2) [range, 4.55-22.14 mm(2)] in group 1; 7.00 [4.29] mm(2) [range, 0.90-13.83 mm(2)] in group 2; and 3.27 [2.29] mm(2) [range, 0.91-7.23 mm(2)] in group 3; P = .007) layer levels. Mean (SD) GA area imaged at the outer retinal layer level was significantly larger than that imaged at the choroidal level in group 3 (difference, 0.67 mm(2)mm(2); 95% CI, 0.31-1.03 mm(2); P = .005), but not in groups 1 or 2. Mean (SD) rate of relative scotoma was significantly higher in the GA area imaged at the outer retinal layer level than at the choroidal level in group 3 (47.70% [31.30%] [range, 13.60%-100%] vs 34.00% [37.30%] [range, 0%-100%]; difference, 13.74%; 95% CI, 3.84%-23.63%; P = .02), but not in groups 1 or 2.
   CONCLUSIONS AND RELEVANCE In the early stage of GA, when retinal sensitivity is relatively good, these data suggest that the GA area imaged on en face OCT at the outer retinal level correctly detects the wide functional degenerative involvement of the photoreceptors. These findings provide novel data that correlate function and structure, which may be of value when assessing treatments that might prevent or reduce the rate of growth of GA.
C1 [Pilotto, Elisabetta; Convento, Enrica; Guidolin, Francesca; Abalsamo, Clelia Karine; Longhin, Evelyn; Midena, Edoardo] Univ Padua, Dept Ophthalmol, Via Giustiniani 2, I-35128 Padua, Italy.
   [Parrozzani, Raffaele; Midena, Edoardo] GB Bietti Fdn, Ist Ricovero & Cura Carattere Sci, Rome, Italy.
C3 University of Padua; IRCCS - Fondazione "G.B. Bietti" per lo Studio e la
   Ricerca in Oftalmologia
RP Midena, E (通讯作者)，Univ Padua, Dept Ophthalmol, Via Giustiniani 2, I-35128 Padua, Italy.
EM edoardo.midena@unipd.it
RI parrozzani, raffaele/K-2034-2016; Parrozzani, Raffaele/W-3341-2017;
   Midena, Edoardo/AAB-6010-2020
OI parrozzani, raffaele/0000-0003-0216-727X; Parrozzani,
   Raffaele/0000-0003-0216-727X; 
FU Fondazione Roma; Ministry of Health (G. B. Bietti Foundation)
FX This study was supported by Fondazione Roma and the Ministry of Health
   (G. B. Bietti Foundation).
CR Bearelly S, 2009, OPHTHALMOLOGY, V116, P1762, DOI 10.1016/j.ophtha.2009.04.015
   Biesemeier A, 2014, NEUROBIOL AGING, V35, P2562, DOI 10.1016/j.neurobiolaging.2014.05.003
   Curcio CA, 1996, INVEST OPHTH VIS SCI, V37, P1236
   Curcio CA, 2000, OPHTHALMOLOGY, V107, P334, DOI 10.1016/S0161-6420(99)00037-8
   Flores-Moreno I, 2015, BRIT J OPHTHALMOL, V99, P1260, DOI 10.1136/bjophthalmol-2014-306422
   General Assembly of the World Medical Association, 2014, J Am Coll Dent, V81, P14
   Holz FG, 2007, AM J OPHTHALMOL, V143, P463, DOI 10.1016/j.ajo.2006.11.041
   Kellner U, 2010, RETINA-J RET VIT DIS, V30, P6, DOI 10.1097/IAE.0b013e3181b8348b
   Klein R, 2007, OPHTHALMOLOGY, V114, P253, DOI 10.1016/j.ophtha.2006.10.040
   KORTE GE, 1984, INVEST OPHTH VIS SCI, V25, P1135
   Leonard DS, 1997, INVEST OPHTH VIS SCI, V38, P1094
   Lujan BJ, 2009, OPHTHAL SURG LAS IM, V40, P96, DOI 10.3928/15428877-20090301-16
   McLeod DS, 2009, INVEST OPHTH VIS SCI, V50, P4982, DOI 10.1167/iovs.09-3639
   Meleth AD, 2011, INVEST OPHTH VIS SCI, V52, P1119, DOI 10.1167/iovs.10-6075
   Midena E, 2007, BRIT J OPHTHALMOL, V91, P1499, DOI 10.1136/bjo.2007.119685
   Nunes RP, 2013, OSLI RETINA, V44, P344, DOI 10.3928/23258160-20130715-06
   Pilotto E, 2015, INVEST OPHTH VIS SCI, V56, P8120, DOI 10.1167/iovs.15-17366
   Pilotto E, 2015, BRIT J OPHTHALMOL, V99, P1082, DOI 10.1136/bjophthalmol-2014-306338
   Pilotto E, 2013, CAN J OPHTHALMOL, V48, P386, DOI 10.1016/j.jcjo.2013.03.022
   Pilotto E, 2013, BRIT J OPHTHALMOL, V97, P622, DOI 10.1136/bjophthalmol-2012-302633
   Pilotto E, 2011, BRIT J OPHTHALMOL, V95, P1140, DOI 10.1136/bjo.2010.187344
   Querques L, 2012, AM J OPHTHALMOL, V153, P1110, DOI 10.1016/j.ajo.2011.11.002
   Sayegh RG, 2014, BRIT J OPHTHALMOL, V98, P1050, DOI 10.1136/bjophthalmol-2014-305195
   SCHATZ H, 1989, OPHTHALMOLOGY, V96, P1541
   Spaide RF, 2009, AM J OPHTHALMOL, V148, P325
   Spaide RF, 2008, AM J OPHTHALMOL, V146, P496, DOI 10.1016/j.ajo.2008.05.032
   Stetson PF, 2014, INVEST OPHTH VIS SCI, V55, P792, DOI 10.1167/iovs.13-13199
   Whitmore SS, 2015, PROG RETIN EYE RES, V45, P1, DOI 10.1016/j.preteyeres.2014.11.005
   Wolff B, 2014, RETINA-J RET VIT DIS, V34, P2072, DOI 10.1097/IAE.0000000000000208
   Wu ZC, 2015, JAMA OPHTHALMOL, V133, P442, DOI 10.1001/jamaophthalmol.2014.5963
   Wu ZC, 2015, INVEST OPHTH VIS SCI, V56, P1546, DOI 10.1167/iovs.14-16211
   Yehoshua Z, 2013, OSLI RETINA, V44, P127, DOI 10.3928/23258160-20130313-05
   Yehoshua Z, 2011, OPHTHALMOLOGY, V118, P679, DOI 10.1016/j.ophtha.2010.08.018
NR 33
TC 8
Z9 8
U1 0
U2 4
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 2168-6165
EI 2168-6173
J9 JAMA OPHTHALMOL
JI JAMA Ophthalmol.
PD AUG
PY 2016
VL 134
IS 8
BP 873
EP 879
DI 10.1001/jamaophthalmol.2016.1535
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA DT1AD
UT WOS:000381213200008
PM 27253760
OA Bronze
DA 2022-11-30
ER

PT J
AU Norval, M
   Lucas, RM
   Cullen, AP
   de Gruijl, FR
   Longstreth, J
   Takizawa, Y
   van der Leun, JC
AF Norval, M.
   Lucas, R. M.
   Cullen, A. P.
   de Gruijl, F. R.
   Longstreth, J.
   Takizawa, Y.
   van der Leun, J. C.
TI The human health effects of ozone depletion and interactions with
   climate change
SO PHOTOCHEMICAL & PHOTOBIOLOGICAL SCIENCES
LA English
DT Review
ID NONMELANOMA SKIN-CANCER; SQUAMOUS-CELL CARCINOMA; VITAMIN-D STATUS;
   TYPE-1 DIABETES-MELLITUS; CUTANEOUS MALIGNANT-MELANOMA; POLYMORPHIC
   LIGHT ERUPTION; CIRCULATING 25-HYDROXYVITAMIN-D LEVELS;
   RADIATION-INDUCED IMMUNOSUPPRESSION; CARDIOVASCULAR-DISEASE MORTALITY;
   AMBIENT ULTRAVIOLET-RADIATION
AB Depletion of the stratospheric ozone layer has led to increased solar UV-B radiation (280-315 nm) at the surface of the Earth. This change is likely to have had an impact on human exposure to UV-B radiation with consequential detrimental and beneficial effects on health, although behavioural changes in society over the past 60 years or so with regard to sun exposure are of considerable importance. The present report concentrates on information published since our previous report in 2007. The adverse effects of UV radiation are primarily on the eye and the skin. While solar UV radiation is a recognised risk factor for some types of cataract and for pterygium, the evidence is less strong, although increasing, for ocular melanoma, and is equivocal at present for age-related macular degeneration. For the skin, the most common harmful outcome is skin cancer, including melanoma and the non-melanoma skin cancers, basal cell carcinoma and squamous cell carcinoma. The incidence of all three of these tumours has risen significantly over the past five decades, particularly in people with fair skin, and is projected to continue to increase, thus posing a significant world-wide health burden. Overexposure to the sun is the major identified environmental risk factor in skin cancer, in association with various genetic risk factors and immune effects. Suppression of some aspects of immunity follows exposure to UV radiation and the consequences of this modulation for the immune control of infectious diseases, for vaccination and for tumours, are additional concerns. In a common sun allergy (polymorphic light eruption), there is an imbalance in the immune response to UV radiation, resulting in a sun-evoked rash. The major health benefit of exposure to solar UV-B radiation is the production of vitamin D. Vitamin D plays a crucial role in bone metabolism and is also implicated in protection against a wide range of diseases. Although there is some evidence supporting protective effects for a range of internal cancers, this is not yet conclusive, but strongest for colorectal cancer, at present. A role for vitamin D in protection against several autoimmune diseases has been studied, with the most convincing results to date for multiple sclerosis. Vitamin D is starting to be assessed for its protective properties against several infectious and coronary diseases. Current methods for protecting the eye and the skin from the adverse effects of solar UV radiation are evaluated, including seeking shade, wearing protective clothing and sunglasses, and using sunscreens. Newer possibilities are considered such as creams that repair UV-induced DNA damage, and substances applied topically to the skin or eaten in the diet that protect against some of the detrimental effects of sun exposure. It is difficult to provide easily understandable public health messages regarding "safe" sun exposure, so that the positive effects of vitamin D production are balanced against the negative effects of excessive exposure. The international response to ozone depletion has included the development and deployment of replacement technologies and chemicals. To date, limited evidence suggests that substitutes for the ozone-depleting substances do not have significant effects on human health. In addition to stratospheric ozone depletion, climate change is predicted to affect human health, and potential interactions between these two parameters are considered.
   These include altering the risk of developing skin tumours, infectious diseases and various skin diseases, in addition to altering th efficiency by which pathogenic microorganisms are inactivated in the environment.
C1 [Norval, M.] Univ Edinburgh, Sch Med, Edinburgh EH8 9AG, Midlothian, Scotland.
   [Lucas, R. M.] Australian Natl Univ, Natl Ctr Epidemiol & Populat Hlth, Canberra, ACT 0200, Australia.
   [Cullen, A. P.] Univ Waterloo, Sch Optometry, Waterloo, ON N2L 5T6, Canada.
   [de Gruijl, F. R.] Leiden Univ, Med Ctr, Dept Dermatol, NL-2300 RC Leiden, Netherlands.
   [Longstreth, J.] Inst Global Risk Res, Bethesda, MD 20817 USA.
   [Takizawa, Y.] Natl Inst Minamata Dis, Minamata, Kumamoto 8670008, Japan.
   [van der Leun, J. C.] Ecofys, NL-3526 KL Utrecht, Netherlands.
C3 University of Edinburgh; Australian National University; University of
   Waterloo; Leiden University; Leiden University Medical Center (LUMC);
   Leiden University - Excl LUMC
RP Norval, M (通讯作者)，Univ Edinburgh, Sch Med, Edinburgh EH8 9AG, Midlothian, Scotland.
EM Mary.Norval@ed.ac.uk
OI Lucas, Robyn/0000-0003-2736-3541
CR ACHESON ED, 1960, AM J HYG, V72, P88, DOI 10.1093/oxfordjournals.aje.a120137
   Ahn J, 2008, JNCI-J NATL CANCER I, V100, P796, DOI 10.1093/jnci/djn152
   *AIHW, 2008, CANC SER, V46
   Alamartine E, 2003, J INVEST DERMATOL, V120, P99, DOI 10.1046/j.1523-1747.2003.12016.x
   Almquist M, 2010, INT J CANCER, V127, P2159, DOI 10.1002/ijc.25215
   Aloia JF, 2007, EPIDEMIOL INFECT, V135, P1095, DOI 10.1017/S0950268807008308
   Applebaum KM, 2007, ENVIRON HEALTH PERSP, V115, P1231, DOI 10.1289/ehp.10096
   Armstrong B., 1997, AUSTRALAS J DERMA S1, V38, pS1, DOI DOI 10.1111/J.1440-0960.1997.TB01000.X
   Ascherio A, 2007, ANN NEUROL, V61, P504, DOI 10.1002/ana.21141
   Asgari M, 2010, J INVEST DERMATOL, V130, pS58
   Asgari MM, 2008, J INVEST DERMATOL, V128, P1409, DOI 10.1038/sj.jid.5701227
   Ateenyi-Agaba C, 2004, BRIT J CANCER, V90, P1777, DOI 10.1038/sj.bjc.6601743
   Atkinson MA, 2001, LANCET, V358, P221, DOI 10.1016/S0140-6736(01)05415-0
   *AUSTR PAED END GR, CLIN PRACT GUID TYP
   Autier P, 2009, BRIT J DERMATOL, V161, P40, DOI 10.1111/j.1365-2133.2009.09448.x
   Autier P, 2007, ARCH INTERN MED, V167, P1730, DOI 10.1001/archinte.167.16.1730
   Autier P, 2007, INT J CANCER, V121, P1, DOI 10.1002/ijc.22745
   Ayala M, 2007, INVEST OPHTH VIS SCI, V48, P4187, DOI 10.1167/iovs.06-0660
   Bahlo M, 2009, NAT GENET, V41, P824, DOI 10.1038/ng.396
   Barnetson RS, 2006, J INVEST DERMATOL, V126, P1869, DOI 10.1038/sj.jid.5700317
   Bath-Hextall F, 2007, INT J CANCER, V121, P2105, DOI 10.1002/ijc.22952
   Becklund BR, 2010, P NATL ACAD SCI USA, V107, P6418, DOI 10.1073/pnas.1001119107
   Beissert S, 2008, PHOTOCHEM PHOTOBIOL, V84, P29, DOI 10.1111/j.1751-1097.2007.00231.x
   Benitez-Aguirre PZ, 2009, MED J AUSTRALIA, V190, P426, DOI 10.5694/j.1326-5377.2009.tb02490.x
   Bennett MF, 2008, J INVEST DERM SYMP P, V13, P15, DOI 10.1038/jidsymp.2008.3
   Berkhout RJM, 2000, J CLIN MICROBIOL, V38, P2087
   Bialek-Szymanska Anna, 2007, Klin Oczna, V109, P127
   Bikle DD, 2004, J NUTR, V134, p3472S, DOI 10.1093/jn/134.12.3472S
   Bimczok R, 2007, SKIN PHARMACOL PHYS, V20, P57, DOI 10.1159/000096173
   Birt B, 2007, J PHOTOCH PHOTOBIO B, V87, P27, DOI 10.1016/j.jphotobiol.2006.12.008
   Bischoff-Ferrari HA, 2006, AM J CLIN NUTR, V84, P18, DOI 10.1093/ajcn/84.1.18
   Blum M, 2008, ENDOCRINE, V33, P90, DOI 10.1007/s12020-008-9051-4
   Bodiwala D, 2003, CANCER LETT, V200, P141, DOI 10.1016/S0304-3835(03)00416-6
   Boehm AB, 2009, ENVIRON SCI TECHNOL, V43, P8046, DOI 10.1021/es9015124
   Bogh MKB, 2010, J INVEST DERMATOL, V130, P546, DOI 10.1038/jid.2009.323
   Bono A, 2008, TUMORI, V94, P11
   Box NF, 2001, J INVEST DERMATOL, V116, P224, DOI 10.1046/j.1523-1747.2001.01224.x
   Braff MH, 2006, CURR TOP MICROBIOL, V306, P91
   Brekke HK, 2007, PEDIATR DIABETES, V8, P11, DOI 10.1111/j.1399-5448.2006.00223.x
   Brewster DH, 2007, BRIT J DERMATOL, V156, P1295, DOI 10.1111/j.1365-2133.2007.07892.x
   Brudnik U, 2009, EXP DERMATOL, V18, P167, DOI 10.1111/j.1600-0625.2008.00760.x
   BRULS WAG, 1984, PHOTOCHEM PHOTOBIOL, V40, P485, DOI 10.1111/j.1751-1097.1984.tb04622.x
   Byers T, 2010, AM J EPIDEMIOL, V172, P1, DOI 10.1093/aje/kwq112
   Camouse MM, 2009, EXP DERMATOL, V18, P522, DOI 10.1111/j.1600-0625.2008.00818.x
   Campbell-Stokes PL, 2005, DIABETOLOGIA, V48, P643, DOI 10.1007/s00125-005-1697-3
   *CANC COUNC AUSTR, RISKS BEN SUN EXP PO
   Cannell JJ, 2006, EPIDEMIOL INFECT, V134, P1129, DOI 10.1017/S0950268806007175
   Cannell JJ, 2008, VIROL J, V5, DOI 10.1186/1743-422X-5-29
   Cannell JJ, 2008, ALTERN MED REV, V13, P6
   Cantorna MT, 2008, MOL ASPECTS MED, V29, P369, DOI 10.1016/j.mam.2008.04.004
   Carless MA, 2008, BRIT J DERMATOL, V159, P804, DOI 10.1111/j.1365-2133.2008.08745.x
   Carter OBJ, 2007, J HEALTH COMMUN, V12, P41, DOI 10.1080/10810730601093371
   Casimiro E, 2006, ENVIRON HEALTH PERSP, V114, P1950, DOI 10.1289/ehp.8431
   Chandler HL, 2010, INVEST OPHTH VIS SCI, V51, P172, DOI 10.1167/iovs.09-3996
   Chang YM, 2009, INT J EPIDEMIOL, V38, P814, DOI 10.1093/ije/dyp166
   Charkaluk ML, 2002, PEDIATR RES, V52, P859, DOI 10.1203/01.PDR.0000034261.44203.26
   Chen ACH, 2008, J GEN VIROL, V89, P2891, DOI 10.1099/vir.0.2008/003665-0
   Chlebowski RT, 2008, JNCI-J NATL CANCER I, V100, P1581, DOI 10.1093/jnci/djn360
   CHOU BR, 1986, CAN J OPTOM, V48, P17
   Christian JB, 2008, JNCI-J NATL CANCER I, V100, P1223, DOI 10.1093/jnci/djn262
   Cinek O, 2003, EUR J PEDIATR, V162, P428, DOI 10.1007/s00431-003-1211-1
   Clark RA, 2008, J EXP MED, V205, P2221, DOI 10.1084/jem.20071190
   CLEMENS TL, 1982, LANCET, V1, P74
   COLDITZ GA, 1994, JAMA-J AM MED ASSOC, V271, P698, DOI 10.1001/jama.271.9.698
   Connelly SJ, 2007, ENVIRON SCI TECHNOL, V41, P7101, DOI 10.1021/es071324r
   Coohill TP, 2009, PHOTOCHEM PHOTOBIOL, V85, P1043, DOI 10.1111/j.1751-1097.2009.00586.x
   Coory M, 2006, CANCER CAUSE CONTROL, V17, P21, DOI 10.1007/s10552-005-3637-4
   Dahlquist G, 1999, DIABETOLOGIA, V42, P51, DOI 10.1007/s001250051112
   Dal H, 2008, J DERMATOL, V35, P55, DOI 10.1111/j.1346-8138.2008.00416.x
   Dal H, 2007, EUR J DERMATOL, V17, P428, DOI 10.1684/ejd.2007.0242
   Dalmas M, 2007, EUR J CANCER, V43, P1604, DOI 10.1016/j.ejca.2007.04.013
   Damian DL, 2008, J INVEST DERMATOL, V128, P447, DOI 10.1038/sj.jid.5701058
   Damian DL, 1998, J INVEST DERMATOL, V110, P824, DOI 10.1046/j.1523-1747.1998.00176.x
   Davies CM, 2009, WATER RES, V43, P643, DOI 10.1016/j.watres.2008.11.016
   DAVIES PDO, 1985, TUBERCLE, V66, P301, DOI 10.1016/0041-3879(85)90068-6
   Dawson-Hughes B, 2005, OSTEOPOROSIS INT, V16, P713, DOI 10.1007/s00198-005-1867-7
   De Fabo EC, 2004, CANCER RES, V64, P6372, DOI 10.1158/0008-5472.CAN-04-1454
   de Feraudy S, 2010, AM J PATHOL, V177, P555, DOI 10.2353/ajpath.2010.090925
   de Gruijl FR, 2010, INT J CANCER, V127, P796, DOI 10.1002/ijc.25097
   de Gruijl FR, 2003, PHOTOCH PHOTOBIO SCI, V2, P16, DOI 10.1039/b211156j
   de Gruijl FR, 2008, PHOTOCHEM PHOTOBIOL, V84, P2, DOI 10.1111/j.1751-1097.2007.00211.x
   de Koning Maurits Nc, 2008, Infect Agent Cancer, V3, P12, DOI 10.1186/1750-9378-3-12
   Dennis LK, 2008, ANN EPIDEMIOL, V18, P614, DOI 10.1016/j.annepidem.2008.04.006
   Dennis LK, 2003, ANN INTERN MED, V139, P966, DOI 10.7326/0003-4819-139-12-200312160-00006
   Detorakis ET, 2009, INT J MOL MED, V23, P439, DOI 10.3892/ijmm_00000149
   Diffey B, 2000, BRIT MED J, V320, P176, DOI 10.1136/bmj.320.7228.176
   Diffey BL, 2010, BRIT J DERMATOL, V162, P1342, DOI 10.1111/j.1365-2133.2010.09697.x
   Diffey BL, 2009, BRIT J DERMATOL, V161, P25, DOI 10.1111/j.1365-2133.2009.09445.x
   Diffey BL, 2002, METHODS, V28, P4, DOI 10.1016/S1046-2023(02)00204-9
   Diffey B, 2008, PHOTOCHEM PHOTOBIOL, V84, P371, DOI 10.1111/j.1751-1097.2007.00271.x
   Diffey BL, 2010, PHOTODERMATOL PHOTO, V26, P172, DOI 10.1111/j.1600-0781.2010.00518.x
   Dobbinson S, 2008, J AM ACAD DERMATOL, V59, P602, DOI 10.1016/j.jaad.2008.06.011
   Dobbinson SJ, 2008, AM J PREV MED, V34, P94, DOI 10.1016/j.amepre.2007.09.024
   Dobbinson SJ, 2009, BMJ-BRIT MED J, V338, DOI 10.1136/bmj.b95
   Dobnig H, 2008, ARCH INTERN MED, V168, P1340, DOI 10.1001/archinte.168.12.1340
   Dong XQ, 2007, EXP EYE RES, V84, P200, DOI 10.1016/j.exer.2006.09.017
   Dongre AM, 2007, INDIAN J DERMATOL VE, V73, P26
   DURRUTY P, 1979, DIABETOLOGIA, V17, P357, DOI 10.1007/BF01236269
   Elliott JC, 2010, PEDIATR DIABETES, V11, P394, DOI 10.1111/j.1399-5448.2009.00620.x
   Ellison TI, 2008, J INVEST DERMATOL, V128, P2508, DOI 10.1038/jid.2008.131
   Ema M, 2010, REPROD TOXICOL, V29, P125, DOI 10.1016/j.reprotox.2009.11.005
   Ema M, 2010, REPROD TOXICOL, V29, P1, DOI 10.1016/j.reprotox.2009.09.005
   Faurschou A, 2007, BRIT J DERMATOL, V156, P716, DOI 10.1111/j.1365-2133.2006.07684.x
   FELDMAN D, 1995, ADV EXP MED BIOL, V375, P53
   Fernandez Anthony, 2008, J Invest Dermatol, V128, P2352, DOI 10.1038/jid.2008.260
   Fioletov VE, 2010, J PHOTOCH PHOTOBIO B, V100, P57, DOI 10.1016/j.jphotobiol.2010.05.002
   Fisman DN, 2007, ANNU REV PUBL HEALTH, V28, P127, DOI 10.1146/annurev.publhealth.28.021406.144128
   Fletcher AE, 2008, ARCH OPHTHALMOL-CHIC, V126, P1396, DOI 10.1001/archopht.126.10.1396
   Forslund O, 2007, J INFECT DIS, V196, P876, DOI 10.1086/521031
   Freedman DM, 2007, JNCI-J NATL CANCER I, V99, P1594, DOI 10.1093/jnci/djm204
   Freedman DM, 2002, OCCUP ENVIRON MED, V59, P257, DOI 10.1136/oem.59.4.257
   Fris M, 2008, GRAEF ARCH CLIN EXP, V246, P551, DOI 10.1007/s00417-007-0747-6
   Fris M, 2007, GRAEF ARCH CLIN EXP, V245, P1705, DOI 10.1007/s00417-007-0620-7
   Fronczak CM, 2003, DIABETES CARE, V26, P3237, DOI 10.2337/diacare.26.12.3237
   Fukazawa T, 1999, J NEUROL SCI, V166, P47, DOI 10.1016/S0022-510X(99)00112-4
   Gallagher RDP, 2000, JAMA-J AM MED ASSOC, V283, P2955, DOI 10.1001/jama.283.22.2955
   Gambichler T, 2006, ARCH DERMATOL RES, V298, P139, DOI 10.1007/s00403-006-0673-1
   Gandini S, 2009, EUR J CANCER, V45, P634, DOI 10.1016/j.ejca.2008.10.003
   Garabedian M., 2006, ACTION SPECTRUM PROD
   Garland CF, 2007, J STEROID BIOCHEM, V103, P708, DOI 10.1016/j.jsbmb.2006.12.007
   Garland CF, 2009, ANN EPIDEMIOL, V19, P468, DOI 10.1016/j.annepidem.2009.03.021
   Geller AC, 1997, J AM ACAD DERMATOL, V37, P935, DOI 10.1016/S0190-9622(97)70068-9
   Gies P, 2007, PHOTODERMATOL PHOTO, V23, P264, DOI 10.1111/j.1600-0781.2007.00309.x
   Gies P, 2007, PHOTOCHEM PHOTOBIOL, V83, P1465, DOI 10.1111/j.1751-1097.2007.00188.x
   Ginde AA, 2009, J AM GERIATR SOC, V57, P1595, DOI 10.1111/j.1532-5415.2009.02359.x
   Ginde AA, 2009, CURR ALLERGY ASTHM R, V9, P81, DOI 10.1007/s11882-009-0012-7
   Ginde AA, 2009, ARCH INTERN MED, V169, P626, DOI 10.1001/archinternmed.2008.604
   Ginde AA, 2009, ARCH INTERN MED, V169, P384, DOI 10.1001/archinternmed.2008.560
   Giovannucci E, 1998, CANCER CAUSE CONTROL, V9, P567, DOI 10.1023/A:1008835903714
   Giovannucci E, 2008, ARCH INTERN MED, V168, P1174, DOI 10.1001/archinte.168.11.1174
   Glasser R, 2009, J ALLERGY CLIN IMMUN, V123, P1117, DOI 10.1016/j.jaci.2009.01.043
   Gordon LG, 2009, J INVEST DERMATOL, V129, P2766, DOI 10.1038/jid.2009.141
   Gorham ED, 2009, DIABETOLOGIA, V52, P2087, DOI 10.1007/s00125-009-1449-x
   Gorham ED, 2007, AM J PREV MED, V32, P210, DOI 10.1016/j.amepre.2006.11.004
   Grant WB, 2002, CANCER-AM CANCER SOC, V94, P1867, DOI 10.1002/cncr.10427
   Grant WB, 2006, ANTICANCER RES, V26, P2687
   Grant WB, 2010, J STEROID BIOCHEM, V121, P456, DOI 10.1016/j.jsbmb.2010.03.089
   Grant WB, 2009, DERM-ENDOCRINOL, V1, P17, DOI 10.4161/derm.1.1.7388
   Grant WB, 2009, ANN EPIDEMIOL, V19, P446, DOI 10.1016/j.annepidem.2008.12.014
   Green A, 1999, LANCET, V354, P723, DOI 10.1016/S0140-6736(98)12168-2
   Green AC, 2007, CANCER EPIDEM BIOMAR, V16, P1921, DOI 10.1158/1055-9965.EPI-07-0477
   Gudbjartsson DF, 2008, NAT GENET, V40, P886, DOI 10.1038/ng.161
   Hagenau T, 2009, OSTEOPOROSIS INT, V20, P133, DOI 10.1007/s00198-008-0626-y
   Haines A, 2000, CAN MED ASSOC J, V163, P729
   Hanwell HEC, 2010, J STEROID BIOCHEM, V121, P334, DOI 10.1016/j.jsbmb.2010.03.023
   Harrison SL, 2008, CANCER EPIDEM BIOMAR, V17, P2318, DOI 10.1158/1055-9965.EPI-07-2801
   Harrison SL, 2005, AM J EPIDEMIOL, V161, P536, DOI 10.1093/aje/kwi081
   Harwood CA, 2000, J MED VIROL, V61, P289, DOI 10.1002/1096-9071(200007)61:3&lt;289::AID-JMV2&gt;3.0.CO;2-Z
   Hawk JLM, 2004, PHOTODERMATOL PHOTO, V20, P312, DOI 10.1111/j.1600-0781.2004.00129.x
   Heitzer E, 2007, J INVEST DERMATOL, V127, P2872, DOI 10.1038/sj.jid.5700923
   Hirakawa M, 2008, BRIT J OPHTHALMOL, V92, P630, DOI 10.1136/bjo.2007.130575
   Holick MF, 2003, J CELL BIOCHEM, V88, P296, DOI 10.1002/jcb.10338
   Holick MF, 2008, MOL ASPECTS MED, V29, P361, DOI 10.1016/j.mam.2008.08.008
   Hollis BW, 2005, J NUTR, V135, P317, DOI 10.1093/jn/135.2.317
   HOLLY EA, 1990, CANCER RES, V50, P5773
   Hu DN, 2008, PHOTOCHEM PHOTOBIOL, V84, P639, DOI 10.1111/j.1751-1097.2008.00316.x
   Hu DN, 2005, AM J OPHTHALMOL, V140, P612, DOI 10.1016/j.ajo.2005.05.034
   Hughes DA, 2009, CLIN EXP IMMUNOL, V158, P20, DOI 10.1111/j.1365-2249.2009.04001.x
   Huncharek M, 2002, AM J PUBLIC HEALTH, V92, P1173, DOI 10.2105/AJPH.92.7.1173
   Hypponen E, 2001, LANCET, V358, P1500, DOI 10.1016/S0140-6736(01)06580-1
   *IARC, 2001, 9283230051 WHO IARC
   Iftner T, 2002, EMBO J, V21, P4741, DOI 10.1093/emboj/cdf443
   Ilyas M, 2007, CURR SCI INDIA, V93, P1604
   International Agency for Research on Cancer (IARC), 2008, IARC WORK GROUP REP
   Jeevan A, 2009, TUBERCULOSIS, V89, P431, DOI 10.1016/j.tube.2009.09.004
   Jeffery LE, 2009, J IMMUNOL, V183, P5458, DOI 10.4049/jimmunol.0803217
   Jenab M, 2010, BRIT MED J, V340, DOI 10.1136/bmj.b5500
   John EM, 2004, J STEROID BIOCHEM, V89-90, P549, DOI 10.1016/j.jsbmb.2004.03.067
   Kannengiesser C, 2008, MOL ONCOL, V1, P425, DOI 10.1016/j.molonc.2008.01.002
   Kaporis HG, 2007, J INVEST DERMATOL, V127, P2391, DOI 10.1038/sj.jid.5700884
   Karatekin G, 2009, EUR J CLIN NUTR, V63, P473, DOI 10.1038/sj.ejcn.1602960
   Karlsson PM, 2007, INT J CANCER, V121, P323, DOI 10.1002/ijc.22692
   Kazantzidis A, 2009, PHOTOCH PHOTOBIO SCI, V8, P45, DOI 10.1039/b811216a
   Ke MS, 2008, PHOTOCHEM PHOTOBIOL, V84, P180, DOI 10.1111/j.1751-1097.2007.00217.x
   Kimlin MG, 2004, PHOTOCH PHOTOBIO SCI, V3, P1067, DOI 10.1039/b404957h
   King BJ, 2008, J APPL MICROBIOL, V104, P1311, DOI 10.1111/j.1365-2672.2007.03658.x
   Kinlin LM, 2009, AM J EPIDEMIOL, V169, P588, DOI 10.1093/aje/kwn383
   Konety B R, 1999, Semin Urol Oncol, V17, P77
   Krause R, 1998, LANCET, V352, P709, DOI 10.1016/S0140-6736(05)60827-6
   KRIPKE ML, 1974, J NATL CANCER I, V53, P1333, DOI 10.1093/jnci/53.5.1333
   Kristal AR, 2002, CANCER EPIDEM BIOMAR, V11, P719
   Kuchuk NO, 2009, J BONE MINER RES, V24, P693, DOI [10.1359/jbmr.081209, 10.1359/JBMR.081209]
   Kyle JW, 2008, PEDIATRICS, V121, pE1074, DOI 10.1542/peds.2007-1400
   Kyu-Won C, 2009, PHOTODERMATOL PHOTO, V25, P286, DOI 10.1111/j.1600-0781.2009.00464.x
   Laaksi I, 2007, AM J CLIN NUTR, V86, P714, DOI 10.1093/ajcn/86.3.714
   Lam LT, 2007, INT J ENVIRON HEAL R, V17, P1, DOI 10.1080/09603120601124264
   Lange JR, 2007, J CLIN ONCOL, V25, P1363, DOI 10.1200/JCO.2006.08.8310
   Lautenschlager S, 2007, LANCET, V370, P528, DOI 10.1016/S0140-6736(07)60638-2
   Lea CS, 2007, ANN EPIDEMIOL, V17, P447, DOI 10.1016/j.annepidem.2007.01.030
   Leiter U, 2008, ADV EXP MED BIOL, V624, P89, DOI 10.1007/978-0-387-77574-6_8
   Lembo S, 2008, BRIT J DERMATOL, V159, P1342, DOI 10.1111/j.1365-2133.2008.08734.x
   Levell NJ, 2009, BRIT J DERMATOL, V161, P630, DOI 10.1111/j.1365-2133.2009.09299.x
   Li XH, 2000, BIOMED ENVIRON SCI, V13, P263
   Linder N, 2011, J TROP PEDIATRICS, V57, P299, DOI 10.1093/tropej/fmp104
   Linos E, 2009, J INVEST DERMATOL, V129, pS59
   Lipozencic J, 2008, ACTA DERMATOVENER CR, V16, P193
   Lips P, 2001, J CLIN ENDOCR METAB, V86, P1212, DOI 10.1210/jc.86.3.1212
   Longstreth J, 1998, J PHOTOCH PHOTOBIO B, V46, P20, DOI 10.1016/S1011-1344(98)00183-3
   Lucas Chere R, 2008, J Cosmet Dermatol, V7, P132, DOI 10.1111/j.1473-2165.2008.00376.x
   Mabruk MJEMF, 2009, J CUTAN PATHOL, V36, P760, DOI 10.1111/j.1600-0560.2008.01164.x
   Macdonald HM, 2008, BONE, V42, P996, DOI 10.1016/j.bone.2008.01.011
   MACLAUGHLIN J, 1985, J CLIN INVEST, V76, P1536, DOI 10.1172/JCI112134
   MACLAUGHLIN JA, 1982, SCIENCE, V216, P1001, DOI 10.1126/science.6281884
   Mainster MA, 2009, AM J OPHTHALMOL, V147, P8, DOI 10.1016/j.ajo.2008.08.020
   Martineau AR, 2007, J STEROID BIOCHEM, V103, P793, DOI 10.1016/j.jsbmb.2006.12.052
   Matsui MS, 2009, J INVEST DERM SYMP P, V14, P56, DOI 10.1038/jidsymp.2009.14
   McKenzie RL, 2011, PHOTOCH PHOTOBIO SCI, V10, P182, DOI 10.1039/c0pp90034f
   McKenzie RL, 2009, PHOTOCHEM PHOTOBIOL, V85, P88, DOI 10.1111/j.1751-1097.2008.00400.x
   MCLEOD JG, 1994, MED J AUSTRALIA, V160, P117, DOI 10.5694/j.1326-5377.1994.tb126553.x
   McMichael AJ, 2009, LANCET, V374, P2123, DOI 10.1016/S0140-6736(09)62031-6
   McMichael AJ, 1997, EPIDEMIOLOGY, V8, P642, DOI 10.1097/00001648-199710000-00005
   Meyer LM, 2008, EXP EYE RES, V86, P282, DOI 10.1016/j.exer.2007.10.019
   Mitchell DL, 2010, P NATL ACAD SCI USA, V107, P9329, DOI 10.1073/pnas.1000324107
   Mnich CD, 2009, EXP DERMATOL, V18, P69, DOI 10.1111/j.1600-0625.2008.00765.x
   Mody VC, 2008, ACTA OPHTHALMOL, V86, P188, DOI 10.1111/j.1600-0420.2007.01022.x
   Moehrie M, 2008, CLIN DERMATOL, V26, P12, DOI 10.1016/j.clindermatol.2007.10.001
   Mohr SB, 2008, DIABETOLOGIA, V51, P1391, DOI 10.1007/s00125-008-1061-5
   Mohr SB, 2008, BREAST J, V14, P255, DOI 10.1111/j.1524-4741.2008.00571.x
   Moise AF, 1999, INT J BIOMETEOROL, V43, P128, DOI 10.1007/s004840050128
   Mokady E, 2000, NUTR CANCER, V38, P65, DOI 10.1207/S15327914NC381_10
   Montella A, 2009, EUR J CANCER, V45, P2360, DOI 10.1016/j.ejca.2009.03.004
   Muller HK, 2008, PHOTOCHEM PHOTOBIOL, V84, P47, DOI 10.1111/j.1751-1097.2007.00246.x
   Munger KL, 2006, JAMA-J AM MED ASSOC, V296, P2832, DOI 10.1001/jama.296.23.2832
   Munger KL, 2004, NEUROLOGY, V62, P60, DOI 10.1212/01.WNL.0000101723.79681.38
   Murray JC, 2008, J AM ACAD DERMATOL, V59, P418, DOI 10.1016/j.jaad.2008.05.004
   Nagano T, 2008, PHOTOCHEM PHOTOBIOL, V84, P63, DOI 10.1111/j.1751-1097.2007.00245.x
   Narbutt J, 2005, PHOTOCH PHOTOBIO SCI, V4, P517, DOI 10.1039/b503166d
   Neale RE, 2007, J AM ACAD DERMATOL, V56, P380, DOI 10.1016/j.jaad.2006.08.039
   Ng K, 2008, J CLIN ONCOL, V26, P2984, DOI 10.1200/JCO.2007.15.1027
   Nicol I, 2007, J INVEST DERMATOL, V127, P41, DOI 10.1038/sj.jid.5700509
   Nikolaou VA, 2008, CANCER CAUSE CONTROL, V19, P671, DOI 10.1007/s10552-008-9130-0
   Nikolova PN, 2007, CANCER IMMUNOL IMMUN, V56, P371, DOI 10.1007/s00262-006-0193-z
   Nnoaham KE, 2008, INT J EPIDEMIOL, V37, P113, DOI 10.1093/ije/dym247
   Nohynek GJ, 2010, TOXICOL APPL PHARM, V243, P239, DOI 10.1016/j.taap.2009.12.001
   Norval M, 2007, PHOTOCH PHOTOBIO SCI, V6, P232, DOI 10.1039/b700018a
   Norval M, 2009, BRIT J DERMATOL, V161, P732, DOI 10.1111/j.1365-2133.2009.09332.x
   Norval M, 2008, PHOTOCHEM PHOTOBIOL, V84, P19, DOI 10.1111/j.1751-1097.2007.00239.x
   Norval M, 2010, PHOTOCH PHOTOBIO SCI, V9, P11, DOI 10.1039/b9pp00012g
   Oberyszyn TM, 2008, CANCER LETT, V261, P127, DOI 10.1016/j.canlet.2008.01.009
   Olsen CM, 2009, INT J CANCER, V124, P937, DOI 10.1002/ijc.24011
   Onkamo P, 1999, DIABETOLOGIA, V42, P1395, DOI 10.1007/s001250051309
   Oriowo OM, 2001, INVEST OPHTH VIS SCI, V42, pS282
   Orton SM, 2008, AM J CLIN NUTR, V88, P441, DOI 10.1093/ajcn/88.2.441
   Ostman J, 2008, J INTERN MED, V263, P386, DOI 10.1111/j.1365-2796.2007.01896.x
   Pakker H, 2000, J PHYCOL, V36, P334, DOI 10.1046/j.1529-8817.2000.99087.x
   Patz JA, 2008, MED CLIN N AM, V92, P1473, DOI 10.1016/j.mcna.2008.07.007
   Peehl DM, 1999, EUR UROL, V35, P392, DOI 10.1159/000019914
   Peguet-Navarro J, 2008, EUR J DERMATOL, V18, P504, DOI 10.1684/ejd.2008.0496
   Pellacani G, 2008, J EUR ACAD DERMATOL, V22, P213, DOI 10.1111/j.1468-3083.2007.02388.x
   Pettijohn KJ, 2009, CANCER EPIDEM BIOMAR, V18, P454, DOI 10.1158/1055-9965.EPI-08-0634
   Pham TQ, 2009, OPHTHAL EPIDEMIOL, V16, P136, DOI 10.1080/09286580701299395
   Pinto AV, 2010, MUTAT RES-FUND MOL M, V688, P3, DOI 10.1016/j.mrfmmm.2010.02.003
   Pleasance ED, 2010, NATURE, V463, P191, DOI 10.1038/nature08658
   Ponsonby AL, 2008, AM J EPIDEMIOL, V168, P358, DOI 10.1093/aje/kwn142
   Pope SJ, 2008, PHOTOCHEM PHOTOBIOL, V84, P1277, DOI 10.1111/j.1751-1097.2008.00373.x
   Pruthi DK, 2009, J AM ACAD DERMATOL, V61, P44, DOI 10.1016/j.jaad.2009.01.020
   Purdie KJ, 1999, EMBO J, V18, P5359, DOI 10.1093/emboj/18.19.5359
   Qureshi AA, 2008, ARCH INTERN MED, V168, P501, DOI 10.1001/archinte.168.5.501
   Ramagopalan SV, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000369
   Reddy KK, 2010, J INVEST DERMATOL, V130, P321, DOI 10.1038/jid.2009.353
   Reich A, 2009, PHOTODERMATOL PHOTO, V25, P242, DOI 10.1111/j.1600-0781.2009.00450.x
   Rhodes LE, 2010, J INVEST DERMATOL, V130, P1411, DOI 10.1038/jid.2009.417
   Rhodes LE, 2010, J INVEST DERMATOL, V130, P626, DOI 10.1038/jid.2009.250
   Richardson A, 2008, NEW ZEAL MED J, V121, P18
   Richmond-Sinclair NM, 2009, J INVEST DERMATOL, V129, P323, DOI 10.1038/jid.2008.234
   Richtig E, 2007, DERMATOLOGY, V214, P246, DOI 10.1159/000099590
   Robinson ES, 2000, PHOTOCHEM PHOTOBIOL, V71, P743, DOI 10.1562/0031-8655(2000)071<0743:TMMMIR>2.0.CO;2
   Roche EF, 2003, J PEDIATR ENDOCR MET, V16, P779
   Rostand SG, 1997, HYPERTENSION, V30, P150, DOI 10.1161/01.HYP.30.2.150
   Rothwell PM, 1999, BRIT MED J, V319, P887, DOI 10.1136/bmj.319.7214.887
   SACN (Scientific Advisory Committee on Nutrition), 2007, UPD VIT D POS STAT S
   Sagripanti JL, 2009, PHOTOCHEM PHOTOBIOL, V85, P978, DOI 10.1111/j.1751-1097.2008.00518.x
   Salmon PJM, 2007, AUSTRALAS J DERMATOL, V48, P208, DOI 10.1111/j.1440-0960.2007.00388.x
   Samuelsson U, 2007, DIABETES RES CLIN PR, V76, P75, DOI 10.1016/j.diabres.2006.07.023
   Santos JL, 2001, REV SAUDE PUBL, V35, P96, DOI 10.1590/S0034-89102001000100014
   Sastre-Garau X, 2009, J PATHOL, V218, P48, DOI 10.1002/path.2532
   Sathyanarayana UG, 2007, CANCER LETT, V245, P112, DOI 10.1016/j.canlet.2005.12.042
   Scelo G, 2007, INT J CANCER, V120, P152, DOI 10.1002/ijc.22159
   Schmidt-Pokrzywniak A, 2009, OPHTHALMOLOGY, V116, P340, DOI 10.1016/j.ophtha.2008.09.040
   Schoof N, 2009, GENES IMMUN, V10, P586, DOI 10.1038/gene.2009.40
   Schwarz T, 2008, PHOTOCHEM PHOTOBIOL, V84, P10, DOI 10.1111/j.1751-1097.2007.00223.x
   Scully M, 2008, AUST NZ J PUBL HEAL, V32, P461, DOI 10.1111/j.1753-6405.2008.00280.x
   SEDDON JM, 1990, ARCH OPHTHALMOL-CHIC, V108, P1274, DOI 10.1001/archopht.1990.01070110090031
   Segerback D, 2008, CANCER EPIDEM BIOMAR, V17, P2388, DOI 10.1158/1055-9965.EPI-08-0248
   Sekelj S, 2007, COLLEGIUM ANTROPOL, V31, P45
   Semba RD, 2010, EUR J CLIN NUTR, V64, P203, DOI 10.1038/ejcn.2009.140
   SETLOW RB, 1993, P NATL ACAD SCI USA, V90, P6666, DOI 10.1073/pnas.90.14.6666
   Shah CP, 2005, OPHTHALMOLOGY, V112, P1599, DOI 10.1016/j.ophtha.2005.04.020
   Shih STF, 2009, PREV MED, V49, P449, DOI 10.1016/j.ypmed.2009.09.008
   Sinclair C, 2009, BRIT J DERMATOL, V161, P116, DOI 10.1111/j.1365-2133.2009.09459.x
   Sinton LW, 2002, APPL ENVIRON MICROB, V68, P1122, DOI 10.1128/AEM.68.3.1122-1131.2002
   Sivapirabu G, 2009, BRIT J DERMATOL, V161, P1357, DOI 10.1111/j.1365-2133.2009.09244.x
   Sleijffers A, 2003, J IMMUNOL, V170, P3423, DOI 10.4049/jimmunol.170.6.3423
   Sleijffers A, 2003, PHOTOCHEM PHOTOBIOL, V77, P271, DOI 10.1562/0031-8655(2003)077<0271:ECUALC>2.0.CO;2
   Sleijffers A, 2001, J INVEST DERMATOL, V117, P1144, DOI 10.1046/j.0022-202x.2001.01542.x
   Sliney DH, 2006, PROG BIOPHYS MOL BIO, V92, P150, DOI 10.1016/j.pbiomolbio.2006.02.007
   Sloka JS, 2008, CAN J NEUROL SCI, V35, P69, DOI 10.1017/S0317167100007587
   Smolders J, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006635
   Sneyd MJ, 2009, CANCER EPIDEM BIOMAR, V18, P1706, DOI 10.1158/1055-9965.EPI-08-0682
   STAPLES JA, 2002, ENV HLTH PERSPECT, V111, P518
   Staples J, 2010, BMJ-BRIT MED J, V340, DOI 10.1136/bmj.c1640
   Staples MP, 2006, MED J AUSTRALIA, V184, P6, DOI 10.5694/j.1326-5377.2006.tb00086.x
   Stene LC, 2000, DIABETOLOGIA, V43, pA94
   Stolzenberg-Solomon RZ, 2010, AM J EPIDEMIOL, V172, P81, DOI 10.1093/aje/kwq120
   Struijk L, 2008, J GEN VIROL, V89, P2303, DOI 10.1099/vir.0.83317-0
   Suarez-Martinez Edu B, 2007, P R Health Sci J, V26, P349
   Sugie N, 2002, PHOTODERMATOL PHOTO, V18, P163, DOI 10.1034/j.1600-0781.2002.00765.x
   Swann MH, 2007, SEMIN ONCOL, V34, P51, DOI 10.1053/j.seminoncol.2006.10.021
   Tang X, 2011, PHOTOCH PHOTOBIO SCI, V10, P280, DOI 10.1039/c0pp90039g
   Taylor BV, 2010, MULT SCLER J, V16, P398, DOI 10.1177/1352458509359724
   TAYLOR BV, 2010, MULT SCLER
   Thieden E, 2009, PHOTOCHEM PHOTOBIOL, V85, P1480, DOI 10.1111/j.1751-1097.2009.00612.x
   THOMPSON SC, 1993, NEW ENGL J MED, V329, P1147, DOI 10.1056/NEJM199310143291602
   TOEWS GB, 1980, J IMMUNOL, V124, P445
   Tommasi S, 1997, CANCER RES, V57, P4727
   Tornesello ML, 2006, BRIT J CANCER, V94, P446, DOI 10.1038/sj.bjc.6602921
   Travis RC, 2009, AM J EPIDEMIOL, V169, P1223, DOI 10.1093/aje/kwp022
   Tremlett H, 2008, NEUROEPIDEMIOLOGY, V31, P271, DOI 10.1159/000166602
   Triay E, 2009, BRIT J OPHTHALMOL, V93, P1524, DOI 10.1136/bjo.2009.157933
   Tsai WT, 2007, J HAZARD MATER, V139, P185, DOI 10.1016/j.jhazmat.2006.10.025
   Tsai WT, 2010, J ENVIRON SCI HEAL C, V28, P125, DOI 10.1080/10590501.2010.481806
   Tsai WT, 2009, ENVIRON INT, V35, P418, DOI 10.1016/j.envint.2008.08.009
   Tsai WT, 2005, J HAZARD MATER, V119, P69, DOI 10.1016/j.jhazmat.2004.12.018
   Tull KI, 2009, AGE AGEING, V38, P609, DOI [10.1093/ageing/afp195, 10.1093/ageing/afp102]
   Underbrink MP, 2008, J VIROL, V82, P10408, DOI 10.1128/JVI.00902-08
   Urashima M, 2010, AM J CLIN NUTR, V91, P1255, DOI 10.3945/ajcn.2009.29094
   Vaiserman AM, 2007, DIABETOLOGIA, V50, P32, DOI 10.1007/s00125-006-0456-4
   Vajdic CM, 2002, INT J CANCER, V101, P175, DOI 10.1002/ijc.10579
   van Doorn R, 2005, SEMIN ONCOL, V32, P479, DOI 10.1053/j.seminoncol.2005.07.001
   van Hattem S, 2009, BRIT J DERMATOL, V161, P840, DOI 10.1111/j.1365-2133.2009.09222.x
   VAN IA, 2003, BMJ-BRIT MED J, V327, P316
   VAN JC, 2006, CANCER EPIDEM BIOMAR, V15, P2546
   VAN JC, 2002, PHOTOCHEM PHOTOBIOL, V1, P324
   VAN JC, 2008, PHOTOCHEM PHOTOBIOL, V7, P730
   van Schanke A, 2006, CANCER RES, V66, P2608, DOI 10.1158/0008-5472.CAN-05-2476
   Vojnikovic B, 2007, COLLEGIUM ANTROPOL, V31, P43
   Vollmer RT, 2007, AM J CLIN PATHOL, V128, P260, DOI 10.1309/7MHX96XH3DTY32TQ
   Wakita D, 2009, CARCINOGENESIS, V30, P1408, DOI 10.1093/carcin/bgp144
   Walsh James E, 2007, Eye Contact Lens, V33, P58, DOI 10.1097/01.icl.0000240515.57520.a6
   Wang GS, 2009, LUPUS, V18, P1037, DOI 10.1177/0961203309106181
   Wang LE, 2007, CLIN CANCER RES, V13, P6532, DOI 10.1158/1078-0432.CCR-07-0969
   Wang L, 2008, INT IMMUNOL, V20, P57, DOI 10.1093/intimm/dxm124
   Wang LN, 2010, IMMUNOBIOLOGY, V215, P124, DOI 10.1016/j.imbio.2009.01.013
   Wang SQ, 2009, BRIT J DERMATOL, V161, P28, DOI 10.1111/j.1365-2133.2009.09446.x
   Wang TJ, 2010, LANCET, V376, P180, DOI 10.1016/S0140-6736(10)60588-0
   Waster PK, 2009, J INVEST DERMATOL, V129, P1769, DOI 10.1038/jid.2008.421
   Wayse V, 2004, EUR J CLIN NUTR, V58, P563, DOI 10.1038/sj.ejcn.1601845
   Wei MY, 2008, CANCER EPIDEM BIOMAR, V17, P2958, DOI 10.1158/1055-9965.EPI-08-0402
   Weis E, 2006, ARCH OPHTHALMOL-CHIC, V124, P54, DOI 10.1001/archopht.124.1.54
   Wejse C, 2009, AM J RESP CRIT CARE, V179, P843, DOI 10.1164/rccm.200804-567OC
   Welsh MM, 2008, CARCINOGENESIS, V29, P1950, DOI 10.1093/carcin/bgn160
   Welsh MM, 2009, CANCER RES, V69, P6158, DOI 10.1158/0008-5472.CAN-09-0415
   White ANJ, 2009, BMC INFECT DIS, V9, DOI 10.1186/1471-2334-9-196
   White JH, 2008, INFECT IMMUN, V76, P3837, DOI 10.1128/IAI.00353-08
   Whiteman DC, 2008, EUR J CANCER PREV, V17, P243, DOI 10.1097/CEJ.0b013e3282b6fe3f
   Whiteman DC, 2007, CANCER CAUSE CONTROL, V18, P485, DOI 10.1007/s10552-007-0123-1
   Widyarini S, 2006, P NATL ACAD SCI USA, V103, P12837, DOI 10.1073/pnas.0603642103
   Willer CJ, 2005, BMJ-BRIT MED J, V330, P120, DOI 10.1136/bmj.38301.686030.63
   Willis JA, 2002, J PEDIATR ENDOCR MET, V15, P645
   Wolf P, 2009, EXP DERMATOL, V18, P350, DOI 10.1111/j.1600-0625.2009.00859.x
   Woolcott CG, 2010, CANCER EPIDEM BIOMAR, V19, P130, DOI 10.1158/1055-9965.EPI-09-0475
   Xiao TZ, 2009, J INVEST DERMATOL, V129, pS32
   Yamshchikov AV, 2009, ENDOCR PRACT, V15, P438, DOI 10.4158/EP09101.ORR
   Yang G, 2007, CANCER RES, V67, P5649, DOI 10.1158/0008-5472.CAN-06-3806
   Yarak S, 2010, CLIN EXP DERMATOL, V35, P581, DOI 10.1111/j.1365-2230.2009.03609.x
   Yesudian PD, 2008, PHOTODERMATOL PHOTO, V24, P97, DOI 10.1111/j.1600-0781.2008.00339.x
   Yetley EA, 2008, AM J CLIN NUTR, V88, p558S, DOI 10.1093/ajcn/88.2.558S
   Yiasemides E, 2009, CARCINOGENESIS, V30, P101, DOI 10.1093/carcin/bgn248
   Yin L, 2010, EUR J CANCER, V46, P2196, DOI 10.1016/j.ejca.2010.03.037
   Yin L, 2009, CANCER EPIDEMIOL, V33, P435, DOI 10.1016/j.canep.2009.10.014
   Yin M, 2009, INT J CLIN EXP MED, V2, P159
   Youl PH, 2009, INT J CANCER, V124, P1963, DOI 10.1002/ijc.24154
   Yu GP, 2006, PHOTOCHEM PHOTOBIOL, V82, P1621, DOI 10.1562/2006-07-17-RA-970
   Yusuf N, 2007, PHOTODERMATOL PHOTO, V23, P48, DOI 10.1111/j.1600-0781.2007.00262.x
   Zanetti R, 2006, BRIT J CANCER, V94, P743, DOI 10.1038/sj.bjc.6602982
   Zhou L, 2009, INVEST OPHTH VIS SCI, V50, P2077, DOI 10.1167/iovs.08-2604
NR 376
TC 144
Z9 150
U1 7
U2 139
PU SPRINGERNATURE
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND
SN 1474-905X
EI 1474-9092
J9 PHOTOCH PHOTOBIO SCI
JI Photochem. Photobiol. Sci.
PY 2011
VL 10
IS 2
BP 199
EP 225
DI 10.1039/c0pp90044c
PG 27
WC Biochemistry & Molecular Biology; Biophysics; Chemistry, Physical
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Biophysics; Chemistry
GA 714UV
UT WOS:000286835400002
PM 21253670
OA Green Submitted
DA 2022-11-30
ER

PT J
AU Wong, P
   Markey, M
   Rapp, CM
   Darrow, RM
   Ziesel, A
   Organisciak, DT
AF Wong, Paul
   Markey, M.
   Rapp, C. M.
   Darrow, R. M.
   Ziesel, A.
   Organisciak, D. T.
TI Enhancing the efficacy of AREDS antioxidants in light-induced retinal
   degeneration
SO MOLECULAR VISION
LA English
DT Article
ID COMPLEMENT FACTOR-H; MACULAR DEGENERATION; THYROID-HORMONE; RAT RETINA;
   PHOTORECEPTOR DEGENERATION; CONE PHOTORECEPTORS; INDUCED RETINOPATHY;
   ADENYLYL-CYCLASE; ROSEMARY EXTRACT; OXIDATIVE STRESS
AB Purpose: Light-induced photoreceptor cell degeneration and disease progression in age-related macular degeneration (AMD) involve oxidative stress and visual cell loss, which can be prevented, or slowed, by antioxidants. Our goal was to test the protective efficacy of a traditional Age-related Eye Disease Study antioxidant formulation (AREDS) and AREDS combined with non-traditional antioxidants in a preclinical animal model of photooxidative retinal damage.
   Methods: Male Sprague-Dawley rats were reared in a low-intensity (20 lux) or high-intensity (200 lux) cyclic light environment for 6 weeks. Some animals received a daily dietary supplement consisting of a small cracker infused with an AREDS antioxidant mineral mixture, AREDS antioxidants minus zinc, or zinc oxide alone. Other rats received AREDS combined with a detergent extract of the common herb rosemary, AREDS plus carnosic acid, zinc oxide plus rosemary, or rosemary alone. Antioxidant efficacy was determined by measuring retinal DNA levels 2 weeks after 6 h of intense exposure to white light (9,000 lux). Western blotting was used to determine visual cell opsin and arrestin levels following intense light treatment. Rhodopsin regeneration was determined after 1 h of exposure to light. Gene array analysis was used to determine changes in the expression of retinal genes resulting from light rearing environment or from antioxidant supplementation.
   Results: Chronic high-intensity cyclic light rearing resulted in lower levels of rod and cone opsins, retinal S-antigen (S-ag), and medium wavelength cone arrestin (mCAR) than found for rats maintained in low cyclic light. However, as determined by retinal DNA, and by residual opsin and arrestin levels, 2 weeks after acute photooxidative damage, visual cell loss was greater in rats reared in low cyclic light. Retinal damage decreased with AREDS plus rosemary, or with zinc oxide plus rosemary whereas AREDS alone and zinc oxide alone (at their daily recommended levels) were both ineffective. One week of supplemental AREDS plus carnosic acid resulted in higher levels of rod and cone cell proteins, and higher levels of retinal DNA than for AREDS alone. Rhodopsin regeneration was unaffected by the rosemary treatment. Retinal gene array analysis showed reduced expression of medium - wavelength opsin 1 and arrestin C in the high-light reared rats versus the low-light rats. The transition of rats from low cyclic light to a high cyclic light environment resulted in the differential expression of 280 gene markers, enriched for genes related to inflammation, apoptosis, cytokine, innate immune response, and receptors. Rosemary, zinc oxide plus rosemary, and AREDS plus rosemary suppressed 131, 241, and 266 of these genes (respectively) in high-light versus low-light animals and induced a small subset of changes in gene expression that were independent of light rearing conditions.
   Conclusions: Long-term environmental light intensity is a major determinant of retinal gene and protein expression, and of visual cell survival following acute photooxidative insult. Rats preconditioned by high-light rearing exhibit lower levels of cone opsin mRNA and protein, and lower mCAR protein, than low-light reared animals, but greater retention of retinal DNA and proteins following photooxidative damage. Rosemary enhanced the protective efficacy of AREDS and led to the greatest effect on the retinal genome in animals reared in high environmental light. Chronic administration of rosemary antioxidants may be a useful adjunct to the therapeutic benefit of AREDS in slowing disease progression in AMD.
C1 [Wong, Paul; Ziesel, A.] Emory Univ, Dept Ophthalmol, Atlanta, GA 30322 USA.
   [Markey, M.] Wright State Univ, Ctr Genom Res, Dayton, OH 45435 USA.
   [Rapp, C. M.; Darrow, R. M.; Organisciak, D. T.] Wright State Univ, Dept Biochem & Mol Biol, Boonshoft Sch Med, Petticrew Res Lab, Dayton, OH 45435 USA.
C3 Emory University; University System of Ohio; Wright State University
   Dayton; University System of Ohio; Wright State University Dayton
RP Organisciak, DT (通讯作者)，Wright State Univ, Biochem & Mol Biol, 3640 Colonel Glenn Highway, Dayton, OH 45435 USA.
EM dto@wright.edu
OI Markey, Michael/0000-0002-8593-2290
FU International Retina Research Foundation, Birmingham, AL; Ohio Lions Eye
   Research Foundation, Columbus, OH; Petticrew Research Laboratory (DTO);
   NIH (NEI) [P30EY006360]; RPB; FFB; Reunette Harris Professorship;
   NATIONAL EYE INSTITUTE [P30EY006360] Funding Source: NIH RePORTER
FX This work was supported by funding from the International Retina
   Research Foundation, Birmingham, AL, the Ohio Lions Eye Research
   Foundation, Columbus, OH and the Petticrew Research Laboratory (DTO),
   NIH (NEI) P30EY006360, RPB, FFB (PW), and the Reunette Harris
   Professorship (PW). We acknowledge with thanks, Drs. John Crabb, Cheryl
   Craft, Larry Donoso and Krzysztof Palczewski for their generous gifts of
   antibodies used in this study. Special thanks to Dr. John Lang for
   providing the ROPUFA and rosemary powder used in this work, Christopher
   Waker and Richard Lee for computer graphics, and Linda Barsalou for DNA
   gel electrophoresis. Dr. D.T. Organisciak (dto@wright.edu) and Dr.
   P.Wong (pwong@emory.edu) are co-corresponding authors for this paper.
CR Age-Related Eye Disease Study 2 Research Group, 2013, JAMA, V309, P2005, DOI 10.1001/jama.2013.4997
   Agudo M, 2008, MOL VIS, V14, P1050
   Bedolla DE, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026334
   Belmonte MA, 2006, INVEST OPHTH VIS SCI, V47, P1193, DOI 10.1167/iovs.05-0446
   Berrow EJ, 2011, EUR OPHTHAL REV, V5, P143
   Blom AM, 2003, ARCH BIOCHEM BIOPHYS, V418, P108, DOI 10.1016/j.abb.2003.08.018
   BROEKHUYSE RM, 1985, CURR EYE RES, V4, P613, DOI 10.3109/02713688508999993
   Carvalho BS, 2010, BIOINFORMATICS, V26, P2363, DOI 10.1093/bioinformatics/btq431
   Cherny VV, 1999, J GEN PHYSIOL, V114, P819, DOI 10.1085/jgp.114.6.819
   Chew EY, 2013, INVEST OPHTH VIS SCI, V54, DOI 10.1167/iovs.13-12914
   Collier RJ, 2011, INVEST OPHTH VIS SCI, V52, P8108, DOI 10.1167/iovs.10-6418
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   Donoso LA, 2006, SURV OPHTHALMOL, V51, P137, DOI 10.1016/j.survophthal.2005.12.001
   Donoso LA, 2010, SURV OPHTHALMOL, V55, P227, DOI 10.1016/j.survophthal.2009.11.001
   Downes GB, 1999, GENOMICS, V62, P544, DOI 10.1006/geno.1999.5992
   Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189
   Elachouri G, 2015, FREE RADICAL BIO MED, V81, P22, DOI 10.1016/j.freeradbiomed.2015.01.003
   Emig D, 2010, NUCLEIC ACIDS RES, V38, pW755, DOI 10.1093/nar/gkq405
   Feng YX, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016865
   Glaschke A, 2011, J NEUROSCI, V31, P4844, DOI 10.1523/JNEUROSCI.6181-10.2011
   Gu XR, 2003, J BIOL CHEM, V278, P42027, DOI 10.1074/jbc.M305460200
   Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359
   Haruta M, 2009, P NATL ACAD SCI USA, V106, P9397, DOI 10.1073/pnas.0808940106
   Hollyfield JG, 2008, NAT MED, V14, P194, DOI 10.1038/nm1709
   Hossain MN, 2006, BIOCHEM BIOPH RES CO, V351, P645, DOI 10.1016/j.bbrc.2006.10.112
   Ishikawa K, 2010, INVEST OPHTH VIS SCI, V51, P4307, DOI 10.1167/iovs.09-4605
   Iwagawa T, 2013, PLOS ONE, P8
   Jackson CR, 2011, EUR J NEUROSCI, V34, P57, DOI 10.1111/j.1460-9568.2011.07734.x
   Jackson CR, 2009, J NEUROCHEM, V109, P148, DOI 10.1111/j.1471-4159.2009.05920.x
   John SK, 2000, MOL VIS, V6, P204
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Komeima K, 2006, P NATL ACAD SCI USA, V103, P11300, DOI 10.1073/pnas.0604056103
   Kowluru RA, 2008, ARCH OPHTHALMOL-CHIC, V126, P1266, DOI 10.1001/archopht.126.9.1266
   Kowluru RA, 2011, INVEST OPHTH VIS SCI, V52, P8665, DOI 10.1167/iovs.10-6768
   Kroeze WK, 2003, J CELL SCI, V116, P4867, DOI 10.1242/jcs.00902
   Lederer DE, 2010, OCULAR DIS MECH MANA, P536
   Lee Na Eun, 2011, Korean J Ophthalmol, V25, P42, DOI 10.3341/kjo.2011.25.1.42
   Liu Y, 2007, VISION RES, V47, P2314, DOI 10.1016/j.visres.2007.04.023
   Mandal MNA, 2011, J BIOL CHEM, V286, P32491, DOI 10.1074/jbc.M111.255877
   Marc RE, 2008, MOL VIS, V14, P782
   Marquardt T, 2001, CELL, V105, P43, DOI 10.1016/S0092-8674(01)00295-1
   McGwin G, 2005, OPHTHALMOLOGY, V112, P488, DOI 10.1016/j.ophtha.2004.10.027
   Ng L, 2001, NAT GENET, V27, P94, DOI 10.1038/83829
   Nir I, 2002, J NEUROSCI, V22, P2063, DOI 10.1523/JNEUROSCI.22-06-02063.2002
   Organisciak D, 2006, PHOTOCHEM PHOTOBIOL, V82, P1088, DOI 10.1562/2005-06-30-RA-599
   Organisciak D, 2012, PHOTOCHEM PHOTOBIOL, V88, P1396, DOI 10.1111/j.1751-1097.2012.01134.x
   Organisciak DT, 2013, MOL VIS, V19, P1433
   Organisciak DT, 2010, PROG RETIN EYE RES, V29, P113, DOI 10.1016/j.preteyeres.2009.11.004
   Petersen Helle V., 2000, Molecular Cell Biology Research Communications, V3, P249, DOI 10.1006/mcbr.2000.0220
   Prunty MC, 2015, INVEST OPHTH VIS SCI, V56, P5862, DOI 10.1167/iovs.15-16810
   Rath MF, 2009, J NEUROCHEM, V108, P285, DOI 10.1111/j.1471-4159.2008.05765.x
   Rezaie T, 2012, INVEST OPHTH VIS SCI, V53, P7847, DOI 10.1167/iovs.12-10793
   Rutar M, 2011, INVEST OPHTH VIS SCI, V52, P5347, DOI 10.1167/iovs.10-7119
   SEDDON JM, 1994, JAMA-J AM MED ASSOC, V272, P1413, DOI 10.1001/jama.272.18.1413
   Seddon JM, 2013, INVEST OPHTH VIS SCI, V54, DOI 10.1167/iovs.13-13234
   SharanjeetKaur, 1997, OPHTHAL PHYSL OPT, V17, P232, DOI 10.1111/j.1475-1313.1997.tb00050.x
   Smith SB, 1999, MOL CELL BIOL, V19, P8272
   Smyth GK, 2005, STAT BIOL HEALTH, P397, DOI 10.1007/0-387-29362-0_23
   Sugawara T, 2000, EXP EYE RES, V70, P693, DOI 10.1006/exer.2000.0842
   Vazquez-Chona F, 2004, INVEST OPHTH VIS SCI, V45, P2737, DOI 10.1167/iovs.03-1047
   Vazquez-Chona FR, 2007, GENE REGUL SYST BIO, V1, P327
   Weismann D, 2011, NATURE, V478, P76, DOI 10.1038/nature10449
   Wenzel A, 2000, J NEUROSCI, V20, P81, DOI 10.1523/JNEUROSCI.20-01-00081.2000
   WHELAN JP, 1988, J NEUROSCI RES, V20, P263, DOI 10.1002/jnr.490200216
   Wilson HL, 2004, AM J OPHTHALMOL, V137, P615, DOI 10.1016/j.ajo.2003.10.025
   WINKLER BS, 1972, VISION RES, V12, P1183, DOI 10.1016/0042-6989(72)90106-X
   Wong P, 2014, SPR SER VIS RES, V1, P131, DOI 10.1007/978-1-4614-9613-7_8
   YANNUZZI LA, 1992, ARCH OPHTHALMOL-CHIC, V110, P1701
   Zarbin M, 2010, OCULAR DIS MECH MANA, P527
   Zhang Y, 2012, J AGR FOOD CHEM, V60, P9305, DOI 10.1021/jf302179c
   Zhu XM, 2002, MOL VIS, V8, P462
   Ziess CJ, 2011, VET PATHOL, V47, P396
NR 73
TC 15
Z9 15
U1 0
U2 5
PU MOLECULAR VISION
PI ATLANTA
PA C/O JEFF BOATRIGHT, LAB B, 5500 EMORY EYE CENTER, 1327 CLIFTON RD, N E,
   ATLANTA, GA 30322 USA
SN 1090-0535
J9 MOL VIS
JI Mol. Vis.
PD OCT 10
PY 2017
VL 23
BP 718
EP 739
PG 22
WC Biochemistry & Molecular Biology; Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Ophthalmology
GA FJ4ES
UT WOS:000412689300003
PM 29062223
DA 2022-11-30
ER

PT J
AU Kjellstrom, U
   Andreasson, S
AF Kjellstrom, Ulrika
   Andreasson, Sten
TI A five-year follow-up of ABCA4 carriers showing deterioration of retinal
   function and increased structural changes
SO MOLECULAR VISION
LA English
DT Article
ID RECESSIVE RETINITIS-PIGMENTOSA; CASSETTE TRANSPORTER GENE;
   STARGARDT-DISEASE; ABCA4 MUTATIONS; VISUAL FUNCTION; RIM PROTEIN;
   PHENOTYPE; PHOTORECEPTORS; DEGENERATION; ASSOCIATION
AB Purpose: To investigate whether the reduced retinal function and morphological retinal changes previously demonstrated in ABCA4 carriers had remained stationary or had deteriorated over time at 5-year follow-up to further explore if carriers of an autosomal recessive trait also express a weak phenotype, although this is not expected for an autosomal recessive disorder. Methods: Thirteen ABCA4 carriers from a previous study that included parents to patients with well known genetically verified ABCA4-associated retinal degenerations were reexamined 5 years after the initial examination. As novel genes and new variants in already established genes are continuously reported, all subjects underwent renewed genetic test-ing with a next-generation sequencing (NGS) panel that included 288 genes associated with retinal dystrophies and an analysis of deep intronic mutations and copy number variations in the ABCA4 gene. Moreover, to evaluate any changes in retinal function and/or structure over time, clinical reassessment with Goldmann perimetry, visual acuity testing, fundus photography, fundus autofluorescence (FAF) imaging, optical coherence tomography (OCT), full-field electro-retinography (ffERG), and multifocal ERG (mfERG) were performed 5 years after the initial investigation. The values of the ffERG parameters were compared between the two time points (the measurements obtained in the initial study versus the measurements at 5-year follow-up) and with the controls. The mfERG results of the carriers were compared with those of the controls. Results: The renewed genetic testing confirmed the previously established ABCA4 mutations but also revealed the hypomorph ABCA4 variant c.5603A > T in five ABCA4 carriers. In three of them, the variant was found to be associated with known disease-causing alleles that always carry the c.5603A > T in cis. According to recent publications, the subjects could still be considered ABCA4 carriers because both variants are on the same allele. In the remaining two subjects, c.5603A > T could be in trans with the previously known ABCA4 variant, and the subjects were therefore excluded from the study since they could no longer be considered as carriers only. Statistical comparison of ffERG parameters showed significant reduction of the isolated rod,-as well as the combined rod-cone amplitudes over the five years of follow-up, but not compared with the controls. Concerning macular function, mfERG amplitudes were reduced for all rings in the carriers compared with the controls. Fundus photographs demonstrated morphological changes in 64% of the carriers, and 36% of them had further changes at follow-up. FAF images showed alterations in 55% of the carriers, with increased changes in 36% of them. Abnormalities on OCT were observed in 82% of the carriers, of whom 9% had newly found abnormalities at follow-up. Conclusions: At 5-year follow-up, the ABCA4 carriers, who previously demonstrated reduced macular function, presented with deterioration of general retinal function, including reduced isolated rod and mixed rod-cone ffERG responses combined with a slight increase in morphological changes in some subjects. This indicates that carriership of at least some ABCA4 variants may cause a condition similar to a subgroup of dry age-related macular degeneration (AMD). In the long run, this might be of importance concerning the possibilities to also treat this subgroup of AMD patients with future gene-based and pharmacological drugs targeting ABCA4-associated disorders.
C1 [Kjellstrom, Ulrika; Andreasson, Sten] Lund Univ, Skane Univ Hosp, Dept Clin Sci Lund, Ophthalmol, Lund, Sweden.
C3 Lund University; Skane University Hospital
RP Kjellstrom, U (通讯作者)，Skanes Univ Sjukhus Lund, Ogonkliniken, Kioskg 1, S-22185 Lund, Sweden.
EM ulrika.kjellstrom@med.lu.se
FU Medical Faculty, Lund University; Armec Lindbergs Stiftelse; Stiftelsen
   foer synskadade i f.d. Malmoehus laen; Stiftelsen Synfraemjandets
   Forskningsfond/OEgonfonden
FX The work was supported by the Medical Faculty, Lund University, and
   grants from; The Armec Lindbergs Stiftelse; Stiftelsen foer synskadade i
   f.d. Malmoehus laen; Stiftelsen Synfraemjandets
   Forskningsfond/OEgonfonden.
CR Allikmets R, 2000, AM J HUM GENET, V67, P793, DOI 10.1086/303100
   Allikmets R, 1997, NAT GENET, V15, P236, DOI 10.1038/ng0397-236
   Allikmets R, 2000, AM J HUM GENET, V67, P487, DOI 10.1086/303018
   Auricchio A, 2015, CSH PERSPECT MED, V5, DOI 10.1101/cshperspect.a017301
   Azarian SM, 1997, FEBS LETT, V409, P247, DOI 10.1016/S0014-5793(97)00517-6
   Bandello Francesco, 2017, F1000Res, V6, P245, DOI 10.12688/f1000research.10664.1
   Birch DG, 2001, EXP EYE RES, V73, P877, DOI 10.1006/exer.2001.1093
   BIRD AEC, 1995, SURV OPHTHALMOL, V39, P367, DOI 10.1016/S0039-6257(05)80092-X
   Burke TR, 2011, OPHTHALMIC GENET, V32, P165, DOI 10.3109/13816810.2011.565397
   Conley SM, 2012, BBA-MOL BASIS DIS, V1822, P1169, DOI 10.1016/j.bbadis.2011.10.007
   Cremers FPM, 1998, HUM MOL GENET, V7, P355, DOI 10.1093/hmg/7.3.355
   Fakin A, 2016, INVEST OPHTH VIS SCI, V57, P4668, DOI 10.1167/iovs.16-19829
   Fishman GA, 2003, ARCH OPHTHALMOL-CHIC, V121, P851, DOI 10.1001/archopht.121.6.851
   Gerth C, 2002, GRAEF ARCH CLIN EXP, V240, P628, DOI 10.1007/s00417-002-0502-y
   Gomes NL, 2009, INVEST OPHTH VIS SCI, V50, P3953, DOI 10.1167/iovs.08-2657
   Han ZC, 2014, ADV EXP MED BIOL, V801, P719, DOI 10.1007/978-1-4614-3209-8_90
   Jaakson K, 2003, HUM MUTAT, V22, P395, DOI 10.1002/humu.10263
   Khan KN, 2018, OPHTHALMOLOGY, V125, P735, DOI 10.1016/j.ophtha.2017.11.020
   Kim SR, 2007, P NATL ACAD SCI USA, V104, P19273, DOI 10.1073/pnas.0708714104
   Kjellstrom U, 2015, MOL VIS, V21, P767
   Kjellstrom U, 2014, MOL VIS, V20, P89
   Klevering BJ, 2005, GRAEF ARCH CLIN EXP, V243, P90, DOI 10.1007/s00417-004-1079-4
   Klevering BJ, 2002, INVEST OPHTH VIS SCI, V43, P1980
   Lewis RA, 1999, AM J HUM GENET, V64, P422, DOI 10.1086/302251
   Maia-Lopes S, 2008, INVEST OPHTH VIS SCI, V49, P1191, DOI 10.1167/iovs.07-1051
   Martinez-Mir A, 1998, NAT GENET, V18, P11, DOI 10.1038/ng0198-11
   Mata NL, 2000, P NATL ACAD SCI USA, V97, P7154, DOI 10.1073/pnas.130110497
   Maugeri A, 2002, EUR J HUM GENET, V10, P197, DOI 10.1038/sj.ejhg.5200784
   Michaelides M, 2003, J MED GENET, V40, P641, DOI 10.1136/jmg.40.9.641
   Molday LL, 2000, NAT GENET, V25, P257, DOI 10.1038/77004
   Mullins RF, 2012, INVEST OPHTH VIS SCI, V53, P1883, DOI 10.1167/iovs.12-9477
   Neelam K, 2009, SURV OPHTHALMOL, V54, P167, DOI 10.1016/j.survophthal.2008.12.003
   Quazi F, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms1927
   Rosenberg T, 2007, MOL VIS, V13, P1962
   Schroeder M, 2018, MOL VIS, V24, P1
   Sears AE, 2017, TRANSL VIS SCI TECHN, V6, DOI 10.1167/tvst.6.5.6
   Shroyer NF, 1999, VISION RES, V39, P2537, DOI 10.1016/S0042-6989(99)00037-1
   Shroyer NF, 2001, HUM MOL GENET, V10, P2671, DOI 10.1093/hmg/10.23.2671
   Sun H, 1997, NAT GENET, V17, P15, DOI 10.1038/ng0997-15
   Takahashi VKL, 2018, OPHTHALMIC GENET, V39, P560, DOI 10.1080/13816810.2018.1495745
   Testa F, 2012, INVEST OPHTH VIS SCI, V53, P4409, DOI 10.1167/iovs.11-8201
   Tsybovsky Y, 2010, ADV EXP MED BIOL, V703, P105, DOI 10.1007/978-1-4419-5635-4_8
   van Driel MA, 1998, OPHTHALMIC GENET, V19, P117, DOI 10.1076/opge.19.3.117.2187
   Weng J, 1999, CELL, V98, P13, DOI 10.1016/S0092-8674(00)80602-9
   Westeneng-van Haaften SC, 2012, OPHTHALMOLOGY, V119, P1199, DOI 10.1016/j.ophtha.2012.01.005
   Yamamoto K, 2011, INVEST OPHTH VIS SCI, V52, P9084, DOI 10.1167/iovs.11-8632
NR 46
TC 0
Z9 0
U1 1
U2 1
PU MOLECULAR VISION
PI ATLANTA
PA C/O JEFF BOATRIGHT, LAB B, 5500 EMORY EYE CENTER, 1327 CLIFTON RD, N E,
   ATLANTA, GA 30322 USA
SN 1090-0535
J9 MOL VIS
JI Mol. Vis.
PD OCT 1
PY 2022
VL 28
BP 300
EP 316
PG 17
WC Biochemistry & Molecular Biology; Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Ophthalmology
GA 5K4ZT
UT WOS:000869736700001
PM 36338671
DA 2022-11-30
ER

PT J
AU Groza, A
   Toderean, L
   Muntean, GA
   Nicoara, SD
AF Groza, Adrian
   Toderean, Liana
   Muntean, George Adrian
   Nicoara, Simona Delia
TI Agents that Argue and Explain Classifications of Retinal Conditions
SO JOURNAL OF MEDICAL AND BIOLOGICAL ENGINEERING
LA English
DT Article
DE Explainable artificial intelligence; Argumentative agents; Machine
   learning; AgentSpeak; Retina conditions
ID THICKNESS
AB Purpose Expertise for auditing AI systems in medical domain is only now being accumulated. Conformity assessment procedures will require AI systems: (1) to be transparent, (2) not to rely decisions solely on algorithms, or (3) to include safety assurance cases in the documentation to facilitate technical audit. We are interested here in obtaining transparency in the case of machine learning (ML) applied to classification of retina conditions. High performance metrics achieved using ML has become common practice. However, in the medical domain, algorithmic decisions need to be sustained by explanations. We aim at building a support tool for ophthalmologists able to: (i) explain algorithmic decision to the human agent by automatically extracting rules from the ML learned models; (ii) include the ophthalmologist in the loop by formalising expert rules and including the expert knowledge in the argumentation machinery; (iii) build safety cases by creating assurance argument patterns for each diagnosis. Methods For the learning task, we used a dataset consisting of 699 OCT images: 126 Normal class, 210 with Diabetic Retinopathy (DR) and 363 with Age Related Macular Degeneration (AMD). The dataset contains patients from the Ophthalmology Department of the County Emergency Hospital of Cluj-Napoca. All ethical norms and procedures, including anonymisation, have been performed. We applied three machine learning algorithms: decision tree (DT), support vector machine (SVM) and artificial neural network (ANN). For each algorithm we automatically extract diagnosis rules. For formalising expert knowledge, we relied on the normative dataset (Invernizzi et al. in Ophthalmol Retina 2(8):808-815, 2018). For arguing between agents, we used the Jason multi-agent platform. We assume different knowledge base and reasoning capabilities for each agent. The agents have their own optical coherence tomography (OCT) images on which they apply a distinct machine learning algorithm. The learned model is used to extract diagnosis rules. With distinct learned rules, the agents engage in an argumentative process. The resolution of the debate outputs a diagnosis that is then explained to the ophthalmologist, by means of assurance cases. Results For diagnosing the retina condition, our AI solution deals with the following three issues: first, the learned models are automatically translated into rules. These rules are then used to build an explanation by tracing the reasoning chain supporting the diagnosis. Hence, the proposed AI solution complies with the requirement that "algorithmic decision should be explained to the human agent". Second, the decision is not solely based on ML-algorithms. The proposed architecture includes expert knowledge. The diagnosis is taken based on exchanging arguments between ML-based algorithms and expert knowledge. The conflict resolution among arguments is verbalised, so that the ophthalmologist can supervise the diagnosis. Third, the assurance cases are generated to facilitate technical audit. The assurance cases structure the evidence among various safety goals such as: machine learning methodology, transparency, or data quality. For each dimension, the auditor can check the provided evidence against the current best practices or safety standards. Conclusion We developed a multi-agent system for retina conditions in which algorithmic decisions are sustained by explanations. The proposed tool goes behind most software in medical domain that focuses only on performance metrics.
   Our approach helps the technical auditor to approve software in the medical domain.
   Interleaving knowledge extracted from ML-models with expert knowledge is a step towards balancing the benefits of ML with explainability, aiming at engineering reliable medical applications.
C1 [Groza, Adrian; Toderean, Liana] Tech Univ Cluj Napoca, Cluj Napoca, Romania.
   [Muntean, George Adrian; Nicoara, Simona Delia] Iuliu Hatieganu Univ Med & Pharm, Cluj Napoca, Romania.
C3 Technical University of Cluj Napoca; Iuliu Hatieganu University of
   Medicine & Pharmacy
RP Groza, A (通讯作者)，Tech Univ Cluj Napoca, Cluj Napoca, Romania.
EM Adrian.Groza@cs.utcluj.ro; Toderean.Io.Liana@utcluj.didatec.ro;
   georgemuntean99@elearn.umfcluj.ro; stalu@umfcluj.ro
RI Toderean, Liana/GSN-1604-2022; Nicoara, Simona Delia/D-3353-2016; Groza,
   Adrian/D-6401-2011; Muntean, George Adrian/GSE-1383-2022
OI Nicoara, Simona Delia/0000-0002-7886-2044; Groza,
   Adrian/0000-0003-0143-5631; 
CR Adadi A, 2018, IEEE ACCESS, V6, P52138, DOI 10.1109/ACCESS.2018.2870052
   [Anonymous], 2021, TECH REP
   Bordini R. H., 2007, PROGRAMMING MULTIAGE, V8
   Chalam KV, 2012, INVEST OPHTH VIS SCI, V53, P8154, DOI 10.1167/iovs.12-10290
   Chan A, 2006, ARCH OPHTHALMOL-CHIC, V124, P193, DOI 10.1001/archopht.124.2.193
   Chang CC, 2011, ACM T INTEL SYST TEC, V2, DOI 10.1145/1961189.1961199
   Coscas G, 2016, DEV OPHTHALMOL, V56, P1, DOI 10.1159/000442768
   Cyras K, 2019, AAAI CONF ARTIF INTE, P2752
   Cyras K, 2019, EXPERT SYST APPL, V127, P141, DOI 10.1016/j.eswa.2019.03.012
   De Graaf M.M., 2017, 2017 AAAI FALL S SER
   Domingos P., 2015, MASTER ALGORITHM QUE
   Guerra-Hernandez A, 2010, LECT NOTES ARTIF INT, V6437, P374, DOI 10.1007/978-3-642-16761-4_33
   Invernizzi A, 2018, OPHTHALMOL RETINA, V2, P808, DOI 10.1016/j.oret.2017.12.012
   Kelly T., 2004, P DEP SYST NETW 2004, P6
   Klikauer T, 2016, TRIPLEC-COMMUN CAPIT, V14, P260
   Liu XX, 2019, LANCET DIGIT HEALTH, V1, pE271, DOI 10.1016/S2589-7500(19)30123-2
   Marginean A, 2019, INT C INTELL COMP CO, P475, DOI 10.1109/ICCP48234.2019.8959714
   Memari N, 2019, J MED BIOL ENG, V39, P713, DOI 10.1007/s40846-018-0454-2
   Ming Y, 2019, IEEE T VIS COMPUT GR, V25, P342, DOI 10.1109/TVCG.2018.2864812
   Nieves-Moreno M, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0180450
   Picardi C, 2019, LECT NOTES COMPUT SC, V11698, P165, DOI 10.1007/978-3-030-26601-1_12
   Russell SJ., 2003, ARTIF INTELL, V2nd
   Sassoon I, 2019, LECT NOTES ARTIF INT, V11763, P186, DOI 10.1007/978-3-030-30391-4_11
   Sendi N, 2019, PROCEDIA COMPUT SCI, V159, P271, DOI 10.1016/j.procs.2019.09.182
   Thulkar D, 2020, J MED BIOL ENG, V40, P798, DOI 10.1007/s40846-020-00561-4
   van VoorstVader, 2018, MULTIAGENT BASED MIL
   Wang Z., 2019, P 2019 INT C INT MED, P48
   Zeng ZW, 2018, PROCEEDINGS OF THE 17TH INTERNATIONAL CONFERENCE ON AUTONOMOUS AGENTS AND MULTIAGENT SYSTEMS (AAMAS' 18), P1114
   Zhang C, 2017, LECT NOTES COMPUT SC, V10552, P67, DOI 10.1007/978-3-319-67534-3_8
NR 29
TC 1
Z9 1
U1 1
U2 3
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY
SN 1609-0985
EI 2199-4757
J9 J MED BIOL ENG
JI J. Med. Biol. Eng.
PD OCT
PY 2021
VL 41
IS 5
SI SI
BP 730
EP 741
DI 10.1007/s40846-021-00647-7
EA SEP 2021
PG 12
WC Engineering, Biomedical
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Engineering
GA WG5RI
UT WOS:000692958200001
OA Green Submitted
DA 2022-11-30
ER

PT J
AU Wang, Y
   Yao, Y
   Li, R
   Wu, BH
   Lu, HQ
   Cheng, J
   Liu, Z
   Du, JH
AF Wang, Yi
   Yao, Yang
   Li, Rong
   Wu, Binghui
   Lu, Huiqin
   Cheng, Jing
   Liu, Zhe
   Du, Junhui
TI Different effects of anti-VEGF drugs (Ranibizumab, Aflibercept,
   Conbercept) on autophagy and its effect on neovascularization in RF/6A
   cells
SO MICROVASCULAR RESEARCH
LA English
DT Article
DE Anti-VEGF; Neovascularization; Recurrence; Autophagy
ID ENDOTHELIAL GROWTH-FACTOR; MACULAR DEGENERATION; INTRAVITREAL
   AFLIBERCEPT; ANGIOGENESIS; BEVACIZUMAB; APOPTOSIS; INHIBITION;
   RADIATION; DRAM
AB Introduction: Choroidal neovascularization (CNV) is the main pathological change of wet age-related macular degeneration. Anti-VEGF drugs are the most commonly used treatment for CNV. The biggest drawback of antiVEGF drugs is the recurrence of CNV, which requires repeated therapy several times. Autophagy activation may be involved in reducing the therapeutic effect of anti-VEGF drugs. So, this study aims to elucidate the effect and mechanism of anti-VEGF drugs on endothelial autophagy and neovascularization in vitro. Methods: RF/6A cells were randomly divided into five groups: The control group, hypoxia group (1% O2, 5% CO2, 94% N2), anti-VEGF group (group1: Ranibizumab 100 mu g/ml; group2: Aflibercept, 400 mu g/ml; group3: Conbercept, 100 mu g/ml). Autophagy-related proteins were examined by Western blot. RFP-GFP-LC3 was used to detect autophagy and autophagic flow. Subsequently, we used autophagy inhibitors (3-MA or CQ) to inhibit Conbercept induced autophagy and to observe its effect on angiogenesis in vitro. Proliferation, migration, and tube formation of endothelial cells can be used to study neovascularization in vitro. In this research, the CCK-8 assay was used to detect cell proliferation. Cell migration and tube formation were assessed by wound assay and matrix method, respectively. Flow cytometry and Tunel were used to detect cell apoptosis. Finally, the mechanism of Conbercept activated autophagy was studied. Western blot was used to detect the expression of p53 and DRAM (damage-regulated autophagy modulator), upstream activators of autophagy. Results: The protein levels of Beclin-1 and LC3-2/1 in Ranibizumab and Conbercept groups were significantly higher than in the hypoxia group(P < 0.05). While the expression of P62 was decreased (P < 0.05). The autophagic flux was showed the same results. However, Aflibercept showed the opposite effect on autophagy. Compared with the Conbercept group, autophagy inhibitor 3-MA or CQ can further inhibit cell proliferation and promotes cell apoptosis (P < 0.05). Conbercept significantly inhibited cell migration compared with the hypoxia group (633.08 +/- 72.52 vs. 546.33 +/- 24.61), while the autophagy inhibitor group (3-MA or CQ) had a more obvious inhibition effect (309.75 +/- 86.36 and 263.33 +/- 68.67) (P < 0.05). For tube formation, the number of tube formation was decreased significantly in the Conbercept group (32.00 +/- 2.00) compared to the hypoxia group (39.00 +/- 1.53) and even further reduced in 3-MA or CQ group (24.00 +/- 3.61, 20.00 +/- 2.65). The length of master segments in the hypoxia group was 15,668.00 +/- 894.11. It was decreased in Conbercept (13,885.34 +/- 730.03). In 3-MA or CQ group, the length of master segments dropped further (11,997.00 +/- 433.66, 10,617.67 +/- 543.21). Compare with the hypoxia group, the expression P53 and DRAM were increased in the Conbercept group (P < 0.05). Autophagy-related proteins LC-3, Beclin-1, and DRAM were inhibited by P53 inhibitor Pifithrin-alpha (PFT alpha) (P < 0.05). Conclusion: Ranibizumab and Conbercept can trigger the autophagy of vascular endothelial cells while Aflibercept can inhibit it. The combination of Conbercept and autophagy inhibitor can significantly inhibit the formation of angiogenesis in vitro. The mechanism of autophagy activation is related to the activation of the p53/DRAM pathway.
C1 [Wang, Yi; Liu, Zhe; Du, Junhui] Xi An Jiao Tong Univ, Ctr Translat Med, Xian Hosp 9, Med Coll, Xian 710054, Shaanxi, Peoples R China.
   [Yao, Yang; Li, Rong] Xian Med Univ, Dept Ophthalmol, Affiliated Hosp 1, West Fenghao Rd 48, Xian 710077, Shaanxi, Peoples R China.
   [Wu, Binghui; Lu, Huiqin] Xian 1 Hosp, Dept Ophthalmol, Xian 710001, Shaanxi, Peoples R China.
   [Cheng, Jing; Du, Junhui] Xi An Jiao Tong Univ, Dept Ophthalmol, Xian Hosp 9, Med Coll, Xian 710054, Shaanxi, Peoples R China.
C3 Xi'an Jiaotong University; Xi'an Medical University; Xi'an Jiaotong
   University
RP Du, JH (通讯作者)，Xi An Jiao Tong Univ, Dept Ophthalmol, Xian Hosp 9, Med Coll, Xian 710054, Shaanxi, Peoples R China.
EM djh79918@163.com
FU Fundamental Research Funds for the Central Universities [1191329116];
   Foundation of Xi'an Science and Technology Project
   [2019114613YX001SF041(4)]; Foundation of Xi'an Health Committee
   [2020MS07]; Natural Science Foundation of Shaanxi Province [2020JM-685]
FX This work was supported by the Fundamental Research Funds for the
   Central Universities (No. 1191329116), the Foundation of Xi'an Science
   and Technology Project [No. 2019114613YX001SF041(4)], the Foundation of
   Xi'an Health Committee (No. 2020MS07), the Natural Science Foundation of
   Shaanxi Province (No.2020JM-685).
CR Chandra A, 2020, SEMIN CANCER BIOL, V66, P75, DOI 10.1016/j.semcancer.2019.08.031
   Chen YS, 2015, MOL MED REP, V12, P1645, DOI 10.3892/mmr.2015.3623
   Choi M, 2020, AM J OPHTHALMOL, V213, P109, DOI 10.1016/j.ajo.2020.01.012
   Crighton D, 2006, CELL, V126, P121, DOI 10.1016/j.cell.2006.05.034
   Cui L, 2016, ONCOL REP, V35, P3639, DOI 10.3892/or.2016.4752
   Darche M, 2020, FASEB J, V34, P5851, DOI 10.1096/fj.201901876R
   Gao ZY, 2018, MOL NEUROBIOL, V55, P1988, DOI 10.1007/s12035-017-0426-5
   Garufi A, 2017, J EXP CLIN CANC RES, V36, DOI 10.1186/s13046-017-0596-z
   Ghiardi GJ, 1999, VISION RES, V39, P2519, DOI 10.1016/S0042-6989(99)00038-3
   Guo XL, 2013, J MOL MED, V91, P473, DOI 10.1007/s00109-012-0966-0
   Hu YL, 2012, AUTOPHAGY, V8, P979, DOI 10.4161/auto.20232
   Hu YL, 2012, CANCER RES, V72, P1773, DOI 10.1158/0008-5472.CAN-11-3831
   Ishima Y, 2015, CANCER SCI, V106, P194, DOI 10.1111/cas.12577
   Korobelnik JF, 2014, OPHTHALMOLOGY, V121, P2247, DOI 10.1016/j.ophtha.2014.05.006
   Li FJ, 2020, BIOMED RES INT, V2020, DOI 10.1155/2020/2428348
   Li R, 2019, J CELL PHYSIOL, V234, P20566, DOI 10.1002/jcp.28659
   Li R, 2018, BMC OPHTHALMOL, V18, DOI 10.1186/s12886-018-0774-6
   Li R, 2016, CURR EYE RES, V41, P1566, DOI 10.3109/02713683.2016.1145234
   Liang J, 2015, ONCOTARGET, V6, P31479, DOI 10.18632/oncotarget.5491
   Liu C, 2020, PLAST RECONSTR SURG, V145, P433, DOI 10.1097/PRS.0000000000006502
   Liu JT, 2016, MED ONCOL, V33, DOI 10.1007/s12032-015-0721-9
   Liu X, 2020, ARTIF CELL NANOMED B, V48, P488, DOI 10.1080/21691401.2019.1709862
   Lytvynchuk L, 2015, J OPHTHALMOL, V2015, DOI 10.1155/2015/934963
   Mitchell P, 2021, RETINA-J RET VIT DIS, V41, P1911, DOI 10.1097/IAE.0000000000003128
   Ohji M, 2020, ADV THER, V37, P2184, DOI 10.1007/s12325-020-01298-x
   Panchmatia HR, 2016, ACTA OPHTHALMOL, V94, P441, DOI 10.1111/aos.12964
   Queguiner F, 2020, INT J OPHTHALMOL-CHI, V13, P252, DOI 10.18240/ijo.2020.02.08
   Ramakrishnan S, 2007, AUTOPHAGY, V3, P512
   Singh SR, 2021, EUR J OPHTHALMOL, V31, P584, DOI 10.1177/1120672120902027
   Valbuena A, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017320
   van Wijngaarden P, 2008, CLIN EXP OPTOM, V91, P427, DOI 10.1111/j.1444-0938.2008.00305.x
   Wang RX, 2020, J OPHTHALMOL, V2020, DOI 10.1155/2020/4016536
   Wons J, 2017, J OPHTHALMOL, V2017, DOI 10.1155/2017/7432739
   Xia DY, 2013, BRAZ J MED BIOL RES, V46, P580, DOI 10.1590/1414-431X20133161
   Xiang DN, 2019, EXP THER MED, V18, P4022, DOI 10.3892/etm.2019.8016
   Xiao MC, 2019, FASEB J, V33, P13920, DOI 10.1096/fj.201901283RR
   Xu JJ, 2019, AGING DIS, V10, P82, DOI 10.14336/AD.2018.0210
   Yu L, 2020, CELL SIGNAL, V71, DOI 10.1016/j.cellsig.2020.109570
   Zhou YD, 2016, SCI REP-UK, V6, DOI 10.1038/srep39301
NR 39
TC 1
Z9 1
U1 2
U2 6
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0026-2862
EI 1095-9319
J9 MICROVASC RES
JI Microvasc. Res.
PD NOV
PY 2021
VL 138
AR 104207
DI 10.1016/j.mvr.2021.104207
EA JUN 2021
PG 11
WC Peripheral Vascular Disease
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cardiovascular System & Cardiology
GA UW3VR
UT WOS:000700088300003
PM 34119535
DA 2022-11-30
ER

PT J
AU Jurklies, B
   Weismann, M
   Husing, J
   Sutter, EE
   Bornfeld, N
AF Jurklies, B
   Weismann, M
   Husing, J
   Sutter, EE
   Bornfeld, N
TI Monitoring retinal function in neovascular maculopathy using multifocal
   electroretinography - early and long-term correlation with clinical
   findings
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
ID MACULAR DEGENERATION; IMAGE QUALITY; IMPLICIT TIME; ERG; TOPOGRAPHY;
   COMPONENTS; AMPLITUDE
AB Purpose: To objectively investigate and longitudinally monitor retinal function in patients with choroidal neovascularization (CNV) due to exudative age-related macular degeneration (AMD) and myopia using multifocal electroretinography (mfERG). Methods: Patients with classic and occult subfoveal CNV secondary either to AMD or to myopia were enrolled in the study. The mfERGs were performed at the beginning of the study and every 3 months subsequently during a follow-up period of 15 months. In addition, standardized visual acuity testing, ophthalmologic examinations, color fundus photographs and fluorescein angiography were performed, The mfERG records were derived with the VERIS-System (Electro-Diagnostic Imaging, San Mateo, Calif., USA); 103 locations within the central 50degrees in diameter were stimulated concurrently by means of the m-sequence technique. Fixation stability was monitored throughout the recording session with an infrared eye monitoring system (VERIS Refractor/Camera unit). The first-order response component was extracted for each stimulated retinal location. The response densities of the first-order kernel were evaluated as a function of eccentricity from the center (ring 1) to the periphery of the stimulated area (ring 6). The results were compared to those derived from age-matched normal control groups. For each patient mfERG responses measured on follow-up visits were compared to each other to evaluate and monitor changes in retinal function. These changes were tested for correlation with those observed in other clinical and electroretinographic findings. Statistical analysis was performed using the Pearson coefficient. Results: Subfoveal neovascular maculopathy was associated with a reduction in response density most prominent within the central 5degrees over the area affected by CNV detected either at the beginning of the study or at the follow-up recordings. During the follow-up period patients 1 and 4 showed stabilization or a slight increase in response densities over the neovascular lesion-complex and a corresponding stabilization or slight increase in visual acuity accompanied by a decrease in the activity of the neovascular lesion as determined by fluorescein angiography. Patient 2 revealed an increase in response density correlating with in increase in visual acuity and decrease in lesion size. In the contralateral eye of this patient the response density dropped in the area of new subfoveal CNV. In patient 3 continuous progression of the disease was documented by fluorescein angiography and visual acuity. It correlated well with a continuous decrease in retinal response densities during the follow-up. Conclusions: Objective monitoring of retinal function and correlation with morphological and psychophysical findings was at least in part possible in patients suffering from AMD and myopia. In all of four patients whose subfoveal CNV was documented by fluorescein angiography. Response densities were reduced particularly in the central 5degrees and in visual acuity. The mfERG data showed a moderate to high statistical correlation with visual function as measured by visual acuity. On the other hand, the greatest linear dimension of the lesion size showed only a weak to moderate statistical correlation with both the response densities of the mfERG and the visual acuity. We conclude that the size of die CNV complex does not represent an accurate measure of retinal function in neovascular maculopathy. The good correlation of the mfERG data with visual acuity suggests that it may serve for objective assessment of retinal function, of the areas overlying the CNV.
C1 Univ Essen Gesamthsch, Hosp Eye, D-45122 Essen, Germany.
   Univ Essen Gesamthsch, Inst Med Informat Biometry & Epidemiol, D-4300 Essen 1, Germany.
   Smith Kettlewell Eye Res Inst, San Francisco, CA 94115 USA.
C3 University of Duisburg Essen; University of Duisburg Essen; The
   Smith-Kettlewell Eye Research Institute
RP Jurklies, B (通讯作者)，Univ Essen Gesamthsch, Hosp Eye, Hufelandstr 55, D-45122 Essen, Germany.
EM bernhard.jurklies@uni-essen.de
CR ARTAL P, 1995, VISION RES, V35, P939, DOI 10.1016/0042-6989(94)00180-T
   Bearse MA, 1996, J OPT SOC AM A, V13, P634
   BIERSDORF WR, 1989, DOC OPHTHALMOL, V73, P313, DOI 10.1007/BF00154487
   CHAMBERLIN JA, 1989, OPHTHALMOLOGY, V96, P1526
   CHEN JC, 1992, INVEST OPHTH VIS SCI, V33, P334
   CURCIO CA, 1990, J COMP NEUROL, V292, P497, DOI 10.1002/cne.902920402
   CURCIO CA, 1990, J COMP NEUROL, V300, P5, DOI 10.1002/cne.903000103
   FERRIS FL, 1982, AM J OPHTHALMOL, V94, P91, DOI 10.1016/0002-9394(82)90197-0
   GREEN WR, 1993, OPHTHALMOLOGY, V100, P1519
   Hood DC, 1997, VISUAL NEUROSCI, V14, P533, DOI 10.1017/S0952523800012190
   Hood DC, 2000, PROG RETIN EYE RES, V19, P607, DOI 10.1016/S1350-9462(00)00013-6
   Jackson GR, 1999, VISION RES, V39, P3975, DOI 10.1016/S0042-6989(99)00092-9
   JENNINGS JAM, 1981, VISION RES, V21, P445, DOI 10.1016/0042-6989(81)90091-2
   JENNINGS JAM, 1978, AM J OPTOM PHYS OPT, V55, P582
   Jurklies B, 1999, INVEST OPHTH VIS SCI, V40, pS315
   Kawabata H, 1997, INVEST OPHTH VIS SCI, V38, P2844
   Keating David, 2000, Documenta Ophthalmologica, V100, P77, DOI 10.1023/A:1002723501303
   Kretschmann U, 1996, OPHTHALMIC RES, V28, P303, DOI 10.1159/000267919
   Kretschmann U, 1998, VISION RES, V38, P3817, DOI 10.1016/S0042-6989(98)00071-6
   Kretschmann U, 1997, DEV OPHTHALMOL, V29, P8
   Li J, 2001, BRIT J OPHTHALMOL, V85, P287, DOI 10.1136/bjo.85.3.287
   Marmor MF, 1999, ARCH OPHTHALMOL-CHIC, V117, P184
   MILLODOT M, 1975, VISION RES, V15, P1357, DOI 10.1016/0042-6989(75)90190-X
   Mohidin N, 1997, OPHTHAL PHYSL OPT, V17, P530, DOI 10.1046/j.1475-1313.1997.97000343.x
   Palmowski AM, 1999, DOC OPHTHALMOL, V99, P41, DOI 10.1023/A:1002432113628
   Palmowski AM, 1999, OPHTHALMOLOGE, V96, P166, DOI 10.1007/s003470050389
   SANDBERG MA, 1979, AM J OPHTHALMOL, V88, P702, DOI 10.1016/0002-9394(79)90669-X
   Seeliger MW, 1998, INVEST OPHTH VIS SCI, V39, P718
   SEIPLE WH, 1986, INVEST OPHTH VIS SCI, V27, P3477
   SMITH WJ, 1966, MODERN OPTICAL ENG, P318
   STEINMETZ RL, 1993, BRIT J OPHTHALMOL, V77, P549, DOI 10.1136/bjo.77.9.549
   Sutter E.E., 1992, NONLINEAR VISION, P171, DOI [10.1201/9781351075060-6, DOI 10.1201/9781351075060-6]
   SUTTER EE, 1991, SIAM J COMPUT, V20, P686, DOI 10.1137/0220043
   SUTTER EE, 1992, VISION RES, V32, P433, DOI 10.1016/0042-6989(92)90235-B
   Sutter EE, 2001, VISION RES, V41, P1241, DOI 10.1016/S0042-6989(01)00078-5
   Sutter EE, 1999, VISION RES, V39, P419, DOI 10.1016/S0042-6989(98)00161-8
   Sutter Erich, 2000, Documenta Ophthalmologica, V100, P49, DOI 10.1023/A:1002702917233
   Weismann M, 1999, INVEST OPHTH VIS SCI, V40, pS715
   Williams DR, 1996, VISION RES, V36, P1103, DOI 10.1016/0042-6989(95)00182-4
NR 39
TC 36
Z9 41
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0721-832X
EI 1435-702X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD APR
PY 2002
VL 240
IS 4
BP 244
EP 264
DI 10.1007/s00417-002-0439-1
PG 21
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 552GV
UT WOS:000175612300002
PM 11981638
DA 2022-11-30
ER

PT J
AU Kondrot, EC
AF Kondrot, Edward C.
TI Improvement in Vision Parameters for Participants Treated With
   Alternative Therapies in a 3-day Program
SO ALTERNATIVE THERAPIES IN HEALTH AND MEDICINE
LA English
DT Article
ID MACULAR DEGENERATION; CATARACT-EXTRACTION; ELECTROACUPUNCTURE
AB Context Eye conditions that are considered progressive and degenerative and for which the causation is generally poorly understood or not understood within conventional medicine can respond to natural therapeutic interventions that result in arrest and/or improvement of morbidity, with enhanced functional results. Because many of the treated conditions are age related, a delay of disease progression for 5 or even 10 y can mean an additional decade of independence for seniors. The 11 included ocular conditions are ordinarily considered incurable by any method except surgery and, even with surgery, the outcomes can be variable and/or transient.
   Objective The research intended to demonstrate the effectiveness of alternative modalities-intravenous (IV) nutrition, oxidative therapy, microcurrent stimulation, and syntonic light therapy-in improving vision in chronic eye conditions, even when administered for a short period.
   Design The study was a retrospective, open-label, single-group design. All participants in the 3-d conference during the period covered were selected.
   Setting The setting was ophthalmologist Edward Kondrot's Healing the Eye and Wellness Center near Tampa, FL, USA.
   Participants The participants in this study were all patients attending 1 of 11 CAM treatment events at the author's center within 2 y. Each session lasted 3 d and the number of participants in each session ranged from 5-15 (mean = 13). The cohort numbered 152 patients who were diagnosed with >= 1 of 11 types of eye disease. Seventy-eight percent of the patients had either age-related macular degeneration (ARMD) or glaucoma, which, taken together, are the leading cause of blindness in persons >65 y.
   Intervention Each of 4 alternative modalities was provided at least once to each participant: (1) IV nutrition, (2) oxidative therapy, (3) microcurrent stimulation, and (4) syntonic light therapy. On the first day, a detailed treatment plan for each participant was developed. Each day consisted of 2 therapeutic eye programs, a stress reduction program, and a detoxification program. Also included were daily lectures and instructions on the methods and use of the equipment.
   Outcome Measures To measure outcomes, changes from baseline were documented through comparison with postprogram results. Pre- and postprogram testing included the following measures: (1) Early Treatment Diabetic Retinopathy Study (ETDRS) eye chart; (2) Lighthouse Letter Contrast Sensitivity test; (3) campimetry; (4) pursuits, saccade, and, fixation tests; (5) pupillary examination; (6) external examination; (7) examination of the anterior segment; (8) intraocular-pressure test; and (9) dilated examination. Additional tests, if necessary, included (1) ocular coherence tomography, (2) infrared thermography, (3) 6-hour urine collection for heavy-metal toxicity, and (4) nocturnal oximetry.
   Results All participants remained in the study for the duration of the program. Following the administration of the protocol, significant improvement in acuity, contrast, and visual field resulted in the majority of participants. None of the interventions was toxic or painful, and all likely contributed to an improved, overall health status for participants.
   Conclusions These treatment protocols should be considered part of a treatment program for all ocular disease processes. Eye health needs to be repositioned within an assessment of general health with the understanding that, with the exception of congenital disorders or accidents, vision decline represents a general diminishment in overall health and results directly from toxicity from both external sources such as air and water, and the internal accumulation of toxic metals; poor nutrition; and other life exposures and habits. Long-term follow-up studies are now in process.
C1 [Kondrot, Edward C.] Amer Med Coll Homeopathy Phoenix, Integrat Med, Phoenix, AZ USA.
RP Kondrot, EC (通讯作者)，Amer Med Coll Homeopathy Phoenix, Integrat Med, Phoenix, AZ USA.
EM info@healingtheeye.com
CR BLAIR CJ, 1979, AM J OPHTHALMOL, V87, P77, DOI 10.1016/0002-9394(79)90195-8
   Bocci VA, 2006, ARCH MED RES, V37, P425, DOI 10.1016/j.arcmed.2005.08.006
   Chan HHL, 2005, J ALTERN COMPLEM MED, V11, P315, DOI 10.1089/acm.2005.11.315
   Cheng N, 1982, Clin Orthop Relat Res, P264
   Chu TC, 2002, J OCUL PHARMACOL TH, V18, P293, DOI 10.1089/10807680260218461
   Glaucoma Research Foundation, GLAUC MED THEIR SID
   GOLDBERG J, 1988, AM J EPIDEMIOL, V128, P700, DOI 10.1093/oxfordjournals.aje.a115023
   Gottlieb RL, 2010, PHOTOMED LASER SURG, V28, P449, DOI 10.1089/pho.2010.9933
   Grunwald JE, 2015, OPHTHALMOLOGY, V122, P809, DOI 10.1016/j.ophtha.2014.11.007
   Haddrill M, 2015, GLAUCOMA TREATMENT E
   Klein BEK, 2012, OPHTHALMOLOGY, V119, P1628, DOI 10.1016/j.ophtha.2012.01.050
   Kondrot EC, 2001, MICROCURRENT STIMULA
   Kondrot EC, 2002, TOWNSEND LETT DOCT P, P65
   Kondrot EC, 2001, HEALING EYE NATURAL
   Kondrot EC, 2012, ESSENTIALS SAVE YOUR
   KRYZHANOVSKII G N, 1980, Byulleten' Eksperimental'noi Biologii i Meditsiny, V89, P535
   Levy T.E., 2002, CURING INCURABLE VIT
   MICHAEL LD, 1993, J ORTHOMOLECULAR MED, V8, P168
   Nguyen QD, 2004, INVEST OPHTH VIS SCI, V45, P617, DOI 10.1167/iovs.03-0557
   PAUL EL, 2002, INT SOC LOW VIS RES
   SANSEVERINO ER, 1990, PANMINERVA MED, V32, P77
   Schaumberg DA, 2004, JAMA-J AM MED ASSOC, V292, P2750, DOI 10.1001/jama.292.22.2750
   ZARETSKAYA RB, 1948, AM J OPHTHALMOL, V31, P721, DOI 10.1016/S0002-9394(48)91920-5
NR 23
TC 2
Z9 2
U1 0
U2 10
PU INNOVISION COMMUNICATIONS
PI ALISO VIEJO
PA 101 COLUMBIA, ALISO VIEJO, CA 92656 USA
SN 1078-6791
J9 ALTERN THER HEALTH M
JI Altern. Ther. Health Med.
PD NOV-DEC
PY 2015
VL 21
IS 6
BP 22
EP 35
PG 14
WC Integrative & Complementary Medicine
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Integrative & Complementary Medicine
GA DB8EK
UT WOS:000368749600003
PM 26567447
DA 2022-11-30
ER

PT J
AU Koksal, M
   Ozdemir, H
   Kargi, S
   Yesilli, C
   Tomac, S
   Mahmutyazicioglu, K
   Mungan, A
AF Koksal, M
   Ozdemir, H
   Kargi, S
   Yesilli, C
   Tomac, S
   Mahmutyazicioglu, K
   Mungan, A
TI The effects of sildenafil on ocular blood flow
SO ACTA OPHTHALMOLOGICA SCANDINAVICA
LA English
DT Article
DE sildenafil; ocular blood flow; colour Doppler ultrasonography; central
   retinal artery; ophthalmic artery; short posterior ciliary artery
ID ENDOTHELIUM-DEPENDENT REGULATION; CITRATE VIAGRA; NITRIC-OXIDE;
   OPTIC-NERVE; RELAXATION; TONE
AB Purpose: To investigate the effects of sildenafil, a popular new drug in the treatment of erectile dysfunction, on ocular blood flow.
   Methods: This study was designed as a prospective, double-blind, placebo-controlled study. Twenty participants with erectile dysfunction were given a single oral dose of 100 mg sildenafil, while 10 participants with erectile dysfunction were given placebo. All the participants underwent routine systemic and ophthalmological examinations. Intraocular pressure, systolic and diastolic blood pressure and ocular blood flow (ophthalmic, central retinal, short posterior ciliary arteries) were measured in both eyes before and 1 hour after the dose of sildenafil or placebo. Ocular blood flow measurements were performed using colour Doppler ultrasonography.
   Results: None of the parameters were significantly different between the groups before study drug intake. Although central retinal artery velocities were not changed, ophthalmic artery and short posterior ciliary artery peak systolic velocity, end-diastolic velocity, and mean velocity values were significantly increased 1 hour after drug intake in the sildenafil group compared to the placebo group (p < 0.05).
   Conclusion: Sildenafil causes a significant increase in blood flow in these arteries. A possible role of inhibition of phosphodiesterase-5 in vascular smooth muscles by sildenafil is implicated. Further studies are needed to investigate the effects of sildenafil on ocular blood flow in patients with senile macular degeneration, diabetic retinopathy and glaucoma.
C1 Zonguldak Karaelmas Univ, Fac Med, Dept Ophthalmol, Zonguldak, Turkey.
   Zonguldak Karaelmas Univ, Fac Med, Radiodiagnost Dept, Zonguldak, Turkey.
   Zonguldak Karaelmas Univ, Fac Med, Dept Urol, Zonguldak, Turkey.
   Zonguldak Karaelmas Univ, Fac Med, Dept Publ Hlth, Zonguldak, Turkey.
C3 Bulent Ecevit University; Bulent Ecevit University; Bulent Ecevit
   University; Bulent Ecevit University
RP Koksal, M (通讯作者)，Zonguldak Karaelmas Univ, Tip Fak, Goz Hastaliklari AD, TR-67100 Zonguldak, Turkey.
EM mrtkksl@hotmail.com
RI Tomaç, Sühan/ABD-4628-2020
OI Tomaç, Sühan/0000-0002-1830-7807
CR Ballard SA, 1998, J UROLOGY, V159, P2164, DOI 10.1016/S0022-5347(01)63299-3
   Birch DG, 2002, AM J OPHTHALMOL, V133, P665, DOI 10.1016/S0002-9394(02)01338-7
   Boolell M, 1996, Int J Impot Res, V8, P47
   CIBIS GW, 2001, BASIC CLIN SCI COURS, V2, P3
   Dundar SO, 2001, EYE, V15, P507, DOI 10.1038/eye.2001.163
   Ebrey T, 2001, PROG RETIN EYE RES, V20, P49, DOI 10.1016/S1350-9462(00)00014-8
   FELDMAN HA, 1994, J UROLOGY, V151, P54, DOI 10.1016/S0022-5347(17)34871-1
   Goldstein I, 1998, NEW ENGL J MED, V338, P1397, DOI 10.1056/NEJM199805143382001
   Grunwald JE, 1999, BRIT J OPHTHALMOL, V83, P162, DOI 10.1136/bjo.83.2.162
   Grunwald JE, 2002, AM J OPHTHALMOL, V133, P809, DOI 10.1016/S0002-9394(02)01391-0
   Grunwald JE, 2001, AM J OPHTHALMOL, V131, P751, DOI 10.1016/S0002-9394(00)00944-2
   HAEFLIGER IO, 1994, INVEST OPHTH VIS SCI, V35, P991
   Herrmann HC, 2000, NEW ENGL J MED, V342, P1622, DOI 10.1056/NEJM200006013422201
   Hotta H, 1998, EUR J PHARMACOL, V344, P49, DOI 10.1016/S0014-2999(98)00015-6
   Jackson G, 1999, AM J CARDIOL, V83, p13C
   Kelly PAT, 1998, BRIT J OPHTHALMOL, V82, P1199, DOI 10.1136/bjo.82.10.1199
   Laties A EP, 1998, OPHTHALMIC RES, V30, P177
   Laties AM, 2000, INVEST OPHTH VIS SCI, V41, pS592
   Laties AM, 2002, PROG RETIN EYE RES, V21, P485, DOI 10.1016/S1350-9462(02)00013-7
   Luksch A, 2000, INVEST OPHTH VIS SCI, V41, P3080
   Marmor MF, 1999, ARCH OPHTHALMOL-CHIC, V117, P518
   Marmor MF, 1999, SURV OPHTHALMOL, V44, P153, DOI 10.1016/S0039-6257(99)00079-X
   McCulley TJ, 2002, OPHTHALMOLOGICA, V216, P455, DOI 10.1159/000067549
   MEYER P, 1993, INVEST OPHTH VIS SCI, V34, P3614
   Pache M, 2002, BRIT J OPHTHALMOL, V86, P156, DOI 10.1136/bjo.86.2.156
   Paris Gianmarco, 2001, International Ophthalmology, V23, P355, DOI 10.1023/A:1014410932321
   ROUFAIL E, 1995, BRAIN RES, V684, P36, DOI 10.1016/0006-8993(95)00394-6
   SINCLAIR AM, 1993, J HUM HYPERTENS, V7, P399
   YAO K, 1991, INVEST OPHTH VIS SCI, V32, P1791
NR 29
TC 39
Z9 39
U1 0
U2 4
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1395-3907
J9 ACTA OPHTHALMOL SCAN
JI Acta Ophthalmol. Scand.
PD JUN
PY 2005
VL 83
IS 3
BP 355
EP 359
DI 10.1111/j.1600-0420.2005.00422.x
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 930AV
UT WOS:000229389100015
PM 15948790
OA Bronze
DA 2022-11-30
ER

PT J
AU Lee, CS
   Woo, SJ
   Kim, YK
   Hwang, DJ
   Kang, HM
   Kim, H
   Lee, SC
AF Lee, Christopher Seungkyu
   Woo, Se Joon
   Kim, Yong-Kyu
   Hwang, Duck Jin
   Kang, Hae Min
   Kim, Hyesun
   Lee, Sung Chul
TI Clinical and Spectral-Domain Optical Coherence Tomography Findings in
   Patients with Focal Choroidal Excavation
SO OPHTHALMOLOGY
LA English
DT Article
ID CENTRAL SEROUS CHORIORETINOPATHY; INDOCYANINE GREEN ANGIOGRAPHY;
   SUBRETINAL NEOVASCULARIZATION; THICKNESS; MYOPIA; EYES
AB Objective: To describe the clinical and spectral-domain optical coherence tomography (SD-OCT) findings in patients with focal choroidal excavation (FCE).
   Design: Retrospective case series.
   Participants: Forty-one eyes of 38 patients with FCE identified in 2 tertiary medical centers in Korea.
   Methods: Clinical features, SD-OCT findings, and associated macular disorders of FCE were analyzed and detailed.
   Main Outcome Measures: Statistical associations among clinical features, including lesion type, size, and choroidal thickness, and frequency of association with central serous chorioretinopathy (CSC), choroidal neovascularization (CNV), and polypoidal choroidal vasculopathy (PCV).
   Results: Mean patient age was 50.1 years (range, 25-76 years). The mean spherical equivalent of refractive error was -3.7 diopters (range, -10.0 to +1.5 diopters). Three patients (8%) had bilateral lesions, and 1 patient (3%) had 2 distinct lesions in the same eye. The mean FCE width and depth were 757 mm and 107 mm, respectively, with a positive correlation between width and depth (P = 0.003). The mean subfoveal choroidal thickness of FCE eyes was 284 mm, which was not statistically different from that of age-, sex-, and refractive error-matched normal subjects. Choroidal thickness in FCE was less in eyes with hyperreflective choroidal tissue under the excavation that was present in 22 eyes (54%) versus eyes without excavation (128 vs. 190 mm, respectively; P = 0.009). Twelve FCEs (29%) were the nonconforming type, revealing separation between the photoreceptor tips and the retinal pigment epithelium on SD-OCT. Nonconforming FCE was associated with visual symptoms (P < 0.001) and the presence of concurrent CSC (P < 0.001). Ten eyes (24%) were associated with CSC, and 9 eyes (22%) were associated with CNV, including 1 eye with PCV features. One eye with FCE and type 1 CNV developed a new excavation, and the excavated area in 1 eye with PCV enlarged slightly during follow-up.
   Conclusions: Focal choroidal excavation is a relatively common entity and frequently associated with choroidal diseases, including CSC, CNV, andPCV. Although FCE is classically thought to be a congenital malformation, acquired FCE forms possibly exist. (C) 2014 by the American Academy of Ophthalmology.
C1 [Lee, Christopher Seungkyu; Kang, Hae Min; Kim, Hyesun; Lee, Sung Chul] Yonsei Univ, Coll Med, Dept Ophthalmol, Inst Vis Res,Shinchon Severance Hosp, Seoul 120752, South Korea.
   [Woo, Se Joon; Kim, Yong-Kyu; Hwang, Duck Jin] Seoul Natl Univ, Bundang Hosp, Coll Med, Dept Ophthalmol, Songnam, South Korea.
   [Hwang, Duck Jin] HanGil Eye Hosp, Dept Ophthalmol, Inchon, South Korea.
C3 Yonsei University; Yonsei University Health System; Seoul National
   University (SNU)
RP Lee, CS (通讯作者)，Yonsei Univ, Coll Med, Dept Ophthalmol, Sodaemungu Shinchondong 134, Seoul 120752, South Korea.
EM sklee219@yuhs.ac
OI , Sung Chul/0000-0001-9438-2385; Hwang, Duck Jin/0000-0002-9684-3998;
   Hwang, Daniel Duck-Jin/0000-0003-1808-3169; Lee,
   Christopher/0000-0001-5054-9470
FU research grant of Yonsei University College of Medicine [6-2011-0068]
FX Supported by a faculty research grant of Yonsei University College of
   Medicine for 2011 (6-2011-0068).
CR Abe Sachi, 2010, Retin Cases Brief Rep, V4, P373, DOI 10.1097/ICB.0b013e3181babe7e
   Chen JC, 2012, CAN J OPHTHALMOL, V47, pE56, DOI 10.1016/j.jcjo.2012.07.006
   Cohen SY, 1996, OPHTHALMOLOGY, V103, P1241, DOI 10.1016/S0161-6420(96)30515-0
   Ellabban AA, 2013, AM J OPHTHALMOL, V156, P673, DOI 10.1016/j.ajo.2013.05.010
   GREEN WR, 1986, OPHTHALMOLOGY, V93, P1169
   GUYER DR, 1994, ARCH OPHTHALMOL-CHIC, V112, P1057, DOI 10.1001/archopht.1994.01090200063023
   Hsu J, 2007, AM J OPHTHALMOL, V143, P163, DOI 10.1016/j.ajo.2006.07.052
   Imamura Y, 2009, RETINA-J RET VIT DIS, V29, P1469, DOI 10.1097/IAE.0b013e3181be0a83
   Jampol LM, 2006, RETINA-J RET VIT DIS, V26, P1072, DOI 10.1097/01.iae.0000248819.86737.a5
   Jirarattanasopa P, 2012, OPHTHALMOLOGY, V119, P1666, DOI 10.1016/j.ophtha.2012.02.021
   Katome T, 2012, CASE REP OPHTHALM, V3, P96, DOI 10.1159/000337880
   Kobayashi W, 2012, CLIN OPHTHALMOL, V6, P1373, DOI 10.2147/OPTH.S33879
   Koh A, 2012, RETINA-J RET VIT DIS, V32, P1453, DOI 10.1097/IAE.0b013e31824f91e8
   Kumano Y, 2013, OPTOMETRY VISION SCI, V90, pE110, DOI 10.1097/OPX.0b013e31828736f3
   Machida S, 2006, RETINA-J RET VIT DIS, V26, P170, DOI 10.1097/00006982-200602000-00008
   Margolis R, 2011, ARCH OPHTHALMOL-CHIC, V129, P1320, DOI 10.1001/archophthalmol.2011.148
   Margolis R, 2009, AM J OPHTHALMOL, V147, P811, DOI 10.1016/j.ajo.2008.12.008
   Maruko I, 2010, OPHTHALMOLOGY, V117, P1792, DOI 10.1016/j.ophtha.2010.01.023
   Mitarai K, 2006, GRAEF ARCH CLIN EXP, V244, P1415, DOI 10.1007/s00417-006-0277-7
   Moon K, 2013, CASE REP OPHTHALM, V4, P70, DOI 10.1159/000354197
   Obata R, 2013, RETINA-J RET VIT DIS, V33, P1201, DOI 10.1097/IAE.0b013e31827b6452
   PICCOLINO FC, 1994, RETINA-J RET VIT DIS, V14, P231, DOI 10.1097/00006982-199414030-00008
   SHWEIKI D, 1992, NATURE, V359, P843, DOI 10.1038/359843a0
   SPITZNAS M, 1991, GRAEF ARCH CLIN EXP, V229, P536, DOI 10.1007/BF00203317
   Tsujikawa A, 2010, RETINA-J RET VIT DIS, V30, P801, DOI 10.1097/IAE.0b013e3181c72068
   Wakabayashi Y, 2010, ACTA OPHTHALMOL, V88, pe87, DOI 10.1111/j.1755-3768.2010.01895.x
   Wang FH, 2012, RETINA-J RET VIT DIS, V32, P679, DOI 10.1097/IAE.0b013e318227ab24
NR 27
TC 59
Z9 61
U1 0
U2 5
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD MAY
PY 2014
VL 121
IS 5
BP 1029
EP 1035
DI 10.1016/j.ophtha.2013.11.043
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AG6BT
UT WOS:000335504200015
PM 24439757
DA 2022-11-30
ER

PT J
AU Owens, SL
   Bunce, C
   Brannon, AJ
   Wormald, R
   Bird, AC
AF Owens, SL
   Bunce, C
   Brannon, AJ
   Wormald, R
   Bird, AC
CA Drusen Laser Study Grp
TI Prophylactic laser treatment appears to promote choroidal
   neovascularisation in high-risk ARM: results of an interim analysis
SO EYE
LA English
DT Article
DE age-related maculopathy; drusen; choroidal neovascularisation; laser;
   controlled clinical trial
ID AGE-RELATED MACULOPATHY; SOFT DRUSEN; PHOTOCOAGULATION
AB Purpose The Drusen Laser Study (DLS) of high-risk age-related maculopathy ( ARM) is a randomised, controlled clinical trial designed to answer two questions: ( 1) Do drusen resolve after macular laser photocoagulation ( 2) Does macular laser photocoagulation prevent choroidal neovascularisation (CNV) in high-risk eyes? In this report, we present the results of the interim, pooled analysis of CNV prophylaxis for patients in the Unilateral Group of the DLS.
   Methods The DLS is a randomised controlled clinical trial of prophylactic macular photocoagulation for high-risk ARM. Patients in the Unilateral Group had a neovascular complication in the first eye; their fellow eye ( Study Eye) had visual acuity of 6/12 or better and drusen. Following informed consent, patients were randomised to the Treatment Group or the No Treatment Group. Patients randomised to treatment received 12 light spots of argon laser photocoagulation to their Study Eye: four burns were placed 750 mum from the centre of the fovea at 12, 3, 6, and 9 o'clock, and the eight remaining burns were placed 1500 mum from the centre of the fovea at 12, 1: 30, 3, 4: 30, 6, 7: 30, 9, and 10: 30 o'clock. Drusen were treated directly only if they were present at the protocol treatment locations. All patients were followed in an identical fashion at regular intervals. Best-corrected visual acuity was measured and recorded by a masked observer. Fluorescein angiography was performed at baseline and yearly review, as well as nonprotocol visits if symptoms suggested CNV. Five clinical centres utilised and conformed to a common DLS protocol. Patient care and data collection methodologies were deemed sufficiently similar to permit a pooled data analysis.
   Results There were 156 patients included in the interim analysis, and timed information was available on 153. CNV occurred in 21 of 81 (26%) patients in the Treatment Group and in 13 of 75 (17%) patients in the No Treatment Group ( P = 0.19). Kaplan - Meier survival analysis showed earlier onset of CNV in the Treatment Group compared to patients in the No Treatment Group ( statistical significance not calculated). Visual acuity loss at 2 years occurred in nine of 54 ( 17%) patients in the Treatment Group compared to the two of 48 (4%) patients in the No Treatment Group ( P = 0.056).
   Conclusions We are only the second group to identify possible laser-induced CNV despite other similar studies in progress. Equipoise of the DLS investigators was lost, and recruitment was halted. We feel ethically bound to notify the ophthalmic community of this finding.
C1 Moorfields Eye Hosp, Professorial Unit, Med Retinal Serv, London EC1V 2PD, England.
   Moorfields Eye Hosp, Dept Res & Dev, London EC1V 2PD, England.
   Univ London, Moorfields Eye Hosp, Inst Ophthalmol, Dept Clin Ophthalmol, London, England.
C3 University of London; University College London; Moorfields Eye Hospital
   NHS Foundation Trust; University of London; University College London;
   Moorfields Eye Hospital NHS Foundation Trust; University of London;
   University College London; Moorfields Eye Hospital NHS Foundation Trust
RP Owens, SL (通讯作者)，Moorfields Eye Hosp, Professorial Unit, Med Retinal Serv, City Rd, London EC1V 2PD, England.
OI Bunce, Catey/0000-0002-0935-3713; Guymer, Robyn/0000-0002-9441-4356
CR Ferris FL, 1996, ARCH OPHTHALMOL-CHIC, V114, P1506, DOI 10.1001/archopht.1996.01100140704011
   Figueroa MS, 1997, RETINA-J RET VIT DIS, V17, P378
   Frennesson C, 1998, BRIT J OPHTHALMOL, V82, P1169, DOI 10.1136/bjo.82.10.1169
   Kaiser RS, 2001, ARCH OPHTHALMOL-CHIC, V119, P826
   Little HL, 1997, OPHTHALMOLOGY, V104, P623, DOI 10.1016/S0161-6420(97)30261-9
   OLIVESTEDT G, 1996, INVEST OPHTH VIS SCI, pS224
   Olk RJ, 1999, OPHTHALMOLOGY, V106, P2082, DOI 10.1016/S0161-6420(99)90487-6
   Owens SL, 1999, AM J OPHTHALMOL, V127, P681, DOI 10.1016/S0002-9394(99)00043-4
   Sarks SH, 1996, AUST NZ J OPHTHALMOL, V24, P15, DOI 10.1111/j.1442-9071.1996.tb01546.x
   Sternberg P, 1998, OPHTHALMOLOGY, V105, P11
   Wetzig P C, 1994, Trans Am Ophthalmol Soc, V92, P299
NR 11
TC 17
Z9 19
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950-222X
J9 EYE
JI Eye
PD JUL
PY 2003
VL 17
IS 5
BP 623
EP 627
DI 10.1038/sj.eye.6700442
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 699QU
UT WOS:000184068100016
PM 12855972
OA Bronze
DA 2022-11-30
ER

PT J
AU Uramoto, K
   Azuma, T
   Watanabe, T
   Takahashi, H
   Igarashi-Yokoi, T
   Shimada, N
   Ohno-Matsui, K
AF Uramoto, Kengo
   Azuma, Takeshi
   Watanabe, Takashi
   Takahashi, Hiroyuki
   Igarashi-Yokoi, Tae
   Shimada, Noriaki
   Ohno-Matsui, Kyoko
TI EXTREME MACULAR SCHISIS-SIMULATING RETINAL DETACHMENT IN EYES WITH
   PATHOLOGIC MYOPIA
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE high myopia; MHRD; MTM; MRS
ID HOLE; RETINOSCHISIS; PROGRESSION
AB Purpose: To determine the clinical and imaging characteristics, natural course, and surgical outcomes of pathologic myopic eyes with an extreme macular schisis simulating a retinal detachment (EMSSRD). Methods: The data of 617 highly myopic eyes with myopic traction maculopathy were studied. The diagnosis of EMSSRD in the optical coherence tomography images was made based on a high elevation of the retina (>500 mu m), less obvious columnar structures, and the presence of thin remnants of outer retinal tissues above the retinal pigment epithelium. Results: Among 617 eyes, 25 eyes had an EMSSRD. All of the eyes with an EMSSRD had macular atrophy caused by myopic macular neovascularization. In the five eyes they had progressed to MHRD, the retinal detachment started away from the macular atrophy. Among the 10 eyes which required surgery, there was no significant difference in the presurgical and postsurgical best-corrected visual acuity between the eyes operated because of a worsening of the EMSSRD and the eyes operated because of a progression to MHRD. Conclusion: In severely myopic eyes with macular neovascularization-related macular atrophy, a novel condition termed EMSSRD can be present. The optical coherence tomography images resemble those of a MHRD except the presence of thin remnants of the retina remaining on the retinal pigment epithelium.
C1 [Uramoto, Kengo; Azuma, Takeshi; Watanabe, Takashi; Takahashi, Hiroyuki; Igarashi-Yokoi, Tae; Shimada, Noriaki; Ohno-Matsui, Kyoko] Tokyo Med & Dent Univ TMDU, Dept Ophthalmol & Visual Sci, Tokyo, Japan.
C3 Tokyo Medical & Dental University (TMDU)
RP Ohno-Matsui, K (通讯作者)，Tokyo Med & Dent Univ TMDU, Dept Ophthalmol & Visual Sci, Bunkyo Ku, 1-5-45 Yushima, Tokyo 1138519, Japan.
EM k.ohno.oph@tmd.ac.jp
CR Akiba J, 1999, AM J OPHTHALMOL, V128, P654, DOI 10.1016/S0002-9394(99)00240-8
   Baba T, 2003, AM J OPHTHALMOL, V135, P338, DOI 10.1016/S0002-9394(02)01937-2
   Bringmann A, 2022, PROG RETIN EYE RES, V86, P1, DOI 10.1016/j.preteyeres.2021.100977
   Curtin B J, 1977, Trans Am Ophthalmol Soc, V75, P67
   Curtin BJ., 1985, THE MYOPIAS, P277
   Fang YX, 2020, RETINA-J RET VIT DIS, V40, P1881, DOI 10.1097/IAE.0000000000002709
   Fang YX, 2018, OPHTHALMOLOGY, V125, P863, DOI 10.1016/j.ophtha.2017.12.005
   Fujimoto M, 2010, AM J OPHTHALMOL, V150, P863, DOI 10.1016/j.ajo.2010.06.023
   Hattori K, 2018, RETINA-J RET VIT DIS, V38, pS23, DOI 10.1097/IAE.0000000000001927
   Ohno-Matsui K, 2014, OPHTHALMOLOGY, V121, P1798, DOI 10.1016/j.ophtha.2014.03.035
   Oie Y, 2005, JPN J OPHTHALMOL, V49, P530, DOI 10.1007/s10384-005-0249-1
   Panozzo G, 2004, ARCH OPHTHALMOL-CHIC, V122, P1455, DOI 10.1001/archopht.122.10.1455
   Shimada N, 2008, BRIT J OPHTHALMOL, V92, P762, DOI 10.1136/bjo.2007.131359
   Shimada N, 2013, AM J OPHTHALMOL, V156, P948, DOI 10.1016/j.ajo.2013.06.031
   SIAM AL, 1969, BRIT J OPHTHALMOL, V53, P62, DOI 10.1136/bjo.53.1.62
   STIRPE M, 1990, RETINA-J RET VIT DIS, V10, P113, DOI 10.1097/00006982-199004000-00004
   Takano M, 1999, AM J OPHTHALMOL, V128, P472, DOI 10.1016/S0002-9394(99)00186-5
   Tokoro T., 1979, STANDARDIZATION DIAG
NR 18
TC 0
Z9 0
U1 2
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD OCT
PY 2022
VL 42
IS 10
BP 1836
EP 1843
DI 10.1097/IAE.0000000000003544
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 4Q1OP
UT WOS:000855855500009
PM 35976254
DA 2022-11-30
ER

PT J
AU Iyer, PG
   Zhou, H
   Zhang, QQ
   Chu, ZD
   Shen, MX
   Shi, YY
   Liu, J
   Trivizki, O
   Lam, BL
   Wang, RK
   Gregori, G
   Rosenfeld, PJ
AF Iyer, Prashanth G.
   Zhou, Hao
   Zhang, Qinqin
   Chu, Zhongdi
   Shen, Mengxi
   Shi, Yingying
   Liu, Jeremy
   Trivizki, Omer
   Lam, Byron L.
   Wang, Ruikang K.
   Gregori, Giovanni
   Rosenfeld, Philip J.
TI SWEPT-SOURCE OPTICAL COHERENCE TOMOGRAPHY DETECTION OF BRUCH MEMBRANE
   AND CHORIOCAPILLARIS ABNORMALITIES IN SORSBY MACULAR DYSTROPHY
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE Bruch membrane; choriocapillaris; Sorsby macular dystrophy;
   swept-source; optical coherence tomography angiography
ID FUNDUS DYSTROPHY; RETICULAR PSEUDODRUSEN; TISSUE INHIBITOR; TIMP-3;
   METALLOPROTEINASES; DEGENERATION; ANGIOGRAPHY; MUTATIONS; EYES
AB Purpose: Swept-source optical coherence tomography angiography (SS-OCTA) was used to analyze Bruch membrane (BM) and choriocapillaris (CC) abnormalities in undiagnosed family members with Sorsby macular dystrophy (SMD). Methods: In a family with SMD (TIMP3 Tyr191Cys), SS-OCTA imaging was performed using the 6 x 6 mm scan patter and previously validated algorithms to detect abnormalities in BM and the CC, as well as the presence of reticular pseudodrusen and macular neovascularization. Genetic analyses were performed for TIMP3 mutations. Results: Of eight family members, two were previously diagnosed with SMD and six were asymptomatic. SS-OCTA imaging of the 33-year-old proband revealed type 1 macular neovascularization in the left eye and bilateral reticular pseudodrusen, thickening of BM, CC thinning, and increases in CC flow deficits. A TIMP3 mutation was confirmed. His niece, despite having no clinical evidence of SMD, showed BM thickening and CC thinning on SS-OCTA. A TIMP3 mutation was confirmed. The proband's younger nephew and niece also carried the TIMP3 mutation without clinical evidence of SMD. Two additional members had normal examinations, unremarkable SS-OCTA findings, and no TIMP3 mutation. Conclusion: Swept-source optical coherence tomography angiography imaging can detect BM and CC abnormalities in vivo in subjects unaware of their TIMP3 status in a family with SMD.
C1 [Iyer, Prashanth G.; Shen, Mengxi; Shi, Yingying; Liu, Jeremy; Trivizki, Omer; Lam, Byron L.; Gregori, Giovanni; Rosenfeld, Philip J.] Univ Miami, Miller Sch Med, Dept Ophthalmol, Bascom Palmer Eye Inst, 900 NW 17th St, Miami, FL 33136 USA.
   [Zhou, Hao; Zhang, Qinqin; Chu, Zhongdi; Wang, Ruikang K.] Univ Washington, Dept Bioengn, Seattle, WA 98195 USA.
   [Wang, Ruikang K.] Univ Washington, Dept Ophthalmol, Seattle, WA 98195 USA.
C3 Bascom Palmer Eye Institute; University of Miami; University of
   Washington; University of Washington Seattle; University of Washington;
   University of Washington Seattle
RP Rosenfeld, PJ (通讯作者)，Univ Miami, Miller Sch Med, Dept Ophthalmol, Bascom Palmer Eye Inst, 900 NW 17th St, Miami, FL 33136 USA.
EM prosenfeld@med.miami.edu
OI Liu, Jeremy/0000-0003-2395-3536
CR An L, 2010, J BIOMED OPT, V15, DOI 10.1117/1.3369811
   ASHTON N, 1951, BRIT J OPHTHALMOL, V35, P751, DOI 10.1136/bjo.35.12.751
   CAPON MRC, 1989, OPHTHALMOLOGY, V96, P1769
   Carr R E, 1977, Trans Am Ophthalmol Soc, V75, P255
   Chatziralli I, 2018, INT OPHTHALMOL, V38, P1887, DOI 10.1007/s10792-017-0671-7
   Choi W, 2015, OPHTHALMOLOGY, V122, P2532, DOI 10.1016/j.ophtha.2015.08.029
   Chong NHV, 2000, INVEST OPHTH VIS SCI, V41, P898
   Chong NHV, 2003, AM J OPHTHALMOL, V136, P954, DOI 10.1016/S0002-9394(03)00482-3
   Chu ZD, 2021, AM J OPHTHALMOL, V222, P92, DOI 10.1016/j.ajo.2020.08.045
   Chu ZD, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-34826-5
   Crabb JW, 2002, P NATL ACAD SCI USA, V99, P14682, DOI 10.1073/pnas.222551899
   ERIKSSON AW, 1990, CLIN GENET, V38, P21
   Finger RP, 2016, OPHTHALMOLOGY, V123, P599, DOI 10.1016/j.ophtha.2015.10.029
   Gliem M, 2015, OPHTHALMOLOGY, V122, P1555, DOI 10.1016/j.ophtha.2015.04.035
   Gliem M, 2015, INVEST OPHTH VIS SCI, V56, P2664, DOI 10.1167/iovs.14-15733
   Handsley MM, 2005, INT J CANCER, V115, P849, DOI 10.1002/ijc.20945
   Hess K, 2022, OPHTHALMOLOGICA, V245, P265, DOI 10.1159/000520931
   HOSKIN A, 1981, BRIT J OPHTHALMOL, V65, P859, DOI 10.1136/bjo.65.12.859
   Kamei M, 1999, INVEST OPHTH VIS SCI, V40, P2367
   Kaye R, 2017, INVEST OPHTH VIS SCI, V58
   Langton KP, 2005, HUM MOL GENET, V14, P3579, DOI 10.1093/hmg/ddi385
   Lee MH, 2010, CANCER LETT, V290, P114, DOI 10.1016/j.canlet.2009.08.029
   Nesper PL, 2017, AM J OPHTHALMOL, V174, P42, DOI 10.1016/j.ajo.2016.10.005
   Ploner SB, 2016, RETINA-J RET VIT DIS, V36, pS118, DOI 10.1097/IAE.0000000000001328
   Rosenfeld PJ, 2022, AM J OPHTHALMOL, V235, P291, DOI 10.1016/j.ajo.2021.08.015
   Schaal KB, 2015, OSLI RETINA, V46, P550, DOI 10.3928/23258160-20150521-06
   SORSBY A, 1949, BRIT J OPHTHALMOL, V33, P67, DOI 10.1136/bjo.33.2.67
   Wang RK, 2010, OPT LETT, V35, P1467, DOI 10.1364/OL.35.001467
   Williams BL, 2021, P NATL ACAD SCI USA, V118, DOI 10.1073/pnas.2103617118
   WILLIAMSON RA, 1990, BIOCHEM J, V268, P267, DOI 10.1042/bj2680267
   Yin X, 2014, J BIOMED OPT, V19, DOI 10.1117/1.JBO.19.8.086020
   Zhang DQ, 2004, ARTIF INTELL MED, V32, P37, DOI [10.1016/j.artmed.2004.01.012, 10.1016/j.artmed. 2004.01.012]
   Zhang QQ, 2018, INVEST OPHTH VIS SCI, V59, P203, DOI 10.1167/iovs.17-22953
   Zhou H, 2020, BIOMED OPT EXPRESS, V11, P1834, DOI 10.1364/BOE.385113
   Zhou Q, 2016, OPHTHALMOLOGY, V123, P1530, DOI 10.1016/j.ophtha.2016.02.043
NR 35
TC 0
Z9 0
U1 1
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD SEP
PY 2022
VL 42
IS 9
BP 1645
EP 1654
DI 10.1097/IAE.0000000000003515
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 3W9IM
UT WOS:000842662100005
PM 35483032
DA 2022-11-30
ER

PT J
AU Arieta, CEL
   Delgado, AMN
   Jose, NK
   Temporini, ER
   Alves, MR
   Moreira, DD
AF Arieta, CEL
   Delgado, AMN
   Jose, NK
   Temporini, ER
   Alves, MR
   Moreira, DD
TI Refractive errors and cataract as causes of visual impairment in Brazil
SO OPHTHALMIC EPIDEMIOLOGY
LA English
DT Article
DE refractive errors; visual impairment; cataract; blindness;
   cost-effectiveness; Brazil
ID BLINDNESS; PREVALENCE; AFRICA
AB PURPOSE To identify the main causes of visual impairment (VA less than or equal to 0.2) within the population over 50 years of age examined in "Cataract Free Zone" projects sponsored by the University of Campinas from 1986 to 1995.
   METHODS A retrospective review of the ophthalmic forms used for 60,404 patients examined in 74 Cataract Projects was performed. Through mass media information, adults of the target region or city were asked to self-test their vision. Patients with VA! 0.2 in the better eye were to come to a visual acuity test. Using Snellen charts, visual acuity testing was done by trained auxiliaries and medical students. The positive cases were then examined by ophthalmologists Criteria were established for the classification of the diagnoses and statistical analysis was performed.
   RESULTS After the self-test of visual acuity, 60,404 patients came to have their visual acuity tested; 11,462 (18.97%) cases were considered positive and were submitted to complete eye examination; 5447 (42.7%) received spectacles for vision improvement, and 2704 (23.59%) had cataract surgery done. Other important causes of visual impairment were senile macular degeneration (5.4%) and glaucoma (4.02%).
   CONCLUSION The main causes of visual impairment were noncorrected refractive errors and senile cataract. Ophthalmic community-based campaigns to serve the older population are recommended in order to detect and treat the identified cases and to indicate possible changes in the health care system.
C1 Univ Estadual Campinas, UNICAMP, Dept Ophthalmol, Sao Paulo, Brazil.
C3 Universidade Estadual de Campinas
RP Arieta, CEL (通讯作者)，Rua Joaquim Floriano 72 Conj 78, BR-04534000 Sao Paulo, Brazil.
RI Alves, Milton R/T-7621-2018
OI arieta, carlos eduardo leite/0000-0003-3175-3147
CR Angra SK, 1997, INDIAN J MED RES, V106, P312
   ARIETA CEL, 1999, OPHTHAL EPIDEMIOL, V6, P113
   Attebo K, 1996, OPHTHALMOLOGY, V103, P357
   AZAR DT, 1994, PRINCIPLES PRACTICE, V5, pCH291
   COOK CD, 1995, S AFR MED J, V85, P26
   Eloff J, 2000, Ophthalmic Epidemiol, V7, P219, DOI 10.1076/0928-6586(200009)7:3;1-V;FT219
   JOSE NK, 1990, INT OPHTHALMOL, V14, P155, DOI 10.1007/BF00158313
   JOSE NK, 1997, REV MED SAO PAULO, V76, P293
   KUPFER C, 1983, AM J OPHTHALMOL, V96, P543, DOI 10.1016/S0002-9394(14)77920-6
   Negrel A D, 1996, Ophthalmic Epidemiol, V3, P127, DOI 10.3109/09286589609080118
   SENNE FMB, 1994, ARQ BRAS OFTALMOL, V57, P225
   STEINKULLER PG, 1983, SOC SCI MED, V17, P1693, DOI 10.1016/0277-9536(83)90379-9
   THYLEFORS B, 1995, B WORLD HEALTH ORGAN, V73, P115
   TIELSCH JM, 1995, NEW ENGL J MED, V332, P1205, DOI 10.1056/NEJM199505043321806
   WEI ZX, 1989, CHUNG HUA KO TSA CHI, V25, P365
NR 15
TC 26
Z9 30
U1 0
U2 6
PU INFORMA HEALTHCARE
PI LONDON
PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND
SN 0928-6586
EI 1744-5086
J9 OPHTHAL EPIDEMIOL
JI Ophthalmic Epidemiol.
PD FEB
PY 2003
VL 10
IS 1
BP 15
EP 22
DI 10.1076/opep.10.1.15.13774
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 655BQ
UT WOS:000181531800003
PM 12607155
DA 2022-11-30
ER

PT S
AU Chader, GJ
   Weiland, J
   Humayun, MS
AF Chader, Gerald J.
   Weiland, James
   Humayun, Mark S.
BE Verhaagen, J
   Hol, EM
   Huitenga, I
   Wijnholds, J
   Bergen, AB
   Boer, GJ
   Swaab, DF
TI Artificial vision: needs, functioning, and testing of a retinal
   electronic prosthesis
SO NEUROTHERAPY: PROGRESS IN RESTORATIVE NEUROSCIENCE AND NEUROLOGY
SE Progress in Brain Research
LA English
DT Review
CT 25th International Summer School of Brain Research
CY AUG 25-28, 2008
CL Royal Netherlands Acad Arts & Sci (KNAW), Amsterdam, NETHERLANDS
SP Netherlands Inst Neurosci (NIN), Abcam, Alzheimer Nederland, Amsterdam Mol Therapeut (AMT), Appl Biosyst, Bio-Connect BV, Boehringer Ingelheim, Bristol-Myers Squibb BV, Corning, Curatis Pharma GmbH, Eurogentec BV, Elsevier Sci Publishers, Genzyme Europe BV, GlaxoSmithKline, Grad Sch Neurosci Amsterdam (ONWA), Hersenstichting Nederland, Invitrogen, Leica Microsyst BV, Landelijke Stichting Blinden Slechtzienden (LSBS), Merck Res Labs, ZonMw, Solvay Pharmaceut BV, Stichting Blindenhulp, Stichting Blinden-penning, Stichting Glaucoomfonds, Stichting MD Fonds, Stichting MS Res, Stichting Van den Houtenfonds, Tebu-Bio, Uitgeverij Nieuwezijds, Zeiss
HO Royal Netherlands Acad Arts & Sci (KNAW)
DE neural retina; brain; retinal degeneration; electronic prosthetic
   devices; artificial vision; retinitis pigmentosa; age-related macular
   degeneration; visual performance; low vision; photoreceptor replacement
ID ELECTRICAL-STIMULATION; PERCEPTUAL THRESHOLDS; MORPHOMETRIC-ANALYSIS;
   VISUAL-PERCEPTION; CANINE MODEL; PHOTORECEPTORS; IMPLANTATION; BLIND;
   CELLS; ROD
AB Hundreds of thousands around the world have poor vision or no vision at all due to inherited retinal degenerations (RDs) like retinitis pigmentosa (RP). Similarly, millions suffer from vision loss due to age-related macular degeneration (AMD). In both of these allied diseases, the primary target for pathology is the retinal photoreceptor cells that dysfunction and die. Secondary neurons though are relatively spared. To replace photoreceptor cell function, an electronic prosthetic device can be used such that retinal secondary neurons receive a signal that simulates an external visual image. The composite device has a miniature video camera mounted on the patient's eyeglasses, which captures images and passes them to a microprocessor that converts the data to an electronic signal. This signal, in turn, is transmitted to an array of electrodes placed on the retinal surface, which transmits the patterned signal to the remaining viable secondary neurons. These neurons (ganglion, bipolar cells, etc.) begin processing the signal and pass it down the optic nerve to the brain for final integration into a visual image. Many groups in different countries have different versions of the device, including brain implants and retinal implants, the latter having epiretinal or subretinal placement. The device furthest along in development is an epiretinal implant sponsored by Second Sight Medical Products (SSMP). Their first-generation device had 16 electrodes with human testing in a Phase 1 clinical trial beginning in 2002. The second-generation device has 60+ electrodes and is currently in Phase 2/3 clinical trial. Increased numbers of electrodes are planned for future versions of the device. Testing of the device's efficacy is a challenge since patients admitted into the trial have little or no vision. Thus, methods must be developed that accurately and reproducibly record small improvements in visual function after implantation. Standard tests such as visual acuity, visual field, electroretinography, or even contrast sensitivity may not adequately capture some aspects of improvement that relate to a better quality of life (QOL). Because of this, some tests are now relying more on "real-world functional capacity" that better assesses possible improvement in aspects of everyday living. Thus, a new battery of tests have been suggested that include (1) standard psychophysical testing, (2) performance in tasks that are used in real-life situations such as object discrimination, mobility, etc., and (3) well-crafted questionnaires that assess the patient's own feelings as to the usefulness of the device. In the Phase 1 trial of the SSMP 16-electrode device, six subjects with severe RP were implanted with ongoing, continuing testing since then. First, it was evident that even limited sight restoration is a slow, learning process that takes months for improvement to become evident. However, light perception was restored in all six patients. Moreover, all subjects ultimately saw discrete phosphenes and could perform simple visual spatial and motion tasks. As mentioned above, a Phase 2/3 trial is now ongoing with a 60+ device. A 250+ device is on the drawing board, and one with over 1000 electrodes is being planned. Each has the possibility of significantly improving a patient's vision and QOL, being smaller and safer in design and lasting for the lifetime of the patient. From theoretical modeling, it is estimated that a device with approximately 1000 electrodes could give good functional vision, i.e., face recognition and reading ability.
   This could be a reality within 5-10 years from now. In summary, no treatments are currently available for severely affected patients with RP and dry AMD. An electrical prosthetic device appears to offer hope in replacing the function of degenerating or dead photoreceptor neurons. Devices with new, sophisticated designs and increasing numbers of electrodes could allow for long-term restoration of functional sight in patients with improvement in object recognition, mobility, independent living, and general QOL.
C1 [Chader, Gerald J.; Weiland, James; Humayun, Mark S.] USC Sch Med, Doheny Retina Inst, Los Angeles, CA 90089 USA.
C3 University of Southern California
RP Chader, GJ (通讯作者)，USC Sch Med, Doheny Retina Inst, Los Angeles, CA 90089 USA.
EM gchader@doheny.org
RI Verhaagen, Joost/G-4773-2012
OI Weiland, James/0000-0003-3453-9074
CR Acland GM, 2005, MOL THER, V12, P1072, DOI 10.1016/j.ymthe.2005.08.008
   Acland GM, 2001, NAT GENET, V28, P92, DOI 10.1038/ng0501-92
   Aguirre GK, 2007, PLOS MED, V4, P1117, DOI 10.1371/journal.pmed.0040230
   BERSON EL, 1993, ARCH OPHTHALMOL-CHIC, V111, P761, DOI 10.1001/archopht.1993.01090060049022
   BRINDLEY GS, 1968, J PHYSIOL-LONDON, V196, P479, DOI 10.1113/jphysiol.1968.sp008519
   Caffe AR, 2001, INVEST OPHTH VIS SCI, V42, P275
   Chow A., 2004, ARCH OPHTHALMOL-CHIC, V122, P1156
   Cideciyan AV, 2007, HUM MUTAT, V28, P1074, DOI 10.1002/humu.20565
   Dagnelie G., 2008, ANNU REV BIOMED ENG, V10, P151
   de Balthasar C, 2008, INVEST OPHTH VIS SCI, V49, P2303, DOI 10.1167/iovs.07-0696
   Dobelle WH, 2000, ASAIO J, V46, P3, DOI 10.1097/00002480-200001000-00002
   Eckhorn R, 2006, VISION RES, V46, P2675, DOI 10.1016/j.visres.2006.01.034
   Fariss RN, 2000, AM J OPHTHALMOL, V129, P215, DOI 10.1016/S0002-9394(99)00401-8
   Feucht M, 2005, OPHTHALMOLOGE, V102, P688, DOI 10.1007/s00347-005-1186-6
   Fine I., 2007, ARTIFICIAL SIGHT BAS, P47
   Gekeler F, 2007, GRAEF ARCH CLIN EXP, V245, P230, DOI 10.1007/s00417-006-0339-x
   Gerding H, 2007, J NEURAL ENG, V4, pS38, DOI 10.1088/1741-2560/4/1/S06
   Haim Marianne, 2002, Acta Ophthalmol Scand Suppl, P1
   Hauswirth William W, 2004, Novartis Found Symp, V255, P179
   Humayun M., 2007, ARTIFICIAL VISION BA
   Humayun M S, 2001, Trans Am Ophthalmol Soc, V99, P271
   Humayun MS, 1999, VISION RES, V39, P2569, DOI 10.1016/S0042-6989(99)00052-8
   Humayun MS, 1996, ARCH OPHTHALMOL-CHIC, V114, P40, DOI 10.1001/archopht.1996.01100130038006
   Humayun MS, 1999, INVEST OPHTH VIS SCI, V40, P143
   Humayun MS, 2003, VISION RES, V43, P2573, DOI 10.1016/S0042-6989(03)00457-7
   Jones Stanton, 2008, Mo Med, V105, P235
   Kassoff A, 2001, ARCH OPHTHALMOL-CHIC, V119, P1417, DOI 10.1001/archopht.119.10.1417
   Kent TL, 2008, INVEST OPHTH VIS SCI, V49, P372, DOI 10.1167/iovs.07-0952
   Kim S., 2002, RETINA, V47, P1
   Kim S., 2002, RETINA, V46, P4
   Komeima K, 2007, J CELL PHYSIOL, V213, P809, DOI 10.1002/jcp.21152
   LAVAIL MM, 1992, P NATL ACAD SCI USA, V89, P11249, DOI 10.1073/pnas.89.23.11249
   MacLaren R., 2006, NATURE, V444, P156
   Mahadevappa M, 2005, IEEE T NEUR SYS REH, V13, P201, DOI 10.1109/TNSRE.2005.848687
   Marc RE, 2003, PROG RETIN EYE RES, V22, P607, DOI 10.1016/S1350-9462(03)00039-9
   Matsuo T, 2007, BRIT J OPHTHALMOL, V91, P888, DOI 10.1136/bjo.2007.114538
   Normann RA, 1999, VISION RES, V39, P2577, DOI 10.1016/S0042-6989(99)00040-1
   Palanker D, 2005, J NEURAL ENG, V2, pS105, DOI 10.1088/1741-2560/2/1/012
   Pardue MT, 2005, J NEURAL ENG, V2, pS39, DOI 10.1088/1741-2560/2/1/006
   Peachey NS, 1999, J REHABIL RES DEV, V36, P371
   Peterman MC, 2004, P NATL ACAD SCI USA, V101, P9951, DOI 10.1073/pnas.0402089101
   Rizzo JF, 2003, INVEST OPHTH VIS SCI, V44, P5362, DOI 10.1167/iovs.02-0817
   Sagdullaev BT, 2003, INVEST OPHTH VIS SCI, V44, P1686, DOI 10.1167/iovs.02-0615
   Santos A, 1997, ARCH OPHTHALMOL-CHIC, V115, P511, DOI 10.1001/archopht.1997.01100150513011
   Sanz MM, 2007, NEUROSCIENCE, V145, P1120, DOI 10.1016/j.neuroscience.2006.12.034
   Schiefer MA, 2006, IEEE T NEUR SYS REH, V14, P5, DOI 10.1109/TNSRE.2006.870488
   Schoth F, 2006, NEUROSCI LETT, V398, P178, DOI 10.1016/j.neulet.2005.12.088
   Smirnakis SM, 2005, NATURE, V435, P300, DOI 10.1038/nature03495
   STONE JL, 1992, ARCH OPHTHALMOL-CHIC, V110, P1634, DOI 10.1001/archopht.1992.01080230134038
   Thomas BB, 2004, J NEUROSCI METH, V138, P7, DOI 10.1016/j.jneumeth.2004.03.007
   Thomas BB, 2004, EXP EYE RES, V79, P29, DOI 10.1016/j.exer.2004.02.016
   Tokuda T, 2007, P ANN INT IEEE EMBS, P5791
   Tropepe V, 2000, SCIENCE, V287, P2032, DOI 10.1126/science.287.5460.2032
   Troyk PR, 2005, P ANN INT IEEE EMBS, P7376, DOI 10.1109/IEMBS.2005.1616216
   Walter M., 2007, ARTIFICIAL VISION BA, P71
   Walter P, 2005, INVEST OPHTH VIS SCI, V46, P1780, DOI 10.1167/iovs.04-0924
   Wang K, 2006, NANO LETT, V6, P2043, DOI 10.1021/nl061241t
   Wang L., 2008, INVEST OPHTHALMOL, V28, P33
   Weiland JD, 2005, ANNU REV BIOMED ENG, V7, P361, DOI 10.1146/annurev.bioeng.7.060804.100435
   Weiland JD, 1999, GRAEF ARCH CLIN EXP, V237, P1007, DOI 10.1007/s004170050337
   Wilke R., 2007, ARTIFICIAL SIGHT BIO, P91, DOI [10.1007/978- 0- 387-49331-2_5, DOI 10.1007/978-0-387-49331-2_5]
   Winter JO, 2007, J BIOMAT SCI-POLYM E, V18, P1031, DOI 10.1163/156856207781494403
   Yanai D, 2007, AM J OPHTHALMOL, V143, P820, DOI 10.1016/j.ajo.2007.01.027
   Ziv OR, 2005, J NEURAL ENG, V2, pS5, DOI 10.1088/1741-2560/2/1/002
   Zrenner E, 2002, SCIENCE, V295, P1022, DOI 10.1126/science.1067996
NR 65
TC 171
Z9 182
U1 3
U2 96
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA SARA BURGERHARTSTRAAT 25, PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0079-6123
BN 978-0-12-374511-8
J9 PROG BRAIN RES
JI Prog. Brain Res.
PY 2009
VL 175
BP 317
EP 332
DI 10.1016/S0079-6123(09)17522-2
PG 16
WC Clinical Neurology; Neurosciences
WE Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology
GA BDJ56
UT WOS:000313549600022
PM 19660665
DA 2022-11-30
ER

PT J
AU Dutheil, C
   Le Goff, M
   Cougnard-Gregoire, A
   Gattoussi, S
   Korobelnik, JF
   Rougier, MB
   Schweitzer, C
   Delcourt, C
   Delyfer, MN
AF Dutheil, Cyril
   Le Goff, Melanie
   Cougnard-Gregoire, Audrey
   Gattoussi, Sarra
   Korobelnik, Jean-Francois
   Rougier, Marie-Benedicte
   Schweitzer, Cedric
   Delcourt, Cecile
   Delyfer, Marie-Noelle
TI Incidence and Risk Factors of Reticular Pseudodrusen Using Multimodal
   Imaging
SO JAMA OPHTHALMOLOGY
LA English
DT Article
ID SUBRETINAL DRUSENOID DEPOSITS; MACULAR DEGENERATION FINDINGS; CHOROIDAL
   THICKNESS; AGE; ASSOCIATION; PREVALENCE; STATINS; REGRESSION; FEATURES;
   EPIDEMIOLOGY
AB Importance Although retinal multimodal imaging is needed for diagnosing reticular pseudodrusen (RPD), the incidence of RPD in the general population typically has been assessed only using fundus photographs, which may underestimate their incidence. Objectives To describe the incidence of RPD using retinal color photographs, spectral-domain optical coherence tomography scans, fundus autofluorescence, and near-infrared reflectance images among individuals 77 years of age or older and to analyze the associated risk factors of RPD. Design, Setting, and Participants The ALIENOR (Antioxydants, Lipides Essentiels, Nutrition et Maladies Oculaires) Study is a cohort of French individuals 77 years of age or older. Data for this study were collected between February 22, 2011, and February 15, 2017, with a mean (SD) follow-up of 3.7 (1.0) years (range, 1.2-5.6 years). At baseline, 501 individuals were eligible to participate. Of 1002 eyes, 197 had prevalent RPD, advanced age-related macular degeneration, or ungradable images. Of the remaining 805 eyes, 333 were missing follow-up data; therefore, the statistical analyses included data from 472 eyes. Data management and statistical analyses were performed between March 15, 2017, and April 5, 2019. Main Outcomes and Measures Reticular pseudodrusen were considered as present if detected by at least 2 of the following imaging methods: color fundus photographs, fundus autofluorescence, near-infrared reflectance, and spectral-domain optical coherence tomography images. Results Of the 472 eyes analyzed, 263 (55.7%) were from female participants, and the mean (SD) age was 81.9 (3.2) years. Forty-three eyes developed RPD, corresponding to an annual incidence rate of 2.9% (95% CI, 1.9%-4.4%) per participant and an estimated 5-year risk of 13.5%. In multivariable analysis, 4 risk factors of incident RPD were identified: subfoveal choroidal thinning (hazard ratio [HR], 0.99; 95% CI, 0.99-1.00 per 10-mu m decrease in thickness; P = .02) and the presence of the minor allelic variants rs10490924 for ARMS2 (HR, 3.57; 95% CI, 1.80-7.10; P < .001), rs1061170 for CFH (HR, 2.12; 95% CI, 1.02-4.41; P = .04), and rs10468017 for LIPC (HR, 2.57; 95% CI, 1.37-4.82; P = .003). Lipophilic statin therapy was associated with a lower incidence of RPD (HR, 0.13; 95% CI, 0.02-0.74; P = .02). Conclusions and Relevance With the use of multimodal imaging, the RPD incidence rate was higher than previously reported in other population-based studies using fundus color images. Individuals with subfoveal choroidal thinning or carrying minor allelic variants for ARMS2, CFH, or LIPC had an increased risk for RPD, whereas lipophilic statin therapy was associated with a lower incidence.
   Question What are the incidence and risk factors of reticular pseudodrusen using multimodal imaging in an elderly French population? Findings This cohort study found an annual incidence of reticular pseudodrusen per participant of 2.9% and an estimated 5-year incidence of 13.5%. Age, choroidal thinning, and genetic background were found to be associated with incident reticular pseudodrusen, whereas lipophilic statin therapy was associated with a lower risk. Meaning This study, based on reticular pseudodrusen diagnosed via multimodal imaging, reports a higher incidence of reticular pseudodrusen than in previous studies based on fundus color images, confirms most known risk factors, and suggests a role for lipid metabolism in the pathophysiologic characteristics of reticular pseudodrusen.
   This cohort study describes the incidence of reticular pseudodrusen using retinal color photographs, spectral-domain optical coherence tomography scans, fundus autofluorescence, and near-infrared reflectance images among individuals 77 years of age or older and analyzes the associated risk factors.
C1 [Dutheil, Cyril; Le Goff, Melanie; Cougnard-Gregoire, Audrey; Gattoussi, Sarra; Korobelnik, Jean-Francois; Rougier, Marie-Benedicte; Schweitzer, Cedric; Delcourt, Cecile; Delyfer, Marie-Noelle] Univ Bordeaux, Bordeaux Populat Hlth Res Ctr, Lifelong Exposure Hlth & Aging Team, INSERM, Bordeaux, France.
   [Dutheil, Cyril; Gattoussi, Sarra; Korobelnik, Jean-Francois; Rougier, Marie-Benedicte; Schweitzer, Cedric; Delyfer, Marie-Noelle] Ctr Hosp Univ Bordeaux, Serv Ophtalmol, Pl Amelie Raba Leon, F-33000 Bordeaux, France.
C3 Institut National de la Sante et de la Recherche Medicale (Inserm);
   UDICE-French Research Universities; Universite de Bordeaux; CHU Bordeaux
RP Delyfer, MN (通讯作者)，Ctr Hosp Univ Bordeaux, Serv Ophtalmol, Pl Amelie Raba Leon, F-33000 Bordeaux, France.
EM marie-noelle.delyfer@chu-bordeaux.fr
RI Delcourt, Cecile/I-2627-2013
OI Delcourt, Cecile/0000-0002-2099-0481; Gattoussi,
   Sarra/0000-0002-8905-7112; Schweitzer, Cedric/0000-0002-2162-9479; LE
   GOFF, Melanie/0000-0003-2848-6287
FU Laboratoires Thea (Clermont-Ferrand, France); Universite de Bordeaux
   (Bordeaux, France); Fondation Voir et Entendre (Paris, France); Agence
   Nationale de la Recherche [2010-PRSP-011]; CNSA (Caisse Nationale pour
   la Solidarite et l'Autonomie) (Paris, France); Programme Hospitalier de
   Recherche Clinique (ECLAIR project-2012); CFSR Recherche (Club
   Francophone des Specialistes de la Retine)
FX This study was supported by Laboratoires Thea (Clermont-Ferrand,
   France), Universite de Bordeaux (Bordeaux, France), Fondation Voir et
   Entendre (Paris, France), Agence Nationale de la Recherche
   (2010-PRSP-011), CNSA (Caisse Nationale pour la Solidarite et
   l'Autonomie) (Paris, France), Programme Hospitalier de Recherche
   Clinique (ECLAIR project-2012), and CFSR Recherche (Club Francophone des
   Specialistes de la Retine).
CR Alperovitch A, 2003, NEUROEPIDEMIOLOGY, V22, P316, DOI 10.1159/000072920
   Alten F, 2013, INVEST OPHTH VIS SCI, V54, P3250, DOI 10.1167/iovs.13-11923
   ARNOLD JJ, 1995, RETINA-J RET VIT DIS, V15, P183, DOI 10.1097/00006982-199515030-00001
   Barbosa DTQ, 2014, EYE, V28, P472, DOI 10.1038/eye.2014.8
   Barteselli G, 2012, OPHTHALMOLOGY, V119, P2572, DOI 10.1016/j.ophtha.2012.06.065
   Boddu S, 2014, AM J OPHTHALMOL, V157, P985, DOI 10.1016/j.ajo.2014.01.023
   Buitendijk GHS, 2016, INVEST OPHTH VIS SCI, V57, P5593, DOI 10.1167/iovs.15-18816
   Chan H, 2016, INVEST OPHTH VIS SCI, V57, P3058, DOI 10.1167/iovs.16-19487
   De Bats F, 2016, RETINA-J RET VIT DIS, V36, P46, DOI 10.1097/IAE.0000000000000648
   Delcourt C, 2010, J NUTR HEALTH AGING, V14, P854, DOI 10.1007/s12603-010-0131-9
   Etminan M, 2008, CURR DRUG SAF, V3, P24, DOI 10.2174/157488608783333952
   Finger RP, 2016, OPHTHALMOLOGY, V123, P599, DOI 10.1016/j.ophtha.2015.10.029
   Fritsche LG, 2008, NAT GENET, V40, P892, DOI 10.1038/ng.170
   Gabrielle PH, 2019, INVEST OPHTH VIS SCI, V60, P4838, DOI 10.1167/iovs.19-27283
   Garg A, 2013, INVEST OPHTH VIS SCI, V54, P7075, DOI 10.1167/iovs.13-12474
   Gattoussi S, 2019, RETINA-J RET VIT DIS, V39, P34, DOI 10.1097/IAE.0000000000002237
   Cheung CM, 2018, OPHTHALMOL RETINA, V2, P1196, DOI 10.1016/j.oret.2018.06.014
   Gil JQ, 2017, EYE, V31, P364, DOI 10.1038/eye.2016.207
   Glynn RJ, 2012, OPHTHAL EPIDEMIOL, V19, P159, DOI 10.3109/09286586.2012.674614
   Guymer RH, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0083759
   Hirata M, 2011, INVEST OPHTH VIS SCI, V52, P4971, DOI 10.1167/iovs.11-7729
   Joachim N, 2014, OPHTHALMOLOGY, V121, P917, DOI 10.1016/j.ophtha.2013.10.043
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   Klein R, 2008, AM J OPHTHALMOL, V145, P317, DOI 10.1016/j.ajo.2007.09.008
   Lim LS, 2012, LANCET, V379, P1728, DOI 10.1016/S0140-6736(12)60282-7
   Lin LY, 2018, JAMA OPHTHALMOL, V136, P682, DOI 10.1001/jamaophthalmol.2018.1231
   Lou LX, 2014, JAMA OPHTHALMOL, V132, P1226, DOI 10.1001/jamaophthalmol.2014.1752
   Ma L, 2015, SCI REP-UK, V5, DOI 10.1038/srep18280
   Merle BMJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0079848
   MIMOUN G, 1990, J FR OPHTALMOL, V13, P511
   Mitchell P, 2002, OPHTHALMOLOGY, V109, P1092, DOI 10.1016/S0161-6420(02)01055-2
   Mrejen S, 2014, RETINA-J RET VIT DIS, V34, P1560, DOI 10.1097/IAE.0000000000000139
   Neale BM, 2010, P NATL ACAD SCI USA, V107, P7395, DOI 10.1073/pnas.0912019107
   Peiretti E, 2014, EXP EYE RES, V124, P11, DOI 10.1016/j.exer.2014.04.017
   Puche N, 2013, RETINA-J RET VIT DIS, V33, P998, DOI 10.1097/IAE.0b013e31827b6483
   Rabiolo A, 2017, CLIN OPHTHALMOL, V11, P1707, DOI 10.2147/OPTH.S130165
   Rothman KJ, 1998, MODERN EPIDEMIOLOGY, P37
   Saunier V, 2018, JAMA OPHTHALMOL, V136, P473, DOI 10.1001/jamaophthalmol.2018.0504
   Seddon JM, 2006, OPHTHALMOLOGY, V113, P260, DOI 10.1016/j.ophtha.2005.11.001
   Seddon JM, 2009, INVEST OPHTH VIS SCI, V50, P586, DOI 10.1167/iovs.08-2514
   Sivaprasad S, 2016, SURV OPHTHALMOL, V61, P521, DOI 10.1016/j.survophthal.2016.02.005
   Smith RT, 2009, AM J OPHTHALMOL, V148, P733, DOI 10.1016/j.ajo.2009.06.028
   Sohrab MA, 2011, INVEST OPHTH VIS SCI, V52, P5743, DOI 10.1167/iovs.10-6942
   Spaide RF, 2018, SURV OPHTHALMOL, V63, P782, DOI 10.1016/j.survophthal.2018.05.005
   Spaide RF, 2016, AM J OPHTHALMOL, V170, P58, DOI 10.1016/j.ajo.2016.07.023
   Spaide RF, 2013, RETINA-J RET VIT DIS, V33, P1800, DOI 10.1097/IAE.0b013e31829c3765
   Tan JSL, 2007, AM J OPHTHALMOL, V143, P685, DOI 10.1016/j.ajo.2006.11.021
   Tsao SW, 2013, DRUG AGING, V30, P205, DOI 10.1007/s40266-013-0061-4
   Ueda-Arakawa N, 2013, RETINA-J RET VIT DIS, V33, P490, DOI 10.1097/IAE.0b013e318276e0ae
   Ueda-Arakawa N, 2013, AM J OPHTHALMOL, V155, P260, DOI 10.1016/j.ajo.2012.08.011
   Vavvas DG, 2016, EBIOMEDICINE, V5, P198, DOI 10.1016/j.ebiom.2016.01.033
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   World Medical Association, 2013, JAMA-J AM MED ASSOC, V310, P2191, DOI [DOI 10.1001/JAMA.2013.281053, 10.1001/jama.2013.281053]
   Wu ZC, 2016, INVEST OPHTH VIS SCI, V57, P1310, DOI 10.1167/iovs.15-18682
   Yoneyama S, 2014, GRAEF ARCH CLIN EXP, V252, P1435, DOI 10.1007/s00417-014-2601-y
   Yun C, 2016, INVEST OPHTH VIS SCI, V57, P6604, DOI 10.1167/iovs.16-19989
   ZEGER SL, 1988, BIOMETRICS, V44, P1049, DOI 10.2307/2531734
   Zheng WC, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037926
   Zweifel SA, 2010, OPHTHALMOLOGY, V117, P303, DOI 10.1016/j.ophtha.2009.07.014
NR 59
TC 15
Z9 15
U1 0
U2 6
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 2168-6165
EI 2168-6173
J9 JAMA OPHTHALMOL
JI JAMA Ophthalmol.
PD MAY
PY 2020
VL 138
IS 5
BP 467
EP 477
DI 10.1001/jamaophthalmol.2020.0266
PG 11
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA LS2QZ
UT WOS:000536235300007
PM 32163116
OA Bronze, Green Published
DA 2022-11-30
ER

PT J
AU Nicita-Mauro, V
   Maltese, G
   Nicita-Mauro, C
   Lasco, A
   Basile, G
AF Nicita-Mauro, V.
   Maltese, G.
   Nicita-Mauro, C.
   Lasco, A.
   Basile, G.
TI Non Smoking for Successful Aging: Therapeutic Perspectives
SO CURRENT PHARMACEUTICAL DESIGN
LA English
DT Review
DE Smoking cessation; cigarette smoking; aging; longevity; elderly
ID RECEPTOR PARTIAL AGONIST; RANDOMIZED CONTROLLED-TRIAL; SUSTAINED-RELEASE
   BUPROPION; MALE BRITISH DOCTORS; CIGARETTE-SMOKING; FOLLOW-UP; MACULAR
   DEGENERATION; GENERAL-POPULATION; ALZHEIMERS-DISEASE; BLOOD-PRESSURE
AB The smoke of cigarettes represents an important accelerator of the aging process, and there is no doubt that smoke is an important risk factor for many diseases, in particular for cardiovascular, neoplastic and respiratory diseases. Smoking plays an important role also in the development of other pathological conditions being particularly frequent in geriatric ages, such as dementia, osteoporosis, diabetes, erectile dysfunction, senile macular degeneration, nuclear cataract and alterations of skin. This means that smoke compromises not only life expectancy, but also the quality of the life, favoring the occurrence of non-autonomy. Non-smokers have a much higher life expectancy than smokers, and the suspension of smoking is accompanied, even in the elderly, by an increase in the survival time due to the reduction of smoke-induced biological damage. The first requirement of stopping smoking certainly is the motivation of the smoker himself to do this, since without this motivation any attempt is futile. Today numerous quitting strategies exist, either of pharmacological or non-pharmacological type, which are also advantageous for the elderly person. Approved pharmacological treatments include nicotine replacement therapies, bupropion, drugs targeting cannabinoid receptors and newer pharmacological approaches including the selective nicotinic partial agonists. Varenicline, an alpha4 beta2 nicotinic acetylcoline receptor partial agonist, is the most recently agent approved for smoking cessation. This drug works by reducing the strength of the smoker's urge to smoke and by relieving withdrawal symptoms. The most effective smoking cessation programs involve a combination of pharmacotherapy and behavioural and/or cognitive counselling to improve abstinence rates.
C1 Univ Messina, Chair Geriatr & Gerontol, I-98100 Messina, Italy.
   Univ Hosp, Div Geriatr Med, Messina, Italy.
C3 University of Messina; AOU Policlinico Gaetano Martino
RP Nicita-Mauro, V (通讯作者)，Via Oratorio S Francesco 306, I-98122 Messina, Italy.
EM nicitav@unime.it
OI BASILE, Giorgio/0000-0002-0040-8618; Maltese,
   Giuseppe/0000-0001-6770-3569
CR Ambrose JA, 2004, J AM COLL CARDIOL, V43, P1731, DOI 10.1016/j.jacc.2003.12.047
   [Anonymous], 2008, REP GLOB TOB EP
   Anstey KJ, 2007, AM J EPIDEMIOL, V166, P367, DOI 10.1093/aje/kwm116
   Barua RS, 2002, J AM COLL CARDIOL, V39, P1758, DOI 10.1016/S0735-1097(02)01859-4
   Bernhard D, 2005, FASEB J, V19, P1096, DOI 10.1096/fj.04-3192com
   Bernhard D, 2007, EXP GERONTOL, V42, P160, DOI 10.1016/j.exger.2006.09.016
   Bhat VM, 2008, STROKE, V39, P2439, DOI 10.1161/STROKEAHA.107.510073
   BURNS DM, 1991, CLIN CHEST MED, V12, P631
   Burstein AH, 2006, J CLIN PHARMACOL, V46, P1234, DOI 10.1177/0091270006291837
   Coe JW, 2005, J MED CHEM, V48, P3474, DOI 10.1021/jm050069n
   Cong RH, 2008, ANN EPIDEMIOL, V18, P647, DOI 10.1016/j.annepidem.2008.04.002
   Cornuz J, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002547
   DeMarini DM, 2004, MUTAT RES-REV MUTAT, V567, P447, DOI 10.1016/j.mrrev.2004.02.001
   DOLL R, 1994, BRIT MED J, V309, P901, DOI 10.1136/bmj.309.6959.901
   Doll R, 2004, BMJ-BRIT MED J, V328, P1519, DOI 10.1136/bmj.38142.554479.AE
   Eisenberg MJ, 2008, CAN MED ASSOC J, V179, P135, DOI 10.1503/cmaj.070256
   Esiri MM, 1999, LANCET, V354, P919, DOI 10.1016/S0140-6736(99)02355-7
   European Medicines Agency, HUM MED
   Ezzati M, 2003, LANCET, V362, P847, DOI 10.1016/S0140-6736(03)14338-3
   Ezzati M, 2005, CIRCULATION, V112, P489, DOI 10.1161/CIRCULATIONAHA.104.521708
   Ferrite S, 2005, OCCUP MED-OXFORD, V55, P48, DOI 10.1093/occmed/kqi002
   Fiore MC, 2008, CLIN PRACTICE GUIDEL
   Fiore MC., 2000, TREATING TOBACCO USE
   Foulds J, 2006, INT J CLIN PRACT, V60, P571, DOI 10.1111/j.1368-5031.2006.00955.x
   Gonzales D, 2006, JAMA-J AM MED ASSOC, V296, P47, DOI 10.1001/jama.296.1.47
   Hajek P, 1999, ARCH INTERN MED, V159, P2033, DOI 10.1001/archinte.159.17.2033
   Halperin RO, 2008, AM J HYPERTENS, V21, P148, DOI 10.1038/ajh.2007.36
   Hughes J., 2004, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD000031.PUB2
   Jorenby DE, 2006, JAMA-J AM MED ASSOC, V296, P56, DOI 10.1001/jama.296.1.56
   Juan D, 2004, EUR J NEUROL, V11, P277, DOI 10.1046/j.1468-1331.2003.00779.x
   Kapoor D, 2005, EUR J ENDOCRINOL, V152, P491, DOI 10.1530/eje.1.01867
   Kodama M, 1997, ANTICANCER RES, V17, P433
   Kojda G, 1999, CARDIOVASC RES, V43, P562, DOI 10.1016/S0008-6363(99)00169-8
   Law MR, 1997, BMJ-BRIT MED J, V315, P841, DOI 10.1136/bmj.315.7112.841
   MANN SJ, 1991, JAMA-J AM MED ASSOC, V265, P2226, DOI 10.1001/jama.265.17.2226
   Maskos U, 2005, NATURE, V436, P103, DOI 10.1038/nature03694
   Mazzone A, 2001, CLIN CHEM LAB MED, V39, P822, DOI 10.1515/CCLM.2001.136
   Meisinger C, 2006, DIABETOLOGIA, V49, P1770, DOI 10.1007/s00125-006-0298-0
   Nagy J, 1997, ENDOTHELIUM-J ENDOTH, V5, P251, DOI 10.3109/10623329709052590
   Nakamura M, 2007, CLIN THER, V29, P1040, DOI 10.1016/j.clinthera.2007.06.012
   *NICE, UPD TECHN APPR NRT B
   Nicita-Mauro V, 2008, EXP GERONTOL, V43, P95, DOI 10.1016/j.exger.2007.06.011
   NICITAMAURO V, 1990, EXP GERONTOL, V25, P393, DOI 10.1016/0531-5565(90)90077-F
   NICITAMAURO V, 2008, IMMUN AGEING, P5
   Nides M, 2006, ARCH INTERN MED, V166, P1561, DOI 10.1001/archinte.166.15.1561
   Nyunoya T, 2006, AM J RESP CELL MOL, V35, P681, DOI 10.1165/rcmb.2006-0169OC
   Oncken C, 2006, ARCH INTERN MED, V166, P1571, DOI 10.1001/archinte.166.15.1571
   Pepine CJ, 1998, CLIN CARDIOL, V21, P331, DOI 10.1002/clc.4960210506
   PRYOR WA, 1983, ENVIRON HEALTH PERSP, V47, P345, DOI 10.1289/ehp.8347345
   Raisz LG, 2005, J CLIN INVEST, V115, P3318, DOI 10.1172/JCI27071
   Reus VI, 2008, INT J CLIN PRACT, V62, P1753, DOI 10.1111/j.1742-1241.2008.01885.x
   RIGGS JE, 1993, LANCET, V342, P793, DOI 10.1016/0140-6736(93)91547-Y
   Rollema H, 2007, NEUROPHARMACOLOGY, V52, P985, DOI 10.1016/j.neuropharm.2006.10.016
   Sastre J, 2003, FREE RADICAL BIO MED, V35, P1, DOI 10.1016/S0891-5849(03)00184-9
   Schmier JK, 2006, PHARMACOECONOMICS, V24, P319, DOI 10.2165/00019053-200624040-00003
   SELTZER CC, 1974, AM HEART J, V87, P558, DOI 10.1016/0002-8703(74)90492-X
   Shiffman S, 2005, J SUBST ABUSE TREAT, V28, P49, DOI 10.1016/j.jsat.2004.10.006
   SHIFFMAN S, 2006, COCHRANE DB SYST REV, V184, P637
   Skoog I, 1998, NEUROEPIDEMIOLOGY, V17, P2, DOI 10.1159/000026147
   Stack NM, 2007, PHARMACOTHERAPY, V27, P1550, DOI 10.1592/phco.27.11.1550
   Stead LF, 2008, COCHRANE DB SYST REV, V23
   Taylor DH, 2002, AM J PUBLIC HEALTH, V92, P990, DOI 10.2105/AJPH.92.6.990
   TAYLOR HJ, 2008, AM J MED, V121, pS32
   Tengs TO, 2001, PREV MED, V32, P447, DOI 10.1006/pmed.2001.0830
   Tonnesen P, 2007, EUR RESPIR J, V29, P390, DOI 10.1183/09031936.00060806
   Tsai ST, 2007, CLIN THER, V29, P1027, DOI 10.1016/j.clinthera.2007.06.011
   Tzourio C, 1997, NEUROLOGY, V49, P1267, DOI 10.1212/WNL.49.5.1267
   *US FDA, EL OR BOOK APPR DRUG
   Vennemann MM, 2008, J NEUROL, V255, P1121, DOI 10.1007/s00415-008-0807-9
   Vollset SE, 2006, ANN INTERN MED, V144, P381, DOI 10.7326/0003-4819-144-6-200603210-00004
NR 70
TC 12
Z9 13
U1 0
U2 11
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 1381-6128
EI 1873-4286
J9 CURR PHARM DESIGN
JI Curr. Pharm. Design
PD MAR
PY 2010
VL 16
IS 7
BP 775
EP 782
DI 10.2174/138161210790883552
PG 8
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA 556CG
UT WOS:000274564600004
PM 20388087
DA 2022-11-30
ER

PT J
AU Kertes, PJ
   Galic, IJ
   Greve, M
   Williams, G
   Baker, J
   Lahaie, M
   Sheidow, T
AF Kertes, Peter J.
   Galic, Ivan J.
   Greve, Mark
   Williams, Geoff
   Baker, Jason
   Lahaie, Marcel
   Sheidow, Tom
TI Efficacy of a Treat-and-Extend Regimen With Ranibizumab in Patients With
   Neovascular Age-Related Macular Disease A Randomized Clinical Trial
SO JAMA OPHTHALMOLOGY
LA English
DT Article
ID TREATMENT OUTCOMES; VISUAL OUTCOMES; DOSING REGIMEN; DEGENERATION;
   THERAPY; VEGF; PATTERNS; VISION
AB Question Does a treat-and-extend approach with potentially less frequent anti-vascular endothelial growth factor injections and visits provide visual outcomes not worse than monthly ranibizumab injections in patients with neovascular acute macular degeneration? Findings In this randomized clinical trial of 580 patients with treatment-naive choroidal neovascularization secondary to acute macular degeneration, at month 24, visual acuity outcomes in the treat-and-extend group were not worse than those in the monthly group. This outcome occurred despite a mean of 17.6 injections and visits in the treat-and-extend group compared with 23.5 in the monthly group. Meaning These 2-year outcomes, combined with those of 1-year trials, appear to support the hypothesis that treat-and-extend regimens are not worse than monthly treatment with ranibizumab for patients with neovascular acute macular degeneration similar to patients enrolled and treated in this trial.
   Importance Although the Canadian Treat-and-Extend Analysis Trial With Ranibizumab in Patients With Neovascular Age-Related Macular Disease (CANTREAT) reported herein and the Treat and Extend study provided data to show noninferiority of treat-and-extend (T&E) at 12 months, to date there are few data on 24-month T&E trials compared with monthly dosing. Objective To compare the efficacy of ranibizumab using a T&E regimen to monthly dosing in treatment-naive patients with neovascular age-related macular degeneration (nAMD) after 24 months. Design, Setting, and Participants A randomized, open-label, multicenter, noninferiority intention-to-treat trial with a margin of -5 letters in best-corrected visual acuity (BCVA) from baseline to 12 months between groups was conducted at 27 treatment centers in Canada. Participants included 580 patients with treatment-naive choroidal neovascularization secondary to AMD. The study was conducted from May 8, 2013, to August 28, 2018, and data analysis was performed between August 29 and September 12, 2018. Interventions Patients with nAMD were randomized 1:1 to receive intravitreal ranibizumab, 0.5 mg, in either a T&E or monthly dosing regimen. Main Outcomes and Measures Mean change in BCVA in Early Treatment of Diabetic Retinopathy Study letters from baseline to month 24. Results Of the 580 randomized patients, 350 were women (60.3%) and 547 were white (94.3%). Mean (SD) age was 78.8 (7.8) years. By the end of month 24, 466 of the 580 randomized patients (80.3%) had completed the study and participants in the T&E arm received a mean of 17.6 injections compared with 23.5 injections for the monthly arm, for a difference of 5.9 injections and visits over 2 years (95% CI, 5.4-6.5; P < .001). The mean (SD) BCVA improvement was not worse with the T&E arm, 6.8 (14.1) letters vs 6.0 (12.6) letters, compared with the monthly arm (difference, 0.9; 95% CI, -1.6 to 3.3; P = .21). There was a gain of 15 or more letters in 25.5% of the T&E group and 23.1% of the monthly treatment group (difference, 2.4%; 95% CI, -6.8% to 11.6%; P = .59) and a loss of 15 or more letters in 6.5% of the T&E group and 5.8% of the monthly treatment group (difference, -0.7%; 95% CI, -9.9% to 8.5%; P = .85). Conclusions and Relevance These findings suggest that change in vision from baseline is not worse with a T&E compared with a monthly regimen of ranibizumab for nAMD through 24 months, achieving clinically meaningful improvements in BCVA despite fewer injections and visits.
   This noninferiority randomized clinical trial evaluates once-monthly vs a treat-and-extend regimen of ranibizumab injections in patients with age-related neovascular macular degeneration.
C1 [Kertes, Peter J.] Sunnybrook Hlth Sci Ctr, John & Liz Tory Eye Ctr, 2075 Bayview Ave,Room M1-202a, Toronto, ON M4N 3M5, Canada.
   [Kertes, Peter J.] Univ Toronto, Dept Ophthalmol & Vis Sci, Toronto, ON, Canada.
   [Galic, Ivan J.] Montreal Retina Inst, Montreal, PQ, Canada.
   [Galic, Ivan J.] McGill Univ, Dept Ophthalmol & Visual Sci, Montreal, PQ, Canada.
   [Greve, Mark] Alberta Retina Consultants, Edmonton, AB, Canada.
   [Greve, Mark] Univ Alberta, Dept Ophthalmol & Visual Sci, Edmonton, AB, Canada.
   [Williams, Geoff] Calgary Retina Consultants, Calgary, AB, Canada.
   [Williams, Geoff] Univ Calgary, Dept Surg, Sect Ophthalmol, Calgary, AB, Canada.
   [Baker, Jason; Lahaie, Marcel] Novartis Pharmaceut Canada Inc, Dorval, PQ, Canada.
   [Sheidow, Tom] Ivey Eye Inst, London, ON, Canada.
   [Sheidow, Tom] Western Univ, London, ON, Canada.
C3 University of Toronto; Sunnybrook Research Institute; University Toronto
   Affiliates; Sunnybrook Health Science Center; University of Toronto;
   McGill University; University of Alberta; University of Calgary;
   Novartis; Western University (University of Western Ontario)
RP Kertes, PJ (通讯作者)，Sunnybrook Hlth Sci Ctr, John & Liz Tory Eye Ctr, 2075 Bayview Ave,Room M1-202a, Toronto, ON M4N 3M5, Canada.
EM peter.kertes@sunnybrook.ca
FU Novartis Pharmaceuticals Canada Inc.
FX This study was funded by Novartis Pharmaceuticals Canada Inc.
CR Agarwal A, 2015, CLIN OPHTHALMOL, V9, P1001, DOI [10.2147/OPTH.S59725, 10.2147/OPTH.S74959]
   Arnold JJ, 2015, OPHTHALMOLOGY, V122, P1212, DOI 10.1016/j.ophtha.2015.02.009
   Barthelmes D, 2015, BRIT J OPHTHALMOL, V99, P359, DOI 10.1136/bjophthalmol-2014-305514
   Berg K, 2015, OPHTHALMOLOGY, V122, P146, DOI 10.1016/j.ophtha.2014.07.041
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Chakravarthy U, 2015, HEALTH TECHNOL ASSES, V19, P1, DOI 10.3310/hta19780
   Chen YFN, 2016, RETINA-J RET VIT DIS, V36, P272, DOI 10.1097/IAE.0000000000000691
   Epstein D, 2016, RETINA-J RET VIT DIS, V36, P1773, DOI 10.1097/IAE.0000000000000978
   Essex RW, 2016, OPHTHALMOLOGY, V123, P2393, DOI 10.1016/j.ophtha.2016.07.012
   Gillies MC, 2019, JAMA OPHTHALMOL, V137, P372, DOI 10.1001/jamaophthalmol.2018.6776
   Gillies MC, 2018, RANZCO 2018
   Hatz K, 2017, ACTA OPHTHALMOL, V95, pE67, DOI 10.1111/aos.13031
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Ho AC, 2014, OPHTHALMOLOGY, V121, P2181, DOI 10.1016/j.ophtha.2014.05.009
   Homer N, 2015, EYE, V29, P1152, DOI 10.1038/eye.2015.87
   Kertes PJ, 2019, OPHTHALMOLOGY, V126, P841, DOI 10.1016/j.ophtha.2019.01.013
   Kim LN, 2016, RETINA-J RET VIT DIS, V36, P1418, DOI 10.1097/IAE.0000000000001142
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Rahimy E, 2016, RETINA-J RET VIT DIS, V36, P875, DOI 10.1097/IAE.0000000000000814
   Rayess N, 2015, AM J OPHTHALMOL, V159, P3, DOI 10.1016/j.ajo.2014.09.011
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rufai SR, 2017, EYE, V31, P1337, DOI 10.1038/eye.2017.67
   Silva R, 2018, OPHTHALMOLOGY, V125, P57, DOI 10.1016/j.ophtha.2017.07.014
   Singh RP, 2018, AM J OPHTHAL CLIN TR, V1, DOI 10.25259/AJOCT-2-2018
   Spaide R, 2007, AM J OPHTHALMOL, V143, P679, DOI 10.1016/j.ajo.2007.02.024
   Stewart MW, 2015, J CLIN MED, V4, P1079, DOI 10.3390/jcm4051079
   Tufail A, 2014, OPHTHALMOLOGY, V121, P1092, DOI 10.1016/j.ophtha.2013.11.031
   Varano M, 2015, CLIN OPHTHALMOL, V9, P2243, DOI 10.2147/OPTH.S92548
   Vardarinos A, 2017, BMC OPHTHALMOL, V17, DOI 10.1186/s12886-017-0451-1
   Wickremasinghe SS, 2016, RETINA-J RET VIT DIS, V36, P1331, DOI 10.1097/IAE.0000000000000902
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   World Med Assoc, 2013, JAMA-J AM MED ASSOC, V310, P2191, DOI 10.1001/jama.2013.281053
   Wykoff CC, 2018, BRIT J OPHTHALMOL, V102, P460, DOI 10.1136/bjophthalmol-2017-310822
   Wykoff CC, 2017, OPHTHALMOL RETINA, V1, P314, DOI 10.1016/j.oret.2016.12.004
   Wykoff CC, 2015, OPHTHALMOLOGY, V122, P2514, DOI 10.1016/j.ophtha.2015.08.009
NR 36
TC 31
Z9 31
U1 0
U2 2
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 2168-6165
EI 2168-6173
J9 JAMA OPHTHALMOL
JI JAMA Ophthalmol.
PD MAR
PY 2020
VL 138
IS 3
BP 244
EP 250
DI 10.1001/jamaophthalmol.2019.5540
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA KW1MQ
UT WOS:000520936000003
PM 31917441
OA hybrid, Green Published
DA 2022-11-30
ER

PT J
AU Virgili, G
   Acosta, R
   Grover, LL
   Bentley, SA
   Giacomelli, G
AF Virgili, Gianni
   Acosta, Ruthy
   Grover, Lori L.
   Bentley, Sharon A.
   Giacomelli, Giovanni
TI Reading aids for adults with low vision
SO COCHRANE DATABASE OF SYSTEMATIC REVIEWS
LA English
DT Review
DE Reading; SensoryAids; Lenses; Randomized Controlled Trials as Topic;
   Vision, Low [rehabilitation]; Visual Acuity; Visually Impaired Persons
   [rehabilitation]; Adult; Humans
ID VISUAL IMPAIRMENT; MACULAR DEGENERATION; FRESNEL PRISMS; PERFORMANCE;
   REHABILITATION; PSYCHOPHYSICS; PEOPLE; IMPACT; SPEED; INTERFACE
AB Background
   The purpose of low-vision rehabilitation is to allow people to resume or to continue to perform daily living tasks, with reading being one of the most important. This is achieved by providing appropriate optical devices and special training in the use of residual-vision and low-vision aids, which range from simple optical magnifiers to high-magnification video magnifiers.
   Objectives
   To assess the effects of reading aids for adults with low vision.
   Search methods
   We searched CENTRAL (which contains the Cochrane Eyes and Vision Group Trials Register) (The Cochrane Library 2013, Issue 1), Ovid MEDLINE, Ovid MEDLINE In-Process and Other Non-Indexed Citations, Ovid MEDLINE Daily, Ovid OLDMEDLINE, (January 1950 to January 2013), EMBASE (January 1980 to January 2013), Latin American and Caribbean Literature on Health Sciences (LILACS) (January 1982 to January 2013), OpenGrey (System for Information on Grey Literature in Europe) (www.opengrey.eu/), the metaRegister of Controlled Trials (mRCT) (www.controlled-trials.com), ClinicalTrials.gov (www.clinicaltrials.gov/) and the WHO International Clinical Trials Registry Platform (ICTRP) (www.who.int/ictrp/search/en). We did not use any date or language restrictions in the electronic searches for trials. We last searched the electronic databases on 31 January 2013. We searched the reference lists of relevant articles and used the Science Citation Index to find articles that cited the included studies and contacted investigators and manufacturers of low-vision aids. We handsearched the British Journal of Visual Impairment from 1983 to 1999 and the Journal of Visual Impairment and Blindness from 1976 to 1991.
   Selection criteria
   This review includes randomised and quasi-randomised trials in which any device or aid used for reading had been compared to another device or aid in people aged 16 or over with low vision as defined by the study investigators.
   Data collection and analysis
   At least two authors independently assessed trial quality and extracted data.
   Main results
   We included nine small studies with a cross-over-like design (181 people overall) and one study with three parallel arms (243 participants) in the review. All studies reported the primary outcome, results for reading speed.
   Two studies including 92 participants found moderate-or low-quality evidence suggesting that reading speed is higher with stand-mounted electronic devices or electronic devices with the camera mounted in a 'mouse' than with optical magnifiers, which in these trials were generally stand-mounted or, less frequently, hand-held magnifiers or microscopic lenses. In another study of 20 participants there was moderate-quality evidence that optical devices are better than head-mounted electronic devices (four types).
   There was low-quality evidence from three studies (93 participants) that reading using head-mounted electronic devices is slower than with stand-based electronic devices. The technology of electronic devices may have changed and improved since these studies were conducted.
   One study suggested no difference between a diffractive spectacle-mounted magnifier and either refractive (15 participants) or aplanatic (15 participants) magnifiers.
   One study of 10 people suggested that several overlay coloured filters were no better and possibly worse than a clear filter.
   A parallel-arm study including 243 participants with age-related macular degeneration found that custom or standard prism spectacles were no different from conventional reading spectacles, although the data did not allow precise estimates of performance to be made.
   Authors' conclusions
   There is insufficient evidence on the effect of different types of low-vision aids on reading performance. It would be necessary to investigate which patient characteristics predict performance with different devices, including costly electronic devices. Better-quality research should also focus on assessing sustained long-term use of each device. Authors of studies testing several devices on the same person should consider design and reporting issues related to their sequential presentation and to the cross-over-like study design.
C1 [Virgili, Gianni; Giacomelli, Giovanni] Univ Florence, Eye Clin, Dept Translat Surg & Med, I-50134 Florence, Italy.
   [Acosta, Ruthy] Hosp Clin IDIBAPS, Fetal & Perinatal Med Res Grp, Barcelona, Spain.
   [Grover, Lori L.] Arizona State Univ, Coll Nursing & Hlth Innovat, Dept Hlth Solut, Phoenix, AZ USA.
   [Bentley, Sharon A.] Deakin Univ, Fac Hlth, Sch Med Optometry, Geelong, Vic 3217, Australia.
C3 University of Florence; University of Barcelona; Hospital Clinic de
   Barcelona; IDIBAPS; Arizona State University; Arizona State
   University-Downtown Phoenix; Deakin University
RP Virgili, G (通讯作者)，Univ Florence, Eye Clin, Dept Translat Surg & Med, Via Morgagni 85, I-50134 Florence, Italy.
EM gianni.virgili@unifi.it
RI giacomelli, giovanni/ABC-6173-2020
FU Department of Health; NATIONAL EYE INSTITUTE [U01EY020522] Funding
   Source: NIH RePORTER
FX Richard Wormald (Co-ordinating Editor for CEVG) acknowledges financial
   support for his CEVG research sessions from the Department of Health
   through the award made by the National Institute for Health Research to
   Moorfields Eye Hospital NHS Foundation Trust and UCL Institute of
   Ophthalmology for a Specialist Biomedical Research Centre for
   Ophthalmology. The views expressed in this publication are those of the
   authors and not necessarily those of the Department of Health.
CR AHN SJ, 1995, VISION RES, V35, P1939, DOI 10.1016/0042-6989(94)00294-V
   AHN SJ, 1995, VISION RES, V35, P1931, DOI 10.1016/0042-6989(94)00293-U
   Alderson P, 2002, COCHRANE COLLABORATI
   Binns AM, 2012, SURV OPHTHALMOL, V57, P34, DOI 10.1016/j.survophthal.2011.06.006
   BLASKEY P, 1990, J LEARN DISABIL, V23, P604, DOI 10.1177/002221949002301007
   Cheng D, 2001, OPHTHAL PHYSL OPT, V21, P312, DOI 10.1046/j.1475-1313.2001.00570.x
   Cheong AMY, 2009, OPTOMETRY VISION SCI, V86, P1078, DOI 10.1097/OPX.0b013e3181b4c4d9
   Cheong AMY, 2005, OPTOMETRY VISION SCI, V82, P114, DOI 10.1097/01.OPX.0000153244.93582.FF
   COHEN JM, 1991, OPTOMETRY VISION SCI, V68, P795, DOI 10.1097/00006324-199110000-00007
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Congdon NG, 2003, JAMA-J AM MED ASSOC, V290, P2057, DOI 10.1001/jama.290.15.2057
   Culham LE, 2004, OPHTHAL PHYSL OPT, V24, P281, DOI 10.1111/j.1475-1313.2004.00193.x
   Culham LE, 2009, OPHTHAL PHYSL OPT, V29, P138, DOI 10.1111/j.1475-1313.2008.00630.x
   Bonatti FAD, 2008, ARQ BRAS OFTALMOL, V71, P385, DOI 10.1590/S0004-27492008000300015
   Deeks JJ, 2005, COCHRANE LIB, V4.2.5
   Deeks JJ, 2011, COCHRANE COLLABORATI
   Demers-Turco P, 2001, INVESTIGATIVE OPHTHA, V42
   Dickinson C., 1998, LOW VISION PRINCIPLE
   Elbourne DR, 2002, INT J EPIDEMIOL, V31, P140, DOI 10.1093/ije/31.1.140
   Eperjesi F, 2004, ACTA OPHTHALMOL SCAN, V82, P695, DOI 10.1111/j.1600-0420.2004.00371.x
   Goodrich G., 2001, OPTOMETRY VISION SCI, V78, P291
   Goodrich G L, 2001, Optometry, V72, P519
   GOODRICH GL, 1977, AM J OPTOM PHYS OPT, V54, P312
   Goodrich GL, 1998, AM ACAD OPTOMETRY, P25
   Goodrich GL, 2004, J VISUAL IMPAIRMENT, V98, P148
   Goodrich GL, 2000, OPTOMETRY VISION SCI, V77, P126
   Goodrich GL, 2000, OPTOMETRY VISION SCI, V77, P125
   HIGGINS JPT, 2011, COCHRANE HDB SYSTEMA, V0001
   Hirji KF, 2009, TRIALS, V10, DOI 10.1186/1745-6215-10-33
   Hooper P, 2008, CAN J OPHTHALMOL, V43, P180, DOI 10.3129/i08-001
   HUMPHRY RC, 1986, T OPHTHAL SOC UK, V105, P296
   JACOBS RJ, 1990, J VISUAL IMPAIR BLIN, V84, P569
   Kaida M, 2005, JAPANESE J CLIN OPHT, V59, P437
   Kleweno CP, 2001, J REHABIL RES DEV, V38, P431
   Kuyk T, 1990, J VISION REHABILITAT, V4, P21
   Langelaan M, 2007, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD006543, DOI 10.1002/14651858.CD006543]
   Lavinsky J, 2001, INT J REHABIL RES, V24, P337, DOI 10.1097/00004356-200112000-00012
   LAWTON TB, 1989, OPHTHALMOLOGY, V96, P115
   LEAT SJ, 1994, OPTOMETRY VISION SCI, V71, P199, DOI 10.1097/00006324-199403000-00009
   LEGGE GE, 1985, VISION RES, V25, P239, DOI 10.1016/0042-6989(85)90117-8
   LEGGE GE, 1985, VISION RES, V25, P253, DOI 10.1016/0042-6989(85)90118-X
   LEGGE GE, 1991, OPTOMETRY VISION SCI, V68, P763, DOI 10.1097/00006324-199110000-00001
   LEGGE GE, 1989, CLIN VISION SCI, V4, P51
   Legge GE, 2007, PSYCHOPHYSICS READIN
   Margrain TH, 1999, BRIT MED J, V318, P1504, DOI 10.1136/bmj.318.7197.1504
   Margrain TH, 2000, BRIT J OPHTHALMOL, V84, P919, DOI 10.1136/bjo.84.8.919
   Markowitz SN, 2013, ACTA OPHTHALMOL, V91, P207, DOI 10.1111/j.1755-3768.2011.02336.x
   Massof RW, 1998, OPTOMETRY VISION SCI, V75, P349, DOI 10.1097/00006324-199805000-00025
   NILSSON UL, 1990, CLIN VISION SCI, V6, P3
   Ortiz A, 1999, OPTOMETRY VISION SCI, V76, P755, DOI 10.1097/00006324-199911000-00024
   Parodi MB, 2004, CLIN REHABIL, V18, P828, DOI 10.1191/0269215504cr801oa
   Pascolini D, 2012, BRIT J OPHTHALMOL, V96, P614, DOI 10.1136/bjophthalmol-2011-300539
   Peterson RC, 2003, AM J OPHTHALMOL, V136, P1129, DOI 10.1016/S0002-9394(03)00567-1
   Rees G, 2006, INVESTIGATIVE OPHTHA, V47
   Reeves BC, 2004, BRIT J OPHTHALMOL, V88, P1443, DOI 10.1136/bjo.2003.037457
   Rohrschneider K, 1998, OPHTHALMOLOGE, V95, P110, DOI 10.1007/s003470050246
   ROSENBERG R, 1989, OPTOMETRY VISION SCI, V66, P747, DOI 10.1097/00006324-198911000-00004
   ROSSI PW, 1990, NEUROLOGY, V40, P1597, DOI 10.1212/WNL.40.10.1597
   Rubin GS, 2013, VISION RES, V90, P43, DOI 10.1016/j.visres.2013.02.015
   Schtinemann HJ, 2011, COCHRANE HDB SYSTEMA
   Scott IU, 1999, AM J OPHTHALMOL, V128, P54, DOI 10.1016/S0002-9394(99)00108-7
   Scott IU, 2002, AM J OPHTHALMOL, V134, P857, DOI 10.1016/S0002-9394(02)01795-6
   SHUTTLEWORTH GN, 1995, BRIT J OPHTHALMOL, V79, P719, DOI 10.1136/bjo.79.8.719
   Sloan L L, 1971, Int Ophthalmol Clin, V11, P19
   Smith HJ, 2005, ARCH OPHTHALMOL-CHIC, V123, P1042, DOI 10.1001/archopht.123.8.1042
   Sonsino J, 2000, OPTOMETRY VISION SCI, V77, P239
   Spitzberg L A, 1995, J Am Optom Assoc, V66, P25
   Stelmack J, 1991, J Am Optom Assoc, V62, P53
   Stelmack JA, 2008, ARCH OPHTHALMOL-CHIC, V126, P608, DOI 10.1001/archopht.126.5.608
   Sterne JAC, 2011, COCHRANE HDB SYSTEMA
   TIELSCH JM, 1990, ARCH OPHTHALMOL-CHIC, V108, P286, DOI 10.1001/archopht.1990.01070040138048
   Veteran Affairs Technology Assessment Program, 2003, OPT DEV AD LOW VIS S
   Virgili G, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003303.pub2
   VIRTANEN P, 1991, ACTA OPHTHALMOL, V69, P484
   Watson GR, 2005, J REHABIL RES DEV, V42, P459, DOI 10.1682/JRRD.2004.11.0137
   Wolffsohn JS, 2002, OPHTHAL PHYSL OPT, V22, P300, DOI 10.1046/j.1475-1313.2002.00036.x
   World Health Organization, 2012, INT CLASS DIS ICD
NR 77
TC 40
Z9 40
U1 0
U2 28
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1469-493X
EI 1361-6137
J9 COCHRANE DB SYST REV
JI Cochrane Database Syst Rev.
PY 2013
IS 10
AR CD003303
DI 10.1002/14651858.CD003303.pub3
PG 82
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA 244FR
UT WOS:000326373000014
OA Green Accepted, Green Published
DA 2022-11-30
ER

PT J
AU Platt, S
   Salomao, DR
   Pulido, J
AF Platt, Sean
   Salomao, Diva R.
   Pulido, Jose
TI Histologic Findings of Choroidal Vasculopathy in Eyes Enucleated
   following Radiation Therapy for Uveal Melanoma: Radiation Choroidopathy
SO KLINISCHE MONATSBLATTER FUR AUGENHEILKUNDE
LA English
DT Article
DE radiation retinopathy; radiation choroidopathy; uveal melanoma; ocular
   radiation
ID IODINE-125 BRACHYTHERAPY; IRRADIATION
AB Introduction Little has been published about the choroidal vascular changes that occur years after radiation exposure. The aim of this study was to review the histological changes observed in the choroidal vasculature following radiotherapy for uveal melanoma.
   Methods Records from a single institution were retrospectively reviewed from June 7, 2007 to June 7, 2017; 101 patients with a diagnosis of uveal melanoma that underwent enucleation had their records reviewed. Out of these, a total of 26 eyes had undergone plaque brachytherapy prior to enucleation, which had been performed at a mean time of 7.2 years (range from 0 years to 30 years) after the initial plaque placement. A histopathologic analysis was conducted on all 26 eyes with special emphasis on the choroidal changes. Of these 26 eyes, 18 demonstrated evidence of radiation-induced vasculopathy.
   Results Of the 18 eyes, 10/18 (55%) had radiation retinopathy and 16/ 18 (89%) had radiation choroidal vasculopathy. One patient had a phthisical eye, and the choroid could not be evaluated because the characteristics of the vasculature could not be determined. Nine cases had vitreous hemorrhage (50%), all cases had radiation retinopathy, and 8/9 (89%) had radiation choroidopathy. Of the 16 cases with radiation choroidal vasculopathy, 3/16 (19%) had only intratumoral radiation choroidal vasculopathy, 3/16 (19%) had only extratumoral radiation choroidal vasculopathy, and, thus, 10/16 (32%) had both intratumoral and extratumoral radiation choroidal vasculopathy. In patients with radiation choroidal vasculopathy, 2/16 (13%) had hyalinization of the choroidal vessels. Another 3/16 (19%) cases with radiation choroidal vasculopathy had ectatic vessels. The other 11/16 (68%) had evidence of both hyalinization of the choroidal vessels as well as ectatic vessels in the choroid. Histological evidence of radiation retinopathy and choroidopathy were seen in 69% of eyes enucleated after receiving radiation therapy, which, in some cases, also had vitreous hemorrhage. Polypoidal choroidal vasculopathy, choroidal neovascularization, and retinal choroidal anastomoses (RAP-type lesions) were seen in 12 of the 16 eyes (75%).
   Discussion/Conclusion Irradiation of malignant tumors of the eye causes not only radiation retinopathy but also radiation choroidopathy. The role of radiation choroidopathy in the subsequent visual loss following radiotherapy and the role of anti-VEGF therapy needs to be recognized and distinguished from radiation retinopathy. Our data adds to the prior limited knowledge that radiation affects the choroid and can induce specific phenotypes similar to the clinical spectrum of CNV, PCV, and RAP.
C1 [Platt, Sean; Pulido, Jose] Mayo Clin, Ophthalmol & Mol Med, Rochester, MN USA.
   [Salomao, Diva R.] Mayo Clin, Anat Pathol, Rochester, MN USA.
   [Pulido, Jose] Wills Eye Hosp & Res Inst, Dept Translat Ophthalmol, 840 Walnut St,Suite 1530, Philadelphia, PA 19107 USA.
C3 Mayo Clinic; Mayo Clinic; Jefferson University
RP Pulido, J (通讯作者)，Wills Eye Hosp & Res Inst, Dept Translat Ophthalmol, 840 Walnut St,Suite 1530, Philadelphia, PA 19107 USA.
EM pulido.jose@mayo.edu
FU Mayo Clinic
FX Ms. Dee Chase for her work in editing the manuscript. Statement of
   Ethics: Institutional Review Board approval was obtained for this
   retrospective study, and research was conducted ethically in accordance
   with the World Medical Association Declaration of Helsinki. Disclosure
   Statement: Jose S. Pulido, M. D. has stock interest in Lagen
   Laboratories, which makes iPSC-retinal pigment epithelial cells for in
   vitro use and is not relevant to this study. Funding Resources:
   Supported in part by Mayo Clinic donations by the Deshong Family and the
   Paul Family. Author Contributions: Jose S. Pulido, M. D. developed the
   idea and helped with the writing, editing, and evaluation of data. Diva
   R. Salomao, M. D. helped with the writing and editing, and evaluation of
   data. Sean Platt, M. D. helped with the writing and editing, and
   evaluation of data.
CR ALBERT, 1990, ARCH OPHTHALMOL-CHIC, V108, P1268
   Amoaku WMK, 1995, EYE, V9, P738, DOI 10.1038/eye.1995.187
   ARCHER D B, 1991, Eye (London), V5, P239
   Avery RB, 2008, ARCH OPHTHALMOL-CHIC, V126, P207, DOI 10.1001/archophthalmol.2007.50
   Bianciotto C, 2010, OPHTHALMOLOGY, V117, P1005, DOI 10.1016/j.ophtha.2009.10.015
   Cavalcante LL, 2010, CLIN OPHTHALMOL, V4, P519
   Diener-West M, 2001, ARCH OPHTHALMOL-CHIC, V119, P969
   EGBERT PR, 1980, BRIT J OPHTHALMOL, V64, P660, DOI 10.1136/bjo.64.9.660
   Gunduz K, 1999, ARCH OPHTHALMOL-CHIC, V117, P609
   MACFAUL PA, 1977, BRIT J OPHTHALMOL, V61, P221, DOI 10.1136/bjo.61.3.221
   Midena E, 1996, OPHTHALMOLOGY, V103, P1651, DOI 10.1016/S0161-6420(96)30450-8
   Pang CE, 2014, OSLI RETINA, V45, P585, DOI 10.3928/23258160-20141008-04
   Peiretti E, 2006, EUR J OPHTHALMOL, V16, P637, DOI 10.1177/112067210601600426
   Pina Y, 2010, RETINA TODAY, P62
   Spaide RF, 2002, AM J OPHTHALMOL, V133, P709, DOI 10.1016/S0002-9394(02)01331-4
   Takahashi K, 1998, AM J OPHTHALMOL, V125, P367, DOI 10.1016/S0002-9394(99)80148-2
   Wen JC, 2009, CURR OPIN OPHTHALMOL, V20, P200, DOI 10.1097/ICU.0b013e328329b62d
NR 17
TC 2
Z9 2
U1 0
U2 1
PU GEORG THIEME VERLAG KG
PI STUTTGART
PA RUDIGERSTR 14, D-70469 STUTTGART, GERMANY
SN 0023-2165
EI 1439-3999
J9 KLIN MONATSBL AUGENH
JI Klinische Monatsblat. Augenheilkunde
PD MAY
PY 2021
VL 238
IS 05
BP 584
EP 590
DI 10.1055/a-1275-0626
EA FEB 2021
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA SK8ZT
UT WOS:000621618500001
PM 33618386
OA Bronze
DA 2022-11-30
ER

PT J
AU Jean-Charles, A
   Merle, H
   Audo, I
   Desoudin, C
   Bocquet, B
   Baudoin, C
   Sidibe, M
   Mauget-Faysse, M
   Wolff, B
   Fichard, A
   Lenaers, G
   Sahel, JA
   Gaudric, A
   Cohen, SY
   Hamel, CP
   Meunier, I
AF Jean-Charles, Albert
   Merle, Harold
   Audo, Isabelle
   Desoudin, Catherine
   Bocquet, Beatrice
   Baudoin, Corinne
   Sidibe, Moro
   Mauget-Faysse, Martine
   Wolff, Benjamin
   Fichard, Agnes
   Lenaers, Guy
   Sahel, Jose-Alain
   Gaudric, Alain
   Cohen, Salomon Yves
   Hamel, Christian P.
   Meunier, Isabelle
TI Martinique Crinkled Retinal Pigment Epitheliopathy Clinical Stages and
   Pathophysiologic Insights
SO OPHTHALMOLOGY
LA English
DT Article
ID SORSBY FUNDUS DYSTROPHY; ACTIVATED PROTEIN-KINASES; P38 SIGNALING
   PATHWAY; OXIDATIVE-STRESS; MAPKAP KINASES; MACULAR-DEGENERATION; CELLS;
   EXPRESSION; DEPOSITS; RPE
AB Purpose: To reappraise the autosomal dominant Martinique crinkled retinal pigment epitheliopathy (MCRPE) in light of the knowledge of its associated mutated gene mitogen-activated protein kinase-activated protein kinase 3 (MAPKAPK3), an actor in the p38 mitogen-activated protein kinase pathway.
   Design: Clinical and molecular study.
   Participants: A total of 45 patients from 3 generations belonging to a family originating from Martinique with an autosomal dominant MCRPE were examined.
   Methods: Best-corrected visual acuity, fundus photographs, and spectral-domain optical coherence tomography (SD OCT) of all clinically affected patients and carriers for the causal mutation were reviewed at the initial visit and 4 years later for 10 of them. Histologic retinal lesions of Mapkapk3(-/-) mice were compared with those of the human disease.
   Main Outcome Measures: The MCRPE natural history in view of MAPKAPK3 function and Mapkapk3(-/-) mouse retinal lesions.
   Results: Eighteen patients had the c. 518T>C mutation. One heterozygous woman aged 20 years was asymptomatic with normal fundus and SD OCT (stage 0). All c. 518T>C heterozygous patients older than 30 years of age had the characteristic dried-out soil fundus pattern (stages 1 and 2). Complications (stage 3) were observed in 7 cases, including polypoidal choroidal vasculopathy (PCV) and macular fibrosis or atrophy. One patient was homozygous and had a form with severe Bruch's membrane (BM) thickening and macular exudation with a dried-out soil pattern in the peripheral retina. The oldest heterozygous patient, who was legally blind, had peripheral nummular pigmentary changes (stage 4). After 4 years, visual acuity was unchanged in 6 of 10 patients. The dried-out soil elementary lesions radically enlarged in patients with a preferential macular extension and confluence. These findings are in line with the progressive thickening of BM noted with age in the mouse model. During follow-up, there was no occurrence of PCV.
   Conclusions: MCRPE is an autosomal dominant, fully penetrant retinal dystrophy with a preclinical stage, an onset after the age of 30 years, and a preserved visual acuity until occurrence of macular complications. The natural history of MCRPE is in relation to the role of MAPKAPK3 in BM modeling, vascular endothelial growth factor activity, retinal pigment epithelial responses to aging, and oxidative stress. (C) 2016 by the American Academy of Ophthalmology.
C1 [Jean-Charles, Albert; Merle, Harold] Univ Hosp Ft de France, Dept Ophthalmol, Fort De France, Martinique, France.
   [Audo, Isabelle; Sidibe, Moro; Mauget-Faysse, Martine; Wolff, Benjamin; Sahel, Jose-Alain] Fdn Adolphe Rothschild, Paris, France.
   [Audo, Isabelle; Sahel, Jose-Alain] CHNO Quinze Vingts, DHU Sight Restore, INSERM DHOS CIC1423, Paris, France.
   [Audo, Isabelle; Sahel, Jose-Alain] Sorborne Univ, UPMC Univ Paris 06, CNRS, INSERM,Inst Vis, Paris, France.
   [Audo, Isabelle; Sahel, Jose-Alain] UCL, Inst Ophthalmol, London, England.
   [Desoudin, Catherine] Eye Clin Ernest Hemingway, Fort De France, Martinique, France.
   [Bocquet, Beatrice; Baudoin, Corinne; Fichard, Agnes; Lenaers, Guy; Hamel, Christian P.; Meunier, Isabelle] Univ Montpellier, Univ Hosp, Genet Sensory Dis, Inst Neurosci Montpellier U1051, Montpellier, France.
   [Wolff, Benjamin] Eye Clin, Strasbourg, France.
   [Sahel, Jose-Alain] Inst France, Acad Sci, Paris, France.
   [Gaudric, Alain] Lariboisiere Hosp, Dept Ophthalmol, Paris, France.
   [Cohen, Salomon Yves] Ophthalm Ctr Imaging & Laser, Paris, France.
   [Cohen, Salomon Yves] Interc Hosp, Dept Ophthalmol, Creteil, France.
   [Cohen, Salomon Yves] Univ Paris Est, Creteil, France.
C3 CHU Martinique; Fondation Adolphe de Rothschild; CHNO des Quinze-Vingts;
   UDICE-French Research Universities; Sorbonne Universite; Centre National
   de la Recherche Scientifique (CNRS); Institut National de la Sante et de
   la Recherche Medicale (Inserm); UDICE-French Research Universities;
   Sorbonne Universite; Universite Paris Cite; University of London;
   University College London; Universite de Montpellier; CHU de
   Montpellier; Assistance Publique Hopitaux Paris (APHP); Hopital
   Universitaire Lariboisiere-Fernand-Widal - APHP; UDICE-French Research
   Universities; Universite Paris Cite; Universite
   Paris-Est-Creteil-Val-de-Marne (UPEC); CHI Creteil; Universite
   Paris-Est-Creteil-Val-de-Marne (UPEC)
RP Meunier, I (通讯作者)，Hop Gui de Chauliac, Ctr Natl Reference, Malad Rares, Affect Sensorielles Genet, 80 Rue Auguste Fliche, F-34295 Montpellier 5, France.
EM isabelannemeunier@yahoo.fr
RI Bocquet, Beatrice/AAY-8447-2020; Lenaers, guy/X-4727-2019; Sahel,
   Jose-Alain/F-3172-2017; lenaers, guy/K-2421-2015
OI Bocquet, Beatrice/0000-0002-6369-4818; Sahel,
   Jose-Alain/0000-0002-4831-1153; lenaers, guy/0000-0003-2736-3349;
   Gaudric, Alain/0000-0002-2486-4722; Audo, Isabelle/0000-0003-0698-5309;
   wolff, benjamin/0000-0003-4709-692X
FU CIL-ASSOC, Association for Education and Research, Paris, France
FX Funded in part by CIL-ASSOC, Association for Education and Research,
   Paris, France. The funding organization had no role in the design or
   conduct of this research.
CR Agarwal A, 2012, GASS ATLAS MACULAR D, P358
   Alge-Priglinger CS, 2009, INVEST OPHTH VIS SCI, V50, P5495, DOI 10.1167/iovs.08-3193
   Bian ZM, 2001, EXP EYE RES, V73, P111, DOI 10.1006/exer.2001.1019
   Ehlting C, 2011, J BIOL CHEM, V286, P24113, DOI 10.1074/jbc.M111.235275
   Felbor U, 1997, ARCH OPHTHALMOL-CHIC, V115, P1569, DOI 10.1001/archopht.1997.01100160739011
   Gaestel M, 2006, NAT REV MOL CELL BIO, V7, P120, DOI 10.1038/nrm1834
   Gliem M, 2015, INVEST OPHTH VIS SCI, V56, P2664, DOI 10.1167/iovs.14-15733
   Guess AJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054239
   Hecquet C, 2002, INVEST OPHTH VIS SCI, V43, P3091
   Hou X, 2009, GRAEF ARCH CLIN EXP, V247, P1477, DOI 10.1007/s00417-009-1135-1
   Jean-Charles A, 2013, RETINA-J RET VIT DIS, V33, P1041, DOI 10.1097/IAE.0b013e3182733ff3
   Kalariya NM, 2009, EXP EYE RES, V89, P494, DOI 10.1016/j.exer.2009.05.011
   Klettner A, 2013, MOL VIS, V19, P281
   Klettner A, 2009, GRAEF ARCH CLIN EXP, V247, P1487, DOI 10.1007/s00417-009-1139-x
   Kuntz CA, 1996, INVEST OPHTH VIS SCI, V37, P1772
   Li YZ, 2004, J BIOL CHEM, V279, P970, DOI 10.1074/jbc.M309927200
   Mayer IA, 2001, J BIOL CHEM, V276, P28570, DOI 10.1074/jbc.M011685200
   Meunier I, 2016, HUM MOL GENET, V25, P916, DOI 10.1093/hmg/ddv624
   Milam AH, 2000, OPHTHALMOLOGY, V107, P2256, DOI 10.1016/S0161-6420(00)00419-X
   Nagai N, 2009, INVEST OPHTH VIS SCI, V50, P1903, DOI 10.1167/iovs.08-2383
   Neufeld B, 2000, J BIOL CHEM, V275, P20239, DOI 10.1074/jbc.C901040199
   Pocrnich CE, 2009, CAN J OPHTHALMOL, V44, P431, DOI 10.3129/i09-109
   Pons M, 2011, AM J PATHOL, V178, P2665, DOI 10.1016/j.ajpath.2011.02.006
   Pons M, 2010, AM J PATHOL, V177, P1198, DOI 10.2353/ajpath.2010.091108
   Roduit R, 2008, APOPTOSIS, V13, P343, DOI 10.1007/s10495-008-0179-8
   Ronkina N, 2007, MOL CELL BIOL, V27, P170, DOI 10.1128/MCB.01456-06
   Ronkina N, 2011, NUCLEIC ACIDS RES, V39, P2503, DOI 10.1093/nar/gkq1178
   Scharf M, 2013, MOL CELL BIOL, V33, P2586, DOI 10.1128/MCB.01692-12
   Stohr H, 2012, ADV EXP MED BIOL, V723, P261, DOI 10.1007/978-1-4614-0631-0_34
   Zhu DH, 2009, J BIOL CHEM, V284, P9529, DOI 10.1074/jbc.M809393200
NR 30
TC 3
Z9 3
U1 1
U2 7
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0161-6420
EI 1549-4713
J9 OPHTHALMOLOGY
JI Ophthalmology
PD OCT
PY 2016
VL 123
IS 10
BP 2196
EP 2204
DI 10.1016/j.ophtha.2016.06.028
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA EE3QI
UT WOS:000389509100018
PM 27474146
DA 2022-11-30
ER

PT J
AU Hady, SK
   Xie, SQ
   Freund, KB
   Cunningham, ET
   Wong, CW
   Cheung, CMG
   Kamoi, K
   Igarashi-Yokoi, T
   Ali, OM
   Wasfi, EI
   Rateb, MF
   Ohno-Matsui, K
AF Hady, Shymaa K.
   Xie, Shiqi
   Freund, K. Bailey
   Cunningham, Emmett T.
   Wong, Chee Wai
   Cheung, Chui Ming Gemmy
   Kamoi, Koju
   Igarashi-Yokoi, Tae
   Ali, Omar M.
   Wasfi, Ehab, I
   Rateb, Mahmoud F.
   Ohno-Matsui, Kyoko
TI PREVALENCE AND CHARACTERISTICS OF MULTIFOCAL CHOROIDITIS/PUNCTATE INNER
   CHOROIDOPATHY IN PATHOLOGIC MYOPIA EYES WITH PATCHY ATROPHY
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE Bruch membrane; multifocal choroiditis; punctate inner choroidopathy;
   macular neovascularization; OCT; patchy atrophy; pigment epithelial
   detachment; pathologic myopia; retinal pigmented epithelium
ID CHOROIDAL NEOVASCULARIZATION; CLINICAL-FEATURES; PUNCTATE; PROGRESSION;
   LESIONS
AB Purpose: To determine the prevalence and characteristics of multifocal choroiditis/punctate inner choroidopathy (MFC/PIC) in eyes with patchy atrophy because of pathologic myopia. Methods: Five hundred eyes of 253 patients with patchy atrophy were examined between 2014 and 2020 at the Advanced Clinical Center for Myopia. The main outcome measures included the prevalence and characteristics of active MFC/PIC lesions diagnosed by optical coherence tomography. Results: Fifty-five of the 500 eyes (11%) diagnosed with patchy atrophy had optical coherence tomography features of active MFC/PIC lesions, such as focal elevations of the retinal pigment epithelium filled with medium hyperreflectivity material, curvilinear scars (Schlaegel lines), and/or areas of outer retinal atrophy. At the time when the MFC/PIC was diagnosed, the mean age was 57.3 +/- 12.0 years, and the mean axial length was 29.2 +/- 1.8 mm. Macular neovascularization was found in 45 of eyes (81.8%) with MFC/PIC versus 151 eyes without such findings (33.9%; P < 0.001). In 25 of the 55 eyes (45.5%), active MFC/PIC lesions were found before the development of the patchy atrophy. The Bruch membrane defects were colocated with these lesions. Conclusion: Active MFC/PIC lesions were identified in a minority of eyes with pathologic myopia, and a subset of these lesions were observed to progress to findings indistinguishable from myopic patchy atrophy. Evidence of MFC/PIC in eyes with pathologic myopia appeared to be a risk factor for the development of macular neovascularization.
C1 [Hady, Shymaa K.; Xie, Shiqi; Kamoi, Koju; Igarashi-Yokoi, Tae; Ohno-Matsui, Kyoko] Tokyo Med & Dent Univ, Dept Ophthalmol & Visual Sci, Tokyo, Japan.
   [Hady, Shymaa K.; Ali, Omar M.; Wasfi, Ehab, I; Rateb, Mahmoud F.] Assiut Univ, Fac Med, Dept Ophthalmol, Assiut, Egypt.
   [Freund, K. Bailey] Vitreous Retina Macula Consultants New York, New York, NY USA.
   [Freund, K. Bailey] NYU, Dept Ophthalmol, 550 1St Ave, New York, NY 10016 USA.
   [Cunningham, Emmett T.] Calif Pacific Med Ctr, Dept Ophthalmol, San Francisco, CA USA.
   [Cunningham, Emmett T.] Stanford Univ, Sch Med, Dept Ophthalmol, Stanford, CA 94305 USA.
   [Cunningham, Emmett T.] UCSF Sch Med, Francis I Proctor Fdn, San Francisco, CA USA.
   [Wong, Chee Wai; Cheung, Chui Ming Gemmy] Singapore Eye Res Inst, Singapore Natl Eye Ctr, Singapore, Singapore.
   [Wong, Chee Wai] Duke NUS Med Sch, Singapore, Singapore.
C3 Tokyo Medical & Dental University (TMDU); Egyptian Knowledge Bank (EKB);
   Assiut University; Vitreous Retina Macula Consultants of New York; New
   York University; California Pacific Medical Center; Stanford University;
   University of California System; University of California San Francisco;
   National University of Singapore; Singapore National Eye Center;
   National University of Singapore
RP Ohno-Matsui, K (通讯作者)，Tokyo Med & Dent Univ, Dept Ophthalmol & Visual Sci, Bunkyo Ku, 1-5-45 Yushima, Tokyo 1138510, Japan.
EM k.ohno.oph@tmd.ac.jp
RI Rateb, Mahmoud/Q-3630-2019
OI Rateb, Mahmoud/0000-0001-5773-111X
CR Ahnood D, 2017, SURV OPHTHALMOL, V62, P113, DOI 10.1016/j.survophthal.2016.10.003
   Amer R, 2011, SURV OPHTHALMOL, V56, P36, DOI 10.1016/j.survophthal.2010.03.009
   Chang L, 2013, AM J OPHTHALMOL, V155, P991, DOI 10.1016/j.ajo.2013.01.016
   Chen S-N., 2020, OCUL IMMUNOL INFLAMM, V29, P1
   Cunningham ET., 2020, INFLAMMATORY CHOROID
   Du R, 2020, RETINA-J RET VIT DIS, V40, P951, DOI 10.1097/IAE.0000000000002575
   Erba S, 2022, OCUL IMMUNOL INFLAMM, V30, P409, DOI 10.1080/09273948.2020.1800048
   Essex RW, 2010, ARCH OPHTHALMOL-CHIC, V128, P982, DOI 10.1001/archophthalmol.2010.157
   Ferrara DC, 2008, ARCH OPHTHALMOL-CHIC, V126, P1562, DOI 10.1001/archopht.126.11.1562
   Freund KB., 2016, RETINAL ATLAS E BOOK
   Fung Adrian T, 2012, Retin Cases Brief Rep, V6, P339, DOI 10.1097/ICB.0b013e318260af4a
   Gan YH, 2021, PHOTODIAGN PHOTODYN, V33, DOI 10.1016/j.pdpdt.2020.102146
   Hua R, 2014, PHOTODIAGN PHOTODYN, V11, P565, DOI 10.1016/j.pdpdt.2014.07.002
   Levison AL, 2017, BRIT J OPHTHALMOL, V101, P616, DOI 10.1136/bjophthalmol-2016-308806
   Ohno-Matsui K, 2003, BRIT J OPHTHALMOL, V87, P570, DOI 10.1136/bjo.87.5.570
   Ohno-Matsui K., 2020, ATLAS PATHOLOGIC MYO
   Ohno-Matsui K, 2018, PROG RETIN EYE RES, V63, P92, DOI 10.1016/j.preteyeres.2017.10.005
   Ohno-Matsui K, 2016, AM J OPHTHALMOL, V166, P22, DOI 10.1016/j.ajo.2016.03.019
   Ohno-Matsui K, 2016, PROG RETIN EYE RES, V52, P156, DOI 10.1016/j.preteyeres.2015.12.001
   Ohno-Matsui K, 2015, AM J OPHTHALMOL, V159, P877, DOI 10.1016/j.ajo.2015.01.022
   Pohlmann D, 2019, BRIT J OPHTHALMOL, V103, P1152, DOI 10.1136/bjophthalmol-2018-312455
   Pohlmann D, 2019, BRIT J OPHTHALMOL, V103, P60, DOI 10.1136/bjophthalmol-2017-311764
   Shi X, 2020, GRAEF ARCH CLIN EXP, V258, P751, DOI 10.1007/s00417-019-04571-0
   Spaide RF, 2008, AM J OPHTHALMOL, V146, P496, DOI 10.1016/j.ajo.2008.05.032
   Tang YT, 2015, OPHTHALMOLOGY, V122, P1480, DOI 10.1016/j.ophtha.2015.03.022
   WATZKE RC, 1984, AM J OPHTHALMOL, V98, P572, DOI 10.1016/0002-9394(84)90243-5
   Wong TY, 2014, AM J OPHTHALMOL, V157, P9, DOI 10.1016/j.ajo.2013.08.010
   Zarranz-Ventura J, 2014, OPHTHALMOLOGY, V121, P1790, DOI 10.1016/j.ophtha.2014.03.011
   Zhang XZ, 2013, OPHTHALMOLOGY, V120, P2678, DOI 10.1016/j.ophtha.2013.05.012
   Zhang XZ, 2011, RETINA-J RET VIT DIS, V31, P1680, DOI 10.1097/IAE.0b013e31820a67ad
NR 30
TC 1
Z9 1
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD APR
PY 2022
VL 42
IS 4
BP 669
EP 678
DI 10.1097/IAE.0000000000003383
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 0A8RN
UT WOS:000774215200011
PM 34934033
DA 2022-11-30
ER

PT J
AU Chakravarthy, U
   Harding, SP
   Rogers, CA
   Downes, S
   Lotery, AJ
   Dakin, HA
   Culliford, L
   Scott, LJ
   Nash, RL
   Taylor, J
   Muldrew, A
   Sahni, J
   Wordsworth, S
   Raftery, J
   Peto, T
   Reeves, BC
AF Chakravarthy, Usha
   Harding, Simon P.
   Rogers, Chris A.
   Downes, Susan
   Lotery, Andrew J.
   Dakin, Helen A.
   Culliford, Lucy
   Scott, Lauren J.
   Nash, Rachel L.
   Taylor, Jodi
   Muldrew, Alyson
   Sahni, Jayashree
   Wordsworth, Sarah
   Raftery, James
   Peto, Tunde
   Reeves, Barnaby C.
CA IVAN Investigators
TI A randomised controlled trial to assess the clinical effectiveness and
   cost-effectiveness of alternative treatments to Inhibit VEGF in
   Age-related choroidal Neovascularisation (IVAN)
SO HEALTH TECHNOLOGY ASSESSMENT
LA English
DT Article
ID QUALITY-OF-LIFE; INTRAVITREAL BEVACIZUMAB AVASTIN; VERTEPORFIN
   PHOTODYNAMIC THERAPY; GROWTH-FACTOR INHIBITORS; MACULAR DEGENERATION;
   MULTIPLE IMPUTATION; MYOCARDIAL-INFARCTION; RANIBIZUMAB LUCENTIS;
   ECONOMIC-EVALUATION; FACTORIAL-DESIGNS
AB Background: Bevacizumab (Avastin (R), Roche), which is used in cancer therapy, is the 'parent' molecule from which ranibizumab (Lucentis (R), Novartis) was derived for the treatment of neovascular age-related macular degeneration (nAMD). There were reports in the literature on the effectiveness of bevacizumab in treating nAMD, but no trials. The cost per dose of bevacizumab is about 5-10% that of ranibizumab. This trial was a head-to-head comparison of these two drugs.
   Objective: To compare the clinical effectiveness and cost-effectiveness of ranibizumab and bevacizumab, and two treatment regimens, for nAMD. Design: Multicentre, factorial randomised controlled trial with within-trial cost-utility and cost-minimisation analyses from the perspective of the UK NHS. Participants, health professionals and researchers were masked to allocation of drug but not regimen. Computer-generated random allocations to combinations of ranibizumab or bevacizumab, and continuous or discontinuous regimen, were stratified by centre, blocked and concealed.
   Setting: Twenty-three ophthalmology departments in NHS hospitals.
   Participants: Patients >= 50 years old with active nAMD in the study eye with best corrected distance visual acuity (BCVA) >= 25 letters measured on a Early Treatment of Diabetic Retinopathy Study (ETDRS) chart. Previous treatment for nAMD, long-standing disease, lesion diameter > 6000 mu m, thick blood at the fovea and any other confounding ocular disease were exclusion criteria. One eye per participant was studied; the fellow eye was treated according to usual care, if required.
   Interventions: Ranibizumab and bevacizumab were procured commercially. Doses were ranibizumab 0.5 mg or bevacizumab 1.25 mg. The repackaged bevacizumab was quality assured. All participants were treated at visits 0, 1 and 2. Participants randomised to the continuous regimen were treated monthly thereafter. Participants randomised to the discontinuous regimen were not retreated after visit 2 unless pre-specified criteria for active disease were met. If retreatment was needed, monthly injections over 3 months were mandated.
   Main outcome measures: The primary outcome was BCVA. The non-inferiority margin was 3.5 letters. Secondary outcomes were contrast sensitivity; near visual acuity; reading index; neovascular lesion morphology; generic and disease-specific patient-reported outcomes, including macular disease-specific quality of life; survival free from treatment failure; resource use; quality-adjusted life-years (QALYs); and development of new geographic atrophy (GA) (outcome added during the trial). Results are reported for the study eye, except for patient-reported outcomes.
   Results: Between 27 March 2008 and 15 October 2010, 610 participants were allocated and treated (314 ranibizumab, 296 bevacizumab; at 3 months, 305 continuous, 300 discontinuous). After 2 years, bevacizumab was neither non-inferior nor inferior to ranibizumab [-1.37 letters, 95% confidence interval (CI) -3.75 to +1.01 letters] and discontinuous treatment was neither non-inferior nor inferior to continuous treatment (-1.63 letters, 95% CI -4.01 to +0.75 letters). Lesion thickness at the fovea was similar by drug [ geometric mean ratio (GMR) 0.96, 95% CI 0.90 to 1.03; p = 0.24] but 9% less with continuous treatment (GMR 0.91, 95% CI 0.85 to 0.97; p = 0.004). Odds of developing new GA during the trial were similar by drug [ odds ratio (OR) 0.87, 95% CI 0.61 to 1.25; p = 0.46] but significantly higher with continuous treatment (OR 1.47, 95% CI 1.03 to 2.11; p = 0.033). Safety outcomes did not differ by drug but mortality was lower with continuous treatment (OR 0.47, 95% CI 0.22 to 1.03; p = 0.05). Continuous ranibizumab cost 3.5M pound per QALY compared with continuous bevacizumab; continuous bevacizumab cost 30,220 pound per QALY compared with discontinuous bevacizumab. These results were robust in sensitivity analyses.
   Conclusions: Ranibizumab and bevacizumab have similar efficacy. Discontinuing treatment and restarting when required results in slightly worse efficacy. Safety was worse with discontinuous treatment, although new GA developed more often with continuous treatment. Ranibizumab is not cost-effective, although it remains uncertain whether or not continuous bevacizumab is cost-effective compared with discontinuous bevacizumab at 20,000 pound per QALY threshold. Future studies should focus on the ocular safety of the two drugs, further optimisation of treatment regimens and criteria for stopping treatment.
C1 [Chakravarthy, Usha; Muldrew, Alyson] Queens Univ Belfast, Inst Clin Sci, Ctr Med Expt, Belfast, Antrim, North Ireland.
   [Harding, Simon P.; Sahni, Jayashree] Univ Liverpool, Inst Ageing & Chron Dis, Dept Eye & Vis Sci, Liverpool L69 3BX, Merseyside, England.
   [Rogers, Chris A.; Culliford, Lucy; Scott, Lauren J.; Nash, Rachel L.; Taylor, Jodi; Reeves, Barnaby C.] Univ Bristol, Sch Clin Sci, Clin Trials & Evaluat Unit, Bristol, Avon, England.
   [Downes, Susan] Oxford Univ Hosp NHS Trust, Oxford, England.
   [Lotery, Andrew J.] Univ Southampton, Fac Med, Clin & Expt Sci, Southampton SO9 5NH, Hants, England.
   [Dakin, Helen A.; Wordsworth, Sarah] Univ Oxford, Nuffield Dept Populat Hlth, Hlth Econ Res Ctr, Oxford, England.
   [Raftery, James] Univ Southampton, Wessex Inst, Southampton, Hants, England.
   [Peto, Tunde] Moorfields Eye Hosp NHS Fdn Trust, Natl Inst Hlth Res NIHR Biomed Res Ctr, London, England.
   [Peto, Tunde] UCL, Inst Ophthalmol, London, England.
C3 Queens University Belfast; University of Liverpool; University of
   Bristol; Oxford University Hospitals NHS Foundation Trust; University of
   Southampton; University of Oxford; University of Southampton; University
   of London; University College London; Moorfields Eye Hospital NHS
   Foundation Trust; University of London; University College London
RP Chakravarthy, U (通讯作者)，Queens Univ Belfast, Inst Clin Sci, Ctr Med Expt, Belfast, Antrim, North Ireland.
EM u.chakravarthy@qub.ac.uk
RI Peto, Tunde/G-8812-2018
OI Peto, Tunde/0000-0001-6265-0381; Dakin, Helen/0000-0003-3255-748X;
   Chakravarthy, Usha/0000-0002-2606-3734; Wordsworth,
   Sarah/0000-0002-2361-3040; Lotery, Andrew/0000-0001-5541-4305; Maishman,
   Rachel/0000-0002-5052-5951; Reeves, Barnaby/0000-0002-5101-9487
FU NIHR Health Technology Assessment programme; MRC [MR/K025643/1] Funding
   Source: UKRI; Medical Research Council [MR/K025643/1] Funding Source:
   researchfish; National Institute for Health Research [NF-SI-0514-10114,
   07/36/01] Funding Source: researchfish
FX This project was funded by the NIHR Health Technology Assessment
   programme and will be published in full in Health Technology Assessment;
   Vol. 19, No. 78. See the NIHR Journals Library website for further
   project information.
CR Abraham P, 2010, AM J OPHTHALMOL, V150, P315, DOI 10.1016/j.ajo.2010.04.011
   Alsheikh-Ali AA, 2008, AM J CARDIOL, V101, p9B, DOI 10.1016/j.amjcard.2008.02.027
   [Anonymous], 1999, Arch Ophthalmol, V117, P1329
   [Anonymous], 1994, BMJ-BRIT MED J, V308, P81, DOI DOI 10.1136/BMJ.308.6921.81
   [Anonymous], 2011, ANN C 2011 FLUCT LEV
   Avery RL, 2006, OPHTHALMOLOGY, V113, P363, DOI 10.1016/j.ophtha.2005.11.019
   BAILEY IL, 1980, AM J OPTOM PHYS OPT, V57, P378
   Billingham L, 1999, HLTH TECHNOL ASSESS, V3
   Blumenkranz MS, 2001, ARCH OPHTHALMOL-CHIC, V119, P198
   Brazier J, 2002, J HEALTH ECON, V21, P271, DOI 10.1016/S0167-6296(01)00130-8
   Briggs A, 2003, HEALTH ECON, V12, P377, DOI 10.1002/hec.766
   Briggs AH, 1997, HEALTH ECON, V6, P327, DOI 10.1002/(SICI)1099-1050(199707)6:4<327::AID-HEC282>3.0.CO;2-W
   Briggs AH, 2001, HEALTH ECON, V10, P179, DOI 10.1002/hec.584
   British Medical Association and Royal Pharmaceutical Society of Great Britain, 2011, BRIT NATL FORMULARY, V62
   BRITTAIN E, 1989, STAT MED, V8, P161, DOI 10.1002/sim.4780080204
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Brown G C, 1999, Trans Am Ophthalmol Soc, V97, P473
   Brown GC, 2000, ARCH OPHTHALMOL-CHIC, V118, P47
   Browne J, 2007, PATIENT REPORTED OUT
   BYAR DP, 1985, CANCER TREAT REP, V69, P1055
   Campbell RJ, 2012, BMJ-BRIT MED J, V344, DOI 10.1136/bmj.e4203
   Chakravarthy U, 2006, OPHTHALMOLOGY, V113, P1508, DOI 10.1016/j.ophtha.2006.02.064
   Chakravarthy U, 2013, LANCET, V382, P1258, DOI 10.1016/S0140-6736(13)61501-9
   Chakravarthy U, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.04.015
   Claxton K, 1999, J HEALTH ECON, V18, P341, DOI 10.1016/S0167-6296(98)00039-3
   Cohen J., 1988, STAT POWER ANAL SOCI, V2nd
   Curtis L, 2008, UNIT COSTS HLTH SOCI
   Curtis L., 2010, UNIT COSTS HLTH SOCI
   Curtis LH, 2010, ARCH OPHTHALMOL-CHIC, V128, P1273, DOI 10.1001/archophthalmol.2010.223
   Dakin H, 2013, HEALTH ECON, V22, P22, DOI 10.1002/hec.1812
   De Clercq C, 2007, Bull Soc Belge Ophtalmol, P15
   Department of Health (DH), 2011, PBR OP GUID TAR 2011
   Department of Health (DH), 2011, NAT SCH REF COSTS 20
   Dewan A, 2006, SCIENCE, V314, P989, DOI 10.1126/science.1133807
   Dolan P, 1997, MED CARE, V35, P1095, DOI 10.1097/00005650-199711000-00002
   Dolan P., 1995, SOCIAL TARIFF EUROQO
   Dong LM, 2003, OPHTHAL EPIDEMIOL, V10, P149, DOI 10.1076/opep.10.3.149.15080
   Drummond M.F., 2005, METHODS EC EVALUATIO
   Drummond MF, 1996, BRIT MED J, V313, P275, DOI 10.1136/bmj.313.7052.275
   Dugel PU, 2013, OPHTHALMOLOGY, V120, P317, DOI 10.1016/j.ophtha.2012.07.068
   Espallargues M, 2005, INVEST OPHTH VIS SCI, V46, P4016, DOI 10.1167/iovs.05-0072
   European Medicines Agency Committee for Medicinal Products for Human Use, 2012, CHMP ASS REP EYL AFL
   Feeny D, 2002, MED CARE, V40, P113, DOI 10.1097/00005650-200202000-00006
   FEENY D, 1995, PHARMACOECONOMICS, V7, P490, DOI 10.2165/00019053-199507060-00004
   Feeny DH., 1996, QUALITY LIFE PHARMAE, V2, P239
   Fenwick E, 2001, HEALTH ECON, V10, P779, DOI 10.1002/hec.635
   Ferrara N, 2006, RETINA-J RET VIT DIS, V26, P859, DOI 10.1097/01.iae.0000242842.14624.e7
   FERRIS FL, 1982, AM J OPHTHALMOL, V94, P91, DOI 10.1016/0002-9394(82)90197-0
   FURLONG W, 1998, 9811 MCM U CTR HLTH
   Ganiats TG, 1996, QUAL LIFE RES, V5, P162, DOI 10.1007/BF00435981
   Gaudreault J, 2005, INVEST OPHTH VIS SCI, V46, P726, DOI 10.1167/iovs.04-0601
   Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760
   Gray A., 2011, APPL METHODS COST EF
   Griffin SC, 2007, BMJ-BRIT MED J, V334, P624, DOI 10.1136/bmj.39129.442164.55
   Gudex C, 1994, TIME TRADE OFF USER
   Hallstrom AP, 1998, MED CARE, V36, P433, DOI 10.1097/00005650-199803000-00019
   Hart PM, 2002, ARCH OPHTHALMOL-CHIC, V120, P1029
   Health and Social Care Information Centre (HSCIC), 2011, NHS STAFF EARN JAN M
   Heier JS, 2006, ARCH OPHTHALMOL-CHIC, V124, P1532, DOI 10.1001/archopht.124.11.1532
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   HM Treasury, 2003, GREEN BOOK APPR EV C
   Holz FG, 2011, OPHTHALMOLOGY, V118, P663, DOI 10.1016/j.ophtha.2010.12.019
   Hughes AE, 2006, NAT GENET, V38, P1173, DOI 10.1038/ng1890
   *ICH, ICH HARM TRIP GUID T
   Jonsson B, 1997, INT J TECHNOL ASSESS, V13, P49, DOI 10.1017/S0266462300010229
   Kemp A, 2013, RETINA-J RET VIT DIS, V33, P920, DOI 10.1097/IAE.0b013e318276e07b
   Kilic U, 2006, J NEUROSCI, V26, P12439, DOI 10.1523/JNEUROSCI.0434-06.2006
   Kind P, 1999, UK POPULATION NORMS
   Kodjikian L, 2013, OPHTHALMOLOGY, V120, P2300, DOI 10.1016/j.ophtha.2013.06.020
   Krebs I, 2013, BRIT J OPHTHALMOL, V97, P266, DOI 10.1136/bjophthalmol-2012-302391
   la Cour M, 2007, ACTA OPHTHALMOL SCAN, V85, P2, DOI 10.1111/j.1600-0420.2006.00869.x
   Lin DY, 1997, BIOMETRICS, V53, P419, DOI 10.2307/2533947
   Longworth L, 2014, HEALTH TECHNOL ASSES, V18, P1, DOI 10.3310/hta18090
   LUBSEN J, 1994, EUR HEART J, V15, P585, DOI 10.1093/oxfordjournals.eurheartj.a060552
   Luyten J, 2011, VALUE HEALTH, V14, P282, DOI 10.1016/j.jval.2010.10.004
   Lynch SS, 2007, ANN PHARMACOTHER, V41, P614, DOI 10.1345/aph.1H316
   Maller J, 2006, NAT GENET, V38, P1055, DOI 10.1038/ng1873
   Manca A, 2005, HEALTH ECON, V14, P487, DOI 10.1002/hec.944
   Martin DF, 2012, OPHTHALMOLOGY, V119, DOI 10.1016/j.ophtha.2012.03.053
   Martin DF, 2011, NEW ENGL J MED, V364, P1897, DOI 10.1056/NEJMoa1102673
   McAlister FA, 2003, JAMA-J AM MED ASSOC, V289, P2545, DOI 10.1001/jama.289.19.2545
   McClure ME, 2000, BRIT J OPHTHALMOL, V84, P244, DOI 10.1136/bjo.84.3.244
   Mitchell J, 2007, QUAL LIFE RES A SUPP, VA120, pA1150
   Mitchell J, 2004, QUAL LIFE RES, V13, P1548, DOI 10.1023/B:QURE.0000031348.51292.4a
   Montgomery Alan A, 2003, BMC Med Res Methodol, V3, P26, DOI 10.1186/1471-2288-3-26
   Moshfeghi AA, 2006, OPHTHALMOLOGY, V113, P2002, DOI 10.1016/j.ophtha.2006.05.070
   National Institute for Health and Care Excellence, 2012, RAN PEG TREATM AG RE
   National Institute for Health and Care Excellence, 2013, GUID METH TECHN APPR
   National Institute for Health and Care Excellence, 2008, SOC VAL JUDG PRINC D
   National Institute for Health and Care Excellence (NICE), 2008, RAN PEG TREATM AG RE, V155
   National Institute for Health and Care Excellence (NICE), 2008, RANIBIZUMAB AND PEGA
   National Institute for Health and Care Excellence (NICE), 2003, NICE TECHN APPR, V68
   O'Hagan A, 2004, J HEALTH ECON, V23, P615, DOI 10.1016/j.jhealeco.2003.06.006
   Pasqualetti G, 2007, PHARMACOGENOMICS, V8, P49, DOI 10.2217/14622416.8.1.49
   PELLI DG, 1988, CLIN VISION SCI, V2, P187
   Penha FM, 2010, OPHTHALMIC RES, V44, P205, DOI 10.1159/000316695
   Petrarca R, 2011, CLIN OPHTHALMOL, V5, P57, DOI 10.2147/OPTH.S16444
   Piaggio G, JAMA, V295, P1152
   Piaggio G, 2012, JAMA-J AM MED ASSOC, V308, P2594, DOI 10.1001/jama.2012.87802
   Raftery J, 2009, EYE, V23, P1247, DOI 10.1038/eye.2009.85
   Raftery J, 2007, BRIT J OPHTHALMOL, V91, P1244, DOI 10.1136/bjo.2007.116616
   Rasanen P, 2006, INT J TECHNOL ASSESS, V22, P235, DOI 10.1017/S0266462306051051
   Reeves BC, 2012, HEALTH TECHNOL ASSES, V16, P1, DOI 10.3310/hta16060
   REEVES BC, 1993, OPHTHAL PHYSL OPT, V13, P17, DOI 10.1111/j.1475-1313.1993.tb00421.x
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   Rosenfeld Philip J, 2006, Ophthalmol Clin North Am, V19, P361
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Royston P, 2007, STATA J, V7, P445, DOI 10.1177/1536867X0700700401
   Royston P, 2005, STATA J, V5, P527, DOI 10.1177/1536867X0500500404
   Royston P, 2004, STATA J, V4, P227, DOI 10.1177/1536867X0400400301
   Saint-Geniez M, 2006, INVEST OPHTH VIS SCI, V47, P3135, DOI 10.1167/iovs.05-1229
   Schmidt-Erfurth U, 2011, OPHTHALMOLOGY, V118, P831, DOI 10.1016/j.ophtha.2010.09.004
   Schmucker C, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042701
   Schmucker C, 2010, CURR OPIN OPHTHALMOL, V21, P218, DOI 10.1097/ICU.0b013e3283386783
   Shah RR, 2005, PHILOS T R SOC B, V360, P1617, DOI 10.1098/rstb.2005.1693
   Silva R, 2013, OPHTHALMOLOGY, V120, P130, DOI 10.1016/j.ophtha.2012.07.026
   Singer MA, 2012, OPHTHALMOLOGY, V119, P1175, DOI 10.1016/j.ophtha.2011.12.016
   Smith F., 1992, HEALTH PROMOT INT, V7, P249, DOI [10.1093/heapro/7.4.249, DOI 10.1093/HEAPRO/7.4.249]
   Spaide RF, 2006, RETINA-J RET VIT DIS, V26, P383, DOI 10.1097/00006982-200604000-00001
   Spencer M, 2005, PHARMACOECONOMICS, V23, P619, DOI 10.2165/00019053-200523060-00008
   Subramanian ML, 2010, EYE, V24, P1708, DOI 10.1038/eye.2010.147
   Szende A, 2004, MEASURING SELF REPOR
   TORRANCE GW, 1995, PHARMACOECONOMICS, V7, P503, DOI 10.2165/00019053-199507060-00005
   Tosh J, 2011, REV GENERIC PREFEREN
   Tosh J, 2012, VALUE HEALTH, V15, P118, DOI 10.1016/j.jval.2011.08.002
   van Wijngaarden P, 2008, CLIN EXP OPTOM, V91, P427, DOI 10.1111/j.1444-0938.2008.00305.x
   White IR, 2011, STAT MED, V30, P377, DOI 10.1002/sim.4067
   WILLIAMS A, 1990, HEALTH POLICY, V16, P199
   WILLIAMS A., 1995, MEASUREMENT VALUATIO
   Williams T, 2012, ARCH OPHTHALMOL-CHIC, V130, P5
   Williams T, 2012, ARCH OPHTHALMOL-CHIC, V130, P124, DOI 10.1001/archopht.130.1.124
   Yu LM, 2007, STAT METHODS MED RES, V16, P243, DOI 10.1177/0962280206074464
NR 132
TC 49
Z9 50
U1 0
U2 20
PU NIHR JOURNALS LIBRARY
PI SOUTHAMPTON
PA UNIV SOUTHAMPTON, EVALUATION, TRIALS & STUDIES COORDINATING CENTRE,
   ALPHA HOUSE, ENTERPRISE RD, SOUTHAMPTON, SO16 7NS, ENGLAND
SN 1366-5278
EI 2046-4924
J9 HEALTH TECHNOL ASSES
JI Health Technol. Assess.
PD OCT
PY 2015
VL 19
IS 78
BP 1
EP +
DI 10.3310/hta19780
PG 299
WC Health Care Sciences & Services
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Health Care Sciences & Services
GA CT5IL
UT WOS:000362842100001
PM 26445075
OA Green Accepted, Green Submitted, gold, Green Published
DA 2022-11-30
ER

PT J
AU Costanzo, E
   Parravano, M
   Giannini, D
   Borrelli, E
   Sacconi, R
   Querques, G
AF Costanzo, Eliana
   Parravano, Mariacristina
   Giannini, Daniela
   Borrelli, Enrico
   Sacconi, Riccardo
   Querques, Giuseppe
TI Imaging Biomarkers of 1-Year Activity in Type 1 Macular
   Neovascularization
SO TRANSLATIONAL VISION SCIENCE & TECHNOLOGY
LA English
DT Article
DE biomarkers; optical coherence tomography (OCT); optical coherence
   tomography angiography (OCTA); predictive models; type 1 macular
   neovascularization (MNV)
ID CHOROIDAL NEOVASCULARIZATION; DEGENERATION; AFLIBERCEPT; PREDICTORS
AB Purpose: The purpose of this study was to evaluate the predictive value of optical coherence tomography (OCT) and OCT angiography (OCTA) parameters at baseline on lesion's activity at the 1-year follow-up in type 1 macular neovascularizations (MNVs) treated with 1-year fixed regimen of intravitreal aflibercept injections (q8 IAIs).
   Methods: All patients were imaged by structural OCT to evaluate central macular thickness (CMT), subretinal fluid (SRF), subretinal hyper-reflective material (SHRM), intraretinal fluid (IRF) and intraretinal hyper-reflective dots (HRDs), and by Swept-Source OCTA to measure baseline MNV area, perfusion density (PD), vessel length density (VLD), and vessel diameter index. At the end of q8 IAI, patients were classified in two groups: activeMNV (A-MNV) and inactive-MNV (I-MNV), considering the OCT signs of activity. Three binary logistic regression models were developed: (1) OCT-based, (2) OCTA-based, and (3) OCT/OCTA-based model.
   Results: Thirty-one treatment-na & iuml;ve type 1 MNVs were enrolled (13 A-MNV and 18 IMNV). No differences were observed in baseline OCT and OCTA characteristics between A-MNV and I-MNV. Among the models developed, model 3 that combined OCT/OCTA parameters showed a performance of 87.5% and excellent sensitivity for A-MNV lesions (100%). By analyzing the model, the A-MNV group appears more likely to show at baseline SRF, greater CMT, wider MNV area, and lower PD and VLD compared to I-MNV.
   Conclusions: Our study demonstrated that the combination of baseline OCT and OCTA parameters allowed to achieve a good models' performance in the prediction of MNV activity permitting to correctly classifying the active lesions at the end of follow-up period, with excellent sensitivity.
   Translational Relevance: OCT/OCTA could integrate statistical models potentially useful for artificial intelligence.
C1 [Costanzo, Eliana; Parravano, Mariacristina; Giannini, Daniela] IRCCS Fdn Bietti, Roma Via Livenza 3, I-00198 Rome, Italy.
   [Borrelli, Enrico; Sacconi, Riccardo; Querques, Giuseppe] Univ Vita Salute, Dept Ophthalmol, IRCCS Osped San Raffaele, Milan, Italy.
C3 IRCCS - Fondazione "G.B. Bietti" per lo Studio e la Ricerca in
   Oftalmologia; Vita-Salute San Raffaele University; IRCCS Ospedale San
   Raffaele
RP Parravano, M (通讯作者)，IRCCS Fdn Bietti, Roma Via Livenza 3, I-00198 Rome, Italy.
EM mcparravano@gmail.com
RI Giannini, Daniela/GPF-4188-2022; Giannini, Daniela/V-5431-2017
OI Giannini, Daniela/0000-0001-5704-3931; Sacconi,
   Riccardo/0000-0003-2891-2012; Querques, Giuseppe/0000-0002-3292-9581
FU Italian Ministry of Health; Fondazione Roma
FX The research for this paper was in part financially supported by Italian
   Ministry of Health and Fondazione Roma. The funders had no role in study
   design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR Al-Sheikh M, 2018, RETINA-J RET VIT DIS, V38, P220, DOI 10.1097/IAE.0000000000001628
   Arrigo A, 2020, TRANSL VIS SCI TECHN, V9, DOI 10.1167/tvst.9.9.48
   Ashraf M, 2018, ACTA OPHTHALMOL, V96, P120, DOI 10.1111/aos.13565
   Bae K, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-55871-8
   Borrelli E, 2020, OPHTHALMOL THER, V9, P697, DOI 10.1007/s40123-020-00286-2
   Borrelli E, 2018, PROG RETIN EYE RES, V67, P30, DOI 10.1016/j.preteyeres.2018.07.002
   Brown DM, 2013, RETINA-J RET VIT DIS, V33, P23, DOI 10.1097/IAE.0b013e318263cedf
   Chu ZD, 2020, AM J OPHTHALMOL, V213, P161, DOI 10.1016/j.ajo.2020.02.003
   Cohen SY, 2007, BRIT J OPHTHALMOL, V91, P1173, DOI 10.1136/bjo.2007.115501
   Corvi F, 2018, AM J OPHTHALMOL, V186, P25, DOI 10.1016/j.ajo.2017.11.011
   Coscas F, 2019, BRIT J OPHTHALMOL, V103, P1342, DOI 10.1136/bjophthalmol-2018-313065
   Coscas F, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0205513
   Gali HE, 2019, CURR OPIN OPHTHALMOL, V30, P13, DOI 10.1097/ICU.0000000000000542
   Galvez MIL, 2020, ACTA OPHTHALMOL, V98, pE820, DOI 10.1111/aos.14399
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Kim JM, 2019, SEMIN OPHTHALMOL, V34, P168, DOI 10.1080/08820538.2019.1620791
   Koo TK, 2016, J CHIROPR MED, V15, P155, DOI 10.1016/j.jcm.2016.02.012
   Levine ES, 2020, INT J RETINA VITR, V6, DOI 10.1186/s40942-020-00242-z
   Miere A, 2019, RETINA-J RET VIT DIS, V39, P548, DOI 10.1097/IAE.0000000000001964
   Parravano M, 2019, TRANSL VIS SCI TECHN, V8, DOI 10.1167/tvst.8.2.8
   Rispoli M, 2020, BIOMED RES INT, V2020, DOI 10.1155/2020/4501395
   Ritter M, 2014, BRIT J OPHTHALMOL, V98, P1629, DOI 10.1136/bjophthalmol-2014-305186
   Roberts PK, 2017, RETINA-J RET VIT DIS, V37, P1492, DOI 10.1097/IAE.0000000000001400
   Sacconi R, 2019, BRIT J OPHTHALMOL, V103, P1320, DOI 10.1136/bjophthalmol-2018-313004
   Schmidt-Erfurth U, 2016, PROG RETIN EYE RES, V50, P1, DOI 10.1016/j.preteyeres.2015.07.007
   Schneider CA, 2012, NAT METHODS, V9, P671, DOI 10.1038/nmeth.2089
   Spaide RF, 2020, OPHTHALMOLOGY, V127, P616, DOI 10.1016/j.ophtha.2019.11.004
   Stattin M, 2019, J OPHTHALMOL, V2019, DOI 10.1155/2019/4806061
   Sulzbacher F, 2017, ACTA OPHTHALMOL, V95, P414, DOI 10.1111/aos.13364
   Wakazono T, 2017, RETINA-J RET VIT DIS, V37, P2062, DOI 10.1097/IAE.0000000000001451
   Waldstein SM, 2016, OPHTHALMOLOGY, V123, P1521, DOI 10.1016/j.ophtha.2016.03.037
   Waldstein SM, 2016, OPHTHALMOLOGY, V123, P60, DOI 10.1016/j.ophtha.2015.09.013
   Wylegala A, 2018, J HEALTHC ENG, V2018, DOI 10.1155/2018/8595278
   Ying GS, 2015, OPHTHALMOLOGY, V122, P2523, DOI 10.1016/j.ophtha.2015.08.015
NR 34
TC 0
Z9 0
U1 0
U2 0
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 2164-2591
J9 TRANSL VIS SCI TECHN
JI Transl. Vis. Sci. Technol.
PD MAY
PY 2021
VL 10
IS 6
AR 18
DI 10.1167/tvst.10.6.18
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA SL4VP
UT WOS:000656917500007
PM 34111264
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Zhou, Q
   Yang, D
   Ombrello, AK
   Zavialov, AV
   Toro, C
   Zavialov, AV
   Stone, DL
   Chae, JJ
   Rosenzweig, SD
   Bishop, K
   Barron, KS
   Kuehn, HS
   Hoffmann, P
   Negro, A
   Tsai, WXL
   Cowen, EW
   Pei, W
   Milner, JD
   Silvin, C
   Heller, T
   Chin, DT
   Patronas, NJ
   Barber, JS
   Lee, CCR
   Wood, GM
   Ling, A
   Kelly, SJ
   Kleiner, DE
   Mullikin, JC
   Ganson, NJ
   Kong, HH
   Hambleton, S
   Candotti, F
   Quezado, MM
   Calvo, KR
   Alao, H
   Barham, BK
   Jones, A
   Meschia, JF
   Worrall, BB
   Kasner, SE
   Rich, SS
   Goldbach-Mansky, R
   Abinun, M
   Chalom, E
   Gotte, AC
   Punaro, M
   Pascual, V
   Verbsky, JW
   Torgerson, TR
   Singer, NG
   Gershon, TR
   Ozen, S
   Karadag, O
   Fleisher, TA
   Remmers, EF
   Burgess, SM
   Moir, SL
   Gadina, M
   Sood, R
   Hershfield, MS
   Boehm, M
   Kastner, DL
   Aksentijevich, I
AF Zhou, Qing
   Yang, Dan
   Ombrello, Amanda K.
   Zavialov, Andrey V.
   Toro, Camilo
   Zavialov, Anton V.
   Stone, Deborah L.
   Chae, Jae Jin
   Rosenzweig, Sergio D.
   Bishop, Kevin
   Barron, Karyl S.
   Kuehn, Hye Sun
   Hoffmann, Patrycja
   Negro, Alejandra
   Tsai, Wanxia L.
   Cowen, Edward W.
   Pei, Wuhong
   Milner, Joshua D.
   Silvin, Christopher
   Heller, Theo
   Chin, David T.
   Patronas, Nicholas J.
   Barber, John S.
   Lee, Chyi-Chia R.
   Wood, Geryl M.
   Ling, Alexander
   Kelly, Susan J.
   Kleiner, David E.
   Mullikin, James C.
   Ganson, Nancy J.
   Kong, Heidi H.
   Hambleton, Sophie
   Candotti, Fabio
   Quezado, Martha M.
   Calvo, Katherine R.
   Alao, Hawwa
   Barham, Beverly K.
   Jones, Anne
   Meschia, James F.
   Worrall, Bradford B.
   Kasner, Scott E.
   Rich, Stephen S.
   Goldbach-Mansky, Raphaela
   Abinun, Mario
   Chalom, Elizabeth
   Gotte, Alisa C.
   Punaro, Marilynn
   Pascual, Virginia
   Verbsky, James W.
   Torgerson, Troy R.
   Singer, Nora G.
   Gershon, Timothy R.
   Ozen, Seza
   Karadag, Omer
   Fleisher, Thomas A.
   Remmers, Elaine F.
   Burgess, Shawn M.
   Moir, Susan L.
   Gadina, Massimo
   Sood, Raman
   Hershfield, Michael S.
   Boehm, Manfred
   Kastner, Daniel L.
   Aksentijevich, Ivona
TI Early- Onset Stroke and Vasculopathy Associated with Mutations in ADA2
SO NEW ENGLAND JOURNAL OF MEDICINE
LA English
DT Article
ID AICARDI-GOUTIERES SYNDROME; ADENOSINE-DEAMINASE 2; GROWTH-FACTOR;
   MACROPHAGES; MONOCYTES
AB BackgroundWe observed a syndrome of intermittent fevers, early-onset lacunar strokes and other neurovascular manifestations, livedoid rash, hepatosplenomegaly, and systemic vasculopathy in three unrelated patients. We suspected a genetic cause because the disorder presented in early childhood.
   MethodsWe performed whole-exome sequencing in the initial three patients and their unaffected parents and candidate-gene sequencing in three patients with a similar phenotype, as well as two young siblings with polyarteritis nodosa and one patient with small-vessel vasculitis. Enzyme assays, immunoblotting, immunohistochemical testing, flow cytometry, and cytokine profiling were performed on samples from the patients. To study protein function, we used morpholino-mediated knockdowns in zebrafish and short hairpin RNA knockdowns in U937 cells cultured with human dermal endothelial cells.
   ResultsAll nine patients carried recessively inherited mutations in CECR1 (cat eye syndrome chromosome region, candidate 1), encoding adenosine deaminase 2 (ADA2), that were predicted to be deleterious; these mutations were rare or absent in healthy controls. Six patients were compound heterozygous for eight CECR1 mutations, whereas the three patients with polyarteritis nodosa or small-vessel vasculitis were homozygous for the p.Gly47Arg mutation. Patients had a marked reduction in the levels of ADA2 and ADA2-specific enzyme activity in the blood. Skin, liver, and brain biopsies revealed vasculopathic changes characterized by compromised endothelial integrity, endothelial cellular activation, and inflammation. Knockdown of a zebrafish ADA2 homologue caused intracranial hemorrhages and neutropenia phenotypes that were prevented by coinjection with nonmutated (but not with mutated) human CECR1. Monocytes from patients induced damage in cocultured endothelial-cell layers.
   ConclusionsLoss-of-function mutations in CECR1 were associated with a spectrum of vascular and inflammatory phenotypes, ranging from early-onset recurrent stroke to systemic vasculopathy or vasculitis. (Funded by the National Institutes of Health Intramural Research Programs and others.)
   Adenosine deaminase 2 (ADA2) is an enzyme involved in purine metabolism and a growth factor that influences the development of endothelial cells and leukocytes. This study shows that defects in ADA2 cause recurrent fevers, vascular pathologic features, and mild immunodeficiency. Patients with autoinflammatory disease sometimes present with clinical findings that encompass multiple organ systems.(1) Three unrelated children presented to the National Institutes of Health (NIH) Clinical Center with intermittent fevers, recurrent lacunar strokes, elevated levels of acute-phase reactants, livedoid rash, hepatosplenomegaly, and hypogammaglobulinemia. Collectively, these findings do not easily fit with any of the known inherited autoinflammatory diseases. Hereditary or acquired vascular disorders can have protean manifestations yet be caused by mutations in a single gene. Diseases such as the Aicardi-Goutieres syndrome,(2),(3) polypoidal choroidal vasculopathy,(4) sickle cell anemia,(5) livedoid vasculopathy,(6) and the small-vessel vasculitides(7),(8) are examples of systemic ...
C1 [Zhou, Qing; Ombrello, Amanda K.; Toro, Camilo; Stone, Deborah L.; Chae, Jae Jin; Bishop, Kevin; Hoffmann, Patrycja; Pei, Wuhong; Silvin, Christopher; Chin, David T.; Wood, Geryl M.; Mullikin, James C.; Candotti, Fabio; Barham, Beverly K.; Jones, Anne; Remmers, Elaine F.; Burgess, Shawn M.; Sood, Raman; Kastner, Daniel L.; Aksentijevich, Ivona] NHGRI, Bethesda, MD 20892 USA.
   [Yang, Dan; Negro, Alejandra; Boehm, Manfred] NHLBI, Bethesda, MD 20892 USA.
   [Rosenzweig, Sergio D.; Barron, Karyl S.; Milner, Joshua D.; Barber, John S.; Moir, Susan L.] NIAID, Bethesda, MD 20892 USA.
   [Kuehn, Hye Sun; Patronas, Nicholas J.; Ling, Alexander; Calvo, Katherine R.; Fleisher, Thomas A.] NIH, Ctr Clin, Bethesda, MD 20892 USA.
   [Tsai, Wanxia L.; Goldbach-Mansky, Raphaela; Gadina, Massimo] NIAMSD, Bethesda, MD 20892 USA.
   [Cowen, Edward W.; Lee, Chyi-Chia R.; Kleiner, David E.; Kong, Heidi H.; Quezado, Martha M.] NCI, Bethesda, MD 20892 USA.
   [Heller, Theo; Alao, Hawwa] NIDDK, Bethesda, MD 20892 USA.
   [Zavialov, Andrey V.; Zavialov, Anton V.] Univ Turku, Turku, Finland.
   [Kelly, Susan J.; Ganson, Nancy J.; Hershfield, Michael S.] Duke Univ Med Ctr, Durham, NC USA.
   [Gershon, Timothy R.] Univ N Carolina Neurosci Ctr, Chapel Hill, NC USA.
   [Hambleton, Sophie; Abinun, Mario] Newcastle Univ, Inst Cellular Med, Newcastle Upon Tyne, Tyne & Wear, England.
   [Meschia, James F.] Mayo Clin Florida, Jacksonville, FL USA.
   [Worrall, Bradford B.; Rich, Stephen S.] Univ Virginia, Charlottesville, VA USA.
   [Kasner, Scott E.] Univ Penn, Philadelphia, PA 19104 USA.
   [Chalom, Elizabeth] Barnabas Hlth, W Orange, NJ USA.
   [Gotte, Alisa C.; Punaro, Marilynn] Texas Scottish Rite Hosp Crippled Children, Dallas, TX USA.
   [Pascual, Virginia] Baylor Inst Immunol Res, Dallas, TX USA.
   [Verbsky, James W.] Med Coll Wisconsin, Milwaukee, WI 53226 USA.
   [Torgerson, Troy R.] Univ Washington, Seattle, WA 98195 USA.
   [Torgerson, Troy R.] Seattle Childrens Res Inst, Seattle, WA 98195 USA.
   [Singer, Nora G.] Metro Hlth Med Ctr, Cleveland, OH USA.
   [Singer, Nora G.] Case Western Reserve Univ, Sch Med, Cleveland, OH USA.
   [Ozen, Seza; Karadag, Omer] Hacettepe Univ, Fac Med, TR-06100 Ankara, Turkey.
C3 National Institutes of Health (NIH) - USA; NIH National Human Genome
   Research Institute (NHGRI); National Institutes of Health (NIH) - USA;
   NIH National Heart Lung & Blood Institute (NHLBI); National Institutes
   of Health (NIH) - USA; NIH National Institute of Allergy & Infectious
   Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH
   Clinical Center (CC); National Institutes of Health (NIH) - USA; NIH
   National Institute of Arthritis & Musculoskeletal & Skin Diseases
   (NIAMS); National Institutes of Health (NIH) - USA; NIH National Cancer
   Institute (NCI); National Institutes of Health (NIH) - USA; NIH National
   Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); University
   of Turku; Duke University; University of North Carolina; University of
   North Carolina Chapel Hill; Newcastle University - UK; Mayo Clinic;
   University of Virginia; University of Pennsylvania; Texas Scottish Rite
   Hospital for Children; Baylor Scott & White Health; Medical College of
   Wisconsin; University of Washington; University of Washington Seattle;
   Seattle Children's Hospital; MetroHealth System; Case Western Reserve
   University; Hacettepe University
RP Aksentijevich, I (通讯作者)，NHGRI, NIH, Bldg 10, Bethesda, MD 20892 USA.
EM askentii@exchange.nih.gov; askentii@exchange.nih.gov
RI Karadag, Omer/AAR-4219-2020; Goldbach-Mansky, Raphaela/N-5917-2017;
   Aksentijevich, Ivona/AAF-1335-2019; OZEN, SEZA/I-9096-2013; Gadina,
   Massimo/R-4195-2019; Kong, Heidi H/L-4856-2018; Zavialov, Anton
   V./C-7664-2015; Gershon, Timothy/H-5398-2019; Lee, Chyi-Chia
   Richard/AAO-1149-2020; Karadag, Omer/AAD-5448-2019; Karadag,
   Omer/I-9042-2013; Kleiner, David E/N-2770-2013; Meschia,
   James/GPP-1636-2022; Moir, Susan/AAC-3676-2020; Pascual,
   Virginia/ABD-3099-2020; Yu, Xiaomin/I-6407-2016; Lee,
   Chyi-Chia/I-1938-2013
OI Karadag, Omer/0000-0002-3443-3117; Kong, Heidi H/0000-0003-4424-064X;
   Zavialov, Anton V./0000-0001-6191-5931; Gershon,
   Timothy/0000-0001-7034-6400; Karadag, Omer/0000-0002-3443-3117; Kleiner,
   David E/0000-0003-3442-4453; Meschia, James/0000-0002-4475-8142; Singer,
   Nora/0000-0001-7041-723X; Lee, Chyi-Chia/0000-0002-5306-7781; Rich,
   Stephen/0000-0003-3872-7793; Remmers, Elaine F/0000-0002-9522-1249;
   Calvo, Katherine/0000-0002-0771-4191; Heller, Theo/0000-0002-2643-6289;
   Candotti, Fabio/0000-0001-6399-6042; Ombrello,
   Amanda/0000-0001-5563-9416; Dichgans, Martin/0000-0002-0654-387X;
   Zavialov, Andrey/0000-0001-6420-0368
FU National Institutes of Health (NIH) Intramural Research Programs;
   National Human Genome Research Institute; National Institute of
   Arthritis and Musculoskeletal and Skin Diseases; National Heart, Lung,
   and Blood Institute (NHLBI); National Institute of Allergy and
   Infectious Diseases; National Institute of Diabetes and Digestive and
   Kidney Diseases; National Cancer Institute; Undiagnosed Diseases Program
   of the Common Fund of the Office of the Director of the NIH; NIH
   Clinical Center; Sigma Tau Pharmaceuticals; Finnish Academy; NATIONAL
   CANCER INSTITUTE [ZIDBC011317, ZICBC010687] Funding Source: NIH
   RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [ZIAHL006079,
   ZIAHL006077] Funding Source: NIH RePORTER; NATIONAL HUMAN GENOME
   RESEARCH INSTITUTE [ZIAHG200372, ZIAHG200392, ZIBHG000196] Funding
   Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS
   DISEASES [ZIAAI001122, ZIAAI001183, ZIAAI000825] Funding Source: NIH
   RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN
   DISEASES [ZICAR041181, ZIDAR041180, ZIHAR041173] Funding Source: NIH
   RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY
   DISEASES [ZIADK075008] Funding Source: NIH RePORTER; CLINICAL CENTER
   [ZIACL010304, ZIACL090025, ZIACL010346] Funding Source: NIH RePORTER;
   The Sir Jules Thorn Charitable Trust [12JTA] Funding Source:
   researchfish
FX Supported by the National Institutes of Health (NIH) Intramural Research
   Programs, including the Intramural Research Programs of the National
   Human Genome Research Institute, the National Institute of Arthritis and
   Musculoskeletal and Skin Diseases, the National Heart, Lung, and Blood
   Institute (NHLBI), the National Institute of Allergy and Infectious
   Diseases, the National Institute of Diabetes and Digestive and Kidney
   Diseases, the National Cancer Institute, the Undiagnosed Diseases
   Program of the Common Fund of the Office of the Director of the NIH, and
   the NIH Clinical Center; and by grants from Sigma Tau Pharmaceuticals
   (to Dr. Hershfield) and the Finnish Academy (to Drs. Andrey and Anton
   Zavialov).
CR ADAMS HP, 1993, STROKE, V24, P35, DOI 10.1161/01.STR.24.1.35
   Butler MG, 2011, METHOD CELL BIOL, V105, P137, DOI 10.1016/B978-0-12-381320-6.00006-0
   Cassani B, 2008, BLOOD, V111, P4209, DOI 10.1182/blood-2007-05-092429
   Chen CJ, 2013, NEW ENGL J MED, V368, P1260, DOI 10.1056/NEJMc1300259
   Crow YJ, 2009, HUM MOL GENET, V18, pR130, DOI 10.1093/hmg/ddp293
   du Moulin M, 2011, P NATL ACAD SCI USA, V108, pE232, DOI 10.1073/pnas.1104699108
   Elkan PN, 2014, NEW ENGL J MED, V370, P921, DOI 10.1056/NEJMoa1307362
   Federico A, 2012, J NEUROL SCI, V322, P25, DOI 10.1016/j.jns.2012.07.041
   Frances C, 1999, MEDICINE, V78, P209, DOI 10.1097/00005792-199907000-00001
   Hershfield M, 2004, IMMUNOLOGIC DISORDER, P480
   Iijima R, 2008, J BIOL CHEM, V283, P2255, DOI 10.1074/jbc.M709279200
   Kastner DL, 2010, CELL, V140, P784, DOI 10.1016/j.cell.2010.03.002
   Kato Gregory J, 2009, Am J Hematol, V84, P618, DOI 10.1002/ajh.21475
   Khenifer S, 2010, CLIN EXP DERMATOL, V35, P693, DOI 10.1111/j.1365-2230.2009.03732.x
   Lima LH, 2010, OPHTHALMOLOGY, V117, P1567, DOI 10.1016/j.ophtha.2009.12.018
   Maier SA, 2001, GENE, V280, P27, DOI 10.1016/S0378-1119(01)00762-4
   Meschia James F, 2002, BMC Med Genet, V3, P1, DOI 10.1186/1471-2350-3-1
   Moore KJ, 2011, CELL, V145, P341, DOI 10.1016/j.cell.2011.04.005
   Rey-Giraud F, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042656
   Rost NS, 2010, NEUROLOGY, V75, P1670, DOI 10.1212/WNL.0b013e3181fc279a
   Talarico R, 2012, CLIN EXP RHEUMATOL, V30, pS130
   Wardlaw JM, 2013, LANCET NEUROL, V12, P483, DOI 10.1016/S1474-4422(13)70060-7
   Woollard KJ, 2010, NAT REV CARDIOL, V7, P77, DOI 10.1038/nrcardio.2009.228
   Zavialov AV, 2010, J LEUKOCYTE BIOL, V88, P279, DOI 10.1189/jlb.1109764
   Zavialov AV, 2010, J BIOL CHEM, V285, P12367, DOI 10.1074/jbc.M109.083527
NR 25
TC 473
Z9 490
U1 5
U2 70
PU MASSACHUSETTS MEDICAL SOC
PI WALTHAM
PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA
SN 0028-4793
EI 1533-4406
J9 NEW ENGL J MED
JI N. Engl. J. Med.
PD MAR 6
PY 2014
VL 370
IS 10
BP 911
EP 920
DI 10.1056/NEJMoa1307361
PG 10
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA AC2EB
UT WOS:000332309800008
PM 24552284
OA Green Published, Green Accepted
HC Y
HP N
DA 2022-11-30
ER

PT J
AU Xie, SQ
   Fang, YX
   Du, R
   Onishi, Y
   Yokoi, T
   Moriyama, M
   Watanabe, T
   Ohno-Matsui, K
AF Xie, Shiqi
   Fang, Yuxin
   Du, Ran
   Onishi, Yuka
   Yokoi, Tae
   Moriyama, Muka
   Watanabe, Takashi
   Ohno-Matsui, Kyoko
TI ROLE OF DILATED SUBFOVEAL CHOROIDAL VEINS IN EYES WITH MYOPIC MACULAR
   NEOVASCULARIZATION
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE dilated choroidal veins; indocyanine green angiography; laminar flow;
   myopic macular neovascularization; pathologic myopia; posterior
   staphyloma; short posterior ciliary artery; vortex vein
ID PATHOLOGICAL MYOPIA; POSTERIOR STAPHYLOMAS; ADULT-POPULATION; VORTEX
   VEINS; LOW-VISION; EPIDEMIOLOGY; PREVALENCE; BLINDNESS; VESSELS; SHAPE
AB Purpose: To investigate the dilated choroidal veins (DCVs) at or around myopic macular neovascularizations (MNVs) and to determine whether there is a hemodynamic relationship between them. Methods: Fifty-eight eyes of 57 patients with myopic MNVs were examined. Dilated choroidal veins were defined as choroidal veins whose diameter was 2X larger than adjacent veins. Indocyanine green angiography and swept-source optical coherence tomography images were reviewed to detect DCVs that crossed the subfoveal area. The filling sequence of the DCVs and MNVs was determined. Results: Patients' mean age was 71.4 +/- 10.6 years. The mean axial length was 29.3 +/- 1.8 mm. Dilated choroidal veins below or around the MNV were found in 17 eyes (29.3%). Emissaries of the short posterior ciliary arteries were seen at or around MNVs in 8 of the 17 eyes. In these eyes, the short posterior ciliary artery was filled first or almost simultaneously with the filling of the MNV, followed by a laminar filling of the DCVs. In one eye, afferent arterioles from the short posterior ciliary arteries and efferent venules connected to DCVs were seen. Conclusion: Dilated choroidal veins are present below or around MNVs in about 30% of eyes with myopic MNVs. Our findings suggest that an MNV might be a vascular unit consisting of short posterior ciliary arteries, afferent arterioles, efferent venules, and DCVs.
C1 [Xie, Shiqi; Fang, Yuxin; Du, Ran; Onishi, Yuka; Yokoi, Tae; Moriyama, Muka; Watanabe, Takashi; Ohno-Matsui, Kyoko] Tokyo Med & Dent Univ, Dept Ophthalmol & Visual Sci, Tokyo, Japan.
C3 Tokyo Medical & Dental University (TMDU)
RP Ohno-Matsui, K (通讯作者)，Tokyo Med & Dent Univ, Dept Ophthalmol & Visual Sci, Bunkyo Ku, 1-5-45 Yushima, Tokyo 1138510, Japan.
EM k.ohno.oph@tmd.ac.jp
OI Ran, DU/0000-0002-8916-775X; Xie, Shiqi/0000-0002-6474-6712
FU Japanese Society for Promotion of Science [19H03808]
FX Supported by grants from the Japanese Society for Promotion of Science
   (number 19H03808).
CR Cheung CMG, 2017, OPHTHALMOLOGY, V124, P1690, DOI 10.1016/j.ophtha.2017.04.028
   Giuffre C, 2017, EUR J OPHTHALMOL, V27, pE39, DOI 10.5301/ejo.5000875
   Ishida T, 2019, BRIT J OPHTHALMOL, V103, P457, DOI 10.1136/bjophthalmol-2018-312015
   Iwase A, 2006, OPHTHALMOLOGY, V113, P1354, DOI 10.1016/j.ophtha.2006.04.022
   Liang YB, 2008, OPHTHALMOLOGY, V115, P1965, DOI 10.1016/j.ophtha.2008.05.030
   Matsumoto H, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-51268-9
   Moriyama M, 2007, OPHTHALMOLOGY, V114, P1755, DOI 10.1016/j.ophtha.2006.11.034
   Moriyama M, 2017, BRIT J OPHTHALMOL, V101, P1179, DOI 10.1136/bjophthalmol-2016-309877
   OHKUMA H, 1983, INVEST OPHTH VIS SCI, V24, P481
   Ohno-Matsui K, 2003, BRIT J OPHTHALMOL, V87, P570, DOI 10.1136/bjo.87.5.570
   Ohno-Matsui K, 2018, PROG RETIN EYE RES, V63, P92, DOI 10.1016/j.preteyeres.2017.10.005
   Ohno-Matsui K, 2016, PROG RETIN EYE RES, V52, P156, DOI 10.1016/j.preteyeres.2015.12.001
   Ohno-Matsui K, 2014, OPHTHALMOLOGY, V121, P1798, DOI 10.1016/j.ophtha.2014.03.035
   Ohno-Matsui K, 2012, INVEST OPHTH VIS SCI, V53, P6046, DOI 10.1167/iovs.12-10161
   OhnoMatsui K, 1996, RETINA-J RET VIT DIS, V16, P419, DOI 10.1097/00006982-199616050-00009
   OhnoMatsui K, 1997, AM J OPHTHALMOL, V123, P494, DOI 10.1016/S0002-9394(14)70175-8
   Pedinielli A, 2013, INVEST OPHTH VIS SCI, V54, P7637, DOI 10.1167/iovs.13-12981
   Shinohara K, 2017, INVEST OPHTH VIS SCI, V58, P3750, DOI 10.1167/iovs.17-22319
   Wong TY, 2014, AM J OPHTHALMOL, V157, P9, DOI 10.1016/j.ajo.2013.08.010
   Wong YL, 2016, ASIA-PAC J OPHTHALMO, V5, P394, DOI 10.1097/APO.0000000000000234
   Xu L, 2006, OPHTHALMOLOGY, V113, P1134, DOI 10.1016/j.ophtha.2006.01.035
   Yoshida T, 2003, OPHTHALMOLOGY, V110, P1297, DOI 10.1016/S0161-6420(03)00461-5
NR 22
TC 4
Z9 4
U1 1
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD MAY
PY 2021
VL 41
IS 5
BP 1063
EP 1070
DI 10.1097/IAE.0000000000002970
PG 8
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA SO2UF
UT WOS:000658831500024
PM 32881785
DA 2022-11-30
ER

PT J
AU Amoaku, WM
   Chakravarthy, U
   Gale, R
   Gavin, M
   Ghanchi, F
   Gibson, J
   Harding, S
   Johnston, RL
   Kelly, S
   Lotery, A
   Mahmood, S
   Menon, G
   Sivaprasad, S
   Talks, J
   Tufail, A
   Yang, Y
AF Amoaku, W. M.
   Chakravarthy, U.
   Gale, R.
   Gavin, M.
   Ghanchi, F.
   Gibson, J.
   Harding, S.
   Johnston, R. L.
   Kelly, S.
   Lotery, A.
   Mahmood, S.
   Menon, G.
   Sivaprasad, S.
   Talks, J.
   Tufail, A.
   Yang, Y.
TI Defining response to anti-VEGF therapies in neovascular AMD
SO EYE
LA English
DT Article
ID ENDOTHELIAL GROWTH-FACTOR; VERTEPORFIN PHOTODYNAMIC THERAPY; MACULAR
   DEGENERATION; INTRAVITREAL AFLIBERCEPT; RANIBIZUMAB TREATMENT; EXUDATIVE
   AMD; VISUAL-ACUITY; 2.0 MG; BEVACIZUMAB; TACHYPHYLAXIS
AB The introduction of anti-vascular endothelial growth factor (anti-VEGF) has made significant impact on the reduction of the visual loss due to neovascular age-related macular degeneration (n-AMD). There are significant inter-individual differences in response to an anti-VEGF agent, made more complex by the availability of multiple anti-VEGF agents with different molecular configurations. The response to anti-VEGF therapy have been found to be dependent on a variety of factors including patient's age, lesion characteristics, lesion duration, baseline visual acuity (VA) and the presence of particular genotype risk alleles. Furthermore, a proportion of eyes with n-AMD show a decline in acuity or morphology, despite therapy or require very frequent re-treatment. There is currently no consensus as to how to classify optimal response, or lack of it, with these therapies. There is, in particular, confusion over terms such as 'responder status' after treatment for n-AMD, 'tachyphylaxis' and 'recalcitrant' n-AMD. This document aims to provide a consensus on definition/categorisation of the response of n-AMD to anti-VEGF therapies and on the time points at which response to treatment should be determined. Primary response is best determined at 1 month following the last initiation dose, while maintained treatment (secondary) response is determined any time after the 4th visit. In a particular eye, secondary responses do not mirror and cannot be predicted from that in the primary phase. Morphological and functional responses to anti-VEGF treatments, do not necessarily correlate, and may be dissociated in an individual eye. Furthermore, there is a ceiling effect that can negate the currently used functional metrics such as >5 letters improvement when the baseline VA is good (ETDRS > 70 letters). It is therefore important to use a combination of both the parameters in determining the response. The following are proposed definitions: optimal (good) response is defined as when there is resolution of fluid (intraretinal fluid; IRF, subretinal fluid; SRF and retinal thickening), and/or improvement of >5 letters, subject to the ceiling effect of good starting VA. Poor response is defined as <25% reduction from the baseline in the central retinal thickness (CRT), with persistent or new IRF, SRF or minimal or change in VA (that is, change in VA of 0+4 letters). Non-response is defined as an increase in fluid (IRF, SRF and CRT), or increasing haemorrhage compared with the baseline and/or loss of >5 letters compared with the baseline or best corrected vision subsequently. Poor or non-response to anti-VEGF may be due to clinical factors including suboptimal dosing than that required by a particular patient, increased dosing intervals, treatment initiation when disease is already at an advanced or chronic stage), cellular mechanisms, lesion type, genetic variation and potential tachyphylaxis); non-clinical factors including poor access to clinics or delayed appointments may also result in poor treatment outcomes. In eyes classified as good responders, treatment should be continued with the same agent when disease activity is present or reactivation occurs following temporary dose holding. In eyes that show partial response, treatment may be continued, although re-evaluation with further imaging may be required to exclude confounding factors.
   Where there is persistent, unchanging accumulated fluid following three consecutive injections at monthly intervals, treatment may be withheld temporarily, but recommenced with the same or alternative anti-VEGF if the fluid subsequently increases (lesion considered active). Poor or non-response to anti-VEGF treatments requires re-evaluation of diagnosis and if necessary switch to alternative therapies including other anti-VEGF agents and/or with photodynamic therapy (PDT). Idiopathic polypoidal choroidopathy may require treatment with PDT monotherapy or combination with anti-VEGF. A committee comprised of retinal specialists with experience of managing patients with n-AMD similar to that which developed the Royal College of Ophthalmologists Guidelines to Ranibizumab was assembled. Individual aspects of the guidelines were proposed by the committee lead (WMA) based on relevant reference to published evidence base following a search of Medline and circulated to all committee members for discussion before approval or modification. Each draft was modified according to feedback from committee members until unanimous approval was obtained in the final draft. A system for categorising the range of responsiveness of n-AMD lesions to anti-VEGF therapy is proposed. The proposal is based primarily on morphological criteria but functional criteria have been included. Recommendations have been made on when to consider discontinuation of therapy either because of success or futility. These guidelines should help clinical decision-making and may prevent over and/or undertreatment with anti-VEGF therapy.
C1 [Amoaku, W. M.] Univ Nottingham, Nottingham Univ Hosp NHS Trust, Dept Ophthalmol Acad Ophthalmol, Div Clin Neurosci, Nottingham NG7 2UH, England.
   [Chakravarthy, U.] Queens Univ Belfast, Dept Ophthalmol, Belfast, Antrim, North Ireland.
   [Chakravarthy, U.] Royal Victoria Hosp Trust,Belfast, Belfast, Antrim, North Ireland.
   [Gale, R.] York Teaching Hosp NHS Fdn Trust, Dept Ophthalmol, York, N Yorkshire, England.
   [Gavin, M.] Gartnavel Hosp, NHSGG, Dept Ophthalmol, Glasgow, Lanark, Scotland.
   [Ghanchi, F.] Bradford Teaching Hosp Fdn Trust, Dept Ophthalmol, Bradford, W Yorkshire, England.
   [Gibson, J.] Aston Univ, Sch Life & Hlth Sci, Dept Ophthalmol, Birmingham B4 7ET, W Midlands, England.
   [Gibson, J.] Heart England NHS Fdn Trust, Birmingham B4 7ET, W Midlands, England.
   [Gibson, J.] Birmingham & Midland Eye Ctr Birmingham, Birmingham, W Midlands, England.
   [Harding, S.] Univ Liverpool, Dept Ophthalmol, Liverpool L69 3BX, Merseyside, England.
   [Harding, S.] Royal Liverpool Univ Hosp, Liverpool L69 3BX, Merseyside, England.
   [Johnston, R. L.] Gloucestershire Hosp NHS Fdn Trust, Dept Ophthalmol, Gloucester, England.
   [Kelly, S.] Royal Bolton Hosp, Dept Ophthalmol, Bolton, England.
   [Lotery, A.] Univ Southampton, Fac Med, Dept Ophthalmol Clin & Expt Sci, Southampton SO9 5NH, Hants, England.
   [Mahmood, S.] Manchester Royal Eye Hosp, Cent Manchester Hosp Fdn Trust, Dept Ophthalmol, Manchester M13 9WH, Lancs, England.
   [Menon, G.] Frimley Pk Hosp NHS Fdn Trust, Dept Ophthalmol, Frimley, Surrey, England.
   [Sivaprasad, S.] Kings Coll Hosp NHS Fdn Trust, NIHR Moorfields Biomed Res Ctr, Dept Ophthalmol, London, England.
   [Talks, J.] Newcastle Univ Hosp NHS Trust, Dept Ophthalmol, Newcastle Upon Tyne, Tyne & Wear, England.
   [Tufail, A.] Moorfields Hosp NHS Trust, Dept Ophthalmol, London, England.
   [Yang, Y.] New Cross Hosp, Royal Wolverhampton NHS Trust, Dept Ophthalmol, Wolverhampton, England.
C3 Nottingham University Hospital NHS Trust; University of Nottingham;
   Queens University Belfast; Aston University; Heart of England NHS
   Foundation Trust; University of Liverpool; Royal Liverpool & Broadgreen
   University Hospitals NHS Trust; Royal Liverpool University Hospital;
   University of Liverpool; Gloucestershire Hospitals NHS Foundation Trust;
   Royal Bolton Hospital; University of Southampton; Manchester Royal Eye
   Hospital; King's College Hospital NHS Foundation Trust; Newcastle Upon
   Tyne Hospitals NHS Foundation Trust; New Cross Hospital
RP Amoaku, WM (通讯作者)，Univ Nottingham, Nottingham Univ Hosp NHS Trust, Dept Ophthalmol Acad Ophthalmol, Div Clin Neurosci, B Floor,Eye & ENT Bldg,Queens Med Ctr, Nottingham NG7 2UH, England.
EM winfried.amoaku@nottingham.ac.uk
RI Sivaprasad, S./D-6876-2015; Mahmood, Sajjad/AAK-7645-2021
OI Sivaprasad, S./0000-0001-8952-0659; Chakravarthy,
   Usha/0000-0002-2606-3734; Tufail, Adnan/0000-0001-6131-7640; Gibson,
   Jonathan M/0000-0002-9281-5244; Lotery, Andrew/0000-0001-5541-4305;
   Amoaku, Winfried/0000-0001-5028-7984; Ghanchi,
   Faruque/0000-0002-4448-8162
FU Allergan; Bayer; Novartis; Pfizer; CentreVue (Italy)
FX WA has provided consultancy services to Alcon, Allergan, Bayer, Novartis
   and Thrombogenics. He has received travel grants from Allergan, Bayer
   and Novartis, and honoraria for lectures from Allergan and Novartis. He
   has participated in clinical trials for which his institution has
   received funding from Allergan, Novartis and Pfizer. His institution has
   further received research grants from Allergan and Novartis for
   non-clinical studies, and CentreVue (Italy) for clinical studies. The
   remaining authors declare no conflict of interest.
CR Almony A, 2011, CAN J OPHTHALMOL, V46, P182, DOI 10.3129/i10-095
   Amoaku W, 2009, EYE, V23, P2140, DOI 10.1038/eye.2008.241
   Amoaku WM, 2013, DURABILITY VISUAL AC
   Arias L, 2009, EYE, V23, P326, DOI 10.1038/sj.eye.6703053
   Avgikos KN, 2009, OPHTHALMOLOGY, V116, P1831, DOI 10.1016/j.ophtha.2009.03.040
   Awad M, 2013, EARLY VISUAL ACUITY
   Bakall B, 2013, AM J OPHTHALMOL, V156, P15, DOI 10.1016/j.ajo.2013.02.017
   Batchelor TT, 2007, CANCER CELL, V11, P83, DOI 10.1016/j.ccr.2006.11.021
   Bloch SB, 2012, AM J OPHTHALMOL, V153, P209, DOI 10.1016/j.ajo.2011.10.016
   Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655
   Brown DM, 2013, OPHTHALMOLOGY, V120, P349, DOI 10.1016/j.ophtha.2012.08.008
   Brown DM, 2009, OPHTHALMOLOGY, V116, P57, DOI 10.1016/j.ophtha.2008.10.018
   Brown SM, 2004, AM J OPHTHALMOL, V138, P149, DOI 10.1016/j.ajo.2004.02.017
   Casanovas O, 2005, CANCER CELL, V8, P299, DOI 10.1016/j.ccr.2005.09.005
   Chakravarthy U, 2013, EYE, V27, P1429, DOI 10.1038/eye.2013.233
   Chakravarthy U, 2010, BMC OPHTHALMOL, V10, DOI 10.1186/1471-2415-10-31
   Cho H, 2013, BRIT J OPHTHALMOL, V97, P1032, DOI 10.1136/bjophthalmol-2013-303344
   Cohen SY, 2013, GRAEF ARCH CLIN EXP, V251, P2499, DOI 10.1007/s00417-013-2338-z
   Dias JRD, 2011, BRIT J OPHTHALMOL, V95, P1631, DOI 10.1136/bjo.2010.186361
   Dreyer R, 2013, INVEST OPHTH VIS SCI, V54
   Eghoj MS, 2012, BRIT J OPHTHALMOL, V96, P21, DOI 10.1136/bjo.2011.203893
   Ehlken C, 2014, EYE, V28, P538, DOI 10.1038/eye.2014.64
   Ellis LM, 2008, CLIN CANCER RES, V14, P6371, DOI 10.1158/1078-0432.CCR-07-5287
   Falavarjani KG, 2009, OPHTHALMOLOGY, V116, P1016, DOI 10.1016/j.ophtha.2009.01.029
   Forooghian F, 2009, RETINA-J RET VIT DIS, V29, P723, DOI 10.1097/IAE.0b013e3181a2c1c3
   Francis Peter James, 2011, Trans Am Ophthalmol Soc, V109, P115
   Frank RN, 1996, AM J OPHTHALMOL, V122, P393, DOI 10.1016/S0002-9394(14)72066-5
   Frank RN, 1997, OPHTHALMIC RES, V31, P243
   Fung AT, 2012, EYE, V26, P1181, DOI 10.1038/eye.2012.174
   Gasperini JL, 2012, BRIT J OPHTHALMOL, V96, P14, DOI 10.1136/bjo.2011.204685
   Gupta OP, 2010, OPHTHALMOLOGY, V117, P2134, DOI 10.1016/j.ophtha.2010.02.032
   Hageman GS, 2014, GENETICS AM IN PRESS
   Hagstrom SA, 2013, OPHTHALMOLOGY, V120, P593, DOI 10.1016/j.ophtha.2012.11.037
   Haller JA, 2013, OPHTHALMOLOGY, V120, pS3, DOI 10.1016/j.ophtha.2013.01.057
   Hariprasad SM, 2012, J OPHTHALMOL, V2012, DOI 10.1155/2012/690641
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Hoffman B.B., 2001, GOODMAN GILMANS PHAR, P115
   Holz FG, 2011, OPHTHALMOLOGY, V118, P663, DOI 10.1016/j.ophtha.2010.12.019
   Holz FG, 2010, INVEST OPHTH VIS SCI, V51, P405, DOI 10.1167/iovs.09-3813
   Jaffe GJ, 2013, OPHTHALMOLOGY, V120, P1860, DOI 10.1016/j.ophtha.2013.01.073
   Kaiser PK, 2007, AM J OPHTHALMOL, V144, P850, DOI 10.1016/j.ajo.2007.08.012
   Keane PA, 2008, INVEST OPHTH VIS SCI, V49, P3115, DOI 10.1167/iovs.08-1689
   Keenan TDL, 2013, BRIT J OPHTHALMOL, V97, P1168, DOI 10.1136/bjophthalmol-2013-303233
   Kelly SP, 2011, EYE, V25, P710, DOI 10.1038/eye.2011.89
   Kitchens JW, 2013, CLIN OPHTHALMOL, V7, P1987, DOI 10.2147/OPTH.S39635
   Koh A, 2012, RETINA-J RET VIT DIS, V32, P1453, DOI 10.1097/IAE.0b013e31824f91e8
   Koh AHC, 2013, RETINA-J RET VIT DIS, V33, P686, DOI 10.1097/IAE.0b013e3182852446
   Krebs I, 2013, BRIT J OPHTHALMOL, V97, P1443, DOI 10.1136/bjophthalmol-2013-303513
   Kumar N, 2013, RETINA-J RET VIT DIS, V33, P1605, DOI 10.1097/IAE.0b013e31828e8551
   Lim JH, 2012, AM J OPHTHALMOL, V153, P678, DOI 10.1016/j.ajo.2011.09.013
   Lotery AJ, 2013, OPHTHALMOLOGY, V120, P2637, DOI 10.1016/j.ophtha.2013.07.046
   Matthe E, 2011, OPHTHALMOLOGE, V108, P237, DOI 10.1007/s00347-010-2282-9
   Mitchell P, 2010, BRIT J OPHTHALMOL, V94, P2, DOI 10.1136/bjo.2009.159160
   Muether PS, 2011, GRAEF ARCH CLIN EXP, V249, P633, DOI 10.1007/s00417-010-1520-9
   Oliver-Fernandez M, 2005, CAN J OPHTHALMOL, V40, P313, DOI 10.1016/S0008-4182(05)80074-2
   Oubraham H, 2011, RETINA-J RET VIT DIS, V31, P26, DOI 10.1097/IAE.0b013e3181de5609
   Pauleikhoff D, 2011, GRAEF ARCH CLIN EXP, V249, P631, DOI 10.1007/s00417-011-1639-3
   Rasmussen A, 2013, OPHTHALMOLOGY, V120, P2630, DOI 10.1016/j.ophtha.2013.05.018
   Regillo CD, 2008, AM J OPHTHALMOL, V145, P239, DOI 10.1016/j.ajo.2007.10.004
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Rostron E, 2012, EYE, V26, P933, DOI 10.1038/eye.2012.61
   Schaal S, 2008, OPHTHALMOLOGY, V115, P2199, DOI 10.1016/j.ophtha.2008.07.007
   Schmidt-Erfurth U, 2014, OPHTHALMOLOGY, V121, P193, DOI 10.1016/j.ophtha.2013.08.011
   Schmidt-Erfurth U, 2011, OPHTHALMOLOGY, V118, P831, DOI 10.1016/j.ophtha.2010.09.004
   Shen WY, 1998, BRIT J OPHTHALMOL, V82, P1063, DOI 10.1136/bjo.82.9.1063
   Shienbaum G, 2012, AM J OPHTHALMOL, V153, P468, DOI 10.1016/j.ajo.2011.08.011
   Skaat A, 2012, AM J OPHTHALMOL, V153, P214, DOI 10.1016/j.ajo.2011.08.035
   Stewart MW, 2012, RETINA-J RET VIT DIS, V32, P434, DOI 10.1097/IAE.0B013E31822C290F
   Svenson M, 2007, RHEUMATOLOGY, V46, P1828, DOI 10.1093/rheumatology/kem261
   Thornton J, 2005, EYE, V19, P935, DOI 10.1038/sj.eye.6701978
   Tsagaraki V, 2006, INT J CLIN PRACT, V60, P415, DOI 10.1111/j.1368-5031.2006.00849.x
   Tufail A, 2014, OPHTHALMOLOGY, V121, P1092, DOI 10.1016/j.ophtha.2013.11.031
   Williams TA, 2011, EYE, V25, P1617, DOI 10.1038/eye.2011.224
   Ying GS, 2013, OPHTHALMOLOGY, V120, P122, DOI 10.1016/j.ophtha.2012.07.042
   Yonekawa Y, 2013, AM J OPHTHALMOL, V156, P29, DOI 10.1016/j.ajo.2013.03.030
   Zarranz-Ventura J, 2014, OPHTHALMOLOGY, V121, P1966, DOI 10.1016/j.ophtha.2014.04.026
NR 77
TC 138
Z9 147
U1 0
U2 22
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950-222X
EI 1476-5454
J9 EYE
JI Eye
PD JUN
PY 2015
VL 29
IS 6
BP 721
EP 731
DI 10.1038/eye.2015.48
PG 11
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA CK4EB
UT WOS:000356172700002
PM 25882328
OA Green Published, Bronze
DA 2022-11-30
ER

PT J
AU Cheng, JM
   Liu, XQ
   Liu, JH
   Pan, WHT
   Zhang, XM
   Hu, L
   Chao, HM
AF Cheng, Ji-Min
   Liu, Xiao-Qian
   Liu, Jorn-Hon
   Pan, Wynn Hwai-Tzong
   Zhang, Xiu-Mei
   Hu, Lei
   Chao, Hsiao-Ming
TI Chi-Ju-Di-Huang-Wan protects rats against retinal ischemia by
   downregulating matrix metalloproteinase-9 and inhibiting p38
   mitogen-activated protein kinase
SO CHINESE MEDICINE
LA English
DT Article
ID STARBURST AMACRINE CELLS; ARTERY-OCCLUSION; MACULAR DEGENERATION;
   DIABETIC-RETINOPATHY; PIGMENT EPITHELIUM; RHESUS-MONKEYS; UP-REGULATION;
   PREVALENCE; MECHANISMS; PRESSURE
AB Background: Retinal ischemia is a retinal disorder related to retinal vascular occlusion, glaucoma, diabetic retinopathy and age-related macular degeneration. The study aimed to evaluate the protective effects and underlying mechanisms of Chi-Ju-Di-Huang-Wan (CJDHW) against retinal ischemia in rats.
   Methods: High intraocular pressure (HIOP)-induced retinal ischemia was established in Wistar rats by raising their intraocular pressure to 120 mmHg for 60 min with in an eye whose anterior chamber was cannulated with a 30-guage needle adapted to a normal saline bottle through an intravenous line. This ischemic insult was followed by 1 or 7 days of reperfusion. The effects of CJDHW were studied by (i) electroretinogram (ERG); (ii) real-time polymerase chain reaction to determine the retinal mRNA levels of Thy-1 and matrix metalloproteinase-9 (MMP-9); (iii) Western blot analysis to determine the retinal protein levels of B cell lymphoma 2 (Bcl-2), heme oxygenase-1 (HO-1), phosphorylated-p38 mitogen-activated protein kinase (P-p38 MAPK) and MMP-9; (iv) hematoxylin and eosin (HE) staining; (v) fluorogold retrograde labeling; and (vi) terminal deoxynucleotidyl-transferase (TdT)-mediated dUTP nick end-labeling (TUNEL) apoptosis assay. Moreover, after fixation with 4 % paraformaldehyde and 30 % sucrose, the isolated retinas were sectioned and immuno-labeled with goat anti-choline acetyltransferase (ChAT) polyclonal antibody, mouse anti-vimentin monoclonal antibody and rabbit anti-glial fibrillary acidic protein (GFAP) polyclonal antibody. The retinal sections were then incubated with rhodamine-conjugated rabbit anti-goat antibody, fluorescein isothiocyanate (FITC)-conjugated goat anti-mouse IgG or FITC-conjugated goat anti-rabbit IgG. A daily oral intake of 3 mL of water (vehicle; Group 2) or CJDHW (2.8 or 4.2 g/kg/day; CJDHW2.8 or CJDHW4.2; Group 3 or 4) was given for 7 consecutive days either before (preischemic drug administration) or after HIOP-induced retinal ischemic injury (postischemic drug administration). In Group 5, an intravitreal injection of 4 mu L of 0.5 mM SB203580 (p38 MAPK inhibitor) was performed on the ischemic eye 15 min before retinal ischemia. The control rats received a sham procedure (Group 1) where the saline reservoir was not raised.
   Results: The ischemia-induced changes (Group 2) were significantly modulated by pretreating the rats with 4.2 g/kg/day of CJDHW (Group 4; ERG: P < 0.001 on I/R day 7; HE stain: P < 0.001 on I/R day 7; TUNEL: P = 0.05 on I/R day 7; retrograde labeling: P = 0.007 on I/R day 7; Thy-1 mRNA: P = 0.02; MMP-9 mRNA: P < 0.001; Bcl-2 protein: P = 0.02; HO-1 protein: P = 0.03; P-p38 MAPK protein: P < 0.001; MMP-9 protein: P = 0.02). These modulations included the following features (Group 2 vs. 4), increased ERG b-wave amplitudes (0.38 +/- 0.04 vs. 0.81 +/- 0.03), increased inner retinal thickness (45.08 +/- 2.85 vs. 67.98 +/- 5.48 mu m), increased ChAT immunolabeling, decreased vimentin/GFAP immunoreactivity, less numerous apoptotic cells in the ganglion cell layer (1.40 +/- 0.55 vs. 0.60 +/- 0.55), and more numerous retinal ganglion cells (887.73 +/- 158.18 vs. 1389.02 +/- 53.20). Moreover, increased Thy-1 (0.31 +/- 0.15 vs. 0.78 +/- 0.32) and decreased MMP-9 mRNA levels were found (4.44 +/- 0.84 vs. 1.13 +/- 0.34), respectively. Furthermore, the Bcl-2 protein level (0.78 +/- 0.08 vs. 1.80 +/- 0.34) was increased while the HO-1 (0.99 +/- 0.20 vs. 4.15 +/- 2.08), P-p38 MAPK (1.12 +/- 0.18 vs. 0.57 +/- 0.18) and MMP-9 levels were decreased (0.70 +/- 0.23 vs. 0.39 +/- 0.10). The ischemia-associated increases in P-p38 and MMP-9 protein levels were also attenuated by 0.5 mM SB203580 (P-p38 MAPK: 1.12 +/- 0.18 vs. 0.18 +/- 0.07, P < 0.001; MMP-9: 0.70 +/- 0.23 vs. 0.21 +/- 0.07, P = 0.002). This was also the case to the MMP_enzyme activity (Group 2 vs. 4: 5.03 +/- 1.57 vs. 1.59 +/- 0.47, P = 0.002; Group 2 vs. 5: 5.03 +/- 1.57 vs. 1.35 +/- 0.41, P = 0.001).
   Conclusion: Treatment of the rats suffering from retinal ischemia with CJDHW inhibited apoptosis, increased antioxidative activity, downregulated MMP-9 and inhibited p38 MAPK.
C1 [Cheng, Ji-Min; Hu, Lei] Taishan Med Univ, Affiliated Hosp, Dept Ophthalmol, Tai An, Shandong, Peoples R China.
   [Liu, Xiao-Qian; Zhang, Xiu-Mei] Shandong Univ, Sch Med, Dept Pharmacol, Jinan, Shandong, Peoples R China.
   [Liu, Jorn-Hon; Chao, Hsiao-Ming] Cheng Hsin Gen Hosp, Dept Ophthalmol, Taipei, Taiwan.
   [Pan, Wynn Hwai-Tzong; Chao, Hsiao-Ming] Natl Yang Ming Univ, Inst Pharmacol, Sch Med, Taipei, Taiwan.
   [Chao, Hsiao-Ming] China Med Univ, Sch Chinese Med, Dept Chinese Med, Taichung, Taiwan.
C3 Shandong First Medical University & Shandong Academy of Medical
   Sciences; Shandong University; Cheng Hsin General Hospital; National
   Yang Ming Chiao Tung University; China Medical University Taiwan
RP Hu, L (通讯作者)，Taishan Med Univ, Affiliated Hosp, Dept Ophthalmol, Tai An, Shandong, Peoples R China.; Chao, HM (通讯作者)，Cheng Hsin Gen Hosp, Dept Ophthalmol, Taipei, Taiwan.; Chao, HM (通讯作者)，Natl Yang Ming Univ, Inst Pharmacol, Sch Med, Taipei, Taiwan.; Chao, HM (通讯作者)，China Med Univ, Sch Chinese Med, Dept Chinese Med, Taichung, Taiwan.
EM misshulei@126.com; hsiaoming.chao@gmail.com
FU  [CHGH102-21]
FX Heartfelt gratitude is conveyed for the financial support from the
   project [CHGH102-21]. Great thanks is given to Ms. Shih-Hsin Wang and
   Ms. Huei-Wen Shiu as well as to Professor Ralph Kirby for their skillful
   techniques in molecular biological assays and his expert correction of
   the manuscript, respectively. We are also indebted to Professor Gordon
   J. Johnson, Honorary Professor, London School of Hygiene and Tropical
   Medicine, UK, for carefully reading and professionally commenting on the
   final draft of this revised manuscript.
CR BUCHI ER, 1991, OPHTHALMOLOGICA, V203, P138
   Chang YH, 2005, PHYTOTHER RES, V19, P349, DOI 10.1002/ptr.1687
   Chao HM, 2000, BRAIN RES, V877, P47, DOI 10.1016/S0006-8993(00)02592-0
   Chao HM, 2014, AM J CHINESE MED, V42, P693, DOI 10.1142/S0192415X14500451
   Chao HM, 2013, J OCUL PHARMACOL TH, V29, P539, DOI 10.1089/jop.2012.0179
   Dong W, 2004, J PHYSIOL-LONDON, V556, P11, DOI 10.1113/jphysiol.2004.060715
   Dulak J, 2008, CIRCULATION, V117, P231, DOI 10.1161/CIRCULATIONAHA.107.698316
   Frank RN, 1999, AM J OPHTHALMOL, V127, P694, DOI 10.1016/S0002-9394(99)00032-X
   Guo L, 2005, INVEST OPHTH VIS SCI, V46, P175, DOI 10.1167/iovs.04-0832
   Hayreh SS, 2004, EXP EYE RES, V78, P723, DOI 10.1016/S0014-4835(03)00214-8
   Hayreh SS, 2000, AM J OPHTHALMOL, V129, P786, DOI 10.1016/S0002-9394(00)00384-6
   He SG, 1997, NATURE, V389, P378, DOI 10.1038/38723
   Hernandez C, 2013, CURR MED CHEM, V20, P3251, DOI 10.2174/09298673113209990024
   Hsu Tsui-Kang, 2013, Retin Cases Brief Rep, V7, P210, DOI 10.1097/ICB.0b013e3182852370
   Jenkins ES, 2000, ATLA-ALTERN LAB ANIM, V28, P333, DOI 10.1177/026119290002800203
   Leung IYF, 2001, INVEST OPHTH VIS SCI, V42, P466
   Liu JH, 2010, J OCUL PHARMACOL TH, V26, P421, DOI 10.1089/jop.2010.0063
   Marecko I, 2014, CROAT MED J, V55, P128, DOI 10.3325/cmj.2014.55.128
   Mason JO, 2008, AM J OPHTHALMOL, V146, P455, DOI 10.1016/j.ajo.2008.05.009
   MILLER RF, 1970, J NEUROPHYSIOL, V33, P323, DOI 10.1152/jn.1970.33.3.323
   Opremcak E, 2008, RETINA-J RET VIT DIS, V28, P226, DOI 10.1097/IAE.0b013e31814b1d6e
   Osborne NN, 2004, PROG RETIN EYE RES, V23, P91, DOI 10.1016/j.preteyeres.2003.12.001
   Park SJ, 2015, OPHTHALMOLOGY, V122, P2063, DOI 10.1016/j.ophtha.2015.06.018
   Park SJ, 2014, OPHTHALMOLOGY, V121, P1933, DOI 10.1016/j.ophtha.2014.04.029
   Peng PH, 2011, CURR EYE RES, V36, P238, DOI 10.3109/02713683.2010.539760
   Perucho J, 2012, CURR ALZHEIMER RES, V9, P334, DOI 10.2174/156720512800107573
   Ranaivo HR, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-68
   Schatz A, 2012, INVEST OPHTH VIS SCI, V53, P5552, DOI 10.1167/iovs.12-10037
   Thomas RL, 2015, BRIT J OPHTHALMOL, V99, P64, DOI 10.1136/bjophthalmol-2013-304017
   Wang JJ, 2013, ARCH MED SCI, V9, P332, DOI 10.5114/aoms.2012.30949
   Wurm A, 2011, INVEST OPHTH VIS SCI, V52, P3360, DOI 10.1167/iovs.10-6901
   Zarbin MA, 2004, ARCH OPHTHALMOL-CHIC, V122, P598, DOI 10.1001/archopht.122.4.598
   Zhao J, 2012, CURR EYE RES, V37, P955, DOI 10.3109/02713683.2012.700753
   Zhao Y, 2015, INDIAN J OPHTHALMOL, V63, P825, DOI 10.4103/0301-4738.171963
NR 34
TC 0
Z9 0
U1 2
U2 15
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1749-8546
J9 CHIN MED-UK
JI Chin. Med.
PD SEP 9
PY 2016
VL 11
AR 39
DI 10.1186/s13020-016-0109-6
PG 16
WC Integrative & Complementary Medicine; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Integrative & Complementary Medicine; Pharmacology & Pharmacy
GA DW1QA
UT WOS:000383416500001
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU [Anonymous]
AF [Anonymous]
TI Aflibercept - AVE 0005, AVE 005, AVE0005, VEGF trap - Regeneron, VEGF
   trap (R1R2), VEGF trap-eye
SO DRUGS IN R&D
LA English
DT Article
AB Aflibercept is a fully human recombinant fusion protein composed of the second Ig domain of VEGFR1 and the third Ig domain of VEGFR2, fused to the Fc region of human IgG(1). Aflibercept is in clinical development with Regeneron Pharmaceuticals and sanofi-aventis for the treatment of cancer, while Regeneron and Bayer are developing the agent for eye disorders. Aflibercept binds to all VEGF-A isoforms as well as placental growth factor (PIGF), thereby preventing these factors from stimulating angiogenesis. Blockade of VEGF can also prevent blood vessel formation and vasuclar leakage associated with wet age-related macular degeneration (AMD). Aflibercept is a member of Regeneron's proprietary family of 'Trap' product candidates that catch, hold and block (i.e. trap) certain harmful cytokines or growth factors.
   Regeneron and Bayer HealthCare entered into a collaboration agreement in October 2006 to develop and commercialize aflibercept for the treatment of eye disorders outside the US. The companies will share equally in profits from this market, while Regeneron will retain exclusive commercialization lights and profits from sales in the US.([1])
   Regeneron and sanofi-aventis amended their aflibercept collaboration agreement to include Japan. Under the terms of the amended agreement, reported in December 2005, the two companies will jointly develop and commercialize aflibercept worldwide in all indications, except for intraocular delivery to the eye. sanofi-aventis paid $US25 million to Regeneron for the inclusion of Japan and will pay milestone payments linked to Japanese regulatory approvals, plus royalties on Japanese sales. sanofi-aventis will lead Japanese development and will pay all development costs; however, Regeneron will repay 50% of these expenses out of profits generated through the commercialization of aflibercept.([2])
   sanofi-aventis reaffirmed its commitment to the aflibercept programme in oncology in January 2005, while the exclusive rights to develop and commercialize the agent for eye diseases through local delivery systems reverted to Regeneron. A $US25 million clinical development milestone payment to Regeneron was also triggered in connection with this agreement.([3])
   Aventis (now sanofi-aventis) and Regeneron entered into a global (excluding Japan) agreement in September 2003 to jointly develop and commercialize aflibercept. Under the terms of the agreement, Aventis was to pay Regeneron $US125 million and fund development costs. An additional early clinical milestone payment of $US25 million was also outlined in the agreement. The two companies will share promotional tights equally, and profits globally. Aventis will also pay Regeneron up to $US360 million at identified milestones related to the receipt of marketing approvals for up to eight indications in Europe and the US. The companies initially agreed to jointly develop aflibercept in oncology, ophthalmology and possibly in other indications.([4])
   Originally, aflibercept was being developed under a research and development alliance between Regeneron and Procter & Gamble. However, in 2000 this agreement was restructured and Regeneron regained all rights.
   An NCI-sponsored phase II trial (NCT00407654) of aflibercept, involving 80 patients with previously treated metastatic colorectal cancer, is also underway in the US and Canada. The trial was initiated in October 2006 and is evaluating the efficacy of aflibercept in this patient group, as measured by objective tumour response and progression-free survival at 4 months.
   In September 2006, a phase II trial in 82 patients with locally advanced, unresectable or metastatic gynaecological soft tissue sarcoma was initiated by NCI and Regeneron in the US and Canada. This ongoing trial (NCT00390234) will evaluate the efficacy of aflibercept, as measured by progression-free survival and tumour response rate.
   Regeneron and sanofi-aventis are conducting a phase II trial of intravenously (IV) administered aflibercept in patients with advanced ovarian cancer who have recurrent symptomatic malignant ascites (SMA). The trial (NCT00327444) began in July 2006 and was continuing to recruit a total of 54 patients at centres in the US, Canada, India and the EU (Austria, Belgium, Hungary, Spain and the UK) in April 2007.
   In October 2006, the companies initiated a second small phase II trial of aflibercept (NCT00396591) in 15 patients with malignant ascites associated with ovarian cancer. The study will assess the efficacy, safety, pharmacokinetics and immunogenicity of aflibercept IV given every 2 weeks in the US and EU (Italy and Sweden) and was recruiting patients in May 2007.
   Regeneron and sanofi-aventis are also conducting a single-agent phase II study of aflibercept in non-small-cell lung adenocarcinoma (NSCLA). The open-label, single-arm study (NCT00284141) has completed enrolment of approximately 100 patients with platinum- and erlotinib-resistant, locally advanced or metastatic NSCLA to receive aflibercept (4.0 mg/kg IV) in the US, France and Canada. Results from the first 37 evaluable patients have been reported showing aflibercept was generally well tolerated and two partial reponses were noted.([5,6])
   Regeneron has completed an open-label phase I trial in patients with solid tumours and non-Hodgkin's lymphoma (NHL) at three sites in the US. The study enrolled 38 patients with incurable, relapsed or refractory solid tumours who received subcutaneous injections. In total, the trial enrolled patients with 15 different types of cancer who were treated with seven subcutaneous doses of aflibercept over 10 weeks. In June 2004, Regeneron presented results from this study showing that the aflibercept was well tolerated and had a good safety profile. The maximum tolerated dose was not established. The company has not conducted any further trials in this indication with aflibercept as a monotherapy, although the NCI has ongoing trials of aflibercept in patients with solid tumours and NHL (e.g. NCT0008283).([7])
   In May 2005, Regeneron announced initiation of a phase I safety and tolerability study with aflibercept in combination with the FOLFOX-4 regimen (oxaliplatin, 5-fluorouracil and leucovorin) in patients with advanced solid tumours. As at August 2006, the maximum tolerated dose had not been reached and dose-escalation was continuing in this study.([8,9])
   The NCI/Regeneron trial in patients with metastatic or unresectable kidney cancer began in September 2007 with continued recruitment in April 2008. This trial (NCT00357760) is anticipated to recruit 120 patients in the US to evaluate the efficacy of two doses of aflibercept.
   Regeneron and Bayer inititiated a phase III trial of aflibercept in approximately 1200 patients with the neovascular form of wet AMD in August 2007. The non-inferiority, VIEW 1 (VEGF Trap: Investigation of Efficacy and safety in Wet age-related macular degeneration) study will evaluate the safety and efficacy of intravitreal aflibercept at doses of 0.5 mg and 2.0 mg administered at 4-week dosing intervals, and 2.0 mg at an 8-week dosing interval, compared with 0.5 mg ranibizumab administered every 4 weeks. The randomized, double-blind trial will be conducted at more than 200 centres throughout the US and Canada, pursuant to a Special Protocol Assessment (SPA) issued by the the US FDA. Patients will continue to be treated and followed for an additional year, after the first year of treatment. The VIEW 1 study is the first in a phase III global development programme in wet AMD, which is expected to be conducted in the US, Europe and other nations. Regeneron received a $US20 million milestone payment from Bayer HealthCare in August 2007 following dosing of the first patient.([10,11])
   A second phase III trial (VIEW 2) in wet AMD began with the first patient dosed in May 2008. The VIEW 2 trial will enrol approximately 1200 patients from the EU, Asia Pacific, Japan and Latin America. This study will evaluate the safety and efficacy of aflibercept at 0.5 mg and 2.0 mg administered at 4-week intervals and 2.0 mg at an 8-week dosing interval, including one additional 2.0 mg dose at week 4. Patients randomized to the ranibizumab arm of the trial will receive a 0.5 mg dose every 4 weeks. The primary endpoint will be the proportion of patients treated with aflibercept who maintain vision at the end of I year compared with ranibizumab patients.([12,13])
   Regeneron has completed a 12-week, phase II trial in patients with wet AMD, to evaluate the safety and efficacy of intravitreal aflibercept using different doses and dose regimens. Two patient groups received monthly doses of 0.5 or 2.0 mg, and three groups received quarterly doses of 0.5, 2.0 or 4.0 mg (baseline and week 12). Analysis of data demonstrated that all five doses of aflibercept met the primary study endpoint of a statistically significant reduction in retinal thickness after 12 weeks and 32 weeks of treatment compared with baseline. The study commenced in April 2006 and enrolled 157 patients at sites in the US. Preliminary phase I trial results in 21 patients have also been presented.([14-16])
   Additionally, Regeneron has conducted a phase I trial of aflibercept in five patients with diabetic macular oedema (DME) in the US. Results presented in May 2007 indicated that a single 4 ring injection resulted in a marked decrease in mean central retinal thickness and mean macular volume throughout the 6-week observation period. The VEGF Trap-Eye was generally well tolerated, and there were no drug-related serious adverse events.([17]) Regeneron plans to conduct advanced studies of the VEGF Trap-Eye in DME.
   Previously, sanofi-aventis and Regeneron had been collaborating on the development of aflibercept for eye diseases through local delivery systems. However, the exclusive rights to develop and commercialize aflibercept for eye diseases through local delivery systems reverted to Regeneron in January 2005. Additionally, Regeneron chose to pursue intravitreal inection, as a route of administration, instead of systemic delivery.([18])
   Results from an earlier phase I trial assessing the safety and tolerability of intravenous infusions of aflibercept in patients with wet AMD have been reported. Preliminary results from the trial showed that the efficacy endpoint was met. Furthermore, systemic delivery of aflibercept was associated with a dose-dependent increase in blood pressure.([19])
CR *AV REG PHARM INC, 2003, AV REG ENT GLOB PART
   *BAY HEALTHCARE AG, 2008, BAY REG START ADD PH
   *BAY HEALTHCARE AG, 2008, BAY REG DOS 1 PAT 2
   *BAY HEALTHCARE RE, 2006, BAY HEALTHCARE REG C
   Byrne AT, 2003, CLIN CANCER RES, V9, P5721
   DUPONT J, 2004, EJC SUPPLEMENTS, V2, P43
   DUPONT J, 2003, 39 ANN M AM SOC CLIN, P194
   Huang JZ, 2003, P NATL ACAD SCI USA, V100, P7785, DOI 10.1073/pnas.1432908100
   *JH WILM EYE I, 2003, INJ PREV BLIND BLOOD
   MASSARELLI E, 2007, J CLIN ONCOLOGY S, V25, P416
   *REG PHARM INC, 2007, VEGF TRAP EYE PHAS 2
   *REG PHARM INC, 2006, REG REP POS PHAS 1 D
   *REG PHARM INC, 2007, REG REP 2 QUART FIN
   *REG PHARM INC, 2007, REG ANN POS PRIM END
   *REG PHARM INC, 2007, REG REC 20 MILL MIL
   *REG PHARM INC, 2006, REG REP 4 Q FULL YEA
   *REG PHARM INC, 2004, REG REP POS PREL RES
   *REG PHARM INC, 2005, SAN AV REG PHARM EXP
   *REG PHARM INC, 2006, REG VEGF TRAP DEM PO
   *REG PHARM INC, 2005, REG VEGF TRAP DEM PO
   *REG PHARM INC, 2005, CLIN PRECL STUD VEGF
   *REG PHARM INC, 2005, REG REP 4 QUART FULL
   *REG PHARM INC BAY, 2008, REG BAY HEALTHCARE A
   *REG PHARM INC BAY, 2007, REG BAY HEALTHCARE I
   *SANOF AV, 2005, SAN AV REG PHARM REA
NR 25
TC 22
Z9 24
U1 1
U2 18
PU ADIS INT LTD
PI AUCKLAND
PA 41 CENTORIAN DR, PRIVATE BAG 65901, MAIRANGI BAY, AUCKLAND 1311, NEW
   ZEALAND
SN 1174-5886
J9 DRUGS R&D
JI Drugs R&D
PY 2008
VL 9
IS 4
BP 261
EP 269
PG 9
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA 328UM
UT WOS:000257823700006
PM 18588357
DA 2022-11-30
ER

PT J
AU Markowska, AI
   Cao, ZY
   Panjwani, N
AF Markowska, Anna I.
   Cao, Zhiyi
   Panjwani, Noorjahan
TI Glycobiology of ocular angiogenesis
SO GLYCOBIOLOGY
LA English
DT Review
DE angiogenesis; choroidal neovascularization; corneal neovascularization;
   galectin-3; glycans; glycosylation; integrins; neovascularization;
   retinal neovascularization
ID ENDOTHELIAL GROWTH-FACTOR; EPITHELIUM-DERIVED FACTOR; EXPERIMENTAL
   CHOROIDAL NEOVASCULARIZATION; PROLIFERATIVE DIABETIC-RETINOPATHY;
   AGE-RELATED MACULOPATHY; CORNEAL NEOVASCULARIZATION; MACULAR
   DEGENERATION; RETINAL NEOVASCULARIZATION; TUMOR ANGIOGENESIS;
   INTRAVITREAL INJECTION
AB Ocular neovascularization can affect almost all the tissues of the eye: the cornea, the iris, the retina, and the choroid. Pathological neovascularization is the underlying cause of vision loss in common ocular conditions such as diabetic retinopathy, retinopathy of prematurity and age-related macular neovascularization. Glycosylation is the most common covalent posttranslational modification of proteins in mammalian cells. A growing body of evidence demonstrates that glycosylation influences the process of angiogenesis and impacts activation, proliferation, and migration of endothelial cells as well as the interaction of angiogenic endothelial cells with other cell types necessary to form blood vessels. Recent studies have provided evidence that members of the galectin class of beta-galactoside-binding proteins modulate angiogenesis by novel carbohydrate-based recognition systems involving interactions between glycans of angiogenic cell surface receptors and galectins. This review discusses the significance of glycosylation and the role of galectins in the pathogenesis of ocular neovascularization.
C1 [Markowska, Anna I.; Cao, Zhiyi; Panjwani, Noorjahan] Tufts Univ, Sch Med, Dept Ophthalmol, Boston, MA 02111 USA.
   [Markowska, Anna I.; Cao, Zhiyi; Panjwani, Noorjahan] Tufts Univ, Sch Med, Dept Dev Mol & Chem Biol, Boston, MA 02111 USA.
   [Markowska, Anna I.] Ymir Genom LLC, Cambridge, MA 02139 USA.
   [Cao, Zhiyi; Panjwani, Noorjahan] New England Eye Ctr, Boston, MA 02111 USA.
C3 Tufts University; Tufts University
RP Panjwani, N (通讯作者)，Tufts Univ, Sch Med, Dept Ophthalmol, Boston, MA 02111 USA.
EM noorjahan.panjwani@tufts.edu
FU National Institutes of Health [EY009349, EY007088]; Massachusetts Lions
   Eye Research Fund; New England Corne al Transplant Fund; Research to
   Prevent Blindness; NATIONAL EYE INSTITUTE [R01EY009349, R01EY007088]
   Funding Source: NIH RePORTER
FX The work carried out in the author's laboratory was supported by
   National Institutes of Health Grants EY009349 and EY007088, the
   Massachusetts Lions Eye Research Fund, the New England Corne al
   Transplant Fund and an unrestricted award from Research to Prevent
   Blindness.
CR Adamis A P, 1999, Angiogenesis, V3, P9, DOI 10.1023/A:1009071601454
   ADAMIS AP, 1994, AM J OPHTHALMOL, V118, P445, DOI 10.1016/S0002-9394(14)75794-0
   Afzal A, 2007, MICROVASC RES, V74, P131, DOI 10.1016/j.mvr.2007.04.011
   AIELLO LP, 1994, NEW ENGL J MED, V331, P1480, DOI 10.1056/NEJM199412013312203
   Asahara T, 1998, CIRC RES, V83, P233, DOI 10.1161/01.RES.83.3.233
   Breen EC, 2007, J CELL BIOCHEM, V102, P1358, DOI 10.1002/jcb.21579
   Canning P, 2007, EXP DIABETES RES, DOI 10.1155/2007/51837
   Cao RH, 2002, FASEB J, V16, P1575, DOI 10.1096/fj.02-0319com
   Delgado VMC, 2011, FASEB J, V25, P242, DOI 10.1096/fj.09-144907
   Chang JH, 2001, CURR OPIN OPHTHALMOL, V12, P242, DOI 10.1097/00055735-200108000-00002
   Contois L, 2009, SEMIN CANCER BIOL, V19, P318, DOI 10.1016/j.semcancer.2009.05.002
   Croci DO, 2014, CELL, V156, P744, DOI 10.1016/j.cell.2014.01.043
   Cross MJ, 2001, TRENDS PHARMACOL SCI, V22, P201, DOI 10.1016/S0165-6147(00)01676-X
   Csaky KG, 2004, EXP EYE RES, V78, P1107, DOI 10.1016/j.exer.2004.01.010
   Cursiefen C, 2004, J CLIN INVEST, V113, P1040, DOI 10.1172/JCI200420465
   Dennis K, 2002, GENE, V294, P269, DOI 10.1016/S0378-1119(02)00801-6
   Dorrell M, 2007, SURV OPHTHALMOL, V52, pS3, DOI 10.1016/j.survophthal.2006.10.017
   Economopoulou M, 2005, BLOOD, V106, P3831, DOI 10.1182/blood-2005-03-0889
   Fernandez-Robredo P, 2014, J OPHTHALMOL, V2014, DOI 10.1155/2014/510285
   Frank RN, 1996, AM J OPHTHALMOL, V122, P393, DOI 10.1016/S0002-9394(14)72066-5
   Friedlander M, 1996, P NATL ACAD SCI USA, V93, P9764, DOI 10.1073/pnas.93.18.9764
   Friedlander M, 2007, J CLIN INVEST, V117, P576, DOI 10.1172/JCI31030
   Fukushi J, 2004, MOL BIOL CELL, V15, P3580, DOI 10.1091/mbc.E04-03-0236
   Funatsu H, 2002, AM J OPHTHALMOL, V133, P70, DOI 10.1016/S0002-9394(01)01269-7
   Garmy-Susini Barbara, 2008, Lymphatic Research and Biology, V6, P155, DOI 10.1089/lrb.2008.1011
   GAUDRIC A, 1992, OPHTHALMIC RES, V24, P181, DOI 10.1159/000267166
   Gurel Z, 2013, MOL VIS, V19, P1047
   Hafez SA, 2007, ANAT REC, V290, P761, DOI 10.1002/ar.20548
   Henderson NC, 2006, P NATL ACAD SCI USA, V103, P5060, DOI 10.1073/pnas.0511167103
   Henderson NC, 2008, AM J PATHOL, V172, P288, DOI 10.2353/ajpath.2008.070726
   Henderson NC, 2012, ACS SYM SER, V1115, P377
   Hera R, 2005, AM J OPHTHALMOL, V139, P589, DOI 10.1016/j.ajo.2004.11.064
   Hoeben A, 2004, PHARMACOL REV, V56, P549, DOI 10.1124/pr.56.4.3
   Honda S, 2009, GRAEF ARCH CLIN EXP, V247, P515, DOI 10.1007/s00417-008-1010-5
   Hsieh SH, 2008, ONCOGENE, V27, P3746, DOI 10.1038/sj.onc.1211029
   Iliaki E, 2009, INVEST OPHTH VIS SCI, V50, P4898, DOI 10.1167/iovs.08-2013
   Jia WZ, 2013, AM J PATHOL, V182, P1821, DOI 10.1016/j.ajpath.2013.01.017
   Jo DH, 2014, BIOMATERIALS, V35, P3052, DOI 10.1016/j.biomaterials.2013.12.031
   KLEIN R, 1995, INVEST OPHTH VIS SCI, V36, P182
   Kliffen M, 1997, MICROSC RES TECHNIQ, V36, P106, DOI 10.1002/(SICI)1097-0029(19970115)36:2<106::AID-JEMT4>3.0.CO;2-N
   Klotz O, 2000, GRAEF ARCH CLIN EXP, V238, P88, DOI 10.1007/s004170050015
   KNIGHTON DR, 1990, J TRAUMA, V30, pS134
   Krzystolik MG, 2002, ARCH OPHTHALMOL-CHIC, V120, P338
   Kuiper EJ, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002675
   Ljubimov AV, 1998, J HISTOCHEM CYTOCHEM, V46, P1033, DOI 10.1177/002215549804600907
   Machado CML, 2014, CANCER MED-US, V3, P201, DOI 10.1002/cam4.173
   Lopez PF, 1996, INVEST OPHTH VIS SCI, V37, P855
   Luna J, 1996, LAB INVEST, V75, P563
   Luo B, 2008, ARTERIOSCL THROM VAS, V28, P651, DOI 10.1161/ATVBAHA.107.159533
   Luttun A, 2002, NAT MED, V8, P831, DOI 10.1038/nm731
   Lynch TP, 2012, J BIOL CHEM, V287, P11070, DOI 10.1074/jbc.M111.302547
   MacKinnon AC, 2008, J IMMUNOL, V180, P2650, DOI 10.4049/jimmunol.180.4.2650
   MacKinnon AC, 2012, AM J RESP CRIT CARE, V185, P537, DOI 10.1164/rccm.201106-0965OC
   Markowska AI, 2011, J BIOL CHEM, V286, P29913, DOI 10.1074/jbc.M111.226423
   Markowska AI, 2010, J EXP MED, V207, P1981, DOI 10.1084/jem.20090121
   Mauris J, 2014, J CELL SCI, V127, P3141, DOI 10.1242/jcs.148510
   Mimura T, 2001, EXP EYE RES, V72, P71, DOI 10.1006/exer.2000.0925
   Mitchell P, 2011, CURR MED RES OPIN, V27, P1465, DOI 10.1185/03007995.2011.585394
   Morello CA, 2007, AM J HEALTH-SYST PH, V64, pS3, DOI 10.2146/ajhp070330
   Mori K, 2002, INVEST OPHTH VIS SCI, V43, P2428
   Muether PS, 2007, EXP EYE RES, V85, P356, DOI 10.1016/j.exer.2007.06.004
   Nakao S, 2007, AM J PATHOL, V171, P1058, DOI 10.2353/ajpath.2007.070172
   Nangia-Makker P, 2002, JNCI-J NATL CANCER I, V94, P1854, DOI 10.1093/jnci/94.24.1854
   Nangia-Makker P, 2000, AM J PATHOL, V156, P899, DOI 10.1016/S0002-9440(10)64959-0
   Nangia-Makker P, 2010, INT J CANCER, V127, P2530, DOI 10.1002/ijc.25254
   NGUYEN M, 1992, J BIOL CHEM, V267, P26157
   Ogata N, 2002, INVEST OPHTH VIS SCI, V43, P1168
   Ogata N, 2007, J CLIN ENDOCR METAB, V92, P1176, DOI 10.1210/jc.2006-2249
   Otrock ZK, 2007, BLOOD CELL MOL DIS, V38, P258, DOI 10.1016/j.bcmd.2006.12.003
   Patel RD, 2011, SEMIN OPHTHALMOL, V26, P372, DOI 10.3109/08820538.2011.570845
   Peters S, 2007, AM J OPHTHALMOL, V143, P995, DOI 10.1016/j.ajo.2007.03.007
   Philipp W, 2000, INVEST OPHTH VIS SCI, V41, P2514
   PILI R, 1995, CANCER RES, V55, P2920
   Qazi Y, 2009, J GENET, V88, P495, DOI 10.1007/s12041-009-0068-0
   Riecke B, 2001, HORM METAB RES, V33, P307, DOI 10.1055/s-2001-15279
   Rofagha S, 2013, OPHTHALMOLOGY, V120, P2292, DOI 10.1016/j.ophtha.2013.03.046
   Rogers MS, 2007, NAT PROTOC, V2, P2545, DOI 10.1038/nprot.2007.368
   Roskoski R, 2008, BIOCHEM BIOPH RES CO, V375, P287, DOI 10.1016/j.bbrc.2008.07.121
   Saishin Y, 2003, INVEST OPHTH VIS SCI, V44, P4989, DOI 10.1167/iovs.03-0600
   Schraermeyer U, 2012, GRAEF ARCH CLIN EXP, V250, P1303, DOI 10.1007/s00417-012-2055-z
   Seo MS, 2000, AM J PATHOL, V157, P995, DOI 10.1016/S0002-9440(10)64612-3
   Shakiba Y, 2009, RECENT PATENTS INFLA, V3, P221, DOI 10.2174/187221309789257450
   Silva RLE, 2007, FASEB J, V21, P3219, DOI 10.1096/fj.06-7359com
   Silva R, 2008, ARTERIOSCL THROM VAS, V28, P1703, DOI 10.1161/ATVBAHA.108.172015
   Sivak JM, 2011, J BIOL CHEM, V286, P44965, DOI 10.1074/jbc.M111.294967
   Spilsbury K, 2000, AM J PATHOL, V157, P135, DOI 10.1016/S0002-9440(10)64525-7
   Stitt AW, 2005, DIABETES, V54, P785, DOI 10.2337/diabetes.54.3.785
   Thijssen VLJL, 2007, BLOOD, V110, P2819, DOI 10.1182/blood-2007-03-077792
   Thijssen VLJL, 2006, P NATL ACAD SCI USA, V103, P15975, DOI 10.1073/pnas.0603883103
   TIGANIS T, 1992, EXP CELL RES, V198, P191, DOI 10.1016/0014-4827(92)90371-E
   Tong JP, 2006, AM J OPHTHALMOL, V141, P456, DOI 10.1016/j.ajo.2005.10.012
   Umeda N, 2006, MOL PHARMACOL, V69, P1820, DOI 10.1124/mol.105.020941
   Van Geest RJ, 2012, BRIT J OPHTHALMOL, V96, P587, DOI 10.1136/bjophthalmol-2011-301005
   Wells JA, 1996, BRIT J OPHTHALMOL, V80, P363, DOI 10.1136/bjo.80.4.363
   Wilkinson-Berka JL, 2006, INVEST OPHTH VIS SCI, V47, P1600, DOI 10.1167/iovs.05-1314
   Witmer AN, 2002, INVEST OPHTH VIS SCI, V43, P849
   Yamazaki T, 2012, OPHTHALMOLOGY, V119, P1621, DOI 10.1016/j.ophtha.2012.02.022
   Yoshida T, 2012, EXP EYE RES, V94, P41, DOI 10.1016/j.exer.2011.11.003
   Zhang HY, 2002, INVEST OPHTH VIS SCI, V43, P955
NR 99
TC 11
Z9 13
U1 1
U2 13
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0959-6658
EI 1460-2423
J9 GLYCOBIOLOGY
JI Glycobiology
PD DEC
PY 2014
VL 24
IS 12
SI SI
BP 1275
EP 1282
DI 10.1093/glycob/cwu078
PG 8
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA AY2HT
UT WOS:000347410300009
PM 25108228
OA Green Published
DA 2022-11-30
ER

PT J
AU Agarwal, A
   Handa, S
   Querques, G
   Gupta, V
AF Agarwal, Aniruddha
   Handa, Sabia
   Querques, Giuseppe
   Gupta, Vishali
TI Clear subretinal fluid in a case of non-neovascular early-onset drusen:
   Swept-source imaging evaluation
SO EUROPEAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE Cuticular drusen; large colloid drusen; optical coherence tomography
   angiography; vitelliform; choroidal neovascularization
ID OPTICAL COHERENCE TOMOGRAPHY; CUTICULAR DRUSEN; ANGIOGRAPHY
AB A 50-year-old male presented with recent metamorphopsia in the right eye. Fundus examination revealed bilateral multiple cuticular drusen along with few large colloid drusen (phenotype 3 cuticular drusen). No vitelliform material was evident in the macula in either eye. Fluorescein angiography (FA), indocyanine green angiography (ICGA) did not demonstrate a macular neovascularization (MNV) in either eye. Swept-source optical coherence tomography (SS-OCT) revealed sub-retinal pigment epithelial (RPE) drusen and a clear space beneath the inter-digitation zone and above the RPE-Bruch's complex. SS-OCTA did not reveal MNV in either eye. The patient was kept under observation, and follow-up at 3 months did not reveal any structural change. Among patients with early-onset drusen, vitelliform detachments may occur due to accumulation of yellow pseudo-vitelliform material. However, serous detachments with an "optically clear" subretinal space can occur by the same mechanism without MNV. Such patients do not merit therapy with anti-vascular endothelial growth factor agents.
C1 [Agarwal, Aniruddha; Handa, Sabia; Gupta, Vishali] Post Grad Inst Med Educ & Res, Dept Ophthalmol, Adv Eye Ctr, Chandigarh, India.
   [Querques, Giuseppe] Univ Vita Salute, IRCCS Osped San Raffaele, Dept Ophthalmol, Milan, Italy.
C3 Post Graduate Institute of Medical Education & Research (PGIMER),
   Chandigarh; Vita-Salute San Raffaele University; IRCCS Ospedale San
   Raffaele
RP Gupta, V (通讯作者)，Post Grad Inst Med Educ & Res, Adv Eye Ctr, Sect 12, Chandigarh 160012, India.
EM vishalisara@yahoo.co.in
OI Gupta, Vishali/0000-0001-8216-4620; Reis,
   AlessanRSS/0000-0001-8486-7469; Querques, Giuseppe/0000-0002-3292-9581
CR Balaratnasingam C, 2018, OPHTHALMOLOGY, V125, P100, DOI 10.1016/j.ophtha.2017.08.033
   Carnevali Adriano, 2018, Retin Cases Brief Rep, V12 Suppl 1, pS41, DOI 10.1097/ICB.0000000000000648
   Carnevali A, 2016, AM J OPHTHALMOL, V169, P189, DOI 10.1016/j.ajo.2016.06.042
   Chong Deborah Y, 2009, Retin Cases Brief Rep, V3, P50, DOI 10.1097/ICB.0b013e318150d72e
   COHEN Y, 1994, BRIT J OPHTHALMOL, V78, P437
   Gass JD., 1977, STEREOSCOPIC ATLAS M, V2
   GASS JDM, 1985, AM J OPHTHALMOL, V99, P445
   Guigui B, 2013, RETINA-J RET VIT DIS, V33, P1346, DOI 10.1097/IAE.0b013e318283127d
   Guigui B, 2011, BRIT J OPHTHALMOL, V95, P238, DOI 10.1136/bjo.2009.178400
   Meunier I, 2004, ARCH OPHTHALMOL-CHIC, V122, P1566, DOI 10.1001/archopht.122.10.1566
   Narita C, 2020, OPHTHALMOLOGY, V127, P637, DOI 10.1016/j.ophtha.2019.11.007
   PIGUET B, 1995, EYE, V9, P34, DOI 10.1038/eye.1995.5
   Porter Rowan G B, 2014, Retin Cases Brief Rep, V8, P326, DOI 10.1097/ICB.0000000000000060
   Querques G, 2011, GRAEF ARCH CLIN EXP, V249, P1617, DOI 10.1007/s00417-011-1702-0
   Roberti NC, 2017, ARQ BRAS OFTALMOL, V80, P122, DOI 10.5935/0004-2749.20170029
   Sakurada Y, 2018, RETINA, DOI [10.1097/IAE.0000000000002399., DOI 10.1097/IAE.0000000000002399.]
   Spaide RF, 2005, OPHTHALMOLOGY, V112, P825, DOI 10.1016/j.ophtha.2005.01.003
   Spaide RF, 2010, RETINA-J RET VIT DIS, V30, P1441, DOI 10.1097/IAE.0b013e3181ee5ce8
   Terao Ryo, 2021, Retin Cases Brief Rep, V15, P581, DOI 10.1097/ICB.0000000000000856
   Zatreanu L, 2019, RETINA, DOI [10.1097/IAE.0000000000002659., DOI 10.1097/IAE.0000000000002659.]
NR 20
TC 0
Z9 0
U1 0
U2 1
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1120-6721
EI 1724-6016
J9 EUR J OPHTHALMOL
JI Eur. J. Ophthalmol.
PD JAN
PY 2022
VL 32
IS 1
BP NP154
EP NP158
AR 1120672120957590
DI 10.1177/1120672120957590
EA SEP 2020
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA YK3MJ
UT WOS:000568576200001
PM 32907404
DA 2022-11-30
ER

PT J
AU Querques, G
   Sacconi, R
   Capuano, V
   Carnevali, A
   Colantuono, D
   Battista, M
   Borrelli, E
   Miere, A
   Parravano, M
   Costanzo, E
   Querques, L
   Souied, EH
   Bandello, F
AF Querques, Giuseppe
   Sacconi, Riccardo
   Capuano, Vittorio
   Carnevali, Adriano
   Colantuono, Donato
   Battista, Marco
   Borrelli, Enrico
   Miere, Alexandra
   Parravano, Mariacristina
   Costanzo, Eliana
   Querques, Lea
   Souied, Eric H.
   Bandello, Francesco
TI Treatment-naive quiescent macular neovascularization secondary to AMD:
   The 2019 Young Investigator Lecture of Macula Society
SO EUROPEAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE Retina; age-related macular degeneration; retina medical therapies;
   choroidal neovascular membranes; uvea; retinal pathology; research
ID COHERENCE TOMOGRAPHY-ANGIOGRAPHY; CHOROIDAL NEOVASCULARIZATION;
   NATURAL-HISTORY; DEGENERATION; TYPE-1
AB Purpose: To analyze different clinical and anatomical features in treatment-naive non-exudative macular neovascularizations (MNVs) secondary to age-related macular disease (AMD). Methods: In this retrospective longitudinal study with a minimum follow-up of 1 year, 31 eyes of 28 consecutive AMD patients (mean age 75 +/- 9 years) with treatment-naive non-exudative MNV were enrolled. Patients were divided in: short-term activated MNV group (exudation before 6-month) and quiescent MNV group (per definition no exudation during a minimum 6-month follow-up) showing no or late activation during follow-up (persistently quiescent and long-term activated MNV group, respectively). Results: During the follow-up (mean duration: 22 +/- 9 months) four eyes (13%) showed exudation before 6-month follow-up (short-term activated MNV group), whereas 21 eyes (68%) did not develop signs of exudation (persistently quiescent group), and six eyes (19%) developed exudation after the minimum 6-month follow-up (long-term activated MNV group). Monthly MNV growth rate was significantly higher in the short-term activated MNV group (growth rate of 13.30%/month), vs persistently quiescent MNV group (0.64%/month, p < 0.001) and long-term activated quiescent MNV group (1.07%/month, p < 0.001). Furthermore, at the baseline, perfusion density of short-term activated MNV group was significantly greater in comparison to persistently quiescent MNV group (p = 0.001) and long-term activated MNV group (p = 0.106). Conclusion: We reported two different patterns for subclinical MNVs: subclinical MNVs characterized by short-term activation which could represent simply a pre-exudative stage in the development of an ordinary type 1 MNV, and quiescent MNVs characterized by low rate of growth and possible long-term activation. Analysis of OCT-A features may predict short-term activation for subclinical MNV but no features could predict the long-term activation.
C1 [Querques, Giuseppe; Sacconi, Riccardo; Battista, Marco; Borrelli, Enrico; Bandello, Francesco] Univ Vita Salute San Raffaele, Sch Med, Milan, Italy.
   [Querques, Giuseppe; Sacconi, Riccardo; Carnevali, Adriano; Battista, Marco; Borrelli, Enrico; Querques, Lea; Bandello, Francesco] IRCCS San Raffaele Sci Inst, Div Head & Neck, Ophthalmol Unit, Milan, Italy.
   [Querques, Giuseppe; Capuano, Vittorio; Colantuono, Donato; Miere, Alexandra; Souied, Eric H.] Univ Paris Est, Dept Ophthalmol, Ctr Hosp Intercommunal Creteil, Creteil, France.
   [Carnevali, Adriano] Univ Hosp Magna Graecia, Dept Ophthalmol, Catanzaro, Italy.
   [Parravano, Mariacristina; Costanzo, Eliana] Fdn GB Bietti IRCCS, Rome, Italy.
C3 Vita-Salute San Raffaele University; Vita-Salute San Raffaele
   University; IRCCS Ospedale San Raffaele; Universite
   Paris-Est-Creteil-Val-de-Marne (UPEC); CHI Creteil; Magna Graecia
   University of Catanzaro; IRCCS - Fondazione "G.B. Bietti" per lo Studio
   e la Ricerca in Oftalmologia
RP Querques, G (通讯作者)，Univ Vita Salute, IRCCS Osped San Raffaele, Dept Ophthalmol, Via Olgettina 60, I-20132 Milan, Italy.
EM giuseppe.querques@hotmail.it
RI Battista, Marco/AAO-3106-2021; Miere, Alexandra/AIC-4074-2022
OI Battista, Marco/0000-0001-5940-6177; Miere,
   Alexandra/0000-0003-4123-8210; Carnevali, Adriano/0000-0002-9950-6743;
   Querques, Giuseppe/0000-0002-3292-9581; Sacconi,
   Riccardo/0000-0003-2891-2012
CR Agarwal A., 2012, GASSATLAS MACULAR DI, P24
   Bailey ST, 2019, OPHTHALMOL RETINA, V3, P629, DOI 10.1016/j.oret.2019.03.008
   Capuano V, 2017, AM J OPHTHALMOL, V182, P45, DOI 10.1016/j.ajo.2017.07.009
   Carnevali A, 2018, OPHTHALMOL RETINA, V2, P922, DOI 10.1016/j.oret.2018.02.002
   Carnevali Adriano, 2018, Retin Cases Brief Rep, V12 Suppl 1, pS41, DOI 10.1097/ICB.0000000000000648
   Carnevali A, 2017, OPHTHALMOL RETINA, V1, P328, DOI 10.1016/j.oret.2017.01.003
   Carnevali A, 2016, AM J OPHTHALMOL, V169, P189, DOI 10.1016/j.ajo.2016.06.042
   Cicinelli MV, 2020, RETINA-J RET VIT DIS, V40, P499, DOI 10.1097/IAE.0000000000002452
   Davis MD, 2005, ARCH OPHTHALMOL-CHIC, V123, P1484
   Dias JRD, 2018, OPHTHALMOLOGY, V125, P255, DOI 10.1016/j.ophtha.2017.08.030
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Grossniklaus HE, 1998, AM J OPHTHALMOL, V126, P59, DOI 10.1016/S0002-9394(98)00145-7
   Hanutsaha P, 1998, OPHTHALMOLOGY, V105, P1632, DOI 10.1016/S0161-6420(98)99030-3
   Lumbroso B, 2015, RETINA-J RET VIT DIS, V35, P2242, DOI 10.1097/IAE.0000000000000879
   Mandadi SKR, 2021, BRIT J OPHTHALMOL, V105, P1280, DOI 10.1136/bjophthalmol-2018-313576
   Mentes Jale, 2018, Am J Ophthalmol Case Rep, V10, P132, DOI 10.1016/j.ajoc.2018.02.014
   Nehemy MB, 2015, OSLI RETINA, V46, P1056, DOI 10.3928/23258160-20151027-13
   Ohayon A, 2020, RETINA-J RET VIT DIS, V40, P521, DOI 10.1097/IAE.0000000000002430
   Peiretti E, 2019, RETINA-J RET VIT DIS, V39, P1693, DOI 10.1097/IAE.0000000000002234
   Pfau M, 2020, OPHTHALMOL RETINA, V4, P238, DOI 10.1016/j.oret.2019.09.016
   Querques G, 2013, INVEST OPHTH VIS SCI, V54, P6886, DOI 10.1167/iovs.13-11665
   Querques L, 2020, BRIT J OPHTHALMOL, V104, P47, DOI 10.1136/bjophthalmol-2018-313685
   Roisman L, 2016, OPHTHALMOLOGY, V123, P1309, DOI 10.1016/j.ophtha.2016.01.044
   Sacconi R, 2021, BRIT J OPHTHALMOL, V105, P222, DOI 10.1136/bjophthalmol-2020-316054
   Sacconi R, 2018, OPHTHALMOL RETINA, V2, P1097, DOI 10.1016/j.oret.2018.04.016
   Sacconi R, 2018, RETINA-J RET VIT DIS, V38, P2350, DOI 10.1097/IAE.0000000000001873
   Sacconi R, 2019, BRIT J OPHTHALMOL, V103, P1320, DOI 10.1136/bjophthalmol-2018-313004
   Seddon Johanna M, 2016, JAMA Ophthalmol, V134, P1272, DOI 10.1001/jamaophthalmol.2016.3519
   Spaide RF, 2015, AM J OPHTHALMOL, V160, P6, DOI 10.1016/j.ajo.2015.04.012
   Xu D, 2018, AM J OPHTHALMOL, V187, P10, DOI 10.1016/j.ajo.2017.12.005
   Yang J, 2019, AM J OPHTHALMOL, V208, P1, DOI 10.1016/j.ajo.2019.06.017
   Zhang QQ, 2017, OPHTHALMOL RETINA, V1, P124, DOI 10.1016/j.oret.2016.08.005
NR 32
TC 2
Z9 2
U1 0
U2 1
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1120-6721
EI 1724-6016
J9 EUR J OPHTHALMOL
JI Eur. J. Ophthalmol.
PD NOV
PY 2021
VL 31
IS 6
BP 3164
EP 3176
AR 1120672120986370
DI 10.1177/1120672120986370
EA JAN 2021
PG 13
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA XA5GJ
UT WOS:000678258800001
PM 33445977
DA 2022-11-30
ER

PT J
AU Milani, P
   Pece, A
   Pierro, L
   Bergamini, F
AF Milani, Paolo
   Pece, Alfredo
   Pierro, Luisa
   Bergamini, Fulvio
TI Imaging of Naive Myopic Choroidal Neovascularization by Spectral-Domain
   Optical Coherence Tomography
SO OPHTHALMOLOGICA
LA English
DT Article
DE Myopia; Pathologic myopia; Optical coherence tomography; Spectral-domain
   optical coherence tomography; Choroidal neovascularization; Myopic
   choroidal neovascularization
ID RETINAL-PIGMENT EPITHELIUM; PATHOLOGICAL MYOPIA; MACULAR DEGENERATION;
   PHOTODYNAMIC THERAPY; INTRAVITREAL RANIBIZUMAB; VITREOMACULAR ADHESION;
   LACQUER CRACKS; FOLLOW-UP; BEVACIZUMAB; FEATURES
AB Purpose:To assess the tomographic features of myopic choroidal neovascularization by spectral-domain optical coherence tomography. Methods: We consecutively reviewed the charts of patients with pathologic myopia, recent visual acuity deterioration and active macular neovascularization. Specific tomographic changes were studied in 25 eyes by two authors independently. Results: The mean age of patients eligible for the study was 63.4 (+/- 18.2) years. Main tomographic outcomes were the hyperreflectivity of the lesion in 88% of cases (95% CI 0.74-1.02), absence of the external limiting membrane in 88% (95% CI 0.84-1.02), and retinal thickening in 83% (95% CI 0.67-0.99). The internal plexiform layer remained discernible in 83% (95% CI 0.67-0.99) of cases, the inner nuclear layer in 62% (95% CI 0.37-0.80), the external plexiform layer in 48% (95% CI 10.27-0.69). Retinal edema was noted in 48% (95% CI 0.26-0.70) of patients. Conclusions: Myopic choroidal neovascularization appears predominantly hyperreflective, causes thickening of the corresponding retina and mainly involves the external retinal segments. Retinal fluid is infrequent. (C) 2014 S. Karger AG, Basel
C1 [Milani, Paolo; Bergamini, Fulvio] Ist Auxol Italian, Milan, Italy.
   [Pece, Alfredo] Fdn Retina 3000, Milan, Italy.
   [Pierro, Luisa] Univ Milan, Osped San Raffaele, I-20127 Milan, Italy.
C3 IRCCS Istituto Auxologico Italiano; University of Milan; Vita-Salute San
   Raffaele University; IRCCS Ospedale San Raffaele
RP Milani, P (通讯作者)，Via Stefini 10, IT-20125 Milan, Italy.
EM dottpaolomilani@hotmail.com
RI Pierro, Luisa/AAN-3900-2020
OI pierro, luisa/0000-0003-2168-5224; Milani, Paolo/0000-0002-0409-6201
FU Retina 3000 Foundation
FX Partially granted by the Retina 3000 Foundation.
CR AVILA MP, 1984, OPHTHALMOLOGY, V91, P1573
   Baba T, 2002, ACTA OPHTHALMOL SCAN, V80, P82, DOI 10.1034/j.1600-0420.2002.800116.x
   Elsner AE, 1996, VISION RES, V36, P191, DOI 10.1016/0042-6989(95)00100-E
   Framme C, 2010, INVEST OPHTH VIS SCI, V51, P5965, DOI 10.1167/iovs.10-5779
   Fujiwara T, 2009, AM J OPHTHALMOL, V148, P445, DOI 10.1016/j.ajo.2009.04.029
   Garcia-Layana A, 2006, BRIT J OPHTHALMOL, V90, P555, DOI 10.1136/bjo.2005.085555
   Gharbiya M, 2010, AM J OPHTHALMOL, V149, P458, DOI 10.1016/j.ajo.2009.10.010
   GROSSNIKLAUS HE, 1992, RETINA-J RET VIT DIS, V12, P127, DOI 10.1097/00006982-199212020-00009
   Harman AM, 1999, VISUAL NEUROSCI, V16, P619, DOI 10.1017/S0952523899164022
   Hartnett ME, 1996, OPHTHALMOLOGY, V103, P58, DOI 10.1016/S0161-6420(96)30731-8
   Hayashi K, 2005, GRAEF ARCH CLIN EXP, V243, P13, DOI 10.1007/s00417-004-0960-5
   Hayashi K, 2010, OPHTHALMOLOGY, V117, P1595, DOI 10.1016/j.ophtha.2009.11.003
   Hayashi K, 2009, GRAEF ARCH CLIN EXP, V247, P609, DOI 10.1007/s00417-008-1021-2
   Ikuno Y, 2010, INVEST OPHTH VIS SCI, V51, P3721, DOI 10.1167/iovs.09-3493
   Ikuno Y, 2009, AM J OPHTHALMOL, V147, P94, DOI 10.1016/j.ajo.2008.07.017
   Introini U, 2012, EYE, V26, P976, DOI 10.1038/eye.2012.75
   Keane PA, 2008, BRIT J OPHTHALMOL, V92, P1081, DOI 10.1136/bjo.2008.138891
   KLEIN RM, 1988, AM J OPHTHALMOL, V106, P282, DOI 10.1016/0002-9394(88)90362-5
   Kojima A, 2004, GRAEF ARCH CLIN EXP, V242, P114, DOI 10.1007/s00417-003-0803-9
   Lalloum F, 2010, RETINA-J RET VIT DIS, V30, P399, DOI 10.1097/IAE.0b013e3181bcef24
   Lalwani GA, 2009, AM J OPHTHALMOL, V148, P43, DOI 10.1016/j.ajo.2009.01.024
   Lee SJ, 2009, AM J OPHTHALMOL, V147, P621, DOI 10.1016/j.ajo.2008.10.003
   Liakopoulos S, 2008, INVEST OPHTH VIS SCI, V49, P5048, DOI 10.1167/iovs.08-1877
   MILLER H, 1986, INVEST OPHTH VIS SCI, V27, P1644
   Ohno-Matsui K, 2003, BRIT J OPHTHALMOL, V87, P570, DOI 10.1136/bjo.87.5.570
   Parodi MB, 2007, ACTA OPHTHALMOL SCAN, V85, P50, DOI 10.1111/j.1600-0420.2006.00738.x
   Sadda SR, 2010, GRAEF ARCH CLIN EXP, V248, P175, DOI 10.1007/s00417-009-1193-4
   Semoun O, 2009, BRIT J OPHTHALMOL, V93, P182, DOI 10.1136/bjo.2008.145235
   Vadala M, 2011, BRIT J OPHTHALMOL, V95, P657, DOI 10.1136/bjo.2009.174243
   Wakabayashi T, 2010, BRIT J OPHTHALMOL, V94, P611, DOI 10.1136/bjo.2009.163535
   Waldstein SM, 2012, RETINA-J RET VIT DIS, V32, P424, DOI 10.1097/IAE.0b013e3182278b80
   Wang NK, 2012, AM J OPHTHALMOL, V153, P669, DOI 10.1016/j.ajo.2011.08.039
   Wolf S, 2010, OPHTHALMOLOGICA, V224, P333, DOI 10.1159/000313814
   Yoshida A, 1996, GRAEF ARCH CLIN EXP, V234, pS239, DOI 10.1007/BF02343079
   Yoshida T, 2003, OPHTHALMOLOGY, V110, P1297, DOI 10.1016/S0161-6420(03)00461-5
NR 35
TC 10
Z9 10
U1 0
U2 4
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0030-3755
EI 1423-0267
J9 OPHTHALMOLOGICA
JI Ophthalmologica
PY 2014
VL 232
IS 1
BP 28
EP 36
DI 10.1159/000357980
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA AJ9AW
UT WOS:000338000200003
PM 24751654
DA 2022-11-30
ER

PT J
AU Virgili, G
   Acosta, R
   Bentley, SA
   Giacomelli, G
   Allcock, C
   Evans, JR
AF Virgili, Gianni
   Acosta, Ruthy
   Bentley, Sharon A.
   Giacomelli, Giovanni
   Allcock, Claire
   Evans, Jennifer R.
TI Reading aids for adults with low vision
SO COCHRANE DATABASE OF SYSTEMATIC REVIEWS
LA English
DT Review
DE *Reading; *Sensory Aids; Eyeglasses; Lenses; Macular Degeneration
   [complications]; Optical Devices [*standards]; Randomized Controlled
   Trials as Topic; Vision; Low [*rehabilitation]; Visual Acuity; Visually
   Impaired Persons [*rehabilitation]; Adult; Humans
ID VISUAL IMPAIRMENT; MACULAR DEGENERATION; FRESNEL PRISMS; PERFORMANCE;
   REHABILITATION; PSYCHOPHYSICS; IMPROVE; FILTERS; PEOPLE; IMPACT
AB Background
   The purpose of low-vision rehabilitation is to allow people to resume or to continue to perform daily living tasks, with reading being one of the most important. This is achieved by providing appropriate optical devices and special training in the use of residual-vision and low-vision aids, which range from simple optical magnifiers to high-magnification video magnifiers.
   Objectives
   To assess the effects of different visual reading aids for adults with low vision.
   Search methods
   We searched the Cochrane Central Register of Controlled Trials (CENTRAL) (which contains the Cochrane Eyes and Vision Trials Register) (2017, Issue 12); MEDLINE Ovid; Embase Ovid; BIREME LILACS, OpenGrey, the ISRCTN registry; ClinicalTrials.gov and the World Health Organization (WHO) International Clinical Trials Registry Platform (ICTRP). The date of the search was 17 January 2018.
   Selection criteria
   This review includes randomised and quasi-randomised trials that compared any device or aid used for reading to another device or aid in people aged 16 or over with low vision as defined by the study investigators. We did not compare low-vision aids with no low-vision aid since it is obviously not possible to measure reading speed, our primary outcome, in people that cannot read ordinary print. We considered reading aids that maximise the person's visual reading capacity, for example by increasing image magnification (optical and electronic magnifiers), augmenting text contrast (coloured filters) or trying to optimise the viewing angle or gaze position (such as prisms). We have not included studies investigating reading aids that allow reading through hearing, such as talking books or screen readers, or through touch, such as Braille-based devices and we did not consider rehabilitation strategies or complex low-vision interventions.
   Data collection and analysis
   We used standard methods expected by Cochrane. At least two authors independently assessed trial quality and extracted data. The primary outcome of the review was reading speed in words per minute. Secondary outcomes included reading duration and acuity, ease and frequency of use, quality of life and adverse outcomes. We graded the certainty of the evidence using GRADE.
   Main results
   We included 11 small studies with a cross-over design (435 people overall), one study with two parallel arms (37 participants) and one study with three parallel arms (243 participants). These studies took place in the USA (7 studies), the UK (5 studies) and Canada (1 study). Age-related macular degeneration (AMD) was the most frequent cause of low vision, with 10 studies reporting 50% or more participants with the condition. Participants were aged 9 to 97 years in these studies, but most were older (the median average age across studies was 71 years). None of the studies were masked; otherwise we largely judged the studies to be at low risk of bias. All studies reported the primary outcome: results for reading speed. None of the studies measured or reported adverse outcomes.
   Reading speed may be higher with stand-mounted closed circuit television (CCTV) than with optical devices (stand or hand magnifiers) (low-certainty evidence, 2 studies, 92 participants). There was moderate-certainty evidence that reading duration was longer with the electronic devices and that they were easier to use. Similar results were seen for electronic devices with the camera mounted in a 'mouse'. Mixed results were seen for head-mounted devices with one study of 70 participants finding a mouse-based head-mounted device to be better than an optical device and another study of 20 participants finding optical devices better (low-certainty evidence). Low-certainty evidence from three studies (93 participants) suggested no important differences in reading speed, acuity or ease of use between stand mounted and head-mounted electronic devices. Similarly, low-certainty evidence from one study of 100 participants suggested no important differences between a 9.7" tablet computer and stand-mounted CCTV in reading speed, with imprecise estimates (other outcomes not reported).
   Low-certainty evidence showed little difference in reading speed in one study with 100 participants that added electronic portable devices to preferred optical devices. One parallel-arm study in 37 participants found low-certainty evidence of higher reading speed at one month if participants received a CCTV at the initial rehabilitation consultation instead of a standard low-vision aids prescription alone.
   A parallel-arm study including 243 participants with AMD found no important differences in reading speed, reading acuity and quality of life between prism spectacles and conventional spectacles. One study in 10 people with AMD found that reading speed with several overlay coloured filters was no better and possibly worse than with a clear filter (low-certainty evidence, other outcomes not reported).
   Authors' conclusions
   There is insufficient evidence supporting the use of a specific type of electronic or optical device for the most common profiles of low vision aid users. However, there is some evidence that stand-mounted electronic devices may improve reading speeds compared with optical devices. There is less evidence to support the use of head-mounted or portable electronic devices; however, the technology of electronic devices may have improved since the studies included in this review took place, and modern portable electronic devices have desirable properties such as flexible use of magnification. There is no good evidence to support the use of filters or prism spectacles. Future research should focus on assessing sustained long-term use of each device and the effect of different training programmes on its use, combined with investigation of which patient characteristics predict performance with different devices, including some of the more costly electronic devices.
C1 [Virgili, Gianni; Giacomelli, Giovanni] Univ Florence, Eye Clin, Dept Translat Surg & Med, Largo Brambilla 3, I-50134 Florence, Italy.
   [Acosta, Ruthy] Growth Hlth Res, Barcelona, Spain.
   [Bentley, Sharon A.] Queensland Univ Technol, Sch Optometry & Vis Sci, Brisbane, Qld, Australia.
   [Evans, Jennifer R.] London Sch Hyg & Trop Med, ICEH, Cochrane Eyes & Vis, London, England.
C3 University of Florence; Queensland University of Technology (QUT);
   University of London; London School of Hygiene & Tropical Medicine
RP Virgili, G (通讯作者)，Univ Florence, Eye Clin, Dept Translat Surg & Med, Largo Brambilla 3, I-50134 Florence, Italy.
EM gianni.virgili@unifi.it
RI giacomelli, giovanni/ABC-6173-2020; Virgili, Gianni/P-6607-2014
OI Virgili, Gianni/0000-0002-9960-2989; Bentley, Sharon/0000-0003-0146-4248
FU The College of Optometrists, UK; National Institute for Health Research
   (NIHR), UK; Department of Health through NIHR; NIHR, via Cochrane
   Infrastructure funding
FX External sources; The College of Optometrists, UK.; The College provided
   funding to Cochrane Eyes and Vision to update this review (2018).;
   National Institute for Health Research (NIHR), UK.; Richard Wormald,
   Co-ordinating Editor for Cochrane Eyes and Vision (CEV) acknowledges
   financial support for his CEV research sessions from the Department of
   Health through the award made by the NIHR to Moorfields Eye Hospital NHS
   Foundation Trust and UCL Institute of Ophthalmology for a Specialist
   Biomedical Research Centre for Ophthalmology.; This review update was
   supported by the NIHR, via Cochrane Infrastructure funding to the CEV UK
   editorial base.; The views and opinions expressed therein are those of
   the authors and do not necessarily reflect those of the Systematic
   Reviews Programme, NIHR, NHS or the Department of Health.
CR Abba K, 2011, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD008122.pub2
   AHN SJ, 1995, VISION RES, V35, P1939, DOI 10.1016/0042-6989(94)00294-V
   AHN SJ, 1995, VISION RES, V35, P1931, DOI 10.1016/0042-6989(94)00293-U
   Alabdulkader B, 2012, OPTOMETRY VISION SCI, V89, P1327, DOI 10.1097/OPX.0b013e318264cb1a
   ALDERSON P, 2002, COCHRANE COLLABORATI
   Bailie M, 2013, CLIN EXP OPTOM, V96, P450, DOI 10.1111/cxo.12031
   Binns AM, 2012, SURV OPHTHALMOL, V57, P34, DOI 10.1016/j.survophthal.2011.06.006
   BLASKEY P, 1990, J LEARN DISABIL, V23, P604, DOI 10.1177/002221949002301007
   Bray N, 2017, ACTA OPHTHALMOL, V95, pE415, DOI 10.1111/aos.13255
   Cheng D, 2001, OPHTHAL PHYSL OPT, V21, P312, DOI 10.1046/j.1475-1313.2001.00570.x
   Cheong AMY, 2009, OPTOMETRY VISION SCI, V86, P1078, DOI 10.1097/OPX.0b013e3181b4c4d9
   Cheong AMY, 2005, OPTOMETRY VISION SCI, V82, P114, DOI 10.1097/01.OPX.0000153244.93582.FF
   COHEN JM, 1991, OPTOMETRY VISION SCI, V68, P795, DOI 10.1097/00006324-199110000-00007
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Congdon NG, 2003, JAMA-J AM MED ASSOC, V290, P2057, DOI 10.1001/jama.290.15.2057
   Culham, 2005, COMMUNICATION
   Culham LE, 2004, OPHTHAL PHYSL OPT, V24, P281, DOI 10.1111/j.1475-1313.2004.00193.x
   Culham LE, 2009, OPHTHAL PHYSL OPT, V29, P138, DOI 10.1111/j.1475-1313.2008.00630.x
   Bonatti FAD, 2008, ARQ BRAS OFTALMOL, V71, P385, DOI 10.1590/S0004-27492008000300015
   Demers-Turco P, 2001, INVESTIGATIVE OPHTHA, V42
   Dickinson, 1998, LOW VISION PRINCIPLE
   Dickinson C., 2017, COMMUNICATION
   Elbourne DR, 2002, INT J EPIDEMIOL, V31, P140, DOI 10.1093/ije/31.1.140
   Eperjesi F, 2004, ACTA OPHTHALMOL SCAN, V82, P695, DOI 10.1111/j.1600-0420.2004.00371.x
   Glanville JM, 2006, J MED LIBR ASSOC, V94, P130
   Goodrich G., 2001, OPTOMETRY VISION SCI, V78, P291
   Goodrich G L, 2001, Optometry, V72, P519
   GOODRICH GL, 1977, AM J OPTOM PHYS OPT, V54, P312
   Goodrich GL, 2004, J VISUAL IMPAIRMENT, V98, P148
   Goodrich GL, 2000, OPTOMETRY VISION SCI, V77, P126
   Goodrich GL, 1998, LOW VISION READING E, P25
   Goodrich GL, 2000, OPTOMETRY VISION SCI, V77, P125
   HIGGINS JPT, 2011, COCHRANE HDB SYSTEMA, V0001
   Higgins J, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.ED000049
   Hirji KF, 2009, TRIALS, V10, DOI 10.1186/1745-6215-10-33
   Hooper P, 2008, CAN J OPHTHALMOL, V43, P180, DOI 10.3129/i08-001
   HUMPHRY RC, 1986, T OPHTHAL SOC UK, V105, P296
   Jackson Mary Lou, 2017, Digit J Ophthalmol, V23, P1, DOI 10.5693/djo.01.2017.02.001
   Jackson ML, 2017, COMMUNICATION
   JACOBS RJ, 1990, J VISUAL IMPAIR BLIN, V84, P569
   Johnson Azeezat, 2017, COMMUNICATION
   Kaida M, 2005, JAPANESE J CLIN OPHT, V59, P437
   Kleweno CP, 2001, J REHABIL RES DEV, V38, P431
   Kuyk T, 1990, J VISION REHABILITAT, V4, P21
   Langelaan M, 2007, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD006543, DOI 10.1002/14651858.CD006543]
   Lavinsky J, 2001, INT J REHABIL RES, V24, P337, DOI 10.1097/00004356-200112000-00012
   LAWTON TB, 1989, OPHTHALMOLOGY, V96, P115
   LEAT SJ, 1994, OPTOMETRY VISION SCI, V71, P199, DOI 10.1097/00006324-199403000-00009
   LEGGE GE, 1985, VISION RES, V25, P239, DOI 10.1016/0042-6989(85)90117-8
   LEGGE GE, 1985, VISION RES, V25, P253, DOI 10.1016/0042-6989(85)90118-X
   LEGGE GE, 1991, OPTOMETRY VISION SCI, V68, P763, DOI 10.1097/00006324-199110000-00001
   LEGGE GE, 1989, CLIN VISION SCI, V4, P51
   Legge GE, 2007, PSYCHOPHYSICS READIN
   Margrain TH, 1999, BRIT MED J, V318, P1504, DOI 10.1136/bmj.318.7197.1504
   Margrain TH, 2000, BRIT J OPHTHALMOL, V84, P919, DOI 10.1136/bjo.84.8.919
   Markowitz SN, 2013, ACTA OPHTHALMOL, V91, P207, DOI 10.1111/j.1755-3768.2011.02336.x
   Massof RW, 1998, OPTOMETRY VISION SCI, V75, P349, DOI 10.1097/00006324-199805000-00025
   *MCMASTER U, 2014, GRADEPRO GDT
   Morrice E, 2017, EYE, V31, P865, DOI 10.1038/eye.2016.309
   NILSSON UL, 1990, CLIN VISION SCI, V6, P3
   Ortiz A, 1999, OPTOMETRY VISION SCI, V76, P755, DOI 10.1097/00006324-199911000-00024
   Parodi MB, 2004, CLIN REHABIL, V18, P828, DOI 10.1191/0269215504cr801oa
   Pascolini D, 2012, BRIT J OPHTHALMOL, V96, P614, DOI 10.1136/bjophthalmol-2011-300539
   Peterson RC, 2003, AM J OPHTHALMOL, V136, P1129, DOI 10.1016/S0002-9394(03)00567-1
   Rees G, 2006, INVESTIGATIVE OPHTHA, V47
   Reeves BC, 2004, BRIT J OPHTHALMOL, V88, P1443, DOI 10.1136/bjo.2003.037457
   Riley AK, 2016, INVEST OPHTHALMOL, V57, P5169
   Rohrschneider K, 1998, OPHTHALMOLOGE, V95, P110, DOI 10.1007/s003470050246
   ROSENBERG R, 1989, OPTOMETRY VISION SCI, V66, P747, DOI 10.1097/00006324-198911000-00004
   ROSSI PW, 1990, NEUROLOGY, V40, P1597, DOI 10.1212/WNL.40.10.1597
   Rubin GS, 2013, VISION RES, V90, P43, DOI 10.1016/j.visres.2013.02.015
   Schtinemann HJ, 2011, COCHRANE HDB SYSTEMA
   Scott IU, 1999, AM J OPHTHALMOL, V128, P54, DOI 10.1016/S0002-9394(99)00108-7
   Scott IU, 2002, AM J OPHTHALMOL, V134, P857, DOI 10.1016/S0002-9394(02)01795-6
   SHUTTLEWORTH GN, 1995, BRIT J OPHTHALMOL, V79, P719, DOI 10.1136/bjo.79.8.719
   Sloan L L, 1971, Int Ophthalmol Clin, V11, P19
   Smallfield S, 2013, AM J OCCUP THER, V67, P288, DOI 10.5014/ajot.2013.004929
   Smith HJ, 2005, ARCH OPHTHALMOL-CHIC, V123, P1042, DOI 10.1001/archopht.123.8.1042
   Sonsino J, 2000, OPTOMETRY VISION SCI, V77, P239
   Spitzberg L A, 1995, J Am Optom Assoc, V66, P25
   Stelmack J, 1991, J Am Optom Assoc, V62, P53
   Stelmack J., 2005, COMMUNICATION
   Stelmack JA, 2008, ARCH OPHTHALMOL-CHIC, V126, P608, DOI 10.1001/archopht.126.5.608
   Sterne JAC, 2011, COCHRANE HDB SYSTEMA
   Taylor JJ, 2017, OPHTHAL PHYSL OPT, V37, P370, DOI 10.1111/opo.12379
   TIELSCH JM, 1990, ARCH OPHTHALMOL-CHIC, V108, P286, DOI 10.1001/archopht.1990.01070040138048
   Veritas Health Innovation, 2015, COV VERS
   Veteran Affairs Technology Assessment Program, 2003, OPT DEV AD LOW VIS S
   Virgili G, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003303.pub2
   Virgili G, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003303.pub3
   VIRTANEN P, 1991, ACTA OPHTHALMOL, V69, P484
   Watson GR, 2005, J REHABIL RES DEV, V42, P459, DOI 10.1682/JRRD.2004.11.0137
   Wolffsohn, 2003, E COMMUNICATION 0131
   Wolffsohn JS, 2002, OPHTHAL PHYSL OPT, V22, P300, DOI 10.1046/j.1475-1313.2002.00036.x
   World Health Organization, INT CLASS DIS ICD
   World Health Organization, COMM LANG FUNCT DIS
NR 96
TC 16
Z9 17
U1 1
U2 24
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1469-493X
EI 1361-6137
J9 COCHRANE DB SYST REV
JI Cochrane Database Syst Rev.
PY 2018
IS 4
AR CD003303
DI 10.1002/14651858.CD003303.pub4
PG 104
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA GE3HX
UT WOS:000431105500037
PM 29664159
OA Green Published, Green Accepted
DA 2022-11-30
ER

PT J
AU Colantuono, D
   Souied, EH
   Borrelli, E
   Capuano, V
   Amoroso, F
   Sacconi, R
   Jung, C
   Querques, G
   Miere, A
AF Colantuono, Donato
   Souied, Eric H.
   Borrelli, Enrico
   Capuano, Vittorio
   Amoroso, Francesca
   Sacconi, Riccardo
   Jung, Camille
   Querques, Giuseppe
   Miere, Alexandra
TI Quantitative deep vascular complex analysis of different AMD stages on
   optical coherence tomography angiography
SO EUROPEAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE Deep vascular complex; deep capillary plexus; OCTA; age-related macular
   degeneration
ID MACULAR DEGENERATION; VESSEL DENSITY; RETINAL NONPERFUSION; THERAPY
AB Aims: To investigate alterations in deep retinal vascular complex (DVC) in patients with non-neovascular intermediate AMD (iAMD), treatment-naive quiescent macular neovascularization (qMNV), exudative AMD (eAMD) by means of OCT angiography (OCTA). Methods: Patients with iAMD, qMNV, eAMD and healthy controls presenting in the Department of Ophthalmology of the Centre Hospitalier Intercommunal de Creteil between January 2016 and January 2018, were retrospectively included. 3 x 3-mm OCTA (AngioVue RTVue XR Avanti) perfusion density (PD) of DVC was computed in all groups at baseline and follow up (12.0 +/- 1.1 months). Results: A total of 46 eyes of 45 patients were enrolled: 11/46 iAMD, 10/46 qMNV, 13/46 eAMD, 12/46 control eyes. PD showed a significant decrease during follow-up in qMNV (p = 0.0059) and iAMD (p = 0.0076) eyes. PD in eAMD and healthy controls didn't show significant changes. Conclusion: PD decreases at the level of DVC in eyes with qMNV and iAMD, while in eAMD eyes, PD is stable throughout follow up, suggesting that repeated anti-vascular endothelial growth factor (VEGF) injections do not impact on the DVC PD.
C1 [Colantuono, Donato; Souied, Eric H.; Capuano, Vittorio; Amoroso, Francesca; Miere, Alexandra] Ctr Hosp Intercommunal Creteil, Dept Ophthalmol, Creteil, France.
   [Borrelli, Enrico; Sacconi, Riccardo; Querques, Giuseppe] Univ Vita Salute San Raffaele, IRCCS San Raffaele Sci Inst, Dept Ophthalmol, Milan, Italy.
   [Jung, Camille] Ctr Hosp Intercommunal Creteil, Clin Res Ctr, GRC Macula, Creteil, France.
   [Jung, Camille] Ctr Hosp Intercommunal Creteil, Biol Ressources Ctr, Creteil, France.
   [Miere, Alexandra] Univ Paris Est Creteil, EA N 3956, Lab Images Signals & Intelligent Syst LISS, Creteil, France.
C3 Universite Paris-Est-Creteil-Val-de-Marne (UPEC); CHI Creteil;
   Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele;
   Universite Paris-Est-Creteil-Val-de-Marne (UPEC); CHI Creteil;
   Universite Paris-Est-Creteil-Val-de-Marne (UPEC); CHI Creteil;
   Universite Paris-Est-Creteil-Val-de-Marne (UPEC)
RP Querques, G (通讯作者)，Univ Vita Salute IRCCS Osped San Raffaele, Dept Ophthalmol, Via Olgettina 60, I-20132 Milan, Italy.
EM querques.giuseppe@hsr.it
RI Miere, Alexandra/AIC-4074-2022
OI Miere, Alexandra/0000-0003-4123-8210; Querques,
   Giuseppe/0000-0002-3292-9581; Sacconi, Riccardo/0000-0003-2891-2012
CR Anand R, 2000, OPHTHALMOLOGY, V107, P2224
   Barash A, 2020, RETINA-J RET VIT DIS, V40, P648, DOI 10.1097/IAE.0000000000002433
   Borrelli E, 2020, EYE, V34, P2264, DOI 10.1038/s41433-020-0804-5
   Borrelli E, 2017, AM J OPHTHALMOL, V181, P1, DOI 10.1016/j.ajo.2017.06.005
   Campochiaro PA, 2014, OPHTHALMOLOGY, V121, P1783, DOI 10.1016/j.ophtha.2014.03.021
   Campochiaro PA, 2013, OPHTHALMOLOGY, V120, P795, DOI 10.1016/j.ophtha.2012.09.032
   Carnevali A, 2016, AM J OPHTHALMOL, V169, P189, DOI 10.1016/j.ajo.2016.06.042
   Coleman HR, 2008, LANCET, V372, P1835, DOI 10.1016/S0140-6736(08)61759-6
   COSCAS F, 2016, INVEST OPHTH VIS SCI, V57, DOI DOI 10.1167/IOVS.15-18793
   Falavarjani KG, 2017, INVEST OPHTH VIS SCI, V58, P30, DOI 10.1167/iovs.16-20579
   Feigl B, 2009, PROG RETIN EYE RES, V28, P63, DOI 10.1016/j.preteyeres.2008.11.004
   Ferris FL, 2013, OPHTHALMOLOGY, V120, P844, DOI 10.1016/j.ophtha.2012.10.036
   Garcia-Layana A, 2017, CLIN INTERV AGING, V12, P1579, DOI 10.2147/CIA.S142685
   Granit R, 1933, J PHYSIOL-LONDON, V77, P207, DOI 10.1113/jphysiol.1933.sp002964
   Hikichi T, 2019, INVEST OPHTH VIS SCI, V60, P1088, DOI 10.1167/iovs.18-24522
   Jia YL, 2012, BIOMED OPT EXPRESS, V3, DOI 10.1364/BOE.3.003127
   Kim SV, 2017, GRAEF ARCH CLIN EXP, V255, P2165, DOI 10.1007/s00417-017-3782-y
   Kim SV, 2019, INVEST OPHTH VIS SCI, V60, P1412, DOI 10.1167/iovs.18-24389
   Lee EK, 2015, INVEST OPHTH VIS SCI, V56, P3976, DOI 10.1167/iovs.15-17013
   Lee SC, 2020, AM J OPHTHALMOL, V212, P7, DOI 10.1016/j.ajo.2019.11.031
   Ma J, 2017, OPHTHALMOL EYE DIS, V9, DOI 10.1177/1179172116686075
   Querques G, 2013, INVEST OPHTH VIS SCI, V54, P6886, DOI 10.1167/iovs.13-11665
   Ramkumar HL, 2018, RETINA-J RET VIT DIS, V38, P2159, DOI 10.1097/IAE.0000000000001867
   Spaide RF, 2015, JAMA OPHTHALMOL, V133, P45, DOI 10.1001/jamaophthalmol.2014.3616
   Toto L, 2016, RETINA-J RET VIT DIS, V36, P1566, DOI 10.1097/IAE.0000000000000962
   Wangsa-Wirawan ND, 2003, ARCH OPHTHALMOL-CHIC, V121, P547, DOI 10.1001/archopht.121.4.547
   You QS, 2020, AM J OPHTHALMOL, V209, P206, DOI 10.1016/j.ajo.2019.09.004
NR 27
TC 4
Z9 4
U1 0
U2 0
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1120-6721
EI 1724-6016
J9 EUR J OPHTHALMOL
JI Eur. J. Ophthalmol.
PD SEP
PY 2021
VL 31
IS 5
BP 2474
EP 2480
AR 1120672120968758
DI 10.1177/1120672120968758
EA NOV 2020
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA XG9FP
UT WOS:000677781500001
PM 33143480
DA 2022-11-30
ER

PT J
AU Scalzo, GC
   Carnevali, A
   Piccoli, G
   Ceravolo, D
   Bruzzichessi, D
   Iuliano, R
   Tallerico, R
   Gatti, V
   Giannaccare, G
   Scorcia, V
AF Scalzo, Giovanna Carnovale
   Carnevali, Adriano
   Piccoli, Gabriele
   Ceravolo, Domenico
   Bruzzichessi, Donatella
   Iuliano, Rodolfo
   Tallerico, Rossana
   Gatti, Valentina
   Giannaccare, Giuseppe
   Scorcia, Vincenzo
TI Multimodal imaging of Hypotrichosis with juvenile macular dystrophy: a
   case report
SO BMC OPHTHALMOLOGY
LA English
DT Article
DE CH3 mutation; Juvenile macular dystrophy; MfERG; Optical coherence
   tomography angiography; Case report
ID CDH3; CADHERIN; ANGIOGRAPHY; EXPRESSION
AB Background To report the first Italian case of hypotrichosis with juvenile macular dystrophy complicated by macular neovascularization diagnosed through multimodal imaging. Case presentation An 11-year-old boy was referred to our Institution for bilateral maculopathy of unknown origin. Multimodal imaging helps the diagnosis of Juvenile Macular Dystrophy with Hypotrichosis (HJMD). Fundus examination showed several alterations of the retinal pigment epithelium and circular pigmented area of chorioretinal atrophy. Structural spectral domain optical coherence tomography (OCT) showed some backscattering phenomenon with several alterations of retinal pigment epithelium and photoreceptor layer in both eyes. Moreover, OCT showed hyperreflective lesion beneath the neuroepithelium in left eye. OCT angiography (OCT-A) revealed a pathologic neovascular network in choriocapillaris plexus, probably the result of a fibrovascular membrane. Multifocal electroretinograms (MfERGs) showed functional alterations in 12.22 degrees of the central retina. In order to confirm the suspicion of HJMD, the child and both parents underwent genetic testing. Both parents resulted to be heterozygous healthy carriers of a single variation. Conclusion Multimodal imaging, in particular OCT-A, is a useful aid, along to clinical findings and genetics, for the diagnosis of inherited retinal dystrophies.
C1 [Scalzo, Giovanna Carnovale; Carnevali, Adriano; Piccoli, Gabriele; Ceravolo, Domenico; Bruzzichessi, Donatella; Gatti, Valentina; Giannaccare, Giuseppe; Scorcia, Vincenzo] Magna Graecia Univ Catanzaro, Dept Ophthalmol, Viale Europa, Catanzaro, Italy.
   [Iuliano, Rodolfo; Tallerico, Rossana] Magna Graecia Univ Catanzaro, Clin & Expt Med Dept, Med Genet Unit, Catanzaro, Italy.
C3 Magna Graecia University of Catanzaro; Magna Graecia University of
   Catanzaro
RP Carnevali, A (通讯作者)，Magna Graecia Univ Catanzaro, Dept Ophthalmol, Viale Europa, Catanzaro, Italy.
EM adrianocarnevali@unicz.it
CR Ahmed A, 2021, SKIN APPENDAGE DISOR, V7, P75, DOI 10.1159/000511741
   Burke JM, 1999, INVEST OPHTH VIS SCI, V40, P2963
   Carnevali A, 2017, OPHTHALMOL RETINA, V1, P328, DOI 10.1016/j.oret.2017.01.003
   Corbelli E, 2018, RETINA-J RET VIT DIS, V38, P2128, DOI 10.1097/IAE.0000000000001859
   Fan Kenneth C, 2019, Am J Ophthalmol Case Rep, V15, P100486, DOI 10.1016/j.ajoc.2019.100486
   Halford S, 2012, ARCH OPHTHALMOL-CHIC, V130, P1490, DOI 10.1001/archophthalmol.2012.708
   Hood DC, 2012, DOC OPHTHALMOL, V124, P1, DOI 10.1007/s10633-011-9296-8
   Hull S, 2016, JAMA OPHTHALMOL, V134, P992, DOI 10.1001/jamaophthalmol.2016.2089
   Indelman M, 2007, CLIN EXP DERMATOL, V32, P191, DOI 10.1111/j.1365-2230.2006.02335.x
   Indelman M, 2005, BRIT J DERMATOL, V153, P635, DOI 10.1111/j.1365-2133.2005.06734.x
   Karczewski KJ, 2020, NATURE, V581, P434, DOI 10.1038/s41586-020-2308-7
   Karti Omer, 2017, Am J Ophthalmol Case Rep, V7, P129, DOI 10.1016/j.ajoc.2017.06.007
   Khan AO, 2016, OPHTHALMIC GENET, V37, P301, DOI 10.3109/13816810.2015.1071411
   Leibu R, 2006, OPHTHALMOLOGY, V113, P841, DOI 10.1016/j.ophtha.2005.10.065
   Lek M, 2016, NATURE, V536, P285, DOI 10.1038/nature19057
   Marano F, 2000, GRAEF ARCH CLIN EXP, V238, P760, DOI 10.1007/s004170000186
   Narayan A, 2019, BMJ CASE REP, V12, DOI 10.1136/bcr-2019-232342
   Nasser F, 2019, DOC OPHTHALMOL, V138, P153, DOI 10.1007/s10633-019-09675-w
   Querques L, 2020, BRIT J OPHTHALMOL, V104, P47, DOI 10.1136/bjophthalmol-2018-313685
   Rabiolo A, 2016, EXPERT REV OPHTHALMO, V11, P243, DOI 10.1080/17469899.2016.1209409
   Shimomura Y, 2008, DEVELOPMENT, V135, P743, DOI 10.1242/dev.006718
   SHIMOYAMA Y, 1989, J CELL BIOL, V109, P1787, DOI 10.1083/jcb.109.4.1787
   Sprecher E, 2001, NAT GENET, V29, P134, DOI 10.1038/ng716
NR 23
TC 0
Z9 0
U1 0
U2 0
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1471-2415
J9 BMC OPHTHALMOL
JI BMC Ophthalmol.
PD JUL 23
PY 2021
VL 21
IS 1
AR 284
DI 10.1186/s12886-021-02037-8
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA TU2WQ
UT WOS:000680902100002
PM 34301208
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Mahajan, VB
   Russell, SR
   Stone, EM
AF Mahajan, Vinit B.
   Russell, Stephen R.
   Stone, Edwin M.
TI A New Macular Dystrophy With Anomalous Vascular Development, Pigment
   Spots, Cystic Spaces, and Neovascularization
SO ARCHIVES OF OPHTHALMOLOGY
LA English
DT Article
ID JUXTAFOVEOLAR RETINAL TELANGIECTASIS; AUTOSOMAL DOMINANT MACULOPATHY;
   ATM GENE
AB Objective: To clinically phenotype an inherited macular dystrophy with peculiar intraretinal pigment spots, cysts, and hemorrhage in a 24-year-old female proband and her family.
   Methods: Extended family members of the proband underwent dilated fundus examination, optical coherence tomography, and, in selected cases, fluorescein angiography and electroretinography.
   Results: Seventeen family members, representing 3 generations and ranging in age from 5 to 64 years, were clinically examined. Visual acuities ranged from 20/20 to 20/200. Amblyopia and strabismus were frequently present in affected individuals. Consistent with an autosomal dominant pattern of inheritance, 7 family members had multiple central macular cystic spaces and flat, round, densely pigmented spots within the retina. There were right-angle vessels and telangiectasis in the central macula. Two subjects showed evidence of active macular neovascularization with leakage on fluorescein angiography at ages 7 and 24 years, which was responsive to either focal laser or a single injection of bevacizumab. In those cases examined, multifocal electroretinography showed a diminished foveal response.
   Conclusions: This spotted cystic neovascular macular dystrophy appears to represent a new autosomal dominant retinal condition. Because these patients are at risk for choroidal neovascularization, identification of the responsible gene may provide insight into the mechanisms of pathological neovascularization.
C1 [Mahajan, Vinit B.; Russell, Stephen R.; Stone, Edwin M.] Univ Iowa, Dept Ophthalmol & Visual Sci, Roy J & Lucille A Carver Coll Med, Carver Family Ctr Macular Degenerat,Vitreoretinal, Iowa City, IA 52242 USA.
   [Stone, Edwin M.] Univ Iowa, Howard Hughes Med Inst, Iowa City, IA 52242 USA.
C3 University of Iowa; Howard Hughes Medical Institute; University of Iowa
RP Stone, EM (通讯作者)，Univ Iowa, Dept Ophthalmol & Visual Sci, Roy J & Lucille A Carver Coll Med, Carver Family Ctr Macular Degenerat,Vitreoretinal, 200 Hawkins Dr, Iowa City, IA 52242 USA.
OI Stone, Edwin M./0000-0003-3343-4414; Russell,
   Stephen/0000-0003-3776-1367; Mahajan, Vinit/0000-0003-1886-1741
FU Howard Hughes Medical Institute; Foundation Fighting Blindness; Research
   to Prevent Blindness
FX This work was supported by the Howard Hughes Medical Institute, the
   Foundation Fighting Blindness, and Research to Prevent Blindness.
CR Barbazetto IA, 2008, INVEST OPHTH VIS SCI, V49, P3806, DOI 10.1167/iovs.07-1357
   CHEW EY, 1986, ARCH OPHTHALMOL-CHIC, V104, P71
   HUTTON WL, 1978, ARCH OPHTHALMOL-CHIC, V96, P1362
   Isaacs TW, 1996, EYE, V10, P639, DOI 10.1038/eye.1996.146
   Leys A, 2000, RETINA-J RET VIT DIS, V20, P184, DOI 10.1097/00006982-200003000-00011
   Mauget-Faysse M, 2003, INVEST OPHTH VIS SCI, V44, P3257, DOI 10.1167/iovs.02-1269
   Menchini U, 2000, AM J OPHTHALMOL, V129, P401, DOI 10.1016/S0002-9394(99)00380-3
   Michaelides M, 2003, J MED GENET, V40, P641, DOI 10.1136/jmg.40.9.641
   NUSSINOV R, 1984, NUCLEIC ACIDS RES, V12, P1749, DOI 10.1093/nar/12.3.1749
   ODONNELL FE, 1979, ARCH OPHTHALMOL-CHIC, V97, P1292, DOI 10.1001/archopht.1979.01020020034007
   Polk TD, 1997, ARCH OPHTHALMOL-CHIC, V115, P878, DOI 10.1001/archopht.1997.01100160048007
   Provis JM, 2001, PROG RETIN EYE RES, V20, P799, DOI 10.1016/S1350-9462(01)00012-X
   SLAGSVOLD JE, 1981, ACTA OPHTHALMOL, V59, P683, DOI 10.1111/j.1755-3768.1981.tb08734.x
   Yannuzzi LA, 2006, ARCH OPHTHALMOL-CHIC, V124, P450, DOI 10.1001/archopht.124.4.450
NR 14
TC 4
Z9 4
U1 0
U2 0
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 0003-9950
EI 1538-3601
J9 ARCH OPHTHALMOL-CHIC
JI Arch. Ophthalmol.
PD NOV
PY 2009
VL 127
IS 11
BP 1449
EP 1457
DI 10.1001/archophthalmol.2009.210
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 516ZY
UT WOS:000271583700006
PM 19901210
OA Bronze
DA 2022-11-30
ER

PT J
AU Lindeke-Myers, A
   Hanif, AM
   Jain, N
AF Lindeke-Myers, Aaron
   Hanif, Adam M.
   Jain, Nieraj
TI Pentosan polysulfate maculopathy
SO SURVEY OF OPHTHALMOLOGY
LA English
DT Review
DE pentosan polysulfate sodium; Elmiron; maculopathy; interstitial
   cystitis; medication reaction; drug toxicity; pattern dystrophy;
   pigmentary maculopathy
ID INTERSTITIAL CYSTITIS; DOUBLE-BLIND; SODIUM; EFFICACY; INSIGHTS; TRIAL
AB Pentosan polysulfate sodium (PPS), a semisynthetic sulfated polysaccharide, is the only FDA-approved oral therapy for interstitial cystitis. Recent studies have described a progressive, vision-threatening macular condition associated with long-term PPS use. We reviewed all publications concerning PPS maculopathy to consolidate known clinical features and to evaluate the strength of this association. Current literature supports a strong dose-dependent association between PPS exposure and a progressive maculopathy impacting the retinal pigment epithelium (RPE) and RPE-photoreceptor interface that may worsen even after drug cessation. Initial symptoms may include prolonged dark adaptation and difficulty reading with relative visual acuity preservation. Fundus examination often shows macular pigment clumps corresponding to lesions of focal RPE thickening. Fundus autofluorescence most clearly depicts the condition, with a distinctive pattern of hypoand hyperautofluorescent spots in the posterior pole that sometimes extends to the retinal periphery. Many cases also show a characteristic peripapillary hypoautofluorescent halo. Near infrared reflectance may aid in early detection. RPE atrophy, cystoid macular edema, and macular neovascularization may also occur, potentially resulting in loss of central acuity. This newly described association implies significant public health risk. Ophthalmologists should screen PPS users with multimodal retinal imaging, and prescribers should minimize dose and duration of PPS use.
C1 [Lindeke-Myers, Aaron] Emory Univ, Sch Med, Atlanta, GA USA.
   [Hanif, Adam M.] Oregon Hlth & Sci Univ, Dept Ophthalmol, Portland, OR 97201 USA.
   [Jain, Nieraj] Emory Univ, Sch Med, Dept Ophthalmol, 1365B Clifton Rd NE,Suite B2400, Atlanta, GA 30322 USA.
C3 Emory University; Oregon Health & Science University; Emory University
RP Jain, N (通讯作者)，Emory Univ, Sch Med, Dept Ophthalmol, 1365B Clifton Rd NE,Suite B2400, Atlanta, GA 30322 USA.
EM nieraj.jain@emory.edu
FU National Eye Institute/National Institutes of Health core grant
   [P30-EY006360]; Foundation Fighting Blindness grant [CD-C-0918-0748-EEC]
FX This project was supported by a National Eye Institute/National
   Institutes of Health core grant P30-EY006360 (Department of
   Ophthalmology, Emory University School of Medicine) and a Foundation
   Fighting Blindness grant, CD-C-0918-0748-EEC (Jain).; Funding sources
   were not involved in any part of the preparation or submission of this
   article. The content is solely the responsibility of the authors and
   does not necessarily represent the official views of the National
   Institutes of Health or the views or policies of the Department of
   Health and Human Services, nor does mention of trade names, commercial
   products, or organizations imply endorsement by the U.S. Government.
CR Abou-Jaoude MM, 2021, OSLI RETINA, V52, P13, DOI 10.3928/23258160-20201223-04
   [Anonymous], 2012, JANSS PHARMACEUTICEL
   [Anonymous], 2020, PRACT ADV POSS DRUG
   Balaratnasingam C, 2017, OPHTHALMOLOGY, V124, P644, DOI 10.1016/j.ophtha.2016.12.034
   Barnes AC, 2020, OPHTHALMOL RETINA, V4, P1196, DOI 10.1016/j.oret.2020.05.008
   Barnett Joshua M, 2022, Retin Cases Brief Rep, V16, P724, DOI 10.1097/ICB.0000000000001090
   Christiansen JS, 2022, CAN J OPHTHALMOL, V57, P16, DOI 10.1016/j.jcjo.2021.02.007
   Cideciyan AV, 2005, INVEST OPHTH VIS SCI, V46, P4739, DOI 10.1167/iovs.05-0805
   Clark SJ, 2011, INVEST OPHTH VIS SCI, V52, P6511, DOI 10.1167/iovs.11-7909
   De Larochelliere Elianne, 2022, Retin Cases Brief Rep, V16, P482, DOI 10.1097/ICB.0000000000001013
   Duncker T, 2015, INVEST OPHTH VIS SCI, V56, P3159, DOI 10.1167/iovs.14-16343
   FRILEUX C, 1951, Presse Med, V59, P159
   Girardot P, 2019, INVEST OPHTH VIS SCI, V60
   Giusto LL, 2018, EXPERT OPIN PHARMACO, V19, P1097, DOI 10.1080/14656566.2018.1491968
   Greenlee T, 2019, OPHTHALMOLOGY, V126, pE51, DOI 10.1016/j.ophtha.2018.12.037
   Hadad A, 2020, OPHTHALMOLOGY, V127, P429, DOI 10.1016/j.ophtha.2019.10.013
   Hanif AM, 2019, JAMA OPHTHALMOL, V137, P1275, DOI 10.1001/jamaophthalmol.2019.3392
   Hanif AM, 2019, OPHTHALMOLOGY, V126, P1464, DOI 10.1016/j.ophtha.2019.04.024
   Hanif Adam M, 2019, Int Ophthalmol Clin, V59, P173, DOI 10.1097/IIO.0000000000000262
   Hanno PM, 2015, J UROLOGY, V193, P1545, DOI 10.1016/j.juro.2015.01.086
   Higgins K, 2020, J OPHTHALMOL, V2020, DOI 10.1155/2020/8866961
   HOLMBENTZEN M, 1987, J UROLOGY, V138, P503, DOI 10.1016/S0022-5347(17)43241-1
   Huckfeldt RM, 2019, OSLI RETINA, V50, P656, DOI 10.3928/23258160-20191009-10
   Hwang P, 1997, UROLOGY, V50, P39, DOI 10.1016/S0090-4295(97)00110-6
   Ishikawa M, 2015, EXP EYE RES, V133, P3, DOI 10.1016/j.exer.2015.02.017
   Jain N, 2020, BRIT J OPHTHALMOL, V104, P1093, DOI 10.1136/bjophthalmol-2019-314765
   KAPLAN J, 1993, NAT GENET, V5, P308, DOI 10.1038/ng1193-308
   LESCHEY KH, 1991, INVEST OPHTH VIS SCI, V32, P1770
   Ludwig CA, 2020, OPHTHALMOLOGY, V127, P535, DOI 10.1016/j.ophtha.2019.10.036
   Ly A, 2016, OPHTHAL PHYSL OPT, V36, P303, DOI 10.1111/opo.12283
   Lyons R, 2020, INVEST OPHTH VIS SCI, V61
   Lyons RJ, 2020, JAMA OPHTHALMOL, V138, P316, DOI 10.1001/jamaophthalmol.2019.4992
   Malde S, 2018, BJU INT, V122, P729, DOI 10.1111/bju.14399
   Mishra K, 2020, OPHTHALMOL RETINA, V4, P111, DOI 10.1016/j.oret.2019.08.006
   MULHOLLAND SG, 1990, UROLOGY, V35, P552, DOI 10.1016/0090-4295(90)80116-5
   Murphy R, 2008, DIABETIC MED, V25, P383, DOI 10.1111/j.1464-5491.2008.02359.x
   Nickel J Curtis, 2018, J Urol, V200, P39, DOI 10.1016/j.juro.2018.02.011
   Nickel JC, 2015, J UROLOGY, V193, P857, DOI 10.1016/j.juro.2014.09.036
   Nickel JC, 2005, UROLOGY, V65, P654, DOI 10.1016/j.urology.2004.10.071
   Parikh D, 2020, JAMA OPHTHALMOL, V138, P1101, DOI 10.1001/jamaophthalmol.2020.2778
   PARSONS CL, 1983, J UROLOGY, V130, P51, DOI 10.1016/S0022-5347(17)50948-9
   PARSONS CL, 1993, J UROLOGY, V150, P845, DOI 10.1016/S0022-5347(17)35629-X
   Patnaik SS, 2017, ARCH GYNECOL OBSTET, V295, P1341, DOI 10.1007/s00404-017-4364-2
   Pearce WA, 2018, OPHTHALMOLOGY, V125, P1793, DOI 10.1016/j.ophtha.2018.04.026
   Sant GR, 2003, J UROLOGY, V170, P810, DOI 10.1097/01.ju.0000083020.06212.3d
   Shah R, 2020, JAMA OPHTHALMOL, V138, P894, DOI 10.1001/jamaophthalmol.2020.2349
   Uner OE, 2021, PENTOSAN POLYSULFATE, DOI [10.1097/IAE.0000000000003078, DOI 10.1097/IAE.0000000000003078]
   United States Food & Drug Administration, DRUG SAF REL LAB CHA
   Vora RA, 2020, OPHTHALMOLOGY, V127, P835, DOI 10.1016/j.ophtha.2020.01.017
   Vora Robin A, 2020, Am J Ophthalmol Case Rep, V17, P100604, DOI 10.1016/j.ajoc.2020.100604
   Wang D, 2020, CAN J OPHTHALMOL, V55, P116, DOI 10.1016/j.jcjo.2019.12.001
   Wannamaker KW, 2020, OPHTHALMOLOGY, V127, P1641, DOI 10.1016/j.ophtha.2020.07.048
   Warrow DJ, 2013, RETINA-J RET VIT DIS, V33, P1659, DOI 10.1097/IAE.0b013e3182953df4
NR 53
TC 3
Z9 3
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0039-6257
EI 1879-3304
J9 SURV OPHTHALMOL
JI Surv. Ophthalmol.
PD JAN-FEB
PY 2022
VL 67
IS 1
BP 83
EP 96
DI 10.1016/j.survophthal.2021.05.005
EA DEC 2021
PG 14
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA XT2FE
UT WOS:000733409100009
PM 34000253
DA 2022-11-30
ER

PT J
AU Downie, LE
   Busija, L
   Keller, PR
AF Downie, Laura E.
   Busija, Ljoudmila
   Keller, Peter R.
TI Blue-light filtering intraocular lenses (IOLs) for protecting macular
   health
SO COCHRANE DATABASE OF SYSTEMATIC REVIEWS
LA English
DT Review
ID AGE-RELATED MACULOPATHY; CONTRAST SENSITIVITY; CATARACT-SURGERY;
   COLOR-VISION; VISUAL PERFORMANCE; PHACOEMULSIFICATION SURGERY; CIRCADIAN
   PHOTOENTRAINMENT; SPECTRAL TRANSMISSION; SPHERICAL-ABERRATION; FLICKER
   PERIMETRY
AB Background
   An intraocular lens (IOL) is a synthetic lens that is surgically implanted within the eye following removal of the crystalline lens, during cataract surgery. While all modern IOLs attenuate the transmission of ultra-violet (UV) light, some IOLs, called blue-blocking or bluelight filtering IOLs, also reduce short-wavelength visible light transmission. The rationale for blue-light filtering IOLs derives primarily fromcell culture and animal studies, which suggest that short-wavelength visible light can induce retinal photoxicity. Blue-light filtering IOLs have been suggested to impart retinal protection and potentially prevent the development and progression of age-related macular degeneration (AMD). We sought to investigate the evidence relating to these suggested benefits of blue-light filtering IOLs, and to consider any potential adverse effects.
   Objectives
   To assess the effects of blue-light filtering IOLs compared with non-blue-light filtering IOLs, with respect to providing protection to macular health and function.
   Search methods
   We searched the Cochrane Central Register of Controlled Trials (CENTRAL) (which contains the Cochrane Eyes and Vision Trials Register) (2017, Issue 9); OvidMEDLINE; Ovid Embase; LILACS; the ISRCTN registry; ClinicalTrials. gov and the ICTRP. The date of the search was 25 October 2017.
   Selection criteria
   We included randomised controlled trials (RCTs), involving adult participants undergoing cataract extraction, where a blue-light filtering IOL was compared with an equivalent non-blue-light filtering IOL.
   Data collection and analysis
   The prespecified primary outcome was the change in distance best-corrected visual acuity (BCVA), as a continuous outcome, between baseline and 12months of follow-up. Prespecified secondary outcomes included postoperative contrast sensitivity, colour discrimination, macular pigment optical density (MPOD), proportion of eyes with a pathological finding at the macula (including, but not limited to the development or progression of AMD, or both), daytime alertness, reaction time and patient satisfaction. We evaluated findings related to ocular and systemic adverse effects.
   Two review authors independently screened abstracts and full-text articles, extracted data from eligible RCTs and judged the risk of bias using the Cochrane tool. We reached a consensus on any disagreements by discussion. Where appropriate, we pooled data relating to outcomes and used random-effects or fixed-effect models for the meta-analyses. We summarised the overall certainty of the evidence using GRADE.
   Main results
   We included 51 RCTs from 17 different countries, although most studies either did not report relevant outcomes, or provided data in a format that could not be extracted. Together, the included studies considered the outcomes of IOL implantation in over 5000 eyes. The number of participants ranged from 13 to 300, and the follow-up period ranged from one month to five years. Only two of the studies had a trial registry record and no studies referred to a published protocol. We did not judge any of the studies to have a low risk of bias in all seven domains. We judged approximately two-thirds of the studies to have a high risk of bias in domains relating to 'blinding of participants and personnel' (performance bias) and 'blinding of outcome assessment' (detection bias).
   We found with moderate certainty, that distance BCVA with a blue-light filtering IOL, at six to 18 months postoperatively, and measured in logMAR, was not clearly different to distance BCVA with a non-blue-light filtering IOL (mean difference (MD) -0.01 logMAR, 95% confidence interval (CI) -0.03 to 0.02, P = 0.48; 2 studies, 131 eyes).
   There was very low-certainty evidence relating to any potential inter-intervention difference for the proportion of eyes that developed late-stage AMD at three years of follow-up, or any stage of AMD at one year of follow-up, as data derived from one trial and two trials respectively, and there were no events in either IOL intervention group, for either outcome. There was very low-certainty evidence for the outcome for the proportion of participants who lost 15 or more letters of distance BCVA at six months of follow-up; two trials that considered a total of 63 eyes reported no events, in either IOL intervention group.
   There were no relevant, combinable data available for outcomes relating to the effect on contrast sensitivity at six months, the proportion of eyes with a measurable loss of colour discrimination from baseline at six months, or the proportion of participants with adverse events with a probable causal link with the study interventions after six months.
   We were unable to draw reliable conclusions on the relative equivalence or superiority of blue-light filtering IOLs versus non-blue-light filtering IOLs in relation to longer-term effects on macular health. We were also not able to determine with any certainty whether blue-light filtering IOLs have any significant effects on MPOD, contrast sensitivity, colour discrimination, daytime alertness, reaction time or patient satisfaction, relative to non-blue-light filtering IOLs.
   Authors' conclusions
   This systematic review shows with moderate certainty that there is no clinically meaningful difference in short-term BCVA with the two types of IOLs. Further, based upon available data, these findings suggest that there is no clinically meaningful difference in short-term contrast sensitivity with the two interventions, although there was a low level of certainty for this outcome due to a small number of included studies and their inherent risk of bias. Based upon current, best-available research evidence, it is unclear whether bluelight filtering IOLs preserve macular health or alter risks associated with the development and progression of AMD, or both. Further research is required to fully understand the effects of blue-light filtering IOLs for providing protection to macular health and function.
C1 [Downie, Laura E.; Keller, Peter R.] Univ Melbourne, Dept Optometry & Vis Sci, Level 4,Alice Hoy Bldg, Parkville, Vic 3010, Australia.
   [Busija, Ljoudmila] Australian Catholic Univ, Inst Hlth & Ageing, Melbourne, Vic, Australia.
C3 University of Melbourne; Australian Catholic University
RP Downie, LE (通讯作者)，Univ Melbourne, Dept Optometry & Vis Sci, Level 4,Alice Hoy Bldg, Parkville, Vic 3010, Australia.
EM ldownie@unimelb.edu.au
OI Downie, Laura/0000-0002-1596-2259
FU National Health and Medical Research Council (NHMRC), Australia; NHMRC
   [APP1091833]; National Institute for Health Research (NIHR), UK;
   Department of Health through NIHR
FX Internal sources; The University of Melbourne, Australia.; Australian
   Catholic University, Australia.; External sources; National Health and
   Medical Research Council (NHMRC), Australia.; This review is undertaken
   as part of a 2015 NHMRC Translating Research Into Practice (TRIP)
   Fellowship (APP1091833, CIA: Dr Laura Downie).; National Institute for
   Health Research (NIHR), UK.; Richard Wormald, Co-ordinating Editor for
   Cochrane Eyes and Vision (CEV) acknowledges financial support for his
   CEV research sessions from the Department of Health through the award
   made by the NIHR to Moorfields Eye Hospital NHS Foundation Trust and UCL
   Institute of Ophthalmology for a Specialist Biomedical Research Centre
   for Ophthalmology.; This review was supported by the NIHR, via Cochrane
   Infrastructure funding to the CEV UK editorial base. The views expressed
   in this publication are those of the authors and not necessarily those
   of the NIHR, NHS, or the Department of Health.
CR Abba K, 2011, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD008122.pub2
   Alexander I, 2014, INVEST OPHTH VIS SCI, V55, P4999, DOI 10.1167/iovs.14-14054
   Alfonso JF, 2007, J CATARACT REFR SURG, V33, P1235, DOI 10.1016/j.jcrs.2007.03.034
   Aose M, 2006, INVESTIGATIVE OPHTHA, V47
   Baatz H, 2008, INVEST OPHTH VIS SCI, V49, P1079, DOI 10.1167/iovs.07-0557
   Bandyopadhyay S, 2016, INT OPHTHALMOL, V36, P313, DOI 10.1007/s10792-015-0120-4
   Barisic A, 2007, COLLEGIUM ANTROPOL, V31, P57
   Beatty S, 1999, BRIT J OPHTHALMOL, V83, P867, DOI 10.1136/bjo.83.7.867
   Behrens-Baumann W, 2005, AM ACAD OPHTHALMOLOG, P185
   Bernstein PS, 2010, VISION RES, V50, P716, DOI 10.1016/j.visres.2009.10.014
   Bhattacharjee H, 2006, J CATARACT REFR SURG, V32, P451, DOI 10.1016/j.jcrs.2005.12.136
   BOETTNER EA, 1962, INVEST OPHTH VISUAL, V1, P776
   Boulton M, 2001, J PHOTOCH PHOTOBIO B, V64, P144, DOI 10.1016/S1011-1344(01)00227-5
   BRESSLER NM, 1994, RETINA-J RET VIT DIS, V14, P130, DOI 10.1097/00006982-199414020-00006
   Brockmann C, 2008, J CATARACT REFR SURG, V34, P1161, DOI 10.1016/j.jcrs.2008.03.039
   Brondsted AE, 2014, INVEST OPHTH VIS SCI, V55
   Brondsted AE, 2017, ACTA OPHTHALMOL, V95, P344, DOI 10.1111/aos.13323
   Brondsted AE, 2015, OPHTHALMOLOGY, V122, P2115, DOI 10.1016/j.ophtha.2015.06.033
   Caporossi A, 2007, J REFRACT SURG, V23, P639, DOI 10.3928/1081-597X-20070901-02
   Caporossi A, 2009, J REFRACT SURG, V25, P578, DOI 10.3928/1081597X-20090610-03
   Casparis H, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006757.pub3
   Chalam KV, 2011, EYE CONTACT LENS, V37, P225, DOI 10.1097/ICL.0b013e31821fbd3e
   Chen C, 2013, INT EYE SCI, V13, P931
   Chew EY, 2009, OPHTHALMOLOGY, V116, P297, DOI 10.1016/j.ophtha.2008.09.019
   Chiosi F, 2006, INVESTIGATIVE OPHTHA, V47
   Cionni RJ, 2006, J CATARACT REFR SURG, V32, P236, DOI 10.1016/j.jcrs.2005.12.129
   Cionni RJ, 2003, AM ACAD OPHTHALMOLOG, P130
   CLARKE MP, 1989, ACTA OPHTHALMOL, V67, P593
   Coleman HR, 2008, LANCET, V372, P1835, DOI 10.1016/S0140-6736(08)61759-6
   Congdon N, 2004, ARCH OPHTHALMOL-CHIC, V122, P477
   Cristóbal JA, 2005, Arch Soc Esp Oftalmol, V80, P245
   Cui HG, 2009, CAN J OPHTHALMOL, V44, P274, DOI 10.3129/i08-121
   Cunha JP, 2010, J SLEEP RES, V19, P189
   Cuthbertson FM, 2009, EYE, V23, P877, DOI 10.1038/eye.2008.122
   de Espindola RF, 2012, ARQ BRAS OFTALMOL, V75, P316, DOI 10.1590/S0004-27492012000500004
   Downes SM, 2016, EYE, V30, P215, DOI 10.1038/eye.2015.267
   Downie LE, 2017, OPHTHAL PHYSL OPT, V37, P640, DOI 10.1111/opo.12414
   Downie LE, 2014, OPTOMETRY VISION SCI, V91, P932, DOI 10.1097/OPX.0000000000000246
   Downie LE, 2014, OPTOMETRY VISION SCI, V91, P821, DOI 10.1097/OPX.0000000000000285
   Downie LE, 2015, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD011977, DOI 10.1002/14651858.CD011977]
   Espindle D, 2005, J CATARACT REFR SURG, V31, P1952, DOI 10.1016/j.jcrs.2005.03.060
   Falkner-Radler CI, 2008, AM J OPHTHALMOL, V145, P499, DOI 10.1016/j.ajo.2007.10.021
   Feng X, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000005648
   Ferris FL, 2005, ARCH OPHTHALMOL-CHIC, V123, P1570
   Gavris Monica, 2006, Oftalmologia, V50, P94
   Gibson GA, 2008, INVESTIGATIVE OPHTHA
   Gin TJ, 2011, INVEST OPHTH VIS SCI, V52, P9267, DOI 10.1167/iovs.11-8517
   Glanville JM, 2006, J MED LIBR ASSOC, V94, P130
   Hahsler B, 2005, KLIN MONATSBLATTE S1, V222, pS8
   Hahsler B, 2004, KLIN MONATSBLATTE S1, V221, pS15
   HAM WT, 1976, NATURE, V260, P153, DOI 10.1038/260153a0
   HAM WT, 1984, CURR EYE RES, V3, P165, DOI 10.3109/02713688408997198
   HAM WT, 1978, INVEST OPHTH VIS SCI, V17, P1029
   Hammond BR, 2010, CLIN OPHTHALMOL, V4, P1465, DOI 10.2147/OPTH.S15102
   Hayashi K, 2006, BRIT J OPHTHALMOL, V90, P1019, DOI 10.1136/bjo.2006.090712
   Hayashi K, 2009, JPN J OPHTHALMOL, V53, P100, DOI 10.1007/s10384-008-0626-7
   HIGGINS JPT, 2011, COCHRANE HDB SYSTEMA, V0001
   Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   Holz F.G., 2013, AGE RELATED MACULAR
   Hyunseok A, 2007, AM ACAD OPHTHALMOLOG, P210
   Ji HL, 2013, INT EYE SCI, V13, P1609
   Jonas JB, 2014, AM J OPHTHALMOL, V158, P808, DOI 10.1016/j.ajo.2014.06.012
   Kara N, 2006, J CATARACT REFR SURG, V32, P1328, DOI 10.1016/j.jcrs.2006.03.033
   Kara N, 2011, J CATARACT REFR SURG, V37, P2115, DOI 10.1016/j.jcrs.2011.06.024
   Kennis H, 2004, Bull Soc Belge Ophtalmol, P49
   Kim Jae-Yun, 2011, Korean J Ophthalmol, V25, P29, DOI 10.3341/kjo.2011.25.1.29
   Kim JH, 2011, CURR EYE RES, V36, P937, DOI 10.3109/02713683.2011.597535
   Klein R, 1998, ARCH OPHTHALMOL-CHIC, V116, P506, DOI 10.1001/archopht.116.4.506
   KLEIN R, 1992, OPHTHALMOLOGY, V99, P933
   Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557
   KRAFF MC, 1985, OPHTHALMOLOGY, V92, P366
   Kuchenbecker J, 2004, KLIN MONATSBLATTE S5, V221, pS11
   Lak Dariusz, 2007, Roczniki Pomorskiej Akademii Medycznej w Szczecinie, V53, P43
   Lavric A, 2014, OPTOMETRY VISION SCI, V91, P1348, DOI 10.1097/OPX.0000000000000390
   Lawrenson JG, 2017, OPHTHAL PHYSL OPT, V37, P644, DOI 10.1111/opo.12406
   Lee RMH, 2012, EYE, V26, P1400, DOI 10.1038/eye.2012.177
   Leibovitch I, 2006, ACTA OPHTHALMOL SCAN, V84, P95, DOI 10.1111/j.1600-0420.2005.00607.x
   Li HW, 2009, GUOJI YANKE ZAZHI, V9, P2092
   LIU IY, 1989, AM J PUBLIC HEALTH, V79, P765, DOI 10.2105/AJPH.79.6.765
   Luu CD, 2013, INVEST OPHTH VIS SCI, V54, P3560, DOI 10.1167/iovs.12-10465
   Mainster MA, 2006, BRIT J OPHTHALMOL, V90, P784, DOI 10.1136/bjo.2005.086553
   Mainster M A, 1978, J Am Intraocul Implant Soc, V4, P84
   Mainster MA, 2005, ARCH OPHTHALMOL-CHIC, V123, P550, DOI 10.1001/archopht.123.4.550
   MAINSTER MA, 1986, AM J OPHTHALMOL, V102, P727, DOI 10.1016/0002-9394(86)90400-9
   Mainster MA, 2011, OPHTHALMOLOGY, V118, P1, DOI 10.1016/j.ophtha.2010.11.016
   Mainster MA, 2010, SURV OPHTHALMOL, V55, P272, DOI 10.1016/j.survophthal.2009.07.006
   Margrain TH, 2004, PROG RETIN EYE RES, V23, P523, DOI 10.1016/j.preteyeres.2004.05.001
   Marshall J, 2005, J CATARACT REFR SURG, V31, P2319, DOI 10.1016/j.jcrs.2004.11.061
   Mayer S, 2006, KLIN MONATSBL AUGENH, V223, P142, DOI 10.1055/s-2005-858867
   Mayer S, 2005, KLIN MONATSBLATTE S1, V222, pS8
   Mester U, 2008, OPHTHALMOLOGE, V105, P1029, DOI 10.1007/s00347-008-1693-3
   Mester U, 2008, J REFRACT SURG, V24, P817, DOI 10.3928/1081597X-20081001-09
   Mester U, 2008, J CATARACT REFR SURG, V34, P608, DOI 10.1016/j.jcrs.2007.11.049
   Monnet D, 2009, J CATARACT REFR SURG, V35, P677, DOI 10.1016/j.jcrs.2008.12.021
   Muller V, 2005, KLIN MONATSBLATTE S7, V222, pS18
   Munoz G, 2012, EUR J OPHTHALMOL, V22, P769, DOI 10.5301/ejo.5000112
   Nagai H, 2015, J CATARACT REFR SURG, V41, P1855, DOI 10.1016/j.jcrs.2015.01.017
   Nakamura T, 2006, INVESTIGATIVE OPHTHA, V47
   Neumaier-Ammerer B, 2010, J CATARACT REFR SURG, V36, P2073, DOI 10.1016/j.jcrs.2010.06.069
   Ng SM, 2014, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD011016, DOI 10.1002/14651858.CD011016]
   Nishi T, 2015, BMJ OPEN, V5, DOI 10.1136/bmjopen-2015-007930
   Nishi T, 2013, CLIN OPHTHALMOL, V7, P2159, DOI 10.2147/OPTH.S52771
   Nolan JM, 2009, INVEST OPHTH VIS SCI, V50, P4777, DOI 10.1167/iovs.08-3277
   *NORD COCHR CTR CO, 2014, REV MAN 5 REVMAN 5 V
   NORREN DV, 1974, VISION RES, V14, P1237, DOI 10.1016/0042-6989(74)90222-3
   Owen CG, 2003, BRIT J OPHTHALMOL, V87, P312, DOI 10.1136/bjo.87.3.312
   Pandita D, 2007, J CATARACT REFR SURG, V33, P603, DOI 10.1016/j.jcrs.2007.01.009
   Parish CA, 1998, P NATL ACAD SCI USA, V95, P14609, DOI 10.1073/pnas.95.25.14609
   Pascolini D, 2012, BRIT J OPHTHALMOL, V96, P614, DOI 10.1136/bjophthalmol-2011-300539
   Prinsen CAC, 2014, TRIALS, V15, DOI 10.1186/1745-6215-15-247
   Raj SM, 2005, J CATARACT REFR SURG, V31, P2324, DOI 10.1016/j.jcrs.2005.08.052
   Rocha KM, 2007, OPHTHALMOLOGY, V114, P2050, DOI 10.1016/j.ophtha.2007.01.024
   Rocha KM, 2006, INVESTIGATIVE OPHTHA, V47
   Rocha KM, 2006, AM ACAD OPHTHALMOLOG, P200
   Rodriguez-Galietero A, 2005, J CATARACT REFR SURG, V31, P2088, DOI 10.1016/j.jcrs.2005.04.029
   Rodriguez-Galietero A, 2005, J CATARACT REFR SURG, V31, P1736, DOI 10.1016/j.jcrs.2005.02.039
   Rudnicka AR, 2012, OPHTHALMOLOGY, V119, P571, DOI 10.1016/j.ophtha.2011.09.027
   Sarks SH, 1999, BRIT J OPHTHALMOL, V83, P358, DOI 10.1136/bjo.83.3.358
   Schmack I, 2012, J CATARACT REFR SURG, V38, P823, DOI 10.1016/j.jcrs.2011.12.028
   Schmidinger G, 2008, J CATARACT REFR SURG, V34, P769, DOI 10.1016/j.jcrs.2007.12.034
   Schmoll C, 2014, BRIT J OPHTHALMOL, V98, P124, DOI 10.1136/bjophthalmol-2013-304024
   Schulz KF, 2002, LANCET, V359, P781, DOI 10.1016/S0140-6736(02)07882-0
   Schunemann HJ, 2011, COCHRANE HDB SYSTEMA
   Shi D, 2008, INT J OPHTHALMOLOGY, V8, P71
   Shpak A A, 2012, Vestn Oftalmol, V128, P48
   Snell R, 1998, CLIN ANATOMY EYE, V2
   Soriano ES, 2006, AM ACAD OPHTHALMOLOG, P209
   Stopyra Wiktor, 2012, Klin Oczna, V114, P266
   Sui GY, 2013, BRIT J OPHTHALMOL, V97, P389, DOI 10.1136/bjophthalmol-2012-302281
   Sun Kang, 2007, Yan Ke Xue Bao, V23, P43
   Symes RJ, 2012, EYE, V26, P1397, DOI 10.1038/eye.2012.178
   Thornton J, 2005, EYE, V19, P935, DOI 10.1038/sj.eye.6701978
   Tognetto D, 2003, OPHTHALMOLOGY, V110, P1935, DOI 10.1016/S0161-6420(03)00736-X
   Ueda T, 2005, INVESTIGATIVE OPHTHA, V46
   Ueda T, 2006, AM J OPHTHALMOL, V142, P856, DOI 10.1016/j.ajo.2006.05.021
   van Norren D, 2007, BRIT J OPHTHALMOL, V91, DOI 10.1136/bjo.2007.117903
   Veritas Health Innovation, COV
   Vuori ML, 2006, ACTA OPHTHALMOL SCAN, V84, P92, DOI 10.1111/j.1600-0420.2005.00579.x
   WALD G, 1945, SCIENCE, V101, P653, DOI 10.1126/science.101.2635.653
   Walter S, 2005, KLIN MONATSBLATTE S6, V222, pS7
   Wang HW, 2010, J CATARACT REFR SURG, V36, P2080, DOI 10.1016/j.jcrs.2010.07.024
   Wen HM, 2012, INT EYE SCI, V12, P1311
   Wirtitsch MG, 2009, OPHTHALMOLOGY, V116, P39, DOI 10.1016/j.ophtha.2008.08.035
   Wohlfart C, 2007, KLIN MONATSBL AUGENH, V224, P23, DOI 10.1055/s-2006-927275
   Wong WL, 2014, LANCET GLOB HEALTH, V2, pE106, DOI 10.1016/S2214-109X(13)70145-1
   Wu ZC, 2013, INVEST OPHTH VIS SCI, V54, P7378, DOI 10.1167/iovs.13-12617
   Yamaguchi T, 2011, CLIN OPHTHALMOL, V5, P1701, DOI 10.2147/OPTH.S21819
   Yamaguchi T, 2009, J CATARACT REFR SURG, V35, P1725, DOI 10.1016/j.jcrs.2009.05.031
   Yang ZL, 2006, SCIENCE, V314, P992, DOI 10.1126/science.1133811
   Youssef PN, 2011, EYE, V25, P1, DOI 10.1038/eye.2010.149
   Yuan ZX, 2004, AM J OPHTHALMOL, V138, P138, DOI 10.1016/j.ajo.2004.02.024
   Zhu XY, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044405
NR 152
TC 36
Z9 37
U1 3
U2 27
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1469-493X
EI 1361-6137
J9 COCHRANE DB SYST REV
JI Cochrane Database Syst Rev.
PY 2018
IS 5
AR CD011977
DI 10.1002/14651858.CD011977.pub2
PG 172
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA GH8AS
UT WOS:000433887900023
PM 29786830
OA Green Published
DA 2022-11-30
ER

PT J
AU Arora, S
   Kulikov, AN
   Maltsev, DS
AF Arora, Supriya
   Kulikov, Alexei N.
   Maltsev, Dmitrii S.
TI Implementation of the new multimodal imaging-based classification of
   central serous chorioretinopathy
SO EUROPEAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE Central serous chorioretinopathy; neurosensory detachment; subretinal
   fluid; classification; multimodal imaging; recurrence; macular
   neovascularization
ID COHERENCE TOMOGRAPHY ANGIOGRAPHY
AB Purpose: To study the implementation of the new multimodal imaging-based classification system of central serous chorioretinopathy (CSCR). Methods: Ninety-three eyes with CSCR with available fundus autofluorescence (FAF), optical coherence tomography (OCT), and OCT angiography at presentation were included in this study. An anonymous data set was classified by two masked graders. Each case was classified as per presence of (i) simple versus complex (< or >2 disc diameters of retinal pigment epithelium abnormality) CSCR; (ii) primary versus recurrent versus resolved CSCR; (iii) persistent (presence of subretinal fluid >6 months) or not; (iv) outer retinal atrophy (ORA); (v) foveal involvement; and (vi) macular neovascularization (MNV). Agreement between the graders was calculated. Results: Kappa value was 0.91 (95% CI 0.8-1.0) for the entire classification; 0.84 (95% CI 0.73-0.95) for simple versus complex; 1.0 (95% CI 1.0-1.0) for primary versus recurrent versus resolved CSCR; 1.0 (95% CI 1.0-1.0) for persistent or not; 0.9 (95% CI 0.81-0.99) for ORA or not; 0.95 (95% CI 0.84-1.0) for presence or absence of MNV; 1.0 (95% CI 1.0-1.0) for presence or absence of foveal involvement. Conclusion: The new multimodal imaging based CSCR classification showed "near perfect" agreement between two retinal experts.
C1 [Arora, Supriya] Princess Margaret Hosp, Eye Care Ctr, Nassau, Bahamas.
   [Kulikov, Alexei N.; Maltsev, Dmitrii S.] Mil Med Acad, Dept Ophthalmol, 21-1 Botkinskaya St, St Petersburg 194044, Russia.
RP Maltsev, DS (通讯作者)，Mil Med Acad, Dept Ophthalmol, 21-1 Botkinskaya St, St Petersburg 194044, Russia.
EM glaz.med@yandex.ru
RI Maltsev, Dmitrii/AAA-9100-2022
OI Maltsev, Dmitrii/0000-0001-6598-3982
CR Albert DM., 2008, ALBERT JAKOBIECS PRI
   Bonini MA, 2015, JAMA OPHTHALMOL, V133, P899, DOI 10.1001/jamaophthalmol.2015.1320
   Bousquet E, 2018, RETINA-J RET VIT DIS, V38, P629, DOI 10.1097/IAE.0000000000001580
   Chhablani J, 2020, OPHTHALMOL RETINA, V4, P1043, DOI 10.1016/j.oret.2020.07.026
   Dansingani KK, 2015, AM J OPHTHALMOL, V160, P1243, DOI 10.1016/j.ajo.2015.08.028
   Daruich A, 2015, PROG RETIN EYE RES, V48, P82, DOI 10.1016/j.preteyeres.2015.05.003
   Quaranta-El Maftouhi M, 2015, AM J OPHTHALMOL, V160, P581, DOI 10.1016/j.ajo.2015.06.016
   Romano MR, 2020, ACTA OPHTHALMOL, V98, pE549, DOI 10.1111/aos.14319
   Schwartz R, 2017, ACTA OPHTHALMOL, V95, pE610, DOI 10.1111/aos.13491
   Singh SR, 2019, BRIT J OPHTHALMOL, V103, P737, DOI 10.1136/bjophthalmol-2018-312435
   Spaide RF, 1996, RETINA-J RET VIT DIS, V16, P203, DOI 10.1097/00006982-199616030-00004
   Sun XH, 2018, BRIT J OPHTHALMOL, V102, P1060, DOI 10.1136/bjophthalmol-2017-311096
   Viera AJ, 2005, FAM MED, V37, P360
   Yannuzzi L A, 1992, Eur J Ophthalmol, V2, P103
   Zola M, 2019, BRIT J OPHTHALMOL, V103, P1184, DOI 10.1136/bjophthalmol-2018-312892
NR 15
TC 2
Z9 2
U1 1
U2 1
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1120-6721
EI 1724-6016
J9 EUR J OPHTHALMOL
JI Eur. J. Ophthalmol.
PD MAR
PY 2022
VL 32
IS 2
BP 1044
EP 1049
AR 11206721211013651
DI 10.1177/11206721211013651
EA MAY 2021
PG 6
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA ZU0VX
UT WOS:000677787500001
PM 33947227
DA 2022-11-30
ER

PT J
AU Bousquet, E
   Torres-Villaros, H
   Provost, J
   Elalouf, M
   Gigon, A
   Mantel, I
   Timsit, A
   Behar-Cohen, F
AF Bousquet, Elodie
   Torres-Villaros, Heloise
   Provost, Julien
   Elalouf, Martine
   Gigon, Anthony
   Mantel, Irmela
   Timsit, Aurelie
   Behar-Cohen, Francine
TI Clinical Characteristics and Multimodal Imaging Findings of Central
   Serous Chorioretinopathy in Women versus Men
SO JOURNAL OF CLINICAL MEDICINE
LA English
DT Article
DE central serous chorioretinopathy; epitheliopathy; gravitational tracks;
   macular neovascularization; women; pachychoroid neovasculopathy
ID MINERALOCORTICOID RECEPTOR; TESTOSTERONE LEVELS; SERUM CORTISOL
AB (1) The aim of this study was to compare the clinical characteristics and multimodal imaging findings of central serous chorioretinopathy (CSCR) between women and men. (2) Women and men with CSCR were compared in terms of their age and risk factors, the clinical form of their disease, multimodal imaging findings and the presence of macular neovascularization (MNV) on optical coherence tomography (OCT)-angiography. (3) Results: The data of 75 women and 75 men were compared. The women were significantly older than the men (52.2 years versus 45.7 years; p < 0.001). Corticosteroid intake was more frequent in the women (56% versus 40%; p = 0.05). The women had a single foveal subretinal detachment more often than the men (73.3% versus 46.9%; p < 0.001) and they often had fewer gravitational tracks (16.3% versus 29.6%; p = 0.03). On mid-phase indocyanine green angiography, hyperfluorescent plaques were detected less often in the women than in the men (48% versus 72.2%, p = 0.001). MNV was detected on OCT-angiography in 35.9% of the women and in 13.3% of the men (p = 0.004). (4) In the women, CSCR occurs at an older age, is more often unifocal foveolar, and is associated with a higher rate of MNV. The reasons for these gender-related differences remain to be determined.
C1 [Bousquet, Elodie; Torres-Villaros, Heloise; Provost, Julien; Timsit, Aurelie; Behar-Cohen, Francine] Univ Paris, Hop Cochin, Assistance Publ Hop Paris, AP HP,Dept Ophthalmol,Ophtalmopole, F-75014 Paris, France.
   [Bousquet, Elodie; Behar-Cohen, Francine] Univ Paris, Ctr Rech Cordeliers, F-75006 Paris, France.
   [Elalouf, Martine; Gigon, Anthony; Mantel, Irmela] Univ Lausanne, Jules Gonin Eye Hosp, Fdn Asile Aveugles, Dept Ophthalmol, CH-1015 Lausanne, Switzerland.
C3 Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin
   - APHP; UDICE-French Research Universities; Aix-Marseille Universite;
   Assistance Publique-Hopitaux de Marseille; Universite Paris Cite;
   Institut National de la Sante et de la Recherche Medicale (Inserm);
   UDICE-French Research Universities; Sorbonne Universite; Universite
   Paris Cite; University of Lausanne
RP Bousquet, E (通讯作者)，Univ Paris, Hop Cochin, Assistance Publ Hop Paris, AP HP,Dept Ophthalmol,Ophtalmopole, F-75014 Paris, France.; Bousquet, E (通讯作者)，Univ Paris, Ctr Rech Cordeliers, F-75006 Paris, France.
EM elodie.bousquet@aphp.fr; heloise.torres.villaros@gmail.com;
   julienOprovost@gmail.com; martine.elalouf@hispeed.ch;
   anthony.gigon@fa2.ch; irmela.mantel@fa2.ch; timsit.aurelie@gmail.com;
   francine.behar@gmail.com
OI Torres-Villaros, Heloise/0000-0002-5090-7845; Julien,
   PROVOST/0000-0003-0277-0810; BOUSQUET, ELODIE/0000-0001-5926-1385; behar
   cohen, francine/0000-0001-8571-9513
CR Araki T, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0213110
   Baker ME, 2020, BIOCHEM PHARMACOL, V177, DOI 10.1016/j.bcp.2020.113976
   Bousquet E, 2021, J CLIN MED, V10, DOI 10.3390/jcm10194525
   Bousquet E, 2019, EXP EYE RES, V187, DOI 10.1016/j.exer.2019.107754
   Bousquet E, 2018, RETINA-J RET VIT DIS, V38, P629, DOI 10.1097/IAE.0000000000001580
   Bousquet E, 2016, AM J OPHTHALMOL, V165, P23, DOI 10.1016/j.ajo.2016.02.012
   Carvalho-Recchia CA, 2002, OPHTHALMOLOGY, V109, P1834, DOI 10.1016/S0161-6420(02)01117-X
   Castro-Navarro V, 2021, GRAEF ARCH CLIN EXP, V259, P1385, DOI 10.1007/s00417-020-04940-0
   Chen YY, 2019, J OPHTHALMOL, V2019, DOI 10.1155/2019/2749296
   Cheung CMG, 2019, EYE, V33, P14, DOI 10.1038/s41433-018-0158-4
   Ciloglu E, 2018, GRAEF ARCH CLIN EXP, V256, P1111, DOI 10.1007/s00417-018-3985-x
   Daruich A, 2015, PROG RETIN EYE RES, V48, P82, DOI 10.1016/j.preteyeres.2015.05.003
   Giannopoulos Konstantinos, 2021, J Genomics, V9, P10, DOI 10.7150/jgen.55545
   Hanumunthadu D, 2018, EYE, V32, P1703, DOI 10.1038/s41433-018-0163-7
   Kaye R, 2020, PROG RETIN EYE RES, V79, DOI 10.1016/j.preteyeres.2020.100865
   Kitzmann AS, 2008, OPHTHALMOLOGY, V115, P169, DOI [10.1016/j.ophtha.2007.02.032, 10.1016/j.ophtha.2008.01.009]
   Liu PK, 2020, RETINA-J RET VIT DIS, V40, P2034, DOI 10.1097/IAE.0000000000002702
   Luchak A, 2020, BMC IMMUNOL, V21, DOI 10.1186/s12865-020-00383-8
   Mateo-Montoya Aranzazu, 2014, World J Gastrointest Pathophysiol, V5, P355, DOI 10.4291/wjgp.v5.i3.355
   Mueller KB, 2014, ENDOCRINOLOGY, V155, P4461, DOI 10.1210/en.2014-1270
   Perkins SL, 2002, OPHTHALMOLOGY, V109, P262, DOI 10.1016/S0161-6420(01)00951-4
   Quillen DA, 1996, OPHTHALMOLOGY, V103, P72, DOI 10.1016/S0161-6420(96)30730-6
   Shiragami C, 2018, AM J OPHTHALMOL, V193, P80, DOI 10.1016/j.ajo.2018.06.009
   Siedlecki J, 2019, OPHTHALMOL RETINA, V3, P1013, DOI 10.1016/j.oret.2019.08.002
   Spaide RF, 2022, PROG RETIN EYE RES, V86, DOI 10.1016/j.preteyeres.2021.100973
   Tanaka C, 2021, JPN J OPHTHALMOL, V65, P761, DOI 10.1007/s10384-021-00861-5
   Tufan HA, 2013, GRAEF ARCH CLIN EXP, V251, P677, DOI 10.1007/s00417-012-2075-8
   Zakir SM, 2009, INDIAN J OPHTHALMOL, V57, P419, DOI 10.4103/0301-4738.57143
   Zhao M, 2012, J CLIN INVEST, V122, P2672, DOI 10.1172/JCI61427
NR 29
TC 0
Z9 0
U1 1
U2 3
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2077-0383
J9 J CLIN MED
JI J. Clin. Med.
PD MAR
PY 2022
VL 11
IS 6
AR 1706
DI 10.3390/jcm11061706
PG 8
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA 0B9PC
UT WOS:000774956800001
PM 35330031
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Ohno-Matsui, K
   Wu, PC
   Yamashiro, K
   Vutipongsatorn, K
   Fang, YX
   Cheung, CMG
   Lai, TYY
   Ikuno, Y
   Cohen, SY
   Gaudric, A
   Jonas, JB
AF Ohno-Matsui, Kyoko
   Wu, Pei-Chang
   Yamashiro, Kenji
   Vutipongsatorn, Kritchai
   Fang, Yuxin
   Cheung, Chui Ming Gemmy
   Lai, Timothy Y. Y.
   Ikuno, Yasushi
   Cohen, Salomon Yves
   Gaudric, Alain
   Jonas, Jost B.
TI IMI Pathologic Myopia
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
DE pathologic myopia; myopic maculopathy; optical coherence tomography;
   gene analyses; myopic macular neovascularization; myopic foveoschisis;
   myopic traction maculopathy; dome-shaped macula
ID DOME-SHAPED MACULA; OPTICAL COHERENCE TOMOGRAPHY; INTERNAL LIMITING
   MEMBRANE; ENDOTHELIAL-GROWTH-FACTOR; LACQUER CRACK LESIONS; SUBFOVEAL
   CHOROIDAL NEOVASCULARIZATION; CEREBROSPINAL-FLUID PRESSURE;
   PROGNOSTIC-FACTOR ANALYSIS; EPITHELIUM-DERIVED FACTOR; CHINESE
   ADULT-POPULATION
AB Pathologic myopia is a major cause of visual impairment worldwide. Pathologic myopia is distinctly different from high myopia. High myopia is a high degree of myopic refractive error, whereas pathologic myopia is defined by a presence of typical complications in the fundus (posterior staphyloma or myopic maculopathy equal to or more serious than diffuse choroidal atrophy). Pathologic myopia often occurs in eyes with high myopia, however its complications especially posterior staphyloma can also occur in eyes without high myopia.
   Owing to a recent advance in ocular imaging, an objective and accurate diagnosis of pathologic myopia has become possible. Especially, optical coherence tomography has revealed novel lesions like dome-shaped macula and myopic traction maculopathy. Wide-field optical coherence tomography has succeeded in visualizing the entire extent of large staphylomas. The effectiveness of new therapies for complications have been shown, such as anti-VEGF therapies for myopic macular neovascularization and vitreoretinal surgery for myopic traction maculopathy.
   Myopia, especially childhood myopia, has been increasing rapidly in the world. In parallel with an increase in myopia, the prevalence of high myopia has also been increasing. However, it remains unclear whether or not pathologic myopia will increase in parallel with an increase of myopia itself. In addition, it has remained unclear whether genes responsible for pathologic myopia are the same as those for myopia in general, or whether pathologic myopia is genetically different from other myopia.
C1 [Ohno-Matsui, Kyoko; Fang, Yuxin] Tokyo Med & Dent Univ, Dept Ophthalmol & Visual Sci, Tokyo, Japan.
   [Wu, Pei-Chang] Kaohsiung Chang Gung Mem Hosp, Dept Ophthalmol, Kaohsiung, Taiwan.
   [Wu, Pei-Chang] Chang Gung Univ, Coll Med, Kaohsiung, Taiwan.
   [Yamashiro, Kenji] Univ Grad Sch Med, Dept Ophthalmol & Visual Sci, Kyoto, Japan.
   [Yamashiro, Kenji] Otsu Red Cross Hosp, Dept Ophthalmol, Otsu, Shiga, Japan.
   [Vutipongsatorn, Kritchai] Imperial Coll London, Sch Med, London, England.
   [Cheung, Chui Ming Gemmy] Singapore Natl Eye Ctr, Singapore Eye Res Inst, Singapore, Singapore.
   [Lai, Timothy Y. Y.] Chinese Univ Hong Kong, Hong Kong Eye Hosp, Dept Ophthalmol Visual Sci, Hong Kong, Peoples R China.
   [Ikuno, Yasushi] Ikuno Eye Ctr, Yodogawa Ku, 2-9-10-3F Juso Higashi, Osaka 5320023, Japan.
   [Ikuno, Yasushi] Osaka Univ, Dept Ophthalmol, Grad Sch Med, Osaka, Japan.
   [Ikuno, Yasushi] Kanazawa Univ, Dept Ophthalmol, Grad Sch Med, Kanazawa, Ishikawa, Japan.
   [Cohen, Salomon Yves; Gaudric, Alain] Ctr Ophtalmol Imagerie & Laser, Paris, France.
   [Cohen, Salomon Yves] Univ Paris Est, Dept Ophthalmol, Creteil, France.
   [Gaudric, Alain] Univ Paris, Hop Lariboisiere, APHP, Dept Ophthalmol, Paris, France.
   [Jonas, Jost B.] Heidelberg Univ, Med Fac Mannheim, Dept Ophthalmol, Mannheim, Germany.
C3 Tokyo Medical & Dental University (TMDU); Chang Gung Memorial Hospital;
   Chang Gung University; Imperial College London; National University of
   Singapore; Singapore National Eye Center; Chinese University of Hong
   Kong; Osaka University; Kanazawa University; Universite
   Paris-Est-Creteil-Val-de-Marne (UPEC); Assistance Publique Hopitaux
   Paris (APHP); Hopital Universitaire Lariboisiere-Fernand-Widal - APHP;
   UDICE-French Research Universities; Universite Paris Cite; Ruprecht
   Karls University Heidelberg
RP Ohno-Matsui, K (通讯作者)，Tokyo Med & Dent Univ, Dept Ophthalmol & Visual Sci, Tokyo, Japan.
EM k.ohno.oph@tmd.ac.jp
OI Vutipongsatorn, Kritchai/0000-0002-8941-8846
FU International Myopia Institute
FX Supported by the International Myopia Institute. The publication costs
   of the International Myopia Institute reports were supported by
   donations from the Brien Holden Vision Institute, Carl Zeiss Vision,
   CooperVision, Essilor, and Alcon.
CR Abdolrahimzadeh S, 2017, CURR EYE RES, V42, P1468, DOI 10.1080/02713683.2017.1347692
   Akagi-Kurashige Y, 2012, INVEST OPHTH VIS SCI, V53, P2349, DOI 10.1167/iovs.11-9405
   Arapi I, 2015, OSLI RETINA, V46, P217, DOI 10.3928/23258160-20150213-15
   Asai T, 2014, INVEST OPHTH VIS SCI, V55, P226, DOI 10.1167/iovs.13-12658
   Asakuma T, 2012, OPHTHALMOLOGY, V119, P1760, DOI 10.1016/j.ophtha.2012.02.034
   AVETISOV ES, 1983, METAB PEDIATR SYST O, V7, P183
   AVILA MP, 1984, OPHTHALMOLOGY, V91, P1573
   Baba T, 2003, AM J OPHTHALMOL, V135, P338, DOI 10.1016/S0002-9394(02)01937-2
   Bagchi A, 2019, EYE, V33, P1111, DOI 10.1038/s41433-019-0378-2
   Bando H, 2005, AM J OPHTHALMOL, V139, P197, DOI 10.1016/j.ajo.2004.07.027
   Barathi VA, 2013, DIS MODEL MECH, V6, P1146, DOI 10.1242/dmm.010967
   Benhamou N, 2002, AM J OPHTHALMOL, V133, P794, DOI 10.1016/S0002-9394(02)01394-6
   Berdahl JP, 2008, OPHTHALMOLOGY, V115, P763, DOI 10.1016/j.ophtha.2008.01.013
   Bikbov MM, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.0567
   Blinder KJ, 2003, OPHTHALMOLOGY, V110, P667, DOI 10.1016/S0161-6420(02)01998-X
   Braimah IZ, 2017, BRIT J OPHTHALMOL, V101, P1201, DOI 10.1136/bjophthalmol-2016-309994
   Bruyere E, 2015, AM J OPHTHALMOL, V160, P749, DOI 10.1016/j.ajo.2015.07.004
   Buch H, 2001, OPHTHALMOLOGY, V108, P2347, DOI 10.1016/S0161-6420(01)00823-5
   Bullimore MA, 2019, OPTOMETRY VISION SCI, V96, P463, DOI 10.1097/OPX.0000000000001367
   Burke TR, 2020, EYE, V34, P1903, DOI 10.1038/s41433-020-0769-4
   Cai BC, 2017, MEDICINE, V96, DOI 10.1097/MD.0000000000009251
   Caillaux V, 2013, AM J OPHTHALMOL, V156, P958, DOI 10.1016/j.ajo.2013.06.032
   Cases O, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0129518
   Ceklic L, 2014, OPHTHALMOLOGY, V121, P2288, DOI 10.1016/j.ophtha.2014.06.012
   Chalam KV, 2019, INT J RETINA VITR, V5, DOI 10.1186/s40942-019-0166-y
   Chang L, 2013, AM J OPHTHALMOL, V155, P991, DOI 10.1016/j.ajo.2013.01.016
   Chen, 2016, ANG EX DEG 2016 M MI
   Chen NN, 2019, OSLI RETINA, V50, pE218, DOI 10.3928/23258160-20190806-16
   Chen YX, 2019, RETINA-J RET VIT DIS, V39, P1985, DOI 10.1097/IAE.0000000000002292
   Cheung CMG, 2019, ACTA OPHTHALMOL, V97, pE729, DOI 10.1111/aos.14035
   Cheung CMG, 2017, OPHTHALMOLOGY, V124, P1690, DOI 10.1016/j.ophtha.2017.04.028
   Chhablani J, 2018, BRIT J OPHTHALMOL, V102, P455, DOI 10.1136/bjophthalmol-2017-310411
   Chinskey ND, 2013, OPHTHAL SURG LAS IM, V44, P593, DOI 10.3928/23258160-20131010-01
   Coco RM, 2012, OPHTHALMOLOGICA, V228, P7, DOI 10.1159/000336910
   Cohen SY, 2013, RETINA-J RET VIT DIS, V33, P1338, DOI 10.1097/IAE.0b013e3182831364
   Cohen SY, 1998, OPHTHALMOLOGY, V105, P1831, DOI 10.1016/S0161-6420(98)91024-7
   Coscas G, 2016, DEV OPHTHALMOL, V56, P30, DOI 10.1159/000442774
   Cotter SA, 2006, OPHTHALMOLOGY, V113, P1574, DOI 10.1016/j.ophtha.2006.05.002
   COULOMBRE AJ, 1973, DEV BIOL, V33, P257, DOI 10.1016/0012-1606(73)90136-X
   Curcio CA., 2012, RETINA-J RET VIT DIS, V1, P466
   Curtin B J, 1977, Trans Am Ophthalmol Soc, V75, P67
   Curtin B J, 1970, Trans Am Ophthalmol Soc, V68, P312
   CURTIN BJ, 1979, ARCH OPHTHALMOL-CHIC, V97, P912, DOI 10.1001/archopht.1979.01020010470017
   CURTIN BJ, 1963, ARCH OPHTHALMOL-CHIC, V69, P166, DOI 10.1001/archopht.1963.00960040172007
   CURTIN BJ, 1987, AM J OPHTHALMOL, V103, P544, DOI 10.1016/S0002-9394(14)74278-3
   CURTIN BJ, 1971, AM J OPHTHALMOL, V71, P42, DOI 10.1016/0002-9394(71)91092-0
   Curtin BJ., 1985, THE MYOPIAS, P277
   Dai FF, 2020, RETINA-J RET VIT DIS, V40, P2119, DOI 10.1097/IAE.0000000000002722
   Dai Y, 2015, INVEST OPHTH VIS SCI, V56, P7076, DOI 10.1167/iovs.14-16033
   Deobhakta A, 2015, OSLI RETINA, V46, P391, DOI 10.3928/23258160-20150323-18
   Dhingra A, 2012, J NEUROSCI, V32, P11343, DOI 10.1523/JNEUROSCI.1436-12.2012
   Dirani A, 2014, CLIN OPHTHALMOL, V8, P999, DOI 10.2147/OPTH.S62267
   Du R, 2020, RETINA-J RET VIT DIS, V40, P951, DOI 10.1097/IAE.0000000000002575
   Duke-Elder S, 1970, PATHOLOGICAL REFRACT
   Ellabban AA, 2014, AM J OPHTHALMOL, V158, P1062, DOI 10.1016/j.ajo.2014.08.006
   Ellabban AA, 2013, AM J OPHTHALMOL, V155, P320, DOI 10.1016/j.ajo.2012.08.007
   Errera MH, 2014, GRAEF ARCH CLIN EXP, V252, P499, DOI 10.1007/s00417-013-2561-7
   FALRE M, 1954, Ophthalmologica, V127, P351
   Fang YX, 2019, OPHTHALMOLOGY, V126, P1018, DOI 10.1016/j.ophtha.2019.01.012
   Fang YX, 2018, OPHTHALMOLOGY, V125, P863, DOI 10.1016/j.ophtha.2017.12.005
   Fernandez-Robredo P, 2008, OPHTHALMOLOGY, V115, P1632, DOI 10.1016/j.ophtha.2008.03.004
   Fledelius HC, 2018, ACTA OPHTHALMOL, V96, P46, DOI 10.1111/aos.13659
   Flitcroft DI, 2019, INVEST OPHTH VIS SCI, V60, pM20, DOI 10.1167/iovs.18-25957
   Flores-Moreno I, 2013, BRIT J OPHTHALMOL, V97, P1010, DOI 10.1136/bjophthalmol-2012-302836
   Flores-Moreno I, 2013, AM J OPHTHALMOL, V155, P314, DOI 10.1016/j.ajo.2012.07.015
   Fox J. G., 2006, MOUSE BIOMEDICAL RES
   Fujiwara T, 2009, AM J OPHTHALMOL, V148, P445, DOI 10.1016/j.ajo.2009.04.029
   Gao LQ, 2011, ARCH OPHTHALMOL-CHIC, V129, P1199, DOI 10.1001/archophthalmol.2011.230
   Gao XX, 2013, AM J OPHTHALMOL, V155, P1021, DOI 10.1016/j.ajo.2013.01.023
   Garcia-Ben A, 2019, BRIT J OPHTHALMOL, V103, P385, DOI 10.1136/bjophthalmol-2018-311895
   Gaucher D, 2007, AM J OPHTHALMOL, V143, P455, DOI 10.1016/j.ajo.2006.10.053
   Gerinec A, 2001, Bratisl Lek Listy, V102, P73
   Giacomelli G, 2017, OSLI RETINA, V48, P822, DOI 10.3928/23258160-20170928-07
   Grewal DS, 2016, JAMA OPHTHALMOL, V134, P229, DOI 10.1001/jamaophthalmol.2015.5237
   GROSSNIKLAUS HE, 1992, RETINA-J RET VIT DIS, V12, P127, DOI 10.1097/00006982-199212020-00009
   Guan HY, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0215827
   Guo Y, 2018, INVEST OPHTH VIS SCI, V59, P1609, DOI 10.1167/iovs.17-21665
   Gupta P, 2015, ACTA OPHTHALMOL, V93, pE585, DOI 10.1111/aos.12631
   Hamilton RD, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0227557
   Hayashi H, 2011, INVEST OPHTH VIS SCI, V52, P4853, DOI 10.1167/iovs.11-7311
   Hayashi K, 2010, OPHTHALMOLOGY, V117, P1595, DOI 10.1016/j.ophtha.2009.11.003
   Hayashi K, 2009, AM J OPHTHALMOL, V148, P396, DOI 10.1016/j.ajo.2009.03.026
   Healey PR, 2007, INVEST OPHTH VIS SCI, V48, P2529, DOI 10.1167/iovs.06-0714
   Hirata A, 1998, GRAEF ARCH CLIN EXP, V236, P138, DOI 10.1007/s004170050054
   Ho M, 2013, OPHTHALMOLOGY, V120, P1909, DOI 10.1016/j.ophtha.2013.02.005
   Ho TC, 2012, RETINA-J RET VIT DIS, V32, P631, DOI 10.1097/IAE.0B013E31824D0A4B
   Hocaoglu M, 2019, GRAEF ARCH CLIN EXP, V257, P2357, DOI 10.1007/s00417-019-04449-1
   Holden BA, 2016, OPHTHALMOLOGY, V123, P1036, DOI 10.1016/j.ophtha.2016.01.006
   Holz FG, 2016, OPHTHALMOLOGICA, V236, P19, DOI 10.1159/000446027
   Hosoda Y, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-03649-3
   Hsu WM, 2004, OPHTHALMOLOGY, V111, P62, DOI 10.1016/j.ophtha.2003.05.011
   Hysi PG, 2020, NAT GENET, V52, P401, DOI 10.1038/s41588-020-0599-0
   Hysi PG, 2010, NAT GENET, V42, P902, DOI 10.1038/ng.664
   Iacono P, 2017, RETINA-J RET VIT DIS, V37, P1931, DOI 10.1097/IAE.0000000000001436
   Ikuno Y, 2006, AM J OPHTHALMOL, V141, P774, DOI 10.1016/j.ajo.2005.11.044
   Ikuno Y, 2005, AM J OPHTHALMOL, V139, P462, DOI 10.1016/j.ajo.2004.09.078
   Ikuno Y, 2003, AM J OPHTHALMOL, V136, P477, DOI 10.1016/S0002-9394(03)00269-1
   Ikuno Y, 2008, JPN J OPHTHALMOL, V52, P269, DOI 10.1007/s10384-008-0544-8
   Ikuno Y, 2015, OPHTHALMOLOGY, V122, P1220, DOI 10.1016/j.ophtha.2015.01.025
   Ikuno Y, 2009, INVEST OPHTH VIS SCI, V50, P3876, DOI 10.1167/iovs.08-3325
   Ikuno Yasushi, 2006, Nippon Ganka Gakkai Zasshi, V110, P855
   Imamura Y, 2011, AM J OPHTHALMOL, V151, P297, DOI 10.1016/j.ajo.2010.08.014
   Iwase A, 2006, OPHTHALMOLOGY, V113, P1354, DOI 10.1016/j.ophtha.2006.04.022
   Jo Y, 2012, BRIT J OPHTHALMOL, V96, P197, DOI 10.1136/bjo.2011.203232
   Johnson Mark W, 2012, Retina, V32 Suppl 2, pS205, DOI 10.1097/IAE.0b013e31825bc0de
   Jonas JB, 2005, AM J OPHTHALMOL, V139, P346, DOI 10.1016/j.ajo.2004.07.047
   Jonas JB, 2004, INVEST OPHTH VIS SCI, V45, P2660, DOI 10.1167/iovs.03-1363
   JONAS JB, 1988, INVEST OPHTH VIS SCI, V29, P1151
   Jonas JB, 2003, INVEST OPHTH VIS SCI, V44, P5189, DOI 10.1167/iovs.03-0174
   JONAS JB, 1988, GRAEF ARCH CLIN EXP, V226, P587, DOI 10.1007/BF02169209
   Jonas JB, 2017, INVEST OPHTH VIS SCI, V58, P5889, DOI 10.1167/iovs.17-21942
   Jonas JB, 2018, ACTA OPHTHALMOL, V96, pe147, DOI 10.1111/aos.13537
   Jonas JB, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0175120
   Jonas JB, 2017, RETINA-J RET VIT DIS, V37, P1428, DOI 10.1097/IAE.0000000000001464
   Jonas JB, 2016, ACTA OPHTHALMOL, V94, pE664, DOI 10.1111/aos.13027
   Jonas JB, 2013, INVEST OPHTH VIS SCI, V54, P1295, DOI 10.1167/iovs.12-11352
   Jonas JB, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047237
   Jonas JB, 2010, ACTA OPHTHALMOL, V88, pe317, DOI 10.1111/j.1755-3768.2010.02022.x
   Jonas RA, 2020, ACTA OPHTHALMOL, V98, pE43, DOI 10.1111/aos.14206
   Kadonosono K, 2001, AM J OPHTHALMOL, V131, P203, DOI 10.1016/S0002-9394(00)00728-5
   Kantarci S, 2007, NAT GENET, V39, P957, DOI 10.1038/ng2063
   Kasahara K, 2017, RETINA-J RET VIT DIS, V37, P1055, DOI 10.1097/IAE.0000000000001313
   Keane Pearse A, 2012, Ophthalmic Surg Lasers Imaging, V43 Online, pe52, DOI 10.3928/15428877-20120524-02
   Kiefer AK, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003299
   Kim M, 2018, OPHTHALMOLOGY, V125, P1215, DOI 10.1016/j.ophtha.2018.01.026
   Kim TW, 2012, OPHTHALMOLOGY, V119, P21, DOI 10.1016/j.ophtha.2011.07.051
   Klaver CCW, 1998, ARCH OPHTHALMOL-CHIC, V116, P653, DOI 10.1001/archopht.116.5.653
   KLEIN RM, 1988, AM J OPHTHALMOL, V106, P282, DOI 10.1016/0002-9394(88)90362-5
   KLEIN RM, 1975, AM J OPHTHALMOL, V79, P386, DOI 10.1016/0002-9394(75)90611-X
   Kobayashi K, 2005, JPN J OPHTHALMOL, V49, P306, DOI 10.1007/S10384-004-0204-6
   Koch T., 1973, ANATOMY CHICKEN DOME
   Kojima A, 2006, GRAEF ARCH CLIN EXP, V244, P1474, DOI 10.1007/s00417-006-0324-4
   Kumagai K, 2010, RETINA-J RET VIT DIS, V30, P874, DOI 10.1097/IAE.0b013e3181c703fc
   Kuriyama S, 2013, AM J OPHTHALMOL, V156, P125, DOI 10.1016/j.ajo.2013.02.014
   Lai CC, 2015, OPHTHALMOLOGY, V122, P1889, DOI 10.1016/j.ophtha.2015.05.040
   Lai TYY, 2012, EYE, V26, P1004, DOI 10.1038/eye.2012.97
   Lai TYY, 2016, RETINA-J RET VIT DIS, V36, P1614, DOI 10.1097/IAE.0000000000001227
   Lee JH, 2017, RETINA-J RET VIT DIS, V37, P1516, DOI 10.1097/IAE.0000000000001384
   Lee KM, 2018, OPHTHALMOLOGY, V125, P1224, DOI 10.1016/j.ophtha.2018.02.002
   Leveziel N, 2012, INVEST OPHTH VIS SCI, V53, P5004, DOI 10.1167/iovs.12-9538
   Li ZX, 2019, INVEST OPHTH VIS SCI, V60, P1096, DOI 10.1167/iovs.18-25800
   Liang IC, 2015, OPHTHALMOLOGY, V122, P1591, DOI 10.1016/j.ophtha.2015.04.012
   Lim LS, 2014, OPHTHALMOLOGY, V121, P305, DOI 10.1016/j.ophtha.2013.08.033
   Lin CX, 2018, OPHTHAL PHYSL OPT, V38, P337, DOI 10.1111/opo.12456
   Lin LLK, 2004, ANN ACAD MED SINGAP, V33, P27
   Liu B, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000003264
   Liu BQ, 2018, BMC OPHTHALMOL, V18, DOI 10.1186/s12886-018-0791-5
   Liu CF, 2014, EYE, V28, P1437, DOI 10.1038/eye.2014.221
   Liu HH, 2010, OPHTHALMOLOGY, V117, P1763, DOI 10.1016/j.ophtha.2010.01.020
   Liu R, 2020, RETINA-J RET VIT DIS, V40, P241, DOI 10.1097/IAE.0000000000002397
   Lo J, 2020, INVEST OPHTH VIS SCI, V61, DOI 10.1167/iovs.61.2.15
   Mao JF, 2006, CURR EYE RES, V31, P983, DOI 10.1080/02713680600910510
   Marchese A, 2019, BRIT J OPHTHALMOL, V103, P1146, DOI 10.1136/bjophthalmol-2018-312780
   Marchese A, 2017, AM J OPHTHALMOL, V182, P56, DOI 10.1016/j.ajo.2017.07.013
   Margolis R, 2009, AM J OPHTHALMOL, V147, P811, DOI 10.1016/j.ajo.2008.12.008
   McBrien NA, 2001, INVEST OPHTH VIS SCI, V42, P2179
   Miere A, 2018, RETINA-J RET VIT DIS, V38, P1301, DOI 10.1097/IAE.0000000000001733
   Miller DG, 2001, CURR OPIN OPHTHALMOL, V12, P222, DOI 10.1097/00055735-200106000-00014
   Miyake M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0107923
   Miyake M, 2014, OPHTHALMOLOGY, V121, P225, DOI 10.1016/j.ophtha.2013.06.043
   Miyake M, 2013, INVEST OPHTH VIS SCI, V54, P4208, DOI 10.1167/iovs.13-12280
   Momose A, 1983, Indian J Ophthalmol, V31, P759
   Montiani-Ferreira F, 2004, J COMP PATHOL, V131, P105, DOI 10.1016/j.jcpa.2004.01.009
   Morgan I, 2005, PROG RETIN EYE RES, V24, P1, DOI 10.1016/j.preteyeres.2004.06.004
   Morgan IG, 2018, PROG RETIN EYE RES, V62, P134, DOI 10.1016/j.preteyeres.2017.09.004
   Morgan IG, 2017, RETINA-J RET VIT DIS, V37, P989, DOI 10.1097/IAE.0000000000001272
   Moriyama M, 2012, INVEST OPHTH VIS SCI, V53, P4510, DOI 10.1167/iovs.12-9426
   Moriyama M, 2011, OPHTHALMOLOGY, V118, P1626, DOI 10.1016/j.ophtha.2011.01.018
   Morizane Y, 2014, AM J OPHTHALMOL, V157, P861, DOI 10.1016/j.ajo.2013.12.028
   Nagaoka N, 2011, AM J OPHTHALMOL, V152, P420, DOI 10.1016/j.ajo.2011.03.002
   Nakanishi H, 2010, EYE, V24, P1078, DOI 10.1038/eye.2009.215
   Nakanishi H, 2008, RETINA-J RET VIT DIS, V28, P1493, DOI 10.1097/IAE.0b013e318183589c
   Nakanishi H, 2008, AM J OPHTHALMOL, V146, P198, DOI 10.1016/j.ajo.2008.04.022
   Naysan Jonathan, 2015, Int J Retina Vitreous, V1, P8
   Neelam K, 2012, PROG RETIN EYE RES, V31, P495, DOI 10.1016/j.preteyeres.2012.04.001
   Ng DSC, 2017, ASIA-PAC J OPHTHALMO, V6, P554, DOI 10.22608/APO.2017308
   Nishida Y, 2012, RETINA-J RET VIT DIS, V32, P1229, DOI 10.1097/IAE.0b013e318242b990
   Nishimura A, 2011, AM J OPHTHALMOL, V151, P148, DOI 10.1016/j.ajo.2010.07.023
   Ohno-Matsui K, 2003, BRIT J OPHTHALMOL, V87, P570, DOI 10.1136/bjo.87.5.570
   Ohno-Matsui K, 1998, JPN J OPHTHALMOL, V42, P293, DOI 10.1016/S0021-5155(98)00008-2
   Ohno-Matsui K, 2019, PROG RETIN EYE RES, V70, P99, DOI 10.1016/j.preteyeres.2018.12.001
   Ohno-Matsui K, 2018, EYE, V32, P1871, DOI 10.1038/s41433-018-0192-2
   Ohno-Matsui K, 2018, PROG RETIN EYE RES, V63, P92, DOI 10.1016/j.preteyeres.2017.10.005
   Ohno-Matsui K, 2017, AM J OPHTHALMOL, V183, P134, DOI 10.1016/j.ajo.2017.09.009
   Ohno-Matsui K, 2016, AM J OPHTHALMOL, V166, P22, DOI 10.1016/j.ajo.2016.03.019
   Ohno-Matsui K, 2016, PROG RETIN EYE RES, V52, P156, DOI 10.1016/j.preteyeres.2015.12.001
   Ohno-Matsui K, 2016, AM J OPHTHALMOL, V162, P133, DOI 10.1016/j.ajo.2015.11.014
   Ohno-Matsui K, 2015, AM J OPHTHALMOL, V159, P877, DOI 10.1016/j.ajo.2015.01.022
   Ohno-Matsui K, 2014, OPHTHALMOLOGY, V121, P1798, DOI 10.1016/j.ophtha.2014.03.035
   Ohno-Matsui K, 2011, INVEST OPHTH VIS SCI, V52, P9644, DOI 10.1167/iovs.11-8597
   OhnoMatsui K, 1996, RETINA-J RET VIT DIS, V16, P29, DOI 10.1097/00006982-199616010-00006
   Ohsugi H, 2014, AM J OPHTHALMOL, V158, P162, DOI 10.1016/j.ajo.2014.02.054
   Oishi M, 2013, INVEST OPHTH VIS SCI, V54, P7492, DOI 10.1167/iovs.13-12825
   Pang CE, 2015, RETINA-J RET VIT DIS, V35, P407, DOI 10.1097/IAE.0000000000000368
   Panozzo G, 2004, ARCH OPHTHALMOL-CHIC, V122, P1455, DOI 10.1001/archopht.122.10.1455
   Pardo-Lopez D, 2011, CASE REP OPHTHALM, V2, P111, DOI 10.1159/000326918
   Parodi MB, 2016, RETINA-J RET VIT DIS, V36, P104, DOI 10.1097/IAE.0000000000000684
   Parolini B, 2015, RETINA-J RET VIT DIS, V35, P2469, DOI 10.1097/IAE.0000000000000613
   PHILLIPS C I, 1958, Br J Ophthalmol, V42, P749, DOI 10.1136/bjo.42.12.749
   Qu J, 2006, CURR EYE RES, V31, P587, DOI 10.1080/02713680600770609
   Querques L, 2017, BRIT J OPHTHALMOL, V101, P609, DOI 10.1136/bjophthalmol-2016-309162
   Ren RJ, 2010, OPHTHALMOLOGY, V117, P259, DOI 10.1016/j.ophtha.2009.06.058
   Ren RJ, 2009, INVEST OPHTH VIS SCI, V50, P2175, DOI 10.1167/iovs.07-1429
   Ripandelli G, 2001, OPHTHALMOLOGY, V108, P2258, DOI 10.1016/S0161-6420(01)00861-2
   Ruiz-Medrano J, 2019, PROG RETIN EYE RES, V69, P80, DOI 10.1016/j.preteyeres.2018.10.005
   Sakaguchi H, 2004, AM J OPHTHALMOL, V138, P1079, DOI 10.1016/j.ajo.2004.06.078
   Samarawickrama C, 2011, OPHTHALMOLOGY, V118, P2050, DOI 10.1016/j.ophtha.2011.02.040
   Sayanagi K, 2009, BRIT J OPHTHALMOL, V93, P1687, DOI 10.1136/bjo.2008.148718
   Sayanagi K, 2008, AM J OPHTHALMOL, V145, P902, DOI 10.1016/j.ajo.2008.01.011
   Sayanagi K, 2006, AM J OPHTHALMOL, V142, P850, DOI 10.1016/j.ajo.2006.05.031
   Sayanagi K, 2017, BRIT J OPHTHALMOL, V101, P1524, DOI 10.1136/bjophthalmol-2016-309628
   Schaeffel F, 2015, CLIN EXP OPTOM, V98, P507, DOI 10.1111/cxo.12312
   Schrauwen I, 2014, CLIN GENET, V86, P282, DOI 10.1111/cge.12265
   Shih YF, 2006, EYE, V20, P888, DOI 10.1038/sj.eye.6702035
   Shimada N, 2006, AM J OPHTHALMOL, V142, P497, DOI 10.1016/j.ajo.2006.03.048
   Shimada N, 2012, AM J OPHTHALMOL, V154, P693, DOI 10.1016/j.ajo.2012.04.013
   Shimada N, 2011, JPN J OPHTHALMOL, V55, P378, DOI 10.1007/s10384-011-0034-2
   Shin E, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0227292
   Shinohara K, 2013, EYE, V27, P1234, DOI 10.1038/eye.2013.202
   Shinohara K, 2018, OPHTHALMOLOGY, V125, P1575, DOI 10.1016/j.ophtha.2018.03.053
   Shinohara K, 2017, INVEST OPHTH VIS SCI, V58, P3750, DOI 10.1167/iovs.17-22319
   Solouki AM, 2010, NAT GENET, V42, P897, DOI 10.1038/ng.663
   Soudier G, 2020, OPHTHALMOLOGICA, V243, P129, DOI 10.1159/000504051
   Soudier G, 2017, CASE REP OPHTHALM, V8, P515, DOI 10.1159/000481703
   Soudier G, 2016, RETINA-J RET VIT DIS, V36, P944, DOI 10.1097/IAE.0000000000000806
   Spaide R.F, 2014, STAPHYLOMA PART 1 PA, P167
   STIRPE M, 1990, RETINA-J RET VIT DIS, V10, P113, DOI 10.1097/00006982-199004000-00004
   STRAZNICKY C, 1987, DEVELOPMENT, V100, P411
   Sundin Olof H, 2005, Ophthalmic Genet, V26, P153, DOI 10.1080/13816810500374359
   Takahashi A, 2012, RETINA-J RET VIT DIS, V32, P127, DOI 10.1097/IAE.0b013e318214d094
   Takahashi H, 2019, AM J OPHTHALMOL, V206, P102, DOI 10.1016/j.ajo.2019.03.011
   Takahashi H, 2019, INT OPHTHALMOL, V39, P521, DOI 10.1007/s10792-018-0841-2
   Takano M, 1999, AM J OPHTHALMOL, V128, P472, DOI 10.1016/S0002-9394(99)00186-5
   Takashima T, 2001, JPN J OPHTHALMOL, V45, P84, DOI 10.1016/S0021-5155(00)00305-1
   Tamura N, 2014, CLIN OPHTHALMOL, V8, P83, DOI 10.2147/OPTH.S54903
   Tan ACS, 2017, RETINA-J RET VIT DIS, V37, P1544, DOI 10.1097/IAE.0000000000001402
   Tan NYQ, 2019, BRIT J OPHTHALMOL, V103, P5, DOI 10.1136/bjophthalmol-2018-313530
   Tan NW, 2018, RETINA-J RET VIT DIS, V38, P2228, DOI 10.1097/IAE.0000000000001858
   Tanaka N, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0218107
   Tanaka Y, 2015, AM J OPHTHALMOL, V159, P677, DOI 10.1016/j.ajo.2015.01.004
   Tang J, 2010, J OPHTHALMOL, V2010, DOI 10.1155/2010/175613
   Tedja MS, 2019, INVEST OPHTH VIS SCI, V60, pM89, DOI 10.1167/iovs.18-25965
   Tedja MS, 2018, NAT GENET, V50, P834, DOI 10.1038/s41588-018-0127-7
   Tokoro, 1998, ATLAS POSTERIOR FUND, P5, DOI 10.1007/978-4-431-67951-6_3
   Tokoro, 1998, ATLAS POSTERIOR FUND, P23
   Tong JP, 2006, AM J OPHTHALMOL, V141, P456, DOI 10.1016/j.ajo.2005.10.012
   Tummala H, 2006, INVEST OPHTH VIS SCI, V47, P4714, DOI 10.1167/iovs.06-0292
   Uemoto R, 2003, GRAEF ARCH CLIN EXP, V241, P792, DOI 10.1007/s00417-003-0750-5
   Ueno C, 2014, RETINA-J RET VIT DIS, V34, P497, DOI 10.1097/IAE.0b013e3182a1ca40
   Velazquez-Villoria A, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0162296
   Verhoeven VJM, 2013, NAT GENET, V45, P314, DOI 10.1038/ng.2554
   Verkicharla PK, 2015, OPHTHAL PHYSL OPT, V35, P465, DOI 10.1111/opo.12238
   Vincent A, 2016, AM J HUM GENET, V98, P1011, DOI 10.1016/j.ajhg.2016.03.021
   Viola F, 2015, AM J OPHTHALMOL, V159, P44, DOI 10.1016/j.ajo.2014.09.026
   Vongphanit J, 2002, OPHTHALMOLOGY, V109, P704, DOI 10.1016/S0161-6420(01)01024-7
   Wakabayashi T, 2018, GRAEF ARCH CLIN EXP, V256, P1387, DOI 10.1007/s00417-018-4046-1
   WALDVOGEL JA, 1990, AM SCI, V78, P342
   Wang NK, 2016, AM J OPHTHALMOL, V162, P180, DOI 10.1016/j.ajo.2015.11.016
   Wang NK, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053660
   Wang NK, 2012, AM J OPHTHALMOL, V153, P669, DOI 10.1016/j.ajo.2011.08.039
   Ward B, 2009, EYE, V23, P2169, DOI 10.1038/eye.2008.433
   Wen Dan, 2006, Zhong Nan Da Xue Xue Bao Yi Xue Ban, V31, P236
   WIESEL TN, 1977, NATURE, V266, P66, DOI 10.1038/266066a0
   Wolf S, 2014, OPHTHALMOLOGY, V121, P682, DOI 10.1016/j.ophtha.2013.10.023
   Wong CW, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-52156-y
   Wong CW, 2019, RETINA-J RET VIT DIS, V39, P1742, DOI 10.1097/IAE.0000000000002233
   Wong CW, 2017, INVEST OPHTH VIS SCI, V58, DOI 10.1167/iovs.16-20742
   Wong TY, 2015, BRIT J OPHTHALMOL, V99, P289, DOI 10.1136/bjophthalmol-2014-305131
   Wong TY, 2014, AM J OPHTHALMOL, V157, P9, DOI 10.1016/j.ajo.2013.08.010
   Wong YL, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0220143
   Wong YL, 2018, INVEST OPHTH VIS SCI, V59, P4603, DOI 10.1167/iovs.18-24032
   Wong YL, 2018, EYE CONTACT LENS, V44, P286, DOI 10.1097/ICL.0000000000000466
   World Health Organization (WHO), 2017, JOINT WORLD HLTH ORG
   Wu PC, 2016, ASIA-PAC J OPHTHALMO, V5, P386, DOI 10.1097/APO.0000000000000236
   Xiao O, 2018, INVEST OPHTH VIS SCI, V59, P4880, DOI 10.1167/iovs.18-24471
   Xie SQ, 2020, RETINA-J RET VIT DIS, V40, P1215, DOI 10.1097/IAE.0000000000002630
   Xiong SY, 2017, SCI REP-UK, V7, DOI 10.1038/srep45059
   Xu LA, 2007, OPHTHALMOLOGY, V114, P216, DOI 10.1016/j.ophtha.2006.06.050
   Xu L, 2006, OPHTHALMOLOGY, V113, P1134, DOI 10.1016/j.ophtha.2006.01.035
   Xu LA, 2010, ACTA OPHTHALMOL, V88, pe350, DOI 10.1111/j.1755-3768.2009.01770.x
   Xu X, 2020, RETINA-J RET VIT DIS, V40, P225, DOI 10.1097/IAE.0000000000002395
   Xu X, 2019, RETINA-J RET VIT DIS, V39, P1299, DOI 10.1097/IAE.0000000000002180
   Xu X, 2019, RETINA-J RET VIT DIS, V39, P1265, DOI 10.1097/IAE.0000000000002168
   Yan YN, 2018, OPHTHALMOLOGY, V125, P1253, DOI 10.1016/j.ophtha.2018.01.035
   Yokoi T, 2018, ASIA-PAC J OPHTHALMO, V7, P415, DOI 10.22608/APO.2018290
   Yokoi T, 2017, INVEST OPHTH VIS SCI, V58, DOI 10.1167/iovs.16-20652
   Yokoi T, 2016, OPHTHALMOLOGY, V123, P1783, DOI 10.1016/j.ophtha.2016.04.029
   Yoshida T, 2003, OPHTHALMOLOGY, V110, P1297, DOI 10.1016/S0161-6420(03)00461-5
   Zhang Q, 2019, INVEST OPHTH VIS SCI, V60, P2591, DOI 10.1167/iovs.19-27331
   Zhao XY, 2018, RETINA-J RET VIT DIS, V38, P462, DOI 10.1097/IAE.0000000000001584
   Zhao XJ, 2020, CURR EYE RES, V45, P1017, DOI 10.1080/02713683.2019.1708955
   Zhao XJ, 2018, BMJ OPEN, V8, DOI 10.1136/bmjopen-2018-021887
   Zhou LX, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-10660-z
   Zhou YP, 2020, EYE, V34, P523, DOI 10.1038/s41433-019-0516-x
   Zhou YP, 2018, J OPHTHALMOL, V2018, DOI 10.1155/2018/2181602
NR 295
TC 33
Z9 35
U1 17
U2 36
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD APR
PY 2021
VL 62
IS 5
SI SI
AR 5
DI 10.1167/iovs.62.5.5
PG 36
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA UA5IR
UT WOS:000685195500005
PM 33909033
OA gold, Green Published
HC Y
HP N
DA 2022-11-30
ER

PT J
AU Novais, EA
   Roisman, L
   de Oliveira, PRC
   Louzada, RN
   Cole, ED
   Lane, M
   Bonini, M
   Romano, A
   Dias, JRD
   Regatieri, CV
   Chow, D
   Belfort, R
   Rosenfeld, P
   Waheed, NK
   Ferrara, D
   Duker, JS
AF Novais, Eduardo A.
   Roisman, Luiz
   de Oliveira, Paulo Ricardo Chaves
   Louzada, Ricardo N.
   Cole, Emily D.
   Lane, Mark
   Bonini Filho, Marco
   Romano, Andre
   de Oliveira Dias, Joao Rafael
   Regatieri, Caio V.
   Chow, David
   Belfort, Rubens, Jr.
   Rosenfeld, Philip
   Waheed, Nadia K.
   Ferrara, Daniela
   Duker, Jay S.
TI Optical Coherence Tomography Angiography of Chorioretinal Diseases
SO OPHTHALMIC SURGERY LASERS & IMAGING RETINA
LA English
DT Article
ID ACUTE MIDDLE MACULOPATHY; CENTRAL SEROUS CHORIORETINOPATHY; INDOCYANINE
   GREEN ANGIOGRAPHY; FOVEAL AVASCULAR ZONE; RETINAL VEIN OCCLUSION;
   POLYPOIDAL CHOROIDAL VASCULOPATHY; IDIOPATHIC MACULAR TELANGIECTASIA;
   DEEP CAPILLARY ISCHEMIA; FLUORESCEIN-ANGIOGRAPHY; OCT ANGIOGRAPHY
AB Fluorescein angiography (FA) and indocyanine green angiography (ICGA) have been the gold standard for the evaluation of retinal and choroidal vasculature in the last three decades and have revolutionized the diagnosis of retinal and choroidal vascular diseases. The advantage of these imaging modalities lies in their ability to document retinal and choroidal vasculature through the dynamic assessment of contrast transit over time in the intravascular and extravascular spaces. However, disadvantages include the absence of depth resolution, blurring of details by contrast leakage, and the inability to selectively evaluate different levels of the retinal and choroidal microvasculature. In addition, these angiographic methods require intravenous dye, which may cause adverse reactions such as nausea, vomiting, and rarely, anaphylaxis.
   Optical coherence tomography angiography (OCTA) is a noninvasive imaging technique that, in contrast to dye-based angiography, is faster and depth-resolved, allowing in some cases for more precise evaluation of the vascular plexuses of the retina and choroid. The method has been demonstrated in the assessment of various vascular diseases such as venous occlusions, diabetic retinopathy, macular neovascularization, and others. Limitations of this imaging modality include a small registered field of view and the inability to visualize leakage and dye transit over time. It is also subject to a variety of artifacts, including those generated by blinking and eye movement during image acquisition. However, more than an alternative for FA and ICGA, OCTA is bringing new insights to our understanding of retinal and choroidal vascular structure and is changing fundamental paradigms in the clinical management of pathologic conditions.
C1 [Novais, Eduardo A.; Roisman, Luiz; Romano, Andre; de Oliveira Dias, Joao Rafael; Regatieri, Caio V.; Belfort, Rubens, Jr.] Univ Fed Sao Paulo, Escola Paulista Med, Sao Paulo, Brazil.
   [Novais, Eduardo A.; Louzada, Ricardo N.; Cole, Emily D.; Lane, Mark; Regatieri, Caio V.; Waheed, Nadia K.; Ferrara, Daniela; Duker, Jay S.] Tufts Med Ctr, New England Eye Ctr, 800 Washington St, Boston, MA 02111 USA.
   [Roisman, Luiz; Romano, Andre; de Oliveira Dias, Joao Rafael; Rosenfeld, Philip] Univ Miami, Miller Sch Med, Bascom Palmer Eye Inst, Dept Ophthalmol, Miami, FL 33136 USA.
   [de Oliveira, Paulo Ricardo Chaves; Chow, David] Toronto Retina Inst, Toronto, ON, Canada.
   [Louzada, Ricardo N.] Univ Fed Goias, Goiania, Go, Brazil.
   [Lane, Mark] Univ Hosp Birmingham NHS Fdn Trust, Queen Elizabeth Hosp Birmingham, Birmingham, W Midlands, England.
   [Bonini Filho, Marco] Inst Olhos Tres Lagoas, Tres Lagoas, MS, Brazil.
   [Bonini Filho, Marco] CDO, Tres Lagoas, MS, Brazil.
C3 Universidade Federal de Sao Paulo (UNIFESP); Tufts Medical Center;
   Bascom Palmer Eye Institute; University of Miami; Universidade Federal
   de Goias; University of Birmingham
RP Duker, JS (通讯作者)，Tufts Med Ctr, New England Eye Ctr, 800 Washington St, Boston, MA 02111 USA.
EM jduker@tuftsmedicalcenter.org
RI Regatieri, Caio/G-8152-2014; BONINI FILHO, MARCO/GLR-8943-2022; roisman,
   luiz/AAD-3822-2019
OI Regatieri, Caio/0000-0003-1511-8696; BONINI FILHO,
   MARCO/0000-0003-0796-8025; 
FU Macula Vision Research Foundation; Massachusetts Lions Club; CAPES
   Foundation; Ministry of Education of Brazil, Brasilia, DF, Brazil; Carl
   Zeiss Meditec; OptoVue
FX Supported in part by a grant from the Macula Vision Research Foundation
   and the Massachusetts Lions Club.; Drs. Novais, Roisman, and Louzada are
   researchers supported by CAPES Foundation, Ministry of Education of
   Brazil, Brasilia, DF, Brazil. Dr. Duker is a consultant for and receives
   research support from Carl Zeiss Meditec and OptoVue. Dr. Ferrara is an
   employee at Genentech and has Roche stock/stock options. Dr. Rosenfeld
   has received research funding and speaker fees from Carl Zeiss Meditec.
   Dr. Waheed has received research support and speaker fees from Carl
   Zeiss Meditec and Optovue. The remaining authors report no relevant
   financial disclosures.
CR Ambati J, 2003, SURV OPHTHALMOL, V48, P257, DOI 10.1016/S0039-6257(03)00030-4
   CARSKI TR, 1978, JAMA-J AM MED ASSOC, V240, P635
   Chen XJ, 2015, AM J OPHTHALMOL, V160, P26, DOI 10.1016/j.ajo.2015.04.004
   Christenbury JG, 2015, OSLI RETINA, V46, P579, DOI 10.3928/23258160-20150521-11
   Coscas G, 2015, OPHTHALMIC RES, V54, P57, DOI 10.1159/000433547
   de Carlo TE, 2016, OSLI RETINA, V47, P108, DOI 10.3928/23258160-20160126-02
   de Carlo Talisa E, 2015, Int J Retina Vitreous, V1, P5
   de Carlo TE, 2015, OPHTHALMOLOGY, V122, P1228, DOI 10.1016/j.ophtha.2015.01.029
   Di G, 2016, GRAEF ARCH CLIN EXP, V254, P873, DOI 10.1007/s00417-015-3143-7
   Do DV, 2013, CURR OPIN OPHTHALMOL, V24, P244, DOI 10.1097/ICU.0b013e32835fd7dd
   Ferrara D, 2014, OPHTHALMOLOGY, V121, P719, DOI 10.1016/j.ophtha.2013.10.014
   Fingler J, 2007, OPT EXPRESS, V15, P12636, DOI 10.1364/OE.15.012636
   Freiberg FJ, 2016, GRAEF ARCH CLIN EXP, V254, P1051, DOI 10.1007/s00417-015-3148-2
   Huang YP, 2015, BIOMED OPT EXPRESS, V6, P1195, DOI 10.1364/BOE.6.001195
   Hwang TS, 2016, JAMA OPHTHALMOL, V134, P367, DOI 10.1001/jamaophthalmol.2015.5658
   Hwang TS, 2015, RETINA-J RET VIT DIS, V35, P2371, DOI 10.1097/IAE.0000000000000716
   Iida T, 1999, RETINA-J RET VIT DIS, V19, P508, DOI 10.1097/00006982-199911000-00005
   Ishibazawa A, 2015, AM J OPHTHALMOL, V160, P35, DOI 10.1016/j.ajo.2015.04.021
   Jia YL, 2014, OPHTHALMOLOGY, V121, P1435, DOI 10.1016/j.ophtha.2014.01.034
   Jia YL, 2012, OPT EXPRESS, V20, P4710, DOI 10.1364/OE.20.004710
   Kashani AH, 2015, RETINA-J RET VIT DIS, V35, P2323, DOI 10.1097/IAE.0000000000000811
   Khan MA, 2015, OSLI RETINA, V46, P972, DOI 10.3928/23258160-20151008-12
   Kim DY, 2011, BIOMED OPT EXPRESS, V2, P1504, DOI 10.1364/BOE.2.001504
   Kotsolis AI, 2010, BRIT J OPHTHALMOL, V94, P1506, DOI 10.1136/bjo.2009.159913
   Kuehlewein L, 2015, RETINA-J RET VIT DIS, V35, P2229, DOI 10.1097/IAE.0000000000000835
   Kuehlewein L, 2015, AM J OPHTHALMOL, V160, P739, DOI 10.1016/j.ajo.2015.06.030
   Kuehlewein L, 2015, INVEST OPHTH VIS SCI, V56, P3984, DOI 10.1167/iovs.15-16510
   Kuehlewein L, 2015, OSLI RETINA, V46, P249, DOI 10.3928/23258160-20150213-19
   Leitgeb RA, 2014, PROG RETIN EYE RES, V41, P26, DOI 10.1016/j.preteyeres.2014.03.004
   Lumbroso B, 2015, CLIN GUIDE ANGIO OCT
   Matsunaga D, 2014, OSLI RETINA, V45, P510, DOI 10.3928/23258160-20141118-04
   Mendis KR, 2010, INVEST OPHTH VIS SCI, V51, P5864, DOI 10.1167/iovs.10-5333
   Musa F, 2006, ACTA OPHTHALMOL SCAN, V84, P740, DOI 10.1111/j.1600-0420.2006.00728.x
   Naftalin CM, 2015, INT J STD AIDS, V26, P803, DOI 10.1177/0956462414553826
   Nemiroff J, 2016, AM J OPHTHALMOL, V162, P121, DOI 10.1016/j.ajo.2015.10.026
   Nishiyama Y, 2001, Jpn J Ophthalmol, V45, P116, DOI 10.1016/S0021-5155(00)00309-9
   Novais EA, 2016, AM J OPHTHALMOL, V164, P80, DOI 10.1016/j.ajo.2016.01.011
   PARODI MB, 1995, INT OPHTHALMOL, V19, P25, DOI 10.1007/BF00156415
   Paunescu LA, 2006, OPHTHALMOLOGY, V113, P48, DOI 10.1016/j.ophtha.2005.08.016
   Pecen PE, 2015, JAMA OPHTHALMOL, V133, P1478, DOI 10.1001/jamaophthalmol.2015.4100
   Prunte C, 1996, AM J OPHTHALMOL, V121, P26
   Quaranta-El Maftouhi M, 2015, AM J OPHTHALMOL, V160, P581, DOI 10.1016/j.ajo.2015.06.016
   Rahimy E, 2014, AM J OPHTHALMOL, V158, P372, DOI 10.1016/j.ajo.2014.04.024
   Roisman L, 2016, OPHTHALMOLOGY, V123, P1309, DOI 10.1016/j.ophtha.2016.01.044
   Ruminski D, 2015, BIOMED OPT EXPRESS, V6, P2738, DOI 10.1364/BOE.6.002738
   Saito M, 2008, RETINA-J RET VIT DIS, V28, P459, DOI 10.1097/IAE.0b013e318156db60
   Sarraf D, 2013, JAMA OPHTHALMOL, V131, P1275, DOI 10.1001/jamaophthalmol.2013.4056
   SNODDERLY DM, 1992, J NEUROSCI, V12, P1169
   Soheilian M, 2007, OPHTHAL SURG LAS IM, V38, P167, DOI 10.3928/15428877-20070301-16
   Spaide RF, 2015, AM J OPHTHALMOL, V160, P6, DOI 10.1016/j.ajo.2015.04.012
   Spaide RF, 2015, JAMA OPHTHALMOL, V133, P45, DOI 10.1001/jamaophthalmol.2014.3616
   Stanga PE, 2003, OPHTHALMOLOGY, V110, P15, DOI 10.1016/S0161-6420(02)01563-4
   Surguch V, 2007, GRAEF ARCH CLIN EXP, V245, P783, DOI 10.1007/s00417-006-0432-1
   Takase N, 2015, RETINA-J RET VIT DIS, V35, P2377, DOI 10.1097/IAE.0000000000000849
   Teussink MM, 2015, INVEST OPHTH VIS SCI, V56, P5229, DOI 10.1167/iovs.15-17140
   Thorell MR, 2014, OSLI RETINA, V45, P369, DOI 10.3928/23258160-20140909-06
   Ueno C, 2012, RETINA-J RET VIT DIS, V32, P2006, DOI 10.1097/IAE.0b013e31825c1c31
   White BR, 2003, OPT EXPRESS, V11, P3490, DOI 10.1364/OE.11.003490
   Yang F, 2014, DRUG DES DEV THER, V8, P1789, DOI 10.2147/DDDT.S62530
   Yannuzzi LA, 2006, ARCH OPHTHALMOL-CHIC, V124, P450, DOI 10.1001/archopht.124.4.450
   Yannuzzi LA, 2001, RETINA-J RET VIT DIS, V21, P416, DOI 10.1097/00006982-200110000-00003
   Yi J, 2014, BIOMED OPT EXPRESS, V5, P3603, DOI 10.1364/BOE.5.003603
   Yu SQ, 2015, AM J OPHTHALMOL, V159, P53, DOI 10.1016/j.ajo.2014.09.027
   Zeimer M, 2015, RETINA-J RET VIT DIS, V35, P2307, DOI 10.1097/IAE.0000000000000868
   Zhang QQ, 2015, RETINA-J RET VIT DIS, V35, P2285, DOI 10.1097/IAE.0000000000000840
   Zhang QQ, 2015, J BIOMED OPT, V20, DOI 10.1117/1.JBO.20.6.066008
NR 66
TC 7
Z9 8
U1 0
U2 4
PU SLACK INC
PI THOROFARE
PA 6900 GROVE RD, THOROFARE, NJ 08086 USA
SN 2325-8160
EI 2325-8179
J9 OSLI RETINA
JI Ophthalmic Surg. Lasers Imag. Retin.
PD SEP
PY 2016
VL 47
IS 9
BP 848
EP 861
DI 10.3928/23258160-20160901-09
PG 14
WC Ophthalmology; Surgery
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology; Surgery
GA EJ3HM
UT WOS:000393103200009
PM 27631482
DA 2022-11-30
ER

PT J
AU Spaide, RF
AF Spaide, Richard F.
TI Treatment of Sorsby fundus dystrophy with anti-tumor necrosis
   factor-alpha medication
SO EYE
LA English
DT Article
ID METALLOPROTEINASES-3 TIMP3; TISSUE INHIBITOR
AB Purpose Tissue inhibitor of matrix metalloproteinase (TIMP)-3 has many functions, including preventing the constituent formation of tumor necrosis factor-alpha (TNF alpha) in tissue. Sorsby macular dystrophy is caused by a mutation in the gene responsible for TIMP-3, suggesting a potential treatment. Methods Comprehensive ophthalmologic examination with multimodal imaging to include optical coherence tomography (OCT) and OCT angiography were used to evaluate a patient with Sorsby fundus dystrophy treated first with intravitreal triamcinolone, then with adalimumab. Results A 35-year-old woman presented in 2003 with aggressive macular neovascularization in both eyes related to Sorsby macular dystrophy c.610A>T (p.Ser204Cys). Her visual acuity was 20/25 in the right and 20/400 in the left eye. She was treated with periodic intravitreal injections of 4 mg triamcinolone, which caused the neovascularization to become inactive. When switched to intravitreal bevacizumab, she showed disease activity. She was switched back to intravitreal triamcinolone with minimal signs of exudation and hemorrhage. Because of the high lifetime risk of complication, she was switched to subcutaneous adalimumab and in follow-up over 18 months had no signs of disease activity. The visual acuity in the right eye was 20/20. Conclusions TIMP3 has numerous effects including controlling local TNF alpha production. It is possible with the mutation in the gene for TIMP-3, abnormally high tissue levels of TNF alpha are produced in the eye. Direct inhibition of TNF alpha action by adalimumab offers a molecularly targeted approach to the disease pathophysiology and merits increased study.
C1 [Spaide, Richard F.] Vitreous Retina Macula Consultants New York, New York, NY 10022 USA.
C3 Vitreous Retina Macula Consultants of New York
RP Spaide, RF (通讯作者)，Vitreous Retina Macula Consultants New York, New York, NY 10022 USA.
EM rickspaide@gmail.com
FU Topcon Medical Systems; Regeneron; Roche; Genentech; Heidelberg
   Engineering; Adverum Biotechnologies; DORC
FX Topcon Medical Systems, Regeneron, Roche, Genentech, Heidelberg
   Engineering, Adverum Biotechnologies, and DORC.
CR An EY, 2008, MOL VIS, V14, P2292
   CAPON MRC, 1989, OPHTHALMOLOGY, V96, P1769
   Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6
   Hongisto H, 2020, J PATHOL, V252, P138, DOI 10.1002/path.5506
   Kalliolias GD, 2016, NAT REV RHEUMATOL, V12, P49, DOI 10.1038/nrrheum.2015.169
   Kawai T, 2021, CELL MOL LIFE SCI, V78, P4161, DOI 10.1007/s00018-021-03779-w
   Meunier I, 2016, SCI REP-UK, V6, DOI 10.1038/srep32544
   Mohammed FF, 2004, NAT GENET, V36, P969, DOI 10.1038/ng1413
   Perkins, 1966, DIS UVEAL TRACT SYST
   Qi JH, 2003, NAT MED, V9, P407, DOI 10.1038/nm846
   Smookler DS, 2006, J IMMUNOL, V176, P721, DOI 10.4049/jimmunol.176.2.721
   SORSBY A, 1949, BRIT J OPHTHALMOL, V33, P67, DOI 10.1136/bjo.33.2.67
   Spaide Richard F, 2022, Retin Cases Brief Rep, V16, P44, DOI 10.1097/ICB.0000000000000946
   WEBER BHF, 1994, NAT GENET, V8, P352, DOI 10.1038/ng1294-352
   Wu JL, 2019, DRUG DES DEV THER, V13, P2413, DOI 10.2147/DDDT.S206355
NR 15
TC 0
Z9 0
U1 0
U2 1
PU SPRINGERNATURE
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND
SN 0950-222X
EI 1476-5454
J9 EYE
JI Eye
PD SEP
PY 2022
VL 36
IS 9
BP 1810
EP 1812
DI 10.1038/s41433-021-01735-3
EA AUG 2021
PG 3
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 3W0KK
UT WOS:000683629700003
PM 34376817
DA 2022-11-30
ER

PT J
AU Spaide, RF
   Ledesma-Gil, G
AF Spaide, Richard F.
   Ledesma-Gil, Gerardo
TI NOVEL METHOD FOR IMAGE AVERAGING OF OPTICAL COHERENCE TOMOGRAPHY
   ANGIOGRAPHY IMAGES
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE choriocapillaris; choroid; swept-source optical coherence tomography
   angiography; image averaging
ID AMPLITUDE-DECORRELATION; CHORIOCAPILLARIS; RETINA
AB Purpose: To develop a method of averaging optical coherence tomography (OCT) angiography to improve visualization of choriocapillaris structure. Methods: A stack of OCT angiographic data from vascular layers were placed into the red-green-blue channels of a conventional digital color image. The superficial plexus was placed in the blue channel, choriocapillaris in the green, and deep vascular plexus in the red channel. The red-green-blue images derived from nine separate OCT angiographic scans were registered using an automatic registration sequence and the images were averaged. The averaged red-green-blue image was then split into the three averaged component layers. The technique is flexible and any vascular layer, such as macular neovascularization, can be used as well. Results: The utility of the imaging method was demonstrated by showing the imaging of two different diseases. A patient with a history of familial amyloidosis, hypertension, kidney failure, kidney transplantation, and prednisone use, followed by central serous chorioretinopathy treated by photodynamic therapy. She had alterations in retinal pigment epithelial pigmentation and widespread abnormalities of autofluorescence. She showed remarkably decreased vascular density and vessel configuration of her choriocapillaris. A patient with pseudoxanthoma elasticum with subretinal drusenoid deposits at an early age also showed marked decreased choriocapillaris density and vascular configuration. These findings were compared with healthy controls of similar age with no abnormalities. Conclusion: The detailed method is capable of averaging choriocapillaris OCT angiographic images using a simple automatic method. Image averaging offers opportunity to improve the noisy OCT angiographic images such that actual vascular structure is visible.
C1 [Spaide, Richard F.; Ledesma-Gil, Gerardo] Vitreous Retina Macula Consultants New York, 950 3rd Ave, New York, NY 10022 USA.
C3 Vitreous Retina Macula Consultants of New York
RP Spaide, RF (通讯作者)，Vitreous Retina Macula Consultants New York, 950 3rd Ave, New York, NY 10022 USA.
EM rickspaide@gmail.com
OI Ledesma-Gil, Gerardo/0000-0002-5882-5940
FU Macula Foundation, Inc, New York, NY
FX This work was supported by The Macula Foundation, Inc, New York, NY.
CR An L, 2011, J BIOMED OPT, V16, DOI 10.1117/1.3642638
   Arganda-Carreras I, 2006, LECT NOTES COMPUT SC, V4241, P85
   Cheng YX, 2015, J BIOMED OPT, V20, DOI 10.1117/1.JBO.20.11.116004
   Gorczynska I, 2016, BIOMED OPT EXPRESS, V7, P911, DOI 10.1364/BOE.7.000911
   HAYREH SS, 1974, A GRAEF ARCH KLIN EX, V192, P165
   Jia YL, 2012, OPT EXPRESS, V20, P4710, DOI 10.1364/OE.20.004710
   Li P, 2016, OPT LETT, V41, P3944, DOI 10.1364/OL.41.003944
   PARVER L M, 1991, Eye (London), V5, P181
   Spaide RF, 2018, PROG RETIN EYE RES, V64, P1, DOI 10.1016/j.preteyeres.2017.11.003
   Spaide RF, 2017, RETINA-J RET VIT DIS, V37, P2008, DOI 10.1097/IAE.0000000000001497
   TORCZYNSKI E, 1976, AM J OPHTHALMOL, V81, P428, DOI 10.1016/0002-9394(76)90298-1
   Uji A, 2017, JAMA OPHTHALMOL, V135, P1197, DOI 10.1001/jamaophthalmol.2017.3904
   Wang RK, 2010, OPT LETT, V35, P1467, DOI 10.1364/OL.35.001467
   Zweifel SA, 2011, RETINA-J RET VIT DIS, V31, P482, DOI 10.1097/IAE.0b013e3181f056ce
NR 14
TC 8
Z9 8
U1 0
U2 4
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD NOV
PY 2020
VL 40
IS 11
BP 2099
EP 2105
DI 10.1097/IAE.0000000000002877
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA OP0WT
UT WOS:000587803100009
PM 32604340
DA 2022-11-30
ER

PT J
AU Kampling, H
   Baumeister, H
   Bengel, J
   Mittag, O
AF Kampling, Hanna
   Baumeister, Harald
   Bengel, Juergen
   Mittag, Oskar
TI Prevention of depression in adults with long-term physical conditions
SO COCHRANE DATABASE OF SYSTEMATIC REVIEWS
LA English
DT Review
ID COMORBID MENTAL-DISORDERS; PROBLEM-SOLVING THERAPY; RANDOMIZED
   CONTROLLED-TRIAL; CORONARY-ARTERY-DISEASE; MEDICALLY ILL PATIENTS;
   HEALTH-CARE COSTS; CHRONIC BACK-PAIN; MAJOR DEPRESSION; POSTSTROKE
   DEPRESSION; DOUBLE-BLIND
AB Background
   Major depression is one of the world's leading causes of disability in adults with long-term physical conditions compared to those without physical illness. This co-morbidity is associated with a negative prognosis in terms of increased morbidity and mortality rates, increased healthcare costs, decreased adherence to treatment regimens, and a substantial decline in quality of life. Therefore, preventing the onset of depressive episodes in adults with long-term physical conditions should be a global healthcare aim.
   In this review, primary or tertiary (in cases of preventing recurrences in those with a history of depression) prevention are the focus. While primary prevention aims at preventing the onset of depression, tertiary prevention comprises both preventing recurrences and prohibiting relapses. Tertiary prevention aims to address a depressive episode that might still be present, is about to subside, or has recently resolved. We included tertiary prevention in the case where the focus was preventing the onset of depression in those with a history of depression (preventing recurrences) but excluded it if it specifically focused on maintaining an condition or implementing rehabilitation services (relapse prevention). Secondary prevention of depression seeks to prevent the progression of depressive symptoms by early detection and treatment and may therefore be considered a 'treatment,' rather than prevention. We therefore exclude the whole spectrum of secondary prevention.
   Objectives
   To assess the effectiveness, acceptability and tolerability of psychological or pharmacological interventions, in comparison to control conditions, in preventing depression in adults with long-term physical conditions; either before first ever onset of depressive symptoms (i.e. primary prevention) or before first onset of depressive symptoms in patients with a history of depression (i.e. tertiary prevention).
   Search methods
   We searched the Cochrane Common Mental Disorders Controlled Trials Register, CENTRAL, MEDLINE, Embase, PsycINFO and two trials registries, up to 6 February 2020.
   Selection criteria
   We included randomised controlled trials (RCTs) of preventive psychological or pharmacological interventions, specifically targeting incidence of depression in comparison to treatment as usual (TAU), waiting list, attention/psychological placebo, or placebo. Participants had to be age 18 years or older, with at least one long-term physical condition, and no diagnosis of major depression at baseline (primary prevention). In addition, we included studies comprising mixed samples of patients with and without a history of depression, which explored tertiary prevention of recurrent depression. We excluded other tertiary prevention studies. We also excluded secondary preventive interventions. Primary outcomes included incidence of depression, tolerability, and acceptability. Secondary outcomes included severity of depression, cost-effectiveness and cost-utility.
   Data collection and analysis
   We used standard methodological procedures expected by Cochrane.
   Main results
   We included 11 RCTs, with one trial on psychological interventions, and 10 trials on pharmacological interventions. Data analyses on the psychological intervention (problem-solving therapy compared to TAU) included 194 participants with age-related macular degeneration.
   Data analyses on pharmacological interventions included 837 participants comparing citalopram (one trial), escitalopram (three trials), a mixed sample of fluoxetine/nortriptyline (one trial), melatonin (one trial), milnacipran (one trial), and sertraline (three trials), each to placebo. Included types of long-term physical conditions were acute coronary syndrome (one trial), breast cancer (one trial), head and neck cancer (two trials), stroke (five trials), and traumatic brain injury (one trial).
   Psychological interventions
   Very low-certainty evidence of one study suggests that problem solving therapy may be slightly more effective than TAU in preventing the incidence of depression, immediately post-intervention (odds ratio (OR) 0.43, 95% confidence interval (CI) 0.20 to 0.95; 194 participants). However, there may be little to no difference between groups at six months follow-up (OR 0.71, 95% CI 0.36 to 1.38; 190 participants; one study; very low-certainty evidence). No data were available regarding incidence of depression after six months. Regarding acceptability (drop-outs due to any cause), slightly fewer drop-outs occurred in the TAU group immediately post-intervention (OR 5.21, 95% CI 1.11 to 24.40; 206 participants; low-certainty evidence). After six months, however, the groups did not differ (OR 1.67, 95% CI 0.58 to 4.77; 206 participants; low-certainty evidence). This study did not measure tolerability.
   Pharmacological interventions
   Post-intervention, compared to placebo, antidepressants may be beneficial in preventing depression in adults with different types of long-term physical conditions, but the evidence is very uncertain (OR 0.31, 95% CI 0.20 to 0.49; 814 participants; nine studies; I-2 =0%; very low-certainty evidence). There may be little to no difference between groups both immediately and at six months follow-up (OR 0.44, 95% CI 0.08 to 2.46; 23 participants; one study; very low-certainty evidence) as well as at six to 12 months follow-up (OR 0.81, 95% CI 0.23 to 2.82; 233 participants; three studies; I-2=49%; very low-certainty evidence). There was very low-certainty evidence from five studies regarding the tolerability of the pharmacological intervention. A total of 669 adverse events were observed in 316 participants from the pharmacological intervention group, and 610 adverse events from 311 participants in the placebo group. There was very low-certainty evidence that dropouts due to adverse events may be less frequent in the placebo group (OR 2.05, 95% CI 1.07 to 3.89; 561 participants; five studies; I-2 = 0%). There was also very low-certainty evidence that drop-outs due to any cause may not differ between groups either post-intervention (OR 1.13, 95% CI 0.73 to 1.73; 962 participants; nine studies; I-2 = 28%), or at six to 12 months (OR 1.13, 95% CI 0.69 to 1.86; 327 participants; three studies; I-2 = 0%).
   Authors' conclusions
   Based on evidence of very low certainty, our results may indicate the benefit of pharmacological interventions, during or directly after preventive treatment. Few trials examined short-term outcomes up to six months, nor the follow-up effects at six to 12 months, with studies suffering from great numbers of drop-outs and inconclusive results. Generalisation of results is limited as study populations and treatment regimes were very heterogeneous. Based on the results of this review, we conclude that for adults with long-term physical conditions, there is only very uncertain evidence regarding the implementation of any primary preventive interventions (psychological/pharmacological) for depression.
C1 [Kampling, Hanna] Justus Liebig Univ Giessen, Univ Clin Giessen & Marburg, Dept Psychosomat Med & Psychotherapy, Giessen, Germany.
   [Kampling, Hanna; Mittag, Oskar] Univ Freiburg, Fac Med, Med Ctr, Sect Hlth Care Res & Rehabil Res,Ctr Med Biometry, Freiburg, Germany.
   [Baumeister, Harald] Ulm Univ, Dept Clin Psychol & Psychotherapy, Inst Psychol & Educ, Ulm, Germany.
   [Bengel, Juergen] Univ Freiburg, Inst Psychol, Dept Rehabil Psychol & Psychotherapy, Freiburg, Germany.
C3 Justus Liebig University Giessen; University Hospital of Giessen &
   Marburg; University of Freiburg; Ulm University; University of Freiburg
RP Kampling, H (通讯作者)，Justus Liebig Univ Giessen, Univ Clin Giessen & Marburg, Dept Psychosomat Med & Psychotherapy, Giessen, Germany.; Kampling, H (通讯作者)，Univ Freiburg, Fac Med, Med Ctr, Sect Hlth Care Res & Rehabil Res,Ctr Med Biometry, Freiburg, Germany.
EM hanna.kampling@psycho.med.uni-giessen.de
RI Kampling, Hanna/GXZ-9506-2022
OI Baumeister, Harald/0000-0002-2040-661X; Kampling,
   Hanna/0000-0002-5213-0179
FU Quality Management and Social Medicine, Germany
FX Quality Management and Social Medicine, Germany; Funding the review
   project
CR Agency for Healthcare Research and Quality (AHRQ), 2012, AHRQ PUBLICATION
   Akechi T, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005537.pub2
   Almeida OP, 2006, J CLIN PSYCHIAT, V67, P1104, DOI 10.4088/JCP.v67n0713
   Almeida OP, 2010, ANN NEUROL, V68, P503, DOI 10.1002/ana.22189
   American psychiatric association, 1980, DIAGNOSTIC STAT MANU
   American Psychiatric Association, 2000, DIAGNOSTIC STAT MANU, V4th, DOI DOI 10.1176/APPI.BOOKS.9780890423349
   American Psychiatric Association, 1987, DIAGNOSTIC STAT MANU
   American Psychiatric Association, 1994, DIAGNOSTIC STAT MANU, V4th
   American Psychiatric Association, 2013, DIAGNOSTIC STAT MANU
   [Anonymous], 2016, BMJ-BRIT MED J, V353, DOI 10.1136/bmj.i1995
   [Anonymous], 2004, CHINESE J CLIN REHAB
   [Anonymous], 2004, CHINESE J CLIN REHAB
   Arroll B, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007954
   Barlow DH, 2012, ESSENTIALS ABNORMAL, V6th, P30
   Baumeister H, 2007, SOC PSYCH PSYCH EPID, V42, P537, DOI 10.1007/s00127-007-0204-1
   Baumeister H, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD008381.pub2
   Baumeister H, 2012, J PSYCHOSOM RES, V73, P79, DOI 10.1016/j.jpsychores.2012.05.008
   Baumeister H, 2011, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD008012.pub3
   Baumeister H, 2011, PSYCHOTHER PSYCHOSOM, V80, P275, DOI 10.1159/000323404
   Bech P, 2001, J AFFECT DISORDERS, V66, P159, DOI 10.1016/S0165-0327(00)00309-8
   BECK AT, 1961, ARCH GEN PSYCHIAT, V4, P561, DOI 10.1001/archpsyc.1961.01710120031004
   Beglinger LJ, 2014, MOVEMENT DISORD, V29, P401, DOI 10.1002/mds.25750
   Beltman MW, 2010, BRIT J PSYCHIAT, V197, P11, DOI 10.1192/bjp.bp.109.064675
   Bengel J., 2007, PSYCHISCHE STORUNGEN, P2
   Borrelli J, 2019, J ORTHOP TRAUMA, V33, pE58, DOI 10.1097/BOT.0000000000001342
   Brody BL, 2005, ARCH OPHTHALMOL-CHIC, V123, P46, DOI 10.1001/archopht.123.1.46
   Browne AL, 2013, DISABIL REHABIL, V35, P1149, DOI 10.3109/09638288.2012.721047
   Burns A, 2007, J AM GERIATR SOC, V55, P75, DOI 10.1111/j.1532-5415.2007.01016.x
   Cipriani A, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006534.pub2
   Cipriani A, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006532.pub2
   Clarke DM, 2009, MED J AUSTRALIA, V190, pS54
   Couch J R, 1976, Trans Am Neurol Assoc, V101, P234
   Cuijpers P, 2008, AM J PSYCHIAT, V165, P1272, DOI 10.1176/appi.ajp.2008.07091422
   de Geus EJC, 2006, PSYCHOSOM MED, V68, P185, DOI 10.1097/01.psy.0000208628.90274.bc
   de Jonge P, 2009, PSYCHOSOMATICS, V50, P227, DOI 10.1176/appi.psy.50.3.227
   Dean G, 1969, S Afr Med J, V43, P86
   Deemer AD, 2017, INVEST OPHTH VIS SCI, V58, P1514, DOI 10.1167/iovs.16-20001
   DGPPN BAK KBV AWMF AkdA BPtK, 2012, S3 LEITLINIE NATIONA
   ENDICOTT J, 1978, ARCH GEN PSYCHIAT, V35, P837
   Evans DL, 2005, BIOL PSYCHIAT, V58, P175, DOI 10.1016/j.biopsych.2005.05.001
   First MB, 1996, STRUCTURED CLIN INTE
   Gill D, 2005, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001312.pub2
   GORDON RS, 1983, PUBLIC HEALTH REP, V98, P107
   GRADEpro GDT, 2020, GRADEPRO GUID DEV TO
   Guneri A, 2006, J NEUROL, V253, P42
   Gunn JM, 2012, SOC PSYCH PSYCH EPID, V47, P175, DOI 10.1007/s00127-010-0330-z
   Guyatt GH, 2011, J CLIN EPIDEMIOL, V64, P1277, DOI 10.1016/j.jclinepi.2011.01.011
   Hackett ML, 2010, INT J STROKE, V5, P52, DOI 10.1111/j.1747-4949.2009.00388.x
   Hackett ML, 2013, INT J STROKE, V8, P707, DOI 10.1111/j.1747-4949.2012.00913.x
   Hackett ML, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003689.pub3
   Hackett ML, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003437.pub3
   Harter M, 2007, PSYCHOTHER PSYCHOSOM, V76, P354, DOI 10.1159/000107563
   HAMILTON M, 1960, J NEUROL NEUROSUR PS, V23, P56, DOI 10.1136/jnnp.23.1.56
   Hammen CL, 2010, HDB DEPRESSION, V2nd, P113
   Hanash JA, 2007, INT J CARDIOL, V119, pS14, DOI 10.1016/j.ijcard.2007.03.038
   Hanash JA, 2012, J CARDIOVASC PHARM, V60, P397, DOI 10.1097/FJC.0b013e3182677041
   Hansen B, 2010, J PSYCHOSOMATIC RES
   Hansen BH, 2012, J PSYCHOSOM RES, V72, P11, DOI 10.1016/j.jpsychores.2011.07.001
   Hansen BH, 2011, NORD J PSYCHIAT, V65, P22, DOI 10.3109/08039488.2010.485326
   Hansen BH, 2009, TRIALS, V10, DOI 10.1186/1745-6215-10-20
   Hansen MV, 2014, BREAST CANCER RES TR, V145, P683, DOI 10.1007/s10549-014-2962-2
   Hansen MV, 2012, BMJ OPEN, V2, DOI 10.1136/bmjopen-2011-000647
   Harald B, 2012, J AFFECT DISORDERS, V139, P126, DOI 10.1016/j.jad.2011.07.015
   Harmer CJ, 2017, LANCET PSYCHIAT, V4, P409, DOI 10.1016/S2215-0366(17)30015-9
   Haschke A, 2012, INT J OCCUP MED ENV, V25, P319, DOI 10.2478/S13382-012-0042-6
   Herzog P, 2019, BRAIN BEHAV, V9, DOI 10.1002/brb3.1447
   Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   Hjorthoj CR, 2015, EARLY INTERV PSYCHIA, V9, P370, DOI 10.1111/eip.12119
   Holahan CJ, 2010, J AFFECT DISORDERS, V123, P222, DOI 10.1016/j.jad.2009.10.006
   Hood KK, 2018, DIABETES CARE, V41, P1623, DOI 10.2337/dc17-2556
   Hutter N, 2010, DIABETOLOGIA, V53, P2470, DOI 10.1007/s00125-010-1873-y
   Hutter N, 2011, GEN HOSP PSYCHIAT, V33, P443, DOI 10.1016/j.genhosppsych.2011.06.013
   Jorge RE, 2010, ARCH GEN PSYCHIAT, V67, P187, DOI 10.1001/archgenpsychiatry.2009.185
   Karp JF, 2016, AM J GERIAT PSYCHIAT, V24, P433, DOI 10.1016/j.jagp.2015.10.012
   Katon W, 2002, J PSYCHOSOM RES, V53, P859, DOI 10.1016/S0022-3999(02)00313-6
   Katon W, 2007, GEN HOSP PSYCHIAT, V29, P147, DOI 10.1016/j.genhosppsych.2006.11.005
   Katon WJ, 2003, BIOL PSYCHIAT, V54, P216, DOI 10.1016/S0006-3223(03)00273-7
   Kessler RC, 2003, JAMA-J AM MED ASSOC, V289, P3095, DOI 10.1001/jama.289.23.3095
   Klatte R, 2018, SYST REV-LONDON, V7, DOI 10.1186/s13643-018-0802-x
   Kredentser MS, 2018, CRIT CARE MED, V46, P1914, DOI 10.1097/CCM.0000000000003367
   Krishnan KRR, 2005, J CLIN PSYCHOPHARM, V25, pS14, DOI 10.1097/01.jcp.0000162808.92194.2a
   Kroenke K, 2001, J GEN INTERN MED, V16, P606, DOI 10.1046/j.1525-1497.2001.016009606.x
   Lazure KE, 2009, HEAD NECK-J SCI SPEC, V31, P888, DOI 10.1002/hed.21046
   Lefebvre C, 2008, EMERG THEMES EPIDEMI, V5, DOI 10.1186/1742-7622-5-13
   [卢瑞春 Lu Ruichun], 2010, [中华神经科杂志, Chinese Journal of Neurology], V43, P355
   Lydiatt WM, 2008, ARCH OTOLARYNGOL, V134, P528, DOI 10.1001/archotol.134.5.528
   Lydiatt WM, 2013, JAMA OTOLARYNGOL, V139, P678, DOI 10.1001/jamaoto.2013.3371
   Macdonald Geraldine, 2012, Cochrane Database Syst Rev, pCD001930, DOI 10.1002/14651858.CD001930.pub3
   Madsen MT, 2017, TRIALS, V18, DOI 10.1186/s13063-017-1806-x
   McAuley L, 2000, LANCET, V356, P1228, DOI 10.1016/S0140-6736(00)02786-0
   McCaffery JM, 2006, PSYCHOSOM MED, V68, P187, DOI 10.1097/01.psy.0000208630.79271.a0
   Mikami K, 2011, STROKE, V42, P3281, DOI 10.1161/STROKEAHA.111.626507
   MONTGOMERY SA, 1979, BRIT J PSYCHIAT, V134, P382, DOI 10.1192/bjp.134.4.382
   Mossey JM, 1996, J GERONTOL A-BIOL, V51, pM172, DOI 10.1093/gerona/51A.4.M172
   Mrazek P.G., 1994, REDUCING RISKS MENTA
   Munoz RF, 1996, AM PSYCHOL, V51, P1116, DOI 10.1037/0003-066X.51.11.1116
   Narushima K, 2002, J NERV MENT DIS, V190, P296, DOI 10.1097/00005053-200205000-00005
   Natale P, 2019, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004542.pub3
   National Institute for Health and Care Excellence, 2009, DEPRESSION ADULTS CH
   Niedermaier N, 2004, J CLIN PSYCHIAT, V65, P1619, DOI 10.4088/JCP.v65n1206
   Nordic Cochrane Centre, 2014, REV MAN REVMAN COMP
   Novack TA, 2009, J NEUROTRAUM, V26, P1921, DOI 10.1089/neu.2009.0895
   OConnell ME, 2009, PREVENTING MENTAL, EMOTIONAL, AND BEHAVIORAL DISORDERS AMONG YOUNG PEOPLE: PROGRESS AND POSSIBILITIES, P1
   Ostuzzi G, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD011006.pub2
   Parker K, 2006, C PAPER
   Patten SB, 2001, J AFFECT DISORDERS, V63, P35, DOI 10.1016/S0165-0327(00)00186-5
   Pitceathly C, 2009, ANN ONCOL, V20, P928, DOI 10.1093/annonc/mdn708
   Pols AD, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0181023
   RADLOFF L S, 1977, Applied Psychological Measurement, V1, P385, DOI 10.1177/014662167700100306
   Raison CL, 2005, J CLIN PSYCHIAT, V66, P41, DOI 10.4088/JCP.v66n0106
   Rasmussen A, 2003, PSYCHOSOMATICS, V44, P216, DOI 10.1176/appi.psy.44.3.216
   Rasmussen A, 2004, PSYCHOSOMATICS, V45, P91
   Rayner L, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007503.pub2
   Read J, 2020, J AFFECT DISORDERS, V264, P464, DOI 10.1016/j.jad.2019.11.077
   Richards SH, 2017, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002902.pub4
   Robinson RG, 2008, JAMA-J AM MED ASSOC, V299, P2391, DOI 10.1001/jama.299.20.2391
   Robinson RG, 2017, AM J GERIAT PSYCHIAT, V25, P512, DOI 10.1016/j.jagp.2016.10.001
   Robinson RG, 2009, JAMA-J AM MED ASSOC, V301, P1023, DOI 10.1001/jama.2009.256
   Rovner BW, 2008, AM J GERIAT PSYCHIAT, V16, P454, DOI 10.1097/JGP.0b013e31816b7342
   Rovner BW, 2007, ARCH GEN PSYCHIAT, V64, P886, DOI 10.1001/archpsyc.64.8.886
   Rovner BW, 2014, OPHTHALMOLOGY, V121, P2204, DOI 10.1016/j.ophtha.2014.05.002
   Rush AJ, 2003, BIOL PSYCHIAT, V54, P573, DOI 10.1016/S0006-3223(02)01866-8
   Sander L, 2017, BMC PSYCHIATRY, V17, DOI 10.1186/s12888-017-1193-6
   Schunemann H, 2013, GRADE HDB GRADING QU
   Sheehan DV, 1998, J CLIN PSYCHIAT, V59, P22, DOI 10.4088/JCP.09m05305whi
   Shinohara K, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD008696.pub2
   Simon GE, 2005, PSYCHOL MED, V35, P271, DOI 10.1017/S0033291704003071
   Stiefel F, 2008, PSYCHOTHER PSYCHOSOM, V77, P247, DOI 10.1159/000129658
   Stockton P, 2004, GEN HOSP PSYCHIAT, V26, P2, DOI 10.1016/S0163-8343(03)00094-X
   Thomas PW, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004431.pub2
   Tsai CS, 2011, INT CLIN PSYCHOPHARM, V26, P263, DOI 10.1097/YIC.0b013e32834a5c64
   van der Aa HPA, 2017, BMC PSYCHIATRY, V17, DOI 10.1186/s12888-017-1437-5
   van der Aa HPA, 2015, BMJ-BRIT MED J, V351, DOI 10.1136/bmj.h6127
   van der Aa HPA, 2013, BMC PSYCHIATRY, V13, DOI 10.1186/1471-244X-13-209
   van Dijk SEM, 2013, BMC PSYCHIATRY, V13, DOI 10.1186/1471-244X-13-128
   van Marwijk H, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007139.pub2
   Wen Z-X, 2006, ACTA ACADEMIAE MEDIC, V42, P253
   Whalley B, 2011, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD002902, 10.1002/14651858.CD002902.pub3]
   WHO, 1990, COMPOSITE INT DIAGNO
   WHO, 2007, WORLD HLTH STAT
   Wichers MC, 2005, PSYCHOL MED, V35, P433, DOI 10.1017/S0033291704003526
   Wing J. K. C., 1974, MEASUREMENT CLASSIFI
   WING JK, 1990, ARCH GEN PSYCHIAT, V47, P589
   Wittchen HU, 2010, GESUNDHEITSBERICHTER
   World Health Organization, 2008, The global burden of disease: 2004 update
   World Health Organization, 1978, 9 REVISION INT CLASS
   World Health Organization, ICD 10 CLASSIFICATIO
   World Health Organization, 2016, PREVENTING DEPRESSIO
   [许晶 XU Jing], 2006, [中国心理卫生杂志, Chinese Mental Health Journal], V20, P186
   Yan Kong, 2007, Neural Regeneration Research, V2, P162
   Yeung A, 2014, BMC COMPLEM ALTERN M, V14, DOI 10.1186/1472-6882-14-411
   Zhang LS, 2013, EUR NEUROL, V69, P336, DOI 10.1159/000345374
   Zhong Y, 2013, CHINESE J GASTROENTE, V18, P658
   [周智林 ZHOU Zhilin], 2008, [中国现代应用药学, Chinese Journal of Modern Applied Pharmacy], V25, P262
   Zhu Jin, 2014, Zhongguo Zhong Xi Yi Jie He Za Zhi, V34, P676
   ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x
NR 156
TC 2
Z9 2
U1 8
U2 19
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1469-493X
EI 1361-6137
J9 COCHRANE DB SYST REV
JI Cochrane Database Syst Rev.
PY 2021
IS 3
AR CD011246
DI 10.1002/14651858.CD011246.pub2
PG 98
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC General & Internal Medicine
GA RH9VR
UT WOS:000636560500028
PM 33667319
OA Green Published
DA 2022-11-30
ER

PT J
AU Arora, S
   Maltsev, DS
   Randhir, SS
   Sahoo, NK
   Jhingan, M
   Parmeshwarappa, D
   Arora, T
   Kulikov, A
   Iovino, C
   Zur, D
   Fainberg, G
   Ibrahim, MN
   Tatti, F
   Gujar, R
   Venkatesh, R
   Reddy, N
   Snehith, R
   Peiretti, E
   Lupidi, M
   Chhablani, J
AF Arora, Supriya
   Maltsev, Dmitrii S.
   Randhir, Sumit Singh
   Sahoo, Niroj Kumar
   Jhingan, Mahima
   Parmeshwarappa, Deepika
   Arora, Tarun
   Kulikov, Alexei
   Iovino, Claudio
   Zur, Dinah
   Fainberg, Gilad
   Ibrahim, Mohammed Nasar
   Tatti, Filippo
   Gujar, Ramkailash
   Venkatesh, Ramesh
   Reddy, Nikitha
   Snehith, Ram
   Peiretti, Enrico
   Lupidi, Marco
   Chhablani, Jay
TI One year outcome and predictors of treatment outcome in central serous
   chorioretinopathy: Multimodal imaging based analysis
SO EUROPEAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE central serous chorioretinopathy < retina; retina; medical therapies <
   retina; techniques of retinal examination < retina; retinal pathology;
   research < retina; CME < retina
AB Purpose To evaluate the follow up and treatment outcome of central serous chorioretinopathy (CSCR) based on the new multimodal imaging-based classification and identify the predictors for anatomic and visual outcome. Methods Retrospective, multicentric study on 95 eyes diagnosed with CSCR and a follow up of at least 12 months were included. Eyes with macular neovascularization, atypical CSCR or any other disease were excluded. Results At the baseline, observation was advised to 70% eyes with simple CSCR whereas photodynamic therapy (PDT) was performed in 49% eyes with complex CSCR. Over the follow up, decrease in CMT was significantly higher in simple CSCR as compared to complex CSCR (P = 0.008) and the recurrences were significantly more in eyes with lower CMT at baseline (P = 0.0002). Median time of resolution of SRF was 3 months and 6 months in simple and complex CSCR respectively (P = 0.09). For the 12 months follow up, the median fluid free period was greater (P = 0.03) while number of interventions performed was lesser in eyes with simple CSCR as compared to complex CSCR (P = 0.006). Multiple regression analysis showed baseline best corrected visual acuity (BCVA) and baseline persistent SRF to be significantly predictive of BCVA and persistent SRF at 12 months (P < 0.0001, 0.04) respectively. Conclusions Complex CSCR more often required PDT, was associated with shorter fluid free interval and longer time for SRF resolution. Baseline BCVA and persistent SRF were predictive of final visual and anatomical outcome. The new multimodal imaging based classification is helpful in establishing objective criteria for planning treatment approaches for CSCR.
C1 [Arora, Supriya; Arora, Tarun] Bahamas Vis Ctr, Nassau, NP, Bahamas.
   [Arora, Supriya; Arora, Tarun] Princess Margaret Hosp, Nassau, NP, Bahamas.
   [Maltsev, Dmitrii S.; Kulikov, Alexei] Mil Med Acad, Dept Ophthalmol, St Petersburg, Russia.
   [Randhir, Sumit Singh; Jhingan, Mahima] Univ Calif San Diego, Jacobs Retina Ctr, Shiley Eye Ctr, San Diego, CA 92103 USA.
   [Sahoo, Niroj Kumar] LV Prasad Eye Inst, Dept Retina & Vitreous, Vijayawada, India.
   [Parmeshwarappa, Deepika] LV Prasad Eye Inst, Smt Kanuri Santhamma Ctr Vitreo Retinal Dis, Hyderabad, India.
   [Iovino, Claudio; Tatti, Filippo; Peiretti, Enrico] Univ Cagliari, Dept Surg Sci, Eye Clin, Cagliari, Italy.
   [Zur, Dinah; Fainberg, Gilad] Tel Aviv Univ, Sackler Fac Med, Tel Aviv Sourasky Med Ctr, Div Ophthalmol, Tel Aviv, Israel.
   [Ibrahim, Mohammed Nasar] Indian Inst Technol, Dept Elect Engn, Hyderabad, India.
   [Gujar, Ramkailash; Lupidi, Marco] Univ Perugia, Dept Surg & Biomed Sci, Sect Ophthalmol, Perugia, Italy.
   [Venkatesh, Ramesh; Reddy, Nikitha; Snehith, Ram] Narayana Nethralaya, Dept Retina & Vitreous, Bengaluru, India.
   [Chhablani, Jay] Univ Pittsburgh, UPMC Eye Ctr, Pittsburgh, PA 15260 USA.
C3 University of California System; University of California San Diego; L.
   V. Prasad Eye Institute; L. V. Prasad Eye Institute; University of
   Cagliari; Tel Aviv University; Sackler Faculty of Medicine; Tel Aviv
   Sourasky Medical Center; Indian Institute of Technology System (IIT
   System); Indian Institute of Technology (IIT) - Hyderabad; University of
   Perugia; Pennsylvania Commonwealth System of Higher Education (PCSHE);
   University of Pittsburgh
RP Chhablani, J (通讯作者)，Univ Pittsburgh, UPMC Eye Ctr, Pittsburgh, PA 15260 USA.
EM jay.chhablani@gmail.com
RI Sahoo, Niroj/AHD-3511-2022; Sahoo, Niroj/AHD-3438-2022; Maltsev,
   Dmitrii/AAA-9100-2022
OI Sahoo, Niroj Kumar/0000-0003-0011-2507; Tatti,
   Filippo/0000-0002-8630-0367
CR Aggio FB, 2010, RETINA-J RET VIT DIS, V30, P1128, DOI 10.1097/IAE.0b013e3181cdf381
   Arora S, 2022, EUR J OPHTHALMOL, V32, P1044, DOI 10.1177/11206721211013651
   Chhablani J, 2020, OPHTHALMOL RETINA, V4, P1043, DOI 10.1016/j.oret.2020.07.026
   Daruich A, 2015, PROG RETIN EYE RES, V48, P82, DOI 10.1016/j.preteyeres.2015.05.003
   FICKER L, 1988, BRIT J OPHTHALMOL, V72, P829, DOI 10.1136/bjo.72.11.829
   Hanumunthadu D, 2018, EYE, V32, P1703, DOI 10.1038/s41433-018-0163-7
   Kaye R, 2020, PROG RETIN EYE RES, V79, DOI 10.1016/j.preteyeres.2020.100865
   Ma JL, 2014, ACTA OPHTHALMOL, V92, pe594, DOI 10.1111/aos.12482
   Maruko I, 2010, OPHTHALMOLOGY, V117, P1792, DOI 10.1016/j.ophtha.2010.01.023
   Mohabati D, 2020, RETINA-J RET VIT DIS, V40, P1742, DOI 10.1097/IAE.0000000000002683
   Mohabati D, 2018, CLIN OPHTHALMOL, V12, P1061, DOI 10.2147/OPTH.S160956
   Salehi M, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD011841.pub2
   Singh SR, 2022, BRIT J OPHTHALMOL, V106, P553, DOI 10.1136/bjophthalmol-2020-317422
   Singh SR, 2019, BRIT J OPHTHALMOL, V103, P737, DOI 10.1136/bjophthalmol-2018-312435
   Spaide R, 2008, RETINA-J RET VIT DIS, V28, P5, DOI 10.1097/IAE.0b013e318158eca4
   van Dijk EHC, 2018, OPHTHALMOLOGY, V125, P1547, DOI 10.1016/j.ophtha.2018.04.021
   van Rijssen TJ, 2019, PROG RETIN EYE RES, V73, DOI 10.1016/j.preteyeres.2019.07.003
   van Rijssen TJ, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0202549
NR 18
TC 3
Z9 3
U1 2
U2 2
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1120-6721
EI 1724-6016
J9 EUR J OPHTHALMOL
JI Eur. J. Ophthalmol.
PD JUL
PY 2022
VL 32
IS 4
BP 2319
EP 2327
AR 11206721211055018
DI 10.1177/11206721211055018
EA NOV 2021
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 3B9CF
UT WOS:000715962200001
PM 34747194
DA 2022-11-30
ER

PT J
AU Meng, LH
   Yuan, MZ
   Zhao, XY
   Yu, WH
   Chen, YX
AF Meng, Li-Hui
   Yuan, Ming-Zhen
   Zhao, Xin-Yu
   Yu, Wei-Hong
   Chen, You-Xin
TI Wide-field swept source optical coherence tomography evaluation of
   posterior segment changes in highly myopic eyes
SO EUROPEAN JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
DE High myopia; swept source optical coherence tomography (SS OCT);
   posterior pole; myopic complications; imaging
ID PRECORTICAL VITREOUS POCKETS; DOME-SHAPED MACULA; PATHOLOGICAL MYOPIA;
   SPECTRAL-DOMAIN; CLASSIFICATION; RETINOSCHISIS; STAPHYLOMAS; SCLERA
AB Background To investigate the features in the posterior pole of highly myopic (HM) eyes using a wide-field high-resolution swept source optical coherence tomography (SS OCT). Methods This observational cross-sectional study involved 262 eyes of 139 patients, who were diagnosed as HM and had consecutively been examined by SS OCT in the Ophthalmology Department of the Peking Union Medical College Hospital between March 2019 and December 2019. The characteristics of OCT images were documented and analyzed. Results In our study, SS OCT could demonstrate the entire layer of the choroid and detect the sclera in all eyes. The mean subfoveal retinal/choroidal/scleral thickness were 204.84 +/- 119.86 mu m, 92.80 +/- 75.78 mu m and 394.734 +/- 123.09 mu m, respectively. 138 eyes (52.67%) had posterior precortical vitreous pocket. Myopic foveoschisis was detected in 110 eyes (41.98%), and significantly associated with the presence of posterior staphyloma. 36 eyes (13.74%) had DSM in our study, of which 8 eyes (22.22%) showed a round dome, 16 (44.44%) were horizontal oval-shaped, 9 (25%) were vertical oval-shaped and 3 (8.34%) were oblique oval-shaped. Both SFCT and SFST were inversely and significantly associated with age and refractive errors. Macular neovascularization was significantly correlated with intrascleral vessels. Different deformation of the sclera and posterior staphyloma were vividly identified on SS OCT images. Conclusions This study provided a relatively comprehensive picture of posterior pole in HM eyes. Such good visualization of ocular fundus provided by wide-field SS OCT could be useful for the therapy option, disease condition monitoring and pathogenesis investigation.
C1 [Meng, Li-Hui; Yuan, Ming-Zhen; Zhao, Xin-Yu; Yu, Wei-Hong; Chen, You-Xin] Chinese Acad Med Sci, Peking Union Med Coll Hosp, Dept Ophthalmol, Beijing 100730, Peoples R China.
   [Yuan, Ming-Zhen] Capital Med Univ, Beijing Tongren Hosp, Beijing Tongren Eye Ctr, Beijing Ophthalmol & Visual Sci Key Lab, Beijing, Peoples R China.
C3 Chinese Academy of Medical Sciences - Peking Union Medical College;
   Peking Union Medical College Hospital; Capital Medical University
RP Chen, YX (通讯作者)，Chinese Acad Med Sci, Peking Union Med Coll Hosp, Dept Ophthalmol, Beijing 100730, Peoples R China.
EM chenyx@pumch.cn
RI meng, li/GVT-2063-2022
CR Alasil T, 2014, OSLI RETINA, V45, P459, DOI 10.3928/23258160-20140909-01
   Ang M, 2019, BRIT J OPHTHALMOL, V103, P855, DOI 10.1136/bjophthalmol-2018-312866
   Baird PN, 2020, NAT REV DIS PRIMERS, V6, DOI 10.1038/s41572-020-00231-4
   Caillaux V, 2013, AM J OPHTHALMOL, V156, P958, DOI 10.1016/j.ajo.2013.06.032
   Corvi F, 2021, DIAGNOSTICS, V11, DOI 10.3390/diagnostics11040658
   Gaucher D, 2008, AM J OPHTHALMOL, V145, P909, DOI 10.1016/j.ajo.2008.01.012
   Gohil R, 2015, EYE, V29, P593, DOI 10.1038/eye.2014.311
   Hayashi K, 2020, INVEST OPHTH VIS SCI, V61, DOI 10.1167/iovs.61.4.33
   Holden BA, 2016, OPHTHALMOLOGY, V123, P1036, DOI 10.1016/j.ophtha.2016.01.006
   Hu GY, 2020, INVEST OPHTH VIS SCI, V61, DOI 10.1167/iovs.61.4.46
   Ikuno Y, 2009, INVEST OPHTH VIS SCI, V50, P3876, DOI 10.1167/iovs.08-3325
   Ishida T, 2019, BRIT J OPHTHALMOL, V103, P457, DOI 10.1136/bjophthalmol-2018-312015
   Itakura H, 2015, INVEST OPHTH VIS SCI, V56, P2898, DOI 10.1167/iovs.15-16451
   Jonas JB, 2017, RETINA-J RET VIT DIS, V37, P1428, DOI 10.1097/IAE.0000000000001464
   Li DJ, 2014, INVEST OPHTH VIS SCI, V55, P2412, DOI 10.1167/iovs.14-13967
   Ng DSC, 2016, EYE, V30, P901, DOI 10.1038/eye.2016.47
   Ohno-Matsui K, 2019, PROG RETIN EYE RES, V70, P99, DOI 10.1016/j.preteyeres.2018.12.001
   Ohno-Matsui K, 2016, PROG RETIN EYE RES, V52, P156, DOI 10.1016/j.preteyeres.2015.12.001
   Ohno-Matsui K, 2015, AM J OPHTHALMOL, V159, P877, DOI 10.1016/j.ajo.2015.01.022
   Ohno-Matsui K, 2014, OPHTHALMOLOGY, V121, P1798, DOI 10.1016/j.ophtha.2014.03.035
   Ohno-Matsui K, 2012, INVEST OPHTH VIS SCI, V53, P7290, DOI 10.1167/iovs.12-10371
   Ohno-Matsui K, 2012, AM J OPHTHALMOL, V154, P382, DOI 10.1016/j.ajo.2012.02.010
   Ohsugi H, 2014, AM J OPHTHALMOL, V158, P162, DOI 10.1016/j.ajo.2014.02.054
   Querques G, 2015, AM J OPHTHALMOL, V160, P759, DOI 10.1016/j.ajo.2015.07.017
   Ruiz-Moreno JM., 2021, RETINA-J RET VIT DIS, DOI [10.1097/IAE.0000000000003290, DOI 10.1097/IAE.0000000000003290]
   Sarao V, 2016, GRAEF ARCH CLIN EXP, V254, P445, DOI 10.1007/s00417-015-3076-1
   Schaal KB, 2014, OPHTHALMOLOGY, V121, P1020, DOI 10.1016/j.ophtha.2013.11.030
   She XJ, 2019, INVEST OPHTH VIS SCI, V60, P4882, DOI 10.1167/iovs.19-27426
   Shimada N, 2006, AM J OPHTHALMOL, V142, P497, DOI 10.1016/j.ajo.2006.03.048
   Shinohara K, 2018, OPHTHALMOLOGY, V125, P1575, DOI 10.1016/j.ophtha.2018.03.053
   Shinohara K, 2017, INVEST OPHTH VIS SCI, V58, P3750, DOI 10.1167/iovs.17-22319
   Takahashi H, 2019, AM J OPHTHALMOL, V206, P102, DOI 10.1016/j.ajo.2019.03.011
   Takano M, 1999, AM J OPHTHALMOL, V128, P472, DOI 10.1016/S0002-9394(99)00186-5
   Zhao XJ, 2018, BMJ OPEN, V8, DOI 10.1136/bmjopen-2018-021887
NR 34
TC 0
Z9 0
U1 2
U2 6
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1120-6721
EI 1724-6016
J9 EUR J OPHTHALMOL
JI Eur. J. Ophthalmol.
PD SEP
PY 2022
VL 32
IS 5
BP 2777
EP 2788
AR 11206721211062362
DI 10.1177/11206721211062362
EA NOV 2021
PG 12
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 3S5GW
UT WOS:000726750000001
PM 34841931
DA 2022-11-30
ER

PT J
AU Cicinelli, MV
   Rabiolo, A
   Montesano, G
   Marchese, A
   Barresi, C
   Introini, U
   Parodi, MB
   Bandello, F
AF Cicinelli, Maria, V
   Rabiolo, Alessandro
   Montesano, Giovanni
   Marchese, Alessandro
   Barresi, Costanza
   Introini, Ugo
   Parodi, Maurizio B.
   Bandello, Francesco
TI CLINICAL ASSOCIATIONS AND PROGNOSTIC IMPLICATIONS OF REPAIR TISSUE
   PROLIFERATION IN EYES WITH RETINAL PIGMENT EPITHELIUM TEARS
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE autofluorescence; macular neovascularization; mixed models; repair
   tissue; retinal pigment epithelium tear
ID GROWTH-FACTOR THERAPY; OPTICAL COHERENCE TOMOGRAPHY; MACULAR
   DEGENERATION; FUNDUS AUTOFLUORESCENCE; INTRAVITREAL INJECTION;
   PATHOGENESIS; MECHANISM
AB Purpose: To investigate demographic and clinical factors influencing the longitudinal changes of retinal pigment epithelium (RPE) dehiscence area after RPE tears, including the presence of RPE tear-associated repair proliferation (TARP), and identify factors associated with TARP development over follow-up. Methods: Retrospective, single-center, observational cohort study of patients with a history of macular neovascularization and RPE tear. The area of RPE dehiscence was measured on repeated short-wavelength fundus autofluorescence imaging. Associations between covariates and RPE dehiscence areas were tested with multivariable linear mixed models. Associations between TARP development and clinical variables were investigated with Cox regression models. Factors associated with visual acuity changing rates were explored with linear mixed models. Results: Thirty-seven eyes of 36 patients were included in this study and followed for a median time of 18 months. Tear-associated repair proliferation was identified in 27 eyes (73%). The median time for TARP detection was 112 days; none of the investigated factors was significantly associated with TARP occurrence. The presence of TARP (estimate: -0.042 mm(2)/month; P = 0.001) and female gender (estimate: -0.035 mm(2)/month; P = 0.006) were associated with slower rates of RPE dehiscence enlargement over time. Faster rates of visual improvement were observed in eyes with TARP compared with those without TARP (estimate = -0.010 logarithm of the minimum angle of resolution/month if TARP was present; P = 0.008). Conclusion: Retinal pigment epithelium tear repair with TARP and female gender were associated with slower RPE degeneration after RPE tears. The presence of TARP was associated better visual prognosis. Additional research on factors promoting TARP development may have therapeutic and prognostic implications.
C1 [Cicinelli, Maria, V; Marchese, Alessandro; Parodi, Maurizio B.; Bandello, Francesco] Univ Vita Salute San Raffaele, Sch Med, Milan, Italy.
   [Cicinelli, Maria, V; Marchese, Alessandro; Barresi, Costanza; Introini, Ugo; Parodi, Maurizio B.; Bandello, Francesco] IRCCS San Raffaele Sci Inst, Dept Ophthalmol, Milan, Italy.
   [Rabiolo, Alessandro] Gloucestershire Hosp NHS Fdn Trust, Dept Ophthalmol, Cheltenham, Glos, England.
   [Montesano, Giovanni] City Univ London, Optometry & Visual Sci, London, England.
   [Montesano, Giovanni] Moorfields Eye Hosp NHS Fdn Trust, NIHR Biomed Res Ctr, London, England.
   [Montesano, Giovanni] UCL Inst Ophthalmol, London, England.
C3 Vita-Salute San Raffaele University; Vita-Salute San Raffaele
   University; IRCCS Ospedale San Raffaele; Gloucestershire Hospitals NHS
   Foundation Trust; City University London; University of London;
   University College London; Moorfields Eye Hospital NHS Foundation Trust;
   University of London; University College London
RP Cicinelli, MV (通讯作者)，Univ Vita Salute, Dept Ophthalmol, IRCCS Osped San Raffaele, Via Olgettina 60, I-20132 Milan, Italy.
EM cicinelli.mariavittoria@hsr.it
OI bandello, francesco/0000-0003-3238-9682; Battaglia Parodi,
   Maurizio/0000-0002-0385-7961
CR Asao K, 2014, RETINA-J RET VIT DIS, V34, P512, DOI 10.1097/IAE.0b013e31829f73eb
   Caramoy A, 2012, BRIT J OPHTHALMOL, V96, P1211, DOI 10.1136/bjophthalmol-2012-301750
   Caramoy A, 2011, ARCH OPHTHALMOL-CHIC, V129, P575, DOI 10.1001/archophthalmol.2011.105
   CHUANG EL, 1988, EYE, V2, P106, DOI 10.1038/eye.1988.22
   Cicinelli MV, 2020, TRANSL VIS SCI TECHN, V9, DOI 10.1167/tvst.9.7.33
   Clemens CR, 2016, OPHTHALMOLOGICA, V235, P1, DOI 10.1159/000439445
   Clemens CR, 2014, RETINA-J RET VIT DIS, V34, P24, DOI 10.1097/IAE.0b013e3182947811
   DelPriore LV, 1996, AM J OPHTHALMOL, V122, P629, DOI 10.1016/S0002-9394(14)70481-7
   Ersoz MG, 2017, SURV OPHTHALMOL, V62, P493, DOI 10.1016/j.survophthal.2017.03.004
   Fitzmaurice GM, 2008, CIRCULATION, V118, P2005, DOI 10.1161/CIRCULATIONAHA.107.714618
   GASS JDM, 1984, BRIT J OPHTHALMOL, V68, P513, DOI 10.1136/bjo.68.8.513
   George SM, 2021, PROG RETIN EYE RES, V85, DOI 10.1016/j.preteyeres.2021.100969
   Heimes B, 2016, RETINA-J RET VIT DIS, V36, P868, DOI 10.1097/IAE.0000000000000823
   Introini U, 2012, GRAEF ARCH CLIN EXP, V250, P1283, DOI 10.1007/s00417-012-1955-2
   Ko F, 2017, OPHTHALMOLOGY, V124, P105, DOI 10.1016/j.ophtha.2016.07.033
   Lafaut BA, 2001, BRIT J OPHTHALMOL, V85, P454, DOI 10.1136/bjo.85.4.454
   Mathews JP, 2007, EYE, V21, P1004, DOI 10.1038/sj.eye.6702805
   Mendis R, 2014, GRAEF ARCH CLIN EXP, V252, P1059, DOI 10.1007/s00417-013-2549-3
   Mukai R, 2015, RETINA-J RET VIT DIS, V35, P473, DOI 10.1097/IAE.0000000000000337
   Nagiel A, 2013, AM J OPHTHALMOL, V156, P981, DOI 10.1016/j.ajo.2013.06.024
   Romano F, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-85270-x
   Ronan SM, 2007, RETINA-J RET VIT DIS, V27, P535, DOI 10.1097/IAE.0b013e3180cc2645
   Team RC, 2013, R LANG ENV STAT COMP
   Vazquez-Alfageme C, 2019, RETINA-J RET VIT DIS, V39, P664, DOI 10.1097/IAE.0000000000002029
   Vilares-Morgado R, 2021, GRAEF ARCH CLIN EXP, V259, P2583, DOI 10.1007/s00417-021-05129-9
   Yehoshua Z, 2011, OPHTHALMOLOGY, V118, P679, DOI 10.1016/j.ophtha.2010.08.018
NR 26
TC 1
Z9 1
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD MAR
PY 2022
VL 42
IS 3
BP 519
EP 528
DI 10.1097/IAE.0000000000003332
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA ZD6KA
UT WOS:000758305500020
PM 34743132
DA 2022-11-30
ER

PT J
AU Arora, S
   Rosario, B
   Mohammed, AR
   Beale, O
   Selvam, A
   Venkatesh, R
   Maltsev, DS
   Chhablani, J
AF Arora, Supriya
   Rosario, Brian
   Mohammed, Abdul Rasheed
   Beale, Oliver
   Selvam, Amrish
   Venkatesh, Ramesh
   Maltsev, Dmitrii S.
   Chhablani, Jay
CA Cent Serous Chorioretinopathy Stud
TI Regression patterns of central serous chorioretinopathy using en face
   optical coherence tomography
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE Central serous chorioretinopathy; En face imaging; Regression pattern;
   Subretinal fluid
AB Purpose To study the regression patterns of subretinal fluid (SRF) in central serous chorioretinopathy (CSCR) on sequential en face optical coherence tomography (OCT) and its relationship to leak locations. Methods Retrospective study on patients with acute CSCR. Inclusion criteria were (i) availability of data, sequential OCT and OCT angiography (B scan and en face OCT) every 2 weeks until resolution of SRF or 6 months, whichever is earlier; (ii) single active leak. Exclusion criteria were (i) presence of macular neovascularization or atypical CSCR, (ii) diffuse pigment epitheliopathy, (iii) multiple leaks. Serial en face OCT scans were evaluated and the area of SRF was measured using ImageJ software. Correlation coefficient was calculated for the regression rate of SRF area and central retinal thickness (CRT) over the first month of follow-up and the time of complete SRF resolution. Results Out of the 25 eyes, 20 eyes demonstrated a centripetal regression, and 5 eyes demonstrated a centrifugal regression. In eyes with a leakage point <1000 mu from the fovea, 86% resolved in a centripetal fashion, and in eyes with leak site >= 1000 mu away from fovea, 70% eyes resolved centripetally. There was a correlation (r=-0.47, p=0.018) of the rate regression of SRF area during the first month and timing of resolution. In contrast, this correlation was absent (r=-0.16, p=0.44) for CRT regression. Conclusion Our en face-based analysis of sequential OCTs of regressing CSCR demonstrated a tendency for the subfoveal SRF to resolve towards the end or a centripetal pattern of regression. Prediction of resolution of SRF at 1 month is better with en face area of SRF in comparison to CRT.
C1 [Arora, Supriya] Bahamas Vis Ctr, Nassau, NP, Bahamas.
   [Arora, Supriya] Princess Margaret Hosp, Nassau, NP, Bahamas.
   [Rosario, Brian; Beale, Oliver; Selvam, Amrish; Chhablani, Jay] Univ Pittsburgh, UPMC Eye Ctr, Pittsburgh, PA 15260 USA.
   [Mohammed, Abdul Rasheed] Univ Waterloo, Sch Optometry & Vis Sci, Waterloo, ON, Canada.
   [Venkatesh, Ramesh] Narayana Nethralaya, Dept Retina & Vitreous, Bengaluru, India.
   [Maltsev, Dmitrii S.] Mil Med Acad, Dept Ophthalmol, St Petersburg, Russia.
C3 Pennsylvania Commonwealth System of Higher Education (PCSHE); University
   of Pittsburgh; University of Waterloo
RP Chhablani, J (通讯作者)，Univ Pittsburgh, UPMC Eye Ctr, Pittsburgh, PA 15260 USA.
EM jay.chhablani@gmail.com
OI Beale, Oliver/0000-0001-8627-3963
CR Arf S, 2017, INT OPHTHALMOL, V37, P483, DOI 10.1007/s10792-016-0286-4
   Arora S, 2022, EYE, V36, P517, DOI 10.1038/s41433-021-01788-4
   Daruich A, 2017, RETINA-J RET VIT DIS, V37, P1905, DOI 10.1097/IAE.0000000000001443
   KLEIN ML, 1974, ARCH OPHTHALMOL-CHIC, V91, P247
   Lotery A, 2020, LANCET, V395, P294, DOI 10.1016/S0140-6736(19)32981-2
   MARMOR MF, 1990, EYE, V4, P340, DOI 10.1038/eye.1990.46
   Mohammad F, 2014, J OPHTHALMOL, V2014, DOI 10.1155/2014/720243
   Mrejen S, 2019, OPHTHALMOLOGY, V126, P576, DOI 10.1016/j.ophtha.2018.12.048
   Sahoo NK, 2019, SEMIN OPHTHALMOL, V34, P380, DOI 10.1080/08820538.2019.1635171
   Schneider CA, 2012, NAT METHODS, V9, P671, DOI 10.1038/nmeth.2089
   Shin YI, 2020, JPN J OPHTHALMOL, V64, P28, DOI 10.1007/s10384-019-00697-0
   Singh SR, 2021, EUR J OPHTHALMOL, V31, P2520, DOI 10.1177/1120672120963456
   van Rijssen TJ, 2019, PROG RETIN EYE RES, V73, DOI 10.1016/j.preteyeres.2019.07.003
NR 13
TC 0
Z9 0
U1 1
U2 1
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0721-832X
EI 1435-702X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD AUG
PY 2022
VL 260
IS 8
BP 2475
EP 2481
DI 10.1007/s00417-022-05636-3
EA MAR 2022
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 3F5UF
UT WOS:000777328900002
PM 35357548
DA 2022-11-30
ER

PT J
AU Arrigo, A
   Aragona, E
   Bordato, A
   Calamuneri, A
   Moretti, AG
   Mercuri, S
   Bandello, F
   Parodi, MB
AF Arrigo, Alessandro
   Aragona, Emanuela
   Bordato, Alessandro
   Calamuneri, Alessandro
   Moretti, Alessio Grazioli
   Mercuri, Stefano
   Bandello, Francesco
   Parodi, Maurizio Battaglia
TI Acute Central Serous Chorioretinopathy Subtypes as Assessed by
   Multimodal Imaging
SO TRANSLATIONAL VISION SCIENCE & TECHNOLOGY
LA English
DT Article
DE central serous chorioretinopathy; OCT; fluorescein angiography;
   indocyanine green angiography; fundus autofluorescence
ID EPLERENONE
AB Purpose: To differentiate acute central serous chorioretinopathy (CSC) subtypes by multimodal imaging.
   Methods: The research was designed as a prospective, interventional study. Naive patients with acute CSC were followed for 24 months. Overall, 96 CSC patients (96 eyes) and 210 controls (210 eyes) were included. Multimodal imaging allowed the study to classify CSC into retinal pigment epithelium-related CSC (RPE-CSC) and choroidalrelated CSC (choroidal-CSC) subtypes. The RPE-CSC type was characterized by normal choroidal thickness (CT) in association with disseminated RPE alterations. The choroidalCSC type was distinguished by identifying a pachychoroid. All the patients underwent eplerenone or verteporfin photodynamic therapy (PDT). Patients developing macular neovascularization (MNV) underwent anti-VEGF injections. Quantitative measurements included central macular thickness (CMT), choroidal thickness (CT), Sattler layer thickness (SLT) and Haller layer thickness (HLT).
   Results: Considering the CSC patients as a whole, baseline BCVA was 0.18 +/- 0.25 LogMAR, increasing to 0.13 +/- 0.21 LogMAR after 24 months (P < 0.01), whereas baseline CMT improved from 337 +/- 126 mu m to 244 +/- 84 mu m after 24 months (P < 0.01). We found the following subdivision of CSC eyes: RPE-CSC type (45%) and choroidal-CSC type (55%). Overall, MNV were detected in 18 eyes (19%), 13 eyes (72%) in the RPE-CSC subgroup and five eyes (28%) in the choroidal-CSC subgroup. Forty eyes responded to eplerenone (57% of RPE-CSC and 47% of choroidal-CSC), whereas 38 eyes required PDT (43% of RPE-CSC and 53% of choroidal-CSC).
   Conclusions: Acute CSC includes two main clinical manifestations, displaying differing features concerning retinal and choroidal involvement.
   Translational Relevance: This study identified two clinically different acute CSC subtypes on the basis of quantitative pachychoroid cutoff values.
C1 [Arrigo, Alessandro; Aragona, Emanuela; Bordato, Alessandro; Moretti, Alessio Grazioli; Mercuri, Stefano; Bandello, Francesco; Parodi, Maurizio Battaglia] Univ Vita Salute, Dept Ophthalmol, IRCCS Osped San Raffaele, Via Olgettina 60, I-20132 Milan, Italy.
   [Calamuneri, Alessandro] IRCCS Bonino Pulejo Neurol, Messina, Italy.
C3 Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele
RP Arrigo, A (通讯作者)，Univ Vita Salute, Dept Ophthalmol, IRCCS Osped San Raffaele, Via Olgettina 60, I-20132 Milan, Italy.
EM alessandro.arrigo@hotmail.com
OI Battaglia Parodi, Maurizio/0000-0002-0385-7961; bandello,
   francesco/0000-0003-3238-9682
CR Cakir B, 2016, GRAEF ARCH CLIN EXP, V254, P2151, DOI 10.1007/s00417-016-3373-3
   Chang AA, 1998, OPHTHALMOLOGY, V105, P1060, DOI 10.1016/S0161-6420(98)96008-0
   Cheung CMG, 2019, EYE, V33, P14, DOI 10.1038/s41433-018-0158-4
   Daruich A, 2015, PROG RETIN EYE RES, V48, P82, DOI 10.1016/j.preteyeres.2015.05.003
   Gattoussi Sarra, 2017, Ophthalmology, V124, P1331, DOI 10.1016/j.ophtha.2017.02.016
   Gaudric Alain, 2017, Retin Cases Brief Rep, V11 Suppl 1, pS81, DOI 10.1097/ICB.0000000000000422
   Iacono P, 2016, OPHTHALMIC RES, V55, P76, DOI 10.1159/000441502
   Iacono P, 2015, GRAEF ARCH CLIN EXP, V253, P1889, DOI 10.1007/s00417-014-2899-5
   Imamura Y, 2011, OPHTHALMOLOGY, V118, P700, DOI 10.1016/j.ophtha.2010.08.017
   Le YZ, 2008, INVEST OPHTHALMOL VI, V49, P857
   Leisser C, 2016, EUR J OPHTHALMOL, V26, P479, DOI 10.5301/ejo.5000727
   Lotery A, 2020, LANCET, V395, P294, DOI 10.1016/S0140-6736(19)32981-2
   Salehi M, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD011841.pub2
   Schwartz R, 2017, ACTA OPHTHALMOL, V95, pE610, DOI 10.1111/aos.13491
   Sparrrow JR, 2010, CURR MOL MED, V10, P802
   van Rijssen TJ, 2019, PROG RETIN EYE RES, V73, DOI 10.1016/j.preteyeres.2019.07.003
   Zucchiatti I, 2018, OPHTHALMOL THER, V7, P109, DOI 10.1007/s40123-018-0121-2
NR 17
TC 2
Z9 2
U1 2
U2 4
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 2164-2591
J9 TRANSL VIS SCI TECHN
JI Transl. Vis. Sci. Technol.
PD NOV
PY 2021
VL 10
IS 13
AR 6
DI 10.1167/tvst.10.13.6
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA XU4XV
UT WOS:000734270600006
PM 34739039
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU Park, UC
   Lee, EK
   Yoon, CK
   Oh, BL
AF Park, Un Chul
   Lee, Eun Kyoung
   Yoon, Chang Ki
   Oh, Baek-Lok
TI Progression pattern of myopic maculopathy according to the severity of
   diffuse chorioretinal atrophy and choroidal thickness
SO SCIENTIFIC REPORTS
LA English
DT Article
ID POSTERIOR STAPHYLOMAS; PATHOLOGICAL MYOPIA; VISUAL IMPAIRMENT; FUNDUS;
   BLINDNESS; CLASSIFICATION; REFLECTANCE; PREVALENCE
AB This observational cohort study aimed to evaluate the progression pattern of diffuse chorioretinal atrophy (DCA) according to its severity. Highly myopic eyes with DCA were graded according to its extent in the 532-nm (green) and 633-nm (red) wavelengths images of the Optos ultra-widefield scanning laser ophthalmoscope at baseline: grade 1 and 2 were defined when increased reflectance at peripapillary region, not beyond the fovea, were observed in red laser image only and in both laser images, respectively; grade 3 and 4 were defined when increased reflectance beyond the fovea were observed in red laser image only and in both laser images, respectively. A total of 307 eyes (221 patients) were included, and progression of myopic maculopathy during follow-up of >= 3 years was evaluated. The mean visual acuity and subfoveal choroidal thickness (CT) differed among DCA grades (P = 0.015 and P < 0.001); a higher DCA grade had worse visual acuity and thinner choroid. During follow-up, development of patchy atrophy (PA) was observed in 3.2%, 5.5%, 12.8%, and 23.2% (P < 0.001), while changes in lacquer crack (LC) and/or development of myopic macular neovascularization were observed in 20.6%, 29.1%, 33.3%, and 15.8% (P = 0.061) of 63, 110, 39, and 95 eyes with DCA grade of 1, 2, 3, and 4 at baseline, respectively. New LC formation tended to occur in eyes with thicker CT at baseline compared to PA development and progression of pre-existing LC. In highly myopic eyes with DCA, progression pattern of myopic maculopathy is different according to its severity and CT at baseline. Grading based on separated wavelength images of ultra-widefield scanning laser ophthalmoscope is useful to evaluate the severity and prognosis of DCA in Asian patients with high myopia.
C1 [Park, Un Chul; Lee, Eun Kyoung; Yoon, Chang Ki; Oh, Baek-Lok] Seoul Natl Univ, Dept Ophthalmol, Coll Med, 103 Daehak Ro, Seoul 110799, South Korea.
C3 Seoul National University (SNU)
RP Park, UC (通讯作者)，Seoul Natl Univ, Dept Ophthalmol, Coll Med, 103 Daehak Ro, Seoul 110799, South Korea.
EM ucpark@snu.ac.kr
CR Ahn SE, 2013, INDIAN J OPHTHALMOL, V61, P38, DOI 10.4103/0301-4738.105054
   Coco-Martin RM, 2021, GRAEF ARCH CLIN EXP, V259, P81, DOI 10.1007/s00417-020-04795-5
   Fang YX, 2019, OPHTHALMOLOGY, V126, P1018, DOI 10.1016/j.ophtha.2019.01.012
   Fang YX, 2018, OPHTHALMOLOGY, V125, P863, DOI 10.1016/j.ophtha.2017.12.005
   Hayashi K, 2010, OPHTHALMOLOGY, V117, P1595, DOI 10.1016/j.ophtha.2009.11.003
   Iwase A, 2006, OPHTHALMOLOGY, V113, P1354, DOI 10.1016/j.ophtha.2006.04.022
   Kernt M, 2010, CLIN OPHTHALMOL, V4, P829
   Li ZX, 2021, BRIT J OPHTHALMOL, V105, P989, DOI 10.1136/bjophthalmol-2020-316691
   Li ZX, 2019, INVEST OPHTH VIS SCI, V60, P1096, DOI 10.1167/iovs.18-25800
   Liu CF, 2014, EYE, V28, P1437, DOI 10.1038/eye.2014.221
   Nagiel A, 2016, RETINA-J RET VIT DIS, V36, P660, DOI 10.1097/IAE.0000000000000937
   Nowroozizadeh S, 2014, INVEST OPHTH VIS SCI, V55, P3439, DOI 10.1167/iovs.14-13880
   Ohno-Matsui K, 2017, RETINA-J RET VIT DIS, V37, P477, DOI 10.1097/IAE.0000000000001327
   Ohno-Matsui K, 2016, PROG RETIN EYE RES, V52, P156, DOI 10.1016/j.preteyeres.2015.12.001
   Ohno-Matsui K, 2015, AM J OPHTHALMOL, V159, P877, DOI 10.1016/j.ajo.2015.01.022
   Ohno-Matsui K, 2014, OPHTHALMOLOGY, V121, P1798, DOI 10.1016/j.ophtha.2014.03.035
   Psomiadi A, 2020, EUR J OPHTHALMOL, V30, P1397, DOI 10.1177/1120672119873210
   Ruiz-Medrano J, 2019, PROG RETIN EYE RES, V69, P80, DOI 10.1016/j.preteyeres.2018.10.005
   Shinohara K, 2017, INVEST OPHTH VIS SCI, V58, P3750, DOI 10.1167/iovs.17-22319
   Varma R, 2016, JAMA OPHTHALMOL, V134, P785, DOI 10.1001/jamaophthalmol.2016.1261
   Wong YL, 2020, INVEST OPHTH VIS SCI, V61, DOI 10.1167/iovs.61.4.14
   Xu L, 2006, OPHTHALMOLOGY, V113, P1134, DOI 10.1016/j.ophtha.2006.01.035
   Xu X, 2019, RETINA-J RET VIT DIS, V39, P1265, DOI 10.1097/IAE.0000000000002168
   Yan YN, 2018, OPHTHALMOLOGY, V125, P1253, DOI 10.1016/j.ophtha.2018.01.035
   Yokoi T, 2017, INVEST OPHTH VIS SCI, V58, DOI 10.1167/iovs.16-20652
   Yokoi T, 2016, OPHTHALMOLOGY, V123, P1783, DOI 10.1016/j.ophtha.2016.04.029
NR 26
TC 0
Z9 0
U1 2
U2 2
PU NATURE PORTFOLIO
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD FEB 23
PY 2022
VL 12
IS 1
AR 3099
DI 10.1038/s41598-022-07172-w
PG 9
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA ZG7FS
UT WOS:000760421800019
PM 35197535
OA gold, Green Published
DA 2022-11-30
ER

PT J
AU van Rensburg, EJ
   Ryu, CL
   Rampakakis, E
   Vila, N
   Chan, EW
   Chen, JC
AF van Rensburg, Ernst Janse
   Ryu, Christina L.
   Rampakakis, Emmanouil
   Vila, Natalia
   Chan, Errol W.
   Chen, John C.
TI OUTER RETINAL TUBULATION MAY RESULT FROM FIBROSED TYPE 2
   NEOVASCULARIZATION Clinical Observations and Model of Pathogenesis
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE age-related macular degeneration; macular neovascularization; outer
   retinal tubulations; subretinal fibrosis
ID MACULAR DEGENERATION; GEOGRAPHIC ATROPHY; EVOLUTION
AB Purpose: To investigate the role of Type 2 macular neovascularization with subsequent subretinal fibrosis in the pathogenesis of outer retinal tubulation (ORT). Methods: We conducted a retrospective cohort study of patients with stabilized inactive exudative macular degeneration who had been treated with intravitreal injections of antivascular endothelial growth factor agents. Baseline fluorescein and optical coherence tomography images were included. Macular neovascularizations (MNVs) were classified by type and size. Consecutive optical coherence tomography images analyzed for ORT development. Results: One hundred forty-four eyes of 134 patients were included in this study. Sixty eyes presented with pure Type 1 MNV. Eighty-four eyes presented with some Type 2 component of MNV. In total, evidence of ORT is shown in 55 (38%) eyes. In the Type 1 group, 6.7% developed ORT. Outer retinal tubulation developed in 61% of eyes with some Type 2 component of the MNV. Among eyes that developed ORT, 92.7% presented with some Type 2 component. In a multivariate analysis, Type 2 membranes on optical coherence tomography (22.2 [6.1-80.8]; P < 0.001), larger MNV size {>1 DA (5.1 [1.1-24.2]; P = 0.041) and >1.5 DA (9.0 [1.8-44.0]; P = 0.007)}, and presence of subretinal fibrovascular material (3.1 [1.1-8.5]; P = < 0.03) are associated with higher odds of ORT formation. Once the ORT is formed, fibrosis was observed directly underlying the ORT on SD-optical coherence tomography in 70.9% of cases. Conclusion: Type 2 membranes at presentation predict ORT formation. Fibrosis often underlies ORT. This suggests that contraction of Type 2 MNV-derived fibrosis may be important in ORT formation.
C1 [van Rensburg, Ernst Janse; Ryu, Christina L.; Vila, Natalia; Chan, Errol W.; Chen, John C.] McGill Univ, Dept Ophthalmol, Hlth Ctr, Montreal, PQ, Canada.
   [Ryu, Christina L.] Minneapolis VA Hlth Care Syst, Minneapolis, MN USA.
   [Ryu, Christina L.] Univ Minnesota, Dept Ophthalmol & Visual Neurosci, Minneapolis, MN USA.
   [Rampakakis, Emmanouil] JSS Med Res, Quebec City, PQ, Canada.
   [Vila, Natalia] Royal Liverpool Univ Hosp, St Pauls Eye Unit, Liverpool, Merseyside, England.
   [Chan, Errol W.] Moorfields Eye Hosp, Vitreoretinal Serv, London, England.
C3 McGill University; US Department of Veterans Affairs; Veterans Health
   Administration (VHA); Minneapolis VA Health Care System; University of
   Minnesota System; University of Minnesota Twin Cities; Royal Liverpool &
   Broadgreen University Hospitals NHS Trust; Royal Liverpool University
   Hospital; University of Liverpool; University of London; University
   College London; Moorfields Eye Hospital NHS Foundation Trust
RP Chen, JC (通讯作者)，McGill Univ, McGill Acad Eye Ctr, Dept Ophthalmol, Hlth Ctr, 5252 Maisonneuve Blvd W, Montreal, PQ H4A 3J1, Canada.
EM john.chen@mcgill.ca
FU Association of Physicians Finance Committee; Research Proposal Funding
   Committee of McGill University
FX Supported by a grant from the Association of Physicians Finance
   Committee and the Research Proposal Funding Committee of McGill
   University.
CR Braimah IZ, 2017, RETINA-J RET VIT DIS, V37, P578, DOI 10.1097/IAE.0000000000001220
   Capuano V, 2017, AM J OPHTHALMOL, V182, P45, DOI 10.1016/j.ajo.2017.07.009
   Carnevali A, 2016, AM J OPHTHALMOL, V169, P189, DOI 10.1016/j.ajo.2016.06.042
   Dolz-Marco R, 2017, OPHTHALMOLOGY, V124, P1353, DOI 10.1016/j.ophtha.2017.03.043
   Hua DA, 2018, SEMIN OPHTHALMOL, V33, P331, DOI 10.1080/08820538.2016.1238099
   Faria-Correia F, 2013, OPHTHALMOLOGICA, V229, P147, DOI 10.1159/000346854
   Hariri A, 2015, OPHTHALMOLOGY, V122, P407, DOI 10.1016/j.ophtha.2014.08.035
   Heymann Hans B, 2019, Retin Cases Brief Rep, V13, P224, DOI 10.1097/ICB.0000000000000562
   Iriyama Aya, 2013, Retina, V33, P1462, DOI 10.1097/IAE.0b013e31828221ae
   Lafaut BA, 2001, BRIT J OPHTHALMOL, V85, P454, DOI 10.1136/bjo.85.4.454
   Lee JY, 2014, OPHTHALMOLOGY, V121, P2423, DOI 10.1016/j.ophtha.2014.06.013
   Preti RC, 2018, RETINA-J RET VIT DIS, V38, P1518, DOI 10.1097/IAE.0000000000001810
   Ryu CL, 2016, RETINA-J RET VIT DIS, V36, P1324, DOI 10.1097/IAE.0000000000000877
   SARKS JP, 1988, EYE, V2, P552, DOI 10.1038/eye.1988.106
   SARKS SH, 1976, BRIT J OPHTHALMOL, V60, P324, DOI 10.1136/bjo.60.5.324
   Schaal KB, 2015, RETINA-J RET VIT DIS, V35, P1339, DOI 10.1097/IAE.0000000000000471
   Spaide RF, 2020, OPHTHALMOLOGY, V127, P616, DOI 10.1016/j.ophtha.2019.11.004
   Spaide RF, 2009, AM J OPHTHALMOL, V147, P644, DOI 10.1016/j.ajo.2008.10.005
   Wolff B, 2012, J OPHTHALMOL, V2012, DOI 10.1155/2012/542417
   Xuan Y, 2018, RETINA-J RET VIT DIS, V38, P49, DOI 10.1097/IAE.0000000000001498
   Zanzottera EC, 2016, RETINA-J RET VIT DIS, V36, pS26, DOI 10.1097/IAE.0000000000001330
   Zweifel SA, 2009, ARCH OPHTHALMOL-CHIC, V127, P1596, DOI 10.1001/archophthalmol.2009.326
NR 22
TC 1
Z9 1
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0275-004X
EI 1539-2864
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD SEP
PY 2021
VL 41
IS 9
BP 1930
EP 1939
DI 10.1097/IAE.0000000000003127
PG 10
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA WN5QE
UT WOS:000711821200039
PM 33492078
OA Green Published, hybrid
DA 2022-11-30
ER

PT J
AU Xie, X
   Liu, TT
   Wang, WQ
   Tian, G
   Wang, JY
   Guan, JT
   Chen, M
   Wang, XC
   Zhou, QJ
AF Xie, Xiao
   Liu, Tingting
   Wang, Wenqi
   Tian, Ge
   Wang, Jinyan
   Guan, Jitian
   Chen, Meng
   Wang, Xunchang
   Zhou, Qingjun
TI Clinical and Multi-Mode Imaging Features of Eyes With Peripapillary
   Hyperreflective Ovoid Mass-Like Structures
SO FRONTIERS IN MEDICINE
LA English
DT Article
DE peripapillary hyperreflective ovoid mass-like structures; optic disc
   drusen; optic disc edema; optical coherence tomography; regional blood
   flow imaging; multi-mode imaging features
ID OPTICAL COHERENCE TOMOGRAPHY; NERVE HEAD DRUSEN
AB PurposeTo observe and analyze the clinical and multi-mode imaging features of eyes with PHOMS, and to introduce two cases of PHOMS which underwent multi-mode imaging. MethodsRetrospective clinical observational study. A total of 26 patients (37 eyes) with hyperreflective structures surrounded by hyporeflective edges around the optic discs who were examined and diagnosed at Shandong Eye Hospital between January 2019 and June 2021 were included in the study. Among these patients, 12 were male and 14 were female. Fifteen were monocular. The average age was 39 years. All patients underwent the following examinations: Best-corrected visual acuity (BCVA), intraocular pressure examinations, slit-lamp anterior segment examinations, indirect ophthalmoscopy, visual field examinations, fundus color photography, fundus autofluorescence (FAF), optical coherence tomography (OCT), and optical coherence tomography angiography (OCTA). Some of the patients were examined with fundus fluorescein angiography (FFA). Clinical data and imaging characteristics from the OCT, OCTA, and FFA were analyzed retrospectively. ResultsWe found the hyperreflective structures surrounded by hyporeflective edges around the optic discs in 37 eyes. EDI-OCT results revealed hyperreflective structures surrounded by hyporeflective edges around the optic discs in all eyes. Typical hyperreflexia lesions occurred around the optic disc, located subretinally and above Bruch's membrane. OCTA revealed that the highly reflective perioptic material also had vascular structures. ConclusionEDI-OCT of PHOMS showed hyperreflective structures surrounded by hyporeflective edges around all of the optic discs. Infra-red photography showed temporal hyperreflexia. These characteristics can be seen in a variety of diseases and may be a relatively common feature revealed by EDI-OCT scanning. These characteristics may also be seen in elderly patients as well as children. PHOMS may be found in optic disc drusen (ODD), tilted disc syndrome (TDS), optic neuritis, ischemic optic neuropathy, and in white dot syndromes. Few patients may be developed into macular neovascularization (MNV). In order to improve the accuracy and robustness of the conclusions and provide better clinical guidance, we need to conduct more comprehensive research in the subsequent clinical work.
C1 [Xie, Xiao; Wang, Wenqi] Shandong Univ Tradit Chinese Med, Clin Med Coll 1, Jinan, Peoples R China.
   [Xie, Xiao; Liu, Tingting; Wang, Wenqi; Tian, Ge; Wang, Jinyan; Guan, Jitian; Wang, Xunchang] Shandong First Med Univ, Eye Hosp, Shandong Eye Hosp, Jinan, Peoples R China.
   [Xie, Xiao; Liu, Tingting; Wang, Wenqi; Tian, Ge; Wang, Jinyan; Guan, Jitian; Wang, Xunchang; Zhou, Qingjun] Shandong Eye Inst, State Key Lab Cultivat Base, Shandong Prov Key Lab Ophthalmol, Qingdao, Peoples R China.
   [Xie, Xiao; Liu, Tingting; Wang, Wenqi; Tian, Ge; Wang, Jinyan; Guan, Jitian; Wang, Xunchang; Zhou, Qingjun] Shandong First Med Univ & Shandong Acad Med Sci, Qingdao, Peoples R China.
   [Liu, Tingting; Tian, Ge; Wang, Jinyan; Guan, Jitian; Wang, Xunchang; Zhou, Qingjun] Shandong First Med Univ, Sch Ophthalmol, Jinan, Peoples R China.
   [Chen, Meng] Zaozhuang Shizhong Dist Peoples Hosp, Zaozhuang, Peoples R China.
   [Zhou, Qingjun] Shandong First Med Univ, Qingdao Eye Hosp, Qingdao, Peoples R China.
C3 Shandong University of Traditional Chinese Medicine; Shandong First
   Medical University & Shandong Academy of Medical Sciences; Shandong
   First Medical University & Shandong Academy of Medical Sciences;
   Shandong First Medical University & Shandong Academy of Medical
   Sciences; Shandong First Medical University & Shandong Academy of
   Medical Sciences; Shandong First Medical University & Shandong Academy
   of Medical Sciences
RP Liu, TT (通讯作者)，Shandong First Med Univ, Eye Hosp, Shandong Eye Hosp, Jinan, Peoples R China.; Liu, TT (通讯作者)，Shandong Eye Inst, State Key Lab Cultivat Base, Shandong Prov Key Lab Ophthalmol, Qingdao, Peoples R China.; Liu, TT (通讯作者)，Shandong First Med Univ & Shandong Acad Med Sci, Qingdao, Peoples R China.; Liu, TT (通讯作者)，Shandong First Med Univ, Sch Ophthalmol, Jinan, Peoples R China.
EM tingtingliu@vip.sina.com
RI Wang, Jin/GYA-2019-2022
FU Natural Key Research and Development Project [2016YFC1305500]
FX Funding This study was supported by Natural Key Research and Development
   Project (2016YFC1305500).
CR Ahn YJ, 2022, EYE, V36, P533, DOI 10.1038/s41433-021-01461-w
   Bassi ST, 2014, INDIAN J OPHTHALMOL, V62, P1146, DOI 10.4103/0301-4738.149136
   Borrelli E, 2021, EYE, V35, P528, DOI 10.1038/s41433-020-0890-4
   Borrelli E, 2019, OPHTHALMOL THER, V8, P215, DOI 10.1007/s40123-019-0178-6
   Chen John J, 2019, Int Ophthalmol Clin, V59, P3, DOI 10.1097/IIO.0000000000000274
   Fraser JA, 2021, J NEURO-OPHTHALMOL, V41, P431, DOI 10.1097/WNO.0000000000001203
   FRIEDMAN AH, 1977, SURV OPHTHALMOL, V21, P375, DOI 10.1016/0039-6257(77)90041-8
   Gili P, 2013, GRAEF ARCH CLIN EXP, V251, P923, DOI 10.1007/s00417-012-2223-1
   Hamann S, 2020, AM J OPHTHALMOL, V217, P174, DOI 10.1016/j.ajo.2020.03.052
   Lee KM, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0196001
   Lee KM, 2013, AM J OPHTHALMOL, V155, P1139, DOI 10.1016/j.ajo.2013.01.024
   Lee KM, 2011, OPHTHALMOLOGY, V118, P971, DOI 10.1016/j.ophtha.2010.09.006
   Lyu IJ, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-58829-3
   Malmqvist L, 2018, J NEURO-OPHTHALMOL, V38, P568, DOI 10.1097/WNO.0000000000000674
   Malmqvist L, 2018, J NEURO-OPHTHALMOL, V38, P299, DOI 10.1097/WNO.0000000000000585
   Mezad-Koursh D, 2021, EYE, V35, P1228, DOI 10.1038/s41433-020-1067-x
   Petzold A, 2020, NEURO-OPHTHALMOLOGY, V44, P413, DOI 10.1080/01658107.2020.1760891
   Petzold A, 2020, ANN NEUROL, V88, P309, DOI 10.1002/ana.25782
   Pichi F, 2014, GRAEF ARCH CLIN EXP, V252, P1661, DOI 10.1007/s00417-014-2701-8
   Shinohara K, 2013, EYE, V27, P1234, DOI 10.1038/eye.2013.202
   Teixeira FJ, 2020, EYE, V34, P1577, DOI 10.1038/s41433-019-0694-6
   TSO MOM, 1981, OPHTHALMOLOGY, V88, P1066
   Wang DD, 2018, EYE, V32, P1145, DOI 10.1038/s41433-017-0009-8
   Wibroe EA, 2021, LIFE-BASEL, V11, DOI 10.3390/life11060584
   Yan Y, 2021, AM J OPHTHALMOL, V225, P18, DOI 10.1016/j.ajo.2020.12.023
NR 25
TC 2
Z9 2
U1 3
U2 5
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
EI 2296-858X
J9 FRONT MED-LAUSANNE
JI Front. Med.
PD FEB 9
PY 2022
VL 9
AR 796667
DI 10.3389/fmed.2022.796667
PG 6
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA ZH1BD
UT WOS:000760681100001
PM 35223899
OA Green Published, gold
DA 2022-11-30
ER

PT J
AU van Nispen, RMA
   Virgili, G
   Hoeben, M
   Langelaan, M
   Klevering, J
   Keunen, JEE
   van Rens, GHMB
AF van Nispen, Ruth M. A.
   Virgili, Gianni
   Hoeben, Mirke
   Langelaan, Maaike
   Klevering, Jeroen
   Keunen, Jan E. E.
   van Rens, Ger H. M. B.
TI Low vision rehabilitation for better quality of life in visually
   impaired adults
SO COCHRANE DATABASE OF SYSTEMATIC REVIEWS
LA English
DT Review
ID RANDOMIZED CONTROLLED-TRIAL; HEALTH-EDUCATION PROGRAM; PSYCHOSOCIAL
   INTERVENTION PROGRAM; DEPRESSION PREVENTION TRIAL; CLOSED-CIRCUIT
   TELEVISION; BASE-LINE CHARACTERISTICS; ITEM RESPONSE THEORY; MACULAR
   DEGENERATION; OLDER-ADULTS; SELF-MANAGEMENT
AB Background
   Low vision rehabilitation aims to optimise the use of residual vision after severe vision loss, but also aims to teach skills in order to improve visual functioning in daily life. Other aims include helping people to adapt to permanent vision loss and improving psychosocial functioning. These skills promote independence and active participation in society. Low vision rehabilitation should ultimately improve quality of life (QOL) for people who have visual impairment.
   Objectives
   To assess the effectiveness of low vision rehabilitation interventions on health-related QOL (HRQOL), vision-related QOL (VRQOL) or visual functioning and other closely related patient-reported outcomes in visually impaired adults.
   Search methods
   We searched relevant electronic databases and trials registers up to 18 September 2019.
   Selection criteria
   We included randomised controlled trials (RCTs) investigating HRQOL, VRQOL and related outcomes of adults, with an irreversible visual impairment (World Health Organization criteria). We included studies that compared rehabilitation interventions with active or inactive control.
   Data collection and analysis
   We used standard methods expected by Cochrane. We assessed the certainty of the evidence using the GRADE approach.
   Main results
   We included 44 studies (73 reports) conducted in North America, Australia, Europe and Asia. Considering the clinical diversity of low vision rehabilitation interventions, the studies were categorised into four groups of related intervention types (and by comparator): (1) psychological therapies and/or group programmes, (2) methods of enhancing vision, (3) multidisciplinary rehabilitation programmes, (4) other programmes. Comparators were no care or waiting list as an inactive control group, usual care or other active control group. Participants included in the reported studies were mainly older adults with visual impairment or blindness, often as a result of age-related macular degeneration (AMD). Study settings were often hospitals or low vision rehabilitation services. Effects were measured at the short-term (six months or less) in most studies. Not all studies reported on funding, but those who did were supported by public or non-profit funders (N = 31), except for two studies.
   Compared to inactive comparators, we found very tow-certainty evidence of no beneficial effects on HRQOLthat was imprecisely estimated for psychological therapies and/or group programmes (SMD 0.26, 95% CI -0.28 to 0.80; participants = 183; studies = 1) and an imprecise estimate suggesting little or no effect of multidisciplinary rehabilitation programmes (SMD -0.08, 95% CI -0.37 to 0.21; participants = 183; studies = 2; I-2 = 0%); no data were available for methods of enhancing vision or other programmes. Regarding VRQOL, we found low- or very tow-certainty evidence of imprecisely estimated benefit with psychological therapies and/or group programmes (SMD -0.23, 95% CI -0.53 to 0.08; studies = 2; I-2 = 24%) and methods of enhancing vision (SMD -0.19, 95% CI -0.54 to 0.15; participants = 262; studies = 5; I-2 = 34%). Two studies using multidisciplinary rehabilitation programmes showed beneficial but inconsistent results, of which one study, which was at low risk of bias and used intensive rehabilitation, recorded a very large and significant effect (SMD: -1.64, 95% CI -2.05 to -1.24), and the other a small and uncertain effect (SMD -0.42, 95%: -0.90 to 0.07).
   Compared to active comparators, we found very low-certainty evidence of small or no beneficial effects on HRQOL that were imprecisely estimated with psychological therapies and/or group programmes including no difference (SMD -0.09, 95% CI -0.39 to 0.20; participants = 600; studies = 4; I-2 = 67%). We also found very low-certainty evidence of small or no beneficial effects with methods of enhancing vision, that were imprecisely estimated (SMD -0.09, 95% CI -0.28 to 0.09; participants =443; studies = 2; I-2 = 0%) and multidisciplinary rehabilitation programmes (SMD -0.10, 95% CI -0.31 to 0.12; participants= 375; studies= 2; I-2 = 0%). Concerning VRQOL, low-certainty evidence of small or no beneficial effects that were imprecisely estimated, was found with psychological therapies and/or group programmes (SMD -0.11, 95% CI -0.24 to 0.01; participants= 1245; studies = 7; I-2 =19%) and moderate-certainty evidence of small effects with methods of enhancing vision (SMD -0.24, 95% CI -0.40 to -0.08; participants = 660; studies = 7; I-2 = 16%). No additional benefit was found with multidisciplinary rehabilitation programmes (SMD 0.01, 95% CI -0.18 to 0.20; participants = 464; studies= 3; I-2 = 0%; low-certainty evidence).
   Among secondary outcomes, very low-certainty evidence of a significant and large, but imprecisely estimated benefit on self-efficacy or self-esteem was found for psychological therapies and/or group programmes versus waiting list or no care (SMD -0.85, 95% CI -1.48 to -0.22; participants = 456; studies = 5; I-2 = 91%). In addition, very low-certainty evidence of a significant and large estimated benefit on depression was found for psychological therapies and/or group programmes versus waiting list or no care (SMD -1.23, 95% CI -2.18 to -0.28; participants =456; studies= 5; I-2 = 94%), and moderate-certainty evidence of a small benefit versus usual care (SMD -0.14, 95% CI -0.25 to -0.04; participants= 1334; studies= 9; I-2 = 0%). In the few studies in which (serious) adverse events were reported, these seemed unrelated to low vision rehabilitation.
   Among secondary outcomes, very low-certainty evidence of a significant and large, but imprecisely estimated benefit on self-efficacy or self-esteem was found for psychological therapies and/or group programmes versus waiting list or no care (SMD -0.85, 95% CI -1.48 to -0.22; participants = 456; studies = 5; I-2 = 91%). In addition, very low-certainty evidence of a significant and large estimated benefit on depression was found for psychological therapies and/or group programmes versus waiting list or no care (SMD -1.23, 95% CI -2.18 to -0.28; participants =456; studies= 5; I-2 = 94%), and moderate-certainty evidence of a small benefit versus usual care (SMD -0.14, 95% CI -0.25 to -0.04; participants= 1334; studies= 9; I-2 = 0%). In the few studies in which (serious) adverse events were reported, these seemed unrelated to low vision rehabilitation.
   Authors' conclusions
   In this Cochrane Review, no evidence of benefit was found of diverse types of low vision rehabilitation interventions on HRQOL. We found low- and moderate-certainty evidence, respectively, of a small benefit on VRQOL in studies comparing psychological therapies or methods for enhancing vision with active comparators.
   The type of rehabilitation varied among studies, even within intervention groups, but benefits were detected even if compared to active control groups. Studies were conducted on adults with visual impairment mainly of older age, living in high-income countries and often having AMD. Most of the included studies on low vision rehabilitation had a short follow-up,
   Despite these limitations, the consistent direction of the effects in this review towards benefit justifies further research activities of better methodological quality including longer maintenance effects and costs of several types of low vision rehabilitation. Research on the working mechanisms of components of rehabilitation interventions in different settings, including low-income countries, is also needed.
C1 [van Nispen, Ruth M. A.; Hoeben, Mirke; van Rens, Ger H. M. B.] Vrije Univ, Amsterdam Univ, Amsterdam Publ Hlth Res Inst, Dept Ophthalmol,Med Ctr, Amsterdam, Netherlands.
   [Virgili, Gianni] Univ Florence, Dept Neurosci Psychol Drug Res & Child Hlth NEURO, Florence, Italy.
   [Langelaan, Maaike] NIVEL Res, Netherlands Inst Hlth Serv, Utrecht, Netherlands.
   [Klevering, Jeroen; Keunen, Jan E. E.] Radboud Univ Nijmegen, Dept Ophthalmol, Med Ctr, Nijmegen, Netherlands.
   [van Rens, Ger H. M. B.] Elkerliek Hosp, Dept Ophthalmol, Helmond, Netherlands.
C3 University of Amsterdam; Vrije Universiteit Amsterdam; University of
   Florence; Netherlands Institute for Health Services Research; Radboud
   University Nijmegen
RP van Nispen, RMA (通讯作者)，Vrije Univ, Amsterdam Univ, Amsterdam Publ Hlth Res Inst, Dept Ophthalmol,Med Ctr, Amsterdam, Netherlands.
EM r.vannispen@vumc.nl
RI ; Virgili, Gianni/P-6607-2014
OI van Nispen, Ruth M.A./0000-0003-1227-1177; Virgili,
   Gianni/0000-0002-9960-2989
FU A.F. Deutman Ophthalmic Research Foundation, Nijmegen, Netherlands;
   National institute for Health Research (NIHR), UK; Department of Health
   through National Institute for Health Research; National Institute for
   Health Research via Cochrane Infrastructure funding
FX A.F. Deutman Ophthalmic Research Foundation, Nijmegen, Netherlands.;
   National institute for Health Research (NIHR), UK.; Richard Wormald,
   Co-ordinating Editor for Cochrane Eyes and Vision (CEV) acknowledges
   financial support for his CEV research sessions from the Department of
   Health through the award made by the National Institute for Health
   Research to Moorfields Eye Hospital NHS Foundation Trust and UCL
   Institute of Ophthalmology for a Specialist Biomedical Research Centre
   for Ophthalmology.; This review was supported by the National Institute
   for Health Research, via Cochrane Infrastructure funding to the CEV UK
   editorial base.; The views and opinions expressed therein are those of
   the authors and do not necessarily reflect those of the Systematic
   Reviews Programme, NIHR, NHS, or the Department of Health.
CR Acton JH, 2016, INVEST OPHTH VIS SCI, V57, P6662, DOI 10.1167/iovs.16-19901
   Acton JH, 2016, TRIALS, V17, DOI 10.1186/s13063-016-1235-2
   Adams N, 2018, BMC GERIATR, V18, DOI 10.1186/s12877-018-0998-6
   Aimola L, 2014, NEUROREHAB NEURAL RE, V28, P207, DOI 10.1177/1545968313503219
   Amtmann D, 2011, ARCH PHYS MED REHAB, V92, pS12, DOI 10.1016/j.apmr.2011.04.025
   ANTONUCCI G, 1995, J CLIN EXP NEUROPSYC, V17, P383, DOI 10.1080/01688639508405131
   Aslam AA, 2017, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD012040.pub2
   Ballemans J, 2012, BMC HEALTH SERV RES, V12, DOI 10.1186/1472-6963-12-141
   Ballinger R, 1996, OPTOMETRY, V71, P764
   Barker L, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD010987.pub2
   Bhatlawande S, 2014, IEEE T NEUR SYS REH, V22, P1148, DOI 10.1109/TNSRE.2014.2324974
   Binns AM, 2012, SURV OPHTHALMOL, V57, P34, DOI 10.1016/j.survophthal.2011.06.006
   Birk T, 2004, GERONTOLOGIST, V44, P836, DOI 10.1093/geront/44.6.836
   Birk T, 2004, Z GERONTOL GERIATR, V37, P363, DOI 10.1007/s00391-004-0261-y
   Boehm RG, 1985, THESIS
   Bookwala J, 2011, GERONTOLOGIST, V51, P798, DOI 10.1093/geront/gnr051
   Bourne RRA, 2017, LANCET GLOB HEALTH, V5, pE888, DOI 10.1016/S2214-109X(17)30293-0
   Bourne RRA, 2014, BRIT J OPHTHALMOL, V98, P629, DOI 10.1136/bjophthalmol-2013-304033
   Bowman EL, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0176534
   Bradley P, 2005, INT C SER, V1282, P211, DOI DOI 10.1016/J.ICS.2005.04.001
   Bray N, 2017, ACTA OPHTHALMOL, V95, pE415, DOI 10.1111/aos.13255
   Bressler NM, 2014, OPHTHALMOLOGY, V121, P2461, DOI 10.1016/j.ophtha.2014.07.008
   Brody BL, 2006, J AM GERIATR SOC, V54, P1557, DOI 10.1111/j.1532-5415.2006.00881.x
   Brody BL, 2002, ARCH OPHTHALMOL-CHIC, V120, P1477, DOI 10.1001/archopht.120.11.1477
   Brody BL, 2001, OPHTHALMOLOGY, V108, P1893, DOI 10.1016/S0161-6420(01)00754-0
   Brody BL, 1999, ANN BEHAV MED, V21, P322, DOI 10.1007/BF02895965
   Brown G, 2016, INVESTIGATIVE OPHTHA, V57
   Bruijning JE, 2013, OPTOMETRY VISION SCI, V90, P806, DOI 10.1097/OPX.0b013e318282cdce
   Brunnstrom G, 2004, OPHTHAL PHYSL OPT, V24, P274, DOI 10.1111/j.1475-1313.2004.00192.x
   Bryan JL, 2016, J HEALTH PSYCHOL, V21, P709, DOI 10.1177/1359105314536453
   Burggraaff MC, 2012, INVEST OPHTH VIS SCI, V53, P3645, DOI 10.1167/iovs.11-9226
   Burggraaff MC, 2012, INVEST OPHTH VIS SCI, V53, P2142, DOI 10.1167/iovs.11-8407
   Burggraaff MC, 2010, BMC HEALTH SERV RES, V10, DOI 10.1186/1472-6963-10-62
   Burggraaff MC, 2013, THESIS
   Campbell AJ, 2005, BMJ-BRIT MED J, V331, P817, DOI 10.1136/bmj.38601.447731.55
   Casten R, 2016, J VISUAL IMPAIR BLIN, V110, P413
   Cavanaugh MR, 2017, NEUROLOGY, V88, P1856, DOI 10.1212/WNL.0000000000003921
   Chebat DR, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0126307
   Chen EW, 2012, AGE AGEING, V41, P254, DOI 10.1093/ageing/afr146
   Christy B., 2012, THESIS
   Christy B, 2010, OPHTHAL EPIDEMIOL, V17, P203, DOI 10.3109/09286586.2010.483752
   Coco-Martin MB, 2017, CURR EYE RES, V42, P1260, DOI 10.1080/02713683.2017.1315140
   Coleman AL, 2006, J AM GERIATR SOC, V54, P883, DOI 10.1111/j.1532-5415.2006.00817.x
   Connors EC, 2014, FRONT HUM NEUROSCI, V8, DOI 10.3389/fnhum.2014.00223
   Conrod BE, 1998, J VISUAL IMPAIR BLIN, V92, P464, DOI 10.1177/0145482X9809200707
   Court H, 2011, BRIT J OPHTHALMOL, V95, P178, DOI 10.1136/bjo.2010.179606
   Culham LE, 2009, OPHTHAL PHYSL OPT, V29, P138, DOI 10.1111/j.1475-1313.2008.00630.x
   Dahlin-Ivanoff S, 1998, PATIENT EDUC COUNS, V34, P63, DOI 10.1016/S0738-3991(98)00041-X
   Dannenbaum E, 2010, ARCH PHYS MED REHAB, V91, pe49
   de Boer MR, 2006, OPHTHAL PHYSL OPT, V26, P535, DOI 10.1111/j.1475-1313.2006.00424.x
   de Boer MR, 2006, QUAL LIFE RES, V15, P233, DOI 10.1007/s11136-005-1524-9
   de Haan GA, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0134459
   Deemer AD, 2017, INVEST OPHTH VIS SCI, V58, P1514, DOI 10.1167/iovs.16-20001
   Dillon L, 2018, BMC HEALTH SERV RES, V18, DOI 10.1186/s12913-018-3304-6
   Draper EM, 2016, OPTOMETRY VISION SCI, V93, P673, DOI 10.1097/OPX.0000000000000870
   Dunbar HMP, 2012, OPHTHAL PHYSL OPT, V32, P282, DOI 10.1111/j.1475-1313.2012.00914.x
   Dunbar HMP, 2013, THESIS
   Eklund K, 2005, DISABIL REHABIL, V27, P1203, DOI 10.1080/09638280500052716
   Eklund K, 2004, DISABIL REHABIL, V26, P401, DOI 10.1080/09638280410001662950
   Eklund K, 2008, SCAND J OCCUP THER, V15, P68, DOI 10.1080/11038120701442963
   Eklund K, 2007, DISABIL REHABIL-ASSI, V2, P326, DOI 10.1080/17483100701714717
   Elliott AF, 2014, OPHTHAL PHYSL OPT, V34, P509, DOI 10.1111/opo.12148
   Elshout JA, 2018, RESTOR NEUROL NEUROS, V36, P1, DOI 10.3233/RNN-170719
   Elshout JA, 2016, FRONT NEUROL, V7, DOI 10.3389/fneur.2016.00092
   Elsman EBM, 2019, SURV OPHTHALMOL, V64, P512, DOI 10.1016/j.survophthal.2019.01.010
   Flores G, 2015, IEEE T HAPTICS, V8, P306, DOI 10.1109/TOH.2015.2409980
   George S, 2011, BMC NEUROL, V11, DOI 10.1186/1471-2377-11-87
   Girdler SJ, 2010, BRIT J OPHTHALMOL, V94, P223, DOI 10.1136/bjo.2008.147538
   Glanville JM, 2006, J MED LIBR ASSOC, V94, P130
   Gleeson M, 2015, CLIN REHABIL, V29, P244, DOI 10.1177/0269215514542636
   Gleeson M, 2014, INJURY PREV, V20, DOI 10.1136/injuryprev-2012-040726
   Goldstein RB, 2007, OPTOMETRY VISION SCI, V84, P208, DOI 10.1097/OPX.0b013e3180339a03
   Gopinath B, 2017, BMJ OPEN, V7, DOI 10.1136/bmjopen-2017-018204
   Griffin-Shirley N., 1994, DISS ABSTR INT, V54, P2805
   Grue EV, 2009, J MULTIDISCIP HEALTH, V2, P1
   Hackney ME, 2015, J AGING PHYS ACTIV, V23, P630, DOI 10.1123/japa.2014-0008
   Hayman KJ, 2007, OPTOMETRY VISION SCI, V84, P1024, DOI 10.1097/OPX.0b013e318157a6b1
   HIGGINS JPT, 2011, COCHRANE HDB SYSTEMA, V0001
   Holloway EE, 2018, TRIALS, V19, DOI 10.1186/s13063-018-3025-5
   Ivanoff SD, 2002, AM J OCCUP THER, V56, P322, DOI 10.5014/ajot.56.3.322
   Ivanov I, 2013, INVEST OPHTH VIS SCI, V54
   Ivanov IV, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0157825
   Jackson Mary Lou, 2017, Digit J Ophthalmol, V23, P1, DOI 10.5693/djo.01.2017.02.001
   Jalali MDM, 2014, J RATION-EMOT COGN-B, V32, P233, DOI 10.1007/s10942-014-0191-6
   Kaltenegger K, 2019, GRAEF ARCH CLIN EXP, V257, P1499, DOI 10.1007/s00417-019-04328-9
   Kaltenegger K, 2016, INVEST OPHTH VIS SCI, V57
   Kaluza G, 1996, J BEHAV MED, V19, P587, DOI 10.1007/BF01904906
   Kamga H, 2017, CLIN EXP OPHTHALMOL, V45, P371, DOI 10.1111/ceo.12890
   KASTEN E, 1995, RESTOR NEUROL NEUROS, V8, P113, DOI 10.3233/RNN-1995-8302
   Keay L, 2018, INJURY PREV, V24, P459, DOI 10.1136/injuryprev-2016-042301
   Keay LJ, 2014, INVESTIGATIVE OPHTHA, V55
   Kempen GIJM, 2012, QUAL LIFE RES, V21, P1405, DOI 10.1007/s11136-011-0061-y
   Kerkhoff G, 2014, NEUROREHAB NEURAL RE, V28, P554, DOI 10.1177/1545968313517757
   Kim DS, 2016, J VISUAL IMPAIR BLIN, V110, P53
   Kim DS, 2014, J VISUAL IMPAIR BLIN, V108, P335
   La Grow SJ, 2004, J VISUAL IMPAIR BLIN, V98, P679, DOI 10.1177/0145482X0409801103
   Langelaan M, 2007, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD006543, DOI 10.1002/14651858.CD006543]
   Leat SJ, 2017, J VISUAL IMPAIR BLIN, V111, P354
   Lim YE, 2014, J VISUAL IMPAIR BLIN, V108, P311
   Lipkova J, 2008, ACTIVITAS NERVOSA SU, V50, P15
   Lundqvist LO, 2014, ARCH PHYS MED REHAB, V95, P1656, DOI 10.1016/j.apmr.2014.05.013
   Maghami Mohammad Hossein, 2014, J Ophthalmic Vis Res, V9, P494, DOI 10.4103/2008-322X.150830
   Margrain TH, 2012, BMC PSYCHIATRY, V12, DOI 10.1186/1471-244X-12-57
   Massof RW, 2007, INVEST OPHTH VIS SCI, V48, P4955, DOI 10.1167/iovs.06-0566
   Massof RW, 2005, ARCH PHYS MED REHAB, V86, P946, DOI 10.1016/j.apmr.2004.09.016
   Massof RW, 2001, SURV OPHTHALMOL, V45, P531, DOI 10.1016/S0039-6257(01)00194-1
   McCabe P, 2000, Ophthalmic Epidemiol, V7, P259, DOI 10.1076/opep.7.4.259.4173
   McKeague C, 2014, TRIALS, V15, DOI 10.1186/1745-6215-15-246
   Mielke A, 2013, OPHTHALMOLOGE, V110, P433, DOI 10.1007/s00347-012-2715-8
   Nelles G, 2001, NEUROSCI LETT, V306, P189, DOI 10.1016/S0304-3940(01)01907-3
   Nguyen NX, 2011, ACTA OPHTHALMOL, V89, pE82, DOI 10.1111/j.1755-3768.2010.02081.x
   Nollett CL, 2016, INVEST OPHTH VIS SCI, V57, P4247, DOI 10.1167/iovs.16-19345
   Ovvsley C, 2009, ARCH OPHTHALMOL-CHIC, V127, P681
   Pankow L, 2004, TOP GERIATR REHABIL, V20, P223
   Pascolini D, 2012, BRIT J OPHTHALMOL, V96, P614, DOI 10.1136/bjophthalmol-2011-300539
   Patodia Y, 2017, CLIN OPHTHALMOL, V11, P683, DOI 10.2147/OPTH.S128425
   Pearce E, 2011, BRIT J OPHTHALMOL, V95, P105, DOI 10.1136/bjo.2009.175703
   Pesudovs K., 2007, BMC OPHTHALMOLOGY, V6, P25
   Peterson RC, 2003, AM J OPHTHALMOL, V136, P1129, DOI 10.1016/S0002-9394(03)00567-1
   Pinniger R, 2013, BRIT J VISUAL IMPA, V31, P47, DOI 10.1177/0264619612470651
   Plow EB, 2012, NEUROREHAB NEURAL RE, V26, P616, DOI 10.1177/1545968311431963
   Pollock A, 2011, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD008389.pub2
   Rees G, 2015, PATIENT EDUC COUNS, V98, P174, DOI 10.1016/j.pec.2014.11.008
   Rees G, 2013, OPHTHAL EPIDEMIOL, V20, P321, DOI 10.3109/09286586.2013.787102
   Reeves BC, 2004, BRIT J OPHTHALMOL, V88, P1443, DOI 10.1136/bjo.2003.037457
   Riazi A, 2014, OPHTHAL PHYSL OPT, V34, P489, DOI 10.1111/opo.12135
   Riley SK, 2016, INVEST OPHTH VIS SCI, V57
   Riley SK, 2017, INVESTIGATIVE OPHTHA, V56
   Robinson DG, 2018, INVEST OPHTH VIS SCI, V59, P4531, DOI 10.1167/iovs.18-24284
   Roentgen UR, 2012, ASSIST TECHNOL, V24, P110, DOI 10.1080/10400435.2012.659794
   Roets-Merken LM, 2015, CLIN REHABIL, V29, P107, DOI 10.1177/0269215514542639
   ROSSI PW, 1990, NEUROLOGY, V40, P1597, DOI 10.1212/WNL.40.10.1597
   Roth T, 2009, NEUROLOGY, V72, P324, DOI 10.1212/01.wnl.0000341276.65721.f2
   Rovner BW, 2008, AM J GERIAT PSYCHIAT, V16, P454, DOI 10.1097/JGP.0b013e31816b7342
   Rovner BW, 2007, ARCH GEN PSYCHIAT, V64, P886, DOI 10.1001/archpsyc.64.8.886
   Rovner BW, 2014, OPHTHALMOLOGY, V121, P2204, DOI 10.1016/j.ophtha.2014.05.002
   Rovner BW, 2013, OPHTHALMOLOGY, V120, P1649, DOI 10.1016/j.ophtha.2013.01.022
   Rovner BW, 2011, CONTEMP CLIN TRIALS, V32, P196, DOI 10.1016/j.cct.2010.10.008
   Rowe B., 2015, NEUROOPHTHALMOLOGY, V39, pS47
   Rowe F, 2015, INT J STROKE, V10, P12
   Rowe FJ, 2017, ACTA NEUROL SCAND, V136, P310, DOI 10.1111/ane.12725
   Rowe FJ, 2014, BMJ OPEN, V4, DOI 10.1136/bmjopen-2014-005885
   Rowe FJ, 2016, NEURO-OPHTHALMOLOGY, V40, P1, DOI 10.3109/01658107.2015.1126288
   Rumrill P.D., 1999, J VOCATIONAL REHABIL, V12, P25
   Russell W, 2001, OPHTHAL PHYSL OPT, V21, P36, DOI 10.1046/j.1475-1313.2001.00569.x
   Sabel BA, 2014, JAMA OPHTHALMOL, V132, P381, DOI 10.1001/jamaophthalmol.2013.7963
   Samoocha David, 2010, J Med Internet Res, V12, pe23, DOI 10.2196/jmir.1286
   Scanlan JM, 2004, J VISUAL IMPAIR BLIN, V98, P601, DOI 10.1177/0145482X0409801005
   Schinzel J, 2012, TRIALS, V13, DOI 10.1186/1745-6215-13-94
   Scott IU, 1999, AM J OPHTHALMOL, V128, P54, DOI 10.1016/S0002-9394(99)00108-7
   Seiple W, 2011, INVEST OPHTH VIS SCI, V52, P2938, DOI 10.1167/iovs.10-6137
   Seki Y, 2011, IEEE T NEUR SYS REH, V19, P95, DOI 10.1109/TNSRE.2010.2064791
   Skelton DA, 2016, BMJ OPEN, V6, DOI 10.1136/bmjopen-2016-011996
   Skelton DA, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD009233.pub2
   Smith HJ, 2005, ARCH OPHTHALMOL-CHIC, V123, P1042, DOI 10.1001/archopht.123.8.1042
   Sorensen S, 2015, CONTEMP CLIN TRIALS, V42, P68, DOI 10.1016/j.cct.2015.03.007
   Soong GP, 2001, OPTOMETRY VISION SCI, V78, P657, DOI 10.1097/00006324-200109000-00011
   Stelmack J, 2001, OPTOMETRY VISION SCI, V78, P335, DOI 10.1097/00006324-200105000-00017
   Stelmack JA, 2002, INVEST OPHTH VIS SCI, V43, P2859
   Stelmack JA, 2008, ARCH OPHTHALMOL-CHIC, V126, P608, DOI 10.1001/archopht.126.5.608
   Stelmack JA, 2007, CLIN TRIALS, V4, P650, DOI 10.1177/1740774507085274
   Stelmack JA, 2017, JAMA OPHTHALMOL, V135, P96, DOI 10.1001/jamaophthalmol.2016.4742
   Stelmack JA, 2012, OPHTHAL PHYSL OPT, V32, P461, DOI 10.1111/j.1475-1313.2012.00933.x
   Stelmack JA, 2012, ARCH OPHTHALMOL-CHIC, V130, P1162, DOI 10.1001/archophthalmol.2012.1820
   Stroupe KT, 2008, OPHTHAL EPIDEMIOL, V15, P84, DOI 10.1080/09286580802027836
   Stroupe KT, 2018, JAMA OPHTHALMOL, V136, P524, DOI 10.1001/jamaophthalmol.2018.0797
   Sun W, 2012, INT EYE SCI, V12, P1619
   Szlyk JP, 1998, OPTOMETRY VISION SCI, V75, P518, DOI 10.1097/00006324-199807000-00021
   Szlyk JP, 2000, J REHABIL RES DEV, V37, P101
   Taylor J, 2014, OPHTHAL PHYSL OPT, V34, P558, DOI 10.1111/opo.12149
   Taylor JJ, 2017, OPHTHAL PHYSL OPT, V37, P370, DOI 10.1111/opo.12379
   Taylor L, 2011, CLIN REHABIL, V25, P43, DOI 10.1177/0269215510375918
   Tey CS, 2019, PATIENT EDUC COUNS, V102, P1150, DOI 10.1016/j.pec.2019.01.014
   Trozzolino L, 2003, J VISUAL IMPAIR BLIN, V97, P230, DOI 10.1177/0145482X0309700404
   Ueda Y, 2013, JPN PSYCHOL RES, V55, P229, DOI 10.1111/jpr.12010
   van der Aa HPA, 2017, BMJ OPEN, V7, DOI 10.1136/bmjopen-2017-018149
   van der Aa HPA, 2017, BMC PSYCHIATRY, V17, DOI 10.1186/s12888-017-1437-5
   van der Aa HPA, 2015, BMJ-BRIT MED J, V351, DOI 10.1136/bmj.h6127
   van der Aa HPA, 2015, QUAL LIFE RES, V24, P2885, DOI 10.1007/s11136-015-1032-5
   van der Aa HPA, 2013, BMC PSYCHIATRY, V13, DOI 10.1186/1471-244X-13-209
   Van Nispen RMA, 2007, OPTOMETRY VISION SCI, V84, P710, DOI 10.1097/OPX.0b013e31813375b8
   van Nispen RMA, 2010, J CLIN EPIDEMIOL, V63, P321, DOI 10.1016/j.jclinepi.2009.06.012
   van Nispen RMA, 2009, HEALTH QUAL LIFE OUT, V7, DOI 10.1186/1477-7525-7-18
   Virgili G, 2010, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD0039251, DOI 10.1002/14651858.CD0039251]
   Virgili G, 2018, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003303.pub4
   Vreeken HL, 2015, EAR HEARING, V36, pe166, DOI 10.1097/AUD.0000000000000153
   Vreeken HL, 2013, BMC GERIATR, V13, DOI 10.1186/1471-2318-13-84
   Vukicevic M, 2009, J VISUAL IMPAIR BLIN, V103, P277, DOI 10.1177/0145482X0910300506
   Wahl HW, 2006, J VISUAL IMPAIR BLIN, V100, P533
   Waterman H, 2016, TRIALS, V17, DOI 10.1186/s13063-016-1565-0
   West SK, 2003, OPHTHALMIC EPIDEMIOL, V10, P193, DOI 10.1076/opep.10.3.193.15081
   Wittich W, 2018, OPTOMETRY VISION SCI, V95, P774, DOI 10.1097/OPX.0000000000001262
   World Health Organisation, 2015, INT STAND VIS REH IN
   Zijlstra GAR, 2009, BMC HEALTH SERV RES, V9, DOI 10.1186/1472-6963-9-153
NR 194
TC 27
Z9 27
U1 2
U2 21
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1469-493X
EI 1361-6137
J9 COCHRANE DB SYST REV
JI Cochrane Database Syst Rev.
PY 2020
IS 1
AR CD006543
DI 10.1002/14651858.CD006543.pub2
PG 146
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)
SC General & Internal Medicine
GA KH1HW
UT WOS:000510398500002
PM 31985055
OA Green Published
DA 2022-11-30
ER

PT J
AU Viggiano, P
   Grassi, MO
   Boscia, G
   Pignataro, M
   Petruzzella, G
   Borrelli, E
   Molfetta, T
   Alessio, G
   Boscia, F
AF Viggiano, Pasquale
   Grassi, Maria Oliva
   Boscia, Giacomo
   Pignataro, Mariagrazia
   Petruzzella, Giovanni
   Borrelli, Enrico
   Molfetta, Teresa
   Alessio, Giovanni
   Boscia, Francesco
TI Short-Term Morphofunctional Changes in Previously Treated Neovascular
   AMD Eyes Switched to Brolucizumab
SO JOURNAL OF CLINICAL MEDICINE
LA English
DT Article
DE age-related macular degeneration; neovascular age-related macular
   degeneration; optical coherence tomography; retinal disease;
   brolucizumab
ID SUBFOVEAL CHOROIDAL NEOVASCULARIZATION; TRIAL INCLUDING LESIONS; MACULAR
   DEGENERATION; INTRAVITREAL AFLIBERCEPT; RANIBIZUMAB INJECTIONS;
   VERTEPORFIN THERAPY; NATURAL-HISTORY; THICKNESS; OCCULT
AB The purpose of the study is to explore the morphofunctional fluctuations in eyes treated for neovascular AMD (nAMD) when treatment is switched from aflibercept or ranibizumab to brolucizumab. A total of 31 eyes of 31 patients with nAMD with type 1 macular neovascularization (MNV) were included. All patients were imaged using spectral domain optical coherence tomography (SD-OCT). The OCT acquisition was performed at the following visits: (i) "T1 visit" corresponding to the last follow-up examination in which an intravitreal injection of aflibercept or ranibizumab was performed before switching to brolucizumab because of the lack of improvement and (ii) "T2 visit" corresponding to the examination performed 1 month after T1, the latter visit corresponding to the day when a switch to brolucizumab injection was performed, (iii) and 1 month after the latter injection "(T3)". The main outcome measures were: (1) central macular thickness (CMT), (2) choroidal vascularity index (CVI), (3) subfoveal choroidal thickness (CT), and best-corrected visual acuity (BCVA). Functional outcome showed significant differences at each time. Mean +/- SD BCVA was 0.43 +/- 0.12 LogMAR at T1 and 0.56 +/- 0.16 LogMAR at T2 (p = 0.038). A significant improvement in BCVA was displayed at T3 (0.34 +/- 0.21 LogMAR) as compared with T2 (p = 0.019). CMT analysis showed fluctuations three times. In detail, T2 displayed a thicker CMT in comparison with T1, although not statistically significant (p = 0.12). Contrariwise, T3 showed a thinner CMT in comparison with T2 (p = 0.002). Analyzing CVI among the three different times, the luminal choroidal area (LCA) and total choroidal area (TCA) showed significantly different values before and after switching to brolucizumab. T2 showed a significant reduction in both vessel lumen and total area compared with T1 (p = 0.032 and p = 0.046, respectively). Moreover, T3 showed a greater value of both LCA and TCA in comparison with T2 (p = 0.008 and p = 0.01, respectively). CT did not show significant differences at each time (p > 0.05). Our results reported early experiences on morphofunctional fluctuations in patients with nAMD who switched to brolucizumab. The anatomical impact of brolucizumab administration appears to result in choroidal vascular enlargement, accompanied by the resolution of subretinal fluid (SRF) and intraretinal fluid (IRF).
C1 [Viggiano, Pasquale; Grassi, Maria Oliva; Pignataro, Mariagrazia; Petruzzella, Giovanni; Molfetta, Teresa; Alessio, Giovanni; Boscia, Francesco] Univ Bari Aldo Moro, Dept Basic Med Sci Neurosci & Sense Organs, I-70121 Bari, Italy.
   [Boscia, Giacomo] Univ Turin, Dept Surg Sci, Ophthalmol Unit, AOU City Hlth & Sci Turin, I-10124 Turin, Italy.
   [Borrelli, Enrico] San Raffaele Univ Hosp, Ophthalmol Dept, I-20132 Milan, Italy.
C3 Universita degli Studi di Bari Aldo Moro; A.O.U. Citta della Salute e
   della Scienza di Torino; University of Turin; Vita-Salute San Raffaele
   University; IRCCS Ospedale San Raffaele
RP Viggiano, P (通讯作者)，Univ Bari Aldo Moro, Dept Basic Med Sci Neurosci & Sense Organs, I-70121 Bari, Italy.
EM pasquale.viggiano90@gmail.com
RI ; Boscia, Giacomo/ABC-9093-2021
OI Grassi, Maria Oliva/0000-0002-5952-7910; Borrelli,
   Enrico/0000-0003-2815-5031; Boscia, Giacomo/0000-0002-8768-899X
CR Agarwal A, 2018, OCUL IMMUNOL INFLAMM, V26, P838, DOI 10.1080/09273948.2017.1370650
   Agrawal R, 2016, SCI REP-UK, V6, DOI 10.1038/srep21090
   [Anonymous], 1993, Arch Ophthalmol, V111, P1200
   Arnold J, 2001, AM J OPHTHALMOL, V131, P541
   Avaylon J, 2020, INT MED CASE REP J, V13, P145, DOI 10.2147/IMCRJ.S252260
   Baumal CR, 2020, OPHTHALMOLOGY, V127, P1345, DOI 10.1016/j.ophtha.2020.04.017
   Bressler NM, 2002, AM J OPHTHALMOL, V133, P168, DOI 10.1016/S0002-9394(01)01237-5
   Bulirsch LM, 2022, BRIT J OPHTHALMOL, V106, P1288, DOI 10.1136/bjophthalmol-2020-318672
   Dugel PU, 2020, OPHTHALMOLOGY, V127, P72, DOI 10.1016/j.ophtha.2019.04.017
   Eghoj MS, 2012, BRIT J OPHTHALMOL, V96, P21, DOI 10.1136/bjo.2011.203893
   Ellabban AA, 2012, CLIN OPHTHALMOL, V6, P837, DOI 10.2147/OPTH.S30907
   Ersoz MG, 2021, RETINA-J RET VIT DIS, V41, P1723, DOI 10.1097/IAE.0000000000003086
   Evans RN, 2020, JAMA OPHTHALMOL, V138, P1043, DOI 10.1001/jamaophthalmol.2020.3001
   Freund KB, 2015, RETINA-J RET VIT DIS, V35, P1489, DOI 10.1097/IAE.0000000000000627
   Haug Sara J, 2020, Am J Ophthalmol Case Rep, V18, P100680, DOI 10.1016/j.ajoc.2020.100680
   Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006
   Holz FG, 2016, OPHTHALMOLOGY, V123, P1080, DOI 10.1016/j.ophtha.2015.12.030
   KAHN HA, 1977, AM J EPIDEMIOL, V106, P17, DOI 10.1093/oxfordjournals.aje.a112428
   Matsumoto H, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-86014-7
   Mones J, 2021, OPHTHALMOLOGY, V128, P1050, DOI 10.1016/j.ophtha.2020.11.011
   Morimoto M, 2017, GRAEF ARCH CLIN EXP, V255, P1891, DOI 10.1007/s00417-017-3718-6
   Pauleikhoff D, 2005, RETINA-J RET VIT DIS, V25, P1065, DOI 10.1097/00006982-200512000-00016
   Pellegrini M, 2021, GRAEF ARCH CLIN EXP, V259, P911, DOI 10.1007/s00417-020-04957-5
   Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481
   Sacconi R, 2022, EYE, DOI 10.1038/s41433-021-01889-0
   Schmidt-Erfurth U, 2016, PROG RETIN EYE RES, V50, P1, DOI 10.1016/j.preteyeres.2015.07.007
   Sharma A, 2021, EYE, V35, P1045, DOI 10.1038/s41433-020-1111-x
   Sonoda S, 2015, AM J OPHTHALMOL, V159, P1123, DOI 10.1016/j.ajo.2015.03.005
   Spaide RF, 2020, OPHTHALMOLOGY, V127, P616, DOI 10.1016/j.ophtha.2019.11.004
   Tamashiro T, 2022, GRAEF ARCH CLIN EXP, V260, P1857, DOI 10.1007/s00417-021-05517-1
   Viggiano P, 2022, EUR J OPHTHALMOL, V32, P460, DOI 10.1177/1120672121992009
   Vupparaboina KK, 2015, COMPUT MED IMAG GRAP, V46, P315, DOI 10.1016/j.compmedimag.2015.09.008
   Wong T, 2008, OPHTHALMOLOGY, V115, P116, DOI 10.1016/j.ophtha.2007.03.008
   Yamazaki T, 2012, OPHTHALMOLOGY, V119, P1621, DOI 10.1016/j.ophtha.2012.02.022
   Yun C, 2016, GRAEF ARCH CLIN EXP, V254, P1693, DOI 10.1007/s00417-015-3260-3
NR 35
TC 0
Z9 0
U1 1
U2 1
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2077-0383
J9 J CLIN MED
JI J. Clin. Med.
PD OCT
PY 2022
VL 11
IS 19
AR 5517
DI 10.3390/jcm11195517
PG 9
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA 5G5EZ
UT WOS:000867023200001
PM 36233385
OA gold, Green Published, Green Submitted
DA 2022-11-30
ER

PT J
AU Arora, S
   Maltsev, DS
   Sahoo, NK
   Parameshwarappa, DC
   Iovino, C
   Arora, T
   Kulikov, AN
   Tatti, F
   Vankatesh, R
   Reddy, NG
   Pulipaka, RS
   Singh, SR
   Peiretti, E
   Chhablani, J
AF Arora, Supriya
   Maltsev, Dmitrii S.
   Sahoo, Niroj Kumar
   Parameshwarappa, Deepika C.
   Iovino, Claudio
   Arora, Tarun
   Kulikov, Alexei N.
   Tatti, Filippo
   Vankatesh, Ramesh
   Reddy, Nikitha Gurram
   Pulipaka, Ram Snehith
   Singh, Sumit Randhir
   Peiretti, Enrico
   Chhablani, Jay
TI Visual acuity correlates with multimodal imaging-based categories of
   central serous chorioretinopathy
SO EYE
LA English
DT Article
ID OPTICAL COHERENCE TOMOGRAPHY; TERM FOLLOW-UP; SUBRETINAL FLUID;
   DETACHMENTS; ANGIOGRAPHY
AB Objective To evaluate visual acuity (VA) and factors influencing VA using new multimodal imaging-based classification of central serous chorioretinopathy (CSCR). Methods Retrospective, observational and cross-sectional study on 229 naive eyes diagnosed as CSCR with available baseline data and multimodal imaging. Each case was classified into (i) simple/complex/atypical; (ii) primary/recurrent/resolved; (iii) persistent or not; (iv) outer retinal atrophy(ORA) present/absent; (v) foveal involvement present/absent; and (vi) macular neovascularization(MNV) present/absent. Best corrected visual acuity (BCVA) was correlated to the classification as well as every parameter of the classification. Results Median BCVA was 0.18 logMAR [95% Confidence Interval (CI)0.16-0.18] with median duration of complaints of one month (95% CI,6.14-13.0 months). Age of the patient (r = -0.24, p = 0.002) and duration of the disease (r = -0.32, p < 0.001) correlated significantly with BCVA. Logistic regression model showed that older age [odds ratio (OR) = 0.96, p = 0.05], female gender (OR = 2.45, p = 0.046), presence of ORA(OR = 0.34, p = 0.012),and foveal involvement(OR = 0.18, p = 0.007) were statistically significantly associated with poorer BCVA. Eyes classified as complex, persistent CSCR, with ORA or foveal involvement demonstrated lower BCVA compared to those with simple, non-persistent CSCR, without ORA or without foveal involvement (p < 0.05). Eyes with complex CSCR (p < 0.001), atypical CSCR(p = 0.025), persistent subretinal fluid (SRF) (p = 0.001) and those with ORA (p < 0.001) demonstrated a trend towards severe visual loss. Prevalence of persistent SRF, recurrent episodes and ORA was significantly higher among eyes with complex CSCR (p < 0.001) while there was no difference in prevalence of resolved cases (p = 0.07), foveal involvement (p = 0.28) and MNV (p = 0.45) between simple and complex cases. Conclusion There is a strong correlation between VA and foveal involvement and ORA using the new classification. Thus, the objective parameters of the classification can be incorporated in establishing the treatment guidelines for CSCR.
C1 [Arora, Supriya; Arora, Tarun] Bahamas Vis Ctr, Nassau, NP, Bahamas.
   [Arora, Supriya; Arora, Tarun] Princess Margaret Hosp, Nassau, NP, Bahamas.
   [Maltsev, Dmitrii S.; Kulikov, Alexei N.] Mil Med Acad, Dept Ophthalmol, St Petersburg, Russia.
   [Sahoo, Niroj Kumar] LV Prasad Eye Inst, Dept Retina & Vitreous, Vijayawada, India.
   [Parameshwarappa, Deepika C.] LV Prasad Eye Inst, Smt Kanuri Santhamma Ctr Vitreoretinal Dis, Hyderabad, India.
   [Iovino, Claudio; Tatti, Filippo; Peiretti, Enrico] Univ Cagliari, Dept Surg Sci, Eye Clin, Cagliari, Italy.
   [Vankatesh, Ramesh; Reddy, Nikitha Gurram; Pulipaka, Ram Snehith] Narayana Nethralaya, Dept Retina & Vitreous, Bengaluru, India.
   [Singh, Sumit Randhir] Univ Calif San Diego, Jacobs Retina Ctr, Shiley Eye Ctr, La Jolla, CA 92093 USA.
   [Chhablani, Jay] Univ Pittsburgh, UPMC Eye Ctr, Pittsburgh, PA 15260 USA.
C3 L. V. Prasad Eye Institute; L. V. Prasad Eye Institute; University of
   Cagliari; University of California System; University of California San
   Diego; Pennsylvania Commonwealth System of Higher Education (PCSHE);
   University of Pittsburgh
RP Chhablani, J (通讯作者)，Univ Pittsburgh, UPMC Eye Ctr, Pittsburgh, PA 15260 USA.
EM jay.chhablani@gmail.com
RI Maltsev, Dmitrii/AAA-9100-2022; Sahoo, Niroj/AHD-3438-2022; Sahoo,
   Niroj/AHD-3511-2022
OI Tatti, Filippo/0000-0002-8630-0367; Sahoo, Niroj
   Kumar/0000-0003-0011-2507; Venkatesh, Ramesh/0000-0002-4479-9390
CR Aggio FB, 2010, RETINA-J RET VIT DIS, V30, P1128, DOI 10.1097/IAE.0b013e3181cdf381
   Arora S, 2022, EUR J OPHTHALMOL, V32, P1044, DOI 10.1177/11206721211013651
   Bonini MA, 2015, JAMA OPHTHALMOL, V133, P899, DOI 10.1001/jamaophthalmol.2015.1320
   Borrelli E, 2021, AM J OPHTHALMOL, V223, P129, DOI 10.1016/j.ajo.2020.10.011
   Bousquet E, 2018, RETINA-J RET VIT DIS, V38, P629, DOI 10.1097/IAE.0000000000001580
   Chhablani J, 2020, OPHTHALMOL RETINA, V4, P1043, DOI 10.1016/j.oret.2020.07.026
   Dansingani KK, 2015, AM J OPHTHALMOL, V160, P1243, DOI 10.1016/j.ajo.2015.08.028
   Daruich A, 2015, PROG RETIN EYE RES, V48, P82, DOI 10.1016/j.preteyeres.2015.05.003
   Gianniou C, 2015, RETINA-J RET VIT DIS, V35, P1195, DOI 10.1097/IAE.0000000000000465
   GILBERT CM, 1984, BRIT J OPHTHALMOL, V68, P815, DOI 10.1136/bjo.68.11.815
   GOVINDAHARI V, 2019, SCI REP-UK, V9
   Han J, 2020, RETINA-J RET VIT DIS, V40, P1387, DOI 10.1097/IAE.0000000000002580
   Imamura Y, 2011, OPHTHALMOLOGY, V118, P700, DOI 10.1016/j.ophtha.2010.08.017
   Kaye R, 2020, PROG RETIN EYE RES, V79, DOI 10.1016/j.preteyeres.2020.100865
   Loo RH, 2002, RETINA-J RET VIT DIS, V22, P19, DOI 10.1097/00006982-200202000-00004
   Matsumoto H, 2009, AM J OPHTHALMOL, V148, P105, DOI 10.1016/j.ajo.2009.01.018
   Mohabati D, 2018, CLIN OPHTHALMOL, V12, P1061, DOI 10.2147/OPTH.S160956
   Mrejen S, 2019, OPHTHALMOLOGY, V126, P576, DOI 10.1016/j.ophtha.2018.12.048
   Nicholson BP, 2018, SEMIN OPHTHALMOL, V33, P804, DOI 10.1080/08820538.2018.1503690
   Piccolino FC, 2005, AM J OPHTHALMOL, V139, P87, DOI 10.1016/j.ajo.2004.08.037
   Quaranta-El Maftouhi M, 2015, AM J OPHTHALMOL, V160, P581, DOI 10.1016/j.ajo.2015.06.016
   SIEDLECKI J, 2020, SCI REP-UK, V10
   Singh SR, 2022, BRIT J OPHTHALMOL, V106, P553, DOI 10.1136/bjophthalmol-2020-317422
   Singh SR, 2019, BRIT J OPHTHALMOL, V103, P737, DOI 10.1136/bjophthalmol-2018-312435
   Spaide RF, 1996, OPHTHALMOLOGY, V103, P2070, DOI 10.1016/S0161-6420(96)30386-2
   Suwal B, 2019, CLIN OPHTHALMOL, V13, P2439, DOI 10.2147/OPTH.S233273
   van Rijssen TJ, 2019, PROG RETIN EYE RES, V73, DOI 10.1016/j.preteyeres.2019.07.003
   Yalcinbayir O, 2014, RETINA-J RET VIT DIS, V34, P705, DOI 10.1097/IAE.0000000000000001
   YANNUZZI LA, 1984, OPHTHALMOLOGY, V91, P1554
NR 29
TC 3
Z9 3
U1 0
U2 0
PU SPRINGERNATURE
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND
SN 0950-222X
EI 1476-5454
J9 EYE
JI Eye
PD MAR
PY 2022
VL 36
IS 3
BP 517
EP 523
DI 10.1038/s41433-021-01788-4
EA OCT 2021
PG 7
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA ZH5FE
UT WOS:000706925300004
PM 34645969
DA 2022-11-30
ER

PT J
AU Babizhayev, MA
   Burke, L
   Micans, P
   Richer, SP
AF Babizhayev, Mark A.
   Burke, Leslie
   Micans, Philip
   Richer, Stuart P.
TI N-Acetylcarnosine sustained drug delivery eye drops to control the signs
   of ageless vision: Glare sensitivity, cataract amelioration and quality
   of vision currently available treatment for the challenging
   50,000-patient population
SO CLINICAL INTERVENTIONS IN AGING
LA English
DT Article
DE age-related ophthalmic diseases; cataract; disability-glare; halos;
   Halometer; visual-acuity; N-acetylcarnosine lubricant eye drops;
   repurchase behavior analysis; 50,000-patients' compliance to
   self-administer eye drops
ID HISTIDINE-CONTAINING DIPEPTIDE; VISUAL-ACUITY; L-CARNOSINE; DISABILITY;
   DRIVERS
AB Background: Innovative Vision Products, Inc. (IVP)'s scientists developed the lubricant eye drops (Can-C (TM)) designed as 1% N-acetylcarnosine (NAC) prodrug of L-carnosine containing a mucoadhesive cellulose-based compound combined with corneal absorption promoters in a sustained drug delivery system. Only the natural L-isomeric form of NAC raw material was specifically synthesized at the cGMP facility and employed for the manufacturing of Can-C (TM) eye drops.
   Objective and study design: In the present clinical study the authors assessed vision before and after 9 month term of topical ocular administration of NAC lubricant eye drops or placebo in 75 symptomatic patients with age-related uncomplicated cataracts in one or both eyes, with acuity in one eye of 20/40 or worse (best-corrected distance), and no previous cataract surgery in either eye and no other ocular abnormality and 72 noncataract subjects ranged in age from 54 to 78 years.
   Setting: Subjects in these subsample groups have reported complaints of glare and wanted to administer eye drops to get quick eye relief and quality of vision for their daily activities including driving and computer works. Following 9 months of treatment with NAC lubricant eye drops, most patients' glare scores were improved or returned to normal in disability glare tests with Halometer DG. Improvement in disability glare was accompanied with independent improvement in acuity. Furthermore, patients with the poorest pretreatment vision were as likely to regain certain better visual function after 9 months of treatment with N-acetylcarnosine lubricant eye drops as those with the worth pretreatment vision.
   Patients or other participants: The authors made a reference to electronic records of the product sales to patients who have been made the repurchase of the Can-C (TM) eye drops since December 2001.
   Intervention: Based on this analysis of recorded adjustments to inventory, various parameters were analyzed during the continued repurchase behavior program, including testimonials from buyers. With these figures, researchers judged on the patients' compliance rate to self-administer NAC eye-drops.
   Main outcome measure and results: The ophthalmic drug showed potential for the nonsurgical treatment of age-related cataracts for participants after controlling for age, gender and daily activities and on a combined basis of repurchases behavior reports in more than 50,000 various cohort survivors, has been demonstrated to have a high efficacy and good tolerability for prevention and treatment of visual impairment determined for the older population with relative stable pattern of causes for blindness and visual impairment. The mechanisms of prevention and reversal of cataracts with NAC ophthalmic drug are considered which include prevention by the intraocular released carnosine of free-radical-induced inactivation of proprietary lens antioxidant enzymes (superoxide dismutase); prevention of carbohydrate and metal-catalyzed autooxidation of ascorbic acid-induced cross-linking glycation reactions to the lens proteins; transglycation properties of carnosine, allowing it to compete for the glycating agent, protecting proteins (lens crystallins) against modification; universal antioxidant and scavenging activity towards lipid hydroperoxides, aldehydes and oxygen radicals; activation with L-carnosine ingredient of proteasome activity in the lens; chaperone-like disaggregating to lens crystallins activity of NAC and of its bioactivated principal carnosine. Blindness incidence increased with advancing age, such as cataract and glaucoma, which are by far the commonest causes of blindness in our sample and in all age groups, glaucomatous neurodegeneration can be treated with developed NAC autoinduction prodrug eye drops equipped with corneal absorption promoters. The common blinding affections presenting in developed countries such as, senile macular degeneration, hereditary chorioretinal dystrophies, diabetic retinopathy are poorly represented in our current summary of vital-statistics and will be reported inherent in next N-acetylcarnosine ophthalmic drug studies.
   Conclusion: The authors present evidence, about why only a certain kind of NAC is safe, and why only certain formulas designed by IVP for drug discovery are efficacious in the prevention and treatment of senile cataract for long-term use. Overall cumulated studies demonstrate that the designed by IVP new vision-saving drug NAC eye drops help the aging eye to recover by improving its clarity, glare sensitivity, color perception and overall vision.
C1 [Babizhayev, Mark A.] Innovat Vis Prod Inc, Delaware, OH USA.
   [Burke, Leslie] Wise Choice Prod LLC, London, England.
   [Micans, Philip] IAS Grp, Sark, England.
   [Richer, Stuart P.] Eye Clin DVA Med Ctr, N Chicago, IL USA.
   [Richer, Stuart P.] Rosalind Franklin Univ Med & Sci, Dept Family & Prevent Med, N Chicago, IL USA.
C3 Rosalind Franklin University Medical & Science
RP Babizhayev, MA (通讯作者)，Innovat Vis Prod Inc, Moscow Div, Ivanovskaya 20,Suite 74, Moscow 127434, Russia.
EM markbabizhayev@mail.ru
FU Innovative Vision Products, Inc. (IVP; County of New Castle, DE, USA)
FX This work was planned, organized, and supported by Innovative Vision
   Products, Inc. (IVP; County of New Castle, DE, USA). IVP is a holder of
   the worldwide patent (including PCT International Publication Number WO
   2004/028536 A1) for the application of N-acetylcarnosine for the
   treatment of ophthalmic disorders, including cataracts. IVP is a
   pharmaceutical and nanotechnology development company with a direct
   practical focus on a clinical research in the fields of ophthalmology,
   research and development of innovative chemical entities, drug-delivery
   systems, and unique medical devices to target specific biomedical
   applications. Over the last decade IVP has developed a track record in
   developing these technologies to effectively address the unmet needs of
   specific diseased populations.
CR Aldini G, 2002, BIOCHEM BIOPH RES CO, V298, P699, DOI 10.1016/S0006-291X(02)02545-7
   [Anonymous], 1990, OPHTHALMOLOGY, V97, P1233
   Babizhayev M.A., 1994, Pharmaceutical compositions containing N-acetylcarnosine for the treatment of cataract, Patent No. [PCT/EP 94/03340 SCB 238 PCT, 9403340]
   Babizhayev M.A., 1999, US Patent No, Patent No. [6,007,203, 6007203]
   BABIZHAYEV MA, 1989, BIOCHIM BIOPHYS ACTA, V1004, P363, DOI 10.1016/0005-2760(89)90085-4
   Babizhayev MA, 1996, BBA-MOL BASIS DIS, V1315, P87, DOI 10.1016/0925-4439(95)00091-7
   Babizhayev MA, 1996, CLIN CHIM ACTA, V254, P1, DOI 10.1016/0009-8981(96)06356-5
   BABIZHAYEV MA, 1989, BIOCHIM BIOPHYS ACTA, V1004, P124, DOI 10.1016/0005-2760(89)90222-1
   Babizhayev MA, 2004, REJUV RES, V7, P186, DOI 10.1089/rej.2004.7.186
   Babizhayev MA, 2003, OPHTHALMIC RES, V35, P19, DOI 10.1159/000068199
   Babizhayev MA, 2001, PEPTIDES, V22, P979, DOI 10.1016/S0196-9781(01)00407-7
   BABIZHAYEV MA, 1994, BIOCHEM J, V304, P509, DOI 10.1042/bj3040509
   Babizhayev MA, 2000, J ANTI-AGING MED, V3, P43, DOI 10.1089/rej.1.2000.3.43
   BABIZHAYEV MA, 2006, J PHARM TOXICOL, V1, P201
   Babizhayev MA, 1993, Italian Patent, Patent No. [A61K gruppo 37/00 20122, 3700201122]
   BABIZHAYEV MA, 2004, Patent No. 2004028536
   Babizhayev MA, 2006, CURR DRUG THER, V1, P91, DOI 10.2174/157488506775268425
   Babizhayev Mark A, 2003, Clin Exp Optom, V86, P157
   Babizhayev Mark A, 2002, Drugs R D, V3, P87, DOI 10.2165/00126839-200203020-00004
   BAILEY IL, 1991, OPTOMETRY VISION SCI, V68, P911, DOI 10.1097/00006324-199112000-00001
   BOLDYREV AA, 1987, BIOCHEM INT, V15, P1105
   CARTER TL, 1994, GERIATRICS, V49, P37
   ELLIOTT DB, 1993, INVEST OPHTH VIS SCI, V34, P108
   FERRIS FL, 1982, AM J OPHTHALMOL, V94, P97, DOI 10.1016/0002-9394(82)90198-2
   FERRIS FL, 1982, AM J OPHTHALMOL, V94, P91, DOI 10.1016/0002-9394(82)90197-0
   FISHMAN GA, 1993, OPHTHALMOLOGY, V100, P1665
   Guiotto A, 2007, BIOORGAN MED CHEM, V15, P6158, DOI 10.1016/j.bmc.2007.06.029
   Gulewitsch W, 1900, BER DTSCH CHEM GES, V33, P1902, DOI 10.1002/cber.19000330275
   Hipkiss AR, 2002, ANN NY ACAD SCI, V959, P285, DOI 10.1111/j.1749-6632.2002.tb02100.x
   Hobart LJ, 2004, LIFE SCI, V75, P1379, DOI 10.1016/j.lfs.2004.05.002
   Kang JH, 2002, BBA-GEN SUBJECTS, V1570, P89, DOI 10.1016/S0304-4165(02)00158-7
   KLEIN R, 1991, HUM FACTORS, V33, P521, DOI 10.1177/001872089103300504
   KUPFER C, 1985, T OPHTHAL SOC UK, V104, P1
   Kupfer C, 1994, LEADING CAUSES VISUA, P1249
   MURAKAMI K, 1990, FREE RADICAL BIO MED, V8, P217, DOI 10.1016/0891-5849(90)90066-R
   Owsley C, 2001, ARCH OPHTHALMOL-CHIC, V119, P881
   Seidler NW, 2004, ARCH BIOCHEM BIOPHYS, V427, P110, DOI 10.1016/j.abb.2004.04.024
   TAYLOR A, 1987, FREE RADICAL BIO MED, V3, P371, DOI 10.1016/0891-5849(87)90015-3
   VANDENBERG TJTP, 1986, DOC OPHTHALMOL, V61, P327, DOI 10.1007/BF00142360
   Vision Research, 1998, NAT PLAN 1999 2002, P59
   WRIGHT IS, 1987, OPHTHALMOLOGY, V94, P1196
   Wu D Z, 1995, J Am Optom Assoc, V66, P39
NR 42
TC 31
Z9 31
U1 0
U2 7
PU DOVE MEDICAL PRESS LTD
PI ALBANY
PA PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND
EI 1178-1998
J9 CLIN INTERV AGING
JI Clin. Interv. Aging
PY 2009
VL 4
BP 31
EP 50
PG 20
WC Geriatrics & Gerontology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Geriatrics & Gerontology
GA V21WZ
UT WOS:000208239000004
PM 19503764
DA 2022-11-30
ER

EF